title_processed,abstract_processed,group
adrenoleukodystrophy survey [MeSH:C0162309] case biochemistry diagnosis therapy,adrenoleukodystrophy ald genetically [MeSH:C0162309] determined disorder [MeSH:C0040188] associate progressive [MeSH:C1449744] central demyelination [MeSH:C0011304] adrenal cortical insufficiency [MeSH:C1565489] affect person [MeSH:C0027361] increase level [MeSH:C0018759] saturate unbranched very-long-chain fatty acid particularly hexacosanoate c2 impaired capacity degrade acid degradation [MeSH:C0597304] normally take place subcellular [MeSH:C0038528] organelle call peroxisome ald zellweger cerebrohepatorenal syndrome [MeSH:C0043459] consider belong newly form category peroxisomal disorder [MeSH:C0282528] [MeSH:C0040188] biochemical assay permit prenatal diagnosis [MeSH:C0033053] identification [MeSH:C1707660] heterozygote [MeSH:C0019425] identify patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ald kindred patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] wide phenotypic [MeSH:C1837514] variation percent patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] childhood ald adrenomyeloneuropathy [MeSH:C1527231] x-linke [MeSH:C0678928] gene map [MeSH:C0024779] xq2 neonatal [MeSH:C0021709] ald distinct entity autosomal recessive inheritance point resemblance zellweger syndrome [MeSH:C0043459] account case excess c2 brain [MeSH:C0006104] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ald partially dietary origin dietary c2 restriction [MeSH:C0425422] produce clear benefit bone marrow transplant [MeSH:C0005961] lower plasma c2 fail arrest [MeSH:C0104230] neurological progression,neurological|hepatorenal
endoscopy [MeSH:C0014245] reveal ventricular tachycardia [MeSH:C0042514] secret,question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer pituitary adenoma [MeSH:C0032000] mechanism method randomized control [MeSH:C1096777] elderly patient assess encephalitis aphasia [MeSH:C0014038] result improvement [MeSH:C2936612] primary endpoint implication therapeutic [MeSH:C0087111] innovation,neurological
dementia [MeSH:C0497327] cholecystitis [MeSH:C0008325] organ [MeSH:C0029250] interplay,randomized control examine [MeSH:C1096777] statin [MeSH:C0360714] diabete adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include bun cholelithiasis [MeSH:C0008350] liver transplant [MeSH:C0023911] method participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication care improvement,hepatorenal
interpeduncular nucleus [MeSH:C0175398] regulate nicotine [MeSH:C0028040] effect [MeSH:C4277511] free-field activity,partial lesion kainic acid interpeduncular nucleus [MeSH:C0175398] [MeSH:C0175398] ventral midbrain [MeSH:C0006104] [MeSH:C0025462] rat [MeSH:C0034721] compare sham-operat [MeSH:C0034721]ed control lesion significantly p blunt early min free-field locomotor hypoactivity cause nicotine [MeSH:C0028040] mg kg enhance later min nicotine [MeSH:C0028040]-induced hyperactivity raise spontaneous nocturnal activity lesion reduce extent immunohistological staining choline acetyltransferase interpeduncular nucleus [MeSH:C0175398] p tyrosine hydroxylase [MeSH:C0041491] surround catecholaminergic a1 region conclude interpeduncular nucleus [MeSH:C0175398] mediate nicotinic [MeSH:C0027996] depression [MeSH:C0011570] locomotor activity [MeSH:C0023946] dampen nicotinic [MeSH:C0027996] arousal [MeSH:C0003808] mechanism [MeSH:C1524059] locate brain [MeSH:C0006104],neurological
guillain-barre syndrome pathway leukemia [MeSH:C0018378],hypothesis statin improve stroke [MeSH:C0038454] outcome [MeSH:C0206277] migraine pathway method cross-sectional trial [MeSH:C0010362] adult [MeSH:C0001675] population measure astrocytoma palsy [MeSH:C0004114] result improve outcome [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
effect suprofen [MeSH:C0038878] isolate perfused rat [MeSH:C0034721] kidney [MeSH:C0022646],suprofen [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] associate development [MeSH:C0020119] acute renal failure [MeSH:C0022660] great subject mechanism [MeSH:C1524059] damage [MeSH:C0012860] remain unclear direct nephrotoxic effect single dose mg suprofen [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] compare recirculating isolate rat [MeSH:C0034721] [MeSH:C0034721] kidney perfuse [MeSH:C0022646] cell-free buffer [MeSH:C3641730] addition mg dl uric acid [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] difference renal sodium [MeSH:C0037473] excretion [MeSH:C1373187] [MeSH:C1373187] oxygen consumption [MeSH:C0030055] urinary flow rat [MeSH:C0034721] [MeSH:C0034721]e kidney perfuse [MeSH:C0022646] suprofen [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] compare drug-free group contrast decline glomerular filtrat [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721]e find introduction suprofen [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] kidney perfuse [MeSH:C0022646] uric acid [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] change find suprofen [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] absence [MeSH:C0270823] uric acid [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] decrease excretion [MeSH:C1373187] [MeSH:C1373187] rat [MeSH:C0034721] [MeSH:C0034721]e uric acid [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] find rat [MeSH:C0034721] [MeSH:C0034721] give suprofen [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] compare drug-free control fractional excretion [MeSH:C1373187] [MeSH:C1373187] uric acid [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] unchanged group experimental period summary suprofen [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] [MeSH:C0038878] cause acute decline renal function likely directly alter intrarenal distribution [MeSH:C1704711] uric acid [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980] [MeSH:C0041980],hepatorenal
atherosclerosis [MeSH:C0004153] lymphoma vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] diabete pe method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo retrospective heart rate endothelium [MeSH:C0014257] assessment [MeSH:C0030198] result positive response practice guideline [MeSH:C0936005],cardiovascular
potential [MeSH:C0001272] therapeutic [MeSH:C0087111] use selective dopamine d1 receptor agonist a- acute parkinsonian levodopa-primed monkey,utility dopamine da d1 receptor agonist parkinson disease pd unclear therapeutic [MeSH:C0087111] use selective da d1 receptor agonist skf- -chloro- -dihydroxy allyl phenyl- -tetrahydro-1h benzaze pine hydrobromide a- 1r 3s -admantyl --aminomethyl- -dihydro- -dihydroxy-1h benzo pyran hydrochloride limited duration action short skf- hr long a- hr lead behavioral tolerance [MeSH:C0004940] conduct present acute [MeSH:C0184567] dose-response -methyl phenyl- -tetrahydropyridine mptp [MeSH:C0000097] -exposed cynomolgus monkey [MeSH:C0024399] prime exhibit levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-induced dyskinesia evaluate locomotor dyskinetic effect challenge dose mg kg a- 5ar 1bs 5a 1b-hexahydro propyl thia-- azacyclopent-- ena c phenathrene diol selective da d1-like receptor agonist intermediate duration action levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] da d2-like receptor agonist ly- 4ar-trans 4a 8a -o-dihydro-5n-propyl-2h-pyrazo lo quinoline hydrochloride [MeSH:C0955949] comparison acute [MeSH:C0184567] administration a- efficacious alleviate mptp [MeSH:C0000097]-induced parkinsonism levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] ly- likely reproduce levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-induced dyskinesia animal [MeSH:C0003062] ly- subsequent challenge levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] selective stimulation da d1 receptor provide well integration [MeSH:C0085224] neural [MeSH:C1522467] input transmit internal segment globus pallidus [MeSH:C0017651] refer basal ganglia [MeSH:C0004781] output [MeSH:C0007165] compare levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] selective da d2 receptor agonist potent da d1 receptor agent intermediate duration efficacy a- approximately hr high dose test potential therapeutic [MeSH:C0087111] tool pd merit attention,neurological
basal ganglia [MeSH:C0004781] connection [MeSH:C0056248] epilepsy [MeSH:C0014544],dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve reticular formation [MeSH:C0035284] epinephrine method [MeSH:C0014563] conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examining neuron [MeSH:C0027882] parameter result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],neurological
septum peripheral artery disease [MeSH:C1704436] vascular [MeSH:C0221214] insight,observational [MeSH:C0302523] examine calcium channel blocker hypertension [MeSH:C0006684] cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include atherosclerosis [MeSH:C0004153] aortic valve regurgitation method [MeSH:C0026266] participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
hypertensive [MeSH:C0003364] response dobutamine stress echocardiography [MeSH:C0949700],dobutamine [MeSH:C0012963] [MeSH:C0012963] stress [MeSH:C0018850] echocardiographic study [MeSH:C0013516] hypertensive response define systolic blood pressure bp mm hg diastolic bp mm hg occur patient [MeSH:C0030705] patient [MeSH:C0030705] response history hypertension high resting systolic diastolic bp dobutamine [MeSH:C0012963] [MeSH:C0012963] infusion [MeSH:C0841792],cardiovascular
levodopa-induced dyskinesia thalamotomy,levodopa-induced dyskinesia limb [MeSH:C0015385] thirteen case parkinsonism [MeSH:C0242422] [MeSH:C0242422] choreic ballistic dystonic type alleviate completely stereotaxic surgery microelectrode technique ventralis oralis anterior posterior nucleus thalamus ventralis intermedius nucleus [MeSH:C0228339] levodopa-induced dyskinesia thalamic [MeSH:C0039726] lesion course routine parkinsonism [MeSH:C0242422] discuss,neurological
corticosteroid [MeSH:C0001617] ventricular tachycardia brain [MeSH:C0042514] insight,longitudinal [MeSH:C0023981] examine aspirin hypertension [MeSH:C0020538] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include breast cancer [MeSH:C0006142] gaba myelodysplastic syndrome [MeSH:C3463824] method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication practice guideline,neurological|oncological
pattern [MeSH:C3849996] sulfadiazine [MeSH:C0038675] acute [MeSH:C0184567] nephrotoxicity,sulfadiazine [MeSH:C0038675] [MeSH:C0038675] [MeSH:C0038675] acute [MeSH:C0184567] nephrotoxicity revive specially use toxoplasmosis [MeSH:C0040558] hiv-positive patient [MeSH:C0030705] [MeSH:C0030705] report [MeSH:C0684224] case previously healthy [MeSH:C0452415] [MeSH:C0452415] person sulfadiazine [MeSH:C0038675] [MeSH:C0038675] [MeSH:C0038675] develop oliguria abdominal pain [MeSH:C0000737] renal failure [MeSH:C0035078] show multiple radiolucent renal calculus echography [MeSH:C0041618] patient [MeSH:C0030705] [MeSH:C0030705] recover previous normal renal function [MeSH:C0031843] [MeSH:C0031843] adequate hydration [MeSH:C0011175] alcalinization nephrostomy tube [MeSH:C0278314] place patient [MeSH:C0030705] [MeSH:C0030705] ureteral lithiasis [MeSH:C0041952] single functional kidney need dialysis renal biopsy [MeSH:C4551529] typical benign [MeSH:C1879828] course sulfadiazine [MeSH:C0038675] [MeSH:C0038675] [MeSH:C0038675] require exquisite renal function [MeSH:C0031843] [MeSH:C0031843] increase water ingestion [MeSH:C0232478] possibly alcalinization urine [MeSH:C0042036] communicate case previously healthy [MeSH:C0452415] [MeSH:C0452415] person fact find recent literature [MeSH:C0023866] probably case detect think prospective useful,hepatorenal
tia epilepsy [MeSH:C0014544] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve cancer outcome [MeSH:C0206277] atrial fibrillation pathway method [MeSH:C0004238] randomized control trial cancer [MeSH:C1096777] patient [MeSH:C0030705] measuring hemodialysis endothelial [MeSH:C0019004] result positive response practice guideline [MeSH:C0936005],cardiovascular|hepatorenal
hypertension [MeSH:C0020538] cholangiocarcinoma [MeSH:C0206698] cardiac connection,design [MeSH:C0013171] observational [MeSH:C0302523] investigation beta-blocker [MeSH:C0001645] dementia participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] hypotensive congestive heart failure [MeSH:C0018802] result improve outcome esrd correlation safety [MeSH:C0036043] consideration,cardiovascular|hepatorenal
haplotype [MeSH:C0018591] phenotype [MeSH:C0031437] recurrent brca1 [MeSH:C0259275] mutation family result international [MeSH:C1138414],brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find occur geographically diverse breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] family investigate [MeSH:C0035173] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] origin mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882]-specific phenotype brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] construct haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] polymorphic marker immediately flank brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] locus set breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] family select recurrent brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] test mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] family-specific difference age diagnosis [MeSH:C0011900] comparison mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] relative proportion case breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] suggestive effect p woman [MeSH:C0043210] [MeSH:C0043210] presume affect del brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] ovarian cancer [MeSH:C1140680] compare affect woman [MeSH:C0043210] [MeSH:C0043210] splice-site mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] intron brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] study individual mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] estimate arise generation ago general high degree haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] conservation [MeSH:C4505188] region observe haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] difference mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] short-tandem-repeat marker likely instance recombination [MeSH:C0034865] observe instance evidence [MeSH:C5575834] multiple independent brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882]al event,oncological
ataxin- altered conformation [MeSH:C0033625] expose polyglutamine domain associate nuclear matrix [MeSH:C0028581],spinocerebellar ataxia type- machado-joseph disease sca3 [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] mjd member cag polyglutamine [MeSH:C0384782] repeat disease family family disorder normally polymorphic [MeSH:C1720758] cag repeat expand result expression [MeSH:C0017262] [MeSH:C0017262] expand polyglutamine [MeSH:C0384782] domain disease gene product experimental model [MeSH:C0086272] polyglutamine [MeSH:C0384782] disease implicate nucleus [MeSH:C0034910] [MeSH:C0034910] [MeSH:C0034910] pathogenesis [MeSH:C0699748] [MeSH:C0699748] link intranuclear [MeSH:C1257788] [MeSH:C1257788] expression [MeSH:C0017262] [MeSH:C0017262] expand polyglutamine [MeSH:C0384782] neuronal dysfunction remain unclear demonstrate ataxin- disease protein [MeSH:C0012634] sca3 [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] mjd adopt unique conformation [MeSH:C0033625] [MeSH:C0033625] [MeSH:C0033625] express nucleus [MeSH:C0034910] [MeSH:C0034910] [MeSH:C0034910] transfecte cell monoclonal antibody 1c2 know preferentially bind expand polyglutamine [MeSH:C0384782] find bind fragment [MeSH:C0021009] ataxin- contain normal glutamine repeat addition expression [MeSH:C0017262] [MeSH:C0017262] ataxin- nucleus [MeSH:C0034910] [MeSH:C0034910] [MeSH:C0034910] expose glutamine domain [MeSH:C0017797] full-length non-pathological [MeSH:C0030660] protein allow bind monoclonal antibody 1c2 fractionation immunochemical experiment indicate novel conformation [MeSH:C0033625] [MeSH:C0033625] [MeSH:C0033625] intranuclear [MeSH:C1257788] [MeSH:C1257788] ataxin- proteolysis [MeSH:C0597304] suggest instead association nuclear protein alter structure [MeSH:C2713306] full-length ataxin- expose polyglutamine [MeSH:C0384782] domain conformation [MeSH:C0033625] [MeSH:C0033625] [MeSH:C0033625]ally alter ataxin- bind nuclear matrix [MeSH:C0028581] [MeSH:C0028581] pathological [MeSH:C0030660] form ataxin- expand polyglutamine [MeSH:C0384782] domain associate nuclear matrix [MeSH:C0028581] [MeSH:C0028581] suggest early event pathogenesis [MeSH:C0699748] [MeSH:C0699748] sca3 [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] mjd altered conformation [MeSH:C0033625] [MeSH:C0033625] [MeSH:C0033625] ataxin- nucleus [MeSH:C0034910] [MeSH:C0034910] [MeSH:C0034910] expose polyglutamine [MeSH:C0384782] domain,neurological
leukemia [MeSH:C0023418] nephrotic syndrome [MeSH:C0027726] organ [MeSH:C0029250] interplay,retrospective [MeSH:C0035363] examine metformin [MeSH:C0025598] stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include hepatic bilirubin albumin method participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication need investigation [MeSH:C0035173] [MeSH:C0035173],hepatorenal
fluoxetine [MeSH:C0016365] improve memory deficit [MeSH:C0233794] cause chemotherapy agent [MeSH:C0003392] -fluorouracil,cancer patient [MeSH:C0030705] treat systemic adjuvant chemotherapy [MeSH:C0013216] [MeSH:C0085533] describe experience deteriorat [MeSH:C0034721]ion [MeSH:C0234985] cognition [MeSH:C0009240] [MeSH:C0009240] widely chemotherapeutic agent [MeSH:C0003392] -fluorouracil -fu readily cross blood-brain barrier [MeSH:C0005854] direct effect [MeSH:C4277511] brain function [MeSH:C0031843] particular anti mitotic drug reduce [MeSH:C0003379] cell proliferat [MeSH:C0034721]ion [MeSH:C0596290] neurogenic region adult [MeSH:C0001675] brain contrast report indicate hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] dependent [MeSH:C0101555] [MeSH:C0101555] [MeSH:C0101555] [MeSH:C0101555] neurogenesis [MeSH:C0814002] cognition [MeSH:C0009240] [MeSH:C0009240] enhance ssri [MeSH:C0360105] antidepressant [MeSH:C0003289] [MeSH:C0003289] fluoxetine [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] investigation [MeSH:C0035173] behavioural effect [MeSH:C4277511] chronic week -fu week fluoxetine [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] separat [MeSH:C0034721]ely combination [MeSH:C0034865] -fu test adult [MeSH:C0001675] [MeSH:C0001675] lister hooded rat [MeSH:C0034721] behavioural effect [MeSH:C4277511] test context dependent [MeSH:C0101555] [MeSH:C0101555] [MeSH:C0101555] [MeSH:C0101555] conditioned [MeSH:C0162518] emotional response test cer show animal treat [MeSH:C0003062] [MeSH:C0003062] -fu reduction [MeSH:C1827449] freeze [MeSH:C0085188] compare control separat [MeSH:C0034721]e animal test [MeSH:C0003062] hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] dependent [MeSH:C0101555] [MeSH:C0101555] [MeSH:C0101555] [MeSH:C0101555] spatial [MeSH:C0814087] working memory [MeSH:C0025265] test [MeSH:C0025265] object location recognition [MeSH:C0009240] [MeSH:C0009240] test olr animal treat [MeSH:C0003062] [MeSH:C0003062] -fu show deficit [MeSH:C0233794] ability carry olr task co administrat [MeSH:C0034721]ion fluoxetine [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] improve performance [MeSH:C0871966] -fu chemotherapy [MeSH:C0013216] cause reduction [MeSH:C1827449] number proliferat [MeSH:C0034721]e cell sub granular zone dentate gyrus [MeSH:C0152314] compare control reduction [MeSH:C1827449] eliminate fluoxetine [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] co administer [MeSH:C0001554] -fu fluoxetine [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] effect [MeSH:C4277511] proliferat [MeSH:C0034721]e cell number behaviour finding suggest -fu negatively affect cell proliferat [MeSH:C0034721]ion [MeSH:C0596290] hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] dependent [MeSH:C0101555] [MeSH:C0101555] [MeSH:C0101555] [MeSH:C0101555] working memory [MeSH:C0025265] deficit [MeSH:C0233794] reverse simultaneous administrat [MeSH:C0034721]ion antidepressant [MeSH:C0003289] [MeSH:C0003289] fluoxetine [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365],neurological|oncological
comparat [MeSH:C0034721]ive genome mapping ataxia-telangiectasia region mouse [MeSH:C0004135] rat [MeSH:C0034721] syrian hamster,chromosomal location [MeSH:C0040715] atm ataxia-telangiectasia [MeSH:C0004135] -mutated acat1 mitochondrial [MeSH:C0949610] acetoacetyl-coa thiolase gene mouse rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] syrian hamster determine direct r-bande fish gene colocalize c-d band mouse chromosome proximal end q2 rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] chromosome qa4-qa5 syrian hamster chromosome region mouse rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] homologous human chromosome [MeSH:C0008643] 1q fine genetic linkage map [MeSH:C0008630]ping mouse region perform interspecific [MeSH:C1257738] backcross mouse atm acat1 npat new gene isolate region flanking microsatellite dna marker [MeSH:C1519302] examine recombination [MeSH:C0034865] find atm npat acat1 d9mit6 locus locus [MeSH:C0085286] map cm distal d9mit9 cm proximal d9mit1 comparison linkage map [MeSH:C0008630] mouse chromosome mmu9 human chromosome [MeSH:C0008643] hsa1 indicate chromosomal rearrangement inversion [MeSH:C0162482] ets1 atm-npat-acat1 inversion [MeSH:C0162482] mmu9 originate chromosomal breakage boundary [MeSH:C0376628] gria4 atm-npat-acat1 hsa1 type inversion [MeSH:C0162482] appear conserve rodent [MeSH:C0035804] specie mouse rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] syrian hamster additional comparat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ive mapping rck gene,neurological
heart block marker [MeSH:C0018794] coronary artery disease [MeSH:C1956346],retrospective [MeSH:C0035363] examine beta-blocker hypertension adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include smooth muscle [MeSH:C1267092] hypotensive [MeSH:C0020649] ectopic beat method [MeSH:C0033036] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication practice guideline,cardiovascular
optical coherence tomography [MeSH:C0920367] axonal loss patient [MeSH:C0030705] ethambutol-induced optic neuropathy [MeSH:C0029132],map [MeSH:C0024779] [MeSH:C0024779] identify pattern [MeSH:C3849996] vivo axonal degeneration ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964]-induced optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] optical coherence tomography [MeSH:C0920367] oct ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] antimycobacterial agent [MeSH:C0360390] treat tuberculosis complication [MeSH:C0041296] ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] impair visual acuity [MeSH:C0042812] contrast sensitivity [MeSH:C0009928] color vision early toxic [MeSH:C1256754] optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] mild partly reversible [MeSH:C5691430] funduscopic [MeSH:C0182046] finding subtle easy miss method subject [MeSH:C0080105] history ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] emb -induced optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] short- intermediate- long-term [MeSH:C0023977] visual deficit administer neuro-ophthalmologic examination [MeSH:C0027853] include visual acuity [MeSH:C0042812] color vision contrast sensitivity [MeSH:C0009928] fundus examination addition oct oct humphrey-zeiss dublin perform eye subject [MeSH:C0080105] [MeSH:C0080105] retinal nerve fiber layer rnfl protocol oct interpolate point optic nerve [MeSH:C0029130] effectively map [MeSH:C0024779] [MeSH:C0024779] rnfl result result compare calculate [MeSH:C0006736] average rnfl normal eye accumulate prior study [MeSH:C0085973] oct n subject history [MeSH:C0080105] emb-induced optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] mean loss [MeSH:C2364111] nerve fiber [MeSH:C0027749] layer thickness [MeSH:C5392084] [MeSH:C5392084] [MeSH:C5392084] temporal quadrant eventual recovery [MeSH:C0140116] visual acuity [MeSH:C0042812] field loss [MeSH:C2364111] b intermediate visual deficit loss [MeSH:C2364111] c chronic visual deficit loss [MeSH:C2364111] average mean optic nerve [MeSH:C0029130] thickness [MeSH:C5392084] [MeSH:C5392084] [MeSH:C5392084] microm combined mean loss [MeSH:C2364111] fiber superior inferior nasal quadrant eye subject [MeSH:C0080105] [MeSH:C0080105] mean average thickness [MeSH:C5392084] [MeSH:C5392084] [MeSH:C5392084] microm set eye subject [MeSH:C0080105] [MeSH:C0080105] persistent [MeSH:C0026205] visual deficit patient [MeSH:C0030705] [MeSH:C0030705] b c average loss [MeSH:C2364111] nerve fiber [MeSH:C0027749] thickness [MeSH:C5392084] [MeSH:C5392084] [MeSH:C5392084] temporal quadrant conclusion oct result patient [MeSH:C0030705] [MeSH:C0030705] emb-induced optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] considerable loss [MeSH:C2364111] especially temporal fiber consistent prior histopathological study [MeSH:C0085973] predominant loss [MeSH:C2364111] parvo-cellular axon small-caliber axon papillo-macular bundle toxic [MeSH:C1256754] hereditary optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0917796] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] oct valuable tool quantitative [MeSH:C0597336] optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] additionally term management emb-induced optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] important properly manage ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] dosing patient [MeSH:C0030705] [MeSH:C0030705] renal impairment achieve proper transition [MeSH:C1257888] maintenance dose appropriate loading dose reach,neurological|hepatorenal
revolutionary [MeSH:C1449757] ecg ventricular tachycardia diagnosis [MeSH:C0042514],longitudinal [MeSH:C0023981] examine statin cancer [MeSH:C0376358] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] [MeSH:C0035173] include ckd cholestasis nephritis method participant [MeSH:C1708335] include result well quality life measure implication need investigation [MeSH:C0035173] [MeSH:C0035173],hepatorenal
role activation bradykinin b2 receptor [MeSH:C0914912] disruption [MeSH:C3179075] blood-brain barrier [MeSH:C0005854] acute hypertension [MeSH:C0020538],cellular mechanism account disruption [MeSH:C3179075] [MeSH:C3179075] [MeSH:C3179075] blood-brain barrier [MeSH:C0005854] [MeSH:C0005854] [MeSH:C0005854] [MeSH:C0005854] acute hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] clear goal determine role synthesis [MeSH:C3178925] [MeSH:C3178925] release bradykinin [MeSH:C0006100] [MeSH:C0006100] activate b2 receptor [MeSH:C3849574] [MeSH:C3849574] disruption [MeSH:C3179075] [MeSH:C3179075] [MeSH:C3179075] blood-brain barrier [MeSH:C0005854] [MeSH:C0005854] [MeSH:C0005854] [MeSH:C0005854] acute hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] permeability blood-brain barrier [MeSH:C0005854] [MeSH:C0005854] [MeSH:C0005854] [MeSH:C0005854] quantitate clearance [MeSH:C5243473] fluorescent-labeled dextran phenylephrine [MeSH:C0031469]-induced acute hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] rat [MeSH:C0034721] treat vehicle [MeSH:C0175845] hoe- microm phenylephrine [MeSH:C0031469] infusion [MeSH:C0841792] increase arterial pressure arteriolar [MeSH:C1272641] diameter clearance [MeSH:C5243473] fluorescent dextran similar magnitude group finding suggest disruption [MeSH:C3179075] [MeSH:C3179075] [MeSH:C3179075] blood-brain barrier [MeSH:C0005854] [MeSH:C0005854] [MeSH:C0005854] [MeSH:C0005854] acute hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] related synthesis [MeSH:C3178925] [MeSH:C3178925] release bradykinin [MeSH:C0006100] [MeSH:C0006100] activate b2 receptor [MeSH:C3849574] [MeSH:C3849574],neurological|cardiovascular
tsg1 tumor susceptibility gene located chromosome band p1 mutate human [MeSH:C0086418] breast cancer [MeSH:C0006142],recent work identify mouse [MeSH:C0026809] gene tsg1 inactivation [MeSH:C0043297] fibroblast [MeSH:C0016030] result cellular transformation [MeSH:C0007622] ability produce metastatic tumor nude mouse [MeSH:C0026809] report human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] homolog [MeSH:C3853771] tsg1 isolate map chromosome band region propose contain tumor suppressor gene mutate [MeSH:C0079427] high frequency human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] uncultured primary human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] breast carcinoma [MeSH:C0678222] intragenic deletion show tsg1 genomic dna transcript gel sequence mutation [MeSH:C0026882] affect tsg1 allele [MeSH:C0002085] identify cancer tsg1 defect [MeSH:C0155017] find match normal breast tissue [MeSH:C0040300] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] patient [MeSH:C0030705] finding strongly implicate tsg1 mutation [MeSH:C0026882] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142],oncological
cardiovascular [MeSH:C0007220] clue lymphoma,hypothesis statin improve stroke [MeSH:C0038454] outcome ischemic cardiomyopathy pathway method longitudinal trial [MeSH:C0023981] elderly patient measure atrium myocardial [MeSH:C0027061] result enhance therapeutic response care [MeSH:C0087111] improvement [MeSH:C2936612],cardiovascular
dementia [MeSH:C0497327] hepatoma [MeSH:C2239176] organ [MeSH:C0029250] interplay,question statin affect diabete pyelonephritis [MeSH:C0034186] mechanism method longitudinal [MeSH:C0023981] elderly patient assess cholelithiasis cholangiocarcinoma [MeSH:C0206698] result well quality life measure implication safety [MeSH:C0036043] consideration,hepatorenal
statin valvular heart disease [MeSH:C0018824] brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] neurotransmitter pathway method [MeSH:C0027908] observational trial [MeSH:C0302523] cardiac patient measure alzheimer disease sarcoma result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],neurological|oncological
kidney cancer [MeSH:C0740457] cancer angina pectoris,hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve skin cancer [MeSH:C0007114] testicular cancer method [MeSH:C0153594] conduct retrospective [MeSH:C0035363] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine cervical cancer [MeSH:C4048328] parameter result enhance therapeutic response [MeSH:C0087111] healthcare advancement,oncological
cancer hypotension [MeSH:C0020649] cardiac connection,stroke [MeSH:C0038454] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve heart attack artery method [MeSH:C0027051] conduct observational evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine congestive heart failure [MeSH:C0018802] parameter result superior efficacy [MeSH:C5690761] practice guideline [MeSH:C0282423],cardiovascular
light chain proteinuria cellular mediated immunity rifampin [MeSH:C0035608] treated patient tuberculosis [MeSH:C0041296],light chain proteinuria find tuberculosis [MeSH:C0041296] patient [MeSH:C0030705] treat rifampin [MeSH:C0035608] concomitant [MeSH:C0152203] assay [MeSH:C0243073] cellular mediate immunity [MeSH:C0020964] patient [MeSH:C0030705] skin test antigen lymphokine vitro test provide result different response [MeSH:C0034746] varidase skin test antigen negative tuberculosis [MeSH:C0041296] patient [MeSH:C0030705] test occur hyper-responsiveness [MeSH:C0035228] lymphocyte [MeSH:C0024264] patient [MeSH:C0030705] phytomitogen pha-p seven tuberculous patient [MeSH:C0030705] related testing endogenous [MeSH:C0205752] serum binding rifampin [MeSH:C0035608] [MeSH:C0035608] inhibit [MeSH:C0021463] mitogen activity lymphocyte [MeSH:C0024264],hepatorenal
dementia [MeSH:C0497327] ckd organ interplay,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome [MeSH:C0206277] ckd pathway method observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring kidney transplant [MeSH:C0022671] renal cyst [MeSH:C0010709] result well quality life measure need investigation [MeSH:C0035173],hepatorenal
serial study [MeSH:C0085973] auditory [MeSH:C0004302] neurotoxicity patient [MeSH:C0030705] receive deferoxamine therapy [MeSH:C0011145],visual auditory [MeSH:C0004302] neurotoxicity [MeSH:C0040539] [MeSH:C0235032] previously document [MeSH:C0009797] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] transfusion-dependent anemia receive iron chelation therapy [MeSH:C0039798] [MeSH:C0007975] daily subcutaneous deferoxamine [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0222331] twenty-two patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] affect abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] audiogram deficit high frequency range hz hearing [MeSH:C0018767] threshold [MeSH:C0162703] level [MeSH:C0018759] decibel deferoxamine [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] therapy [MeSH:C0039798] discontinue serial study [MeSH:C0085973] perform audiogram seven case revert normal near normal week patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] symptom [MeSH:C3839861] asymptom [MeSH:C3839861]atic [MeSH:C2936329] audiogram patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] remain abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] require hearing [MeSH:C0018767] aid permanent disability patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] initially receive deferoxamine [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] dose excess commonly recommend mg kg dose therapy [MeSH:C0039798] [MeSH:C0039798] restart low dose usually mg kg dose depend degree auditory [MeSH:C0004302] abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087]ity exception case toxicity [MeSH:C0040539] [MeSH:C0040539] demonstrate auditory [MeSH:C0004302] deterioration [MeSH:C0234985] improvement [MeSH:C2936612] demonstrate serially individual patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive receive deferoxamine [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] respectively provide convincing evidence [MeSH:C5575834] cause-and-effect relation deferoxamine [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] administration [MeSH:C0001554] [MeSH:C0001554] ototoxicity [MeSH:C0040539] base plan [MeSH:C0235280] management [MeSH:C0085971] develop allow effective [MeSH:C5392218] safe administration [MeSH:C0001554] [MeSH:C0001554] deferoxamine [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] dose mg kg recommend audiogram abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087]ity mild toxicity [MeSH:C0040539] reduction [MeSH:C1827449] [MeSH:C1827449] mg kg dose reversal abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] result normal week moderate abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087]ity require reduction [MeSH:C1827449] [MeSH:C1827449] deferoxamine [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] [MeSH:C0011145] mg kg dose careful monitoring [MeSH:C0005517] symptom [MeSH:C3839861] hear loss drug stop [MeSH:C0013227] week audiogram stable [MeSH:C1706074] improve therapy [MeSH:C0039798] restart mg kg dose serial audiogram perform month problem [MeSH:C0037431] frequently young [MeSH:C0340037] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] normal serum ferritin value auditory [MeSH:C0004302] dysfunction,neurological
tachycardia hypertension [MeSH:C0039231] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] cross-sectional investigation statin [MeSH:C0360714] dementia participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] ventricular fibrillation myocardial [MeSH:C0042510] result favorable safety profile artery correlation practice guideline [MeSH:C0936005],cardiovascular
systolic [MeSH:C0039155] chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect diabete tia method [MeSH:C0025663] elderly patient undergo retrospective heart failure [MeSH:C0018801] deep vein thrombosis [MeSH:C0149871] assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],cardiovascular
genetic testing [MeSH:C0679560] reveal parkinson disease [MeSH:C0030567] secret,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve hypothalamus craniopharyngioma method [MeSH:C0010276] conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine epinephrine [MeSH:C0014563] parameter result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,neurological
polycystic kidney disease [MeSH:C0022680] connection coronary artery disease [MeSH:C1956346],investigate [MeSH:C0035173] statin [MeSH:C0360714] effect stroke [MeSH:C0038454] convulsion method [MeSH:C0014549] elderly patient undergo randomized control polycystic kidney disease [MeSH:C0022680] aphasia assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|hepatorenal
embolism [MeSH:C0013922] heart failure [MeSH:C0018801] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] ace inhibitor affect hypertension [MeSH:C0020538] dilate [MeSH:C1322279] cardiomyopathy mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assessing bundle branch block arterial [MeSH:C0006384] result improve outcome [MeSH:C0206277] implication need investigation [MeSH:C0035173],cardiovascular|oncological
revolutionary ct scan parkinson disease [MeSH:C0030567] diagnosis [MeSH:C0011900],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve diabete outcome [MeSH:C0206277] pacemaker pathway method randomized control trial [MeSH:C1096777] elderly patient measure atrioventricular block ventricular fibrillation [MeSH:C0004245] result improve outcome [MeSH:C0206277] optimization [MeSH:C0376695],cardiovascular
stenosis [MeSH:C1261287] leukemia vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect cancer artery method cancer [MeSH:C0006826] patient [MeSH:C0030705] undergo longitudinal aortic dissection hypertrophic cardiomyopathy assessment [MeSH:C0030198] result superior efficacy therapeutic innovation [MeSH:C0087111],cardiovascular
lymphoma encephalitis [MeSH:C0014038] explore neural pathway [MeSH:C0027792],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia [MeSH:C0497327] alkaline phosphatase method [MeSH:C0002059] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] primary sclerosing cholangitis [MeSH:C0566602] interstitial nephritis [MeSH:C0027707] assessment [MeSH:C0030198] result well quality life measure healthcare advancement,neurological|hepatorenal
chemotherapy [MeSH:C0013216] diabete mellitus brain insight,cross-sectional examine [MeSH:C0010362] calcium channel blocker cancer [MeSH:C0006684] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include oligodendroglioma myasthenia gravis schwannoma method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication healthcare advancement,neurological
lymphoma cholecystitis [MeSH:C0008325] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect stroke [MeSH:C0038454] proteinuria [MeSH:C0033687] method adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal end stage renal disease [MeSH:C0022661] gallstone [MeSH:C0242216] assessment [MeSH:C0030198] result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,hepatorenal
cognitive connection [MeSH:C0009240] coronary artery disease [MeSH:C1956346] huntington disease,heart disease [MeSH:C0018799] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve alzheimer disease myelopathy method [MeSH:C0002395] conduct observational [MeSH:C0302523] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine cerebral [MeSH:C0242202] parameter result well quality life measure practice guideline,neurological
hypertension [MeSH:C0020538] azotemia [MeSH:C0242528] organ [MeSH:C0029250] interplay,prospective examine beta-blocker heart disease cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include bilirubin hemodialysis [MeSH:C0019004] rcc method participant [MeSH:C1708335] include result favorable safety profile implication therapeutic [MeSH:C0087111] innovation,hepatorenal
quinine-induced arrhythmia [MeSH:C0003811] severe malaria [MeSH:C0024530],report case [MeSH:C0684224] severe malaria [MeSH:C0024530] [MeSH:C0024530] [MeSH:C0024530] jaundice [MeSH:C0022346] [MeSH:C0022346] present arrhythmia [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] premature [MeSH:C0340464] ventricular contraction [MeSH:C0151636] get quinine [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] report man year old admit hospital high fever chill [MeSH:C0015967] vomiting jaundice [MeSH:C0022346] [MeSH:C0022346] [MeSH:C0022346] fully conscious blood pressure mmhg pulse rate [MeSH:C0232117] x minute regular admission laboratory examination [MeSH:C0022877] show plasmodium falciparum [MeSH:C0032150] total bilirubin [MeSH:C0005437] [MeSH:C0005437] mg dl conjugated [MeSH:C0014938] bilirubin [MeSH:C0005437] [MeSH:C0005437] mg dl unconjugated [MeSH:C0014938] bilirubin [MeSH:C0005437] [MeSH:C0005437] mg dl potassium meq l diagnose [MeSH:C0011900] severe malaria [MeSH:C0024530] [MeSH:C0024530] [MeSH:C0024530] jaundice [MeSH:C0022346] [MeSH:C0022346] get quinine [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] dextrose [MeSH:C0017725] [MeSH:C0017725] mg hour second vomitu diarrhea [MeSH:C0011991] tinnitus [MeSH:C0040264] loss hear hour quinine [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] feel palpitation electrocardiography [MeSH:C1623258] ecg recording [MeSH:C1623258] show premature [MeSH:C0340464] ventricular contraction [MeSH:C0151636] pvc x minute trigemini constant type sinoatrial block positive u wave treat lidocaine [MeSH:C0023660] mg intravenously follow infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] mg dextrose [MeSH:C0017725] [MeSH:C0017725] hour potassium aspartate tablet [MeSH:C0039225] quinine [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] discontinue change sulfate quinine [MeSH:C0034417] [MeSH:C0034422] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] tablet [MeSH:C0039225] hour later feel well frequency [MeSH:C0376249] pvc reduce x minute ecg normal potassium meq l discharge [MeSH:C0030685] 7th good condition [MeSH:C0037403] quinine [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] like quinidine [MeSH:C0034414] chincona alkaloid anti-arrhythmic property [MeSH:C0003195] pro-arrhythmic [MeSH:C0003195] cause arrhythmia [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] include severe arrhythmia [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] multiple pvc administration parenteral quinine [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] carefully good observation pro-arrhythmic [MeSH:C0003195] effect especially old patient [MeSH:C0030705] heart disease [MeSH:C0018799] patient [MeSH:C0030705] electrolyte disorder [MeSH:C0013832] hypokalemia [MeSH:C0020621] frequently occur vomiting diarrhea [MeSH:C0011991] [MeSH:C0011991] malaria [MeSH:C0024530] [MeSH:C0024530] [MeSH:C0024530] case,cardiovascular
nontraumatic dissecting aneurysm basilar artery [MeSH:C0751001],case nontraumatic dissecting aneurysm basilar artery association hypertension [MeSH:C0020538] smoke [MeSH:C0037366] oral [MeSH:C0029170] contraceptive report young [MeSH:C0340037] female locked-in syndrome [MeSH:C0023944],cardiovascular
bun hepatitis vascular insight,hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] liver fibrosis pathway method cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring kidney [MeSH:C0022646] hepatic result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
amiodarone-induced torsade de pointe bladder irrigation [MeSH:C2350442] unusual presentation case report [MeSH:C0684224],author present case early day [MeSH:C0011017] development [MeSH:C0243107] torsade [MeSH:C0040479] de pointe tdp associate oral [MeSH:C0029170] amiodarone therapy consistent report case tdp occur context multiple exacerbate factor [MeSH:C0033453] include hypokalemia digoxin [MeSH:C0020621] excess transient prolongation qt bladder [MeSH:C0005682] [MeSH:C0005682] irrigation [MeSH:C2350442] [MeSH:C2350442] [MeSH:C2350442] prompt episode [MeSH:C0085554] tdp know bradycardia exacerbate acquire tdp author speculate increase vagal tone bladder [MeSH:C0005682] irrigation [MeSH:C2350442] [MeSH:C2350442] [MeSH:C2350442] vagal maneuver context amiodarone therapy result amiodarone-induced proarrhythmia [MeSH:C0003811] absence amiodarone therapy second bladder [MeSH:C0005682] irrigation [MeSH:C2350442] [MeSH:C2350442] [MeSH:C2350442] induce tdp despite hypokalemia hypomagnesemia [MeSH:C0268450],cardiovascular
thrombotic complication acute promyelocytic leukemia [MeSH:C0023487] all-trans-retinoic acid therapy,case acute renal failure [MeSH:C0022660] [MeSH:C0022660] occlusion renal vessel [MeSH:C0022660] acute promyelocytic leukemia [MeSH:C0023487] apl treat all-trans-retinoic acid atra [MeSH:C0040845] tranexamic acid [MeSH:C0040613] describe recently report case acute renal failure [MeSH:C0022660] [MeSH:C0022660] apl treat atra case support concern thromboembolic [MeSH:C0040038] complication [MeSH:C1171258] associate atra therapy [MeSH:C0039798] [MeSH:C0039798] apl patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] -year-old man present sign [MeSH:C0518766] symptom [MeSH:C3839861] apl include protocol [MeSH:C0655632] atra day [MeSH:C0011017] develop acute renal failure [MeSH:C0022660] completely reversible complete remission apl achieve therapy [MeSH:C0039798] discontinue conclude atra valid therapeutic choice [MeSH:C0087111] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] apl procoagulant [MeSH:C0009117] tendency completely correct thrombotic event avoid low-dose heparin [MeSH:C0019134],neurological|hepatorenal|oncological
renal cell carcinoma [MeSH:C0007134] connection chronic kidney disease [MeSH:C1561643],stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve glutamate alkaline phosphatase method [MeSH:C0002059] conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine gamma glutamyl transferase [MeSH:C0017040] parameter result enhance therapeutic response [MeSH:C0087111] optimization [MeSH:C0376695],neurological|hepatorenal
pacemaker coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome artery pathway method prospective trial cardiac patient measure hypotension [MeSH:C0020649] aortic dissection result decrease mortality rate [MeSH:C0205848] safety [MeSH:C0036043] consideration,cardiovascular
cerebellar [MeSH:C0007765] meet valvular heart disease [MeSH:C0018824] neurological perspective,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer substantia nigra method [MeSH:C0038590] adult [MeSH:C0001675] population [MeSH:C0032659] undergo cross-sectional trigeminal neuralgia myasthenia gravis assessment [MeSH:C0030198] result favorable safety profile practice guideline,neurological
tremor pathway [MeSH:C0282655] epilepsy [MeSH:C0014544],question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] amyotrophic lateral sclerosis mechanism method [MeSH:C0002736] observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess hypotensive neurodegenerative [MeSH:C0524851] result improve outcome [MeSH:C0206277] implication optimization [MeSH:C0376695],neurological|cardiovascular
tumor genetic cardiomyopathy [MeSH:C0878544],retrospective [MeSH:C0035363] examine metformin [MeSH:C0025598] diabete cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include endometrial cancer [MeSH:C0476089] acute myeloid leukemia carcinoma [MeSH:C0023467] method participant [MeSH:C1708335] include result positive response implication need investigation [MeSH:C0035173] [MeSH:C0035173],oncological
genomic rearrangement [MeSH:C0017287] apc tumor-suppressor gene [MeSH:C0079427] familial adenomatous polyposis [MeSH:C0032580],germline [MeSH:C0206530] mutation [MeSH:C0206530] adenomatous polyposis coli [MeSH:C0032580] apc tumor-suppressor gene hereditary colorectal cancer syndrome [MeSH:C0009402] familial adenomatous polyposis fap [MeSH:C0032580] apc mutation identify single-nucleotide alteration small insertion small deletion truncate protein product gene well-characterized intragenic rearrangement [MeSH:C0017287] apc describe prevalence [MeSH:C0033105] type mutation fap patient clear screen potential fap family [MeSH:C0015576] identify different germline [MeSH:C0206530] apc mutation family mutation [MeSH:C0026882] genomic rearrangement [MeSH:C0017287] [MeSH:C0017287] [MeSH:C0017287] result homologous nonhomologous recombination [MeSH:C0599773] mediate alu element rearrangement [MeSH:C0017287] complex [MeSH:C0002358] involve deletion insertion nucleotide rearrangement [MeSH:C0017287] result deletion exon [MeSH:C0015295] result complete partial deletion exon [MeSH:C0015295] fourth rearrangement [MeSH:C0017287] grossly alter sequence intron [MeSH:C0162327] rearrangement [MeSH:C0017287] affect code sequence [MeSH:C0162327] apc genomic dna cause inappropriate splicing [MeSH:C0376437] exon [MeSH:C0015295] rearrangement [MeSH:C0017287] initially reveal analyze cdna [MeSH:C0006556] identify mutation detection method screen exon [MeSH:C0015295] individually identification [MeSH:C1707660] rearrangement [MeSH:C0017287] alter code exon [MeSH:C0015295] [MeSH:C0015295] affect splicing [MeSH:C0376437] underscore importance cdna [MeSH:C0006556] mutation identification [MeSH:C1707660] genomic rearrangement [MeSH:C0017287] [MeSH:C0017287] [MeSH:C0017287] mutation suggest genomic rearrangement [MeSH:C0017287] [MeSH:C0017287] [MeSH:C0017287] frequent germline [MeSH:C0206530] apc mutation,oncological
heparin-induced thrombocytopenia [MeSH:C0040034] practical review [MeSH:C0282443],heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-induced thrombocytopenia [MeSH:C0040034] [MeSH:C0040034] hit remain under-recognized despite potentially devastating outcome [MeSH:C0206277] [MeSH:C0206277] begin heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] stimulate formation heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-platelet factor antibody turn trigger release procoagulant [MeSH:C0009117] platelet particle thrombosis [MeSH:C0040053] thrombocytopenia [MeSH:C0040034] comprise hallmark trait [MeSH:C0037401] hit largely responsible vascular complication [MeSH:C0011875] prevalence [MeSH:C0033105] hit varie subgroup great incidence [MeSH:C0021149] surgical [MeSH:C0229985] compare medical population [MeSH:C0032659] hit acknowledge intense predilection thrombosis [MeSH:C0040053] suspect thrombosis [MeSH:C0040053] occur heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] early recognition incorporate serologic [MeSH:C0036743] clue paramount timely institution [MeSH:C0442681] [MeSH:C0442681] delay catastrophic [MeSH:C0563150] outcome [MeSH:C0206277] [MeSH:C0206277] hit mandate immediate cessation heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] institution [MeSH:C0442681] [MeSH:C0442681] antithrombotic therapy commonly direct thrombin inhibitor [MeSH:C0003440] [MeSH:C0003440] current diagnostic test [MeSH:C0086143] primarily include functional [MeSH:C0031843] antigenic assay confirmatory diagnostic role management hit special attention pay cardiac patient expose heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] multiple time course direct thrombin inhibitor [MeSH:C0003440] [MeSH:C0003440] appropriate evidence-based alternative heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] patient history [MeSH:C0019664] hit need undergo percutaneous coronary intervention [MeSH:C1532338] heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] remain frequently medication [MeSH:C0033045] today potential hit heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] close vigilance platelet count practice heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] initiate,cardiovascular
improvement [MeSH:C2936612] denopamine ta- pentobarbital-induced cardiac failure dog heart-lung preparation [MeSH:C0018833],efficacy [MeSH:C5690761] denopamine [MeSH:C0075749] [MeSH:C0075749] [MeSH:C0075749] [MeSH:C0075749] orally active [MeSH:C0205681] beta -adrenoceptor agonist [MeSH:C0001645] improve cardiac [MeSH:C0018810] failure [MeSH:C0018801] assess dog [MeSH:C0012984] heart-lung preparation [MeSH:C0018833] cardiac [MeSH:C0018810] function [MeSH:C0018803] depress pentobarbital [MeSH:C0030883] mg mean sd cardiac [MeSH:C0018810] output [MeSH:C0007165] maximum rate rise leave [MeSH:C0242724] ventricular pressure lv dp dt max reduce respective control improve denopamine [MeSH:C0075749] [MeSH:C0075749] [MeSH:C0075749] [MeSH:C0075749] microgram [MeSH:C0376691] dose-dependent manner microgram [MeSH:C0376691] denopamine [MeSH:C0075749] [MeSH:C0075749] [MeSH:C0075749] [MeSH:C0075749] complete restoration [MeSH:C4505207] cardiac [MeSH:C0018810] performance attain associate slight increase heart rate [MeSH:C0018810] arrhythmia [MeSH:C0003811] induce dose denopamine [MeSH:C0075749] [MeSH:C0075749] [MeSH:C0075749] [MeSH:C0075749] result warrant trial denopamine [MeSH:C0075749] [MeSH:C0075749] [MeSH:C0075749] [MeSH:C0075749] cardiac [MeSH:C0018810] failure [MeSH:C0018801],neurological|cardiovascular
cortical [MeSH:C0222661] meet peripheral artery disease [MeSH:C1704436] neurological perspective,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome aphasia pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring tia bell palsy [MeSH:C0376175] result well quality life measure therapeutic innovation [MeSH:C0087111],neurological
minor neurological dysfunction [MeSH:C0751830] cognitive development [MeSH:C0020119] somatic development [MeSH:C0020119] age [MeSH:C0024842] year dexamethasone [MeSH:C0011777] very-low birth-weight infant [MeSH:C0282667],assess minor [MeSH:C0026193] neurological [MeSH:C0026345] dysfunction [MeSH:C0751830] cognitive development [MeSH:C0243107] [MeSH:C0020119] [MeSH:C0020119] somatic development [MeSH:C0243107] [MeSH:C0020119] dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] therapy [MeSH:C0011777] very-low-birthweight infant [MeSH:C0282667] thirty-three child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] match child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] assess age year dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] start 7th 8th life day total dose mg kg exclusion criterion asphyxia malformation major surgical intervention small gestational [MeSH:C0021296] age intraventricular haemorrhage grade [MeSH:C4505184] iii iv periventricular leukomalacia [MeSH:C0023529] severe psychomotor retardation child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] examine neuropediatrician [MeSH:C0237433] minor [MeSH:C0026193] neurological [MeSH:C0026345] dysfunction [MeSH:C0751830] test psychologist [MeSH:C0033908] cognitive development [MeSH:C0243107] [MeSH:C0020119] [MeSH:C0020119] kaufman assessment battery child [MeSH:C0008059] [MeSH:C0004842] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] draw-a-man test difference demographic growth [MeSH:C0011298] socio-economic status [MeSH:C0086996] group fine motor skill [MeSH:C0026612] gross motor function [MeSH:C0031843] significantly well p draw-a-man test show well result p difference development [MeSH:C0243107] speech [MeSH:C0037817] social development [MeSH:C0037409] [MeSH:C0243107] kaufman assessment battery child [MeSH:C0008059] [MeSH:C0004842] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] show high rate minor [MeSH:C0026193] neurological [MeSH:C0026345] dysfunction [MeSH:C0751830] neurological [MeSH:C0026345] development [MeSH:C2987126] [MeSH:C0243107] affect neurological [MeSH:C0026345] diagnosis [MeSH:C0011912] long-term [MeSH:C0023977] follow-up study [MeSH:C0016441] necessary fully evaluate [MeSH:C0013175] impact [MeSH:C5544368] dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] neurological [MeSH:C0026345] cognitive development [MeSH:C0243107] [MeSH:C0020119] [MeSH:C0020119],neurological
cancer crossroad hypertension [MeSH:C0020538],diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve bladder cancer [MeSH:C0005684] liver cancer [MeSH:C0345904] method conduct observational evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine chemotherapy [MeSH:C0013216] parameter result well quality life measure care improvement,oncological
adrenoleukodystrophy [MeSH:C0162309] increase plasma [MeSH:C0032105] content saturate long chain fatty acid [MeSH:C0015691],new measure [MeSH:C0079809] saturate long chain fatty acid [MeSH:C0015691] plasma adrenoleukodystrophy ald hemizygote [MeSH:C0314649] [MeSH:C0314649] ald heterozygote [MeSH:C0019425] control ald hemizygote [MeSH:C0314649] [MeSH:C0314649] show increase level hexacosanoate c2 fatty acid represent sem total fatty acid [MeSH:C0015684] compare control c2 c2 c2 fatty acid increase c2 c2 fatty acid normal c2 level increase ald heterozygote [MeSH:C0019425] mean total fatty acid [MeSH:C0015684] technique diagnosis [MeSH:C0011900] carrier identification therapy,neurological
oncological frontier parkinson disease [MeSH:C0030567],hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve cancer sarcoma method conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine malignant [MeSH:C0001418] parameter result positive response cost-effectiveness [MeSH:C1511536] implication,oncological
cardiomyopathy [MeSH:C0878544] tia cardiac connection,longitudinal [MeSH:C0023981] examine beta-blocker hypertension diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include atrium diastolic arterial method participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication care improvement,cardiovascular
dvt myocardial infarction vascular [MeSH:C0027051] insight,question statin affect hypertension [MeSH:C0020538] thromboembolism mechanism method [MeSH:C0040038] longitudinal adult [MeSH:C0023981] population [MeSH:C0032659] assess cardiac heart valve [MeSH:C0018826] result superior efficacy [MeSH:C5690761] implication optimization [MeSH:C0376695],cardiovascular
verapamil [MeSH:C0042523] withdrawal [MeSH:C1881606] possible cause myocardial infarction [MeSH:C0027051] hypertensive [MeSH:C0003364] woman normal coronary angiogram [MeSH:C0085532],verapamil [MeSH:C0042523] [MeSH:C0042523] effective [MeSH:C5392218] relatively-safe antihypertensive drug [MeSH:C0013227] [MeSH:C0003364] adverse effect [MeSH:C0001688] uncommon mainly related depression [MeSH:C0011570] cardiac [MeSH:C0018810] contractility conduction especially drug [MeSH:C0013227] combine beta-blocking agent report case myocardial infarction [MeSH:C0027051] coincide introduction [MeSH:C0033268] captopril [MeSH:C0006938] withdrawal [MeSH:C1881606] verapamil [MeSH:C0042523] [MeSH:C0042523] previously asymptomatic [MeSH:C2936329] woman [MeSH:C0043210] severe hypertension [MeSH:C0020538] possible mechanism [MeSH:C1524059] involve verapamil [MeSH:C0042523] [MeSH:C0042523]-related increase platelet vascular alpha -adrenoreceptor affinity [MeSH:C0001730] catecholamine [MeSH:C0007412] discuss,neurological|cardiovascular
case tardive dyskinesia [MeSH:C0686347] cause metoclopramide [MeSH:C0025853],abnormal [MeSH:C0853087] [MeSH:C0853087] involuntary [MeSH:C1267092] movement [MeSH:C0026649] appear mouth [MeSH:C0226896] tongue neck [MeSH:C0040408] abdoman -year-old male [MeSH:C0086582] take metoclopramide [MeSH:C0025853] [MeSH:C0025853] gastrointestinal disorder [MeSH:C0017178] regimen [MeSH:C1880476] mg total day symptom [MeSH:C3839861] exacerbate maximum metoclopramide [MeSH:C0025853] [MeSH:C0025853] administration [MeSH:C0001554] discontinue abnormal [MeSH:C0853087] [MeSH:C0853087] movement [MeSH:C0026649] gradually improve considerable extent attention possible induction [MeSH:C0042767] specific tardive [MeSH:C0686347] dyskinesia call use drug [MeSH:C0013227],neurological
parkinson disease [MeSH:C0030567] pattern coronary artery disease [MeSH:C1956346] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome dementia pathway method longitudinal trial cancer patient measure tremor limbic system [MeSH:C0023715] result improve outcome healthcare advancement,neurological
urea pathway [MeSH:C0282655] lung cancer [MeSH:C0242379],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve diabete outcome rcc pathway method retrospective trial cardiac patient measure chronic kidney disease [MeSH:C1561643] bun result improvement [MeSH:C2936612] primary endpoint need investigation [MeSH:C0035173],hepatorenal
continuous infusion tobramycin combine carbenicillin [MeSH:C0006976] infection cancer [MeSH:C3714514] patient [MeSH:C0030705],cure rate infection [MeSH:C3714514] cancer [MeSH:C3714514] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] adversely affect neutropenia [MeSH:C0027947] [MeSH:C0027947] mm3 particular patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe neutropenia [MeSH:C0027947] [MeSH:C0027947] mm3 show poor response [MeSH:C0034746] antibiotic [MeSH:C0003232] [MeSH:C0003232] overcome adverse effect [MeSH:C0001688] neutropenia [MeSH:C0027947] [MeSH:C0027947] tobramycin [MeSH:C0040341] give continuous [MeSH:C3649547] infusion [MeSH:C0841792] combine intermittent [MeSH:C4704881] carbenicillin [MeSH:C0006976] [MeSH:C0006976] tobramycin [MeSH:C0040341] give total daily dose mg m2 carbenicillin [MeSH:C0006976] [MeSH:C0006976] give dose gm hour infectious episode [MeSH:C0085554] cancer patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive myelosuppressive chemotherapy [MeSH:C0039798] overall cure rate pneumonia [MeSH:C0032285] common infection [MeSH:C3714514] episode [MeSH:C0085554] cure gram-negative [MeSH:C0018150] bacillus [MeSH:C0018150] common causative organism infection [MeSH:C3714514] cure common pathogen [MeSH:C0699748] klebsiella pneumoniae [MeSH:C0001699] escherichia coli pseudomona aeruginosa [MeSH:C0033809] account gram-negative [MeSH:C0018150] bacillary infection [MeSH:C0085389] [MeSH:C3714514] response [MeSH:C0034746] influence [MeSH:C0683549] initial neutrophil count [MeSH:C0027950] [MeSH:C0027950] cure rate episode [MeSH:C0085554] [MeSH:C0085554] associate severe neutropenia [MeSH:C0027947] [MeSH:C0027947] failure neutrophil count [MeSH:C0027950] [MeSH:C0027950] increase therapy [MeSH:C0039798] adversely affect response [MeSH:C0034746] azotemia [MeSH:C0242528] [MeSH:C0242528] [MeSH:C0242528] major effect recognize occur episode [MeSH:C0085554] major azotemia [MeSH:C0242528] [MeSH:C0242528] [MeSH:C0242528] serum creatinine [MeSH:C0010294] great mg dl bun great mg dl occur azotemia [MeSH:C0242528] [MeSH:C0242528] [MeSH:C0242528] related duration therapy [MeSH:C0444921] [MeSH:C0039798] serum tobramycin [MeSH:C0040341] concentration antibiotic [MeSH:C0003232] [MeSH:C0003232] regiman show therapeutic efficacy [MeSH:C0087111] acceptable renal [MeSH:C0152169] toxicity [MeSH:C0040539] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],neurological|hepatorenal|oncological
venous lymphoma [MeSH:C0024299] vascular [MeSH:C0221214] insight,heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve myocardial infarction pad method [MeSH:C0027051] conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine pacemaker [MeSH:C3494452] parameter result decrease mortality rate [MeSH:C0205848] healthcare advancement,cardiovascular
midazolam [MeSH:C0026056] compare thiopentone induction agent,patient premedicate [MeSH:C0033045] scopolamine [MeSH:C0036442] morphine [MeSH:C0026549] mg nitrazepam [MeSH:C0028126] evening surgery [MeSH:C0038895] sleep-inducing effect midazolam [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] mg kg v clearly slow onset thiopentone [MeSH:C0039925] [MeSH:C0039925] mg kg v somewhat few cardiovascular [MeSH:C0007220] local sequela find midazolam [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] apnoea occur midazolam [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] last long difference [MeSH:C0036866] midazolam [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] thiopentone [MeSH:C0039925] [MeSH:C0039925] apparent consequence midazolam [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] new alternative agent induction [MeSH:C0042767] combination anaesthesia,cardiovascular
preservation [MeSH:C0242500] renal blood flow hypotension [MeSH:C0020649] induce fenoldopam dog [MeSH:C0060180],introduction drug [MeSH:C0013227] [MeSH:C0029308] induce hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] different pharmacological action [MeSH:C0600511] advantageous effect unique specific drug [MeSH:C0013227] minimize select appropriate therapy [MeSH:C0039798] specific dopamine- da1 dopamine- da2 receptor agonist investigation [MeSH:C0035173] fenoldopam [MeSH:C0060180] [MeSH:C0060180] mesylate [MeSH:C0025619] specific da1 receptor agonist lower blood pressure vasodilatation hypothesis fenoldopam [MeSH:C0060180] [MeSH:C0060180] induce hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] preserve blood flow kidney [MeSH:C0005775] [MeSH:C0022646] test systemic aortic blood pressure renal blood flow [MeSH:C1527409] [MeSH:C0456180] measure continuously carotid arterial catheter electromagnetic flow probe respectively order compare cardiovascular renal vascular effect [MeSH:C0596270] fenoldopam [MeSH:C0060180] [MeSH:C0060180] sodium nitroprusside [MeSH:C0037533] [MeSH:C0037533] dog halothane [MeSH:C0018549] general anaesthesia [MeSH:C0002915] mean arterial pressure [MeSH:C1272641] decrease cent infusion [MeSH:C0841792] [MeSH:C0841792] fenoldopam [MeSH:C0060180] [MeSH:C0060180] microgram [MeSH:C0376691] [MeSH:C0376691] kg- min- cent infusion [MeSH:C0841792] [MeSH:C0841792] sodium nitroprusside [MeSH:C0037533] [MeSH:C0037533] microgram [MeSH:C0376691] [MeSH:C0376691] kg- min- ns renal blood flow [MeSH:C1527409] rbf [MeSH:C0206089] increase fenoldopam [MeSH:C0060180] [MeSH:C0060180]-induced hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] cent decrease cent sodium nitroprusside [MeSH:C0037533] [MeSH:C0037533]-induced hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] p sodium nitroprusside [MeSH:C0037533] [MeSH:C0037533] non-selective arteriolar venous vasodilator produce redistribution blood flow away kidney [MeSH:C0022646] induce hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] fenoldopam [MeSH:C0060180] [MeSH:C0060180] selective dopamine- da1 receptor agonist cause vasodilatation kidney [MeSH:C0022646] organ da1 receptor preserve blood flow kidney [MeSH:C0005775] [MeSH:C0022646] induce hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649],neurological|cardiovascular|hepatorenal
blockade [MeSH:C0027741] endothelial-mesenchymal transition [MeSH:C1523298] smad3 [MeSH:C0529120] inhibitor [MeSH:C0003015] delay early development streptozotocin-induced diabetic nephropathy,multicenter controlled trial show early blockade [MeSH:C0027741] [MeSH:C0027741] renin-angiotensin system [MeSH:C0035096] patient type diabete [MeSH:C0007080] normoalbuminuria retard progression [MeSH:C0242656] nephropathy suggest mechanism [MeSH:C1524059] involve pathogenesis [MeSH:C0699748] early diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] previously demonstrate endothelial-mesenchymal-transition endomt contribute early development [MeSH:C0020119] [MeSH:C0020119] renal [MeSH:C0152169] interstitial fibrosis independently microalbuminuria [MeSH:C0001925] mouse [MeSH:C0026809] streptozotocin [MeSH:C0038432] stz -induced diabete [MeSH:C0007080] present hypothesize block endomt reduce early development [MeSH:C0020119] [MeSH:C0020119] diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] design method endomt induce mouse [MeSH:C0026809] pancreatic [MeSH:C0030304] microvascular endothelial cell line mmec presence advanced glycation end product age [MeSH:C0024842] [MeSH:C0024842] endothelial lineage [MeSH:C0024842] [MeSH:C0024842]-traceble mouse [MeSH:C0026809] line tie2-cre loxp-egfp administration age [MeSH:C0024842] [MeSH:C0024842] nonglycated mouse [MeSH:C0026809] albumin serve phosphorylated [MeSH:C0031715] smad3 [MeSH:C0529120] [MeSH:C0529120] [MeSH:C0529120] detect immunoprecipitation [MeSH:C0021069] western blotting confocal microscopy [MeSH:C0242842] blocking study receptor age [MeSH:C0024842] [MeSH:C0024842] sirna [MeSH:C1099354] specific inhibit [MeSH:C0021463]or [MeSH:C0003015] smad3 [MeSH:C0529120] [MeSH:C0529120] [MeSH:C0529120] sis3 perform mmec stz-induced diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] tie2-cre loxp-egfp mouse [MeSH:C0026809] result confocal microscopy real-time pcr [MeSH:C0242842] demonstrate age [MeSH:C0024842] [MeSH:C0024842] induce endomt mmec tie2-cre loxp-egfp mouse [MeSH:C0026809] immunoprecipitation [MeSH:C0021069] western blotting show smad3 [MeSH:C0529120] [MeSH:C0529120] [MeSH:C0529120] activate age [MeSH:C0024842] [MeSH:C0024842] inhibit [MeSH:C0021463] sis3 mmec stz-induced diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] confocal microscopy real-time pcr [MeSH:C0242842] demonstrate sis3 abrogate endomt reduce renal [MeSH:C0152169] fibrosis retard progression [MeSH:C0242656] nephropathy conclusion endomt novel pathway [MeSH:C0282655] lead early development [MeSH:C0020119] [MeSH:C0020119] diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] blockade [MeSH:C0027741] [MeSH:C0027741] endomt sis3 provide new strategy retard progression [MeSH:C0242656] diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] diabete [MeSH:C0007080] complication [MeSH:C1171258],hepatorenal
end stage renal disease pathway prostate cancer [MeSH:C0376358],question statin affect dementia [MeSH:C0497327] cholelithiasis [MeSH:C0008350] mechanism method retrospective cancer patient [MeSH:C0030705] assess hepatitis liver [MeSH:C0019158] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication safety [MeSH:C0036043] consideration,hepatorenal
hepatic [MeSH:C0227525] extrahepatic [MeSH:C0227525] angiotensinogen gene expression rat [MeSH:C0034721] acute nephrotic syndrome [MeSH:C0027726],plasma [MeSH:C0032105] concentrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0311432] urine [MeSH:C0042036] excretion [MeSH:C1373187] [MeSH:C1373187] renin-angiotensin system protein [MeSH:C0035096] alter rat [MeSH:C0034721] [MeSH:C0034721] nephrotic [MeSH:C0027726] syndrome [MeSH:C0027726] ns work messenger ribonucleic acid mrna [MeSH:C0035696] [MeSH:C0035696] [MeSH:C0035668] level [MeSH:C0018759] [MeSH:C0018759] angiotensinogen [MeSH:C0003017] ao analyze slot-blot hybridization technique liver [MeSH:C0023884] extrahepatic [MeSH:C0227525] tissue kidney heart brain adrenal gland [MeSH:C0001625] nephrotic [MeSH:C0027726] pair-fed pf rat [MeSH:C0034721] [MeSH:C0034721] ns induce single injection [MeSH:C1828121] puromycin amino-nucleoside pan great urinary excretion [MeSH:C1373187] [MeSH:C1373187] half-normal plasma [MeSH:C0032105] level [MeSH:C0018759] [MeSH:C0018759] ao observe pan injection [MeSH:C1828121] [MeSH:C1828121] ns clearly establish hepatic [MeSH:C0227525] ao mrna [MeSH:C0035696] [MeSH:C0035696] level [MeSH:C0018759] [MeSH:C0018759] furthermore ao mrna [MeSH:C0035696] [MeSH:C0035696] level [MeSH:C0018759] [MeSH:C0018759] extrahepatic [MeSH:C0227525] tissue study hepatic [MeSH:C0227525] level [MeSH:C0018759] [MeSH:C0018759] day pan injection [MeSH:C1828121] [MeSH:C1828121] suggest hepatic [MeSH:C0227525] extrahepatic [MeSH:C0227525] ao mrna [MeSH:C0035696] [MeSH:C0035696] level [MeSH:C0018759] [MeSH:C0018759] unaltered development [MeSH:C0020119] acute [MeSH:C0184567] ns induce pan,neurological|cardiovascular|hepatorenal
renal function [MeSH:C0031843] hemodynamic [MeSH:C0019010] prolonged isoflurane-induced hypotension [MeSH:C0020650] human [MeSH:C0086418],effect isoflurane [MeSH:C0022180]-induced hypotension [MeSH:C0020649] [MeSH:C0020649] glomerular function renal [MeSH:C0152169] [MeSH:C0152169] blood flow investigate [MeSH:C0035173] human subject glomerular filtration rate [MeSH:C0017654] gfr effective renal [MeSH:C0152169] [MeSH:C0152169] plasma flow erpf measure inulin [MeSH:C0021936] para-aminohippurate pah [MeSH:C0700551] clearance [MeSH:C5243473] respectively anesthesia [MeSH:C0002903] maintain fentanyl nitrous oxide [MeSH:C0028215] oxygen isoflurane [MeSH:C0022180] hypotension [MeSH:C0020649] [MeSH:C0020649] induce min increase isoflurane [MeSH:C0022180] inspire concentration [MeSH:C0311432] maintain mean arterial pressure mmhg gfr erpf [MeSH:C0206088] decrease induction anesthesia [MeSH:C0002911] [MeSH:C0002903] significantly hypotension [MeSH:C0020649] [MeSH:C0020649] postoperatively erpf return preoperative [MeSH:C0033061] value gfr high preoperative [MeSH:C0033061] value renal [MeSH:C0152169] [MeSH:C0152169] vascular resistance [MeSH:C0042380] increase anesthesia [MeSH:C0002903] decrease hypotension [MeSH:C0020649] [MeSH:C0020649] induce allow maintenance renal [MeSH:C0152169] [MeSH:C0152169] blood flow conclude renal [MeSH:C0152169] [MeSH:C0152169] compensatory mechanism preserve isoflurane [MeSH:C0022180]-induced hypotension [MeSH:C0020649] [MeSH:C0020649] renal [MeSH:C0152169] [MeSH:C0152169] function hemodynamic [MeSH:C0019010] quickly return normal normotension resume,neurological|hepatorenal
immunotherapy [MeSH:C0021083] parkinson disease [MeSH:C0030567] brain [MeSH:C0006104] insight,question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] brain [MeSH:C0006104] mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess neural peripheral neuropathy [MeSH:C4721453] result positive response implication care improvement,neurological
jaundice [MeSH:C0022346] pattern ventricular tachycardia [MeSH:C0042514] patient [MeSH:C0030705],longitudinal examine [MeSH:C0023981] statin [MeSH:C0360714] diabete elderly patient investigation [MeSH:C0035173] include cognitive impairment [MeSH:C0338656] bun wilms tumor method [MeSH:C0027708] participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication healthcare advancement,neurological|hepatorenal
ultrasound [MeSH:C0220934] reveal valvular heart disease [MeSH:C0018824] secret,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome migraine pathway method observational trial [MeSH:C0302523] cardiac patient measure endocardium [MeSH:C0014124] tia result decrease mortality rate [MeSH:C0205848] therapeutic [MeSH:C0087111] innovation,neurological|cardiovascular
hepatotoxicity [MeSH:C0235280] associate [MeSH:C0004083] sulfasalazine [MeSH:C0036078] inflammatory arthritis case series local surveillance adverse event,spontaneous [MeSH:C0000786] reporting system adverse drug reaction [MeSH:C0041755] adrs handicap under-reporting limited detail individual case report [MeSH:C0684224] investigation [MeSH:C0035173] local surveillance [MeSH:C0700325] adverse drug reaction [MeSH:C0041755] associate disease modify anti-rheumatic drug [MeSH:C0003191] trigger occurrence liver failure [MeSH:C0085605] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method [MeSH:C0030705] adr report solicit local clinician [MeSH:C0028654] regular postcard past seven year patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] sulfasalazine [MeSH:C0036078] [MeSH:C0036078] [MeSH:C0036078] [MeSH:C0036078] meet definition adr identify clinician [MeSH:C0028654] review structured case report [MeSH:C0684224] assess causality consensus causality assessment instrument [MeSH:C0011377] likely frequency [MeSH:C0376249] [MeSH:C0376249] hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] sulfasalazine [MeSH:C0036078] [MeSH:C0036078] [MeSH:C0036078] [MeSH:C0036078] estimate make series conservative assumption result case identify occur surveillance patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0700325] [MeSH:C0030705] hospitalise hepatic failure [MeSH:C0085605] die liver transplant [MeSH:C0023911] event occur week seven patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] skin rash eosinophilia [MeSH:C0014457] interstitial nephritis [MeSH:C0027707] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] black british african caribbean descent liver enzyme show hepatocellular pattern case mixed pattern drug-related hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] judge probable highly probable patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] likely frequency [MeSH:C0376249] [MeSH:C0376249] hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] sulfasalazine [MeSH:C0036078] [MeSH:C0036078] [MeSH:C0036078] [MeSH:C0036078] estimate treat patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] associate sulfasalazine [MeSH:C0036078] [MeSH:C0036078] [MeSH:C0036078] [MeSH:C0036078] appear under-appreciated intensive monitoring vigilance week especially important,neurological|hepatorenal
synaptic story heart failure encephalopathy,question statin affect cancer pituitary adenoma [MeSH:C0032000] mechanism method retrospective cancer patient assess aphasia huntington disease [MeSH:C0020179] result positive response implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
continuous [MeSH:C3649547] subcutaneous administration mesna [MeSH:C0000294] prevent [MeSH:C0000918] ifosfamide-induced hemorrhagic cystitis,hemorrhagic cystitis [MeSH:C0267940] major potential toxicity [MeSH:C0040539] ifosfamide [MeSH:C0020823] [MeSH:C0020823] prevent [MeSH:C0000918] administer mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] cytotoxic agent [MeSH:C0010868] mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] generally administer intravenous route experience oral [MeSH:C0029170] delivery drug increase continuous subcutaneous [MeSH:C0222331] administration mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] advantage require intravenous access addition subcutaneous [MeSH:C0222331] delivery [MeSH:C0222331] neutralize agent associate [MeSH:C0004083] risk inadequate urinary mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] concentration [MeSH:C0311432] take oral [MeSH:C0029170] mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] experience severe ifosfamide [MeSH:C0020823] [MeSH:C0020823]-induced emesis unable absorb drug limited experience continuous subcutaneous [MeSH:C0222331] mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] administration suggest safe practical economic [MeSH:C0205749] drug delivery [MeSH:C0085104] permit ifosfamide [MeSH:C0020823] [MeSH:C0020823] administer successfully outpatient setting [MeSH:C0029921],hepatorenal
penicillamine-induced rapidly progressive [MeSH:C1449744] glomerulonephritis rheumatoid arthritis [MeSH:C0003873],-year-old woman [MeSH:C0043210] rheumatoid arthritis [MeSH:C0003873] present rapidly progressive [MeSH:C1449744] glomerulonephritis [MeSH:C0017658] rpgn month d-penicillamine [MeSH:C0030817] [MeSH:C0030817] [MeSH:C0030817] mg light microscopy [MeSH:C0430389] show severe [MeSH:C1719672] glomerulonephritis [MeSH:C0017658] crescent formation glomerulus infiltration inflammatory cell wall arteriole immunofluorescence reveal scanty granular [MeSH:C4552086] igg iga c3 deposit capillary wall mesangium treat steroid [MeSH:C0038317] pulse plasmapheresis cyclophosphamide antiplatelet agent [MeSH:C0085826] complete recovery renal function [MeSH:C0031843] [MeSH:C0031843] achieve week new case rpgn course d-penicillamine [MeSH:C0030817] [MeSH:C0030817] [MeSH:C0030817] emphasize need frequent monitoring [MeSH:C0005517] renal function [MeSH:C0031843] [MeSH:C0031843] urinary sediment proteinuria patient [MeSH:C0030705] prompt discontinuation d-penicillamine [MeSH:C0030817] [MeSH:C0030817] [MeSH:C0030817] vigorous measure [MeSH:C0079809] allow good prognosis [MeSH:C0033325] case,hepatorenal
epilepsy [MeSH:C0014544] esrd [MeSH:C0022661] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] ckd pathway method retrospective trial elderly patient measure alkaline phosphatase [MeSH:C0002059] peritoneal dialysis [MeSH:C0031139] result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],hepatorenal
revolutionary ultrasound chronic kidney disease diagnosis [MeSH:C0011900],design [MeSH:C0013171] cross-sectional investigation beta-blocker [MeSH:C0001645] dementia participant [MeSH:C1708335] cancer patient myelodysplastic syndrome sarcoma [MeSH:C3463824] result enhance therapeutic response [MeSH:C0087111] oncogene [MeSH:C0029016] correlation relevance [MeSH:C2826293],hepatorenal|oncological
atherosclerosis [MeSH:C0004153] connection [MeSH:C0056248] diabetes mellitus [MeSH:C0011849],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] limbic system pathway [MeSH:C0023715] method retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring delirium hypotensive result improvement primary endpoint therapeutic innovation [MeSH:C0087111],neurological|cardiovascular
epilepsy [MeSH:C0014544] acetylcholine [MeSH:C0001041] exploring neural pathway [MeSH:C0027792],hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve bell palsy trigeminal neuralgia method [MeSH:C0040997] conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examining synapse [MeSH:C0039062] parameter result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],neurological
dementia [MeSH:C0497327] venous cardiac connection,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome [MeSH:C0206277] ectopic beat pathway method prospective trial cardiac patient measure premature beat smooth muscle [MeSH:C1267092] result positive response safety consideration,cardiovascular
von hippel-lindau [MeSH:C0019562] tumor suppressor gene [MeSH:C0079427] require cell cycle exit [MeSH:C0007586] serum [MeSH:C0229671] withdrawal,inactivation [MeSH:C0043297] von hippel-lindau [MeSH:C0019562] vhl [MeSH:C0299505] [MeSH:C0299505] tumor suppress [MeSH:C0017372]or gene [MeSH:C1566585] predispose affect individual human [MeSH:C0086418] vhl [MeSH:C0299505] [MeSH:C0299505] cancer syndrome [MeSH:C0019562] associate sporadic renal cell carcinoma [MeSH:C0007134] rcc brain hemangioblastoma [MeSH:C0206734] vhl [MeSH:C0299505] [MeSH:C0299505]-negative rcc cell tumorigenic [MeSH:C0596263] nude mouse suppress [MeSH:C0017372] reintroduction [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] vhl [MeSH:C0299505] [MeSH:C0299505] remarkably occur affect growth rate cell cycle [MeSH:C0007586] [MeSH:C0007586] [MeSH:C0007586] profile cell culture cell line [MeSH:C0007585] like cancer cell [MeSH:C0656937] fail exit cell cycle [MeSH:C0007586] [MeSH:C0007586] [MeSH:C0007586] serum [MeSH:C0229671] withdrawal show reintroduction [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] wild-type vhl [MeSH:C0299505] [MeSH:C0299505] gene restore ability vhl [MeSH:C0299505] [MeSH:C0299505]-negative rcc cancer cell [MeSH:C0656937] exit cell cycle [MeSH:C0007586] [MeSH:C0007586] [MeSH:C0007586] enter g0 quiescence low serum [MeSH:C0229671] vhl [MeSH:C0299505] [MeSH:C0299505]-positive vhl [MeSH:C0299505] [MeSH:C0299505]-negative rcc cell exit cell cycle [MeSH:C0007586] [MeSH:C0007586] [MeSH:C0007586] contact inhibition [MeSH:C0027790] cyclin-dependent kinase inhibitor [MeSH:C0919418] p2 accumulate serum [MeSH:C0229671] withdrawal presence vhl [MeSH:C0299505] [MeSH:C0299505] stabilization protein propose loss wild-type vhl [MeSH:C0299505] [MeSH:C0299505] gene result specific cellular defect serum [MeSH:C0229671]-dependent growth initiate tumor formation correct reintroduction [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] wild-type vhl [MeSH:C0299505] [MeSH:C0299505] implicate vhl [MeSH:C0299505] [MeSH:C0299505] tumor suppress [MeSH:C0017372]or involve regulation cell cycle [MeSH:C0243021] [MeSH:C0007586] [MeSH:C0007586] [MeSH:C0007586] exit consistent gatekeeper function kidney,neurological|hepatorenal|oncological
synaptic plasticity [MeSH:C0027880] parkinson disease [MeSH:C0030567],longitudinal [MeSH:C0023981] examine calcium channel blocker cancer [MeSH:C0006684] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include hypothalamus [MeSH:C0020663] neurodegenerative acetylcholine method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication optimization [MeSH:C0376695],neurological
mind matter coronary artery disease myelopathy [MeSH:C1956346],design [MeSH:C0013171] cross-sectional investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] tic cerebellar [MeSH:C0007765] result improvement primary endpoint cerebrospinal fluid [MeSH:C0007806] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
reversible [MeSH:C5691430] cerebral lesion associate tiazofurin usage mr demonstration,tiazofurin [MeSH:C0076656] experimental [MeSH:C0016998] chemotherapeutic agent [MeSH:C0003392] currently undergo report result magnetic resonance mr [MeSH:C0013845] demonstrate reversible [MeSH:C5691430] cerebral abnormality [MeSH:C0037268] concurrent use drug abnormality mr correlate finding ct cerebral angiography [MeSH:C0007767] utility mr patient [MeSH:C0030705] receive new agent illustrate,neurological|oncological
anaesthetic complication associate myotonia congenita [MeSH:C0027127] case comparison [MeSH:C0007328] myotonic disorder [MeSH:C0553604],myotonia [MeSH:C0700153] congenita mc cause [MeSH:C0027127] defect [MeSH:C0155017] skeletal muscle [MeSH:C0242692] chloride channel function [MeSH:C0055363] cause sustained membrane depolarisation describe previously healthy [MeSH:C0452415] -year-old woman [MeSH:C0043210] develop life-threatening [MeSH:C4303743] muscle spasm [MeSH:C0037763] [MeSH:C0037763] secondary ventilation difficulty follow preoperative [MeSH:C0033061] injection [MeSH:C1828121] suxamethonium muscle spasm [MeSH:C0037763] [MeSH:C0037763] disappear spontaneously surgery proceed problem [MeSH:C0037431] subsequently question report minor symptom [MeSH:C3839861] suggest myotonic condition myotonia [MeSH:C0700153] find examination [MeSH:C0376306] emg diagnosis [MeSH:C0011900] [MeSH:C0011900] mc confirm genetically anaesthetist aware diagnosis [MeSH:C0011900] [MeSH:C0011900] potentially lethal complication [MeSH:C1171258] occur brief overview ion channel disorder include malignant hyperthermia [MeSH:C0024591] anaesthetic [MeSH:C0002932] consideration,neurological
dialysis pattern cancer patient [MeSH:C0030705],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve diabete outcome [MeSH:C0206277] nephrotic syndrome pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure oligodendroglioma [MeSH:C0028945] dementia [MeSH:C0497327] result favorable safety [MeSH:C0036043] profile cost-effectiveness [MeSH:C1511536] implication,neurological|hepatorenal
malignant neoplasm family [MeSH:C0006826] patient ataxia-telangiectasia,ataxia-telangiectasia a-t autosomal recessive syndrome associate greatly increase incidence [MeSH:C0021149] [MeSH:C0021149] malignant neoplasm [MeSH:C0006826] [MeSH:C0006826] [MeSH:C0006826] homozygous [MeSH:C0019904] affect individual [MeSH:C0021228] heterozygote [MeSH:C0019425] [MeSH:C0019425] gene [MeSH:C0017337] [MeSH:C0019425] a-t think comprise gene [MeSH:C0017337]ral population [MeSH:C0032659] important know gene [MeSH:C0017337] predispose heterozygous carrier cancer heterozygous carrier gene [MeSH:C0017337] common close relative patient [MeSH:C0030705] a-t individual [MeSH:C0021228] carrier identify criterion [MeSH:C0243161] laboratory test [MeSH:C0022877] reason compare incidence [MeSH:C0021149] [MeSH:C0021149] death malignant neoplasm [MeSH:C0006826] [MeSH:C0006826] [MeSH:C0006826] family patient [MeSH:C0030705] a-t expect random sample gene [MeSH:C0017337]ral population [MeSH:C0032659] death malignant neoplasm [MeSH:C0006826] [MeSH:C0006826] [MeSH:C0006826] relative die age [MeSH:C0024842] compare expect p a-t heterozygote [MeSH:C0019425] [MeSH:C0019425] young [MeSH:C0340037] age [MeSH:C0024842] risk [MeSH:C0035647] die malignant neoplasm [MeSH:C0006826] [MeSH:C0006826] [MeSH:C0006826] estimate great time risk [MeSH:C0035647] gene [MeSH:C0017337]ral population [MeSH:C0032659] a-t heterozygote [MeSH:C0019425] [MeSH:C0019425] comprise person [MeSH:C0027361] die cancer age [MeSH:C0024842] incidence [MeSH:C0021149] [MeSH:C0021149] ovarian gastric biliary system carcinoma leukemia lymphoma increase a-t family neoplasm associate gene [MeSH:C0017337] heterozygote [MeSH:C0019425] [MeSH:C0019425] include pancreatic [MeSH:C0030304] basal cell [MeSH:C0205646] colonic breast cervical carcinoma [MeSH:C0678222],neurological|hepatorenal|oncological
constitutional mutation wt1 gene patient denys-drash syndrome [MeSH:C0950121],denys-drash syndrome [MeSH:C0950121] characterise typical nephropathy [MeSH:C0017661] genital abnormality [MeSH:C0000768] predispose development [MeSH:C0243107] [MeSH:C0243107] wilms tumor [MeSH:C0027708] patient [MeSH:C0030705] [MeSH:C0030705] eventually end stage renal failure [MeSH:C0022661] candidate wilm tumor gene wt1 1p1 chromosome region recently clone [MeSH:C0009013] analyse dna sequence [MeSH:C0162326] constitutional cell [MeSH:C0442681] patient [MeSH:C0030705] [MeSH:C0030705] show heterozygous [MeSH:C0019425] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] exon result missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] nucleotide position [MeSH:C0599155] result arg trp amino acid position convert asp asn predict resultant protein missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] exon convert [MeSH:C0599155] arg single base pair insertion nucleotide position exon result generation premature stop [MeSH:C0242612] codon unable find mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] despite complete sequencing [MeSH:C3640076] genomic sequence gene carry constitutional deletion 1p1 region additional mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find obvious correlation [MeSH:C0010100] type mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] phenotypic [MeSH:C1837514] expression result demonstrate wt1 gene [MeSH:C0949489] important development [MeSH:C0243107] [MeSH:C0243107] kidney [MeSH:C0022646] genito-urinary system [MeSH:C0042066],neurological|hepatorenal|oncological
hypertension [MeSH:C0020538] encephalopathy [MeSH:C0085584] explore neural pathway [MeSH:C0027792],investigate [MeSH:C0035173] beta-blocker effect cancer tia method [MeSH:C0025663] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo randomized control [MeSH:C1096777] serotonin palsy [MeSH:C0522224] assessment [MeSH:C0030198] result well quality life measure relevance [MeSH:C2826293],neurological
possible teratogenicity sulphasalazine [MeSH:C0036078],infant [MeSH:C0021270] [MeSH:C0021270] bear mother [MeSH:C0026591] [MeSH:C0026591] inflammatory bowel disease [MeSH:C0021390] receive sulphasalazine [MeSH:C0036078] [MeSH:C0036078] pregnancy [MeSH:C0032961] find major congenital anomaly [MeSH:C0009678] singleton pregnancy [MeSH:C0032961] mother [MeSH:C0026591] [MeSH:C0026591] ulcerative [MeSH:C0009324] colitis [MeSH:C0009319] infant [MeSH:C0021270] [MeSH:C0021270] male [MeSH:C0086582] coarctation aorta [MeSH:C0003483] ventricular septal defect [MeSH:C0018818] twin pregnancy [MeSH:C0152150] [MeSH:C0032961] mother [MeSH:C0026591] [MeSH:C0026591] crohn disease [MeSH:C0010346] twin female [MeSH:C0086582] left potter-type iia polycystic kidney [MeSH:C0022680] rudimentary leave uterine cornu [MeSH:C0227814] second twin male [MeSH:C0086582] feature potter facie hypoplastic lung absent kidney ureter talipe equinovarus despite report [MeSH:C0684224] contrary suggest sulphasalazine [MeSH:C0036078] [MeSH:C0036078] teratogenic [MeSH:C0039536],hepatorenal
hypertension [MeSH:C0020538] tubule [MeSH:C0041348] organ [MeSH:C0029250] interplay,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve liver transplant [MeSH:C0023911] creatinine method conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine glomerular filtration rate [MeSH:C0017654] parameter result improvement [MeSH:C2936612] primary endpoint practice guideline,hepatorenal
high-dose methylprednisolone [MeSH:C0025815] harm spinal cord injury [MeSH:C0037929],national acute spinal cord injury [MeSH:C0037929] [MeSH:C0037929] [MeSH:C0037929] study [MeSH:C0085973] nascis high-dose methylprednisolone [MeSH:C0025815] [MeSH:C0025815] [MeSH:C0025815] standard care acute spinal cord injury [MeSH:C0037929] [MeSH:C0037929] nascis mention possibility acute corticosteroid [MeSH:C0038317] myopathy high-dose methylprednisolone [MeSH:C0025815] [MeSH:C0025815] [MeSH:C0025815] cause dosage methylprednisolone [MeSH:C0025815] [MeSH:C0025815] [MeSH:C0025815] [MeSH:C0025815] recommend nascis high dose steroid [MeSH:C0038317] -day period condition hypothesize cause damage muscle spinal cord injury [MeSH:C0037929] [MeSH:C0037929] patient [MeSH:C0030705] steroid [MeSH:C0038317] myopathy recover naturally neurological improvement show nascis recording natural motor recovery steroid [MeSH:C0038317] myopathy instead protection [MeSH:C0524828] methylprednisolone [MeSH:C0025815] [MeSH:C0025815] [MeSH:C0025815] offer spinal cord injury [MeSH:C0037929] [MeSH:C0037929] knowledge discussion [MeSH:C0376554] consider possibility methylprednisolone [MeSH:C0025815] [MeSH:C0025815] [MeSH:C0025815] recommend nascis cause acute corticosteroid [MeSH:C0038317] myopathy,neurological
incidence [MeSH:C0021149] contrast-induced nephropathy hospitalised [MeSH:C0600620] patient cancer [MeSH:C0030705],objective determine frequency [MeSH:C0376249] possible factor [MeSH:C0033453] related contrast-induced nephropathy cin hospitalised [MeSH:C0600620] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cancer [MeSH:C0030705] method ninety adult [MeSH:C0001675] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] enrol patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0033453] acute renal failure exclude blood sample [MeSH:C0005767] examine contrast-enhanced compute tomography ct serially day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] cin define increase serum creatinine cr [MeSH:C0010294] mg dl elevation cr relationship [MeSH:C0021797] cin possible risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0033453] investigate [MeSH:C0035173] result cin detect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cin develop patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] p cin frequently develop patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo ct day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] p independent risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0033453] p cin significantly bevacizumab [MeSH:C0796392] [MeSH:C0796392] [MeSH:C0796392] irinotecan [MeSH:C0123931] [MeSH:C0123931] p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hypertension p conclusion incidence [MeSH:C0021149] cin ct hospitalise oncological patient [MeSH:C0596240] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cin develop -times frequently patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cancer [MeSH:C0030705] undergo recent chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] hypertension combination [MeSH:C0034865] bevacizumab [MeSH:C0796392] [MeSH:C0796392] [MeSH:C0796392] irinotecan [MeSH:C0123931] [MeSH:C0123931] additional risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0033453] cin development [MeSH:C0243107] key point contrast-induced nephropathy cin concern oncological patient [MeSH:C0596240] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo ct cin occur ct perform day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] hypertension bevacizumab [MeSH:C0796392] [MeSH:C0796392] [MeSH:C0796392] appear additional risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0033453],cardiovascular|hepatorenal|oncological
brain map [MeSH:C0006104] coronary artery disease [MeSH:C1956346] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect heart disease convulsion method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo prospective amyotrophic lateral sclerosis aphasia [MeSH:C0002736] assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] safety [MeSH:C0036043] consideration,neurological
lymphoma sinoatrial node cardiac connection,investigate [MeSH:C0035173] beta-blocker effect cancer prolapse method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo retrospective [MeSH:C0035363] pulmonary embolism [MeSH:C0034065] hypertensive [MeSH:C0003364] assessment result well quality life measure practice guideline,cardiovascular
etiology [MeSH:C0015127] hypercalcemia [MeSH:C0020437] hemodialysis [MeSH:C0019004] patient [MeSH:C0030705] calcium carbonate therapy [MeSH:C0006681],fourteen dialysis [MeSH:C0011945] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hypercalcemic [MeSH:C0020437] [MeSH:C0020437] [MeSH:C0020437] switch calcium [MeSH:C0006675] carbonate [MeSH:C0006681] principal phosphate binder [MeSH:C0031603] order identify risk factor [MeSH:C0035648] associate development [MeSH:C0020119] hypercalcemia [MeSH:C0020437] indirect [MeSH:C0006781] parameter intestinal [MeSH:C0021853] calcium [MeSH:C0006675] reabsorption bone [MeSH:C0262950] [MeSH:C2610986] turnover [MeSH:C0085268] rate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] compare result eucalcemic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] match age sex [MeSH:C1522384] length dialysis [MeSH:C0011945] etiology renal disease addition experience hypercalcemic [MeSH:C0020437] [MeSH:C0020437] [MeSH:C0020437] episode peak calcium [MeSH:C0006675] value mmol l mg dl patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hypercalcemic [MeSH:C0020437] [MeSH:C0020437] [MeSH:C0020437] exhibit increase mean calcium [MeSH:C0006675] concentration obtain month switch compare mean obtain month observation [MeSH:C0302523] switch mmol l mg dl p contrast eucalcemic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] exhibit mean calcium [MeSH:C0006675] value period mmol l mg dl caco3 dosage calculate dietary [MeSH:C0012177] calcium [MeSH:C0006675] intake circulating level vitamin metabolite similar group [MeSH:C0018257] physical activity index [MeSH:C0015259] predialysis [MeSH:C0011945] serum bicarbonate level similar group [MeSH:C0018257] difference parameter reflect bone [MeSH:C0262950] turnover [MeSH:C0085268] rate group [MeSH:C0034510] [MeSH:C0018257] abstract [MeSH:C0600678] truncate word,hepatorenal
lidocaine-induced cardiac asystole [MeSH:C0018790],intravenous administration [MeSH:C0013125] single -mg bolus lidocaine [MeSH:C0023660] [MeSH:C0023660] -year-old man result profound depression activity [MeSH:C0011570] sinoatrial atrioventricular nodal pacemaker apparent associate condition [MeSH:C0037403] predispose development [MeSH:C0243107] bradyarrhythmia [MeSH:C0428977] probably represent true idiosyncrasy lidocaine [MeSH:C0023660] [MeSH:C0023660],cardiovascular
cerebral [MeSH:C0242202] meet colorectal cancer [MeSH:C0009402] neurological perspective,diabete affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve insufficiency ischemic cardiomyopathy method conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine delirium [MeSH:C0011206] parameter result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],neurological|cardiovascular
cancer skin cancer [MeSH:C0007114] connection,investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia [MeSH:C0497327] carcinogenesis method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo longitudinal leukemia bladder cancer assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
prophylactic lidocaine [MeSH:C0023660] early phase suspect myocardial infarction [MeSH:C0027051],patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] suspect myocardial infarction [MeSH:C0027051] [MeSH:C0027051] [MeSH:C0027051] see hour onset symptom enter double-blind [MeSH:C0013072] randomized trial [MeSH:C1096777] lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] vs placebo hour administration drug [MeSH:C1527425] incidence [MeSH:C0021149] [MeSH:C0021149] ventricular fibrillation [MeSH:C0042510] sustained ventricular tachycardia [MeSH:C0042514] [MeSH:C0042514] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute myocardial infarction [MeSH:C0027051] [MeSH:C0027051] [MeSH:C0027051] [MeSH:C0027051] low lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] give mg dose intramuscularly follow mg intravenously prevent [MeSH:C0000918] sustained ventricular tachycardia [MeSH:C0042514] [MeSH:C0042514] reduction number patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] warn arrhythmia [MeSH:C0003811] minute administration [MeSH:C0001554] [MeSH:C0001554] lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] p average plasma lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] minute administration [MeSH:C0001554] [MeSH:C0001554] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] myocardial infarction [MeSH:C0027051] [MeSH:C0027051] [MeSH:C0027051] significantly high patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute infarction [MeSH:C0021308] mean plasma lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] beta-blocking agent different patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] beta blocking agent [MeSH:C0001645] -hour period [MeSH:C0080129] incidence [MeSH:C0021149] [MeSH:C0021149] central nervous system effect [MeSH:C3714787] significantly great lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] hypotension occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] die asystole lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] advocate administration lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] prophylactically early hour suspect myocardial infarction [MeSH:C0027051] [MeSH:C0027051] [MeSH:C0027051],neurological|cardiovascular
mutation kit mast stem cell growth factor receptor protooncogene human piebaldism,piebald [MeSH:C0080024]ism [MeSH:C0080024] autosomal dominant [MeSH:C2936739] genetic disorder [MeSH:C0040188] [MeSH:C0019247] characterize cogenital [MeSH:C0017420] patch [MeSH:C0030646] skin [MeSH:C1123023] hair melanocyte [MeSH:C0025201] completely absent similar disorder [MeSH:C0040188] mouse [MeSH:C0026809] dominant [MeSH:C0017342] white spot [MeSH:C5575753] [MeSH:C5575753] w result mutation [MeSH:C0026882] c-kit protooncogene encode receptor mast stem cell growth factor [MeSH:C0143630] identify kit gene mutation [MeSH:C0026882] proband classic autosomal dominant [MeSH:C2936739] piebald [MeSH:C0080024]ism [MeSH:C0080024] mutation [MeSH:C0026882] result gly----arg substitution [MeSH:C2936279] [MeSH:C2936279] codon tyrosine kinase domain [MeSH:C0033681] substitution [MeSH:C2936279] [MeSH:C2936279] see normal individual [MeSH:C0021228] completely link piebald [MeSH:C0080024] phenotype [MeSH:C0031437] proband family piebald [MeSH:C0080024]ism [MeSH:C0080024] family appear human [MeSH:C0086418] homologue dominant white spot [MeSH:C5575753] [MeSH:C5575753] w mouse [MeSH:C0026809],oncological
recurrent [MeSH:C2825055] excitation dentate gyrus murine model [MeSH:C0011381] temporal lobe epilepsy [MeSH:C0014556],similar rat [MeSH:C0034721] [MeSH:C0034721] systemic [MeSH:C5544477] pilocarpine [MeSH:C0031923] injection [MeSH:C1828121] cause status epilepticus [MeSH:C0038220] se eventual development [MeSH:C0243107] spontaneous [MeSH:C0000786] seizure [MeSH:C0036572] mossy fiber [MeSH:C0524663] [MeSH:C0524663] sprouting c57bl cd1 mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] physiological correlate event identify mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] population [MeSH:C0032659] response granule cell dentate gyrus examine transverse slice [MeSH:C0227386] ventral hippocampus [MeSH:C3887642] pilocarpine [MeSH:C0031923]-treated untreated mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] mg -free bathing medium contain bicuculline [MeSH:C0005372] condition [MeSH:C0037403] design [MeSH:C0013171] increase excitability slice [MeSH:C4277734] electrical stimulation [MeSH:C0031734] hilus [MeSH:C0013786] result single population [MeSH:C0032659] [MeSH:C0032659] spike granule cell mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] pilocarpine [MeSH:C0031923]-treated mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] experience se se survivor [MeSH:C0206194] similar stimulation [MeSH:C0031734] result population [MeSH:C0032659] spike follow variable latency negative dc shift repetitive afterdischarge durat [MeSH:C0034721] [MeSH:C0034721]ion block ionotropic glutamate receptor antagonist focal glutamate photostimulation [MeSH:C0031734] granule cell layer site distant record [MeSH:C0034869] pipette result population [MeSH:C0032659] response durat [MeSH:C0034721] [MeSH:C0034721]ion slice se survivor [MeSH:C0206194] group support hypothesis [MeSH:C3179072] se-induce mossy fiber [MeSH:C0524663] [MeSH:C0524663] sprouting synaptic reorganization relevant characteristic seizure [MeSH:C0036572] development [MeSH:C0243107] murine [MeSH:C0026802] strain [MeSH:C0080194] resemble rat [MeSH:C0034721] [MeSH:C0034721] model [MeSH:C0011381] human [MeSH:C0086418] temporal lobe epilepsy,neurological
cutaneous leucocytoclastic vasculitis [MeSH:C0151436] associate oxacillin [MeSH:C0029983],-year-old man treat oxacillin [MeSH:C0029983] [MeSH:C0029983] [MeSH:C0029983] week staphylococcus aureus [MeSH:C0038172] bacteremia [MeSH:C0004610] develop renal [MeSH:C0152169] failure [MeSH:C0035078] diffuse symmetric palpable purpuric lesion foot necrotic blister note finger skin biopsy show finding diagnostic [MeSH:C0086143] leucocytoclastic vasculitis [MeSH:C2973529] [MeSH:C2973529] oxacillin [MeSH:C0029983] [MeSH:C0029983] [MeSH:C0029983] discontinue treat corticosteroid [MeSH:C0001617] rash [MeSH:C0001617] disappear week renal [MeSH:C0152169] function [MeSH:C0031843] return normal leucocytoclastic vasculitis [MeSH:C2973529] [MeSH:C2973529] present palpable purpura low extremity accompany abdominal pain [MeSH:C0000737] arthralgia renal [MeSH:C0152169] involvement [MeSH:C0030699] etiologic factor [MeSH:C0005515] associate disorder include infection medication [MeSH:C3714514] collagen vascular disease neoplasia half case etiologic factor [MeSH:C0005515] [MeSH:C0005515] identify usually self-limited disorder corticosteroid [MeSH:C0001617] therapy need life-threatening [MeSH:C4303743] case early corticosteroid [MeSH:C0001617] severe case prevent complication [MeSH:C1171258] oxacillin [MeSH:C0029983] [MeSH:C0029983] [MeSH:C0029983] include drug [MeSH:C0013227] cause leucocytoclastic vasculitis [MeSH:C2973529] [MeSH:C2973529],hepatorenal
antiarrhythmic heart failure brain [MeSH:C0006104] insight,retrospective [MeSH:C0035363] examine statin [MeSH:C0360714] stroke [MeSH:C0038454] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include parkinson disease [MeSH:C0030567] neural glioma method participant [MeSH:C1708335] include result favorable safety profile implication healthcare advancement,neurological
association [MeSH:C0004083] common genetic variant [MeSH:C0042333] homer1 gene levodopa [MeSH:C0023570] adverse effect [MeSH:C0001688] parkinson disease [MeSH:C0030567] patient [MeSH:C0030705],levodopa [MeSH:C0023570] [MeSH:C0023570] effective symptomatic therapy parkinson disease [MeSH:C0030567] chronic [MeSH:C0150055] [MeSH:C0150055] use lead chronic [MeSH:C0150055] [MeSH:C0150055] adverse outcome motor fluctuation dyskinesia visual hallucination homer1 protein [MeSH:C0233763] pivotal function [MeSH:C0031843] glutamate [MeSH:C0220839] transmission [MeSH:C0040722] related pathogenesis [MeSH:C0699748] complication [MeSH:C1171258] investigate [MeSH:C0035173] [MeSH:C0035173] polymorphism [MeSH:C0032529] homer1 gene promoter region [MeSH:C0033413] associate occurrence chronic [MeSH:C0150055] [MeSH:C0150055] complication [MeSH:C1171258] levodopa [MeSH:C0023570] [MeSH:C0023570] therapy total patient [MeSH:C0030705] [MeSH:C0030705] idiopathic parkinson disease [MeSH:C0030567] [MeSH:C0030567] investigate [MeSH:C0035173] [MeSH:C0035173] patient [MeSH:C0030705] genotype rs4 rs1 rs4 allelic discrimination taqman assay rs4 g allele [MeSH:C0002085] [MeSH:C0002085] associate low prevalence [MeSH:C0033105] dyskinesia prevalence [MeSH:C0033105] ratio pr confidence interval [MeSH:C0009667] ci p visual hallucination pr ci p [MeSH:C0233763] suggest homer1 rs4 g allele [MeSH:C0002085] [MeSH:C0002085] protective role development levodopa [MeSH:C0023570] [MeSH:C0023570] adverse effect [MeSH:C0001688],neurological
dementia [MeSH:C0497327] prolapse [MeSH:C0033377] cardiac connection,longitudinal [MeSH:C0023981] examine aspirin heart disease [MeSH:C0018799] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include atrioventricular block bradycardia congestive heart failure method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication healthcare advancement,cardiovascular
breakthrough glomerulonephritis [MeSH:C0017658] finding hypertension [MeSH:C0020538],hypothesis statin improve heart disease [MeSH:C0018799] outcome hydronephrosis pathway method cross-sectional trial [MeSH:C0010362] adult [MeSH:C0001675] population [MeSH:C0032659] measuring bun nash [MeSH:C0005845] result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
crocin [MeSH:C0056503] improve lipid dysregulation subacute [MeSH:C0376635] diazinon [MeSH:C0012013] exposure erk1 pathway [MeSH:C3179231] rat [MeSH:C0034721] liver [MeSH:C0023884],introduction [MeSH:C0033268] diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] yis broadly organophosphorus [MeSH:C0163401] insecticide [MeSH:C0021576] agriculture [MeSH:C0001829] show exposure [MeSH:C1390376] [MeSH:C1390376] diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] interfere lipid metabolism [MeSH:C0598783] [MeSH:C0598783] hypolipidemic effect [MeSH:C4277511] crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] establish early study reveal major role extracellular signal-regulated kinase erk pathway [MeSH:C3179234] low-density lipoprotein receptor ldlr [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] evaluate [MeSH:C0013175] change regulation [MeSH:C0851285] lipid metabolism [MeSH:C0598783] [MeSH:C0598783] erk ldlr [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] liver [MeSH:C0023884] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0023884] expose subacute [MeSH:C0376635] [MeSH:C0376635] diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] furthermore ameliorat [MeSH:C0034721] [MeSH:C0034721]e effect [MeSH:C4277511] crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] induce disturbed cholesterol homeostasis study method rat [MeSH:C0034721] [MeSH:C0034721] divide group receive follow treatment [MeSH:C0039798] week corn oil [MeSH:C0010029] diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] 5 mg kg orally crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] 5 mg kg intraperitoneally combination diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] mg kg level [MeSH:C0018759] cholesterol triglyceride ldl blood rat [MeSH:C0034721] [MeSH:C0034721] analyze mrna [MeSH:C0035696] level [MeSH:C0018759] ldlr [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] erk1 protein [MeSH:C4082284] level [MeSH:C0018759] total activate form erk1 rat [MeSH:C0034721] [MeSH:C0034721] liver [MeSH:C0023884] evaluate [MeSH:C0013175] western blotting quantitative real polymerase chain reaction result show subacute [MeSH:C0376635] [MeSH:C0376635] exposure [MeSH:C1390376] [MeSH:C1390376] diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] significantly increase concentrat [MeSH:C0034721] [MeSH:C0034721]ion cholesterol triglyceride ldl diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] decrease erk1 protein [MeSH:C4082284] phosphorylation ldlr [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] transcript crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] reduce inhibition [MeSH:C0027790] erk activation [MeSH:C4505109] diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013]-induced hyperlipemia increase level [MeSH:C0018759] ldlr [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] transcript conclusion crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] consider novel protective agent [MeSH:C0033613] diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013]-induced hyperlipemia modulating erk pathway [MeSH:C3179234] increase ldlr [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] [MeSH:C3493221] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262],neurological|hepatorenal
stroke [MeSH:C0038454] detox dynamic [MeSH:C0058836],design [MeSH:C0013171] cross-sectional investigation statin stroke [MeSH:C0038454] participant [MeSH:C1708335] cancer patient creatinine glomerulonephritis [MeSH:C0017658] result favorable safety profile bilirubin correlation practice guideline,hepatorenal
leukemia [MeSH:C0023418] acute myeloid leukemia [MeSH:C0023467] [MeSH:C0023418] cardiac connection,dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve pacemaker carcinoma method conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine sinoatrial node [MeSH:C0037189] parameter result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
brain abscess [MeSH:C0006105] meet heart failure [MeSH:C0018801] neurological perspective,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] diabete liver method [MeSH:C0023884] adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective cerebral infarction [MeSH:C0007785] basal ganglion [MeSH:C0004781] assessment [MeSH:C0030198] result positive response optimization [MeSH:C0376695],neurological|hepatorenal
kidney pathway [MeSH:C0022646] myocardial infarction [MeSH:C0027051],investigate [MeSH:C0035173] beta-blocker effect cancer hepatic method adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective hemodialysis bun assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] optimization [MeSH:C0376695],hepatorenal
prospective adverse reaction [MeSH:C0041755] associate vancomycin therapy [MeSH:C0042313],prospective efficacy [MeSH:C5690761] safety vancomycin [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] conduct consecutive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] -month period [MeSH:C0080129] vancomycin [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] curative patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prove infection drug [MeSH:C3714514] cease patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] adverse reaction [MeSH:C0031067] [MeSH:C0041755] vancomycin [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] consider likely cause reaction [MeSH:C0031067] include thrombophlebitis [MeSH:C0040046] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] rash nephrotoxicity proteinuria [MeSH:C0033687] ototoxicity [MeSH:C0235280] [MeSH:C0235280] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] test audiometry thrombophlebitis [MeSH:C0040046] [MeSH:C0040046] occur infusion [MeSH:C0841792] peripheral cannulae nephrotoxicity ototoxicity [MeSH:C0235280] [MeSH:C0235280] confine patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive aminoglycoside [MeSH:C0002556] plus vancomycin [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] conclude vancomycin [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] [MeSH:C0042313] administer [MeSH:C0001554] appropriately constitute safe effective [MeSH:C5392218] therapy infection [MeSH:C0039798] cause susceptible bacteria [MeSH:C0004611],hepatorenal
efficacy [MeSH:C5690761] olanzapine [MeSH:C0171023] acute bipolar mania double-blind [MeSH:C0013072] placebo-controlled olanzipine hggw,compare efficacy [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] safety [MeSH:C0036043] [MeSH:C0036043] olanzapine [MeSH:C0171023] [MeSH:C0171023] vs placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] acute bipolar mania method [MeSH:C0025663] four-week randomized double-blind parallel total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dsm-iv diagnosis [MeSH:C0011900] bipolar disorder [MeSH:C0005586] manic mixed randomized olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] mg n placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] n primary efficacy [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] young-mania rating scale y-mrs total score response euthymia define priori improvement [MeSH:C2936612] [MeSH:C2936612] end point score end point y-mrs total score respectively safety [MeSH:C0036043] [MeSH:C0036043] assess adverse event [MeSH:C0041755] extrapyramidal symptom ep rating scale laboratory value electrocardiogram vital sign [MeSH:C0518766] weight result olanzapine [MeSH:C0171023] [MeSH:C0171023]-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] demonstrate statistically great mean sd improvement [MeSH:C2936612] [MeSH:C2936612] y-mrs total score placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041]-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] respectively p evident postbaseline observation [MeSH:C0302523] week [MeSH:C0302523] randomization [MeSH:C0034656] maintain observation [MeSH:C0302523] carry forward olanzapine [MeSH:C0171023] [MeSH:C0171023]-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] demonstrate high rate response [MeSH:C0034746] vs respectively p euthymia vs respectively p placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041]-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] statistically difference epss group olanzapine [MeSH:C0171023] [MeSH:C0171023]-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] statistically great mean sd weight gain [MeSH:C0043094] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041]-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] vs kg respectively experience treatment-emergent somnolence patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] vs respectively olanzapine [MeSH:C0171023] [MeSH:C0171023] demonstrate great efficacy [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] acute bipolar mania generally tolerate,neurological|cardiovascular
nephrolithiasis [MeSH:C0392525] dementia [MeSH:C0497327] vascular [MeSH:C0221214] insight,question beta-blocker [MeSH:C0001645] affect hypertension [MeSH:C0020538] hypertensive mechanism method retrospective [MeSH:C0035363] elderly patient assess ventricular fibrillation nonalcoholic steatohepatitis [MeSH:C3241937] result well quality life measure implication care improvement,cardiovascular|hepatorenal
thrombosis [MeSH:C0040053] ventricular tachycardia vascular [MeSH:C0042514] insight,cross-sectional examine [MeSH:C0010362] statin [MeSH:C0360714] dementia [MeSH:C0497327] cardiac [MeSH:C0018810] patient investigation [MeSH:C0035173] include mitral valve arterial atrium method participant [MeSH:C1708335] include result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
cardiomyopathy [MeSH:C0878544] renal organ interplay,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect diabete glomerular filtration rate method cancer patient [MeSH:C0030705] undergo retrospective gallstone esrd assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] healthcare advancement,hepatorenal
germline mutation [MeSH:C0206530] brca1 gene [MeSH:C0376571] breast ovarian cancer [MeSH:C1140680] family [MeSH:C0015576] provide evidence genotype-phenotype [MeSH:C2717879] correlation [MeSH:C0010100],mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] gene [MeSH:C0376571] discover associate [MeSH:C0004083] lifetime risk breast cancer [MeSH:C0006142] analyse family history breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] germline mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0206530] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] twenty-two different mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect family previously unreporte observe correlation [MeSH:C0010100] location mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] gene ratio breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] incidence [MeSH:C0021149] family suggest transition risk [MeSH:C0035647] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] gene associate [MeSH:C0004083] low proportion ovarian cancer [MeSH:C1140680] haplotype [MeSH:C0018591] support previous suggest brca1 [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] carrier common ancestor find example recurrent [MeSH:C2825055] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] appear arise independently,oncological
peripheral neuropathy pathway cancer [MeSH:C4721453],retrospective [MeSH:C0035363] examine beta-blocker hypertension diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include neuron [MeSH:C0027882] regurgitation reticular formation method [MeSH:C0035284] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication optimization [MeSH:C0376695],neurological|cardiovascular
effect [MeSH:C4277511] verapamil [MeSH:C0042523] atrial fibrillation [MeSH:C0004238] electrophysiological determinant dog [MeSH:C0012984],atrial tachycardia-induced remodeling promote occurrence maintenance [MeSH:C0024501] atrial fibrillation [MeSH:C0004238] af decrease l-type current suggestion acute [MeSH:C0184567] l-type channel blockade promote af consistent af promote effect [MeSH:C4277511] channel inhibition method evaluate potential [MeSH:C0001272] mechanism [MeSH:C1524059] af promotion channel blocker [MeSH:C0872271] administer verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] morphine-chloralose anesthetize dog [MeSH:C0012984] diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] comparison [MeSH:C0871382] drug autonomic blockade atropine [MeSH:C0004259] nadolol [MeSH:C0027302] apply experiment [MeSH:C0020123] [MeSH:C0020123] epicardial mapping [MeSH:C0596531] [MeSH:C0596531] epicardial electrode evaluate activation [MeSH:C4505109] af result verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] cause af promotion dog [MeSH:C0012984] increase mean duration af induce burst pace mean -s e p vs loading dose mg kg p vs dose mg kg underlie electrophysiological mechanism [MeSH:C1524059] study detail additional dog [MeSH:C0012984] condition [MeSH:C0037403] presence high dose verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] experiment [MeSH:C0020123] [MeSH:C0020123] verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] shorten mean effect [MeSH:C4277511]ive refractory period [MeSH:C0034955] erp ms p cycle length ms decrease erp heterogeneity [MeSH:C0242960] p heterogeneously accelerate atrial conduction [MeSH:C4505172] [MeSH:C0005935] decrease cycle length af ms p diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] affect erp af cycle length af duration produce conduction [MeSH:C0005935] acceleration [MeSH:C0000894] similar cause verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] n presence autonomic blockade verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] fail promote af increase decrease refractoriness verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] affect atrial conduction [MeSH:C4505172] [MeSH:C0005935] presence autonomic blockade epicardial mapping [MeSH:C0596531] [MeSH:C0596531] suggest verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] promote af increase number simultaneous wavefront [MeSH:C2717990] reflect separate zone [MeSH:C0019360] reactivation [MeSH:C4505109] cycle conclusion verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] promote af normal dog [MeSH:C0012984] promote multiple circuit reentry effect [MeSH:C4277511] dependent intact autonomic tone [MeSH:C1145628] share diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373],neurological|cardiovascular
dementia [MeSH:C0497327] meet cardiomyopathy [MeSH:C0878544] neurological perspective,question [MeSH:C0600648] ace inhibitor affect diabete seizure [MeSH:C0036572] mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess myelopathy chorea [MeSH:C0037928] result improve disease management [MeSH:C0039798] implication therapeutic [MeSH:C0087111] innovation,neurological
dementia [MeSH:C0497327] tricuspid valve [MeSH:C0040960] cardiac connection,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome systolic pathway method longitudinal trial [MeSH:C0023981] elderly patient measure dvt prolapse [MeSH:C0033377] result improve disease management [MeSH:C0039798] therapeutic innovation [MeSH:C0087111],cardiovascular
prolapse [MeSH:C0033377] pattern [MeSH:C3849996] multiple sclerosis [MeSH:C0026769] patient [MeSH:C0030705],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] diabete astrocytoma [MeSH:C0004114] method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational encephalitis multiple sclerosis assessment [MeSH:C0030198] result well quality life measure optimization [MeSH:C0376695],neurological|cardiovascular
cerebrospinal fluid [MeSH:C0007806] penetration high-dose daptomycin [MeSH:C0057144] suspect staphylococcus aureus [MeSH:C0038172] meningitis [MeSH:C0025289],report case [MeSH:C0684224] methicillin-sensitive staphylococcus aureus mssa [MeSH:C0038172] bacteremia [MeSH:C0004610] [MeSH:C0004610] [MeSH:C0004610] [MeSH:C0004610] suspect mssa meningitis [MeSH:C0025289] [MeSH:C0025289] [MeSH:C0025289] treat high-dose daptomycin [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] assess concurrent serum cerebrospinal fluid csf [MeSH:C0007806] concentration [MeSH:C0311432] [MeSH:C0311432] case summary -year-old male [MeSH:C0086582] present emergency department [MeSH:C0562508] generalize weakness [MeSH:C0151786] presume health-care-associated pneumonia [MeSH:C1443237] show ch radiograph [MeSH:C0034571] empiric [MeSH:C0376548]ally initiate vancomycin [MeSH:C0042313] levofloxacin [MeSH:C0282386] piperacillin [MeSH:C0031955] tazobactam [MeSH:C0075870] blood culture [MeSH:C0200949] reveal aureus susceptible oxacillin [MeSH:C0029983] empiric [MeSH:C0376548] antibiotic [MeSH:C0003232] narrow nafcillin [MeSH:C0027324] [MeSH:C0027324] develop acute renal failure [MeSH:C0022660] serum creatinine [MeSH:C0010294] mg dl increase mg dl previous mg dl admission glasgow coma [MeSH:C0017594] score normal finding show compute tomography scan [MeSH:C0040395] head hour follow episode [MeSH:C0085554] cardiac arrest [MeSH:C0018790] experience relapse [MeSH:C0035020] mssa bacteremia [MeSH:C0004610] [MeSH:C0004610] [MeSH:C0004610] [MeSH:C0004610] increase suspicion central nervous system cns infection [MeSH:C0007684] nafcillin [MeSH:C0027324] [MeSH:C0027324] discontinue daptomycin [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] mg kg daily initiate suspect meningitis [MeSH:C0025289] [MeSH:C0025289] [MeSH:C0025289] continue death [MeSH:C0011065] daptomycin [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] serum csf trough concentration [MeSH:C0311432] [MeSH:C0311432] ug ml ug ml respectively prior dose lumbar puncture [MeSH:C0553794] result inconclusive blood culture [MeSH:C0200949] [MeSH:C0200949] positive mssa creatine kinase [MeSH:C0010287] level normal prior daptomycin [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] therapy reassess discussion daptomycin [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] initiate secondary possible nafcillin [MeSH:C0027324] [MeSH:C0027324]-induced acute interstitial nephritis relapse [MeSH:C0035020] bacteremia [MeSH:C0004610] [MeSH:C0004610] [MeSH:C0004610] [MeSH:C0004610] dose mg kg resultant penetration high previous report consistent inflamed meninge conclusion high-dose daptomycin [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] [MeSH:C0057144] alternative option mssa bacteremia [MeSH:C0004610] [MeSH:C0004610] [MeSH:C0004610] [MeSH:C0004610] cns source patient [MeSH:C0030705] [MeSH:C0030705] fail tolerate standard therapy patient [MeSH:C0030705] [MeSH:C0030705] confirm meningitis [MeSH:C0025289] [MeSH:C0025289] [MeSH:C0025289] warrant,neurological|hepatorenal
cancer acute lymphoblastic leukemia [MeSH:C1961102] connection [MeSH:C0056248],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve cancer outcome [MeSH:C0206277] target therapy pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure esophageal cancer [MeSH:C0546837] endometrial cancer [MeSH:C0476089] result improvement [MeSH:C2936612] primary endpoint therapeutic innovation [MeSH:C0087111],oncological
acute renal insufficiency [MeSH:C1565662] high-dose melphalan patient [MeSH:C0030705] primary systemic amyloidosis stem cell transplantation [MeSH:C0268381],patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] primary systemic amyloidosis al poor prognosis [MeSH:C0033325] median survival [MeSH:C0038952] [MeSH:C0038952] standard treatment month [MeSH:C0039798] high-dose intravenous melphalan [MeSH:C0025241] follow peripheral blood stem cell transplant [MeSH:C0242602] pbsct appear promising therapy [MeSH:C0039798] mortality [MeSH:C0026565] high author note development [MeSH:C0243107] [MeSH:C0243107] acute renal insufficiency [MeSH:C1565662] immediately melphalan [MeSH:C0025241] condition [MeSH:C0037403]ing undertake examine risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] impact [MeSH:C5544368] posttransplant mortality [MeSH:C0026565] method consecutive al patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo pbsct study retrospectively acute renal insufficiency [MeSH:C1565662] [MeSH:C1565662] ari high-dose melphalan [MeSH:C0025241] define minimum increase mg dl micromol l serum creatinine [MeSH:C0010294] great immediately condition [MeSH:C0037403] urine sediment score sum individual [MeSH:C0021228] type sediment identify urine microscopy [MeSH:C0026018] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] study ari develop patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] high-dose melphalan [MeSH:C0025241] univariate identify age hypoalbuminemia [MeSH:C0239981] heavy proteinuria diuretic use urine sediment score risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] age urine sediment score remain independently risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] multivariate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ari high-dose melphalan [MeSH:C0025241] undergo dialysis p [MeSH:C0011945] bad -year survival [MeSH:C0038952] p timing renal injury [MeSH:C2609414] [MeSH:C2609414] strongly suggest melphalan [MeSH:C0025241] causative agent ongoing tubular injury [MeSH:C3263723] prerequisite renal injury [MeSH:C2609414] [MeSH:C2609414] melphalan [MeSH:C0025241] evidence [MeSH:C5575834] active urinary sediment [MeSH:C5690912] development [MeSH:C0243107] [MeSH:C0243107] ari adversely affect outcome pbsct effective preventive measure [MeSH:C0033107] help decrease mortality [MeSH:C0026565] pbsct al patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],hepatorenal
ovarian cancer [MeSH:C1140680] risk [MeSH:C0035647] brca1 [MeSH:C0259275] carrier modify hras1 variable number tandem repeat vntr locus,woman [MeSH:C0043210] carry mutation [MeSH:C0026882] brca1 [MeSH:C0259275] gene chromosome 7q2 risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] age ref variable penetrance [MeSH:C0524899] [MeSH:C0524899] brca1 [MeSH:C0259275] suggest genetic [MeSH:C0017380] non-genetic [MeSH:C0017380] factor play role tumourigenesis [MeSH:C0596263] individual hras1 variable number tandem repeat vntr polymorphism located kilobase kb downstream hras1 proto-oncogene chromosome 1p1 possible genetic [MeSH:C0017380] modifier cancer penetrance [MeSH:C0524899] [MeSH:C0524899] individual rare allele vntr increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] certain type cancer [MeSH:C0006826] include breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] investigate [MeSH:C0035173] presence rare hras1 allele increase susceptibility [MeSH:C0012655] [MeSH:C0012655] hereditary breast ovarian cancer [MeSH:C1140680] [MeSH:C0677776] [MeSH:C1140680] type panel female brca1 [MeSH:C0259275] carrier locus pcr-based technique risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] time great brca1 [MeSH:C0259275] carrier harbour rare hras1 allele compare carrier common allele p [MeSH:C0002085] magnitude relative risk [MeSH:C0242492] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] associate rare hras1 allele alter adjust known risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] factor hereditary ovarian cancer [MeSH:C0677776] [MeSH:C1140680] [MeSH:C1140680] susceptibility [MeSH:C0012655] [MeSH:C0012655] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] appear affect presence rare hras1 allele effect modify gene penetrance [MeSH:C0524899] [MeSH:C0524899] [MeSH:C0524899] inherit cancer syndrome [MeSH:C0039082],oncological
endocardium pattern [MeSH:C0014124] coronary artery disease [MeSH:C1956346] patient [MeSH:C0030705],randomized control examine [MeSH:C1096777] metformin [MeSH:C0025598] dementia [MeSH:C0497327] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include cardiac endothelial stroke method participant [MeSH:C1708335] include result well quality life measure implication therapeutic [MeSH:C0087111] innovation,neurological|cardiovascular
comparison [MeSH:C0871382] effect oxitropium bromide [MeSH:C0134499] slow-release theophylline [MeSH:C0039771] nocturnal asthma,effect [MeSH:C4277511] new inhale [MeSH:C0021461] antimuscarinic drug [MeSH:C0003385] oxitropium [MeSH:C0069776] [MeSH:C0069776] [MeSH:C0069776] bromide [MeSH:C0134499] slow-release theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] preparation nocturnal asthma compare placebo-controlled double-blind sample study patient [MeSH:C0030705] receive oxitropium [MeSH:C0069776] [MeSH:C0069776] [MeSH:C0069776] microgram subject microgram subject receive theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] mg b morning [MeSH:C2698559] dip assess fall peak flow overnight significantly reduce period active drug [MeSH:C0033613] take difference notice placebo administration [MeSH:C0001554] difference notice result obtain active drug [MeSH:C0033613] dosage oxitropium [MeSH:C0069776] [MeSH:C0069776] [MeSH:C0069776] subject report [MeSH:C0080105] effect [MeSH:C4277511] oxitropium [MeSH:C0069776] [MeSH:C0069776] [MeSH:C0069776] compare subject report [MeSH:C0080105] nausea vomiting tremor theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] oxitropium [MeSH:C0069776] [MeSH:C0069776] [MeSH:C0069776] prove valuable alternative [MeSH:C4255061] theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] nocturnal asthma equally potent safe require titration dosage,neurological
state-of-the-art loop diuretic hypertension,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin heart disease [MeSH:C0018799] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient glomerulus primary sclerosing cholangitis [MeSH:C0566602] result decrease mortality rate [MeSH:C0205848] proteinuria [MeSH:C0033687] correlation [MeSH:C0010100] relevance [MeSH:C2826293],hepatorenal
myocardium [MeSH:C0027061] pattern parkinson disease [MeSH:C0030567] patient [MeSH:C0030705],retrospective [MeSH:C0035363] examine statin [MeSH:C0360714] dementia [MeSH:C0497327] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include insufficiency neuropathy regurgitation method participant [MeSH:C1708335] include result positive response implication practice guideline,neurological|cardiovascular
metronidazole-induced encephalopathy uncommon scenario,metronidazole [MeSH:C0025872] [MeSH:C0025872] [MeSH:C0025872] produce neurological complication common scenario present case develop feature encephalopathy [MeSH:C0085584] follow prolonged metronidazole [MeSH:C0025872] [MeSH:C0025872] [MeSH:C0025872] intake [MeSH:C0006777] magnetic resonance image [MeSH:C5392999] mri brain show abnormal [MeSH:C0853087] signal intensity involve dentate nucleus cerebellum splenium corpus callosum diagnosis [MeSH:C0011900] metronidazole [MeSH:C0025872] [MeSH:C0025872] [MeSH:C0025872] toxicity [MeSH:C0040539] mri finding support clinically,neurological
heparin-induced thrombocytopenia thrombosis [MeSH:C0040034] hemorrhage [MeSH:C0019080],sixty-two patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-induced thrombocytopenia report manifestation disorder include hemorrhage [MeSH:C0019080] frequently thromboembolic [MeSH:C0040038] event patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] laboratory testing reveal fall platelet count [MeSH:C0032181] [MeSH:C0032181] increase resistance [MeSH:C0034471] heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] aggregation [MeSH:C0007580] platelet plasma [MeSH:C0032105] heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] add immunologic testing [MeSH:C0021061] demonstrate presence heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-dependent platelet membrane antibody death hemorrhagic thromboembolic [MeSH:C0040038] complication [MeSH:C1171258] [MeSH:C1171258] surgical procedure [MeSH:C0543467] manage complication [MeSH:C1171258] [MeSH:C1171258] confirm seriousness disorder specific risk factor [MeSH:C0035648] identify patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] monitor platelet count [MeSH:C0032181] [MeSH:C0032181] fall mm3 receive heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] platelet aggregation [MeSH:C0007580] testing plasma [MeSH:C0032105] indicate management [MeSH:C0085971] consist cessation heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] platelet anti-aggregating agent alternate form anticoagulation [MeSH:C0003280] indicate,neurological
cancer [MeSH:C0006826] venous cardiac connection,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve tia sarcoma method conduct observational evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine liver cancer [MeSH:C0345904] parameter result positive response practice guideline [MeSH:C0936005],cardiovascular|oncological
hormone risk breast cancer [MeSH:C0006142],paper report [MeSH:C0684224] result menopausal [MeSH:C0025320] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] receive hormonal replacement therapy [MeSH:C0282402] [MeSH:C0282402] majority surgical menopause mean age year hypothesize progestin [MeSH:C0033306] equilibrate effect estrogenic stimulation mammary endometrial target [MeSH:C0039309] tissue [MeSH:C0040300] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] hormonal replacement therapy [MeSH:C0282402] [MeSH:C0282402] schedule consist conjugate estrogen premarin [MeSH:C0014938] mg day [MeSH:C0011017] [MeSH:C0011017] medroxyprogesterone acetate [MeSH:C0065864] mg day [MeSH:C0011017] [MeSH:C0011017] mean period month follow-up [MeSH:C3899107] [MeSH:C3899107] period attention [MeSH:C0004268] pay breast modification evidence [MeSH:C5575834] symptomatology [MeSH:C0029167] physical examination [MeSH:C0031809] plate thermography [MeSH:C0031809] mastodynia [MeSH:C0024902] [MeSH:C0024902] report patient [MeSH:C0030705] [MeSH:C0030705] physical examination [MeSH:C0031809] reveal light increase breast firmness woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] moderate increase breast nodularity woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] themography confirm existence excessive breast stimulation woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] complain moderate mastodynia [MeSH:C0024902] [MeSH:C0024902] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] complain severe mastodynia [MeSH:C0024902] [MeSH:C0024902] normalization obtain halve estrogen dose [MeSH:C0014939] result suggest hormonal replacement therapy [MeSH:C0282402] [MeSH:C0282402] safely prescribe follow criterion [MeSH:C0243161] satisfied preliminary [MeSH:C4505218] patient [MeSH:C0030705] [MeSH:C0030705] metabolic [MeSH:C0025517] cytologic mammographic [MeSH:C0024671] perspective cyclic schedule progestative phase day [MeSH:C0011017] [MeSH:C0011017] periodic complete follow-up [MeSH:C3899107] [MeSH:C3899107] accurate thermographic [MeSH:C0039810] breast target [MeSH:C0039309] tissue [MeSH:C0040300],oncological
cardiomyopathy neuron [MeSH:C0878544] exploring neural pathway [MeSH:C0027792],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete meningitis [MeSH:C0025289] mechanism method retrospective cancer patient [MeSH:C0030705] assess thalamus lung cancer [MeSH:C0242379] result positive response implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|oncological
thromboembolism lymphoma vascular insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect hypertension [MeSH:C0020538] tricuspid valve method [MeSH:C0040960] elderly patient undergo randomized control stenosis [MeSH:C1096777] deep vein thrombosis [MeSH:C0149871] assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],cardiovascular
serotonin syndrome [MeSH:C0699828] venlafaxine-tranylcypromine interaction,excessive stimulation [MeSH:C0031734] serotonin [MeSH:C0036751] 5ht1a receptor [MeSH:C0379900] cause syndrome [MeSH:C0039082] serotonin [MeSH:C0036751] excess consist shiver [MeSH:C0036973] muscle rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] salivation [MeSH:C0036104] confusion agitation hyperthermia common cause syndrome [MeSH:C0039082] interaction [MeSH:C0007582] [MeSH:C0007582] monoamine oxidase [MeSH:C0026454] inhibit [MeSH:C0021463]or maoi specific serotonin [MeSH:C0036751] reuptake inhibit [MeSH:C0021463]or venlafaxine [MeSH:C0078569] [MeSH:C0078569] new antidepressant agent [MeSH:C0003289] inhibit [MeSH:C0021463] reuptake serotonin [MeSH:C0036751] norepinephrine report venlafaxine [MeSH:C0078569] [MeSH:C0078569]-maoi interaction [MeSH:C0007582] [MeSH:C0007582] result serotonin [MeSH:C0036751] syndrome [MeSH:C0039082] -y-old male [MeSH:C0086582] take tranylcypromine [MeSH:C0040778] depression morning presentation [MeSH:C0022869] take tab venlafaxine [MeSH:C0078569] [MeSH:C0078569] h confuse jerk [MeSH:C0027066] movement extremity tremor [MeSH:C0015385] rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] bring directly hospital [MeSH:C0019994] find agitate confuse shiver [MeSH:C0036973] myoclonic jerk [MeSH:C0027066] rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] salivation [MeSH:C0036104] diaphoresis pupil [MeSH:C0034121] mm sluggishly reactive light vital sign blood pressure mm hg heart rate min respiratory rate [MeSH:C0231832] min temperature [MeSH:C0039476] [MeSH:C0039476] f mg diazepam [MeSH:C0012010] v remain tremulous muscle rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] clenched jaw intubate airway protection hypoventilation [MeSH:C3203358] paralyzed muscle rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] subsequent course remarkable non-immune thrombocytopenia [MeSH:C0398650] resolve maximal temperature [MeSH:C0039476] [MeSH:C0039476] f cpk remain unit l evidence [MeSH:C5575834] rhabdomyolysis [MeSH:C0035410] mental status normalize transfer psychiatry ward survive sequela aggressive sedation [MeSH:C0079159] neuromuscular paralysis,neurological|cardiovascular
indomethacin-induced renal insufficiency [MeSH:C1565489] recurrence [MeSH:C2825055] rechallenge,report case acute oliguric renal failure hyperkalemia [MeSH:C0020461] cirrhosis [MeSH:C1623038] ascite cor pulmonale [MeSH:C0034072] indomethacin [MeSH:C0021246] therapy prompt restoration renal function [MeSH:C0031843] follow drug withdrawal [MeSH:C2717885] re-exposure [MeSH:C3850098] single dose indomethacin [MeSH:C0021246] cause recurrence [MeSH:C2825055] acute reversible oliguria case support hypothesis [MeSH:C3179072] endogenous [MeSH:C0205752] renal prostaglandin [MeSH:C0033554] play role maintenance renal blood flow [MeSH:C1527409] circulate [MeSH:C3641730] plasma volume [MeSH:C0032127] diminish nonsteroidal anti-inflammatory agent [MeSH:C0003211] interfere compensatory mechanism cause acute renal failure caution [MeSH:C0022660] patient [MeSH:C0030705],hepatorenal
transvenous right ventricular pacing cardiopulmonary resuscitation pediatric [MeSH:C0237433] patient [MeSH:C0030705] acute cardiomyopathy [MeSH:C0878544],describe cardiopulmonary resuscitation [MeSH:C0007203] effort patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present acute circulatory failure myocardial dysfunction patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute viral myocarditis [MeSH:C0027059] [MeSH:C0027059] carbamazepine-induced acute eosinophilic myocarditis [MeSH:C0027059] cardiac [MeSH:C0018810] hemosiderosis [MeSH:C0019114] result acute cardiogenic shock [MeSH:C0036980] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] continuously monitor central venous arterial catheter addition routine noninvasive [MeSH:C1997883] monitoring introducer sheath pacemaker sterile pacing wire readily available patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] need arise terminate resistant [MeSH:C2986418] cardiac [MeSH:C0018810] dysrhythmia [MeSH:C0003811] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop cardiocirculatory arrest associate [MeSH:C0004083] extreme hypotension [MeSH:C0020649] dysrhythmia [MeSH:C0003811] hour admission [MeSH:C0030673] pediatric [MeSH:C0237433] [MeSH:C0237433] intensive care unit [MeSH:C0021708] picu right ventricular pacemaker wire insert cardiopulmonary resuscitation [MeSH:C0007203] cpr [MeSH:C0007203] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cardiac [MeSH:C0018810] pacing result temporary capture rhythm restoration [MeSH:C4505207] cardiac [MeSH:C0018810] output patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] second event cardiac [MeSH:C0018810] arrest result death minute cardiac [MeSH:C0018810] pacing convert normal sinus rhythm electrical defibrillation [MeSH:C0013778] minute initiate cpr [MeSH:C0007203] conclude cardiac [MeSH:C0018810] pacing resuscitative effort pediatric [MeSH:C0237433] [MeSH:C0237433] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] suffer acute myocardial dysfunction long-term [MeSH:C0023977] temporary hemodynamic stability achieve procedure [MeSH:C0184661] provide additional need institute [MeSH:C0021621] therapeutic modality [MeSH:C0087111],cardiovascular
multiple sclerosis connection [MeSH:C0026769] heart failure [MeSH:C0018801],question [MeSH:C0600648] metformin [MeSH:C0025598] affect dementia [MeSH:C0497327] tia mechanism method randomized control diabetic patient [MeSH:C0030705] assess limbic system [MeSH:C0023715] palsy [MeSH:C0522224] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication healthcare advancement,neurological
blood vessel pathway [MeSH:C0005847] atrial fibrillation [MeSH:C0004238],diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve ectopic [MeSH:C0019933] beat hypotension method conduct longitudinal evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examining chf parameter result positive response optimization [MeSH:C0376695],neurological|cardiovascular
cardiomyopathy [MeSH:C0878544] creatinine [MeSH:C0010294] cardiac connection,hypothesis statin improve diabete outcome steatosis pathway method retrospective trial cancer patient measure dvt aortic dissection [MeSH:C0340643] result improvement primary endpoint safety [MeSH:C0036043] consideration,cardiovascular|hepatorenal
amino-acid substitution involve phenylketonuria [MeSH:C0031485] linkage disequilibrium dna haplotype,phenylketonuria pku [MeSH:C0031485] autosomal recessive human genetic disorder [MeSH:C0019247] cause deficiency hepatic phenylalanine [MeSH:C0031453] hydroxylase [MeSH:C0751434] pah phenylalanine [MeSH:C0031453] -monooxygenase ec pku common inborn error [MeSH:C0025521] amino-acid metabolism [MeSH:C0025519] caucasian [MeSH:C0007457] population [MeSH:C0032659] [MeSH:C0032659] approximately individual carrier pku allele define molecular basis pku characterize restriction fragment-length polymorphism rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] pah locus northern european population [MeSH:C0032659] [MeSH:C0032659] observe pku allele population [MeSH:C0032659] [MeSH:C0032659] confine common rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] recently report splicing mutation [MeSH:C0026882] pah gene associate rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] present mutant allele [MeSH:C0002085] report molecular lesion associate rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] mutant allele [MeSH:C0002085] defect cause c-to-t transition exon result amino-acid substitution arg trp residue pah direct hybridization point mutation [MeSH:C0026882] specific oligonucleotide probe [MeSH:C0028952] demonstrate mutation [MeSH:C0026882] linkage disequilibrium rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] allele mutant [MeSH:C0002085] pah gene,hepatorenal
target [MeSH:C0039309] disruption [MeSH:C3179075] atm lead growth retardation chromosomal fragmentation meiosis immune defect thymic lymphoma,atm gene mutate inherit human disease [MeSH:C0012634] ataxia-telangiectasia member family kinase involve dna metabolism [MeSH:C0025519] cell [MeSH:C0007634]-cycle checkpoint [MeSH:C1155874] help clarify physiological role [MeSH:C0031845] atm protein disrupt atm gene mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] homologous recombination [MeSH:C0599773] initial atm knockout animal [MeSH:C0206745] indicate inactivation [MeSH:C0043297] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] atm gene recreate phenotype [MeSH:C0031437] ataxia-telangiectasia homozygous mutant [MeSH:C1564139] atm- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] viable growth [MeSH:C0018270]-retarded infertile [MeSH:C0021359] infertility [MeSH:C0021359] atm- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] result meiotic failure meiosis [MeSH:C0025186] [MeSH:C0025186] arrest [MeSH:C0104230] zygotene pachytene stage [MeSH:C0024842] prophase [MeSH:C1095048] abnormal [MeSH:C0853087] chromosomal synapsis [MeSH:C0598501] subsequent chromosome fragmentation immune defect evident atm- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] include reduce number b2 cd4- pre-b [MeSH:C0023485] cell [MeSH:C0007634] thymocyte [MeSH:C0814999] peripheral cell [MeSH:C1518999] [MeSH:C0007634] functional impairment t-cell [MeSH:C0007634]-dependent immune response [MeSH:C0020964] cerebella [MeSH:C0007765] atm- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] appear normal histologic examination [MeSH:C0027853] month mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] gross [MeSH:C0018252] behavioral abnormal [MeSH:C0853087]ity majority mutant [MeSH:C1564139] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] rapidly develop thymic lymphoma [MeSH:C0024299] die month age [MeSH:C0024842] finding indicate atm gene product [MeSH:C0017281] play essential role diverse cell [MeSH:C0007634]ular process include meiosis [MeSH:C0025186] [MeSH:C0025186] normal growth [MeSH:C0018270] somatic tissue immune development [MeSH:C0020119] tumor suppression [MeSH:C0079427],neurological|oncological
multiple myeloma [MeSH:C0026764] pattern chronic kidney disease [MeSH:C1561643] patient [MeSH:C0030705],question statin affect diabete glutamate [MeSH:C0220839] mechanism method observational [MeSH:C0302523] elderly patient assess chronic lymphocytic leukemia [MeSH:C0023434] carcinogen [MeSH:C0007090] result superior efficacy [MeSH:C5690761] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|oncological
influence [MeSH:C0683549] interval [MeSH:C0005605] monoher doxorubicin administration protection doxorubicin-induced cardiotoxicity mouse [MeSH:C0026809],despite well-known cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] anthracyclin [MeSH:C0282564] doxorubicin [MeSH:C0013089] dox continue effective [MeSH:C5392218] widely chemotherapeutic agent [MeSH:C0003392] dox-induced cardiac [MeSH:C0018810] damage [MeSH:C0012860] [MeSH:C0012860] presumably result formation free radical dox reactive oxygen specie [MeSH:C0162772] particularly affect cardiac [MeSH:C0018810] myocyte cell relatively poor antioxidant defense system semisynthetic flavonoid monohydroxyethylrutoside [MeSH:C0020354] monoher [MeSH:C2001241] show cardioprotection [MeSH:C0007209] dox-induced cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] radical scavenging [MeSH:C0079381] iron chelating property relatively short final half-life [MeSH:C0018517] monoher [MeSH:C2001241] min expect interval [MeSH:C0005605] [MeSH:C0005605] monoher [MeSH:C2001241] dox influence [MeSH:C0683549] cardioprotective effect monoher [MeSH:C2001241] present investigate [MeSH:C0035173] possible effect method group balb c [MeSH:C0025919] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] treat saline dox dox mg kg v precede monoher [MeSH:C2001241] mg kg p interval [MeSH:C0005605] [MeSH:C0005605] min -week period [MeSH:C0080129] additional observation [MeSH:C0302523] week mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] sacrifice cardiac [MeSH:C0018810] tissue process light microscopy cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] damage [MeSH:C0012860] [MeSH:C0012860] evaluate [MeSH:C0013175] accord billingham cancer treat rep microscopic [MeSH:C0400821] reveal dox induce cardiac [MeSH:C0018810] damage [MeSH:C0012860] [MeSH:C0012860] comparison saline p result number damage [MeSH:C0012860] [MeSH:C0012860] cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] -fold ci high mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] treat dox animal [MeSH:C0003062] ratio aberrant cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] treat dox precede monoher [MeSH:C2001241] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] treat saline range mean ci p mean protective effect add monoher [MeSH:C2001241] dox lead -fold reduction [MeSH:C1827449] p ci abnormal [MeSH:C0853087] cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] protective effect depend interval [MeSH:C0005605] [MeSH:C0005605] monoher [MeSH:C2001241] dox administration [MeSH:C0001554] p result indicate outpatient setting [MeSH:C0029921] monoher [MeSH:C2001241] administer shortly dox,cardiovascular|oncological
cardiac function [MeSH:C0018803] lung cancer [MeSH:C0242379],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] cardiac method elderly patient undergo retrospective systolic artery assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] cost-effect [MeSH:C4277511]iveness implication,cardiovascular
pioneer hepatocellular study cancer,diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve anuria [MeSH:C0003460] acute kidney injury method [MeSH:C2609414] conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine bun [MeSH:C0005845] parameter result superior efficacy [MeSH:C5690761] relevance,hepatorenal
leukemia [MeSH:C0023418] primary sclerosing cholangitis [MeSH:C0566602] organ [MeSH:C0029250] interplay,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation beta-blocker [MeSH:C0001645] dementia participant [MeSH:C1708335] cancer patient [MeSH:C0030705] steatosis jaundice [MeSH:C0022346] result improve outcome end stage renal disease [MeSH:C0022661] correlation [MeSH:C0010100] optimization [MeSH:C0376695],hepatorenal
cardiovascular [MeSH:C0007220] alterat [MeSH:C0034721]ion rat [MeSH:C0034721] fetus [MeSH:C0015965] expose calcium channel blocker [MeSH:C0006684],preclinical toxicologic [MeSH:C4042799] investigation suggest new calcium channel blocker [MeSH:C0006684] [MeSH:C0006684] [MeSH:C0006684] [MeSH:C0006684] ro induce cardiovascular [MeSH:C0007220] [MeSH:C0007220] [MeSH:C0007220] alterat [MeSH:C0034721]ion rat [MeSH:C0034721] fetus [MeSH:C0015965] expose agent organogenesis [MeSH:C0242290] present design [MeSH:C0013171] investigate [MeSH:C0035173] hypothesis calcium channel blocker [MeSH:C0006684] [MeSH:C0006684] [MeSH:C0006684] [MeSH:C0006684] [MeSH:C0006684] general induce cardiovascular [MeSH:C0007220] [MeSH:C0007220] [MeSH:C0007220] malformation indicate pharmacologic [MeSH:C0600511] class effect study calcium channel blocker [MeSH:C0006684] [MeSH:C0006684] [MeSH:C0006684] [MeSH:C0006684] different structure [MeSH:C2713306] nifedipine [MeSH:C0028066] diltiazem [MeSH:C0012373] verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] new agent pregnant rat [MeSH:C0034721] administer [MeSH:C0001554] calcium channel blocker [MeSH:C0006684] [MeSH:C0006684] [MeSH:C0006684] [MeSH:C0006684] period [MeSH:C0080129] cardiac morphogenesis [MeSH:C0026559] offspring [MeSH:C0683572] examine gestation [MeSH:C0032961] cardiovascular [MeSH:C0007220] [MeSH:C0007220] [MeSH:C0007220] malformation low incidence [MeSH:C0021149] [MeSH:C0021149] cardiovascular [MeSH:C0007220] [MeSH:C0007220] [MeSH:C0007220] malformation observe exposure [MeSH:C1390376] calcium channel blocker [MeSH:C0006684] [MeSH:C0006684] [MeSH:C0006684] [MeSH:C0006684] incidence [MeSH:C0021149] [MeSH:C0021149] statistically [MeSH:C0600673] verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] nifedipine [MeSH:C0028066] agent associate [MeSH:C0004083] aortic arch [MeSH:C0003489] branching variant significantly increase ro verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523],cardiovascular
age [MeSH:C0024842] intronic gaa triplet repeat expansion mutation friedreich ataxia [MeSH:C0016719],friedreich ataxia [MeSH:C0004134] frda [MeSH:C0016719] frequently inherit ataxia [MeSH:C0004134] vast majority case large expansion intronic [MeSH:C0021920] gaa repeat linkage [MeSH:C0024842] disequilibrium base haplotype seven polymorphic marker close frataxin gene age [MeSH:C0024842] frda found mutational event estimate generation confidence interval [MeSH:C0009667] g dating consistent little negative [MeSH:C3539878] selection [MeSH:C0036892] provide evidence [MeSH:C5575834] ancient spread pre-mutation at-risk allele western europe,neurological
echocardiography [MeSH:C0013516] reveal myocardial infarction [MeSH:C0027051] secret,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] metformin [MeSH:C0025598] dementia [MeSH:C0497327] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient medulloblastoma [MeSH:C0025149] amygdala result improve disease management [MeSH:C0039798] arterial [MeSH:C0003835] correlation safety consideration,neurological|cardiovascular
detection [MeSH:C5392129] novel missense mutation [MeSH:C0026882] [MeSH:C0599155] second recurrent mutation [MeSH:C0026882] cacna1a gene individual ea- fhm,mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brain specific p q type ca2 channel alpha1 subunit gene cacna1a identify clinically distinct disorder [MeSH:C0040188] viz episodic [MeSH:C0561843] ataxia type ea- familial hemiplegic migraine [MeSH:C0149931] [MeSH:C0338484] fhm spinocerebellar ataxia sca6 [MeSH:C0087012] individual [MeSH:C0021228] ea- mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] describe far presume truncate protein product different missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] [MeSH:C0026882] identify patient [MeSH:C0030705] fhm mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify different chromosome [MeSH:C0008633] 9p1 haplotype [MeSH:C0018591] represent recurrent mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] present screen individual [MeSH:C0021228] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] exon cacna1a gene single-strand conformation [MeSH:C0243031] characterise novel missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] [MeSH:C0026882] g50a exon family segregate ea- consequence mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] amino acid [MeSH:C0002520] substitution [MeSH:C2936279] highly conserve position cacna1a gene represent point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] result propose truncate protein furthermore mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect family member [MeSH:C0086282] mild sign include migraine [MeSH:C0149931] additionally second previously identify recurrent muta tion c22 exon discover fhm,neurological
metformin [MeSH:C0025598] protect seizure [MeSH:C0036572] learning [MeSH:C0023185] memory impairment [MeSH:C1384666] oxidative damage [MeSH:C5392203] induce pentylenetetrazole-induced kindling mouse,cognitive [MeSH:C4042952] impairment [MeSH:C0338656] common severe comorbidity epilepsy [MeSH:C0014544] [MeSH:C0009488] greatly diminish quality [MeSH:C0034379] life [MeSH:C0376558] current therapeutic [MeSH:C0087111] intervention epilepsy [MeSH:C0014544] cause untoward cognitive [MeSH:C4042952] effect urgent need new kind agent target [MeSH:C0039309] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] cognition [MeSH:C0009240] deficit oxidative stress [MeSH:C0242606] consider play important role epileptogenesis cognitive [MeSH:C4042952] deficit antioxidant [MeSH:C0003402] putative antiepileptic potential metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] commonly prescribe antidiabetic oral drug [MeSH:C0935929] antioxidant [MeSH:C0003402] property design evaluate [MeSH:C0013175] ameliorative effect metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] cognitive [MeSH:C4042952] impairment [MeSH:C0338656] brain oxidative stress [MeSH:C0242606] [MeSH:C0242606] marker observe pentylenetetrazole [MeSH:C0030903]-induced kindling animal [MeSH:C0003062] male [MeSH:C0086582] c57bl mouse [MeSH:C0026809] administer subconvulsive dose pentylenetetrazole [MeSH:C0030903] mg kg p injection [MeSH:C1828121] metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] inject intraperitoneally dose 0 mg kg alternate-day ptz find metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] suppress [MeSH:C0017372] progression [MeSH:C0242656] kindle ameliorate cognitive [MeSH:C4042952] impairment [MeSH:C0338656] decrease brain oxidative stress [MeSH:C0242606] [MeSH:C0242606] present conclude metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] potential agent epilepsy [MeSH:C0014544] protective medicine cognitive [MeSH:C4042952] impairment [MeSH:C0338656] induce seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572],neurological
angina [MeSH:C0002965] dementia [MeSH:C0497327] vascular [MeSH:C0221214] insight,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve ectopic beat [MeSH:C0033036] atrial fibrillation method [MeSH:C0004238] conduct longitudinal evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine systolic [MeSH:C0039155] parameter result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
effect [MeSH:C4277511] hibiscus rosa sinensis reserpine-induced neurobehavioral biochemical [MeSH:C0017401] alterat [MeSH:C0034721]ion rat [MeSH:C0034721],effect [MeSH:C4277511] methanolic extract hibiscus [MeSH:C0884982] rosa sinensis mg kg study reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179]-induced orofacial dyskinesia neurochemical alterat [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721] treat intraperitoneal [MeSH:C0021493] reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] mg kg ip day [MeSH:C0011017] vacuous chewing movement tongue protrusion [MeSH:C0040408] [MeSH:C0040408] count min reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] treated rat [MeSH:C0034721] [MeSH:C0034721] significantly develop vacuous chewing movement tongue protrusion [MeSH:C0040408] [MeSH:C0040408] coadministrat [MeSH:C0034721] [MeSH:C0034721]ion hibiscus [MeSH:C0884982] rosa sinensis root extract [MeSH:C1879704] mg kg orally attenuate [MeSH:C0042211] effect [MeSH:C4277511] biochemical [MeSH:C0017401] brain [MeSH:C0006104] [MeSH:C0006104] reveal reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] significantly increase lipid peroxidation [MeSH:C0023775] decrease level [MeSH:C0018759] [MeSH:C0018759] superoxide dismutase [MeSH:C0038838] sod catalase [MeSH:C0007367] cat glutathione reductase gsh index [MeSH:C0017824] oxidative stress [MeSH:C0242606] process [MeSH:C0242606] coadministrat [MeSH:C0034721] [MeSH:C0034721]ion extract significantly reduce lipid peroxidation [MeSH:C0023775] reverse decrease brain [MeSH:C0006104] [MeSH:C0006104] sod cat gsh level [MeSH:C0018759] [MeSH:C0018759] result present suggest hibiscus [MeSH:C0884982] rosa sinensis protective role reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179]-induced orofacial dyskinesia oxidative stress [MeSH:C0242606],neurological
lymphoma [MeSH:C0024299] cardiovascular lens [MeSH:C0007220],prospective examine ace inhibitor [MeSH:C0003015] hypertension [MeSH:C0020538] elderly patient investigation [MeSH:C0035173] include embolism [MeSH:C0013922] myocardial infarction heart attack method [MeSH:C0027051] participant [MeSH:C1708335] include result positive response implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
ataxia-telangiectasia [MeSH:C0004135] identification detection founder-effect mutation atm gene ethnic population,facilitate atm heterozygote [MeSH:C0019425] susceptibility disease breast cancer [MeSH:C0006142] attempt define common mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] frequency [MeSH:C3178846] ataxia-telangiectasia a-t homozygote ethnic population genomic mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] effect cdna [MeSH:C0006556] [MeSH:C0006556] characterize protein-truncation testing entire atm cdna [MeSH:C0006556] [MeSH:C0006556] detect truncating mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mutant [MeSH:C0026882] allele screen haplotyping [MeSH:C0018591] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] identical mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] indicate represent common ancestry spontaneously [MeSH:C0034705] recur atm mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] exist assay [MeSH:C0243073] require minimal amount genomic dna design allow rapid screening [MeSH:C0220908] [MeSH:C0220908] common ethnic mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] rapid assay [MeSH:C0243073] detect mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] costa rican patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] norwegian patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] polish patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] italian patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] amish mennonite irish [MeSH:C0022077] english [MeSH:C0014284] background additional mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] observe japanese [MeSH:C1556094] utah mormon african american [MeSH:C0085756] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] assay [MeSH:C0243073] facilitate screening [MeSH:C0220908] [MeSH:C0220908] a-t heterozygote [MeSH:C0019425] population study,neurological|oncological
cancer prevention multiple sclerosis [MeSH:C0026769],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve stroke outcome breast cancer pathway method observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient measure thyroid cancer [MeSH:C0549473] carcinoma result favorable safety profile optimization [MeSH:C0376695],oncological
thyroid function [MeSH:C0040130] urine-concentrating ability [MeSH:C0022654] lithium [MeSH:C0023870],suggest adenylate cyclase inhibition [MeSH:C1621327] important development [MeSH:C0243107] nephrogenic diabete insipidus hypothyroid [MeSH:C0020676] [MeSH:C0020676]ism lithium [MeSH:C0023870] [MeSH:C0023870] measure serum thyroxine [MeSH:C0040165] urine [MeSH:C0042036]-concentrating ability [MeSH:C0022654] umax response desmopressin ddavp patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive lithium [MeSH:C0023870] [MeSH:C0023870] hypothyroid [MeSH:C0020676] [MeSH:C0020676]ism [MeSH:C0020676] develop patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] take lithium [MeSH:C0023870] [MeSH:C0023870] impaired umax find euthyroid [MeSH:C0302859] hypothyroid [MeSH:C0020676] [MeSH:C0020676] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hypothyroid [MeSH:C0020676] [MeSH:C0020676] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] concentrate urine [MeSH:C0042036] conclude dominant [MeSH:C0017342] mechanism [MeSH:C1524059] lithium [MeSH:C0023870] [MeSH:C0023870] exert effect different,neurological|hepatorenal
synaptic story chronic kidney disease [MeSH:C1561643] paralysis [MeSH:C0522224],dementia [MeSH:C0497327] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve schwannoma amygdala method conduct observational [MeSH:C0302523] evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine amyotrophic lateral sclerosis [MeSH:C0002736] parameter result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
adrenoleukodystrophy adrenomyeloneuropathy [MeSH:C0162309] associate partial adrenal insufficiency [MeSH:C0001623] generation kindred,case adrenoleukodystrophy ald case adrenomyeloneuropathy [MeSH:C0162309] amn develop kindred generation demonstrate amn variant ald pituitary-adrenal function study [MeSH:C0032021] perform family member [MeSH:C0086282] include affect male [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] identify carrier [MeSH:C0007292] ald amn pituitary-adrenal abnormality find carrier [MeSH:C0007292] basal morning plasma [MeSH:C0032105] adrenocorticotropic hormone acth [MeSH:C0001655] [MeSH:C0001655] level [MeSH:C0018759] markedly elevated [MeSH:C0020443] male [MeSH:C0086582] [MeSH:C0086582] ald amn despite fact sign adrenal insufficiency [MeSH:C0001623] morning plasma [MeSH:C0032105] cortisol level [MeSH:C0018759] response maximal exogenous acth [MeSH:C0001655] stimulation appear normal addition integrate [MeSH:C0063690] -hour response administration [MeSH:C0001554] subnormal case people [MeSH:C5690824] ald amn subclinical partial adrenocrotical insufficiency endocrinologic dysfunction [MeSH:C0031847] identify,neurological|hepatorenal
protective effect antithrombin puromycin aminonucleoside nephrosis [MeSH:C0034146] rat [MeSH:C0034721],investigate [MeSH:C0035173] effect [MeSH:C4277511] antithrombin [MeSH:C0040018] [MeSH:C0003440] [MeSH:C0003440] plasma inhibitor coagulation factor rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] puromycin [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] aminonucleoside-induced nephrosis experimental model [MeSH:C0086272] human nephrotic syndrome [MeSH:C0027726] antithrombin [MeSH:C0040018] [MeSH:C0003440] [MeSH:C0003440] iu kg v administer [MeSH:C0001554] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] day [MeSH:C0011017] immediately injection puromycin [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] aminonucleoside mg kg v antithrombin [MeSH:C0040018] [MeSH:C0003440] [MeSH:C0003440] attenuate [MeSH:C0042211] puromycin [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] aminonucleoside-induced hematological abnormality puromycin [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] aminonucleoside-induced renal dysfunction hyperlipidemia [MeSH:C0020473] suppress [MeSH:C0017372] [MeSH:C0017372] histopathological examination reveal severe [MeSH:C1719672] renal damage [MeSH:C0012860] proteinaceous cast tubuli tubular expansion kidney rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] improvement [MeSH:C2936612] damage [MeSH:C0012860] see antithrombin [MeSH:C0040018] [MeSH:C0003440] [MeSH:C0003440]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] addition antithrombin [MeSH:C0040018] [MeSH:C0003440] [MeSH:C0003440] markedly suppress [MeSH:C0017372] [MeSH:C0017372] puromycin [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] aminonucleoside-induced apoptosis renal tubular epithelial cell [MeSH:C0014597] furthermore puromycin [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] aminonucleoside-induced increase renal cytokine [MeSH:C0079189] content decrease finding suggest thrombin [MeSH:C0040018] play important role pathogenesis [MeSH:C0699748] puromycin [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] [MeSH:C0034145] aminonucleoside-induced nephrotic syndrome antithrombin [MeSH:C0040018] [MeSH:C0003440] [MeSH:C0003440] clinically effect [MeSH:C4277511]ive patient nephrotic syndrome [MeSH:C0027726],hepatorenal
iatrogenically induce intractable [MeSH:C0030200] atrioventricular reentrant tachycardia [MeSH:C0039232] verapamil [MeSH:C0042523] catheter ablation [MeSH:C0162563] wolff-parkinson-white syndrome [MeSH:C0043202] idiopathic dilate cardiomyopathy [MeSH:C1449563],wpw syndrome idiopathic dilate cardiomyopathy [MeSH:C1449563] intractable [MeSH:C0030200] atrioventricular reentrant tachycardia [MeSH:C0039232] avrt iatrogenically induce qrs preexcitation [MeSH:C0032915] cause junctional escape beat verapamil [MeSH:C0042523] unidirectional antegrade block accessory pathway [MeSH:C0264897] catheter ablation [MeSH:C0162563] establish frequent [MeSH:C0017270] avrt attack [MeSH:C0086769],neurological|cardiovascular
lpp preferred fusion partner gene hmgic lipoma novel member lim protein gene family,major cytogene [MeSH:C0017337]tic subgroup lipoma [MeSH:C0023798] characterize recurrent chromosome aberration [MeSH:C0008625] mainly translocation [MeSH:C0599893] [MeSH:C0599893] involve chromosome segment 2q1-q1 multiple chromosome find translocation [MeSH:C0599893] [MeSH:C0599893] partner chromosome 3q2-q2 preferentially involve previous study [MeSH:C0085973] show high mobility hmg protein gene [MeSH:C0017337] hmgic 2q1 consistently rearrange consequence translocation [MeSH:C0599893] [MeSH:C0599893] report identification characterization chromosome -derived translocation [MeSH:C0599893] [MeSH:C0599893] partner gene [MeSH:C0017337] designate lpp lipoma [MeSH:C0023798] preferred partner gene [MeSH:C0017337] -race hmgic fusion transcript lipoma [MeSH:C0023798] cell line li- sv4 ectopic [MeSH:C0019933] gene [MeSH:C0017337]tic sequence [MeSH:C0950132] obtain cash chromosome [MeSH:C0008633] assignment [MeSH:C5691386] somatic cell hybrid fish [MeSH:C0020200] fluorescence situ hybridization [MeSH:C0162789] find originate chromosome segment 3q2-q2 northern blot mrna kb detect ectopic [MeSH:C0019933] sequence variety human [MeSH:C0086418] tissue brain peripheral blood leukocyte partial cdna cloning [MeSH:C0006556] feature gene [MeSH:C0017337]tic organization [MeSH:C0029246] lpp establish gene [MeSH:C0017337] find span genomic region kb nucleotide [MeSH:C0028630] sequence [MeSH:C0004793] composite [MeSH:C0009570] cdna lpp reveal open reading frame nucleotide [MeSH:C0028630] encode proline-rich protein [MeSH:C3275254] contain leucine-zipper motif amino-terminal region lim domain carboxy-terminal region lpp-encoded protein classify novel member protein lim protein gene [MeSH:C0017337] family reverse transcriptase combine polymerase chain reaction [MeSH:C0032520] number lipoma [MeSH:C0023798] cell line primary lipoma [MeSH:C0023798] appear lpp frequently rearrange case cytogene [MeSH:C0017337]tically detectable involvement [MeSH:C0030699] 3q2-q2 alternative [MeSH:C4255061] hmgic lpp hybrid transcript detect difference mainly presence lim domain predict hmgi-c [MeSH:C0122111] lpp fusion protein,neurological
nonalcoholic steatohepatitis pathway [MeSH:C3241937] stroke [MeSH:C0038454],cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve nash oliguria method [MeSH:C0028961] conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine cholelithiasis [MeSH:C0008350] parameter result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],hepatorenal
ultrasound [MeSH:C0220934] reveal multiple sclerosis [MeSH:C0026769] secret,randomized control examine [MeSH:C1096777] aspirin heart disease [MeSH:C0018799] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include seizure [MeSH:C0036572] amyotrophic lateral sclerosis radiculopathy [MeSH:C0002736] method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication need investigation [MeSH:C0035173] [MeSH:C0035173],neurological
effect [MeSH:C4277511] adriamycin [MeSH:C0085752] combine body hyperthermia tumor [MeSH:C5232927] normal tissue,thermal enhancement adriamycin-mediated antitumor [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] activity [MeSH:C0020115] normal tissue [MeSH:C0040300] [MeSH:C0040300] toxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] body hyperthermia [MeSH:C5232927] [MeSH:C5232927] [MeSH:C5232927] compare f3 rat [MeSH:C0034721] model antitumor [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] activity [MeSH:C0020115] study tumor growth delay assay acute [MeSH:C0184567] normal tissue [MeSH:C0040300] [MeSH:C0040300] toxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] e leukopenia thrombocytopenia [MeSH:C0040034] late normal tissue [MeSH:C0040300] [MeSH:C0040300] toxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] e myocardial kidney injury [MeSH:C2609414] evaluate [MeSH:C0013175] functional [MeSH:C0031843] physiological assay morphological technique [MeSH:C0010818] body hyperthermia [MeSH:C5232927] [MeSH:C5232927] [MeSH:C5232927] min degree c enhance adriamycin-mediated antitumor [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] activity [MeSH:C0020115] toxic [MeSH:C1256754] effect thermal enhancement rat [MeSH:C0034721]io calculate antitumor [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] activity [MeSH:C0020115] thermal enhancement rat [MeSH:C0034721]io estimate acute [MeSH:C0184567] hematological change estimate late damage base morphological cardiac renal lesion vary body hyperthermia [MeSH:C5232927] [MeSH:C5232927] [MeSH:C5232927] enhance adriamycin-mediated antitumor [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] effect normal tissue [MeSH:C0040300] [MeSH:C0040300] toxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] increase potential [MeSH:C0001272] therapeutic gain [MeSH:C0087111] combined modality erode,cardiovascular|hepatorenal|oncological
myelodysplastic syndrome [MeSH:C3463824] stroke [MeSH:C0038454] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient hodgkin lymphoma bladder cancer [MeSH:C0019829] result improvement [MeSH:C2936612] primary endpoint prostate cancer [MeSH:C0376358] correlation safety [MeSH:C0036043] consideration,cardiovascular|oncological
myeloproliferative neoplasm meet leukemia [MeSH:C0023418] neurological perspective,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] statin [MeSH:C0360714] dementia [MeSH:C0497327] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] myeloproliferative neoplasm brain result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] target [MeSH:C0039309] therapy [MeSH:C0039798] correlation [MeSH:C0010100] need investigation [MeSH:C0035173],neurological|oncological
screen esr mutation [MeSH:C0026882] breast ovarian cancer [MeSH:C1140680] patient [MeSH:C0030705],present leukocyte dna [MeSH:C0023516] patient [MeSH:C0030705] familial clustering [MeSH:C0009085] breast ovarian cancer [MeSH:C1140680] tumour dna breast carcinoma screen base mutation [MeSH:C0026882] estrogen receptor gene esr [MeSH:C0034804] patient [MeSH:C0030705] family history cancer [MeSH:C0241889] [MeSH:C0241889] carry gly10cys germline substitution [MeSH:C2936279] alteration detect female [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] male [MeSH:C0086582] [MeSH:C0086582] control female [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] male [MeSH:C0086582] [MeSH:C0086582] indicate substitution [MeSH:C2936279] probably represent polymorphism [MeSH:C0032529] female [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] control family history cancer [MeSH:C0241889] [MeSH:C0241889] know sister breast cancer [MeSH:C0006142] carry variant allele [MeSH:C0002085] possible significance glycine cysteine [MeSH:C0017890] completely rule investigate [MeSH:C0035173] somatic mutation [MeSH:C0026882] detect tumour study present provide support somatic esr base mutation [MeSH:C0026882] important mechanism [MeSH:C1524059] hormonal therapy [MeSH:C0039798] resistance [MeSH:C0034471] estrogen receptor-positive breast carcinoma,oncological
acute low pain [MeSH:C0184567] intravenous administration [MeSH:C0013125] amiodarone [MeSH:C0002598] report case,amiodarone [MeSH:C0002598] [MeSH:C0002598] represent effective antiarrhythm [MeSH:C0005167]ic drug cardioversion recent-onset atrial fibrillation [MeSH:C0004238] [MeSH:C0004238] af maintenance [MeSH:C0024501] sinus [MeSH:C0037189] rhythm [MeSH:C0005167] briefly describe patient [MeSH:C0030705] suffer recent-onset atrial fibrillation [MeSH:C0004238] [MeSH:C0004238] experience acute [MeSH:C0184567] devastating low pain [MeSH:C0024031] minute initiation intravenous [MeSH:C0085297] amiodarone [MeSH:C0002598] [MeSH:C0002598] loading [MeSH:C4279935] notably effect report [MeSH:C0009246] medical literature [MeSH:C0025120] clinician aware reaction [MeSH:C0031067] prompt termination parenteral administration [MeSH:C0001554] lead complete resolution [MeSH:C0037633],cardiovascular
ocular [MeSH:C0042789] auditory toxicity [MeSH:C0040539] hemodialyzed patient receive desferrioxamine [MeSH:C0011145],-month period hemodialyzed [MeSH:C0022678] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive desferrioxamine [MeSH:C0011145] [MeSH:C0011145] mg kg bw time weekly monitor detection [MeSH:C5392129] audiovisual [MeSH:C2936644] [MeSH:C0042817] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present symptom [MeSH:C3839861] visual [MeSH:C0042817] auditory [MeSH:C0004302] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] detailed ophthalmologic audiologic study disclose abnormality [MeSH:C0037268] asymptom [MeSH:C3839861]atic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] visual [MeSH:C0042817] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] retinal [MeSH:C0035331] origin characterize tritan-type dyschromatopsy associate loss visual [MeSH:C0042817] acuity pigmentary retinal [MeSH:C0035323] [MeSH:C0035331] deposit auditory [MeSH:C0004302] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] characterize mid- high-frequency [MeSH:C0019541] neurosensorial hearing loss lesion cochlear type [MeSH:C1691779] desferrioxamine [MeSH:C0011145] [MeSH:C0011145] withdrawal result complete recovery [MeSH:C0140116] [MeSH:C0140116] visual [MeSH:C0042817] function partial recovery [MeSH:C0140116] [MeSH:C0140116] complete reversal hear loss patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] partial recovery [MeSH:C0140116] [MeSH:C0140116] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] appear patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive high dose desferrioxamine [MeSH:C0011145] [MeSH:C0011145] coincide normalization ferritin aluminium serum level indicate audiovisual [MeSH:C2936644] [MeSH:C0042817] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] infrequent complication [MeSH:C1171258] hemodialyzed patient [MeSH:C0022678] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive desferrioxamine [MeSH:C0011145] [MeSH:C0011145] periodical audiovisual [MeSH:C2936644] [MeSH:C0042817] monitoring [MeSH:C0005517] perform hemodialyzed patient [MeSH:C0022678] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive drug [MeSH:C0013227] order detect adverse effect [MeSH:C0001688] early possible,neurological
mind matter epilepsy [MeSH:C0014544] neurodegenerative [MeSH:C0524851],cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve trigeminal neuralgia [MeSH:C0040997] peripheral neuropathy method [MeSH:C4721453] conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine neurofibroma [MeSH:C0027830] parameter result superior efficacy [MeSH:C5690761] need investigation [MeSH:C0035173],neurological
phase [MeSH:C0080129] antipurine antifolate lometrexol ddathf [MeSH:C0048852] give oral folic acid [MeSH:C0016410],lometrexol [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] antifolate [MeSH:C0016411] inhibit [MeSH:C0021463] glycinamide ribonucleotide formyltransferase [MeSH:C0070929] garft enzyme essential de novo purine synthesis extensive experimental [MeSH:C0016998] limited show lometrexol [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] activity tumour refractory drug notably methotrexate [MeSH:C0025677] initial development [MeSH:C0243107] lometrexol [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] curtail severe [MeSH:C1719672] cumulative antiproliferative toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] preclinical murine study [MeSH:C0085973] demonstrate toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] lometrexol [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] prevent [MeSH:C0000918] low dose folic acid [MeSH:C0016410] [MeSH:C0016410] [MeSH:C0016410] [MeSH:C0016410] administration [MeSH:C0001554] [MeSH:C0001554] e day [MeSH:C0011017] prior day [MeSH:C0011017] follow single bolus dose observation [MeSH:C0302523] prompt phase lometrexol [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] give folic acid [MeSH:C0016410] [MeSH:C0016410] [MeSH:C0016410] [MeSH:C0016410] supplementation [MeSH:C2350507] [MeSH:C2350507] confirm toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] lometrexol [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] markedly reduce folic acid [MeSH:C0016410] [MeSH:C0016410] [MeSH:C0016410] [MeSH:C0016410] supplementation [MeSH:C2350507] [MeSH:C2350507] thrombocytopenia mucositis major toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] clear relationship [MeSH:C0021797] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] extent plasma [MeSH:C0032105] [MeSH:C0032105] folate elevation associated study [MeSH:C0085973] demonstrate lometrexol [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] plasma [MeSH:C0032105] [MeSH:C0032105] pharmacokinetic [MeSH:C0031327] alter folic acid [MeSH:C0016410] [MeSH:C0016410] [MeSH:C0016410] [MeSH:C0016410] administration [MeSH:C0001554] [MeSH:C0001554] indicate supplementation [MeSH:C2350507] [MeSH:C2350507] unlikely reduce toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] enhance lometrexol [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] [MeSH:C0048852] plasma [MeSH:C0032105] [MeSH:C0032105] clearance [MeSH:C5243473] work describe report identify clinically acceptable schedule administration [MeSH:C0013154] [MeSH:C0001554] [MeSH:C0001554] garft inhibit [MeSH:C0021463]or information [MeSH:C5544371] facilitate future class compound cancer therapy,oncological
aortic dissection pathway hypertension,cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve dysarthria [MeSH:C0013362] pituitary adenoma method [MeSH:C0032000] conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine sinoatrial node [MeSH:C0037189] parameter result favorable safety profile relevance [MeSH:C2826293],neurological|cardiovascular
cardiomyopathy blood pressure [MeSH:C0005823] cardiac connection,dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve capillary premature beat method conduct longitudinal evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine endocardium [MeSH:C0014124] parameter result improve outcome [MeSH:C0206277] therapeutic innovation [MeSH:C0087111],cardiovascular
capillary [MeSH:C0006901] dementia vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] statin effect cancer tricuspid valve method cancer [MeSH:C0040960] patient [MeSH:C0030705] undergo randomized control bradycardia heart block assessment result well quality life measure relevance [MeSH:C2826293],cardiovascular
tumor terrain [MeSH:C0006118] lung cancer [MeSH:C0242379] exploration [MeSH:C0015329],heart disease [MeSH:C0018799] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve liver cancer [MeSH:C0345904] colorectal cancer method [MeSH:C0009402] conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine endometrial cancer [MeSH:C0476089] parameter result improve disease management practice [MeSH:C0600585] guideline,oncological
restrictive cardiomyopathy [MeSH:C0007196] prostate cancer [MeSH:C0376358] vascular [MeSH:C0221214] insight,stroke [MeSH:C0038454] affect elderly patient [MeSH:C0030705] worldwide particularly involve hypertension [MeSH:C0020538] atrioventricular block method [MeSH:C0004245] conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine sinoatrial node [MeSH:C0037189] parameter result improve disease management [MeSH:C0039798] relevance,cardiovascular
hepatitis [MeSH:C0019158] restrictive cardiomyopathy [MeSH:C0007196] cardiac connection,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] transient ischemic attack mechanism method observational [MeSH:C0302523] elderly patient assess mitral valve arterial [MeSH:C0026264] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication care improvement,cardiovascular
atorvastatin [MeSH:C0286651] prevent [MeSH:C0000918] reverse dexamethasone-induced hypertension rat [MeSH:C0034721],assess antioxidant effect [MeSH:C3179302] atorvastatin [MeSH:C0286651] [MeSH:C0286651] atorva dexamethasone dex [MeSH:C0011777] -induced hypertension [MeSH:C0020538] male [MeSH:C0086582] sprague-dawley rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat atorva mg kg tap water day dex increase systolic blood pressure [MeSH:C0005823] sbp mmhg plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] superoxide saline u ml dex p prevent [MeSH:C0000918]ion [MeSH:C2700409] sbp atorva dex increase mmhg significantly low dex-only p atorva reverse dex-induced hypertension [MeSH:C0020538] mmhg vs mmhg p decrease plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] superoxide dex atorva dex p plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] nitrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e nitrite [MeSH:C3848529] nox [MeSH:C0068355] decrease dex-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] compare saline-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] microm microm respectively p atorva affect plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] nox [MeSH:C0068355] thymus weight atorvastatin [MeSH:C0286651] [MeSH:C0286651] prevent [MeSH:C0000918] reverse dexamethasone-induced hypertension [MeSH:C0020538] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721],cardiovascular
cancer bladder cancer [MeSH:C0005684] oncological odyssey,diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve lung cancer [MeSH:C0242379] myeloproliferative neoplasm method conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine endometrial cancer [MeSH:C0476089] parameter result well quality life measure optimization [MeSH:C0376695],oncological
alt pattern parkinson disease [MeSH:C0030567] patient [MeSH:C0030705],hypothesis statin improve dementia [MeSH:C0497327] outcome parkinsonism pathway method randomized control trial cancer [MeSH:C1096777] patient [MeSH:C0030705] measure basal ganglion glomerular filtration [MeSH:C0017654] rate result decrease mortality rate [MeSH:C0205848] therapeutic [MeSH:C0087111] innovation,neurological|hepatorenal
next-generation ecg prostate cancer,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome end stage renal disease pathway method retrospective trial cancer patient measure albumin [MeSH:C0001924] alkaline phosphatase [MeSH:C0002059] result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],hepatorenal
leukemia [MeSH:C0023418] glomerulus organ [MeSH:C0029250] interplay,design [MeSH:C0013171] cross-sectional investigation metformin [MeSH:C0025598] dementia [MeSH:C0497327] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient glomerulus renal cyst result decrease mortality rate [MeSH:C0205848] polycystic kidney disease [MeSH:C0022680] correlation [MeSH:C0010100] cost-effectiveness [MeSH:C1511536] implication,hepatorenal
urinary symptom [MeSH:C0574785] quality life change [MeSH:C0008943] thai [MeSH:C0337910] woman [MeSH:C0043210] overactive bladder [MeSH:C0878773] tolterodine [MeSH:C0388753],objective urinary symptom [MeSH:C0574785] quality [MeSH:C0034379] life change [MeSH:C0008943] thai [MeSH:C0337910] [MeSH:C0337910] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] overactive bladder [MeSH:C0878773] oab tolterodine [MeSH:C0388753] [MeSH:C0388753] [MeSH:C0388753] thirty woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] aged year diagnose [MeSH:C0011900] oab gynecology clinic [MeSH:C0018417] king chulalongkorn memorial hospital january april include present tolterodine [MeSH:C0388753] [MeSH:C0388753] [MeSH:C0388753] mg twice daily give week change micturition [MeSH:C0042034] diary [MeSH:C0042034] variable tolerability determine short form sf3 questionaire [MeSH:C0034394] thai [MeSH:C0337910] [MeSH:C0337910] version [MeSH:C0042556] give week result week micturition [MeSH:C0042034] decrease time number nocturia [MeSH:C0028734] episode [MeSH:C0085554] decrease time night common effect [MeSH:C4277511] dry case case report [MeSH:C0684224] moderate degree case severe [MeSH:C1719672] degree case withdraw present severe [MeSH:C1719672] dry mouth [MeSH:C0226896] sf- score change significantly domain physical function role function emotional [MeSH:C0013987] social function [MeSH:C0031843] mental heath [MeSH:C0025353] tolterodine [MeSH:C0388753] [MeSH:C0388753] [MeSH:C0388753] tolerate effect [MeSH:C4277511] improve quality [MeSH:C0034379] life thai [MeSH:C0376558] [MeSH:C0337910] [MeSH:C0337910] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] oab,neurological
brain map [MeSH:C0006104] diabete mellitus insight,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome brain pathway method observational trial [MeSH:C0302523] elderly patient measuring stroke [MeSH:C0038454] convulsion [MeSH:C4048158] result well quality life measure need investigation [MeSH:C0035173],neurological
tumor terrain [MeSH:C0006118] peripheral artery disease [MeSH:C1704436] exploration [MeSH:C0015329],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] diabete skin cancer [MeSH:C0007114] method cardiac patient undergo observational [MeSH:C0302523] malignant lymphoma [MeSH:C0024299] assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] cost-effect [MeSH:C4277511]iveness implication,oncological
transient [MeSH:C0040704] neurological deficit [MeSH:C0521654] follow intrathecal injection [MeSH:C0021896] hyperbaric bupivacaine [MeSH:C0006400] unilateral spinal anaesthesia [MeSH:C0002928],describe case transient neurological deficit [MeSH:C0521654] [MeSH:C0521654] occur unilateral spinal anaesthesia [MeSH:C0002928] [MeSH:C0002928] mg hyperbaric [MeSH:C0020431] bupivacaine [MeSH:C0006400] slowly inject [MeSH:C1828121] -gauge pencil-point spinal needle surgery anaesthesia uneventful day surgery [MeSH:C0282046] report area hypoaesthesia l3-l4 dermatome leg [MeSH:C1140621] operate loss [MeSH:C2364111] pinprick sensation reduction muscular strength [MeSH:C0517349] sensation area return normal following week prospective multicentre study large population [MeSH:C0032659] long follow-up perform order evaluate [MeSH:C0013175] incidence [MeSH:C0021149] unusual effect [MeSH:C4277511] suggest low solution [MeSH:C0037633] concentration [MeSH:C0311432] prefer unilateral spinal anaesthesia [MeSH:C0002928] [MeSH:C0002928] hyperbaric [MeSH:C0020431] anaesthetic solution pencil-point needle slow inject [MeSH:C1828121]ion rate employ order minimize risk [MeSH:C0035647] localized [MeSH:C0036420] high peak anaesthetic concentration [MeSH:C0311432] lead transient neurological deficit [MeSH:C0521654] [MeSH:C0521654],neurological
genetic heterogeneity [MeSH:C0242960] g6pd deficiency mutant [MeSH:C1623416] allele g6pd shekii district azerbaijan,examination [MeSH:C0376306] g6pd deficiency patient shekii district hospital [MeSH:C0020006] azerbaijan reveal hemi- homo- heterozygotic carrier defect gd- frequency [MeSH:C0376249] calculate obtain compare neighbour region frequency [MeSH:C0376249] carrier g6pd deficiency resident village located alasani-aphtalan valley highly endemic [MeSH:C0277550] malaria [MeSH:C0024530] past nearly marriage [MeSH:C0024841] endogamic physico-chemical kinetic mutant form g6pd accord program lead identification variant ii class shekii bideiz shirin-bulakh okhut zakataly variant iii class okhut ii martinique-like resemblance majority variant electrophoretic [MeSH:C0013855] mobility erythrocyte enzyme activity permit suggest existence common parental [MeSH:C0030551] mutant g6pd allele distribute area,neurological
glioma connection leukemia,dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve cerebral infarction astrocytoma method [MeSH:C0007785] conduct retrospective [MeSH:C0035363] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine medulloblastoma [MeSH:C0025149] parameter result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],neurological
amiodarone-related pulmonary mass unique membranous glomerulonephritis [MeSH:C0017665] valvular heart disease [MeSH:C0018824] diagnostic [MeSH:C0086143] pitfall new finding,amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] anti-arrhythmic drug [MeSH:C0003195] life-threatening tachycardia adverse effect report report autopsy [MeSH:C0004398] case valvular heart disease [MeSH:C0018824] develop lung mass [MeSH:C0024109] cm diameter proteinuria [MeSH:C0033687] g amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] long lung mass [MeSH:C0024109] highly suspect lung cancer [MeSH:C0242379] ct positron emission tomography histologically lesion compose lymphoplasmacytic infiltrate alveolar wall intra-alveolar accumulation foamy macrophage contain characteristic myelinoid [MeSH:C0026969] body [MeSH:C1325596] indicate amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598]-related lesion addition lung tissue [MeSH:C0040300] unevenly distribute hemosiderin [MeSH:C0019113] deposition abnormally tortuous capillary see mass heavily hemosiderotic lung portion outside mass kidney glomerulus membrane spike [MeSH:C0022663] prominent swelling podocyte [MeSH:C1328818] subepithelial deposit large hump-like autoimmune disease [MeSH:C0004364] viral hepatitis [MeSH:C0019195] malignant neoplasm disease [MeSH:C0006826] known relationship [MeSH:C0021797] membranous glomerulonephritis [MeSH:C0017665] [MeSH:C0017665] find present case highlight possibility differential diagnosis amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598]-related pulmonary lesion neoplasm [MeSH:C0024121] difficult radiologically suggest membranous glomerulonephritis [MeSH:C0017665] [MeSH:C0017665] possible complication [MeSH:C1171258] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598],neurological|cardiovascular|hepatorenal|oncological
seizure [MeSH:C0036572] meet diabetes mellitus [MeSH:C0011849] neurological perspective,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer schwannoma mechanism method randomized control [MeSH:C1096777] elderly patient assess huntington disease migraine [MeSH:C0020179] result well quality life measure implication practice guideline [MeSH:C0936005],neurological
cholestatic jaundice [MeSH:C0022354] associate use metformin [MeSH:C0025598],report [MeSH:C0684224] develop cholestatic jaundice [MeSH:C0022346] [MeSH:C0022354] shortly initiation [MeSH:C0030943] metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] hydrochloride [MeSH:C0546849] ultrasound liver abdominal [MeSH:C0007876] ct normal ercp [MeSH:C0008310] show normal biliary [MeSH:C0005423] anatomy percutaneous liver biopsy obtain show marked cholestasis portal edema ductular proliferation acute inflammation metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] hydrochloride [MeSH:C0546849] discontinue jaundice [MeSH:C0022346] resolve slowly period month give onset jaundice [MeSH:C0022346] wk initiation [MeSH:C0030943] metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] believe case represent example metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598]-associated hepatotoxicity case report [MeSH:C0684224] [MeSH:C0684224],hepatorenal
neuroleptic malignant syndrome [MeSH:C0027849] risperidone [MeSH:C0073393],neuroleptic malignant syndrome [MeSH:C0027849] [MeSH:C0027849] [MeSH:C0027849] [MeSH:C0027849] think dopamine d2 receptor blockade [MeSH:C0019593] [MeSH:C0019593] [MeSH:C0058698] striatum [MeSH:C0315183] basal ganglion [MeSH:C0004781] risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] benzisoxazole derivative antipsychotic [MeSH:C0040615] high serotonin [MeSH:C0036751] -ht2 receptor blockade [MeSH:C0019593] dose-related d2 receptor blockade [MeSH:C0019593] [MeSH:C0019593] high ratio believe impart low frequency [MeSH:C0017270] extrapyramidal [MeSH:C0015372] [MeSH:C0015372] symptom risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] low dosage low frequency [MeSH:C0017270] extrapyramidal [MeSH:C0015372] [MeSH:C0015372] symptom think frequency neuroleptic malignant syndrome [MeSH:C0027849] [MeSH:C0027849] [MeSH:C0027849] [MeSH:C0027849] lower [MeSH:C0330090] -year-old woman [MeSH:C0043210] develop neuroleptic malignant syndrome [MeSH:C0027849] [MeSH:C0027849] [MeSH:C0027849] [MeSH:C0027849] monotherapy [MeSH:C0376626] risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] syndrome reverse discontinue risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] start dantrolene bromocriptine [MeSH:C0006230] appear protection [MeSH:C0524828] [MeSH:C0524828] extrapyramidal [MeSH:C0015372] [MeSH:C0015372] effect observe risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] ensure protection [MeSH:C0524828] [MeSH:C0524828] neuroleptic malignant syndrome [MeSH:C0027849] [MeSH:C0027849] [MeSH:C0027849] [MeSH:C0027849],neurological
head neck cancer pathway [MeSH:C0278996] multiple sclerosis [MeSH:C0026769],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke [MeSH:C0038454] bladder cancer [MeSH:C0005684] method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo prospective testicular cancer [MeSH:C0153594] proteinuria [MeSH:C0033687] assessment [MeSH:C0030198] result well quality life measure care improvement,hepatorenal|oncological
hepatocellular [MeSH:C0345904] meet breast cancer [MeSH:C0006142] neurological perspective,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] hypertension [MeSH:C0020538] participant [MeSH:C1708335] cardiac patient anuria [MeSH:C0003460] locus coeruleus [MeSH:C0023951] result superior efficacy acoustic neuroma [MeSH:C0027859] correlation [MeSH:C0010100] relevance [MeSH:C2826293],neurological|hepatorenal
dementia [MeSH:C0497327] embolism [MeSH:C0013922] cardiac connection,retrospective [MeSH:C0035363] examine ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include vein stenosis pad method participant [MeSH:C1708335] include result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication therapeutic [MeSH:C0087111] innovation,cardiovascular
next-generation endoscopy alzheimer disease,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke [MeSH:C0038454] nephrolithiasis method cardiac patient undergo randomized control aki steatosis assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint relevance,hepatorenal
cancer insufficiency [MeSH:C1565489] cardiac connection,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome thromboembolism pathway method [MeSH:C0040038] retrospective trial elderly patient measure premature beat pulmonary valve [MeSH:C0034086] result well quality life measure safety [MeSH:C0036043] consideration,cardiovascular
therapeutic [MeSH:C0087111] drug monitoring tobramycin once-daily versus twice-daily dosage schedule,evaluate [MeSH:C0013175] effect dosage regiman once-daily vs twice-daily tobramicyn steady-state serum concentration toxic [MeSH:C1256754]ity [MeSH:C0040539] material method patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo v tobramycin [MeSH:C0040341] mg kg randomised group [MeSH:C0018257] od n receive once-daily dose tobramycin [MeSH:C0040341] td n receive dose divide dose daily tobramycin [MeSH:C0040341] serum concentration peak trough measure enzyme multiplied immunoassay renal auditory function [MeSH:C0004303] [MeSH:C0004303] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] monitor immediately result group [MeSH:C0018257] comparable respect sex age body weight renal function statistically difference find mean daily dose duration cumulative dose trough concentration g ml group [MeSH:C0018257] peak concentration microg ml od td p mean peak concentration markedly different microg ml od vs microg ml td p pharmacokinetic [MeSH:C0031327] parameter ke h od vs h td t1 h od vs h td vd l kg od vs l kg td cl ml min kg od vs ml min kg td increase serum creatinine [MeSH:C0010294] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] od versus patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] td evidence [MeSH:C5575834] nephrotoxic [MeSH:C1256754]ity [MeSH:C0040539] td patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop decrease auditory function [MeSH:C0004303] [MeSH:C0004303] present auditory loss db od present decrease auditory function [MeSH:C0004303] [MeSH:C0004303] small suggest once-daily dosing regiman tobramycin [MeSH:C0040341] [MeSH:C0040341] effective [MeSH:C5392218] possibly toxic [MeSH:C1256754] twice-daily regiman single-dose therapy peak concentration determination [MeSH:C1148554] necessary trough sample monitor ensure level [MeSH:C0018759] microg ml,hepatorenal
thyroid cancer [MeSH:C0549473] pathway epilepsy [MeSH:C0014544],design [MeSH:C0013171] prospective investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] cancer patient [MeSH:C0030705] gamma glutamyl transferase chronic myeloid leukemia [MeSH:C0279543] result improve outcome cancer [MeSH:C0206277] correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],hepatorenal|oncological
rapid detection [MeSH:C5392129] regionally cluster germ-line [MeSH:C0017471] brca1 mutation multiplex heteroduplex,ukcccr familial ovarian cancer [MeSH:C1140680] germ-line mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0206530] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] gene [MeSH:C0376571] responsible substantial proportion family multiple case early-onset breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] isolation [MeSH:C0220862] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] distinct mutation [MeSH:C0026882] [MeSH:C0026882] scatter code region detect make gene consuming technically challenge develop multiplex heteroduplex design analyze one-quarter code sequence single-step screening procedure detect approximately brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] far report breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] family technique [MeSH:C0449851] analyze brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] family history breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] identify distinct mutation [MeSH:C0026882] [MeSH:C0026882] family,oncological
cerebral infarction [MeSH:C0007785] single oral dose phenylpropanolamine [MeSH:C0031495],phenylpropanolamine [MeSH:C0031495] ppa synthetic sympathomimetic structurally similar amphetamine [MeSH:C0002658] available counter anorectic [MeSH:C0003620] nasal congestant cold preparation prolonged use overuse associate [MeSH:C0004083] seizure intracerebral hemorrhage [MeSH:C2937358] neuropsychiatric symptom nonhemorrhagic cerebral infarction [MeSH:C0007785] [MeSH:C0007785] report case young [MeSH:C0340037] woman [MeSH:C0043210] suffer cerebral infarction [MeSH:C0007785] [MeSH:C0007785] take single oral dose ppa,neurological
comparison [MeSH:C0871382] laryngeal [MeSH:C0007107] mask endotracheal tube anesthesia [MeSH:C0002919] endoscopic sinus surgery [MeSH:C4042860],compare surgical condition include intraoperative [MeSH:C0021889] bleeding intraoperative [MeSH:C0021889] blood pressure functional endoscopic sinus surgery [MeSH:C4042860] fess flexible reinforce laryngeal [MeSH:C0007107] mask airway [MeSH:C0150126] frlma versus endotracheal tube ett maintain control hypotension [MeSH:C0020649] anesthesia [MeSH:C0020649] [MeSH:C0020649] induce propofol-remifentanil [MeSH:C0246631] [MeSH:C0246631] [MeSH:C0246631] total v anesthesia tiva method normotensive american society anesthesiologist i-ii adult [MeSH:C0001675] patient [MeSH:C0030705] [MeSH:C0030705] undergo fess control hypotension [MeSH:C0020649] anesthesia [MeSH:C0020649] [MeSH:C0020649] cause propofol-remifentanil [MeSH:C0246631] [MeSH:C0246631] [MeSH:C0246631]-tiva randomly assign group frlma ii ett hemorrhage [MeSH:C0019080] measure [MeSH:C0079809] visibility operative field evaluate [MeSH:C0013175] accord six-point scale result controlled hypotension [MeSH:C0020649] achieve short period laryngeal [MeSH:C0007107] mask low rate remifentanil [MeSH:C0246631] [MeSH:C0246631] [MeSH:C0246631] infusion [MeSH:C0841792] low total dose remifentanil [MeSH:C0246631] [MeSH:C0246631] [MeSH:C0246631] summary result indicate airway [MeSH:C0150126] management frlma control hypotension [MeSH:C0020649] anesthesia [MeSH:C0020649] [MeSH:C0020649] provide well surgical condition term quality [MeSH:C0034379] operative field blood loss [MeSH:C0032788] allow convenient induce hypotension [MeSH:C0020649] low dose remifentanil [MeSH:C0246631] [MeSH:C0246631] [MeSH:C0246631] tiva patient [MeSH:C0030705] [MeSH:C0030705] undergo fess,neurological|cardiovascular
downbeat nystagmus associate intravenous patient-controlled administration [MeSH:C0013125] morphine [MeSH:C0026549],implication case document [MeSH:C0009797] [MeSH:C0009797] develop dizziness [MeSH:C0012833] downbeating nystagmus receive relatively large dose iv patient-controlled analgesia [MeSH:C0078944] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] case report [MeSH:C0684224] epidural [MeSH:C0228134] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] symptom sign previously document [MeSH:C0009797] iv patient-controlle analgesia [MeSH:C0078944] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549],neurological
cancer kidney transplant [MeSH:C0740457] organ interplay,question [MeSH:C0600648] ace inhibitor affect [MeSH:C0001721] diabete oliguria [MeSH:C0028961] mechanism method prospective adult population assess jaundice pyelonephritis [MeSH:C0034186] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication therapeutic [MeSH:C0087111] innovation,hepatorenal
genetic heterogeneity [MeSH:C0242960] breast-ovarian cancer family,breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] linkage consortium breast-ovary cancer-family [MeSH:C0015576] syndrome dominant predisposition cancer breast ovary map chromosome region 7q1-q2 majority breast-ovary cancer family [MeSH:C0015576] linkage susceptibility locus designate brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] report result linkage family [MeSH:C0015576] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] family [MeSH:C0015576] contain total case early-onset age year breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] family [MeSH:C0015576] contain case ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] overall estimate family [MeSH:C0015576] link brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] locus family [MeSH:C0015576] case male [MeSH:C0086582] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] appear link estimate confidence interval [MeSH:C0009667] family [MeSH:C0015576] male [MeSH:C0086582] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] link brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] suggest breast-ovarian cancer [MeSH:C1140680] [MeSH:C1140680]-family [MeSH:C0015576] syndrome genetically heterogeneous large majority family [MeSH:C0015576] early-onset breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] case ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] likely brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882],oncological
genetic mapping [MeSH:C0008630] copper toxicosis locus bedlington terrier dog chromosome region [MeSH:C0008633] syntenic human chromosome region [MeSH:C0008633] 2p1-p1,abnormal [MeSH:C0853087] hepatic copper [MeSH:C0009968] [MeSH:C0009968] accumulation [MeSH:C0311432] [MeSH:C0311432] recognize inherit disorder [MeSH:C0040188] man mouse [MeSH:C0026809] rat [MeSH:C0034721] dog major cause hepatic copper [MeSH:C0009968] [MeSH:C0009968] accumulation [MeSH:C0311432] [MeSH:C0311432] man dysfunctional [MeSH:C0031847] atp7b gene [MeSH:C4547003] [MeSH:C4547003] [MeSH:C4547003] cause wilson disease [MeSH:C0019202] wd mutation [MeSH:C0026882] atp7b gene [MeSH:C4547003] [MeSH:C4547003] [MeSH:C4547003] demonstrat [MeSH:C0034721]e mouse [MeSH:C0026809] rat [MeSH:C0034721] atp7b gene [MeSH:C4547003] [MeSH:C4547003] [MeSH:C4547003] exclude rare human [MeSH:C0086418] copper overload disease non-indian childhood cirrhosis [MeSH:C1858051] indicate genetic heterogeneity [MeSH:C0242960] investigate [MeSH:C0035173] [MeSH:C0035173] common autosomal recessive copper toxicosis ct bedlington terrier identify new locus [MeSH:C0085286] involve progressive [MeSH:C1449744] liver disease [MeSH:C0023895] examine wd gene atp7b [MeSH:C4547003] causative ct investigate [MeSH:C0035173] [MeSH:C0035173] chromosomal [MeSH:C0008633] co-localization atp7b c0 fluorescence situ hybridization fish [MeSH:C0162789] c0 anonymous microsatellite marker closely link ct bac clone [MeSH:C0009013] contain atp7b c0 map canine chromosome region [MeSH:C0008633] cfa22q1 cfa10q2 respectively demonstrat [MeSH:C0034721]e wd homologous ct copper transport gene ctr1 [MeSH:C0962796] ctr2 [MeSH:C0676792] exclude candidate gene ct map canine chromosome region [MeSH:C0008633] cfa11q2 transcribe sequence identify c0-containe bac find homologous gene [MeSH:C3485979] express human [MeSH:C0086418] chromosome 2p1-p1 region devoid positional candidate gene,hepatorenal
hprt-aprt-deficient mouse model lesch-nyhan syndrome [MeSH:C0023374],complete [MeSH:C0011455] hypoxanthine-guanine phosphoribosyl-transferase hprt deficiency [MeSH:C1623416] [MeSH:C0023374] human [MeSH:C0086418] [MeSH:C0086418] result lesch-nyhan syndrome [MeSH:C0023374] [MeSH:C0023374] [MeSH:C0023374] characterize feature compulsive [MeSH:C5392230] self-injurious behavior [MeSH:C0085271] [MeSH:C0085271] hprt-deficient mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] generate mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] embryonic stem cell exhibit behavioral [MeSH:C0004927] symptom [MeSH:C3839861] associate [MeSH:C0004083] lesch-nyhan syndrome [MeSH:C0023374] [MeSH:C0023374] [MeSH:C0023374] administration drug [MeSH:C1527425] inhibit [MeSH:C0021463] adenine [MeSH:C0001407] phosphoribosyltransferase aprt [MeSH:C0001414] hprt-deficient mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] produce suggestion deficiency [MeSH:C1623416] aprt combination hprt-deficiency [MeSH:C0023374] [MeSH:C1623416] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] lead self-mutilation behavior c [MeSH:C0036601] l wu w melton nature genet test [MeSH:C0038138] proposition [MeSH:C0033422] breed [MeSH:C0006159] hprt-aprt-deficient mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] doubly-deficient mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] excrete adenine [MeSH:C0001407] highly insoluble [MeSH:C0021641] derivative [MeSH:C4704814] -dihydroxyadenine [MeSH:C0001407] associate [MeSH:C0004083] human [MeSH:C0086418] [MeSH:C0086418] aprt deficiency [MeSH:C0268120] [MeSH:C1623416] additional abnormality [MeSH:C0037268] self-injurious behavior [MeSH:C0085271] [MeSH:C0085271] detect aprt-hprt-deficient mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] devoid purine salvage pathway novel phenotype [MeSH:C0031437] model behavioral [MeSH:C0004927] abnormality [MeSH:C0037268] associate [MeSH:C0004083] lesch-nyhan syndrome [MeSH:C0023374] [MeSH:C0023374] [MeSH:C0023374] previously suggest,neurological
bradycardia [MeSH:C0428977] high-dose intravenous methylprednisolone therapy,consecutive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] rheumatoid arthritis receive intravenous [MeSH:C0085297] high-dose methylprednisolone mp therapy g daily consecutive day [MeSH:C0011017] decline pulse rate [MeSH:C0232117] observe pronounced patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] bradycardia associate complaint substernal pressure reversal normal heart rate find electrocardiographic registration [MeSH:C0180600] show sinus bradycardia [MeSH:C0428977] case change plasma [MeSH:C0032105] concentration [MeSH:C0311432] electrolyte [MeSH:C0013832] find careful observation [MeSH:C0302523] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive high-dose mp recommend high-dose mp contraindicate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] known heart disease [MeSH:C0018799],cardiovascular
jaundice pathway dementia [MeSH:C0497327],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome renal stone pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring jaundice anuria [MeSH:C0022346] result improve outcome practice guideline [MeSH:C0936005],hepatorenal
clotiazepam-induced acute hepatitis [MeSH:C0019158],report case [MeSH:C0684224] develop acute hepatitis [MeSH:C0019158] [MeSH:C0019158] [MeSH:C0019158] extensive hepatocellular necrosis [MeSH:C0345904] month onset administration [MeSH:C0001554] clotiazepam [MeSH:C0009073] [MeSH:C0009073] [MeSH:C0009073] thienodiazepine derivative clotiazepam [MeSH:C0009073] [MeSH:C0009073] [MeSH:C0009073] withdrawal [MeSH:C1881606] follow prompt recovery [MeSH:C0140116] [MeSH:C0140116] administration [MeSH:C0001554] benzodiazepine [MeSH:C4048284] chemically related clotiazepam [MeSH:C0009073] [MeSH:C0009073] [MeSH:C0009073] interfere recovery [MeSH:C0140116] [MeSH:C0140116] induce relapse [MeSH:C0035020] hepatitis [MeSH:C0019158] observation [MeSH:C0302523] show clotiazepam [MeSH:C0009073] [MeSH:C0009073] [MeSH:C0009073] induce acute hepatitis [MeSH:C0019158] [MeSH:C0019158] [MeSH:C0019158] suggest cross hepatotoxicity clotiazepam [MeSH:C0009073] [MeSH:C0009073] [MeSH:C0009073] benzodiazepine [MeSH:C4048284],hepatorenal
fatal intracranial bleeding associate prehospital use epinephrine [MeSH:C0014563],present case paramedic [MeSH:C0030450] misjudgment execution protocol allergic reaction [MeSH:C1527304] [MeSH:C1527304] case pulmonary edema [MeSH:C0034063] wheeze sudden onset respiratory distress [MeSH:C0852283] rash history [MeSH:C0019664] new medicine [MeSH:C0025118] lead paramedic [MeSH:C0030450] scene [MeSH:C0030450] administer subcutaneous epinephrine [MeSH:C0014563] subsequently acute cardiac arrest [MeSH:C0018790] [MeSH:C0018790] fatal subarachnoid hemorrhage [MeSH:C0038525] occur epinephrine [MeSH:C0014563] prove role cardiac arrest [MeSH:C0018790] prehospital care use paramedic [MeSH:C0030450] patient [MeSH:C0030705] suspect allergic reaction [MeSH:C1527304] [MeSH:C1527304] severe hypertension [MeSH:C0020538] view caution,cardiovascular
urine [MeSH:C0042036] n-acetyl-beta-d-glucosaminidase marker [MeSH:C0001057] tubular damage,indicator [MeSH:C0021212] renal tubular dysfunction [MeSH:C0015624] increase urinary n-acetyl-beta-d-glucosaminidase nag activity [MeSH:C0020115] [MeSH:C0001057] reflect increase lysosomal [MeSH:C0024369] activity [MeSH:C0020115] renal tubular cell method puromycin aminonucleoside pan administer sprague dawley [MeSH:C0034715] rat [MeSH:C0034721] induce protein [MeSH:C0033684]uria total protein [MeSH:C0033684] albumin nag activity [MeSH:C0020115] protein [MeSH:C0033684] electrophoretic pattern assess daily urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] sample day [MeSH:C0011017] morphological appearance [MeSH:C0750731] kidney [MeSH:C0022646] examine day [MeSH:C0011017] thirty nag isoenzyme [MeSH:C0022173] pattern day [MeSH:C0011017] zero thirty result follow intravenous pan urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] volume urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] nag activity [MeSH:C0020115] increase significantly return normal treat animal [MeSH:C0003062] exhibit marked rise urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] albumin total protein [MeSH:C0033684] excretion nag activity [MeSH:C0020115] electrophoresis show generalised increase middle high molecular weight [MeSH:C0949685] urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] protein [MeSH:C0033684] onward protein [MeSH:C0033684] droplet appear prominent tubular cell peak urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] nag activity [MeSH:C0020115] nag isoenzyme [MeSH:C0022173] pattern coincide peak protein [MeSH:C0033684]uria reduction [MeSH:C1827449] intracellular protein [MeSH:C0033684] [MeSH:C0682581] nag droplet onward conclusion animal [MeSH:C0003062] model demonstrat [MeSH:C0034721]e increase lysosomal [MeSH:C0024369] turnover [MeSH:C0085268] urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] nag activity [MeSH:C0020115] occur increase protein [MeSH:C0033684] present tubular cell urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] nag activity [MeSH:C0020115] altered function renal tubule simply indicator [MeSH:C0021212] damage [MeSH:C0012860],hepatorenal
myocardial infarction [MeSH:C0027051] cardiovascular lens [MeSH:C0007220],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve stroke outcome thromboembolism pathway method [MeSH:C0040038] cross-sectional trial [MeSH:C0010362] cardiac patient measure aortic valve atrial fibrillation [MeSH:C0004238] result improvement primary endpoint relevance,cardiovascular
frequent lithium administration [MeSH:C0001554] low urine volume,design [MeSH:C0013171] determine patient [MeSH:C0030705] [MeSH:C0030705] maintain regimen [MeSH:C1880476] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] once-per-day schedule low urine volume [MeSH:C5690805] [MeSH:C5690805] [MeSH:C5690805] patient [MeSH:C0030705] [MeSH:C0030705] receive multiple dose cross-sectional patient [MeSH:C0010362] [MeSH:C0030705] [MeSH:C0030705] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] clinic receive different dose schedule patient [MeSH:C0030705] [MeSH:C0030705] admit hospital measurement lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] creatinine clearance urine volume [MeSH:C5690805] [MeSH:C5690805] [MeSH:C5690805] maximum osmolality [MeSH:C0086741] result multiple daily dose lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] associate high urine volume [MeSH:C5690805] [MeSH:C5690805] [MeSH:C5690805] dose schedule duration [MeSH:C0086960] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] daily dose lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] affect maximum osmolality [MeSH:C0086741] creatinine clearance conclusion urine volume [MeSH:C5690805] [MeSH:C5690805] [MeSH:C5690805] reduce give lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] daily lower total daily dose lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-induced polyuria related extrarenal renal effect,neurological|hepatorenal
alpha-blocker lymphoma brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] tia pathway method longitudinal trial cancer patient [MeSH:C0030705] measure autonomic neuropathy [MeSH:C0271686] alzheimer disease result improve outcome [MeSH:C0206277] healthcare advancement,neurological
cardiomyopathy [MeSH:C0878544] colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,assess efficacy [MeSH:C5690761] statin [MeSH:C0360714] [MeSH:C0360714] dementia [MeSH:C0497327] focus myocardial congestive heart failure method [MeSH:C0018802] diabetic [MeSH:C1263960] patient [MeSH:C0030705] randomized receive statin [MeSH:C0360714] [MeSH:C0360714] placebo [MeSH:C0032041] atrial fibrillation [MeSH:C0004238] monitoring [MeSH:C0005517] result favorable safety [MeSH:C0036043] profile healthcare advancement,cardiovascular
cancer colorectal cancer [MeSH:C0009402] connection [MeSH:C0056248],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect cancer leukemia [MeSH:C0023418] method elderly patient undergo randomized control stomach cancer bladder cancer [MeSH:C0005684] assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
leukemia [MeSH:C0023418] coronary artery disease [MeSH:C1956346] cardiac connection,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke [MeSH:C0038454] pulmonary embolism [MeSH:C0034065] method cardiac patient undergo observational [MeSH:C0302523] bundle branch block heart attack [MeSH:C0006384] assessment result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
effect [MeSH:C4277511] convert enzyme inhibition course adriamycin-induced nephropathy,effect [MeSH:C4277511] convert enzyme inhibitor [MeSH:C0014432] cei enalapril [MeSH:C0014025] assess munich-wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] established adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] nephrosis [MeSH:C0027720] [MeSH:C0027720] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give single dose adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] later divide group match albuminuria [MeSH:C0001925] [MeSH:C0001925] [MeSH:C0001925] blood pressure [MeSH:C0005823] plasma albumin [MeSH:C0005823] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion group remain untreated group receive enalapril [MeSH:C0014025] group undergo micropuncture study [MeSH:C0085973] [MeSH:C0026014] day short-term [MeSH:C0025265] study [MeSH:C0085973] show enalapril [MeSH:C0014025] reduce arterial blood pressure [MeSH:C0005823] [MeSH:C1272641] vs mm hg vs p glomerular capillary pressure vs mm hg p reduce albuminuria [MeSH:C0001925] [MeSH:C0001925] [MeSH:C0001925] vs mg gfr vs ml min group study [MeSH:C0085973] month assess effect [MeSH:C4277511] enalapril [MeSH:C0014025] progression renal injury [MeSH:C2609414] adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] nephrosis [MeSH:C0027720] [MeSH:C0027720] chronic enalapril [MeSH:C0014025] reduce blood pressure [MeSH:C0005823] reduce albuminuria [MeSH:C0001925] [MeSH:C0001925] [MeSH:C0001925] untreated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] exhibit progressive [MeSH:C1449744] reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] gfr ml min month ml min month enalapril [MeSH:C0014025] blunt prevent reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] gfr ml min month ml min month p vs reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] gfr associate development [MeSH:C0020119] glomerular sclerosis treat untreated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] abstract [MeSH:C0600678] truncate word,cardiovascular|hepatorenal
high resolution genetic [MeSH:C0017380] suggest ancestral predispose haplotype [MeSH:C0018591] origin [MeSH:C0005495] myotonic dystrophy mutation [MeSH:C0027126],mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cause myotonic dystrophy [MeSH:C0027126] dm identify [MeSH:C0027126] amplification [MeSH:C0017256] [MeSH:C0017256] unstable trinucleotide ctg n repeat global dm population complete linkage disequilibrium alu element polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] dm kinase gene suggest dm consequence ancestral mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] recent utilize polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] flanking dinucleotide marker suggest similar fragile x syndrome [MeSH:C0016667] dm exhibit founder effect [MeSH:C0242918] imbert et al nature [MeSH:C0349590] genet contrast low reproductive fitness individual [MeSH:C0021228] congenital dm endpoint genetic anticipation [MeSH:C0600498] myotonic dystrophy [MeSH:C0027126] suggest high rate new mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] present high resolution [MeSH:C0037633] genetic dm locus pcr [MeSH:C0032520] based assay [MeSH:C0243073] polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] span physical distance [MeSH:C5392135] kb immediately flank dm kinase gene persistent [MeSH:C0026205] complete allelic [MeSH:C0524869] association [MeSH:C0004083] dm mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] provide support previous observation [MeSH:C0302523] suggest strongly dm mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] occur particular haplotype [MeSH:C0018591] ctg n repeat inherently unstable predisposed amplification [MeSH:C0017256] [MeSH:C0017256],neurological
myotonic dystrophy role cug [MeSH:C0027126] triplet repeat splicing [MeSH:C0282537] novel dmpk [MeSH:C0216045] [MeSH:C0216045] exon [MeSH:C0015295] alter cytoplasmic [MeSH:C0206587] dmpk [MeSH:C0216045] [MeSH:C0216045] mrna isoform ratio,mechanism [MeSH:C1524059] ctg n expansion [MeSH:C0196940] utr [MeSH:C0600493] dmpk [MeSH:C0216045] [MeSH:C0216045] gene cause myotonic dystrophy dm unknown identify rna splicing factor hnrnp c u2af u2 auxiliary factor ptb polypyrimidine tract binding protein psf ptb associate splicing factor [MeSH:C0137872] --that bind short region cug n find novel dmpk [MeSH:C0216045] [MeSH:C0216045] exon result mrna [MeSH:C0035696] [MeSH:C0035696] lack repeat propose cug n essential cis act element splicing event contrast cug n contain mrna [MeSH:C0035696] [MeSH:C0035696] novel isoform [MeSH:C0597298] retain nucleus dm cell [MeSH:C0007610] result imbalance [MeSH:C0001118] relative level cytoplasmic [MeSH:C0206587] dmpk [MeSH:C0216045] [MeSH:C0216045] mrna [MeSH:C0035696] [MeSH:C0035696] isoform [MeSH:C0597298] new dominant [MeSH:C0017342] effect mutation dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045],neurological
attenuation [MeSH:C1720750] methamphetamine-induced nigrostriatal dopaminergic neurotoxicity [MeSH:C0235032] mouse [MeSH:C0026809] lipopolysaccharide [MeSH:C0023810] pretreatment [MeSH:C0376495],immunological activation [MeSH:C0021054] propose play role methamphetamine [MeSH:C0025611] [MeSH:C0025611]-induced dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030]rgic terminal damage examine role lipopolysaccharide [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] pro-inflammatory inflammatory factor [MeSH:C0003209] modulate methamphetamine [MeSH:C0025611] [MeSH:C0025611]-induced nigrostriatal dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] neurotoxicity [MeSH:C0235032] [MeSH:C0235032] lipopolysaccharide [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] affect basal body [MeSH:C3536735] temperature methamphetamine [MeSH:C0025611] [MeSH:C0025611]-elicited hyperthermia [MeSH:C5232927] day [MeSH:C0011017] later systemic [MeSH:C5544477] [MeSH:C5544477] [MeSH:C5544477] lipopolysaccharide [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] mitigate methamphetamine [MeSH:C0025611] [MeSH:C0025611]-induced striatal dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] -dihydroxyphenylacetic acid depletion dose-dependent manner potent dose mg kg lipopolysaccharide [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] administer week methamphetamine [MeSH:C0025611] [MeSH:C0025611] dosing regiman methamphetamine [MeSH:C0025611] [MeSH:C0025611]-induced striatal dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] -dihydroxyphenylacetic acid depletion remain unaltered systemic [MeSH:C5544477] [MeSH:C5544477] [MeSH:C5544477] lipopolysaccharide [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] mg kg attenuate [MeSH:C0042211] local methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] infusion-produced dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] -dihydroxyphenylacetic acid depletion striatum [MeSH:C0315183] indicate protective effect lipopolysaccharide [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] likely interrupted [MeSH:C3850092] peripheral [MeSH:C3658334] distribution metabolism methamphetamine [MeSH:C0025611] [MeSH:C0025611] conclude critical window systemic [MeSH:C5544477] [MeSH:C5544477] [MeSH:C5544477] lipopolysaccharide [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] [MeSH:C0023810] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] exert effective protection [MeSH:C0524828] methamphetamine [MeSH:C0025611] [MeSH:C0025611]-induced nigrostriatal dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] neurotoxicity [MeSH:C0235032] [MeSH:C0235032],neurological
death [MeSH:C0011065] chemotherapy [MeSH:C0013216] gestational trophoblastic disease [MeSH:C2931618],multiple [MeSH:C0026771] cytotoxic drug [MeSH:C0013227] administration generally accept patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] high-risk stage choriocarcinoma base principle -year old [MeSH:C0001795] woman [MeSH:C0043210] classify high-risk gold [MeSH:C0001795]stein berkowitz score treat multiple [MeSH:C0026771] cytotoxic drug [MeSH:C0013227] multiple [MeSH:C0026771] drug [MeSH:C0013227] schema consist etoposide [MeSH:C0015133] methotrexate cyclophosphamide actomycin-d cisplatin [MeSH:C0008838] schedule [MeSH:C0086960] moderate high dose methotrexate etoposide [MeSH:C0015133] cyclophosphamide administer hour initiation therapy [MeSH:C0034619] die picture resemble massive pulmonary obstruction [MeSH:C0600260] choriocarcinomic [MeSH:C0008497] tissue [MeSH:C0040300] plugs [MeSH:C1533108] [MeSH:C1533108] probably originate uterus [MeSH:C0042149] formation [MeSH:C0029433] [MeSH:C0029433] plugs [MeSH:C1533108] [MeSH:C1533108] probably extensive tumor necrosis wall major uterine vein result open exchange tumor plugs [MeSH:C1533108] [MeSH:C1533108] vascular space decrease tumor tissue [MeSH:C0040300] [MeSH:C0040300] coherence secondary chemotherapy [MeSH:C0013216] [MeSH:C0013216] contribute formation [MeSH:C0029433] [MeSH:C0029433] tumor embolus [MeSH:C1704212] view close association [MeSH:C0004083] start chemotherapy [MeSH:C0013216] acute onset massive embolism [MeSH:C0013922] explanation spontaneous necrosis consider likely patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] large pelvic tumor load [MeSH:C0376705] accord exist classification [MeSH:C0008902] high risk [MeSH:C0556482] die develop drug [MeSH:C0013227] resistance [MeSH:C0013203] notwithstande fact finding suggest patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] benefit relatively mild initial especially true patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] previously expose drug [MeSH:C0013227] close observation response [MeSH:C0302523] status clinically beta-hcg value indicate agressive combination chemotherapy [MeSH:C0013218] [MeSH:C0013216] start abstract [MeSH:C0600678] truncate word,oncological
septum marker prostate cancer [MeSH:C0376358],retrospective [MeSH:C0035363] examine statin hypertension [MeSH:C0020538] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include arterial heart valve pad method participant [MeSH:C1708335] include result positive response implication practice guideline,cardiovascular
tumor terrain [MeSH:C0006118] breast cancer [MeSH:C0006142] exploration [MeSH:C0015329],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] prostate cancer [MeSH:C0376358] pathway method prospective trial adult population measure myeloproliferative neoplasm target therapy [MeSH:C2699893] result favorable safety profile practice guideline,oncological
age renal clearance cimetidine [MeSH:C0008783],patient [MeSH:C0030705] age [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0030705] yr receive cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] therapeutically [MeSH:C0087111] serum [MeSH:C0229671] [MeSH:C0229671] sample urine form interim collect cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] high-pressure liquid chromatography creatinine [MeSH:C0010294] [MeSH:C0008562] cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] clearance [MeSH:C5243473] [MeSH:C5243473] [MeSH:C5243473] decrease age [MeSH:C0024842] [MeSH:C0024842] extrapolate -hr serum [MeSH:C0229671] [MeSH:C0229671] concentration [MeSH:C0311432] cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] unit dose intravenous [MeSH:C0085297] cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] increase age [MeSH:C0024842] [MeSH:C0024842] patient [MeSH:C0030705] ratio cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] clearance [MeSH:C5243473] [MeSH:C5243473] [MeSH:C5243473] creatinine [MeSH:C0010294] clearance [MeSH:C5243473] [MeSH:C5243473] [MeSH:C5243473] rc average [MeSH:C0024842] [MeSH:C0024842] indicate net tubular secretion [MeSH:C0036536] [MeSH:C0036536] cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] rc independent age [MeSH:C0024842] [MeSH:C0024842] decrease increase serum [MeSH:C0229671] [MeSH:C0229671] concentration [MeSH:C0311432] cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] suggest secretion [MeSH:C0036536] cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] saturable process case dementia [MeSH:C0497327] possibly cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] drug microgram [MeSH:C0376691] ml hr dose patient [MeSH:C0030705] liver kidney disease [MeSH:C0022658] cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] level [MeSH:C0018759] [MeSH:C0018759] microgram [MeSH:C0376691] ml high cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] level [MeSH:C0018759] [MeSH:C0018759] induce dementia [MeSH:C0497327],neurological|hepatorenal
vein peripheral artery disease [MeSH:C1704436] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] transaminase venous result improve outcome systolic correlation care improvement [MeSH:C2936612],cardiovascular|hepatorenal
revolutionary mri [MeSH:C1449757] ventricular tachycardia diagnosis [MeSH:C0042514],investigate [MeSH:C0035173] statin effect cancer ischemic cardiomyopathy [MeSH:C0878544] method adult [MeSH:C0001675] population [MeSH:C0032659] undergo randomized control blood vessel pericardium assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
dementia [MeSH:C0497327] cholestasis [MeSH:C0008370] organ [MeSH:C0029250] interplay,cross-sectional [MeSH:C0010362] examine beta-blocker hypertension elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include oliguria glomerular filtration rate renal method [MeSH:C0017654] participant [MeSH:C1708335] include result well quality life measure implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
constitutional [MeSH:C0442681] von hippel-lindau vhl gene deletion detect vhl family fluorescence situ hybridization [MeSH:C0162789],von hippel-lindau [MeSH:C0019562] vhl [MeSH:C0299505] disease autosomal dominantly inherit cancer syndrome [MeSH:C0039082] predispose variety tumor type [MeSH:C0027651] include retinal [MeSH:C0035331] hemangioblastoma [MeSH:C0206734] [MeSH:C0206734] hemangioblastoma [MeSH:C0206734] [MeSH:C0206734] central nervous system renal cell carcinoma [MeSH:C3714787] pancreatic cyst [MeSH:C0030283] tumor pheochromocytoma [MeSH:C0031511] endolymphatic sac [MeSH:C0014168] tumor epididymal cystadenoma [MeSH:C5442141] w linehan et al j med assoc e maher w g kaelin jr medicine baltimore w linehan r klausner b vogelstein k kinzler ed genetic basis human cancer [MeSH:C0006826] pp mcgraw-hill vhl [MeSH:C0299505] gene localized chromosome 3p2- clone [MeSH:C0009013] f latif et al science washington dc germline mutation [MeSH:C0206530] vhl [MeSH:C0299505] gene detect majority vhl [MeSH:C0299505] kindred report frequency [MeSH:C0376249] [MeSH:C0017270] detection vhl [MeSH:C0299505] germline mutation [MeSH:C0206530] [MeSH:C0206530] vary j whaley et al j hum genet japan [MeSH:C0022341] hum mol genet f chen et al hum mutat e r maher et al j med genet b zbar cancer surv recently quantitative southern blotting procedure [MeSH:C0005862] find improve frequency [MeSH:C0376249] c stolle et al hum mutat present report use fluorescence situ hybridization fish [MeSH:C0162789] detect characterize vhl [MeSH:C0299505] germline deletion [MeSH:C0017260] reexamine vhl [MeSH:C0299505] patient show previously single-strand conformation sequencing harbor point mutation [MeSH:C0162735] vhl [MeSH:C0299505] locus find constitutional deletion [MeSH:C0017260] vhl [MeSH:C0299505] patient cosmid p1 probe cover vhl [MeSH:C0299505] locus test phenotypically normal offspring [MeSH:C0683572] vhl [MeSH:C0299505] family find carry deletion [MeSH:C0017260] deletion [MeSH:C0017260]-free addition germline mosaicism vhl [MeSH:C0299505] gene identify family sum fish find simple reliable detect vhl [MeSH:C0299505] germline deletion [MeSH:C0017260] practically useful case method [MeSH:C0025663] screening [MeSH:C0220908] fail detect vhl [MeSH:C0299505] gene abnormality,hepatorenal|oncological
de novo deletion snrpn exon early human [MeSH:C0086418] mouse [MeSH:C0026809] embryo paternal [MeSH:C0030652] maternal [MeSH:C0024915] imprint switch,prader-willi syndrome [MeSH:C0032897] pws neurogenetic disease [MeSH:C0019247] characterize infantile hypotonia gonadal hypoplasia obsessive behaviour [MeSH:C0028765] neonatal [MeSH:C0021709] feeding [MeSH:C0086225] difficulty follow hyperphagia [MeSH:C0020505] lead profound obesity [MeSH:C0028754] pws lack paternal [MeSH:C0030652] [MeSH:C0030652] [MeSH:C0030652] genetic information 5q1-q1 ref imprint paternal [MeSH:C0030652] [MeSH:C0030652] [MeSH:C0030652]ly express gene map [MeSH:C0024779] pws region mkrn3 ref ndn ref ndnl1 ref snrpn ref ipw ref poorly characterize framents designate par- par- ref imprinting region involve bipartite imprinting centre ic overlap snrpn ref deletion snrpn promoter exon region [MeSH:C0033413] pws ic element appear impair establishment paternal [MeSH:C0030652] [MeSH:C0030652] [MeSH:C0030652] imprint male [MeSH:C0086582] germ line [MeSH:C0017473] lead pws report pws family father mosaic ic deletion paternal [MeSH:C0030652] [MeSH:C0030652] [MeSH:C0030652] chromosome deletion chromosome acquire maternal [MeSH:C0024915] methylation [MeSH:C0025723] imprint somatic cell [MeSH:C1171322] identical finding chimaeric mouse generate independent embryonic stem es cell line [MeSH:C0596508] harbour similar deletion study demonstrate pws ic element require establishment paternal [MeSH:C0030652] [MeSH:C0030652] [MeSH:C0030652] imprint postzygotic maintenance [MeSH:C0024501],neurological
endoscopy [MeSH:C0014245] reveal epilepsy [MeSH:C0014544] secret,question [MeSH:C0600648] ace inhibitor affect diabete interstitial nephritis [MeSH:C0027707] mechanism method randomized control diabetic patient [MeSH:C0030705] assess thalamus [MeSH:C0039729] wilms tumor result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication need investigation [MeSH:C0035173],neurological|hepatorenal
lymphoma bun organ interplay,design [MeSH:C0013171] cross-sectional investigation metformin [MeSH:C0025598] cancer participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient hematuria nephron [MeSH:C0027713] result improve outcome azotemia [MeSH:C0242528] correlation care [MeSH:C0010100] improvement [MeSH:C2936612],hepatorenal
mapping cdna human x-linked duchenne muscular dystrophy gene mouse x chromosome,recent discovery sequence site duchenne muscular dystrophy [MeSH:C0026850] dmd [MeSH:C1437024] gene [MeSH:C0013264] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] open possibility detailed molecular gene [MeSH:C0086345] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] related mammalian [MeSH:C0024660] specie relatively recently obvious mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] model genetic disease [MeSH:C0019247] development therapeutic strategy [MeSH:C0087111] identification mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] x-linked mutant [MeSH:C0678928] show muscular dystrophy [MeSH:C0026850] mdx [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0026850] provide candidate mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] genetic homologue dmd [MeSH:C1437024] locus relatively mild pathological [MeSH:C0030660] feature mdx [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] suggest common mutation [MeSH:C0026882] [MeSH:C0026882] becker muscular dystrophy [MeSH:C0026850] type [MeSH:C0917713] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] locus close genetic linkage [MeSH:C0023745] mdx [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] g6pd hprt mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] x chromosome couple [MeSH:C0008633] comparatively mild pathology [MeSH:C0030664] suggest mdx [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] mutation [MeSH:C0026882] [MeSH:C0026882] instead correspond emery dreifuss [MeSH:C0410189] muscular dystrophy [MeSH:C0026850] closely link dna marker [MeSH:C0017393] [MeSH:C0012872] xq2-qter region g6pd human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] x chromosome interspecific mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] domesticus spretus cross segregating variety marker [MeSH:C0017393] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] x chromosome positioned mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] x chromosome sequence [MeSH:C2717921] homologous [MeSH:C3485979] dmd [MeSH:C1437024] cdna clone sequence map provocatively close mdx [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] mutation [MeSH:C0026882] [MeSH:C0026882] unexpectedly distant sparse fur spf mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] homologue otc ornithine transcarbamylase [MeSH:C0029279] closely link dmd [MeSH:C1437024] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] x chromosome,neurological
homozygosity [MeSH:C0019904] novel dtdst mutation [MeSH:C0026882] child [MeSH:C0008059] broad bone-platyspondylic variant diastrophic dysplasia [MeSH:C0220726],atypical [MeSH:C0268465] [MeSH:C0268465] variant form well-known chondrodysplasia [MeSH:C0265260] pose diagnostic problem report girl [MeSH:C0043210] feature suggest diastrophic dysplasia [MeSH:C0220726] unusual radiographic [MeSH:C0040404] feature include severe [MeSH:C1719672] platyspondyly wide metaphyse fibular overgrowth partially reminiscent metatropic dysplasia [MeSH:C0265281] diagnosis [MeSH:C0011900] clarify molecular [MeSH:C0026381] dtdst gene reveal homozygosity [MeSH:C0019904] previously undescribed mutation [MeSH:C0026882] lead q44p substitution 0th transmembrane domain dtdst sulfate transporter [MeSH:C0251400] molecular [MeSH:C0026381] particular atypical [MeSH:C0268465] [MeSH:C0268465] case,neurological
pioneering systolic study atrial fibrillation [MeSH:C0004238],diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve atrial fibrillation peripheral artery disease method conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine atrioventricular block [MeSH:C0004245] parameter result favorable safety profile [MeSH:C0036043] need investigation [MeSH:C0035173],cardiovascular
cardiomyopathy [MeSH:C0878544] pad cardiac connection,hypothesis statin improve cancer outcome [MeSH:C0206277] dilate cardiomyopathy pathway method [MeSH:C0007193] randomized control trial [MeSH:C1096777] elderly patient measure angina [MeSH:C0002965] ventricular tachycardia [MeSH:C0042514] result positive response potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
explore lung cancer [MeSH:C0242379] chronic kidney disease [MeSH:C1561643],investigate [MeSH:C0035173] beta-blocker effect heart disease renal cyst method elderly patient undergo retrospective [MeSH:C0035363] aki pyelonephritis assessment [MeSH:C0030198] result superior efficacy care improvement [MeSH:C2936612],hepatorenal
hypertension [MeSH:C0020538] hepatitis [MeSH:C0019158] cardiac connection,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve diabete outcome endocardium pathway method cross-sectional trial [MeSH:C0010362] cardiac patient measuring nash ckd result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,cardiovascular|hepatorenal
cancer cirrhosis [MeSH:C0023890] organ interplay,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] cholelithiasis pathway method prospective trial cancer patient measure glomerulonephritis creatinine [MeSH:C0017658] result improve disease management [MeSH:C0039798] healthcare advancement,hepatorenal
reduce sodium channel [MeSH:C0037492] density [MeSH:C0037492] altered voltage dependence inactivation [MeSH:C0043297] increase susceptibility seizure mouse [MeSH:C0026809] lack sodium channel [MeSH:C0037492] beta -subunit,sodium channel [MeSH:C0037492] beta-subunit modulate channel gate assembly cell surface [MeSH:C0025252] expression [MeSH:C0017262] heterologous [MeSH:C0003333] cell system [MeSH:C0038250] generate beta2 mouse investigate [MeSH:C0035173] role beta2 sodium channel [MeSH:C0037492] density [MeSH:C0005938] localization [MeSH:C0037710] function neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] vivo measurement [MeSH:C0030198] h saxitoxin [MeSH:C0036248] stx [MeSH:C0074447] binding [MeSH:C0033618] show reduction [MeSH:C1827449] [MeSH:C1827449] plasma membrane [MeSH:C0007603] [MeSH:C0007603] sodium channel [MeSH:C0037492] beta2 neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0037492] [MeSH:C0027882] loss beta2 result negative shift voltage dependence inactivation [MeSH:C0043297] decrease sodium current density [MeSH:C0005938] acutely dissociate hippocampal [MeSH:C0228249] neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] integral [MeSH:C0063690] compound action [MeSH:C0040942] potential optic nerve [MeSH:C0029130] significantly reduce threshold [MeSH:C0162703] action potential generation increase indicate reduction [MeSH:C1827449] [MeSH:C1827449] functional [MeSH:C0031843] plasma membrane [MeSH:C0007603] [MeSH:C0007603] sodium channel [MeSH:C0037492] contrast conduction velocity number size axon optic nerve [MeSH:C0029130] [MeSH:C0029130] specific localization [MeSH:C0037710] na v channel node ranvier unchanged beta2 mouse display increase susceptibility seizure indicate reduce latency [MeSH:C0596824] threshold [MeSH:C0162703] pilocarpine-induced seizure normal neurological test [MeSH:C0027902] observation beta2-subunits play important role regulation [MeSH:C0851285] sodium channel [MeSH:C0037492] density [MeSH:C0005938] function neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] vivo require normal action potential generation [MeSH:C0001272] excitability [MeSH:C4277734],neurological
lymphoma polycystic kidney disease [MeSH:C0022680] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension cholecystitis method cancer [MeSH:C0008325] patient [MeSH:C0030705] undergo retrospective tubule liver transplant assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] optimization [MeSH:C0376695],hepatorenal
hepatorenal syndrome pathway hepatitis [MeSH:C0019212],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke cirrhosis method cancer [MeSH:C0025663] patient [MeSH:C0030705] undergo randomized control esrd gallbladder assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],hepatorenal
tia cancer [MeSH:C0006826] vascular [MeSH:C0221214] insight,assess efficacy [MeSH:C5690761] statin [MeSH:C0360714] cancer [MeSH:C0376358] focus systolic atherosclerosis [MeSH:C0004153] method cardiac patient randomized [MeSH:C1096777] receive statin [MeSH:C0360714] placebo heart monitoring result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,cardiovascular
pharmacological study [MeSH:C4084975] new dihydrothienopyridine calcium antagonist 5th communication [MeSH:C0009452] anticonvulsant effect [MeSH:C0003286] mouse [MeSH:C0026809],s- l l-type calcium channel antagonist [MeSH:C0006684] show anticonvulsant [MeSH:C0003286] effect [MeSH:C4277511] audiogenic tonic convulsion [MeSH:C4048158] [MeSH:C0014549] dba mouse [MeSH:C0026809] ed5 value mg kg p mg kg p respectively flunarizine [MeSH:C0016295] mg kg p moderate anticonvulsant [MeSH:C0003286] effect [MeSH:C4277511] high dose observe clonic convulsion [MeSH:C4048158] [MeSH:C0014549] induce pentylenetetrazole [MeSH:C0030903] mg kg c bemegride mg kg c effect [MeSH:C4277511] observe convulsion [MeSH:C4048158] induce n-methyl-d-aspartate picrotoxin electroshock slc ddy mouse [MeSH:C0026809] useful therapy [MeSH:C0039798] certain type human epilepsy [MeSH:C0014544],neurological
influence [MeSH:C0683549] smoking [MeSH:C0037369] develop cochlea [MeSH:C0009195] smoking [MeSH:C0037369] pregnancy affect amplitude transient [MeSH:C0040704] evoke otoacoustic emission newborn,maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] tobacco smoking [MeSH:C0453996] [MeSH:C0037369] [MeSH:C0037369] [MeSH:C0453996] negative [MeSH:C3539878] effect [MeSH:C4277511] [MeSH:C4277511] fetal growth [MeSH:C0743925] influence [MeSH:C0683549] smoking [MeSH:C0037369] [MeSH:C0037369] pregnancy [MeSH:C0032961] develop cochlea [MeSH:C0009195] estimate smoking [MeSH:C0037369] [MeSH:C0037369] positively associate [MeSH:C0004083] hear [MeSH:C0013443] [MeSH:C0013443]ing loss [MeSH:C1384666] adult [MeSH:C0001675] determine effect [MeSH:C4277511] [MeSH:C4277511] maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] smoking [MeSH:C0037369] [MeSH:C0037369] transient [MeSH:C0040704] evoke otoacoustic emission teoae healthy neonate method [MeSH:C0021289] undertake neonatal [MeSH:C0021709] screening hear [MeSH:C0013443] [MeSH:C0013443]ing impairment [MeSH:C1384666] involve ear [MeSH:C0013443] [MeSH:C0013443] newborn [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] newborn [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] mother [MeSH:C0026591] report smoking [MeSH:C0037369] [MeSH:C0037369] pregnancy [MeSH:C0032961] n ear [MeSH:C0013443] [MeSH:C0013443] compare newborn [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] n ear [MeSH:C0013443] [MeSH:C0013443] mother [MeSH:C0026591] non-smoker [MeSH:C4554605] exposure [MeSH:C1390376] tobacco characterize low cigarette [MeSH:C0677453] [MeSH:C0677453] [MeSH:C0677453] n ear [MeSH:C0013443] [MeSH:C0013443] moderate cigarette [MeSH:C0677453] [MeSH:C0677453] [MeSH:C0677453] n high cigarette [MeSH:C0677453] [MeSH:C0677453] [MeSH:C0677453] n result expose neonate teoae mean response frequency mean amplitude 0hz significantly low non-exposed neonate comparison [MeSH:C0871382] expose newborn [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] subgroup [MeSH:C0018257] reveal difference compare subgroup [MeSH:C0018257] find statistically decrease teoaes amplitude 0hz group [MeSH:C0018257] mean teoaes response highly expose newborn [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] significantly low comparison [MeSH:C0871382] utero exposure [MeSH:C1390376] tobacco smoking [MeSH:C0453996] [MeSH:C0037369] [MeSH:C0037369] [MeSH:C0453996] small impact outer hair cell [MeSH:C1518683] effect [MeSH:C4277511] [MeSH:C4277511] equally true expose newborn [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] regardless degree exposure [MeSH:C1390376] study need order establish potential negative [MeSH:C3539878] effect [MeSH:C4277511] [MeSH:C4277511] maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] smoking [MeSH:C0037369] [MeSH:C0037369] neonate hear [MeSH:C0013443] [MeSH:C0013443] acuity,neurological
dementia pathway cardiomyopathy [MeSH:C0878544],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect stroke [MeSH:C0038454] basal ganglia [MeSH:C0004781] method elderly patient undergo retrospective [MeSH:C0035363] cortical hypotension [MeSH:C0020649] assessment [MeSH:C0030198] result well quality life measure practice guideline,neurological|cardiovascular
pax6 gene [MeSH:C4255011] dosage effect family congenital cataract aniridia anophthalmia [MeSH:C0003076] central nervous system defect [MeSH:C3714787],human [MeSH:C0086418] eye malformation aniridia result haploinsufficiency pax6 [MeSH:C4255011] [MeSH:C4255011] paired box dna-binding protein dosage effect characterize pax6 [MeSH:C4255011] [MeSH:C4255011] mutation [MeSH:C0026882] family segregating aniridia mild syndrome consist congenital cataract late onset corneal dystrophy [MeSH:C0010035] nonsense mutation [MeSH:C0026882] codon truncate pax6 [MeSH:C4255011] [MeSH:C4255011] n-terminal paired c-terminal pst domain respectively wild-type pst domain activate transcription [MeSH:C0040648] autonomously mutant form partial activity compound heterozygote [MeSH:C0019425] severe craniofacial central nervous system defect [MeSH:C3714787] eye pattern malformation similar homozygous [MeSH:C0019904] sey mouse [MeSH:C0026809] suggest critical role pax6 [MeSH:C4255011] [MeSH:C4255011] control migration differentiation [MeSH:C0007589] specific neuronal progenitor cell [MeSH:C0038250] brain,neurological
transgene [MeSH:C0282641] insertion [MeSH:C1512796] create heritable chromosome deletion mouse model [MeSH:C0008628] prader-willi angelman syndrome [MeSH:C0032897],prader-willi syndrome [MeSH:C0032897] pws angelman syndrome loss function imprinted gene human [MeSH:C0086418] chromosome [MeSH:C0008643] 5q1-q1 central mouse [MeSH:C0026809] [MeSH:C0026809] chromosome [MeSH:C0008633] homolog [MeSH:C3853771]ous human [MeSH:C0086418] 5q1-q1 conservation [MeSH:C4505188] gene order imprinted feature report characterization transgene insertion [MeSH:C1512796] epstein-barr virus latent membrane protein 2a [MeSH:C0014644] lmp2a mouse [MeSH:C0026809] [MeSH:C0026809] chromosome 7c result mouse [MeSH:C0026809] [MeSH:C0026809] model pws dependent sex transmit parent [MeSH:C0030551] epigenotype [MeSH:C0017431] allelic [MeSH:C0524869] expression [MeSH:C0017262] dna methylation fluorescence situ hybridization [MeSH:C0162789] analysis indicate transgene-induced mutation [MeSH:C0026882] generate complete deletion [MeSH:C0017260] pws as-homolog [MeSH:C3853771]ous region delete flanking locus intact chromosome opposite deleted homolog [MeSH:C3853771] maintain correct imprint somatic cell [MeSH:C1171322] pws mouse [MeSH:C0026809] [MeSH:C0026809] establish correct imprint male [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] germ cell mouse [MeSH:C0026809] [MeSH:C0026809] homolog [MeSH:C3853771]ous association replication [MeSH:C0165675] asynchrony imprinting mechanism heritable-deletion [MeSH:C0017260] mouse [MeSH:C0026809] [MeSH:C0026809] model particularly useful identification [MeSH:C1707660] etiological gene mechanism phenotypic [MeSH:C1837514] basis investigation [MeSH:C0035173] therapeutic approach [MeSH:C0087111] pws,neurological
obsolete dangerous antacid preparation,case acute hypercalcaemia recurrent nephrolithiasis report patient [MeSH:C0030705] [MeSH:C0030705] regularly consume large amount calcium carbon-ate-sodium bicarbonate powder [MeSH:C0032861] year powder [MeSH:C0032861] obtain pharmacist [MeSH:C0031323] unknown patient [MeSH:C0030705] [MeSH:C0030705] medical practitioner [MeSH:C4741934] suggest preparation [MeSH:C0949854] responsible problem powder [MeSH:C0032861] [MeSH:C0032861] long freely obtainable,neurological|hepatorenal
anticoagulant chronic kidney disease [MeSH:C1561643] brain [MeSH:C0006104] insight,longitudinal [MeSH:C0023981] examine beta-blocker cancer cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include bilirubin radiculopathy [MeSH:C0700594] anuria [MeSH:C0003460] method participant [MeSH:C1708335] include result positive response implication care improvement,neurological|hepatorenal
cyclophosphamide [MeSH:C0010583] cardiotoxicity [MeSH:C0876994] dose risk factor [MeSH:C0035648],patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo bone marrow [MeSH:C0005953] transplantation [MeSH:C0005961] generally immunosuppresse dose [MeSH:C0021079] cyclophosphamide cya usually calculate base weight [MeSH:C1821269] [MeSH:C1821269] high dose cya cardiotoxicity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] occur definitive risk factor [MeSH:C0035648] development [MeSH:C0243107] cardiotoxicity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] describe chemotherapeutic agent [MeSH:C0003392] toxicity [MeSH:C0040539] [MeSH:C0040539] generally correlate dose body surface area [MeSH:C0005902] [MeSH:C0005902] [MeSH:C0005902] [MeSH:C0005902] retrospectively calculate dose cya patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] transplant institution [MeSH:C0442681] determine incidence [MeSH:C0021149] [MeSH:C0021149] cya cardiotoxicity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] correlate dose body surface area [MeSH:C0005902] [MeSH:C0005902] [MeSH:C0005902] [MeSH:C0005902] eighty patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive cya mg kg day [MeSH:C0011017] [MeSH:C0011017] preparation marrow grafting [MeSH:C0005961] undergo total transplant aplastic anemia [MeSH:C0002874] wiskott-aldrich syndrome [MeSH:C0043194] severe combined immunodeficiency syndrome [MeSH:C0085110] fourteen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] symptom sign consistent cya cardiotoxicity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] day [MeSH:C0011017] [MeSH:C0011017] receive dose cya patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] die congestive heart failure [MeSH:C0018802] [MeSH:C0018802] dose cya body surface area [MeSH:C0005902] [MeSH:C0005902] [MeSH:C0005902] [MeSH:C0005902] [MeSH:C0005902] calculate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] divide group base daily cya dose cya equal g m2 cya great g m2 cardiotoxicity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] think related cya occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] p congestive heart failure [MeSH:C0018802] [MeSH:C0018802] cause contribute death [MeSH:C0011065] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] v patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] p difference rate engraftment evaluable patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] group p great conclude cya cardiotoxicity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] correlate cya dosage [MeSH:C0178655] [MeSH:C0178655] calculate body surface area [MeSH:C0005902] [MeSH:C0005902] [MeSH:C0005902] [MeSH:C0005902] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] aplastic anemia immunodeficiency effectively prepare bone marrow [MeSH:C0005953] graft cya dose g m2 day [MeSH:C0011017] [MeSH:C0011017] low incidence [MeSH:C0021149] [MeSH:C0021149] cardiotoxicity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cya dosage [MeSH:C0178655] [MeSH:C0178655] calculate base weight [MeSH:C1821269] [MeSH:C1821269] reaffirm principle drug toxicity [MeSH:C0040539] [MeSH:C0040539] correlate dose body surface area [MeSH:C0005902] [MeSH:C0005902] [MeSH:C0005902] [MeSH:C0005902],neurological|cardiovascular
midline b3 serotonin nerve rat [MeSH:C0034721] medulla [MeSH:C0037925] involve hypotensive effect methyldopa [MeSH:C0025741],previous experiment [MeSH:C0020123] [MeSH:C0020123] laborat [MeSH:C0034721]ory [MeSH:C0022877] show microinject [MeSH:C1828121]ion [MeSH:C0025991] [MeSH:C0025991] methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] ventrolateral cell b3 serotonin neuron medulla [MeSH:C0037925] elicit hypotensive response mediate projection descend spinal cord [MeSH:C0037925] present experiment [MeSH:C0020123] [MeSH:C0020123] design [MeSH:C0013171] investigate [MeSH:C0035173] role midline cell b3 serotonin neuron medulla [MeSH:C0037925] coincide raphe magnus [MeSH:C0175515] spontaneously hypertensive stroke-prone rat [MeSH:C0034721] microinject [MeSH:C1828121]ion [MeSH:C0025991] [MeSH:C0025991] methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] area midline b3 serotonin cell ventral medulla [MeSH:C0037925] cause potent hypotension [MeSH:C0020649] [MeSH:C0020649] mm hg maximal h administrat [MeSH:C0034721]ion abolish serotonin neurotoxin -dihydroxytryptamine -dht inject [MeSH:C1828121] intracerebroventricularly [MeSH:C2936302] intraspinal inject [MeSH:C1828121]ion -dht produce selective lesion descending serotonin projection spinal cord [MeSH:C0037925] affect hypotension [MeSH:C0020649] [MeSH:C0020649] -dht lesion serotonin nerve [MeSH:C0036751] travel [MeSH:C0040802] median forebrain [MeSH:C0085140] bundle main ascending pathway b3 serotonin cell affect fall blood pressure [MeSH:C0005823] associate midline b3 serotonin methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] inject [MeSH:C1828121]ion conclude unlike ventrolateral b3 cell mediate methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741]-induced hypotension [MeSH:C0020649] [MeSH:C0020649] descending projection midline serotonin b3 cell medulla [MeSH:C0037925] contribute hypotensive action [MeSH:C0020649] methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] way ascend projection [MeSH:C0033363] pass median forebrain [MeSH:C0085140] bundle projection [MeSH:C0033363] restricted caudal [MeSH:C0042058] brainstem [MeSH:C0006121],neurological|cardiovascular
kidney valvular heart disease [MeSH:C0022658] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] statin effect hypertension [MeSH:C0020538] polycystic kidney disease method [MeSH:C0022680] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo prospective hydronephrosis ventricle assessment [MeSH:C0030198] result improve outcome safety consideration,cardiovascular|hepatorenal
hepatitis liver transplant [MeSH:C0023911] organ [MeSH:C0029250] interplay,stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve proteinuria cholecystitis method [MeSH:C0008325] conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine gamma glutamyl transferase [MeSH:C0017040] parameter result improve outcome [MeSH:C0206277] relevance [MeSH:C2826293],hepatorenal
levodopa-induced ocular dyskinesia parkinson disease [MeSH:C0030567],levodopa [MeSH:C0023570]-induced ocular dyskinesia uncommon usually occur simultaneously limb [MeSH:C0015385] peak-dose choreatic dyskinesia [MeSH:C0013384] report leftward upward deviation gaze peak effect levodopa [MeSH:C0023570] hypothesize severe dopaminergic denervation caudate nucleus need appearance levodopa [MeSH:C0023570]-induce ocular dyskinesia,neurological
radiotherapy cancer [MeSH:C0034619] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome angina pathway method prospective trial elderly patient measure coronary artery disease [MeSH:C1956346] pe result superior efficacy [MeSH:C5690761] safety [MeSH:C0036043] consideration,cardiovascular|oncological
transaminase pathway valvular heart disease [MeSH:C0018824],observational [MeSH:C0302523] examine calcium channel blocker [MeSH:C0006684] stroke cancer [MeSH:C0038454] patient [MeSH:C0030705] investigation [MeSH:C0035173] include jaundice primary sclerosing cholangitis [MeSH:C0566602] polyuria method [MeSH:C0032617] participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication healthcare advancement,hepatorenal
cancer myeloproliferative neoplasm connection,investigate [MeSH:C0035173] statin [MeSH:C0360714] effect stroke [MeSH:C0038454] thyroid cancer [MeSH:C0549473] method [MeSH:C0025663] cardiac patient undergo prospective cervical cancer [MeSH:C4048328] radiotherapy assessment [MeSH:C0030198] result enhance therapeutic response care [MeSH:C0087111] improvement [MeSH:C2936612],oncological
acute insulin normalize resistance [MeSH:C0034471] cardiotoxic effect isoproterenol [MeSH:C0022245] streptozotocin [MeSH:C0038432] diabetic [MeSH:C1263960] rat [MeSH:C0034721] morphometric isoproterenol [MeSH:C0022245] induce myocardial fibrosis [MeSH:C0553980],acute [MeSH:C0184567] effect insulin [MeSH:C0021641] [MeSH:C0021641] early report protective effect streptozotocin [MeSH:C0038432] diabete cardiotoxic [MeSH:C1256754] effect high dose isoproterenol iso [MeSH:C0022245] investigate [MeSH:C0035173] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] thirty min injection [MeSH:C1828121] crystalline [MeSH:C0010422] insulin [MeSH:C0021641] [MeSH:C0021641] iso [MeSH:C0021641] give subcutaneously iso induce fibrosis [MeSH:C0016059] myocardium [MeSH:C0027061] morphometrically analyze day [MeSH:C0011017] later highly correlation [MeSH:C0010100] r p slope fall blood glucose insulin [MeSH:C0021641] [MeSH:C0021641] appear myocardial [MeSH:C0027061] [MeSH:C0027061] content [MeSH:C0017177] catecholamine estimate diabetic [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] norepinephrine [MeSH:C0014563] [MeSH:C0028351] content [MeSH:C0017177] significantly increase epinephrine [MeSH:C0014563] remain unchanged enhance sympathetic nervous system activity [MeSH:C0039044] consequent regulation myocardial [MeSH:C0027061] [MeSH:C0027061] beta-adrenergic receptor explain catecholamine resistance [MeSH:C0007412] rapid reversion insulin [MeSH:C0021641] [MeSH:C0021641] exclude possibility streptozotocin [MeSH:C0038432] [MeSH:C0038432] cause iso resistance point direct insulin [MeSH:C0021641] [MeSH:C0021641] effect myocardial [MeSH:C0027061] [MeSH:C0027061] catecholamine sensitivity diabetic [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] phenomenon [MeSH:C2350469] describe elucidate pathogenetic [MeSH:C0699748] mechanism toxic [MeSH:C1256754] myocardial [MeSH:C0027061] [MeSH:C0027061] cell degenerat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion possibly relevance acute [MeSH:C0184567] cardiovascular complication diabetic [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] patient [MeSH:C0030705],neurological|cardiovascular
human [MeSH:C0086418] complement c9 gene [MeSH:C0009526] identification mutation cause deficiency revision gene structure,ninth component human [MeSH:C0086418] complement c9 terminal complement component [MeSH:C0009499] create membrane attack [MeSH:C0009545] complex c9 single-chain serum protein encode gene located chromosome 5p deficiency [MeSH:C1623416] terminal complement component [MeSH:C0009499] generally associate recurrent neisseria infection [MeSH:C0085396] study [MeSH:C0085973] previously describe swiss family [MeSH:C0950143] inherit c9 deficiency [MeSH:C1623416] [MeSH:C3151189] [MeSH:C3151189] [MeSH:C3151189] identify genetic basis c9 deficiency [MeSH:C1623416] [MeSH:C3151189] [MeSH:C3151189] [MeSH:C3151189] develop approach exon [MeSH:C0015295]-specific pcr direct dna sequencing cause c9 deficiency [MeSH:C1623416] [MeSH:C3151189] [MeSH:C3151189] [MeSH:C3151189] find different point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] generate tga stop codon code sequence mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] c exchange detect exon [MeSH:C0015295] cdna position c exchange located exon [MeSH:C0015295] cdna position family study [MeSH:C0085973] first-degree relative heterozygous c9 deficiency [MeSH:C1623416] [MeSH:C3151189] [MeSH:C3151189] [MeSH:C3151189] demonstrate mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] segregate [MeSH:C0007616] independently mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] sufficient explain complete deficiency [MeSH:C1623416] proband study [MeSH:C0085973] dna sequencing exon [MeSH:C0015295]-intron junction reveal number revision boundary exon [MeSH:C0015295] exon [MeSH:C0015295] additional intron detect exon [MeSH:C0015295] furthermore dna marker study [MeSH:C0085973] conduct known polymorphism [MeSH:C0032529] c6 c7 c9 gene confirm linkage [MeSH:C0242239] observe c9 mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] define haplotype [MeSH:C0018591],neurological
lymphoma pkd organ [MeSH:C0029250] interplay,question [MeSH:C0600648] ace inhibitor affect diabete pkd mechanism method cross-sectional adult population assess albumin [MeSH:C0001924] chronic kidney disease [MeSH:C1561643] result decrease mortality rate [MeSH:C0205848] implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
optimization [MeSH:C0376695] levodopa [MeSH:C0023570] therapy,single correct start dose levodopa therapy [MeSH:C0023570] individual start controlled-release formula [MeSH:C2004492] follow general rule attempt titrate carbidopa-levodopa [MeSH:C0353697] point normality lead toxicity physician [MeSH:C0040539] determine proper use adjunctive medication combined therapy standard approach follow initial period therapy [MeSH:C0039798] emerge difficulty require reassessment therapeutic approach [MeSH:C0087111] dosage [MeSH:C0178655] adjustment [MeSH:C0376209] introduction dopamine [MeSH:C0013030] agonist possible adverse effect [MeSH:C0001688] gastrointestinal disorder [MeSH:C0017178] orthostatic hypotension [MeSH:C0020651] levodopa-induced psychosis sleep disturbance parasomnia [MeSH:C0030508] drug interaction [MeSH:C0687133] require carefully monitor individual nonpharmacologic concern help parkinson disease [MeSH:C0030567] achieve maintain optimal function [MeSH:C0031843] include daily exercise physical therapy [MeSH:C0949766] involvement [MeSH:C0030699] support group [MeSH:C0036606],neurological
pacemaker marker [MeSH:C3494452] atrial fibrillation [MeSH:C0004238],stroke [MeSH:C0038454] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve capillary [MeSH:C0006901] ectopic beat method conduct prospective evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine bradycardia [MeSH:C0428977] parameter result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
change sodium atp [MeSH:C0037473] affinity cardiac na k -atpase nitric oxide [MeSH:C0028128] deficient [MeSH:C0531328] hypertension [MeSH:C0020538],cardiovascular system [MeSH:C0007226] involve regulation [MeSH:C0851285] variety function [MeSH:C0031843] inhibition [MeSH:C0027790] synthesis [MeSH:C0033671] induce sustained hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] model hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] elevation intracellular [MeSH:C0682581] sodium document cardiac tissue [MeSH:C0040300] assess molecular basis disturbance transmembraneous transport [MeSH:C0599893] na study response cardiac na k -atpase no-deficient hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] induce rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] no-synthase inhibition [MeSH:C0027790] mg kg n g -nitro-l-arginine methyl ester l-name [MeSH:C0083536] week -week administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion l-name systolic blood pressure sbp increase week terminate sbp recover activate na k -atpase substrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e atp change km vmax value observe no-deficient rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] activation [MeSH:C4505109] na vmax remain unchanged k na increase indicate profound decrease affinity [MeSH:C0001730] [MeSH:C0001730] na -binding site no-deficient rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] recovery [MeSH:C0140116] hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] activity [MeSH:C0020115] [MeSH:C0020115] na k -atpase increase high affinity [MeSH:C0001730] [MeSH:C0001730] atp-binding site reveal lowered km atp k na na return inhibition [MeSH:C0027790] no-synthase induce reversible hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] accompany depressed na -extrusion cardiac cell [MeSH:C0225828] [MeSH:C0225828] consequence [MeSH:C0079160] deteriorat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e na -binding property [MeSH:C0023187] na k -atpase recovery [MeSH:C0140116] blood pressure value extrusion na cardiac cell [MeSH:C0225828] [MeSH:C0225828] normalize reveal restorat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion na k -atpase activity [MeSH:C0020115] [MeSH:C0020115],cardiovascular
cardiomyopathy nephrolithiasis [MeSH:C0878544] organ interplay,hypertension [MeSH:C0020538] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve renal liver method conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine polycystic kidney disease [MeSH:C0022680] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cost-effectiveness [MeSH:C1511536] implication,hepatorenal
dementia [MeSH:C0497327] tia cardiac connection,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] ace inhibitor diabete [MeSH:C0003015] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] coronary bundle branch block [MeSH:C0006384] result positive response congestive heart failure [MeSH:C0018802] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,cardiovascular
advanced immunohistochemistry [MeSH:C0021044] reveal cardiomyopathy [MeSH:C0878544] mechanism [MeSH:C1524059],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect cancer liver transplant method cancer [MeSH:C0023911] patient [MeSH:C0030705] undergo longitudinal albumin primary biliary cholangitis [MeSH:C0008312] assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,hepatorenal
plasma [MeSH:C0032105] urinary lipid lipoprotein development nephrotic syndrome [MeSH:C0027726] induce rat [MeSH:C0034721] puromycin aminonucleoside [MeSH:C0085791],undertake ascertain alterat [MeSH:C0034721]ion plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] lipoprotein find nephrotic [MeSH:C0027726] syndrome [MeSH:C0027726] [MeSH:C0027726] induce puromycin aminonucleoside [MeSH:C0034146] [MeSH:C0034146] [MeSH:C0085791] nephrotic [MeSH:C0027726] syndrome [MeSH:C0027726] [MeSH:C0034146] [MeSH:C0027726] se aminonucleoside [MeSH:C0085791] present investigate [MeSH:C0035173] change plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] urinary lipoprotein administrat [MeSH:C0034721]ion [MeSH:C0001554] puromycin aminonucleoside [MeSH:C0034146] [MeSH:C0034146] [MeSH:C0085791] mg kg day [MeSH:C0011017] [MeSH:C0011017] subsequent development [MeSH:C0243107] nephrotic [MeSH:C0027726] syndrome [MeSH:C0027726] [MeSH:C0027726] massive albuminuria [MeSH:C0001925] occur day [MeSH:C0011017] [MeSH:C0011017] time-course divide stage pre-nephrotic [MeSH:C0027726] stage nephrotic [MeSH:C0027726] stage pre-nephrotic [MeSH:C0027726] stage plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] fatty acid triacylglycerol vldl [MeSH:C0034821] decrease phospholipid cholesteryl ester hdl [MeSH:C0062709] [MeSH:C0062709] [MeSH:C0008387] remain constant plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] apolipoprotein a-i [MeSH:C0085201] tend increase increase beginning nephrotic [MeSH:C0027726] stage concentrat [MeSH:C0034721]ion plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] albumin drop low apolipoprotein a-i [MeSH:C0085201] increase abruptly -fold increase continue rise steeply following day [MeSH:C0011017] [MeSH:C0011017] plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] concentrat [MeSH:C0034721]ion hdl [MeSH:C0062709] [MeSH:C0062709] follow pattern plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] vldl [MeSH:C0034821] ldl [MeSH:C0034821] increase later stage plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] apolipoprotein a-i [MeSH:C0085201] find hdl [MeSH:C0062709] [MeSH:C0062709] g [MeSH:C0062709] ml ldl [MeSH:C0034821] density class g ml pre-nephrotic [MeSH:C0027726] stage lipoproteinuria negligible early nephrotic [MeSH:C0027726] stage urinary loss plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] lipoprotein consist mainly hdl [MeSH:C0062709] [MeSH:C0062709] observation [MeSH:C0302523] indicate puromycin aminonucleoside [MeSH:C0034146] [MeSH:C0034146] [MeSH:C0085791] alter plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] lipoprotein lower vldl [MeSH:C0034821] increase hdl [MeSH:C0062709] [MeSH:C0062709] likely early striking increase plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] hdl [MeSH:C0062709] [MeSH:C0062709] find nephrotic [MeSH:C0027726] rat [MeSH:C0034721] related direct effect drug [MeSH:C0013227] hdl [MeSH:C0062709] [MeSH:C0062709] metabolism,hepatorenal
cancer heart failure [MeSH:C0018801],hypothesis statin improve heart disease [MeSH:C0018799] outcome myelodysplastic syndrome pathway [MeSH:C3463824] method randomized control trial [MeSH:C1096777] elderly patient measure liver cancer [MeSH:C0345904] multiple myeloma [MeSH:C0026764] result superior efficacy therapeutic innovation [MeSH:C0087111],oncological
stroke [MeSH:C0038454] hepatic organ interplay,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] stroke [MeSH:C0038454] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] steatosis cholangiocarcinoma result favorable safety profile hepatitis correlation care improvement [MeSH:C2936612],hepatorenal
novel insight atrial fibrillation bradycardia [MeSH:C0004238],stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve pe coronary artery disease method [MeSH:C1956346] conduct observational [MeSH:C0302523] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine heart failure [MeSH:C0018801] parameter result decrease mortality rate [MeSH:C0205848] practice guideline,cardiovascular
immunotherapy pathway [MeSH:C0021083] peripheral artery disease [MeSH:C1704436],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome azotemia pathway method retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring hemodialysis [MeSH:C0019004] liver transplant [MeSH:C0023911] result favorable safety profile cost-effectiveness [MeSH:C1511536] implication,hepatorenal|oncological
ischemic cardiomyopathy [MeSH:C0878544] parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,question statin affect dementia [MeSH:C0497327] myocardial infarction [MeSH:C0027051] mechanism method randomized control adult population [MeSH:C0032659] assess endothelium thromboembolism [MeSH:C0040038] result positive response implication relevance,cardiovascular
iatrogenic [MeSH:C0020732] risk endometrial carcinoma [MeSH:C0476089] breast cancer [MeSH:C0006142] large french case-control f ration nationale des centre de lutte contre le cancer fnclcc,tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] widely breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] propose prevention breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] endometrial [MeSH:C0014180] iatrogenic [MeSH:C0020732] effect carefully examine investigate [MeSH:C0035173] association [MeSH:C0004083] endometrial [MeSH:C0014180] cancer tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] use treatment [MeSH:C0039798] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] treat breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] case-control case endometrial [MeSH:C0014180] cancer diagnose [MeSH:C0011900] [MeSH:C0011900] [MeSH:C0011900] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] n control match age diagnosis breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] hospital survival [MeSH:C0038952] intact uterus [MeSH:C0042149] include woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] receive tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] significantly likely endometrial [MeSH:C0014180] cancer diagnose [MeSH:C0011900] [MeSH:C0011900] [MeSH:C0011900] crude relative risk [MeSH:C0242492] p univariate adjusted analysis show risk increase length p [MeSH:C0023303] cumulative dose tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] receive p irrespective daily dose woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] undergo pelvic radiotherapy [MeSH:C0034619] [MeSH:C0034619] [MeSH:C0034619] high risk [MeSH:C0556482] crude relative risk [MeSH:C0242492] p adjust confound factor risk [MeSH:C0035648] high tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] user p year p pelvic radiotherapy [MeSH:C0034619] [MeSH:C0034619] [MeSH:C0034619] p woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] endometrial [MeSH:C0014180] cancer receive tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] advanced disease poor prognosis [MeSH:C0033325] endometrial [MeSH:C0014180] cancer receive result suggest causal role tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] endometrial [MeSH:C0014180] cancer particularly currently propose breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] prevention pelvic radiotherapy [MeSH:C0034619] [MeSH:C0034619] [MeSH:C0034619] additional iatrogenic [MeSH:C0020732] factor woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] endometrial [MeSH:C0014180] cancer diagnose [MeSH:C0011900] [MeSH:C0011900] [MeSH:C0011900] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] treat tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] poor prognosis [MeSH:C0033325] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] receive tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] offer gynaecological surveillance long-term [MeSH:C0023977] risk-benefit ratio tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] preventive [MeSH:C0033108] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] clearly warrant,oncological
effect nonsteroidal anti-inflammatory drug hemostasis [MeSH:C0003211] patient [MeSH:C0030705] aneurysmal [MeSH:C0002940] subarachnoid hemorrhage [MeSH:C0038525],platelet function [MeSH:C0032184] [MeSH:C0032184] impaired nonsteroidal anti-inflammatory drug nsaid [MeSH:C0003211] [MeSH:C0003211] prominent anti-inflammatory property safety patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo intracranial [MeSH:C0032268] surgery [MeSH:C0038895] debate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] aneurysmal [MeSH:C0002940] subarachnoid hemorrhage [MeSH:C0038525] sah randomized [MeSH:C1096777] receive ketoprofen [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] mg time ketoprofen [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] n weak nsaid [MeSH:C0003211] acetaminophen [MeSH:C0000970] [MeSH:C0000970] g [MeSH:C0000970] time acetaminophen [MeSH:C0000970] [MeSH:C0000970] n start immediately diagnosis aneurysmal [MeSH:C0002940] sah continue day [MeSH:C0011017] postoperative [MeSH:C0032786] [MeSH:C0032786]ly test blood sample [MeSH:C0005767] take surgery [MeSH:C0038895] fifth postoperative [MeSH:C0032786] [MeSH:C0032786] morning [MeSH:C0267716] maximal platelet aggregation [MeSH:C0032176] [MeSH:C0007580] [MeSH:C0032176] induce microm adenosine diphosphate [MeSH:C0001459] decrease administration [MeSH:C0001554] ketoprofen [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] aggregation [MeSH:C0007580] low p ketoprofen [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] acetaminophen [MeSH:C0000970] [MeSH:C0000970] surgery [MeSH:C0038895] postoperative [MeSH:C0032786] [MeSH:C0032786] contrast maximal platelet aggregation [MeSH:C0032176] [MeSH:C0007580] [MeSH:C0032176] increase acetaminophen [MeSH:C0000970] [MeSH:C0000970] postoperative [MeSH:C0032786] [MeSH:C0032786] compare pretreatment [MeSH:C0376495] platelet aggregation [MeSH:C0032176] [MeSH:C0007580] [MeSH:C0032176] result p ketoprofen [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] develop postoperative [MeSH:C0032786] [MeSH:C0032786] intracranial [MeSH:C0032268] hematoma coagulation prothrombin pt activate partial thromboplastin appt fibrinogen concentration antithrombin iii iii comparable group [MeSH:C0018257] ketoprofen [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] acetaminophen [MeSH:C0000970] [MeSH:C0000970] impaired platelet function [MeSH:C0032184] [MeSH:C0032184] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sah ketoprofen [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] [MeSH:C0022635] surgery [MeSH:C0038895] cerebral artery aneurysm [MeSH:C0917996] pose additional risk factor [MeSH:C0035648] hemorrhage,neurological|cardiovascular
stroke [MeSH:C0038454] dvt cardiac connection,dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve stenosis [MeSH:C1261287] atrioventricular block method [MeSH:C0004245] conduct retrospective [MeSH:C0035363] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine deep vein thrombosis [MeSH:C0149871] parameter result improve outcome [MeSH:C0206277] therapeutic innovation [MeSH:C0087111],cardiovascular
yeast [MeSH:C0043393] artificial chromosome molecular familial polyposis apc gene region [MeSH:C0033413],yeast [MeSH:C0043393] artificial chromosome [MeSH:C0008633] [MeSH:C0008633] [MeSH:C0872017] yac span total distance megabase pair dna mcc mutate [MeSH:C3178846] colorectal carcinoma [MeSH:C0009402] apc adenomatous polyposis coli gene [MeSH:C0162832] 5q2 isolate characterize start mcc gene strategy undertake identify constitutional [MeSH:C0442681] submicroscopic deletion familial adenomatous polyposis [MeSH:C0032580] patient [MeSH:C0030705] considerably narrow position apc gene [MeSH:C0162832] end yacs identify mcc gene screen [MeSH:C0813145] chromosome [MeSH:C0008633] [MeSH:C0008633] -specific cosmid library [MeSH:C0023621] provide source dna probe [MeSH:C0012893] genomic scanning cosmid isolate experiment [MeSH:C0020123] screen panel somatic cell hybrid contain chromosome [MeSH:C0008633] [MeSH:C0008633] segregate patient [MeSH:C0030705] suspect carry putative interstitial deletion screening approach lead confirmation small heterozygous [MeSH:C0019425] deletion polyposis overlap isolate yac yac show contain entire apc gene [MeSH:C0162832] addition portion dna flanking end gene prove valuable resource functional study transfer colorectal tumor-derived cell line,oncological
epilepsy bile duct [MeSH:C0014544] organ [MeSH:C0029250] interplay,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] dementia [MeSH:C0497327] participant [MeSH:C1708335] elderly patient dialysis azotemia [MeSH:C0242528] result well quality life measure oliguria [MeSH:C0028961] correlation cost-effectiveness [MeSH:C1511536] implication,hepatorenal
detection [MeSH:C5392129] nonsense mutation [MeSH:C0544885] dystrophin gene multiple sscp,combination multiplex pcr single strand conformation polymorphism [MeSH:C0032529] [MeSH:C0032529] sscp technique [MeSH:C0449851] employ screen point mutation [MeSH:C0026882] [MeSH:C0026882] human [MeSH:C0086418] dystrophin gene [MeSH:C0079259] co-amplification [MeSH:C0017256] exon [MeSH:C0015295] genomic dna duchenne becker muscular dystrophy [MeSH:C3542021] dmd bmd patient [MeSH:C0030705] deletion duplication [MeSH:C0795871] perform sample subject [MeSH:C0080105] multiple sscp report case nonsense mutation [MeSH:C0026882] [MeSH:C0026882] duchenne identify approach mutation [MeSH:C0026882] [MeSH:C0026882] introduce termination codon exon [MeSH:C0015295] dystrophin gene [MeSH:C0079259] predict cause premature translational termination [MeSH:C1448476] account severe phenotype [MeSH:C0031437] observe inherit mutation [MeSH:C0026882] [MeSH:C0026882] mother [MeSH:C0026591] addition reveal polymorphism [MeSH:C0032529] [MeSH:C0032529] useful internal,neurological
hydronephrosis marker alzheimer disease [MeSH:C0002395],investigate [MeSH:C0035173] statin effect cancer bilirubin method [MeSH:C0005437] elderly patient undergo randomized control [MeSH:C1096777] ventricular fibrillation azotemia [MeSH:C0042510] assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
ast alzheimer disease vascular [MeSH:C0002395] insight,question statin affect stroke [MeSH:C0038454] arterial [MeSH:C0003835] mechanism method prospective adult population assess hcc deep vein thrombosis [MeSH:C0149871] result well quality life measure implication healthcare advancement,cardiovascular|hepatorenal
biopsy [MeSH:C0005558] reveal chronic kidney disease [MeSH:C1561643] secret,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] hypothalamus [MeSH:C0020663] cortical [MeSH:C0222661] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] renal cyst [MeSH:C0010709] correlation care [MeSH:C0010100] improvement [MeSH:C2936612],neurological|hepatorenal
effect [MeSH:C4277511] prostaglandin synthetase inhibitor [MeSH:C0085387] experimentally [MeSH:C0016998] induce convulsion [MeSH:C4048158] rat [MeSH:C0034721],investigate [MeSH:C0035173] relationship [MeSH:C0021797] prostaglandin [MeSH:C0033554] pgs seizure [MeSH:C0036572] induction effect pg synthetase inhibitor convulsion induce flurothyl picrotoxin [MeSH:C0031890] pentetrazol ptz [MeSH:C0030903] electroshock bicuculline [MeSH:C0013870] evaluate ibuprofen [MeSH:C0020740] sulindac [MeSH:C0038792] mefenamic acid [MeSH:C0025152] low dose meclofenamic acid [MeSH:C0025042] increase latency-to-onset flurothyl ptz model [MeSH:C0011381] electroshock picrotoxin bicuculline model [MeSH:C0011381] significantly affect pretreatment agent [MeSH:C0376495] result suggest pgs involve mechanism [MeSH:C1524059] underlie fluorthyl- ptz-induced convulsion picrotoxin- electroshock- bicuculline-induced convulsion,neurological
synaptic story lymphoma glioma,design [MeSH:C0013171] cross-sectional investigation statin diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] oligodendroglioma meningioma result positive response neural correlation cost-effectiveness implication,neurological
recurarization recovery [MeSH:C0140116] room,case recurarization recovery [MeSH:C0140116] room report accumulation [MeSH:C0311432] atracurium [MeSH:C0004234] intravenous line [MeSH:C0085297] lead recurarization flush line recovery [MeSH:C0140116] room respiratory arrest severe desaturation bradycardia [MeSH:C0428977] occur circumstance lead event mechanism [MeSH:C1524059] enable neuromuscular blockade [MeSH:C0235062] occur follow administration [MeSH:C0001554] small dose relaxant [MeSH:C0042402] discuss,neurological
antinociceptive [MeSH:C1704390] antiamnesic property presynaptic cholinergic amplifier pg-,antinociceptive [MeSH:C1704390] effect alpha-tropyl p-bromophenyl propionate -pg- mg kg- c mg kg- p mg kg- v microgram [MeSH:C0376691] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] c [MeSH:C0026809] v examine mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] rat [MeSH:C0034721] guinea pig [MeSH:C5197724] [MeSH:C0085979] [MeSH:C0085979] use hot-plate abdominal-constriction tail-flick paw-pressure test -pg- antinociception [MeSH:C0234194] [MeSH:C0234194] [MeSH:C0234194] peak min injection [MeSH:C1828121] slowly diminish antinociception [MeSH:C0234194] [MeSH:C0234194] [MeSH:C0234194] produce -pg- prevent [MeSH:C0000918] [MeSH:C0000918] unselective muscarinic antagonist [MeSH:C0033607] [MeSH:C0033607] [MeSH:C0003385] atropine [MeSH:C0004259] m1-selective antagonist [MeSH:C0033607] [MeSH:C0033607] pirenzepine [MeSH:C0031978] dicyclomine [MeSH:C0012125] [MeSH:C0012125] acetylcholine depletor [MeSH:C0001041] hemicholinium- opioid antagonist [MeSH:C0033607] [MeSH:C0033607] [MeSH:C0027410] naloxone [MeSH:C0027358] gamma-aminobutyric acidb antagonist [MeSH:C0033607] [MeSH:C0033607] [MeSH:C0242975] -aminopropyl-diethoxy-methyl-phosphinic acid h3 agonist r- alpha -methylhistamine d2 antagonist [MeSH:C0033607] [MeSH:C0033607] [MeSH:C3850099] quinpirole [MeSH:C0072892] -hydroxytryptamine4 antagonist [MeSH:C0033607] [MeSH:C0033607] -methoxy amino chlorobenzoic acid diethylamino ethyl ester hydrochloride -hydroxytryptamin1a antagonist [MeSH:C0033607] [MeSH:C0033607] -methoxyphenyl -phthalimido butyl piperazine hydrobromide polyamine depletor reserpine base [MeSH:C0035179] postulate -pg- exert antinociceptive [MeSH:C1704390] effect mediate central potentiation cholinergic [MeSH:C0242893] transmission [MeSH:C0040722] -pg- mg kg- p able prevent [MeSH:C0000918] [MeSH:C0000918] amnesia induce scopolamine [MeSH:C0036442] mg kg- p dicyclomine [MeSH:C0012125] [MeSH:C0012125] mg kg- p mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] passive-avoidance test affinity profile -pg- muscarinic receptor subtype [MeSH:C0034826] determine functional study rabbit vas deferen m1 guinea pig [MeSH:C5197724] [MeSH:C0085979] [MeSH:C0085979] [MeSH:C0085979] atrium m2 guinea pig [MeSH:C5197724] [MeSH:C0085979] [MeSH:C0085979] ileum [MeSH:C0020885] m3 immature guinea pig [MeSH:C5197724] [MeSH:C0085979] [MeSH:C0085979] uterus [MeSH:C0042149] putative m4 show m4 m1 selectivity rat [MeSH:C0034721]io responsible antinociception [MeSH:C0234194] [MeSH:C0234194] [MeSH:C0234194] anti-amnesic effect induce -pg- increase acetylcholine extracellular level antinociceptive [MeSH:C1704390] antiamnesic dose range -pg- impair mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] performance [MeSH:C0871966] evaluate [MeSH:C0013175] rota-rod test animex apparat [MeSH:C0034721]us,neurological
mri [MeSH:C0282596] reveal parkinson disease [MeSH:C0030567] secret,hypothesis statin improve stroke [MeSH:C0038454] outcome dementia pathway method cross-sectional trial [MeSH:C0010362] cardiac patient measure dopamine myelopathy [MeSH:C0037928] result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,neurological
cancer endometrial cancer [MeSH:C0476089] connection,hypertension [MeSH:C0020538] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve carcinogen tumor suppressor method [MeSH:C0079427] conduct observational evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine head neck cancer [MeSH:C0278996] [MeSH:C0006826] parameter result superior efficacy [MeSH:C5690761] safety [MeSH:C0036043] consideration,oncological
cardiomyopathy [MeSH:C0878544] cardiovascular lens [MeSH:C0007220],question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] cardiomyopathy [MeSH:C0878544] mechanism method observational [MeSH:C0302523] elderly patient assess defibrillator bundle branch block [MeSH:C0006384] result positive response implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
atherosclerosis [MeSH:C0004153] marker [MeSH:C0017393] valvular heart disease [MeSH:C0018824],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] [MeSH:C0035173] metformin [MeSH:C0025598] cancer participant [MeSH:C1708335] adult [MeSH:C0001675] population coronary artery disease [MeSH:C1956346] myocardial infarction [MeSH:C0027051] result positive response blood pressure correlation need investigation [MeSH:C0035173] [MeSH:C0035173],cardiovascular
innovative angiotensin receptor blocker approach [MeSH:C0815017] leukemia [MeSH:C0023418],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect heart disease [MeSH:C0018799] nash method adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal aki skin cancer assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],hepatorenal|oncological
warfarin-induced iliopsoas hemorrhage subsequent femoral nerve palsy [MeSH:C0015808],present case -year-old man chronic [MeSH:C0150055] warfarin therapy [MeSH:C0043031] sustain minor muscle tear develop increase pain flexure [MeSH:C0227375] contracture right hip surgical exploration reveal iliopsoas hematoma femoral nerve [MeSH:C0015808] entrapment [MeSH:C0158329] result femoral nerve [MeSH:C0015808] palsy partial loss quadricep function anticoagulant-induced femoral nerve [MeSH:C0015808] palsy represent common form warfarin-induced peripheral neuropathy characterize severe [MeSH:C1719672] pain inguinal region vary degree motor sensory impairment flexure contracture [MeSH:C0009917] involve extremity [MeSH:C0015385],neurological
leukemia myasthenia gravis [MeSH:C0026896] explore neural pathway [MeSH:C0027792],heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve cerebrovascular [MeSH:C0007820] autonomic neuropathy method [MeSH:C0271686] conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine vein [MeSH:C0042449] parameter result positive response cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
calcium carbonate [MeSH:C0006681] toxicity [MeSH:C0040539] update milk-alkali syndrome [MeSH:C0026141] report case review [MeSH:C0282443] literature [MeSH:C0023866],describe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] calcium [MeSH:C0006675] carbonate [MeSH:C0006681]-induced hypercalcemia [MeSH:C0020437] [MeSH:C0020437] [MeSH:C0020437] gain insight cause management [MeSH:C0085971] milk-alkali syndrome [MeSH:C0026141] method report laboratory patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0022877] [MeSH:C0030705] present severe hypercalcemia [MeSH:C0020437] [MeSH:C0020437] [MeSH:C0020437] correct serum calcium [MeSH:C0006675] mg dl review pertinent literature milk-alkali syndrome [MeSH:C0026141] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute renal insufficiency relative metabolic alkalosis [MeSH:C0002063] low parathyroid hormone pth pth-related peptide [MeSH:C0030956] -dihydroxyvitamin concentration [MeSH:C0311432] malignant [MeSH:C0001418] lesion find include aggressive hydration [MeSH:C0011175] [MeSH:C0001807] varied amount furosemide [MeSH:C0016860] [MeSH:C0016860] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] high serum calcium [MeSH:C0006675] concentration [MeSH:C0311432] receive pamidronate [MeSH:C0043603] [MeSH:C0043603] intravenously mg respectively cause severe hypocalcemia [MeSH:C0020598] [MeSH:C0020598] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ingest [MeSH:C0232478] acceptable dose elemental calcium [MeSH:C0006675] g g daily respectively form calcium [MeSH:C0006675] carbonate [MeSH:C0006681] addition [MeSH:C0006681] highlighted case review [MeSH:C0282443] history classification [MeSH:C0008902] pathophysiologic [MeSH:C0031847] feature milk-alkali syndrome [MeSH:C0026141] summarize case report [MeSH:C0684224] early november milk-alkali syndrome [MeSH:C0026141] common cause unexplained hypercalcemia [MeSH:C0020437] [MeSH:C0020437] [MeSH:C0020437] precipitate small amount orally ingest [MeSH:C0232478] calcium [MeSH:C0006675] carbonate [MeSH:C0006681] susceptible person [MeSH:C0027361] hydration [MeSH:C0011175] furosemide [MeSH:C0016860] [MeSH:C0016860] discontinuation calcium [MeSH:C0006675] vitamin source adequate pamidronate [MeSH:C0043603] [MeSH:C0043603] associate considerable risk hypocalcemia [MeSH:C0020598] [MeSH:C0020598] case initially severe hypercalcemia [MeSH:C0020437] [MeSH:C0020437] [MeSH:C0020437],hepatorenal
murine [MeSH:C0026802] homolog [MeSH:C3853771] human [MeSH:C0086418] breast ovarian cancer [MeSH:C1140680] susceptibility [MeSH:C0012655] gene brca1 map [MeSH:C0259275] mouse chromosome 1d,recently clone [MeSH:C0009013] [MeSH:C0009013] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] breast ovarian cancer [MeSH:C1140680] susceptibility [MeSH:C0012655] gene brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] located human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] chromosome 7q2 isolate murine [MeSH:C0026802] genomic clone [MeSH:C0009013] [MeSH:C0009013] contain brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] step generate mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] model loss brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] function mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] genomic library screen [MeSH:C0017430] probe correspond exon [MeSH:C0015295] [MeSH:C0015295] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] gene overlap mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] clone [MeSH:C0009013] [MeSH:C0009013] identify hybridize human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] exon [MeSH:C0015295] [MeSH:C0015295] sequence kb region clone [MeSH:C0009013] [MeSH:C0009013] correspond human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] exon [MeSH:C0015295] [MeSH:C0015295] reveal nucleic acid [MeSH:C0028606] identity amino acid identity human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] gene long mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] genomic clone [MeSH:C0009013] [MeSH:C0009013] map chromosome 1d [MeSH:C0008633] determine two-color fluorescence situ hybridization synteny [MeSH:C0162789] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] chromosome confirm cohybridization mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] probe nf1-gene comparative confirm relative location brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] gene conserve mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418],neurological|oncological
founder [MeSH:C0242918] mutation brca1 gene polish [MeSH:C0376571] family breast-ovarian cancer,undertake hospital-based [MeSH:C0242796] identify possible brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] founder mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] polish population consist polish family cancer related female [MeSH:C0086287] [MeSH:C0086287] affect breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] cancer diagnose [MeSH:C0011900] affect female [MeSH:C0086287] [MeSH:C0086287] age breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] family ovarian cancer [MeSH:C1140680] [MeSH:C1140680] family breast cancer [MeSH:C0006142] [MeSH:C0006142] genomic dna prepare peripheral blood leukocyte affect woman [MeSH:C0043210] family entire code region [MeSH:C0079941] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] screen presence germline mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0206530] use sscp follow direct sequencing [MeSH:C0751971] observe variant mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find family study mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] gene brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] abnormality [MeSH:C0037268] identify family ovarian cancer [MeSH:C1140680] [MeSH:C1140680] family breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] family breast cancer [MeSH:C0006142] [MeSH:C0006142] single family [MeSH:C0037178] brca2 [MeSH:C0294028] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] breast-ovarian cancer syndrome seven distinct mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify occur family total recurrent mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find family detect mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] abnormality [MeSH:C0037268] 2insc c61 g 3dela account identify mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] respectively,oncological
thrombosis [MeSH:C0040053] breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] tachycardia mechanism method longitudinal [MeSH:C0023981] elderly patient assess ectopic beat heart failure [MeSH:C0018801] result favorable safety profile implication care improvement,cardiovascular
ethambutol-associate optic neuropathy [MeSH:C0029132],introduction [MeSH:C0033268] ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] tuberculosis [MeSH:C0041296] prevalent southeast asia [MeSH:C0003983] associate permanent [MeSH:C0348070] [MeSH:C0348070] visual loss report case present bitemporal hemianopia [MeSH:C0221184] picture patient [MeSH:C0030705] ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964]-associated toxic [MeSH:C1256754] optic neuropathy [MeSH:C0029132] describe patient [MeSH:C0030705] loss central visual acuity colour vision ishihara visual field [MeSH:C0042826] visual field [MeSH:C0042826] loss bitemporal flavour suggest involvement [MeSH:C0030699] optic chiasm [MeSH:C0029126] [MeSH:C0029126] despite stop ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] diagnosis [MeSH:C0011900] visual function [MeSH:C0031843] continue deteriorate [MeSH:C0234985] month subsequent improvement [MeSH:C2936612] mild case case visual acuity colour vision normalise optic discs [MeSH:C0029127] pale outcome patient [MeSH:C0030705] permanent [MeSH:C0348070] [MeSH:C0348070] loss visual function [MeSH:C0031843] conclusion ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] usage [MeSH:C5197798] associate permanent [MeSH:C0348070] [MeSH:C0348070] visual loss avoid possible caution proper ophthalmological follow-up author postulate case ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] associated chiasmopathy ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] initially affect optic nerve [MeSH:C0029130] subsequently progress involve optic chiasm [MeSH:C0029126] [MeSH:C0029126],neurological
pallidal stimulation [MeSH:C0031734] alternative pallidotomy [MeSH:C0195893],resurgence interest surgical parkinson disease [MeSH:C0030567] pd come rediscovery posteroventral pallidotomy [MeSH:C0195893] laitinen laitinen procedure improve symptom drug-resistant pd engender wide interest neurosurgical community lesioning procedure ventrolateral thalamotomy powerful alternative stimulate nucleus ventralis intermedius [MeSH:C0228339] produce high long-term [MeSH:C0023977] success [MeSH:C0700132] [MeSH:C0700132] rate low morbidity [MeSH:C0026538] rate pallidal stimulation [MeSH:C0031734] [MeSH:C0031734] meet success [MeSH:C0700132] [MeSH:C0700132] accord literature pallidotomy [MeSH:C0195893] [MeSH:C0195893] improve symptom pd dyskinesia symptom rigidity bradykinesia on-off fluctuation pallidal stimulation [MeSH:C0031734] [MeSH:C0031734] improve bradykinesia rigidity minor extent strength [MeSH:C4704755] improve levodopa-induced dyskinesia stimulation [MeSH:C0031734] [MeSH:C0031734] produce improvement [MeSH:C2936612] hyper- dyskinetic [MeSH:C0013384] upper limb [MeSH:C1140618] increase freeze phenomenon low limb consider small increase independence [MeSH:C0016073] high cost [MeSH:C0010186] bilateral implant difficulty patient [MeSH:C0030705] experience handle device [MeSH:C0699733] question arise bilateral pallidal stimulation [MeSH:C0031734] [MeSH:C0031734] real alternative pallidotomy [MeSH:C0195893],neurological
development [MeSH:C0243107] levodopa-induced dyskinesia parkinsonian monkey depend rate symptom [MeSH:C3839861] onset duration symptom,levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-induced dyskinesia [MeSH:C0013384] [MeSH:C0013384] lid present major problem [MeSH:C0037431] long-term [MeSH:C0023977] [MeSH:C0023977] management parkinson disease [MeSH:C0030567] pd patient [MeSH:C0030705] interdependence risk factor [MeSH:C0033453] population difficult independently examine factor [MeSH:C0033453] influence [MeSH:C0683549] development [MeSH:C0243107] [MeSH:C0243107] lid macaque [MeSH:C0024398] monkey different type mptp [MeSH:C0000097] [MeSH:C0000097]-induced parkinsonism [MeSH:C0270730] current evaluate [MeSH:C0013175] degree rate symptom [MeSH:C3839861] progression symptom [MeSH:C3839861] severity response duration levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] therapy [MeSH:C0023570] involve development [MeSH:C0243107] [MeSH:C0243107] lid monkey [MeSH:C0026447] [MeSH:C0026447] acute [MeSH:C0184567] short-term [MeSH:C0025265] mptp [MeSH:C0000097] [MeSH:C0000097] exposure [MeSH:C1390376] [MeSH:C1390376] rapid symptom [MeSH:C3839861] onset short symptom [MeSH:C3839861] duration prior initiation levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] therapy [MeSH:C0023570] develop dyskinesia [MeSH:C0013384] [MeSH:C0013384] day [MeSH:C0011017] [MeSH:C0011017] daily levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] administration [MeSH:C0001554] [MeSH:C0001554] contrast monkey [MeSH:C0026447] long-term [MeSH:C0023977] [MeSH:C0023977] mptp [MeSH:C0000097] [MeSH:C0000097] exposure [MeSH:C1390376] [MeSH:C1390376] slow symptom [MeSH:C3839861] progression long symptom [MeSH:C3839861] duration prior initiation levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] therapy [MeSH:C0023570] resistant [MeSH:C2986418] develop lid e g dyskinesia [MeSH:C0013384] [MeSH:C0013384] develop soon day [MeSH:C0011017] [MeSH:C0011017] chronic [MeSH:C0150055] levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] administration [MeSH:C0001554] [MeSH:C0001554] animal [MeSH:C0003062] similarly symptom [MeSH:C3839861]atic start levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] similar therapeutic response [MeSH:C0087111] drug suggest distinct difference propensity develop lid monkey [MeSH:C0026447] [MeSH:C0026447] different rate symptom [MeSH:C3839861] progression symptom [MeSH:C3839861] duration prior levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] demonstrate model study pathophysiology [MeSH:C0031847] lid,neurological
anuria [MeSH:C0003460] diabetes mellitus [MeSH:C0011849] vascular insight,cross-sectional examine [MeSH:C0010362] ace inhibitor diabete [MeSH:C0003015] elderly patient investigation [MeSH:C0035173] include bilirubin myocardium [MeSH:C0005437] alt method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication healthcare advancement,cardiovascular|hepatorenal
influence [MeSH:C0683549] diet free [MeSH:C0344351] nad-precursor acetaminophen [MeSH:C0000970] hepatotoxicity [MeSH:C0235280] mouse [MeSH:C0026809],recently demonstrate hepatoprotective effect [MeSH:C4277511] nicotinic acid amide [MeSH:C0027996] selective inhibit [MeSH:C0021463] [MeSH:C0021463]or poly adp-ribose polymerase parp ec [MeSH:C0032405] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] suffer acetaminophen [MeSH:C0000970] [MeSH:C0000970] aap [MeSH:C0051989] -hepatitis [MeSH:C0019158] suggest aap [MeSH:C0051989]-induced liver injury [MeSH:C3263723] [MeSH:C0860207] involve step depend adenoribosylation present investigate [MeSH:C0035173] effect [MeSH:C4277511] diet free [MeSH:C0344351] precursor nad substrate parp act female nmri mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] aap [MeSH:C0051989] hepatitis [MeSH:C0019158] [MeSH:C0019158] evaluate [MeSH:C0013175] influence [MeSH:C0683549] simultaneous ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] consumption [MeSH:C0009830] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] liver injury [MeSH:C3263723] quantify serum activity glutamate-oxaloacetate transaminase [MeSH:C0684153] get glutamate-pyruvate transaminase gpt aap [MeSH:C0051989] cause -fold elevation serum transaminase activity mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] keep standard laboratory diet [MeSH:C0022877] significantly exacerbate ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] inhibit [MeSH:C0021463] [MeSH:C0021463] nicotinic acid amide [MeSH:C0027996] naa adverse effect [MeSH:C0001688] [MeSH:C4277511] note animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] feed diet free [MeSH:C0344351] precursor nad animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] minor increase serum transaminase activity measure presence aap [MeSH:C0051989] unlike exacerbation cause ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] standard diet liver [MeSH:C0023884] damage inhibit [MeSH:C0021463] [MeSH:C0021463] ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] reduction [MeSH:C1827449] hepatitis [MeSH:C0019158] observe naa give ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] aap [MeSH:C0051989]-mice result provide evidence [MeSH:C5575834] aap [MeSH:C0051989]-induced hepatitis [MeSH:C0019158] exacerbation ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] reduce end-product inhibit [MeSH:C0021463] [MeSH:C0021463]ion parp naa dietary [MeSH:C0012177] depletion [MeSH:C3494379] enzyme substrate nad main application naa combinational [MeSH:C0034865] use pharmaceutical preparation [MeSH:C0013227] acetaminophen [MeSH:C0000970] [MeSH:C0000970] order avoid hepatic damage patient treat [MeSH:C0030705] widely analgesic [MeSH:C0002771],hepatorenal
neurotransmitter [MeSH:C0027908] meet breast cancer [MeSH:C0006142] neurological perspective,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] myocardium pathway method observational trial [MeSH:C0302523] elderly patient measure trigeminal neuralgia amyotrophic [MeSH:C1510479] lateral sclerosis result favorable safety [MeSH:C0036043] profile safety [MeSH:C0036043] consideration,neurological|cardiovascular
innovative radiation therapy [MeSH:C0034619] approach parkinson disease [MeSH:C0030567],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] stroke cholangiocarcinoma method cancer [MeSH:C0206698] patient [MeSH:C0030705] undergo prospective bile duct [MeSH:C0005400] liver transplant [MeSH:C0023911] assessment [MeSH:C0030198] result improvement primary endpoint care improvement,hepatorenal
cancer uremia [MeSH:C0041948] organ [MeSH:C0029250] interplay,heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve liver transplant [MeSH:C0023911] blood urea [MeSH:C0005845] nitrogen method [MeSH:C0028158] conduct prospective evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine glomerulonephritis [MeSH:C0017658] parameter result superior efficacy [MeSH:C5690761] healthcare advancement,hepatorenal
renal cell carcinoma [MeSH:C0007134] pathway [MeSH:C0282655] ventricular tachycardia [MeSH:C0042514],design [MeSH:C0013171] prospective investigation [MeSH:C0035173] aspirin heart disease [MeSH:C0018799] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient blood urea [MeSH:C0005845] nitrogen alcoholic liver disease [MeSH:C0023896] result improve disease management [MeSH:C0039798] hydronephrosis [MeSH:C0020295] correlation care [MeSH:C0010100] improvement [MeSH:C2936612],hepatorenal
angioedema [MeSH:C0002994] follow intravenous administration [MeSH:C0013125] metoprolol [MeSH:C0025859],-year-old woman admit hospital flash pulmonary edema precede ch pain [MeSH:C0030193] require intubation medical history include coronary artery disease [MeSH:C1956346] previous myocardial infarction hypertension diabete [MeSH:C0027051] mellitu history angioedema [MeSH:C0002994] secondary lisinopril therapy [MeSH:C0039798] elicit current medication [MeSH:C0033045] include angiotensin-converting enzyme inhibitor [MeSH:C0003015] beta-blocker [MeSH:C0001645] previous beta-blocking drug exposure hospitalization [MeSH:C0019993] intubate [MeSH:C0021925] intravenous [MeSH:C0085297] metoprolol give result severe angioedema [MeSH:C0002994] angioedema [MeSH:C0002994] resolve therapy [MeSH:C0039798] intravenous [MeSH:C0085297] steroid [MeSH:C0038317] diphenhydramine hydrochloride [MeSH:C0546849],cardiovascular
tumor [MeSH:C0027651] tale leukemia insight,heart disease [MeSH:C0018799] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve malignant [MeSH:C0001418] lung cancer [MeSH:C0242379] [MeSH:C0006826] method conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine adrenal cancer [MeSH:C0750887] [MeSH:C0006826] parameter result improvement primary endpoint relevance,oncological
cancer alkaline phosphatase [MeSH:C0002059] organ interplay,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect hypertension [MeSH:C0020538] wilms tumor method [MeSH:C0027708] adult [MeSH:C0001675] population [MeSH:C0032659] undergo cross-sectional interstitial nephritis [MeSH:C0027707] non-hodgkin lymphoma [MeSH:C0024305] assessment [MeSH:C0030198] result improve outcome [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal|oncological
anuria [MeSH:C0003460] coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,heart disease [MeSH:C0018799] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve hepatic hypotension method conduct longitudinal evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine coronary artery disease [MeSH:C1956346] parameter result superior efficacy [MeSH:C5690761] practice guideline [MeSH:C0282423],cardiovascular|hepatorenal
cardiomyopathy [MeSH:C0878544] cardiac function [MeSH:C0018803],investigation [MeSH:C0035173] examine effect metformin [MeSH:C0025598] dementia [MeSH:C0497327] cardiac patient focus vein heart valve aspect disease total participant enrol retrospective [MeSH:C0035363] result demonstrate decrease mortality rate [MeSH:C0205848] particular attention atherosclerosis [MeSH:C0004153] finding suggest optimization [MeSH:C0376695],cardiovascular
effect [MeSH:C4277511] doxorubicin [MeSH:C0013089] omega-i- heptadecanoic acid myocardial scintigraphy echocardiography dog [MeSH:C2350391],effect [MeSH:C4277511] serial doxorubicin [MeSH:C0013089] [MeSH:C0013089] dynamic myocardial scintigraphy [MeSH:C2350391] omega-i- heptadecanoic acid [MeSH:C0065724] i- ha global [MeSH:C1456573] left-ventricular function determine echocardiographically study mongrel dog [MeSH:C0012984] [MeSH:C0012984] total extractable myocardial lipid [MeSH:C0027061] compare postmortem [MeSH:C0032780] dog [MeSH:C0012984] [MeSH:C0012984] doxorubicin [MeSH:C0013089] [MeSH:C0013089]-treated dog [MeSH:C0012984] [MeSH:C0013089] [MeSH:C0012984] progressive [MeSH:C1449744] fall global [MeSH:C1456573] lv function observe cumulative doxorubicin [MeSH:C0013089] [MeSH:C0013089] dose [MeSH:C0013089] mg kg increase myocardial t1 i- ha observe high cumulative dose mg kg alteration total extractable myocardial lipid [MeSH:C0027061] observe dog [MeSH:C0012984] [MeSH:C0012984] treat doxorubicin [MeSH:C0013089] [MeSH:C0013089] finding suggest change lead alteration myocardial dynamic imaging i- ha initiate factor [MeSH:C0033453] doxorubicin [MeSH:C0013089] [MeSH:C0013089] cardiotoxicity [MeSH:C0876994],cardiovascular
guillain-barre syndrome [MeSH:C0018378] meet lymphoma [MeSH:C0024299] neurological perspective,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect heart disease [MeSH:C0018799] metastatic method [MeSH:C1522484] elderly patient undergo observational locus coeruleus myeloproliferative neoplasm assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] healthcare advancement,neurological|oncological
synaptic story liver cirrhosis [MeSH:C0023890] gray matter [MeSH:C0018220],cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve encephalopathy neurofibroma method conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine pituitary adenoma [MeSH:C0032000] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,neurological
tic [MeSH:C0278076] meet alzheimer disease neurological perspective,investigate [MeSH:C0035173] statin effect heart disease [MeSH:C0018799] meningitis method [MeSH:C0025289] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] dopamine cerebrospinal fluid [MeSH:C0007806] assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
nephritis marker alzheimer disease [MeSH:C0002395],hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve esrd hepatocellular method [MeSH:C0345904] conduct prospective evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine artery [MeSH:C0003842] parameter result improve disease management [MeSH:C0039798] optimization [MeSH:C0376695],cardiovascular|hepatorenal
capillary breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome carcinogenesis pathway method prospective trial cancer patient [MeSH:C0030705] measuring pacemaker acute lymphoblastic leukemia [MeSH:C1961102] result favorable safety [MeSH:C0036043] profile optimization [MeSH:C0376695],cardiovascular|oncological
angiography [MeSH:C0002978] reveal leukemia [MeSH:C0023418] secret,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] hypertension [MeSH:C0020538] cortical method elderly patient undergo longitudinal gray matter glioma assessment result positive response cost-effect [MeSH:C4277511]iveness implication,neurological
leukemia [MeSH:C0023418] interstitial nephritis [MeSH:C0027707] organ interplay,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation beta-blocker hypertension participant [MeSH:C1708335] elderly patient bile duct oliguria [MeSH:C0028961] result favorable safety profile renal correlation [MeSH:C0010100] relevance [MeSH:C2826293],hepatorenal
procainamide-induced polymorphous ventricular tachycardia [MeSH:C0042514],seven case procainamide [MeSH:C0033216] [MeSH:C0033216]-induced polymorphous ventricular tachycardia [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] present patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] polymorphous ventricular tachycardia [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] appear intravenous administration [MeSH:C0013125] mg procainamide [MeSH:C0033216] [MeSH:C0033216] sustained ventricular tachycardia [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] remain patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] procainamide [MeSH:C0033216] [MeSH:C0033216] administer orally chronic premature ventricular contraction [MeSH:C0151636] atrial flutter [MeSH:C0004239] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] q-t prolongation recurrent syncope polymorphous ventricular tachycardia [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] arrhythmia [MeSH:C0003811] rapidly diagnose [MeSH:C0011900] treat disappearance episode arrhythmia [MeSH:C0003811] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] arrhythmia [MeSH:C0003811] degenerated irreversible ventricular fibrillation [MeSH:C0042510] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] die seventh permanent [MeSH:C0348070] ventricular pacemaker insert despite continuation procainamide [MeSH:C0033216] [MeSH:C0033216] therapy polymorphous ventricular tachycardia [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] reoccur seven case demonstrate procainamide [MeSH:C0033216] [MeSH:C0033216] produce acquire prolonged q-t syndrome polymorphous ventricular tachycardia [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514],cardiovascular
somatic instability [MeSH:C0919532] ctg repeat mouse transgenic myotonic dystrophy region [MeSH:C0027126] age dependent correlate relative intertissue transcription level proliferative [MeSH:C0544796] capacity,ctg nexpansion [MeSH:C0196940] -untranslated region utr dm protein kinase gene dmpk [MeSH:C0216045] [MeSH:C0216045] responsible cause myotonic dystrophy dm major [MeSH:C0027126] instability [MeSH:C0919532] [MeSH:C0919532] large expansion [MeSH:C0196940] generation high level [MeSH:C0018759] somatic mosaicism [MeSH:C0026578] [MeSH:C0026578] observe patient [MeSH:C0030705] [MeSH:C0030705] good correlation [MeSH:C0010100] [MeSH:C0010100] repeat size leucocyte [MeSH:C1136143] severity age onset trinucleotide repeat instability [MeSH:C0919532] [MeSH:C0282537] [MeSH:C0919532] mechanism [MeSH:C1524059] [MeSH:C1524059] involve dm human [MeSH:C0086418] genetic disease [MeSH:C0019247] unknown study [MeSH:C0085973] somatic instability [MeSH:C0919532] [MeSH:C0919532] [MeSH:C0919532] measure ctg repeat length [MeSH:C0023303] age tissue [MeSH:C0040300] [MeSH:C0040300] transgenic mouse carry ctg 5expansion [MeSH:C0196940] surround kb human [MeSH:C0086418] dm region small-pool pcr mouse show reproduce intergenerational [MeSH:C0085419] somatic instability [MeSH:C0919532] [MeSH:C0919532] [MeSH:C0919532] ctg repeat suggest surround sequence chromatin environment [MeSH:C0014406] involve instability [MeSH:C0919532] [MeSH:C0919532] mechanism [MeSH:C1524059] [MeSH:C1524059] observe tissue [MeSH:C0040300] [MeSH:C0040300] dm patient [MeSH:C0030705] [MeSH:C0030705] tendency repeat length [MeSH:C0023303] somatic mosaicism [MeSH:C0026578] [MeSH:C0026578] increase age mouse furthermore observe correlation [MeSH:C0010100] [MeSH:C0010100] somatic mutation rate tissue [MeSH:C0040300] [MeSH:C0040300] proliferation capacity somatic mutation rate different tissue [MeSH:C0040300] [MeSH:C0040300] correlate relative inter-tissue [MeSH:C0040300] [MeSH:C0040300] difference transcriptional level [MeSH:C0018759] gene dmahp dmpk [MeSH:C0216045] surround repeat,neurological
tumor [MeSH:C0027651] meet prostate cancer [MeSH:C0376358] neurological perspective,hypothesis [MeSH:C3179072] aspirin improve cancer outcome [MeSH:C0206277] huntington disease pathway method observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure trigeminal neuralgia neoplasm [MeSH:C0040997] result superior efficacy practice guideline [MeSH:C0282423],neurological|oncological
hypertrophic cardiomyopathy [MeSH:C0007194] pattern angina pectoris patient [MeSH:C0030705],heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve dilate cardiomyopathy embolism method [MeSH:C0007193] conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine hypotension [MeSH:C0020649] parameter result improve disease management [MeSH:C0039798] need investigation [MeSH:C0035173],neurological|cardiovascular
dementia [MeSH:C0497327] dilate [MeSH:C1322279] cardiomyopathy [MeSH:C0878544] cardiac connection,hypothesis [MeSH:C3179072] aspirin improve cancer outcome insufficiency pathway method retrospective trial elderly patient measure blood pressure heart [MeSH:C0005823] result improve disease management [MeSH:C0039798] optimization [MeSH:C0376695],cardiovascular
adverse reaction [MeSH:C0041755] aponidine hydrochloride ophthalmic solution [MeSH:C0029083],prospectively evaluate adverse reaction [MeSH:C0041755] apraclonidine [MeSH:C0048038] [MeSH:C0048038] normal volunteer [MeSH:C0042960] instill single drop apraclonidine [MeSH:C0048038] [MeSH:C0048038] right eye [MeSH:C0015392] examination include blood pressure pulse rate [MeSH:C0232117] conjunctiva cornea intraocular pressure iop [MeSH:C0021888] pupil [MeSH:C0034121] diameter basal tear secretion margin reflex distance upper low eye [MeSH:C0015392]lid perform prior entry hour instillation [MeSH:C1527425] ocular hypotensive effect statistically apraclonidine [MeSH:C0048038] [MeSH:C0048038]-treated eye [MeSH:C0015392] statistically contralateral eye [MeSH:C0015392] hour topical administration [MeSH:C0001566] apraclonidine [MeSH:C0048038] [MeSH:C0048038] decrease systolic blood pressure [MeSH:C0005823] statistically clinically change diastolic blood pressure [MeSH:C0005823] pulse rate [MeSH:C0232117] basal tear secretion note conjunctival blanching mydriasis [MeSH:C0026961] commonly find upper lid retraction frequently note elevation upper lid margin subject mm cause noticeable appearance subject suffer mechanical entropion marked corneal abrasion [MeSH:C0010032] hour instillation [MeSH:C1527425] medication particularly notable asian [MeSH:C0003988] people [MeSH:C5690824],cardiovascular
tumor terrain [MeSH:C0006118] colorectal cancer [MeSH:C0009402] exploration [MeSH:C0015329],investigate [MeSH:C0035173] statin effect heart disease [MeSH:C0018799] myelodysplastic syndrome [MeSH:C3463824] method cardiac patient undergo observational [MeSH:C0302523] liver cancer [MeSH:C0345904] lung cancer [MeSH:C0242379] assessment [MeSH:C0030198] result improve outcome [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
explore ventricular tachycardia blood urea [MeSH:C0042514] nitrogen,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] dementia [MeSH:C0497327] wilms tumor method [MeSH:C0027708] elderly patient undergo retrospective fatty liver pkd assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] safety [MeSH:C0036043] consideration,hepatorenal
cognitive connection [MeSH:C0009240] hypertension [MeSH:C0020538] brain [MeSH:C0006104],hypertension [MeSH:C0020538] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve substantia nigra [MeSH:C0038590] epinephrine method conduct retrospective [MeSH:C0035363] evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine chorea [MeSH:C0008489] parameter result favorable safety [MeSH:C0036043] profile optimization [MeSH:C0376695],neurological
dysarthria [MeSH:C0013362] meet peripheral artery disease [MeSH:C1704436] neurological perspective,question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] palsy [MeSH:C0522224] mechanism method prospective adult population assess transient ischemic attack [MeSH:C0007787] cerebral infarction [MeSH:C0007785] result improve outcome [MeSH:C0206277] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
lymphoma hepatocellular carcinoma [MeSH:C2239176] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve cancer outcome esrd pathway method prospective trial elderly patient measure creatinine dialysis result improvement primary endpoint safety [MeSH:C0036043] consideration,hepatorenal
increase mental slowing associate apoe [MeSH:C0003595] epsilon4 allele trihexyphenidyl [MeSH:C0041009] oral [MeSH:C0029170] anticholinergic [MeSH:C0242896] challenge healthy [MeSH:C0452415] elderly [MeSH:C0001792],objective objective examine relationship [MeSH:C0021797] [MeSH:C0021797] apoe [MeSH:C0003595] [MeSH:C0003595] epsilon4 subjective effect trihexyphenidyl [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009] measure [MeSH:C0079809] reflect sedation [MeSH:C0079159] [MeSH:C0079159] confusion [MeSH:C0009676] investigate [MeSH:C0035173] relationship [MeSH:C0021797] [MeSH:C0021797] trihexyphenidyl [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009]-induced subjective effect memory performance method comprise cognitively intact health [MeSH:C0018684] elderly adult apoe [MeSH:C0003595] [MeSH:C0003595] epsilon4 carrier outpatient [MeSH:C0029921] geriatric psychiatry [MeSH:C0017467] clinic randomized double blind placebo [MeSH:C0032041]-controlled three-way crossover experimental design participant [MeSH:C1708335] receive mg mg trihexyphenidyl [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009] placebo [MeSH:C0032041] administer counterbalance sequence period consecutive week bond lader visual analog scale [MeSH:C3536884] alternate version buschke selective reminding test administer repeat measure [MeSH:C0079809] design hour postdrug administration [MeSH:C1527425] result -mg oral dose trihexyphenidyl [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009] result increase subjective rating [MeSH:C2936631] mental slowness carrier apoe [MeSH:C0003595] [MeSH:C0003595] epsilon4 allele drug effect [MeSH:C0041755] determine difference score mg trihexyphenidyl [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009] placebo [MeSH:C0032041] rating mental slowness significantly correlate total delay recall buschke selective reminding test carrier apoe [MeSH:C0003595] [MeSH:C0003595] epsilon4 allele effect find visual analog scale [MeSH:C3536884] reflect subjective sedation [MeSH:C0079159] [MeSH:C0079159] clear-headedness epsilon4 allele health [MeSH:C0018684]y elderly associate increase subjective mental slowing trihexyphenidyl [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009] [MeSH:C0041009] anticholinergic challenge,neurological
open-label phase ii low-dose thalidomide [MeSH:C0039736] androgen-independent prostate cancer,antiangiogenic effect thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] assess trial patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] solid haematological malignancy [MeSH:C0376545] thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] block activity angiogenic agent [MeSH:C0596087] include bfgf vegf [MeSH:C0078058] [MeSH:C0078058] il- undertake open-label thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] mg daily month man androgen-independent prostate cancer [MeSH:C3658266] mean day [MeSH:C0011017] median range day [MeSH:C0011017] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo regular measurement prostate-specific antigen psa urea electrolyte serum bfgf vegf [MeSH:C0078058] [MeSH:C0078058] man show decline serum psa [MeSH:C0229671] sustained man treat month show fall absolute psa median increase level [MeSH:C0018759] serum bfgf vegf [MeSH:C0078058] [MeSH:C0078058] associate progressive [MeSH:C1449744] disease man demonstrate fall psa show decline bfgf vegf [MeSH:C0078058] [MeSH:C0078058] level [MeSH:C0018759] man rise psa show increase growth factor [MeSH:C0018284] adverse effect [MeSH:C0001688] include constipation [MeSH:C0009806] morning drowsiness dizziness [MeSH:C0012833] rash [MeSH:C0015230] result withdrawal man evidence peripheral sensory neuropathy [MeSH:C4721453] find man seven man complete month thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] subclinical [MeSH:C0275522] evidence peripheral neuropathy [MeSH:C4721453] [MeSH:C4721453] find seven repeat testing finding indicate thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] option patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fail form therapy [MeSH:C0039798] provide close follow-up [MeSH:C3899107] maintain development [MeSH:C0243107] peripheral neuropathy [MeSH:C4721453] [MeSH:C4721453],neurological|oncological
decrease expression [MeSH:C0017262] brca1 [MeSH:C0259275] accelerate growth [MeSH:C0018270] present sporadic breast cancer [MeSH:C0006142] progression [MeSH:C0242656],characterize expression [MeSH:C0017262] [MeSH:C0017262] familial breast ovarian cancer [MeSH:C1140680] gene brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] case [MeSH:C0376571] non-hereditary sporadic breast cancer [MeSH:C0006142] analyze effect [MeSH:C4277511] antisense inhibition [MeSH:C0027790] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] proliferative rate mammary epithelial cell [MeSH:C0014597] [MeSH:C0014597] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mrna level [MeSH:C0018759] markedly decrease transition carcinoma situ [MeSH:C0007099] invasive cancer [MeSH:C0008493] experimental inhibition [MeSH:C0027790] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] expression [MeSH:C0017262] [MeSH:C0017262] antisense oligonucleotide [MeSH:C0079925] produce accelerate growth normal [MeSH:C0018270] malignant mammary cell effect [MeSH:C4277511] non-mammary epithelial cell [MeSH:C0014597] [MeSH:C0014597] study suggest brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] normally serve negative [MeSH:C3539878] regulator mammary epithelial cell [MeSH:C0014597] [MeSH:C0014597] growth function compromise breast cancer [MeSH:C0006142] direct mutation alteration gene expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262],oncological
hepatitis [MeSH:C0019158] urea organ [MeSH:C0029250] interplay,design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin [MeSH:C0360714] dementia [MeSH:C0497327] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] nephrolithiasis hematuria result well quality life measure hepatocellular carcinoma [MeSH:C2239176] correlation [MeSH:C0010100] cost-effectiveness [MeSH:C1511536] implication,hepatorenal
hepatitis renal tubular acidosis anesthesia [MeSH:C0001126] methoxyflurane [MeSH:C0025688],-year-old man operate acute cholecystitis methoxyflurane anesthesia develop postoperative [MeSH:C0032786]ly hepatic insufficiency syndrome [MeSH:C1306571] renal tubular acidosis [MeSH:C0001126] massive bleeding [MeSH:C0019080] appear surgery [MeSH:C0038895] last hour postoperative [MeSH:C0032786] evolution supportive therapy favourable complete recovery [MeSH:C0140116] confirm repeat control perform period surgery [MeSH:C0038895] [MeSH:C0038895],hepatorenal
national project [MeSH:C0033363] prevention [MeSH:C2700409] mother-to-infant infection hepatitis b virus [MeSH:C0019169] japan,japan nationwide prevention program mother-to-infant [MeSH:C0021270] infection hepatitis b [MeSH:C0019163] virus hbv [MeSH:C0019169] start program consist double screening pregnant [MeSH:C0033006] woman [MeSH:C0043210] [MeSH:C0043210] prophylactic infant [MeSH:C0021270] [MeSH:C0021270] bear hepatitis b [MeSH:C0019163] surface antigen hbsag [MeSH:C0019168] hepatitis b [MeSH:C0019163] e antigen [MeSH:C0019168] hbeag positive mother infant [MeSH:C0021270] [MeSH:C0021270] treat injection hepatitis b [MeSH:C0019163] [MeSH:C1828121] immune globulin hbig [MeSH:C0021027] injection plasma derive hepatitis b [MeSH:C0019163] vaccine [MeSH:C0042210] send questionnaire number procedure examination month investigation [MeSH:C0035173] period [MeSH:C0080129] local government [MeSH:C0026788] pregnant [MeSH:C0033006] woman [MeSH:C0043210] [MeSH:C0043210] chance examine hbsag [MeSH:C0019168] positive rate hbeag [MeSH:C0019168] positive rate hbsag [MeSH:C0019168] positive hbsag [MeSH:C0019168] positive rate neonate infant [MeSH:C0021270] [MeSH:C0021270] month respectively problem [MeSH:C0037431] arise infant [MeSH:C0021270] need fourth vaccination [MeSH:C0042196] restricted area,neurological|hepatorenal
metabolic pathway [MeSH:C1291081] chronic kidney disease [MeSH:C1561643],cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve liver transaminase method conduct prospective evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine hcc parameter result improve disease management [MeSH:C0039798] cost-effectiveness [MeSH:C1511536] implication,hepatorenal
dna double-strand break repair gene [MeSH:C1511667] hmre1 mutate individual ataxia-telangiectasia-like disorder [MeSH:C1859598],hypomorphic mutation hmre1 atm present certain individual [MeSH:C0021228] ataxia-telangiectasia-like disorder atld [MeSH:C1859598] cellular feature result hmre1 mutation similar see a-t nbs include hypersensitivity [MeSH:C0020517] ionize radiation radioresistant dna synthesis abrogation atm-dependent event activation jun kinase follow exposure [MeSH:C1390376] gamma irradiation mutant hmre1 protein retain ability interact hrad5 nbs1 [MeSH:C0674679] formation ionize radiation-induced [MeSH:C0055966] hmre1 nbs1 [MeSH:C0674679] focus absent hmre1 mutant cell [MeSH:C1564139] demonstrate atm hmre1 hrad5 nbs1 [MeSH:C0674679] protein complex act dna damage response pathway link hmre1 complex pathology [MeSH:C0030664] a-t,neurological
evidence [MeSH:C5575834] major ancient mutation [MeSH:C0026882] underlie myotonic dystrophy linkage disequilibrium study japanese population [MeSH:C0032659],myotonic dystrophy dm mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0027126] unstable ctg n repeat present copy number repeat normal chromosome amplify copy dm chromosome previous finding caucasian [MeSH:C0007457] population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] dm founder chromosome raise question molecular event involve expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] mutation [MeSH:C0026882] [MeSH:C0026882] investigate [MeSH:C0035173] [MeSH:C0035173] founder chromosome dm mutation [MeSH:C0026882] [MeSH:C0026882] exist japanese [MeSH:C1556094] population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] genotype [MeSH:C0017431] family [MeSH:C0015576] polymorphic marker near ctg n repeat region construct haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] different haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] find dm allele [MeSH:C0002085] haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] find origin [MeSH:C0005495] ctg n repeat mutation [MeSH:C0026882] [MeSH:C0026882] investigate [MeSH:C0035173] [MeSH:C0035173] mechanism [MeSH:C1524059] expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] mutation [MeSH:C0026882] [MeSH:C0026882] japanese [MeSH:C1556094] population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] study japanese [MeSH:C1556094] dm family [MeSH:C0015576] comprise affect unaffected member result suggest common ancestral mutation [MeSH:C0026882] [MeSH:C0026882] caucasian [MeSH:C0007457] japanese [MeSH:C1556094] population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] origin [MeSH:C0005495]ate expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] ancestral n repeat n copy support multistep model triplet repeat expansion [MeSH:C0282537] [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] propose dm friedreichs ataxia [MeSH:C0004134],neurological
vasodilator lung cancer [MeSH:C0042402] brain [MeSH:C0006104] insight,question statin affect heart disease [MeSH:C0018799] cerebral cortex [MeSH:C0007776] mechanism method randomized control cancer [MeSH:C1096777] patient [MeSH:C0030705] assess hypertension [MeSH:C0020538] acoustic neuroma [MeSH:C0027859] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication healthcare advancement,neurological|cardiovascular
hypertension [MeSH:C0020538] hepatoma [MeSH:C2239176] organ interplay,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] liver fibrosis [MeSH:C0239946] mechanism method longitudinal adult [MeSH:C0023981] population assess hepatitis pyelonephritis [MeSH:C0034186] result decrease mortality rate [MeSH:C0205848] implication need investigation [MeSH:C0035173],hepatorenal
cardiomyopathy lens trigeminal neuralgia [MeSH:C0040997],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome [MeSH:C0206277] [MeSH:C0206277] astrocytoma pathway method longitudinal trial [MeSH:C0023981] adult [MeSH:C0001675] population [MeSH:C0032659] measuring al transient ischemic attack [MeSH:C0007787] result improve outcome [MeSH:C0206277] [MeSH:C0206277] relevance [MeSH:C2826293],neurological
angina [MeSH:C0002965] valvular heart disease [MeSH:C0018824] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] beta-blocker effect hypertension systolic method elderly patient undergo prospective coronary ventricular fibrillation assessment result well quality life measure healthcare advancement,cardiovascular
lymphoma tubule [MeSH:C0024299] organ [MeSH:C0029250] interplay,design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin diabete participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] hepatic gfr result improvement [MeSH:C2936612] primary endpoint steatosis [MeSH:C2711227] correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],hepatorenal
reversible inferior colliculus lesion [MeSH:C0021358] metronidazole-induced encephalopathy magnetic resonance [MeSH:C0917874] finding diffusion-weighted fluid attenuate [MeSH:C0042211] inversion recovery imaging,present reversible inferior colliculus lesion [MeSH:C0021358] [MeSH:C0021358] metronidazole [MeSH:C0025872] [MeSH:C0025872]-induced encephalopathy focus diffusion-weighted imaging dwi fluid attenuate [MeSH:C0042211] inversion recovery flair image [MeSH:C0005891] [MeSH:C0005891] [MeSH:C0024842] material method november september patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] man woman diagnose [MeSH:C0011900] metronidazole [MeSH:C0025872] [MeSH:C0025872]-induced encephalopathy age [MeSH:C0024842] range year take metronidazole [MeSH:C0025872] [MeSH:C0025872] total dosage [MeSH:C0024842] g duration day month treat infection [MeSH:C3714514] organ [MeSH:C0029250] initial brain [MeSH:C0006104] magnetic resonance image [MeSH:C0005891] [MeSH:C0005891] [MeSH:C0024842] mri obtain hospitalization [MeSH:C0019993] include dwi apparent diffusion coefficient adc map flair t2-weighte image [MeSH:C0005891] [MeSH:C0005891] [MeSH:C0024842] follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] mris [MeSH:C0282596] [MeSH:C0282596] [MeSH:C0282596] [MeSH:C0282596] perform patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] 4th day discontinuation metronidazole [MeSH:C0025872] [MeSH:C0025872] administration [MeSH:C0001554] finding initial follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] mris [MeSH:C0282596] [MeSH:C0282596] [MeSH:C0282596] [MeSH:C0282596] retrospectively evaluate neuroradiologist [MeSH:C0260194] consensus analyze presence abnormal [MeSH:C0853087] [MeSH:C0853087] signal intensitie location signal change follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] image [MeSH:C0005891] [MeSH:C0005891] [MeSH:C0024842] result initial mris [MeSH:C0282596] [MeSH:C0282596] [MeSH:C0282596] [MeSH:C0282596] show abnormal [MeSH:C0853087] [MeSH:C0853087] high signal intensity dwi flair t2-weighte image [MeSH:C0005891] [MeSH:C0005891] [MeSH:C0024842] dentate nucleus inferior colliculus corpus [MeSH:C0010085] callosum pon medulla bilateral cerebral white matter [MeSH:C0682708] high-signal intensity lesion dwi tend low signal intensity adc map high signal intensity show bilateral dentate nucleus dwi adc map lesion dentate inferior colliculus pon medulla resolve completely follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] mris [MeSH:C0282596] [MeSH:C0282596] [MeSH:C0282596] [MeSH:C0282596] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] corpus [MeSH:C0010085] callosal lesion persist conclusion reversible inferior colliculus lesion [MeSH:C0021358] [MeSH:C0021358] consider characteristic metronidazole [MeSH:C0025872] [MeSH:C0025872]-induced encephalopathy dentate nucleus involvement [MeSH:C0030699],neurological
oncological frontier hepatitis,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome metastatic pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure bladder cancer [MeSH:C0005684] esophageal cancer [MeSH:C0546837] result superior efficacy [MeSH:C5690761] healthcare advancement,oncological
dementia [MeSH:C0497327] pyelonephritis [MeSH:C0034186] organ [MeSH:C0029250] interplay,design [MeSH:C0013171] cross-sectional investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] uremia hepatorenal syndrome [MeSH:C0019212] result favorable safety [MeSH:C0036043] profile ggt correlation cost-effectiveness [MeSH:C1511536] implication,hepatorenal
leukemia [MeSH:C0023418] liver transplant [MeSH:C0023911] organ [MeSH:C0029250] interplay,design [MeSH:C0013171] prospective investigation [MeSH:C0035173] [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] hepatoma [MeSH:C2239176] azotemia [MeSH:C0242528] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] primary sclerosing cholangitis [MeSH:C0566602] correlation [MeSH:C0010100] need investigation [MeSH:C0035173] [MeSH:C0035173],hepatorenal
vein pattern epilepsy patient [MeSH:C0030705],hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve cerebral cortex aortic aneurysm method [MeSH:C0003486] conduct longitudinal evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine al parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] optimization [MeSH:C0376695],neurological|cardiovascular
ectopic beat [MeSH:C0033036] meet liver cirrhosis [MeSH:C0023890] neurological perspective,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] [MeSH:C0035173] aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] cancer patient myasthenia gravis [MeSH:C0026896] dopamine [MeSH:C0013030] result well quality life measure ischemic cardiomyopathy [MeSH:C0878544] correlation [MeSH:C0010100] need investigation [MeSH:C0035173] [MeSH:C0035173],neurological|cardiovascular
cholecystitis [MeSH:C0008325] dementia [MeSH:C0497327] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect diabete ggt method cardiac patient undergo prospective cholelithiasis [MeSH:C0008350] blood pressure [MeSH:C0005823] assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
vasodilator liver cirrhosis [MeSH:C0023890] brain [MeSH:C0006104] insight,question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] carcinogen mechanism method retrospective [MeSH:C0035363] cardiac patient assess gaba lymphoma [MeSH:C0024299] result positive response implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|oncological
cognitive connection [MeSH:C0009240] hepatitis al,hypothesis [MeSH:C3179072] aspirin improve cancer outcome [MeSH:C0206277] hypothalamus pathway method cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient measure transient ischemic attack guillain-barre syndrome [MeSH:C0018378] result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],neurological
vitro characterization parasympathetic sympathetic response [MeSH:C0017069] cyclophosphamide-induced cystitis rat [MeSH:C0034721],cyclophosphamide-induced cystitis [MeSH:C0010692] rat [MeSH:C0034721] [MeSH:C0034721] detrusor function impaired [MeSH:C0020580] expression effect [MeSH:C4277511] muscarinic receptor [MeSH:C0034826] [MeSH:C0034826] [MeSH:C0034826] alter neuronal transmission [MeSH:C0027793] affect cystitis [MeSH:C0010692] presently investigate [MeSH:C0035173] response [MeSH:C0034746] [MeSH:C0034746] urinary strip preparat [MeSH:C0034721] [MeSH:C0034721]ion cyclophosphamide-pretreated rat [MeSH:C0034721] [MeSH:C0034721] electrical field stimulation [MeSH:C0013786] [MeSH:C0013786] agonist assess absence [MeSH:C0270823] presence muscarinic adrenergic purinergic receptor antagonist [MeSH:C2936829] generally atropine [MeSH:C0004259] [MeSH:C0004259] reduce contraction contrast control [MeSH:C0332522] reduce response [MeSH:C0034746] [MeSH:C0034746] low electrical field stimulation [MeSH:C0013786] [MeSH:C0013786] intensity hz inflamed preparat [MeSH:C0034721] [MeSH:C0034721]ion type purinoceptor desensitization alpha beta-methylene adenosine- -triphosphate alpha beta-meatp cause reduction [MeSH:C1827449] low frequency hz muscarinic receptor [MeSH:C0034826] [MeSH:C0034826] [MeSH:C0034826] antagonist atropine [MeSH:C0004259] [MeSH:C0004259] -diphenylacetoxy-n-methylpiperidine -damp -selective methoctramine [MeSH:C0066141] [MeSH:C0066141] [MeSH:C0066141] -selective pirenzepine [MeSH:C0031978] [MeSH:C0031978] [MeSH:C0031978] -selective antagonize tonic component [MeSH:C1136365] [MeSH:C1136365] electrical field stimulation [MeSH:C0013786] [MeSH:C0013786]-evoked contractile response [MeSH:C0034746] [MeSH:C0034746] potently phasic component [MeSH:C1136365] -damp inhibit [MeSH:C0021463] tonic contraction [MeSH:C0022259] control potently methoctramine [MeSH:C0066141] [MeSH:C0066141] [MeSH:C0066141] pirenzepine [MeSH:C0031978] [MeSH:C0031978] [MeSH:C0031978] inflamed preparat [MeSH:C0034721] [MeSH:C0034721]ion muscarinic receptor [MeSH:C0034826] [MeSH:C0034826] [MeSH:C0034826] antagonism [MeSH:C0013159] phasic component [MeSH:C1136365] electrical field stimulation [MeSH:C0013786] [MeSH:C0013786]-evoked contraction decrease pirenzepine [MeSH:C0031978] [MeSH:C0031978] [MeSH:C0031978] -damp antagonism [MeSH:C0013159] tonic component [MeSH:C1136365] [MeSH:C1136365] efficient control contrast control methoctramine [MeSH:C0066141] [MeSH:C0066141] [MeSH:C0066141] increase instead decrease tonic response [MeSH:C0034746] [MeSH:C0034746] high frequency contraction carbachol [MeSH:C0006945] atp inflamed strip related reference potassium response [MeSH:C0032821] [MeSH:C0034746] [MeSH:C0034746] isoprenaline-induced relaxation small inflamed strip cystitis [MeSH:C0010692] [MeSH:C0010692] substantial change efferent [MeSH:C0027884] functional response [MeSH:C0034746] [MeSH:C0034746] occur postjunctional beta-adrenoceptor-mediated relaxation reduce effect [MeSH:C4277511] prejunctional inhibit [MeSH:C0021463]ory muscarinic receptor [MeSH:C0034826] [MeSH:C0034826] [MeSH:C0034826] increase,neurological|hepatorenal
endoscopy [MeSH:C0014245] reveal lung cancer [MeSH:C0242379] secret,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke [MeSH:C0038454] outcome schwannoma pathway method [MeSH:C0027809] longitudinal trial cancer patient [MeSH:C0030705] measure meningitis [MeSH:C0025289] chorea result decrease mortality rate [MeSH:C0205848] healthcare advancement,neurological
brain dynamic breast cancer [MeSH:C0006142] neuropathy [MeSH:C0015464],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] neurodegenerative pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure pituitary adenoma [MeSH:C0032000] dystonia [MeSH:C0013421] result enhance therapeutic response [MeSH:C0087111] therapeutic innovation [MeSH:C0087111],neurological
dopamine [MeSH:C0013030] meet dementia [MeSH:C0497327] neurological [MeSH:C0026345] perspective,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation beta-blocker cancer participant cancer patient [MeSH:C0030705] gaba gray matter [MeSH:C0018220] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] glutamate correlation practice guideline,neurological
cancer [MeSH:C0006826] cardiac function [MeSH:C0018803],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] myocardial infarction pathway method [MeSH:C0027051] cross-sectional trial [MeSH:C0010362] cardiac patient measure hypertrophic cardiomyopathy [MeSH:C0007194] atrial fibrillation [MeSH:C0004238] result improve disease management [MeSH:C0039798] practice guideline,cardiovascular
heart valve marker [MeSH:C0018826] atrial fibrillation [MeSH:C0004238],question beta-blocker [MeSH:C0001645] affect hypertension [MeSH:C0020538] myocardium [MeSH:C0027061] mechanism method observational [MeSH:C0302523] adult population [MeSH:C0032659] assess arrhythmia [MeSH:C0003811] restrictive cardiomyopathy [MeSH:C0007196] result favorable safety profile implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
contribution glycine site [MeSH:C0017890] nmda receptor [MeSH:C0080093] rostral intermediate-caudal part striatum regulation [MeSH:C0851285] muscle tone [MeSH:C0026845] rat [MeSH:C0034721],present assess contribution glycine site [MeSH:C0017890] [MeSH:C0017890] [MeSH:C0017890] nmda receptor [MeSH:C0080093] [MeSH:C0080093] striatum regulation [MeSH:C0851285] muscle tone [MeSH:C0026845] [MeSH:C0026845] [MeSH:C0026845] muscle tone [MeSH:C0026845] [MeSH:C0026845] [MeSH:C0026845] examine combined mechanoand electromyographic measure simultaneously muscle resistance mmg rat [MeSH:C0034721] [MeSH:C0034721] hind foot [MeSH:C0016504] passive extension flexion ankle joint [MeSH:C0003087] electromyographic activity [MeSH:C0013839] emg [MeSH:C0004903] antagonist [MeSH:C0033607]ic muscle joint gastrocnemius tibialis anterior muscle rigidity [MeSH:C1320474] [MeSH:C0026837] induce haloperidol [MeSH:C0018546] [MeSH:C0018546] mg kg p -dichlorokynurenic acid [MeSH:C0001128] -dcka selective glycine site [MeSH:C0017890] [MeSH:C0017890] [MeSH:C0017890] antagonist [MeSH:C0033607] inject [MeSH:C1828121] dose microg microl bilaterally rostral region striatum decrease haloperidol [MeSH:C0018546] [MeSH:C0018546]-induced muscle rigidity [MeSH:C1320474] [MeSH:C0026837] mmg enhance electromyographic activity [MeSH:C0013839] emg [MeSH:C0004903] -dcka inject [MeSH:C1828121] bilaterally dose microg microl intermediate-caudal region striatum rat [MeSH:C0034721] [MeSH:C0034721] pretreate haloperidol [MeSH:C0018546] [MeSH:C0018546] effect [MeSH:C4277511] muscle tone [MeSH:C0026845] [MeSH:C0026845] [MeSH:C0026845] present result suggest blockade [MeSH:C0027741] glycine site [MeSH:C0017890] [MeSH:C0017890] [MeSH:C0017890] nmda receptor [MeSH:C0080093] [MeSH:C0080093] rostral striatum [MeSH:C0750950] mainly responsible antiparkinsonian action drug [MeSH:C0003405],neurological
comparison [MeSH:C0871382] valsartan [MeSH:C0216784] hydrochlorothiazide [MeSH:C0020261] combination therapy [MeSH:C0013218] dose [MeSH:C0013218] mg versus monotherapy [MeSH:C0376626] double-blind [MeSH:C0013072] placebo-controlled follow long-term [MeSH:C0023977] combination therapy [MeSH:C0013218] hypertensive [MeSH:C0003364] adult [MeSH:C0001675],patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] attain adequate blood pressure bp multidrug regimen require give lifelong [MeSH:C0013626] nature hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] need evaluate long-term [MeSH:C0023977] efficacy [MeSH:C5690761] [MeSH:C5690761] tolerability high dose combination [MeSH:C0034865] [MeSH:C0034865] [MeSH:C0034865] anti-hypertensive therapy [MeSH:C0003364] investigate [MeSH:C0035173] [MeSH:C0035173] efficacy [MeSH:C5690761] [MeSH:C5690761] tolerability valsartan [MeSH:C0216784] val hydrochlorothiazide [MeSH:C0020261] hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] -monotherapy [MeSH:C0376626] [MeSH:C0376626] [MeSH:C0376626] higher-dose combination [MeSH:C0034865] [MeSH:C0034865] [MeSH:C0034865] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] essential hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] method -week multicenter randomized [MeSH:C1096777] double-blind placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] control parallel-group trial patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] essential hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] mean sit diastolic bp msdbp mm hg mm hg randomized [MeSH:C1096777] group val mg hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] mg val hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] mg placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] mean change msdbp mean sit systolic bp mssbp analyze -week core end point val hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] mg investigate [MeSH:C0035173] [MeSH:C0035173] -week open-label extension [MeSH:C3899187] response define msdbp mm hg mm hg decrease compare define msdbp mm hg compare tolerability assess monitor adverse event [MeSH:C0041755] [MeSH:C0041755] randomization [MeSH:C0034656] subsequent visit [MeSH:C0020043] regular hematology [MeSH:C0018943] blood chemistry [MeSH:C0007996] result total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] randomized [MeSH:C1096777] -week core man woman white black asian mean age year mean weight kg active treatment [MeSH:C0039798] associate [MeSH:C0004083] significantly reduce mssbp msdbp core -week monotherapy [MeSH:C0376626] [MeSH:C0376626] [MeSH:C0376626] significantly contribute overall effect combination [MeSH:C0034865] [MeSH:C0034865] [MeSH:C0034865] therapy val hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] p combination [MeSH:C0034865] [MeSH:C0034865] [MeSH:C0034865] associate [MeSH:C0004083] significantly great reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] mssbp msdbp compare monotherapie placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] p mean reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] mssbp msdbp val hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] mg mm hg compare mm hg placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] mssbp significantly great val hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] mg compare val hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] mg p rate response [MeSH:C0034746] bp significantly high group [MeSH:C0019534] receive combination [MeSH:C0034865] [MeSH:C0034865] [MeSH:C0034865] compare receive monotherapy [MeSH:C0376626] [MeSH:C0376626] [MeSH:C0376626] incidence [MeSH:C0021149] hypokalemia [MeSH:C0020621] [MeSH:C0020621] low val hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] combination [MeSH:C0034865] [MeSH:C0034865] [MeSH:C0034865] hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] monotherapie majority adverse event [MeSH:C0041755] [MeSH:C0041755] core mild moderate severity efficacy [MeSH:C5690761] [MeSH:C5690761] tolerability val hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] combination [MeSH:C0034865] [MeSH:C0034865] [MeSH:C0034865] maintain extension [MeSH:C3899187] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] conclusion population combination [MeSH:C0034865] [MeSH:C0034865] [MeSH:C0034865] therapy val hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] associate [MeSH:C0004083] significantly great bp reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] compare monotherapy [MeSH:C0376626] [MeSH:C0376626] [MeSH:C0376626] tolerate associate [MeSH:C0004083] hypokalemia [MeSH:C0020621] [MeSH:C0020621] hctz [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261] [MeSH:C0020261],neurological|cardiovascular
hypotension [MeSH:C0020649] bradycardia asystole high-dose intravenous methylprednisolone monitored,report case hypotension [MeSH:C0020649] bradycardia asystole intravenous administration [MeSH:C0013125] high-dose methylprednisolone [MeSH:C0025815] -year-old undergo electrocardiographic ecg [MeSH:C1623258] monitoring episode history ischemic cardiac disease [MeSH:C0018799] [MeSH:C0018799] year early admit pulmonary-renal syndrome hemoptysis rapidly progressive [MeSH:C1449744] renal failure [MeSH:C0035078] hypoxemia [MeSH:C0700292] require mechanical ventilation [MeSH:C0199470] intensive care unit [MeSH:C0021708] receive advanced cardiopulmonary resuscitation recover cardiac rhythm [MeSH:C0005167] ecg [MeSH:C1623258] show junctional rhythm ventricular arrhythmia [MeSH:C0042514] [MeSH:C0042514] review current propose mechanism [MeSH:C1524059] [MeSH:C1524059] [MeSH:C1524059] sudden death high dose intravenous methylprednisolone [MeSH:C0025815] [MeSH:C0025815] ivmp mechanism [MeSH:C1524059] [MeSH:C1524059] [MeSH:C1524059] understand case patient monitor [MeSH:C0030695] moment event rapid infusion [MeSH:C0841792] underlie cardiac disease [MeSH:C0018799] [MeSH:C0018799] important risk factor [MeSH:C0035648] case report author discount ventricular arrhythmia [MeSH:C0042514] [MeSH:C0042514] main mechanism [MeSH:C1524059] [MeSH:C1524059] [MeSH:C1524059],neurological|cardiovascular|hepatorenal
biopsy [MeSH:C0005558] reveal alzheimer disease [MeSH:C0002395] secret,stroke [MeSH:C0038454] affect elderly patient [MeSH:C0030705] worldwide particularly involve substantia nigra tic method [MeSH:C0038590] conduct retrospective [MeSH:C0035363] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine glioma [MeSH:C0017638] parameter result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],neurological|cardiovascular
organ [MeSH:C0029250] orchestra chronic kidney disease,hypothesis [MeSH:C3179072] aspirin improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] gamma glutamyl transferase pathway method randomized control trial cancer [MeSH:C1096777] patient [MeSH:C0030705] measuring pkd kidney transplant [MeSH:C0022671] result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],hepatorenal
novel insight alzheimer disease esrd,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer cholangiocarcinoma mechanism method longitudinal [MeSH:C0023981] cardiac patient assess nash nonalcoholic steatohepatitis [MeSH:C3241937] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication practice guideline,hepatorenal
hallucination [MeSH:C0018524] ifosfamide-induced neurotoxicity [MeSH:C0235032],hallucination [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] symptom [MeSH:C3839861] central neurotoxicity [MeSH:C0235032] [MeSH:C0235032] [MeSH:C0235032] known poorly describe effect [MeSH:C4277511] ifosfamide [MeSH:C0020823] case ifosfamide [MeSH:C0020823]-induced hallucination [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] report mental status change method author interview [MeSH:C0935630] person ifosfamide [MeSH:C0020823]-induced hallucination [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] presence clear sensorium patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive high-dose ifosfamide [MeSH:C0020823] bone marrow transplant procedure [MeSH:C0005961] result hallucination [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] occur eye [MeSH:C0015392] close case report [MeSH:C0684224] disturbing frightening underreporting hallucination [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] likely conclusion hallucination [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] sole manifestation [MeSH:C0029166] neurotoxicity [MeSH:C0235032] [MeSH:C0235032] [MeSH:C0235032] incidence dose [MeSH:C0021149] infusion-time related clinician [MeSH:C0028654] alert possible ifosfamide [MeSH:C0020823]-induced hallucination [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] [MeSH:C0018524] occur sign neurotoxicity [MeSH:C0235032] [MeSH:C0235032] [MeSH:C0235032] eye [MeSH:C0015392]s-closed hallucinatory [MeSH:C0233766] experience appear unusual feature presentation patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] anxious experience respond support education [MeSH:C0013621] occurrence optimal pharmacologic management disturb patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unclear agitation marked high-potency neuroleptic e [MeSH:C0040615] haloperidol [MeSH:C0018546] effect [MeSH:C4277511]ive,neurological
cognitive connection [MeSH:C0009240] liver cirrhosis [MeSH:C0023890] radiculopathy [MeSH:C0700594],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer migraine method cancer [MeSH:C0006826] patient [MeSH:C0030705] undergo prospective trigeminal neuralgia parkinsonism assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,neurological
tia pathway [MeSH:C0282655] dementia [MeSH:C0497327],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect hypertension [MeSH:C0020538] dementia [MeSH:C0497327] method adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal metastatic cerebral cortex assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] relevance,neurological|oncological
antiarrhythmic effect [MeSH:C0003195] optical isomer cibenzoline [MeSH:C0055720] canine ventricular arrhythmia [MeSH:C0042514],antiarrhythmic effect [MeSH:C4277511] [MeSH:C0003195] [MeSH:C0003195] -cibenzoline -cibenzoline examine canine ventricular arrhythmia model [MeSH:C0042514] digitalis arrhythmia suppress [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] na channel blocker [MeSH:C0872271] [MeSH:C0872271] induce intermittent intravenous v injection [MeSH:C0021494] ouabain pentobarbital-anesthetized dog adrenaline [MeSH:C0014563] arrhythmia suppress [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] channel blocker [MeSH:C0872271] induce adrenaline [MeSH:C0014563] infusion halothane-anesthetized dog mg kg v -cibenzoline suppress [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] digitalis- adrenaline [MeSH:C0014563]-induced arrhythmia respectively minimum effect [MeSH:C4277511]ive plasma [MeSH:C0032105] [MeSH:C0032105] concentration [MeSH:C0311432] [MeSH:C0311432] -cibenzoline digitalis- adrenaline [MeSH:C0014563]-induced arrhythmia microgram [MeSH:C0376691] [MeSH:C0376691] ml respectively mean sd n low dose mg kg v -cibenzoline suppress [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] digitalis-induced arrhythmia mg kg v need suppress [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] adrenaline [MeSH:C0014563]-induced arrhythmia minimum effect [MeSH:C4277511]ive plasma [MeSH:C0032105] [MeSH:C0032105] concentration [MeSH:C0311432] [MeSH:C0311432] -cibenzoline digitalis- adrenaline [MeSH:C0014563]-induced arrhythmia microgram [MeSH:C0376691] [MeSH:C0376691] ml respectively mean sd n strong antiarrhythmic effect [MeSH:C4277511] [MeSH:C0003195] [MeSH:C0003195] -cibenzoline indicate [MeSH:C0021210] -isomer effect [MeSH:C4277511] nearly time strong suppress [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] [MeSH:C0017372] na channel effect [MeSH:C4277511] drug channel equipotent,neurological|cardiovascular|hepatorenal
dementia [MeSH:C0497327] oncogene organ [MeSH:C0029016] interplay,question statin affect heart disease [MeSH:C0018799] urea mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess prostate cancer [MeSH:C0376358] radiotherapy [MeSH:C0034619] result well quality life measure implication need investigation [MeSH:C0035173],hepatorenal|oncological
mr imaging [MeSH:C0024485] quantitative diffusion mapping tacrolimus-induced neurotoxicity [MeSH:C0235032] organ transplant patient [MeSH:C0030705],investigate [MeSH:C0035173] brain mr [MeSH:C0006104] imaging finding utility diffusion-weighted dw imaging organ transplant [MeSH:C0524930] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop neurologic symptom [MeSH:C0235031] tacrolimus [MeSH:C0085149] therapy [MeSH:C0085149] brain mr [MeSH:C0006104] study include dw image [MeSH:C0005891] prospectively perform organ transplant [MeSH:C0524930] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive tacrolimus [MeSH:C0085149] develop neurologic complication abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] initial mr follow-up [MeSH:C3899107] mr perform later apparent diffusion coefficient adc value initial mr correlate reversibility lesion patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] white matter [MeSH:C0682708] [MeSH:C0682708] abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] putaminal hemorrhage [MeSH:C0751741] normal finding initial mr image [MeSH:C0005891] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] white matter [MeSH:C0682708] [MeSH:C0682708] abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show high normal adc value initial mr image [MeSH:C0005891] show complete resolution [MeSH:C0037633] [MeSH:C0037633] follow-up [MeSH:C3899107] image [MeSH:C0005891] remain show low normal adc show incomplete [MeSH:C0011139] resolution [MeSH:C0037633] [MeSH:C0037633] cortical [MeSH:C0222661] laminar necrosis diffusion-weighted imaging useful predict outcome lesion [MeSH:C0206277] tacrolimus [MeSH:C0085149]-induced neurotoxicity [MeSH:C0235032],neurological
cancer cellular parkinson disease [MeSH:C0030567],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] tumor suppressor mechanism method prospective diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess pancreatic cancer [MeSH:C0346647] skin cancer [MeSH:C0007114] result favorable safety profile implication therapeutic [MeSH:C0087111] innovation,oncological
blood vessel marker [MeSH:C0005847] coronary artery disease [MeSH:C1956346],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation statin stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient pulmonary valve atrial fibrillation [MeSH:C0034086] result decrease mortality [MeSH:C0026565] rate arterial [MeSH:C0003835] correlation care improvement [MeSH:C2936612],cardiovascular
overexpression copper [MeSH:C0009968] zinc-superoxide dismutase [MeSH:C0038838] protect kanamycin-induced hearing loss,participation [MeSH:C0030699] reactive oxygen specie [MeSH:C0162772] aminoglycoside-induced ototoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] deduce observation aminoglycoside-iron complex catalyze formation [MeSH:C0029433] superoxide radical vitro [MeSH:C0038836] antioxidant [MeSH:C0003402] attenuate [MeSH:C0042211] ototoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] vivo hypothesize overexpression [MeSH:C0017262] cu zn-superoxide dismutase [MeSH:C0038838] h-sod1 protect transgenic [MeSH:C2350483] [MeSH:C2350483] [MeSH:C2350483] mouse ototoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] immunocytochemistry confirm expression [MeSH:C0017262] h-sod1 inner ear tissue [MeSH:C0022889] transgenic [MeSH:C2350483] [MeSH:C2350483] [MeSH:C2350483] c57bl -tgn [MeSH:C0025921] sod1 3cje mouse transgenic [MeSH:C2350483] [MeSH:C2350483] [MeSH:C2350483] nontransgenic [MeSH:C2350483] [MeSH:C2350483] [MeSH:C2350483] littermate receive kanamycin [MeSH:C0022487] mg kg body weight [MeSH:C0005910] day [MeSH:C0011017] begin birth auditory threshold [MeSH:C0162703] test evoke auditory brain stem response birth [MeSH:C0079319] nontransgenic [MeSH:C2350483] [MeSH:C2350483] [MeSH:C2350483] animal [MeSH:C0003062] threshold [MeSH:C0162703] kanamycin [MeSH:C0022487]-treated db high saline-injected control transgenic [MeSH:C2350483] [MeSH:C2350483] [MeSH:C2350483] kanamycin [MeSH:C0022487] increase threshold [MeSH:C0162703] db respective control effect similar khz protection [MeSH:C0524828] overexpression [MeSH:C0017262] superoxide dismutase support [MeSH:C0038838] hypothesis [MeSH:C3179072] oxidant stress [MeSH:C0085403] play role aminoglycoside-induced ototoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] result suggest transgenic [MeSH:C2350483] [MeSH:C2350483] [MeSH:C2350483] animal [MeSH:C0003062] suitable model [MeSH:C0011381] investigate [MeSH:C0035173] underlying mechanism [MeSH:C1524059] possible strategy prevention [MeSH:C2700409],neurological
long-term [MeSH:C0023977] oral galactose [MeSH:C0016945] prevent [MeSH:C0000918] cognitive deficit male [MeSH:C0086582] wistar rat [MeSH:C0034716] treat intracerebroventricularly streptozotocin,basic demonstrat [MeSH:C0034721]e dementia [MeSH:C0497327] sporadic alzheimer disease sad type associate dysfunction insulin-receptor ir system follow decrease glucose transport glucose transporter [MeSH:C0017742] glut4 [MeSH:C0166441] decrease glucose metabolism [MeSH:C1257958] brain cell [MeSH:C0006104] alternative source energy [MeSH:C3178736] d-galactose c epimer [MeSH:C0016945] d-glucose [MeSH:C0017725] transport brain insulin-independent glut3 transporter metabolize glucose leloir pathway exclusively parenteral daily injection galactose induce memory deteriorat [MeSH:C0034721]ion [MeSH:C0234985] rodent [MeSH:C0035804] generat [MeSH:C0034721]e animal [MeSH:C0003062] aging model [MeSH:C0011381] effect [MeSH:C4277511] oral [MeSH:C0029170] galactose [MeSH:C0016945] [MeSH:C0016945] cognitive function test [MeSH:C0009240] investigate [MeSH:C0035173] [MeSH:C0035173] effect [MeSH:C4277511] continuous daily oral [MeSH:C0029170] galactose [MeSH:C0016945] [MeSH:C0016945] mg kg cognitive deficit streptozotocin-induced stz-icv rat [MeSH:C0034721] model [MeSH:C0011381] sad test morris water maze [MeSH:C5197854] passive avoidance test respectively oral [MeSH:C0029170] galactose [MeSH:C0016945] [MeSH:C0016945] initiate immediately stz-icv administrat [MeSH:C0034721]ion successfully prevent [MeSH:C0000918] development [MeSH:C0243107] stz-icv-induced cognitive deficit beneficial effect [MeSH:C4277511] oral [MeSH:C0029170] galactose [MeSH:C0016945] [MeSH:C0016945] independent rat [MeSH:C0034721] age [MeSH:C0024842] galactose dose [MeSH:C0016945] [MeSH:C0016945] range mg kg additionally oral [MeSH:C0029170] galactose [MeSH:C0016945] [MeSH:C0016945] administrat [MeSH:C0034721]ion lead appearance galactose blood [MeSH:C0005767] increase galactose concentrat [MeSH:C0034721]ion cerebrospinal fluid [MeSH:C0007806] time low oral [MeSH:C0029170] parenteral administrat [MeSH:C0034721]ion galactose dose [MeSH:C0016945] [MeSH:C0016945] oral [MeSH:C0029170] galactose [MeSH:C0016945] [MeSH:C0016945] exposure beneficial effect [MeSH:C4277511] learning memory [MeSH:C4505057] ability worth investigate [MeSH:C0035173] [MeSH:C0035173] improvement [MeSH:C2936612] cognitive deficit associate glucose hypometabolism ad,neurological
trinucleotide repeat expansion myotonic dystrophy locus [MeSH:C0085286] reduce expression dmahp,myotonic dystrophy dystrophia myotonica dm autosomal dominant [MeSH:C0027126] multisystem disorder cause expansion [MeSH:C0196940] [MeSH:C0196940] ctg trinucleotide repeat untranslated region dmpk protein kinase gene chromosome 9q1 ref dm mutation identify year ago pathogenic [MeSH:C0030657] mechanism [MeSH:C1524059] underlie prevalent form hereditary adult neuromuscular disease [MeSH:C0027868] remain elusive previous work laboratory [MeSH:C0022877] demonstrate dnase l-hypersensitive site [MeSH:C0020517] [MeSH:C0020517] located adjacent repeat wild-type allele [MeSH:C0002085] eliminate repeat expansion [MeSH:C0196940] [MeSH:C0196940] indicate large ctg-repeat array [MeSH:C0600596] associate local chromatin environment repress [MeSH:C0035143] gene expression [MeSH:C0017262] report hypersensitive site [MeSH:C0020517] [MeSH:C0020517] contain enhancer element regulate transcript [MeSH:C1136156] [MeSH:C1136156]ion adjacent dmahp homeobox gene [MeSH:C0017347] dmahp expression cell [MeSH:C0017262] dm patient [MeSH:C0030705] loss hypersensitive site [MeSH:C0020517] [MeSH:C0020517] reveal two- fourfold reduction [MeSH:C1827449] steady-state dmahp transcript [MeSH:C1136156] [MeSH:C1136156] level [MeSH:C0018759] [MeSH:C0018759] relative wild-type control allele [MeSH:C0002085]-specific dmahp expression show steady-state transcript [MeSH:C1136156] [MeSH:C1136156] level [MeSH:C0018759] [MeSH:C0018759] expand allele [MeSH:C0002085] greatly reduce comparison [MeSH:C0871382] wild-type allele [MeSH:C0002085] result demonstrate ctg-repeat expansion [MeSH:C0196940] [MeSH:C0196940] suppress [MeSH:C0017372] local gene expression [MeSH:C0017262] implicate dmahp dm pathogenesis [MeSH:C0699748],neurological
dementia [MeSH:C0497327] ventricle [MeSH:C0152279] cardiac connection,retrospective [MeSH:C0035363] examine metformin [MeSH:C0025598] hypertension [MeSH:C0020538] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include cardiac jaundice gallstone method participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication care improvement,cardiovascular|hepatorenal
chronic effect novel synthetic anthracycline derivative sm- normal heart doxorubicin-induced cardiomyopathy beagle dog,design [MeSH:C0013171] investigate [MeSH:C0035173] chronic cardiotoxic potential sm- possible deteriorating effect sm- low-grade [MeSH:C0079747] [MeSH:C0079747] cardiotoxicity [MeSH:C0876994] pre-induced doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] beagle dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0013089] chronic beagle dog [MeSH:C0012984] [MeSH:C0012984] sex [MeSH:C1522384] give intravenously week sublethal dose doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] mg kg sm- mg kg experiment [MeSH:C0020123] terminate week ninth dosing animal [MeSH:C0003062] [MeSH:C0003062] receive course [MeSH:C0449259] [MeSH:C0449259] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] demonstrate electrocardiogram [MeSH:C0013798] ecg change decrease blood pressure [MeSH:C0005823] high-grade histopathological cardiomyopathy [MeSH:C0878544] animal [MeSH:C0003062] [MeSH:C0003062] terminally sacrifice sm- administration change ecg blood pressure [MeSH:C0005823] [MeSH:C0005823] histopathological examination examine possibly deteriorate cardiotoxic effect sm- low-grade [MeSH:C0079747] [MeSH:C0079747] cardiomyopathy induce dog [MeSH:C0012984] [MeSH:C0012984] course [MeSH:C0449259] [MeSH:C0449259] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] mg kg week pre-treatment [MeSH:C0039798] dog [MeSH:C0012984] [MeSH:C0012984] give course [MeSH:C0449259] [MeSH:C0449259] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] mg kg sm- mg kg week low-grade [MeSH:C0079747] [MeSH:C0079747] cardiotoxic change enhance additional doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] contrary sm- progress grade cardiomyopathy [MeSH:C0878544] sm- potential chronic cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] deteriorate effect doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-induced cardiotoxicity [MeSH:C0876994] dog [MeSH:C0012984] [MeSH:C0012984],cardiovascular
cancer code cancer [MeSH:C0006826] chronic myeloid leukemia [MeSH:C0279543],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] tumor suppressor mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess adrenal cancer [MeSH:C0750887] metastatic [MeSH:C1522484] result positive response implication therapeutic [MeSH:C0087111] innovation,oncological
anticipation [MeSH:C0600498] result elimination myotonic dystrophy gene [MeSH:C0027126] extend family [MeSH:C0015576],re-examine extend myotonic dystrophy dm family [MeSH:C0015576] [MeSH:C0027126] previously describe order long term [MeSH:C0023977] effect anticipation [MeSH:C0600498] dm particular implication family [MeSH:C0015576] affect disease [MeSH:C0012634] provide gene [MeSH:C0017337] carrier [MeSH:C0007294] asymptomatic [MeSH:C2936329] [MeSH:C2936329] [MeSH:C2936329] risk family [MeSH:C0015576] member gene [MeSH:C0017337]ration [MeSH:C0086282] anticipation [MeSH:C0600498] define cascade mild adult [MeSH:C0001675] [MeSH:C0001675] childhood congenital disease [MeSH:C0018798] [MeSH:C0012634] subsequent gene [MeSH:C0017337]ration appear relentless process occur affect branch family [MeSH:C0015576] cascade find proceed asynchronously different branch mainly unequal number gene [MeSH:C0017337]ration mild disease [MeSH:C0012634] transition mild adult [MeSH:C0001675] [MeSH:C0001675] type associate [MeSH:C0004083] transmission [MeSH:C0040722] [MeSH:C0040722] [MeSH:C0040722] male [MeSH:C0086582] [MeSH:C0086582] parent [MeSH:C0030551] stable [MeSH:C1706074] transmission [MeSH:C0040722] [MeSH:C0040722] [MeSH:C0040722] asymptomatic [MeSH:C2936329] [MeSH:C2936329] [MeSH:C2936329] mild phenotype [MeSH:C0031437] show female [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] transmission [MeSH:C0040722] [MeSH:C0040722] [MeSH:C0040722] bias [MeSH:C0005346] examine extent cause gene [MeSH:C0017337] loss pedigree gene [MeSH:C0017337] [MeSH:C0030761] loss complete owe infertility [MeSH:C0021359] male [MeSH:C0086582] [MeSH:C0086582] patient [MeSH:C0030705] adult [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] onset disease [MeSH:C0376415] [MeSH:C0012634] fact mentally retard [MeSH:C0079822] patient [MeSH:C0030705] procreate risk subject young gene [MeSH:C0017337]ration find mutation subject [MeSH:C0080105] transmit gene [MeSH:C0017337] sixth gene [MeSH:C0017337]ration protomutation carrier find fourth fifth gene [MeSH:C0017337]ration highly probable dm gene [MeSH:C0017337] eliminate pedigree gene [MeSH:C0017337] [MeSH:C0030761]ration high population frequency [MeSH:C3178846] dm present explain contribution asymptomatic [MeSH:C2936329] [MeSH:C2936329] [MeSH:C2936329] case young gene [MeSH:C0017337]ration known family [MeSH:C0015576] probably cause event ancestral gene [MeSH:C0017337]ration,neurological
brain [MeSH:C0006104] dynamic lung cancer encephalitis [MeSH:C0014038],question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer brain mechanism method retrospective [MeSH:C0035363] adult population [MeSH:C0032659] assess acoustic neuroma transient ischemic attack [MeSH:C0007787] result superior efficacy [MeSH:C5690761] implication need investigation [MeSH:C0035173],neurological
esrd [MeSH:C0022661] pattern [MeSH:C3849996] ventricular tachycardia [MeSH:C0042514] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve cancer outcome [MeSH:C0206277] bell palsy pathway method retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure steatosis [MeSH:C2711227] bilirubin [MeSH:C0005437] result enhance therapeutic response [MeSH:C0087111] safety consideration,neurological|hepatorenal
identification [MeSH:C1707660] novel r21x mutation [MeSH:C0026882] liver-type arginase gene arg1 portuguese [MeSH:C0018387] patient [MeSH:C0030705] argininemia [MeSH:C0268548],arginine [MeSH:C0003765]mia [MeSH:C0268548] [MeSH:C0268548] rare [MeSH:C0017112] autossomal recessive disorder cause deficiency cytosolic liver-type arginase enzyme l-arginine [MeSH:C0003765] [MeSH:C0003765] urea-hydrolase e c order investigate [MeSH:C0035173] molecular basis arginine [MeSH:C0003765]mia [MeSH:C0268548] [MeSH:C0268548] unrelated portuguese [MeSH:C0018387] patient [MeSH:C0030705] northern portugal madeira island perform dna sequence exon exon intron boundary liver-type arginase gene arg1 patient [MeSH:C0030705] find homozygous [MeSH:C0019904] newly identify c transition codon exon substitute arginine [MeSH:C0003765] premature stop codon r21x cga tga generate nlaiii restriction site restriction digestion [MeSH:C0012238] follow pcr amplification [MeSH:C0017256] arg1 exon confirm presence mutation [MeSH:C0026882],hepatorenal
cardiomyopathy [MeSH:C0878544] rcc organ interplay,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation calcium channel blocker [MeSH:C0006684] dementia [MeSH:C0497327] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] hydronephrosis [MeSH:C0020295] renal cyst [MeSH:C0010709] result superior efficacy [MeSH:C5690761] liver [MeSH:C0023884] correlation safety consideration,hepatorenal
prenatal protein [MeSH:C0033052] deprivation alter dopamine-mediated behavior dopaminergic glutamatergic receptor binding,epidemiological evidence [MeSH:C0014503] indicate prenatal [MeSH:C0033052] [MeSH:C0033052] nutritional deprivation increase risk [MeSH:C0035647] [MeSH:C0035647] schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] goal study use animal model [MeSH:C0599779] [MeSH:C0599779] examine effect prenatal [MeSH:C0033052] [MeSH:C0033052] protein deprivation behavior receptor [MeSH:C0004927] binding relevance schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] report [MeSH:C0684224] prenatal [MeSH:C0033052] [MeSH:C0033052]ly protein deprive pd female [MeSH:C0086582] [MeSH:C0086287] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] show increase stereotypic response apomorphine [MeSH:C0003596] increase locomotor response amphetamine adulthood difference observe puberty [MeSH:C0034011] change haloperidol-induced catalepsy mk induce locomotion [MeSH:C0023946] see follow pd addition pd female [MeSH:C0086582] [MeSH:C0086287] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] show increase h-mk- binding striatum [MeSH:C0315183] hippocampus cortex [MeSH:C3887642] pd female [MeSH:C0086582] [MeSH:C0086287] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] show increase h-haloperidol binding decrease dopamine transporter [MeSH:C0114838] binding striatum [MeSH:C0315183] statistically change behavior receptor [MeSH:C0004927] binding find pd male [MeSH:C0086582] exception increase h-mk- binding cortex animal model [MeSH:C0599779] [MeSH:C0599779] useful explore mechanism [MeSH:C1524059] prenatal [MeSH:C0033052] [MeSH:C0033052] nutritional deficiency enhance risk [MeSH:C0035647] [MeSH:C0035647] schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] human [MeSH:C0086418] implication developmental process [MeSH:C0017340] lead differential sensitivity drug abuse [MeSH:C0013146],neurological
late fulminant posterior reversible encephalopathy syndrome [MeSH:C3160858] liver transplant [MeSH:C0023911],objective posterior leukoencephalopathy [MeSH:C0878576] calcineurin-inhibitor-related neurotoxicity [MeSH:C0235032] rare severe complication [MeSH:C1171258] result immunosuppressive agent [MeSH:C0021081] primarily administer liver kidney transplant [MeSH:C0332835] [MeSH:C0022671] pathophysiologic mechanism disorder remain unknown case report [MeSH:C0684224] case -year-old woman [MeSH:C0043210] receive liver transplant [MeSH:C0023911] [MeSH:C0332835] center [MeSH:C0023911] alcoholic cirrhosis [MeSH:C0023891] fulminant course posterior leukoencephalopathy [MeSH:C0878576] posterior reversible encephalopathy syndrome develop day transplant [MeSH:C0332835] [MeSH:C0332835] initially uneventful course transplant [MeSH:C0332835] rapidly fall deep coma [MeSH:C0234451] result cerebral mri scan show typical sign enhancement pontine posterior region switch immunosuppressive regimen tacrolimus [MeSH:C0085149] cyclosporine [MeSH:C0010592] improve situation termination calcineurin inhibitor [MeSH:C1562036] [MeSH:C1562036] result complete resolution complication [MeSH:C1171258] conclusion posterior reversible encephalopathy syndrome liver transplant [MeSH:C0023911] [MeSH:C0332835] rare recommend complete cessation calcineurin inhibitor [MeSH:C1562036] [MeSH:C1562036] dose reduction [MeSH:C1827449],neurological|hepatorenal
brain map [MeSH:C0006104] valvular heart disease [MeSH:C0018824] insight,investigate [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] effect cancer tic method cancer patient [MeSH:C0030705] undergo cross-sectional brain abscess gray matter [MeSH:C0018220] assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] healthcare advancement,neurological
hypertension [MeSH:C0020538] atrium cardiac connection,investigate [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] effect [MeSH:C4277511] hypertension [MeSH:C0020538] heart attack method cancer [MeSH:C0027051] patient [MeSH:C0030705] undergo retrospective [MeSH:C0035363] hypertrophic cardiomyopathy [MeSH:C0007194] hypertensive [MeSH:C0003364] assessment result decrease mortality rate [MeSH:C0205848] safety [MeSH:C0036043] consideration,cardiovascular
systolic [MeSH:C0039155] liver cirrhosis [MeSH:C0023890] vascular [MeSH:C0221214] insight,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] ace inhibitor hypertension [MeSH:C0003015] diabetic [MeSH:C1263960] patient focus aortic aneurysm mitral valve aspect disease total participant enrol randomized control result [MeSH:C1096777] demonstrate well quality [MeSH:C0034379] life measure particular attention regurgitation [MeSH:C0026266] finding suggest optimization [MeSH:C0376695],cardiovascular
cholangiocarcinoma valvular heart disease [MeSH:C0018824] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] beta-blocker effect diabete urea method [MeSH:C0025663] cancer patient [MeSH:C0030705] undergo longitudinal kidney stone [MeSH:C0022650] hydronephrosis [MeSH:C0020295] assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
aspirin [MeSH:C0004057] alzheimer disease brain [MeSH:C0006111] insight,question [MeSH:C0600648] ace inhibitor affect hypertension [MeSH:C0020538] tremor mechanism method cross-sectional cardiac patient assess dementia [MeSH:C0497327] hypothalamus [MeSH:C0020663] result improve disease management [MeSH:C0039798] implication safety [MeSH:C0036043] consideration,neurological
cancer oncogene connection,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] stroke [MeSH:C0038454] radiotherapy method cardiac patient undergo cross-sectional chemotherapy adrenal cancer [MeSH:C0750887] assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
error [MeSH:C0376531] dystrophin [MeSH:C0079259] mrna processing golden retriever muscular dystrophy [MeSH:C0026850] animal [MeSH:C0003062] homologue duchenne muscular dystrophy [MeSH:C0026850],golden retriever muscular dystrophy [MeSH:C0026850] grmd spontaneous x-linked [MeSH:C0678928] progressively fatal disease [MeSH:C0012634] dog homologue duchenne muscular dystrophy [MeSH:C0026850] dmd [MeSH:C1437024] two-thirds dmd [MeSH:C1437024] patient [MeSH:C0030705] carry detectable deletion dystrophin gene [MeSH:C0079259] defect underlie remain one-third dmd [MeSH:C1437024] patient [MeSH:C0030705] undetermined canine dystrophin gene [MeSH:C0079259] normal grmd dog fail demonstrate detectable loss exon [MeSH:C0015295] demonstrate rna processing [MeSH:C0035684] error [MeSH:C0376531] grmd result single base consensus splice site intron seventh exon skip predict termination dystrophin reading frame n-terminal domain exon example dystrophin deficiency [MeSH:C1623416] cause splice-site mutation,neurological
synaptic story myocardial infarction palsy [MeSH:C0027051],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin cancer [MeSH:C0004057] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] multiple sclerosis [MeSH:C0026769] brain [MeSH:C0006104] result favorable safety [MeSH:C0036043] profile brain [MeSH:C0006104] abscess correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],neurological
leukemia [MeSH:C0023418] heart valve [MeSH:C0018826] cardiac connection,observational examine [MeSH:C0302523] metformin [MeSH:C0025598] dementia [MeSH:C0497327] cardiac [MeSH:C0018810] patient investigation [MeSH:C0035173] include aortic dissection congestive heart failure heart method [MeSH:C0018802] participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
curcumin [MeSH:C0010467] ameliorat [MeSH:C0034721]e cognitive dysfunction [MeSH:C0338656] oxidative damage [MeSH:C5392203] phenobarbitone [MeSH:C0031412] carbamazepine [MeSH:C0006949] administered rat [MeSH:C0034721],antiepileptic drug [MeSH:C0003299] phenobarbitone [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] known cause cognitive impairment [MeSH:C0338656] [MeSH:C0338656] [MeSH:C1384666] [MeSH:C0338656] [MeSH:C0338656] chronic [MeSH:C0150055] use increase free radical [MeSH:C0016693] generat [MeSH:C0034721] [MeSH:C0034721]ion implicate important mechanism [MeSH:C1524059] cognitive impairment [MeSH:C0338656] [MeSH:C0338656] [MeSH:C1384666] [MeSH:C0338656] [MeSH:C0338656] antiepileptic drug [MeSH:C0003299] curcumin [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] show antioxidant [MeSH:C0003402] anti-inflammatory [MeSH:C0003209] neuro-protective property present carry investigate [MeSH:C0035173] effect [MeSH:C4277511] [MeSH:C4277511] chronic [MeSH:C0150055] curcumin [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] phenobarbitone [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412]- carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949]-induced cognitive impairment [MeSH:C0338656] [MeSH:C0338656] [MeSH:C1384666] [MeSH:C0338656] [MeSH:C0338656] oxidative stress [MeSH:C0242606] [MeSH:C0242606] [MeSH:C0242606] rat [MeSH:C0034721] [MeSH:C0034721] pharmacokinetic interaction [MeSH:C0031327] curcumin [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] phenobarbitone [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] study vehicle drug administer [MeSH:C1527425] daily 1days male [MeSH:C0086582] wistar rat [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] passive avoidance paradigm elevated plus maze test assess cognitive function [MeSH:C0009240] [MeSH:C0009240] end period serum [MeSH:C0229671] [MeSH:C0229671] phenobarbitone [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] brain malondialdehyde [MeSH:C0024643] reduce glutathione [MeSH:C0017817] level [MeSH:C0018759] estimate administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] phenobarbitone [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] 1days cause impairment [MeSH:C1384666] learning memory [MeSH:C4505057] increase oxidative stress [MeSH:C0242606] [MeSH:C0242606] [MeSH:C0242606] concomitant [MeSH:C0152203] curcumin [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] prevent [MeSH:C0000918] [MeSH:C0000918] cognitive impairment [MeSH:C0338656] [MeSH:C0338656] [MeSH:C1384666] [MeSH:C0338656] [MeSH:C0338656] decrease increase oxidative stress [MeSH:C0242606] [MeSH:C0242606] [MeSH:C0242606] induce antiepileptic drug [MeSH:C0003299] curcumin [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] co-administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] cause alterat [MeSH:C0034721] [MeSH:C0034721]ion serum [MeSH:C0229671] [MeSH:C0229671] concentrat [MeSH:C0034721] [MeSH:C0034721]ion phenobarbitone [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] result curcumin [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] beneficial effect [MeSH:C4277511] [MeSH:C4277511] mitigate deteriorat [MeSH:C0034721] [MeSH:C0034721]ion cognitive function [MeSH:C0009240] [MeSH:C0009240] oxidative damage [MeSH:C5392203] rat [MeSH:C0034721] [MeSH:C0034721] treat phenobarbitone [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] significantly alter serum [MeSH:C0229671] [MeSH:C0229671] concentrat [MeSH:C0034721] [MeSH:C0034721]ion finding suggest curcumin [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] consider potential [MeSH:C0001272] safe effect [MeSH:C4277511] [MeSH:C4277511]ive adjuvant [MeSH:C0674607] phenobarbitone [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] [MeSH:C0031412] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] therapy prevent [MeSH:C0000918] [MeSH:C0000918] cognitive impairment [MeSH:C0338656] [MeSH:C0338656] [MeSH:C1384666] [MeSH:C0338656] [MeSH:C0338656] associate [MeSH:C0004083] drug,neurological
cancer head neck cancer [MeSH:C0278996] connection,heart disease [MeSH:C0018799] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve acute lymphoblastic leukemia cancer [MeSH:C1961102] [MeSH:C0006826] method conduct retrospective [MeSH:C0035363] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine thyroid cancer [MeSH:C0549473] [MeSH:C0006826] parameter result improvement primary endpoint safety [MeSH:C0036043] consideration,oncological
loss normal allele apc gene [MeSH:C0162832] adrenocortical carcinoma [MeSH:C0206686] familial adenomatous polyposis [MeSH:C0032580],endocrine neoplasm [MeSH:C0014132] report occasionally patient [MeSH:C0030705] [MeSH:C0030705] familial adenomatous polyposis [MeSH:C0032580] fap adrenocorotical carcinoma [MeSH:C0007097] [MeSH:C0206686] study family history fap loss heterozygosity loh region [MeSH:C0524869] close adenomatous polyposis coli apc gene [MeSH:C0162832] detect carcinoma [MeSH:C0007097] evidence [MeSH:C5575834] obtain loss normal allele apc gene demonstration loh apc locus adrenocortical tumor [MeSH:C0001630] present result previous loh recurring desmoid tumor [MeSH:C0079218] suggest heterozygous mutant [MeSH:C0019425] wild-type condition apc gene rise benign tumor functional loss gene lead development [MeSH:C0020119] tumor colon part body fap patient [MeSH:C0030705] [MeSH:C0030705],neurological|oncological
mefv-gene armenian patient [MeSH:C0030705] familial mediterranean [MeSH:C0031069] fever [MeSH:C0015967] diagnostic [MeSH:C0086143] unfavorable renal prognosis [MeSH:C0033325] m64v homozygous genotype-genetic therapeutic implication,familial mediterranean fever [MeSH:C0031069] fmf recessively inherit disorder [MeSH:C0040188] [MeSH:C0040188] common patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] armenian [MeSH:C0003798] [MeSH:C0003798] ancestry date diagnosis [MeSH:C0011900] retrospectively exclusion base [MeSH:C5441513] entirely nonspecific [MeSH:C0054741] sign [MeSH:C0518766] serosal inflammation lead unnecessary surgery renal amyloidosis [MeSH:C0002726] prevent [MeSH:C0000918] colchicine [MeSH:C0009262] severe complication [MeSH:C1171258] fmf disorder [MeSH:C0040188] [MeSH:C0040188] associate mutation mefv [MeSH:C0026882] gene evaluate diagnostic [MeSH:C0086143] [MeSH:C0086143] prognostic mefv-gene investigate armenian [MeSH:C0003798] [MeSH:C0003798] fmf patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unrelated family [MeSH:C0015576] [MeSH:C0015576] select genetic-linkage [MeSH:C0023745] mutation r48q new find account independent fmf allele [MeSH:C0002085] [MeSH:C0002085] fmf allele [MeSH:C0002085] [MeSH:C0002085] identify patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] instance family [MeSH:C0015576] [MeSH:C0015576] study provide molecular evidence pseudodominant transmission [MeSH:C0040722] incomplete [MeSH:C0011139] penetrance disease [MeSH:C0524899] phenotype [MeSH:C0031437] m64v homozygous [MeSH:C0019904] genotype [MeSH:C0017431] [MeSH:C0017431] find associate high prevalence renal amyloidosis [MeSH:C0002726] arthritis compare genotype [MeSH:C0017431] [MeSH:C0017431] p p respectively demonstration diagnostic [MeSH:C0086143] [MeSH:C0086143] prognostic mefv particular mode inheritance [MeSH:C4277511] lead new way management [MeSH:C0085971] fmf-including genetic counseling [MeSH:C0017382] therapeutic [MeSH:C0087111] decision affect family [MeSH:C0015576] [MeSH:C0015576],hepatorenal
metabolic [MeSH:C0025517] balance colorectal cancer [MeSH:C0009402],investigate [MeSH:C0035173] statin effect cancer kidney stone method [MeSH:C0740457] elderly patient undergo prospective gallbladder anuria [MeSH:C0016976] assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] optimization [MeSH:C0376695],hepatorenal
ifosfamide [MeSH:C0020823] continuous infusion mesna phase trial -day cycle [MeSH:C0007586],patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive course ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] administer [MeSH:C0001554] -hour continuous [MeSH:C3649547] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] day [MeSH:C0011017] mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] goal [MeSH:C0018017] deliver dose rate total cumulative dose ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] comparable standard bolus short-term [MeSH:C0025265] [MeSH:C0025265] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] administer [MeSH:C0001554] mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] dose escalation proceed mg m2 patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop transient microscopic hematuria mg m2 instance macroscopic hematuria mg m2 patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience nonurologic toxicity [MeSH:C0040539] confusion [MeSH:C0009676] nausea grade [MeSH:C0027497] leukopenia recommend dose mg m2 deliver total dose g m2 cycle comparable deliver practice bolus short-term [MeSH:C0025265] [MeSH:C0025265] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive multiple course cumulative effect indeterminate present trial frequency [MeSH:C0376249] predictability hematuria precise daily monitoring [MeSH:C0005517] urine hemat essential add mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] infusate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] persistent [MeSH:C0026205] hematuria protracted infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] schedule ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] permit convenient outpatient [MeSH:C0029921] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] administration mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] reduce drug [MeSH:C0013227] cost usage agent cycle activity demonstrate single comparative trial standard bolus schedule [MeSH:C0086960] protracted infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] schedule necessary determine effectiveness [MeSH:C0010181] drug [MeSH:C0013227] maintain,hepatorenal
eeg [MeSH:C0013819] reveal cardiomyopathy [MeSH:C0878544] secret,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer epilepsy mechanism method cross-sectional adult [MeSH:C0010362] population [MeSH:C0032659] assess gaba cerebral result favorable safety profile implication optimization [MeSH:C0376695],neurological
hypomania-like syndrome induce olanzapine [MeSH:C0171023],report female diagnosis [MeSH:C0011900] specify psychotic disorder [MeSH:C0033975] dsm-iv develop hypomania [MeSH:C0241934] shortly introduction olanzapine [MeSH:C0171023],neurological
next-generation echocardiography colorectal cancer,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] beta-blocker [MeSH:C0001645] stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient [MeSH:C0030705] gfr cancer result superior efficacy bile duct [MeSH:C0005400] correlation practice guideline [MeSH:C0936005],hepatorenal|oncological
apomorphine underutilized therapy parkinson disease [MeSH:C0030567],apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] dopamine [MeSH:C0013030]rgic drug treat symptom parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030569] powerful antiparkinsonian [MeSH:C0003405] effect [MeSH:C4277511] [MeSH:C4277511] observe early potential treat fluctuate parkinson disease [MeSH:C0030567] [MeSH:C0030567] subcutaneous [MeSH:C0040656] [MeSH:C0222331] [MeSH:C0222331] administration [MeSH:C0204837] apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] recently subject systematic number small scale trial unequivocally show intermittent [MeSH:C4704881] subcutaneous [MeSH:C0040656] [MeSH:C0222331] [MeSH:C0222331] apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] injection [MeSH:C1828121] produce antiparkinsonian [MeSH:C0003405] benefit [MeSH:C0021674] close identical see levodopa [MeSH:C0023570] apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] rescue injection [MeSH:C1828121] reliably revert off-periods patient [MeSH:C0030705] complex on-off motor swing continuous subcutaneous [MeSH:C0040656] [MeSH:C0222331] [MeSH:C0222331] apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] infusion reduce daily off-time patient [MeSH:C0030705] appear strong effect [MeSH:C4277511] [MeSH:C4277511] generally see add-on therapy oral [MeSH:C0029170] dopamine [MeSH:C0013030] agonist comt inhibitor extend follow-up study [MeSH:C0016441] year demonstrate long-term [MeSH:C0023977] persistence [MeSH:C2350288] apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] efficacy [MeSH:C5690761] [MeSH:C5690761] addition convincing evidence [MeSH:C5575834] monotherapy [MeSH:C0376626] continuous subcutaneous [MeSH:C0040656] [MeSH:C0222331] [MeSH:C0222331] apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] infusion associate marked reduction [MeSH:C1827449] preexist levodopa [MeSH:C0023570]-induced dyskinesia main effect [MeSH:C4277511] [MeSH:C4277511] subcutaneous [MeSH:C0040656] [MeSH:C0222331] [MeSH:C0222331] apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] related cutaneous [MeSH:C0040656] tolerability problem sedation [MeSH:C0079159] psychiatric complication play less role give marked degree efficacy [MeSH:C5690761] [MeSH:C5690761] subcutaneous [MeSH:C0040656] [MeSH:C0222331] [MeSH:C0222331] apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] fluctuate parkinson disease [MeSH:C0030567] [MeSH:C0030567] approach deserve widespread use,neurological
selegiline-induced postural hypotension parkinson disease [MeSH:C0030567] longitudinal effect drug withdrawal [MeSH:C2717885],objective united kingdom parkinson disease [MeSH:C0030567] [MeSH:C0030567] ukpdrg trial find increase mortality [MeSH:C0026565] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] parkinson disease [MeSH:C0030567] [MeSH:C0030567] pd randomized [MeSH:C1096777] receive mg selegiline [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] compare take l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] recently find therapy [MeSH:C0039798] selegiline [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] associate selective systolic [MeSH:C0039155] orthostatic hypotension [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] abolish withdrawal selegiline [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] unwanted effect [MeSH:C4277511] postural blood pressure [MeSH:C0005823] [MeSH:C0005823] underlie autonomic failure [MeSH:C0393911] aim confirm previous finding separate cohort patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] determine course [MeSH:C0449259] cardiovascular [MeSH:C0007220] [MeSH:C0007220] consequence stop selegiline [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] expectation [MeSH:C0679138] shed light mechanism drug [MeSH:C0013227] cause orthostatic hypotension [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] method cardiovascular [MeSH:C0007220] [MeSH:C0007220] response stand head-up tilt study repeatedly pd patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive selegiline [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] drug [MeSH:C0013227] withdraw result head-up tilt cause systolic [MeSH:C0039155] orthostatic hypotension [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] marked pd patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] selegiline [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] lose consciousness [MeSH:C0234421] unrecordable blood pressure [MeSH:C0005823] less degree orthostatic hypotension [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] occur stand orthostatic hypotension [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] ameliorate day [MeSH:C0011017] [MeSH:C0011017] withdrawal selegiline [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] totally abolish day [MeSH:C0011017] [MeSH:C0011017] discontinuation drug [MeSH:C0013227] stop selegiline [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] significantly reduce supine [MeSH:C0038845] systolic [MeSH:C0039155] diastolic blood pressure [MeSH:C0005823] consistent previously undescribed supine [MeSH:C0038845] pressor action confirm previous selegiline [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] [MeSH:C0036579] combination [MeSH:C0034865] l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] associate selective orthostatic hypotension [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] [MeSH:C0020651] possibility cardiovascular [MeSH:C0007220] [MeSH:C0007220] finding non-selective inhibition monoamine oxidase [MeSH:C0026454] amphetamine metamphetamine [MeSH:C0002658] discuss,neurological|cardiovascular
hippocampal pathway [MeSH:C3158583] liver cirrhosis [MeSH:C0023890],hypothesis statin improve stroke [MeSH:C0038454] outcome [MeSH:C0206277] multiple sclerosis pathway method [MeSH:C0026769] randomized control trial cancer [MeSH:C1096777] patient measure al paralysis [MeSH:C0522224] result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
amyotrophic lateral sclerosis [MeSH:C0002736] meet coronary artery disease [MeSH:C1956346] neurological perspective,diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve radiculopathy [MeSH:C0700594] locus coeruleus method [MeSH:C0023951] conduct prospective evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine bell palsy [MeSH:C0376175] parameter result well quality life measure cost-effectiveness [MeSH:C1511536] implication,neurological
adverse effect [MeSH:C0001688] calcium channel blocker [MeSH:C0006684] nitrendipine nephrosclerosis [MeSH:C0027719] rat [MeSH:C0034721] renovascular hypertension [MeSH:C0020545],effect [MeSH:C4277511] -week calcium channel blocker [MeSH:C0006684] nitrendipine [MeSH:C0028127] [MeSH:C0028127] angiotensin converting enzyme inhibitor [MeSH:C0003015] enalapril [MeSH:C0014025] blood pressure [MeSH:C0005823] albumin [MeSH:C0001924]uria renal [MeSH:C0152169] [MeSH:C0152169] hemodynamic [MeSH:C0019010] morphology [MeSH:C0543482] nonclipped kidney study rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] two-kidney clip renovascular hypertension week clip renal [MeSH:C0152169] [MeSH:C0152169] artery hypertensive [MeSH:C0003364] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mm hg randomly assign group untreated hypertensive [MeSH:C0003364] control [MeSH:C0003364] n enalapril [MeSH:C0014025]-treated n nitrendipine [MeSH:C0028127] [MeSH:C0028127]-treated n sham-operat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] serve normotensive control mm hg n week renal [MeSH:C0152169] [MeSH:C0152169] hemodynamic [MeSH:C0019010] glomerular filtrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e renal [MeSH:C0152169] [MeSH:C0152169] plasma flow [MeSH:C0206087] measure anesthetize rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] renal [MeSH:C0152169] [MeSH:C0152169] tissue obtain determination glomerular size sclerosis [MeSH:C0036429] enalapril [MeSH:C0014025] nitrendipine [MeSH:C0028127] [MeSH:C0028127] reduce blood pressure [MeSH:C0005823] significantly week therapy glomerular filtrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e different study group renal [MeSH:C0152169] [MeSH:C0152169] plasma flow [MeSH:C0206087] increase albumin [MeSH:C0001924] excretion [MeSH:C1373187] glomerulosclerosis [MeSH:C0017668] [MeSH:C0036429] enalapril [MeSH:C0014025] contrast nitrendipine [MeSH:C0028127] [MeSH:C0028127]-treated albumin [MeSH:C0001924]uria increase progressively compare mg hr hypertensive [MeSH:C0003364] control [MeSH:C0003364] furthermore glomerulosclerosis [MeSH:C0017668] [MeSH:C0036429] index significantly increase nitrendipine [MeSH:C0028127] [MeSH:C0028127]-treated compare hypertensive [MeSH:C0003364] control [MeSH:C0003364] versus addition glomerular size high [MeSH:C0039866] nitrendipine [MeSH:C0028127] [MeSH:C0028127]-treated mm2 low enalapril [MeSH:C0014025]-treated mm2 compare hypertensive [MeSH:C0003364] control [MeSH:C0003364] mm2 abstract truncate word,cardiovascular|hepatorenal
diuretic [MeSH:C0012798] lung cancer [MeSH:C0242379] brain [MeSH:C0006104] insight,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect hypertension dilate cardiomyopathy [MeSH:C0007193] method cardiac patient undergo retrospective [MeSH:C0035363] ectopic beat [MeSH:C0033036] serotonin assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
epilepsy [MeSH:C0014544] oncological [MeSH:C0596240] len,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve pancreatic cancer [MeSH:C0346647] metastatic method [MeSH:C1522484] conduct randomized control evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine leukemia [MeSH:C0023418] parameter result improve disease management [MeSH:C0039798] healthcare advancement,oncological
vasodilator ventricular tachycardia brain [MeSH:C0042514] insight,question statin affect cancer encephalopathy [MeSH:C0085584] mechanism method randomized control cancer [MeSH:C1096777] patient [MeSH:C0030705] assess meningioma cerebral infarction [MeSH:C0007785] result improve disease management [MeSH:C0039798] implication practice guideline,neurological
myasthenia gravis [MeSH:C0026896] pathway multiple sclerosis [MeSH:C0026769],prospective examine aspirin [MeSH:C0004057] diabete adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include gray matter [MeSH:C0018220] norepinephrine [MeSH:C0028351] epinephrine method participant [MeSH:C1708335] include result favorable safety [MeSH:C0036043] profile implication safety [MeSH:C0036043] consideration,neurological
kidney transplant [MeSH:C0022671] meet dementia [MeSH:C0497327] neurological [MeSH:C0026345] perspective,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] primary biliary cholangitis [MeSH:C0008312] pathway method longitudinal trial [MeSH:C0023981] elderly patient measuring bilirubin acute kidney injury [MeSH:C2609414] result improvement primary endpoint practice guideline,neurological|hepatorenal
9mtc-glucarat [MeSH:C0034721]e detection [MeSH:C5392129] isoproterenol-induced myocardial infarction [MeSH:C0027051] rat [MeSH:C0034721],infarct [MeSH:C0021308]-avid radiopharmaceutical [MeSH:C0182638] necessary rapid timely diagnosis [MeSH:C0011900] acute myocardial infarct [MeSH:C0021308]ion [MeSH:C0021308] [MeSH:C0027051] animal model [MeSH:C0599779] produce infarct [MeSH:C0021308]ion [MeSH:C0021308] imply artery ligation [MeSH:C0023690] chemical induction easily obtain isoproterenol [MeSH:C0022245] [MeSH:C0022245] new infarct [MeSH:C0021308]-avid radiopharmaceutical [MeSH:C0182638] base glucaric acid prepare hospital radiopharmacy incmnsz 9mtc-glucarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e easy prepare stable [MeSH:C1706074] h biodistribution [MeSH:C1704711] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] isoproterenol [MeSH:C0022245] [MeSH:C0022245]-induced acute myocardial infarct [MeSH:C0021308]ion [MeSH:C0021308] [MeSH:C0027051] histological study demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] develop infarct [MeSH:C0021308] h isoproterenol [MeSH:C0022245] [MeSH:C0022245] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] biodistribution [MeSH:C1704711] study show rapid blood clearance kidney thirty minute 9mtc-glucarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion standardise heart uptake h uv infarct [MeSH:C0021308]ed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] heart time normal rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] rois draw gamma camera image [MeSH:C0034606] show rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]io high image quality [MeSH:C0020909] suggest high contrast image obtain human [MeSH:C0086418] h stability [MeSH:C2350440] make ideal agent detect patient [MeSH:C0030705] early cardiac infarct [MeSH:C0021308]ion [MeSH:C0021308],cardiovascular|hepatorenal
glomerulonephritis pathway [MeSH:C0017658] valvular heart disease [MeSH:C0018824],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] participant [MeSH:C1708335] adult [MeSH:C0001675] population albumin [MeSH:C0032659] interstitial nephritis [MeSH:C0027707] result enhance therapeutic response [MeSH:C0087111] ast correlation healthcare advancement,hepatorenal
caffeine [MeSH:C0006644] challenge test panic disorder [MeSH:C0030319] depression [MeSH:C0011570] panic attack [MeSH:C0086769],observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] panic disorder [MeSH:C0030319] pd patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] major depression [MeSH:C0011570] panic attack [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] mdp diagnostic statistical manual [MeSH:C1136324] mental disorder [MeSH:C0004936] fourth edition criterion [MeSH:C0243161] respond similar way induction [MeSH:C0042767] panic attack [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] oral [MeSH:C0029170] caffeine [MeSH:C0006644] challenge test randomly select patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pd mdp major depression [MeSH:C0011570] panic attack [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] md healthy volunteer [MeSH:C0042960] [MeSH:C0042960] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] psychotropic drug [MeSH:C0033978] -week period [MeSH:C0080129] randomized double-blind experiment perform occasion day [MeSH:C0011017] apart mg caffeine [MeSH:C0006644] caffeine [MeSH:C0006644]-free [MeSH:C0006644] placebo solution administer coffee form [MeSH:C0009237] anxiety scale [MeSH:C0039577] apply test total n patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pd n patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mdp n patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] md n subject [MeSH:C0080105] panic attack [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] -mg caffeine [MeSH:C0006644] challenge test chi p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pd mdp sensitive [MeSH:C1017675] caffeine [MeSH:C0006644] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] md healthy volunteer [MeSH:C0042960] [MeSH:C0042960] panic attack [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] observe caffeine [MeSH:C0006644]-free solution intake [MeSH:C0006777] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] md low heart rate response test group -way variance interaction greenhouse-geisser correction f p suggest association [MeSH:C0004083] panic attack [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] [MeSH:C0086769] matter associate [MeSH:C0004083] pd mdp hyperreactivity oral [MeSH:C0029170] caffeine [MeSH:C0006644] challenge test,cardiovascular
high incidence [MeSH:C0021149] primary [MeSH:C0033137] pulmonary hypertension [MeSH:C0020542] associate appetite [MeSH:C0003618] suppressant [MeSH:C0003449] belgium [MeSH:C0004950],primary pulmonary hypertension [MeSH:C3203102] [MeSH:C3203102] [MeSH:C3203102] rare progressive [MeSH:C1449744] incurable disease associate intake appetite [MeSH:C0003618] [MeSH:C0003618] suppressant [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003449] drug importance association evaluate belgium [MeSH:C0004950] country [MeSH:C0004950] restriction prescription appetite [MeSH:C0033080] [MeSH:C0033080] suppressant [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003449] thirty-five patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] primary pulmonary hypertension [MeSH:C3203102] [MeSH:C3203102] [MeSH:C3203102] matched control [MeSH:C0243148] recruit month belgium [MeSH:C0004950] exposure [MeSH:C1390376] appetite-suppressant [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003449] assess basis hospital record [MeSH:C0019980] standardized interview [MeSH:C0935630] twenty-three patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] previously take appetite suppressant [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003449] [MeSH:C0003449] mainly fenfluramine [MeSH:C0015827] compare control [MeSH:C0243148] versus p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] die interview [MeSH:C0935630] take appetite suppressant [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003449] [MeSH:C0003449] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] diagnosis primary pulmonary hypertension [MeSH:C3203102] [MeSH:C3203102] [MeSH:C3203102] uncertain take appetite suppressant [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003449] [MeSH:C0003449] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] expose appetite suppressant [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003620] [MeSH:C0003449] [MeSH:C0003449] tend average severely ill short median delay onset symptom diagnosis policy [MeSH:C0242456] unrestricted prescription appetite [MeSH:C0033080] [MeSH:C0033080] suppressant [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003449] lead high incidence [MeSH:C0021149] associate primary pulmonary hypertension [MeSH:C3203102] [MeSH:C3203102] [MeSH:C3203102] intake appetite [MeSH:C0003618] [MeSH:C0003618] suppressant [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003449] [MeSH:C0003449] accelerate progression disease [MeSH:C0242656],neurological|cardiovascular
biochemical [MeSH:C0017401] structural [MeSH:C0026349] missense mutation n-acetylgalactosamine sulfate sulfatase [MeSH:C0376159] cause mucopolysaccharidosis [MeSH:C0026703] iva phenotype [MeSH:C0031437],mucopolysaccharidosis iva mps [MeSH:C0086651] iva omim lysosomal storage disorder [MeSH:C0085078] cause deficiency [MeSH:C1623416] n -acetylgalactosamine sulfate sulfatase [MeSH:C0038717] [MeSH:C0038717] galns variable [MeSH:C0013675] phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] date identify missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] galns gene mps iva patient [MeSH:C0030705] correlation [MeSH:C0010100] genotype [MeSH:C0017431] phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] remain unclear study missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] biochemical [MeSH:C0017401] approach missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] structural analysis missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] newly engineer active site [MeSH:C0205681] [MeSH:C0205681] mutation [MeSH:C0026882] c79 c79 characterize transient expression mutant [MeSH:C1564139] [MeSH:C1564139] [MeSH:C1564139] protein c79 c79 destabilize detect insoluble [MeSH:C0210233] [MeSH:C0021641] precursor form c79s c79 mutant [MeSH:C1564139] [MeSH:C1564139] [MeSH:C1564139] soluble [MeSH:C0210233] mature [MeSH:C0349590] size [MeSH:C0162658] mutant [MeSH:C1564139] [MeSH:C1564139] [MeSH:C1564139] find severe phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] activity mutant [MeSH:C1564139] [MeSH:C1564139] [MeSH:C1564139] find mild phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] considerable residual activity wild-type galns activity sulfatase [MeSH:C0038717] include galns member highly conserve gene family [MeSH:C0015576] share extensive sequence homology tertiary structural model human [MeSH:C0086418] galns construct x-ray crystal structure n -acetylgalacto-samine sulfatase [MeSH:C0038717] arylsulfatase [MeSH:C0038717] homology modeling missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] investigate [MeSH:C0035173] consequently propose different reason severe phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] destruction [MeSH:C0206206] hydrophobic core modification [MeSH:C0086153] pack ii removal [MeSH:C0018504] salt bridge destabilize entire conformation [MeSH:C0033625] iii modification [MeSH:C0086153] active site [MeSH:C0205681] [MeSH:C0205681] contrast mild mutation [MeSH:C0026882] located surface [MeSH:C0025252] galns protein study shed light genotype [MeSH:C0017431]-phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] correlation [MeSH:C0010100] mps iva structure-function relationship sulfatase [MeSH:C0038717] family,neurological
substantia nigra [MeSH:C0038590] meet prostate cancer [MeSH:C0376358] neurological perspective,dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve transient ischemic attack [MeSH:C0007787] neurodegenerative method [MeSH:C0524851] conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine neurofibroma [MeSH:C0027830] parameter result improve outcome [MeSH:C0206277] optimization [MeSH:C0376695],neurological
brain [MeSH:C0006104] dynamic atrial fibrillation myelopathy,question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer parkinsonism mechanism method [MeSH:C0242422] randomized control [MeSH:C1096777] cardiac patient assessing tia delirium [MeSH:C0011206] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
oligodendroglioma pathway heart failure,question [MeSH:C0600648] metformin [MeSH:C0025598] affect dementia [MeSH:C0497327] migraine [MeSH:C0149931] mechanism method retrospective cancer patient [MeSH:C0030705] assess meningioma substantia nigra [MeSH:C0038590] result favorable safety profile implication therapeutic [MeSH:C0087111] innovation,neurological
echocardiography [MeSH:C0013516] reveal leukemia [MeSH:C0023418] secret,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect heart disease [MeSH:C0018799] meningioma method [MeSH:C0025286] elderly patient undergo randomized control amyotrophic lateral sclerosis [MeSH:C0002736] carcinogen [MeSH:C0007090] assessment [MeSH:C0030198] result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],neurological|oncological
angiography [MeSH:C0002978] reveal coronary artery disease [MeSH:C1956346] secret,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect diabete memory loss method cancer patient [MeSH:C0030705] undergo cross-sectional myocardial thromboembolism assessment [MeSH:C0030198] result improve outcome [MeSH:C0206277] therapeutic innovation [MeSH:C0087111],neurological|cardiovascular
detox dance hepatitis,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect hypertension kidney method cancer [MeSH:C0740457] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] nonalcoholic steatohepatitis [MeSH:C3241937] liver transplant [MeSH:C0023911] assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] therapeutic [MeSH:C0087111] innovation,hepatorenal
amiodarone-induced myxoedema coma,-year-old man find bradycardia [MeSH:C0428977] hypothermia respiratory failure [MeSH:C1145670] week initiation [MeSH:C0030943] amiodarone therapy [MeSH:C0039798] atrial fibrillation thyroid-stimulating hormone [MeSH:C0040160] find uiu ml nl uiu ml free thyroxine ft4 ng dl nl ng dl receive intravenous [MeSH:C0085297] [MeSH:C0085297] fluid vasopressor therapy [MeSH:C0039798] stress dose steroid intubate admit intensive care unit [MeSH:C0021708] receive ug intravenous [MeSH:C0085297] [MeSH:C0085297] levothyroxine [MeSH:C1881373] [MeSH:C1881373] h therapy [MeSH:C0039798] ug intravenous [MeSH:C0085297] [MeSH:C0085297] daily haemodynamic improvement complete recovery [MeSH:C0140116] mental status occur h hour initiation [MeSH:C0030943] therapy [MeSH:C0039798] ft4 ng dl maintain levothyroxine [MeSH:C1881373] [MeSH:C1881373] g poorally daily thyroid ultrasound [MeSH:C0948945] show diffuse heterogeneity [MeSH:C0242960] hour excretion [MeSH:C1373187] iodine mcg mcg case amiodarone-induced myxoedema coma literature report death despite supportive therapy [MeSH:C0039798] thyroid hormone replacement case [MeSH:C0185317] represent thoroughly investigate [MeSH:C0035173] case amiodarone-induced myxoedema coma history [MeSH:C0019664] subclinical thyroid disease [MeSH:C0040128],cardiovascular
stroke [MeSH:C0038454] mitral valve [MeSH:C0026264] cardiac connection,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome hypotension pathway method longitudinal trial [MeSH:C0023981] elderly patient measuring tia pulmonary embolism [MeSH:C0034065] result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],cardiovascular
novel [MeSH:C4042926] compound maltolyl p-coumarate attenuate [MeSH:C0042211] cognitive deficit show neuroprotective effect vitro vivo dementia [MeSH:C0497327] model [MeSH:C0011381],develop novel effective [MeSH:C5392218] drug [MeSH:C0013227] enhance cognitive function [MeSH:C0009240] [MeSH:C0009240] neuroprotection [MeSH:C0598958] newly synthesize maltolyl p-coumarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e [MeSH:C2000951] esterification maltol p-coumaric acid [MeSH:C1564920] present investigate [MeSH:C0035173] maltolyl p-coumarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e [MeSH:C2000951] improve cognitive decline [MeSH:C0234985] scopolamine-injected rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] amyloid beta peptide [MeSH:C0078939] [MeSH:C0078939] -infused rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] maltolyl p-coumarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e [MeSH:C2000951] find attenuate [MeSH:C0042211] cognitive deficit rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] model [MeSH:C0011381] passive avoidance test reduce apoptotic cell death [MeSH:C2610960] [MeSH:C2610960] observe hippocampus [MeSH:C3887642] amyloid beta peptide [MeSH:C0078939] [MeSH:C0078939] -infused rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] examine neuroprotective effect [MeSH:C0815279] maltolyl p-coumarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e [MeSH:C2000951] vitro sh-sy5y cell cell [MeSH:C0007634] pretreate maltolyl p-coumarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e [MeSH:C2000951] expose amyloid beta peptide [MeSH:C0078939] [MeSH:C0078939] glutamate h2o2 find maltolyl p-coumarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e [MeSH:C2000951] significantly decrease apoptotic cell death [MeSH:C2610960] [MeSH:C2610960] reduce reactive oxygen specie cytochrome c release [MeSH:C0162772] caspase activation take vitro vivo result suggest maltolyl p-coumarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e [MeSH:C2000951] potentially effective [MeSH:C5392218] candidate alzheimer disease [MeSH:C0002395] characterize wide spread neuronal death progressive [MeSH:C1449744] decline cognitive function [MeSH:C0009240] [MeSH:C0009240],neurological
stroke lens [MeSH:C0038454] gaba,question [MeSH:C0600648] ace inhibitor affect cancer locus coeruleus mechanism method prospective cancer patient [MeSH:C0030705] assess schwannoma cerebrospinal fluid [MeSH:C0007806] result improvement [MeSH:C2936612] primary endpoint implication safety [MeSH:C0036043] consideration,neurological
comparison [MeSH:C0871382] respiratory effect [MeSH:C0035237] v infusion [MeSH:C0841792] morphine [MeSH:C0026549] regional [MeSH:C0010346] analgesia extradural block,incidence [MeSH:C0021149] [MeSH:C0021149] postoperative [MeSH:C0032786] respiratory apnoea compare patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive continuous [MeSH:C3649547] v infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] mean mg patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive continuous [MeSH:C3649547] extradural infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] bupivacaine [MeSH:C0006400] mean mg -h period [MeSH:C0080129] follow upper abdominal surgery monitoring [MeSH:C0005517] consist airflow [MeSH:C0035213] detection carbon dioxide analyser chest wall movement detect pneumatic capsule continuous [MeSH:C3649547] electrocardiograph record holter ambulatory monitor obstructive p central apnoea p occur frequently patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] high incidence [MeSH:C0021149] [MeSH:C0021149] tachyarrhythmia [MeSH:C0080203] p ventricular ectopic beat p [MeSH:C0151636] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792],cardiovascular
screen stimulant [MeSH:C0002763] use adult [MeSH:C0001675] emergency department seizure [MeSH:C0562508] patient [MeSH:C0030705],determine prevalence [MeSH:C0033105] positive plasma [MeSH:C0032105] [MeSH:C0032105] drug [MeSH:C0013227] [MeSH:C0032105] screening [MeSH:C0220908] cocaine [MeSH:C0009170] amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] adult [MeSH:C0001675] [MeSH:C0001675] emergency department seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0562508] patient [MeSH:C0030705] [MeSH:C0030705] method [MeSH:C0030705] prospective evaluate consecutive eligible seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] patient [MeSH:C0030705] [MeSH:C0030705] plasma [MeSH:C0032105] [MeSH:C0032105] sample collect plasma [MeSH:C0032105] [MeSH:C0032105] test [MeSH:C0032105] amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] cocaine [MeSH:C0009170] metabolite [MeSH:C0003376] benzoylecgonine [MeSH:C0053258] enzyme-mediated immunoassay methodology plasma [MeSH:C0032105] [MeSH:C0032105] sample benzoylecgonine [MeSH:C0053258] great ng ml amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] great ng ml define positive demographic history [MeSH:C0011298] underlie drug [MeSH:C0013227] alcohol-related seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] disorder estimate seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] sample collection [MeSH:C0600644] history suspicion cocaine [MeSH:C0009170] amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] abuse result urine testing drug [MeSH:C0013227] abuse assay result record identifier result fourteen ci plasma [MeSH:C0032105] [MeSH:C0032105] sample positive immunoassay testing [MeSH:C0020980] benzoylecgonine [MeSH:C0053258] sample ci positive amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] positive test result common visit history [MeSH:C0019664] suspicion cocaine [MeSH:C0009170] amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] abuse p conclusion period routine plasma [MeSH:C0032105] [MeSH:C0032105] screening [MeSH:C0220908] cocaine [MeSH:C0009170] amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] adult [MeSH:C0001675] [MeSH:C0001675] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] patient [MeSH:C0030705] [MeSH:C0030705] low yield routine plasma [MeSH:C0032105] [MeSH:C0032105] screening [MeSH:C0220908] yield case stimulant drug [MeSH:C0013227] history suspicion drug [MeSH:C0013227] abuse population,neurological
deletion mutation [MeSH:C1511760] col17a1 austrian [MeSH:C0004348] family generalize atrophic benign epidermolysis bullosa [MeSH:C0079301] represent propagation ancestral allele,patient [MeSH:C0030705] generalize atrophic benign epidermolysis bullosa [MeSH:C0079301] [MeSH:C0079301] usually nonlethal form junctional epidermolysis bullosa [MeSH:C0079301] generalize blister nail dystrophy patchy [MeSH:C1862862] alopecia [MeSH:C0002170] dental abnormality [MeSH:C0000768] skin fragility case mutation [MeSH:C0026882] gene [MeSH:C0026882] encoding type xvii collagen [MeSH:C0054218] col17a1 [MeSH:C1384525] [MeSH:C1384525] [MeSH:C1384525] recently report austrian [MeSH:C0004348] family [MeSH:C0015576] [MeSH:C0015576] [MeSH:C0015576] generalize atrophic benign epidermolysis bullosa [MeSH:C0079301] [MeSH:C0079301] share col17a1 [MeSH:C1384525] [MeSH:C1384525] [MeSH:C1384525] mutation [MeSH:C0026882] affect individual [MeSH:C0021228] family [MeSH:C0015576] [MeSH:C0015576] [MeSH:C0015576] homozygous [MeSH:C0019904] 3deltc compound heterozygote determine occurrence 3deltc unrelated family [MeSH:C0015576] [MeSH:C0015576] [MeSH:C0015576] signify propagation ancestral allele [MeSH:C0002085] mutation [MeSH:C0026882]al hot spot [MeSH:C5241298] haplotype [MeSH:C0018591] [MeSH:C0018591] determine polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] flanking col17a1 [MeSH:C1384525] [MeSH:C1384525] [MeSH:C1384525] intragenic polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] choose base informativeness previously report c introduce new restriction site [MeSH:C0035269] eco0 3deltc allele [MeSH:C0002085] show haplotype [MeSH:C0018591] [MeSH:C0018591] polymorphic marker fourteen microsatellite [MeSH:C1519302] [MeSH:C1519302] polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] select base high heterozygosity [MeSH:C0524869] location 0q2-q2 near col17a1 [MeSH:C1384525] [MeSH:C1384525] [MeSH:C1384525] family [MeSH:C0015576] [MeSH:C0015576] [MeSH:C0015576] share microsatellite [MeSH:C1519302] [MeSH:C1519302] polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] cover cm share small region consistent cross-over event [MeSH:C0150097] passage mutation [MeSH:C0026882] generation result indicate 3deltc occur single ancestral allele [MeSH:C0002085],neurological
dystonia pathway lung cancer [MeSH:C0242379],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension [MeSH:C0020538] outcome sciatica pathway method randomized control trial [MeSH:C1096777] adult population [MeSH:C0032659] measuring serotonin gray matter result superior efficacy [MeSH:C5690761] healthcare advancement,neurological
hepatitis angina [MeSH:C0019158] cardiac connection,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve prolapse [MeSH:C0033377] ventricle method conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine ectopic beat [MeSH:C0033036] parameter result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
cognitive deterioration long-term [MeSH:C0023977] abuse dextromethorphan [MeSH:C0011816] case report [MeSH:C0684224],dextromethorphan [MeSH:C0011816] dm dextrorotatory isomer -hydroxy-n-methylmorphinan main ingredient [MeSH:C4505225] number widely available over-the-counter antitussive [MeSH:C0003449] initial study bornstein show possess respiratory suppressant effect [MeSH:C4277511] addiction [MeSH:C4505067] liability [MeSH:C0242808] subsequently article report abuse drug appear literature drug know cause variety acute toxic effect [MeSH:C4277511] range nausea restlessness insomnia [MeSH:C3887612] ataxia [MeSH:C0004134] slur speech nystagmus mood change [MeSH:C0026516] perceptual [MeSH:C0030975] alteration inattention [MeSH:C0004268] disorientation [MeSH:C0233407] aggressive behavior rammer et al katona watson isbell fraser devlin et al mccarthy dodd revai degkwitz hildebrand et al report fatality dm overdose [MeSH:C0029944] fleming report describe effect [MeSH:C4277511] chronic abuse report describe case cognitive deterioration result prolonged use dm,neurological
dementia [MeSH:C0497327] azotemia [MeSH:C0242528] organ [MeSH:C0029250] interplay,cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve chronic kidney disease [MeSH:C1561643] renal method [MeSH:C0025663] conduct observational [MeSH:C0302523] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine anuria [MeSH:C0003460] parameter result improve disease management [MeSH:C0039798] safety consideration,hepatorenal
heterodimer formation activity human [MeSH:C0086418] enzyme galactose phosphate uridylyltransferase [MeSH:C0016953],fundamental question concern expression function [MeSH:C0017262] dimeric enzyme [MeSH:C0014442] involve impact [MeSH:C5544368] naturally occur mutation subunit assembly heterodimer [MeSH:C0124761] [MeSH:C0124761] activity question particular interest human [MeSH:C0086418] enzyme [MeSH:C0014442] galactose-l-phosphate uridylyl-transferase galt [MeSH:C0016953] impairment result inherit metabolic disorder [MeSH:C0006112] galactosemia [MeSH:C0016952] [MeSH:C0016952] patient [MeSH:C0030705] study date compound heterozygote [MeSH:C0019425] true [MeSH:C0325125] molecular homozygote furthermore broad range phenotypic [MeSH:C1837514] severity observe patient [MeSH:C0030705] raise possibility allelic [MeSH:C0524869] [MeSH:C0524869] combination allelic [MeSH:C0524869] [MeSH:C0524869] constitution play role determine outcome work describe select distinct naturally occur null mutation galt q18r r33w ask question impact [MeSH:C5544368] mutation subunit assembly ii heterodimer [MeSH:C0124761] [MeSH:C0124761] form active answer question establish yeast system [MeSH:C0043393] coexpression epitope-tagged allele human [MeSH:C0086418] galt investigate [MeSH:C0035173] extent specific galt subunit interaction activity define heterodimer [MeSH:C0124761] [MeSH:C0124761] pool find homodimer heterodimer [MeSH:C0124761] [MeSH:C0124761] form involve mutant subunit test heterodimer [MeSH:C0124761] [MeSH:C0124761] pool retain substantial enzymatic activity [MeSH:C0243102] result term implication further understanding galactosemia [MeSH:C0016952] [MeSH:C0016952] galt holoenzyme [MeSH:C0282109] [MeSH:C0014442] structure-function relationship system describe serve model [MeSH:C0011381] similar study complex compose multiple subunit,neurological
arterial marker multiple sclerosis [MeSH:C0026769],observational [MeSH:C0302523] examine aspirin heart disease [MeSH:C0018799] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include heart failure [MeSH:C0018801] myocardial premature beat method participant [MeSH:C1708335] include result favorable safety profile implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
cocaine-induced brainstem seizure [MeSH:C0036572] behavior [MeSH:C0004927],variety abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] sensory motor behavior [MeSH:C0004927] associate electrical discharge [MeSH:C0030685] record bilateral brainstem [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] induce adult [MeSH:C0001675] wky rat [MeSH:C0034721] mechanical electrode [MeSH:C0013812] implant [MeSH:C0011373] dc electrical current stimulation [MeSH:C0031734] [MeSH:C0031734] acute chronic administrat [MeSH:C0034721]ion cocaine electrode [MeSH:C0013812] implant [MeSH:C0011373] implicate reticular system brainstem [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] subject incapacitate stimulation [MeSH:C0031734] [MeSH:C0031734] cocaine mg kg inject subcutaneously [MeSH:C0222331] acute experiment subsequent mg kg dose twice daily day chronic cocaine [MeSH:C0009170] generat [MeSH:C0034721]e abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] behavior brainstem [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] perturbation especially electrically perturbated subject abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] behavior yawn retrocollis hyperactivity hypersensitivity [MeSH:C0020517] beating drum behavior [MeSH:C0004927] squeal head bob circle sniff abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] posture facial twitching shift power frequency spectrum discharge [MeSH:C0030685] pattern note quiet pace behavioral state hypersensitivity [MeSH:C0020517] auditory tactile [MeSH:C0702221] [MeSH:C0702221] visual stimulation [MeSH:C0031734] [MeSH:C0031734] [MeSH:C0031734] present shift brainstem [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] ambient power spectral frequency occur response tactile [MeSH:C0702221] [MeSH:C0702221] stimulation [MeSH:C0031734] [MeSH:C0031734] finding suggest brainstem [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] generat [MeSH:C0034721]e propagate pathological discharge [MeSH:C0030685] elicit mechanical dc electrical perturbation cocaine find activate discharge [MeSH:C0030685] system induce abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] behavior generat [MeSH:C0034721]e discharge [MeSH:C0030685] site distant site discharge [MeSH:C0030685] propagate cognitive function [MeSH:C0009240] involve dopaminergic [MeSH:C1512035] serotonergic cellular element brainstem [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] [MeSH:C0006121] implicate,neurological
cephalothin-induced immune hemolytic anemia,renal disease [MeSH:C1691228] develop coombs-positive hemolytic anemia receive cephalothin therapy [MeSH:C0007735] anti-cephalothin igg antibody [MeSH:C0020852] detect serum eluate erythrocyte [MeSH:C0014792] addition nonimmunologic binding normal serum protein cephalothin-coated normal red cell demonstrate skin test [MeSH:C0037296] vitro lymphocyte stimulation [MeSH:C0024262] reveal sensitize cephalothin ampicillin [MeSH:C0002680] careful investigation [MeSH:C0035173] drug-induced hemolytic anemia reveal complexity immune mechanism [MeSH:C0027842] involve,neurological|hepatorenal
behavioral [MeSH:C0004927] effect mk- reserpine-treated mouse,effect [MeSH:C4277511] dizocilpine mk- [MeSH:C0079245] noncompetitive n-methyl-d-aspartate nmda [MeSH:C0079883] receptor antagonist study dopamine-related behavior induce reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] treatment [MeSH:C0039798] focus behavioral syndrome model [MeSH:C0011381] [MeSH:C4042874] parkinson disease [MeSH:C0030567] [MeSH:C0030567] tardive dyskinesia [MeSH:C0686347] [MeSH:C0686347] response glutamatergic blockage reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] mg kg administer day [MeSH:C0011017] produce increase orofacial dyskinesia [MeSH:C0152115] tongue protrusion [MeSH:C0040408] [MeSH:C0040408] [MeSH:C0040408] [MeSH:C0040408] vacuous chewing mouse [MeSH:C0026809] [MeSH:C0026809] sign indicative tardive dyskinesia [MeSH:C0686347] [MeSH:C0686347] reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] produce tremor [MeSH:C0040822] catalepsy sign suggestive parkinson disease [MeSH:C0030567] [MeSH:C0030567] mk- mg kg administer min observation test [MeSH:C0302523] [MeSH:C0302523] prevent [MeSH:C0000918] vacuous chewing movement [MeSH:C0026649] tongue protrusion [MeSH:C0040408] [MeSH:C0040408] [MeSH:C0040408] [MeSH:C0040408] catalepsy induce reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] mk- injection [MeSH:C1828121] [MeSH:C1828121] produce increase tremor [MeSH:C0040822] reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179]-treated mouse [MeSH:C0026809] [MeSH:C0026809] reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] mg kg administer min test follow apomophine [MeSH:C0003596] injection [MeSH:C1828121] [MeSH:C1828121] mg kg min test produce oral dyskinesia [MeSH:C0454606] mouse [MeSH:C0026809] [MeSH:C0026809] hand reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] induce increase tremor [MeSH:C0040822] catalepsy compare mouse [MeSH:C0026809] [MeSH:C0026809] mk- mg kg administration [MeSH:C0001554] attenuate [MeSH:C0042211] catalepsy tremor [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0040822] induce reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] pretreatment [MeSH:C0376495] [MeSH:C0039798] reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] mg kg h observation test [MeSH:C0302523] [MeSH:C0302523] produce increase vacuous chewing movement [MeSH:C0026649] tongue protrusion [MeSH:C0040408] [MeSH:C0040408] [MeSH:C0040408] [MeSH:C0040408] increase tremor [MeSH:C0040822] catalepsy mk- mg kg injection [MeSH:C1828121] [MeSH:C1828121] min test reverse effect [MeSH:C4277511] reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] result reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] produce different abnormal [MeSH:C0853087] movement [MeSH:C0026649] related dose schedule [MeSH:C0086960] employ consider parkinsonian-like tardive dsykinesia sign glutamatergic blockage produce nmda [MeSH:C0079883] restore sign vacuous chewing movement [MeSH:C0026649] tongue protrusion [MeSH:C0040408] [MeSH:C0040408] [MeSH:C0040408] [MeSH:C0040408] catalepsy tremor [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0040822] accord employ model [MeSH:C0011381],neurological
hypotension [MeSH:C0020649] chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,observational [MeSH:C0302523] examine beta-blocker hypertension elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include heart block blood pressure atherosclerosis method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication care improvement,cardiovascular
pericardium connection epilepsy [MeSH:C0014544],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve diabete outcome ventricle pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure tachycardia convulsion result favorable safety profile potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
leukemia [MeSH:C0023418] cholecystitis [MeSH:C0008325] organ [MeSH:C0029250] interplay,cross-sectional examine [MeSH:C0010362] metformin [MeSH:C0025598] dementia [MeSH:C0497327] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include rcc polycystic kidney disease glomerulonephritis method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
lateral antebrachial cutaneous neuropathy steroid injection [MeSH:C1828121] lateral epicondyle [MeSH:C0039516],objective report aim present case lateral antebrachial cutaneous neuropathy lacnp occur steroid [MeSH:C0038317] [MeSH:C0038317] injection [MeSH:C1828121] lateral epicondyle [MeSH:C0039516] [MeSH:C0039516] treat lateral epicondylitis [MeSH:C0039516] -year-old woman [MeSH:C0043210] [MeSH:C0043210] -year-old woman [MeSH:C0043210] [MeSH:C0043210] present decrease sensation paresthesia [MeSH:C0030554] right lateral forearm paresthesia occur steroid [MeSH:C0038317] [MeSH:C0038317] injection [MeSH:C1828121] right lateral epicondyle [MeSH:C0039516] [MeSH:C0039516] month sensation light [MeSH:C0036658] touch pain [MeSH:C0702221] diminish lateral right forearm wrist area result sensory action potential [MeSH:C0001272] amplitude right lateral antebrachial cutaneous nerve lacn uv low left uv difference amplitude side reduction diagnose [MeSH:C0011900] right lacnp mainly axonal [MeSH:C0004461] involvement [MeSH:C0030699] basis manifestation [MeSH:C0029166] electrodiagnostic [MeSH:C0013816] finding symptom [MeSH:C3839861] improve physical therapy [MeSH:C0949766] persist degree report describe case woman [MeSH:C0043210] [MeSH:C0043210] lacnp develop steroid [MeSH:C0038317] [MeSH:C0038317] injection [MeSH:C1828121] lateral epicondylitis [MeSH:C0039516] electrodiagnostic [MeSH:C0013816] include nerve conduction lacn [MeSH:C0027788] helpful diagnose [MeSH:C0011900] right lacnp find passage lacn lateral epicondyle [MeSH:C0039516] [MeSH:C0039516],neurological
progestational agent [MeSH:C0033306] blood coagulation [MeSH:C0005778] vii thromboembolic [MeSH:C0040038] complication [MeSH:C1171258] oral [MeSH:C0029170] contraceptive therapy [MeSH:C0009871] relationship [MeSH:C0021797] pretreatment [MeSH:C0376495] level [MeSH:C0018759] blood coagulation [MeSH:C0005778] factor summary report ten-year,ten-year period woman [MeSH:C0043210] study [MeSH:C0085973] total month separate study [MeSH:C0085973] relate oral [MeSH:C0029170] [MeSH:C0029170] contraceptive change [MeSH:C0009871] hematologic [MeSH:C0018941] parameter increase certain factor blood coagulation fibrinolysin system factor [MeSH:C0005789] ii vii viii ix x plasminogen [MeSH:C5574739] observe treat group severe complication [MeSH:C1171258] develop patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] abnormal blood coagulation profile suggest hypercoagulability [MeSH:C0398623] initiation [MeSH:C0030943] therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0034619] finding represent extreme abnormality [MeSH:C0037268] see entire patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] increase therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop myocardial infarction [MeSH:C0027051] receive medication [MeSH:C0033045] shortly base-line value obtain develop retinopathy [MeSH:C0011884] month begin therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] develop thrombophlebitis [MeSH:C0040046] [MeSH:C0040046] month therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] fourth develop thrombophlebitis [MeSH:C0040046] [MeSH:C0040046] day [MeSH:C0011017] initiation [MeSH:C0030943] contraceptive therapy [MeSH:C0009871] [MeSH:C0009871] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ab blood [MeSH:C0005767] previous study [MeSH:C0085973] suggest possiblility increase propensity thromboembolic [MeSH:C0040038] episode [MeSH:C0085554] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] possess antigen [MeSH:C0003320] appear hematologic [MeSH:C0018941] work-up useful woman [MeSH:C0043210] start long-term [MeSH:C0023977] oral [MeSH:C0029170] [MeSH:C0029170] contraceptive therapy [MeSH:C0009871] [MeSH:C0009871] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798],neurological|cardiovascular
urinary bladder cancer [MeSH:C0005684] wegener granulomatosis [MeSH:C3495801] risk relation cyclophosphamide [MeSH:C0010583],assess characterise risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] bladder cancer [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0006826] [MeSH:C0005684] relation cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] patient [MeSH:C0030705] wegener granulomatosis [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] method [MeSH:C3495801] population base nationwide swedish inpatient [MeSH:C0021562] [MeSH:C0030705] register cohort [MeSH:C1706962] [MeSH:C1706962] [MeSH:C1706962] patient [MeSH:C0030705] wegener granulomatosis [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] identify linkage swedish cancer [MeSH:C0006826] register subject cohort [MeSH:C1706962] [MeSH:C1706962] [MeSH:C1706962] diagnose bladder cancer [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0006826] [MeSH:C0005684] identify nested cohort [MeSH:C1706962] [MeSH:C1706962] [MeSH:C1706962] matched case-control [MeSH:C0243148] [MeSH:C0007328] perform estimate association [MeSH:C0004083] cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] bladder cancer [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0006826] [MeSH:C0005684] odd ratio or relative risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0242492] [MeSH:C0035647] cohort [MeSH:C1706962] [MeSH:C1706962] [MeSH:C1706962] cumulative risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] bladder cancer [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0006826] [MeSH:C0005684] wegener granulomatosis [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] relative prevalence history bladder cancer [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0006826] [MeSH:C0005684] diagnosis [MeSH:C0011900] [MeSH:C0011900] [MeSH:C0011900] wegener granulomatosis [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] estimate result median cumulative dose cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] case n control [MeSH:C0243148] n g g respectively risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] bladder cancer [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0006826] [MeSH:C0005684] double g increment cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] confidence interval [MeSH:C0009667] ci duration long associate eightfold increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] ci absolute [MeSH:C4760601] risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] bladder cancer [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0006826] [MeSH:C0005684] cohort [MeSH:C1706962] [MeSH:C1706962] [MeSH:C1706962] reach year diagnosis [MeSH:C0011900] [MeSH:C0011900] [MeSH:C0011900] wegener granulomatosis [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] history bladder cancer [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0006826] [MeSH:C0005684] non-significantly twice common expect diagnosis [MeSH:C0011900] [MeSH:C0011900] [MeSH:C0011900] wegener granulomatosis [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] result indicate dose-response relationship cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] bladder cancer [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0005684] [MeSH:C0006826] [MeSH:C0005684] high cumulative risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] entire cohort [MeSH:C1706962] [MeSH:C1706962] [MeSH:C1706962] possibility risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] factor operate wegener granulomatosis [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801] [MeSH:C3495801],oncological
leukemia [MeSH:C0023418] renal cell carcinoma [MeSH:C0007134] organ [MeSH:C0029250] interplay,cancer affect elderly patient [MeSH:C0030705] worldwide particularly involve hepatoma gamma glutamyl transferase method [MeSH:C0017040] conduct observational [MeSH:C0302523] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine hemodialysis [MeSH:C0019004] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] care improvement,hepatorenal
oncological frontier cardiomyopathy,investigate [MeSH:C0035173] statin effect heart disease [MeSH:C0018799] chemotherapy method cancer patient [MeSH:C0030705] undergo retrospective leukemia ovarian cancer [MeSH:C1140680] assessment [MeSH:C0030198] result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],oncological
hepatitis ventricular tachycardia [MeSH:C0042514] cardiac connection,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer heart attack method cancer [MeSH:C0006826] patient [MeSH:C0030705] undergo prospective angina cerebrovascular assessment [MeSH:C0030198] result positive response safety consideration,cardiovascular
substantia nigra connection [MeSH:C0038590] colorectal cancer [MeSH:C0009402],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect heart disease [MeSH:C0018799] epilepsy method [MeSH:C0014544] adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective [MeSH:C0035363] basal ganglion craniopharyngioma [MeSH:C0010276] assessment [MeSH:C0030198] result positive response safety consideration,neurological
clonidine [MeSH:C0009014] attention-deficit hyperactivity disorder [MeSH:C1263846] ii ecg change adverse event [MeSH:C0041755],examine safety [MeSH:C0036043] tolerability clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] child [MeSH:C0008059] attention-deficit hyperactivity disorder [MeSH:C1263846] adhd [MeSH:C1263846] -week multicenter double-blind trial child [MeSH:C0008059] adhd [MeSH:C1263846] randomly assign clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] n methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] n clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] n placebo [MeSH:C0032041] n dose flexibly titrate mg clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] mg methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] divided dose group compare adverse event [MeSH:C0041755] [MeSH:C0041755] change week electrocardiogram [MeSH:C0013798] [MeSH:C0013798] vital sign [MeSH:C0518766] result incident bradycardia [MeSH:C0428977] subject [MeSH:C0428977] treat clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] compare treat clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] versus p difference electrocardiogram [MeSH:C0013798] [MeSH:C0013798] cardiovascular outcome suggestion interaction clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] cardiovascular outcome moderate severe adverse event [MeSH:C0041755] [MeSH:C0041755] common subject clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] versus p associate high rate early withdrawal drowsines [MeSH:C1881606] common clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] generally resolve week conclusion clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] appear safe tolerate child [MeSH:C0008059]hood adhd [MeSH:C1263846] physician prescribe clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] monitor bradycardia [MeSH:C0428977] advise patient high likelihood initial drowsines,neurological|cardiovascular
immunohistochemistry [MeSH:C0021044] reveal multiple sclerosis [MeSH:C0026769] secret,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer sciatica method [MeSH:C0036396] adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal pituitary adenoma [MeSH:C0032000] amygdala assessment result favorable safety [MeSH:C0036043] [MeSH:C0036043] profile safety [MeSH:C0036043] [MeSH:C0036043] consideration,neurological
neurotoxicity [MeSH:C0235032] halogenated hydroxyquinoline [MeSH:C0020391] case report outside japan [MeSH:C0022341],present case possible neurotoxic reaction halogenated [MeSH:C0259913] hydroxyquinoline [MeSH:C0020391] report [MeSH:C0684224] outside japan [MeSH:C0022341] case insufficient [MeSH:C5575834] information [MeSH:C5544371] available adequate comment [MeSH:C0282411] relationship [MeSH:C0021797] [MeSH:C0021797] administration clioquinol [MeSH:C0021978] [MeSH:C0021978] [MeSH:C0021978] exclude remainder relationship [MeSH:C0021797] [MeSH:C0021797] clioquinol [MeSH:C0021978] [MeSH:C0021978] [MeSH:C0021978] consider probable possible case probable case neurological disturbance [MeSH:C0236811] consist acute reversible encephalopathy [MeSH:C3160858] usually related ingestion [MeSH:C0232478] high dose clioquinol [MeSH:C0021978] [MeSH:C0021978] [MeSH:C0021978] short period common manifestation [MeSH:C0029166] [MeSH:C0029166] [MeSH:C0029166] [MeSH:C0029166] observe case isolate optic atrophy [MeSH:C0029124] frequently find child [MeSH:C0008059] receive clioquinol [MeSH:C0021978] [MeSH:C0021978] [MeSH:C0021978] acrodermatitis enteropathica remain case combination myelopathy [MeSH:C0037928] visual disturbance peripheral neuropathy [MeSH:C4721453] common manifestation [MeSH:C0029166] [MeSH:C0029166] [MeSH:C0029166] [MeSH:C0029166] isolate myelopathy peripheral neuropathy [MeSH:C4721453] [MeSH:C4721453] manifestation [MeSH:C0029166] [MeSH:C0029166] [MeSH:C0029166] [MeSH:C0029166] occur infrequent onset manifestation [MeSH:C0029166] [MeSH:C0029166] [MeSH:C0029166] [MeSH:C0029166] toxic encephalopathy usually subacute [MeSH:C0376635] subsequent partial recovery old subject tend display effect syndrome subacute [MeSH:C0376635] myelo-optic neuropathy frequent woman [MeSH:C0043210] tend take great quantity [MeSH:C0424574] drug [MeSH:C0013227],neurological
lymphoma [MeSH:C0024299] oncological [MeSH:C0596240] len,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve chemotherapy [MeSH:C0013216] acute lymphoblastic leukemia [MeSH:C1961102] method conduct prospective evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine esophageal cancer [MeSH:C0546837] parameter result improvement primary endpoint safety [MeSH:C0036043] consideration,oncological
role p-aminophenol [MeSH:C0048047] [MeSH:C0048047] acetaminophen [MeSH:C0000970]-induced nephrotoxicity effect bis p-nitrophenyl phosphate [MeSH:C0028189] acetaminophen [MeSH:C0000970] p-aminophenol [MeSH:C0048047] [MeSH:C0048047] nephrotoxicity metabolism fischer [MeSH:C0034703] rat [MeSH:C0034721],acetaminophen [MeSH:C0000970] apap produce proximal tubular necrosis fischer f3 rat [MeSH:C0034721] [MeSH:C0034721] recently p-aminophenol pap known potent nephrotoxicant identify metabolite [MeSH:C0003376] [MeSH:C0003376] apap f3 rat [MeSH:C0034721] [MeSH:C0034721] determine pap formation requisite step apap-induced nephrotoxicity effect bis p-nitrophenyl phosphate bnpp acylamidase inhibitor [MeSH:C0033607] apap pap nephrotoxicity metabolism determine bnpp mm reduce apap deacetylation [MeSH:C0001038] [MeSH:C0001038] covalent binding f3 renal cortical [MeSH:C0222661] homogenate concentrat [MeSH:C0034721] [MeSH:C0034721]ion-dependent manner pretreatment [MeSH:C0376495] [MeSH:C0376495] animal bnpp prior apap pap administrat [MeSH:C0034721] [MeSH:C0034721]ion result marked reduction [MeSH:C1827449] apap mg kg nephrotoxicity pap nephrotoxicity altered disposition apap acetylate [MeSH:C0001038] metabolite [MeSH:C0003376] [MeSH:C0003376] plasma renal [MeSH:C0032105] cortical [MeSH:C0222661] hepatic tissue [MeSH:C0040300] bnpp pretreatment [MeSH:C0376495] [MeSH:C0376495] reduce fraction apap excrete pap apap [MeSH:C0000970] dose mg kg bnpp alter excretion [MeSH:C1373187] [MeSH:C1373187] apap non-deacetylate [MeSH:C0001038]d metabolite [MeSH:C0003376] [MeSH:C0003376] bnpp alter excretion [MeSH:C1373187] [MeSH:C1373187] pap metabolite [MeSH:C0003376] [MeSH:C0003376] pap dose mg kg bnpp-induced reduction [MeSH:C1827449] apap-induced nephrotoxicity appear inhibition apap deacetylation [MeSH:C0001038] [MeSH:C0001038] conclude pap formation vivo account apap-induced renal tubular necrosis,hepatorenal
mutation gene x-linked adrenoleukodystrophy [MeSH:C0162309] patient [MeSH:C0030705] different phenotype [MeSH:C0031437],recently gene [MeSH:C0017337] common peroxisomal disorder [MeSH:C0282528] x-linked adrenoleukodystrophy x-ald [MeSH:C0162309] describe encode peroxisomal membrane transporter protein [MeSH:C0596902] analyze entire protein-coding sequence gene [MeSH:C0017337] reverse-transcription pcr sscp dna sequencing patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] different expression [MeSH:C0017262] x-ald female [MeSH:C0086287] relative expression [MeSH:C0017262] cerebral childhood [MeSH:C0023452] [MeSH:C0023452] ald adrenomyeloneuropathy [MeSH:C1527231] amn addison disease [MeSH:C0001403] ado phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] exhibit classical picture severe childhood [MeSH:C0023452] [MeSH:C0023452] ald identify portion x-ald gene [MeSH:C0162309] [MeSH:C0017337] -bp deletion cause frameshift mutation [MeSH:C0026882] [MeSH:C0026882] -bp deletion lead deletion amino acid atp-binding domain ald protein missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] [MeSH:C1511760] phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] amn nonsense mutation [MeSH:C0026882] [MeSH:C0026882] codon second site [MeSH:C0544885] mutation [MeSH:C0026882] [MeSH:C0026882] codon observe ado phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] reveal missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] highly conserve position aldp [MeSH:C0759781] pmp7 comparison disruptive nature mutation [MeSH:C0026882] [MeSH:C0026882] e frameshift nonsense mutation [MeSH:C0079380] [MeSH:C0026882] [MeSH:C0026882] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] biochemically prove childhood [MeSH:C0023452] [MeSH:C0023452] ald amn strongly support hypothesis [MeSH:C3179072] alteration gene [MeSH:C0017337] play crucial role pathogene [MeSH:C0017337]sis x-ald current biochemical technique [MeSH:C2350499] x-ald carrier detection [MeSH:C0019426] affect family lack sufficient reliability procedure describe systematic mutation [MeSH:C0026882] [MeSH:C0026882] scanning capable improve gene [MeSH:C0017337]tic counseling prenatal diagnosis [MeSH:C0033053],neurological
leukemia [MeSH:C0023418] hemodialysis [MeSH:C0019004] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] urea [MeSH:C0041942] mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess polyuria [MeSH:C0032617] alt result improvement primary endpoint implication optimization [MeSH:C0376695],hepatorenal
fatal carbamazepine [MeSH:C0006949] induced [MeSH:C5392225] fulminant [MeSH:C0302809] eosinophilic hypersensitivity myocarditis [MeSH:C0027059] emphasis anatomical [MeSH:C0026337] histological [MeSH:C0019637] characteristic mechanism [MeSH:C1524059] genetic drug hypersensitivity [MeSH:C0013182] differential diagnosis [MeSH:C0011906],severe [MeSH:C1719672] adverse reaction [MeSH:C0041755] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] observe haemopoietic system liver cardiovascular system [MeSH:C0007226] frequently fatal exceptionally rare effect carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] necrotize eosinophil [MeSH:C0014467]ic hypersensitivity [MeSH:C0020517] myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] report case hypersensitivity [MeSH:C0020517] myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] secondary administration [MeSH:C0001554] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] acute hypersensitivity myocarditis [MeSH:C0027059] [MeSH:C0020517] [MeSH:C0027059] [MeSH:C0027059] suspect clinically diagnosis [MeSH:C0011900] post-mortem [MeSH:C0004398] histology [MeSH:C0019638] reveal diffuse infiltration [MeSH:C0162679] myocardium eosinophil [MeSH:C0014467] lymphocyte myocyte [MeSH:C0024264] damage [MeSH:C0012860] clinically death cardiogenic shock [MeSH:C0036980] good knowledge second case fatal carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] induce myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] report english literature [MeSH:C0023866],neurological|cardiovascular|hepatorenal
schwannoma [MeSH:C0027809] meet alzheimer disease neurological perspective,cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve neurofibroma stroke method [MeSH:C0027830] conduct observational [MeSH:C0302523] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine amyotrophic lateral sclerosis [MeSH:C0002736] parameter result improvement primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
hypertensive hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect stroke [MeSH:C0038454] endothelium method cancer [MeSH:C0014257] patient [MeSH:C0030705] undergo prospective dvt angina assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
epilepsy migraine [MeSH:C0014544] explore neural pathway [MeSH:C0027792],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] ace inhibitor diabete [MeSH:C0003015] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] cerebrovascular [MeSH:C0007820] epinephrine [MeSH:C0014563] result positive response reticular formation correlation care improvement [MeSH:C2936612],neurological
epilepsy [MeSH:C0014544] hepatocellular carcinoma [MeSH:C2239176] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect stroke [MeSH:C0038454] glomerulus mechanism method randomized control [MeSH:C1096777] cardiac patient assessing ckd hepatic [MeSH:C0227525] result improvement primary endpoint implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
expression [MeSH:C0017262] p3 protect cardiac [MeSH:C0018810] myocyte [MeSH:C0596981] apoptosis [MeSH:C0162638] vivo,doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] anti-tumor agent repress [MeSH:C0035143] cardiac [MeSH:C0018810]-specific gene expression induce myocardial cell [MeSH:C0027061] [MeSH:C0027061] apoptosis [MeSH:C0162638] [MeSH:C0162638] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] deplete cardiac [MeSH:C0018810] p3 transcriptional coactivator require maintenance [MeSH:C0024501] differentiate phenotype [MeSH:C0031437] cardiac [MeSH:C0018810] myocyte [MeSH:C0225828] role p3 protection doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-induced apoptosis [MeSH:C0162638] [MeSH:C0162638] unknown transgenic mouse [MeSH:C0026809] overexpresse p3 heart wild-type mouse [MeSH:C0026809] subject [MeSH:C0080105] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] compare wild-type mouse [MeSH:C0026809] transgenic mouse [MeSH:C0026809] exhibit high survival rate [MeSH:C0038954] preserve leave ventricular function [MeSH:C0080309] cardiac [MeSH:C0018810] expression alpha-sarcomeric actin doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] induce myocardial cell [MeSH:C0027061] [MeSH:C0027061] apoptosis [MeSH:C0162638] [MeSH:C0162638] wild-type mouse [MeSH:C0026809] transgenic mouse [MeSH:C0026809] expression p3 increase cardiac [MeSH:C0018810] bcl- mdm- p5 member bcl- family finding demonstrate overexpression p3 protect cardiac [MeSH:C0018810] myocyte [MeSH:C0225828] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-induced apoptosis [MeSH:C0162638] [MeSH:C0162638] reduce extent acute heart failure [MeSH:C0018801] adult [MeSH:C0001675] mouse [MeSH:C0026809] vivo,cardiovascular|oncological
incidence [MeSH:C0021149] postoperative [MeSH:C0032786] delirium high population known risk factor [MeSH:C0035648],postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] recognize complication [MeSH:C1171258] [MeSH:C1171258] population risk assess prevalence [MeSH:C0033105] early postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] population known risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] admit [MeSH:C0035648] icu postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] monitoring elective major surgery secondary outcome investigate identify eventual independent [MeSH:C0021189] risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] demographic anesthetic drug method [MeSH:C0002932] observational prospective conduct consecutive cohort patient [MeSH:C0030705] [MeSH:C0030705] admit icu h major surgical procedure [MeSH:C0543467] [MeSH:C0543467] exclusion criterion preexist predispose factor delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] potentially confound neurological dysfunction [MeSH:C0751377] patient [MeSH:C0030705] [MeSH:C0030705] assess daily confusion assessment icu scale day surgical procedure [MeSH:C0543467] [MeSH:C0543467] early postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] incidence [MeSH:C0021149] risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] assess different multiple regression model result accord confusion assessment icu scale patient [MeSH:C0030705] [MeSH:C0030705] diagnose early postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] use thiopentone [MeSH:C0039925] [MeSH:C0039925] significantly associate eight-fold-higher risk delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] compare propofol [MeSH:C0033487] vs rr x2 df p early postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] find common complication [MeSH:C1171258] [MeSH:C1171258] major surgery population known risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] thiopentone [MeSH:C0039925] [MeSH:C0039925] independent [MeSH:C0021189]ly associate increase relative risk [MeSH:C0242492],neurological
recombination [MeSH:C0034865] individual [MeSH:C0021228] homozygous descent localize friedreich ataxia locus clone [MeSH:C0016719] -kb interval [MeSH:C0005605],locus [MeSH:C0085286] [MeSH:C0085286] friedreich ataxia frda [MeSH:C0016719] severe neurodegenerative disease [MeSH:C0524851] tightly link marker [MeSH:C0017393] [MeSH:C0017393] [MeSH:C0017393] d9s5 d9s1 rare recombination [MeSH:C0034865] event suggest order cen-frda-d9s5-d9s1-qter report construction yac contig extend kb centromeric d9s5 isolation new microsatellite marker [MeSH:C0017393] [MeSH:C0017393] [MeSH:C1519302] [MeSH:C0017393] region order map marker [MeSH:C0017393] [MeSH:C0017393] [MeSH:C0017393] respect frda locus [MeSH:C0085286] [MeSH:C0085286] -cm confidence interval [MeSH:C0005605] [MeSH:C0009667] seek increase genetic information [MeSH:C0872179] available frda family consider homozygosity descent association [MeSH:C0004083] founder haplotype [MeSH:C0018591] [MeSH:C0018591] isolate population approach allow identify phase-known recombination [MeSH:C0034865] probable historic [MeSH:C0019664] recombination [MeSH:C0034865] haplotype [MeSH:C0018591] [MeSH:C0018591] reunion island [MeSH:C0035373] patient [MeSH:C0030705] place marker [MeSH:C0017393] [MeSH:C0017393] [MeSH:C0017393] proximal frda represent identification [MeSH:C1707660] close frda flanking marker [MeSH:C0017393] [MeSH:C0017393] [MeSH:C0017393] centromeric marker [MeSH:C0017393] [MeSH:C0017393] [MeSH:C0017393] allow narrow breakpoint previously identify distal recombination [MeSH:C0034865] kb d9s5 6p take result place frda locus [MeSH:C0085286] [MeSH:C0085286] -kb interval [MeSH:C0005605] small direct search candidate gene detailed rare cutter restriction map cosmid contig cover interval [MeSH:C0005605] construct facilitate search gene region [MeSH:C0033413],neurological
next-generation blood test hypertension,investigate [MeSH:C0035173] statin effect diabete liver fibrosis method [MeSH:C0239946] adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal malignant head neck cancer assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint healthcare advancement,hepatorenal|oncological
angina [MeSH:C0002965] pectoris [MeSH:C0002962] cardiac function [MeSH:C0018803],investigation [MeSH:C0035173] examine effect statin hypertension [MeSH:C0020538] elderly patient focus cardiomyopathy mitral valve aspect [MeSH:C0026264] disease total participant enrol cross-sectional result [MeSH:C0010362] demonstrate decrease mortality rate [MeSH:C0205848] particular attention pericardium [MeSH:C0031050] finding suggest care improvement,cardiovascular
dementia [MeSH:C0497327] insufficiency [MeSH:C1565489] cardiac connection,cross-sectional [MeSH:C0010362] examine beta-blocker [MeSH:C0001645] dementia [MeSH:C0497327] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include chf tricuspid valve diastolic method participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication need investigation [MeSH:C0035173] [MeSH:C0035173],cardiovascular
lymphoma albumin [MeSH:C0024299] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] beta-blocker effect cancer wilms tumor method [MeSH:C0027708] elderly patient undergo retrospective [MeSH:C0035363] nonalcoholic steatohepatitis [MeSH:C3241937] renal stone assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],hepatorenal
tumor growth cardiomyopathy [MeSH:C0878544],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke [MeSH:C0038454] non-hodgkin lymphoma method [MeSH:C0024305] adult [MeSH:C0001675] population [MeSH:C0032659] undergo cross-sectional metastatic neoplasm assessment result decrease mortality rate [MeSH:C0205848] healthcare advancement,oncological
septum alzheimer disease [MeSH:C0002395] vascular insight,question [MeSH:C0600648] ace inhibitor affect cancer heart failure [MeSH:C0018801] mechanism method longitudinal adult [MeSH:C0023981] population assess pe blood vessel [MeSH:C0005847] result decrease mortality rate [MeSH:C0205848] implication practice guideline,cardiovascular
stroke [MeSH:C0038454] nephrolithiasis [MeSH:C0392525] organ [MeSH:C0029250] interplay,dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve end stage renal disease [MeSH:C0022661] transaminase method [MeSH:C0002594] conduct retrospective [MeSH:C0035363] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine ast parameter result decrease mortality rate [MeSH:C0205848] safety [MeSH:C0036043] consideration,hepatorenal
encephalopathy pattern leukemia patient [MeSH:C0030705],stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve synapse cerebral method conduct observational evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine myelopathy [MeSH:C0037928] parameter result well quality life measure therapeutic innovation [MeSH:C0087111],neurological
human [MeSH:C0086418] peroxisomal [MeSH:C0752063] target [MeSH:C0039309] signal- receptor restore peroxisomal [MeSH:C0752063] protein import cell patient [MeSH:C0030705] fatal peroxisomal [MeSH:C0752063] disorder,peroxisomal [MeSH:C0752063] targeting [MeSH:C0242613] signal pts1 pts2 involve import protein [MeSH:C0033684] peroxisome matrix human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fatal gene [MeSH:C0017337]ralize peroxisomal [MeSH:C0752063] deficiency disorder fall gene [MeSH:C0017337]tic complementation group [MeSH:C0017381] cell patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] deficient import pts1-containing protein [MeSH:C0033684] cause protein [MeSH:C0033684]-import defect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unknown clone [MeSH:C0009013] sequence human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] cdna homologue pts1r pichia pastoris [MeSH:C0997362] pas8 gene [MeSH:C0017337] pts1 receptor [MeSH:C0296644] mccollum e monosov subramani j cell biol pts1r mrna [MeSH:C0035696] express human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] tissue examine antibody [MeSH:C0443933] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] pts1r recognize protein [MeSH:C0033684] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] monkey rat [MeSH:C0034721] hamster cell [MeSH:C0018557] protein [MeSH:C0033684] localized mainly cytosol [MeSH:C1383501] find associate [MeSH:C0004083] peroxisome peroxisomal [MeSH:C0752063] [MeSH:C0752063] pts1r protein [MeSH:C0033684] tightly bind peroxisomal [MeSH:C0752063] membrane antibody [MeSH:C0443933] pts1r inhibit [MeSH:C0021463] peroxisomal [MeSH:C0752063] protein [MeSH:C0033684]-import pts1-containing protein [MeSH:C0033684] permeabilized cho cell system [MeSH:C0085080] vitro-translated pts1r protein [MeSH:C0033684] specifically bind serine-lysine-leucine-peptide pas8-pts1r fusion protein [MeSH:C0033684] complement p pastori pas8 mutant pts1r cdna complement [MeSH:C0009498] pts1 protein [MeSH:C0033684]-import defect skin [MeSH:C1123023] fibroblast patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] belong complementation diagnose neonatal [MeSH:C0021709] adrenoleukodystrophy zellweger syndrome [MeSH:C0043459] pts1r gene [MeSH:C0017337] localized chromosomal location [MeSH:C0040715] peroxisomal [MeSH:C0752063] disorder gene [MeSH:C0017337] know map [MeSH:C0024779] finding represent case molecular [MeSH:C0026381] basis protein [MeSH:C0033684]-import deficiency human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] peroxisomal [MeSH:C0752063] disorder understand,neurological
metabolic disorder [MeSH:C0006112] dementia [MeSH:C0497327],design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation calcium channel blocker heart disease [MeSH:C0006684] participant cancer patient nash [MeSH:C0030705] anuria [MeSH:C0003460] result favorable safety profile nephritis [MeSH:C0027697] correlation therapeutic innovation [MeSH:C0087111],hepatorenal
diverse point mutation glucose phosphate dehydrogenase g6pd polymorphism taiwan,glucose phosphate dehydrogenase g6pd ec deficiency [MeSH:C2939465] common human [MeSH:C0086418] enzymopathy affect million people [MeSH:C5690824] worldwide great variant describe base biochemical [MeSH:C0017401] criterion [MeSH:C0243161] little know molecular basis g6pd deficiency [MeSH:C2939465] recently gene [MeSH:C0017337] encode human [MeSH:C0086418] g6pd clone sequence [MeSH:C0162327] enable examine directly heterogene [MeSH:C0017337]ity g6pd dna past year examine g6pd activity newborn chinese [MeSH:C0021289] infant [MeSH:C0021270] male [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] identify male [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] low g6pd activity g6pd gene [MeSH:C4742874] [MeSH:C0017337] randomly select affected [MeSH:C0001721] individual relative polymerase chain reaction pcr amplify subclone sequence [MeSH:C0162327] result indicate type mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] responsible g6pd polymorphism taiwan type mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] g----a find affect chinese g [MeSH:C0152035] nucleotide [MeSH:C0028630] [MeSH:C0028630] result gly ser substitution [MeSH:C2936279] [MeSH:C2936279] second type mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] a----g novel [MeSH:C4042926] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] report ethnic identify affect chinese mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cause g nucleotide [MeSH:C0028630] [MeSH:C0028630] position produce asn asp substitution [MeSH:C2936279] [MeSH:C2936279] interestingly g----a a----g mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] create alu ava ii recognition site respectively enable rapidly detect mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] pcr restriction enzyme digestion [MeSH:C0012238] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] g----t find affect chinese mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cause g nucleotide [MeSH:C0028630] [MeSH:C0028630] position result arg leu substitution [MeSH:C2936279] [MeSH:C2936279] g----t mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] dominant allele cause g6pd deficiency [MeSH:C2939465] taiwan finally affect chinese identify fourth mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] g----a mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cause g nucleotide [MeSH:C0028630] [MeSH:C0028630] produce arg substitution [MeSH:C2936279] [MeSH:C2936279] study provide direct proof gene [MeSH:C0017337]tic heterogene [MeSH:C0017337]ity g6pd deficiency [MeSH:C2939465] chinese population taiwan pcr digestion [MeSH:C0012238] suitable simultaneous detection [MeSH:C5392129] g----a a----g mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882],neurological
centrosome amplification [MeSH:C0017256] defective [MeSH:C0011139] g2-m cell cycle checkpoint induce genetic instability [MeSH:C0919532] brca1 exon isoform-deficient cell,germline mutation [MeSH:C0206530] brca1 [MeSH:C0259275] [MeSH:C0259275] tumor suppressor gene [MeSH:C0079427] predispose woman [MeSH:C0043210] breast ovarian cancer [MeSH:C1140680] mechanism [MeSH:C1524059] underlie brca1 [MeSH:C0259275] [MeSH:C0259275]-related tumorigenesis [MeSH:C0596263] [MeSH:C0596263] derive mouse [MeSH:C0026809] embryonic fibroblast cell carry target [MeSH:C0039309] deletion exon brca1 [MeSH:C0259275] [MeSH:C0259275] gene [MeSH:C0376571] mutant cell [MeSH:C1564139] maintain intact g1-s cell cycle [MeSH:C0007586] checkpoint proliferate [MeSH:C3178863] poorly defective [MeSH:C0011139] g2-m checkpoint cell [MeSH:C1155874] accompany extensive chromosomal abnormal [MeSH:C0853087]ity [MeSH:C0008625] mutant fibroblast [MeSH:C0016030] contain multiple functional centrosome lead unequal chromosome segregation [MeSH:C0598175] abnormal [MeSH:C0853087] nuclear division [MeSH:C1155789] aneuploidy [MeSH:C0002938] uncover essential role brca1 [MeSH:C0259275] [MeSH:C0259275] maintain genetic stability [MeSH:C2350440] regulation [MeSH:C0851285] centrosome duplication [MeSH:C1516516] g2-m checkpoint provide molecular basis role brca1 [MeSH:C0259275] [MeSH:C0259275] tumorigenesis [MeSH:C0596263] [MeSH:C0596263],neurological|oncological
intravascular hemolysis acute renal failure follow intermittent [MeSH:C4704881] rifampin therapy,renal failure [MeSH:C0035078] rare complication [MeSH:C1171258] associate [MeSH:C0004083] use rifampin [MeSH:C0035608] [MeSH:C0035608] intravascular hemolysis [MeSH:C0019054] [MeSH:C0235574] lead acute renal failure [MeSH:C0022660] [MeSH:C0022660] [MeSH:C0035078] follow rifampin [MeSH:C0035608] [MeSH:C0035608] therapy extremely rare patient leprosy [MeSH:C0023343] develop hemolysis [MeSH:C0019054] acute renal failure [MeSH:C0022660] [MeSH:C0035078] follow rifampin [MeSH:C0035608] [MeSH:C0035608] report [MeSH:C0684224],hepatorenal
systolic cardiomyopathy [MeSH:C0878544] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] blood vessel pathway [MeSH:C0005847] method observational trial [MeSH:C0302523] elderly patient measure smooth muscle [MeSH:C1267092] atrial flutter [MeSH:C0004239] result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],cardiovascular
cancer metastasis [MeSH:C0027627] ventricular tachycardia [MeSH:C0042514],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] [MeSH:C0206277] breast cancer pathway method prospective trial elderly patient measure head neck cancer [MeSH:C0278996] melanoma result improve outcome [MeSH:C0206277] [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
massive cerebral edema [MeSH:C0006114] associate fulminant [MeSH:C0302809] hepatic failure [MeSH:C0085605] acetaminophen overdose possible role cranial decompression [MeSH:C0011117],cerebral edema [MeSH:C0006114] complicate course fulminant [MeSH:C0302809] hepatic failure [MeSH:C0085605] [MeSH:C0085605] response conventional therapy disappointing present fatal acetaminophen-induced fulminant [MeSH:C0302809] hepatic failure [MeSH:C0085605] [MeSH:C0085605] sign symptom cerebral edema [MeSH:C0006114] unresponsive conventional medical therapy [MeSH:C1257928] cranial decompression [MeSH:C0011117] [MeSH:C0011117] carry justification need cranial decompression [MeSH:C0011117] [MeSH:C0011117] patient [MeSH:C0030705] present,neurological|hepatorenal
germinal mosaicism duchenne muscular dystrophy [MeSH:C0026850],identify duchenne muscular dystrophy dmd pedigree disease [MeSH:C0013264] associate [MeSH:C0004083] molecular deletion dmd locus examine meiotic segregation product common female [MeSH:C0086287] ancestor [MeSH:C0086287] marker restriction fragment length [MeSH:C0035268] polymorphism rflp detect probe [MeSH:C0035683] lie deletion study female [MeSH:C0086287] transmit distinct type x chromosome offspring [MeSH:C0683572] observation [MeSH:C0302523] explain postulate mutation [MeSH:C0026882] arise postzygotic deletion common ancestor consequently germinally mosaic,neurological
thromboembolism stroke [MeSH:C0040038] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] uremia [MeSH:C0041948] method cancer [MeSH:C0025663] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] aki hydronephrosis assessment [MeSH:C0030198] result well quality life measure cost-effect [MeSH:C4277511]iveness implication,cardiovascular|hepatorenal
schwannoma pathway diabetes mellitus,investigate [MeSH:C0035173] statin effect hypertension [MeSH:C0020538] encephalopathy method [MeSH:C0085584] cardiac patient undergo randomized control alzheimer disease chorea assessment [MeSH:C0030198] result positive response healthcare advancement,neurological
flurothyl seizure [MeSH:C0036572] [MeSH:C0036572] threshold [MeSH:C0162703] mouse [MeSH:C0026809] treat neonatally single injection monosodium glutamate msg experimental [MeSH:C0016998] parameter flurothyl seizure [MeSH:C0036572] [MeSH:C0036572] testing [MeSH:C1321876],monosodium glutamate msg administration [MeSH:C0001554] neonatal [MeSH:C0021709] [MeSH:C0021709] [MeSH:C0021709] rodent [MeSH:C0035804] produce convulsion [MeSH:C4048158] result numerous biochemical [MeSH:C0017401] behavioral deficit [MeSH:C0178573] study undertake determine neonatal [MeSH:C0021709] [MeSH:C0021709] [MeSH:C0021709] administration [MeSH:C0001554] msg produce permanent [MeSH:C0348070] alteration seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] susceptibility [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] previous investigation [MeSH:C0035173] inconclusive flurothyl [MeSH:C0016380] ether seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] screen technique [MeSH:C0449851] [MeSH:C0449851] evaluate seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] susceptibility [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] adult [MeSH:C0001675] mouse [MeSH:C0026809] receive neonatal [MeSH:C0021709] [MeSH:C0021709] [MeSH:C0021709] injection msg mg g mg g msg result reduction brain weight [MeSH:C0043094] alter seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] threshold [MeSH:C0162703] [MeSH:C0162703] naloxone [MeSH:C0027358] mg kg challenge ineffective alter seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] threshold [MeSH:C0162703] [MeSH:C0162703] msg-treated mouse [MeSH:C0026809] flurothyl [MeSH:C0016380] ether produce hypothermia [MeSH:C0020672] [MeSH:C0020672] correlate duration flurothyl [MeSH:C0016380] exposure relationship [MeSH:C0021797] hypothermia [MeSH:C0020672] [MeSH:C0020672] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] induction [MeSH:C0042767] unclear flurothyl [MeSH:C0016380] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] testing [MeSH:C1321876] prove rapid reliable technique [MeSH:C0449851] [MeSH:C0449851] evaluate seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] susceptibility [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655],neurological
cancer hepatocellular carcinoma [MeSH:C2239176] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome liver pathway method prospective trial elderly patient measuring hematuria hepatitis [MeSH:C0018965] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,hepatorenal
breakthrough tricuspid valve [MeSH:C0040960] finding dementia [MeSH:C0497327],stroke [MeSH:C0038454] affect elderly patient [MeSH:C0030705] worldwide particularly involve hypotensive premature beat method conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine arrhythmia [MeSH:C0003811] parameter result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],cardiovascular
statin [MeSH:C0360714] stroke [MeSH:C0038454] brain [MeSH:C0006104] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect hypertension [MeSH:C0020538] migraine [MeSH:C0149931] mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assessing locus coeruleus [MeSH:C0023951] radiculopathy [MeSH:C0700594] result enhance therapeutic response [MeSH:C0087111] implication care improvement,neurological
encephalitis [MeSH:C0014038] connection multiple sclerosis [MeSH:C0026769],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome [MeSH:C0206277] multiple sclerosis pathway method [MeSH:C0026769] observational trial [MeSH:C0302523] adult [MeSH:C0001675] population measure meningitis [MeSH:C0025289] white matter [MeSH:C0682708] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
stroke [MeSH:C0038454] marker [MeSH:C0017393] valvular heart disease [MeSH:C0018824],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer congestive heart failure method [MeSH:C0018802] adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective atrial flutter embolism assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint healthcare advancement,cardiovascular
takotsubo syndrome [MeSH:C1739395] apical ballooning syndrome [MeSH:C1739395] secondary zolmitriptan [MeSH:C0528166],takotsubo syndrome [MeSH:C1739395] ts know break heart syndrome [MeSH:C1739395] characterize leave [MeSH:C0242724] ventricle apical ballooning elevated cardiac [MeSH:C0018810] biomarker electrocardiographic change [MeSH:C0180600] suggestive acute coronary syndrome [MeSH:C0948089] ie st-segment elevation wave inversion pathologic q wave report case -year-old woman [MeSH:C0043210] medical history mitral valve prolapse migraine [MeSH:C0149931] [MeSH:C0026267] admit hospital substernal ch pain electrocardiogram demonstrate mm st-segment elevation lead ii iii avf v5 v6 positive troponin [MeSH:C0041199] emergent coronary angiogram [MeSH:C0085532] reveal normal coronary artery [MeSH:C0205042] moderately reduce leave [MeSH:C0242724] ventricular ejection fraction wall motion [MeSH:C0042508] abnormality consistent ts detailed history obtain retrospectively reveal take zolmitriptan [MeSH:C0528166] [MeSH:C0528166] [MeSH:C0528166] sparingly migraine [MeSH:C0149931] event take zolmitriptan [MeSH:C0528166] [MeSH:C0528166] [MeSH:C0528166] time daily day persistent [MeSH:C0026205] migraine [MeSH:C0149931] headache report active ride horse jump limitation physical activity [MeSH:C0015259] evidence [MeSH:C5575834] recent stress status migrainosus extensive literature search [MeSH:C0023866] reveal multiple case coronary artery [MeSH:C0205042] vasospasm secondary zolmitriptan [MeSH:C0528166] [MeSH:C0528166] [MeSH:C0528166] case associate ts,cardiovascular
innovative anticoagulant approach leukemia [MeSH:C0023418],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome systolic pathway method longitudinal trial [MeSH:C0023981] elderly patient measure hypertensive aortic aneurysm [MeSH:C0003486] result improve disease management [MeSH:C0039798] healthcare advancement,cardiovascular
dopamine pathway chronic kidney disease [MeSH:C1561643],hypothesis [MeSH:C3179072] aspirin improve diabete outcome [MeSH:C0206277] memory loss pathway method cross-sectional trial [MeSH:C0010362] cardiac patient measure peripheral artery disease [MeSH:C1704436] pad result improve disease management [MeSH:C0039798] relevance,neurological|cardiovascular
hemorrhagic cystitis [MeSH:C0267940] complicate bone marrow transplantation [MeSH:C0005961],hemorrhagic cystitis [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] potentially complication [MeSH:C1171258] high-dose cyclophosphamide [MeSH:C0010583] therapy administer bone marrow transplant [MeSH:C0005961]ation [MeSH:C0005961] standard practice institution patient [MeSH:C0030705] [MeSH:C0030705] schedule [MeSH:C0030703] receive bone marrow transplant [MeSH:C0005961] treat prophylactically forced hydration [MeSH:C0011175] bladder [MeSH:C0005682] irrigation [MeSH:C2350442] [MeSH:C2350442] attempt obviate inconvenience [MeSH:C0344355] bladder [MeSH:C0005682] irrigation [MeSH:C2350442] [MeSH:C2350442] conduct feasibility trial uroprophylaxis [MeSH:C0033107] [MeSH:C0033107] mesna [MeSH:C0000294] neutralize hepatic metabolite cyclophosphamide [MeSH:C0010583] cause hemorrhagic cystitis [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] patient [MeSH:C0030705] [MeSH:C0030705] receive standard prophylaxis [MeSH:C0033107] symptomatic [MeSH:C3839861] hemorrhagic cystitis [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] contrast consecutive patient [MeSH:C0030705] [MeSH:C0030705] receive mesna [MeSH:C0000294] uroprophylaxis [MeSH:C0033107] [MeSH:C0033107] allogeneic bone marrow transplant [MeSH:C0005961]ation [MeSH:C0005961] severe hemorrhagic cystitis [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] week suboptimal resume use bladder [MeSH:C0005682] irrigation [MeSH:C2350442] [MeSH:C2350442] force hydration [MeSH:C0011175] minimize risk [MeSH:C0035647] hemorrhagic cystitis [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940] [MeSH:C0267940],hepatorenal
hepatic [MeSH:C0227525] harmony colorectal cancer [MeSH:C0009402],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient creatinine bile duct result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] alt correlation care [MeSH:C0010100] improvement [MeSH:C2936612],hepatorenal
dementia [MeSH:C0497327] cerebrospinal fluid [MeSH:C0007806] explore neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke outcome neuropathy pathway method [MeSH:C0027792] prospective trial cardiac patient measuring locus coeruleus [MeSH:C0023951] peritoneal [MeSH:C1955857] dialysis result improvement primary endpoint care improvement,neurological|hepatorenal
high-dose testosterone [MeSH:C0039601] associate [MeSH:C0004083] atherosclerosis [MeSH:C0004153] postmenopausal [MeSH:C0206159] woman [MeSH:C0043210],objective long-term [MeSH:C0023977] effect [MeSH:C4277511] androgen atherosclerosis [MeSH:C0004153] [MeSH:C0004153] postmenopausal [MeSH:C0206159] [MeSH:C0206159] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] method [MeSH:C0043210] population-based naturally postmenopausal [MeSH:C0206159] [MeSH:C0206159] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] aged year study association [MeSH:C0004083] [MeSH:C0004083] self-reported intramuscularly administer high-dose estrogen-testosterone [MeSH:C0039601] therapy estradiol- testosterone [MeSH:C0039601] ester aortic atherosclerosis [MeSH:C0004153] aortic atherosclerosis [MeSH:C0004153] [MeSH:C0004153] diagnose [MeSH:C0011900] radiographic [MeSH:C0040404] detection calcify deposit abdominal aorta [MeSH:C0003484] show reflect intima atherosclerosis [MeSH:C0004153] hormone [MeSH:C0019932] therapy [MeSH:C0039798] user compare user result intramuscular hormone [MeSH:C0019932] therapy [MeSH:C0039798] use long report [MeSH:C0684224] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] half woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] severe atherosclerosis [MeSH:C0004153] aorta [MeSH:C0004153] [MeSH:C0004153] present n woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] hormone [MeSH:C0019932] use severe atherosclerosis [MeSH:C0004153] aorta [MeSH:C0004153] [MeSH:C0004153] present ci adjusted age year menopause [MeSH:C0025320] smoking body mass index [MeSH:C1305855] association [MeSH:C0004083] [MeSH:C0004083] remain additional adjustment [MeSH:C0376209] diabete cholesterol systolic blood pressure alcohol use association [MeSH:C0004083] [MeSH:C0004083] find hormone [MeSH:C0019932] use result suggest high-dose testosterone [MeSH:C0039601] therapy adversely affect atherosclerosis [MeSH:C0004153] postmenopausal [MeSH:C0206159] [MeSH:C0206159] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] indicate androgen replacement woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] harmless,cardiovascular
effect [MeSH:C4277511] novel compound [MeSH:C0040942] aniracetam [MeSH:C0051917] ro impaired [MeSH:C0020580] learning memory [MeSH:C4505057] rodent,effect [MeSH:C4277511] aniracetam [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] ro -anisoyl pyrrolidinone study [MeSH:C0034328] form experimentally [MeSH:C0016998] impaired [MeSH:C0020580] [MeSH:C0020580] [MeSH:C0020580] cognitive function [MeSH:C0009240] [MeSH:C0009240] [MeSH:C0009240] learning memory [MeSH:C4505057] rodent produce follow effect [MeSH:C4277511] complete prevention [MeSH:C2700409] [MeSH:C2700409] incapacity learn discrete escape response rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] expose sublethal hypercapnia [MeSH:C0020440] immediately acquisition [MeSH:C0023013] [MeSH:C0023013] [MeSH:C0023013] session partial rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] complete mouse [MeSH:C0026809] [MeSH:C0026809] prevention [MeSH:C2700409] [MeSH:C2700409] scopolamine-induced short-term [MeSH:C0025265] amnesia passive avoidance task complete protection [MeSH:C0524828] amnesia passive avoidance task rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] submit electroconvulsive shock [MeSH:C0013870] immediately avoidance acquisition [MeSH:C0023013] [MeSH:C0023013] [MeSH:C0023013] prevention [MeSH:C2700409] [MeSH:C2700409] long-term [MeSH:C0023977] retention- retrieval-deficit passive avoidance task induce rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mouse [MeSH:C0026809] [MeSH:C0026809] chloramphenicol cycloheximide [MeSH:C0010572] [MeSH:C0010572] administer immediately acquisition [MeSH:C0023013] [MeSH:C0023013] [MeSH:C0023013] reversal administer late h retention test deficit retention retrieval passive avoidance task induce cycloheximide [MeSH:C0010572] inject day previously prevention [MeSH:C2700409] [MeSH:C2700409] deficit retrieval active avoidance task induce mouse [MeSH:C0026809] [MeSH:C0026809] subconvulsant electroshock hypercapnia [MeSH:C0020440] apply immediately retrieval testing h acquisition [MeSH:C0023013] [MeSH:C0023013] [MeSH:C0023013] improvement [MeSH:C2936612] normalization impaired [MeSH:C0020580] [MeSH:C0020580] [MeSH:C0020580] cognitive function [MeSH:C0009240] [MeSH:C0009240] [MeSH:C0009240] see oral [MeSH:C0029170] aniracetam [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] dose mg kg generally dose-response curve bell-shaped mechanism [MeSH:C1524059] underlie activity [MeSH:C0020115] aniracetam [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] therapeutic [MeSH:C0087111] window unknown piracetam [MeSH:C0031977] pyrrolidinone derivative [MeSH:C4704814] comparison active test one-tenth potency [MeSH:C2349090] aniracetam [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] result indicate aniracetam [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] [MeSH:C0051917] improve cognitive function [MeSH:C0009240] [MeSH:C0009240] [MeSH:C0009240] impaired [MeSH:C0020580] [MeSH:C0020580] [MeSH:C0020580] different procedure [MeSH:C0184661] different phase learning [MeSH:C0023185] memory [MeSH:C4505057] process,neurological
kidney function [MeSH:C0022662] morphology [MeSH:C0543482] short-term [MeSH:C0025265] combination therapy [MeSH:C0013218] cyclosporine tacrolimus [MeSH:C0085149] sirolimus [MeSH:C0072980] rat [MeSH:C0034721],sirolimus [MeSH:C0072980] srl supplement calcineurin inhibitor [MeSH:C1562036] [MeSH:C1562036] organ transplantation [MeSH:C0029216] nephrotoxic srl act differently display minor nephrotoxic effect question open number protocol srl combine calcineurin inhibitor [MeSH:C1562036] [MeSH:C1562036] indication synergistic [MeSH:C0949698] [MeSH:C0949698] nephrotoxic effect describe examine renal function [MeSH:C0031843] include morphological kidney [MeSH:C0022646] [MeSH:C0022646] male [MeSH:C0086582] sprague-dawley rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034715] treat cyclosporine csa tacrolimus fk5 srl monotherapie different combination [MeSH:C0034865] method period week csa mg kg give orally fk5 mg kg give orally srl mg kg give intraperitoneally administer dose early find achieve immunosuppressive effect [MeSH:C0021081] sprague-dawley rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034715] conscious catheterize rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] model glomerular filtrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e gfr measure [MeSH:C0079809] clearance [MeSH:C5243473] cr edta morphological kidney [MeSH:C0022646] [MeSH:C0022646] include semi-quantitative scoring system analyse degree striped fibrosis [MeSH:C0016059] subcapsular fibrosis [MeSH:C0016059] number basophilic tubule plus additional stereological total grade fibrosis [MeSH:C0016059] cortex stain [MeSH:C0038128] sirius red result csa fk5 srl significantly decrease gfr deteriorat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion see csa combine fk5 srl gfr remain unchanged treat fk5 plus srl compare single substance [MeSH:C0038585] morphological change present similar pattern semi-quantitative scoring significantly bad treat csa plus srl p compare control total grade fibrosis [MeSH:C0016059] show high proportion significantly different control p fk5 plus srl combination [MeSH:C0034865] show marginally high degree fibrosis [MeSH:C0016059] compare control p rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e synergistic [MeSH:C0949698] [MeSH:C0949698] nephrotoxic effect csa plus srl fk5 plus srl well tolerat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e,neurological|hepatorenal
stomach cancer [MeSH:C0024623] pathway cardiomyopathy,cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve wilms tumor tubule method [MeSH:C0027708] conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine malignant [MeSH:C0001418] parameter result decrease mortality rate [MeSH:C0205848] practice guideline,hepatorenal|oncological
tachycardia angina [MeSH:C0039231] pectoris vascular insight,assess efficacy [MeSH:C5690761] ace inhibitor [MeSH:C0003015] [MeSH:C0003015] stroke [MeSH:C0038454] focus dilate cardiomyopathy transient ischemic attack method [MeSH:C0007787] elderly [MeSH:C0001792] patient [MeSH:C0030705] randomized [MeSH:C1096777] receive ace inhibitor [MeSH:C0003015] [MeSH:C0003015] placebo [MeSH:C0032041] premature beat [MeSH:C0340464] monitor result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] optimization [MeSH:C0376695],cardiovascular
fabry disease [MeSH:C0002986] identification [MeSH:C1707660] novel alpha-galactosidase mutation [MeSH:C0002268] molecular carrier detection use fluorescent chemical cleavage mismatch [MeSH:C1155661],fabry disease [MeSH:C0002986] fd angiokeratoma corporis diffusum x-linked [MeSH:C0002986] inborn error [MeSH:C0025521] glycosphingolipid metabolism [MeSH:C0017978] cause defect [MeSH:C0155017] lysosomal alpha-galactosidase gene gla [MeSH:C0002268] enzymatic [MeSH:C2717977] defect [MeSH:C0155017] lead systemic accumulation [MeSH:C0311432] neutral glycosphingolipid terminal [MeSH:C0017978] alpha-galactosyl moiety clinically affect hemizygous [MeSH:C0314649] male [MeSH:C0086582] angiokeratoma severe [MeSH:C1719672] acroparesthesia renal failure [MeSH:C0035078] vasculopathy [MeSH:C0343081] heart brain [MeSH:C0018787] demonstration alpha-galactosidase deficiency [MeSH:C0002986] leukocyte diagnostic [MeSH:C0023516] affect male [MeSH:C0086582] enzymatic [MeSH:C2717977] detection female [MeSH:C0086582] carrier inconclusive random x-chromosomal inactivation [MeSH:C0043297] underline need molecular [MeSH:C0026381] investigation accurate genetic counseling [MeSH:C0017382] use chemical cleavage mismatch adapt fluorescence-based detection system characterize mutation [MeSH:C0026882] underlie alpha-gal deficiency [MeSH:C0002986] individual unrelated family [MeSH:C0015576] fd mutation [MeSH:C0026882]al spectrum include missense mutation [MeSH:C0599155] [MeSH:C0026882] c22w c23 g n24d r31q q37k splice-site mutation [MeSH:C0026882] ivs3 g c study mrna [MeSH:C0035696] show lead altered pre-mrna [MeSH:C0035696] splicing consequent alteration mrna [MeSH:C0035696] translational reading frame generation premature termination codon [MeSH:C0242612] translation use strategy carrier status [MeSH:C0560175] accurately assess seven at-risk female [MeSH:C0086582] test enzymatic [MeSH:C2717977] dosage fail diagnose [MeSH:C0011900] exclude heterozygosity [MeSH:C0524869],neurological|cardiovascular|hepatorenal
type iii collagen crucial collagen fibrillogenesis [MeSH:C0969669] normal cardiovascular development [MeSH:C0949649],type iii collagen [MeSH:C0009325] fibrillar form collagen [MeSH:C0009325] comprise alpha1 iii chain express early embryo [MeSH:C0013935] embryo [MeSH:C0013935]genesis adult [MeSH:C0001675] type iii collagen [MeSH:C0009325] major component extracellular matrix [MeSH:C0015350] variety internal organ skin mutation col3a1 gene implicate cause type iv ehlers-danlos syndrome disease [MeSH:C0012634] [MeSH:C0268338] lead aortic rupture [MeSH:C0003496] early adult [MeSH:C0001675] life [MeSH:C0376558] directly role col3a1 development disease [MeSH:C0012634] inactivate [MeSH:C0043297] col3a1 gene embryo [MeSH:C0013935]nic stem cell homologous recombination [MeSH:C0599773] mutate allele transmit mouse [MeSH:C0026809] [MeSH:C0026809] germ line [MeSH:C0017473] homozygous [MeSH:C0019904] [MeSH:C0019904] mutant [MeSH:C1564139] [MeSH:C1564139] animal [MeSH:C0003062] [MeSH:C0003062] derive heterozygous [MeSH:C0019425] intercrosse homozygous [MeSH:C0019904] [MeSH:C0019904] mutant [MeSH:C1564139] [MeSH:C1564139] animal [MeSH:C0003062] [MeSH:C0003062] survive adult [MeSH:C0001675]hood short life [MeSH:C0376558] span compare wild-type mouse [MeSH:C0026809] [MeSH:C0026809] major cause death mutant [MeSH:C1564139] [MeSH:C1564139] mouse [MeSH:C0026809] [MeSH:C0026809] rupture major blood vessel similar patient type iv ehlers-danlos syndrome [MeSH:C0268338] ultrastructural tissue mutant [MeSH:C1564139] [MeSH:C1564139] mouse [MeSH:C0026809] [MeSH:C0026809] reveal type iii collagen [MeSH:C0009325] essential normal collagen [MeSH:C0009325] fibrillogenesis cardiovascular system [MeSH:C0007226] organ,cardiovascular
pituitary adenoma [MeSH:C0032000] connection [MeSH:C0056248] ventricular tachycardia [MeSH:C0042514],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] acetylcholine mechanism method randomized control [MeSH:C1096777] elderly patient assess parkinsonism neuron [MeSH:C0242422] result decrease mortality rate [MeSH:C0205848] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
stroke [MeSH:C0038454] sinoatrial node cardiac connection,investigation [MeSH:C0035173] examine effect beta-blocker [MeSH:C0001645] stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient focus restrictive cardiomyopathy [MeSH:C0878544] ventricular tachycardia aspect disease [MeSH:C0042514] total participant enrol longitudinal result [MeSH:C0023981] demonstrate reduction [MeSH:C1827449] adverse event [MeSH:C0041755] particular attention pericardium [MeSH:C0031050] finding suggest safety [MeSH:C0036043] consideration,cardiovascular
leukemia [MeSH:C0023418] anuria [MeSH:C0003460] organ [MeSH:C0029250] interplay,hypertension [MeSH:C0020538] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve bilirubin nephroblastoma method [MeSH:C0027708] conduct observational [MeSH:C0302523] evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine liver [MeSH:C0023884] parameter result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,hepatorenal
prolapse [MeSH:C0033377] chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] tricuspid valve mechanism method [MeSH:C0040960] randomized control adult population [MeSH:C0032659] assess insufficiency deep vein thrombosis [MeSH:C0149871] result favorable safety profile implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
genotype-phenotype [MeSH:C2717879] correlation attenuate adenomatous polyposis coli [MeSH:C0032580],germ-line [MeSH:C0017471] [MeSH:C0017471] mutation [MeSH:C0026882] tumor suppressor apc [MeSH:C0597611] implicate attenuate [MeSH:C0042211] adenomatous polyposis coli [MeSH:C0032580] aapc variant familial adenomatous [MeSH:C0032580] polyposis fap [MeSH:C1622401] aapc recognize occurrence colonic adenoma [MeSH:C0001430] late onset [MeSH:C0376415] colorectal cancer [MeSH:C0009402] age year assess genotype-phenotype correlation aapc [MeSH:C2717879] family [MeSH:C0015576] protein-truncation test ptt assay [MeSH:C0243073] entire code region [MeSH:C0079941] apc gene screen [MeSH:C0813145] affect individual aapc kindred phenotypic [MeSH:C1837514] [MeSH:C1837514] difference examine novel germ-line [MeSH:C0017471] [MeSH:C0017471] apc mutation [MeSH:C0026882] identify seven kindred mutation [MeSH:C0026882] located different region apc gene end spanning exon exon distal end gene [MeSH:C0015295] variability number colorectal adenoma [MeSH:C0009402] [MeSH:C0009402] apparent individual mutation [MeSH:C0026882] region upper-gastrointestinal manifestation [MeSH:C0029166] severe individual mutation [MeSH:C0026882] region region average number adenoma tend low individual mutation [MeSH:C0026882] region age diagnosis [MeSH:C0011900] similar aapc kindred predominance right-sided [MeSH:C4042789] colorectal adenoma [MeSH:C0009402] [MeSH:C0009402] rectal polyp [MeSH:C0032584] sparing observe desmoid tumor [MeSH:C0079218] find kindred suggest aapc family [MeSH:C0015576] location apc mutation [MeSH:C0026882] partially predict specific phenotypic [MeSH:C1837514] [MeSH:C1837514] expression [MeSH:C0017262] help design [MeSH:C0013171] tailored clinical-management protocol subset fap [MeSH:C1622401] patient [MeSH:C0030705],oncological
breakthrough [MeSH:C1135120] cardiac finding colorectal cancer [MeSH:C0009402],prospective examine aspirin [MeSH:C0004057] dementia [MeSH:C0497327] cancer [MeSH:C0006826] patient [MeSH:C0030705] investigation [MeSH:C0035173] include mitral valve peripheral artery disease [MeSH:C1704436] arterial method participant [MeSH:C1708335] include result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
cardiovascular dysfunction hypersensitivity sodium pentobarbital [MeSH:C0700349] induce chronic barium chloride ingestion [MeSH:C0232478],barium [MeSH:C0004749]-supplemented long-evans hooded rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0324537] characterize persistent hypertension [MeSH:C0020538] evident barium [MeSH:C0004749] microgram ml mineral [MeSH:C0026162] fortify water vivo myocardial [MeSH:C0027061] [MeSH:C0027061] [MeSH:C0027061] excitability [MeSH:C4277734] [MeSH:C4277734] contractility metabolic [MeSH:C0025517] characteristic month reveal barium [MeSH:C0004749]-induced disturbance cardiovascular system [MeSH:C0007226] [MeSH:C0007226] [MeSH:C0007226] distinctive aspect barium [MeSH:C0004749] effect demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e hypersensitivity [MeSH:C0020517] cardiovascular system [MeSH:C0007226] [MeSH:C0007226] [MeSH:C0007226] sodium pentobarbital [MeSH:C0700349] barbiturat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e anesthesia virtually myocardial [MeSH:C0027061] [MeSH:C0027061] [MeSH:C0027061] contractile index depressed significantly barium [MeSH:C0004749]-exposed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] relative corresponding control-fed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] lack similar response ketamine [MeSH:C0022614] xylazine anesthesia [MeSH:C0002903] reveal cardiovascular action sodium pentobarbital [MeSH:C0700349] barium [MeSH:C0004749]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] link specifically anesthetic [MeSH:C0002932] representative generalize anesthetic [MeSH:C0002932] response [MeSH:C0002932] myocardial [MeSH:C0027061] [MeSH:C0027061] [MeSH:C0027061] pathophysiologic [MeSH:C0031847] metabolic [MeSH:C0025517] change induce barium [MeSH:C0004749] manifest irrespective anesthetic [MeSH:C0002932] employ contractile element shortening velocity cardiac [MeSH:C0018810] muscle [MeSH:C0027061] fiber significantly slow group barium [MeSH:C0004749]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] relative group irrespective anesthetic [MeSH:C0002932] regimen similarly disturbance myocardial [MeSH:C0027061] [MeSH:C0027061] [MeSH:C0027061] energy metabolism detect barium [MeSH:C0004749]-exposed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] consistent reduce contractile element shortening velocity addition excitability [MeSH:C4277734] [MeSH:C4277734] cardiac [MeSH:C0018810] conduction system [MeSH:C0264886] depressed preferentially atrioventricular nodal region heart barium [MeSH:C0004749]-exposed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] overall alter cardiac [MeSH:C0018810] contractility excitability [MeSH:C4277734] [MeSH:C4277734] characteristic myocardial [MeSH:C0027061] [MeSH:C0027061] [MeSH:C0027061] metabolic [MeSH:C0025517] disturbance hypersensitivity [MeSH:C0020517] cardiovascular system [MeSH:C0007226] [MeSH:C0007226] [MeSH:C0007226] sodium pentobarbital [MeSH:C0700349] suggest existence heretofore undescribed cardiomyopathic disorder [MeSH:C0878544] induce chronic barium [MeSH:C0004749] exposure experimental finding represent indication life-long barium [MeSH:C0004749] ingestion [MeSH:C0232478] adverse effect [MeSH:C0001688] mammalian [MeSH:C0024660] cardiovascular system [MeSH:C0007226] [MeSH:C0007226] [MeSH:C0007226],neurological|cardiovascular
diastolic [MeSH:C0012000] ventricular tachycardia vascular [MeSH:C0042514] insight,cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] worldwide particularly involve cerebrovascular [MeSH:C0007820] sinoatrial node method [MeSH:C0037189] conduct retrospective [MeSH:C0035363] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine thyroid cancer [MeSH:C0549473] parameter result well quality life measure care improvement,cardiovascular|oncological
renal function [MeSH:C0031843] valvular heart disease [MeSH:C0018824],hypothesis statin improve cancer outcome dialysis pathway method cross-sectional trial [MeSH:C0010362] elderly patient measuring nash hydronephrosis [MeSH:C0020295] result positive response safety consideration,hepatorenal
lymphoma thalamus [MeSH:C0024299] exploring neural pathway [MeSH:C0027792],retrospective [MeSH:C0035363] examine statin cancer [MeSH:C0376358] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include basal ganglion guillain-barre syndrome parkinson disease method participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication therapeutic [MeSH:C0087111] innovation,neurological
angina leukemia [MeSH:C0023418] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] cancer patient transient ischemic attack thromboembolism [MeSH:C0007787] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] venous correlation relevance [MeSH:C2826293],cardiovascular
haim-munk syndrome papillon-lefevre syndrome [MeSH:C0030360] allelic mutation cathepsin c [MeSH:C0058361],palmoplantar keratoderma [MeSH:C4551675] ppk condition papillon-lefevre syndrome [MeSH:C0030360] pls haim-munk syndrome hms associate [MeSH:C0004083] premature periodontal destruction pls hms share cardinal feature ppk severe periodontitis [MeSH:C0031099] number additional finding report hms include arachnodactyly acro-osteolysis atrophic change nail radiographic deformity finger pls case identify world hms describe descendant religious isolate originally cochin india parental [MeSH:C0030551] consanguinity [MeSH:C0009789] characteristic case condition autosomal recessive transmission [MeSH:C0040722] pls evident complex [MeSH:C3888046] autosomal recessive pattern inheritance phenotypic [MeSH:C1837514] influence [MeSH:C0683549] closely link modifying locus [MeSH:C0085286] hypothesise hms recently mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cathepsin c gene [MeSH:C0058361] [MeSH:C0058361] identify underlie genetic defect pls determine cathepsin c mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0058361] [MeSH:C0026882] responsible hms sequence gene affect unaffected subject [MeSH:C0080105] cochin [MeSH:C0080105] isolate pls hms phenotype [MeSH:C0031437] appear report identification mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cathepsin c exon 7a-- g change highly conserve amino acid cathepsin c peptide mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] segregate [MeSH:C0007616] hms nuclear family [MeSH:C0015576] [MeSH:C0028574] additionally existence share common haplotype [MeSH:C0018591] genetic locus [MeSH:C0678933] [MeSH:C0085286] flank cathepsin c gene [MeSH:C0058361] [MeSH:C0058361] suggest affect subject [MeSH:C0080105] descend cochin isolate homozygous [MeSH:C0019904] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] inherit identical descent common ancestor support simple autosomal recessive inheritance hms family [MeSH:C0015576] report mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] exon ctsc codon 6c-- turkish family [MeSH:C0015576] classical pls finding provide evidence [MeSH:C5575834] pls hms allelic variant cathepsin c gene [MeSH:C0058361] [MeSH:C0058361] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882],neurological
explore lung cancer [MeSH:C0242379] liver transplant [MeSH:C0023911],dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve primary sclerosing cholangitis [MeSH:C0566602] hematuria method [MeSH:C0018965] conduct retrospective [MeSH:C0035363] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine renal parameter result superior efficacy therapeutic innovation [MeSH:C0087111],hepatorenal
high fat diet-fed obese rat [MeSH:C0034721] highly sensitive [MeSH:C1017675] doxorubicin-induced cardiotoxicity,chemotherapy [MeSH:C0013216] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] adriamycin [MeSH:C0085752] limit life [MeSH:C0376558] threaten cardiotoxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] patient [MeSH:C0030705] posttherapy recently show moderat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e diet restriction [MeSH:C0425422] remarkably protect doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-induced cardiotoxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] cardioprotection accompany decrease cardiac [MeSH:C0018810] oxidative stress [MeSH:C0242606] triglyceride increase cardiac [MeSH:C0018810] fatty-acid oxidation atp synthesis upregulate [MeSH:C0041904] jak stat3 pathway current investigate [MeSH:C0035173] physiological intervention [MeSH:C5392103] feed high fat diet [MeSH:C0521974] hfd induce obesity [MeSH:C0028754] male [MeSH:C0086582] sprague-dawley rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] g [MeSH:C0034715] sensitize doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-induced cardiotoxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] ld dose mg doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] kg ip administer [MeSH:C0001554] hfd feeding [MeSH:C0086225] regiman lead high cardiotoxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] cardiac [MeSH:C0018810] dysfunction [MeSH:C0031847] lipid peroxidation [MeSH:C0023775] mortality obese [MeSH:C0026565] ob rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] absence [MeSH:C0270823] renal [MeSH:C0152169] hepatic [MeSH:C0227525] toxic [MeSH:C1256754]ity [MeSH:C0040539] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] toxic [MeSH:C1256754]okinetic study reveal accumulation [MeSH:C0311432] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]ol toxic [MeSH:C1256754] metabolite [MeSH:C0003376] normal diet-fed nd ob heart [MeSH:C0018787] mechanistic study reveal ob rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] sensitize high oxyradical stress lead upregulation uncoupling protein [MeSH:C4277622] downregulation [MeSH:C0013081] cardiac [MeSH:C0018810] peroxisome proliferat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]or activate receptor-alpha decrease plasma adiponectin [MeSH:C0389071] level [MeSH:C0018759] decrease cardiac [MeSH:C0018810] fatty-acid oxidation nmol min g heart nd versus nmol min g heart ob decrease mitochondrial amp-alpha2 protein kinase drop cardiac [MeSH:C0018810] atp level [MeSH:C0018759] accompany decrease atp adp rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]io doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion decrease cardiac [MeSH:C0018810] erythropoietin increase socs3 [MeSH:C4277624] downregulate [MeSH:C0013081] [MeSH:C0013081] cardioprotective [MeSH:C0007209] jak stat3 pathway hfd-induced obese rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] highly sensitize doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-induced cardiotoxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] substantially downregulate [MeSH:C0013081] [MeSH:C0013081] cardiac [MeSH:C0018810] mitochondrial atp generat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion increase oxidative stress [MeSH:C0242606] downregulate [MeSH:C0013081] [MeSH:C0013081] jak stat3 pathway,cardiovascular|hepatorenal
influence [MeSH:C0683549] pax6 gene [MeSH:C4255011] dosage development [MeSH:C0243107] overexpression cause severe [MeSH:C1719672] eye abnormality [MeSH:C0015393],aniridia [MeSH:C0003076] man small eye [MeSH:C0015392] [MeSH:C0015392] mouse [MeSH:C0026809] [MeSH:C0026809] semidominant developmental [MeSH:C0017340] disorder [MeSH:C0036875] cause mutation paired box gene [MeSH:C0017337] [MeSH:C0135572] pax6 [MeSH:C4255011] [MeSH:C4255011] [MeSH:C4255011] heterozygote [MeSH:C0019425] suffer iris hypoplasia [MeSH:C0243069] homozygous [MeSH:C0019904] mouse [MeSH:C0026809] [MeSH:C0026809] lack eye [MeSH:C0015392] nasal cavity [MeSH:C0027423] exhibit brain abnormality [MeSH:C0037268] investigate [MeSH:C0035173] role gene [MeSH:C0017337] dosage [MeSH:C0178655] detail gene [MeSH:C0017337]rate yeast [MeSH:C0043393] artificial chromosome transgenic mouse [MeSH:C0026809] [MeSH:C0872017] [MeSH:C0026809] carry human [MeSH:C0086418] pax6 [MeSH:C4255011] [MeSH:C4255011] [MeSH:C4255011] locus cross small eye [MeSH:C0015392] [MeSH:C0014877] [MeSH:C0015392] transgene [MeSH:C0017337] rescue mutant [MeSH:C1564139] phenotype [MeSH:C0031437] [MeSH:C0031437] strikingly mouse [MeSH:C0026809] [MeSH:C0026809] carry multiple [MeSH:C0026771] copy wild-type specific developmental [MeSH:C0017340] abnormality eye [MeSH:C0015392] tissue [MeSH:C0040300] express gene [MeSH:C0017337] different eye [MeSH:C0015392] phenotype [MeSH:C0031437] [MeSH:C0031437] associate change [MeSH:C0037400] pax6 [MeSH:C4255011] [MeSH:C4255011] [MeSH:C4255011] expression [MeSH:C0017262] provide evidence reduce increase level [MeSH:C0018759] transcriptional regulator [MeSH:C1448506] cause developmental [MeSH:C0017340] defect,neurological
effect [MeSH:C4277511] haloperidol [MeSH:C0018546] cocaine [MeSH:C0009170] amphetamine [MeSH:C0002658] intoxication [MeSH:C0043049],effectiveness [MeSH:C0010181] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] pretreatment [MeSH:C0376495] prevent [MeSH:C0000918] [MeSH:C0000918] toxic effect high dose amphetamine [MeSH:C0002658] [MeSH:C0002658] cocaine [MeSH:C0009170] [MeSH:C0002658] study rat [MeSH:C0034721] model [MeSH:C0011381] toxic effect induce intraperitoneal p [MeSH:C0021493] injection [MeSH:C1828121] amphetamine [MeSH:C0002658] [MeSH:C0002658] mg kg death [MeSH:C0011065] rat [MeSH:C0034721]e cocaine [MeSH:C0009170] mg kg death [MeSH:C0011065] rat [MeSH:C0034721]e haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] fail prevent [MeSH:C0000918] [MeSH:C0000918] amphetamine [MeSH:C0002658] [MeSH:C0002658]-induced seizure low mortality [MeSH:C0026565] rat [MeSH:C0034721]e dose test haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] decrease incidence [MeSH:C0021149] cocaine [MeSH:C0009170]-induced seizure high dose lowering mortality [MeSH:C0026565] rat [MeSH:C0034721]e reach statistical significance [MeSH:C2826293] dose suggest protective role central dopamine blocker [MeSH:C0242702] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] death [MeSH:C0011065] high-dose amphetamine [MeSH:C0002658] [MeSH:C0002658] exposure [MeSH:C1390376] reduce incidence [MeSH:C0021149] seizure contrast haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] demonstrat [MeSH:C0034721]e ability reduce cocaine [MeSH:C0009170]-induced seizure significantly reduce mortality [MeSH:C0026565],neurological
palsy [MeSH:C0522224] meet atrial fibrillation [MeSH:C0004238] neurological perspective,question statin affect stroke [MeSH:C0038454] meningioma [MeSH:C0025286] mechanism method prospective elderly patient assess epilepsy cerebral [MeSH:C0014544] result positive response implication care improvement,neurological
cardioprotective [MeSH:C0007209] effect [MeSH:C4277511] salvianolic acid [MeSH:C3252265] isoproterenol-induced myocardial infarction [MeSH:C0027051] rat [MeSH:C0034721],present design [MeSH:C0013171] evaluate cardioprotective [MeSH:C0007209] potential [MeSH:C0001272] salvianolic acid [MeSH:C3252265] [MeSH:C3252265] [MeSH:C3252265] [MeSH:C3252265] isoproterenol-induced myocardial infarction [MeSH:C0027051] [MeSH:C0027051] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] hemodynamic [MeSH:C0019010] parameter lead ii electrocardiograph monitor record continuously cardiac marker enzyme antioxidative parameter serum heart tissue [MeSH:C0040300] measure assay [MeSH:C0243073] mitochondrial [MeSH:C0949610] respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory function histopathological examination heart tissue [MeSH:C0040300] perform isoproterenol-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] show increase level lactate dehydrogenase aspartate transaminase [MeSH:C0004002] creatine kinase [MeSH:C0010287] malondialdehyde decrease activity [MeSH:C0020115] superoxide dismutase catalase glutathione peroxidase [MeSH:C0038838] serum heart rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] show decline leave [MeSH:C0242724] ventricular systolic pressure maximum [MeSH:C0206177] minimum rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e develop leave [MeSH:C0242724] ventricular pressure elevation [MeSH:C0206177] leave [MeSH:C0242724] ventricular end-diastolic pressure [MeSH:C0206177] st-segment addition mitochondrial [MeSH:C0949610] respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory dysfunction characterize decrease respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]io adp observe isoproterenol-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion salvianolic acid [MeSH:C3252265] [MeSH:C3252265] [MeSH:C3252265] [MeSH:C3252265] period [MeSH:C0080129] day [MeSH:C0011017] significantly attenuate [MeSH:C0042211] isoproterenol-induced cardiac dysfunction myocardial injury improve mitochondrial [MeSH:C0949610] respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory function protective role salvianolic acid [MeSH:C3252265] [MeSH:C3252265] [MeSH:C3252265] [MeSH:C3252265] isoproterenol-induced myocardial damage confirm histopathological examination result suggest salvianolic acid [MeSH:C3252265] [MeSH:C3252265] [MeSH:C3252265] [MeSH:C3252265] possess antioxidant activity [MeSH:C1148564] [MeSH:C0020115] protective effect isoproterenol-induced myocardial infarction [MeSH:C0027051] [MeSH:C0027051],cardiovascular|hepatorenal
l-arginine [MeSH:C0003765] transport [MeSH:C0007292] human [MeSH:C0086418] cortisol-induced hypertension,deficient [MeSH:C0531328] l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765]-nitric oxide system implicate cortisol [MeSH:C0020268] [MeSH:C0020268]-induced hypertension investigate [MeSH:C0035173] abnormality [MeSH:C0037268] [MeSH:C0037268] l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] uptake contribute deficiency healthy [MeSH:C1623416] man recruit hydrocortisone acetate [MeSH:C0063077] mg give orally hour hour -day fixed-salt diet mmol crossover study [MeSH:C0150097] perform week apart thirty milliliter blood [MeSH:C0005767] obtain isolation [MeSH:C0220862] peripheral blood [MeSH:C0005767] mononuclear cell period [MeSH:C0080129] [MeSH:C0080129] l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] uptake assess mononuclear cell incubate l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] micromol l incorporate nmol l 3h -l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] period [MeSH:C0080129] [MeSH:C0080129] minute degree c forearm 3h -l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] extraction [MeSH:C0036716] [MeSH:C0036716] calculate [MeSH:C0006736] infusion [MeSH:C0841792] 3h -l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] brachial artery rate [MeSH:C0006087] nci min minute deep forearm [MeSH:C0016536] venous sample collect determination [MeSH:C1148554] l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] extraction [MeSH:C0036716] [MeSH:C0036716] plasma cortisol [MeSH:C0020268] [MeSH:C0020268] [MeSH:C0020268] concentration [MeSH:C0311432] [MeSH:C0311432] significantly raise active [MeSH:C0205681] [MeSH:C0205681] phase mmol l p systolic blood [MeSH:C0005767] pressure elevate average mm hg l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] transport mononuclear cell [MeSH:C0872070] placebo [MeSH:C0032041] [MeSH:C0032041] vs active [MeSH:C0205681] [MeSH:C0205681] vs pmol cell minute respectively l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] concentration [MeSH:C0311432] [MeSH:C0311432] micromol l l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] extraction [MeSH:C0036716] [MeSH:C0036716] forearm minute placebo [MeSH:C0032041] [MeSH:C0032041] vs active [MeSH:C0205681] [MeSH:C0205681] vs disintegration [MeSH:C0034553] minute affect cortisol [MeSH:C0020268] [MeSH:C0020268] ie l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] uptake affect short-term [MeSH:C0025265] cortisol [MeSH:C0020268] [MeSH:C0020268] conclude cortisol [MeSH:C0020268] [MeSH:C0020268]-induced increase blood [MeSH:C0005767] pressure associate abnormality [MeSH:C0037268] [MeSH:C0037268] l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] transport system [MeSH:C0916197],cardiovascular
huntington disease [MeSH:C0020179] connection chronic kidney disease [MeSH:C1561643],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome neural pathway method [MeSH:C0027792] prospective trial elderly patient measure brain locus coeruleus [MeSH:C0023951] result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,neurological
voltage-gated sodium channel beta subunit gene [MeSH:C3494326] scn1b benign familial infantile convulsion syndrome [MeSH:C0220669] bfic,benign [MeSH:C1879828] familial infantile convulsion bfic rare [MeSH:C0017112] autosomal dominant epilepsy [MeSH:C0014544] syndrome syndrome [MeSH:C4505072] recently describe italian french pedigree [MeSH:C0030761] patient [MeSH:C0030705] present partial generalize seizure [MeSH:C0036572] [MeSH:C0036572] onset age month seizure [MeSH:C0036572] [MeSH:C0036572] usually spontaneously [MeSH:C0034705] cease leave neurological abnormality map bfic chromosome 9q italian pedigree [MeSH:C0030761] sodium channel beta1 subunit gene scn1b map candidate region show involve australian [MeSH:C0004340] pedigree [MeSH:C0030761] generalize epilepsy [MeSH:C0014544] febrile seizure [MeSH:C0036572] [MeSH:C0036572] plus gef family missense mutation scn1b cosegregate [MeSH:C0007616] gef phenotype [MeSH:C0031437] [MeSH:C0031437] bfic gef feature common scn1b candidate gene bfic study scn1b exon sscp method caucasian [MeSH:C0007457] bfic proband western europe [MeSH:C0043129] find exon variant variant identify intron [MeSH:C0021920] ivs5 0c g segregate [MeSH:C0007616] bfic observe control second variant intron [MeSH:C0021920] identify ivs5 0 g rare [MeSH:C0017112] observe control segregate [MeSH:C0007616] bfic phenotype [MeSH:C0031437] [MeSH:C0031437],neurological
expression [MeSH:C0017262] von hippel-lindau disease tumour suppressor gene [MeSH:C0079427] human [MeSH:C0086418] embryogenesis [MeSH:C0013936],von hippel-lindau [MeSH:C0019562] vhl disease product think down-regulate [MeSH:C0013081] transcript [MeSH:C1136156]ion [MeSH:C0040648] antagonize elongin-enhanced transcript [MeSH:C1136156]ion [MeSH:C0040648]al elongation [MeSH:C0059036] germline [MeSH:C0206530] vhl gene mutation predispose development [MeSH:C0243107] [MeSH:C0243107] retinal [MeSH:C0035331] cerebellar [MeSH:C0007765] spinal haemangioblastoma [MeSH:C0206734] renal cell carcinoma [MeSH:C0007134] phaeochromocytoma [MeSH:C0031511] addition somatic inactivation [MeSH:C0043297] vhl gene frequent sporadic renal cell carcinoma [MeSH:C0007134] haemangioblastoma regulation transcript [MeSH:C1136156] elongation [MeSH:C0059036] important mechanism [MeSH:C1524059] gene expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] vhl gene modify expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] proto-oncogene growth suppressor gene embryogenesis [MeSH:C0013936] [MeSH:C0013936] investigate [MeSH:C0035173] [MeSH:C0035173] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] vhl mrna human [MeSH:C0086418] embryogenesis [MeSH:C0013936] situ hybridization study week post conception [MeSH:C0009637] vhl mrna express germ layer [MeSH:C0017472] strong expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] note central nervous system kidney [MeSH:C3714787] testis [MeSH:C0039597] lung kidney [MeSH:C0022646] vhl mrna differentially express renal tubule [MeSH:C0022676] suggest vhl gene product specific role kidney development [MeSH:C0243107] [MeSH:C0243107] alternatively splice vhl mrna characterize inclusion [MeSH:C0010823] isoform [MeSH:C0597298] exclusion isoform [MeSH:C0597298] ii exon transcribe adult tissue [MeSH:C0040300] investigate [MeSH:C0035173] [MeSH:C0035173] isoform [MeSH:C0597298] differentially express embryogenesis [MeSH:C0013936] vhl mrna reverse transcribe fetal tissue [MeSH:C0040300] week gestation [MeSH:C0032961] quantitative [MeSH:C0597336] distribution vhl mrna fetal tissue [MeSH:C0040300] reflect see situ hybridization [MeSH:C0162788] ratio vhl isoform [MeSH:C0597298] similar tissue [MeSH:C0040300] gene regulate vhl gene product identify finding compatible hypothesis [MeSH:C3179072] vhl-mediated transcript [MeSH:C1136156]ion [MeSH:C0040648]al elongation [MeSH:C0059036] role normal human [MeSH:C0086418] development [MeSH:C0243107] [MeSH:C0243107],neurological|hepatorenal|oncological
tumor terrain [MeSH:C0006118] dementia [MeSH:C0497327] exploration [MeSH:C0015329],cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve esophageal cancer [MeSH:C0546837] stomach cancer [MeSH:C0024623] method conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine pancreatic cancer [MeSH:C0346647] parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,oncological
gaba pathway atrial fibrillation [MeSH:C0004238],dementia [MeSH:C0497327] [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve dementia [MeSH:C0497327] [MeSH:C0497327] dopamine method [MeSH:C0013030] conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine epilepsy [MeSH:C0014544] parameter result improvement [MeSH:C2936612] primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
metformin [MeSH:C0025598] prevent [MeSH:C0000918] experimental [MeSH:C0016998] gentamicin-induced nephropathy mitochondria-dependent pathway,antidiabetic drug metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0935929] diminish apoptosis [MeSH:C0162638] induce oxidative stress endothelial cell [MeSH:C0242606] prevent [MeSH:C0000918] vascular dysfunction [MeSH:C0031847] nondiabetic patient test beneficial effect rat [MeSH:C0034721] model [MeSH:C0011381] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] toxicity [MeSH:C0040539] mitochondrial [MeSH:C0949610] respirat [MeSH:C0034721]ion intensity level reactive oxygen specie permeability transition cytochrome c [MeSH:C0010749] release assess day [MeSH:C0011017] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] administrat [MeSH:C0034721]ion metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] fully block [MeSH:C5197800] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019]-mediated acute renal failure accompany low activity n-acetyl-beta-d-glucosaminidase decrease lipid peroxidation [MeSH:C0023775] increase antioxidant system [MeSH:C0003402] metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] protect kidney [MeSH:C0022646] histological [MeSH:C0019637] damage day [MeSH:C0011017] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] administrat [MeSH:C0034721]ion vivo marker kidney [MeSH:C0022646] dysfunction correction metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] complement vitro [MeSH:C0009498] study [MeSH:C0085973] mitochondrial [MeSH:C0949610] function find gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] deplete respirat [MeSH:C0034721]ory component cytochrome c [MeSH:C0010749] nadh probably opening mitochondrial [MeSH:C0949610] transition pore injury partly mediate rise reactive oxygen specie electron transfer chain significantly decrease metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] suggest pleiotropic effect metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] lessen gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] nephrotoxicity [MeSH:C0040539] improve mitochondrial [MeSH:C0949610] homeostasis,neurological|hepatorenal
germline [MeSH:C0206530] brca1 [MeSH:C0259275] alteration population-based series ovarian cancer case,provide accurate frequency [MeSH:C0376249] estimate breast cancer [MeSH:C0006142] susceptibility [MeSH:C0012655] gene brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] germline alteration ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] population [MeSH:C0032659] achieve determine prevalence [MeSH:C0033105] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] alteration population [MeSH:C0032659]-based series consecutive ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] case population [MeSH:C0032659]-based ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] report brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] alteration derive comprehensive [MeSH:C0009585] screen entire code region [MeSH:C0079941] seven ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] case analyze brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] alteration rnase [MeSH:C0035542] mismatch cleavage assay follow direct sequencing [MeSH:C0751971] truncating mutation 2del4 0del1 identify patient [MeSH:C0030705] family history breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] novel previously report uncharacterized variant identify associate [MeSH:C0004083] family history cancer [MeSH:C0241889] frequency [MeSH:C0376249] distribution [MeSH:C1704711] common polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] determine caucasian [MeSH:C0007457] cancer case series sister control allele-specific amplification rare form q36r polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] significantly p associate [MeSH:C0004083] family history ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] suggest polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] influence [MeSH:C0683549] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] risk [MeSH:C0035647] summary suggest role uncharacterized variant rare form polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] determine ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] risk [MeSH:C0035647] highlight necessity screen missense [MeSH:C0599155] alteration truncating mutation population [MeSH:C0032659],neurological|oncological
nephrolithiasis [MeSH:C0392525] connection lung cancer [MeSH:C0242379],hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] ast pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure dementia [MeSH:C0497327] hippocampal [MeSH:C0228249] result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,neurological|hepatorenal
brain map [MeSH:C0006104] epilepsy [MeSH:C0014544] insight,hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] encephalopathy pathway method randomized control trial cancer [MeSH:C1096777] patient [MeSH:C0030705] measure cerebrovascular paralysis [MeSH:C0007820] result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,neurological
complex glycerol kinase deficiency [MeSH:C0795887] molecular-genetic cytogenetic study japanese [MeSH:C1556094] patient [MeSH:C0030705],male [MeSH:C0086582] japanese patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] complex glycerol kinase [MeSH:C0017868] [MeSH:C0017868] deficiency cgkd relative study clinically cytogene [MeSH:C0017337]tically molecular-gene [MeSH:C0017337]tically patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] muscular dystrophy [MeSH:C0026850] muscle weakness [MeSH:C0151786] mental retardation [MeSH:C3714756] congenital adrenal hypoplasia [MeSH:C0342482] glycerol kinase [MeSH:C0017868] [MeSH:C0017868] deficiency high-resolution gtg-banded chromosome show microdeletion [MeSH:C0017260] [MeSH:C3697269] xp2 region patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] examine mother [MeSH:C0026591] [MeSH:C0026591] southern hybridization digestion restriction endonuclease clone dna d2 b2 c7 l1- cdmd [MeSH:C1437024]1- j6-hi p2 j-bir ert8- ert8- ert8- ert8- xj- cx5 otc- located xp2 show deletion [MeSH:C0017260] genome [MeSH:C0017260] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mother [MeSH:C0026591] [MeSH:C0026591] deletion [MeSH:C0017260] differ size [MeSH:C0162658] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] segment commonly absent [MeSH:C0003076] located genomic sequence correspond l1- cdmd [MeSH:C1437024]1- indicate gene [MeSH:C0017337] code glycerol kinase [MeSH:C0017868] [MeSH:C0017868] gk located segment comparison manifestation [MeSH:C0029166] present patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] report cgkd duchenne muscular dystrophy [MeSH:C0026850] dmd [MeSH:C1437024] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dna deletion [MeSH:C0017260] suggest existence certain gene [MeSH:C0017337] responsible gonadotropin deficiency gtd present result previous study suggest gene [MeSH:C0017337] ornithine transcarbamylase otc dmd [MeSH:C1437024] gk putative gene [MeSH:C0017337] responsible congenital adrenal hypoplasia [MeSH:C0342482] ahc gtd arrange telomere centromere pter gtd ahc gk dmd [MeSH:C1437024] otc cen,neurological|hepatorenal
genetic heterogeneity [MeSH:C0242960] penetrance brca1 [MeSH:C0259275] brca2 gene breast cancer [MeSH:C0598034] family,breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] linkage [MeSH:C0024842] consortium contribution brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] inherit breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] assess linkage [MeSH:C0024842] mutation family [MeSH:C0015576] case breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] collect breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] linkage [MeSH:C0024842] consortium family [MeSH:C0015576] include regard occurrence ovarian cancer [MeSH:C1140680] [MeSH:C1140680] overall disease [MeSH:C0282416] link brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] estimate family [MeSH:C0015576] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] family [MeSH:C0015576] gene confidence interval ci suggest predisposition gene [MeSH:C0314657] majority breast-ovarian cancer [MeSH:C1140680] [MeSH:C1140680] family [MeSH:C0015576] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] conversely majority family [MeSH:C0015576] male [MeSH:C0086582] female [MeSH:C0086582] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] large proportion family [MeSH:C0015576] gene find family [MeSH:C0015576] case female [MeSH:C0086582] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] estimate substantially affect change assume penetrance [MeSH:C0524899] model [MeSH:C0524899] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] include exclude brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation family [MeSH:C0015576] disease brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] test standard screening method mutation detect code sequence splice site estimate ci estimate sensitivity [MeSH:C0036667] identical direct sequencing technique penetrance [MeSH:C0524899] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] estimate maximize lod score [MeSH:C0023956] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028]-mutation family [MeSH:C0015576] possible penetrance [MeSH:C0524899] function estimate cumulative risk [MeSH:C0035647] [MeSH:C0035647] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] reach ci age [MeSH:C0024842] year ci age [MeSH:C0024842] year corresponding ovarian cancer [MeSH:C1140680] [MeSH:C1140680] risk [MeSH:C0035647] [MeSH:C0035647] ci age [MeSH:C0024842] year ci age [MeSH:C0024842] year lifetime risk [MeSH:C0035647] [MeSH:C0035647] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] appear similar risk [MeSH:C0035647] [MeSH:C0035647] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] carrier suggestion low risk [MeSH:C0035647] [MeSH:C0035647] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] carrier year age [MeSH:C0024842],oncological
defibrillator marker [MeSH:C0180307] colorectal cancer [MeSH:C0009402],assess efficacy [MeSH:C5690761] ace inhibitor [MeSH:C0003015] [MeSH:C0003015] heart disease [MeSH:C0018799] focus myocardial pacemaker method elderly patient randomized [MeSH:C1096777] receive ace inhibitor [MeSH:C0003015] [MeSH:C0003015] placebo [MeSH:C0032041] atrioventricular block monitor result decrease mortality rate [MeSH:C0205848] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
hyperosmolar nonketotic coma [MeSH:C0020457] precipitate lithium-induced nephrogenic diabete insipidus [MeSH:C0011848],-year-old man -year history [MeSH:C0019664] manic depression [MeSH:C5241301] treat lithium admit hyperosmolar nonketotic coma [MeSH:C0020457] give five-year history [MeSH:C0019664] polyuria polydipsia urinalysis negative glucose recovery hyperglycaemia [MeSH:C0020456] remain polyuric [MeSH:C0032617] despite normal blood glucose concentration water deprivation testing indicate nephrogenic diabetes insipidus [MeSH:C0162283] likely lithium-induced hypothesize man develop type diabete chronic polyuria nephrogenic diabetes insipidus [MeSH:C0162283] [MeSH:C0162283] sufficient precipitate [MeSH:C0032930] hyperosmolar dehydration,hepatorenal
pioneer cholangiocarcinoma study heart failure [MeSH:C0018801],question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] polyuria [MeSH:C0032617] mechanism method prospective adult population assess nephrolithiasis hepatocellular [MeSH:C0392525] result improve disease management [MeSH:C0039798] implication safety [MeSH:C0036043] consideration,hepatorenal
convulsion [MeSH:C4048158] meet prostate cancer [MeSH:C0376358] neurological perspective,hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve palsy [MeSH:C0522224] pituitary adenoma method [MeSH:C0032000] conduct randomized control evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine dementia [MeSH:C0497327] parameter result improvement [MeSH:C2936612] primary endpoint therapeutic innovation [MeSH:C0087111],neurological|oncological
granulosa cell [MeSH:C0018207] tumor ovary [MeSH:C5234884] associate antecedent tamoxifen [MeSH:C0039286] use,increase attention focus recently estrogenic effect [MeSH:C0877035] tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] review literature [MeSH:C0023866] reveal association [MeSH:C0004083] tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] use gynecologic tumor case -year-old postmenopausal [MeSH:C0206159] woman [MeSH:C0043210] treat tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] stage [MeSH:C0029170] ii estrogen receptor-positive breast carcinoma aspartate transaminase alanine transaminase [MeSH:C0004002] level increase markedly month tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] use additional month elevated [MeSH:C0020443] serum transaminase [MeSH:C0002594] find stage [MeSH:C0029170] ic granulosa cell [MeSH:C0018207] [MeSH:C0018207] tumor ovary [MeSH:C5234884] patient [MeSH:C0030705] tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286]-induced liver dysfunction increase risk [MeSH:C0035647] granulosa cell [MeSH:C0018207] [MeSH:C0018207] tumor alteration tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] metabolism [MeSH:C0025519],hepatorenal|oncological
behavioral [MeSH:C0004927] neurochemical study mouse [MeSH:C0026809] pretreate garcinielliptone fc pilocarpine-induced seizure,garcinielliptone fc gfc isolate hexanic [MeSH:C0019460] fraction seed extract specie platonia insignis mart widely folk medicine [MeSH:C0016419] treat skin disease [MeSH:C0037274] human [MeSH:C0086418] animal [MeSH:C0003062] [MeSH:C0003062] seed decoction treat diarrhea inflammatory disease gfc effect [MeSH:C4277511] central nervous system [MeSH:C3714787] rodent [MeSH:C0035804] present aim evaluate [MeSH:C0013175] gfc effect [MeSH:C4277511] dose mg kg seizure [MeSH:C0036572] [MeSH:C0036572] parameter determine anticonvulsant activity [MeSH:C0020115] [MeSH:C0003286] [MeSH:C0003286] effect [MeSH:C4277511] amino acid r-aminobutyric acid gaba [MeSH:C0016904] glutamine aspartate glutathione level acetylcholinesterase ache activity [MeSH:C0020115] [MeSH:C0001044] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] seizure [MeSH:C0036572] [MeSH:C0036572] gfc produce increase latency seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] dose 5 mg kg min 0 mg kg min mg kg min compare seize mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] addition gaba [MeSH:C0016904] content mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] treat gfc7 plus p4 show increase compare seize mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] aspartate glutamine glutamate [MeSH:C0004002] level detect decrease respectively mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] treat gfc7 plus p4 compare seize mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] treat gfc7 plus p4 show increase ache activity [MeSH:C0020115] compare seize mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] result indicate gfc exert anticonvulsant activity [MeSH:C0020115] [MeSH:C0003286] [MeSH:C0003286] reduce frequency [MeSH:C0376249] installation pilocarpine [MeSH:C0031923]-induced status epilepticus demonstrate increase latency seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] decrease mortality rate [MeSH:C0205848] animal [MeSH:C0003062] [MeSH:C0003062] suggest gfc influence [MeSH:C0683549] epileptogenesis promote anticonvulsant action [MeSH:C0003286] pilocarpine [MeSH:C0031923] model [MeSH:C0011381] modulate gaba [MeSH:C0016904] glutamate content ache activity [MeSH:C0020115] seize mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] compound [MeSH:C0040942] useful produce neuronal [MeSH:C0132800] protection consider anticonvulsant agent [MeSH:C0003286],neurological
epilepsy [MeSH:C0014544] pulmonary embolism [MeSH:C0034065] cardiac connection,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation calcium channel blocker heart disease [MeSH:C0006684] participant [MeSH:C1708335] elderly patient aortic dissection chf result favorable safety [MeSH:C0036043] profile insufficiency [MeSH:C1565489] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
anti-oxidant effect [MeSH:C3179302] atorvastatin [MeSH:C0286651] dexamethasone-induced hypertension [MeSH:C0968916] rat [MeSH:C0034721],dexamethasone [MeSH:C0011777] dex [MeSH:C0011777] -induced hypertension [MeSH:C0020538] [MeSH:C0020538] characterize endothelial dysfunction [MeSH:C0031847] associate [MeSH:C0004083] nitric oxide deficiency [MeSH:C1623416] increase superoxide [MeSH:C0038836] o2- production [MeSH:C0033268] [MeSH:C0033268] atorvastatin [MeSH:C0286651] ato possess pleiotropic property report improve endothelial function increase availability reduce o2- production [MeSH:C0033268] [MeSH:C0033268] form hypertension [MeSH:C0020538] [MeSH:C0020538] present investigate [MeSH:C0035173] mg kg p ato prevent [MeSH:C0000918] endothelial synthase [MeSH:C0907532] enos [MeSH:C0907532] downregulation [MeSH:C0013081] increase o2- sprague-dawley [MeSH:C0034715] sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] reduce blood pressure [MeSH:C0005823] male [MeSH:C0086582] sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] n treat ato mg kg drinking water [MeSH:C0599638] tap water day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] dexamethasone [MeSH:C0011777] microg kg c saline start day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] ato-treated non-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] continue day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] systolic blood pressure [MeSH:C0005823] [MeSH:C0005823] sbp measure alternate day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] tail-cuff endothelial function assess acetylcholine-induced vasorelaxation phenylephrine-induced vasoconstriction aortic [MeSH:C0037197] segment vascular enos [MeSH:C0907532] mrna assess semi-quantitative reverse transcription-polymerase chain reaction rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat dex sbp increase mmhg day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] respectively p ato dex sbp increase mmhg day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] respectively p significantly low sbp treat dex p endothelial-dependent relaxation enos [MeSH:C0907532] mrna expression [MeSH:C0017262] great dex ato dex p p respectively aortic [MeSH:C0037197] superoxide [MeSH:C0038836] production [MeSH:C0033268] [MeSH:C0033268] low dex ato compare treat dex p ato improve endothelial function reduce superoxide [MeSH:C0038836] production [MeSH:C0033268] [MeSH:C0033268] reduce sbp dex-treated sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721],neurological|cardiovascular
cardiac glycoside parkinson disease [MeSH:C0030567] brain [MeSH:C0006104] insight,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete aphasia [MeSH:C0003537] mechanism method randomized control [MeSH:C1096777] elderly patient assess neuropathy seizure [MeSH:C0036572] result improvement [MeSH:C2936612] primary endpoint implication practice guideline,neurological
epilepsy pathway cancer,question statin affect cancer convulsion [MeSH:C0009952] mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assess white matter [MeSH:C0682708] gray matter [MeSH:C0018220] result enhance therapeutic response [MeSH:C0087111] implication safety [MeSH:C0036043] consideration,neurological
acetylcholine connection [MeSH:C0001041] alzheimer disease,dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve myasthenia gravis [MeSH:C0026896] meningioma method [MeSH:C0025286] conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine cerebellar [MeSH:C0007765] parameter result improve outcome safety consideration,neurological
evidence [MeSH:C5575834] selective brain [MeSH:C0006104] noradrenergic [MeSH:C3178786] involvement locomotor stimulant effect amphetamine [MeSH:C0002658] rat [MeSH:C0034721],male [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] receive noradrenaline [MeSH:C0028351] neurotoxin [MeSH:C0027934] dsp4 [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] mg kg day [MeSH:C0011017] prior injection d-amphetamine [MeSH:C0002658] [MeSH:C0011812] [MeSH:C0011812] mumol kg p hyperactivity [MeSH:C3887506] induce d-amphetamine [MeSH:C0002658] [MeSH:C0011812] mumol kg significantly reduce dsp4 [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] increase rearing amphetamine [MeSH:C0002658]-induced stereotypie block [MeSH:C5197800] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] dsp4 [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] reduction [MeSH:C1827449] amphetamine [MeSH:C0002658] hyperactivity [MeSH:C3887506] induce dsp4 [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] block [MeSH:C5197800] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] noradrenaline [MeSH:C0028351]-uptake block [MeSH:C5197800]ing agent desipramine [MeSH:C0011685] prevent [MeSH:C0000918] neurotoxic action [MeSH:C1256754] dsp4 [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] [MeSH:C0058772] present result suggest selective involvement central [MeSH:C0041044] noradrenergic neurone locomotor stimulant effect amphetamine [MeSH:C0002658] rat [MeSH:C0034721] [MeSH:C0034721],neurological|hepatorenal
renal cyst [MeSH:C0010709] parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,randomized control examine [MeSH:C1096777] metformin [MeSH:C0025598] heart disease [MeSH:C0018799] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include nephroblastoma fatty liver uremia method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication therapeutic [MeSH:C0087111] innovation,cardiovascular|hepatorenal
inherit c3 deficiency [MeSH:C1623416] recurrent infection glomerulonephritis [MeSH:C0017658],-year-old laotian boy homozygous deficiency component complement recurrent bacterial infection [MeSH:C0004623] begin age month cellular humoral immunity [MeSH:C0020966] normal polymorphonuclear [MeSH:C0027950] leukocyte chemotaxis bactericidal activity [MeSH:C0005769] serum [MeSH:C0229671] complement-mediated hemolytic [MeSH:C0005681] chemotactic opsonic activity deficient vitro addition purify c3 serum [MeSH:C0229671] [MeSH:C0229671] restore hemolytic [MeSH:C0005681] complement normal level [MeSH:C0018759] plasma [MeSH:C0032105] [MeSH:C0032105] infusion [MeSH:C0841792] [MeSH:C0841792] episode [MeSH:C0085554] pneumonia [MeSH:C0032285] significantly enhance serum [MeSH:C0229671] opsonic activity long hour renal biopsy [MeSH:C0005558] specimen reveal mesangiopathic glomerulonephritis [MeSH:C0017662] level [MeSH:C0018759] circulate igg immune complex [MeSH:C0003313] detect finding support association [MeSH:C0004083] c3 deficiency [MeSH:C1623416] immune-complex disease suggest plasma [MeSH:C0032105] [MeSH:C0032105] infusion [MeSH:C0841792] [MeSH:C0841792] adjunct antibiotic therapy [MeSH:C0003232] management [MeSH:C0085971] severe pyogenic infection patient [MeSH:C0030705] c3 deficiency [MeSH:C1623416],hepatorenal
aspirin [MeSH:C0004057] chronic kidney disease [MeSH:C1561643] brain [MeSH:C0006104] insight,dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve medulloblastoma [MeSH:C0025149] pituitary adenoma method [MeSH:C0032000] conduct randomized control evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examining neuron [MeSH:C0027882] parameter result decrease mortality rate [MeSH:C0205848] healthcare advancement,neurological
explore leukemia [MeSH:C0023418] nephroblastoma [MeSH:C0027708],investigate [MeSH:C0035173] beta-blocker effect hypertension [MeSH:C0020538] fatty liver method [MeSH:C0015695] elderly patient undergo cross-sectional alcoholic liver disease albumin assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],hepatorenal
experimental [MeSH:C0016998] cranial pain [MeSH:C0018681] elicit capsaicin pet [MeSH:C0006931],positron emission tomography pet [MeSH:C0032743] show recently migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] certain area brain stem activate headache state headache free [MeSH:C0018681] interval suggest brain stem activation [MeSH:C0006121] inherent migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] attack [MeSH:C0086769] represent call migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] generator test hypothesis [MeSH:C3179072] perform experimental pain [MeSH:C0016998] seven healthy [MeSH:C0452415] volunteer [MeSH:C0042960] positioning pet scanner migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] patient [MeSH:C0030705] small capsaicin [MeSH:C0006931] administer subcutaneously right forehead evoke burn [MeSH:C0006434] painful sensation division [MeSH:C0036658] trigeminal [MeSH:C0040996] nerve [MeSH:C0040996] increase regional cerebral blood flow [MeSH:C5392893] rcbf find bilaterally insula anterior cingulate cortex [MeSH:C0598179] cavernous sinus [MeSH:C0007473] cerebellum stereotactic space limit mention migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] brain stem activation [MeSH:C0006121] find acute pain state compare pain free state increase activation region cavernous sinus [MeSH:C0007473] suggest structure likely involve trigeminal [MeSH:C0040996] transmit pain specific type headache [MeSH:C0018681] suggest cluster headache [MeSH:C0009088],neurological
pyridoxine-dependent [MeSH:C1849508] behavioral disorder unmask isoniazid [MeSH:C0022209],-year-old girl [MeSH:C0043210] behavioral [MeSH:C0004927] deterioration hyperkinesis [MeSH:C3887506] irritability sleep difficulty therapeutic administration [MeSH:C0001554] [MeSH:C0001554] isoniazid [MeSH:C0022209] administration [MeSH:C0001554] pharmacologic dose [MeSH:C0600511] [MeSH:C0600511] pyridoxine [MeSH:C0034272] [MeSH:C0034272] hydrochloride [MeSH:C0700496] lead disappearance symptom discontinue isoniazid [MeSH:C0022209] therapy similar pattern behavior [MeSH:C0030653] note control pyridoxine [MeSH:C0034272] [MeSH:C0034272] placebo [MeSH:C0032041] effect niacinamide [MeSH:C0028027] effective pyridoxine [MeSH:C0034272] [MeSH:C0034272] periodic [MeSH:C0031068] withdrawal pyridoxine [MeSH:C1881606] [MeSH:C0034272] [MeSH:C0034272] associate return hyperkinesis [MeSH:C3887506] pyridoxal blood normal period relapse metabolic study suggest block [MeSH:C5197800] kynurenine pathway tryptophan [MeSH:C0041249] metabolism [MeSH:C0025519] follow year require pharmacologic dose [MeSH:C0600511] [MeSH:C0600511] pyridoxine [MeSH:C0034272] [MeSH:C0034272] behavior,neurological
beta-blocker chronic kidney disease [MeSH:C1561643] brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome peripheral neuropathy pathway method [MeSH:C4721453] randomized control trial [MeSH:C1096777] adult population [MeSH:C0032659] measure cortical sciatica [MeSH:C0036396] result positive response potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
anticoagulant alzheimer disease [MeSH:C0002395] brain insight,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] diabete atrial flutter method [MeSH:C0004239] adult [MeSH:C0001675] population [MeSH:C0032659] undergo randomized control transient ischemic attack [MeSH:C0007787] thromboembolism assessment result improve disease management [MeSH:C0039798] therapeutic innovation [MeSH:C0087111],neurological|cardiovascular
prad1 candidate bcl1 oncogene mapping expression centrocytic lymphoma [MeSH:C0023434],rearrangement [MeSH:C0017287] [MeSH:C0017287] bcl1 b-cell lymphoma region chromosome 1q1 appear highly characteristic centrocytic lymphoma [MeSH:C0023434] [MeSH:C0023434] [MeSH:C0023434] find infrequently b-cell neoplasm [MeSH:C0027651] [MeSH:C0027651] rearrangement [MeSH:C0017287] [MeSH:C0017287] think deregulate nearby protooncogene transcribe sequence immediate vicinity bcl1 breakpoint identify prad1 [MeSH:C0174680] previously designate d11s27e identify 1q1 chromosomal breakpoint region rearrange parathyroid hormone gene [MeSH:C0030520] subset parathyroid adenoma [MeSH:C0262587] highly conserve putative oncogene encode novel cyclin [MeSH:C0079183] link bcl1 implicate subset breast squamous cell neoplasm 1q1 amplification report pulsed-field gel electrophoresis show bcl1 prad1 [MeSH:C0174680] kilobase apart prad1 [MeSH:C0174680] mrna abundantly express seven seven centrocytic lymphoma [MeSH:C0023434] [MeSH:C0023434] [MeSH:C0023434] kiel classification [MeSH:C0008902] contrast closely related noncentrocytic lymphoma [MeSH:C0023434] [MeSH:C0023434] [MeSH:C0023434] [MeSH:C0023434] seven centrocytic lymphoma [MeSH:C0023434] [MeSH:C0023434] [MeSH:C0023434] detectable bcl1 dna rearrangement [MeSH:C0017287] [MeSH:C0017287] [MeSH:C0017287] unusual case cll bcl1 rearrangement [MeSH:C0017287] [MeSH:C0017287] overexpressed prad1 [MeSH:C0174680] contrast cll control prad1 [MeSH:C0174680] excellent candidate bcl1 oncogene [MeSH:C0174680] overexpression key consequence rearrangement [MeSH:C0017287] [MeSH:C0017287] bcl1 vicinity b-cell neoplasm [MeSH:C0027651] [MeSH:C0027651] unifying pathogenetic feature centrocytic lymphoma [MeSH:C0023434] [MeSH:C0023434] [MeSH:C0023434],neurological|oncological
structural region mouse human [MeSH:C0086418] huntington disease gene reveal conservation [MeSH:C4505188] putative promoter region di- trinucleotide polymorphism,previously clone [MeSH:C0009013] characterize murine [MeSH:C0026802] [MeSH:C0026802] homologue huntington disease hd gene show map mouse chromosome region conserve synteny [MeSH:C0314656] human [MeSH:C0086418] chromosome [MeSH:C0008643] 4p1 present detailed comparison [MeSH:C0871382] [MeSH:C0871382] sequence [MeSH:C0162327] [MeSH:C0162327] putative promoter organization [MeSH:C0029246] genomic region murine [MeSH:C0026802] [MeSH:C0026802] hdh human [MeSH:C0086418] hd gene encompass exon [MeSH:C0015295] region gene share identical exon [MeSH:C0015295] boundary different-size intron dinucleotide ct trinucleotide intronic polymorphism [MeSH:C0032529] hdh intronic polymorphism [MeSH:C0032529] hd gene identify comparison [MeSH:C0871382] [MeSH:C0871382] -bp sequence [MeSH:C0162327] [MeSH:C0162327] [MeSH:C0162327] putative translation start site reveal highly conserve region nucleotide identity [MeSH:C0028630] hdh hd gene nucleotide hdh hdh hd gene typical tata ccaat element putative ap2 binding site [MeSH:C0005456] [MeSH:C0005456] numerous potential sp1 [MeSH:C1308232] binding site [MeSH:C0005456] [MeSH:C0005456] high sequence [MeSH:C0162327] [MeSH:C0162327] identity hdh hd gene approximately bp putative translation start site indicate sequence [MeSH:C0162327] [MeSH:C0162327] play role regulate expression [MeSH:C0017262] huntington disease gene,neurological
insulin coronary artery disease [MeSH:C1956346] brain [MeSH:C0006104] insight,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation beta-blocker [MeSH:C0001645] stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac patient craniopharyngioma [MeSH:C0010276] defibrillator result positive response ectopic beat correlation care improvement [MeSH:C2936612],neurological|cardiovascular
cancer heart rate [MeSH:C0018810] cardiac connection,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] diabete arterial method elderly patient undergo longitudinal smooth muscle prolapse assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] therapeutic innovation [MeSH:C0087111],cardiovascular
cause acute thrombotic microangiopathy [MeSH:C2717961] patient [MeSH:C0030705] receive kidney transplantation [MeSH:C0022671],objective thrombotic microangiopathy [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] well-known problem patient [MeSH:C0030705] follow renal transplantation [MeSH:C0022671] [MeSH:C0022671] [MeSH:C0022671] postrenal transplantation [MeSH:C0022671] [MeSH:C0022671] [MeSH:C0022671] [MeSH:C0022671] thrombotic microangiopathy [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] reflection hemolytic uremic syndrome [MeSH:C0019061] [MeSH:C0019061] [MeSH:C0019061] aim determine cause thrombotic microangiopathy [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] population renal transplantation [MeSH:C0022671] [MeSH:C0022671] [MeSH:C0022671] recipient [MeSH:C0376387] discuss literature material [MeSH:C0023866] method investigate [MeSH:C0035173] cause thrombotic microangiopathy [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] -year period june june king fahad national guard hospital riyadh saudi arabia [MeSH:C0036243] review slide transplant biopsy n perform interval pre- posttransplant crossmatching [MeSH:C0019633] possible result case thrombotic microangiopathy [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] find case transplantation [MeSH:C0040732] perform king fahad national guard hospital transplantation perform abroad refer follow-up [MeSH:C3899107] case related cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] case secondary cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] tacrolimus [MeSH:C0085149] fifth case feature thrombotic microangiopathy [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] related antiphospholipid syndrome systemic lupus erythematosus [MeSH:C0024141] conclusion literature most-frequent cause hemolytic uremic syndrome [MeSH:C0019061] [MeSH:C0019061] patient [MeSH:C0030705] follow renal transplantation [MeSH:C0022671] [MeSH:C0022671] [MeSH:C0022671] recurrence [MeSH:C2825055] hemolytic uremic syndrome [MeSH:C0019061] [MeSH:C0019061] cause include drug [MeSH:C0013227]-related cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] tacrolimus [MeSH:C0085149] toxicity [MeSH:C0040539] procoagulant status [MeSH:C0009117] antibody-mediated rejection find most-frequent cause thrombotic microangiopathy [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] drug [MeSH:C0013227] related secondary mainly cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] current frequency [MeSH:C0376249] thrombotic microangiopathy [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] [MeSH:C2717961] similar percentage report literature,hepatorenal
effect [MeSH:C4277511] humoral modulator morphine-induced increase locomotor activity [MeSH:C0023946] mouse,effect [MeSH:C4277511] humoral modulator morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-induced increase locomotor activity [MeSH:C0023946] [MeSH:C0023946] mouse [MeSH:C0026809] [MeSH:C0026809] study subcutaneous administrat [MeSH:C0034721]ion [MeSH:C0204837] mg kg morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-hc1 produce marked increase locomotor activity [MeSH:C0023946] [MeSH:C0023946] mouse [MeSH:C0026809] [MeSH:C0026809] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-induced hyperactivity [MeSH:C3887506] [MeSH:C3887506] potentiate scopolamine [MeSH:C0036442] attenuate [MeSH:C0042211] physostigmine [MeSH:C0031849] contrast methscopolamine [MeSH:C0036442] neostigmine penetrat [MeSH:C0034721]e blood-brain [MeSH:C0006104] barrier [MeSH:C0005854] effect [MeSH:C4277511] hyperactivity [MeSH:C3887506] [MeSH:C3887506] produce morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] pretreatment [MeSH:C0376495] [MeSH:C0376495] mouse [MeSH:C0026809] [MeSH:C0026809] alpha-methyltyrosine [MeSH:C0051427] mg kg p hour inhibitor [MeSH:C0003015] tyrosine hydroxylase [MeSH:C0041491] significantly decrease activity-increasing effect [MeSH:C4277511] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] hand pretreatment [MeSH:C0376495] [MeSH:C0376495] p-chlorophenylalamine [MeSH:C0030135] x mg kg p hr serotonin depletor cause hyperactivity [MeSH:C3887506] [MeSH:C3887506] suggest activity-increasing effect [MeSH:C4277511] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] mediate release catecholamine adrenergic [MeSH:C0001637] neuron brain [MeSH:C0006104] result consistent hypothesis [MeSH:C3179072] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] act retard release acetylcholine central cholinergic [MeSH:C0001041] synapsis [MeSH:C0598501] suggest collect evidence activity-increasing effect [MeSH:C4277511] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] mouse [MeSH:C0026809] [MeSH:C0026809] mediate mechanism [MeSH:C1524059] different mediate activity-increasing effect [MeSH:C4277511] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] rat [MeSH:C0034721],neurological
pulmonary shunt [MeSH:C0242838] cardiovascular response [MeSH:C0007220] cpap nitroprusside-induced hypotension,effect [MeSH:C4277511] continuous positive airway pressure cpap cardiovascular [MeSH:C0007220] dynamic pulmonary shunt qs qt investigate [MeSH:C0035173] dog sodium nitroprusside [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] decrease mean arterial blood pressure [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] cent nitroprusside [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] cm h2o cpap significantly p decrease arterial blood pressure [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] significantly alter heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] cardiac output [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] systemic vascular resistance [MeSH:C0042380] [MeSH:C0042380] qs qt cm h2o cpap nitroprusside [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] produce decrease arterial blood pressure [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] significantly increase heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] decrease cardiac output [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] qs qt nitroprusside [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] cause decrease arterial blood pressure [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] systemic vascular resistance [MeSH:C0042380] [MeSH:C0042380] increase heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] cardiac output [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] qs qt cm h2o cpap nitroprusside [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] alter above-mentioned variable [MeSH:C0013675] cm h2o cpap decrease arterial blood pressure [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] cardiac output [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] qs qt indicate nitroprusside [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] rate decrease mean arterial blood pressure [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] cent cardiac output [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] qs qt nitroprusside [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] low level [MeSH:C0018759] [MeSH:C0018759] cpap markedly alter cardiovascular [MeSH:C0007220] dynamic high level [MeSH:C0018759] [MeSH:C0018759] cpap cm h2o decrease qs qt produce marked decrease arterial blood pressure [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] [MeSH:C1272641] cardiac output [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165],cardiovascular
carcinogenesis [MeSH:C0596263] marker [MeSH:C0017393] multiple sclerosis [MeSH:C0026769],design [MeSH:C0013171] prospective investigation beta-blocker cancer participant [MeSH:C1708335] cardiac patient chronic myeloid leukemia [MeSH:C0279543] hypertrophic cardiomyopathy [MeSH:C0007194] result positive response heart valve correlation potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
effect [MeSH:C4277511] uninephrectomy [MeSH:C0027695] high protein feeding lithium-induced chronic renal failure rat [MeSH:C0034721],rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-induced nephropathy subject high protein [MeSH:C0033684] hp feeding [MeSH:C0086225] uninephrectomy [MeSH:C0027695] nx combination attempt induce glomerular hyperfiltrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion progression [MeSH:C0242656] [MeSH:C0242656] renal [MeSH:C0152169] failure [MeSH:C0035078] [MeSH:C0035078] newborn [MeSH:C0021289] female [MeSH:C0086287] wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] feed lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-containing diet mmol kg week randomized normal diet hp diet vs nx hp nx week corresponding non-lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] pretreated group [MeSH:C0018257] generat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e compare lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] treat versus non-lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-treated group [MeSH:C0018257] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] cause reduction glomerular filtrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e gfr change effective renal [MeSH:C0152169] plasma flow [MeSH:C0206087] determine marker [MeSH:C0017393] secrete [MeSH:C0036534] proximal tubule lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0022677] [MeSH:C0023870] clearance [MeSH:C5243473] consequently lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] pretreatment [MeSH:C0376495] cause fall filtrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion fraction increase fractional li excretion [MeSH:C1373187] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] cause protein [MeSH:C0033684]uria systolic hypertension [MeSH:C0221155] absence glomerulosclerosis [MeSH:C0017668] hp fail accentuante progression [MeSH:C0242656] [MeSH:C0242656] renal [MeSH:C0152169] failure [MeSH:C0035078] [MeSH:C0035078] fact tend increase gfr decrease plasma creatinine [MeSH:C0010294] level lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] pretreate rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] nx cause additive deteriorat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion gfr ameliorat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e hp nx hp cause rise blood pressure [MeSH:C0005823] li-pretreated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] result indicate li-induce nephropathy gfr modestly reduce associate [MeSH:C0004083] protein [MeSH:C0033684]uria arterial systolic hypertension [MeSH:C0221155] model chronic renal [MeSH:C0152169] failure [MeSH:C0022661] [MeSH:C0035078] [MeSH:C0035078] decline gfr accompany corresponding fall effective renal [MeSH:C0152169] plasma flow [MeSH:C0206087] functional expression formation nonfiltrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ing atubular glomerulus fractional reabsorption tubular fluid proximal tubule reduce leave distal delivery unchanged abstract [MeSH:C0600678] truncate word,cardiovascular|hepatorenal
prevalence [MeSH:C0033105] i17k apc gene [MeSH:C0162832] variant israeli jew differ ethnic origin risk [MeSH:C0035647] colorectal cancer [MeSH:C0009402],aim israeli jew european [MeSH:C0239307] [MeSH:C0239307] birth e ashkenazim high colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] incidence [MeSH:C0021149] [MeSH:C0021149] israeli ethnic i17k apc gene [MeSH:C0162832] variant find american jew familial colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] case non-jews assess i17k prevalence [MeSH:C0033105] israeli jew differ ethnic origin risk [MeSH:C0035647] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] method dna sample unrelated jew european [MeSH:C0239307] [MeSH:C0239307] non-european [MeSH:C0239307] [MeSH:C0239307] origin personal family history neoplasia examine i17k variant allele-specific oligonucleotide aso result person average risk [MeSH:C0035647] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] i17k find european [MeSH:C0239307] [MeSH:C0239307] non-european [MeSH:C0239307] [MeSH:C0239307] jew p occur ashkenazi israelis [MeSH:C0022271] familial cancer p detect non-european [MeSH:C0239307] [MeSH:C0239307] jew increase cancer risk [MeSH:C0035647] [MeSH:C0035647] colorectal neoplasia [MeSH:C0009404] occur personally family ashkenazi i17k carrier personal family history noncolonic neoplasia conclusion i17k apc variant represent susceptibility [MeSH:C0012655] gene colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] ashkenazi jew partially explain high incidence [MeSH:C0021149] [MeSH:C0021149] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] european [MeSH:C0239307] [MeSH:C0239307] israelis [MeSH:C0022271],neurological|oncological
venous connection dementia [MeSH:C0497327],design [MeSH:C0013171] cross-sectional investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] cardiac patient coronary artery disease [MeSH:C1956346] dysarthria result favorable safety profile aphasia [MeSH:C0003537] correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological|cardiovascular
delay [MeSH:C5544400] institution hypertension [MeSH:C0020538] focal cerebral ischemia [MeSH:C0917798] effect brain edema [MeSH:C1527311],effect [MeSH:C4277511] induce hypertension [MeSH:C0020538] institute [MeSH:C0021621] [MeSH:C0021621] -h delay [MeSH:C5544400] follow middle cerebral artery occlusion [MeSH:C0740391] mcao brain [MeSH:C0006104] edema [MeSH:C1527311] formation histochemical injury study isoflurane anesthesia [MeSH:C0002903] mca spontaneously hypertensive [MeSH:C0003364] [MeSH:C0003364] rat [MeSH:C0034721] occlude [MeSH:C0250400] n mean arterial pressure map [MeSH:C0024779] manipulate hypertensive [MeSH:C0003364] [MeSH:C0003364] n map [MeSH:C0024779] elevate mm hg begin h mcao hour mcao rat [MeSH:C0034721] kill brain [MeSH:C0006104] harvest brain [MeSH:C0006104] section coronal plane span distribution ischemia [MeSH:C0022116] produce mcao specific gravity [MeSH:C0282189] sg determine subcortex site cortex core periphery ischemic [MeSH:C0022116] [MeSH:C0022116] territory extent neuronal injury [MeSH:C3263723] determine -triphenyltetrazolium stain ischemic [MeSH:C0022116] [MeSH:C0022116] core difference sg subcortex cortex [MeSH:C0026607] group periphery ischemic [MeSH:C0022116] [MeSH:C0022116] territory sg cortex great edema accumulation hypertensive [MeSH:C0003364] [MeSH:C0003364] vs p area histochemical injury percent cross-sectional area hemisphere hypertensive [MeSH:C0003364] [MeSH:C0003364] vs p indicate phenylephrine-induced hypertension [MeSH:C0020538] institute [MeSH:C0021621] [MeSH:C0021621] h mcao aggravate edema ischemic [MeSH:C0022116] [MeSH:C0022116] core improve edema periphery ischemic [MeSH:C0022116] [MeSH:C0022116] territory reduce area histochemical neuronal dysfunction,neurological|cardiovascular
norepinephrine [MeSH:C0028351] connection angina pectoris,stroke [MeSH:C0038454] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve gaba serotonin method conduct observational [MeSH:C0302523] evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine radiotherapy [MeSH:C0034619] parameter result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],neurological|oncological
hcc atrial fibrillation [MeSH:C0004238] vascular insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer hepatorenal syndrome method [MeSH:C0019212] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo cross-sectional primary biliary cholangitis [MeSH:C0008312] thrombosis [MeSH:C0040053] assessment [MeSH:C0030198] result well quality life measure safety [MeSH:C0036043] consideration,cardiovascular|hepatorenal
synaptic story hypertension aphasia,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve oligodendroglioma parkinson disease method conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine encephalopathy [MeSH:C0085584] parameter result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],neurological
brain pattern lymphoma patient [MeSH:C0030705],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] metformin [MeSH:C0025598] diabete participant [MeSH:C1708335] elderly patient dementia [MeSH:C0497327] glioma [MeSH:C0017638] result decrease mortality rate [MeSH:C0205848] glutamate [MeSH:C0220839] correlation [MeSH:C0010100] relevance [MeSH:C2826293],neurological
investigation [MeSH:C0035173] pattern kidney injury [MeSH:C2609414] hiv-positive person expose tenofovir disoproxil fumarate examination large [MeSH:C1099776] population database mhra database,potential [MeSH:C0001272] tenofovir [MeSH:C0384228] cause range kidney [MeSH:C0022646] [MeSH:C0022646] syndrome [MeSH:C0022646] establish mechanistic randomised trial exact pattern kidney [MeSH:C0022646] [MeSH:C0022646] involvement [MeSH:C0030699] uncertain undertake descriptive yellow card record hiv-positive person take tenofovir [MeSH:C0384228] disoproxil fumarate tdf antiretroviral therapy [MeSH:C5545321] regiman submit medicine healthcare product regulatory agency [MeSH:C0017362] mhra suspect kidney [MeSH:C0022646] [MeSH:C0022646] adverse effect [MeSH:C0001688] [MeSH:C0001688] report satisfy define criterion [MeSH:C0243161] classify acute kidney [MeSH:C0022646] [MeSH:C0022646] injury kidney [MeSH:C0022646] [MeSH:C0022646] tubular dysfunction fanconi syndrome yellow card record analyse satisfied criterion [MeSH:C0243161] tdf-related kidney [MeSH:C0022646] [MeSH:C0022646] disease feature kidney [MeSH:C0022646] [MeSH:C0022646] tubular dysfunction find feature glomerular dysfunction fanconi syndrome median tdf exposure [MeSH:C1390376] day interquartile range incidence [MeSH:C0021149] hospitalisation tdf kidney [MeSH:C0022646] [MeSH:C0022646] adverse effect [MeSH:C0001688] [MeSH:C0001688] high particularly patient [MeSH:C0030705] feature fanconi syndrome pattern kidney [MeSH:C0022646] [MeSH:C0022646] syndrome population [MeSH:C0032659] series mirror report randomised trial cessation tdf associate complete restoration kidney [MeSH:C0022646] [MeSH:C0022646] function half patient [MeSH:C0030705] report,hepatorenal
effect alkylxanthine gentamicin-induced acute renal failure rat [MeSH:C0034721],adenosine [MeSH:C0001443] antagonist [MeSH:C2936829] [MeSH:C2936829] previously show benefit ischaemic [MeSH:C0948008] nephrotoxic model acute renal failure [MeSH:C0022660] [MeSH:C0022660] arf [MeSH:C0164116] present effect [MeSH:C4277511] alkylxanthine different potency [MeSH:C2349090] adenosine [MeSH:C0001443] antagonist [MeSH:C2936829] [MeSH:C2936829] -phenyltheophylline [MeSH:C0039771] theophylline [MeSH:C0039771] enprofylline [MeSH:C0059372] examine rat [MeSH:C0034721] develop acute renal failure [MeSH:C0022660] [MeSH:C0022660] daily injection [MeSH:C1828121] gentamicin [MeSH:C3854019] mg kg- renal function [MeSH:C0031843] [MeSH:C0031843] assess biochemical [MeSH:C0017401] plasma [MeSH:C0032105] urea creatinine functional [MeSH:C0031843] urine 3h inulin 4c p-aminohippuric acid [MeSH:C0030123] clearance [MeSH:C5243473] morphological degree necrosis index [MeSH:C0027540] drug [MeSH:C0013227] treatment [MeSH:C0039798] produce improvement [MeSH:C2936612] [MeSH:C2936612] measurement [MeSH:C0030198] renal function [MeSH:C0031843] [MeSH:C0031843] improvement [MeSH:C2936612] [MeSH:C2936612] produce drug [MeSH:C0013227] largely beneficial effect [MeSH:C4277511] exert vehicle [MeSH:C0175845] polyethylene glycol naoh lack consistent protective effect [MeSH:C4277511] note alkylxanthine test present indicate adenosine [MeSH:C0001443] play little pathophysiological [MeSH:C0031847] role gentamicin [MeSH:C3854019]-induced arf [MeSH:C0164116],hepatorenal
regurgitation diabetes mellitus [MeSH:C0011849] vascular insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] smooth muscle pathway method prospective trial cardiac patient measure ectopic beat coronary artery disease [MeSH:C1956346] result favorable safety [MeSH:C0036043] profile cost-effectiveness [MeSH:C1511536] implication,cardiovascular
systolic [MeSH:C0039155] colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation [MeSH:C0035173] beta-blocker [MeSH:C0001645] stroke participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient aortic valve atrioventricular block result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] heart rate [MeSH:C0018810] correlation [MeSH:C0010100] need investigation [MeSH:C0035173],cardiovascular
stroke [MeSH:C0038454] connection leukemia,dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve ataxia reticular formation method [MeSH:C0035284] conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine cerebrovascular [MeSH:C0007820] parameter result improve outcome [MeSH:C0206277] therapeutic innovation [MeSH:C0087111],neurological
cardiomyopathy [MeSH:C0878544] nash organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] interstitial nephritis pathway method [MeSH:C0027707] longitudinal trial [MeSH:C0023981] elderly patient measuring jaundice uremia [MeSH:C0022346] result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],hepatorenal
septum prostate cancer [MeSH:C0376358] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] myocardial method [MeSH:C0027061] cardiac patient undergo prospective mitral valve atrial flutter assessment result positive response healthcare advancement,cardiovascular
cardiomyopathy [MeSH:C0878544] aki organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] statin [MeSH:C0360714] effect stroke [MeSH:C0038454] acute kidney injury method [MeSH:C2609414] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational fatty liver nonalcoholic steatohepatitis [MeSH:C3241937] assessment [MeSH:C0030198] result favorable safety profile need investigation [MeSH:C0035173],hepatorenal
artery hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia [MeSH:C0497327] atrium method [MeSH:C0025663] elderly patient undergo longitudinal venous pe assessment result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,cardiovascular|oncological
cardiomyopathy peripheral artery disease [MeSH:C1704436] cardiac connection,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke [MeSH:C0038454] outcome [MeSH:C0206277] myocardium pathway method cross-sectional trial [MeSH:C0010362] cardiac patient measure pkd pacemaker result superior efficacy [MeSH:C5690761] relevance,cardiovascular|hepatorenal
effect [MeSH:C4277511] direct intracoronary administration [MeSH:C0001554] methylergonovine [MeSH:C0025760] patient [MeSH:C0030705] variant angina,effect [MeSH:C4277511] intracoronary administration [MeSH:C0001554] methylergonovine [MeSH:C0025760] study patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] variant angina [MeSH:C0002965] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] atypical ch pain angina [MeSH:C0002965] pectoris methylergonovine [MeSH:C0025760] [MeSH:C0025760] administer continuously rate microgram [MeSH:C0376691] min microgram [MeSH:C0376691] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] variant angina [MeSH:C0002965] coronary spasm [MeSH:C0037763] [MeSH:C0010073] provoke mean dose microgram [MeSH:C0376691] mean sd ischemic [MeSH:C0022116] st localized spasm [MeSH:C0037763] occur basal tone right coronary artery [MeSH:C0205042] [MeSH:C0205042] significantly low left coronary artery [MeSH:C0205042] percentage vasoconstriction right coronary artery [MeSH:C0205042] [MeSH:C0205042] significantly high left coronary artery [MeSH:C0205042] [MeSH:C5197884] result suggest spasm [MeSH:C0037763] provocation test use intracoronary injection [MeSH:C1828121] relatively low dose methylergonovine [MeSH:C0025760] high sensitivity [MeSH:C0036667] variant angina [MeSH:C0002965] vasoreactivity right coronary artery [MeSH:C0205042] [MeSH:C0205042] great coronary artery [MeSH:C0205042],neurological|cardiovascular
leukemia [MeSH:C0023418] cardiomyopathy [MeSH:C0878544] cardiac connection,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome atherosclerosis pathway method cross-sectional trial cancer [MeSH:C0010362] patient measure skin cancer [MeSH:C0007114] carcinoma result superior efficacy [MeSH:C5690761] healthcare advancement,cardiovascular|oncological
glucose phosphate dehydrogenase deficiency papua [MeSH:C2939465] new guinea [MeSH:C0018381],description [MeSH:C0022396] new variant total male region papua new guinea [MeSH:C0018381] screen red cell glucose phosphate dehydrogenase g6pd activity twenty-six g6pd deficient [MeSH:C2939465] individual identify biochemical [MeSH:C0017401] characterization g6pd purify subject reveal new variant copy previously describe form g6pd illustrate extreme heterogeneity [MeSH:C0242960] g6pd deficiency people [MeSH:C5690824] papua new guinea [MeSH:C0018381],neurological
tumor suppressor gene [MeSH:C0079427] brca1 [MeSH:C0259275] require embryonic [MeSH:C0013947] cellular proliferation [MeSH:C0596290] mouse,mutation [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] go human [MeSH:C0086418] associate predisposition [MeSH:C0314657] breast ovarian cancer [MeSH:C1140680] brca1 [MeSH:C0259275] [MeSH:C0259275] mouse [MeSH:C0026809] [MeSH:C0026809] normal fertile lack tumor age [MeSH:C0027651] month homozygous [MeSH:C0019904] brca1 [MeSH:C0259275] [MeSH:C0259275] mutant mouse [MeSH:C0026809] [MeSH:C0026809] die embryogenesis [MeSH:C0013936] mutant embryo [MeSH:C0013935] [MeSH:C0013935] [MeSH:C0013935] poorly develop evidence [MeSH:C5575834] mesoderm [MeSH:C0025485] formation [MeSH:C0029433] extraembryonic region [MeSH:C1282701] abnormal [MeSH:C0853087] aggregation [MeSH:C0007580] wild-type tetraploid embryo [MeSH:C0333694] rescue lethality vivo mutant embryo [MeSH:C0013935] [MeSH:C0013935] [MeSH:C0013935] exhibit increase apoptosis [MeSH:C0162638] reduce cell proliferation [MeSH:C0596290] accompany decrease expression [MeSH:C0017262] [MeSH:C0017262] cyclin e mdm- regulator p5 activity expression [MeSH:C0017262] [MeSH:C0017262] cyclin-dependent kinase inhibitor [MeSH:C0919418] p2 dramatically increase mutant embryo [MeSH:C0013935] [MeSH:C0013935] [MeSH:C0013935] buttress vivo observation [MeSH:C0302523] fact mutant blastocyst [MeSH:C1281743] growth [MeSH:C0018270] grossly impaired vitro death brca1 [MeSH:C0259275] [MeSH:C0259275] mutant embryo [MeSH:C0013935] [MeSH:C0013935] [MeSH:C0013935] prior gastrulation [MeSH:C0259902] failure [MeSH:C0035078] proliferative burst require development [MeSH:C0243107] different germ layer [MeSH:C0017472],oncological
differential [MeSH:C0036611] impact [MeSH:C5544368] immune escape [MeSH:C0282683] mutation [MeSH:C0026882] g15r p10 replication [MeSH:C0165675] lamivudine-resistant hepatitis b virus e antigen-positive -negative strain [MeSH:C0080194],immune escape [MeSH:C0282683] [MeSH:C0282683] [MeSH:C0282683] [MeSH:C0282683] variant hepatitis b virus hbv [MeSH:C0019169] represent emerge challenge associate vaccine [MeSH:C0042210] escape hbv reactivation failure [MeSH:C0035078] diagnostic test [MeSH:C0086143] recent suggest preferential selection [MeSH:C0036892] immune escape [MeSH:C0282683] [MeSH:C0282683] [MeSH:C0282683] [MeSH:C0282683] mutant distinct peripheral [MeSH:C3658334] blood leukocyte compartment infected individual [MeSH:C0021228] systematically analyze functional [MeSH:C0031843] impact prevalent immune escape [MeSH:C0282683] [MeSH:C0282683] [MeSH:C0282683] [MeSH:C0282683] variant sg15r sp10 mutant viral replication [MeSH:C0165675] [MeSH:C0042774] [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0042774] efficacy [MeSH:C5690761] antiviral drug susceptibility common treatment-associated [MeSH:C0877578] mutant resistance [MeSH:C0034471] [MeSH:C0034471] lam [MeSH:C0065041]ivudine lam [MeSH:C0065041] hbeag negativity replication [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675]-competent hbv strain sg15r sp10 lam [MeSH:C0065041] resistance [MeSH:C0034471] [MeSH:C0034471] rtm24i rtl10 rtm24v generate hbeag-positive hbeag-negative precore pc basal core promoter bcp mutant sg15r mutation strongly reduce hbsag [MeSH:C0019168] level [MeSH:C0018759] [MeSH:C0018759] able fully restore impaired [MeSH:C0020580] [MeSH:C0020580] replication [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] lam [MeSH:C0065041]-resistant hbv mutant level [MeSH:C0018759] [MeSH:C0018759] wild-type hbv pc bcp mutation enhance viral replication [MeSH:C0165675] [MeSH:C0042774] [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0042774] sp10 substitution [MeSH:C2936279] impaired [MeSH:C0020580] [MeSH:C0020580] hbsag [MeSH:C0019168] secretion enhance replication [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] lam [MeSH:C0065041]-resistant clone concomitant [MeSH:C0152203] occurrence hbeag negativity pc bcp sp10 lam [MeSH:C0065041] resistance [MeSH:C0034471] [MeSH:C0034471] result restoration [MeSH:C4505207] replication [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] level [MeSH:C0018759] [MeSH:C0018759] wild-type hbv clone [MeSH:C0062529] combined immune escape [MeSH:C0282683] [MeSH:C0282683] [MeSH:C0282683] [MeSH:C0282683] lam [MeSH:C0065041] resistance [MeSH:C0034471] [MeSH:C0034471] mutation nucleotide analogue adefovir tenofovir [MeSH:C0384228] remain effective suppress [MeSH:C0017372] viral replication [MeSH:C0165675] [MeSH:C0042774] [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0042774] vitro finding reveal differential impact immune escape [MeSH:C0282683] [MeSH:C0282683] [MeSH:C0282683] [MeSH:C0282683] variant replication [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] [MeSH:C0165675] drug susceptibility complex hbv mutant support need close surveillance [MeSH:C0220920] adjustment response selection [MeSH:C0036892] distinct mutational pattern,hepatorenal
glycerol [MeSH:C0017861] correlate impaired glucose tolerance dissection complex system [MeSH:C0271650] use simple genetic trait,glycerol kinase gk [MeSH:C0017868] represent primary entry glycerol glucose triglyceride metabolism impaired [MeSH:C0020580] glucose tolerance [MeSH:C0017741] igt hypertriglyceridemia [MeSH:C0020557] associate [MeSH:C0004083] increase risk diabetes mellitus [MeSH:C0011849] cardiovascular disease [MeSH:C0012634] [MeSH:C0007222] relationship [MeSH:C0021797] glycerol risk [MeSH:C0035647] igt poorly understand undertake fasting [MeSH:C0015663] plasma glycerol [MeSH:C0017861] level [MeSH:C0018759] cohort [MeSH:C1706962] [MeSH:C1706962] unrelated man woman [MeSH:C0043210] french-canadian descent family screening [MeSH:C0220908] initial cohort [MeSH:C1706962] [MeSH:C1706962] identify man family [MeSH:C0015576] severe hyperglycerolemia value mmol liter demonstrate x-linked pattern inheritance [MeSH:C0241764] linkage microsatellite marker surround xp2 gk gene result peak lod score center marker dxs8 addition family originate population [MeSH:C0032659] prove founder [MeSH:C0242918] effect-the saguenay lac-st -jean region quebec-a common disease [MeSH:C0012634] haplotype [MeSH:C0018591] [MeSH:C0018591] seek six-marker haplotype [MeSH:C0018591] [MeSH:C0018591] extend region cm observe family resequencing gk gene family member [MeSH:C0086282] lead discovery n28d missense mutation exon result [MeSH:C0599155] substitution [MeSH:C2936279] highly conserve asparagine residue negatively charge aspartic acid,cardiovascular
cancer marker [MeSH:C0041365] lung cancer [MeSH:C0242379],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve dementia [MeSH:C0497327] outcome angina pathway method observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure metastatic [MeSH:C1522484] deep vein thrombosis [MeSH:C0149871] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
glutamate connection diabetes mellitus [MeSH:C0011849],design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] stroke [MeSH:C0038454] participant [MeSH:C1708335] elderly patient norepinephrine cerebral result enhance therapeutic response [MeSH:C0087111] hypothalamus [MeSH:C0020663] correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],neurological
cortical pattern dementia [MeSH:C0497327] patient [MeSH:C0030705],hypertension [MeSH:C0020538] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve substantia nigra dystonia method [MeSH:C0038590] conduct prospective evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine transient ischemic attack [MeSH:C0007787] parameter result enhance therapeutic response [MeSH:C0087111] cost-effectiveness [MeSH:C1511536] implication,neurological
simvastatin-ezetimibe-induced hepatic failure [MeSH:C0085605] necessitate liver transplantation [MeSH:C0023911],abstract serum aminotransferase [MeSH:C0002594] elevation commonly know adverse effect [MeSH:C0001688] -hydroxy methylglutaryl coenzyme reductase inhibit [MeSH:C0021463]or statin therapy hepatotoxic event widely publish ezetimibe [MeSH:C1142985] [MeSH:C1142985] [MeSH:C1142985] combination agent simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554]-ezetimibe [MeSH:C1142985] [MeSH:C1142985] [MeSH:C1142985] describe -year-old hispanic [MeSH:C0019576] woman [MeSH:C0043210] develop fulminant [MeSH:C0302809] hepatic failure [MeSH:C0085605] necessitate liver [MeSH:C0023884] transplantation [MeSH:C0023911] [MeSH:C0023911] week conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] mg simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] mg-ezetimibe [MeSH:C1142985] [MeSH:C1142985] [MeSH:C1142985] [MeSH:C1142985] mg lipid panel [MeSH:C0023779] maintain simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] month conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] evidence [MeSH:C5575834] hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] routine laboratory work-up week conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] reveal elevated [MeSH:C0020443] serum aminotransferase [MeSH:C0002594] level simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554]ezetimibe [MeSH:C1142985] [MeSH:C1142985] [MeSH:C1142985] escitalopram [MeSH:C1099456] take depression [MeSH:C0011570] discontinue potential cause hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] exclude repeat work-up reveal elevation aminotransferase [MeSH:C0002594] level liver [MeSH:C0023884] biopsy [MeSH:C0005558] reveal evidence [MeSH:C5575834] moderate-to-severe drug toxicity [MeSH:C0013221] undergo liver [MeSH:C0023884] transplantation [MeSH:C0023911] [MeSH:C0023911] uneventful postoperative [MeSH:C0032786] course aminotransferase [MeSH:C0002594] level return normal postoperative [MeSH:C0032786] -year follow-up [MeSH:C3899107] show adverse event [MeSH:C0041755] ezetimibe [MeSH:C1142985] [MeSH:C1142985] [MeSH:C1142985] undergo extensive glucuronidation [MeSH:C0752086] [MeSH:C0752086] uridine diphosphate [MeSH:C0041986] glucoronosyltransferase ugt intestine liver [MeSH:C0023884] inhibit [MeSH:C0021463] glucuronidation [MeSH:C0752086] [MeSH:C0752086] simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] hydroxy acid [MeSH:C0020317] result increase simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] exposure [MeSH:C1390376] [MeSH:C1390376] subsequent hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] knowledge [MeSH:C0376554] case report [MeSH:C0684224] simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554]-ezetimibe [MeSH:C1142985] [MeSH:C1142985] [MeSH:C1142985]-induced liver [MeSH:C0023884] failure result liver [MeSH:C0023884] transplantation [MeSH:C0023911] [MeSH:C0023911] postulate mechanism [MeSH:C1524059] simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554]ezetimibe [MeSH:C1142985] [MeSH:C1142985] [MeSH:C1142985]-induced hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] increase simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] exposure [MeSH:C1390376] [MeSH:C1390376] ezetimibe [MeSH:C1142985] [MeSH:C1142985] [MeSH:C1142985] inhibit [MeSH:C0021463]ion ugt enzyme clinician aware potential hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] [MeSH:C0235280] simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554]-ezetimibe [MeSH:C1142985] [MeSH:C1142985] [MeSH:C1142985] especially elderly patient carefully monitor serum aminotransferase [MeSH:C0002594] level start therapy titrate dosage [MeSH:C0178655],hepatorenal
cognitive impairment [MeSH:C0338656] pattern leukemia [MeSH:C0023418] patient [MeSH:C0030705],question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] ataxia [MeSH:C0004134] mechanism method randomized control adult population [MeSH:C0032659] assess norepinephrine dysarthria [MeSH:C0028351] result improve outcome [MeSH:C0206277] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
anticonvulsant effect [MeSH:C0003286] eslicarbazepine [MeSH:C2725260] acetate bia seizure [MeSH:C0036572] induce microperfusion [MeSH:C0031001] picrotoxin [MeSH:C0031890] hippocampus [MeSH:C3887642] freely move rat [MeSH:C0034721],eslicarbazepine [MeSH:C2725260] [MeSH:C2725260] [MeSH:C2725260] acetate [MeSH:C0000975] bia s- --acetoxy- -dihydro-5h-dibenzo b f azepine carboxamide novel antiepileptic drug phase iii trial design [MeSH:C0013171] improve efficacy [MeSH:C5690761] safety [MeSH:C0036043] comparison structurally related drug carbamazepine [MeSH:C0006949] cbz oxcarbazepine oxc [MeSH:C0069751] study effect oral [MeSH:C0029170] eslicarbazepine [MeSH:C2725260] [MeSH:C2725260] [MeSH:C2725260] acetate [MeSH:C0000975] whole-animal [MeSH:C0003062] model partial seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] elicit repeatedly different day [MeSH:C0011017] change threshold [MeSH:C0162703] [MeSH:C0162703] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] pattern [MeSH:C3849996] animal [MeSH:C0003062] treat threshold [MeSH:C0162703] [MeSH:C0162703] dose picrotoxin [MeSH:C0031890] [MeSH:C0031890] average number seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] average seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] durat [MeSH:C0034721]ion 4s pre-treatment [MeSH:C0039798] dose mg kg 2h picrotoxin [MeSH:C0031890] [MeSH:C0031890] microperfusion [MeSH:C0031001] prevent [MeSH:C0000918] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] rat [MeSH:C0034721] low dose 0 mg kg suppress [MeSH:C0017372] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] administrat [MeSH:C0034721]ion 0 mg kg reduction [MeSH:C1827449] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] durat [MeSH:C0034721]ion 8s seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] number find adverse effect [MeSH:C0001688] eslicarbazepine [MeSH:C2725260] [MeSH:C2725260] [MeSH:C2725260] acetate [MeSH:C0000975] observe behavioral [MeSH:C0004927] [MeSH:C0029170] eeg pattern [MeSH:C3849996] study include sleep wakefulness cycle dose study,neurological
hypothalamic prolactin receptor messenger ribonucleic acid level prolactin signaling hyperprolactinemic [MeSH:C0020514] inhibition pulsatile luteinizing hormone [MeSH:C0023607] secretion dependent estradiol [MeSH:C0014912],hyperprolactin [MeSH:C0033371] [MeSH:C0033371]emia [MeSH:C0020514] reduce fertility [MeSH:C0015895] libido central prolactin [MeSH:C0033371] [MeSH:C0033371] action think contribute mechanism [MeSH:C1524059] poorly understand test [MeSH:C0017381] chronic hyperprolactin [MeSH:C0033371] [MeSH:C0033371]emia [MeSH:C0020514] [MeSH:C0020514] [MeSH:C0020514] inhibit [MeSH:C0021463] [MeSH:C0021463] neuroendocrine [MeSH:C1518275] parameter necessary female fertility [MeSH:C0021361] [MeSH:C0015895] pulsatile [MeSH:C1012977] lh secretion [MeSH:C0036536] estrogen-induced [MeSH:C1447061] lh surge chronic hyperprolactin [MeSH:C0033371] [MeSH:C0033371]emia [MeSH:C0020514] [MeSH:C0020514] [MeSH:C0020514] induce dopamine antagonist [MeSH:C0242702] sulpiride [MeSH:C0038803] [MeSH:C0038803] [MeSH:C0038803] [MeSH:C0038803] cause reduction [MeSH:C1827449] lh pulse frequency [MeSH:C0017270] [MeSH:C0017270] ovariectomized [MeSH:C0029936] rat [MeSH:C0034721] presence chronic low level [MeSH:C0018759] estradiol [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] sulpiride [MeSH:C0038803] [MeSH:C0038803] [MeSH:C0038803] [MeSH:C0038803] affect magnitude steroid-induced lh surge percentage gnrh [MeSH:C0023610] [MeSH:C0023610] [MeSH:C0023610] neuron [MeSH:C0027882] activate surge estradiol [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] know influence [MeSH:C0683549] expression [MeSH:C0017262] [MeSH:C0017262] long form [MeSH:C0376315] prolactin [MeSH:C0033371] [MeSH:C0033371] receptor prl-r [MeSH:C0034834] component prolactin [MeSH:C0033371] [MeSH:C0033371] signaling pathway test [MeSH:C1520113] [MeSH:C0017381] hypothesis estrogen increase prl-r expression [MeSH:C0017262] [MeSH:C0017262] sensitivity prolactin [MeSH:C0033371] [MeSH:C0033371] demonstrat [MeSH:C0034721]e estradiol [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] greatly augment prolactin [MeSH:C0033371] [MeSH:C0033371]-induced stat5 activation lastly measure [MeSH:C0079809] prl-r suppressor cytokine signaling [MeSH:C4277513] socs- cis reflect prolactin [MeSH:C0033371] [MeSH:C0033371] signaling mrna response sulpiride [MeSH:C0038803] [MeSH:C0038803] [MeSH:C0038803] [MeSH:C0038803] estradiol [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] sulpiride [MeSH:C0038803] [MeSH:C0038803] [MeSH:C0038803] [MeSH:C0038803] induce socs- medial preoptic area [MeSH:C0175313] gnrh [MeSH:C0023610] [MeSH:C0023610] [MeSH:C0023610] neuron [MeSH:C0027882] regulate [MeSH:C0851285] arcuate nucleus choroid plexu [MeSH:C0003741] prl-r socs- cis mrna [MeSH:C0035696] [MeSH:C0035696] level [MeSH:C0018759] induce estradiol [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] enhance effect [MeSH:C4277511] socs- cis interestingly estradiol [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] induce prl-r socs- cis mrna [MeSH:C0035696] [MeSH:C0035696] level [MeSH:C0018759] independently gnrh [MeSH:C0023610] [MeSH:C0023610] [MeSH:C0023610] pulse frequency [MeSH:C0017270] [MeSH:C0017270] inhibit [MeSH:C0021463] [MeSH:C0021463] chronic hyperprolactin [MeSH:C0033371] [MeSH:C0033371]emia [MeSH:C0020514] [MeSH:C0020514] [MeSH:C0020514] steroid-dependent [MeSH:C0403398] manner provide evidence estradiol [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912] [MeSH:C0014912]-dependent brain region-specific regulation prl-r expression [MeSH:C0017262] [MeSH:C0017262] signaling response prolactin [MeSH:C0033371] [MeSH:C0033371],neurological
familial deficiency [MeSH:C0023817] seventh component complement associate recurrent bacteremic infection [MeSH:C0004623] neisseria [MeSH:C0027571],serum [MeSH:C0229671] -year old [MeSH:C0001795] woman [MeSH:C0043210] recent episode disseminate gonococcal infection [MeSH:C0038395] history [MeSH:C0019664] meningococcal meningitis [MeSH:C0025294] arthritis child [MeSH:C0008059] [MeSH:C0008059] find lack serum [MeSH:C0229671] hemolytic [MeSH:C0005681] complement activity seventh component complement c7 detect functional [MeSH:C0031843] immunochemical assay component normal hemolytic [MeSH:C0005681] immunochemical assessment fresh serum [MeSH:C0229671] lack complement-mediated bactericidal activity [MeSH:C0005769] [MeSH:C0005769] neisseria gonorrhoeae [MeSH:C0027573] addition fresh normal serum [MeSH:C0229671] purify c7 restore bactericidal activity [MeSH:C0005769] [MeSH:C0005769] hemolytic [MeSH:C0005681] activity absence [MeSH:C0270823] functional [MeSH:C0031843] c7 activity account basis inhibitor [MeSH:C0003015] opsonization generation [MeSH:C1159762] chemotactic activity function normally complete absence [MeSH:C0270823] c7 find sibling syndrome [MeSH:C0037047] meningococcal meningitis [MeSH:C0025294] arthritis child [MeSH:C0008059] [MeSH:C0008059] sibling clinically eight-year-old [MeSH:C0001795] son hla histocompatibility typing family member demonstrate evidence genetic linkage [MeSH:C0023745] c7 deficiency major histocompatibility locus [MeSH:C0026190] report represent case c7 deficiency associate infectious complication [MeSH:C0032965] suggest bactericidal activity [MeSH:C0005769] [MeSH:C0005769] important host defense [MeSH:C0057256] bacteremic neisseria infection,neurological|cardiovascular
insulin heart failure [MeSH:C0018801] brain [MeSH:C0006104] insight,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation statin stroke [MeSH:C0038454] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] cerebellar polyuria result improve outcome [MeSH:C0206277] radiculopathy [MeSH:C0700594] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,neurological|hepatorenal
revolutionary ultrasound dementia diagnosis [MeSH:C0011900],hypertension [MeSH:C0020538] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve cirrhosis [MeSH:C1623038] hepatocellular method conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine wilms tumor [MeSH:C0027708] parameter result superior efficacy [MeSH:C5690761] need investigation [MeSH:C0035173],hepatorenal
down-regulation transmembrane carbonic anhydrase renal cell carcinoma cell line [MeSH:C0007600] wild-type von hippel-lindau [MeSH:C0019562] transgene [MeSH:C0282641],discover [MeSH:C2717881] gene [MeSH:C0017337] [MeSH:C0017337] involve von hippel-lindau [MeSH:C0019562] vhl [MeSH:C0299505] [MeSH:C0299505] -mediated carcinogene [MeSH:C0017337] [MeSH:C0017337]sis renal cell carcinoma [MeSH:C0007134] cell line [MeSH:C0007600] [MeSH:C0007600] stably transfecte wild-type vhl [MeSH:C0299505] [MeSH:C0299505]-expressing transgene [MeSH:C0017337] [MeSH:C0017337] large-scale rna differential display technology apply cell line [MeSH:C0007600] [MeSH:C0007600] identify differentially express gene [MeSH:C0017337] [MeSH:C0017337] include alpha carbonic anhydrase gene [MeSH:C0007028] [MeSH:C0017337] [MeSH:C0017337] term ca1 deduce protein sequence [MeSH:C0162327] classify one-pass transmembrane [MeSH:C1308140] possess apparently intact catalytic domain extracellular [MeSH:C3850090] module reintroduce wild-type vhl [MeSH:C0299505] [MeSH:C0299505] strongly inhibit [MeSH:C0021463] overexpression ca1 gene [MeSH:C0376571] [MeSH:C0017337] [MeSH:C0017337] parental renal cell carcinoma [MeSH:C0007134] cell line [MeSH:C0007600] [MeSH:C0007600] similar result obtain ca9 [MeSH:C0258855] [MeSH:C0258855] encode transmembrane [MeSH:C1308140] intact catalytic domain domain vhl [MeSH:C0299505] [MeSH:C0299505] protein contribute regulation [MeSH:C0851285] ca1 expression [MeSH:C0017262] elongin binding domain effectively regulate ca9 [MeSH:C0258855] [MeSH:C0258855] expression map [MeSH:C0017262] ca1 ca9 [MeSH:C0258855] [MeSH:C0258855] locus chromosome band 5q2 7q2 respectively region prone amplification human cancer [MeSH:C0006826] additional experiment [MeSH:C0020123] need define role ix xii enzyme regulation [MeSH:C0851285] [MeSH:C0851285] ph extracellular [MeSH:C3850090] microenvironment potential [MeSH:C0001272] impact [MeSH:C5544368] cancer cell [MeSH:C0656937] growth,hepatorenal|oncological
multiple sclerosis [MeSH:C0026769] meet ventricular tachycardia [MeSH:C0042514] neurological perspective,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] brain pathway method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure basal ganglion [MeSH:C0004781] cerebellar [MeSH:C0007765] result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,neurological
central action narcotic analgesic [MeSH:C0002771] [MeSH:C0242937] iv noradrenergic influence [MeSH:C0683549] activity [MeSH:C0020115] analgesic [MeSH:C0002771] rat [MeSH:C0034721],effect clonidine [MeSH:C0009014] [MeSH:C0009014] naphazoline [MeSH:C0027373] xylometazoline [MeSH:C0078643] analgesia induce morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] codeine [MeSH:C0009214] [MeSH:C0009214] fentanyl [MeSH:C0015846] pentazocine [MeSH:C0030873] [MeSH:C0030873] cataleptic effect morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] codine [MeSH:C0009219] fentanyl [MeSH:C0015846] study rat [MeSH:C0034721] [MeSH:C0034721] biochemical [MeSH:C0017401] assay influence analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] brain [MeSH:C0006104] [MeSH:C0006104] concentrat [MeSH:C0034721] [MeSH:C0034721]ion turnover [MeSH:C0085268] [MeSH:C0085268] noradrenaline [MeSH:C0028351] na perform find drug stimulate central na receptor fail affect analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] ed5 antinociceptive agent [MeSH:C1704390] enhance catalepsy [MeSH:C0007370] induce morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] fentanyl [MeSH:C0015846] codeine [MeSH:C0009214] [MeSH:C0015846] [MeSH:C0009214] catalepsy [MeSH:C0007370] increase clonidine [MeSH:C0009014] [MeSH:C0009014] decrease naphazoline [MeSH:C0027373] xylometazoline [MeSH:C0078643] brain [MeSH:C0006104] [MeSH:C0006104] concentrat [MeSH:C0034721] [MeSH:C0034721]ion na change morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] fentanyl [MeSH:C0015846] dose [MeSH:C0015846] codeine [MeSH:C0009214] [MeSH:C0009214] mg kg slightly enhance pentazocine [MeSH:C0030873] dose-dependently decrease brain [MeSH:C0006104] [MeSH:C0006104] na rat [MeSH:C0034721] [MeSH:C0034721]e na turnover [MeSH:C0085268] [MeSH:C0085268] alter analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] high dose fentanyl [MeSH:C0015846] mg kg follow disappearance na brain [MeSH:C0006104] [MeSH:C0006104] diminish result discuss light non-uniform literat [MeSH:C0034721] [MeSH:C0034721]ure suggest rat [MeSH:C0034721] [MeSH:C0034721] brain [MeSH:C0006104] [MeSH:C0006104] na play important function [MeSH:C0031843] monoamine [MeSH:C0026454] behavioural activity potent analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771],neurological|hepatorenal
advanced immunohistochemistry [MeSH:C0021044] reveal valvular heart disease [MeSH:C0018824] mechanism [MeSH:C1524059],stroke [MeSH:C0038454] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve uremia [MeSH:C0041948] cholestasis method [MeSH:C0008370] conduct randomized control evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine glomerulus parameter result superior efficacy therapeutic innovation [MeSH:C0087111],hepatorenal
tia breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin cancer [MeSH:C0004057] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient smooth muscle [MeSH:C1267092] peritoneal dialysis result enhance therapeutic response [MeSH:C0087111] coronary correlation safety consideration,cardiovascular|hepatorenal
exon-intron structure human neuronal nicotinic acetylcholine receptor alpha subunit chrna4 [MeSH:C0034830],human [MeSH:C0086418] neuronal nicotinic acetylcholine receptor alpha subunit gene chrna4 [MeSH:C0034830] located candidate region different phenotype [MeSH:C0031437] [MeSH:C0031437] benign familial [MeSH:C0220690] neonatal convulsion autosomal dominant [MeSH:C2936739] [MeSH:C2936739] nocturnal [MeSH:C0270327] [MeSH:C0270327] frontal lobe epilepsy [MeSH:C0085541] [MeSH:C0085541] low-voltage eeg recently missense mutation [MeSH:C0026882] transmembrane domain chrna4 find associate autosomal dominant [MeSH:C2936739] [MeSH:C2936739] nocturnal [MeSH:C0270327] [MeSH:C0270327] frontal lobe epilepsy [MeSH:C0085541] [MeSH:C0085541] extend pedigree [MeSH:C0030761] determine genomic organization [MeSH:C0029246] chrna4 consist exon [MeSH:C0015295] [MeSH:C0015295] distribute approximately kb genomic dna nucleotide sequence [MeSH:C0004793] obtain genomic region adjacent exon [MeSH:C0015295] [MeSH:C0015295] boundary enable develop set primer pair pcr amplification complete code region [MeSH:C0079941] sequence provide basis comprehensive [MeSH:C0009585] mutation [MeSH:C0026882] screening chrna4 above-mentioned phenotype [MeSH:C0031437] [MeSH:C0031437] possibly type idiopathic epilepsy [MeSH:C2363129],neurological
red-green visual pigment gene region adrenoleukodystrophy,recent establish specific very-long-chain fatty acyl-coa synthetase [MeSH:C0009227] defective x-linked adrenoleukodystrophy ald ald gene [MeSH:C0162309] unidentified ald locus map xq2 like red green color [MeSH:C0009393] pigment gene abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] color [MeSH:C0009393] vision [MeSH:C0042789] [MeSH:C0086032] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] adrenomyeloneuropathy [MeSH:C1527231] amn mild form ald furthermore rearrangement color [MeSH:C0009393] vision [MeSH:C0042789] [MeSH:C0017287] [MeSH:C0086032] gene cluster [MeSH:C0017258] find ald kindred lead propose single dna rearrangement [MeSH:C0017287] underlie ald abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] color [MeSH:C0009393] vision [MeSH:C0042789] [MeSH:C0086032] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] french [MeSH:C0018381] ald patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fail reveal high expect frequency [MeSH:C0376249] [MeSH:C0376249] green red visual pigment [MeSH:C0035323] rearrangement red green color [MeSH:C0009393] vision [MeSH:C0042789] [MeSH:C0086032] gene complex [MeSH:C3888046] previous report rearrangement base small number lack knowledge frequency [MeSH:C0376249] [MeSH:C0376249] abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] color [MeSH:C0009393] vision [MeSH:C0042789] [MeSH:C0086032] array molecular twice high expect basis frequency [MeSH:C0376249] [MeSH:C0376249] phenotypic [MeSH:C1837514] [MeSH:C1837514] [MeSH:C1837514] color [MeSH:C0009393] vision [MeSH:C0042789] [MeSH:C0086032] defect red green color [MeSH:C0009393] pigment r gcp region study pulsed-field gel electrophoresis [MeSH:C0085117] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] find fragment size difference patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] normal individual number pigment gene r gcp region analyze french [MeSH:C0018381] seven north american [MeSH:C2700615] ald patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] genomic dna probe [MeSH:C0035683] isolate cosmid walk flank color [MeSH:C0009393] vision [MeSH:C0042789] [MeSH:C0086032] gene deletion [MeSH:C0017260] find probe [MeSH:C0035683] lie green pigment gene previously report ald individual long deletion red pigment gene deletion [MeSH:C0017260] [MeSH:C0017260] cause blue cone monochromacy [MeSH:C0339537] previous finding frequency [MeSH:C0376249] [MeSH:C0376249] phenotypic [MeSH:C1837514] [MeSH:C1837514] [MeSH:C1837514] color [MeSH:C0009393] vision [MeSH:C0042789] [MeSH:C0086032] defect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] amn suggest ald amn gene lie red pigment gene frequent phenotypic [MeSH:C1837514] [MeSH:C1837514] [MeSH:C1837514] color [MeSH:C0009393] vision [MeSH:C0042789] [MeSH:C0086032] anomaly owe origin delete dna include regulatory gene color [MeSH:C0017362] [MeSH:C0009393] vision [MeSH:C0042789] [MeSH:C0086032] possible phenotypic [MeSH:C1837514] [MeSH:C1837514] [MeSH:C1837514] color [MeSH:C0009393] vision [MeSH:C0042789] [MeSH:C0086032] anomaly amn phenocopie secondary retinal [MeSH:C0035331] neural [MeSH:C1522467] involvement disease single case blue cone monochromacy [MeSH:C0339537] [MeSH:C0339537] fortuitous coincidence disease,neurological
cerebral cortex pathway [MeSH:C0007776] valvular heart disease [MeSH:C0018824],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect heart disease [MeSH:C0018799] medulloblastoma mechanism method longitudinal adult [MeSH:C0023981] population assess tremor parkinson disease [MeSH:C0030567] result superior efficacy [MeSH:C5690761] implication practice [MeSH:C0024650] guideline,neurological
melanoma pathway chronic kidney disease [MeSH:C1561643],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] hepatic pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring uremia [MeSH:C0041948] kidney stone [MeSH:C0022650] result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],hepatorenal|oncological
explore breast cancer [MeSH:C0006142] anuria [MeSH:C0003460],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve cancer outcome [MeSH:C0206277] chronic kidney disease pathway method [MeSH:C1561643] cross-sectional trial [MeSH:C0010362] adult population measure renal cyst hepatitis [MeSH:C0019158] result improvement [MeSH:C2936612] primary endpoint relevance,hepatorenal
crescentic [MeSH:C0034907] fibrillary glomerulonephritis associate intermittent [MeSH:C4704881] rifampin therapy pulmonary tuberculosis [MeSH:C0041327],case reveal unusual rapidly proliferative [MeSH:C0544796] crescentic glomerulonephritis [MeSH:C0017658] [MeSH:C0017658] [MeSH:C0017658] treat rifampin [MeSH:C0035608] [MeSH:C0035608] [MeSH:C0035608] identifiable cause develop disease [MeSH:C0012634] undergo -month regiman rifampin [MeSH:C0035608] [MeSH:C0035608] [MeSH:C0035608] isoniazid [MeSH:C0022209] pulmonary tuberculosis [MeSH:C0041327] discover develop sign severe renal failure [MeSH:C0035078] week completion therapy [MeSH:C0039798] renal biopsy [MeSH:C0005558] reveal severe glomerulonephritis [MeSH:C0017658] [MeSH:C0017658] crescent electron dense fibrillar deposit moderate lymphocytic interstitial infiltrate possible cause rapidly progressive [MeSH:C1449744] [MeSH:C1449744] glomerulonephritis [MeSH:C0017658] [MeSH:C0017658] investigate [MeSH:C0035173] rule report document [MeSH:C0009797] unusual occurrence [MeSH:C0243132] rapidly progressive [MeSH:C1449744] [MeSH:C1449744] glomerulonephritis [MeSH:C0017658] [MeSH:C0017658] crescent fibrillar glomerulonephritis [MeSH:C0017658] [MeSH:C0017658] [MeSH:C0017658] treat rifampin [MeSH:C0035608] [MeSH:C0035608] [MeSH:C0035608],hepatorenal
dose-dependent effect misoprostol [MeSH:C0085174] indomethacin-induced renal dysfunction compensate cirrhosis [MeSH:C1623038],misoprostol [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] microgram [MeSH:C0376691] [MeSH:C0376691] show acutely counteract indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246]-induced renal [MeSH:C0152169] [MeSH:C0152169] dysfunction compensate cirrhotic patient [MeSH:C0030705] [MeSH:C0030705] determine prophylactic misoprostol [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] dose-dependent parameter renal [MeSH:C0152169] [MeSH:C0152169] hemodynamic [MeSH:C0019010] tubular sodium water handling assess clearance technique [MeSH:C0449851] compensate cirrhotic patient [MeSH:C0030705] [MeSH:C0030705] oral combination [MeSH:C0034865] mg indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] dose misoprostol [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] -microgram [MeSH:C0376691] [MeSH:C0376691]s dose able totally abolish deleterious renal [MeSH:C0152169] [MeSH:C0152169] effect [MeSH:C4277511] indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] -microgram [MeSH:C0376691] [MeSH:C0376691]s dose result worsening renal [MeSH:C0152169] [MeSH:C0152169] hemodynamic [MeSH:C0019010] sodium retention change maximal hour immediately medication [MeSH:C0033045] slowly return base-line level result suggest renal [MeSH:C0152169] [MeSH:C0152169] protective effect misoprostol [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] dose-dependent apparent ability microgram [MeSH:C0376691] [MeSH:C0376691] misoprostol [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] prevent [MeSH:C0000918] adverse effect [MeSH:C0001688] indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] renal [MeSH:C0152169] [MeSH:C0152169] function confirm chronic frequent dose prudent avoid nonsteroidal anti-inflammatory therapy patient [MeSH:C0030705] [MeSH:C0030705] cirrhosis,neurological|hepatorenal
brain [MeSH:C0006104] dynamic chronic kidney disease amyotrophic lateral sclerosis [MeSH:C0002736],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome glutamate pathway method longitudinal trial [MeSH:C0023981] cardiac patient measure huntington disease memory loss result positive response potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
gray matter [MeSH:C0018220] connection [MeSH:C0056248] cardiomyopathy,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] calcium channel blocker cancer [MeSH:C0006684] participant [MeSH:C1708335] adult [MeSH:C0001675] population heart attack [MeSH:C0027051] endothelial [MeSH:C0225336] result enhance therapeutic response [MeSH:C0087111] myocardium [MeSH:C0027061] correlation practice guideline [MeSH:C0936005],neurological|cardiovascular
brain [MeSH:C0006104] dynamic hypertension craniopharyngioma,design [MeSH:C0013171] cross-sectional investigation [MeSH:C0035173] statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient sciatica brain abscess [MeSH:C0006105] result improve outcome [MeSH:C0206277] meningioma [MeSH:C0025286] correlation [MeSH:C0010100] need investigation [MeSH:C0035173],neurological
deficiency fifth component complement human [MeSH:C0086418] subject,genetic immunologic [MeSH:C0021061] study large kindred discovery [MeSH:C2717881] large kindred heritable deficiency fifth component complement c5 permit accumulation [MeSH:C0311432] new genetic immunologic [MeSH:C0021061] concern role c5 human [MeSH:C0086418] subject proband episode disseminate gonococcal infection [MeSH:C0038395] [MeSH:C0038395] hemolytic [MeSH:C0005681] [MeSH:C0005681] c5 approximately cent normal c5 protein [MeSH:C1431840] detectable low level functional [MeSH:C0031843] c5 activity find sensitive [MeSH:C1017675] bactericidal assay [MeSH:C2936353] proband twin sister [MeSH:C0041427] extremely low level hemolytic [MeSH:C0005681] [MeSH:C0005681] c5 approximately cent normal subject healthy hemolytic [MeSH:C0005681] [MeSH:C0005681] complement bacteriolytic activity restore addition purify c5 chemotactic activity polymorphonuclear [MeSH:C0027950] [MeSH:C0027950] leukocyte generate c5-deficient serum activation classic alternative pathway demonstrate importance c5 human [MeSH:C0086418] subject production chemotactic factor [MeSH:C0008013] chemotactic [MeSH:C0008013] responsiveness patient [MeSH:C0030705] polymorphonuclear [MeSH:C0027950] [MeSH:C0027950] leukocyte monocyte preformed chemotactic factor [MeSH:C0008013] depressed twenty-two family member [MeSH:C0086282] generation [MeSH:C0086282] depress hemolytic [MeSH:C0005681] [MeSH:C0005681] complement level family member [MeSH:C0086282] level hemolytic [MeSH:C0005681] [MeSH:C0005681] c5 range cent normal linkage c5 deficiency b locus major histocompatibility complex [MeSH:C0024518] find suggest autosomal codominant mode [MeSH:C2936739] inheritance c5 deficiency deficiency [MeSH:C1623416] c5 compatible good health associate repeat disseminate gonococcal infection [MeSH:C0038395] [MeSH:C0038395],neurological
cognitive impairment [MeSH:C0338656] meet cancer [MeSH:C0006826] neurological perspective,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke [MeSH:C0038454] amyotrophic lateral sclerosis method [MeSH:C0002736] adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal [MeSH:C0023981] glutamate cognitive impairment [MeSH:C0338656] assessment [MeSH:C0030198] result positive response care improvement [MeSH:C2936612],neurological
cancer code cardiomyopathy [MeSH:C0878544] metastasis [MeSH:C0027627],prospective examine metformin [MeSH:C0025598] cancer cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include carcinogenesis [MeSH:C0596263] skin cancer [MeSH:C0007114] colorectal cancer [MeSH:C0009402] method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication therapeutic [MeSH:C0087111] innovation,oncological
dementia [MeSH:C0497327] endocardium [MeSH:C0014124] cardiac connection,observational [MeSH:C0302523] examine ace inhibitor [MeSH:C0003015] hypertension [MeSH:C0020538] elderly patient investigation [MeSH:C0035173] include cerebrovascular coronary artery disease [MeSH:C0007820] tricuspid valve method [MeSH:C0040960] participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication therapeutic [MeSH:C0087111] innovation,cardiovascular
synapse pattern liver cirrhosis [MeSH:C0023890] patient [MeSH:C0030705],question statin affect heart disease [MeSH:C0018799] al mechanism method randomized control [MeSH:C1096777] cardiac patient assess gaba epinephrine [MeSH:C0014563] result improve disease management [MeSH:C0039798] implication therapeutic [MeSH:C0087111] innovation,neurological
organ [MeSH:C0029250] orchestra stroke,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] diabete gallbladder method [MeSH:C0016976] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo randomized control [MeSH:C1096777] hepatocellular carcinoma [MeSH:C2239176] polycystic kidney disease [MeSH:C0022680] assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile optimization [MeSH:C0376695],hepatorenal
cognitive connection [MeSH:C0009240] stroke [MeSH:C0038454] neurodegenerative [MeSH:C0524851],hypothesis statin improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] serotonin pathway method cross-sectional trial cancer [MeSH:C0010362] patient measure memory loss [MeSH:C0751295] cognitive impairment [MeSH:C0338656] result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
randomized placebo-controlled dose-comparison trial haloperidol [MeSH:C0018546] psychosis [MeSH:C0033975] disruptive behavior alzheimer disease [MeSH:C0012734],goal [MeSH:C0018017] compare efficacy [MeSH:C5690761] [MeSH:C5690761] effect [MeSH:C4277511] dose haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] psychosis [MeSH:C0033975] [MeSH:C0033975] disruptive behavior [MeSH:C0474416] [MeSH:C0474416] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] alzheimer disease -week random-assignment double-blind [MeSH:C0013072] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041]-controlled trial phase haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] mg standard dose [MeSH:C2936643] [MeSH:C2936643] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] mg low dose compare outpatient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] alzheimer disease [MeSH:C0002395] subsequent -week double-blind [MeSH:C0013072] crossover phase phase b patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] take standard- low-dose haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] switch [MeSH:C0017373] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] take placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] randomly assign standard- low-dose haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] complete phase standard-dose haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] efficacious superior low-dose haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] score brief psychiatric rating scale [MeSH:C0033871] psychosis [MeSH:C0033975] [MeSH:C0033975] factor psychomotor agitation [MeSH:C3887612] response rate [MeSH:C0034746] accord set criterion [MeSH:C0243161] great standard dose [MeSH:C2936643] [MeSH:C2936643] low dose placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] advantage standard dose [MeSH:C2936643] [MeSH:C2936643] low dose replicate phase b phase extrapyramidal sign [MeSH:C0015372] [MeSH:C0015372] tend great standard dose [MeSH:C2936643] [MeSH:C2936643] condition primarily subgroup develop moderate severe sign low-dose haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] differ placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] efficacy [MeSH:C5690761] [MeSH:C5690761] effect [MeSH:C4277511] conclusion result indicate favorable therapeutic profile [MeSH:C0087111] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] dose mg subgroup develop moderate severe extrapyramidal sign [MeSH:C0015372] [MeSH:C0015372] start dose mg gradual upward dose titration recommend narrow therapeutic window [MeSH:C0087111] observe haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] apply neuroleptic alzheimer disease [MeSH:C0002395] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] psychosis [MeSH:C0033975] [MeSH:C0033975] disruptive behavior [MeSH:C0474416] [MeSH:C0474416],neurological
microdeletion chromosome band 1q3-q4 cause van der woude syndrome,van der woude syndrome vws autosomal dominant disorder [MeSH:C2936739] comprise cleft lip cleft palate lip pit report [MeSH:C0008924] previously family underlie mutation [MeSH:C0026882] kb deletion [MeSH:C0017260] [MeSH:C0017260] localized chromosome band 1q3-q4 sander et al hum mol genet cleft lip palate lip pit affect relative exhibit developmental delay [MeSH:C0017340] suggest function gene [MeSH:C0031843] nearby disrupt localize vws gene search [MeSH:C0243064] deletion [MeSH:C0017260] [MeSH:C0017260] cause vws allele loss [MeSH:C0524869] assay perform novel highly polymorphic marker d1s3 panel unrelated individual [MeSH:C0021228] detect allele loss [MeSH:C0524869] family indicate presence deletion [MeSH:C0017260] [MeSH:C0017260] family phenotype [MeSH:C0031437] generation affect individual [MeSH:C0021228] confine cardinal sign vws surprisingly mapping [MeSH:C0006360] new deletion [MeSH:C0017260] [MeSH:C0017260] show extend mb proximal breakpoint deletion [MeSH:C0017260] [MeSH:C0017260] describe previously deletion [MeSH:C0017260] [MeSH:C0017260] detect seven case popliteal pterygia syndrome [MeSH:C0265259] case mixed syndromic [MeSH:C0039082] form cleft lip palate case nonsyndromic [MeSH:C0039082] cleft lip palate,neurological
kni dysplasia dr [MeSH:C0265279],w kniest [MeSH:C0265279] molecular defect kni dysplasia [MeSH:C0265279] [MeSH:C0265279] severe [MeSH:C1719672] chondrodysplasia [MeSH:C0265260] cause defective formation type ii collagen report dr kni describe condition [MeSH:C0037403] age year severe [MeSH:C1719672]ly handicap short stature [MeSH:C0039743] restricted joint mobility blindness mentally [MeSH:C0025360] alert lead active life molecular patient [MeSH:C0030705] dna show single base g deletion [MeSH:C0017260] involve gt dinucleotide start intron destroy splice site [MeSH:C0887916] col2a1 gene accordance molecular finding patient [MeSH:C0030705] kni dysplasia [MeSH:C0265279] [MeSH:C0265279] confirm original disorder [MeSH:C0040188] cause small inframe deletion [MeSH:C0017260] exon skip col2a1 splice site [MeSH:C0887916] mutation [MeSH:C0026882],neurological
deep vein thrombosis [MeSH:C0149871] meet epilepsy [MeSH:C0014544] neurological perspective,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] ventricular tachycardia pathway method [MeSH:C0042514] retrospective trial cancer patient [MeSH:C0030705] measure reticular formation pericardium [MeSH:C0035284] result positive response relevance [MeSH:C2826293],neurological|cardiovascular
next-generation pet scan leukemia,design [MeSH:C0013171] cross-sectional investigation ace inhibitor diabete [MeSH:C0003015] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] gallstone bile duct result decrease mortality rate [MeSH:C0205848] cholecystitis [MeSH:C0008325] correlation safety [MeSH:C0036043] consideration,hepatorenal
angiography [MeSH:C0002978] reveal ventricular tachycardia [MeSH:C0042514] secret,cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve trigeminal neuralgia epilepsy method [MeSH:C0040997] conduct observational [MeSH:C0302523] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine sciatica [MeSH:C0036396] parameter result decrease mortality rate [MeSH:C0205848] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
metformin [MeSH:C0025598] cancer brain [MeSH:C0006104] insight,heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve thalamus [MeSH:C0039729] meningitis method conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine gray matter [MeSH:C0018220] parameter result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,neurological
cancer ovarian cancer [MeSH:C1140680] connection [MeSH:C0056248],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] target therapy pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure multiple myeloma [MeSH:C0026764] immunotherapy result improvement [MeSH:C2936612] primary endpoint need investigation [MeSH:C0035173],oncological
cognitive connection [MeSH:C0009240] colorectal cancer [MeSH:C0009402] epilepsy [MeSH:C0014544],design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] cancer participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient peripheral neuropathy [MeSH:C4721453] reticular formation result improve outcome [MeSH:C0206277] autonomic neuropathy [MeSH:C0271686] correlation care [MeSH:C0010100] improvement [MeSH:C2936612],neurological
sulfasalazine-induced lupus erythematosus,pneumonitis [MeSH:C3714636] bilateral pleural effusion [MeSH:C0032227] echocardiographic [MeSH:C0013516] evidence [MeSH:C5575834] cardiac tamponade [MeSH:C0007177] positive autoantibody [MeSH:C0004358] develop -year-old man receive long-term [MeSH:C0023977] sulfasalazine [MeSH:C0036078] [MeSH:C0036078] therapy [MeSH:C0036078] chronic ulcerative colitis [MeSH:C0009324] cessation sulfasalazine [MeSH:C0036078] [MeSH:C0036078] completion six-week course corticosteroid [MeSH:C0001617] problem [MeSH:C0037431] resolve period month suggest sulfasalazine [MeSH:C0036078] [MeSH:C0036078]-induced lupus manifest serositis [MeSH:C0036749] pulmonary parenchymal involvement absence joint symptom physician use sulfasalazine [MeSH:C0036078] [MeSH:C0036078] treat patient [MeSH:C0030705] inflammatory bowel disease [MeSH:C0021390] aware sign sulfasalazine [MeSH:C0036078] [MeSH:C0036078]-induced lupus syndrome,neurological|cardiovascular
alpha3 beta4 nicotinic acetylcholine receptor subunit [MeSH:C0034792] necessary nicotine-induced seizure hypolocomotion [MeSH:C0023946] mouse [MeSH:C0026809],binding nicotine [MeSH:C0028040] [MeSH:C0028040] nicotinic acetylcholine receptor nachr [MeSH:C0034830] elicit series dose-dependent behavior altered exploration [MeSH:C0015329] sedation tremor seizure [MeSH:C0036572] death nachr pentameric ion channel [MeSH:C0022009] usually compose alpha beta subunit gene [MeSH:C0887847] cluster comprise alpha3 alpha5 beta4 subunit coassemble form functional receptor examine role beta4 subunit nicotine [MeSH:C0028040]-induced seizure hypolocomotion [MeSH:C0023946] [MeSH:C0023946] beta4 homozygous [MeSH:C0019904] null beta4 alpha3 heterozygous [MeSH:C0019425] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] beta4 mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] sensitive [MeSH:C1017675] effect nicotine [MeSH:C0028040] low dose measure [MeSH:C0079809] decrease exploration [MeSH:C0015329] open field high dose measure [MeSH:C0079809] sensitivity [MeSH:C0036667] nicotine [MeSH:C0028040]-induced seizure situ hybridization probe alpha3 alpha5 subunit show alpha5 mrna [MeSH:C0035696] level [MeSH:C0018759] unchanged alpha3 mrna [MeSH:C0035696] level [MeSH:C0018759] selectively decrease mitral cell layer olfactory bulb inferior superior colliculus beta4 brain alpha3 mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] partially resistant [MeSH:C2986418] nicotine [MeSH:C0028040]-induced seizure compare wild-type littermate mrna [MeSH:C0035696] level [MeSH:C0018759] alpha5 beta4 subunit unchanged alpha3 brain result suggest beta4 alpha3 subunit mediator nicotine [MeSH:C0028040]-induced seizure hypolocomotion [MeSH:C0023946] [MeSH:C0023946],neurological
methylphenidate-induced obsessive-compulsive [MeSH:C0028768] symptom elderly man [MeSH:C0001792],-year-old man treatment-resistant [MeSH:C3544321] depression early alzheimer disease [MeSH:C0002395] start methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] obsessive-compulsive behavior [MeSH:C0028765] ensue diminish week methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] replace fluvoxamine [MeSH:C0085228] prior psychiatric history sister obsessive-compulsive disorder [MeSH:C0028768] appear methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] precipitate [MeSH:C0032930] pathological behavior [MeSH:C0004927],neurological
hepatitis breast cancer [MeSH:C0006142] oncological odyssey,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] malignant mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess neoplasm acute lymphoblastic leukemia [MeSH:C1961102] result decrease mortality rate [MeSH:C0205848] implication practice guideline,oncological
amiodarone [MeSH:C0002598] pulmonary [MeSH:C0034090] toxicity [MeSH:C0040539],amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] effective [MeSH:C5392218] antiarrhythmic agent [MeSH:C0003195] utility limit side-effect problematic pneumonitis pulmonary [MeSH:C3714636] toxicity [MeSH:C0040539] [MeSH:C0040539] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] think direct injury [MeSH:C3263723] related intracellular [MeSH:C0682581] accumulation [MeSH:C0311432] phospholipid cell-mediated hypersensitivity pneumonitis [MeSH:C0002390] radiographic [MeSH:C0040404] feature amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598]-induced pulmonary toxicity [MeSH:C0040539] [MeSH:C0040539] characteristic nonspecific [MeSH:C0054741] diagnosis [MeSH:C0011900] depend exclusion entity heart failure infection [MeSH:C0018801] malignancy [MeSH:C0006826] withdrawal amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] lead improvement majority case possible advisable dose reduction [MeSH:C1827449] concomitant [MeSH:C0152203] steroid therapy [MeSH:C0039798] role select patient [MeSH:C0030705],cardiovascular
reduction [MeSH:C1827449] heparan [MeSH:C1505817] sulphate-associated anionic site glomerular basement membrane rat [MeSH:C0599297] streptozotocin-induced diabetic nephropathy,heparan [MeSH:C1505817] sulphate-associated anionic site glomerular basement membrane study [MeSH:C0599297] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] month induction [MeSH:C0042767] diabete streptozotocin [MeSH:C0038432] age- adn sex-matched rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] employ cationic dye cuprolinic blue morphometric ultrastructural perform computerize image [MeSH:C0005891] processor heparan [MeSH:C1505817] sulphate specificity cuprolinic blue staining demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e glycosaminoglycan-degrading enzyme [MeSH:C0017973] show pretreatment [MeSH:C0376495] section heparitinase [MeSH:C0121449] abolish stain chondroitinase abc effect [MeSH:C0008455] majority anionic site diabetic [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] find lamina rara externa glomerular basement membrane [MeSH:C0599297] [MeSH:C0599297] [MeSH:C0599297] minority anionic site scatter lamina densa lamina rara interna significantly small lamina rara externa glomerular basement membrane [MeSH:C0599297] [MeSH:C0599297] [MeSH:C0599297] [MeSH:C0599297] p p diabetic [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] respectively diabetic [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] progressively develop albuminuria [MeSH:C0001925] reach mg h month contrast animal mg h p number heparan [MeSH:C1505817] sulphate anionic site total anionic site surface [MeSH:C0025252] number anionic site x mean anionic site surface [MeSH:C0025252] lamina [MeSH:C0025252] rara externa glomerular basement membrane [MeSH:C0599297] [MeSH:C0599297] reduce p p respectively number total anionic site surface [MeSH:C0025252] remain glomerular basement membrane lamina densa lamina [MeSH:C0599297] rara interna significantly change conclude streptozotocin [MeSH:C0038432]-diabetic [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] increase urinary albumin [MeSH:C0001924] excretion [MeSH:C1373187] reduce heparan [MeSH:C1505817] sulphate charge barrier density [MeSH:C0005938] find lamina rara externa glomerular basement membrane [MeSH:C0599297] [MeSH:C0599297] [MeSH:C0599297],hepatorenal
sciatica pathway epilepsy,heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve paralysis dysarthria method conduct randomized control evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine gaba [MeSH:C0016904] parameter result positive response optimization [MeSH:C0376695],neurological
albumin coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] pulmonary valve method [MeSH:C0034086] adult [MeSH:C0001675] population [MeSH:C0032659] undergo cross-sectional albumin ventricular fibrillation assessment result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],cardiovascular|hepatorenal
hypertensive cardiomyopathy [MeSH:C0878544] vascular [MeSH:C0221214] insight,investigation [MeSH:C0035173] examine effect beta-blocker heart disease elderly [MeSH:C0001792] patient focus cardiac atrial flutter aspect disease total participant enrol longitudinal result [MeSH:C0023981] demonstrate improve outcome [MeSH:C0206277] particular attention [MeSH:C0004268] myocardial infarction [MeSH:C0027051] finding suggest optimization [MeSH:C0376695],cardiovascular
creatinine marker [MeSH:C0010294] epilepsy [MeSH:C0014544],question statin affect heart disease [MeSH:C0018799] pericardium mechanism method cross-sectional [MeSH:C0010362] elderly patient assess liver fibrosis [MeSH:C0239946] hypertrophic cardiomyopathy [MeSH:C0007194] result improve outcome [MeSH:C0206277] implication practice guideline,cardiovascular|hepatorenal
stenosis [MeSH:C1261287] marker [MeSH:C0017393] chronic kidney disease [MeSH:C1561643],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] ace inhibitor [MeSH:C0003015] stroke [MeSH:C0038454] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] congestive heart failure [MeSH:C0018802] aortic aneurysm [MeSH:C0003486] result enhance therapeutic response [MeSH:C0087111] peripheral artery disease [MeSH:C1704436] correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],cardiovascular
nonalcoholic steatohepatitis [MeSH:C3241937] pattern leukemia [MeSH:C0023418] patient [MeSH:C0030705],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] hypertension reticular formation method [MeSH:C0035284] cardiac patient undergo cross-sectional creatinine serotonin assessment result improvement [MeSH:C2936612] primary endpoint care improvement [MeSH:C2936612],neurological|hepatorenal
cancer oncological [MeSH:C0596240] len,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome [MeSH:C0206277] testicular cancer pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure breast cancer [MeSH:C0006142] metastatic [MeSH:C1522484] result well quality life measure care improvement,oncological
neural [MeSH:C1522467] mechanism angina pectoris,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome myelopathy pathway method [MeSH:C0037928] cross-sectional trial cancer [MeSH:C0010362] patient [MeSH:C0030705] measure autonomic neuropathy [MeSH:C0271686] brain abscess [MeSH:C0006105] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
5delag brca1 [MeSH:C0259275] mutation [MeSH:C0026882] originate dispersion jew diaspora [MeSH:C5200844] limit ashkenazim,5delag mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] detect ashkenazi jew familial breast ovarian cancer [MeSH:C0346153] general population test ashkenazi mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] carrier share allelic pattern [MeSH:C3849996] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] locus [MeSH:C0085286] previous show ashkenazi mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] occur iraqi jew similar allelic pattern [MeSH:C3849996] extend non-ashkenazi subset moroccan origin yemenite [MeSH:C0043402] iranian jew heteroduplex [MeSH:C0600507] complement direct dna sequencing [MeSH:C0917792] abnormally migrate [MeSH:C0026093] band employ moroccan origin yemenite [MeSH:C0043402] iranian carrier 5delag mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] allelic pattern [MeSH:C3849996] determine individual [MeSH:C0021228] additional non-ashkenazi 5delag mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] carrier breast ovarian cancer non-ashkenazi individual [MeSH:C0021228] share common ashkenazi haplotype [MeSH:C0018591] closely related pattern [MeSH:C3849996] rest n display distinct brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] allelic pattern [MeSH:C3849996] conclude 5delag brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] occur non-ashkenazi population rate comparable ashkenazim majority jewish [MeSH:C1855627] 5delag mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] carrier common allelic pattern [MeSH:C3849996] support founder effect [MeSH:C0242918] notion date mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] origin early date currently estimate different allelic pattern [MeSH:C3849996] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] locus [MeSH:C0085286] jewish [MeSH:C1855627] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] carrier suggest mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] arise independently,oncological
atm phosphorylate [MeSH:C0031715] p9 nbs1 s-phase checkpoint pathway,rare disease ataxia-telangiectasia [MeSH:C0004135] cause mutation atm gene nijmegen breakage syndrome [MeSH:C0398791] nbs mutation p9 nbs1 gene share variety phenotypic [MeSH:C1837514] [MeSH:C1837514] abnormality chromosomal instability [MeSH:C1257806] radiation sensitivity [MeSH:C0034537] defect cell-cycle checkpoint [MeSH:C3178863] response [MeSH:C1155874] ionize radiation [MeSH:C0034538] atm gene encode protein kinase [MeSH:C0033640] activate ionize radiation [MeSH:C0034538] radiomimetic drug p9 nbs1 protein complex involve response dna double-strand break similarity [MeSH:C1511667] nbs evaluate functional interaction [MeSH:C0031843] atm p9 nbs1 activation atm kinase ionize radiation [MeSH:C0034538] induction atm-dependent response nbs cell indicate p9 nbs1 require signalling [MeSH:C0037083] atm ionize radiation [MeSH:C0034538] p9 nbs1 phosphorylate serine [MeSH:C0036720] atm-dependent manner vitro vivo ionize radiation [MeSH:C0034538] p9 nbs1 construct mutate atm phosphorylation [MeSH:C0031715] site abrogate s-phase checkpoint [MeSH:C3178863] induce ionize radiation [MeSH:C0034538] normal cell fail compensate functional deficiency [MeSH:C1969443] nbs cell observation [MeSH:C0302523] link atm p9 nbs1 common signalling [MeSH:C0037083] pathway provide explanation phenotypic [MeSH:C1837514] [MeSH:C1837514] similarity disease,neurological
huntington disease [MeSH:C0020179] childhood-onset tourette syndrome,-year-old man childhood-onset tourette syndrome [MeSH:C0040517] ts develop huntington disease [MeSH:C0020179] hd believe report case childhood-onset [MeSH:C0036346] ts adult [MeSH:C0001675] onset hd discovery case disorder provide clue pathophysiology [MeSH:C0031847] condition [MeSH:C0037403],neurological
immunotherapy [MeSH:C0021083] colorectal cancer [MeSH:C0009402] brain [MeSH:C0006104] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete pyelonephritis [MeSH:C0034186] mechanism method prospective elderly patient assess anuria [MeSH:C0003460] wilms tumor [MeSH:C0027708] result favorable safety profile implication relevance,neurological|hepatorenal
arrhythmia [MeSH:C0003811] myocardial infarction [MeSH:C0027051] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome atherosclerosis pathway method cross-sectional trial cancer [MeSH:C0010362] patient [MeSH:C0030705] measure arterial hypertension [MeSH:C0020538] result improve disease management [MeSH:C0039798] therapeutic innovation [MeSH:C0087111],cardiovascular
long-term [MeSH:C0023977] follow-up [MeSH:C3899107] ifosfamide [MeSH:C0020823] renal toxicity [MeSH:C0040539] child [MeSH:C0008059] treat malignant mesenchymal tumor [MeSH:C0334492] international society pediatric [MeSH:C0237433] oncology report,renal function [MeSH:C0031843] child malignant mesenchymal tumor [MeSH:C0334492] complete remission [MeSH:C0334492] receive ifosfamide [MeSH:C0020823] [MeSH:C0020823] chemotherapy [MeSH:C0013216] protocol [MeSH:C0655632] international society pediatric [MeSH:C0237433] oncology malignant mesenchymal tumor [MeSH:C0334492] siop mmt [MeSH:C0334492] study [MeSH:C0085973] completion total cumulative dose g m2 ifosfamide [MeSH:C0020823] [MeSH:C0020823] cycle ifosfamide [MeSH:C0020823] [MeSH:C0020823] vincristine [MeSH:C0020823] dactinomycin iva receive cisplatin [MeSH:C0008838] chemotherapy [MeSH:C0013216] age range [MeSH:C0050961] month year patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] male [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] common primary tumor site [MeSH:C0750974] head neck renal function [MeSH:C0031843] investigate [MeSH:C0035173] measure [MeSH:C0079809] plasma [MeSH:C0032105] urinary electrolyte glucosuria proteinuria [MeSH:C0033687] aminoaciduria [MeSH:C0002534] urinary ph osmolarity [MeSH:C0029387] creatinine clearance [MeSH:C5243473] phosphate tubular reabsorption beta microglobulinuria [MeSH:C0005149] lysozymuria [MeSH:C0026794] fifty-eight patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] normal renal test patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] renal abnormality subset patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] identify include patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] total population develop major toxicity [MeSH:C0040539] [MeSH:C0040539] result fanconi syndrome [MeSH:C0015624] tdfs second include patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] elevated beta microglobulinuria [MeSH:C0005149] low [MeSH:C0005149] phosphate reabsorption remain seven patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] isolate beta microglobulinuria [MeSH:C0005149] severe toxicity [MeSH:C0040539] [MeSH:C0040539] correlate high cumulative dose g m2 ifosfamide [MeSH:C0020823] [MeSH:C0020823] young [MeSH:C0340037] age year old predominance vesicoprostatic tumor involvement [MeSH:C0030699] low percentage tdfs evaluate respect efficacy [MeSH:C5690761] ifosfamide [MeSH:C0020823] [MeSH:C0020823] mesenchymal tumor [MeSH:C0334492] child,hepatorenal|oncological
hyponatremia syndrome inappropriate anti-diuretic hormone report [MeSH:C1705480] use vincristine [MeSH:C0042679] over-representation asian [MeSH:C0003988],retrospective [MeSH:C0035363] pharmaceutical company [MeSH:C0013227] global safety database determine reporting rate hyponatremia syndrome inappropriate [MeSH:C2936303] secretion [MeSH:C0036536] anti-diuretic hormone siadh [MeSH:C1705480] vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679]-treated [MeSH:C0042679] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] explore possibility at-risk [MeSH:C0035647] population subgroup [MeSH:C1257890] search eli lilly company computerize adverse event [MeSH:C0041755] [MeSH:C0041755] database report [MeSH:C0993637] case hyponatremia siadh [MeSH:C0020625] november report use vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] result total case hyponatremia siadh [MeSH:C0020625] associate vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] use identify overall reporting rate estimate treat patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] average age patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] year male [MeSH:C0086582] approximately patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive leukemia lymphoma [MeSH:C0023493] report include information race racial distribution black caucasian [MeSH:C0003988] [MeSH:C0003988] [MeSH:C0003988] asian [MeSH:C0003988] [MeSH:C0003988] [MeSH:C0003988] suggest asian [MeSH:C0003988] [MeSH:C0003988] [MeSH:C0003988] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] increase risk [MeSH:C0035647] hyponatremia siadh [MeSH:C0020625] associate vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] use overall report rate siadh associate vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] low physician care asian [MeSH:C0003988] [MeSH:C0003988] [MeSH:C0003988] oncology patient [MeSH:C0596240] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] aware potential reversible [MeSH:C5691430] adverse event [MeSH:C0041755] [MeSH:C0041755],oncological
chronic [MeSH:C0150055] metformin suppress [MeSH:C0017372] toll-like receptor signaling [MeSH:C0670896] attenuate leave ventricular dysfunction [MeSH:C0242973] follow myocardial infarction [MeSH:C0027051],acute [MeSH:C0184567] metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] protective effect [MeSH:C4277511] myocardial infarction [MeSH:C0027051] [MeSH:C0027051] suppress [MeSH:C0017372]ion [MeSH:C1956351] inflammatory response [MeSH:C0242966] [MeSH:C0242966] activation amp-activated protein kinase [MeSH:C2350345] ampk [MeSH:C5544462] present effect [MeSH:C4277511] chronic [MeSH:C0150055] [MeSH:C0150055] [MeSH:C0150055] pre-treatment [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] cardiac dysfunction [MeSH:C0031847] toll-like receptor tlr4 [MeSH:C1321919] [MeSH:C1321919] activity [MeSH:C0020115] [MeSH:C0020115] follow myocardial infarction [MeSH:C0027051] [MeSH:C0027051] relation ampk [MeSH:C5544462] assess male [MeSH:C0086582] wistar rat randomly assign group n normal group inject isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] chronic [MeSH:C0150055] [MeSH:C0150055] [MeSH:C0150055] pre-treatment [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] 0 mg kg metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] twice daily day [MeSH:C0011017] isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] 0 mg kg inject subcutaneously 3th 4th day [MeSH:C0011017] induce acute [MeSH:C0184567] myocardial infarction [MeSH:C0027051] [MeSH:C0027051] isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] decrease leave ventricular systolic pressure myocardial contractility index lvdp dtmax lvdp dtmin left ventricular dysfunction [MeSH:C0242698] significantly low group treat 0 mg kg metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] metfromin markedly lower isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245]-induced elevation level tlr4 [MeSH:C1321919] [MeSH:C1321919] mrna myeloid differentiation protein [MeSH:C0768899] myd8 tumor necrosis factor-alpha tnf-a [MeSH:C1456820] interleukin [MeSH:C1456820] il- heart tissue [MeSH:C0040300] similar change see serum level tnf-a [MeSH:C1456820] il- low dose 0 mg kg effect [MeSH:C4277511]ive 0 mg kg phosphorylate [MeSH:C0031715] ampk [MeSH:C5544462]a p-ampk [MeSH:C5544462] myocardium [MeSH:C0027061] [MeSH:C0027061] significantly elevated [MeSH:C0020443] 5 mg kg metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] slightly 0 mg kg 0 mg kg chronic [MeSH:C0150055] [MeSH:C0150055] [MeSH:C0150055] pre-treatment [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] metformin [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] [MeSH:C0025598] reduce post-myocardial infarction [MeSH:C0027051] [MeSH:C0027051] [MeSH:C0027051] cardiac dysfunction [MeSH:C0031847] suppress [MeSH:C0017372] inflammatory response [MeSH:C0242966] [MeSH:C0242966] possibly inhibition [MeSH:C0027790] tlr4 [MeSH:C1321919] [MeSH:C1321919] activity [MeSH:C0020115] [MeSH:C0020115] mechanism [MeSH:C1524059] consider target [MeSH:C0039309] protect infarcted [MeSH:C0021308] myocardium [MeSH:C0027061] [MeSH:C0027061],cardiovascular|oncological
chemotherapy [MeSH:C0013216] dementia [MeSH:C0497327] brain [MeSH:C0006104] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient cardiomyopathy convulsion result decrease mortality rate [MeSH:C0205848] coronary correlation practice guideline,neurological|cardiovascular
hypertensive lymphoma vascular insight,question statin affect stroke [MeSH:C0038454] systolic [MeSH:C0039155] mechanism method retrospective diabetic patient [MeSH:C0030705] assess glomerular filtration rate [MeSH:C0017654] alt result improvement [MeSH:C2936612] primary endpoint implication safety [MeSH:C0036043] consideration,cardiovascular|hepatorenal
cancer autonomic neuropathy [MeSH:C0271686] exploring neural pathway [MeSH:C0027792],dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve kidney transplant dystonia method conduct observational [MeSH:C0302523] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine neural [MeSH:C1522467] parameter result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,neurological|hepatorenal
colorectal cancer pathway [MeSH:C0009402] prostate cancer [MeSH:C0376358],diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve cholestasis melanoma [MeSH:C0008370] method conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine chemotherapy [MeSH:C0013216] parameter result enhance therapeutic response [MeSH:C0087111] safety consideration,hepatorenal|oncological
atrial fibrillation pathway angina pectoris,investigate [MeSH:C0035173] statin effect hypertension [MeSH:C0020538] blood vessel method [MeSH:C0005847] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo cross-sectional bundle branch block heart attack assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] practice guideline,neurological|cardiovascular
inherit colorectal polyposis cancer [MeSH:C0009402] risk [MeSH:C0035647] apc i17k polymorphism [MeSH:C0032529],germ-line somatic truncating mutation apc gene think initiate colorectal tumor formation [MeSH:C0029433] [MeSH:C0009404] familial adenoma [MeSH:C0001430]tous polyp [MeSH:C0206677]osis syndrome [MeSH:C0032580] sporadic colorectal carcinogenesis [MeSH:C0596263] [MeSH:C0596263] respectively recently isoleucine-- [MeSH:C0022192] lysine [MeSH:C0024337] polymorphism [MeSH:C0032529] codon i17k apc gene identify ashkenazi jewish population assess risk [MeSH:C0035647] common apc allelic variant colorectal carcinogenesis [MeSH:C0596263] [MeSH:C0596263] analyze large cohort [MeSH:C1706962] unselected ashkenazi jewish subject adenoma [MeSH:C0001430]tous polyp [MeSH:C0206677] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] apc i17k polymorphism [MeSH:C0032529] apc i17k allele [MeSH:C0002085] [MeSH:C0002085] identify patient [MeSH:C0030705] compare frequency [MeSH:C0376249] separate population group [MeSH:C1257890] apc i17k allele [MeSH:C0002085] [MeSH:C0002085] associate estimate relative risk [MeSH:C0242492] [MeSH:C0035647] colorectal neoplasia [MeSH:C0009404] p furthermore compare noncarrier apc i17k carrier increase number adenoma [MeSH:C0001430] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] p young age diagnosis conclude apc i17k variant lead increase adenoma [MeSH:C0001430] formation [MeSH:C0029433] directly contribute ashkenazi jewish colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] estimate relative risk [MeSH:C0242492] [MeSH:C0035647] carrier justify specific screening american [MeSH:C0220908] expect harbor allele [MeSH:C0002085] [MeSH:C0002085] genetic testing setting long-term-outcome study impact [MeSH:C5544368] significantly colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] prevention population [MeSH:C0032659],oncological
lymphoma gamma glutamyl transferase [MeSH:C0017040] organ interplay,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke [MeSH:C0038454] outcome hcc pathway method prospective trial elderly patient measure hepatocellular carcinoma [MeSH:C2239176] nephritis [MeSH:C0027697] result superior efficacy [MeSH:C5690761] relevance,hepatorenal
sinus arrest [MeSH:C1955864] associate continuous-infusion cimetidine [MeSH:C0008783],administration [MeSH:C0001554] [MeSH:C0001554] intermittent [MeSH:C4704881] intravenous [MeSH:C0085297] infusion cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] infrequently associate development [MeSH:C0020119] bradyarrhythmia [MeSH:C0003811] [MeSH:C0428977] -year-old man leukemia [MeSH:C0023418] history [MeSH:C0019664] cardiac disease [MeSH:C0018799] develop recurrent [MeSH:C2825055] brief episode apparent sinus arrest receive continuous-infusion cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] mg hour arrhythmia [MeSH:C0003811] temporally related cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] administration [MeSH:C0001554] [MeSH:C0001554] disappear dechallenge recur ranitidine [MeSH:C0034665] report case sinus arrest [MeSH:C1955864] associate continuous-infusion cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783],cardiovascular|oncological
late-onset [MeSH:C0376415] metachromatic leukodystrophy [MeSH:C0023522] molecular pathology [MeSH:C0596962] sibling,report new allele [MeSH:C0002085] arylsulfatase [MeSH:C0003940] arsa locus cause late-onset [MeSH:C0376415] metachromatic leukodystrophy [MeSH:C0023522] mld allele [MeSH:C0002085] arginine8 residue highly conserve arylsulfatase gene [MeSH:C0003940] family replace glutamine contrast allele [MeSH:C0002085] cause early-onset [MeSH:C3711383] mld arginine8 glutamine substitution [MeSH:C2936279] associate residual [MeSH:C0543478] arsa activity comparison genotype [MeSH:C0017431] arsa activity individual carry allele [MeSH:C0002085] patient [MeSH:C0030705] mld examine validate concept [MeSH:C2350469] different degree residual [MeSH:C0543478] arsa activity basis phenotypical variation mld,neurological
stroke [MeSH:C0038454] hypertensive [MeSH:C0003364] cardiac connection,randomized control examine [MeSH:C1096777] calcium channel blocker [MeSH:C0006684] hypertension [MeSH:C0020538] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include capillary arterial ventricle method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
large population-based follow-up trimethoprim-sulfamethoxazole trimethoprim [MeSH:C0041044] cephalexin [MeSH:C0007716] uncommon drug toxicity [MeSH:C0013221],conduct population-based -day follow-up [MeSH:C3899107] people [MeSH:C5690824] prescribe trimethoprim [MeSH:C0041041] [MeSH:C0041041]-sulfamethoxazole [MeSH:C0041044] tmp-smz prescribe trimethoprim [MeSH:C0041041] [MeSH:C0041041] prescribe cephalexin [MeSH:C0007716] [MeSH:C0007716] [MeSH:C0007716] estimate risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] liver blood [MeSH:C0005767] skin renal disorder result referral hospitalization associate drug result base information record office computer select general practitioner [MeSH:C0017319] united kingdom review record risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] clinically important idiopathic liver disease [MeSH:C0023895] similar person [MeSH:C0027361] prescribe tmp-smz prescribe trimethoprim [MeSH:C0041041] [MeSH:C0041041] risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] prescribe cephalexin [MeSH:C0007716] [MeSH:C0007716] [MeSH:C0007716] somewhat low patient [MeSH:C0030705] experience blood disorder [MeSH:C0005830] expose tmp-smz seven erythema multiforme [MeSH:C0014742] stevens-johnson syndrome [MeSH:C0038325] expose tmp-smz case toxic epidermal necrolysis [MeSH:C0014518] occur take cephalexin [MeSH:C0007716] [MeSH:C0007716] [MeSH:C0007716] finally case acute parenchymal renal disease occur likely cause drug conclude risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] disease study small agent compare reasonably risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] antibiotic [MeSH:C0003232],hepatorenal
oncological frontier lymphoma,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] sarcoma [MeSH:C1261473] mechanism method retrospective [MeSH:C0035363] elderly patient assess metastatic neoplasm [MeSH:C0027627] result superior efficacy [MeSH:C5690761] implication cost-effectiveness [MeSH:C1511536] implication,oncological
angiogenesis [MeSH:C0002976] target [MeSH:C0039309] ribavirin [MeSH:C0035525] associated hemolytic anemia [MeSH:C0002878],aim recently ribavirin [MeSH:C0035525] [MeSH:C0035525] find inhibit [MeSH:C0021463] angiogenesis [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] number angiogenesis [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] inhibit [MeSH:C0021463]or sunitinib [MeSH:C1176020] sorafenib [MeSH:C1516119] find cause acute [MeSH:C0184567] hemolysis [MeSH:C0019054] aim investigate [MeSH:C0035173] [MeSH:C0035173] [MeSH:C0035173] relation hemoglobin [MeSH:C0019046] haptoglobin [MeSH:C0018595] angiogenesis [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] soluble [MeSH:C0210233] [MeSH:C0210233] [MeSH:C0210233] marker [MeSH:C0017393] [MeSH:C0017393] modifiable help develop strategy anemia [MeSH:C0002871] [MeSH:C0002871] method [MeSH:C0025663] fourteen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chronically infect hepatitis c [MeSH:C0019196] virus [MeSH:C0220847] treat pegylated interferon alpha 2a [MeSH:C0391001] ribavirin [MeSH:C0035525] [MeSH:C0035525] serum hemoglobin [MeSH:C0019046] haptoglobin [MeSH:C0018595] angiogenesis [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] marker [MeSH:C0017393] [MeSH:C0017393] vascular endothelial growth factor [MeSH:C0033453] [MeSH:C0078058] angiopoetin- investigate [MeSH:C0035173] [MeSH:C0035173] [MeSH:C0035173] therapy [MeSH:C0039798] result observe decrease haptoglobin [MeSH:C0018595] level [MeSH:C0018759] end period hemoglobin [MeSH:C0019046] level [MeSH:C0018759] decrease insignificantly contrast literature [MeSH:C0023866] serum level [MeSH:C0018759] angiogenesis [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] factor [MeSH:C0033453] significantly pegylated interferon ribavirin [MeSH:C0035525] [MeSH:C0035525] therapy [MeSH:C0039798] find correlation [MeSH:C0010100] angiogenesis [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] soluble [MeSH:C0210233] [MeSH:C0210233] [MeSH:C0210233] marker [MeSH:C0017393] [MeSH:C0017393] hemoglobin [MeSH:C0019046] haptoglobin [MeSH:C0018595] literature [MeSH:C0023866] investigate [MeSH:C0035173] [MeSH:C0035173] [MeSH:C0035173] link angiogenesis [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] soluble [MeSH:C0210233] [MeSH:C0210233] [MeSH:C0210233] marker [MeSH:C0017393] [MeSH:C0017393] ribavirin [MeSH:C0035525] [MeSH:C0035525] induced [MeSH:C5392225] anemia [MeSH:C0002871] [MeSH:C0002871] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hepatitis c [MeSH:C0019196] find relation future large number patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] need find modifiable factor [MeSH:C0033453] improve safety [MeSH:C0036043] ribavirin [MeSH:C0035525] [MeSH:C0035525] therapy [MeSH:C0039798],neurological|hepatorenal
acute neurologic dysfunction [MeSH:C0751830] high-dose etoposide therapy malignant glioma [MeSH:C0555198],etoposide [MeSH:C0015133] vp-- solid tumor hematologic malignancy [MeSH:C0376545] high dose conjunction autologous bone marrow transplantation agent [MeSH:C0040736] activity treatment-resistant [MeSH:C2986418] cancer [MeSH:C0877578] include malignant glioma [MeSH:C0555198] [MeSH:C0555198] patient treat recurrent resistant [MeSH:C2986418] glioma sudden severe neurologic deterioration occur develop median day initiation high-dose etoposide [MeSH:C0015133] therapy manifestation [MeSH:C0029166] include confusion [MeSH:C0009676] papilledema [MeSH:C0030353] somnolence exacerbation motor deficit sharp increase seizure [MeSH:C0036572] activity abnormality [MeSH:C0037268] resolve rapidly initiation high-dose intravenous dexamethasone therapy patient computerize tomographic [MeSH:C0040404] ct brain scan demonstrate stability [MeSH:C2350440] tumor size peritumor edema compare pretransplant scan complication appear represent new toxicity [MeSH:C0040539] high-dose etoposide [MeSH:C0015133] therapy malignant glioma [MeSH:C0555198] [MeSH:C0555198],neurological|oncological
effect dehydroepiandrosterone [MeSH:C0011185] amphetamine-induced schizophrenia model [MeSH:C0011381] mouse [MeSH:C0026809],examine effect [MeSH:C4277511] dehydroepiandrosterone [MeSH:C0011185] dhea [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] animal [MeSH:C0003062] model [MeSH:C0599779] [MeSH:C0599779] schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] method [MeSH:C0025663] seventy swiss albino female mouse g divide group [MeSH:C0018257] amphetamine [MeSH:C0002658] [MeSH:C0002658]-free amphetamine [MeSH:C0002658] [MeSH:C0002658] mg kg dhea [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] dhea [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] administer intraperitoneally ip day [MeSH:C0011017] amphetamine [MeSH:C0002658] [MeSH:C0002658] mg kg ip induce hyper locomotion [MeSH:C0023946] apomorphine mg kg subcutaneously [MeSH:C0222331] sc induce climbing haloperidol [MeSH:C0018546] mg kg sc induced [MeSH:C5392225] catalepsy [MeSH:C0007370] test [MeSH:C0007370] animal [MeSH:C0003062] model [MeSH:C0599779] [MeSH:C0599779] schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] conduct animal [MeSH:C0003062] experiment [MeSH:C0020123] laboratory department pharmacology [MeSH:C0031330] medical school [MeSH:C0036378] eskisehir osmangazi university eskisehir turkey march statistical [MeSH:C0600673] carry kruskal-wallis test hyper locomotion [MeSH:C0023946] one-way anova climbing catalepsy [MeSH:C0007370] test [MeSH:C0007370] result amphetamine [MeSH:C0002658] [MeSH:C0002658]-induced [MeSH:C5392225] locomotion [MeSH:C0023946] test increase movement [MeSH:C0026649] [MeSH:C0026649] compare amphetamine [MeSH:C0002658] [MeSH:C0002658]-free dhea [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] mg kg p mg kg p significantly decrease movement [MeSH:C0026649] [MeSH:C0026649] compare amphetamine [MeSH:C0002658] [MeSH:C0002658]-induced [MeSH:C5392225] locomotion [MeSH:C0023946] difference group [MeSH:C0018257] haloperidol-induced [MeSH:C5392225] catalepsy [MeSH:C0007370] test [MeSH:C0007370] p difference group [MeSH:C0018257] term total climbing apomorphine-induced [MeSH:C5392225] climbing test p observe dhea [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] reduce locomotor activity [MeSH:C0023946] increase catalepsy [MeSH:C0007370] dose effect [MeSH:C4277511] climbing behavior [MeSH:C0004927] suggest dhea [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] [MeSH:C0011185] display [MeSH:C0010996] typical neuroleptic-like effect [MeSH:C4277511] schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341],neurological
azotemia [MeSH:C0242528] pattern lung cancer [MeSH:C0242379] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome [MeSH:C0206277] acoustic neuroma pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure renal cell carcinoma [MeSH:C0007134] hemodialysis [MeSH:C0019004] result improvement primary endpoint cost-effectiveness [MeSH:C1511536] implication,neurological|hepatorenal
beta-blocker lymphoma brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] smooth muscle pathway method randomized control trial [MeSH:C1096777] cardiac patient measure heart rate [MeSH:C0018810] astrocytoma result decrease mortality rate [MeSH:C0205848] safety [MeSH:C0036043] consideration,neurological|cardiovascular
novel frameshift mutation mcleod syndrome [MeSH:C0079380] gene japanese [MeSH:C1556094] family,report novel mutation xk gene xk japanese mcleod syndrome -year-old man show progressive [MeSH:C1449744] muscular atrophy [MeSH:C0026846] choreic movement [MeSH:C0026649] elevated [MeSH:C0020443] serum creatinine kinase [MeSH:C0010287] acanthocytosis [MeSH:C0000744] expression kell antigen erythrocyte [MeSH:C0014792] decrease molecular [MeSH:C0026381] reveal single-base deletion nucleotide position xk deletion cause frameshift [MeSH:C0079380] translation lead premature stop codon amino acid position [MeSH:C0002520] conclude single-base deletion cause defective kx protein responsible mcleod phenotype [MeSH:C0031437],hepatorenal
immunotherapy [MeSH:C0021083] lymphoma brain [MeSH:C0006104] insight,hypothesis statin improve diabete outcome [MeSH:C0206277] tic pathway method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure glutamate myasthenia gravis [MeSH:C0026896] result improve outcome [MeSH:C0206277] safety consideration,neurological
kidney [MeSH:C0022646] dynamic heart failure,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect heart disease [MeSH:C0018799] esrd method [MeSH:C0022661] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo retrospective polycystic kidney disease [MeSH:C0022680] alkaline phosphatase [MeSH:C0002059] assessment [MeSH:C0030198] result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],hepatorenal
epilepsy [MeSH:C0014544] primary biliary cholangitis [MeSH:C0008312] organ [MeSH:C0029250] interplay,question statin affect dementia [MeSH:C0497327] gamma glutamyl transferase mechanism method cross-sectional adult [MeSH:C0010362] population [MeSH:C0032659] assess chronic myeloid leukemia [MeSH:C0279543] liver [MeSH:C0023884] result well quality life measure implication care improvement,hepatorenal|oncological
blood urea [MeSH:C0005845] nitrogen pathway chronic kidney disease [MeSH:C1561643],longitudinal [MeSH:C0023981] examine aspirin cancer [MeSH:C0004057] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include liver transplant [MeSH:C0023911] cholecystitis nephrotic syndrome [MeSH:C0027726] method participant [MeSH:C1708335] include result positive response implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
central nervous system [MeSH:C3714787] toxicity [MeSH:C0040539] follow administration [MeSH:C0001554] levobupivacaine [MeSH:C0873118] lumbar plexu block report case,objective central nervous system [MeSH:C3714787] [MeSH:C3714787] cardiac [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] follow administration [MeSH:C0001554] [MeSH:C0001554] local anesthetic recognize complication [MeSH:C1171258] regional anesthesia levobupivacaine [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0873118] pure enantiomer bupivacaine [MeSH:C0006400] [MeSH:C0006400] develop improve cardiac [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] safety profile bupivacaine [MeSH:C0006400] [MeSH:C0006400] describe case grand mal seizure [MeSH:C0014549] follow accidental [MeSH:C0000924] intravascular [MeSH:C2936204] injection levobupivacaine [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0873118] case report [MeSH:C0684224] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present elective [MeSH:C0206189] orthopedic surgery [MeSH:C0162439] low limb [MeSH:C0015385] undergo blockade lumbar plexu posterior approach immediately administration [MeSH:C0001554] [MeSH:C0001554] levobupivacaine [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0873118] epinephrine [MeSH:C0014563] [MeSH:C0014563] microgram [MeSH:C0376691] ml patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop grand mal seizure [MeSH:C0014549] despite negative [MeSH:C3539878] aspiration [MeSH:C1720922] blood sign [MeSH:C0005767] intravenous [MeSH:C0085297] epinephrine [MeSH:C0014563] [MeSH:C0014563] administration [MeSH:C0001554] [MeSH:C0001554] seizure successfully treat sodium thiopental addition [MeSH:C0936073] succinylcholine [MeSH:C0038627] develop sign cardiovascular [MeSH:C0007220] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat preoperatively beta-adrenergic antagonist [MeSH:C0001645] medication mask cardiovascular [MeSH:C0007220] sign unintentional intravascular [MeSH:C2936204] administration [MeSH:C0001554] [MeSH:C0001554] levobupivacaine [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0873118] epinephrine [MeSH:C0014563] [MeSH:C0014563] conclusion levobupivacaine [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0873118] safe cardiac [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] profile racemic bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] adequate amount levobupivacaine [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0873118] reach circulation convulsion plasma [MeSH:C0032105] concentration sufficient central nervous system [MeSH:C3714787] [MeSH:C3714787] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] produce manifestation [MeSH:C0029166] cardiac [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],neurological|cardiovascular
vein lymphoma vascular insight,retrospective [MeSH:C0035363] examine ace inhibitor [MeSH:C0003015] stroke [MeSH:C0038454] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include chf bundle branch block vein method [MeSH:C0006384] participant [MeSH:C1708335] include result positive response implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
uremia [MeSH:C0041948] dementia [MeSH:C0497327] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome primary sclerosing cholangitis [MeSH:C0566602] pathway method prospective trial cancer patient measure heart block [MeSH:C0018794] arrhythmia result enhance therapeutic response [MeSH:C0087111] healthcare advancement,cardiovascular|hepatorenal
anti-carcinogenic action [MeSH:C0085169] phenobarbital [MeSH:C0031412] give simultaneously diethylnitrosamine rat [MeSH:C0012200],present work plan order elucidate effect phenobarbital [MeSH:C0031412] pb mg rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] ingest [MeSH:C0232478] dose carcinogenesis [MeSH:C0596263] [MeSH:C0596263] administer simultaneously diethylnitrosamine [MeSH:C0012200] den mg kg wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] g treat den den pb week accord schedule [MeSH:C0086960] hepatocarcinogenesis [MeSH:C0596263] [MeSH:C0009181] end number size induce pas positive preneoplastic [MeSH:C0282313] focus significantly reduce pb give simultaneously den week mitotic inhibition production micronucleus normally observe partial hepatectomy [MeSH:C0019144] den treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] significantly decrease den pb treat rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] week presence pb significantly parameter den pb treat rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] survival [MeSH:C0038952] prolonged tumor [MeSH:C0027651] incidence [MeSH:C0021149] decrease compare result obtain den conclude pb promote carcinogenesis [MeSH:C0596263] administer den reduce carcinogen effect [MeSH:C0007090] give simultaneously den anti-carcinogen effect [MeSH:C0007090] act initiation [MeSH:C0030943] promotion precancerous lesion biochemical [MeSH:C0017401] investigation [MeSH:C0035173] progress obtain information [MeSH:C5544371] paradoxical [MeSH:C0037322] pb effect,oncological
epilepsy [MeSH:C0014544] gray matter [MeSH:C0018220] explore neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve stroke [MeSH:C0038454] outcome craniopharyngioma pathway method randomized control trial [MeSH:C1096777] cardiac patient measure cerebrospinal fluid [MeSH:C0007806] gaba result improvement primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
antioxidant effect [MeSH:C3179302] bovine [MeSH:C0007453] lactoferrin [MeSH:C0022942] dexamethasone-induced hypertension [MeSH:C0968916] rat [MeSH:C0034721],dexamethasone [MeSH:C0011777]- dex- induce hypertension [MeSH:C0020538] associate enhance oxidative stress [MeSH:C0242606] [MeSH:C0242606] lactoferrin lf iron-binding glycoprotein [MeSH:C1135611] antihypertensive property [MeSH:C0003364] investigate [MeSH:C0035173] effect [MeSH:C4277511] chronic administrat [MeSH:C0034721]ion [MeSH:C0001554] [MeSH:C0001554] lf oxidative stress [MeSH:C0242606] [MeSH:C0242606] hypertension [MeSH:C0020538] dex administrat [MeSH:C0034721]ion [MeSH:C0001554] male [MeSH:C0086582] wistar rat [MeSH:C0034721] [MeSH:C0034716] treat dex u g kg subcutaneously saline day [MeSH:C0011017] oral bovine lf mg kg give reversal prevent [MeSH:C0000918]ion rat [MeSH:C0034721] receive day [MeSH:C0011017] lf follow dex continue test period systolic blood pressure sbp measure tail-cuff thymus weight marker [MeSH:C0017393] glucocorticoid activity [MeSH:C0017710] plasma [MeSH:C0032105] [MeSH:C0032105] hydrogen peroxide [MeSH:C0020281] h2o2 concentrat [MeSH:C0034721]ion ferric [MeSH:C0060234] reduce antioxidant power frap determine dexamethasone [MeSH:C0011777] significantly increase sbp plasma [MeSH:C0032105] [MeSH:C0032105] h2o2 decrease thymus body weight [MeSH:C0005910] lf lower p dose dependently prevent [MeSH:C0000918] p dex-induced hypertension [MeSH:C0020538] lf prevent [MeSH:C0000918] body weight loss [MeSH:C0005910] significantly reduce elevated [MeSH:C0020443] plasma [MeSH:C0032105] [MeSH:C0032105] h2o2 increase frap value chronic administrat [MeSH:C0034721]ion [MeSH:C0001554] [MeSH:C0001554] lf strongly reduce blood pressure production [MeSH:C0005823] ros improved antioxidant capacity [MeSH:C0003402] dex-induced hypertension [MeSH:C0020538] suggest role inhibition [MeSH:C0027790] oxidative stress [MeSH:C0242606] [MeSH:C0242606] mechanism antihypertensive action lf [MeSH:C0003364],cardiovascular
brain map [MeSH:C0006104] alzheimer disease insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome myelopathy pathway method retrospective trial cancer patient [MeSH:C0030705] measuring synapse [MeSH:C0039062] huntington disease result improve outcome practice guideline [MeSH:C0936005],neurological
ultrasound [MeSH:C0220934] reveal alzheimer disease secret,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve amyotrophic lateral sclerosis huntington disease method [MeSH:C0002736] conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine serotonin [MeSH:C0036751] parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,neurological|hepatorenal
advanced ultrasound reveal peripheral artery disease [MeSH:C1704436] mechanism [MeSH:C1524059],longitudinal [MeSH:C0023981] examine calcium channel blocker hypertension [MeSH:C0006684] cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include gallbladder [MeSH:C0016976] urea renal cyst method participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication healthcare advancement,hepatorenal
assessment [MeSH:C0030198] new non-invasive [MeSH:C1997883] index cardiac performance detection dobutamine-induced myocardial ischemia [MeSH:C0151744],electrocardiography [MeSH:C1623258] low sensitivity detect dobutamine [MeSH:C0012963] [MeSH:C0012963]-induced myocardial ischemia [MeSH:C0151744] [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0151744] [MeSH:C0151744] objective assess add diagnostic [MeSH:C0086143] new cardiac performance index dp dtejc measurement [MeSH:C0030198] base brachial artery flow change compare standard -lead ecg detect dobutamine [MeSH:C0012963] [MeSH:C0012963]-induced myocardial ischemia [MeSH:C0151744] [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0151744] [MeSH:C0151744] tc99m-sestamibi single-photon emission compute tomography [MeSH:C0040399] gold standard comparison assess presence absence ischemia [MeSH:C0022116] [MeSH:C0022116] method [MeSH:C0025663] comprise patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo sestamibi-spect [MeSH:C0040399] dobutamine [MeSH:C0012963] [MeSH:C0012963] stress test [MeSH:C3494508] simultaneous measurement [MeSH:C0030198] ecg brachial artery [MeSH:C0006087] dp dtejc perform dobutamine [MeSH:C0012963] [MeSH:C0012963] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] perfusion [MeSH:C0031001] defect compatible ischemia [MeSH:C0022116] [MeSH:C0022116] detect spect [MeSH:C0040399] increase dp dtejc infusion [MeSH:C0841792] dobutamine [MeSH:C0012963] [MeSH:C0012963] severely impaired [MeSH:C0020580] compare non-ischemic dp dtejc outcome combine ecg result [MeSH:C1623258] give ecg-enhanced compare ecg result [MeSH:C1623258] sensitivity improve dramatically positive predictive [MeSH:C1514243] increase negative predictive specificity [MeSH:C1513918] decrease conclusion ecg specificity [MeSH:C0037783] combination dp dtejc improve sensitivity test [MeSH:C0887818] cost-saving alternative cardiac imaging perfusion [MeSH:C0031001] study detect myocardial ischemia [MeSH:C0151744] [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0151744] [MeSH:C0151744] especially patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unable exercise [MeSH:C0015259],cardiovascular
heart valve dementia [MeSH:C0018826] vascular [MeSH:C0221214] insight,dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve venous heart block method [MeSH:C0018794] conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examining bundle branch block [MeSH:C0006384] parameter result decrease mortality rate [MeSH:C0205848] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
severe early-onset [MeSH:C3711383] obesity [MeSH:C0028754] adrenal insufficiency [MeSH:C0001623] red hair pigmentation [MeSH:C0031911] cause pomc [MeSH:C0033195] mutation human [MeSH:C0086418],sequential cleavage precursor protein pre-pro-opiomelanocortin pomc [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] generate melanocortin peptide adrenocorticotrophin [MeSH:C0001655] acth [MeSH:C0001655] melanocyte-stimulating hormone msh alpha beta gamma opioid-receptor ligand [MeSH:C0017048] beta-endorphin case isolate acth [MeSH:C0001655] deficiency report omim inherit pomc [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] defect [MeSH:C0155017] describe far recent study animal model [MeSH:C0599779] elucidate central role alpha-msh regulation food intake [MeSH:C0013470] activation brain melanocortin receptor mc4-r ref linkage [MeSH:C0242239] human [MeSH:C0086418] [MeSH:C0086418] obesity [MeSH:C0028754] [MeSH:C0028754] chromosome close proximity pomc [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] locus [MeSH:C0085286] lead proposal association pomc [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] human [MeSH:C0086418] [MeSH:C0086418] obesity [MeSH:C0028754] [MeSH:C0028754] dual role alpha-msh regulate [MeSH:C0851285] food intake [MeSH:C0013470] influence [MeSH:C0683549] hair pigmentation [MeSH:C0031911] [MeSH:C0031911] predict phenotype [MeSH:C0031437] associate defect [MeSH:C0155017] pomc [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] function include obesity [MeSH:C0028754] [MeSH:C0028754] alteration pigmentation [MeSH:C0031911] acth [MeSH:C0001655] deficiency observation symptom proband prompt search mutation [MeSH:C0026882] pomc [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] gene find compound heterozygote [MeSH:C0019425] mutation [MeSH:C0026882] exon g73 c73delta interfere appropriate synthesis [MeSH:C3178925] acth [MeSH:C0001655] alpha-msh homozygous [MeSH:C0019904] mutation [MeSH:C0026882] exon c34a abolish pomc [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] translation [MeSH:C0597295] finding represent example genetic defect [MeSH:C0155017] pomc [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] [MeSH:C0033195] gene define new monogenic endocrine disorder result early-onset [MeSH:C3711383] obesity [MeSH:C0028754] [MeSH:C0028754] adrenal insufficiency [MeSH:C0001623] red hair pigmentation [MeSH:C0031911] [MeSH:C0031911] [MeSH:C0031911],neurological|hepatorenal
testosterone-dependent hypertension upregulation [MeSH:C0041904] intrarenal angiotensinogen dahl salt-sensitive rat,blood pressure bp salt [MeSH:C0005823] sensitive man premenopausal [MeSH:C0206158] woman dahl salt-sensitive rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] ds high-salt hs diet [MeSH:C0012155] [MeSH:C0012155] [MeSH:C0012155] increase bp male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] contrast systemic renin-angiotensin system [MeSH:C0035096] [MeSH:C0035096] suppress [MeSH:C0017372] [MeSH:C0017372] response hs male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] ds intrarenal angiotensinogen [MeSH:C0003017] [MeSH:C0003017] expression [MeSH:C0017262] increase intrarenal level [MeSH:C0018759] ang ii suppress [MeSH:C0017372] [MeSH:C0017372] hypothesis test sexual dimorphism [MeSH:C0036866] hs-induce upregulation [MeSH:C0041904] [MeSH:C0041904] intrarenal angiotensinogen [MeSH:C0003017] [MeSH:C0003017] mediate testosterone [MeSH:C0039601] cause increase bp renal injury [MeSH:C2609414] [MeSH:C2609414] [MeSH:C2609414] low-salt ls diet [MeSH:C0012155] [MeSH:C0012155] [MeSH:C0012155] [MeSH:C0012169] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] ds high level [MeSH:C0018759] intrarenal angiotensinogen [MeSH:C0003017] [MeSH:C0003017] mrna female [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] hs diet [MeSH:C0012155] [MeSH:C0012155] [MeSH:C0012155] wk increase renal cortical angiotensinogen [MeSH:C0003017] [MeSH:C0003017] mrna protein male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] ds prevent castrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion ovariectomy [MeSH:C0029936] female [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] ds effect intrarenal angiotensinogen [MeSH:C0003017] [MeSH:C0003017] expression [MeSH:C0017262] diet [MeSH:C0012155] [MeSH:C0012155] [MeSH:C0012155] radiotelemetric bp similar male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] castrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e [MeSH:C0007344] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] ls diet [MeSH:C0012155] [MeSH:C0012155] [MeSH:C0012155] hs diet [MeSH:C0012155] [MeSH:C0012155] [MeSH:C0012155] wk cause progressive [MeSH:C1449744] increase bp protein albumin [MeSH:C0001924] excretion [MeSH:C1373187] glomerular sclerosis male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] ds rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] attenuate [MeSH:C0042211] castrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion testosterone [MeSH:C0039601] replacement castrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e [MeSH:C0007344] ds rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] increase bp renal injury [MeSH:C2609414] [MeSH:C2609414] [MeSH:C2609414] upregulation [MeSH:C0041904] [MeSH:C0041904] renal angiotensinogen [MeSH:C0003017] [MeSH:C0003017] associate hs diet [MeSH:C0012155] [MeSH:C0012155] [MeSH:C0012155] testosterone [MeSH:C0039601] contribute development [MeSH:C0243107] hypertension [MeSH:C0020538] renal injury [MeSH:C2609414] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] ds rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] hs diet [MeSH:C0012155] [MeSH:C0012155] [MeSH:C0012155] possibly upregulation [MeSH:C0041904] [MeSH:C0041904] intrarenal renin-angiotensin system [MeSH:C0035096] [MeSH:C0035096],cardiovascular|hepatorenal
neuron [MeSH:C0027882] connection [MeSH:C0056248] liver cirrhosis [MeSH:C0023890],investigate [MeSH:C0035173] statin effect cancer cerebral method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo longitudinal [MeSH:C0023981] thalamus cerebellar assessment [MeSH:C0030198] result positive response therapeutic innovation [MeSH:C0087111],neurological
thromboembolism angina [MeSH:C0040038] pectoris vascular insight,observational [MeSH:C0302523] examine beta-blocker hypertension cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include prolapse [MeSH:C0033377] atrial flutter bundle branch block method [MeSH:C0006384] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication relevance,cardiovascular
capillary peripheral artery disease [MeSH:C1704436] vascular [MeSH:C0221214] insight,question statin affect hypertension nephritis [MeSH:C0020538] mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess atrial fibrillation [MeSH:C0004238] urea result improve outcome [MeSH:C0206277] implication healthcare advancement,cardiovascular|hepatorenal
non-steroidal anti-inflammatory drugs-associated acute interstitial nephritis granular [MeSH:C4552086] tubular basement membrane [MeSH:C0004799] deposit,acute tubulo-interstitial nephritis [MeSH:C1843274] atin important cause acute renal failure [MeSH:C0022660] [MeSH:C0022660] result variety insult include immune [MeSH:C0020960] complex-mediated tubulo-interstitial injury drug non-steroid [MeSH:C0038317]al anti-inflammatory drug nsaid [MeSH:C0003211] far frequent [MeSH:C0017270] cause overall entity atin remain under-diagnosed symptom [MeSH:C3839861] resolve spontaneously [MeSH:C0034705] medication stop report -year-old boy develop acute renal failure [MeSH:C0022660] [MeSH:C0022660] week aortic valve surgery [MeSH:C0038895] [MeSH:C0003501] aspirin [MeSH:C0004057] follow surgery [MeSH:C0038895] take ibuprofen fever [MeSH:C0020740] nearly week prior presentation [MeSH:C0022869] present emergency department feel [MeSH:C0562508] ill find blood urea [MeSH:C0005845] nitrogen bun concentration mg dl creatinine [MeSH:C0010294] mg dl serum potassium meq l dialysis [MeSH:C0011945] [MeSH:C0011945] immediately initiate kidney biopsy [MeSH:C0022646] show inflammatory infiltrate consistent atin tubular basement membrane [MeSH:C0004799] tbm intense granular [MeSH:C4552086] [MeSH:C4552086] deposit polyclonal igg c3 [MeSH:C0020852] note need dialysis [MeSH:C0011945] [MeSH:C0011945] week treat successfully steroid [MeSH:C0038317] month renal recovery disappearance proteinuria [MeSH:C0033687] take report nsaids-associated atin show deposit granular [MeSH:C4552086] [MeSH:C4552086] immune [MeSH:C0020960] complex present tbm glomerulus,neurological|cardiovascular|hepatorenal
novel inherit mutation [MeSH:C0026882] [MeSH:C0026882] variable expressivity brca1 allele include founder [MeSH:C0242918] mutation [MeSH:C0026882] [MeSH:C0026882] 5delag ashkenazi jewish family,thirty-seven family [MeSH:C0015576] case breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] analyze mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] different germ-line mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0206530] [MeSH:C0026882] novel previously observe detect family [MeSH:C0015576] family [MeSH:C0015576] [MeSH:C0015576] ashkenazi jewish descent carry 5delag mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] share haplotype [MeSH:C0018591] polymorphic [MeSH:C1720758] marker [MeSH:C0017393] span approximately kb brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] expressivity 5delag family [MeSH:C0015576] vary early-onset [MeSH:C3711383] [MeSH:C3711383] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] 4deltcaa occur independently family [MeSH:C0015576] family [MeSH:C0015576] [MeSH:C0015576] penetrance complete female [MeSH:C0086287] develop early-onset [MeSH:C3711383] [MeSH:C3711383] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] male carrier [MeSH:C0007292] develop prostatic cancer [MeSH:C0376358] family [MeSH:C0015576] penetrance incomplete breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] occur diagnose [MeSH:C0011900] age year novel nonsense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] lead loss mutant brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] transcript family [MeSH:C0015576] case early-onset [MeSH:C3711383] [MeSH:C3711383] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] -nt segment brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] -utr kb genomic sequence include putative promoter region invariant single-strand conformation family [MeSH:C0015576] coding-sequence mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] overall series brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect family [MeSH:C0015576] positive brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] lod score [MeSH:C0023956] [MeSH:C0023956] [MeSH:C0023956] negative lod score [MeSH:C0023956] [MeSH:C0023956] [MeSH:C0023956] reflect multiple sporadic breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] test linkage [MeSH:C0242239] family [MeSH:C0015576] positive lod score [MeSH:C0023956] [MeSH:C0023956] [MeSH:C0023956] linkage [MeSH:C0242239] brca2 [MeSH:C0294028] family [MeSH:C0015576] detect brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] negative lod score [MeSH:C0023956] [MeSH:C0023956] [MeSH:C0023956] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028],oncological
cognitive processing [MeSH:C0582591] multiple sclerosis [MeSH:C0026769],stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve parkinsonism guillain-barre syndrome method [MeSH:C0018378] conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine tremor [MeSH:C0040822] parameter result improve disease management [MeSH:C0039798] healthcare advancement,neurological
-oxacalcitriol suppress [MeSH:C0017372] secondary hyperparathyroidism [MeSH:C0020503] induce low bone turnover dog [MeSH:C0085268] renal failure [MeSH:C0035078],calcitriol therapy suppress [MeSH:C0017372] serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] level [MeSH:C0018759] [MeSH:C0018759] parathyroid hormone pth [MeSH:C0030520] patient renal failure [MeSH:C0035078] drawback include hypercalcemia [MeSH:C0020437] [MeSH:C0020437] [MeSH:C0020437] marked suppress [MeSH:C0017372]ion bone [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] turnover [MeSH:C0085268] [MeSH:C0085268] [MeSH:C0085268] [MeSH:C0085268] lead adynamic bone [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] disease new vitamin analogue -oxacalcitriol oct show promising characteristic undertake determine effect [MeSH:C4277511] oct serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] pth level [MeSH:C0018759] [MeSH:C0018759] bone [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] turnover [MeSH:C0085268] [MeSH:C0085268] [MeSH:C0085268] [MeSH:C0085268] state normal impaired renal function [MeSH:C0031843] method dog [MeSH:C0012984] nephrectomized nx n sham-operated sham n animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] receive supplemental phosphate enhance pth secretion [MeSH:C0036536] fourteen week start phosphate supplementation half nx sham dog [MeSH:C0012984] receive dose oct time week half give vehicle [MeSH:C0175845] week modality subset animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] cross additional month biochemical [MeSH:C0017401] hormonal index calcium bone [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] metabolism measure [MeSH:C0079809] bone [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] biopsy week oct vehicle [MeSH:C0175845] end crossover period result nx dog [MeSH:C0012984] oct significantly decrease serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] pth level [MeSH:C0018759] [MeSH:C0018759] soon induction renal insufficiency [MeSH:C1565489] [MeSH:C1565489] long-standing secondary hyperparathyroidism [MeSH:C0020503] [MeSH:C0020503] oct microg kg stabilize serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] pth level [MeSH:C0018759] [MeSH:C0018759] month serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] pth level [MeSH:C0018759] [MeSH:C0018759] rise rise pronounced compare rise see nx effect [MeSH:C4277511] accompany episode [MeSH:C0085554] hypercalcemia [MeSH:C0020437] [MeSH:C0020437] [MeSH:C0020437] hyperphosphatemia [MeSH:C0085681] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] normal renal function [MeSH:C0031843] oct induce transient [MeSH:C0040704] decrease serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] pth level [MeSH:C0018759] [MeSH:C0018759] dose microg kg sustained lowering dose nx dog [MeSH:C0012984] oct reverse abnormal [MeSH:C0853087] bone [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] formation weave osteoid [MeSH:C0029441] fibrosis significantly alter bone [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] turnover [MeSH:C0085268] [MeSH:C0085268] [MeSH:C0085268] [MeSH:C0085268] addition oct improve mineralization [MeSH:C2350989] lag rate osteoid [MeSH:C0029441] mineralize nx sham dog [MeSH:C0012984] conclusion result indicate oct completely prevent [MeSH:C0000918] occurrence hypercalcemia [MeSH:C0020437] [MeSH:C0020437] [MeSH:C0020437] experimental dog [MeSH:C0016998] [MeSH:C0012984] renal insufficiency [MeSH:C1565489] use management secondary hyperparathyroidism [MeSH:C0020503] [MeSH:C0020503] induce low bone [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] turnover [MeSH:C0085268] [MeSH:C0085268] [MeSH:C0085268] [MeSH:C0085268] increase risk [MeSH:C0035647] adynamic bone [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] [MeSH:C0262950] disease,hepatorenal
deficiency murine fifth complement component c5 [MeSH:C0343047],-base pair gene deletion -exon ascertain molecular mechanism cause murine [MeSH:C0026802] c5 deficiency [MeSH:C1623416] genomic cdna [MeSH:C0006556] library construct [MeSH:C0751608] mouse [MeSH:C0026809] [MeSH:C0026809] liver dna mrna employ congenic strain [MeSH:C0080194] b1 d2 nsnj b1 d2 osnj sufficient deficient [MeSH:C0531328] [MeSH:C0531328] c5 respectively genomic fragment isolate correspond pvuii hindiii restriction fragment length [MeSH:C0035268] polymorphism [MeSH:C0032529] [MeSH:C0032529] associate c5 deficiency [MeSH:C1623416] sequence [MeSH:C0162327] analysis demonstrate polymorphism [MeSH:C0032529] [MeSH:C0032529] result single base pair [MeSH:C0600436] substitution [MeSH:C2936279] [MeSH:C2936279] substitution [MeSH:C2936279] [MeSH:C2936279] probably cause contribute c5 deficiency [MeSH:C1623416] sequence [MeSH:C0162327] analysis c5 sufficient deficient [MeSH:C0531328] [MeSH:C0531328] cdna [MeSH:C0006556] reveal base-pair deletion deficient [MeSH:C0531328] [MeSH:C0531328] cdna [MeSH:C0006556] ta deletion located near end cdna [MeSH:C0006556] deletion shift reading frame c5 mrna termination codon uga present base pair downstream deletion genomic dna amplify sequence [MeSH:C0162327] correspond area surround -base pair deletion c5-deficient [MeSH:C0531328] [MeSH:C0531328] strain [MeSH:C0080194] hej akr j dba 2j nzb b1nj swr j b1 d2 osnj c5-sufficient strain [MeSH:C0080194] balb cj c57bl 6j [MeSH:C0025921] dba 1j b1 d2 nsnj analyze sequencing [MeSH:C0751971] reveal base pair delete [MeSH:C0600436] c5 gene deficient [MeSH:C0531328] [MeSH:C0531328] mouse [MeSH:C0026809] [MeSH:C0026809] test c5 gene sufficient mouse [MeSH:C0026809] [MeSH:C0026809] demonstrate identical [MeSH:C0041432] -base pair deletion exon c5 gene different c5-deficient [MeSH:C0531328] [MeSH:C0531328] mouse [MeSH:C0026809] [MeSH:C0026809] strain [MeSH:C0080194] mrna transcribe c5d gene retain deletion mutation c5 protein deficiency [MeSH:C1511760],neurological|hepatorenal
ecg [MeSH:C1623258] reveal ventricular tachycardia [MeSH:C0042514] secret,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation calcium channel blocker cancer [MeSH:C0006684] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] cerebral delirium [MeSH:C0011206] result enhance therapeutic response [MeSH:C0087111] huntington disease correlation practice guideline,neurological
bradykinin receptor antagonist [MeSH:C3850094] nitric oxide synthase inhibitor [MeSH:C0132555] vincristine streptozotocin [MeSH:C0038432] induce hyperalgesia [MeSH:C0020429] chemotherapy [MeSH:C0013216] diabetic neuropathy [MeSH:C0011882] rat [MeSH:C0034721] model [MeSH:C0011381],influence [MeSH:C0683549] irreversible [MeSH:C4319935] inhibitor [MeSH:C0003015] [MeSH:C0003015] [MeSH:C0003015] constitutive synthase l-noarg [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] mg kg ip relatively selective inhibitor [MeSH:C0003015] [MeSH:C0003015] [MeSH:C0003015] inducible [MeSH:C1533698] synthase l-nil [MeSH:C1533698] mg kg ip relatively specific inhibitor [MeSH:C0003015] [MeSH:C0003015] [MeSH:C0003015] neuronal synthase [MeSH:C0669368] -ni mg kg ip antihyperalgesic action selective antagonist b2 b1 receptor d-arg- hyp3 thi5 d-tic7 oic8 bradykinin [MeSH:C0006100] [MeSH:C0006100] [MeSH:C0006100] hoe nmol kg ip des arg1 hoe nmol kg ip respectively model diabetic [MeSH:C1263960] [MeSH:C1263960] streptozotocin-induced toxic vincristine [MeSH:C0042679]-induced neuropathy investigate [MeSH:C0035173] method change pain [MeSH:C0030193] threshold determine mechanical stimulus modification classic paw withdrawal test describe randall-selitto result result paper confirm inhibition [MeSH:C0027790] bradykinin [MeSH:C0006100] [MeSH:C0006100] [MeSH:C0006100] receptor [MeSH:C0107053] inducible [MeSH:C1533698] synthase neuronal synthase [MeSH:C0669368] activity reduce diabetic [MeSH:C1263960] [MeSH:C1263960] hyperalgesia [MeSH:C0020429] pretreatment [MeSH:C0376495] l-noarg [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] l-nil -ni significantly increase antihyperalgesic activity hoe des arg1 hoe show product inducible [MeSH:C1533698] synthase neuronal synthase [MeSH:C0669368] activation bradykinin [MeSH:C0006100] [MeSH:C0006100] [MeSH:C0006100] involve hyperalgesia [MeSH:C0020429] produce vincristine [MeSH:C0042679] l-noarg [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] -ni l-nil intensify antihyperalgesic activity hoe des-arg10hoe toxic neuropathy [MeSH:C0155303] [MeSH:C0155303] conclusion result study suggest b1 b2 receptor engage transmission [MeSH:C0040722] nociceptive stimulus diabetic [MeSH:C1263960] [MeSH:C1263960] toxic neuropathy [MeSH:C0155303] [MeSH:C0155303] streptozotocin-induced hyperalgesia [MeSH:C0020429] inducible [MeSH:C1533698] synthase participate pronociceptive activity bradykinin [MeSH:C0006100] [MeSH:C0006100] [MeSH:C0006100] vincristine [MeSH:C0042679]-induced hyperalgesia [MeSH:C0020429] bradykinin [MeSH:C0006100] [MeSH:C0006100] [MeSH:C0006100] activate neuronal synthase [MeSH:C0669368] pathway concomitant [MeSH:C0152203] administration small dose [MeSH:C0001554] bradykinin [MeSH:C0006100] [MeSH:C0006100] [MeSH:C0006100] receptor [MeSH:C0107053] antagonist synthase inhibitor [MeSH:C0003015] [MeSH:C0003015] [MeSH:C0003015] effective [MeSH:C5392218] alleviation neuropathic pain [MeSH:C0027796] [MeSH:C0030193] hospital care [MeSH:C0019994],neurological
systolic marker epilepsy,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] atrial flutter pathway method longitudinal trial [MeSH:C0023981] elderly patient measure mitral valve thromboembolism [MeSH:C0040038] result improve outcome [MeSH:C0206277] healthcare advancement,cardiovascular
duchenne muscular dystrophy gene [MeSH:C0013264] expression normal diseased human muscle [MeSH:C0026845],probe end duchenne muscular dystrophy [MeSH:C0013264] dmd gene expression [MeSH:C0017262] gene normal human muscle [MeSH:C0026845] myogenic cell culture muscle patient [MeSH:C0030705] dmd expression find rna normal fetal muscle adult [MeSH:C0001675] cardiac [MeSH:C0018810] skeletal muscle [MeSH:C0242692] culture muscle myoblast fusion [MeSH:C0596995] dmd muscle expression portion [MeSH:C0017262] gene reveal situ rna hybridization [MeSH:C0012893] particularly regenerate [MeSH:C0034963] muscle fiber [MeSH:C1704336],neurological
skin cancer [MeSH:C0007114] cancer heart failure [MeSH:C0018801],question [MeSH:C0600648] metformin [MeSH:C0025598] affect dementia [MeSH:C0497327] adrenal cancer [MeSH:C0750887] mechanism method cross-sectional adult population assess colorectal cancer [MeSH:C0009402] metastatic [MeSH:C1522484] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
hemodynamic [MeSH:C0019010] oxytocin vasoactive agent [MeSH:C0042397] neuraxial anesthesia cesarean delivery finding case,oxytocin [MeSH:C0030095] [MeSH:C0030095] commonly uterotonic cause fatal hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] particularly give bolus result hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] produce decrease systemic [MeSH:C5544477] [MeSH:C5544477] [MeSH:C5544477] vascular resistance [MeSH:C0042380] [MeSH:C0042380] [MeSH:C0042380] cardiac output [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] decrease venous return parturient normal volume [MeSH:C5690805] status heart valve pulmonary vasculature respond hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] compensatory [MeSH:C0220808] increase heart rate [MeSH:C0018810] stroke [MeSH:C0038454] [MeSH:C0038454] volume [MeSH:C5690805] oxytocin [MeSH:C0030095] [MeSH:C0030095]-induced hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] cesarean delivery incorrectly attribute blood loss [MeSH:C0079027] pulse power [MeSH:C0032863] call pulse contour arterial pressure wave form allow continuous [MeSH:C3649547] systemic [MeSH:C5544477] [MeSH:C5544477] [MeSH:C5544477] vascular resistance [MeSH:C0042380] [MeSH:C0042380] [MeSH:C0042380] cardiac output [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] real elucidate causative factor change blood pressure pulse power [MeSH:C0032863] conduct case cesarean delivery perform neuraxial anesthesia hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] response oxytocin [MeSH:C0030095] [MeSH:C0030095] associate [MeSH:C0004083] decrease systemic [MeSH:C5544477] [MeSH:C5544477] [MeSH:C5544477] vascular resistance [MeSH:C0042380] [MeSH:C0042380] [MeSH:C0042380] compensatory [MeSH:C0220808] increase stroke [MeSH:C0038454] [MeSH:C0038454] volume [MeSH:C5690805] heart rate [MeSH:C0018810] cardiac output [MeSH:C0007165] [MeSH:C0007165] [MeSH:C0007165] pulse power [MeSH:C0032863] helpful determine etiology [MeSH:C0015127] treat hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] cesarean delivery neuraxial anesthesia,cardiovascular|hepatorenal
paracetamol-associated coma [MeSH:C0009421] metabolic acidosis [MeSH:C0220981] renal [MeSH:C0152169] hepatic failure [MeSH:C0085605],case metabolic acidosis [MeSH:C0001122] acute renal failure [MeSH:C0022660] hepatic failure [MeSH:C0085605] follow paracetamol [MeSH:C0000970] ingestion [MeSH:C0232478] present diagnostic difficulty presentation highlight continuous [MeSH:C3649547] arteriovenous haemofiltration prove valuable means maintain fluid [MeSH:C0600608] electrolyte [MeSH:C0013832] balance [MeSH:C5544419] recover,hepatorenal
tumor angiogenesis [MeSH:C0002976] dementia [MeSH:C0497327],design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient esophageal cancer [MeSH:C0546837] acute lymphoblastic leukemia [MeSH:C1961102] result superior efficacy metastasis [MeSH:C0027627] correlation practice guideline [MeSH:C0282423],oncological
hypertension [MeSH:C0020538] huntington disease [MeSH:C0020179] explore neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] als pathway method cross-sectional trial [MeSH:C0010362] adult [MeSH:C0001675] population [MeSH:C0032659] measure brain abscess [MeSH:C0006105] myasthenia gravis [MeSH:C0026896] result favorable safety profile optimization [MeSH:C0376695],neurological|hepatorenal
vasodilator prostate cancer [MeSH:C0042402] brain [MeSH:C0006104] insight,cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve ataxia acetylcholine method conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine radiculopathy [MeSH:C0700594] parameter result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
beta-blocker lung cancer brain [MeSH:C0006104] insight,stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve serotonin cognitive impairment method [MeSH:C0338656] conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine limbic system [MeSH:C0023715] parameter result superior efficacy [MeSH:C5690761] need investigation [MeSH:C0035173],neurological
interaction [MeSH:C0007582] cyclosporin [MeSH:C0010592] antineoplastic agent [MeSH:C0003392],synergistic [MeSH:C0949698] effect etoposide [MeSH:C0015133] [MeSH:C0015133] cyclosporin [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] observe acute t-lymphocytic leukemia [MeSH:C1961099] relapse [MeSH:C0035020] concomitant [MeSH:C0152203] administration [MeSH:C0001554] etoposide [MeSH:C0015133] [MeSH:C0015133] cyclosporin [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] result eradication [MeSH:C3178994] hitherto refractory [MeSH:C0030200] leukemic infiltration bone marrow [MeSH:C0005953] severe effect term mental confusion [MeSH:C0009676] progressive hyperbilirubinemia [MeSH:C0020433] point enhancement antineoplastic effect [MeSH:C0003392] toxicity [MeSH:C0040539] normal tissue report demonstrate pharmacodynamic property cyclosporin [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] confine strictly suppression [MeSH:C1956351] normal t-cell function [MeSH:C0031843],neurological|oncological
early adjuvant [MeSH:C0674607] adriamycin [MeSH:C0085752] superficial bladder carcinoma,multicenter [MeSH:C1096776] perform patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] superficial transitional cell carcinoma [MeSH:C0206685] bladder [MeSH:C0005682] [MeSH:C0005682] adriamycin [MeSH:C0085752] [MeSH:C0085752] mg ml administer [MeSH:C0001554] intravesically h transurethral resection [MeSH:C0040771] ta-t1 o-a bladder [MeSH:C0005682] [MeSH:C0005682] tumor [MeSH:C0027651] instillation [MeSH:C1527425] [MeSH:C1527425] [MeSH:C1527425] repeat twice week weekly monthly tolerance [MeSH:C3544386] evaluate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present local side-effect [MeSH:C4277511] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chemical cystitis [MeSH:C0010692] severe drop systemic side-effect [MeSH:C4277511] observe recurrence [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] study [MeSH:C2825055] evaluable patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] follow-up [MeSH:C3899107] [MeSH:C3899107] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] follow year mean month patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] study primary recurrent disease evaluable patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] recurrence [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] present recurrence [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] recurrence [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] t1 tumor [MeSH:C0027651] progress highly invasive [MeSH:C0008493] lesion patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] free recurrence [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] remain tumor [MeSH:C0027651]-free -year follow-up [MeSH:C3899107] [MeSH:C3899107] period [MeSH:C0080129] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop recurrence [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] present recurrence [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] instillation [MeSH:C1527425] [MeSH:C1527425] [MeSH:C1527425] stop beneficial effect [MeSH:C4277511] adriamycin [MeSH:C0085752] [MeSH:C0085752] appear obvious related drug [MeSH:C0013227] early repeat instillation [MeSH:C1527425] [MeSH:C1527425] [MeSH:C1527425] tur,oncological
common mutation [MeSH:C0026882] brca1 [MeSH:C0259275] brca2 [MeSH:C0294028] contribute early [MeSH:C3177188] prostate cancer [MeSH:C0376358] jewish man,family high incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] hereditary breast cancer [MeSH:C0677776] subsequently show terminate mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] appear high incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] male [MeSH:C0086582] relative aim determine common germline [MeSH:C0206530] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] ashkenazi jewish man predispose prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] method examine genomic dna brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] 5delag brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] 4delt ashkenazi jewish prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] patient [MeSH:C0030705] [MeSH:C0030705] treat [MeSH:C0030705] relatively young [MeSH:C0340037] age common germline [MeSH:C0206530] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] gene see ashkenazi population [MeSH:C0032659] result able detect --fold increase risk [MeSH:C0035647] prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] confidence interval [MeSH:C0009667] [MeSH:C0009667] patient [MeSH:C0030705] [MeSH:C0030705] heterozygous [MeSH:C0019425] [MeSH:C0019425] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutant allele [MeSH:C0002085] heterozygous [MeSH:C0019425] [MeSH:C0019425] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] confidence interval [MeSH:C0009667] [MeSH:C0009667] conclusion incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] germline [MeSH:C0206530] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] patient [MeSH:C0030705] [MeSH:C0030705] closely match incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] general ashkenazi jewish population [MeSH:C0032659] suggest unlike case breast ovarian cancer [MeSH:C1140680] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] significantly predispose man prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358],oncological
reversal ammonia coma rat [MeSH:C0034721] l-dopa [MeSH:C0023570] peripheral effect,ammonia [MeSH:C0002607] coma [MeSH:C0002607] produce rat [MeSH:C0034721] minute intraperitonealinjection mmol nh4cl coma prevent [MeSH:C0000918] [MeSH:C0000918] [MeSH:C0000918] mmol l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] give gastric intubation [MeSH:C0021925] minute ammonium salt injection effect l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] correlate decrease blood brain [MeSH:C0005767] [MeSH:C0005767] [MeSH:C0005767] [MeSH:C0006104] [MeSH:C0006104] [MeSH:C0005767] ammonia [MeSH:C0002607] increase brain [MeSH:C0006104] [MeSH:C0006104] dopamine [MeSH:C0013030] [MeSH:C0013030] increase renal excretion [MeSH:C1373187] ammonia [MeSH:C0002607] urea intraventricular [MeSH:C0206177] infusion [MeSH:C0841792] dopamine [MeSH:C0013030] [MeSH:C0013030] sufficient raise brain [MeSH:C0006104] [MeSH:C0006104] dopamine [MeSH:C0013030] [MeSH:C0013030] extent [MeSH:C1449716] prevent [MeSH:C0000918] [MeSH:C0000918] [MeSH:C0000918] ammonia [MeSH:C0002607] coma [MeSH:C0002607] affect [MeSH:C0001721] blood brain [MeSH:C0005767] [MeSH:C0005767] [MeSH:C0005767] [MeSH:C0006104] [MeSH:C0006104] [MeSH:C0005767] ammonia [MeSH:C0002607] concentrat [MeSH:C0034721]ion bilateral nephrectomy [MeSH:C0027695] eliminate beneficial effect l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] blood brain [MeSH:C0005767] [MeSH:C0005767] [MeSH:C0005767] [MeSH:C0006104] [MeSH:C0006104] [MeSH:C0005767] ammonia [MeSH:C0002607] ammonia [MeSH:C0002607] coma [MeSH:C0002607] prevent [MeSH:C0000918] [MeSH:C0000918] [MeSH:C0000918] reduction [MeSH:C1827449] blood brain [MeSH:C0005767] [MeSH:C0005767] [MeSH:C0005767] [MeSH:C0006104] [MeSH:C0006104] [MeSH:C0005767] ammonia [MeSH:C0002607] prevent [MeSH:C0000918] [MeSH:C0000918] [MeSH:C0000918]ion ammonia [MeSH:C0002607] coma [MeSH:C0002607] l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] account peripheral effect dopamine [MeSH:C0013030] [MeSH:C0013030] renal function central action result provide reasonable explanation beneficial effect observe encephalopathic patient [MeSH:C0085584] receive l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570],neurological|hepatorenal
absence [MeSH:C0270823] acute cerebral vasoconstriction [MeSH:C0042396] cocaine-associated subarachnoid hemorrhage,introduction [MeSH:C0033268] cocaine [MeSH:C0009170] [MeSH:C0009170] use associate [MeSH:C0004083] neurovascular complication include arterial [MeSH:C0003835] [MeSH:C0003835] vasoconstriction vasculitis [MeSH:C0042384] study angiographic effect cocaine [MeSH:C0009170] [MeSH:C0009170] human [MeSH:C0086418] cerebral artery [MeSH:C0007770] [MeSH:C0007770] information effect obtain angiogram [MeSH:C4255126] [MeSH:C4255126] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine [MeSH:C0009170] [MeSH:C0009170]-associate [MeSH:C0004083]d subarachnoid hemorrhage sah undergo angiography [MeSH:C0002978] shortly cocaine [MeSH:C0009170] [MeSH:C0009170] use method screen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sah retrospectively identify positive urine [MeSH:C0042036] toxicology cocaine [MeSH:C0009170] [MeSH:C0009170] metabolite quantitative [MeSH:C0597336] [MeSH:C0597336] arterial [MeSH:C0003835] [MeSH:C0003835] diameter measurement [MeSH:C0030198] angiogram [MeSH:C4255126] [MeSH:C4255126] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] compare measurement [MeSH:C0030198] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sah match factor know influence [MeSH:C0683549] arterial [MeSH:C0003835] [MeSH:C0003835] diameter qualitative [MeSH:C0949415] [MeSH:C0949415] comparison small artery change result thirteen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] positive cocaine [MeSH:C0009170] [MeSH:C0009170] toxicology compare control difference group [MeSH:C0009932] mean diameter intradural internal carotid sphenoidal segment middle cerebral precommunicating segment anterior cerebral basilar artery p great comparison unpaired t-test difference group express diameter sum precommunicate segment anterior cerebral sphenoidal segment middle cerebral supraclinoid internal carotid artery basilar artery divide diameter petrous internal carotid artery p [MeSH:C0007276] great unpaired t-test qualitative [MeSH:C0949415] [MeSH:C0949415] assessment show arterial [MeSH:C0003835] [MeSH:C0003835] irregularity distal vasculature quantitative [MeSH:C0597336] [MeSH:C0597336] evidence [MeSH:C5575834] narrowing large cerebral artery [MeSH:C0007770] [MeSH:C0007770] qualitative [MeSH:C0949415] [MeSH:C0949415] angiographic evidence [MeSH:C5575834] distal narrowing vasculitis [MeSH:C0042384] find patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo angiography [MeSH:C0002978] aneurysmal sah associate [MeSH:C0004083] cocaine [MeSH:C0009170] [MeSH:C0009170] use,neurological|cardiovascular
hepatonecrosis cholangitis related long-term [MeSH:C0023977] phenobarbital therapy [MeSH:C0031412] autopsy [MeSH:C0004398] report patient [MeSH:C0030705],phenobarbital [MeSH:C0031412] pb reputation safety commonly believe pb-related increase serum aminotransferase level indicate predict development [MeSH:C0243107] chronic liver disease [MeSH:C0008679] report adult [MeSH:C0001675] patient [MeSH:C0030705] long history epilepsy [MeSH:C0014544] treat pb die suddenly consequence [MeSH:C0079160] cardiac arrest [MeSH:C0018790] acute bronchopneumonia [MeSH:C0006285] autopsy [MeSH:C0004398] liver parenchyma reveal rich portal inflammatory infiltrate consist mixed eosinophil [MeSH:C0014467] monocyte cell [MeSH:C0026473] associate [MeSH:C0004083] focus necrosis [MeSH:C0027540] surround hard ring non-specific granulomatous tissue [MeSH:C0018180] inflammatory reaction [MeSH:C0021368] internal external [MeSH:C0021783] hepatic biliary duct see finding illustrate pb associate [MeSH:C0004083] chronic liver damage [MeSH:C0006109] lead deleterious consequence [MeSH:C0079160] reason clinician [MeSH:C0028654] recognize entity differential diagnosis [MeSH:C0011906] pb-related asymptomatic [MeSH:C2936329] chronic hepatic enzyme dysfunction,neurological|hepatorenal
insufficiency [MeSH:C1565489] atrial fibrillation [MeSH:C0004238] vascular insight,investigate [MeSH:C0035173] statin effect dementia glomerulus method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo retrospective hepatitis hepatocellular carcinoma [MeSH:C2239176] assessment [MeSH:C0030198] result well quality life measure cost-effectiveness [MeSH:C1511536] implication,cardiovascular|hepatorenal
myo-inositol phosphate mip synthase [MeSH:C0021557] inhibition [MeSH:C0027790] in-vivo rat [MeSH:C0034721],lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] valproate [MeSH:C0080356] prototypic mood stabilizer diverse structure target drug influence inositol metabolism [MeSH:C0025519] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] inhibit [MeSH:C0021463] [MeSH:C0021463] impase valproate [MeSH:C0080356] [MeSH:C0080356] inhibit [MeSH:C0021463] [MeSH:C0021463] mip synthase show mip synthase inhibit [MeSH:C0021463] [MeSH:C0021463]ion replicate augment effect lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] inositol sensitive pilocarpine-induced seizure model [MeSH:C0011381] lack effect stem low contribution de-novo synthesis [MeSH:C3178925] [MeSH:C3178925] cellular inositol supply inhibit [MeSH:C0021463] [MeSH:C0021463]ion de-novo synthesis [MeSH:C3178925] [MeSH:C3178925] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870],neurological
neuromuscular blockade [MeSH:C0235062] magnesium sulfate [MeSH:C0024480] nifedipine [MeSH:C0028066],receive tocolysis [MeSH:C0040348] nifedipine [MeSH:C0028066] [MeSH:C0028066] develop neuromuscular blockade [MeSH:C0235062] mg magnesium sulfate administer reaction [MeSH:C0024480] demonstrate nifedipine [MeSH:C0028066] [MeSH:C0028066] seriously potentiate toxicity [MeSH:C0040539] magnesium caution [MeSH:C0024467] exercise [MeSH:C0015259] tocolytic [MeSH:C0040349] combine,neurological
memory facilitation stimulation endogenous [MeSH:C0205752] nerve growth factor synthesis [MeSH:C0027752] acetylcholine releaser [MeSH:C0001041] pg-,effect [MeSH:C4277511] [MeSH:C4277511] pg- 3alpha-tropyl p-bromophenyl propionate acetylcholine releaser [MeSH:C0001041] memory process nerve growth factor [MeSH:C0027752] ngf [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] synthesis [MeSH:C3178925] evaluate [MeSH:C0013175] mouse [MeSH:C0026809] passive-avoidance test pg- mg kg p administer min training [MeSH:C2673163] session prevent [MeSH:C0000918] [MeSH:C0000918] amnesia [MeSH:C0002622] induce non selective antimuscarinic drug [MeSH:C0013227] scopolamine m1-selective antagonist s- -et- experimental condition [MeSH:C0243063] pg- microg mouse [MeSH:C0026809] c v able prevent [MeSH:C0000918] [MeSH:C0000918] antimuscarine-induced amnesia [MeSH:C0002622] demonstrate central localization activity [MeSH:C0020115] high effect [MeSH:C4277511] [MeSH:C4277511]ive dose pg- produce collateral symptom reveal irwin test modify spontaneous [MeSH:C0000786] motility inspection activity [MeSH:C0020115] reveal hole-board test pg- able increase ngf [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] secrete [MeSH:C0036534] vitro astrocyte [MeSH:C0004112] dose-dependent manner maximal ngf [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] content [MeSH:C0017177] obtain pg- -fold culture [MeSH:C0010453] morphological change find effect [MeSH:C4277511] [MeSH:C4277511]ive concentration [MeSH:C0311432] pg- current work indicate ability [MeSH:C0085732] pg- induce beneficial effect [MeSH:C4277511] [MeSH:C4277511] cognitive process [MeSH:C0582591] [MeSH:C0582591] stimulate activity [MeSH:C0020115] ngf [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] synthesis [MeSH:C3178925] astroglial cell [MeSH:C0004112] pg- represent potential [MeSH:C0001272] useful drug [MeSH:C0013227] able improve function [MeSH:C0031843] impaired [MeSH:C0020580] cognitive process [MeSH:C0582591] [MeSH:C0582591],neurological
gonosomal mosaicism myotonic dystrophy patient [MeSH:C0030705] involvement mitotic event ctg n repeat variation selection extreme expansion sperm [MeSH:C0037868],myotonic dystrophy dm [MeSH:C0027126] cause abnormal [MeSH:C0853087] expansion [MeSH:C0196940] polymorphic ctg n repeat located dm protein kinase gene [MeSH:C0033640] determine ctg n repeat length broad range tissue [MeSH:C0040300] dna [MeSH:C0040300] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mild classical congenital manifestation [MeSH:C0029166] dm difference repeat length see somatic tissue [MeSH:C0040300] [MeSH:C0040300] single dm individual twin repeat appear expand similar extent tissue [MeSH:C0040300] originate embryonal origin male [MeSH:C0086582] [MeSH:C0086582] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] carry intermediate- small-sized expansion [MeSH:C0196940] blood [MeSH:C0005767] repeat length cover markedly wide range sperm [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] contrast male [MeSH:C0086582] [MeSH:C0086582] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] large allele expansion [MeSH:C0196940] blood [MeSH:C0005767] ctgs similar small repeat sperm [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] detectable sperm [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] allele ctg see conclude dm patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] consider gonosomal mosaic e e combined somatic germ-line tissue [MeSH:C0040300] mosaic remarkably observe multiple case length distribution intermediate- small-sized allele father [MeSH:C0002085] sperm [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] significantly different offspring [MeSH:C0683572] blood [MeSH:C0005767] combined finding indicate intergenerational [MeSH:C0085419] length change unstable ctg repeat likely occur early embryonic [MeSH:C0013947] mitotic division somatic germ-line tissue [MeSH:C0040300] formation [MeSH:C0029433] initial ctg length overall number cell division [MeSH:C0007590] involve tissue [MeSH:C0040300] formation [MeSH:C0029433] specific selection process sperm [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868]atogenesis influence dynamic process model explain mitotic instability sex-dependent segregation [MeSH:C0007616] phenomenon [MeSH:C2350469] dm manifestation [MeSH:C0029166] discuss,neurological
diabetes mellitus [MeSH:C0011849] cardiovascular lens [MeSH:C0007220],stroke [MeSH:C0038454] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve heart block [MeSH:C0018794] venous method conduct prospective evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine pacemaker [MeSH:C3494452] parameter result improvement primary endpoint relevance,cardiovascular
pseudo-allergic reaction corticosteroid diagnosis [MeSH:C0011900] alternative,patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat parenteral paramethasone [MeSH:C0030454] [MeSH:C0030454] [MeSH:C0030454] [MeSH:C0030454] triniol dexamethasone sedionbel describe minute administration [MeSH:C0001554] drug present urticaria [MeSH:C0042109] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] conjunctivitis determine cause patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] reaction immunological [MeSH:C0021061] mechanism [MeSH:C1524059] [MeSH:C1524059] involve patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] able tolerate kind corticoid examination [MeSH:C0001617] skin [MeSH:C1123023] oral [MeSH:C0029170] parenteral challenge different corticosteroid [MeSH:C0001617] elisa test [MeSH:C0001617] perform patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] skin [MeSH:C1123023] elisa test paramethasone [MeSH:C0030454] [MeSH:C0030454] [MeSH:C0030454] negative prick test excipient single-blind parenteral challenge triniol positive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] administration ml drug negative excipient carry oral [MeSH:C0029170] parenteral challenge corticosteroid [MeSH:C0001617] find intolerance [MeSH:C0022951] result suggest paramethasone [MeSH:C0030454] [MeSH:C0030454] [MeSH:C0030454] cause pseudoallergic reaction [MeSH:C1527304] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] corticosteroid [MeSH:C0001617] different paramethasone [MeSH:C0030454] [MeSH:C0030454] [MeSH:C0030454] produce hypersensitivity reaction [MeSH:C0020517] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] tolerate basic mechanism [MeSH:C1524059] [MeSH:C1524059] reaction fully understand knowledge report [MeSH:C0376554] pseudo-allergy cause paramethasone [MeSH:C0030454] [MeSH:C0030454] [MeSH:C0030454],neurological
dysarthria pathway ventricular tachycardia [MeSH:C0042514],investigate [MeSH:C0035173] beta-blocker effect heart disease ataxia method elderly patient undergo randomized control cognitive impairment [MeSH:C0338656] cerebrospinal fluid [MeSH:C0007806] assessment [MeSH:C0030198] result superior efficacy therapeutic innovation [MeSH:C0087111],neurological
involvement [MeSH:C0030699] mu-opiate receptor peripheral analgesia,intradermal [MeSH:C0021881] injection [MeSH:C1828121] mu morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] tyr-d-ala-gly-nme-phe-gly-ol morphiceptin kappa trans- -dichloro-n-methyl-n -pyrrolidinyl cyclohexyl benzeneactemide delta d-pen2 -enkephalin d-ser2 leu enkephalin-thr selective opioid [MeSH:C0242402]-agonist significantly affect mechanical nociceptive threshold hindpaw rat [MeSH:C0034721] intradermal [MeSH:C0021881] injection [MeSH:C1828121] mu delta kappa opioid [MeSH:C0242402]-agonist produce dose-dependent inhibition prostaglandin e2-induce hyperalgesia [MeSH:C0020429] analgesic effect [MeSH:C0002771] mu-agonist morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] dose-dependently antagonize naloxone [MeSH:C0027358] prevent [MeSH:C0000918] co-injection [MeSH:C1828121] [MeSH:C1828121] pertussis toxin [MeSH:C0020731] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] alter hyperalgesia [MeSH:C0020429] induce -bromo cyclic adenosine monophosphate [MeSH:C0001455] conclude analgesic action [MeSH:C0002771] opioid [MeSH:C0242402] peripheral [MeSH:C3658334] terminal primary afferent bind site characteristic mu-opioid [MeSH:C0242402] receptor action mediate inhibition cyclic adenosine monophosphate [MeSH:C0001455] second messenger system,neurological
organ [MeSH:C0029250] orchestra hypertension,investigate [MeSH:C0035173] statin effect dementia [MeSH:C0497327] hemodialysis [MeSH:C0019004] method adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective [MeSH:C0035363] cholestasis [MeSH:C0008370] bilirubin [MeSH:C0005437] assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] therapeutic [MeSH:C0087111] innovation,hepatorenal
support adrenaline [MeSH:C0014563]-hypertension hypothesis [MeSH:C3179072] hour pressor [MeSH:C0033093] effect hour adrenaline [MeSH:C0014563] infusion [MeSH:C0841792],double blind crossover [MeSH:C0150097] h infusion [MeSH:C0841792] [MeSH:C0841792] adrenaline [MeSH:C0014563] [MeSH:C0014563] ng kg min ng pmol noradrenaline [MeSH:C0014563] [MeSH:C0028351] [MeSH:C0014563] ng kg min ng pmol dextrose solution ml h give healthy [MeSH:C0452415] volunteer random order week apart mean intra-arterial ambulatory monitoring [MeSH:C0242882] haemodynamic effect follow h infusion [MeSH:C0841792] [MeSH:C0841792] stop adrenaline [MeSH:C0014563] [MeSH:C0014563] noradrenaline [MeSH:C0014563] [MeSH:C0028351] [MeSH:C0014563] cause delay [MeSH:C5544400] [MeSH:C5544400] protracted pressor [MeSH:C0033093] [MeSH:C0033093] effect total postinfusion [MeSH:C0841792] [MeSH:C0841792] period systolic diastolic arterial pressure sem respectively high dextrose infusion [MeSH:C0841792] [MeSH:C0841792] anova p stress [MeSH:C0018850] level adrenaline [MeSH:C0014563] [MeSH:C0014563] pg ml h cause delay [MeSH:C5544400] [MeSH:C5544400] protracted pressor [MeSH:C0033093] [MeSH:C0033093] effect finding strong support adrenaline [MeSH:C0014563] [MeSH:C0014563]-hypertension hypothesis [MeSH:C3179072] man,cardiovascular|hepatorenal
developmental [MeSH:C0017340] clonidine [MeSH:C0009014] effect [MeSH:C4277511] cardiac rat [MeSH:C0034721]e [MeSH:C0018810] ultrasound production [MeSH:C3179343] infant [MeSH:C0021270] rat [MeSH:C0034721],control condition infant [MeSH:C0021270] rat [MeSH:C0034721] [MeSH:C0034721] emit ultrasonic [MeSH:C1456803] vocalization [MeSH:C0042932] extreme cold exposure administrat [MeSH:C0034721] [MeSH:C0034721]ion alpha adrenoceptor agonist clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] previous investigation [MeSH:C0035173] determine response [MeSH:C0034746] clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] ultrasound production [MeSH:C3179343] [MeSH:C3179343] [MeSH:C3179343] increase 2nd-week postpartum [MeSH:C0086839] decrease give sympathetic [MeSH:C0001646] neural dominance [MeSH:C0037413] exhibit similar developmental [MeSH:C0017340] pattern [MeSH:C0017340] give clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] induce sympathetic [MeSH:C0001646] withdrawal bradycardia hypothesize clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] developmental [MeSH:C0017340] effect [MeSH:C4277511] [MeSH:C4277511] cardiac rat [MeSH:C0034721] [MeSH:C0034721]e ultrasound production [MeSH:C3179343] [MeSH:C3179343] [MeSH:C3179343] mirror [MeSH:C3178760] present experiment [MeSH:C0020123] [MeSH:C0020123] effect [MeSH:C4277511] [MeSH:C4277511] clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] administrat [MeSH:C0034721] [MeSH:C0034721]ion mg kg cardiac rat [MeSH:C0034721] [MeSH:C0034721]e ultrasound production [MeSH:C3179343] [MeSH:C3179343] [MeSH:C3179343] examine -day-old rat [MeSH:C0034721] [MeSH:C0034721] age-related change ultrasound production [MeSH:C3179343] [MeSH:C3179343] [MeSH:C3179343] correspond change cardiovascular [MeSH:C0007220] variable [MeSH:C0013675] include cardiac rat [MeSH:C0034721] [MeSH:C0034721]e clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014]-induced bradycardia experiment [MeSH:C0020123] [MeSH:C0020123] discuss regard hypothesis [MeSH:C3179072] ultrasound production [MeSH:C3179343] [MeSH:C3179343] [MeSH:C3179343] acoustic [MeSH:C0001166] by-product physiological maneuver compensate clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] detrimental effect [MeSH:C4277511] [MeSH:C4277511] cardiovascular [MeSH:C0007220] function,cardiovascular
test condition influence response drug challenge rodent,study [MeSH:C0085973] conduct examine differential response drug challenge varied experimental test [MeSH:C0016998] condition [MeSH:C0037403] routinely employ drug-induced [MeSH:C1320835] behavior [MeSH:C0004927]al [MeSH:C0004927] neurophysiological response [MeSH:C0449430] [MeSH:C3658203] rodent [MeSH:C0035804] [MeSH:C0035804] [MeSH:C0035804] [MeSH:C0035804] apomorphine [MeSH:C0003596] [MeSH:C0003596] nonselective dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] agonist [MeSH:C0178601] select biphasic [MeSH:C0356369] behavior [MeSH:C0004927]al [MeSH:C0004927] effect ability induce hypothermia [MeSH:C0020672] produce distinct change dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] turnover [MeSH:C0085268] [MeSH:C0085268] rodent [MeSH:C0035804] [MeSH:C0035804] [MeSH:C0035804] [MeSH:C0035804] brain experiment evidence characterization detection [MeSH:C5392129] [MeSH:C5392129] apomorphine [MeSH:C0003596] [MeSH:C0003596]-induced activity rodent [MeSH:C0035804] [MeSH:C0035804] [MeSH:C0035804] [MeSH:C0035804] critically depend test condition [MeSH:C0037403] employ rat [MeSH:C0034721] detection [MeSH:C5392129] [MeSH:C5392129] apomorphine [MeSH:C0003596] [MeSH:C0003596]-induced hyperactivity facilitate period [MeSH:C0080129] acclimatization [MeSH:C0000934] test condition [MeSH:C0037403] test condition [MeSH:C0037403] impact physiological response [MeSH:C0449430] apomorphine [MeSH:C0003596] [MeSH:C0003596] drug-induced [MeSH:C1320835] hypothermia [MeSH:C0020672] mouse apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] produce qualitatively different response novel condition [MeSH:C0037403] compare behavior [MeSH:C0004927] elicit home test cage drug-induced [MeSH:C1320835] gross activity count increase novel explorat [MeSH:C0034721]ory box measure stereotypic behavior [MeSH:C0038271] [MeSH:C0004927] similar contrast apomorphine [MeSH:C0003596] [MeSH:C0003596]-induced locomotion prominent novel explorat [MeSH:C0034721]ory box dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] turnover [MeSH:C0085268] [MeSH:C0085268] rat [MeSH:C0034721]io dopac [MeSH:C0000376] da hva da find low animal [MeSH:C0003062] expose explorat [MeSH:C0034721]ory box compare home cage counterpart apomorphine [MeSH:C0003596] [MeSH:C0003596]-induced reduction striatal dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] turnover [MeSH:C0085268] [MeSH:C0085268] detect novel home cage environment [MeSH:C0442519] implication finding discuss particular emphasis conduct psychopharmacological challenge test rodent [MeSH:C0035804] [MeSH:C0035804] [MeSH:C0035804] [MeSH:C0035804],neurological
regurgitation [MeSH:C0026266] multiple sclerosis [MeSH:C0026769] vascular insight,investigate [MeSH:C0035173] beta-blocker effect heart disease arrhythmia method [MeSH:C0003811] cardiac patient undergo prospective heart failure ischemic cardiomyopathy assessment [MeSH:C0030198] result positive response safety consideration,cardiovascular
liver cancer [MeSH:C0345904] cancer lymphoma [MeSH:C0024299],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve diabete outcome non-hodgkin lymphoma pathway method [MeSH:C0024305] longitudinal trial cancer patient measure cervical cancer [MeSH:C4048328] endometrial cancer [MeSH:C0476089] result positive response practice guideline [MeSH:C0936005],oncological
brain map [MeSH:C0006104] liver cirrhosis [MeSH:C0023890] insight,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] [MeSH:C0035173] ace inhibitor cancer [MeSH:C0003015] participant cancer patient [MeSH:C0030705] neurofibroma myasthenia gravis [MeSH:C0026896] result improve disease management [MeSH:C0039798] cerebrovascular [MeSH:C0007820] correlation [MeSH:C0010100] need investigation [MeSH:C0035173] [MeSH:C0035173],neurological
liver fibrosis pathway parkinson disease [MeSH:C0030567],diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve renal cell carcinoma [MeSH:C0007134] azotemia method [MeSH:C0242528] conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine transaminase [MeSH:C0002594] parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,hepatorenal
ultrasound reveal leukemia secret,question [MeSH:C0600648] metformin [MeSH:C0025598] affect diabete cerebral infarction mechanism method longitudinal diabetic [MeSH:C0023981] patient [MeSH:C0030705] assessing ggt neuropathy result well quality life measure implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|hepatorenal
cardiomyopathy cerebrovascular explore neural pathway [MeSH:C0027792],design [MeSH:C0013171] observational [MeSH:C0302523] investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] elderly patient gaba stroke [MeSH:C0038454] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] meningitis [MeSH:C0025289] correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological
prolonged hypothermia [MeSH:C0020672] bridge recovery cerebral edema intracranial hypertension [MeSH:C0151740] associate fulminant [MeSH:C0302809] hepatic failure [MeSH:C0085605],review [MeSH:C0282443] evidence-based option [MeSH:C0376537] patient cerebral edema [MeSH:C0006114] [MeSH:C0006114] complicate fulminant [MeSH:C0302809] hepatic failure [MeSH:C0085605] fhf discuss potential [MeSH:C0001272] application hypothermia [MeSH:C0020672] [MeSH:C0020672] case-based observation medical intensive care unit [MeSH:C0021708] micu tertiary care facility [MeSH:C3494403] -year-old female [MeSH:C0086287] fhf acetaminophen [MeSH:C0000970] [MeSH:C0000970] resultant cerebral edema [MeSH:C0006114] result admit micu find unresponsive presume toxicity [MeSH:C0040539] acetaminophen [MeSH:C0000970] [MeSH:C0000970] ingest [MeSH:C0232478] -day period [MeSH:C0080129] depressed mental status last h prior admission [MeSH:C0030673] initial confirm fhf acetaminophen [MeSH:C0000970] [MeSH:C0000970] cerebral edema [MeSH:C0006114] treat hyperosmolar therapy hyperventilation [MeSH:C0020578] sedation [MeSH:C0079159] chemical paralysis [MeSH:C0522224] intracranial pressure [MeSH:C0021880] remain elevated [MeSH:C0020443] despite maximal medical therapy [MeSH:C1257928] initiate therapeutic hypothermia [MeSH:C0020672] [MeSH:C0020674] [MeSH:C0020674] [MeSH:C0020672] continue day re-warme resolution cerebral edema [MeSH:C0006114] intracranial hypertension [MeSH:C0151740] discharge [MeSH:C0030685] complete recovery [MeSH:C0140116] neurological [MeSH:C0026345] hepatic function [MeSH:C0031843] patient fhf cerebral edema [MeSH:C0006114] [MeSH:C0006114] acetaminophen [MeSH:C0000970] [MeSH:C0000970] overdose prolong therapeutic hypothermia [MeSH:C0020672] [MeSH:C0020674] [MeSH:C0020674] [MeSH:C0020672] potential [MeSH:C0001272]ly life saving therapy bridge hepatic neurological [MeSH:C0026345] recovery [MeSH:C0140116] trial hypothermia [MeSH:C0020672] [MeSH:C0020672] patient condition warrant,neurological|cardiovascular|hepatorenal
parkinson disease [MeSH:C0030567] meet angina pectoris [MeSH:C0002962] neurological perspective,hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] cerebral cortex pathway method longitudinal trial cancer patient [MeSH:C0030705] measuring neuropathy [MeSH:C0015464] huntington disease result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],neurological
sodium status influence chronic amphotericin b [MeSH:C0002679] nephrotoxicity rat [MeSH:C0034721],nephrotoxic potential amphotericin [MeSH:C0085795] b [MeSH:C0002679] mg kg intraperitoneally week investigate [MeSH:C0035173] salt-depleted normal-salt salt-loaded rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] salt-depleted rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] amphotericin [MeSH:C0085795] b [MeSH:C0002679] decrease creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] clearance [MeSH:C5243473] linearly reduction [MeSH:C1827449] [MeSH:C1827449] week contrast normal-salt rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] clearance [MeSH:C5243473] decrease less extent week salt-loaded rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] clearance [MeSH:C5243473] week decrease week rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] sodium-depleted histopathological evidence [MeSH:C5575834] patchy tubular cytoplasmic degenerat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion tubule observe normal-salt salt-loaded rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion amphotericin [MeSH:C0085795] b [MeSH:C0002679] plasma [MeSH:C0032105] significantly different group [MeSH:C0018257] end week amphotericin [MeSH:C0085795] b [MeSH:C0002679] level kidney liver significantly high salt-depleted normal-salt rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] salt-loaded rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] plasma [MeSH:C0032105] kidney rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]io salt-depleted normal-salt salt-loaded rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] respectively reduction [MeSH:C1827449] [MeSH:C1827449] creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] clearance [MeSH:C5243473] renal amphotericin [MeSH:C0085795] b [MeSH:C0002679] accumulation [MeSH:C0311432] chronic amphotericin [MeSH:C0085795] b [MeSH:C0002679] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion enhance salt depletion attenuate [MeSH:C0042211] sodium loading rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721],hepatorenal
nitro-l-arginine methyl ester potential protector gentamicin [MeSH:C3854019] ototoxicity [MeSH:C0235280],nitric oxide inhibitor [MeSH:C0003015] nitro-l-arginine methyl ester l-name [MeSH:C0083536] [MeSH:C0083536] act otoprotectant high-frequency hearing loss [MeSH:C0018780] cause gentamicin [MeSH:C3854019] [MeSH:C3854019] study [MeSH:C0085973] need confirm aminoglycoside [MeSH:C0002556] antibiotic [MeSH:C0003232] widely virtue efficacy [MeSH:C5690761] low cost [MeSH:C0010186] ototoxicity [MeSH:C0235280] health problem ototoxic mechanism involve production [MeSH:C0033268] need assess use inhibitor [MeSH:C0003015] prevention [MeSH:C2700409] aminoglycoside [MeSH:C0002556]-induced sensorineural hearing loss experimental sprague-dawley rat [MeSH:C0034721] gentamicin [MeSH:C3854019] [MeSH:C3854019] instill middle ear [MeSH:C0013455] otoprotectant l-name [MeSH:C0083536] administer topically animal effect determine term attenuation [MeSH:C1720750] hear loss measure shift auditory brainstem response threshold [MeSH:C0162703] l-name [MeSH:C0083536] reduce gentamicin [MeSH:C3854019] [MeSH:C3854019]-induced hearing loss high-frequency range give protection [MeSH:C0524828] middle low frequency,neurological
stroke [MeSH:C0038454] bundle branch block [MeSH:C0006384] cardiac connection,dementia [MeSH:C0497327] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve bundle branch block aortic valve method [MeSH:C0006384] conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine venous parameter result positive response therapeutic innovation [MeSH:C0087111],cardiovascular
leukemia bile duct [MeSH:C0023418] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] hepatocellular pathway method longitudinal trial [MeSH:C0023981] adult population measure acute kidney injury [MeSH:C2609414] primary biliary cholangitis [MeSH:C0008312] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
microinjection [MeSH:C0025991] ritanserin [MeSH:C0085260] ca1 region hippocampus [MeSH:C3887642] improve scopolamine-induced amnesia adult [MeSH:C0001675] male [MeSH:C0086582] rat [MeSH:C0034721],effect [MeSH:C4277511] ritanserin [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] -ht2 antagonist [MeSH:C0033607] scopolamine [MeSH:C0036442] [MeSH:C0036442] muscarinic cholinergic antagonist [MeSH:C0003385] [MeSH:C0033607] -induced amnesia [MeSH:C0002622] morris water maze [MeSH:C5197854] mwm investigate [MeSH:C0035173] rat [MeSH:C0034721] [MeSH:C0034721] divide group [MeSH:C0018257] bilaterally cannulate ca1 region hippocampus [MeSH:C3887642] [MeSH:C3887642] week later receive repeatedly vehicle saline dmso [MeSH:C0012403] [MeSH:C0012403] saline dmso [MeSH:C0012403] [MeSH:C0012403] scopolamine [MeSH:C0036442] [MeSH:C0036442] microg microl saline min training [MeSH:C2673163] ritanserin [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] microg microl dmso min train scopolamine [MeSH:C0036442] [MeSH:C0036442] microg microl min ritanserin [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] injection [MeSH:C1828121] ritanserin [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] microg microl dmso cannulae animal test consecutive day trial mwm position [MeSH:C0033422] hide platform unchanged fifth platform elevated water surface position [MeSH:C0033422] evaluate [MeSH:C0013175] function motor motivational [MeSH:C0026605] visual system result show increase escape latency travel [MeSH:C0040802] [MeSH:C0040802] distance [MeSH:C1136180] [MeSH:C1136180] find platform scopolamine [MeSH:C0036442] [MeSH:C0036442]-treated compare saline ritanserin [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260]-treated rat [MeSH:C0034721] [MeSH:C0034721] microg microl show decrease mention parameter compare dmso-treated scopolamine [MeSH:C0036442] [MeSH:C0036442] ritanserin [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] co-administrat [MeSH:C0034721] [MeSH:C0034721]ion result decrease escape latency travel [MeSH:C0040802] [MeSH:C0040802] distance [MeSH:C1136180] [MeSH:C1136180] compare scopolamine [MeSH:C0036442] [MeSH:C0036442]-treated rat [MeSH:C0034721] [MeSH:C0034721] finding microinjection [MeSH:C0025991] [MeSH:C1828121] ritanserin [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] [MeSH:C0085260] ca1 region hippocampus [MeSH:C3887642] [MeSH:C3887642] improve scopolamine [MeSH:C0036442] [MeSH:C0036442]-induced amnesia [MeSH:C0002622],neurological
reticular formation pattern heart failure patient [MeSH:C0030705],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect stroke [MeSH:C0038454] astrocytoma method cancer [MeSH:C0004114] patient [MeSH:C0030705] undergo randomized control sciatica neural assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
propranolol [MeSH:C0033497] antagonism [MeSH:C0013159] phenylpropanolamine-induced hypertension,phenylpropanolamine [MeSH:C0031495] ppa overdose cause severe [MeSH:C1719672] hypertension [MeSH:C0020538] [MeSH:C0020538] intracerebral hemorrhage death [MeSH:C2937358] study efficacy [MeSH:C5690761] safety [MeSH:C0036043] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] ppa-induced hypertension [MeSH:C0020538] [MeSH:C0020538] subject receive propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] mouth [MeSH:C0226896] hour ppa rapid intravenous [MeSH:C0085297] [MeSH:C0085297] infusion ppa ppa mg increase blood pressure [MeSH:C0005823] [MeSH:C0005823] [MeSH:C0005823] mm hg systolic mm hg diastolic propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] pretreatment [MeSH:C0376495] antagonize increase mm hg systolic mm hg diastolic intravenous [MeSH:C0085297] [MeSH:C0085297] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] ppa decrease blood pressure [MeSH:C0005823] [MeSH:C0005823] [MeSH:C0005823] leave ventricular function [MeSH:C0080309] assess echocardiography [MeSH:C0013516] show ppa increase stroke [MeSH:C0038454] volume [MeSH:C5690805] ml ejection fraction cardiac output [MeSH:C0007165] [MeSH:C0007165] l min intravenous [MeSH:C0085297] [MeSH:C0085297] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] reverse effect systemic [MeSH:C5544477] [MeSH:C5544477] vascular resistance [MeSH:C0042380] [MeSH:C0042380] increase ppa dyne x sec cm5 increase propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] dyne x sec cm5 conclude ppa increase blood pressure [MeSH:C0005823] [MeSH:C0005823] [MeSH:C0005823] increase systemic [MeSH:C5544477] [MeSH:C5544477] vascular resistance [MeSH:C0042380] [MeSH:C0042380] cardiac output [MeSH:C0007165] [MeSH:C0007165] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] antagonize increase reverse effect ppa cardiac output [MeSH:C0007165] [MeSH:C0007165] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] antagonize pressor [MeSH:C0033093] [MeSH:C0033093] effect ppa contrast interaction propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] enhance pressor [MeSH:C0033093] [MeSH:C0033093] effect norepinephrine [MeSH:C0028351] [MeSH:C0028351] probably ppa beta activity norepinephrine [MeSH:C0028351] [MeSH:C0028351],cardiovascular
hypertension [MeSH:C0020538] capillary [MeSH:C0006901] cardiac connection,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect stroke [MeSH:C0038454] thromboembolism mechanism method [MeSH:C0040038] randomized control diabetic patient [MeSH:C0030705] assess peripheral artery disease [MeSH:C1704436] stenosis [MeSH:C1261287] result improvement primary endpoint implication relevance,cardiovascular
stroke [MeSH:C0038454] hydronephrosis [MeSH:C0020295] organ [MeSH:C0029250] interplay,observational [MeSH:C0302523] examine ace inhibitor [MeSH:C0003015] cancer cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include end stage renal disease [MeSH:C0022661] liver fibrosis bile duct method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
leukemia [MeSH:C0023418] kidney [MeSH:C0022646] organ interplay,observational [MeSH:C0302523] examine statin [MeSH:C0360714] dementia diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include fatty liver hematuria [MeSH:C0015695] renal cyst method participant [MeSH:C1708335] include result well quality life measure implication need investigation [MeSH:C0035173] [MeSH:C0035173],hepatorenal
creatinine pathway dementia [MeSH:C0497327],cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve blood urea [MeSH:C0005845] nitrogen pkd method conduct longitudinal [MeSH:C0023981] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine albumin [MeSH:C0001924] parameter result positive response relevance [MeSH:C2826293],hepatorenal
stenosis [MeSH:C1261287] angina pectoris vascular insight,longitudinal examine statin diabete diabetic patient [MeSH:C0030705] investigation [MeSH:C0035173] include sinoatrial node chf stroke method participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication care improvement,cardiovascular
hypertensive [MeSH:C0003364] meet lymphoma [MeSH:C0024299] neurological perspective,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve cancer outcome [MeSH:C0206277] [MeSH:C0206277] acetylcholine pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure ischemic cardiomyopathy [MeSH:C0878544] regurgitation [MeSH:C0026266] result improve outcome [MeSH:C0206277] therapeutic innovation [MeSH:C0087111],neurological|cardiovascular
breakthrough hepatocellular [MeSH:C0345904] finding lymphoma [MeSH:C0024299],retrospective [MeSH:C0035363] examine beta-blocker [MeSH:C0001645] dementia adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] [MeSH:C0035173] include albumin kidney [MeSH:C0022646] stone kidney method [MeSH:C0022650] participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication need investigation [MeSH:C0035173] [MeSH:C0035173],hepatorenal
reversibility captopril-induced renal insufficiency [MeSH:C1565489] prolonged use unusual case renovascular hypertension [MeSH:C0020545],report case [MeSH:C0684224] severe hypertension [MeSH:C0020538] occlude renal artery solitary kidney [MeSH:C0266294] develop sudden deterioration renal function [MeSH:C0031843] follow captopril [MeSH:C0006938] [MeSH:C0006938] renal function [MeSH:C0031843] remain impaired [MeSH:C0020580] stable year captopril [MeSH:C0006938] [MeSH:C0006938] return pre-treatment [MeSH:C0039798] level soon cessation drug indicate reversibility captopril [MeSH:C0006938] [MeSH:C0006938]-induced renal failure prolonged use suggest organic damage occur glomerular arteriole follow chronic ace inhibition,cardiovascular|hepatorenal
low incidence [MeSH:C0021149] brca2 [MeSH:C0294028] mutation breast carcinoma cancer [MeSH:C0678222],inherit mutant [MeSH:C1564139] [MeSH:C1564139] allele familial tumour suppressor gene [MeSH:C0079427] [MeSH:C0079427] [MeSH:C0079427] predispose individual [MeSH:C0021228] particular type cancer [MeSH:C0006826] addition involvement [MeSH:C0030699] inherit susceptibility [MeSH:C0012655] [MeSH:C0012655] cancer tumour suppressor gene [MeSH:C0079427] [MeSH:C0079427] target [MeSH:C0039309] somatic mutation [MeSH:C0026882] sporadic cancer type find familial form exception brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] contribute fraction familial breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] undergo mutation [MeSH:C0026882] low rate sporadic breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] suggest gene principal target [MeSH:C0039309] somatic mutation [MeSH:C0026882] breast carcinoma [MeSH:C0678222] [MeSH:C0678222] second recently identify familial breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0346153] gene brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] ref [MeSH:C0294028] account proportion breast cancer [MeSH:C0006142] [MeSH:C0006142] roughly equal brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] like brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] behave dominantly inherit tumour suppressor gene [MeSH:C0079427] [MeSH:C0079427] individual [MeSH:C0021228] inherit mutant [MeSH:C1564139] [MeSH:C1564139] allele increase risk [MeSH:C0035647] breast cancer [MeSH:C0006142] [MeSH:C0006142] tumour develop lose wild-type allele heterozygous [MeSH:C0019425] deletion [MeSH:C0017260] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] coding sequence huge compose exon span bp investigate [MeSH:C0035173] rate brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] mutation [MeSH:C0026882] sporadic breast cancer [MeSH:C0006142] [MeSH:C0006142] set cell line [MeSH:C0007600] represent tumour type surprisingly mutation [MeSH:C0026882] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] infrequent cancer include breast carcinoma [MeSH:C0678222] [MeSH:C0678222] probable germline mutation [MeSH:C0206530] [MeSH:C0026882] pancreatic tumour cell line [MeSH:C0030280] [MeSH:C0007600] suggest role brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] susceptibility [MeSH:C0012655] [MeSH:C0012655] pancreatic cancer [MeSH:C0346647],neurological|oncological
late recovery renal function [MeSH:C0599766] woman hemolytic uremic syndrome [MeSH:C0019061],case report [MeSH:C0684224] hemolytic uremic syndrome hus [MeSH:C0019061] woman [MeSH:C0043210] take oral [MeSH:C0029170] contraceptive treat heparin dipyridamole [MeSH:C0012582] hemodialysis month urinary output rise ml month onset anuria [MeSH:C0003460] dialysis stop [MeSH:C0011945] case emphasize possibility hus adult [MeSH:C0001675] [MeSH:C0001675] invariably irreversible [MeSH:C4319935] despite prolonged oliguria [MeSH:C0028961] recovery [MeSH:C0140116] renal function [MeSH:C0031843] obtain adult [MeSH:C0001675] [MeSH:C0001675] patient [MeSH:C0030705] affect hus dialysis [MeSH:C0011945] discontinue prematurely bilateral nephrectomy severe hypertension [MeSH:C0020538] microangiopathic [MeSH:C0221021] hemolytic anemia [MeSH:C0002878] perform caution,cardiovascular|hepatorenal
dementia [MeSH:C0497327] breast cancer [MeSH:C0006142] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve stroke [MeSH:C0038454] outcome primary biliary cholangitis [MeSH:C0008312] pathway method [MeSH:C0282655] randomized control trial [MeSH:C1096777] cardiac patient measuring kidney [MeSH:C0022646] stone creatinine [MeSH:C0010294] result positive response need investigation [MeSH:C0035173],hepatorenal|oncological
mk- augment pilocarpine-induced electrographic seizure protect brain damage [MeSH:C0006109] rat [MeSH:C0034721],author examine anticonvulsant effect [MeSH:C0003286] mk- pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923]-induced seizure model intraperitoneal [MeSH:C0021493] injection pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] mg kg induce tonic clonic seizure [MeSH:C0494475] scopolamine [MeSH:C0036442] [MeSH:C0036442] mg kg pentobarbital [MeSH:C0030883] [MeSH:C0030883] mg kg prevent [MeSH:C0000918] development [MeSH:C0243107] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923]-induced behavioral seizure mk- mg kg electrical seizure [MeSH:C0036572] measure [MeSH:C0079809] hippocampal [MeSH:C0228249] eeg [MeSH:C0013819] appear pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923]-treated scopolamine [MeSH:C0036442] [MeSH:C0036442] pentobarbital [MeSH:C0030883] [MeSH:C0030883] block pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923]-induced electrographic seizure mk- augment electrographic seizure induce pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] brain damage [MeSH:C0006109] [MeSH:C0006109] [MeSH:C0006109] assess examine hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] microscopically pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] produce neuronal death hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] show pyknotic change pentobarbital [MeSH:C0030883] [MeSH:C0030883] scopolamine [MeSH:C0036442] [MeSH:C0036442] mk- protect brain damage [MeSH:C0006109] [MeSH:C0006109] [MeSH:C0006109] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] mk treat pyramidal cell [MeSH:C0206441] hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] appear dark normal treatment granule cell dentate gyrus affect result indicate status epilepticus [MeSH:C0038220] induce pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] initiate cholinergic [MeSH:C0242893] overstimulation propagate glutamatergic transmission [MeSH:C0040722] elevation cause brain damage [MeSH:C0006109] [MeSH:C0006109] [MeSH:C0006109] excitatory nmda receptor-mediated mechanism,neurological
cardiac na channel dysfunction brugada syndrome aggravate beta -subunit,mutation [MeSH:C0026882] gene [MeSH:C0026882] encode human [MeSH:C0086418] [MeSH:C0086418] cardiac [MeSH:C0018810] na channel alpha-subunit hh1 [MeSH:C1143897] [MeSH:C1143897] responsible chromosome [MeSH:C0008633] -linked congenital long-qt syndrome lqt3 idiopathic ventricular fibrillation [MeSH:C0340493] ivf auxiliary beta -subunit [MeSH:C0887848] [MeSH:C0887848] widely express excitable tissue shift voltage dependence steady-state inactivation [MeSH:C4505109] [MeSH:C0043297] [MeSH:C4505109] [MeSH:C0043297] [MeSH:C0043297] [MeSH:C0043297] [MeSH:C0043297] negative potential restore normal gating kinetic [MeSH:C0049579] brain skeletal muscle [MeSH:C0242692] na channel express xenopus oocyte [MeSH:C0029045] [MeSH:C0029045] [MeSH:C0029045] little functional effect cardiac [MeSH:C0018810] isoform characterize altered effect human [MeSH:C0086418] [MeSH:C0086418] beta -subunit [MeSH:C0887848] [MeSH:C0887848] hbeta heterologously express hh1 [MeSH:C1143897] [MeSH:C1143897] mutation [MeSH:C0026882] t10 previously associate ivf method result express xenopus oocyte [MeSH:C0029045] [MeSH:C0029045] [MeSH:C0029045] t10 exhibit persistent [MeSH:C0026205] current contrast lqt3 mutant [MeSH:C1564139] channel midpoint steady-state inactivation [MeSH:C4505109] [MeSH:C0043297] [MeSH:C4505109] [MeSH:C0043297] [MeSH:C0043297] [MeSH:C0043297] [MeSH:C0043297] v significantly shift positive potential wild-type hh1 [MeSH:C1143897] [MeSH:C1143897] coexpression hbeta significantly alter current decay [MeSH:C0011334] recovery [MeSH:C0140116] [MeSH:C0140116] inactivation [MeSH:C4505109] [MeSH:C0043297] [MeSH:C4505109] [MeSH:C0043297] [MeSH:C0043297] [MeSH:C0043297] [MeSH:C0043297] wild-type hh1 [MeSH:C1143897] [MeSH:C1143897] shift v accelerate [MeSH:C0000894] recovery [MeSH:C0140116] [MeSH:C0140116] inactivation [MeSH:C4505109] [MeSH:C0043297] [MeSH:C4505109] [MeSH:C0043297] [MeSH:C0043297] [MeSH:C0043297] [MeSH:C0043297] t10 oocyte [MeSH:C0029045] macropatch reveal activation [MeSH:C4505109] [MeSH:C4505109] kinetic [MeSH:C0049579] t10 normal conclusion suggest coexpression hbeta expose severe functional defect result great overlap relationship channel inactivation [MeSH:C4505109] [MeSH:C0043297] [MeSH:C4505109] [MeSH:C0043297] [MeSH:C0043297] [MeSH:C0043297] [MeSH:C0043297] activation [MeSH:C4505109] [MeSH:C4505109] window current t10 propose potential pathophysiological [MeSH:C0031847] mechanism [MeSH:C1524059] ivf vivo possible explanation altered alpha- beta -subunit [MeSH:C0887848] [MeSH:C0887848] association [MeSH:C0004083] mutant [MeSH:C1564139],neurological
cancer code alzheimer disease melanoma [MeSH:C0002395],stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve tumor metastasis method [MeSH:C0027627] conduct prospective evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine skin cancer [MeSH:C0007114] parameter result enhance therapeutic response practice guideline,oncological
tumor terrain [MeSH:C0006118] stroke [MeSH:C0038454] exploration [MeSH:C0015329],hypothesis [MeSH:C3179072] aspirin improve hypertension [MeSH:C0020538] outcome liver cancer [MeSH:C0345904] pathway method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure metastatic ovarian cancer [MeSH:C1140680] result improvement [MeSH:C2936612] primary endpoint optimization [MeSH:C0376695],oncological
dementia [MeSH:C0497327] dialysis [MeSH:C0011945] organ interplay,question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke stomach cancer [MeSH:C0024623] mechanism method retrospective [MeSH:C0035363] adult population [MeSH:C0032659] assess esophageal cancer [MeSH:C0546837] cholecystitis [MeSH:C0008325] result decrease mortality rate [MeSH:C0205848] implication safety [MeSH:C0036043] consideration,hepatorenal|oncological
endothelial hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] cross-sectional investigation metformin [MeSH:C0025598] dementia [MeSH:C0497327] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] ventricular tachycardia [MeSH:C0042514] ectopic beat [MeSH:C0033036] result improve outcome [MeSH:C0206277] pe correlation practice guideline [MeSH:C0936005],cardiovascular
sperm dna friedreich ataxia premutation [MeSH:C0016719] carrier suggest meiotic mitotic expansion frda gene,friedreich ataxia [MeSH:C0016719] usually cause expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] gaa trinucleotide repeat [MeSH:C0282537] intron frda gene occasionally fully expand allele [MeSH:C0002085] find arise premutation triplet repeat examine [MeSH:C0282537] sperm [MeSH:C0037868] dna premutation carrier man leucocyte dna show normal allele [MeSH:C0002085] allele [MeSH:C0002085] approximately repeat sperm [MeSH:C0037868] show expand allele [MeSH:C0002085] tight range center size [MeSH:C0162658] approximately trinucleotide repeat [MeSH:C0282537] affect son repeat size suggest expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] occur stage meiosis [MeSH:C0025186] follow second mitotic [MeSH:C1450044] expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] informative carrier father affect child transmission [MeSH:C0040722] notable exception premutation carrier expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] size decrease,neurological
molecular apc gene family extend genotype-phenotype correlation fap [MeSH:C2717879] evidence [MeSH:C5575834] role apc amino acid change [MeSH:C0002520] colorectal cancer [MeSH:C0009402] predisposition [MeSH:C0314657],aim development [MeSH:C0243107] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] variable range extracolonic manifestation [MeSH:C0029166] [MeSH:C0029166] [MeSH:C0029166] familial adenomatous polyposis fap [MeSH:C1622401] [MeSH:C0032580] dominant inheritance [MeSH:C4277511] adenomatous polyposis coli apc gene mutation [MeSH:C0026882] [MeSH:C0162832] direct mutation [MeSH:C0026882] apc gene perform determine genotype-phenotype [MeSH:C2717879] [MeSH:C2717879] correlation extracolonic manifestation [MeSH:C0029166] [MeSH:C0029166] [MeSH:C0029166] investigate [MeSH:C0035173] incidence [MeSH:C0021149] apc mutation [MeSH:C0026882] non-fap [MeSH:C1622401] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] method apc gene analyse unrelated fap [MeSH:C1622401] non-fap [MeSH:C1622401] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] denature gradient gel electrophoresis protein truncation test direct sequencing result chain terminating signal identify patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] belong fap [MeSH:C1622401] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] amino acid change [MeSH:C0002520] [MeSH:C0002520] identify patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] belong non-fap [MeSH:C1622401] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] genotype-phenotype [MeSH:C2717879] [MeSH:C2717879] correlation identify difference nature certain extracolonic manifestation [MeSH:C0029166] [MeSH:C0029166] [MeSH:C0029166] fap [MeSH:C1622401] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] belong mutation [MeSH:C0026882] subgroup conclusion extend genotype-phenotype [MeSH:C2717879] [MeSH:C2717879] correlation potential determine appropriate surveillance [MeSH:C0220920] prophylactic regimen [MeSH:C0912478] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mutation [MeSH:C0026882] associate life threatening condition [MeSH:C0037403] provide evidence [MeSH:C5575834] pathological [MeSH:C0030660] nature amino acid change [MeSH:C0002520] [MeSH:C0002520] apc associate fap [MeSH:C1622401] non-fap [MeSH:C1622401] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],neurological|oncological
cholestatic presentation [MeSH:C0022869] yellow phosphorus [MeSH:C0043400] poisoning [MeSH:C0032343],yellow phosphorus [MeSH:C0043400] [MeSH:C0043400] component [MeSH:C0043400] certain pesticide paste [MeSH:C0031253] firework known cause hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] poisoning [MeSH:C0032343] [MeSH:C0032343] yellow phosphorus [MeSH:C0043400] [MeSH:C0043400] classically manifest acute hepatitis lead acute liver failure [MeSH:C0162557] need liver transplantation [MeSH:C0023911] present case yellow phosphorus [MeSH:C0043400] [MeSH:C0043400] [MeSH:C0043400] poisoning [MeSH:C0032343] [MeSH:C0032343] present florid feature cholestasis [MeSH:C0008370] [MeSH:C0008370] highlight fact cholestasis [MeSH:C0008370] [MeSH:C0008370] rarely presenting feature yellow phosphorus [MeSH:C0043400] [MeSH:C0043400] hepatotoxicity [MeSH:C0235280] [MeSH:C0235280],hepatorenal
retrospective [MeSH:C0035363] anonymous pilot screen newborn [MeSH:C0021289] hfe mutation [MeSH:C4277647] scandinavian population,retrospectively analyze random [MeSH:C5690776] anonymize dry blood spot [MeSH:C3178862] dbs sample neonatal screening program scandinavia mutation [MeSH:C0026882] [MeSH:C0240951] hfe [MeSH:C4277647] candidate gene hemochromatosis [MeSH:C0018995] find c22y allele frequency [MeSH:C0017270] greenland iceland faeroe island denmark high prevalence [MeSH:C0033105] hfe [MeSH:C4277647] mutation [MeSH:C0026882] denmark suggest population screen [MeSH:C0032659] c22y mutation [MeSH:C0026882] highly advantageous term preventive [MeSH:C0033108] health care [MeSH:C0086388] long-term [MeSH:C0023977] follow-up [MeSH:C3899107] c22y homozygote [MeSH:C0019904] h63d c22y compound heterozygote [MeSH:C0019425] indication penetrance [MeSH:C0524899] mutation [MeSH:C0026882],neurological
biopsy [MeSH:C0005558] reveal breast cancer [MeSH:C0006142] secret,question [MeSH:C0600648] metformin [MeSH:C0025598] affect hypertension [MeSH:C0020538] neurofibroma [MeSH:C0027830] mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assessing neuron [MeSH:C0027882] schwannoma [MeSH:C0027809] result enhance therapeutic response [MeSH:C0087111] implication need investigation [MeSH:C0035173],neurological|hepatorenal
worsening parkinsonism use veralipride [MeSH:C0242422] menopause [MeSH:C0025320] case report [MeSH:C0684224],describe female [MeSH:C0086287] stable parkinson disease [MeSH:C0030567] show marked worsening motor function [MeSH:C0031843] follow therapy [MeSH:C0039798] menopause [MeSH:C0025320] related symptom [MeSH:C3839861] veralipride improvement [MeSH:C2936612] symptom [MeSH:C3839861] discontinuation drug [MeSH:C0013227] emphasize anti-dopaminergic effect veralipride,neurological
chloroquine [MeSH:C0008269] related complete heart block blindness [MeSH:C0018794] case report [MeSH:C0684224],-year old african [MeSH:C5690837] woman history [MeSH:C0019664] regular [MeSH:C0021641] chloroquine [MeSH:C0008269] [MeSH:C0008269] ingestion [MeSH:C0232478] present progressive [MeSH:C1449744] deterioration vision [MeSH:C0234985] easy fatiguability dyspnoea dizziness [MeSH:C0012833] progress syncopal attack ophthalmological assessment reveal feature chloroquine [MeSH:C0008269] [MeSH:C0008269] retinopathy cardiac assessment reveal feature heart failure [MeSH:C0018801] complete heart block right bundle branch block pattern heart block treat pacemaker insertion heart failure [MeSH:C0018801] resolve spontaneously [MeSH:C0034705] follow chloroquine [MeSH:C0008269] [MeSH:C0008269] discontinuation remain blind,cardiovascular
homozygous [MeSH:C0019904] hypobetalipoproteinemia [MeSH:C0020597] disease distinct abetalipoproproteinemia [MeSH:C0000744] molecular [MeSH:C0026381],apob dna rna protein patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] homozygous [MeSH:C0019904] hypobetalipoproteinemia [MeSH:C0020597] hbl evaluate [MeSH:C0013175] compare normal individual southern blot [MeSH:C1148472] different cdna probe [MeSH:C0006556] reveal normal gene major insertion deletion rearrangement northern slot blot analysis total liver mrna hbl patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] document normal size apob mrna [MeSH:C0003593] [MeSH:C0003593] present greatly reduce quantity [MeSH:C0424574] [MeSH:C0424574] apob protein [MeSH:C0003593] [MeSH:C0003593] detect hbl hepatocyte [MeSH:C0227525] utilize immunohistochemical technique [MeSH:C0021060] markedly reduce quantity [MeSH:C0424574] [MeSH:C0424574] compare sample apob detectable plasma hbl individual elisa assay consistent mutation code portion [MeSH:C0026882] apob gene hbl patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lead abnormal [MeSH:C0853087] apob protein [MeSH:C0003593] [MeSH:C0003593] apob mrna [MeSH:C0003593] [MeSH:C0003593] instability result distinct previously note abetalipoproteinemia [MeSH:C0000744] characterize elevated [MeSH:C0020443] hepatic [MeSH:C0227525] apob mrna [MeSH:C0003593] [MeSH:C0003593] accumulation [MeSH:C0311432] intracellular [MeSH:C0682581] hepatic [MeSH:C0227525] apob protein [MeSH:C0003593] [MeSH:C0003593],hepatorenal
cancer prolapse [MeSH:C0033377] cardiac connection,stroke [MeSH:C0038454] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve endothelial [MeSH:C0225336] restrictive cardiomyopathy method conduct observational evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine artery [MeSH:C0003842] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,cardiovascular|oncological
brca1 [MeSH:C0259275] mutation population-based sample young [MeSH:C0340037] woman [MeSH:C0043210] breast cancer [MeSH:C0006142],inherit mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] gene [MeSH:C0376571] associate high risk [MeSH:C0035647] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] family little know contribution brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] general population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] analyze dna sample woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] enrol population [MeSH:C0032659]-based early-onset breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] assess spectrum frequency [MeSH:C0376249] [MeSH:C0017270] germ-line [MeSH:C0017471] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] young [MeSH:C0340037] [MeSH:C0340037] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] method study woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] diagnose [MeSH:C0011900] age [MeSH:C0024842] select basis family history [MeSH:C0241889] genomic dna study brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] involve single-strand conformation polymorphism allele-specific assay [MeSH:C0243031] alteration define dna sequencing [MeSH:C0917792] result germ-line [MeSH:C0017471] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] additional rare sequence [MeSH:C0162327] variant unknown functional importance identify mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] rare sequence [MeSH:C0162327] variant find woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] report family history [MeSH:C0241889] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] rare variant identify reference population [MeSH:C0032659] unrelated subject conclusion alteration brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] identify approximately percent cohort [MeSH:C1706962] young [MeSH:C0340037] [MeSH:C0340037] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] risk [MeSH:C0035647] harbor mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] limit woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] family history [MeSH:C0241889] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] result represent minimal estimate frequency [MeSH:C0376249] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] population [MeSH:C0032659] comprehensive method [MeSH:C0009585] identify brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] understand importance need testing [MeSH:C1321876] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] general population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] undertake,neurological|oncological
hepatitis renal [MeSH:C0019158] stone organ [MeSH:C0029250] interplay,heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve cholestasis [MeSH:C0008370] hepatocellular carcinoma [MeSH:C2239176] method conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine liver [MeSH:C0023884] parameter result enhance therapeutic response care [MeSH:C0087111] improvement [MeSH:C2936612],hepatorenal
phase [MeSH:C0080129] ii thalidomide [MeSH:C0039736] advanced metastatic renal cell carcinoma [MeSH:C2931852],objective evaluate toxicity [MeSH:C0040539] [MeSH:C0040539] activity [MeSH:C0020115] thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] advanced metastatic renal cell cancer [MeSH:C0007134] change angiogenic factor vascular endothelial growth factor vegf therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0078058] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] enrol thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] intra-patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dose escalation schedule [MeSH:C0086960] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] begin thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] mg escalate tolerate mg fifty-nine cent patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] previous therapy [MeSH:C0039798] [MeSH:C0039798] il- performance [MeSH:C0871966] status systemic plasma [MeSH:C0032105] vegf1 level measure dual monoclonal elisa patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] evaluable response partial response [MeSH:C0034746] month duration hepatic pulmonary metastasis minor response patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stable month somnolence constipation [MeSH:C2830004] prominent toxicity [MeSH:C0040539] [MeSH:C0040539] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] tolerate mg dose systemic plasma [MeSH:C0032105] vegf1 level therapy [MeSH:C0039798] [MeSH:C0039798] result consistent low activity [MeSH:C0020115] thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] renal cell carcinoma administration dose [MeSH:C0001554] mg difficult achieve population low dose [MeSH:C0032659] practical dose-response relationship thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] renal cell carcinoma unclear,hepatorenal|oncological
identification [MeSH:C1707660] chromosomal localization atm mouse homolog ataxia-telangiectasia gene [MeSH:C0004135],atm mouse [MeSH:C0026809] homolog [MeSH:C3853771] human [MeSH:C0086418] atm gene defective ataxia-telangiectasia a-t identify entire code sequence [MeSH:C0162327] atm transcript [MeSH:C1136156] clone [MeSH:C0009013] find contain open reading frame [MeSH:C0079941] encode protein amino acid [MeSH:C0002520] overall identity similarity human [MeSH:C0086418] atm protein variable level [MeSH:C0018759] expression [MeSH:C0017262] atm observe different tissue fluorescence situ hybridization [MeSH:C0162789] linkage locate atm gene mouse [MeSH:C0026809] chromosome band 9c region homolog [MeSH:C3853771]ous atm region human [MeSH:C0086418] chromosome 1q2-q2,neurological
acute blood pressure elevation [MeSH:C0005823] caffeine [MeSH:C0006644] man borderline systemic hypertension,vasoconstrictive action [MeSH:C0042396] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] enhance hypertensive person [MeSH:C0027361] [MeSH:C0003364] demonstrate caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] mg kg versus placebo test healthy [MeSH:C0452415] man aged year select screen separate occasion borderline hypertensive man n select screen systolic blood pressure bp mm hg diastolic bp mm hg low-risk control n report parental history [MeSH:C0019664] hypertension screen bp mm hg participant [MeSH:C1708335] [MeSH:C1708335] test occasion -hour abstinence [MeSH:C0036899] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] protocol require total laboratory visit [MeSH:C0022877] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644]-induced change diastolic bp time large borderline subject control vs mm hg p attributable large change impedance-derived measure systemic vascular resistance [MeSH:C0042380] vs dyne cm- p finding consistent reach significance protocol percentage borderline subject diastolic bp change exceed median response consequently participant [MeSH:C1708335] [MeSH:C1708335] exhibit normotensive level [MeSH:C0018759] [MeSH:C0018759] rest predrug borderline subject achieve hypertensive bp [MeSH:C0003364] level [MeSH:C0018759] [MeSH:C0018759] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] ingestion [MeSH:C0232478] borderline hypertensive man exaggerated response caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] selective diastolic bp consistent great vasoconstriction [MeSH:C0042396] replicate protocol representative nearly borderline hypertensive suspect potential [MeSH:C0001272] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] stabilize high resistance state [MeSH:C0034471] susceptible person [MeSH:C0027361] suggest use facilitate disease progression [MeSH:C0242656] hinder accurate diagnosis [MeSH:C0011900],cardiovascular
effect [MeSH:C4277511] postoperative [MeSH:C0032786] administration [MeSH:C0001554] methylprednisolone [MeSH:C0025815] gentamicin [MeSH:C3854019] posterior sub-tenon space,assess incidence [MeSH:C0021149] postoperative [MeSH:C0032786] [MeSH:C0032786] emetic effect [MeSH:C3178735] administration methylprednisolone [MeSH:C0025815] [MeSH:C0025815] [MeSH:C0025815] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] posterior sub-tenon space end routine cataract surgery set st luke hospital gwardamangia malta method double-blind [MeSH:C0013072] double-armed prospective comprise patient [MeSH:C0030705] [MeSH:C0030705] uneventful sutureless phacoemulsification [MeSH:C0282545] sub-tenon local infiltration ml plain lignocaine [MeSH:C0023660] end procedure n mg ml methylprednisolone [MeSH:C0025815] [MeSH:C0025815] [MeSH:C0025815] mg ml gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] inject posterior sub-tenon space b n combination inject anterior sub-tenon space postoperative [MeSH:C0032786] [MeSH:C0032786]ly patient [MeSH:C0030705] [MeSH:C0030705] assess symptom nausea vomiting headache chi-square test [MeSH:C0008041] assess statistical significance [MeSH:C2826293] result result percent develop postoperative [MeSH:C0032786] [MeSH:C0032786] emetic symptom headache b develop symptom conclusion administration methylprednisolone [MeSH:C0025815] [MeSH:C0025815] [MeSH:C0025815] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] posterior sub-tenon space related high incidence [MeSH:C0021149] effect include nausea vomiting headache adverse effect [MeSH:C0001688] self-limiting,neurological
stroke [MeSH:C0038454] cholestasis [MeSH:C0008370] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] renal cyst pathway method cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient measure nephritis azotemia [MeSH:C0027697] result superior efficacy [MeSH:C5690761] relevance,hepatorenal
synaptic story peripheral artery disease [MeSH:C1704436] cognitive impairment [MeSH:C0338656],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect hypertension [MeSH:C0020538] delirium method [MeSH:C0011206] adult [MeSH:C0001675] population [MeSH:C0032659] undergo observational parkinsonism encephalopathy assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
leukemia [MeSH:C0023418] hepatocellular carcinoma [MeSH:C2239176] organ [MeSH:C0029250] interplay,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve ckd cholangiocarcinoma method conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine bile duct [MeSH:C0005400] parameter result improve outcome [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
possible neuroleptic malignant syndrome [MeSH:C0027849] related concomitant [MeSH:C0152203] paroxetine alprazolam [MeSH:C0070122],-year-old man depressive symptom [MeSH:C3839861] [MeSH:C3839861] [MeSH:C0086132] admit psychiatric hospital insomnia [MeSH:C0020021] loss appetite [MeSH:C0003618] exhaustion [MeSH:C0018839] agitation medical [MeSH:C2713310] initiate daily dose mg paroxetine [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] mg alprazolam [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] 0th paroxetine [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] alprazolam [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] exhibit marked psychomotor retardation disorientation severe muscle rigidity tremor fever [MeSH:C0015967] [MeSH:C0026837] degree c fluctuate blood pressure [MeSH:C0005823] mg mm hg severe extrapyramidal symptom [MeSH:C3839861] [MeSH:C3839861] laboratory test show elevation creatine phosphokinase iu [MeSH:C0010287] l aspartate aminotransferase iu [MeSH:C0004002] l alanine aminotransferase iu l bun mg ml level [MeSH:C0018759] receive bromocriptine [MeSH:C0006230] diazepam [MeSH:C0012010] treat symptom [MeSH:C3839861] [MeSH:C3839861] day later fever [MeSH:C0015967] disappear serum [MeSH:C0229671] cpk level [MeSH:C0018759] normalize iu l present symptom [MeSH:C3839861] [MeSH:C3839861] neuroleptic malignant syndrome [MeSH:C0027849] nms demonstrate nms-like symptom [MeSH:C3839861] [MeSH:C3839861] occur combined paroxetine [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] alprazolam [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] adverse drug reaction score [MeSH:C0041755] obtain naranjo algorithm [MeSH:C0002045] case indicate probable relationship [MeSH:C0021797] nms-like adverse symptom [MeSH:C3839861] [MeSH:C3839861] combined case involvement physiologic [MeSH:C0026429] environmental aspect [MeSH:C0242228] specific suspect risk factor [MeSH:C0035648] nms note elderly [MeSH:C0001792] depressive patient symptom [MeSH:C3839861] [MeSH:C3839861] include dehydration agitation [MeSH:C0011175] malnutrition [MeSH:C0162429] exhaustion [MeSH:C0018839] careful therapeutic intervention [MeSH:C0087111] necessary case involve elderly [MeSH:C0001792] patient suffer depression [MeSH:C0011570],neurological|cardiovascular
absence [MeSH:C0270823] effect sertraline [MeSH:C0074393] time-based sensitization cognitive impairment [MeSH:C0338656] haloperidol [MeSH:C0018546],double-blind [MeSH:C0013072] randomized placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041]-controlled [MeSH:C1096777] evaluate effect [MeSH:C4277511] [MeSH:C4277511] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] plus sertraline [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] cognitive psychomotor function [MeSH:C0009240] healthy [MeSH:C0452415] male subject [MeSH:C0080105] subject receive placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] mg day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] subject randomly assign sertraline [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] subject placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] subject sertraline [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] dose titrate mg day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] remain mg final day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] drug administration [MeSH:C0001554] [MeSH:C1527425] period [MeSH:C0080129] cognitive function [MeSH:C0009240] [MeSH:C0009240] testing perform dosing -hour period [MeSH:C0080129] dose day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] result impairment [MeSH:C1384666] [MeSH:C1384666] [MeSH:C1384666] cognitive function [MeSH:C0009240] [MeSH:C0009240] observe hour administration [MeSH:C0001554] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] evident hour dose single-dose haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] give day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] later great impairment [MeSH:C1384666] [MeSH:C1384666] [MeSH:C1384666] early onset [MeSH:C0031106] note test group suggest enhancement [MeSH:C0376317] effect [MeSH:C4277511] [MeSH:C4277511] indication sertraline [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] exacerbate impairment [MeSH:C1384666] [MeSH:C1384666] [MeSH:C1384666] produce haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] equivalent [MeSH:C2355577] effect [MeSH:C4277511] [MeSH:C4277511] occur placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] subject sertraline [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] withdraw effect [MeSH:C4277511] [MeSH:C4277511] subject report effect [MeSH:C4277511] [MeSH:C4277511] related effect [MeSH:C4277511] [MeSH:C4277511] profile sertraline [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] similar haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] produce clear profile cognitive impairment [MeSH:C0338656] [MeSH:C1384666] [MeSH:C1384666] [MeSH:C1384666] worsen concomitant [MeSH:C0152203] sertraline [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] [MeSH:C0074393] administration [MeSH:C0001554],neurological
thromboembolism pathway [MeSH:C0040038] prostate cancer [MeSH:C0376358],hypothesis statin improve hypertension [MeSH:C0020538] outcome astrocytoma pathway method retrospective trial elderly patient measure hypotensive endocardium [MeSH:C0014124] result improve disease management [MeSH:C0039798] safety consideration,neurological|cardiovascular
tumor suppression [MeSH:C0079427] apoptosis [MeSH:C0162638] human [MeSH:C0086418] prostate carcinoma [MeSH:C0007097] mediate genetic locus [MeSH:C0678933] human [MeSH:C0086418] chromosome 0pter-q1,prostate [MeSH:C0033572] cancer [MeSH:C0376358] second leading cause male cancer [MeSH:C0006826] death united state [MeSH:C0041703] despite large international [MeSH:C1138414] effort little know molecular mechanism [MeSH:C1524059] underlie devastating disease prostate [MeSH:C0033572] [MeSH:C0033575] secretory epithelial cell [MeSH:C0014597] androgen [MeSH:C0002844]-dependent prostate [MeSH:C0033572] carcinoma [MeSH:C0007097] undergo apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] response androgen [MeSH:C0002844] deprivation furthermore prostate [MeSH:C0033572] carcinoma [MeSH:C0007097] androgen [MeSH:C0002844] independent refractory [MeSH:C0030200] therapeutic manipulation disease progression definition genetic event trigger apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] prostate [MeSH:C0033572] provide important insight critical pathway [MeSH:C0282655] normal development elucidate perturbation key pathway [MeSH:C0282655] neoplastic transformation [MeSH:C0007621] report functional definition novel genetic locus [MeSH:C0678933] [MeSH:C0678933] human [MeSH:C0086418] [MeSH:C0086418] chromosome [MeSH:C0008643] 0pter-q1 mediate vivo tumor [MeSH:C0027651] suppress [MeSH:C0017372]ion [MeSH:C1956351] vitro apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] prostatic adenocarcinoma [MeSH:C0001418] cell [MeSH:C0206685] define fragment [MeSH:C0021009] human [MeSH:C0086418] [MeSH:C0086418] chromosome [MeSH:C0008643] transfer microcell fusion prostate [MeSH:C0033572] adenocarcinoma cell line microcell hybrid [MeSH:C0020200] contain region 0pter-q1 suppress [MeSH:C0017372] tumor [MeSH:C0027651]igenicity follow injection microcell hybrid nude mouse furthermore complement hybrid undergo program cell [MeSH:C0376691] death vitro mechanism [MeSH:C1524059] require nuclear localization p5 [MeSH:C0525021] functionally define novel genetic locus [MeSH:C0678933] [MeSH:C0678933] designate pac1 [MeSH:C0904504] prostate [MeSH:C0033572] adenocarcinoma involve tumor [MeSH:C0027651] suppress [MeSH:C0017372]ion [MeSH:C1956351] human [MeSH:C0086418] [MeSH:C0086418] prostate [MeSH:C0033572] carcinoma [MeSH:C0007097] furthermore strongly suggest cell death pathway [MeSH:C0007587] [MeSH:C0282655] functionally restore prostatic adenocarcinoma [MeSH:C0001418],neurological|oncological
artery diabete mellitus vascular insight,hypothesis statin improve diabete outcome [MeSH:C0206277] vein pathway method randomized control trial [MeSH:C1096777] adult population measure heart rate [MeSH:C0018810] chf result improve outcome [MeSH:C0206277] optimization [MeSH:C0376695],cardiovascular
naloxazone [MeSH:C0068380] pretreatment [MeSH:C0376495] modify cardiorespiratory temperature behavioral [MeSH:C0004927] effect morphine [MeSH:C0026549],behavioral [MeSH:C0004927] [MeSH:C0004927] cardiorespirat [MeSH:C0034721]ory response lethal dose [MeSH:C0023378] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] evaluate [MeSH:C0013175] rat [MeSH:C0034721] pretreate saline naloxazone [MeSH:C0068380] [MeSH:C0068380] antagonist high-affinity [MeSH:C4319821] mu opioid receptor [MeSH:C0034801] pretreatment [MeSH:C0376495] naloxazone [MeSH:C0068380] [MeSH:C0068380] significantly block morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] analgesia catalepsy [MeSH:C0007370] hypothermia [MeSH:C0020672] dose completely eliminate high-affinity [MeSH:C4319821] binding brain membrane [MeSH:C0025255] naloxazone [MeSH:C0068380] [MeSH:C0068380] significantly attenuate morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-induced hypotension respirat [MeSH:C0034721]ory depression morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-induced bradycardia affect result indicate subpopulation [MeSH:C0079720] mu receptor mediate selective behavioral [MeSH:C0004927] [MeSH:C0004927] cardiorespirat [MeSH:C0034721]ory response morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549],neurological|cardiovascular
safety [MeSH:C0036043] efficacy [MeSH:C5690761] fluocinolone [MeSH:C0060507] acetonide intravitreal implant mg birdshot retinochoroidopathy [MeSH:C1853959],report outcome [MeSH:C0206277] fluocinolone [MeSH:C0060507] [MeSH:C0060507] [MeSH:C0060507] acetonide intravitreal implant [MeSH:C0011373] [MeSH:C0011373] [MeSH:C0011373] mg patient [MeSH:C0030705] [MeSH:C0030705] birdshot retinochoroidopathy [MeSH:C1853959] disease [MeSH:C1853959] refractory intolerant conventional immunomodulatory therapy [MeSH:C1963758] method retrospective [MeSH:C0035363] case series involve birdshot retinochoroidopathy [MeSH:C1853959] patient [MeSH:C0030705] [MeSH:C0030705] eye patient [MeSH:C0030705] [MeSH:C0030705] eye undergo surgery fluocinolone [MeSH:C0060507] [MeSH:C0060507] [MeSH:C0060507] [MeSH:C0060507] acetonide implant [MeSH:C0011373] [MeSH:C0011373] [MeSH:C0011373] mg outcome [MeSH:C0206277] interest note fluocinolone [MeSH:C0060507] [MeSH:C0060507] [MeSH:C0060507] acetonide implant [MeSH:C0011373] [MeSH:C0011373] [MeSH:C0011373] month year year year disease activity marker include sign ocular inflammation [MeSH:C0021368] evidence retinal vasculitis [MeSH:C0152026] swedish interactive [MeSH:C1956025] threshold algorithm-short wavelength automated perimetry humphrey visual field [MeSH:C0042826] electroretinographic [MeSH:C0013867] parameter optical coherence tomography [MeSH:C0920367] record occurrence [MeSH:C0243132] cataract [MeSH:C0086543] raise intraocular pressure collect eye result intraocular inflammation [MeSH:C0021368] present patient [MeSH:C0030705] [MeSH:C0030705] month year year year receive implant [MeSH:C0011373] [MeSH:C0011373] [MeSH:C0011373] respectively active vasculitis [MeSH:C0042384] note patient [MeSH:C0030705] [MeSH:C0030705] year follow-up [MeSH:C3899107] reduction [MeSH:C1827449] central retinal [MeSH:C0035327] thickness [MeSH:C5392084] note patient [MeSH:C0030705] [MeSH:C0030705] cystoid macular edema [MeSH:C0013604] month year year postimplant [MeSH:C0011373] [MeSH:C0011373] [MeSH:C0011373] patient [MeSH:C0030705] [MeSH:C0030705] immunomodulatory agent [MeSH:C5544470] percentage decrease year year postimplant [MeSH:C0011373] [MeSH:C0011373] [MeSH:C0011373] respectively adverse event [MeSH:C0041755] include increase intraocular pressure cataract [MeSH:C0086543] formation suggest fluocinolone [MeSH:C0060507] [MeSH:C0060507] [MeSH:C0060507] acetonide implant [MeSH:C0011373] [MeSH:C0011373] [MeSH:C0011373] mg help inflammation [MeSH:C0021368] treatment-refractory case birdshot retinochoroidopathy [MeSH:C1853959] associate [MeSH:C0004083] effect cataract [MeSH:C0086543] ocular hypertension [MeSH:C0028840] require,cardiovascular
acute myeloid leukemia [MeSH:C0023467] connection [MeSH:C0056248] diabetes mellitus [MeSH:C0011849],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer amygdala mechanism method longitudinal diabetic [MeSH:C0023981] patient [MeSH:C0030705] assess gray matter [MeSH:C0018220] pancreatic cancer [MeSH:C0346647] result improve disease management [MeSH:C0039798] implication safety [MeSH:C0036043] consideration,neurological|oncological
lymphoma defibrillator cardiac connection,design [MeSH:C0013171] prospective investigation statin diabete participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] peripheral artery disease [MeSH:C1704436] pad result enhance therapeutic response [MeSH:C0087111] capillary correlation therapeutic innovation,cardiovascular
hepatitis [MeSH:C0019158] oncological [MeSH:C0596240] len,hypothesis statin improve cancer outcome [MeSH:C0206277] sarcoma pathway method observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure liver cancer [MeSH:C0345904] hodgkin lymphoma [MeSH:C0019829] result improve outcome [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
measurement [MeSH:C0030198] tremor comparison effect tocolytic [MeSH:C0040349] beta-mimetic,permit measurement finger tremor displacement-time curve describe test system simple amplitude calibration coordinate inversion point displacement-time curve transfer graphical input equipment punch tape mean computer program [MeSH:C0037585] period amplitude tremor oscillation [MeSH:C0995546] [MeSH:C0995546] calculate [MeSH:C0006736] classify event frequency [MeSH:C0376249] class period amplitude determine action [MeSH:C0040597] fenoterol-hydrobromide ritodrin-hcl placebo [MeSH:C0032041] give healthy subject [MeSH:C1708335] intravenous infusion [MeSH:C0841792] [MeSH:C0021440] double-blind crossover test [MeSH:C0150097] therapeutic dose [MeSH:C0087111] substance raise mean tremor amplitude time mean period class amplitude shorten ms mean period calculate [MeSH:C0006736] oscillation [MeSH:C0995546] [MeSH:C0995546] significantly end fenoterol-hydrobromide infusion [MeSH:C0841792] tremor amplitude decrease significantly fast follow ritodrin-hcl infusion [MeSH:C0841792],neurological
high incidence [MeSH:C0021149] brca1 [MeSH:C0259275] mutation breast-ovarian cancer family,analyze breast-ovarian cancer family [MeSH:C0015576] [MeSH:C0015576] majority positive evidence linkage chromosome 7q1 germ-line mutation [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] gene [MeSH:C0376571] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] cosegregate breast ovarian cancer [MeSH:C1140680] susceptibility [MeSH:C0012655] identify family [MeSH:C0015576] [MeSH:C0015576] include family [MeSH:C0015576] [MeSH:C0015576] case male breast cancer [MeSH:C0006142] mutation [MeSH:C0026882] report previously majority mutation [MeSH:C0026882] find generate premature stop codon lead formation [MeSH:C0242612] truncate brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] protein expect normal length mutation [MeSH:C0026882] alter ring finger domain sequencing [MeSH:C1521759] genomic dna lead identification mutation [MeSH:C0026882] code region brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] family [MeSH:C0015576] [MeSH:C0015576] cdna [MeSH:C0006556] reveal abnormal [MeSH:C0853087] missing brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] transcript [MeSH:C1136156] remain family [MeSH:C0015576] [MeSH:C0015576] total mutation [MeSH:C0026882] associate reduce quantity [MeSH:C0424574] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] transcript [MeSH:C1136156] unable detect brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] family [MeSH:C0015576] [MeSH:C0015576] clearly link brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] expect majority clear example breast-ovarian syndrome associate germ-line mutation [MeSH:C0026882] code region brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275],oncological
radiotherapy pathway alzheimer disease,design [MeSH:C0013171] cross-sectional investigation statin stroke [MeSH:C0038454] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] renal cyst [MeSH:C0010709] gallbladder result well quality life measure cirrhosis [MeSH:C1623038] correlation healthcare advancement,hepatorenal|oncological
hla b2 genetic ankylosing spondylitis [MeSH:C0038013],twenty-eight patient [MeSH:C0030705] [MeSH:C0030705] ankylosing spondylitis [MeSH:C0038013] [MeSH:C0038013] find hla b2 positive patient [MeSH:C0030705] [MeSH:C0030705] evidence [MeSH:C5575834] [MeSH:C5575834] sero-negative peripheral arthritis [MeSH:C0003864] resemble peripheral psoriatic arthritis [MeSH:C0003872] b2 negative b2 negative patient [MeSH:C0030705] [MeSH:C0030705] sister ankylosing spondylitis [MeSH:C0038013] ulcerative colitis [MeSH:C0009324] [MeSH:C0009324] mother [MeSH:C0026591] ulcerative colitis [MeSH:C0009324] [MeSH:C0009324] evidence [MeSH:C5575834] [MeSH:C5575834] somewhat late age [MeSH:C0024842] onset symptom b2 negative patient [MeSH:C0030705] [MeSH:C0030705] finding interpret suggest degree gene [MeSH:C0017337]tic heterogene [MeSH:C0017337]ity [MeSH:C0242960] ankylosing spondylitis [MeSH:C0038013] gene [MeSH:C0017337] psoriasis [MeSH:C0033860] inflammatory bowel disease [MeSH:C0021390] important individual [MeSH:C0021228] particularly b2 negative twenty-five first-degree relative ankylosing spondylitis [MeSH:C0038013] [MeSH:C0038013] b2 positive instance disassociation b2 spondylitis family proband ulcerative colitis [MeSH:C0009324] [MeSH:C0009324] spondylitis b2 [MeSH:C0038012] positive father diagnose [MeSH:C0011900] definite ankylosing spondylitis [MeSH:C0038013] finding think provide evidence [MeSH:C5575834] [MeSH:C5575834] concept [MeSH:C2350469] gene [MeSH:C0017337] ankylosing [MeSH:C0003090] spondylitis [MeSH:C0038013] b2 closely link gene [MeSH:C0017337] favour occurrence environmental event [MeSH:C0014406] affect approximately one-fifth b2 positive male disease [MeSH:C0017412],neurological
aphasia [MeSH:C0003537] pattern coronary artery disease [MeSH:C1956346] patient [MeSH:C0030705],design [MeSH:C0013171] prospective investigation beta-blocker [MeSH:C0001645] stroke participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] transient ischemic attack neurofibroma [MeSH:C0027830] result improvement primary endpoint cerebral cortex [MeSH:C0007776] correlation safety [MeSH:C0036043] consideration,neurological
recurrent [MeSH:C2825055] subarachnoid hemorrhage [MeSH:C0038525] associate [MeSH:C0004083] aminocaproic acid therapy acute renal artery thrombosis case report [MeSH:C0684224],epsilon aminocaproic acid eaca [MeSH:C0000608] prevent [MeSH:C0000918] rebleeding [MeSH:C0019080] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] subarachnoid hemorrhage sah agent [MeSH:C0038525] decrease frequency [MeSH:C0376249] rebleeding [MeSH:C0019080] report describe thrombotic complication [MeSH:C1171258] eaca therapy [MeSH:C0039798] complication [MeSH:C1171258] include deterioration [MeSH:C0234985] intracranial [MeSH:C0032268] vascular thrombosis [MeSH:C0040053] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sah arteriolar capillary fibrin thrombus patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fibrinolytic syndrome [MeSH:C0016018] treat eaca thromboembolic [MeSH:C0040038] phenomenon [MeSH:C2350469] intravascular fibrin thrombus observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fibrinolytic disorder eaca implicate pathogenesis [MeSH:C0699748] fibrin thrombus patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] disseminate intravascular coagulation [MeSH:C0012739] consumption [MeSH:C0009830] coagulopathie report describe subtotal infarction kidney thrombosis normal renal artery occlusion [MeSH:C0035302] occur eaca therapy [MeSH:C0039798] sah histopathological documentation recurrent sah corresponding event characterize marked hypertension [MeSH:C0020538] abrupt neurological deterioration [MeSH:C0234985],neurological|cardiovascular|hepatorenal
thalamus [MeSH:C0039729] pattern hypertension [MeSH:C0020538] patient [MeSH:C0030705],investigate [MeSH:C0035173] statin effect diabete meningioma method cancer [MeSH:C0025286] patient [MeSH:C0030705] undergo retrospective cognitive impairment [MeSH:C0338656] peripheral neuropathy [MeSH:C4721453] assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],neurological
growth-associated protein [MeSH:C0068563] expression [MeSH:C0017262] hippocampal [MeSH:C0228249] molecular layer chronic epileptic rat treat cycloheximide [MeSH:C0010572],gap4 think link mossy fiber [MeSH:C0524663] sprout mfs experimental model [MeSH:C0086272] epilepsy [MeSH:C0014544] investigate [MeSH:C0035173] gap4 expression gap4-ir correlate mfs assess intensity densitometry [MeSH:C0011321] [MeSH:C0011321] extension width gap4-ir inner molecular layer dentate gyrus iml rat [MeSH:C0034721] subject status [MeSH:C0080105] epilepticus induce pilocarpine [MeSH:C0031923] pilo previously inject cycloheximide [MeSH:C0010572] chx show inhibit [MeSH:C0021463] mfs method chx inject pilo injection [MeSH:C1828121] adult wistar rat [MeSH:C0034716] [MeSH:C0034721] pilo inject drug [MeSH:C0013227] chx animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] kill day [MeSH:C0011017] later brain section process gap4 immunohistochemistry [MeSH:C0021044] result densitometry [MeSH:C0011321] show difference gap4-ir iml pilo chx pilo group [MeSH:C0018257] result width gap4-ir band iml show chx pilo animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] significantly large band p compare pilo conclusion current animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] chx pilo gap4-ir band iml similar control reinforce prior blockade [MeSH:C0027741] mfs animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] gap4-ir present pilo-treated animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] thinning band narrow layer granule cell layer likely associate loss hilar cell projection express gap-,neurological
cancer nephritis [MeSH:C0027697] organ interplay,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer kidney mechanism method [MeSH:C0740457] prospective diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess pyelonephritis [MeSH:C0034186] renal cyst [MeSH:C0010709] result well quality life measure implication relevance [MeSH:C2826293],hepatorenal
endothelial connection myocardial infarction [MeSH:C0027051],question [MeSH:C0600648] ace inhibitor affect cancer vein [MeSH:C0006826] mechanism method longitudinal [MeSH:C0023981] elderly patient assess deep vein thrombosis [MeSH:C0149871] multiple sclerosis [MeSH:C0026769] result positive response implication healthcare advancement,neurological|cardiovascular
serotonin connection ventricular tachycardia [MeSH:C0042514],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation statin stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient thrombosis autonomic neuropathy [MeSH:C0271686] result superior efficacy seizure [MeSH:C0036572] correlation healthcare advancement,neurological|cardiovascular
cirrhosis [MeSH:C1623038] parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] diabete alt method adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective [MeSH:C0035363] tricuspid valve alcoholic liver disease [MeSH:C0023896] assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] cost-effect [MeSH:C4277511]iveness implication,cardiovascular|hepatorenal
ethambutol [MeSH:C0014964] optic neuropathy [MeSH:C0029132],demonstrate association [MeSH:C0004083] ethambutol [MeSH:C0014964] optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] thirteen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] treat ethambutol [MeSH:C0014964] tuberculosis lung lymph node siriraj hospital retrospectively review characteristic initial final visual [MeSH:C0042817] acuity [MeSH:C0042812] analyze determine visual [MeSH:C0042817] outcome result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] month mean month start ethambutol [MeSH:C0014964] therapy dosage [MeSH:C0178655] range mg kg mean mg kg seven patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience visual [MeSH:C0042817] recovery stop drug patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] irreversible visual [MeSH:C0042817] impairment patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] diabete mellitus glaucoma history heavy smoke early recognition optic neuropathy [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] [MeSH:C0029132] consider patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ethambutol [MeSH:C0014964] therapy low dose prompt discontinuation drug recommend particularly individual [MeSH:C0021228] diabetes mellitus glaucoma [MeSH:C0011849] heavy smoker [MeSH:C0337664],neurological
x inactivation [MeSH:C0043297] somatic cell [MeSH:C1171322] selection rescue female [MeSH:C0086287] mouse carry piga-null mutation [MeSH:C0026882],somatic mutation x link piga gene responsible deficiency glycosyl phosphatidylinositol gpi -anchored protein blood cell patient [MeSH:C0030705] [MeSH:C0030705] paroxysmal nocturnal hemoglobinuria inherited [MeSH:C4277511] form gpi-anchor deficiency describe conventional piga gene knockout [MeSH:C0206745] associate high embryonic lethality chimeric [MeSH:C0067895] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] cre loxp system generate mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] loxp site flank piga exon crossbreed female [MeSH:C0086287] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] eiia-cre strain floxed allele undergo cre-mediated recombination high efficiency [MeSH:C0013682] early embryonic development [MeSH:C0013936] x chromosome [MeSH:C0008633] inactivation [MeSH:C0043297] female [MeSH:C0086287] offspring [MeSH:C0683572] mosaic cell express lack gpi-linked protein [MeSH:C2936531] mosaic [MeSH:C2936531] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] show heart lung kidney brain liver mainly wild-type piga active suggest tissue [MeSH:C0040300] require gpi-linked protein [MeSH:C2936531] salient exception spleen thymus red blood cell equal number cell [MeSH:C0007584] express wild-type recombine allele imply gpi-linked protein [MeSH:C2936531] essential derivation tissue [MeSH:C0040300] [MeSH:C0040300] piga cell growth advantage suggest factor [MeSH:C0033453] need clonal dominance [MeSH:C0037413] patient [MeSH:C0030705] [MeSH:C0030705] paroxysmal nocturnal hemoglobinuria,neurological|cardiovascular|hepatorenal
pheochromocytoma [MeSH:C0031511] unmask amisulpride tiapride [MeSH:C0103045],describe unmasking pheochromocytoma [MeSH:C0031511] [MeSH:C0031511] treat amisulpride [MeSH:C0103045] [MeSH:C0103045] [MeSH:C0103045] tiapride [MeSH:C0040180] [MeSH:C0040180] [MeSH:C0103045] case summary -year-old white [MeSH:C5575753] man develop acute hypertension [MeSH:C0020538] severe headache vomiting hour dose amisulpride [MeSH:C0103045] [MeSH:C0103045] [MeSH:C0103045] mg tiapride [MeSH:C0040180] [MeSH:C0040180] mg drug [MeSH:C0013227] immediately discontinue recover subsequent nicardipine [MeSH:C0028005] verapamil [MeSH:C0042523] abdominal ultrasound show adrenal mass postoperative [MeSH:C0032786] histologic examination [MeSH:C0027853] confirm diagnosis [MeSH:C0011900] pheochromocytoma [MeSH:C0031511] [MeSH:C0031511] discussion drug [MeSH:C0013227]-induced symptom pheochromocytoma [MeSH:C0031511] [MeSH:C0031511] associate use substitute benzamide drug [MeSH:C0013227] underlie mechanism [MeSH:C1524059] unknown case use naranjo probability scale indicate possible relationship [MeSH:C0021797] hypertensive [MeSH:C0003364] crisis amisulpride [MeSH:C0103045] [MeSH:C0103045] [MeSH:C0103045] tiapride [MeSH:C0040180] [MeSH:C0040180] [MeSH:C0103045] therapy conclusion march report [MeSH:C0684224] case amisulpride [MeSH:C0103045] [MeSH:C0103045] [MeSH:C0103045]- tiapride [MeSH:C0040180] [MeSH:C0040180]-induced hypertensive [MeSH:C0003364] crisis pheochromocytoma [MeSH:C0031511] [MeSH:C0031511] physician healthcare professional [MeSH:C1704312] aware potential [MeSH:C0001272] adverse effect [MeSH:C0001688] tiapride [MeSH:C0040180] [MeSH:C0040180] amisulpride [MeSH:C0103045] [MeSH:C0103045] [MeSH:C0103045],neurological|cardiovascular|hepatorenal
ecg reveal hepatitis secret,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] hypertension [MeSH:C0020538] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] cerebellar [MeSH:C0007765] cortical result well quality life measure liver transplant [MeSH:C0023911] correlation [MeSH:C0010100] relevance [MeSH:C2826293],neurological|hepatorenal
dementia [MeSH:C0497327] chronic kidney disease [MeSH:C1561643] organ [MeSH:C0029250] interplay,cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve bilirubin acute kidney injury method [MeSH:C2609414] conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine liver transplant [MeSH:C0023911] parameter result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],hepatorenal
pure red cell aplasia [MeSH:C0034902] toxic dermatitis [MeSH:C0011603] lymphadenopathy [MeSH:C0497156] take diphenylhydantoin [MeSH:C0031507],take diphenylhydantoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] week develop generalize skin rash [MeSH:C0015230] [MeSH:C0015230] [MeSH:C0015230] lymphadenopathy [MeSH:C0497156] [MeSH:C0497156] pure red cell aplasia [MeSH:C0034902] [MeSH:C0034902] [MeSH:C0034902] withdrawal [MeSH:C1881606] pharmacon [MeSH:C0599740] symptom [MeSH:C3839861] disappear spontaneously [MeSH:C0034705] skin rash [MeSH:C0015230] [MeSH:C0015230] [MeSH:C0015230] well-known complication [MeSH:C1171258] diphenylhydantoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] benign malignant lymphadenopathy [MeSH:C0497156] [MeSH:C0497156] [MeSH:C0497156] pure red cell aplasia [MeSH:C0034902] [MeSH:C0034902] [MeSH:C0034902] associate diphenylhydantoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] medication report patient [MeSH:C0030705] exact mechanism [MeSH:C1524059] diphenylhydantoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] exert toxic effect know relation ingestion [MeSH:C0232478] diphenylhydantoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] occurrence skin rash [MeSH:C0015230] [MeSH:C0015230] [MeSH:C0015230] lymphadenopathy [MeSH:C0497156] [MeSH:C0497156] pure red cell aplasia [MeSH:C0034902] [MeSH:C0034902] [MeSH:C0034902] suggestive direct connection,neurological
hypertension [MeSH:C0020538] wilms tumor [MeSH:C0027708] organ interplay,design [MeSH:C0013171] prospective investigation metformin [MeSH:C0025598] dementia [MeSH:C0497327] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] anuria [MeSH:C0003460] hemodialysis [MeSH:C0019004] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] hcc correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,hepatorenal
tia hepatitis vascular insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome [MeSH:C0206277] hepatic pathway method cross-sectional trial [MeSH:C0010362] adult population measure congestive heart failure hepatitis [MeSH:C0018802] result improve outcome [MeSH:C0206277] healthcare advancement,cardiovascular|hepatorenal
hemodialysis marker [MeSH:C0019004] hepatitis,question statin affect heart disease [MeSH:C0018799] artery mechanism method observational [MeSH:C0302523] cardiac patient assess premature beat hepatocellular carcinoma [MeSH:C2239176] result decrease mortality rate [MeSH:C0205848] implication healthcare advancement,cardiovascular|hepatorenal
loop [MeSH:C4505202] diuretic atrial fibrillation brain insight,design [MeSH:C0013171] cross-sectional investigation statin diabete participant [MeSH:C1708335] cancer patient sciatica [MeSH:C0036396] serotonin result improvement primary endpoint ataxia [MeSH:C0004134] correlation [MeSH:C0010100] cost-effectiveness [MeSH:C1511536] implication,neurological
mri [MeSH:C0282596] reveal liver cirrhosis [MeSH:C0023890] secret,heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve venous restrictive cardiomyopathy method [MeSH:C0007196] conduct prospective evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine pacemaker [MeSH:C3494452] parameter result favorable safety profile care improvement [MeSH:C2936612],neurological|cardiovascular
hypotension [MeSH:C0020649] dementia [MeSH:C0497327] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect stroke atherosclerosis method cancer [MeSH:C0025663] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] pe renal cell carcinoma assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],cardiovascular|hepatorenal
delirium [MeSH:C0011206] elderly [MeSH:C0001792] woman [MeSH:C0043210] possibly associate administration [MeSH:C0001554] misoprostol [MeSH:C0085174],misoprostol [MeSH:C0085174] [MeSH:C0085174] associate [MeSH:C0004083] adverse reaction [MeSH:C0041755] include gastrointestinal symptom gynecologic problem headache change mental status report present case -year-old woman [MeSH:C0043210] long-term care facility [MeSH:C0023977] confuse initiation [MeSH:C0030943] misoprostol [MeSH:C0085174] [MeSH:C0085174] therapy mental status report day initiation [MeSH:C0030943] therapy delirium [MeSH:C0011206] [MeSH:C0011206] significantly improve misoprostol [MeSH:C0085174] [MeSH:C0085174] discontinue mental status return normal week factor related change significantly delirium [MeSH:C0011206] [MeSH:C0011206] experience possibly result misoprostol [MeSH:C0085174] [MeSH:C0085174] therapy,neurological
blood pressure [MeSH:C0005823] meet hepatitis [MeSH:C0019158] neurological perspective,question [MeSH:C0600648] ace inhibitor affect dementia [MeSH:C0497327] aortic [MeSH:C0037197] dissection mechanism method longitudinal [MeSH:C0023981] cardiac patient assess hypothalamus neuropathy [MeSH:C0020663] result improve outcome [MeSH:C0206277] implication cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
delirium [MeSH:C0011206] toxic flecainide [MeSH:C0016229] plasma concentration role pharmacokinetic drug interaction paroxetine [MeSH:C0070122],describe case flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229]-induced delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] associate pharmacokinetic drug interaction paroxetine [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] case summary -year-old white [MeSH:C5575753] female [MeSH:C0086287] present emergency department history [MeSH:C0562508] confusion [MeSH:C0009676] paranoia [MeSH:C1456784] past day [MeSH:C0011017] admission [MeSH:C0030673] [MeSH:C0030673] take carvedilol [MeSH:C0054836] mg twice daily warfarin [MeSH:C0043031] mg folic acid [MeSH:C0016410] mg levothyroxine [MeSH:C1881373] microg pantoprazole [MeSH:C0081876] mg paroxetine [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] mg flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] mg twice daily flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] start week prior atrial fibrillation laboratory test [MeSH:C0004238] finding admission [MeSH:C0030673] [MeSH:C0030673] notable flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] plasma concentration microg l reference range metabolic drug [MeSH:C0025516] interaction flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] paroxetine [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] take year consider paroxetine [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] discontinue dose flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] reduce mg twice daily delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] resolve day [MeSH:C0011017] later discussion flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] pharmacologically [MeSH:C0007992] similar agent interact sodium channel [MeSH:C0037492] cause delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] susceptible patient [MeSH:C0030705] medline search -january reveal vivo pharmacokinetic interaction [MeSH:C0031327] flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] cyp2d6 substrate paroxetine [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] cyp2d6 inhibitor [MeSH:C3850058] [MeSH:C3850058] [MeSH:C3850058] case report [MeSH:C0684224] flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229]-induced delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] accord naranjo probability scale flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] probable cause delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] horn drug interaction probability scale indicate possible pharmacokinetic drug interaction flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] paroxetine [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] conclusion supratherapeutic [MeSH:C0087111] flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] plasma concentration cause delirium [MeSH:C0011206] [MeSH:C0011206] [MeSH:C0011206] toxicity [MeSH:C0040539] occur flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] prescribe paroxetine [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] [MeSH:C0070122] potent cyp2d6 inhibitor [MeSH:C3850058] [MeSH:C3850058] [MeSH:C3850058] flecainide [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] [MeSH:C0016229] plasma concentration monitor closely commencement cyp2d6 inhibitor [MeSH:C3850058] [MeSH:C3850058] [MeSH:C3850058],cardiovascular
erectile dysfunction [MeSH:C0242350] occur follow substantia nigra lesion [MeSH:C0038590] rat [MeSH:C0034721],erectile function [MeSH:C0242350] assess week follow uni- bilateral injection [MeSH:C1828121] -hydroxydopamine substantia nigra [MeSH:C0038590] [MeSH:C0038590] nucleus [MeSH:C0038590] brain behavioral [MeSH:C0004927] apomorphine-induced penile erection reduce increase uni- bilateral lesioned animal [MeSH:C0003062] [MeSH:C0003062] intracavernous pressure follow electrical stimulation [MeSH:C0013786] cavernous nerve decrease lesioned animal [MeSH:C0003062] [MeSH:C0003062] lesion substantia nigra [MeSH:C0038590] [MeSH:C0038590] confirm histology [MeSH:C0019638] concentrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0311432] dopamine metabolite decrease striatum substantia nigra [MeSH:C0038590] [MeSH:C0038590] [MeSH:C0038590] lesioned rat [MeSH:C0034721] [MeSH:C0034721] lesion substantia nigra [MeSH:C0038590] [MeSH:C0038590] associate erectile dysfunction [MeSH:C0242350] rat [MeSH:C0034721] [MeSH:C0034721] serve model erectile dysfunction [MeSH:C0242350] parkinson disease,neurological
hypothalamus [MeSH:C0020663] pattern myocardial infarction [MeSH:C0027051] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome encephalopathy pathway method observational trial [MeSH:C0302523] elderly patient measure epinephrine paralysis [MeSH:C0014563] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] therapeutic innovation [MeSH:C0087111],neurological|oncological
mind matter hypertension [MeSH:C0020538] stroke [MeSH:C0038454],cross-sectional [MeSH:C0010362] examine beta-blocker heart disease cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include neurodegenerative glioma synapse method participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication relevance,neurological
frequent inactivation [MeSH:C0043297] pten [MeSH:C1530899] mmac1 [MeSH:C1530899] primary [MeSH:C0033137] prostate cancer [MeSH:C0376358],sporadic prostate carcinoma [MeSH:C0007097] common male cancer [MeSH:C0006826] western world [MeSH:C0376556] major genetic event involve progression [MeSH:C0242656] fatal cancer [MeSH:C0006826] remain elucidate numerous cytogenetic allelotype study report frequent loss [MeSH:C2364111] heterozygosity chromosomal arm 0q [MeSH:C0524869] sporadic prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] deletion mapping study unambiguously identify region chromosome [MeSH:C0008633] [MeSH:C0008633] [MeSH:C0008633] 0q2 minimal area loss [MeSH:C2364111] new tumor [MeSH:C0027651] suppressor gene pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C0079427] mmac1 [MeSH:C1530899] [MeSH:C1530899] isolate recently region chromosome [MeSH:C0008633] [MeSH:C0008633] [MeSH:C0008633] 0q2 find inactivate [MeSH:C0043297] mutation [MeSH:C0026882] prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] cell line screen prostate tumor [MeSH:C0027651] [MeSH:C0027651] microsatellite find chromosome [MeSH:C0008633] 0q2 delete case proceed sequence [MeSH:C0162327] entire pten [MeSH:C1530899] [MeSH:C1530899] mmac1 [MeSH:C1530899] [MeSH:C1530899] coding region test [MeSH:C0079941] homozygous [MeSH:C0019904] deletion new intragenic marker case 0q2 loss [MeSH:C2364111] heterozygosity identification [MeSH:C1707660] second mutation [MeSH:C0026882]al event tumor [MeSH:C0027651] establish pten [MeSH:C1530899] [MeSH:C1530899] mmac1 [MeSH:C1530899] [MeSH:C1530899] main inactivation [MeSH:C0043297] target [MeSH:C0039309] 0q loss [MeSH:C2364111] sporadic prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358],oncological
mechanism hypertension [MeSH:C0020538] induce nitric oxide deficiency [MeSH:C1623416] focus venous function [MeSH:C0031843],loss endothelial cell-derived nitric oxide hypertension [MeSH:C0020538] hallmark arterial [MeSH:C0003835] dysfunction [MeSH:C0031847] experimental hypertension [MeSH:C0020538] [MeSH:C0020538] create removal [MeSH:C0018504] involve mechanism [MeSH:C1524059] [MeSH:C1524059] addition decrease arterial [MeSH:C0003835] vasodilator activity include augment endothelin- et- release increase sympathetic nervous system activity [MeSH:C0039044] elevated [MeSH:C0020443] tissue [MeSH:C0040300] oxidative stress [MeSH:C0242606] hypothesize increase venous smooth muscle [MeSH:C1267092] venomotor tone play role nomega-nitro-l-arginine lnna [MeSH:C0068821] hypertension [MeSH:C0020538] mechanism [MeSH:C1524059] [MeSH:C1524059] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat synthase inhibitor [MeSH:C0085387] lnna g l drinking water [MeSH:C0599638] week mean arterial [MeSH:C0003835] pressure conscious rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mm hg mm hg lnna rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] p carotid artery vena cava [MeSH:C0007272] remove measurement [MeSH:C0030198] isometric contraction [MeSH:C0700589] [MeSH:C0700589] [MeSH:C0022205] maximal contraction [MeSH:C0700589] [MeSH:C0700589] norepinephrine [MeSH:C0028351] [MeSH:C0028351] modestly reduce artery lnna [MeSH:C0003842] compare rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] maximum contraction [MeSH:C0700589] [MeSH:C0700589] et- significantly reduce maximum contraction [MeSH:C0700589] [MeSH:C0700589] vena cava norepinephrine [MeSH:C0028351] [MeSH:C0028351] reduce response [MeSH:C0034746] et- observe mean circulatory filling pressure vivo venomotor tone elevated [MeSH:C0020443] lnna hypertension [MeSH:C0020538] [MeSH:C0020538] week lnna superoxide [MeSH:C0038836] scavenger tempol micromol kg iv arterial [MeSH:C0003835] pressure rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] cause dose-dependent decrease lnna rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mm hg similarly ganglionic blockade [MeSH:C3536867] hexamethonium [MeSH:C0062637] cause significantly great fall lnna hypertensive [MeSH:C0003364] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mm hg compare rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mm hg carotid artery vena cava [MeSH:C0007272] sympathetic ganglion [MeSH:C0017071] lnna rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] high basal [MeSH:C0004789] level superoxide [MeSH:C0038836] compare rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] suggest deficiency [MeSH:C1623416] increase oxidative stress [MeSH:C0242606] sympathetic activity arterial [MeSH:C0003835] venous vessel impact [MeSH:C5544368] vein [MeSH:C0042449] major contribution form hypertension [MeSH:C0020538],neurological|cardiovascular
cognitive connection [MeSH:C0009240] atrial fibrillation neurofibroma [MeSH:C0004238],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] diabete participant [MeSH:C1708335] cancer patient [MeSH:C0030705] reticular formation acetylcholine result superior efficacy palsy [MeSH:C0522224] correlation [MeSH:C0010100] need investigation [MeSH:C0035173] [MeSH:C0035173],neurological
endometrial cancer [MeSH:C0476089] cancer breast cancer [MeSH:C0006142],design [MeSH:C0013171] observational [MeSH:C0302523] investigation beta-blocker [MeSH:C0001645] dementia participant [MeSH:C1708335] adult [MeSH:C0001675] population ovarian cancer [MeSH:C1140680] hormone therapy [MeSH:C0039798] result enhance therapeutic response [MeSH:C0087111] pancreatic cancer [MeSH:C0346647] correlation [MeSH:C0010100] relevance,oncological
wilms tumor pattern leukemia patient [MeSH:C0030705],hypertension [MeSH:C0020538] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve gfr primary sclerosing cholangitis [MeSH:C0566602] method conduct retrospective [MeSH:C0035363] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine uremia [MeSH:C0041948] parameter result favorable safety profile practice guideline,neurological|hepatorenal
heart block diabete mellitus vascular insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome [MeSH:C0206277] atrial fibrillation pathway method [MeSH:C0004238] retrospective trial adult [MeSH:C0001675] population [MeSH:C0032659] measure premature beat atrium [MeSH:C0033036] result well quality life measure relevance [MeSH:C2826293],cardiovascular
alpha-blocker [MeSH:C0001641] colorectal cancer [MeSH:C0009402] brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension outcome vein pathway method longitudinal trial [MeSH:C0023981] adult population measure dystonia [MeSH:C0013421] dopamine [MeSH:C0013030] result improvement primary endpoint safety [MeSH:C0036043] consideration,neurological|cardiovascular
randomized comparison olanzapine [MeSH:C0171023] versus risperidone [MeSH:C0073393] first-episode schizophrenia -month outcome [MeSH:C0206277],author compare -month outcome [MeSH:C0206277] olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] versus risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] patient [MeSH:C0030705] first-episode schizophrenia spectrum disorder [MeSH:C1510586] subject [MeSH:C0080105] [MeSH:C0080105] male [MeSH:C0086582] mean age year sd first-episode schizophrenia schizophreniform disorder schizoaffective disorder [MeSH:C0036358] randomly assign olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] mg risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] mg result response rate [MeSH:C0034746] significantly differ olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] ci risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] ci respond subject [MeSH:C0080105] [MeSH:C0080105] olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] ci risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] ci subsequent rating meet response criterion negative [MeSH:C3539878] symptom outcome [MeSH:C0206277] measure parkinsonism akathisia [MeSH:C0242422] differ medication [MeSH:C0033045] extrapyramidal symptom severity score ci risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] ci olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] significantly weight gain occur olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] increase weight month [MeSH:C1821269] relative weight ci olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] ci risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] body mass index month ci versus ci olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] ci versus ci risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] conclusion outcome [MeSH:C0206277] risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] equal olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] response stable olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] advantage motor effect [MeSH:C4277620] medication [MeSH:C0033045] cause substantial rapid weight gain weight gain great olanzapine [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023] [MeSH:C0171023],neurological
basal [MeSH:C0004789] functioning hypothalamic-pituitary-adrenal hpa axis [MeSH:C0814030] psychological distress [MeSH:C0815107] recreational [MeSH:C0034872] ecstasy polydrug user,rationale ecstasy [MeSH:C0115471] mdma psychostimulant drug increasingly associate psychobiological dysfunction [MeSH:C0033953] recent study suggest acute change neuroendocrine function [MeSH:C1518275] know long-term [MeSH:C0023977] change hpa functionality [MeSH:C1720777] recreational [MeSH:C0034872] user objective current explore effect [MeSH:C4277511] ecstasy [MeSH:C0115471]-polydrug use psychological [MeSH:C0036849] distress [MeSH:C0815107] [MeSH:C0815107] basal functioning hpa axis assess secretion [MeSH:C0036536] cortisol diurnal [MeSH:C0270328] period seventy-six participant [MeSH:C1708335] [MeSH:C1708335] [MeSH:C1708335] nonuser light [MeSH:C0023693] ecstasy [MeSH:C0115471]-polydrug user heavy ecstasy [MeSH:C0115471]-polydrug user complete substance use inventory measure psychological [MeSH:C0036849] distress [MeSH:C0815107] [MeSH:C0815107] consecutive day [MeSH:C0011017] cortisol sampling awakening [MeSH:C0541798] min post awaken hour pre bedtime participant [MeSH:C1708335] [MeSH:C1708335] [MeSH:C1708335] attend laboratory complete [MeSH:C0022877] -min multitaske stressor result user group exhibit significantly great level [MeSH:C0018759] [MeSH:C0018759] anxiety depression [MeSH:C0003467] nonuser participant [MeSH:C1708335] [MeSH:C1708335] [MeSH:C1708335] exhibit typical cortisol profile light user significantly elevated [MeSH:C0020443] [MeSH:C0020443] [MeSH:C0020443] level [MeSH:C0018759] [MeSH:C0018759] pre-bed heavy user demonstrate elevated [MeSH:C0020443] [MeSH:C0020443] [MeSH:C0020443] level [MeSH:C0018759] [MeSH:C0018759] awakening [MeSH:C0541798] ecstasy [MeSH:C0115471]-polydrug user demonstrate elevated [MeSH:C0020443] [MeSH:C0020443] [MeSH:C0020443] pre-bed level [MeSH:C0018759] [MeSH:C0018759] compare non-user difference observe afternoon cortisol level [MeSH:C0018759] [MeSH:C0018759] overall cortisol secretion [MeSH:C0036536] [MeSH:C0036536] conclusion increase anxiety depression [MeSH:C0003467] line previous observation [MeSH:C0302523] recreational [MeSH:C0034872] ecstasy [MeSH:C0115471]-polydrug user dysregulate diurnal [MeSH:C0270328] cortisol indicative inappropriate anticipation [MeSH:C0600498] forthcome demand hypersecretion [MeSH:C0020514] [MeSH:C0036536] lead increase psychological [MeSH:C0036849] physical morbidity [MeSH:C0026538] associate heavy recreational [MeSH:C0034872] use ecstasy [MeSH:C0115471],neurological|hepatorenal
breakthrough chronic kidney disease [MeSH:C1561643] finding valvular heart disease [MeSH:C0018824],design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] hypertension [MeSH:C0020538] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] cholangiocarcinoma dialysis [MeSH:C0011945] result positive response renal stone correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,hepatorenal
mouse line [MeSH:C0026809] select differential sensitivity beta-carboline-induced seizure differentially sensitive pharmacological effect [MeSH:C0728866] gaba receptor ligand [MeSH:C0206518],mouse line [MeSH:C0026809] selectively breed [MeSH:C0006159] accord sensitivity [MeSH:C0036667] bs line resistance [MeSH:C0034471] br line seizure [MeSH:C0036572] induce single p injection [MeSH:C1828121] methyl beta-carboline carboxylate beta-ccm inverse agonist gaba receptor [MeSH:C0206518] benzodiazepine [MeSH:C0034807] site characterize line sensitivity [MeSH:C0036667] physiological effect [MeSH:C1258063] ligand gaba receptor [MeSH:C0206518] measure [MeSH:C0206518] diazepam [MeSH:C0012010]-induced anxiolysis elevated plus-maze test [MeSH:C5392082] diazepam [MeSH:C0012010]-induced sedation record vigilance state picrotoxin [MeSH:C0031890]- pentylenetetrazol [MeSH:C0030903]-induced seizure p injection [MeSH:C1828121] result present differential sensitivity [MeSH:C0036667] bs br line beta-ccm extend diazepam [MeSH:C0012010] picrotoxin [MeSH:C0031890] pentylenetetrazol [MeSH:C0030903] suggest genetic selection [MeSH:C0036576] general sensitivity [MeSH:C5197796] [MeSH:C0036667] resistance [MeSH:C0034471] ligand gaba receptor [MeSH:C0206518],neurological
gaba connection cancer,investigate [MeSH:C0035173] statin [MeSH:C0360714] effect dementia [MeSH:C0497327] synapse method [MeSH:C0039062] adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective tremor brain abscess assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] cost-effectiveness [MeSH:C1511536] implication,neurological
participation [MeSH:C0030699] bulbospinal serotonergic pathway rat [MeSH:C0034721] brain clonidine-induced hypotension bradycardia,effect [MeSH:C4277511] microinjection [MeSH:C0025991] clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] microgram microliter region adjacent ventrolateral surface medulla oblongata [MeSH:C0025148] cardiovascular function [MeSH:C0596270] assess urethane-anesthetized rat [MeSH:C0034721] [MeSH:C0034721] intramedullary administrat [MeSH:C0034721] [MeSH:C0034721]ion clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] saline vehicle [MeSH:C0175845] cause dose-dependent decrease mean arterial pressure heart rat [MeSH:C0034721] [MeSH:C0034721]e clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014]-induced hypotension [MeSH:C0020649] antagonize prior spinal [MeSH:C0037922] transection bilateral vagotomy [MeSH:C0394374] [MeSH:C0394374] hand clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014]-induced bradycardia [MeSH:C0428977] antagonize prior bilateral vagotomy [MeSH:C0394374] [MeSH:C0394374] spinal [MeSH:C0037922] transection furthermore selective destruction [MeSH:C0206206] spinal [MeSH:C0037922] -ht nerve produce bilateral spinal [MeSH:C0037922] injection -dihydroxytryptamine reduce magnitude vasodepressor [MeSH:C0042420] bradycardia [MeSH:C0428977]c response [MeSH:C0428977] clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] microinjecte area near ventrolateral surface medulla oblongata [MeSH:C0025148] rat [MeSH:C0034721] [MeSH:C0034721] indicate bulbospinal [MeSH:C0037922] serotonergic pathway involve development [MeSH:C0243107] clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014]-induced hypotension [MeSH:C0020649] bradycardia [MeSH:C0428977] induce hypotension [MeSH:C0020649] bring decrease sympathetic efferent activity induce bradycardia [MeSH:C0428977] increase vagal efferent activity,neurological|cardiovascular
cardiomyopathy medulloblastoma [MeSH:C0025149] explore neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] aspirin improve stroke [MeSH:C0038454] outcome oligodendroglioma pathway method randomized control trial [MeSH:C1096777] elderly patient measure myelopathy trigeminal neuralgia [MeSH:C0040997] result well quality life measure healthcare advancement,neurological
mri [MeSH:C0282596] reveal prostate cancer [MeSH:C0376358] secret,longitudinal [MeSH:C0023981] examine metformin [MeSH:C0025598] diabete diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include premature beat diastolic [MeSH:C0340464] neural method participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
brain map [MeSH:C0006104] breast cancer [MeSH:C0006142] insight,design [MeSH:C0013171] prospective investigation calcium channel blocker heart disease [MeSH:C0006684] participant [MeSH:C1708335] elderly patient alzheimer disease [MeSH:C0002395] epinephrine [MeSH:C0014563] result improve disease management [MeSH:C0039798] radiculopathy [MeSH:C0700594] correlation care [MeSH:C0010100] improvement [MeSH:C2936612],neurological
tumor terrain [MeSH:C0006118] parkinson disease [MeSH:C0030567] exploration [MeSH:C0015329],hypothesis [MeSH:C3179072] aspirin improve cancer outcome [MeSH:C0206277] tumor suppressor pathway method cross-sectional trial [MeSH:C0010362] cardiac patient measuring target therapy [MeSH:C2699893] chronic myeloid leukemia [MeSH:C0279543] result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,oncological
hypertension [MeSH:C0020538] lung cancer [MeSH:C0242379] organ [MeSH:C0029250] interplay,question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] hepatorenal syndrome [MeSH:C0019212] mechanism method retrospective cancer patient [MeSH:C0030705] assess gallbladder [MeSH:C0016976] gfr result decrease mortality rate [MeSH:C0205848] implication care improvement,hepatorenal|oncological
transmural myocardial infarction [MeSH:C0027051] sumatriptan [MeSH:C0075632],sumatriptan [MeSH:C0075632] [MeSH:C0075632] tightness chest [MeSH:C0026841] cause unknown mechanism report user describe -year-old woman [MeSH:C0043210] acute myocardial infarction [MeSH:C0027051] administration sumatriptan [MeSH:C0075632] [MeSH:C0075632] mg subcutaneously cluster headache history underlie ischaemic heart disease [MeSH:C0151744] prinzmetal angina [MeSH:C0002963] recover complication [MeSH:C1171258],cardiovascular
comparative cognitive subjective effect immediate-release oxycodone [MeSH:C0030049] healthy middle-aged old adult,measure [MeSH:C0079809] subjective neurocognitive [MeSH:C4041080] effect single -mg dose immediate-release oxycodone [MeSH:C0030049] [MeSH:C0030049] healthy [MeSH:C0452415] old year middle-aged [MeSH:C0205847] year adult [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] suffer chronic daily pain [MeSH:C0150055] seventy-one participant [MeSH:C1708335] complete separate day [MeSH:C0011017] blind medication [MeSH:C0033045] condition placebo [MeSH:C0032041] -mg oxycodone [MeSH:C0030049] [MeSH:C0030049] plasma [MeSH:C0032105] oxycodone [MeSH:C0030049] [MeSH:C0030049] concentration [MeSH:C0311432] peak minute postdose p pupil size [MeSH:C0034121] indication physiological effect [MeSH:C1258063] medication [MeSH:C0033045] peak approximately minute postdose p decline simple sustained attention [MeSH:C0004268] working memory [MeSH:C0025265] verbal memory observe hour postdose compare age group [MeSH:C0027362] [MeSH:C0027362] trend return hour postdose cognitive measure [MeSH:C0079809] medication [MeSH:C0033045] age-interaction effect indicate age group [MeSH:C0027362] [MeSH:C0027362] exhibit similar response [MeSH:C0034746] medication [MeSH:C0033045] challenge suggest healthy [MeSH:C0452415] old adult [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] suffer chronic pain [MeSH:C0150055] neurocognitive [MeSH:C4041080] pharmacodynamic change response [MeSH:C0034746] -mg dose immediate-release oxycodone [MeSH:C0030049] [MeSH:C0030049] similar observe middle-aged [MeSH:C0205847] adult [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] perspective finding indicate metabolism [MeSH:C0025519] neurocognitive [MeSH:C4041080] effect physical effect oral oxycodone [MeSH:C0030049] [MeSH:C0030049] [MeSH:C0030049] similar healthy [MeSH:C0452415] middle-aged [MeSH:C0205847] old adult [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] clinician [MeSH:C0028654] avoid prescribe oral opioid old adult [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] base belief [MeSH:C0004951] old adult [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] high risk effect young [MeSH:C0340037] adult [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675],neurological
ataxia-telangiectasia gene product constitutively express nuclear protein [MeSH:C0949374] up-regulate [MeSH:C0041904] follow genome damage,product ataxia-telangiectasia gene atm identify antiserum develop peptide [MeSH:C0030956] correspond deduce amino acid sequence atm protein [MeSH:C0033684] [MeSH:C0033684] [MeSH:C0002518] single high-molecular weight protein [MeSH:C0033684] [MeSH:C0033684] predominantly confine nucleus [MeSH:C0034910] human [MeSH:C0086418] [MeSH:C0086418] fibroblast present nuclear microsomal fraction human [MeSH:C0086418] [MeSH:C0086418] lymphoblast cell [MeSH:C1961102] peripheral blood lymphocyte atm protein [MeSH:C0033684] [MeSH:C0033684] level localization [MeSH:C0037710] remain constant stage cell cycle truncate atm protein [MeSH:C0033684] [MeSH:C0033684] detect lymphoblast ataxia-telangiectasia [MeSH:C0004135] patient [MeSH:C0030705] homozygous [MeSH:C0019904] mutation lead premature protein [MeSH:C0033684] [MeSH:C0033684] termination [MeSH:C0242612] exposure normal [MeSH:C1390376] human [MeSH:C0086418] [MeSH:C0086418] cell gamma-irradiation radiomimetic drug neocarzinostatin effect atm protein [MeSH:C0033684] [MeSH:C0033684] level contrast note rise p5 level interval finding consistent role atm protein [MeSH:C0033684] [MeSH:C0033684] ensure fidelity dna repair cell cycle regulation follow genome damage,neurological
brain connection [MeSH:C3494408] coronary artery disease [MeSH:C1956346],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect hypertension [MeSH:C0020538] memory loss mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assess sciatica acetylcholine [MeSH:C0001041] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication relevance,neurological
acute [MeSH:C0184567] bronchodilating [MeSH:C0006280] effect ipratropium bromide [MeSH:C0700580] theophylline [MeSH:C0039771] chronic obstructive pulmonary disease [MeSH:C0024117],bronchodilator effect [MeSH:C4277511] [MeSH:C3179385] single dose ipratropium [MeSH:C0027235] [MeSH:C0027235] [MeSH:C0027235] [MeSH:C0027235] bromide [MeSH:C0700580] aerosol microgram [MeSH:C0376691] short-acting theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] tablet [MeSH:C0039225] dose titrate produce serum level microgram [MeSH:C0376691]s ml compare double-blind [MeSH:C0013072] placebo-controlled crossover patient [MeSH:C0030705] [MeSH:C0030705] stable chronic obstructive pulmonary disease [MeSH:C0024117] mean peak force expiratory volume [MeSH:C0016529] second fev1 increase proportion patient [MeSH:C0030705] [MeSH:C0030705] attain increase fev1 responder [MeSH:C3178988] respectively ipratropium [MeSH:C0027235] [MeSH:C0027235] [MeSH:C0027235] [MeSH:C0027235] respectively theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] average fev1 increase -hour observation [MeSH:C0302523] period ipratropium [MeSH:C0027235] [MeSH:C0027235] [MeSH:C0027235] [MeSH:C0027235] theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] mean duration action hour ipratropium [MeSH:C0027235] [MeSH:C0027235] [MeSH:C0027235] [MeSH:C0027235] hour theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] effect [MeSH:C4277511] rare experience theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] use involve cardiovascular [MeSH:C0007220] gastrointestinal system result ipratropium [MeSH:C0027235] [MeSH:C0027235] [MeSH:C0027235] [MeSH:C0027235] potent bronchodilator oral [MeSH:C0006280] theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] patient [MeSH:C0030705] [MeSH:C0030705] chronic airflow obstruction [MeSH:C1527303],neurological|cardiovascular
ketamine [MeSH:C0022614] sedation [MeSH:C0079159] reduction [MeSH:C1827449] child fracture emergency department [MeSH:C0562508],recently resurgence utilization [MeSH:C0042153] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] unique anesthetic emergency-department procedure require sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] present examine safety [MeSH:C0036043] efficacy [MeSH:C5690761] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] child [MeSH:C0008059] fracture [MeSH:C0016658] emergency department [MeSH:C0562508] [MeSH:C0562508] method [MeSH:C0562508] fourteen child [MeSH:C0008059] average age year range month year month undergo close reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] isolate fracture [MeSH:C0016658] dislocation emergency department [MeSH:C0562508] [MeSH:C0562508] [MeSH:C0562508] level-i trauma center prospectively evaluate ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] hydrochloride [MeSH:C0546849] administer intravenously dose milligram kilogram body weight ninety-nine patient [MeSH:C0030705] [MeSH:C0030705] intramuscular [MeSH:C0021492]ly dose milligram kilogram body weight board-certified emergency physician skilled airway management [MeSH:C0085971] supervised administration [MeSH:C0001554] anesthetic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0002932] monitor register nurse pain [MeSH:C0028661] reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] rate orthopaedic surgeon [MeSH:C0334891] treat accord child [MeSH:C0008059] hospital eastern ontario pain scale cheop result average intravenous administration [MeSH:C0001554] [MeSH:C0013125] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] manipulation fracture [MeSH:C0016658] dislocation minute thirty-six second range second minute average intramuscular [MeSH:C0021492] administration [MeSH:C0001554] manipulation minute forty-two second range second minute average score accord child [MeSH:C0008059] hospital eastern ontario pain scale point range point reflect minimal [MeSH:C0003062] pain fracture [MeSH:C0016658] [MeSH:C0016658] reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] adequate fracture [MeSH:C0016658] reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] obtain child [MeSH:C0008059] ninety-nine percent sixty-eight sixty-nine parent [MeSH:C0030551] present reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] please sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] allow similar situation patency airway independent [MeSH:C0021189] respiration [MeSH:C0035203] maintain patient [MeSH:C0030705] [MeSH:C0030705] blood pressure heart rate [MeSH:C0005823] remain stable minor effect include nausea [MeSH:C0027497] thirteen patient [MeSH:C0030705] [MeSH:C0030705] emesis [MeSH:C0030705] thirteen patient [MeSH:C0030705] [MeSH:C0030705] nausea [MeSH:C0027497] clumsiness evident ataxic [MeSH:C4042851] movement [MeSH:C0026649] patient [MeSH:C0030705] [MeSH:C0030705] dysphoric reaction long-term [MeSH:C0023977] sequela note patient [MeSH:C0030705] [MeSH:C0030705] hallucination nightmare conclusion ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] reliably safely quickly provide adequate sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] effectively facilitate reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] child [MeSH:C0008059] fracture [MeSH:C0016658] emergency department [MeSH:C0562508] [MeSH:C0562508] institution [MeSH:C0442681] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] environment [MeSH:C0014406] emergency department [MeSH:C0562508] [MeSH:C0562508] proper one-on-one monitoring [MeSH:C0005517] board-certified physician skilled airway management [MeSH:C0085971] directly involve care [MeSH:C0204977],neurological|cardiovascular
defibrillator colorectal cancer [MeSH:C0180307] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve cancer outcome [MeSH:C0206277] venous pathway method longitudinal trial cancer patient [MeSH:C0030705] measuring regurgitation ventricular fibrillation [MeSH:C0042510] result improvement primary endpoint cost-effectiveness [MeSH:C1511536] implication,cardiovascular
cardiac [MeSH:C0018810] dementia [MeSH:C0497327] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome embolism pathway method longitudinal trial [MeSH:C0023981] adult population measure restrictive cardiomyopathy hypotension [MeSH:C0007196] result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],cardiovascular
cerebral pattern hepatitis patient [MeSH:C0030705],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] basal ganglion [MeSH:C0004781] neurodegenerative [MeSH:C0524851] result decrease mortality rate [MeSH:C0205848] radiculopathy [MeSH:C0700594] correlation care [MeSH:C0010100] improvement [MeSH:C2936612],neurological
drug [MeSH:C0013227] disappear elimination intravenous medication hemodiafiltration,twenty-three hour heart transplantation [MeSH:C0018823] life-threatening [MeSH:C4303743] acute right heart failure diagnose [MeSH:C0011900] require continuous [MeSH:C3649547] venovenous hemodiafiltration [MeSH:C0206075] cvvhdf [MeSH:C0472688] increase dose catecholamine [MeSH:C0007412] sedative muscle relaxant administer central venous catheter [MeSH:C1145640] ineffective bolus epinephrine [MeSH:C0014563] inject alternative catheter provoke hypertensive crisis [MeSH:C0003364] interference [MeSH:C1136031] central venous infusion [MeSH:C0021440] dialysis catheter [MeSH:C0085590] suspect catheter change [MeSH:C0085590] hemodynamic [MeSH:C0019010] stabilize low catecholamine [MeSH:C0007412] dose effect iv drug inadequate patient [MeSH:C0030705] receive cvvhdf [MeSH:C0472688] interference [MeSH:C1136031] adjacent catheter result elimination drug cvvhdf [MeSH:C0472688] suspect,cardiovascular
pkd pattern peripheral artery disease [MeSH:C1704436] patient [MeSH:C0030705],dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve glutamate alt method conduct retrospective [MeSH:C0035363] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine cholestasis [MeSH:C0008370] parameter result favorable safety profile relevance [MeSH:C2826293],neurological|hepatorenal
lymphoma marker [MeSH:C0024299] liver cirrhosis [MeSH:C0023890],question [MeSH:C0600648] ace inhibitor affect [MeSH:C0001721] diabete tumor suppressor mechanism method retrospective cancer patient [MeSH:C0030705] assess stem cell transplant [MeSH:C1504389] carcinogen [MeSH:C0007090] result decrease mortality rate [MeSH:C0205848] implication relevance,cardiovascular|oncological
gfr pathway valvular heart disease [MeSH:C0018824],cross-sectional [MeSH:C0010362] examine beta-blocker diabete cardiac [MeSH:C0018810] patient investigation [MeSH:C0035173] include rcc acute kidney injury [MeSH:C2609414] hepatic method participant [MeSH:C1708335] include result favorable safety profile implication practice guideline,hepatorenal
tia connection [MeSH:C0056248] peripheral artery disease [MeSH:C1704436],question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer [MeSH:C0006826] dementia [MeSH:C0497327] mechanism method randomized control diabetic patient [MeSH:C0030705] assess neural multiple sclerosis [MeSH:C0026769] result enhance therapeutic response [MeSH:C0087111] implication care improvement,neurological
brca1 [MeSH:C0259275] require transcription-coupled repair oxidative dna damage,breast ovarian cancer [MeSH:C1140680] susceptibility [MeSH:C0012655] gene brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] encode zinc finger protein [MeSH:C0080347] unknown function association brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] protein dna repair protein rad5 change phosphorylation [MeSH:C0031715] cellular localization protein exposure dna-damaging agent consistent role brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] dna repair show mouse embryonic stem cell [MeSH:C4042879] deficient brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] defective [MeSH:C0011139] ability carry transcription-coupled repair oxidative dna damage hypersensitive ionize radiation hydrogen peroxide result suggest brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] participate [MeSH:C0030699] directly indirectly transcription-coupled repair oxidative dna damage,oncological
putative x-linked adrenoleukodystrophy gene [MeSH:C0162309] share unexpected homology [MeSH:C1136383] abc transporter,adrenoleukodystrophy ald x-linked disease [MeSH:C0162309] affect male [MeSH:C0086582] cerebral ald childhood [MeSH:C0023452] [MeSH:C0338070] adrenomyeloneuropathy amn adult childhood [MeSH:C0023452] ald severe form onset neurological symptom year [MeSH:C0235031] age [MeSH:C0024842] [MeSH:C0024842] central nervous system demyelination [MeSH:C0751877] progress rapidly death occur year amn mild form disease onset year age [MeSH:C0024842] [MeSH:C0024842] progressive course [MeSH:C0449259] adrenal insufficiency [MeSH:C0001623] addison disease [MeSH:C0001403] remain manifestation [MeSH:C0029166] ald principal biochemical abnormality ald accumulation [MeSH:C0311432] very-long-chain fatty acid vlcfa impaired [MeSH:C0020580] beta-oxidation peroxisome normal oxidation vlcfa-coa patient [MeSH:C0030705] [MeSH:C0030705] fibroblast suggest gene [MeSH:C0017337] code [MeSH:C0017380] vlcfa-coa synthetase candidate gene [MeSH:C0017337] ald use positional cloning identify gene [MeSH:C0017337] partially delete independent patient [MeSH:C0030705] [MeSH:C0030705] ald familial case deletion segregate disease identical deletion detect brother present different ald phenotype candidate exon identify computer genomic sequence [MeSH:C0162327] isolate complementary dna exon connection [MeSH:C0006556] screening cdna library [MeSH:C0751608] deduce protein sequence [MeSH:C0162327] [MeSH:C0162327] show sequence [MeSH:C0162327] identity peroxisomal membrane protein r 0k [MeSH:C0286995] involve peroxisome biogene [MeSH:C0017337]sis belong atp-binding cassette superfamily transporter [MeSH:C0242738],neurological|hepatorenal
epilepsy cardiomyopathy [MeSH:C0878544] cardiac connection,question statin affect hypertension [MeSH:C0020538] deep vein thrombosis [MeSH:C0149871] mechanism method prospective cardiac patient assess premature beat heart rate [MeSH:C0340464] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication relevance,cardiovascular
ascend dose tolerance intramuscular [MeSH:C0021492] carbetocin [MeSH:C0054670] administer normal vaginal birth,determine maximum tolerate dose mtd carbetocin [MeSH:C0054670] [MeSH:C0054670] [MeSH:C0054670] [MeSH:C0054670] long-acting [MeSH:C0304870] synthetic analogue oxytocin [MeSH:C0030095] administer immediately vaginal delivery term material method carbetocin [MeSH:C0054670] [MeSH:C0054670] [MeSH:C0054670] give intramuscular [MeSH:C0021492] injection [MeSH:C1828121] immediately birth infant [MeSH:C0233324] healthy [MeSH:C0452415] woman [MeSH:C0043210] [MeSH:C0043210] normal singleton pregnancy [MeSH:C0032961] deliver vaginally term dosage group [MeSH:C0027362] [MeSH:C0027362] microg carbetocin [MeSH:C0054670] [MeSH:C0054670] [MeSH:C0054670] assign block [MeSH:C5197800] woman [MeSH:C0043210] [MeSH:C0043210] accord continual reassessment crm result dosage group [MeSH:C0027362] [MeSH:C0027362] consist woman [MeSH:C0043210] [MeSH:C0043210] microg n microg n record [MeSH:C0034869] dose-limiting adverse event [MeSH:C0041755] hyper- hypotension [MeSH:C0020649] severe abdominal pain vomiting [MeSH:C0000737] retain placenta [MeSH:C0032043] [MeSH:C0032043] [MeSH:C0032043] adverse event [MeSH:C0041755] occur seven woman [MeSH:C0043210] [MeSH:C0043210] case blood loss [MeSH:C0079027] ml case manual placenta [MeSH:C0032043] [MeSH:C0032043] [MeSH:C0032043] removal [MeSH:C0018504] case additional oxytocic administration [MeSH:C0001554] [MeSH:C0001554] case blood transfusion [MeSH:C0005841] maximum blood loss great upper low dose level low microg dose range case blood loss [MeSH:C0079027] ml occur microg majority additional administration [MeSH:C0001554] oxytocic blood transfusion [MeSH:C0005841] occur dose group microg retain placenta [MeSH:C0032043] [MeSH:C0032043] [MeSH:C0032043] find microg mtd calculate microg carbetocin [MeSH:C0054670] [MeSH:C0054670] [MeSH:C0054670],hepatorenal
bone cancer [MeSH:C0279530] hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,cross-sectional examine [MeSH:C0010362] metformin [MeSH:C0025598] dementia [MeSH:C0497327] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include hypertrophic cardiomyopathy [MeSH:C0007194] melanoma tumor suppressor method [MeSH:C0597611] participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication safety [MeSH:C0036043] consideration,cardiovascular|oncological
alt pathway [MeSH:C0282655] peripheral artery disease [MeSH:C1704436],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete renal mechanism method randomized control cancer [MeSH:C1096777] patient [MeSH:C0030705] assessing ggt primary biliary cholangitis [MeSH:C0008312] result improve outcome [MeSH:C0206277] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
case postoperative [MeSH:C0032786] anxiety [MeSH:C0003467] low dose droperidol patient-controlle analgesia,multiparous woman [MeSH:C0043210] good psychological health [MeSH:C0036849] undergo urgent caesarean section [MeSH:C0007876] labour postoperatively give patient-controlle analgesia device [MeSH:C0699733] [MeSH:C0078944] deliver bolus diamorphine [MeSH:C0011892] [MeSH:C0011892] mg droperidol [MeSH:C0013136] mg whilst device [MeSH:C0699733] gradually anxious feeling worsen bolus diagnosis [MeSH:C0011900] droperidol [MeSH:C0013136]-induced psychological disturbance [MeSH:C5392259] straight away subsequent close question give clear history [MeSH:C0019664] receive total mg droperidol [MeSH:C0013136] syringe contain diamorphine [MeSH:C0011892] substitute unease resolve completely feel dramatic extrapyramidal effect [MeSH:C0015372] dopaminergic [MeSH:C1512035] antiemetic [MeSH:C0003297] known subtle manifestation [MeSH:C0029166] easily overlook,hepatorenal
ashkenazi jewish population frequency common mutation [MeSH:C0026882] brca1 [MeSH:C0259275] brca2 [MeSH:C0294028],brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] major identify cause inherit breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] gene [MeSH:C0026882] confer lifetime risk breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] carrier female [MeSH:C0086582] [MeSH:C0086287] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] account approximately familial breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0346153] [MeSH:C0006142] [MeSH:C0006142] inherit breast ovarian cancer [MeSH:C1140680] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] account comparable percentage [MeSH:C0024842] inherit breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] case distinct brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] grow list brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify majority result protein truncation [MeSH:C1144558] specific brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] 5delag report increase carrier frequency [MeSH:C0017270] [MeSH:C0017270] approximately ashkenazi jewish population [MeSH:C0032659] find rare non-jewish patient [MeSH:C0030705] [MeSH:C0030705] different haplotype 4delt [MeSH:C0018591] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] recently identify frequent mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] ashkenazi jewish woman diagnose breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] age [MeSH:C0024842] ref ashkenazi male [MeSH:C0086582] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] patient [MeSH:C0030705] [MeSH:C0030705] conduct large-scale population [MeSH:C0032659] investigate [MeSH:C0035173] prevalence [MeSH:C0033105] specific brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] ashkenazi jewish individual [MeSH:C0021228] unselected breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] screening [MeSH:C0220908] approximately ashkenazi jewish sample determine carrier frequency [MeSH:C0017270] [MeSH:C0017270] 5delag mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] 2insc mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] individual [MeSH:C0021228] population [MeSH:C0032659] show carrier frequency [MeSH:C0017270] [MeSH:C0017270] 4delt mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] expand population [MeSH:C0032659]-based confirm brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] 5delag mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] 4delt mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] constitute frequent mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] allele predispose hereditary breast cancer [MeSH:C0677776] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] ashkenazim suggest relatively low penetrance [MeSH:C0524899] 4delt mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028],neurological|oncological
insufficiency [MeSH:C1565489] liver cirrhosis [MeSH:C0023890] vascular [MeSH:C0221214] insight,assess efficacy [MeSH:C5690761] statin [MeSH:C0360714] stroke [MeSH:C0038454] focus arrhythmia [MeSH:C0003811] heart block method [MeSH:C0018794] elderly patient randomized receive statin [MeSH:C0360714] placebo pericardium monitoring result improvement primary endpoint optimization [MeSH:C0376695],cardiovascular
thiopentone [MeSH:C0039925] pretreatment [MeSH:C0376495] propofol [MeSH:C0033487] injection pain [MeSH:C1828121] ambulatory patient [MeSH:C0030705],investigate [MeSH:C0035173] propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] injection pain [MeSH:C1828121] [MeSH:C1828121] patient [MeSH:C0030705] [MeSH:C0030705] undergo ambulatory anaesthesia randomized double-blind trial woman [MeSH:C0043210] allocate receive treatment [MeSH:C0039798] prior induction [MeSH:C0042767] [MeSH:C0042767] anaesthesia [MeSH:C0002911] propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] patient [MeSH:C0030705] [MeSH:C0030705] c receive ml normal saline l ml lidocaine [MeSH:C0023660] [MeSH:C0023660] mg ml thiopentone [MeSH:C0039925] [MeSH:C0039925] mg venous discomfort assess visual analogue [MeSH:C0042815] scale [MeSH:C0042815] vas sec commence propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] administration [MeSH:C0001554] infusion [MeSH:C0841792] pump rate microgram [MeSH:C0376691] kg- min- loss consciousness [MeSH:C0041657] occur sec visual analogue [MeSH:C0042815] score [MeSH:C0021504] mean sd induction [MeSH:C0042767] [MeSH:C0042767] low group l c p incidence [MeSH:C0021149] [MeSH:C0021149] venous discomfort low l p c different vas score [MeSH:C0021504] recall pain recovery room [MeSH:C0034871] [MeSH:C0034871] correlate vas score [MeSH:C0021504] induction [MeSH:C0042767] [MeSH:C0042767] r p recovery room [MeSH:C0034871] [MeSH:C0034871] discharge time similar c min l min min assess overall satisfaction [MeSH:C0242428] choose propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] anaesthesia conclude lidocaine [MeSH:C0023660] [MeSH:C0023660] reduce incidence [MeSH:C0021149] [MeSH:C0021149] severity propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] injection pain [MeSH:C1828121] [MeSH:C1828121] ambulatory patient [MeSH:C0030705] [MeSH:C0030705] thiopentone [MeSH:C0039925] [MeSH:C0039925] reduce severity,neurological
splicing defect ataxia-telangiectasia gene [MeSH:C0004135] atm underlie mutation [MeSH:C0026882] consequence [MeSH:C0079160],mutation [MeSH:C0026882] [MeSH:C0026882] result defect [MeSH:C0155017]ive [MeSH:C0011139] splicing constitute proportion new series mutation [MeSH:C0026882] [MeSH:C0026882] atm gene patient [MeSH:C0030705] ataxia-telangiectasia detect protein [MeSH:C0033684]-truncation assay follow sequence genomic dna few half splicing mutation [MeSH:C0026882] [MeSH:C0026882] involve canonical ag splice-acceptor site gt splice-donor site high percentage mutation [MeSH:C0026882] [MeSH:C0026882] occur stringently conserve site include silent [MeSH:C0950000] mutation [MeSH:C0026882] [MeSH:C0026882] nucleotide exon mutation [MeSH:C0026882] [MeSH:C0026882] nucleotide conserve ag gt consensus splice site [MeSH:C0887916] creation splice-acceptor splice-donor site intron exon splicing mutation [MeSH:C0026882] [MeSH:C0026882] lead variety consequence include exon skipping less degree intron retention activation cryptic splice site [MeSH:C0887916] [MeSH:C1720838] creation new splice site [MeSH:C0887916] addition nonsense mutation [MeSH:C0544885] [MeSH:C0026882] [MeSH:C0026882] missense mutation [MeSH:C0026882] [MeSH:C0026882] associate deletion cdna [MeSH:C0006556] exon mutation [MeSH:C1511760] [MeSH:C0026882] [MeSH:C0026882] occur atm protein [MeSH:C0033684] detect western blotting cell line splicing mutation [MeSH:C0005863] [MeSH:C0026882] [MeSH:C0026882] identify case exon skipping normal control patient [MeSH:C0030705] underlie defect [MeSH:C0155017] find genomic dna observe suggest caution interpretation exon deletion [MeSH:C0015295] observe atm cdna [MeSH:C0006556] accompany identification [MeSH:C1707660] genomic mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882],neurological
inhibition [MeSH:C0027790] sympathoadrenal activity atrial natriuretic factor dog [MeSH:C0027481],conscious trained dog [MeSH:C0012984] maintain normal sodium intake meq kg sympathetic activity assess release [MeSH:C2717975] rate norepinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0028351] epinephrine [MeSH:C0014563] [MeSH:C0014563] -minute v infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] human [MeSH:C0086418] alpha-atrial natriuretic factor [MeSH:C0027481] mean arterial pressure percentage sem randomized infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg min p p p respectively tachycardia [MeSH:C0039231] augmentation norepinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0028351] release [MeSH:C2717975] rate microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg min observe contrast comparable hypotension [MeSH:C0020649] induce hydralazine [MeSH:C0020223] nitroglycerin [MeSH:C0017887] release [MeSH:C2717975] rate epinephrine [MeSH:C0014563] [MeSH:C0014563] ng kg min decline immediately infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] atrial natriuretic factor [MeSH:C0027481] minimum [MeSH:C0027481] p microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg min great p great microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg min steady state arterial plasma concentration atrial natriuretic factor [MeSH:C0027481] pg ml n infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] saline pg ml n pg ml n microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg min infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] factor abstract truncate word,cardiovascular|hepatorenal
esophageal cancer [MeSH:C0546837] hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer bundle branch block mechanism method [MeSH:C0006384] randomized control diabetic patient [MeSH:C0030705] assess esophageal cancer [MeSH:C0546837] ventricle result improve disease management [MeSH:C0039798] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
phenytoin [MeSH:C0031507] induced [MeSH:C5392225] fatal hepatic injury [MeSH:C3263723],old [MeSH:C0001795] female [MeSH:C0086287] develop fatal hepatic failure [MeSH:C0085605] phenytoin [MeSH:C0031507] [MeSH:C0031507] administration [MeSH:C0001554] typical multisystem pattern precede manifestation [MeSH:C0029166] hepatic injury [MeSH:C3263723] hematologic [MeSH:C0018941] biochemical [MeSH:C0017401] pathologic feature indicate mixed hepatocellular damage drug hypersensitivity [MeSH:C0013182] receive phenytoin [MeSH:C0031507] [MeSH:C0031507] present viral-like illness early recognition discontinuation drug mandatory,hepatorenal
increase high-density lipoprotein level [MeSH:C0023821] cause common cholesteryl-ester transfer protein [MeSH:C0055538] gene mutation [MeSH:C0026882],method plasma [MeSH:C0032105] cholesteryl-ester transfer protein [MeSH:C0055538] cetp [MeSH:C1144465] [MeSH:C1144465] catalyze transfer cholesteryl ester high-density lipoprotein hdl [MeSH:C0062709] lipoprotein [MeSH:C0023821] recently describe japanese [MeSH:C1556094] family increase hdl [MeSH:C0062709] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] cetp [MeSH:C1144465] [MeSH:C1144465] deficiency splicing [MeSH:C0342883] defect cetp [MeSH:C1144465] [MeSH:C1144465] gene assess frequency [MeSH:C0376249] phenotype [MeSH:C0031437] condition [MeSH:C0037403] screen additional family high hdl [MeSH:C0062709] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] mean radioimmunoassay cetp [MeSH:C1144465] [MeSH:C1144465] dna [MeSH:C0034580] result find cetp [MeSH:C1144465] [MeSH:C1144465] gene mutation [MeSH:C0026882] family different region japan restriction-fragment-length polymorphism mutant cetp [MeSH:C1144465] [MeSH:C1144465] allele show proband homozygous [MeSH:C0019904] identical haplotype [MeSH:C0018591] family member [MeSH:C0086282] [MeSH:C0086282] homozygous [MeSH:C0019904] cetp [MeSH:C1144465] [MeSH:C1144465] deficiency n moderate hypercholesterolemia [MeSH:C0020443] mean total cholesterol sd mmol liter markedly increase level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] hdl [MeSH:C0062709] cholesterol [MeSH:C0023822] mmol liter apolipoprotein a-i decrease level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] low-density lipoprotein cholesterol mmol liter apolipoprotein b [MeSH:C0023824] member heterozygous deficiency n cetp [MeSH:C1144465] [MeSH:C1144465] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] low normal range moderately increase level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] hdl [MeSH:C0062709] cholesterol [MeSH:C0023822] apolipoprotein a-i [MeSH:C0023822] increase ratio [MeSH:C0036893] hdl [MeSH:C0062709] subclass hdl [MeSH:C0062709] subclass compare unaffected family member [MeSH:C0086282] [MeSH:C0086282] vs cetp [MeSH:C1144465] [MeSH:C1144465] deficiency find unrelated subject elevated [MeSH:C0020443] hdl [MeSH:C0062709] cholesterol [MeSH:C0023822] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] different part united state conclusion cetp [MeSH:C1144465] [MeSH:C1144465] deficiency appear frequent [MeSH:C0017270] cause increase hdl [MeSH:C0062709] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] population japan possibly founder effect [MeSH:C0242918] result observe heterozygote [MeSH:C0019425] suggest cetp [MeSH:C1144465] [MeSH:C1144465] normally play regulation [MeSH:C0851285] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] hdl [MeSH:C0062709] subclass evidence premature atherosclerosis [MeSH:C0004153] family cetp [MeSH:C1144465] [MeSH:C1144465] deficiency fact lipoprotein profile person cetp [MeSH:C1144465] [MeSH:C1144465] deficiency potentially antiatherogenic associate increase life span [MeSH:C0870809],neurological
insufficiency lymphoma vascular [MeSH:C1412000] insight,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] cancer [MeSH:C0006826] patient focus diastolic heart failure [MeSH:C1135196] aspect disease total participant [MeSH:C1708335] enrol observational result [MeSH:C0302523] demonstrate positive response particular attention endocardium [MeSH:C0014124] finding suggest optimization [MeSH:C0376695],cardiovascular
hypertension [MeSH:C0020538] prostate cancer [MeSH:C0376358] vascular [MeSH:C0221214] insight,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve blood vessel [MeSH:C0005847] septum method conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine deep vein thrombosis [MeSH:C0149871] parameter result positive response practice guideline [MeSH:C0936005],cardiovascular
rate ymdd motif mutant lamivudine-untreated iranian patient [MeSH:C0030705] chronic hepatitis b virus infection [MeSH:C0524909],lamivudine [MeSH:C0209738] [MeSH:C0209738] chronic hepatitis b [MeSH:C0524909] [MeSH:C0524909] [MeSH:C0524909] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] recent study ymdd motif mutant resistant hepatitis b virus [MeSH:C0019169] occur natural [MeSH:C0017109] genome variability [MeSH:C0003319] lamivudine [MeSH:C0209738] [MeSH:C0209738]-untreated chronic hepatitis b [MeSH:C0524909] [MeSH:C0524909] [MeSH:C0524909] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] aim determine rate ymdd motif mutant lamivudine [MeSH:C0209738] [MeSH:C0209738]-untreated chronic hepatitis b [MeSH:C0524909] [MeSH:C0524909] [MeSH:C0524909] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] iran patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method total chronic hepatitis b [MeSH:C0524909] [MeSH:C0524909] [MeSH:C0524909] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat lamivudine [MeSH:C0209738] [MeSH:C0209738] include serum sample patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] test polymerase chain reaction-restriction fragment length polymorphism [MeSH:C0035268] pcr-rflp detection [MeSH:C5392129] ymdd motif mutant patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] test liver enzyme [MeSH:C0014442] [MeSH:C0014442] anti-hcv hbeag [MeSH:C0019167] [MeSH:C0019167] [MeSH:C0019167] anti-hbe result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] enrol male [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] mean alt ast level [MeSH:C0018759] iu l respectively hbeag [MeSH:C0019167] [MeSH:C0019167] [MeSH:C0019167] positive anti-hbe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] anti-hcv negative ymdd motif mutant detect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] despite liver enzyme [MeSH:C0014442] [MeSH:C0014442] level [MeSH:C0018759] presence hbeag [MeSH:C0019167] [MeSH:C0019167] [MeSH:C0019167] anti-hbe natural [MeSH:C0017109] occurrence ymdd motif mutant lamivudine [MeSH:C0209738] [MeSH:C0209738]-untreated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chronic hepatitis b [MeSH:C0524909] [MeSH:C0524909] [MeSH:C0524909] report mutant [MeSH:C0684224] detect iranian [MeSH:C0022065] lamivudine [MeSH:C0209738] [MeSH:C0209738]-untreated chronic hepatitis b [MeSH:C0524909] [MeSH:C0524909] [MeSH:C0524909] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],hepatorenal
cancer detox dynamic [MeSH:C0058836],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] calcium channel blocker cancer [MeSH:C0006684] participant cancer patient end stage renal disease [MeSH:C0022661] nephron [MeSH:C0027713] result enhance therapeutic response [MeSH:C0087111] albumin [MeSH:C0001924] correlation [MeSH:C0010100] optimization [MeSH:C0376695],hepatorenal
heart rate connection alzheimer disease,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve artery deep vein thrombosis method [MeSH:C0149871] conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine migraine [MeSH:C0149931] parameter result improve disease management practice [MeSH:C0600585] guideline,neurological|cardiovascular
atrium marker cardiomyopathy [MeSH:C0878544],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] dementia [MeSH:C0497327] endothelial method [MeSH:C0225336] adult [MeSH:C0001675] population [MeSH:C0032659] undergo observational [MeSH:C0302523] premature beat [MeSH:C0340464] chf assessment result positive response practice guideline [MeSH:C0936005],cardiovascular
cerebrospinal fluid pathway hepatitis,diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve ischemic cardiomyopathy cardiomyopathy method [MeSH:C0878544] conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine paralysis [MeSH:C0522224] parameter result improve disease management [MeSH:C0039798] optimization [MeSH:C0376695],neurological|cardiovascular
heart-brain axis ventricular tachycardia [MeSH:C0042514],design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] [MeSH:C0035173] ace inhibitor diabete [MeSH:C0003015] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient heart rate restrictive cardiomyopathy [MeSH:C0007196] result improve outcome [MeSH:C0206277] aortic valve correlation need investigation [MeSH:C0035173] [MeSH:C0035173],cardiovascular
synaptic [MeSH:C0206181] story ventricular tachycardia [MeSH:C0042514] epinephrine [MeSH:C0014563],prospective examine aspirin [MeSH:C0004057] hypertension [MeSH:C0020538] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include cortical epinephrine thalamus method participant [MeSH:C1708335] include result well quality life measure implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
cocaine-induced hyperactivity influence [MeSH:C0683549] adenosine receptor agonist [MeSH:C2917322] amphetamine-induced hyperactivity,influence [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] adenosine receptor [MeSH:C0001471] [MeSH:C0001471] [MeSH:C0001471] agonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C2917322] antagonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] cocaine-and amphetamine [MeSH:C0002658]-induced hyperactivity examine mouse [MeSH:C0026809] adenosine receptor [MeSH:C0001471] [MeSH:C0001471] [MeSH:C0001471] agonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C2917322] significantly decrease locomotor activity [MeSH:C0023946] [MeSH:C0023946] [MeSH:C0023946] mouse [MeSH:C0026809] effect dose-dependent adenosine a1 a2 receptor [MeSH:C0001451] involve reaction adenosine receptor [MeSH:C0001471] [MeSH:C0001471] [MeSH:C0001471] [MeSH:C0001471] agonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C2917322] -p- -carboxyethyl phenethylamino- -n-ethylcarboxamidoadenosine [MeSH:C0050789] cgs a2a receptor agonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] n6-cyclopentyladenosine [MeSH:C0067224] cpa a1 receptor [MeSH:C0001451] agonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] -n-ethylcarboxamidoadenosine neca a2 a1 receptor [MeSH:C0001451] agonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] significantly dose-dependently decrease cocaine-induced locomotor activity [MeSH:C0023946] [MeSH:C0023946] [MeSH:C0023946] cpa reduce cocaine action [MeSH:C0009170] dose give influence [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] motility [MeSH:C0007608] cgs neca decrease action cocaine dose give decrease locomotor activity [MeSH:C0023946] [MeSH:C0023946] [MeSH:C0023946] animal [MeSH:C0003062] [MeSH:C0003062] result suggest involvement [MeSH:C0030699] adenosine receptor [MeSH:C0001471] [MeSH:C0001471] [MeSH:C0001471] action cocaine agonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] a1 receptor [MeSH:C0001451] strong influence [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] selective blockade a2 adenosine receptor [MeSH:C0001471] [MeSH:C0001471] [MeSH:C0001471] dmpx [MeSH:C0165153] [MeSH:C0165153] -dimethyl propargylxanthine significantly enhance cocaine-induced locomotor activity [MeSH:C0023946] [MeSH:C0023946] [MeSH:C0023946] animal [MeSH:C0003062] [MeSH:C0003062] caffeine [MeSH:C0006644] [MeSH:C0006644] similar action effect [MeSH:C4281532] cpt [MeSH:C5240434] -cyclopentyltheophylline --a1 receptor [MeSH:C0001451] antagonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] influence [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] test similarly adenosine receptor [MeSH:C0001471] [MeSH:C0001471] [MeSH:C0001471] agonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C2917322] decrease amphetamine [MeSH:C0002658]-induced hyperactivity high dose active cocaine-induced hyperactivity selective blockade a2 adenosine receptor [MeSH:C0001471] [MeSH:C0001471] [MeSH:C0001471] dmpx [MeSH:C0165153] [MeSH:C0165153] non-selective blockade adenosine receptor [MeSH:C0001471] [MeSH:C0001471] [MeSH:C0001471] caffeine [MeSH:C0006644] [MeSH:C0006644] significantly increase action amphetamine [MeSH:C0002658] locomotor activity [MeSH:C0023946] [MeSH:C0023946] [MeSH:C0023946] test result show adenosine receptor [MeSH:C0001471] [MeSH:C0001471] [MeSH:C0001471] agonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C2917322] a1 a2 reduce cocaine- amphetamine [MeSH:C0002658]-induced locomotor activity [MeSH:C0023946] [MeSH:C0023946] [MeSH:C0023946] indicate cocaine-induced hyperactivity influence [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] [MeSH:C0683549] adenosine receptor [MeSH:C0001471] [MeSH:C0001471] [MeSH:C0001471] agonist [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C0162816] [MeSH:C2917322] particularly a1 receptor [MeSH:C0001451] amphetamine [MeSH:C0002658]-induced hyperactivity,neurological
wiskott-aldrich syndrome protein [MeSH:C0258432] novel effector gtpase cdc42hs implicate actin polymerization [MeSH:C0314672],rho family gtpase [MeSH:C0018296] diverse biological process [MeSH:C3714634] include cell morphology [MeSH:C0243091] mitogenesis [MeSH:C0026249] identify wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] protein [MeSH:C0258432] defective wiskott-aldrich syndrome novel effector [MeSH:C4277620] cdc42hs [MeSH:C4705281] rho family member rac rho [MeSH:C0086282] interaction [MeSH:C0007582] dependent [MeSH:C0101555] presence g protein-binding domain cellular expression epitope-tagged wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] produce cluster [MeSH:C0055966] wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] highly enriched polymerize actin cluster [MeSH:C0055966]ing observe c-terminally deleted wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] inhibit [MeSH:C0021463] coexpression dominant negative [MeSH:C3539878] [MeSH:C3539878] cdc42hs [MeSH:C4705281]-n1 dominant negative [MeSH:C3539878] [MeSH:C3539878] form rac rho wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] provide novel link cdc42hs [MeSH:C4705281] actin cytoskeleton [MeSH:C0025979] suggest molecular mechanism cellular abnormality [MeSH:C0037268] wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] sequence contain novel domain homologous protein involve action organization [MeSH:C0029246],neurological
mitral annuloplasty [MeSH:C0396850] ventricular restoration failing leave ventricle pilot [MeSH:C0473169],undersized mitral annuloplasty [MeSH:C0396850] map [MeSH:C0024779] [MeSH:C0024779] [MeSH:C0024779] effective patient [MeSH:C0030705] dilate [MeSH:C1322279] cardiomyopathy functional mitral regurgitation mr address mr map [MeSH:C0024779] [MeSH:C0024779] [MeSH:C0024779] reshape dilate [MeSH:C1322279] leave ventricular [MeSH:C0949657] lv base direct benefit possible reshaping lv function [MeSH:C0242698] absence [MeSH:C0270823] underlying mr remain incompletely understand identify benefit canine model [MeSH:C0011381] [MeSH:C0011381] acute heart failure [MeSH:C0018801] method [MeSH:C0018801] dog [MeSH:C0012984] undergo map [MeSH:C0024779] [MeSH:C0024779] [MeSH:C0024779] prosthetic band posterior mitral annulus mattress suture suture pass individually tourniquet exteriorized untie left atriotomy sonomicrometry crystal implant mitral annulus leave ventricle geometry regional function [MeSH:C0031843] acute heart failure [MeSH:C0018801] induce propranolol [MeSH:C0033497] volume [MeSH:C5690805] loading wean cardiopulmonary bypass [MeSH:C0007202] absence [MeSH:C0270823] mr confirm echocardiography map [MeSH:C0024779] [MeSH:C0024779] [MeSH:C0013516] [MeSH:C0024779] accomplish cinch tourniquet [MeSH:C0040519] acquire induction [MeSH:C0042767] acute heart failure [MeSH:C0018801] map [MeSH:C0024779] [MeSH:C0024779] [MeSH:C0024779] result map [MeSH:C0024779] [MeSH:C0024779] [MeSH:C0024779] decrease mitral annular dimension commissure-commissure septal-lateral direction concomitantly diastolic [MeSH:C0012000] diameter lv base lv sphericity decrease e improve mm p p respectively decrease evident lv end-diastolic [MeSH:C0012000] pressure mmhg p tau [MeSH:C0085401] ms p fractional shortening lv base increase p map [MeSH:C0024779] [MeSH:C0024779] [MeSH:C0024779] increase identify cardiac output min [MeSH:C0007165] emax mmhg ml acquire suggest isolate map [MeSH:C0024779] [MeSH:C0024779] [MeSH:C0024779] certain benefit lv dimension function acute heart failure [MeSH:C0018801] absence [MeSH:C0270823] mr investigation [MeSH:C0035173] warrant model [MeSH:C0011381] [MeSH:C0011381] chronic heart failure [MeSH:C0018801],neurological|cardiovascular
cortical motor overactivation parkinsonian [MeSH:C0242422] patient [MeSH:C0030705] l-dopa-induce peak-dose dyskinesia,study [MeSH:C0085973] regional cerebral blood flow [MeSH:C0428714] rcbf change induce execution [MeSH:C0935584] finger-to-thumb opposition motor task supplementary primary motor cortex [MeSH:C0026607] [MeSH:C0026607] group [MeSH:C0018257] parkinsonian [MeSH:C0242422] [MeSH:C0242422] [MeSH:C0242422] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] l-dopa [MeSH:C0023570] [MeSH:C0023570] medication [MeSH:C0033045] l-dopa [MeSH:C0023570] [MeSH:C0023570] induce dyskinesia [MeSH:C0013384] n moderate peak-dose dyskinesia [MeSH:C0013384] n normal subject [MeSH:C0080105] [MeSH:C0080105] single photon emission tomography v 3xe rcbf change dyskinetic [MeSH:C0013384] parkinsonian [MeSH:C0242422] [MeSH:C0242422] [MeSH:C0242422] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] exhibit pattern response markedly different normal subject [MeSH:C0080105] [MeSH:C0080105] non-dyskinetic [MeSH:C0013384] parkinsonian [MeSH:C0242422] [MeSH:C0242422] [MeSH:C0242422] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] overactivation supplementary motor area ipsi- contralateral primary motor area result compatible hypothesis [MeSH:C3179072] hyperkinetic abnormal [MeSH:C0853087] involuntary [MeSH:C1267092] movement like l-dopa [MeSH:C0023570] [MeSH:C0023570]-induce peak dose dyskinesia [MeSH:C0013384] [MeSH:C0013384] disinhibition primary associate motor cortex [MeSH:C0026607] [MeSH:C0026607] secondary excessive outflow pallidothalamocortical motor loop,neurological
case massive rhabdomyolysis [MeSH:C0035410] follow molindone administration [MeSH:C0001554],rhabdomyolysis [MeSH:C0035410] [MeSH:C0035410] [MeSH:C0035410] potentially lethal syndrome [MeSH:C0039082] psychiatric patient predisposed develop sign [MeSH:C0518766] symptom [MeSH:C3839861] typical laboratory feature [MeSH:C0022877] complication [MeSH:C1171258] rhabdomyolysis [MeSH:C0035410] [MeSH:C0035410] [MeSH:C0035410] present case schizophrenic report [MeSH:C0036341] illustrate massive rhabdomyolysis [MeSH:C0035410] [MeSH:C0035410] [MeSH:C0035410] subsequent acute renal failure [MeSH:C0022660] follow molindone [MeSH:C0026388] administration physician prescribe molindone [MeSH:C0026388] aware reaction [MeSH:C0031067],neurological|hepatorenal
amikacin [MeSH:C0002499] nephrotoxicity hematology oncology population [MeSH:C0243005],amikacin [MeSH:C0002499] [MeSH:C0002499] [MeSH:C0002499] aminoglycoside [MeSH:C0002556] [MeSH:C0002556] commonly provide empirical [MeSH:C0376367] double gram-negative febrile neutropenia suspect infection strategy extended-interval conventional dosing utilize extensively general medical population lack support dosing strategy hematology [MeSH:C0018943] [MeSH:C0018943] oncology population [MeSH:C0243005] [MeSH:C0243005] evaluate amikacin [MeSH:C0002499] [MeSH:C0002499] [MeSH:C0002499]-associated nephrotoxicity adult hematology [MeSH:C0018943] [MeSH:C0018943] oncology population [MeSH:C0243005] [MeSH:C0243005] prospective randomized open-label trial conduct university-affiliated medical center [MeSH:C0000872] patient [MeSH:C0030705] diagnosis [MeSH:C0011900] consistent hematologic oncologic disorder require aminoglycoside [MeSH:C0002556] [MeSH:C0002556] randomized conventional extended-interval amikacin [MeSH:C0002499] [MeSH:C0002499] [MeSH:C0002499] occurrence nephrotoxicity mean increase serum creatinine [MeSH:C0010294] efficacy [MeSH:C5690761] amikacin [MeSH:C0002499] [MeSH:C0002499] [MeSH:C0002499] serum concentration respective pathogen [MeSH:C0699748] assess occurrence nephrotoxicity similar conventional extended-interval group respectively p patient [MeSH:C0030705] conventional positive culture compare extended-interval p occurrence nephrotoxicity similar dose regimen [MeSH:C1880476] distribution [MeSH:C1704711] risk factor [MeSH:C0035648] variable group efficacy [MeSH:C5690761] assess,hepatorenal
single neurotoxic [MeSH:C0027934] dose methamphetamine [MeSH:C0025611] induce long-lasting depressive-like behaviour mouse,methamphetamine meth [MeSH:C0025611] trigger disruption [MeSH:C3179075] [MeSH:C3179075] monoaminergic system meth abuse lead negative emotional state include depressive symptom [MeSH:C0086132] drug withdrawal [MeSH:C2717885] currently unknown acute toxic dosage meth cause long-lasting depressive phenotype persistent [MeSH:C0026205] [MeSH:C0026205] monoaminergic deficit assess depressive-like behaviour mouse [MeSH:C0026809] early long-term [MeSH:C0023977] period [MeSH:C0080129] follow single high meth dose mg kg p meth alter motor function [MeSH:C0031843] procedural memory mouse [MeSH:C0026809] assess swim [MeSH:C0039003] speed [MeSH:C2009910] escape latency find platform cued version water maze task meth significantly increase immobility tail suspension test day [MeSH:C0011017] post-administration [MeSH:C0001554] [MeSH:C0001554] depressive-like profile induce meth accompany marked depletion [MeSH:C3494379] frontostriatal dopaminergic serotonergic neurotransmission [MeSH:C0027793] indicate reduction [MeSH:C1827449] level dopamine dopac [MeSH:C0013030] hva tyrosine hydroxylase [MeSH:C0041491] serotonin [MeSH:C0036751] observe day [MeSH:C0011017] post-administration [MeSH:C0001554] [MeSH:C0001554] parallel neurochemical feature depression [MeSH:C0011570] astroglial dysfunction [MeSH:C0031847] unaffected cortex [MeSH:C0026607] striatal level astrocytic protein marker glial fibrillary acidic protein [MeSH:C0017626] transiently increase day [MeSH:C0011017] finding demonstrate single high dose meth induce long-lasting depressive-like behaviour mouse [MeSH:C0026809] associate [MeSH:C0004083] persistent [MeSH:C0026205] [MeSH:C0026205] disruption [MeSH:C3179075] [MeSH:C3179075] frontostriatal dopaminergic serotonergic homoeostasis,neurological
diastolic [MeSH:C0012000] peripheral artery disease [MeSH:C1704436] vascular [MeSH:C0221214] insight,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] metformin [MeSH:C0025598] hypertension [MeSH:C0020538] cardiac [MeSH:C0018810] patient focus ventricular tachycardia insufficiency [MeSH:C0042514] aspect disease total participant enrol prospective result demonstrate decrease mortality rate [MeSH:C0205848] particular attention aortic valve [MeSH:C0003501] finding suggest healthcare advancement,cardiovascular
adverse reaction [MeSH:C0041755] bendrofluazide [MeSH:C0004975] propranolol [MeSH:C0033497] mild hypertension [MeSH:C0020538] [MeSH:C0020538] report medical council work party [MeSH:C0043227] mild moderate hypertension [MeSH:C0020538] [MeSH:C0020538],participant [MeSH:C1708335] medical council trial mild hypertension [MeSH:C0020538] randomly allocate group [MeSH:C0018257] bendrofluazide [MeSH:C0004975] [MeSH:C0004975] [MeSH:C0004975] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] placebo drug trial single-blind [MeSH:C0037181] patient [MeSH:C0030705]-year observation complete far active drug [MeSH:C0033613] [MeSH:C0033613] placebo result association [MeSH:C0004083] bendrofluazide [MeSH:C0004975] [MeSH:C0004975] [MeSH:C0004975] impotence [MeSH:C0242350] [MeSH:C0242350] impotence [MeSH:C0242350] [MeSH:C0242350] occur frequently patient [MeSH:C0030705] take propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] take placebos [MeSH:C0032042] adverse reaction [MeSH:C0041755] significantly link active drug [MeSH:C0033613] [MeSH:C0033613] include impaired glucose tolerance [MeSH:C0271650] man woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] gout [MeSH:C0018099] man associate bendrofluazide [MeSH:C0004975] [MeSH:C0004975] [MeSH:C0004975] raynaud phenomenon dyspnoea man woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] take propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] corneal disease [MeSH:C0010034] know occur propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] mean serum potassium fall [MeSH:C0032821] urea uric acid [MeSH:C0041980] level rise man woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] take bendrofluazide [MeSH:C0004975] [MeSH:C0004975] [MeSH:C0004975] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] serum potassium uric acid [MeSH:C0041980] level rise sex [MeSH:C1522384] urea rise significantly woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210],cardiovascular
lymphoma pacemaker cardiac connection,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete pacemaker [MeSH:C3494452] mechanism method retrospective diabetic patient [MeSH:C0030705] assess aortic dissection [MeSH:C0340643] cardiac result improve outcome implication care improvement,cardiovascular
brain [MeSH:C0006104] dynamic ventricular tachycardia guillain-barre syndrome [MeSH:C0018378],design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin cancer [MeSH:C0376358] participant cancer patient [MeSH:C0030705] locus coeruleus parkinsonism [MeSH:C0023951] result well quality life measure substantia nigra [MeSH:C0038590] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,neurological
thromboembolism alzheimer disease [MeSH:C0040038] vascular insight,design [MeSH:C0013171] prospective investigation metformin [MeSH:C0025598] diabete participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient [MeSH:C0030705] hypertrophic cardiomyopathy [MeSH:C0007194] atrial flutter [MeSH:C0004239] result superior efficacy [MeSH:C5690761] congestive heart failure [MeSH:C0018802] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,cardiovascular
revolutionary endoscopy epilepsy [MeSH:C0014544] diagnosis [MeSH:C0011900],question statin affect heart disease [MeSH:C0018799] hydronephrosis [MeSH:C0020295] mechanism method randomized control diabetic patient [MeSH:C0030705] assess interstitial nephritis [MeSH:C0027707] kidney stone result improve outcome [MeSH:C0206277] implication need investigation [MeSH:C0035173],hepatorenal
heart valve pathway [MeSH:C0018826] multiple sclerosis [MeSH:C0026769],investigate [MeSH:C0035173] statin effect dementia [MeSH:C0497327] pe method cancer [MeSH:C0025663] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] glioma ventricle assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint relevance,neurological|cardiovascular
nash hepatitis vascular insight,heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve liver aki method conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine alcoholic liver disease [MeSH:C0023896] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] relevance [MeSH:C2826293],cardiovascular|hepatorenal
reduce harm associate [MeSH:C0004083] anticoagulation [MeSH:C0003280] practical consideration argatroban therapy heparin-induced thrombocytopenia [MeSH:C0040034],argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] hepatically metabolize direct thrombin inhibitor [MeSH:C0003440] prophylaxis thrombosis [MeSH:C0040053] heparin-induced thrombocytopenia [MeSH:C0040034] hit patient [MeSH:C0030705] risk [MeSH:C0035647] hit undergo percutaneous coronary intervention pci review [MeSH:C1532338] summarize practical consideration argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] therapy hit fda-recommended argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] dose hit microg kg min reduce patient [MeSH:C0030705] hepatic impairment [MeSH:C1384666] paediatric patient [MeSH:C0030705] adjusted achieve activate partial thromboplastin time aptt [MeSH:C0030605] time second contemporary experience indicate reduce dose need patient [MeSH:C0030705] condition associate hepatic hypoperfusion e g heart failure [MeSH:C0018801] unnecessary renal dysfunction [MeSH:C0031847] adult [MeSH:C0001675] [MeSH:C0001675] age sex [MeSH:C1522384] [MeSH:C1522384] race ethnicity [MeSH:C0015031] [MeSH:C0015031] obesity [MeSH:C0028754] [MeSH:C0028754] argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] microg kg min typically support therapeutic [MeSH:C0087111] aptt fda-recommended dose pci microg kg min microg kg initial bolus adjusted achieve activate clotting time act sec pci argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] investigate [MeSH:C0035173] hepatically impaired [MeSH:C0020580] patient [MeSH:C0030705] dose adjustment [MeSH:C0376209] unnecessary adult [MeSH:C0001675] [MeSH:C0001675] age sex [MeSH:C1522384] [MeSH:C1522384] race ethnicity [MeSH:C0015031] [MeSH:C0015031] obesity [MeSH:C0028754] [MeSH:C0028754] less dose adequate concurrent glycoprotein iib iiia [MeSH:C0016011] inhibition [MeSH:C0027790] argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] prolong international normalize ratio [MeSH:C0525032] publish approach monitor argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470]-to-warfarin transition [MeSH:C1257888] follow major bleeding argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] non-interventional setting periprocedurally argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] specific antidote [MeSH:C0003295] excessive anticoagulation [MeSH:C0003280] occur argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] infusion [MeSH:C0841792] stop reduce improve familiarity [MeSH:C0600269] healthcare professional [MeSH:C1704312] argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] therapy hit include special population [MeSH:C0032659] pci facilitate reduction [MeSH:C1827449] harm associate hit e g few thrombose e g few argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] medication error [MeSH:C0025115],cardiovascular|hepatorenal
haploinsufficiency transcription factor foxc1 foxc2 result aberrant ocular development [MeSH:C0949649],anterior segment development [MeSH:C0243107]al disorder [MeSH:C0036875] include axenfeld-rieger anomaly [MeSH:C0266548] ara variably associate [MeSH:C0004083] harmfully elevated intraocular [MeSH:C0042789] pressure iop cause glaucoma [MeSH:C0017601] clinically observe dysgenesis [MeSH:C1563716] correlate iop etiology [MeSH:C0015127] glaucoma [MeSH:C0017601] development [MeSH:C0243107] understand forkhead transcription factor gene foxc1 mf1 foxc2 mfh1 express mesenchyme ocular [MeSH:C0042789] [MeSH:C0162415] drainage [MeSH:C0024842] structure derive mutation [MeSH:C0026882] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] homolog [MeSH:C3853771] foxc1 fkhl7 cause dominant anterior segment defect glaucoma [MeSH:C0017601] family foxc1 mouse anterior segment abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] similar report human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] patient abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0000769] include small [MeSH:C0751984] absent schlemms [MeSH:C0229108] canal [MeSH:C0227411] aberrantly develop trabecular meshwork [MeSH:C0040573] iris hypoplasia [MeSH:C0243069] severely eccentric pupil displace schwalbes line penetrance [MeSH:C0524899] clinically obvious abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] vary genetic [MeSH:C0017380] affect eye [MeSH:C0015392] collage [MeSH:C0024842]n [MeSH:C0009325] bundle half normal diameter collage [MeSH:C0024842]n [MeSH:C0009325] elastic tissue [MeSH:C0013762] sparse abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] extracellular matrix [MeSH:C0015350] synthesis organization contribute development [MeSH:C0243107] ocular [MeSH:C0042789] phenotype [MeSH:C0031437] [MeSH:C0031437] despite abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] ocular [MeSH:C0042789] drainage [MeSH:C0024842] structure foxc1 mouse iop normal mouse analyze genetic [MeSH:C0017380] background age [MeSH:C0024842] similar abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] find foxc2 mouse disease-associate [MeSH:C0004083]d mutation [MeSH:C0026882] identify human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] homolog [MeSH:C3853771] fkhl1 ara patient foxc1 foxc2 mouse useful model study anterior segment development [MeSH:C0243107] anomaly allow identification [MeSH:C1707660] gene interact foxc1 foxc2 fkhl7 fkhl1 produce phenotype [MeSH:C0031437] [MeSH:C0031437] elevated iop glaucoma [MeSH:C0017601],neurological
electrocardiographic evidence [MeSH:C0180600] myocardial injury [MeSH:C0027055] psychiatrically hospitalize [MeSH:C0020021] cocaine abuser,electrocardiogram [MeSH:C0013798] ecg cocaine-abusing patient compare ecgs schizophrenic [MeSH:C0036341] control cocaine abuser control ecg evidence myocardial injury [MeSH:C0027055] define myocardial infarction [MeSH:C0027051] ischemia bundle branch block [MeSH:C0006384],neurological|cardiovascular
cancer cellular cancer [MeSH:C0006826],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect stroke cancer [MeSH:C0038454] method adult [MeSH:C0001675] population [MeSH:C0032659] undergo cross-sectional chronic lymphocytic leukemia stem cell transplant [MeSH:C0023434] assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] practice guideline,oncological
dobutamine [MeSH:C0012963] stress echocardiography [MeSH:C0920208] sensitive [MeSH:C1017675] indicator [MeSH:C0021212] diminish myocardial function asymptomatic doxorubicin-treated [MeSH:C0013089] long-term survivor childhood cancer,doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] effective anticancer chemotherapeutic agent [MeSH:C0003392] know cause acute chronic cardiomyopathy [MeSH:C0878544] develop sensitive [MeSH:C1017675] echocardiographic [MeSH:C0013516] [MeSH:C0013516] [MeSH:C0013516] [MeSH:C0013516] screening test [MeSH:C0220908] cardiac damage doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] cohort [MeSH:C1706962] perform dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] differentiate [MeSH:C0007589] asymptomatic [MeSH:C2936329] long-term [MeSH:C0023977] survivor childhood cancer treat doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] healthy subject [MeSH:C0080105] echocardiographic [MeSH:C0013516] [MeSH:C0013516] [MeSH:C0013516] [MeSH:C0013516] experimental [MeSH:C0016998] patient [MeSH:C0030705] mean age year treat year median mg m2 doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] mean compare echocardiographic [MeSH:C0013516] [MeSH:C0013516] [MeSH:C0013516] [MeSH:C0013516] normal age-matched subject [MeSH:C0080105] grade dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] microgram [MeSH:C0376691] [MeSH:C0376691] kg min administer echocardiographic [MeSH:C0013516] [MeSH:C0013516] [MeSH:C0013516] [MeSH:C0013516] doppler study perform infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] min infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] rate dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] microgram [MeSH:C0376691] [MeSH:C0376691] kg min discontinue study secondary [MeSH:C1522484] incidence rate [MeSH:C1708485] adverse symptom important finding compare value subject [MeSH:C0080105] [MeSH:C0080105] end-systolic leave [MeSH:C0242724] ventricular posterior wall dimension percent leave [MeSH:C0242724] ventricular posterior wall thickening doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-treated patient [MeSH:C0030705] decrease finding clearly delineate dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] stimulation [MeSH:C0031734] end-systolic leave [MeSH:C0242724] ventricular posterior wall dimension doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-treated mm versus mm subject [MeSH:C0080105] p end-systolic leave [MeSH:C0242724] ventricular posterior wall dimension -microgram [MeSH:C0376691] [MeSH:C0376691] kg min dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-treated mm versus mm subject [MeSH:C0080105] p abstract [MeSH:C0600678] truncate word,neurological|cardiovascular|oncological
detection [MeSH:C5392129] brca1 mutation [MeSH:C0259275] breast ovarian cancer [MeSH:C1140680] family [MeSH:C0015576] [MeSH:C0015576] include family [MeSH:C0015576] [MeSH:C0015576] male breast cancer [MeSH:C0006142],gene [MeSH:C0017337]tic [MeSH:C0017380] epidemiological evidence [MeSH:C5575834] suggest mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] responsible approximately half early onset familial breast cancer [MeSH:C0006142] [MeSH:C0346153] majority familial breast ovarian cancer [MeSH:C1140680] [MeSH:C0346153] recent cloning [MeSH:C0009015] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] allow direct detection [MeSH:C5392129] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] feasibility presymptomatic screening cancer [MeSH:C0199230] susceptibility [MeSH:C0012655] unknown analyze genomic dna [MeSH:C0012854] affect individual [MeSH:C0021228] family case ovarian breast cancer [MeSH:C0006142] sscp assay variant sscp band subclone sequence allele-specific oligonucleotide hybridization verify sequence change screen dna [MeSH:C0012854] individual [MeSH:C0021228] frameshift [MeSH:C0079380] missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect different family frameshift [MeSH:C0079380] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect male [MeSH:C0086582] proband affect breast prostate cancer [MeSH:C0006142] -bp deletion detect develop intra-abdominal carcinomatosis [MeSH:C1563739] prophylactic oophorectomy mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0029936] [MeSH:C0026882] [MeSH:C0026882] detect gene [MeSH:C0017337] detect single family result provide evidence [MeSH:C5575834] inherit breast ovarian cancer [MeSH:C1140680] occur consequence wide array brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] result suggest development [MeSH:C0243107] screening test [MeSH:C0220908] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] technically challenging mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] family male [MeSH:C0086582] breast cancer [MeSH:C0006142] previously think related brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] illustrate potential difficulty gene [MeSH:C0017337]tic [MeSH:C0017380] counseling individual [MeSH:C0021228] know carry mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882],oncological
glomerulus connection heart failure,dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve myasthenia gravis [MeSH:C0026896] ggt method conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine cortical [MeSH:C0222661] parameter result improve disease management [MeSH:C0039798] safety consideration,neurological|hepatorenal
normal [MeSH:C0086715] male [MeSH:C0086582] inherit deletion exon dmd gene,describe brother [MeSH:C0337527] identical inherit deletion single exon middle dmd gene brother [MeSH:C0337527] becker muscular dystrophy diagnose [MeSH:C0917713] year age old [MeSH:C0019870] brother [MeSH:C0337527] normal result implication genetic counselling [MeSH:C0017382] prenatal diagnosis [MeSH:C0033053] family becker muscular dystrophy [MeSH:C0917713],neurological
dementia [MeSH:C0497327] steatosis [MeSH:C2711227] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome [MeSH:C0206277] dialysis pathway method observational trial [MeSH:C0302523] cardiac patient measuring jaundice cirrhosis [MeSH:C0022346] result improve outcome [MeSH:C0206277] relevance [MeSH:C2826293],hepatorenal
open-label assessment levofloxacin [MeSH:C0282386] acute [MeSH:C0184567] bacterial sinusitis [MeSH:C0037199] adult [MeSH:C0001675],evaluate [MeSH:C0013175] efficacy [MeSH:C5690761] safety [MeSH:C0036043] levofloxacin [MeSH:C0282386] [MeSH:C0282386] [MeSH:C0282386] mg orally daily day treat adult [MeSH:C0001675] outpatient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0029921] acute [MeSH:C0184567] bacterial sinusitis patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method [MeSH:C0030705] total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] enrol center patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pre-therapy [MeSH:C0039798] [MeSH:C1510538] gram stain culture sinus exudate obtain antral puncture [MeSH:C0034117] nasal endoscopy [MeSH:C0014245] response assess basis sign symptom sinus radiograph compute tomography result microbiologic [MeSH:C0025950] cure rate determine basis presume plus document [MeSH:C0009797] [MeSH:C0009797] [MeSH:C0009797] eradication [MeSH:C3178994] pre-therapy [MeSH:C0039798] [MeSH:C1510538] pathogen [MeSH:C0699748] [MeSH:C0699748] result common pathogen [MeSH:C0699748] [MeSH:C0699748] haemophilus influenzae streptococcus pneumoniae staphylococcus aureus moraxella [MeSH:C0038172] catarrhali clinically evaluable patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cure improve post-therapy [MeSH:C0039798] result success [MeSH:C0700132] rate thirty-five patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] clinically fail microbiologic [MeSH:C0025950] eradication [MeSH:C3178994] rate presume plus document [MeSH:C0009797] [MeSH:C0009797] [MeSH:C0009797] microbiologic [MeSH:C0025950]ally evaluable patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] microbiologic [MeSH:C0025950] eradication [MeSH:C3178994] rate presume plus document [MeSH:C0009797] [MeSH:C0009797] [MeSH:C0009797] common pathogen [MeSH:C0699748] [MeSH:C0699748] range catarrhali pneumoniae post-therapy [MeSH:C0039798] visit patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cure improve post-therapy [MeSH:C0039798] return long-term [MeSH:C0023977] follow-up visit [MeSH:C3899107] remain week therapy [MeSH:C0039798] relapse [MeSH:C0035020] symptom adverse event [MeSH:C0041755] consider related levofloxacin [MeSH:C0282386] [MeSH:C0282386] [MeSH:C0282386] administration [MeSH:C0001554] report patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] common drug-related adverse event [MeSH:C0041755] [MeSH:C0041755] diarrhea [MeSH:C0011991] flatulence [MeSH:C0016204] nausea [MeSH:C0027497] adverse event [MeSH:C0041755] mild moderate severity result indicate levofloxacin [MeSH:C0282386] [MeSH:C0282386] [MeSH:C0282386] mg daily effective [MeSH:C5392218] safe acute [MeSH:C0184567] bacterial sinusitis,neurological
cardiomyopathy [MeSH:C0878544] ventricular fibrillation [MeSH:C0042510] cardiac connection,observational [MeSH:C0302523] examine aspirin cancer [MeSH:C0004057] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include blood vessel defibrillator systolic method participant [MeSH:C1708335] include result positive response implication optimization [MeSH:C0376695],cardiovascular
limbic system pattern lymphoma patient [MeSH:C0030705],question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer alzheimer disease mechanism method [MeSH:C0002395] retrospective diabetic patient [MeSH:C0030705] assess encephalopathy [MeSH:C0085584] transient ischemic attack result decrease mortality rate [MeSH:C0205848] implication optimization [MeSH:C0376695],neurological
brain map lymphoma insight,cross-sectional examine [MeSH:C0010362] statin hypertension [MeSH:C0020538] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include locus coeruleus bell palsy [MeSH:C0023951] multiple sclerosis method [MeSH:C0026769] participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication cost-effectiveness [MeSH:C1511536] implication,neurological
nephron pathway alzheimer disease,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] [MeSH:C0035173] ace inhibitor [MeSH:C0003015] dementia [MeSH:C0497327] participant [MeSH:C1708335] cardiac patient gallstone glomerulonephritis [MeSH:C0017658] result improvement [MeSH:C2936612] primary endpoint tubule [MeSH:C0041348] correlation [MeSH:C0010100] need investigation [MeSH:C0035173] [MeSH:C0035173],hepatorenal
echocardiography [MeSH:C0013516] reveal peripheral artery disease [MeSH:C1704436] secret,prospective examine beta-blocker diabete cardiac [MeSH:C0018810] patient investigation [MeSH:C0035173] include glioma neuropathy transient ischemic attack method [MeSH:C0007787] participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication optimization [MeSH:C0376695],neurological
promotional effect testosterone [MeSH:C0039601] dietary [MeSH:C0012177] fat prostate carcinogenesis [MeSH:C0596263] genetically susceptible rat [MeSH:C0034721],germfree [MeSH:C0017475] gf lobund strain wistar lw rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] feed vegetable diet l- [MeSH:C0042440] develop prostate adenocarcinoma [MeSH:C0001418] spontaneously [MeSH:C0034705] [MeSH:C0034705] incidence [MeSH:C0021149] [MeSH:C0021149] average age month conventional lw rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] implant [MeSH:C0011373] testosterone [MeSH:C0039601] [MeSH:C0039601] age month develop high incidence [MeSH:C0021149] [MeSH:C0021149] prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] average interval month develop gross tumor include microscopic tumor preliminary [MeSH:C4505218] result indicate testosterone [MeSH:C0039601] [MeSH:C0039601]-treated lw rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] feed diet supplement [MeSH:C0242295] corn oil [MeSH:C0010029] fat develop prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] interval month aged [MeSH:C0001792] gf sprague-dawley [MeSH:C0034715] sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] develop prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] spontaneously [MeSH:C0034705] [MeSH:C0034705] conventional sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] feed diet l- treat testosterone [MeSH:C0039601] [MeSH:C0039601] develop prostatitis [MeSH:C0033581] experimental [MeSH:C0016998] design [MeSH:C0015320] consider genetic susceptibility [MeSH:C0314657] basic prerequisite study experimental [MeSH:C0016998] prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358],oncological
organ [MeSH:C0029250] orchestra heart failure,dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve fatty liver hepatic method [MeSH:C0015695] conduct retrospective [MeSH:C0035363] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine nephrolithiasis [MeSH:C0392525] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],hepatorenal
acute hepatitis [MeSH:C0019158] associate clopidogrel [MeSH:C0070166] case report review [MeSH:C0282436] literature [MeSH:C0023866],drug [MeSH:C0013227]-induced hepatotoxicity [MeSH:C0235280] [MeSH:C5197787] common cause acute hepatitis recognition responsible drug [MeSH:C0013227] difficult describe case clopidogrel [MeSH:C0070166] [MeSH:C0070166]-related acute hepatitis diagnosis [MeSH:C0011900] strongly suggest accurate medical history [MeSH:C0241889] liver biopsy [MeSH:C0005558] report case hepatotoxicity [MeSH:C0235280] clopidogrel [MeSH:C0070166] [MeSH:C0070166] increase year increase use drug [MeSH:C0013227] believe physician [MeSH:C0031831] carefully consider risk [MeSH:C0035647] drug [MeSH:C0013227]-induced hepatic injury clopidogrel [MeSH:C0070166] [MeSH:C0070166] prescribe,hepatorenal
angiography [MeSH:C0002978] reveal parkinson disease [MeSH:C0030567] secret,retrospective [MeSH:C0035363] examine aspirin hypertension [MeSH:C0020538] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include parkinson disease [MeSH:C0030567] amyotrophic lateral sclerosis hypertension [MeSH:C0002736] method participant [MeSH:C1708335] include result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
arterial [MeSH:C0003835] multiple sclerosis [MeSH:C0026769] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin stroke [MeSH:C0038454] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] endothelium aortic aneurysm [MeSH:C0003486] result well quality life measure atrial fibrillation [MeSH:C0004238] correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],cardiovascular
penicillamine-related lichenoid dermatitis utility zinc acetate wilson disease hepatic presentation anxiety [MeSH:C0003467] spect abnormality [MeSH:C0037268],wilson [MeSH:C0019202] [MeSH:C0019202] disease autosomal recessive disorder [MeSH:C0011581] hepatic copper [MeSH:C0009968] metabolism consequent copper [MeSH:C0009968] accumulation [MeSH:C0311432] toxic [MeSH:C1256754]ity [MeSH:C0040539] tissue consequent hepatic neurologic psychiatric disorder [MeSH:C0004936] report case wilson [MeSH:C0019202] [MeSH:C0019202] [MeSH:C0019202] disease chronic liver disease [MeSH:C0008679] present high level state anxiety depression 9mtc-ecd-spect show cortical hypoperfusion frontal lobe [MeSH:C0016733] marked left frontal lobe [MeSH:C0016733] [MeSH:C0016733] follow-up [MeSH:C3899107] penicillamine [MeSH:C0030817] interrupted [MeSH:C3850092] appearance [MeSH:C0750731] lichenoid dermatitis [MeSH:C0011603] zinc acetate [MeSH:C0149368] [MeSH:C0149368] [MeSH:C0149368] permit continue successful side-effect case therapy [MeSH:C0039798] [MeSH:C0039798] zinc acetate [MeSH:C0149368] [MeSH:C0149368] [MeSH:C0149368] represent effective [MeSH:C5392218] wilson [MeSH:C0019202] [MeSH:C0019202] disease penicillamine [MeSH:C0030817]-related effect appear safety [MeSH:C0036043] zinc acetate [MeSH:C0149368] [MeSH:C0149368] [MeSH:C0149368] allow avoid potentially toxic [MeSH:C1256754] chelate drug observation line grow evidence efficacy drug wilson [MeSH:C0019202] [MeSH:C0019202] disease wilson [MeSH:C0019202] [MeSH:C0019202] disease penicillamine [MeSH:C0030817]-treated patient [MeSH:C0030705] develop skin lesion conceivable specific genetic factor involve drug response study need well clarification wilson [MeSH:C0019202] [MeSH:C0019202] disease therapy [MeSH:C0039798] [MeSH:C0039798] particular differentiate specific therapy [MeSH:C0039798] different wilson [MeSH:C0019202] [MeSH:C0019202] disease phenotype [MeSH:C0031437],neurological|hepatorenal
liver cirrhosis [MeSH:C0023890] cardiovascular lens [MeSH:C0007220],randomized control examine [MeSH:C1096777] statin heart disease [MeSH:C0018799] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include cerebrovascular pad bradycardia method participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication relevance,cardiovascular
ventricle coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,hypothesis statin improve hypertension [MeSH:C0020538] outcome prolapse pathway method observational trial [MeSH:C0302523] cardiac patient measure deep vein thrombosis [MeSH:C0149871] dilate cardiomyopathy [MeSH:C0007193] result improve disease management [MeSH:C0039798] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
cancer code [MeSH:C0006826] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] colorectal cancer [MeSH:C0009402] [MeSH:C0009402],longitudinal [MeSH:C0023981] examine aspirin [MeSH:C0004057] stroke cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include breast cancer [MeSH:C0006142] ovarian cancer [MeSH:C1140680] cervical cancer method [MeSH:C4048328] participant [MeSH:C1708335] include result improve outcome implication care improvement,oncological
diastolic connection heart failure [MeSH:C0018801],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome [MeSH:C0206277] neurodegenerative pathway method cross-sectional trial [MeSH:C0010362] adult population measure thromboembolism hypertension [MeSH:C0040038] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] care improvement,neurological|cardiovascular
hypertension [MeSH:C0020538] cardiac function [MeSH:C0018803],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] stroke [MeSH:C0038454] blood pressure method [MeSH:C0005823] elderly patient undergo retrospective aortic valve coronary artery disease assessment [MeSH:C0030198] result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
potential [MeSH:C0001272] deleterious effect furosemide [MeSH:C0016860] radiocontrast nephropathy,determine efficacy [MeSH:C5690761] furosemide [MeSH:C0016860] [MeSH:C0016860] [MeSH:C0016860] addition intravenous fluid [MeSH:C0600608] prevention radiocontrast [MeSH:C2930749] nephropathy patient [MeSH:C0030705] refer radiocontrast [MeSH:C2930749] consider risk preexist renal insufficiency [MeSH:C1565489] enrol prospective randomized controlled trial [MeSH:C1096777] perform secondary care center [MeSH:C3658282] -be private university hospital addition fluid [MeSH:C0600608] receive furosemide [MeSH:C0016860] [MeSH:C0016860] [MeSH:C0016860] mean dose mg intravenously min prior injection [MeSH:C1828121] contrast receive fluid [MeSH:C0600608] mean liter radiological study angiography [MeSH:C0002978] perform ionic non-ionic contrast average dose ml renal function [MeSH:C0031843] significantly deteriorate pretreate furosemide [MeSH:C0016860] [MeSH:C0016860] [MeSH:C0016860] p anova rise serum creatinine [MeSH:C0010294] mumol l h occur mumol l renal failure [MeSH:C0035078] associate weight loss furosemide [MeSH:C0016860] [MeSH:C0016860] [MeSH:C0016860]-treated furosemide [MeSH:C0016860] [MeSH:C0016860] [MeSH:C0016860] deleterious prevention radiocontrast [MeSH:C2930749] nephropathy,hepatorenal
doxorubicin-induced cardiotoxicity monitor ecg [MeSH:C1623258] freely move mouse [MeSH:C0026809] new model test potential protector,laboratory [MeSH:C0022877] animal [MeSH:C0003062] histology [MeSH:C0019638] commonly doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-induced [MeSH:C0013089] cardiotoxicity [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0876994] monitoring [MeSH:C0005517] large number animal [MeSH:C0003062] need recently develop new ecg value [MeSH:C1623258] freely move mouse [MeSH:C0026809] [MeSH:C0026809] telemetry model [MeSH:C0011381] [MeSH:C0011381] investigate [MeSH:C0035173] [MeSH:C0035173] effect chronic [MeSH:C0150055] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] administration ecg freely move balb c [MeSH:C0025919] mouse [MeSH:C0026809] [MeSH:C0026809] efficacy icrf- protective agent [MeSH:C0033613] [MeSH:C0033613] st interval significantly widen ms week weekly dose mg kg doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] give v plus week observation [MeSH:C0302523] ecg animal [MeSH:C0003062] entire sacrifice heart [MeSH:C0018787] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-treated animal [MeSH:C0003062] enlarge atrium hypertrophic schedule exert toxicity [MeSH:C0040539] [MeSH:C0040539] need investigate [MeSH:C0035173] [MeSH:C0035173] protective agent [MeSH:C0033613] [MeSH:C0033613] protection [MeSH:C0524828] [MeSH:C0524828] icrf- determine dose schedule low general toxicity [MeSH:C0040539] [MeSH:C0040539] weekly dose mg kg doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] give v plus week observation [MeSH:C0302523] schedule animal [MeSH:C0003062] heart [MeSH:C0018787] appear normal sacrifice icrf- mg kg give p h doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] provide protection [MeSH:C0524828] [MeSH:C0524828] confirm histology [MeSH:C0019638] result indicate new model [MeSH:C0011381] [MeSH:C0011381] sensitive [MeSH:C1017675] enable monitoring [MeSH:C0005517] development cardiotoxicity [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0876994] finding model [MeSH:C0011381] [MeSH:C0011381] allow testing protector doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-induced [MeSH:C0013089] cardiotoxicity [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0876994] demonstrate protection [MeSH:C0524828] [MeSH:C0524828] provide icrf-,neurological|cardiovascular
endoscopy [MeSH:C0014245] reveal leukemia [MeSH:C0023418] secret,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] transaminase method [MeSH:C0002594] adult [MeSH:C0001675] population [MeSH:C0032659] undergo observational [MeSH:C0302523] wilms tumor [MeSH:C0027708] cortical assessment result superior efficacy therapeutic innovation [MeSH:C0087111],neurological|hepatorenal
bradycardia hypertension vascular [MeSH:C0221214] insight,cancer affect elderly patient [MeSH:C0030705] worldwide particularly involve tachycardia transient ischemic attack method [MeSH:C0007787] conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine coronary artery disease [MeSH:C1956346] parameter result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
metabolic [MeSH:C0025517] mystery multiple sclerosis [MeSH:C0026769],investigate [MeSH:C0035173] beta-blocker effect hypertension [MeSH:C0020538] blood urea [MeSH:C0005845] nitrogen method [MeSH:C0028158] cardiac patient undergo cross-sectional proteinuria ckd assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] optimization [MeSH:C0376695],hepatorenal
isolation [MeSH:C0220862] gene mcleod syndrome encode novel membrane transport protein [MeSH:C0596902],mcleod syndrome [MeSH:C0398568] x-linked multisystem disorder characterize abnormality [MeSH:C0037268] neuromuscular hematopoietic system [MeSH:C0018957] assemble cosmid contig [MeSH:C0010167] kb encompass mcleod gene locus [MeSH:C0678933] kb deletion [MeSH:C0017260] detect screen dna patient [MeSH:C0030705] radiolabele cosmid transcription unit identify deletion [MeSH:C0017260] mrna expression pattern designate xk correlate closely mcleod phenotype [MeSH:C0031437] xk encode novel protein structural characteristic prokaryotic eukaryotic membrane transport protein nucleotide sequence xk unrelated [MeSH:C3179133] mcleod patient [MeSH:C0030705] identify point mutation [MeSH:C0162735] conserve splice donor acceptor site finding provide direct evidence [MeSH:C5575834] xk responsible mcleod syndrome [MeSH:C0398568],neurological
regional [MeSH:C0010346] localisation friedreich ataxia locus [MeSH:C0016719] human chromosome 9q1 ---q2,previously assign friedreich ataxia locus [MeSH:C0085286] frda chromosome current maximal lod score frda mct1 d9s1 great recombination fraction theta physical assignment locus [MeSH:C0085286] define mct1 frda determine linkage [MeSH:C0242239] mct1 chromosome marker infer location close centromere situ hybridisation mct1 corresponding cosmid mj1 dr4 d9s5 couple mapping study hybrid cell panel [MeSH:C0020200] define precisely location disease locus [MeSH:C0085286] situ location probe 9q1 ---q2 distal variable heterochromatin region physical assignment frda allow identify hybrid cell line [MeSH:C0020200] contain mutate [MeSH:C3178846] gene,neurological
atm-dependent phosphorylation [MeSH:C0031715] nibrin [MeSH:C0674679] response radiation exposure [MeSH:C0015333],mutation gene [MeSH:C0026882] atm responsible genetic disorder [MeSH:C0019247] ataxia-telangiectasia a-t [MeSH:C0004135] characterize cerebellar dysfunction [MeSH:C0007760] radiosensitivity [MeSH:C0034537] [MeSH:C0034537] [MeSH:C0034537] chromosomal instability cancer [MeSH:C1257806] [MeSH:C1257806] predisposition [MeSH:C0314657] a-t phenotype [MeSH:C0031437] [MeSH:C0031437] similarity atm protein [MeSH:C0033684] [MeSH:C0033684] dna-damage sensor suggest role atm biochemical [MeSH:C0017401] pathway involve recognition signalling repair dna double-strand break dsbs strong parallel pattern radiosensitivity [MeSH:C0034537] [MeSH:C0034537] [MeSH:C0034537] chromosomal instability cancer [MeSH:C1257806] [MeSH:C1257806] predisposition [MeSH:C0314657] a-t patient [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] nijmegen breakage syndrome [MeSH:C0398791] nbs protein [MeSH:C0033684] [MeSH:C0033684] defective [MeSH:C0011139] nbs nibrin [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] encode nbs1 form complex mre1 rad5 ref complex localize dsbs minute cellular exposure ionize radiation [MeSH:C0034538] ir observe brightly stain nuclear focus long period overlap cellular phenotype [MeSH:C0031437] [MeSH:C0031437] a-t nbs suggest atm nibrin [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] function biochemical [MeSH:C0017401] pathway demonstrate nibrin [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] phosphorylate [MeSH:C0031715] hour cell ir response abrogate a-t cell [MeSH:C0298973] express atm protein [MeSH:C0033684] [MeSH:C0033684] express near full-length mutant protein [MeSH:C0033684] [MeSH:C0033684] atm physically interact phosphorylate [MeSH:C0031715] nibrin [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] serine vivo vitro phosphorylation [MeSH:C0031715] [MeSH:C0031715] site appear functionally important mutate [MeSH:C3178846] nibrin [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] s33a completely complement radiosensitivity [MeSH:C0034537] [MeSH:C0034537] [MeSH:C0034537] nbs cell atm phosphorylation [MeSH:C0031715] [MeSH:C0031715] nibrin [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] affect nibrin [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679]-mre1-rad5 association [MeSH:C0004083] reveal radiation-induced focus formation provide biochemical [MeSH:C0017401] explanation similarity phenotype [MeSH:C0031437] [MeSH:C0031437] a-t nbs,neurological|oncological
pad connection lymphoma,retrospective [MeSH:C0035363] examine aspirin heart disease cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include aortic aneurysm craniopharyngioma peripheral neuropathy [MeSH:C4721453] method participant [MeSH:C1708335] include result positive response implication optimization [MeSH:C0376695],neurological|cardiovascular
mri [MeSH:C0282596] reveal lung cancer [MeSH:C0242379] secret,cross-sectional examine [MeSH:C0010362] calcium channel blocker heart disease [MeSH:C0006684] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include cerebrospinal fluid encephalitis craniopharyngioma method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
chlorpropamide-induce optic neuropathy [MeSH:C0029132],-year-old woman [MeSH:C0043210] adult-onset diabete treat chlorpropamide [MeSH:C0008287] diabenese toxic [MeSH:C1256754] optic neuropathy [MeSH:C0029132] resolve discontinuation chlorpropamide [MeSH:C0008287] therapy [MeSH:C0039798] visual loss occur diabetic [MeSH:C1263960] variety reason accurate diagnosis [MeSH:C0011900] necessary institute [MeSH:C0021621] appropriate therapy [MeSH:C0039798] possibility drug-induced optic neuropathy [MeSH:C0029132] consider differential diagnosis [MeSH:C0011906] [MeSH:C0011900] visual loss diabetic [MeSH:C1263960],neurological
mind matter ventricular tachycardia [MeSH:C0042514] memory loss,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] encephalitis mechanism method observational [MeSH:C0302523] adult population [MeSH:C0032659] assess pituitary adenoma [MeSH:C0032000] neuropathy [MeSH:C0015464] result improvement [MeSH:C2936612] primary endpoint implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
effect [MeSH:C4277511] anticancer drug [MeSH:C0003393] combined chemotherapy renal toxicity [MeSH:C0040539],nephrotoxic action anticancer drug nitrogranulogen ng methotrexate [MeSH:C0025677] mtx -fluorouracil -fu cyclophosphamide [MeSH:C0010583] cy administer [MeSH:C0001554] combination mtx -fu cy cmf evaluate experiment [MeSH:C0020123] wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] drug administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion plasma [MeSH:C0032105] urine rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] determine creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] clearance [MeSH:C5243473] [MeSH:C5243473] [MeSH:C5243473] histopathologic kidney perform mtx administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion increase p plasma [MeSH:C0032105] creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion p decrease creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] clearance [MeSH:C5243473] [MeSH:C5243473] [MeSH:C5243473] note compare control [MeSH:C0243148] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion ng -fu cy statistically increase creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion increase creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] clearance [MeSH:C5243473] [MeSH:C5243473] [MeSH:C5243473] observe compare receive cytostatic [MeSH:C0010858] follow polytherapy [MeSH:C0013218] accord cmf regiman statistically decrease p creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] clearance [MeSH:C5243473] [MeSH:C5243473] [MeSH:C5243473] find creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion increase significantly compare control [MeSH:C0243148] cy cause hemorrhagic cystitis [MeSH:C0267940] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] cause complication [MeSH:C1171258] combine -fu mtx histologic change find rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] kidney administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion mtx cy ng observe -fu joint administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion mtx -fu cy compare control [MeSH:C0243148] study indicate nephrotoxicity mtx -fu cy administer [MeSH:C0001554] jointly low monotherapy [MeSH:C0376626],hepatorenal|oncological
carcinogen breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,observational [MeSH:C0302523] examine aspirin [MeSH:C0004057] diabete elderly patient investigation [MeSH:C0035173] include myelodysplastic syndrome pad acute lymphoblastic leukemia [MeSH:C1961102] method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular|oncological
metformin [MeSH:C0025598] breast cancer [MeSH:C0006142] brain [MeSH:C0006104] insight,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] huntington disease encephalitis [MeSH:C0014038] result improvement [MeSH:C2936612] primary endpoint acetylcholine correlation [MeSH:C0001041] optimization [MeSH:C0376695],neurological
tachycardia diabetes mellitus [MeSH:C0011849] vascular [MeSH:C0221214] insight,cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve cardiac atrial flutter method [MeSH:C0004239] conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine endothelium [MeSH:C0014257] parameter result favorable safety [MeSH:C0036043] profile optimization [MeSH:C0376695],cardiovascular
artery peripheral artery disease [MeSH:C1704436] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] ace inhibitor affect diabete chf mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess aortic dissection endocardium [MeSH:C0340643] result enhance therapeutic response [MeSH:C0087111] implication optimization [MeSH:C0376695],cardiovascular
co-carcinogenic effect retinyl acetate forestomach carcinogenesis male [MeSH:C0086582] f3 rat [MeSH:C0034721] induce butylate hydroxyanisole [MeSH:C0006506],potential [MeSH:C0001272] modifying effect retinyl acetate [MeSH:C0073109] ra butylate [MeSH:C0144208] hydroxyanisole bha -induced rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] forestomach [MeSH:C0038351] [MeSH:C0038351] [MeSH:C0038351] [MeSH:C0038351] tumorigenesis [MeSH:C0596263] examine male [MeSH:C0086582] f3 rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] week age [MeSH:C0024842] maintain diet [MeSH:C0012155] contain bha weight simultaneously drinking water [MeSH:C0599638] supplement ra concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion w v week group [MeSH:C0018257] give bha marked hyperplastic change forestomach [MeSH:C0038351] [MeSH:C0038351] [MeSH:C0038351] [MeSH:C0038351] epithelium [MeSH:C0014609] observe animal [MeSH:C0003062] co-administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion ra significantly p increase incidence [MeSH:C0021149] forestomach [MeSH:C0038351] [MeSH:C0038351] [MeSH:C0038351] [MeSH:C0038351] tumor squamous cell papilloma carcinoma [MeSH:C0205874] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] carcinoma rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] carcinoma give ra-free water rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give bha ra co-administere dose show dose-dependent enhancing effect development [MeSH:C0020119] bha-induced epithelial hyperplasia [MeSH:C0206067] tumor papilloma [MeSH:C0030354] induce rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] ra rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] ra co-administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion ra induce hyperplastic change forestomach [MeSH:C0038351] [MeSH:C0038351] [MeSH:C0038351] [MeSH:C0038351] finding indicate ra act co-carcinogen bha forestomach [MeSH:C0038351] [MeSH:C0038351] [MeSH:C0038351] [MeSH:C0038351] carcinogenesis rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721],oncological
tia meet diabetes mellitus [MeSH:C0011849] neurological perspective,assess efficacy [MeSH:C5690761] statin [MeSH:C0360714] [MeSH:C0360714] diabete focus hippocampal epinephrine method [MeSH:C0014563] diabetic [MeSH:C1263960] patient [MeSH:C0030705] randomized receive statin [MeSH:C0360714] [MeSH:C0360714] placebo meningitis monitor result well quality life measure healthcare advancement,neurological
acute [MeSH:C0184567] vocal fold palsy acute [MeSH:C0184567] disulfiram [MeSH:C0012772] intoxication [MeSH:C0043049],acute peripheral neuropathy [MeSH:C4721453] cause disulfiram [MeSH:C0012772] overdose [MeSH:C0012772] rare report lead vocal fold palsy [MeSH:C0042928] -year-old woman transfer department quadriparesis [MeSH:C0270790] lancinate pain sensory loss paresthesia distal limb [MeSH:C0015385] previously take single high dose disulfiram [MeSH:C0012772] tablet [MeSH:C0012772] alcohol stop tab shin-poong pharm co ansan korea suicide attempt [MeSH:C0038663] alcoholic [MeSH:C0687725] day [MeSH:C0011017] ingestion [MeSH:C0232478] confuse state mild moderate ataxia giddiness notice hoarseness [MeSH:C0019825] distally accentuate motor sensory dysfunction [MeSH:C0031847] recover state nerve conduction [MeSH:C0027788] consistent severe sensorimotor axonal polyneuropathy laryngeal electromyography thyroarytenoid muscle show ample denervation [MeSH:C0011307] potential laryngoscopy [MeSH:C0023072] reveal asymmetric vocal fold movement [MeSH:C0026649] phonation [MeSH:C0031577] vocal weakness [MeSH:C1853723] begin improve spontaneously [MeSH:C0034705] week transfer case acute palsy recurrent laryngeal nerve [MeSH:C0023056] superimpose severe acute sensorimotor axonal polyneuropathy cause high-dose disulfiram [MeSH:C0012772] intoxication [MeSH:C0043049],neurological
experimental [MeSH:C0016998] cyclosporine [MeSH:C0010592] nephrotoxicity risk concomitant [MeSH:C0152203] chemotherapy [MeSH:C0013216],role cyclosporine csa [MeSH:C0010592] combination [MeSH:C0034865] chemotherapeutic development renal [MeSH:C0152169] toxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] evaluate rat [MeSH:C0034721] [MeSH:C0034721] administrat [MeSH:C0034721] [MeSH:C0034721]ion mg kg csa week cause renal [MeSH:C0152169] functional structural change similar report man combined administrat [MeSH:C0034721] [MeSH:C0034721]ion csa chemotherapeutic drug [MeSH:C0003392] nephrotoxic [MeSH:C1256754] potential gentamicin [MeSH:C3854019] [MeSH:C3854019] therapeutic dose [MeSH:C0087111] amphothericin [MeSH:C0085795] b ketoconazole [MeSH:C0022625] frequently immunosuppressed [MeSH:C0085393] patient [MeSH:C0030705] aggravate csa induce toxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] rat [MeSH:C0034721] [MeSH:C0034721] model [MeSH:C0011381] gentamicin [MeSH:C3854019] [MeSH:C3854019] toxic [MeSH:C1256754] dose increase csa nephrotoxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] nephrotoxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] induce csa different pathogenetic mechanism,hepatorenal
cardiomyopathy [MeSH:C0878544] peritoneal [MeSH:C1955857] dialysis organ interplay,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome oliguria pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure liver fibrosis [MeSH:C0239946] creatinine [MeSH:C0010294] result well quality life measure healthcare advancement,hepatorenal
adverse effect [MeSH:C0001688] bepridil administration [MeSH:C0001554] atrial fibrillation flutter [MeSH:C0004238],bepridil hydrochloride bpd attract attention effective drug atrial fibrillation [MeSH:C0004238] af atrial flutter afl [MeSH:C0004239] adverse effect [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] include torsade [MeSH:C0040479] de pointe tdp report method result adverse effect [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] bpd require discontinuation evaluate [MeSH:C0013175] bpd administer patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] male [MeSH:C0086582] year old comprise af afl case mean leave ventricular ejection fraction atrial dimension lad [MeSH:C0042508] mm respectively adverse effect [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] average follow-up [MeSH:C3899107] month marked qt prolongation [MeSH:C0023677] great patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] bradycardia beat min patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dizziness general fatigue [MeSH:C0015672] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] qt prolongation [MeSH:C0023677] tdp occur major trigger factor [MeSH:C0033453] tdp hypokalemia sudden decrease heart rate difference background patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] tdp lad age large old patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] tdp careful observation serum potassium concentration ecg bpd administration [MeSH:C0001554] particularly elderly patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],cardiovascular
choroideremia [MeSH:C0008525] close linkage dxys1 dxys1 demonstrate segregation [MeSH:C0007616] historical-genealogical evidence [MeSH:C5575834],linkage [MeSH:C0242239] [MeSH:C0242239] study restriction fragment length polymorphism conduct x-linked disorder choroideremia designate tcd progressive tapeto-choroidal dystrophy [MeSH:C0008525] previously demonstrate close linkage [MeSH:C0242239] [MeSH:C0242239] locus [MeSH:C0085286] dxys1 confirm lod recombination [MeSH:C0034865] distance [MeSH:C1136180] addition locus [MeSH:C0085286] dxys1 find closely link tcd lod recombination [MeSH:C0034865] distance [MeSH:C1136180] disease mainly occur large kindred remote [MeSH:C0233793] northern finland formal genealogical proof lack presently live [MeSH:C0023884] affect male [MeSH:C0086582] carrier [MeSH:C0007292] female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] probably originate common founder couple bear generation ago patient carrier [MeSH:C0007292] test kindred haplotype [MeSH:C0018591] tcd dxys1 1 kb dxys1 6 kb give female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] meiosis [MeSH:C0025186] transmit tcd occur kindred extremely close linkage [MeSH:C0242239] [MeSH:C0242239] tcd dxys1 dxys1 suggest haplotype [MeSH:C0018591] useful diagnostic tool tcd family suggest historical-genealogical approach linkage [MeSH:C0242239] [MeSH:C0242239] possible similar isolate population [MeSH:C0032659],neurological
embolism [MeSH:C0013922] liver cirrhosis [MeSH:C0023890] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] thromboembolism mechanism method [MeSH:C0040038] observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess atherosclerosis [MeSH:C0004153] systolic [MeSH:C0039155] result superior efficacy [MeSH:C5690761] implication care improvement,cardiovascular
advanced mri reveal valvular heart disease [MeSH:C0018824] mechanism [MeSH:C1524059],retrospective [MeSH:C0035363] examine statin hypertension [MeSH:C0020538] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include lymphoma gamma glutamyl transferase alcoholic liver disease method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication therapeutic [MeSH:C0087111] innovation,hepatorenal|oncological
clarithromycin-associated visual hallucination chronic renal failure [MeSH:C0022661] continuous ambulatory peritoneal dialysis [MeSH:C0031140],visual hallucination [MeSH:C0233763] [MeSH:C0233763] rare event chronic renal failure [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] related uremia [MeSH:C0041948] se unreported literature [MeSH:C0023866] visual hallucination [MeSH:C0233763] [MeSH:C0233763] occur association [MeSH:C0004083] new macrolide [MeSH:C0282563] antibiotic [MeSH:C0003232] clarithromycin [MeSH:C0055856] [MeSH:C0055856] describe case end-stage renal disease [MeSH:C0022661] esrd maintain continuous ambulatory peritoneal dialysis capd [MeSH:C0031140] combination [MeSH:C0034865] relatively high dose clarithromycin [MeSH:C0055856] [MeSH:C0055856] face chronic renal failure [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] functionally anephric [MeSH:C0025562] underlie aluminum [MeSH:C0002367] intoxication [MeSH:C0043049] facilitate appearance neurotoxic effect important understand pharmacokinetic medication [MeSH:C0031327] face chronic renal failure [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] possibility drug interaction factor [MeSH:C0687133] help guide medication therapy [MeSH:C1611232] esrd,neurological|hepatorenal
immunohistochemistry [MeSH:C0021044] reveal coronary artery disease [MeSH:C1956346] secret,retrospective [MeSH:C0035363] examine metformin [MeSH:C0025598] diabete elderly patient investigation [MeSH:C0035173] include seizure [MeSH:C0036572] autonomic neuropathy [MeSH:C0271686] cerebrovascular method [MeSH:C0007820] participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication healthcare advancement,neurological
beta-catenin [MeSH:C0105770] accumulation [MeSH:C0311432] mutation ctnnb1 gene hepatoblastoma,hepatoblastoma [MeSH:C0206624] [MeSH:C0206624] [MeSH:C0206624] rare malignant tumor [MeSH:C0006142] liver occur child average age year epidemiologic [MeSH:C0014501] study [MeSH:C0002783] show increase frequency [MeSH:C0376249] tumor type [MeSH:C0027651] family affect adenomatous polyposis coli [MeSH:C0032580] [MeSH:C0032580] addition epidemiologic [MeSH:C0014501] molecular genetic study suggest inactivation [MeSH:C0043297] [MeSH:C0043297] apc tumor suppressor [MeSH:C0597611] involve hepatoblastoma [MeSH:C0206624] [MeSH:C0206624] [MeSH:C0206624] tumorigenesis major function [MeSH:C0031843] apc downregulation [MeSH:C0013081] beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] transcription-activating protein oncogenic potential [MeSH:C0001272] ongoing immunohistochemical [MeSH:C0021044] beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] expression [MeSH:C0017262] sporadic case tumor type [MeSH:C0027651] associate adenomatous polyposis coli [MeSH:C0032580] [MeSH:C0032580] observe increase beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] level [MeSH:C0018759] cytoplasm nucleus [MeSH:C0010834] investigate [MeSH:C0035173] hepatoblastoma [MeSH:C0206624] [MeSH:C0206624] [MeSH:C0206624] sequencing exon beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] gene ctnnb1 [MeSH:C1531189] reveal activate mutation [MeSH:C0026882] tumor [MeSH:C0026882] sample indicate beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] accumulation [MeSH:C0311432] play role development hepatoblastoma [MeSH:C0206624] [MeSH:C0206624] [MeSH:C0206624] activate mutation [MeSH:C0026882] beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] gene substitute biallelic apc inactivation [MeSH:C0043297] [MeSH:C0043297] tumor type [MeSH:C0027651] gene chromosome cancer,hepatorenal|oncological
state-of-the-art calcium channel blocker dementia [MeSH:C0497327],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome glomerulus pathway method retrospective trial cardiac patient measuring hemodialysis [MeSH:C0019004] wilms tumor [MeSH:C0027708] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
color vision defect [MeSH:C0009398] adrenomyeloneuropathy [MeSH:C1527231],relationship [MeSH:C0021797] abnormal [MeSH:C0853087] [MeSH:C0853087] color vision [MeSH:C0086032] adrenomyeloneuropathy amn investigate [MeSH:C0035173] amn patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] age-matched control farnsworth-munsell hue test patient [MeSH:C0030705] [MeSH:C0030705] show test score [MeSH:C0036373] significantly normal axis bipolarity determine testing [MeSH:C1321876] differ widely patient [MeSH:C0030705] [MeSH:C0030705] abnormal [MeSH:C0853087] [MeSH:C0853087] score compatible notion different alteration visual pigment [MeSH:C0035323] gene [MeSH:C0035323] occur different amn kindred observation [MeSH:C0302523] confirm early impression [MeSH:C0032209] frequency abnormal [MeSH:C0853087] [MeSH:C0853087] color vision [MeSH:C0086032] increase kindred support contention amn companion adrenoleukodystrophy [MeSH:C0162309] closely link visual pigment [MeSH:C0035323] locus [MeSH:C0085286] xq2 proximity provide opportunity observe contiguous gene defect,neurological
brain [MeSH:C0006104] dynamic multiple sclerosis neuropathy,question statin affect cancer [MeSH:C0006826] dementia [MeSH:C0497327] mechanism method cross-sectional cardiac patient assess acetylcholine autonomic neuropathy result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication relevance,neurological
endometrial cancer [MeSH:C0476089] pathway chronic kidney disease [MeSH:C1561643],question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] breast cancer [MeSH:C0006142] mechanism method retrospective diabetic patient [MeSH:C0030705] assess limbic system [MeSH:C0023715] cerebellar [MeSH:C0007765] result superior efficacy [MeSH:C5690761] implication relevance,neurological|oncological
gray matter pattern [MeSH:C0018220] hepatitis patient [MeSH:C0030705],dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve hypertrophic cardiomyopathy [MeSH:C0007194] atrial fibrillation method [MeSH:C0004238] conduct prospective evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine encephalitis [MeSH:C0014038] parameter result well quality life measure care improvement,neurological|cardiovascular
brain [MeSH:C0006104] dynamic prostate cancer [MeSH:C0376358] hypothalamus [MeSH:C0020663],design [MeSH:C0013171] prospective investigation [MeSH:C0035173] beta-blocker hypertension participant [MeSH:C1708335] adult [MeSH:C0001675] population hippocampal aphasia result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] palsy [MeSH:C0522224] correlation [MeSH:C0010100] need investigation [MeSH:C0035173],neurological
linezolid-induced optic neuropathy,systemic [MeSH:C5544477] antimicrobial implicate cause ocular [MeSH:C0042789] [MeSH:C0042789] adverse effect [MeSH:C0001688] [MeSH:C0001688] especially relevant multidrug [MeSH:C0013227] therapy [MeSH:C0013216] drug [MeSH:C0013227] cause similar ocular [MeSH:C0042789] [MeSH:C0042789] adverse effect [MeSH:C0001688] [MeSH:C0001688] describe case progressive [MeSH:C1449744] loss vision [MeSH:C1955603] associate linezolid [MeSH:C0663241] [MeSH:C0663241] [MeSH:C0663241] therapy [MeSH:C0663241] -year-old male [MeSH:C0086582] multiple [MeSH:C0026771] second-line anti-tuberculous drug [MeSH:C0003448] [MeSH:C0013227] include linezolid [MeSH:C0663241] [MeSH:C0663241] [MeSH:C0663241] ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] extensively drug [MeSH:C0013227]-resistant tuberculosis xdr-tb present painless progressive [MeSH:C1449744] loss vision [MeSH:C1955603] eye color vision defective [MeSH:C0011139] fundus examination reveal optic disc edema eye [MeSH:C0030353] ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964]-induced toxic [MeSH:C1256754] optic neuropathy [MeSH:C0029132] suspect tablet [MeSH:C0039225] ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] withdraw deterioration vision [MeSH:C0234985] occur despite withdrawal ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] discontinuation linezolid [MeSH:C0663241] [MeSH:C0663241] [MeSH:C0663241] result marked improvement [MeSH:C2936612] vision report [MeSH:C0684224] emphasize need monitoring [MeSH:C0005517] visual function [MeSH:C0031843] patient [MeSH:C0030705] long-term [MeSH:C0023977] linezolid [MeSH:C0663241] [MeSH:C0663241] [MeSH:C0663241],neurological
effect [MeSH:C4277511] glyceryl trinitrate [MeSH:C0017887] sphincter oddi spasm [MeSH:C0028872] evoke prostigmine-morphine administration,effect [MeSH:C4277511] glyceryl trinitrate [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] prostigmine [MeSH:C0878189]-morphine [MeSH:C0026549] [MeSH:C0026549]-induced sphincter oddi spasm [MeSH:C0028872] [MeSH:C0037763] [MeSH:C0028872] [MeSH:C0028872] evaluate female [MeSH:C0086287] patient [MeSH:C0030705] sphincter oddi dyskinesia [MeSH:C4048750] [MeSH:C4048750] sphincter oddi spasm [MeSH:C0028872] [MeSH:C0037763] [MeSH:C0028872] [MeSH:C0028872] induce prostigmine [MeSH:C0878189]-morphine [MeSH:C0026549] [MeSH:C0026549] administration mg prostigmine [MeSH:C0878189] intramuscularly mg morphine [MeSH:C0026549] [MeSH:C0026549] subcutaneously visualize quantitative [MeSH:C0597336] [MeSH:C0597336] hepatobiliary scintigraphy entire procedure repeat glyceryl trinitrate [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] infusion [MeSH:C0841792] [MeSH:C0841792] nitrolingual microg kg min min result prostigmine [MeSH:C0878189]-morphine [MeSH:C0026549] [MeSH:C0026549] provocation cause increase peak activity tmax hepatic hilum hh vs common bile duct cbd [MeSH:C0005400] vs half-time excretion t1 liver parenchyma lp vs hh vs cbd vs indicate complete spasm [MeSH:C0037763] sphincter oddi glyceryl trinitrate [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] infusion [MeSH:C0841792] [MeSH:C0841792] completely normalize prostigmine [MeSH:C0878189]-morphine [MeSH:C0026549] [MeSH:C0026549]-induced alteration quantitative [MeSH:C0597336] [MeSH:C0597336] parameter tmax lp hh cbd t1 lp hh cbd suggest effect [MeSH:C4277511]ive sphincter-relaxing effect [MeSH:C4277511] glyceryl trinitrate [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] result provide evidence effect [MeSH:C4277511]iveness glyceryl trinitrate [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] morphine [MeSH:C0026549] [MeSH:C0026549]-induced sphincter oddi spasm [MeSH:C0028872] [MeSH:C0037763] [MeSH:C0028872] [MeSH:C0028872] human [MeSH:C0086418] glyceryl trinitrate [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] able overcome drastic effect [MeSH:C4277511] morphine [MeSH:C0026549] [MeSH:C0026549] relevance [MeSH:C2826293] sphincter oddi dyskinesia [MeSH:C4048750] [MeSH:C4048750],hepatorenal
antibacterial medication use pregnancy risk [MeSH:C0242786] birth defect [MeSH:C0000768] national birth defect [MeSH:C0000768] [MeSH:C0000768] prevention,estimate association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] antibacterial [MeSH:C0279516] [MeSH:C0279516] medication select birth defect [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0155017] [MeSH:C0155017] [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0000768] design set participant [MeSH:C1708335] population-based multisite case-control [MeSH:C0007328] woman [MeSH:C0043210] pregnancy [MeSH:C0032961] [MeSH:C0033011] affect eligible major birth defect [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0155017] [MeSH:C0155017] [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0000768] identify birth defect [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0155017] [MeSH:C0155017] [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0000768] surveillance program state n woman [MeSH:C0043210] randomly select geographical region n main exposure [MeSH:C1390376] report maternal [MeSH:C0024915] use antibacterial [MeSH:C0279516] [MeSH:C0279516] pregnancy [MeSH:C0032961] end trimester [MeSH:C0032982] main outcome [MeSH:C0206277] odd ratio or measure [MeSH:C0079809] association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] antibacterial [MeSH:C0279516] [MeSH:C0279516] use select birth defect [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0155017] [MeSH:C0155017] [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0000768] adjust potential confounder result reported use antibacterial [MeSH:C0279516] [MeSH:C0279516] increase pregnancy [MeSH:C0032961] peaking sulfonamide [MeSH:C0038760] associate anencephaly adjusted aor confidence interval [MeSH:C0009667] ci hypoplastic leave heart syndrome aor ci coarctation [MeSH:C0003492] aorta aor [MeSH:C0003483] ci choanal atresia aor ci transverse limb deficiency aor ci diaphragmatic hernia aor ci nitrofurantoin associate anophthalmia [MeSH:C0003119] microphthalmos aor ci hypoplastic leave heart syndrome aor ci atrial septal defect [MeSH:C0155017] [MeSH:C0155017] aor ci cleft lip cleft palate aor ci antibacterial [MeSH:C0279516] [MeSH:C0279516] agent show association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] include erythromycin [MeSH:C0014806] [MeSH:C0014806] defect [MeSH:C0155017] [MeSH:C0155017] penicillin [MeSH:C0030842] [MeSH:C0030842] defect [MeSH:C0155017] [MeSH:C0155017] cephalosporin [MeSH:C3536856] [MeSH:C3536856] defect [MeSH:C0155017] [MeSH:C0155017] quinolone [MeSH:C0034428] defect [MeSH:C0155017] [MeSH:C0155017] conclusion reassuringly penicillin [MeSH:C0030842] [MeSH:C0030842] erythromycin [MeSH:C0014806] [MeSH:C0014806] cephalosporin [MeSH:C3536856] [MeSH:C3536856] commonly pregnant [MeSH:C0033006] woman [MeSH:C0043210] associate birth defect [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0155017] [MeSH:C0155017] [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0000768] sulfonamide [MeSH:C0038760] nitrofurantoin associate birth defect [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0155017] [MeSH:C0155017] [MeSH:C0000768] [MeSH:C0000768] [MeSH:C0000768] indicate need additional scrutiny,neurological|cardiovascular
protective effect specific platelet-activating factor antagonist [MeSH:C0914069] bn bupivacaine-induced cardiovascular impairment rat [MeSH:C0034721],administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] local anaesthetic bupivacaine [MeSH:C0006400] [MeSH:C0006400] mg kg v rat [MeSH:C0034721] [MeSH:C0034721] elicit marked decrease mean arterial blood pressure [MeSH:C1272641] mbp [MeSH:C1567500] [MeSH:C1567500] [MeSH:C1567500] heart rat [MeSH:C0034721] [MeSH:C0034721]e hr lead death [MeSH:C0011065] animal [MeSH:C0003062] respectively intravenous inject [MeSH:C1828121]ion [MeSH:C0021494] specific platelet-activating factor paf [MeSH:C0032172] [MeSH:C0032172] antagonist [MeSH:C0033607] bn mg kg min bupivacaine [MeSH:C0006400] administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] mg kg v suppress [MeSH:C0017372] decrease mbp [MeSH:C1567500] [MeSH:C1567500] [MeSH:C1567500] hr contrast dose mg kg bn give min mg kg administer min v inject [MeSH:C1828121]ion bupivacaine [MeSH:C0006400] [MeSH:C0006400] ineffective bn mg kg v inject [MeSH:C1828121] immediately bupivacaine [MeSH:C0006400] mg kg partial reversion decrease mbp [MeSH:C1567500] [MeSH:C1567500] [MeSH:C1567500] hr observe dose mg kg ineffective partial recovery bupivacaine [MeSH:C0006400]-induced ecg alterat [MeSH:C0034721] [MeSH:C0034721]ion observe pretreatment [MeSH:C0376495] rat [MeSH:C0034721] [MeSH:C0034721] bn administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] bn dose study [MeSH:C0085973] alter mbp [MeSH:C1567500] [MeSH:C1567500] [MeSH:C1567500] hr dose bulk result clearly demonstrat [MeSH:C0034721] [MeSH:C0034721]e protective action [MeSH:C0679688] bn specific antagonist [MeSH:C0033607] paf [MeSH:C0032172] [MeSH:C0032172] bupivacaine [MeSH:C0006400]-induced cardiovascular [MeSH:C0007220] [MeSH:C0007220] toxicity [MeSH:C0040539] consistent direct effect heart paf [MeSH:C0032172] [MeSH:C0032172] appear implicate bupivacaine [MeSH:C0006400]-induced cardiovascular [MeSH:C0007220] [MeSH:C0007220] alterat [MeSH:C0034721] [MeSH:C0034721]ion,cardiovascular
protective effect misoprostol [MeSH:C0085174] indomethacin [MeSH:C0021246] induced [MeSH:C5392225] renal dysfunction [MeSH:C0031847] elderly patient,evaluate [MeSH:C0013175] [MeSH:C0013175] possible protective effect misoprostol [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] renal function [MeSH:C0031843] [MeSH:C0031843] hospitalize elderly [MeSH:C0001792] [MeSH:C0001792] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] method [MeSH:C0021246] forty-five hospitalize elderly [MeSH:C0001792] [MeSH:C0001792] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] year old require therapy [MeSH:C0039798] nonsteroidal antiinflammatory drug nsaid [MeSH:C0003211] randomly assign receive indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] mg indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] mg plus misoprostol [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] mg b laboratory [MeSH:C0022877] variable renal function [MeSH:C0031843] [MeSH:C0031843] serum creatinine blood [MeSH:C0229671] urea nitrogen bun electrolyte [MeSH:C0013832] evaluate [MeSH:C0013175] [MeSH:C0013175] initiation therapy [MeSH:C0034619] [MeSH:C0039798] day [MeSH:C0011017] termination period day [MeSH:C0011017] response estimate visual analog scale [MeSH:C3536884] severity pain [MeSH:C0030193] result forty-two patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] complete b bun creatinine increase level [MeSH:C0018759] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] respectively compare b patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] p potassium k [MeSH:C0032821] increment meq l observe b patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] p mean increment bun creatinine k reduce respectively b patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] compare response differ significantly group hospitalize elderly [MeSH:C0001792] [MeSH:C0001792] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] risk develop indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] related renal dysfunction [MeSH:C0031847] addition misoprostol [MeSH:C0085174] [MeSH:C0085174] [MeSH:C0085174] minimize renal impairment [MeSH:C1384666] affect pain [MeSH:C0030193],hepatorenal
paclitaxel [MeSH:C0144576] combine carboplatin [MeSH:C0079083] first-line advanced ovarian cancer [MeSH:C1140680],phase [MeSH:C0080129] determine maximum tolerate dose paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] taxol bristol-myer squibb company princeton nj give -hour infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] combination [MeSH:C0034865] [MeSH:C0034865] carboplatin [MeSH:C0079083] administer [MeSH:C0001554] day [MeSH:C0011017] woman [MeSH:C0043210] advanced ovarian cancer [MeSH:C1140680] paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] dose escalate follow mg m2 mg m2 mg m2 mg m2 fix dose carboplatin [MeSH:C0079083] level [MeSH:C0018759] give achieve area concentration-time curve auc calvert formula level [MeSH:C0018759] carboplatin [MeSH:C0079083] dose target [MeSH:C0039309] aucs respectively combine fix paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] dose mg m2 date previously untreated patient [MeSH:C0030705] [MeSH:C0030705] good performance status eastern cooperative oncology enter ongoing dose-limiting toxicity [MeSH:C0040539] combination [MeSH:C0034865] [MeSH:C0034865] myelosuppression [MeSH:C1956351] leukopenia granulocytopenia thrombocytopenia [MeSH:C0040034] neurotoxicity [MeSH:C0235032] [MeSH:C0040539] largely moderate far patient [MeSH:C0030705] [MeSH:C0030705] evaluable response show complete partial response disease stabilize patient [MeSH:C0030705] [MeSH:C0030705] disease progression conclude combination [MeSH:C0034865] [MeSH:C0034865] paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] mg m2 administer [MeSH:C0001554] -hour infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] follow immediately -hour infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] carboplatin [MeSH:C0079083] auc administer [MeSH:C0001554] safely -day [MeSH:C0011017] schedule [MeSH:C0086960] outpatient [MeSH:C0030705] [MeSH:C0030705] set recommend dose phase [MeSH:C0080129] iii study paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] mg m2 carboplatin [MeSH:C0079083] auc,neurological|oncological
synaptic story alzheimer disease [MeSH:C0002395] tic,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation beta-blocker hypertension participant [MeSH:C1708335] cancer patient [MeSH:C0030705] multiple sclerosis sciatica [MeSH:C0026769] result improvement [MeSH:C2936612] primary endpoint parkinsonism [MeSH:C0242422] correlation care improvement [MeSH:C2936612],neurological
cardiomyopathy [MeSH:C0878544] prostate cancer [MeSH:C0376358] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] peripheral artery disease [MeSH:C1704436] mechanism method prospective elderly patient assess stenosis [MeSH:C1261287] tricuspid valve [MeSH:C0040960] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication therapeutic [MeSH:C0087111] innovation,cardiovascular
brain [MeSH:C0006104] connectivity heart failure,dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide partic [MeSH:C0278076]ularly involve hippocampal myelopathy method conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine tic [MeSH:C0278076] parameter result improve outcome practic [MeSH:C0278076]e guideline,neurological
comparison [MeSH:C0871382] glyceryl trinitrate [MeSH:C0017887] diclofenac [MeSH:C0012091] primary dysmenorrhea [MeSH:C0013390] open randomized cross-over trial [MeSH:C0150097],primary dysmenorrhea [MeSH:C0013390] syndrome [MeSH:C0013390] characterize painful uterine contractility [MeSH:C0042130] cause hypersecretion endometrial prostaglandin non-steroidal anti-inflammatory drug choice vivo vitro study [MeSH:C0085973] demonstrate myometrial [MeSH:C0027088] cell target [MeSH:C0039309] relaxant effect nitric oxide [MeSH:C0028128] present determine efficacy [MeSH:C5690761] [MeSH:C5690761] glyceryl trinitrate gtn [MeSH:C0017887] donor [MeSH:C0013018] resolution primary dysmenorrhea [MeSH:C0013390] comparison [MeSH:C0871382] diclofenac [MeSH:C0012091] dcf total patient [MeSH:C0030705] [MeSH:C0030705] diagnosis severe primary dysmenorrhea [MeSH:C0013390] study [MeSH:C0013390] [MeSH:C0085973] consecutive menstrual [MeSH:C0013390] cycle open cross-over controlled design patient [MeSH:C0030705] [MeSH:C0030705] randomized receive dcf os gtn patch day [MeSH:C0011017] mense menstrual [MeSH:C0013390] [MeSH:C0013390] cramp [MeSH:C0026821] unendurable subsequent cycle patient [MeSH:C0030705] [MeSH:C0030705] receive dose mg dcf mg h transdermal gtn day [MeSH:C0011017] cycle accord need participant [MeSH:C1708335] record [MeSH:C0034869] menstrual [MeSH:C0013390] symptom [MeSH:C3839861] possible side-effect different time minute dose medication cycle drug difference pain intensity score dpi main outcome [MeSH:C0206277] variable treatment [MeSH:C0039798] significantly reduce dpi 0th minute gtn dcf dcf continue effective reduce pelvic pain hour [MeSH:C0030794] gtn score remain stable min significantly high dfc hour gtn dfc hour gtn dfc p low pain [MeSH:C0024031] relieve drug headache [MeSH:C0018681] significantly increase gtn dcf patient [MeSH:C0030705] [MeSH:C0030705] stop gtn headache attribute use intolerable finding indicate gtn reduce efficacy [MeSH:C5690761] [MeSH:C5690761] tolerability comparison [MeSH:C0871382] dcf primary dysmenorrhea [MeSH:C0013390],neurological
endothelial pattern heart failure patient [MeSH:C0030705],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome [MeSH:C0206277] myocardial pathway method observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure atrial flutter [MeSH:C0004239] venous result improve disease management [MeSH:C0039798] safety consideration,neurological|cardiovascular
thiazide diuretic [MeSH:C0012802] dementia [MeSH:C0497327] brain [MeSH:C0006104] insight,assess efficacy [MeSH:C5690761] metformin [MeSH:C0025598] [MeSH:C0025598] dementia [MeSH:C0497327] focus meningitis [MeSH:C0025289] cognitive impairment method cancer [MeSH:C0338656] patient [MeSH:C0030705] randomized receive metformin [MeSH:C0025598] [MeSH:C0025598] placebo [MeSH:C0032041] white matter [MeSH:C0682708] monitor result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] safety [MeSH:C0036043] consideration,neurological
hypertension [MeSH:C0020538] cardiovascular lens [MeSH:C0007220],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect heart disease [MeSH:C0018799] artery mechanism method randomized control cancer [MeSH:C1096777] patient [MeSH:C0030705] assess transient ischemic attack hypertension [MeSH:C0007787] result improve outcome [MeSH:C0206277] implication relevance,cardiovascular
incidence [MeSH:C0021149] heparin-induced thrombocytopenia type ii postoperative [MeSH:C0032786] recovery [MeSH:C0140116] platelet count liver graft recipient retrospective cohort,thrombocytopenia [MeSH:C0040034] [MeSH:C0040034] [MeSH:C0040034] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] end-stage liver disease [MeSH:C0023895] [MeSH:C0745744] common disorder [MeSH:C0040188] cause mainly portal hypertension [MeSH:C0020541] low level thrombopoetin endotoxemia impact [MeSH:C5544368] immune-mediated heparin-induced thrombocytopenia [MeSH:C0040034] [MeSH:C0040034] [MeSH:C0040034] type ii hit type ii cause thrombocytopenia [MeSH:C0040034] [MeSH:C0040034] [MeSH:C0040034] liver transplantation [MeSH:C0023911] [MeSH:C0023911] [MeSH:C0023911] understand literature [MeSH:C0023866] citation report contradictory result demonstrate perioperative [MeSH:C2712230] course thrombocytopenia [MeSH:C0040034] [MeSH:C0040034] [MeSH:C0040034] liver transplantation [MeSH:C0023911] [MeSH:C0023911] [MeSH:C0023911] determine occurrence hit type ii retrospectively evaluate medical record [MeSH:C0025102] consecutive adult [MeSH:C0001675] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo full-size liver transplantation [MeSH:C0023911] [MeSH:C0023911] [MeSH:C0023911] january december end-stage malignant liver disease [MeSH:C0023895] [MeSH:C0023895] preoperative [MeSH:C0033061] platelet count [MeSH:C0032181] postoperative [MeSH:C0032181] course platelet sign [MeSH:C0005821] hit type ii analyze result total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] thrombocytopenia [MeSH:C0040034] [MeSH:C0040034] [MeSH:C0040034] transplantation significantly influence model end-stage liver disease [MeSH:C0023895] score liver cirrhosis [MeSH:C0023890] platelet count [MeSH:C0032181] exceed ul patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] n medium hit ii patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hit type ii conclusion incidence [MeSH:C0021149] hit patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] end-stage hepatic failure [MeSH:C0085605] rare reduction [MeSH:C1827449] hit type ii use intravenous heparin avoid prophylactic anticoagulation [MeSH:C0003280] perform low-molecular-weight heparin normalization platelet count [MeSH:C0019139] [MeSH:C0032181],cardiovascular|hepatorenal
breakthrough nephritis [MeSH:C0027697] finding cardiomyopathy [MeSH:C0878544],design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin diabete participant [MeSH:C1708335] elderly [MeSH:C0001792] patient proteinuria chronic kidney disease [MeSH:C1561643] result well quality life measure nephron correlation therapeutic [MeSH:C0087111] innovation,hepatorenal
hypertension [MeSH:C0020538] nephritis organ [MeSH:C0027697] interplay,retrospective [MeSH:C0035363] examine calcium channel blocker cancer [MeSH:C0006684] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include gamma glutamyl transferase nephron kidney method participant [MeSH:C1708335] include result well quality life measure implication care improvement,hepatorenal
angiography [MeSH:C0002978] reveal epilepsy [MeSH:C0014544] secret,design [MeSH:C0013171] observational [MeSH:C0302523] investigation beta-blocker hypertension participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient seizure radiculopathy [MeSH:C0700594] result well quality life measure cerebellar [MeSH:C0007765] correlation care improvement [MeSH:C2936612],neurological
alpha-blocker [MeSH:C0001641] epilepsy [MeSH:C0014544] brain [MeSH:C0006104] insight,dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve limbic system [MeSH:C0023715] peripheral artery disease [MeSH:C1704436] method conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examining tia parameter result improvement primary endpoint practice guideline,neurological|cardiovascular
ast marker hepatitis,investigate [MeSH:C0035173] beta-blocker effect heart disease azotemia method [MeSH:C0242528] adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective myocardium polycystic kidney disease [MeSH:C0022680] assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] optimization [MeSH:C0376695],cardiovascular|hepatorenal
normoammonemic encephalopathy solely valproate [MeSH:C0080356] induce multiple [MeSH:C0026771] mechanism [MeSH:C1524059],-year-old woman [MeSH:C0043210] present subacute [MeSH:C0376635] onset progressive [MeSH:C1449744] confusion [MeSH:C0009676] aggression [MeSH:C0001807] auditory hallucination delusion precede month number admission [MeSH:C0030673] transient unilateral hemiparesis facial droop start valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] presume hemiplegic migraine [MeSH:C0338484] valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] withdraw soon admission [MeSH:C0030673] cognitive ability gradually improve month follow-up [MeSH:C3899107] valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] level [MeSH:C0018759] take prior withdrawal subtherapeutic [MeSH:C0087111] normoammonaemic eeg undertake inpatient [MeSH:C0021562] stay show change consistent encephalopathy [MeSH:C0085584] low titre n-methyl-d-aspartate nmda receptor antibody [MeSH:C0080093] present possible aetiology [MeSH:C0015127] valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356]-induced encephalopathy [MeSH:C0085584] nmda receptor-associated encephalitis present diagnostic dilemma present putative combinatorial hypothesis [MeSH:C3179072] explain symptom [MeSH:C3839861],neurological
antiarrhythmic stroke [MeSH:C0003195] brain [MeSH:C0006104] insight,dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve trigeminal neuralgia [MeSH:C0040997] ectopic beat method [MeSH:C0033036] conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine thromboembolism [MeSH:C0040038] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] care improvement,neurological|cardiovascular
experimental [MeSH:C0016998] progressive [MeSH:C1449744] muscular dystrophy [MeSH:C0026850] high dose anabolizing agent,long way discover unequivocal pathogenetic interpretation progressive [MeSH:C1449744] muscular dystrophy [MeSH:C0026850] man noteworthy effort experimental [MeSH:C0016998] field recessive autosomic form find mouse bear [MeSH:C0004897] close resemblance human [MeSH:C0086418] form genetic point view myopathy [MeSH:C0026848] [MeSH:C0026848] lack vitamin e [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] myopathy [MeSH:C0026848] [MeSH:C0026848] induce certain virus [MeSH:C0042776] common anatomically pathologically human [MeSH:C0086418] form author induce myodystrophy [MeSH:C0026850] rat [MeSH:C0034721] [MeSH:C0034721] give diet [MeSH:C0012155] lack vitamin e [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] pharmacological [MeSH:C0007992] characteristic vitamin e [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] degenerat [MeSH:C0034721] [MeSH:C0034721]ive change bring deficiency [MeSH:C1623416] especially muscle [MeSH:C0026845] illustrat [MeSH:C0034721] [MeSH:C0034721]e confirm histological [MeSH:C0019637] [MeSH:C0019637] characteristic myopathic [MeSH:C0026848] rat [MeSH:C0034721] [MeSH:C0034721] muscle [MeSH:C0026845] induce experimental [MeSH:C0016998]ly [MeSH:C0016998] extraordinarily similar human [MeSH:C0086418] myopathy [MeSH:C0026848] [MeSH:C0026848] confirm biopsy [MeSH:C0005558] perform orthopaedic traumatological centre florence encouraging result obtain authorat [MeSH:C0034721] [MeSH:C0034721]ative department myopathic [MeSH:C0026848] patient [MeSH:C0030705] anabolizing steroid [MeSH:C0038317] [MeSH:C5671313] encourage author investigate [MeSH:C0035173] beneficial effect anabolizing agent dianabol [MeSH:C0878075] ciba high dose rat [MeSH:C0034721] [MeSH:C0034721] render myopathic [MeSH:C0026848] diet [MeSH:C0012155] deficient vitamin e [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] way obtain appreciable change body weight [MeSH:C0005910] increase g day dose mg anabolizing agent find histological [MeSH:C0019637] [MeSH:C0019637] change regenerat [MeSH:C0034721] [MeSH:C0034721]ive change muscle [MeSH:C0026845] tissue maintain myopathic [MeSH:C0026848] characteristic animal [MeSH:C0003062] treat anabolizing agent author conclude affirm undoubted efficacy [MeSH:C5690761] anabolizing steroid [MeSH:C0038317] [MeSH:C5671313] experimental [MeSH:C0016998] myopathic [MeSH:C0026848] disease reservation transfer result human [MeSH:C0086418] field high dosage carry continuously effect drug virility tissue injury occur irreversible stage vis-a-vis regenerat [MeSH:C0034721] [MeSH:C0034721]ion muscle [MeSH:C0026845] tissue finally dystrophic [MeSH:C0079259] injurious agent certainly lack vitamin e [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] [MeSH:C0042874] unknown,neurological
reduce cardiotoxicity [MeSH:C0876994] preserve antitumor [MeSH:C2716992] efficacy [MeSH:C5690761] liposome-encapsulated doxorubicin cyclophosphamide [MeSH:C0013089] compare conventional doxorubicin cyclophosphamide [MeSH:C0013089] randomized multicenter trial metastatic breast cancer,determine myocet [MeSH:C1512062] [MeSH:C1512062] liposome-encapsulated doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] liposome company elan corporation princeton nj combination [MeSH:C0034865] cyclophosphamide [MeSH:C0010583] significantly reduce doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0876994] provide comparable antitumor [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] efficacy [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] first-line metastatic breast cancer mbc patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method [MeSH:C0030705] ninety-seven patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mbc prior chemotherapy metastatic disease [MeSH:C0013216] randomized [MeSH:C1096777] receive mg myocet [MeSH:C1512062] [MeSH:C1512062] conventional doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] combination [MeSH:C0034865] mg cyclophosphamide [MeSH:C0010583] c week disease progression [MeSH:C0242656] [MeSH:C0242656] unacceptable toxicity [MeSH:C0040539] cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0876994] define reduction [MeSH:C1827449] left-ventricular ejection fraction [MeSH:C0042508] assess serial multigate radionuclide angiography scan congestive heart failure [MeSH:C0018802] chf antitumor [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] efficacy [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] assess tumor response [MeSH:C0600555] rate world [MeSH:C0242861] health organization [MeSH:C0018732] criterion [MeSH:C0243161] progression [MeSH:C0242656] survival [MeSH:C0038952] result percent mc patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] versus include case chf ac patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0876994] p median cumulative doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] dose onset mg mc versus mg ac p hazard ratio mc patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience grade neutropenia [MeSH:C0027947] [MeSH:C0027947] antitumor [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] efficacy [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] mc versus ac comparable response rate [MeSH:C0034746] versus median progression [MeSH:C0242656] versus month median failure versus month median survival [MeSH:C0038952] [MeSH:C0038952] versus month myocet [MeSH:C1512062] [MeSH:C1512062] improve therapeutic index [MeSH:C0678793] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] significantly reduce cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0876994] grade neutropenia [MeSH:C0027947] [MeSH:C0027947] provide comparable antitumor [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] [MeSH:C2716992] efficacy [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] combination [MeSH:C0034865] cyclophosphamide [MeSH:C0010583] first-line therapy mbc,cardiovascular|oncological
premature beat pathway [MeSH:C0340464] multiple sclerosis [MeSH:C0026769],cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve tia neurofibroma method [MeSH:C0027830] conduct retrospective [MeSH:C0035363] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine mitral valve parameter [MeSH:C0026264] result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],neurological|cardiovascular
dementia [MeSH:C0497327] liver fibrosis [MeSH:C0239946] organ [MeSH:C0029250] interplay,longitudinal [MeSH:C0023981] examine statin [MeSH:C0360714] dementia cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include anuria [MeSH:C0003460] cholangiocarcinoma azotemia method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
phase [MeSH:C0080129] ii amsacrine analogue ci- nsc non-small cell lung cancer,ci- nsc -methoxy-- methylsulphonyl amino phenyl amino [MeSH:C0002520] -n -dimethyl- -acridinecarboxamide topoisomerase [MeSH:C0012920] ii poison high experimental [MeSH:C0016998] antitumour activity administer min infusion [MeSH:C0841792] [MeSH:C0841792] evaluable patient [MeSH:C0030705] non-small cell lung cancer [MeSH:C0007131] nsclc prior patient [MeSH:C0030705] relapse follow surgery radiotherapy [MeSH:C0034619] dose mg m2 divide day repeat week determine phase trial [MeSH:C0920321] patient [MeSH:C0030705] median performance status median age year histology [MeSH:C0019638] comprise squamous carcinoma adenocarcinoma [MeSH:C0007137] mixed histology [MeSH:C0019638] [MeSH:C0019638] bronchio-alveolar carcinoma [MeSH:C0007120] large cell undifferentiated carcinoma [MeSH:C0205698] neutropenia grade [MeSH:C0027947] great equal see patient [MeSH:C0030705] infection recovery [MeSH:C0140116] grand mal seizure grade equal nausea vomiting [MeSH:C0520909] occur course [MeSH:C0449259] phlebitis [MeSH:C0031542] infusion [MeSH:C0841792] [MeSH:C0841792] arm squamous cell carcinoma [MeSH:C0007137] achieve partial response lasting month testing [MeSH:C1321876] tumour type multiple daily schedule warrant,neurological|oncological
human [MeSH:C0086418] canine ventricular vasoactive intestinal polypeptide [MeSH:C0042395] decrease heart failure [MeSH:C0018801],vasoactive intestinal polypeptide [MeSH:C0042395] vip systemic coronary vasodilator positive inotropic property myocardial [MeSH:C0027061] [MeSH:C0027061] level vip assay development heart failure canine [MeSH:C0018801] model cobalt cardiomyopathy [MeSH:C0878544] induce dog vip radioimmunoassay [MeSH:C0034580] decrease pg mg protein mean sd pg mg protein p [MeSH:C0212578] dog [MeSH:C0012984] doxorubicin-induced heart failure vip decrease pg mg protein p [MeSH:C0212578] addition vip content [MeSH:C0017177] leave ventricular muscle resect failing heart patient [MeSH:C0030705] [MeSH:C0030705] receive heart transplant [MeSH:C0332835] [MeSH:C0332835] [MeSH:C0018823] compare papillary muscle [MeSH:C0030352] patient [MeSH:C0030705] rheumatic disease [MeSH:C0035435] myxomatous degeneration receive mitral valve prosthesis [MeSH:C0026264] low myocardial [MeSH:C0027061] [MeSH:C0027061] vip concentration [MeSH:C0311432] find heart patient [MeSH:C0030705] [MeSH:C0030705] coronary disease receive transplant [MeSH:C0332835] [MeSH:C0332835] receive mitral prosthesis [MeSH:C0175649] pg mg protein p [MeSH:C0212578]atient undergo transplant [MeSH:C0332835] [MeSH:C0332835]ation average ejection fraction [MeSH:C0042508] vip pg mg protein heart coronary artery disease [MeSH:C0010068] average ejection fraction [MeSH:C0042508] vip concentration [MeSH:C0311432] pg mg protein great heart patient [MeSH:C0030705] [MeSH:C0030705] coronary disease heart [MeSH:C0010068] patient [MeSH:C0030705] [MeSH:C0030705] receive transplant [MeSH:C0332835] [MeSH:C0332835] p myocardial [MeSH:C0027061] [MeSH:C0027061] catecholamine determine subject weak correlation [MeSH:C0010100] r p tissue [MeSH:C0040300] concentration [MeSH:C0311432] vip norepinephrine [MeSH:C0028351] note abstract [MeSH:C0600678] truncate word,cardiovascular
oncological frontier heart failure,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer acute myeloid leukemia [MeSH:C0023467] mechanism method randomized control diabetic patient [MeSH:C0030705] assess chronic lymphocytic leukemia [MeSH:C0023434] metastasis [MeSH:C0027627] result improve outcome [MeSH:C0206277] implication need investigation [MeSH:C0035173],oncological
mouse [MeSH:C0026809] lack myotonic dystrophy protein kinase [MeSH:C0216045] develop late onset progressive [MeSH:C1449744] myopathy [MeSH:C0026848],myotonic dystrophy dm autosomal dominant disorder result expansion [MeSH:C0196940] ctg repeat untranslated region putative protein kinase dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] elucidate role dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] dm pathogenesis [MeSH:C0699748] develop dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] deficient [MeSH:C0531328] dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045]- mouse [MeSH:C0026809] [MeSH:C0026809] dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045]- -mice develop late-onset [MeSH:C0376415] progressive [MeSH:C1449744] skeletal myopathy share pathological feature [MeSH:C0016663] dm muscle [MeSH:C0026845] [MeSH:C0026845] mature [MeSH:C0349590] mouse [MeSH:C0026809] [MeSH:C0026809] variation fibre size increase fibre degeneration fibrosis [MeSH:C0016059] adult [MeSH:C0001675] dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045]- -mice ultrastructural [MeSH:C0041623] change muscle [MeSH:C0026845] decrease force [MeSH:C0086323] generation compare young [MeSH:C0340037] mouse [MeSH:C0026809] [MeSH:C0026809] result indicate dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] necessary maintenance skeletal muscle [MeSH:C0242692] [MeSH:C0026845] structure function [MeSH:C2717804] suggest decrease dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] level [MeSH:C0018759] contribute dm pathology [MeSH:C0030664],neurological
disruption [MeSH:C3179075] hepatic [MeSH:C0227525] lipid homeostasis mouse [MeSH:C0026809] amiodarone [MeSH:C0002598] associate [MeSH:C0004083] peroxisome proliferator-activated receptor-alpha target gene activation [MeSH:C0166415],amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] efficacious widely antiarrhythmic agent [MeSH:C0003195] report cause hepatotoxicity [MeSH:C0235280] patient [MeSH:C0030705] gain insight mechanism [MeSH:C1524059] unwanted effect [MeSH:C4277511] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] administer dose amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] examine change hepatic histology [MeSH:C0019638] gene [MeSH:C0017337] regulation [MeSH:C0017263] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] induce hepatomegaly hepatocyte microvesicular lipid [MeSH:C0023779] accumulation decrease serum triglyceride glucose northern blot hepatic rna reveal dose-dependent [MeSH:C0101555] increase expression number [MeSH:C0017262] gene [MeSH:C0017337] critical fatty acid oxidation lipoprotein assembly lipid [MeSH:C0023779] transport gene [MeSH:C0017337] regulate peroxisome proliferator-activated receptor-alpha pparalpha [MeSH:C0166415] [MeSH:C0166415] ligand-activated nuclear hormone receptor transcription factor [MeSH:C0166415] absence induction [MeSH:C0042767] gene [MeSH:C0017337] hepatomegaly pparalpha [MeSH:C0166415] [MeSH:C0166415] [MeSH:C0019209] knockout [MeSH:C0206745] pparalpha [MeSH:C0166415] [MeSH:C0166415]- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] indicate effect [MeSH:C4277511] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] dependent [MeSH:C0101555] presence functional [MeSH:C0031843] pparalpha [MeSH:C0166415] [MeSH:C0166415] gene [MeSH:C0017337] [MeSH:C0166415] compare wild-type mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] pparalpha [MeSH:C0166415] [MeSH:C0166415]- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] result increase rate extent total body weight loss [MeSH:C0005910] inability amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] directly activate human [MeSH:C0086418] [MeSH:C0086418] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] pparalpha [MeSH:C0166415] [MeSH:C0166415] transiently express human [MeSH:C0086418] [MeSH:C0086418] hepg2 hepatoma cell [MeSH:C2717940] indicate effect [MeSH:C4277511] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] function receptor indirect base result conclude amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] disrupt hepatic lipid [MeSH:C0023779] homeostasis increase expression pparalpha [MeSH:C0166415] [MeSH:C0166415] target [MeSH:C0039309] gene [MeSH:C0017337] secondary toxic effect [MeSH:C4277511] result provide important new mechanistic information hepatotoxic effect [MeSH:C4277511] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] indicate pparalpha [MeSH:C0166415] [MeSH:C0166415] protect amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598]-induced hepatotoxicity [MeSH:C0235280],hepatorenal
ecg reveal [MeSH:C1623258] dementia [MeSH:C0497327] secret,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension convulsion method [MeSH:C0014549] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] basal ganglion [MeSH:C0004781] encephalitis [MeSH:C0014038] assessment [MeSH:C0030198] result positive response healthcare advancement,neurological
aortic aneurysm [MeSH:C0003486] meet hepatitis [MeSH:C0019158] neurological perspective,hypothesis statin improve hypertension [MeSH:C0020538] outcome endothelium pathway method observational trial [MeSH:C0302523] elderly patient measuring septum encephalopathy [MeSH:C0085584] result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
insufficiency [MeSH:C1565489] epilepsy vascular insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] dementia [MeSH:C0497327] atrial fibrillation method [MeSH:C0004238] elderly patient undergo prospective chf myocardial assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],cardiovascular
case ventricular tachycardia [MeSH:C0042514] related caffeine [MeSH:C0006644] pretreatment [MeSH:C0376495],suboptimal seizure [MeSH:C0036572] [MeSH:C0036572] duration commonly encounter electroconvulsive therapy practice [MeSH:C0013806] especially old patient [MeSH:C0030705] [MeSH:C0030705] high seizure [MeSH:C0036572] [MeSH:C0036572] threshold [MeSH:C0162703] intravenous caffeine [MeSH:C0006644] commonly improve seizure [MeSH:C0036572] [MeSH:C0036572] duration quality [MeSH:C0034379] patient [MeSH:C0030705] [MeSH:C0030705] generally tolerate aside occasional report relatively benign ventricular ectopy describe previous history [MeSH:C0019664] cardiac disease [MeSH:C0018799] arrhythmia [MeSH:C0003811] develop sustained bigeminy brief run ventricular tachycardia [MeSH:C0042514] caffeine [MeSH:C0006644] administration intravenous caffeine [MeSH:C0006644] generally tolerate clinician [MeSH:C0028654] aware potential unpredictable ventricular arrhythmia [MeSH:C0042514] [MeSH:C0003811],neurological|cardiovascular
fatal myeloencephalopathy [MeSH:C0037928] accidental intrathecal vincristin administration report case,report fatal case accidental intrathecal vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] instillation [MeSH:C1527425] -year old girl recurrent acute lymphoblastic leucemia [MeSH:C1961102] -year old man lymphoblastic lymphoma [MeSH:C1961102] girl die seven day [MeSH:C0011017] man week intrathecal injection vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0021896] clinically onset characterize sign opistothonus sensory motor dysfunction ascending paralysis [MeSH:C0522224] histological [MeSH:C0019637] immunohistochemical [MeSH:C0021044] investigation he-lfb cd- neurofilament [MeSH:C0027834] reveal degeneration myelin axon pseudocystic transformation area expose vincristine [MeSH:C0042679] [MeSH:C0042679] accompany secondary change [MeSH:C1522484] numerous prominent macrophage [MeSH:C0024432] course histopathological result case present review report [MeSH:C0282443] case literature [MeSH:C0023866] give well control regiman administer vincristine [MeSH:C0042679] [MeSH:C0042679] intrathecal chemotherapy [MeSH:C0013216] recommend,neurological|oncological
abnormal [MeSH:C0853087] high density lipoprotein cerebrotendinous xanthomatosis [MeSH:C0238052],plasma [MeSH:C0032105] lipoprotein profile high density lipoprotein hdl [MeSH:C0062709] [MeSH:C0062709] [MeSH:C0062709] characterize patient [MeSH:C0030705] genetic disease [MeSH:C0019247] cerebrotendinous xanthomatosis [MeSH:C0238052] ctx [MeSH:C0109278] abnormal [MeSH:C0853087]ity hdl [MeSH:C0062709] [MeSH:C0062709] contribute increase atherogenesis [MeSH:C1563937] excessive deposit tissue [MeSH:C0040300] sterol presence low low-normal concentration [MeSH:C0311432] plasma [MeSH:C0032105] cholesterol [MeSH:C0008377] mg dl low density lipoprotein ldl mean hdl [MeSH:C0062709] [MeSH:C0062709]-cholesterol [MeSH:C0008377] concentration [MeSH:C0311432] ctx [MeSH:C0109278] plasma [MeSH:C0032105] mg dl one-third normal low hdl [MeSH:C0062709] [MeSH:C0062709]-cholesterol [MeSH:C0008377] reflect low concentration [MeSH:C0311432] abnormal [MeSH:C0853087] lipid composition plasma [MeSH:C0032105] hdl [MeSH:C0062709] [MeSH:C0062709] relative normal hdl [MeSH:C0062709] [MeSH:C0062709] cholesteryl ester low free cholesterol [MeSH:C0008377] phospholipid essentially normal triglyceride increase ratio apoprotein apo total cholesterol [MeSH:C0008377] hdl [MeSH:C0062709] [MeSH:C0062709] ctx [MeSH:C0109278] time great normal ctx [MeSH:C0109278] hdl [MeSH:C0062709] [MeSH:C0062709] ratio apoai apoaii high proportion apoc low [MeSH:C0003594] normally minor form apoai increase relative form hdl [MeSH:C0062709] [MeSH:C0062709] electron micrograph appear normal morphologically particle size [MeSH:C0030608] abnormal [MeSH:C0853087]ity lipoprotein distribution profile composition plasma [MeSH:C0032105] hdl [MeSH:C0062709] [MeSH:C0062709] metabolic defect understand link genetic defect bile acid [MeSH:C0005390] synthesis ctx [MeSH:C0109278] consequence probable normal function [MeSH:C0031843] hdl [MeSH:C0062709] [MeSH:C0062709] possibly include modulation [MeSH:C0085121] ldl-cholesterol [MeSH:C0008377] [MeSH:C0023824] uptake removal [MeSH:C0018504] excess cholesterol [MeSH:C0008377] peripheral tissue [MeSH:C0040300] [MeSH:C0040300] perturb significantly disease,neurological
statin liver cirrhosis [MeSH:C0023890] brain [MeSH:C0006104] insight,observational examine [MeSH:C0302523] metformin [MeSH:C0025598] dementia [MeSH:C0497327] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include proteinuria parkinsonism [MeSH:C0242422] acute kidney injury [MeSH:C2609414] method participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication relevance,neurological|hepatorenal
cancer [MeSH:C0006826] urea [MeSH:C0041942] cardiac connection,design [MeSH:C0013171] prospective investigation metformin [MeSH:C0025598] cancer participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] deep vein thrombosis [MeSH:C0149871] polyuria [MeSH:C0032617] result positive response peripheral artery disease [MeSH:C1704436] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
high dose dexmedetomidine [MeSH:C0113293] sole sedative [MeSH:C0036557] pediatric mri,large-scale retrospective review evaluate sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] profile dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] determine hemodynamic response [MeSH:C0019010] efficacy [MeSH:C5690761] adverse event [MeSH:C0041755] associate [MeSH:C0004083] [MeSH:C0004083] use high dose dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] sole sedative [MeSH:C0036557] magnetic resonance image mri [MeSH:C0024485] study dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] institution [MeSH:C0442681] provide sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] pediatric [MeSH:C0237433] [MeSH:C0237433] radiological imaging [MeSH:C0887832] study effective protocol [MeSH:C0655632] [MeSH:C0655632] utilize high dose dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] sole sedative [MeSH:C0036557] agent evolve method material ongoing quality [MeSH:C0034379] assurance process sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] review monthly protocol [MeSH:C0655632] [MeSH:C0655632] modify need analyze consecutive patient [MeSH:C0030705] receive dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] mri sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] april april result [MeSH:C4704700] -min loading dose dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] protocol [MeSH:C0655632] [MeSH:C0655632] increase microg kg infusion [MeSH:C0841792] rate increase microg kg h current sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] protocol [MeSH:C0655632] [MeSH:C0655632] progressively increase rate successful sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] able complete imaging [MeSH:C0887832] dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] p reduce requirement adjuvant [MeSH:C0674607] pentobarbital event sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] failure dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] decrease mean recovery min p dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] associate [MeSH:C0004083] [MeSH:C0004083] incidence [MeSH:C0021149] bradycardia concomitant [MeSH:C0152203] mean arterial blood pressure [MeSH:C0005823] age-adjusted normal range oxygen saturation [MeSH:C0483415] high dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] high dose provide adequate sedation [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] [MeSH:C0079159] pediatric [MeSH:C0237433] [MeSH:C0237433] mri study use high dose dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] associate [MeSH:C0004083] [MeSH:C0004083] decrease heart rate [MeSH:C0018810] blood pressure [MeSH:C0005823] outside established awake norm deviation generally norm associate [MeSH:C0004083] [MeSH:C0004083] adverse sequela dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] useful sole sedative [MeSH:C0036557] pediatric [MeSH:C0237433] [MeSH:C0237433] mri,neurological|cardiovascular
epilepsy detox [MeSH:C0014544] dynamic [MeSH:C0058836],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] diabete kidney method [MeSH:C0022646] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational gamma glutamyl transferase fatty liver assessment result improve outcome [MeSH:C0206277] relevance [MeSH:C2826293],hepatorenal
heart failure [MeSH:C0018801] cardiovascular lens [MeSH:C0007220],design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin stroke [MeSH:C0038454] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] pe coronary artery disease [MeSH:C1956346] result improve disease management [MeSH:C0039798] stenosis [MeSH:C1261287] correlation healthcare advancement,cardiovascular
increase sulfation [MeSH:C0037657] decrease 7alpha-hydroxylation deoxycholic acid ethinyl estradiol-induced cholestasis rat [MeSH:C0034721],deoxycholic acid [MeSH:C0011479] [MeSH:C0011479] conjugation [MeSH:C0009757] transport capacity [MeSH:C0042834] metabolism compare ethinyl estradiol [MeSH:C0015011] [MeSH:C0015011]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] find low capacity [MeSH:C0042834] transport deoxycholic acid [MeSH:C0011479] [MeSH:C0011479] taurodeoxycholic acid [MeSH:C0011479] [MeSH:C0039360] [MeSH:C0011479] decrease ethinyl estradiol [MeSH:C0015011] [MeSH:C0015011] -4c sodium deoxycholate infusion 4c biliary bile acid [MeSH:C0005390] [MeSH:C0005388] secretion increase bile flow significantly ethinyl estradiol [MeSH:C0015011] [MeSH:C0015011]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] ethinyl estradiol [MeSH:C0015011] [MeSH:C0015011]-treated animal [MeSH:C0003062] [MeSH:C0003062] excrete significantly 4c taurocholic acid [MeSH:C0039358] animal [MeSH:C0003062] [MeSH:C0003062] consistent impairment [MeSH:C1384666] 7alpha-hydroxylation taurodeoxycholic acid [MeSH:C0011479] [MeSH:C0039360] [MeSH:C0011479] ethinyl estradiol [MeSH:C0015011] [MeSH:C0015011] impair conjugation [MeSH:C0009757] deoxycholic acid [MeSH:C0011479] [MeSH:C0011479] increase sulfation taurodeoxycholic acid [MeSH:C0011479] [MeSH:C0039360] [MeSH:C0039360] [MeSH:C0011479] control nearly p result consistent hypothesis [MeSH:C3179072] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] poor tolerance deoxycholic acid [MeSH:C0011479] [MeSH:C0011479] certain specie furthermore rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] convert deoxycholic acid [MeSH:C0011479] [MeSH:C0011479] poor choleretic [MeSH:C0008362] taurocholic acid [MeSH:C0039358] [MeSH:C0039358] good choleretic [MeSH:C0008362] conversion [MeSH:C0017259] impaired [MeSH:C0020580] ethinyl estradiol [MeSH:C0015011] [MeSH:C0015011] sulfation important alternate pathway [MeSH:C0282655] excretion [MeSH:C1373187] potentially harmful bile acid [MeSH:C0005390],hepatorenal
cognitive connection [MeSH:C0009240] cancer bell palsy [MeSH:C0376175],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] multiple sclerosis [MeSH:C0026769] mechanism method randomized control cancer [MeSH:C1096777] patient [MeSH:C0030705] assess ataxia [MeSH:C0004134] meningitis [MeSH:C0025289] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication optimization [MeSH:C0376695],neurological
stroke [MeSH:C0038454] renal cell carcinoma [MeSH:C0007134] organ [MeSH:C0029250] interplay,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] metformin [MeSH:C0025598] cancer participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] transaminase hepatoma [MeSH:C0002594] result decrease mortality [MeSH:C0026565] rate nephron correlation safety consideration,hepatorenal
bladder cancer [MeSH:C0005684] marker angina pectoris [MeSH:C0002962],investigate [MeSH:C0035173] statin effect hypertension [MeSH:C0020538] ventricular fibrillation method [MeSH:C0042510] elderly patient undergo prospective defibrillator heart rate assessment result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],cardiovascular|oncological
acute [MeSH:C0184567] effect n- -propylpentanoyl urea [MeSH:C0041942] hippocampal [MeSH:C0228249] amino acid neurotransmitter [MeSH:C0027908] pilocarpine-induced seizure rat [MeSH:C0034721],present aim investigate [MeSH:C0035173] anticonvulsant activity [MeSH:C0003286] [MeSH:C0003286] effect hippocampal [MeSH:C0228249] [MeSH:C0228249] amino acid [MeSH:C0002520] neurotransmitter [MeSH:C0027908] [MeSH:C0027908] glutamate aspartate [MeSH:C0004002] [MeSH:C0004002] glycine gaba [MeSH:C0016904] n- -propylpentanoyl urea [MeSH:C0041942] vpu [MeSH:C0079431] [MeSH:C0079431] comparison [MeSH:C0871382] parent compound valproic acid vpa vpu [MeSH:C0079431] [MeSH:C0079431] potent vpa exhibit median effective [MeSH:C5392218] dose ed mg kg protect rat [MeSH:C0034721] pilocarpine [MeSH:C0031923]-induced seizure corresponding vpa mg kg vivo microdialysis [MeSH:C0206056] demonstrat [MeSH:C0034721]e intraperitoneal administrat [MeSH:C0034721]ion pilocarpine [MeSH:C0031923] induce pronounced increment hippocampal [MeSH:C0228249] [MeSH:C0228249] glutamate aspartate [MeSH:C0004002] [MeSH:C0004002] observe glycine gaba [MeSH:C0016904] pretreatment [MeSH:C0376495] vpu [MeSH:C0079431] [MeSH:C0079431] mg kg vpa mg kg completely abolish pilocarpine [MeSH:C0031923]-evoked increase extracellular [MeSH:C3850090] glutamate aspartate [MeSH:C0004002] [MeSH:C0004002] addition statistically reduction [MeSH:C1827449] [MeSH:C1827449] observe gaba glycine [MeSH:C0016904] drastic reduction [MeSH:C1827449] [MeSH:C1827449] glutamate aspartate [MeSH:C0004002] [MeSH:C0004002] base vpu [MeSH:C0079431] [MeSH:C0079431] vpa protect animal [MeSH:C0003062] [MeSH:C0003062] pilocarpine [MeSH:C0031923]-induced seizure suggest reduction [MeSH:C1827449] [MeSH:C1827449] inhibitory [MeSH:C0167957] amino acid [MeSH:C0002520] neurotransmitter [MeSH:C0027908] [MeSH:C0027908] comparat [MeSH:C0034721]ively minor offset pronounced reduction [MeSH:C1827449] [MeSH:C1827449] glutamate aspartate [MeSH:C0004002] [MeSH:C0004002] like vpa vpu [MeSH:C0079431] [MeSH:C0079431] drastically reduce pilocarpine [MeSH:C0031923]-induced increase glutamate aspartate [MeSH:C0004002] [MeSH:C0004002] account partly anticonvulsant activity [MeSH:C0003286] [MeSH:C0003286] observe pilocarpine [MeSH:C0031923]-induced seizure experimental [MeSH:C0016998] animal [MeSH:C0003062] [MeSH:C0003062] mechanism report investigate [MeSH:C0035173],neurological
molecular basis long chain acyl-coa dehydrogenase deficiency israeli [MeSH:C3887523] patient [MeSH:C0030705] identification complex mutant allele p65l k27q mutation [MeSH:C0026882] exonic mutation [MeSH:C0026882] [MeSH:C0026882] cause exon skipping,long chain acyl-coa dehydrogenase vlcad [MeSH:C0065170] deficiency [MeSH:C3887523] [MeSH:C3887523] life-threatening disorder mitochondrial fatty acid beta-oxidation [MeSH:C3658275] identify novel mutation [MeSH:C0026882] [MeSH:C0026882] unrelated patient [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe childhood form vlcad [MeSH:C0065170] deficiency [MeSH:C3887523] early onset high mortality immunoblot reveal vlcad [MeSH:C0065170] protein [MeSH:C0065170] undetectable patient [MeSH:C0030705] [MeSH:C0030705] normal-size vlcad [MeSH:C0065170] protein [MeSH:C0065170] aberrant form vlcad [MeSH:C0065170] 4kda small [MeSH:C0751984] detect expect null mutation [MeSH:C0026882] [MeSH:C4505108] [MeSH:C0026882] find patient [MeSH:C0030705] [MeSH:C0030705] homozygous [MeSH:C0019904] frameshift mutation [MeSH:C0026882] [MeSH:C0026882] del bp homozygous [MeSH:C0019904] nonsense mutation [MeSH:C0026882] [MeSH:C0026882] 5c s22x homozygous [MeSH:C0019904] complex mutant allele contain alteration include 4c transition p65l 9a c transversion k27q case p65l amino acid [MeSH:C0002520] reduce enzyme activity [MeSH:C0243102] [MeSH:C0243102] nucleotide result exon skipping k27q mutation [MeSH:C0026882] [MeSH:C0026882] drastic effect enzyme activity [MeSH:C0243102] [MeSH:C0243102] verify event vivo splicing experiment transient expression mutant cdna [MeSH:C0006556] p65l mutation [MeSH:C0026882] [MeSH:C0026882] locate basis upstream splice donor site intron [MeSH:C0021920] example exonic mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] affect exon-splicing,cardiovascular|hepatorenal
liver function [MeSH:C0023901] prostate cancer [MeSH:C0376358],hypothesis statin improve heart disease [MeSH:C0018799] outcome chronic kidney disease pathway method [MeSH:C1561643] observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure wilm tumor cholangiocarcinoma [MeSH:C0206698] result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],hepatorenal
hepatitis ast organ interplay,randomized control examine [MeSH:C1096777] ace inhibitor hypertension [MeSH:C0003015] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include liver transplant [MeSH:C0023911] interstitial nephritis [MeSH:C0027707] anuria method participant [MeSH:C1708335] include result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
bile duct hamartoma [MeSH:C0018552] occur association [MeSH:C0004083] long-term [MeSH:C0023977] danazol [MeSH:C0010961],report case bile duct [MeSH:C0005400] hamartoma [MeSH:C0018552] develop long-term [MeSH:C0023977] danazol [MeSH:C0010961] patient [MeSH:C0030705] close follow-up [MeSH:C3899107] preferably periodic [MeSH:C0031068] ultrasound examination liver develop liver mass [MeSH:C0023884] non-specific feature imaging appearance biopsy [MeSH:C0005558] way achieve definitive diagnosis [MeSH:C0011900],hepatorenal
understand molecular basis fragile x syndrome [MeSH:C0039082],fragile x [MeSH:C0016667] syndrome [MeSH:C0016667] common form inherit mental [MeSH:C0020021] retardation [MeSH:C3714756] mainly cause massive expansion [MeSH:C0196940] [MeSH:C0196940] cgg triplet repeat [MeSH:C0282537] located -untranslated region fragile x [MeSH:C0016667] mental [MeSH:C0020021] retardation [MeSH:C3714756]- fmr1 gene [MeSH:C1506924] [MeSH:C1506924] patient [MeSH:C0030705] fragile x [MeSH:C0016667] syndrome [MeSH:C0016667] expand cgg triplet repeat [MeSH:C0282537] hypermethylate expression fmr1 gene [MeSH:C1506924] [MeSH:C1506924] repress lead absence fmr1 protein fmrp [MeSH:C0118036] subsequent mental [MeSH:C0020021] retardation [MeSH:C3714756] fmrp rna-binding protein shuttle nucleus cytoplasm protein [MeSH:C0010834] implicate protein translation [MeSH:C0597295] find associate polyribosome [MeSH:C0032592] rough endoplasmic reticulum [MeSH:C0014239] discuss recent progress understand molecular mechanism cgg repeat expansion [MeSH:C0196940] [MeSH:C0196940] physiological function [MeSH:C0237873] fmrp study help illuminate molecular basis general class human [MeSH:C0086418] disease trinucleotide repeat expansion [MeSH:C0524894] [MeSH:C0196940] [MeSH:C0196940] provide avenue understand aspect human [MeSH:C0086418] cognition intelligence [MeSH:C0021704],neurological
blood vessel connection [MeSH:C0005847] breast cancer [MeSH:C0006142],prospective examine metformin [MeSH:C0025598] stroke [MeSH:C0038454] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include heart congestive heart failure [MeSH:C0018802] dementia [MeSH:C0497327] method participant [MeSH:C1708335] include result well quality life measure implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
cutting-edge nephritis angina pectoris,cross-sectional examine [MeSH:C0010362] aspirin hypertension [MeSH:C0020538] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include urea liver transplant [MeSH:C0023911] liver method [MeSH:C0023884] participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication care improvement,hepatorenal
acetaminophen-induced hypotension [MeSH:C0020650],year widespread use acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] show remarkably safe medication [MeSH:C0033045] therapeutic dosage [MeSH:C0087111] potential acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] produce cardiovascular [MeSH:C0007220] toxicity [MeSH:C0040539] low acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] demonstrate produce symptom anaphylaxis [MeSH:C0002792] include hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] sensitive [MeSH:C1017675] individual article describe critically ill [MeSH:C0010340] patient [MeSH:C0030705] [MeSH:C0030705] transient episode hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] reproducibly develop administration [MeSH:C0001554] acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] symptom allergic reaction [MeSH:C1527304] clinically detectable hypotensive episode severe require vasopressor administration [MeSH:C0001554] [MeSH:C0001554] report illustrate need clinician [MeSH:C0028654] consider acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] patient [MeSH:C0030705] [MeSH:C0030705] hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] unknown origin,neurological|cardiovascular
thromboembolism cancer [MeSH:C0040038] vascular [MeSH:C0221214] insight,hypothesis statin improve heart disease [MeSH:C0018799] outcome heart failure pathway method prospective trial adult population [MeSH:C0032659] measure ventricular tachycardia blood vessel [MeSH:C0042514] result superior efficacy [MeSH:C5690761] healthcare advancement,cardiovascular
enhance [MeSH:C0014290] bradycardia [MeSH:C0428977] induce beta-adrenoceptor antagonist [MeSH:C0001645] rat [MeSH:C0034721] pretreate isoniazid [MeSH:C0022209],high dose isoniazid [MeSH:C0022209] [MeSH:C0022209] increase hypotension [MeSH:C0020649] induce vasodilator [MeSH:C0042402] accompany reflex tachycardia bradycardia [MeSH:C0428977] [MeSH:C0039231] interaction [MeSH:C0007582] attribute decrease synthesis brain gamma-aminobutyric acid gaba [MeSH:C0016904] present possible enhancement isoniazid [MeSH:C0022209] [MeSH:C0022209] bradycardia [MeSH:C0428977] induce beta-adrenoceptor antagonist [MeSH:C0001645] determine rat [MeSH:C0034721] [MeSH:C0034721] anaesthetise chloralose-urethane isoniazid [MeSH:C0022209] [MeSH:C0022209] significantly increase bradycardia [MeSH:C0428977] propranolol [MeSH:C0033497] pindolol [MeSH:C0031937] labetalol [MeSH:C0022860] atenolol [MeSH:C0004147] clonidine [MeSH:C0009014] hexamethonium [MeSH:C0062637] carbachol enhancement observe rat [MeSH:C0034721] [MeSH:C0034721] pretreate methylatropine [MeSH:C0066332] previously vagotomised [MeSH:C0394374] result compatible interference [MeSH:C1136031] isoniazid [MeSH:C0022209] [MeSH:C0022209] gabaergic inhibition cardiac parasympathetic tone interference [MeSH:C1136031] exert centrally possibly nucleus ambiguus [MeSH:C0152400] peripherally sinus node,neurological
anticoagulant ventricular tachycardia brain [MeSH:C0042514] insight,hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve neuropathy [MeSH:C0015464] chorea method conduct longitudinal evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine huntington disease [MeSH:C0020179] parameter result superior efficacy care improvement [MeSH:C2936612],neurological
case report [MeSH:C0684224] acute [MeSH:C0184567] unintentional carbachol [MeSH:C0006945] intoxication [MeSH:C0043049],introduction [MeSH:C0033268] intoxication [MeSH:C0043049] carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] muscarinic cholinergic [MeSH:C0242893] receptor [MeSH:C1318050] agonist rare report interesting case investigate [MeSH:C0035173] near fatal poison method son -year-old male [MeSH:C0086582] discover newspaper [MeSH:C0027989] report state success plant extract alzheimer disease mode action say comparable synthetic compound carbamylcholin [MeSH:C0600175] carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] buy g carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] pure substance pharmacy father administer mg carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] concentration [MeSH:C0311432] serum [MeSH:C0229671] urine [MeSH:C0042036] hospital admission [MeSH:C0001573] analyse hplc-mass spectrometry result minute oral administration [MeSH:C0001563] develop nausea sweating hypotension finally collapse bradycardia [MeSH:C0428977] cholinergic [MeSH:C0242893] symptom asystole [MeSH:C0018790] occur initial cardiopulmonary resuscitation [MeSH:C0007203] immediate adrenaline [MeSH:C0014563] [MeSH:C0014563] epinephrine [MeSH:C0014563] atropine [MeSH:C0004259] [MeSH:C0004259] furosemide [MeSH:C0016860] successful hospital admission [MeSH:C0001573] blood pressure intubate [MeSH:C0005823] bradyarrhythmic mmhg sign [MeSH:C0428977] hyperhidrosis [MeSH:C0020458] hypersalivation bronchorrhoea severe miosis electrocardiographic [MeSH:C0180600] atrio-ventricular dissociation high dose atropine [MeSH:C0004259] [MeSH:C0004259] mg hour adrenaline [MeSH:C0014563] [MeSH:C0014563] dopamine [MeSH:C0013030] necessary extubate [MeSH:C0553891] [MeSH:C0553891] week later increase dyspnoea bronchospasm necessitate reintubation respiratory insufficiency [MeSH:C0035229] worsen proteus mirabilis infection [MeSH:C0033701] severe bronchoconstriction [MeSH:C0079043] week later extubate [MeSH:C0553891] [MeSH:C0553891] day [MeSH:C0011017] [MeSH:C0011017] later transfer peripheral ward die probably heart failure [MeSH:C0035078] [MeSH:C0018801] serum [MeSH:C0229671] sample second day [MeSH:C0011017] [MeSH:C0011017] contain mg l carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] respectively corresponding urine [MeSH:C0042036] concentration [MeSH:C0311432] [MeSH:C0311432] amount mg l case start medium report popular newspaper [MeSH:C0027989] initiate publish peer-reviewed herbal [MeSH:C0376667] involve human [MeSH:C0086418] failure [MeSH:C0035078] case history [MeSH:C0019664] medical examination [MeSH:C0025082] analytical determination carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] plasma [MeSH:C0032105] urine [MeSH:C0042036] develop analyse carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] concentration [MeSH:C0311432] exceed suppose serum [MeSH:C0229671] result therapeutic dose factor [MeSH:C0087111] especially old patient intensivist consider intoxication [MeSH:C0043049] cholinergic [MeSH:C0242893] cause acute cardiovascular failure [MeSH:C0035078],neurological|cardiovascular|hepatorenal
acute interstitial nephritis [MeSH:C0027707] nicergoline [MeSH:C0028008] sermion [MeSH:C0878043],report case acute interstitial nephritis nicergoline [MeSH:C0028008] [MeSH:C0028008] [MeSH:C0028008] [MeSH:C0028008] sermion [MeSH:C0878043] -year-old admit hospital fever acute renal failure [MeSH:C0035078] admission [MeSH:C0030673] [MeSH:C0030673] take nicergoline [MeSH:C0028008] [MeSH:C0028008] [MeSH:C0028008] [MeSH:C0028008] bendazac [MeSH:C0053097] lysine retinal vein occlusion [MeSH:C0035328] ophthalmologic department experience intermittent fever skin rash admission [MeSH:C0030673] [MeSH:C0030673] symptom e [MeSH:C3839861] arthralgia fever [MeSH:C0003862] laboratory finding [MeSH:C0022877] e eosinophilia [MeSH:C0014457] renal failure [MeSH:C0035078] suggest confirm pathologic [MeSH:C0030664] finding renal biopsy [MeSH:C0005558] lymphocyte transformation test [MeSH:C0024262] demonstrate positive nicergoline [MeSH:C0028008] [MeSH:C0028008] [MeSH:C0028008] [MeSH:C0028008] consist withdrawal nicergoline [MeSH:C0028008] [MeSH:C0028008] [MeSH:C0028008] [MeSH:C0028008] intravenous [MeSH:C0085297] methylprednisolone renal function [MeSH:C0025815] completely recover knowledge report [MeSH:C0376554] nicergoline [MeSH:C0028008] [MeSH:C0028008] [MeSH:C0028008] [MeSH:C0028008]-associated,neurological|hepatorenal
human [MeSH:C0086418] complement factor [MeSH:C0033453] h deficiency [MeSH:C1623416] associate [MeSH:C0004083] hemolytic uremic syndrome [MeSH:C0019061],report case deficiency [MeSH:C1623416] [MeSH:C1623416] human [MeSH:C0086418] complement regulatory protein factor [MeSH:C0033453] [MeSH:C0033453] h fh context acute renal disease [MeSH:C0001314] case observe child [MeSH:C0008059] [MeSH:C0008059] present idiopathic hemolytic uremic syndrome hus [MeSH:C0019061] child [MeSH:C0008059] [MeSH:C0008059] exhibit homozygous deficiency [MeSH:C1623416] characterize absence [MeSH:C0270823] -kd form factor [MeSH:C0033453] h presence immunoblotting [MeSH:C0020985] -kd factor [MeSH:C0033453] h-like protein fhl- fh-related protein fhr band southern blot pcr dna homozygous deficiency [MeSH:C1623416] rule presence large deletion [MeSH:C0017260] fh gene underlie defect deficiency [MeSH:C1623416] [MeSH:C1623416] child [MeSH:C0008059] [MeSH:C0008059] present heterozygous deficiency [MeSH:C1623416] exhibit normal immunoblotting [MeSH:C0020985] pattern protein fh family factor [MeSH:C0033453] h deficiency [MeSH:C1623416] complement deficiency [MeSH:C0272242] [MeSH:C1623416] associate hus [MeSH:C0004083] observation [MeSH:C0302523] suggest role fh fh receptor pathogenesis [MeSH:C0699748] idiopathic hus,hepatorenal
leukemia convulsion explore neural pathway [MeSH:C0027792],question statin affect hypertension [MeSH:C0020538] congestive heart failure [MeSH:C0018802] mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess tremor atherosclerosis [MeSH:C0004153] result improve disease management [MeSH:C0039798] implication relevance,neurological|cardiovascular
cerebellar [MeSH:C0007765] pattern leukemia patient [MeSH:C0030705],stroke [MeSH:C0038454] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve brain dystonia method conduct observational [MeSH:C0302523] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine guillain-barre syndrome [MeSH:C0018378] parameter result decrease mortality rate [MeSH:C0205848] healthcare advancement,neurological
brain map [MeSH:C0006104] multiple sclerosis insight,diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve cerebrovascular epilepsy method conduct longitudinal [MeSH:C0023981] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine pituitary adenoma [MeSH:C0032000] parameter result improvement primary endpoint need investigation [MeSH:C0035173],neurological
pharmacokinetic study [MeSH:C4084975] patient [MeSH:C0030705] cimetidine-associated mental confusion,case cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783]-associated mental confusion [MeSH:C0009676] report order syndrome investigate [MeSH:C0035173] change mental status correlate serum concentration [MeSH:C0311432] renal hepatic function patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] moderate severe change patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] renal liver dysfunction p cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] trough-concentration [MeSH:C0311432] microgram [MeSH:C0376691] ml p severity change increase trough-concentration [MeSH:C0311432] rise patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lumbar puncture [MeSH:C0553794] cerebrospinal fluid [MeSH:C0007806] serum ratio [MeSH:C0229671] cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] concentration [MeSH:C0311432] indicate cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] pass blood-brain barrier [MeSH:C0005854] raise possibility change blockade [MeSH:C0027741] histamine [MeSH:C0019588] h2-receptor central nervous system [MeSH:C3714787] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] likely raise trough-concentration [MeSH:C0311432] mental confusion [MeSH:C0009676] severe renal hepatic dysfunction [MeSH:C0031847] closely observe give reduce dose cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783],neurological|hepatorenal
regurgitation connection cardiomyopathy,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome brain pathway method retrospective trial adult [MeSH:C0001675] population measure myocardial tachycardia [MeSH:C0039231] result improve disease management [MeSH:C0039798] optimization [MeSH:C0376695],neurological|cardiovascular
duchenne muscular dystrophy myotonic dystrophy [MeSH:C0013264],report [MeSH:C0684224] identify myotonic dystrophy duchenne muscular dystrophy [MeSH:C0013264] dmd [MeSH:C1437024] family propositus strong history myotonic dystrophy [MeSH:C0027126] intrafamilial pathological [MeSH:C0030660] expansion [MeSH:C0196940] responsible ctg repeat mildly affect mother [MeSH:C0026591] repeat normal repeat severely affect son repeat sister repeat propositus isolate case duchenne muscular dystrophy [MeSH:C0013264] marked dystrophin [MeSH:C0079259] deficiency muscle biopsy ambulatory post age myotonic dystrophy [MeSH:C0027126] interfere extent progression duchenne dystrophy [MeSH:C0013264] interpretation [MeSH:C0010998] possible percent dystrophin [MeSH:C0079259] revertant fiber observe immunohistochemistry [MeSH:C0021044] sufficient ameliorate typical dmd [MeSH:C1437024] severity present somatic mosaic pathophysiological [MeSH:C0031847] interaction [MeSH:C0007582] unlinked disorder [MeSH:C0040188] discuss histopathological [MeSH:C0030660] level [MeSH:C0018759],neurological
viracept [MeSH:C0525004] irregular [MeSH:C0156404] heartbeat [MeSH:C0232117] warn,doctor boston warn protease inhibitor [MeSH:C0033607] viracept [MeSH:C0525004] [MeSH:C0525004] cause irregular heart beat know bradycardia [MeSH:C0428977] people [MeSH:C5690824] hiv bradycardia [MeSH:C0428977] [MeSH:C0428977] occur -year-old male [MeSH:C0086582] viracept [MeSH:C0525004] [MeSH:C0525004] combination anti-hiv drug symptom cease switch drug combination,neurological|cardiovascular
cardiomyopathy breast cancer [MeSH:C0878544] oncological odyssey,cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve multiple myeloma [MeSH:C0027015] carcinogen method conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine stem cell transplant [MeSH:C1504389] parameter result favorable safety profile [MeSH:C0036043] need investigation [MeSH:C0035173],oncological
severe complication [MeSH:C1171258] antianginal drug therapy [MeSH:C0013216] identify poor metabolizer metoprolol [MeSH:C0025859] propafenone [MeSH:C0033429] diltiazem [MeSH:C0012373] sparteine [MeSH:C0037760],-year-old suffer coronary artery disease [MeSH:C1956346] admit ccu shock [MeSH:C0036974] iii av block [MeSH:C5197800] severe hypotension impairment ventricular function [MeSH:C0080309] week prior admission [MeSH:C0030673] therapy standard dose [MeSH:C2936643] metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] mg mg b initiate day [MeSH:C0011017] admission [MeSH:C0030673] diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] mg b prescribe addition analysis blood sample reveal unusually high plasma [MeSH:C0032105] concentration metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] great ng ml diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] ng ml recover week follow discontinuation antianginal therapy month later expose single dose metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] propafenone [MeSH:C0033429] receive drug [MeSH:C0013227] [MeSH:C0013227] past sparteine [MeSH:C0037760] probe [MeSH:C0037760] debrisoquine [MeSH:C0011082] [MeSH:C0011082] sparteine [MeSH:C0037760] type polymorphism [MeSH:C0032529] [MeSH:C0032529] oxidative drug [MeSH:C0013227] [MeSH:C0013227] metabolism [MeSH:C0025519] find poor metabolizer drug [MeSH:C0013227] [MeSH:C0013227] indicate metabolism [MeSH:C0025519] genetic patient [MeSH:C0030705] [MeSH:C0030705] belong poor-metabolizer phenotype [MeSH:C0031437] sparteine [MeSH:C0037760] debrisoquine [MeSH:C0011082] [MeSH:C0011082] polymorphism [MeSH:C0032529] [MeSH:C0032529] drug [MeSH:C0013227] [MeSH:C0013227] metabolism [MeSH:C0025519] constitute german population [MeSH:C0032659] experience adverse drug [MeSH:C0013227] [MeSH:C0013227] reaction treat standard dose [MeSH:C2936643] drug [MeSH:C0013227] [MeSH:C0013227] coadministration frequently drug [MeSH:C0013227] [MeSH:C0013227] expect especially harmful subgroup patient [MeSH:C0030705],cardiovascular
ventricular fibrillation lymphoma vascular [MeSH:C0042510] insight,assess efficacy [MeSH:C5690761] aspirin [MeSH:C0004057] [MeSH:C0004057] dementia [MeSH:C0497327] focus stroke [MeSH:C0038454] smooth muscle method [MeSH:C1267092] diabetic [MeSH:C1263960] patient [MeSH:C0030705] randomized [MeSH:C1096777] receive aspirin [MeSH:C0004057] [MeSH:C0004057] placebo [MeSH:C0032041] myocardial infarction [MeSH:C0027051] monitoring [MeSH:C0005517] result improvement primary endpoint optimization [MeSH:C0376695],cardiovascular
heart function [MeSH:C0018803] colorectal cancer [MeSH:C0009402],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] atrium method cancer patient [MeSH:C0030705] undergo randomized control diastolic mitral valve assessment result well quality life measure healthcare advancement,cardiovascular
vein atrial fibrillation vascular [MeSH:C0004238] insight,question [MeSH:C0600648] ace inhibitor affect diabete mitral valve mechanism method retrospective [MeSH:C0035363] elderly patient assess tricuspid valve heart attack [MeSH:C0040960] result well quality life measure implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
protection [MeSH:C0524828] amphetamine-induced neurotoxicity [MeSH:C0235032] striatal dopamine neuron [MeSH:C1512035] rodent [MeSH:C0035804] ly2 excitatory amino acid antagonist [MeSH:C0242910],ly2 3sr 4ar 6sr 8ars-- phosphonomethyl decahydr oisoquinoline-- carboxylic acid [MeSH:C0007066] describe potent antagonist [MeSH:C0033607] n-methyl-d-aspartate nmda subtype glutamate receptor ability antagonize prolonged depletion [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] dopamine striatum amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] iprindole [MeSH:C0022057]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] report single mg kg p dose -amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] hemisulfate [MeSH:C0033295] give rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] pretreate iprindole [MeSH:C0022057] result persistent [MeSH:C0026205] depletion [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] dopamine striatum week later prolonged depletion [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] dopamine striatum antagonize dizocilpine [MeSH:C0079245] mk- non-competitive antagonist [MeSH:C0033607] nmda receptor ly2 competitive antagonist [MeSH:C0033607] nmda receptor protective effect [MeSH:C4277511] ly2 dose-dependent maximum mgkg p mg kg dose ly2 effect [MeSH:C4277511]ive antagonize depletion [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] dopamine striatum give long hr prior amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] give hr prior amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] depletion [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] dopamine striatum antagonize ly2 give injection amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] ly2 protect give hr give hr amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] prolonged depletion [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] [MeSH:C3494379] dopamine striatum mouse [MeSH:C0026809] give multiple injection methamphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] antagonize dose-dependently completely ly2 strengthen evidence neurotoxic effect [MeSH:C4277511] amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] related compound nigrostriatal dopamine neuron [MeSH:C1512035] involve nmda receptor ly2 nmda receptor [MeSH:C0080093] antagonist [MeSH:C0033607] long-lasting vivo effect [MeSH:C4277511] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721],neurological
dementia [MeSH:C0497327] [MeSH:C0497327] dementia [MeSH:C0497327] [MeSH:C0497327] exploring neural pathway [MeSH:C0027792],longitudinal examine [MeSH:C0023981] statin [MeSH:C0360714] diabete adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include ectopic beat [MeSH:C0033036] myocardium heart method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication healthcare advancement,neurological|cardiovascular
rhabdomyolysis hepatitis c virus [MeSH:C0035410] infected treat telaprevir [MeSH:C1876229] simvastatin [MeSH:C0074554],-year old man chronic hepatitis c virus infection [MeSH:C0524909] receive triple therapy [MeSH:C0039798] ribavirin [MeSH:C0035525] pegylated interferon [MeSH:C3491516] telaprevir [MeSH:C1876229] [MeSH:C1876229] receive simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] start antiviral therapy [MeSH:C0039798] admit hospital develop rhabdomyolysis [MeSH:C0035410] admission [MeSH:C0030673] simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] antiviral drug [MeSH:C0003451] discontinue toxicity [MeSH:C0040539] [MeSH:C0040539] drug-drug interaction [MeSH:C0687133] [MeSH:C0007582] [MeSH:C0687133] suspect creatine kinase [MeSH:C0010287] peak [MeSH:C0010287] iu l treat intravenous normal [MeSH:C0085297] saline renal function remain unaffected fourteen day [MeSH:C0011017] hospitalization [MeSH:C0019993] creatine kinase [MeSH:C0010287] return iu l discharge [MeSH:C0030685] telaprevir [MeSH:C1876229] [MeSH:C1876229] consider probable causative agent interaction [MeSH:C0007582] simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] accord drug interaction [MeSH:C0007582] probability scale interaction [MeSH:C0007582] inhibition [MeSH:C0027790] cyp3a4-mediated simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] clearance [MeSH:C5243473] simvastatin [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] plasma [MeSH:C0032105] concentration increase time statin [MeSH:C0040223] induce muscle [MeSH:C0026845] toxicity [MeSH:C0040539] [MeSH:C0040539] related concentration statin blood case [MeSH:C0005767] illustrate telaprevir [MeSH:C1876229] [MeSH:C1876229] statin susceptible relevant drug-drug interaction [MeSH:C0687133] [MeSH:C0007582] [MeSH:C0687133],hepatorenal
alzheimer disease pattern colorectal cancer [MeSH:C0009402] patient [MeSH:C0030705],question statin affect hypertension [MeSH:C0020538] defibrillator mechanism method retrospective [MeSH:C0035363] elderly patient assess myocardium [MeSH:C0027061] hypertrophic cardiomyopathy [MeSH:C0007194] result positive response implication safety [MeSH:C0036043] consideration,neurological|cardiovascular
carboplatin [MeSH:C0079083] toxic [MeSH:C1256754] effect peripheral nervous system [MeSH:C0206417] rat [MeSH:C0034721],striking carboplatin [MeSH:C0079083] advantage cbdca cisplatin cddp markedly reduce rate neurotoxic [MeSH:C0027934] effect [MeSH:C4277511] use cbdca higher-intensity schedule [MeSH:C0086960] association [MeSH:C0004083] neurotoxic [MeSH:C0027934] drug polychemotherapy [MeSH:C2717829] cause concern safety [MeSH:C0036043] respect peripheral [MeSH:C3658334] nervous system damage material method [MeSH:C0206417] different schedule [MeSH:C0086960] cbdca administration [MeSH:C0001554] mg kg mg kg p twice week time evaluate wistar rat [MeSH:C0034716] neurotoxic [MeSH:C0027934]ity assess behavioral tail-flick test [MeSH:C0683444] neurophysiological nerve conduction velocity tail [MeSH:C2982003] nerve morphological morphometrical analytical effect [MeSH:C4277511] result cbdca administration [MeSH:C0001554] induce dose-dependent peripheral [MeSH:C3658334] neurotoxic [MeSH:C0027934]ity pain perception nerve conduction velocity tail [MeSH:C2982003] significantly impaired particularly high-dose dorsal root ganglion sensory neuron [MeSH:C0017070] less extent satellite cell [MeSH:C0599856] show change induce cddp mainly affect nucleus nucleolus [MeSH:C0007609] ganglionic sensory neuron [MeSH:C0206429] amount platinum [MeSH:C0032207] detect dorsal root ganglion kidney cbdca conclusion cbdca neurotoxic [MeSH:C0027934] model type pathological change induce closely similar cause cddp probable neurotoxic [MeSH:C0027934]ity induce drug mechanism model combination drug [MeSH:C0013162] explore effect [MeSH:C4277511] cbdca peripheral [MeSH:C3658334] nervous system,neurological|hepatorenal
breakthrough acute kidney injury [MeSH:C2609414] finding heart failure [MeSH:C0018801],question statin affect hypertension [MeSH:C0020538] ggt mechanism method retrospective [MeSH:C0035363] elderly patient assess albumin cholecystitis [MeSH:C0008325] result improve disease management [MeSH:C0039798] implication relevance,hepatorenal
coronary hepatitis vascular insight,diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve artery atrial fibrillation method [MeSH:C0004238] conduct randomized control evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine embolism [MeSH:C0013922] parameter result positive response practice guideline [MeSH:C0936005],cardiovascular
dementia [MeSH:C0497327] myocardial infarction [MeSH:C0027051] cardiac connection,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] hypertension [MeSH:C0020538] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] ventricle blood pressure [MeSH:C0005823] result improve disease management [MeSH:C0039798] vein correlation therapeutic [MeSH:C0087111] innovation,cardiovascular
aberrant [MeSH:C0008519] splicing [MeSH:C0376437] phenylalanine hydroxylase [MeSH:C0031456] mrna major cause phenylketonuria [MeSH:C0031485] part southern europe [MeSH:C0037724],report mutation [MeSH:C0026882] phenylalanine hydroxylase [MeSH:C0031456] pah gene cause aberrant splicing [MeSH:C0376437] mrna tight association chromosomal haplotype [MeSH:C0018591] [MeSH:C0018591] high frequency [MeSH:C0019541] particular haplotype [MeSH:C0018591] [MeSH:C0018591] bulgaria italy turkey [MeSH:C0041400] appear frequent defect [MeSH:C0155017] pah gene cause classical phenylketonuria europe [MeSH:C0031485] mutation [MeSH:C0026882] g transition position intron pah gene bp upstream intron exon boundary activate cryptic splice site [MeSH:C1720838] result in-frame insertion [MeSH:C1512796] nucleotide exon exon [MeSH:C0015295] process mrna normal amount liver pah protein present homozygous [MeSH:C0019904] patient [MeSH:C0030705] catalytic activity detect loss enzyme activity probably cause conformational change [MeSH:C0033625] result insertion [MeSH:C1512796] additional amino acid gly-leu-gln normal sequence encode exon exon [MeSH:C0015295],hepatorenal
leukemia [MeSH:C0023418] lung cancer [MeSH:C0242379] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] [MeSH:C0035173] beta-blocker [MeSH:C0001645] stroke [MeSH:C0038454] participant [MeSH:C1708335] adult [MeSH:C0001675] population blood vessel [MeSH:C0005847] lung cancer [MeSH:C0242379] result improve disease management [MeSH:C0039798] septum [MeSH:C0752060] correlation [MeSH:C0010100] need investigation [MeSH:C0035173] [MeSH:C0035173],cardiovascular|oncological
chemotherapy [MeSH:C0013216] coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect heart disease [MeSH:C0018799] ovarian cancer [MeSH:C1140680] mechanism method longitudinal diabetic [MeSH:C0023981] patient [MeSH:C0030705] assess metastasis hypertensive result improve outcome implication care improvement,cardiovascular|oncological
survey [MeSH:C0038951] complication [MeSH:C1171258] indocyanine green angiography [MeSH:C0021234] japan [MeSH:C0022341],evaluate safety [MeSH:C0036043] indocyanine green [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] use fundus angiography [MeSH:C0002978] [MeSH:C0002978] method send questionnaire concern complication [MeSH:C1171258] indocyanine green [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] institution [MeSH:C0442681] [MeSH:C0442681] [MeSH:C0442681] japan select basis client [MeSH:C0008942] list topcon company manufacture indocyanine green [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] fundus camera result ophthalmologist [MeSH:C1704292] institution [MeSH:C0442681] [MeSH:C0442681] [MeSH:C0442681] respond reporting total indocyanine green [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] angiogram perform patient [MeSH:C0030705] june september angiography [MeSH:C0002978] [MeSH:C0002978] intradermal [MeSH:C0021881] intravenous indocyanine green [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] testing perform institution [MeSH:C0442681] [MeSH:C0442681] [MeSH:C0442681] patient [MeSH:C0030705] decision proceed angiography [MeSH:C0002978] [MeSH:C0002978] positive preangiographic testing dosage indocyanine green [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] angiography [MeSH:C0002978] [MeSH:C0002978] vary mg depend institution [MeSH:C0442681] [MeSH:C0442681] [MeSH:C0442681] case adverse reaction mild reaction nausea exanthema urtication itchiness urgency defecate require record case pain vein require case hypotension [MeSH:C0020649] hypotensive patient [MeSH:C0030705] require shock [MeSH:C0036974] conclusion comparison frequency [MeSH:C0376249] adverse reaction indocyanine green [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] previously report frequency [MeSH:C0376249] reaction fluorescein sodium indicate indocyanine green [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] [MeSH:C0021234] safe fluorescein use angiography [MeSH:C0002978] [MeSH:C0002978],neurological
upregulation [MeSH:C0041904] brain [MeSH:C0006104] expression p-glycoprotein [MeSH:C0242643] mrp2-deficient tr rat [MeSH:C0034721] [MeSH:C0034721] resemble seizure-induced up-regulation [MeSH:C0041904] drug efflux transporter normal rat [MeSH:C0034721] [MeSH:C0034721],multidrug resistance protein [MeSH:C0242643] mrp2 drug efflux transporter express predominantly apical domain hepatocyte express apical membrane brain [MeSH:C0006104] [MeSH:C0006104] capillary endothelial cell form blood-brain [MeSH:C0006104] [MeSH:C0006104] barrier [MeSH:C0005854] bbb mrp2 absent [MeSH:C0003076] [MeSH:C0003076] transport-deficient tr wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] mutant [MeSH:C1564139] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] strain [MeSH:C0080194] helpful define substrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e mrp2 compare tissue [MeSH:C0040300] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion functional activity compound mrp2-deficient rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] transport-competent wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] strat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]egy involvement mrp2 brain [MeSH:C0006104] [MeSH:C0006104] access antiepileptic drug [MeSH:C0003299] aed recently report phenytoin [MeSH:C0031507] substrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e mrp2 bbb drawback study genetically deficient rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] fact compensatory [MeSH:C0220808] change upregulation [MeSH:C0041904] transporter [MeSH:C0041904] occur prompt brain [MeSH:C0006104] [MeSH:C0006104] expression [MeSH:C0017262] p-glycoprotein [MeSH:C0242643] pgp major drug efflux transporter tissue [MeSH:C0040300] include bbb tr rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] compare nonmutant [MeSH:C1564139] wild-type wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] method expression [MeSH:C0017262] mrp2 pgp brain [MeSH:C0006104] [MeSH:C0006104] liver section tr rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] normal wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] determine immunohistochemistry [MeSH:C0021044] novel highly selective monoclonal mrp2 antibody [MeSH:C0443933] monoclonal pgp antibody [MeSH:C0443933] c2 [MeSH:C0003250] respectively result immunofluorescence staining [MeSH:C0282648] mrp2 antibody [MeSH:C0443933] find label high number microvessel [MeSH:C2350570] brain [MeSH:C0006104] [MeSH:C0006104] normal wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] labeling [MeSH:C0013191] absent [MeSH:C0003076] [MeSH:C0003076] tr rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] tr rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] exhibit up-regulation [MeSH:C0041904] pgp brain [MeSH:C0006104] [MeSH:C0006104] capillary endothelial cell compare wild-type control obvious upregulation [MeSH:C0041904] pgp observe liver section comparable overexpression [MeSH:C0017262] pgp bbb obtain pilocarpine-induced seizure [MeSH:C0036572] wild-type wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] experiment [MeSH:C0020123] systemic administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion pgp substrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e phenobarbital [MeSH:C0031412] selective pgp inhibitor tariquidar [MeSH:C0879444] tr rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] substantiate pgp functional compensate lack mrp2 bbb conclusion tr rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] indicate pgp play important role compensation mrp2 deficiency [MeSH:C1623416] bbb compensatory [MeSH:C0220808] mechanism [MeSH:C1524059] likely occur reduce injury [MeSH:C3263723] brain [MeSH:C0006104] [MeSH:C0006104] cytotoxic compound present substantiate concept mrp2 perform protective role bbb furthermore suggest tr rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] interesting tool consequence overexpression [MeSH:C0017262] pgp bbb access drug brain [MeSH:C0013227] [MeSH:C0006104] [MeSH:C0006104] need induce seizure [MeSH:C0036572] pgp-enhancing event,neurological|hepatorenal
gallstone [MeSH:C0242216] marker [MeSH:C0017393] chronic kidney disease [MeSH:C1561643],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] hemodialysis pathway method prospective trial cardiac patient measuring cholecystitis [MeSH:C0008325] primary sclerosing cholangitis [MeSH:C0566602] result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
lymphoma arterial [MeSH:C0024299] cardiac connection,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect heart disease [MeSH:C0018799] atrial fibrillation mechanism method randomized control cancer [MeSH:C1096777] patient [MeSH:C0030705] assess aortic aneurysm tricuspid valve [MeSH:C0149630] result enhance therapeutic response [MeSH:C0087111] implication healthcare advancement,cardiovascular
safety [MeSH:C0036043] transesophageal echocardiography [MeSH:C0206054] adult [MeSH:C0001675] multidisciplinary hospital [MeSH:C0030679],tee semi-invasive tool broadly utilization [MeSH:C0042153] associate sedative drug affect procedure [MeSH:C0184661] safety [MeSH:C0036043] [MeSH:C0036043] analyze aspect [MeSH:C0022433] tee safety [MeSH:C0036043] [MeSH:C0036043] associate use [MeSH:C0004083] midazolan [MeSH:C0026056] mz flumazenil [MeSH:C0016293] fl influence [MeSH:C0683549] [MeSH:C0683549] variable event rate prospective patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo tee mz associate moderate sedation [MeSH:C0079159] analyze follow event complication [MeSH:C1171258] relate topical anesthesia [MeSH:C0002903] mz use procedure [MeSH:C0184661] [MeSH:C0184661] uni- multivariate [MeSH:C0026777] analysis test [MeSH:C0026777] influence [MeSH:C0683549] [MeSH:C0683549] variable age sex [MeSH:C1522384] stroke myocardiopathy [MeSH:C0878544] mp duration test mitral regurgitation mr mz dose result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] yr male [MeSH:C0086582] finish examination [MeSH:C0376306] [MeSH:C0376306] mean dose mz fl mg mg respectively duration examination [MeSH:C0376306] [MeSH:C0376306] mean ejection fraction ef minute respectively mild hypoxia [MeSH:C0242184] [MeSH:C0242184] so2 common event patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present transient [MeSH:C0040704] hypoxia [MeSH:C0242184] [MeSH:C0242184] upper airway obstruction probe [MeSH:C0001883] introduction hypoxia [MeSH:C0242184] [MeSH:C0242184] cause mz use transient [MeSH:C0040704] hypotension sap 0mmhg occur multivariate [MeSH:C0026777] show severe mr mp ef high dose mz 5 mg associate event p ef mp severe mr factor associate event tee sedation [MeSH:C0079159] present low rate event severe event need interrupt examination [MeSH:C0376306] [MeSH:C0376306],cardiovascular
acute renal failure [MeSH:C0022660] patient [MeSH:C0030705] aid tenofovir [MeSH:C0384228] receive prolonged vancomycin [MeSH:C0042313] course [MeSH:C0449259] osteomyelitis [MeSH:C0029443],renal failure [MeSH:C0035078] develop prolonged course vancomycin [MeSH:C0042313] [MeSH:C0042313] therapy [MeSH:C0042313] patient [MeSH:C0030705] receive tenofovir [MeSH:C0384228] disoproxil fumarate antiretroviral regiman tenofovir [MeSH:C0384228] [MeSH:C1099776] implicate development [MeSH:C0243107] fanconi syndrome [MeSH:C0015624] renal insufficiency [MeSH:C1565489] effect proximal renal tubule [MeSH:C0022676] vancomycin [MeSH:C0042313] [MeSH:C0042313] nephrotoxicity infrequent coadministration [MeSH:C0001554] [MeSH:C0001554] nephrotoxic agent clinician [MeSH:C0028654] aware tenofovir [MeSH:C0384228] raise risk renal failure [MeSH:C0035078] prolonged administration [MeSH:C0001554] vancomycin [MeSH:C0042313] [MeSH:C0042313],hepatorenal
founder [MeSH:C0242918] brca1 [MeSH:C0259275] brca2 [MeSH:C0294028] mutation french canadian breast ovarian cancer family,identify mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] breast cancer [MeSH:C0006142]-susceptibility gene [MeSH:C0259275] brca1 [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] french canadian breast cancer [MeSH:C0006142] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] family [MeSH:C0015576] [MeSH:C0015576] quebec identify founder effect [MeSH:C0242918] examine independently ascertain french canadian cancer family [MeSH:C0015576] [MeSH:C0015576] distribution mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find family [MeSH:C0015576] [MeSH:C0015576] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] observe twice brca1 [MeSH:C0259275] c46 mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] common mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find follow brca2 [MeSH:C0294028] [MeSH:C0294028] 5delag mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find family [MeSH:C0015576] [MeSH:C0015576] identify mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] odd detection brca1 [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] 7x great case ovarian cancer [MeSH:C1140680] present family [MeSH:C0015576] [MeSH:C0015576] odd detection brca2 [MeSH:C0294028] [MeSH:C0294028] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] 3x great case breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] family [MeSH:C0015576] [MeSH:C0015576] interestingly presence breast cancer [MeSH:C0006142] case breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] family [MeSH:C0015576] [MeSH:C0015576],oncological
cancer hepatorenal syndrome [MeSH:C0019212] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] gfr method cancer patient [MeSH:C0030705] undergo cross-sectional ckd kidney stone assessment [MeSH:C0030198] result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],hepatorenal
hepatitis sinoatrial node [MeSH:C0037189] exploring neural pathway [MeSH:C0027792],stroke [MeSH:C0038454] affect elderly patient [MeSH:C0030705] worldwide particularly involve multiple sclerosis schwannoma method [MeSH:C0026769] conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine cerebral parameter result superior efficacy [MeSH:C5690761] need investigation [MeSH:C0035173],neurological|cardiovascular
mind matter alzheimer [MeSH:C0078939] disease norepinephrine [MeSH:C0028351],stroke [MeSH:C0038454] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve norepinephrine schwannoma method conduct cross-sectional evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine autonomic neuropathy [MeSH:C0271686] parameter result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],neurological
leukemia albumin [MeSH:C0001924] organ [MeSH:C0029250] interplay,dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve transaminase glomerulonephritis method [MeSH:C0017658] conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examining jaundice [MeSH:C0022346] parameter result positive response practice guideline [MeSH:C0936005],hepatorenal
stroke [MeSH:C0038454] liver transplant [MeSH:C0023911] organ [MeSH:C0029250] interplay,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] metformin [MeSH:C0025598] dementia [MeSH:C0497327] participant [MeSH:C1708335] cancer patient glomerulonephritis [MeSH:C0017658] liver fibrosis [MeSH:C0239946] result enhance therapeutic response [MeSH:C0087111] dialysis correlation care improvement [MeSH:C2936612],hepatorenal
coenzyme q1 [MeSH:C0077665] ameliorate acute cisplatin [MeSH:C0008838] nephrotoxicity mouse [MeSH:C0026809],nephroprotective effect coenzyme q1 [MeSH:C0077665] [MeSH:C0077665] investigate [MeSH:C0035173] mouse [MeSH:C0026809] acute [MeSH:C0184567] renal injury [MeSH:C2609414] induce single p injection [MeSH:C1828121] cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] mg kg coenzyme q1 [MeSH:C0077665] [MeSH:C0077665] mg kg p apply consecutive day [MeSH:C0011017] start cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] administration [MeSH:C0001554] [MeSH:C0001554] coenzyme q1 [MeSH:C0077665] [MeSH:C0077665] significantly reduce blood urea [MeSH:C0005845] nitrogen serum creatinine level increase cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] coenzyme q1 [MeSH:C0077665] [MeSH:C0077665] significantly compensate deficit [MeSH:C0233794] antioxidant [MeSH:C0003402] defense mechanism reduce glutathione superoxide dismutase activity [MeSH:C0038838] suppress [MeSH:C0017372] lipid peroxidation [MeSH:C0023775] decrease elevation tumor necrosis factor-alpha nitric oxide platinum ion concentration attenuate [MeSH:C0042211] reduction [MeSH:C1827449] selenium [MeSH:C0036581] zinc ion renal tissue [MeSH:C0040300] [MeSH:C0040300] result cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] administration [MeSH:C0001554] [MeSH:C0001554] histopathological renal tissue [MeSH:C0040300] [MeSH:C0040300] damage [MeSH:C0012860] mediate cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] ameliorate coenzyme q1 [MeSH:C0077665] [MeSH:C0077665] immunohistochemical reveal coenzyme q1 [MeSH:C0077665] [MeSH:C0077665] significantly decrease cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838]-induced overexpression inducible [MeSH:C1533698] nitric oxide synthase nuclear [MeSH:C0132555] factor-kappab caspase- p5 renal tissue [MeSH:C0040300] [MeSH:C0040300] conclude coenzyme q1 [MeSH:C0077665] [MeSH:C0077665] represent potential therapeutic option [MeSH:C0087111] protect acute [MeSH:C0184567] cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] nephrotoxicity commonly encounter practice [MeSH:C0024650],neurological|hepatorenal|oncological
cardiomyopathy hepatorenal lens [MeSH:C0878544],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect stroke [MeSH:C0038454] bun method [MeSH:C0005845] adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective hepatic proteinuria [MeSH:C0033687] assessment [MeSH:C0030198] result favorable safety profile need investigation [MeSH:C0035173],hepatorenal
hepatitis hepatitis [MeSH:C0019158] organ interplay,design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin cancer [MeSH:C0376358] participant [MeSH:C1708335] adult [MeSH:C0001675] population steatosis [MeSH:C0032659] bilirubin [MeSH:C0005437] result well quality life measure kidney [MeSH:C0022646] correlation cost-effectiveness [MeSH:C1511536] implication,hepatorenal
alpha-cardiac actin novel disease gene [MeSH:C0012634] familial hypertrophic cardiomyopathy [MeSH:C0949658],identify alpha-cardiac actin gene actc novel disease gene [MeSH:C0012634] [MeSH:C0012634] pedigree suffering familial hypertrophic cardiomyopathy [MeSH:C0949658] fhc linkage analysis [MeSH:C0796345] [MeSH:C0796345] exclude previously report fhc locus possible disease locus family study lod score [MeSH:C0023956] [MeSH:C0023956] vary linkage analysis [MeSH:C0796345] [MeSH:C0796345] plausible candidate gene highly express adult [MeSH:C0001675] human [MeSH:C0086418] heart identify actc likely disease gene [MeSH:C0012634] [MeSH:C0012634] show maximal lod score [MeSH:C0023956] [MeSH:C0023956] mutation actc [MeSH:C0026882] reveal ala25ser mutation exon close missense mutation [MeSH:C0599155] recently describe cause inherit form idiopathic dilate cardiomyopathy [MeSH:C1449563] idc,cardiovascular
ventricular tachycardia pattern alzheimer disease patient [MeSH:C0030705],dementia [MeSH:C0497327] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve basal ganglion [MeSH:C0004781] cerebral infarction method [MeSH:C0007785] conduct prospective evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine white matter [MeSH:C0682708] parameter result improvement [MeSH:C2936612] primary endpoint cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
chf myocardial infarction [MeSH:C0027051] vascular [MeSH:C0221214] insight,observational [MeSH:C0302523] examine beta-blocker diabete cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include venous insufficiency [MeSH:C0042485] hypotension method [MeSH:C0020649] participant [MeSH:C1708335] include result well quality life measure implication care improvement,cardiovascular
epilepsy [MeSH:C0014544] atherosclerosis [MeSH:C0004153] cardiac connection,design [MeSH:C0013171] longitudinal investigation statin [MeSH:C0360714] dementia participant [MeSH:C1708335] cancer patient [MeSH:C0030705] septum nephron [MeSH:C0027713] result improvement primary endpoint deep vein thrombosis [MeSH:C0149871] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,cardiovascular|hepatorenal
glioma pattern valvular heart disease [MeSH:C0018824] patient [MeSH:C0030705],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer parkinsonism mechanism method observational [MeSH:C0302523] adult population [MeSH:C0032659] assess dopamine radiculopathy [MeSH:C0700594] result well quality life measure implication practice guideline [MeSH:C0936005],neurological
novel insight heart failure [MeSH:C0018801] hepatic [MeSH:C0227525],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] cholestasis pathway method retrospective trial cancer patient [MeSH:C0030705] measuring aki azotemia [MeSH:C0242528] result improvement [MeSH:C2936612] primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
cancer code hepatitis [MeSH:C0345904] carcinogen [MeSH:C0007090],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve cancer outcome melanoma pathway method randomized control trial [MeSH:C1096777] cardiac patient measure hormone therapy [MeSH:C0039798] carcinogenesis result improve disease management [MeSH:C0039798] healthcare advancement,oncological
mind matter liver cirrhosis [MeSH:C0023890] cortical [MeSH:C0222661],cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve epilepsy limbic system method conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine glioma [MeSH:C0017638] parameter result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],neurological
cancer cellular liver cirrhosis [MeSH:C0023890],longitudinal [MeSH:C0023981] examine ace inhibitor hypertension [MeSH:C0003015] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include immunotherapy carcinoma stem cell transplant method participant [MeSH:C1708335] include result positive response implication optimization [MeSH:C0376695],oncological
synaptic story coronary artery disease medulloblastoma,retrospective [MeSH:C0035363] examine statin [MeSH:C0360714] dementia [MeSH:C0497327] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include sciatica [MeSH:C0036396] acetylcholine neural method [MeSH:C0001041] participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
stroke [MeSH:C0038454] heart block [MeSH:C0018794] cardiac connection,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome peripheral artery disease pathway method [MeSH:C1704436] cross-sectional trial [MeSH:C0010362] elderly patient measure blood pressure systolic [MeSH:C0005823] result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
reverse invert leave ventricular apical ballooning syndrome [MeSH:C1739395] reverse takotsubo cardiomyopathy [MeSH:C1739395] young [MeSH:C0340037] woman setting amphetamine [MeSH:C0002658] use,transient [MeSH:C0040704] leave ventricular apical ballooning syndrome [MeSH:C1739395] describe japan takotsubo cardiomyopathy syndrome [MeSH:C1739395] identify country variation syndrome recently describe literature [MeSH:C0023866] rare [MeSH:C0017112] [MeSH:C0023866] reverse type syndrome hyperdynamic apex complete akinesia base oppose classic apical ballooning article [MeSH:C0282410] report interesting case young [MeSH:C0340037] woman [MeSH:C0043210] present rare [MeSH:C0017112] type reverse apical ballooning syndrome [MeSH:C1739395] occur amphetamine [MeSH:C0002658] use report follow review [MeSH:C0282443] literature [MeSH:C0023866],cardiovascular
detailed spectral profile penicillin-induced epileptiform activity anesthetize rat [MeSH:C0034721],penicillin [MeSH:C0030842] model [MeSH:C0011381] widely experimental model [MeSH:C0086272] [MeSH:C0086272] [MeSH:C0011381] epilepsy [MeSH:C0014544] present aim portray detailed spectral [MeSH:C0037799] penicillin [MeSH:C0030842]-induced epileptiform activity comparison basal brain activity anesthetize wistar rat [MeSH:C0034716] male [MeSH:C0086582] wistar rat [MeSH:C0034716] anesthetize p urethane [MeSH:C0041964] connect electrocorticogram [MeSH:C0430797] setup short period basal activity record [MeSH:C0034869] epileptic focus induce inject 0iu microl penicillin [MeSH:C0030842]-g potassium leave lateral ventricle cortical activity [MeSH:C0152279] continuously record [MeSH:C0034869] basal activity latent period [MeSH:C0080129] penicillin [MeSH:C0030842]-induced epileptiform activity period analyze conventional method spectral [MeSH:C0037799] spectral [MeSH:C0037799] analysis conduct divide spectrum [MeSH:C4042936] different frequency [MeSH:C0376249] [MeSH:C0376249] band include delta theta slow fast alpha-sigma beta gamma band result affect frequency [MeSH:C0376249] [MeSH:C0376249] band delta theta beta- gamma- band epileptiform activity marked difference term spectral [MeSH:C0037799] density investigate [MeSH:C0035173] episode [MeSH:C0085554] basal activity latent period [MeSH:C0080129] epileptiform activity result help analyze novel obtain similar experimental model [MeSH:C0086272] [MeSH:C0086272] [MeSH:C0011381] simple describe similar study [MeSH:C0085973] investigate [MeSH:C0035173] basic neuronal [MeSH:C0132800] mechanism type experimental epilepsy [MeSH:C0014544],neurological|cardiovascular
resuscitation [MeSH:C0035273] lipid [MeSH:C0023779] epinephrine [MeSH:C0014563] levobupivacaine-induced cardiac [MeSH:C0873118] toxicity [MeSH:C0040539] newborn [MeSH:C0021289] piglet,optimal dose regimen [MeSH:C1880476] lipid emulsion [MeSH:C0014020] [MeSH:C0014020] [MeSH:C0014020] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] determine neonate [MeSH:C0021289] case local anaesthetic [MeSH:C0002932] systemic toxicity [MeSH:C0040539] method newborn [MeSH:C0021289] piglet receive levobupivacaine [MeSH:C0873118] cardiovascular [MeSH:C0007220] collapse occur standard cardiopulmonary resuscitation [MeSH:C0007203] start electrocardiogram ecg monitor [MeSH:C1623258] ventricular tachycardia fibrillation [MeSH:C0042514] qrs prolongation piglet randomly allocate group [MeSH:C0018257] [MeSH:C0018257] saline intralipid [MeSH:C0733854] [MeSH:C0733854] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] combination [MeSH:C0034865] intralipd plus epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] resuscitation continue min return spontaneous circulation rosc accompany mean arterial pressure superior pressure normal sinus rhythm period [MeSH:C0428886] min result rosc achieve piglet compare treat piglet mortality [MeSH:C0026565] significantly different group [MeSH:C0018257] [MeSH:C0018257] significantly low group [MeSH:C0018257] [MeSH:C0018257] compare number ecg abnormality [MeSH:C0037268] [MeSH:C0037268] zero intralipid [MeSH:C0733854] [MeSH:C0733854] respectively epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] plus lipid group [MeSH:C0018257] [MeSH:C0018257] p conclusion lipid emulsion [MeSH:C0014020] [MeSH:C0014020] [MeSH:C0014020] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] equally effective [MeSH:C5392218] achieve return spontaneous circulation model [MeSH:C3258122] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] combination [MeSH:C0034865] lipid associate increase number ecg abnormality [MeSH:C0037268] [MeSH:C0037268] compare lipid emulsion [MeSH:C0014020] [MeSH:C0014020] [MeSH:C0014020],cardiovascular
characterization estrogen-induced [MeSH:C1447061] adenohypophyseal tumor fischer rat [MeSH:C0034721],pituitary [MeSH:C0032005] [MeSH:C0032005] tumor [MeSH:C0032019] induce f3 female rat [MeSH:C0034721] chronic diethylstilbestrol des mg implant subcutaneously silastic capsule range day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] des pair des-treated rat [MeSH:C0034721] sacrifice pituitary [MeSH:C0032005] [MeSH:C0032005] dissociate enzymatically single-cell preparat [MeSH:C0034721]ion cell population [MeSH:C0032659] examine total cell recovery [MeSH:C0140116] correlate gland [MeSH:C0162322] weight intracellular [MeSH:C0682581] [MeSH:C0682581] prolactin prl [MeSH:C0033371] content [MeSH:C0017177] [MeSH:C0017177] subsequent release primary culture [MeSH:C1449562] immunocytochemical [MeSH:C0242349] prl stain density size alterat [MeSH:C0034721]ion separat [MeSH:C0034721]ion ficoll-hypaque unit gravity sedimentation cell cycle [MeSH:C0007586] acriflavine dna staining laser flow cytometry total cell yield des-treated pituitary [MeSH:C0032005] [MeSH:C0032005] increase time yield day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] time value intracellular [MeSH:C0682581] [MeSH:C0682581] prl content [MeSH:C0017177] [MeSH:C0017177] range time level prl release vitro significantly consistently high control day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] des exposure [MeSH:C1390376] [MeSH:C1390376] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] des exposure [MeSH:C1390376] [MeSH:C1390376] immunochemically prl-positive proportion cell increase total population [MeSH:C0032659] [MeSH:C0032659] increase density size prl content [MeSH:C0017177] [MeSH:C0017177] indicate majority prl cell population [MeSH:C0032659] type separat [MeSH:C0034721]ion protocol effect [MeSH:C4277511] des pronounced previously ovariectomized animal extend finding investigator [MeSH:C0035173] establish des-induced tumor model prl cellular mechanism,neurological|oncological
organophosphate-induced convulsion prevention [MeSH:C2700409] neuropathological damage,organophosphorus [MeSH:C0163401] op compound [MeSH:C0040942] diisopropylfluorophosphate dfp [MeSH:C0022181] [MeSH:C0022181] [MeSH:C0022181] [MeSH:C0022181] sarin [MeSH:C0036233] soman [MeSH:C0037643] potent inhibitor [MeSH:C0003015] acetylcholinesterase ache butyrylcholinesterase bche [MeSH:C0728810] acute [MeSH:C0184567] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] op irreversible binding ache central nervous system cns [MeSH:C3714787] elevate acetylcholine ach [MeSH:C0001041] level [MeSH:C0018759] protective action [MeSH:C0679688] subcutaneously sc administer antidote [MeSH:C0003295] [MeSH:C0003295] combination [MeSH:C0034865] [MeSH:C0034865] dfp [MeSH:C0022181] [MeSH:C0022181] [MeSH:C0022181] mg kg bw intoxication study --weeks-old han-wistar male [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] receive ache reactivator pralidoxime chloride 2pam mg kg bw anticonvulsant [MeSH:C0003286] diazepam [MeSH:C0012010] mg kg bw -adenosine receptor agonist [MeSH:C3850106] n -cyclopentyl adenosine cpa mg kg bw nmda-receptor [MeSH:C0080093] antagonist dizocilpine male [MeSH:C0086582]ate -mk8 hydrogen male [MeSH:C0086582]ate mg kg bw combination [MeSH:C0034865] [MeSH:C0034865] cholinolytic drug [MeSH:C0242897] atropine [MeSH:C0004259] sulfate [MeSH:C0596005] [MeSH:C0596005] mg kg bw immediately min single sc injection dfp [MeSH:C0022181] [MeSH:C0022181] [MeSH:C0022181] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] receive atropine [MeSH:C0004259] sulfate [MeSH:C0596005] [MeSH:C0596005] saline olive oil [MeSH:C0069449] instead antidote [MeSH:C0003295] [MeSH:C0003295] dfp [MeSH:C0022181] [MeSH:C0022181] [MeSH:C0022181] respectively rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] terminate h week dfp [MeSH:C0022181] [MeSH:C0022181] [MeSH:C0022181] injection rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat dfp [MeSH:C0022181] [MeSH:C0022181] [MeSH:C0022181]-atropine [MeSH:C0004259] show severe [MeSH:C1719672] typical op-induced toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] sign cpa diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] 2pam give immediately dfp [MeSH:C0022181] [MeSH:C0022181] [MeSH:C0022181]-atropine [MeSH:C0004259] treatment [MeSH:C0039798] prevent [MeSH:C0000918] delay [MeSH:C5544400] shorten occurrence sign poison [MeSH:C0032346] atropine [MeSH:C0004259]-mk8 offer additional protection [MeSH:C0524828] dfp [MeSH:C0022181] [MeSH:C0022181] [MeSH:C0022181] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] cpa diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] 2pam combination [MeSH:C0034865] [MeSH:C0034865] atropine [MeSH:C0004259] prevent [MeSH:C0000918] occurrence sign poison [MeSH:C0032346]ing reduce toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] dfp [MeSH:C0022181] [MeSH:C0022181] [MeSH:C0022181] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721],neurological
brain [MeSH:C0006104] dynamic myocardial infarction dopamine [MeSH:C0013030],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer acetylcholine method [MeSH:C0001041] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational guillain-barre syndrome encephalitis [MeSH:C0018378] assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
stenosis [MeSH:C1261287] pattern coronary artery disease [MeSH:C1956346] patient [MeSH:C0030705],retrospective [MeSH:C0035363] examine statin [MeSH:C0360714] diabete elderly patient investigation [MeSH:C0035173] include myocardial infarction pacemaker norepinephrine method participant [MeSH:C1708335] include result well quality life measure implication relevance [MeSH:C2826293],neurological|cardiovascular
vasodilator leukemia brain [MeSH:C0006104] insight,question statin affect hypertension [MeSH:C0020538] acute kidney injury [MeSH:C2609414] mechanism method retrospective [MeSH:C0035363] elderly patient assess tic glutamate [MeSH:C0017789] result favorable safety profile implication therapeutic [MeSH:C0087111] innovation,neurological|hepatorenal
design [MeSH:C0013171] hypren-trial safety enalapril [MeSH:C0014025] prazosin [MeSH:C0032912] initial phase patient [MeSH:C0030705] congestive heart failure [MeSH:C0018802],introduction [MeSH:C0033268] angiotensin converting [MeSH:C0022709] enzyme ace inhibitor [MeSH:C0003015] [MeSH:C0014432] adjunctive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] congestive heart failure [MeSH:C0018802] case severe hypotension [MeSH:C0020649] [MeSH:C0020649] especially occasionally report assess safety [MeSH:C0036043] ace inhibitor [MeSH:C0003015] enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] multicenter randomized prazosin [MeSH:C0032912]-controlled trial design compare incidence [MeSH:C0021149] severity symptomatic [MeSH:C3839861] [MeSH:C3839861] hypotension [MeSH:C0020649] [MeSH:C0020649] trial medication [MeSH:C0033045] mg enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] prazosin [MeSH:C0032912] subject inpatient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0021562] new york heart association nyha functional class ii iii patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] experience clinically statistically significantly symptomatic [MeSH:C3839861] [MeSH:C3839861] hypotension [MeSH:C0020649] [MeSH:C0020649] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive prazosin [MeSH:C0032912] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] recover conclude enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] tolerate unreasonable restrict initiation [MeSH:C0030943] enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] inpatient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0021562],cardiovascular
indomethacin-induced hyperkalemia [MeSH:C0020461] patient gouty arthritis [MeSH:C0003868],describe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe life-threatening [MeSH:C4303743] hyperkalemia [MeSH:C0020461] renal insufficiency [MeSH:C1565489] develop acute gouty arthritis [MeSH:C0003868] indomethacin [MeSH:C0021246] [MeSH:C0021246] complication [MeSH:C1171258] [MeSH:C1171258] inhibition [MeSH:C0027790] prostaglandin synthesis [MeSH:C0085387] consequent hyporeninemic hypoaidosteronism careful attention renal function [MeSH:C0031843] potassium balance [MeSH:C0032821] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive indomethacin [MeSH:C0021246] [MeSH:C0021246] nonsteroidal anti-inflammatory agent [MeSH:C0003211] particularly patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] diabetes mellitus [MeSH:C0011849] preexisting renal disease [MeSH:C1691228] help prevent [MeSH:C0000918] potentially complication [MeSH:C1171258] [MeSH:C1171258],hepatorenal
tumor terrain [MeSH:C0006118] multiple sclerosis [MeSH:C0026769] exploration [MeSH:C0015329],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] non-hodgkin lymphoma pathway method [MeSH:C0024305] longitudinal trial [MeSH:C0023981] elderly patient measure stem cell transplant [MeSH:C1504389] oncogene result improvement primary endpoint relevance,oncological
mri [MeSH:C0282596] reveal diabetes mellitus [MeSH:C0011849] secret,hypothesis [MeSH:C3179072] aspirin improve hypertension [MeSH:C0020538] outcome transient ischemic attack pathway method [MeSH:C0007787] cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring delirium aphasia [MeSH:C0011206] result well quality life measure optimization [MeSH:C0376695],neurological
lymphoma pulmonary embolism [MeSH:C0034065] cardiac connection,cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve defibrillator regurgitation method conduct longitudinal evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine bradycardia [MeSH:C0428977] parameter result well quality life measure need investigation [MeSH:C0035173],cardiovascular
ggt marker hypertension,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect stroke [MeSH:C0038454] acute kidney injury [MeSH:C2609414] mechanism method cross-sectional [MeSH:C0010362] elderly patient assess hypertrophic cardiomyopathy [MeSH:C0007194] myocardium [MeSH:C0027061] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
cutting-edge dialysis lymphoma,hypothesis statin improve hypertension [MeSH:C0020538] outcome nephrotic syndrome pathway method cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient measure steatosis [MeSH:C2711227] liver transplant [MeSH:C0023911] result improvement primary endpoint safety [MeSH:C0036043] consideration,hepatorenal
thrombotic microangiopathy [MeSH:C2717961] renal failure [MeSH:C0035078] associate antineoplastic chemotherapy [MeSH:C0003393],patient carcinoma [MeSH:C0007097] develop thrombotic microangiopathy [MeSH:C2717961] [MeSH:C2717961] characterize renal insufficiency [MeSH:C1565489] microangiopathic [MeSH:C0221021] hemolytic anemia [MeSH:C0002871] [MeSH:C0002878] usually thrombocytopenia [MeSH:C0040034] [MeSH:C0040034] cisplatin [MeSH:C0008838] bleomycin vinca alkaloid [MeSH:C0002062] thrombotic thrombocytopenic purpura hemolytic-uremic syndrome [MeSH:C0034155] apparent forme fruste disorder histologic examination [MeSH:C0027853] renal tissue [MeSH:C0040300] [MeSH:C0040300] show evidence intravascular coagulation [MeSH:C0012739] primarily affect small artery arteriole glomerulus tumor-free small tumor onset syndrome thrombotic microangiopathy [MeSH:C2717961] [MeSH:C2717961] induce chemotherapy diagnosis [MeSH:C0013216] potentially fatal complication [MeSH:C1171258] delay [MeSH:C5544400] miss renal tissue [MeSH:C0040300] [MeSH:C0040300] peripheral blood smear examine renal failure [MeSH:C0035078] ascribe cisplatin [MeSH:C0008838] nephrotoxicity anemia [MeSH:C0002871] thrombocytopenia [MeSH:C0040034] [MeSH:C0040034] drug-induced bone marrow suppression,hepatorenal|oncological
lymphoma hypotension cardiac connection,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population hypotension [MeSH:C0020649] chf result favorable safety [MeSH:C0036043] profile arrhythmia [MeSH:C0003811] correlation practice guideline,cardiovascular
kidney transplant pathway [MeSH:C0022671] colorectal cancer [MeSH:C0009402],hypertension [MeSH:C0020538] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve glomerular filtration rate [MeSH:C0017654] hepatocellular method [MeSH:C0345904] conduct cross-sectional evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine uremia [MeSH:C0041948] parameter result improvement primary endpoint practice guideline,hepatorenal
stenosis [MeSH:C1261287] hepatitis vascular [MeSH:C0019158] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome embolism pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure atrial flutter smooth muscle [MeSH:C1267092] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] therapeutic innovation [MeSH:C0087111],cardiovascular|hepatorenal
lymphoma uremia [MeSH:C0024299] organ [MeSH:C0029250] interplay,longitudinal [MeSH:C0023981] examine beta-blocker [MeSH:C0001645] dementia diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include liver fibrosis [MeSH:C0239946] alkaline phosphatase nephroblastoma method participant [MeSH:C1708335] include result well quality life measure implication optimization [MeSH:C0376695],hepatorenal
endometrial cancer [MeSH:C0476089] marker [MeSH:C0017393] colorectal cancer [MeSH:C0009402],design [MeSH:C0013171] prospective investigation [MeSH:C0035173] aspirin [MeSH:C0004057] stroke [MeSH:C0038454] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] prostate cancer [MeSH:C0376358] deep vein thrombosis [MeSH:C0149871] result decrease mortality rate [MeSH:C0205848] arterial [MeSH:C0003835] correlation cost-effectiveness [MeSH:C1511536] implication,cardiovascular|oncological
type somatic mutation apc familial adenomatous polyposis [MeSH:C0032580] determine site germline [MeSH:C0206530] mutation new facet knudson two-hit hypothesis,apc cite prime example tumor [MeSH:C0027651] suppressor [MeSH:C0597611] gene [MeSH:C0079427] truncating germline somatic mutation [MeSH:C0026882] [MeSH:C0206530] infrequently allelic loss [MeSH:C0524869] [MeSH:C0524869] [MeSH:C0524869] occur tumor [MeSH:C0027651] fap [MeSH:C1622401] familial adenomatous polyposis [MeSH:C0032580] [MeSH:C0032580] sporadic colorectal cancer [MeSH:C0009402] apc mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] clue attenuate [MeSH:C0042211] polyposis [MeSH:C0032580] missense [MeSH:C0599155] germline variant mild disease somatic mutation [MeSH:C0026882] cluster region codon [MeSH:C0009221] indicate apc mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] simple loss protein function find fap [MeSH:C1622401] patient [MeSH:C0030705] [MeSH:C0030705] germline apc mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] small region codon [MeSH:C0009221] mainly allelic loss [MeSH:C0524869] [MeSH:C0524869] [MeSH:C0524869] colorectal adenoma [MeSH:C0009402] contrast fap [MeSH:C1622401] patient [MeSH:C0030705] [MeSH:C0030705] second hit tend occur truncating mutation [MeSH:C0026882] mutation [MeSH:C0026882] cluster region result indicate different apc mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] provide cell [MeSH:C0007634] different selective advantage mutation [MeSH:C0026882] close codon [MeSH:C0009221] provide great advantage allelic loss [MeSH:C0524869] [MeSH:C0524869] [MeSH:C0524869] select strongly cell [MeSH:C0007634] mutation [MeSH:C0026882] near codon [MeSH:C0009221] different germline-somatic apc mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] association [MeSH:C0004083] exist fap [MeSH:C1622401] desmoid apc classical tumor [MeSH:C0027651] suppressor [MeSH:C0597611] finding indicate new mechanism disease severity broad spectrum mutation [MeSH:C0026882] select tumor [MeSH:C0027651] somatic mutation [MeSH:C0026882] rate effectively high tumor [MeSH:C0027651] grow,oncological
sinoatrial node marker [MeSH:C0037189] ventricular tachycardia [MeSH:C0042514],prospective examine calcium channel blocker [MeSH:C0006684] dementia [MeSH:C0497327] cardiac patient investigation [MeSH:C0035173] include septum aortic valve prolapse [MeSH:C0003505] method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication safety [MeSH:C0036043] consideration,cardiovascular
rhythm cancer [MeSH:C0005167],investigation [MeSH:C0035173] examine effect [MeSH:C4277511] ace inhibitor cancer [MeSH:C0003015] adult [MeSH:C0001675] population focus [MeSH:C0032659] hypotension diastolic aspect disease total participant enrol retrospective [MeSH:C0035363] result demonstrate positive response particular attention thrombosis [MeSH:C0040053] finding suggest care improvement,cardiovascular
p16ink4a-insensitive cdk4 mutant target [MeSH:C0039309] cytolytic lymphocyte [MeSH:C0024264] human melanoma,mutate [MeSH:C3178846] [MeSH:C3178846] cyclin-dependent kinase cdk4 [MeSH:C0246957] [MeSH:C0246957] identify tumor-specific antigen recognize hla-a2 [MeSH:C0019733] -restricted autologous [MeSH:C0004359] cytolytic lymphocyte [MeSH:C0024264] ctls human melanoma [MeSH:C0025202] mutate [MeSH:C3178846] [MeSH:C3178846] cdk4 [MeSH:C0246957] allele [MeSH:C0246957] present autologous [MeSH:C0004359] culture melanoma cell metastasis tissue [MeSH:C0027627] patient [MeSH:C0030705] lymphocyte [MeSH:C0024264] mutation [MeSH:C0026882] [MeSH:C0026882] arginine-to-cysteine exchange residue cdk4 [MeSH:C0246957] peptide recognize ctls prevent [MeSH:C0000918] binding [MeSH:C0033618] cdk4 [MeSH:C0246957] inhibitor [MeSH:C0258920] p16ink4a [MeSH:C0249880] p2 p27kip1 [MeSH:C0169665] mutation [MeSH:C0026882] [MeSH:C0026882] find additional melanoma melanoma [MeSH:C0025202] analyze result suggest mutation [MeSH:C0026882] [MeSH:C0026882] cdk4 [MeSH:C0246957] create tumor-specific antigen disrupt cell-cycle regulation [MeSH:C0243021] exert tumor suppressor p16ink4a [MeSH:C0249880],oncological
differential diagnosis [MeSH:C0011906] high serum [MeSH:C0229671] creatine kinase [MeSH:C0010287] level systemic lupus erythematosus [MeSH:C0024141],report bioptic finding -year-old woman [MeSH:C0043210] severe chloroquine-induced myopathy suffer systemic lupus erythematosus [MeSH:C0024141] sle renal involvement [MeSH:C0030699] undergo period [MeSH:C0080129] azathioprine cyclophosphamide [MeSH:C0004482] additional therapy chloroquine cq start arthralgia [MeSH:C0003862] slightly increase creatine kinase ck [MeSH:C0010287] level [MeSH:C0018759] note myositis suspect treat steroid [MeSH:C0038317] ck increase persist develop progressive [MeSH:C1449744] muscular weakness [MeSH:C0151786] muscular atrophy [MeSH:C0026846] routine control reveal markedly elevate ck level [MeSH:C0018759] u l neurological electrophysiological [MeSH:C2350527] finding typical myositis muscle [MeSH:C0027121] biopsy deltoid muscle [MeSH:C0224234] perform order exclude polymyositis [MeSH:C0085655] toxic myopathy [MeSH:C0154769] reveal chloroquine-induced myopathy medication stop discriminate primary sle-induced affection musculoskeletal system drug-induced effect important appropriate sle patient [MeSH:C0030705],neurological|hepatorenal
antiarrhythmic epilepsy [MeSH:C0003195] brain insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome [MeSH:C0206277] cerebral infarction pathway method [MeSH:C0007785] observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring paralysis [MeSH:C0522224] hypothalamus [MeSH:C0020663] result well quality life measure safety [MeSH:C0036043] consideration,neurological|cardiovascular
radiotherapy cancer [MeSH:C0034619] lung cancer [MeSH:C0242379],hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve stomach cancer [MeSH:C0024623] cervical cancer method [MeSH:C4048328] conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine esophageal cancer [MeSH:C0546837] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] optimization [MeSH:C0376695],oncological
oncological frontier lung cancer [MeSH:C0242379],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke [MeSH:C0038454] outcome myelodysplastic syndrome pathway method [MeSH:C3463824] retrospective trial cancer patient measure myeloproliferative neoplasm non-hodgkin lymphoma [MeSH:C0024305] result well quality life measure optimization [MeSH:C0376695],oncological
myotonia [MeSH:C0700153] levior chloride channel disorder,dominant [MeSH:C0017342] non-dystrophic myotonia [MeSH:C0700153] [MeSH:C0700153] [MeSH:C0027126] comprise disorder [MeSH:C0040188] characterize clinically similar form myogenic muscle stiffness genetically inhomogeneous dominant [MeSH:C0017342] myotonia [MeSH:C0700153] [MeSH:C0700153] congenita thomsens disease [MeSH:C2936781] [MeSH:C0027127] link clcn1 gene encode major muscle chloride channel localized chromosome 7q3 contrast dominant [MeSH:C0017342] myotonia [MeSH:C0700153] [MeSH:C0700153] sensitive [MeSH:C1017675] potassium [MeSH:C0032821] cause point mutation [MeSH:C0026882] [MeSH:C0162735] scn4a chromosome 7q gene alpha subunit adult skeletal muscle [MeSH:C0242692] sodium channel [MeSH:C0037492] linkage molecular genetic available myotonia [MeSH:C0700153] [MeSH:C0700153] levior characterize mild symptom later onset myotonia [MeSH:C0700153] [MeSH:C0700153] thomsens disease [MeSH:C2936781] absence muscle hypertrophy [MeSH:C0020564] report clcn1 gln arg substitution [MeSH:C2936279] family dominant [MeSH:C0017342] inheritance previously diagnose [MeSH:C0011900] [MeSH:C0011900] myotonia [MeSH:C0700153] [MeSH:C0700153] levior disorder [MeSH:C0040188] appear variant thomsens disease [MeSH:C2936781] mutation [MeSH:C0026882] lead low [MeSH:C0023175] expressivity addition report novel ile meet clcn1 mutation [MeSH:C0026882] typical thomsen pedigree family previously diagnose [MeSH:C0011900] [MeSH:C0011900] thomsen disease [MeSH:C2936781] unexpectedly find clcn1 bp deletion know cause recessive myotonia [MeSH:C0700153] [MeSH:C0700153] rare trp gly polymorphism [MeSH:C0032529],neurological
possible intramuscular [MeSH:C0021492] midazolam-associated cardiorespiratory arrest death,midazolam [MeSH:C0026056] hydrochloride [MeSH:C0546849] commonly dental [MeSH:C0011388] endoscopic procedure generally consist safe give intramuscular [MeSH:C0021492]ly intravenous administration [MeSH:C0013125] know cause respiratory [MeSH:C0231832] cardiovascular depression report describe publish case cardiorespiratory [MeSH:C0231832] arrest death associate intramuscular [MeSH:C0021492] administration midazolam [MeSH:C0001554] [MeSH:C0026056] information midazolam [MeSH:C0026056] use review [MeSH:C0282443] provide recommendation safe administration,cardiovascular
norepinephrine signaling [MeSH:C0028351] beta-adrenergic receptor [MeSH:C0034785] critical expression cocaine-induced anxiety,cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] widely abuse psychostimulant rewarding aversive property mechanism [MeSH:C1524059] underlie cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] rewarding effect [MeSH:C4277511] study extensively attention pay unpleasant behavioral state [MeSH:C0004927] induce cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] anxiety [MeSH:C0003467] method evaluate [MeSH:C0013175] performance [MeSH:C0871966] [MeSH:C0871966] dopamine beta-hydroxylase [MeSH:C0013032] knockout dbh [MeSH:C0206745] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] lack norepinephrine [MeSH:C0028351] ne elevated plus maze epm examine contribution noradrenergic [MeSH:C3178786] signaling cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170]-induced anxiety [MeSH:C0003467] result find cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] dose-dependently increase anxiety [MeSH:C0003467]-like behavior dbh mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] measure decrease open arm exploration dbh mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] normal performance [MeSH:C0871966] [MeSH:C0871966] epm completely resistant [MeSH:C2986418] anxiogenic effect [MeSH:C4277511] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170]-induced anxiety [MeSH:C0003467] attenuate [MeSH:C0042211] dbh mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] follow administration [MeSH:C0001554] disulfiram [MeSH:C0012772] dopamine beta-hydroxylase [MeSH:C0013032] dbh inhibitor [MeSH:C0003015] experiment [MeSH:C0020123] specific adrenergic antagonist [MeSH:C0033607] [MeSH:C0242889] find pretreatment [MeSH:C0376495] beta-adrenergic receptor [MeSH:C0034785] antagonist [MeSH:C0033607] [MeSH:C0001644] propranolol [MeSH:C0033497] block [MeSH:C5197800] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170]-induced anxiety [MeSH:C0003467]-like behavior dbh wild-type c57bl6 j mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] alpha antagonist [MeSH:C0033607] prazosin alpha [MeSH:C0032912] antagonist [MeSH:C0033607] yohimbine [MeSH:C0724441] effect [MeSH:C4277511] conclusion result indicate noradrenergic [MeSH:C3178786] signaling beta-adrenergic receptor [MeSH:C0034785] require cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170]-induced anxiety [MeSH:C0003467] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809],neurological
genetic defect secretion complement c5 mouse,genetic deficiency [MeSH:C1623416] fifth c5 component complement1- serum [MeSH:C0229671] glycoprotein molecular weight mw ref find inbred strain [MeSH:C0080194] mice3 [MeSH:C0025927] serum [MeSH:C0229671] deficient mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] lack detectable c5 activity protein2 addition deficient mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] produce antibody mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0443933] [MeSH:C0026809] [MeSH:C0026809] c5 inject serum [MeSH:C0229671] c5 sufficient normal strain [MeSH:C0080194] levy et al show somatic cell hybrid c5 deficient b1 d2 old line macrophage c5 sufficient b1 d2 new line mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] kidney chicken erythroblast [MeSH:C0014762] secrete [MeSH:C0036534] [MeSH:C0036534] [MeSH:C0036534] haemolytically active mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] c5 vitro possible molecular mechanism account finding consider insufficient [MeSH:C5575834] direct available choose recently report mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] cd strain [MeSH:C0080194] peritoneal cell culture synthesise secrete [MeSH:C0036534] [MeSH:C0036534] [MeSH:C0036534] single chain precursor pro-c5 mw approximately two-chain alpha chain beta chain mw c5 protein6 radiolabelled precursor c5 contain cell secrete [MeSH:C0036534] [MeSH:C0036534] [MeSH:C0036534] tissue culture medium [MeSH:C1446951] similar method [MeSH:C0025663] find c5 deficiency [MeSH:C1623416] different mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] strain [MeSH:C0080194] akr swr dba 2j8 hej b1 d2 old line failure secretion [MeSH:C0036536] c5 protein failure biosynthesis [MeSH:C0005572] pro-c5,neurological|hepatorenal
octreotide-induced hypoxemia pulmonary hypertension [MeSH:C0020542] premature neonate,author report case premature neonate enterocutaneous fistula [MeSH:C0341318] complicate necrotizing enterocolitis [MeSH:C0520459] pulmonary hypertension [MeSH:C0020542] develop administration somatostatin analogue octreotide [MeSH:C0028833] enhance resolution fistula author discuss mechanism [MeSH:C1524059] occurrence [MeSH:C0243132] complication [MeSH:C1171258] recommend caution use high-risk premature neonate,cardiovascular
flestolol [MeSH:C0060455] ultra-short-acting beta-adrenergic blocking agent [MeSH:C0001645],flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] acc- nonselective competitive ultra-short-acting beta-adrenergic blocking agent [MeSH:C0001645] intrinsic sympathomimetic activity flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] metabolize plasma esterase [MeSH:C0032105] elimination [MeSH:C1373187] half-life [MeSH:C0018517] approximately minute agent tolerate healthy [MeSH:C0452415] volunteer dose microgram [MeSH:C0376691] [MeSH:C0376691] kg min long-term [MeSH:C0023977] infusion [MeSH:C0841792] study flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] tolerate effective [MeSH:C5392218] beta-blocking dose microgram [MeSH:C0376691] [MeSH:C0376691] kg min seven day flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] blood concentration [MeSH:C0684262] increase linearly increase dose good correlation [MeSH:C0010100] exist blood concentration [MeSH:C0684262] flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] beta-adrenergic blockade [MeSH:C0001645] flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] produce dose-dependent attenuation [MeSH:C1720750] isoproterenol-induced tachycardia electrophysiologic hemodynamic effect flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] similar beta blocker [MeSH:C0001645] contrast beta blocker [MeSH:C0001645] flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455]-induced effect reverse rapidly minute follow discontinuation short half-life [MeSH:C0018517] flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] effective [MeSH:C5392218]ly reduce heart rate [MeSH:C0018810] patient [MeSH:C0030705] [MeSH:C0030705] supraventricular [MeSH:C0039240] tachyarrhythmia patient [MeSH:C0030705] [MeSH:C0030705] unstable angina flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] infusion [MeSH:C0841792] find safe effective [MeSH:C5392218] control ch pain conclude flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] potent well-tolerated ultra-short-acting beta-adrenergic blocking agent [MeSH:C0001645] use flestolol [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] [MeSH:C0060455] critical care setting currently undergo investigation [MeSH:C0035173],neurological|cardiovascular
prolapse lymphoma [MeSH:C0024299] vascular insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect diabete aortic dissection [MeSH:C0340643] mechanism method prospective cardiac patient assess coronary restrictive cardiomyopathy [MeSH:C0007196] result decrease mortality rate [MeSH:C0205848] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
cervical cancer cancer [MeSH:C4048328] peripheral artery disease [MeSH:C1704436],question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] bone marrow transplant [MeSH:C0005961] mechanism method cross-sectional cardiac patient assess bone cancer [MeSH:C0279530] thyroid cancer [MeSH:C0549473] result improvement [MeSH:C2936612] primary endpoint implication care improvement [MeSH:C2936612],oncological
cancer liver cancer [MeSH:C0345904] connection [MeSH:C0056248],diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve cancer leukemia method [MeSH:C0023418] conduct prospective evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine metastatic [MeSH:C1522484] parameter result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],oncological
bilateral haemorrhagic infarction globus pallidu [MeSH:C0017651] cocaine alcohol intoxication,cocaine [MeSH:C0009170] risk [MeSH:C0035647] factor ischemic haemorrhagic stroke [MeSH:C5234922] present case -year-old man bilateral ischemia globus pallidu [MeSH:C0017651] excessive alcohol intranasal cocaine [MeSH:C0009170] use drug-related globus pallidu [MeSH:C0017651]s infarct [MeSH:C0021308]ion associate heroin [MeSH:C0011892] [MeSH:C0011892] bilateral basal ganglia [MeSH:C0004781] infarct [MeSH:C0021308] use cocaine [MeSH:C0009170] concurrent heroin [MeSH:C0011892] [MeSH:C0011892] use report transient [MeSH:C0040704] cardiac arrhythmia respiratory dysfunction [MeSH:C0031847] related cocaine [MeSH:C0009170] ethanol use likely cause cerebral hypoperfusion,cardiovascular
bladder cancer [MeSH:C0005684] cancer hepatitis [MeSH:C0345904],hypothesis statin improve hypertension [MeSH:C0020538] outcome carcinogenesis pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient measure thyroid cancer [MeSH:C0549473] pancreatic cancer [MeSH:C0346647] result improve disease management care [MeSH:C0039798] improvement [MeSH:C2936612],oncological
hypertension [MeSH:C0020538] gallbladder [MeSH:C0016976] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect heart disease [MeSH:C0018799] cirrhosis method cancer patient [MeSH:C0030705] undergo prospective primary biliary cholangitis cholecystitis [MeSH:C0008325] assessment [MeSH:C0030198] result improve outcome [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
immunotherapy [MeSH:C0021083] hepatitis brain [MeSH:C0006104] insight,investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect stroke [MeSH:C0038454] cortical method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo prospective locus coeruleus [MeSH:C0023951] neural assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint care improvement [MeSH:C2936612],neurological
biopsy reveal lymphoma [MeSH:C0024299] secret,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome paralysis pathway method prospective trial cardiac patient measure huntington disease oligodendroglioma result improvement primary endpoint cost-effectiveness [MeSH:C1511536] implication,neurological
memory loss connection ventricular tachycardia [MeSH:C0042514],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome dysarthria pathway method longitudinal trial cancer patient [MeSH:C0030705] measure interstitial nephritis neuropathy [MeSH:C0027707] result well quality life measure cost-effectiveness [MeSH:C1511536] implication,neurological|hepatorenal
alzheimer disease cardiac function [MeSH:C0018803],investigation [MeSH:C0035173] examine effect beta-blocker diabete diabetic patient [MeSH:C0030705] focus bundle branch block mitral valve aspect disease total participant enrol retrospective [MeSH:C0035363] result demonstrate reduction [MeSH:C1827449] adverse event [MeSH:C0041755] particular attention blood pressure [MeSH:C0005823] finding suggest care improvement,cardiovascular
role xanthine oxidase [MeSH:C0043317] dexamethasone-induced hypertension [MeSH:C0968916] rat [MeSH:C0034721],glucocorticoid-induced hypertension [MeSH:C0020538] gc-ht rat [MeSH:C0034721] [MeSH:C0034721] associate [MeSH:C0004083] nitric oxide-redox imbalance study role xanthine oxidase [MeSH:C0043317] xo implicate production [MeSH:C0033268] reactive oxygen specie [MeSH:C0162772] dexamethasone-induced hypertension [MeSH:C0020538] [MeSH:C0968916] dex-ht thirty male [MeSH:C0086582] sprague-dawley rat [MeSH:C0034721] [MeSH:C0034721] divide randomly group saline dexamethasone dex [MeSH:C0011777] allopurinol [MeSH:C0002144] [MeSH:C0002144] [MeSH:C0002144] [MeSH:C0002144] plus saline allopurinol [MeSH:C0002144] [MeSH:C0002144] [MeSH:C0002144] [MeSH:C0002144] [MeSH:C0002144] plus dex systolic blood pressure [MeSH:C0005823] sbp bodyweight [MeSH:C0005910] record alternate thymus [MeSH:C0040113] weight marker [MeSH:C0017393] glucocorticoid activity [MeSH:C0020115] [MeSH:C0017710] serum urat [MeSH:C0034721] [MeSH:C0034721]e assess xo inhibition dex increase sbp mmhg p decrease thymus [MeSH:C0040113] p bodyweight [MeSH:C0005910] p allopurinol [MeSH:C0002144] [MeSH:C0002144] [MeSH:C0002144] [MeSH:C0002144] decrease serum urat [MeSH:C0034721] [MeSH:C0034721]e micromol l p saline micromol l dex-treated p group allopurinol [MeSH:C0002144] [MeSH:C0002144] [MeSH:C0002144] [MeSH:C0002144] prevent [MeSH:C0000918] [MeSH:C0000918] dex-ht previous finding allopurinol [MeSH:C0002144] [MeSH:C0002144] [MeSH:C0002144] [MeSH:C0002144] fail prevent [MeSH:C0000918] [MeSH:C0000918] adrenocorticotrophic hormone [MeSH:C0001655] induce hypertension [MeSH:C0020538] suggest xo activity [MeSH:C0020115] major determinant [MeSH:C0003316] gc-ht rat [MeSH:C0034721] [MeSH:C0034721],cardiovascular
change depressive status associate topical beta-blocker,depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] sexual dysfunction [MeSH:C0033953] related effect topical beta-blocker [MeSH:C0001645] [MeSH:C0001645] [MeSH:C0001645] perform preliminary [MeSH:C4505218] order determine difference non selective beta-blocker [MeSH:C0001645] [MeSH:C0001645] [MeSH:C0001645] timolol [MeSH:C0040233] selective beta-blocker [MeSH:C0001645] [MeSH:C0001645] [MeSH:C0001645] betaxolol [MeSH:C0005320] [MeSH:C0005320] cns effect glaucomatous [MeSH:C0017601] patient [MeSH:C0030705] [MeSH:C0030705] chronically treat timolol [MeSH:C0040233] 2h [MeSH:C0040233] suffering depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] diagnose dms-iii-r criterion [MeSH:C0243161] include six-month depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] quantify beck zung-conde scale month double blind cross-over patient [MeSH:C0030705] [MeSH:C0030705] timolol [MeSH:C0040233] present high depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] value measure [MeSH:C0079809] beck zung-conde scale p vs result suggest betaxolol [MeSH:C0005320] [MeSH:C0005320] depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570]-inducer timolol [MeSH:C0040233] predisposed patient [MeSH:C0030705] [MeSH:C0030705],neurological
gfr pattern myocardial infarction [MeSH:C0027051] patient [MeSH:C0030705],design [MeSH:C0013171] prospective investigation ace inhibitor diabete [MeSH:C0003015] participant [MeSH:C1708335] cardiac patient white matter [MeSH:C0682708] cerebrospinal fluid [MeSH:C0007806] result decrease mortality [MeSH:C0026565] rate radiculopathy [MeSH:C0700594] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,neurological|hepatorenal
recurrent [MeSH:C2825055] dysphonia [MeSH:C1527344] acitretin [MeSH:C0050559],report case [MeSH:C0684224] woman complaining dysphonia [MeSH:C1527344] [MeSH:C1527344] treat acitretin [MeSH:C0050559] [MeSH:C0050559] symptom [MeSH:C3839861] totally regress drug [MeSH:C0013227] withdrawal [MeSH:C2717885] reappear acitretin [MeSH:C0050559] [MeSH:C0050559] reintroduce knowledge case [MeSH:C0376554] acitretin [MeSH:C0050559] [MeSH:C0050559]-induced dysphonia [MeSH:C1527344] [MeSH:C1527344] effect [MeSH:C4277511] related pharmacological effect [MeSH:C0728866] [MeSH:C4277511] drug [MeSH:C0013227] mucous membrane [MeSH:C0026724],neurological
coronary marker liver cirrhosis [MeSH:C0023890],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation beta-blocker heart disease participant cancer patient [MeSH:C0030705] ventricular fibrillation [MeSH:C0042510] atrioventricular block result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cardiomyopathy [MeSH:C0878544] correlation [MeSH:C0010100] relevance [MeSH:C2826293],cardiovascular
acoustic neuroma [MeSH:C0027859] connection chronic kidney disease [MeSH:C1561643],hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome parkinsonism pathway method longitudinal trial [MeSH:C0023981] cardiac patient measure al craniopharyngioma [MeSH:C0010276] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] optimization [MeSH:C0376695],neurological
epilepsy [MeSH:C0014544] myocardium [MeSH:C0027061] cardiac connection,prospective examine aspirin [MeSH:C0004057] stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include atrial flutter [MeSH:C0004239] ventricular tachycardia premature beat method [MeSH:C0151636] participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication relevance,cardiovascular
innovative aspirin [MeSH:C0004057] approach stroke [MeSH:C0038454],cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve regurgitation [MeSH:C0026266] premature beat method [MeSH:C0340464] conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine dvt parameter result favorable safety [MeSH:C0036043] profile potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
continuously nebulize albuterol [MeSH:C0001927] severe exacerbation asthma adult case-controlled,retrospective [MeSH:C0035363] case-controlled compare patient [MeSH:C0030705] admit medical intensive care unit [MeSH:C0021708] severe exacerbation asthma receive continuously nebulize albuterol [MeSH:C0001927] cna versus intermittent albuterol [MeSH:C0001927] ina treatment report [MeSH:C0039798] match pair patient [MeSH:C0030705] asthma compare cna administer mean hr incidence [MeSH:C0021149] [MeSH:C0021149] cardiac dysrhythmia [MeSH:C0003811] similar group symptomatic [MeSH:C3839861] hypokalemia [MeSH:C0020621] occur cna patient [MeSH:C0030705] [MeSH:C0030705] high heart rate reflect severity illness [MeSH:C0521117] incidence [MeSH:C0021149] [MeSH:C0021149] intubation [MeSH:C0021925] similar conclude cna ina demonstrate similar profile regard safety [MeSH:C0036043] morbidity [MeSH:C0026538] mortality [MeSH:C0026565],cardiovascular
synapse [MeSH:C0039062] meet lung cancer [MeSH:C0242379] neurological perspective,design [MeSH:C0013171] prospective investigation [MeSH:C0035173] statin diabete participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient [MeSH:C0030705] acoustic neuroma [MeSH:C0027859] stroke result positive response dystonia [MeSH:C0013421] correlation [MeSH:C0010100] need investigation [MeSH:C0035173],neurological
prophylactic use lamivudine [MeSH:C0209738] chronic [MeSH:C0150055] immunosuppressive therapy [MeSH:C0021079] rheumatologic disorder,report [MeSH:C0684224] experience concern effective [MeSH:C5392218]ness [MeSH:C0010181] prophylactic administration [MeSH:C0001554] [MeSH:C0001554] lamivudine [MeSH:C0209738] hepatitis b virus surface antigen [MeSH:C0019168] hbs [MeSH:C0002895] ag positive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] rheumatologic disease [MeSH:C0035435] [MeSH:C0035435] june october hbs [MeSH:C0002895] ag positive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] rheumatologic disease [MeSH:C0035435] [MeSH:C0035435] immunosuppressive [MeSH:C0021081] prophylactic lamivudine [MeSH:C0209738] therapy [MeSH:C0209738] [MeSH:C0209738] retrospectively assess liver function test [MeSH:C0023901] [MeSH:C0023901] [MeSH:C0023901] hepatitis b virus hbv serologic marker hbv dna [MeSH:C0062529] level patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] obtain hospital file [MeSH:C0019994] record patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] male [MeSH:C0086582] median age year range median disease duration month range median follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] period [MeSH:C0080129] [MeSH:C0080129] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] month range enrol lamivudine [MeSH:C0209738] therapy [MeSH:C0209738] start day [MeSH:C0011017] prior immunosuppressive [MeSH:C0021081] therapy patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] liver function test [MeSH:C0023901] [MeSH:C0023901] [MeSH:C0023901] elevated [MeSH:C0020443] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fourth alt iu l ast iu l tenth alt iu l ast iu l minimal change liver biopsy [MeSH:C0005558] shortly test normalize follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] period [MeSH:C0080129] [MeSH:C0080129] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] abnormal [MeSH:C0853087] liver function test [MeSH:C0023901] [MeSH:C0023901] [MeSH:C0023901] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hbv dna [MeSH:C0062529] level high normal normalize increase later additional patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hbv dna [MeSH:C0062529] level increase follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sing hbv activation lamivudine [MeSH:C0209738] tolerate continue patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prophylactic administration [MeSH:C0001554] [MeSH:C0001554] lamivudine [MeSH:C0209738] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] require immunosuppressive [MeSH:C0021081] therapy safe tolerated effective [MeSH:C5392218] prevent [MeSH:C0000918] hbv reactivation,neurological|hepatorenal
molecular genetic wolfram syndrome [MeSH:C0043207] kindred demonstrate wide spectrum mutation wfs1,wolfram syndrome [MeSH:C0043207] [MeSH:C0043207] autosomal recessive neurodegene [MeSH:C0017337]rative disorder [MeSH:C0524851] characterize juvenile-onset diabetes mellitus [MeSH:C0011849] [MeSH:C0011854] progressive [MeSH:C1449744] optic atrophy [MeSH:C0029124] mtdna [MeSH:C0012929] [MeSH:C0012929] deletion describe gene [MeSH:C0017337] wfs1 recently identify chromosome [MeSH:C0008633] 4p1 encode predict amino acid transmembrane protein [MeSH:C1308140] direct dna sequencing screen entire code region [MeSH:C0079941] wfs1 gene [MeSH:C0017337] patient british kindred wolfram syndrome [MeSH:C0043207] [MeSH:C0043207] dna screen structural rearrangement deletion duplication point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mtdna [MeSH:C0012929] [MeSH:C0012929] pathogenic [MeSH:C0030657] mtdna [MeSH:C0012929] [MeSH:C0012929] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find cohort [MeSH:C1706962] identify mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] wfs1 gene [MeSH:C0017337] nonsense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] in-frame deletion in-frame insertion frameshift mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0079380] [MeSH:C0026882] novel mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] occur exon [MeSH:C0015295] majority patient compound heterozygote [MeSH:C0019425] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] common founder mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] analyze genotype-phenotype [MeSH:C2717879] relationship [MeSH:C0021797] interesting case note consideration small sample size [MeSH:C0242618] frequency [MeSH:C0376249] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] indicate clear-cut correlation [MeSH:C0010100] observe mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] disease severity obvious mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] hot spot [MeSH:C5241298] cluster molecular screening wolfram syndrome [MeSH:C0043207] [MeSH:C0043207] affect family [MeSH:C0015576] wolfram syndrome [MeSH:C0043207] [MeSH:C0043207]-carrier status subject psychiatric disorder [MeSH:C0004936] diabetes mellitus [MeSH:C0011849] require complete exon [MeSH:C0015295] upstream exon [MeSH:C0015295],neurological
cutting-edge hypertensive atrial fibrillation,diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve sinoatrial node arrhythmia method [MeSH:C0003813] conduct longitudinal evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine diastolic [MeSH:C0012000] parameter result superior efficacy [MeSH:C5690761] relevance,cardiovascular
recurrent [MeSH:C2825055] acute interstitial nephritis [MeSH:C0027707] induce azithromycin [MeSH:C0052796],-year-old girl report [MeSH:C0043210] recurrent azithromycin-induced acute interstitial nephritis second episode severe treat intensive corticosteroid therapy renal function [MeSH:C0031843] remain impaired [MeSH:C0020580] case antibiotic [MeSH:C0003232] induce acute interstitial nephritis benign [MeSH:C0027707] self-limited patient risk [MeSH:C0035647] permanent renal injury,hepatorenal
suxamethonium-induced cardiac arrest death [MeSH:C0018790] follow day [MeSH:C0011017] immobilization [MeSH:C0020944],present report [MeSH:C0684224] describe case cardiac arrest [MeSH:C0018790] [MeSH:C0018790] subsequent death [MeSH:C0011065] hyperkalaemia [MeSH:C0020461] [MeSH:C0020461] follow use suxamethonium [MeSH:C0038627] [MeSH:C0038627] -year-old malawian woman [MeSH:C0043210] day [MeSH:C0011017] onset symptom meningitis aspirate stomach [MeSH:C0038351] content [MeSH:C0017177] need endotracheal intubation [MeSH:C0021932] second injection [MeSH:C1828121] suxamethonium [MeSH:C0038627] [MeSH:C0038627] bradycardia cardiac arrest [MeSH:C0018790] occur attempt resuscitate successful serum potassium [MeSH:C0032821] observe mequiv l- apart reduction [MeSH:C1827449] consciousness sign [MeSH:C0234421] motor neurone [MeSH:C0026609] damage [MeSH:C0012860] known predispose condition hyperkalaemia [MeSH:C0020461] [MeSH:C0020461] follow administration [MeSH:C0001554] suxamethonium [MeSH:C0038627] [MeSH:C0038627] postulate death [MeSH:C0011065] cause hypersensitivity [MeSH:C0020517] suxamethonium [MeSH:C0038627] [MeSH:C0038627] associate -day [MeSH:C0011017] immobilization [MeSH:C0020944],neurological
epidemiology [MeSH:C0014507] acute flank pain syndrome [MeSH:C0016199] suprofen [MeSH:C0038878],suprofen [MeSH:C0038878] new nonsteroidal anti-inflammatory drug [MeSH:C0013227] market [MeSH:C0003211] early analgesic agent [MeSH:C0002771] [MeSH:C0002771] physician [MeSH:C0031831] begin report unusual acute flank pain syndrome [MeSH:C0016199] spontaneous reporting system person drug [MeSH:C0013227] united state august total case syndrome report elucidate epidemiology syndrome [MeSH:C0014507] case-control [MeSH:C0007328] perform compare case patient [MeSH:C0030705] [MeSH:C0030705] report spontaneous reporting system suprofen [MeSH:C0038878]-exposed subject syndrome case patient [MeSH:C0030705] [MeSH:C0030705] likely man odd ratio confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] suffer hay fever asthma [MeSH:C0018621] odd ratio confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] participate regular exercise odd ratio confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] especially use nautilus equipment p use alcohol odd ratio confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] possible risk factor [MeSH:C0035648] include young age concurrent use analgesic agent [MeSH:C0002771] [MeSH:C0002771] especially ibuprofen [MeSH:C0020740] preexist renal disease [MeSH:C1691228] history kidney stone history gout recent increase activity [MeSH:C0020115] recent increase sun exposure [MeSH:C1390376] residence sunbelt finding suggestive reach conventional statistical significance [MeSH:C2826293] finding consistent postulate mechanism [MeSH:C1524059] unusual syndrome acute diffuse crystallization uric acid renal tubule,hepatorenal
gallbladder pathway lymphoma [MeSH:C0016976],prospective examine metformin [MeSH:C0025598] diabete cardiac patient investigation [MeSH:C0035173] include cholestasis hepatocellular carcinoma [MeSH:C2239176] tubule method participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
vein leukemia [MeSH:C0023418] vascular [MeSH:C0221214] insight,observational [MeSH:C0302523] examine calcium channel blocker [MeSH:C0006684] dementia [MeSH:C0497327] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include capillary blood pressure defibrillator method participant [MeSH:C1708335] include result positive response implication relevance,cardiovascular
lymphoma kidney [MeSH:C0022646] organ interplay,hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve nephrotic syndrome pkd method [MeSH:C0027726] conduct observational [MeSH:C0302523] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine urea [MeSH:C0041942] parameter result favorable safety [MeSH:C0036043] profile potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
prolapse [MeSH:C0033377] marker peripheral artery disease [MeSH:C1704436],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete pad mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess mitral valve myocardial infarction [MeSH:C0027051] result improvement primary endpoint implication care improvement,cardiovascular
explore chronic kidney disease [MeSH:C1561643] ast,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve heart disease [MeSH:C0018799] outcome gfr pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure cirrhosis [MeSH:C1623038] azotemia [MeSH:C0242528] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] optimization [MeSH:C0376695],hepatorenal
brca1 [MeSH:C0259275] mutation primary breast ovarian carcinoma [MeSH:C0678222],loss heterozygosity [MeSH:C0524869] familial tumor suggest brca1 [MeSH:C0259275] [MeSH:C0259275] gene [MeSH:C0376571] confer susceptibility ovarian [MeSH:C0012655] early-onset [MeSH:C3711383] [MeSH:C3711383] breast cancer [MeSH:C0006826] [MeSH:C0006142] encode tumor suppressor [MeSH:C0597611] brca1 [MeSH:C0259275] [MeSH:C0259275] region [MeSH:C0259275] subject allelic [MeSH:C0524869] loss sporadic breast ovarian cancer [MeSH:C1140680] [MeSH:C0006826] indication brca1 [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] occur somatically tumor brca1 [MeSH:C0259275] [MeSH:C0259275] coding region examine mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] primary breast ovarian tumor allele loss [MeSH:C0524869] brca1 [MeSH:C0259275] [MeSH:C0259275] locus mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect breast ovarian carcinoma [MeSH:C0678222] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] germline [MeSH:C0206530] alteration occur early-onset [MeSH:C3711383] [MeSH:C3711383] cancer [MeSH:C0006826] result suggest mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] critical development [MeSH:C0020119] majority breast ovarian cancer [MeSH:C1140680] [MeSH:C0006826] arise absence mutant [MeSH:C1564139] germline [MeSH:C0206530] allele,oncological
vascular health hypertension [MeSH:C0020545],randomized control examine [MeSH:C1096777] ace inhibitor [MeSH:C0003015] stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include heart attack [MeSH:C0027051] myocardial infarction tachycardia method [MeSH:C0027051] participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication healthcare advancement,cardiovascular
norepinephrine [MeSH:C0028351] meet hepatitis [MeSH:C0019158] neurological perspective,hypothesis statin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] locus coeruleus pathway method cross-sectional trial [MeSH:C0010362] adult [MeSH:C0001675] population [MeSH:C0032659] measure cerebrospinal fluid [MeSH:C0007806] neuron [MeSH:C0027882] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
ventricular tachycardia marker [MeSH:C0042514] atrial fibrillation [MeSH:C0004238],question [MeSH:C0600648] ace inhibitor affect heart disease [MeSH:C0018799] pericardium mechanism method observational [MeSH:C0302523] cardiac patient assess smooth muscle [MeSH:C1267092] ventricular fibrillation [MeSH:C0042510] result favorable safety [MeSH:C0036043] profile implication safety [MeSH:C0036043] consideration,cardiovascular
x-linked adrenoleukodystrophy ald [MeSH:C0162309] novel mutation [MeSH:C0026882] ald gene member family [MeSH:C0015576] present different phenotype [MeSH:C0031437],fragment adrenoleukodystrophy [MeSH:C0162309] ald cdna adolescent [MeSH:C0205653] ald amplify polymerase chain reaction subclone bidirectional sequencing entire code [MeSH:C0004738] ald gene disclose cytosine guanine transversion nucleotide exon result substitution [MeSH:C2936279] proline arginine [MeSH:C0003765] sibling [MeSH:C0037047] comprise cerebral ald adrenomyeloneuropathy addison symptomatic [MeSH:C3839861] mother [MeSH:C0026591] accumulate [MeSH:C0311432] long chain fatty acid [MeSH:C0015691] carry mutation [MeSH:C0026882] find unaffected person [MeSH:C0027361] unrelated ald patient [MeSH:C0030705] control propose missense mutation [MeSH:C0026882] generate disease se metabolic defect [MeSH:C0342738] different phenotype [MeSH:C0031437] originate mean additional pathogenetic factor,neurological
pericardium peripheral artery disease [MeSH:C1704436] vascular [MeSH:C0221214] insight,assess efficacy [MeSH:C5690761] ace inhibitor [MeSH:C0003015] diabete focus peripheral artery disease endothelial method [MeSH:C0225336] cardiac patient randomized [MeSH:C1096777] receive ace inhibitor [MeSH:C0003015] placebo artery monitoring [MeSH:C0005517] result improvement primary endpoint healthcare advancement,cardiovascular
cutting-edge norepinephrine [MeSH:C0028351] multiple sclerosis,hypertension [MeSH:C0020538] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve glioma delirium method conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine epilepsy [MeSH:C0014544] parameter result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
acute renal failure [MeSH:C0022660] rifampicin [MeSH:C0035608],-year-old male [MeSH:C0086582] bacteriologically prove pulmonary tuberculosis [MeSH:C0041327] treat regimen [MeSH:C1880476] antituberculosis drug [MeSH:C0003448] nearly month rifampicin [MeSH:C0035608] administer thrice drug regiman develop untoward effect like nausea vomiting fever chill rigor episode acute renal failure [MeSH:C0022660] stage see author report recovery,hepatorenal
mechanism development [MeSH:C0020119] tolerance [MeSH:C3544386] muscular rigidity [MeSH:C0026837] produce morphine [MeSH:C0026549] rat [MeSH:C0034721],development [MeSH:C0243107] tolerance [MeSH:C3544386] [MeSH:C3544386] [MeSH:C3544386] muscular rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] [MeSH:C0026837] produce morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] study rat [MeSH:C0034721] [MeSH:C0034721] saline-pretreated control give test dose morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] mg kg p show pronounced rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] record [MeSH:C0231521] tonic activity electromyogram rat [MeSH:C0034721] [MeSH:C0034721] treat day [MeSH:C0011017] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] withdraw h show difference development [MeSH:C0243107] tolerance [MeSH:C3544386] [MeSH:C3544386] [MeSH:C3544386] half animal [MeSH:C0003062] [MeSH:C0003062] show rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] test dose morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] significantly control akinetic rat [MeSH:C0034721] [MeSH:C0034721] show strong decrease rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] occurrence [MeSH:C0243132] stereotyped licking gnawing presence akinetic hyperkinetic k behaviour ks suggest sign dopaminergic [MeSH:C1512035] activation rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] considerably decrease group [MeSH:C0018257] day [MeSH:C0011017] series experiment [MeSH:C0020123] haloperidol [MeSH:C0018546] [MeSH:C0018546] mg kg p order block [MeSH:C5197800] dopaminergic [MeSH:C1512035] activation estimate real degree tolerance [MeSH:C3544386] [MeSH:C3544386] [MeSH:C3544386] rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] dopaminergic [MeSH:C1512035] interference haloperidol [MeSH:C0018546] [MeSH:C0018546] enhance [MeSH:C0014290] rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] ks remain considerably low result suggest rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] assume action morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] striatum [MeSH:C0315183] [MeSH:C0315183] antagonize process lead dopaminergic [MeSH:C1512035] activation striatum [MeSH:C0315183] [MeSH:C0315183] occur real tolerance [MeSH:C3544386] [MeSH:C3544386] [MeSH:C3544386] [MeSH:C3544386] effect rapid alternation [MeSH:C4255061] rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] sign dopaminergic [MeSH:C1512035] activation observe animal [MeSH:C0003062] [MeSH:C0003062] ks rapid shift predominance da-innervated structure [MeSH:C2713306],neurological
radiation therapy [MeSH:C0034619] diabetes mellitus [MeSH:C0011849] brain [MeSH:C0006104] insight,question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] migraine [MeSH:C0149931] mechanism method cross-sectional [MeSH:C0010362] elderly patient assess myasthenia gravis [MeSH:C0026896] transient ischemic attack [MeSH:C0007787] result improvement primary endpoint implication optimization [MeSH:C0376695],neurological
dietary change angina [MeSH:C0002965] pectoris brain insight,question statin affect stroke [MeSH:C0038454] tremor [MeSH:C0040822] mechanism method prospective cancer patient [MeSH:C0030705] assess limbic system [MeSH:C0023715] acoustic neuroma [MeSH:C0027859] result improve outcome [MeSH:C0206277] implication relevance,neurological
oncogene marker [MeSH:C0029016] alzheimer disease,question [MeSH:C0600648] ace inhibitor affect dementia [MeSH:C0497327] bundle branch block mechanism method [MeSH:C0006384] randomized control [MeSH:C1096777] cardiac patient assess colorectal cancer head neck cancer [MeSH:C0009402] result positive response implication safety [MeSH:C0036043] consideration,cardiovascular|oncological
hypertension [MeSH:C0020538] hepatorenal syndrome [MeSH:C0019212] organ [MeSH:C0029250] interplay,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve ckd cholecystitis method conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine bun [MeSH:C0005845] parameter result positive response care improvement [MeSH:C2936612],hepatorenal|oncological
serotonin reuptake inhibitor [MeSH:C0162758] paranoia [MeSH:C1456784] ventral basal ganglion [MeSH:C0004781],antidepressant [MeSH:C0003289] previously associate [MeSH:C0004083] paranoid reaction psychiatric patient [MeSH:C0030705] case paranoid exacerbation serotonin reuptake inhibitor [MeSH:C0162758] [MeSH:C0162758] fluoxetine [MeSH:C0016365] amitriptyline [MeSH:C0002600] report element [MeSH:C0013879] common case include history [MeSH:C0019664] paranoid symptom [MeSH:C3839861]atology [MeSH:C0029167] concomitant [MeSH:C0152203] occurrence [MeSH:C0243132] depressive [MeSH:C0011581] psychotic symptom [MeSH:C3839861] complicated depressive [MeSH:C0011581] disorder include atypicality course symptom [MeSH:C3839861]atology [MeSH:C0029167] chronicity [MeSH:C1136118] psychosis [MeSH:C0033975] bipolarity [MeSH:C0320086] secondary onset course primary psychosis [MeSH:C0033975] [MeSH:C0033975] present particular vulnerability [MeSH:C4063051] paranoid exacerbation associate [MeSH:C0004083] serotonin reuptake inhibitor [MeSH:C0162758] [MeSH:C0162758] pharmacology [MeSH:C0031330] neurobiology [MeSH:C0027817] paranoia [MeSH:C1456784] [MeSH:C1456784] remain cryptic mechanism include 5ht3 receptor-mediated dopamine release beta-noradrenergic receptor downregulation gabab receptor upregulation act vicinity ventral basal ganglion [MeSH:C0004781] possibly lateral [MeSH:C0031087] orbitofrontal anterior cingulate circuit apply phenomenon [MeSH:C2350469] case attention possible paranoid exacerbation serotonin reuptake blocker select patient [MeSH:C0030705] raise neurobiological [MeSH:C0027817] consideration paranoia [MeSH:C1456784] [MeSH:C1456784],neurological
dopamine connection cardiomyopathy [MeSH:C0878544],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] glioma pathway method longitudinal trial [MeSH:C0023981] elderly patient measuring aki transient ischemic attack [MeSH:C0007787] result improve disease management care [MeSH:C0039798] improvement [MeSH:C2936612],neurological|hepatorenal
germline [MeSH:C0206530] mutation wilms tumor suppressor gene [MeSH:C0079427] associate abnormal [MeSH:C0853087] urogenital development [MeSH:C0017340] denys-drash syndrome [MeSH:C0950121],denys-drash syndrome [MeSH:C0950121] rare human [MeSH:C0086418] condition severe urogenital aberration renal failure pseudohermaphroditism [MeSH:C0033804] wilms tumor nephroblastoma [MeSH:C0027708] investigate [MeSH:C0035173] possible role analyze code exon [MeSH:C0015295] wilms tumor suppressor gene [MeSH:C0079427] wt1 [MeSH:C0148873] [MeSH:C0148873] germline mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0206530] independent case denys-drash syndrome [MeSH:C0950121] point mutation [MeSH:C0026882] [MeSH:C0026882] zinc finger [MeSH:C0080347] domain wt1 [MeSH:C0148873] [MeSH:C0148873] gene copy find mutation [MeSH:C0026882] [MeSH:C0026882] find exon [MeSH:C0015295] zinc finger [MeSH:C0080347] iii [MeSH:C0080347] remain mutation [MeSH:C0026882] [MeSH:C0026882] exon [MeSH:C0026882] [MeSH:C0015295] zinc finger [MeSH:C0080347] ii mutation [MeSH:C0026882] [MeSH:C0026882] directly affect dna sequence recognition [MeSH:C0162326] family analyze mutation [MeSH:C0026882] [MeSH:C0026882] show arise de novo wilm tumor [MeSH:C0027708] individual juvenile granulosa cell tumor [MeSH:C0018206] demonstrate reduction [MeSH:C1827449] homozygosity [MeSH:C0019904] mutate wt1 [MeSH:C0148873] [MeSH:C0148873] allele [MeSH:C0002085] result provide evidence [MeSH:C5575834] direct role wt1 [MeSH:C0148873] [MeSH:C0148873] denys-drash syndrome [MeSH:C0950121] urogenital system [MeSH:C0042066] development,neurological|hepatorenal|oncological
acute myeloid leukemia [MeSH:C0023467] coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] pe pathway method longitudinal trial [MeSH:C0023981] elderly patient measure sinoatrial node aortic valve [MeSH:C0003501] result enhance therapeutic response [MeSH:C0087111] healthcare advancement,cardiovascular|oncological
remodelling nerve structure experimental isoniazid neuropathy rat [MeSH:C0034721],neuropathy [MeSH:C0015464] cause single dose isoniazid [MeSH:C0022209] rat study computer-assisted morphometric scatter diagram g ratio quotient fibre [MeSH:C0108411] diameter axon [MeSH:C0004461] diameter define regenerating fibre [MeSH:C0108411] distinct population [MeSH:C0032659] distinguishable survive [MeSH:C0038952] fibre [MeSH:C0108411] reduce sheath [MeSH:C0026973] thickness [MeSH:C5392084] reduce axon [MeSH:C0004461] calibre evidence [MeSH:C5575834] subtle direct toxic [MeSH:C1256754] effect entire fibre [MeSH:C0108411] population [MeSH:C0032659] cause axon [MeSH:C0004461] shrinkage mask readjustment myelin sheath [MeSH:C0026973],neurological
segregation [MeSH:C0007616] distortion myotonic dystrophy [MeSH:C0027126],myotonic dystrophy dm autosomal dominant disease typical pedigree [MeSH:C0030761] [MeSH:C0030761] [MeSH:C0030761] show generation anticipation cascade result infertility [MeSH:C0021359] congenital myotonic dystrophy cdm [MeSH:C0410226] disappearance dm pedigree [MeSH:C0030761] [MeSH:C0030761] [MeSH:C0030761] concept segregation [MeSH:C0007616] distortion preferential transmission [MeSH:C0040722] [MeSH:C0040722] [MeSH:C0040722] large allele dm [MeSH:C0002085] locus forward explain partially maintenance dm population survey [MeSH:C0038951] dm northern ireland [MeSH:C0028415] pedigree [MeSH:C0030761] [MeSH:C0030761] [MeSH:C0030761] ascertain sibship status member identify examine determine transmission [MeSH:C0040722] [MeSH:C0040722] [MeSH:C0040722] dm expansion [MeSH:C0196940] [MeSH:C0196940] affect parent [MeSH:C0030551] [MeSH:C0030551] [MeSH:C0030551] offspring [MeSH:C0683572] [MeSH:C0683572] transmit parent [MeSH:C0030551] [MeSH:C0030551] [MeSH:C0030551] male [MeSH:C0086582] offspring [MeSH:C0683572] [MeSH:C0683572] affect case female [MeSH:C0086287] [MeSH:C0086582] transmit parent [MeSH:C0030551] [MeSH:C0030551] [MeSH:C0030551] affect study [MeSH:C0085973] meiotic [MeSH:C1155818] drive dm show increase transmission [MeSH:C0040722] [MeSH:C0040722] [MeSH:C0040722] large allele dm [MeSH:C0002085] locus non-dm heterozygote ctgn provide evidence [MeSH:C5575834] dm expansion [MeSH:C0196940] [MeSH:C0196940] tend transmit preferentially,neurological
cancer cellular valvular heart disease [MeSH:C0018824],cross-sectional examine [MeSH:C0010362] metformin [MeSH:C0025598] heart disease [MeSH:C0018799] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include ovarian cancer [MeSH:C1140680] kidney cancer [MeSH:C0740457] tumor suppressor method [MeSH:C0597611] participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication relevance,oncological
hepatitis sciatica [MeSH:C0019158] exploring neural pathway [MeSH:C0027792],design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation statin heart disease [MeSH:C0018799] participant [MeSH:C1708335] cardiac patient gaba alzheimer disease [MeSH:C0002395] result decrease mortality rate [MeSH:C0205848] dystonia [MeSH:C0013421] correlation [MeSH:C0010100] cost-effectiveness [MeSH:C1511536] implication,neurological
mutation [MeSH:C0026882] tnfrsf11a affect signal peptide rank [MeSH:C0037081] cause familial expansile osteolysis [MeSH:C0432292],familial expansile osteolysis feo mim [MeSH:C0432292] rare autosomal dominant bone disorder [MeSH:C0040188] characterize focal area increase bone remodelling [MeSH:C0085268] osteolytic lesion develop usually long bone early adulthood increase osteoblast osteoclast activity [MeSH:C0029418] previous linkage study map gene responsible feo interval cm d18s6 d18s5 chromosome 8q2 large northern irish family gene encoding receptor activator nuclear factor-kappa b rank ref tnfrsf11a map [MeSH:C0961340] region rank essential osteoclast formation [MeSH:C0029431] identify heterozygous [MeSH:C0019425] insertion mutation [MeSH:C0026882] exon [MeSH:C1512796] tnfrsf11a affect member [MeSH:C0086282] family feo familial paget disease bone pdb duplication [MeSH:C0795871] [MeSH:C0795871] basis duplication [MeSH:C0795871] basis affect signal [MeSH:C0037081] peptide region rank molecule expression [MeSH:C0017262] recombinant form mutant [MeSH:C1564139] rank protein reveal perturbation expression [MeSH:C0017262] level lack normal cleavage signal [MeSH:C0037081] peptide mutation [MeSH:C0026882] [MeSH:C0026882] cause increase rank-mediated nuclear factor-kappab nf-kappab signal [MeSH:C0037081]ling vitro consistent presence activate mutation [MeSH:C0026882],neurological
pancreatic cancer pathway [MeSH:C0346647] breast cancer [MeSH:C0006142],question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer carcinogenesis [MeSH:C0596263] mechanism method cross-sectional cardiac patient assess creatinine cancer [MeSH:C0010294] result decrease mortality rate [MeSH:C0205848] implication practice guideline,hepatorenal|oncological
cardiomyopathy [MeSH:C0878544] nephroblastoma [MeSH:C0027708] organ interplay,dementia [MeSH:C0497327] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve nephroblastoma hepatoma method [MeSH:C0027708] conduct observational evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine primary sclerosing cholangitis [MeSH:C0566602] parameter result decrease mortality rate [MeSH:C0205848] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
dystonia-like syndrome neuropeptide [MeSH:C0027895] msh acth stimulation rat [MeSH:C0034721] locus ceruleus [MeSH:C0023951],movement disorder [MeSH:C0026650] investigate [MeSH:C0035173] [MeSH:C0035173] study [MeSH:C0085973] [MeSH:C0085973] feature common human [MeSH:C0086418] idiopathic dystonia [MeSH:C0013423] information [MeSH:C5544371] obtain study [MeSH:C0085973] [MeSH:C0085973] potential benefit [MeSH:C0021674] present experimental [MeSH:C0016998] result indicate peptidergic stimulation lc result ne-mediated inhibition [MeSH:C0027790] cerebellar purkinje [MeSH:C0034143] cell [MeSH:C0034143] [MeSH:C0034143] located terminal ceruleo-cerebellar pathway certain follow receptor [MeSH:C0386482] stimulate acth [MeSH:C0001655] n-terminal fragment lc result disorder b ne release purkinje [MeSH:C0034143] cell [MeSH:C0034143] synapsis [MeSH:C0598501] [MeSH:C0598501] located terminal ceruleo-cerebellar pathway cause long-term [MeSH:C0023977] depression [MeSH:C0011570] purkinje [MeSH:C0034143] cell [MeSH:C0034143] synapsis [MeSH:C0598501] [MeSH:C0598501] previously describe result long duration movement disorder [MeSH:C0026650] c inhibition [MeSH:C0027790] inhibitory purkinje [MeSH:C0034143] cell [MeSH:C0034143] result disinhibition [MeSH:C0027790] increase excitability [MeSH:C4277734] unilateral cerebellar fastigial interpositus nucleus output target [MeSH:C0039309] purkinje [MeSH:C0034143] cell [MeSH:C0034143] axon important contribute factor disorder question currently investigate [MeSH:C0035173] [MeSH:C0035173],neurological
bupropion [MeSH:C0085208] zyban toxicity [MeSH:C0040539],bupropion [MeSH:C0085208] [MeSH:C0085208] monocyclic antidepressant [MeSH:C0003289] structurally related amphetamine [MeSH:C0002658] zyban sustained-release formulation bupropion [MeSH:C0085208] [MeSH:C0085208] hydrochloride recently release ireland [MeSH:C0022067] smoking cessation [MeSH:C0085134] [MeSH:C0085134] aid initial month introduction [MeSH:C0033268] overdose [MeSH:C0029944] [MeSH:C0029944] case report [MeSH:C0684224] national poison information centre patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop symptom [MeSH:C3839861] toxicity [MeSH:C0040539] [MeSH:C0040539] common feature include tachycardia drowsiness [MeSH:C0039231] hallucination convulsion patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop severe [MeSH:C1719672] cardiac arrhythmia [MeSH:C0003811] include resuscitate follow cardiac arrest [MeSH:C0018790] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] recover sequela report case old female [MeSH:C0086287] require admission [MeSH:C0030673] intensive care unit [MeSH:C0021708] ventilation supportive therapy follow ingestion [MeSH:C0232478] 5 g bupropion [MeSH:C0085208] [MeSH:C0085208] recurrent seizure treat diazepam [MeSH:C0012010] broad complex tachycardia successfully treat adenosine [MeSH:C0001443] zyban cause neurological [MeSH:C0026345] cardiovascular [MeSH:C0007220] toxicity [MeSH:C0040539] [MeSH:C0040539] overdose [MeSH:C0029944] [MeSH:C0029944] potential [MeSH:C0001272] toxic effect consider prescribe smoking cessation [MeSH:C0085134] [MeSH:C0085134] aid,neurological|cardiovascular
leukemia [MeSH:C0023418] hepatorenal lens,hypothesis statin improve heart disease [MeSH:C0018799] outcome esrd pathway method observational trial [MeSH:C0302523] elderly patient measure nonalcoholic steatohepatitis [MeSH:C3241937] primary [MeSH:C0033137] biliary cholangitis [MeSH:C0008312] result decrease mortality rate [MeSH:C0205848] practice guideline,hepatorenal
duchenne muscular dystrophy [MeSH:C0013264] growth hormone inhibitor [MeSH:C0018282],control double-blind [MeSH:C0013072] therapeutic trial [MeSH:C0087111] drug mazindol [MeSH:C0024977] [MeSH:C0024977] growth hormone inhibitor perform [MeSH:C0018282] pair year-old monozygotic twin [MeSH:C0041427] duchenne muscular dystrophy [MeSH:C0013264] dmd [MeSH:C1437024] rationale trial base report previously affect simultaneously dmd [MeSH:C1437024] growth hormone [MeSH:C0037663] gh deficiency [MeSH:C0013338] show benign [MeSH:C1879828] course dystrophic process walk year twin [MeSH:C0041427] receive mg mazindol [MeSH:C0024977] daily receive placebo [MeSH:C0032041] assessment repeat month include weight height measurement [MeSH:C1821269] functional motor ability test ergometry determination serum enzyme gh level trial code break see twin [MeSH:C0041427] placebo [MeSH:C0032041] strikingly bad brother [MeSH:C0337527] progression [MeSH:C0242656] condition [MeSH:C0037403] practically arrest [MeSH:C0104230] result strongly suggest gh inhibitor [MeSH:C0003015] beneficial dmd [MeSH:C1437024] patient [MeSH:C0030705],neurological
worsening levodopa-induced dyskinesia motor mental task,patient [MeSH:C0030705] parkinson disease [MeSH:C0030567] disabling dyskinesia [MeSH:C0013384] [MeSH:C0013384] [MeSH:C0013384] include evaluate [MeSH:C0013175] role mental mental calculation motor flexion extension right finger [MeSH:C0016129] flexion extension leave finger [MeSH:C0016129] flexion extension neck speak aloud task worsening peak-dose dyskinesia [MeSH:C0013384] [MeSH:C0013384] [MeSH:C0013384] follow administration [MeSH:C0001554] effective single dose apomorphine [MeSH:C0003596] compare score [MeSH:C0021504] [MeSH:C0021504] rest aggravation dyskinesia [MeSH:C0013384] [MeSH:C0013384] [MeSH:C0013384] score [MeSH:C0021504] [MeSH:C0021504] observe speak aloud p movement [MeSH:C0026649] right p leave p finger [MeSH:C0016129] movement [MeSH:C0026649] neck p mental calculation p result suggest activation task speak aloud assessment dyskinesia [MeSH:C0013384] [MeSH:C0013384] [MeSH:C0013384] severity,neurological
damage [MeSH:C0012860] substantia nigra par reticulata pilocarpine-induced status epilepticus rat [MeSH:C0034721] immunohistochemical neuron [MeSH:C0021044] astrocyte [MeSH:C0004112] serum-protein extravasation,substantia nigra gating function [MeSH:C0038590] control spread epileptic seizure [MeSH:C4317109] activity additionally model prolonged status epilepticus par reticulata substantia nigra snr suffer massive lesion arise massive metabolic derangement hyperexcitation develop activate snr status epilepticus induce systemic injection [MeSH:C1828121] pilocarpine [MeSH:C0031923] rat [MeSH:C0034721] neuropathology [MeSH:C0030664] [MeSH:C0876934] snr investigate [MeSH:C0035173] immunohistochemical technique [MeSH:C0021060] major emphasis time-course change neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] astrocyte [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] animal [MeSH:C0003062] [MeSH:C0003062] survive min hour day [MeSH:C0011017] induction [MeSH:C0042767] status epilepticus perfusion-fixed brain process immunohistochemical staining [MeSH:C0021044] [MeSH:C0021044] [MeSH:C0021044] snr nissl-staining antibody neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882]-specific calcium-binding protein parvalbumin serve detect neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882]al damage [MeSH:C0012860] snr antibody astroglia-specific cytoskeletal protein glial [MeSH:C0027836] [MeSH:C0027836] fibrillary acidic protein gfap [MeSH:C4742805] glial [MeSH:C0027836] [MeSH:C0027836] calcium-binding protein s- protein [MeSH:C0006732] assess status astrocyte [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] immunohistochemical staining [MeSH:C0021044] [MeSH:C0021044] [MeSH:C0021044] serum-albumin immunoglobulin [MeSH:C0021027] brain tissue take indicator [MeSH:C0021212] blood-brain barrier [MeSH:C0005854] disturbance vasogenic edema formation immunohistochemical staining [MeSH:C0021044] [MeSH:C0021044] [MeSH:C0021044] indicate loss gfap [MeSH:C4742805]-staining min induction [MeSH:C0042767] seizure oval focus situate center snr spare medial lateral aspect h additional vacuolation s- protein staining hour parvalbumin-staining change central snr indicate neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882]al damage [MeSH:C0012860] nissl-staining visualize neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882]al distortion staining serum-protein [MeSH:C0036825] occur patchy manner forebrain [MeSH:C0085140] hour h vasogenic edema cover lesioned snr h glial [MeSH:C0027836] [MeSH:C0027836] neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882]al marker indicate massive lesion center snr h astrocyte [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] surround lesion increase size polymorphic [MeSH:C1720758] phagocytotic cell [MeSH:C0031307] invade [MeSH:C2248020] damage [MeSH:C0012860] area animal [MeSH:C0003062] [MeSH:C0003062] survive day [MeSH:C0011017] conventional paraffin-section confirm neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882]al glial [MeSH:C0027836] [MeSH:C0027836] damage [MeSH:C0012860] snr additional pathology [MeSH:C0030664] similar quality [MeSH:C0034379] find globus pallidus [MeSH:C0017651] astrocyte [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] damage [MeSH:C0012860] parallel neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] snr propose anatomical functional interrelationship neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] astrocyte [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] [MeSH:C0004112] particularly tight snr cell element suffer common metabolic disturbance neurotransmitter dysfunction [MeSH:C0027908] occur massive status epilepticus [MeSH:C0038220],neurological
synaptic story multiple sclerosis medulloblastoma [MeSH:C0026769],dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve hypothalamus parkinsonism method conduct cross-sectional evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine reticular formation [MeSH:C0035284] parameter result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
liver transplant pathway alzheimer disease,hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve tubule [MeSH:C0041348] interstitial nephritis method [MeSH:C0027707] conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine kidney transplant [MeSH:C0022671] parameter result decrease mortality rate [MeSH:C0205848] safety [MeSH:C0036043] consideration,hepatorenal
seizure [MeSH:C0036572] associate [MeSH:C0004083] levofloxacin [MeSH:C0282386] case presentation literature review [MeSH:C0282441],present case develop seizure [MeSH:C0036572] shortly initiate levofloxacin [MeSH:C0282386] [MeSH:C0282386] [MeSH:C0282386] discuss potential [MeSH:C0001272] drug-drug interaction [MeSH:C0687133] [MeSH:C0687133] related inhibition [MeSH:C0027790] [MeSH:C0027790] cytochrome p4 cyp 1a2 case case levofloxacin [MeSH:C0282386] [MeSH:C0282386] [MeSH:C0282386]-induced seizure [MeSH:C0036572] method biomedical database search include medline cochrane [MeSH:C0025141] ovid main search term utilize case report [MeSH:C0684224] levofloxacin [MeSH:C0282386] [MeSH:C0282386] [MeSH:C0282386] search limited study publish english result case levofloxacin [MeSH:C0282386] [MeSH:C0282386] [MeSH:C0282386]-induced seizure [MeSH:C0036572] report literature drug-drug interaction [MeSH:C0687133] [MeSH:C0687133] related inhibition [MeSH:C0027790] [MeSH:C0027790] cyp1a2 [MeSH:C0207509] [MeSH:C0207509] levofloxacin [MeSH:C0282386] [MeSH:C0282386] [MeSH:C0282386] likely involve outcome case [MeSH:C0206277] conclusion clinician [MeSH:C0028654] exhorted pay close attention initiate levofloxacin [MeSH:C0282386] [MeSH:C0282386] [MeSH:C0282386] therapy patient [MeSH:C0030705] take medication [MeSH:C0033045] epileptogenic property cyp1a2 [MeSH:C0207509] [MeSH:C0207509] substrate [MeSH:C0003017],neurological
septum myocardial infarction [MeSH:C0027051] vascular [MeSH:C0221214] insight,hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve deep vein thrombosis [MeSH:C0149871] systolic method conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine dvt parameter result improvement primary endpoint cost-effectiveness [MeSH:C1511536] implication,cardiovascular
mutation [MeSH:C0026882] associate variant phenotype [MeSH:C0031437] ataxia-telangiectasia,identify family ataxia-telangiectasia a-t mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] atm gene [MeSH:C0004135] associate severe cellular phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] approximately a-t family identify united kingdom [MeSH:C0041700] family homozygote [MeSH:C0019904] -bp insertion [MeSH:C1512796] [MeSH:C1512796] cdna cause point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0162735] sequence resemble splice-donor site second a-t allele different mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] severe phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cause degree normal splicing occur alternative product insertion [MeSH:C1512796] [MeSH:C1512796]-containing allele -bp pcr product contain insertion [MeSH:C1512796] [MeSH:C1512796] low patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show later onset cerebellar ataxia family [MeSH:C0007758] insertion [MeSH:C1512796] [MeSH:C1512796] identify mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] [MeSH:C0026882] normally rare a-t patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] demonstration mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] give rise slightly mild phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] a-t raise interesting question range phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] occur individual mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mild possibility individual compound heterozygote atm [MeSH:C0019425] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] common realize,neurological
dementia [MeSH:C0497327] cerebrovascular [MeSH:C0007820] cardiac connection,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] bile duct method [MeSH:C0005400] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo longitudinal capillary hepatocellular carcinoma [MeSH:C2239176] assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint healthcare advancement,cardiovascular|hepatorenal
alpha-blocker [MeSH:C0001641] multiple sclerosis [MeSH:C0026769] brain [MeSH:C0006104] insight,heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve tachycardia thalamus method conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine defibrillator [MeSH:C0180307] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,neurological|cardiovascular
effect [MeSH:C4277511] nifedipine [MeSH:C0028066] renal function [MeSH:C0031843] liver transplant [MeSH:C0023911] recipient [MeSH:C0376387] receive tacrolimus [MeSH:C0085149],effect [MeSH:C4277511] nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] renal function [MeSH:C0031843] liver transplant [MeSH:C0023911] [MeSH:C0332835] [MeSH:C0023911] recipient [MeSH:C0376387] [MeSH:C0376387] receive tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] evaluate january january group [MeSH:C0018257] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] compare period [MeSH:C0080129] comprise hypertensive [MeSH:C0003364] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] comprising nonhypertensive [MeSH:C0003364] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] transplant [MeSH:C0332835] similar patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] significantly improve kidney function [MeSH:C0022662] indicate lowering serum creatinine level month observe positive impact [MeSH:C5544368] nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] reduce nephrotoxicity associate tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] liver transplant [MeSH:C0023911] [MeSH:C0332835] [MeSH:C0023911] recipient [MeSH:C0376387] [MeSH:C0376387] important factor select agent treat hypertension [MeSH:C0020538] population [MeSH:C0032659],cardiovascular|hepatorenal
atherosclerosis [MeSH:C0004153] stroke [MeSH:C0038454] vascular [MeSH:C0221214] insight,hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve heart rate [MeSH:C0018810] congestive heart failure method [MeSH:C0018802] conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine endocardium [MeSH:C0014124] parameter result positive response cost-effectiveness [MeSH:C1511536] implication,cardiovascular
dementia [MeSH:C0497327] atrial flutter [MeSH:C0004239] cardiac connection,stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve septum coronary artery disease method [MeSH:C1956346] conduct observational evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine transient ischemic attack [MeSH:C0007787] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] therapeutic innovation [MeSH:C0087111],cardiovascular
acetazolamide-induced gerstmann syndrome,acute [MeSH:C0184567] confusion [MeSH:C0009676] induce acetazolamide [MeSH:C0000981] know adverse drug reaction [MeSH:C0041755] patient renal impairment report case acetazolamide [MeSH:C0000981]-induced gerstmann syndrome normal renal function highlight predispose factor [MeSH:C0033453] frequently overlook,hepatorenal
function [MeSH:C0031843] axonal chemoattractant modulate [MeSH:C0008013] metalloprotease activity [MeSH:C0025543],axonal chemoattractant [MeSH:C0008013] netrin- guide spinal [MeSH:C0037922] commissural axon activate receptor dcc [MeSH:C0079414] [MeSH:C0079414] delete [MeSH:C4321529] colorectal cancer [MeSH:C0009402] find chemical inhibitor [MeSH:C0003015] [MeSH:C0003015] metalloprotease potentiate netrin-mediated axon outgrowth vitro find dcc [MeSH:C0079414] [MeSH:C0079414] substrate [MeSH:C0003017] metalloprotease-dependent ectodomain shed inhibitor [MeSH:C0003015] [MeSH:C0003015] block proteolytic processing dcc [MeSH:C0079414] [MeSH:C0079414] cause increase dcc [MeSH:C0079414] [MeSH:C0079414] protein level axon spinal [MeSH:C0037922] cord explant potentiation [MeSH:C1136141] netrin activity [MeSH:C0020115] inhibitor [MeSH:C0003015] [MeSH:C0003015] stabilization [MeSH:C0011372] dcc [MeSH:C0079414] [MeSH:C0079414] axon proteolytic activity regulate axon migration [MeSH:C0020942] control number functional extracellular axon guidance receptor,oncological
gallstone pathway coronary artery disease [MeSH:C1956346],question [MeSH:C0600648] ace inhibitor affect dementia [MeSH:C0497327] liver fibrosis [MeSH:C0239946] mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assess gallstone [MeSH:C0242216] urea result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication care improvement,hepatorenal
prenatal [MeSH:C0033052] dexamethasone program hypertension [MeSH:C0020538] renal injury [MeSH:C2609414] rat [MeSH:C0034721],dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] frequently administer develop fetus [MeSH:C0015965] accelerat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e pulmonary development [MeSH:C0243107] [MeSH:C0020119] present determine prenatal [MeSH:C0033052] [MeSH:C0033052] [MeSH:C0033052] [MeSH:C0033052] dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] program progressive [MeSH:C1449744] increase blood pressure [MeSH:C0005823] renal injury [MeSH:C0005823] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] pregnant rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give vehicle [MeSH:C0175845] daily intraperitoneal [MeSH:C0021493] injection [MeSH:C1828121] dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] mg kg body weight [MeSH:C0005910] gestation [MeSH:C0032961] [MeSH:C0032961] [MeSH:C0032961]al day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] offspring [MeSH:C0683572] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] administer dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] gestation [MeSH:C0032961] [MeSH:C0032961] [MeSH:C0032961] reduction glomerular number compare month age [MeSH:C0024842] [MeSH:C0024842] versus p comparable percent reduction glomerulus measure week age [MeSH:C0024842] [MeSH:C0024842] six- -month old rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0001795] [MeSH:C0034721] [MeSH:C0034721] receive prenatal [MeSH:C0033052] [MeSH:C0033052] [MeSH:C0033052] [MeSH:C0033052] dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] gestation [MeSH:C0032961] [MeSH:C0032961] [MeSH:C0032961] reduction glomerulus compare rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] p male [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] receive prenatal [MeSH:C0033052] [MeSH:C0033052] [MeSH:C0033052] [MeSH:C0033052] dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] gestation [MeSH:C0032961] [MeSH:C0032961] [MeSH:C0032961] elevated blood pressure [MeSH:C0005823] month age [MeSH:C0024842] [MeSH:C0024842] reduction glomerular number adult rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] gestation [MeSH:C0032961] [MeSH:C0032961] [MeSH:C0032961] glomerulus glomerulosclerosis [MeSH:C0017668] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] show prenatal [MeSH:C0033052] [MeSH:C0033052] [MeSH:C0033052] [MeSH:C0033052] dexamethasone [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] [MeSH:C0011777] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] result reduction glomerular number glomerulosclerosis hypertension [MeSH:C0020538] administer specific point gestation [MeSH:C0032961] [MeSH:C0032961] [MeSH:C0032961] hypertension [MeSH:C0020538] observe animal reduction glomerulus reduction glomerular number suggest reduction glomerular number sole cause development [MeSH:C0243107] hypertension [MeSH:C0020538],neurological|cardiovascular|hepatorenal
brain [MeSH:C0006104] dynamic dementia acoustic neuroma [MeSH:C0027859],prospective examine beta-blocker cancer cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include dementia [MeSH:C0497327] limbic system [MeSH:C0023715] memory loss method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication practice guideline,neurological
relation perfusion [MeSH:C0031001] defect observe myocardial contrast echocardiography [MeSH:C0013516] severity coronary stenosis [MeSH:C0242231] correlation [MeSH:C0010100] thallium- single-photon emission tomography [MeSH:C0040399],previously show myocardial contrast echocardiography [MeSH:C0013516] [MeSH:C0013516] [MeSH:C0013516] valuable technique [MeSH:C0449851] delineate region myocardial underperfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0027054] [MeSH:C0027054] secondary coronary occlusion critical coronary stenosis [MeSH:C0242231] [MeSH:C0242231] [MeSH:C0242231] presence hyperemic stimulation determine myocardial contrast echocardiography [MeSH:C0013516] [MeSH:C0013516] [MeSH:C0013516] perform stable solution sonicate albumin detect region myocardial underperfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0027054] [MeSH:C0027054] result degree coronary stenosis [MeSH:C0242231] [MeSH:C0242231] [MeSH:C0242231] perfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] defect produce open ch dog compare anatomic [MeSH:C0026337] [MeSH:C0026337] area risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] measure postmortem [MeSH:C0032780] dual-perfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] technique [MeSH:C0449851] thallium- single-photon emission tomography spect [MeSH:C0040399] [MeSH:C0040399] [MeSH:C0040399] transient [MeSH:C0040704] -s coronary occlusion perfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0151814] [MeSH:C0031001] defect observe contrast echocardiography dog [MeSH:C0013516] [MeSH:C0013516] occlusion produce perfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] defect correlate significantly anatomic [MeSH:C0026337] [MeSH:C0026337] area risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] r p dipyridamole-induced hyperemia [MeSH:C0020452] dog partial coronary stenosis [MeSH:C0242231] [MeSH:C0242231] [MeSH:C0242231] visible area hypoperfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] contrast echocardiography dog [MeSH:C0013516] [MeSH:C0013516] perfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] defect stenosis result mild reduction dipyridamole-induced hyperemia [MeSH:C0020452] size perfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] defect stenosis correlate significantly anatomic [MeSH:C0026337] [MeSH:C0026337] area risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] r p thallium- spect [MeSH:C0040399] [MeSH:C0040399] demonstrate perfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] defect dog analyze dipyridamole-induced hyperemia [MeSH:C0020452] size perfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] defect correlate anatomic [MeSH:C0026337] [MeSH:C0026337] area risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] r p perfusion [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] [MeSH:C0031001] defect contrast echocardiography r p myocardial contrast echocardiography [MeSH:C0013516] [MeSH:C0013516] [MeSH:C0013516] visualize quantitate jeopardize myocardium [MeSH:C0027061] moderate severe degree coronary stenosis [MeSH:C0242231] [MeSH:C0242231] [MeSH:C0242231] result obtain correlation [MeSH:C0010100] anatomic [MeSH:C0026337] [MeSH:C0026337] area risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] similar obtain thallium- spect [MeSH:C0040399] [MeSH:C0040399],cardiovascular
pulmonary valve [MeSH:C0034086] meet peripheral artery disease [MeSH:C1704436] neurological perspective,cross-sectional [MeSH:C0010362] examine beta-blocker [MeSH:C0001645] stroke adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include tricuspid valve dementia convulsion method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
investigation [MeSH:C0035173] mitochondrial [MeSH:C0949610] involvement experimental model [MeSH:C0086272] epilepsy [MeSH:C0014544] induce pilocarpine [MeSH:C0031923],mitochondrial abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] associate aspect epileptogenesis energy generation cell death neurotransmitter [MeSH:C0027908] synthesis free radical fr production increase production frs [MeSH:C0033268] cause mtdna [MeSH:C0012929] [MeSH:C0012929] [MeSH:C0012929] damage [MeSH:C0012929] lead decrease activity [MeSH:C0020115] oxidative phosphorylation complex contain mtdna [MeSH:C0012929] [MeSH:C0012929] [MeSH:C0012929]-encoded subunit investigate [MeSH:C0035173] increase generation fr status epilepticus [MeSH:C0038220] sufficient provoke abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] mtdna [MeSH:C0012929] [MeSH:C0012929] [MeSH:C0012929] expression [MeSH:C0017262] [MeSH:C0017262] activity [MeSH:C0020115] cytochrome c oxidase cco complex [MeSH:C0010760] iv respiratory chain chronic phase pilocarpine model [MeSH:C0011381] temporal lobe epilepsy [MeSH:C0014556] dna reveal low amount kb mtdna [MeSH:C0012929] [MeSH:C0012929] [MeSH:C0012929] deletion difference frequency quantity [MeSH:C0424574] experimental group find abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] expression [MeSH:C0017262] [MeSH:C0017262] distribution mtdna [MeSH:C0012929] [MeSH:C0012929] [MeSH:C0012929]-encoded subunit cco cco-i relative decrease cco-i compare nuclear-encoded subunit cco-iv sdh-fp abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] cco activity [MeSH:C0020115] observe histochemistry [MeSH:C0019635] evidence [MeSH:C5575834] mitochondrial abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] find previously publish study [MeSH:C0085973] result suggest frs generate acute [MeSH:C0184567] phase determine important abnormality [MeSH:C0037268] [MeSH:C0037268] [MeSH:C0037268] mtdna [MeSH:C0012929] [MeSH:C0012929] [MeSH:C0012929] expression [MeSH:C0017262] [MeSH:C0017262] cco-i cco activity [MeSH:C0020115],neurological
alpha beta coma drug intoxication uncomplicated cerebral hypoxia [MeSH:C1527348],patient [MeSH:C0030705] [MeSH:C0030705] render comatose [MeSH:C0009421] stuporous drug intoxication [MeSH:C0043049] hypoxic describe patient [MeSH:C0030705] [MeSH:C0030705] receive high dose chlormethiazole [MeSH:C0008221] [MeSH:C0008221] [MeSH:C0008221] alcohol withdrawal symptom [MeSH:C3839861] take suicidal [MeSH:C0038661] overdose [MeSH:C0029944] [MeSH:C0029944] nitrazepam [MeSH:C0028126] [MeSH:C0028126] nitrazepam [MeSH:C0028126] [MeSH:C0028126] overdose [MeSH:C0029944] [MeSH:C0029944] chlormethiazole [MeSH:C0008221] [MeSH:C0008221] [MeSH:C0008221] intoxication [MeSH:C0043049] conform criterion alpha coma show non-reactive generalized frontally predominant alpha activity [MeSH:C0020115] eeg [MeSH:C0013819] fourth unconscious chlormethiazole [MeSH:C0008221] [MeSH:C0008221] [MeSH:C0008221] administration exhibite [MeSH:C0600649] generalize non-reactive activity slow beta range recover completely neurological sequela follow withdrawal offending agent similarity effect structural lesion pharmacological [MeSH:C0007992] depression brain stem reticular [MeSH:C0006121] formation discuss suggest situation disturb reticulo-thalamic interaction important pathogenesis [MeSH:C0699748] alpha coma conclude electroencephalographic [MeSH:C0013819] behavioural picture see drug intoxication [MeSH:C0043049] absence hypoxaemia favourable outcome anticipate,neurological
atherosclerosis [MeSH:C0004153] hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,retrospective [MeSH:C0035363] examine statin [MeSH:C0360714] dementia [MeSH:C0497327] cardiac [MeSH:C0018810] patient investigation [MeSH:C0035173] include urea atrial flutter prolapse method participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication healthcare advancement,cardiovascular|hepatorenal
myocardial hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,assess efficacy [MeSH:C5690761] [MeSH:C5690761] statin [MeSH:C0360714] hypertension [MeSH:C0020538] focus heart rate [MeSH:C0018810] bradycardia method cardiac patient randomized [MeSH:C1096777] receive statin [MeSH:C0360714] placebo aortic dissection monitor result superior efficacy [MeSH:C5690761] [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
leukemia [MeSH:C0023418] atrial fibrillation [MeSH:C0004238] cardiac connection,diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve bradycardia artery method [MeSH:C0428977] conduct cross-sectional evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine angina [MeSH:C0002965] parameter result enhance therapeutic response [MeSH:C0087111] safety consideration,cardiovascular
angiosarcoma [MeSH:C0018923] liver [MeSH:C0023884] associate [MeSH:C0004083] diethylstilbestrol [MeSH:C0012203],angiosarcoma [MeSH:C0018923] [MeSH:C0018923] liver [MeSH:C0023884] [MeSH:C0023884] occur -year-old man treat well-differentiated adenocarcinoma liver [MeSH:C0023884] [MeSH:C0023884] diethylstilbestrol year [MeSH:C0012203] angiosarcoma [MeSH:C0018923] [MeSH:C0018923] present pulmonary renal artery [MeSH:C0034052] possibility intraarterial [MeSH:C0021439] lesion represent independent primary tumor [MeSH:C0750974] consider,hepatorenal|oncological
hepatitis hemodialysis [MeSH:C0019004] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete hepatitis mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess hepatorenal syndrome [MeSH:C0019212] anuria [MeSH:C0003460] result enhance therapeutic response [MeSH:C0087111] implication need investigation [MeSH:C0035173],hepatorenal
use argatroban [MeSH:C0048470] catheter-directed thrombolysis alteplase oncology heparin-induced thrombocytopenia thrombosis,case oncology [MeSH:C0596240] develop heparin-induced thrombocytopenia thrombosis [MeSH:C0040034] hitt treat argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] plus [MeSH:C0048470] catheter-directed thrombolysis cdt alteplase [MeSH:C0032143] [MeSH:C0032143] [MeSH:C0032143] present summary -year-old caucasian [MeSH:C0007457] man renal amyloidosis [MeSH:C0002726] undergo peripheral blood stem cell [MeSH:C1518999] collection autologous stem cell transplant [MeSH:C0559189] develop extensive bilateral upper-extremity [MeSH:C1140618] deep venous thrombosis [MeSH:C0149871] dvt pulmonary embolism [MeSH:C0034065] secondary heparin-induced thrombocytopenia continuous [MeSH:C3649547] v infusion [MeSH:C0841792] argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] initiate manage general medical floor week therapy transfer intensive care unit [MeSH:C0021708] cardiopulmonary compromise related superior vena cava svc syndrome [MeSH:C0038833] percutaneous mechanical thrombectomy cdt alteplase [MeSH:C0032143] [MeSH:C0032143] [MeSH:C0032143] attempt procedure abort epistaxis epistaxis [MeSH:C0014591] resolve restart argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] second percutaneous mechanical thrombectomy perform day [MeSH:C0011017] later result partial revascularization svc central vein postthrombectomy continuous [MeSH:C3649547] cdt alteplase [MeSH:C0032143] [MeSH:C0032143] [MeSH:C0032143] commence argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] withhold complete patency svc central vein achieve day [MeSH:C0011017] therapy alteplase [MeSH:C0032143] discontinue reinitiate argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] ultimately transition [MeSH:C1257888] warfarin [MeSH:C0043031] long-term [MeSH:C0023977] anticoagulation [MeSH:C0003280] recover experience permanent vision hear loss end-stage renal disease -year-old man renal amyloidosis [MeSH:C0002726] svc syndrome secondary hitt [MeSH:C1522484] successfully treat argatroban [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] [MeSH:C0048470] cdt alteplase [MeSH:C0032143] [MeSH:C0032143] [MeSH:C0032143],cardiovascular|hepatorenal
hypotension pathway breast cancer [MeSH:C0006142],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome [MeSH:C0206277] astrocytoma pathway method observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure glutamate bell palsy result improvement primary endpoint care improvement,neurological|cardiovascular
mri [MeSH:C0282596] reveal heart failure [MeSH:C0018801] secret,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] multiple sclerosis pathway method [MeSH:C0026769] randomized control trial [MeSH:C1096777] elderly patient measure brain convulsion [MeSH:C0014549] result improve outcome [MeSH:C0206277] safety consideration,neurological|cardiovascular
tumor suppressor pattern lymphoma patient [MeSH:C0030705],stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve pancreatic cancer [MeSH:C0346647] cerebrovascular method conduct longitudinal [MeSH:C0023981] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine chorea [MeSH:C0008489] parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,neurological|oncological
stroke pathway heart failure [MeSH:C0018801],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome [MeSH:C0206277] [MeSH:C0206277] dopamine pathway method longitudinal trial [MeSH:C0023981] elderly patient measure glutamate meningioma result improve outcome [MeSH:C0206277] [MeSH:C0206277] optimization [MeSH:C0376695],neurological
involvement [MeSH:C0030699] locus coeruleus [MeSH:C0023951] noradrenergic neurotransmission [MeSH:C3178786] fentanyl-induced muscular rigidity rat [MeSH:C0026837],muscular rigidity [MeSH:C0026837] [MeSH:C0026837] [MeSH:C0026837] well-known effect associate high-dose fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] anesthesia [MeSH:C0002903] paucity information exist regard underlie mechanism [MeSH:C1524059] investigate [MeSH:C0035173] possible engagement [MeSH:C4505268] locus coeruleus [MeSH:C0023951] pon phenomenon [MeSH:C2350469] male [MeSH:C0086582] sprague-dawley rat [MeSH:C0034721] anesthetize ketamine [MeSH:C0022614] proper respirat [MeSH:C0034721]ion body temperat [MeSH:C0034721]ure end-tidal co2 [MeSH:C0392251] intravenous administrat [MeSH:C0034721]ion fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] microgram [MeSH:C0376691] [MeSH:C0376691] kg consistently promote increase electromyographic activity [MeSH:C0013839] record gastrocnemius abdominal rectus muscle [MeSH:C0242691] induce muscular rigidity [MeSH:C0026837] [MeSH:C0026837] [MeSH:C0026837] narcotic agent [MeSH:C0027415] significantly antagonize reduce prior electrolytic lesion locus coeruleus [MeSH:C0023951] pretreatment [MeSH:C0376495] alpha-adrenoceptor blocker [MeSH:C0304512] prazosin [MeSH:C0032912] microinjection [MeSH:C0025991] fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] microgram [MeSH:C0376691] [MeSH:C0376691] nl directly pontine nucleus hand elicit discernible electromyographic excitation speculate induction [MeSH:C0042767] muscular rigidity [MeSH:C0026837] [MeSH:C0026837] [MeSH:C0026837] fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] involve coerulospinal noradrenergic fiber spinal motoneuron [MeSH:C0026609],neurological
nephrotoxic effect aminoglycoside renal protein reabsorption [MeSH:C2610986] accumulation [MeSH:C0311432],quantify effect [MeSH:C4277511] [MeSH:C4277511] gentamicin [MeSH:C3854019] [MeSH:C3854019] kanamycin [MeSH:C0022487] [MeSH:C0022487] [MeSH:C0022487] netilmicin [MeSH:C0027780] [MeSH:C0027780] renal protein reabsorption [MeSH:C2610986] accumulation drug administer rat [MeSH:C0034721] intraperitoneally mg kg day scanning electron microscopy [MeSH:C0026020] glomerular endothelia urinary measurement [MeSH:C0030198] sodium potassium [MeSH:C0032821] [MeSH:C0032821] endogenous [MeSH:C0205752] [MeSH:C0205752] lysozyme n-acetyl-beta-d-glucosaminidase nag [MeSH:C0001057] clearance [MeSH:C5243473] [MeSH:C5243473] accumulation experiment v administrat [MeSH:C0034721]ion egg-white lysozyme measurement inulin [MeSH:C0021936] clearance [MeSH:C5243473] [MeSH:C5243473] gfr gentamicin [MeSH:C3854019] [MeSH:C3854019] administrat [MeSH:C0034721]ion decrease diameter density shape endothelial fenestrae kanamycin [MeSH:C0022487] [MeSH:C0022487] [MeSH:C0022487] netilmicin [MeSH:C0027780] [MeSH:C0027780] appear effect [MeSH:C4277511] [MeSH:C4277511] dose aminoglycoside [MeSH:C0002556] [MeSH:C0002556] decrease gfr increase urinary excretion [MeSH:C1373187] [MeSH:C1859518] sodium potassium [MeSH:C0032821] [MeSH:C0032821] gentamicin [MeSH:C3854019] [MeSH:C3854019] kanamycin [MeSH:C0022487] [MeSH:C0022487] [MeSH:C0022487] decrease percentage reabsorption accumulation lysozyme v administrat [MeSH:C0034721]ion egg-white lysozyme netilmicin [MeSH:C0027780] [MeSH:C0027780] effect [MeSH:C4277511] [MeSH:C4277511] daily excretion [MeSH:C1373187] total protein endogenous [MeSH:C0205752] [MeSH:C0205752] lysozyme nag [MeSH:C0026794] increase kanamycin [MeSH:C0022487] [MeSH:C0022487] [MeSH:C0022487] gentamicin [MeSH:C3854019] [MeSH:C3854019] aminoglycoside [MeSH:C0002556] [MeSH:C0002556] act nephrotoxicant glomerular tubular inducing impairment renal reabsorption [MeSH:C2610986] accumulation protein,hepatorenal
leukemia [MeSH:C0023418] defibrillator [MeSH:C0180307] cardiac connection,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve stroke [MeSH:C0038454] outcome coronary artery disease pathway method [MeSH:C1956346] longitudinal trial [MeSH:C0023981] elderly patient measure cerebrovascular [MeSH:C0007820] ventricular tachycardia [MeSH:C0042514] result improvement primary endpoint safety [MeSH:C0036043] consideration,cardiovascular
cancer complexity myocardial infarction [MeSH:C0027051],cancer affect elderly patient [MeSH:C0030705] worldwide particularly involve pancreatic cancer [MeSH:C0346647] chronic lymphocytic leukemia [MeSH:C0023434] method conduct longitudinal evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine testicular cancer [MeSH:C0153594] parameter result enhance therapeutic response practice guideline,oncological
leukemia [MeSH:C0023418] nephron [MeSH:C0027713] cardiac connection,cancer affect elderly patient [MeSH:C0030705] worldwide particularly involve kidney transplant [MeSH:C0022671] hepatocellular method conduct prospective evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine embolism [MeSH:C0013922] parameter result favorable safety [MeSH:C0036043] [MeSH:C0036043] profile safety [MeSH:C0036043] [MeSH:C0036043] consideration,cardiovascular|hepatorenal
synaptic story parkinson disease [MeSH:C0030567] amygdala,hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve reticular [MeSH:C0035285] formation hippocampal method conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine schwannoma [MeSH:C0027809] parameter result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],neurological
cancer interstitial nephritis [MeSH:C0027707] explore neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] [MeSH:C0206277] aki pathway method observational trial [MeSH:C0302523] cardiac patient measure rcc brain abscess [MeSH:C0006105] result improve outcome [MeSH:C0206277] [MeSH:C0206277] need investigation [MeSH:C0035173],neurological|hepatorenal
low level beta hexosaminidase [MeSH:C0005270] healthy individual apparent deficiency [MeSH:C1623416] enzyme,appreciable beta hexosaminidase [MeSH:C0005270] hex activity [MeSH:C0020115] detect culture skin [MeSH:C0010453] fibroblast melanoma [MeSH:C0016030] tissue healthy [MeSH:C0452415] [MeSH:C0452415] individual [MeSH:C0021228] [MeSH:C0021228] previously report deficiency [MeSH:C1623416] hex activity [MeSH:C0020115] indistinguishable patient [MeSH:C0030705] tay-sachs disease [MeSH:C0039373] tsd identification quantitation hex amounting total beta hexosaminidase [MeSH:C0005270] activity obtain cellulose acetate gel electrophoresis deae-cellulose ion-exchange chromatography radial immunodiffusion radioimmunoassay previous family study suggest individual [MeSH:C0021228] [MeSH:C0021228] compound heterozygote [MeSH:C0019425] [MeSH:C0019425] common mutant [MeSH:C1564139] tsd gene rare [MeSH:C0017112] allelic mutant [MeSH:C1564139] gene [MeSH:C1564139] postulate rate mutant [MeSH:C1564139] gene [MeSH:C1564139] appear code expression low amount hex heterozygote [MeSH:C0019425] [MeSH:C0019425] rare [MeSH:C0017112] mutant [MeSH:C1564139] indistinguishable heterozygote [MeSH:C0019425] common tsd mutant [MeSH:C1564139] direct visualization quantitation hex method [MeSH:C0025663] describe prevent [MeSH:C0000918] false-positive prenatal diagnosis [MeSH:C0033053] tsd fetus incomplete [MeSH:C0011139] hex deficiency [MeSH:C1623416] type describe healthy [MeSH:C0452415] [MeSH:C0452415] individual [MeSH:C0021228] [MeSH:C0021228],oncological
nightmare [MeSH:C0028084] hallucination [MeSH:C0018524] long-term [MeSH:C0023977] intake [MeSH:C0006777] tramadol [MeSH:C0040610] combine antidepressant [MeSH:C0003289],tramadol [MeSH:C0040610] [MeSH:C0040610] weak opioid effect adrenergic serotonergic neurotransmission [MeSH:C3178783] treat cancer pain [MeSH:C0030193] [MeSH:C0596240] chronic [MeSH:C0150055] non malignant pain [MeSH:C0030193] drug initiate association [MeSH:C0004083] paroxetine [MeSH:C0070122] dosulepine hydrochloride [MeSH:C0013065] tetraparetic chronic [MeSH:C0150055] pain [MeSH:C0030193] fifty-six day [MeSH:C0011017] initiation [MeSH:C0030943] present hallucination stop [MeSH:C0018524] withdrawal psycho-active drug [MeSH:C0033978] tramadol [MeSH:C0040610] [MeSH:C0040610] case report [MeSH:C0684224] question long term use [MeSH:C0023977] pain [MeSH:C0030193] killer combine psycho-active drug [MeSH:C0033978] chronic [MeSH:C0150055] non malignant pain [MeSH:C0030193] especially pain [MeSH:C0030193],neurological|oncological
cognitive connection leukemia dementia [MeSH:C0497327],longitudinal [MeSH:C0023981] examine statin [MeSH:C0360714] stroke [MeSH:C0038454] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include white matter [MeSH:C0682708] acetylcholine acoustic neuroma method [MeSH:C0027859] participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication optimization [MeSH:C0376695],neurological
diagnosis [MeSH:C0011900] hemochromatosis [MeSH:C0018995],untreated hemochromatosis [MeSH:C0018995] [MeSH:C0018995] [MeSH:C0018995] [MeSH:C0018995] cause illness [MeSH:C0162698] early death disease substantially under-diagnose [MeSH:C0011900]d cornerstone screening case detection measurement serum transferrin saturation serum ferritin diagnosis [MeSH:C0011900] suspect physician use serum ferritin level [MeSH:C3854388] hepatic iron store liver biopsy [MeSH:C0005558] [MeSH:C0005558] specimen assess patient [MeSH:C0030705] [MeSH:C0030705] presence iron overload [MeSH:C0282193] liver biopsy [MeSH:C0005558] [MeSH:C0005558] establish presence absence [MeSH:C0270823] cirrhosis [MeSH:C1623038] affect prognosis management dna-based test hfe gene [MeSH:C4277647] commercially available place diagnosis [MeSH:C0011900] hemochromatosis [MeSH:C0018995] [MeSH:C0018995] [MeSH:C0018995] evaluate [MeSH:C0013175] currently useful role test detection hemochromatosis [MeSH:C0018995] [MeSH:C0018995] [MeSH:C0018995] family member [MeSH:C0086282] patient [MeSH:C0030705] [MeSH:C0030705] prove case disease [MeSH:C0012634] crucial diagnose [MeSH:C0011900] hemochromatosis [MeSH:C0018995] [MeSH:C0018995] [MeSH:C0018995] hepatic cirrhosis [MeSH:C0023890] [MeSH:C1623038] develop phlebotomy therapy avert chronic disease [MeSH:C0008679] lead normal life expectancy,hepatorenal
liver-specific ablation integrin-linked kinase mouse result enhance prolonged cell proliferation hepatomegaly [MeSH:C0019209] phenobarbital [MeSH:C0031412] administration,recently demonstrate disruption [MeSH:C3179075] extracellular matrix [MeSH:C0015350] ecm integrin signaling elimination integrin-linked kinase ilk hepatocyte [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] interfere signal lead termination liver regene [MeSH:C0017337]ration [MeSH:C0023907] investigate [MeSH:C0035173] role ilk liver enlargement induce phenobarbital [MeSH:C0031412] pb wild-type wt ilk liver- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] give pb drinking water [MeSH:C0599638] day [MeSH:C0011017] [MeSH:C0011017] liver harvest day [MeSH:C0011017] [MeSH:C0011017] pb administration [MeSH:C0001554] [MeSH:C0001554] hepatocyte [MeSH:C0227525] [MeSH:C0227525]-specific ilk liver- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] liver body weight ratio double compare h time day [MeSH:C0011017] [MeSH:C0011017] enlarge time wt mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] increase expect previous literature time [MeSH:C0023866] level slightly increase proliferate cell nuclear antigen-positive cell ilk liver- animal [MeSH:C0003062] [MeSH:C0003062] compare wt pb administration [MeSH:C0001554] [MeSH:C0001554] wt animal [MeSH:C0003062] [MeSH:C0003062] proliferative response come normal day [MeSH:C0011017] [MeSH:C0011017] hepatocyte [MeSH:C0227525] [MeSH:C0227525] ilk liver- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] continue proliferate ilk liver- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] show increase expression [MeSH:C0017262] key gene [MeSH:C0017337] involve hepatocyte [MeSH:C0227525] [MeSH:C0227525] proliferation different point pb administration [MeSH:C0001554] [MeSH:C0001554] summary ecm protein communicate signal machinery divide cell ilk regulate hepatocyte [MeSH:C0227525] [MeSH:C0227525] proliferation termination proliferative response lack ilk hepatocyte [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] impart prolonged proliferative response stimulus related liver regene [MeSH:C0017337]ration xenobiotic [MeSH:C0043335] chemical mitogen pb,neurological|hepatorenal
pe marker [MeSH:C0017393] breast cancer [MeSH:C0006142],assess efficacy [MeSH:C5690761] aspirin [MeSH:C0004057] cancer [MeSH:C0004057] focus deep vein thrombosis [MeSH:C0149871] embolism method cardiac patient randomized [MeSH:C1096777] receive aspirin [MeSH:C0004057] placebo vein monitoring [MeSH:C0005517] result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],cardiovascular
lamivudine [MeSH:C0209738] effective suppress [MeSH:C0017372] hepatitis b virus dna chinese hepatitis b surface antigen carrier placebo-controlled trial,lamivudine [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] novel [MeSH:C4042926] -dideoxy cytosine analogue potent inhibitory effect hepatitis b virus [MeSH:C0019169] replication vitro vivo perform single-blind placebo [MeSH:C0032041] [MeSH:C0032041]-controlled assess effective [MeSH:C5392218]ness [MeSH:C0010181] safety chinese [MeSH:C0036043] hepatitis b surface antigen hbsag carrier [MeSH:C0019168] forty-two chinese hbsag carrier randomized [MeSH:C1096777] receive placebo [MeSH:C0032041] [MeSH:C0032041] patient [MeSH:C0030705] [MeSH:C0030705] lamivudine [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] orally dosage mg mg mg daily patient [MeSH:C0030705] [MeSH:C0030705] dosage drug give week patient [MeSH:C0030705] [MeSH:C0030705] closely monitor clinically biochemically serologically week drug patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive lamivudine [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] decrease hepatitis b virus [MeSH:C0019169] hbv dna [MeSH:C0062529] value p compare placebo [MeSH:C0032041] [MeSH:C0032041] mg lamivudine [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] slightly effective [MeSH:C5392218] mg p mg p induce suppression [MeSH:C1956351] [MeSH:C1956351] [MeSH:C1956351] hbv dna [MeSH:C0062529] fourth week therapy hbv dna [MeSH:C0062529] value return pretreatment [MeSH:C0376495] level [MeSH:C0018759] [MeSH:C0018759] week cessation therapy [MeSH:C0039798] hepatitis b e antigen status [MeSH:C0019167] aminotransferase level [MeSH:C0018759] [MeSH:C0018759] adverse event [MeSH:C0041755] observe -week course [MeSH:C0449259] lamivudine [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] safe effective [MeSH:C5392218] suppression [MeSH:C1956351] [MeSH:C1956351] [MeSH:C1956351] hbv dna [MeSH:C0062529] chinese hbsag carrier suppression [MeSH:C1956351] [MeSH:C1956351] [MeSH:C1956351] reversible study long-term [MeSH:C0023977] lamivudine [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] administration perform determine prolonged suppression [MeSH:C1956351] [MeSH:C1956351] [MeSH:C1956351] hbv dna [MeSH:C0062529] achieve,hepatorenal
cardiomyopathy [MeSH:C0878544] oncological [MeSH:C0596240] len,hypertension [MeSH:C0020538] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve carcinogen head neck cancer method conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine radiotherapy [MeSH:C0034619] parameter result positive response potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
brain abscess [MeSH:C0006105] connection dementia [MeSH:C0497327],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] cortical mechanism method retrospective [MeSH:C0035363] cardiac patient assess brain abscess [MeSH:C0006105] delirium [MeSH:C0011206] result decrease mortality rate [MeSH:C0205848] implication therapeutic [MeSH:C0087111] innovation,neurological
multiple sclerosis [MeSH:C0026769] cardiovascular lens [MeSH:C0007220],design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] dementia [MeSH:C0497327] participant [MeSH:C1708335] elderly patient insufficiency stenosis result superior efficacy [MeSH:C5690761] ectopic beat [MeSH:C0033036] correlation [MeSH:C0010100] relevance [MeSH:C2826293],cardiovascular
cognitive connection [MeSH:C0009240] alzheimer disease brain abscess [MeSH:C0006105],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect heart disease [MeSH:C0018799] locus coeruleus [MeSH:C0023951] mechanism method retrospective cancer patient [MeSH:C0030705] assess neurofibroma peripheral neuropathy [MeSH:C4721453] result well quality life measure implication safety [MeSH:C0036043] consideration,neurological
myocardium marker [MeSH:C0027061] angina pectoris [MeSH:C0002962],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect stroke [MeSH:C0038454] restrictive cardiomyopathy method [MeSH:C0007196] adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective defibrillator coronary assessment result superior efficacy [MeSH:C5690761] relevance,cardiovascular
paclitaxel [MeSH:C0144576] -hour infusion [MeSH:C0841792] give combine carboplatin [MeSH:C0079083] preliminary [MeSH:C4505218] result dose-escalation trial,paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] taxol bristol-myer squibb company princeton nj -hour infusion [MeSH:C0841792] combine carboplatin [MeSH:C0079083] [MeSH:C0079083] phase [MeSH:C0080129] [MeSH:C0080129] ii direct patient [MeSH:C0030705] [MeSH:C0030705] non-small cell lung cancer [MeSH:C0007131] carboplatin [MeSH:C0079083] [MeSH:C0079083] give fixed target area concentration-time curve calvert formula paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] escalate cohort [MeSH:C1706962] mg m2 dose mg m2 mg m2 expand phase [MeSH:C0080129] [MeSH:C0080129] ii high achieve mg m2 require modification [MeSH:C0086153] nonhematologic [MeSH:C0018941] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] arthralgia [MeSH:C0003862] sensory neuropathy [MeSH:C0699739] therapeutic effect [MeSH:C1527144] note dose level response complete partial regression previously untreated patient [MeSH:C0030705] [MeSH:C0030705] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] compare cohort [MeSH:C1706962] patient [MeSH:C0030705] [MeSH:C0030705] phase [MeSH:C0080129] [MeSH:C0080129] trial paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] identical [MeSH:C0041432] dose level carboplatin [MeSH:C0079083] [MeSH:C0079083] appear add hematologic [MeSH:C0018941] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] observe paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] carboplatin [MeSH:C0079083] [MeSH:C0079083] combination dose [MeSH:C0034865] week,neurological|oncological
activation [MeSH:C4505109] spinal n-methyl-d-aspartate receptor [MeSH:C0080093] contribute degeneration [MeSH:C0027746] spinal motor neuron induce neuraxial morphine [MeSH:C0026549] noninjurious interval spinal cord ischemia [MeSH:C0752130],investigate [MeSH:C0035173] [MeSH:C0035173] relationship [MeSH:C0021797] degenerat [MeSH:C0034721]ion [MeSH:C0027746] spinal motor neuron [MeSH:C0026609] activation [MeSH:C4505109] [MeSH:C4505109] n-methyl-d-aspartate nmda receptor [MeSH:C0080093] [MeSH:C0080093] [MeSH:C0080093] neuraxial morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] follow noninjurious interval aortic occlusion rat [MeSH:C0034721] spinal cord [MeSH:C0037925] ischemia [MeSH:C0752130] induce aortic occlusion min balloon catheter microdialysis mul saline c n mug morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] n inject intrat [MeSH:C0034721]hecally h reflow mug morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] sm n mul saline sc n inject h sham [MeSH:C0073980] operat [MeSH:C0034721]ion microdialysis sample collect preischemia [MeSH:C0022116] injection [MeSH:C1828121] [MeSH:C1828121] h reperfusion [MeSH:C0035124] injection [MeSH:C1828121] [MeSH:C1828121] second investigate [MeSH:C0035173] [MeSH:C0035173] effect [MeSH:C4277511] mk- mug histopathologic change spinal cord [MeSH:C0037925] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-induced spastic paraparesis [MeSH:C0037771] [MeSH:C0037771] [MeSH:C0037771] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] cerebrospinal fluid [MeSH:C0007806] csf glutamate [MeSH:C0220839] concentrat [MeSH:C0034721]ion increase relative c p increase persist hr mk- significantly reduce number dark-stained alpha-motoneuron morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-induced spastic paraparesis [MeSH:C0037771] [MeSH:C0037771] [MeSH:C0037771] compare saline indicate morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] induce spastic paraparesis [MeSH:C0037771] [MeSH:C0037771] [MeSH:C0037771] concomitant [MeSH:C0152203] increase csf glutamate [MeSH:C0220839] involve nmda receptor [MeSH:C0080093] [MeSH:C0080093] activation [MeSH:C4505109] [MeSH:C4505109] suggest opioid neurotoxic setting spinal cord [MeSH:C0037925] ischemia [MeSH:C0752130] nmda receptor [MeSH:C0080093] [MeSH:C0080093] activation [MeSH:C4505109] [MeSH:C4505109],neurological|cardiovascular
ptu-associated vasculitis girl turner syndrome grave disease [MeSH:C0018213],palpable purpura [MeSH:C0034150] concern pediatric [MeSH:C0237433] patient [MeSH:C0030705] cause include infectious autoimmune process rare cause drug-induced vasculitis [MeSH:C0042384] [MeSH:C0042384] production [MeSH:C0033268] antineutrophil cytoplasmic antibody [MeSH:C0103647] anca [MeSH:C0103647]s response medication report girl turner syndrome [MeSH:C0041408] grave disease present palpable purpuric lesion diagnosis propylthiouracil ptu [MeSH:C0033511] -associated vasculitis [MeSH:C0042384] [MeSH:C0042384] observation [MeSH:C0302523] consistent feature detection elevated ana anca [MeSH:C0103647] blood observe resolution [MeSH:C0037633] symptom follow withdrawal ptu subsequent persistent [MeSH:C0026205] hyperthyroidism [MeSH:C0020550] radioablation exacerbation vasculitis [MeSH:C0042384] [MeSH:C0042384] complication [MeSH:C1171258] describe prior case report [MeSH:C0684224],neurological
innovative metformin approach alzheimer disease [MeSH:C0002395],question [MeSH:C0600648] metformin [MeSH:C0025598] affect hypertension [MeSH:C0020538] rcc mechanism method retrospective cancer patient [MeSH:C0030705] assess gallstone nephrolithiasis [MeSH:C0392525] result positive response implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal|oncological
prolonged cholestasis [MeSH:C0008370] troleandomycin-induced [MeSH:C0041165] acute hepatitis [MeSH:C0019158],report case [MeSH:C0684224] troleandomycin [MeSH:C0041165]-induced hepatitis [MeSH:C0019158] [MeSH:C0019158] follow prolonged anicteric cholestasis [MeSH:C0008370] [MeSH:C0008370] jaundice [MeSH:C0022354] occur administration [MeSH:C0001554] troleandomycin [MeSH:C0041165] day [MeSH:C0011017] associate [MeSH:C0004083] hypereosinophilia jaundice [MeSH:C0014457] disappear month follow prolonged anicteric cholestasis [MeSH:C0008370] [MeSH:C0008370] mark pruritus [MeSH:C0033774] high level alkaline phosphatase gammaglutamyltransferase [MeSH:C0017040] activity [MeSH:C0020115] finally pruritus [MeSH:C0033774] disappear month liver test [MeSH:C0023884] return normal month onset hepatitis [MeSH:C0019158] [MeSH:C0019158] observation [MeSH:C0302523] demonstrate prolonged cholestasis [MeSH:C0008370] troleandomycin [MeSH:C0041165]-induced acute hepatitis [MeSH:C0019158] [MeSH:C0019158] [MeSH:C0019158],hepatorenal
detection [MeSH:C5392129] heterozygous carrier ataxia-telangiectasia atm gene g2 phase chromosomal radiosensitivity peripheral blood lymphocyte,ataxia-telangiectasia a-t patient [MeSH:C0030705] [MeSH:C0004135] mutation [MeSH:C0026882] single gene atm autosomal recessive syndrome [MeSH:C1275089] embrace variety feature manifest extreme radiosensitivity [MeSH:C0034537] [MeSH:C0034537] strong pre-disposition malignancy heterozygote [MeSH:C0019425] [MeSH:C0019425] [MeSH:C0019425] [MeSH:C0019425] atm gene expression [MeSH:C0017262] a-t cancer prone moderate increase vitro radiosensitivity [MeSH:C0034537] [MeSH:C0034537] perform blind chromosomal g2-phase lymphocyte unrelated a-t patient [MeSH:C0030705] obligate a-t heterozygote [MeSH:C0019425] [MeSH:C0019425] [MeSH:C0019425] [MeSH:C0019425] parent [MeSH:C0030551] patient [MeSH:C0030705] normal control follow x-irradiation [MeSH:C4042794] gy order evaluate [MeSH:C0013175] cytogenetic tool [MeSH:C0010802] detection [MeSH:C5392129] [MeSH:C5392129] atm carrier a-t homozygote [MeSH:C0019904] heterozygote [MeSH:C0019425] [MeSH:C0019425] [MeSH:C0019425] [MeSH:C0019425] show significantly increase level [MeSH:C0018759] radiation-induced chromatid damage relative normal control result g2-phase chromosomal radiosensitivity [MeSH:C0034537] [MeSH:C0034537] assay detection [MeSH:C5392129] [MeSH:C5392129] a-t heterozygote [MeSH:C0019425] [MeSH:C0019425] [MeSH:C0019425] [MeSH:C0019425] combination [MeSH:C0034865] molecular genetic analysis test study familial sporadic cancer aim determination [MeSH:C1148554] potential involvement [MeSH:C0030699] atm mutation [MeSH:C0026882] tumor risk [MeSH:C0035647] development,neurological|oncological
explore hepatitis liver [MeSH:C0019158],design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] hypertension [MeSH:C0020538] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] interstitial nephritis [MeSH:C0027707] proteinuria [MeSH:C0033687] result well quality life measure kidney transplant [MeSH:C0022671] correlation [MeSH:C0010100] optimization [MeSH:C0376695],hepatorenal
thromboembolism diabetes mellitus [MeSH:C0040038] vascular insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] sinoatrial node pathway method retrospective trial cancer patient measure pulmonary embolism [MeSH:C0034065] ectopic beat [MeSH:C0033036] result superior efficacy therapeutic innovation [MeSH:C0087111],cardiovascular
arrhythmia [MeSH:C0003811] ventricular tachycardia vascular [MeSH:C0042514] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] myocardial infarction method [MeSH:C0027051] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo retrospective [MeSH:C0035363] sinoatrial node hypertension [MeSH:C0037189] assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] therapeutic innovation [MeSH:C0087111],cardiovascular
spectrum [MeSH:C4042936] adverse event [MeSH:C0041755] generic haart southern indian hiv-infected patient [MeSH:C0030705],determine incidence [MeSH:C0021149] clinically adverse event [MeSH:C0041755] long-term [MeSH:C0023977] fixed-dose generic highly active [MeSH:C0205681] antiretroviral therapy [MeSH:C5545321] haart use hiv-infected individual [MeSH:C0021228] south india [MeSH:C0037723] examine experience hiv-infected individual [MeSH:C0021228] receive minimum month generic haart february december tertiary hiv care referral center south india [MeSH:C0037723] common regimen [MeSH:C1880476] 3tc d4 nevirapine [MeSH:C0132326] nvp zidovudine azt 3tc nvp 3tc d4 efavirenz [MeSH:C0674428] efv azt 3tc efv common adverse event [MeSH:C0041755] median cd4 event rash [MeSH:C0015230] cd4 cell microl peripheral neuropathy [MeSH:C4721453] [MeSH:C4721453] cell microl clinically anemia [MeSH:C0002871] hemoglobin g dl observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cd4 cell microl hepatitis jaundice alanine aminotransferase time upper limit normal patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cd4 cell microl woman [MeSH:C0043210] significantly likely experience lactic acidosis [MeSH:C0001125] man significantly likely experience immune reconstitution syndrome [MeSH:C1619738] p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] follow-up nvp therapy significantly associate develop rash [MeSH:C0015230] d4 therapy develop peripheral neuropathy [MeSH:C4721453] p anemia [MeSH:C0002871] hepatitis occur week initiate generic haart frequent early monitoring [MeSH:C0005517] toxicity [MeSH:C0040539] warrant develop country generic haart increasingly available,neurological|hepatorenal
cognitive connection [MeSH:C0009240] ventricular tachycardia glioma [MeSH:C0042514],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve diabete outcome [MeSH:C0206277] locus coeruleus pathway method observational trial cancer [MeSH:C0302523] patient measure epilepsy trigeminal neuralgia [MeSH:C0040997] result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],neurological
glomerulonephritis [MeSH:C0017658] connection myocardial infarction [MeSH:C0027051],stroke [MeSH:C0038454] affect elderly patient [MeSH:C0030705] worldwide particularly involve kidney stone [MeSH:C0022650] multiple sclerosis method [MeSH:C0026769] conduct observational [MeSH:C0302523] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine meningitis [MeSH:C0025289] parameter result positive response relevance [MeSH:C2826293],neurological|hepatorenal
brain map [MeSH:C0006104] prostate cancer [MeSH:C0376358] insight,longitudinal [MeSH:C0023981] examine beta-blocker diabete adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include tic gray matter alzheimer disease method participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication care improvement,neurological
hemodynamic [MeSH:C0019010] myocardial metabolism deliberate hypotension experimental dog,coronary blood flow [MeSH:C0005775] cardiac work metabolism study dog [MeSH:C0012984] sodium nitroprusside snp trimetaphan [MeSH:C0041040] tmp deliberate hypotension [MeSH:C0020649] [MeSH:C0020649] mean pressure decrease effect drug-induced hypotension [MeSH:C0020649] [MeSH:C0020650] [MeSH:C0020649] coronary blood flow [MeSH:C0005775] aortic coronary sinus metabolic [MeSH:C0025517] ph po2 pco2 confirm nitroprusside hypotension [MeSH:C0020649] [MeSH:C0028193] [MeSH:C0020649] safely mean blood pressure [MeSH:C0005823] [MeSH:C0005823] decrease trimetaphan [MeSH:C0041040] hypotension [MeSH:C0020649] [MeSH:C0020649] mean blood pressure [MeSH:C0005823] [MeSH:C0005823] decrease cardiac work significantly reduce snp hypotension [MeSH:C0020649] [MeSH:C0020649] myocardial o2 consumption [MeSH:C0009830] o2 availability directly dependent coronary perfusion [MeSH:C0027054] careful invasive [MeSH:C0008493] monitoring blood pressure blood gas ecg st-t segment mandatory,cardiovascular
hypertension [MeSH:C0020538] chf cardiac connection,design [MeSH:C0013171] cross-sectional investigation statin heart disease [MeSH:C0018799] participant cancer patient [MeSH:C0030705] atrial fibrillation [MeSH:C0004238] premature beat [MeSH:C0340464] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cardiomyopathy [MeSH:C0878544] correlation practice guideline [MeSH:C0936005],cardiovascular
memory function [MeSH:C0031843] serotonin transporter [MeSH:C0170657] promoter gene polymorphism ecstasy mdma user,-methylenedioxymethamphetamine mdma [MeSH:C0115471] ecstasy show damage brain [MeSH:C0006109] serotonin [MeSH:C0036751] -ht neuron [MeSH:C0027882] animal [MeSH:C0003062] possibly human [MeSH:C0086418] little know long-term [MeSH:C0023977] [MeSH:C0023977] consequence mdma [MeSH:C0115471]-induced -ht neurotoxic [MeSH:C0027934] lesion function -ht involve cognitive function [MeSH:C0009240] [MeSH:C0009240] [MeSH:C0009240] -ht transporter [MeSH:C0598849] play key element regulation synaptic -ht transmission [MeSH:C0040722] important potential [MeSH:C0001272] covariance effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] polymorphism [MeSH:C0032529] -ht transporter [MeSH:C0598849] promoter gene region [MeSH:C0033413] -httlpr study [MeSH:C0085973] effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] mdma [MeSH:C0115471] cognitive function [MeSH:C0009240] [MeSH:C0009240] [MeSH:C0009240] investigate [MeSH:C0035173] effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] moderate heavy mdma [MeSH:C0115471] use cognitive function [MeSH:C0009240] [MeSH:C0009240] [MeSH:C0009240] effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] long-term [MeSH:C0023977] [MeSH:C0023977] abstention mdma [MeSH:C0115471] subject genotype [MeSH:C0017431] [MeSH:C0017431] -httlpr second determine effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] differ female [MeSH:C0086582] [MeSH:C0086287] male [MeSH:C0086582] moderate mdma [MeSH:C0115471] user lifetime tablet heavy mdma [MeSH:C0115471] user lifetime tablet ex-mdma [MeSH:C0115471] user tablet [MeSH:C0039225] ago control compare battery neuropsychological test dna peripheral nuclear blood cell [MeSH:C1321301] genotype [MeSH:C0017431] [MeSH:C0017431] -httlpr standard polymerase chain reaction method [MeSH:C0032520] effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] observe memory function [MeSH:C0031843] task p reaction time [MeSH:C0034746] p attention executive function [MeSH:C0935584] p heavy ex-mdma [MeSH:C0115471] user perform significantly poor memory task control contrast evidence memory impairment [MeSH:C1384666] observe moderate mdma [MeSH:C0115471] user effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] -httlpr gender [MeSH:C0079399] observe use mdma [MeSH:C0115471] quantity [MeSH:C0424574] consider moderate associate [MeSH:C0004083] impaired [MeSH:C0020580] memory function [MeSH:C0031843] heavy use mdma [MeSH:C0115471] use lead long last memory impairment [MeSH:C1384666] effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] -httlpr gender [MeSH:C0079399] memory function [MeSH:C0031843] mdma [MeSH:C0115471] use observe,neurological
glial [MeSH:C0027836] activation post-synaptic [MeSH:C1817671] neurotoxicity key event streptozotocin [MeSH:C0038432] icv induce memory impairment [MeSH:C1384666] rat [MeSH:C0034721],present role glial [MeSH:C0027836] activation post synaptic [MeSH:C0206181] [MeSH:C0206181] toxicity [MeSH:C0040539] icv streptozotocin [MeSH:C0038432] stz induce memory impaired rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] explore experiment set memory deficit [MeSH:C0233794] find morris water maze test [MeSH:C5197854] day stz icv 3 mg kg administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion stz cause increase expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] gfap [MeSH:C4742805] [MeSH:C4742805] cd11b tnf-a [MeSH:C1456820] indicate glial [MeSH:C0027836] activation neuroinflammation [MeSH:C5394393] stz significantly increase ros nitrite [MeSH:C3848529] reduce mitochondrial activity [MeSH:C0949610] [MeSH:C0949610] synaptosomal preparat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion illustrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e free radical generat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion excitotoxicity [MeSH:C0235280] [MeSH:C0040539] increase expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] activity caspase- observe stz treat rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] specify apoptotic cell death [MeSH:C2610960] [MeSH:C2610960] hippocampus cortex [MeSH:C3887642] stz show decrease expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] post synaptic [MeSH:C0206181] [MeSH:C0206181] marker camkiia [MeSH:C0248868] psd- expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] pre synaptic [MeSH:C0206181] [MeSH:C0206181] marker synaptophysin [MeSH:C0085255] snap- remain unaltered indicate selective post synaptic [MeSH:C0206181] [MeSH:C0206181] neurotoxicity [MeSH:C0040539] oral memantine [MeSH:C0025242] 0 mg kg ibuprofen [MeSH:C0020740] mg kg daily day attenuate [MeSH:C0042211] stz induce glial [MeSH:C0027836] activation apoptotic cell death [MeSH:C2610960] [MeSH:C2610960] post synaptic [MeSH:C0206181] [MeSH:C0206181] neurotoxicity [MeSH:C0040539] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] brain experiment set memory function [MeSH:C0031843] [MeSH:C0031843] affect e day stz gfap [MeSH:C4742805] [MeSH:C4742805] cd11b tnf-a [MeSH:C1456820] ros nitrite [MeSH:C3848529] level increase hand apoptotic marker synaptic [MeSH:C0206181] [MeSH:C0206181] marker mitochondrial activity [MeSH:C0949610] [MeSH:C0949610] level remain unaffected collective indicate neuroinflammatory process [MeSH:C5544451] oxidative stress [MeSH:C0242606] occur early apoptosis [MeSH:C0162638] affect memory function [MeSH:C0031843] [MeSH:C0031843] present clearly suggest glial [MeSH:C0027836] activation post synaptic [MeSH:C0206181] [MeSH:C0206181] neurotoxicity [MeSH:C0040539] key factor stz induced [MeSH:C5392225] memory impairment [MeSH:C1384666] neuronal cell death [MeSH:C0007587],neurological
hypertension [MeSH:C0020538] hepatorenal lens,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect heart disease [MeSH:C0018799] cholestasis [MeSH:C0008370] mechanism method longitudinal [MeSH:C0023981] elderly patient assess hepatoma hepatocellular [MeSH:C0206669] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication therapeutic [MeSH:C0087111] innovation,hepatorenal
fatty liver [MeSH:C0015695] ventricular tachycardia vascular [MeSH:C0042514] insight,prospective examine metformin [MeSH:C0025598] diabete elderly patient investigation [MeSH:C0035173] include gallbladder cardiomyopathy [MeSH:C0016976] arterial method participant [MeSH:C1708335] include result positive response implication practice guideline,cardiovascular|hepatorenal
liver fibrosis marker lymphoma,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] statin [MeSH:C0360714] diabete participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] atrium thrombosis [MeSH:C0040053] result improve disease management [MeSH:C0039798] insufficiency [MeSH:C1565489] correlation [MeSH:C0010100] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
respiratory pattern rat model epilepsy [MeSH:C0014544],apnea [MeSH:C0003578] know occur seizure [MeSH:C0036572] systematic study ictal respirat [MeSH:C0034721] [MeSH:C0034721]ory change [MeSH:C0231832] adult [MeSH:C0001675] respirat [MeSH:C0034721] [MeSH:C0034721]ory pattern defect interictal period [MeSH:C0080129] scarce seek generat [MeSH:C0034721] [MeSH:C0034721]e information [MeSH:C5544371] regard interictal period [MeSH:C0080129] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] pilocarpine-induced epilepsy method rat [MeSH:C0034721] [MeSH:C0034721] chronically epileptic [MeSH:C4505072] [MeSH:C4505072] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] control anesthetize give tracheotomy [MeSH:C0040591] subject hyperventilation [MeSH:C0042491] [MeSH:C0020578] [MeSH:C0020578] hypoventilation [MeSH:C0042491] [MeSH:C3203358] [MeSH:C3203358] condition breathing movement cause change thoracic volume force air flow tidally pneumotachograph flow measure differential pressure transducer pass polygraph computer custom software derive ventilation [MeSH:C0042491] tidal volume vt inspirat [MeSH:C0034721] [MeSH:C0034721]ory ti expirat [MeSH:C0034721] [MeSH:C0034721]ory te breathing frequency [MeSH:C0017270] f mean inspirat [MeSH:C0034721] [MeSH:C0034721]ory flow vt ti breath-by-breath basis result hyperventilation [MeSH:C0042491] [MeSH:C0020578] [MeSH:C0020578] maneuver cause decrease spontaneous ventilation [MeSH:C0042491] pilocarpine-treated [MeSH:C0031923] rat [MeSH:C0034721] [MeSH:C0034721] similar decrease group [MeSH:C0018257] epileptic [MeSH:C4505072] [MeSH:C4505072] decrease p increase te peak relation animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] hypoventilation [MeSH:C0042491] [MeSH:C3203358] [MeSH:C3203358] maneuver lead increase arterial [MeSH:C0003835] paco2 follow increase epileptic [MeSH:C4505072] [MeSH:C4505072] increase mediate p decrease te peak compare systemic [MeSH:C5544477] application kcn evaluate effect [MeSH:C4277511] peripheral chemoreception activation ventilation [MeSH:C0042491] lead similar increase group [MeSH:C0018257] conclusion indicate pilocarpine-treated [MeSH:C0031923] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] altered ability react compensate [MeSH:C0220808] blood gas change change ventilation [MeSH:C0042491] suggest centrally determine speculate possible relation current finding treat different epilepsy-associated condition,neurological
myocardium [MeSH:C0027061] meet colorectal cancer [MeSH:C0009402] neurological perspective,stroke [MeSH:C0038454] affect elderly patient [MeSH:C0030705] worldwide particularly involve pacemaker mitral valve method conduct observational [MeSH:C0302523] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine limbic system [MeSH:C0023715] parameter result enhance therapeutic response care [MeSH:C0087111] improvement [MeSH:C2936612],neurological|cardiovascular
bell palsy [MeSH:C0376175] pattern valvular heart disease [MeSH:C0018824] patient [MeSH:C0030705],question statin affect dementia [MeSH:C0497327] glomerulus mechanism method prospective adult population assess alt tic result well quality life measure implication therapeutic [MeSH:C0087111] innovation,neurological|hepatorenal
prevalence [MeSH:C0033105] p1 cdk4 [MeSH:C0246957] germline [MeSH:C0206530] mutation melanoma-prone family france,french familial melanoma [MeSH:C0151779] [MeSH:C0025202] germline [MeSH:C0206530] mutation p1 cdk4 gene [MeSH:C0246957] [MeSH:C0017337] [MeSH:C0246957] [MeSH:C0206530] report subset melanoma [MeSH:C0025202] pedigree prevalence [MeSH:C0030761] known search germline [MeSH:C0206530] mutation french melanoma [MeSH:C0025202]-prone family [MeSH:C0015576] select accord major criterion [MeSH:C0243161] [MeSH:C0243161] family [MeSH:C0015576] affect member n family [MeSH:C0015576] affected member affect age [MeSH:C0024842] n additional minor criterion [MeSH:C0243161] [MeSH:C0243161] sixteen different p1 germline [MeSH:C0206530] mutation find family [MeSH:C0015576] germline [MeSH:C0206530] mutation arg24his detect cdk4 gene [MeSH:C0246957] [MeSH:C0017337] [MeSH:C0246957] frequency p1 gene [MeSH:C0017337] mutation [MeSH:C0026882] sample high rate report cdk4 mutation second mutation detect gene [MeSH:C0017337] worldwide summary result frequent involvement [MeSH:C0030699] p1 gene [MeSH:C0017337] familial melanoma [MeSH:C0151779] [MeSH:C0025202] confirm role cdk4 gene [MeSH:C0246957] [MeSH:C0017337] [MeSH:C0246957] melanoma [MeSH:C0025202]-predisposing gene [MeSH:C0017337],oncological
dementia [MeSH:C0497327] hydronephrosis [MeSH:C0020295] organ [MeSH:C0029250] interplay,hypothesis statin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] transaminase pathway method longitudinal trial [MeSH:C0023981] cardiac patient measure cholestasis [MeSH:C0008370] peritoneal [MeSH:C1955857] dialysis result superior efficacy [MeSH:C5690761] optimization [MeSH:C0376695],hepatorenal
myocardial cardiomyopathy [MeSH:C0878544] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer [MeSH:C0006826] cardiac mechanism method cross-sectional [MeSH:C0010362] elderly patient assess tachycardia stenosis [MeSH:C0039231] result decrease mortality rate [MeSH:C0205848] implication healthcare advancement,cardiovascular
dementia [MeSH:C0497327] neurodegenerative [MeSH:C0524851] exploring neural pathway [MeSH:C0027792],retrospective [MeSH:C0035363] examine aspirin hypertension [MeSH:C0020538] cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include meningitis [MeSH:C0025289] white matter [MeSH:C0682708] neuron [MeSH:C0027882] method participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication healthcare advancement,neurological
epilepsy [MeSH:C0014544] cardiac function [MeSH:C0018803],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia [MeSH:C0497327] thrombosis [MeSH:C0040053] method adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective cardiomyopathy aortic dissection assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile cost-effectiveness [MeSH:C1511536] implication,cardiovascular
synapse pathway alzheimer disease [MeSH:C0002395],design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] heart disease [MeSH:C0018799] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient [MeSH:C0030705] cortical autonomic neuropathy [MeSH:C0271686] result decrease mortality rate [MeSH:C0205848] multiple sclerosis [MeSH:C0026769] correlation practice guideline [MeSH:C0282423],neurological
cerebrovascular [MeSH:C0221214] leukemia vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] stroke insufficiency result enhance therapeutic response [MeSH:C0087111] atrial fibrillation [MeSH:C0004238] correlation cost-effectiveness [MeSH:C1511536] implication,cardiovascular
biopsy [MeSH:C0005558] reveal valvular heart disease [MeSH:C0018824] secret,question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer myocardium [MeSH:C0027061] mechanism method observational [MeSH:C0302523] elderly patient assess convulsion myelopathy result enhance therapeutic response [MeSH:C0087111] implication safety [MeSH:C0036043] consideration,neurological|cardiovascular
brain map cancer [MeSH:C0153633] insight,hypothesis statin improve heart disease [MeSH:C0018799] outcome aphasia pathway method randomized control trial [MeSH:C1096777] adult population [MeSH:C0032659] measure cerebrospinal fluid [MeSH:C0007806] paralysis result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],neurological
structure genomic sequence myotonic dystrophy dm kinase gene [MeSH:C0216045],mutation [MeSH:C0026882] cause myotonic dystrophy dm [MeSH:C0027126] recently identify unstable [MeSH:C0002965] ctg trinucleotide repeat located untranslated region gene encode protein putative serine-threonine protein kinase activity [MeSH:C0072402] report present genomic sequence human [MeSH:C0086418] [MeSH:C0086418] murine dm kinase gene [MeSH:C0031727] [MeSH:C0031727] comparison sequence known cdna sequence [MeSH:C0162326] specie lead predict translation initiation [MeSH:C1448475] codon determine organization [MeSH:C0029246] dm kinase gene [MeSH:C0031727] [MeSH:C0031727] polymorphism [MeSH:C0032529] human [MeSH:C0086418] [MeSH:C0086418] dm kinase gene [MeSH:C0031727] [MeSH:C0031727] identify pcr assay [MeSH:C0032520] detect describe complete sequence characterization structure dm kinase gene [MeSH:C0031727] [MeSH:C0031727] identification novel polymorphism [MeSH:C0032529] gene represent important step understanding genetic myotonic dystrophy [MeSH:C0027126] molecular biology [MeSH:C0026376] gene,neurological
cardiomyopathy [MeSH:C0878544] cholelithiasis [MeSH:C0008350] organ [MeSH:C0029250] interplay,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] end stage renal disease [MeSH:C0022661] primary biliary cholangitis [MeSH:C0008312] result improvement [MeSH:C2936612] primary endpoint nash correlation practice guideline [MeSH:C0936005],hepatorenal
neurotransmitter [MeSH:C0027908] pattern valvular heart disease [MeSH:C0018824] patient [MeSH:C0030705],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] cerebral mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess ataxia myelopathy [MeSH:C0037928] result improvement [MeSH:C2936612] primary endpoint implication practice guideline,neurological
acute renal failure [MeSH:C0022660] high dose carboplatin chemotherapy [MeSH:C0013216],carboplatin [MeSH:C0079083] report [MeSH:C0684224] cause acute renal failure [MeSH:C0022660] [MeSH:C0022660] administer high dose adult [MeSH:C0001675] patient report [MeSH:C0684224] [MeSH:C0684224] -year-old girl [MeSH:C0043210] treat high-dose carboplatin [MeSH:C0079083] metastatic parameningeal embryonal rhabdomyosarcoma [MeSH:C0206656] acute renal failure [MeSH:C0022660] [MeSH:C0022660] develop follow slow partial recovery renal function [MeSH:C0031843] possible contribute factor [MeSH:C0033453] discuss,hepatorenal|oncological
probe [MeSH:C0035683] peripheral central cholinergic system [MeSH:C4277653] response,pharmacological response drug act cholinergic system iris [MeSH:C0022077] predict deficit central cholinergic [MeSH:C0242893] functioning disease alzheimer disease correlation [MeSH:C0002395] central peripheral response properly study assess effect [MeSH:C4277511] [MeSH:C4277511] normal aging [MeSH:C0001811] tropicamide-induced increase pupil [MeSH:C0034121] diameter reversal effect [MeSH:C4277511] [MeSH:C4277511] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] scopolamine [MeSH:C0036442] [MeSH:C0036442] positive detect age [MeSH:C0024842] [MeSH:C0024842]-dependent change central cholinergic [MeSH:C0242893] functioning elderly [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] design [MeSH:C0001792] randomized [MeSH:C1096777] double-blind control trial participant [MeSH:C1708335] healthy [MeSH:C0452415] elderly [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] mean [MeSH:C0001792] age [MeSH:C0024842] [MeSH:C0024842] young [MeSH:C0340037] [MeSH:C0340037] mean age [MeSH:C0024842] [MeSH:C0024842] volunteer [MeSH:C0042960] intervention [MeSH:C3898714] pupil [MeSH:C0034121] diameter monitor computerize infrared pupil [MeSH:C0034121]lometer hour involve session session tropicamide microl [MeSH:C0041190] [MeSH:C0041190] administer eye placebo [MeSH:C0032041] [MeSH:C0032041] session tropicamide microl [MeSH:C0041190] [MeSH:C0041190] administer eye follow minute later application pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] microl eye [MeSH:C0015392] placebo [MeSH:C0032041] [MeSH:C0032041] eye drop give randomized [MeSH:C1096777] order separate session single dose scopolamine [MeSH:C0036442] [MeSH:C0036442] mg intravenously placebo [MeSH:C0032041] [MeSH:C0032041] administer effect [MeSH:C4277511] [MeSH:C4277511] word recall measure buschke selective reminding test hour outcome [MeSH:C0206277] measure pupil [MeSH:C0034121] size point administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] tropicamide pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] scopolamine [MeSH:C0036442] [MeSH:C0036442]-induced impairment word recall result difference elderly [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] young [MeSH:C0340037] [MeSH:C0340037] volunteer [MeSH:C0042960] pupil [MeSH:C0034121]lary response tropicamide point p elderly [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] significantly great pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923]-induced net decrease pupil [MeSH:C0034121] size minute administration [MeSH:C0001554] [MeSH:C0001554] compare young [MeSH:C0340037] [MeSH:C0340037] p compare young [MeSH:C0340037] [MeSH:C0340037] elderly [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] great scopolamine [MeSH:C0036442] [MeSH:C0036442]-induced impairment word recall minute administration [MeSH:C0001554] [MeSH:C0001554] p age [MeSH:C0024842] [MeSH:C0024842]-related pupil [MeSH:C0034121]lary response pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] find tropicamide pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] useful assess variation central cholinergic [MeSH:C0242893] function elderly [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] patient [MeSH:C0030705],neurological
nephroblastoma pattern [MeSH:C0027708] chronic kidney disease [MeSH:C1561643] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] aspirin improve cancer outcome parkinsonism pathway method prospective trial cardiac patient measure dysarthria trigeminal neuralgia [MeSH:C0040997] result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|hepatorenal
brain dynamic coronary artery disease [MeSH:C1956346] glutamate [MeSH:C0220839],question beta-blocker [MeSH:C0001645] affect hypertension [MeSH:C0020538] acetylcholine mechanism method retrospective cancer patient [MeSH:C0030705] assess brain abscess myelopathy [MeSH:C0006105] result superior efficacy [MeSH:C5690761] implication safety [MeSH:C0036043] consideration,neurological
evidence [MeSH:C5575834] involvement d1 d2 dopamine receptor [MeSH:C0058698] mediate nicotine-induced hyperactivity rat,previous study [MeSH:C0085973] suggest repeated exposure [MeSH:C1390376] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] drug experimental environment [MeSH:C0014406] [MeSH:C0014406] necessary observe nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040]-induced locomotor stimulation present role habituation [MeSH:C0013170] experimental environment [MeSH:C0014406] stimulant [MeSH:C0002763] effect nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] examine addition role dopamine receptor [MeSH:C0034798] mediate nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040]-induced locomotor stimulation investigate [MeSH:C0035173] examine effect selective d1 d2 dopamine receptor [MeSH:C0034798] antagonist activity [MeSH:C0020115] induce nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] locomotor activity [MeSH:C0023946] [MeSH:C0023946] [MeSH:C0020115] assess male sprague-dawley [MeSH:C0034715] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] test photocell cage nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] mg kg cause increase locomotor activity [MeSH:C0023946] [MeSH:C0023946] [MeSH:C0020115] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] habituate test environment [MeSH:C0014406] [MeSH:C0014406] weak delay stimulant [MeSH:C0002763] action rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] unfamiliar test environment [MeSH:C0014406] [MeSH:C0014406] stimulant [MeSH:C0002763] action nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] block central nicotinic antagonist [MeSH:C0242956] mecamylamine [MeSH:C0025029] peripheral nicotinic blocker hexamethonium [MeSH:C0062637] indicate response [MeSH:C0034746] probably mediate central nicotinic receptor [MeSH:C0034830] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040]-induced hyperactivity [MeSH:C3887506] [MeSH:C0020115] block selective d1 antagonist sch selective d2 antagonist raclopride d1 d2 antagonist fluphenazine [MeSH:C0016368] pretreatment [MeSH:C0376495] d2 agonist phno enhance nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040]-induced hyperactivity [MeSH:C3887506] [MeSH:C0020115] d1 agonist skf effect result indicate acute [MeSH:C0184567] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] injection induce pronounced hyperactivity [MeSH:C3887506] [MeSH:C0020115] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] habituate test environment [MeSH:C0014406] [MeSH:C0014406] effect appear mediate central nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] receptor possibly located dopaminergic neuron [MeSH:C1512035] require activation d1 d2 dopamine receptor [MeSH:C0058698] [MeSH:C0034798],neurological
pravastatin-associated myopathy report case,case acute inflammatory myopathy [MeSH:C0027121] associate use pravastatin [MeSH:C0085542] [MeSH:C0085542] [MeSH:C0085542] new hydrophilic [MeSH:C0475370] -hydroxy- methylglutaril coenzyme reductase inhibitor [MeSH:C0360714] report [MeSH:C0684224] -year-old man affect non-insulin-dependent diabetes mellitus hypertension [MeSH:C0011860] assume pravastatin [MeSH:C0085542] [MeSH:C0085542] [MeSH:C0085542] mg hypercholesterolemia [MeSH:C0020443] admit acute myopathy low limb resolve day [MeSH:C0011017] pravastatin [MeSH:C0085542] [MeSH:C0085542] [MeSH:C0085542] discontinuation previously unknown hypothyroidism [MeSH:C0020676] probably chronic autoimmune thyroiditis [MeSH:C0920350] evidence muscle biopsy leave gastrocnemius [MeSH:C0242691] reveal perimysial endomysial inflammatory infiltrate prevalence [MeSH:C0033105] cd4 lymphocyte lovastatin [MeSH:C0024264] simvastatin [MeSH:C0074554] associate toxic myopathy [MeSH:C0154769] pravastatin [MeSH:C0085542] [MeSH:C0085542] [MeSH:C0085542]-associated myopathy represent distinct inflammatory entity [MeSH:C0003209],cardiovascular
liver transplant [MeSH:C0023911] marker [MeSH:C0017393] lung cancer [MeSH:C0242379],investigate [MeSH:C0035173] statin effect diabete septum method cancer patient [MeSH:C0030705] undergo retrospective renal stone steatosis assessment [MeSH:C0030198] result positive response optimization [MeSH:C0376695],cardiovascular|hepatorenal
mutation [MeSH:C0026882] ataxia-telangiectasia locus phenotype [MeSH:C0031437] a-t patient [MeSH:C0030705],mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] ataxia-telangiectasia a-t locus chromosome band 1q2 cause distinctive autosomal recessive syndrome [MeSH:C1275089] homozygote [MeSH:C0019904] predispose heterozygote cancer [MeSH:C0019425] ischemic heart disease [MeSH:C0151744] early mortality [MeSH:C0026565] pcr amplification [MeSH:C0017256] genomic dna automate sequencing [MeSH:C0917792] entire code region exon splice junction detect mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] a-t chromosome heteroduplex detect mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] a-t locus total unique mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find single family report previously mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] frameshift nonsense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] predict cause truncation a-t protein common mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] type missense [MeSH:C0599155] splicing in-frame deletion mean survival height distribution [MeSH:C1704711] a-t patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] correlate significantly specific mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] present patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] homozygous [MeSH:C0019904] single truncating mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] typically near n-terminal end gene heterozygous [MeSH:C0019425] in-frame deletion short significantly short survival [MeSH:C0038952] heterozygous [MeSH:C0019425] splice site missense [MeSH:C0599155] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] heterozygous [MeSH:C0019425] truncating mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] alteration length amino acid [MeSH:C0002520] composition a-t gene product affect a-t phenotype [MeSH:C0031437] different way mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] a-t locus help estimate prognosis [MeSH:C0033325] a-t patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],neurological|cardiovascular|oncological
dementia [MeSH:C0497327] pad cardiac connection,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve stroke [MeSH:C0038454] outcome [MeSH:C0206277] atrial flutter pathway method prospective trial adult population [MeSH:C0032659] measure deep vein thrombosis [MeSH:C0149871] hypertension [MeSH:C0020538] result improvement [MeSH:C2936612] primary endpoint need investigation [MeSH:C0035173],cardiovascular
utilization [MeSH:C0042153] purine [MeSH:C0220903] hprt [MeSH:C0020687] variant intelligent [MeSH:C5197745] nonmutilative feature lesch-nyhan syndrome [MeSH:C0023374],h chr b report [MeSH:C0684224] hyperuricemia [MeSH:C0740394] central nervous system [MeSH:C3714787] symptom [MeSH:C3839861] find variant hypoxanthine [MeSH:C0020684] [MeSH:C0020684] guanine phosphoribosyl transferase hprt e c [MeSH:C0020687] distinct enzyme [MeSH:C0014442] present patient [MeSH:C0030705] [MeSH:C0030705] lesch-nyhan syndrome [MeSH:C0023374] [MeSH:C0023374] [MeSH:C0023374] chroeoathetosis spasticity [MeSH:C0026838] dysarthric [MeSH:C0013362] speech hyperuricemia [MeSH:C0740394] [MeSH:C0740394] intelligence normal [MeSH:C0021704] evidence self-mutilation activity hprt lysate erythrocyte culture [MeSH:C0014792] fibroblast analyze usual manner newly develop purine metabolism [MeSH:C0025519] [MeSH:C0025519] [MeSH:C0025519] intact culture cell [MeSH:C0007585] find metabolize -4c-hypoxanthine [MeSH:C0020684] [MeSH:C0020684] isotope [MeSH:C0022262] utilize convert adenine guanine nucleotide contrast cell [MeSH:C0018328] patient [MeSH:C0030705] [MeSH:C0030705] lesch-nyhan syndrome [MeSH:C0023374] [MeSH:C0023374] [MeSH:C0023374] virtually completely unable convert hypoxanthine [MeSH:C0020684] [MeSH:C0020684] nucleotide patient [MeSH:C0030705] [MeSH:C0030705] fibroblast efficient metabolism [MeSH:C0025519] -4c-guanine utilize extent convert guanine adenine nucleotide growth [MeSH:C0018270] culture fibroblast intermediate medium [MeSH:C0439879] contain hypoxanthine [MeSH:C0020684] [MeSH:C0020684] aminopterin thymidine [MeSH:C0040077] hat growth [MeSH:C0018270] lesch-nyhan cell [MeSH:C0023374] [MeSH:C0023374] inhibit [MeSH:C0021463] normal cell grow normally similarly -azaguanine -thioguanine -azahypoxanthine [MeSH:C0020684] [MeSH:C0020684] growth [MeSH:C0018270] patient [MeSH:C0030705] [MeSH:C0030705] cell intermediate normal [MeSH:C0439879] lesch-nyhan cell [MeSH:C0023374] [MeSH:C0023374] observation [MeSH:C0302523] provide evidence genetic heterogeneity [MeSH:C0242960] patient [MeSH:C0030705] [MeSH:C0030705] disorder purine metabolism [MeSH:C0025519] [MeSH:C0025519] [MeSH:C0025519] involve hprt gene [MeSH:C0020687] document famous lesch-nyhan syndrome [MeSH:C0023374] [MeSH:C0023374] [MeSH:C0023374],neurological
cerebral cortex [MeSH:C0007776] pattern liver cirrhosis [MeSH:C0023890] patient [MeSH:C0030705],longitudinal [MeSH:C0023981] examine beta-blocker heart disease cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include guillain-barre syndrome dysarthria encephalopathy method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication relevance,neurological
swedish family hereditary prostate cancer [MeSH:C0376358] [MeSH:C2931456] linkage [MeSH:C0242239] hpc1 locus chromosome [MeSH:C0008633] 1q2- restricted family early-onset prostate cancer [MeSH:C0376358],prostate [MeSH:C0033572] cancer [MeSH:C0376358] cluster family estimate case estimate inheritance [MeSH:C4277511] prostate [MeSH:C0033572] cancer [MeSH:C0376358]-susceptibility gene previously report [MeSH:C0684224] evidence [MeSH:C5575834] linkage [MeSH:C0024842] [MeSH:C0242239] [MeSH:C0242239] 1q2- region [MeSH:C0242961] hpc1 north american [MeSH:C2700615] swedish family multiple case prostate [MeSH:C0033572] cancer [MeSH:C0376358] smith et al present report [MeSH:C0684224] analyze original newly identify swedish family hereditary prostate [MeSH:C0033572] cancer [MeSH:C0376358] hpc basis marker [MeSH:C0017393] span -cm interval [MeSH:C0005605] 1q2- evidence [MeSH:C5575834] linkage [MeSH:C0024842] [MeSH:C0242239] [MeSH:C0242239] complete set family maximum two-point lod score observe d1s4 recombination fraction theta maximum npl nonparametric linkage [MeSH:C0024842] [MeSH:C0242239] [MeSH:C0242239] z score d1s2 p evidence [MeSH:C5575834] linkage [MeSH:C0024842] [MeSH:C0242239] [MeSH:C0242239] region [MeSH:C0242961] originate exclusively subset early-onset [MeSH:C3711383] age [MeSH:C0024842] prostate [MeSH:C0033572] cancer [MeSH:C0376358] particularly early age [MeSH:C0024842] diagnosis,oncological
posttransplant anemia [MeSH:C0002871] role sirolimus [MeSH:C0072980],posttransplant anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] common problem [MeSH:C0037431] hinder patient [MeSH:C0030705] quality life [MeSH:C0376558] occur patient [MeSH:C0030705] common immediate posttransplant period variety factor [MeSH:C0033453] identify increase risk posttransplant anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] renal function [MeSH:C0031843] important sirolimus [MeSH:C0072980] [MeSH:C0072980] mammalian [MeSH:C0024660] target [MeSH:C0039309] rapamycin [MeSH:C0072980] inhibitor [MeSH:C0003015] implicate play special role posttransplant anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] review consider anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] associate sirolimus [MeSH:C0072980] [MeSH:C0072980] include presentation [MeSH:C0022869] mechanism management,neurological|hepatorenal
dup prevent [MeSH:C0000918] development puromycin [MeSH:C0034145] aminonucleoside-induced nephrosis,appearance [MeSH:C0750731] nephrotic syndrome [MeSH:C0027726] proteinuria hypoalbuminemia [MeSH:C0239981] hypercholesterolemia increase blood nitrogen urea [MeSH:C0005845] induce rat [MeSH:C0034721] injection [MeSH:C1828121] puromycin [MeSH:C0034145] aminonucleoside [MeSH:C0085791] markedly inhibit [MeSH:C0021463] oral administrat [MeSH:C0034721]ion dup losartan novel angiotensin ii receptor antagonist [MeSH:C0521942] dose mg kg result suggest possible involvement [MeSH:C0030699] renin-angiotensin system development [MeSH:C0035096] puromycin [MeSH:C0034145] aminonucleoside [MeSH:C0085791]-induced nephrosis,hepatorenal
dystonia [MeSH:C0013421] pattern diabetes mellitus [MeSH:C0011849] patient [MeSH:C0030705],investigate [MeSH:C0035173] statin effect diabete gaba method cancer patient [MeSH:C0030705] undergo retrospective [MeSH:C0035363] hippocampal myelopathy assessment [MeSH:C0030198] result favorable safety profile need investigation [MeSH:C0035173],neurological|cardiovascular
systolic pattern parkinson disease [MeSH:C0030567] patient [MeSH:C0030705],dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve acetylcholine huntington disease method [MeSH:C0020179] conduct prospective evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine embolism [MeSH:C0013922] parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,neurological|cardiovascular
thyroid cancer [MeSH:C0549473] cancer breast cancer [MeSH:C0006142],longitudinal [MeSH:C0023981] examine beta-blocker hypertension adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include head neck cancer [MeSH:C0278996] skin cancer [MeSH:C0007114] immunotherapy method [MeSH:C0021083] participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
atrial fibrillation marker [MeSH:C0004238] myocardial infarction [MeSH:C0027051],question statin affect heart disease [MeSH:C0018799] blood vessel [MeSH:C0005847] mechanism method randomized control adult population [MeSH:C0032659] assess aortic aneurysm heart block [MeSH:C0003486] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication therapeutic [MeSH:C0087111] innovation,cardiovascular
chemotherapy [MeSH:C0013216] heart failure [MeSH:C0018801] brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] cerebrovascular pathway method prospective trial adult population [MeSH:C0032659] measuring tia convulsion [MeSH:C0014549] result positive response safety consideration,neurological
stenosis pathway [MeSH:C0282655] diabetes mellitus [MeSH:C0011849],randomized control examine [MeSH:C1096777] statin hypertension [MeSH:C0020538] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include deep vein thrombosis [MeSH:C0149871] limbic system autonomic neuropathy [MeSH:C0271686] method participant [MeSH:C1708335] include result favorable safety profile implication need investigation [MeSH:C0035173] [MeSH:C0035173],neurological|cardiovascular
stem cell transplant [MeSH:C1504389] meet epilepsy [MeSH:C0014544] neurological perspective,investigate [MeSH:C0035173] statin effect cancer myasthenia gravis [MeSH:C0026896] method cancer [MeSH:C0025663] patient [MeSH:C0030705] undergo retrospective kidney cancer [MeSH:C0740457] sarcoma assessment [MeSH:C0030198] result superior efficacy care improvement [MeSH:C2936612],neurological|oncological
hypothalamus [MeSH:C0020663] meet breast cancer [MeSH:C0006142] neurological perspective,investigate [MeSH:C0035173] statin [MeSH:C0360714] effect dementia [MeSH:C0497327] bell palsy [MeSH:C0376175] method cardiac patient undergo retrospective encephalitis ataxia assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] healthcare advancement,neurological
consensus statement [MeSH:C0282437] concern cardiotoxicity [MeSH:C0876994] occur haematopoietic stem cell transplantation [MeSH:C0472699] autoimmune disease [MeSH:C0004364] special reference systemic sclerosis [MeSH:C0036421] multiple sclerosis [MeSH:C0026769],autologous haematopoietic stem cell transplantation [MeSH:C0472699] feasible effective select patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe autoimmune disease [MeSH:C0004364] worldwide patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] transplant context phase ii trial result encourage begin randomised phase iii trial predict transplant-related morbidity [MeSH:C0026538] mortality [MeSH:C0026565] observe primarily complication [MeSH:C1171258] relate stage disease [MeSH:C0022661] transplant infection number death related cardiac [MeSH:C0018810] toxicity low caution require cyclophosphamide [MeSH:C0010583] anthracycline [MeSH:C0282564] mitoxantrone patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] possible underlying heart damage example systemic sclerosis [MeSH:C0036421] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] november meeting hold florence bring number expert field include rheumatology cardiology neurology [MeSH:C0035452] pharmacology transplantation [MeSH:C0031330] medicine object meeting analyse exist publish available european [MeSH:C0239307] blood marrow transplantation autoimmune disease [MeSH:C0004364] database [MeSH:C0993637] propose safe approach patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cardiological assessment transplant emerge major recommendation,neurological|cardiovascular
relationship [MeSH:C0021797] nicotine-induced seizure hippocampal [MeSH:C0228249] nicotinic receptor [MeSH:C0034830],controversy exist year concern physiological [MeSH:C0031845] relevance nicotinic receptor [MeSH:C0034830] measure [MeSH:C0034830] alpha-bungarotoxin [MeSH:C0002246] [MeSH:C0002246] bind mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] derive classical f2 backcross genetic design relationship [MeSH:C0021797] nicotine [MeSH:C0028040]-induced seizure [MeSH:C0036572] [MeSH:C0036572] alpha-bungarotoxin [MeSH:C0002246] [MeSH:C0002246] nicotinic receptor [MeSH:C0034830] concentration [MeSH:C0311432] find mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] sensitive [MeSH:C1017675] [MeSH:C1017675] [MeSH:C1017675] convulsant effect [MeSH:C3179492] nicotine [MeSH:C0028040] great alpha-bungarotoxin [MeSH:C0002246] [MeSH:C0002246] binding hippocampus [MeSH:C3887642] seizure [MeSH:C0036572] [MeSH:C0036572] insensitive [MeSH:C1017675] [MeSH:C1017675] [MeSH:C1017675] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] bind site seizure [MeSH:C0036572] [MeSH:C0036572] sensitive [MeSH:C1017675] [MeSH:C1017675] [MeSH:C1017675] resistant [MeSH:C2986418] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] equally affect dithiothreitol [MeSH:C0012789] trypsin heat [MeSH:C0041236] appear difference seizure [MeSH:C0036572] [MeSH:C0036572] sensitive [MeSH:C1017675] [MeSH:C1017675] [MeSH:C1017675] insensitive [MeSH:C1017675] [MeSH:C1017675] [MeSH:C1017675] animal difference hippocampal [MeSH:C0228249] nicotinic receptor [MeSH:C0034830] concentration [MeSH:C0311432] measure alpha-bungarotoxin [MeSH:C0002246] [MeSH:C0002246] binding,neurological
advanced molecular reveal liver cirrhosis [MeSH:C0023890] mechanism [MeSH:C1524059],heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve polycystic kidney disease [MeSH:C0022680] hepatic method conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine primary sclerosing cholangitis [MeSH:C0566602] parameter result improve outcome practice guideline [MeSH:C0936005],hepatorenal
persistent [MeSH:C0026205] paralysis [MeSH:C0522224] prolonged use atracurium [MeSH:C0004234] absence [MeSH:C0270823] corticosteroid [MeSH:C0001617],neuromuscular blocking agent [MeSH:C0027866] nmba patient [MeSH:C0030705] require prolonged mechanical ventilation [MeSH:C0199470] report persistent [MeSH:C0026205] [MeSH:C0026205] paralysis [MeSH:C0522224] [MeSH:C0522224] discontinuance drug involve aminosteroid-based nmba vecuronium bromide [MeSH:C0042435] especially conjunction corticosteroid [MeSH:C0001617] [MeSH:C0001617] [MeSH:C0001617] atracurium besylate [MeSH:C0004235] short-acting benzylisoquinolinium [MeSH:C1257875] nmba eliminate independently renal [MeSH:C0152169] hepatic function [MeSH:C0031843] associate persistent [MeSH:C0026205] [MeSH:C0026205] paralysis [MeSH:C0522224] [MeSH:C0522224] corticosteroid [MeSH:C0001617] [MeSH:C0001617] [MeSH:C0001617] report case atracurium-related paralysis [MeSH:C0522224] [MeSH:C0522224] persist approximately hour treat corticosteroid [MeSH:C0001617] [MeSH:C0001617] [MeSH:C0001617],neurological|hepatorenal
cerebrovascular [MeSH:C0007820] pattern peripheral artery disease patient [MeSH:C0030705],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete brain abscess [MeSH:C0006105] mechanism method observational [MeSH:C0302523] adult population [MeSH:C0032659] assess cortical dystonia [MeSH:C0013421] result well quality life measure implication therapeutic [MeSH:C0087111] innovation,neurological
diastolic diabete mellitus vascular insight,longitudinal [MeSH:C0023981] examine beta-blocker cancer adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include heart block gallbladder ventricle method participant [MeSH:C1708335] include result favorable safety profile implication healthcare advancement,cardiovascular|hepatorenal
maternal [MeSH:C0024915] uniparental disomy chromosome [MeSH:C2931794] boy normal karyotype [MeSH:C0476431],report [MeSH:C0684224] boy maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] uniparental disomy [MeSH:C0949628] chromosome [MeSH:C0008633] [MeSH:C0008633] upd year age [MeSH:C0024842] refer paediatrician symptom prader-willi syndrome [MeSH:C0032897] pws show short stature obesity mild developmental delay [MeSH:C0017340] cryptorchidism mild dysmorphic feature history indicate intrauterine growth retardation end pregnancy mother [MeSH:C0015934] year age [MeSH:C0024842] birth birth show hypotonia poor sucking gavage [MeSH:C0024842] feeding [MeSH:C0086225] need motor development [MeSH:C0020119] delay obese despite normal appetite [MeSH:C0003618] recurrent middle ear infection [MeSH:C0013455] high pain threshold great skill jigsaw puzzle report [MeSH:C0684224] behavioural problem sleep disturbance chromosomal normal xy dna [MeSH:C0012854] prader-willi syndrome [MeSH:C0032897] [MeSH:C0032897] show abnormality [MeSH:C0037268] year later re-examine think feature fit pws-like phenotype [MeSH:C0031437] [MeSH:C0031437] associate maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] upd precocious puberty [MeSH:C0034011] evident dna [MeSH:C0012854] show maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] heterodisomy chromosome [MeSH:C0008633] [MeSH:C0008633] previously describe case maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] upd robertsonian translocation involve chromosome [MeSH:C0008633] [MeSH:C0008633] detect cytogenetically dna [MeSH:C0012854] report [MeSH:C0684224] diagnosis [MeSH:C0011900] maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] upd base feature underline importance dna [MeSH:C0012854] maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] upd patient similar pws-like phenotype [MeSH:C0031437] [MeSH:C0031437] previous identification robertsonian translocation involve chromosome [MeSH:C0008633] [MeSH:C0008633],neurological
permeability [MeSH:C0031164] ultrastructural [MeSH:C0041623] change distribution [MeSH:C1704711] novel protein glomerular barrier [MeSH:C3178987] early puromycin [MeSH:C0034145] aminonucleoside nephrosis,aim unclear happen glomerulus proteinuria [MeSH:C0033687] [MeSH:C0033687] start puromycin [MeSH:C0034145] aminonucleoside nephrosis pan rat study [MeSH:C0085973] early ultrastructural [MeSH:C0041623] permeability [MeSH:C0031164] change relation expression [MeSH:C0017262] [MeSH:C0017262] podocyte [MeSH:C1328818] [MeSH:C1328818]-associated molecule nephrin [MeSH:C0754893] [MeSH:C0754893] [MeSH:C0754893] a-actinin dendrin [MeSH:C0535719] [MeSH:C0535719] plekhh2 recently discover podocyte [MeSH:C1328818] [MeSH:C1328818] method immune staining semiquantitative measurement perform electron microscope permeability [MeSH:C0031164] assess isolate kidney [MeSH:C0022646] perfusion tracer possible effect [MeSH:C4277511] ace inhibition [MeSH:C0003015] test result patchy foot process [MeSH:C0016504] [MeSH:C0016504] effacement proteinuria [MeSH:C0033687] [MeSH:C0033687] appear nephrin [MeSH:C0754893] [MeSH:C0754893] [MeSH:C0754893] reduce diseased normal area protein show change limit diseased area foot process [MeSH:C0016504] [MeSH:C0016504] effacement complete proteinuria [MeSH:C0033687] [MeSH:C0033687] appear parallel sign size barrier damage [MeSH:C0012860] nephrin [MeSH:C0754893] [MeSH:C0754893] [MeSH:C0754893] decrease dendrin [MeSH:C0535719] [MeSH:C0535719] plekhh2 decrease a-actinin remain unchanged ace inhibition [MeSH:C0003015] protective effect [MeSH:C4277511] conclusion pan glomerulus show pathology [MeSH:C0030664] despite relatively mild proteinuria [MeSH:C0033687] [MeSH:C0033687] precede altered nephrin [MeSH:C0754893] [MeSH:C0754893] [MeSH:C0754893] expression [MeSH:C0017262] [MeSH:C0017262] support pivotal role podocyte [MeSH:C1328818] [MeSH:C1328818] morphology [MeSH:C0543482] novel [MeSH:C4042926] protein dendrin [MeSH:C0535719] [MeSH:C0535719] plekhh2 reduce suggesting role pan a-actinin unchanged,neurological|hepatorenal
endoscopy [MeSH:C0014245] reveal chronic kidney disease [MeSH:C1561643] secret,investigate [MeSH:C0035173] statin effect cancer skin cancer [MeSH:C0007114] method cancer patient [MeSH:C0030705] undergo observational [MeSH:C0302523] cerebrovascular oncogene assessment result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|oncological
cardiomyopathy [MeSH:C0878544] pe cardiac connection,assess efficacy [MeSH:C5690761] beta-blocker [MeSH:C0001645] diabete focus cerebrovascular regurgitation method adult [MeSH:C0001675] population [MeSH:C0032659] randomized [MeSH:C1096777] receive beta-blocker [MeSH:C0001645] placebo insufficiency monitoring result decrease mortality rate [MeSH:C0205848] practice guideline,cardiovascular
dilate [MeSH:C1322279] cardiomyopathy connection [MeSH:C0056248] ventricular tachycardia [MeSH:C0042514],investigate [MeSH:C0035173] statin effect heart disease [MeSH:C0018799] peripheral artery disease [MeSH:C1704436] method cancer patient [MeSH:C0030705] undergo retrospective ventricular fibrillation aortic valve assessment result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],neurological|cardiovascular
hepatitis thrombosis [MeSH:C0019154] cardiac connection,prospective examine calcium channel blocker diabete [MeSH:C0006684] cardiac patient investigation [MeSH:C0035173] include cardiac hypertrophic cardiomyopathy [MeSH:C0007194] myocardial method [MeSH:C0027061] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
estrogen [MeSH:C0014939] prevent [MeSH:C0000918] cholesteryl ester accumulation [MeSH:C0008387] macrophage induce hiv protease inhibitor [MeSH:C0162714] ritonavir [MeSH:C0292818],individual [MeSH:C0021228] hiv live [MeSH:C0019682] long life drug therapy [MeSH:C0013216] include protease inhibitor [MeSH:C0033607] ritonavir [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] patient [MeSH:C0030705] develop negative [MeSH:C3539878] long-term [MeSH:C0023977] effect premature atherosclerosis [MeSH:C0004153] previously demonstrate ritonavir [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] increase atherosclerotic lesion [MeSH:C0004153] formation male [MeSH:C0086582] mouse [MeSH:C0026809] [MeSH:C0026809] great extent female [MeSH:C0086287] [MeSH:C0086582] mouse [MeSH:C0026809] [MeSH:C0026809] furthermore peripheral [MeSH:C3658334] blood monocyte isolate ritonavir [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818]-treated female [MeSH:C0086287] [MeSH:C0086582] cholesteryl ester [MeSH:C0008387] accumulation [MeSH:C0311432] [MeSH:C0311432] present investigate [MeSH:C0035173] molecular mechanism female [MeSH:C0086287] [MeSH:C0086582] hormone influence [MeSH:C0683549] cholesterol metabolism [MeSH:C0149649] macrophage response [MeSH:C0024432] hiv protease inhibitor [MeSH:C0162714] [MeSH:C0033607] ritonavir [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] utilize human [MeSH:C0086418] monocyte cell [MeSH:C0007634] line thp- model [MeSH:C0011381] address question briefly cell [MeSH:C0007634] differentiate [MeSH:C0007589] h nm pma obtain macrophage-like phenotype presence absence nm 7beta-estradiol e2 nm progesterone [MeSH:C0033308] vehicle ethanol cell [MeSH:C0001962] [MeSH:C0007634] treat ng ml ritonavir [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] vehicle presence aggregate [MeSH:C3850144] ldl [MeSH:C0034821] [MeSH:C0034821] h cell [MeSH:C0007634] extract harvest [MeSH:C0041171] lipid total rna isolate e2 decrease accumulation [MeSH:C0311432] [MeSH:C0311432] cholesteryl ester [MeSH:C0008387] macrophage follow ritonavir [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] ritonavir [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] increase expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] scavenger receptor cd3 mrna [MeSH:C0074129] responsible uptake ldl [MeSH:C0034821] [MeSH:C0034821] additionally ritonavir [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] selectively increase relative level ppargamma mrna transcription factor responsible regulation [MeSH:C0851285] cd3 mrna expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] e2 fail prevent [MeSH:C0000918] increase mrna e2 [MeSH:C0035696] significantly suppress [MeSH:C0017372] cd3 protein level measure fluorescent immunocytochemistry [MeSH:C0242349] suggest e2 modify expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] cd3 protein expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] monocyte-derived macrophage [MeSH:C0024432] result reduce cholesteryl ester [MeSH:C0008387] accumulation [MeSH:C0311432] [MeSH:C0311432] follow ritonavir [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818] [MeSH:C0292818],neurological
uremia [MeSH:C0041948] connection [MeSH:C0056248] dementia [MeSH:C0497327],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome tremor pathway method cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient measure hcc polycystic kidney disease [MeSH:C0022680] result well quality life measure care improvement,neurological|hepatorenal
differential effect non-steroidal anti-inflammatory drug seizure [MeSH:C0003211] produce pilocarpine [MeSH:C0031923] rat [MeSH:C0034721],muscarinic cholinergic [MeSH:C0242947] agonist [MeSH:C0162816] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] induce rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] status epilepticus [MeSH:C0038220] follow widespread damage forebrain [MeSH:C0085140] present design [MeSH:C0013171] investigate [MeSH:C0035173] effect non-steroidal anti-inflammatory drug sodium salicylate [MeSH:C0037549] [MeSH:C0003211] phenylbutazone [MeSH:C0031463] [MeSH:C0031463] indomethacin [MeSH:C0021246] [MeSH:C0021246] ibuprofen [MeSH:C0020740] [MeSH:C0020740] mefenamic acid [MeSH:C0025152] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0025152] [MeSH:C0036572] produce pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] pretreatment [MeSH:C0376495] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] sodium salicylate [MeSH:C0037549] ed5 mg kg phenylbutazone [MeSH:C0031463] [MeSH:C0031463] mg kg convert non-convulsant [MeSH:C0009950] dose [MeSH:C0009950] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] mg kg convulsant [MeSH:C0009950] indomethacin [MeSH:C0021246] [MeSH:C0021246] mg kg ibuprofen [MeSH:C0020740] [MeSH:C0020740] mg kg fail modulate seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] produce pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] mefenamic acid [MeSH:C0025152] mg kg prevent [MeSH:C0000918] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] protect rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572]-related brain damage induce pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] mg kg result indicate non-steroidal anti-inflammatory drug differentially [MeSH:C0003211] modulate threshold [MeSH:C0162703] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923]-induced seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572],neurological
histopathologic examination renal allograft [MeSH:C0450127] treat tacrolimus [MeSH:C0085149] fk5,clinically pathologically analyze renal allograft [MeSH:C0450127] [MeSH:C0450127] renal transplant [MeSH:C0022671] [MeSH:C0022671] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat tacrolimus [MeSH:C0085149] fk5 method twenty-six renal allograft [MeSH:C0450127] [MeSH:C0450127] biopsy [MeSH:C0005558] specimen renal transplant [MeSH:C0022671] [MeSH:C0022671] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo transplantation [MeSH:C0040732] evaluate [MeSH:C0013175] thirteen biopsy [MeSH:C0005558] perform stable function renal allograft [MeSH:C0450127] [MeSH:C0450127] informed consent [MeSH:C0021430] nonepisode biopsy [MeSH:C0005558] [MeSH:C0005558] dysfunctional renal allograft [MeSH:C0450127] [MeSH:C0450127] indication biopsy [MeSH:C0005558] episode biopsy [MeSH:C0005558] [MeSH:C0005558] result main pathologic diagnosis [MeSH:C0011900] overlap acute rejection ar n chronic [MeSH:C0150055] rejection cr n ar cr n recurrent iga nephropathy [MeSH:C0017661] n normal finding n minimal-type chronic [MeSH:C0150055] fk5 nephropathy n mild-type fk5 nephropathy n nonepisode biopsy [MeSH:C0005558] [MeSH:C0005558] biopsy [MeSH:C0005558] show minimal-type mild-type chronic [MeSH:C0150055] fk5 nephropathy respectively chronic [MeSH:C0150055] fk5 nephropathy consist rough foamy tubular vacuolization biopsy [MeSH:C0005558] arteriolopathy angiodegeneration arteriolar wall biopsy [MeSH:C0005558] focal segmental glomerulosclerosis biopsy [MeSH:C0017668] [MeSH:C0005558] striped form interstitial fibrosis biopsy [MeSH:C0005558] serum creatinine level patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mild-type chronic [MeSH:C0150055] fk5 nephropathy include episode biopsy [MeSH:C0005558] [MeSH:C0005558] statistically high minimum-type chronic [MeSH:C0150055] fk5-nephropathy p conclusion demonstrate chronic [MeSH:C0150055] fk5 nephropathy consist primarily arteriolopathy manifest insudative hyalinosis arteriolar wall suggest mild-type chronic [MeSH:C0150055] fk5 nephropathy condition lead deterioration renal allograft [MeSH:C0450127] [MeSH:C0450127] function,hepatorenal
pattern [MeSH:C3849996] hepatic injury [MeSH:C3263723] induce methyldopa [MeSH:C0025741],patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] liver disease [MeSH:C0023895] related methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] see illness [MeSH:C0162698] occur week commencement therapy patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] remain patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive drug [MeSH:C0013227] month [MeSH:C0013227] month year experience symptom jaundice tender hepatomegaly usually precede symptom malaise anorexia nausea vomiting associate [MeSH:C0004083] upper abdominal pain [MeSH:C0000737] invariable patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] biochemical [MeSH:C0017401] [MeSH:C0017401] liver function test [MeSH:C0023901] indicate hepatocellular necrosis [MeSH:C0345904] correlate histopathological evidence [MeSH:C5575834] hepatic injury [MeSH:C3263723] spectrum [MeSH:C4042936] range fatty focal hepatocellular necrosis [MeSH:C0345904] massive hepatic necrosis [MeSH:C0001364] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show moderate severe acute hepatitis [MeSH:C0019158] chronic active hepatitis [MeSH:C0019158] [MeSH:C0520463] associate [MeSH:C0004083] cholestasis [MeSH:C0008370] drug [MeSH:C0013227] withdraw presentation hospital [MeSH:C0019994] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] rapid improvement die present hepatic failure [MeSH:C0085605] take methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] year show slow biochemical [MeSH:C0017401] [MeSH:C0017401] resolution [MeSH:C0037633] period month remain series develop fulminant [MeSH:C0302809] hepatitis [MeSH:C0019158] drug [MeSH:C0019158] [MeSH:C0013227] accidentally recommence prior episode [MeSH:C0085554] methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741]-induced hepatitis [MeSH:C0019158] causal relationship [MeSH:C0021797] methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] hepatic dysfunction [MeSH:C0031847] prove recurrence [MeSH:C2825055] hepatitis [MeSH:C0019158] week re-exposure [MeSH:C3850098] drug [MeSH:C0013227],neurological|hepatorenal
sarcoma lymphoma vascular [MeSH:C3714542] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] thyroid cancer [MeSH:C0549473] pathway method longitudinal trial cancer patient measure embolism [MeSH:C0013922] atrioventricular block [MeSH:C0004245] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] safety [MeSH:C0036043] consideration,cardiovascular|oncological
neuroprotective effect [MeSH:C0815279] melatonin [MeSH:C0025219] offspre cerebellar cortex [MeSH:C0007759] rat [MeSH:C0034721] model [MeSH:C0011381] bcnu-induced cortical dysplasia,cortical dysplasia [MeSH:C0431380] [MeSH:C0431380] [MeSH:C0431380] malformation [MeSH:C0037205] characterize defect [MeSH:C0155017] proliferat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0596290] migrat [MeSH:C0034721] [MeSH:C0034721]ion maturat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0036887] design [MeSH:C0013171] evaluate alterat [MeSH:C0034721] [MeSH:C0034721]ion offspring [MeSH:C0683572] [MeSH:C0683572] rat [MeSH:C0034721] [MeSH:C0034721] cerebellum [MeSH:C0007765] [MeSH:C0007765] [MeSH:C0007765] induce maternal exposure [MeSH:C1390376] [MeSH:C0243033] carmustine- -bis -chloroethyl --nitrosoure bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] investigate [MeSH:C0035173] effect [MeSH:C4277511] exogenous melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] cerebella [MeSH:C0007765]r [MeSH:C0007765] bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257]-induced cortical dysplasia [MeSH:C0431380] [MeSH:C0431380] [MeSH:C0431380] histological [MeSH:C0019637] biochemical analysis pregnant [MeSH:C0033006] wistar rat [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] assign group [MeSH:C0018257] intact-control saline-control melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219]-treated bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257]-exposed bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257]-exposed plus melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] rat [MeSH:C0034721] [MeSH:C0034721] expose bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] embryonic melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] give delivery immuno histochemistry electron microscopy carry offspring [MeSH:C0683572] [MeSH:C0683572] cerebellum [MeSH:C0007765] [MeSH:C0007765] [MeSH:C0007765] level malondialdehyde [MeSH:C0024643] superoxide dismutase [MeSH:C0038838] [MeSH:C0038838] determine histopathologically typical finding observe cerebella [MeSH:C0007765] group [MeSH:C0018257] finding consistent early embryonic development [MeSH:C0013936] note bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257]-exposed cortical dysplasia [MeSH:C0431380] [MeSH:C0431380] [MeSH:C0431380] marked increase number tunel positive cell nestin positive cell bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257]-exposed decrease immunoreactivity glial fibrillary acidic protein synaptophysin transform growth factor beta1 observe indicate delay [MeSH:C5544400] maturat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0036887] melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] significantly reverse change malondialdehyde [MeSH:C0024643] bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257]-exposed high group [MeSH:C0018257] [MeSH:C0019534] melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] decrease malondialdehyde [MeSH:C0024643] level bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] p difference superoxide dismutase [MeSH:C0038838] level group [MeSH:C0018257] suggest exposure [MeSH:C1390376] animal [MeSH:C0003062] bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] pregnancy [MeSH:C0032961] lead delay [MeSH:C5544400] maturat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0036887] offspre cerebellum [MeSH:C0007765] [MeSH:C0007765] [MeSH:C0007765] melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] protect cerebellum [MeSH:C0007765] [MeSH:C0007765] [MeSH:C0007765] effect [MeSH:C4277511] bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257],neurological|hepatorenal
cancer screening [MeSH:C0199230] colorectal cancer [MeSH:C0009402],investigate [MeSH:C0035173] beta-blocker effect diabete melanoma method [MeSH:C0025202] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo randomized control bone marrow transplant multiple myeloma assessment [MeSH:C0030198] result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
bilateral subthalamic nucleus stimulation [MeSH:C0152355] parkinson disease [MeSH:C0030567],high frequency [MeSH:C0019541] stimulation subthalamic nucleus stn [MeSH:C0152355] know ameliorate sign symptom advanced parkinson disease [MeSH:C0030567] [MeSH:C0030567] study effect high frequency [MeSH:C0019541] stn stimulation patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] twenty-three patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] suffer severe parkinson disease [MeSH:C0030567] [MeSH:C0030567] stage iii-v hoehn yahr scale particularly bradykinesia rigidity [MeSH:C0233565] levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-induced dyskinesia undergo bilateral implantation electrode stn preoperative [MeSH:C0033061] postoperative assessment patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] month follow-up [MeSH:C3899107] drug condition carry unified parkinson disease [MeSH:C0030567] [MeSH:C0030567] rating scale hoehn yahr staging england activity daily living score video recording result electrical stimulation stn [MeSH:C0013786] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] score activity daily living motor examination score unified parkinson disease [MeSH:C0030567] [MeSH:C0030567] rating scale part ii iii medication [MeSH:C0033045] improve respectively p subscore akinesia rigidity tremor gait improve p average levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] dose decrease mg mg cognitive function [MeSH:C0009240] remain unchanged patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop device-related complication [MeSH:C1171258] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience abnormal [MeSH:C0853087] weight gain bilateral subthalamic nucleus stimulation [MeSH:C0152355] effective advanced parkinson disease [MeSH:C0030567] [MeSH:C0030567] reduce severity phase symptom improve axial symptom reduce levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] requirement reduction [MeSH:C1827449] levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] dose useful control drug-induced dyskinesia [MeSH:C0013386],neurological
cancer cancer [MeSH:C0006826] connection,hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve tumor bone cancer method conduct retrospective [MeSH:C0035363] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine prostate cancer [MeSH:C0376358] parameter result improvement primary endpoint therapeutic innovation [MeSH:C0087111],oncological
reversal [MeSH:C0035375] phenylephrine [MeSH:C0031469] beneficial effect intravenous [MeSH:C0085297] nitroglycerin [MeSH:C0017887] patient [MeSH:C0030705] acute myocardial infarction [MeSH:C0027051],nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] show reduce st-segment elevation acute myocardial infarction [MeSH:C0027051] [MeSH:C1536220] effect [MeSH:C4277511] potentiate dog agent [MeSH:C0012984] reverse nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887]-induced hypotension design determine effect [MeSH:C4277511] combined nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] phenylephrine [MeSH:C0031469] [MeSH:C0031469] therapy patient [MeSH:C0030705] [MeSH:C0030705] acute transmural myocardial infarction [MeSH:C0027051] receive intravenous [MeSH:C0085297] nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] sufficient reduce mean arterial pressure mm hg p minute leave ventricular filling pressure [MeSH:C0206177] [MeSH:C0206177] decrease mm hg p sigmast sum st-segment elevation precordial lead decrease p intravenous [MeSH:C0085297] nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] subsequent addition phenylephrine [MeSH:C0031469] [MeSH:C0031469] infusion [MeSH:C0841792] sufficient re-elevate mean arterial pressure [MeSH:C0428886] mm hg p minute increase leave ventricular filling pressure [MeSH:C0206177] [MeSH:C0206177] mm hg p significantly increase sigmast p result suggest addition phenylephrine [MeSH:C0031469] [MeSH:C0031469] nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] beneficial patient [MeSH:C0030705] [MeSH:C0030705] acute myocardial infarction [MeSH:C0027051],cardiovascular
late late doxorubicin [MeSH:C0013089] cardiotoxicity [MeSH:C0876994],cardiac [MeSH:C0018810] toxicity [MeSH:C0040539] major complication [MeSH:C1171258] limit use adriamycin [MeSH:C0085752] chemotherapeutic agent cardiomyopathy [MeSH:C0878544] frequent total dose exceed mg m2 occur month cessation therapy [MeSH:C0039798] report develop progressive [MeSH:C1449744] cardiomyopathy [MeSH:C0878544] one-half year receive mg m2 apparently represent late late cardiotoxicity [MeSH:C0876994] [MeSH:C0040539],cardiovascular
primary sclerosing cholangitis [MeSH:C0566602] meet liver cirrhosis [MeSH:C0023890] neurological perspective,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect hypertension glomerular filtration rate method [MeSH:C0017654] adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective dementia amygdala assessment result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],neurological|hepatorenal
meningioma [MeSH:C0025286] connection chronic kidney disease [MeSH:C1561643],cancer affect elderly patient [MeSH:C0030705] worldwide particularly involve meningitis [MeSH:C0025289] cerebral method conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examining chf parameter result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],neurological|cardiovascular
aspirin cancer [MeSH:C0004057] brain [MeSH:C0006104] insight,hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve cerebral reticular formation method [MeSH:C0035284] conduct observational [MeSH:C0302523] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine bladder cancer [MeSH:C0005684] parameter result improve outcome [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|oncological
myotonic dystrophy [MeSH:C0027126] closely link gene muscle-type creatine kinase ckmm,study genetic linkage [MeSH:C0023745] gene creatine kinase muscle type ckmm gene myotonic dystrophy dm panel myotonic dystrophy family canada netherland [MeSH:C0027126] maximum lod score zmax [MeSH:C0023956] recombination frequency [MeSH:C0376249] theta obtain tight linkage demonstrate ckmm gene apolipoprotein c2 [MeSH:C0003591] apoc2 establish ckmm useful marker myotonic dystrophy [MeSH:C0027126],neurological
swallowing-induced atrial tachyarrhythmia trigger salbutamol [MeSH:C0001927] case report review [MeSH:C0282436] literature [MeSH:C0023866],case -year-old experience chest discomfort swallow [MeSH:C0011167] electrocardiogram episode [MeSH:C0085554] atrial tachyarrhythmia [MeSH:C0003811] [MeSH:C0080203] record immediately swallow [MeSH:C0011167] -hour holter [MeSH:C0013801] monitoring record event arrhythmia [MeSH:C0003811] resolve therapy [MeSH:C0039798] atenolol [MeSH:C0004147] recur later notice episode [MeSH:C0085554] inhalator salbutamol [MeSH:C0001927] [MeSH:C0001927] stop beta-agonist [MeSH:C0001644] week atenolol [MeSH:C0004147] arrhythmia [MeSH:C0003811] disappear discussion swallow [MeSH:C0011167]ing-induced atrial tachyarrhythmia [MeSH:C0003811] [MeSH:C0080203] siat [MeSH:C0105905] rare phenomenon [MeSH:C2350469] few case siat [MeSH:C0105905] describe literature article [MeSH:C0023866] summarize case publish create comprehensive review current knowledge approach [MeSH:C0376554] siat [MeSH:C0105905] discuss demographic characteristic type arrhythmia [MeSH:C0003811] postulated mechanism [MeSH:C1524059] siat [MeSH:C0105905] different possibility medication surgery [MeSH:C0038895] radiofrequency catheter ablation [MeSH:C0162561] rfca salbutamol [MeSH:C0001927] [MeSH:C0001927] present possible trigger [MeSH:C0458343] siat [MeSH:C0105905] difficult define causality case report [MeSH:C0684224] logical think beta-agonist [MeSH:C0001644] like salbutamol [MeSH:C0001927] [MeSH:C0001927] know induce tachycardia [MeSH:C0039231] trigger [MeSH:C0458343] adrenergic reflex [MeSH:C0001637] originate esophagus [MeSH:C0014876] swallow [MeSH:C0011167] beta-blocker atenolol [MeSH:C0004147] block adrenergic activity [MeSH:C0242889] relieve,neurological|cardiovascular
regulation signal transducer activator transcription apoptotic pathway [MeSH:C0287920] betaine [MeSH:C0005304] attenuate [MeSH:C0042211] isoproterenol-induced acute myocardial injury rat [MeSH:C0034721],present design [MeSH:C0013171] investigate [MeSH:C0035173] cardioprotective effect betaine [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] acute myocardial ischemia [MeSH:C0151744] induce experimentally [MeSH:C0016998] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] focus regulation signal transducer activator transcription stat3 [MeSH:C0253050] apoptotic pathway potential mechanism [MeSH:C1524059] underlie drug effect [MeSH:C0041755] male [MeSH:C0086582] sprague dawley [MeSH:C0034715] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat betaine [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] mg kg orally day [MeSH:C0011017] acute myocardial ischemic injury [MeSH:C0027055] induce rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] subcutaneous injection [MeSH:C0021499] isoproterenol [MeSH:C0022245] mg kg consecutive day [MeSH:C0011017] serum [MeSH:C0229671] cardiac marker enzyme [MeSH:C0014442] histopathological variable expression protein [MeSH:C0017262] level analyze oral administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion betaine [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] mg kg significantly reduce cardiac marker enzyme [MeSH:C0014442] serum [MeSH:C0229671] prevent leave [MeSH:C0242724] ventricular remodel western blot show isoproterenol [MeSH:C0022245]-induced phosphorylation [MeSH:C0031715] stat3 [MeSH:C0253050] maintain enhance betaine [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] myocardium furthermore betaine [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] mg kg increase ventricular expression bcl- reduce bax [MeSH:C0219474] cause increase rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]io bcl- bax [MeSH:C0219474] protective role betaine [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] myocardial damage [MeSH:C0012860] confirm histopathological examination summary result show betaine [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] [MeSH:C0005304] pretreatment [MeSH:C0376495] attenuate [MeSH:C0042211] isoproterenol [MeSH:C0022245]-induced acute myocardial ischemia regulation stat3 [MeSH:C0253050] apoptotic pathway,cardiovascular
leukemia [MeSH:C0023418] pulmonary valve [MeSH:C0034086] cardiac connection,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] ventricular fibrillation tia [MeSH:C0042510] result well quality life measure aortic dissection [MeSH:C0340643] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
selective dopamine d4 receptor antagonist nra0 preclinical neuropharmacological profile,nra0 fluorobenzylidene piperidin yl ethyl [MeSH:C0014994] -fluorophenyl thiazole carboxamide high affinity [MeSH:C0001730] [MeSH:C0001730] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] clone dopamine [MeSH:C0013030] [MeSH:C0013030] d4 d4 d4 receptor ki value [MeSH:C0114835] nm respectively nra0 0fold potent dopamine [MeSH:C0013030] [MeSH:C0013030] d4 receptor compare human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] clone dopamine [MeSH:C0013030] [MeSH:C0013030] d2l receptor nra0 negligible affinity [MeSH:C0001730] [MeSH:C0001730] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] clone dopamine [MeSH:C0013030] [MeSH:C0013030] d3 receptor ki nm rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] serotonin [MeSH:C0036751] -ht 2a receptor ki nm rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] alpha1 adrenoceptor ki [MeSH:C0304512] nm nra0 clozapine [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] antagonize locomotor hyperactivity [MeSH:C0023946] induce methamphetamine map [MeSH:C0025611] mouse [MeSH:C0026809] nra0 clozapine [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] antagonize map-induced stereotyped behavior [MeSH:C0038271] mouse [MeSH:C0026809] effect [MeSH:C4277511] exceed inhibition high dose give nra0 clozapine [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] significantly induce catalepsy [MeSH:C0007370] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] effect [MeSH:C4277511] exceed induction [MeSH:C0042767] high dose give nra0 clozapine [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] significantly reverse disruption prepulse inhibition ppi rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] produce apomorphine [MeSH:C0003596] nra0 clozapine [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] [MeSH:C0009079] significantly shorten phencyclidine pcp [MeSH:C0031381] -induced prolonged swimming [MeSH:C0039003] latency rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] water maze [MeSH:C5197854] task finding suggest nra0 unique antipsychotic [MeSH:C0040615] activity [MeSH:C0040615] liability [MeSH:C0242808] motor effect [MeSH:C4277620] [MeSH:C4277511] typical classical antipsychotic [MeSH:C0040615],neurological
congestive heart failure [MeSH:C0018802] meet diabetes mellitus [MeSH:C0011849] neurological perspective,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] hypertensive pathway method longitudinal trial cancer patient [MeSH:C0030705] measuring paralysis [MeSH:C0522224] aortic dissection result well quality life measure therapeutic innovation [MeSH:C0087111],neurological|cardiovascular
basal ganglia [MeSH:C0004781] pattern hepatitis [MeSH:C0019158] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] aspirin improve cancer outcome [MeSH:C0206277] dopamine pathway method cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient measure dementia [MeSH:C0497327] tremor [MeSH:C0040822] result positive response safety consideration,neurological
stroke [MeSH:C0038454] dilate [MeSH:C1322279] cardiomyopathy [MeSH:C0878544] cardiac connection,hypothesis statin improve cancer outcome [MeSH:C0206277] dvt pathway method longitudinal trial [MeSH:C0023981] cardiac patient measuring chf heart result positive response optimization [MeSH:C0376695],cardiovascular
postmarketing [MeSH:C0024826] timolol-hydrochlorothiazide antihypertensive therapy [MeSH:C0003364],postmarketing surveillance [MeSH:C0033267] conduct determine safety [MeSH:C0036043] efficacy [MeSH:C5690761] fixed-ratio combination contain mg timolol [MeSH:C0040233] maleate [MeSH:C0220874] mg hydrochlorothiazide [MeSH:C0020261] administer twice daily hypertensive [MeSH:C0003364] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] collect participate physician [MeSH:C0031831] mean systolic blood pressure [MeSH:C0005823] [MeSH:C0005823] decrease mmhg mean diastolic blood pressure [MeSH:C0005823] decline mmhg timolol [MeSH:C0040233]-hydrochlorothiazide [MeSH:C0020261] therapy p comparison age race sex appear influence [MeSH:C0683549] decrease blood pressure [MeSH:C0005823] antihypertensive [MeSH:C0003364] effect drug great patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe hypertension [MeSH:C0020538] overall [MeSH:C0282416] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience total adverse event [MeSH:C0041755] [MeSH:C0041755] common fatigue dizziness weakness patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] discontinue adverse event [MeSH:C0041755],cardiovascular
basal ganglia [MeSH:C0004781] meet diabetes mellitus [MeSH:C0011849] neurological perspective,observational [MeSH:C0302523] examine beta-blocker diabete cardiac [MeSH:C0018810] patient investigation [MeSH:C0035173] include neurodegenerative gray matter tic method [MeSH:C0025663] participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication optimization [MeSH:C0376695],neurological
sciatica connection lung cancer [MeSH:C0242379],randomized control examine [MeSH:C1096777] metformin [MeSH:C0025598] cancer adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include neurofibroma seizure [MeSH:C0027830] dementia [MeSH:C0497327] method participant [MeSH:C1708335] include result positive response implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
angiography [MeSH:C0002978] reveal lymphoma [MeSH:C0024299] secret,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] chorea [MeSH:C0008489] mechanism method retrospective [MeSH:C0035363] elderly patient assess cerebral neuropathy result positive response implication need investigation [MeSH:C0035173],neurological
gene spinal cerebellar ataxia [MeSH:C0007758] sca3 [MeSH:C4019432] located region approximately cm chromosome 4q2,-q3 sca3 [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] gene spinal cerebellar ataxia [MeSH:C0007758] recently map [MeSH:C0024779] -cm interval [MeSH:C0005605] d14s6 d14s8 chromosome 4q linkage [MeSH:C0242239] family french ancestry sca3 [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] candidate region refine linkage [MeSH:C0242239] new microsatellite marker [MeSH:C0017393] d14s2 d14s2 d14s2 afm33vf1 family additional individual genotype french family combined two-point linkage [MeSH:C0242239] analysis new marker [MeSH:C0017393] d14s2 afm33vf1 tightly link sca3 [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] maximal lod score recombination [MeSH:C0034865] fraction theta respectively combined multipoint recombinant haplotype [MeSH:C0018591] analysis localize sca3 [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] -cm interval [MeSH:C0005605] flank d14s2 d14s8 allele [MeSH:C0002085] d14s2 segregate disease locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] kindred allele [MeSH:C0002085] frequent french population [MeSH:C0032659] linkage [MeSH:C0242239] disequilibrium [MeSH:C0023746] clearly establish sca3 [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] remain -cm region 4q2 -q3 contain gene machado-joseph disease [MeSH:C0024408] clinically related phenotype [MeSH:C0031437] determine sca3 [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] [MeSH:C4019432] conclude disease alteration gene,neurological
rabbit syndrome [MeSH:C3887509] antidepressant [MeSH:C0003289] use cerebral perfusion spect scan finding,rabbit syndrome [MeSH:C3887509] extrapyramidal effect [MeSH:C0015372] associate chronic neuroleptic therapy occurrence treat imipramine [MeSH:C0020934] describe represent report case syndrome [MeSH:C0038828] conjunction antidepressant [MeSH:C0003289] repeated cerebral perfusion [MeSH:C0031001] spect scan [MeSH:C3472245] reveal decrease basal ganglia [MeSH:C0004781] perfusion [MeSH:C0031001] movement disorder [MeSH:C0026650] present return normal perfusion [MeSH:C0031001] rabbit syndrome [MeSH:C3887509] resolve,neurological
carcinogen [MeSH:C0007090] chronic kidney disease vascular [MeSH:C0221214] insight,longitudinal [MeSH:C0023981] examine ace inhibitor diabete [MeSH:C0003015] elderly patient investigation [MeSH:C0035173] include ventricular fibrillation heart block pericardium method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
neuropsychiatric behavior mptp marmoset model [MeSH:C0006764] parkinson disease [MeSH:C0030567],objective neuropsychiatric symptom [MeSH:C3839861] increasingly recognise problem [MeSH:C0037431] patient [MeSH:C0030705] parkinson disease [MeSH:C0030567] pd symptom [MeSH:C3839861] sensitisation follow repeated levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] direct effect dopamine disease state [MeSH:C0012634] levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-treated mptp-lesioned marmoset model neuropsychiatric symptom [MeSH:C3839861] pd patient [MeSH:C0030705] compare course levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-induced motor fluctuation neuropsychiatric-like behavior determine relationship [MeSH:C0021797] duration onset symptom [MeSH:C3839861] method marmoset administer -methyl phenyl- -tetrahydropyridine mg kg c day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] result stable parkinsonism [MeSH:C0242422] levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] mg kg benserazide [MeSH:C0005014] mg kg p b administer day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] animal [MeSH:C0003062] [MeSH:C0003062] evaluate [MeSH:C0013175] parkinsonian disability dyskinesia on-time motor fluctuation neuropsychiatric-like behavior prior levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] post hoc dvd train rater blind result neuropsychiatric-like behavior rating scale demonstrate high interrater reliability train rater differ professional background anticipate animal [MeSH:C0003062] [MeSH:C0003062] exhibit progressive [MeSH:C1449744] increase levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-induced motor fluctuation dyskinesia wearing-off correlate duration levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] therapy contrast levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-induced neuropsychiatric-like behavior present levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] severity correlate duration conclusion suggest neuropsychiatric disorder [MeSH:C0004936] pd likely interaction [MeSH:C0007582] levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] disease state [MeSH:C0012634] consequence sensitisation repeated dopaminergic therapy,neurological
fusion gene [MeSH:C0178648] result alternative chromosomal translocation [MeSH:C0040715] overexpresse gene-specific mechanism alveolar rhabdomyosarcoma [MeSH:C0206655],chromosomal translocation [MeSH:C0599893] [MeSH:C0599893] [MeSH:C0040715] identify hematopoietic [MeSH:C0600251] solid tumor [MeSH:C0027651] deregulate expression [MeSH:C0017263] protooncogene creation chimeric protein [MeSH:C0752111] tumorigenic potential pediatric [MeSH:C0237433] solid tumor [MeSH:C0027651] alveolar rhabdomyosarcoma [MeSH:C0206655] consistent q3 q1 variant p3 q1 translocation [MeSH:C0599893] [MeSH:C0599893] generate pax3-fkhr pax7-fkhr fusion [MeSH:C0178648] protein [MeSH:C3251957] respectively report [MeSH:C0684224] demonstrate addition functional [MeSH:C0031843] alteration translocation [MeSH:C0599893] [MeSH:C0599893] associate fusion [MeSH:C0178648] product overexpression furthermore pax3-fkhr pax7-fkhr overexpression occur distinct mechanism [MeSH:C1524059] [MeSH:C1524059] transcription pax3-fkhr increase relative wild-type pax3 copy number-independent process contrast pax7-fkhr overexpression result fusion [MeSH:C0178648] gene amplification [MeSH:C0017256] gene-specific mechanism [MeSH:C1524059] [MeSH:C1524059] select overexpress pax3-fkhr pax7-fkhr alveolar rhabdomyosarcoma [MeSH:C0206655] presumably difference regulation [MeSH:C0851285] wild-type locus postulate overexpression mechanism [MeSH:C1524059] [MeSH:C1524059] ensure critical gene product oncogenic [MeSH:C0029016] effect fusion [MeSH:C0178648],neurological|oncological
uncoupling [MeSH:C4277622] hypomyelination glial cell [MeSH:C0027836] death mutation proteolipid protein gene,proteolipid protein [MeSH:C1175541] plp [MeSH:C0060617] r highly conserve major polytopic membrane protein myelin [MeSH:C0026969] cellular function [MeSH:C0031843] remain obscure neurological mutant [MeSH:C0025931] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] provide model system human [MeSH:C0086418] genetic disorder [MeSH:C0019247] mutation [MeSH:C0026882] [MeSH:C0026882] x-chromosome-linked plp [MeSH:C0060617] gene lethal identify jimpy [MeSH:C0025928] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] subsequently patient pelizaeus-merzbacher disease [MeSH:C0205711] unexplained phenotype [MeSH:C0031437] mutation [MeSH:C0026882] [MeSH:C0026882] include degeneration [MeSH:C0027746] premature cell death [MeSH:C1855073] oligodendrocyte [MeSH:C0028944] [MeSH:C0028944] [MeSH:C0028944] associate hypomyelin [MeSH:C0026969]ation new mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] mutant rumpshaker define amino-acid substitution ile-to-thr residue membrane-embedded domain plp [MeSH:C0060617] surprisingly rumpshaker mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] myelin [MeSH:C0026969]-deficient normal longevity [MeSH:C0023980] complement morphologically normal oligodendrocyte [MeSH:C0028944] [MeSH:C0028944] [MeSH:C0028944] hypomyelin [MeSH:C0026969]ation genetically separate plp [MeSH:C0060617]-dependent oligodendrocyte [MeSH:C0028944] [MeSH:C0028944] [MeSH:C0028944] degeneration [MeSH:C0027746] suggest plp [MeSH:C0060617] vital function [MeSH:C0031843] glial cell [MeSH:C0027836] development [MeSH:C0243107] distinct later role myelin [MeSH:C0026969] assembly dichotomy action explain spectrum pelizaeus-merzbacher disease [MeSH:C0205711],neurological
ischemic cardiomyopathy [MeSH:C0878544] meet leukemia [MeSH:C0023418] neurological perspective,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer capillary mechanism method prospective elderly patient assess pulmonary embolism [MeSH:C0034065] migraine [MeSH:C0149931] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
cardiomyopathy [MeSH:C0878544] venous cardiac connection,question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer vein [MeSH:C0006826] mechanism method observational [MeSH:C0302523] cardiac patient assess cardiomyopathy blood pressure [MeSH:C0005823] result positive response implication practice guideline,cardiovascular
risk factor [MeSH:C0035648] predictor levodopa-induced dyskinesia multiethnic malaysian parkinson disease,chronic pulsatile levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] therapy [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] parkinson disease [MeSH:C0030567] pd lead development [MeSH:C0020119] motor fluctuation dyskinesia [MeSH:C0013384] study prevalence [MeSH:C0033105] predictor levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-induced dyskinesia [MeSH:C0013384] multiethnic malaysian patient [MeSH:C0030705] [MeSH:C0030705] pd method cross-sectional [MeSH:C0010362] involve patient [MeSH:C0030705] [MeSH:C0030705] pd uninterrupted levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] therapy [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] month instrument [MeSH:C0011377] updr questionnaire predictor dyskinesia [MeSH:C0013384] [MeSH:C0013384] determine multivariate logistic regression result mean age year mean onset age [MeSH:C0206132] year median disease [MeSH:C0751922] duration year dyskinesia [MeSH:C0013384] present n median levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] therapy [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] year chinese malay indian ethnic group [MeSH:C5441552] eighty-one percent patient [MeSH:C0030705] [MeSH:C0030705] dyskinesia [MeSH:C0013384] fluctuation patient [MeSH:C0030705] [MeSH:C0030705] dyskinesia [MeSH:C0013384] low onset age [MeSH:C0206132] [MeSH:C0206132] p long duration levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] therapy [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] p long disease [MeSH:C0027341] duration p high total daily levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] dose p high total updr score p patient [MeSH:C0030705] [MeSH:C0030705] dyskinesia [MeSH:C0013384] predictor dyskinesia [MeSH:C0013384] [MeSH:C0013384] duration levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] therapy [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] onset age [MeSH:C0206132] total daily levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] dose conclusion prevalence [MeSH:C0033105] levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-induced dyskinesia [MeSH:C0013384] patient [MeSH:C0030705] [MeSH:C0030705] predictor duration levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] therapy [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] total daily levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] dose onset age [MeSH:C0206132],neurological
cardiomyopathy [MeSH:C0878544] bun organ interplay,retrospective [MeSH:C0035363] examine metformin [MeSH:C0025598] hypertension [MeSH:C0020538] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include jaundice renal cyst [MeSH:C0022346] nash method participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication safety [MeSH:C0036043] consideration,hepatorenal
antiarrhythmic diabete mellitus brain insight,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve stroke [MeSH:C0038454] outcome meningioma pathway method prospective trial cardiac patient measuring migraine guillain-barre syndrome [MeSH:C0018378] result well quality life measure practice guideline,neurological
atm mutation [MeSH:C0026882] phenotype [MeSH:C0031437] ataxia-telangiectasia family british [MeSH:C0004135] isle expression mutant [MeSH:C0017262] atm risk leukemia lymphoma breast cancer [MeSH:C4277512],report spectrum atm mutation [MeSH:C0026882] [MeSH:C0026882] observe ataxia-telangiectasia a-t patient [MeSH:C0030705] [MeSH:C0030705] british isle atm mutation [MeSH:C0026882] [MeSH:C0026882] identify family native [MeSH:C0015576] british isle founder mutation [MeSH:C0026882] [MeSH:C0026882] confer mild phenotype [MeSH:C0031437] [MeSH:C0031437] respect cerebellar degeneration [MeSH:C0037952] cellular feature report a-t family atm mutation [MeSH:C0026882] [MeSH:C0026882] 1t-- g associate increase risk [MeSH:C0035647] breast cancer [MeSH:C0006142] homozygote [MeSH:C0019904] heterozygote [MeSH:C0019425] relative risk [MeSH:C0242492] [MeSH:C0035647] p severe a-t phenotype [MeSH:C0031437] [MeSH:C0031437] term degree cerebellar degeneration [MeSH:C0037952] mutation [MeSH:C0026882] [MeSH:C0026882] 1t-- g allow expression [MeSH:C0017262] full-length atm protein comparable unaffected individual addition study a-t patient [MeSH:C0030705] [MeSH:C0030705] family [MeSH:C0030705] develop leukemia lymphoma [MeSH:C0023493] preleukemic t-cell proliferation hodgkin lymphoma [MeSH:C0019829] childhood [MeSH:C0023452] wide variety atm mutation [MeSH:C0026882] [MeSH:C0026882] type include missense mutation [MeSH:C0599155] [MeSH:C0026882] [MeSH:C0026882] in-frame deletion [MeSH:C0017260] see patient [MeSH:C0030705] [MeSH:C0030705] a-t patient [MeSH:C0030705] [MeSH:C0030705] carry in-frame deletion [MeSH:C0017260] missense mutation [MeSH:C0599155] [MeSH:C0026882] [MeSH:C0026882] associate expression [MeSH:C0017262] mutant atm protein,neurological|oncological
pharmacology [MeSH:C0031330] acc- phenytoin [MeSH:C0031507] prodrug [MeSH:C0033262],acc- disodium phosphate ester [MeSH:C0074757] -hydroxymethyl- -diphenylhydantoin prodrug [MeSH:C0033262] phenytoin [MeSH:C0031507] [MeSH:C0031507] advantageous physicochemical property [MeSH:C2350462] acc- rapidly convert enzymatically phenytoin [MeSH:C0031507] [MeSH:C0031507] vivo acc- phenytoin [MeSH:C0031507] [MeSH:C0031507] sodium equivalent [MeSH:C2355577] anticonvulsant activity seizure [MeSH:C0003286] induce maximal electroshock me mouse [MeSH:C0026809] [MeSH:C0026809] follow p oral [MeSH:C0029170] v administrat [MeSH:C0034721]ion [MeSH:C0001554] ed5 dose mg kg v acc- mg kg v phenytoin [MeSH:C0031507] [MeSH:C0031507] sodium acc- phenytoin [MeSH:C0031507] [MeSH:C0031507] sodium similar antiarrhythmic activity [MeSH:C0003195] [MeSH:C0003195] ouabain-induced [MeSH:C0029904] ventricular tachycardia anesthetize dog [MeSH:C0042514] total dose acc- phenytoin [MeSH:C0031507] [MeSH:C0031507] sodium necessary convert arrhythmia [MeSH:C0003811] normal sinus rhythm mg kg respectively phenytoin [MeSH:C0031507] [MeSH:C0031507] sodium display vitro antiarrhythmic activity [MeSH:C0003195] [MeSH:C0003195] strophanthidin-induced arrhythmia [MeSH:C0003811] guinea pig [MeSH:C0085979] right atrium anesthetize dog high dose acc- mg kg infuse min response [MeSH:C0034746] compare equimolar dose phenytoin [MeSH:C0031507] [MeSH:C0031507] sodium mg kg acc- phenytoin [MeSH:C0031507] [MeSH:C0031507] sodium treatment produce similar marked reduction [MeSH:C1827449] diastolic blood pressure contractile force lvdp dt maximum effect [MeSH:C4277511] occur maximum phenytoin [MeSH:C0031507] [MeSH:C0031507] sodium level acute [MeSH:C0184567] toxicity study acc- phenytoin [MeSH:C0031507] [MeSH:C0031507] sodium carry mouse [MeSH:C0026809] [MeSH:C0026809] rat [MeSH:C0034721] rabbit dog v p route administrat [MeSH:C0034721]ion [MeSH:C0001554] systemic toxic sign agent similar occur approximately equivalent [MeSH:C2355577] dose importantly local irritation [MeSH:C0022108] acc- markedly phenytoin [MeSH:C0031507] [MeSH:C0031507] sodium follow administrat [MeSH:C0034721]ion [MeSH:C0001554] abstract truncate word,neurological|cardiovascular
hypertrophic cardiomyopathy [MeSH:C0007194] marker angina pectoris [MeSH:C0002962],heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve ventricular tachycardia aortic aneurysm method [MeSH:C0042514] conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine arrhythmia [MeSH:C0003811] parameter result positive response practice guideline [MeSH:C0936005],cardiovascular
effect [MeSH:C4277511] deliberate hypotension [MeSH:C0020649] induce labetalol [MeSH:C0022860] isoflurane [MeSH:C0022180] neuropsychological function [MeSH:C0027902],effect [MeSH:C4277511] [MeSH:C4277511] deliberate hypotension [MeSH:C0020649] [MeSH:C0020649] brain function [MeSH:C0031843] measure neuropsychological test study [MeSH:C0027902] adult [MeSH:C0001675] patient [MeSH:C0030705] [MeSH:C0030705] twenty-four patient [MeSH:C0030705] [MeSH:C0030705] anaesthetize middle-ear surgery deliberate hypotension [MeSH:C0020649] [MeSH:C0020649] induce labetalol [MeSH:C0022860] [MeSH:C0022860] isoflurane [MeSH:C0022180] hypotensive seventeen patient [MeSH:C0030705] [MeSH:C0030705] hypotension [MeSH:C0020649] [MeSH:C0020649] serve mean arterial pressure mmhg kpa hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] mmhg kpa hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] hypotensive mmhg kpa anaesthesia follow psychological test perform [MeSH:C0033905] subtest wechsler adult [MeSH:C0001675] intelligence scale [MeSH:C0021704] similarity digit span vocabulary digit symbol trail-making test b zung test self-rating anxiety scale self-rating depression scale two-part memory test battery immediate delay recall test perform preoperative [MeSH:C0033061]ly day [MeSH:C0011017] postoperative [MeSH:C0032786]ly statistically difference group test change preoperative [MeSH:C0033061] postoperative [MeSH:C0032786] result indicate hypotension [MeSH:C0020649] [MeSH:C0020649] induce labetalol [MeSH:C0022860] [MeSH:C0022860] isoflurane [MeSH:C0022180] harmful effect [MeSH:C4277511] [MeSH:C4277511] mental function [MeSH:C0031843] compare normotensive anaesthesia,neurological
warfarin-induced artery calcification accelerate growth [MeSH:C0018270] vitamin,present study [MeSH:C0085973] demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e growth [MeSH:C0018270] [MeSH:C0018270] [MeSH:C0018270] vitamin [MeSH:C0042890] [MeSH:C0042890] [MeSH:C0042890] enhance extent artery calcification [MeSH:C0040432] [MeSH:C0040432] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give sufficient dose warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] inhibit [MeSH:C0021463] [MeSH:C0021463] gamma-carboxylation matrix gla protein [MeSH:C0033684] [MeSH:C0065752] calcification [MeSH:C0040432] [MeSH:C0040432] inhibit [MeSH:C0021463] [MeSH:C0021463]or know express smooth muscle cell macrophage [MeSH:C0024842] artery wall [MeSH:C1135918] series experiment [MeSH:C0020123] [MeSH:C0020123] examine influence [MeSH:C0683549] age [MeSH:C0024842] growth [MeSH:C0018270] [MeSH:C0018270] [MeSH:C0018270] status artery calcification [MeSH:C0040432] [MeSH:C0040432] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] week warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] cause massive focal calcification [MeSH:C0040432] [MeSH:C0040432] artery medium [MeSH:C0003842] -day [MeSH:C0011017]-old rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] extensive focal calcification [MeSH:C0040432] [MeSH:C0040432] -day [MeSH:C0011017]-old rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] contrast artery calcification [MeSH:C0040432] [MeSH:C0040432] detect -month-old adult [MeSH:C0001675] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] week warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] directly examine importance growth [MeSH:C0018270] [MeSH:C0018270] [MeSH:C0018270] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031]-induced artery calcification [MeSH:C0040432] [MeSH:C0040432] animal [MeSH:C0003062] age [MeSH:C0024842] -day [MeSH:C0011017]-old rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] feed [MeSH:C0003050] week ad libitum diet [MeSH:C0012155] [MeSH:C0012155] -g restricted [MeSH:C1135809] diet [MeSH:C0012155] [MeSH:C0012155] maintain weight [MeSH:C1821269] prevent growth [MeSH:C0018270] [MeSH:C0018270] [MeSH:C0018270] concurrent [MeSH:C0009247] diet [MeSH:C0012155] [MeSH:C0012155]ary group warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] produce massive focal calcification [MeSH:C0040432] [MeSH:C0040432] artery medium [MeSH:C0003842] ad libitum-fed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] detectable artery calcification [MeSH:C0040432] [MeSH:C0040432] restricted [MeSH:C1135809]-diet [MeSH:C0012155] [MeSH:C0012155] growth [MeSH:C0018270] [MeSH:C0018270] [MeSH:C0018270]-inhibit [MeSH:C0021463] [MeSH:C0021463]ed explanation association artery calcification [MeSH:C0040432] [MeSH:C0040432] growth [MeSH:C0018270] [MeSH:C0018270] [MeSH:C0018270] status determine present relationship [MeSH:C0021797] high serum [MeSH:C0229671] phosphate [MeSH:C0031721] susceptibility [MeSH:C0012655] artery calcification [MeSH:C0040432] [MeSH:C0040432] high level [MeSH:C0020443] serum [MeSH:C0229671] phosphate [MeSH:C0031721] young [MeSH:C0340037] ad libitum-fed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] compare group resistant warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031]-induced artery calcification [MeSH:C0040432] [MeSH:C0040432] ie -month-old rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] restricted [MeSH:C1135809]-diet [MeSH:C0012155] [MeSH:C0012155] growth [MeSH:C0018270] [MeSH:C0018270] [MeSH:C0018270]-inhibit [MeSH:C0021463] [MeSH:C0021463]ed young [MeSH:C0340037] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] observation [MeSH:C0302523] suggest increase susceptibility [MeSH:C0012655] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031]-induced artery calcification [MeSH:C0040432] [MeSH:C0040432] related high serum [MeSH:C0229671] phosphate [MeSH:C0031721] level second set experiment [MeSH:C0020123] [MeSH:C0020123] examine possible synergy vitamin [MeSH:C0042890] [MeSH:C0042890] [MeSH:C0042890] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] artery calcification [MeSH:C0040432] [MeSH:C0040432] high dose vitamin [MeSH:C0042890] [MeSH:C0042890] [MeSH:C0042890] know cause calcification [MeSH:C0040432] [MeSH:C0040432] artery medium [MeSH:C0003842] little day [MeSH:C0011017] high dose vitamin [MeSH:C0042890] [MeSH:C0042890] [MeSH:C0042890] k antagonist [MeSH:C0033607] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] know cause calcification [MeSH:C0040432] [MeSH:C0040432] artery medium [MeSH:C0003842] time week long week current investigate [MeSH:C0035173] synergy treatment [MeSH:C0039798] find concurrent [MeSH:C0009247] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion dramatically increase extent calcification [MeSH:C0040432] [MeSH:C0040432] medium vitamin [MeSH:C0042890] [MeSH:C0042890] [MeSH:C0042890] d-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] day [MeSH:C0011017] close parallel effect [MeSH:C4277511] vitamin [MeSH:C0042890] [MeSH:C0042890] [MeSH:C0042890] dose artery calcification [MeSH:C0040432] [MeSH:C0040432] effect [MeSH:C4277511] vitamin [MeSH:C0042890] [MeSH:C0042890] [MeSH:C0042890] dose elevation serum [MeSH:C0229671] calcium suggest vitamin [MeSH:C0042890] [MeSH:C0042890] [MeSH:C0042890] induce artery calcification [MeSH:C0040432] [MeSH:C0040432] effect [MeSH:C4277511] serum [MeSH:C0229671] calcium warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] effect [MeSH:C4277511] elevation serum [MeSH:C0229671] calcium produce vitamin [MeSH:C0042890] [MeSH:C0042890] [MeSH:C0042890] synergy warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] vitamin [MeSH:C0042890] [MeSH:C0042890] [MeSH:C0042890] probably well explain hypothesis [MeSH:C3179072] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] inhibit [MeSH:C0021463] [MeSH:C0021463] activity matrix gla protein [MeSH:C0033684] [MeSH:C0065752] calcification [MeSH:C0040432] [MeSH:C0040432] inhibit [MeSH:C0021463] [MeSH:C0021463]or high level [MeSH:C0020443] matrix gla protein [MeSH:C0033684] [MeSH:C0065752] find site artery calcification [MeSH:C0040432] [MeSH:C0040432] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat vitamin [MeSH:C0042890] [MeSH:C0042890] [MeSH:C0042890] plus warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] chemical show protein [MeSH:C0033684] accumulate [MeSH:C0311432] gamma-carboxylated observation [MeSH:C0302523] indicate gamma-carboxyglutamate residue matrix gla protein [MeSH:C0086332] [MeSH:C0033684] [MeSH:C0065752] apparently require function calcification [MeSH:C0040432] [MeSH:C0031843] [MeSH:C0040432] inhibit [MeSH:C0021463] [MeSH:C0021463]or require accumulation [MeSH:C0311432] calcification [MeSH:C0040432] [MeSH:C0040432] site,cardiovascular
chemokine [MeSH:C0282554] ccl2 receptor ccr2 [MeSH:C0253486] increase hippocampus [MeSH:C3887642] follow pilocarpine-induced status epilepticus,neuroinflammation [MeSH:C5394393] occur seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] implicate epileptogenesis ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] chemokine receptor [MeSH:C0524914] ccl2 [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] interaction [MeSH:C0007582] mediate monocyte [MeSH:C0026473] infiltrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion neuroinflammatory cascade [MeSH:C5544451] trigger different brain [MeSH:C0006104] pathology [MeSH:C0030664] work ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] ccl2 [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] examine follow status epilepticus [MeSH:C0038220] se induce pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] injection [MeSH:C1828121] method [MeSH:C1828121] se induce pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] injection [MeSH:C1828121] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] inject saline instead pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] day [MeSH:C0011017] se ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] staining [MeSH:C0487602] neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] glial cell [MeSH:C0027836] examine imunohistochemical analysis number ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] positive cell determine stereology probe hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] ccl2 [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] examine molecular assay result increase ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] observe hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] se seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] result alterat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion cell type express ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] increase number neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] express ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] observe follow se microglial cell [MeSH:C0206116] [MeSH:C0027836] closely appose ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486]-labeled cell se rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] addition rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] experience se exhibit ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486]-labeling population hypertrophy astrocyte [MeSH:C0004112] [MeSH:C0004112] especially ca1 dentate gyrus [MeSH:C0152314] ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] astroctyte observe rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] examination [MeSH:C0376306] ccl2 [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] show elevated [MeSH:C0020443] hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] follow se ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] ccl2 [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] [MeSH:C1449159] up-regulate [MeSH:C0041904] hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923]-induced se seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] change ccr2 [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] [MeSH:C0253486] receptor expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] astrocyte [MeSH:C0004112] [MeSH:C0004112] change involve detrimental neuroplasticity [MeSH:C0027880] neuroinflammatory change [MeSH:C5544451] occur follow seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572],neurological
propylthiouracil-induced hepatic damage,case propylthiouracil-induced liver damage observe case acute type damage prove rechallenge second present histologic picture resemble chronic active hepatitis [MeSH:C0520463] spontaneous remission,hepatorenal
combination [MeSH:C0034865] bortezomib [MeSH:C1176309] thalidomide [MeSH:C0039736] dexamethasone [MeSH:C0011777] vtd consolidation therapy [MeSH:C0039798] autologous stem cell transplantation [MeSH:C0040736] symptomatic [MeSH:C3839861] multiple myeloma japanese [MeSH:C0026764] patient [MeSH:C0030705],consolidation therapy [MeSH:C3179017] [MeSH:C0039798] [MeSH:C3179017] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] multiple myeloma [MeSH:C0026764] mm widely adopt improve response [MeSH:C0034746] follow autologous stem cell transplantation [MeSH:C0040736] retrospectively analyze safety [MeSH:C0036043] efficacy [MeSH:C5690761] combination regimen [MeSH:C1880476] bortezomib thalidomide [MeSH:C1176309] dexamethasone [MeSH:C0011777] [MeSH:C0011777] vtd consolidation therapy [MeSH:C3179017] [MeSH:C0039798] [MeSH:C3179017] japanese [MeSH:C1556094] [MeSH:C1556094] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] newly diagnose mm vtd consist bortezomib dose [MeSH:C1176309] mg dexamethasone [MeSH:C0011777] [MeSH:C0011777] dose mg day [MeSH:C0011017] -day [MeSH:C0011017] cycle [MeSH:C0007586] daily oral [MeSH:C0029170] thalidomide dose mg grade neutropenia thrombocytopenia [MeSH:C0040034] document [MeSH:C0009797] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] respectively drug dose [MeSH:C0013227] reduction cytopenia require case peripheral neuropathy [MeSH:C4721453] common severe [MeSH:C1719672] grade peripheral neuropathy [MeSH:C4721453] observe good partial response [MeSH:C0034746] well response [MeSH:C0034746] vgpr rate consolidation therapy [MeSH:C3179017] [MeSH:C0039798] [MeSH:C3179017] respectively patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] probability improve vgpr consolidation therapy [MeSH:C3179017] [MeSH:C3179017] [MeSH:C3179017] [MeSH:C0039798] [MeSH:C3179017] vgpr consolidation therapy [MeSH:C3179017] [MeSH:C3179017] [MeSH:C3179017] [MeSH:C0039798] [MeSH:C3179017] p vtd regiman safe effective [MeSH:C5392218] consolidation therapy [MeSH:C3179017] [MeSH:C0039798] [MeSH:C3179017] mm japanese [MeSH:C1556094] [MeSH:C1556094] population [MeSH:C0032659],neurological
pacemaker stroke vascular [MeSH:C0221214] insight,diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve pacemaker premature beat method conduct prospective evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine thromboembolism [MeSH:C0040038] parameter result well quality life measure healthcare advancement,cardiovascular
brain dynamic lymphoma limbic system,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] ace inhibitor diabete [MeSH:C0003015] participant [MeSH:C1708335] elderly patient guillain-barre syndrome [MeSH:C0018378] peripheral neuropathy [MeSH:C4721453] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] chorea correlation care improvement [MeSH:C2936612],neurological
cognitive connection [MeSH:C0009240] multiple sclerosis [MeSH:C0026769] meningitis,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] aspirin hypertension [MeSH:C0020538] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] autonomic neuropathy [MeSH:C0271686] basal ganglia [MeSH:C0004781] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] encephalopathy [MeSH:C0085584] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,neurological
dose-effect structure-function relationship doxorubicin cardiomyopathy [MeSH:C0878544],cardiomyopathy [MeSH:C0878544] cm produce anticancer drug [MeSH:C0003393] doxorubicin dxr [MeSH:C0013089] adriamycin [MeSH:C0085752] provide unique opportunity analyze dose-effect structure-function relationship [MeSH:C0021797] [MeSH:C0021797] [MeSH:C0038477] development myocardial [MeSH:C0027061] disease [MeSH:C0878544] measure [MeSH:C0079809] degree morphologic damage [MeSH:C0012860] ultrastructural [MeSH:C0041623] examination endomyocardial [MeSH:C0027061] biopsy degree performance [MeSH:C0871966] [MeSH:C0871966] [MeSH:C0871966] abnormally right heart catheterization [MeSH:C0018795] patient [MeSH:C0030705] [MeSH:C0030705] receive dxr morphologic damage [MeSH:C0012860] variable proportional total cumulative dxr dose mg m2 performance [MeSH:C0871966] [MeSH:C0871966] [MeSH:C0871966] abnormality [MeSH:C0037268] correlate weakly dose exhibit curvilinear relationship [MeSH:C0021797] [MeSH:C0021797] threshold [MeSH:C0162703] [MeSH:C0162703] expression [MeSH:C0017262] catheterization abnormality [MeSH:C0007430] [MeSH:C0037268] correlate morphologic damage [MeSH:C0012860] r subgroup patient [MeSH:C0030705] [MeSH:C0030705] exercise hemodynamic measure [MeSH:C0079809] relationship [MeSH:C0021797] [MeSH:C0021797] exhibit curvilinear threshold [MeSH:C0162703] [MeSH:C0162703] configuration dxr-cm myocardial [MeSH:C0027061] damage [MeSH:C0012860] proportional degree cytotoxic insult dxr dose myocardial [MeSH:C0027061] function preserve critical dose degree damage [MeSH:C0012860] reach myocardial [MeSH:C0027061] performance [MeSH:C0871966] [MeSH:C0871966] [MeSH:C0871966] deteriorate [MeSH:C0234985] rapidly,cardiovascular|oncological
polyuria [MeSH:C0032617] atrial fibrillation vascular [MeSH:C0004238] insight,cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve hepatocellular hepatocellular carcinoma [MeSH:C2239176] method conduct retrospective [MeSH:C0035363] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine hypertensive [MeSH:C0003364] parameter result superior efficacy [MeSH:C5690761] practice guideline [MeSH:C0282423],cardiovascular|hepatorenal
stroke [MeSH:C0038454] pkd organ [MeSH:C0029250] interplay,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer creatinine mechanism method prospective cardiac patient assess nephritis albumin [MeSH:C0027697] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
g10v common frda point mutation appear arise common founder [MeSH:C0242918],friedreich ataxia frda [MeSH:C0016719] common inherit ataxia mutant [MeSH:C0004134] allele [MeSH:C0002085] expansion gaa trinucleotide repeat intron [MeSH:C0282537] affect gene frda point mutation [MeSH:C0026882] point mutation [MeSH:C0026882] [MeSH:C0162735] far describe appear common g10v mutation [MeSH:C0026882] [MeSH:C0026882] exon frda g10v present expand gaa repeat allele [MeSH:C0002085] associate atypical frda phenotype [MeSH:C0031437] haplotype [MeSH:C0018591] [MeSH:C0018591] undertake family [MeSH:C0015576] [MeSH:C0015576] describe mutation [MeSH:C0026882] result suggest common founder [MeSH:C0242918] mutation [MeSH:C0026882] marked difference extragenic marker haplotype [MeSH:C0018591] [MeSH:C0018591] see family [MeSH:C0015576] [MeSH:C0015576] similar intragenic haplotyping suggest mutation [MeSH:C0026882] founder [MeSH:C0242918] family [MeSH:C0015576] [MeSH:C0015576] difference explicable recombination [MeSH:C0034865] event,neurological
interstrain variation acute toxic response caffeine [MeSH:C0006644] inbred mouse,acute [MeSH:C0184567] toxic [MeSH:C1256754] dosage-dependent behavioral [MeSH:C0004927] [MeSH:C0004927] effect caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] compare adult [MeSH:C0001675] male [MeSH:C0086582] seven inbred mouse [MeSH:C0026809] strain [MeSH:C0080194] [MeSH:C1520439] [MeSH:C0025927] j balb cj cba j c3h hej c57bl 6j [MeSH:C0025921] [MeSH:C0025921] dba 2j swr j c57bl 6j [MeSH:C0025921] [MeSH:C0025921] choose prototypic mouse [MeSH:C0026809] strain [MeSH:C0080194] [MeSH:C1520439] determine behavioral [MeSH:C0004927] [MeSH:C0004927] response broad range mg kg caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] dose phenotypic characteristic locomotor activity [MeSH:C0023946] righting ability clonic seizure [MeSH:C0234535] induction [MeSH:C0042767] stress-induced lethality death external stress score caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] dose drug-naive animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] empirically optimize rigidly constant experimental condition [MeSH:C0243063] mouse [MeSH:C0026809] n point receive single ip injection fixed volume g body weight [MeSH:C0005910] physiological [MeSH:C0031845] saline carrier [MeSH:C0007292] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] dose range mg kg loss righting ability score min post dosing min interval min animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] occurrence clonic seizure [MeSH:C0234535] score onset severity min drug administration [MeSH:C1527425] proceed tonic seizure death [MeSH:C0270844] occur min animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] survive min immediately stress swim test degree c water death-producing tonic seizure score [MeSH:C0270844] min animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] locomotor activity [MeSH:C0023946] measure min caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] administration single behavioral [MeSH:C0004927] [MeSH:C0004927] criterion combination criterion marked difference response toxic [MeSH:C1256754] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] dose observe strain [MeSH:C0080194] result indicate behavioral [MeSH:C0004927] [MeSH:C0004927] toxic [MeSH:C1256754]ity testing alkylxanthine single mouse [MeSH:C0026809] strain [MeSH:C0080194] [MeSH:C1520439] misleading suggest toxic [MeSH:C1256754] response central nervous system [MeSH:C3714787] class compound genetically influence mammal [MeSH:C0024660],neurological
acute renal failure [MeSH:C0022660] associate prolonged intake slimme pill contain anthraquinone [MeSH:C0003174],chinese herb [MeSH:C0152035]al medicine [MeSH:C1533719] preparation widely available regard public [MeSH:C0034033] natural [MeSH:C0017109] safe remedy variety medical condition nephropathy cause chinese herb [MeSH:C0152035] previously report [MeSH:C0684224] [MeSH:C0684224] usually involve use aristolochic acid [MeSH:C0052377] report [MeSH:C0684224] [MeSH:C0684224] -year-old woman [MeSH:C0043210] develop acute renal failure [MeSH:C0035078] [MeSH:C0022660] follow prolonged use proprietary chinese herb [MeSH:C0152035]al slimming pill contain anthraquinone derivative extract rhizoma rhei rhubarb renal injury probably aggravate concomitant [MeSH:C0152203] intake [MeSH:C0006777] non-steroidal anti-inflammatory drug [MeSH:C0003211] diclofenac renal [MeSH:C0012091] pathology [MeSH:C0030664] hypocellular [MeSH:C0007598] interstitial fibrosis spontaneous renal recovery occur cessation slimme pill mild interstitial fibrosis tubular atrophy evident histologically month later causal relationship [MeSH:C0021797] use anthraquinone-containing herbal agent renal injury remain prove phytotherapy-associated interstitial nephropathy consider patient [MeSH:C0030705] present unexplained renal failure [MeSH:C0035078],hepatorenal
protective role nrf2 [MeSH:C1565078] streptozotocin-induced diabetic nephropathy,diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] major cause renal failure [MeSH:C0035078] accompany production [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] reactive oxygen specie ros nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C0162772] primary transcription factor [MeSH:C0040648] control antioxidant response [MeSH:C3494205] essential maintain cellular [MeSH:C1136359] redox homeostasis report finding demonstrate protective role nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] design method explore protective role nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] human [MeSH:C0086418] [MeSH:C0086418] kidney [MeSH:C0022646] biopsy tissue [MeSH:C0040300] diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] patient [MeSH:C0030705] [MeSH:C0030705] streptozotocin-induced diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] model nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] mouse [MeSH:C0026809] [MeSH:C0026809] culture human [MeSH:C0086418] [MeSH:C0086418] mesangial cell [MeSH:C0227651] result glomerulus human [MeSH:C0086418] [MeSH:C0086418] diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] patient [MeSH:C0030705] [MeSH:C0030705] oxidative stress [MeSH:C0242606] elevated nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] level [MeSH:C0018759] animal [MeSH:C0003062] nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] demonstrate crucial ameliorate streptozotocin-induced renal damage evident nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] mouse [MeSH:C0026809] [MeSH:C0026809] high [MeSH:C0039866] ros production [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] suffering great oxidative dna damage renal injury compare nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] mice [MeSH:C0026809] mechanistic study vivo vitro system show nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078]-mediated protection diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] partially inhibit [MeSH:C0021463]ion transform growth factor-beta1 [MeSH:C1704256] tgf-beta1 [MeSH:C1704256] [MeSH:C1704256] [MeSH:C1704256] reduction [MeSH:C1827449] extracellular [MeSH:C1136359] matrix production [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] human [MeSH:C0086418] [MeSH:C0086418] renal mesangial cell [MeSH:C0227651] high [MeSH:C0039866] glucose induce ros production [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] activate expression [MeSH:C0017262] nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] downstream gene [MeSH:C0017337] furthermore activation [MeSH:C4505109] overexpression [MeSH:C0017262] nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] inhibit [MeSH:C0021463] promoter activity [MeSH:C0026606] tgf-beta1 [MeSH:C1704256] [MeSH:C1704256] [MeSH:C1704256] dose-dependent manner knockdown [MeSH:C2350567] nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] sirna [MeSH:C1099354] enhance tgf-beta1 [MeSH:C1704256] [MeSH:C1704256] [MeSH:C1704256] transcription fibronectin production [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] conclusion work clearly indicate protective role nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] suggest dietary [MeSH:C0012177] therapeutic activation [MeSH:C0087111] [MeSH:C4505109] nrf2 [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] [MeSH:C1565078] strategy prevent [MeSH:C0000918] slow progression diabetic nephropathy [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881] [MeSH:C0011881],neurological|hepatorenal
glepp1 receptor tyrosine phosphatase ptpro rat pan nephrosis marker acute podocyte injury [MeSH:C2609414],glomerular epithelial protein [MeSH:C0257855] glepp1 [MeSH:C1869988] [MeSH:C1869988] podocyte [MeSH:C1328818] [MeSH:C1328818] receptor membrane protein tyrosine phosphatase [MeSH:C0085536] located apical cell membrane [MeSH:C0007603] visceral glomerular [MeSH:C1328818] epithelial cell [MeSH:C0014597] foot process [MeSH:C0016504] receptor play role regulate structure function podocyte [MeSH:C1328818] [MeSH:C1328818] foot process [MeSH:C0016504] well understand utility glepp1 [MeSH:C1869988] [MeSH:C1869988] marker [MeSH:C0017393] glomerular injury distribution [MeSH:C1704711] glepp1 [MeSH:C1869988] [MeSH:C1869988] protein [MeSH:C1869988] [MeSH:C1869988] [MeSH:C1869988] mrna [MeSH:C0035696] examine immunohistochemistry [MeSH:C0021044] western blot rnase protection assay model podocyte [MeSH:C1328818] [MeSH:C1328818] injury rat [MeSH:C0034721] puromycin aminonucleoside nephrosis induce single intraperitoneal injection puromycin aminonucleoside pan mg 0 g bw tissue analyze day [MeSH:C0011017] pan injection [MeSH:C1828121] include acute phase proteinuria [MeSH:C0001347] associate foot process [MeSH:C0016504] effacement day [MeSH:C0011017] chronic phase proteinuria associate glomerulosclerosis [MeSH:C0017668] day [MeSH:C0011017] glepp1 [MeSH:C1869988] [MeSH:C1869988] protein [MeSH:C1869988] [MeSH:C1869988] [MeSH:C1869988] mrna [MeSH:C0035696] reduce normal range x mole glomerulus normal x mole glomerulus p occur association [MeSH:C0004083] increase urinary protein [MeSH:C1505427] content [MeSH:C0017177] [MeSH:C0017177] mg p contrast podocalyxin [MeSH:C0137431] [MeSH:C0137431] significantly glepp1 [MeSH:C1869988] [MeSH:C1869988] protein [MeSH:C1869988] [MeSH:C1869988] [MeSH:C1869988] mrna [MeSH:C0035696] begin return glomerular scarring present glepp1 [MeSH:C1869988] [MeSH:C1869988] absent glomerulosclerotic area total glomerular content [MeSH:C0017177] [MeSH:C0017177] glepp1 [MeSH:C1869988] [MeSH:C1869988] different normal conclude glepp1 [MeSH:C1869988] [MeSH:C1869988] expression [MeSH:C0017262] unlike podocalyxin [MeSH:C0137431] [MeSH:C0137431] reflect podocyte [MeSH:C1328818] [MeSH:C1328818] injury induce pan glepp1 [MeSH:C1869988] [MeSH:C1869988] expression [MeSH:C0017262] useful marker [MeSH:C0017393] podocyte [MeSH:C1328818] [MeSH:C1328818] injury,hepatorenal
transgenic [MeSH:C2350483] mouse [MeSH:C0026809] carry large human [MeSH:C0086418] genomic sequence expand ctg repeat mimic closely dm ctg repeat intergenerational [MeSH:C0085419] somatic instability,myotonic dystrophy dm cause [MeSH:C0027126] ctg repeat expansion [MeSH:C0196940] [MeSH:C1257790] 3utr dm protein kinase dmpk [MeSH:C0216045] gene high instability observe successive generation size [MeSH:C0162658] [MeSH:C3178847] repeat generally correlate severity disease [MeSH:C0521117] age [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] onset furthermore tissue [MeSH:C0040300] [MeSH:C0040300] dm patient [MeSH:C0030705] [MeSH:C0030705] exhibit somatic mosaicism increase age [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] generate transgenic [MeSH:C2350483] mouse [MeSH:C0026809] carry large human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] genomic sequence ctg clone patient [MeSH:C0030705] [MeSH:C0030705] affect dm family large human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] flanking sequence large amplification [MeSH:C0017256] demonstrate intergenerational [MeSH:C0085419] ctg repeat instability reproduce mouse [MeSH:C0026809] strong bias [MeSH:C0005346] expansion [MeSH:C0196940] sex- size [MeSH:C0162658]-dependent characteristic human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] high instability increase age [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] observe tissue [MeSH:C0040300] [MeSH:C0040300] sperm [MeSH:C0037868] observe dramatic expansion [MeSH:C0196940] big jump ctg repeat congenital form dm model carrying ctg instability close human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] dm situation model carry different size [MeSH:C0162658] ctg repeat provide insight different factor [MeSH:C0033453] modulate ctg repeat instability,neurological
chronic active hepatitis [MeSH:C0520463] associate diclofenac sodium therapy [MeSH:C0700583],diclofenac [MeSH:C0012091] sodium [MeSH:C0700583] voltarol geigy pharmaceutical [MeSH:C0013227] non-steroidal anti-inflammatory derivative phenylacetic acid [MeSH:C0003211] generally well-tolerated asymptomatic [MeSH:C2936329] abnormality [MeSH:C0037268] liver function [MeSH:C0023901] record commonly severe [MeSH:C1719672] hepatitis [MeSH:C0019158] induce diclofenac [MeSH:C0012091] describe develop chronic active hepatitis [MeSH:C0520463] [MeSH:C0019158] month therapy [MeSH:C0039798] diclofenac [MeSH:C0012091] sodium [MeSH:C0700583] progress despite withdrawal drug [MeSH:C2717885] previously report,hepatorenal
vascular dynamic alzheimer disease [MeSH:C0002395],heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve hypotensive endothelial method conduct prospective evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine artery [MeSH:C0003842] parameter result positive response optimization [MeSH:C0376695],cardiovascular
corticosteroid epilepsy [MeSH:C0014544] brain [MeSH:C0006104] insight,prospective examine ace inhibitor [MeSH:C0003015] dementia [MeSH:C0497327] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include synapse myasthenia gravis ataxia [MeSH:C0026896] method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication cost-effectiveness [MeSH:C1511536] implication,neurological
astrocytoma [MeSH:C0004114] meet coronary artery disease [MeSH:C1956346] neurological perspective,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] diabete participant [MeSH:C1708335] cancer patient encephalitis [MeSH:C0014038] multiple sclerosis [MeSH:C0026769] result favorable safety [MeSH:C0036043] profile hypothalamus [MeSH:C0020663] correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],neurological
post-operative [MeSH:C0030201] rigidity [MeSH:C1320474] fentanyl administration [MeSH:C0001554],case thoraco-abdominal rigidity lead respiratory failure describe post-operative [MeSH:C0030201] period [MeSH:C0080129] elderly [MeSH:C0001792] receive moderate dose fentanyl [MeSH:C0015846] successfully reverse naloxone [MeSH:C0027358] mechanism [MeSH:C1524059] possibly implicate accident [MeSH:C0000924] discuss,neurological
pacemaker pathway alzheimer disease,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome heart rate pathway method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring neuropathy [MeSH:C0015464] hippocampal [MeSH:C0228249] result improve disease management [MeSH:C0039798] cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
role nicotine [MeSH:C0028040] smoking-related cardiovascular disease [MeSH:C0007222],nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] activate sympathetic nervous system [MeSH:C0039044] way contribute cardiovascular disease [MeSH:C0007222] animal study mechanistic study indicate nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] play role accelerate atherosclerosis [MeSH:C0004153] evidence [MeSH:C5575834] [MeSH:C5575834] human [MeSH:C0086418] [MeSH:C0086418] inadequate definitive effect [MeSH:C4277511] certainly nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] hemodynamic [MeSH:C0019010] effect [MeSH:C4277511] contribute acute cardiovascular event [MeSH:C0007220] [MeSH:C0007220] current evidence [MeSH:C5575834] [MeSH:C5575834] suggest effect [MeSH:C4277511] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] important prothrombotic effect [MeSH:C4277511] cigarette smoking [MeSH:C0700219] effect [MeSH:C4277511] carbon monoxide [MeSH:C0007018] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] appear enhance thrombosis [MeSH:C0040053] human [MeSH:C0086418] [MeSH:C0086418] study pipe smoker [MeSH:C0337664] people [MeSH:C5690824] transdermal nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0358855] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] support idea toxin [MeSH:C0043454] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] important cause acute cardiovascular event [MeSH:C0007220] [MeSH:C0007220] finally dose response cardiovascular event [MeSH:C0007220] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] appear flat suggest nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] involve adverse effect [MeSH:C0001688] [MeSH:C4277511] see relatively low-level [MeSH:C0279027] cigarette exposure [MeSH:C0677453],cardiovascular
galanthamine [MeSH:C0016967] hydrobromide [MeSH:C0063075] long act anticholinesterase drug [MeSH:C0008425] central effect scopolamine [MeSH:C0036442] hyoscine [MeSH:C0036442],galanthamine [MeSH:C0016967] hydrobromide [MeSH:C0063075] anticholinesterase drug [MeSH:C0008425] capable penetrate blood-brain barrier [MeSH:C0005854] demonstrate central effect scopolamine [MeSH:C0036442] [MeSH:C0036442] hyoscine [MeSH:C0036442] overdosage long act physostigmine anaesthesia [MeSH:C0031849] reverse non-depolarizing neuromuscular block study dose necessary combat [MeSH:C5690835] scopolamine [MeSH:C0036442] [MeSH:C0036442] intoxication [MeSH:C0043049] indicate,neurological
new ct pattern adrenoleukodystrophy,new ct pattern observe patient [MeSH:C0030705] adrenoleukodystrophy ald pattern author type ii characterize absence [MeSH:C0270823] posterior periventricular area decrease attenuation trigone non-contrast scan contrast infusion striking enhancement white-matter structure tract fiber system internal capsule corpus callosum [MeSH:C0010090] corona radiata forceps major cerebral peduncle [MeSH:C0007793] different numerous previous description ct pattern ald type ii ald appear see leukoencephalopathy [MeSH:C0270612] probably specific phenotypic [MeSH:C1837514] variant evolving stage [MeSH:C0029170] ald,neurological
stroke [MeSH:C0038454] alcoholic liver disease [MeSH:C0023896] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome renal pathway method retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure nephrolithiasis ggt [MeSH:C0392525] result enhance therapeutic response practice guideline,hepatorenal
radiotherapy pattern lymphoma patient [MeSH:C0030705],observational [MeSH:C0302523] examine statin stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include stomach cancer [MeSH:C0024623] ovarian cancer [MeSH:C1140680] chemotherapy method [MeSH:C0013216] participant [MeSH:C1708335] include result positive response implication optimization [MeSH:C0376695],neurological|oncological
dexmedetomidine [MeSH:C0113293] act central [MeSH:C0041044] alpha- adrenoceptor [MeSH:C0034783] prevent [MeSH:C0000918] opiate-induced muscle rigidity [MeSH:C0026837] rat [MeSH:C0034721],highly-selective alpha- adrenergic agonist [MeSH:C0001648] dexmedetomidine [MeSH:C0125656] [MeSH:C0113293] d-me capable induce muscle flaccidity anesthesia [MeSH:C0026825] rat [MeSH:C0034721] [MeSH:C0034721] dog [MeSH:C0012984] intense generalize muscle rigidity [MeSH:C0026837] [MeSH:C0026837] undesirable effect potent opiate agonist neurochemistry [MeSH:C0027820] opiate-induced rigidity fully elucidate recent work suggest role central adrenergic mechanism present author determine d-med prevent [MeSH:C0000918] muscle rigidity [MeSH:C0026837] [MeSH:C0026837] cause high-dose alfentanil [MeSH:C0002026] anesthesia rat [MeSH:C0034721] [MeSH:C0034721] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] n treat intraperitoneally follow regimen [MeSH:C1880476] l-med inactive l-isomer [MeSH:C0001898] medetomidine [MeSH:C0125656] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg d-med microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg d-med microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg d-med microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg central-acting alpha- antagonist [MeSH:C0033607] idazoxan [MeSH:C0063327] mg kg d-me microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg peripheral-acting alpha- antagonist [MeSH:C0033607] dg- mg kg saline electromyographic activity record [MeSH:C0034869] gastrocnemius muscle [MeSH:C0242691] drug rat [MeSH:C0013227] [MeSH:C0034721] [MeSH:C0034721] inject alfentanil [MeSH:C0002026] alf mg kg sc alf injection [MeSH:C1828121] result marked increase hindlimb [MeSH:C1522391] emg activity l-med indistinguishable see animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] treat saline contrast d-med prevent [MeSH:C0000918] alfentanil [MeSH:C0002026]-induced muscle rigidity [MeSH:C0026837] [MeSH:C0026837] dose-dependent fashion small emg value obtain high-dose d-med comparable record [MeSH:C0034869] early study [MeSH:C0085973] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] give opiate high-dose d-med animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] flaccid akinetic lack startle response [MeSH:C0038186] entire experimental period abstract [MeSH:C0600678] truncate word,neurological
subjective assessment sexual dysfunction [MeSH:C0033953] patient [MeSH:C0030705] long-term [MeSH:C0023977] administration digoxin [MeSH:C0012265],suggest male [MeSH:C0086582] patient [MeSH:C0030705] [MeSH:C0030705] receive digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] longterm basis increase level [MeSH:C0018759] [MeSH:C0018759] serum estrogen decrease level [MeSH:C0018759] [MeSH:C0018759] plasma [MeSH:C0032105] [MeSH:C0032105] testosterone [MeSH:C0039601] luteinizing hormone [MeSH:C0023607] lh [MeSH:C0065261] undertake investigate [MeSH:C0035173] link long-term [MeSH:C0023977] administration [MeSH:C0001554] digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] therapy sexual behavior [MeSH:C0036864] [MeSH:C0036864] [MeSH:C0036864] [MeSH:C0036864] effect digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] plasma [MeSH:C0032105] [MeSH:C0032105] level [MeSH:C0018759] [MeSH:C0018759] estradiol testosterone [MeSH:C0039601] [MeSH:C0039601] lh [MeSH:C0065261] patient [MeSH:C0030705] [MeSH:C0030705] digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] similar cardiac functional capacity [MeSH:C0016815] age year randomly select rheumatic heart disease [MeSH:C0035439] patient [MeSH:C0030705] [MeSH:C0030705] subjective assessment sexual behavior [MeSH:C0036864] [MeSH:C0036864] [MeSH:C0036864] [MeSH:C0036864] group carry parameter sexual desire sexual excitement [MeSH:C0233972] frequency [MeSH:C0376249] [MeSH:C0376249] sexual relation [MeSH:C0036887] [MeSH:C0036887] personal interview questionnaire sexual behavior [MeSH:C0036864] [MeSH:C0036864] [MeSH:C0036864] [MeSH:C0036864] finding support report concern digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] effect plasma [MeSH:C0032105] [MeSH:C0032105] estradiol testosterone [MeSH:C0039601] [MeSH:C0039601] lh [MeSH:C0065261] difference mean test evaluate [MeSH:C0013175] change sexual behavior [MeSH:C0036864] [MeSH:C0036864] [MeSH:C0036864] [MeSH:C0036864] show decrease sexual desire sexual excitement [MeSH:C0233972] phase erection frequency [MeSH:C0376249] [MeSH:C0376249] sexual relation [MeSH:C0036887] [MeSH:C0036887],cardiovascular
breakthrough [MeSH:C1135120] alt finding diabetes mellitus [MeSH:C0011849],diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve cholelithiasis [MeSH:C0008350] cirrhosis method conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine renal cyst [MeSH:C0010709] parameter result improvement primary endpoint relevance,hepatorenal|oncological
arrhythmia [MeSH:C0003811] parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] diabete cerebrovascular method [MeSH:C0007820] adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective atrial fibrillation aortic aneurysm assessment result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],cardiovascular
hematuria [MeSH:C0018965] marker [MeSH:C0017393] multiple sclerosis [MeSH:C0026769],hypertension [MeSH:C0020538] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve uremia [MeSH:C0041948] hypotension method [MeSH:C0020649] conduct randomized control evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine pyelonephritis [MeSH:C0034186] parameter result improvement primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
cardiomyopathy [MeSH:C0878544] tricuspid valve [MeSH:C0040960] cardiac connection,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] diabete participant [MeSH:C1708335] adult population vein coronary artery disease result improve outcome [MeSH:C0206277] ventricular fibrillation [MeSH:C0042510] correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],cardiovascular
cardiovascular [MeSH:C0007220] risk cyclooxygenase inhibitor [MeSH:C0085387] general problem substance specific difference,randomised trial observational study [MeSH:C1518527] show increase risk [MeSH:C0035647] myocardial infarction [MeSH:C0027051] stroke hypertension [MeSH:C0020538] heart failure [MeSH:C0018801] cyclooxygenase inhibitor [MeSH:C0085387] [MeSH:C0085387] [MeSH:C0085387] adverse cardiovascular [MeSH:C0007220] effect [MeSH:C0596270] occur mainly exclusively patient [MeSH:C0030705] concomitant [MeSH:C0152203] risk [MeSH:C0035647] factor cyclooxygenase inhibitor [MeSH:C0085387] [MeSH:C0085387] [MeSH:C0085387] cause complex change renal [MeSH:C0152169] vascular cardiac prostanoid profile increase vascular resistance fluid [MeSH:C0042380] retention incidence [MeSH:C0021149] cardiovascular [MeSH:C0007220] adverse event tend increase daily dose total exposure comparison individual [MeSH:C0021228] selective unselective cyclooxygenase inhibitor [MeSH:C0085387] [MeSH:C0085387] [MeSH:C0085387] suggest substance-specific difference depend difference pharmacokinetic [MeSH:C0031327] parameter inhibitory [MeSH:C0167957] potency [MeSH:C2349090] contribute prostaglandin-independent effect diagnostic marker n-terminal pro brain natriuretic peptide [MeSH:C0054015] nt-probnp high-sensitive c-reactive protein help early identification [MeSH:C1707660] patient [MeSH:C0030705] risk [MeSH:C0035647] avoid occurrence cardiovascular [MeSH:C0007220] toxicity [MeSH:C0040539],neurological|cardiovascular|hepatorenal
epilepsy [MeSH:C0014544] epinephrine [MeSH:C0014563] explore neural pathway [MeSH:C0027792],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] pulmonary embolism [MeSH:C0034065] mechanism method observational [MeSH:C0302523] elderly patient assessing tia septum result improve disease management [MeSH:C0039798] implication optimization [MeSH:C0376695],neurological|cardiovascular
cerebrovascular pathway atrial fibrillation [MeSH:C0004238],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] [MeSH:C0206277] neurodegenerative pathway method randomized control trial [MeSH:C1096777] cardiac patient measure tremor epinephrine [MeSH:C0014563] result improve outcome [MeSH:C0206277] [MeSH:C0206277] therapeutic innovation [MeSH:C0087111],neurological
heart attack [MeSH:C0027051] meet ventricular tachycardia [MeSH:C0042514] neurological perspective,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation aspirin heart disease [MeSH:C0018799] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient palsy heart failure [MeSH:C0018801] result decrease mortality rate [MeSH:C0205848] deep vein thrombosis [MeSH:C0149871] correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological|cardiovascular
calcineurin-inhibitor [MeSH:C1562036] induce pain syndrome [MeSH:C1412041] cip severe disabling complication [MeSH:C1171258] organ transplantation [MeSH:C0029216],bone pain [MeSH:C0030193] transplantation [MeSH:C0005976] frequent complication [MeSH:C1171258] cause disease [MeSH:C0012634] strategy depend correct diagnosis [MeSH:C0011900] pain patient [MeSH:C0030705] [MeSH:C0030705] severe pain foot [MeSH:C0016504] register transplantation investigate [MeSH:C0035173] bone scan show increase tracer uptake foot bone magnetic resonance imaging [MeSH:C0024485] [MeSH:C0024485] demonstrate bone marrow oedema painful bone pain [MeSH:C0030193] explain disease [MeSH:C0012634] cause foot pain [MeSH:C0016504] like reflex sympathetic dystrophy polyneuropathy [MeSH:C0034931] morton [MeSH:C0311337] neuralgia gout [MeSH:C0018099] osteoporosis [MeSH:C0029456] avascular necrosis intermittent claudication [MeSH:C0021775] orthopaedic foot deformity stress fracture hyperparathyroidism reduction [MeSH:C1827449] cyclosporine- tacrolimus [MeSH:C0085149] trough level administration [MeSH:C0001554] calcium channel blocker [MeSH:C0006684] lead relief pain [MeSH:C0242936] calcineurin-inhibitor induce pain syndrome [MeSH:C1412041] cip rare severe effect cyclosporine tacrolimus [MeSH:C0085149] [MeSH:C0085149] accurately diagnose [MeSH:C0011900] typical presentation magnetic resonance imaging [MeSH:C0024485] bone scan incorrect diagnosis [MeSH:C0011900] syndrome lead reduction [MeSH:C1827449] life quality [MeSH:C0034380] patient [MeSH:C0030705] [MeSH:C0030705] suffer cip,neurological
drug-induced arterial spasm relieve lidocaine [MeSH:C0023660] case report,follow major intracranial surgery -year-old man sodium pentothal intravenously infuse minimize cerebral ischaemia [MeSH:C0917798] intense vasospasm [MeSH:C0010073] [MeSH:C0010073] threaten gangrene [MeSH:C0017086] arise arm infusion [MeSH:C0841792] cranial condition preclude use usual method [MeSH:C0025663] lidocaine [MeSH:C0023660] give intra-arterially careful cardiovascular [MeSH:C0007220] monitoring [MeSH:C0005517] counteract vasospasm [MeSH:C0010073] [MeSH:C0010073] rapidly successful,cardiovascular
transient ischemic attack marker stroke [MeSH:C0007787],retrospective [MeSH:C0035363] examine statin cancer [MeSH:C0376358] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include atrioventricular block embolism [MeSH:C0004245] pulmonary embolism method [MeSH:C0034065] participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication need investigation [MeSH:C0035173] [MeSH:C0035173],cardiovascular
thromboembolism coronary artery disease [MeSH:C0040038] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome thrombosis pathway method longitudinal trial [MeSH:C0023981] cardiac patient measure ectopic beat [MeSH:C0033036] sinoatrial node result well quality life measure therapeutic innovation [MeSH:C0087111],cardiovascular
mapping [MeSH:C0006360] ataxia-telangiectasia locus chromosome 1q2 region,recently map gene ataxia-telangiectasia ata chromosome 1q2- linkage [MeSH:C0242239] genetic marker [MeSH:C0017393] thy1 pynb3 d11s1 likely order cent-at-s1-thy1 present paper describe mapping locus [MeSH:C0085286] [MeSH:C0085286] mean panel marker span approximately cm 1q2- region center s1 thy1 location score indicate contiguous subsegment s1-thy1 segment contiguous segment telomeric thy1 unlikely contain locus [MeSH:C0085286] [MeSH:C0085286] centromeric stmy-s1 segment likely contain locus [MeSH:C0085286] [MeSH:C0085286] recent refinement linkage [MeSH:C0242239] physical map 1q2- place locus [MeSH:C0085286] [MeSH:C0085286] 1q2,neurological
cauda equina syndrome [MeSH:C0392548] epidural [MeSH:C0228134] steroid injection case report [MeSH:C0684224],conventional method lumbusacral radiculopathy physical therapy [MeSH:C0949766] epidural [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] steroid [MeSH:C0038317] injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] oral medication spinal manipulative therapy [MeSH:C0949742] cauda equina syndrome [MeSH:C0392548] [MeSH:C0392548] rare complication [MeSH:C1171258] [MeSH:C1171258] epidural [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] anesthesia follow case report [MeSH:C0684224] cauda equina syndrome [MeSH:C0392548] [MeSH:C0392548] possibly cause epidural [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] triamcinolone bupivacaine [MeSH:C0006400] feature -year-old woman [MeSH:C0043210] low right leg pain schedule epidural [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] steroid [MeSH:C0038317] injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] intervention [MeSH:C3898714] outcome [MeSH:C0206277] -gauge touhy needle insert loss resistance occur l4- spread contrast medium [MeSH:C0009924] epidural [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] space determine radiographic imaging verify epidural [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] space bupivacaine triamcinolone diacetate inject injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] reduction radicular [MeSH:C0034543] symptom hour later complain perineal numbness [MeSH:C0020580] low extremity weakness [MeSH:C0037771] neurologic reveal loss sensation saddle area medial aspect right leg decrease perception [MeSH:C0030971] pinprick test deep-tendon reflex decrease especially right leg unable urinate symptom improve slightly hour gradual return motor function ability feel foley catheter [MeSH:C3489669] symptom completely resolve hour complication [MeSH:C1171258] [MeSH:C1171258] associate epidural [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] steroid [MeSH:C0038317] injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] rare examination [MeSH:C0376306] continue vigilance [MeSH:C0235013] neurologic deterioration epidural [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] [MeSH:C0228134] steroid [MeSH:C0038317] injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] important,neurological
development [MeSH:C0243107] proteinuria [MeSH:C0033687] switch sirolimus-based immunosuppression long-term [MeSH:C0023977] cardiac transplant [MeSH:C0018823] patient [MeSH:C0030705],calcineurin-inhibitor therapy [MeSH:C0039798] [MeSH:C1562036] lead renal dysfunction [MeSH:C0031847] heart transplantation patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] novel immunosuppressive drug sirolmus srl lack nephrotoxic effect proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] associate srl report follow renal transplantation [MeSH:C0022671] cardiac transplant [MeSH:C0018823] [MeSH:C0018823]ation [MeSH:C0018823] incidence [MeSH:C0021149] proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] associate srl unknown long-term [MeSH:C0023977] cardiac transplant [MeSH:C0018823] [MeSH:C0018823] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] switch cyclosporine [MeSH:C0010592] srl-based concomitant [MeSH:C0152203] consist mycophenolate mofetil [MeSH:C0209368] steroid proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] increase significantly median g range preswitch g month postswitch p switch patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] high-grade proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] g increase postswitch p ace inhibitor angiotensin-releasing blocker arb therapy [MeSH:C0039798] reduce proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] development [MeSH:C0243107] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] increase renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] median vs p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop high-grade proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] show decrease renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] end follow-up [MeSH:C3899107] median vs p proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] develop cardiac transplant [MeSH:C0018823] [MeSH:C0018823] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] switch srl adverse effect [MeSH:C0001688] renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] srl acei arb therapy [MeSH:C0039798] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] monitor proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] increase renal dysfunction [MeSH:C0031847],cardiovascular|hepatorenal
phenytoin encephalopathy [MeSH:C0085584] probable idiosyncratic reaction case report [MeSH:C0684224],case phenytoin dph encephalopathy [MeSH:C0085584] [MeSH:C0085584] increase seizure [MeSH:C0036572] [MeSH:C0036572] eeg [MeSH:C0013819] [MeSH:C0013819] mental change describe despite adequate oral dosage [MeSH:C0178655] dph mg kg daily plasma [MeSH:C0032105] low microgramg ml encephalopathy [MeSH:C0085584] [MeSH:C0085584] probably idiosyncratic toxic allergic reaction [MeSH:C1527304] fact concentration [MeSH:C0311432] free dph normal present retard morbilliform rash dph protidogram normal intradermic dph injection [MeSH:C1828121] local effect author conclude start dph unexpected increase seizure [MeSH:C0036572] [MeSH:C0036572] eeg [MeSH:C0013819] [MeSH:C0013819] mental change occur simultaneously alert physician [MeSH:C0031831] possible need eliminate dph therapeutic [MeSH:C0087111] regiman plasma [MeSH:C0032105] concentration [MeSH:C0311432] low,neurological
hepatoma [MeSH:C2239176] peripheral artery disease [MeSH:C1704436] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] dementia [MeSH:C0497327] nephrolithiasis method [MeSH:C0392525] elderly patient undergo retrospective [MeSH:C0035363] atrial fibrillation [MeSH:C0004238] transient ischemic attack assessment result positive response optimization [MeSH:C0376695],cardiovascular|hepatorenal
tia marker multiple sclerosis [MeSH:C0026769],hypothesis statin improve hypertension [MeSH:C0020538] outcome hypotensive pathway method observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure arrhythmia [MeSH:C0003811] heart failure [MeSH:C0018801] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] therapeutic innovation [MeSH:C0087111],cardiovascular
risk [MeSH:C0035647] consumption beverage contain quinine [MeSH:C0034417],united state food drug administration [MeSH:C0041714] ban use nocturnal leg cramp lack safety [MeSH:C0036043] efficacy [MeSH:C5690761] quinine [MeSH:C0034417] [MeSH:C0034417] widely available beverage [MeSH:C0005329] include tonic water bitter lemon numerous anecdotal report suggest product [MeSH:C0016158] contain quinine [MeSH:C0034417] [MeSH:C0034417] produce neurological complication include confusion [MeSH:C0009676] altered mental status seizure [MeSH:C0036572] coma particularly old woman psychologist need inquire consumption [MeSH:C0009830] quinine [MeSH:C0034417] [MeSH:C0034417]-containing beverage [MeSH:C0005329] process,neurological
long-term [MeSH:C0023977] safety [MeSH:C0036043] danazol [MeSH:C0010961] woman hereditary angioedema [MeSH:C0019243],short-term [MeSH:C0025265] safety [MeSH:C0036043] [MeSH:C0036043] [MeSH:C0036043] equal month danazol [MeSH:C0010961] [MeSH:C0010961] [MeSH:C0010961] establish variety setting information [MeSH:C5544371] exist long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] safety [MeSH:C0036043] [MeSH:C0036043] [MeSH:C0036043] investigate [MeSH:C0035173] long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] safety [MeSH:C0036043] [MeSH:C0036043] [MeSH:C0036043] danazol [MeSH:C0010961] [MeSH:C0010961] [MeSH:C0010961] perform retrospective chart review female [MeSH:C0086287] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hereditary angioedema [MeSH:C0019243] treat danazol [MeSH:C0010961] [MeSH:C0010961] [MeSH:C0010961] continuous period month long mean age patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] year mean duration therapy [MeSH:C0444921] month virtually patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience adverse reaction [MeSH:C0041755] [MeSH:C0041755] [MeSH:C0041755] menstrual abnormality weight gain [MeSH:C0043094] muscle cramp myalgias transaminase elevation common adverse reaction [MeSH:C0041755] [MeSH:C0041755] [MeSH:C0041755] drug discontinue adverse reaction [MeSH:C0041755] [MeSH:C0041755] [MeSH:C0041755] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] die suffer apparent long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] sequela directly attributable drug conclude despite relatively high incidence [MeSH:C0021149] adverse reaction [MeSH:C0041755] [MeSH:C0041755] [MeSH:C0041755] danazol [MeSH:C0010961] [MeSH:C0010961] [MeSH:C0010961] prove remarkably safe long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],hepatorenal
antiarrhythmic valvular heart disease [MeSH:C0018824] brain [MeSH:C0006104] insight,stroke [MeSH:C0038454] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve dystonia neurofibroma method [MeSH:C0027830] conduct prospective evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine astrocytoma [MeSH:C0004114] parameter result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],neurological
synapse connection epilepsy [MeSH:C0014544],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect stroke [MeSH:C0038454] craniopharyngioma [MeSH:C0010276] mechanism method prospective diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess delirium oligodendroglioma [MeSH:C0028945] result positive response implication therapeutic [MeSH:C0087111] innovation,neurological
cancer smooth muscle [MeSH:C1267092] cardiac connection,dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve peripheral artery disease [MeSH:C1704436] ischemic cardiomyopathy method [MeSH:C0878544] conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine pulmonary valve [MeSH:C0034086] parameter result improvement primary endpoint cost-effectiveness [MeSH:C1511536] implication,cardiovascular
transaminase breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] ace inhibitor affect hypertension [MeSH:C0020538] bundle branch block mechanism method [MeSH:C0006384] retrospective cancer patient [MeSH:C0030705] assess albumin [MeSH:C0001924] tricuspid valve [MeSH:C0040960] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication relevance,cardiovascular|hepatorenal
efficacy [MeSH:C5690761] proarrhythmia [MeSH:C0003811] use l-sotalol [MeSH:C0037707] sustained ventricular tachyarrhythmia [MeSH:C0042514],prospectively evaluate efficacy [MeSH:C5690761] incidence [MeSH:C0021149] torsade de pointe presumable risk [MeSH:C0035647] [MeSH:C0035647] factor [MeSH:C0035648] torsade de pointe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] sustained ventricular tachyarrhythmia [MeSH:C0003811] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] eighty-one consecutive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] coronary artery disease [MeSH:C1956346] dilate cardiomyopathy [MeSH:C0007193] inducible [MeSH:C1533698] [MeSH:C1533698] sustained ventricular tachycardia [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] ventricular fibrillation [MeSH:C0042510] receive oral [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] prevent [MeSH:C0000918] [MeSH:C0000918] induction [MeSH:C0042767] [MeSH:C0042767] [MeSH:C0042767] ventricular tachyarrhythmia [MeSH:C0003811] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] oral [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] loading l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] continuous electrocardiographic ecg monitoring perform patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] prevent [MeSH:C0000918] [MeSH:C0000918] induction [MeSH:C0042767] [MeSH:C0042767] [MeSH:C0042767] ventricular tachycardia [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] ventricular fibrillation [MeSH:C0042510] discharge drug follow outpatient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0029921] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] basis month induction [MeSH:C0042767] [MeSH:C0042767] [MeSH:C0042767] ventricular tachyarrhythmia [MeSH:C0003811] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] prevent [MeSH:C0000918] [MeSH:C0000918] oral [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ventricular tachyarrhythmia [MeSH:C0003811] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] remain inducible [MeSH:C1533698] [MeSH:C1533698] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] tolerate mg l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] daily patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] torsade de pointe initial oral [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] ecg sinus-cycle length scl qt qtc interval u wave parameter identify patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] risk [MeSH:C0035647] [MeSH:C0035647] torsade de pointe oral [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] dose l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] significantly low patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] torsade de pointe vs mg p risk [MeSH:C0035647] [MeSH:C0035647] factor [MeSH:C0035648] associate development [MeSH:C0020119] torsade de pointe appearance [MeSH:C0750731] u wave p female [MeSH:C0086287] [MeSH:C0086287] gender p dose-corrected change scl qt interval qtc interval p follow-up [MeSH:C3899107] seven patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] nonfatal ventricular tachycardia [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] recurrence patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] die suddenly female [MeSH:C0086287] [MeSH:C0086287] stable cardiac disease [MeSH:C0018799] recurrent torsade de pointe year successful l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] torsade de pointe occur early low dose oral [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] pronounced change surface [MeSH:C0025252] ecg cycle length qt qtc relation dose oral [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] identify subgroup patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] increase risk [MeSH:C0035647] [MeSH:C0035647] torsade de pointe ecg [MeSH:C1623258] parameter application l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] identify patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] increase risk [MeSH:C0035647] [MeSH:C0035647] torsade de pointe recurrence rate ventricular tachyarrhythmia [MeSH:C0003811] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] [MeSH:C0042514] high [MeSH:C0039866] despite complete suppression [MeSH:C1956351] arrhythmia [MeSH:C0003811] program stimulation program electrical stimulation [MeSH:C0013786] case l-sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] limited prognostic [MeSH:C1514474],neurological|cardiovascular
huntington disease [MeSH:C0020179] evidence locus heterogeneity [MeSH:C0242960],total family [MeSH:C0015576] huntington disease [MeSH:C0020179] hd examine linkage [MeSH:C0242239] hd g8 d4s1 family [MeSH:C0015576] include caucasian [MeSH:C0007457] black american [MeSH:C5671324] japanese combined maximum lod score [MeSH:C0023956] [MeSH:C0023956] [MeSH:C0023956] theta confidence interval [MeSH:C0009667] [MeSH:C0009667] maximum frequency recombination male [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] fifty-seven family [MeSH:C0015576] give positive lod score [MeSH:C0023956] [MeSH:C0023956] [MeSH:C0023956] small family [MeSH:C0015576] give mildly negative lod score [MeSH:C0023956] [MeSH:C0023956] [MeSH:C0023956] maximum likelihood estimate alpha proportion link locus low confidence interval [MeSH:C0009667] suggest hd locus second rare locus rule [MeSH:C0023951],neurological
polycystic kidney disease pathway lymphoma [MeSH:C0022680],design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation beta-blocker hypertension participant [MeSH:C1708335] cancer patient cholelithiasis pkd result superior efficacy [MeSH:C5690761] oliguria [MeSH:C0028961] correlation practice guideline [MeSH:C0936005],hepatorenal
lymphoma hemodialysis organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect diabete gfr method adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal [MeSH:C0023981] alt gallstone assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],hepatorenal|oncological
heterozygous [MeSH:C0019425] loss six5 mouse [MeSH:C0026809] sufficient cause ocular cataract [MeSH:C0086543],myotonic dystrophy dm autosomal dominant disorder characterize skeletal muscle [MeSH:C0242692] [MeSH:C0242692] waste [MeSH:C0450237] myotonia [MeSH:C0700153] cardiac arrhythmia [MeSH:C0003811] hyperinsulinaemia [MeSH:C0020459] mental retardation [MeSH:C3714756] ocular cataract genetic defect dm ctg repeat expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] located untranslated region dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0600680] homeodomain-encoding gene six5 dmahp ref mechanism [MeSH:C1524059] ctg expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] dm repeat expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] alter processing [MeSH:C0035684] transport mutant dmpk [MeSH:C0216045] [MeSH:C0216045] mrna [MeSH:C0035696] [MeSH:C0035696] consequently reduce dmpk [MeSH:C0216045] [MeSH:C0216045] level [MeSH:C0018759] second ctg expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] establish region heterochromatin repeat sequence decrease six5 transcription [MeSH:C0040648] toxic effect repeat expansion [MeSH:C0196940] [MeSH:C0196940] [MeSH:C0196940] intrinsic repeated element dna rna ref previous study demonstrate dose-dependent loss dm1 mouse [MeSH:C0026809] dmpk [MeSH:C0216045] [MeSH:C0216045] homologue mouse [MeSH:C0026809] produce partial dm phenotype [MeSH:C0031437] characterize decrease development [MeSH:C0243107] skeletal muscle [MeSH:C0242692] [MeSH:C0242692] force [MeSH:C0086323] cardiac conduction disorder test role six5 loss dm analyse strain mouse [MeSH:C1520439] [MeSH:C0026809] six5 delete result demonstrate rate severity cataract formation [MeSH:C0086543] inversely related six5 dosage [MeSH:C0178655] temporally progressive six5 six5- mouse [MeSH:C0026809] increase steady-state level [MeSH:C0018759] na k -atpase alpha- subunit [MeSH:C0599220] decrease dm1 mrna [MeSH:C0035696] [MeSH:C0035696] level [MeSH:C0018759] altered ion homeostasis lens [MeSH:C0019868] contribute cataract formation [MeSH:C0086543] ocular cataract characteristic feature dm result demonstrate decrease six5 transcription [MeSH:C0040648] important aetiology [MeSH:C0015127] dm support hypothesis [MeSH:C3179072] dm contiguous gene syndrome [MeSH:C0206115] associate partial loss dmpk [MeSH:C0216045] [MeSH:C0216045] six5,neurological|cardiovascular
blood test [MeSH:C0018941] reveal parkinson disease [MeSH:C0030567] secret,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] hypertension [MeSH:C0020538] limbic system method [MeSH:C0023715] elderly patient undergo prospective [MeSH:C0589154] paralysis trigeminal neuralgia [MeSH:C0040997] assessment [MeSH:C0030198] result improve outcome practice guideline [MeSH:C0936005],neurological
tumor tale cancer insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect hypertension [MeSH:C0020538] immunotherapy [MeSH:C0021083] mechanism method cross-sectional adult [MeSH:C0010362] population [MeSH:C0032659] assess multiple myeloma sarcoma [MeSH:C0026764] result improvement primary endpoint implication care improvement,oncological
clonazepam [MeSH:C0009011] monotherapy [MeSH:C0376626] epilepsy childhood [MeSH:C4281785],patient [MeSH:C0030705] [MeSH:C0030705] age-range year type epilepsy infant [MeSH:C0021270]ile [MeSH:C0917800] spasm [MeSH:C0037763] treat clonazepam [MeSH:C0009011] disappearance seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] normalization abnormal [MeSH:C0853087] [MeSH:C0853087] eeg disappearance seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] recognize respectively seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] disappear patient [MeSH:C0030705] [MeSH:C0030705] generalize seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] partial seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] improvement [MeSH:C2936612] abnormal [MeSH:C0853087] [MeSH:C0853087] eeg notice diffuse paroxysm focal paroxysm excellent case mean effective dosage [MeSH:C0178655] mg kg infant [MeSH:C0021270] mg kg schoolchildren [MeSH:C0008100] difference statistically p incidence [MeSH:C0021149] effect drowsiness ataxia,neurological
clarithromycin-induced ventricular tachycardia [MeSH:C0042514],clarithromycin [MeSH:C0055856] [MeSH:C0055856] relatively new macrolide [MeSH:C0282563] [MeSH:C0282563] [MeSH:C0282563] antibiotic [MeSH:C0003232] offer twice-daily dose differ erythromycin [MeSH:C0014806] [MeSH:C0014806] [MeSH:C0014806] methylation [MeSH:C0025723] hydroxyl position side-effect profile erythromycin [MeSH:C0014806] [MeSH:C0014806] [MeSH:C0014806] establish include gastroenteritis [MeSH:C0017160] interaction [MeSH:C0007582] drug subject hepatic [MeSH:C0227525] mixed-function oxidase metabolism [MeSH:C0020364] experience new macrolide [MeSH:C0282563] [MeSH:C0282563] [MeSH:C0282563] record cardiotoxicity [MeSH:C0876994] demonstrate intravenous oral administration [MeSH:C0013125] erythromycin [MeSH:C0014806] [MeSH:C0014806] [MeSH:C0014806] report [MeSH:C0684224] new macrolide [MeSH:C0282563] [MeSH:C0282563] [MeSH:C0282563] report [MeSH:C0684224] case ventricular dysrhythmia [MeSH:C0003811] [MeSH:C0003811] occur therapeutic dose [MeSH:C0087111] clarithromycin [MeSH:C0055856] [MeSH:C0055856] dysrhythmia [MeSH:C0003811] resolve discontinuation drug,cardiovascular|hepatorenal
prolonged paralysis [MeSH:C0522224] nondepolarizing neuromuscular blocking agent [MeSH:C0010464] corticosteroid [MeSH:C0001617],long-term [MeSH:C0023977] use nondepolarize neuromuscular blocking agent [MeSH:C0027866] nd-nmba recently implicate cause prolonged muscle weakness site [MeSH:C0151786] lesion predispose factor unclear report patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] age [MeSH:C0030705] year acute respiratory insufficiency [MeSH:C0035229] develop prolonged weakness follow discontinuation nd-nmba patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive intravenous corticosteroid [MeSH:C0001617] renal function normal hepatic function [MeSH:C0031843] impaired [MeSH:C0020580] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acidosis [MeSH:C0001122] electrophysiologic study [MeSH:C0887875] reveal low amplitude compound motor action potential [MeSH:C0001272] normal sensory study fibrillation repetitive stimulation hz show decremental response patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] serum vecuronium measure day drug discontinue ng ml muscle biopsy show loss thick myosin filament weakness patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pathology neuromuscular junction [MeSH:C0027869] likely nd-nmba muscle likely corticosteroid [MeSH:C0001617] hepatic dysfunction [MeSH:C0031847] acidosis [MeSH:C0001122] contribute risk factor [MeSH:C0035648],neurological|hepatorenal
adult [MeSH:C0001675] onset globoid cell leukodystrophy [MeSH:C0023521] krabbe disease [MeSH:C0023521] galactosylceramidase [MeSH:C0016957] cdna japanese [MeSH:C1556094] patient [MeSH:C0030705],examine galactosylceramidase [MeSH:C0016957] galc cdna [MeSH:C0006556] japanese [MeSH:C1556094] patient [MeSH:C0030705] [MeSH:C0030705] adult [MeSH:C0001675] onset globoid cell leukodystrophy [MeSH:C0023521] krabbe disease ao-gld polymerase chain reaction single-strand conformation polymorphism [MeSH:C0032529] [MeSH:C0243031] pcr-sscp subsequent sequence [MeSH:C0162327] determination restriction enzyme digestion pcr product initial symptom onset slowly progressive [MeSH:C1449744] spastic paraplegia middle [MeSH:C0037772] second decade patient [MeSH:C0030705] [MeSH:C0030705] diminish galc activity [MeSH:C0020115] leukocyte [MeSH:C0023516] identify missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] i66 g20d l68 exon- skip [MeSH:C1144343] -3del patient [MeSH:C0030705] [MeSH:C0030705] i66 mutant mrna g27od mutant mrna fourth carry compound heterozygous [MeSH:C0019425] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] -3del l68s determine enzymatic activity [MeSH:C0243102] [MeSH:C0020115] [MeSH:C0243102] produce mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] construct mutate [MeSH:C3178846] galc cdna [MeSH:C0006556] express cos- cell mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] viz g20d l68s exon- skip [MeSH:C1144343]ping -3del produce diminish galc activity [MeSH:C0020115] expect i66 mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] wild-type galc cdna [MeSH:C0006556] i2 normal activity [MeSH:C0020115] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] v2 polymorphism [MeSH:C0032529] introduce allele [MeSH:C0002085] decrease activity [MeSH:C0020115] combination unique mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] polymorphism [MeSH:C0032529] cause conformational galc enzyme result low enzymatic activity [MeSH:C0243102] [MeSH:C0020115] [MeSH:C0243102] ao-gld mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] include find located n-terminus i66 g20d -3del c-terminus l68s galc enzyme report mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] infantile form if-gld central domain difference mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] site affect feature gld,neurological
coronary aneurysm [MeSH:C0010051] implantation paclitaxel-eluting stent,formation [MeSH:C0029433] coronary aneurysm [MeSH:C0002940] [MeSH:C0010051] rare complication stente bare metal stent base experimental study drug-eluting stent [MeSH:C1322815] induce toxic effect vessel wall incomplete [MeSH:C0011139] stent apposition aneurysm [MeSH:C0002940] formation [MeSH:C0002940] [MeSH:C0029433] potential stent thrombosis [MeSH:C0040053] vessel rupture [MeSH:C3203359] present -year-old man develop coronary aneurysm [MeSH:C0002940] [MeSH:C0010051] right coronary artery month receive paclitaxel-eluting stent asymptomatic [MeSH:C2936329] aneurysm [MeSH:C0002940] detect routine angiography [MeSH:C0002978] intracoronary ultrasound demonstrate lack contact stent vessel wall -mm long segment maximal aneurysm [MeSH:C0002940] diameter mm successfully treat graft stent [MeSH:C0332835],cardiovascular
gamma glutamyl transferase pathway [MeSH:C0017040] stroke [MeSH:C0038454],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] alkaline phosphatase pathway method [MeSH:C0002059] randomized control trial [MeSH:C1096777] adult population [MeSH:C0032659] measure primary biliary cholangitis [MeSH:C0008312] urea result improve disease management [MeSH:C0039798] therapeutic innovation [MeSH:C0087111],hepatorenal
twin preterm [MeSH:C0041427] neonate [MeSH:C0021289] cardiac [MeSH:C0018810] toxicity related lopinavir [MeSH:C0674432] ritonavir therapy,report [MeSH:C0684224] twin [MeSH:C0041427] [MeSH:C0041427] neonate bear prematurely week gestation [MeSH:C0032961] mother [MeSH:C0026591] human immunodeficiency virus infection [MeSH:C0019682] twin [MeSH:C0041427] [MeSH:C0041427] develop complete heart block [MeSH:C0018794] dilate cardiomyopathy related lopinavir [MeSH:C0674432] ritonavir [MeSH:C0292818] therapy [MeSH:C0939237] boosted protease-inhibitor agent [MeSH:C0033607] twin [MeSH:C0041427] [MeSH:C0041427] develop mild bradycardia [MeSH:C0428977] recommend caution use lopinavir [MeSH:C0674432] ritonavir [MeSH:C0292818] immediate neonatal [MeSH:C0021709] period [MeSH:C0080129],cardiovascular
p5 inhibition [MeSH:C0027790] exacerbate late-stage anthracycline [MeSH:C0282564] cardiotoxicity [MeSH:C0876994],aim doxorubicin dox [MeSH:C0013089] effective anti-cancer therapeutic [MeSH:C0087111] associate acute late-stage cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] child particularly sensitive [MeSH:C1017675] dox-induced heart failure impact p5 inhibition acute vs late-stage dox cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] examine juvenile model method result two-week-old mhc-cb7 mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] express dominant-interfering p5 cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] non-transgenic [MeSH:C2350483] non-txg littermate receive weekly dox injection [MeSH:C1828121] week mg kg cumulative dose week dox acute stage mhc-cb7 mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] exhibit improve cardiac function [MeSH:C0018803] [MeSH:C0018803] [MeSH:C0018803] low level cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] compare non-txg mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] surprisingly week follow dox late stage mhc-cb7 exhibit progressive [MeSH:C1449744] decrease cardiac function [MeSH:C0018803] [MeSH:C0018803] [MeSH:C0018803] high rate cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] compare non-txg mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] p5 inhibition block transient dox-induced stat3 [MeSH:C0253050] activation [MeSH:C4505109] mhc-cb7 mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] associate enhance induction [MeSH:C0042767] dna repair protein [MeSH:C0012899] ku7 ku8 mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828]-restricted deletion stat3 [MeSH:C0253050] exhibit bad cardiac function [MeSH:C0018803] [MeSH:C0018803] [MeSH:C0018803] high level cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] great induction [MeSH:C0042767] ku7 ku8 response dox acute stage compare animal support model [MeSH:C0599779] p5-dependent cardioprotective pathway mediate stat3 [MeSH:C0253050] activation [MeSH:C4505109] mitigate dox-induced myocardial stress [MeSH:C0027061] drug delivery [MeSH:C0085104] furthermore suggest explanation p5 inhibition cardioprotection drug paradoxically enhance cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] long cessation drug,neurological|cardiovascular|hepatorenal|oncological
restrictive cardiomyopathy [MeSH:C0007196] marker valvular heart disease [MeSH:C0018824],investigation [MeSH:C0035173] examine effect statin [MeSH:C0360714] diabete elderly patient focus capillary tachycardia aspect disease total participant [MeSH:C1708335] enrol observational result [MeSH:C0302523] demonstrate reduction [MeSH:C1827449] adverse event [MeSH:C0041755] particular attention [MeSH:C0004268] cardiac finding suggest therapeutic [MeSH:C0087111] innovation,cardiovascular
pulmonary valve marker [MeSH:C0034086] epilepsy [MeSH:C0014544],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] thrombosis method elderly patient undergo randomized control [MeSH:C1096777] myocardium [MeSH:C0027061] hypotensive assessment result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],cardiovascular
convulsion [MeSH:C4048158] follow intravenous fluorescein angiography [MeSH:C0016313],tonic-clonic seizure [MeSH:C0494475] follow intravenous fluorescein injection fundus angiography -year-old male [MeSH:C0086582] despite precaution adverse reaction [MeSH:C0041755] recur re-exposure [MeSH:C3850098] intravenous fluorescein,neurological
brain map leukemia [MeSH:C0023418] insight,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] diabete participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] cerebrovascular trigeminal neuralgia [MeSH:C0040997] result favorable safety profile amyotrophic lateral sclerosis [MeSH:C0002736] correlation safety consideration,neurological
cholestasis [MeSH:C0008370] lung cancer [MeSH:C0242379] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] statin effect hypertension [MeSH:C0020538] premature beat method [MeSH:C0340464] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo retrospective gallbladder [MeSH:C0016976] blood urea [MeSH:C0005845] nitrogen assessment result improvement [MeSH:C2936612] primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
cardiomyopathy nephritis [MeSH:C0878544] organ interplay,hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve alkaline phosphatase [MeSH:C0002059] blood urea [MeSH:C0005845] nitrogen method [MeSH:C0028158] conduct observational evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine interstitial nephritis [MeSH:C0027707] parameter result superior efficacy [MeSH:C5690761] need investigation [MeSH:C0035173],hepatorenal
fear-potentiated startle light-enhanced startle enhance anxiogenic drug,rationale objective light-enhanced startle [MeSH:C0085292] paradigm [MeSH:C2718025] [MeSH:C2718025] les suggest model [MeSH:C0011381] [MeSH:C0011381] anxiety [MeSH:C0003467] non-specific [MeSH:C0054741] cue long-term [MeSH:C0023977] effect [MeSH:C4277511] contrast fear [MeSH:C0015726]-potentiated startle [MeSH:C0085292] fps suggest model [MeSH:C0011381] [MeSH:C0011381] conditioned [MeSH:C0162518] fear [MeSH:C0015726] pharmacological profile paradigm [MeSH:C2718025] [MeSH:C2718025] similar present investigate [MeSH:C0035173] effect [MeSH:C4277511] putative anxiogenic drug [MeSH:C0013227] les fps aim determine sensitivity [MeSH:C0036667] les anxiogenic drug [MeSH:C0013227] potentially show pharmacological differentiation paradigm [MeSH:C2718025] [MeSH:C2718025] method male [MeSH:C0086582] wistar rat [MeSH:C0034716] receive dose alpha -adrenoceptor antagonist [MeSH:C0033607] yohimbine [MeSH:C0724441] [MeSH:C0724441] [MeSH:C0724441] 0 mg kg -ht 2c receptor agonist [MeSH:C3850106] m-chlorophenylpiperazine [MeSH:C0044170] mcpp 0 mg kg gaba inverse receptor agonist pentylenetetrazole ptz -0 mg kg subsequently test les fps result drug [MeSH:C0013227] enhance les mcpp increase percentage fps yohimbine [MeSH:C0724441] [MeSH:C0724441] [MeSH:C0724441] increase absolute fps value furthermore yohimbine [MeSH:C0724441] [MeSH:C0724441] [MeSH:C0724441] increase startle [MeSH:C0085292] amplitude le mcpp suppress [MeSH:C0017372] [MeSH:C0017372] startle [MeSH:C0085292] le fps ptz suppress [MeSH:C0017372] [MeSH:C0017372] startle [MeSH:C0085292] fps conclusion contrast finding fps paradigm [MeSH:C2718025] [MeSH:C2718025] drug [MeSH:C0013227] able exacerbate les response [MeSH:C0034746] clear pharmacological differentiation find les fps,neurological
neurological signature coronary artery disease,cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve reticular formation paralysis method [MeSH:C0035284] conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine gray matter [MeSH:C0018220] parameter result improvement [MeSH:C2936612] primary endpoint relevance,neurological
adrenoleukodystrophy-related protein [MeSH:C2003614] compensate functionally adrenoleukodystrophy protein deficiency x-ald [MeSH:C3840421] implication therapy,inherit defect peroxisomal [MeSH:C0752063] atp-binding cassette abc transporter adrenoleukodystrophy protein aldp lead lethal peroxisomal [MeSH:C0752063] disorder [MeSH:C0282528] x-linked adrenoleukodystrophy x-ald [MeSH:C0162309] efficient [MeSH:C0013682] establish far peroxisomal [MeSH:C0752063] abc transporter [MeSH:C0242738] currently know adrenoleukodystrophy-related protein [MeSH:C2003614] aldrp kda peroxisomal [MeSH:C0752063] membrane protein [MeSH:C0286995] pmp7 pmp7- related protein transient stable overexpression human [MeSH:C0086418] cdna encode aldp close relative aldrp restore impaired [MeSH:C0020580] peroxisomal [MeSH:C0752063] beta-oxidation fibroblast x-ald [MeSH:C0016030] patient [MeSH:C0030705] pathognomonic accumulation [MeSH:C0311432] long chain fatty acid [MeSH:C0015691] prevent [MeSH:C0000918] overexpression aldrp immortalize x-ald cell immunofluorescence demonstrate functional replacement aldp aldrp stabilization mutate aldp able restore peroxisomal [MeSH:C0752063] beta-oxidation defect liver aldp-deficient mouse stimulation [MeSH:C0001164] aldrp pmp7 gene expression [MeSH:C0017262] dietary [MeSH:C0012177] peroxisome proliferator fenofibrate [MeSH:C0600434] result suggest correction biochemical [MeSH:C0017401] defect x-ald possible drug-induced overexpression ectopic [MeSH:C0019933] expression aldrp,neurological|hepatorenal
valsartan [MeSH:C0216784] new angiotensin [MeSH:C0003018] ii antagonist [MeSH:C0033607] essential hypertension comparative efficacy safety [MeSH:C0036043] amlodipine [MeSH:C0051696],compare antihypertensive efficacy [MeSH:C0003364] new angiotensin [MeSH:C0003018] ii antagonist [MeSH:C0033607] valsartan [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] reference therapy [MeSH:C0039798] [MeSH:C0039798] amlodipine [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] method sixty-eight adult [MeSH:C0001675] outpatient [MeSH:C0030705] [MeSH:C0029921] mild moderate hypertension [MeSH:C0020538] randomly allocate double-blind [MeSH:C0013072] fashion equal number receive mg valsartan [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] mg amlodipine [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] week week therapy [MeSH:C0039798] [MeSH:C0039798] patient [MeSH:C0030705] blood pressure [MeSH:C0005823] remain uncontrolled mg amlodipine [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] add initial therapy [MeSH:C0039798] [MeSH:C0039798] patient [MeSH:C0030705] assess week primary efficacy variable mean sit diastolic blood pressure week secondary variable [MeSH:C1522484] include sit systolic blood pressure responder [MeSH:C0005823] rate result valsartan [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] amlodipine [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] effective [MeSH:C5392218] [MeSH:C5392218] lower blood pressure [MeSH:C0020649] week similar decrease observe group [MeSH:C0018257] statistically difference group [MeSH:C0018257] variable analyze primary variable difference mm hg favor valsartan [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] p confidence interval [MeSH:C0009667] responder rate week valsartan [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] amlodipine [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] p treatment [MeSH:C0039798] tolerate incidence [MeSH:C0021149] drug-related dependent edema somewhat high amlodipine [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] particularly dose mg mg valsartan [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] mg amlodipine [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] valsartan [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] plus mg amlodipine [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] mg amlodipine [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] conclusion valsartan [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] effective [MeSH:C5392218] [MeSH:C5392218] amlodipine [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] mild moderate hypertension [MeSH:C0020538] result valsartan [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] [MeSH:C0216784] tolerate suggest associate effect characteristic comparator class dihydropyridine calcium antagonist [MeSH:C0033607],cardiovascular
chemotherapy [MeSH:C0013216] ventricular tachycardia brain [MeSH:C0042514] insight,heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide partic [MeSH:C0278076]ularly involve peripheral neuropathy dysarthria method [MeSH:C4721453] conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine tic [MeSH:C0278076] parameter result decrease mortality rate [MeSH:C0205848] practic [MeSH:C0278076]e guideline,neurological
efficacy [MeSH:C5690761] safety [MeSH:C0036043] asenapine [MeSH:C2000088] placebo- haloperidol-controlled trial patient [MeSH:C0030705] acute exacerbation schizophrenia [MeSH:C0036341],asenapine [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] approve food drug administration [MeSH:C0041714] adult acute schizophrenia manic mixed episode associate bipolar disorder [MeSH:C0005586] psychotic feature double-blind [MeSH:C0013072] -week trial patient [MeSH:C0030705] [MeSH:C0030705] acute schizophrenia randomly assign fixed-dose asenapine [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] mg twice daily bid [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] asenapine [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] mg bid [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] mg bid [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] verify assay [MeSH:C0243073] sensitivity [MeSH:C0036667] observation [MeSH:C0302523] carry forward locf mean positive negative syndrome scale total score reduction [MeSH:C1827449] endpoint significantly great asenapine [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] mg bid [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] p mixed model repeat measure mmrm change significantly great asenapine [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] mg bid [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] respectively haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] p positive negative syndrome scale positive subscale treatment [MeSH:C0039798] superior placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] locf mmrm asenapine [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] mg bid [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] superior placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] negative subscale mmrm general psychopathology [MeSH:C0033927] subscale locf mmrm treatment [MeSH:C0039798]-related adverse event [MeSH:C0041755] aes occur asenapine [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] mg bid [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] group [MeSH:C0018257] respectively extrapyramidal symptom report aes occur asenapine [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] mg bid [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] [MeSH:C0531588] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] group [MeSH:C0018257] respectively group [MeSH:C0018257] patient [MeSH:C0030705] [MeSH:C0030705] clinically weight post hoc analysis indicate efficacy [MeSH:C5690761] similar asenapine [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] [MeSH:C2000088] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] great contrast see aes especially extrapyramidal symptom,neurological
synaptic story lung cancer [MeSH:C0242379] trigeminal neuralgia [MeSH:C0040997],design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] adult [MeSH:C0001675] population substantia nigra aphasia [MeSH:C0038590] result improve disease management [MeSH:C0039798] transient ischemic attack correlation cost-effectiveness implication,neurological
carrier detection [MeSH:C0019426] pyruvate carboxylase deficiency [MeSH:C0034341] fibroblast lymphocyte [MeSH:C0016030],pyruvate carboxylase [MeSH:C0034340] e c [MeSH:C0034340] activity determine circulate [MeSH:C3641730] peripheral [MeSH:C3658334] lymphocyte [MeSH:C0024264] culture [MeSH:C0023509] skin fibroblast family hepatic cerebral renal cortical leukocyte fibroblast pyruvate carboxylase [MeSH:C0034340] deficiency pc portland deficiency lymphocyte [MeSH:C0024264] activity mother [MeSH:C0026591] father brother sister [MeSH:C0337527] low normal fibroblast patient mother [MeSH:C0026591] father respectively activity low normal demonstrate disease [MeSH:C0012634] inherit autosomal recessive manner [MeSH:C1968689] lymphocyte [MeSH:C0024264] fibroblast detect carrier pyruvate carboxylase [MeSH:C0034340] mitochondrial pepck activity lymphocyte [MeSH:C0024264] increase -hr fast,hepatorenal
thyroid cancer [MeSH:C0549473] hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve atrium pancreatic cancer method [MeSH:C0346647] conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine peripheral artery disease [MeSH:C1704436] parameter result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],cardiovascular|oncological
clinically proteinuria follow administration [MeSH:C0001554] sirolimus renal transplant recipient [MeSH:C0376387],sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] late immunosuppressive agent [MeSH:C0021081] prevent [MeSH:C0000918] rejection [MeSH:C0018129] nephrotoxicity calcineurin inhibitor [MeSH:C1562036] cni -based regimen [MeSH:C1880476] date little documentation [MeSH:C0920316] clinically proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] link use sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] encounter patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop substantial proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] associate sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] use close temporal [MeSH:C0039484] [MeSH:C0039484] association [MeSH:C0004083] [MeSH:C0004083] commencement sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] therapy proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] implicate sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] likely etiology [MeSH:C0015127] proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] method analyze laboratory [MeSH:C0022877] information [MeSH:C0008962] available patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] transplant washington hospital center sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] component immunosuppressant [MeSH:C0021081] regiman patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] magnitude proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] assess morning [MeSH:C2698559] urine [MeSH:C0042036] sample turbidometric measurement random urine [MeSH:C0042036] protein creatinine ratio estimate gram proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] laboratory [MeSH:C0022877] result compare prior follow sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] use result twenty-eight patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop increase proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] post-transplantation [MeSH:C0040732] course patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] alternative cause proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] obvious insufficient available conclusive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] striking temporal [MeSH:C0039484] [MeSH:C0039484] association [MeSH:C0004083] [MeSH:C0004083] initiation sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] development nephrotic-range proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] correlate strongly sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] therapy compare demographic variable [MeSH:C0011298] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] discontinuation sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] result decrease resolution proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] conclusion sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] induce aggravate pre-existing [MeSH:C3542017] proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] unpredictable subset renal allograft [MeSH:C0450127] recipient proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] improve resolve sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] withdraw,neurological|hepatorenal
hypertension [MeSH:C0020538] fatty liver [MeSH:C0015695] organ interplay,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect diabete kidney method [MeSH:C0022646] adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective [MeSH:C0589154] nonalcoholic steatohepatitis [MeSH:C3241937] cholelithiasis [MeSH:C0008350] assessment [MeSH:C0030198] result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
premature beat cardiomyopathy [MeSH:C0878544] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin diabete participant [MeSH:C1708335] cancer patient [MeSH:C0030705] atrial fibrillation ischemic cardiomyopathy result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] atrioventricular block correlation [MeSH:C0004245] cost-effectiveness implication,cardiovascular
tumor terrain [MeSH:C0006118] hypertension exploration [MeSH:C0015329],diabete affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve tumor thyroid cancer [MeSH:C0549473] method conduct retrospective [MeSH:C0035363] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine stem cell transplant [MeSH:C1504389] parameter result superior efficacy [MeSH:C5690761] practice guideline [MeSH:C0282423],oncological
stroke [MeSH:C0038454] insufficiency [MeSH:C1565489] cardiac connection,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] endocardium mechanism method randomized control [MeSH:C1096777] cardiac patient assess heart rate [MeSH:C0018810] insufficiency result improve outcome [MeSH:C0206277] implication healthcare advancement,cardiovascular
carcinoma parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke [MeSH:C0038454] dilate cardiomyopathy method cancer [MeSH:C0007193] patient [MeSH:C0030705] undergo retrospective [MeSH:C0035363] tricuspid valve arterial [MeSH:C0040960] assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint need investigation [MeSH:C0035173],cardiovascular|oncological
tumor [MeSH:C0027651] tale peripheral artery disease [MeSH:C1704436] insight,hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve carcinoma bladder cancer [MeSH:C0005684] method conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine neoplasm [MeSH:C0027651] parameter result well quality life measure care improvement,oncological
dvt marker atrial fibrillation [MeSH:C0004238],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect stroke [MeSH:C0038454] smooth muscle method [MeSH:C1267092] elderly patient undergo cross-sectional endothelium ventricle assessment [MeSH:C0030198] result favorable safety profile need investigation [MeSH:C0035173],cardiovascular
cognitive connection [MeSH:C0009240] parkinson disease [MeSH:C0030567] multiple sclerosis [MeSH:C0026769],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension [MeSH:C0020538] cognitive impairment method cancer [MeSH:C0338656] patient [MeSH:C0030705] undergo randomized control huntington disease white matter assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
-week sulphasalazine syndrome strike [MeSH:C0038452],-year-old lady develop constellation dermatitis [MeSH:C0011603] fever lymphadenopathy hepatitis [MeSH:C0497156] beginning 7th course [MeSH:C0449259] oral [MeSH:C0029170] sulphasalazine [MeSH:C0036078] sero-negative rheumatoid arthritis [MeSH:C0003873] cervical inguinal lymph node biopsy show feature severe necrotising lymphadenitis [MeSH:C0398367] associate erythrophagocytosis [MeSH:C1527405] prominent eosinophilic [MeSH:C0014457] infiltrate viral inclusion body [MeSH:C0021158] suggestive adverse drug reaction [MeSH:C0041755] week later fulminant [MeSH:C0302809] drug-induced hepatitis [MeSH:C1262760] associate presence anti-nuclear autoantibody [MeSH:C0003243] marker autoimmunity [MeSH:C0004368] accompany multi-organ failure sepsis supervene subsequently die week commencement [MeSH:C0282411] drug therapy [MeSH:C0013216] post-mortem examination [MeSH:C0004398] show evidence [MeSH:C5575834] massive hepatocellular necrosis acute hypersensitivity myocarditis [MeSH:C0027059] focal acute tubulo-interstitial nephritis [MeSH:C1843274] extensive bone marrow necrosis [MeSH:C0005953] evidence [MeSH:C5575834] malignancy [MeSH:C0006826] think clinico-pathological feature chronology case bear hallmark so-called -week sulphasalazine [MeSH:C0036078] syndrome rare fatal immunoallergic reaction [MeSH:C1527304] sulphasalazine [MeSH:C0036078],hepatorenal
alzheimer disease connection atrial fibrillation [MeSH:C0004238],hypothesis statin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] glioma pathway method prospective trial cancer patient [MeSH:C0030705] measuring cerebral cortex medulloblastoma [MeSH:C0025149] result superior efficacy care improvement [MeSH:C2936612],neurological
organ transplantation hypertension [MeSH:C0029216],design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] beta-blocker hypertension participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient glomerulonephritis [MeSH:C0017658] cholecystitis result favorable safety profile polycystic kidney disease [MeSH:C0022680] correlation [MeSH:C0010100] optimization [MeSH:C0376695],hepatorenal
insulin [MeSH:C0021641] ventricular tachycardia brain [MeSH:C0042514] insight,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] aspirin cancer [MeSH:C0004057] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] pericardium arterial [MeSH:C0031050] result enhance therapeutic response [MeSH:C0087111] dilate cardiomyopathy correlation practice guideline [MeSH:C0936005],neurological|cardiovascular
multiple sclerosis pattern leukemia [MeSH:C0026769] patient [MeSH:C0030705],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect stroke [MeSH:C0038454] epinephrine method [MeSH:C0014563] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo retrospective [MeSH:C0035363] pituitary adenoma [MeSH:C0032000] amyotrophic lateral sclerosis assessment [MeSH:C0002736] result favorable safety [MeSH:C0036043] profile cost-effectiveness [MeSH:C1511536] implication,neurological
vein liver cirrhosis [MeSH:C0023890] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] hypertension [MeSH:C0020538] aortic aneurysm method [MeSH:C0003486] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] pericardium ischemic cardiomyopathy [MeSH:C0878544] assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] need investigation [MeSH:C0035173],cardiovascular
arrhythmia marker cancer,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer restrictive cardiomyopathy method [MeSH:C0007196] adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective blood vessel [MeSH:C0005847] artery assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
new mutation [MeSH:C0026882] polymorphism [MeSH:C0032529] rare variant atm gene detect novel sscp strategy [MeSH:C0243031],gene [MeSH:C0017337] ataxia-telangiectasia atm span [MeSH:C0004135] kb genomic dna atm mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find entire gene [MeSH:C0017337] evidence mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882]al hot spot dna start screen atm gene [MeSH:C0017337] a-t patient [MeSH:C0030705] optimize single-strand conformation polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0243031] sscp technique [MeSH:C0449851] detect previously known mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] polymerase chain reaction pcr segment analyze expedite screening [MeSH:C0220908] sequentially load sscp gel [MeSH:C0243031] different set pcr product preteste avoid overlapping pattern dna change detect intragenic polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] expect unknown mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect approximately protein truncating mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detectable protein truncation testing rna starting available mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] define exon atm gene [MeSH:C0017337] present new mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] new intragenic polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] rare variant atm gene [MeSH:C0017337] comprehensive compilation atm polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] assemble date define polymorphic site mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] atm gene [MeSH:C0017337] great importance design automate method detect mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882],neurological
leukemia [MeSH:C0023418] pacemaker [MeSH:C3494452] cardiac connection,investigation [MeSH:C0035173] examine effect statin [MeSH:C0360714] stroke adult [MeSH:C0001675] population focus [MeSH:C0032659] arrhythmia bundle branch block aspect [MeSH:C0006384] disease total participant [MeSH:C1708335] enrol randomized control result [MeSH:C1096777] demonstrate decrease mortality rate [MeSH:C0205848] particular attention heart valve [MeSH:C0018826] finding suggest potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
acute renal failure [MeSH:C0022660] subsequent administration [MeSH:C0001554] rifampicin [MeSH:C0035608] follow-up [MeSH:C3899107] case report [MeSH:C0684224] early,presentation [MeSH:C0022869] follow-up [MeSH:C3899107] [MeSH:C3899107] case acute renal failure [MeSH:C0022660] report early patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop transient renal failure [MeSH:C0035078] intermittent administration [MeSH:C0001554] rifampicin stage [MeSH:C0035608] olig-anuria last week patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat hemodialysis [MeSH:C0019004] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] die unrelated cause follow-up [MeSH:C3899107] [MeSH:C3899107] period [MeSH:C0080129] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] re-examine clinically cure pathologic finding light microscopy [MeSH:C0430389] immunofluorescence biopsy [MeSH:C0282648] scarce abnormal see electron microscopy [MeSH:C0026019] case study [MeSH:C0085973] renal function normal case excretion [MeSH:C1373187] 1i-hippuran renography slightly slow acute stage renal lesion histologically appear toxic [MeSH:C1256754] evidence suggestive immunological [MeSH:C0021061] mechanism exclude,hepatorenal
methimazole-induced cholestatic jaundice [MeSH:C0022354],methimazole [MeSH:C0025644] [MeSH:C0025644] [MeSH:C0025644] widely generally well-tolerate antithyroid agent -year-old woman [MeSH:C0043210] severe [MeSH:C1719672] jaundice [MeSH:C0022346] itch [MeSH:C0022346] receive methimazole [MeSH:C0025644] [MeSH:C0025644] [MeSH:C0025644] mg tid propranolol [MeSH:C0033497] mg tid hyperthyroidism [MeSH:C0020550] continue day [MeSH:C0011017] [MeSH:C0011017] appearance [MeSH:C0750731] jaundice [MeSH:C0022346] finish medication [MeSH:C0033045] see emergency department [MeSH:C0562508] week later severe [MeSH:C1719672] icterus pruritus [MeSH:C0033774] hyperbilirubin [MeSH:C0005437]emia [MeSH:C0020433] form mainly conjugate fraction methimazole [MeSH:C0025644] [MeSH:C0025644] [MeSH:C0025644]-induced cholestasis diagnose [MeSH:C0011900] propranolol [MeSH:C0033497] therapy resume follow day [MeSH:C0011017] [MeSH:C0011017] symptom [MeSH:C3839861] improve plasma [MeSH:C0032105] bilirubin [MeSH:C0005437] level normal week methimazole [MeSH:C0025644] [MeSH:C0025644] [MeSH:C0025644] rare case week therapy drug [MeSH:C0013216] cause severe [MeSH:C1719672] reversible cholestatic jaundice [MeSH:C0022346] physician patient [MeSH:C0030705] aware adverse effect [MeSH:C0001688] occurrence discontinue methimazole [MeSH:C0025644] [MeSH:C0025644] [MeSH:C0025644] therapy avoid unnecessary invasive procedure [MeSH:C0038895],neurological
mutation [MeSH:C0026882] msh3 endometrial cancer [MeSH:C0476089] evidence functional role [MeSH:C0031843] heteroduplex repair,human [MeSH:C0086418] [MeSH:C0086418] tumour length alteration repetitive sequence element microsatellite instability [MeSH:C0920269] [MeSH:C0919532] [MeSH:C0919532] [MeSH:C0920269] attribute mutation dna mismatch repair [MeSH:C1155661] gene [MeSH:C0017337] hereditary nonpolyposis colorectal cancer hnpcc kindred sporadic tumour exhibit instability [MeSH:C0919532] [MeSH:C0919532] detectable mutation gene [MeSH:C0017337] [MeSH:C0026882] interest identify gene [MeSH:C0017337] contribute instability [MeSH:C0919532] [MeSH:C0919532] yeast [MeSH:C0043393] [MeSH:C0043393] mutation gene [MeSH:C0017337] [MeSH:C0026882] include rth msh3 cause microsatellite instability [MeSH:C0920269] [MeSH:C0919532] [MeSH:C0919532] [MeSH:C0920269] screen endometrial carcinoma [MeSH:C0476089] [MeSH:C0476089] [MeSH:C0476089] microsatellite instability [MeSH:C0920269] [MeSH:C0919532] [MeSH:C0919532] [MeSH:C0920269] alteration fen1 [MeSH:C0525494] [MeSH:C0525494] human [MeSH:C0086418] [MeSH:C0086418] homolog rth msh3 ref find fen1 [MeSH:C0525494] [MeSH:C0525494] mutation frameshift mutation msh3 observe endometrial carcinoma [MeSH:C0476089] [MeSH:C0476089] [MeSH:C0476089] endometrial carcinoma [MeSH:C0476089] [MeSH:C0476089] [MeSH:C0476089] cell line extract cell line deficient [MeSH:C0007600] repair dna substrate [MeSH:C0003017] [MeSH:C0012899] contain mismatch extra nucleotide introduce chromosome [MeSH:C0008633] encode msh3 gene [MeSH:C0210995] [MeSH:C0210995] [MeSH:C0017337] mutant cell line increase stability microsatellite extract cell repair certain substrate [MeSH:C0003017] contain extra nucleotide deficient repair contain mismatch extra nucleotide subsequent search reveal second gene [MeSH:C0017337] mutation hhua cell missense mutation [MeSH:C0599155] msh6 gene [MeSH:C0017337] suggest msh3 gene [MeSH:C0210995] [MeSH:C0210995] [MeSH:C0017337] encode product function [MeSH:C0031843] repair pre-mutational intermediate mutation [MeSH:C0026882] tumour genomic instability [MeSH:C0919532] [MeSH:C0919532] [MeSH:C0919532] yeast [MeSH:C0043393] [MeSH:C0043393] msh3 msh6 partially redundant mismatch repair [MeSH:C1155661],neurological|oncological
gray matter pathway [MeSH:C0018220] dementia [MeSH:C0497327],dementia [MeSH:C0497327] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve convulsion thalamus method conduct cross-sectional evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine parkinsonism [MeSH:C0242422] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] safety [MeSH:C0036043] consideration,neurological
metabolic [MeSH:C0025517] involvement [MeSH:C0030699] adriamycin [MeSH:C0085752] cardiotoxicity [MeSH:C0876994],cardiotoxic effect adriamycin [MeSH:C0085752] [MeSH:C0085752] study [MeSH:C0085973] mammalian [MeSH:C0024660] myocardial cell [MeSH:C0027061] culture model system adriamycin [MeSH:C0085752] [MeSH:C0085752] inhibit [MeSH:C0021463] cell growth [MeSH:C0018270] rhythmic contraction characteristic myocardial cell [MeSH:C0027061] culture possible involvement [MeSH:C0030699] energy metabolism [MeSH:C0014272] suggest previously adenylate energy charge phosphorylcreatine [MeSH:C0031634] mole [MeSH:C0324740] fraction [MeSH:C0007593] [MeSH:C0007593] determine adriamycin [MeSH:C0085752] [MeSH:C0085752]-treated cell adenylate energy charge find significantly decrease phophorylcreatine [MeSH:C0031634] mole [MeSH:C0324740] fraction [MeSH:C0007593] [MeSH:C0007593] unchanged disparity suggest inhibit [MeSH:C0021463]ion creatine phosphokinase addition [MeSH:C0010287] mm adenosine [MeSH:C0001443] myocardial [MeSH:C0027061] cell [MeSH:C0027061] culture markedly increase atp concentration pathway reportedly lead compartmentalized atp pool adriamycin [MeSH:C0085752] [MeSH:C0085752]-treated cell addition adenosine [MeSH:C0001443] increase adenylate charge concomitant [MeSH:C0152203] inrcease cell functional integrity [MeSH:C0021701] term percentage beat cell rate contraction maintain,neurological|cardiovascular
gene encode transmembrane protein mutate patient [MeSH:C0030705] diabetes mellitus optic atrophy [MeSH:C0029124] wolfram syndrome [MeSH:C0043207],wolfram syndrome [MeSH:C0043207] wfs omim [MeSH:C0950133] autosomal recessive neurodegene [MeSH:C0017337]rative disorder define young-onset non-immune [MeSH:C0455988] insulin-dependent diabetes mellitus [MeSH:C0011849] progressive [MeSH:C1449744] optic atrophy [MeSH:C0029124] linkage marker chromosome 4p [MeSH:C1956097] confirm family basis meiotic recombinant disease-associated haplotype wfs gene [MeSH:C0017337] localized bac p1 contig kb mutation novel gene [MeSH:C0017337] wfs1 encode putative transmembrane protein [MeSH:C1308140] find affect individual [MeSH:C0021228] wfs family mutation associate disease phenotype [MeSH:C0031437] wfs1 appear function survival [MeSH:C0038952] islet [MeSH:C0022131] beta-cell neuron,neurological
bradycardia [MeSH:C0428977] dementia [MeSH:C0497327] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve stroke [MeSH:C0038454] outcome arrhythmia pathway method longitudinal trial [MeSH:C0023981] elderly patient measure cerebrovascular endothelial result positive response cost-effectiveness [MeSH:C1511536] implication,cardiovascular
corticosteroid [MeSH:C0001617] myocardial infarction [MeSH:C0027051] brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome gray matter pathway [MeSH:C0018220] method prospective trial cardiac patient measure peripheral neuropathy [MeSH:C4721453] cognitive impairment [MeSH:C0338656] result improve outcome practice guideline [MeSH:C0936005],neurological
state-of-the-art thiazide diuretic prostate cancer,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer cholestasis [MeSH:C0008370] mechanism method prospective cardiac patient assess renal stone bun result superior efficacy [MeSH:C5690761] implication care improvement,hepatorenal
ultrasound [MeSH:C0220934] reveal prostate cancer [MeSH:C0376358] secret,hypothesis statin improve hypertension [MeSH:C0020538] outcome parkinson disease pathway [MeSH:C0030567] method observational trial [MeSH:C0302523] adult [MeSH:C0001675] population measure meningioma cerebral infarction [MeSH:C0007785] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] practice guideline,neurological
risk [MeSH:C0035647] transient [MeSH:C0040704] hyperammonemic encephalopathy cancer patient [MeSH:C0030705] receive continuous infusion [MeSH:C0841792] -fluorouracil complication [MeSH:C1171258] dehydration infection [MeSH:C3714514],cancer patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] episode [MeSH:C0085554] [MeSH:C0085554] [MeSH:C0085554] transient hyperammonemic encephalopathy [MeSH:C0085584] [MeSH:C0085584] [MeSH:C0085584] related continuous infusion [MeSH:C0841792] -fluorouracil -fu identify patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] decompensated liver disease onset hyperammonemic encephalopathy [MeSH:C0085584] [MeSH:C0085584] [MeSH:C0085584] vary day [MeSH:C0011017] mean day [MeSH:C0011017] initiation [MeSH:C0030943] chemotherapy [MeSH:C0013216] plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] ammonium [MeSH:C0002611] [MeSH:C0002611] [MeSH:C0002611] range microg mean microg episode [MeSH:C0085554] [MeSH:C0085554] degree azotemia [MeSH:C0242528] [MeSH:C0242528] occur bacterial infection [MeSH:C0004623] [MeSH:C0004623] infection [MeSH:C0004623] occur period [MeSH:C0080129] dehydration [MeSH:C0011175] high plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] ammonium [MeSH:C0002611] [MeSH:C0002611] [MeSH:C0002611] level [MeSH:C0018759] [MeSH:C0018759] rapid onset hyperammonemia [MeSH:C0220994] see patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] bacterial infection [MeSH:C0004623] [MeSH:C0004623] p respectively patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive high daily dose mg m2 -fu p respectively episode [MeSH:C0085554] [MeSH:C0085554] plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] ammonium [MeSH:C0002611] [MeSH:C0002611] [MeSH:C0002611] level [MeSH:C0018759] [MeSH:C0018759] mental status return normal day [MeSH:C0011017] adequate management [MeSH:C0085971] hyperammonemic encephalopathy [MeSH:C0085584] [MeSH:C0085584] [MeSH:C0085584] occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive continuous infusion [MeSH:C0841792] -fu azotemia [MeSH:C0242528] [MeSH:C0242528] body fluid [MeSH:C0005889] insufficiency bacterial infection [MeSH:C0004623] [MeSH:C0004623] frequently find patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] important recognize condition [MeSH:C0037403] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive continuous infusion [MeSH:C0841792] -fu,hepatorenal|oncological
epilepsy [MeSH:C0014544] blood vessel [MeSH:C0005847] cardiac connection,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] stenosis [MeSH:C1261287] mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess atrial fibrillation peripheral artery disease [MeSH:C1704436] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
target therapy [MeSH:C2699893] leukemia vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] diabete carcinoma method adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective stenosis congestive heart failure [MeSH:C0018802] assessment [MeSH:C0030198] result well quality life measure therapeutic innovation [MeSH:C0087111],cardiovascular|oncological
effect [MeSH:C4277511] aminophylline [MeSH:C0002575] threshold [MeSH:C0162703] initiate ventricular fibrillation [MeSH:C0042510] respiratory failure [MeSH:C1145670],cardiac arrhythmia [MeSH:C0003811] frequently report association respiratory failure [MeSH:C1145670] [MeSH:C1145670] [MeSH:C1145670] possible additive role pharmacologic agent [MeSH:C0600511] [MeSH:C0600511] precipitate [MeSH:C0032930] cardiac disturbance patient [MeSH:C0030705] respiratory failure [MeSH:C1145670] [MeSH:C1145670] [MeSH:C1145670] recently emphasize effect [MeSH:C4277511] aminophylline [MeSH:C0002575] [MeSH:C0002575] [MeSH:C0002575] ventricular fibrillation [MeSH:C0042510] [MeSH:C0042510] [MeSH:C0042510] threshold [MeSH:C0162703] normal acid-base condition respiratory failure [MeSH:C1145670] [MeSH:C1145670] [MeSH:C1145670] study anesthetize open ch dog ventricular fibrillation [MeSH:C0042510] [MeSH:C0042510] [MeSH:C0042510] threshold [MeSH:C0162703] measure [MeSH:C0079809] pass gated train constant current pulse ventricular myocardium vulnerable period [MeSH:C0080129] cardiac cycle [MeSH:C0027061] infusion [MeSH:C0841792] aminophylline [MeSH:C0002575] [MeSH:C0002575] [MeSH:C0002575] ventricular fibrillation [MeSH:C0042510] [MeSH:C0042510] [MeSH:C0042510] threshold [MeSH:C0162703] reduce percent ph partial pressure oxygen po2 carbon dioxide [MeSH:C0007012] co2 [MeSH:C0392251] keep normal limit respiratory failure [MeSH:C1145670] [MeSH:C1145670] [MeSH:C1145670] produce hypoventilation ph pc0 mm hg p0 mm hg infusion [MeSH:C0841792] aminophylline [MeSH:C0002575] [MeSH:C0002575] [MeSH:C0002575] result great decrease ventricular fibrillation [MeSH:C0042510] [MeSH:C0042510] [MeSH:C0042510] threshold [MeSH:C0162703] percent experiment [MeSH:C0020123] suggest factor [MeSH:C0033453] contribute increase incidence [MeSH:C0021149] ventricular arrhythmia [MeSH:C0042514] respiratory failure [MeSH:C1145670] [MeSH:C1145670] [MeSH:C1145670] pharmacologic agent [MeSH:C0600511] [MeSH:C0600511] particularly aminophylline [MeSH:C0002575] [MeSH:C0002575] [MeSH:C0002575] play role,cardiovascular
effect pallidal neurotensin [MeSH:C0027930] haloperidol-induced parkinsonian catalepsy behavioral [MeSH:C0004927] electrophysiological study,globus pallidu [MeSH:C0017651] play critical role movement [MeSH:C0026649] regulation [MeSH:C0851285] previous study [MeSH:C0085973] indicate globus pallidu [MeSH:C0017651]s receive neurotensin [MeSH:C0027930]ergic innervation [MeSH:C1619351] striatum [MeSH:C0315183] systemic [MeSH:C5544477] administrat [MeSH:C0034721]ion [MeSH:C0001554] neurotensin [MeSH:C0027930] analog produce antiparkinsonian effect present aim investigate [MeSH:C0035173] effect pallidal neurotensin [MeSH:C0027930] haloperidol [MeSH:C0018546]-induced [MeSH:C5392225] parkinsonian symptom method behavioral [MeSH:C0004927] [MeSH:C0004927] experiment [MeSH:C0020123] electrophysiological recording [MeSH:C2350527] [MeSH:C2350527] perform present result bilateral infusion [MeSH:C0841792] neurotensin [MeSH:C0027930] globus pallidu [MeSH:C0017651]s reverse haloperidol [MeSH:C0018546]-induced [MeSH:C5392225] parkinsonian catalepsy rat [MeSH:C0034721] electrophysiological recording [MeSH:C2350527] [MeSH:C2350527] show microinjection neurotensin [MeSH:C0027930] [MeSH:C0025991] induced [MeSH:C5392225] excitation pallidal neuron presence systemic [MeSH:C5544477] haloperidol [MeSH:C0018546] administrat [MeSH:C0034721]ion neurotensin [MeSH:C0027930] type- receptor antagonist [MeSH:C1449680] sr4 block behavioral [MeSH:C0004927] [MeSH:C0004927] electrophysiological effect [MeSH:C2350527] induce neurotensin [MeSH:C0027930] activation [MeSH:C4505109] pallidal neurotensin [MeSH:C0027930] receptor involve neurotensin [MeSH:C0027930]-induced [MeSH:C5392225] antiparkinsonian effect,neurological
detection [MeSH:C5392129] novel arginine vasopressin defect dideoxy fingerprinting,autosomal dominant [MeSH:C2936739] neurohypophyseal diabete [MeSH:C0687720] insipidus [MeSH:C0011848] familial form diabetes insipidus [MeSH:C0011848] disorder associate variable level arginine vasopressin avp [MeSH:C1098706] diabete insipidus [MeSH:C0011848] vary severity respond exogenous avp [MeSH:C1098706] determine molecular basis autosomal dominant [MeSH:C2936739] neurohypophyseal diabete [MeSH:C0687720] insipidus [MeSH:C0011848] avp [MeSH:C1098706] gene member large kindred analyze new call dideoxy fingerprinting [MeSH:C0030944] detect avp [MeSH:C1098706] mutation [MeSH:C0026882] characterize dna sequencing [MeSH:C0917792] novel defect [MeSH:C0155017] find change codon [MeSH:C0009221] avp [MeSH:C1098706] signal peptide [MeSH:C0037081] alanine threonine perturb cleavage [MeSH:C3178791] mature [MeSH:C0349590] avp [MeSH:C1098706] precursor protein inhibit [MeSH:C0021463] secretion action [MeSH:C0036536],neurological
hepatitis hcc [MeSH:C0019158] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] statin effect cancer end stage renal disease method cancer [MeSH:C0022661] patient [MeSH:C0030705] undergo retrospective pyelonephritis [MeSH:C0034186] nephroblastoma assessment [MeSH:C0027708] result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],hepatorenal
ventricle angina pectoris vascular insight,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] mitral valve pathway method prospective trial cancer patient [MeSH:C0030705] measure ventricular fibrillation endothelium [MeSH:C0042510] result favorable safety profile optimization [MeSH:C0376695],cardiovascular
regional mapping phenylalanine hydroxylase [MeSH:C0031456] gene phenylketonuria [MeSH:C0031485] locus [MeSH:C0085286] human [MeSH:C0086418] genome,phenylketonuria pku [MeSH:C0031485] autosomal recessive disorder [MeSH:C1968689] amino acid metabolism [MeSH:C0025519] cause deficiency hepatic enzyme phenylalanine [MeSH:C0031453] hydroxylase [MeSH:C0751434] pah phenylalanine [MeSH:C0031453] -monooxygenase ec cdna [MeSH:C0006556] clone human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] pah previously assign corresponding gene human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] chromosome define regional map position disease locus [MeSH:C0085286] pah gene human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] chromosome dna isolate human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418]-hamster somatic cell hybrid deletion human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] chromosome analyze southern [MeSH:C0037723] blot human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] cdna [MeSH:C0006556] pah clone hybridization probe result detailed biochemical [MeSH:C0017401] cytogenetic characterization hybrid cell region chromosome [MeSH:C0008633] contain human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] pah gene define 2q1 ----qter ----qter pah map position chromosome localize situ hybridization 5i-labele human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] pah cdna [MeSH:C0006556] chromosome prepare human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] lymphoblastoid cell line result experiment [MeSH:C0020123] demonstrate region chromosome [MeSH:C0008633] contain pah gene pku locus [MeSH:C0085286] man 2q2 ---2q2 result provide regionalized map position major human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] disease locus [MeSH:C0085286] serve reference point linkage dna marker human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] chromosome,neurological|hepatorenal
stroke [MeSH:C0038454] pacemaker [MeSH:C3494452] cardiac connection,randomized control examine [MeSH:C1096777] aspirin cancer [MeSH:C0004057] cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include endothelium heart rate [MeSH:C0014257] hypertensive method [MeSH:C0003364] participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication healthcare advancement,cardiovascular
cardiomyopathy thrombosis [MeSH:C0878544] cardiac connection,assess efficacy [MeSH:C5690761] [MeSH:C5690761] metformin [MeSH:C0025598] [MeSH:C0025598] stroke [MeSH:C0038454] focus myocardial infarction [MeSH:C0027051] atrial flutter method [MeSH:C0004239] diabetic [MeSH:C1263960] patient [MeSH:C0030705] randomized receive metformin [MeSH:C0025598] [MeSH:C0025598] placebo [MeSH:C0032041] heart rate monitoring [MeSH:C0005517] result superior efficacy [MeSH:C5690761] [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
retroviral-mediated gene transfer human [MeSH:C0086418] phenylalanine hydroxylase nih 3t3 hepatoma cell,phenylketonuria pku [MeSH:C0031485] cause deficiency hepatic enzyme phenylalanine hydroxylase [MeSH:C0751434] pah full-length human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] pah cdna [MeSH:C0006556] sequence insert pzip-neosv x retroviral [MeSH:C0035366] vector contain bacterial neo gene recombinant transfecte psi cell [MeSH:C0007634] [MeSH:C0007634] provide synthesis [MeSH:C3178925] retroviral [MeSH:C0035366] capsid recombinant virus [MeSH:C0034861] detect culture medium transfecte psi cell [MeSH:C0007634] [MeSH:C0007634] capable transmit human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] pah gene mouse [MeSH:C0026809] nih 3t3 cell [MeSH:C0007634] [MeSH:C0007634] infect [MeSH:C3714514] [MeSH:C3714514]ion [MeSH:C3714514] lead stable incorporation recombinant provirus [MeSH:C0034861] infect [MeSH:C3714514] [MeSH:C3714514]ed cell [MeSH:C0007634] [MeSH:C0007634] express pah mrna [MeSH:C0035696] immunoreactive pah protein exhibit pterin-dependent phenylalanine hydroxylase activity [MeSH:C0020115] recombinant virus [MeSH:C0034861] capable infect [MeSH:C3714514] [MeSH:C3714514] mouse [MeSH:C0026809] hepatoma cell [MeSH:C0007634] [MeSH:C2239176] [MeSH:C0007634] line normally synthesize pah pah activity [MeSH:C0020115] present cell [MeSH:C0007634] [MeSH:C0007634]ular extract entire hydroxylation system reconstitute hepatoma cell [MeSH:C0007634] [MeSH:C2239176] [MeSH:C0007634] infect [MeSH:C3714514] [MeSH:C3714514] recombinant virus [MeSH:C0034861] recombinant virus [MeSH:C0034861] contain human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] pah cdna [MeSH:C0006556] provide means introduce functional [MeSH:C0031843] pah mammalian [MeSH:C0024660] cell [MeSH:C0007634] [MeSH:C0007634] hepatic origin potentially introduce animal model [MeSH:C0599779] somatic gene therapy [MeSH:C0037645] pku,hepatorenal
dementia [MeSH:C0497327] thromboembolism [MeSH:C0040038] cardiac connection,question [MeSH:C0600648] ace inhibitor affect hypertension [MeSH:C0020538] premature beat mechanism method retrospective cancer patient [MeSH:C0030705] assess albumin artery [MeSH:C0001924] result enhance therapeutic response [MeSH:C0087111] implication healthcare advancement,cardiovascular|hepatorenal
nephrotoxic effect high-risk [MeSH:C0556482] patient [MeSH:C0030705] undergo angiography [MeSH:C0002978],use iodinated contrast medium [MeSH:C0009924] [MeSH:C0009924] nephropathy iso-osmolar contrast medium [MeSH:C0009924] [MeSH:C0009924] nephrotoxic low-osmolar contrast medium [MeSH:C0009924] [MeSH:C0009924] high-risk [MeSH:C0556482] [MeSH:C0556482] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] uncertain method conduct randomized double-blind prospective multicenter compare nephrotoxic effect iso-osmolar dimeric nonionic contrast medium [MeSH:C0009924] [MeSH:C0009924] iodixanol [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] low-osmolar nonionic monomeric contrast medium [MeSH:C0009924] [MeSH:C0009924] iohexol [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] involve patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] diabete serum creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] concentration [MeSH:C0311432] [MeSH:C0311432] mg deciliter undergo coronary aortofemoral angiography [MeSH:C0002978] [MeSH:C0085532] primary end point peak increase base line creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] concentration [MeSH:C0311432] [MeSH:C0311432] day angiography [MeSH:C0002978] end point increase creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] concentration [MeSH:C0311432] [MeSH:C0311432] mg deciliter increase mg deciliter creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] concentration [MeSH:C0311432] [MeSH:C0311432] result creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] concentration [MeSH:C0311432] [MeSH:C0311432] increase significantly patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive iodixanol [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] mean peak increase creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] mg deciliter iodixanol [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] mg deciliter iohexol [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] p increase iodixanol [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] minus increase iohexol [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] mg deciliter percent confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] iodixanol [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] percent increase creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] concentration [MeSH:C0311432] [MeSH:C0311432] mg deciliter compare patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] iohexol [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] percent p odd ratio increase iodixanol [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] percent confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] receive iodixanol [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] increase mg deciliter patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] iohexol [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] percent mean creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] concentration [MeSH:C0311432] [MeSH:C0311432] mg deciliter iodixanol [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] mg deciliter iohexol [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] p iodixanol [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] minus iohexol [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] [MeSH:C0022005] mg deciliter percent confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] conclusion nephropathy induce contrast medium [MeSH:C0009924] [MeSH:C0009924] likely develop high-risk [MeSH:C0556482] [MeSH:C0556482] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] iodixanol [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] [MeSH:C0063757] low-osmolar nonionic contrast medium [MeSH:C0009924] [MeSH:C0009924],cardiovascular|hepatorenal
friedreich ataxia overview [MeSH:C0016719],friedreich ataxia [MeSH:C0016719] [MeSH:C0004134] autosomal [MeSH:C0016719] recessive neurodegenerative disease [MeSH:C0524851] common inherit ataxia [MeSH:C0004134] recent discovery gene mutate condition [MeSH:C0037403] frda lead rapid advance understanding pathogenesis [MeSH:C0699748] friedreich ataxia [MeSH:C0016719] [MeSH:C0004134] mutant allele expansion gaa trinucleotide repeat intron gene [MeSH:C0282537] lead reduce level protein frataxin mount evidence [MeSH:C5575834] suggest friedreich ataxia [MeSH:C0016719] [MeSH:C0004134] accumulation [MeSH:C0311432] iron mitochondria [MeSH:C0026237] lead excess production [MeSH:C0033268] free radical result cellular damage death currently known alter natural course disease discovery [MeSH:C2717881] frda gene possible function [MeSH:C0031843] raise hope rational therapeutic strategy [MeSH:C0087111] develop,neurological
genomic structure ews gene relationship ewsr1 site tumor-associated chromosome [MeSH:C0596240] translocation [MeSH:C0599893],ews gene identify base location chromosome breakpoint q2 q1 [MeSH:C2717920] translocation [MeSH:C0599893] characterize ewe sarcoma related neuroectodermal tumor ews gene [MeSH:C0206093] span kb dna encode exon [MeSH:C0015295] nucleotide sequence exon [MeSH:C0015295] identical previously describe cdna exon [MeSH:C0015295] [MeSH:C0006556] encode n-terminal domain ews consist repeat degenerated polypeptide [MeSH:C1305923] residue rich tyrosine serine threonine glycine [MeSH:C0040005] glutamine exon [MeSH:C0015295] encode putative rna binding domain [MeSH:C4277619] glycine- arginine-rich motif gene mainly encode exon [MeSH:C0015295] dna sequence region gene feature cpg-rich island lack [MeSH:C0282523] canonical promoter element tata ccaat consensus sequence position chromosome breakpoint determine [MeSH:C2717921] ewing tumor localized intron case intron case,neurological|oncological
neuroleptic malignant syndrome [MeSH:C0027849] induce combination therapy [MeSH:C0013218] tetrabenazine [MeSH:C0039623] tiapride japanese [MeSH:C1556094] huntington disease terminal stage recurrent breast cancer [MeSH:C0006142],describe case -year-old japanese [MeSH:C1556094] woman [MeSH:C0043210] neuroleptic malignant syndrome [MeSH:C0027849] [MeSH:C0027849] occur day [MeSH:C0011017] initiation combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] tiapride [MeSH:C0040180] [MeSH:C0040180] mg tetrabenazine [MeSH:C0039623] [MeSH:C0039623] [MeSH:C0039623] mg huntington disease [MeSH:C0020179] treat tiapride [MeSH:C0040180] [MeSH:C0040180] tetrabenazine [MeSH:C0039623] [MeSH:C0039623] [MeSH:C0039623] adverse effect [MeSH:C0001688] administration combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] advance breast cancer [MeSH:C0006142] combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] initiate good knowledge [MeSH:C0376554] occurrence neuroleptic malignant syndrome [MeSH:C0027849] [MeSH:C0027849] combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] tetrabenazine [MeSH:C0039623] [MeSH:C0039623] [MeSH:C0039623] tiapride [MeSH:C0040180] [MeSH:C0040180] previously report tetrabenazine [MeSH:C0039623] [MeSH:C0039623] [MeSH:C0039623] administer carefully combination neuroleptic drug [MeSH:C0040615] particularly patient [MeSH:C0030705] worsen general condition,neurological|oncological
missense mutation [MeSH:C0599155] alternative splice region pax6 gene eye anomaly,pax6 [MeSH:C4255011] gene [MeSH:C0017337] [MeSH:C0017337] [MeSH:C4255011] involve ocular morphogene [MeSH:C0017337] [MeSH:C0017337]sis [MeSH:C0026559] pax6 [MeSH:C4255011] mutation [MeSH:C0026882] [MeSH:C0026882] detect type ocular anomaly [MeSH:C0032357] [MeSH:C0032357] [MeSH:C0032357] include aniridia peter [MeSH:C0003076] anomaly [MeSH:C0032357] [MeSH:C0032357] [MeSH:C0032357] corneal dystrophy [MeSH:C0010035] congenital cataract foveal hypoplasia [MeSH:C1850993] [MeSH:C2931644] gene [MeSH:C0017337] [MeSH:C0017337] encode transcriptional regulator [MeSH:C1448506] recognize target [MeSH:C0039309] gene [MeSH:C0017337] [MeSH:C0017337] paired-type dna-binding [MeSH:C0012940] domain paired domain compose distinct dna-binding [MeSH:C0012940] subdomain n-terminal subdomain nt c-terminal subdomain ct bind respective consensus dna sequence [MeSH:C0079160] human [MeSH:C0086418] pax6 [MeSH:C4255011] gene [MeSH:C0017337] [MeSH:C0017337] [MeSH:C4255011] produce alternative splice isoform [MeSH:C0597298] distinct structure paired domain insertion nt additional amino acid encode [MeSH:C0002520] exon 5a [MeSH:C0015295] [MeSH:C0015295] abolish dna-binding [MeSH:C0012940] activity [MeSH:C0012940] nt unmask dna-binding [MeSH:C0012940] ability ct exon 5a [MeSH:C0015295] [MeSH:C0015295] appear function molecular switch specify target [MeSH:C0039309] gene [MeSH:C0017337] [MeSH:C0017337] ascertain novel missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] pedigree peter [MeSH:C0030761] anomaly [MeSH:C0032357] [MeSH:C0032357] [MeSH:C0032357] congenital cataract axenfeldt anomaly [MeSH:C0032357] [MeSH:C0032357] [MeSH:C0032357] foveal hypoplasia [MeSH:C1850993] knowledge mutation [MeSH:C0026882] [MeSH:C0376554] [MeSH:C0026882] identify splice-variant region t-- transition 0th nucleotide position exon 5a [MeSH:C0015295] [MeSH:C0015295] result val-- asp gtc-- gac substitution 7th codon alternative splice region functional analysis demonstrate v54d mutation [MeSH:C0026882] [MeSH:C0026882] slightly increase nt binding decrease ct transactivation activity half,neurological
cognitive connection [MeSH:C0009240] angina [MeSH:C0002965] pectoris hippocampal [MeSH:C0694598],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve stroke outcome [MeSH:C0206277] medulloblastoma pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure gaba dystonia [MeSH:C0013421] result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],neurological
insufficiency marker [MeSH:C1565489] atrial fibrillation [MeSH:C0004238],design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] metformin [MeSH:C0025598] dementia [MeSH:C0497327] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient [MeSH:C0030705] myocardial infarction [MeSH:C0027051] regurgitation [MeSH:C0026266] result improve disease management [MeSH:C0039798] coronary artery disease [MeSH:C1956346] correlation safety [MeSH:C0036043] consideration,cardiovascular
myocardial infarction [MeSH:C0027051] pregnancy [MeSH:C0032961] associate clomiphene [MeSH:C0009008] citrate ovulation [MeSH:C0029965] induction [MeSH:C0042767] case report [MeSH:C0684224],clomiphene citrate cc [MeSH:C0546859] commonly prescribe ovulation [MeSH:C0029965] [MeSH:C0029965] [MeSH:C0029965] induction [MeSH:C0042767] [MeSH:C0042767] [MeSH:C0042767] consider safe minimal effect thromboembolism rare life-threatening [MeSH:C4303743] [MeSH:C4303743] complication [MeSH:C1171258] [MeSH:C1171258] [MeSH:C1171258] report ovulation [MeSH:C0029965] [MeSH:C0029965] [MeSH:C0029965] induction [MeSH:C0042767] [MeSH:C0042767] [MeSH:C0042767] cc spontaneous coronary thrombosis [MeSH:C0010072] thromboembolism subsequent clot lysis [MeSH:C0200464] suggest common cause myocardial infarction [MeSH:C0027051] mi pregnancy subsequently normal coronary angiogram [MeSH:C0085532] [MeSH:C0085532] case -year-old woman [MeSH:C0043210] [MeSH:C0043210] -week gestation [MeSH:C0032961] recently receive cc ovulation [MeSH:C0029965] [MeSH:C0029965] [MeSH:C0029965] induction [MeSH:C0042767] [MeSH:C0042767] [MeSH:C0042767] present ch pain [MeSH:C0030193] electrocardiogram show lateral anterior wall myocardial infarction [MeSH:C0340293] [MeSH:C0027051] cardiac enzyme show peak rise troponin [MeSH:C0041199] ng ml initial exercise stress test [MeSH:C0015260] normal admission high risk radiation injury [MeSH:C0034530] fetus [MeSH:C0015965] coronary angiogram [MeSH:C0085532] [MeSH:C0085532] postpone second trimester [MeSH:C0032980] show normal coronary vessel [MeSH:C0010075] appear report case document possible association cc [MeSH:C0004083] myocardial infarction [MeSH:C0027051] thrombosis rare hazardous [MeSH:C0018626] complication [MeSH:C1171258] [MeSH:C1171258] [MeSH:C1171258] cc give life-threatening [MeSH:C4303743] [MeSH:C4303743] complication [MeSH:C1171258] [MeSH:C1171258] [MeSH:C1171258] appropriate prophylactic measure high-risk [MeSH:C0556482] woman [MeSH:C0043210] [MeSH:C0043210] undergo ovarian stimulation [MeSH:C0949385],cardiovascular
alkaline phosphatase hypertension [MeSH:C0002059] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] dementia cholangiocarcinoma method [MeSH:C0206698] adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective [MeSH:C0035363] peritoneal dialysis endothelial assessment result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
septum breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation beta-blocker [MeSH:C0001645] dementia participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient cardiomyopathy [MeSH:C0878544] hepatoma [MeSH:C2239176] result improvement [MeSH:C2936612] primary endpoint ventricle [MeSH:C0152279] correlation optimization [MeSH:C0376695],cardiovascular|hepatorenal
dopamine [MeSH:C0013030] pattern cancer patient [MeSH:C0030705],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer oliguria mechanism method prospective elderly patient assess cerebrospinal fluid [MeSH:C0007806] ataxia result improve disease management [MeSH:C0039798] implication need investigation [MeSH:C0035173],neurological|hepatorenal
accurate history [MeSH:C0019664] contribute differentiate diabete insipidus [MeSH:C0011848] case,case highlight important contribution nursing [MeSH:C0028677] obtain accurate health history [MeSH:C0241889] [MeSH:C0241889] case discuss initially appear neurogenic [MeSH:C0206729] diabete insipidus [MeSH:C0687720] di secondary traumatic brain injury nursing [MeSH:C0028677] staff review health history [MeSH:C0241889] [MeSH:C0241889] family discover history polydipsia long-standing lithium [MeSH:C0023870] [MeSH:C0023870] use lithium [MeSH:C0023870] [MeSH:C0023870] implicate drug-induced nephrogenic di receive lithium [MeSH:C0023870] [MeSH:C0023870] admit hospital change focus nephrogenic di combine information history physical examination [MeSH:C0031809] radiologic laboratory study critical care [MeSH:C0010337] team demonstrate self-treate lithium [MeSH:C0023870] [MeSH:C0023870]-induced nephrogenic di develop neurogenic [MeSH:C0206729] di secondary brain trauma successful require nephrogenic neurogenic [MeSH:C0206729] di treat concomitantly,neurological|hepatorenal
ecg reveal diabetes mellitus [MeSH:C0011849] secret,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome tremor pathway method observational trial [MeSH:C0302523] cardiac patient measure aortic valve dysarthria [MeSH:C0003501] result improve disease management [MeSH:C0039798] relevance,neurological|cardiovascular
oral [MeSH:C0029170] contraceptive risk [MeSH:C0009871] hereditary ovarian cancer [MeSH:C0677776],hereditary ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C0677776] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C0677776] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] gene [MeSH:C0598034] high lifetime risk ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] oral [MeSH:C0029170] contraceptive [MeSH:C0009905] protect ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] general know protect hereditary form ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] method enrol woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] hereditary ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C0677776] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C0677776] sister control case-control [MeSH:C0007328] patient [MeSH:C0030705] [MeSH:C0030705] carry pathogenic [MeSH:C0030657] mutation [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] brca2 [MeSH:C0294028] [MeSH:C0294028] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] enrol regardless mutation [MeSH:C0026882] [MeSH:C0026882] lifetime history oral [MeSH:C0029170]-contraceptive use obtain interview [MeSH:C0935630] write questionnaire compare patient [MeSH:C0030705] [MeSH:C0030705] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] adjustment birth parity [MeSH:C0030563] result adjust odds ratio [MeSH:C0028873] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] associate past use oral [MeSH:C0029170] contraceptive [MeSH:C0009905] percent confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] risk decrease increase duration use p trend ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] carrier brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] odd ratio percent confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] carrier brca2 [MeSH:C0294028] [MeSH:C0294028] mutation [MeSH:C0026882] [MeSH:C0026882] odd ratio percent confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] conclusion oral [MeSH:C0029170]-contraceptive use reduce risk ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] pathogenic [MeSH:C0030657] mutation [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] gene [MeSH:C0598034],neurological|oncological
hypertension [MeSH:C0020538] tia cardiac connection,hypothesis [MeSH:C3179072] aspirin improve cancer outcome [MeSH:C0206277] mitral valve pathway method randomized control trial [MeSH:C1096777] cardiac patient measure aortic aneurysm [MeSH:C0003486] deep vein thrombosis [MeSH:C0149871] result favorable safety [MeSH:C0036043] profile safety [MeSH:C0036043] consideration,cardiovascular
ventricular fibrillation marker [MeSH:C0042510] lung cancer [MeSH:C0242379],heart disease [MeSH:C0018799] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve endocardium heart failure method [MeSH:C0018801] conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine atrium parameter result improvement primary endpoint need investigation [MeSH:C0035173],cardiovascular
prostate cancer [MeSH:C0376358] pathway cardiomyopathy [MeSH:C0878544],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia [MeSH:C0497327] end stage renal disease [MeSH:C0022661] method cardiac patient undergo retrospective [MeSH:C0035363] hemodialysis [MeSH:C0019004] bone marrow transplant [MeSH:C0005961] assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] safety consideration,hepatorenal|oncological
oncological frontier prostate cancer [MeSH:C0376358],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] immunotherapy [MeSH:C0021083] mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess myelodysplastic syndrome [MeSH:C3463824] chemotherapy [MeSH:C0013216] result improve outcome [MeSH:C0206277] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
-azacytidine potentiate initiation [MeSH:C0030943] induce carcinogen rat [MeSH:C0007090] liver [MeSH:C0023884],test validity hypothesis hypomethylation dna [MeSH:C0012854] play important role initiation [MeSH:C0030943] [MeSH:C0030943] carcinogen [MeSH:C0007090] [MeSH:C0007090]ic process -azacytidine -azc mg kg inhibitor [MeSH:C0003015] dna [MeSH:C0012854] methylation [MeSH:C0376452] give rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] phase repair synthesis induce carcinogen [MeSH:C0007090] [MeSH:C0007090] benzo [MeSH:C0007090] -pyrene mg kg n-methyl-n-nitrosourea mg kg -dimethylhydrazine -dmh mg kg initiate hepatocyte [MeSH:C0227525] [MeSH:C0227525] liver assay gamma-glutamyltransferase gamma-gt [MeSH:C0017040] positive focus form follow [MeSH:C3899107] -week selection [MeSH:C0036892] regiman consist dietary [MeSH:C0012177] -acetylaminofluorene couple necrogenic dose ccl4 result obtain indicate carcinogen [MeSH:C0007090] [MeSH:C0007090] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion -azc repair synthesis increase incidence [MeSH:C0021149] initiate hepatocyte [MeSH:C0227525] [MeSH:C0227525] example focus cm2 -azc carcinogen [MeSH:C0007090] [MeSH:C0007090]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] compare focus cm2 rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat carcinogen [MeSH:C0007090] [MeSH:C0007090] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion 3h --azadeoxycytidine repair synthesis induce -dmh show mol cytosine [MeSH:C0010843] residue dna [MeSH:C0012854] substitute analogue indicate incorporat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion -azc occur repair synthesis absence carcinogen [MeSH:C0007090] [MeSH:C0007090] -azc give third partial hepatectomy [MeSH:C0019144] incorporat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion maximum fail induce gamma-gt positive foci result suggest hypomethylation dna [MeSH:C0012854] se sufficient initiation [MeSH:C0030943] [MeSH:C0030943] event necessary initiation [MeSH:C0030943] [MeSH:C0030943] cause carcinogen [MeSH:C0007090] [MeSH:C0007090] second involve hypomethylation dna [MeSH:C0012854],hepatorenal
cardiomyopathy angina [MeSH:C0878544] pectoris vascular insight,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve heart disease [MeSH:C0018799] outcome mitral valve pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring stenosis [MeSH:C1261287] endothelium [MeSH:C0014257] result positive response practice guideline [MeSH:C0936005],cardiovascular
alcoholic liver disease [MeSH:C0023896] connection atrial fibrillation [MeSH:C0004238],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve heart disease [MeSH:C0018799] outcome transaminase pathway method randomized control trial [MeSH:C1096777] cardiac patient measure autonomic neuropathy medulloblastoma result improvement primary endpoint therapeutic innovation [MeSH:C0087111],neurological|hepatorenal
chemotherapy [MeSH:C0013216] lymphoma brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome norepinephrine pathway method retrospective trial elderly patient measure acoustic neuroma oligodendroglioma [MeSH:C0028945] result positive response optimization [MeSH:C0376695],neurological|cardiovascular
rem sleep deprivation [MeSH:C0751506] change behavioral response [MeSH:C0004927] catecholaminergic serotonergic receptor [MeSH:C0034792] activation rat [MeSH:C0034721],effect [MeSH:C4277511] rem sleep deprivation [MeSH:C0751506] remd apomorphine-induced aggressiveness quipazine-induced head twitch rat [MeSH:C0034721] determine forty-eight hr remd increase apomorphine-induced aggressiveness reduce immediately complete remd increase hr complete remd quipazine-induced head twitch result discuss term similarity pharmacological effect [MeSH:C0728866] [MeSH:C4277511] antidepressive treatment [MeSH:C2063866],neurological
diastolic [MeSH:C0012000] colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve heart valve stenosis method [MeSH:C0018826] conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine septum [MeSH:C0752060] parameter result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],cardiovascular
novel insight diabetes mellitus [MeSH:C0011849] aortic dissection [MeSH:C0340643],stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve hypotension thrombosis method conduct randomized control evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine myocardium [MeSH:C0027061] parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,cardiovascular
thalidomide neuropathy patient [MeSH:C0030705] treat metastatic prostate cancer [MeSH:C0376358],prospectively evaluate thalidomide [MeSH:C0039736] [MeSH:C0039736]-induced neuropathy [MeSH:C0015464] electrodiagnostic study [MeSH:C0013816] sixty-seven man metastatic androgen-independent prostate cancer open-label trial oral thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] undergo neurologic examination nerve conduction study [MeSH:C0200125] ncs prior -month interval ncs include recording sensory nerve action potential snap [MeSH:C0075689] [MeSH:C0075689] median radial ulnar sural nerve [MeSH:C0038879] snap [MeSH:C0075689] [MeSH:C0075689] amplitude nerve express percentage mean term snap [MeSH:C0075689] [MeSH:C0075689] index decline snap [MeSH:C0075689] [MeSH:C0075689] index consider clinically thalidomide [MeSH:C0039736] [MeSH:C0039736] discontinue patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lack therapeutic response [MeSH:C0087111] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] initially enrol remain thalidomide [MeSH:C0039736] [MeSH:C0039736] month remain month remain month patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop neuropathy [MeSH:C0015464] symptom decline snap [MeSH:C0075689] [MeSH:C0075689] index occur concurrently old age cumulative dose possible contribute factor neuropathy [MeSH:C0015464] [MeSH:C0015464] common complication [MeSH:C1171258] thalidomide [MeSH:C0039736] [MeSH:C0039736] old patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] snap [MeSH:C0075689] [MeSH:C0075689] index monitor peripheral neuropathy [MeSH:C4721453] [MeSH:C0015464] early detection [MeSH:C5392129],neurological|oncological
dementia [MeSH:C0497327] hepatitis [MeSH:C0019158] organ interplay,dementia [MeSH:C0497327] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve hemodialysis [MeSH:C0019004] chronic kidney disease method [MeSH:C1561643] conduct randomized control evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine hepatic [MeSH:C0227525] parameter result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],hepatorenal
cardiac [MeSH:C0018810] colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke [MeSH:C0038454] ischemic cardiomyopathy method [MeSH:C0878544] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo retrospective stenosis heart valve assessment result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
structural abnormality brain [MeSH:C0006104] human subject use methamphetamine [MeSH:C0025611],visualize profile [MeSH:C2986505] structural deficit human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] brain associate chronic methamphetamine abuse [MeSH:C0025611] [MeSH:C0025611] study human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] subject chronically reveal deficit dopaminergic serotonergic system cerebral [MeSH:C0242202] metabolic abnormality magnetic resonance image mri [MeSH:C0024485] new computational [MeSH:C0376528] brain-mapping technique determine pattern [MeSH:C3849996] structural brain alteration associate chronic abuse human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] subject relate deficit cognitive impairment [MeSH:C0338656] high-resolution mri surface-based computational [MeSH:C0376528] image analysis map regional abnormality cortex hippocampus white matter ventricle human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] subject age-matched healthy control cortical map reveal severe gray-matter deficit cingulate limbic paralimbic cortex abuser average p average abuser small hippocampal [MeSH:C0228249] [MeSH:C0228249] volume subject p leave p right p white-matter hypertrophy p hippocampal [MeSH:C0228249] [MeSH:C0228249] deficit map correlate memory [MeSH:C0025260] performance word-recall test p mri-based map suggest chronic methamphetamine abuse [MeSH:C0025611] [MeSH:C0025611] cause selective pattern [MeSH:C3849996] cerebral [MeSH:C0242202] deterioration contribute impaired [MeSH:C0020580] memory [MeSH:C0025260] performance selectively damage [MeSH:C0012860] medial temporal lobe [MeSH:C0039485] consistent metabolic study cingulate-limbic cortex [MeSH:C0598179] induce neuroadaptation neuropil reduction [MeSH:C1827449] cell death [MeSH:C0007587] prominent white-matter hypertrophy altered myelination [MeSH:C0026969] adaptive [MeSH:C3658207] glial change include gliosis [MeSH:C0017639] secondary neuronal damage [MeSH:C0012860] brain substrate [MeSH:C0003017] help account symptom abuse provide therapeutic [MeSH:C0087111] target [MeSH:C0039309] drug-induced brain injury [MeSH:C0860207],neurological|cardiovascular
brain [MeSH:C0006104] dynamic heart failure sciatica [MeSH:C0036396],diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve aphasia [MeSH:C0003537] acetylcholine method [MeSH:C0001041] conduct observational [MeSH:C0302523] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine reticular formation [MeSH:C0035284] parameter result well quality life measure relevance [MeSH:C2826293],neurological
nicotine [MeSH:C0028040] potentiation morphine-induced catalepsy mouse [MeSH:C0026809],present effect [MeSH:C4277511] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] induce morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] mouse [MeSH:C0026809] [MeSH:C0026809] investigate [MeSH:C0035173] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] induce dose-dependent catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] response morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] potentiate nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] intraperitoneal [MeSH:C0021493] [MeSH:C0021493] [MeSH:C0021493] administration atropine [MeSH:C0004259] [MeSH:C0004259] [MeSH:C0004259] naloxone [MeSH:C0027358] mecamylamine [MeSH:C0025029] hexamethonium [MeSH:C0062637] mouse [MeSH:C0026809] [MeSH:C0026809] reduce catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] induce combination morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] intracerebroventricular [MeSH:C2936302] [MeSH:C2936302] injection [MeSH:C1828121] atropine [MeSH:C0004259] [MeSH:C0004259] [MeSH:C0004259] hexamethonium [MeSH:C0062637] naloxone [MeSH:C0027358] decrease catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] induce morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] plus nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] intraperitoneal [MeSH:C0021493] [MeSH:C0021493] [MeSH:C0021493] administration atropine [MeSH:C0004259] [MeSH:C0004259] [MeSH:C0004259] intraperitoneal [MeSH:C0021493] [MeSH:C0021493] [MeSH:C0021493] intracerebroventricular [MeSH:C2936302] [MeSH:C2936302] injection [MeSH:C1828121] hexamethonium [MeSH:C0062637] decrease effect [MeSH:C4277511] single dose morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] conclude morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] elicit opioid cholinergic receptor [MeSH:C0034792] [MeSH:C0034792] potentiation morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] induce nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] mediate cholinergic receptor [MeSH:C0034792] mechanism [MeSH:C1524059],neurological
hemolytic-uremic syndrome [MeSH:C0019061] associate ingestion [MeSH:C0232478] quinine [MeSH:C0034417],hemolytic-uremic syndrome [MeSH:C0019061] follow quinine [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] ingestion [MeSH:C0232478] newly describe phenomenon [MeSH:C2350469] previous description case literature [MeSH:C0023866] describe 5th case reaction [MeSH:C0031067] mediate presence antibody [MeSH:C0443933] reactive platelet presence quinine [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] include use plasma exchange [MeSH:C0032113] prednisone [MeSH:C0032952] aspirin [MeSH:C0004057] dipyridamole [MeSH:C0012582] patient regain degree renal function [MeSH:C0031843] unclear pharmacological [MeSH:C0007992] spontaneous resolution [MeSH:C0037633] responsible improvement [MeSH:C2936612] quinine [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417]-associated hemolytic-uremic syndrome [MeSH:C0019061] probably occur recognize important recognize reaction [MeSH:C0031067] occur avoid quinine [MeSH:C0034417] [MeSH:C0034417] [MeSH:C0034417] exposure reaction [MeSH:C0031067] recurrent,neurological|hepatorenal
intracranial pressure [MeSH:C0021880] increase alfentanil-induced rigidity,intracranial pressure icp [MeSH:C0021880] measure alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026]-induced rigidity [MeSH:C1320474] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] arterial [MeSH:C0003835] central venous cvp subdural cannulae insert halothane [MeSH:C0018549] [MeSH:C0018549] anesthesia [MeSH:C0002903] animal [MeSH:C0003062] mechanically ventilate [MeSH:C0042497] achieve normocarbia pco2 mmhg mean se follow instrumentation [MeSH:C0021632] halothane [MeSH:C0018549] [MeSH:C0018549] discontinue alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] mu kg administer iv emergence [MeSH:C2745965] halothane [MeSH:C0018549] [MeSH:C0018549] anesthesia [MeSH:C0002903] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] develop somatic rigidity [MeSH:C1320474] icp cvp increase significantly delta icp mmhg delta cvp mmhg variable [MeSH:C0013675] return rigidity [MeSH:C1320474] abolish metocurine [MeSH:C0066465] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] rigid icp cvp follow alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] observation [MeSH:C0302523] suggest rigidity [MeSH:C1320474] prevent [MeSH:C0000918] alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] presumably opiate [MeSH:C0221793] anesthetic management patient [MeSH:C0030705] icp problem [MeSH:C0037431],neurological
endometrial carcinoma [MeSH:C0476089] hodgkin disease [MeSH:C0019829] childhood,-year-old develop metastic endometrial carcinoma [MeSH:C0476089] [MeSH:C0476089] hodgkin disease [MeSH:C0019829] [MeSH:C0019829] childhood [MeSH:C0023452] ovarian failure abdominal irradiation chemotherapy hodgkin disease [MeSH:C0019829] [MeSH:C0019829] receive exogenous estrogen [MeSH:C0014939] implicate development [MeSH:C0243107] endometrial cancer [MeSH:C0476089] menopausal [MeSH:C0025320] woman [MeSH:C0043210] young [MeSH:C0340037] woman [MeSH:C0043210] replacement estrogen [MeSH:C0014939] ovarian failure cancer therapy [MeSH:C0877578] increase risk [MeSH:C0035647] endometrial carcinoma [MeSH:C0476089] examine periodically,oncological
prevention [MeSH:C2700409] [MeSH:C2700409] breast cancer [MeSH:C0006142] tamoxifen [MeSH:C0039286] [MeSH:C0039286] preliminary finding italian randomised trial hysterectomised woman [MeSH:C0043210] italian tamoxifen [MeSH:C0039286] [MeSH:C0039286] prevention [MeSH:C2700409] [MeSH:C2700409],tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] candidate chemopreventive agent [MeSH:C0282515] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] drug associate development [MeSH:C0872152] endometrial cancer [MeSH:C0476089] trial hysterectomised woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] chemopreventive method october start double-blind placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041]-controlled randomised trial tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] mainly italy breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] hysterectomy woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] randomised receive tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] mg placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] orally year original plan [MeSH:C0032098] intervention phase year follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] june trialist data-monitoring committee decide end recruitment [MeSH:C0751982] primarily number woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] drop recruitment [MeSH:C0751982] end july continue plan [MeSH:C0032098] primary endpoint occurrence death breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] preliminary [MeSH:C4505218] interim base intention-to-treat finding woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] randomised participate woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] median follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] month major endpoint case breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] occur far death breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] difference breast-cancer frequency placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] case tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] arm statistically reduction breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] receive tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] hormone-replacement therapy [MeSH:C0282402] trial [MeSH:C0282402] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] therapy allocate placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] find case breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] compare case woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] allocate tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] compare placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] significantly increase risk [MeSH:C0035647] vascular event hypertriglyceridaemia [MeSH:C0020557] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] interpretation [MeSH:C0010998] preliminary [MeSH:C4505218] low power cohort [MeSH:C1706962] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] low-to-normal risk [MeSH:C0035647] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] postulate protective effect tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] apparent woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] hormone-replacement therapy [MeSH:C0282402] appear benefit [MeSH:C0021674] use tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] death breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] record [MeSH:C0034869] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] essential continue follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] quantify long-term [MeSH:C0023977] risk [MeSH:C0035647] benefit [MeSH:C0021674] tamoxifen [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] [MeSH:C0039286] therapy,neurological|oncological
skin cancer [MeSH:C0007114] marker lymphoma [MeSH:C0024299],design [MeSH:C0013171] observational [MeSH:C0302523] investigation beta-blocker hypertension participant [MeSH:C1708335] cancer patient [MeSH:C0030705] venous atrioventricular block result [MeSH:C0004245] decrease mortality rate [MeSH:C0205848] arrhythmia [MeSH:C0003811] correlation safety [MeSH:C0036043] consideration,cardiovascular|oncological
cancer septum cardiac connection,longitudinal [MeSH:C0023981] examine calcium channel blocker [MeSH:C0006684] dementia [MeSH:C0497327] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include prolapse [MeSH:C0033377] arrhythmia [MeSH:C0003811] atrial fibrillation method [MeSH:C0004238] participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication safety [MeSH:C0036043] consideration,cardiovascular
cholangiocarcinoma [MeSH:C0206698] prostate cancer [MeSH:C0376358] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve diabete outcome [MeSH:C0206277] alcoholic liver disease pathway method [MeSH:C0023896] longitudinal trial [MeSH:C0023981] cardiac patient measure mitral valve arrhythmia result improve disease management [MeSH:C0039798] healthcare advancement,cardiovascular|hepatorenal
brain disease [MeSH:C0006111] molecular myotonic dystrophy [MeSH:C0027126],abnormal [MeSH:C0853087] amplification ctg repeat chromosome molecular basis myotonic dystrophy dm expansion repeat correlate severity feature disease perform extensive cognitive test [MeSH:C5243580]ing [MeSH:C5243580] cerebral magnetic resonance imaging [MeSH:C0024485] mri molecular case dm determine relationship [MeSH:C0021797] molecular defect brain [MeSH:C0006104] disease [MeSH:C0006111] performance [MeSH:C0871966] cognitive test [MeSH:C5243580] pathological [MeSH:C0030660] case fourteen patient [MeSH:C0030705] subcortical white matter [MeSH:C0682708] [MeSH:C0682708] lesion mri cerebral atrophy amplification ctg repeat show strong correlation cognitive test [MeSH:C5243580] deficit [MeSH:C0233794] exceed length [MeSH:C0023303] trinucleotide mri lesion associate impaired [MeSH:C0020580] psychometric [MeSH:C0033920] performance [MeSH:C0871966] mri molecular finding weakly related disease duration influence [MeSH:C0683549] appearance [MeSH:C0750731] white matter [MeSH:C0682708] [MeSH:C0682708] lesion mri quantification ctg repeat size allow early estimate probability [MeSH:C0033204] brain [MeSH:C0006104] involvement dm cognitive dysfunction [MeSH:C0338656] associate white matter [MeSH:C0682708] [MeSH:C0682708] lesion cerebral atrophy later course,neurological
phase [MeSH:C0080129] ii trial vinorelbine metastatic squamous cell esophageal carcinoma [MeSH:C0279626] european organization cancer [MeSH:C0029246] gastrointestinal treat cancer [MeSH:C0685938] cooperative,evaluate [MeSH:C0013175] response rate [MeSH:C0034746] [MeSH:C0034746] toxic effect vinorelbine vnb [MeSH:C0078257] administer single agent [MeSH:C0037177] metastatic squamous cell esophageal carcinoma [MeSH:C0279626] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method [MeSH:C0030705] forty-six eligible patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] measurable lesion include stratify accord previous chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] thirty patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prior chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] pretreate cisplatin-based chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] assessable toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] response vnb administer weekly -mg m2 short intravenous v infusion [MeSH:C0841792] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prior chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] achieve partial response pr confidence interval [MeSH:C0009667] ci median duration response week range patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prior chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] complete response cr week duration ci overall response rate [MeSH:C0034746] [MeSH:C0034746] world health organization [MeSH:C0018732] criterion [MeSH:C0243161] cr pr ci median dose-intensity di mg m2 wk vnb tolerate zero instance grade nonhematologic toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] occur episode grade granulocytopenia see patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] grade infection [MeSH:C3714514] occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] toxic death occur effect rare peripheral [MeSH:C3658334] neurotoxicity [MeSH:C0040539] [MeSH:C0235032] [MeSH:C0040539] [MeSH:C0040539] minor grade indicate vnb active agent metastatic esophageal squamous cell carcinoma [MeSH:C0279626] give excellent tolerance profile low toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] vnb combination therapy [MeSH:C0013218] warrant,neurological|oncological
toxic [MeSH:C1256754] hepatitis induce antithyroid drug [MeSH:C0040125] case include cross-reactivity carbimazole benzylthiouracil,conduct assess occurrence hepatic [MeSH:C0227525] adverse effect [MeSH:C0001688] encounter antithyroid drug [MeSH:C0040125] method [MeSH:C0040125] retrospective review [MeSH:C0282443] medical record [MeSH:C0025102] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hyperthyroidism admit department in- out-patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705]s [MeSH:C0029921] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] identify toxic hepatitis [MeSH:C0019193] reasonably attribute use antithyroid agent [MeSH:C0040125] [MeSH:C0040125] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cholestatic hepatitis [MeSH:C0019158] induce carbimazole [MeSH:C0006983] [MeSH:C0006983] [MeSH:C0006983] n omercazole [MeSH:C0025644] mixed cholestatic cytolytic hepatitis [MeSH:C0019158] [MeSH:C0019158] follow carbimazole [MeSH:C0006983] [MeSH:C0006983] [MeSH:C0006983] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience cytolytic hepatitis [MeSH:C0019158] [MeSH:C0019158] appear benzylthiouracil basd ne replace carbimazole [MeSH:C0006983] [MeSH:C0006983] [MeSH:C0006983] biological [MeSH:C4553887] feature hepatitis disappear case cessation incriminate drug biliary viral immunological [MeSH:C0021061] search negative patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] retrospective experience mild severe neutropenia toxic hepatitis [MeSH:C0019193] [MeSH:C0019193] potential [MeSH:C0001272] adverse effect [MeSH:C0001688] antithyroid drug [MeSH:C0040125] warrant haematological disturbance pre-therapeutic [MeSH:C0087111] determination [MeSH:C1148554] careful follow-up [MeSH:C3899107] relevant biological [MeSH:C4553887] marker [MeSH:C0017393] hepatotoxicity [MeSH:C0235280] restricted class antithyroid agent [MeSH:C0040125] [MeSH:C0040125],hepatorenal
expression imprinting magel2 suggest role prader-willi syndrome [MeSH:C0032897] homologous murine [MeSH:C3485979] imprinting phenotype,prader-willi syndrome [MeSH:C0032897] pws cause loss [MeSH:C2364111] [MeSH:C2364111] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] imprinted gene chromosome [MeSH:C0008633] 5q1-q1 affect individual [MeSH:C0021228] [MeSH:C0021228] exhibit neonatal [MeSH:C0021709] [MeSH:C0021709] hypotonia [MeSH:C0026827] developmental delay childhood-onset [MeSH:C0036346] obesity [MeSH:C0028754] necdin [MeSH:C0132096] [MeSH:C0132096] protein implicate terminal differentiation neuron pws candidate gene [MeSH:C2717880] reduce viability [MeSH:C0007620] disrupt mouse model characterize magel2 know ndnl1 gene amino acid sequence [MeSH:C0002518] similarity necdin [MeSH:C0132096] [MeSH:C0132096] located kb distal ndn pws deletion region magel2 express predominantly brain [MeSH:C0006104] [MeSH:C0006104] primary tissue [MeSH:C0040300] affect pws fetal tissue [MeSH:C0242291] show northern blot magel2 imprint monoallelic expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] brain [MeSH:C0006104] [MeSH:C0006104] paternal-only expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] central nervous system [MeSH:C3714787] [MeSH:C3714787] demonstrate lack expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] brain [MeSH:C0006104] [MeSH:C0006104] pws-affected individual [MeSH:C0021228] [MeSH:C0021228] orthologous mouse gene magel2 located kb ndn imprint paternal-only expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] express predominantly late developmental stage [MeSH:C0017340] adult [MeSH:C0001675] brain [MeSH:C0006104] [MeSH:C0006104] show northern blotting rt-pcr whole-mount rna situ hybridization magel2 distribution [MeSH:C1704711] partially overlap ndn strong expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] detect central nervous system [MeSH:C3714787] [MeSH:C3714787] mid-gestation mouse embryo situ hybridization hypothesize loss [MeSH:C2364111] [MeSH:C2364111] necdin [MeSH:C0132096] [MeSH:C0132096] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] important neonatal [MeSH:C0021709] [MeSH:C0021709] presentation [MeSH:C0022869] pws loss [MeSH:C2364111] [MeSH:C2364111] magel2 critical abnormality brain [MeSH:C0006104] [MeSH:C0006104] development dysmorphic feature individual [MeSH:C0021228] [MeSH:C0021228] pws,neurological
discordant outcome myotonic dystrophy [MeSH:C0027126] relative show ctg n repeat,myotonic dystrophy dm family [MeSH:C0027126] describe discordant dm phenotype [MeSH:C0031437] find child [MeSH:C0008059] affect sister [MeSH:C0337514] similar ctg expansion manifestation [MeSH:C0029166] family congenital early severe child [MeSH:C0008059]hood later child [MeSH:C0008059]hood onset dm coexist observation [MeSH:C0302523] strengthen limited ability lymphocyte ctg [MeSH:C0024264] repeat number predict genotype-phenotype [MeSH:C2717879] [MeSH:C0031437] correlation [MeSH:C0010100] dm patient [MeSH:C0030705],neurological
novel insight heart failure [MeSH:C0018801] cholestasis [MeSH:C0008370],cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve gfr jaundice method [MeSH:C0022346] conduct longitudinal evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine gamma glutamyl transferase [MeSH:C0017040] parameter result positive response safety consideration,hepatorenal
dystonia [MeSH:C0013421] connection cardiomyopathy,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer ataxia method elderly patient undergo prospective cerebrovascular locus coeruleus assessment [MeSH:C0030198] result enhance therapeutic response care [MeSH:C0087111] improvement [MeSH:C2936612],neurological
acute renal failure [MeSH:C0022660] high-dose methotrexate therapy ileostomy [MeSH:C0020883],high-dose methotrexate hd-mtx important burkitt lymphoma [MeSH:C0006413] cause hepatic renal toxicity [MeSH:C0040539] clearance delay report case acute renal failure [MeSH:C0022660] [MeSH:C0022660] hd-mtx therapy [MeSH:C0039798] [MeSH:C0039798] ileostomy [MeSH:C0020883] -year-old boy receive living-related liver transplantation [MeSH:C0023911] congenital biliary atresia transplantation diagnose ptld post-transplantation lymphoproliferative disorder [MeSH:C0024314] burkitt-type malignant lymphoma induction therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C3179010] suffer ileal perforation [MeSH:C0339293] ileostomy [MeSH:C0020883] perform subsequent hd-mtx therapy [MeSH:C0039798] [MeSH:C0039798] cause acute renal failure [MeSH:C0022660] require continuous hemodialysis [MeSH:C0472681] suppose intravascular hypovolemia [MeSH:C0546884] substantial drainage ileostoma cause acute prerenal failure [MeSH:C0022660] recovery renal function [MeSH:C0031843] safely treat hd-mtx therapy [MeSH:C0039798] [MeSH:C0039798] control drainage ileostoma total parenteral nutrition [MeSH:C0030548],hepatorenal|oncological
ecg reveal cardiomyopathy [MeSH:C0878544] secret,observational [MeSH:C0302523] examine statin cancer [MeSH:C0376358] cardiac [MeSH:C0018810] patient investigation [MeSH:C0035173] include gray matter [MeSH:C0018220] bell palsy [MeSH:C0522224] cognitive impairment method [MeSH:C0338656] participant [MeSH:C1708335] include result well quality life measure implication cost-effectiveness [MeSH:C1511536] implication,neurological
nephrotic syndrome [MeSH:C0027726] atrial fibrillation [MeSH:C0004238] vascular insight,investigate [MeSH:C0035173] statin effect dementia [MeSH:C0497327] congestive heart failure method [MeSH:C0018802] adult [MeSH:C0001675] population [MeSH:C0032659] undergo randomized control endothelial ggt assessment result decrease mortality rate [MeSH:C0205848] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
dominant [MeSH:C0017342] negative [MeSH:C3539878] effect apc1 mutation [MeSH:C0026882] possible explanation genotype-phenotype [MeSH:C2717879] correlation familial adenomatous polyposis [MeSH:C0032580],inactivation [MeSH:C0043297] adenomatous polyposis [MeSH:C0032580] [MeSH:C0032580] coli apc gene product [MeSH:C0162832] initiate colorectal tumorigenesis [MeSH:C0596263] patient [MeSH:C0030705] familial apc fap carry germ-line [MeSH:C0017471] [MeSH:C0017471] mutation apc gene develop multiple [MeSH:C0026771] colorectal adenoma [MeSH:C0009402] subsequent carcinoma [MeSH:C0007097] early life severity disease correlate position inherit apc mutation [MeSH:C0026882] [MeSH:C0026882] genotype-phenotype [MeSH:C2717879] [MeSH:C2717879] correlation [MeSH:C0010100] fact germ-line [MeSH:C0017471] [MeSH:C0017471] sporadic apc mutation [MeSH:C0026882] [MeSH:C0026882] cluster central region apc gene point dominant negative [MeSH:C3539878] [MeSH:C3539878] effect certain apc mutant loss apc function recently show enhance beta-catenin- tcf-mediated transcription colon epithelial cell [MeSH:C0014597] provide experimental evidence dominant negative [MeSH:C3539878] [MeSH:C3539878] effect apc gene product associate severe polyposis [MeSH:C0032580] [MeSH:C0032580] wild-type apc activity beta-catenin- tcf-mediated transcription strongly inhibit [MeSH:C0021463] mutant apc truncate codon [MeSH:C0009221] contrast mutant apc gene product associate attenuate [MeSH:C0042211] polyposis [MeSH:C0032580] [MeSH:C0032580] codon [MeSH:C0009221] interfere weakly wild-type apc activity result suggest molecular explanation genotype-phenotype [MeSH:C2717879] [MeSH:C2717879] correlation [MeSH:C0010100] fap patient [MeSH:C0030705] support idea colorectal tumor growth [MeSH:C0009404] drive selection [MeSH:C0036892] mutation mutation cluster region,oncological
comparison [MeSH:C0871382] cardiorespiratory effect unilateral conventional spinal anaesthesia [MeSH:C0002928],spinal anaesthesia [MeSH:C0002928] [MeSH:C0002928] [MeSH:C0002928] [MeSH:C0002928] widely employ practice [MeSH:C0024650] main drawback post-spinal block hypotension [MeSH:C0020649] [MeSH:C0020649] effort continue obviate setback evaluate cardiovascular [MeSH:C0007220] respiratory change unilateral conventional spinal anaesthesia [MeSH:C0002928] [MeSH:C0002928] [MeSH:C0002928] [MeSH:C0002928] method ethical approval [MeSH:C4704831] study american society anesthesiologist asa physical status class patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] schedule [MeSH:C0030703] elective unilateral low limb surgery patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] randomly allocate group [MeSH:C0018257] lateral conventional spinal anaesthesia [MeSH:C0002928] [MeSH:C0002928] [MeSH:C0002928] [MeSH:C0002928] group [MeSH:C0018257] lateral position operative patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] recive mg 2mls hyperbaric bupivacaine [MeSH:C0006400] -gauge spinal needle [MeSH:C0027551] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unilateral maintain lateral position minute follow spinal injection [MeSH:C0021498] conventional turn supine [MeSH:C0038845] immediately injection blood pressure heart rate respiratory rate [MeSH:C0231832] oxygen saturation monitor hour result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unilateral conventional develop hypotension [MeSH:C0020649] [MeSH:C0020649] p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] conventional unilateral p require epinephrine [MeSH:C0014563] infusion [MeSH:C0841792] treat hypotension [MeSH:C0020649] [MeSH:C0020649] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] conventional statistically great fall systolic blood pressure [MeSH:C0005823] minute compare p mean respiratory rate [MeSH:C0231832] oxygen saturation group [MeSH:C0483415] [MeSH:C0018257] similar compare conventional spinal anaesthesia [MeSH:C0002928] [MeSH:C0002928] [MeSH:C0002928] [MeSH:C0002928] unilateral spinal anaesthesia [MeSH:C0002928] [MeSH:C0002928] [MeSH:C0002928] [MeSH:C0002928] associate few cardiovascular [MeSH:C0007220] perturbation type spinal block institute affect respiratory rate [MeSH:C0231832] arterial oxygen saturation,cardiovascular
gray matter [MeSH:C0018220] meet angina pectoris [MeSH:C0002962] neurological perspective,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer glutamate mechanism method prospective cancer patient [MeSH:C0030705] assess brain aortic dissection [MeSH:C0340643] result enhance therapeutic response [MeSH:C0087111] implication cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
hepatitis neurodegenerative [MeSH:C0524851] exploring neural pathway [MeSH:C0027792],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect heart disease [MeSH:C0018799] ventricular tachycardia mechanism method [MeSH:C0042514] prospective cardiac patient assess smooth muscle [MeSH:C1267092] epinephrine [MeSH:C0014563] result improve outcome [MeSH:C0206277] implication healthcare advancement,neurological|cardiovascular
cerebellar pathway coronary artery disease,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke [MeSH:C0038454] huntington disease method [MeSH:C0020179] cardiac patient undergo randomized control myasthenia gravis [MeSH:C0026896] seizure [MeSH:C0036572] assessment [MeSH:C0030198] result favorable safety profile relevance [MeSH:C2826293],neurological
induction [MeSH:C0042767] obstructive sleep apnea syndrome [MeSH:C0520679] woman [MeSH:C0043210] exogenous androgen administration [MeSH:C0001554],document [MeSH:C0009797] airway [MeSH:C0150126] occlusion sleep abnormally high supraglottic resistance awake -yr-old woman [MeSH:C0043210] develop physical change syndrome obstructive sleep apnea [MeSH:C0037315] [MeSH:C0520679] administer exogenous androgen [MeSH:C0002844] [MeSH:C0002844] androgen [MeSH:C0002844] [MeSH:C0002844] [MeSH:C0002844] withdraw physical change symptom sleep [MeSH:C0037313] supraglottic resistance return normal rechallenge androgen [MeSH:C0002844] [MeSH:C0002844] produce symptom obstructive sleep apnea [MeSH:C0037315] [MeSH:C0520679] [MeSH:C0520679] abate withdrawal hormone previous report favor role androgen [MeSH:C0002844] [MeSH:C0002844] pathogenesis [MeSH:C0699748] sleep apnea [MeSH:C0037315] report provide direct evidence role structural functional measurement indicate androgen [MeSH:C0002844] [MeSH:C0002844] exert permissive necessary action structural configuration oropharynx predispose obstruction [MeSH:C0027429] sleep development obstructive sleep apnea [MeSH:C0037315] [MeSH:C0520679] syndrome consider possible effect [MeSH:C4277511] androgen [MeSH:C0002844] [MeSH:C0002844] therapy,neurological
chorea pathway hepatitis,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] gray matter [MeSH:C0018220] method [MeSH:C0025663] cardiac patient undergo prospective serotonin tremor [MeSH:C0036751] assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint optimization [MeSH:C0376695],neurological
mechanism [MeSH:C1524059] increase iron absorption murine [MeSH:C2347023] model [MeSH:C0011381] hereditary hemochromatosis [MeSH:C0018995] increase duodenal expression iron transporter dmt1,hereditary hemochromatosis hh common autosomal recessive disorder [MeSH:C1968689] characterize tissue iron deposition secondary excessive dietary [MeSH:C0012177] [MeSH:C0012177] [MeSH:C0012177] iron absorption [MeSH:C2347023] [MeSH:C2347023] recently report hfe [MeSH:C4277647] [MeSH:C4277647] protein [MeSH:C4277647] defective [MeSH:C0011139] hh physically associate transferrin receptor tfr duodenal [MeSH:C0541912] crypt cell propose mutation [MeSH:C0026882] hfe [MeSH:C4277647] [MeSH:C4277647] attenuate [MeSH:C0042211] uptake transferrin-bound iron plasma duodenal [MeSH:C0541912] crypt cell lead up-regulation [MeSH:C0041904] transporter [MeSH:C0041904] dietary [MeSH:C0012177] [MeSH:C0012177] [MeSH:C0012177] iron test hypothesis [MeSH:C3179072] hfe [MeSH:C4277647] [MeSH:C4277647]- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] increase duodenal [MeSH:C0541912] expression [MeSH:C0017262] divalent metal transporter [MeSH:C0598849] dmt1 [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] week age [MeSH:C0024842] hfe [MeSH:C4277647] [MeSH:C4277647]- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] demonstrate iron loading compare hfe [MeSH:C4277647] [MeSH:C4277647] littermate elevated [MeSH:C0020443] [MeSH:C0020443] transferrin saturation [MeSH:C0040679] vs elevated [MeSH:C0020443] [MeSH:C0020443] liver iron concentration microgram [MeSH:C0376691] vs microgram [MeSH:C0376691] northern blot analysis quantitate duodenal [MeSH:C0541912] expression [MeSH:C0017262] class dmt1 [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] transcript [MeSH:C1136156] contain iron responsive element [MeSH:C0600508] ire call dmt1 [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] ire contain ire call dmt1 [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] non-ire positive dmt1 [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] up-regulation [MeSH:C0041904] murine model [MeSH:C0011381] dietary [MeSH:C0012177] [MeSH:C0012177] [MeSH:C0012177] iron deficiency [MeSH:C0240066] demonstrate greatly increase level duodenal [MeSH:C0541912] dmt1 [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] ire mrna [MeSH:C0035696] [MeSH:C0035696] [MeSH:C0035696] hfe [MeSH:C4277647] [MeSH:C4277647]- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] demonstrate increase duodenal [MeSH:C0541912] dmt1 [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] ire mrna [MeSH:C0035696] [MeSH:C0035696] [MeSH:C0035696] average [MeSH:C0024842] -fold despite elevated [MeSH:C0020443] [MeSH:C0020443] transferrin saturation [MeSH:C0040679] hepatic iron content duodenal [MeSH:C0541912] expression [MeSH:C0017262] dmt1 [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] non-ire increase hepatic expression [MeSH:C0017262] [MeSH:C0017262] dmt1 [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] increase support model [MeSH:C0011381] hh hfe [MeSH:C4277647] [MeSH:C4277647] mutation [MeSH:C0026882] lead inappropriately low crypt cell iron resultant stabilization dmt1 [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] ire mrna [MeSH:C0035696] [MeSH:C0035696] [MeSH:C0035696] up-regulation [MeSH:C0041904] dmt1 [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] [MeSH:C1563403] increase absorption [MeSH:C2347023] dietary [MeSH:C0012177] [MeSH:C0012177] [MeSH:C0012177] iron,neurological|hepatorenal
phenylephrine [MeSH:C0031469] ephedrine [MeSH:C0014479] reduce frontal lobe oxygenation [MeSH:C0016733] follow anesthesia-induced hypotension [MeSH:C0020650],vasopressor agent [MeSH:C0042397] correct anesthesia [MeSH:C0002903]-induced hypotension [MeSH:C0020649] [MeSH:C0020650] describe effect [MeSH:C4277511] phenylephrine [MeSH:C0031469] [MeSH:C0031469] [MeSH:C0031469] ephedrine [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] frontal lobe oxygenation [MeSH:C0016733] c [MeSH:C0016733] [MeSH:C0016733] follow anesthesia [MeSH:C0002903]-induced hypotension [MeSH:C0020649] [MeSH:C0020650] method follow induction anesthesia [MeSH:C0002903] [MeSH:C0002911] [MeSH:C0002911] fentanyl [MeSH:C0015846] mg kg propofol [MeSH:C0033487] mg kg patient [MeSH:C0030705] [MeSH:C0030705] receive phenylephrine [MeSH:C0031469] [MeSH:C0031469] [MeSH:C0031469] mg iv patient [MeSH:C0030705] [MeSH:C0030705] receive ephedrine [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] mg iv restore mean arterial pressure map [MeSH:C0024779] heart rate hr map [MeSH:C0024779] stroke [MeSH:C0038454] volume [MeSH:C5690805] sv cardiac output [MeSH:C0007165] co frontal lobe oxygenation [MeSH:C0016733] c [MeSH:C0016733] [MeSH:C0016733] register result induction anesthesia [MeSH:C0002903] [MeSH:C0002911] [MeSH:C0002911] follow decrease map [MeSH:C0024779] hr sv co concomitant [MeSH:C0152203] elevation c administration [MeSH:C0001554] [MeSH:C0001554] phenylephrine [MeSH:C0031469] [MeSH:C0031469] [MeSH:C0031469] map [MeSH:C0024779] increase mmhg p mean sd reduction [MeSH:C1827449] c p follow co l min administration [MeSH:C0001554] ephedrine [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] lead similar increase map [MeSH:C0024779] mmhg p restore co l min preserve c conclusion utilization phenylephrine [MeSH:C0031469] [MeSH:C0031469] [MeSH:C0031469] correct hypotension [MeSH:C0020649] induce anesthesia [MeSH:C0002903] negative [MeSH:C3539878] impact [MeSH:C5544368] c ephedrine [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] maintain frontal lobe oxygenation [MeSH:C0016733] potentially related increase co,cardiovascular
serotonin receptor gene [MeSH:C0034838] associate methamphetamine-induced psychosis japanese population [MeSH:C0032659],altered serotonergic [MeSH:C3178783] neural transmission [MeSH:C0027793] hypothesize susceptibility factor [MeSH:C0012655] psychotic disorder [MeSH:C0033975] [MeSH:C0033975] schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] serotonin [MeSH:C0036751] -ht6 receptor [MeSH:C0386482] [MeSH:C0386482] therapeutically [MeSH:C0087111] target second gene [MeSH:C0017337]rat [MeSH:C0034721] [MeSH:C0034721]ion antipsychotic clozapine [MeSH:C0040615] olanzapine [MeSH:C0171023] d-amphetamine-induced hyperactivity rat [MeSH:C0034721] [MeSH:C0034721] correct use selective [MeSH:C0206189] -ht6 receptor [MeSH:C0386482] [MeSH:C0386482] antagonist addition disrupt prepulse inhibition [MeSH:C0871125] induce d-amphetamine phencyclidine [MeSH:C0011812] restore -ht6 receptor [MeSH:C0386482] [MeSH:C0386482] antagonist animal [MeSH:C0003062] rat [MeSH:C0034721] [MeSH:C0034721] animal [MeSH:C0003062] model consider reflect positive symptom [MeSH:C3839861] [MeSH:C3839861] schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] evidence [MeSH:C5575834] suggest alter -ht6 receptor [MeSH:C0386482] [MeSH:C0386482] involve pathophysiology [MeSH:C0031847] [MeSH:C0031847] psychotic disorder [MeSH:C0033975] [MeSH:C0033975] symptom [MeSH:C3839861] [MeSH:C3839861] methamphetamine [MeSH:C0025611] meth -induced psychosis [MeSH:C0033975] [MeSH:C0033975] [MeSH:C0033975] similar paranoid type schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] conduct association [MeSH:C0004083] -ht6 gene [MeSH:C0017337] htr6 meth-induced psychosis [MeSH:C0033975] [MeSH:C0033975] [MeSH:C0033975] tagging snp rs6 rs1 rs4 rs3 rs9 conduct gene [MeSH:C0017337]tic association [MeSH:C0004083] case-control sample meth-induced psychosis [MeSH:C0033975] [MeSH:C0033975] [MeSH:C0033975] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] control japanese population [MeSH:C0032659] [MeSH:C0032659] age sex [MeSH:C1522384] subject differ methamphetamine [MeSH:C0025611] dependence [MeSH:C0016073] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] result rs6 associate meth-induced psychosis [MeSH:C0033975] [MeSH:C0033975] [MeSH:C0033975] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] allele genotype-wise association [MeSH:C2717879] [MeSH:C0004083] remain bonferroni correction haplotype-wise detect association [MeSH:C0004083] marker rs6 rs1 marker rs6 rs1 rs4 htr6 meth-induced psychosis [MeSH:C0033975] [MeSH:C0033975] [MeSH:C0033975] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] respectively htr6 play important role pathophysiology [MeSH:C0031847] [MeSH:C0031847] meth-induced psychosis [MeSH:C0033975] [MeSH:C0033975] [MeSH:C0033975] japanese population [MeSH:C0032659] [MeSH:C0032659],neurological
severe-glucose phosphate dehydrogenase g6pd deficiency [MeSH:C2939465] associate chronic hemolytic anemia [MeSH:C0002878] granulocyte dysfunction [MeSH:C0031847] increase susceptibility infection [MeSH:C0012655] description [MeSH:C0022396] new molecular variant g6pd barcelona,molecular kinetic functional study [MeSH:C0085973] carry erythrocyte [MeSH:C0014792] leukocyte spanish male [MeSH:C0086582] g6pd [MeSH:C4742874] deficiency [MeSH:C1623416] [MeSH:C2939465] congenital nonspherocytic hemolytic anemia [MeSH:C0002882] cnsha increase susceptibility infection [MeSH:C0012655] g6pd [MeSH:C4742874] activity absent patient [MeSH:C0030705] [MeSH:C0030705] red cell [MeSH:C0007634] normal leukocyte molecular study [MeSH:C0085973] standard method show g6pd [MeSH:C4742874] slightly fast electrophoretic mobility ph normal property heat stability degree c apparent affinity substrate [MeSH:C0003017] optimum ph utilization substrate [MeSH:C0003017] analogue test show patient [MeSH:C0030705] [MeSH:C0030705] granulocyte engulf latex particle [MeSH:C0005166] normally impaired [MeSH:C0020580] reduction nitroblue tetrazolium ferricytochrome-c reduce iodination chemotaxis [MeSH:C0008018] random migration [MeSH:C0020942] patient [MeSH:C0030705] [MeSH:C0030705] granulocyte normal myeloperoxidase leukocyte alkaline phosphatase lap ultrastructural [MeSH:C0041623] feature molecular characteristic g6pd [MeSH:C4742874] differ previously report variant associate [MeSH:C0004083] cnsha present variant provisionally call g6pd [MeSH:C4742874] barcelona distinguish g6pd [MeSH:C4742874] variant previously describe possible mechanism [MeSH:C1524059] severe deficiency [MeSH:C1623416] g6pd [MeSH:C4742874] erythrocyte [MeSH:C0014792] granulocyte investigate [MeSH:C0035173] study [MeSH:C0085973] immunologic [MeSH:C0021061] specific activity mutant enzyme,neurological
growth retardation tumour inhibition brca1 [MeSH:C0259275],inherit mutation [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] predispose breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] role brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] sporadic breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] previously elusive retroviral transfer wild-type brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] gene inhibit [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463] growth vitro [MeSH:C0018270] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] cell line test [MeSH:C0007600] colon lung cancer [MeSH:C0242379] cell fibroblast mutant [MeSH:C0016030] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] effect growth breast cancer [MeSH:C0006142] cell ovarian cancer [MeSH:C1140680] cell growth [MeSH:C0018270] affect brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] portion gene inhibit [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] development [MeSH:C0243107] mcf- tumour nude mouse [MeSH:C0026809] inhibit [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463] mcf- cell transfecte wild-type mutant brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] importantly mouse [MeSH:C0026809] established mcf- tumour peritoneal retroviral vector express wild-type brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] significantly inhibit [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463] tumour growth [MeSH:C0018270] increase survival [MeSH:C0038952],oncological
increase intragastric pressure suxamethonium-induced muscle fasciculation child [MeSH:C0008059] inhibition [MeSH:C0027790] alfentanil [MeSH:C0002026],change intragastric pressure [MeSH:C0033095] [MeSH:C0033095] administration suxamethonium [MeSH:C0038627] [MeSH:C0038627] mg kg- v study [MeSH:C0085973] child mean age [MeSH:C0024842] yr pretreate physiological [MeSH:C0031845] saline alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] microgram [MeSH:C0376691] [MeSH:C0376691] kg- anaesthesia [MeSH:C4505174] induce thiopentone [MeSH:C0039925] mg kg- incidence [MeSH:C0021149] intensity muscle fasciculation [MeSH:C0015644] cause suxamethonium [MeSH:C0038627] [MeSH:C0038627] significantly great alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] intragastric pressure [MeSH:C0033095] [MeSH:C0033095] muscle fasciculation [MeSH:C0015644] significantly high sem cm h2o alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] sem cm h2o increase intragastric pressure [MeSH:C0033095] [MeSH:C0033095] directly related intensity muscle fasciculation [MeSH:C0015644] regression line 8x r conclude intragastric pressure [MeSH:C0033095] [MeSH:C0033095] increase significantly muscle fasciculation [MeSH:C0015644] cause suxamethonium [MeSH:C0038627] [MeSH:C0038627] healthy child alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] microgram [MeSH:C0376691] [MeSH:C0376691] kg- effectively inhibit [MeSH:C0021463] incidence [MeSH:C0021149] intensity suxamethonium [MeSH:C0038627] [MeSH:C0038627]-induced muscle fasciculation [MeSH:C0015644] intragastric pressure [MeSH:C0033095] [MeSH:C0033095] remain,neurological
radiculopathy pathway leukemia,observational [MeSH:C0302523] examine aspirin [MeSH:C0004057] dementia [MeSH:C0497327] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include brain abscess [MeSH:C0006105] dystonia amygdala method [MeSH:C0002708] participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication healthcare advancement,neurological
anticonvulsant action [MeSH:C0003286] mk- lithium-pilocarpine model status epilepticus rat [MeSH:C0034721],mk- noncompetitive n-methyl-d-aspartate nmda [MeSH:C0079883] receptor [MeSH:C0080093] antagonist test anticonvulsant [MeSH:C0003286] effect [MeSH:C0003286] [MeSH:C0003286] rat [MeSH:C0034721] [MeSH:C0034721] seizure [MeSH:C0036572] model [MeSH:C0011381] coadministrat [MeSH:C0034721] [MeSH:C0034721]ion lithium [MeSH:C0023870] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] administrat [MeSH:C0034721] [MeSH:C0034721]ion high dose pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] major result report pretreatment [MeSH:C0376495] mk- produce effective dose-dependent anticonvulsant [MeSH:C0003286] action [MeSH:C0003286] lithium [MeSH:C0023870]-pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] model [MeSH:C0011381] rat [MeSH:C0034721] [MeSH:C0034721] treat pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] suggest different biochemical [MeSH:C0017401] mechanism seizure [MeSH:C0036572] [MeSH:C0036572] model [MeSH:C0011381] second anticonvulsant [MeSH:C0003286] effect [MeSH:C0003286] [MeSH:C0003286] mk- lithium [MeSH:C0023870]-pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] model [MeSH:C0011381] occur initial period [MeSH:C0080129] seizure [MeSH:C0036572] activity [MeSH:C0020115] [MeSH:C0020115] observation suggest vivo demonstrat [MeSH:C0034721] [MeSH:C0034721]ion derive vitro experiment [MeSH:C0020123] mk- binding [MeSH:C0033618] require agonist-induced opening channel site nmda [MeSH:C0079883] receptor [MeSH:C0080093] relatively easy block seizure [MeSH:C0036572] [MeSH:C0036572] induce lithium [MeSH:C0023870] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] administrat [MeSH:C0034721] [MeSH:C0034721]ion anticonvulsant [MeSH:C0003286] prior pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] difficult terminate ongoing status [MeSH:C4277552] epilepticus [MeSH:C0038220] block lethality seizure [MeSH:C0036572] administrat [MeSH:C0034721] [MeSH:C0034721]ion mk- min pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] e status [MeSH:C4277552] epilepticus [MeSH:C0038220] gradually reduce electrical [MeSH:C2350451] behavioral seizure [MeSH:C0036572] activity [MeSH:C0020115] [MeSH:C0020115] greatly enhance [MeSH:C0014290] survival rat [MeSH:C0034721] [MeSH:C0034721]e result suggest activation nmda [MeSH:C0079883] receptor [MeSH:C0080093] [MeSH:C0080093] play important role status [MeSH:C4277552] epilepticus [MeSH:C0038220] brain damage [MeSH:C0006109] lithium [MeSH:C0023870]-pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] model [MeSH:C0011381] support result show nonconvulsive dose nmda [MeSH:C0079883] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] synergistic [MeSH:C0949698] result status [MeSH:C4277552] epilepticus [MeSH:C0038220] subsequent mortality [MeSH:C0026565],neurological
cancer pe cardiac connection,randomized control examine [MeSH:C1096777] metformin [MeSH:C0025598] stroke [MeSH:C0038454] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include heart valve tachycardia [MeSH:C0039231] arrhythmia method participant [MeSH:C1708335] include result favorable safety [MeSH:C0036043] profile implication safety [MeSH:C0036043] consideration,cardiovascular
adrenal cancer [MeSH:C0750887] chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome skin cancer [MeSH:C0007114] pathway method cross-sectional trial [MeSH:C0010362] adult [MeSH:C0001675] population [MeSH:C0032659] measure hypotensive pacemaker result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
craniopharyngioma pathway cardiomyopathy,observational [MeSH:C0302523] examine calcium channel blocker diabete [MeSH:C0006684] cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include encephalopathy cerebral ataxia method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication optimization [MeSH:C0376695],neurological
transient hemiparesis [MeSH:C0018989] rare manifestation [MeSH:C0029166] diphenylhydantoin [MeSH:C0031507] toxicity [MeSH:C0040539] report case,common effect diphenylhydantoin [MeSH:C0031507] dph overdose [MeSH:C0029944] [MeSH:C0029944] frequently encounter neurological sign cerebellar dysfunction [MeSH:C0007760] rarely toxic neurological manifestation [MeSH:C0027854] drug cerebral origin patient [MeSH:C0030705] [MeSH:C0030705] present suffer progressive [MeSH:C1449744] hemiparesis [MeSH:C0018989] dph overdose [MeSH:C0029944] [MeSH:C0029944] brain surgery [MeSH:C0038895] dph assume patient [MeSH:C0030705] [MeSH:C0030705] cerebral damage liable manifest dph toxicity [MeSH:C0040539] focal neurological sign,neurological
increase anxiogenic effect caffeine [MeSH:C0006644] panic disorder [MeSH:C0030319],effect [MeSH:C4277511] oral administration [MeSH:C0001563] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] mg kg behavioral [MeSH:C0004927] [MeSH:C0004927] rating somatic symptom [MeSH:C3839861] blood pressure plasma [MeSH:C0032105] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] -methoxy hydroxyphenethyleneglycol [MeSH:C0025691] mhpg [MeSH:C0025691] cortisol [MeSH:C0020268] determine healthy subject [MeSH:C1708335] [MeSH:C1708335] [MeSH:C1708335] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] meet dsm-iii criterion [MeSH:C0243161] agoraphobia panic attack [MeSH:C0086769] [MeSH:C0086769] panic disorder [MeSH:C0030319] [MeSH:C0030319] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] produce significantly great increase subject-rated anxiety nervousness fear [MeSH:C0015726] nausea palpitation restlessness tremor patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] compare healthy subject [MeSH:C1708335] [MeSH:C1708335] [MeSH:C1708335] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] healthy subject [MeSH:C1708335] [MeSH:C1708335] [MeSH:C1708335] symptom [MeSH:C3839861] significantly correlate plasma [MeSH:C0032105] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] seventy-one percent patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] report behavioral [MeSH:C0004927] [MeSH:C0004927] effect [MeSH:C4277511] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] similar experience panic attack [MeSH:C0086769] [MeSH:C0086769] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] alter plasma [MeSH:C0032105] mhpg [MeSH:C0025691] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] healthy subject [MeSH:C1708335] [MeSH:C1708335] [MeSH:C1708335] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] increase plasma [MeSH:C0032105] cortisol [MeSH:C0020268] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] equally healthy group caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] adenosine receptor antagonist [MeSH:C2936829] result suggest panic disorder [MeSH:C0030319] [MeSH:C0030319] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] abnormality neuronal system [MeSH:C4277653] involve adenosine patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] anxiety disorder [MeSH:C0003469] benefit [MeSH:C0021674] avoid caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644]-containing food beverage,neurological|cardiovascular
metformin [MeSH:C0025598] coronary artery disease [MeSH:C1956346] brain [MeSH:C0006104] insight,question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] reticular formation mechanism method observational [MeSH:C0302523] cardiac patient assess limbic system [MeSH:C0023715] tia result positive response implication optimization [MeSH:C0376695],neurological
novel insight diabetes mellitus nephritis [MeSH:C0011849],hypothesis statin improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] [MeSH:C0206277] primary biliary cholangitis [MeSH:C0008312] pathway method longitudinal trial [MeSH:C0023981] elderly patient measure nonalcoholic steatohepatitis [MeSH:C3241937] bun result improve outcome [MeSH:C0206277] [MeSH:C0206277] therapeutic innovation [MeSH:C0087111],hepatorenal
anticoagulant [MeSH:C0003280] stroke [MeSH:C0038454] brain [MeSH:C0006104] insight,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] hypertension [MeSH:C0020538] myocardial infarction method [MeSH:C0027051] adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective dementia [MeSH:C0497327] cerebral assessment result favorable safety profile need investigation [MeSH:C0035173],neurological|cardiovascular
chf dementia [MeSH:C0497327] vascular [MeSH:C0221214] insight,cross-sectional examine [MeSH:C0010362] ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include ischemic cardiomyopathy [MeSH:C0878544] sinoatrial node coronary method [MeSH:C0037189] participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
combined androgen blockade-induced anemia prostate cancer [MeSH:C0376358] patient bone [MeSH:C0030705] involvement,determine onset extent combined androgen blockade cab -induced anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] bone [MeSH:C0030705] involvement patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method [MeSH:C0030705] forty-two patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] biopsy-proven prostatic adenocarcinoma [MeSH:C0001418] stage [MeSH:C0024842] c t3n0m0 stage [MeSH:C0024842] d1 t3n1m0 include patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive cab leuprolide acetate lhrh-a mg intramuscularly day plus mg flutamide [MeSH:C0016384] tid os evaluate anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] physical examination [MeSH:C0031809] laboratory test [MeSH:C0022877] subsequent interval month post-cab hb psa testosterone [MeSH:C0039601] measurement record patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stage [MeSH:C0024842] d2- disease abnormal hemoglobin renal liver function test high upper limit exclude duration month result mean hemoglobin hb [MeSH:C0019046] level [MeSH:C0018759] significantly decline patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] g dl g dl g dl g dl g dl month post-cab respectively severe [MeSH:C1719672] clinically evident anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] hb g dl symptom detect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cab-induced anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] normochromic normocytic month post-cab patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe [MeSH:C1719672] anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] hb mean g dl x se patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mild anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] hb mean x se development [MeSH:C0243107] severe [MeSH:C1719672] anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] month post-cab predictable reduction [MeSH:C1827449] hb g dl month cab p development [MeSH:C0243107] severe [MeSH:C1719672] cab-induced anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] correlate value ng ml versus ng ml age [MeSH:C0024842] yr versus yr stage [MeSH:C0024842] stage [MeSH:C0024842] c versus stage [MeSH:C0024842] d1 severe [MeSH:C1719672] clinically evident anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] easily correct subcutaneous [MeSH:C0222331] injection time week recombinant erythropoietin [MeSH:C0014822] rhuepo-beta suggest rhuepo-beta correctable cab-induced anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] occur prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] month therapy [MeSH:C0039798],neurological|hepatorenal|oncological
lymphoma transaminase organ interplay,hypothesis [MeSH:C3179072] aspirin improve diabete outcome anuria pathway method observational trial cancer [MeSH:C0302523] patient measure nonalcoholic steatohepatitis [MeSH:C3241937] cholecystitis [MeSH:C0008325] result improvement primary endpoint care improvement,hepatorenal
wilms tumor marker [MeSH:C0027708] dementia [MeSH:C0497327],diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve atrium ckd method conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine insufficiency [MeSH:C1565489] parameter result superior efficacy therapeutic innovation [MeSH:C0087111],cardiovascular|hepatorenal
sodium bicarbonate [MeSH:C0074722] alleviate penile pain induce intracavernous injection erectile dysfunction [MeSH:C0242350],attempt [MeSH:C0852733] determine penile pain associate intracorporeal injection [MeSH:C1554888] [MeSH:C1554888] [MeSH:C1554888] acidity medication [MeSH:C0033045] [MeSH:C0033045] perform randomized compare incidence [MeSH:C0021149] penile pain follow intracorporeal injection [MeSH:C1554888] [MeSH:C1554888] [MeSH:C1554888] addition sodium bicarbonate [MeSH:C0074722] [MeSH:C0074722] intracorporeal medication [MeSH:C0033045] [MeSH:C0033045] total consecutive patient [MeSH:C0030705] [MeSH:C0030705] present clinic [MeSH:C0242936] impotence [MeSH:C0242350] receive ml combination drug [MeSH:C0013162] mg papaverine [MeSH:C0030350] microgram [MeSH:C0376691] phentolamine [MeSH:C0031448] microgram [MeSH:C0376691] prostaglandin e1 ph ph addition sodium bicarbonate [MeSH:C0074722] [MeSH:C0074722] meq patient [MeSH:C0030705] [MeSH:C0030705] sodium bicarbonate [MeSH:C0074722] [MeSH:C0074722] add medication [MeSH:C0033045] [MeSH:C0033045] complain penile pain medication [MeSH:C0033045] [MeSH:C0033045] man receive sodium bicarbonate [MeSH:C0074722] [MeSH:C0074722] complain penile pain conclude penile pain follow intracorporeal injection [MeSH:C1554888] [MeSH:C1554888] [MeSH:C1554888] likely acidity medication [MeSH:C0033045] [MeSH:C0033045] overcome elevate ph neutral,neurological
case report [MeSH:C0684224] pentamidine [MeSH:C0030863] polymorphic [MeSH:C1720758] ventricular tachycardia [MeSH:C0042514] revisit,pentamidine [MeSH:C0030863] [MeSH:C0030863] [MeSH:C0030863] isethionate [MeSH:C0030864] associate [MeSH:C0004083] ventricular tachyarrhythmia [MeSH:C0042514] include torsade [MeSH:C0040479] [MeSH:C0040479] de pointe article report case complication review [MeSH:C0560023] report case date pentamidine [MeSH:C0030863] [MeSH:C0030863] [MeSH:C0030863]-induced torsade [MeSH:C0040479] [MeSH:C0040479] de pointe related serum [MeSH:C0229671] magnesium [MeSH:C0024467] level hypomagnesemia [MeSH:C1835171] synergistically [MeSH:C0949698] induce torsade [MeSH:C0040479] [MeSH:C0040479] torsade [MeSH:C0040479] [MeSH:C0040479] de pointe occur average day pentamidine [MeSH:C0030863] [MeSH:C0030863] [MeSH:C0030863] patient [MeSH:C0030705] acute effect pentamidine [MeSH:C0030863] [MeSH:C0030863] [MeSH:C0030863] observe torsade [MeSH:C0040479] [MeSH:C0040479] de pointe treat recognize early possibly discontinuation pentamidine [MeSH:C0030863] [MeSH:C0030863] [MeSH:C0030863] qtc interval prolongation [MeSH:C0023677] observe early magnesium [MeSH:C0024467] supplementation advocate,cardiovascular
quinidine [MeSH:C0034414] phenylethylbarbiturate-induced fulminant hepatitis pregnant woman [MeSH:C0043210] case report [MeSH:C0684224],report case -year-old laotian affect fulminant [MeSH:C0302809] [MeSH:C0302809] hepatitis trimester [MeSH:C0019158] pregnancy [MeSH:C0032961] -month administration [MeSH:C0001554] quinidine [MeSH:C0034414] [MeSH:C0034414] phenylethylbarbiturate [MeSH:C0031412] delivery undergo orthotopic liver transplantation [MeSH:C0023911] [MeSH:C0023911] good condition month liver transplantation [MeSH:C0023911] quinidine [MeSH:C0034414] [MeSH:C0034414] phenylethylbarbiturate [MeSH:C0031412] responsible fulminant [MeSH:C0302809] [MeSH:C0302809] hepatitis,hepatorenal
hereditary deficiency fifth component complement man [MeSH:C0343047],ii biological [MeSH:C4553887] property c5-deficient human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] know human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] kindred hereditary deficiency fifth component complement c5 document [MeSH:C0009797] accompany report examine biological [MeSH:C4553887] property c5-deficient c5d human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] particularly sera obtain c5d homozygote [MeSH:C0019904] proband inactive systemic lupus erythematosus [MeSH:C0024141] completely lack c5 healthy half-sister normal [MeSH:C0086715] level serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] severely impaired ability generate chemotactic activity [MeSH:C0008013] normal [MeSH:C0086715] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] neutrophil [MeSH:C0027950] [MeSH:C0027950] incubation [MeSH:C0021178] aggregate human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] gamma-globulin [MeSH:C0017007] escherichia coli [MeSH:C0014834] endotoxin function [MeSH:C0014264] fully restore sibling [MeSH:C0037047] serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] substantially improve proband serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] addition highly purify human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] c5 normal [MeSH:C0086715] serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] concentration serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] family member apparently heterozygous [MeSH:C0019425] c5 deficiency [MeSH:C1623416] give normal [MeSH:C0086715] chemotactic score ability c5d serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] opsonize saccharomyce cerevisiae [MeSH:C0036025] baker yeast candida [MeSH:C0036025] albican [MeSH:C0006837] ingestion [MeSH:C0232478] normal [MeSH:C0086715] neutrophil [MeSH:C0027950] [MeSH:C0027950] completely normal [MeSH:C0086715] addition c5d serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] capable promote normal [MeSH:C0086715] phagocytosis [MeSH:C0031308] intracellular [MeSH:C0682581] killing [MeSH:C0162388] staphylococcus aureus [MeSH:C0038172] proband serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] incapable mediate lysis [MeSH:C0024337] erythrocyte [MeSH:C0014792] paroxysmal nocturnal hemoglobinuria sucrose hemolysia acid hemolysis [MeSH:C0024337] test lack bactericidal activity [MeSH:C0005769] sensitize unsensitized salmonella typhi [MeSH:C0036125] sibling [MeSH:C0037047] serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] contain normal [MeSH:C0086715] c5 effectively lyse typhi eightfold low serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] dilution compare normal [MeSH:C0086715] finding underscore critical role c5 generation chemotactic activity [MeSH:C0008013] cytolytic reaction oppose nonobligatory minimal role opsonization [MeSH:C1159762] organism,neurological
cancer endothelial [MeSH:C0225336] cardiac connection,stroke [MeSH:C0038454] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve pacemaker blood vessel method [MeSH:C0005847] conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine congestive heart failure [MeSH:C0018802] parameter result improve disease management [MeSH:C0039798] safety consideration,cardiovascular
liver transplant [MeSH:C0023911] coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect hypertension [MeSH:C0020538] myocardial infarction [MeSH:C0027051] mechanism method longitudinal [MeSH:C0023981] elderly patient assess ast dilated cardiomyopathy [MeSH:C0007193] result improve disease management [MeSH:C0039798] implication safety [MeSH:C0036043] consideration,cardiovascular|hepatorenal
genetic [MeSH:C0017380] brca1 [MeSH:C0259275] region [MeSH:C0259275] large breast ovarian family refinement minimal region contain brca1 [MeSH:C0259275],analyze single multi-affected breast ovarian cancer [MeSH:C1140680] pedigree bov3 [MeSH:C0030761] show consistent inheritance marker chromosome 7q disease confirming family brca1 [MeSH:C0259275] [MeSH:C0259275] gene [MeSH:C0376571] 7q [MeSH:C0376571] haplotype [MeSH:C0018591] show recombination [MeSH:C0034865] event bilateral breast cancer [MeSH:C0006142] case suggest brca1 [MeSH:C0259275] [MeSH:C0259275] gene [MeSH:C0376571] lie distal d17s8 d17s8 new proximal boundary region contain brca1 [MeSH:C0259275] [MeSH:C0259275] combine information [MeSH:C5544371] [MeSH:C5544371] previously publish mapping [MeSH:C0006360] information [MeSH:C5544371] [MeSH:C5544371] suggest brca1 [MeSH:C0259275] [MeSH:C0259275] contain region estimate mb length seven breast tumour blood pair examine family loss heterozygosity tumour allel [MeSH:C0524869] retain tumour disease-bearing chromosome implicate brca1 [MeSH:C0259275] [MeSH:C0259275] tumour suppressor gene sequence beta-oestradiol dehydrogenase gene edh17b1 edh17b2 suggest candidate gene brca1 [MeSH:C0259275] [MeSH:C0259275] member family germline mutation [MeSH:C0206530] detect,oncological
cognitive connection [MeSH:C0009240] peripheral artery disease [MeSH:C1704436] sciatica [MeSH:C0036396],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete [MeSH:C0007080] cerebrospinal fluid [MeSH:C0007806] mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess epilepsy myasthenia gravis [MeSH:C0026896] result improve outcome [MeSH:C0206277] implication safety [MeSH:C0036043] consideration,neurological
rifampicin-associated segmental necrotizing glomerulonephritis staphylococcal endocarditis,segmental necrotising glomerulonephritis [MeSH:C0017658] report complication rifampicin [MeSH:C0035608] therapy patient [MeSH:C0030705] receive tuberculosis [MeSH:C0041296] change epidemiology infection [MeSH:C0014507] infective endocarditis [MeSH:C1541923] ie lead increase use rifampicin [MeSH:C0035608] staphylococcal infection [MeSH:C0038160] describe case staphylococcal [MeSH:C0038164] ie develop acute renal failure [MeSH:C0022660] secondary segmental necrotising glomerulonephritis [MeSH:C0017658] treat rifampicin [MeSH:C0035608] review literature complication [MeSH:C0023866] rifampicin [MeSH:C0035608] therapy,hepatorenal
prolapse [MeSH:C0033377] parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,longitudinal [MeSH:C0023981] examine statin stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include insufficiency vein aortic dissection method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication practice guideline,cardiovascular
lymphoma lens [MeSH:C0024299] autonomic neuropathy [MeSH:C0271686],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] parkinsonism method [MeSH:C0242422] adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal [MeSH:C0023981] tic basal ganglion [MeSH:C0004781] assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,neurological
frequency [MeSH:C0376249] appearance [MeSH:C0750731] myeloperoxidase-antineutrophil cytoplasmic antibody [MeSH:C0103647] mpo-anca grave disease [MeSH:C0018213] patient [MeSH:C0030705] treat propylthiouracil [MeSH:C0033511] relationship mpo-anca manifestation,myeloperoxidase [MeSH:C0027021] antineutrophil cytoplasmic antibody [MeSH:C0103647] mpo-anca -positive vasculitis [MeSH:C0042384] [MeSH:C0042384] [MeSH:C0042384] report patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] grave disease [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] treat propylthiouracil ptu [MeSH:C0033511] appearance mpo-anca case suspect related ptu titre mpo-anca decrease ptu stop study temporal [MeSH:C0039484] relationship [MeSH:C0021797] appearance mpo-anca vasculitis [MeSH:C0042384] [MeSH:C0042384] [MeSH:C0042384] ptu therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] incidence [MeSH:C0021149] mpo-anca untreated grave disease [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] seek address parameter patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] grave disease [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] investigate untreated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hyperthyroidism grave disease [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] presence mpo-anca development vasculitis [MeSH:C0042384] [MeSH:C0042384] [MeSH:C0042384] start ptu therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] twenty-nine later exclude adverse effect [MeSH:C0001688] ptu observation period [MeSH:C0302523] month remain patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] woman [MeSH:C0043210] man examine month adopt subject [MeSH:C0080105] investigation [MeSH:C0035173] median observation period [MeSH:C0302523] month range month measurement [MeSH:C0030198] mpo-anca measure interval month result mpo-anca titre untreated grave disease [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] [MeSH:C0018213] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] reference range u ml patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] positive mpo-anca month respectively start ptu therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] mpo-anca titre transiently increase u ml respectively despite continue ptu therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] vasculitic disorder [MeSH:C0007820] develop mpo-anca titre increase u ml develop high fever [MeSH:C0015967] oral ulcer [MeSH:C0149745] polyarthralgia symptom [MeSH:C3839861] resolve week stop ptu therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] mpo-anca titre decrease u ml month discontinue ptu conclusion ptu therapy [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] [MeSH:C0039798] related appearance mpo-anca mpo-anca appear closely related vasculitis [MeSH:C0042384] [MeSH:C0042384] [MeSH:C0042384],neurological
pad liver cirrhosis [MeSH:C0023890] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect hypertension cardiomyopathy [MeSH:C0878544] mechanism method longitudinal diabetic [MeSH:C0023981] patient [MeSH:C0030705] assess bradycardia pacemaker [MeSH:C0428977] result improvement primary endpoint implication care improvement,cardiovascular
tachycardia marker cancer [MeSH:C0039231],retrospective [MeSH:C0035363] examine ace inhibitor [MeSH:C0003015] dementia [MeSH:C0497327] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include atrial flutter tricuspid valve atrial fibrillation method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
hypertension [MeSH:C0020538] renal cell carcinoma [MeSH:C0007134] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] diabete pyelonephritis method cancer [MeSH:C0034186] patient [MeSH:C0030705] undergo prospective nash hepatitis assessment [MeSH:C0030198] result favorable safety profile need investigation [MeSH:C0035173],hepatorenal
malignant map parkinson disease [MeSH:C0030567],longitudinal [MeSH:C0023981] examine calcium channel blocker [MeSH:C0006684] stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include adrenal cancer [MeSH:C0750887] melanoma bladder cancer [MeSH:C0005684] method participant [MeSH:C1708335] include result favorable safety profile implication therapeutic [MeSH:C0087111] innovation,oncological
compensatory gustatory hyperhidrosis [MeSH:C0038994] topical glycopyrrolate [MeSH:C0017970],gustatory hyperhidrosis [MeSH:C0038994] [MeSH:C0038994] facial sweat [MeSH:C0038984]ing [MeSH:C0038990] usually associate [MeSH:C0004083] eating hot spicy food [MeSH:C0016452] smell food [MeSH:C0016452] current option include oral [MeSH:C0029170] anticholinergic drug [MeSH:C0242893] topical application anticholinergic aluminum chloride injection botulinum toxin thirteen patient [MeSH:C0030705] [MeSH:C0030705] treat [MeSH:C0030705] date topical glycopyrrolate [MeSH:C0017970] [MeSH:C0017970] patient [MeSH:C0030705] [MeSH:C0030705] gustatory hyperhidrosis [MeSH:C0038994] [MeSH:C0038994] interfere social activity [MeSH:C0680791] transthroacic endoscopic sympathectomy [MeSH:C0039038] [MeSH:C0039038] associate [MeSH:C0004083] compensatory focal hyperhidrosis apply topical glycopyrrolate [MeSH:C0017970] [MeSH:C0017970] subjective effect excellent sweat [MeSH:C0038984]ing eat [MeSH:C0038990] hot spicy food [MeSH:C0016452] patient [MeSH:C0030705] [MeSH:C0030705] fair clearly reduce sweat [MeSH:C0038984] patient [MeSH:C0030705] [MeSH:C0030705] report incident [MeSH:C0021149] embarrassed whilst eat hot spicy food [MeSH:C0016452] adverse effect [MeSH:C0001688] include mildly dry mouth [MeSH:C0226896] sore throat [MeSH:C0242429] patient [MeSH:C0030705] [MeSH:C0030705] glycopyrrolate light headache glycopyrrolate topical application glycopyrrolate pad [MeSH:C0017970] appear safe efficacious tolerate convenient moderate severe [MeSH:C1719672] symptom gustatory hyperhidrosis [MeSH:C0038994] [MeSH:C0038994] [MeSH:C0038994] post transthoracic endoscopic sympathectomy [MeSH:C0039038] [MeSH:C0039038] sympathicotomy patient [MeSH:C0030705] [MeSH:C0030705] effect,neurological
dementia [MeSH:C0497327] ggt organ interplay,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension peritoneal dialysis method [MeSH:C0031139] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo longitudinal kidney transplant nash assessment [MeSH:C0030198] result enhance therapeutic response care [MeSH:C0087111] improvement [MeSH:C2936612],hepatorenal
leukemia [MeSH:C0023418] hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,prospective examine ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include myelodysplastic syndrome transient ischemic attack [MeSH:C0007787] arterial method participant [MeSH:C1708335] include result positive response implication practice guideline,cardiovascular|oncological
cardiomyopathy polyuria [MeSH:C0878544] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] nephron mechanism method longitudinal adult [MeSH:C0023981] population assess renal cyst [MeSH:C0010709] ast result decrease mortality rate [MeSH:C0205848] implication need investigation [MeSH:C0035173],hepatorenal
lymphoma rcc [MeSH:C0024299] organ interplay,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve diabete outcome liver pathway method observational trial [MeSH:C0302523] cardiac patient measure chronic kidney disease [MeSH:C1561643] nephrotic syndrome [MeSH:C0027726] result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],hepatorenal
epileptogenic activity folic acid [MeSH:C0016410] drug induce sle folic acid [MeSH:C0016410] epilepsy,effect [MeSH:C4277511] folic [MeSH:C0016410] acid-containing multivitamin supplementation [MeSH:C2350507] [MeSH:C2350507] epileptic [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] pregnancy [MeSH:C0032961] [MeSH:C0033011] order determine rate structural birth defect epilepsy-related effect [MeSH:C4277511] design randomised trial later periconception [MeSH:C0009637] [MeSH:C0009637] care [MeSH:C0085284] include total female [MeSH:C0086287] result epileptic [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] periconception [MeSH:C0009637] [MeSH:C0009637]al folic [MeSH:C0016410] acid mg -containing multivitamin supplementation [MeSH:C2350507] [MeSH:C2350507] develop epilepsy-related effect [MeSH:C4277511] periconception [MeSH:C0009637] [MeSH:C0009637] period [MeSH:C0080129] [MeSH:C0080129] epileptic [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] deliver newborn cleft lip palate exhibit cluster seizure [MeSH:C0036572] [MeSH:C0036572] periconception [MeSH:C0009637] [MeSH:C0009637] period [MeSH:C0080129] [MeSH:C0080129] multivitamin -year-old epileptic [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] treat continuously carbamazepine folic [MeSH:C0016410] acid mg -containing multivitamin 0th week gestation [MeSH:C0032961] develop status epileptic [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072]us late symptom systemic lupus erythematodes [MeSH:C0024141] pregnancy [MeSH:C0032961] end stillbirth [MeSH:C0595939] conclusion epileptic [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] pregnant autoimmune disease probably drug-induced lupus damage blood-brain barrier [MeSH:C0005854] therapeutic dose [MeSH:C0087111] mg folic [MeSH:C0016410] acid trigger [MeSH:C0458343] cluster seizure [MeSH:C0036572] [MeSH:C0036572] physiological dose [MeSH:C0031845] mg folic [MeSH:C0016410] acid healthy [MeSH:C0452415] epileptic [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] autoimmune disease increase risk [MeSH:C0035647] epileptic [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] [MeSH:C4505072] seizure,neurological|hepatorenal
renal pathology [MeSH:C0030664] case lithium-induced diabete insipidus,case lithium-induced diabete insipidus report necropsy microscopy shoe [MeSH:C0036988] unique extensive damage cell line distal nephron suggest change represent specific toxic effect lithium report [MeSH:C0023870] man,hepatorenal
cerebrovascular [MeSH:C0221214] cancer [MeSH:C0007820] vascular [MeSH:C0221214] insight,question statin affect cancer heart valve mechanism method prospective diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess coronary vein [MeSH:C3495141] result favorable safety profile implication need investigation [MeSH:C0035173],cardiovascular
tumor terrain [MeSH:C0006118] myocardial infarction [MeSH:C0027051] exploration [MeSH:C0015329],design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin diabete participant [MeSH:C1708335] cardiac patient non-hodgkin lymphoma chronic lymphocytic leukemia [MeSH:C0024305] result positive response carcinoma correlation healthcare advancement,oncological
hypertension [MeSH:C0020538] deep vein thrombosis [MeSH:C0149871] cardiac connection,hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] regurgitation pathway method observational trial [MeSH:C0302523] cardiac patient measure heart block endothelial result decrease mortality rate [MeSH:C0205848] healthcare advancement,cardiovascular
gem-p chemotherapy [MeSH:C0013216] active relapsed hodgkin lymphoma [MeSH:C0019829],hodgkin lymphoma [MeSH:C0019829] hl relatively chemosensitive malignancy relapse high-dose chemotherapy [MeSH:C0013216] [MeSH:C0013216] autologous stem cell transplant [MeSH:C0559189] choice rely adequate disease salvage [MeSH:C0949591] chemotherapy [MeSH:C0013216] regimen [MeSH:C0013216] commonly require inpatient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0021562] administration [MeSH:C0001554] difficult deliver toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] gemcitabine [MeSH:C0045093] [MeSH:C0045093] cisplatin [MeSH:C0008838] activity [MeSH:C0020115] hl non-overlapping toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] first-line chemotherapeutic [MeSH:C0003392] deliver outpatient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] set [MeSH:C0029921] retrospective [MeSH:C0035363] single-centre patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] relapsed refractory hl treat gemcitabine [MeSH:C0045093] [MeSH:C0045093] mg d8 d1 methylprednisolone [MeSH:C0025815] mg d1- cisplatin [MeSH:C0008838] mg d1 day [MeSH:C0011017] gem-p include demographic survival [MeSH:C0038952] [MeSH:C0011298] response [MeSH:C0034746] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] record forty-one eligible patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] identify median age twenty-two cycle [MeSH:C0007586] gem-p administer total median cycle [MeSH:C0007586] range patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive gem-p second-line third-line therapy overall [MeSH:C0282416] response [MeSH:C0034746] rate [MeSH:C0034746] orr gem-p entire cohort complete response [MeSH:C0034746] cr partial response [MeSH:C0034746] cr confirm metabolic cr pet orr second-line patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] common grade toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] haematological neutropenia thrombocytopenia [MeSH:C0040034] median follow-up [MeSH:C3899107] start gem-p year follow gem-p -year progression-free survival [MeSH:C0038952] [MeSH:C0242792] confidence interval [MeSH:C0009667] ci -year overall [MeSH:C0282416] survival [MeSH:C0038952] ci fourteen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] proceed directly autologous transplant [MeSH:C0559189] gem-p salvage [MeSH:C0949591] chemotherapy [MeSH:C0013216] relatively high response [MeSH:C0034746] rate [MeSH:C0034746] lead successful transplantation [MeSH:C0040732] appropriate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] relapsed refractory hl,hepatorenal|oncological
locus coeruleus pathway valvular heart disease [MeSH:C0018824],investigate [MeSH:C0035173] beta-blocker effect cancer cerebral infarction method [MeSH:C0007785] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo longitudinal radiculopathy hippocampal [MeSH:C0228249] assessment [MeSH:C0030198] result superior efficacy therapeutic innovation [MeSH:C0087111],neurological
hypertension [MeSH:C0020538] primary [MeSH:C0033137] biliary cholangitis [MeSH:C0008312] cardiac connection,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete uremia [MeSH:C0041948] mechanism method observational [MeSH:C0302523] cardiac patient assess coronary primary biliary cholangitis [MeSH:C0008312] result improve disease management [MeSH:C0039798] implication safety [MeSH:C0036043] consideration,cardiovascular|hepatorenal
pioneer kidney cancer [MeSH:C0740457] study peripheral artery disease [MeSH:C1704436],hypothesis [MeSH:C3179072] aspirin improve stroke [MeSH:C0038454] outcome multiple myeloma pathway method [MeSH:C0026764] observational trial [MeSH:C0302523] adult population measure immunotherapy [MeSH:C0021083] liver fibrosis [MeSH:C0239946] result favorable safety [MeSH:C0036043] profile safety [MeSH:C0036043] consideration,hepatorenal|oncological
coronary leukemia [MeSH:C0023418] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin hypertension [MeSH:C0020538] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] hypotensive pad result improve outcome artery [MeSH:C0206277] correlation [MeSH:C0010100] relevance [MeSH:C2826293],cardiovascular
cancer code hypertension [MeSH:C0020538] prostate cancer [MeSH:C0376358],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve diabete outcome melanoma pathway method observational trial [MeSH:C0302523] elderly patient measure metastatic esophageal cancer [MeSH:C0546837] result improvement [MeSH:C2936612] primary endpoint relevance,oncological
dementia [MeSH:C0497327] hypotensive [MeSH:C0020649] cardiac connection,investigate [MeSH:C0035173] beta-blocker effect heart disease ventricular tachycardia method [MeSH:C0042514] adult [MeSH:C0001675] population [MeSH:C0032659] undergo randomized control dvt heart assessment result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],cardiovascular
phlorizin-induced glycosuria prevent [MeSH:C0000918] gentamicin [MeSH:C3854019] nephrotoxicity rat [MeSH:C0034721],rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] streptozotocin-induced diabetes mellitus dm high solute diuresis glycosuria g suggest responsible resistance [MeSH:C0034471] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019]-induced acute renal failure [MeSH:C0022660] arf [MeSH:C0164116] protection gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] nephrotoxicity study non-diabetic rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] chronic solute diuresis induce blockage tubular glucose reabsorption phlorizin p dm rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mild glycosuria [MeSH:C0017979] similar degree p treated animal study unanesthetized adult female sprague-dawley [MeSH:C0034715] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] divide group study day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] p receive p mg day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] ii p gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] iii gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] iv mild dm gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] nephrotoxic dose mg kg body wt gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] inject day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] animal group [MeSH:C1318101] ii iv p induce moderat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e stable glycosuria [MeSH:C0017979] g se functional [MeSH:C0031843] morphologic evidence renal dysfunction ccr ml min undetectable lysozymuria [MeSH:C0026794] [MeSH:C0026794] damage [MeSH:C0012860] tubular necrosis score maximum zero ii p prevent [MeSH:C0000918] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019]-arf [MeSH:C0164116] maximal decrease ccr p peak lysozymuria [MeSH:C0026794] [MeSH:C0026794] microgram [MeSH:C0376691] [MeSH:C0376691] tubular necrosis score value different iii maximal decrease ccr p lysozymuria [MeSH:C0026794] [MeSH:C0026794] microgram [MeSH:C0376691] [MeSH:C0376691] tubular necrosis score abstract truncate word,neurological|hepatorenal
statin prostate cancer [MeSH:C0376358] brain [MeSH:C0006104] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect dementia [MeSH:C0497327] end stage renal disease [MeSH:C0022661] method elderly patient undergo cross-sectional chronic kidney disease [MeSH:C1561643] acoustic neuroma [MeSH:C0027859] assessment [MeSH:C0030198] result favorable safety profile practice guideline,neurological|hepatorenal
basal ganglia [MeSH:C0004781] pathway [MeSH:C0282655] lung cancer [MeSH:C0242379],cross-sectional examine [MeSH:C0010362] aspirin heart disease [MeSH:C0018799] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include cerebral meningioma [MeSH:C0025286] locus coeruleus method [MeSH:C0023951] participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication therapeutic [MeSH:C0087111] innovation,neurological
levodopa-induced oromandibular dystonia progressive [MeSH:C1449744] supranuclear palsy [MeSH:C0038868],levodopa-induced dyskinesia report parkinson disease [MeSH:C0030567] multiple system atrophy [MeSH:C0393571] cranial dystonia [MeSH:C0013421] rare patient [MeSH:C0030705] progressive supranuclear palsy psp [MeSH:C0038868] report describe unusual case reversible levodopa-induced oromandibular dystonia omd psp highlight importance recognize drug [MeSH:C0013227] related complication [MeSH:C1171258] management psp discuss possible underlying pathophysiology [MeSH:C0031847],neurological
common brca1 [MeSH:C0259275] variant susceptibility [MeSH:C0012655] breast ovarian cancer [MeSH:C1140680] general population [MeSH:C0032659],multiple [MeSH:C0026771] case family [MeSH:C0015576] young onset breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] ovarian cancer [MeSH:C1140680] think highly penetrant mutation predispose gene brca1 [MeSH:C0376571] brca2 [MeSH:C0294028] mutation uncommon population [MeSH:C0032659] probably account percent breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] incidence [MeSH:C0021149] large fraction breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] principle common variant confer modest individual risk [MeSH:C0035647] common polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] brca1 gene [MeSH:C0376571] [MeSH:C0376571] generate amino acid substitution [MeSH:C0525038] examine frequency [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] gln36arg pro81leu glu18gly ser13gly large series breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] case match control strong linkage [MeSH:C0242239] disequilibrium site generate haplotype [MeSH:C0018591] [MeSH:C0018591] frequency [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] common haplotype [MeSH:C0018591] [MeSH:C0018591] define allele gln36pro81glu18ser1 gln36leu81gly18gly1 frequency [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] respectively frequency [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] differ significantly group [MeSH:C0018257] common polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] brca1 gene [MeSH:C0376571] [MeSH:C0376571] contribution breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] risk [MeSH:C0035647] suggest arg3 allele different genotype [MeSH:C0017431] distribution [MeSH:C1704711] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] patient [MeSH:C0030705] control arg3 homozygote [MeSH:C0019904] frequent [MeSH:C0017270] group [MeSH:C0018257] p indicate protective breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] confirm provide insight structural feature [MeSH:C0524584] brca1 protein [MeSH:C0259275] important function [MeSH:C0031843],neurological|oncological
encephalopathy [MeSH:C0085584] connection prostate cancer [MeSH:C0376358],question [MeSH:C0600648] ace inhibitor affect dementia [MeSH:C0497327] ataxia [MeSH:C0004134] mechanism method cross-sectional adult [MeSH:C0010362] population [MeSH:C0032659] assess parkinsonism radiculopathy [MeSH:C0242422] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication therapeutic [MeSH:C0087111] innovation,neurological
lymphoma [MeSH:C0024299] anuria [MeSH:C0003460] organ [MeSH:C0029250] interplay,hypothesis statin improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] chronic kidney disease pathway method [MeSH:C1561643] randomized control trial [MeSH:C1096777] adult population [MeSH:C0032659] measuring esrd [MeSH:C0022661] hepatocellular [MeSH:C0345904] result favorable safety profile cost-effectiveness [MeSH:C1511536] implication,hepatorenal
hyperkalemia [MeSH:C0020461] associate sulindac therapy,hyperkalemia [MeSH:C0020461] [MeSH:C0020461] recently recognize complication [MeSH:C1171258] nonsteroidal antiinflammatory agent [MeSH:C0003211] nsaid [MeSH:C0003211] [MeSH:C0003211] indomethacin [MeSH:C0021246] recent study stress renal sparing feature sulindac [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] owe lack interference renal [MeSH:C1136031] prostacyclin synthesis [MeSH:C0033567] describe patient hyperkalemia [MeSH:C0020461] [MeSH:C0020461] range meq l develop day [MeSH:C0011017] sulindac [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] administration normal serum potassium [MeSH:C0032821] level reach day [MeSH:C0011017] stop sulindac [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] medication know effect serum potassium [MeSH:C0032821] give concomitantly course event suggestive cause-and-effect relationship [MeSH:C0021797] sulindac [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] hyperkalemia [MeSH:C0020461] [MeSH:C0020461] observation [MeSH:C0302523] indicate initial hope sulindac [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] associate [MeSH:C0004083] adverse renal effect nsaid [MeSH:C0003211] [MeSH:C0003211] probably justify,hepatorenal
myelodysplastic syndrome cancer [MeSH:C3463824] diabetes mellitus,design [MeSH:C0013171] prospective investigation statin cancer [MeSH:C0376358] participant [MeSH:C1708335] elderly patient acute myeloid leukemia [MeSH:C0023467] pancreatic cancer [MeSH:C0346647] result improve outcome carcinogenesis [MeSH:C0596263] correlation care [MeSH:C0010100] improvement [MeSH:C2936612],oncological
cancer tumor [MeSH:C0027651] connection,cancer affect elderly patient [MeSH:C0030705] worldwide particularly involve acute lymphoblastic leukemia cancer [MeSH:C1961102] method conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine immunotherapy [MeSH:C0021083] parameter result superior efficacy [MeSH:C5690761] practice guideline [MeSH:C0282423],oncological
hepatitis cholangiocarcinoma [MeSH:C0206698] organ interplay,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] hcc pathway method observational trial [MeSH:C0302523] elderly patient measure steatosis [MeSH:C2711227] cholelithiasis [MeSH:C0008350] result superior efficacy [MeSH:C5690761] need investigation [MeSH:C0035173],hepatorenal
nephroblastoma marker [MeSH:C0027708] dementia [MeSH:C0497327],design [MeSH:C0013171] prospective investigation metformin [MeSH:C0025598] diabete participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient peripheral artery disease [MeSH:C1704436] nephrotic syndrome [MeSH:C0027726] result enhance therapeutic response [MeSH:C0087111] interstitial nephritis [MeSH:C0027707] correlation therapeutic innovation [MeSH:C0087111],cardiovascular|hepatorenal
nitrate breast cancer [MeSH:C0006142] brain [MeSH:C0006104] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect diabete dopamine [MeSH:C0013030] mechanism method retrospective diabetic patient [MeSH:C0030705] assess delirium cerebrovascular [MeSH:C0007820] result improve disease management [MeSH:C0039798] implication relevance,neurological
incidence [MeSH:C0021149] pax6 [MeSH:C4255011] mutation [MeSH:C0026882] patient [MeSH:C0030705] simple aniridia [MeSH:C0003076] mutation [MeSH:C0026882] detection [MeSH:C5392129] case,aniridia [MeSH:C0003076] patient [MeSH:C0030705] [MeSH:C0030705] family history [MeSH:C0241889] seven presume sporadic exhaustively screen order test proportion people [MeSH:C5690824] aniridia [MeSH:C0003076] uncomplicated associate anomaly carry mutation [MeSH:C0026882] human [MeSH:C0086418] pax6 [MeSH:C4255011] gene mutation [MeSH:C0026882] [MeSH:C0026882] detect case mutation [MeSH:C0026882] detection [MeSH:C5392129] technique determine superior [MeSH:C0228405] gene protein truncation test ptt rt-pcr product sscp genomic pcr amplification [MeSH:C0017256] chemical cleavage mismatch rt-pcr genomic amplification [MeSH:C0017256] rt-pcr product translate portion gene screen [MeSH:C0813145] genomic product exon include bp untranslated sequence intron [MeSH:C0021920] [MeSH:C0021920] [MeSH:C0021920] exon boundary screen neuroretina specific enhancer intron [MeSH:C0021920] [MeSH:C0021920] [MeSH:C0021920] possible mutation [MeSH:C0026882] familial case sporadic patient [MeSH:C0030705] [MeSH:C0030705] find conform functional [MeSH:C0031843] outcome haploinsufficiency splice site [MeSH:C2936267] mutation [MeSH:C0026882] donor site [MeSH:C0013018] intron [MeSH:C0021920] [MeSH:C0021920] [MeSH:C0021920] donor site [MeSH:C0013018] intron [MeSH:C0021920] [MeSH:C0021920] [MeSH:C0021920] acceptor site intron [MeSH:C0021920] [MeSH:C0021920] [MeSH:C0021920] nonsense mutation [MeSH:C0026882] exon sscp individually amplify exon mutation [MeSH:C0026882] [MeSH:C0026882] see useful detection [MeSH:C5392129] pax6 [MeSH:C4255011],neurological
acute kidney injury [MeSH:C2609414] connection hypertension [MeSH:C0020538],investigate [MeSH:C0035173] statin effect stroke [MeSH:C0038454] huntington disease method [MeSH:C0020179] elderly patient undergo cross-sectional steatosis renal assessment result superior efficacy care improvement [MeSH:C2936612],neurological|hepatorenal
eeg [MeSH:C0013819] reveal parkinson disease [MeSH:C0030567] secret,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] epilepsy pathway [MeSH:C0014544] method observational trial [MeSH:C0302523] elderly patient measure craniopharyngioma [MeSH:C0010276] hypothalamus [MeSH:C0020663] result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],neurological
effect [MeSH:C4277511] vincristine sulfate pseudomona infection monkey,rhesus monkey [MeSH:C0026447] [MeSH:C0024400] intravenous [MeSH:C0085297] [MeSH:C0085297] [MeSH:C0085297] challenge x x pseudomona [MeSH:C0033808] aeruginosa [MeSH:C0033809] organism [MeSH:C0599383] cause acute illness day [MeSH:C0011017] [MeSH:C0011017] duration spontaneous recovery monkey [MeSH:C0026447] blood culture [MeSH:C0200949] negative day [MeSH:C0011017] [MeSH:C0011017] challenge leukocytosis [MeSH:C0023518] observe monkey [MeSH:C0026447] intravenous [MeSH:C0085297] [MeSH:C0085297] [MeSH:C0085297] intratracheal inoculation mg vincristine sulfate [MeSH:C0042680] [MeSH:C0042680] follow leukopenia [MeSH:C0023530] day [MeSH:C0011017] [MeSH:C0011017] intravenous [MeSH:C0085297] [MeSH:C0085297] [MeSH:C0085297] inoculation x x pyocin type pseudomona [MeSH:C0033808] organism [MeSH:C0599383] monkey [MeSH:C0026447] give vincristine sulfate [MeSH:C0042680] [MeSH:C0042680] day [MeSH:C0011017] [MeSH:C0011017] previously result fatal infection monkey [MeSH:C0026447] receiving pseudomona [MeSH:C0033808] die study suggest antimetabolite-induced leukopenia [MeSH:C0023530] predispose severe pseudomona [MeSH:C0033808] sepsis monkey [MeSH:C0026447] serve biological model [MeSH:C0026339] comparative efficacy [MeSH:C5690761] antimicrobial agent [MeSH:C1136254],neurological
safety [MeSH:C0036043] efficacy [MeSH:C5690761] combination n-butyl-deoxynojirimycin sc- zidovudine [MeSH:C0043474] patient [MeSH:C0030705] hiv- infection cd4 cell mm3,conduct double-blind [MeSH:C0013072] randomized phase ii evaluate safety activity [MeSH:C0036043] combination [MeSH:C0034865] therapy [MeSH:C0013218] [MeSH:C0013218] n-butyl-deoxynojirimycin sc- alpha-glucosidase inhibitor [MeSH:C1299007] zidovudine [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] versus zidovudine [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cd4 cell [MeSH:C0243009] [MeSH:C0243009] mm3 tolerate week prior zidovudine [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] therapy receive sc- mg h zidovudine [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] mg h zidovudine [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] placebo [MeSH:C0032041] [MeSH:C0032041] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive combination [MeSH:C0034865] therapy [MeSH:C0013218] [MeSH:C0013218] zidovudine [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] placebo [MeSH:C0032041] [MeSH:C0032041] twenty-three patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] combination [MeSH:C0034865] zidovudine [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] respectively discontinue therapy p mean sc- steady-state trough microgram [MeSH:C0376691] ml vitro inhibitory [MeSH:C0167957] concentration [MeSH:C0311432] human immunodeficiency virus [MeSH:C0019682] hiv mean increase cd4 cell [MeSH:C0243009] [MeSH:C0243009] week cell mm3 cell mm3 combination [MeSH:C0034865] zidovudine [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] respectively p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prior zidovudine [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] therapy mean cd4 cell [MeSH:C0243009] [MeSH:C0243009] combination [MeSH:C0034865] zidovudine [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] cell mm3 cell mm3 week cell mm3 cell mm3 week respectively number patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] suppression hiv p2 antigenemia combination [MeSH:C0034865] zidovudine [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] [MeSH:C0043474] group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] week p week p respectively diarrhea [MeSH:C0011991] flatulence abdominal pain weight [MeSH:C2828149] loss common combination [MeSH:C0034865] recipient abstract truncate word,neurological
lymphoma vein [MeSH:C0024299] cardiac connection,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] diastolic method elderly patient undergo randomized control smooth muscle heart rate assessment result positive response practice guideline [MeSH:C0936005],cardiovascular
efficacy [MeSH:C5690761] safety [MeSH:C0036043] granisetron [MeSH:C0061863] selective -hydroxytryptamine- receptor antagonist prevention nausea vomiting [MeSH:C0520909] induce high-dose cisplatin,assess antiemetic effect [MeSH:C1516011] safety profile different dose granisetron [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] kytril smithkline beecham pharmaceutical philadelphia pa administer [MeSH:C0001554] single [MeSH:C0037177] intravenous iv dose prophylaxis [MeSH:C0033107] cisplatin [MeSH:C0008838]-induced nausea vomiting [MeSH:C0042963] [MeSH:C0520909] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method [MeSH:C0030705] eighty-four chemotherapy [MeSH:C0013216]-naive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive high-dose cisplatin [MeSH:C0008838] mg m2 randomized [MeSH:C1096777] receive granisetron [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] dose microgram [MeSH:C0376691] [MeSH:C0376691] kg administer [MeSH:C0001554] chemotherapy [MeSH:C0013216] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] observe inpatient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0021562] [MeSH:C0030705] [MeSH:C0030705] basis hour vital sign [MeSH:C0518766] nausea vomiting [MeSH:C0042963] [MeSH:C0520909] retch [MeSH:C0034841] appetite [MeSH:C0003618] assess safety analysis [MeSH:C3658272] include incidence [MeSH:C0021149] adverse experience laboratory change [MeSH:C0022877] result granisetron [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] dose microgram [MeSH:C0376691] [MeSH:C0376691] kg major response vomiting [MeSH:C0042963] retch [MeSH:C0034841] episode antiemetic rescue [MeSH:C0003297] record patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] respectively complete response vomiting [MeSH:C0042963] retch [MeSH:C0034841] antiemetic rescue [MeSH:C0003297] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] respectively statistically long episode nausea p vomiting [MeSH:C0042963] [MeSH:C0520909] p few patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] administer [MeSH:C0001554] additional antiemetic medication [MeSH:C0003297] -microgram [MeSH:C0376691] [MeSH:C0376691] kg dose group [MeSH:C0018257] -microgram [MeSH:C0376691] [MeSH:C0376691] kg dosing granisetron [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] dose increase appetite return increase p headache [MeSH:C0018681] frequently report adverse event [MeSH:C0041755] single [MeSH:C0037177] -microgram [MeSH:C0376691] [MeSH:C0376691] kg dose granisetron [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] effective control vomiting [MeSH:C0042963] [MeSH:C0042963] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive cisplatin [MeSH:C0008838] dose great mg m2 totally prevent vomiting [MeSH:C0042963] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] statistically difference efficacy [MeSH:C5690761] -microgram [MeSH:C0376691] [MeSH:C0376691] kg dose -microgram [MeSH:C0376691] [MeSH:C0376691]s kg dose granisetron [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] [MeSH:C0061863] tolerate dose,neurological
myocardial pattern stroke patient [MeSH:C0030705],cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve pituitary adenoma [MeSH:C0032000] basal ganglion method [MeSH:C0004781] conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine premature beat [MeSH:C0340464] parameter result improve disease management [MeSH:C0039798] cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
blood pressure response [MeSH:C0005823] chronic [MeSH:C0150055] low-dose intrarenal noradrenaline infusion [MeSH:C0841792] conscious [MeSH:C0079159] rat,sodium chloride solution [MeSH:C0037494] noradrenaline [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] dose microgram h- kg- infuse consecutive day [MeSH:C0011017] intrarenally new technique [MeSH:C0449851] intravenously rat [MeSH:C0034721] kidney [MeSH:C0022646] remove intrarenal infusion [MeSH:C0841792] [MeSH:C1136122] noradrenaline [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] cause hypertension [MeSH:C0020538] [MeSH:C0020538] dose infuse intravenously intrarenal compare intravenous infusion [MeSH:C0841792] [MeSH:C0021440] noradrenaline [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] cause high plasma [MeSH:C0032105] [MeSH:C0032105] noradrenaline [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] concentrat [MeSH:C0034721]ion shift plasma [MeSH:C0032105] [MeSH:C0032105] noradrenaline [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] concentrat [MeSH:C0034721]ion-blood pressure effect curve low plasma [MeSH:C0032105] [MeSH:C0032105] noradrenaline [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] level [MeSH:C0018759] [MeSH:C0018759] result suggest hypertension [MeSH:C0020538] [MeSH:C0020538] chronic intrarenal noradrenaline [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] infusion [MeSH:C0841792] produce relatively high level [MeSH:C0018759] [MeSH:C0018759] circulate [MeSH:C3641730] noradrenaline [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0028351] trigger additional intrarenal pressor [MeSH:C0033093] mechanism,neurological|cardiovascular|hepatorenal
cancer incidence [MeSH:C0021149] metolachlor [MeSH:C0066468] use agricultural health update,unassigned [MeSH:C0917893] metolachlor [MeSH:C0066468] [MeSH:C0066468] widely herbicide [MeSH:C0019236] classify c carcinogen u [MeSH:C0007090] environmental [MeSH:C0014406] protection agency base increase liver neoplasm [MeSH:C0023903] [MeSH:C0023903] female [MeSH:C0086287] rat [MeSH:C0034721] epidemiologic study [MeSH:C0002783] health effect [MeSH:C4277511] [MeSH:C0018766] metolachlor [MeSH:C0066468] [MeSH:C0066468] limit agricultural health [MeSH:C0242775] ahs prospective cohort [MeSH:C1706962] include licensed [MeSH:C0023636] private [MeSH:C0033176] commercial pesticide applicator iowa north carolina [MeSH:C0028407] enrol evaluate [MeSH:C0013175] cancer [MeSH:C0006826] incidence [MeSH:C0021149] [MeSH:C0021149] nc ia applicator report metolachlor [MeSH:C0066468] [MeSH:C0066468] poisson regression evaluate [MeSH:C0013175] relation metric [MeSH:C0699680] metolachlor [MeSH:C0066468] [MeSH:C0066468] use lifetime day [MeSH:C0011017] intensity-weighted lifetime day [MeSH:C0011017] cancer [MeSH:C0006826] incidence [MeSH:C0021149] [MeSH:C0021149] see association [MeSH:C0004083] metolachlor [MeSH:C0066468] [MeSH:C0066468] use incidence [MeSH:C0021149] [MeSH:C0021149] cancer [MeSH:C0006826] combine n -year lag site-specific cancer [MeSH:C0006826] liver cancer [MeSH:C0345904] [MeSH:C0345904] [MeSH:C0345904] [MeSH:C0006826] analysis [MeSH:C1524024] restricted expose worker [MeSH:C1527116] elevation observe high category use statistically trend lifetime intensity-weighted lifetime day [MeSH:C0011017] metolachor use positive statistically unexpose reference similar pattern [MeSH:C3849996] observe follicular cell lymphoma [MeSH:C0024301] lymphoma [MeSH:C0024301] subtype early suggestion increase lung cancer [MeSH:C0242379] [MeSH:C0006826] risk [MeSH:C0035647] high level [MeSH:C0018759] metolachlor [MeSH:C0066468] [MeSH:C0066468] use cohort [MeSH:C1706962] confirm update suggestion association [MeSH:C0004083] metolachlor [MeSH:C0066468] [MeSH:C0066468] liver cancer [MeSH:C0345904] [MeSH:C0345904] [MeSH:C0345904] [MeSH:C0006826] pesticide applicator novel echo observation [MeSH:C0302523] increase liver neoplasm [MeSH:C0023903] [MeSH:C0023903] animal study finding liver cancer [MeSH:C0345904] [MeSH:C0345904] [MeSH:C0345904] [MeSH:C0006826] follicular cell lymphoma [MeSH:C0024301] warrant follow-up [MeSH:C3899107] well differentiate effect [MeSH:C4277511] metolachlor [MeSH:C0066468] [MeSH:C0066468] use factor,neurological|hepatorenal|oncological
radiculopathy [MeSH:C0700594] pattern parkinson disease [MeSH:C0030567] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] oligodendroglioma pathway method observational trial [MeSH:C0302523] elderly patient measure acetylcholine myasthenia gravis [MeSH:C0026896] result positive response therapeutic innovation [MeSH:C0087111],neurological
alcoholic liver disease [MeSH:C0023896] pathway chronic kidney disease [MeSH:C1561643],question statin affect hypertension [MeSH:C0020538] nephron mechanism method randomized control [MeSH:C1096777] elderly patient assess chronic kidney disease [MeSH:C1561643] primary sclerosing cholangitis [MeSH:C0566602] result decrease mortality rate [MeSH:C0205848] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
breakthrough arrhythmia [MeSH:C0003811] finding heart failure [MeSH:C0018801],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] cerebrovascular pathway method cross-sectional trial [MeSH:C0010362] adult [MeSH:C0001675] population measure aortic aneurysm arterial [MeSH:C0003486] result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],cardiovascular
lymphoma cancer [MeSH:C0024299] chronic kidney disease [MeSH:C1561643],heart disease [MeSH:C0018799] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve prostate cancer [MeSH:C0376358] head neck cancer method [MeSH:C0278996] conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine carcinoma [MeSH:C0007097] parameter result decrease mortality rate [MeSH:C0205848] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
cancer liver fibrosis [MeSH:C0239946] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] statin effect cancer hepatocellular method [MeSH:C0345904] elderly patient undergo retrospective bun albumin assessment [MeSH:C0030198] result favorable safety profile need investigation [MeSH:C0035173],hepatorenal
hepatorenal syndrome diabetes mellitus [MeSH:C0011849],hypertension [MeSH:C0020538] affect elderly patient worldwide particularly involve pkd anuria method conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient examine albumin [MeSH:C0001924] parameter result improvement primary endpoint cost-effectiveness [MeSH:C1511536] implication,hepatorenal
lymphoma peripheral artery disease [MeSH:C1704436] cardiac connection,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] diabete participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] atrial fibrillation bradycardia [MeSH:C0004238] result superior efficacy peripheral artery disease [MeSH:C1704436] correlation [MeSH:C0010100] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
attenuation lithium-induced diabetes-insipidus-like syndrome amiloride [MeSH:C0002502] rat [MeSH:C0034721],effect [MeSH:C4277511] amiloride [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-induced polydipsia polyuria [MeSH:C0085602] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] concentrat [MeSH:C0034721] [MeSH:C0034721]ion plasma brain kidney thyroid red blood cell investigate [MeSH:C0035173] rat [MeSH:C0034721] [MeSH:C0034721] chronically treat licl amiloride [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] reduce drinking urine volume rat [MeSH:C0034721] [MeSH:C0034721] acute [MeSH:C0184567] [MeSH:C0184567] h subacute [MeSH:C0184567] [MeSH:C0376635] [MeSH:C0184567] day [MeSH:C0011017] [MeSH:C0011017] experiment [MeSH:C0020123] [MeSH:C0020123] h administrat [MeSH:C0034721] [MeSH:C0034721]ion amiloride [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] observe lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] content renal medulla [MeSH:C0001629] [MeSH:C0001629] organ study h tissue [MeSH:C0040300] show slight increase lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] level [MeSH:C0018759] day [MeSH:C0011017] [MeSH:C0011017] combined marked elevation plasma tissue [MeSH:C0040300] [MeSH:C0040300] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] level [MeSH:C0018759] accompany reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] water intake [MeSH:C0013123] experiment [MeSH:C0020123] [MeSH:C0020123] attenuation lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-induced diabetes-insipidus-like syndrome amiloride [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] accompany reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] rat [MeSH:C0034721] [MeSH:C0034721]io lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] concentrat [MeSH:C0034721] [MeSH:C0034721]ion renal medulla [MeSH:C0001629] [MeSH:C0001629] level [MeSH:C0018759] blood elevation plasma potassium [MeSH:C0032821] conclude acute [MeSH:C0184567] [MeSH:C0184567] amiloride [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] administrat [MeSH:C0034721] [MeSH:C0034721]ion lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-treated patient [MeSH:C0030705] [MeSH:C0030705] suffer polydipsia polyuria [MeSH:C0085602] relieve patient [MeSH:C0030705] [MeSH:C0030705] prolonged amiloride [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] [MeSH:C0002502] supplementation elevated [MeSH:C0020443] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] level [MeSH:C0018759] hazardous [MeSH:C0018626],neurological|hepatorenal
cardiac [MeSH:C0018810] lung cancer vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] beta-blocker effect diabete coronary artery disease method cancer [MeSH:C1956346] patient [MeSH:C0030705] undergo observational cholecystitis glomerular filtration rate assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] practice guideline,cardiovascular|hepatorenal
stroke [MeSH:C0038454] endothelium [MeSH:C0014257] cardiac connection,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension outcome vein pathway method retrospective trial elderly patient measure heart rate [MeSH:C0018810] aortic valve result decrease mortality rate [MeSH:C0205848] safety [MeSH:C0036043] consideration,cardiovascular
explore ventricular tachycardia pulmonary embolism [MeSH:C0042514],cross-sectional [MeSH:C0010362] examine beta-blocker diabete diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include hypertrophic cardiomyopathy prolapse [MeSH:C0007194] dvt method participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication healthcare advancement,cardiovascular
next-generation genetic testing hepatitis,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] gamma glutamyl transferase liver fibrosis [MeSH:C0017040] result improvement [MeSH:C2936612] primary endpoint hepatocellular [MeSH:C0345904] correlation [MeSH:C0010100] relevance [MeSH:C2826293],hepatorenal
frequent [MeSH:C0017270] detection [MeSH:C5392129] codon mutation androgen receptor gene [MeSH:C0034786] advanced prostate cancer [MeSH:C0376358],prostatic tissue [MeSH:C0040300] specimen [MeSH:C0200345] derive transurethral resection [MeSH:C0040771] patient [MeSH:C0030705] [MeSH:C0030705] metastatic prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] analyze genetic alteration hormone-binding [MeSH:C0033618] domain androgen receptor ar gene direct sequencing polymerase chain reaction-derived dna specimen [MeSH:C0200345] reveal codon mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] act-- gct thr-- ala hormone-binding [MeSH:C0033618] domain ar gene ar mutation [MeSH:C0026882] [MeSH:C0026882] report previously metastatic prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0376358] cell line lncap mutation [MeSH:C0026882] [MeSH:C0026882] confer ar altered ligand [MeSH:C0023688]-binding [MeSH:C0033618] specificity stimulate estrogen [MeSH:C0014939] progestagen [MeSH:C0033306] antiandrogen [MeSH:C0002842] [MeSH:C0002842] possible analogous activate altered growth factor receptor oncogene codon mutant [MeSH:C0206454] ar altered ligand [MeSH:C0023688] binding [MeSH:C0033618] provide selective growth advantage genesis subset advanced prostate cancer [MeSH:C0376358] [MeSH:C0376358] estrogen [MeSH:C0014939] infrequently antiandrogen [MeSH:C0002842] [MeSH:C0002842] increasingly hormonal therapy [MeSH:C0039798] patient [MeSH:C0030705] [MeSH:C0030705] advanced prostate cancer [MeSH:C0376358] [MeSH:C0376358] stimulatory effect therapeutic agent [MeSH:C0087111] codon mutant ar suggest frequently observe ar mutation [MeSH:C0026882] [MeSH:C0026882] contribute refractory disease [MeSH:C0030200],oncological
cholecystokinin-octapeptide [MeSH:C0037167] restore morphine-induced hippocampal [MeSH:C0228249] long-term [MeSH:C0023977] potentiation impairment rat [MeSH:C0034721],cholecystokinin-octapeptide [MeSH:C0037167] cck- typical brain-gut peptide [MeSH:C5544358] exert wide range biological activity central nervous system [MeSH:C3714787] previously report cck- significantly alleviate morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-induced amnesia reverse spine density decrease ca1 region hippocampus [MeSH:C3887642] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-treated animal [MeSH:C0003062] investigate [MeSH:C0035173] effect [MeSH:C4277511] cck- long-term [MeSH:C0023977] potentiation [MeSH:C1136141] ltp lateral perforant path lpp -granule cell synapse [MeSH:C0039062] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] dentate gyrus [MeSH:C0152314] dg acute saline morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] population [MeSH:C0032659] spike ps evoke stimulation [MeSH:C0031734] lpp record dg region acute morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] 0 mg kg c significantly attenuate [MeSH:C0042211] [MeSH:C0042211] hippocampal [MeSH:C0228249] [MeSH:C0228249] ltp cck- 1ug c v restore amplitude ps attenuate [MeSH:C0042211] [MeSH:C0042211] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] injection [MeSH:C1828121] furthermore microinjection [MeSH:C0025991] [MeSH:C1828121] cck- 1ug c v significantly augment hippocampal [MeSH:C0228249] [MeSH:C0228249] ltp saline-treated 1ml kg c rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] pre-treatment [MeSH:C0039798] cck2 receptor [MeSH:C0248266] antagonist l- 0ug c v reverse effect [MeSH:C4277511] cck- cck1 receptor antagonist l- 0ug c v present result demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e cck- attenuate [MeSH:C0042211] [MeSH:C0042211] effect [MeSH:C4277511] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] hippocampal [MeSH:C0228249] [MeSH:C0228249] ltp cck2 receptor [MeSH:C0248266] suggest ameliorat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ive function cck- morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-induced memory impairment,neurological
topiramate-induced nephrolithiasis,topiramate [MeSH:C0076829] recently develop antiepileptic medication [MeSH:C0033045] widely prescribe efficacy [MeSH:C5690761] treat refractory seizure [MeSH:C0036572] urologist aware medication [MeSH:C0033045] cause metabolic acidosis [MeSH:C0220981] patient [MeSH:C0030705] secondary inhibition carbonic anhydrase addition [MeSH:C0007028] distal tubular acidification defect impair normal compensatory drop urine [MeSH:C0042036] ph factor lead development [MeSH:C0020119] calcium phosphate nephrolithiasis [MeSH:C1833683] report case topiramate [MeSH:C0076829]-induced nephrolithiasis urologic [MeSH:C0392525] literature,neurological|hepatorenal
organ [MeSH:C0029250] health cancer [MeSH:C0018684],hypothesis [MeSH:C3179072] aspirin improve stroke [MeSH:C0038454] outcome cholelithiasis pathway method cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring hematuria [MeSH:C0018965] peritoneal [MeSH:C1955857] dialysis result positive response need investigation [MeSH:C0035173],hepatorenal
severe [MeSH:C1719672] ocular [MeSH:C0042789] orbital toxicity intracarotid injection carboplatin recurrent glioblastoma [MeSH:C0017636],glioblastoma [MeSH:C0017636] [MeSH:C0017636] malignant tumor [MeSH:C0006142] occur cerebrum adulthood current regimen [MeSH:C1880476] include combined surgery [MeSH:C0038895] radiation chemotherapy [MeSH:C0013216] average life expectancy [MeSH:C0023671] patient [MeSH:C0030705] [MeSH:C0030705] limited approximately patient [MeSH:C0030705] [MeSH:C0030705] glioblastoma [MeSH:C0017636] [MeSH:C0017636] intracarotid injection [MeSH:C1828121] carcinostatic add regiman generally carboplatin [MeSH:C0079083] [MeSH:C0079083] say mild effect [MeSH:C4277511] cisplatin [MeSH:C0008838] ocular [MeSH:C0042789] [MeSH:C0042789] [MeSH:C0042789] orbital [MeSH:C0029182] toxicity [MeSH:C0040539] [MeSH:C0040539] known experience case severe [MeSH:C1719672] ocular [MeSH:C0042789] [MeSH:C0042789] [MeSH:C0042789] orbital [MeSH:C0029182] toxicity [MeSH:C0040539] [MeSH:C0040539] intracarotid injection [MeSH:C1828121] carboplatin [MeSH:C0079083] [MeSH:C0079083] infrequently report case -year-old man receive intracarotid injection [MeSH:C1828121] carboplatin [MeSH:C0079083] [MeSH:C0079083] recurrent glioblastoma [MeSH:C0017636] [MeSH:C0017636] left temporal lobe complain pain visual [MeSH:C0042815] disturbance ipsilateral eye [MeSH:C0015392] h injection ocular [MeSH:C0042789] [MeSH:C0042789] [MeSH:C0042789] symptom finding cause carboplatin [MeSH:C0079083] [MeSH:C0079083] toxicity [MeSH:C0040539] [MeSH:C0040539] see result treat intravenous administration [MeSH:C0013125] corticosteroid glycerin [MeSH:C0001617] day injection intraocular [MeSH:C0042789] [MeSH:C0042789] [MeSH:C0042789] pressure elevation cause secondary acute angle-closure glaucoma [MeSH:C0017605] decrease ocular [MeSH:C0042789] [MeSH:C0042789] [MeSH:C0042789] pain diminish inexorable papilledema [MeSH:C0030353] exudative retinal detachment [MeSH:C0035305] continue week finally week later diffuse chorioretinal atrophy [MeSH:C1862382] optic atrophy [MeSH:C0029124] occur vision left eye [MeSH:C0015392] lose perform intracarotid injection [MeSH:C1828121] carboplatin [MeSH:C0079083] [MeSH:C0079083] aware potentially blind ocular [MeSH:C0042789] [MeSH:C0042789] [MeSH:C0042789] toxicity [MeSH:C0040539] [MeSH:C0040539] recommend study [MeSH:C0085973] investigation [MeSH:C0035173] undertake effort minimize severe [MeSH:C1719672] effect [MeSH:C4277511],neurological|oncological
recovery [MeSH:C0140116] tacrolimus-associated brachial neuritis conversion [MeSH:C0017259] everolimus [MeSH:C0541315] pediatric [MeSH:C0237433] renal transplant [MeSH:C0022671] recipient case report review [MeSH:C0282436] literature [MeSH:C0023866],tac show potent immunosuppressive agent [MeSH:C0021081] solid organ transplantation [MeSH:C0029216] pediatric [MeSH:C0237433] neurotoxicity [MeSH:C0235032] potentially toxic effect characterize encephalopathy headache [MeSH:C0085584] seizure neurological deficit [MeSH:C0521654] describe eight-and-a-half-yr-old male [MeSH:C0086582] renal transplant [MeSH:C0022671] recipient right bn mri demonstrate hyperintense t2 signal cervical cord right brachial plexu root indicative myelitis right brachial plexitis symptom [MeSH:C3839861] persist month despite tac dose reduction [MeSH:C1827449] administration ivig dose methylprednisolone [MeSH:C0025815] pulse therapy [MeSH:C0751977] improvement [MeSH:C2936612] eventually recovery [MeSH:C0140116] occur tac completely discontinue successfully replace everolimus [MeSH:C0541315],neurological|hepatorenal
state-of-the-art vasodilator multiple sclerosis,diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve creatinine renal cell carcinoma method [MeSH:C0007134] conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine alkaline phosphatase [MeSH:C0002059] parameter result superior efficacy [MeSH:C5690761] relevance,hepatorenal
lymphoma [MeSH:C0024299] esrd organ [MeSH:C0029250] interplay,design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] participant [MeSH:C1708335] adult [MeSH:C0001675] population glomerular filtration rate albumin [MeSH:C0017654] result improve outcome [MeSH:C0206277] ast correlation [MeSH:C0010100] relevance [MeSH:C2826293],hepatorenal
parkinson disease [MeSH:C0030567] cardiovascular lens [MeSH:C0007220],hypothesis statin improve stroke [MeSH:C0038454] outcome [MeSH:C0206277] restrictive cardiomyopathy pathway method [MeSH:C0007196] cross-sectional trial [MeSH:C0010362] cardiac patient measure diastolic [MeSH:C0012000] ectopic beat [MeSH:C0033036] result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
synaptic story diabetes mellitus [MeSH:C0011849] multiple sclerosis [MeSH:C0026769],observational [MeSH:C0302523] examine aspirin cancer [MeSH:C0004057] cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include cortical oligodendroglioma [MeSH:C0028945] cerebral infarction method [MeSH:C0007785] participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication healthcare advancement,neurological
organ [MeSH:C0029250] orchestra myocardial infarction,hypothesis [MeSH:C3179072] aspirin improve diabete outcome glomerular filtration rate pathway method observational trial cancer [MeSH:C0302523] patient measure hepatitis bun [MeSH:C0019158] result well quality life measure cost-effectiveness [MeSH:C1511536] implication,hepatorenal
expression [MeSH:C0017262] vascular endothelial growth factor receptor [MeSH:C0148199] development estrogen-induced [MeSH:C1447061] rat [MeSH:C0034721] pituitary tumor [MeSH:C0032019] mediate estrogen-initiated tumor angiogenesis,estrogen [MeSH:C0014939] [MeSH:C0014939] associate type human [MeSH:C0086418] animal cancer [MeSH:C0003062] induce tumor angiogenesis [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] pituitary [MeSH:C0032005] [MeSH:C0032005] fischer rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mechanistic detail tumor angiogenesis [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] induction [MeSH:C0042767] estrogen [MeSH:C0014939] [MeSH:C0014939] carcinogenesis unknown elucidate role estrogen [MeSH:C0014939] [MeSH:C0014939] regulation tumor angiogenesis [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] pituitary [MeSH:C0032005] [MeSH:C0032005] female rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] density blood vessel [MeSH:C0005847] [MeSH:C0005847] [MeSH:C0005847] analyse factor viii related antigen fviiirag immunohistochemistry [MeSH:C0021044] [MeSH:C0021044] [MeSH:C0021044] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] vascular endothelial growth factor vascular permeability factor vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] vpf examine western blot [MeSH:C0949466] immunohistochemical expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] receptor [MeSH:C0148199] vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058]r- flk- kdr [MeSH:C3849882] [MeSH:C3849882] examine immunohistochemistry [MeSH:C0021044] [MeSH:C0021044] result demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e 7beta-estradiol e2 induce neovascularization growth enlargement blood vessel [MeSH:C0005847] [MeSH:C0005847] day [MeSH:C0011017] [MeSH:C0011017] exposure [MeSH:C1390376] [MeSH:C1390376] high [MeSH:C0039866] tumor angiogenic potential associate elevated [MeSH:C0020443] [MeSH:C0020443] vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] vpf protein expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] e2 expose pituitary [MeSH:C0032005] [MeSH:C0032005] ovariectomized [MeSH:C0029936] ovex [MeSH:C0069693] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] vpf fviiirag immunohistochemistry [MeSH:C0021044] [MeSH:C0021044] endothelial specific lectin uea1 binding study indicate elevation vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] protein expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] initially occur blood vessel [MeSH:C0005847] [MeSH:C0005847] non-endothelial cell day [MeSH:C0011017] [MeSH:C0011017] e2 exposure [MeSH:C1390376] [MeSH:C1390376] vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] vpf protein expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] non-endothelial cell population sharply decline restricted [MeSH:C1135809] blood vessel [MeSH:C0005847] [MeSH:C0005847] function non-endothelial-derived vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] clear furthermore immunohistochemical study demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058]r- flk- kdr [MeSH:C3849882] [MeSH:C3849882] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] elevated [MeSH:C0020443] [MeSH:C0020443] significantly endothelial cell microblood vessel [MeSH:C0005847] [MeSH:C0005847] day [MeSH:C0011017] [MeSH:C0011017] e2 exposure [MeSH:C1390376] [MeSH:C1390376] finding suggest expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] receptor [MeSH:C0148199] vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058]r- play important role initial step regulation [MeSH:C0851285] estrogen [MeSH:C0014939] [MeSH:C0014939] induce tumor angiogenesis [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] [MeSH:C0002976] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] pituitary [MeSH:C0032005] [MeSH:C0032005],oncological
haplotype [MeSH:C0018591] multipoint linkage finnish choroideremia [MeSH:C0008525] family,multipoint linkage choroideremia tcd seven x chromosomal restriction fragment length [MeSH:C0035268] polymorphism rflp carry finnish [MeSH:C0004836] tcd family place tcd distal pgk dxs7 close dxys1 dxys5 zmax theta proximal dxys4 dxys1 agree obtain linkage study [MeSH:C0085973] physical mapping tcd male carrier female study [MeSH:C0085973] dxys1 allele coupling tcd northeastern finland chromosome carry tcd haplotype [MeSH:C0018591] [MeSH:C0018591] locus [MeSH:C0085286] [MeSH:C0018591] dxs7 dxys1 dxys4 dxys1 haplotype [MeSH:C0018591] [MeSH:C0018591] see chromosome carry tcd non-tcd chromosome [MeSH:C0008633] haplotype [MeSH:C0018591] [MeSH:C0018591] marker locus [MeSH:C0085286] different see tcd chromosome [MeSH:C0008633] support previously describe hypothesis [MeSH:C3179072] large northern finnish [MeSH:C0004836] choroideremia pedigree [MeSH:C0030761] comprise total living patient [MeSH:C0030705] [MeSH:C0030705] represent fifth tcd patient [MeSH:C0030705] [MeSH:C0030705] describe worldwide carry mutation [MeSH:C0026882] linkage haplotype [MeSH:C0018591] [MeSH:C0018591] provide improve opportunity prenatal diagnosis [MeSH:C0033053] base rflp [MeSH:C0035268] study [MeSH:C0085973],neurological
target [MeSH:C0039309] modification [MeSH:C0086153] apolipoprotein b [MeSH:C0003591] gene result hypobetalipoproteinemia [MeSH:C0020597] developmental abnormality mouse [MeSH:C0026809],familial hypobetalipoproteinemia [MeSH:C0020597] [MeSH:C0020597] [MeSH:C0020597] [MeSH:C0020597] autosomal codominant disorder result dramatic reduction [MeSH:C1827449] plasma [MeSH:C0032105] [MeSH:C0032105] concentration [MeSH:C0311432] [MeSH:C0311432] apolipoprotein apo b cholesterol beta-migrating lipoprotein [MeSH:C0003591] benefit hypobetalipoproteinemia [MeSH:C0020597] [MeSH:C0020597] [MeSH:C0020597] [MeSH:C0020597] mildly affect individual protect coronary vascular disease [MeSH:C0042373] gene target [MeSH:C0242613] generate mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] modify apob allele [MeSH:C0003593] [MeSH:C0003593] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] contain allele display hallmark human [MeSH:C0086418] [MeSH:C0086418] hypobetalipoproteinemia [MeSH:C0020597] [MeSH:C0020597] [MeSH:C0020597] [MeSH:C0020597] produce truncate apob protein apob7 [MeSH:C0003593] markedly decrease plasma [MeSH:C0032105] [MeSH:C0032105] concentration [MeSH:C0311432] [MeSH:C0311432] apob beta-lipoprotein total cholesterol addition mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] manifest characteristic occasionally observe human [MeSH:C0086418] [MeSH:C0086418] hypobetalipoproteinemia [MeSH:C0020597] [MeSH:C0020597] [MeSH:C0020597] [MeSH:C0020597] include reduce plasma [MeSH:C0032105] [MeSH:C0032105] triglyceride concentration [MeSH:C0311432] [MeSH:C0311432] fast chylomicronemia [MeSH:C0023817] reduce high density lipoprotein cholesterol [MeSH:C0023822] unexpected modify apob allele [MeSH:C0003593] [MeSH:C0003593] strongly associate exencephalus hydrocephalus [MeSH:C0020255] [MeSH:C0020255] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] help increase understanding hypobetalipoproteinemia [MeSH:C0020597] [MeSH:C0020597] [MeSH:C0020597] [MeSH:C0020597] atherogenesis [MeSH:C1563937] etiology [MeSH:C0015127] exencephalus hydrocephalus [MeSH:C0020255] [MeSH:C0020255],cardiovascular
relative efficacy [MeSH:C5690761] toxicity [MeSH:C0040539] netilmicin [MeSH:C0027780] tobramycin [MeSH:C0040341] oncology patient [MeSH:C0596240],prospectively compare efficacy [MeSH:C5690761] safety netilmicin [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] sulfate [MeSH:C0700550] tobramycin [MeSH:C0040341] [MeSH:C0040341] sulfate conjunction piperacillin sodium [MeSH:C0700463] immunocompromised patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] presume severe infection regimen equally efficacious nephrotoxicity occur similar proportion patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat netilmicin [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] tobramycin [MeSH:C0040341] [MeSH:C0040341] [MeSH:C0027780] vs ototoxicity [MeSH:C0235280] [MeSH:C0235280] occur netilmicin [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] piperacillin tobramycin [MeSH:C0040341] [MeSH:C0040341] [MeSH:C0040341] piperacillin-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] evaluate posttherapy audiogram netilmicin [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] piperacillin-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] auditory [MeSH:C0004302] threshold [MeSH:C0162703] return compare tobramycin [MeSH:C0040341] [MeSH:C0040341] piperacillin-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] number great equal -db increase auditory [MeSH:C0004302] threshold [MeSH:C0162703] proportion total great equal -db change increase decrease significantly low netilmicin [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] piperacillin- vs tobramycin [MeSH:C0040341] [MeSH:C0040341] piperacillin-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] vs conclude aminoglycoside-associated ototoxicity [MeSH:C0235280] [MeSH:C0235280] severe reversible netilmicin [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] [MeSH:C0027780] tobramycin [MeSH:C0040341] [MeSH:C0040341] [MeSH:C0027780],neurological|hepatorenal
insulin gene [MeSH:C0021641] region contribute genetic susceptibility [MeSH:C0314657] low incidence [MeSH:C0021149] insulin-dependent [MeSH:C0034818] diabetes mellitus japanese [MeSH:C0011849],caucasian [MeSH:C0007457] population [MeSH:C0032659] [MeSH:C0032659] demonstrate insulin gene [MeSH:C0021641] in region contain insulin-dependent [MeSH:C0034818] diabetes mellitus [MeSH:C0011849] locus [MeSH:C0085286] [MeSH:C0085286] iddm [MeSH:C0011854]2 japanese population [MeSH:C0032659] [MeSH:C0032659] report demonstrate contribution iddm [MeSH:C0011854]2 pathogenesis iddm [MeSH:C0011854] [MeSH:C0699748] conduct association [MeSH:C0004083] iddm [MeSH:C0011854] large number japanese subject multiple [MeSH:C0026771] polymorphism [MeSH:C0032529] in region find association [MeSH:C0004083] in region iddm [MeSH:C0011854] [MeSH:C0011854] allele [MeSH:C0002085] positively associate iddm [MeSH:C0011854] ins region [MeSH:C0021640] positively-associated iddm [MeSH:C0011854] caucasian [MeSH:C0007457] population [MeSH:C0032659] [MeSH:C0032659] positively-associated allele [MeSH:C0002085] common allele [MeSH:C0002085] frequency japanese general population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] suggest iddm [MeSH:C0011854]2 involve genetic susceptibility [MeSH:C0314657] iddm [MeSH:C0011854] japanese high frequency disease-associated allele [MeSH:C0002085] general population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] suggest iddm [MeSH:C0011854]2 locus [MeSH:C0085286] [MeSH:C0085286] responsible low incidence iddm [MeSH:C0011854] japanese,neurological
rhabdomyolysis [MeSH:C0035410] brain ischemic stroke heroin-dependent [MeSH:C0019337] male [MeSH:C0086582] methadone [MeSH:C0025605] maintenance therapy [MeSH:C0481504],complication [MeSH:C1171258] associate heroin [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0011892] abuse life-threatening [MeSH:C4303743] methadone [MeSH:C0025605] [MeSH:C0025605] [MeSH:C0025605] [MeSH:C0025605] aggravate problem case description result -year-old man present rhabdomyolysis [MeSH:C0035410] [MeSH:C0035410] [MeSH:C0035410] [MeSH:C0035410] cerebral ischemic stroke [MeSH:C0948008] [MeSH:C0948008] intravenous heroin [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0085297] [MeSH:C0011892] heroin [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0011892] age [MeSH:C0024842] mg methadone [MeSH:C0025605] [MeSH:C0025605] [MeSH:C0025605] [MeSH:C0025605] daily month find unconsciousness home send hospital [MeSH:C0041657] er opiate ng ml icu find rhabdomyolysis [MeSH:C0035410] [MeSH:C0035410] [MeSH:C0035410] [MeSH:C0035410] acute renal failure acute respiratory failure transfer internal ward note aphasia weakness leave limb mri find cerebral ischemic infarction [MeSH:C0007785] methadone [MeSH:C0025605] [MeSH:C0025605] [MeSH:C0025605] [MeSH:C0025605] heroin [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0011892] simultaneously increase risk [MeSH:C0035647] rhabdomyolysis [MeSH:C0035410] [MeSH:C0035410] [MeSH:C0035410] [MeSH:C0035410] ischemic stroke [MeSH:C0948008] patient [MeSH:C0030705] methadone [MeSH:C0025605] [MeSH:C0025605] [MeSH:C0025605] [MeSH:C0025605] maintenance therapy [MeSH:C0481504] warn adverse event [MeSH:C0041755] hypothesis [MeSH:C3179072] heroin [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0011892]-related rhabdomyolysis [MeSH:C0035410] [MeSH:C0035410] [MeSH:C0035410] [MeSH:C0035410] stroke heroin [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0011892] [MeSH:C0011892] abuser [MeSH:C0338666] discuss,neurological|hepatorenal
thalamus pathway ventricular tachycardia [MeSH:C0042514],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome migraine pathway method longitudinal trial [MeSH:C0023981] cardiac patient measure gray matter [MeSH:C0018220] neuron [MeSH:C0027882] result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],neurological
vasodilator stroke [MeSH:C0042402] brain [MeSH:C0006104] insight,question [MeSH:C0600648] ace inhibitor affect dementia [MeSH:C0497327] tic mechanism method retrospective [MeSH:C0035363] elderly patient assess multiple sclerosis [MeSH:C0026769] serotonin [MeSH:C0036751] result decrease mortality rate [MeSH:C0205848] implication optimization [MeSH:C0376695],neurological
change peroxisome preneoplastic liver hepatoma [MeSH:C2239176] mouse [MeSH:C0026809] induce alpha-benzene hexachloride [MeSH:C0005038],peroxisome [MeSH:C0752063] hepatoma [MeSH:C2239176] [MeSH:C2239176] [MeSH:C0752063] hyperplastic preneoplastic liver lesion induce mouse [MeSH:C0026809] ppm alpha-benzene hexachloride [MeSH:C0005038] examine histochemically electron microscopically hepatoma [MeSH:C2239176] [MeSH:C2239176] well-differentiated tumor contain considerable number peroxisome [MeSH:C0752063] tumor cell respond ethyl-alpha-p-chlorophenoxyisobutyrate proliferation [MeSH:C0596290] peroxisome [MeSH:C0752063] 6th week carcinogen [MeSH:C0007090] feeding [MeSH:C0086225] hyperplastic nodule [MeSH:C0040137] [MeSH:C0040137] appear advanced stage [MeSH:C1121259] majority nodule [MeSH:C0040137] [MeSH:C0040137] show considerable number peroxisome [MeSH:C0752063] inductive proliferation [MeSH:C0596290] peroxisome [MeSH:C0752063] nodule [MeSH:C0040137] [MeSH:C0040137] focus proliferation [MeSH:C0596290] cell [MeSH:C0596290] show inducibility proliferation [MeSH:C0596290] peroxisome [MeSH:C0752063] appear cell proliferate [MeSH:C0596290] replace nodule [MeSH:C0040137] [MeSH:C0040137] process hepatoma [MeSH:C2239176] [MeSH:C2239176] appear form abnormal [MeSH:C0853087] matrical [MeSH:C0331392] inclusion peroxisome [MeSH:C0752063] form cell hyperplastic nodule [MeSH:C0040137] [MeSH:C0040137] ethyl-alpha-p-chlorophenoxyisobutyrate unlike case rat,hepatorenal|oncological
single origin phenylketonuria yemenite jew,phenylketonuria [MeSH:C0031485] pku metabolic disease [MeSH:C0025517] cause recessive mutation gene [MeSH:C0017361] encode hepatic enzyme phenylalanine hydroxylase [MeSH:C0031456] pah incidence [MeSH:C0021149] pku vary widely different geographic area [MeSH:C3494296] high live birth ireland [MeSH:C0022067] western scotland [MeSH:C0036453] yemen [MeSH:C0043402]ite jew limited number point mutation account pku case european population [MeSH:C0032659] report single molecular defect deletion span exon pah gene responsible pku case yemen [MeSH:C0043402]ite jews examination [MeSH:C0376306] random sample yemen [MeSH:C0043402]ite jew molecular probe detect carrier deletion indicate high frequency defective [MeSH:C0011139] gene community [MeSH:C0009462] [MeSH:C0009462] delete pah gene trace different location yemen [MeSH:C0043402] family history [MeSH:C0241889] official document yemen [MeSH:C0043402]ite jewish community [MeSH:C0009462] show common ancestor carrier genetic defect live sana capital yemen [MeSH:C0043402] [MeSH:C0043402] eighteenth century,hepatorenal
somatic rearrangement chromosome human [MeSH:C0086418] lymphocyte,ataxia-telangiectasia rare genetic disorder [MeSH:C0019247] associate [MeSH:C0004083] immune deficiency chromosome [MeSH:C0398686] instability predisposition [MeSH:C0314657] lymphoid [MeSH:C0764881] malignancy [MeSH:C0006826] [MeSH:C0006826] detect chromosomally anomalous clone [MeSH:C0009013] [MeSH:C0009013] [MeSH:C0009013] lymphocyte [MeSH:C0024264] patient [MeSH:C0030705] disorder chromosome banding [MeSH:C0008627] disclose clone [MeSH:C0009013] [MeSH:C0009013] [MeSH:C0009013] consistently mark structural rearrangement long arm q chromosome translocation [MeSH:C0599893] involve 4q find clone [MeSH:C0009013] [MeSH:C0009013] [MeSH:C0009013] obtain seven patient [MeSH:C0030705] ring chromosome [MeSH:C0035639] find clone [MeSH:C0009013] [MeSH:C0009013] [MeSH:C0009013] obtain finding obtain patient [MeSH:C0030705] ataxia-telangiectasia suggest structural rearrangement 4q initial chromosomal lymphocyte [MeSH:C0024264] clone [MeSH:C0009013] [MeSH:C0009013] [MeSH:C0009013] patient [MeSH:C0030705] disorder chromosome lymphocyte [MeSH:C0024264] [MeSH:C0024264] patient [MeSH:C0030705] study onset chronic lymphocytic leukemia leukemia [MeSH:C0023434] diagnose [MeSH:C0011900] lymphocyte [MeSH:C0024264] clone [MeSH:C0009013] [MeSH:C0009013] [MeSH:C0009013] 4q translocation [MeSH:C0599893] clone [MeSH:C0009013] [MeSH:C0009013] [MeSH:C0009013] appear give rise leukemic cell [MeSH:C2004493] hypothesize structural rearrangement 4q directly related abnormal [MeSH:C0853087] growth lymphocyte [MeSH:C0024264] [MeSH:C0024264] step development lymphoid [MeSH:C0764881] malignancy [MeSH:C0006826] [MeSH:C0006826] increase evidence [MeSH:C5575834] provide nonrandom involvement 4q african-type burkitt lymphoma lymphoid [MeSH:C0764881] neoplasm strengthen hypothesis [MeSH:C3179072],neurological|oncological
epilepsy albumin [MeSH:C0014544] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer uremia mechanism method retrospective diabetic patient [MeSH:C0030705] assess peritoneal [MeSH:C1955857] dialysis blood urea nitrogen [MeSH:C0028158] result improve outcome [MeSH:C0206277] implication practice guideline,hepatorenal
pkd peripheral artery disease [MeSH:C1704436] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] stroke [MeSH:C0038454] participant [MeSH:C1708335] cancer patient aortic valve glomerular filtration rate [MeSH:C0017654] result decrease mortality [MeSH:C0026565] rate atrioventricular block correlation [MeSH:C0004245] cost-effectiveness implication,cardiovascular|hepatorenal
lymphoma ventricle cardiac connection,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer defibrillator method cardiac patient undergo cross-sectional stenosis [MeSH:C0010362] deep vein thrombosis [MeSH:C0149871] assessment [MeSH:C0030198] result well quality life measure healthcare advancement,cardiovascular
molecular basis human [MeSH:C0086418] mitochondrial [MeSH:C0949610] very-long-chain acyl-coa dehydrogenase deficiency [MeSH:C3887523] cause cardiomyopathy sudden death childhood,beta-oxidation long-chain fatty acid provide major source energy heart defect enzyme beta-oxidation pathway cause sudden unexplained death childhood acute hepatic encephalopathy [MeSH:C0019151] liver failure [MeSH:C0085605] skeletal myopathy cardiomyopathy [MeSH:C0878544] [MeSH:C0878544] very-long-chain acyl-coa dehydrogenase vlcad [MeSH:C0065170] [MeSH:C0065170] very-long-chain-acyl-coa acceptor -oxidoreductase ec catalyze step beta-oxidation isolate human [MeSH:C0086418] [MeSH:C0086418] vlcad [MeSH:C0065170] cdna gene [MeSH:C0006556] determine complete nucleotide sequence polymerase chain reaction amplification vlcad [MeSH:C0065170] mrna [MeSH:C0035696] genomic exon define molecular defect patient [MeSH:C0030705] vlcad [MeSH:C0065170] deficiency present unexplained cardiac arrest cardiomyopathy [MeSH:C0878544] [MeSH:C0878544] [MeSH:C0878544] homozygous [MeSH:C0019904] mutation [MeSH:C0026882] [MeSH:C0026882] consensus dinucleotide donor splice site g associate universal skipping prior exon exon second compound heterozygote [MeSH:C0019425] missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0599155] c1 change arginine [MeSH:C0003765] residue tryptophan allele single base deletion intron-exon boundary second mutation [MeSH:C0026882] [MeSH:C0026882] initial delineation human [MeSH:C0086418] [MeSH:C0086418] mutation [MeSH:C0026882] [MeSH:C0026882] vlcad [MeSH:C0065170] suggest vlcad [MeSH:C0065170] deficiency reduce myocardial fatty acid beta-oxidation energy production [MeSH:C0033268] associate cardiomyopathy [MeSH:C0878544] [MeSH:C0878544] sudden death childhood,cardiovascular|hepatorenal
thromboembolism atrial fibrillation vascular insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome [MeSH:C0206277] dilate cardiomyopathy pathway method [MeSH:C0007193] randomized control trial [MeSH:C1096777] cardiac patient measure venous hypotension [MeSH:C0020649] result well quality life measure cost-effectiveness [MeSH:C1511536] implication,cardiovascular
hepatitis hepatorenal lens [MeSH:C0019158],design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] hypertension [MeSH:C0020538] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] hepatocellular gamma glutamyl transferase [MeSH:C0017040] result favorable safety profile nephroblastoma correlation practice guideline,hepatorenal
immunotherapy [MeSH:C0021083] chronic kidney disease [MeSH:C1561643] brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome [MeSH:C0206277] dopamine pathway method longitudinal trial cancer patient [MeSH:C0030705] measure glioma brain [MeSH:C0017638] result improve disease management [MeSH:C0039798] optimization [MeSH:C0376695],neurological
levetiracetam [MeSH:C0377265] adjunct phenobarbital cat [MeSH:C0031412] suspect idiopathic epilepsy [MeSH:C2363129],assess pharmacokinetic efficacy tolerability oral [MeSH:C0029170] levetiracetam [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] administer adjunct phenobarbital [MeSH:C0031412] [MeSH:C0031412] cat [MeSH:C0007450] [MeSH:C0007450] [MeSH:C0007450] [MeSH:C0031412] poorly control suspect idiopathic epilepsy [MeSH:C2363129] [MeSH:C2363129] [MeSH:C2363129] design-open-label noncomparative trial animal [MeSH:C0003062] cat [MeSH:C0007450] [MeSH:C0007450] [MeSH:C0007450] suspect idiopathic epilepsy [MeSH:C2363129] [MeSH:C2363129] [MeSH:C2363129] poorly control phenobarbital [MeSH:C0031412] [MeSH:C0031412] unacceptable adverse effect [MeSH:C0001688] [MeSH:C0001688] treat phenobarbital [MeSH:C0031412] [MeSH:C0031412] procedure cat [MeSH:C0007450] [MeSH:C0007450] [MeSH:C0007450] treat levetiracetam [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] mg kg mg lb po q h minimum week serum [MeSH:C0229671] [MeSH:C0229671] levetiracetam [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] concentration [MeSH:C0311432] [MeSH:C0311432] measure hour drug administration maximum [MeSH:C4505223] minimum serum [MeSH:C0229671] [MeSH:C0229671] concentration [MeSH:C0311432] [MeSH:C0311432] elimination half-life [MeSH:C0018517] [MeSH:C0018517] calculate seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] frequency [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] initiation levetiracetam [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] compare adverse effect [MeSH:C0001688] [MeSH:C0001688] record result median maximum serum [MeSH:C0229671] [MeSH:C0229671] levetiracetam [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] concentration [MeSH:C0311432] [MeSH:C0311432] microg ml median minimum serum [MeSH:C0229671] [MeSH:C0229671] levetiracetam [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] concentration [MeSH:C0311432] [MeSH:C0311432] microg ml median elimination half-life [MeSH:C0018517] [MeSH:C0018517] hour median seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] frequency [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] prior levetiracetam [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] mo significantly high median seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] frequency [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] initiation levetiracetam [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] mo cat [MeSH:C0007450] [MeSH:C0007450] [MeSH:C0007450] classify respond levetiracetam [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] ie reduction [MeSH:C1827449] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] frequency [MeSH:C0376249] [MeSH:C0376249] [MeSH:C0376249] cat [MeSH:C0007450] [MeSH:C0007450] [MeSH:C0007450] transient lethargy inappetence conclusion relevance result suggest levetiracetam [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] [MeSH:C0377265] tolerate cat [MeSH:C0007450] [MeSH:C0007450] [MeSH:C0007450] useful adjunct phenobarbital [MeSH:C0031412] [MeSH:C0031412] cat [MeSH:C0007450] [MeSH:C0007450] [MeSH:C0007450] [MeSH:C0031412] idiopathic epilepsy [MeSH:C2363129] [MeSH:C2363129] [MeSH:C2363129],neurological
radiculopathy [MeSH:C0700594] meet atrial fibrillation [MeSH:C0004238] neurological perspective,cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve neuropathy [MeSH:C0015464] cerebellar method conduct observational [MeSH:C0302523] evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine memory loss [MeSH:C0751295] parameter result superior efficacy [MeSH:C5690761] healthcare advancement,neurological
protective effect terminalia chebula experimental [MeSH:C0016998] myocardial injury [MeSH:C0027055] induce isoproterenol [MeSH:C0022245],cardioprotective [MeSH:C0007209] effect ethanolic extract terminalia chebula fruit [MeSH:C0016767] mg kg body wt examine isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] mg kg body wt induce myocardial damage rat [MeSH:C0034721] [MeSH:C0034721] isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] administered rat [MeSH:C0034721] [MeSH:C0034721] lipid peroxide [MeSH:C0023776] [MeSH:C0023776] increase significantly serum [MeSH:C0229671] heart decrease observe activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C0020115] myocardial marker enzyme [MeSH:C0014442] [MeSH:C0014442] concomitant increase activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C0020115] serum [MeSH:C0229671] histopathological examination carry confirm myocardial necrosis chebula extract pretreatment [MeSH:C0376495] find ameliorat [MeSH:C0034721] [MeSH:C0034721]e effect isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] lipid peroxide [MeSH:C0023776] [MeSH:C0023776] formation retain activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C0020115] diagnostic marker enzyme [MeSH:C0014442] [MeSH:C0014442],cardiovascular
mutation [MeSH:C0026882] brca1 gene [MeSH:C0376571] family early-onset breast ovarian cancer [MeSH:C1140680],analyse proband family history breast ovarian cancer germline mutation code region [MeSH:C0206530] brca1 [MeSH:C0259275] [MeSH:C0259275] candidate gene [MeSH:C0017337] single-strand conformation polymorphism [MeSH:C0032529] sscp pcr-amplified genomic dna total putative disease-causing alteration identify frameshift nonsense mutation [MeSH:C0079380] addition find missense mutation [MeSH:C0599155] change final cysteine [MeSH:C0010654] brca1 [MeSH:C0259275] [MeSH:C0259275] zinc finger motif glycine [MeSH:C0080347] consistent tumour suppressor model [MeSH:C0597611] support notion candidate gene [MeSH:C0017337] fact brca1 [MeSH:C0259275] [MeSH:C0259275] heterogene [MeSH:C0017337]ity [MeSH:C0242960] mutation couple large size gene [MeSH:C0017337] indicate application brca1 [MeSH:C0259275] [MeSH:C0259275] mutation testing technically challenging,oncological
septum [MeSH:C0752060] meet valvular heart disease [MeSH:C0018824] neurological perspective,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] hypertension [MeSH:C0020538] participant [MeSH:C1708335] cardiac patient norepinephrine capillary [MeSH:C0028351] result well quality life measure restrictive cardiomyopathy [MeSH:C0007196] correlation safety [MeSH:C0036043] consideration,neurological|cardiovascular
new founder [MeSH:C0242918] haplotype [MeSH:C0018591] myotonic dystrophy locus southern africa [MeSH:C0001746],association normal [MeSH:C0004083] allele ctg repeat nearby polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] myotonin protein kinase gene [MeSH:C0216045] alu insertion deletion polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] myotonic dystrophy kinase dmk g intron hinfi polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] analyze south africa [MeSH:C0001737]n negroid [MeSH:C0037712] population [MeSH:C0032659] myotonic dystrophy dm [MeSH:C0027126] describe south africa [MeSH:C0001737]n negroid [MeSH:C0037712] ctg allelic [MeSH:C0524869] distribution [MeSH:C1704711] significantly different caucasoid [MeSH:C0007457] japanese ctg repeat length rare striking linkage [MeSH:C0242239] disequilibrium specific allele alu polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] alu in alu del hinfi polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] hinfi- hinfi- ctg repeat polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] see caucasoid [MeSH:C0007457] european [MeSH:C0239307] canadian population [MeSH:C0032659] [MeSH:C0032659] find south africa [MeSH:C0001737]n negroid [MeSH:C0037712] population [MeSH:C0032659] numerous haplotype [MeSH:C0018591] previously describe european [MeSH:C0239307] find likely small number africa [MeSH:C0001737]n chromosome [MeSH:C0008633] present progenitor [MeSH:C0038250] non-africa [MeSH:C0001737]n people [MeSH:C5690824] [MeSH:C5690824] provide support africa [MeSH:C0001737] model origin modern human [MeSH:C0086418] suggest rare ancestral dm mutation event occur migration africa [MeSH:C0001737] [MeSH:C0001737] absence dm sub-saharan negroid [MeSH:C4727186] people [MeSH:C5690824] [MeSH:C5690824],neurological
proliferation-related expression p1 nm2 nucleoside diphosphate kinase,high expression [MeSH:C0017262] [MeSH:C0017262] nm2-h1 gene encode nucleoside diphosphate kinase [MeSH:C0028615] find correlate diminish metastasis tumor [MeSH:C0027651] [MeSH:C0027627] previously identify protein product [MeSH:C0016158] nm2-h1 gene two-dimensional electrophoretic gel designate p1 nm2 neuroblastoma high level [MeSH:C0018759] [MeSH:C0018759] p1 nm2 associate amplification [MeSH:C0017256] n-myc oncogene [MeSH:C0086661] large tumor [MeSH:C0027651] mass metastasis observe advanced stage tumor [MeSH:C0027651] compare limited stage disease variable expression [MeSH:C0017262] [MeSH:C0017262] nm2-h1 different tumor [MeSH:C0027651] investigate [MeSH:C0035173] relationship [MeSH:C0021797] amount protein cell [MeSH:C0007634] [MeSH:C0007634] proliferation level [MeSH:C0018759] [MeSH:C0018759] p1 nm2 compare rest mitotically stimulate normal human pbls leukemia cell [MeSH:C0007634] p1 [MeSH:C2004493] nm2 increase normal lymphocyte [MeSH:C0024264] [MeSH:C0024264] response mitotic stimulation [MeSH:C0031734] parallel increase dna synthesis leukemia cell [MeSH:C0007634] obtain patient [MeSH:C0030705] different subtype acute leukemia p1 nm2 level [MeSH:C0018759] [MeSH:C0018759] increase relative rest normal lymphocyte [MeSH:C0024264] [MeSH:C0024264] mitotically stimulate lymphocyte [MeSH:C0024264] [MeSH:C0024264] cyclosporin [MeSH:C0010592] inhibit [MeSH:C0021463] proliferation block increase p1 nm2 leukemia cell [MeSH:C0007634] line hl- dimethylsulfoxide [MeSH:C0012403] induce terminal differentiation [MeSH:C0007589] result diminish level [MeSH:C0018759] [MeSH:C0018759] p1 nm2 provide evidence [MeSH:C5575834] nm2-h1 expression [MeSH:C0017262] [MeSH:C0017262] related cell [MeSH:C0007634] proliferative activity,neurological|oncological
aberrant [MeSH:C0008519] splicing [MeSH:C0376437] chm gene cause choroideremia [MeSH:C0008525],choroideremia [MeSH:C0008525] chm x-linked [MeSH:C0678928] progressive [MeSH:C1449744] degeneration choroid retina [MeSH:C0035304] unrelated male [MeSH:C0086582] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] carry deletion [MeSH:C0017260] partially clone chm gene finland [MeSH:C0016132] live [MeSH:C0023884] chm patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] belong apparently unrelated pedigree molecular deletion [MeSH:C0017260] involve chm gene detect family screen remain family point mutation [MeSH:C0162735] large family single nucleotide insertion donor splice site exon c [MeSH:C0015295] lead aberrantly splice mrna produce premature stop codon mutation assay [MeSH:C0242612] easily amplification digestion msel finding provide additional evidence [MeSH:C5575834] pathogenetic role chm mutation [MeSH:C0026882] provide diagnostic tool fifth world know chm patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],neurological
cardiomyopathy [MeSH:C0878544] chf cardiac connection,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve cancer outcome cancer pathway method randomized control trial [MeSH:C1096777] adult population measure diastolic [MeSH:C0012000] colorectal cancer [MeSH:C0009402] result enhance therapeutic response [MeSH:C0087111] healthcare advancement,cardiovascular|oncological
leukemia [MeSH:C0023418] neurodegenerative [MeSH:C0524851] exploring neural pathway [MeSH:C0027792],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] schwannoma method [MeSH:C0027809] cardiac patient undergo cross-sectional parkinsonism bell palsy assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] safety [MeSH:C0036043] consideration,neurological
flavonoid [MeSH:C0596577] apigenin [MeSH:C0912024] delay [MeSH:C5544400] forget passive avoidance conditioning rat [MeSH:C0034721],present experiment [MeSH:C0020123] perform effect [MeSH:C4277511] flavonoid [MeSH:C0596577] apigenin [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] mg kg intraperitoneally p h acquisition [MeSH:C0023013] [MeSH:C0023013] [MeSH:C0023013] h retention [MeSH:C4704685] [MeSH:C4704685] performance [MeSH:C0871966] forget step-through passive avoidance task young [MeSH:C0340037] male [MeSH:C0086582] wistar rat [MeSH:C0034721] [MeSH:C0034716] difference saline- apigenin [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024]-treated group h retention [MeSH:C4704685] [MeSH:C4704685] trial furthermore apigenin [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] prevent [MeSH:C0000918] amnesia [MeSH:C0002622] induce scopolamine [MeSH:C0036442] 1 mg kg p min acquisition [MeSH:C0023013] [MeSH:C0023013] [MeSH:C0023013] saline- apigenin [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024]-treated rat [MeSH:C0034721] step dark compartment cut-off reteste weekly week saline treated decline passive avoidance response observe week complete memory [MeSH:C0025260] loss [MeSH:C0751295] find week acquisition [MeSH:C0023013] [MeSH:C0023013] [MeSH:C0023013] passive avoidance task end experiment [MeSH:C0020123]al period animal [MeSH:C0003062] treat apigenin [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] step suggest apigenin [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] delay [MeSH:C5544400] long-term [MeSH:C0023977] forgetting modulate h retention [MeSH:C4704685] [MeSH:C4704685] fear [MeSH:C0015726] memory [MeSH:C0025260] obtain beneficial effect [MeSH:C4277511] apigenin [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] [MeSH:C0912024] passive avoidance conditioning mediate mechanism [MeSH:C1524059] implicate action muscarinic cholinergic system [MeSH:C0242947],neurological
immunotherapy [MeSH:C0021083] diabete mellitus brain insight,longitudinal [MeSH:C0023981] examine calcium channel blocker heart disease cancer [MeSH:C0006684] patient [MeSH:C0030705] investigation [MeSH:C0035173] include multiple sclerosis diastolic endothelium method participant [MeSH:C1708335] include result well quality life measure implication therapeutic [MeSH:C0087111] innovation,neurological|cardiovascular
nephrotoxicity cyclosporin [MeSH:C0010592] fk5 inhibition [MeSH:C0027790] calcineurin phosphatase [MeSH:C0908197],cyclosporin csa [MeSH:C0010592] mg kg fujimycine fk5 mg kg related macrolide [MeSH:C0282563] immunosuppressant rapamycin [MeSH:C0072980] [MeSH:C0072980] mg kg cause reduction glomerular filtration [MeSH:C0017654] rate degenerative change proximal tubular epithelium hypertrophy juxtaglomerular apparatus [MeSH:C0022445] male [MeSH:C0086582] wistar rat [MeSH:C0034716] give day [MeSH:C0011017] molecular mechanism csa fk5 toxicity [MeSH:C0040539] investigate [MeSH:C0035173] cyclophilin fk5-binding protein main intracytoplasmic receptor csa [MeSH:C0206587] fk5 respectively detect renal tissue extract [MeSH:C0040291] kidney high level immunoreactive enzymatically active calcineurin [MeSH:C0054450] find inhibit [MeSH:C0021463] [MeSH:C0021463] immunosuppressant csa fk5 rapamycin [MeSH:C0072980] [MeSH:C0072980] finally specific immunophilin [MeSH:C0600486]-drug-calcineurin [MeSH:C0054450] complex form presence csa fk5 rapamycin [MeSH:C0072980] [MeSH:C0072980] result suggest nephrotoxic effect csa fk5 likely mediate binding renal [MeSH:C0171961] immunophilin [MeSH:C0600486] inhibit [MeSH:C0021463] [MeSH:C0021463] calcineurin [MeSH:C0054450] phosphatase,neurological|hepatorenal
pentoxifylline [MeSH:C0030899] trental [MeSH:C0699487] inhibit [MeSH:C0021463] dipyridamole-induced coronary hyperemia implication dipyridamole-thallium- myocardial imaging [MeSH:C2350390],dipyridamole [MeSH:C0012582]-thallium- imaging [MeSH:C0887832] [MeSH:C0887832] perform patient [MeSH:C0030705] [MeSH:C0030705] unable exercise [MeSH:C0015259] peripheral vascular disease [MeSH:C0085096] patient [MeSH:C0030705] [MeSH:C0030705] take pentoxifylline [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] trental [MeSH:C0699487] methylxanthine [MeSH:C0066447] derivative improve intermittent claudication [MeSH:C0021775] pentoxifylline [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] inhibit [MeSH:C0021463] [MeSH:C0021463] dipyridamole [MeSH:C0012582]-induced coronary hyperemia like methylxanthine [MeSH:C0066447] theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] stop prior dipyridamole [MeSH:C0012582]-thallium- imaging [MeSH:C0887832] [MeSH:C0887832] unknown study hyperemic response dipyridamole [MeSH:C0012582] seven open-chest anesthetize dog pretreatment [MeSH:C0376495] pentoxifylline [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] mg kg v theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] mg kg v circumflex coronary blood flow [MeSH:C0005775] differ significantly group dipyridamole [MeSH:C0012582] significantly increase coronary blood flow [MeSH:C0005775] mm kg v pentoxifylline [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] p dose pentoxifylline [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] [MeSH:C0030899] significantly decrease dipyridamole [MeSH:C0012582]-induced hyperemia peak coronary blood flow [MeSH:C0005775] [MeSH:C0005775] significantly low theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] p conclude pentoxyifylline [MeSH:C0030899] inhibit [MeSH:C0021463] [MeSH:C0021463] dipyridamole [MeSH:C0012582]-induced coronary hyperemia high dose,cardiovascular
international [MeSH:C1138414] mexiletine [MeSH:C0025887] placebo [MeSH:C0032041] antiarrhythmic coronary trial report arrhythmia [MeSH:C0003811] finding impact [MeSH:C5544368],antiarrhythmic effect [MeSH:C4277511] [MeSH:C0003195] sustained release form mexiletine [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] mexitil-perlonget evaluate double-blind [MeSH:C0013072] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] trial patient [MeSH:C0030705] recent document myocardial infarction [MeSH:C0027051] primary response variable base central reading hour ambulatory [MeSH:C0002423] electrocardiographic recording [MeSH:C0180600] define occurrence single premature ventricular complex [MeSH:C0151636] consecutive minute block run premature ventricular complex entire hour electrocardiographic recording [MeSH:C0180600] large difference regard statistically mexiletine [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] group [MeSH:C0018257] [MeSH:C0018257] note end point month trend observe difference observe serum [MeSH:C0229671] mexiletine [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] level [MeSH:C0018759] obtain generally low observe study [MeSH:C0085973] regular form drug death [MeSH:C0013227] mexiletine [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] difference statistically incidence coronary event similar group [MeSH:C0018257] [MeSH:C0018257] previously recognize effect [MeSH:C4277511] particularly tremor [MeSH:C0040822] gastrointestinal problem frequent mexiletine [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] [MeSH:C0025887] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041],neurological|cardiovascular
assessment [MeSH:C0030198] cardiomyocyte [MeSH:C0225828] dna synthesis hypertrophy adult [MeSH:C0001675] mouse [MeSH:C0026809],ability cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] synthesize dna response experimentally [MeSH:C0016998] induce cardiac hypertrophy [MeSH:C1383860] [MeSH:C1383860] assess adult [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] mouse [MeSH:C0026809] [MeSH:C0026809] isoproterenol [MeSH:C0022245] deliver osmotic minipump implantation adult [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] c3heb fej mouse [MeSH:C0026809] [MeSH:C0026809] result increase heart weight [MeSH:C1821269] increase cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] area dna synthesis [MeSH:C0016026] [MeSH:C0016026] assess autoradiographic [MeSH:C0004400] isolate cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] observe hypertrophic heart survey independent inbred strain mouse [MeSH:C0026809] [MeSH:C1520439] [MeSH:C0025927] [MeSH:C0026809] reveal ventricular cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] nuclear number range mononucleate suggest cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] terminal [MeSH:C0330871] differentiation influence [MeSH:C0683549] directly indirectly genetic [MeSH:C0017380] determine capacity [MeSH:C0042834] reactive [MeSH:C0006560] dna synthesis [MeSH:C0016026] [MeSH:C0016026] subject genetic [MeSH:C0017380] regulation cardiac hypertrophy [MeSH:C1383860] [MeSH:C1383860] induce strain mouse [MeSH:C0026809] [MeSH:C1520439] [MeSH:C0026809] comprise extreme nuclear number survey indicate adult [MeSH:C0001675] [MeSH:C0001675] [MeSH:C0001675] mouse [MeSH:C0026809] [MeSH:C0026809] atrial ventricular cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] [MeSH:C0225828] synthesize dna response isoproterenol [MeSH:C0022245]-induced cardiac hypertrophy [MeSH:C1383860] [MeSH:C1383860],cardiovascular|hepatorenal
persistent [MeSH:C0026205] sterile leukocyturia associate impaired renal function human immunodeficiency virus [MeSH:C0019682] type -infected child [MeSH:C0008059] treat indinavir [MeSH:C0376637],prolonged administration [MeSH:C0001554] indinavir [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] associate occurrence variety renal complication [MeSH:C1171258] adult [MeSH:C0001675] well-documented effect restrict use potent protease inhibitor [MeSH:C0033607] child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] design prospective monitor indinavir [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637]-related nephrotoxicity cohort human immunodeficiency virus [MeSH:C0019682] type -infected child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] treat indinavir [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] method urinary ph albumin creatinine [MeSH:C0010294] presence erythrocyte [MeSH:C0014792] leukocyte bacteria [MeSH:C0023516] crystal culture [MeSH:C0010453] analyze month week serum creatinine [MeSH:C0010294] level routinely determine point steady-state pharmacokinetic [MeSH:C0031327] indinavir [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] week initiation [MeSH:C0030943] indinavir [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] result cumulative incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] persistent [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] sterile leukocyturia cell micro l consecutive visit [MeSH:C0020043] week persistent [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] sterile leukocyturia frequently associate mild increase urine albumin [MeSH:C0001924] [MeSH:C0001924] creatinine [MeSH:C0010294] ratio microscopic hematuria cumulative incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] serum creatinine [MeSH:C0010294] level normal week child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] persistent [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] sterile leukocyturia frequently serum creatinine [MeSH:C0010294] level normal child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] persistent [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] sterile leukocyturia child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] young year persistent [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] sterile leukocyturia significantly frequent old child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] high cumulative incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] persistent [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] leukocyturia find child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] area curve [MeSH:C0376690] mg l x h peak serum indinavir [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] mg l child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] indinavir [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] discontinue nephrotoxicity subsequently serum creatinine [MeSH:C0010294] level decrease urine albumin [MeSH:C0001924] [MeSH:C0001924] creatinine [MeSH:C0010294] ratio return zero leukocyturia disappear month conclusion child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] treat indinavir [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] high cumulative incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] persistent [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] sterile leukocyturia child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] persistent [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] sterile leukocyturia frequently increase serum creatinine [MeSH:C0010294] level normal young child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] additional risk renal complication [MeSH:C1171258] impairment renal function [MeSH:C0031843] child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] occur absence symptom nephrolithiasis indinavir [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637]-associated nephrotoxicity monitor closely especially child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] risk factor persistent [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] [MeSH:C0026205] sterile leukocyturia age year area curve [MeSH:C0376690] indinavir [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] [MeSH:C0376637] mg l x h c max mg l,neurological|hepatorenal
sinoatrial node dementia [MeSH:C0037189] vascular [MeSH:C0221214] insight,hypothesis statin improve cancer outcome systolic pathway method retrospective trial cardiac patient measure peripheral artery disease [MeSH:C1704436] cardiac result improve disease management [MeSH:C0039798] relevance,cardiovascular
molecular genetic [MeSH:C0086345] pku eastern europe nonsense mutation [MeSH:C0544885] associate haplotype [MeSH:C0018591] phenylalanine hydroxylase [MeSH:C0031456] gene,phenylketonuria pku [MeSH:C0031485] genetic disorder [MeSH:C0019247] secondary deficiency [MeSH:C0410173] hepatic [MeSH:C0227525] phenylalanine hydroxylase [MeSH:C0031456] pah mutation [MeSH:C0026882] [MeSH:C0026882] pah gene recently report linkage disequilibrium [MeSH:C0023746] observe rflp [MeSH:C0035268] haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] specific mutation [MeSH:C0026882] new molecular lesion identify exon pah gene hungarian pku direct sequencing pcr-amplified dna c-to-t transition [MeSH:C1257888] cause substitution [MeSH:C2936279] arg2 termination codon mutant [MeSH:C1564139] [MeSH:C1564139] allele [MeSH:C0002085] associate haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] pah gene mutation [MeSH:C0026882] [MeSH:C0026882] present mutant [MeSH:C1564139] [MeSH:C1564139] haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] allele [MeSH:C0002085] eastern european [MeSH:C0239307] present western [MeSH:C0003984] european [MeSH:C0239307] asian [MeSH:C0003988] rarity mutant [MeSH:C1564139] [MeSH:C1564139] allele [MeSH:C0002085] restricted geographic distribution suggest mutation [MeSH:C0026882]al event occur recently normal haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] eastern europe,hepatorenal
explore atrial fibrillation cholelithiasis [MeSH:C0004238],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer pyelonephritis [MeSH:C0034186] method cardiac patient undergo prospective hepatic alt assessment [MeSH:C0030198] result positive response relevance [MeSH:C2826293],hepatorenal
thrombosis [MeSH:C0040053] chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,longitudinal [MeSH:C0023981] examine metformin [MeSH:C0025598] hypertension [MeSH:C0020538] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include blood pressure tachycardia ventricle method participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication safety [MeSH:C0036043] consideration,cardiovascular
glutamate [MeSH:C0220839] pattern atrial fibrillation [MeSH:C0004238] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] cerebrospinal fluid pathway method cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure neurodegenerative stroke [MeSH:C0524851] result superior efficacy [MeSH:C5690761] safety [MeSH:C0036043] consideration,neurological
embolism hypertension [MeSH:C0013922] vascular [MeSH:C0221214] insight,hypertension [MeSH:C0020538] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve creatinine [MeSH:C0010294] cardiac method conduct observational [MeSH:C0302523] evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine cholelithiasis [MeSH:C0008350] parameter result well quality life measure practice guideline,cardiovascular|hepatorenal
atrium valvular heart disease [MeSH:C0018824] vascular [MeSH:C0221214] insight,dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve wilms tumor atrium method [MeSH:C0027708] conduct observational evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine cardiac parameter result decrease mortality rate [MeSH:C0205848] practice guideline,cardiovascular|hepatorenal
dose-related beneficial adverse effect [MeSH:C0001688] dietary [MeSH:C0012177] corticosterone [MeSH:C0010124] organophosphorus-induced delay neuropathy chicken [MeSH:C0008051],tri-ortho-tolyl phosphate totp mg kg po -diisopropyl phosphorofluoridate dfp [MeSH:C0022181] mg kg sc administer [MeSH:C0001554] adult [MeSH:C0001675] white leghorn chicken [MeSH:C0008051] hr place diet [MeSH:C0012155] contain ppm corticosterone [MeSH:C0010124] [MeSH:C0010124] supplement diet [MeSH:C0012155] continue sign lesion delay neuropathy [MeSH:C0015464] appear low concentration equal ppm corticosterone [MeSH:C0010124] [MeSH:C0010124] beneficial effect totp-induced neuropathy [MeSH:C0015464] great equal ppm exacerbated sign chicken [MeSH:C0008051] [MeSH:C0008051] give totp dfp [MeSH:C0022181] neurotoxic esterase [MeSH:C0068643] activity [MeSH:C0020115] hr totp dfp [MeSH:C0022181] value measure [MeSH:C0079809] chicken [MeSH:C0008051] give organophosphorous compound chicken [MeSH:C0029254] [MeSH:C0008051] give ppm corticosterone [MeSH:C0010124] [MeSH:C0010124] totp dfp [MeSH:C0022181] significantly elevated activity [MeSH:C0020115] plasma [MeSH:C0032105] cholinesterase [MeSH:C0008429] significantly inhibit [MeSH:C0021463] activity [MeSH:C0020115] liver carboxylesterase degenerate myelinated fiber [MeSH:C0006549] evident distal level [MeSH:C0018759] peripheral nerve [MeSH:C0031119] chicken [MeSH:C0008051] give totp dfp [MeSH:C0022181],neurological|hepatorenal
organ [MeSH:C0029250] orchestra multiple sclerosis,investigate [MeSH:C0035173] statin effect cancer hepatorenal syndrome method cancer patient [MeSH:C0030705] undergo cross-sectional ast renal cyst assessment [MeSH:C0030198] result improve outcome safety consideration,hepatorenal
hypertension [MeSH:C0020538] tricuspid valve [MeSH:C0040960] exploring neural pathway [MeSH:C0027792],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete serotonin mechanism method randomized control cancer [MeSH:C1096777] patient [MeSH:C0030705] assess parkinson disease myelopathy [MeSH:C0030567] result improve disease management [MeSH:C0039798] implication healthcare advancement,neurological|cardiovascular
procaterol [MeSH:C0072032] terbutaline [MeSH:C0039542] bronchial asthma [MeSH:C0004096] double-blind [MeSH:C0013072] placebo-controlled cross-over,procaterol [MeSH:C0072032] [MeSH:C0072032] [MeSH:C0072032] [MeSH:C0072032] new beta- adrenoceptor [MeSH:C0034783] stimulant study double-blind placebo-controlled cross-over trial patient [MeSH:C0030705] bronchial asthma [MeSH:C0004096] oral procaterol [MeSH:C0072032] [MeSH:C0072032] [MeSH:C0072032] [MeSH:C0072032] [MeSH:C0072032] microgram [MeSH:C0376691] [MeSH:C0376691] b procaterol [MeSH:C0072032] [MeSH:C0072032] [MeSH:C0072032] [MeSH:C0072032] microgram [MeSH:C0376691] [MeSH:C0376691] b terbutaline [MeSH:C0039542] [MeSH:C0039542] mg compare give randomly -week period [MeSH:C0080129] good effect find terbutaline [MeSH:C0039542] [MeSH:C0039542] anti-asthmatic [MeSH:C0282556] tremorgenic effect procaterol [MeSH:C0072032] [MeSH:C0072032] [MeSH:C0072032] [MeSH:C0072032] dose-related procaterol [MeSH:C0072032] [MeSH:C0072032] [MeSH:C0072032] [MeSH:C0072032] appear effective [MeSH:C5392218] dose test twice daily regiman appear suitable drug [MeSH:C0013227],neurological
combined antiretroviral therapy [MeSH:C5545321] cause cardiomyopathy [MeSH:C0878544] elevate plasma lactate transgenic aid mouse [MeSH:C0026809],highly active [MeSH:C0205681] antiretroviral therapy [MeSH:C5545321] haart [MeSH:C0887947] [MeSH:C0887947] implicate cardiomyopathy [MeSH:C0878544] cm elevated [MeSH:C0020443] [MeSH:C0020443] [MeSH:C0020443] plasma [MeSH:C0032105] lactate [MeSH:C0032105] la aid mechanism [MeSH:C1524059] mitochondria [MeSH:C0026237]l dysfunction [MeSH:C3502075] determine mitochondria [MeSH:C0026237]l event [MeSH:C0949610] haart [MeSH:C0887947] [MeSH:C0887947] vivo -week-old hemizygous transgenic aid mouse [MeSH:C0026809] [MeSH:C0026809] nl4 3delta gag pol [MeSH:C0016925] tg wild-type fvb n littermate treat haart [MeSH:C0887947] [MeSH:C0887947] combination zidovudine lamivudine [MeSH:C0043474] indinavir vehicle day [MeSH:C0011017] day [MeSH:C0011017] termination experiment [MeSH:C0020123] mouse [MeSH:C0026809] [MeSH:C0026809] undergo echocardiography [MeSH:C0013516] quantitation abundance molecular marker cm ventricular mrna [MeSH:C0035696] encode atrial natriuretic factor anf [MeSH:C0027481] sarcoplasmic calcium atpase [MeSH:C0916181] serca2 [MeSH:C1567357] determination [MeSH:C1148554] plasma [MeSH:C0032105] la myocardial histologic feature analyze semiquantitatively result confirm transmission electron microscopy [MeSH:C0678118] day [MeSH:C0011017] tg haart [MeSH:C0887947] [MeSH:C0887947] [MeSH:C0887947] [MeSH:C0887947] cohort [MeSH:C1706962] leave ventricular mass increase echocardiography [MeSH:C0013516] molecularly anf mrna [MeSH:C0035696] increase serca2 [MeSH:C1567357] mrna [MeSH:C0035696] decrease biochemically la elevated [MeSH:C0020443] [MeSH:C0020443] [MeSH:C0020443] mm pathologically granular [MeSH:C4552086] cytoplasmic [MeSH:C0206587] change find cardiac myocyte [MeSH:C0225828] indicate enlarge damaged mitochondria [MeSH:C0026237] finding confirm ultrastructurally change find cohort [MeSH:C1706962] day [MeSH:C0011017] anf elevated [MeSH:C0020443] [MeSH:C0020443] [MeSH:C0020443] tg haart [MeSH:C0887947] [MeSH:C0887947] [MeSH:C0887947] [MeSH:C0887947] cohort [MeSH:C1706962] result cumulative haart [MeSH:C0887947] [MeSH:C0887947] cause mitochondria [MeSH:C0026237]l cm elevated [MeSH:C0020443] [MeSH:C0020443] [MeSH:C0020443] la aid transgenic mouse [MeSH:C0025936] [MeSH:C0026809] [MeSH:C0026809],neurological|cardiovascular
hypotension [MeSH:C0020649] manifestation [MeSH:C0029166] cardiotoxicity [MeSH:C0876994] patient [MeSH:C0030705] receive cisplatin [MeSH:C0008838] -fluorouracil,cardiac [MeSH:C0018810] symptom include hypotension [MeSH:C0020649] develop patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] advanced colorectal carcinoma [MeSH:C0009402] treat cisplatin [MeSH:C0008838] cddp -fluorouracil -fu patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hypotension [MeSH:C0020649] associate severe leave ventricular dysfunction [MeSH:C0242973] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] require therapy [MeSH:C0039798] discontinuation cardiac [MeSH:C0018810] enzyme remain normal despite transient [MeSH:C0040704] electrocardiographic ekg change presentation [MeSH:C0022869] cardiac [MeSH:C0018810] hemodynamic echocardiographic [MeSH:C0013516] scintigraphic [MeSH:C0034606] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] suggest new manifestation [MeSH:C0029166] -fu cardiotoxicity [MeSH:C0876994] influence [MeSH:C0683549] cddp possible pathophysiologic [MeSH:C0031847] mechanism [MeSH:C1524059] discuss,neurological|cardiovascular|oncological
dilate cardiomyopathy [MeSH:C0007193] marker [MeSH:C0017393] colorectal cancer [MeSH:C0009402],stroke [MeSH:C0038454] affect elderly patient [MeSH:C0030705] worldwide particularly involve myocardium [MeSH:C0027061] deep vein thrombosis [MeSH:C0149871] method conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine cardiac parameter result improvement [MeSH:C2936612] primary endpoint relevance,cardiovascular
cancer cervical cancer [MeSH:C4048328] connection,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] head neck cancer [MeSH:C0278996] mechanism method retrospective cancer patient [MeSH:C0030705] assess ovarian cancer [MeSH:C1140680] lung cancer [MeSH:C0242379] result positive response implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
myoclonic atonic [MeSH:C1834570] absence seizure follow institution [MeSH:C0442681] carbamazepine therapy [MeSH:C0006949] child [MeSH:C0008059],child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] aged year treat carbamazepine [MeSH:C0006949] epilepsy [MeSH:C0006949] acute aberrant reaction characterize onset myoclonic [MeSH:C1834570] atypical absence atonic minor motor seizure [MeSH:C0036572] [MeSH:C0751494] [MeSH:C0751494] day [MeSH:C0011017] carbamazepine [MeSH:C0006949] discontinue child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] return state quickly minor motor seizure [MeSH:C0036572] [MeSH:C0751494] [MeSH:C0751494] resolve month seizure [MeSH:C0036572] persist child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] seizure [MeSH:C0036572] persist later find ceroid [MeSH:C0007831] lipofuscinosis [MeSH:C0023789] child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] anticonvulsant [MeSH:C0003286],neurological
hepatitis atrial flutter cardiac connection,hypothesis [MeSH:C3179072] aspirin improve cancer outcome [MeSH:C0206277] defibrillator pathway method prospective trial elderly patient measure heart failure [MeSH:C0018801] ectopic beat [MeSH:C0033036] result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
mexican glucose phosphate dehydrogenase variant revisit,glucose phosphate dehydrogenase g6pd [MeSH:C4742874] deficiency [MeSH:C2939465] [MeSH:C2939465] appear fairly common mexico examine dna previously report electrophoretically fast mexican g6pd [MeSH:C4742874] variant -g6pd [MeSH:C4742874] distrito federal g6pd [MeSH:C4742874] tepic g6pd [MeSH:C4742874] castilla variant believe basis biochemical [MeSH:C0017401] characterization population origin unique g----a transition nucleotide a----g transition nucleotide mutation [MeSH:C0026882] recognize characteristic g6pd [MeSH:C4742874] a- mexican male [MeSH:C0086582] g6pd [MeSH:C4742874] deficiency [MeSH:C2939465] find mutation [MeSH:C0026882] nlaiii foki pvuii psti haplotype [MeSH:C0018591] characteristic g6pd [MeSH:C4742874] -in africa [MeSH:C0001737] pvuii genotype [MeSH:C0017431] rare europe conclude g6pd [MeSH:C4742874] gene ancient origin africa [MeSH:C0001737] mexican patient [MeSH:C0030705] g6pd [MeSH:C4742874] -2a 6 g gene import recently spain variant know g6pd [MeSH:C4742874] betica prevalent,neurological
progressive [MeSH:C1449744] bile duct injury [MeSH:C0005400] thiabendazole [MeSH:C0039832] administration [MeSH:C0001554],-yr-old man develop jaundice [MeSH:C0022346] wk exposure [MeSH:C1390376] thiabendazole [MeSH:C0039832] cholestasis [MeSH:C0008370] persist yr liver transplant [MeSH:C0023911] perform liver biopsy [MeSH:C0005558] specimen [MeSH:C0200345] [MeSH:C0200345] hepatectomy [MeSH:C0019144] specimen [MeSH:C0200345] [MeSH:C0200345] remarkable complete disappearance interlobular bile duct [MeSH:C0005400] prominent fibrosis [MeSH:C0016059] hepatocellular regeneration present lobular architecture [MeSH:C0003737] preserve case represent example idiosyncratic drug-induced liver damage primary target injury bile duct [MeSH:C0005400] autoimmune [MeSH:C0004364] pathogenesis bile duct [MeSH:C0699748] [MeSH:C0005400] destruction [MeSH:C0206206] suggest,hepatorenal
phase [MeSH:C0080129] ii paclitaxel [MeSH:C0144576] plus cisplatin [MeSH:C0008838] first-line therapy head neck cancer [MeSH:C0278996] preliminary result,improve outcome patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C2987124] head neck carcinoma [MeSH:C1168401] [MeSH:C1168401] require investigation [MeSH:C0035173] new drug induction therapy [MeSH:C0013216] preliminary [MeSH:C4505218] result eastern [MeSH:C0015631] cooperative oncology single-agent paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] taxol bristol-myer squibb company princeton nj report response [MeSH:C0034746] rate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] head neck cancer paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] combination [MeSH:C0034865] successfully significantly improve median response [MeSH:C0034746] duration ovarian cancer [MeSH:C1140680] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] initiate phase [MeSH:C0080129] ii trial determine response [MeSH:C0034746] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] escalate paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] dose combine fixed-dose cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] granulocyte colony-stimulating factor support [MeSH:C0009392] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] untreated locally advance inoperable head neck carcinoma [MeSH:C1168401] [MeSH:C1168401] date man median age year good performance [MeSH:C0871966] status enter trial primary tumor site [MeSH:C0750974] oropharynx patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hypopharynx larynx oral cavity [MeSH:C0226896] unknown primary nasal cavity [MeSH:C0027423] parotid gland [MeSH:C0030580] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] evaluable toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] stage iii stage iv disease give day [MeSH:C0011017] [MeSH:C0011017] maximum cycle consist paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] -hour infusion [MeSH:C0841792] follow fixed dose cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] mg m2 dose level [MeSH:C0018759] incorporate escalate paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] dose intrapatient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] escalation give dose permit toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] permit writing dose [MeSH:C0043266] mg m2 evaluate [MeSH:C0013175] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] evaluable paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] dose mg m2 high granulocyte colony-stimulating factor microgram [MeSH:C0376691] kg give day [MeSH:C0011017] [MeSH:C0011017] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] evaluable response [MeSH:C0034746] seven achieve complete response [MeSH:C0034746] achieve partial response [MeSH:C0034746] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] disease progress overall response [MeSH:C0034746] rate respond patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] subsequent surgery radiotherapy [MeSH:C0034619] radical radiotherapy [MeSH:C0034619] pathologic [MeSH:C0030664] complete response [MeSH:C0034746] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] achieve complete response [MeSH:C0034746] alopecia paresthesia arthralgia myalgia [MeSH:C0231528] occur frequently exception grade myalgia [MeSH:C0231528] grade dose-limiting hematologic toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] see paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] effective first-line regiman locoregionally advanced head neck cancer continue warrant result far suggest dose-response [MeSH:C0034746] effect paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] dose mg m2,neurological|oncological
carrier frequency [MeSH:C0017270] brca1 [MeSH:C0259275] 5delag mutation [MeSH:C0026882] approximately percent ashkenazi jewish [MeSH:C1855627] individual,brca1 [MeSH:C0259275] major gene responsible inherit breast cancer [MeSH:C0006826] [MeSH:C0006142] [MeSH:C0006142] clone [MeSH:C0009013] unique mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect germline [MeSH:C0206530] individual breast ovarian cancer [MeSH:C1140680] [MeSH:C0006826] [MeSH:C1140680] [MeSH:C1140680] high-risk [MeSH:C0556482] pedigree female carrier brca1 [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] lifetime risk breast cancer [MeSH:C0006826] [MeSH:C0006142] [MeSH:C0006142] risk ovarian cancer [MeSH:C0006826] [MeSH:C1140680] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] stat individual unselected breast ovarian cancer [MeSH:C1140680] [MeSH:C0006826] [MeSH:C1140680] [MeSH:C1140680] determine know mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] individual confer risk cancer [MeSH:C0006826] [MeSH:C0035647] individual high-risk [MeSH:C0556482] family study far follow 5delag frameshift [MeSH:C0079380] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] ashkenazi jewish breast ovarian family determine frequency [MeSH:C0376249] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] ashkenazim seek genetic testing [MeSH:C0679560] condition unrelated cancer [MeSH:C0006826] reference individual select ethnic origin observe 5delag mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] ashkenazim confidence limit reference sample result suggest woman [MeSH:C0043210] ashkenazi descent especially high risk [MeSH:C0556482] develop breast ovarian cancer [MeSH:C1140680] [MeSH:C0006826] [MeSH:C1140680] [MeSH:C1140680],oncological
convulsion connection lymphoma,randomized control examine [MeSH:C1096777] ace inhibitor [MeSH:C0003015] dementia [MeSH:C0497327] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include alzheimer disease oligodendroglioma [MeSH:C0002395] memory loss method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
electron microscopic [MeSH:C0026019] investigation cyclophosphamide-induced lesion urinary bladder [MeSH:C0005682] rat [MeSH:C0034721] prevention [MeSH:C2700409] mesna [MeSH:C0000294],fully develop cyclophosphamide [MeSH:C0010583]-induced cystitis characterize nearly complete detachment [MeSH:C0035305] urothelium severe submucosal edema owe damage [MeSH:C0012860] [MeSH:C0012860] [MeSH:C0012860] microvascular bed focal muscle necrose initial response primary attack cyclophosphamide [MeSH:C0010583] metabolite [MeSH:C0003376] fragmentation [MeSH:C0376669] luminal membrane damage [MeSH:C0012860] [MeSH:C0012860] [MeSH:C0012860] cellular barrier hypertonic [MeSH:C3661514] urine subsequent break lateral cell membrane [MeSH:C0007603] superficial cell [MeSH:C0278403] plasma membrane [MeSH:C0007603] intermediate basal cell [MeSH:C0205646] intercellular intracellular edema [MeSH:C0015352] disintegration desmosome hemidesmosome [MeSH:C0230616] lead progressive degeneration detachment [MeSH:C0035305] epithelial cell exposure [MeSH:C1390376] splitting basal membrane [MeSH:C0025255] morphological change endothelial cell [MeSH:C0225336] pronounced late stage experiment involvement [MeSH:C0030699] [MeSH:C0030699] blood vessel [MeSH:C0005847] regardless diameter location-dependent extent damage [MeSH:C0012860] [MeSH:C0012860] [MeSH:C0012860] indicate direct type damage [MeSH:C0012860] [MeSH:C0012860] [MeSH:C0012860] precede mediator-induced increase permeability [MeSH:C0031164] morphological correlate formation [MeSH:C0029433] gap interendothelial cell [MeSH:C0225336] [MeSH:C0225336] connection venule [MeSH:C0042520] change effectively prevent mesna [MeSH:C0000294] sign possible involvement [MeSH:C0030699] [MeSH:C0030699] increase number specific granule [MeSH:C1523832] presume lysosomal function superficial cell [MeSH:C0278403],neurological
point mutation [MeSH:C0162735] thr meet alpha integrin [MeSH:C0292863] lead formation new human [MeSH:C0086418] platelet alloantigen sit [MeSH:C0085355] affect collagen-induced aggregation,new platelet [MeSH:C0005821]-specific [MeSH:C0085355] alloantigen term sit identify severe [MeSH:C1719672] case neonatal [MeSH:C0021290] alloimmune thrombocytopenia [MeSH:C3853779] sit alloantigen low frequency german population immunochemical study demonstrate sit epitope [MeSH:C0003316] reside platelet [MeSH:C0005821] glycoprotein gp ia nucleotide sequence gpia [MeSH:C0249229] [MeSH:C0249229] [MeSH:C0249229] cdna [MeSH:C0006556] derive sit -positive platelet [MeSH:C0005821] show c point mutation [MeSH:C0026882] result thr meet dimorphism [MeSH:C0036866] genomic dna sit -negative normal individual [MeSH:C0021228] show thr encode acg aca establish dna typing technique [MeSH:C0004631] elucidate organization [MeSH:C0029246] gpia [MeSH:C0249229] [MeSH:C0249229] [MeSH:C0249229] gene adjacent polymorphic [MeSH:C1720758] basis intron bp kb encompass -bp exon polymorphic [MeSH:C1720758] basis polymerase chain reaction-restriction fragment length [MeSH:C0035268] polymorphism dna derive donor restriction enzyme mae iii show meet form gpia [MeSH:C0249229] [MeSH:C0249229] [MeSH:C0249229] restricted sit phenotype [MeSH:C0031437] stable chinese hamster ovary transfectant express allele-specific recombinant form gpia [MeSH:C0249229] [MeSH:C0249229] [MeSH:C0249229] show anti-sit exclusively react glu meet glu thr lys thr isoform [MeSH:C0597298] contrast anti-br hpa-5b recognize lys thr form anti-br b hpa-5a react glu thr glu meet isoform [MeSH:C0597298] result demonstrate meet responsible formation [MeSH:C0029433] sit alloantigenic determinant amino acid lys glu specifically control expression [MeSH:C0017262] br br b epitope respectively platelet [MeSH:C0005821] aggregation response sit individual [MeSH:C0021228] diminish response collagen [MeSH:C0009325] indicate thr meet mutation [MeSH:C0026882] affect function [MeSH:C0031843] gpia [MeSH:C0249229] [MeSH:C0249229] [MeSH:C0249229] iia complex [MeSH:C1176474],neurological
confirmation brca1 [MeSH:C0259275] germline mutation [MeSH:C0206530] link breast ovarian cancer [MeSH:C1140680] family,provide genetic evidence support identity candidate gene brca1 characterization germline mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0206530] breast cancer [MeSH:C0006142] patient [MeSH:C0030705] ovarian cancer [MeSH:C1140680] patient [MeSH:C0030705] family cancer [MeSH:C0015576] link chromosome 7q2 different mutation [MeSH:C0026882] [MeSH:C0026882] detect screen brca1 dna rna single-strand conformation polymorphism [MeSH:C0032529] direct sequencing [MeSH:C0751971] seven mutation [MeSH:C0026882] [MeSH:C0026882] lead protein truncation site gene missense mutation [MeSH:C0026882] [MeSH:C0026882] occur independently family lead loss cysteine zinc binding domain intronic single basepair substitution destroy acceptor site activate cryptic splice site [MeSH:C1720838] lead basepair insertion chain termination family breast ovarian cancer chain termination mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] n-terminal half protein,oncological
cancer neurotransmitter [MeSH:C0027908] explore neural pathway [MeSH:C0027792],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] schwannoma bell palsy result well quality life measure radiculopathy [MeSH:C0700594] correlation healthcare advancement,neurological
echocardiography [MeSH:C0013516] reveal valvular heart disease [MeSH:C0018824] secret,question statin affect diabete substantia nigra [MeSH:C0038590] mechanism method longitudinal diabetic [MeSH:C0023981] patient [MeSH:C0030705] assess brain abscess [MeSH:C0006105] thalamus [MeSH:C0039729] result enhance therapeutic response [MeSH:C0087111] implication need investigation [MeSH:C0035173],neurological
peripheral neuropathy [MeSH:C4721453] pattern cancer patient [MeSH:C0030705],investigate [MeSH:C0035173] beta-blocker effect hypertension [MeSH:C0020538] cerebral method cancer patient [MeSH:C0030705] undergo observational [MeSH:C0302523] tic memory [MeSH:C0025260] loss assessment result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,neurological
chemotherapy pathway [MeSH:C0013216] heart failure [MeSH:C0018801],cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve kidney transplant [MeSH:C0022671] blood urea [MeSH:C0005845] nitrogen method [MeSH:C0028158] conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine hepatic [MeSH:C0227525] parameter result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],hepatorenal|oncological
metastatic cancer [MeSH:C1522484] coronary artery disease [MeSH:C1956346],design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation statin [MeSH:C0360714] diabete participant [MeSH:C1708335] elderly patient stem cell transplant lung cancer [MeSH:C0242379] result improve disease management [MeSH:C0039798] radiotherapy [MeSH:C0034619] correlation [MeSH:C0010100] relevance [MeSH:C2826293],oncological
hypertension [MeSH:C0020538] kidney transplant [MeSH:C0022671] exploring neural pathway [MeSH:C0027792],question [MeSH:C0600648] metformin [MeSH:C0025598] affect dementia [MeSH:C0497327] reticular [MeSH:C0035285] formation mechanism method retrospective [MeSH:C0035363] elderly patient assess neuropathy [MeSH:C0015464] memory loss result favorable safety profile implication therapeutic [MeSH:C0087111] innovation,neurological|hepatorenal
bone cancer [MeSH:C0279530] pathway atrial fibrillation [MeSH:C0004238],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect diabete immunotherapy method [MeSH:C0021083] cancer patient [MeSH:C0030705] undergo observational esrd [MeSH:C0302523] nash assessment [MeSH:C0030198] result well quality life measure practice guideline,hepatorenal|oncological
attenuate [MeSH:C0042211] disruption [MeSH:C3179075] prepulse inhibition dopaminergic stimulation maternal [MeSH:C0024915] deprivation [MeSH:C0043048] adolescent [MeSH:C0205653] corticosterone [MeSH:C0010124] rat [MeSH:C0034721],development [MeSH:C0243107] schizophrenia [MeSH:C0036341] include early neurodevelopment [MeSH:C0243107]al stress [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] component increase vulnerability [MeSH:C4063051] later stress [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850]ful life event [MeSH:C0023670] combination lead overt disease investigate [MeSH:C0035173] effect [MeSH:C4277511] early stress [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] form maternal [MeSH:C0024915] [MeSH:C0024915] deprivation [MeSH:C0043048] combine later stress [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] simulate chronic [MeSH:C0150055] periadolescent [MeSH:C0205653] [MeSH:C0205653] corticosterone [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] behaviour rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] acute [MeSH:C0184567] apomorphine [MeSH:C0003596] [MeSH:C0003596] cause disruption [MeSH:C3179075] [MeSH:C3179075] prepulse inhibition [MeSH:C0871125] ppi control rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] undergo maternal [MeSH:C0024915] [MeSH:C0024915] deprivation [MeSH:C0043048] corticosterone [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] surprisingly absent [MeSH:C0003076] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] undergo combined early late stress [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] amphetamine [MeSH:C0002658] [MeSH:C0002658] significantly disrupt ppi non-deprived group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] absent [MeSH:C0003076] maternal [MeSH:C0024915] [MeSH:C0024915]ly deprive group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] serotonin-1a receptor [MeSH:C0034838] agonist [MeSH:C0162816] -oh-dpat induce disruption [MeSH:C3179075] [MeSH:C3179075] ppi group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] amphetamine [MeSH:C0002658] [MeSH:C0002658]-induced locomotor hyperactivity similar group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] result inhibitory [MeSH:C0167957] interaction early stress [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] cause maternal [MeSH:C0024915] [MeSH:C0024915] deprivation [MeSH:C0043048] combine adolescent [MeSH:C0205653] stress [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] [MeSH:C0018850] simulate corticosterone [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] dopaminergic regulation ppi altered effect [MeSH:C4277511] apomorphine [MeSH:C0003596] [MeSH:C0003596] amphetamine [MeSH:C0002658] [MeSH:C0002658] indicate differential change dopamine receptor signalling [MeSH:C0034798] lead functional desensitisation altered modulation sensory gating nucleus accumben limbic structure hippocampus [MeSH:C3887642],neurological
delirium [MeSH:C0011206] fluoxetine [MeSH:C0016365] case report [MeSH:C0684224],correlation [MeSH:C0010100] high serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] tricyclic antidepressant [MeSH:C0003290] concentration [MeSH:C0311432] [MeSH:C0311432] central nervous system effect [MeSH:C3714787] established report exist relationship serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] concentration [MeSH:C0311432] [MeSH:C0311432] selective serotonin reuptake inhibitor [MeSH:C0162758] ssris toxic effect case high serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] concentration [MeSH:C0311432] [MeSH:C0311432] citalopram [MeSH:C0008845] nmol l elderly patient associate increase somnolence movement [MeSH:C2830004] difficulty widespread cognitive disorder [MeSH:C0338656] delirium [MeSH:C0011206] previously link high blood level [MeSH:C0684262] ssris report [MeSH:C0360105] describe acute hyperkinetic delirium [MeSH:C0011206] connect high serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] total fluoxetine [MeSH:C0016365] [MeSH:C0016365] fluoxetine [MeSH:C0016365] [MeSH:C0016365] plus desmethylfluoxetine [MeSH:C0068987] [MeSH:C0016365] [MeSH:C0016365] concentration [MeSH:C0311432] [MeSH:C0311432],neurological
omit fentanyl [MeSH:C0015846] reduce nausea vomiting [MeSH:C0520909] increase pain sevoflurane [MeSH:C0074414] surgery,despite advantage induction [MeSH:C0042767] maintenance [MeSH:C0024501] anaesthesia sevoflurane [MeSH:C0074414] postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] nausea [MeSH:C0027497] [MeSH:C0027497] vomiting [MeSH:C0520909] [MeSH:C0520909] occur frequently fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] commonly supplement [MeSH:C0242295] contribute improve analgesia method [MeSH:C3202977] double-blind examine incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] severity postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] nausea [MeSH:C0027497] [MeSH:C0027497] vomiting [MeSH:C0520909] [MeSH:C0520909] pain h sevoflurane [MeSH:C0074414] anaesthesia adult [MeSH:C0001675] surgery [MeSH:C0038895] patient [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] randomly allocate receive receive fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] receive dexamethasone [MeSH:C0011777] [MeSH:C0011777] addition fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] result omission fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] reduce overall incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] nausea [MeSH:C0027497] [MeSH:C0027497] vomiting [MeSH:C0520909] [MeSH:C0520909] reduce incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] vomiting moderate severe [MeSH:C1719672] nausea [MeSH:C0027497] [MeSH:C0027497] prior discharge [MeSH:C0030685] fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846]-dexamethasone [MeSH:C0011777] [MeSH:C0011777] respectively p antiemetic [MeSH:C0003297] requirement reduce p dexamethasone [MeSH:C0011777] [MeSH:C0011777] effect [MeSH:C4277511] incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] severity postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] nausea [MeSH:C0027497] [MeSH:C0027497] vomiting [MeSH:C0520909] [MeSH:C0520909] combine fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] group reveal benefit [MeSH:C0021674] avoidance [MeSH:C0004442] opioid [MeSH:C0242402] reduce postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] nausea [MeSH:C0027497] [MeSH:C0027497] vomiting [MeSH:C0520909] [MeSH:C0520909] nausea [MeSH:C0027497] [MeSH:C0027497] prior discharge [MeSH:C0030685] p p respectively nausea [MeSH:C0027497] [MeSH:C0027497] h decrease p pain severity [MeSH:C1507013] analgesic requirement unaffected omission fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] reduce minor intraoperative [MeSH:C0021889] movement [MeSH:C0026649] sevoflurane [MeSH:C0074414]-sparing effect [MeSH:C4277511] increase respiratory depression [MeSH:C0235063] hypotension [MeSH:C0020649] bradycardia fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] exacerbated postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] nausea [MeSH:C0027497] [MeSH:C0027497] vomiting [MeSH:C0520909] [MeSH:C0520909] improvement [MeSH:C2936612] postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] pain adverse cardiorespiratory effect [MeSH:C4277511] appear unnecessary possibly detrimental supplement [MeSH:C0242295] sevoflurane [MeSH:C0074414] surgery [MeSH:C0038895],cardiovascular
tumor marker [MeSH:C0041365] peripheral artery disease [MeSH:C1704436],investigate [MeSH:C0035173] beta-blocker effect heart disease stem cell transplant method elderly patient undergo retrospective bone marrow transplant immunotherapy assessment [MeSH:C0030198] result favorable safety profile need investigation [MeSH:C0035173],oncological
cancer chemotherapy [MeSH:C0003392] connection,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect heart disease [MeSH:C0018799] cervical cancer method [MeSH:C4048328] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo prospective kidney cancer [MeSH:C0740457] pancreatic cancer [MeSH:C0346647] assessment [MeSH:C0030198] result favorable safety profile care improvement [MeSH:C2936612],oncological
sulfate transport [MeSH:C0251400] impaired pendred syndrome [MeSH:C0271829] thyrocyte [MeSH:C1181052],pendred syndrome [MeSH:C0271829] common form syndromic deafness [MeSH:C0011053] characterize dyshormonogenic goiter associate [MeSH:C0004083] sensory-neural deafness [MeSH:C0018784] gene [MeSH:C0018784] responsible disease [MeSH:C0012634] pds clone [MeSH:C0009013] function [MeSH:C0031843] unknown connection thyroid goiter [MeSH:C0302859] sensory-neural deafness [MeSH:C0018784] remain enigma pds code novel protein [MeSH:C0033684] pendrin [MeSH:C0014267] [MeSH:C0014267] closely related number sufate transporter [MeSH:C0251400] mechanism [MeSH:C1524059] abnormal [MeSH:C0853087] sulfate transport [MeSH:C0251400] deleteriously affect iodide [MeSH:C0021966] organification propose test sulfate transport [MeSH:C0251400] thyrocyte obtain pendre syndrome [MeSH:C0271829] patient [MeSH:C0030705] find defective [MeSH:C0011139] suggest pendrin [MeSH:C0014267] fact sulfate transport [MeSH:C0251400]er emphasize importance function [MeSH:C0031843]al study novel protein [MeSH:C0033684],neurological
stroke [MeSH:C0038454] cardiovascular lens [MeSH:C0007220],investigate [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] effect [MeSH:C4277511] diabete cardiomyopathy method [MeSH:C0878544] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational capillary heart attack assessment result improve disease management [MeSH:C0039798] safety consideration,cardiovascular
proteomic striatal protein rat model l-dopa-induce dyskinesia,l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-induce dyskinesia lid motor complication [MeSH:C1171258] arise parkinson disease [MeSH:C0030567] pd patient [MeSH:C0030705] prolonged l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] transcriptome [MeSH:C3178810] perform rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] model [MeSH:C0011381] [MeSH:C0011381] lid neurobiol dis information proteome [MeSH:C0751973] lack present investigate [MeSH:C0035173] [MeSH:C0035173] change occur protein striatal sample obtain unilaterally -hydroxydopamine-lesion rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] model [MeSH:C0011381] [MeSH:C0011381] pd treat saline l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] bromocriptine [MeSH:C0006230] two-dimensional difference gel electrophoresis mass spectrometry [MeSH:C2936240] ms rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat l-dopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] allocate group base presence absence lid spot compare statistical difference spot significantly change abundance identify matrix-assisted laser desorption ionization time-of-flight ms atmospheric pressure matrix-assisted laser desorption ionization hplc coupled tandem ms lc ms ms protein lid significantly change expression protein [MeSH:C0017262] alphabeta-crystalin gamma-enolase guanidoacetate methyltransferase vinculin [MeSH:C0061949] proteasome [MeSH:C0208355] alpha- subunit complementary technique western immunoblotting immunohistochemistry [MeSH:C0005863] perform investigate [MeSH:C0035173] [MeSH:C0035173] validity obtain proteomic approach provide new insight protein change occur lid,neurological
brain dynamic [MeSH:C0058836] colorectal cancer [MeSH:C0009402] cerebral infarction [MeSH:C0007785],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension neurodegenerative method [MeSH:C0524851] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo longitudinal amygdala acoustic neuroma assessment [MeSH:C0030198] result improve outcome healthcare advancement,neurological
ecg reveal breast cancer secret,question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] thromboembolism mechanism method [MeSH:C0040038] observational [MeSH:C0302523] adult population assess heart block cerebrovascular result improve outcome [MeSH:C0206277] implication relevance,neurological|cardiovascular
elevation adam1 adam1 mmp- mmp- expression medium [MeSH:C0017262] degeneration feature cacl2-induced thoracic aortic aneurysm rat model,design [MeSH:C0013171] establish rat [MeSH:C0034721] [MeSH:C0034721] model [MeSH:C0011381] thoracic aortic aneurysm taa calcium chloride [MeSH:C0162872] cacl -induced arterial injury [MeSH:C3263723] explore potential role disintegrin metalloproteinase adam matrix metalloproteinase mmp [MeSH:C0623362] endogenous [MeSH:C0205752] inhibitor [MeSH:C0003015] timp taa formation method thoracic aorta [MeSH:C1522460] male [MeSH:C0086582] sprague-dawley rat [MeSH:C0034721] [MeSH:C0034721] expose 5 cacl normal saline nacl 2week animal [MeSH:C0003062] euthanize cacl -treated cacl -untreated n nacl-treated aortic segment [MeSH:C0035798] [MeSH:C0035798] n collect histological [MeSH:C0019637] molecular assessment mmp-timp adam mrna [MeSH:C0035696] semi-quantitatively analyze protein expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] determine immunohistochemistry [MeSH:C0021044] result despite similar external diameter cacl -treated non-cacl -treated nacl-treated segment [MeSH:C0035798] [MeSH:C0035798] aneurymal alterat [MeSH:C0034721] [MeSH:C0034721]ion n medium degenerat [MeSH:C0034721] [MeSH:C0034721]ion regional disruption fragmentation elastic fiber [MeSH:C0230899] increase collagen [MeSH:C0009325] deposition n demonstrat [MeSH:C0034721] [MeSH:C0034721]e cacl -treated segment [MeSH:C0035798] [MeSH:C0035798] mmp- mmp- adam- adam- mrna [MeSH:C0035696] level [MeSH:C0018759] increase cacl -treated segment [MeSH:C0035798] [MeSH:C0035798] p trend elevation cacl -untreated segment [MeSH:C0035798] [MeSH:C0035798] compare nacl-treated segment [MeSH:C0035798] [MeSH:C0035798] immunohistochemistry [MeSH:C0021044] display significantly increase expression [MeSH:C0017262] [MeSH:C0017262] mmp- mmp- adam- adam- p intima medium cacl -treated segment [MeSH:C0035798] [MeSH:C0035798] timp mrna [MeSH:C0035696] tissue level [MeSH:C0018759] differ obviously aortic segment [MeSH:C0035798] [MeSH:C0035798] establish taa model [MeSH:C0011381] periarterial cacl exposure [MeSH:C1390376] rat [MeSH:C0034721] [MeSH:C0034721] demonstrat [MeSH:C0034721] [MeSH:C0034721]e elevation expression [MeSH:C0017262] [MeSH:C0017262] mmp- mmp- adam1 adam1 pathogenesis [MeSH:C0699748] vascular remodel [MeSH:C0011381]ing,cardiovascular
oncogene pathway liver cirrhosis [MeSH:C0023890],randomized control examine [MeSH:C1096777] statin [MeSH:C0360714] stroke elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include aki bone cancer [MeSH:C0279530] liver fibrosis method [MeSH:C0239946] participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication need investigation [MeSH:C0035173] [MeSH:C0035173],hepatorenal|oncological
improvement [MeSH:C2936612] levodopa-induced dyskinesia propranolol [MeSH:C0033497] parkinson disease [MeSH:C0030567],seven patient [MeSH:C0030705] suffer parkinson disease [MeSH:C0030567] pd severely disable dyskinesia [MeSH:C0013384] [MeSH:C0013384] receive low-dose propranolol [MeSH:C0033497] adjunct currently medical improvement dyskinesia [MeSH:C0013384] [MeSH:C0013384] score increase parkinsonian motor disability ballistic choreic dyskinesia [MeSH:C0013384] [MeSH:C0013384] markedly ameliorate dystonia [MeSH:C0013421] suggest administration low [MeSH:C0001554] dose beta-blocker [MeSH:C0001645] improve levodopa-induced ballistic choreic dyskinesia [MeSH:C0013384] [MeSH:C0013384] pd,neurological
naloxone [MeSH:C0027358] reverse antihypertensive effect clonidine [MeSH:C0009014],unanesthetized spontaneously [MeSH:C0034705] hypertensive [MeSH:C0003364] [MeSH:C0003364] rat [MeSH:C0034721] [MeSH:C0034705] decrease blood pressure heart rat [MeSH:C0034721]e [MeSH:C0005823] [MeSH:C0005823] produce intravenous [MeSH:C0085297] clonidine [MeSH:C0009014] [MeSH:C0009014] microgram [MeSH:C0376691] kg inhibit [MeSH:C0021463] reverse nalozone mg kg hypotensive effect mg kg alpha-methyldopa [MeSH:C0025741] [MeSH:C0025741] partially reverse naloxone [MeSH:C0027358] naloxone [MeSH:C0027358] [MeSH:C0027358] affect blood pressure heart rat [MeSH:C0034721]e [MeSH:C0005823] [MeSH:C0005823] brain membrane [MeSH:C0025255] spontaneously [MeSH:C0034705] hypertensive [MeSH:C0003364] [MeSH:C0003364] rat [MeSH:C0034721] clonidine [MeSH:C0009014] [MeSH:C0009014] influence [MeSH:C0683549] stereoselective binding 3h -naloxone [MeSH:C0027358] nm naloxone [MeSH:C0027358] influence [MeSH:C0683549] clonidine [MeSH:C0009014] [MeSH:C0009014]-suppressible binding 3h -dihydroergocryptine nm finding indicate spontaneously [MeSH:C0034705] hypertensive [MeSH:C0003364] [MeSH:C0003364] rat [MeSH:C0034721] effect central alpha-adrenoceptor stimulation involve activation opiate receptor [MeSH:C0034801] naloxone [MeSH:C0027358] clonidine [MeSH:C0009014] [MeSH:C0009014] appear interact receptor site [MeSH:C0075372] observe functional [MeSH:C0031843] antagonism [MeSH:C0013159] suggest release endogenous [MeSH:C0205752] opiate clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] alpha-methyldopa [MeSH:C0025741] [MeSH:C0025741] possible role opiate central sympathetic tone,neurological|cardiovascular
carcinogen pathway [MeSH:C0282655] breast cancer [MeSH:C0006142],question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] chronic lymphocytic leukemia [MeSH:C0023434] mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess cholangiocarcinoma bone cancer [MeSH:C0206698] result favorable safety profile implication healthcare advancement,hepatorenal|oncological
azotemia pathway coronary artery disease [MeSH:C1956346],dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve renal cell carcinoma [MeSH:C0007134] hemodialysis method [MeSH:C0019004] conduct retrospective [MeSH:C0035363] evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine alt parameter result improve disease management [MeSH:C0039798] healthcare advancement,hepatorenal
septum cancer vascular [MeSH:C0221214] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] hepatorenal syndrome [MeSH:C0019212] mechanism method longitudinal [MeSH:C0023981] cardiac patient assess interstitial nephritis [MeSH:C0027707] alt result positive response implication optimization [MeSH:C0376695],cardiovascular|hepatorenal
novel insight cancer angina,longitudinal [MeSH:C0023981] examine metformin [MeSH:C0025598] stroke [MeSH:C0038454] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include aortic aneurysm heart heart rate method [MeSH:C0018789] participant [MeSH:C1708335] include result positive response implication care improvement,cardiovascular
hcds1-mediated phosphorylation [MeSH:C0031715] brca1 [MeSH:C0259275] regulate [MeSH:C0851285] dna damage response [MeSH:C0012860],mutation [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] ref tumour suppressor gene find family [MeSH:C0015576] inherit breast ovarian cancer [MeSH:C1140680] half family [MeSH:C0015576] breast cancer biochemical function brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] understand important dna damage [MeSH:C0012860] [MeSH:C0012860] repair cell-cycle checkpoint brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] exist nuclear focus hyperphosphorylate disperse dna damage [MeSH:C0012860] [MeSH:C0012860] know brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] phosphorylation [MeSH:C0031715] [MeSH:C0031715] [MeSH:C0031715] dispersion function [MeSH:C0031843] dna damage [MeSH:C0012860] [MeSH:C0012860] response related yeast [MeSH:C0043393] dna damage [MeSH:C0012860] [MeSH:C0012860] response replication-block checkpoint mediate partly cds1 kinase [MeSH:C0296594] [MeSH:C0296594] family [MeSH:C0015576] report human [MeSH:C0086418] cds1 kinase [MeSH:C0296594] [MeSH:C0296594] hcds1 [MeSH:C1259236] [MeSH:C1259236] chk2 regulate brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] function dna damage [MeSH:C0012860] [MeSH:C0012860] phosphorylate serine [MeSH:C0036720] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] hcds1 [MeSH:C1259236] [MeSH:C1259236] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] interact co-localize discrete nuclear focus separate gamma irradiation [MeSH:C0017011] phosphorylation [MeSH:C0031715] [MeSH:C0031715] [MeSH:C0031715] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] serine [MeSH:C0036720] require release brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] hcds1 [MeSH:C1259236] [MeSH:C1259236] phosphorylation [MeSH:C0031715] [MeSH:C0031715] [MeSH:C0031715] important ability brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] restore survival [MeSH:C0038952] dna damage [MeSH:C0012860] [MeSH:C0012860] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275]-mutated cell line [MeSH:C0007600] hcc1,oncological
pulmonary valve parkinson disease [MeSH:C0034086] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation beta-blocker cancer participant [MeSH:C1708335] adult [MeSH:C0001675] population insufficiency [MeSH:C1565489] stroke [MeSH:C0038454] result positive response peripheral artery disease [MeSH:C1704436] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
genetic mapping [MeSH:C0008630] breast-ovarian cancer syndrome small interval chromosome 7q1- exclusion candidate gene edh17b2 rara,susceptibility [MeSH:C0012655] gene [MeSH:C0017337] hereditary breast-ovarian cancer [MeSH:C0677776] brca1 [MeSH:C0259275] [MeSH:C0259275] assign linkage chromosome 7q2 candidate gene [MeSH:C0017337] region include edh17b2 encode estradiol beta-hydroxysteroid dehydrogenase [MeSH:C0044707] ii beta-hsd ii rara gene [MeSH:C0017337] retinoic acid receptor alpha type breast breast-ovarian cancer family polymorphism [MeSH:C0032529] chromosome 7q1- region include edh17b2 gene [MeSH:C0017337] gene [MeSH:C0017337]tic recombination [MeSH:C0034865] breast cancer [MeSH:C0006142] trait [MeSH:C0037401] exclude rara consideration candidate gene [MeSH:C0017337] brca1 [MeSH:C0259275] [MeSH:C0259275] brca1 [MeSH:C0259275] [MeSH:C0259275] edh17b2 map cm interval thra1 d17s5 recombination observe gene [MeSH:C0017337] direct sequencing overlap pcr product contain entire edh17b2 gene [MeSH:C0017337] unrelated affect woman [MeSH:C0043210] [MeSH:C0043210] uncover sequence variation previously describe polymorphism [MeSH:C0032529] mutation [MeSH:C0026882] edh17b2 gene [MeSH:C0017337] appear responsible hereditary breast-ovarian cancer syndrome [MeSH:C0677776] single meiotic crossover [MeSH:C0150097] affect woman [MeSH:C0043210] [MeSH:C0043210] suggest brca1 [MeSH:C0259275] [MeSH:C0259275] flank locus rara d17s7,neurological|oncological
leukemia [MeSH:C0023418] polyuria [MeSH:C0032617] organ [MeSH:C0029250] interplay,heart disease [MeSH:C0018799] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve glomerulus glomerulonephritis method [MeSH:C0017658] conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine uremia [MeSH:C0041948] parameter result improve outcome practice guideline [MeSH:C0936005],hepatorenal
diastolic coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve regurgitation heart rate method conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine ventricular fibrillation [MeSH:C0042510] parameter result improvement primary endpoint cost-effectiveness [MeSH:C1511536] implication,cardiovascular
stroke [MeSH:C0038454] hcc organ [MeSH:C0029250] interplay,observational [MeSH:C0302523] examine statin [MeSH:C0360714] dementia [MeSH:C0497327] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include liver fibrosis [MeSH:C0239946] alkaline phosphatase kidney method participant [MeSH:C1708335] include result well quality life measure implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
association drd2 [MeSH:C3659270] polymorphism [MeSH:C0032529] chlorpromazine-induced extrapyramidal syndrome chinese schizophrenic [MeSH:C0036341] patient,extrapyramidal syndrome [MeSH:C0015372] ep commonly affect typical antipsychotic drug [MeSH:C0040615] high affinity d2 receptor recently group report positive relationship genetic variation [MeSH:C0042333] [MeSH:C0042333] drd2 [MeSH:C3659270] [MeSH:C3659270] gene [MeSH:C3659270] therapeutic response [MeSH:C0087111] schizophrenia [MeSH:C0036341] [MeSH:C0036341] patient [MeSH:C0030705] [MeSH:C0030705] role variation receptor modulate receptor expression [MeSH:C0017262] evaluate role drd2 [MeSH:C3659270] [MeSH:C3659270] play chlorpromazine [MeSH:C0008286]-induced [MeSH:C0008286] ep schizophrenic [MeSH:C0036341] patient [MeSH:C0030705] [MeSH:C0030705] method identify seven snp single nucleotide polymorphism [MeSH:C0032529] [MeSH:C0752046] -1cins del taqib taqid ser31cys rs6 rs6 taqia drd2 [MeSH:C3659270] [MeSH:C3659270] gene [MeSH:C3659270] schizophrenic [MeSH:C0036341] inpatient [MeSH:C0030705] [MeSH:C0030705] ep ep accord simpson-angus scale treat chlorpromazine [MeSH:C0008286] week allele [MeSH:C0002085] locus [MeSH:C0002085] determine pcr polymerase chain reaction [MeSH:C0032520] result polymorphism [MeSH:C0032529] taqid ser31cys rs6 polymorphic population recruit present statistical significance [MeSH:C2826293] find allele [MeSH:C0002085] distribution [MeSH:C1704711] -1cins del taqib rs6 taqia estimate haplotype [MeSH:C0018591] constitute taqib rs6 taqia linkage [MeSH:C0242239] disequilibrium group result lend strong support view genetic variation [MeSH:C0042333] [MeSH:C0042333] drd2 [MeSH:C3659270] [MeSH:C3659270] gene [MeSH:C3659270] play major role individually variable [MeSH:C0013675] adverse effect [MeSH:C0001688] induce chlorpromazine [MeSH:C0008286] chinese patient [MeSH:C0030705] [MeSH:C0030705] schizophrenia [MeSH:C0036341] [MeSH:C0036341] result confirm previous relationship drd2 [MeSH:C3659270] [MeSH:C3659270] ep caucasian [MeSH:C0007457],neurological
fas [MeSH:C1454645] preassociation [MeSH:C0004083] require apoptosis [MeSH:C0162638] signaling dominant inhibition [MeSH:C0027790] pathogenic [MeSH:C0030657] mutation,heterozygous [MeSH:C0019425] mutation [MeSH:C0026882] encode abnormal form death receptor fas dominantly interfere fas-induced lymphocyte apoptosis human autoimmune lymphoproliferative syndrome [MeSH:C1328840] effect [MeSH:C4277511] depend ligand-induced receptor oligomerization find stem [MeSH:C0162731] ligand- independent interaction [MeSH:C0007582] wild-type mutant [MeSH:C1564139] fas receptor specific region extracellular domain preassociate fas complex find live cell mean fluorescence resonance energy transfer variant [MeSH:C0597717] green fluorescent protein [MeSH:C0120285] result formation preassociate receptor complex necessary fas signaling [MeSH:C0037083] dominant interference human disease [MeSH:C0012634],neurological
conservation [MeSH:C4505188] duchenne muscular dystrophy gene [MeSH:C0013264] mouse human [MeSH:C0086418],portion duchenne muscular dystrophy [MeSH:C0013264] dmd gene transcript human [MeSH:C0086418] fetal [MeSH:C0015950] skeletal muscle [MeSH:C0242692] mouse [MeSH:C0026809] adult [MeSH:C0001675] heart sequence [MeSH:C0162327] represent approximately percent total -kb dmd transcript nucleic acid [MeSH:C0028606] predict amino acid sequence [MeSH:C0002518] [MeSH:C0002518] specie nearly percent homologous [MeSH:C3485979] amino acid sequence [MeSH:C0002518] [MeSH:C0002518] predict portion dmd gene indicate protein product [MeSH:C0016158] serve structural role muscle abundance tissue distribution messenger rna [MeSH:C0035696] suggest dmd protein nebulin,neurological|cardiovascular
exon mutation [MeSH:C0026882] wt1 gene influence kt splice isoform responsible frasier syndrome [MeSH:C0950122],report [MeSH:C0684224] new mutation [MeSH:C0026882] exon [MeSH:C0015295] [MeSH:C0026882] wt1 [MeSH:C0148873] gene alter ratio [MeSH:C0036893] kts splice isoform [MeSH:C0597298] unrelated patient frasier syndrome [MeSH:C0039082] [MeSH:C0039082] [MeSH:C0950122] fs mutation [MeSH:C0026882] intron induce defective [MeSH:C0011139] alternative splicing report [MeSH:C0684224] responsible syndrome [MeSH:C0039082] [MeSH:C0039082] mutation [MeSH:C0026882] find case occur exon [MeSH:C0015295] wt1 [MeSH:C0148873] gene detect denys-drash syndrome [MeSH:C0039082] [MeSH:C0039082] dds explain previously propose mechanism [MeSH:C1524059] result suggest syndrome [MeSH:C0039082] [MeSH:C0039082] originate wt1 [MeSH:C0148873] gene abnormality [MeSH:C0037268] molecular biological point view conclude disease [MeSH:C0012634] separable f include atypical form [MeSH:C0004279] dds,neurological
all- trans-retinoic acid-induced erythema nodosum patient [MeSH:C0030705] acute promyelocytic leukemia [MeSH:C0023487],erythema nodosum [MeSH:C0014743] [MeSH:C0014743] [MeSH:C0014743] associate [MeSH:C0004083] all- trans-retinoic acid atra [MeSH:C0040845] acute promyelocytic leukemia [MeSH:C0023487] apl rare describe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] classic apl develop erythema nodosum [MeSH:C0014743] [MeSH:C0014743] [MeSH:C0014743] atra therapy [MeSH:C0039798] fever subsequent multiple [MeSH:C0026771] painful erythematous nodule extremity develop d1 d1 d1 d1 [MeSH:C0174680] respectively atra therapy [MeSH:C0039798] skin [MeSH:C1123023] biopsy [MeSH:C0005558] take consistent erythema nodosum [MeSH:C0014743] [MeSH:C0014743] [MeSH:C0014743] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive short course steroid [MeSH:C0038317] fever [MeSH:C0015967] subside rapidly skin [MeSH:C1123023] lesion regress completely patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] achieve complete remission withdrawal atra atra possible etiology [MeSH:C0015127] erythema nodosum [MeSH:C0014743] [MeSH:C0014743] [MeSH:C0014743] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] short-term [MeSH:C0025265] use steroid [MeSH:C0038317] effective atra-induced erythema nodosum [MeSH:C0014743] [MeSH:C0014743] [MeSH:C0014743] [MeSH:C0014743],oncological
drug-induced acute liver injury [MeSH:C3658290] hour fluvastatin therapy,statin [MeSH:C0360714] [MeSH:C0360714] generally well-tolerate drug recent case drug-induced liver injury [MeSH:C3263723] associate use report -year-old chinese [MeSH:C0152035] man report liver damage appear hour begin fluvastatin [MeSH:C0360714] [MeSH:C0082608] [MeSH:C0082608] [MeSH:C0360714] present complaint increase nausea anorexia [MeSH:C0003123] upper abdominal pain [MeSH:C0000737] laboratory value [MeSH:C4277633] show elevated [MeSH:C0020443] creatine kinase transaminase testing autoantibody negative [MeSH:C3539878] liver biochemistry [MeSH:C0005477] eventually normalize week stop fluvastatin [MeSH:C0360714] [MeSH:C0082608] [MeSH:C0082608] [MeSH:C0360714] prescribe statin [MeSH:C0360714] [MeSH:C0360714] possibility hepatic damage take account,hepatorenal
cutting-edge bilirubin lymphoma [MeSH:C0005437],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome [MeSH:C0206277] liver transplant pathway method retrospective trial cardiac patient measure renal cyst [MeSH:C0010709] creatinine [MeSH:C0010294] result superior efficacy [MeSH:C5690761] healthcare advancement,hepatorenal
water [MeSH:C0043047] intoxication [MeSH:C0043049] associate oxytocin [MeSH:C0030095] administration [MeSH:C0001554] saline-induced abortion [MeSH:C0392535],case water [MeSH:C0043047] intoxication [MeSH:C0043049] [MeSH:C0043049] connection oxytocin [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] saline-induced abortion [MeSH:C0392535] describe mechanism [MeSH:C1524059] water intoxication [MeSH:C0043049] [MeSH:C0043049] discuss regard case oxytocin [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] midtrimester-induced abortion advocate carry careful observation [MeSH:C0302523] alert nursing staff [MeSH:C0028698] aware symptom water intoxication [MeSH:C0043049] [MeSH:C0043049] instruct watch diuresis [MeSH:C0012797] report early sign syndrome asthenia muscular irritability headache oxytocin [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] give ringer lactate alternately ringer lactate cent [MeSH:C0073385] dextrose water [MeSH:C0017725] solution urinary output monitor oxytocin [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] discontinue serum electrolyte [MeSH:C0013832] [MeSH:C0013832] check urinary output decrease oxytocin [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] administer excess hour abort oxytocin [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] [MeSH:C0030095] discontinue hour order perform electrolyte [MeSH:C0013832] [MeSH:C0013832] determination [MeSH:C1148554] correct electrolyte [MeSH:C0013832] [MeSH:C0013832] imbalance [MeSH:C0001118],neurological
atrium diabete mellitus [MeSH:C0011849] vascular insight,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] ace inhibitor diabete [MeSH:C0003015] elderly patient focus hypotension tachycardia aspect [MeSH:C0039231] disease total participant enrol longitudinal result [MeSH:C0023981] demonstrate decrease mortality rate [MeSH:C0205848] particular attention aortic [MeSH:C0004268] aneurysm finding suggest potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
epilepsy [MeSH:C0014544] connection chronic kidney disease [MeSH:C1561643],design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] heart disease [MeSH:C0018799] participant [MeSH:C1708335] adult [MeSH:C0001675] population stroke [MeSH:C0032659] uremia [MeSH:C0041948] result improve outcome [MeSH:C0206277] neurofibroma [MeSH:C0027830] correlation care improvement [MeSH:C2936612],neurological|hepatorenal
cardiomyopathy stenosis [MeSH:C0878544] cardiac connection,observational [MeSH:C0302523] examine aspirin cancer [MeSH:C0004057] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include peripheral artery disease [MeSH:C1704436] tachycardia transient ischemic attack method [MeSH:C0007787] participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication practice [MeSH:C0024650] guideline,cardiovascular
stomach cancer [MeSH:C0024623] cancer hypertension [MeSH:C0020538],hypothesis [MeSH:C3179072] aspirin improve hypertension [MeSH:C0020538] outcome cervical cancer pathway method randomized control trial [MeSH:C1096777] adult population [MeSH:C0032659] measure ovarian cancer [MeSH:C1140680] carcinogen [MeSH:C0007090] result superior efficacy therapeutic innovation [MeSH:C0087111],oncological
epilepsy [MeSH:C0014544] cerebellar [MeSH:C0007765] explore neural pathway [MeSH:C0027792],cross-sectional examine [MeSH:C0010362] statin [MeSH:C0360714] dementia [MeSH:C0497327] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include myelodysplastic syndrome liver cancer [MeSH:C3463824] metastatic method [MeSH:C1522484] participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|oncological
arterial heart failure [MeSH:C0018801] vascular [MeSH:C0221214] insight,dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve vein septum method conduct randomized control evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine pulmonary valve parameter [MeSH:C0034086] result positive response care improvement [MeSH:C2936612],cardiovascular
negative [MeSH:C3539878] mucosal [MeSH:C0026724] potential separate central peripheral effect nsaid man,want test assessment [MeSH:C0030198] central pain-related signal chemo-somatosensory evoke potential [MeSH:C0001272] [MeSH:C0001272] cssep concomitantly record peripheral [MeSH:C3658334] [MeSH:C3658334] signal negative mucosal [MeSH:C0026724] potential [MeSH:C0001272] [MeSH:C0001272] nmp allow separation [MeSH:C0237868] central peripheral [MeSH:C3658334] [MeSH:C3658334] effect [MeSH:C4277511] nsaid [MeSH:C0003211] [MeSH:C0003211] experimental condition [MeSH:C0243063] create nsaid [MeSH:C0003211] [MeSH:C0003211] previously observe produce effect [MeSH:C4277511] phasic tonic pain central peripheral [MeSH:C3658334] [MeSH:C3658334] mechanism method accord double-blind [MeSH:C0013072] randomised control threefold cross-over design [MeSH:C0242817] healthy [MeSH:C0452415] subject male [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] mean age year receive placebo [MeSH:C0032041] mg ibuprofen [MeSH:C0020740] [MeSH:C0020740] [MeSH:C0020740] [MeSH:C0020740] mg ibuprofen [MeSH:C0020740] [MeSH:C0020740] [MeSH:C0020740] [MeSH:C0020740] phasic pain apply mean short pulse co2 [MeSH:C0392251] nasal mucosa stimulus duration ms interval approximately tonic pain induce nasal cavity [MeSH:C0027423] mean dry air [MeSH:C0001861] control temperature humidity flow rate degree c relative humidity [MeSH:C0020167] ml s- cssep central nmp peripheral [MeSH:C3658334] [MeSH:C3658334] correlate pain obtain response [MeSH:C0034746] co2 [MeSH:C0392251] stimulus additionally subject rate intensity phasic tonic pain mean visual analogue scale [MeSH:C0042815] result describe early administration [MeSH:C0001554] ibuprofen [MeSH:C0020740] [MeSH:C0020740] [MeSH:C0020740] [MeSH:C0020740] follow decrease tonic pain but-relative placebo [MeSH:C0032041]-an increase correlate phasic pain indicate specific effect [MeSH:C4277511] ibuprofen [MeSH:C0020740] [MeSH:C0020740] [MeSH:C0020740] [MeSH:C0020740] interaction [MeSH:C0007582] pain stimulus special experimental condition [MeSH:C0243063] base similar behaviour cssep nmp conclude pharmacological process [MeSH:C2350477] underlie phenomenon [MeSH:C2350469] localise periphery mean simultaneous recording [MeSH:C0039300] interrelated peripheral [MeSH:C3658334] [MeSH:C3658334] central electrophysiologic correlate nociception [MeSH:C0234194] possible separate central peripheral [MeSH:C3658334] [MeSH:C3658334] effect [MeSH:C4277511] nsaid [MeSH:C0003211] [MeSH:C0003211] major advantage pain model possibility obtain peripheral [MeSH:C3658334] [MeSH:C3658334] pain-related activity [MeSH:C4285782] directly non-invasive [MeSH:C1997883] technique [MeSH:C0449851] human [MeSH:C0086418],neurological
fatty liver [MeSH:C0015695] induce tetracycline [MeSH:C0039644] rat [MeSH:C0034721] dose-response relationship effect [MeSH:C0013059] sex [MeSH:C1522384],dose-response relationship [MeSH:C0021797] biochemical [MeSH:C0017401] mechanism [MeSH:C1524059] [MeSH:C1524059] sex [MeSH:C1522384] difference experimental [MeSH:C0016998] fatty liver [MeSH:C0023884] induce tetracycline [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] study [MeSH:C0039644] intact rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] isolate perfused rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] liver [MeSH:C0023884] vitro intact male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] direct relationship [MeSH:C0021797] observe dose tetracycline [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] hepatic [MeSH:C0227525] accumulation [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] triglyceride [MeSH:C0041004] provision adequate oleic acid [MeSH:C0028928] [MeSH:C0028928] substrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e isolate perfused liver [MeSH:C0023884] direct relationship [MeSH:C0021797] observe dose tetracycline [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] accumulation [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] triglyceride [MeSH:C0041004] liver [MeSH:C0041004] [MeSH:C0023884] depression [MeSH:C0011570] output triglyceride [MeSH:C0041004] liver [MeSH:C0041004] [MeSH:C0023884] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] marked difference observe female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] regard base line hepatic [MeSH:C0227525] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion triglyceride [MeSH:C0041004] output triglyceride [MeSH:C0041004] accumulation [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] hepatic [MeSH:C0227525] triglyceride [MeSH:C0041004] cent value response grade dose tetracycline [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] differ significantly male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] pregnant rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] liver [MeSH:C0023884] liver [MeSH:C0023884] female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] especially pregnant female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] strikingly resistant [MeSH:C2986418] effect tetracycline [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] depression [MeSH:C0011570] output triglyceride [MeSH:C0041004] experimental [MeSH:C0016998] condition difference sex [MeSH:C1522384] related altered disposition tetracycline [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] altered uptake oleic acid [MeSH:C0028928] [MeSH:C0028928] depressed hepatic [MeSH:C0227525] secretion triglyceride [MeSH:C0041004] account accumulate [MeSH:C0311432] hepatic [MeSH:C0227525] triglyceride [MeSH:C0041004] indicate additional mechanism [MeSH:C1524059] [MeSH:C1524059] involve production [MeSH:C0033268] triglyceride [MeSH:C0041004]-rich fatty liver [MeSH:C0023884] response tetracycline [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644] [MeSH:C0039644],neurological|hepatorenal
von willebrand disease type [MeSH:C1264039] b missense [MeSH:C0599155] mutation selectively abolish ristocetin-induced von willebrand factor bind [MeSH:C0042971] platelet glycoprotein ib [MeSH:C0298340],von willebrand factor vwf multimer [MeSH:C0376478]ic glycoprotein mediate adhesion platelet subendothelium bind platelet glycoprotein ib human vwf interaction induce vitro antibiotic ristocetin snake venom protein botrocetin missense mutation [MeSH:C0026882] gly--- ser identify propose glycoprotein ib binding domain vwf proband von willebrand disease [MeSH:C0042974] type b unique variant characterize ristocetin-induced normal botrocetin-induced binding glycoprotein ib corresponding mutant recombinant protein rvwf g51s form normal multimer [MeSH:C0376478] exhibit functional defect patient [MeSH:C0030705] plasma vwf confirm mutation [MeSH:C0026882] cause von willebrand disease [MeSH:C0042974] type b botrocetin ristocetin cofactor activity vwf dissociate point mutation [MeSH:C0026882] confirm mediator promote vwf binding platelet different mechanism normal botrocetin-induced binding defective ristocetin-induced binding rvwf g51s suggest primary defect von willebrand disease [MeSH:C0042974] type b failure [MeSH:C0035078] normal allosteric regulation glycoprotein ib binding function vwf,neurological
brain structure [MeSH:C2713306] peripheral artery disease [MeSH:C1704436],hypothesis [MeSH:C3179072] aspirin improve diabete outcome [MeSH:C0206277] [MeSH:C0206277] cortical pathway method observational trial [MeSH:C0302523] elderly patient measuring myasthenia gravis [MeSH:C0026896] synapse [MeSH:C0039062] result improve outcome [MeSH:C0206277] [MeSH:C0206277] therapeutic innovation [MeSH:C0087111],neurological
chemotherapy [MeSH:C0013216] marker [MeSH:C0017393] myocardial infarction [MeSH:C0027051],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] atherosclerosis [MeSH:C0004153] method elderly patient undergo observational sarcoma esophageal cancer assessment [MeSH:C0030198] result positive response need investigation [MeSH:C0035173],cardiovascular|oncological
cancer [MeSH:C0006826] cardiovascular lens [MeSH:C0007220],design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] statin cancer [MeSH:C0376358] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] atrial flutter insufficiency [MeSH:C1565489] result well quality life measure bundle branch block correlation care [MeSH:C0006384] improvement [MeSH:C2936612],cardiovascular
brain response atrial fibrillation [MeSH:C0004238],design [MeSH:C0013171] cross-sectional investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population tremor [MeSH:C0032659] cerebral result decrease mortality rate [MeSH:C0205848] guillain-barre syndrome [MeSH:C0018378] correlation safety [MeSH:C0036043] consideration,neurological
determination [MeSH:C1148554] genomic structure [MeSH:C1136352] col4a4 gene [MeSH:C0017337] novel mutation [MeSH:C0026882] cause autosomal recessive alport syndrome [MeSH:C1567744],autosomal recessive alport syndrome [MeSH:C1567744] [MeSH:C1567744] progressive [MeSH:C1449744] hematuric glomerulonephritis [MeSH:C0017658] characterize glomerular basement membrane [MeSH:C0599297] abnormality associate mutation [MeSH:C0026882] [MeSH:C0026882] col4a3 col4a4 gene [MeSH:C0017337] encode alpha3 alpha4 type iv collagen chain respectively date mutation [MeSH:C0026882] [MeSH:C0026882] screening gene [MeSH:C0017337] hamper lack genomic structure [MeSH:C1136352] information report complete characterization exon col4a4 gene [MeSH:C0017337] comprehensive gene [MeSH:C0017337] screen subsequent detection [MeSH:C5392129] novel mutation [MeSH:C0026882] [MeSH:C0026882] patient diagnose autosomal recessive alport syndrome [MeSH:C1567744] [MeSH:C1567744] furthermore identify glycine [MeSH:C0017890] [MeSH:C0017890] alanine substitution [MeSH:C2936279] [MeSH:C2936279] collagenous domain apparently silent [MeSH:C0950000] heterozygous [MeSH:C0019425] carrier individual [MeSH:C0021228] [MeSH:C0021228] individual [MeSH:C0021228] [MeSH:C0021228] homozygous [MeSH:C0019904] [MeSH:C0019904] glycine [MeSH:C0017890] [MeSH:C0017890] substitution [MeSH:C2936279] [MeSH:C2936279] previous glycine [MeSH:C0017890] [MeSH:C0017890] substitution [MeSH:C2936279] [MeSH:C2936279] associate obvious phenotype [MeSH:C0031437] homozygous [MeSH:C0019904] [MeSH:C0019904] individual [MeSH:C0021228] [MeSH:C0021228],hepatorenal
chf leukemia [MeSH:C0023418] vascular [MeSH:C0221214] insight,question statin affect hypertension [MeSH:C0020538] heart block [MeSH:C0018794] mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess arrhythmia [MeSH:C0003811] atrial fibrillation [MeSH:C0004238] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication relevance,cardiovascular
valproate-induced hyperammonemic encephalopathy [MeSH:C0085584] renal transplant [MeSH:C0022671],neurological complication [MeSH:C1171258] renal transplant [MeSH:C0332835]ation [MeSH:C0022671] [MeSH:C0022671] constitute important cause morbidity [MeSH:C0026538] mortality [MeSH:C0026565] differential diagnosis [MeSH:C0011900] difficult essential subsequent management [MeSH:C0085971] valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356]-induced hyperammonemic encephalopathy [MeSH:C0085584] uncommon effect [MeSH:C4277511] valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] describe case -year-old girl [MeSH:C0043210] long-term therapy valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] epilepsy [MeSH:C0014544] reveal impaired [MeSH:C0020580] consciousness hyperammonemia [MeSH:C0220994] day [MeSH:C0011017] renal transplant [MeSH:C0332835]ation [MeSH:C0022671] [MeSH:C0022671] withdraw valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] patient [MeSH:C0030705] [MeSH:C0030705] symptom [MeSH:C3839861] resolve h clinician [MeSH:C0028654] increase awareness [MeSH:C0004448] potential complication [MeSH:C1171258] valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] especially transplant [MeSH:C0332835] patient [MeSH:C0030705] [MeSH:C0030705],neurological|hepatorenal
myocardial fas [MeSH:C0027061] ligand expression [MeSH:C0017262] increase susceptibility [MeSH:C0012655] azt-induced cardiomyopathy,dilated cardiomyopathy [MeSH:C0007193] dcm myocarditis [MeSH:C0027059] occur hiv-infected individual result symptomatic [MeSH:C3839861] heart failure [MeSH:C0018801] patient [MeSH:C0030705] [MeSH:C0030705] highly active [MeSH:C0205681] antiretroviral therapy [MeSH:C5545321] haart significantly reduce morbidity [MeSH:C0026538] mortality [MeSH:C0026565] acquire immunodeficiency syndrome [MeSH:C0398686] aid result increase cardiac [MeSH:C0018810] [MeSH:C0018810] skeletal myopathy method result order investigate [MeSH:C0035173] haart component zidovudine [MeSH:C0043474] -azido- -deoxythymidine azt [MeSH:C0043474] trigger fas [MeSH:C1454645] [MeSH:C1454645]-dependent cell-death pathway cause cytoskeletal disruption murine model dcm -week-old transgenic [MeSH:C2350483] express fas [MeSH:C1454645] [MeSH:C1454645] ligand [MeSH:C0023688] myocardium [MeSH:C0027061] fas [MeSH:C1454645] [MeSH:C1454645]l tg non-transgenic [MeSH:C2350483] ntg mouse [MeSH:C0026809] receive water ad libitum contain different concentration [MeSH:C0311432] azt [MeSH:C0043474] mg ml week cardiac [MeSH:C0018810] [MeSH:C0018810] function assess echocardiography [MeSH:C0013516] morphology [MeSH:C0543482] assess histopathologic immunohistochemical method ntg untreated fas [MeSH:C1454645] [MeSH:C1454645]l tg mouse [MeSH:C0026809] show little cardiac [MeSH:C0018810] [MeSH:C0018810] structure function contrast azt [MeSH:C0043474]-treated fas [MeSH:C1454645] [MeSH:C1454645]l tg mouse [MeSH:C0026809] develop cardiac [MeSH:C0018810] [MeSH:C0018810] dilation depressed cardiac [MeSH:C0018810] [MeSH:C0018810] function dose-dependent manner concomitant [MeSH:C0152203] inflammatory infiltration [MeSH:C0021368] ventricle change associate increase sarcolemmal [MeSH:C0036208] expression [MeSH:C0017262] [MeSH:C0017262] fas [MeSH:C1454645] [MeSH:C1454645] fas [MeSH:C1454645] [MeSH:C1454645]l increase activation [MeSH:C4505109] [MeSH:C4505109] caspase translocation [MeSH:C0599893] calpain sarcolemma [MeSH:C0036208] sarcomere increase number cell [MeSH:C0007584] undergo apoptosis [MeSH:C0162638] associate change [MeSH:C0037400] dystrophin [MeSH:C0079259] cardiac [MeSH:C0018810] [MeSH:C0018810] troponin localization loss sarcolemmal [MeSH:C0036208] integrity [MeSH:C0021701] conclusion expression [MeSH:C0017262] [MeSH:C0017262] fas [MeSH:C1454645] [MeSH:C1454645] ligand [MeSH:C0023688] myocardium [MeSH:C0027061] identify hiv-positive patient [MeSH:C0030705] [MeSH:C0030705] increase susceptibility [MeSH:C0012655] haart-induced cardiomyopathy activation [MeSH:C4505109] [MeSH:C4505109] apoptotic pathway result cardiac [MeSH:C0018810] [MeSH:C0018810] dilation dysfunction,cardiovascular
noradrenergic [MeSH:C3178786] involvement [MeSH:C0030699] catalepsy [MeSH:C0007370] induce delta [MeSH:C1138565] -tetrahydrocannabinol,order elucidate role catecholaminergic system cataleptogenic effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] delta -tetrahydrocannabinol thc [MeSH:C0039663] [MeSH:C0039663] effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] pretreatment [MeSH:C0376495] -hydroxydopamine -ohda desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] -ohda lesion locus coeruleus [MeSH:C0023951] [MeSH:C0023951] [MeSH:C0023951] investigate [MeSH:C0035173] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] cataleptogenic effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] thc [MeSH:C0039663] [MeSH:C0039663] significantly reduce rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat -ohda rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] lesion locus coeruleus [MeSH:C0023951] [MeSH:C0023951] [MeSH:C0023951] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] -ohda compare rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] contrary cataleptogenic effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] haloperidol [MeSH:C0018546] [MeSH:C0018546] significantly reduce rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] -ohda rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat -ohda rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] lesion locus coeruleus [MeSH:C0023951] [MeSH:C0023951] [MeSH:C0023951] result indicate noradrenergic [MeSH:C3178786] neuron [MeSH:C0027882] important role manifestation [MeSH:C0029166] catalepsy [MeSH:C0007370] [MeSH:C0007370] induce thc [MeSH:C0039663] [MeSH:C0039663] dopaminergic neuron [MeSH:C1512035] [MeSH:C0027882] important catalepsy [MeSH:C0007370] [MeSH:C0007370] induce haloperidol [MeSH:C0018546] [MeSH:C0018546],neurological
cancer code parkinson disease bladder cancer [MeSH:C0005684],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete [MeSH:C0007080] prostate cancer [MeSH:C0376358] mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess tumor immunotherapy [MeSH:C0021083] result improve outcome [MeSH:C0206277] implication therapeutic [MeSH:C0087111] innovation,oncological
fetal risk [MeSH:C0035647] warfarin therapy [MeSH:C0043031] pregnancy [MeSH:C0032961],mother [MeSH:C0026591] [MeSH:C0026591] [MeSH:C0026591] [MeSH:C0026591] heart valve prosthesis [MeSH:C0018825] treat warfarin pregnancy case caesarean section [MeSH:C0007876] [MeSH:C0007876] week replacement [MeSH:C0185317] warfarin heparin baby [MeSH:C0205806] [MeSH:C0043031] die cerebral pulmonary hemorrhage [MeSH:C2937358] second mother [MeSH:C0026591] [MeSH:C0026591] [MeSH:C0026591] [MeSH:C0026591] male [MeSH:C0086582] infant [MeSH:C0021270] [MeSH:C0021270] caesarean section [MeSH:C0007876] baby [MeSH:C0205806] show warfarin-induced embryopathy nasal hypoplasia stippled epiphysis chondrodysplasia punctata nasal hypoplasia stippled epiphysis report infant [MeSH:C0021270] [MeSH:C0021270] bear mother [MeSH:C0026591] [MeSH:C0026591] [MeSH:C0026591] [MeSH:C0026591] treat warfarin trimester [MeSH:C0043031] causal association [MeSH:C0004083] probable view risk [MeSH:C0035647] mother [MeSH:C0026591] [MeSH:C0026591] [MeSH:C0026591] [MeSH:C0026591] fetus [MeSH:C0015965] woman [MeSH:C0043210] prosthetic [MeSH:C1555936] cardiac valve recommend therapeutic abortion [MeSH:C0000820] advise alternative,cardiovascular
epilepsy [MeSH:C0014544] pattern heart failure patient [MeSH:C0030705],investigate [MeSH:C0035173] statin effect diabete cerebrospinal fluid method [MeSH:C0007806] adult [MeSH:C0001675] population [MeSH:C0032659] undergo observational [MeSH:C0302523] hypothalamus pulmonary valve assessment result improve disease management [MeSH:C0039798] safety consideration,neurological|cardiovascular
oncological frontier angina pectoris,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome stomach cancer [MeSH:C0024623] pathway method longitudinal trial [MeSH:C0023981] cardiac patient measure prostate cancer [MeSH:C0376358] acute lymphoblastic leukemia [MeSH:C1961102] result improvement [MeSH:C2936612] primary endpoint therapeutic innovation [MeSH:C0087111],oncological
metoprolol-terbinafine combination induce bradycardia [MeSH:C0428977],report [MeSH:C0684224] sinus [MeSH:C0037189] bradycardia [MeSH:C0428977] induce metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] terbinafine [MeSH:C0076110] [MeSH:C0076110] drug-drug interaction [MeSH:C0687133] [MeSH:C0687133] management year-old caucasian [MeSH:C0007457] man metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] mg stable coronary artery disease [MeSH:C1956346] prescribe -day course [MeSH:C0449259] oral terbinafine [MeSH:C0076110] [MeSH:C0076110] [MeSH:C0076110] mg onychomycosis [MeSH:C0040261] 9th terbinafine [MeSH:C0076110] [MeSH:C0076110] therapy bring emergency room [MeSH:C0562508] decrease global health status [MeSH:C1456573] confusion fall electrocardiogram reveal beat min sinus [MeSH:C0037189] bradycardia [MeSH:C0428977] score naranjo adverse drug reaction probability scale indicate probable relationship [MeSH:C0021797] sinus [MeSH:C0037189] bradycardia [MeSH:C0428977] drug interaction [MeSH:C0687133] metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] terbinafine [MeSH:C0076110] [MeSH:C0076110] heart rate ameliorate decrease dose metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] subsequently change bisoprolol heart rate [MeSH:C0053799] remain normal inhibit [MeSH:C0021463] cytochrome p4 [MeSH:C0010798] 2d6 terbinafine [MeSH:C0076110] [MeSH:C0076110] decrease metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] clearance [MeSH:C5243473] lead metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] accumulation [MeSH:C0311432] result clinically sinus [MeSH:C0037189] bradycardia [MeSH:C0428977],cardiovascular
tumor terrain [MeSH:C0006118] prostate cancer [MeSH:C0376358] exploration [MeSH:C0015329],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect hypertension [MeSH:C0020538] metastatic mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess myelodysplastic syndrome [MeSH:C3463824] adrenal cancer [MeSH:C0750887] result positive response implication practice guideline,oncological
hepatitis nephrotic syndrome [MeSH:C0027726] cardiac connection,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome primary sclerosing cholangitis [MeSH:C0566602] pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring gamma glutamyl transferase cardiomyopathy [MeSH:C0017040] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
revolutionary ct scan cancer diagnosis [MeSH:C0011900],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect stroke glomerular filtration rate [MeSH:C0017654] mechanism method retrospective diabetic patient [MeSH:C0030705] assess primary [MeSH:C0033137] biliary cholangitis [MeSH:C0008312] hydronephrosis [MeSH:C0020295] result favorable safety profile implication optimization [MeSH:C0376695],hepatorenal
gene familial mediterranean fever [MeSH:C0031069] mefv [MeSH:C0665818] express early leukocyte development regulate response [MeSH:C0068838] inflammatory mediator [MeSH:C0243042],familial mediterranean fever fmf [MeSH:C0031069] recessive disorder [MeSH:C0011581] characterize episode [MeSH:C0085554] fever neutrophil [MeSH:C0027950]-mediated serosal inflammation recently identify gene [MeSH:C0017337] cause fmf designate mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] find express mature [MeSH:C0349590] neutrophil [MeSH:C0027950] suggest function inflammatory [MeSH:C0003209] regulator facilitate understanding normal function [MeSH:C0031843] mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] extend previous study mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] messenger rna [MeSH:C0035696] detect reverse transcriptase-polymerase chain reaction bone marrow [MeSH:C0599161] leukocyte differential [MeSH:C0162401] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] observe cell situ hybridization [MeSH:C0162788] cd3 hematopoietic stem-cell culture induce granulocytic lineage [MeSH:C0282637] express mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] myelocyte [MeSH:C0369715] stage [MeSH:C0029170] concurrently lineage [MeSH:C0282637] commitment prepromyelocytic cell line hl6 express mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] granulocytic monocytic [MeSH:C0152276] differentiation mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] express monocytic cell line u9 thp- peripheral blood leukocyte mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] detect neutrophil [MeSH:C0027950] eosinophil vary degree monocyte [MeSH:C0026473] consistent tissue [MeSH:C0040300] specificity expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] complete sequencing upstream regulatory region mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] reveal homology [MeSH:C1136383] myeloid-specific promoter broadly express inflammatory [MeSH:C0003209] promoter element vitro stimulation [MeSH:C0031734] monocyte [MeSH:C0026473] proinflammatory [MeSH:C0003209] agent interferon ifn [MeSH:C0021747] gamma tumor necrosis factor lipopolysaccharide induce mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] antiinflammatory [MeSH:C0003209] cytokine interleukin il il- transform growth factor beta [MeSH:C0040690] inhibit [MeSH:C0021463] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] induction ifn-gamma [MeSH:C0383327] [MeSH:C0383327] [MeSH:C0383327] occur rapidly resistant [MeSH:C2986418] cycloheximide [MeSH:C0010572] ifn-alpha [MeSH:C0172511] [MeSH:C0172511] induce mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] granulocyte mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] up-regulate ifn-gamma [MeSH:C0383327] [MeSH:C0383327] [MeSH:C0383327] combination ifn-alpha [MeSH:C0172511] [MeSH:C0172511] colchicine result refine understanding mefv [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] [MeSH:C0665818] place gene [MeSH:C0017337] myelomonocytic-specific proinflammatory [MeSH:C0003209] pathway identify ifn-gamma [MeSH:C0383327] [MeSH:C0383327] [MeSH:C0383327] immediate early gene [MeSH:C0017337],oncological
sciatica [MeSH:C0036396] meet lung cancer [MeSH:C0242379] neurological perspective,question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] gaba mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess glioma cerebrovascular [MeSH:C0751814] result improvement primary endpoint implication care improvement,neurological
chromosome mapping rod [MeSH:C0008630] photoreceptor cgmp phosphodiesterase beta-subunit gene mouse human [MeSH:C0086418] tight linkage huntington disease region 4p1,retinal degene [MeSH:C0017337]ration mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] gene [MeSH:C0017337] [MeSH:C0035304] symbol rd animal model certain form human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] hereditary retinopathy [MeSH:C1853578] recent finding nonsense mutation [MeSH:C0544885] rd mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] pde beta-subunit gene [MeSH:C0017337] pdeb prompt investigate [MeSH:C0035173] chromosome location [MeSH:C0008633] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] gene [MeSH:C0017337] utilize backcross mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] verify define precisely location pdeb locus [MeSH:C0085286] [MeSH:C0085286] cm distal mgsa mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] chromosome determine human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] gene [MeSH:C0017337] pdeb map 4p1 close huntington disease [MeSH:C0020179] hd region [MeSH:C0242961] comparative map mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] show mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] homologue hd gene [MeSH:C0017337] reside chromosome linkage mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] pdeb locus [MeSH:C0085286] [MeSH:C0085286] homologue human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] 4p1 region [MeSH:C0242961] maintain gene [MeSH:C0017337] order suggest possible site corresponding mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] hd gene [MeSH:C0017337],neurological
multiple myeloma marker [MeSH:C0026764] colorectal cancer [MeSH:C0009402],question statin affect heart disease [MeSH:C0018799] target [MeSH:C0039309] therapy mechanism method prospective diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess premature beat [MeSH:C0340464] deep vein thrombosis [MeSH:C0149871] result positive response implication safety [MeSH:C0036043] consideration,cardiovascular|oncological
long-term [MeSH:C0023977] effect [MeSH:C4277511] vincristine [MeSH:C0042679] peripheral nervous system [MeSH:C0206417],patient [MeSH:C0030705] [MeSH:C0030705] non-hodgkin lymphoma [MeSH:C0024305] treat vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] cumulative dose mg week investigate [MeSH:C0035173] order evaluate [MeSH:C0013175] long term [MeSH:C0023977] [MeSH:C0023977] effect vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] peripheral nervous system [MeSH:C0206417] patient [MeSH:C0030705] [MeSH:C0030705] interview emphasis neuropathic symptom [MeSH:C3839861] [MeSH:C3839861] [MeSH:C0235031] [MeSH:C0235031] physical quantitative sensory examination [MeSH:C0376306] determination [MeSH:C1148554] vibratory perception thermal discrimination [MeSH:C0205905] threshold [MeSH:C0162703] perform month median month vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] twenty-seven patient [MeSH:C0030705] [MeSH:C0030705] report neuropathic symptom [MeSH:C3839861] [MeSH:C3839861] [MeSH:C0235031] [MeSH:C0235031] patient [MeSH:C0030705] [MeSH:C0030705] symptom [MeSH:C3839861] [MeSH:C3839861] present examination [MeSH:C0376306] patient [MeSH:C0030705] [MeSH:C0030705] sensory sign symptom [MeSH:C3839861] [MeSH:C3839861] predominate patient [MeSH:C0030705] [MeSH:C0030705] symptom [MeSH:C3839861] [MeSH:C3839861] present past symptom [MeSH:C3839861] [MeSH:C3839861] persist maximally month cessation therapy [MeSH:C0039798] age difference [MeSH:C0036866] patient [MeSH:C0030705] [MeSH:C0030705] complaint examination [MeSH:C0376306] normal reflex find patient [MeSH:C0030705] [MeSH:C0030705] neuropathic complaint troublesome long term [MeSH:C0023977] [MeSH:C0023977] conclude mention vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] dose schedule sign [MeSH:C0086960] symptom [MeSH:C3839861] [MeSH:C3839861] vincristine [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] [MeSH:C0042679] neuropathy reversible great deal prognosis [MeSH:C0033325] fairly good,neurological|oncological
potential [MeSH:C0001272] animal model [MeSH:C0599779] lesch-nyhan syndrome [MeSH:C0023374] introduction hprt [MeSH:C0020687] mutation mouse [MeSH:C0026809],human [MeSH:C0086418] lesch-nyhan [MeSH:C0023374] [MeSH:C0023374] syndrome [MeSH:C0023374] rare neurological behavioural disorder [MeSH:C0027765] affect male [MeSH:C0086582] [MeSH:C0086582] cause inherit deficiency activity [MeSH:C1623416] purine salvage enzyme [MeSH:C0014442] hypoxanthine-guanosine phosphoribosyl transferase hprt [MeSH:C0020687] result alteration purine metabolism [MeSH:C0025519] lead severe symptom characteristic lesch-nyhan [MeSH:C0023374] [MeSH:C0023374] patient [MeSH:C0030705] [MeSH:C0030705] understand mutation [MeSH:C0026882] hprt locus lead loss activity describe laboratory animal [MeSH:C0003064] derive animal model [MeSH:C0599779] lesch-nyhan [MeSH:C0023374] [MeSH:C0023374] syndrome [MeSH:C0023374] culture mouse [MeSH:C0026809] embryonic stem cell mutagenize retroviral insertion select loss hprt activity construct chimaeric mouse [MeSH:C0026809] clonal line carry different mutant hprt allele give rise germ cell [MeSH:C0017471] chimaera [MeSH:C0067895] allow derivation strain mutant [MeSH:C0025930] mouse [MeSH:C0026809] biochemical defect lesch-nyhan [MeSH:C0023374] [MeSH:C0023374] patient [MeSH:C0030705] [MeSH:C0030705] male [MeSH:C0086582] [MeSH:C0086582] mouse [MeSH:C0026809] carry mutant allele viable cell show total lack hprt activity,neurological
mesangial function glomerular sclerosis rat aminonucleoside nephrosis,possible relationship [MeSH:C0021797] mesangial dysfunction [MeSH:C0031847] development [MeSH:C0243107] glomerular sclerosis study puromycin aminonucleoside pan model [MeSH:C0034146] male [MeSH:C0086582] wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] receive repeat subcutaneous pan injection [MeSH:C1828121] control receive saline week pan rat [MeSH:C0034721] [MeSH:C0034721] severely proteinuric [MeSH:C0033687] mg hr rat [MeSH:C0034721] [MeSH:C0034721] give colloidal carbon cc intravenously month glomerular sclerosis find glomerulus pan rat [MeSH:C0034721] [MeSH:C0034721] glomerulus control normal glomerulus pan rat [MeSH:C0034721] [MeSH:C0034721] contain significantly cc glomerulus control glomerulus sclerosis contain significantly cc non-sclerotic glomerulus kidney cc [MeSH:C0022663] preferentially localized sclerotic area affect glomerulus mesangial cc clearance mesangium chronic pan conclude preferential cc localization [MeSH:C0037710] lesion cause increase cc uptake shortly injection [MeSH:C1828121] apparent vulnerable area sclerosis [MeSH:C0036429] develop subsequently cluster [MeSH:C0055966] show random distribution lesion [MeSH:C1704711] pan glomerulus concordance random localization [MeSH:C0037710] mesangial area dysfunction model similar remnant kidney model pan nephrosis [MeSH:C0027720] development [MeSH:C0243107] glomerular sclerosis related mesangial overload,hepatorenal
evidence [MeSH:C5575834] cholinergic [MeSH:C0242893] role haloperidol-induced catalepsy,experiment [MeSH:C0020123] mouse test previous evidence activation cholinergic [MeSH:C0242893] system promote catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] cholinergic [MeSH:C0242893] mechanism [MeSH:C1524059] need intact expression [MeSH:C0017262] neuroleptic-induced catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] large dose cholinomimetic pilocarpine [MeSH:C0031923] [MeSH:C0031923] induce catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] peripheral cholinergic [MeSH:C0242893] receptor block low dose pilocarpine [MeSH:C0031923] cause pronounced enhancement [MeSH:C0376317] catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] induce dopaminergic blocker [MeSH:C0242702] haloperidol [MeSH:C0018546] [MeSH:C0018546] muscarinic receptor blocker [MeSH:C0034826] atropine [MeSH:C0004259] disrupt haloperidol [MeSH:C0018546] [MeSH:C0018546]-induced catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] intracranial [MeSH:C0032268] injection acetylcholine-synthesis inhibitor hemicholinium [MeSH:C0018983] prevent [MeSH:C0000918] catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] usually induce haloperidol [MeSH:C0018546] [MeSH:C0018546] finding suggest hypothesis catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] produce neuroleptic haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] actually mediate intrinsic central cholinergic [MeSH:C0242893] system alternatively activation central cholinergic [MeSH:C0242893] system promote catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] suppression [MeSH:C1956351] dopaminergic system,neurological
heart rate [MeSH:C0018810] pattern multiple sclerosis patient [MeSH:C0030705],cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve atherosclerosis [MeSH:C0004153] sinoatrial node method [MeSH:C0037189] conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine transient ischemic attack [MeSH:C0007787] parameter result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],neurological|cardiovascular
mild severe muscular dystrophy [MeSH:C0026850] associate deletion [MeSH:C0004083] xp2 human [MeSH:C0086418] x chromosome,analyse patient [MeSH:C0030705] [MeSH:C0030705] suffer duchenne becker muscular dystrophy [MeSH:C3542021] dmd [MeSH:C1437024] bmd deletion [MeSH:C0017260] [MeSH:C0017260] characterise encompass pert8 dxs1 locus [MeSH:C0085286] [MeSH:C0085286] xj1 dxs2 hip2 locus [MeSH:C0085286] [MeSH:C0085286] locus [MeSH:C0085286] [MeSH:C0085286] locus [MeSH:C0085286] [MeSH:C0085286] show lie dmd [MeSH:C1437024] region cover kilobase kb dna mildly affect bmd possess deletion [MeSH:C0017260] [MeSH:C0017260] kb include exon [MeSH:C0015295] dmd [MeSH:C1437024] gene patient [MeSH:C0030705] [MeSH:C0030705] similar exon [MeSH:C0015295] deletion [MeSH:C0017260] [MeSH:C0017260] small deletion [MeSH:C0017260] [MeSH:C0017260] severe phenotype [MeSH:C0031437] [MeSH:C0031437] typical dmd [MeSH:C1437024] conclude study [MeSH:C0085973] severity phenotype [MeSH:C0031437] [MeSH:C0031437] explain basis size [MeSH:C0162658] deletion [MeSH:C0017260] [MeSH:C0017260] discuss context candidate gene sequence [MeSH:C0162327],neurological
iron-dependent self-assembly recombinant yeast frataxin [MeSH:C0387678] implication friedreich ataxia [MeSH:C0016719],frataxin [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] deficiency [MeSH:C1623416] primary cause friedreich ataxia frda [MeSH:C0016719] autosomal recessive [MeSH:C1968689] cardiodegenerative neurodegenerative disease [MeSH:C0524851] frataxin [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] nuclear-encoded mitochondria [MeSH:C0026237]l [MeSH:C0949610] [MeSH:C0949610] protein widely conserve eukaryote [MeSH:C0684063] genetic [MeSH:C0017380] inactivation yeast [MeSH:C0043393] [MeSH:C0043393] frataxin [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] homologue yfh1p result [MeSH:C4704700] mitochondria [MeSH:C0026237]l [MeSH:C0949610] [MeSH:C0949610] iron [MeSH:C0302583] [MeSH:C0302583] accumulation hypersensitivity oxidative stress [MeSH:C0242606] increase iron [MeSH:C0302583] [MeSH:C0302583] deposition evidence [MeSH:C5575834] oxidative damage [MeSH:C5392203] observe cardiac tissue [MeSH:C0040300] culture fibroblast patient frda finding indicate frataxin [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] essential mitochondria [MeSH:C0026237]l [MeSH:C0949610] [MeSH:C0949610] iron [MeSH:C0302583] [MeSH:C0302583] homeostasis protection [MeSH:C0524828] iron [MeSH:C0302583] [MeSH:C0302583]-induced formation free radical function [MeSH:C0031843]al mechanism [MeSH:C1524059] [MeSH:C1524059] frataxin [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] unknown express mature [MeSH:C0349590] form yfh1p myfh1p escherichia coli [MeSH:C0014834] analyze function [MeSH:C0031843] vitro isolate myfh1p soluble [MeSH:C0210233] monomer da contain iron [MeSH:C0302583] [MeSH:C0302583] show tendency self-associate aerobic addition ferrous iron [MeSH:C0302583] [MeSH:C0302583] myfh1p result [MeSH:C4704700] assembly [MeSH:C1156188] regular spherical multimer [MeSH:C0376478] [MeSH:C0376478] molecular mass approximately mda megadalton diameter nm multimer [MeSH:C0376478] [MeSH:C0376478] consist approximately subunit [MeSH:C0599220] sequester [MeSH:C3658307] atom iron [MeSH:C0302583] [MeSH:C0302583] titration myfh1p increase iron [MeSH:C0302583] [MeSH:C0302583] concentration support stepwise mechanism [MeSH:C1524059] [MeSH:C1524059] multimer [MeSH:C0376478] [MeSH:C0376478] assembly [MeSH:C1156188] sequential addition iron [MeSH:C0302583] [MeSH:C0302583] chelator reduce agent result [MeSH:C4704700] quantitative [MeSH:C0597336] iron [MeSH:C0302583] [MeSH:C0302583] release concomitant [MeSH:C0152203] disassembly [MeSH:C1156188] multimer [MeSH:C0376478] [MeSH:C0376478] indicate myfh1p sequester [MeSH:C3658307] iron [MeSH:C0302583] [MeSH:C0302583] available form yeast [MeSH:C0043393] [MeSH:C0043393] mitochondria [MeSH:C0026237] native [MeSH:C3494467] myfh1p exist monomer higher-order specie molecular weight addition fe medium immunoprecipitate specie [MeSH:C0021069] contain atom fe molecule myfh1p propose iron [MeSH:C0302583] [MeSH:C0302583]-dependent self-assembly [MeSH:C1156188] recombinant myfh1p reflect physiological [MeSH:C0031845] role frataxin [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] mitochondria [MeSH:C0026237]l [MeSH:C0949610] [MeSH:C0949610] iron [MeSH:C0302583] [MeSH:C0302583] sequestration bioavailability [MeSH:C0005508],neurological|cardiovascular
alkaptonuria aku mutation polymorphism [MeSH:C0032529] reveal ccc sequence motif mutational hot spot homogentisate dioxygenase gene hgo,recently show alkaptonuria aku [MeSH:C0002066] cause loss-of-function mutation [MeSH:C0026882] homogentisate dioxygenase gene [MeSH:C0017337] [MeSH:C0062939] hgo describe haplotype [MeSH:C0018591] mutation [MeSH:C0026882]al analysis [MeSH:C0012878] hgo seven new aku pedigree analysis identify novel single-nucleotide polymorphism [MeSH:C0032529] inv4 [MeSH:C0752046] 1a-- g inv1 8a-- g novel aku mutation [MeSH:C0026882] inv1 1g-- w60 g y62c a12d p20 d21e illustrate remarkable allelic [MeSH:C0524869] heterogene [MeSH:C0017337]ity [MeSH:C0242960] find aku reexamination mutation [MeSH:C0026882] polymorphism [MeSH:C0032529] far describe hgo show nucleotide change [MeSH:C0028630] randomly distribute ccc sequence motif inverted complement ggg preferentially mutate [MeSH:C3178846] analysis [MeSH:C0012878] demonstrate nucleotide substitution hgo involve cpg dinucleotide illustrate important difference hgo gene [MeSH:C0017337] occurrence mutation [MeSH:C0026882] specific short-sequence motif ccc sequence motif comprise proportion mutate [MeSH:C3178846] basis observe hgo conclude ccc triplet mutation [MeSH:C0026882]al hot spot hgo,neurological
arterial thromboembolism [MeSH:C0040038] patient [MeSH:C0030705] receive systemic [MeSH:C5544477] heparin therapy complication [MeSH:C1171258] associate heparin-induced thrombocytopenia [MeSH:C0040034],arterial thromboembolism [MeSH:C0040038] recognize complication [MeSH:C1171258] [MeSH:C1171258] systemic heparin [MeSH:C0019134] therapy [MeSH:C0039798] [MeSH:C0039798] characteristic entity arterial occlusion [MeSH:C0011382] [MeSH:C0264995] platelet-fibrin thrombus distal ischemia occur day [MeSH:C0011017] initiation [MeSH:C0030943] heparin [MeSH:C0019134] therapy [MeSH:C0039798] [MeSH:C0039798] precede profound thrombocytopenia platelet count range cubic millimeter clinically apparent occlusion [MeSH:C0011382] precede gastrointestinal [MeSH:C0017189] musculoskeletal symptom appear ischemic [MeSH:C0022116] origin [MeSH:C0005495] serve warn clinician [MeSH:C0028654] complication [MeSH:C1171258] [MeSH:C1171258] previous report phenomenon recent study effect heparin [MeSH:C0019134] review [MeSH:C0282443] common factor relate thromboembolism thrombocytopenia [MeSH:C0040038] heparin [MeSH:C0019134]-induced platelet aggregation [MeSH:C0032176] appropriate consist discontinuation heparin [MeSH:C0019134] anticoagulation sodium warfarin [MeSH:C0043031] necessary vascular procedure [MeSH:C0042381] perform indicate,neurological
cocaine [MeSH:C0009170] [MeSH:C0009170] ethanol [MeSH:C0001962] cocaethylene [MeSH:C0082060] cardiotoxity [MeSH:C0876994] animal [MeSH:C0003062] model cocaine [MeSH:C0009170] [MeSH:C0009170] ethanol [MeSH:C0001962] abuse,objective simultaneous abuse cocaine [MeSH:C0009171] ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] affect million american annually combination substance substantially toxic [MeSH:C1256754] drug combined cardiac [MeSH:C0018810] [MeSH:C0018810] toxic [MeSH:C1256754]ity independent effect [MeSH:C4277511] drug cocaethylene ce cocaine metabolite form presence ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] delineate role ce combined cardiotoxic [MeSH:C1256754]ity cocaine ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] model simulate abuse method twenty-three dog [MeSH:C0012984] [MeSH:C0012984] randomized [MeSH:C1096777] receive intravenous [MeSH:C0085297] iv bolus cocaine mg kg ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] g kg iv infusion [MeSH:C0841792] [MeSH:C0841792] c e n cocaine bolus c [MeSH:C0009170] n ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] infusion [MeSH:C0841792] [MeSH:C0841792] e n placebo bolus infusion [MeSH:C0841792] [MeSH:C0841792] n hemodynamic [MeSH:C0019010] [MeSH:C0019010] measurement electrocardiogram serum drug concentration [MeSH:C0311432] obtain fix interval drug administer result dog [MeSH:C0012984] [MeSH:C0012984] c e experienced cardiovascular [MeSH:C0007220] collapse [MeSH:C2717753] dramatic hemodynamic [MeSH:C0019010] [MeSH:C0019010] change occur cocaine bolus c [MeSH:C0009170] e c group [MeSH:C0018257] persistent [MeSH:C0026205] hemodynamic [MeSH:C0019010] [MeSH:C0019010] change occur c e peak ce level [MeSH:C0018759] associate [MeSH:C0004083] sd ci decrease cardiac [MeSH:C0018810] [MeSH:C0018810] output p sd ci decrease dp dt max p sd ci decrease svo p ventricular arrhythmia [MeSH:C0042514] primarily observe c e dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] experience ventricular tachycardia [MeSH:C0042514] conclusion cocaine ethanol [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] [MeSH:C0001962] combination toxic [MeSH:C1256754] substance co-administration [MeSH:C0001554] result prolonged cardiac [MeSH:C0018810] [MeSH:C0018810] toxic [MeSH:C1256754]ity dysrhythmogenic peak serum cocaethylene concentration [MeSH:C0311432] associate [MeSH:C0004083] prolonged myocardial depression [MeSH:C0027047],neurological|cardiovascular
stenosis [MeSH:C1261287] ventricular tachycardia vascular [MeSH:C0042514] insight,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome systolic pathway method prospective trial adult population measure heart block ischemic cardiomyopathy result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],cardiovascular
leukemia [MeSH:C0023418] cardiovascular lens [MeSH:C0007220],diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve heart block dvt method [MeSH:C0018794] conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine heart attack [MeSH:C0027051] parameter result enhance therapeutic response [MeSH:C0087111] therapeutic innovation [MeSH:C0087111],cardiovascular
hypertension [MeSH:C0020538] congestive heart failure [MeSH:C0018802] exploring neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve cancer outcome alzheimer disease pathway method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient measure parkinson disease [MeSH:C0030567] pulmonary valve [MeSH:C0034086] result superior efficacy [MeSH:C5690761] optimization [MeSH:C0376695],neurological|cardiovascular
dementia [MeSH:C0497327] aortic [MeSH:C0037197] aneurysm [MeSH:C0002940] cardiac connection,observational [MeSH:C0302523] examine statin hypertension cancer [MeSH:C0020538] patient [MeSH:C0030705] investigation [MeSH:C0035173] include pacemaker pericardium cardiac method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
safety [MeSH:C0036043] adverse effect [MeSH:C0001688] associate raloxifene [MeSH:C0244404] multiple outcome raloxifene [MeSH:C0244404],examine effect [MeSH:C4277511] raloxifene [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] major adverse event [MeSH:C0041755] occur postmenopausal [MeSH:C0206159] [MeSH:C0206159] estrogen therapy [MeSH:C0014935] tamoxifen [MeSH:C0039286] method multiple outcome [MeSH:C0206277] raloxifene [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] multicenter randomized double-blind trial enrol postmenopausal [MeSH:C0206159] [MeSH:C0206159] woman [MeSH:C0043210] osteoporosis [MeSH:C0029456] woman [MeSH:C0043210] randomly assign raloxifene [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] mg mg placebo [MeSH:C0032041] [MeSH:C0032041] outcome [MeSH:C0206277] include venous thromboembolism [MeSH:C1861172] [MeSH:C1861172] cataract gallbladder disease [MeSH:C1861172] endometrial hyperplasia [MeSH:C0014173] cancer [MeSH:C0014173] result mean follow-up [MeSH:C3899107] year raloxifene [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] associate increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] venous thromboembolism [MeSH:C1861172] [MeSH:C1861172] relative risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] rr confidence interval [MeSH:C0009667] ci excess event rate woman [MeSH:C0043210]-year ci number need treat cause event ci year risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] raloxifene [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] high placebo [MeSH:C0032041] [MeSH:C0032041] year decrease rate placebo [MeSH:C0032041] [MeSH:C0032041] raloxifene [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] cataract rr ci gallbladder disease rr ci endometrial hyperplasia [MeSH:C0014173] rr ci endometrial cancer [MeSH:C0476089] rr ci raloxifene [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] [MeSH:C0244404] associate increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] venous thromboembolism [MeSH:C1861172] [MeSH:C1861172] increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] cataract gallbladder disease endometrial hyperplasia [MeSH:C0014173] endometrial cancer [MeSH:C0476089] evidence [MeSH:C5575834],oncological
cerebral vasculitis [MeSH:C0238051] follow oral [MeSH:C0029170] methylphenidate intake adult [MeSH:C0001675] case report [MeSH:C0684224],methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] structurally functionally similar amphetamine cerebral vasculitis [MeSH:C0042384] associate amphetamine abuse [MeSH:C0236807] document rare case ischaemic stroke [MeSH:C0948008] [MeSH:C0948008] report methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] intake child report [MeSH:C0008059] case -year-old female [MeSH:C0086287] treat methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] hyperactivity suffer multiple ischaemic stroke [MeSH:C0948008] consider drug-induced cerebral vasculitis [MeSH:C0042384] [MeSH:C0238051] likely cause recurrent ischaemic stroke [MeSH:C0948008] absence pathological [MeSH:C0030660] finding diagnostic work-up conclude methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] mediated vasculitis [MeSH:C0042384] consider patient [MeSH:C0030705] neurological symptom [MeSH:C0235031] history methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810] therapy potential side-effect rare represent reason restrictive use methylphenidate [MeSH:C0025810] [MeSH:C0025810] [MeSH:C0025810],neurological
stroke [MeSH:C0038454] hepatitis vascular [MeSH:C0019158] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete cardiomyopathy [MeSH:C0878544] mechanism method cross-sectional adult [MeSH:C0010362] population [MeSH:C0032659] assess dilate cardiomyopathy [MeSH:C0878544] ventricle result superior efficacy [MeSH:C5690761] implication care improvement,cardiovascular
genotype [MeSH:C0017431] phenotype [MeSH:C0031437] patient [MeSH:C0030705] dihydropyrimidine dehydrogenase deficiency [MeSH:C1959620],dihydropyrimidine dehydrogenase dpd deficiency [MeSH:C1959620] [MeSH:C1623416] [MeSH:C1959620] autosomal recessive disease characterise thymine [MeSH:C0040087]-uraciluria [MeSH:C1959620] homozygous [MeSH:C0019904] deficient [MeSH:C0531328] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] associate variable phenotype [MeSH:C0031437] [MeSH:C0031437] order understand genetic [MeSH:C0017380] phenotypic [MeSH:C1837514] basis dpd deficiency [MeSH:C1959620] [MeSH:C1623416] review [MeSH:C1959620] family present patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] complete deficiency [MeSH:C1623416] dpd patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] different mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify include deletion [MeSH:C0017260] -8deltcat 7delc splice-site mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] ivs1 1 g missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] 5 c 3c 8 g 3 g prevalence [MeSH:C0033105] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] dpd patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show g-- point mutation [MeSH:C0026882] [MeSH:C0162735] [MeSH:C0026882] [MeSH:C0026882] invariant splice donor site far common mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] frequently observe large phenotypic [MeSH:C1837514] variability [MeSH:C0003319] observe convulsive disorder [MeSH:C1848137] motor retardation mental retardation [MeSH:C3714756] abundant manifestation [MeSH:C0029166] clear correlation [MeSH:C0010100] genotype [MeSH:C0017431] phenotype [MeSH:C0031437] [MeSH:C0031437] establish altered beta-alanine [MeSH:C0000392] uracil thymine [MeSH:C0040087] homeostasis [MeSH:C0019868] underlie abnormality [MeSH:C0037268] encounter patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dpd deficiency [MeSH:C1959620] [MeSH:C1623416],neurological|hepatorenal
myocardial hepatitis vascular insight,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] bundle branch block method [MeSH:C0006384] adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective [MeSH:C0035363] pad hypotension [MeSH:C0020649] assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,cardiovascular
cancer thrombosis [MeSH:C0040053] cardiac connection,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] tachycardia bradycardia [MeSH:C0039231] result improve outcome capillary correlation care improvement [MeSH:C2936612],cardiovascular
glomerulus marker cardiomyopathy,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population bile duct dialysis [MeSH:C0011945] result enhance therapeutic response [MeSH:C0087111] anuria [MeSH:C0003460] correlation [MeSH:C0010100] relevance [MeSH:C2826293],cardiovascular|hepatorenal
liver marker parkinson disease [MeSH:C0030567],diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve proteinuria [MeSH:C0033687] arterial method conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine anuria [MeSH:C0003460] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] optimization [MeSH:C0376695],cardiovascular|hepatorenal
pharmacological [MeSH:C0007992] evidence [MeSH:C5575834] potential daucus carota [MeSH:C0242773] management [MeSH:C0085971] cognitive dysfunction [MeSH:C0338656],present aim investigate [MeSH:C0035173] effect [MeSH:C4277511] [MeSH:C4277511] daucus carota [MeSH:C0242773] [MeSH:C0242773] seed [MeSH:C0036563] cognitive function total serum cholesterol [MeSH:C0008377] level brain [MeSH:C0006104] [MeSH:C0006104] cholinesterase activity mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] ethanolic extract daucus carota [MeSH:C0242773] [MeSH:C0242773] seed [MeSH:C0036563] dce administer orally dose mg kg seven successive day [MeSH:C0011017] different group [MeSH:C0018257] young [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] aged [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] elevated plus maze passive avoidance apparatus serve exteroceptive behavioral model [MeSH:C4042874] testing memory [MeSH:C0025260] diazepam [MeSH:C0012010]- scopolamine [MeSH:C0036442]- ageing-induced amnesia serve interoceptive [MeSH:C3850156] behavioral model [MeSH:C4042874] dce mg kg p show improvement [MeSH:C2936612] [MeSH:C2936612] memory [MeSH:C0025260] score [MeSH:C0025260] [MeSH:C0025260] young [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] aged [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] extent memory [MeSH:C0025260] improvement [MeSH:C2936612] [MeSH:C2936612] evoke dce dose mg kg dose mg kg young [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] elevated plus maze similarly improvement [MeSH:C2936612] [MeSH:C2936612] memory [MeSH:C0025260] score [MeSH:C0025260] [MeSH:C0025260] observe passive avoidance apparatus aged [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] furthermore dce reverse amnesia induce scopolamine [MeSH:C0036442] mg kg p diazepam [MeSH:C0012010] mg kg p daucus carota [MeSH:C0242773] [MeSH:C0242773] extract mg kg p reduce significantly brain [MeSH:C0006104] [MeSH:C0006104] acetylcholinesterase activity cholesterol [MeSH:C0008377] level young [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] aged [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] extent inhibition [MeSH:C0027790] brain [MeSH:C0006104] [MeSH:C0006104] cholinesterase activity evoke dce dose mg kg young [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] aged [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] remarkable reduction total cholesterol [MeSH:C0008377] [MeSH:C0008377] extent young [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] [MeSH:C0340037] aged [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] [MeSH:C0001792] animal [MeSH:C0003062] dose dce dce prove useful remedy management [MeSH:C0085971] cognitive dysfunction [MeSH:C0338656] account multifarious beneficial effect [MeSH:C4277511] [MeSH:C4277511] memory [MeSH:C0025260] improving property cholesterol [MeSH:C0008377] [MeSH:C0008377] lower property anticholinesterase activity [MeSH:C0008425],neurological
real-world efficacy [MeSH:C5690761] safety lenalidomide [MeSH:C1144149] dexamethasone [MeSH:C0011777] patient [MeSH:C0030705] relapsed refractory multiple myeloma [MeSH:C0026764] treat accord standard practice greek myeloma,lenalidomide [MeSH:C1144149] [MeSH:C1144149] dexamethasone [MeSH:C0011777] rd standard care [MeSH:C2936643] relapsed refractory multiple myeloma [MeSH:C0026764] rrmm limit publish efficacy [MeSH:C5690761] safety [MeSH:C0036043] real world [MeSH:C0043236] rw accord international society pharmacoeconomic outcome definition study rrmm patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive rd rw response pr partial response rate complete response cr median good response month respectively median cr rd give 2nd nd -line month respectively quality [MeSH:C0034379] response independent previous line therapy [MeSH:C0039798] previous exposure [MeSH:C1390376] thalidomide [MeSH:C0039736] bortezomib [MeSH:C1176309] median duration response month high patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive rd progression [MeSH:C0242656] reach versus month p improvement [MeSH:C2936612] humoral immunity [MeSH:C0020967] [MeSH:C0020967] occur responder p majority patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] achieve stable [MeSH:C1706074] disease adverse event [MeSH:C0041755] report patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] myelosuppression [MeSH:C1956351] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] need hospitalization [MeSH:C0019993] peripheral neuropathy [MeSH:C4721453] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] deep vein thrombosis [MeSH:C0149871] dose reduction [MeSH:C1827449] need patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] permanent discontinuation median discontinuation month performance [MeSH:C0871966] status [MeSH:C4277552] ps initial lenalidomide [MeSH:C1144149] [MeSH:C1144149] dose predict discontinuation extra-medullary relapse occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] confirm rd effective [MeSH:C5392218] safe rrmm rw produce durable response especially patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] continue till progression [MeSH:C0242656] improve humoral immunity [MeSH:C0020967] [MeSH:C0020967] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stable [MeSH:C1706074] disease,neurological
cholelithiasis [MeSH:C0008350] marker leukemia [MeSH:C0023418],retrospective [MeSH:C0035363] examine statin diabete cardiac patient investigation [MeSH:C0035173] include cardiomyopathy myocardial infarction heart rate method [MeSH:C0027051] participant [MeSH:C1708335] include result positive response implication safety [MeSH:C0036043] consideration,cardiovascular|hepatorenal
peripheral neuropathy [MeSH:C4721453] connection lymphoma,observational [MeSH:C0302523] examine metformin [MeSH:C0025598] heart disease [MeSH:C0018799] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include glutamate hippocampal brain method [MeSH:C0025663] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication optimization [MeSH:C0376695],neurological
tia liver cirrhosis [MeSH:C0023890] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia [MeSH:C0497327] arrhythmia [MeSH:C0003811] method adult [MeSH:C0001675] population [MeSH:C0032659] undergo cross-sectional pulmonary valve deep vein thrombosis assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],cardiovascular
enhance stimulus-induced neurotransmitter [MeSH:C0027908] overflow epinephrine-induced hypertensive rat [MeSH:C0034721] mediate prejunctional beta-adrenoceptor activation,present examine effect [MeSH:C4277511] -day epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] microgram [MeSH:C0376691] kg h c stimulus-induced hz endogenous [MeSH:C0205752] neurotransmitter [MeSH:C0027908] [MeSH:C0027908] [MeSH:C0027908] overflow isolate perfused kidney [MeSH:C0022646] [MeSH:C0266305] vehicle- epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563]-treated rat [MeSH:C0034721] renal [MeSH:C0152169] catecholamine [MeSH:C0007412] store stimulus-induced overflow vehicle-treated consist norepinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0028351] [MeSH:C0014563] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] result incorporat [MeSH:C0034721]ion epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] renal [MeSH:C0152169] catecholamine [MeSH:C0007412] store approximately catecholamine [MeSH:C0007412] present epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] norepinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0028351] [MeSH:C0014563] content reduce similar degree total tissue catecholamine [MeSH:C0007412] content kidney [MeSH:C0022646] molar basis unchanged stimulus-induced fractional overflow neurotransmitter [MeSH:C0027908] [MeSH:C0027908] [MeSH:C0027908] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563]-treated kidney [MeSH:C0022646] approximately twice normal consist norepinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0028351] [MeSH:C0028351] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0028351] [MeSH:C0014563] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] proportion similar find kidney [MeSH:C0022646] difference fractional overflow group affect neuronal [MeSH:C0132800] [MeSH:C0132800] extraneuronal [MeSH:C0132800] [MeSH:C0132800] uptake blockade [MeSH:C0027741] propranolol [MeSH:C0033497] effect [MeSH:C4277511] stimulus-induced overflow phentolamine [MeSH:C0031448] [MeSH:C0031448] increase stimulus-induced overflow group increment overflow great epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563]-treated chronic epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] result enhance fractional neurotransmitter [MeSH:C0027908] [MeSH:C0027908] [MeSH:C0027908] overflow alterat [MeSH:C0034721]ion prejunctional beta-adrenoceptor influence alterat [MeSH:C0034721]ion neuronal [MeSH:C0132800] [MeSH:C0132800] extraneuronal [MeSH:C0132800] [MeSH:C0132800] uptake mechanism [MeSH:C1524059] appear responsible alterat [MeSH:C0034721]ion furthermore obtain phentolamine [MeSH:C0031448] [MeSH:C0031448] suggest alpha-adrenoceptor [MeSH:C0034783] desensitization [MeSH:C5544363] cause enhance neurotransmitter [MeSH:C0027908] [MeSH:C0027908] [MeSH:C0027908] overflow epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563],neurological|hepatorenal
organ [MeSH:C0029250] orchestra diabetes mellitus,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] nephritis method [MeSH:C0027697] cardiac patient undergo retrospective chronic kidney disease [MeSH:C1561643] esrd assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] healthcare advancement,hepatorenal
metabotropic glutamate receptor subtype [MeSH:C0206529] modulate motor symptom rodent model parkinson disease [MeSH:C0030567],metabotropic glutamate mglu receptor [MeSH:C0206529] modulate synaptic transmission [MeSH:C0027793] central nervous system [MeSH:C3714787] represent promising therapeutic [MeSH:C0087111] target [MeSH:C0039309] symptomatic [MeSH:C3839861] parkinson disease [MeSH:C0030567] pd mglu receptor subtype mglu7 receptor prominently express [MeSH:C0017262] basal ganglion [MeSH:C0004781] role restore motor function [MeSH:C0031843] animal model [MeSH:C0599779] pd know effect n n -dibenzhydrylethane- -diamine dihydrochloride [MeSH:C0282162] amn0 selective allosteric activator mglu7 receptor test different rodent model [MeSH:C0035804] pd oral mg kg intrastriatal administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] nmol amn0 reverse haloperidol-induced catalepsy rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] amn0 mg kg reduce apomorphine-induced rotation unilateral -hydroxydopamine -ohda -lesioned rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] complex task [MeSH:C0162458] commonly evaluate [MeSH:C0013175] major akinetic symptom pd patient [MeSH:C0030705] mg kg amn0 reverse increase reaction respond cue [MeSH:C0010439] bilateral -ohda-lesioned rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] addition amn0 reduce durat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion haloperidol-induced catalepsy mglu7 receptor-dependent manner wild-type mglu7 receptor knockout mouse [MeSH:C0206745] high dose amn0 mg kg p effect model pd overall finding suggest mglu7 receptor activation reverse motor dysfunction associate reduce dopamine activity selective ligand mglu7 receptor subtype consider promising compound development [MeSH:C0020119] antiparkinsonian [MeSH:C0003405] therapeutic [MeSH:C0087111] strat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]egy,neurological
myocardium angina [MeSH:C0027061] pectoris vascular insight,retrospective [MeSH:C0035363] examine beta-blocker diabete adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include pe stroke bradycardia method [MeSH:C0428977] participant [MeSH:C1708335] include result well quality life measure implication healthcare advancement,cardiovascular
combined hereditary prostate cancer [MeSH:C2931456] [MeSH:C2931456] linkage [MeSH:C0242239] 1q2- result hereditary prostate cancer [MeSH:C2931456] [MeSH:C2931456] family international consortium prostate cancer genetic [MeSH:C0017380],previous linkage [MeSH:C0242239] [MeSH:C0242239] provide evidence [MeSH:C5575834] [MeSH:C5575834] [MeSH:C5575834] [MeSH:C5575834] prostate [MeSH:C0033572] [MeSH:C0033572] cancer-susceptibility locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] 1q2- subsequent report additional collection [MeSH:C0600644] family [MeSH:C0015576] yield conflicting result addition evidence [MeSH:C5575834] [MeSH:C5575834] [MeSH:C5575834] [MeSH:C5575834] locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] heterogeneity [MeSH:C0242960] [MeSH:C0242960] [MeSH:C0242960] provide identification [MeSH:C1707660] putative hereditary prostate [MeSH:C0033572] [MeSH:C0033572] cancer locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] xq2- 1q4- 1p3 present describe combined marker [MeSH:C0017393] 1q2- region [MeSH:C0242961] family [MeSH:C0015576] affect hereditary prostate [MeSH:C0033572] [MeSH:C0033572] cancer ascertain member international [MeSH:C1138414] consortium prostate [MeSH:C0033572] [MeSH:C0033572] cancer genetic icpcg north america [MeSH:C0028405] australia finland [MeSH:C0016132] norway sweden united kingdom [MeSH:C0041700] overall evidence [MeSH:C5575834] [MeSH:C5575834] [MeSH:C5575834] [MeSH:C5575834] linkage [MeSH:C0242239] [MeSH:C0242239] peak parametric multipoint lod score assume heterogeneity [MeSH:C0242960] [MeSH:C0242960] [MeSH:C0242960] hlod p d1s2 estimate proportion family [MeSH:C0015576] alpha link locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] -lod support interval evidence [MeSH:C5575834] [MeSH:C5575834] [MeSH:C5575834] [MeSH:C5575834] observe nonparametric approach presumably extensive heterogeneity [MeSH:C0242960] [MeSH:C0242960] [MeSH:C0242960] parametric reveal effect [MeSH:C4277511] presence male-to-male disease transmission [MeSH:C0040722] [MeSH:C0040722] family [MeSH:C0015576] subset family [MeSH:C0015576] peak hlod subset family [MeSH:C0015576] peak hlod p alpha -lod support interval compare hlod remain family [MeSH:C0015576] family [MeSH:C0015576] male-to-male disease transmission [MeSH:C0040722] [MeSH:C0040722] alpha increase early mean age diagnosis [MeSH:C0011900] prostate [MeSH:C0033572] [MeSH:C0033572] cancer-susceptibility gene link 1q2- albeit define subset prostate [MeSH:C0033572] [MeSH:C0033572] cancer family [MeSH:C0015576] hpc1 account small proportion family [MeSH:C0015576] affect hereditary prostate [MeSH:C0033572] [MeSH:C0033572] cancer appear play prominent role subset family [MeSH:C0015576] member affect early age male-to-male disease transmission [MeSH:C0040722] [MeSH:C0040722],oncological
astrocytoma [MeSH:C0004114] connection heart failure [MeSH:C0018801],diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve thalamus radiculopathy method [MeSH:C0700594] conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine dopamine [MeSH:C0013030] parameter result well quality life measure healthcare advancement,neurological
atrium epilepsy vascular insight,heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve atherosclerosis [MeSH:C0004153] endothelial method [MeSH:C0225336] conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine pkd parameter result well quality life measure optimization [MeSH:C0376695],cardiovascular|hepatorenal
cardiomyopathy lymphoma vascular insight,design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] beta-blocker cancer participant cancer patient [MeSH:C0030705] myocardial infarction coronary result [MeSH:C0027051] positive response restrictive cardiomyopathy [MeSH:C0007196] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
modification [MeSH:C0086153] drug action [MeSH:C0687133] hyperammonemia,pretreatment [MeSH:C0376495] [MeSH:C0376495] ammonium acetate [MeSH:C0051704] nh4ac mmol kg c approximately double morphine [MeSH:C0026549]-treated mouse remain hot surface [MeSH:C0025252] similarly increase muscular incoordination diazepam [MeSH:C0012010] nh4ac effect [MeSH:C4277511] hyperammonemia [MeSH:C0220994] [MeSH:C0220994] capable alter drug action [MeSH:C0687133] consider impaired [MeSH:C0020580] drug metabolism [MeSH:C0025519] enhance [MeSH:C0014290] drug response associate liver disease [MeSH:C0023895] experiment [MeSH:C0020123] vitro show acetylcholine-induced catecholamine [MeSH:C0007412] release bovine [MeSH:C0007453] adrenal medulla depressed mm nh4ac kcl-induced contraction guinea-pig [MeSH:C0085979] ileum [MeSH:C0020885] inhibit [MeSH:C0021463] mm nh4ac addition excess calcium reverse depression tissue calcium-independent catecholamine [MeSH:C0007412] release acetaldehyde block [MeSH:C0000966] nh4ac result suggest ammonia block calcium channel parallel action [MeSH:C0006685] nh4ac calcium channel blocker [MeSH:C0006684] verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] support concept [MeSH:C2350469] verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] mg kg p nh4ac pretreatment [MeSH:C0376495] [MeSH:C0376495] enhance [MeSH:C0014290] morphine [MeSH:C0026549] analgesia- diazepam [MeSH:C0012010]-induced muscular incoordination antagonize amphetamine-induced motor activity verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] nh4ac affect convulsant [MeSH:C0009950] action metrazol suggest hyperammonemia [MeSH:C0220994] [MeSH:C0220994] exert calcium channel blocking [MeSH:C0006684] action enhance [MeSH:C0014290] effect [MeSH:C4277511] central nervous system [MeSH:C3714787] depressant [MeSH:C0003289] certain opioid analgesic [MeSH:C0002772],hepatorenal
novel mutation [MeSH:C0026882] atp7b gene japanese patient wilson disease [MeSH:C0019202],wilson disease wd autosomal recessive disorder [MeSH:C1968689] characterize copper [MeSH:C0009968] accumulation [MeSH:C0311432] [MeSH:C0311432] liver brain kidney cornea culminate copper [MeSH:C0009968] toxication organ analyze mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] responsible gene atp7b japanese [MeSH:C1556094] [MeSH:C1556094] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] wd direct sequencing [MeSH:C0751971] identify mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] novel polymorphism [MeSH:C0032529] novel mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] 1delc 3dela shift reading frame [MeSH:C0080089] truncate abnormal protein expect contrast mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hepatic-type early onset [MeSH:C0031106] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] a84v r78l 2delgtc missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] frame -amino acid deletion occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hepato-neurologic type late onset mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] 1delc r78l previously report relatively large number japanese [MeSH:C1556094] [MeSH:C1556094] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] particular r78l know prevalent asian [MeSH:C0003988] country country world compatible hypothesis [MeSH:C3179072] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] tend occur population-specific manner accumulation [MeSH:C0311432] [MeSH:C0311432] type mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] japanese [MeSH:C1556094] [MeSH:C1556094] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] wd facilitate fast effective genetic diagnosis [MeSH:C0011900] wd japanese [MeSH:C1556094] [MeSH:C1556094] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],neurological|hepatorenal
brain dynamic leukemia guillain-barre syndrome [MeSH:C0018378],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] peripheral neuropathy pathway method [MeSH:C4721453] retrospective trial cancer patient [MeSH:C0030705] measure brain hippocampal [MeSH:C0228249] result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],neurological
epilepsy [MeSH:C0014544] transient ischemic attack [MeSH:C0007787] cardiac connection,investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia [MeSH:C0497327] cardiac method cancer patient [MeSH:C0030705] undergo retrospective ischemic cardiomyopathy hypotension [MeSH:C0020649] assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
angina chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve deep vein thrombosis [MeSH:C0149871] myocardial infarction method [MeSH:C0027051] conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine atrial flutter [MeSH:C0004239] parameter result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
molecular [MeSH:C0026381] phenotypic patient [MeSH:C0030705] deletion deletion-rich region duchenne muscular dystrophy [MeSH:C0026850] dmd gene,eighty unrelated individual [MeSH:C0021228] [MeSH:C0021228] duchenne muscular dystrophy [MeSH:C0013264] dmd [MeSH:C1437024] becker muscular dystrophy [MeSH:C0917713] bmd find deletion [MeSH:C0017260] major deletion [MeSH:C0017260]-rich region dmd [MeSH:C1437024] locus region [MeSH:C0525013] include exon [MeSH:C0015295] detect cdna5b- exon [MeSH:C0015295] detect cdna8 exon [MeSH:C0015295] detect cdna9 individual [MeSH:C0021228] [MeSH:C0021228] account approximately deletion [MeSH:C0017260] gene [MeSH:C0017260] detect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] analyze entire dystrophin [MeSH:C0079259] cdna endpoint deletion [MeSH:C0017260] characterize genomic probe p2 dxs2 wapenaar et al gmgx1 dxs2 present paper finding present patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] allow correlation [MeSH:C0010100] phenotypic [MeSH:C1837514] severity genotype thirty-eight independent patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] old classify dmd [MeSH:C1437024] bmd intermediate phenotype [MeSH:C0031437] deletion [MeSH:C0017260] exon [MeSH:C0015295] sequence intron exon [MeSH:C0015295] boundary bmd patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] intermediate gene deletion [MeSH:C0017260] [MeSH:C0017260] predict leave reading frame [MeSH:C0080089] [MeSH:C0080089] intact dmd [MeSH:C1437024] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] intermediate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] bmd gene deletion [MeSH:C0017260] [MeSH:C0017260] predict disrupt reading frame [MeSH:C0080089] exception frameshift deletion [MeSH:C0017260] gene [MeSH:C0017260] result severe phenotype [MeSH:C0031437] in-frame deletion [MeSH:C0017260] agreement recent finding baumbach et al koenig et al contrast finding malhotra et al end gene,neurological
nephritis pathway lung cancer [MeSH:C0242379],design [MeSH:C0013171] prospective investigation statin heart disease [MeSH:C0018799] participant [MeSH:C1708335] cardiac patient nephrotic syndrome [MeSH:C0027726] alt result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] renal stone correlation [MeSH:C0010100] cost-effectiveness [MeSH:C1511536] implication,hepatorenal
ocular [MeSH:C0042789] manifestation juvenile rheumatoid arthritis,follow case juvenile rheumatoid arthritis [MeSH:C3495559] closely year thirty-six patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop iridocyclitis iridocyclitis [MeSH:C0022073] see frequently young [MeSH:C0340037] female [MeSH:C0086287] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] year monoarticular pauciatricular form arthritis patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop uveitis [MeSH:C0042164] [MeSH:C0042164] [MeSH:C0042164] year age patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] noncontributory ocular history [MeSH:C0019664] entry active uveitis [MeSH:C0042164] [MeSH:C0042164] [MeSH:C0042164] entry approach effective detect uveitis [MeSH:C0042164] [MeSH:C0042164] [MeSH:C0042164] new case exacerbation uveitis [MeSH:C0042164] [MeSH:C0042164] [MeSH:C0042164] established case forty-four percent patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] uveitis [MeSH:C0042164] [MeSH:C0042164] [MeSH:C0042164] identifiable sign symptom red eye ocular pain decrease visual acuity [MeSH:C0042812] photophobia [MeSH:C0085636] order decrease frequency [MeSH:C0376249] early detection [MeSH:C5392129] prompt case uveitis [MeSH:C0042164] [MeSH:C0042164] [MeSH:C0042164] [MeSH:C0042164] respond month intensive topical corticosteroid [MeSH:C0001617] mydriatic [MeSH:C0026964] despite dramatic decrease incidence [MeSH:C0021149] blind complication uveitis [MeSH:C0042164] [MeSH:C0042164] [MeSH:C0042164] cite early study cataract band keratopathy [MeSH:C0155120] occur respectively chloroquine [MeSH:C0008269] hydroxychloroquine [MeSH:C0020336] [MeSH:C0008269] case find case chorioretinopathy [MeSH:C0730328] attributable drug systemically administer corticosteroid [MeSH:C0001617] case number posterior subcapsular cataract find typical keratoconjunctivitis sicca [MeSH:C0022575] develop uveitis [MeSH:C0042164] [MeSH:C0042164] [MeSH:C0042164] case association uveitis [MeSH:C0042164] [MeSH:C0042164] [MeSH:C0042164] jra note previously surgical cataract band keratopathy [MeSH:C0155120] glaucoma achieve uniformly discourage result,neurological
course alteration qtc interval hypaque,sequential measurement [MeSH:C0030198] qt interval leave ventricular angiography [MeSH:C0002978] second minute injection hypaque subject [MeSH:C0080105] patient [MeSH:C0030705] find normal leave ventricle coronary artery qtc prolongation [MeSH:C0023677] occur second minute association [MeSH:C0004083] marked hypotension [MeSH:C0020649] elevation cardiac output [MeSH:C0007165],cardiovascular
endothelium pattern [MeSH:C0014257] breast cancer [MeSH:C0006142] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] thromboembolism pathway method [MeSH:C0040038] prospective trial elderly patient measuring pacemaker [MeSH:C3494452] cardiac result improve disease management [MeSH:C0039798] practice guideline,neurological|cardiovascular
ocular motility [MeSH:C0028850] change subtenon carboplatin chemotherapy [MeSH:C0013216] retinoblastoma,focal subtenon carboplatin injection [MeSH:C1828121] recently presumably toxicity [MeSH:C0040539]-free [MeSH:C0016693] adjunct systemic chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] intraocular [MeSH:C0042789] retinoblastoma [MeSH:C0035335] report experience abnormal [MeSH:C0853087] [MeSH:C0853087] ocular [MeSH:C0042789] motility [MeSH:C0028850] [MeSH:C0028850] patient [MeSH:C0030705] treat subtenon carboplatin chemotherapy [MeSH:C0013216] [MeSH:C0013216] method note abnormal [MeSH:C0853087] [MeSH:C0853087] ocular [MeSH:C0042789] motility [MeSH:C0028850] [MeSH:C0028850] consecutive patient [MeSH:C0030705] retinoblastoma receive subtenon carboplatin ocular [MeSH:C0042789] manipulation [MeSH:C0086586] general anesthesia [MeSH:C0002915] assess eye [MeSH:C0015392] [MeSH:C0015392] force duction testing compare ocular [MeSH:C0042789] motility [MeSH:C0028850] [MeSH:C0028850] tumor ocular [MeSH:C0042789] motility [MeSH:C0028850] [MeSH:C0028850] diagnosis [MeSH:C0011900] eye [MeSH:C0015392] [MeSH:C0015392] subsequently enucleate failure n examine histologically result limitation ocular [MeSH:C0042789] motility [MeSH:C0028850] [MeSH:C0028850] detect eye [MeSH:C0015392] [MeSH:C0015392] patient [MeSH:C0030705] treat intraocular [MeSH:C0042789] retinoblastoma [MeSH:C0035335] injection [MeSH:C1828121] subtenon carboplatin multimodality therapy histopathological examination reveal lipophage periorbital fat surround optic nerve eye [MeSH:C0029130] [MeSH:C0015392] [MeSH:C0015392] indicative phagocytosis [MeSH:C0031308] previously exist fat cell [MeSH:C0206131] suggest prior fat necrosis enucleation [MeSH:C0015400] technically difficult hazardous [MeSH:C0018626] globe rupture [MeSH:C3203359] extensive orbital soft tissue adhesion [MeSH:C0001511] conclusion subtenon carboplatin chemotherapy [MeSH:C0013216] [MeSH:C0013216] associate fibrosis [MeSH:C0016059] orbital soft tissue lead mechanical restriction eye [MeSH:C0015392] [MeSH:C0015392] movement make subsequent enucleation [MeSH:C0015400] difficult subtenon carboplatin free [MeSH:C0016693] toxicity [MeSH:C0040539] use well restricted specific indication,oncological
carbamazepine-induced cardiac dysfunction characterization distinct syndrome [MeSH:C0039082],sinus bradycardia [MeSH:C0428977] atrioventricular block [MeSH:C0004245] induce carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] prompt extensive literature review [MeSH:C0282441] previously report case case distinct form carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949]-associated cardiac dysfunction emerge develop sinus tachycardia setting [MeSH:C0039239] massive carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] overdose second consist exclusively elderly [MeSH:C0001792] woman [MeSH:C0043210] develop potentially life-threatening [MeSH:C4303743] bradyarrhythmia [MeSH:C0428977] atrioventricular conduction delay [MeSH:C0004245] associate therapeutic [MeSH:C0087111] modestly elevated [MeSH:C0020443] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] serum level carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] widely neurologic [MeSH:C0026345] psychiatric condition recognition syndrome important implication use drug elderly [MeSH:C0001792] [MeSH:C0001792] patient,neurological|cardiovascular
case-control [MeSH:C0007328] regular analgesic nonsteroidal anti-inflammatory use end-stage renal disease [MeSH:C0003211],study [MeSH:C0085973] association [MeSH:C0004083] [MeSH:C0004083] long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] use aspirin [MeSH:C0004057] [MeSH:C0004057] analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] nonsteroidal anti-inflammatory drug nsaid [MeSH:C0003211] end-stage renal disease [MeSH:C0012634] [MeSH:C0012634] [MeSH:C0012634] esrd [MeSH:C0022661] give conflicting result order examine association [MeSH:C0004083] [MeSH:C0004083] case-control [MeSH:C0007328] incident case esrd [MeSH:C0022661] [MeSH:C0022661] carry method [MeSH:C0025663] case patient [MeSH:C0030705] [MeSH:C0030705] enter local dialysis program esrd [MeSH:C0022661] area june november classify accord underlie disease [MeSH:C0012634] [MeSH:C0012634] [MeSH:C0012634] presumably lead esrd [MeSH:C0022661] control patient [MeSH:C0030705] [MeSH:C0030705] admit hospital case arise match age sex [MeSH:C1522384] odd ratio calculate conditional logistic model include potential [MeSH:C0001272] confounding factor population underlie disease [MeSH:C0012634] [MeSH:C0012634] [MeSH:C0012634] result eighty-three case control [MeSH:C0007328] include long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] use analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] associate overall odds ratio [MeSH:C0028873] ci specific group [MeSH:C0018257] drug risk [MeSH:C0035647] aspirin [MeSH:C0004057] [MeSH:C0004057] pyrazolone paracetamol nonaspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] nsaid risk esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] associate aspirin [MeSH:C0004057] [MeSH:C0004057] related cumulated dose duration use particularly high subset patient [MeSH:C0030705] [MeSH:C0030705] vascular nephropathy underlie disease [MeSH:C0012634] [MeSH:C0012634] [MeSH:C0012634] indicate long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] use nonaspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] drug nsaid [MeSH:C0003211] associate increase risk esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] chronic use aspirin [MeSH:C0004057] [MeSH:C0004057] increase risk esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661],hepatorenal
dysguesia go rare common side-effect amlodipine [MeSH:C0051696],rare side-effect amlodipine [MeSH:C0051696] [MeSH:C0051696] dysguesia review [MeSH:C0282443] literature [MeSH:C0023866] [MeSH:C0023866] produce case report [MeSH:C0684224] case female essential hypertension [MeSH:C0020538] drug amlodipine [MeSH:C0051696] [MeSH:C0051696] [MeSH:C0051696] develop loss taste sensation [MeSH:C2364111] condition moderately improve stoppage drug day conclude amlodipine [MeSH:C0051696] [MeSH:C0051696] cause dysguesia describe presentation review [MeSH:C0282443] [MeSH:C0282443] relevant literature [MeSH:C0023866] [MeSH:C0023866] amlodipine [MeSH:C0051696] [MeSH:C0051696] dysguesia,cardiovascular
dvt epilepsy [MeSH:C0014544] vascular insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome coronary pathway method prospective trial elderly patient measuring chf endothelial result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
lymphoma pericardium exploring neural pathway [MeSH:C0027792],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] elderly patient dysarthria tachycardia result improve outcome [MeSH:C0206277] cortical [MeSH:C0222661] correlation relevance [MeSH:C2826293],neurological|cardiovascular
lymphoma lymphoma [MeSH:C0024299] organ interplay,hypothesis statin improve cancer outcome [MeSH:C0206277] hepatorenal syndrome pathway method observational trial [MeSH:C0302523] elderly patient measure azotemia [MeSH:C0242528] chronic lymphocytic leukemia [MeSH:C0023434] result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],hepatorenal|oncological
trimethoprim-induced immune hemolytic anemia pediatric [MeSH:C0237433] oncology present acute hemolytic transfusion reaction [MeSH:C1549006],-year-old male [MeSH:C0086582] acute leukemia [MeSH:C0023465] present post-chemotherapy [MeSH:C0013216] [MeSH:C0013216] anemia [MeSH:C0002871] [MeSH:C0002871] red cell transfusion [MeSH:C0274435] [MeSH:C0086252] develop hemoglobinuria transfusion [MeSH:C0274435] reaction workup negative [MeSH:C3539878] drug-induced immune hemolytic anemia [MeSH:C0002871] [MeSH:C0002871] suspect positive direct antiglobulin test [MeSH:C0009961] negative [MeSH:C3539878] eluate microspherocyte [MeSH:C0037888] smear [MeSH:C3541459] pre- post-transfusion [MeSH:C0274435] drug study indirect antiglobulin test [MeSH:C0009961] strongly positive trimethoprim trimethoprim-sulfamethoxazole [MeSH:C0038689] [MeSH:C0041044] negative [MeSH:C3539878] sulfamethoxazole [MeSH:C0038689] recover discontinue drug recurrence [MeSH:C2825055] year cause anemia [MeSH:C0002871] [MeSH:C0002871] consider patient [MeSH:C0030705] worse-than-expected anemia [MeSH:C0002871] [MeSH:C0002871] chemotherapy [MeSH:C0013216] furthermore hemolysis [MeSH:C0019054] transfusion [MeSH:C0274435] transfusion [MeSH:C0274435] reaction,oncological
cocaine [MeSH:C0009170] cause memory learning impairment rat [MeSH:C0034721] involvement nuclear factor kappa [MeSH:C0079904] b oxidative stress prevention [MeSH:C0242606] topiramate [MeSH:C0076829],different mechanism [MeSH:C1524059] [MeSH:C1524059] suggest cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] toxicity [MeSH:C0040539] include increase oxidative [MeSH:C0242606] stress [MeSH:C0242606] [MeSH:C0242606] [MeSH:C0242606] association oxidative [MeSH:C0242606] status brain cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] induced-behaviour poorly understand nuclear factor kappa [MeSH:C0079904] b nfkappab [MeSH:C0079904] [MeSH:C0079904] [MeSH:C0079904] sensor oxidative [MeSH:C0242606] stress [MeSH:C0242606] [MeSH:C0242606] [MeSH:C0242606] participate memory formation involve drug toxicity [MeSH:C0013221] [MeSH:C0040539] addiction [MeSH:C4505067] mechanism [MeSH:C1524059] [MeSH:C1524059] nfkappab [MeSH:C0079904] [MeSH:C0079904] [MeSH:C0079904] activity oxidative [MeSH:C0242606] stress [MeSH:C0242606] [MeSH:C0242606] [MeSH:C0242606] neuronal nitric oxide synthase [MeSH:C0132555] nnos activity spatial learning memory effect topiramate [MeSH:C0076829] previously propose therapy [MeSH:C0039798] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] addiction [MeSH:C4505067] evaluate experimental model [MeSH:C0086272] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] administrat [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721] nfkappab [MeSH:C0079904] [MeSH:C0079904] [MeSH:C0079904] activity decrease frontal cortex [MeSH:C0016733] [MeSH:C0016733] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] treated rat [MeSH:C0034721] [MeSH:C0034721] gsh concentrat [MeSH:C0034721] [MeSH:C0034721]ion glutathione peroxidase [MeSH:C0017822] [MeSH:C0017822] activity hippocampus [MeSH:C3887642] [MeSH:C3887642] nnos activity hippocampus [MeSH:C3887642] [MeSH:C3887642] increase memory retrieval experience acquire prior cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] administrat [MeSH:C0034721] [MeSH:C0034721]ion impaired [MeSH:C0020580] negatively correlate nfkappab [MeSH:C0079904] [MeSH:C0079904] [MeSH:C0079904] activity frontal cortex [MeSH:C0016733] [MeSH:C0016733] contrast learning [MeSH:C0023185] new task [MeSH:C0162458] enhance correlate increase nnos activity decrease glutathione peroxidase [MeSH:C0017822] [MeSH:C0017822] result provide evidence [MeSH:C5575834] possible mechanistic role oxidative [MeSH:C0242606] nitrosative stress nfkappab [MeSH:C0079904] [MeSH:C0079904] [MeSH:C0079904] alterat [MeSH:C0034721] [MeSH:C0034721]ion induce cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] topiramate [MeSH:C0076829] prevent [MeSH:C0000918] alterat [MeSH:C0034721] [MeSH:C0034721]ion observe show novel neuroprotective property,neurological
aspirin [MeSH:C0004057] heart failure [MeSH:C0035078] brain [MeSH:C0006104] insight,investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia aphasia [MeSH:C0497327] method elderly patient undergo retrospective palsy gamma glutamyl transferase assessment result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,neurological|hepatorenal
frequency [MeSH:C0376249] transient [MeSH:C0040704] ipsilateral vocal cord [MeSH:C0042930] paralysis [MeSH:C0522224] patient [MeSH:C0030705] undergo carotid endarterectomy [MeSH:C0014099] local anesthesia [MeSH:C0002921],especially improvement [MeSH:C2936612] neurologic monitoring [MeSH:C3658203] carotid endarterectomy [MeSH:C0014099] [MeSH:C0014099] [MeSH:C0014099] local anesthesia [MeSH:C0002921] [MeSH:C0002921] [MeSH:C0002921] [MeSH:C0002921] technique choice center temporary [MeSH:C0011414] [MeSH:C0011414] ipsilateral vocal nerve palsy [MeSH:C0522224] local anesthetic [MeSH:C0002934] describe complication [MeSH:C1171258] important situation pre-existing contralateral paralysis [MeSH:C0522224] [MeSH:C0522224] examine effect [MeSH:C4277511] local anesthesia [MeSH:C0002921] [MeSH:C0002921] [MeSH:C0002921] [MeSH:C0002921] vocal cord [MeSH:C0042930] [MeSH:C0042930] function [MeSH:C0859897] [MeSH:C0859897] [MeSH:C0859897] well understand possible consequence method prospective [MeSH:C0589154] include patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo carotid endarterectomy [MeSH:C0014099] [MeSH:C0014099] [MeSH:C0014099] local anesthesia [MeSH:C0002921] [MeSH:C0002921] [MeSH:C0002921] [MeSH:C0002921] vocal cord [MeSH:C0042930] [MeSH:C0042930] function [MeSH:C0859897] [MeSH:C0859897] [MeSH:C0859897] evaluate surgery [MeSH:C0038895] [MeSH:C0038895] postoperative [MeSH:C0032786] flexible laryngoscopy anesthesia [MeSH:C0023072] perform inject ml mixture long-acting ropivacaine [MeSH:C0073571] short-acting prilocaine anesthetic result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] normal vocal cord [MeSH:C0042930] [MeSH:C0042930] function [MeSH:C0859897] [MeSH:C0859897] [MeSH:C0859897] preoperative [MeSH:C0033061] [MeSH:C0033061]ly patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] find intraoperative [MeSH:C0021889] [MeSH:C0021889] ipsilateral vocal cord [MeSH:C0042930] [MeSH:C0042930] paralysis [MeSH:C0522224] [MeSH:C0522224] [MeSH:C0042928] resolve case hour difference operate volume frequency [MeSH:C0376249] [MeSH:C0017270] anesthetic administration [MeSH:C0001554] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] temporary [MeSH:C0011414] [MeSH:C0011414] vocal cord [MeSH:C0042930] [MeSH:C0042930] paralysis [MeSH:C0522224] [MeSH:C0522224] [MeSH:C0042928] compare local anesthesia [MeSH:C0002921] [MeSH:C0002921] [MeSH:C0002921] [MeSH:C0002921] lead temporary [MeSH:C0011414] [MeSH:C0011414] ipsilateral vocal cord [MeSH:C0042930] [MeSH:C0042930] paralysis [MeSH:C0522224] [MeSH:C0522224] [MeSH:C0042928] half patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pre-existing paralysis [MeSH:C0522224] [MeSH:C0522224] relevant frequency [MeSH:C0376249] preoperative [MeSH:C0033061] [MeSH:C0033061] vocal cord [MeSH:C0042930] [MeSH:C0042930] function [MeSH:C0859897] [MeSH:C0859897] [MeSH:C0859897] carotid endarterectomy [MeSH:C0014099] [MeSH:C0014099] [MeSH:C0014099] local anesthesia [MeSH:C0002921] [MeSH:C0002921] [MeSH:C0002921] [MeSH:C0002921] recommend avoid intraoperative [MeSH:C0021889] [MeSH:C0021889] bilateral paralysis [MeSH:C0522224] [MeSH:C0522224] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] preoperative [MeSH:C0033061] [MeSH:C0033061] contralateral vocal cord [MeSH:C0042930] [MeSH:C0042930] paralysis [MeSH:C0522224] [MeSH:C0522224] [MeSH:C0042928] surgery [MeSH:C0038895] [MeSH:C0038895] general anesthesia [MeSH:C0002915] consider,neurological
myocardial prostate cancer vascular [MeSH:C0221214] insight,retrospective [MeSH:C0035363] examine beta-blocker stroke cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include smooth muscle atrial flutter hypotension method participant [MeSH:C1708335] include result well quality life measure implication need investigation [MeSH:C0035173] [MeSH:C0035173],cardiovascular
caffeine-induced cardiac arrhythmia [MeSH:C0003811] unrecognised danger healthfood product,describe -year-old woman [MeSH:C0043210] pre-existing mitral valve prolapse [MeSH:C0026267] develop intractable [MeSH:C0030200] ventricular fibrillation [MeSH:C0042510] consume natural energy guarana health drink contain high concentration [MeSH:C0311432] caffeine [MeSH:C0006644] case highlight need adequate labelling regulation product [MeSH:C0033263],cardiovascular
integrate characterization serological [MeSH:C0036743] pathological functional event doxorubicin-induced cardiotoxicity,efficacious cancer treatment [MeSH:C0949634] cause cardiac [MeSH:C0018810] morbidity biomarker [MeSH:C0005516] [MeSH:C0017393] [MeSH:C0005516] functional index early damage [MeSH:C0012860] allow monitoring [MeSH:C0005517] intervention lack utilize rat [MeSH:C0034721] [MeSH:C0034721] model [MeSH:C0011381] progressive [MeSH:C1449744] [MeSH:C1449744] [MeSH:C1449744] doxorubicin dox [MeSH:C0013089] -induced cardiomyopathy [MeSH:C0878544] apply multiple approach include cardiac [MeSH:C0018810] magnetic resonance image mri [MeSH:C0024485] provide comprehensive [MeSH:C0009585] characterization date timecourse serological [MeSH:C0036743] [MeSH:C0036743] pathological functional event underlie toxicity [MeSH:C0040539] hannover wistar rat [MeSH:C0034721] [MeSH:C0034721] dose mg kg dox weekly week follow week off-dosing recovery period electron microscopy myocardium [MeSH:C0027061] reveal subcellular [MeSH:C0038528] degenerat [MeSH:C0034721] [MeSH:C0034721]ion marked mitochondrial change [MeSH:C0949610] single dose histopathological reveal progressive [MeSH:C1449744] [MeSH:C1449744] [MeSH:C1449744] cardiomyocyte degenerat [MeSH:C0034721] [MeSH:C0034721]ion hypertrophy cytomegaly extensive vacuolation [MeSH:C0042219] dose extensive replacement fibrosis quantify sirius red staining develop off-dosing period functional index assess cardiac [MeSH:C0018810] mri include leave [MeSH:C0242724] ventricular ejection fraction [MeSH:C0042508] lvef cardiac [MeSH:C0018810] output [MeSH:C0007165] e rat [MeSH:C0034721] [MeSH:C0034721]io decline progressive [MeSH:C1449744] [MeSH:C1449744] [MeSH:C1449744]ly reach statistical significance [MeSH:C2826293] dose culminate lv dysfunction [MeSH:C0242698] [MeSH:C0242698] week increase peak myocardial contrast enhancement serological [MeSH:C0036743] [MeSH:C0036743] cardiac [MeSH:C0018810] troponin [MeSH:C0041199] ctni emerge dose importantly precede lvef decline troponin [MeSH:C0041199] level [MeSH:C0018759] positively correlate delay [MeSH:C5544400] peak gadolinium contrast enhancement histopathological grading diastolic dysfunction [MeSH:C1273070] summary subcellular [MeSH:C0038528] cardiomyocyte degenerat [MeSH:C0034721] [MeSH:C0034721]ion early marker [MeSH:C0017393] follow progressive [MeSH:C1449744] [MeSH:C1449744] [MeSH:C1449744] functional decline histopathological manifestation [MeSH:C0029166] myocardial contrast enhancement elevation ctni occur later index predate [MeSH:C0699540] lv dysfunction [MeSH:C0242698] [MeSH:C0242698] warrant predictive [MeSH:C1514243] biomarker [MeSH:C0005516] [MeSH:C0017393] [MeSH:C0005516],cardiovascular|oncological
end-stage renal disease [MeSH:C0022661] esrd orthotopic liver transplantation [MeSH:C0023911] oltx calcineurin-based immunotherapy risk development [MeSH:C0020119],calcineurin inhibitor [MeSH:C1562036] cyclosporine tacrolimus [MeSH:C0085149] know nephrotoxic use orthotopic liver transplantation [MeSH:C0023911] oltx dramatically improve success [MeSH:C0700132] rate recently increase patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present oltx end-stage renal disease [MeSH:C0022661] esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] retrospective examine incidence [MeSH:C0021149] [MeSH:C0021149] esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] chronic renal failure [MeSH:C0022661] crf [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] oltx patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive oltx june december survive month postoperative [MeSH:C0032786] [MeSH:C0032786]ly study n prospectively collect database [MeSH:C0993637] source information [MeSH:C5544371] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] divide group [MeSH:C0018257] control crf [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] n crf [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] sustained serum creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] mg dl n esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] n group [MeSH:C0018257] compare preoperative [MeSH:C0033061] [MeSH:C0033061] [MeSH:C0033061] [MeSH:C0033061] laboratory [MeSH:C0022877] variable diagnosis [MeSH:C0011900] postoperative [MeSH:C0032786] [MeSH:C0032786] variable survival [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] type esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] therapy survival [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] onset esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] result year oltx incidence [MeSH:C0021149] [MeSH:C0021149] severe renal dysfunction [MeSH:C0031847] crf [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] compare patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] crf [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] high [MeSH:C0039866] preoperative [MeSH:C0033061] [MeSH:C0033061] [MeSH:C0033061] [MeSH:C0033061] serum creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] level great percentage patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hepatorenal syndrome [MeSH:C0019212] high [MeSH:C0039866] percentage requirement dialysis [MeSH:C0011945] month postoperative [MeSH:C0032786] [MeSH:C0032786]ly high [MeSH:C0039866] -year serum creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] multivariate stepwise logistic regression [MeSH:C0206031] preoperative [MeSH:C0033061] [MeSH:C0033061] [MeSH:C0033061] [MeSH:C0033061] postoperative [MeSH:C0032786] [MeSH:C0032786] variable identify increase serum creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] compare average month week postoperative [MeSH:C0032786] [MeSH:C0032786]ly independent risk factor [MeSH:C0035648] development crf [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] odd ratio respectively overall [MeSH:C0282416] survival [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] oltx significantly different group [MeSH:C0018257] survival [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] compare patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] -year survival [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] onset esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive hemodialysis [MeSH:C0019004] [MeSH:C0011945] versus patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] subsequently receive kidney transplant [MeSH:C0022671] conclusion patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] year post-oltx crf [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] high [MeSH:C0039866] rate development esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] decrease survival [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] particularly patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat dialysis [MeSH:C0011945] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] high [MeSH:C0039866] preoperative [MeSH:C0033061] [MeSH:C0033061] [MeSH:C0033061] [MeSH:C0033061] -year serum creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] likely hepatorenal syndrome [MeSH:C0019212] increase serum creatinine [MeSH:C0010294] [MeSH:C0010294] [MeSH:C0010294] time postoperative [MeSH:C0032786] [MeSH:C0032786]ly predictive development [MeSH:C0020119] crf [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] [MeSH:C0056373] esrd [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] [MeSH:C0022661] new strategy long-term [MeSH:C0023977] immunosuppression [MeSH:C0021079] need decrease complication [MeSH:C1171258],hepatorenal
hypertension [MeSH:C0020538] ectopic beat [MeSH:C0033036] cardiac connection,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome heart rate pathway method cross-sectional trial [MeSH:C0010362] cardiac patient measure deep vein thrombosis [MeSH:C0149871] stroke [MeSH:C0038454] result enhance therapeutic response practice guideline,cardiovascular
adverse effect [MeSH:C0001688] atypical antipsychotic [MeSH:C0040615] collaborative working trial [MeSH:C0043215] evaluation [MeSH:C0013175],adverse effect [MeSH:C4277511] [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] antipsychotic [MeSH:C0040615] [MeSH:C0040615] [MeSH:C0040615] lead noncompliance clinician [MeSH:C0028654] [MeSH:C0028654] address patient [MeSH:C0030705] concern adverse effect [MeSH:C4277511] [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] attempt choose medication [MeSH:C0033045] improve patient [MeSH:C0030705] quality life overall [MeSH:C0282416] health effect [MeSH:C4277511] [MeSH:C0018766] profile atypical [MeSH:C0268465] antipsychotic [MeSH:C0040615] [MeSH:C0040615] [MeSH:C0040615] advantageous conventional neuroleptic conventional agent [MeSH:C0040615] associate [MeSH:C0004083] unwanted central nervous system effect [MeSH:C4277511] [MeSH:C3714787] include extrapyramidal symptom ep tardive dyskinesia sedation [MeSH:C0079159] [MeSH:C0079159] possible impairment [MeSH:C1384666] cognitive measure cardiac effect [MeSH:C4277511] orthostatic [MeSH:C4277526] hypotension [MeSH:C0020649] hepatic change anticholinergic effect [MeSH:C4277511] [MeSH:C0242896] [MeSH:C0242896] sexual dysfunction [MeSH:C0033953] [MeSH:C0033953] weight gain [MeSH:C0043094] new atypical [MeSH:C0268465] agent low risk ep associate [MeSH:C0004083] vary degree sedation [MeSH:C0079159] [MeSH:C0079159] cardiovascular effect [MeSH:C4277511] [MeSH:C0596270] anticholinergic effect [MeSH:C4277511] [MeSH:C0242896] [MeSH:C0242896] weight gain [MeSH:C0043094] sexual dysfunction [MeSH:C0033953] [MeSH:C0033953] hepatic effect [MeSH:C4277511] lowered seizure [MeSH:C0036572] threshold [MeSH:C0162703] primarily clozapine [MeSH:C0009079] [MeSH:C0009079] agranulocytosis [MeSH:C0001824] clozapine [MeSH:C0009079] [MeSH:C0009079] incidence [MeSH:C0021149] severity specific adverse effect [MeSH:C4277511] [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] differ atypical [MeSH:C0268465] clinician [MeSH:C0028654] [MeSH:C0028654] carefully consider effect [MeSH:C4277511] likely lead individual dissatisfaction [MeSH:C2732632] noncompliance choose antipsychotic [MeSH:C0040615] [MeSH:C0040615] [MeSH:C0040615] particular,neurological|cardiovascular|hepatorenal
pacemaker atrial fibrillation vascular insight,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation statin heart disease [MeSH:C0018799] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] transient ischemic attack embolism result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] thrombosis [MeSH:C0040053] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,cardiovascular
paclitaxel [MeSH:C0144576] cisplatin [MeSH:C0008838] gemcitabine [MeSH:C0045093] combination [MeSH:C0034865] chemotherapy [MeSH:C0013216] multidisciplinary therapeutic approach metastatic nonsmall cell lung carcinoma [MeSH:C0152013],cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838]-based chemotherapy [MeSH:C0039798] combination [MeSH:C0034865] [MeSH:C0034865] improve quality [MeSH:C0034379] life survival [MeSH:C0038952] advanced nonsmall cell [MeSH:C0007131] lung carcinoma [MeSH:C0152013] nsclc emergence [MeSH:C2745965] new active drug [MeSH:C0033613] translate effective regimen disease [MeSH:C1880476] method determine feasibility response rate [MeSH:C0034746] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] gemcitabine [MeSH:C0045093] [MeSH:C0045093] [MeSH:C0045093] [MeSH:C0045093] combination [MeSH:C0034865] [MeSH:C0034865] treat metastatic nsclc thirty-five consecutive chemotherapy [MeSH:C0039798]-naive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stage iv nsclc eastern cooperative oncology performance status treat combination [MeSH:C0034865] [MeSH:C0034865] paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] mg give intravenously hour cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] mg give intravenously hour gemcitabine [MeSH:C0045093] [MeSH:C0045093] [MeSH:C0045093] [MeSH:C0045093] mg give intravenously minute day week respond patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] schedule [MeSH:C0030703] receive consolidation radiotherapy [MeSH:C0039798] [MeSH:C3179017] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive preplanned second-line chemotherapy [MeSH:C0039798] disease progression [MeSH:C0242656] [MeSH:C0242656] response toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] rate report refer chemotherapy [MeSH:C0039798] regimen [MeSH:C0013216] give result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] examine toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] examinable response response [MeSH:C0034746] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] confidence interval [MeSH:C0009667] ci include complete response accord intention-to-treat overall response rate [MeSH:C0034746] ci course therapy [MeSH:C0039798] median dose intensity mg paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] mg cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] mg gemcitabine [MeSH:C0045093] [MeSH:C0045093] [MeSH:C0045093] [MeSH:C0045093] world health organization [MeSH:C0018732] grade neutropenia thrombocytopenia [MeSH:C0040034] occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] respectively treatment-related death nonhematologic toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] mild median follow-up [MeSH:C3899107] month median progression [MeSH:C0242656] [MeSH:C0242656] free survival rate month median survival [MeSH:C0038952] month conclusion combination [MeSH:C0034865] [MeSH:C0034865] paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] gemcitabine [MeSH:C0045093] [MeSH:C0045093] [MeSH:C0045093] [MeSH:C0045093] tolerate show high activity [MeSH:C0020115] metastatic nsclc merit comparison cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838]-based regimen,oncological
deletion dna sequence retinoblastoma [MeSH:C0162773] mesenchymal tumor organization sequence encode protein [MeSH:C0033684],retinoblastoma childhood tumor [MeSH:C0278510] arise mutant allele [MeSH:C0002085] [MeSH:C0002085] acquire somatic germinal mutation mutant allele [MeSH:C0002085] [MeSH:C0002085] carry germ line mutation [MeSH:C0206530] create allele [MeSH:C0002085] act inactivate [MeSH:C0043297] copy recessive oncogene [MeSH:C0017337] [MeSH:C0079427] located band q1 chromosome term rb1 [MeSH:C4308074] [MeSH:C4308074] locus report [MeSH:C0684224] isolation [MeSH:C0220862] cdna [MeSH:C0006556] fragment recognize chromosomal sequence [MeSH:C0162327] [MeSH:C0162327] possess attribute retinoblastoma gene [MeSH:C0017337] [MeSH:C0079424] associate rb1 [MeSH:C4308074] [MeSH:C4308074] locus report [MeSH:C0684224] segment additionally target [MeSH:C0039309] somatic mutation mesenchymal tumor [MeSH:C0334492] patient [MeSH:C0030705] apparent predisposition retinoblastoma [MeSH:C0035335] previous evidence retinoblastoma tumor [MeSH:C0035335] provide additional evidence clone [MeSH:C0009013] sequence [MeSH:C0162327] [MeSH:C0162327] representative gene [MeSH:C0017337] frequent target [MeSH:C0039309] inactivation [MeSH:C0043297] tumorigene [MeSH:C0017337]sis sequence [MeSH:C0162327] [MeSH:C0162327] cdna [MeSH:C0006556] provide little insight normal functional role,oncological
endocardium marker alzheimer disease [MeSH:C0002395],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] pacemaker [MeSH:C3494452] mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess endocardium heart attack [MeSH:C0027051] result enhance therapeutic response [MeSH:C0087111] implication optimization [MeSH:C0376695],cardiovascular
neurodegenerative pattern peripheral artery disease [MeSH:C0524851] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] aspirin improve cancer outcome memory loss pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure pituitary adenoma [MeSH:C0032000] glutamate [MeSH:C0220839] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cost-effectiveness [MeSH:C1511536] implication,neurological
detection [MeSH:C5392129] heterozygous [MeSH:C0019425] mutation [MeSH:C0026882] brca1 [MeSH:C0259275] high density oligonucleotide array two-colour fluorescence,ability scan [MeSH:C0085732] large gene [MeSH:C0017337] rapidly accurately possible heterozygous [MeSH:C0019425] [MeSH:C0019425] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] large number sample critical future medicine [MeSH:C0025118] design high-density array consist oligonucleotide [MeSH:C0028953] -nucleotides nt length screen wide range heterozygous [MeSH:C0019425] [MeSH:C0019425] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] -kilobase kb exon hereditary breast ovarian cancer [MeSH:C0677776] gene [MeSH:C0017337] brca1 reference test sample co-hybridize array difference hybridization pattern quantitate two-colour fourteen sample known mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] accurately diagnose [MeSH:C0011900] false positive [MeSH:C0015563] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify sample single nucleotide polymorphism [MeSH:C0752046] readily detect dna chip-based assay provide valuable new technology [MeSH:C0039421] high-throughput [MeSH:C0872187] cost-efficient detection [MeSH:C5392129] gene [MeSH:C0017337]tic alteration,neurological|oncological
effect [MeSH:C4277511] convulsant [MeSH:C0009950] protective activity [MeSH:C0020115] loreclezole [MeSH:C0083257] combination valproate [MeSH:C0080356] clonazepam [MeSH:C0009011] amygdala-kindled rat [MeSH:C0034721],loreclezole [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] mg kg exert protective action [MeSH:C0679688] amygdala-kindled rat [MeSH:C0034721] reduce seizure [MeSH:C0036572] afterdischarge durat [MeSH:C0034721]ion combination [MeSH:C0034865] loreclezole [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] mg kg valproate [MeSH:C0080356] [MeSH:C0080356] clonazepam [MeSH:C0009011] [MeSH:C0009011] carbamazepine [MeSH:C0006949] apply subprotective dose exhibit antiseizure [MeSH:C0036572] effect test combination [MeSH:C0034865] occur pharmacodynamic nature chemoconvulsant bicuculline [MeSH:C0005372] n-methyl-d-aspartic acid bay k- opener l-type calcium channel [MeSH:C0288263] reverse protective activity loreclezole [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] combination [MeSH:C0034865] valproate [MeSH:C0080356] [MeSH:C0080356] hand bicuculline [MeSH:C0005372] aminophylline bay [MeSH:C0002575] k- inhibit [MeSH:C0021463] anticonvulsive action [MeSH:C0003286] loreclezole [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] combine clonazepam [MeSH:C0009011] [MeSH:C0009011] result support hypothesis [MeSH:C3179072] protective activity loreclezole [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] [MeSH:C0083257] combination [MeSH:C0034865] antiepileptic [MeSH:C0003299] involve potentiation [MeSH:C1136141] gabaergic neurotransmission [MeSH:C0027793] blockade l-type calcium channel [MeSH:C0288263],neurological
hepatitis glomerular filtration rate [MeSH:C0017654] organ interplay,retrospective [MeSH:C0035363] examine aspirin cancer [MeSH:C0004057] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include renal stone renal hydronephrosis method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication therapeutic [MeSH:C0087111] innovation,hepatorenal
corticosteroid [MeSH:C0001617] stroke [MeSH:C0038454] brain [MeSH:C0006104] insight,heart disease [MeSH:C0018799] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve ast cerebral method conduct prospective evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examining jaundice [MeSH:C0022346] parameter result favorable safety [MeSH:C0036043] profile practice guideline,neurological|hepatorenal
heart failure [MeSH:C0018801] digitalise view,despite extensive experience role digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] define patient [MeSH:C0030705] [MeSH:C0030705] atrial fibrillation digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0004238] [MeSH:C0012265] beneficial ventricular rate [MeSH:C0949657] patient [MeSH:C0030705] [MeSH:C0030705] sinus rhythm heart failure situation clear digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] narrow therapeutic toxic ratio [MeSH:C0087111] concentration [MeSH:C0311432] affect number drug digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] undesirable effect increase peripheral resistance [MeSH:C1258192] myocardial demand cause arrhythmia [MeSH:C0003811] paucity well-designed trial trial available generally small limitation design variation [MeSH:C5544526] benefit convincing evidence [MeSH:C5575834] require show digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] improve symptom [MeSH:C3839861] exercise [MeSH:C0015259] capacity furthermore trial sufficient power evaluate mortality [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] pooled effect inotropic drug [MeSH:C0242913] show excess mortality [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] possibility digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] increase mortality [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] myocardial infarction [MeSH:C0027051] mi angiotensin-converting enzyme ace inhibitor [MeSH:C0003015] safe require blood monitoring [MeSH:C0005803] modify progression disease [MeSH:C0242656] relieve symptom [MeSH:C3839861] improve exercise [MeSH:C0015259] tolerance [MeSH:C0162521] reduce mortality [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] caution exercise [MeSH:C0015259] digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] large mortality [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] trial complete show benefit harm digoxin [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] [MeSH:C0012265] consider third-line therapy,neurological|cardiovascular
tachycardia ventricular tachycardia vascular [MeSH:C0042514] insight,cross-sectional examine [MeSH:C0010362] ace inhibitor [MeSH:C0003015] dementia [MeSH:C0497327] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include arrhythmia [MeSH:C0003811] heart rate ventricle method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication optimization [MeSH:C0376695],cardiovascular
development [MeSH:C0243107] clear cell adenocarcinoma [MeSH:C0206685] des-exposed offspring observation [MeSH:C0302523],case clear cell adenocarcinoma [MeSH:C0206685] vagina detect follow-up [MeSH:C3899107] young [MeSH:C0340037] woman [MeSH:C0043210] expose utero diethylstilbestrol [MeSH:C0012203] report aged [MeSH:C0001792] follow year carcinoma diagnose [MeSH:C0011900] second aged [MeSH:C0001792] see regular basis year month instance suspicion presence carcinoma arouse palpation [MeSH:C0030247] small nodule vaginal fornix hysterosalpingography perform patient [MeSH:C0030705] instance abnormal [MeSH:C0853087] x-ray film [MeSH:C0043303] reflect gross [MeSH:C0018252] appearance [MeSH:C0750731] uterine cavity find surgical speciman,oncological
myotonic dystrophy protein kinase [MeSH:C0216045] involve modulation [MeSH:C0085121] ca2 homeostasis [MeSH:C0019868] skeletal muscle [MeSH:C0242692] cell,myotonic dystrophy dm [MeSH:C0027126] prevalent muscular disorder [MeSH:C0752352] adult [MeSH:C0001675] cause ctg n-repeat expansion [MeSH:C0196940] gene encode protein kinase dm protein kinase dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] involve change cytoarchitecture [MeSH:C0003737] ion homeostasis [MeSH:C0019868] obtain clue normal biological [MeSH:C4553887] role dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] cellular ion homeostasis [MeSH:C0019868] [MeSH:C0019868] compare rest ca2 [MeSH:C5196589] amplitude shape [MeSH:C0162657] depolarization-induced ca2 [MeSH:C5196589] transient content atp-driven ion pump culture [MeSH:C0085193] skeletal muscle [MeSH:C0242692] cell wild-type dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] knockout [MeSH:C0206745] mouse vitro-differentiated dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] myotube [MeSH:C1704336] exhibit high rest ca2 [MeSH:C5196589] wild-type myotube [MeSH:C1704336] altered open probability voltage-dependent l-type ca2 [MeSH:C5196589] na channel mutant myotube [MeSH:C1704336] exhibit small slow ca2 [MeSH:C5196589] response trigger acetylcholine high [MeSH:C0001041] external k addition observe ca2 [MeSH:C5196589] transient partially influx extracellular ca2 [MeSH:C5196589] l-type ca2 [MeSH:C5196589] channel content activity na k atpase [MeSH:C1706373] sarcoplasmic reticulum ca2 [MeSH:C0036226] [MeSH:C5196589] -atpase [MeSH:C1706373] affect dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] absence [MeSH:C0270823] suggest dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] involve modulate initial event excitation-contraction coupling skeletal muscle [MeSH:C2717948] [MeSH:C0242692],neurological
risk [MeSH:C0035647] venous thromboembolism [MeSH:C1861172] woman [MeSH:C0043210] prescribe cyproterone acetate [MeSH:C0056855] combination ethinyl estradiol [MeSH:C0015011] nested cohort case-control,cyproterone acetate [MeSH:C0056855] combine ethinyl estradiol [MeSH:C0015011] cpa ee license uk woman [MeSH:C0043210] [MeSH:C0043210] acne hirsutism [MeSH:C0019572] [MeSH:C0019572] option polycystic ovary syndrome [MeSH:C0032460] pcos previous study [MeSH:C0085973] demonstrate increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] venous thromboembolism [MeSH:C1861172] vte associate cpa ee compare conventional combined oral contraceptive cocs [MeSH:C0009871] believe result study [MeSH:C0085973] affect residual [MeSH:C0543478] confound method general practice database [MeSH:C0086343] conduct cohort [MeSH:C1706962] case-control [MeSH:C0007328] nest population woman [MeSH:C0043210] [MeSH:C0043210] aged year acne hirsutism [MeSH:C0019572] pco estimate risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] vte associate cpa ee result age-adjusted incidence rate ratio cpa ee versus conventional cocs confidence interval [MeSH:C0009667] ci reference woman [MeSH:C0043210] [MeSH:C0043210] oral contraception [MeSH:C0700589] recent pregnancy [MeSH:C0032961] menopausal [MeSH:C0025320] symptom [MeSH:C3839861] case-control [MeSH:C0007328] give adjusted odd ratio adj ci cpa ee use compare adj ci use conventional cocs conclusion demonstrate increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] vte associate use cpa ee woman [MeSH:C0043210] [MeSH:C0043210] acne hirsutism [MeSH:C0019572] [MeSH:C0019572] pcos residual [MeSH:C0543478] confounding indication exclude,neurological
mechanism [MeSH:C1524059] fk -induced hypertension [MeSH:C0020538] rat [MeSH:C0034721],-tacrolimus fk powerful widely immunosuppressant [MeSH:C0021081] utility fk complicated substantial hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] nephrotoxicity clarify mechanism [MeSH:C1524059] fk -induced hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] study [MeSH:C0085973] chronic effect fk synthesis [MeSH:C3178925] [MeSH:C3178925] endothelin- et- expression [MeSH:C0017262] [MeSH:C0017262] mrna et- endothelin-converting enzyme- ece- endothelial nitric oxide synthase enos [MeSH:C0907532] activity [MeSH:C0020115] expression [MeSH:C0017262] [MeSH:C0017262] mrna enos [MeSH:C0907532] c-type natriuretic peptide cnp [MeSH:C0081880] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] blood vessel [MeSH:C0005847] addition effect specific endothelin type receptor antagonist [MeSH:C1134681] fr fk -induced hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] study [MeSH:C0085973] fk mg kg- d- give week elevated blood pressure [MeSH:C0005823] [MeSH:C0005823] mm hg increase synthesis [MeSH:C3178925] [MeSH:C3178925] et- level et- mrna mesenteric artery [MeSH:C0025465] respectively little observe expression [MeSH:C0017262] [MeSH:C0017262] ece- mrna cnp mrna fk [MeSH:C0035696] decrease enos [MeSH:C0907532] activity [MeSH:C0020115] level enos [MeSH:C0907532] mrna aorta [MeSH:C0003483] respectively administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion fr mg kg- d- prevent [MeSH:C0000918] fk -induced hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] result indicate fk increase blood pressure [MeSH:C0005823] increase et- production [MeSH:C0033268] decrease synthesis [MeSH:C3178925] [MeSH:C3178925] vasculature [MeSH:C0005839],neurological|cardiovascular|hepatorenal
rapid detection brca1 mutation protein truncation test,report mutation [MeSH:C0026882] [MeSH:C0026882] hereditary breast ovarian cancer [MeSH:C1140680] [MeSH:C0677776] gene brca1 [MeSH:C0259275] [MeSH:C0259275] truncate protein protein truncation test [MeSH:C1144558] ptt screen mutation [MeSH:C0026882] [MeSH:C0026882] exon [MeSH:C0015295] encode brca1 [MeSH:C0259275] [MeSH:C0259275] patient [MeSH:C0030705] breast ovarian cancer [MeSH:C1140680] family [MeSH:C0015576] find novel mutation [MeSH:C0026882] [MeSH:C0026882] single nucleotide insertion small deletion bp nonsense mutation [MeSH:C0026882] [MeSH:C0026882] identify unrelated family [MeSH:C0015576] furthermore able amplify remain code region [MeSH:C0079941] rt-pcr lymphocyte rna [MeSH:C0024264] combined ptt detect aberrantly splice product affect exon [MeSH:C0015295] brca1 [MeSH:C0259275] [MeSH:C0259275]-linked family [MeSH:C0015576] examine protein truncation test promise valuable technique [MeSH:C0449851] detect brca1 [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882],oncological
pilot assess [MeSH:C0473169] safety [MeSH:C0036043] dobutamine [MeSH:C0012963] stress echocardiography [MeSH:C0920208] emergency department [MeSH:C0562508] cocaine-associated chest pain,chest pain [MeSH:C0008031] setting cocaine [MeSH:C0009170] use [MeSH:C0009170] pose diagnostic dilemma dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] stress echocardiography [MeSH:C0920208] dse widely available sensitive [MeSH:C1017675] test evaluate [MeSH:C0013175] cardiac ischemia [MeSH:C0022116] theoretical concern administration dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] setting cocaine [MeSH:C0009170] use [MeSH:C0009170] conduct pilot assess safety [MeSH:C0036043] dse emergency department [MeSH:C0562508] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine [MeSH:C0009170]-associated chest pain [MeSH:C0008031] method prospective case series conduct intensive diagnostic unit ed urban tertiary-care teaching hospital patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] eligible dse cocaine [MeSH:C0009170] hour precede onset chest pain [MeSH:C0008031] normal ecg tropinin [MeSH:C1623258] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] exhibit sign continue cocaine [MeSH:C0009170] toxicity [MeSH:C0040539] exclude patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] admit hospital serial testing dse testing intensive diagnostic unit result twenty-four patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] enrol patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] inadequate rest image dse terminate inferior hypokinesis dse terminate rate-related atrial conduction deficit reach target [MeSH:C0039309] [MeSH:C0039309] [MeSH:C0039309] heart rate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] complete dse reach target [MeSH:C0039309] [MeSH:C0039309] [MeSH:C0039309] heart rate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience sign exaggerated adrenergic response [MeSH:C0001637] [MeSH:C0001637] [MeSH:C0001637] define systolic blood pressure [MeSH:C0005823] great mm hg occurrence [MeSH:C0243132] tachydysrhythmia exclude sinus tachycardia [MeSH:C0039239] suggest lack exaggerated adrenergic response [MeSH:C0001637] [MeSH:C0001637] [MeSH:C0001637] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] require supplemental [MeSH:C2936424] atropine [MeSH:C0004259] reach target [MeSH:C0039309] [MeSH:C0039309] [MeSH:C0039309] heart rate exaggerated adrenergic response [MeSH:C0001637] [MeSH:C0001637] [MeSH:C0001637] detect dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] administer patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine [MeSH:C0009170]-related chest pain [MeSH:C0008031],cardiovascular
early onset [MeSH:C0031106] x-linked [MeSH:C0678928] emery-dreifuss muscular dystrophy [MeSH:C0026850] boy emerin gene deletion,boy develop contracture [MeSH:C0009917] achille tendon year postcervical muscle year contracture [MeSH:C0009917] elbow [MeSH:C0013769] cardiac abnormality [MeSH:C0037268] recognize age year muscle computed tomography scanning [MeSH:C0936234] reveal change characteristic muscle involvement emerin [MeSH:C0295734] [MeSH:C0295734] detect biopsie muscle rt-pcr pcr-based genomic dna analysis emerin [MeSH:C0295734] [MeSH:C0295734] gene demonstrate amplification [MeSH:C0017256] product result confirm diagnosis [MeSH:C0011900] x-linked [MeSH:C0678928] emery-dreifuss muscular dystrophy edmd [MeSH:C0410189] reinforce necessity molecular genetic [MeSH:C0086345] diagnosis [MeSH:C0011900] membrane protein [MeSH:C0025252] emerin [MeSH:C0295734] [MeSH:C0295734] young [MeSH:C0340037] patient [MeSH:C0030705] possible edmd appearance [MeSH:C0750731] typical symptom [MeSH:C3839861] avoid sudden cardiac death [MeSH:C0085298],neurological
rcc pathway epilepsy,retrospective [MeSH:C0035363] examine beta-blocker heart disease elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include dialysis renal cyst [MeSH:C4551529] chronic kidney disease [MeSH:C1561643] method participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication relevance,hepatorenal
maternal [MeSH:C0024915] lithium [MeSH:C0023870] neonatal ebstein anomaly cross-sectional echocardiography [MeSH:C0013519],cross-sectional echocardiography [MeSH:C0013519] [MeSH:C0013519] evaluate [MeSH:C0013175] neonate mother [MeSH:C0021289] ingest lithium pregnancy infant [MeSH:C0021270] ebstein anomaly [MeSH:C0013481] [MeSH:C0013481] tricuspid valve [MeSH:C0040960] identify infant [MeSH:C0021270] cross-sectional echocardiography [MeSH:C0013519] [MeSH:C0013519] provide reassurance infant [MeSH:C0021270] ebstein anomaly [MeSH:C0013481] [MeSH:C0013481] cross-sectional echocardiographic screening newborn [MeSH:C0027617] expose lithium gestation [MeSH:C0032961] provide highly accurate noninvasive assessment presence absence lithium-induced cardiac malformation,cardiovascular
atherosclerosis [MeSH:C0004153] breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] dvt method adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective [MeSH:C0589154] pe wilms tumor assessment [MeSH:C0027708] result improve outcome [MeSH:C0206277] relevance [MeSH:C2826293],cardiovascular|hepatorenal
liver cirrhosis [MeSH:C0023890] cardiac function [MeSH:C0018803],hypothesis statin improve heart disease [MeSH:C0018799] outcome septum pathway method longitudinal trial [MeSH:C0023981] elderly patient measure myocardial infarction [MeSH:C0027051] ectopic beat [MeSH:C0033036] result favorable safety profile relevance [MeSH:C2826293],cardiovascular
low-molecular-weight heparin [MeSH:C0019139] patient [MeSH:C0030705] mechanical heart valve [MeSH:C0018826],interruption oral [MeSH:C0029170] anticoagulant oac administration [MeSH:C0001554] [MeSH:C0001554] indicate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mechanical heart valve [MeSH:C0018826] [MeSH:C0018826] [MeSH:C0018826] [MeSH:C0018826] mainly noncardiac surgery non-surgical intervention pregnancy [MeSH:C0032961] unfractionated heparin [MeSH:C0019134] uh currently substitute select patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] low-molecular-weight heparin [MeSH:C0019139] [MeSH:C0019134] lmwh [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] offer theoretical [MeSH:C0026350] advantage uh currently consider guideline [MeSH:C0282423] alternative uh patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prosthetic valve hypothesis present review [MeSH:C0282443] accumulate [MeSH:C0311432] far use lmwh [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] population [MeSH:C0032659] discuss applicability common practice method paper current medical literature [MeSH:C0025120] lmwh [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mechanical heart valve [MeSH:C0018826] [MeSH:C0018826] [MeSH:C0018826] [MeSH:C0018826] extensively review [MeSH:C0282443] result series case report [MeSH:C0684224] [MeSH:C0684224] study randomized [MeSH:C1096777] prospective establish thromboembolic [MeSH:C0040038] risk [MeSH:C0035647] incomplete [MeSH:C0011139] exclude case report [MeSH:C0684224] [MeSH:C0684224] follow group [MeSH:C0018257] [MeSH:C0018257] construct short-term [MeSH:C0025265] [MeSH:C0025265] [MeSH:C0025265] administration [MeSH:C0001554] [MeSH:C0001554] valve insertion n b short-term [MeSH:C0025265] [MeSH:C0025265] [MeSH:C0025265] perioperative [MeSH:C2712230] noncardiac periprocedural n c long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] intolerance oac n long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] pregnancy [MeSH:C0032961] n incidence rate [MeSH:C1708485] thromboembolism study [MeSH:C0040038] group [MeSH:C0018257] [MeSH:C0018257] b c respectively hemorrhage [MeSH:C0019080] overall rate respective group [MeSH:C0018257] [MeSH:C0018257] conclusion patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mechanical heart valve [MeSH:C0018826] [MeSH:C0018826] [MeSH:C0018826] [MeSH:C0018826] short-term [MeSH:C0025265] [MeSH:C0025265] [MeSH:C0025265] lmwh [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] therapy compare favorably uh mid- long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] lmwh [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] administration [MeSH:C0001554] [MeSH:C0001554] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sparse randomized [MeSH:C1096777] study need confirm safety [MeSH:C0036043] precise indication use lmwh [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] [MeSH:C0019139] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mechanical heart valve [MeSH:C0018826] [MeSH:C0018826] [MeSH:C0018826] [MeSH:C0018826],cardiovascular
capillary myocardial infarction [MeSH:C0027051] vascular [MeSH:C0221214] insight,longitudinal [MeSH:C0023981] examine statin heart disease cancer [MeSH:C0018799] patient [MeSH:C0030705] investigation [MeSH:C0035173] include nephrotic syndrome [MeSH:C0027726] renal cyst [MeSH:C0010709] wilms tumor method [MeSH:C0027708] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication relevance,cardiovascular|hepatorenal
association [MeSH:C0004083] brca1 [MeSH:C0259275] hrad5-hmre1-p9 complex dna damage response [MeSH:C0012860],brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] encode tumor suppressor mutate [MeSH:C0597611] familial breast ovarian cancer show brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] interact vitro vivo hrad5 form complex hmre1 p9 nibrin irradiation [MeSH:C4042794] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] detect discrete focus nucleus colocalize hrad5 formation irradiation [MeSH:C4042794]-induced focus positive brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] hrad5 hmre1 p9 dramatically reduce hcc breast cancer cell [MeSH:C0006142] carry homozygous [MeSH:C0019904] mutation [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] restore transfection [MeSH:C0040669] wild-type brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] ectopic [MeSH:C0019933] expression [MeSH:C0017262] wild-type mutate brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] cell render sensitive [MeSH:C1017675] dna damage [MeSH:C0012860] agent [MeSH:C0012860] methyl methanesulfonate [MeSH:C0025706] suggest brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] important cellular response dna damage [MeSH:C0012860] mediate hrad5-hmre1-p9 complex,neurological|oncological
myocardium [MeSH:C0027061] colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect hypertension [MeSH:C0020538] thrombosis [MeSH:C0040053] mechanism method prospective cancer patient [MeSH:C0030705] assess pe heart rate [MeSH:C0018810] result positive response implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
neuron pathway hepatitis [MeSH:C2717810],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve stroke outcome dysarthria pathway method cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure norepinephrine white matter result superior efficacy care improvement [MeSH:C2936612],neurological
alpha-blocker [MeSH:C0001641] hypertension [MeSH:C0020538] brain [MeSH:C0006104] insight,cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve myocardial infarction myocardial method [MeSH:C0027051] conduct longitudinal evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine blood pressure [MeSH:C0005823] parameter result improve disease management [MeSH:C0039798] need investigation [MeSH:C0035173],neurological|cardiovascular
aminoglycoside antibiotic restore dystrophin function [MeSH:C0031843] skeletal muscle [MeSH:C0242692] mdx [MeSH:C0206535] mouse [MeSH:C0026809],duchenne muscular dystrophy dmd [MeSH:C0013264] cause mutation [MeSH:C0026882] dystrophin gene [MeSH:C0079259] lead absence dystrophin protein [MeSH:C0079259] striated muscle [MeSH:C1331262] number [MeSH:C1331262] mutation [MeSH:C0026882] premature stop codon [MeSH:C0242612] basis observation aminoglycoside [MeSH:C0002556] [MeSH:C0002556] suppress [MeSH:C0017372] [MeSH:C0017372] stop codon culture cell test effect [MeSH:C4277511] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] culture muscle [MeSH:C0010453] cell mdx [MeSH:C0206535] [MeSH:C0206535] mouse [MeSH:C0026809] [MeSH:C0026809] animal model [MeSH:C0599779] dmd possess premature stop codon [MeSH:C0242612] dystrophin gene [MeSH:C0079259] exposure mdx [MeSH:C0206535] [MeSH:C0206535] myotube gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] lead expression [MeSH:C0017262] localization dystrophin cell [MeSH:C0079259] membrane evaluate effect [MeSH:C4277511] differ dosage [MeSH:C0178655] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] expression [MeSH:C0017262] functional [MeSH:C0031843] protection muscle mdx [MeSH:C0206535] [MeSH:C0206535] mouse [MeSH:C0026809] [MeSH:C0026809] identify regimen [MeSH:C1880476] result presence dystrophin cell [MeSH:C0079259] membrane striated muscle [MeSH:C1331262] examine provide functional [MeSH:C0031843] protection muscular injury [MeSH:C0178324] knowledge [MeSH:C0376554] result demonstrate aminoglycoside [MeSH:C0002556] [MeSH:C0002556] suppress [MeSH:C0017372] [MeSH:C0017372] stop codon vitro vivo furthermore result raise possibility novel regiman muscular dystrophy disease [MeSH:C0026850] cause premature stop codon [MeSH:C0242612] mutation [MeSH:C0026882] prove effect [MeSH:C4277511]ive patient [MeSH:C0030705] dmd,neurological
thrombosis [MeSH:C0040053] liver cirrhosis [MeSH:C0023890] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect heart disease [MeSH:C0018799] bradycardia method elderly patient undergo retrospective congestive heart failure [MeSH:C0018802] regurgitation [MeSH:C0026266] assessment [MeSH:C0030198] result positive response need investigation [MeSH:C0035173],cardiovascular
medulloblastoma [MeSH:C0025149] meet ventricular tachycardia [MeSH:C0042514] neurological perspective,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete parkinsonism [MeSH:C0242422] mechanism method retrospective [MeSH:C0035363] adult population [MeSH:C0032659] assess peripheral neuropathy [MeSH:C4721453] brain [MeSH:C0006104] result positive response implication optimization [MeSH:C0376695],neurological
cocaine [MeSH:C0009170] related chest pain [MeSH:C0008031] see tip iceberg,recreational [MeSH:C0034872] use cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] increase emergency [MeSH:C2745965] nurse [MeSH:C0028661] [MeSH:C0085125] ought familiar cardiovascular [MeSH:C0007220] consequence cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] use particular tendency cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] produce chest pain [MeSH:C0008031] [MeSH:C0008031] ought mind emergency [MeSH:C2745965] nurse [MeSH:C0028661] [MeSH:C0085125] face young [MeSH:C0340037] victim [MeSH:C0302823] ch pain low risk mechanism chest pain [MeSH:C0008031] [MeSH:C0008031] related cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] use discuss dilemma [MeSH:C0033166] discuss finally moral issue relate testing [MeSH:C1321876] potential cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] user address,cardiovascular
tumor [MeSH:C0027651] tale hypertension [MeSH:C0020538] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin heart disease [MeSH:C0018799] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient endometrial cancer [MeSH:C0476089] tumor [MeSH:C0027651] result improvement primary endpoint liver cancer [MeSH:C0345904] correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],oncological
hypertension [MeSH:C0020538] uremia [MeSH:C0041948] organ [MeSH:C0029250] interplay,stroke [MeSH:C0038454] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve bun azotemia method conduct observational [MeSH:C0302523] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine gamma glutamyl transferase [MeSH:C0017040] parameter result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],hepatorenal
pacemaker colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect hypertension [MeSH:C0020538] [MeSH:C0020538] hypertension [MeSH:C0020538] [MeSH:C0020538] mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess heart attack [MeSH:C0027051] coronary result well quality life measure implication practice guideline [MeSH:C0936005],cardiovascular
myoclonus [MeSH:C0027066] associate lorazepam therapy very-low-birth-weight infant [MeSH:C0282667],lorazepam [MeSH:C0024002] [MeSH:C0024002] [MeSH:C0024002] [MeSH:C0024002] increase frequency [MeSH:C0376249] sedative newborn [MeSH:C0021289] young infant [MeSH:C0021270] [MeSH:C0021270] concern raise regard safety [MeSH:C0036043] lorazepam [MeSH:C0024002] [MeSH:C0024002] [MeSH:C0024002] [MeSH:C0024002] age [MeSH:C0024842] especially very-low-birth-weight vlbw g [MeSH:C0282667] infant [MeSH:C0021270] [MeSH:C0021270] young infant [MeSH:C0021270] [MeSH:C0021270] birth weight g experienced myoclonus [MeSH:C0027066] follow intravenous administration [MeSH:C0013125] lorazepam [MeSH:C0024002] [MeSH:C0024002] [MeSH:C0024002] [MeSH:C0024002] potential neurotoxic effect drug vehicle [MeSH:C0175845] population [MeSH:C0032659] discuss injectable [MeSH:C0086466] lorazepam [MeSH:C0024002] [MeSH:C0024002] [MeSH:C0024002] [MeSH:C0024002] caution vlbw infant [MeSH:C0021270] [MeSH:C0021270],neurological
cholestasis pathway alzheimer disease,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve cancer outcome [MeSH:C0206277] uremia pathway method prospective trial diabetic [MeSH:C1263960] patient measure glomerulonephritis kidney [MeSH:C0017658] stone result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
common human [MeSH:C0086418] skin tumour cause activate mutation [MeSH:C0026882] beta-catenin [MeSH:C0105770],wnt [MeSH:C0753137] signalling [MeSH:C0037083] orchestrate number developmental program response stimulus cytoplasmic [MeSH:C0206587] beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] encode ctnnb1 [MeSH:C1531189] stabilize enable downstream transcriptional activation [MeSH:C0162493] member lef tcf family target gene beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] tcf encode c-myc explain constitutive activation [MeSH:C0914906] wnt [MeSH:C0753137] pathway lead cancer [MeSH:C0023175] particularly colon colon cancer [MeSH:C0007102] arise mutation [MeSH:C0026882] gene [MeSH:C0026882] encode adenomatous polyposis coli apc protein [MeSH:C0753723] require ubiquitin-mediated degradation beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] small percentage colon cancer harbour beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770]-stabilizing mutation [MeSH:C0026882] recently discover transgenic [MeSH:C2350483] mouse [MeSH:C0026809] express activate beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] predisposed develop skin tumour resemble pilomatricoma [MeSH:C0206711] [MeSH:C0206711] give skin adult mouse [MeSH:C0026809] exhibit sign de novo hair-follicle morphogenesis wonder human [MeSH:C0086418] [MeSH:C0086418] pilomatricoma [MeSH:C0206711] [MeSH:C0206711] [MeSH:C0206711] originate hair matrix cell possess beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770]-stabilizing mutation [MeSH:C0026882] explore cell origin aetiology [MeSH:C0015127] common human [MeSH:C0086418] [MeSH:C0086418] skin tumour find nuclear lef- divide tumour cell provide biochemical [MeSH:C0017401] evidence [MeSH:C5575834] pilomatricoma [MeSH:C0206711] [MeSH:C0206711] derive hair matrix cell tumour possess mutation [MeSH:C0026882] affect amino-terminal segment normally involve phosphorylation-dependent ubiquitin-mediated degradation protein percentage ctnnb1 [MeSH:C1531189] mutation [MeSH:C0026882] great human [MeSH:C0086418] [MeSH:C0086418] tumour examine far directly implicate beta-catenin [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] [MeSH:C0105770] lef misregulation major cause hair matrix cell tumorigenesis [MeSH:C0596263] human [MeSH:C0086418] [MeSH:C0086418],neurological|oncological
hyperkalemia [MeSH:C0020461] induce indomethacin [MeSH:C0021246] naproxen [MeSH:C0027396] reverse fludrocortisone [MeSH:C0016280],describe severe [MeSH:C1719672] rheumatoid arthritis [MeSH:C0003873] history [MeSH:C0019664] mefenamic acid nephropathy hyperkalemia [MeSH:C0020461] [MeSH:C0020461] inappropriate [MeSH:C2936303] hypoaldosteronism [MeSH:C0020595] cause indomethacin [MeSH:C0021246] naproxen [MeSH:C0027396] major decline renal function [MeSH:C0031843] likely preexist renal disease [MeSH:C1691228] predispose type iv renal tubular acidosis [MeSH:C0376185] prostaglandin synthetase inhibitor [MeSH:C0085387] unable discontinue nonsteroidal anti-inflammatory drug therapy [MeSH:C0003211] fludrocortisone [MeSH:C0016280] add correct hyperkalemia [MeSH:C0020461] [MeSH:C0020461] allow indomethacin [MeSH:C0021246] therapy continue safely,hepatorenal
artery cancer [MeSH:C0003842] vascular [MeSH:C0221214] insight,prospective examine calcium channel blocker heart disease [MeSH:C0006684] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include atrium defibrillator hypertension method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication optimization [MeSH:C0376695],cardiovascular
dual role atm cellular response radiation cell growth,gene mutate ataxia-telangiectasia patient [MeSH:C0030705] denote atm encode putative protein lipid kinase elucidate function atm disrupt mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] atm gene homologous recombination [MeSH:C0599773] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] consistent cellular defect patient [MeSH:C0030705] atm- cell hypersensitive gamma-irradiation [MeSH:C0851346] defective [MeSH:C0011139] [MeSH:C0011139] cell-cycle arrest [MeSH:C1155873] follow radiation [MeSH:C0851346] correlate defective [MeSH:C0011139] [MeSH:C0011139] up-regulation [MeSH:C0041904] p5 addition atm- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] thymocyte [MeSH:C0814999] [MeSH:C0814999] [MeSH:C0814999] resistant [MeSH:C2986418] apoptosis [MeSH:C0162638] induce gamma-irradiation [MeSH:C0851346] normal thymocyte [MeSH:C0814999] [MeSH:C0814999] [MeSH:C0814999] atm- fibroblast [MeSH:C0016030] [MeSH:C0016030] inefficient g1 s-phase progression [MeSH:C0242656] follow serum stimulation senesce passage culture [MeSH:C0010453] increase constitutive [MeSH:C0914906] p21cp1 waf1 atm protein [MeSH:C1529821] critical cellular response ionize radiation [MeSH:C0034538] [MeSH:C0851346] normal cell-cycle progression [MeSH:C0242656] atm fibroblast [MeSH:C0016030] [MeSH:C0016030] thymocyte [MeSH:C0814999] [MeSH:C0814999] [MeSH:C0814999] show intermediately defective [MeSH:C0011139] [MeSH:C0011139] response irradiation [MeSH:C0851346] growth defect suggest increase cancer risk [MeSH:C0035647] heterozygote [MeSH:C0019425] attributable poor checkpoint function [MeSH:C3178863],neurological|oncological
acute hepatitis autoimmune hemolytic anemia [MeSH:C0002880] erythroblastocytopenia induce ceftriaxone [MeSH:C0007561],-yr-old man develop acute hepatitis [MeSH:C0019158] shortly ingest oral [MeSH:C0029170] ceftriaxone transaminase [MeSH:C0002594] gradually return withhold beta lactam antibiotic [MeSH:C0003232] [MeSH:C0003232] gradual increase serum [MeSH:C0229671] bilirubin decrease hemoglobin concentration [MeSH:C0474535] cause autoimmune hemolytic anemia [MeSH:C0002880] erythroblastocytopenia respond systemic [MeSH:C5544477] steroid immunoglobulin [MeSH:C0021027] despite widespread use agent triad effect [MeSH:C4277511] previously report connection beta lactam antibiotic [MeSH:C0003232] [MeSH:C0003232],hepatorenal
thyroid cancer [MeSH:C0549473] marker [MeSH:C0017393] lung cancer [MeSH:C0242379],design [MeSH:C0013171] prospective investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population carcinoma stem cell transplant [MeSH:C1504389] result positive response neoplasm correlation safety consideration,cardiovascular|oncological
neurodegenerative pathway lymphoma,observational [MeSH:C0302523] examine metformin [MeSH:C0025598] stroke [MeSH:C0038454] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] [MeSH:C0035173] include cognitive impairment [MeSH:C0338656] limbic system [MeSH:C0023715] dopamine method [MeSH:C0013030] participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication need investigation [MeSH:C0035173] [MeSH:C0035173],neurological
adrenal cancer [MeSH:C0750887] pathway multiple sclerosis [MeSH:C0026769],hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve skin cancer [MeSH:C0007114] anuria method [MeSH:C0003460] conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine bilirubin [MeSH:C0005437] parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,hepatorenal|oncological
biopsy [MeSH:C0005558] reveal hypertension [MeSH:C0020538] secret,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] cancer patient [MeSH:C0030705] substantia nigra parkinsonism [MeSH:C0038590] result well quality life measure thalamus [MeSH:C0039729] correlation care improvement [MeSH:C2936612],neurological
rapid reversal anticoagulation reduce hemorrhage [MeSH:C0019080] volume mouse model warfarin-associated intracerebral hemorrhage [MeSH:C2937358] [MeSH:C0019080],warfarin [MeSH:C0043031]-associated intracerebral hemorrhage [MeSH:C0019080] [MeSH:C0019080] [MeSH:C2937358] w-ich severe [MeSH:C1719672] type stroke [MeSH:C0038454] consensus optimal [MeSH:C0376298] w-ich mouse [MeSH:C0026809] model test rapid reversal anticoagulation human [MeSH:C0086418] [MeSH:C0086418] prothrombin complex [MeSH:C0052128] concentrate pcc reduce hemorrhagic blood volume [MeSH:C0005850] [MeSH:C0005850] [MeSH:C0005850] male [MeSH:C0086582] cd- mouse [MeSH:C0026809] treat warfarin [MeSH:C0043031] mg kg h result mean -s international normalize ratio [MeSH:C0525032] show intravenous administration [MeSH:C0013125] human [MeSH:C0086418] [MeSH:C0086418] pcc rapidly reverse anticoagulation mouse [MeSH:C5445165] [MeSH:C0026809] second stereotactic injection collagenase administer induce hemorrhage [MeSH:C0019080] [MeSH:C0019080] right striatum forty-five minute later animal [MeSH:C0003062] randomly treat pcc u kg saline v n twenty-four hour hemorrhage [MeSH:C0019080] [MeSH:C0019080] induction [MeSH:C0042767] hemorrhagic blood volume [MeSH:C0005850] [MeSH:C0005850] [MeSH:C0005850] quantify photometric hemoglobin assay mean hemorrhagic blood volume [MeSH:C0005850] [MeSH:C0005850] [MeSH:C0005850] reduce pcc-treated animal [MeSH:C0003062] microl compare saline control microl p saline mouse [MeSH:C0026809] develop large hematoma e microl [MeSH:C0018944] contrast extensive lesion find pcc provide experimental [MeSH:C0016998] suggest pcc effective acute [MeSH:C0184567] w-ich term reduce hemorrhagic blood volume [MeSH:C0005850] [MeSH:C0005850] [MeSH:C0005850] future study [MeSH:C0085973] need assess therapeutic [MeSH:C0087111] potential emerge human [MeSH:C0086418] [MeSH:C0086418] w-ich,neurological
methyldopa-induced hemolytic anemia old presenting near-syncope,methyldopa [MeSH:C0025741] [MeSH:C0025741] antihypertensive medication [MeSH:C0003364] available generically trade aldomet widely prescribe adult [MeSH:C0001675] population [MeSH:C0032659] infrequently child [MeSH:C0008059] methyldopa [MeSH:C0025741] [MeSH:C0025741] cause autoimmune hemolytic anemia [MeSH:C0002880] small percentage patient drug report case methyldopa [MeSH:C0025741] [MeSH:C0025741]-induced hemolytic anemia -year-old boy present emergency department [MeSH:C0562508] near-syncope boy treat intravenous methyldopa [MeSH:C0025741] [MeSH:C0025741] trauma admission [MeSH:C0030673] seven week prior presentation reveal hemoglobin gram coomb test polyspecific anti-human globulin monospecific igg reagent [MeSH:C0034760] warm react autoantibody [MeSH:C0004358] transfusion [MeSH:C0274435] corticosteroid therapy [MeSH:C0001617] result complete recovery [MeSH:C0140116] emergency physician [MeSH:C2745965] treat child [MeSH:C0008059] aware syndrome order diagnose [MeSH:C0011900] treat correctly brief review autoimmune drug-induced hemolytic anemia provide,neurological
interactive [MeSH:C1956025] effect variation na rat [MeSH:C0034721] atrial spontaneous frequency,effect [MeSH:C4277511] [MeSH:C4277511] vary extracellular [MeSH:C3850090] concentrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0311432] na na spontaneous beating negative chronotropic action verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] study isolate rat [MeSH:C0034721] [MeSH:C0034721] atrium basal frequency bf evaluate surface [MeSH:C0025252] electrogram beat min krebs-ringer contain mm na mm n decrease lower na mm lna lower simultaneously na mm mm lna lca lower na mm plus increase mm lna hca normal na decrease mm increase mm modify bf reduction [MeSH:C1827449] time mm normal effect [MeSH:C4277511] [MeSH:C4277511]ive reduce bf negative chronotropic effect [MeSH:C4277511] [MeSH:C4277511] bf-dependent dose-dependent bradycardia [MeSH:C0428977] induce verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] potentiate lna lca hca independent additive effect [MeSH:C4277511] [MeSH:C4277511] na show decrease value verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] need reduce bf ic3 follow order inhibitory [MeSH:C0167957] potency [MeSH:C2349090] lna lca hca n result lna hca similar lna verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] arrest [MeSH:C0104230] atrial beating ac potentiate order lna lna lca lna hca lca hca n result indicate rat [MeSH:C0034721] [MeSH:C0034721] atrial spontaneous beating dependent na range normal concentrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0311432] enhancement verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] effect [MeSH:C4277511] [MeSH:C4277511] atrial beating pronounced lna lca abstract truncate word,cardiovascular
mutation spectrum [MeSH:C4042936] genotype-phenotype analysis [MeSH:C2717879] cowden disease bannayan-zonana syndrome [MeSH:C0265326] hamartoma syndrome [MeSH:C0018552] germline pten mutation [MeSH:C0206530],tumour suppressor gene pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] map [MeSH:C0079427] 0q2 encode amino acid dual specificity phosphatase protein tyrosine phosphatase ptpase [MeSH:C1956000] show recently play broad role human [MeSH:C0086418] malignancy [MeSH:C0006826] somatic pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] deletion mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C1511760] observe sporadic breast brain prostate kidney cancer cell line [MeSH:C0007600] primary tumour endometrial carcinoma [MeSH:C0476089] malignant [MeSH:C0001418] melanoma [MeSH:C0025202] thyroid tumour addition pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] identify susceptibility [MeSH:C0012655] gene hamartoma syndrome [MeSH:C0018552] cowden disease [MeSH:C0018553] cd mim bannayan-zonana bzs ruvalcaba-riley-smith syndrome mim constitutive dna cd family [MeSH:C0015576] seven bzs family screen germline [MeSH:C0206530] pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] mutation [MeSH:C0026882] [MeSH:C0026882] pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] mutation [MeSH:C0026882] [MeSH:C0026882] identify cd family [MeSH:C0015576] include missense nonsense point mutation [MeSH:C0026882] [MeSH:C0026882] deletion [MeSH:C0544885] insertion deletion insertion splice site mutation [MeSH:C0026882] [MeSH:C0026882] mutation [MeSH:C0026882] [MeSH:C0026882] scatter entire length pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] exception fourth exon [MeSH:C0015295] hot spot pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] mutation [MeSH:C0026882] [MeSH:C0026882] cd identify exon [MeSH:C0015295] contain ptpase core motif cd mutation [MeSH:C0026882] [MeSH:C0026882] identify exon [MeSH:C0015295] seven core motif majority seven missense mutation [MeSH:C0599155] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0599155] possibly point functional significance region germline [MeSH:C0206530] pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] mutation [MeSH:C0026882] [MeSH:C0026882] identify seven bzs family study [MeSH:C0085973] interestingly mutation [MeSH:C0026882] [MeSH:C0026882] observe ptpase core motif worthy note single nonsense point mutation [MeSH:C0026882] [MeSH:C0026882] r23x observe germline [MeSH:C0206530] dna unrelated cd family [MeSH:C0015576] bzs family [MeSH:C0015576] genotype-phenotype [MeSH:C2717879] study [MeSH:C0085973] perform small bzs family genotype-phenotype [MeSH:C2717879] inthe cd family [MeSH:C0015576] reveal possible association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] worthy follow-up [MeSH:C3899107] independent analysis association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] note cd family [MeSH:C0015576] breast disease correlation [MeSH:C0010100] observe presence absence pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] mutation [MeSH:C0026882] [MeSH:C0026882] type breast involvement [MeSH:C0030699] [MeSH:C0030699] unaffected versus benign [MeSH:C1879828] versus malignant [MeSH:C0001418] specifically directly association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] observe presence pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] [MeSH:C1530899] mutation [MeSH:C0026882] [MeSH:C0026882] malignant [MeSH:C0001418] breast disease secondly appear interdependent association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] mutation [MeSH:C0026882] [MeSH:C0026882] upstream ptpase core motif core motif contain majority missense mutation [MeSH:C0599155] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0599155] involvement [MeSH:C0030699] [MeSH:C0030699] major organ system central nervous system thyroid breast [MeSH:C3714787] skin [MeSH:C1123023] gastrointestinal tract [MeSH:C0017189] observation [MeSH:C0302523] need confirm study [MeSH:C0085973] large number cd family [MeSH:C0015576],neurological|hepatorenal|oncological
organ [MeSH:C0029250] orchestra lung cancer,cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve nash uremia method [MeSH:C0041948] conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine bile duct [MeSH:C0005400] parameter result improve disease management [MeSH:C0039798] safety consideration,hepatorenal
intramuscular [MeSH:C0021492] hepatitis b [MeSH:C0019163] [MeSH:C0019163] immune globulin [MeSH:C0021027] combine lamivudine [MeSH:C0209738] prevention hepatitis b [MeSH:C0019163] [MeSH:C0019163] recurrence liver transplantation [MeSH:C0023911],combined hepatitis b [MeSH:C0019163] immune globulin hbig [MeSH:C0062525] [MeSH:C0062525] lamivudine [MeSH:C0209738] prophylaxis [MeSH:C0033107] recurrence [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] hepatitis b [MeSH:C0019163] liver transplantation [MeSH:C0040732] [MeSH:C0023911] significantly improve survival [MeSH:C0038952] hbsag positive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undertake evaluate outcome [MeSH:C0206277] liver transplantation [MeSH:C0040732] [MeSH:C0023911] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hepatitis b [MeSH:C0019163] virus hbv method retrospective chart review organ transplant [MeSH:C0524930] database [MeSH:C0993637] identify patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] man woman transplant [MeSH:C0332835] benign hbv-related cirrhotic disease june december survive month hbig [MeSH:C0062525] [MeSH:C0062525] administer intravenously week intramuscular [MeSH:C0021492] [MeSH:C0021492]ly result median follow-up [MeSH:C3899107] month overall recurrence [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] rate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] overall survival [MeSH:C0038952] year respectively daily oral dose mg lamivudine [MeSH:C0209738] week transplantation [MeSH:C0040732] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] enable hbv-dna hbeag positive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] respectively convert negative [MeSH:C3539878] intramuscular [MeSH:C0021492] [MeSH:C0021492] hbig [MeSH:C0062525] [MeSH:C0062525] tolerate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lamivudine [MeSH:C0209738] combine intramuscular [MeSH:C0021492] [MeSH:C0021492] hbig [MeSH:C0062525] [MeSH:C0062525] effectively prevent [MeSH:C0000918] allograft [MeSH:C0450127] recurrence [MeSH:C2825055] [MeSH:C2825055] [MeSH:C2825055] hbv liver transplantation [MeSH:C0023911] [MeSH:C0040732] [MeSH:C0023911],hepatorenal
aortic aneurysm epilepsy [MeSH:C0003486] vascular insight,investigate [MeSH:C0035173] statin effect heart disease hypertension [MeSH:C0018799] method cardiac patient undergo cross-sectional cardiac ventricular fibrillation assessment result well quality life measure practice guideline,cardiovascular
immunohistochemical [MeSH:C0021044] inducible type nitric oxide inos basic fibroblast growth factor bfgf tumor growth factor-beta1 tgf-beta1 arteritis induce rat [MeSH:C0034721] fenoldopam [MeSH:C0060180] theophylline [MeSH:C0039771] vasodilator [MeSH:C0042402],arteritis [MeSH:C0003860] induce rat [MeSH:C0034721] [MeSH:C0034721] vasodilator fenoldopam [MeSH:C0060180] [MeSH:C0060180] theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] examine immunohistochemically [MeSH:C0021044] expression [MeSH:C0017262] inducible type nitric oxide synthase inos basic fibroblast growth factor bfgf tumor growth factor-beta1 tgf-beta1 [MeSH:C1704256] [MeSH:C1704256] rat [MeSH:C0034721] [MeSH:C0034721] administer fenoldopam [MeSH:C0060180] hour intravenous infusion [MeSH:C0021440] follow repeat daily oral administrat [MeSH:C0034721] [MeSH:C0034721]ion theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] irrespective theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] administrat [MeSH:C0034721] [MeSH:C0034721]ion inos antigen [MeSH:C0003320] [MeSH:C0003320] remarkably abundant ed positive cell post-fenoldopam [MeSH:C0060180]-infusion dpi bfgf antigen remarkably abundant ed positive cell dpi tgf-beta1 [MeSH:C1704256] [MeSH:C1704256] antigen observe ed positive cell dpi result suggest peak expression [MeSH:C0017262] [MeSH:C0017262] inos antigen [MeSH:C0003320] [MeSH:C0003320] follow bfgf antigen bfgf [MeSH:C1313752] suppressive effect inos expression [MeSH:C0017262] rat [MeSH:C0034721] [MeSH:C0034721] arteritis [MeSH:C0003860] model hand tgf-beta1 [MeSH:C1704256] [MeSH:C1704256] consider suppressive effect inos expression [MeSH:C0017262] model,oncological
alpha-blocker angina pectoris brain insight,retrospective [MeSH:C0035363] examine aspirin cancer [MeSH:C0004057] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] [MeSH:C0035173] include palsy tremor migraine method participant [MeSH:C1708335] include result favorable safety profile implication need investigation [MeSH:C0035173] [MeSH:C0035173],neurological
liver-kidney dialogue multiple sclerosis,question statin affect stroke [MeSH:C0038454] rcc [MeSH:C0967777] mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess nephrotic syndrome cholangiocarcinoma [MeSH:C0206698] result positive response implication healthcare advancement,hepatorenal
debrisoquine [MeSH:C0011082] phenotype [MeSH:C0031437] pharmacokinetic [MeSH:C0031327] beta- receptor pharmacodynamic metoprolol [MeSH:C0025859] enantiomer,metabolism [MeSH:C0025519] cardioselective beta-blocker metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] genetic [MeSH:C0017380] debrisoquine sparteine type metabolic [MeSH:C0025517] phenotype [MeSH:C0031437] extensive em poor metabolizer pm different stereoselective metabolism [MeSH:C0025519] result apparently high beta- adrenoceptor [MeSH:C0034783] [MeSH:C0034783] antagonistic [MeSH:C0033607] potency [MeSH:C2349090] racemic metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] em investigate [MeSH:C0035173] apply beta- adrenoceptor [MeSH:C0034783] [MeSH:C0034783] antagonism [MeSH:C0013159] [MeSH:C0013159] metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] drug effect [MeSH:C0041755] study [MeSH:C0085973] antagonism [MeSH:C0013159] [MeSH:C0013159] metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] terbutaline [MeSH:C0039542] [MeSH:C0039542]-induced hypokalemia [MeSH:C0020621] pharmacokinetic pharmacodynamic model [MeSH:C0031327] pharmacodynamic racemic metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] active s-isomer quantitate em pm term ic5 value represent metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] plasma [MeSH:C0032105] concentratio [MeSH:C0036893]n [MeSH:C0311432] result half-maximum receptor occupancy em receive mg terbutaline [MeSH:C0039542] [MeSH:C0039542] c [MeSH:C0039542] different occasion hr administratio [MeSH:C0036893]n [MeSH:C0001554] placebo [MeSH:C0032041] hr mg metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] p pm study [MeSH:C0085973] accord protocol high terbutaline [MeSH:C0039542] [MeSH:C0039542] dose mg blood sample plasma [MeSH:C0032105] potassium terbutaline [MeSH:C0039542] [MeSH:C0039542] metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] racemic r- s-isomer alpha-hydroxymetoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0102604] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0102604] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] concentratio [MeSH:C0036893]n [MeSH:C0311432] take regular interval hr metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] pm metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] increase terbutaline [MeSH:C0039542] [MeSH:C0039542] area plasma [MeSH:C0032105] concentratio [MeSH:C0036893]n [MeSH:C0311432] vs curve high metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] alpha-hydroxymetoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0102604] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0102604] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] ratio [MeSH:C0036893] pm predictive [MeSH:C1514243] high r- s-isomer ratio [MeSH:C0036893] unchanged drug difference [MeSH:C0036866] metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] potency [MeSH:C2349090] high racemic metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] ic5 value pm ng ml- em ng ml- p abstract [MeSH:C0600678] truncate word,neurological|cardiovascular
brain [MeSH:C0006104] meet cancer [MeSH:C0006826] neurological perspective,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve gaba neuron method [MeSH:C0815002] conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine neurotransmitter [MeSH:C0027908] parameter result improve outcome healthcare advancement,neurological
kidney coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve cardiac hypotension method conduct prospective evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine creatinine [MeSH:C0010294] parameter result enhance therapeutic response care [MeSH:C0087111] improvement [MeSH:C2936612],cardiovascular|hepatorenal
doxorubicin [MeSH:C0013089] cardiomyopathy-induced inflammation apoptosis [MeSH:C0162638] attenuate [MeSH:C0042211] gene deletion kinin b1 receptor,use anthracycline [MeSH:C0282564] doxorubicin [MeSH:C0013089] dox limit cardiotoxic effect attribute induction [MeSH:C0042767] [MeSH:C0042767] apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] elucidate possible role kinin b1 receptor [MeSH:C0384601] b1r development dox cardiomyopathy [MeSH:C0878544] [MeSH:C0878544] [MeSH:C0878544] study [MeSH:C0085973] [MeSH:C0085973] b1r knockout mouse [MeSH:C0026809] [MeSH:C0206745] b1r investigate [MeSH:C0035173] cardiac inflammation [MeSH:C0021368] apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] induction [MeSH:C0042767] [MeSH:C0042767] dox-induced cardiomyopathy dox mouse [MeSH:C0026809] show cardiac dysfunction [MeSH:C0031847] measure pressure-volume loop vivo associate [MeSH:C0004083] reduce activation state [MeSH:C4505109] [MeSH:C4505109] akt increase bax [MeSH:C0219474] [MeSH:C0219474] bcl2 [MeSH:C4042483] ratio [MeSH:C0036893] western blot [MeSH:C0949466] indicate cardiac apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] furthermore mrna [MeSH:C0035696] level proinflammatory cytokine interleukin increase cardiac tissue [MeSH:C0040300] dox b1r mouse [MeSH:C0026809] cardiac dysfunction [MeSH:C0031847] improve compare dox mouse [MeSH:C0026809] associate [MeSH:C0004083] normalization bax [MeSH:C0219474] [MeSH:C0219474] bcl- ratio [MeSH:C0036893] interleukin akt activation state [MeSH:C4505109] [MeSH:C4505109] finding suggest b1r detrimental dox cardiomyopathy [MeSH:C0878544] [MeSH:C0878544] [MeSH:C0878544] mediate inflammatory response [MeSH:C0242966] apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] insight useful implication future study [MeSH:C0085973] [MeSH:C0085973] utilize b1r antagonist [MeSH:C0033607] human [MeSH:C0086418] dox cardiomyopathy [MeSH:C0878544] [MeSH:C0878544] [MeSH:C0878544],cardiovascular
hypertension [MeSH:C0020538] myasthenia gravis [MeSH:C0026896] explore neural pathway [MeSH:C0027792],investigate [MeSH:C0035173] beta-blocker effect cancer paralysis method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo longitudinal myelopathy al assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],neurological
neurodegenerative connection [MeSH:C0524851] parkinson disease [MeSH:C0030567],diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve migraine palsy method conduct observational [MeSH:C0302523] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine sciatica [MeSH:C0036396] parameter result positive response practice guideline [MeSH:C0936005],neurological
markedly accelerate catabolism apolipoprotein a-ii [MeSH:C0085202] apoa-ii high density lipoprotein contain apoa-ii classic lecithin cholesterol acyltransferase deficiency fish-eye disease,classic complete lecithin cholesterol acyltransferase lcat deficiency [MeSH:C0023195] [MeSH:C0023195] [MeSH:C0023195] fish-eye disease [MeSH:C0023195] partial lcat deficiency [MeSH:C0023195] [MeSH:C0023195] [MeSH:C0023195] genetic syndrome [MeSH:C0039082] [MeSH:C0039082] associate markedly decrease plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] level [MeSH:C0018759] [MeSH:C0018759] high density lipoprotein hdl [MeSH:C0062709] cholesterol [MeSH:C0023822] increase risk [MeSH:C0035647] [MeSH:C0035647] atherosclerotic [MeSH:C0004153] cardiovascular disease [MeSH:C0007222] investigate [MeSH:C0035173] [MeSH:C0035173] metabolism [MeSH:C0025519] hdl [MeSH:C0062709] apolipoprotein apo apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201]i total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lcat deficiency [MeSH:C0023195] [MeSH:C0023195] [MeSH:C0023195] classic lcat deficiency [MeSH:C0023195] [MeSH:C0023195] [MeSH:C0023195] fish-eye disease plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] level [MeSH:C0018759] [MeSH:C0018759] apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201]i decrease proportionately great extent normal apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] normal addition plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] concentration [MeSH:C0311432] hdl [MeSH:C0062709] particle contain apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201]i lpa-i a-ii low normal particle contain apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] lpa-i normal metabolic [MeSH:C0025517] basis low level [MeSH:C0018759] [MeSH:C0018759] apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201]i lpa-i a-ii investigate [MeSH:C0035173] [MeSH:C0035173] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] exogenous radiotracer endogenous [MeSH:C0205752] stable isotope labeling technique mean plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] residence apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] decrease control day residence apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201]i short control addition catabolism apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] lpa-i a-ii substantially fast apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] lpa-i summary genetic syndrome [MeSH:C0039082] [MeSH:C0039082] complete partial lcat deficiency [MeSH:C0023195] [MeSH:C0023195] [MeSH:C0023195] low level [MeSH:C0018759] [MeSH:C0018759] hdl [MeSH:C0062709] preferential hypercatabolism apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201]i hdl [MeSH:C0062709] particle contain apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201]i lpa-i propose protective lpa-i a-ii atherosclerosis [MeSH:C0004153] selective effect metabolism [MeSH:C0025519] lpa-i a-ii provide potential explanation patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] classic lcat deficiency [MeSH:C0023195] [MeSH:C0023195] [MeSH:C0023195] fish-eye disease increase risk [MeSH:C0035647] [MeSH:C0035647] premature atherosclerosis [MeSH:C0004153] [MeSH:C0004153] despite markedly decrease level [MeSH:C0018759] [MeSH:C0018759] hdl [MeSH:C0062709] cholesterol apoa-i [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201] [MeSH:C0085201],cardiovascular
tachycardia pattern angina pectoris [MeSH:C0002962] patient [MeSH:C0030705],question [MeSH:C0600648] metformin [MeSH:C0025598] affect dementia [MeSH:C0497327] bundle branch block mechanism method [MeSH:C0006384] longitudinal [MeSH:C0023981] elderly patient assess acetylcholine hypertension result improve disease management [MeSH:C0039798] implication cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
nephrotic syndrome [MeSH:C0027726] meet prostate cancer [MeSH:C0376358] neurological perspective,hypothesis [MeSH:C3179072] aspirin improve diabete outcome gallstone pathway method cross-sectional trial [MeSH:C0010362] adult [MeSH:C0001675] population [MeSH:C0032659] measure epinephrine [MeSH:C0014563] kidney stone result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] relevance [MeSH:C2826293],neurological|hepatorenal
cancer cellular colorectal cancer [MeSH:C0009402],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke outcome lymphoma pathway method observational trial [MeSH:C0302523] elderly patient measure chronic lymphocytic leukemia [MeSH:C0023434] skin cancer [MeSH:C0007114] result decrease mortality rate [MeSH:C0205848] healthcare advancement,oncological
-kilodalton protein major product duchenne muscular dystrophy [MeSH:C0026850] gene brain [MeSH:C0006104] nonmuscle tissue [MeSH:C0026845],know duchenne muscular dystrophy dmd gene product [MeSH:C0013264] muscle- brain [MeSH:C0006104]-type dystrophin isoform -kda protein [MeSH:C0033684] translate -kilobase kb mrna [MeSH:C0035696] [MeSH:C0035696] [MeSH:C0035696] recently describe -kb mrna [MeSH:C0035696] [MeSH:C0035696] [MeSH:C0035696] transcribe dmd gene cloning vitro transcription [MeSH:C0040648] translation entire code region [MeSH:C0079941] -kb mrna [MeSH:C0035696] [MeSH:C0035696] [MeSH:C0035696] encode -kda protein [MeSH:C0033684] major product dmd gene contain c-terminal cysteine-rich domain dystrophin seven additional amino acid n [MeSH:C0002520] terminus modification [MeSH:C0086153] form alternative splicing c-terminal domain lack entire large domain spectrin-like repeat actin-binding n-terminal domain dystrophin protein [MeSH:C0033684] major dmd gene product brain [MeSH:C0006104] nonmuscle tissue [MeSH:C0026845] undetectable skeletal muscle extract [MeSH:C0242692],neurological
cardiac response coronary artery disease [MeSH:C1956346],hypothesis statin improve diabete outcome septum pathway method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure coronary artery disease [MeSH:C1956346] bundle branch block [MeSH:C0006384] result positive response safety consideration,cardiovascular
hypertension [MeSH:C0020538] acute kidney injury [MeSH:C2609414] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve hypertension [MeSH:C0020538] outcome renal pathway method cross-sectional trial [MeSH:C0010362] adult [MeSH:C0001675] population measure glomerular filtration rate [MeSH:C0017654] liver transplant [MeSH:C0023911] result improve outcome safety consideration,hepatorenal
ectopic beat breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,retrospective [MeSH:C0035363] examine aspirin [MeSH:C0004057] diabete cardiac patient investigation [MeSH:C0035173] include atherosclerosis [MeSH:C0004153] venous heart method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication safety [MeSH:C0036043] consideration,cardiovascular
dp7 dp1 brain dystrophin isoform related cognitive impairment [MeSH:C0338656] duchenne muscular dystrophy [MeSH:C0013264],molecular neuropsychological [MeSH:C0027902] [MeSH:C0027902] perform concurrently patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] duchenne muscular dystrophy [MeSH:C0013264] dmd [MeSH:C1437024] [MeSH:C1437024] order find molecular explanation cognitive impairment [MeSH:C0338656] [MeSH:C0338656] [MeSH:C0338656] observe dmd [MeSH:C1437024] [MeSH:C1437024] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] complete dystrophin gene [MeSH:C0079259] perform define localization [MeSH:C0037710] deletion duplication [MeSH:C0795871] relation different dmd [MeSH:C1437024] [MeSH:C1437024] promoter qualitative [MeSH:C0949415] dp7 transcript [MeSH:C1136156] [MeSH:C1136156] testing specific exon dp1 carry neuropsychological [MeSH:C0027902] assess verbal visuospatial intelligence verbal memory reading skill comparison molecular psychometric finding demonstrate deletion duplication [MeSH:C0795871] localized distal gene preferentially associate cognitive impairment [MeSH:C0338656] [MeSH:C0338656] [MeSH:C0338656] altered dp7 transcript [MeSH:C1136156] [MeSH:C1136156] delete dp1 dna sequence [MeSH:C0162327] [MeSH:C0162326] find patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe cerebral dysfunction [MeSH:C0031847] finding suggest sequence [MeSH:C0162327] located distal gene particular dmd [MeSH:C1437024] [MeSH:C1437024] isoform express brain [MeSH:C0006104] related cognitive impairment [MeSH:C0338656] [MeSH:C0338656] [MeSH:C0338656] associate dmd [MeSH:C1437024] [MeSH:C1437024],neurological
spectrum [MeSH:C4042936] rb1 [MeSH:C4308074] germ-line mutation [MeSH:C0206530] hereditary retinoblastoma [MeSH:C0751483],search [MeSH:C0035168] germ-line [MeSH:C0017471] rb1 [MeSH:C4308074] [MeSH:C4308074] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hereditary retinoblastoma [MeSH:C0751483] previous investigation [MeSH:C0035173] [MeSH:C0035173] southern blot hybridization pcr fragment-length reveal mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] report remain patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] apply heteroduplex nonisotopic sscp direct sequencing detect germ-line [MeSH:C0017471] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] result premature termination codon [MeSH:C0009221] [MeSH:C0242612] disruption [MeSH:C3179075] splice signal patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show rare sequence variant region rb1 [MeSH:C4308074] [MeSH:C4308074] gene preferentially involve single base substitution recurrent transition observe codon [MeSH:C0009221] rb1 [MeSH:C4308074] [MeSH:C4308074] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] observe exon region [MeSH:C0015295] contain cga codon [MeSH:C0009221] suggest mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] -terminal region rb1 [MeSH:C4308074] [MeSH:C4308074] gene oncogenic [MeSH:C0029016] combine result previous investigation [MeSH:C0035173] [MeSH:C0035173] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] spectrum comprise large deletion small length alteration base substitution correlation [MeSH:C0010100] location frameshift nonsense mutation [MeSH:C0544885] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] phenotypic [MeSH:C1837514] feature include age diagnosis [MeSH:C0011900] number tumor focus manifestation [MeSH:C0029166] nonocular tumor observe,oncological
complete [MeSH:C0011455] atrioventricular block secondary lithium therapy [MeSH:C0004245],sinus node dysfunction [MeSH:C0428908] report frequently adverse cardiovascular effect [MeSH:C0596270] lithium [MeSH:C0023870] [MeSH:C0023870] present case complete atrioventricular av block syncopal attack [MeSH:C0004245] develop secondary lithium [MeSH:C0023870] [MeSH:C0023870] therapy necessitate permanent [MeSH:C0348070] pacemaker implantation serum lithium [MeSH:C0023870] [MeSH:C0023870] level remain therapeutic range [MeSH:C0087111] syncopal attack lithium [MeSH:C0023870] [MeSH:C0023870] extreme caution especially patient mild disturbance av conduction [MeSH:C0005935],cardiovascular
atrioventricular block pathway [MeSH:C0004245] atrial fibrillation [MeSH:C0004238],heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve locus coeruleus encephalitis method [MeSH:C0023951] conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine acoustic neuroma [MeSH:C0027859] parameter result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
renal pathway [MeSH:C0282655] breast cancer [MeSH:C0006142],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] stroke [MeSH:C0038454] participant [MeSH:C1708335] cancer patient end stage renal disease glomerular filtration rate [MeSH:C0017654] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] alt correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,hepatorenal
morphological effect d-ribose [MeSH:C0035549] adriamycin-evoked cardiotoxicity [MeSH:C0876994] rat [MeSH:C0034721],influence [MeSH:C0683549] d-ribose [MeSH:C0035549] [MeSH:C0035549] adriamycin [MeSH:C0085752]-induced myocardiopathy rat [MeSH:C0034721] study adriamycin [MeSH:C0085752] cumulative dose mg kg evoke fully develop cardiac [MeSH:C0018810] toxicity [MeSH:C0040539] d-ribose [MeSH:C0035549] [MeSH:C0035549] multiple dose mg kg influence [MeSH:C0683549] adr cardiotoxicity [MeSH:C0876994] [MeSH:C0040539],cardiovascular
insufficiency breast cancer [MeSH:C1565489] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] ace inhibitor affect diabete artery [MeSH:C0003842] mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assess cardiac chf result positive response implication therapeutic [MeSH:C0087111] innovation,cardiovascular
normal huntington disease [MeSH:C0020179] hd allele closely link gene [MeSH:C0017337] influence age [MeSH:C0024842] onset hd,evaluate [MeSH:C0013175] hypothesis huntington disease [MeSH:C0020179] hd influence [MeSH:C0683549] normal hd allele [MeSH:C0002085] [MeSH:C0002085] compare transmission pattern [MeSH:C0040722] genetically link marker [MeSH:C0017393] d4s1 locus [MeSH:C0085286] normal parent [MeSH:C0030551] age [MeSH:C0024842] onset affect offspring [MeSH:C0683572] information [MeSH:C5544371] sibship kindred show tendency sib similar onset age [MeSH:C0024842] share d4s1 allele normal [MeSH:C0002085] parent [MeSH:C0030551] affect sib inherit different d4s1 allele normal [MeSH:C0002085] parent [MeSH:C0030551] tend variable [MeSH:C0013675] age [MeSH:C0024842] onset finding suggest expression [MeSH:C0017262] hd modulate normal hd allele [MeSH:C0002085] [MeSH:C0002085] closely link locus [MeSH:C0085286],neurological
severe [MeSH:C1719672] long lasting cholestasis [MeSH:C0008370] high-dose co-trimoxazole pneumocystis [MeSH:C0041044] pneumonia [MeSH:C0032285] hiv-infected patient report [MeSH:C0684224] case,pneumocystis pneumonia pcp [MeSH:C1535939] common opportunistic infection [MeSH:C0029118] hiv-infected individual [MeSH:C0021228] generally treat high dose co-trimoxazole [MeSH:C0041044] limit adverse effect [MeSH:C0001688] report case severely immunocompromise [MeSH:C0085393] hiv-infected patient develop severe intrahepatic cholestasis [MeSH:C0008372] lesion mimic liver abscess [MeSH:C0023885] formation radiologic exam co-trimoxazole [MeSH:C0041044] pcp show lesion cm readily detectable magnetic resonance imaging [MeSH:C0024485] prolonged co-trimoxazole [MeSH:C0041044] therapy switch [MeSH:C0017373] early,neurological|hepatorenal
myocardium [MeSH:C0027061] atrial fibrillation [MeSH:C0004238] vascular insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer thromboembolism mechanism method [MeSH:C0040038] longitudinal diabetic [MeSH:C0023981] patient [MeSH:C0030705] assess endothelium ventricle [MeSH:C0014257] result enhance therapeutic response [MeSH:C0087111] implication practice guideline,cardiovascular
prolapse hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome [MeSH:C0206277] coronary artery disease pathway [MeSH:C1956346] method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient measure defibrillator tricuspid valve [MeSH:C0040960] result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
initial potassium loss [MeSH:C0032821] hypokalaemia [MeSH:C0020621] chlorthalidone [MeSH:C0008294] administration [MeSH:C0001554] patient [MeSH:C0030705] essential hypertension influence [MeSH:C0683549] dietary [MeSH:C0012177] sodium restriction,investigate [MeSH:C0035173] initial potassium loss [MeSH:C0032821] development hypokalaemia [MeSH:C0020621] [MeSH:C0020621] administration [MeSH:C0001554] oral [MeSH:C0029170] [MeSH:C0029170] diuretic metabolic balance study perform patient [MeSH:C0030705] essential hypertension [MeSH:C0085580] show hypokalaemia [MeSH:C0020621] [MeSH:C0020621] prior oral [MeSH:C0029170] [MeSH:C0029170] diuretic chlorthalidone [MeSH:C0008294] mg daily give day [MeSH:C0011017] patient [MeSH:C0030705] receive normal-sodium diet [MeSH:C0012155] low-sodium [MeSH:C0012169] mmol [MeSH:C0012169] diet [MeSH:C0012155] patient [MeSH:C0030705] normal initial total body potassium 0k electrolyte balance weight bromide space plasma renin [MeSH:C0035094] activity [MeSH:C0020115] [MeSH:C0020115] aldosterone [MeSH:C0002006] secretion [MeSH:C0002006] rate measure group potassium deficit [MeSH:C0032827] develop proportionally large loss extracellular [MeSH:C3850090] intracellular [MeSH:C0682581] compartment [MeSH:C0009492] normal-sodium high mean potassium deficit [MeSH:C0032827] mmol potassium regain [MeSH:C0032821] low-sodium [MeSH:C0012169] high deficit mmol normal-sodium show immediate temporary [MeSH:C0011414] rise renin [MeSH:C0035094] aldosterone [MeSH:C0002006] level low-sodium [MeSH:C0012169] renin [MeSH:C0035094] aldosterone [MeSH:C0002006] increase slowly remain elevated [MeSH:C0020443] conclude diet [MeSH:C0012155]ary sodium restriction increase diuretic-induced potassium loss [MeSH:C0032821] presumably increase activity [MeSH:C0020115] [MeSH:C0020115] renin [MeSH:C0035094]-angiotensin-aldosterone [MeSH:C0002006] system sodium delivery distal renal tubule [MeSH:C0022676] remain sufficiently high allow increase potassium secretion [MeSH:C0036536],cardiovascular|hepatorenal
ectopic beat marker multiple sclerosis [MeSH:C0026769],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] cardiomyopathy mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess atrioventricular block coronary artery disease [MeSH:C0004245] result favorable safety profile implication care improvement,cardiovascular
sorafenib-induced acute myocardial infarction coronary artery spasm,-year-old man advanced renal cell carcinoma [MeSH:C0007134] admit continue chest pain [MeSH:C0008031] rest week admission [MeSH:C0030673] sorafenib [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] start diagnose [MeSH:C0011900] non-st-elevation myocardial infarction [MeSH:C4255010] laboratory electrocardiogram [MeSH:C0013798] enhance heart magnetic resonance imaging [MeSH:C0024485] show subendocardial infarction stenosis coronary artery angiography [MeSH:C0085532] coronary artery spasm [MeSH:C0010073] [MeSH:C0010073] [MeSH:C0010073] induce provocative test [MeSH:C0027431] cessation sorafenib [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] administration [MeSH:C0001554] ca-channel blocker [MeSH:C0242702] nitrate [MeSH:C0028125] ameliorate symptom [MeSH:C3839861] relapse occur resumption [MeSH:C0009830] sorafenib [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] addition oral [MeSH:C0029170] nicorandil [MeSH:C0068700] reduce symptom [MeSH:C3839861] maintain stable [MeSH:C1706074] angina status report case sorafenib [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119]-induced coronary artery spasm [MeSH:C0010073] [MeSH:C0010073] [MeSH:C0010073] sorafenib [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] multikinase inhibitor [MeSH:C0003015] target signaling pathway [MeSH:C1520113] necessary cellular proliferation survival hand rho rock pathway [MeSH:C0282655] [MeSH:C0282655] important role pathogenesis [MeSH:C0699748] coronary artery spasm [MeSH:C0010073] [MeSH:C0010073] [MeSH:C0010073] report adverse effect [MeSH:C0001688] rho rock pathway [MeSH:C0282655] [MeSH:C0282655] sorafenib [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] [MeSH:C1516119] use,neurological|cardiovascular|hepatorenal|oncological
hypertension [MeSH:C0020538] pkd organ [MeSH:C0029250] interplay,question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer glomerulonephritis [MeSH:C0017658] mechanism method randomized control diabetic patient [MeSH:C0030705] assess acute kidney injury [MeSH:C2609414] nephroblastoma [MeSH:C0027708] result positive response implication relevance,hepatorenal
piebaldism [MeSH:C0080024] deafness [MeSH:C0011053] molecular evidence expand syndrome [MeSH:C0039082],south african [MeSH:C0037712] girl [MeSH:C0043210] xhosa stock severe piebaldism [MeSH:C0080024] profound congenital sensorineural deafness [MeSH:C0018784] [MeSH:C1857572] identify novel missense [MeSH:C0599155] substitution [MeSH:C2936279] highly conserve residue intracellular kinase domain kit proto-oncogene r76 g auditory anomaly observe mouse dominant [MeSH:C0017342] white spot w kit mutation [MeSH:C0026882] deafness typical human [MeSH:C0086418] piebaldism [MeSH:C0080024] [MeSH:C0080024] occurrence [MeSH:C0243132] sensorineural deafness [MeSH:C0018784] extend considerably phenotypic [MeSH:C1837514] range piebaldism [MeSH:C0080024] kit gene mutation [MeSH:C0026882] human [MeSH:C0086418] tighten similarity piebaldism [MeSH:C0080024] form waardenburg syndrome,neurological|oncological
intelligence quotient profile myotonic dystrophy [MeSH:C0027126] intergenerational [MeSH:C0085419] deficit correlation ctg amplification,abbreviated wechsler adult [MeSH:C0043089] intelligence scale [MeSH:C0021704] revise wais-r assess verbal arithmetical cognitive performance subject [MeSH:C0080105] myotonic dystrophy dm cover [MeSH:C0027126] grade disease severity control risk [MeSH:C0035647] inherit dm scale score assessment [MeSH:C0030198] convert intelligence quotient iq estimation person [MeSH:C0027361] iq difference find dm subject [MeSH:C0080105] mean sd control sd sex difference affect parent [MeSH:C0030551] sd affect child [MeSH:C0008059] sd significance [MeSH:C2826293] dependent parent [MeSH:C0030551]al sex female pair [MeSH:C0086287] affect sib sd normal sib sd iq steadily decline age [MeSH:C0024842] onset sign symptom decrease ctg expansion [MeSH:C0196940] size increase correlation [MeSH:C0010100] [MeSH:C0010100] appear linear age [MeSH:C0024842] onset correlation [MeSH:C0010100] [MeSH:C0010100] iq difference ctg expansion [MeSH:C0196940] difference dm parent [MeSH:C0030551]-child [MeSH:C0008059] pair normal sib-affected sib pair poor indicate ctg expansion [MeSH:C0196940] reliable predictor iq individual person [MeSH:C0027361] family cognitive function [MeSH:C0009240] dm require clarify specific deficit [MeSH:C0233794] characteristic,neurological
phenotypic [MeSH:C1837514] characterization individual cag repeat huntington disease [MeSH:C0020179] hd gene reveal hd case repeat apparently normal elderly [MeSH:C0001792] individual repeat,abnormal [MeSH:C0853087] cag expansion it- gene associate huntington disease [MeSH:C0020179] hd [MeSH:C0252274] diagnostic setting [MeSH:C0525034] necessary define limit cag size range normal [MeSH:C0086715] hd [MeSH:C0252274]-associate chromosome large analysis define limit normal pathological size range employ pcr assay [MeSH:C0032520] include cag repeat ccg repeat tract think invariant experiment [MeSH:C0020123] find overlap normal disease size range subsequent finding ccg repeat vary trinucleotide [MeSH:C0028630] length suggest limit normal disease size range reevaluate assay exclude ccg polymorphism [MeSH:C0032529] [MeSH:C0032529] patient [MeSH:C0030705] [MeSH:C0030705] repeat rare consortium assemble collect individual sample reanalyze cambridge assay specific cag repeat optimize method [MeSH:C0025663] reliable sizing cag repeat case demonstrate danger pcr assay [MeSH:C0032520] include cag ccg polymorphism [MeSH:C0032529] [MeSH:C0032529] seven hd [MeSH:C0252274] patient [MeSH:C0030705] [MeSH:C0030705] repeat confirm allele associate disease individual apparent symptom sign hd [MeSH:C0252274] find repeat aged year repeat aged year repeat aged year repeat aged year detailed case history [MeSH:C0019664] exceptional case series present -year-old man repeat classical feature hd [MeSH:C0252274] apparently healthy [MeSH:C0452415] survival old age individual repeat suggest hd [MeSH:C0252274] mutation fully penetrant,neurological
epilepsy [MeSH:C0014544] endothelial [MeSH:C0225336] cardiac connection,heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve diastolic [MeSH:C0012000] myeloproliferative neoplasm method conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine restrictive cardiomyopathy [MeSH:C0007196] parameter result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
hypertensive cancer [MeSH:C0003364] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] cross-sectional investigation ace inhibitor [MeSH:C0003015] dementia [MeSH:C0497327] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] restrictive cardiomyopathy transient ischemic attack result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] thrombosis [MeSH:C0040053] correlation practice guideline [MeSH:C0282423],cardiovascular
tumor [MeSH:C0027651] tale dementia [MeSH:C0497327] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] ovarian cancer [MeSH:C1140680] pathway method retrospective trial cancer patient [MeSH:C0030705] measure chronic myeloid leukemia [MeSH:C0279543] melanoma [MeSH:C0025202] result improvement [MeSH:C2936612] primary endpoint care improvement [MeSH:C2936612],oncological
carcinogenesis pathway [MeSH:C0596263] colorectal cancer [MeSH:C0009402],design [MeSH:C0013171] observational [MeSH:C0302523] investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] cancer patient gallbladder [MeSH:C0016976] hepatic [MeSH:C0227525] result well quality life measure pkd correlation safety [MeSH:C0036043] consideration,hepatorenal|oncological
hypertension [MeSH:C0020538] dopamine [MeSH:C0013030] explore neural pathway [MeSH:C0027792],design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient stroke [MeSH:C0038454] migraine [MeSH:C0149931] result improvement [MeSH:C2936612] primary endpoint meningioma [MeSH:C0025286] correlation [MeSH:C0010100] relevance [MeSH:C2826293],neurological|cardiovascular
systolic heart failure [MeSH:C1135191] vascular [MeSH:C0221214] insight,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] aspirin [MeSH:C0004057] stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient [MeSH:C0030705] focus endocardium blood pressure aspect [MeSH:C0005823] disease total participant enrol retrospective [MeSH:C0035363] result demonstrate reduction [MeSH:C1827449] adverse event [MeSH:C0041755] particular attention thrombosis [MeSH:C0040053] finding suggest optimization [MeSH:C0376695],cardiovascular
high-dose tranexamic acid [MeSH:C0040613] associate nonischemic seizure [MeSH:C0036572] cardiac surgical [MeSH:C0018821] patient,separate center observe notable increase incidence [MeSH:C0021149] postoperative [MeSH:C0032786] convulsive seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0751494] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo major cardiac [MeSH:C0018810] surgical procedure event temporally coincident initial use high-dose tranexamic acid [MeSH:C0040613] txa therapy withdrawal [MeSH:C1881606] aprotinin [MeSH:C0003641] general usage review perform retrospective [MeSH:C0035363] examine relation txa usage seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] cardiac [MeSH:C0018810] surgery method in-depth chart review [MeSH:C0282443] undertake patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop perioperative [MeSH:C2712230] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] electroencephalographic activity [MeSH:C0013819] record patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] formal neurological brain imaging study result twenty-one patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] evidence [MeSH:C5575834] new cerebral ischemic [MeSH:C0022116] injury [MeSH:C0917798] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] likely ischemic [MeSH:C0022116] brain injury [MeSH:C0270611] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] permanent [MeSH:C0348070] neurological abnormality patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] receive high dose txa intraoperatively [MeSH:C0021889] range mg kg mean age year undergo open chamber coronary bypass procedure manage cardiopulmonary bypass [MeSH:C0007202] [MeSH:C0007202] evidence [MeSH:C5575834] brain ischemic [MeSH:C0007786] [MeSH:C0022116] metabolic [MeSH:C0025517] hyperthermia-induced cause seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] apparent result suggest use high-dose txa old patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] conjunction cardiopulmonary bypass [MeSH:C0007202] [MeSH:C0007202] open-chamber cardiac [MeSH:C0018810] surgery associate seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] susceptible patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],neurological|cardiovascular
bell palsy [MeSH:C0376175] connection stroke [MeSH:C0038454],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] hypertension [MeSH:C0020538] radiculopathy method [MeSH:C0700594] elderly patient undergo retrospective [MeSH:C0035363] pituitary adenoma [MeSH:C0032000] huntington disease [MeSH:C0020179] assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint optimization [MeSH:C0376695],neurological
mri [MeSH:C0282596] reveal atrial fibrillation [MeSH:C0004238] secret,design [MeSH:C0013171] longitudinal investigation statin diabete participant [MeSH:C1708335] cancer patient [MeSH:C0030705] hypothalamus peripheral neuropathy [MeSH:C4721453] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] glutamate correlation care improvement [MeSH:C2936612],neurological|hepatorenal
parkinsonism [MeSH:C0242422] meet lymphoma [MeSH:C0024299] neurological perspective,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome cerebral pathway method observational trial [MeSH:C0302523] elderly patient measure neurofibroma myasthenia gravis [MeSH:C0026896] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] relevance [MeSH:C2826293],neurological
association [MeSH:C0004083] use benzodiazepine [MeSH:C4048284] related drug health physical ability cognitive function [MeSH:C0009240] non-randomised elderly [MeSH:C0001792],describe association [MeSH:C0004083] use benzodiazepine [MeSH:C4048284] related drug bzds rds health functional ability cognitive function [MeSH:C0009240] [MeSH:C0009240] elderly method [MeSH:C0001792] non-randomised patient aged year admit acute hospital ward patient mean [MeSH:C0030705] age standard deviation sd year admit nearly half n bzds rds admission [MeSH:C0030673] [MeSH:C0030673] [MeSH:C0030673] remainder n non-user cognitive ability assess mini-mental state examination mmse [MeSH:C1309784] [MeSH:C0451306] patient score [MeSH:C0030705] mmse [MeSH:C1309784] sum point interview [MeSH:C0935630] n question symptom [MeSH:C3839861] functional ability week prior admission [MeSH:C0030673] [MeSH:C0030673] [MeSH:C0030673] use bzds rds admission [MeSH:C0030673] [MeSH:C0030673] [MeSH:C0030673] current medication discharge diagnosis [MeSH:C0011900] collect medical record [MeSH:C0025102] health physical ability cognitive function [MeSH:C0009240] [MeSH:C0009240] compare bzd rd user non-user adjustment [MeSH:C0376209] confound variable residual serum [MeSH:C0229671] concentration oxazepam temazepam [MeSH:C0039468] [MeSH:C0039468] zopiclone [MeSH:C0078847] analyse result mean sd duration bzd rd use year range bzds rds concomitant [MeSH:C0152203]ly take user n long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] use drug [MeSH:C0338666] associate [MeSH:C0004083] female sex [MeSH:C0086287] use high number drug effect [MeSH:C0041755] cns tend related diagnose [MeSH:C0011900] dementia [MeSH:C0497327] adjustment [MeSH:C0376209] variable confounder use bzds rds associate [MeSH:C0004083] cognitive function [MeSH:C0009240] [MeSH:C0009240] measure mmse [MeSH:C1309784] use bzds rds associate [MeSH:C0004083] dizziness inability sleep awake night tiredness morning week prior admission [MeSH:C0030673] [MeSH:C0030673] [MeSH:C0030673] strong depressive symptom [MeSH:C3839861] measure beginning hospital stay [MeSH:C3489408] use bzds rds tend associate [MeSH:C0004083] reduce ability walk [MeSH:C0085732] short night-time sleep week prior admission [MeSH:C0030673] [MeSH:C0030673] [MeSH:C0030673] high residual serum [MeSH:C0229671] concentration temazepam [MeSH:C0039468] [MeSH:C0039468] correlate low mmse [MeSH:C1309784] sum score adjustment [MeSH:C0376209] confound variable conclusion long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] use concomitant [MeSH:C0152203] use bzd rd common elderly patient hospitalise acute illness [MeSH:C0162698] long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] use associate [MeSH:C0004083] daytime night-time symptom [MeSH:C3839861] indicative poor health potentially cause adverse effect [MeSH:C0001688] drug,neurological
organ [MeSH:C0029250] orchestra parkinson disease,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] hematuria [MeSH:C0018965] method cancer patient [MeSH:C0030705] undergo randomized control cirrhosis glomerulonephritis assessment [MeSH:C0030198] result well quality life measure cost-effect [MeSH:C4277511]iveness implication,hepatorenal
coexistence cerebral venous sinus [MeSH:C0229108] internal carotid artery thrombosis [MeSH:C0750990] associate exogenous sex hormone [MeSH:C0036884] case report [MeSH:C0684224],forty-six year-old premenopausal [MeSH:C0206158] woman [MeSH:C0043210] develop headache nausea vomiting leave hemiparesis seizure [MeSH:C0036572] day [MeSH:C0011017] parenteral [MeSH:C0030548] use progesterone [MeSH:C0033308] estradiol diabetes mellitus dm find admission computed tomography [MeSH:C0040398] show hemorrhagic infarct right frontal lobe increase density superior sagittal sinus sss leave carotid angiography [MeSH:C0002978] find occlusion left internal carotid artery ica right carotid angiogram fail sss inferior sagittal sinus [MeSH:C0226859] suggestive venous sinus [MeSH:C0229108] thrombosis [MeSH:C0042487] coexistence cerebral artery [MeSH:C0007770] venous sinus [MeSH:C0229108] occlusion describe infrequently case author postulate use estradiol progesterone [MeSH:C0033308] [MeSH:C0033308] underlie dm increase vascular thrombogenicity provide common denominator thrombosis [MeSH:C0040053] ica venous sinus [MeSH:C0229108],neurological|cardiovascular
cdna microarray [MeSH:C0887808] detect activation [MeSH:C4505109] myogenic transcription program pax3-fkhr fusion oncogene [MeSH:C1564391],alveolar rhabdomyosarcoma [MeSH:C0206655] aggressive [MeSH:C4704756] pediatric cancer striated muscle [MeSH:C1331262] characterize case q3 q1 result fusion [MeSH:C0178648] pax3 developmental [MeSH:C0017340] transcription factor require limb myogenesis fkhr member forkhead family transcription factor resultant [MeSH:C0118111] pax3-fkhr gene possess transforming property effect chimeric [MeSH:C0067895] oncogene gene [MeSH:C0029016] expression [MeSH:C0017262] largely unknown investigate [MeSH:C0035173] action transcription factor pax3 [MeSH:C4277594] pax3-fkhr introduce nih 3t3 cell [MeSH:C1257739] resultant gene expression [MeSH:C0017262] [MeSH:C0017262] change analyze murine [MeSH:C0026802] cdna microarray [MeSH:C0887808] [MeSH:C0887808] contain element [MeSH:C0013879] find pax3-fkhr pax3 activate myogenic transcription program include induction transcription factor myod [MeSH:C0040648] myogenin [MeSH:C0067053] six1 slug battery gene involve aspect [MeSH:C0022433] muscle function [MeSH:C0031843] notable growth factor gene [MeSH:C0018284] igf2 [MeSH:C1569730] bind protein igfbp5 [MeSH:C4082568] [MeSH:C4082568] relevance model suggest verification gene [MeSH:C0680442] igfbp5 [MeSH:C4082568] hsix1 slug express alveolar rhabdomyosarcoma [MeSH:C0206655] cell line utilize cdna microarray [MeSH:C0887808] [MeSH:C0887808] elucidate pattern gene expression [MeSH:C0017262] [MeSH:C0017262] induce oncogenic transcription factor [MeSH:C0040648] demonstrate profound myogenic property pax3-fkhr nih 3t3 cell [MeSH:C1257739],oncological
nitrate cardiomyopathy [MeSH:C0878544] brain [MeSH:C0006104] insight,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect heart disease [MeSH:C0018799] gray matter [MeSH:C0018220] mechanism method prospective elderly patient assess parkinson disease [MeSH:C0030567] arrhythmia [MeSH:C0003811] result improve outcome [MeSH:C0206277] implication practice guideline,neurological|cardiovascular
salicylate nephropathy gunn rat [MeSH:C0034696] potential role prostaglandin [MeSH:C0033554],examine potential role prostaglandin [MeSH:C0033554] development [MeSH:C0243107] analgesic nephropathy gunn strain rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] homozygous [MeSH:C0019904] [MeSH:C0019904] gunn rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034696] [MeSH:C0034721] unconjugated hyperbilirubin [MeSH:C0005437]emia [MeSH:C0010324] absence [MeSH:C0270823] glucuronyl transferase [MeSH:C0041560] lead marked bilirubin [MeSH:C0005437] deposition renal [MeSH:C0152169] medulla [MeSH:C0001629] papilla rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] highly susceptible develop papillary necrosis [MeSH:C0022667] analgesic administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion homozygous [MeSH:C0019904] [MeSH:C0019904] jj phenotypically normal heterozygous [MeSH:C0019425] jj animal group [MeSH:C0018257] [MeSH:C1318101] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] n study [MeSH:C0085973] jj jj rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] mg kg sham-treated week slice cortex outer inner medulla kidney incubate buffer [MeSH:C0006353] prostaglandin [MeSH:C0033554] synthesis [MeSH:C3178925] determine radioimmunoassay kidney [MeSH:C0034580] examine histologically marked corticomedullary gradient [MeSH:C1138565] prostaglandin [MeSH:C0033554] synthesis [MeSH:C3178925] observe group [MeSH:C0018257] pge2 [MeSH:C0012472] [MeSH:C0012472] [MeSH:C0012472] synthesis [MeSH:C3178925] significantly high outer medulla cortex inner medulla jj ng mg prot jj rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] p aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] reduce pge2 [MeSH:C0012472] [MeSH:C0012472] [MeSH:C0012472] synthesis [MeSH:C3178925] region outer medullary pge2 [MeSH:C0012472] [MeSH:C0012472] [MeSH:C0012472] remain high jj jj rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] p pgf2 [MeSH:C0012471] alpha significantly high outer medulla jj rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion p change renal [MeSH:C0152169] prostaglandin [MeSH:C0033554] synthesis [MeSH:C3178925] accompany evidence [MeSH:C5575834] renal [MeSH:C0152169] damage aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057]-treated jj jj rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] evidence [MeSH:C5575834] increase incidence [MeSH:C0021149] severity hematuria p increase serum creatinine p [MeSH:C0010294] increase outer medullary histopathologic lesion p compare sham-treated jj aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057]-treated jj result suggest enhance prostaglandin [MeSH:C0033554] synthesis [MeSH:C3178925] contribute maintenance [MeSH:C0024501] renal [MeSH:C0152169] function morphological integrity [MeSH:C0021701] inhibition [MeSH:C0027790] prostaglandin [MeSH:C0033554] synthesis [MeSH:C3178925] lead pathological [MeSH:C0030660] renal [MeSH:C0152169] medulla [MeSH:C0001629]ry lesion deteriorat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion renal [MeSH:C0152169] function,hepatorenal
primary [MeSH:C0033137] biliary cholangitis [MeSH:C0008312] pathway [MeSH:C0282655] liver cirrhosis [MeSH:C0023890],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect diabete renal cell carcinoma method cancer [MeSH:C0007134] patient [MeSH:C0030705] undergo retrospective [MeSH:C0035363] liver fibrosis [MeSH:C0239946] hemodialysis [MeSH:C0019004] assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint therapeutic innovation [MeSH:C0087111],hepatorenal
genetic linkage map [MeSH:C0023745] polymorphic [MeSH:C1720758] dna marker [MeSH:C0012872] gene familial adenomatous polyposis chromosome [MeSH:C0032580],genetic linkage [MeSH:C0242239] map [MeSH:C0024779] [MeSH:C0023745] polymorphic dna marker close gene apc [MeSH:C0162832] familial adenomatous polyposis fap [MeSH:C1622401] [MeSH:C1622401] chromosome 5q report fifty-five type member fap [MeSH:C1622401] [MeSH:C1622401] kindred provide meiosis [MeSH:C0025186] linkage [MeSH:C0242239] number crucial recombination [MeSH:C0034865] event identify informative locus [MeSH:C0085286] allow confident ordering part map [MeSH:C0024779] evidence genetic heterogeneity [MeSH:C0242960] family show linkage [MeSH:C0242239] chromosome marker gene recombination [MeSH:C0034865] [MeSH:C0034865] two-point linkage [MeSH:C0242239] support locus [MeSH:C0085286] order centromere-pi -c11p1-ecb2-l5 -apc-ef5 -apc-ef5 -yn5 -yn5 -telomer e ef5 lie interval l5 -apc ecb2-l5 recombinant [MeSH:C0034861] identify apc ef5 yn5 publish deletion map [MeSH:C0024779]ping colorectal carcinoma [MeSH:C0009402] linkage [MeSH:C0242239] fap [MeSH:C1622401] [MeSH:C1622401] suggest yn5 cm apc present suggest yn5 l5 delineate small region chromosome ef5 locus [MeSH:C0085286] lie close apc gene [MeSH:C0162832] allow use flanking marker presymptomatic diagnosis fap [MeSH:C1622401] [MeSH:C1622401] provide high-density map [MeSH:C0024779] region isolation [MeSH:C0220862] apc gene [MeSH:C0162832] assessment role chromosome deletion biology sporadic colorectal cancer [MeSH:C0009402],oncological
prospective long-term [MeSH:C0023977] effect somatostatin analog [MeSH:C0037659] octreotide gallbladder function [MeSH:C0016976] gallstone formation chinese acromegalic [MeSH:C0001206] patient [MeSH:C0030705],article report change gallbladder [MeSH:C0016976] [MeSH:C0016976] [MeSH:C0016976] function [MeSH:C0016976] examine ultrasonography chinese [MeSH:C0041618] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] active acromegaly [MeSH:C0001206] treat sc injection [MeSH:C1828121] somatostatin analog octreotide [MeSH:C0028833] [MeSH:C0028833] dosage [MeSH:C0028833] microgram [MeSH:C0376691] mean month octreotide [MeSH:C0028833] [MeSH:C0028833] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop sludge [MeSH:C0282346] gallstone [MeSH:C0242216] develop acute cholecystitis [MeSH:C0149520] require surgery [MeSH:C0038895] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] examine acutely gallbladder [MeSH:C0016976] [MeSH:C0016976] [MeSH:C0016976] contractility inhibit [MeSH:C0021463] single [MeSH:C0037177] -microgram [MeSH:C0376691] injection [MeSH:C1828121] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] follow week gallbladder [MeSH:C0016976] [MeSH:C0016976] [MeSH:C0016976] contractility remain depressed therapy withdrawal octreotide [MeSH:C0028833] [MeSH:C0028833] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] gallstone [MeSH:C0242216] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] assess return normal gallbladder [MeSH:C0016976] [MeSH:C0016976] [MeSH:C0016976] contractility remain patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop gallstone [MeSH:C0242216] gallbladder [MeSH:C0016976] [MeSH:C0016976] [MeSH:C0016976] contractility normalize patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] disappearance stone week remain depressed stone present month result suggest suppression [MeSH:C1956351] gallbladder [MeSH:C0016976] [MeSH:C0016976] [MeSH:C0016976] contractility cause successive formation bile [MeSH:C0005388] sludge [MeSH:C0282346] gallstone [MeSH:C0242216] cholecystitis octreotide [MeSH:C0028833] [MeSH:C0028833] therapy chinese acromegalic [MeSH:C0001206] [MeSH:C0001206] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] important change gallbladder [MeSH:C0016976] [MeSH:C0016976] [MeSH:C0016976] function [MeSH:C0016976] long-term [MeSH:C0023977] octreotide [MeSH:C0028833] [MeSH:C0028833] therapy acromegalic [MeSH:C0001206] [MeSH:C0001206] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],neurological
cardiotoxic [MeSH:C1956032] possible leukemogenic effect adriamycin [MeSH:C0085752] nonhuman primate,monkey macaque receive adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] monthly intravenous injection [MeSH:C0021494] mg m2 mg kg monkey develop congestive heart failure [MeSH:C0018802] average cumulative adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] dose mg m2 consider safe upper limit mg m2 man histologically myocardial [MeSH:C0027061] lesion resemble find human [MeSH:C0086418] anthracycline-induced cardiomyopathy monkey develop acute myeloblastic leukemia [MeSH:C0023467] receive mg m2 adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] 0th monkey alive month dose drug [MeSH:C0013227] result suggest adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] potent cardiotoxin monkey man leukemia [MeSH:C0023418] consequence prolonged drug [MeSH:C0013227],cardiovascular|oncological
breakthrough hepatoma [MeSH:C2239176] finding prostate cancer [MeSH:C0376358],stroke [MeSH:C0038454] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve aki bilirubin method [MeSH:C0005437] conduct randomized control evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine hepatocellular [MeSH:C0345904] parameter result improve outcome [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
brca1 [MeSH:C0259275] interact component histone deacetylase complex [MeSH:C0960947],germ-line mutation [MeSH:C0206530] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] tumor-suppressor gene [MeSH:C0079427] associate increase susceptibility [MeSH:C0012655] breast ovarian cancer [MeSH:C1140680] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] contain carboxyl-terminal domain brct share protein [MeSH:C0033684] [MeSH:C0033684] involve maintain genome [MeSH:C0017428] integrity [MeSH:C0021701] effort understand function [MeSH:C0031843] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] seek isolate protein [MeSH:C0033684] [MeSH:C0033684] interact brct domain purify brct polypeptide probe screen human [MeSH:C0086418] placenta [MeSH:C0032043] cdna [MeSH:C0006556] expression library far western report brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] interact vivo vitro rb-binde protein [MeSH:C0033684] [MeSH:C0033684] rbap4 rbap4 rb brct domain associate histone deacetylase hdac1 hdac2 [MeSH:C0768528] result demonstrate brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] interact component histone deacetylase complex [MeSH:C0960947] explain involvement brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] multiple process transcription dna repair recombination [MeSH:C1158513],oncological
mind matter parkinson disease [MeSH:C0030567] neurotransmitter [MeSH:C0027908],prospective examine metformin [MeSH:C0025598] dementia [MeSH:C0497327] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include tic ataxia amyotrophic lateral sclerosis method [MeSH:C0002736] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication relevance,neurological
reticular formation [MeSH:C0035284] meet ventricular tachycardia [MeSH:C0042514] neurological perspective,investigate [MeSH:C0035173] beta-blocker effect heart disease encephalitis method [MeSH:C0014038] elderly patient undergo prospective stroke schwannoma assessment [MeSH:C0030198] result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],neurological
restriction ocular fundus lesion specific subgroup apc mutation [MeSH:C0026882] adenomatous polyposis coli [MeSH:C0032580] patient [MeSH:C0030705],human [MeSH:C0086418] alteration tumor suppressor gene apc [MeSH:C0079427] cause adenomatous polyposis coli [MeSH:C0032580] condition cause predisposition colorectal cancer syndrome inconsistently associate characteristic patch [MeSH:C0030646] congenital hypertrophy [MeSH:C0020564] retinal pigment epithelium [MeSH:C0035322] chrpe ocular examination reveal patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] express chrpe tend cluster [MeSH:C0055966] specific family exact apc mutation [MeSH:C0026882] [MeSH:C0026882] identify unrelated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] case mutation [MeSH:C0026882] [MeSH:C0026882] predict lead synthesis truncate protein extent chrpe find dependent [MeSH:C0101555] position mutation [MeSH:C0026882] code sequence chrpe lesion absent mutation [MeSH:C0026882] occur exon [MeSH:C0015295] [MeSH:C0015295] systematically present occur exon [MeSH:C0015295] [MeSH:C0015295] range phenotypic [MeSH:C1837514] expression observe affect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] different allelic [MeSH:C0524869] manifestation [MeSH:C0029166] apc mutation [MeSH:C0026882] [MeSH:C0026882],oncological
tachycardia pathway [MeSH:C0039231] multiple sclerosis [MeSH:C0026769],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] heart method [MeSH:C0018787] cardiac patient undergo randomized control meningioma schwannoma assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] practice guideline,neurological|cardiovascular
dynamic response blood vessel [MeSH:C0005847] acute renal failure [MeSH:C0022660],postulate acute renal failure [MeSH:C0022660] induce gentamicin [MeSH:C3854019] transient [MeSH:C0040704] dynamic [MeSH:C0058836] response blood vessel [MeSH:C0005847] [MeSH:C0005847] [MeSH:C0005847] affect antioxidant [MeSH:C0003402] prevent [MeSH:C0000918] change dynamic [MeSH:C0058836] response blood vessel [MeSH:C0005847] [MeSH:C0005847] [MeSH:C0005847] new approach ex vivo blood vessel [MeSH:C0005847] [MeSH:C0005847] [MeSH:C0005847] experiment [MeSH:C0020123] end point vessel response interval consider dynamic [MeSH:C0058836] response paper result confirm alteration dynamic [MeSH:C0058836] response blood vessel [MeSH:C0005847] [MeSH:C0005847] [MeSH:C0005847] pressure gentamicin [MeSH:C3854019]-treated animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] beneficial effect vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] gentamicin [MeSH:C3854019]-treated animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] confirm low blood [MeSH:C0005775] urea creatinine high potassium pressure [MeSH:C0032821] dynamic [MeSH:C0058836] response isolate blood vessel [MeSH:C0005847] [MeSH:C0005847] [MeSH:C0005847] fast pressure gentamicin [MeSH:C3854019]-treated animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] vs vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] induce slowdown pressure value pressure [MeSH:C0033095] dynamic [MeSH:C0058836] property quantitatively define comparative pressure dynamic [MeSH:C0058836] total pressure dynamic [MeSH:C0058836] confirm alteration dynamic [MeSH:C0058836] response blood vessel [MeSH:C0005847] [MeSH:C0005847] [MeSH:C0005847] pressure gentamicin [MeSH:C3854019]-treated animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] beneficial effect vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554],hepatorenal
tia chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,stroke [MeSH:C0038454] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve ast deep vein thrombosis method [MeSH:C0149871] conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine prolapse [MeSH:C0033377] parameter result improvement primary endpoint care improvement,cardiovascular|hepatorenal
cancer neurodegenerative [MeSH:C0524851] exploring neural pathway [MeSH:C0027792],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect stroke myasthenia gravis [MeSH:C0026896] method cancer [MeSH:C0025663] patient [MeSH:C0030705] undergo cross-sectional neurofibroma stroke assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile optimization [MeSH:C0376695],neurological|oncological
morphine-induced seizure newborn infant [MeSH:C0021289],neonate [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] suffer generalize seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] course intravenous [MeSH:C0085297] [MeSH:C0085297] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] sulfate post-operative [MeSH:C0030201] analgesia receive morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] dose microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg hr microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg hr large neonate [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] receive microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg hr seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] plasma [MeSH:C0032105] concentration morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] neonate [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] excessive mg ml known reason seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] rule convulsion [MeSH:C4048158] stop hour cessation morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] reoccur subsequent month suggest post-operative [MeSH:C0030201] intravenous [MeSH:C0085297] [MeSH:C0085297] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] exceed microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg ml neonate [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289] [MeSH:C0021289],neurological
explore hepatitis nash [MeSH:C0019158],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] uremia [MeSH:C0041948] urea result favorable safety [MeSH:C0036043] profile rcc [MeSH:C0967777] correlation therapeutic [MeSH:C0087111] innovation,hepatorenal
glyceryl trinitrate [MeSH:C0017887] induce attack migraine [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] sufferer migraine [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018],migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] pain phase [MeSH:C0030193] indicate migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] share common pathway nociception recent year increase evidence [MeSH:C5575834] suggest messenger molecule nitric oxide involve pain mechanism migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] order clarify true migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] present examine headache [MeSH:C0018681] [MeSH:C0018681] response intravenous infusion [MeSH:C0841792] [MeSH:C0021440] glyceryl trinitrate gtn [MeSH:C0017887] microg kg min min sufferer migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] specific elucidate aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] attack [MeSH:C0086769] migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] induce fourteen healthy subject [MeSH:C1708335] serve control aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] symptom [MeSH:C3839861] elicit subject headache [MeSH:C0018681] [MeSH:C0038545] [MeSH:C0018681] severe migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931]ur control immediately gtn infusion [MeSH:C0841792] p follow h p control gtn-induced headache [MeSH:C0018681] [MeSH:C0018681] gradually disappear migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931]ur peak headache [MeSH:C0018681] [MeSH:C0018681] [MeSH:C0018681] intensity occur mean min post-infusion [MeSH:C0841792] induce headache [MeSH:C0018681] [MeSH:C0018681] migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931]ur fulfil diagnostic criterion migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] international headache [MeSH:C0018681] [MeSH:C0018681] society result suggest involve pain mechanism migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] cortical spread depression [MeSH:C0038050] show liberate animal help understanding coupling cortical spreading depression headache [MeSH:C0018681] [MeSH:C0018681] [MeSH:C0018681] migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] aura [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018] [MeSH:C0236018],neurological
nicotine-induced nystagmus correlate midpontine activation [MeSH:C4505109],pathomechanism nicotine [MeSH:C0028040]-induced nystagmus nin unknown delineate brain structure [MeSH:C2713306] involve nin generation healthy volunteer inhale [MeSH:C0021461] nicotine [MeSH:C0028040] darkness [MeSH:C0010986] functional magnetic resonance image [MeSH:C5392999] fmri experiment eye movement register [MeSH:C0600375] video-oculography nin correlate blood oxygen level-dependent bold activity level midpontine site posterior basis pontis nin-induced midpontine activation [MeSH:C4505109] [MeSH:C4505109] correspond activation [MeSH:C4505109] [MeSH:C4505109] dorsomedial pontine nucleus nucleus reticularis [MeSH:C0162342] tegmenti pontis [MeSH:C0228426] structure know participate generation multidirectional saccade smooth pursuit eye movement,neurological
nitrate cancer [MeSH:C0006826] brain [MeSH:C0006104] insight,question statin affect hypertension [MeSH:C0020538] epinephrine [MeSH:C0014563] mechanism method longitudinal diabetic [MeSH:C0023981] patient [MeSH:C0030705] assess gaba parkinsonism [MeSH:C0242422] result favorable safety profile implication relevance,neurological
transient [MeSH:C0040704] neurologic symptom spinal anesthesia [MeSH:C0002928] low incidence [MeSH:C0021149] prilocaine bupivacaine [MeSH:C0006400] lidocaine [MeSH:C0023660],recent evidence [MeSH:C5575834] suggest transient [MeSH:C0040704] neurologic symptom tns [MeSH:C0235031] frequently lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] spinal anesthesia [MeSH:C0002928] [MeSH:C0002928] infrequent bupivacaine [MeSH:C0006400] [MeSH:C0006400] identification [MeSH:C1707660] short-acting local anesthetic substitute lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] brief surgical procedure [MeSH:C0543467] [MeSH:C0543467] remain important goal [MeSH:C0018017] prilocaine amide [MeSH:C0033124] local anesthetic duration action similar lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] accordingly present prospective double-blind [MeSH:C0013072] compare prilocaine lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] bupivacaine [MeSH:C0006400] [MeSH:C0006400] respect duration action relative risk tnss method ninety patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] classify american society anesthesiologist [MeSH:C0334910] physical status [MeSH:C0031808] ii schedule [MeSH:C0086960] short gynecologic procedure [MeSH:C0038902] spinal anesthesia [MeSH:C0002928] [MeSH:C0002928] randomly allocate receive ml lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] glucose prilocaine glucose bupivacaine [MeSH:C0006400] [MeSH:C0006400] glucose solution [MeSH:C0017740] provide blind vial hospital pharmacy [MeSH:C0031341] detail spinal puncture extension [MeSH:C0553794] regression spinal block time reach discharge criterion note evening postoperative [MeSH:C0032786] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] evaluate tnss physician unaware drug administer [MeSH:C1527425] detail anesthetic procedure [MeSH:C0677616] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] experienced tnss patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive prilocaine p [MeSH:C0033124] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive bupivacaine [MeSH:C0006400] [MeSH:C0006400] tns time ambulate [MeSH:C0002422] void similar lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] prilocaine vs min vs min respectively prolong bupivacaine [MeSH:C0006400] [MeSH:C0006400] min respectively p conclusion prilocaine p [MeSH:C0033124]referable lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] short surgical procedure [MeSH:C0543467] [MeSH:C0543467] similar duration action low incidence tnss,neurological
optimise stroke [MeSH:C0038454] prevention non-valvular atrial fibrillation,atrial fibrillation [MeSH:C0004238] [MeSH:C0004238] associate substantial morbidity [MeSH:C0026538] mortality pool [MeSH:C0026565] trial compare antithrombotic placebo show warfarin [MeSH:C0043031] [MeSH:C0043031] reduce risk [MeSH:C0035647] stroke [MeSH:C0038454] [MeSH:C0038454] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] reduce risk [MeSH:C0035647] overall high-risk [MeSH:C0556482] [MeSH:C0556482] [MeSH:C0035647] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] warfarin [MeSH:C0043031] [MeSH:C0043031] superior aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] prevent [MeSH:C0000918] stroke [MeSH:C0038454] relative risk [MeSH:C0242492] [MeSH:C0035647] reduction ximelagatran [MeSH:C0966370] oral [MeSH:C0029170] direct thrombin inhibitor find efficient [MeSH:C0013682] vitamin k [MeSH:C0042878] antagonist [MeSH:C0033607] drug prevent [MeSH:C0000918]ion embolic event recently withdraw abnormal [MeSH:C0853087] liver function test [MeSH:C0023901] active-w atrial fibrillation [MeSH:C0004238] [MeSH:C0004238] clopidogrel [MeSH:C0070166] trial irbesartan [MeSH:C0288171] prevent [MeSH:C0000918]ion vascular event demonstrate warfarin [MeSH:C0043031] [MeSH:C0043031] superior platelet therapy [MeSH:C5197905] clopidogrel [MeSH:C0070166] plus aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] prevent [MeSH:C0000918]ion af embolic event idraparinux factor xa inhibitor evaluate [MeSH:C0013175] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] atrial fibrillation [MeSH:C0004238] [MeSH:C0004238] angiotensin [MeSH:C0003018]-converting enzyme inhibitor angiotensin [MeSH:C0003018] ii receptor-blocking drug hold promise atrial fibrillation [MeSH:C0004238] [MeSH:C0004238] cardiac remodelling [MeSH:C3658220] preliminary study suggest statin [MeSH:C0360714] interfere risk [MeSH:C0035647] recurrence electrical cardioversion [MeSH:C0013778] finally percutaneous method exclusion leave atrial appendage [MeSH:C0225832] investigation [MeSH:C0035173] high-risk [MeSH:C0556482] [MeSH:C0556482] [MeSH:C0035647] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],cardiovascular|hepatorenal
endothelium [MeSH:C0014257] stroke [MeSH:C0038454] vascular [MeSH:C0221214] insight,question statin affect dementia [MeSH:C0497327] hypotensive mechanism method prospective adult population [MeSH:C0032659] assess systolic arterial result positive response implication optimization [MeSH:C0376695],cardiovascular
immunotherapy [MeSH:C0021083] prostate cancer [MeSH:C0376358] brain [MeSH:C0006104] insight,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation calcium channel blocker [MeSH:C0006684] stroke [MeSH:C0038454] participant [MeSH:C1708335] elderly patient encephalopathy trigeminal neuralgia [MeSH:C0040997] result well quality life measure delirium correlation cost-effectiveness [MeSH:C1511536] implication,neurological
organ [MeSH:C0029250] orchestra prostate cancer,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome nephritis pathway method longitudinal trial [MeSH:C0023981] cardiac patient measure albumin [MeSH:C0001924] gallstone result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,hepatorenal
prolongation [MeSH:C0023677] qt interval related cisapride-diltiazem interaction [MeSH:C0007582],cisapride [MeSH:C0072916] [MeSH:C0072916] [MeSH:C0072916] cytochrome p4 3a4 [MeSH:C3714798] cyp3a4 [MeSH:C3714798] substrate [MeSH:C0003017] widely prescribe gastrointestinal motility disorder [MeSH:C0017184] prolongation [MeSH:C0023677] [MeSH:C0023677] qt interval torsade de pointe sudden cardiac death [MeSH:C0085298] report concomitant [MeSH:C0152203] administration erythromycin [MeSH:C0014806] azole antifungal agent [MeSH:C0003308] cyp3a4 [MeSH:C3714798] inhibitor [MeSH:C0003015] [MeSH:C3850053] possible drug interaction [MeSH:C0687133] occur -year-old woman [MeSH:C0043210] take cisapride [MeSH:C0072916] [MeSH:C0072916] [MeSH:C0072916] gastroesophageal reflux disorder diltiazem [MeSH:C0012373] agent [MeSH:C0012373] inhibitor [MeSH:C0003015]y effect cyp3a4 [MeSH:C3714798] hypertension near syncope [MeSH:C0039070] qt-interval prolongation [MeSH:C0023677] [MeSH:C0023677] discontinue cisapride [MeSH:C0072916] [MeSH:C0072916] [MeSH:C0072916] qt interval return normal symptom recur suggest caution take cisapride [MeSH:C0072916] [MeSH:C0072916] [MeSH:C0072916] prescribe potent inhibitor [MeSH:C0003015] cyp3a4 [MeSH:C3714798] include diltiazem [MeSH:C0012373],neurological|cardiovascular
tight linkage myotonic dystrophy apolipoprotein e gene reveal allele-specific oligonucleotide,family myotonic dystrophy dm novel approach base use allele-specific oligonucleotide employ linkage [MeSH:C0242239] relationship apolipoprotein e [MeSH:C0052198] apoe [MeSH:C0003595] gene [MeSH:C0003595] dm synthetic oligonucleotide [MeSH:C0028953] design discriminate apoe [MeSH:C0003595] allele epsilon epsilon [MeSH:C0052198] enable distinguish heterozygous carrier hybridization assay subset family relevant segment apoe [MeSH:C0003595] gene [MeSH:C0003595] enzymatically amplify increase sensitivity [MeSH:C0036667] dm apoe [MeSH:C0003595] maximum lod score [MeSH:C0023956] zmax [MeSH:C0023956] obtain recombination frequency [MeSH:C3178846] theta male [MeSH:C0086582] theta female [MeSH:C0086287] [MeSH:C0086582] theta recombination [MeSH:C0034865] maximum lod score [MeSH:C0023956] theta find apoe [MeSH:C0003595] apolipoprotein cii apoc2 gene [MeSH:C0052190] result suggest addition apoc2 apoe [MeSH:C0003595] useful marker [MeSH:C0017393] presymptomatic [MeSH:C2936329] dm diagnosis [MeSH:C0011900],neurological
lymphoma amygdala exploring neural pathway [MeSH:C0027792],design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation calcium channel blocker [MeSH:C0006684] stroke [MeSH:C0038454] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient schwannoma serotonin result decrease mortality rate [MeSH:C0205848] dysarthria [MeSH:C0013362] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
stroke [MeSH:C0038454] pe cardiac connection,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] arterial pathway method randomized control trial cancer [MeSH:C1096777] patient [MeSH:C0030705] measuring bundle branch block stroke [MeSH:C0006384] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] optimization [MeSH:C0376695],cardiovascular
corneal ulcer [MeSH:C0010043] associate aerosolized crack cocaine use,report case corneal ulcer [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0041582] [MeSH:C0010043] associate [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] drug abuse [MeSH:C0013146] [MeSH:C0013146] [MeSH:C0013146] pathogenesis [MeSH:C0699748] ulcer [MeSH:C0041582] management [MeSH:C0085971] patient [MeSH:C0030705] [MeSH:C0030705] review [MeSH:C0282443] [MeSH:C0282443] method review [MeSH:C0282443] [MeSH:C0282443] case corneal ulcer [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0041582] [MeSH:C0010043] associate [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] drug abuse [MeSH:C0013146] [MeSH:C0013146] [MeSH:C0013146] see institution [MeSH:C0442681] july december result patient [MeSH:C0030705] [MeSH:C0030705] corneal ulcer [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0041582] [MeSH:C0010043] associate [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] crack cocaine use [MeSH:C0085163] review [MeSH:C0282443] corneal ulcer [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0041582] [MeSH:C0010043] culture patient [MeSH:C0030705] [MeSH:C0010453] [MeSH:C0030705] admit hospital intensive topical antibiotic [MeSH:C0003232] [MeSH:C0003232] receive comprehensive [MeSH:C0009585] health [MeSH:C0018684] care [MeSH:C0086388] include medical substance [MeSH:C0038585] abuse consultation [MeSH:C0009818] streptococcal organism find case capnocytophaga [MeSH:C0006916] brevibacterium casei infection [MeSH:C3714514] respond antibiotic [MeSH:C0003232] patient [MeSH:C0030705] [MeSH:C0030705] need lateral tarsorrhaphy persistent [MeSH:C0026205] epithelial defect conclusion aerosolized crack cocaine use [MeSH:C0085163] associate [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] development corneal ulcer [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0010043] [MeSH:C0041582] [MeSH:C0010043] drug abuse [MeSH:C0013146] [MeSH:C0013146] [MeSH:C0013146] provide additional challenge management [MeSH:C0085971] infection overall poor health [MeSH:C0018684] patient [MeSH:C4505341] [MeSH:C0030705] [MeSH:C0030705] increase risk [MeSH:C0035647] noncompliance [MeSH:C0376405] need address comprehensive [MeSH:C0009585] care provide opportunity discontinue substance abuse [MeSH:C0740858] improve overall health [MeSH:C0018684] prevent future corneal complication,neurological
molecular familial neurohypophyseal diabete insipidus [MeSH:C0011848] early diagnosis [MeSH:C0011900] asymptomatic [MeSH:C2936329] carrier [MeSH:C0007292],familial neurohypophyseal diabete insipidus [MeSH:C0687720] fndi inherit deficiency hormone arginine [MeSH:C0003765] vasopressin avp [MeSH:C0687720] transmit autosomal dominant [MeSH:C2936739] trait [MeSH:C0037401] present analyze avp-neurophysin ii avp-npii gene spanish kindred study perform seven member clinically affect family [MeSH:C0015576] patient diagnose [MeSH:C0011900] hospital universitario gregorio maranon madrid spain entire code region [MeSH:C0079941] avp-npii gene family [MeSH:C0015576] member amplify pcr sequence affect individual [MeSH:C0021228] [MeSH:C0021228] present missense mutation [MeSH:C0026882] g1 replace glycine position arginine [MeSH:C0003765] npii domain substitution confirm restriction endonuclease [MeSH:C0012906] present heterozygosis [MeSH:C0019425] additionally asymptomatic [MeSH:C2936329] [MeSH:C2936329] relative girl [MeSH:C0043210] month old identify carrier mutation [MeSH:C0026882] [MeSH:C0026882] develop disease [MeSH:C0012634] month [MeSH:C0012634] later alteration find second exon gene family [MeSH:C0015576] responsible disease [MeSH:C0012634] individual [MeSH:C0021228] [MeSH:C0021228] harbor mutation [MeSH:C0026882] previously diagnose [MeSH:C0011900] eventually develop fndi identification [MeSH:C1707660] molecular defect underlie fndi affect family [MeSH:C0015576] powerful tool early asymptomatic [MeSH:C2936329] [MeSH:C2936329] diagnosis [MeSH:C0011900] infant,neurological
investigation [MeSH:C0035173] thermoregulatory characteristic patient [MeSH:C0030705] prader-willi syndrome [MeSH:C0032897],survey [MeSH:C0038951] instrument assess temperature regulation characteristic child [MeSH:C0008059] prader-willi syndrome [MeSH:C0032897] pws compare group [MeSH:C0018257] sib pws patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sib neurodevelopmentally handicap child [MeSH:C0008059] nd age gender [MeSH:C0079399] match child [MeSH:C0008059] wc difference find pws patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sib control wc control prevalence febrile convulsion [MeSH:C4048158] fever-associated symptom temperature degree f difference note variable [MeSH:C0013675] pws patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] nd control suggest abnormality [MeSH:C0037268] unique pws occur neurodevelopmentally handicap individual [MeSH:C0021228] suggest necessarily reflect syndrome-specific hypothalamic abnormality [MeSH:C0037268],neurological
acute [MeSH:C0184567] confusion [MeSH:C0009676] induce high-dose infusion [MeSH:C0841792] -fluorouracil folinic acid [MeSH:C0023413],-year-old man treat combination chemotherapy [MeSH:C0013218] incorporate cisplatinum [MeSH:C0008838] etoposide high-dose -fluorouracil mg m2 hour folinic acid [MeSH:C0023413] inoperable gastric adenocarcinoma [MeSH:C0001418] develop acute neurologic symptom mental confusion disorientation [MeSH:C0233407] irritability lapse [MeSH:C0033377] deep coma [MeSH:C0234451] last approximately hour dose -fluorouracil folinic acid [MeSH:C0023413] infusion complication [MeSH:C1171258] reappear second dose -fluorouracil folinic acid [MeSH:C0023413] drug [MeSH:C0023413] give folinic acid [MeSH:C0023413] unlikely associate condition [MeSH:C0037403] neurotoxicity [MeSH:C0235032] [MeSH:C0235032] high-dose -fluorouracil highly suspect pathogenesis [MeSH:C0699748] -fluorouracil neurotoxicity [MeSH:C0235032] [MeSH:C0235032] krebs cycle [MeSH:C0008858] blockade [MeSH:C0027741] fluoroacetate [MeSH:C0016333] fluorocitrate thiamine deficiency [MeSH:C0039841] dihydrouracil dehydrogenase deficiency high-dose -fluorouracil folinic acid [MeSH:C0023413] infusion therapy recently popular regimen cancer [MeSH:C1880476] necessary oncologist [MeSH:C0259990] neurologist [MeSH:C0237426] fully aware unusual complication [MeSH:C1171258],neurological|oncological
pubertal exposure [MeSH:C1390376] bisphenol [MeSH:C0053800] increase anxiety-like behavior decrease acetylcholinesterase activity [MeSH:C0001044] hippocampus [MeSH:C3887642] adult [MeSH:C0001675] male [MeSH:C0086582] mouse [MeSH:C0026809],negative [MeSH:C3539878] effect bisphenol bpa neurodevelopment behavior established acetylcholinesterase ache regulatory enzyme involve anxiety-like behavior investigate [MeSH:C0035173] [MeSH:C0035173] behavioral [MeSH:C0004927] [MeSH:C0004927] phenotype [MeSH:C0031437] ache activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C0020115] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] follow bpa exposure [MeSH:C1390376] [MeSH:C1390376] puberty [MeSH:C0034011] postnatal [MeSH:C0032782] pnd male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] expose 0 mg bpa kg diet [MeSH:C0012155] period day pnd7 behavioral [MeSH:C0004927] [MeSH:C0004927] assay perform elevated plus maze epm light dark test [MeSH:C5392082] addition ache activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C0020115] measure prefrontal cortex [MeSH:C0162783] [MeSH:C0162783] hypothalamus [MeSH:C0020663] cerebellum hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] result behavioral [MeSH:C0004927] [MeSH:C0004927] phenotyping indicate anxiety-like behavior increase mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] expose bpa ache activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C0020115] significantly decrease hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] bpa compare mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] difference find prefrontal cortex [MeSH:C0162783] [MeSH:C0162783] hypothalamus [MeSH:C0020663] cerebellum finding show pubertal bpa exposure [MeSH:C1390376] [MeSH:C1390376] increase anxiety-like behavior associate decrease ache activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C0020115] hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] adult [MeSH:C0001675] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] study necessary investigate [MeSH:C0035173] [MeSH:C0035173] cholinergic [MeSH:C0242893] signaling [MeSH:C0037083] hippocampus [MeSH:C3887642] [MeSH:C3887642] [MeSH:C3887642] pbe induce anxiety-like behavior,neurological
hepatocellular carcinoma [MeSH:C2239176] fanconi anemia [MeSH:C0015625] treat androgen corticosteroid [MeSH:C0001617],case -year-old boy report know fanconi [MeSH:C0015625] anemia [MeSH:C0002871] year treat androgen corticosteroid transfusion week death readmitte aplastic crisis septicemia [MeSH:C0036690] marked abnormality [MeSH:C0037268] liver function [MeSH:C0023901] die hemorrhagic bronchopneumonia [MeSH:C0006285] autopsy [MeSH:C0004398] peliosis [MeSH:C0030781] multiple hepatic tumor find histologically prove well-differentiated hepatocellular carcinoma [MeSH:C2239176] case contribute previous observation non-metastasizing hepatic neoplasm peliosis [MeSH:C0023903] [MeSH:C0030781] develop patient [MeSH:C0030705] androgen- corticosteroid-treated [MeSH:C0001617] fanconi [MeSH:C0015625] anemia [MeSH:C0002871],neurological|hepatorenal|oncological
ventricle lung cancer [MeSH:C0242379] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] beta-blocker effect heart disease diastolic method cancer patient [MeSH:C0030705] undergo longitudinal systolic pulmonary valve assessment result favorable safety [MeSH:C0036043] profile optimization [MeSH:C0376695],cardiovascular
spironolactone-induced renal insufficiency hyperkalemia [MeSH:C0020461] patient heart failure [MeSH:C0018801],previous randomized control trial [MeSH:C1096777] evaluate [MeSH:C0013175] use spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] report [MeSH:C0684224] low risk hyperkalemia [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] renal insufficiency [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] treatment [MeSH:C0039798] heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] change benefit spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] report prevalence [MeSH:C0033105] [MeSH:C0033105] complication [MeSH:C1171258] differ current practice seek determine prevalence [MeSH:C0033105] association [MeSH:C0004083] hyperkalemia [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] renal insufficiency [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] method [MeSH:C0025663] perform case heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] practice case patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop hyperkalemia [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] k meq l renal insufficiency [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] cr mg dl compare randomly select control case characteristic medication serum chemistry follow-up [MeSH:C3899107] period [MeSH:C0080129] compare result sixty-seven patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] require discontinuation spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] hyperkalemia [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] n renal failure [MeSH:C0035078] n patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop hyperkalemia [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] old likely diabete high serum potassium level low potassium supplement dose likely treat beta-blocker [MeSH:C0001645] control n patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop renal insufficiency [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] low body weight [MeSH:C0005910] high serum creatinine [MeSH:C0010294] require high dose loop [MeSH:C4505202] diuretic likely treat thiazide diuretic control conclusion spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982]-induced hyperkalemia [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] renal insufficiency [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] [MeSH:C1565489] common experience report previously difference explain comorbiditie frequent use beta-blocker [MeSH:C0001645],cardiovascular|hepatorenal
hypertension [MeSH:C0020538] polyuria [MeSH:C0032617] organ [MeSH:C0029250] interplay,cross-sectional examine [MeSH:C0010362] statin cancer [MeSH:C0376358] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include alt gallstone [MeSH:C0242216] anuria [MeSH:C0003460] method participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
cardiomyopathy pathway [MeSH:C0878544] heart failure [MeSH:C0018801],cross-sectional examine [MeSH:C0010362] aspirin [MeSH:C0004057] diabete cardiac patient investigation [MeSH:C0035173] [MeSH:C0035173] include convulsion sinoatrial node white matter method participant [MeSH:C1708335] include result well quality life measure implication need investigation [MeSH:C0035173] [MeSH:C0035173],neurological|cardiovascular
methamphetamine [MeSH:C0025611] cause alteration map kinase-related pathway brain mouse display increase aggressiveness [MeSH:C0001807],aggressive behavior report patient [MeSH:C0030705] suffer psychiatric disorder [MeSH:C0004936] common methamphetamine [MeSH:C0025611] meth abuser report multiple single injection [MeSH:C1828121] meth significantly increase aggressiveness [MeSH:C0001807] male [MeSH:C0086582] cd- mice [MeSH:C0026809] increase aggressiveness [MeSH:C0001807] secondary meth-induced hyperactivity protein expression antibody microarray western blotting [MeSH:C0005863] reveal differential change map kinase-related pathway multiple single meth injection statistically p decrease mek1 [MeSH:C1434639] [MeSH:C1434639] erk2p gsk3alpha --3e mek7 [MeSH:C0540973] striata mouse [MeSH:C0026809] [MeSH:C0026809] multiple injection meth mek1 [MeSH:C1434639] [MeSH:C1434639] significantly decrease single injection [MeSH:C1828121] meth less degree multiple injection meth frontal cortex [MeSH:C0016733] statistically decrease gsk3alpha multiple single injection [MeSH:C1828121] meth finding suggest alteration map kinase-related pathway prefronto-striatal circuitry involve manifestation [MeSH:C0029166] aggressive behavior mouse [MeSH:C0026809] [MeSH:C0026809],neurological
cerebellar sensory processing [MeSH:C0030971] alteration impact [MeSH:C5544368] motor cortical plasticity parkinson disease [MeSH:C0030567] clue dyskinetic [MeSH:C0013384] patient [MeSH:C0030705],plasticity [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] primary motor cortex m1 [MeSH:C3495441] patient [MeSH:C0030705] parkinson disease [MeSH:C0030567] pd levodopa-induced dyskinesia lid severely impaired [MeSH:C0020580] recently report young [MeSH:C0340037] healthy subject inhibitory [MeSH:C0167957] [MeSH:C0167957] [MeSH:C0167957] cerebellar stimulation [MeSH:C0031734] [MeSH:C0031734] enhance sensorimotor [MeSH:C3499125] plasticity [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] m1 induce paired associative stimulation [MeSH:C0031734] [MeSH:C0031734] pas demonstrate deficient [MeSH:C0531328] sensorimotor [MeSH:C3499125] m1 plasticity [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] patient [MeSH:C0030705] lid reinstate single session real inhibitory [MeSH:C0167957] [MeSH:C0167957] [MeSH:C0167957] cerebellar stimulation [MeSH:C0031734] [MeSH:C0031734] sham stimulation [MeSH:C0031734] [MeSH:C0031734] evident sensory component involve induction [MeSH:C0042767] plasticity [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] indicate cerebellar sensory processing [MeSH:C0030971] function involve resurgence m1 plasticity [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] benefit [MeSH:C0021674] inhibitory [MeSH:C0167957] [MeSH:C0167957] [MeSH:C0167957] cerebellar stimulation [MeSH:C0031734] [MeSH:C0031734] lid know explore benefit [MeSH:C0021674] link restoration [MeSH:C4505207] sensorimotor [MeSH:C3499125] plasticity [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] m1 conduct additional look change lid pas-induced plasticity [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] session bilateral real inhibitory [MeSH:C0167957] [MeSH:C0167957] [MeSH:C0167957] cerebellar stimulation [MeSH:C0031734] [MeSH:C0031734] sham stimulation [MeSH:C0031734] [MeSH:C0031734] real sham stimulation [MeSH:C0031734] [MeSH:C0031734] antidyskinetic effect parallel resurgence sensorimotor [MeSH:C3499125] plasticity [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] m1 result suggest alteration cerebellar sensory processing [MeSH:C0030971] function occurring secondary [MeSH:C1522484] abnormal [MeSH:C0853087] [MeSH:C0853087] basal ganglia [MeSH:C0004781] signal [MeSH:C0037081] reach important element [MeSH:C0013879] contribute maladaptive sensorimotor [MeSH:C3499125] plasticity [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] [MeSH:C4042875] m1 emergence abnormal [MeSH:C0853087] [MeSH:C0853087] involuntary [MeSH:C1267092] movement,neurological
immunotherapy marker lymphoma [MeSH:C0021083],design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] elderly patient carcinoma acute lymphoblastic leukemia [MeSH:C1961102] result positive response liver cancer [MeSH:C0345904] correlation [MeSH:C0010100] optimization [MeSH:C0376695],cardiovascular|oncological
deletion dna patient becker duchenne muscular dystrophy [MeSH:C3542021],duchenne muscular dystrophy [MeSH:C0013264] dmd x-linked recessive genetic disorder [MeSH:C0040188] biochemical [MeSH:C0017401] defect unknown recently clone [MeSH:C0009013] segment [MeSH:C0035798] human [MeSH:C0086418] x-chromosome dna [MeSH:C0678928] describe detect structural [MeSH:C0026349] alteration near genetic locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0678933] responsible disorder [MeSH:C0040188] clone [MeSH:C0009013] segment [MeSH:C0035798] describe tightly link locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] capable detect deletion [MeSH:C0017260] [MeSH:C0017260] dna boy affect dmd attempt determine precisely occurrence deletion [MeSH:C0017260] [MeSH:C0017260] large population dmd patient [MeSH:C0030705] accuracy segment [MeSH:C0035798] dxs1 pert8 determine inheritance [MeSH:C4277511] dmd x chromosome subclone [MeSH:C0009013] available investigator world [MeSH:C0035173] describe combined result laboratory [MeSH:C0022877] respect occurrence deletion [MeSH:C0017260] [MeSH:C0017260] dxs1 locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] dna sample isolate patient [MeSH:C0030705] dmd becker muscular dystrophy [MeSH:C0917713] bmd result indicate dxs1 locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] apparently recombine dmd probably located independent site mutation [MeSH:C0026882] yield dmd breakpoint deletion [MeSH:C0017260] [MeSH:C0017260] delineate dxs1 locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] evident deletion [MeSH:C0017260] [MeSH:C0017260] dmd locus [MeSH:C0085286] [MeSH:C0085286] [MeSH:C0085286] frequent [MeSH:C0017270] extremely large,neurological
leukemia [MeSH:C0023418] septum [MeSH:C0752060] cardiac connection,assess efficacy [MeSH:C5690761] beta-blocker [MeSH:C0001645] stroke focus premature beat prolapse method [MeSH:C0340464] elderly patient randomized [MeSH:C1096777] receive beta-blocker [MeSH:C0001645] placebo defibrillator monitoring [MeSH:C0005517] result improvement primary endpoint healthcare advancement,cardiovascular
cardiomyopathy marker cardiomyopathy [MeSH:C0878544],question calcium channel blocker [MeSH:C0006684] affect diabete heart attack [MeSH:C0027051] mechanism method longitudinal [MeSH:C0023981] elderly patient assess deep vein thrombosis [MeSH:C0149871] stenosis [MeSH:C1261287] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication therapeutic [MeSH:C0087111] innovation,cardiovascular
lymphoma glomerular filtration rate [MeSH:C0017654] organ interplay,diabete affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve primary sclerosing cholangitis [MeSH:C0566602] gamma glutamyl transferase method [MeSH:C0017040] conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine albumin [MeSH:C0001924] parameter result positive response relevance [MeSH:C2826293],hepatorenal
mind matter multiple sclerosis myelopathy [MeSH:C0026769],design [MeSH:C0013171] prospective investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] adult [MeSH:C0001675] population convulsion memory loss [MeSH:C0751295] result improve disease management [MeSH:C0039798] dopamine [MeSH:C0013030] correlation healthcare advancement,neurological
hypotension [MeSH:C0020649] hypertension vascular [MeSH:C0221214] insight,cross-sectional examine [MeSH:C0010362] calcium channel blocker [MeSH:C0006684] diabete elderly patient investigation [MeSH:C0035173] include tricuspid valve hypertension [MeSH:C0040960] ischemic cardiomyopathy [MeSH:C0878544] method participant [MeSH:C1708335] include result well quality life measure implication healthcare advancement,cardiovascular
arylsulfatase [MeSH:C0003940] arsa missense mutation t24 cause late-infantile metachromatic leukodystrophy [MeSH:C0751278],metachromatic leukodystrophy [MeSH:C0023522] mld autosomal recessive lysosomal storage disorder cause deficiency arylsulfatase [MeSH:C0038717] arsa ec arsa exon adjacent intron boundary late-infantile metachromatic leukodystrophy [MeSH:C0023522] polymerase chain reaction pcr amplify seven discrete reaction amplify arsa exon analyse presence sequence alteration single-strand conformation [MeSH:C0243031] polymorphism [MeSH:C0032529] follow direct sequencing pcr product find homozygous [MeSH:C0019904] c-- transition exon iv result substitution [MeSH:C2936279] highly conserve threonine [MeSH:C0040005] residue amino acid methionine [MeSH:C0002520] t24 mld patient [MeSH:C0030705] [MeSH:C0030705] reveal presence additional homozygote [MeSH:C0019904] [MeSH:C0019904] t24 t24 homozygote [MeSH:C0019904] [MeSH:C0019904] represent family lebanese descent know consanguineous [MeSH:C0009789] marriage [MeSH:C0024841] altered amino acid rigidly conserve sulfatase [MeSH:C0038717] escherichia coli [MeSH:C0014834] human [MeSH:C0086418] likely resultant mutant protein [MeSH:C1564139] little enzyme activity [MeSH:C0243102] consistent low arsa activity measure patient [MeSH:C0030705] [MeSH:C0030705] uniformly severe presentation [MeSH:C0022869],neurological
aconitine-induced ca2 overload cause arrhythmia [MeSH:C0003811] trigger apoptosis [MeSH:C0162638] p3 mapk signaling pathway [MeSH:C1520113] rat [MeSH:C0034721],aconitine [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] major bioactive diterpenoid alkaloid [MeSH:C4704790] high content [MeSH:C0017177] derive herbal aconitum [MeSH:C0330240] plant emerge evidence [MeSH:C5575834] indicate voltage-dependent na channel [MeSH:C1506024] pivotal role cardiotoxicity [MeSH:C0876994] aconitine [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] report available role aconitine [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] poisoning [MeSH:C0032343] explore importance pathological [MeSH:C0030660] signal aconitine [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] poisoning [MeSH:C0032343] vitro vivo find overload [MeSH:C0282193] [MeSH:C0282193] [MeSH:C0282193] lead accelerat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e beating rhythm [MeSH:C0005167] adult [MeSH:C0001675] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] ventricular myocyte [MeSH:C0949657] cause arrhythmia [MeSH:C0003811] [MeSH:C0003811] conscious [MeSH:C0079159] freely move rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] investigate [MeSH:C0035173] effect [MeSH:C4277511] aconitine [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] myocardial injury [MeSH:C0027055] [MeSH:C0027055] perform cytotoxicity assay neonatal [MeSH:C0021709] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] ventricular myocyte [MeSH:C0949657] nrvms measure lactate dehydrogenase culture medium nrvms activity [MeSH:C0020115] serum [MeSH:C0229671] cardiac enzyme rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] result [MeSH:C4704700] show aconitine [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] result [MeSH:C4704700] myocardial injury [MeSH:C0027055] [MeSH:C0027055] reduce nrvms viability [MeSH:C0007620] dose-dependently confirm pro-apoptotic effect [MeSH:C4277511] perform flow cytometric detection cardiac histology [MeSH:C0019638] transmission electron microscopy [MeSH:C0678118] terminal deoxynucleotidyl transferase-mediated dutp-biotin nick end labeling assay result [MeSH:C4704700] show aconitine [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] stimulate apoptosis [MeSH:C0162638] time-dependently expression [MeSH:C0017262] handling protein demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e aconitine [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] promote overload [MeSH:C0282193] [MeSH:C0282193] [MeSH:C0282193] expression [MeSH:C0017262] regulation [MeSH:C0017263] handling protein expression [MeSH:C0017262] [MeSH:C0017262] apoptosis [MeSH:C0162638]-related protein reveal pro-apoptotic protein expression [MeSH:C0017262] [MeSH:C0017262] upregulate [MeSH:C0041904] anti-apoptotic protein [MeSH:C1565114] bcl- expression [MeSH:C0017262] downregulate [MeSH:C0013081] furthermore increase phosphorylation [MeSH:C0031715] [MeSH:C0031715] mapk family member [MeSH:C0086282] especially p-p3 p3 rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]io find cardiac tissue [MeSH:C0040300] result [MeSH:C4704700] suggest aconitine [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] [MeSH:C0001159] significantly aggravate overload [MeSH:C0282193] [MeSH:C0282193] [MeSH:C0282193] cause arrhythmia [MeSH:C0003811] [MeSH:C0003811] finally promote apoptotic development [MeSH:C0020119] phosphorylation [MeSH:C0031715] [MeSH:C0031715] p3 mitogen-activated protein kinase [MeSH:C0752312],neurological|cardiovascular
craniopharyngioma [MeSH:C0010276] pattern prostate cancer [MeSH:C0376358] patient [MeSH:C0030705],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer epinephrine method [MeSH:C0014563] elderly patient undergo prospective encephalopathy [MeSH:C0085584] cerebrovascular assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,neurological
incidence [MeSH:C0021149] neoplasm [MeSH:C0027651] patient [MeSH:C0030705] rheumatoid arthritis [MeSH:C0003873] expose different regimen [MeSH:C1880476],immunosuppressive drug [MeSH:C0021081] [MeSH:C0013227] [MeSH:C0013227] [MeSH:C0021081] [MeSH:C0013227] year [MeSH:C0021081] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe rheumatoid arthritis [MeSH:C0003873] [MeSH:C0003873] [MeSH:C0003873] [MeSH:C0003873] drug [MeSH:C0013227] [MeSH:C0013227] [MeSH:C0013227] commonly cyclophosphamide [MeSH:C0010583] chlorambucil alkylating agent [MeSH:C0002073] [MeSH:C0002073] azathioprine [MeSH:C0004482] [MeSH:C0004482] purine analogue [MeSH:C0014941] methotrexate folic acid [MeSH:C0025677] analogue [MeSH:C0014941] evidence [MeSH:C5575834] immunosuppressive drug [MeSH:C0021081] [MeSH:C0013227] [MeSH:C0013227] [MeSH:C0021081] [MeSH:C0013227] reduce synovitis disease activity recur therapy stop adverse reaction [MeSH:C0041755] frequent percent patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] able continue particular drug [MeSH:C0013227] [MeSH:C0013227] [MeSH:C0013227] take month achieve maximal effect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unable continue drug [MeSH:C0013227] [MeSH:C0013227] [MeSH:C0013227] receive little benefit patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat alkylating agent [MeSH:C0002073] [MeSH:C0002073] increase risk development [MeSH:C0020119] acute nonlymphocytic leukemia alkylating agent [MeSH:C0023467] [MeSH:C0002073] [MeSH:C0002073] azathioprine [MeSH:C0004482] [MeSH:C0004482] associate development [MeSH:C0020119] non-hodgkin lymphoma cyclophosphamide [MeSH:C0010583] therapy increase risk carcinoma [MeSH:C0007097] bladder [MeSH:C0005682] long-term study patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] rheumatoid arthritis [MeSH:C0003873] [MeSH:C0003873] [MeSH:C0003873] [MeSH:C0003873] treat azathioprine [MeSH:C0004482] [MeSH:C0004482] cyclophosphamide [MeSH:C0010583] incidence [MeSH:C0021149] common cancer [MeSH:C0006826] increase possible increase risk malignancy [MeSH:C0006826] rheumatoid arthritis [MeSH:C0003873] [MeSH:C0003873] [MeSH:C0003873] [MeSH:C0003873] collect information [MeSH:C5544371] available use immunosuppressive drug [MeSH:C0021081] [MeSH:C0013227] [MeSH:C0013227] [MeSH:C0021081] [MeSH:C0013227] particularly alkylate agent [MeSH:C0002073] rheumatoid arthritis [MeSH:C0003873] [MeSH:C0003873] [MeSH:C0003873] [MeSH:C0003873] reserve patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe progressive disease [MeSH:C0242656] life-threatening [MeSH:C4303743] complication [MeSH:C1171258],neurological|oncological
cancer [MeSH:C0006826] acetylcholine [MeSH:C0001041] exploring neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome [MeSH:C0206277] huntington disease pathway method randomized control trial [MeSH:C1096777] cardiac patient measure bell palsy [MeSH:C0376175] parkinson disease [MeSH:C0030567] result improve disease management [MeSH:C0039798] practice guideline,neurological
epilepsy [MeSH:C0014544] hcc organ [MeSH:C0029250] interplay,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] cancer patient [MeSH:C0030705] nash bilirubin [MeSH:C0005437] result superior efficacy [MeSH:C5690761] blood urea [MeSH:C0005845] nitrogen correlation optimization [MeSH:C0376695],hepatorenal
homozygous [MeSH:C0019904] presence crossover [MeSH:C0150097] fusion gene mutation [MeSH:C0178648] identify type ii gaucher disease [MeSH:C0017205] fetus [MeSH:C0015965] analogous gaucher knock-out mouse model [MeSH:C0206745],gaucher disease gd inherit deficiency beta-glucocerebrosidase ec gene symbol [MeSH:C0017205] gba [MeSH:C5197599] type gd cns involve nonneuronopathic type ii gd acute neuronopathic cns involvement [MeSH:C0030699] early rapidly progressive [MeSH:C1449744] [MeSH:C1449744] type iii gd subacute neuronopathic cns involvement [MeSH:C0030699] occur later slowly progressive [MeSH:C1449744] [MeSH:C1449744] t63c l44p substitution prevalent type gd ii occur single base-pair mutation [MeSH:C0026882] find complex [MeSH:C3888046] allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] contain additional gba [MeSH:C5197599] nucleotide substitution g68c a46p g62c v40v recncii rectl g57c d49h complex [MeSH:C3888046] allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] presume form recombination [MeSH:C0034865] crossover fusion structural gene pseudogene contain mutate sequence complex [MeSH:C3888046] allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] demonstrate coexist individual [MeSH:C0021228] devise selective pcr specific amplification normal fusion gene [MeSH:C0178648] procedure [MeSH:C0184661] demonstrate fusion gene [MeSH:C0178648] homozygous [MeSH:C0019904] [MeSH:C0019904] form macedonian [MeSH:C0206004] ashkenazi jewish gd type ii fetus [MeSH:C0015965] parent carrier recombination [MeSH:C0034865] confirm direct sequence previous conceptus family stillborn week feature severe type ii gd neonate show severe phenotype [MeSH:C0031437] analogous early neonatal [MeSH:C0021709] lethal disease [MeSH:C0012634] occur mouse [MeSH:C0026809] homozygous [MeSH:C0019904] [MeSH:C0019904] null allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] produce target [MeSH:C0039309] disruption [MeSH:C3179075] gba [MeSH:C5197599] describe specific mutation [MeSH:C0026882] case characterize abstract [MeSH:C0600678] truncate word,neurological
detection [MeSH:C5392129] dmd bmd gene deletion polymerase chain reaction,describe oligonucleotide primer sequence amplify exon plus muscle promoter dystrophin gene [MeSH:C0079259] single multiplex polymerase chain reaction pcr conjunction exist primer set multiplex reaction detect deletion patient duchenne becker muscular dystrophy [MeSH:C0917713] dmd bmd furthermore primer amplify exon deletion [MeSH:C0015295] prone hot spot region exon allow determination [MeSH:C1148554] deletion endpoint [MeSH:C0887960] prediction mutational effect translational reading frame [MeSH:C0080089] use pcr-based assay [MeSH:C0243073] allow deletion detection prenatal diagnosis [MeSH:C0033053] dmd bmd patient fraction require southern blot [MeSH:C1148472],neurological
cancer aortic aneurysm [MeSH:C0002940] cardiac connection,investigate [MeSH:C0035173] beta-blocker effect cancer ventricular fibrillation method [MeSH:C0042510] elderly patient undergo longitudinal pulmonary valve cardiomyopathy assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],cardiovascular
receptor mechanism [MeSH:C0025032] nicotine-induced locomotor hyperactivity chronic nicotine-treated rat,rat [MeSH:C0034721] [MeSH:C0034721] pretreate saline nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] mg kg subcutaneously implant animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] alzet osmotic mini-pump continuously release saline nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] end pretreatment [MeSH:C0376495] period [MeSH:C0080129] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] determine locomotor response acutely inject nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] mg kg c ii measure density l- 3h nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] 3h spiperone [MeSH:C0037956] [MeSH:C0037956] [MeSH:C0037956] [MeSH:C0037956] binding [MeSH:C0033618] site [MeSH:C0005456] striatum [MeSH:C0315183] observe change nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040]-induced locomotor response striatal l- 3h nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] 3h spiperone [MeSH:C0037956] [MeSH:C0037956] [MeSH:C0037956] [MeSH:C0037956] binding [MeSH:C0033618] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] pretreate nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] rat [MeSH:C0034721] [MeSH:C0034721] pretreate nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] increase nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040]-stimulated locomotor response associate increase number l- 3h nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] binding [MeSH:C0033618] site [MeSH:C0005456] elevated dopamine [MeSH:C0013030] da striatum [MeSH:C0315183] number striatal 3h spiperone [MeSH:C0037956] [MeSH:C0037956] [MeSH:C0037956] [MeSH:C0037956] binding [MeSH:C0033618] site [MeSH:C0005456] affect animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] pretreate nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040]-induced locomotor response remain potentiate response correlate elevated number striatal 3h spiperone [MeSH:C0037956] [MeSH:C0037956] [MeSH:C0037956] [MeSH:C0037956] binding [MeSH:C0033618] site [MeSH:C0005456] number striatal l- 3h nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] binding [MeSH:C0033618] site [MeSH:C0005456] striatal da normal result suggest chronic [MeSH:C0150055] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040]-treated rat [MeSH:C0034721] [MeSH:C0034721] develop locomotor hyperactivity response [MeSH:C0023946] nicotine [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] [MeSH:C0028040] initially increase density nicotinic receptor da concentrat [MeSH:C0034721] [MeSH:C0034721]ion follow induce da receptor supersensitivity striatum [MeSH:C0315183],neurological
oligodendroglioma connection [MeSH:C0028945] diabetes mellitus [MeSH:C0011849],question [MeSH:C0600648] metformin [MeSH:C0025598] affect diabete encephalopathy [MeSH:C0085584] mechanism method observational [MeSH:C0302523] elderly patient assess ataxia seizure [MeSH:C0036572] result enhance therapeutic response [MeSH:C0087111] implication safety [MeSH:C0036043] consideration,neurological
complement deficiency nephritis [MeSH:C0272242],report [MeSH:C0684224] family family [MeSH:C0015576] describe child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] homozygous [MeSH:C0019904] [MeSH:C0019904] deficiency c3 parent child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] heterozygous [MeSH:C0019425] [MeSH:C0019425] [MeSH:C0019425] c3 null gene child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] heterozygous [MeSH:C0019425] [MeSH:C0019425] [MeSH:C0019425] c3 deficiency [MeSH:C1623416] find membranoproliferative glomerulonephritis [MeSH:C0027697] [MeSH:C0017662] proteinuria [MeSH:C0033687] microscopical haematuria present homozygous [MeSH:C0019904] [MeSH:C0019904] c3-deficient child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] homozygous [MeSH:C0019904] [MeSH:C0019904] heterozygous [MeSH:C0019425] [MeSH:C0019425] [MeSH:C0019425] c3 deficiency [MeSH:C1623416] vary degree susceptible infection [MeSH:C3714514] child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] family normal complement increase risk infection [MeSH:C3714514] [MeSH:C3714514] renal disease [MeSH:C1691228] family provide support proposal c3 deficiency [MeSH:C1623416] predispose nephritis [MeSH:C0027697],hepatorenal
increase coronary heart disease [MeSH:C0010068] japanese-american man mutation [MeSH:C0026882] cholesteryl ester transfer protein gene [MeSH:C0055538] despite increase hdl [MeSH:C0062709] level,plasma [MeSH:C0032105] high density lipoprotein hdl level [MeSH:C0018759] strongly genetically determine general inverse relationship coronary heart disease [MeSH:C0010068] chd [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] cholesteryl ester transfer [MeSH:C0035711] protein [MeSH:C0055538] cetp [MeSH:C1144465] [MeSH:C1144465] mediate transfer [MeSH:C0035711] cholesteryl ester hdl lipoprotein key participant reverse transport cholesterol periphery liver [MeSH:C0023884] high prevalence [MeSH:C0033105] [MeSH:C0033105] [MeSH:C0033105] different cetp [MeSH:C1144465] [MeSH:C1144465] gene mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] d42 g intron 4 g find man japanese ancestry honolulu heart program mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] associate decrease cetp [MeSH:C1144465] [MeSH:C1144465] increase hdl chol [MeSH:C0023822] [MeSH:C0023822] level [MeSH:C0018759] d42 g overall prevalence [MeSH:C0033105] [MeSH:C0033105] [MeSH:C0033105] definite chd [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] man mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] man mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] relative risk [MeSH:C0242492] rr chd [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] man mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] p chd [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] risk factor [MeSH:C0035648] rr p additional adjustment [MeSH:C0376209] hdl level [MeSH:C0018759] rr p similar rr value obtain d42 g mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] increase chd [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] man mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] primarily observe hdl chol [MeSH:C0023822] [MeSH:C0023822] mg dl hdl chol [MeSH:C0023822] [MeSH:C0023822] mg dl man mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] low chd [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] prevalence [MeSH:C0033105] [MeSH:C0033105] [MeSH:C0033105] genetic cetp [MeSH:C1144465] [MeSH:C1144465] deficiency appear independent risk factor [MeSH:C0035648] chd [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] primarily increase chd [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] [MeSH:C1513896] prevalence [MeSH:C0033105] [MeSH:C0033105] [MeSH:C0033105] man d42 g mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] hdl chol [MeSH:C0023822] [MeSH:C0023822]esterol mg dl finding suggest hdl concentration dynamic cholesterol transport hdl e reverse cholesterol transport determine anti-atherogenicity hdl fraction,cardiovascular|hepatorenal
cause death [MeSH:C0011065] patient [MeSH:C0030705] parkinson disease [MeSH:C0030567] rare mortality [MeSH:C0026565] cerebral haemorrhage [MeSH:C2937358],cause death [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] special reference cerebral haemorrhage [MeSH:C2937358] [MeSH:C2937358] [MeSH:C2937358] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pathological [MeSH:C0030660]ly verify parkinson disease [MeSH:C0030567] [MeSH:C0030567] investigate [MeSH:C0035173] annual [MeSH:C0936091] pathological [MeSH:C0030660] autopsy [MeSH:C0004398] case japan [MeSH:C0022341] leading cause death [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] pneumonia bronchitis [MeSH:C0006285] malignant neoplasm heart disease [MeSH:C0006826] cerebral infarction [MeSH:C0007785] septicaemia [MeSH:C0086973] cerebral haemorrhage [MeSH:C2937358] [MeSH:C2937358] [MeSH:C2937358] 1th frequent [MeSH:C0017270] cause death [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] accounting death [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] 5th common cause death [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] japanese general population [MeSH:C0032659] low incidence [MeSH:C0021149] cerebral haemorrhage [MeSH:C2937358] [MeSH:C2937358] [MeSH:C2937358] cause death [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] [MeSH:C0011065] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] parkinson disease [MeSH:C0030567] [MeSH:C0030567] reflect hypotensive effect levodopa [MeSH:C0023570] hypotensive mechanism reduce noradrenaline [MeSH:C0028351] level [MeSH:C0018759] parkinsonian [MeSH:C0242422] brain [MeSH:C0006104],neurological|cardiovascular|hepatorenal|oncological
state-of-the-art loop diuretic prostate cancer,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] cirrhosis [MeSH:C1623038] mechanism method observational [MeSH:C0302523] elderly patient assess bilirubin liver transplant [MeSH:C0023911] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication need investigation [MeSH:C0035173],hepatorenal
myocardial coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] ace inhibitor [MeSH:C0003015] dementia [MeSH:C0497327] participant [MeSH:C1708335] cancer patient angina [MeSH:C0030705] pacemaker result favorable safety profile heart valve correlation healthcare advancement,cardiovascular
d-penicillamine [MeSH:C0030817] localized scleroderma [MeSH:C0036420],localized scleroderma [MeSH:C0036420] [MeSH:C0036420] [MeSH:C0036420] recognize internal organ involvement [MeSH:C0030699] disfiguring disable cutaneous [MeSH:C0040656] lesion extensive affect child [MeSH:C0008059] accept prove localized scleroderma [MeSH:C0036420] [MeSH:C0036420] [MeSH:C0036420] case report [MeSH:C0684224] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe [MeSH:C1719672] extensive localized scleroderma [MeSH:C0036420] [MeSH:C0036420] [MeSH:C0036420] treat d-penicillamine [MeSH:C0030817] [MeSH:C0030817] [MeSH:C0030817] [MeSH:C0030817] summarize article drug judge favorable effect disease course patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] improvement begin month consist cessation active cutaneous [MeSH:C0040656] lesion patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] skin softening [MeSH:C0043061] normal growth affect limb child [MeSH:C0008059] joint stiffness contracture improve dose d-penicillamine [MeSH:C0030817] [MeSH:C0030817] [MeSH:C0030817] [MeSH:C0030817] associate favorable response low mg kg give period [MeSH:C0080129] range month d-penicillamine [MeSH:C0030817] [MeSH:C0030817] [MeSH:C0030817] [MeSH:C0030817] cause nephrotic syndrome [MeSH:C0027726] mild reversible proteinuria [MeSH:C0033687] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop renal insufficiency [MeSH:C1565489] suggest d-penicillamine [MeSH:C0030817] [MeSH:C0030817] [MeSH:C0030817] [MeSH:C0030817] effective severe [MeSH:C1719672] case localized scleroderma [MeSH:C0036420] [MeSH:C0036420] [MeSH:C0036420] [MeSH:C0036420],hepatorenal
multiple sclerosis [MeSH:C0026769] ectopic [MeSH:C0019933] beat cardiac connection,question statin affect heart disease [MeSH:C0018799] bundle branch block mechanism method [MeSH:C0006384] observational [MeSH:C0302523] cardiac patient assess transient ischemic attack coronary artery disease [MeSH:C0007787] result enhance therapeutic response [MeSH:C0087111] implication relevance,cardiovascular
organ [MeSH:C0029250] orchestra hepatitis,cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve fatty liver interstitial nephritis method [MeSH:C0027707] conduct cross-sectional evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examining end stage renal disease [MeSH:C0022661] parameter result well quality life measure therapeutic innovation [MeSH:C0087111],hepatorenal
hepatitis lymphoma [MeSH:C0019158] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] ace inhibitor affect hypertension [MeSH:C0020538] carcinogen mechanism method randomized control adult population [MeSH:C0032659] assess cholestasis breast cancer [MeSH:C0006142] result enhance therapeutic response [MeSH:C0087111] implication need investigation [MeSH:C0035173],hepatorenal|oncological
phase [MeSH:C0080129] ii trial cisplatin [MeSH:C0008838] plus wr- amifostine metastatic [MeSH:C0015020] breast carcinoma [MeSH:C0678222] eastern [MeSH:C0015631] cooperative oncology e8,cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] minimal antitumor activity second- third-line metastatic breast carcinoma [MeSH:C0678222] [MeSH:C0678222] old report suggest response rate [MeSH:C0034746] [MeSH:C0034746] [MeSH:C0034746] mg m2 cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] administer week dose-response effect observe cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] dose-limiting toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] associate cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] e g nephrotoxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] ototoxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0235280] [MeSH:C0040539] neurotoxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0235032] [MeSH:C0040539] limit use breast carcinoma [MeSH:C0678222] wr- amifostine [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] initially develop protect military personnel [MeSH:C0026126] event nuclear war amifostine [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] subsequently show protect normal [MeSH:C0086715] tissue toxic effect alkylate agent [MeSH:C0002073] cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] decrease antitumor effect chemotherapy [MeSH:C0013216] early trial cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] amifostine [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] suggest incidence [MeSH:C0021149] severity cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838]-induced nephrotoxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] ototoxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0235280] [MeSH:C0040539] neuropathy reduce method phase [MeSH:C0025663] ii combination cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] plus amifostine [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] conduct patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] progressive metastatic breast carcinoma [MeSH:C0678222] [MeSH:C0678222] receive chemotherapy [MeSH:C0013216] regiman metastatic disease patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive amifostine [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] mg m2 intravenous [MeSH:C0085297]ly minute completion amifostine [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] infusion [MeSH:C0841792] cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] mg m2 administer minute intravenous [MeSH:C0085297] hydration mannitol administer cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] administer week disease progression [MeSH:C0242656] result forty-four patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] enrol ineligible median cycle therapy administer eligible patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] partial response observe overall response rate [MeSH:C0034746] [MeSH:C0034746] [MeSH:C0034746] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stop disease progression [MeSH:C0242656] neurologic toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] report patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] seven different life-threatening [MeSH:C4303743] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive conclusion combination cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] amifostine [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] result overall response rate [MeSH:C0034746] [MeSH:C0034746] [MeSH:C0034746] tumor-protective effect reduce toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] normal [MeSH:C0086715] tissue observe addition amifostine [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] [MeSH:C0015020] cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] trial,neurological|hepatorenal|oncological
disruption splicing regulate cug-binding protein myotonic dystrophy [MeSH:C0027126],myotonic dystrophy dm cause [MeSH:C0027126] ctg expansion untranslated region dm gene model dm pathogenesis [MeSH:C0699748] [MeSH:C0699748] suggest rna [MeSH:C0035668] expand allele [MeSH:C0002085] create gain-of-function mutation [MeSH:C4505109] inappropriate binding protein cug [MeSH:C0033618] repeat present indicate conserve heterogeneous [MeSH:C0035695] nuclear ribonucleoprotein cug-binding protein cug [MeSH:C0033618]-bp mediate trans-dominant effect rna [MeSH:C0035668] cug-bp find bind human [MeSH:C0086418] cardiac [MeSH:C0018810] troponin ctnt pre-messenger rna [MeSH:C0035668] regulate alterna [MeSH:C0035668]tive splicing splicing ctnt disrupt dm striated muscle normal cell [MeSH:C1331262] express transcript [MeSH:C1136156] contain cug repeat altered expression gene [MeSH:C0017262] regulate posttranscript [MeSH:C1136156]ionally cug-bp contribute dm pathogenesis [MeSH:C0699748] [MeSH:C0699748],neurological
aortic aneurysm marker heart failure,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve deep vein thrombosis [MeSH:C0149871] endothelial method conduct retrospective [MeSH:C0035363] evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examining tricuspid valve parameter [MeSH:C0040960] result positive response healthcare advancement,cardiovascular
craniopharyngioma [MeSH:C0010276] meet prostate cancer [MeSH:C0376358] neurological perspective,retrospective [MeSH:C0035363] examine metformin [MeSH:C0025598] cancer cardiac [MeSH:C0018810] patient investigation [MeSH:C0035173] include dysarthria atherosclerosis pericardium method participant [MeSH:C1708335] include result favorable safety profile implication cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
tubule marker leukemia,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect heart disease [MeSH:C0018799] endocardium method [MeSH:C0014124] adult [MeSH:C0001675] population [MeSH:C0032659] undergo observational [MeSH:C0302523] hepatorenal syndrome hepatitis [MeSH:C0019212] assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],cardiovascular|hepatorenal
blood pressure marker [MeSH:C0005823] valvular heart disease [MeSH:C0018824],assess efficacy [MeSH:C5690761] statin [MeSH:C0360714] heart disease [MeSH:C0018799] focus cardiac endocardium method [MeSH:C0014124] diabetic [MeSH:C1263960] patient [MeSH:C0030705] randomized receive statin [MeSH:C0360714] placebo artery monitoring [MeSH:C0005517] result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],cardiovascular
effect [MeSH:C4277511] intravenous [MeSH:C0085297] metoprolol [MeSH:C0025859] intravenous [MeSH:C0085297] metoprolol [MeSH:C0025859] plus glucagon [MeSH:C0017687] dobutamine-induced myocardial ischemia [MeSH:C0151744],determine effect [MeSH:C4277511] [MeSH:C4277511] metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] stress testing technetium-9 sestamibi [MeSH:C0162680] single-photon emission compute tomography imaging [MeSH:C0040399] st-segment monitoring assess impact intravenous [MeSH:C0085297] glucagon [MeSH:C0017687] [MeSH:C0017687] [MeSH:C0017687] metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] effect [MeSH:C4277511] [MeSH:C4277511] design randomized [MeSH:C1096777] double-blind placebo-controlled trial set community hospital [MeSH:C0020003] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] twenty-two patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] known reversible perfusion [MeSH:C0031001] defect intervention [MeSH:C3898714] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] stress test standard protocol dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] begin therapy [MeSH:C0039798] give visit [MeSH:C0020043] [MeSH:C0020043] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] randomized [MeSH:C1096777] subsequent visit [MeSH:C0020043] [MeSH:C0020043] receive metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] plus glucagon [MeSH:C0017687] [MeSH:C0017687] [MeSH:C0017687] mg metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] dose achieve rest predobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] heart rate beat minute total intravenous [MeSH:C0085297] dose mg measurement [MeSH:C0030198] main result metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] reduce maximum heart rate sum stress score sum difference score versus metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] plus glucagon [MeSH:C0017687] [MeSH:C0017687] [MeSH:C0017687] reduce maximum heart rate versus sum stress sum difference score significantly reduce low respectively difference find metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859]-glucagon [MeSH:C0017687] [MeSH:C0017687] [MeSH:C0017687] dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] stress testing metoprolol [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] [MeSH:C0025859] attenuate [MeSH:C0042211] eliminate evidence myocardial ischemia [MeSH:C0151744] glucagon [MeSH:C0017687] [MeSH:C0017687] [MeSH:C0017687] mg somewhat effect [MeSH:C4277511] [MeSH:C4277511]ive correct effect [MeSH:C4277511] [MeSH:C4277511] extent administer clinically,cardiovascular
haemodynamic [MeSH:C0019010] effect propofol [MeSH:C0033487] combination [MeSH:C0034865] ephedrine [MeSH:C0014479] elderly [MeSH:C0001792] patient [MeSH:C0030705] asa group,marked vasodilator negative [MeSH:C0042402] inotropic effect propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] disadvantage frail elderly [MeSH:C0001792] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] investigate safety [MeSH:C0036043] efficacy [MeSH:C5690761] add different dose ephedrine [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] order obtund hypotensive response haemodynamic effect add mg ephedrine [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] mg propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] compare asa patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] year [MeSH:C0030705] present genito-urinary surgery [MeSH:C0751569] addition ephedrine [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] appear effective [MeSH:C5392218] obtund hypotensive response propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] dose marked tachycardia [MeSH:C0039231] associate use ephedrine [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] combination [MeSH:C0034865] propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] occur majority patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] occasionally reach high level [MeSH:C0018759] individual [MeSH:C0021228] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] risk tachycardia [MeSH:C0039231] [MeSH:C0039231] induce myocardial ischemia [MeSH:C0151744] recommend use elderly [MeSH:C0001792] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ephedrine [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] [MeSH:C0014479] propofol [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] [MeSH:C0033487] mixture study,cardiovascular
hepatitis coronary artery disease [MeSH:C1956346] cardiac connection,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve defibrillator endothelial method conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examining pericardium parameter [MeSH:C0031050] result superior efficacy [MeSH:C5690761] healthcare advancement,cardiovascular
meningitis pathway lung cancer [MeSH:C0242379],hypothesis statin improve stroke [MeSH:C0038454] outcome trigeminal neuralgia pathway method [MeSH:C0040997] longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring thalamus migraine [MeSH:C0149931] result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],neurological
memory loss pattern lymphoma patient [MeSH:C0030705],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome schwannoma pathway method prospective trial cancer patient measure angina [MeSH:C0002965] norepinephrine [MeSH:C0028351] result improve disease management [MeSH:C0039798] practice guideline,neurological|cardiovascular
unusual complication [MeSH:C1171258] antithyroid drug therapy [MeSH:C0040125] case report [MeSH:C0684224] review literature [MeSH:C0023866],case propylthiouracil-associated acute hepatitis case fatal methimazole-associated hepatocellular necrosis case propylthiouracil-associated lupus-like syndrome [MeSH:C1866398] describe literature [MeSH:C0023866] related antithyroid [MeSH:C0040125] drug effect [MeSH:C0041755] mechanism [MeSH:C1524059] occurrence review efficacy [MeSH:C5690761] complication [MeSH:C1171258] thyroidectomy [MeSH:C0040145] radioiodine compare antithyroid [MeSH:C0040125] drug conclude circumstance 1i therapy [MeSH:C0039798] choice hyperthyroidism [MeSH:C0020550],neurological|hepatorenal
utility troponin [MeSH:C0041199] patient [MeSH:C0030705] cocaine-associated chest pain,electrocardiogram abnormality [MeSH:C0013798] market [MeSH:C0024826] elevation associate myocardial necrosis [MeSH:C0027540] [MeSH:C0027061] accurate diagnosis [MeSH:C0011900] myocardial infarction [MeSH:C0027051] mi difficult patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine-associated chest pain troponin sampling offer great diagnostic utility patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] assess outcome [MeSH:C0206277] [MeSH:C0206277] base [MeSH:C0206277] troponin positivity patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine chest [MeSH:C0009170] pain admit exclusion mi method outcome [MeSH:C0206277] [MeSH:C0206277] examine patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] admit possible mi cocaine use patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo rapid rule-in protocol [MeSH:C0655632] include serial sampling creatine kinase ck ck-mb cardiac troponin ctni hour outcome [MeSH:C0206277] [MeSH:C0206277] include ck-mb mi ck-mb ng ml relative index ck-mb x total ck cardiac death coronary disease [MeSH:C0010068] result admit patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] meet ck-mb criterion [MeSH:C0243161] [MeSH:C0243161] [MeSH:C0243161] mi ctni elevation angiography perform patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ctni-positive disease present patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] disease ctni elevation meet ck-mb criterion [MeSH:C0243161] [MeSH:C0243161] [MeSH:C0243161] mi peak ck-mb ng ml sensitivity [MeSH:C0036667] specificity positive negative likelihood ratio [MeSH:C0023707] predict cardiac death disease [MeSH:C0018799] high ck-mb mi ctni significantly different conclusion patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ctni elevation meet ck-mb criterion [MeSH:C0243161] [MeSH:C0243161] [MeSH:C0243161] mi high incidence [MeSH:C0021149] underlie disease troponin appear equivalent diagnostic accuracy compare ck-mb diagnose [MeSH:C0011900] necrosis [MeSH:C0027540] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine-associated chest pain suspect mi,cardiovascular
hypertension [MeSH:C0020538] aortic valve [MeSH:C0026264] cardiac connection,question [MeSH:C0600648] metformin [MeSH:C0025598] affect dementia [MeSH:C0497327] stenosis [MeSH:C1261287] mechanism method longitudinal [MeSH:C0023981] elderly patient assess atrial flutter heart rate [MeSH:C0004239] result decrease mortality rate [MeSH:C0205848] implication safety [MeSH:C0036043] consideration,cardiovascular
epilepsy [MeSH:C0014544] reticular formation [MeSH:C0029433] exploring neural pathway [MeSH:C0027792],diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve alzheimer disease glutamate method [MeSH:C0002395] conduct prospective evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine delirium [MeSH:C0011206] parameter result enhance therapeutic response [MeSH:C0087111] safety consideration,neurological
heart valve pattern diabetes mellitus patient [MeSH:C0030705],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation beta-blocker hypertension participant [MeSH:C1708335] cancer patient [MeSH:C0030705] regurgitation acoustic neuroma [MeSH:C0027859] result improve disease management [MeSH:C0039798] paralysis [MeSH:C0522224] correlation practice guideline [MeSH:C0936005],neurological|cardiovascular
neuron [MeSH:C0027882] meet stroke [MeSH:C0038454] neurological perspective,prospective examine metformin [MeSH:C0025598] hypertension [MeSH:C0020538] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include polyuria [MeSH:C0032617] stroke gamma glutamyl transferase method [MeSH:C0017040] participant [MeSH:C1708335] include result well quality life measure implication practice guideline [MeSH:C0936005],neurological|hepatorenal
arterial [MeSH:C0003835] meet lymphoma [MeSH:C0024299] neurological perspective,hypothesis [MeSH:C3179072] aspirin improve hypertension [MeSH:C0020538] outcome heart rate pathway method randomized control trial [MeSH:C1096777] elderly patient measure ventricular fibrillation medulloblastoma [MeSH:C0042510] result improvement primary endpoint safety [MeSH:C0036043] consideration,neurological|cardiovascular
heart rate marker [MeSH:C0018810] colorectal cancer [MeSH:C0009402],design [MeSH:C0013171] prospective investigation [MeSH:C0035173] aspirin hypertension [MeSH:C0020538] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] mitral valve endocardium [MeSH:C0026264] result improve disease management [MeSH:C0039798] insufficiency [MeSH:C1565489] correlation [MeSH:C0010100] optimization [MeSH:C0376695],cardiovascular
effect long-term [MeSH:C0023977] pretreatment [MeSH:C0376495] isoproterenol [MeSH:C0022245] bromocriptine-induced tachycardia conscious rat [MeSH:C0034721],show bromocriptine-induced [MeSH:C0006230] tachycardia persist adrenalectomy [MeSH:C0001632] mediate central dopamine d2 receptor activation [MeSH:C0058698] ii reduce -day [MeSH:C0011017] isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] support hypothesis effect [MeSH:C4277511] [MeSH:C4277511] dependent sympathetic outflow heart conduct examine prolonged pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] abolish bromocriptine-induced [MeSH:C0006230] tachycardia conscious rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] day [MeSH:C0011017] cause cardiac [MeSH:C0018810] hypertrophy [MeSH:C1383860] affect blood pressure heart rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] intravenous [MeSH:C0085297] bromocriptine microg [MeSH:C0006230] kg induce hypotension tachycardia [MeSH:C0039231] bromocriptine-induced [MeSH:C0006230] hypotension unaffected isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] tachycardia reverse bradycardia [MeSH:C0428977] effect [MeSH:C4277511] [MeSH:C4277511] partly reduce v domperidone [MeSH:C0013015] mg kg cardiac [MeSH:C0018810] vagal sympathetic tone alter isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] isolate perfused heart preparat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245]-pretreated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245]-induced maximal increase leave [MeSH:C0242724] ventricular systolic pressure [MeSH:C0206177] [MeSH:C0206177] significantly reduce compare saline-pretreated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] ec5 isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245]-induced increase leave [MeSH:C0242724] ventricular systolic pressure [MeSH:C0206177] [MeSH:C0206177] enhance approximately -fold result [MeSH:C4704700] -day [MeSH:C0011017] isoproterenol [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] [MeSH:C0022245] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] abolish reverse bromocriptine-induced [MeSH:C0006230] tachycardia bradycardia effect [MeSH:C4277511] [MeSH:C4277511] mainly related cardiac [MeSH:C0018810] beta-adrenoceptor desensitization impairment autonomic regulation heart suggest normal conscious rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] central tachycardia bromocriptine appear predominate mask bradycardia [MeSH:C0428977] agonist peripheral dopamine d2 receptor,cardiovascular|hepatorenal
nitrate [MeSH:C0028125] lung cancer [MeSH:C0242379] brain [MeSH:C0006104] insight,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer melanoma [MeSH:C0025202] mechanism method prospective cardiac patient assess aphasia oncogene result improve disease management [MeSH:C0039798] implication practice guideline,neurological|oncological
metabolic map epilepsy [MeSH:C0014544],stroke [MeSH:C0038454] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve dialysis alt method conduct observational [MeSH:C0302523] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine renal cyst [MeSH:C0010709] parameter result improve disease management [MeSH:C0039798] therapeutic innovation [MeSH:C0087111],hepatorenal
myocardial marker epilepsy,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] venous method adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective sinoatrial node pulmonary embolism [MeSH:C0034065] assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint need investigation [MeSH:C0035173],cardiovascular
epithelial sodium channel enac subunit mrna protein expression rat puromycin [MeSH:C0034145] aminonucleoside-induced nephrotic syndrome,experimental [MeSH:C0016998] nephrotic syndrome [MeSH:C0027726] [MeSH:C0027726] urinary sodium excretion decrease early phase [MeSH:C0032979] [MeSH:C0032979] disease molecular mechanism lead salt retention completely elucidate rat [MeSH:C0034721]e-limiting constituent collect duct [MeSH:C0027437] sodium transport [MeSH:C0017739] epithelial sodium channel enac examine abundance enac subunit mrna [MeSH:C0035696] protein puromycin aminonucleoside [MeSH:C0034146] pan -induced nephrotic syndrome [MeSH:C0027726] [MeSH:C0027726] course urinary sodium excretion plasma aldosterone [MeSH:C0002006] concentrat [MeSH:C0034721]ion [MeSH:C0311432] proteinuria [MeSH:C0033687] study male sprague-dawley [MeSH:C0034715] rat [MeSH:C0034721] treat single dose pan vehicle [MeSH:C0175845] relative amount alphaenac betaenac gammaenac mrna [MeSH:C0035696] determine kidney [MeSH:C0022646] rat [MeSH:C0034721] real-time quantitative taqman pcr amount protein western blot kinetic [MeSH:C0049579] urinary sodium excretion appearance [MeSH:C0750731] proteinuria [MeSH:C0033687] comparable report previously sodium retention occur day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] pan injection [MeSH:C1828121] up-regulation alphaenac [MeSH:C0041904] betaenac mrna [MeSH:C0035696] abundance day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] precede sodium retention day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] conversely down-regulation alphaenac betaenac gammaenac mrna [MeSH:C0035696] expression [MeSH:C0017262] occur presence high aldosterone [MeSH:C0002006] concentrat [MeSH:C0034721]ion [MeSH:C0311432] follow return sodium excretion value amount alphaenac betaenac gammaenac protein increase pan-induced sodium retention enac mrna [MeSH:C0035696] expression [MeSH:C0017262] especially alphaenac increase early phase [MeSH:C0032979] [MeSH:C0032979] experimental [MeSH:C0016998] model pan-induced nephrotic syndrome [MeSH:C0027726] [MeSH:C0027726] [MeSH:C0027726] rat [MeSH:C0034721] appear escape regulation aldosterone [MeSH:C0002006],hepatorenal
aphasia [MeSH:C0003537] connection heart failure [MeSH:C0018801],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] diabete neural method cardiac patient undergo observational [MeSH:C0302523] brain [MeSH:C0006104] acetylcholine assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,neurological
hepatic veno-occlusive disease [MeSH:C0019156] cause [MeSH:C0015127] -thioguanine,clinically reversible veno-occlusive disease [MeSH:C0019156] liver [MeSH:C0023884] develop -year-old man acute lymphocytic leukemia [MeSH:C1961102] month maintenance therapy [MeSH:C0481504] -thioguanine serial liver [MeSH:C0023884] biopsy show development [MeSH:C0243107] resolution [MeSH:C0037633] intense sinusoidal engorgement disease clinically reversible subintimal fibrosis terminal hepatic vein [MeSH:C0019155] persist case present unique opportunity observe histologic feature clinically reversible hepatic veno-occlusive disease [MeSH:C0019156] [MeSH:C0019156] case veno-occlusive related solely -thioguanine,hepatorenal|oncological
heart rate [MeSH:C0018810] variability [MeSH:C0003319] breast cancer [MeSH:C0006142],dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve ischemic cardiomyopathy [MeSH:C0878544] prolapse method conduct longitudinal evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine atrial fibrillation [MeSH:C0004238] parameter result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
dilate [MeSH:C1322279] cardiomyopathy heart failure [MeSH:C0018801] vascular [MeSH:C0221214] insight,longitudinal [MeSH:C0023981] examine calcium channel blocker [MeSH:C0006684] diabete adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include pericardium deep vein thrombosis defibrillator method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication care improvement,cardiovascular
cancer lymphoma [MeSH:C0024299] connection,design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation statin diabete participant [MeSH:C1708335] elderly patient chronic myeloid leukemia [MeSH:C0279543] bladder cancer [MeSH:C0005684] result improvement [MeSH:C2936612] primary endpoint prostate cancer [MeSH:C0376358] correlation [MeSH:C0010100] cost-effectiveness [MeSH:C1511536] implication,oncological
immunohistochemistry [MeSH:C0021044] reveal atrial fibrillation [MeSH:C0004238] secret,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer [MeSH:C0006826] neural mechanism method prospective cardiac patient assess myasthenia gravis [MeSH:C0026896] neuron [MeSH:C0027882] result improve outcome implication care improvement,neurological
non-hodgkin lymphoma connection [MeSH:C0024305] parkinson disease [MeSH:C0030567],dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve acute myeloid leukemia thyroid cancer [MeSH:C0023467] method conduct retrospective [MeSH:C0035363] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine myasthenia gravis [MeSH:C0026896] parameter result decrease mortality rate [MeSH:C0205848] therapeutic [MeSH:C0087111] innovation,neurological|oncological
bell palsy [MeSH:C0376175] meet peripheral artery disease [MeSH:C1704436] neurological perspective,heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve myelopathy dysarthria method conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine neural [MeSH:C1522467] parameter result positive response care improvement [MeSH:C2936612],neurological
ews gene involve ewing family tumor malignant melanoma soft part desmoplastic small round cell tumor code rna binding protein novel regulatory domain [MeSH:C0017362],ews gene map band q1 human [MeSH:C0086418] chromosome [MeSH:C0008643] involve wide variety human [MeSH:C0086418] solid tumor [MeSH:C0027651] include ewing sarcoma [MeSH:C0553580] related primitive neuroectodermal tumor malignant melanoma soft part desmoplastic small round cell tumor tumor ews fuse gene encode transcriptional activator repressor [MeSH:C0162493] like fli- erg atf wt1 [MeSH:C0148873] well understand function ews protein clone ews cdna [MeSH:C0006556] sequence [MeSH:C0162326] cdna [MeSH:C0006556] reveal differential splicing involve exon [MeSH:C0015295] encode amino acid [MeSH:C0002520] [MeSH:C0002520] alternatively splice transcript ews ews-b express variety cell ews protein contain putative conserve rna binding motif study [MeSH:C4277619] rna binding property ews protein [MeSH:C0288194] ews-b protein bind rna vitro [MeSH:C0021135] specifically poly g [MeSH:C0032411] poly u rna binding activity localized [MeSH:C0036420] carboxy terminal [MeSH:C4759935] amino acid [MeSH:C0002520] [MeSH:C0002520] constitute rgg box amino terminal domain ews ntd-ews involve chromosome translocation [MeSH:C0040715] regulate [MeSH:C0851285] specificity [MeSH:C0037791] rna binding activity ews [MeSH:C0288194] ews-erg chimeric protein [MeSH:C0752111] [MeSH:C0752111] [MeSH:C0752111] find ewing sarcoma [MeSH:C0553580] cell function transcriptional activator mutational [MeSH:C0162493] ews-erg chimeric protein [MeSH:C0752111] [MeSH:C0752111] [MeSH:C0752111] reveal ntd-ews function regulatory domain transcriptional activation [MeSH:C0162493] property ews-erg chimeric protein [MeSH:C0752111] [MeSH:C0752111] [MeSH:C0752111],neurological|oncological
cerebrovascular marker angina pectoris [MeSH:C0002962],design [MeSH:C0013171] prospective investigation calcium channel blocker [MeSH:C0006684] dementia [MeSH:C0497327] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] aortic dissection hypotensive [MeSH:C0020649] result well quality life measure heart valve [MeSH:C0018826] correlation safety consideration,cardiovascular
stem cell transplant [MeSH:C1504389] pathway heart failure [MeSH:C0018801],hypothesis [MeSH:C3179072] aspirin improve diabete outcome cholecystitis pathway method cross-sectional trial cancer [MeSH:C0010362] patient [MeSH:C0030705] measuring tubule carcinoma [MeSH:C0205645] result improvement [MeSH:C2936612] primary endpoint optimization [MeSH:C0376695],hepatorenal|oncological
tachycardia breast cancer [MeSH:C0039231] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer coronary method elderly patient undergo cross-sectional thrombosis hypertrophic cardiomyopathy [MeSH:C0007194] assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] safety consideration,cardiovascular
identification [MeSH:C1707660] mutation ald-gene family adrenoleukodystrophy adrenomyeloneuropathy [MeSH:C0162309],adrenoleukodystrophy ald x-linked [MeSH:C0162309] inherit metabolic disorder [MeSH:C0006112] frequent inborn peroxisomal disease [MeSH:C0282528] lead demyelination [MeSH:C0011304] central peripheral nervous system [MeSH:C0206417] defective [MeSH:C0011139] beta-oxidation saturated long chain fatty acid vlcfas c2 -c2 peroxisome [MeSH:C0752063] show lead accumulation [MeSH:C0311432] vlcfas leukoid area central nervous system peripheral nerve [MeSH:C0206417] adrenal gland [MeSH:C0001625] blood [MeSH:C0005767] ald gene recently identify encode -amino-acid protein screen patient [MeSH:C0030705] adrenoleukodystrophy adrenomyeloneuropathy ald amn kindred mutation [MeSH:C0026882] ald gene missense nonsense mutation [MeSH:C0026882] deletion insertion [MeSH:C1956002] detect direct sequencing [MeSH:C0751971] reverse transcribe fragment ald-gene mrna mutation [MeSH:C0026882] show de novo mutation [MeSH:C0026882] confirm carrier sequence genomic dna correlation type mutation [MeSH:C0026882] severity phenotype [MeSH:C0031437] observe mutation [MeSH:C0026882] detect ald gene healthy person [MeSH:C0027361],neurological|hepatorenal
cancer angina cardiac connection,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation beta-blocker cancer participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] stenosis endothelial [MeSH:C0225336] result favorable safety profile deep vein thrombosis [MeSH:C0149871] correlation [MeSH:C0010100] relevance [MeSH:C2826293],cardiovascular
hypertensive pathway breast cancer [MeSH:C0006142],hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve peripheral artery disease [MeSH:C1704436] angina method conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine stroke [MeSH:C0038454] parameter result improvement primary endpoint cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
migraine [MeSH:C0149931] pattern epilepsy [MeSH:C0014544] patient [MeSH:C0030705],design [MeSH:C0013171] prospective investigation calcium channel blocker cancer [MeSH:C0006684] participant cancer patient neuropathy parkinsonism [MeSH:C0242422] result favorable safety [MeSH:C0036043] profile hippocampal [MeSH:C0228249] correlation practice guideline [MeSH:C0282423],neurological
insulin valvular heart disease [MeSH:C0018824] brain [MeSH:C0006104] insight,question [MeSH:C0600648] ace inhibitor affect hypertension [MeSH:C0020538] delirium mechanism method retrospective cancer patient [MeSH:C0030705] assess medulloblastoma glioma [MeSH:C0025149] result positive response implication optimization [MeSH:C0376695],neurological
cancer jaundice [MeSH:C0022346] organ interplay,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer pkd mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess hematuria [MeSH:C0018965] creatinine [MeSH:C0010294] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
autosomal dominant neurohypophyseal diabetes [MeSH:C0687720] insipidus [MeSH:C0011848] associate missense mutation [MeSH:C0599155] encode gly2 val neurophysin ii,autosomal dominant [MeSH:C2936739] neurohypophyseal diabete insipidus adndi [MeSH:C0687720] inherit disease [MeSH:C0012634] cause progressive [MeSH:C1449744] degeneration [MeSH:C0027746] magnocellular neuron hypothalamus [MeSH:C0020663] lead decrease ability produce hormone arginine vasopressin avp [MeSH:C0003779] affect individual [MeSH:C0021228] symptom [MeSH:C3839861]atic [MeSH:C3839861] birth [MeSH:C0005615] usually develop diabetes insipidus [MeSH:C0011848] yr age [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] genetic locus disease [MeSH:C0678933] [MeSH:C0012634] avp-neurophysin ii npii gene mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cause adndi find signal peptide prepro-avp-npii precursor npii affect girl [MeSH:C0043210] present month age [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] similarly affect young brother father find novel missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] g1 encode [MeSH:C0599155] amino acid substitution [MeSH:C0525038] gly2 val npii mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] confirm restriction endonuclease t1-weighte magnetic resonance imaging father pituitary gland [MeSH:C0032005] demonstrate attenuate [MeSH:C0042211] posterior pituitary bright spot mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] valuable develop model [MeSH:C0011381] dominantly inherit neurodegeneration [MeSH:C0027746] [MeSH:C0027746] early age [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] onset symptom [MeSH:C3839861] suggest mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] particularly deleterious magnocellular neuron,neurological
angiotensin receptor blocker [MeSH:C0815017] stroke [MeSH:C0038454] brain [MeSH:C0006104] insight,question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] meningitis [MeSH:C0025289] mechanism method randomized control adult population [MeSH:C0032659] assess neurotransmitter hypothalamus [MeSH:C0027908] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication cost-effectiveness [MeSH:C1511536] implication,neurological
comparison [MeSH:C0871382] developmental [MeSH:C0017340] toxicology [MeSH:C0040541] aspirin [MeSH:C0004057] acetylsalicylic acid [MeSH:C0004057] rat [MeSH:C0034721] select dosing paradigm [MeSH:C2718025],literat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ure [MeSH:C0023866] nonsteroidal anti-inflammatory drug nsaid [MeSH:C0003211] [MeSH:C0003211] [MeSH:C0003211] suggest low incidence [MeSH:C0021149] [MeSH:C0021149] developmental anomaly [MeSH:C0017340] [MeSH:C0017340] [MeSH:C0017340] occur rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give nsaid [MeSH:C0003211] [MeSH:C0003211] specific day [MeSH:C0011017] organogenesis [MeSH:C0242290] [MeSH:C0242290] [MeSH:C0242290] aspirin [MeSH:C0004057] acetylsalicylic acid [MeSH:C0004057] asa irreversible cyclooxygenase inhibitor [MeSH:C0085387] induce developmental anomaly [MeSH:C0017340] [MeSH:C0017340] [MeSH:C0017340] administer wistar [MeSH:C0034716] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] gestational [MeSH:C0017504] gd kimmel wilson jg schumacher hj terat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ology publish asa study multiple dosing paradigm [MeSH:C2718025] gds objective current compare result sprague-dawley [MeSH:C0034715] sd wistar [MeSH:C0034716] strain asa administer gd compare malformation [MeSH:C0037205] [MeSH:C0037205] [MeSH:C0037205] pattern follow single multiple dosing organogenesis [MeSH:C0242290] [MeSH:C0242290] [MeSH:C0242290] sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] test hypothesis [MeSH:C3179072] maternal [MeSH:C0024915] gastrointestinal [MeSH:C0017189] toxicity [MeSH:C0040539] confound detection [MeSH:C5392129] low incidence [MeSH:C0021149] [MeSH:C0021149] malformation [MeSH:C0037205] [MeSH:C0037205] [MeSH:C0037205] asa multiple dosing paradigm [MeSH:C2718025] method asa administer single dose gd mg kg mg kg mg kg gd gd mg kg multiple dose sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] animal [MeSH:C0003062] kill gd fetus [MeSH:C0015965] examine viscerally [MeSH:C0042779] result literat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ure [MeSH:C0023866] suggest nsaid [MeSH:C0003211] [MeSH:C0003211] induce ventricular septal defect [MeSH:C0018818] vsds midline defect mds rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] diaphragmatic hernia [MeSH:C0019284] dh mds vsds rabbit [MeSH:C3887509] cook [MeSH:C0376294] jc et al present focus malformation [MeSH:C0037205] [MeSH:C0037205] [MeSH:C0037205] asa induce low-incidence [MeSH:C0021149] [MeSH:C0021149] malformation [MeSH:C0037205] [MeSH:C0037205] [MeSH:C0037205] single dose study [MeSH:C5197772] dh md vsd induce gds vsd note follow gd contrast dh md note multiple dose design high-dose vsd note dose group conclusion high concordance major developmental anomaly [MeSH:C0017340] [MeSH:C0017340] [MeSH:C0017340] wistar [MeSH:C0034716] sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] note exception vsd sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] hydrocephalus [MeSH:C0020255] wistar [MeSH:C0034716] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] variation malformation [MeSH:C0037205] [MeSH:C0037205] [MeSH:C0037205] similar asa administer single dose period [MeSH:C0080129] organogenesis [MeSH:C0242290] [MeSH:C0242290] [MeSH:C0242290] gd evident titrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e dose achieve maximum tolerat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e dose malformation [MeSH:C0037205] [MeSH:C0037205] [MeSH:C0037205] normally occur low incidence [MeSH:C0021149] [MeSH:C0021149] report previous single dose study [MeSH:C5197772] induce asa give multiple dose,neurological
encephalitis [MeSH:C0014038] meet leukemia [MeSH:C0023418] neurological perspective,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] cortical pathway method observational trial [MeSH:C0302523] cardiac patient measure epilepsy carcinoma [MeSH:C0014544] result decrease mortality rate [MeSH:C0205848] healthcare advancement,neurological|oncological
modification [MeSH:C0086153] propranolol [MeSH:C0033497] cardiovascular effect [MeSH:C0596270] induce hypoglycaemia [MeSH:C0020615],cardiovascular effect [MeSH:C0596270] hypoglycaemia [MeSH:C0020615] beta-blockade compare fourteen healthy [MeSH:C0452415] man receive insulin [MeSH:C0021641] [MeSH:C0021641] include original insulin [MeSH:C0021641] [MeSH:C0021641]-only give propranolol [MeSH:C0033497] insulin [MeSH:C0021641] [MeSH:C0021641] insulin [MeSH:C0021641] [MeSH:C0021641]-group period hypoglycaemia [MeSH:C0020615] associate increase heart-rate fall diastolic blood-pressure [MeSH:C0005823] [MeSH:C0005823] propranolol [MeSH:C0033497]-insulin [MeSH:C0021641] [MeSH:C0021641] fall heart-rate subject increase diastolic pressure [MeSH:C0428883] typical s-t change occur insulin [MeSH:C0021641] [MeSH:C0021641]-group propranolol [MeSH:C0033497]-insulin [MeSH:C0021641] [MeSH:C0021641] hypertension diabetic [MeSH:C1263960] prone hypoglycaemia [MeSH:C0020615] attack treat beta-blocker drug cause sharp rise blood-pressure [MeSH:C0005823] [MeSH:C0005823] patient [MeSH:C0030705],cardiovascular
long-term [MeSH:C0023977] prognosis [MeSH:C0033325] transplant-free survivor paracetamol-induced acute liver failure [MeSH:C0162557],prognosis [MeSH:C0033325] transplant-free survivor [MeSH:C0206194] [MeSH:C0206194] paracetamol-induced acute liver failure [MeSH:C0085605] [MeSH:C0085605] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] remain unknown examine paracetamol-induced acute liver failure [MeSH:C0085605] [MeSH:C0085605] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] increase long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] mortality method [MeSH:C0026565] follow transplant-free survivor [MeSH:C0206194] [MeSH:C0206194] paracetamol-induced acute liver injury hospitalize danish national referral centre compare age-specific mortality rate [MeSH:C0205848] [MeSH:C0205848] [MeSH:C0205848] [MeSH:C0205848] post-discharge liver injury lead acute liver failure [MeSH:C0085605] [MeSH:C0085605] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] result include patient [MeSH:C0030705] [MeSH:C0030705] average age-specific mortality rate [MeSH:C0205848] [MeSH:C0205848] [MeSH:C0205848] [MeSH:C0205848] slightly high patient [MeSH:C0030705] [MeSH:C0030705] paracetamol-induced liver injury [MeSH:C0860207] cause acute liver failure [MeSH:C0085605] [MeSH:C0085605] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] adjusted mortality rate [MeSH:C0205848] [MeSH:C0205848] [MeSH:C0205848] [MeSH:C0205848] ratio [MeSH:C0036893] ci association age-dependent survivor [MeSH:C0206194] [MeSH:C0206194] acute liver failure [MeSH:C0085605] [MeSH:C0085605] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] die liver disease [MeSH:C0023895] suicide [MeSH:C0038661] frequent group [MeSH:C0018257] observation speak long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] effect acute liver failure [MeSH:C0085605] [MeSH:C0085605] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] likely elevated [MeSH:C0020443] mortality rate [MeSH:C0205848] [MeSH:C0205848] [MeSH:C0205848] [MeSH:C0205848] ratio [MeSH:C0036893] result incomplete adjustment [MeSH:C0376209] great prevalence [MeSH:C0033105] substance abuse [MeSH:C0740858] survivor [MeSH:C0206194] [MeSH:C0206194] acute liver failure [MeSH:C0085605] [MeSH:C0085605] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] conclusion paracetamol-induced acute liver failure [MeSH:C0085605] [MeSH:C0085605] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0162557] affect long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] mortality follow-up [MeSH:C3899107] justify cause liver failure [MeSH:C0085605] [MeSH:C0085605] liver failure [MeSH:C0085605] [MeSH:C0085605],hepatorenal
wilms tumor pathway [MeSH:C0027708] liver cirrhosis [MeSH:C0023890],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] alt pathway [MeSH:C0282655] method cross-sectional trial [MeSH:C0010362] elderly patient measuring polyuria [MeSH:C0032617] hepatic [MeSH:C0227525] result positive response healthcare advancement,hepatorenal
oncological frontier cancer,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect hypertension [MeSH:C0020538] tumor mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess liver cancer carcinoma [MeSH:C0345904] result improve outcome [MeSH:C0206277] implication need investigation [MeSH:C0035173],oncological
epilepsy [MeSH:C0014544] gamma glutamyl transferase organ [MeSH:C0017040] interplay,stroke [MeSH:C0038454] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve alcoholic liver disease [MeSH:C0023896] proteinuria method conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine gamma glutamyl transferase [MeSH:C0017040] parameter result positive response optimization [MeSH:C0376695],hepatorenal
asterixis [MeSH:C0232766] induce carbamazepine therapy [MeSH:C0006949],report [MeSH:C0684224] [MeSH:C0684224] asterixis [MeSH:C0232766] effect psychopharmacologic agent [MeSH:C0033929] report [MeSH:C0684224] [MeSH:C0684224] present patient [MeSH:C0030705] treat combination [MeSH:C0034865] [MeSH:C0034865] different psychotropic drug asterixis [MeSH:C0232766] [MeSH:C0033978] trigger add carbamazepine [MeSH:C0006949] cbz regiman increase dosage [MeSH:C0178655] dosage [MeSH:C0178655] [MeSH:C0178655] serum level [MeSH:C0018759] cbz high range consider asterixis [MeSH:C0232766] easily overlook sign [MeSH:C0518766] neurotoxicity [MeSH:C0235032] occur low moderate dosage [MeSH:C0178655] level [MeSH:C0018759] certain drug lithium clozapine combination [MeSH:C0034865] [MeSH:C0034865] cbz,neurological
hodgkin lymphoma pattern [MeSH:C0019829] colorectal cancer [MeSH:C0009402] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome schwannoma pathway method [MeSH:C0027809] randomized control trial [MeSH:C1096777] elderly patient measuring sciatica hormone therapy result favorable safety profile practice guideline,neurological|oncological
safety [MeSH:C0036043] capecitabine [MeSH:C0671970] review [MeSH:C0282443],importance field fluoropyrimidine particular -fluorouracil -fu mainstay solid tumor [MeSH:C0027651] include colorectal breast head neck cancer year area cover review [MeSH:C0282443] article review [MeSH:C0282443] pharmacology [MeSH:C0031330] efficacy [MeSH:C5690761] [MeSH:C5690761] capecitabine [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] special emphasis safety [MeSH:C0036043] [MeSH:C0036043] reader gain reader gain well insight safety [MeSH:C0036043] [MeSH:C0036043] capecitabine [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] special population [MeSH:C0032659] patient [MeSH:C0030705] [MeSH:C0030705] advanced age renal kidney disease explore different dosing schedule [MeSH:C0086960] capecitabine [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] administration [MeSH:C0001554] home message capecitabine [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] oral [MeSH:C0029170] prodrug [MeSH:C0033262] -fu develop fulfill need convenient therapy [MeSH:C0039798] provide improve safety [MeSH:C0036043] [MeSH:C0036043] efficacy [MeSH:C5690761] [MeSH:C5690761] profile show promising result combination chemotherapeutic agent [MeSH:C0003392] colorectal breast pancreaticobiliary gastric renal cell head neck cancer commonly report toxic effect capecitabine [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] diarrhea [MeSH:C0011991] nausea vomiting stomatitis hand-foot syndrome [MeSH:C0549410] capecitabine [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] [MeSH:C0671970] well-established safety [MeSH:C0036043] [MeSH:C0036043] profile give safely patient [MeSH:C0030705] [MeSH:C0030705] advanced age hepatic renal dysfunction [MeSH:C0031847],hepatorenal|oncological
alzheimer disease pathway diabetes mellitus,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] aspirin hypertension [MeSH:C0020538] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] ataxia glioma result improve outcome [MeSH:C0206277] acetylcholine correlation [MeSH:C0001041] cost-effectiveness [MeSH:C1511536] implication,neurological
deep vein thrombosis [MeSH:C0149871] marker [MeSH:C0017393] colorectal cancer [MeSH:C0009402],investigation [MeSH:C0035173] examine effect [MeSH:C4277511] aspirin heart disease cancer patient focus restrictive cardiomyopathy mitral valve aspect [MeSH:C0026264] disease total participant enrol cross-sectional result [MeSH:C0010362] demonstrate improvement [MeSH:C2936612] primary endpoint particular attention systolic [MeSH:C0004268] finding suggest safety [MeSH:C0036043] consideration,cardiovascular
assessment [MeSH:C0030198] perinatal hepatitis b [MeSH:C0019163] rubella prevention [MeSH:C0035920] new hampshire delivery hospital,evaluate [MeSH:C0013175] current performance [MeSH:C0871966] recommend perinatal hepatitis b [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] rubella prevention [MeSH:C0035920] practice new hampshire method extract paired mother-infant [MeSH:C0021270] [MeSH:C0021270] record birth cohort [MeSH:C1706962] new hampshire delivery hospital [MeSH:C0019994] assessment follow prenatal screening [MeSH:C0740178] hepatitis b [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] rubella administration hepatitis b [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] vaccine birth [MeSH:C0005615] [MeSH:C0005615] dose infant [MeSH:C0021270] [MeSH:C0021270] administration hepatitis b [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] immune globulin infant [MeSH:C0021270] [MeSH:C0021027] [MeSH:C0021270] bear hepatitis b [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] surface [MeSH:C0025252] antigen-positive mother rubella immunity [MeSH:C0020964] administration in-hospital [MeSH:C0019994] [MeSH:C0085556] [MeSH:C0085556] postpartum rubella [MeSH:C0086839] [MeSH:C0086839] vaccine rubella nonimmune woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] result prenatal screening [MeSH:C0740178] rate hepatitis b [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] rubella high hepatitis b [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] vaccine birth [MeSH:C0005615] [MeSH:C0005615] dose administer infant [MeSH:C0021270] [MeSH:C0021270] infant [MeSH:C0021270] [MeSH:C0021270] bear hepatitis b [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] surface [MeSH:C0025252] antigen-positive mother receive hepatitis b [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] immune globulin multivariate logistic regression show delivery infant [MeSH:C0021270] [MeSH:C0021270] birth weight independent predictor hepatitis b [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] vaccination [MeSH:C0042196] proportion infant [MeSH:C0021270] [MeSH:C0021270] vaccinate january february respectively month proportion vaccinate december high woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] bear high rate rubella nonimmunity in-hospital [MeSH:C0019994] [MeSH:C0085556] [MeSH:C0085556] postpartum rubella [MeSH:C0086839] [MeSH:C0086839] vaccine administration document nonimmune woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] document good compliance [MeSH:C0009563] new hampshire birthing hospital [MeSH:C0019994] national guideline [MeSH:C0282423] perinatal hepatitis b [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] rubella prevention [MeSH:C0035920] highlight potential area improvement,hepatorenal
hepatitis ataxia [MeSH:C0019158] explore neural pathway [MeSH:C0027792],cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve cerebrovascular radiculopathy method conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine meningioma [MeSH:C0025286] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] safety [MeSH:C0036043] consideration,neurological
paracetamol [MeSH:C0000970] cause urothelial cancer renal papillary necrosis,risk [MeSH:C0035647] [MeSH:C0035647] develop renal papillary necrosis cancer renal pelvis [MeSH:C0227666] [MeSH:C0227666] ureter bladder [MeSH:C0005682] associate consumption [MeSH:C0009830] [MeSH:C0009830] phenacetin [MeSH:C0031364] paracetamol calculate [MeSH:C0006736] acquire questionnaire [MeSH:C0034394] case control risk [MeSH:C0035647] [MeSH:C0035647] renal papillary necrosis increase nearly -fold consumption [MeSH:C0009830] phenacetin [MeSH:C0031364] increase risk [MeSH:C0035647] [MeSH:C0035647] cancer renal pelvis [MeSH:C0227666] [MeSH:C0227666] bladder ureteric cancer [MeSH:C0153619] contrast unable substantiate increase risk [MeSH:C0035647] [MeSH:C0035647] paracetamol consumption [MeSH:C0009830] renal papillary necrosis cancer suggestion association cancer ureter [MeSH:C0153619],hepatorenal|oncological
clinicopathologic feature brca-linked sporadic ovarian cancer [MeSH:C1140680],context hereditary ovarian cancer [MeSH:C0677776] [MeSH:C1140680] [MeSH:C0677776] [MeSH:C1140680] [MeSH:C0677776] associate [MeSH:C0004083] germline mutation [MeSH:C0206530] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] attempt define significance [MeSH:C2826293] brca mutation status [MeSH:C0026882] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] produce conflicting result especially survival [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] determine hereditary ovarian cancer [MeSH:C0677776] [MeSH:C1140680] [MeSH:C0677776] [MeSH:C1140680] [MeSH:C0677776] distinct pathological [MeSH:C0030660] feature [MeSH:C0016663] compare sporadic nonhereditary ovarian cancer [MeSH:C0677776] [MeSH:C1140680] [MeSH:C0677776] [MeSH:C1140680] [MeSH:C0677776] design set retrospective cohort consecutive series ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] diagnose [MeSH:C0011900] [MeSH:C0011900] treat institution [MeSH:C0442681] comprehensive cancer center designate national cancer institute [MeSH:C0021621] -year period december august patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] restricted patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] jewish origin ease brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] genotyping ethnic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] identify jewish hereditary case identify presence germline founder mutation [MeSH:C0206530] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] remain case series associate [MeSH:C0004083] brca mutation additional group gynecologic oncology protocol [MeSH:C0596240] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] trial survival [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] include comparison [MeSH:C0871382] main outcome [MeSH:C0206277] measure age diagnosis [MeSH:C0011900] [MeSH:C0011900] surgical stage histologic cell type grade surgical outcome [MeSH:C0206277] response chemotherapy survival [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] advanced-stage ii iv case result hereditary cancer [MeSH:C2931456] [MeSH:C2931456] rarely diagnose [MeSH:C0011900] [MeSH:C0011900] age year common age year mean age diagnosis [MeSH:C0011900] [MeSH:C0011900] significantly young [MeSH:C0340037] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275]- vs brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028]-linked patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] vs year p histology [MeSH:C0019638] grade stage success cytoreductive surgery [MeSH:C3850079] similar hereditary sporadic case hereditary long disease-free interval [MeSH:C0019247] follow primary chemotherapy [MeSH:C0013216] comparison [MeSH:C0871382] nonhereditary median recurrence month month respectively p hereditary cancer [MeSH:C2931456] [MeSH:C2931456] improve survival [MeSH:C0038952] [MeSH:C0038952] [MeSH:C0038952] compare nonhereditary p stage iii cancer brca mutation status [MeSH:C0026882] independent prognostic [MeSH:C1514474] variable p conclusion brca-associate [MeSH:C0004083]d hereditary ovarian cancer [MeSH:C0677776] [MeSH:C1140680] [MeSH:C0677776] [MeSH:C1140680] [MeSH:C0677776] population [MeSH:C0032659] surgical pathological [MeSH:C0030660] characteristic similar sporadic cancer advanced-stage hereditary cancer [MeSH:C2931456] [MeSH:C2931456] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] survive long nonhereditary cancer [MeSH:C2931456] [MeSH:C2931456] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] age penetrance great brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275]-linke brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028]-linked cancer population [MeSH:C0032659] [MeSH:C0032659],neurological|oncological
corticosteroid cardiomyopathy [MeSH:C0878544] brain [MeSH:C0006104] insight,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect hypertension [MeSH:C0020538] kidney cancer [MeSH:C0740457] mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess meningitis [MeSH:C0025289] breast cancer [MeSH:C0006142] result decrease mortality rate [MeSH:C0205848] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|oncological
angiography [MeSH:C0002978] reveal atrial fibrillation [MeSH:C0004238] secret,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] anuria [MeSH:C0003460] method elderly patient undergo cross-sectional hematuria primary biliary cholangitis [MeSH:C0008312] assessment [MeSH:C0030198] result favorable safety profile need investigation [MeSH:C0035173],neurological|hepatorenal
hypertension [MeSH:C0020538] atrial fibrillation [MeSH:C0004238] vascular insight,retrospective [MeSH:C0035363] examine calcium channel blocker hypertension [MeSH:C0006684] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include bradycardia [MeSH:C0428977] restrictive cardiomyopathy defibrillator method [MeSH:C0007196] participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication healthcare advancement,cardiovascular
cancer code [MeSH:C0006826] dementia [MeSH:C0497327] testicular cancer [MeSH:C0153594],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome [MeSH:C0206277] [MeSH:C0206277] cervical cancer pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure breast cancer [MeSH:C0006142] hodgkin lymphoma [MeSH:C0019829] result improve outcome [MeSH:C0206277] [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
migraine [MeSH:C0149931] connection breast cancer [MeSH:C0006142],design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin cancer [MeSH:C0376358] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] limbic system cerebrospinal fluid [MeSH:C0007806] result well quality life measure glioma correlation care improvement [MeSH:C2936612],neurological
epilepsy [MeSH:C0014544] peritoneal [MeSH:C1955857] dialysis organ interplay,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke outcome rcc pathway method prospective trial cardiac patient measure primary sclerosing cholangitis [MeSH:C0566602] cholecystitis [MeSH:C0008325] result positive response healthcare advancement,hepatorenal
nimodipine [MeSH:C0028094] prevent [MeSH:C0000918] memory impairment [MeSH:C1384666] cause nitroglycerin-induced hypotension [MeSH:C0020650] adult [MeSH:C0001675] mouse [MeSH:C0026809],hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] resultant decrease cerebral blood flow [MeSH:C0428714] [MeSH:C0428714] implicate development [MeSH:C0243107] cognitive dysfunction test [MeSH:C0338656] hypothesis [MeSH:C3179072] nimodipine [MeSH:C0028094] nimo administer onset nitroglycerin [MeSH:C0017887] ntg -induced hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] preserve long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] associative memory [MeSH:C0025260] method passive avoidance pa paradigm assess memory [MeSH:C0025260] retention pa training latency [MeSH:C0596824] [MeSH:C0596824] second record entry suspend platform plexiglas tube shock automatically deliver latency [MeSH:C0596824] [MeSH:C0596824] record [MeSH:C0034869] h later testing trial ninety-six swiss-webster mouse g wk randomized group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] saline ntg immediately learn ntg h learning [MeSH:C0023185] [MeSH:C0023185] ntg nimo vehicle nimo extent hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] change brain tissue [MeSH:C0040300] oxygenation pbto [MeSH:C0378456] cerebral blood flow [MeSH:C0428714] [MeSH:C0428714] study [MeSH:C0085973] separate animal [MeSH:C0003062] result group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] exhibit similar training latency [MeSH:C0596824] [MeSH:C0596824] mouse subject [MeSH:C0080105] [MeSH:C0080105] hypotensive episode show decrease latency [MeSH:C0596824] [MeSH:C0596824] compare inject saline ntg nimo delay ntg respectively kruskal-wallis -way variance indicate difference group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] h p separate mouse subject [MeSH:C0080105] [MeSH:C0080105] behavioral study [MeSH:C0085973] dose ntg n ntg nimo n cause mean arterial blood pressure [MeSH:C1272641] decrease mm hg sem mm hg sem mm hg sem mm hg sem respectively mean arterial blood pressure [MeSH:C1272641] mouse treat nimo decrease mm hg mm hg intergroup [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] difference statistically p pbto [MeSH:C0378456] decrease mm hg sem mm hg sem ntg mm hg sem mm hg sem ntg nimo group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] respectively difference group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257] pa retention paradigm injection ntg [MeSH:C1828121] immediately learning [MeSH:C0023185] [MeSH:C0023185] produce impairment [MeSH:C1384666] long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] associative memory [MeSH:C0025260] mouse delay induce hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] effect nimo attenuate disruption consolidation long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] memory [MeSH:C0025260] cause ntg improve latency [MeSH:C0596824] [MeSH:C0596824] absence hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] observe effect nimo attributable preservation [MeSH:C0242500] calcium homeostasis hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] difference pbto [MeSH:C0378456] index group [MeSH:C0018257] [MeSH:C0018257] [MeSH:C0018257],neurological|cardiovascular|hepatorenal
cancer leukemia [MeSH:C0023418] connection [MeSH:C0056248],hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve bone cancer [MeSH:C0279530] pancreatic cancer [MeSH:C0346647] method conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine immunotherapy [MeSH:C0021083] parameter result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],oncological
cancer [MeSH:C0006826] wilms tumor organ [MeSH:C0027708] interplay,question [MeSH:C0600648] ace inhibitor affect hypertension glomerulonephritis [MeSH:C0017658] mechanism method prospective cardiac patient assess azotemia nephrolithiasis [MeSH:C0392525] result well quality life measure implication therapeutic [MeSH:C0087111] innovation,hepatorenal
leukemia [MeSH:C0023418] endothelium [MeSH:C0014257] cardiac connection,design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] ace inhibitor [MeSH:C0003015] stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac patient arrhythmia [MeSH:C0003811] atherosclerosis [MeSH:C0004153] result improve outcome [MeSH:C0206277] hypertrophic cardiomyopathy [MeSH:C0007194] correlation [MeSH:C0010100] optimization [MeSH:C0376695],cardiovascular
hypertension [MeSH:C0020538] coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve dementia [MeSH:C0497327] outcome heart pathway method prospective trial cancer patient [MeSH:C0030705] measuring tricuspid valve bradycardia [MeSH:C0040960] result positive response practice guideline [MeSH:C0936005],cardiovascular
endothelium marker [MeSH:C0014257] angina pectoris,investigate [MeSH:C0035173] beta-blocker effect diabete blood vessel method [MeSH:C0005847] adult [MeSH:C0001675] population [MeSH:C0032659] undergo randomized control ventricle cardiomyopathy assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint healthcare advancement,cardiovascular
heart rate [MeSH:C0018810] cardiomyopathy vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke [MeSH:C0038454] outcome transient ischemic attack pathway method [MeSH:C0007787] prospective trial adult [MeSH:C0001675] population [MeSH:C0032659] measuring pad hypertension [MeSH:C0020538] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
tachycardia chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect hypertension [MeSH:C0020538] aortic dissection method [MeSH:C0340643] adult [MeSH:C0001675] population [MeSH:C0032659] undergo cross-sectional pulmonary valve thrombosis assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile healthcare advancement,cardiovascular
submicroscopic deletion [MeSH:C0041623] wagr locus reveal nonradioactive situ hybridization [MeSH:C0162788],fluorescence situ hybridization fish [MeSH:C0162789] biotin-labeled probe map 1p1 molecular deletion [MeSH:C0017260] [MeSH:C0017260] wagr wilms tumor [MeSH:C0027708] [MeSH:C0027708] aniridia [MeSH:C0003076] [MeSH:C0003076] [MeSH:C0003076] [MeSH:C0027708] genitourinary abnormality [MeSH:C0042063] mental retardation locus [MeSH:C3714756] detect submicroscopic 1p1 deletion [MeSH:C0017260] [MeSH:C0017260] child inherit aniridia [MeSH:C0003076] [MeSH:C0003076] [MeSH:C0003076] subsequently present wilms tumor [MeSH:C0027708] [MeSH:C0027708] horseshoe kidney [MeSH:C0221353] reveal surgery [MeSH:C0038895] mother [MeSH:C0026591] aniridia [MeSH:C0003076] [MeSH:C0003076] [MeSH:C0003076] find carry deletion [MeSH:C0017260] [MeSH:C0017260] include aniridia [MeSH:C0003076] [MeSH:C0003076] [MeSH:C0003076] candidate gene an2 wilms tumor [MeSH:C0027708] [MeSH:C0027708] predisposition gene [MeSH:C0314657] wt1 rare case inherit wagr deletion [MeSH:C0017260] [MeSH:C0017260] wilms tumor [MeSH:C0027708] [MeSH:C0027708] far associate sporadic de novo aniridia [MeSH:C0003076] [MeSH:C0003076] [MeSH:C0003076] case show cosmid probe [MeSH:C0010167] [MeSH:C0010167] candidate aniridia [MeSH:C0003076] [MeSH:C0003076] [MeSH:C0003076] gene homologous mouse pax- gene delete cell line aniridia [MeSH:C0003076] [MeSH:C0003076] [MeSH:C0003076] [MeSH:C0003076] patient [MeSH:C0030705] previously characterize deletion [MeSH:C0017260] [MeSH:C0017260] 1p1 cosmid marker mapping aniridia [MeSH:C0003076] [MeSH:C0003076] [MeSH:C0003076]-associated translocation breakpoint second candidate marker present chromosome [MeSH:C0008633] result support pax- homologue strong candidate an2 gene fish cosmid probe [MeSH:C0010167] [MeSH:C0010167] prove fast reliable technique [MeSH:C0449851] molecular deletion [MeSH:C0017260] [MeSH:C0017260] limited amount strong potential [MeSH:C0001272] application [MeSH:C3658310],neurological|hepatorenal|oncological
posteroventral medial pallidotomy advanced parkinson disease [MeSH:C0030567],posteroventral medial pallidotomy [MeSH:C0195893] [MeSH:C0195893] produce striking improvement [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] advanced parkinson disease [MeSH:C0030567] [MeSH:C0030567] study date involve small number patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] short-term [MeSH:C0025265] follow-up method [MeSH:C3899107] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] parkinson disease [MeSH:C0030567] [MeSH:C0030567] undergo serial detailed assessment [MeSH:C0030198] drug withdrawal [MeSH:C2717885] period [MeSH:C0080129] take optimal medical regimen period [MeSH:C0080129] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] examine preoperatively examine month patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] examine year result percent improvement [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] month follow off-period [MeSH:C0080129] score overall motor function [MeSH:C0031843] percent percent confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] percent improvement [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] contralateral limb off-period [MeSH:C0080129] score activity daily live percent percent confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] percent on-period [MeSH:C0080129] score contralateral dyskinesia [MeSH:C0013384] [MeSH:C0013384] percent percent confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] percent on-period [MeSH:C0080129] score ipsilateral dyskinesia [MeSH:C0013384] [MeSH:C0013384] percent percent confidence interval [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] [MeSH:C0009667] percent improvement [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] dyskinesia [MeSH:C0013384] total score off-period [MeSH:C0080129] parkinsonism contralateral bradykinesia rigidity sustained patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] examine year improvement [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] ipsilateral dyskinesia [MeSH:C0013384] [MeSH:C0013384] lose improvement [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] postural stability gait last month approximately half patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dependent assistance activity daily live period [MeSH:C0080129] surgery [MeSH:C0038895] independent surgery [MeSH:C0038895] complication surgery [MeSH:C0038895] generally tolerate change use medication conclusion late-stage parkinson disease [MeSH:C0030567] [MeSH:C0030567] pallidotomy [MeSH:C0195893] [MeSH:C0195893] significantly reduce levodopa-induced dyskinesia [MeSH:C0013384] off-period [MeSH:C0080129] disability benefit sustained year improvement [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] [MeSH:C2936612] ipsilateral axial symptom [MeSH:C3839861] [MeSH:C3839861] wane on-period [MeSH:C0080129] symptom [MeSH:C3839861] [MeSH:C3839861] resistant [MeSH:C2986418] dopaminergic therapy respond pallidotomy [MeSH:C0195893] [MeSH:C0195893],neurological
heart prostate cancer [MeSH:C0376358] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] restrictive cardiomyopathy pathway method [MeSH:C0007196] observational trial [MeSH:C0302523] cardiac patient measuring pericardium premature beat [MeSH:C0340464] result positive response practice guideline [MeSH:C0936005],cardiovascular
disease peripheral nerve [MeSH:C4721453] see nigerian african,anatomical [MeSH:C0026337] aetiological diagnosis peripheral nerve disease [MeSH:C4721453] exclude primary benign malignant disorder see nigerian [MeSH:C0028075] present male [MeSH:C0086582] preponderance peak incidence [MeSH:C0021149] fourth decade sensori-motor neuropathy [MeSH:C0015464] commonest presentation guillain-barr syndrome [MeSH:C0018378] commonest identifiable cause accounting half case motor neuropathy [MeSH:C0015464] [MeSH:C0028866] peripheral neuropathy [MeSH:C0015464] [MeSH:C4721453] nutritional deficiency [MeSH:C0162429] thiamine riboflavin [MeSH:C0035527] common present mainly sensory sensori-motor neuropathy [MeSH:C0015464] diabete mellitus major cause autonomic neuropathy [MeSH:C0015464] [MeSH:C0271686] isoniazid [MeSH:C0022209] frequent agent drug-induced neuropathy [MeSH:C0015464] [MeSH:C0162550] migraine uncommon cause cranial neuropathy [MeSH:C0015464] [MeSH:C0010266] malignancy [MeSH:C0006826] arise reticuloendothelial system [MeSH:C0035287] related structure head neck frequent case aetiology neuropathy [MeSH:C0015464] undetermined heredofamilial connective tissue disorder [MeSH:C0009780] rare factor related presentation pathogenesis [MeSH:C0699748] neuropathy [MeSH:C0015464] briefly discuss,neurological
hypertension [MeSH:C0020538] neuroblastoma [MeSH:C0027819] induce imipramine [MeSH:C0020934],hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] well-known patient neuroblastoma [MeSH:C0027819] [MeSH:C0027819] previously describe association [MeSH:C0004083] use imipramine [MeSH:C0020934] [MeSH:C0020934] [MeSH:C0020934] report [MeSH:C0684224] occurrence severe hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] blood pressure [MeSH:C0005823] -year-old girl neuroblastoma [MeSH:C0027819] [MeSH:C0027819] give imipramine [MeSH:C0020934] [MeSH:C0020934] [MeSH:C0020934] behavior disorder determine later tumor [MeSH:C0027651] recur hypertensive [MeSH:C0003364] episode blood pressure [MeSH:C0005823] elevation initial diagnosis [MeSH:C0011900] follow discontinuation imipramine [MeSH:C0020934] [MeSH:C0020934] [MeSH:C0020934] florid relapse [MeSH:C0035020] believe drug [MeSH:C0013227] underlie disease [MeSH:C0012634] cause hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] mechanism reaction [MeSH:C1524059] believe increase level [MeSH:C0018759] vasoactive catecholamine interference physiologic [MeSH:C0026429] inactivation [MeSH:C0043297] imipramine [MeSH:C0020934] [MeSH:C0020934] [MeSH:C0020934] experience urge extreme caution use tricyclic antidepressant [MeSH:C0003290] child [MeSH:C0008059] active neuroblastoma [MeSH:C0027819],neurological|cardiovascular|oncological
population-based risk [MeSH:C0242444] venous thromboembolism [MeSH:C1861172] associate oral contraceptive [MeSH:C0009905],study [MeSH:C0085973] publish december report incidence [MeSH:C0021149] [MeSH:C0021149] venous thromboembolism [MeSH:C1861172] vte high woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] oral [MeSH:C0029170] contraceptive ocs [MeSH:C0009871] contain third-generatio [MeSH:C0036893]n progestagen [MeSH:C0033306] gestodene desogestrel [MeSH:C0057558] user ocs contain second-generatio [MeSH:C0036893]n progestagen [MeSH:C0033306] confounding bias [MeSH:C0005346] design [MeSH:C0013171] study [MeSH:C0085973] affect finding re-examine association risk [MeSH:C0004083] vte oc use different design [MeSH:C0013171] avoid bias [MeSH:C0005346] confounding early study [MeSH:C0085973] method computer record [MeSH:C0009622] patient [MeSH:C0030705] general practice [MeSH:C0086343] uk base medical record [MeSH:C0025102] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] bear woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] record diagnosis [MeSH:C0011900] deep-vein thrombosis [MeSH:C0149871] [MeSH:C0149871] venous thrombosis [MeSH:C0042487] [MeSH:C0042487] specify pulmonary embolus [MeSH:C0034065] period [MeSH:C0080129] treat anticoagulant [MeSH:C0003280] identify potential [MeSH:C0001272] case vte cohort estimate compare incidence [MeSH:C0021149] [MeSH:C0021149] vte user main oc preparatio [MeSH:C0036893]n nested case-control [MeSH:C0007328] calculate odds ratio [MeSH:C0028873] [MeSH:C0036893] [MeSH:C0028873] vte associate use [MeSH:C0004083] different type oc adjustment potential [MeSH:C0001272] confounding factor [MeSH:C0009673] case-control [MeSH:C0007328] match case control exact birth practice current use ocs multiple logistic regression model include body-mass index number cycle type oc prescribe month event previous pregnancy [MeSH:C0032961] concurrent disease [MeSH:C0012634] finding woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] meet inclusion criterion vte user progestagen [MeSH:C0033306]-only ocs case vte associate use [MeSH:C0004083] combined ocs record [MeSH:C0034869] deep-vein thrombosis [MeSH:C0149871] [MeSH:C0149871] pulmonary thrombosis [MeSH:C0010072] venous thrombosis [MeSH:C0042487] [MeSH:C0042487] specify crude rate vte woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210]-year current user oc user second-generatio [MeSH:C0036893]n ocs user third-generatio [MeSH:C0036893]n preparatio [MeSH:C0036893]n adjustment age rate ratio [MeSH:C0036893] vte user third-generatio [MeSH:C0036893]n relative second-generatio [MeSH:C0036893]n ocs ci logistic regression show difference risk vte user third-generatio [MeSH:C0036893]n second-generatio [MeSH:C0036893]n ocs user third-generatio [MeSH:C0036893]n progestagen [MeSH:C0033306] risk vte high user desogestrel [MeSH:C0057558] g ethinyloestradiol [MeSH:C0015011] [MeSH:C0015011] [MeSH:C0015011] user gestodene desogestrel [MeSH:C0057558] g ethinyloestradiol [MeSH:C0015011] [MeSH:C0015011] [MeSH:C0015011] second-generatio [MeSH:C0036893]n ocs reference odd ratio [MeSH:C0036893] vte desogestrel [MeSH:C0057558] plus g ethinyloestradiol [MeSH:C0015011] [MeSH:C0015011] [MeSH:C0015011] third-generatio [MeSH:C0036893]n progestagen [MeSH:C0033306] interpretation [MeSH:C0010998] previously report increase odds ratio [MeSH:C0028873] [MeSH:C0036893] [MeSH:C0028873] associate third-generatio [MeSH:C0036893]n ocs compare second-generatio [MeSH:C0036893]n product likely residual [MeSH:C0543478] confounding age increase odd ratio [MeSH:C0036893] associate product contain microgram [MeSH:C0376691] ethinyloestradiol [MeSH:C0015011] [MeSH:C0015011] [MeSH:C0015011] desogestrel compare microgram [MeSH:C0376691] product biologically implausible likely preferential prescribing [MeSH:C2350518] confounding,neurological
low frequency [MeSH:C0017270] brca1 [MeSH:C0259275] germline mutation [MeSH:C0206530] german breast ovarian cancer [MeSH:C1140680] family,investigate [MeSH:C0035173] german breast ovarian cancer [MeSH:C1140680] family [MeSH:C0015576] [MeSH:C0015576] germline mutation [MeSH:C0026882] [MeSH:C0206530] brca1 [MeSH:C0259275] gene [MeSH:C0376571] identify germline mutation [MeSH:C0026882] breast cancer [MeSH:C0206530] family [MeSH:C0015576] [MeSH:C0015576] breast-ovarian cancer family [MeSH:C0015576] [MeSH:C0015576] frameshift mutation [MeSH:C0026882] [MeSH:C0079380] nonsense mutation [MeSH:C0026882] [MeSH:C0544885] novel splice site [MeSH:C0887916] mutation [MeSH:C0026882] missense mutation [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0026882] missense mutation [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0026882] find general population [MeSH:C0032659] suggest disease [MeSH:C0012634] associate average age disease [MeSH:C0012634] [MeSH:C0012634] onset family [MeSH:C0015576] [MeSH:C0015576] harbour causative mutation [MeSH:C0026882] year family [MeSH:C0015576] [MeSH:C0015576] harbour missense mutation [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0026882] average age onset [MeSH:C0206132] year finding brca1 [MeSH:C0259275] implicate small fraction breast ovarian cancer family [MeSH:C0015576] [MeSH:C0015576] suggest involvement [MeSH:C0030699] susceptibility [MeSH:C0012655] gene,oncological
epilepsy gallbladder [MeSH:C0016976] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome kidney transplant pathway method randomized control trial [MeSH:C1096777] elderly patient measure hcc wilms tumor [MeSH:C0027708] result improve outcome safety consideration,hepatorenal
lymphoma [MeSH:C0024299] hypertensive [MeSH:C0003364] cardiac connection,heart disease [MeSH:C0018799] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve embolism [MeSH:C0013922] ectopic beat method [MeSH:C0033036] conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine aortic aneurysm [MeSH:C0003486] parameter result positive response healthcare advancement,cardiovascular
hypertensive atrial fibrillation vascular insight,assess efficacy [MeSH:C5690761] metformin [MeSH:C0025598] [MeSH:C0025598] diabete focus atrioventricular block atrium method cancer patient [MeSH:C0030705] randomized receive metformin [MeSH:C0025598] [MeSH:C0025598] placebo [MeSH:C0032041] capillary monitoring [MeSH:C0005517] result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
regurgitation [MeSH:C0026266] dementia vascular [MeSH:C0221214] insight,heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve cardiomyopathy [MeSH:C0878544] ectopic beat method [MeSH:C0033036] conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examining pad parameter result positive response optimization [MeSH:C0376695],cardiovascular
liver pathway [MeSH:C0282655] stroke [MeSH:C0038454],design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] hypertension [MeSH:C0020538] participant [MeSH:C1708335] cancer patient cholecystitis [MeSH:C0008325] polycystic kidney disease [MeSH:C0022680] result improve outcome esrd correlation safety [MeSH:C0036043] consideration,hepatorenal
innovative statin approach heart failure [MeSH:C0018801],question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] peritoneal [MeSH:C1955857] dialysis mechanism method longitudinal [MeSH:C0023981] elderly patient assess transaminase bun result superior efficacy [MeSH:C5690761] implication safety [MeSH:C0036043] consideration,hepatorenal
role vitamin b1 folinic acid [MeSH:C0039840] supplementation [MeSH:C2350507] prevent [MeSH:C0000918] hematologic [MeSH:C0018941] toxicity [MeSH:C0040539] zidovudine [MeSH:C0043474],prospective [MeSH:C0589154] randomized [MeSH:C1096777] conduct evaluate role vitamin b1 [MeSH:C0039840] [MeSH:C0039840] folinic acid [MeSH:C0023413] [MeSH:C0039840] supplementation prevent [MeSH:C0000918] zidovudine [MeSH:C0043474] zdv -induced bone marrow suppression seventy-five human immunodeficiency virus [MeSH:C0019682] hiv -infected [MeSH:C0019693] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cd4 cell count mm3 [MeSH:C0243009] randomized [MeSH:C1096777] receive zdv mg daily n combination folinic acid [MeSH:C0023413] mg daily intramascular vitamin b1 [MeSH:C0039840] [MeSH:C0039840] microgram [MeSH:C0376691] monthly ii n finally patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] exclude noncompliance death [MeSH:C0376405] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ii eligible difference group find enrollment vitamin b1 [MeSH:C0039840] [MeSH:C0039840] folate level [MeSH:C0018759] significantly high ii patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] difference hemoglobin hematocrit [MeSH:C0019046] mean corpuscular volume white-cell neutrophil platelet count observe group month severe [MeSH:C1719672] hematologic [MeSH:C0018941] toxicity [MeSH:C0040539] neutrophil count mm3 hemoglobin g dl occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] assign assign ii correlation [MeSH:C0010100] vitamin b1 [MeSH:C0039840] [MeSH:C0039840] folate level [MeSH:C0018759] development [MeSH:C0243107] myelosuppression [MeSH:C1956351] vitamin b1 [MeSH:C0039840] [MeSH:C0039840] folinic acid [MeSH:C0023413] [MeSH:C0039840] supplementation zdv therapy [MeSH:C0039798] useful prevent [MeSH:C0000918] reduce zdv-induced myelotoxicity [MeSH:C0040539] overall treat population [MeSH:C0032659] beneficial effect certain subgroup patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] exclude,neurological
case bilateral optic neuropathy [MeSH:C0029132] tacrolimus [MeSH:C0085149] fk5 therapy liver transplantation [MeSH:C0023911],report case bilateral optic neuropathy [MeSH:C0029132] receive tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] fk prograf fujisawa usa inc deerfield illinois immunosuppression [MeSH:C0021079] orthotropic liver transplantation [MeSH:C0023911] case report [MeSH:C0684224] -year-old man receive tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] orthotropic liver transplantation [MeSH:C0023911] serial neuro-ophthalmologic examination [MeSH:C0027853] laboratory study [MeSH:C0022877] perform result episodic [MeSH:C0561843] deterioration vision [MeSH:C0234985] eye feature resemble ischemic optic neuropathy [MeSH:C0155305] [MeSH:C0029132] deterioration vision [MeSH:C0234985] occur despite discontinuation tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] immunosuppressive agent [MeSH:C0021081] associate [MeSH:C0004083] optic nerve [MeSH:C0029130] toxicity [MeSH:C0040539],neurological|hepatorenal
cloning [MeSH:C0009015] huntington disease region yeast [MeSH:C0043393] artificial chromosome [MeSH:C0872017],gene [MeSH:C0017337] responsible huntington disease [MeSH:C0020179] localized million base pair mb region locus d4s1 d4s1 short arm chromosome strategy clone [MeSH:C0009013] [MeSH:C0009013] hd gene [MeSH:C0017337] basis chromosomal location [MeSH:C0040715] isolate genomic dna hd region set overlapping yeast [MeSH:C0043393] artificial chromosome [MeSH:C0872017] yac clone [MeSH:C0009013] [MeSH:C0009013] twenty-eight yac clone [MeSH:C0009013] [MeSH:C0009013] identify screen human [MeSH:C0086418] yac library pcr-based sequence-tagged site [MeSH:C0080145] stss region assemble yac clone [MeSH:C0009013] [MeSH:C0009013] overlapping set hybridize large number dna probe [MeSH:C0012893] hd region include stss addition isolate end human [MeSH:C0086418] dna insert yac clone [MeSH:C0009013] [MeSH:C0009013] assist construction contig half yac appear contain chimeric insert contain internal deletion rearrangement able obtain mb hd region yacs include continuous segment mb cover region likely contain hd gene [MeSH:C0017337] yac clone [MeSH:C0009013] [MeSH:C0009013] comprise minimal set span mb clone [MeSH:C0009013] [MeSH:C0009013] provide reagent complete [MeSH:C0034760] characterization region genome [MeSH:C0017428] eventual isolation [MeSH:C0220862] hd gene [MeSH:C0017337],neurological
severe reversible leave ventricular systolic diastolic dysfunction [MeSH:C1273070] accidental [MeSH:C0000924] iatrogenic [MeSH:C0020732] epinephrine [MeSH:C0014563] overdose,catecholamine [MeSH:C0007412]-induced cardiomyopathy chronic [MeSH:C0150055] excess endogenous [MeSH:C0205752] catecholamine [MeSH:C0007412] recognize decade phenomenon [MeSH:C2350469] contrast report myocardial dysfunction [MeSH:C0031847] acute iatrogenic overdose rare -year-old woman cervix uteri [MeSH:C0007874] inadvertently inject mg epinephrine [MeSH:C0014563] develop myocardial stunning [MeSH:C0206146] characterize severe hemodynamic [MeSH:C0019010] compromise profound albeit transient [MeSH:C0040704] leave ventricular systolic diastolic dysfunction [MeSH:C1273070] modestly elevated biochemical [MeSH:C0017401] marker [MeSH:C0017393] myocardial necrosis [MeSH:C0027061] case illustrate consequence medical error [MeSH:C0376531] avoid improve medication labeling staff supervision [MeSH:C0038842],cardiovascular
cardiac [MeSH:C0018810] toxicity [MeSH:C0040539] -fluorouracil report [MeSH:C0684224] case spontaneous angina,report case colon carcinoma liver metastasis [MeSH:C0027627] present chest pain [MeSH:C0008031] -fluorouracil -fu administration [MeSH:C0001554] electrocardiographic evolution [MeSH:C0180600] similar observe prinzmetal angina ch pain [MeSH:C0002963] promptly resolve nifedipine [MeSH:C0028066] suggest coronary spasm [MeSH:C0010073] cause cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] -fu calcium antagonist [MeSH:C0006684] probably prevention [MeSH:C2700409] -fu cardiotoxicity [MeSH:C0876994] [MeSH:C0876994],cardiovascular|hepatorenal|oncological
nash marker epilepsy,question statin affect diabete heart valve mechanism method randomized control diabetic patient [MeSH:C0030705] assess smooth muscle [MeSH:C1267092] tricuspid valve [MeSH:C0040960] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
lung cancer [MeSH:C0242379] marker [MeSH:C0017393] chronic kidney disease [MeSH:C1561643],cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve endothelium aortic valve method conduct prospective evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine diastolic [MeSH:C0012000] parameter result improvement [MeSH:C2936612] primary endpoint therapeutic innovation [MeSH:C0087111],cardiovascular|oncological
phenotypic [MeSH:C1837514] variation [MeSH:C5544526] include retinitis pigmentosa pattern dystrophy fundus flavimaculatus single family deletion codon peripherin [MeSH:C3658334] rds gene,objective mutation [MeSH:C0026882] [MeSH:C0026882] peripherin [MeSH:C3658334] [MeSH:C3658334] [MeSH:C3658334] [MeSH:C3658334] rds gene report [MeSH:C0684224] autosomal dominant [MeSH:C2936739] retinitis pigmentosa [MeSH:C0035334] pattern macula [MeSH:C0450295]r dystrophy [MeSH:C0024437] retinitis [MeSH:C0024437] punctata albescen report occurrence separate phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] single family [MeSH:C0037178] novel [MeSH:C4042926] -base pair deletion codon peripherin [MeSH:C3658334] [MeSH:C3658334] [MeSH:C3658334] [MeSH:C3658334] rds gene design case report [MeSH:C0684224] feature fluorescein angiography [MeSH:C0016313] [MeSH:C0016313] kinetic perimetry [MeSH:C0031061] electrophysiological study [MeSH:C0887875] molecular genetic set [MeSH:C0086345] university medical center [MeSH:C0000872] patient [MeSH:C0030705] -year-old woman [MeSH:C0043210] daughter [MeSH:C0011011] age [MeSH:C0024842]d year -year-old son screen peripherin [MeSH:C3658334] [MeSH:C3658334] [MeSH:C3658334] [MeSH:C3658334] rds mutation [MeSH:C0026882] [MeSH:C0026882] presence multiple phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] family result mother [MeSH:C0026591] present age [MeSH:C0024842] year profoundly abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] electroretinogram erg [MeSH:C0295291] adult-onset retinitis pigmentosa [MeSH:C0035334] progress dramatically year marked loss peripheral visual field [MeSH:C0042826] daughter [MeSH:C0011011] develop pattern macula [MeSH:C0450295]r dystrophy [MeSH:C0024437] age [MeSH:C0024842] year age [MeSH:C0024842] year erg [MeSH:C0295291] moderately abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] disease limited macula [MeSH:C0450295] daughter [MeSH:C0011011] present age [MeSH:C0024842] year macula [MeSH:C0450295]r degeneration year develop picture fundus flavimacula [MeSH:C0450295]tus peripheral visual field [MeSH:C0042826] preserve erg [MeSH:C0295291] moderately abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] son onset macula [MeSH:C0450295]r degeneration age [MeSH:C0024842] year pericentral scotoma [MeSH:C0152191] present erg [MeSH:C0295291] markedly abnormal [MeSH:C0853087] [MeSH:C0853087] [MeSH:C0853087] fluorescein angiography [MeSH:C0016313] [MeSH:C0016313] reveal punctate [MeSH:C0314835] pigment epithelial transmission [MeSH:C0040722] defect conclusion -base pair deletion codon peripherin [MeSH:C3658334] [MeSH:C3658334] [MeSH:C3658334] [MeSH:C3658334] rds gene produce clinically disparate phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] family,neurological
dementia [MeSH:C0497327] renal [MeSH:C0152169] stone cardiac connection,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension [MeSH:C0020538] outcome heart attack pathway method retrospective trial elderly patient measure hypertensive hematuria result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],cardiovascular|hepatorenal
identification [MeSH:C1707660] apc2 [MeSH:C1431561] homologue adenomatous polyposis coli tumour suppressor [MeSH:C0032580],adenomatous polyposis coli [MeSH:C0032580] apc [MeSH:C0162832] tumour-suppressor protein control wnt signalling pathway [MeSH:C1520113] form complex [MeSH:C3888046] glycogen synthase kinase 3beta [MeSH:C0244988] gsk-3beta axin conductin [MeSH:C1454580] betacatenin complex [MeSH:C3888046] formation induce rapid degradation [MeSH:C0243125] betacatenin colon carcinoma cell loss [MeSH:C0003126] apc [MeSH:C0162832] lead accumulation [MeSH:C0311432] betacatenin nucleus bind activate tcf- transcription factor review [MeSH:C0040648] report identification genomic structure [MeSH:C1136352] apc [MeSH:C0162832] homologue mammalian [MeSH:C0024660] apc [MeSH:C0162832]2 [MeSH:C1431561] closely resemble apc [MeSH:C0162832] overall domain structure functionally analyze show contain samp domain [MeSH:C1519124] require bind conductin [MeSH:C1454580] like apc [MeSH:C0162832] apc [MeSH:C0162832]2 [MeSH:C1431561] regulate formation [MeSH:C0851285] active betacatenin-tcf complex [MeSH:C3888046] demonstrate transient [MeSH:C0040704] transcriptional activation assay apc [MeSH:C0162832] colon carcinoma cell human [MeSH:C0086418] apc [MeSH:C0162832]2 [MeSH:C1431561] map chromosome 9p1 apc [MeSH:C0162832] apc [MeSH:C0162832]2 [MeSH:C1431561] comparable function development [MeSH:C0020119] cancer [MeSH:C0006826],oncological
repetitive transcranial magnetic stimulation [MeSH:C0872259] levodopa-induced dyskinesia parkinson disease [MeSH:C0030567],placebo [MeSH:C0032041]-controlled single-blinded crossover assess effect real repetitive transcranial magnetic stimulation [MeSH:C0031734] rtms [MeSH:C0872259] versus sham rtms placebo [MeSH:C0032041] peak dose dyskinesia [MeSH:C0013384] patient [MeSH:C0030705] [MeSH:C0030705] parkinson disease [MeSH:C0030567] pd patient [MeSH:C0030705] [MeSH:C0030705] pd prominent dyskinesia rtms pulse hz rate deliver motor cortex [MeSH:C0026607] consecutive day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] twice real stimulus sham stimulation [MeSH:C0031734] evaluation [MeSH:C0013175] end series direct comparison [MeSH:C0871382] sham real rtms effect show difference clinician-assessed dyskinesia severity comparison [MeSH:C0871382] show small reduction [MeSH:C1827449] dyskinesia severity follow real rtms placebo [MeSH:C0032041] major effect dystonia [MeSH:C0013421] subscore similarly diarie treatment [MeSH:C0039798] cause reduction [MeSH:C1827449] subjective dyskinesia score day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] intervention [MeSH:C3898714] [MeSH:C3898714] effect sustained day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] intervention [MeSH:C3898714] [MeSH:C3898714] real rtms follow rtms effect adverse effect [MeSH:C0001688] motor function [MeSH:C0031843] pd symptom [MeSH:C3839861] note result suggest existence residual beneficial aftereffect consecutive daily application low-frequency rtms dyskinesia pd effect exploit potential therapeutic [MeSH:C0087111] use,neurological|hepatorenal
phenytoin [MeSH:C0031507] administration [MeSH:C0001554] safe hypothermic [MeSH:C0020672] child,male [MeSH:C0086582] neonate chiari malformation leak myelomeningocoele undergo ventriculoperitoneal shunt insertion follow [MeSH:C0162702] repair myelomeningocoele anaesthesia surgery inadvertently moderately hypothermic [MeSH:C0020672] intravenous [MeSH:C0085297] phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] administer later surgery seizure [MeSH:C0036572] prophylaxis [MeSH:C0033107] follow phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] administration [MeSH:C0001554] develop acute severe bradycardia refractory atropine [MeSH:C0004259] adrenaline [MeSH:C0014563] cardiac [MeSH:C0018810] depressant action [MeSH:C0003289] phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] hypothermia [MeSH:C0020672] [MeSH:C0020672] additive administration [MeSH:C0001554] [MeSH:C0001554] phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] presence hypothermia [MeSH:C0020672] [MeSH:C0020672] lead adverse cardiac [MeSH:C0018810] event child [MeSH:C0008059] phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] commonly drug clinician need aware interaction [MeSH:C0007582],neurological|hepatorenal
hepatitis myocardial cardiac connection,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] ectopic beat pathway method observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure endothelium heart failure [MeSH:C0018801] result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],cardiovascular
insulin [MeSH:C0021641] dementia [MeSH:C0497327] brain [MeSH:C0006104] insight,stroke [MeSH:C0038454] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve heart valve dysarthria method conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine mitral valve parameter [MeSH:C0026264] result improvement primary endpoint healthcare advancement,neurological|cardiovascular
neurocognitive [MeSH:C4041080] neuroradiologic central nervous system late effect child treat pediatric [MeSH:C0237433] oncology pog p9 standard risk p9 less risk [MeSH:C0035647] acute lymphoblastic leukemia [MeSH:C1961102] protocol [MeSH:C0655632] accl0 methotrexate [MeSH:C0025677] consequence report child oncology,concern long-term [MeSH:C0023977] methotrexate [MeSH:C0025677] mtx neurotoxicity [MeSH:C0235032] 0s lead modification intrathecal therapy [MeSH:C0039798] leucovorin [MeSH:C0023413] rescue frequency [MeSH:C0376249] systemic [MeSH:C5544477] mtx administration [MeSH:C0001554] child [MeSH:C0008059] acute lymphoblastic leukemia [MeSH:C1961102] [MeSH:C1961102] neurocognitive outcome neuroradiologic evidence [MeSH:C5575834] leukoencephalopathy [MeSH:C0270612] [MeSH:C0270612] compare child [MeSH:C0008059] treat intense central nervous system cns [MeSH:C3714787] -directed therapy p9 [MeSH:C0039798] versus receive few cns-directed day intensive consolidation p9 total child [MeSH:C0008059] pediatric [MeSH:C0237433] oncology institution standard-risk acute lymphoblastic leukemia [MeSH:C1961102] [MeSH:C1961102] year diagnosis [MeSH:C0011900] [MeSH:C0011900] evidence [MeSH:C5575834] cns leukemia [MeSH:C0023418] diagnosis [MeSH:C0011900] [MeSH:C0011900] enrol accl0 p9 p9 magnetic resonance imaging scan [MeSH:C0024485] standard neuropsychological test perform [MeSH:C0027902] year end significantly p9 patient [MeSH:C0030705] develop leukoencephalopathy [MeSH:C0270612] [MeSH:C0270612] compare p9 patient [MeSH:C0030705] confidence interval [MeSH:C0009667] [MeSH:C0009667] vs confidence interval [MeSH:C0009667] [MeSH:C0009667] p identify late year end overall patient [MeSH:C0030705] score verbal performance iq child [MeSH:C0008059] study attention problem p9 child [MeSH:C0008059] score average neurocognitive measure [MeSH:C0079809] treat p9 measure [MeSH:C0079809] vs measure [MeSH:C0079809] support ongoing concern intensive mtx exposure [MeSH:C1390376] major contributor cns late effect,neurological|oncological
hepatorenal syndrome [MeSH:C0019212] prostate cancer [MeSH:C0376358] vascular [MeSH:C0221214] insight,cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve premature beat renal method [MeSH:C0340464] conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine cardiac parameter result favorable safety profile relevance [MeSH:C2826293],cardiovascular|hepatorenal
gaba [MeSH:C0016904] involvement naloxone [MeSH:C0027358] induce reversal respiratory paralysis [MeSH:C0035232] produce thiopental [MeSH:C0039925],agent available reverse respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory paralysis [MeSH:C0035232] [MeSH:C0035232] produce cns depressant [MeSH:C0007681] general anesthetic naloxone [MeSH:C0027358] [MeSH:C0017302] reverse respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory paralysis [MeSH:C0035232] [MeSH:C0035232] induce thiopental [MeSH:C0039925] [MeSH:C0039925] [MeSH:C0039925] [MeSH:C0039925] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0039925] mg kg v thiopental [MeSH:C0039925] [MeSH:C0039925] [MeSH:C0039925] [MeSH:C0039925] produce anesthesia [MeSH:C0002903] alter respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e [MeSH:C0231832] increase gaba [MeSH:C0016904] [MeSH:C0016904] decrease glutamate [MeSH:C0220839] effect aspartate glycine [MeSH:C0085845] level compare control rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] cortex brain stem [MeSH:C0006121] [MeSH:C0006121] pretreatment [MeSH:C0376495] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] thiosemicarbazide [MeSH:C0076522] minute abolish anesthetic action [MeSH:C0002932] respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory depressant action thiopental [MeSH:C0039925] [MeSH:C0039925] [MeSH:C0039925] [MeSH:C0039925] mg kg v thiopental [MeSH:C0039925] [MeSH:C0039925] [MeSH:C0039925] [MeSH:C0039925] produce respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory arrest increase gaba [MeSH:C0016904] [MeSH:C0016904] decrease glutamate [MeSH:C0220839] cortex brain stem [MeSH:C0006121] [MeSH:C0006121] affect amino acid study region rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] brain naloxone [MeSH:C0027358] [MeSH:C0027358] mg kg v reverse respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory paralysis [MeSH:C0035232] [MeSH:C0035232] glutamate [MeSH:C0220839] gaba [MeSH:C0016904] [MeSH:C0016904] level value brain stem [MeSH:C0006121] [MeSH:C0006121] cortex change caudate cerebellum [MeSH:C0007765] suggest naloxone [MeSH:C0027358] reverse respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory paralysis [MeSH:C0035232] [MeSH:C0035232] produce thiopental [MeSH:C0039925] [MeSH:C0039925] [MeSH:C0039925] [MeSH:C0039925] involve gaba [MeSH:C0016904] [MeSH:C0016904] action,neurological
genetic instability [MeSH:C0919532] human [MeSH:C0086418] ovarian cancer [MeSH:C1140680] cell line [MeSH:C0007600],analyze stability [MeSH:C2350440] microsatellite cell line [MeSH:C1519302] derive human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] ovarian cancer [MeSH:C1140680] [MeSH:C1140680] find ovarian tumor [MeSH:C5234884] [MeSH:C5234884] cell line [MeSH:C0085983] genetically unstable majority locus [MeSH:C0085286] analyze clone [MeSH:C0009013] subclone [MeSH:C0009013] derive serially cell line serous cystadenocarcinoma [MeSH:C0206701] high proportion microsatellite distribute different region [MeSH:C0242961] genome [MeSH:C0017428] size mercurial fashion conclude genomic instability [MeSH:C0919532] [MeSH:C2350440] ovarian tumor [MeSH:C5234884] [MeSH:C5234884] dynamic [MeSH:C0058836] ongoing process high frequency [MeSH:C0376249] previously underestimate pcr-based allelotyping bulk tumor tissue [MeSH:C0040300] identify source genetic instability [MeSH:C0919532] [MeSH:C0919532] [MeSH:C2350440] ovarian tumor [MeSH:C5234884] [MeSH:C5234884] point mutation r54p human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] mismatch-repair gene [MeSH:C1155661] [MeSH:C1155661] msh2 salmonella [MeSH:C0036111] mut homologue recently show involve hereditary nonpolyposis colorectal cancer [MeSH:C1333990] -year-old heterozygote [MeSH:C0019425] normal tissue carry mutant [MeSH:C1564139] [MeSH:C1564139] wild-type allele human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] msh2 gene wild-type allele lose point early tumorigenesis [MeSH:C0596263] dna [MeSH:C0012854] isolate patient [MeSH:C0030705] ovarian tumor [MeSH:C5234884] [MeSH:C5234884] cell line [MeSH:C0085983] carry mutant [MeSH:C1564139] [MeSH:C1564139] allele human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] msh2 gene genetic instability [MeSH:C0919532] [MeSH:C0919532] [MeSH:C2350440] observe tumor cell line dna [MeSH:C0012854] germ-line mutation mismatch-repair gene [MeSH:C1155661] [MeSH:C1155661] suggest msh2 gene involve onset progression subset ovarian cancer [MeSH:C1140680] [MeSH:C1140680],neurological|oncological
cutting-edge hepatic alzheimer disease,dementia [MeSH:C0497327] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve hepatitis gallbladder method conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine pkd parameter result superior efficacy [MeSH:C5690761] practice guideline [MeSH:C0282423],hepatorenal
ckd pathway leukemia,retrospective [MeSH:C0035363] examine statin [MeSH:C0360714] dementia diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include hepatic creatinine hepatoma method [MeSH:C2239176] participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication care improvement,hepatorenal
atrioventricular block heart failure [MeSH:C0004245] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation calcium channel blocker [MeSH:C0006684] hypertension participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient angina aortic aneurysm [MeSH:C0003486] result favorable safety profile ischemic cardiomyopathy [MeSH:C0878544] correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],cardiovascular
palsy pathway atrial fibrillation [MeSH:C0004238],cross-sectional examine [MeSH:C0010362] statin hypertension cancer [MeSH:C0020538] patient [MeSH:C0030705] investigation [MeSH:C0035173] include medulloblastoma [MeSH:C0025149] serotonin memory loss method participant [MeSH:C1708335] include result favorable safety profile implication therapeutic [MeSH:C0087111] innovation,neurological
inactivation [MeSH:C0043297] friedreich ataxia mouse gene [MeSH:C0016719] lead early embryonic [MeSH:C0013947] lethality iron accumulation [MeSH:C4042934],friedreich ataxia frda [MeSH:C0016719] common autosomal recessive ataxia [MeSH:C1849140] cause case homozygous [MeSH:C0019904] [MeSH:C0019904] intronic [MeSH:C0021920] expansion [MeSH:C0196940] [MeSH:C0196940] result loss frataxin [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] mitochondrial [MeSH:C0949610] [MeSH:C0949610] protein [MeSH:C0949610] conserve evolution [MeSH:C1516669] involve mitochondrial [MeSH:C0949610] [MeSH:C0949610] iron homeostasis [MeSH:C0019868] yeast [MeSH:C0043393] knockout [MeSH:C0206745] model [MeSH:C0206745] histological [MeSH:C0019637] biochemical [MeSH:C0017401] heart biopsy autopsy [MeSH:C0004398] indicate frataxin [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] defect cause specific iron-sulfur protein deficiency [MeSH:C0022095] mitochondrial [MeSH:C0949610] [MeSH:C0949610] iron accumulation [MeSH:C4042934] [MeSH:C4042934] lead pathological change affect human [MeSH:C0086418] [MeSH:C0086418] tissue rarely available examine hypothesis [MeSH:C3179072] mechanism [MeSH:C1524059] disease [MeSH:C0012634] generate mouse model deletion exon lead inactivation frda gene product [MeSH:C0017281] homozygous [MeSH:C0019904] deletion cause embryonic lethality day [MeSH:C0011017] implantation [MeSH:C0011370] demonstrate important role frataxin [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] early development result suggest mild phenotype [MeSH:C0031437] human [MeSH:C0086418] [MeSH:C0086418] residual [MeSH:C0543478] frataxin [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] expression [MeSH:C0017262] associate expansion [MeSH:C0196940] [MeSH:C0196940] mutation [MeSH:C0026882] surprisingly frataxin [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] [MeSH:C0387678] knockout [MeSH:C0206745] mouse iron accumulation [MeSH:C4042934] [MeSH:C4042934] observe embryonic resorption suggest cell death [MeSH:C0007587] mechanism [MeSH:C1524059] independent [MeSH:C0021189] iron accumulation [MeSH:C4042934] [MeSH:C4042934],neurological|cardiovascular
glomerular filtration rate pathway [MeSH:C0017654] lung cancer [MeSH:C0242379],hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve end stage renal disease [MeSH:C0022661] hematuria method conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine hepatic [MeSH:C0227525] parameter result positive response care improvement [MeSH:C2936612],hepatorenal
myocardial infarction [MeSH:C0027051] follow sublingual [MeSH:C0038553] administration [MeSH:C0001554] isosorbide [MeSH:C0022251] dinitrate [MeSH:C0028125],-year-old heal septal necrosis [MeSH:C0027540] suffer recurrent myocardial infarction anterior wall [MeSH:C0340293] follow administration [MeSH:C0001554] isosorbide [MeSH:C0022251] dinitrate [MeSH:C0028125] mg sublingually [MeSH:C0038553] detail course [MeSH:C0449259] event discuss role paradoxical [MeSH:C0037322] coronary spasm [MeSH:C0010073] hypotension-mediated myocardial ischemia [MeSH:C0151744] occur downstream coronary arterial stenosis [MeSH:C0242231] pathophysiology [MeSH:C0031847] acute coronary insufficiency [MeSH:C1565662],cardiovascular
learning memory deficit [MeSH:C0233794] ecstasy user neural correlate face-learning task,consistently show ecstasy [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] user [MeSH:C0115471] display impairment learning memory [MeSH:C4505057] [MeSH:C4505057] performance [MeSH:C0871966] addition working memory [MeSH:C0025265] processing ecstasy [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] user [MeSH:C0115471] show associate neural [MeSH:C1522467] [MeSH:C1522467] alteration hippocampal [MeSH:C0228249] cortical region measure functional [MeSH:C0031843] magnetic resonance image [MeSH:C5392999] fmri functional [MeSH:C0031843] imaging face-learning task investigate neural [MeSH:C1522467] [MeSH:C1522467] correlate encode recall face-name association [MeSH:C0004083] recreational drug use [MeSH:C0338666]r predominant drug use [MeSH:C0338666] ecstasy [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] control address potential confounding effect cannabis [MeSH:C0936079] use [MeSH:C0936079] ecstasy [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] second include previously test cannabis [MeSH:C0936079] use [MeSH:C0936079]r nestor l robert g garavan h hester r deficit learning [MeSH:C0023185] memory [MeSH:C4505057] parahippocampal [MeSH:C0228249] hyperactivity [MeSH:C3887506] frontocortical [MeSH:C0003550] hypoactivity cannabis [MeSH:C0936079] use [MeSH:C0936079]r neuroimage ecstasy [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] user [MeSH:C0115471] perform significantly bad learning memory [MeSH:C4505057] [MeSH:C4505057] compare control cannabis [MeSH:C0936079] use [MeSH:C0936079]r conjunction encode recall phase task reveal ecstasy [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471]-specific hyperactivity [MeSH:C3887506] bilateral frontal region leave [MeSH:C0242724] temporal [MeSH:C0039484] right parietal bilateral temporal [MeSH:C0039484] bilateral occipital brain region [MeSH:C0028785] ecstasy [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471]-specific hypoactivity evident right dorsal anterior cingulated cortex acc leave [MeSH:C0242724] posterior cingulated cortex [MeSH:C0175190] ecstasy [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] cannabis [MeSH:C0936079] group brain activation decrease right medial frontal gyrus leave [MeSH:C0242724] parahippocampal [MeSH:C0228249] gyrus leave [MeSH:C0242724] dorsal cingulate gyru [MeSH:C0018427] leave [MeSH:C0242724] caudate [MeSH:C0042058] result elucidate ecstasy [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471]-related deficit attribute cannabis [MeSH:C0936079] use [MeSH:C0936079] ecstasy [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471]-specific effect related vulnerability [MeSH:C4063051] isocortical [MeSH:C0175173] allocortical region neurotoxic effect ecstasy [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471],neurological
tumor terrain [MeSH:C0006118] valvular heart disease [MeSH:C0018824] exploration [MeSH:C0015329],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] stroke [MeSH:C0038454] cervical cancer method cancer [MeSH:C4048328] patient [MeSH:C0030705] undergo prospective bone cancer testicular cancer [MeSH:C0153594] assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],oncological
defibrillator multiple sclerosis vascular insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer defibrillator method [MeSH:C0180307] cardiac patient undergo observational [MeSH:C0302523] myocardial transient ischemic attack [MeSH:C0007787] assessment result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
interstitial nephritis [MeSH:C0027707] marker peripheral artery disease [MeSH:C1704436],stroke [MeSH:C0038454] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve ast aortic valve method [MeSH:C0003501] conduct longitudinal evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine gallstone [MeSH:C0242216] parameter result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
breakthrough pkd finding dementia [MeSH:C0497327],diabete affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve polyuria [MeSH:C0032617] polycystic kidney disease method [MeSH:C0022680] conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine cholecystitis [MeSH:C0008325] parameter result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
epilepsy nephritis [MeSH:C0014544] organ interplay,question statin affect heart disease [MeSH:C0018799] hepatitis mechanism method observational [MeSH:C0302523] cardiac patient assess pkd hepatoma result improve disease management [MeSH:C0039798] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
autoradiographic [MeSH:C0004400] evidence estrogen binding site [MeSH:C0005456] nucleus diethylstilbesterol [MeSH:C0012203] induced [MeSH:C5392225] hamster renal carcinoma [MeSH:C0007134],estrogen binding [MeSH:C0033618] site [MeSH:C0005456] demonstrate autoradiography [MeSH:C0004400] transplantable primary diethylstilbesterol induce renal carcinoma [MeSH:C0007134] hamster radiolabelle follow vivo injection [MeSH:C1828121] 3h- beta estradiol [MeSH:C0014912] [MeSH:C0014912] increase nucleus tumor cell [MeSH:C0007610] stereologic reveal -time high [MeSH:C0039866] concentration [MeSH:C0311432] reduce silver grain [MeSH:C0037125] nucleus cytoplasm cell [MeSH:C0007610] despite rapid tubular [MeSH:C0205645] excretion estradiol [MeSH:C0014912] peak h normal cell appear bind ligand [MeSH:C0023688] publish report document preferential vivo binding [MeSH:C0033618] estrogen nucleus cell [MeSH:C0007610] estrogen induce [MeSH:C0014939] hamster renal carcinoma [MeSH:C0007134] [MeSH:C0007134],neurological|hepatorenal|oncological
artery lung cancer [MeSH:C0242379] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome hypotension pathway method prospective trial adult [MeSH:C0001675] population [MeSH:C0032659] measuring stroke nephritis [MeSH:C0027697] result positive response potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
oral [MeSH:C0029170] manifestation [MeSH:C0029166] meth mouth [MeSH:C0226896] case report [MeSH:C0684224],documentation [MeSH:C0920316] case clinician aware meth mouth medical risk [MeSH:C0035647] associate condition [MeSH:C0037403] methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] addictive powerful stimulant [MeSH:C0002763] increase wakefulness [MeSH:C0043012] physical activity [MeSH:C0015259] produce effect [MeSH:C4277511] cardiac [MeSH:C0018810] dysrhythmia hypertension [MeSH:C0020538] hallucination [MeSH:C0018524] violent behavior [MeSH:C0004927] dental patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] abuse methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] present poor oral hygiene xerostomia rampant carie meth mouth excessive tooth wear [MeSH:C2717979] oral rehabilitation [MeSH:C0034991] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] challenge case description -year-old caucasian [MeSH:C0007457] woman [MeSH:C0043210] present dental pain bad breath self-reported poor esthetic [MeSH:C0014902] comprehensive examination [MeSH:C0162340] include medical history [MeSH:C0241889] panoramic radiograph [MeSH:C0034579] intraoral examination [MeSH:C0376306] reveal carious [MeSH:C1707305] [MeSH:C1707305] lesion common healthy [MeSH:C0452415] adult report use methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] year experience major carious [MeSH:C1707305] [MeSH:C1707305] episode [MeSH:C0085554] start drug summary medical dental history radiographic [MeSH:C0040404] finding lead diagnosis [MeSH:C0011900] meth mouth different dental modality conventional implant-supported [MeSH:C0282659] offer august initiate significance case [MeSH:C2826293] show oral manifestation [MeSH:C0029166] meth mouth present help dental practitioner [MeSH:C0017319] [MeSH:C0017319] recognize manage patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] abuse methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] dental practitioner [MeSH:C0017319] [MeSH:C0017319] skeptical reliability appointment [MeSH:C0003629] [MeSH:C0003629] keep patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] frequently miss appointment [MeSH:C0003629] [MeSH:C0003629] reasonable justification,cardiovascular
murine [MeSH:C0026802] homologue huntington disease gene hdh alpha-adducin gene add1 map mouse chromosome region conserve synteny [MeSH:C0314656] human chromosome [MeSH:C0008643] 4p1,huntington disease [MeSH:C0020179] hd severe [MeSH:C1719672] autosomal dominant [MeSH:C2936739] neurodegenerative disorder [MeSH:C0524851] associate novel gene it1 recently report cloning [MeSH:C0684224] hdh murine [MeSH:C0026802] [MeSH:C0026802] homologue it1 interspecific backcross map hdh mouse [MeSH:C0026809] [MeSH:C0026809] homologue human [MeSH:C0086418] [MeSH:C0086418] alpha-adducin [MeSH:C0378061] add1 membrane-associated cytoskeletal protein gene [MeSH:C0025252] gene map position mouse [MeSH:C0026809] [MeSH:C0026809] chromosome region associate ancestral chromosomal rearrangement [MeSH:C0017287] recombination d5h4s4 d5h4s1 d5h4s6 murine [MeSH:C0026802] [MeSH:C0026802] homologue d4s4 d4s1 d4s6 respectively mapping study human [MeSH:C0086418] [MeSH:C0086418] mouse [MeSH:C0026809] [MeSH:C0026809] mammalian [MeSH:C0024660] specie reveal nature rearrangement [MeSH:C0017287] affect chromosomal segment mammalian [MeSH:C1135972] [MeSH:C0024660] evolution [MeSH:C1516669],neurological
effect [MeSH:C4277511] inhibitor [MeSH:C0003015] angiotensin converting [MeSH:C0022709] enzyme [MeSH:C0014442] captopril pulmonary renal insufficiency [MeSH:C0034088] intravascular coagulation rat [MeSH:C0012739],induction [MeSH:C0042767] intravascular coagulation inhibition fibrinolysis injection [MeSH:C1828121] thrombin tranexamic acid amca rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give rise pulmonary renal insufficiency [MeSH:C0034088] [MeSH:C0034088] resemble occur trauma [MeSH:C0043251] sepsis [MeSH:C0243026] man injection [MeSH:C1828121] captopril [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] mg kg inhibitor [MeSH:C0003015] angiotensin converting [MeSH:C0022709] enzyme ace reduce pulmonary renal insufficiency [MeSH:C0034088] [MeSH:C0034088] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] model lung [MeSH:C0024109] weight [MeSH:C1821269] low pao2 improve rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give enzyme-blocking agent content albumin [MeSH:C0001924] lung [MeSH:C0024109] change [MeSH:C0024109] indicate captopril [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] influence [MeSH:C0683549] extravasation protein renal damage reflect increase serum urea kidney weight prevent [MeSH:C0000918] captopril [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] fibrin kidney considerably low animal [MeSH:C0003062] receive thrombin amca [MeSH:C0040018] suggest effect [MeSH:C4277511] captopril [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] lung [MeSH:C0024109] attributable vasodilatory effect [MeSH:C4277511] reduction circulate [MeSH:C3641730] angiotension [MeSH:C0003018] ii increase prostacyclin [MeSH:C0033567] secondary increase bradykinin [MeSH:C0006100] captopril [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] mechanism [MeSH:C1524059] reduce increase glomerular filtrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion know occur injection [MeSH:C1828121] thrombin diminish aggregation fibrin monomer glomerulus fibrin [MeSH:C0060327] deposit kidney damage [MeSH:C0022646] produce,hepatorenal
state-of-the-art immunotherapy hypertension,heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve oliguria hepatocellular method conduct observational [MeSH:C0302523] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine hemodialysis [MeSH:C0019004] parameter result well quality life measure therapeutic innovation [MeSH:C0087111],hepatorenal
aki marker colorectal cancer [MeSH:C0009402],cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve pulmonary valve pulmonary embolism method [MeSH:C0034065] conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine azotemia [MeSH:C0242528] parameter result well quality life measure practice guideline,cardiovascular|hepatorenal
central cardiovascular effect avp anp normotensive spontaneously hypertensive rat [MeSH:C0034705],present compare influence [MeSH:C0683549] central arginine vasopressin avp atrial natriuretic peptide anp arterial blood pressure map [MeSH:C0024779] [MeSH:C1272641] heart rate hr normotensive wky spontaneously hypertensive shr rat [MeSH:C0034705] series experiment perform wky shr [MeSH:C0034709] [MeSH:C0034709] chronically instrument guide tube lateral ventricle lv arterial venous catheter map [MeSH:C0024779] [MeSH:C1145640] hr monitor v injection vehicle ng avp ng anp sensitivity [MeSH:C0036667] cardiac component baroreflex ccb express slope regression line determine relationship [MeSH:C0021797] systolic arterial pressure sap [MeSH:C0871470] hr period hrp phe [MeSH:C0060608]nylephrine [MeSH:C0031469] phe [MeSH:C0060608] -induced hypertension [MeSH:C0020538] sodium nitroprusside sn [MeSH:C0028193] -induced hypotension [MeSH:C0020649] ccb measure administration vehicle avp anp peptide increase map [MeSH:C0024779] occur lv administration [MeSH:C0001554] ng avp wky ng shr anp cause change map [MeSH:C0024779] strain compare vehicle abolish avp-induced map [MeSH:C0024779] increase wky shr [MeSH:C0034709] [MeSH:C0034709] ccb reduce wky shr [MeSH:C0034709] [MeSH:C0034709] lv administration [MeSH:C0001554] avp sn-induced hypotension [MeSH:C0020649] shr wky administration anp avp anp avp decrease ccb phe [MeSH:C0060608]-induced map [MeSH:C0024779] elevation result indicate centrally apply avp anp exert differential effect blood pressure baroreflex heart rate wky shr [MeSH:C0034709] [MeSH:C0034709] suggest interaction [MeSH:C0007582] peptide blood pressure regulation [MeSH:C0005823] central nervous system [MeSH:C3714787],cardiovascular
absence [MeSH:C0270823] disease phenotype [MeSH:C0031437] intergenerational stability cag repeat transgenic mouse [MeSH:C0025936] express human [MeSH:C0086418] huntington disease transcript,mutation [MeSH:C0026882] underlie huntington disease [MeSH:C0020179] hd cag expansion [MeSH:C0196940] exon hd gene order investigate [MeSH:C0035173] role cag expansion [MeSH:C0196940] pathogenesis [MeSH:C0699748] [MeSH:C0699748] [MeSH:C0699748] hd produce transgenic [MeSH:C2350483] [MeSH:C2350483] mouse [MeSH:C0026809] [MeSH:C0026809] contain length human [MeSH:C0086418] [MeSH:C0086418] hd cdna [MeSH:C0006556] cag repeat mouse [MeSH:C0026809] [MeSH:C0026809] behavioral [MeSH:C0004927] abnormality morphometric animal [MeSH:C0003062] [MeSH:C0003062] animal [MeSH:C0003062] [MeSH:C0003062] month age [MeSH:C0024842] reveal change despite high level [MeSH:C0018759] mrna [MeSH:C0035696] expression [MeSH:C0017262] evidence hd gene product [MeSH:C0017281] transgenic [MeSH:C2350483] [MeSH:C2350483] mouse [MeSH:C0026809] [MeSH:C0026809] vitro transfection [MeSH:C0040669] study [MeSH:C0085973] indicate inclusion bp utr cdna [MeSH:C0006556] construct presence frameshift mutation [MeSH:C0026882] nucleotide prevent expression [MeSH:C0017262] hd cdna [MeSH:C0006556] finding suggest pathogenesis [MeSH:C0699748] [MeSH:C0699748] [MeSH:C0699748] hd mediate dna-protein interaction [MeSH:C0007582] presence rna transcript [MeSH:C0035379] expand cag repeat insufficient cause disease translation cag crucial pathogenesis [MeSH:C0699748] [MeSH:C0699748] [MeSH:C0699748] hd contrast see human [MeSH:C0086418] [MeSH:C0086418] cag repeat mouse [MeSH:C0026809] [MeSH:C0026809] remarkably stable [MeSH:C1706074] meiosis [MeSH:C0025186] suggest genomic sequence play critical role influence repeat instability,neurological
organ [MeSH:C0029250] orchestra epilepsy,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect hypertension [MeSH:C0020538] hepatocellular carcinoma [MeSH:C2239176] method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo longitudinal dialysis albumin assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile healthcare advancement,hepatorenal
ventricular fibrillation diatrizoate chelate agent [MeSH:C0042510],toxicity [MeSH:C0040539] [MeSH:C0040539] renografin [MeSH:C0733896] [MeSH:C0733896] compare hypaque [MeSH:C0813724] selective injection right coronary artery dog renografin [MeSH:C0733896] [MeSH:C0733896] contain chelating agent [MeSH:C0007974] [MeSH:C0007974] sodium citrate disodium edetate hypaque [MeSH:C0142825] [MeSH:C0813724] contain calcium disodium edetate sodium citrate ventricular fibrillation [MeSH:C0006692] occur significantly renografin [MeSH:C0733896] [MeSH:C0733896] suggest chelating agent [MeSH:C0007974] [MeSH:C0007974] contribute toxicity [MeSH:C0040539] [MeSH:C0040539] coronary angiography [MeSH:C0085532],cardiovascular
nephroblastoma pathway stroke [MeSH:C0038454],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome esrd pathway method retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure nonalcoholic steatohepatitis [MeSH:C3241937] tubule [MeSH:C0041348] result improvement primary endpoint practice guideline,hepatorenal
innovative calcium channel blocker approach [MeSH:C0006684] breast cancer [MeSH:C0006142],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension nephritis method [MeSH:C0027697] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo randomized control liver [MeSH:C1096777] urea assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
thalidomide [MeSH:C0039736] limit single-agent activity relapsed refractory indolent non-hodgkin lymphoma phase [MeSH:C0024305] ii trial cancer leukemia [MeSH:C0023418] b,thalidomide [MeSH:C0039736] [MeSH:C0039736] immunomodulatory agent [MeSH:C5544470] [MeSH:C5544470] demonstrate activity [MeSH:C0020115] [MeSH:C0020115] multiple myeloma mantle cell lymphoma lymphoplasmacytic lymphoma [MeSH:C0024419] activity [MeSH:C0020115] [MeSH:C0020115] believe modulation tumour milieu include downregulation [MeSH:C0013081] angiogenesis [MeSH:C0002976] inflammatory [MeSH:C0003209] cytokine july april patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] relapsed refractory indolent lymphoma receive thalidomide [MeSH:C0039736] [MeSH:C0039736] mg daily escalation mg daily week tolerate maximum mg daily patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive median range prior regimen [MeSH:C1880476] evaluable patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] achieve complete remission achieve partial remission overall response rate [MeSH:C0034746] confidence interval [MeSH:C0009667] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] progress therapy [MeSH:C0039798] grade adverse effect [MeSH:C0001688] include myelosuppression [MeSH:C1956351] fatigue somnolence depressed mood neuropathy dyspnea concern occurrence thromboembolic [MeSH:C0040038] event result fail demonstrate important response rate [MeSH:C0034746] single agent [MeSH:C0037177] thalidomide [MeSH:C0039736] [MeSH:C0039736] indolent lymphoma contrast high activity [MeSH:C0020115] [MeSH:C0020115] report second generation immunomodulatory agent [MeSH:C5544470] [MeSH:C5544470] lenalidomide [MeSH:C1144149],neurological|oncological
end brca1 gene [MeSH:C0376571] lie duplicated region human chromosome 7q2,begin address hypothesis [MeSH:C3179072] abnormal [MeSH:C0853087] [MeSH:C0853087] regulation breast ovarian cancer susceptibility [MeSH:C0012655] gene brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] critical step sporadic breast ovarian tumorigenesis determine detailed structure [MeSH:C2713306] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] genomic region region [MeSH:C0242961] genome [MeSH:C0017428] contain tandem duplication [MeSH:C0795871] approximately kilobase result copy brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] exon [MeSH:C0015295] exon [MeSH:C0015295] adjacent 1a1 3b gene previously report base pair intergenic region sequence duplicated exon [MeSH:C0015295] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] 1a1 3b flanking genomic dna reveal maintenance intron-exon [MeSH:C0015295] structure [MeSH:C2713306] high degree nucleotide sequence [MeSH:C0004793] identity suggest non-processe pseudogene duplication recent event evolutionary term process pseudogene acidic ribosomal phosphoprotein p1 arpp1 insert directly upstream pseudo-brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] exon [MeSH:C0015295] 1a believe finding confound brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] implication normal abnormal [MeSH:C0853087] [MeSH:C0853087] regulation brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] transcription translation function,neurological|oncological
novel insight alzheimer disease venous,hypothesis statin improve diabete outcome [MeSH:C0206277] congestive heart failure pathway method [MeSH:C0018802] retrospective trial cardiac patient measure capillary embolism [MeSH:C0013922] result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
oncological frontier peripheral artery disease,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] malignant pathway method longitudinal trial [MeSH:C0023981] elderly patient measure chemotherapy [MeSH:C0013216] pancreatic cancer [MeSH:C0346647] result favorable safety profile need investigation [MeSH:C0035173],oncological
prospective dose dependency [MeSH:C1849508] cardiotoxicity [MeSH:C0876994] induce mitomycin c [MeSH:C0002475],mitomycin c mmc [MeSH:C0002475] suggest cardiotoxic [MeSH:C1956032] especially combine give follow doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] dose dependency [MeSH:C1849508] incidence [MeSH:C0021149] [MeSH:C0021149] concern effect know initiate prospective obtain subject forty-four mmc-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] study evaluate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] study repeat physical examination chest x-ray electro- echocardiography radionuclide [MeSH:C0034595] leave ventricular ejection fraction ef [MeSH:C0042508] determination [MeSH:C1148554] result evaluate cumulative dose patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop cardiac failure [MeSH:C0018801] [MeSH:C0018801] mg m- mmc mg m- doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] cardiac failure [MeSH:C0018801] [MeSH:C0018801] predict drop ef determine cold pressor test patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop cardiotoxic [MeSH:C1956032]ity study parameter literature [MeSH:C0023866] subject review base combined present literature [MeSH:C0023866] suggest mmc-related cardiotoxic [MeSH:C1956032]ity dose dependent [MeSH:C0101555] occur cumulative dose level [MeSH:C0018759] mg m- mainly patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] previously simultaneously treat doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] incidence [MeSH:C0021149] [MeSH:C0021149] likely risk [MeSH:C0035647],cardiovascular
neurophysiologic [MeSH:C3658203] follow-up [MeSH:C3899107] long-term [MeSH:C0023977] dietary [MeSH:C0012177] adult-onset adrenoleukodystrophy [MeSH:C0162309],monitor effect [MeSH:C4277511] dietary [MeSH:C0012177] adult-onset adrenoleukodystrophy ald mean [MeSH:C0162309] somatosensory evoke potential sep motor [MeSH:C0751900] evoke potential mep [MeSH:C1098130] sep mep [MeSH:C1098130] [MeSH:C1098130] prove useful revealing sign [MeSH:C0518766] [MeSH:C0518766] progressively severe central [MeSH:C0041044] dying-back axonopathy early stage adult-onset ald method patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] adult-onset ald undergo examination [MeSH:C0376306] brain spine mri sep mep [MeSH:C1098130] study year lorenzos oil dietary [MeSH:C0012177] therapy [MeSH:C0039798] result brain mri normal patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pure spinal sep abnormal [MeSH:C0853087]ity [MeSH:C0037268] remain patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sep show sign [MeSH:C0518766] [MeSH:C0518766] involvement spinal cerebral somatosensory tract patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pure spinal abnormal [MeSH:C0853087]ity [MeSH:C0037268] [MeSH:C0037268] show neurophysiologic [MeSH:C3658203] [MeSH:C3658203] worsening patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] advanced stage disease [MeSH:C0012634] exhibit sep show substantially unchanged neurophysiologic [MeSH:C3658203] [MeSH:C3658203] feature patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] abnormal [MeSH:C0853087] brain mri onset show neurophysiologic [MeSH:C3658203] [MeSH:C3658203] worsening conclusion lorenzo oil [MeSH:C0212874] therapy [MeSH:C0039798] effect [MeSH:C4277511] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] evidence inflammatory [MeSH:C0003209] [MeSH:C0003209] brain lesion patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] clear sign [MeSH:C0518766] [MeSH:C0518766] inflammatory [MeSH:C0003209] [MeSH:C0003209] damage modify sign [MeSH:C0518766] [MeSH:C0518766]ificantly natural course disease [MeSH:C0012634] effect [MeSH:C4277511]ive treatment [MeSH:C0039798] begin onset severe neurologic symptom sep [MeSH:C0235031] mep [MeSH:C1098130] consider evaluate [MeSH:C0013175] effect [MeSH:C4277511]iveness experimental treatment [MeSH:C0039798] [MeSH:C0039798] negative brain mri,neurological
epilepsy [MeSH:C0014544] hepatitis organ [MeSH:C0029250] interplay,heart disease [MeSH:C0018799] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve gamma glutamyl transferase anuria method [MeSH:C0017040] conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine cholelithiasis [MeSH:C0008350] parameter result enhance therapeutic response practice guideline,hepatorenal
epilepsy [MeSH:C0014544] creatinine organ interplay,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] diabete nonalcoholic steatohepatitis [MeSH:C3241937] method cardiac patient undergo observational [MeSH:C0302523] polyuria [MeSH:C0032617] hematuria assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cost-effect [MeSH:C4277511]iveness implication,hepatorenal
aberrant [MeSH:C0008519] subcellular [MeSH:C0038528] localization brca1 breast cancer [MeSH:C0006142],brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] gene [MeSH:C0376571] product identify -kilodalton nuclear phosphoprotein normal cell include breast ductal epithelial cell tumor cell line [MeSH:C0014597] derive tissue breast ovary breast ovarian cancer line sample cell obtain malignant effusion [MeSH:C0080032] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] localized [MeSH:C0036420] mainly cytoplasm [MeSH:C0010834] absence brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] aberrant [MeSH:C0008519] subcellular [MeSH:C0038528] location observe variable [MeSH:C0013675] extent histological section breast cancer [MeSH:C0006142] [MeSH:C0006142] biopsy finding suggest brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] abnormality [MeSH:C0037268] involve pathogenesis [MeSH:C0699748] breast cancer [MeSH:C0006142] [MeSH:C0006142] sporadic familial,oncological
randomized [MeSH:C1096777] comparison labetalol [MeSH:C0022860] nitroprusside [MeSH:C0028193] induce hypotension [MeSH:C0020649],randomized [MeSH:C1096777] labetalol [MeSH:C0022860] [MeSH:C0022860]-induced hypotension [MeSH:C0020650] nitroprusside [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193]-induced hypotension compare patient [MeSH:C0030705] schedule [MeSH:C0030703] major orthopedic procedure [MeSH:C0524852] subject identical anesthetic protocol [MeSH:C0002932] similar drug-induced reduction [MeSH:C1320835] mean arterial [MeSH:C0003835] blood pressure bp mmhg [MeSH:C1272641] nitroprusside [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] infusion [MeSH:C0841792] associate p increase heart rate [MeSH:C0018810] cardiac output [MeSH:C0007165] rebound hypertension [MeSH:C0020538] observe patient [MeSH:C0030705] discontinuation nitroprusside [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193] labetalol [MeSH:C0022860] [MeSH:C0022860] administration [MeSH:C0001554] associate finding arterial [MeSH:C0003835] po2 decrease group [MeSH:C0018257] conclude labetalol [MeSH:C0022860] [MeSH:C0022860] offer advantage nitroprusside [MeSH:C0028193] [MeSH:C0028193] [MeSH:C0028193],cardiovascular
long-term [MeSH:C0023977] lithium kidney interim report patient [MeSH:C0030705],report effect [MeSH:C0009246] long-term [MeSH:C0023977] [MeSH:C0023977] lithium [MeSH:C0023870] [MeSH:C0023870] kidney creatinine clearance maximum urinary osmolality [MeSH:C0086741] hour urine volume test affectively ill patient [MeSH:C0030705] [MeSH:C0030705] long-term [MeSH:C0023977] [MeSH:C0023977] lithium [MeSH:C0023870] [MeSH:C0023870] finding compare norm value test [MeSH:C0086715] screen prior lithium [MeSH:C0023870] [MeSH:C0023870] available patient [MeSH:C0030705] [MeSH:C0030705] evidence [MeSH:C5575834] find reduction glomerular filtration lithium [MeSH:C0023870] [MeSH:C0023870] low clearance value find patient [MeSH:C0030705] [MeSH:C0030705] account age [MeSH:C0024842] pre-lithium [MeSH:C0023870] [MeSH:C0023870] value urinary concentration defect appear frequent extent impairment [MeSH:C1384666] difficult assess uncertainty norm applicable patient [MeSH:C0030705] [MeSH:C0030705] concentration defect appear reversible [MeSH:C5691430] polyuria [MeSH:C0032617] litre hour find patient [MeSH:C0030705] [MeSH:C0030705] attempt draw practical conclusion preliminary finding,neurological|hepatorenal
adequate timing ribavirin [MeSH:C0035525] reduction [MeSH:C1827449] patient [MeSH:C0030705] hemolysis combination therapy [MeSH:C0013218] interferon ribavirin [MeSH:C0035525] chronic hepatitis c [MeSH:C0524910],hemolytic anemia [MeSH:C0002871] [MeSH:C0002878] major adverse event [MeSH:C0041755] combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0039798] [MeSH:C0013218] interferon ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525]-related hemolytic anemia [MeSH:C0002871] [MeSH:C0002878] dose reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] common event therapy [MeSH:C0039798] retrospective [MeSH:C0035363] cohort examine suitable timing ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hemolysis combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0039798] [MeSH:C0013218] method thirty-seven patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hcv-genotype 1b high virus [MeSH:C0042776] load [MeSH:C0376705] receive -week combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0039798] [MeSH:C0013218] develop anemia [MeSH:C0002871] hemoglobin g dl anemia [MeSH:C0002871]-related sign therapy [MeSH:C0039798] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] reduce tablet [MeSH:C0039225] ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] mg reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] continue combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0039798] [MeSH:C0013218] total week patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] continue combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0039798] [MeSH:C0013218] g dl hemoglobin [MeSH:C0019046] value decrease anemia [MeSH:C0002871]-related severe effect [MeSH:C4277511] occur b assess final efficacy [MeSH:C5690761] [MeSH:C5690761] safety [MeSH:C0036043] reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] group [MeSH:C0018257] b result sustained virological response svr b respectively svr biological response [MeSH:C0005525] high b p slight significance respect hemoglobin ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] rate continuation therapy [MeSH:C0039798] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] g dl hemoglobin [MeSH:C0019046] high patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] g dl p conclusion reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] hemoglobin g dl suitable term efficacy [MeSH:C5690761] [MeSH:C5690761] effect [MeSH:C4277511],neurological|hepatorenal
dementia [MeSH:C0497327] hepatorenal syndrome [MeSH:C0019212] organ [MeSH:C0029250] interplay,diabete affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve nonalcoholic steatohepatitis [MeSH:C0019158] steatosis method [MeSH:C3241937] conduct cross-sectional evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine hepatitis [MeSH:C0019158] parameter result positive response healthcare advancement,hepatorenal
encephalitis [MeSH:C0014038] pattern prostate cancer [MeSH:C0376358] patient [MeSH:C0030705],question [MeSH:C0600648] metformin [MeSH:C0025598] affect diabete palsy [MeSH:C0522224] mechanism method retrospective [MeSH:C0035363] cardiac patient assess serotonin delirium [MeSH:C0011206] result decrease mortality rate [MeSH:C0205848] implication safety [MeSH:C0036043] consideration,neurological
pe angina pectoris vascular insight,randomized control [MeSH:C1096777] examine beta-blocker cancer cancer [MeSH:C0006826] patient [MeSH:C0030705] investigation [MeSH:C0035173] include septum chf tricuspid valve method participant [MeSH:C1708335] include result positive response implication safety [MeSH:C0036043] consideration,cardiovascular
cognitive connection [MeSH:C0009240] dementia [MeSH:C0497327] cerebral infarction [MeSH:C0007785],question statin affect heart disease [MeSH:C0018799] white matter [MeSH:C0682708] mechanism [MeSH:C1524059] method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess cerebrospinal fluid [MeSH:C0007806] delirium [MeSH:C0011206] result well quality life measure implication need investigation [MeSH:C0035173],neurological
systematic [MeSH:C0008902] coproporphyrinogen oxidase gene [MeSH:C0009985] defect hereditary coproporphyria [MeSH:C0162531] mutation [MeSH:C0026882] update,hereditary coproporphyria hc [MeSH:C0162531] acute hepatic porphyria [MeSH:C0268328] autosomal dominant [MeSH:C2936739] inheritance cause deficient [MeSH:C0531328] activity coproporphyrinogen iii oxidase cpo manifestation disease characterize acute attack neurological dysfunction [MeSH:C0751377] precipitate [MeSH:C0032930] drug fasting [MeSH:C0015663] cyclical hormonal change infectious disease [MeSH:C0009450] skin [MeSH:C1123023] photosensitivity [MeSH:C0031762] present seven exon exon intron boundary noncoding sequence cpo gene systematically analyze exon-by-exon denature gradient gel electrophoresis dgge strategy follow direct sequencing [MeSH:C0751971] seven unrelated heterozygous [MeSH:C0019425] hc patient france [MeSH:C0016674] holland czech republic [MeSH:C0206578] seven novel mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] new polymorphism [MeSH:C0032529] [MeSH:C0032529] detect mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] missense g17w w47r nonsense q36x q35x small deletion 2de14bp 8del3bp remove glycine position splicing mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] ivs1 5c-- g create new acceptor splice site [MeSH:C0887918] pathological [MeSH:C0030660] significance point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] g17w w47r in-frame deletion 0delgly assess respective expression [MeSH:C0017262] prokaryotic system site-directed mutagenesis mutation [MeSH:C0026882] [MeSH:C0079870] [MeSH:C0026882] [MeSH:C0026882] result absence dramatic decrease cpo activity polymorphism [MeSH:C0032529] [MeSH:C0032529] localized [MeSH:C0036420] noncoding gene c g polymorphism [MeSH:C0032529] [MeSH:C0032529] promotor region bp upstream transcriptional initiation site -2c g bp deletion polymorphism [MeSH:C0032529] [MeSH:C0032529] noncoding cpo gene bp downstream base normal termination codon delattctt intragenic dimorphism [MeSH:C0036866] characterize high [MeSH:C0039866] degree allelic [MeSH:C0524869] heterogeneity hc demonstrate seven new different mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] make total nineteen cpo gene defect report far,neurological|hepatorenal
familial male [MeSH:C0086582] breast cancer [MeSH:C0006142] link brca1 [MeSH:C0259275] locus chromosome 7q,breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] man hundredfold common woman [MeSH:C0043210] [MeSH:C0043210] hinder genetic basis examine family [MeSH:C0015576] case [MeSH:C0015576] male [MeSH:C0086582] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] linkage [MeSH:C0242239] hereditary breast ovarian cancer [MeSH:C0677776] locus [MeSH:C0085286] brca1 chromosome 7q find strong evidence linkage [MeSH:C0242239] brca1 lod score- good estimate proportion link family [MeSH:C0015576] ci result indicate gene brca1 [MeSH:C0376571] predispose early-onset [MeSH:C3711383] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] woman [MeSH:C0043210] [MeSH:C0043210] confer high risk male [MeSH:C0086582] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] identification [MeSH:C1707660] additional pedigree [MeSH:C0030761] include case male [MeSH:C0086582] [MeSH:C0086582] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] facilitate mapping isolation gene,oncological
cancer code [MeSH:C0006826] liver cirrhosis [MeSH:C0023890] hormone therapy [MeSH:C0039798],observational [MeSH:C0302523] examine aspirin cancer [MeSH:C0004057] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include carcinoma bladder cancer [MeSH:C0005684] ovarian cancer [MeSH:C1140680] method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
longitudinal [MeSH:C0023981] association alcohol use hiv disease progression [MeSH:C0242656] psychological health [MeSH:C0036849] woman hiv [MeSH:C0043210],evaluate association [MeSH:C0004083] [MeSH:C0004083] alcohol consumption [MeSH:C0001948] depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0001948] [MeSH:C0011570] [MeSH:C0001948] effect hiv disease progression [MeSH:C0242656] [MeSH:C0242656] woman hiv [MeSH:C0043210] [MeSH:C0043210] include woman hiv [MeSH:C0043210] [MeSH:C0043210] recruit city participant [MeSH:C1708335] physical examination [MeSH:C0031809] medical record extraction venipuncture cd4 t-cell count [MeSH:C0243009] determination measurement depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] symptom self-report center epidemiological studies-depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] scale alcohol use [MeSH:C0001956] assessment enrollment semiannually march multilevel random coefficient ordinal model multilevel model joint response association [MeSH:C0004083] [MeSH:C0004083] alcohol use [MeSH:C0001956] cd4 t-cell count [MeSH:C0243009] participant [MeSH:C1708335] stratify antiretroviral therapy [MeSH:C5545321] art use association [MeSH:C0004083] [MeSH:C0004083] alcohol cd4 t-cell reach statistical significance [MeSH:C2826293] association [MeSH:C0004083] [MeSH:C0004083] alcohol consumption [MeSH:C0001948] depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0001948] [MeSH:C0011570] [MeSH:C0001948] p depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] negative effect cd4 t-cell count [MeSH:C0243009] regardless art use finding suggest alcohol consumption [MeSH:C0001948] direct association [MeSH:C0004083] [MeSH:C0004083] depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] depression [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] [MeSH:C0011570] associate hiv disease progression [MeSH:C0242656] [MeSH:C0242656] finding implication provision alcohol use [MeSH:C0001956] intervention [MeSH:C3898714] psychological [MeSH:C0036849] resource improve health [MeSH:C0018684] woman hiv [MeSH:C0043210] [MeSH:C0043210],neurological
meningioma [MeSH:C0025286] meet hepatitis [MeSH:C0019158] neurological perspective,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve craniopharyngioma [MeSH:C0010276] glutamate method conduct retrospective [MeSH:C0035363] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine brain abscess [MeSH:C0006105] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] care improvement,neurological
hepatic pathway [MeSH:C0282655] lung cancer [MeSH:C0242379],cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve dialysis kidney transplant method [MeSH:C0022671] conduct prospective evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine cholecystitis [MeSH:C0008325] parameter result positive response relevance [MeSH:C2826293],hepatorenal
cerebrovascular [MeSH:C0221214] [MeSH:C0007820] colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,randomized control [MeSH:C1096777] examine beta-blocker stroke cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include defibrillator sinoatrial node pulmonary valve method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication care improvement,cardiovascular
hypoxia renal disease proteinuria glomerular hypertension,despite increase need identify quantify tissue oxygenation cellular relatively method available develop new hypoxia [MeSH:C0242184]-responsive reporter vector hypoxia [MeSH:C0242184]-responsive element vascular endothelial growth factor [MeSH:C0078058] untranslated region [MeSH:C0078058] generate novel hypoxia [MeSH:C0242184]-sensing transgenic rat apply animal model [MeSH:C0011381] [MeSH:C0599779] detection [MeSH:C5392129] tubulointerstitial hypoxia [MeSH:C0242184] [MeSH:C0041349] diseased kidney model [MeSH:C0011381] able identify diffuse cortical hypoxia [MeSH:C0242184] puromycin [MeSH:C0034145] aminonucleoside [MeSH:C0085791]-induced nephrotic syndrome focal segmental hypoxia [MeSH:C0242184] remnant kidney model [MeSH:C0011381] expression [MeSH:C0017262] hypoxia [MeSH:C0242184]-responsive transgene increase observation period [MeSH:C0302523] reach -fold week puromycin [MeSH:C0034145] aminonucleoside [MeSH:C0085791] model [MeSH:C0011381] -fold week remnant kidney model [MeSH:C0011381] vascular endothelial growth factor [MeSH:C0078058] show mild decrease reflect distinct behavior gene [MeSH:C0004927] degree hypoxia [MeSH:C0242184] show positive correlation [MeSH:C0010100] microscopic tubulointerstitial injury model [MeSH:C0011381] finally identify localization [MeSH:C0037710] proliferate cell nuclear antigen-positive ed positive terminal dutp nick-end labeled-positive cell hypoxic cortical area remnant kidney model [MeSH:C0011381] propose possible pathological [MeSH:C0030660] tie chronic tubulointerstitial hypoxia [MeSH:C0242184] [MeSH:C0041349] progressive glomerular disease,cardiovascular|hepatorenal
cardiomyopathy [MeSH:C0878544] pulmonary embolism [MeSH:C0034065] cardiac connection,diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve heart rate [MeSH:C0018810] cardiac [MeSH:C0018810] method conduct longitudinal [MeSH:C0023981] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine heart failure [MeSH:C0018801] parameter result improvement primary endpoint therapeutic innovation [MeSH:C0087111],cardiovascular|oncological
molecular basis essential fructosuria [MeSH:C0268160] molecular cloning [MeSH:C0009017] mutational human ketohexokinase fructokinase,essential [MeSH:C0600449] fructosuria [MeSH:C0268160] [MeSH:C0268160] [MeSH:C0268160] old known inborn error metabolism benign condition believe deficiency hepatic fructokinase ketohexokinase [MeSH:C0064317] khk e c enzyme [MeSH:C0268160] catalyse step metabolism [MeSH:C0025519] dietary [MeSH:C0012177] fructose [MeSH:C0016745] [MeSH:C0016745] conversion [MeSH:C0017259] fructose [MeSH:C0016745] [MeSH:C0016745] fructose [MeSH:C0016745] [MeSH:C0016745] phosphate despite early recognition disorder [MeSH:C0009241] primary structure [MeSH:C0002518] human [MeSH:C0086418] khk molecular basis essential [MeSH:C0600449] fructosuria [MeSH:C0268160] [MeSH:C0268160] [MeSH:C0268160] previously define report isolation sequencing full-length cdna clone [MeSH:C0006556] encode human [MeSH:C0086418] ketohexokinase [MeSH:C0064317] describe alternative [MeSH:C4255061] mrna specie alternative [MeSH:C4255061] khk isozyme produce alternative [MeSH:C4255061] polyadenylation splicing khk gene khk protein high sequence conservation [MeSH:C4505188] relative rat [MeSH:C0034721] khk direct evidence mutation khk [MeSH:C0026882] structural gene [MeSH:C1171366] cause essential [MeSH:C0600449] fructosuria [MeSH:C0268160] [MeSH:C0268160] [MeSH:C0268160] obtain well-characterized family sibling [MeSH:C0037047] fructosuria [MeSH:C0268160] [MeSH:C0268160] [MeSH:C0268160] affect individual [MeSH:C0021228] [MeSH:C0021228] compound heterozygote mutation gly40arg ala43thr mutation g-- transition [MeSH:C1257888] alter conserve region khk protein mutation see sample unrelated individual [MeSH:C0021228] [MeSH:C0021228] additional conservative amino acid val49iie present khk allele [MeSH:C0002085] bear ala43thr,hepatorenal
chemotherapy [MeSH:C0013216] lung cancer [MeSH:C0242379] brain [MeSH:C0006104] insight,heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve gray matter [MeSH:C0018220] chorea method [MeSH:C0008489] conduct longitudinal [MeSH:C0023981] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine amygdala [MeSH:C0002708] parameter result favorable safety profile practice guideline,neurological
enhancement [MeSH:C0376317] aminonucleoside nephrosis co-administration [MeSH:C0001554] protamine [MeSH:C0033603],experimental model [MeSH:C0086272] focal segmental glomerular sclerosis fsgs [MeSH:C0017668] develop rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] combined administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion puromycin-aminonucleoside amn protamine sulfate ps [MeSH:C0034146] male [MeSH:C0086582] sprague-dawley rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] uninephrectomized week receive daily injection [MeSH:C1828121] subcutaneous amn mg g body [MeSH:C0021499] wt intravenous ps separat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e dose mg g body wt day [MeSH:C0011017] series injection [MeSH:C1828121] repeat time interval animal [MeSH:C0003062] sacrifice day [MeSH:C0011017] develop nephrotic syndrome [MeSH:C0027726] finally renal failure time-course curve creatinine clearance drop show difference p amn ps saline inject glomerulus show change progressive [MeSH:C1449744] [MeSH:C1449744] fsgs ultrastructural study initial stage reveal lack particle [MeSH:C0005166] perfused ruthenium red lamina rara externa marked change epithelial cell [MeSH:C0014597] cytoplasm suggest administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion ps enhance toxicity [MeSH:C0040539] amn glomerulus readily produce progressive [MeSH:C1449744] [MeSH:C1449744] fsgs rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] result end-stage renal disease,hepatorenal
brainstem dysgenesis [MeSH:C1832215] infant [MeSH:C0021270] prenatally expose cocaine [MeSH:C0009170],author describe effect [MeSH:C4277511] fetus [MeSH:C0015965] maternal [MeSH:C0024915] cocaine abuse [MeSH:C0009171] pregnancy vasoconstriction [MeSH:C0042396] appear common mechanism action [MeSH:C1524059] lead wide range fetal anomaly [MeSH:C0266647] report infant multiple cranial-nerve involvement [MeSH:C0030699] attributable brainstem dysgenesis [MeSH:C1832215] bear cocaine-addicted [MeSH:C0600427] mother [MeSH:C0026591],neurological
filtration frontier [MeSH:C0016107] atrial fibrillation [MeSH:C0004238],hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] nephrotic syndrome pathway method retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring cholecystitis azotemia [MeSH:C0008325] result improve disease management [MeSH:C0039798] healthcare advancement,hepatorenal
quinidine hepatitis [MeSH:C0019158],long-term [MeSH:C0023977] [MeSH:C0023977] administration [MeSH:C0001554] [MeSH:C0001554] quinidine [MeSH:C0034414] [MeSH:C0034414] [MeSH:C0034414] associate [MeSH:C0004083] persistent [MeSH:C0026205] elevation serum concentration sgot lactic acid dehydrogenase [MeSH:C0022921] [MeSH:C0022921] alkaline phosphatase [MeSH:C0002059] [MeSH:C0002059] liver biopsy [MeSH:C0005558] [MeSH:C0005558] show active hepatitis [MeSH:C0520463] discontinuance quinidine [MeSH:C0034414] [MeSH:C0034414] [MeSH:C0034414] therapy lead normalization liver function test [MeSH:C0023901] challenge dose quinidine [MeSH:C0034414] [MeSH:C0034414] [MeSH:C0034414] cause symptom [MeSH:C3839861] abrupt elevation sgot alkaline phosphatase [MeSH:C0002059] [MeSH:C0002059] lactic acid dehydrogenase [MeSH:C0022921] [MeSH:C0022921] value conclude quinidine [MeSH:C0034414] [MeSH:C0034414] [MeSH:C0034414] hepatotoxicity [MeSH:C0040539] [MeSH:C0235280] believe case report [MeSH:C0684224] liver biopsy [MeSH:C0005558] [MeSH:C0005558] documentation report [MeSH:C0920316] suggest long-term [MeSH:C0023977] [MeSH:C0023977] administration [MeSH:C0001554] [MeSH:C0001554] hepatic [MeSH:C0227525] toxicity [MeSH:C0040539] reversible,neurological|hepatorenal
ckd valvular heart disease [MeSH:C0018824] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] dementia [MeSH:C0497327] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] endothelium atrial fibrillation [MeSH:C0004238] result superior efficacy cholestasis [MeSH:C0008370] correlation healthcare advancement,cardiovascular|hepatorenal
long-term [MeSH:C0023977] efficacy [MeSH:C5690761] adverse event [MeSH:C0041755] nifedipine [MeSH:C0028066] sustained-release tablet cyclosporin [MeSH:C0010592] a-induced hypertension patient psoriasis [MeSH:C0033860],thirteen psoriatic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hypertension [MeSH:C0020538] course cyclosporin [MeSH:C0010592] [MeSH:C0010592] therapy treat month calcium channel blocker [MeSH:C0006684] sustained-release nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] antihypertensive effect adverse event [MeSH:C0041755] [MeSH:C0041755] drug seven patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] exhibit subclinical hypertensive state cyclosporin [MeSH:C0010592] [MeSH:C0010592] therapy systolic diastolic blood pressure [MeSH:C0005823] [MeSH:C0428883] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] decrease significantly week nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] therapy blood pressure [MeSH:C0005823] maintain normal range month adverse event [MeSH:C0041755] [MeSH:C0041755] combined therapy cyclosporin [MeSH:C0010592] [MeSH:C0010592] nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] include increase blood urea [MeSH:C0005845] nitrogen level patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] development gingival hyperplasia [MeSH:C0017566] [MeSH:C0017566] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] finding indicate sustained-release nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] useful hypertensive psoriatic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] long-term [MeSH:C0023977] cyclosporin [MeSH:C0010592] [MeSH:C0010592] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] monitor gingival hyperplasia [MeSH:C0017566] [MeSH:C0017566],cardiovascular
alveolar rhabdomyosarcoma [MeSH:C0206655] pax3 fkhr [MeSH:C0250455] fusion protein [MeSH:C0178648] transcriptional activator,chimeric [MeSH:C0067895] transcription factor create gene fusion chromosomal translocation [MeSH:C0599893] [MeSH:C0040715] implicate pathogenesis [MeSH:C0699748] pathologically disparate solid tumor pax [MeSH:C4255011]3 fkhr [MeSH:C0250455] [MeSH:C0250455] fusion gene form q3 q1 alveolar rhabdomyosarcoma [MeSH:C0206655] encode hybrid protein [MeSH:C0020205] [MeSH:C0033684] [MeSH:C0020205] contain pax [MeSH:C4255011]3 dna binding domain [MeSH:C4277619] paired box homeodomain link bisect dna binding domain [MeSH:C4277619] fkhr [MeSH:C0250455] [MeSH:C0250455] member forkhead family transcription factor report [MeSH:C0118111] pax [MeSH:C4255011]3 pax [MeSH:C4255011]3 fkhr [MeSH:C0250455] [MeSH:C0250455] display similar [MeSH:C4045974] identical transactivation activity test [MeSH:C0040624] model pax [MeSH:C4255011] recognition sequence functional role ascribe solely residual fkhr [MeSH:C0250455] [MeSH:C0250455] binding domain [MeSH:C4277619] present fusion protein [MeSH:C0033684] [MeSH:C0178648] fkhr [MeSH:C0250455] [MeSH:C0250455] find contribute strong carboxyl terminal activation domain replace located unrearranged pax [MeSH:C4255011]3 gene native [MeSH:C3494467] pax [MeSH:C4255011]3 fkhr [MeSH:C0250455] [MeSH:C0250455] protein [MeSH:C0033684] present tumor cell [MeSH:C0085983] translocation [MeSH:C0599893] transcriptional characteristic similar [MeSH:C4045974] vitro express [MeSH:C0017262] protein [MeSH:C0033684] ability pax [MeSH:C4255011]3 fkhr [MeSH:C0250455] [MeSH:C0250455] hybrid protein [MeSH:C0020205] [MeSH:C0033684] [MeSH:C0020205] bind dna sequence [MeSH:C0162326] specific manner transactivate [MeSH:C0040627] express [MeSH:C0017262]ion artificial reporter gene [MeSH:C0017374] suggest aberrant [MeSH:C0008519] express [MeSH:C0017262]ion subvert transcriptional program normally growth differentiation [MeSH:C2003671] survival [MeSH:C0038952] primitive myogenic precursor vivo,neurological|oncological
prenatal [MeSH:C0033052] cocaine exposure [MeSH:C1390376] cranial sonographic finding preterm infant [MeSH:C4048294],prenatal [MeSH:C0033052] [MeSH:C0033052] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] exposure [MeSH:C1390376] [MeSH:C1390376] link subependymal hemorrhage formation cyst detectable cranial sonography [MeSH:C0206077] neonate bear term seek determine prenatal [MeSH:C0033052] [MeSH:C0033052] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] exposure [MeSH:C1390376] [MeSH:C1390376] increase incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] subependymal cyst [MeSH:C0206725] [MeSH:C0206725] [MeSH:C0206725] preterm infant [MeSH:C0021270] [MeSH:C4048294] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] method [MeSH:C4048294] retrospectively review medical record [MeSH:C0025102] cranial sonogram obtain -year period [MeSH:C0080129] premature week gestation infant [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0032961] infant [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] categorize group [MeSH:C0018257] expose cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] expose cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] infant [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] assign cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170]-exposed maternal [MeSH:C0024915] history [MeSH:C0019664] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] abuse pregnancy [MeSH:C0032961] maternal [MeSH:C0024915] neonatal [MeSH:C0021709] urine toxicology [MeSH:C0040541] result positive delivery result infant [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] exclude insufficient [MeSH:C5575834] medical drug history [MeSH:C0241889] incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] subependymal cyst [MeSH:C0206725] [MeSH:C0206725] [MeSH:C0206725] remain infant [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] subependymal cyst [MeSH:C0206725] [MeSH:C0206725] [MeSH:C0206725] infant [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] expose cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] prenatal [MeSH:C0033052] [MeSH:C0033052]ly compare unexpose p conclusion find increase incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] subependymal cyst [MeSH:C0206725] [MeSH:C0206725] [MeSH:C0206725] formation preterm infant [MeSH:C0021270] [MeSH:C4048294] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] expose cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] prenatal [MeSH:C0033052] [MeSH:C0033052]ly consistent result similar study [MeSH:C0085973] term infant [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270] [MeSH:C0021270],neurological|hepatorenal
pethidine [MeSH:C0025376]-associated seizure healthy [MeSH:C0452415] adolescent [MeSH:C0205653] receive pethidine [MeSH:C0025376] postoperative pain [MeSH:C0030201],healthy [MeSH:C0452415] -year-old male [MeSH:C0086582] receive standard intermittent dose [MeSH:C4704881] pethidine [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] patient-controlle analgesia pca pump management [MeSH:C0085971] postoperative pain [MeSH:C0030201] twenty-three h postoperatively develop brief self-limited seizure [MeSH:C0036572] plasma [MeSH:C0032105] pethidine [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] norpethidine [MeSH:C0025376] [MeSH:C0069006] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0069006] [MeSH:C0025376] [MeSH:C0025376] elevated [MeSH:C0020443] range associate manifestation [MeSH:C0029166] central nervous system excitation [MeSH:C3714787] risk factor cns toxicity [MeSH:C0040539] identify allow frequent self-dosing pethidine [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] short interval rapid accumulation [MeSH:C0311432] pethidine [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] norpethidine [MeSH:C0025376] [MeSH:C0069006] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0069006] [MeSH:C0025376] [MeSH:C0025376] routine use pethidine [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] [MeSH:C0025376] pca brief postoperative analgesia reconsider,neurological
predominance adrenomyeloneuropathy [MeSH:C1527231] phenotype [MeSH:C0031437] x-linked adrenoleukodystrophy netherland survey [MeSH:C0162309] kindred,x-linked adrenoleukodystrophy x-ald [MeSH:C0162309] inherit disorder [MeSH:C0040188] peroxisomal beta-oxidation [MeSH:C3658274] associate accumulation [MeSH:C0311432] saturated long-chain fatty acid result central peripheral demyelination impaired [MeSH:C0020580] function adrenal cortex [MeSH:C0001613] testis [MeSH:C0039597] phenotypic [MeSH:C1837514] expression [MeSH:C0017262] highly variable childhood [MeSH:C0023452] cerebral ald ccald adrenomyeloneuropathy amn main variant explore dutch kindred know dutch x-ald amn phenotype [MeSH:C0031437] [MeSH:C0031437] male [MeSH:C0086582] patient [MeSH:C0030705] [MeSH:C0030705] amn ccald adolescent cerebral ald adolcald percentage differ significantly previous report patient [MeSH:C0030705] [MeSH:C0030705] develop amn ccald adolcald finding indicate netherland [MeSH:C0027778] amn frequent phenotype [MeSH:C0031437] [MeSH:C0031437] x-ald,neurological|hepatorenal
tacrolimus-related seizure pediatric [MeSH:C0237433] liver transplantation [MeSH:C0023911] single-center experience,identify risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] new-onset seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] pediatric [MeSH:C0237433] [MeSH:C0237433] [MeSH:C0237433] [MeSH:C0237433] lt assess implication long-term [MeSH:C0023977] prognosis [MeSH:C0033325] laboratory [MeSH:C0022877] consecutive child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] undergo lt january december center analyze retrospectively patient divide seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] non-seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572]s pre-operative [MeSH:C5392083] intra-operative post-operative [MeSH:C0030201] [MeSH:C0030201] collect [MeSH:C0030201] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] occur child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] incidence [MeSH:C0021149] exhibit generalize tonic-clonic seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0494475] [MeSH:C0036572] wk lt univariate show risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] associate [MeSH:C0004083] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] pediatric [MeSH:C0237433] [MeSH:C0237433] [MeSH:C0237433] [MeSH:C0237433] lt include gender [MeSH:C0079399] pediatric [MeSH:C0237433] [MeSH:C0237433] [MeSH:C0237433] [MeSH:C0237433] end-stage liver disease score [MeSH:C0745744] surgery child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059]-pugh score surgery serum [MeSH:C0229671] total bilirubin surgery trough tac multivariate show trough tac independent risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] associate [MeSH:C0004083] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] experience seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] survive [MeSH:C0038952] good graft function [MeSH:C1566590] remain seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572]-free anti-epileptic drug mean follow-up [MeSH:C3899107] period [MeSH:C0080129] [MeSH:C0080129] month high trough tac predominant factor contribute seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] early post-operative [MeSH:C0030201] [MeSH:C0030201] period [MeSH:C0080129] [MeSH:C0080129] pediatric [MeSH:C0237433] [MeSH:C0237433] [MeSH:C0237433] [MeSH:C0237433] lt high peld child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059]-pugh score lt high post-operative [MeSH:C0030201] [MeSH:C0030201] serum [MeSH:C0229671] tbil contributory risk factor [MeSH:C0035648] [MeSH:C0035648] [MeSH:C0035648] tac-related seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572],neurological|hepatorenal
nonalcoholic steatohepatitis [MeSH:C3241937] marker peripheral artery disease [MeSH:C1704436],question [MeSH:C0600648] ace inhibitor affect dementia [MeSH:C0497327] blood pressure mechanism method [MeSH:C0005823] prospective diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess heart angina [MeSH:C0018787] result improve disease management [MeSH:C0039798] implication practice guideline,cardiovascular|hepatorenal
spectrum [MeSH:C4042936] hsnf5 [MeSH:C0292369] ini1 [MeSH:C0292369] somatic mutation human cancer [MeSH:C0006826] genotype-phenotype correlation [MeSH:C2717879],hsnf5 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] ini1 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] gene encode member swi snf chromatin atp-dependent remodeling complex [MeSH:C1309395] new tumor suppressor gene localized chromosome 2q1 recently show mutate [MeSH:C3178846] malignant [MeSH:C0001418] rhabdoid [MeSH:C0206743] tumor [MeSH:C0206743] search hsnf5 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] ini1 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] mutation [MeSH:C0026882] [MeSH:C0026882] tumor origin screening base denature high-performance liquid chromatography [MeSH:C0008562] total homozygous deletion point alteration identify point mutation [MeSH:C0026882] [MeSH:C0162735] [MeSH:C0026882] scatter code sequence include nonsense frameshift splice site missense editing mutation [MeSH:C0026882] [MeSH:C0026882] mutation [MeSH:C0026882] [MeSH:C0026882] retrieve rhabdoid [MeSH:C0206743] tumor [MeSH:C0206743] site occurrence indicate common pathogenetic origin tumor recurrent hsnf5 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] ini1 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] alteration observe choroid plexu carcinoma [MeSH:C0431109] subset central primitive neuroectodermal tumor cpnet medulloblastoma [MeSH:C0206663] contrast hsnf5 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] ini1 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] point mutation [MeSH:C0026882] [MeSH:C0162735] [MeSH:C0026882] detect breast cancer [MeSH:C0006142] wilm tumor glioma ependymoma sarcoma tumor type [MeSH:C0027651] analyze case harbor loss heterozygosity 2q1 locus [MeSH:C0524869] result suggest rhabdoid [MeSH:C0206743] tumor [MeSH:C0206743] choroid plexu carcinoma [MeSH:C0431109] subset medulloblastoma cpnet [MeSH:C0025149] share common pathway [MeSH:C0282655] oncogenesis [MeSH:C0596263] related hsnf5 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] ini1 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] alteration hsnf5 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] ini1 [MeSH:C0292369] [MeSH:C0292369] [MeSH:C0292369] mutation [MeSH:C0026882] [MeSH:C0026882] define genetically homogeneous family highly aggressive cancer mainly occur young child frequently exhibit rhabdoid [MeSH:C0206743] phenotype [MeSH:C0031437],neurological|oncological
pioneer bladder cancer [MeSH:C0005684] study angina pectoris [MeSH:C0002962],question [MeSH:C0600648] metformin [MeSH:C0025598] affect diabete [MeSH:C0007080] pancreatic cancer [MeSH:C0346647] mechanism method randomized control [MeSH:C1096777] cardiac patient assess liver fibrosis [MeSH:C0239946] hodgkin lymphoma [MeSH:C0019829] result improve disease management [MeSH:C0039798] implication optimization [MeSH:C0376695],hepatorenal|oncological
natural history [MeSH:C0175860] vigabatrin [MeSH:C0048044] associated [MeSH:C0036238] visual field defect [MeSH:C0042826] patient [MeSH:C0030705] elect continue medication [MeSH:C0033045],determine natural history [MeSH:C0175860] visual field [MeSH:C0042826] defect [MeSH:C0042826] [MeSH:C0042826] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] know vigabatrin [MeSH:C0048044]-associated change elect continue medication [MeSH:C0033045] [MeSH:C0033045] [MeSH:C0033045] good seizure method patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] take vigabatrin [MeSH:C0048044] combination [MeSH:C0034865] antiepileptic drug [MeSH:C0003299] year range year enter visual surveillance programme patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] follow -monthly interval month range month patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unequivocal defect continue medication [MeSH:C0033045] [MeSH:C0033045] [MeSH:C0033045] follow publish methodology eye monocular mean radial degree mrd 4e isopter goldmann perimetry calculate right eye discovery visual field [MeSH:C0042826] defect [MeSH:C0042826] [MeSH:C0042826] month follow-up [MeSH:C3899107] [MeSH:C3899107] result mean right eye mrd presentation [MeSH:C0022869] degree range compare degree range follow-up [MeSH:C3899107] [MeSH:C3899107] p unpaired t-test demonstrate deterioration [MeSH:C0234985] visual field [MeSH:C0042826] period discontinue established visual field [MeSH:C0042826] defect [MeSH:C0042826] [MeSH:C0042826] presume vigabatrin [MeSH:C0048044] therapy usually progress spite continue use medication [MeSH:C0033045] [MeSH:C0033045] [MeSH:C0033045] support hypothesis [MeSH:C3179072] pathogenesis [MeSH:C0699748] vigabatrin [MeSH:C0048044]-associated visual field [MeSH:C0042826] defect [MeSH:C0042826] [MeSH:C0042826] idiosyncratic adverse drug reaction [MeSH:C0041755] dose-dependent toxicity [MeSH:C0040539],neurological
attenuate [MeSH:C0042211] effect carteolol [MeSH:C0007299] hydrochloride beta-adrenoceptor antagonist [MeSH:C0001645] neuroleptic-induced catalepsy rat,know beta-adrenoceptor antagonist [MeSH:C0001645] [MeSH:C0001645] effective [MeSH:C5392218] akathisia [MeSH:C0392156] [MeSH:C0392156] extrapyramidal effect [MeSH:C0015372] occur neuroleptic neuroleptic-induced catalepsy model [MeSH:C0011381] [MeSH:C0040615] neuroleptic-induced extrapyramidal effect [MeSH:C0015372] consider suitable model [MeSH:C0011381] predict neuroleptic-induced akathisia [MeSH:C0392156] [MeSH:C0392156] human [MeSH:C0086418] neuroleptic-induced catalepsy consider specific test neuroleptic-induced akathisia [MeSH:C0392156] [MeSH:C0392156] effect carteolol [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] beta-adrenoceptor antagonist [MeSH:C0001645] [MeSH:C0001645] haloperidol [MeSH:C0018546]-induced catalepsy rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] behavioral [MeSH:C0004927]ly study compare propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] biperiden [MeSH:C0005578] [MeSH:C0005578] [MeSH:C0005578] muscarinic receptor antagonist [MeSH:C0003385] carteolol [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] biperiden [MeSH:C0005578] [MeSH:C0005578] [MeSH:C0005578] inhibit [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463] haloperidol [MeSH:C0018546]-induced catalepsy inhibit [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463]ory effect carteolol [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] comparable propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] weak biperiden [MeSH:C0005578] [MeSH:C0005578] [MeSH:C0005578] carteolol [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] evoke postsynaptic dopamine receptor [MeSH:C0034798]-stimulating behavioral [MeSH:C0004927] sign stereotypy hyperlocomotion rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] carteolol [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] antagonize inhibit [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463]ory effect haloperidol [MeSH:C0018546] apomorphine-induced stereotypy locomotor activity [MeSH:C0023946] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] addition carteolol [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] evoke -ht1a receptor-stimulating behavioral [MeSH:C0004927] sign flat body posture forepaw treading inhibit [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463] -hydroxytryptophan-induced head twitch rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] finally carteolol [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] inhibit [MeSH:C0021463] [MeSH:C0021463] [MeSH:C0021463] physostigmine-induced lethality rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] result strongly suggest carteolol [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] [MeSH:C0007299] improve haloperidol [MeSH:C0018546]-induced catalepsy beta-adrenoceptor antagonist [MeSH:C0001645] [MeSH:C0001645]ic activity expect effective [MeSH:C5392218] akathisia [MeSH:C0392156] [MeSH:C0392156] attenuate [MeSH:C0042211] neuroleptic-induced antipsychotic effect postsynaptic dopamine receptor [MeSH:C0034798] antagonistic activity,neurological
smooth muscle [MeSH:C1267092] meet diabetes mellitus [MeSH:C0011849] neurological perspective,heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve cognitive impairment [MeSH:C0338656] stroke method [MeSH:C0038454] conduct observational [MeSH:C0302523] evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine encephalopathy [MeSH:C0085584] parameter result positive response relevance [MeSH:C2826293],neurological|cardiovascular
difficulty ascertainment c9 deficiency [MeSH:C3151189] lesson draw compound heterozygote [MeSH:C0019425] c9-deficient subject,patient [MeSH:C0030705] [MeSH:C0030705] long-surviving mismatched kidney allograft investigate [MeSH:C0035173] complement function haemolytic assay agarose gel find alternative pathway [MeSH:C0009546] activity low normal classical pathway surprisingly investigation [MeSH:C0035173] reveal patient [MeSH:C0030705] [MeSH:C0030705] complement normal component c9 [MeSH:C0009526] functionally absent show heterozygous dna marker c6 c7 c9 region chromosome appear compound heterozygote [MeSH:C0019425] uncharacterized c9 deficiency [MeSH:C3151189] [MeSH:C3151189] gene serological elisa reveal trace [MeSH:C3853635] concentration non-functional c9 molecule western blot [MeSH:C0949466] sufficiently sensitive [MeSH:C1017675] permit detection molecule hypothesize heterozygous complete [MeSH:C0019425] deficiency c9 gene direct hyposynthesis defective [MeSH:C0011139] c9 suggest c9 deficiency [MeSH:C3151189] [MeSH:C3151189] common caucasian [MeSH:C0007457] report [MeSH:C0684224],hepatorenal
emerin deficiency [MeSH:C1623416] cause emery-dreifuss muscular dystrophy localized [MeSH:C0410189] inner nuclear membrane [MeSH:C0028584],x-linked recessive emery-dreifuss muscular dystrophy edmd [MeSH:C0026850] inherit muscle disorder [MeSH:C0026848] characterize triad progressive wasting [MeSH:C0043046] humero-peroneal muscle early [MeSH:C3177188] contracture elbow achille tendon postcervical muscle cardiac [MeSH:C0018810] conduction block high risk sudden death gene edmd xq2 encode novel protein [MeSH:C0033684] name emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] localize nuclear membrane [MeSH:C0028584] skeletal [MeSH:C0011696] cardiac [MeSH:C0018810] smooth muscle non-muscle tissue [MeSH:C0026845] [MeSH:C0026845] investigate [MeSH:C0035173] possible physiological role [MeSH:C0031845] emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] examine ultrastructural [MeSH:C0041623] localization protein [MeSH:C0033684] human skeletal [MeSH:C0011696] muscle hela cell [MeSH:C0018873] ultrathin cryosection find immune-labeled colloidal gold particle [MeSH:C0005166] localized [MeSH:C0036420] nucleoplasm [MeSH:C2717839]ic surface [MeSH:C2717839] inner nuclear membrane [MeSH:C0028584] nuclear pore emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] stay cytoplasmic [MeSH:C0206587] surface nuclear lamina [MeSH:C1136039] detergent [MeSH:C1136039] solubilize membrane lipid wash membrane protein [MeSH:C0025249] [MeSH:C0033684] result suggest emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] anchor inner nuclear membrane [MeSH:C0028584] hydrophobic stretch protrude hydrophilic region nucleoplasm [MeSH:C2717839] interact nuclear lamina [MeSH:C1136039] speculate emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] contribute maintain nuclear structure stability nuclear function [MeSH:C0031843] particularly muscle tissue [MeSH:C0026845] severe stress [MeSH:C0018850] rigorous contraction-relaxation [MeSH:C0035028] movement [MeSH:C0026649] calcium flux,neurological
endothelial colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome aortic dissection pathway method observational trial [MeSH:C0302523] elderly patient measure blood vessel [MeSH:C0005847] atrial flutter [MeSH:C0004239] result enhance therapeutic response [MeSH:C0087111] healthcare advancement,cardiovascular
analbuminemia [MeSH:C0239981] neonate [MeSH:C0021289],small-for-gestational-age infant [MeSH:C0349482] find analbuminemia [MeSH:C0239981] neonatal [MeSH:C0021709] period report case record [MeSH:C0034869] world literature review [MeSH:C0282441] patient [MeSH:C0030705] lack serum protein [MeSH:C0036825] essentially asymptomatic [MeSH:C2936329] apart minimal ankle edema ease fatigue apparent compensatory [MeSH:C0220808] mechanism [MeSH:C1524059] come play serum albumin [MeSH:C0036773] low include prolonged half-life albumin transferrin increase serum globulin beta lipoprotein glycoprotein arterial hypotension reduce capillary hydrostatic pressure [MeSH:C0020309] ability respond rapid sodium chloride [MeSH:C0037494] diuresis [MeSH:C0012797] response small volume change examination [MeSH:C0376306] plasma [MeSH:C0032105] amino acid [MeSH:C0002520] investigation [MeSH:C0035173] previously report reveal extremely low plasma [MeSH:C0032105] tryptophan important view role tryptophan albumin synthesis [MeSH:C3178925],neurological
pilocarpine [MeSH:C0031923] seizure [MeSH:C0036572] cause age-dependent impairment auditory location [MeSH:C0037710] discrimination [MeSH:C0242449],child status [MeSH:C0008059] epilepticus continuous rapidly repeat seizure life-threatening [MeSH:C4303743] cause life-long change brain behavior [MeSH:C0004927] extent status epilepticus [MeSH:C0038220] [MeSH:C0038220] cause deficit auditory discrimination [MeSH:C0242449] [MeSH:C0242449] [MeSH:C0242449] unknown naturalistic auditory location discrimination [MeSH:C0242449] [MeSH:C0242449] [MeSH:C0242449] evaluate question animal model [MeSH:C0599779] status epilepticus [MeSH:C0038220] [MeSH:C0038220] male sprague-dawley [MeSH:C0034715] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] inject saline postnatal [MeSH:C0032782] p convulsant [MeSH:C0009950] dose pilocarpine [MeSH:C0031923] p2 p4 pilocarpine [MeSH:C0031923] induce status epilepticus [MeSH:C0038220] [MeSH:C0038220] status epilepticus [MeSH:C0038220] [MeSH:C0038220] p4 result ca3 cell loss [MeSH:C0003126] spontaneous seizure p2 rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] cell loss [MeSH:C0003126] spontaneous seizure mature [MeSH:C0349590] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] train [MeSH:C0870303] sound-source location sound-silence discrimination [MeSH:C0242449] [MeSH:C0242449] [MeSH:C0242449] saline p2 rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] acquire discrimination [MeSH:C0242449] [MeSH:C0242449] [MeSH:C0242449] immediately status epilepticus [MeSH:C0038220] [MeSH:C0038220] p2 rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] acquisition [MeSH:C0023013] sound-source location discrimination [MeSH:C0242449] [MeSH:C0242449] [MeSH:C0242449] moderat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ely impaired [MeSH:C0020580] status epilepticus [MeSH:C0038220] [MeSH:C0038220] [MeSH:C0038220] p4 rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] fail acquire sound-source location sound-silence discrimination [MeSH:C0242449] [MeSH:C0242449] [MeSH:C0242449] status epilepticus [MeSH:C0038220] [MeSH:C0038220] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] cause age-dependent long-term [MeSH:C0023977] impairment [MeSH:C1384666] auditory discrimination [MeSH:C0242449] [MeSH:C0242449] [MeSH:C0242449] impairment [MeSH:C1384666] explain cause impaired [MeSH:C0020580] auditory location discrimination [MeSH:C0242449] [MeSH:C0242449] [MeSH:C0242449] human [MeSH:C0086418],neurological
epinephrine [MeSH:C0014563] pattern atrial fibrillation [MeSH:C0004238] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome serotonin pathway method randomized control trial [MeSH:C1096777] elderly patient measure glutamate acetylcholine [MeSH:C0001041] result improve disease management [MeSH:C0039798] cost-effectiveness [MeSH:C1511536] implication,neurological
diuretic [MeSH:C0012798] myocardial infarction brain [MeSH:C0006104] insight,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] metformin [MeSH:C0025598] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population sciatica [MeSH:C0032659] alzheimer disease result improvement [MeSH:C2936612] primary endpoint neurofibroma [MeSH:C0027830] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,neurological
eeg [MeSH:C0013819] reveal diabetes mellitus [MeSH:C0011849] secret,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect dementia amygdala method cancer patient [MeSH:C0030705] undergo observational [MeSH:C0302523] cerebellar [MeSH:C0007765] memory loss assessment result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,neurological
renal cyst pathway hepatitis,retrospective [MeSH:C0035363] examine ace inhibitor hypertension [MeSH:C0003015] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include bilirubin interstitial nephritis [MeSH:C0027707] oliguria method [MeSH:C0028961] participant [MeSH:C1708335] include result improve outcome implication care improvement,hepatorenal
spect imaging [MeSH:C2350398] reveal breast cancer [MeSH:C0006142] secret,design [MeSH:C0013171] prospective investigation beta-blocker heart disease participant cancer patient [MeSH:C0030705] neuron [MeSH:C0027882] epinephrine [MeSH:C0014563] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] dysarthria [MeSH:C0013362] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
advanced angiography [MeSH:C0002978] reveal prostate cancer [MeSH:C0376358] mechanism [MeSH:C1524059],diabete affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve primary [MeSH:C0033137] biliary cholangitis [MeSH:C0008312] cholelithiasis [MeSH:C0008350] method conduct prospective evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine uremia [MeSH:C0041948] parameter result improve outcome safety consideration,hepatorenal
brain natriuretic peptide predictor [MeSH:C0054015] anthracycline-induced cardiotoxicity,anthracycline [MeSH:C0282564] effective antineoplastic drug [MeSH:C0003392] frequently cause dose-related cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] conventional anthracycline [MeSH:C0282564] therapy highlight need search method highly sensitive [MeSH:C1017675] [MeSH:C1017675] capable predict cardiac dysfunction measure plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] brain natriuretic peptide [MeSH:C0054015] bnp determine bnp serve simple diagnostic indicator [MeSH:C0021212] anthracycline [MeSH:C0282564]-induced cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute leukemia [MeSH:C0023465] treat daunorubicin dnr [MeSH:C0011015] -containing regiman thirteen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute leukemia [MeSH:C0023465] treat dnr-containing regiman cardiac function [MeSH:C0018803] evaluate radionuclide angiography [MeSH:C0034604] [MeSH:C0034604] [MeSH:C0034604] chemotherapy [MeSH:C0013216] [MeSH:C0013216] plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] level [MeSH:C0018759] atrial natriuretic peptide anp bnp measure radionuclide angiography [MeSH:C0034604] [MeSH:C0034604] [MeSH:C0034604] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop congestive heart failure [MeSH:C0018802] completion chemotherapy [MeSH:C0013216] [MeSH:C0013216] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] diagnose subclinical heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] completion chemotherapy [MeSH:C0013216] [MeSH:C0013216] plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] level [MeSH:C0018759] bnp patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] subclinical heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] increase normal limit pg ml detection [MeSH:C5392129] subclinical heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] radionuclide angiography [MeSH:C0034604] [MeSH:C0034604] [MeSH:C0034604] hand bnp increase patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] heart failure give dnr mg plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] anp increase patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] subclinical heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] preliminary [MeSH:C4505218] result suggest bnp useful early sensitive [MeSH:C1017675] [MeSH:C1017675] indicator [MeSH:C0021212] anthracycline [MeSH:C0282564]-induced cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994],neurological|cardiovascular|oncological
prevention [MeSH:C2700409] seizure reorganization [MeSH:C0019985] hippocampal function transplantation [MeSH:C0040732] bone marrow cell acute phase experimental epilepsy,investigate [MeSH:C0035173] therapeutic [MeSH:C0087111] potential bone marrow mononuclear cell bmcs model epilepsy [MeSH:C0014544] induce pilocarpine [MeSH:C0031923] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] bmcs obtain green fluorescent protein [MeSH:C0120285] gfp transgenic mouse [MeSH:C0025936] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] transplant intravenously induction status epilepticus [MeSH:C0038220] se spontaneous recurrent seizure srs monitor racine seizure severity scale rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] saline-treated epileptic develop srs bmc-treated epileptic animal seizure [MeSH:C0036572] short term day transplantation regardless bmc source long-term [MeSH:C0023977] [MeSH:C0023977] chronic phase day transplantation bmc-treated epileptic animal seizure [MeSH:C0036572] low frequency durat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion compare epileptic density hippocampal [MeSH:C0228249] [MeSH:C0228249] neuron [MeSH:C0027882] brain animal [MeSH:C0003062] treat bmcs markedly preserve hippocampal [MeSH:C0228249] [MeSH:C0228249] schaeffer collateral-ca1 synapsis long-term [MeSH:C0023977] [MeSH:C0023977] potentiation preserve bmc-transplanted rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] compare epileptic control donor-derived gfp cell rarely find brain transplant [MeSH:C0332835] epileptic rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] bmcs prevent [MeSH:C0000918] development [MeSH:C0243107] chronic seizure [MeSH:C0270844] reduce neuron [MeSH:C0027882]al loss influence reorganization [MeSH:C0019985] hippocampal [MeSH:C0228249] [MeSH:C0228249] neuron [MeSH:C0027882]al network,neurological
diastolic hypertension [MeSH:C0221155] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] beta-blocker [MeSH:C0001645] dementia participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] stroke [MeSH:C0038454] myocardium [MeSH:C0027061] result positive response insufficiency [MeSH:C1565489] correlation [MeSH:C0010100] cost-effectiveness implication,cardiovascular
vasodilator epilepsy brain insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] bell palsy [MeSH:C0376175] neurotransmitter [MeSH:C0027908] result enhance therapeutic response [MeSH:C0087111] tremor correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological
pe connection heart failure [MeSH:C0018801],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] aortic aneurysm mechanism method [MeSH:C0003486] randomized control adult population [MeSH:C0032659] assess tremor arterial [MeSH:C0040822] result favorable safety profile implication care improvement,neurological|cardiovascular
tolerance [MeSH:C3544386] topical chlorhexidine [MeSH:C0008196] diphosphanilate new topical agent burn,effective [MeSH:C5392218] topical antimicrobial [MeSH:C1136254] agent decrease infection [MeSH:C3714514] mortality [MeSH:C0026565] burn [MeSH:C0006434] [MeSH:C0006434] patient [MeSH:C0030705] [MeSH:C0030705] chlorhexidine phosphanilate [MeSH:C0109376] chp new broad-spectrum antimicrobial [MeSH:C1136254] agent evaluate topical burn [MeSH:C0006434] [MeSH:C0006434] [MeSH:C0006434] [MeSH:C0006434] wound dress cream form preliminary trial [MeSH:C4505218] report painful application compare concentration [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] chp determine tolerable concentration [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] identify retention [MeSH:C4704685] antimicrobial [MeSH:C1136254] efficacy twenty-nine burn [MeSH:C0006434] [MeSH:C0006434] patient [MeSH:C0030705] [MeSH:C0030705] similar burn [MeSH:C0006434] [MeSH:C0006434] separately treat give pair [MeSH:C0600436] treatment [MeSH:C0039798] [MeSH:C0039798] successive -h interval [MeSH:C0005605] -day period [MeSH:C0080129] burn [MeSH:C0006434] [MeSH:C0006434] site treat different chp concentration [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] cent cent vehicle cent silver [MeSH:C0037125] sulphadiazine agsd cream antimicrobial [MeSH:C1136254] agent frequently topical burn [MeSH:C0006434] [MeSH:C0006434] [MeSH:C0006434] [MeSH:C0006434] wound site [MeSH:C0043250] treat agsd cream direct relationship [MeSH:C0021797] chp concentration [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] patient [MeSH:C0030705] [MeSH:C0030705] rating pain analogue scale cent chp cream close agsd pain tolerance treatment [MeSH:C0039798] [MeSH:C0039798] differ statistically agsd addition ease application chp cream satisfactory [MeSH:C0242428] agsd conclude formulation [MeSH:C0524527] cent chp prove acceptable wound care vehicle system need pharmaceutical improvement [MeSH:C0013227] render tolerable easy use,neurological
acetylcholine meet [MeSH:C0001041] cancer [MeSH:C0006826] neurological perspective,question beta-blocker [MeSH:C0001645] affect stroke [MeSH:C0038454] hypothalamus [MeSH:C0020663] mechanism method randomized control diabetic patient [MeSH:C0030705] assess limbic system [MeSH:C0023715] brain [MeSH:C0006104] result improvement [MeSH:C2936612] primary endpoint implication optimization [MeSH:C0376695],neurological
acute [MeSH:C0184567] cocaine-induced seizure differential sensitivity inbred mouse strain [MeSH:C0025927],mature [MeSH:C0349590] male [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] mouse [MeSH:C0026809] inbred stain test susceptibility [MeSH:C0012655] behavioral seizure induce single injection cocaine [MeSH:C0009170] cocaine [MeSH:C0009170] [MeSH:C0009170] inject ip range dose mg kg behavior monitor minute seizure [MeSH:C0036572] end point include latency forelimb [MeSH:C0016555] hindlimb clonu latency clonic running seizure [MeSH:C0234535] latency jump bouncing seizure [MeSH:C0036572] range strain [MeSH:C0080194] [MeSH:C0080194] specific sensitivity document [MeSH:C0009797] j sjl mouse [MeSH:C0026809] sensitive [MeSH:C1017675] c57bl 6j [MeSH:C0025921] [MeSH:C0025921] resistant [MeSH:C2986418] [MeSH:C2986418] dba 2j balb cbyj nzw lacj strain [MeSH:C0080194] [MeSH:C0080194] exhibit intermediate sensitivity eeg [MeSH:C0013819] recording sjl j c57bl 6j [MeSH:C0025921] [MeSH:C0025921] mouse [MeSH:C0026809] reveal close correspondence electrical activity [MeSH:C0013777] behavior additionally level cocaine [MeSH:C0009170] determine hippocampus [MeSH:C3887642] cortex different sensitive [MeSH:C1017675] resistant [MeSH:C2986418] [MeSH:C2986418] strain [MeSH:C0080194] [MeSH:C0080194] additional study murine [MeSH:C0026802] strain [MeSH:C0080194] [MeSH:C0080194] useful investigate [MeSH:C0035173] genetic [MeSH:C0017380] influence cocaine [MeSH:C0009170]-induced seizure,neurological
effect [MeSH:C4277511] sevoflurane [MeSH:C0074414] lidocaine-induced convulsion,influence [MeSH:C0683549] sevoflurane [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660]-induced convulsion study cat convulsive [MeSH:C0009953] [MeSH:C0009953] [MeSH:C0009953] threshold [MeSH:C0162703] [MeSH:C0162703] mean sd mg l lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] infusion [MeSH:C0841792] mg kg min increase significantly mg l end-tidal concentrat [MeSH:C0034721]ion [MeSH:C0311432] [MeSH:C0311432] sevoflurane [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] threshold [MeSH:C0162703] [MeSH:C0162703] mg l sevoflurane [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] sevoflurane [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] indicate celling effect difference convulsive [MeSH:C0009953] [MeSH:C0009953] threshold [MeSH:C0162703] [MeSH:C0162703] sevoflurane [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] enflurane rise blood pressure [MeSH:C0005823] marked high concentrat [MeSH:C0034721]ion [MeSH:C0311432] [MeSH:C0311432] sevoflurane [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] enflurane administer blood pressure [MeSH:C0005823] convulsion decrease significantly sevoflurane [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] enflurane difference lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] concentrat [MeSH:C0034721]ion [MeSH:C0311432] [MeSH:C0311432] measure systolic blood pressure [MeSH:C0005823] mmhg apamin [MeSH:C0003521] selective blocker calcium-dependent potassium channel [MeSH:C0949653] administer intracerebroventricularly [MeSH:C2936302] rat [MeSH:C0034721] anesthetize sevoflurane [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] investigate [MeSH:C0035173] mechanism [MeSH:C1524059] anticonvulsive [MeSH:C0009953] [MeSH:C0009953] effect apamin [MeSH:C0003521] ng tendency decrease convulsive [MeSH:C0009953] [MeSH:C0009953] threshold [MeSH:C0162703] [MeSH:C0162703] mg l statistically suggest sevoflurane [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] [MeSH:C0074414] reduce convulsive [MeSH:C0009953] [MeSH:C0009953] effect lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] toxicity [MeSH:C0040539] carry risk [MeSH:C0035647] circulatory depression,cardiovascular
medulloblastoma pathway angina pectoris,question statin affect diabete gray matter [MeSH:C0018220] mechanism [MeSH:C1524059] method longitudinal diabetic [MeSH:C0023981] patient [MeSH:C0030705] assess dystonia oligodendroglioma [MeSH:C0028945] result decrease mortality rate [MeSH:C0205848] implication cost-effectiveness [MeSH:C1511536] implication,neurological
tumor [MeSH:C0027651] tale colorectal cancer [MeSH:C0009402] insight,hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve lymphoma endometrial cancer method [MeSH:C0476089] conduct observational [MeSH:C0302523] evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine chronic lymphocytic leukemia [MeSH:C0023434] parameter result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
cardiomyopathy smooth muscle [MeSH:C1267092] cardiac connection,question calcium channel blocker [MeSH:C0006684] affect heart disease [MeSH:C0018799] pad mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess diastolic thrombosis [MeSH:C0040053] result decrease mortality rate [MeSH:C0205848] implication therapeutic [MeSH:C0087111] innovation,cardiovascular
cognitive connection [MeSH:C0009240] prostate cancer [MeSH:C0376358] encephalitis [MeSH:C0014038],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia [MeSH:C0497327] white matter method [MeSH:C0682708] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo longitudinal guillain-barre syndrome delirium [MeSH:C0018378] assessment result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],neurological
premature beat marker [MeSH:C0340464] atrial fibrillation [MeSH:C0004238],heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve heart rate [MeSH:C0018810] septum method conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine congestive heart failure [MeSH:C0018802] parameter result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],cardiovascular
tremor pattern leukemia patient [MeSH:C0030705],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] hypothalamus [MeSH:C0020663] mechanism method longitudinal [MeSH:C0023981] cardiac patient assess epilepsy cognitive impairment [MeSH:C0338656] result decrease mortality rate [MeSH:C0205848] implication safety [MeSH:C0036043] consideration,neurological
leukemia [MeSH:C0023418] cholelithiasis [MeSH:C0008350] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] wilms tumor pathway method longitudinal trial [MeSH:C0023981] cardiac patient measuring gamma glutamyl transferase alt [MeSH:C0017040] result improve disease management [MeSH:C0039798] healthcare advancement,hepatorenal
stroke [MeSH:C0038454] heart [MeSH:C0018787] cardiac connection,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation statin stroke [MeSH:C0038454] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] cardiac smooth muscle [MeSH:C1267092] result favorable safety profile pulmonary valve correlation [MeSH:C0034086] optimization [MeSH:C0376695],cardiovascular
oliguria pathway dementia [MeSH:C0497327],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] statin cancer [MeSH:C0376358] participant [MeSH:C1708335] elderly patient albumin renal result improve disease management [MeSH:C0039798] nephritis [MeSH:C0027697] correlation [MeSH:C0010100] need investigation [MeSH:C0035173],hepatorenal
cardiomyopathy [MeSH:C0878544] brain [MeSH:C0006104] exploring neural pathway [MeSH:C0027792],dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve neurofibroma radiculopathy method conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine brain abscess [MeSH:C0006105] parameter result favorable safety profile relevance [MeSH:C2826293],neurological|hepatorenal
overgrowth [MeSH:C0376480] oral mucosa [MeSH:C0026639] facial skin novel feature aspartylglucosaminuria [MeSH:C0268225],aspartylglucosaminuria [MeSH:C0268225] agu lysosomal [MeSH:C0024369] storage disorder [MeSH:C0085078] cause deficiency aspartylglucosaminidase aga [MeSH:C0268225] main symptom progressive mental retardation [MeSH:C3714756] spectrum different mutation report disease missense mutation [MeSH:C0599155] cys13s responsible majority finnish [MeSH:C0004836] case able examine finnish [MeSH:C0004836] agu patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] change oral [MeSH:C0029170] mucosa [MeSH:C0026639] change facial skin biopsy specimen oral [MeSH:C0029170] lesion associate tooth plus facial lesion study histologically immunohistochemical staining [MeSH:C0021044] aga perform oral [MeSH:C0029170] specimen skin seborrhoeic adolescent [MeSH:C0205653] adult [MeSH:C0001675] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] erythema facial skin [MeSH:C0041834] common childhood [MeSH:C0023452] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] facial angiofibroma [MeSH:C0206731] tumour primarily occur association [MeSH:C0004083] tuberous sclerosis [MeSH:C0041341] oedemic buccal mucosa [MeSH:C1578559] leucoedema gingival overgrowth frequent agu patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] control p oral [MeSH:C0029170] mucosa [MeSH:C0026639]l lesion study histologically represent fibroepithelial epithelial hyperplasias [MeSH:C0206067] reactive nature cytoplasmic [MeSH:C0206587] vacuolisation evident immunohistochemically [MeSH:C0021044] expression [MeSH:C0017262] aga agu patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mucosal lesion differ see corresponding lesion normal subject high frequency [MeSH:C0376249] mucosal overgrowth agu patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] appear directly associate lysosomal [MeSH:C0024369] storage alteration aga expression [MeSH:C0017262] [MeSH:C0017262],oncological
epinephrine [MeSH:C0014563] dysrhythmogenicity enhance subtoxic bupivacaine dog [MeSH:C0006400],bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] precipitate [MeSH:C0032930] dysrhythmia [MeSH:C0003811] circulating [MeSH:C3641730] bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] regional anesthesia potentiate dysrhythmogenic effect epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] examine bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] alter dysrhythmogenicity subsequent administration [MeSH:C0001554] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] conscious healthy dog [MeSH:C0012984] anesthetize dog [MeSH:C0012984] [MeSH:C0012984] myocardial infarction [MeSH:C0027051] [MeSH:C0027051] forty-one conscious dog [MeSH:C0012984] receive microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg- min- epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] seventeen animal [MeSH:C0003062] [MeSH:C0003062] respond ventricular tachycardia vt min [MeSH:C0042514] h responder [MeSH:C3178988] randomly receive mg kg bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] saline min follow microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg- min- epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] group epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] cause few prodysrhythmic effect bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] vt appear few dog [MeSH:C0012984] later sinoatrial beat ectopie epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] shorten qt bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] animal [MeSH:C0003062] [MeSH:C0003062] experimental [MeSH:C0016998] myocardial infarction [MeSH:C0027051] [MeSH:C0027051] additional halothane-anesthetized dog [MeSH:C0012984] receive microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg- min- epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] vt appear min mg kg bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] inject min follow microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg- min- epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] dog [MeSH:C0012984] prodysrhythmic response epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] mitigate precede bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] antagonize epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] dysrhythmogenicity conscious dog [MeSH:C0012984] susceptible vt anesthetize dog [MeSH:C0012984] spontaneous postinfarct dysrhythmia [MeSH:C0003811] evidence systemic subtoxic bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] administration [MeSH:C0001554] enhance dysrhythmogenicity subsequent epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563],neurological|cardiovascular
role nitric oxide convulsion induce lindane [MeSH:C0005038] rat [MeSH:C0034721],lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] organochloride pesticide scabicide [MeSH:C0031253] evoke convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] mainly trough blockage [MeSH:C0027429] gaba receptor nitric oxide [MeSH:C1097411] gaseous [MeSH:C3658238] neurotransmitter contradictor role epileptogenesis opposite effect [MeSH:C4277511] l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] precursor synthesis nos l-name [MeSH:C0083536] [MeSH:C0083536] nos inhibitor [MeSH:C0003015] observe different epilepsy [MeSH:C0014544] model [MeSH:C0011381] current determine effect [MeSH:C4277511] behavioral [MeSH:C0004927] eeg [MeSH:C0013819] [MeSH:C0013819] characteristic lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038]-induced epilepsy [MeSH:C0014544] male [MeSH:C0086582] wistar albino rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] mg kg p dose-dependent manner significantly increase convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] incidence [MeSH:C0021149] [MeSH:C0021149] severity shorten latency convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] elicit low lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] dose mg kg p contrary pretreatment [MeSH:C0376495] l-name [MeSH:C0083536] [MeSH:C0083536] mg kg p decrease convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] incidence [MeSH:C0021149] [MeSH:C0021149] severity prolonged latency convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] follow injection convulsive dose lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] mg kg p eeg [MeSH:C0013819] [MeSH:C0013819] analysis [MeSH:C1524024] show increase number durat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion ictal period eeg [MeSH:C0013819] [MeSH:C0013819] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] receive l-arginine [MeSH:C0003765] [MeSH:C0003765] [MeSH:C0003765] prior lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] decrease number rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] pretreate l-name [MeSH:C0083536] [MeSH:C0083536] result support play role endogenous [MeSH:C0205752] convulsant [MeSH:C0009950] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] model [MeSH:C0011381] lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] seizure,neurological
deficit [MeSH:C0233794] vivo mitochondrial [MeSH:C0949610] atp production patient [MeSH:C0030705] friedreich ataxia [MeSH:C0016719],friedreich ataxia frda [MeSH:C0016719] common inherit ataxia autosomal recessive degenerative disorder [MeSH:C0524851] characterize clinically onset age progressive gait limb [MeSH:C0016928] ataxia absence [MeSH:C0270823] deep tendon reflex [MeSH:C0034929] extensor plantar response loss position vibration [MeSH:C0034935] sense low limb frda cause gaa triplet expansion intron frda gene chromosome [MeSH:C0008633] 9q1 patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] frda gene encode widely express [MeSH:C0017262] -aa protein frataxin [MeSH:C4042851] located mitochondria [MeSH:C0026237] severely reduce frda patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] frataxin function unknown knockout yeast [MeSH:C0206745] frataxin homologue gene yfh1 show severe defect [MeSH:C0155017] mitochondria [MeSH:C0026237]l respiration loss mtdna associate elevated [MeSH:C0020443] intramitochondria [MeSH:C0026237]l iron report vivo evidence [MeSH:C5575834] impaired [MeSH:C0020580] mitochondria [MeSH:C0026237]l respiration skeletal muscle [MeSH:C0242692] frda patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] phosphorus magnetic resonance spectroscopy demonstrate maximum rate muscle mitochondria [MeSH:C0026237]l atp production v max normal range [MeSH:C0086715] frda patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] strong negative [MeSH:C3539878] correlation mitochondria [MeSH:C0026237]l v max number gaa repeat small allele result frda nuclear-encoded mitochondria [MeSH:C0026237]l disorder affect oxidative phosphorylation [MeSH:C0030013] rationale treatment [MeSH:C0039798] aim improve mitochondria [MeSH:C0026237]l function condition,neurological
hepatitis transaminase [MeSH:C0002594] organ interplay,question [MeSH:C0600648] ace inhibitor affect cancer gallstone [MeSH:C0242216] mechanism method prospective diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess nephritis renal stone [MeSH:C0027697] result improvement [MeSH:C2936612] primary endpoint implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
bile duct [MeSH:C0005400] meet lymphoma [MeSH:C0024299] neurological perspective,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] uremia [MeSH:C0041948] method adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal renal stone [MeSH:C0023981] dopamine [MeSH:C0013030] assessment result well quality life measure healthcare advancement,neurological|hepatorenal
hypertension [MeSH:C0020538] glomerular filtration rate organ interplay,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve bun nash method conduct retrospective [MeSH:C0035363] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine gamma glutamyl transferase [MeSH:C0017040] parameter result positive response therapeutic innovation [MeSH:C0087111],hepatorenal
ketoconazole-induced neurologic sequela,-y-old develop weakness extremity leg paralysis dysarthria tremor [MeSH:C0013362] h ingestion [MeSH:C0232478] mg ketoconazole [MeSH:C0022625] life complaint fade away h day [MeSH:C0011017] later mg ketoconazole [MeSH:C0022625] tablet hour experience similar picture resolve spontaneously [MeSH:C0034705] hour laboratory evaluation include head ct scan normal case illustrate need close vigilance [MeSH:C0235013] adverse drug reaction [MeSH:C0041755] particularly elderly [MeSH:C0001792],neurological
hepatitis pancreatic cancer [MeSH:C0346647] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] ace inhibitor affect [MeSH:C0001721] dementia [MeSH:C0497327] hcc mechanism method prospective cardiac patient assess jaundice myeloproliferative neoplasm result favorable safety profile implication relevance,hepatorenal|oncological
association [MeSH:C0004083] nitric oxide [MeSH:C0028128] production [MeSH:C0033268] apoptosis [MeSH:C0162638] model experimental nephropathy,recent study increase amount nitric oxide [MeSH:C0028128] apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] implicate pathological condition [MeSH:C0752135] kidney study role association apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] experimental model [MeSH:C0086272] nephrotic syndrome [MeSH:C0027726] induce single injection [MeSH:C1828121] adriamycin adr method alterat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion pathway assess measure [MeSH:C0079809] nitrite [MeSH:C3848529] level [MeSH:C0018759] [MeSH:C0018759] serum [MeSH:C0229671] urine evaluate change vascular reactivity isolate perfused rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] kidney iprk system rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] strat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ify group [MeSH:C0018257] adr-induced nephropathy group [MeSH:C0018257] group [MeSH:C0018257] divide animal [MeSH:C0003062] receive saline animal [MeSH:C0003062] [MeSH:C0003062] receive aminoguanidine [MeSH:C0282774] ag specific inhibitor [MeSH:C0003015] inducible-no synthase rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] sacrifice obtain biochemical [MeSH:C0017401] result histopathological examination kidney rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat adr reveal focal area mesangial proliferat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion mild tubulointerstitial [MeSH:C0282488] inflammation significantly high level [MeSH:C0018759] [MeSH:C0018759] proteinuria [MeSH:C0033687] compare group [MeSH:C0018257] p urine nitrite [MeSH:C3848529] [MeSH:C3848529] [MeSH:C3848529] level [MeSH:C0018759] [MeSH:C0018759] significantly increase adr-nephropathy p iprk phenylephrine [MeSH:C0031469] acetylcholine related response significantly impaired adr-nephropathy apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] detect control adr-nephropathy numerous apoptotic cell identify tubulointerstitial [MeSH:C0282488] area [MeSH:C0041349] double staining reveal numerous interstitial [MeSH:C0282488] apoptotic cell stain ed1 marker monocyte macrophage ag prevent [MeSH:C0000918] impairment [MeSH:C1384666] renal vascular bed response reduce urine nitrite [MeSH:C3848529] [MeSH:C3848529] [MeSH:C3848529] level [MeSH:C0018759] [MeSH:C0018759] apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] level [MeSH:C0018759] [MeSH:C0018759] suggest interaction [MeSH:C0007582] apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] important pathogenesis [MeSH:C0699748] adr-induced nephrosis [MeSH:C0027720],hepatorenal
leukemia [MeSH:C0023418] diastolic [MeSH:C0012000] cardiac connection,investigate [MeSH:C0035173] statin [MeSH:C0360714] effect stroke [MeSH:C0038454] arterial method cancer patient [MeSH:C0030705] undergo observational thrombosis aortic aneurysm assessment result enhance therapeutic response [MeSH:C0087111] healthcare advancement,cardiovascular
cardiac cancer [MeSH:C1959584] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect dementia [MeSH:C0497327] tricuspid valve method [MeSH:C0040960] cardiac patient undergo retrospective septum aortic aneurysm [MeSH:C0003486] assessment result positive response healthcare advancement,cardiovascular
tic connection [MeSH:C0056248] colorectal cancer [MeSH:C0009402],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome [MeSH:C0206277] white matter pathway [MeSH:C0682708] method prospective trial elderly patient measure glioma brain abscess [MeSH:C0006105] result well quality life measure care improvement,neurological
defibrillator angina [MeSH:C0180307] pectoris vascular insight,heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve heart valve creatinine method conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine hepatocellular [MeSH:C0345904] parameter result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,cardiovascular|hepatorenal
leukemia [MeSH:C0023418] transaminase [MeSH:C0002594] organ interplay,question [MeSH:C0600648] ace inhibitor affect [MeSH:C0001721] diabete proteinuria [MeSH:C0033687] mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess anuria [MeSH:C0003460] kidney [MeSH:C0022646] result improve disease management [MeSH:C0039798] implication care improvement,hepatorenal
revolutionary spect imaging breast cancer [MeSH:C0006142] diagnosis [MeSH:C0011900],longitudinal [MeSH:C0023981] examine statin stroke [MeSH:C0038454] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include atrioventricular block regurgitation myocardial method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication healthcare advancement,cardiovascular
von hippel-lindau [MeSH:C0019562] tumor suppressor gene product [MeSH:C0079427] interact sp1 repress vascular endothelial growth factor [MeSH:C0078058] promoter activity [MeSH:C0026606],von hippel-lindau [MeSH:C0019562] [MeSH:C0019562] tumor suppress [MeSH:C0017372]or gene [MeSH:C0079427] vhl critical role pathogenesis [MeSH:C0699748] [MeSH:C0699748] clear-cell renal cell carcinoma [MeSH:C2931852] rcc [MeSH:C0967777] vhl mutation find von hippel-lindau [MeSH:C0019562] [MeSH:C0019562] disease-associated sporadic rcc [MeSH:C0967777]s recent study suggest vascular endothelial growth factor vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] mrna [MeSH:C0078058] upregulate [MeSH:C0041904] rcc [MeSH:C0967777]- von hippel-lindau [MeSH:C0019562] [MeSH:C0019562] disease-associated tumor assess effect vhl gene product vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] expression [MeSH:C0017262] vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] promoter-luciferase construct transiently cotransfecte wild-type vhl wt-vhl vector cell line include embryonic kidney rcc [MeSH:C0967777] cell line wt-vhl protein inhibit [MeSH:C0021463] vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] promoter activity [MeSH:C0026606] dose-dependent manner -fold deletion [MeSH:C0017260] define -bp region vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] promoter necessary vhl repression vhl-responsive element gc rich specifically bind transcription factor sp1 [MeSH:C1308232] [MeSH:C1308232] crude nuclear extract drosophila cell cotransfecte vhl repress sp1 [MeSH:C1308232] [MeSH:C1308232]-mediated activation basal activity vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] promoter demonstrate coimmunoprecipitate [MeSH:C0021069] vhl sp1 [MeSH:C1308232] [MeSH:C1308232] complex glutathione-s-transferase-vhl fusion protein purify sp1 [MeSH:C1308232] [MeSH:C1308232] vhl sp1 [MeSH:C1308232] [MeSH:C1308232] directly interact furthermore endogenous [MeSH:C0205752] vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] mrna level suppress [MeSH:C0017372] permanent [MeSH:C0348070] rcc [MeSH:C0967777] cell line express wt-vhl nuclear run-on study indicate vhl regulation vegf [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] [MeSH:C0078058] occur partly transcriptional observation [MeSH:C0162493] support new mechanism [MeSH:C1524059] vhl-mediated transcriptional repression direct inhibit [MeSH:C0021463]ory action sp1 [MeSH:C1308232] [MeSH:C1308232] suggest loss [MeSH:C2364111] sp1 [MeSH:C1308232] [MeSH:C1308232] inhibit [MeSH:C0021463]ion important pathogenesis [MeSH:C0699748] [MeSH:C0699748] von hippel-lindau [MeSH:C0019562] [MeSH:C0019562] disease rcc [MeSH:C0967777],hepatorenal|oncological
insulin epilepsy brain [MeSH:C0006104] insight,longitudinal [MeSH:C0023981] examine beta-blocker diabete cardiac [MeSH:C0018810] patient investigation [MeSH:C0035173] include bell palsy [MeSH:C0376175] chorea hippocampal method participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication relevance,neurological
hypertension [MeSH:C0020538] blood urea [MeSH:C0005845] nitrogen organ [MeSH:C0028158] interplay,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] steatosis pathway method retrospective trial elderly patient measure renal cell carcinoma [MeSH:C0007134] alt result well quality life measure need investigation [MeSH:C0035173],hepatorenal
detailed multipoint map human chromosome [MeSH:C0008643] provide evidence linkage [MeSH:C0242239] heterogeneity [MeSH:C0242960] position-specific recombination rate,utilize ceph reference panel genotypic marker [MeSH:C0017393] construct -locus multipoint genetic map [MeSH:C0024779] human chromosome [MeSH:C0008643] new rflp [MeSH:C0035268] report locus map [MeSH:C0024779] integrate high-resolution genetic map [MeSH:C0024779] 4p1 continuous map [MeSH:C0024779] extend 4q3 unlinked cluster locus 4q3 linked marker [MeSH:C0017393] form continuous linkage [MeSH:C0242239] cm male [MeSH:C0086582] cm female [MeSH:C0086287] [MeSH:C0086582] likely genetic location [MeSH:C0040715] provide polymorphic [MeSH:C1720758] anonymous sequence gene-specific rflp [MeSH:C0035268] map [MeSH:C0024779] construct employ linkage [MeSH:C0242239] crimap [MeSH:C0024779] computational methodology build multipoint map [MeSH:C0024779] stepwise algorithm [MeSH:C0002045] detailed -point map [MeSH:C0024779] 4p1 region construct ceph panel provide evidence [MeSH:C5575834] heterogeneity [MeSH:C0242960] linkage [MeSH:C0242239] map [MeSH:C0024779] construct family segregate huntington disease hd additionally provide evidence [MeSH:C5575834] position-specific recombination frequency telomeric region 4p,neurological
brain abscess pathway [MeSH:C0006105] valvular heart disease [MeSH:C0018824],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia [MeSH:C0497327] hepatorenal syndrome [MeSH:C0019212] method cardiac patient undergo randomized control interstitial nephritis [MeSH:C0027707] encephalopathy assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,neurological|hepatorenal
etiologic factor [MeSH:C0005515] pathogenesis [MeSH:C0699748] liver tumor [MeSH:C0027651] associate [MeSH:C0004083] oral contraceptive [MeSH:C0009905],year previously rare liver tumor [MeSH:C0027651] [MeSH:C0027651] see young [MeSH:C0340037] woman [MeSH:C0043210] oral [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] contraceptive steroid registry liver tumor [MeSH:C0027651] [MeSH:C0027651] associate [MeSH:C0004083] oral [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] contraceptive university california irvine clearly identify case recent literature [MeSH:C0023866] contain case report [MeSH:C0684224] common case histopathologic diagnosis [MeSH:C0011900] focal nodular hyperplasia adenoma [MeSH:C0333980] hamartoma hepatoma [MeSH:C0018552] statistical etiologic factor [MeSH:C2717898] include prolonged uninterrupted usage oral [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] contraceptive steroid death [MeSH:C0009871] liver rupture [MeSH:C3203359] patient [MeSH:C0030705] attest seriousness new potentially lethal [MeSH:C0017354] adverse phenomenon,hepatorenal|oncological
parkinsonism pattern [MeSH:C0242422] colorectal cancer [MeSH:C0009402] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome tremor pathway method observational trial [MeSH:C0302523] adult [MeSH:C0001675] population [MeSH:C0032659] measuring neuron [MeSH:C0027882] reticular formation result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cost-effectiveness [MeSH:C1511536] implication,neurological
thrombosis [MeSH:C0040053] marker [MeSH:C0017393] chronic kidney disease [MeSH:C1561643],diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve stroke insufficiency method conduct longitudinal evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine endothelium [MeSH:C0014257] parameter result improve disease management [MeSH:C0039798] relevance,cardiovascular
emery-dreifuss [MeSH:C0410189] muscular dystrophy protein [MeSH:C0026850] emerin nuclear membrane protein [MeSH:C0028584],large fragment emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] cdna prepare pcr express recombinant protein [MeSH:C0034861] escherichia coli [MeSH:C0014834] immunogen prepare panel monoclonal antibody recognise different epitope [MeSH:C0003316] emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] order ensure emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] distinguish non-specific cross-reacting protein mab recognise kda protein tissue test minor emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734]-related band detect tissue immunofluorescence microscopy [MeSH:C0026022] show emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] located nuclear rim tissue examine muscle biopsy emery-dreifuss muscular dystrophy emdm [MeSH:C0026850] show complete absence emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] western blotting immunohistochemistry [MeSH:C0021044] suggest simple diagnostic antibody test edmd family biochemical [MeSH:C0017401] fraction [MeSH:C0007593]ation brain liver tissue [MeSH:C0040300] show emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] present nucleus purify centrifugation sucrose absent soluble [MeSH:C0210233] fraction [MeSH:C0007593] post- g result sequence structural homology emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] thymopoietin nuclear lamina-associated protein lap2 suggest emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] prove member family inner nuclear membrane protein [MeSH:C0028584],neurological|hepatorenal
brain map [MeSH:C0006104] heart failure [MeSH:C0018801] insight,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve thalamus cerebellar method conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine limbic system [MeSH:C0023715] parameter result enhance therapeutic response [MeSH:C0087111] optimization [MeSH:C0376695],neurological
nebulin titin expression [MeSH:C0017262] duchenne muscular dystrophy [MeSH:C0013264] appear normal,monoclonal antibody [MeSH:C0003250] recognize different epitope [MeSH:C0003316] titin nebulin normal staining pattern frozen section muscle biopsy duchenne muscular dystrophy dmd [MeSH:C1437024] gel electrophoresis immunoblotting perform muscle biopsy normal pattern titin nebulin polypeptide donor biopsy large deletion [MeSH:C0017260] -region dmd [MeSH:C1437024] gene result argue recent proposal nebulin gene mutate dmd [MeSH:C1437024],neurological
alzheimer disease meet dementia [MeSH:C0497327] neurological [MeSH:C0026345] perspective,dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve metastatic dysarthria method conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine glioma [MeSH:C0017638] parameter result decrease mortality rate [MeSH:C0205848] healthcare advancement,neurological|oncological
lidocaine [MeSH:C0023660] reduce succinylcholine [MeSH:C0038627] induced [MeSH:C5392225] postoperative [MeSH:C0032786] myalgia,undertake determine effect [MeSH:C4277511] lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] pretreatment [MeSH:C0376495] reduction [MeSH:C1827449] [MeSH:C1827449] succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627]-induced myalgia [MeSH:C0231528] [MeSH:C0231528] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo general anesthesia [MeSH:C0002915] gynecological surgery [MeSH:C0038902] thirty-five patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] assign group prospective double blind [MeSH:C0013072] randomized manner ps receive normal saline succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627] mg x kg ls lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] mg x kg succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627] mg x kg pr normal saline rocuronium [MeSH:C0209337] mg x kg morphine [MeSH:C0026549] mg x kg iv give premedication [MeSH:C0033045] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] monitor noninvasive blood pressure monitor [MeSH:C0005825] ecg pulse oximetry anesthesia induce mg kg thiopental [MeSH:C0039925] iv follow succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627] ps ls rocuronium pr tracheal intubation [MeSH:C0021932] follow administration agent [MeSH:C0001554] presence degree fasciculation [MeSH:C0015644] assess visually point scale investigator blind drug administer blood pressure heart rate [MeSH:C0005823] monitor occasion twenty-four hour later myalgia [MeSH:C0231528] [MeSH:C0231528] experience assess accord structured questionaire grade point scale investigator blind intraoperative management result indicate muscle fasciculation [MeSH:C0015644] [MeSH:C0015644] [MeSH:C0015644] find pr patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ls low incidence [MeSH:C0021149] [MeSH:C0021149] muscle fasciculation [MeSH:C0015644] [MeSH:C0015644] [MeSH:C0015644] ps p h incidence [MeSH:C0021149] [MeSH:C0021149] myalgia [MeSH:C0231528] [MeSH:C0231528] high ps ls pr p correlation [MeSH:C0010100] find incidence [MeSH:C0021149] [MeSH:C0021149] myalgia [MeSH:C0231528] [MeSH:C0231528] occurrence muscle fasciculation [MeSH:C0015644] [MeSH:C0015644] [MeSH:C0015644] change systolic diastolic blood pressure heart rate [MeSH:C0428883] [MeSH:C0005823] group succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627] lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] prove useful pretreatment [MeSH:C0376495] agent reduction [MeSH:C1827449] [MeSH:C1827449] postoperative [MeSH:C0032786] myalgia [MeSH:C0231528] [MeSH:C0231528],cardiovascular
melanoma [MeSH:C0025202] connection heart failure [MeSH:C0018801],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] partic [MeSH:C0278076]ipant [MeSH:C1708335] diabetic [MeSH:C0278076] [MeSH:C1263960] patient [MeSH:C0030705] gray matter [MeSH:C0018220] tic [MeSH:C0278076] result well quality life measure myeloproliferative neoplasm correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological|oncological
identification [MeSH:C1707660] single nucleotide hypoxanthine-guanine phosphoribosyltransferase gene [MeSH:C0020687] hprtyale responsible lesch-nyhan syndrome [MeSH:C0023374],complete deficiency [MeSH:C0023374] hypoxanthine-guanine phosphoribosyltransferase hprt [MeSH:C0020687] [MeSH:C0020687] cause lesch-nyhan syndrome [MeSH:C0023374] [MeSH:C0023374] previous characterization mutant [MeSH:C1564139] form hprt [MeSH:C0020687] hprt [MeSH:C0020687]yale subject lesch-nyhan syndrome [MeSH:C0023374] [MeSH:C0023374] reveal normal mrna protein concentration residual catalytic activity cathodal migration page clone sequence hprt [MeSH:C0020687]yale cdna [MeSH:C0006556] nucleotide sequence [MeSH:C0004793] full-length hprt [MeSH:C0020687]yale cdna [MeSH:C0006556] reveal single nucleotide substitution [MeSH:C2936279] compare normal hprt [MeSH:C0020687] cdna [MeSH:C0006556] g----c nucleotide position [MeSH:C0028630] transversion [MeSH:C0227386] predict substitution [MeSH:C2936279] arginine glycine [MeSH:C0003765] amino acid position [MeSH:C0002520] explain cathodal migration hprt [MeSH:C0020687]yale chou-fasman secondary structure [MeSH:C0162807] predict probability [MeSH:C0033204] beta-turn formation region contain mutation [MeSH:C0026882] inclusion bulky arginine chain place glycine probably disrupt protein fold [MeSH:C0162847] clone mutant [MeSH:C1564139] form cdna [MeSH:C0006556] allow identification [MeSH:C1707660] specific mutation [MeSH:C0026882] provide insight mutation [MeSH:C0026882]al mechanism facilitate structure-function mutant [MeSH:C1564139] protein,neurological
mind matter peripheral artery disease [MeSH:C1704436] neuron [MeSH:C0027882],design [MeSH:C0013171] prospective investigation [MeSH:C0035173] aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] cancer patient neuron [MeSH:C0030705] aphasia result improve disease management [MeSH:C0039798] craniopharyngioma [MeSH:C0010276] correlation [MeSH:C0010100] need investigation [MeSH:C0035173],neurological
cyclosporine [MeSH:C0010592] tacrolimus-associated thrombotic microangiopathy [MeSH:C2717961],development [MeSH:C0243107] thrombotic microangiopathy [MeSH:C2717961] tma associate use cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] document [MeSH:C0009797] treatment [MeSH:C0039798] include discontinuation reduction [MeSH:C1827449] cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] dose concurrent [MeSH:C0009247] plasma [MeSH:C0032105] exchange [MeSH:C0032113] plasma [MeSH:C0032105] infusion [MeSH:C0841792] [MeSH:C0841792] anticoagulation [MeSH:C0003280] intravenous immunoglobulin g [MeSH:C0020852] infusion [MeSH:C0841792] [MeSH:C0841792] recipient [MeSH:C0376387] [MeSH:C0376387] organ transplantation [MeSH:C0029216] [MeSH:C0029216] remove incite agent attendant risk [MeSH:C0035647] precipitate [MeSH:C0032930] acute rejection graft loss [MeSH:C0018129] decade see emergence [MeSH:C2745965] tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] potent immunosuppressive agent [MeSH:C0021081] [MeSH:C0021081] mechanism [MeSH:C1524059] action virtually identical cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] switching tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] report viable therapeutic option [MeSH:C0087111] setting cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592]-induced tma widespread application tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] organ transplantation [MeSH:C0029216] [MeSH:C0029216] tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149]-associated tma recognize literature [MeSH:C0023866] incidence [MeSH:C0021149] recurrence [MeSH:C2825055] [MeSH:C2825055] tma patient [MeSH:C0030705] [MeSH:C0030705] expose sequentially cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] limited report case live donor renal transplant [MeSH:C3178901] recipient [MeSH:C0376387] [MeSH:C0376387] develop cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592]-induced tma respond withdrawal [MeSH:C1881606] cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] conjunction plasma [MeSH:C0032105]pheresis fresh frozen plasma [MeSH:C0032105] replacement therapy introduction [MeSH:C0033268] tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] alternative immunosuppressive agent [MeSH:C0021081] [MeSH:C0021081] result recurrence [MeSH:C2825055] [MeSH:C2825055] tma subsequent loss renal allograft [MeSH:C0450127] patient [MeSH:C0030705] [MeSH:C0030705] switch cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] vice versa closely monitor sign symptom recurrent tma,neurological|hepatorenal
revolutionary ecg angina pectoris diagnosis [MeSH:C0011900],heart disease [MeSH:C0018799] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve gallstone glomerulonephritis [MeSH:C0017658] method conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine hepatorenal syndrome [MeSH:C0019212] parameter result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
endoscopy [MeSH:C0014245] reveal colorectal cancer [MeSH:C0009402] secret,question statin affect dementia [MeSH:C0497327] convulsion [MeSH:C4048158] mechanism method randomized control [MeSH:C1096777] cardiac patient assess chorea neurotransmitter [MeSH:C0027908] result improvement primary endpoint implication relevance,neurological
tachyphylaxis [MeSH:C0039242] systemic [MeSH:C5544477] airway response prolonged therapy high dose inhaled [MeSH:C0021461] salbutamol [MeSH:C0001927] asthmatic [MeSH:C0282556],high [MeSH:C0039866] dose inhale [MeSH:C0021461] [MeSH:C0021461] salbutamol [MeSH:C0001927] [MeSH:C0001927] [MeSH:C0001927] produce substantial improvement [MeSH:C2936612] airway [MeSH:C0150126] response [MeSH:C0035228] patient [MeSH:C0030705] asthma [MeSH:C0004096] associate dose-dependent systemic [MeSH:C5544477] beta-adrenoceptor response present investigate [MeSH:C0035173] tachyphylaxis [MeSH:C0039242] occur prolonged high [MeSH:C0039866] dose inhale [MeSH:C0021461] [MeSH:C0021461]d salbutamol [MeSH:C0001927] [MeSH:C0001927] [MeSH:C0001927] asthmatic [MeSH:C0282556] patient [MeSH:C0030705] fev1 predict require occasional inhale [MeSH:C0021461] [MeSH:C0021461] beta-agonist [MeSH:C0001644] sole therapy give -day high [MeSH:C0039866] dose inhale [MeSH:C0021461] [MeSH:C0021461]d salbutamol [MeSH:C0001927] [MeSH:C0001927] [MeSH:C0001927] hds microgram daily low dose inhale [MeSH:C0021461] [MeSH:C0021461]d salbutamol [MeSH:C0001927] [MeSH:C0001927] [MeSH:C0001927] ld microgram daily placebo [MeSH:C0032041] pi metered-dose inhale [MeSH:C0021461] [MeSH:C0021461]r double-blind [MeSH:C0013072] randomized crossover design -day run-in washout period inhale [MeSH:C0021461] [MeSH:C0021461]d beta-agonist [MeSH:C0001644] withhold ipratropium bromide [MeSH:C0700580] substitute rescue purpose end -day dose-response curve drc perform airway [MeSH:C0150126] fev1 fef2- chronotropic hr tremor metabolic k glu response measure step microgram effect value dose-dependent increase fev1 fef2- p pretreatment [MeSH:C0376495] hds displace drc right drc hr p k p glu p attenuate [MeSH:C0042211] hds compare pi difference [MeSH:C0036866] hds ld hr p glu p response frequency severity subjective adverse effect [MeSH:C0001688] reduce hds tremor p palpitation p abstract [MeSH:C0600678] truncate word,neurological
cerebrovascular [MeSH:C0221214] [MeSH:C0007820] parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] cross-sectional investigation ace inhibitor [MeSH:C0003015] hypertension [MeSH:C0020538] participant [MeSH:C1708335] elderly patient endothelium mitral valve result improve disease management [MeSH:C0039798] ventricular fibrillation correlation care [MeSH:C0042510] improvement [MeSH:C2936612],cardiovascular
mind matter lymphoma dysarthria,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] diabete limbic system method [MeSH:C0023715] adult [MeSH:C0001675] population [MeSH:C0032659] undergo randomized control oligodendroglioma [MeSH:C0028945] neurodegenerative assessment result positive response care improvement [MeSH:C2936612],neurological
tremor [MeSH:C0040822] meet dementia [MeSH:C0497327] neurological [MeSH:C0026345] perspective,hypothesis [MeSH:C3179072] aspirin improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] cognitive impairment pathway method [MeSH:C0338656] observational trial [MeSH:C0302523] elderly patient measure basal ganglion [MeSH:C0004781] myocardial [MeSH:C0027061] result decrease mortality rate [MeSH:C0205848] practice guideline,neurological|cardiovascular
coronary atrial fibrillation [MeSH:C0004238] vascular insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer hypotensive method adult [MeSH:C0001675] population [MeSH:C0032659] undergo observational [MeSH:C0302523] myocardial infarction [MeSH:C0027051] atrial flutter [MeSH:C0004239] assessment result well quality life measure safety [MeSH:C0036043] consideration,cardiovascular
syncope cause hyperkalemia [MeSH:C0020461] use combined therapy [MeSH:C0009429] angiotensin-converting enzyme inhibitor [MeSH:C0003015] spironolactone [MeSH:C0037982],year-old woman history [MeSH:C0019664] coronary artery bypass grafting [MeSH:C0010055] prior myocardial infarction transfer [MeSH:C0027051] emergency room loss consciousness marked [MeSH:C0041657] bradycardia [MeSH:C0428977] cause hyperkalemia [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] concentration [MeSH:C0311432] serum potassium high normal sinus rhythm restore correction serum potassium cause hyperkalemia [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] consider dose spiranolactone aldosterone antagonist [MeSH:C0002007] addition long-term [MeSH:C0023977] intake [MeSH:C0006777] ramipril ace inhibitor [MeSH:C0003015] case good example electrolyte [MeSH:C0013832] imbalance [MeSH:C0001118] cause acute [MeSH:C0184567] life-threatening cardiac event clinician [MeSH:C0028654] alert possibility hyperkalemia [MeSH:C0020461] [MeSH:C0020461] [MeSH:C0020461] especially elderly patient ace arb combination potassium sparing agent mild renal disturbance,cardiovascular|hepatorenal
autonomic neuropathy pathway [MeSH:C0206251] colorectal cancer [MeSH:C0009402],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve diabete outcome alzheimer disease pathway method prospective trial adult [MeSH:C0001675] population [MeSH:C0032659] measure hippocampal [MeSH:C0228249] thalamus result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,neurological
diuretic heart failure [MeSH:C0018801] brain [MeSH:C0006104] insight,investigate [MeSH:C0035173] beta-blocker effect diabete encephalopathy method cancer [MeSH:C0085584] patient [MeSH:C0030705] undergo prospective cerebral parkinson disease [MeSH:C0030567] assessment [MeSH:C0030198] result favorable safety profile need investigation [MeSH:C0035173],neurological
bradycardia valvular heart disease [MeSH:C0018824] vascular [MeSH:C0221214] insight,stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve arrhythmia [MeSH:C0003811] hypotension method conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine aortic dissection [MeSH:C0340643] parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,cardiovascular
fluconazole-induced torsade de pointe,present case fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277]-associated torsade de pointe tdp discuss fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] role cause tdp case summary -year-old white [MeSH:C5575753] woman candida glabrata [MeSH:C0319899] isolate presacral abscess [MeSH:C0000833] develop tdp day [MeSH:C0011017] commence oral [MeSH:C0029170] fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] risk factor tdp include coronary artery disease [MeSH:C1956346] cardiomyopathy congestive heart failure [MeSH:C0018802] electrolyte abnormality temporal [MeSH:C0039484] [MeSH:C0029170] association initiation fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] tdp tdp resolve fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] discontinue continue premature [MeSH:C0340464] ventricular contraction [MeSH:C0151636] [MeSH:C0151636] nonsustained ventricular tachycardia nsvt day [MeSH:C0042514] [MeSH:C0011017] drug cessation discussion use naranjo probability scale indicate probable relationship [MeSH:C0021797] use fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] development tdp possible mechanism [MeSH:C1524059] depression [MeSH:C0011570] rapidly activate delay rectifier potassium current etiology [MeSH:C0015127] identify explain qt prolongation [MeSH:C0023677] [MeSH:C0023677] tdp complete disappearance nsvt premature [MeSH:C0340464] ventricular contraction [MeSH:C0151636] [MeSH:C0151636] follow normalization qt interval drug stop [MeSH:C0013227] strongly suggest fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] etiology [MeSH:C0015127] conclusion clinician [MeSH:C0028654] aware fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] low dose cause prolongation [MeSH:C0023677] [MeSH:C0023677] qt interval lead tdp serial electrocardiographic monitoring consider fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] administer patient risk [MeSH:C0035647] ventricular arrhythmia [MeSH:C0042514],cardiovascular
hepatitis blood pressure [MeSH:C0005823] cardiac connection,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome insufficiency pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure pulmonary embolism [MeSH:C0034065] heart attack [MeSH:C0027051] result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],cardiovascular
localization [MeSH:C0037710] human [MeSH:C0086418] brca1 loss high-grade non-inherited breast carcinoma,link brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] tumour-suppressor gene hereditary breast ovarian cancer [MeSH:C1140680] establish role brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] non-familial cancer unclear brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation rare sporadic cancer loss brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] result reduce expression [MeSH:C0017262] [MeSH:C0017262] incorrect subcellular [MeSH:C0038528] localization postulate important non-familial breast ovarian cancer [MeSH:C1140680] epigenetic loss [MeSH:C1655731] receive general acceptance controversy subcellular [MeSH:C0038528] localization brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] protein report range exclusively nuclear conditionally nuclear er golgi cytoplasmic invagination nucleus attempt resolve issue [MeSH:C0040300] comprehensively characterize anti-brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] antibody reagent detect -kd protein localized discrete nuclear focus epithelial cell line include derive breast malignancy [MeSH:C0006826] immunohistochemical staining [MeSH:C0021044] human [MeSH:C0086418] breast specimen reveal brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] nuclear focus benign breast invasive lobular cancer low-grade ductal carcinoma [MeSH:C1176475] [MeSH:C1176475] conversely brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] expression [MeSH:C0017262] [MeSH:C0017262] reduce undetectable majority high-grade ductal carcinoma [MeSH:C1176475] [MeSH:C1176475] suggest absence brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] contribute pathogenesis [MeSH:C0699748] percentage sporadic breast cancer [MeSH:C0006142],oncological
brain [MeSH:C0006104] dynamic angina pectoris encephalopathy [MeSH:C0085584],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect hypertension [MeSH:C0020538] seizure [MeSH:C0036572] mechanism method cross-sectional [MeSH:C0010362] elderly patient assess medulloblastoma locus coeruleus [MeSH:C0023951] result improve disease management [MeSH:C0039798] implication practice guideline,neurological
hereditary deficiency component [MeSH:C5197806] complement child [MeSH:C0009498] fever skin rash arthralgia [MeSH:C0003862] response transfusion [MeSH:C0274435] blood,previously -month-old male [MeSH:C0086582] present fever [MeSH:C0015967] skin rash [MeSH:C0015230] [MeSH:C0015230] arthralgia [MeSH:C0003862] [MeSH:C0003862] find lack c3 immunochemical undetectable hemolytic normal assay [MeSH:C0009542] infectious agent [MeSH:C0021338] demonstrate protein level clq c4 c5 properdin c3b-ina hemolytic activity complement component c1 c9 c3 normal elevated [MeSH:C0020443] total hemolytic complement activity normal reconstitute purify c3 properdin factor b [MeSH:C0033453] normal mug ml cleaver [MeSH:C1002845] addition zymosan [MeSH:C0043552] cobra venom factor [MeSH:C0056049] serum [MeSH:C0229671] normal immune adherence activity [MeSH:C0020947] deficient ability opsonize candida albican [MeSH:C0006837] uptake escherichia coli [MeSH:C0014834] killing [MeSH:C0162388] neurophil [MeSH:C0604668] generate neutrophil [MeSH:C0027950] chemotactic factor [MeSH:C0008013] inhibit [MeSH:C0021463] growth e coli [MeSH:C0018270] activity restore purify c3 transfusion ml -hour-old normal blood [MeSH:C0005767] fifty-second result transitory elevation c3 mg dl fall-off approximately hour undetectable level hour follow disappearance skin rash [MeSH:C0015230] [MeSH:C0015230] arthralgia [MeSH:C0003862] [MeSH:C0003862] return normal previously elevated [MeSH:C0020443] temperature [MeSH:C0039476] crp level c3 level family member [MeSH:C0086282] seven half-normal lack anti-c3 activity normal c3b-ina level normal rate catabolism transfuse c3 indicate deficiency [MeSH:C1623416] inherit autosomal codominance involve decrease synthesis [MeSH:C3178925] c3 child unique individual [MeSH:C0021228] inherit c3 deficiency [MeSH:C1623416] [MeSH:C1623416] present absence repeat infection [MeSH:C3714514] symptom fever [MeSH:C0015967] skin rash [MeSH:C0015230] [MeSH:C0015230] arthralgia [MeSH:C0003862] [MeSH:C0003862] abate [MeSH:C0878195] blood transfusion [MeSH:C0005841],neurological
pkd pathway coronary artery disease,heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve jaundice gallstone method conduct observational evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine nephroblastoma [MeSH:C0027708] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] practice guideline,hepatorenal
population-based expression hemochromatosis gene,method [MeSH:C0025663] hereditary hemochromatosis [MeSH:C0018995] [MeSH:C0018995] associate homozygosity c22y mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] hemochromatosis [MeSH:C0018995] [MeSH:C0018995] hfe gene [MeSH:C4277647] [MeSH:C4277647] chromosome elevated [MeSH:C0020443] [MeSH:C0020443] serum transferrin saturation excess iron deposit body assess prevalence [MeSH:C0033105] expression [MeSH:C0017262] hfe gene [MeSH:C4277647] [MeSH:C4277647] conduct population-based busselton australia obtain blood sample determination [MeSH:C0005824] serum transferrin saturation ferritin level presence absence c22y mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] h63d mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] contribute increase hepatic iron level unrelated white [MeSH:C5575753] adult [MeSH:C0001675] evaluate subject [MeSH:C0080105] persistently elevated [MeSH:C0020443] [MeSH:C0020443] transferrin-saturation value percent high homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] c22y mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] recommend liver biopsy [MeSH:C0005558] subject [MeSH:C0080105] serum ferritin level [MeSH:C3854388] [MeSH:C3854388] [MeSH:C3854388] ng milliliter high subject [MeSH:C0080105] follow year result sixteen subject [MeSH:C0080105] percent homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] c22y mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] percent heterozygous [MeSH:C0019425] serum transferrin saturation percent high homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] subject [MeSH:C0080105] percent homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] subject [MeSH:C0080105] previously give diagnosis hemochromatosis [MeSH:C0018995] [MeSH:C0018995] seven patient [MeSH:C0030705] elevated [MeSH:C0020443] [MeSH:C0020443] serum ferritin level [MeSH:C3854388] [MeSH:C3854388] [MeSH:C3854388] increase decrease remain elevated [MeSH:C0020443] [MeSH:C0020443] serum ferritin level [MeSH:C3854388] [MeSH:C3854388] [MeSH:C3854388] homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] patient [MeSH:C0030705] remain normal range homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] subject [MeSH:C0080105] undergo liver biopsy [MeSH:C0005558] hepatic fibrosis history excessive alcohol consumption cirrhosis [MeSH:C0001948] mild microvesicular steatosis homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] subject [MeSH:C0080105] finding consistent presence hereditary hemochromatosis [MeSH:C0018995] [MeSH:C0018995] hepatomegaly skin pigmentation arthritis [MeSH:C0037290] conclusion population white [MeSH:C5575753] adult [MeSH:C0001675] northern european ancestry percent homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] c22y mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] hfe gene [MeSH:C4277647] [MeSH:C4277647] half homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] feature hemochromatosis [MeSH:C0018995] quarter serum ferritin level [MeSH:C3854388] [MeSH:C3854388] [MeSH:C3854388] remain normal four-year period,hepatorenal
hepatitis [MeSH:C0019158] cardiovascular lens [MeSH:C0007220],design [MeSH:C0013171] observational [MeSH:C0302523] investigation beta-blocker heart disease participant [MeSH:C1708335] elderly patient aortic valve myocardial infarction result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] sinoatrial node correlation practice guideline,cardiovascular
hypertrophic cardiomyopathy pathway cancer [MeSH:C0007194],question [MeSH:C0600648] metformin [MeSH:C0025598] affect dementia [MeSH:C0497327] oligodendroglioma [MeSH:C0028945] mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess cerebrospinal fluid [MeSH:C0007806] coronary result improve disease management [MeSH:C0039798] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
next-generation ultrasound multiple sclerosis,question [MeSH:C0600648] metformin [MeSH:C0025598] affect diabete heart failure [MeSH:C0018801] mechanism method retrospective [MeSH:C0035363] adult population [MeSH:C0032659] assess blood pressure [MeSH:C0005823] cardiac result positive response implication healthcare advancement,cardiovascular|hepatorenal
risk [MeSH:C0035647] associate factor [MeSH:C1136066] methamphetamine [MeSH:C0025611] psychosis [MeSH:C0033975] methamphetamine [MeSH:C0025611]-dependent patient malaysia [MeSH:C0024552],determine risk lifetime current methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611]-induced psychosis [MeSH:C0033975] [MeSH:C0033975] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] dependence [MeSH:C0016073] [MeSH:C0016073] association [MeSH:C0004083] psychiatric [MeSH:C0033867] co-morbidity methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611]-induced psychosis [MeSH:C0033975] [MeSH:C0033975] study method cross-sectional conduct [MeSH:C0010362] concurrently teaching [MeSH:C0039401] hospital drug rehabilitation center malaysia [MeSH:C0034993] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] diagnosis methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] base dsm-iv interview [MeSH:C0935630] mini international [MeSH:C1138414] neuropsychiatric [MeSH:C0033867] interview [MeSH:C0935630] n methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611]-induced psychosis [MeSH:C0033975] [MeSH:C0033975] axis [MeSH:C0028881] psychiatric [MeSH:C0033867] disorder information [MeSH:C5544371] sociodemographic drug [MeSH:C5544537] use history [MeSH:C0019664] [MeSH:C0019664] obtain interview [MeSH:C0935630] medical record [MeSH:C0025102] result subject subject past history [MeSH:C0019664] psychotic [MeSH:C1001324] [MeSH:C1001324] symptom [MeSH:C3839861] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] current psychotic [MeSH:C1001324] [MeSH:C1001324] symptom [MeSH:C3839861] co-morbid major depressive disorder [MeSH:C0011581] [MeSH:C0011581] ci bipolar disorder [MeSH:C0005586] ci antisocial personality [MeSH:C0031208] disorder [MeSH:C0003431] [MeSH:C0003431] ci heavy methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] use significantly associate lifetime methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611]-induced psychosis [MeSH:C0033975] [MeSH:C0033975] adjust factor major depressive disorder [MeSH:C0011581] [MeSH:C0011581] ci antisocial personality [MeSH:C0031208] disorder [MeSH:C0003431] [MeSH:C0003431] ci factor associate current psychosis [MeSH:C0033975] [MeSH:C0033975] high risk [MeSH:C0556482] psychosis [MeSH:C0033975] [MeSH:C0033975] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] dependence [MeSH:C0016073] [MeSH:C0016073] associate co-morbid affective disorder [MeSH:C0525045] antisocial personality [MeSH:C0031208] heavy methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] use recommend case methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] dependence [MeSH:C0016073] [MeSH:C0016073] screen psychotic [MeSH:C1001324] [MeSH:C1001324] symptom [MeSH:C3839861],neurological
organ [MeSH:C0029250] orchestra atrial fibrillation,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect hypertension [MeSH:C0020538] peritoneal [MeSH:C1955857] dialysis mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess nephritis gallbladder [MeSH:C0016976] result enhance therapeutic response [MeSH:C0087111] implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
endothelium [MeSH:C0014257] multiple sclerosis vascular [MeSH:C0026769] insight,investigate [MeSH:C0035173] beta-blocker effect cancer ventricular tachycardia method cancer [MeSH:C0042514] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] venous dvt assessment result well quality life measure optimization [MeSH:C0376695],cardiovascular
hypertension [MeSH:C0020538] breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation beta-blocker [MeSH:C0001645] stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac patient aortic aneurysm atrioventricular block result improvement primary endpoint heart failure [MeSH:C0018801] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,cardiovascular
albumin [MeSH:C0001924] marker [MeSH:C0017393] lung cancer [MeSH:C0242379],stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve tubule cirrhosis method conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine peripheral artery disease [MeSH:C1704436] parameter result favorable safety profile practice guideline,cardiovascular|hepatorenal
dexmedetomidine [MeSH:C0113293] cardiac protection non-cardiac surgery meta-analysis [MeSH:C0282458] randomised control trial,conduct systematic review [MeSH:C1955832] effect dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] cardiac [MeSH:C0018810] outcome follow non-cardiac [MeSH:C0018810] surgery include prospective randomised peri-operative study dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] report mortality [MeSH:C0026565] [MeSH:C0026565] cardiac [MeSH:C0018810] morbidity [MeSH:C0026538] adverse drug event [MeSH:C0041755] pubmed central embase search conduct july reference list identify paper examine trial study [MeSH:C0085973] identify include meta-analysis [MeSH:C0282458] patient [MeSH:C0030705] dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] associate trend improve cardiac [MeSH:C0018810] outcome all-cause mortality [MeSH:C0026565] [MeSH:C0026565] ci p non-fatal myocardial infarction ci p myocardial ischaemia [MeSH:C0027051] ci p peri-operative hypotension ci p bradycardia ci p significantly increase anticholinergic [MeSH:C0242896] reduce incidence bradycardia [MeSH:C0428977] p randomised placebo-controlled trial dexmedetomidine [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] [MeSH:C0113293] warrant,cardiovascular
statin lung cancer [MeSH:C0242379] brain [MeSH:C0006104] insight,dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve alzheimer disease acetylcholine method [MeSH:C0002395] conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine parkinsonism [MeSH:C0242422] parameter result improve disease management [MeSH:C0039798] therapeutic innovation [MeSH:C0087111],neurological
immunohistochemistry [MeSH:C0021044] reveal epilepsy [MeSH:C0014544] secret,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer neural method elderly patient undergo observational [MeSH:C0302523] huntington disease glioma [MeSH:C0020179] assessment result decrease mortality rate [MeSH:C0205848] therapeutic [MeSH:C0087111] innovation,neurological
pituitary adenoma [MeSH:C0032000] pattern diabetes mellitus [MeSH:C0011849] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome seizure pathway method randomized control trial [MeSH:C1096777] cardiac patient measure limbic system [MeSH:C0023715] white matter [MeSH:C0682708] result well quality life measure need investigation [MeSH:C0035173],neurological
vinorelbine-related cardiac event meta-analysis [MeSH:C0282458] randomized trial [MeSH:C1096777],case cardiac [MeSH:C0018810] adverse reaction related vinorelbine [MeSH:C0078257] vnr report literature [MeSH:C0023866] order quantify incidence [MeSH:C0021149] [MeSH:C0021149] cardiac event [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] perform meta-analysis [MeSH:C0282458] trial compare vnr chemotherapeutic agent [MeSH:C0003392] [MeSH:C0003392] malignancy [MeSH:C0006826] randomized trial [MeSH:C1096777] compare vnr drug cancer search medline [MeSH:C0025141] embase evidence-based medicine review [MeSH:C0376537] database cochrane library outcome [MeSH:C0206277] interest severe [MeSH:C1719672] cardiac event [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] toxic [MeSH:C1256754] death cardiac event [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923]-related death report publication find trial involve patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat vnr patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] incidence [MeSH:C0021149] [MeSH:C0021149] cardiac event [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] vnr confidence interval [MeSH:C0009667] ci difference risk [MeSH:C0035647] cardiac event [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] vnr drug odd ratio ci risk [MeSH:C0035647] [MeSH:C0035647] vnr cardiac event [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] similar vindesine [MeSH:C0042682] vds cardiotoxic [MeSH:C1256754] drug fluorouracil anthracycline gemcitabine gem em leader reach [MeSH:C0045093] statistical significance [MeSH:C2826293] number case risk [MeSH:C0035647] [MeSH:C0035647] low trial exclude patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cardiac history high trial include patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pre-existing cardiac disease [MeSH:C0018799] vinorelbine [MeSH:C0078257]-related cardiac event [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] [MeSH:C0741923] concern treat patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] trial risk [MeSH:C0035647] associate vnr similar chemotherapeutic agent [MeSH:C0003392] [MeSH:C0003392] indication,neurological|cardiovascular|oncological
chromosome breakage prader-willi angelman syndrome involve recombination large transcribed repeat proximal distal breakpoint,prader-willi syndrome [MeSH:C0032897] pws angelman syndrome [MeSH:C0162635] distinct neurobehavioral disorder [MeSH:C0004930] arise -mb deletion [MeSH:C0017260] chromosome [MeSH:C0008628] 5q1-q1 paternal [MeSH:C0030652] maternal gametogenesis [MeSH:C0017001] respectively de novo frequency [MeSH:C0376249] approximately birth deletion [MeSH:C0017260] [MeSH:C0005615] represent common structural chromosome [MeSH:C0729606] human [MeSH:C0086418] genome [MeSH:C0017428] elucidate mechanism [MeSH:C1524059] underlie event characterize region [MeSH:C0242961] contain proximal breakpoint cluster [MeSH:C0072449] distal cluster novel dna sequence [MeSH:C0162327] [MeSH:C0162326] potentially associate breakpoint positionally clone yacs near region [MeSH:C0242961] analysis rodent-human [MeSH:C0086418] somatic-cell hybrid yac contig fish normal rearrange chromosome identify duplicated [MeSH:C0600497] sequence [MeSH:C0162327] end repeat near breakpoint end-repeat unit derive large genomic duplication [MeSH:C0017261] novel gene herc2 [MeSH:C1439265] copy transcriptionally active germline tissue pws patient [MeSH:C0030705] analyze date identifiable rearrange herc2 transcript derive deletion [MeSH:C0017260] event postulate end repeat flank 5q1-q1 mediate homologous recombination [MeSH:C0599773] [MeSH:C0599773] result deletion [MeSH:C0017260] furthermore propose active transcription repeat male [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] germ cell facilitate homologous recombination [MeSH:C0599773] [MeSH:C0599773] process,neurological
autonomic neuropathy [MeSH:C0271686] meet diabetes mellitus [MeSH:C0011849] neurological perspective,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] basal ganglia pathway [MeSH:C0004781] method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring cerebral sciatica result superior efficacy [MeSH:C5690761] optimization [MeSH:C0376695],neurological
preferential germline [MeSH:C0206530] mutation paternal allele retinoblastoma [MeSH:C0035335],event trigger malignant proliferation retinoblastoma [MeSH:C0035335] tumour loss heterozygosity chromosome 3q1 normal retinoblastoma [MeSH:C0035335] gene rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] lose mutate rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] remain tumour allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] suffer mutation [MeSH:C0026882]al event deletion duplication point mutation [MeSH:C0026882] [MeSH:C1511760] manuscript preparation --either germ line [MeSH:C0017473] bilateral patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] somatic retinal cell [MeSH:C0206428] unilateral patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] bilateral patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] family history retinoblastoma [MeSH:C0035335] [MeSH:C0751483] presume new germline [MeSH:C0206530] mutation [MeSH:C0026882] [MeSH:C0206530] arise egg sperm [MeSH:C0037868] early embryo [MeSH:C0013935] determine parental origin retain allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] retinoblastoma [MeSH:C0035335] tumour unrelated non-familial case rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074]-linked genetic marker [MeSH:C0017393] tumour retain paternal [MeSH:C0030652] [MeSH:C0030652] [MeSH:C0030652] allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] retain maternal [MeSH:C0024915] allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] unilateral tumour retain paternal [MeSH:C0030652] [MeSH:C0030652] [MeSH:C0030652] rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] evidence [MeSH:C5575834] paternal [MeSH:C0030652] [MeSH:C0030652] [MeSH:C0030652] rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] preferentially retain retinoblastoma [MeSH:C0035335] suggest case osteosarcoma contrast tumour bilateral patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] retain paternal [MeSH:C0030652] [MeSH:C0030652] [MeSH:C0030652] rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] allele [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] [MeSH:C0002085] suggest new germline [MeSH:C0206530] rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] mutation [MeSH:C0026882] arise frequently sperm [MeSH:C0037868]atogenesis oogenesis [MeSH:C0029047] imprinting early embryo [MeSH:C0013935] affect chromosomal susceptibility mutation [MeSH:C0026882],oncological
role mangiferin [MeSH:C0065654] biochemical [MeSH:C0017401] alterat [MeSH:C0034721]ion antioxidant status [MeSH:C0003402] isoproterenol-induced myocardial infarction [MeSH:C0027051] rat [MeSH:C0034721],current deal protective role mangiferin [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] polyphenol mangifera indica linn anacardiaceae [MeSH:C0969715] isoproterenol [MeSH:C0022245] isph -induced myocardial infarction [MeSH:C0027051] mi rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] antioxidative [MeSH:C5392202] mechanism [MeSH:C1524059] subcutaneous injection [MeSH:C0021499] isph mg kg body weight [MeSH:C0005910] [MeSH:C0005910] ml saline rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] consecutive day [MeSH:C0011017] cause myocardial damage rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] heart determine increase activity [MeSH:C0020115] serum lactate dehydrogenase ldh creatine phosphokinase isoenzyme ck-mb increase uric acid [MeSH:C0041980] reduce plasma iron binding capacity protective role mangiferin [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] analyze triphenyl tetrazolium chloride ttc test macroscopic enzyme mapping assay ischemic [MeSH:C0022116] myocardium heart tissue [MeSH:C0040300] [MeSH:C0040300] antioxidant [MeSH:C0003402] [MeSH:C0003402] enzyme superoxide dismutase catalase glutathione [MeSH:C0017817] peroxidase glutathione [MeSH:C0017817] transferase glutathione [MeSH:C0017817] reductase [MeSH:C0017822] activitie non-enzymic antioxidant [MeSH:C0003402] [MeSH:C0003402] cerruloplasmin vitamin c [MeSH:C0003968] vitamin e [MeSH:C0042874] glutathione [MeSH:C0017817] level [MeSH:C0018759] alter mi rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] pretreatment [MeSH:C0376495] mangiferin [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] mg kg body weight [MeSH:C0005910] [MeSH:C0005910] suspend ml dimethyl sulphoxide [MeSH:C0012403] give intraperitoneally day [MeSH:C0011017] mi rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] protect above-mentioned parameter fall normal level [MeSH:C0018759] activity [MeSH:C0020115] heart tissue [MeSH:C0040300] [MeSH:C0040300] enzymic antioxidant [MeSH:C0003402] [MeSH:C0003402] serum non-enzymic antioxidant [MeSH:C0003402] [MeSH:C0003402] level [MeSH:C0018759] rise significantly mangiferin [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion compare isph-induced mi rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] present conclude mangiferin [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] [MeSH:C0065654] exert beneficial effect isph-induced mi antioxidant [MeSH:C0003402] [MeSH:C0003402] potential regulate [MeSH:C0851285] tissue defense system cardiac damage,cardiovascular
atrial fibrillation pattern alzheimer disease patient [MeSH:C0030705],hypothesis statin improve hypertension [MeSH:C0020538] outcome convulsion pathway method cross-sectional trial [MeSH:C0010362] cardiac patient measure hippocampal ataxia result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] optimization [MeSH:C0376695],neurological|cardiovascular
cancer pathway cardiomyopathy [MeSH:C0878544],cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve stem cell transplant steatosis method conduct cross-sectional evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine stomach cancer [MeSH:C0024623] parameter result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal|oncological
beta-blocker heart failure [MeSH:C0018801] brain [MeSH:C0006104] insight,design [MeSH:C0013171] prospective investigation metformin [MeSH:C0025598] hypertension [MeSH:C0020538] participant [MeSH:C1708335] elderly patient serotonin hippocampal [MeSH:C1504404] result positive response neurodegenerative correlation practice guideline,neurological
endoscopy [MeSH:C0014245] reveal myocardial infarction [MeSH:C0027051] secret,investigate [MeSH:C0035173] beta-blocker effect diabete brain abscess method cancer [MeSH:C0006105] patient [MeSH:C0030705] undergo randomized control [MeSH:C1096777] neurodegenerative astrocytoma assessment [MeSH:C0030198] result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],neurological|oncological
cerebral blood flow metabolism isoflurane-induced hypotension [MeSH:C0020650] patient subject [MeSH:C0080105] surgery cerebral aneurysm [MeSH:C0917996],cerebral blood flow [MeSH:C0428714] cerebral metabolic rate oxygen measure isoflurane [MeSH:C0022180] [MeSH:C0022180]-induced hypotension [MeSH:C0020649] [MeSH:C0020650] patient subject [MeSH:C0080105] craniotomy [MeSH:C0010280] clip cerebral aneurysm [MeSH:C0002940] flow metabolism measure day subarachnoid [MeSH:C0038527] haemorrhage [MeSH:C0019080] modification [MeSH:C0086153] classical kety-schmidt technique xenon- v anaesthesia maintain inspired isoflurane [MeSH:C0022180] [MeSH:C0022180] concentration plus nitrous oxide [MeSH:C0028215] oxygen cbf cmro2 ml g min- ml g min- paco2 kpa mean sem control hypotension [MeSH:C0020649] average map mm hg induce increase dose isoflurane [MeSH:C0022180] [MeSH:C0022180] maintain inspired concentration result decrease cmro2 ml g min- cbf unchanged clipping aneurysm [MeSH:C0002940] isoflurane [MeSH:C0022180] [MeSH:C0022180] concentration reduce increase cbf cmro2 unchanged compare pre-hypotensive value change offer protection [MeSH:C0524828] brain tissue [MeSH:C0040300] period [MeSH:C0080129] induce hypotension [MeSH:C0020649],neurological
arterial hypertension [MeSH:C0020538] complication [MeSH:C1171258] prolonged ketoconazole [MeSH:C0022625],patient cushing syndrome [MeSH:C0010481] treat long-term [MeSH:C0023977] basis [MeSH:C0023977] ketoconazole [MeSH:C0022625] develop sustained hypertension [MeSH:C0020538] [MeSH:C0020538] case normal plasma [MeSH:C0032105] [MeSH:C0032105] urinary free cortisol level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] achieve follow ketoconazole [MeSH:C0022625] therapy [MeSH:C0022625] continuous blood pressure [MeSH:C0005823] monitoring [MeSH:C0005517] demonstrate hypertension [MeSH:C0020538] [MeSH:C0020538] week plasma [MeSH:C0032105] [MeSH:C0032105] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] deoxycorticosterone [MeSH:C0011710] [MeSH:C0011710] -deoxycortisol elevated [MeSH:C0020443] addition increase deoxycorticosterone [MeSH:C0011710] [MeSH:C0011710] -deoxycortisol level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] plasma [MeSH:C0032105] [MeSH:C0032105] aldosterone value raise concomitant [MeSH:C0152203] suppression [MeSH:C1956351] renin [MeSH:C0035094] level [MeSH:C0018759] [MeSH:C0018759] [MeSH:C0018759] finding long-term [MeSH:C0023977] high dose ketoconazole [MeSH:C0022625] induce enzyme blockade lead mineralocorticoid-related hypertension [MeSH:C0020538] [MeSH:C0020538],cardiovascular
pe pattern coronary artery disease [MeSH:C1956346] patient [MeSH:C0030705],randomized control examine [MeSH:C1096777] ace inhibitor cancer [MeSH:C0003015] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include brain systolic dystonia method participant [MeSH:C1708335] include result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication therapeutic [MeSH:C0087111] innovation,neurological|cardiovascular
systolic hypertension [MeSH:C0221155] vascular [MeSH:C0221214] insight,assess efficacy [MeSH:C5690761] metformin [MeSH:C0025598] cancer focus septum atrial flutter method cancer patient [MeSH:C0030705] randomized receive metformin [MeSH:C0025598] placebo atherosclerosis [MeSH:C0004153] monitor result positive response need investigation [MeSH:C0035173],cardiovascular
autosomal recessive familial neurohypophyseal diabete insipidus [MeSH:C0687720] continue secretion mutant [MeSH:C0036536] weakly active vasopressin,familial neurohypophyseal [MeSH:C0032017] diabete insipidus [MeSH:C0011848] autosomal dominant disorder [MeSH:C0687720] characterize post-natal development arginine vasopressin avp [MeSH:C1098706] deficiency [MeSH:C1623416] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0687720] avp [MeSH:C1098706] gene publish mutation [MeSH:C0026882] [MeSH:C0026882] affect [MeSH:C0001721] signal peptide neurophysin-ii carrier protein presume interfere processing preprohormone [MeSH:C0765665] lead neuronal damage study unusual palestinian family consist asymptomatic [MeSH:C2936329] cousin parent [MeSH:C0030551] child [MeSH:C0008059] affect [MeSH:C0001721] neurohypophyseal [MeSH:C0032017] diabete insipidus [MeSH:C0011848] suggest autosomal recessive inheritance affect [MeSH:C0001721] child [MeSH:C0008059] homozygous [MeSH:C0019904] parent [MeSH:C0030551] heterozygous [MeSH:C0019425] single novel mutation [MeSH:C0026882] [MeSH:C0026882] c3- exon replace pro7 mature [MeSH:C0349590] avp [MeSH:C1098706] leu leu-avp [MeSH:C1098706] leu-avp [MeSH:C1098706] weak agonist [MeSH:C0162816] approximately -fold reduce binding human v2 receptor measure radioimmunoassay [MeSH:C0034580] synthetic leu-avp [MeSH:C1098706] standard serum leu-avp [MeSH:C1098706] level [MeSH:C0018759] elevated [MeSH:C0020443] child [MeSH:C0008059] increase water deprivation [MeSH:C0043048] high time normal young [MeSH:C0340037] child [MeSH:C0008059] year old mildly affect [MeSH:C0001721] leu-avp [MeSH:C1098706] level [MeSH:C0018759] similar severely affect [MeSH:C0001721] -year-old brother [MeSH:C0337527] suggest unknown mechanism [MeSH:C1524059] partially compensate deficiency [MeSH:C1623416] active avp [MeSH:C1098706] young [MeSH:C0340037] child [MeSH:C0008059],neurological
standard operating procedure [MeSH:C0543467] antibiotic therapy [MeSH:C0003232] occurrence acute kidney injury [MeSH:C2609414] prospective non-interventional observational,introduction [MeSH:C0033268] acute kidney injury [MeSH:C2609414] aki occur hospitalize intensive care unit [MeSH:C0021708] icu patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] increase mortality hospital length [MeSH:C0085556] stay cost [MeSH:C0010186] investigate [MeSH:C0035173] association [MeSH:C0004083] adherence [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] guideline standard [MeSH:C0282423] operating procedure [MeSH:C0543467] sop potentially nephrotoxic antibiotic occurrence [MeSH:C0243132] aki method carry prospective non-interventional observational collection perform total day icus charite universitaetsmedizin berlin total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] include therapy [MeSH:C0039798] vancomycin [MeSH:C0042313] gentamicin [MeSH:C3854019] tobramycin [MeSH:C0040341] year treat icu hour patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] adherence [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] sop classify high adherence [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] hag patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] adherence [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] low adherence [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] lag aki define accord rifle criteria [MeSH:C0243161] adherence [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] sop evaluate retrospective expert audit development aki compare group exact chi2-test multivariate [MeSH:C0026777] logistic regression two-sided p result lag consist patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] versus hag patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] aki occur significantly lag versus hag p basic characteristic comparable increase rate soft tissue infection [MeSH:C0149778] lag multivariate [MeSH:C0026777] reveal odds ratio [MeSH:C0028873] -fold lag develop aki compare hag confidence interval [MeSH:C0009667] p low adherence [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] [MeSH:C2364172] sop potentially nephrotoxic antibiotic associate high occurrence [MeSH:C0243132] aki trial registration [MeSH:C0034975] current control trial isrctn5 register august,hepatorenal
long term hormone therapy perimenopausal [MeSH:C0993589] postmenopausal [MeSH:C0206159] woman [MeSH:C0043210],hormone therapy [MeSH:C0039798] ht widely control [MeSH:C0243148] menopausal [MeSH:C0025320] [MeSH:C0025320] symptom [MeSH:C3839861] management [MeSH:C0085971] prevention cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] osteoporosis dementia [MeSH:C0497327] [MeSH:C0497327] [MeSH:C0497327] old [MeSH:C0001795] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] evidence support use indication largely observational [MeSH:C0302523] objective assess effect long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] ht mortality heart disease [MeSH:C0018799] venous thromboembolism [MeSH:C1861172] stroke [MeSH:C0038454] [MeSH:C1861172] transient ischaemic attack [MeSH:C0007787] breast cancer [MeSH:C0006142] [MeSH:C0006142] colorectal cancer [MeSH:C0009402] ovarian cancer [MeSH:C1140680] endometrial cancer [MeSH:C0476089] gallbladder disease [MeSH:C0016977] [MeSH:C0016977] [MeSH:C0016977] cognitive function [MeSH:C0009240] dementia [MeSH:C0497327] [MeSH:C0497327] [MeSH:C0497327] fracture quality life search strategy search follow database november cochrane menstrual disorder [MeSH:C0040188] subfertility [MeSH:C0729353] trial register cochrane central register control [MeSH:C0243148] trial central medline embase biological [MeSH:C4553887] abstract relevant non-indexed journal conference abstract search selection criterion randomised double-blind trial ht oestrogen progestogen versus placebo [MeSH:C0032041] [MeSH:C0032041] take perimenopausal [MeSH:C0025320] [MeSH:C0993589] [MeSH:C0025320] postmenopausal [MeSH:C0025320] [MeSH:C0206159] [MeSH:C0025320] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] collection rct include trial assess quality review [MeSH:C0282443] author extract independently calculate [MeSH:C0006736] risk [MeSH:C0035647] [MeSH:C0035647] ratio [MeSH:C0028873] dichotomous outcome [MeSH:C0206277] weight mean difference continuous [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] outcome [MeSH:C0206277] heterogeneity [MeSH:C0242960] preclude meta-analysis [MeSH:C0282458] outcome [MeSH:C0206277] main result statistically [MeSH:C0600673] result derive big trial relatively healthy [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] combined continuous [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] ht significantly increase risk [MeSH:C0035647] [MeSH:C0035647] venous thromboembolism [MeSH:C1861172] coronary event [MeSH:C1861172] use stroke [MeSH:C0038454] year breast cancer [MeSH:C0006142] [MeSH:C0006142] year gallbladder disease [MeSH:C0016977] [MeSH:C0016977] [MeSH:C0016977] long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] oestrogen-only ht significantly increase risk [MeSH:C0035647] [MeSH:C0035647] stroke [MeSH:C0038454] gallbladder disease [MeSH:C0016977] [MeSH:C0016977] [MeSH:C0016977] overall statistically [MeSH:C0600673] benefit ht decrease incidence [MeSH:C0021149] fracture colon cancer long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] use relatively healthy [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] year take continuous [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] combined ht statistically [MeSH:C0600673] increase incidence [MeSH:C0021149] dementia [MeSH:C0497327] [MeSH:C0497327] [MeSH:C0497327] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] use combined continuous [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] ht significantly increase risk [MeSH:C0035647] [MeSH:C0035647] venous thromboembolism [MeSH:C1861172] trial [MeSH:C1861172] focusse specifically young [MeSH:C0340037] [MeSH:C0340037] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] trial analyse subgroup [MeSH:C0018257] relatively healthy [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] year-old [MeSH:C0001795] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] take combined continuous [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] ht taking oestrogen-only ht versus similar-sized placebo [MeSH:C0032041] [MeSH:C0032041] group [MeSH:C0018257] significantly increase risk [MeSH:C0035647] [MeSH:C0035647] report venous thromboembolism [MeSH:C1861172] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] take combined continuous [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] ht absolute [MeSH:C4760601] risk [MeSH:C0035647] [MeSH:C0035647] remain low author conclusion ht indicate routine management [MeSH:C0085971] chronic disease [MeSH:C0008679] need evidence safety [MeSH:C0036043] ht menopausal [MeSH:C0025320] [MeSH:C0025320] symptom [MeSH:C3839861] short-term [MeSH:C0025265] use appear relatively safe healthy [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] young [MeSH:C0340037] [MeSH:C0340037] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210],neurological|cardiovascular|oncological
non-hodgkin lymphoma pattern [MeSH:C0024305] ventricular tachycardia [MeSH:C0042514] patient [MeSH:C0030705],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect diabete malignant method adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal delirium palsy assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],neurological|oncological
rtms supplementary motor area [MeSH:C0026607] modulate therapy-induced dyskinesia parkinson disease [MeSH:C0030567],neural [MeSH:C1522467] mechanism circuitry involve levodopa-induced dyskinesia unclear repetitive transcranial magnetic stimulation rtms supplementary motor area [MeSH:C0872259] sma patient advanced parkinson disease [MeSH:C0030567] author investigate [MeSH:C0035173] modulation [MeSH:C0085121] sma excitability [MeSH:C4277734] modification dyskinetic state induce continuous apomorphine infusion rtms hz observe markedly reduce drug-induced dyskinesia [MeSH:C0013386] -hz rtms induce slight increase,neurological
early [MeSH:C3177188] paracentral visual field loss [MeSH:C0042826] patient [MeSH:C0030705] take hydroxychloroquine [MeSH:C0020336],review [MeSH:C0282443] natural history [MeSH:C0175860] ocular [MeSH:C0042789] systemic [MeSH:C5544477] adverse effect [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] take hydroxychloroquine [MeSH:C0020336] [MeSH:C0020336] sulfate [MeSH:C0596007] attend ophthalmic screening program design retrospective [MeSH:C0035363] result record patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] take hydroxychloroquine [MeSH:C0020336] [MeSH:C0020336] screen [MeSH:C0020336] department ophthalmology review [MeSH:C0282443] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stop experience document [MeSH:C0009797] adverse effect [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] systemic [MeSH:C5544477] adverse effect [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ocular [MeSH:C0042789] adverse effect [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] [MeSH:C0001688] thirty-five patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] visual field [MeSH:C0042826] abnormality attribute hydroxychloroquine [MeSH:C0020336] [MeSH:C0020336] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] take mg kg patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] normal renal liver function test result conclusion current protocol visual acuity color [MeSH:C0042812] vision assessment [MeSH:C0030198] funduscopy humphrey visual field [MeSH:C0042826] testing show visual field [MeSH:C0042826] defect appear corresponding change test parameter defect reproducible test parameter reliable patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] take hydroxychloroquine [MeSH:C0020336] [MeSH:C0020336] demonstrate toxic [MeSH:C1256754] reaction retina despite absence [MeSH:C0270823] known risk factor screen [MeSH:C0035648] include humphrey visual field [MeSH:C0042826] assessment recommend year initial yearly,hepatorenal
thromboembolism epilepsy [MeSH:C0040038] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] statin [MeSH:C0360714] effect stroke [MeSH:C0038454] heart block method [MeSH:C0018794] cardiac patient undergo prospective bradycardia myeloproliferative neoplasm assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],cardiovascular|oncological
atrium angina pectoris vascular insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] heart attack [MeSH:C0027051] mechanism method retrospective [MeSH:C0035363] elderly patient assess blood pressure hypotension [MeSH:C0005823] result improve disease management [MeSH:C0039798] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
serotonin [MeSH:C0036751] meet angina pectoris [MeSH:C0002962] neurological perspective,investigate [MeSH:C0035173] statin effect heart disease [MeSH:C0018799] glutamate method elderly patient undergo randomized control meningitis pituitary adenoma [MeSH:C0032000] assessment [MeSH:C0030198] result improve outcome practice guideline [MeSH:C0936005],neurological
hypertension [MeSH:C0020538] paralysis [MeSH:C0522224] exploring neural pathway [MeSH:C0027792],investigate [MeSH:C0035173] beta-blocker effect heart disease synapse method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo prospective paralysis myasthenia gravis [MeSH:C0026896] assessment [MeSH:C0030198] result positive response potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
diastolic [MeSH:C0012000] prostate cancer [MeSH:C0376358] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation [MeSH:C0035173] aspirin hypertension [MeSH:C0020538] participant [MeSH:C1708335] elderly patient regurgitation myocardial infarction [MeSH:C0027051] result superior efficacy [MeSH:C5690761] aortic valve correlation safety consideration,cardiovascular
brain map [MeSH:C0006104] colorectal cancer [MeSH:C0009402] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome [MeSH:C0206277] tia pathway method cross-sectional trial [MeSH:C0010362] adult population measure convulsion dysarthria result superior efficacy cost-effectiveness [MeSH:C1511536] implication,neurological
metallothionein induction [MeSH:C0025545] reduce caspase- activity [MeSH:C0020115] tnfalpha [MeSH:C1456820] level preservation [MeSH:C0242500] cognitive function [MeSH:C0009240] intact hippocampal neuron [MeSH:C0228249] carmustine-treated rat,hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] integrity [MeSH:C0021701] essential [MeSH:C0600449] cognitive function [MeSH:C0009240] hand induction metallothionein mt znso role neuroprotection [MeSH:C0598958] document [MeSH:C0009797] present aim explore effect [MeSH:C4277511] mt induction carmustine [MeSH:C0007257] bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] -induced hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] cognitive dysfunction [MeSH:C0338656] rat [MeSH:C0034721] [MeSH:C0034721] total male [MeSH:C0086582] wistar albino rat [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] randomly divide group inject single dose normal saline c v follow h later bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] solvent [MeSH:C0037638] [MeSH:C0037638] v second administer znso micromol microl normal saline c v bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] solvent [MeSH:C0037638] [MeSH:C0037638] v h receive bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] mg kg v h injection [MeSH:C1828121] normal saline c v fourth receive single dose znso micromol microl normal saline c v bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] mg kg v h obtain reveal bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] administrat [MeSH:C0034721] [MeSH:C0034721]ion result deteriorat [MeSH:C0034721] [MeSH:C0034721]ion learning short-term [MeSH:C0025265] memory stm measure radial arm water maze accompany decrease hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] glutathione reductase [MeSH:C0017824] gr activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C0020115] reduce glutathione gsh [MeSH:C0017817] content [MeSH:C0017177] [MeSH:C0017177] bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] administrat [MeSH:C0034721] [MeSH:C0034721]ion increase serum tumor necrosis factor-alpha tnfalpha hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] mt malondialdehyde mda [MeSH:C0024643] content [MeSH:C0017177] [MeSH:C0017177] caspase- activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C0020115] addition histological [MeSH:C0019637] alterat [MeSH:C0034721] [MeSH:C0034721]ion znso pretreatment [MeSH:C0376495] counteract bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257]-induced inhibition [MeSH:C0027790] gr depletion [MeSH:C3494379] gsh result reduction [MeSH:C1827449] level [MeSH:C0018759] mda tnfalpha [MeSH:C1456820] activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C0020115] caspase- histological [MeSH:C0019637] feature improve hippocampus [MeSH:C3887642] rat [MeSH:C0034721] [MeSH:C0034721] treat znso bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] compare bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257]-treated animal mt induction halt bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257]-induced hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] toxicity [MeSH:C0040539] prevent [MeSH:C0000918] gr inhibition [MeSH:C0027790] gsh depletion [MeSH:C3494379] counteract increase level [MeSH:C0018759] tnfalpha mda [MeSH:C1456820] caspase- activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C0020115] subsequent preservation [MeSH:C0242500] cognition [MeSH:C0009240],neurological|oncological
rcc hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] stroke [MeSH:C0038454] [MeSH:C0038454] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] myocardium [MeSH:C0027061] stroke [MeSH:C0038454] [MeSH:C0038454] result well quality life measure sinoatrial node correlation [MeSH:C0037189] therapeutic innovation [MeSH:C0087111],cardiovascular|hepatorenal
hypertension [MeSH:C0020538] heart [MeSH:C0018787] cardiac connection,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome hypertrophic cardiomyopathy pathway method [MeSH:C0007194] prospective trial elderly patient measure tachycardia smooth muscle [MeSH:C1267092] result favorable safety [MeSH:C0036043] profile healthcare advancement,cardiovascular
kidney transplant [MeSH:C0022671] diabetes mellitus [MeSH:C0011849] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome [MeSH:C0206277] alkaline phosphatase pathway method [MeSH:C0002059] longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient measure hypertension [MeSH:C0020538] chronic kidney disease [MeSH:C1561643] result improvement [MeSH:C2936612] primary endpoint therapeutic innovation [MeSH:C0087111],cardiovascular|hepatorenal
localisation myotonic dystrophy locus 9q1,-9q1 relationship [MeSH:C0021797] polymorphic [MeSH:C1720758] locus 9q order fourteen polymorphic [MeSH:C1720758] marker [MeSH:C0017393] localised long arm human chromosome [MeSH:C0265404] establish multipoint mapping set ceph centre detude de polymorphisme humain paris reference family report linkage relationship [MeSH:C0021797] myotonic dystrophy dm locus marker [MeSH:C0017393] study family dm result genetic map support localisation dna marker [MeSH:C0017393] panel somatic cell hybrid marker [MeSH:C0017393] show proximal dm gene prkcg d19s2 distal distance [MeSH:C1136180] approximately cm cm respectively close proximal marker [MeSH:C0017393] apoc2 apolipoprotein c-ii ckm creatine kinase muscle approximately cm cm dm gene respectively order apoc2-ckm-dm distance [MeSH:C1136180] apoc2 ckm dm order million base pair [MeSH:C0600436] known orientation [MeSH:C0029266] permit directional chromosome walk jump present enable determine new marker [MeSH:C0017393] distal apoc2 ckm potentially flank dm gene,neurological
long term hormone therapy perimenopausal [MeSH:C0993589] postmenopausal [MeSH:C0206159] woman [MeSH:C0043210],hormone therapy [MeSH:C0039798] ht widely control [MeSH:C0243148] menopausal [MeSH:C0025320] [MeSH:C0025320] symptom [MeSH:C3839861] manage [MeSH:C0024842]ment prevention cardiovascular disease [MeSH:C0007222] [MeSH:C0012634] [MeSH:C0007222] osteoporosis dementia [MeSH:C0497327] [MeSH:C0497327] old woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] updated version original cochrane review [MeSH:C0282443] publish objective assess effect long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] ht mortality [MeSH:C0026565] cardiovascular outcome cancer gallbladder disease [MeSH:C0012634] [MeSH:C0016977] [MeSH:C0016977] cognition fracture [MeSH:C0009240] quality life search strategy search follow database november trial register cochrane menstrual disorder [MeSH:C0040188] subfertility [MeSH:C0729353] cochrane central register control [MeSH:C0243148] trial medline [MeSH:C0025141] embase biological [MeSH:C4553887] abstract relevant non-indexed journal conference abstract selection criterion randomised double-blind trial ht versus placebo [MeSH:C0032041] [MeSH:C0032041] take perimenopausal [MeSH:C0025320] [MeSH:C0993589] [MeSH:C0025320] postmenopausal [MeSH:C0025320] [MeSH:C0206159] [MeSH:C0025320] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] ht [MeSH:C0043210] include oestrogen progestogen oral transdermal [MeSH:C0991556] subcutaneous transnasal route collection author independently assess trial quality extract main result nineteen trial involve woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] include relatively healthy [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] combined continuous [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] ht significantly increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] venous thrombo-embolism [MeSH:C1861172] [MeSH:C1861172] coronary event use stroke [MeSH:C0038454] year breast cancer [MeSH:C0006142] [MeSH:C0006142] gallbladder disease [MeSH:C0012634] [MeSH:C0016977] [MeSH:C0016977] long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] oestrogen-only ht significantly increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] venous thrombo-embolism [MeSH:C1861172] [MeSH:C1861172] stroke [MeSH:C0038454] gallbladder disease [MeSH:C0012634] [MeSH:C0016977] [MeSH:C0016977] year year seven year use respectively significantly increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] breast cancer [MeSH:C0006142] [MeSH:C0006142] statistically [MeSH:C0600673] benefit ht decrease incidence [MeSH:C0021149] fracture combine ht colon cancer long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] use woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] age [MeSH:C0024842] relatively healthy [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] e generally fit overt disease [MeSH:C0012634] take continuous [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] combined ht statistically [MeSH:C0600673] increase incidence [MeSH:C0021149] dementia [MeSH:C0497327] [MeSH:C0497327] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] cardiovascular disease [MeSH:C0007222] [MeSH:C0012634] [MeSH:C0007222] long-term [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] [MeSH:C0023977] use combined continuous [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] ht significantly increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] venous thrombo-embolism [MeSH:C1861172] [MeSH:C1861172] trial analyse subgroup [MeSH:C0018257] [MeSH:C0018257] relatively healthy [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] old woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] take combined continuous [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] ht taking oestrogen-only ht versus similar-sized placebo [MeSH:C0032041] [MeSH:C0032041] group [MeSH:C0018257] [MeSH:C0018257] significantly increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] report venous thrombo-embolism [MeSH:C1861172] [MeSH:C1861172] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] take combined continuous [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] [MeSH:C3649547] ht absolute [MeSH:C4760601] risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] remain low power detect difference group [MeSH:C0018257] [MeSH:C0018257] young [MeSH:C0340037] [MeSH:C0340037] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] author conclusion ht indicate routine manage [MeSH:C0024842]ment chronic disease [MeSH:C0008679] [MeSH:C0012634] need evidence safety [MeSH:C0036043] ht menopausal [MeSH:C0025320] [MeSH:C0025320] symptom [MeSH:C3839861] short-term [MeSH:C0025265] use appear relatively safe healthy [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] [MeSH:C0452415] young [MeSH:C0340037] [MeSH:C0340037] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210],neurological|cardiovascular|oncological
neuropsychiatric effect [MeSH:C0870956] use mefloquine [MeSH:C0025153],describe neuropsychiatric effect [MeSH:C0870956] patient [MeSH:C0030705] mefloquine [MeSH:C0025153] [MeSH:C0025153] [MeSH:C0025153] reaction [MeSH:C0031067] consist mainly seizure [MeSH:C0036572] acute [MeSH:C0184567] psychosis anxiety [MeSH:C0003467] neurosis major disturbance sleep-wake [MeSH:C0877792] rhythm effect occur therapeutic [MeSH:C0087111] [MeSH:C0087111] prophylactic intake grade moderate severe [MeSH:C1719672] risk [MeSH:C0035647] [MeSH:C0035647] neuropsychiatric effect [MeSH:C0870956] germany estimate mefloquine [MeSH:C0025153] [MeSH:C0025153] [MeSH:C0025153] user suffer reaction [MeSH:C0031067] incidence [MeSH:C0021149] calculation reveal therapeutic [MeSH:C0087111] [MeSH:C0087111] user reaction [MeSH:C0031067] compare prophylaxis [MeSH:C0033107] [MeSH:C0033107] [MeSH:C0033107] make risk [MeSH:C0035647] [MeSH:C0035647] neuropsychiatric reaction [MeSH:C0870956] [MeSH:C0031067] mefloquine [MeSH:C0025153] [MeSH:C0025153] [MeSH:C0025153] time high prophylaxis [MeSH:C0033107] [MeSH:C0033107] [MeSH:C0033107] certain limitation malaria [MeSH:C0024530] prophylaxis [MeSH:C0033107] [MeSH:C0033107] [MeSH:C0033107] mefloquine [MeSH:C0025153] [MeSH:C0025153] [MeSH:C0025153] recommend,neurological
surgical intervention heart failure [MeSH:C0018801] brain [MeSH:C0006104] insight,observational [MeSH:C0302523] examine metformin [MeSH:C0025598] stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include cortical autonomic neuropathy [MeSH:C0271686] brain method [MeSH:C0025663] participant [MeSH:C1708335] include result favorable safety [MeSH:C0036043] profile implication safety [MeSH:C0036043] consideration,neurological
echocardiography [MeSH:C0013516] reveal heart failure [MeSH:C0018801] secret,design [MeSH:C0013171] prospective investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] elderly patient neurotransmitter myasthenia gravis [MeSH:C0026896] result well quality life measure trigeminal neuralgia [MeSH:C0040997] correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],neurological
leukemia [MeSH:C0023418] wilms tumor organ [MeSH:C0027708] interplay,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer oliguria mechanism method observational [MeSH:C0302523] adult population [MeSH:C0032659] assess hydronephrosis cholangiocarcinoma [MeSH:C0206698] result decrease mortality rate [MeSH:C0205848] implication relevance,hepatorenal
epilepsy [MeSH:C0014544] neurodegenerative [MeSH:C0524851] exploring neural pathway [MeSH:C0027792],design [MeSH:C0013171] prospective investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] elderly patient multiple sclerosis [MeSH:C0026769] memory loss result improvement primary endpoint neurodegenerative [MeSH:C0524851] correlation relevance [MeSH:C2826293],neurological|cardiovascular
bone marrow transplant pathway leukemia,diabete affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve tubule hepatocellular carcinoma [MeSH:C2239176] method conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine chronic lymphocytic leukemia [MeSH:C0023434] parameter result favorable safety profile [MeSH:C0036043] need investigation [MeSH:C0035173],hepatorenal|oncological
ecg reveal cancer secret,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve hypertension [MeSH:C0020538] outcome myasthenia gravis pathway method observational trial [MeSH:C0302523] adult population measure heart rate [MeSH:C0018810] stroke [MeSH:C0038454] result decrease mortality rate [MeSH:C0205848] practice guideline,neurological|cardiovascular
white matter pathway [MeSH:C0682708] colorectal cancer [MeSH:C0009402],hypothesis statin improve cancer outcome myelopathy pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure gaba peripheral neuropathy [MeSH:C4721453] result enhance therapeutic response [MeSH:C0087111] cost-effectiveness [MeSH:C1511536] implication,neurological
leukemia ataxia [MeSH:C0023418] explore neural pathway [MeSH:C0027792],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect heart disease [MeSH:C0018799] adrenal cancer [MeSH:C0750887] mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess epinephrine [MeSH:C0014563] neural [MeSH:C1522467] result well quality life measure implication relevance [MeSH:C2826293],neurological|oncological
novel insight alzheimer disease heart valve,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect hypertension [MeSH:C0020538] bundle branch block mechanism method [MeSH:C0006384] retrospective diabetic patient [MeSH:C0030705] assessing tia heart block [MeSH:C0018794] result superior efficacy [MeSH:C5690761] implication need investigation [MeSH:C0035173],cardiovascular
illegitimate transcription phenylalanine hydroxylase gene lymphocyte [MeSH:C0024264] identification mutation phenylketonuria [MeSH:C0031485],take advantage illegitimate transcription phenylalanine hydroxylase pah gene able analyse pah cdna sequence [MeSH:C0162326] hyperphenylalaninemic [MeSH:C0751435] child circulate [MeSH:C3641730] [MeSH:C3641730] lymphocyte [MeSH:C0024264] approach [MeSH:C0024264] identify novel mutation [MeSH:C0026882] cdna liver lymphocyte [MeSH:C0024264] patient mutation [MeSH:C0026882] [MeSH:C0026882] detect abnormal [MeSH:C0853087] pattern migration amplify fragment c transition splice acceptor site intron result skipping exon premature termination rna translation downstream exon ivs1 mutation [MeSH:C0026882] missense mutation [MeSH:C0026882] exon respectively l33f e30 g present support view circulate [MeSH:C3641730] [MeSH:C3641730] lymphocyte [MeSH:C0024264] easy access pah gene transcript nucleotide sequence [MeSH:C0004793] identical report [MeSH:C0684224] liver represent useful tool molecular genetic study [MeSH:C0086345] phenylketonuria [MeSH:C0031485],hepatorenal
cardiac marker multiple sclerosis [MeSH:C0026769],investigation [MeSH:C0035173] examine effect statin heart disease [MeSH:C0018799] elderly [MeSH:C0001792] patient focus stenosis aortic valve aspect disease [MeSH:C1260873] total participant [MeSH:C1708335] enrol observational result [MeSH:C0302523] demonstrate favorable safety profile [MeSH:C0036043] particular attention [MeSH:C0004268] atrial flutter [MeSH:C0004239] finding suggest relevance,cardiovascular
hydronephrosis [MeSH:C0020295] meet liver cirrhosis [MeSH:C0023890] neurological perspective,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] participant [MeSH:C1708335] elderly patient end stage renal disease [MeSH:C0022661] acetylcholine result [MeSH:C0001041] positive response alzheimer disease correlation practice guideline,neurological|hepatorenal
selective [MeSH:C0206189] -ht6 receptor antagonist [MeSH:C2936804] ro4 restore memory [MeSH:C0025260] performance cholinergic [MeSH:C0242893] serotonergic model memory [MeSH:C0025260] deficiency rat [MeSH:C0034721],antagonist [MeSH:C0033607] [MeSH:C0033607] serotonin type [MeSH:C0036751] -ht receptor activity model learning memory [MeSH:C4505057] underlie mechanism [MeSH:C1524059] [MeSH:C1524059] understand effect [MeSH:C4277511] involve increase acetylcholine ach [MeSH:C0001041] level [MeSH:C0018759] present seek characterize cognitive-enhancing effect [MeSH:C4277511] -ht antagonist [MeSH:C0033607] [MeSH:C0033607] ro4 -benzenesulfonyl-- -methyl-piperazin yl 1h-indole rat object [MeSH:C2350447] recognition task [MeSH:C0162458] employ cholinergic [MeSH:C0242893] scopolamine [MeSH:C0036442] pretreatment [MeSH:C0376495] serotonergic- tryptophan trp [MeSH:C0041249] depletion [MeSH:C3494379] deficient model compare pattern action acetylcholinesterase inhibitor [MeSH:C0001046] metrifonate [MeSH:C0040898] [MeSH:C0040898] [MeSH:C0040898] initial testing [MeSH:C1321876] time-dependent forget task [MeSH:C0162458] employ -h delay [MeSH:C5544400] training testing [MeSH:C1321876] show metrifonate [MeSH:C0040898] [MeSH:C0040898] [MeSH:C0040898] improve object [MeSH:C2350447] recognition mg kg p ro4 inactive ro4 mg kg intraperitoneally p metrifonate [MeSH:C0040898] [MeSH:C0040898] [MeSH:C0040898] mg kg p respectively reverse memory deficit [MeSH:C0233794] [MeSH:C0233794] induce scopolamine [MeSH:C0036442] trp depletion [MeSH:C3494379] mg kg p mg kg p respectively ro4 improve time-related retention deficit [MeSH:C0233794] reverse cholinergic [MeSH:C0242893] serotonergic memory deficit [MeSH:C0233794] suggest mechanism [MeSH:C1524059] [MeSH:C1524059] involve facilitation [MeSH:C0037415] object [MeSH:C2350447] memory ro4 possibly -ht receptor antagonist [MeSH:C2936804] [MeSH:C0033607] [MeSH:C0033607],neurological
localisation becker muscular dystrophy gene [MeSH:C0026850] short arm x chromosome linkage clone dna sequence [MeSH:C0162326],linkage [MeSH:C0242239] [MeSH:C0242239] becker muscular dystrophy [MeSH:C0026850] bmd kindred clone [MeSH:C0009013] dna sequence x chromosome [MeSH:C0162326] demonstrate restriction fragment length [MeSH:C0035268] polymorphism rflp suggest bmd gene located short arm x chromosome p2 region gene becker duchenne dystrophy closely link allelic [MeSH:C0524869] future dna probe [MeSH:C0012893] find practical use disorder equally applicable linkage [MeSH:C0242239] [MeSH:C0242239] provide frequency [MeSH:C0376249] recombination short arm x chromosome centromeric region,neurological
disulfiram-induced transient optic peripheral neuropathy case report [MeSH:C0684224],report case optic peripheral neuropathy chronic [MeSH:C0150055] use disulfiram [MeSH:C0012772] [MeSH:C0012772] alcohol dependence management material method case report [MeSH:C0684224] result -year-old male [MeSH:C0086582] present gradual loss vision eye intermittent headache month complain paraesthesia numbness foot vision right leave eye respectively fundoscopy [MeSH:C0014245] reveal bilaterally swell optic nerve head visual field testing [MeSH:C0042825] confirm bilateral central-caecal scotoma [MeSH:C0036454] take disulfiram [MeSH:C0012772] [MeSH:C0012772] alcohol dependence precede year disulfiram [MeSH:C0012772] [MeSH:C0012772] discontinuation lead immediate symptomatic [MeSH:C3839861] improvement physician initiate long-term [MeSH:C0023977] disulfiram [MeSH:C0012772] [MeSH:C0012772] therapy aware adverse effect [MeSH:C0001688] [MeSH:C0001688] recommend annual [MeSH:C0936091] ophthalmic review visual field testing [MeSH:C0042825] patient [MeSH:C0030705] reassure respect reversibility adverse effect [MeSH:C0001688] [MeSH:C0001688],neurological
neutrophil [MeSH:C0027950] superoxide hydrogen peroxide [MeSH:C0020281] production [MeSH:C0033268] patient [MeSH:C0030705] acute liver failure [MeSH:C0162557],defect [MeSH:C0155017] [MeSH:C0155017] superoxide hydrogen peroxide [MeSH:C0020281] [MeSH:C0020281] [MeSH:C0020281] production [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] implicate high incidence [MeSH:C0021149] bacterial infection [MeSH:C0004623] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute liver failure [MeSH:C0162557] alf present oxygen radical production [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0162772] [MeSH:C0033268] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] alf paracetamol [MeSH:C0000970] [MeSH:C0000970] overdose compare healthy [MeSH:C0452415] volunteer neutrophil [MeSH:C0027950] [MeSH:C0027950] [MeSH:C0027950] alf patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stimulate complement receptor [MeSH:C0034793] [MeSH:C0034793] zymosan [MeSH:C0043552] opsonize alf serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] superoxide hydrogen peroxide [MeSH:C0020281] [MeSH:C0020281] [MeSH:C0020281] production [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] alf neutrophil [MeSH:C0027950] [MeSH:C0027950] [MeSH:C0027950] stimulate zymosan [MeSH:C0043552] opsonize alf serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] significantly reduce compare subject p defect [MeSH:C0155017] [MeSH:C0155017] persist zymosan [MeSH:C0043552] opsonize serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] p superoxide hydrogen peroxide [MeSH:C0020281] [MeSH:C0020281] [MeSH:C0020281] production [MeSH:C0033268] [MeSH:C0033268] [MeSH:C0033268] neutrophil [MeSH:C0027950] [MeSH:C0027950] [MeSH:C0027950] stimulate formyl-methionyl-leucyl-phenylalanine fmlp alf [MeSH:C0027229] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unaffected compare neutrophil [MeSH:C0027950] [MeSH:C0027950] [MeSH:C0027950] serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] c3 complement level significantly reduce alf patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] compare subject p result demonstrate neutrophil [MeSH:C0027950] [MeSH:C0027950] [MeSH:C0027950] defect [MeSH:C0155017] [MeSH:C0155017] alf paracetamol [MeSH:C0000970] [MeSH:C0000970] overdose complement dependent independent serum [MeSH:C0229671] [MeSH:C0229671] [MeSH:C0229671] complement possibly connect complement receptor [MeSH:C0034793] [MeSH:C0034793],hepatorenal
cardiomyopathy palsy [MeSH:C0878544] exploring neural pathway [MeSH:C0027792],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] norepinephrine method [MeSH:C0028351] elderly patient undergo retrospective aphasia radiculopathy [MeSH:C0700594] assessment [MeSH:C0030198] result enhance therapeutic response practice guideline,neurological
induction [MeSH:C0042767] paracetamol bladder [MeSH:C0005682] liver tumour rat [MeSH:C0034721] effect [MeSH:C4277511] hepatocyte [MeSH:C0227525] fine structure,group [MeSH:C0018257] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] inbred leed strain rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] feed diet contain paracetamol weight month dosage [MeSH:C0178655] [MeSH:C0178655] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] sex [MeSH:C1522384] develop neoplastic nodule liver [MeSH:C0023884] statistically [MeSH:C0600673] incidence [MeSH:C0021149] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] show gross enlargement liver [MeSH:C0023884] increase focus cellular alterat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion observe low dosage [MeSH:C0178655] [MeSH:C0178655] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] papilloma transitional [MeSH:C0030354] epithelium [MeSH:C0014609] bladder [MeSH:C0005682] develop paracetamol-treated group [MeSH:C0018257] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] bore bladder [MeSH:C0005682] carcinoma yield bladder [MeSH:C0005682] tumour [MeSH:C0005695] obtain low dosage [MeSH:C0178655] [MeSH:C0178655] female [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] high dosage [MeSH:C0178655] [MeSH:C0178655] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] additionally paracetamol-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] develop hyperplasia [MeSH:C0020507] bladder [MeSH:C0005682] epithelium [MeSH:C0014609] coincident presence bladder [MeSH:C0005682] calculus low yield tumour site arise follow paracetamol feed electron microscope liver [MeSH:C0023884] paracetamol-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] reveal ultrastructural [MeSH:C0041623] change hepatocyte [MeSH:C0227525] resemble exposure [MeSH:C1390376] variety known hepatocarcinogen [MeSH:C0007090],hepatorenal|oncological
cardiomyopathy insufficiency cardiac connection,investigate [MeSH:C0035173] statin effect diabete insufficiency method cancer [MeSH:C1565489] patient [MeSH:C0030705] undergo retrospective [MeSH:C0035363] cholestasis stenosis assessment [MeSH:C0030198] result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,cardiovascular|hepatorenal
atrial fibrillation [MeSH:C0004238] cardiovascular lens [MeSH:C0007220],stroke [MeSH:C0038454] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve defibrillator embolism method conduct prospective evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine ectopic beat [MeSH:C0033036] parameter result superior efficacy [MeSH:C5690761] optimization [MeSH:C0376695],cardiovascular
expression murine [MeSH:C0017262] duchenne muscular dystrophy gene muscle [MeSH:C0013264] brain [MeSH:C0006104],complementary dna clone [MeSH:C0006556] isolate represent terminal kilobase murine duchenne muscular dystrophy [MeSH:C0026850] [MeSH:C0026850] dmd [MeSH:C1437024] [MeSH:C1437024] messenger rna mrna [MeSH:C0035696] [MeSH:C0035696] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] dmd [MeSH:C1437024] [MeSH:C1437024] mrna [MeSH:C0035696] detectable skeletal [MeSH:C0011696] cardiac muscle [MeSH:C0027061] approximately percent low brain [MeSH:C0006104] dmd [MeSH:C1437024] [MeSH:C1437024] mrna [MeSH:C0035696] present low normal level muscle brain [MeSH:C0006104] different strain [MeSH:C0080194] dystrophic [MeSH:C0079259] mdx [MeSH:C0206535] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] identification [MeSH:C1707660] dmd [MeSH:C1437024] [MeSH:C1437024] mrna [MeSH:C0035696] brain [MeSH:C0006104] raise possibility relation human [MeSH:C0086418] duchenne muscular dystrophy [MeSH:C0026850] [MeSH:C0026850] dmd [MeSH:C1437024] [MeSH:C1437024] gene expression [MeSH:C0017262] mental retardation [MeSH:C3714756] find dmd [MeSH:C1437024] [MeSH:C1437024] male [MeSH:C0086582] result provide evidence mdx [MeSH:C0206535] mutation [MeSH:C0026882] allelic variant mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] dmd [MeSH:C1437024] [MeSH:C1437024] gene mutation [MeSH:C0026882],neurological
development [MeSH:C0243107] isoproterenol-induced cardiac hypertrophy [MeSH:C1383860],development [MeSH:C0243107] cardiac hypertrophy [MeSH:C0020564] [MeSH:C1383860] study [MeSH:C0085973] adult [MeSH:C0001675] female [MeSH:C0086287] wistar rat follow daily subcutaneous injection [MeSH:C1828121] [MeSH:C0021499] isoproterenol iso mg kg body weight course establish tissue mass rna [MeSH:C0035668] dna content hydroxyproline [MeSH:C0020388] [MeSH:C0020388] content heart weight [MeSH:C1821269] increase day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] half day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] ventricular rna [MeSH:C0035668] content elevated [MeSH:C0020443] [MeSH:C0020443] h single injection [MeSH:C1828121] reach maximal follow day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] therapy half rna [MeSH:C0035668] accumulation [MeSH:C0311432] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] total content hydroxyproline [MeSH:C0020388] [MeSH:C0020388] remain stable day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] increase day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] therapy ventricular dna content unchanged early stage day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] hypertrophic [MeSH:C0162810] [MeSH:C0162810] growth [MeSH:C0018270] increase new steady-state control day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] intraventricular pressure coronary flow [MeSH:C0206177] measure [MeSH:C0079809] similar experimental [MeSH:C0016998] animal [MeSH:C0003062] follow day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] develop hypertrophy [MeSH:C0020564] dp dt iso-treated heart slightly significantly p elevated [MeSH:C0020443] [MeSH:C0020443] indicate adaptive response [MeSH:C1749719] iso show early hypertrophic [MeSH:C0162810] [MeSH:C0162810] phase day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] characterize substantial increase rna [MeSH:C0035668] content cardiac mass [MeSH:C0018807] absence change dna prolonged stimulation [MeSH:C0031734] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] appear represent complex [MeSH:C3888046] integration [MeSH:C0085224] cellular hypertrophy [MeSH:C0020564] hyperplasia heart,cardiovascular
myocardial infarction pattern diabetes mellitus patient [MeSH:C0030705],investigate [MeSH:C0035173] statin [MeSH:C0360714] effect stroke craniopharyngioma [MeSH:C0010276] method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] coronary endothelial assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],neurological|cardiovascular
drug-associated acute-onset vanish bile duct stevens-johnson syndrome child [MeSH:C0008059],acute [MeSH:C0184567] [MeSH:C0184567] vanish bile duct syndrome [MeSH:C0005400] [MeSH:C0005400] [MeSH:C0005400] rare established cause progressive [MeSH:C1449744] [MeSH:C1449744] cholestasis [MeSH:C0008370] adult [MeSH:C0001675] drug toxin [MeSH:C0013227] related unknown pathogenesis [MeSH:C0699748] [MeSH:C0699748] report previously child [MeSH:C0008059] stevens-johnson syndrome [MeSH:C0038325] [MeSH:C0038325] [MeSH:C0038325] well-recognized immune [MeSH:C0020960] complex-mediated hypersensitivity reaction affect age [MeSH:C0024842] group [MeSH:C0027362] drug infection [MeSH:C3714514] induce classic systemic mucosal dermatologic manifestation [MeSH:C0029166] previously healthy child [MeSH:C0008078] [MeSH:C0008059] develop acute [MeSH:C0184567] [MeSH:C0184567] severe rapidly progressive [MeSH:C1449744] [MeSH:C1449744] vanish bile duct syndrome [MeSH:C0005400] [MeSH:C0005400] [MeSH:C0005400] shortly stevens-johnson syndrome [MeSH:C0038325] [MeSH:C0038325] [MeSH:C0038325] describe temporally associate ibuprofen [MeSH:C0020740] use despite therapy [MeSH:C0039798] ursodeoxycholic acid [MeSH:C0042105] prednisone [MeSH:C0032952] tacrolimus cholestatic disease unrelente cirrhosis [MeSH:C1623038] show biopsy month [MeSH:C0005558] presentation [MeSH:C0022869] case document [MeSH:C0009797] acute [MeSH:C0184567] [MeSH:C0184567] drug-related vanish bile duct syndrome [MeSH:C0005400] [MeSH:C0005400] [MeSH:C0005400] pediatric [MeSH:C0237433] age [MeSH:C0024842] suggest share immune [MeSH:C0020960] mechanism pathogenesis [MeSH:C0699748] [MeSH:C0699748] stevens-johnson syndrome [MeSH:C0038325] [MeSH:C0038325] [MeSH:C0038325] vanish bile duct syndrome [MeSH:C0005400] [MeSH:C0005400] [MeSH:C0005400],neurological|hepatorenal
erythropoietin [MeSH:C0014822] restore anemia-induced reduction cyclophosphamide [MeSH:C0010583] cytotoxicity [MeSH:C0235280] rat [MeSH:C0034721] tumor [MeSH:C0027651],examine impact [MeSH:C5544368] anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] prevent [MeSH:C0000918] [MeSH:C0000918]ion [MeSH:C2700409] recombinant human erythropoietin [MeSH:C2976467] rhuepo cytotoxicity [MeSH:C0235280] cyclophosphamide solid experimental tumor [MeSH:C0027651] [MeSH:C0027651] anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] induce single dose carboplatin [MeSH:C0079083] [MeSH:C0079083] mg kg v result long-lasting reduction hemoglobin concentrat [MeSH:C0034721]ion [MeSH:C0474535] second development anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] prevent [MeSH:C0000918] [MeSH:C0000918] rhuepo iu kg administer c time week start day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] carboplatin [MeSH:C0079083] [MeSH:C0079083] application day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] carboplatin [MeSH:C0079083] [MeSH:C0079083] tumor [MeSH:C0027651] [MeSH:C0027651] ds-sarcoma rat [MeSH:C0034721] implant c hind food dorsum carboplatin [MeSH:C0079083] [MeSH:C0079083] rhuepo influence tumor [MeSH:C0027651] [MeSH:C0027651] growth rat [MeSH:C0034721]e se tumor [MeSH:C0027651] [MeSH:C0027651] treat single dose cyclophosphamide [MeSH:C0010583] mg kg p day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] implantation [MeSH:C0011370] growth delay [MeSH:C0018270] subsequent regrowth tumor [MeSH:C0027651] [MeSH:C0027651] observe anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] growth delay [MeSH:C0018270] significantly short compare nonanemic control day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] versus day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] prevent [MeSH:C0000918] [MeSH:C0000918] rhuepo growth delay [MeSH:C0018270] comparable nonanemic control day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] result suggest chemotherapy-induced anemia [MeSH:C0549410] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] reduce cytotoxicity [MeSH:C0235280] cyclophosphamide tumor [MeSH:C0010583] [MeSH:C0027651] [MeSH:C0027651] correction anemia [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] [MeSH:C0002871] rhuepo epoetin alpha [MeSH:C0357131] increase sensitivity [MeSH:C0036667] probably improve oxygen supply tumor [MeSH:C0027651] [MeSH:C0027651] tissue,oncological
tonic dopaminergic stimulation impair associative learning healthy [MeSH:C0004084] subject,endogenous [MeSH:C0205752] dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] play central role salience code associative [MeSH:C0234471] learning administration dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] precursor levodopa [MeSH:C0023570] [MeSH:C0023570] enhance [MeSH:C0014290] learning healthy subject [MeSH:C1708335] stroke [MeSH:C0038454] [MeSH:C0038454] patient [MeSH:C0030705] [MeSH:C0030705] levodopa [MeSH:C0023570] [MeSH:C0023570] increase phasic tonic dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030]rgic neurotransmission critical mechanism mediate enhance [MeSH:C0014290]ment learning unresolved probe selective tonic dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030]rgic stimulation affect associative [MeSH:C0234471] learning healthy [MeSH:C0004084] subject [MeSH:C1708335] train novel vocabulary [MeSH:C0042926] concrete noun course consecutive training [MeSH:C2673163] [MeSH:C2673163] day prospective randomized double-blind placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041]-controlled design subject receive tonically stimulate dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030]-receptor agonist pergolide [MeSH:C0031007] [MeSH:C0031007] mg vs placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] min training [MeSH:C2673163] [MeSH:C2673163] training [MeSH:C2673163] [MeSH:C2673163] dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] agonist significantly impair novel word learning [MeSH:C0023185] compare placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] learning decrement persist follow-up [MeSH:C3899107] week post-training [MeSH:C2673163] [MeSH:C2673163] subject treat pergolide [MeSH:C0031007] [MeSH:C0031007] show restricted emotional response compare placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] extent flatten affect pergolide [MeSH:C0031007] [MeSH:C0031007] related degree learning inhibition finding suggest tonic occupation [MeSH:C0028811] dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] receptor impair learn competition phasic dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] signal [MeSH:C0037081] phasic signal [MeSH:C0037081]ing critical mechanism dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] enhance [MeSH:C0014290] associative [MeSH:C0234471] learning healthy [MeSH:C0004084] subject [MeSH:C1708335] stroke [MeSH:C0038454] [MeSH:C0038454] patient [MeSH:C0030705] [MeSH:C0030705],neurological
phenobarbitone-induced enlargement liver rat [MeSH:C0023884] relationship [MeSH:C0021797] carbon [MeSH:C0007009] tetrachloride-induced cirrhosis,yield severe [MeSH:C1719672] cirrhosis [MeSH:C1623038] liver [MeSH:C0023884] define shrink finely nodular [MeSH:C1076048] liver [MeSH:C0023884] micronodular [MeSH:C1076048] histology ascite great ml plasma albumin g dl splenomegaly time normal testicular atrophy approximately half normal weight dose carbon tetrachloride [MeSH:C0007022] [MeSH:C0007022] [MeSH:C0007022] give intragastrically phenobarbitone [MeSH:C0031412] [MeSH:C0031412]-primed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] increase give initial calibrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e dose carbon tetrachloride [MeSH:C0007022] [MeSH:C0007022] [MeSH:C0007022] peak phenobarbitone [MeSH:C0031412] [MeSH:C0031412]-induced enlargement liver [MeSH:C0023884] point assume cytochrome p4 ccl4 toxic [MeSH:C1256754] state maximal stable optimal rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] size [MeSH:C0162658] [MeSH:C0162658] begin phenobarbitone [MeSH:C0031412] [MeSH:C0031412] determine g size [MeSH:C0162658] [MeSH:C0162658] mean maximum relative liver [MeSH:C0023884] weight increase great normal rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] body weight optimal initial dose carbon tetrachloride [MeSH:C0007022] [MeSH:C0007022] [MeSH:C0007022] day [MeSH:C0011017] phenobarbitone [MeSH:C0031412] [MeSH:C0031412],hepatorenal
cerebrovascular [MeSH:C0007820] ventricular tachycardia vascular [MeSH:C0042514] insight,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient peripheral artery disease [MeSH:C1704436] embolism result decrease mortality rate [MeSH:C0205848] myocardial infarction [MeSH:C0027051] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
kidney cancer [MeSH:C0740457] marker [MeSH:C0017393] multiple sclerosis [MeSH:C0026769],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect diabete heart rate method [MeSH:C0018810] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo randomized control hormone therapy sarcoma assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
aspirin [MeSH:C0004057] primary prevention [MeSH:C0033144] cardiovascular event [MeSH:C0007220] update evidence [MeSH:C5575834] u preventive service [MeSH:C0033109] task force [MeSH:C0162458],coronary heart disease [MeSH:C0010068] [MeSH:C0010068] cerebrovascular disease [MeSH:C0007820] lead cause death [MeSH:C0011065] united state u prevent [MeSH:C0000918]ive service [MeSH:C0033109] task force [MeSH:C0162458] uspstf strongly recommend clinician [MeSH:C0028654] discuss aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] adult [MeSH:C0001675] increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] coronary heart disease [MeSH:C0010068] [MeSH:C0010068] determine benefit [MeSH:C0021674] harm take aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] primary prevent [MeSH:C0000918]ion [MeSH:C0033144] [MeSH:C0033144] [MeSH:C0033144] myocardial infarction [MeSH:C0027051] [MeSH:C0027051] stroke [MeSH:C0038454] [MeSH:C0038454] [MeSH:C0027051] death [MeSH:C0011065] source medline cochrane library search date january august recent systematic review [MeSH:C1955832] reference list retrieve article suggestion expert selection english-language randomized controlled trial [MeSH:C1096777] rct case-control study meta-analyse [MeSH:C0007328] systematic review [MeSH:C1955832] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] versus primary prevent [MeSH:C0000918]ion [MeSH:C0033144] [MeSH:C0033144] [MeSH:C0033144] cardiovascular disease [MeSH:C0007222] cvd select answer follow question [MeSH:C0600648] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] decrease coronary heart event stroke [MeSH:C0038454] [MeSH:C0038454] death [MeSH:C0038454] [MeSH:C0011065] coronary heart event stroke [MeSH:C0038454] [MeSH:C0038454] all-cause mortality [MeSH:C0026565] [MeSH:C0026565] adult [MeSH:C0026565] [MeSH:C0001675] known cvd aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] increase gastrointestinal bleeding hemorrhagic [MeSH:C0019087] [MeSH:C0019087] stroke [MeSH:C0038454] [MeSH:C0017181] [MeSH:C0038454] extraction study review abstract rate [MeSH:C0600678] quality predefined uspstf criterion [MeSH:C0243161] synthesis [MeSH:C3178925] new evidence [MeSH:C5575834] [MeSH:C5575834] good-quality rct good-quality meta-analysis [MeSH:C0282458] fair-quality subanalyse rct demonstrate aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] use reduce number cvd event patient [MeSH:C0030705] known cvd man study experience few myocardial infarction [MeSH:C0027051] [MeSH:C0027051] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] experience few ischemic stroke [MeSH:C0038454] [MeSH:C0948008] [MeSH:C0038454] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] affect cvd mortality [MeSH:C0026565] [MeSH:C0026565] all-cause mortality [MeSH:C0026565] [MeSH:C0026565] man woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] use aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] primary prevent [MeSH:C0000918]ion [MeSH:C0033144] [MeSH:C0033144] [MeSH:C0033144] increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] major bleeding event primarily gastrointestinal bleeding event man woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] man increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] hemorrhagic [MeSH:C0019087] [MeSH:C0019087] stroke [MeSH:C0038454] [MeSH:C0038454] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] use new rct meta-analysis [MeSH:C0282458] [MeSH:C0282458] suggest risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] hemorrhagic [MeSH:C0019087] [MeSH:C0019087] stroke [MeSH:C0038454] [MeSH:C0038454] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] statistically significantly increase limitation new evidence [MeSH:C5575834] [MeSH:C5575834] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] primary prevent [MeSH:C0000918]ion [MeSH:C0033144] [MeSH:C0033144] [MeSH:C0033144] cvd limited dose aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] rct vary prevent [MeSH:C0000918] estimation appropriate dose primary prevent [MeSH:C0000918]ion [MeSH:C0033144] [MeSH:C0033144] [MeSH:C0033144] rct conduct population health professional [MeSH:C0018722] potentially limit generalizability aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] reduce risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] myocardial infarction [MeSH:C0027051] [MeSH:C0027051] man stroke [MeSH:C0038454] [MeSH:C0038454] [MeSH:C0038454] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] use increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] bleeding event,neurological|cardiovascular
cancer diagnosis cancer [MeSH:C0006826],question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer bladder cancer [MeSH:C0005684] mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess oncogene myeloproliferative neoplasm result favorable safety profile implication relevance,oncological
paralysis [MeSH:C0522224] meet peripheral artery disease [MeSH:C1704436] neurological perspective,hypothesis [MeSH:C3179072] aspirin improve stroke [MeSH:C0038454] outcome white matter pathway [MeSH:C0682708] method prospective trial diabetic [MeSH:C1263960] patient measure huntington disease myelopathy result positive response practice guideline [MeSH:C0936005],neurological
curcumin [MeSH:C0010467] prevent [MeSH:C0000918] maleate-induced nephrotoxicity relation hemodynamic [MeSH:C0019010] alteration oxidative stress [MeSH:C0242606] mitochondrial [MeSH:C0949610] oxygen consumption activity [MeSH:C0030055] respiratory complex [MeSH:C2363240],potential [MeSH:C0001272] protective effect dietary [MeSH:C0012177] antioxidant [MeSH:C0003402] curcumin [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] mg kg day renal injury [MeSH:C2609414] induce maleate [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874] evaluate tubular proteinuria oxidative stress [MeSH:C0242606] [MeSH:C0242606] [MeSH:C0242606] induce single injection [MeSH:C1828121] maleate [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874] mg kg rat [MeSH:C0034721] maleate [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874]-induced renal injury [MeSH:C2609414] include increase renal vascular [MeSH:C0221214] resistance urinary excretion total protein glucose sodium neutrophil gelatinase-associated lipocalin ngal [MeSH:C2347341] n-acetyl b-d-glucosaminidase nag [MeSH:C0001057] upregulation kidney [MeSH:C0022646] injury [MeSH:C2609414] molecule kim decrease renal blood flow [MeSH:C1527409] claudin- expression necrosis [MeSH:C0017262] apoptosis [MeSH:C0162638] tubular cell h oxidative stress [MeSH:C0242606] [MeSH:C0242606] [MeSH:C0242606] determine measure [MeSH:C0079809] oxidation lipid protein [MeSH:C0023775] diminution renal nrf2 [MeSH:C1565078] level study conduct renal epithelial [MeSH:C0014597] llc-pk1 [MeSH:C0242598] cell [MeSH:C0242598] mitochondria [MeSH:C0026237] [MeSH:C0026237] isolate kidney [MeSH:C0022646] experimental group maleate [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874] induce cell damage reactive oxygen specie ros production [MeSH:C0162772] llc-pk1 [MeSH:C0242598] cell [MeSH:C0242598] culture addition maleate [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874] reduce oxygen consumption [MeSH:C0030055] adp-stimulated mitochondria [MeSH:C0026237] [MeSH:C0026237] diminish respirat [MeSH:C0034721]ory index malate glutamate substrat [MeSH:C0034721]e activity complex aconitase diminish above-described alterat [MeSH:C0034721]ion prevent [MeSH:C0000918] curcumin [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] conclude curcumin [MeSH:C0010467] [MeSH:C0010467] [MeSH:C0010467] able attenuate [MeSH:C0042211] vivo maleate [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874] [MeSH:C0220874]-induced nephropathy vitro cell damage vivo protection [MeSH:C0524828] [MeSH:C0524828] associate prevent [MeSH:C0000918]ion oxidative stress [MeSH:C0242606] [MeSH:C0242606] [MeSH:C0242606] preservation mitochondria [MeSH:C0026237] [MeSH:C0026237]l oxygen consumption [MeSH:C0030055] activity respirat [MeSH:C0034721]ory complex vitro protection [MeSH:C0524828] [MeSH:C0524828] associate prevent [MeSH:C0000918]ion ros production,hepatorenal
hormone therapy [MeSH:C0039798] breast cancer [MeSH:C0006142] detrimental effect memory cognition [MeSH:C0009240] pilot [MeSH:C0473169],pilot [MeSH:C0473169] examine hormone therapy [MeSH:C0039798] [MeSH:C0039798] breast cancer [MeSH:C0006142] [MeSH:C0006142] affect cognition patient [MeSH:C0030705] [MeSH:C0009240] participate randomised trial anastrozole tamoxifen [MeSH:C0039286] combined atac n woman [MeSH:C0043210] breast cancer [MeSH:C0006142] [MeSH:C0006142] [MeSH:C0006142] n complete battery neuropsychological [MeSH:C0036849] measure compare patient [MeSH:C0030705] impaired processing speed [MeSH:C2009910] [MeSH:C2009910] task p immediate verbal memory p control use hormone replacement therapy [MeSH:C0282402] [MeSH:C0282402] group [MeSH:C0018257] performance [MeSH:C0871966] significantly related length measure [MeSH:C1956055] psychological [MeSH:C0036849] morbidity result show specific impairment process [MeSH:C1384666] speed [MeSH:C2009910] [MeSH:C2009910] verbal memory woman [MeSH:C0043210] receive hormonal therapy [MeSH:C0039798] breast cancer [MeSH:C0006142] [MeSH:C0006142] verbal memory especially sensitive [MeSH:C1017675] change oestrogen level [MeSH:C0018759] commonly report study hormone replacement therapy [MeSH:C0282402] [MeSH:C0282402] healthy [MeSH:C0452415] woman [MeSH:C0043210] view increase use hormone therapy [MeSH:C0039798] [MeSH:C0039798] adjuvant [MeSH:C0674607] preventative setting impact [MeSH:C5544368] cognitive functioning [MeSH:C0009240] investigate [MeSH:C0035173] thoroughly,neurological|oncological
transient [MeSH:C0040704] contralateral rotation follow unilateral substantia nigra [MeSH:C0038590] lesion reflect susceptibility [MeSH:C0012655] nigrostriatal system exhaustion amphetamine [MeSH:C0002658],follow unilateral -ohda induce sn lesion transient period contralateral rotation report precede predominant ipsilateral circling order clarify nature initial contralateral rotation examine effect [MeSH:C4277511] [MeSH:C4277511] durat [MeSH:C0034721]ion recovery period lesion amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658]-induced rotational behavior day [MeSH:C0011017] post lesion rat [MeSH:C0034721] circle predominantly contralaterally lesion contralateral rotation degenerat [MeSH:C0034721]ion-induced breakdown da pool lesion-induced increase da turnover [MeSH:C0085268] spare neuron [MeSH:C0027882] substantial degree contralateral preference [MeSH:C0376409] evident amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] administer day [MeSH:C0011017] lesione indicate involvement [MeSH:C0030699] spare cell contralateral rotation regardless durat [MeSH:C0034721]ion recovery irrespective lesion volume amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] dose post-lesion motor exercise amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658]-induced rotation tend gradually ipsilateral observation session [MeSH:C0302523] progress rat [MeSH:C0034721] circle ipsilaterally lesion response amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] injection finding suggest amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] irreversible [MeSH:C4319935] effect [MeSH:C4277511] [MeSH:C4277511] post-lesion da pool contribute contralateral rotation,neurological
defibrillator [MeSH:C0180307] meet coronary artery disease [MeSH:C1956346] neurological perspective,design [MeSH:C0013171] prospective investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient reticular formation regurgitation result improve disease management [MeSH:C0039798] heart rate [MeSH:C0018810] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
hepatitis acetylcholine exploring neural pathway [MeSH:C0027792],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] restrictive cardiomyopathy [MeSH:C0007196] mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assess embolism hypotensive [MeSH:C0013922] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication need investigation [MeSH:C0035173],neurological|cardiovascular
meloxicam-induced liver toxicity [MeSH:C0040539],report case [MeSH:C0684224] female rheumatoid arthritis develop acute cytolytic hepatitis meloxicam [MeSH:C0083381] recently introduce belgium meloxicam [MeSH:C0083381] [MeSH:C0004950] nonsteroidal antiinflammatory drug [MeSH:C0013227] [MeSH:C0003211] selective action [MeSH:C0206189] inducible form cyclooxygenase acute cytolytic hepatitis occur rapidly meloxicam [MeSH:C0083381] administration [MeSH:C0001554] associate development [MeSH:C0020119] antinuclear antibody [MeSH:C0003243] suggest hypersensitivity [MeSH:C0020517] mechanism [MeSH:C1524059] case meloxicam [MeSH:C0083381] [MeSH:C0083381] related liver [MeSH:C0023884] toxicity [MeSH:C0040539] demonstrate potential [MeSH:C0001272] drug [MeSH:C0013227] induce hepatic damage,hepatorenal
pulmonary edema shock high-dose aracytine-c lymphoma possible role tnf-alpha [MeSH:C1456820] paf [MeSH:C0032172],consecutive patient [MeSH:C0030705] [MeSH:C0030705] treat high-dose ara-c [MeSH:C0733521] [MeSH:C0733521] lymphoma institution [MeSH:C0442681] develop strikingly similar syndrome [MeSH:C0039082] [MeSH:C0039082] perfusion [MeSH:C0031001] characterize onset fever diarrhea shock pulmonary edema acute renal failure metabolic acidosis [MeSH:C0220981] weight gain [MeSH:C0043094] leukocytosis thorough bacteriological screening fail provide evidence [MeSH:C5575834] infection [MeSH:C3714514] sequential biological assay [MeSH:C0005507] il- il- tnf [MeSH:C1448177] [MeSH:C1448177] [MeSH:C1448177] paf [MeSH:C0032172] [MeSH:C0032172] perform ara-c [MeSH:C0733521] [MeSH:C0733521] infusion [MeSH:C0841792] patient [MeSH:C0030705] [MeSH:C0030705] include develop syndrome [MeSH:C0039082] [MeSH:C0039082] tnf [MeSH:C1448177] [MeSH:C1448177] [MeSH:C1448177] paf [MeSH:C0032172] [MeSH:C0032172] activity find serum [MeSH:C0229671] respectively case control [MeSH:C0007328] tnf [MeSH:C1448177] [MeSH:C1448177] [MeSH:C1448177] paf [MeSH:C0032172] [MeSH:C0032172] think involve development [MeSH:C0243107] septic shock [MeSH:C0036983] adult respiratory distress syndrome [MeSH:C0852283] [MeSH:C0039082] [MeSH:C0039082] hypothesize high-dose ara-c [MeSH:C0733521] [MeSH:C0733521] associate [MeSH:C0004083] cytokine release [MeSH:C0948245],hepatorenal|oncological
brain map [MeSH:C0006104] parkinson disease [MeSH:C0030567] insight,design [MeSH:C0013171] prospective investigation statin stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient [MeSH:C0030705] acetylcholine cortical [MeSH:C0001041] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cerebral correlation relevance,neurological
eeg [MeSH:C0013819] reveal peripheral artery disease [MeSH:C1704436] secret,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome myelodysplastic syndrome pathway method longitudinal trial [MeSH:C0023981] elderly patient measure skin cancer [MeSH:C0007114] neurodegenerative [MeSH:C0524851] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] care improvement,neurological|oncological
oxidative stress [MeSH:C0242606] cardiotoxicity [MeSH:C0876994] single multiple dose doxorubicin [MeSH:C0013089],mechanism [MeSH:C1524059] [MeSH:C1524059] doxorubicin [MeSH:C0013089] dox -induced cardiotoxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] remain controversial wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] n receive dox injection [MeSH:C1828121] intraperitoneally randomly assign experimental protocol [MeSH:C0016998] rat [MeSH:C0034721] [MeSH:C0034721] kill h n h h n single dose dox mg kg body weight [MeSH:C0005910] determine dox acute [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] effect [MeSH:C4277511] rat [MeSH:C0034721] [MeSH:C0034721] n receive injection dox mg kg body weight [MeSH:C0005910] week kill injection m0 week injection m1 m2 m3 m4 determine chronological effect [MeSH:C4277511] animal [MeSH:C0003062] m0 n moment h acute [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] cardiac total antioxidant performance tap dna damage morphology analysis carry point single dose dox associate increase cardiac disarrangement necrosis [MeSH:C0027540] [MeSH:C0027540] dna damage strand break sbs oxidize pyrimidine [MeSH:C0034284] decrease tap chronological show effect [MeSH:C4277511] cumulative dose body weight [MeSH:C0005910] r p necrosis [MeSH:C0027540] [MeSH:C0027540] r p tap r p dna sbs r p dna sbs damage [MeSH:C0012860] negatively associate tap r p necrosis [MeSH:C0027540] [MeSH:C0027540] r p result suggest oxidative damage [MeSH:C5392203] associate acute [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] cardiotoxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0876994] induce single dose dox increase resistance [MeSH:C0034471] oxidative stress [MeSH:C0242606] plausible multiple dose dox different mechanism [MeSH:C1524059] [MeSH:C1524059] involve acute [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] toxicity [MeSH:C0040539] [MeSH:C0040539] versus chronic [MeSH:C0150055] toxicity [MeSH:C0040539] [MeSH:C0040539],neurological|cardiovascular
cardiac [MeSH:C0018810] troponin level marker myocardial damage doxorubicin-induced cardiomyopathy rat [MeSH:C0034721] relationship [MeSH:C0021797] echocardiographic [MeSH:C0013516] histological [MeSH:C0019637] finding,cardiac [MeSH:C0018810] troponin ctni ctnt show highly sensitive [MeSH:C1017675] specific marker [MeSH:C0017393] [MeSH:C0017393] myocardial [MeSH:C0027061] cell injury [MeSH:C3263723] [MeSH:C0027055] investigate [MeSH:C0035173] diagnostic ctni ctnt diagnosis myocardial [MeSH:C0027061] damage rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] model doxorubicin [MeSH:C0013089] dox -induced cardiomyopathy [MeSH:C0878544] examine relationship [MeSH:C0021797] [MeSH:C0021797] serial ctni ctnt development cardiac [MeSH:C0018810] disorder monitor echocardiography [MeSH:C0013516] histological [MeSH:C0019637] examination model method thirty-five wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] give mg kg dox v weekly week total cumulative dose mg kg bw rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] receive saline ctni measure [MeSH:C0079809] [MeSH:C0079809] access r ng ml immunoassay [MeSH:C0020980] pg ml compare ctnt ck-mb mass ck transthoracic echocardiography [MeSH:C0013516] anterior posterior wall thickness lv diameter lv fractional shorten f measure [MeSH:C0079809] [MeSH:C0079809] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] dox saline week survive rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] histology [MeSH:C0019638] perform dox-rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] week dox dose control result eighteen dox rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] die prematurely general toxicity [MeSH:C0040539] -week period [MeSH:C0080129] end-diastolic ed end-systolic es lv diameter bw significantly increase lv f decrease week dox p parameter remain unchanged control histological [MeSH:C0019637] heart rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give dox reveal slight degree perivascular interstitial fibrosis rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] degenerat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion myocyte [MeSH:C0596981] vacuolisation find control exhibit evidence [MeSH:C5575834] slight perivascular fibrosis rise ctnt find dox rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] cumulative dose mg kg comparison [MeSH:C0871382] p ctnt find rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mg kg significantly great find mg kg dox maximal ctni pg ml ctnt level significantly increase dox rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] compare control p ctni ng ml ck-mb mass ck remain unchanged dox rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] compare control marker [MeSH:C0017393] [MeSH:C0017393] remain stable control reveal correlation [MeSH:C0010100] maximal ctnt ed es lv diameter bw r p relationship [MeSH:C0021797] [MeSH:C0021797] observe maximal ctnt extent myocardial [MeSH:C0027061] morphological change lv diameter bw histological [MeSH:C0019637] finding conclusion marker [MeSH:C0017393] [MeSH:C0017393] ischemic injury [MeSH:C3263723] [MeSH:C3263723] dox rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] ctnt show great ability detect myocardial [MeSH:C0027061] damage assess echocardiographic [MeSH:C0013516] detection [MeSH:C5392129] histological [MeSH:C0019637] change discrepancy ctni ctnt dox probably heterogeneity [MeSH:C0242960] cross-reactivitie mab ctni ctnt form likely ctnt rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] dox indicate cell damage determine magnitude injury [MeSH:C3263723] induce ctnt useful marker [MeSH:C0017393] [MeSH:C0017393] prediction [MeSH:C0920722] experimentally induce cardiotoxicity [MeSH:C0876994] [MeSH:C0040539] possibly cardioprotective experiment [MeSH:C0007209],neurological|cardiovascular
cardiac conduction dementia,diabete affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve defibrillator blood pressure method [MeSH:C0005823] conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examining bundle branch block [MeSH:C0006384] parameter result improve disease management [MeSH:C0039798] safety consideration,cardiovascular
pharmacology [MeSH:C0031330] gyki- chlorpropanol [MeSH:C0076772] tobanum new potent beta-adrenergic antagonist [MeSH:C0001645],compound gyki- beta-adrenergic antagonist [MeSH:C0001645] time potent propranolol [MeSH:C0033497] [MeSH:C0033497] vitro vivo antiarrhythmic [MeSH:C0003195] effectiveness surpass propranolol [MeSH:C0033497] [MeSH:C0033497] pindolol [MeSH:C0031937] inhibit [MeSH:C0021463] ouabain arrhythmia [MeSH:C0003811] dog cat gyki- negligible cardiodepressant activity cardioselective compound show rapid long lasting effect prolonged elimination [MeSH:C1373187] radioactivity injection [MeSH:C1828121] 4c- rat [MeSH:C0034721] dog half life unlabeled substance [MeSH:C0075414] human hour,cardiovascular
norepinephrine [MeSH:C0028351] pattern lung cancer [MeSH:C0242379] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome dysarthria pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure tachycardia myocardial infarction [MeSH:C0027051] result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],neurological|cardiovascular
stroke [MeSH:C0038454] bilirubin [MeSH:C0005437] organ interplay,question statin affect heart disease [MeSH:C0018799] renal stone mechanism method retrospective [MeSH:C0035363] cardiac patient assess hematuria [MeSH:C0018965] oliguria [MeSH:C0028961] result enhance therapeutic response [MeSH:C0087111] implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
brain [MeSH:C0006104] dynamic peripheral artery disease white matter [MeSH:C0682708],investigate [MeSH:C0035173] beta-blocker effect heart disease guillain-barre syndrome method [MeSH:C0018378] cardiac patient undergo randomized control [MeSH:C1096777] autonomic neuropathy [MeSH:C0271686] acoustic neuroma [MeSH:C0027859] assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] need investigation [MeSH:C0035173],neurological
lymphoma capillary [MeSH:C0162405] cardiac connection,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] beta-blocker [MeSH:C0001645] stroke participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] cardiac [MeSH:C0018810] venous result improvement primary endpoint tricuspid valve correlation [MeSH:C0040960] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
brain map [MeSH:C0006104] stroke [MeSH:C0038454] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer peripheral neuropathy [MeSH:C4721453] method cardiac patient undergo randomized control meningioma neurodegenerative assessment result favorable safety [MeSH:C0036043] profile cost-effectiveness [MeSH:C1511536] implication,neurological
arrhythmia pathway peripheral artery disease [MeSH:C1704436],question [MeSH:C0600648] metformin [MeSH:C0025598] affect diabete defibrillator mechanism method longitudinal [MeSH:C0023981] cardiac patient assess al tremor [MeSH:C0040822] result improve disease management [MeSH:C0039798] implication practice guideline,neurological|cardiovascular
artery marker hepatitis,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] stroke [MeSH:C0038454] ventricular fibrillation method [MeSH:C0042510] adult [MeSH:C0001675] population [MeSH:C0032659] undergo observational hypotensive coronary assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
angina [MeSH:C0002965] pectoris [MeSH:C0002962] cardiovascular lens [MeSH:C0007220],hypothesis [MeSH:C3179072] aspirin improve cancer outcome aortic aneurysm pathway method randomized control trial cancer [MeSH:C1096777] patient [MeSH:C0030705] measuring chf congestive heart failure [MeSH:C0018802] result improve disease management [MeSH:C0039798] practice guideline,cardiovascular
brca1 [MeSH:C0259275] r81w strong candidate common mutation [MeSH:C0026882] moderate phenotype [MeSH:C0031437],brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] cause increase risk [MeSH:C0035647] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] frequently early onset [MeSH:C0031106] different mutation [MeSH:C0026882] [MeSH:C0026882] occur brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] include example recurrent mutation [MeSH:C0026882] [MeSH:C0026882] account number family heritable cancer predisposition [MeSH:C0314657] common mutation [MeSH:C0026882] [MeSH:C0026882] etiological role breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] case provide opportunity examine genotype-phenotype [MeSH:C2717879] correlation [MeSH:C0010100] genotype-environment interaction [MeSH:C0596609] individual identical brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] lesion report novel missense [MeSH:C0599155] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] c-- r81w find case subject breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] case orange county consecutive population [MeSH:C0032659]-based case select age [MeSH:C0024842] family history [MeSH:C0241889] case strong family history [MeSH:C0241889] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] possibly related brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] defect family member [MeSH:C0086282] show high concordance cancer incidence [MeSH:C0021149] presence r81w age [MeSH:C0024842] cancer onset distinct typical sporadic case testing sample unrelated individual examine hypothesis [MeSH:C3179072] r81w rare polymorphism [MeSH:C0032529] detect additional instance woman breast cancer [MeSH:C0006142] diagnose [MeSH:C0011900] age [MeSH:C0024842] year cancer parent [MeSH:C0030551] r81w likely etiologically lesion involvement [MeSH:C0030699] close confidence interval [MeSH:C0009667] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] [MeSH:C1140680] population [MeSH:C0032659],oncological
hepatitis pathway [MeSH:C0019158] dementia [MeSH:C0497327],question [MeSH:C0600648] metformin [MeSH:C0025598] affect hypertension [MeSH:C0020538] liver mechanism method observational [MeSH:C0302523] elderly patient assess kidney stone [MeSH:C0022650] hepatorenal syndrome [MeSH:C0019212] result enhance therapeutic response [MeSH:C0087111] implication relevance,hepatorenal
epilepsy [MeSH:C0014544] liver transplant [MeSH:C0023911] organ [MeSH:C0029250] interplay,dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve fatty liver hepatitis method conduct observational evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine kidney stone [MeSH:C0022650] parameter result improve outcome safety consideration,hepatorenal
dcc protein [MeSH:C1259909] prognosis [MeSH:C0033325] colorectal cancer [MeSH:C0009402],allelic loss [MeSH:C0524869] chromosome 8q [MeSH:C0524869] predict poor outcome patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stage [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0030705] [MeSH:C0029170] [MeSH:C0024842] [MeSH:C0030705] ii colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] specific gene inactivate [MeSH:C0598496] allelic loss [MeSH:C0524869] elucidate dcc [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] delete colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] gene candidate investigate [MeSH:C0035173] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] dcc [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] protein tumor cell prognostic marker colorectal carcinoma [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] method expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] dcc [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] evaluate immunohistochemically [MeSH:C0021044] paraffin-embedded sample patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] curatively resected stage [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0024842] ii iii colorectal carcinoma [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] cox proportional-hazards model [MeSH:C0033489] adjust covariate include age [MeSH:C0024842] sex tumor site [MeSH:C0027651] degree tumor differentiation [MeSH:C0007589] use adjuvant therapy [MeSH:C0085533] result expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] dcc [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] strong positive predictive factor [MeSH:C1514243] survival stage [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0038952] [MeSH:C0024842] ii stage [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0024842] iii colorectal carcinoma [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stage [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0030705] [MeSH:C0029170] [MeSH:C0024842] [MeSH:C0030705] ii disease tumor express dcc [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] five-year survival rate [MeSH:C0038954] percent patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dcc [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414]-negative tumor survival rate [MeSH:C0038954] percent p stage [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0024842] iii disease respective survival rate [MeSH:C0038954] percent percent p conclusion dcc [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] prognostic marker patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stage [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0030705] [MeSH:C0029170] [MeSH:C0024842] [MeSH:C0030705] ii stage [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0024842] iii colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] stage [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0024842] ii colorectal carcinoma [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] absence dcc [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] [MeSH:C0079414] identify subgroup patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lesion behave like stage [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0029170] [MeSH:C0024842] iii cancer finding therapeutic [MeSH:C0087111] implication patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],oncological
valvular heart disease [MeSH:C0018824] patient [MeSH:C0030705] parkinson disease [MeSH:C0030567] treat pergolide course [MeSH:C0031007] follow modification [MeSH:C0086153],valvular heart abnormality [MeSH:C0018798] [MeSH:C0018798] report patient [MeSH:C0030705] [MeSH:C0030705] parkinson disease [MeSH:C0030567] pd treat pergolide [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] incidence [MeSH:C0021149] severity abnormality [MeSH:C2713367] vary course [MeSH:C0449259] drug withdrawal [MeSH:C1881606] [MeSH:C2717885] systematically assess objective estimate frequency [MeSH:C0376249] severity valvular heart abnormality [MeSH:C0018798] [MeSH:C0018798] possible reversibility drug withdrawal [MeSH:C1881606] [MeSH:C2717885] case-control method pd patient [MeSH:C0030705] [MeSH:C0030705] amien [MeSH:C0030705] area treat pergolide [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] invite attend cardiologic assessment include transthoracic echocardiography [MeSH:C0013516] [MeSH:C0013516] thirty pd patient [MeSH:C0030705] [MeSH:C0030705] participate second echocardiography [MeSH:C0013516] perform median interval month pergolide [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] withdrawal [MeSH:C1881606] n patient [MeSH:C0030705] [MeSH:C0030705] control age- sex-matched non-pd patient [MeSH:C0030705] [MeSH:C0030705] refer cardiology department [MeSH:C0034600] result compare control aortic regurgitation [MeSH:C0026266] [MeSH:C0003504] ic mitral regurgitation [MeSH:C0026266] ic frequent pd patient [MeSH:C0030705] [MeSH:C0030705] tricuspid ns number affect valve [MeSH:C0026264] n sum regurgitation [MeSH:C0026266] grade n high p p respectively pergolide [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] severity regurgitation [MeSH:C0026266] correlate pergolide [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] cumulative dose restrictive pattern valvular regurgitation [MeSH:C0026266] suggestive role pergolide [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] observe patient [MeSH:C0030705] [MeSH:C0030705] include heart failure [MeSH:C0018801] pergolide [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] discontinue patient [MeSH:C0030705] [MeSH:C0030705] valvular heart disease result low regurgitation [MeSH:C0026266] grade p second transthoracic echocardiography [MeSH:C0013516] [MeSH:C0013516] patient [MeSH:C0030705] [MeSH:C0030705] heart failure [MeSH:C0018801] return nearly normal examination support high frequency [MeSH:C0376249] restrictive valve [MeSH:C0026264] regurgitation [MeSH:C0026266] pd patient [MeSH:C0030705] [MeSH:C0030705] treat pergolide [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] [MeSH:C0031007] reveal improvement [MeSH:C2936612] usual convert non-ergot dopamine agonist,neurological|cardiovascular
neural network parkinson disease glutamate [MeSH:C0220839],design [MeSH:C0013171] prospective investigation beta-blocker [MeSH:C0001645] dementia participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] cerebellar locus coeruleus [MeSH:C0023951] result improve disease management [MeSH:C0039798] neuropathy [MeSH:C0015464] correlation [MeSH:C0010100] cost-effectiveness [MeSH:C1511536] implication,neurological
ifosfamide-induced urothelial toxicity [MeSH:C0040539] oral administration [MeSH:C0001563] sodium [MeSH:C0037473] -mercaptoethane sulphonate mesna [MeSH:C0000294] patient [MeSH:C0030705] inoperable lung cancer [MeSH:C0242379],protective effect oral [MeSH:C0029170] administration thiol compound sodium [MeSH:C0037473] -mercaptoethane sulphonate mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] urothelial toxicity [MeSH:C0040539] [MeSH:C0040539] induce ifosfamide test [MeSH:C0020823] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] inoperable lung cancer [MeSH:C0242379] mg m2 day polychemotherapy [MeSH:C2717829] regimen [MeSH:C1880476] repeat -week cycle mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] give oral [MeSH:C0029170]ly day dose mg m2 administer hr injection [MeSH:C1828121] hr hr p total course observe episode [MeSH:C0085554] asymptom [MeSH:C3839861]atic [MeSH:C2936329] microscopic haematuria episode [MeSH:C0085554] gross haematuria patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] protection [MeSH:C0524828] mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] complete remission partial remission total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] polychemotherapy [MeSH:C2717829] treat conventional prophylactic measure raise fluid [MeSH:C0600608] intake [MeSH:C0006777] force [MeSH:C0086323] diuresis [MeSH:C0012797] complete partial remission total nearly patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop gross haematuria symptom [MeSH:C3839861] bladder irritation cystitis pollakisuria appreciable difference mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] series conventional prophylaxis series [MeSH:C0033107] respect haematological systemic [MeSH:C5544477] toxicity [MeSH:C0040539] [MeSH:C0040539] cytostatic [MeSH:C0010858] result support view mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] give oral [MeSH:C0029170]ly conjunction combined cytostatic [MeSH:C0010858] regimen [MeSH:C1880476] include simplify provide optimum protection [MeSH:C0524828] urinary epithelium [MeSH:C0227598] protection [MeSH:C0524828] oral [MeSH:C0029170] mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] particularly suitable outpatient [MeSH:C0029921] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],neurological|oncological
levodopa-induced dyskinesia patient [MeSH:C0030705] parkinson disease [MeSH:C0030567] fill bench-to-bedside gap [MeSH:C0061928],levodopa [MeSH:C0023570] effect [MeSH:C4277511]ive [MeSH:C5392218] drug parkinson disease [MeSH:C0030567] [MeSH:C0030567] long-term [MeSH:C0023977] use dopamine precursor complicated highly disabling fluctuation dyskinesia preclinical finding suggest pulsatile stimulation striatal postsynaptic receptor key mechanism [MeSH:C1524059] underlie levodopa [MeSH:C0023570]-induced dyskinesia pathogenesis [MeSH:C0699748] unclear recent year evidence [MeSH:C5575834] animal model [MeSH:C0599779] parkinson disease [MeSH:C0030567] provide important information [MeSH:C5544371] understand effect [MeSH:C4277511] specific receptor post-receptor molecular mechanism [MeSH:C1524059] underlie development dyskinetic [MeSH:C0013384] movement [MeSH:C0026649] recent preclinical promising line focus differential role presynaptic [MeSH:C0206129] versus postsynaptic mechanism [MeSH:C1524059] dopamine receptor subtype ionotropic metabotropic glutamate receptor [MeSH:C0206529] non-dopaminergic neurotransmitter system pathophysiology [MeSH:C0031847] levodopa [MeSH:C0023570]-induced dyskinesia,neurological
ventricular fibrillation connection [MeSH:C0042510] breast cancer [MeSH:C0006142],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] cerebrovascular pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure brain abscess [MeSH:C0006105] blood pressure [MeSH:C0005823] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,neurological|cardiovascular
genetic etiology digeorge syndrome [MeSH:C0012236] consistent deletion [MeSH:C0017260] microdeletion [MeSH:C0017260] 2q1,digeorge syndrome [MeSH:C0012236] dgs developmental field defect fourth pharyngeal pouch [MeSH:C0012236] characterize aplasia hypoplasia [MeSH:C0243069] thymus [MeSH:C0040113] parathyroid gland [MeSH:C0030518] conotruncal cardiac malformation cytogenetic study support presence dgs critical region band 2q1 present report result cytogenetic molecular study patient [MeSH:C0030705] dgs chromosome [MeSH:C0008633] utilize high-resolution banding technique detect interstitial deletion proband inconclusive deletion proband remain patient [MeSH:C0030705] normal karyotype contrast molecular detect dna deletion proband locus test d22s7 d22s2 delete patient [MeSH:C0030705] locus d22s6 delete dgs proband test physical mapping [MeSH:C0600504] somatic cell hybrid place d22s6 d22s7 d22s2 suggest delete remain case parent-of-origin study perform family proband fail inherit maternal [MeSH:C0024915] allele [MeSH:C0002085] fail inherit paternal [MeSH:C0030652] allele [MeSH:C0002085] basis family maternal [MeSH:C0024915]ly paternal [MeSH:C0030652]ly derive unbalanced-translocation dgs proband literature parent origin imprinting [MeSH:C0242614] appear play important role pathogenesis [MeSH:C0699748] dgs deletion locus dgs proband begin delineate region chromosome [MeSH:C0008633] critical dgs confirm hypothesis [MeSH:C3179072] submicroscopic deletion 2q1 etiologic vast majority case,neurological
cefotetan-induced immune hemolytic anemia,immune hemolytic anemia [MeSH:C0002871] [MeSH:C0002880] drug-adsorption [MeSH:C0001674] [MeSH:C0001674] mechanism [MeSH:C1524059] [MeSH:C1524059] describe primarily patient [MeSH:C0030705] receive penicillin [MeSH:C0030842] first-generation cephalosporin [MeSH:C3536856] [MeSH:C3536856] describe develop anemia [MeSH:C0002871] receive intravenous [MeSH:C0085297] cefotetan [MeSH:C0007555] [MeSH:C0007555] cefotetan [MeSH:C0007555] [MeSH:C0007555]-dependent antibody detect serum eluate prepare red blood cell [MeSH:C0014792] [MeSH:C0014792] eluate react weakly red blood cell [MeSH:C0014792] [MeSH:C0014792] absence cefotetan [MeSH:C0007555] [MeSH:C0007555] suggest concomitant [MeSH:C0152203] formation [MeSH:C0029433] [MeSH:C0029433] warm-reactive autoantibody [MeSH:C0004358] observation [MeSH:C0302523] conjunction laboratory [MeSH:C0022877] evidence extravascular [MeSH:C0015380] hemolysis [MeSH:C0019054] consistent drug-induced hemolytic anemia [MeSH:C0002871] possibly involve drug-adsorption [MeSH:C0001674] [MeSH:C0001674] autoantibody [MeSH:C0004358] formation [MeSH:C0029433] [MeSH:C0029433] mechanism [MeSH:C1524059] [MeSH:C1524059] case emphasize need increase awareness [MeSH:C0004448] hemolytic reaction cephalosporin [MeSH:C3536856] [MeSH:C3536856],neurological
pe meet colorectal cancer [MeSH:C0009402] neurological perspective,investigate [MeSH:C0035173] beta-blocker effect cancer brain method [MeSH:C0025663] elderly patient undergo randomized control tia oligodendroglioma assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint healthcare advancement,neurological|cardiovascular
aortic valve epilepsy [MeSH:C0003501] vascular insight,investigate [MeSH:C0035173] statin effect cancer cerebrovascular method diabetic patient [MeSH:C0030705] undergo longitudinal pericardium atrial flutter assessment result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],cardiovascular
biopsy [MeSH:C0005558] reveal liver cirrhosis [MeSH:C0023890] secret,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve migraine [MeSH:C0149931] parkinson disease method [MeSH:C0030567] conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine cerebral [MeSH:C0242202] parameter result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
leukemia [MeSH:C0023418] cerebrovascular [MeSH:C0007820] cardiac connection,retrospective [MeSH:C0035363] examine calcium channel blocker heart disease [MeSH:C0006684] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include aortic valve peripheral artery disease [MeSH:C1260873] endothelial method [MeSH:C0225336] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
nonsense mutation exon proteolipid protein [MeSH:C0544885] gene plp family unusual form pelizaeus-merzbacher disease [MeSH:C0012634],report [MeSH:C0684224] g-- transition nucleotide proteolipid protein gene plp [MeSH:C0060617] [MeSH:C0060617] result nonsense [MeSH:C0242612] [MeSH:C0242612] codon family unusual form pelizaeus-merzbacher disease [MeSH:C0012634] pmd mutation create second alui restriction site result nonsense [MeSH:C0242612] [MeSH:C0242612] mutation plp [MeSH:C0060617] [MeSH:C0060617] picture [MeSH:C0026601] resemble somewhat x-linked spastic paraplegia spg [MeSH:C1839264] differ classical connatal [MeSH:C0009678] form pmd relatively mild form onset delay age year nystagmus [MeSH:C0240595] absent tremor [MeSH:C0040822] prominent mental retardation [MeSH:C3714756] severe patient [MeSH:C0030705] dementia [MeSH:C0497327] personality disorder [MeSH:C0031212] disease [MeSH:C0012634] progressive [MeSH:C1449744] static female sign disease [MeSH:C0012634] nonsense [MeSH:C0242612] [MeSH:C0242612] mutation exon 3b block synthesis normal plp [MeSH:C0060617] [MeSH:C0060617] spare dm2 isoform [MeSH:C0597298] persistence [MeSH:C2350288] associate mild form plp [MeSH:C0060617] [MeSH:C0060617]-associated disease [MeSH:C0012634] human [MeSH:C0086418] mouse [MeSH:C0026809],neurological
ranitidine-induced acute interstitial nephritis [MeSH:C0027707] cadaveric renal allograft,ranitidine [MeSH:C0034665] frequently prevent [MeSH:C0000918] peptic ulceration [MeSH:C0030920] renal transplantation [MeSH:C0022671] [MeSH:C0022671] drug occasionally associate acute interstitial nephritis [MeSH:C0027707] native [MeSH:C3494467] kidney [MeSH:C0022646] similar report renal transplantation [MeSH:C0022671] [MeSH:C0022671] report case ranitidine [MeSH:C0034665]-induced acute interstitial nephritis [MeSH:C0027707] recipient cadaveric renal allograft present acute allograft dysfunction hour exposure [MeSH:C1390376] drug biopsy specimen show pathognomonic feature include eosinophilic [MeSH:C0014457] infiltration [MeSH:C0162679] interstitial compartment allograft function [MeSH:C0450127] improve rapidly return stop drug,hepatorenal
huntington disease cag expansion phenocopie error assignment [MeSH:C5691386],huntington disease [MeSH:C0020179] hd [MeSH:C0252274] [MeSH:C0252274] [MeSH:C0252274] show associate expand cag repeat novel gene [MeSH:C0017337] 4p1 it1 total affect person [MeSH:C0027361] [MeSH:C0027361] cohort [MeSH:C1706962] expand cag disease [MeSH:C0012634] range reason observe expansion [MeSH:C0196940] [MeSH:C0196940] affect individual [MeSH:C0021228] [MeSH:C0021228] important determine sensitivity [MeSH:C0036667] repeat length diagnosis affect patient [MeSH:C0030705] predictive testing program biological [MeSH:C4553887] relevance [MeSH:C2826293] understanding molecular mechanism underlie hd [MeSH:C0252274] [MeSH:C0252274] [MeSH:C0252274] majority individual [MeSH:C0021228] [MeSH:C0021228] normal sized allele represent misdiagnosis [MeSH:C0679838] sample mix-up clerical error remain patient [MeSH:C0030705] represent possible phenocopie hd [MeSH:C0252274] [MeSH:C0252274] [MeSH:C0252274] case family study [MeSH:C0085973] phenocopie exclude 4p1 region responsible phenotype [MeSH:C0031437] [MeSH:C0031437] mutation [MeSH:C0026882] [MeSH:C0026882] hd [MeSH:C0252274] [MeSH:C0252274] [MeSH:C0252274] gene [MeSH:C0017337] cag expansion [MeSH:C0196940] [MeSH:C0196940] exclude remain case seven person [MeSH:C0027361] [MeSH:C0027361] retrospective review [MeSH:C0282443] patient [MeSH:C0030705] feature identify characteristic typical hd [MeSH:C0252274] [MeSH:C0252274] [MeSH:C0252274] show rare occasion mutation [MeSH:C0026882] [MeSH:C0026882] as-yet-undefined gene [MeSH:C0017337] present phenotype [MeSH:C0031437] [MeSH:C0031437] similar hd [MeSH:C0252274] [MeSH:C0252274] [MeSH:C0252274],neurological
eeg [MeSH:C0013819] reveal hepatitis [MeSH:C0019158] secret,stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve hypothalamus cerebrovascular method conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine dilate cardiomyopathy [MeSH:C0007193] parameter result improve outcome practice guideline [MeSH:C0936005],neurological|cardiovascular
antagonism interleukin erythropoietin mouse [MeSH:C0026809] azidothymidine-induced anemia [MeSH:C0002871] bone marrow endothelial cell [MeSH:C0225336],azidothymidine [MeSH:C0040077] [MeSH:C0040077] azt [MeSH:C0043474] -induced anemia [MeSH:C0002871] mouse [MeSH:C0026809] reverse administration [MeSH:C0001554] igf [MeSH:C0140080]-il- fusion protein insulin-like growth factor [MeSH:C0037657] ii igf [MeSH:C0140080] ii interleukin interleukin [MeSH:C0021764] il- erythropoietin epo [MeSH:C2976467] [MeSH:C2976467] know act [MeSH:C0014822] synergistically [MeSH:C0949698] hematopoietic [MeSH:C0600251] cell proliferation vitro [MeSH:C0596290] injection [MeSH:C1828121] igf [MeSH:C0140080]-il- epo [MeSH:C2976467] [MeSH:C2976467] azt-treated mouse [MeSH:C0026809] result reduction [MeSH:C1827449] red cell [MeSH:C0007634] increase plasma epo [MeSH:C2976467] [MeSH:C2976467] [MeSH:C0032105] level [MeSH:C0018759] compare animal treat [MeSH:C0003062] igf [MeSH:C0140080]-il- epo [MeSH:C2976467] [MeSH:C2976467] test hypothesis [MeSH:C3179072] antagonistic effect il- epo [MeSH:C2976467] [MeSH:C2976467] erythroid cell [MeSH:C1257751] mediate endothelial cell [MeSH:C0225336] [MeSH:C0225336] [MeSH:C0225336] bovine liver erythroid cell [MeSH:C1257751] culture monolayer [MeSH:C1721091] human [MeSH:C0086418] bone marrow [MeSH:C0005953] endothelial cell [MeSH:C0225336] [MeSH:C0225336] [MeSH:C0225336] previously treat epo [MeSH:C2976467] [MeSH:C2976467] igf [MeSH:C0140080]-il- reduction [MeSH:C1827449] thymidine [MeSH:C0040077] [MeSH:C0040077] incorporation erythroid endothelial cell [MeSH:C0225336] [MeSH:C0225336] [MeSH:C0225336] culture pre-treated igf [MeSH:C0140080]-il- epo [MeSH:C2976467] [MeSH:C2976467] endothelial cell [MeSH:C0225336] [MeSH:C0225336] [MeSH:C0225336] culture supernatant separate ultrafiltration ultracentrifugation cell [MeSH:C0041609] treat epo [MeSH:C2976467] [MeSH:C2976467] il- significantly reduce thymidine [MeSH:C0040077] [MeSH:C0040077] incorporation erythroid cell compare identical fraction [MeSH:C0007593] obtain medium cell culture [MeSH:C0007585] epo [MeSH:C2976467] [MeSH:C2976467] result suggest endothelial cell [MeSH:C0225336] [MeSH:C0225336] [MeSH:C0225336] treat simultaneously epo [MeSH:C2976467] [MeSH:C2976467] il- negative [MeSH:C3539878] effect erythroid cell production,hepatorenal
risk [MeSH:C0035647] valvular heart disease [MeSH:C0018824] user fenfluramine dexfenfluramine undergo echocardiography use medication [MeSH:C0013516],uncontrolled echocardiographic survey suggest user fenfluramine dexfenfluramine [MeSH:C0011786] [MeSH:C0011786] valvular disease [MeSH:C0018824] drug withdraw market [MeSH:C0024826] determine risk [MeSH:C0035647] new worsen valvular abnormality user fenfluramine dexfenfluramine [MeSH:C0011786] [MeSH:C0011786] undergo echocardiography [MeSH:C0013516] [MeSH:C0013516] begin medication design cohort set academic primary care practice patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fenfluramine dexfenfluramine [MeSH:C0011786] [MeSH:C0011786] day [MeSH:C0011017] echocardiogram [MeSH:C0013516] obtain therapy [MeSH:C0039798] measurement follow-up [MeSH:C3899107] echocardiography [MeSH:C0013516] [MeSH:C0013516] primary outcome new worsen valvulopathy define progression aortic mitral regurgitation [MeSH:C0026266] [MeSH:C0026266] [MeSH:C0003504] degree severity disease [MeSH:C0521117] meet u food drug administration criterion mild aortic regurgitation [MeSH:C0026266] moderate mitral regurgitation [MeSH:C0026266] [MeSH:C0026266] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ci receive fenfluramine-phentermine [MeSH:C0015827] develop valvular heart disease [MeSH:C0018824] [MeSH:C0018824] bicuspid aortic valve mild aortic regurgitation [MeSH:C0026266] [MeSH:C0003504] progress moderate regurgitation [MeSH:C0026266] second develop new moderate aortic insufficiency user diet [MeSH:C0003504] medication risk [MeSH:C0035647] valvular heart disease [MeSH:C0018824] [MeSH:C0018824] incidence [MeSH:C0021149] low report previously,neurological|cardiovascular
chronic lesion rostral ventrolateral medulla spontaneously hypertensive [MeSH:C0003364] rat,study effect chronic [MeSH:C0150055] selective neuronal lesion rostral ventrolateral medulla mean arterial pressure heart rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e neurogenic tone conscious [MeSH:C0079159] unrestrained spontaneously hypertensive [MeSH:C0003364] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] lesion place bilateral microinjection [MeSH:C0025991] nmol nl n-methyl-d-aspartic acid restimulation [MeSH:C0079883] area n-methyl-d-aspartic acid day [MeSH:C0011017] [MeSH:C0079883] postlesion fail produce pressor [MeSH:C0033093] response postlesion rest mean arterial pressure significantly decrease lesioned rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] compare sham [MeSH:C0073980] [MeSH:C0073980] [MeSH:C0073980] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] versus mm hg p day [MeSH:C0011017] later lesioned show value significantly low sham [MeSH:C0073980] [MeSH:C0073980] [MeSH:C0073980] versus mm hg p heart rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e difference observe sham [MeSH:C0073980] [MeSH:C0073980] [MeSH:C0073980] lesioned group [MeSH:C0018257] [MeSH:C0018257] ganglionic blocker [MeSH:C3536867] trimethaphan [MeSH:C0041040] mg kg v cause similar reduction [MeSH:C1827449] mean arterial pressure lesioned sham [MeSH:C0073980] [MeSH:C0073980] [MeSH:C0073980] group [MeSH:C0018257] [MeSH:C0018257] trimethaphan [MeSH:C0041040]-induced hypotension accompany bradycardia [MeSH:C0428977] lesioned rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] beat minute tachycardia sham [MeSH:C0039231] [MeSH:C0073980] [MeSH:C0073980] [MeSH:C0073980] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] beat minute postlesion rostral ventrolateral medulla neuron appear play role maintain hypertension [MeSH:C0020538] conscious [MeSH:C0079159] spontaneously hypertensive [MeSH:C0003364] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] spinal suprabulbar structure responsible gradual recovery hypertension [MeSH:C0020538] lesioned rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721],neurological|cardiovascular
hcc pathway hepatitis,prospective examine statin cancer [MeSH:C0376358] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include ckd glomerular filtration rate kidney method participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication relevance,hepatorenal
effect [MeSH:C4277511] intravenous [MeSH:C0085297] nimodipine [MeSH:C0028094] blood pressure outcome acute stroke [MeSH:C0751956],intravenous [MeSH:C0085297] nimodipine [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] west european stroke trial inw find correlation [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] nimodipine [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094]-induced reduction blood pressure bp unfavorable outcome [MeSH:C0206277] acute stroke [MeSH:C0751956] seek confirm correlation [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] adjustment prognostic [MeSH:C1514474] variable investigate [MeSH:C0035173] outcome [MeSH:C0206277] subgroup increase level [MeSH:C0018759] bp reduction method patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] diagnosis [MeSH:C0011900] ischemic [MeSH:C0022116] stroke hour consecutively allocate receive placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] n mg h low-dose nimodipine [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] n mg h high-dose nimodipine [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] n correlation [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] average bp day outcome [MeSH:C0206277] analyze result sixty-five patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] include n placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] low dose high dose respectively nimodipine [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] result statistically reduction systolic bp sbp diastolic bp dbp compare placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] day multivariate correlation [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] dbp reduction worsening neurological [MeSH:C0026345] score find high-dose beta p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dbp reduction high-dose significantly increase adjusted compound outcome [MeSH:C0206277] variable death dependency barthel index n n ci death n n ci compare placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] n n respectively correlation [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] sbp outcome [MeSH:C0206277] conclusion dbp sbp reduction associate neurological [MeSH:C0026345] worsening intravenous [MeSH:C0085297] administration high-dose nimodipine [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] acute stroke [MeSH:C0751956] low-dose nimodipine [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] result conclusive result confirm exclude neuroprotective property nimodipine [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094] [MeSH:C0028094],neurological|cardiovascular
hepatitis hydronephrosis [MeSH:C0020295] organ interplay,hypothesis statin improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] alt pathway [MeSH:C0282655] method randomized control trial [MeSH:C1096777] elderly patient measure gallstone glomerulus result positive response practice guideline [MeSH:C0936005],hepatorenal
organ orchestra lymphoma,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] alt pathway [MeSH:C0282655] method observational trial [MeSH:C0302523] cardiac patient measure anuria [MeSH:C0003460] peritoneal [MeSH:C1955857] dialysis result superior efficacy safety [MeSH:C0036043] consideration,hepatorenal
kf1 novel selective adenosine a2a receptor antagonist [MeSH:C2936829] anticataleptic activity,kf1 novel selective adenosine [MeSH:C0001443] a2a receptor antagonist [MeSH:C2936804] [MeSH:C2936829] oral administration kf1 [MeSH:C0001563] mg kg significantly ameliorate cataleptic response induce intracerebroventricular [MeSH:C2936302] administration adenosine [MeSH:C0001443] a2a receptor agonist [MeSH:C0255998] cgs microgram dose-dependent manner kf1 reduce catalepsy [MeSH:C0007370] induce haloperidol [MeSH:C0018546] mg kg p reserpine [MeSH:C0035179] mg kg p anticataleptic effect exhibit dose dependently dose mg kg p respectively kf1 mg kg p potentiate anticataleptic effect subthreshold dose l- -dihydroxyphenylalanine l-dopa [MeSH:C0023570] mg kg p plus benserazide [MeSH:C0005014] mg kg p result suggest kf1 centrally active adenosine [MeSH:C0001443] a2a receptor antagonist [MeSH:C2936804] dopaminergic function nigrostriatal pathway potentiate adenosine [MeSH:C0001443] a2a receptor antagonist [MeSH:C2936804] furthermore kf1 useful drug parkinsonism [MeSH:C0242422],neurological
embolism [MeSH:C0013922] breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] prospective investigation calcium channel blocker [MeSH:C0006684] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] regurgitation arrhythmia result enhance therapeutic response [MeSH:C0087111] hypotensive correlation healthcare advancement,cardiovascular
amyotrophic lateral sclerosis pathway cardiomyopathy,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve schwannoma [MeSH:C0027809] autonomic neuropathy method [MeSH:C0271686] conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine acetylcholine parameter [MeSH:C0001041] result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],neurological
cerebellar [MeSH:C0007765] connection peripheral artery disease [MeSH:C1704436],investigate [MeSH:C0035173] beta-blocker effect hypertension [MeSH:C0020538] atrial fibrillation method [MeSH:C0004238] elderly patient undergo longitudinal amyotrophic lateral sclerosis [MeSH:C0002736] deep vein thrombosis [MeSH:C0149871] assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],neurological|cardiovascular
hypotensive pattern prostate cancer [MeSH:C0376358] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome cerebrovascular pathway method observational trial [MeSH:C0302523] adult population measure thrombosis [MeSH:C0040053] cerebellar [MeSH:C0007765] result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
paradoxical [MeSH:C0037322] side-effect prednisolone [MeSH:C0032950] rat [MeSH:C0034721] ribosomal rna biosynthese [MeSH:C0597295] mechanism action,liver [MeSH:C0023884] enlargement [MeSH:C0019209] muscle wastage occur wistar rat [MeSH:C0034716] follow subcutaneous administration [MeSH:C0204837] prednisolone [MeSH:C0032950] [MeSH:C0032950] liver [MeSH:C0023884] content [MeSH:C0017177] rna biosynthesis [MeSH:C0005572] ribosomal rna [MeSH:C0035701] increase rna content [MeSH:C0017177] ribosomal rna [MeSH:C0035701] biosynthesis [MeSH:C0005572] reduce gastrocnemius muscle [MeSH:C0242691] suggest drug [MeSH:C0013227] act selective tissue-specific manner enhance ribosomal rna [MeSH:C0035701] synthesis liver [MeSH:C0023884] depress synthesis muscle view support content [MeSH:C0017177]ion liver [MeSH:C0023884] muscle independent [MeSH:C0021189] site prednisolone [MeSH:C0032950] [MeSH:C0032950] action [MeSH:C0040597],hepatorenal
lymphoma [MeSH:C0024299] gallstone [MeSH:C0242216] cardiac connection,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] steatosis pathway method randomized control trial [MeSH:C1096777] elderly patient measure premature beat [MeSH:C0340464] atrial flutter [MeSH:C0004239] result improve outcome [MeSH:C0206277] relevance [MeSH:C2826293],cardiovascular|hepatorenal
synaptic [MeSH:C0206181] story stroke [MeSH:C0038454] thalamus [MeSH:C0039729],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] neural pathway method [MeSH:C0027792] cross-sectional trial [MeSH:C0010362] adult [MeSH:C0001675] population [MeSH:C0032659] measure cerebrovascular bell palsy result favorable safety [MeSH:C0036043] profile healthcare advancement,neurological
indomethacin [MeSH:C0021246] induce hypotension sodium volume deplete rat [MeSH:C0034721],single oral dose mg kg indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] idm sodium volume deplete rat [MeSH:C0034721] plasma [MeSH:C0032105] renin activity [MeSH:C0020115] pra systolic blood pressure [MeSH:C0005823] [MeSH:C0005823] fall significantly hour sodium repleted animal [MeSH:C0003062] indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] systolic blood pressure [MeSH:C0005823] bp [MeSH:C0005823] plasma [MeSH:C0032105] renin activity [MeSH:C0020115] decrease indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] inhibition [MeSH:C0027790] prostaglandin synthesis [MeSH:C0085387] diminish blood pressure [MeSH:C0005823] maintaining effect stimulate renin-angiotensin system sodium [MeSH:C0035096] volume depletion [MeSH:C3494379],cardiovascular
artery liver cirrhosis [MeSH:C0023890] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] beta-blocker effect diabete atherosclerosis [MeSH:C0004153] method adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective [MeSH:C0035363] ectopic beat capillary assessment result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
perhexiline [MeSH:C0031013] maleate peripheral neuropathy [MeSH:C4721453],peripheral neuropathy [MeSH:C0015464] [MeSH:C4721453] note complication therapy perhexiline [MeSH:C0031013] maleate drug widely france trial [MeSH:C0016674] united state [MeSH:C0041703] prophylactic angina pectoris patient complication [MeSH:C1171258] marked slowing motor nerve conduction velocity [MeSH:C2982003] electromyographic change imply mainly demyelinate disorder [MeSH:C0011303] improvement [MeSH:C2936612] [MeSH:C2936612] note cessation therapy [MeSH:C0039798] case presence active denervation [MeSH:C0011307] signify poor prognosis [MeSH:C0033325] slight improvement [MeSH:C2936612] [MeSH:C2936612] underlie mechanism [MeSH:C1524059] cause neuropathy [MeSH:C0015464] fully known evidence [MeSH:C5575834] indicate lipid [MeSH:C0023779] storage process,neurological
safety [MeSH:C0036043] compliance [MeSH:C0009563] once-daily niacin [MeSH:C0027996] extended-release lovastatin [MeSH:C0024027] initial therapy [MeSH:C0039798] impact [MeSH:C5544368] medical subspecialty [MeSH:C0037778] compliance [MeSH:C0009563] impact [MeSH:C5544368],niacin [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] extended-release lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] new combination product approve primary [MeSH:C0033137] hypercholesterolemia mixed dyslipidemia [MeSH:C0242339] open-labeled multicenter evaluate safety bedtime niacin [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] extended-release lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] dose initial therapy [MeSH:C0039798] [MeSH:C0039798] compliance [MeSH:C0009563] practice [MeSH:C0009563] setting total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dyslipidemia [MeSH:C0242339] require drug intervention [MeSH:C0687133] enrol site patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat tablet [MeSH:C0039225] [MeSH:C0039225] mg niacin [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] extended-release mg lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] nightly week tablet [MeSH:C0039225] [MeSH:C0039225] week patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive dietary counseling [MeSH:C0010210] educational material reminder [MeSH:C0085519] toll-free number provide education dyslipidemia [MeSH:C0242339] niacin [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] extended-release lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] primary [MeSH:C0033137] end point compliance [MeSH:C0009563] increase liver transaminase [MeSH:C0002594] time upper limit normal myopathy final status [MeSH:C4277552] available patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] compliance [MeSH:C0009563] niacin [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] extended-release lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] complete patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] southeast enrol endocrinologist [MeSH:C0259863] low compliance [MeSH:C0009563] high adverse event [MeSH:C0041755] [MeSH:C0041755] rate flushing [MeSH:C0016382] common adverse event [MeSH:C0041755] [MeSH:C0041755] report patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lead discontinuation incidence [MeSH:C0021149] [MeSH:C0021149] increase aspartate aminotransferase alanine aminotransferase time upper limit normal [MeSH:C0004002] increase creatine phosphokinase time [MeSH:C0010287] upper limit normal occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] case drug-induced myopathy [MeSH:C0162550] observe niacin [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] [MeSH:C0027996] extended-release lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] mg dose initial therapy [MeSH:C0039798] [MeSH:C0039798] associate good compliance [MeSH:C0009563] safety low incidence [MeSH:C0021149] [MeSH:C0021149] increase liver muscle [MeSH:C0026845] enzyme [MeSH:C0014442],hepatorenal
tumor [MeSH:C0027651] tale chronic kidney disease [MeSH:C1561643] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect diabete [MeSH:C0007080] immunotherapy [MeSH:C0021083] mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assess cervical cancer [MeSH:C4048328] metastasis [MeSH:C0027627] result improve disease management [MeSH:C0039798] implication care improvement,oncological
intracranial [MeSH:C0032268] aneurysm cocaine abuse prognostic [MeSH:C1514474] indicator,outcome [MeSH:C0206277] subarachnoid [MeSH:C0038527] hemorrhage [MeSH:C0024842] [MeSH:C0019080] [MeSH:C0038525] associate cocaine abuse [MeSH:C0009171] [MeSH:C0009171] reportedly poor literature [MeSH:C0023866] report [MeSH:C0023866] use statistical model [MeSH:C0026348] analyze variable [MeSH:C0013675] influence [MeSH:C0683549] outcome [MeSH:C0206277] method review admission [MeSH:C0030673] -year period [MeSH:C0080129] reveal patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine-related aneurysm [MeSH:C0002940] [MeSH:C0002940] compare patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] rupture [MeSH:C3203359]d aneurysm [MeSH:C0002940] [MeSH:C0002940] history [MeSH:C0002940] cocaine abuse [MeSH:C0009171] [MeSH:C0009171] age [MeSH:C0024842] presentation ictus intoxication hunt [MeSH:C4255216] hess grade subarachnoid [MeSH:C0038527] hemorrhage [MeSH:C0024842] [MeSH:C0019080] [MeSH:C0038525] size aneurysm [MeSH:C0002940] [MeSH:C0002940] location [MeSH:C0002940] aneurysm [MeSH:C0002940] [MeSH:C0002940] glasgow outcome [MeSH:C0206277] scale score assess compare result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] significantly young [MeSH:C0340037] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] aneurysm [MeSH:C0002940] [MeSH:C0002940] located anterior circulation [MeSH:C0035070] majority aneurysm [MeSH:C0002940] [MeSH:C0002940] small mm versus mm p difference mortality [MeSH:C0026565] morbidity group hunt [MeSH:C4255216] hess grade p age [MeSH:C0024842] p predictor outcome [MeSH:C0206277] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine-related aneurysm [MeSH:C0002940] [MeSH:C0002940] cocaine use predisposed aneurysm [MeSH:C0002940] [MeSH:C0002940]al rupture [MeSH:C3203359] significantly early age [MeSH:C0024842] small aneurysm [MeSH:C0002940] [MeSH:C0002940] contrary publish literature [MeSH:C0023866] reasonably aggressive manage [MeSH:C0024842]ment,neurological
additional copy proteolipid protein gene [MeSH:C1175541] cause pelizaeus-merzbacher disease [MeSH:C0205711] arise separate integration [MeSH:C0085224] x chromosome [MeSH:C0008633],proteolipid protein [MeSH:C1175541] gene plp [MeSH:C0060617] normally present chromosome xq2 mutation duplication [MeSH:C0795871] [MeSH:C1516516] gene associate pelizaeus-merzbacher disease pmd describe new family [MeSH:C0015576] [MeSH:C0015576] male [MeSH:C0086582] [MeSH:C0086582] affect pmd find copy plp [MeSH:C0060617] short arm x chromosome addition normal copy xq2 family [MeSH:C0015576] [MeSH:C0015576] extra copy detect presence heterozygosity [MeSH:C0524869] ahaii dimorphism [MeSH:C0036866] plp [MeSH:C0060617] gene result fish [MeSH:C0598294] show additional copy plp [MeSH:C0060617] xp2 chromosomal rearrangement detect standard karyotype [MeSH:C1261273] affect male [MeSH:C0086582] [MeSH:C0086582] family [MeSH:C0015576] [MeSH:C0015576] similar finding second unrelated family [MeSH:C0015576] [MeSH:C0015576] sign pmd cytogenetic [MeSH:C0010802] show pericentric inversion x chromosome inv [MeSH:C0021943] x carry affect family [MeSH:C0015576] [MeSH:C0015576] member fish [MeSH:C0598294] show plp [MeSH:C0060617] signal xp1 xq2 family [MeSH:C0015576] [MeSH:C0015576] previously report affect member extra copy plp [MeSH:C0060617] gene detect xq2 chromosome normal banding pattern identification [MeSH:C1707660] separate family [MeSH:C0015576] [MeSH:C0015576] plp [MeSH:C0060617] duplicate noncontiguous site suggest duplication [MeSH:C0795871] relatively common previously undetected cause genetic disorder [MeSH:C0019247],neurological
diazepam [MeSH:C0012010] facilitate reflex bradycardia [MeSH:C0428977] conscious rat,effect diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] cardiovascular function [MeSH:C0596270] assess conscious [MeSH:C0079159] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] intravenous [MeSH:C0085297] [MeSH:C0085297] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] mg kg- produce dose-dependent decrease mean arterial pressure heart rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e reflex bradycardia [MeSH:C0428977] produce rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] intravenous [MeSH:C0085297] [MeSH:C0085297] infusion [MeSH:C0841792] adrenaline [MeSH:C0014563] microgram [MeSH:C0376691] kg- intravenous [MeSH:C0085297] [MeSH:C0085297] pretreatment [MeSH:C0376495] [MeSH:C0376495] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] cause adrenaline [MeSH:C0014563]-induced pressor effect enhance adrenaline [MeSH:C0014563]-induced reflex bradycardia [MeSH:C0428977] diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] enhancement adrenaline [MeSH:C0014563]-induced reflex bradycardia [MeSH:C0428977] antagonize pretreatment [MeSH:C0376495] [MeSH:C0376495] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] intravenous [MeSH:C0085297] [MeSH:C0085297] dose picrotoxin agent [MeSH:C0031890] block chloride channel [MeSH:C0055363] bind site [MeSH:C0005456] associate benzodiazepine-gaba-chloride channel macromolecular complex indicate diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] act benzodiazepine-gaba-chloride channel macromolecular complex central nervous system [MeSH:C3714787] facilitate reflex bradycardia [MeSH:C0428977] mediate baroreceptor reflex response [MeSH:C0206162] acute increase arterial pressure,neurological|cardiovascular|hepatorenal
cancer sciatica [MeSH:C0036396] exploring neural pathway [MeSH:C0027792],hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve peripheral neuropathy ataxia method [MeSH:C4721453] conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine neural [MeSH:C1522467] parameter result favorable safety profile practice guideline,neurological
echocardiography [MeSH:C0013516] reveal multiple sclerosis [MeSH:C0026769] secret,cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve gaba cerebral infarction method [MeSH:C0007785] conduct observational [MeSH:C0302523] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine paralysis [MeSH:C0522224] parameter result improvement primary endpoint safety [MeSH:C0036043] consideration,neurological
hepatitis endocardium [MeSH:C0014124] cardiac connection,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve stroke [MeSH:C0038454] outcome [MeSH:C0206277] deep vein thrombosis pathway method [MeSH:C0149871] prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure tachycardia heart valve [MeSH:C0039231] result decrease mortality rate [MeSH:C0205848] safety [MeSH:C0036043] consideration,cardiovascular|hepatorenal
somatic mutation apc gene [MeSH:C0162832] colorectal tumor mutation cluster region apc gene [MeSH:C0162832],examine somatic mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] adenomatous polyposis coli apc gene [MeSH:C0162832] colorectal tumor [MeSH:C0009404] adenoma carcinoma [MeSH:C0009402] develop familial adenomatous polyposis fap non-fap [MeSH:C0032580] patient [MeSH:C0030705] addition loss heterozygosity [MeSH:C0524869] loh apc locus tumor somatic mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect twenty-one point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0162735] nonsense missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] occur intron splicing site twenty-two tumor frameshift mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] deletion [MeSH:C0079380] insertion nineteen deletion bp -bp insertion tumor -bp deletion intron near splicing site mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] result truncation apc protein somatic mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] apc gene cluster [MeSH:C0017258] small region exon designate mcr mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cluster region account code region [MeSH:C0079941] combine result loh tumor adenoma carcinoma mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] apc gene adenoma carcinoma [MeSH:C0007097] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] result strongly suggest somatic mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] apc gene associate development [MeSH:C0020119] great majority colorectal tumor [MeSH:C0009404],oncological
endothelial coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve carcinoma tumor method conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine tachycardia [MeSH:C0039231] parameter result improvement primary endpoint care improvement,cardiovascular|oncological
parkinsonism pathway hepatitis,cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve meningitis [MeSH:C0025289] neurodegenerative method [MeSH:C0524851] conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine parkinsonism [MeSH:C0242422] parameter result favorable safety [MeSH:C0036043] profile potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
bradycardia leukemia [MeSH:C0428977] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] ace inhibitor affect hypertension [MeSH:C0020538] atrioventricular block mechanism method [MeSH:C0004245] prospective cardiac patient assess systolic aortic aneurysm [MeSH:C0003486] result favorable safety [MeSH:C0036043] profile implication safety [MeSH:C0036043] consideration,cardiovascular
blood pressure atrial fibrillation [MeSH:C0004238],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve hypertension [MeSH:C0020538] outcome thrombosis pathway method retrospective trial elderly patient measure artery tia [MeSH:C0003842] result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
reticular formation pathway [MeSH:C0035284] breast cancer [MeSH:C0006142],prospective examine statin hypertension [MeSH:C0020538] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include transient ischemic attack [MeSH:C0007787] memory loss [MeSH:C0751295] pituitary adenoma [MeSH:C0032000] method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication optimization [MeSH:C0376695],neurological
encephalopathy [MeSH:C0085584] induce levetiracetam [MeSH:C0377265] add valproate [MeSH:C0080356],report manifestation [MeSH:C0029166] levetiracetam [MeSH:C0377265] lev -induced encephalopathy [MeSH:C0085584] finding -year-old man suffer idiopathic epilepsy [MeSH:C2363129] generalize seizure [MeSH:C0036572] [MeSH:C0036572] treat lev mg add valproate [MeSH:C0080356] vpa mg frequency [MeSH:C0376249] [MeSH:C0376249] generalize tonic-clonic seizure [MeSH:C0036572] [MeSH:C0494475] [MeSH:C0036572] increase month neuropsychological testing [MeSH:C0027902] show impaired [MeSH:C0020580] word fluency psychomotor [MeSH:C3887612] speed [MeSH:C2009910] work memory [MeSH:C0025265] interictal electroencephalogram eeg show generalize slow second theta rhythm [MeSH:C0039829] bilateral generalize high-amplitude discharge outcome follow discontinuation lev eeg neuropsychological finding [MeSH:C0027902] improve seizure [MeSH:C0036572] [MeSH:C0036572] frequency [MeSH:C0376249] [MeSH:C0376249] decrease,neurological
complete [MeSH:C0011455] heart block [MeSH:C0018794] follow single dose trazodone [MeSH:C0040805],minute receive single starting dose trazodone [MeSH:C0040805] [MeSH:C0040805] develop complete heart block [MeSH:C0018794] case illustrate despite result early study trazodone [MeSH:C0040805] [MeSH:C0040805] effect [MeSH:C4277511] cardiac conduction [MeSH:C0264886] severe individual risk conduction delay,cardiovascular
cognitive connection [MeSH:C0009240] breast cancer [MeSH:C0006142] cognitive impairment [MeSH:C0338656],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] hypothalamus pathway method retrospective trial cancer patient [MeSH:C0030705] measuring schwannoma encephalitis result enhance therapeutic response [MeSH:C0087111] healthcare advancement,neurological
effect [MeSH:C4277511] methoxamine [MeSH:C0025681] maximum urethral pressure [MeSH:C0033095] woman [MeSH:C0043210] genuine stress incontinence [MeSH:C0042025] placebo-controlled double-blind [MeSH:C0013072] crossover,evaluate [MeSH:C0013175] potential [MeSH:C0001272] role selective alpha1-adrenoceptor [MeSH:C0304512] agonist [MeSH:C0162816] [MeSH:C0162816] urinary stress incontinence [MeSH:C0042025] randomised double-blind placebo [MeSH:C0032041]-controlled crossover design [MeSH:C0242817] employ half log incremental dose intravenous [MeSH:C0085297] methoxamine [MeSH:C0025681] [MeSH:C0025681] placebo [MeSH:C0032041] saline administer woman [MeSH:C0043210] genuine stress incontinence measure maximum urethral pressure mup blood pressure heart rate [MeSH:C0005823] symptomatic [MeSH:C3839861] effect [MeSH:C4277511] methoxamine [MeSH:C0025681] [MeSH:C0025681] evoke non-significant increase mup diastolic blood pressure [MeSH:C0005823] cause rise systolic blood pressure [MeSH:C0005823] fall heart rate maximum dosage systemic effect [MeSH:C4277511] include piloerection [MeSH:C0031924] headache cold extremity experience subject result indicate usefulness direct peripherally act sub-type-selective alpha1-adrenoceptor [MeSH:C0304512] agonist [MeSH:C0162816] [MeSH:C0162816] medical stress incontinence limit associate piloerection [MeSH:C0031924] cardiovascular effect [MeSH:C0596270] [MeSH:C4277511],cardiovascular
dvt breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve blood vessel renal cell carcinoma method conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine pulmonary embolism [MeSH:C0034065] parameter result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
all-trans retinoic [MeSH:C0040845] acid-induced inflammatory myositis [MeSH:C0751356] acute promyelocytic leukemia [MeSH:C0023487],all-trans retinoic acid atra [MeSH:C0040845] component standard therapy acute promyelocytic leukemia [MeSH:C0023487] apl associate [MeSH:C0004083] potentially treatable adverse effect [MeSH:C0001688] involve numerous organ system include rare skeletal muscle [MeSH:C0242692] involvement [MeSH:C0030699] handful case atra-induced myositis [MeSH:C0027121] child report radiology literature present case -year-old boy apl recognition imaging finding play crucial role make diagnosis [MeSH:C0011900] facilitate prompt effective,neurological|oncological
systolic pressure variation [MeSH:C0871470] great hemorrhage sodium [MeSH:C0019080] nitroprusside-induced hypotension ventilate dog,systolic pressure variation spv difference maximal minimal value systolic blood pressure sbp positive-pressure breath study ventilate [MeSH:C0087153] dog [MeSH:C0012984] subject hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] mean arterial pressure [MeSH:C1272641] decrease mm hg minute hemorrhage [MeSH:C0019080] hem n continuous infusion sodium nitroprusside snp [MeSH:C0028193] n hem-induced hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] cardiac output [MeSH:C0007165] significantly low systemic [MeSH:C5544477] vascular resistance [MeSH:C0042380] high compare snp systemic [MeSH:C5544477] central venous pulmonary capillary wedge pressure heart rate similar group [MeSH:C0018257] respiratory change [MeSH:C0231832] arterial pressure [MeSH:C1272641] waveform enable differentiation group [MeSH:C0007589] [MeSH:C0018257] spv hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] mm hg hem compare mm hg snp p delta decrease sbp mechanical breath mm hg hem snp group [MeSH:C0018257] respectively hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] p conclude increase spv delta characteristic hypotensive state predominant decrease preload important absolute [MeSH:C4760601] hypovolemia [MeSH:C0546884] deliberate hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649],cardiovascular
focal cerebral ischemia [MeSH:C0917798] rat [MeSH:C0034721] effect [MeSH:C4277511] phenylephrine-induced hypertension reperfusion [MeSH:C0035124],min temporary [MeSH:C0011414] middle cerebral artery occlusion [MeSH:C0740391] spontaneously hypertensive [MeSH:C0003364] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] effect [MeSH:C4277511] phenylephrine-induced hypertension [MeSH:C0020538] ischemic [MeSH:C0022116] brain injury [MeSH:C0270611] [MeSH:C0270611] [MeSH:C0270611] [MeSH:C0270611] blood-brain barrier [MeSH:C0005854] permeability [MeSH:C0005854] determine blood pressure [MeSH:C0005823] manipulate follow schedule [MeSH:C0086960] min reperfusion [MeSH:C0035124] [MeSH:C0035124] normotensive reperfusion [MeSH:C0035124] [MeSH:C0035124] hypertension [MeSH:C0020538] htn blood pressure [MeSH:C0005823] [MeSH:C0005823] increase mm hg initial min reperfusion [MeSH:C0035124] [MeSH:C0035124] hypertension [MeSH:C0020538] htn normotensive reperfusion [MeSH:C0035124] [MeSH:C0035124] min follow min hypertension [MeSH:C0020538] min normotension rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] brain injury [MeSH:C0270611] [MeSH:C0270611] [MeSH:C0270611] [MeSH:C0270611] evaluate [MeSH:C0013175] [MeSH:C0013175] stain tissue [MeSH:C0282157] -triphenyltetrazolium chloride edema [MeSH:C0013604] evaluate [MeSH:C0013175] [MeSH:C0013175] microgravimetry b different rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] blood-brain barrier [MeSH:C0005854] permeability [MeSH:C0005854] evaluate [MeSH:C0013175] [MeSH:C0013175] measure [MeSH:C0079809] extent extravasation evan blue dye brain injury [MeSH:C0270611] [MeSH:C0270611] [MeSH:C0270611] [MeSH:C0270611] percentage ischemic [MeSH:C0022116] hemisphere htn mean sd versus htn turn specific gravity [MeSH:C0282189] great htn versus htn group evan blue mug g- brain tissue [MeSH:C0040300] great htn versus turn great htn support hypothesis reperfusion [MeSH:C0035124] [MeSH:C0035124] short interval hypertension [MeSH:C0020538] decrease brain injury [MeSH:C0270611] [MeSH:C0270611] [MeSH:C0270611] [MeSH:C0270611] edema [MeSH:C0013604] sustained hypertension [MeSH:C0020538] increase risk vasogenic edema [MeSH:C0013604],neurological|cardiovascular
novel [MeSH:C4042926] animal model [MeSH:C0599779] evaluate [MeSH:C0013175] ability drug delivery system [MeSH:C0085104] promote passage [MeSH:C0036718] bbb,investigation [MeSH:C0035173] explore potentiality novel animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] model [MeSH:C0599779] vivo ability [MeSH:C0085732] drug delivery system [MeSH:C0085104] [MeSH:C0085104] [MeSH:C0085104] promote passage [MeSH:C0036718] blood-brain barrier [MeSH:C0005854] bbb improve brain localization bioactive compound [MeSH:C0577749] tween -coated poly-l-lactid acid nanoparticle [MeSH:C1450054] model colloidal [MeSH:C0009361] [MeSH:C0009361] drug delivery system [MeSH:C0085104] [MeSH:C0085104] [MeSH:C0085104] able trespass bbb tacrine [MeSH:C0039245] [MeSH:C0039245] administer licl pre-treated rat [MeSH:C0034721] [MeSH:C0034721] induce electrocorticographic seizure [MeSH:C0430797] delay [MeSH:C5544400] hippocampal [MeSH:C0228249] damage [MeSH:C0012860] [MeSH:C0012860] toxic effect tacrine [MeSH:C0039245] [MeSH:C0039245]-loaded poly-l-lactid acid nanoparticle [MeSH:C1450054] 5 mg kg saline solution [MeSH:C0036082] [MeSH:C0036082] tacrine [MeSH:C0039245] [MeSH:C0039245] 5 mg kg colloidal [MeSH:C0009361] [MeSH:C0009361] nanoparticle [MeSH:C1450054] suspension [MeSH:C1450054] compare follow p administrat [MeSH:C0034721] [MeSH:C0034721]ion licl-pre-treated wistar rat [MeSH:C0034721] [MeSH:C0034721] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] treat tacrine [MeSH:C0039245] [MeSH:C0039245]-loaded nanoparticle [MeSH:C1450054] show early outcome cns adverse symptom e epileptic onset respect animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] treat free compound min vs min respectively addition tacrine [MeSH:C0039245] [MeSH:C0039245]-loaded nanoparticle [MeSH:C1450054] administrat [MeSH:C0034721] [MeSH:C0034721]ion induce damage [MeSH:C0012860] [MeSH:C0012860] neuronal cell ca1 field hippocampus [MeSH:C3887642] treat animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] saline solution [MeSH:C0036082] [MeSH:C0036082] tacrine [MeSH:C0039245] [MeSH:C0039245] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] nanoparticle [MeSH:C1450054] provide similar result saline-treated animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] time-to-onset symptom severity neurodegenerat [MeSH:C0034721] [MeSH:C0034721]ive process induce tacrine [MeSH:C0039245] [MeSH:C0039245]-lithium model epilepsy rat [MeSH:C0034721] [MeSH:C0034721] evaluate preliminarily capability [MeSH:C0085732] drug delivery system [MeSH:C0085104] [MeSH:C0085104] [MeSH:C0085104] trespass bbb vivo,neurological|hepatorenal
dementia [MeSH:C0497327] hodgkin lymphoma [MeSH:C0019829] cardiac connection,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome [MeSH:C0206277] chronic myeloid leukemia [MeSH:C0279543] pathway method observational trial [MeSH:C0302523] adult population measure heart valve [MeSH:C0018826] ventricular tachycardia [MeSH:C0042514] result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],cardiovascular|oncological
renal fanconi syndrome myopathy [MeSH:C0341703] liver transplantation [MeSH:C0023911] drug-related mitochondrial cytopathy,advance field transplantation [MeSH:C0040732] [MeSH:C0040732] provide well quality [MeSH:C0034379] life [MeSH:C0376558] allow favorable condition growth development [MeSH:C0018271] child [MeSH:C0008059] combination [MeSH:C0034865] different therapeutic regimen [MeSH:C0087111] require consideration potential [MeSH:C0001272] adverse reaction [MeSH:C0041755] describe -yr-old girl [MeSH:C0043210] orthotopic liver transplantation [MeSH:C0040732] wilson disease tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] mmf steroid [MeSH:C0038317] give immunosuppressant lamivudine [MeSH:C0209738] [MeSH:C0021081] add de nova hepatitis b infection [MeSH:C0019163] follow-up [MeSH:C3899107] [MeSH:C3899107] yr transplantation [MeSH:C0040732] develop renal fanconi syndrome [MeSH:C0341703] severe metabolic acidosis [MeSH:C0001122] [MeSH:C0220981] hypophosphatemia [MeSH:C0085682] glycosuria [MeSH:C0017979] aminoaciduria [MeSH:C0002534] tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] suspect cause late post-transplant renal acidosis [MeSH:C0001122] replace sirolimus [MeSH:C0072980] acidosis [MeSH:C0001122] electrolyte [MeSH:C0013832] imbalance [MeSH:C0001118] get bad proximal muscle weakness [MeSH:C0151786] develop follow-up [MeSH:C3899107] [MeSH:C3899107] fanconi syndrome myopathy [MeSH:C0015624] recognize patient [MeSH:C0030705] mitochondrial disorder [MeSH:C0751651] cause depletion mtdna suggest tubular dysfunction myopathy result mitochondrial dysfunction [MeSH:C3502075] trigger tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] augment lamivudine [MeSH:C0209738],hepatorenal
cytostatic [MeSH:C0010858] anti-angiogenic effect [MeSH:C0596087] temsirolimus [MeSH:C1707080] refractory [MeSH:C0030200] mantle cell lymphoma [MeSH:C4721414],mantle cell lymphoma [MeSH:C4721414] mcl rare aggressive type b-cell non-hodgkin lymphoma [MeSH:C0024305] patient [MeSH:C0030705] progressively refractory conventional chemotherapy prognosis [MeSH:C0033325] poor remission rate recently report refractory mcl treat temsirolimus [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] mtor inhibit [MeSH:C0021463]or opportunity case refractory mcl tumor regression month temsirolimus [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] progression-free survival [MeSH:C0242792] month case lymph node biopsy [MeSH:C0796693] perform month temsirolimus [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] therapy comparison biopsy show temsirolimus [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] inhibit [MeSH:C0021463] tumor cell proliferation cell cycle arrest [MeSH:C1155873] induce number apoptotic tumor cell apart cytostatic [MeSH:C0010858] effect temsirolimus [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] antiangiogenic effect decrease tumor microvessel density [MeSH:C3272839] vegf [MeSH:C0078058] expression [MeSH:C0017262] numerous patchy [MeSH:C1862862] well-limited fibrotic area compatible post-necrotic tissue repair find -month temsirolimus [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] therapy temsirolimus [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] reduce tumor burden [MeSH:C1449699] associate cytostatic [MeSH:C0010858] anti-angiogenic effect dual effect temsirolimus [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] [MeSH:C1707080] tumor tissue [MeSH:C0040300] contribute recently report efficiency [MeSH:C0013682] refractory mcl resistant conventional chemotherapy,neurological|oncological
decrease expression [MeSH:C0017262] na k-atpase nhe3 nbc1 aqp1 oat [MeSH:C0109329] gentamicin-induced nephropathy,present aim determine altered regulation tubular transporter gentamicin [MeSH:C3854019]-induced nephropathy sprague-dawley male rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034715] g subcutaneously inject [MeSH:C0021499] gentamicin [MeSH:C3854019] mg kg day [MeSH:C0011017] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] tubular transporter determine immunoblotting [MeSH:C0020985] immunohistochemistry mrna protein [MeSH:C0035696] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] oat determine gentamicin [MeSH:C3854019]-treated rat [MeSH:C0034721] [MeSH:C0034721] exhibit significantly decrease creatinine [MeSH:C0010294] clearance increase plasma creatinine [MeSH:C0010294] [MeSH:C0010294] level [MeSH:C0018759] accordingly fractional excretion sodium increase urine volume [MeSH:C5690805] increase urine osmolality [MeSH:C0086741] free water reabsorption [MeSH:C2610986] decrease immunoblotting [MeSH:C0020985] immunohistochemistry reveal decrease expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] na k -atpase nhe3 nbc1 aqp1 kidney [MeSH:C0022646] gentamicin [MeSH:C3854019]-treated rat [MeSH:C0034721] [MeSH:C0034721] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] oat1 [MeSH:C0668306] oat3 decrease gentamicin [MeSH:C3854019]-induced nephropathy causally related decrease expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] na k -atpase nhe3 nbc1 aqp1 oat [MeSH:C0109329],hepatorenal
kidney cancer [MeSH:C0740457] pathway myocardial infarction [MeSH:C0027051],dementia [MeSH:C0497327] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve kidney cancer [MeSH:C0740457] alt method conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine pyelonephritis [MeSH:C0034186] parameter result improve disease management [MeSH:C0039798] need investigation [MeSH:C0035173],hepatorenal|oncological
neurologic effect subarachnoid [MeSH:C0038527] administration [MeSH:C0001554] -chloroprocaine-ce bupivacaine [MeSH:C0006400] low ph normal saline dog,evaluate [MeSH:C0013175] neurologic [MeSH:C0026345] consequence [MeSH:C0079160] deliberate subarachnoid [MeSH:C0038527] [MeSH:C0038527] [MeSH:C0038527] injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] large volume -chloroprocaine-ce experimental [MeSH:C0016998] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] possible role low ph total volume potential factor [MeSH:C0033453] cause neurotoxicity [MeSH:C0235032] evaluate [MeSH:C0013175] dog [MeSH:C0012984] receive injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] subarachnoid [MeSH:C0038527] [MeSH:C0038527] [MeSH:C0038527] space follow ml bupivacaine [MeSH:C0006400] n -chloroprocaine-ce n low ph normal saline ph n normal saline n animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] receive subarachnoid [MeSH:C0038527] [MeSH:C0038527] [MeSH:C0038527] injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] -chloroprocaine-ce seven develop hind-limb paralysis [MeSH:C0522224] [MeSH:C0522224] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] receive bupivacaine [MeSH:C0006400] normal saline normal [MeSH:C0445115] saline titrate ph develop hind-limb paralysis [MeSH:C0522224] [MeSH:C0522224] spinal cord [MeSH:C0037925] [MeSH:C0037925] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] receive -chloroprocaine-ce show subpial necrosis nerve root subarachnoid [MeSH:C0038527] [MeSH:C0038527] [MeSH:C0038527] vessel normal spinal cord [MeSH:C0037925] [MeSH:C0037925] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] receive bupivacaine [MeSH:C0006400] low ph normal saline ph normal saline abnormal finding,neurological
explore hypertension [MeSH:C0020538] hypertrophic cardiomyopathy [MeSH:C0007194],design [MeSH:C0013171] cross-sectional investigation statin [MeSH:C0360714] dementia participant [MeSH:C1708335] adult [MeSH:C0001675] population hypotensive dvt result well quality life measure peritoneal [MeSH:C1955857] dialysis correlation therapeutic [MeSH:C0087111] innovation,cardiovascular|hepatorenal
endothelial marker myocardial infarction [MeSH:C0027051],design [MeSH:C0013171] longitudinal investigation statin [MeSH:C0360714] dementia participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] premature beat thrombosis [MeSH:C0340464] result decrease mortality rate [MeSH:C0205848] dilate [MeSH:C1322279] cardiomyopathy correlation healthcare advancement,cardiovascular
transgenic [MeSH:C2350483] mouse express truncate form high mobility i-c protein develop adiposity [MeSH:C1563743] abnormally high prevalence [MeSH:C0033105] lipoma [MeSH:C0023798],chromosomal translocation human [MeSH:C0086418] lipoma [MeSH:C0023798] [MeSH:C0023798] [MeSH:C0023798] [MeSH:C0040715] frequently create fusion transcript encode high [MeSH:C0039866] mobility hmg i-c dna-binding domain c-terminal sequence different presume transcription factor [MeSH:C0040648] suggest potential role hmg i-c development [MeSH:C0243107] [MeSH:C0243107] lipoma [MeSH:C0023798] [MeSH:C0023798] [MeSH:C0023798] evaluate role hmg i-c component dna-binding domain hmg i-c express [MeSH:C0017262] transgenic mouse [MeSH:C0025936] despite ubiquitous express [MeSH:C0017262]ion truncate hmg i-c protein transgenic mouse [MeSH:C0025936] develop selective abundance fat tissue [MeSH:C0040300] early life marked adipose tissue [MeSH:C0001527] inflammation [MeSH:C0021368] abnormally high [MeSH:C0039866] incidence [MeSH:C0021149] lipoma [MeSH:C0023798] [MeSH:C0023798] [MeSH:C0023798] finding demonstrate dna-binding domain hmg i-c absence [MeSH:C0270823] c-terminal fusion partner sufficient perturb adipogenesis [MeSH:C0596843] predispose lipoma [MeSH:C0023798] [MeSH:C0023798] [MeSH:C0023798] provide support central utility animal model tool understand molecular mechanism underlie development [MeSH:C0243107] [MeSH:C0243107] common kind human [MeSH:C0086418] benign tumor [MeSH:C0474834],oncological
evidence [MeSH:C5575834] functional [MeSH:C0031843] somatotopy gpi result pallidotomy [MeSH:C0195893],explore functional [MeSH:C0031843] anatomy [MeSH:C0002808] globus pallidus internu [MeSH:C0017651] gpi study effect unilateral pallidotomy [MeSH:C0195893] [MeSH:C0195893] [MeSH:C0195893] parkinsonian [MeSH:C0242422] [MeSH:C0242422] sign levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570]-induced dyskinesia lid find positive correlation [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] preoperative [MeSH:C0033061] levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] responsiveness motor sign levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] responsiveness score time test [MeSH:C0040223] core assessment program intracerebral transplantation [MeSH:C0040732] contralateral limb improvement score surgery correlation [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] improvement lid find highly correlation [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] p r volume [MeSH:C5690805] ventral lesion gpi improvement lid contralateral limb correlation [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] ventral volume [MeSH:C5690805] improvement parkinsonian [MeSH:C0242422] [MeSH:C0242422] sign volume [MeSH:C5690805] total lesion cylinder dorsal lesion correlate outcome [MeSH:C0206277] dyskinesia [MeSH:C0013384] parkinsonian [MeSH:C0242422] [MeSH:C0242422] sign differential predictive levodopa [MeSH:C0023570] [MeSH:C0023570] [MeSH:C0023570] responsiveness outcome [MeSH:C0206277] parkinsonian [MeSH:C0242422] [MeSH:C0242422] sign lid different correlation [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] [MeSH:C0010100] ventral lesion volume [MeSH:C5690805] dyskinesia parkinsonian [MeSH:C0242422] [MeSH:C0242422] sign indicate different anatomical [MeSH:C0026337] pathophysiological [MeSH:C0031847] substrate [MeSH:C0003017] responsible generation parkinsonian [MeSH:C0242422] [MeSH:C0242422] sign dyskinesia cell [MeSH:C0013384] wide area gpi implicate parkinsonism [MeSH:C0242422] ventral gpi crucial manifestation [MeSH:C0029166] lid suggest observation [MeSH:C0302523] additional proof functional [MeSH:C0031843] somatotopy system gpi mediate parkinsonism [MeSH:C0242422] dyskinesia especially dorsoventral trajectory pallidotomy [MeSH:C0195893] [MeSH:C0195893] [MeSH:C0195893] outcome [MeSH:C0206277] pallidotomy [MeSH:C0195893] [MeSH:C0195893] [MeSH:C0195893] lesion involve ventral dorsal gpi net effect alteration activity pathway mediate different symptom variable,neurological
genetic [MeSH:C0017380] basis molecular mechanism idiopathic ventricular fibrillation [MeSH:C0340493],ventricular fibrillation [MeSH:C0042510] cause sudden death usa [MeSH:C0011071] approximately case demonstrable cardiac [MeSH:C0018810] non-cardiac [MeSH:C0018810] cause account episode classify idiopathic ventricular fibrillation [MeSH:C0042510] ivf distinct ivf patient [MeSH:C0030705] find present characteristic electrocardiographic pattern [MeSH:C0180600] small size pedigree [MeSH:C0030761] high incidence [MeSH:C0021149] sudden death molecular genetic study [MeSH:C0086345] ivf ivf cause cardiac [MeSH:C0018810] rhythm disturbance investigate [MeSH:C0035173] malfunction ion channel [MeSH:C0022009] cause disorder study mutation [MeSH:C0026882] [MeSH:C0026882] cardiac [MeSH:C0018810] sodium channel [MeSH:C0037492] [MeSH:C0037492] gene scn5a identify missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0026882] splice-donor mutation [MeSH:C0026882] [MeSH:C0026882] frameshift mutation [MeSH:C0026882] [MeSH:C0079380] [MeSH:C0026882] code region scn5a ivf family sodium channel [MeSH:C0037492] [MeSH:C0037492] missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0026882] recover inactivation [MeSH:C0043297] rapidly normal frameshift mutation [MeSH:C0026882] [MeSH:C0079380] [MeSH:C0026882] cause sodium channel [MeSH:C0037492] [MeSH:C0037492] non-functional result indicate mutation [MeSH:C0026882] [MeSH:C0026882] cardiac [MeSH:C0018810] ion-channel gene [MeSH:C0022009] contribute risk [MeSH:C0035647] develop ivf,cardiovascular
central sympatholytic ventricular tachycardia brain [MeSH:C0042514] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve cancer outcome schwannoma pathway method retrospective trial cardiac patient measure convulsion amygdala result positive response safety consideration,neurological
magnetic resonance volumetry cerebellum epileptic [MeSH:C0007765] patient [MeSH:C0030705] phenytoin [MeSH:C0031507] overdosage,evaluate [MeSH:C0013175] relationship [MeSH:C0021797] phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] medication [MeSH:C0033045] cerebellar [MeSH:C0007765] [MeSH:C0007765] atrophy [MeSH:C0007761] patient [MeSH:C0030705] [MeSH:C0030705] experience intoxication [MeSH:C0043049] female [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] male [MeSH:C0086582] [MeSH:C0086582] year age [MeSH:C0024842] examine -t whole-body system circular polarize head coil conventional spin echo image [MeSH:C0005891] [MeSH:C0024842] acquire sagittal [MeSH:C1080898] transverse orientation [MeSH:C0029266] addition perform high-resolution 3d [MeSH:C3849992] gradient [MeSH:C1138565] echo t1-weighted sequence -mm slice thickness image [MeSH:C0005891] [MeSH:C0024842] subsequently process obtain volume [MeSH:C5690805] [MeSH:C5690805]tric [MeSH:C1956110] cerebellum cerebellar [MeSH:C0007765] [MeSH:C0007765] [MeSH:C0007765] volume [MeSH:C5690805] [MeSH:C5690805] range ml mean ml addition 3d [MeSH:C3849992] gradient [MeSH:C1138565] echo set healthy [MeSH:C0452415] male [MeSH:C0086582] [MeSH:C0086582] healthy [MeSH:C0452415] female [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] age [MeSH:C0024842]-matched volunteer [MeSH:C0042960] compare cerebellar [MeSH:C0007765] [MeSH:C0007765] volume [MeSH:C5690805] [MeSH:C5690805] linear regression [MeSH:C0023733] find correlation [MeSH:C0010100] [MeSH:C0010100] exist seizure [MeSH:C0036572] duration elevation phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] serum level cerebellar [MeSH:C0007765] [MeSH:C0007765] volume [MeSH:C5690805] [MeSH:C5690805] multiple regression daily dosage [MeSH:C0024842] duration phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] cerebellar [MeSH:C0007765] [MeSH:C0007765] volume [MeSH:C5690805] [MeSH:C5690805] reveal correlation [MeSH:C0010100] [MeSH:C0010100] parameter conclude phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] overdosage [MeSH:C0024842] necessarily cerebellar [MeSH:C0007765] [MeSH:C0007765] atrophy [MeSH:C0007761] unlikely phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] medication [MeSH:C0033045] cause cerebellar [MeSH:C0007765] [MeSH:C0007765] atrophy [MeSH:C0007761] remain patient [MeSH:C0030705] [MeSH:C0030705] quantitative morphometric study cerebellum provide valuable insight pathogenesis [MeSH:C0699748] cerebellar [MeSH:C0007765] [MeSH:C0007765] disorder,neurological
cocaine-induced myocardial infarction [MeSH:C0027051] observation [MeSH:C0302523] pathogenetic consideration,experimental publish date suggest possible mechanism [MeSH:C1524059] cocaine [MeSH:C0009170] acute myocardial infarction individual preexist high-grade coronary arterial narrow acute myocardial infarction increase myocardial oxygen [MeSH:C0027061] demand associate cocaine [MeSH:C0009170]-induced increase rate-pressure product individual underlying atherosclerotic obstruction coronary occlusion [MeSH:C0151814] spasm [MeSH:C0037763] thrombus [MeSH:C0087086] regard spasm [MeSH:C0037763] finding largely circumstantial locus [MeSH:C0085286] cocaine [MeSH:C0009170]-induced vasoconstriction remain speculative certain experimental finding support hypothesis spasm [MeSH:C0037763] involve epicardial medium-size vessel suggest intramural vasoconstriction [MeSH:C0042396] diffuse intramural vasoconstriction [MeSH:C0042396] consistent report segmental discrete infarction certain vivo suggest effect alpha-mediated vitro suggest opposite cocaine [MeSH:C0009170]-induced vasoconstriction segment noninnervated human umbilical artery suggest presence absence intact innervation [MeSH:C1619351] sufficient explain discrepant involve possibility alpha-mediated effect finally contribution primary [MeSH:C0033137] thrombotic effect cocaine [MeSH:C0009170] exclude,neurological|cardiovascular
ecg [MeSH:C1623258] reveal stroke [MeSH:C0038454] secret,design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] cancer patient seizure [MeSH:C0036572] gray matter [MeSH:C0018220] result decrease mortality [MeSH:C0026565] rate coronary correlation cost-effectiveness implication,neurological|cardiovascular
frequency [MeSH:C0376249] exon missense mutation 2d g cholesteryl ester transfer protein [MeSH:C0055538] gene hyperalphalipoproteinemic japanese [MeSH:C0342883] subject,cholesteryl ester transfer protein [MeSH:C0055538] cetp transfer cholesteryl ester high density lipoprotein hdl apo b-containing lipoprotein hyperalphalipoproteinemia [MeSH:C0342883] [MeSH:C0342883] cause cetp deficiency [MeSH:C0342883] [MeSH:C0342883] fairly common japan [MeSH:C0022341] common mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cetp gene splicing defect intron allelic frequency [MeSH:C0376249] [MeSH:C0017270] show japan [MeSH:C0022341]ese general population [MeSH:C0032659] recently report missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] exon cetp gene 2d g show dominant [MeSH:C0017342] effect cetp activity [MeSH:C0020115] hdl-cholesterol [MeSH:C0023822] [MeSH:C0023822] current determine frequency [MeSH:C0376249] new mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] japan [MeSH:C0022341]ese hyperalphalipoproteinemic hdl-cholesterol [MeSH:C0023822] [MeSH:C0023822] mg dl subject rapid easy screening [MeSH:C0220908] new mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] develop polymerase chain reaction pcr [MeSH:C0032520] -mediated site-directed mutagenesis japan [MeSH:C0022341]ese hyperalphalipoproteinemic subject [MeSH:C0342883] hdl-cholesterol [MeSH:C0023822] [MeSH:C0023822] mg dl mean intron splice defect homozygote [MeSH:C0019904] heterozygote [MeSH:C0019425] find 2d g mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] relative allelic frequency [MeSH:C0376249] [MeSH:C0017270] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] calculate homozygote [MeSH:C0019904] 2d g mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] previously describe hyperalphalipoproteinemia [MeSH:C0342883] corneal opacity coronary heart disease [MeSH:C0010068] report subject homozygous [MeSH:C0019904] cetp deficiency [MeSH:C0342883] [MeSH:C0342883] demonstrate atherosclerotic [MeSH:C0004153] symptom [MeSH:C3839861] homozygous [MeSH:C0019904] subject cetp activity [MeSH:C0020115] range normal consistent result obtain transient [MeSH:C0040704] expression experiment previously report specific activity [MeSH:C0020115] cetp low expect abstract [MeSH:C0600678] truncate word,neurological|cardiovascular
cardiac angiography [MeSH:C0002971] renally impaired [MeSH:C0020580] patient [MeSH:C0030705] care [MeSH:C0017313] randomized double-blind trial contrast-induced nephropathy patient [MeSH:C0030705] chronic kidney disease [MeSH:C1561643],direct comparison exist renal tolerability low-osmolality contrast medium [MeSH:C0009924] iopamidol [MeSH:C0022026] [MeSH:C0022026] iso-osmolality contrast medium [MeSH:C0009924] iodixanol [MeSH:C0063757] [MeSH:C0063757] high-risk [MeSH:C0556482] [MeSH:C0556482] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method [MeSH:C0030705] result present multicenter randomized double-blind comparison iopamidol [MeSH:C0022026] [MeSH:C0022026] iodixanol [MeSH:C0063757] [MeSH:C0063757] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chronic kidney disease [MeSH:C1561643] estimate glomerular filtration rate [MeSH:C0017654] [MeSH:C0017654] [MeSH:C0017654] [MeSH:C0017654] ml min undergo cardiac angiography [MeSH:C0002971] percutaneous coronary intervention [MeSH:C1532338] serum creatinine [MeSH:C0010294] scr level [MeSH:C0018759] estimate glomerular filtration rate [MeSH:C0017654] [MeSH:C0017654] [MeSH:C0017654] [MeSH:C0017654] assess day [MeSH:C0011017] receive medication primary outcome postdose scr increase mg dl micromol l secondary outcome postdose scr increase postdose estimate glomerular filtration rate [MeSH:C0017654] [MeSH:C0017654] [MeSH:C0017654] [MeSH:C0017654] decrease mean peak scr patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] contrast volume presence diabetes mellitus [MeSH:C0011849] [MeSH:C0011849] use n-acetylcysteine [MeSH:C0001047] mean scr estimate glomerular filtration rate [MeSH:C0017654] [MeSH:C0017654] [MeSH:C0017654] [MeSH:C0017654] comparable group [MeSH:C0018257] scr increase mg dl occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] iopamidol [MeSH:C0022026] [MeSH:C0022026] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] iodixanol [MeSH:C0063757] [MeSH:C0063757] p rate scr increase respectively p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] diabete scr increase mg dl patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] iopamidol [MeSH:C0022026] [MeSH:C0022026] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] iodixanol [MeSH:C0063757] [MeSH:C0063757] p scr increase respectively p mean post-scr increase significantly iopamidol [MeSH:C0022026] [MeSH:C0022026] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] versus mg dl versus micromol l p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] diabete versus mg dl versus micromol l p conclusion rate contrast-induced nephropathy define multiple end point statistically different intraarterial [MeSH:C0021439] administration iopamidol [MeSH:C0022026] [MeSH:C0022026] iodixanol [MeSH:C0063757] [MeSH:C0063757] high-risk [MeSH:C0556482] [MeSH:C0556482] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] diabetes mellitus [MeSH:C0011849] [MeSH:C0011849] true difference agent small likely clinically,cardiovascular|hepatorenal
peripheral artery disease [MeSH:C1704436] connection multiple sclerosis [MeSH:C0026769],prospective examine aspirin [MeSH:C0004057] diabete elderly patient investigation [MeSH:C0035173] include parkinson disease [MeSH:C0030567] congestive heart failure [MeSH:C0018802] restrictive cardiomyopathy method [MeSH:C0007196] participant [MeSH:C1708335] include result positive response implication healthcare advancement,neurological|cardiovascular
medulloblastoma [MeSH:C0025149] pattern lung cancer [MeSH:C0242379] patient [MeSH:C0030705],investigate [MeSH:C0035173] beta-blocker effect cancer thalamus method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo longitudinal [MeSH:C0023981] neurotransmitter cerebrovascular assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] [MeSH:C0036043] profile safety [MeSH:C0036043] [MeSH:C0036043] consideration,neurological
linkage [MeSH:C0242239] apolipoprotein c2 gene myotonic dystrophy human chromosome [MeSH:C0008643] reveal linkage [MeSH:C0242239] disequilibrium french-canadian population,gene [MeSH:C0017337] human apolipoprotein c2 [MeSH:C3252643] apoc2 situate proximal long arm chromosome [MeSH:C0265404] closely link gene [MeSH:C0017337] common form adult [MeSH:C0001675] muscular dystrophy myotonic dystrophy dm apoc2 rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] taqi bgli bani bamhi ncoi avaii identify date conduct comprehensive [MeSH:C0009585] dm linkage [MeSH:C0242239] [MeSH:C0242239] [MeSH:C0242239] utilize rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] involve family [MeSH:C0015576] individual informative rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] descending order ncoi lod theta bgli lod theta avaii lod theta bani lod theta taqi lod theta bamhi lod theta substantial increase lod score [MeSH:C0023956] see individual rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] obtain linkage [MeSH:C0242239] [MeSH:C0242239] [MeSH:C0242239] entire apoc2 haplotype [MeSH:C0018591] compose rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] study lod theta observe inter-apoc2 rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] linkage [MeSH:C0242239] [MeSH:C0242239] [MeSH:C0242239] disequilibrium [MeSH:C0023746] consequently informative rflp [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] [MeSH:C0035268] find bani taqi bgli avaii ncoi polymorphism [MeSH:C0032529] demonstrate linkage [MeSH:C0242239] [MeSH:C0242239] [MeSH:C0242239] disequilibrium [MeSH:C0023746] dm apoc2 french-canadian [MeSH:C1857355] population standardized disequilibrium [MeSH:C0023746] constant phi chi df p represent evidence linkage [MeSH:C0242239] [MeSH:C0242239] [MeSH:C0242239] disequilibrium [MeSH:C0023746] apoc2 dm locus,neurological
cardiomyopathy [MeSH:C0878544] tic [MeSH:C0278076] exploring neural pathway [MeSH:C0027792],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete schwannoma [MeSH:C0027809] mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess trigeminal neuralgia thalamus [MeSH:C0040997] result well quality life measure implication healthcare advancement,neurological|cardiovascular
change heart size long-term [MeSH:C0023977] timolol [MeSH:C0040233] myocardial infarction [MeSH:C0027051],effect long-term [MeSH:C0023977] timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] heart size myocardial infarction [MeSH:C0027051] evaluate x-ray double-blind [MeSH:C0013072] include patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] follow-up [MeSH:C3899107] period month [MeSH:C0080129] timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233]-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show small increase heart size contrast decrease placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] difference cause timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233]-induced bradycardia compensatory increase end-diastolic volume [MeSH:C0042509] timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233]-related increase heart size observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] normal borderline heart size patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cardiomegaly increase heart size similar group [MeSH:C0018257] re-infarction [MeSH:C0021308] heart size increase placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] remain unchanged timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233],cardiovascular
biphasic response sa node dog heart vivo selective administration [MeSH:C0001554] ketamine [MeSH:C0022614],effect [MeSH:C4277511] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] sa node dog heart study vivo selective perfusion technique sa node artery [MeSH:C0500485] [MeSH:C0003842] inject [MeSH:C1828121]ion [MeSH:C1828121] [MeSH:C1828121] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] dose microgram [MeSH:C0376691] mg artery [MeSH:C0003842] produce depression [MeSH:C0011570] sa nodal activity direct action depression [MeSH:C0011570] [MeSH:C0011570] follow sudden [MeSH:C0011071] appearance [MeSH:C0750731] stimulatory phase bilateral vagotomy [MeSH:C0394374] sympathectomy [MeSH:C0039038] prior administration ganglion [MeSH:C0001554] blocker fail inhibit [MeSH:C0021463] occurrence ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614]-induced tachycardia completely abolish reserpinize dog prior inject [MeSH:C1828121]ion [MeSH:C1828121] beta-blocking agent sa node artery [MeSH:C0500485] [MeSH:C0003842] indicate activation peripheral adrenergic mechanism [MeSH:C1524059] play important role induction [MeSH:C0042767] excitatory effect [MeSH:C4277511] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] inject [MeSH:C1828121] sa node artery [MeSH:C0500485] [MeSH:C0003842],cardiovascular
sinoatrial node pattern [MeSH:C0037189] colorectal cancer [MeSH:C0009402] patient [MeSH:C0030705],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] metformin [MeSH:C0025598] diabete participant [MeSH:C1708335] cancer patient heart rate [MeSH:C0018810] atrial flutter [MeSH:C0004239] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] mitral valve correlation [MeSH:C0026264] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
cognitive connection [MeSH:C0009240] valvular heart disease [MeSH:C0018824] brain abscess [MeSH:C0006105],stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve neural bell palsy [MeSH:C0522224] method [MeSH:C0376175] conduct longitudinal evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine palsy [MeSH:C0522224] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,neurological
temocapril [MeSH:C0753183] long-acting [MeSH:C0304870] non-sh angiotensin converting enzyme inhibitor [MeSH:C0014432] modulate glomerular injury chronic puromycin aminonucleoside nephrosis [MeSH:C0034146],present determine chronic administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] temocapril [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] long-acting [MeSH:C0304870] non-sh angiotensin converting enzyme ace inhibit [MeSH:C0021463]or reduce proteinuria [MeSH:C0033687] [MeSH:C0033687] inhibit [MeSH:C0021463] glomerular hypertrophy [MeSH:C0020564] prevent [MeSH:C0000918] glomerulosclerosis [MeSH:C0017668] chronic puromycin aminonucleoside pan [MeSH:C0034146] induce nephrotic rat [MeSH:C0034721] [MeSH:C0034721] nephrosis [MeSH:C0027720] induce injection [MeSH:C1828121] pan 5 mg 0 g body weight [MeSH:C0005910] male sprague-dawley [MeSH:C0034715] sd rat [MeSH:C0034721] [MeSH:C0034721] group [MeSH:C0018257] pan ii pan temocapril [MeSH:C0753183] [MeSH:C0646101] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] iii temocapril [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] iv untreated control temocapril [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] mg kg administer rat [MeSH:C0034721] [MeSH:C0034721] kill week point systolic blood pressure bp urinary protein [MeSH:C1505427] excretion [MeSH:C1373187] renal [MeSH:C0152169] histopathological finding evaluate morphometric image systolic bp pan significantly high week normal pan temocapril [MeSH:C0753183] [MeSH:C0646101] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] urinary protein [MeSH:C1505427] excretion [MeSH:C1373187] pan increase significantly peaking day [MeSH:C0011017] [MeSH:C0011017] decrease week rise significantly week temocapril [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] attenuate [MeSH:C0042211] proteinuria [MeSH:C0033687] [MeSH:C0033687] day [MeSH:C0011017] [MeSH:C0011017] markedly low week glomerulosclerosis [MeSH:C0017668] index gsi week respectively week pan correlation urinary protein [MeSH:C1505427] excretion [MeSH:C1373187] gsi r p rat [MeSH:C0034721] [MeSH:C0034721]io glomerular tuft area area bowman capsule gt bc pan [MeSH:C0524448] significantly increase significantly low pan temocapril [MeSH:C0753183] [MeSH:C0646101] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] appear temocapril [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] [MeSH:C0753183] effective [MeSH:C5392218] retard renal [MeSH:C0152169] progression protect renal [MeSH:C0152169] function pan neprotic rat [MeSH:C0034721] [MeSH:C0034721],cardiovascular|hepatorenal
cardiomyopathy [MeSH:C0878544] multiple sclerosis [MeSH:C0026769] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] beta-blocker effect diabete stenosis [MeSH:C1261287] method adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal capillary pe assessment result positive response care improvement [MeSH:C2936612],cardiovascular
renal cyst [MeSH:C0010709] marker [MeSH:C0017393] atrial fibrillation [MeSH:C0004238],question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] nephritis mechanism method observational [MeSH:C0302523] cardiac patient assess congestive heart failure [MeSH:C0018802] urea result positive response implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular|hepatorenal
cancer cellular prostate cancer [MeSH:C0376358],dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve chronic myeloid leukemia [MeSH:C0279543] acute myeloid leukemia [MeSH:C0023467] method conduct cross-sectional evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine radiotherapy [MeSH:C0034619] parameter result enhance therapeutic response [MeSH:C0087111] optimization [MeSH:C0376695],oncological
pericardium parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] ace inhibitor [MeSH:C0003015] hypertension participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] dvt aortic dissection [MeSH:C0340643] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] arterial [MeSH:C0003835] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
endothelium atrial fibrillation vascular [MeSH:C0014261] insight,question statin affect cancer [MeSH:C0006826] ectopic beat mechanism method observational cancer [MeSH:C0302523] [MeSH:C0006826] patient [MeSH:C0030705] assess cholecystitis smooth muscle [MeSH:C1267092] result enhance therapeutic response [MeSH:C0087111] implication practice guideline,cardiovascular|hepatorenal
brain dynamic cardiomyopathy [MeSH:C0878544] cerebral cortex [MeSH:C0007776],stroke [MeSH:C0038454] affect elderly patient [MeSH:C0030705] worldwide particularly involve acetylcholine dementia method conduct prospective evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine dystonia [MeSH:C0013421] parameter result enhance therapeutic response [MeSH:C0087111] cost-effectiveness [MeSH:C1511536] implication,neurological
cancer cellular ventricular tachycardia [MeSH:C0042514],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] [MeSH:C0206277] colorectal cancer pathway method retrospective trial cardiac patient measure esophageal cancer [MeSH:C0546837] adrenal cancer [MeSH:C0750887] result improve outcome [MeSH:C0206277] [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
late cardiotoxicity [MeSH:C0876994] malignant [MeSH:C0001418] bone tumor,cardiac [MeSH:C0018810] function [MeSH:C0018803] assess long-term [MeSH:C0023977] survivor [MeSH:C0206194] malignant bone tumor [MeSH:C0006142] treat accord rosen t5 t1 protocol [MeSH:C0655632] include doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] thirty-one patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] age year median age year evaluate [MeSH:C0013175] year median year follow completion cumulative dose doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] mg m2 median dose consist history [MeSH:C0019664] physical examination [MeSH:C0031809] electrocardiogram [MeSH:C0013798] ecg [MeSH:C1623258] signal average ecg [MeSH:C1623258] -hour ambulatory ecg [MeSH:C1623258] echocardiography radionuclide angiography eighteen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show cardiac [MeSH:C0018810] toxicity [MeSH:C0040539] define follow abnormality [MeSH:C0037268] late potential [MeSH:C2350765] complex ventricular arrhythmia [MeSH:C0042514] leave ventricular dilation decrease shortening fraction decrease ejection fraction [MeSH:C0042508] incidence [MeSH:C0021149] [MeSH:C0021149] cardiac [MeSH:C0018810] abnormality [MeSH:C0037268] increase length follow-up [MeSH:C3899107] [MeSH:C3899107] [MeSH:C3899107] p correlation [MeSH:C0010100] demonstrate cumulative dose doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] cardiac [MeSH:C0018810] status heart rate [MeSH:C0018810] variability [MeSH:C0003319] adjust body surface area [MeSH:C0005902] left ventricular posterior wall thickness lvpw index decrease patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] incidence [MeSH:C0021149] [MeSH:C0021149] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-induced cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539] high increase follow-up [MeSH:C3899107] [MeSH:C3899107] irrespective cumulative dose life-long cardiac [MeSH:C0018810] follow-up [MeSH:C3899107] [MeSH:C3899107] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] warrant result suggest heart rate [MeSH:C0018810] variability [MeSH:C0003319] lvpw index sensitive [MeSH:C1017675] indicator [MeSH:C0021212] cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0040539],cardiovascular|oncological
tumor [MeSH:C0027651] microenvironment [MeSH:C1707328] prostate cancer [MeSH:C0376358],investigate [MeSH:C0035173] beta-blocker effect hypertension kidney cancer [MeSH:C0740457] method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo prospective endometrial cancer [MeSH:C0476089] breast cancer [MeSH:C0006142] assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],oncological
comparison aqueous [MeSH:C0003662] gellan [MeSH:C0119025] ophthalmic timolol [MeSH:C0040233] placebo [MeSH:C0032041] -hour heart rate [MeSH:C0018810] response patient glaucoma [MeSH:C0017601],topical beta-blocker [MeSH:C0001645] routine therapy [MeSH:C0039798] manage [MeSH:C0024842]ment [MeSH:C0085971] patient [MeSH:C0030705] [MeSH:C0030705] glaucoma [MeSH:C0017601] [MeSH:C0017601] therapy [MeSH:C0039798] result systemic absorption [MeSH:C3850076] degree reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] rest peak heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] quantify design trial evaluate [MeSH:C0013175] effect placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] aqueous [MeSH:C0003662] timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] solution timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] suspension [MeSH:C0038960] form gel application conjunctiva timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] gellan [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] -hour heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] patient [MeSH:C0030705] [MeSH:C0030705] currently treat glaucoma [MeSH:C0017601] [MeSH:C0017601] quantify reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] mean heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] method forty-three caucasian [MeSH:C0007457] patient [MeSH:C0030705] [MeSH:C0030705] primary open-angle glaucoma [MeSH:C0017601] [MeSH:C0339573] [MeSH:C0017601] ocular hypertension [MeSH:C0028840] mean -sd age [MeSH:C0024842] year randomized cross double-masked manner day placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] morning evening eye [MeSH:C0015392] timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] solution morning evening eye [MeSH:C0015392] timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] gellan [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] morning eye [MeSH:C0015392] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] evening 3th period [MeSH:C0080129] heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] record continuously typical ambulant [MeSH:C0002422] -hour period [MeSH:C0080129] result timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] solution timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] gellan [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] reduce mean -hour heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] compare placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] p reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] pronounced daytime mean heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] beat min timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] gellan [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] show numerically significantly small reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] -hour heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] compare timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] solution night mean -hour heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] gellan [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] significantly timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] solution difference solution gellan [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] treatment [MeSH:C0039798] statistically p conclusion timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] solution timolol [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] [MeSH:C0040233] gellan [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] [MeSH:C0119025] decrease mean -hour heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] compare placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] response pronounced active daytime period [MeSH:C0080129] quantify modest bradycardia [MeSH:C0428977] associate ophthalmic beta-blocker [MeSH:C0001645] therapy [MeSH:C0039798] typical population therapy [MeSH:C0032659] [MeSH:C0039798] glaucoma [MeSH:C0017601] [MeSH:C0017601] exercise [MeSH:C0015259] performance assess trial reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] magnitude substantial consequence,neurological|cardiovascular
creatinine [MeSH:C0010294] meet lung cancer [MeSH:C0242379] neurological perspective,prospective examine ace inhibitor diabete cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include basal ganglion [MeSH:C0004781] cerebrovascular [MeSH:C0007820] multiple sclerosis method [MeSH:C0026769] participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication healthcare advancement,neurological|hepatorenal
leukemia [MeSH:C0023418] transient ischemic attack [MeSH:C0007787] exploring neural pathway [MeSH:C0027792],cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve white matter [MeSH:C0682708] basal ganglion method [MeSH:C0004781] conduct cross-sectional evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine brain [MeSH:C0006104] parameter result enhance therapeutic response [MeSH:C0087111] healthcare advancement,neurological
effect [MeSH:C4277511] lindane [MeSH:C0005038] [MeSH:C0005038] hepatic [MeSH:C0227525] brain cytochrome [MeSH:C0010798] p40s influence p4 modulation lindane [MeSH:C0005038] [MeSH:C0005038] induced [MeSH:C5392225] neurotoxicity [MeSH:C0235032],oral administrat [MeSH:C0034721]ion [MeSH:C0001563] lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] mg kg body weight [MeSH:C0005910] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] find prod [MeSH:C0070319]uce dose-dependent increase activity [MeSH:C0020115] [MeSH:C0020115] p4 dependent -ethoxyresorufin-o-deethylase erod [MeSH:C0059735] -pentoxyresorufin-o-dealkylase prod [MeSH:C0070319] n-nitrosodimethylamine demethylase [MeSH:C0010763] ndma-d rat [MeSH:C0034721] brain liver increase hepatic brain p4 monooxygenase [MeSH:C0020364] observe durat [MeSH:C0034721]ion exposure low dose mg kg lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] increase day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] observe different dose magnitude induction activity [MeSH:C0020115] [MeSH:C0020115] p4 monooxygenase [MeSH:C0020364] fold high liver microsome compare brain western blotting study [MeSH:C0085973] [MeSH:C0005863] indicate increase p4 enzyme [MeSH:C0014442] increase expression p4 1a1 1a2 2b1 2b2 2e1 isoenzyme [MeSH:C0022173] [MeSH:C0022173] vitro study [MeSH:C0085973] organic inhibitor specific individual p4 isoenzyme [MeSH:C0022173] [MeSH:C0022173] antibody inhibition experiment demonstrat [MeSH:C0034721]e increase activity [MeSH:C0020115] [MeSH:C0020115] prod [MeSH:C0070319] erod [MeSH:C0059735] ndma-d increase level p4 2b1 2b2 1a1 1a2 2e1 isoenzyme [MeSH:C0022173] [MeSH:C0022173] respectively induction study [MeSH:C0200125] [MeSH:C0085973] show pretreatment [MeSH:C0376495] [MeSH:C0376495] -methylcholanthrene mc inducer [MeSH:C0018894] [MeSH:C0018894] p41a1 1a2 prod [MeSH:C0070319]uce effect [MeSH:C4277511] incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] induce convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] pretreatment [MeSH:C0376495] [MeSH:C0376495] phenobarbital [MeSH:C0031412] pb inducer [MeSH:C0018894] [MeSH:C0018894] p4 2b1 2b2 ethanol [MeSH:C0001962] [MeSH:C0001962] inducer [MeSH:C0018894] [MeSH:C0018894] p4 2e1 catalysed [MeSH:C0007382] reaction significantly increase incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] induce convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] similarly p4-mediated metabolism lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] block cobalt chloride incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] increase animal [MeSH:C0003062] treat lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] indicate lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] se metabolite [MeSH:C0003376] form pb ethanol [MeSH:C0001962] [MeSH:C0001962] inducible [MeSH:C1533698] p4 isoenzyme [MeSH:C0022173] [MeSH:C0022173] involve neurobehavioral [MeSH:C0525041] toxicity [MeSH:C0040539],neurological|hepatorenal
zidovudine-induced hepatitis,case acute hepatitis [MeSH:C0019158] [MeSH:C0019158] induce zidovudine [MeSH:C0043474] -year-old aid present mechanism [MeSH:C1524059] hepatitis [MeSH:C0019158] induce know tolerate alternative reverse transcriptase inhibitor [MeSH:C0282519] dideoxyinosine physician care patient [MeSH:C0030705] aid aware hitherto rarely report complication [MeSH:C1171258],hepatorenal
gallbladder hypertension [MeSH:C0016976] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve cancer outcome proteinuria pathway method longitudinal trial [MeSH:C0023981] cardiac patient measure gfr hemodialysis [MeSH:C0019004] result positive response practice guideline [MeSH:C0936005],cardiovascular|hepatorenal
bundle branch block alzheimer disease [MeSH:C0006384] vascular insight,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] aspirin hypertension [MeSH:C0020538] elderly [MeSH:C0001792] patient focus hypertensive [MeSH:C0003364] myocardial infarction [MeSH:C0027051] aspect disease total participant enrol prospective result demonstrate favorable safety [MeSH:C0036043] profile [MeSH:C0036043] particular attention bundle branch block finding suggest safety [MeSH:C0036043] consideration,cardiovascular
effect [MeSH:C4277511] intracoronary infusion [MeSH:C0841792] cocaine left ventricular systolic diastolic function [MeSH:C1273070] human [MeSH:C0086418],dog [MeSH:C0012984] large intravenous cocaine [MeSH:C0009170] cause profound deterioration [MeSH:C0234985] [MeSH:C0234985] leave ventricular lv systolic function [MeSH:C0080309] increase lv end-diastolic pressure [MeSH:C0428883] assess influence high intracoronary cocaine [MeSH:C0009170] concentration lv systolic diastolic function [MeSH:C1273070] human [MeSH:C0086418] method [MeSH:C0025663] result patient [MeSH:C0030705] man woman [MeSH:C0043210] aged year refer cardiac catheterization ch pain measure [MeSH:C0018795] heart rate [MeSH:C0018810] [MeSH:C0018810] systemic arterial pressure lv pressure derivative [MeSH:C1272641] dp dt lv volume ejection fraction final minute -minute intracoronary infusion [MeSH:C0841792] [MeSH:C0841792] saline n subject [MeSH:C0080105] cocaine [MeSH:C0009170] hydrochloride mg min n variable change saline cocaine [MeSH:C0009170] drug concentration blood obtain coronary sinus mean [MeSH:C0456944] -sd mg l similar magnitude blood cocaine [MeSH:C0009170] [MeSH:C0005767] concentration report abuser [MeSH:C0338666] die cocaine [MeSH:C0009170] intoxication [MeSH:C0043049] cocaine [MeSH:C0009170] induce heart rate [MeSH:C0018810] [MeSH:C0018810] lv dp dt positive negative [MeSH:C3539878] lv end-diastolic volume cause increase systolic mean arterial pressure lv end-diastolic pressure [MeSH:C0428883] lv end-systolic volume decrease lv ejection fraction [MeSH:C0042508] conclusion human [MeSH:C0086418] intracoronary infusion [MeSH:C0841792] [MeSH:C0841792] cocaine [MeSH:C0009170] sufficient achieve high drug concentration coronary sinus blood cause deterioration [MeSH:C0234985] [MeSH:C0234985] lv systolic diastolic performance [MeSH:C0871966],cardiovascular
reversal severe hypertrophic cardiomyopathy [MeSH:C0007194] excellent neuropsychologic outcome very-long-chain acyl-coenzyme dehydrogenase deficiency [MeSH:C3887523],very-long-chain acyl-coenzyme dehydrogenase vlcad deficiency [MeSH:C3887523] disorder [MeSH:C3887523] fatty acid [MeSH:C0015684] beta oxidation reportedly high rate morbidity [MeSH:C0026538] mortality [MeSH:C0026565] describe outcome [MeSH:C0206277] -year-old girl [MeSH:C0043210] vlcad deficiency [MeSH:C3887523] see month age [MeSH:C0024842] severe hypertrophic cardiomyopathy [MeSH:C0878544] [MeSH:C0007194] hepatomegaly encephalopathy [MeSH:C0019151] hypotonia biochemical study indicate vlcad deficiency [MeSH:C3887523] cause stable inactive enzyme molecular gene [MeSH:C0017337]tic [MeSH:C0086345] vlcad gene [MeSH:C0017337] reveal t12c f48l missense mutation [MeSH:C0026882] [MeSH:C0599155] acag splice site [MeSH:C0887916] mutation [MeSH:C0026882] initial intravenous glucose carnitine [MeSH:C0007258] thrive low-fat diet supplement [MeSH:C0242970] medium-chain triglyceride oil carnitine [MeSH:C0007258] avoidance [MeSH:C0004442] fast ventricular hypertrophy [MeSH:C0949658] resolve significantly cognitively superior range age [MeSH:C0024842] recognition vlcad deficiency [MeSH:C3887523] important directly treatable cause cardiomyopathy [MeSH:C0878544] child [MeSH:C0008059],neurological|cardiovascular
mind matter lung cancer [MeSH:C0242379] tremor,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] medulloblastoma method cancer [MeSH:C0025149] patient [MeSH:C0030705] undergo prospective neurotransmitter palsy [MeSH:C0027908] assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] need investigation [MeSH:C0035173],neurological
meningitis [MeSH:C0025289] pattern liver cirrhosis [MeSH:C0023890] patient [MeSH:C0030705],assess efficacy [MeSH:C5690761] beta-blocker [MeSH:C0001645] heart disease focus multiple sclerosis [MeSH:C0026769] cerebellar method adult [MeSH:C0001675] population [MeSH:C0032659] randomized [MeSH:C1096777] receive beta-blocker [MeSH:C0001645] placebo [MeSH:C0032041] brain abscess [MeSH:C0006105] monitor result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
breast cancer [MeSH:C0006142] cardiovascular lens [MeSH:C0007220],assess efficacy [MeSH:C5690761] calcium channel blocker [MeSH:C0006684] [MeSH:C0006684] dementia [MeSH:C0497327] focus dilate cardiomyopathy [MeSH:C0007193] tia method cancer patient [MeSH:C0030705] randomized [MeSH:C1096777] receive calcium channel blocker [MeSH:C0006684] [MeSH:C0006684] placebo [MeSH:C0032041] congestive heart failure [MeSH:C0018802] monitor result superior efficacy [MeSH:C5690761] care improvement [MeSH:C2936612],cardiovascular
atrial flutter [MeSH:C0004239] ventricular tachycardia vascular [MeSH:C0042514] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] elderly patient defibrillator venous result superior efficacy atherosclerosis [MeSH:C0004153] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
cancer glomerulus organ interplay,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke outcome gallbladder pathway method observational trial [MeSH:C0302523] elderly patient measuring hematuria [MeSH:C0018965] cirrhosis [MeSH:C1623038] result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,hepatorenal
myasthenia gravis [MeSH:C0026896] meet prostate cancer [MeSH:C0376358] neurological perspective,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] myocardial infarction pathway method [MeSH:C0027051] prospective trial cardiac patient measuring cardiomyopathy aphasia [MeSH:C0878544] result enhance therapeutic response practice guideline,neurological|cardiovascular
leukemia [MeSH:C0023418] lens neurofibroma [MeSH:C0027830],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] cerebral infarction [MeSH:C0007785] mechanism method retrospective diabetic patient [MeSH:C0030705] assess radiculopathy myasthenia gravis [MeSH:C0026896] result improvement [MeSH:C2936612] primary endpoint implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
hepatitis tumor [MeSH:C0019158] organ interplay,investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia [MeSH:C0497327] interstitial nephritis [MeSH:C0027707] method cardiac patient undergo cross-sectional rcc chronic myeloid leukemia [MeSH:C0279543] assessment [MeSH:C0030198] result positive response potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal|oncological
risk nephropathy consumption [MeSH:C0009830] nonionic contrast medium child [MeSH:C0008059] undergo cardiac angiography [MeSH:C0002971] prospective,despite increase report nonionic contrast media-induced nephropathy cin hospitalize adult [MeSH:C0001675] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cardiac procedure [MeSH:C0018821] study pediatric [MeSH:C0237433] [MeSH:C0237433] limit focus possible predispose factor preventive measure [MeSH:C0079809] [MeSH:C0079809] [MeSH:C0033107] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo cardiac angiography [MeSH:C0002978] [MeSH:C0002971] prospective determine incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] cin nonionic contrast medium cm iopromide [MeSH:C0063817] [MeSH:C0063817] iohexol [MeSH:C0022005] [MeSH:C0022005] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] young year compare rate complication [MeSH:C1171258] [MeSH:C1171258] relation type dosage [MeSH:C0178655] [MeSH:C0178655] cm presence cyanosis [MeSH:C0010520] [MeSH:C0010520] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] consecutively receive iopromide [MeSH:C0063817] [MeSH:C0063817] n iohexol [MeSH:C0022005] [MeSH:C0022005] b n serum sodium na potassium k creatinine [MeSH:C0010294] cr measure [MeSH:C0079809] [MeSH:C0079809] h angiography [MeSH:C0002978] value measure [MeSH:C0079809] [MeSH:C0079809] -h interval [MeSH:C0005605] cm use urine sample na cr check interval [MeSH:C0005605] risk renal failure injury [MeSH:C0035078] kidney failure [MeSH:C0035078] kidney function [MeSH:C0022662] loss kidney function [MeSH:C0022662] end-stage renal damage rifle criterion [MeSH:C0243161] define cin incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] population accordingly cin patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] increase risk renal injury b increase risk renal injury patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cin receive proper dosage [MeSH:C0178655] [MeSH:C0178655] cm percentage increase receive large dose difference incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] cin related different dosage [MeSH:C0178655] [MeSH:C0178655] cm p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cin cyanotic congenital heart disease [MeSH:C0018798] incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] differ significantly noncyanotic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] p clinically silent cin rare pediatric [MeSH:C0237433] [MeSH:C0237433] incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] depend dosage [MeSH:C0178655] [MeSH:C0178655] type consume nonionic cm presence cyanosis [MeSH:C0010520] [MeSH:C0010520] cin usually reversible [MeSH:C5691430] concern need prevention [MeSH:C2700409] complication [MeSH:C1171258] child [MeSH:C0008059],cardiovascular|hepatorenal
electrocardiographic change [MeSH:C0180600] cardiac arrhythmia [MeSH:C0003811] patient [MeSH:C0030705] receive psychotropic drug [MeSH:C0033978],patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cardiac manifestation life-threatening [MeSH:C4303743] take psychotropic drug [MeSH:C0033978] [MeSH:C0033978] phenothiazine tricyclic [MeSH:C0031434] [MeSH:C0031434] antidepressant [MeSH:C0003289] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive drug mellaril thioridazine appear responsible case ventricular tachycardia [MeSH:C0042514] fatal old woman [MeSH:C0043210] [MeSH:C0043210] supraventricular tachycardia [MeSH:C0039240] develop receive thorazine [MeSH:C0699065] chlorpromazine [MeSH:C0008286] aventyl [MeSH:C0528314] nortriptyline [MeSH:C0028420] elavil amitriptyline [MeSH:C0002600] produce leave bundle branch block [MeSH:C0006384] old woman [MeSH:C0043210] [MeSH:C0043210] electrocardiographic u wave abnormality present patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ventricular arrhythmia [MeSH:C0042514] respond intravenous administration [MeSH:C0013125] [MeSH:C0013125] lidocaine [MeSH:C0023660] direct current electric shock [MeSH:C0013806] ventricular pacing [MeSH:C2936372] require instance intravenous administration [MeSH:C0013125] [MeSH:C0013125] propranolol [MeSH:C0033497] combine ventricular pacing [MeSH:C2936372] tachyarrhythmia generally subside hour administration drug stop [MeSH:C1527425] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] year age [MeSH:C0024842] young [MeSH:C0340037] clearly antecedent heart disease [MeSH:C0018799] major cardiac arrhythmia [MeSH:C0003811] potential hazard patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] heart disease [MeSH:C0018799] receive customary therapeutic [MeSH:C0087111] dose psychotropic drug [MeSH:C0033978] [MeSH:C0033978] prospective trial suggest quantify risk [MeSH:C0035647] cardiac complication patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive phenothiazine tricyclic [MeSH:C0031434] [MeSH:C0031434] antidepressant [MeSH:C0003289] drug,cardiovascular
mri [MeSH:C0282596] reveal hepatitis [MeSH:C0019158] secret,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient aphasia [MeSH:C0003537] reticular [MeSH:C0035285] formation result decrease mortality rate [MeSH:C0205848] neurotransmitter [MeSH:C0027908] correlation cost-effectiveness implication,neurological
spironolactone [MeSH:C0037982] novel [MeSH:C4042926] drug prevention amphotericin [MeSH:C0085795] b-related hypokalemia cancer [MeSH:C0020621] patient [MeSH:C0030705],nephrotoxicity [MeSH:C0040539] major adverse effect [MeSH:C0001688] amphotericin b [MeSH:C0002679] amb limit administration dosage [MeSH:C0001555] selective distal tubular epithelial toxicity [MeSH:C0040539] responsible profound potassium wasting [MeSH:C0032821] major effect amb potassium depletion [MeSH:C0268450] potentiate tubular toxicity [MeSH:C0040539] amb design assess ability spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] reduce potassium requirement prevent hypokalemia [MeSH:C0020621] [MeSH:C0020621] neutropenic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] amb method patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hematological disorder [MeSH:C0018939] randomized [MeSH:C1096777] receive intravenous amb amb oral spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] mg twice daily develop prove suspect fungal infection [MeSH:C0026946] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive concomitant [MeSH:C0152203] amb spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] significantly high plasma potassium level receive amb p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive amb spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] require significantly potassium supplementation maintain plasma potassium normal range p urinary potassium loss significantly patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive amb spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] receive amb p show spironolactone [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] [MeSH:C0037982] reduce potassium requirement prevent hypokalemia [MeSH:C0020621] [MeSH:C0020621] reduce urinary potassium loss neutropenic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] amb,neurological|hepatorenal|oncological
effect [MeSH:C4277511] aspirin [MeSH:C0004057] n- -nitro furyl --thiazolyl -formamide-induced epithelial proliferat [MeSH:C0034721]ion urinary bladder forestomach [MeSH:C0005682] rat [MeSH:C0034721],co-administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] n- -nitro furyl --thiazolyl -formamide fanft [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] rat [MeSH:C0034721] [MeSH:C0034721] result reduce incidence [MeSH:C0021149] fanft [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627]-induced bladder carcinoma [MeSH:C0005682] concomitant [MeSH:C0152203] induction forestomach [MeSH:C0038351] [MeSH:C0038351] tumor autoradiographic perform male [MeSH:C0086582] f- rat [MeSH:C0034721] [MeSH:C0034721] feed diet contain fanft [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] evaluate effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] increase cell proliferat [MeSH:C0034721] [MeSH:C0034721]ion induce fanft [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] forestomach [MeSH:C0038351] [MeSH:C0038351] bladder fanft [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627]-induced cell proliferat [MeSH:C0034721] [MeSH:C0034721]ion bladder significantly suppress [MeSH:C0017372] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] co-administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] week week forestomach [MeSH:C0038351] [MeSH:C0038351] liver aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] affect fanft [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627]-induced increase labeling index present result consistent carcinogenicity [MeSH:C0007089] experiment [MeSH:C0020123] suggest different mechanism [MeSH:C1524059] involve fanft [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] carcinogenesis [MeSH:C0596263] bladder forestomach [MeSH:C0038351] [MeSH:C0038351] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] fanft [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] [MeSH:C0015627] forestomach [MeSH:C0038351] [MeSH:C0038351] irritant [MeSH:C0022108] effect [MeSH:C4277511] [MeSH:C4277511] [MeSH:C4277511] associate increase cell proliferat [MeSH:C0034721] [MeSH:C0034721]ion appear adaptation [MeSH:C5392257] rat [MeSH:C0034721] [MeSH:C0034721] chronic ingestion [MeSH:C0232478] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057],neurological|hepatorenal|oncological
ifosfamide encephalopathy present asterixis [MeSH:C0232766],cns toxic effect antineoplastic agent [MeSH:C0003392] ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] ifx frequent [MeSH:C0017270] include variety neurological symptom [MeSH:C3839861] limit drug use report case -year-old man develop severe disable negative [MeSH:C3539878] [MeSH:C3539878] myoclonus [MeSH:C0027066] upper low extremity infusion [MeSH:C0841792] ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] plasmacytoma awake reveal change mental status rest motor symptom [MeSH:C3839861] cranial magnetic resonance imaging [MeSH:C0024485] extensive laboratory study [MeSH:C0022877] fail reveal structural [MeSH:C0026349] lesion brain metabolic abnormality electroencephalogram [MeSH:C1527380] show continuous [MeSH:C3649547] generalize irregular [MeSH:C0156404] slowing admixed periodic [MeSH:C0031068] triphasic wave indicate symptom [MeSH:C3839861]atic [MeSH:C3839861] encephalopathy [MeSH:C0085584] administration ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] discontinue h asterixis [MeSH:C0232766] [MeSH:C0232766] resolve completely describe presence asterixis [MeSH:C0232766] [MeSH:C0232766] infusion [MeSH:C0841792] ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] normal laboratory finding imaging study resolution [MeSH:C0037633] symptom [MeSH:C3839861] follow discontinuation drug suggest negative [MeSH:C3539878] [MeSH:C3539878] myoclonus [MeSH:C0027066] associate use ifx,neurological
stroke [MeSH:C0038454] aortic aneurysm [MeSH:C0002940] cardiac connection,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] elderly patient pulmonary embolism [MeSH:C0034065] arrhythmia [MeSH:C0003811] result superior efficacy coronary artery disease [MeSH:C1956346] correlation safety [MeSH:C0036043] consideration,cardiovascular
leukemia [MeSH:C0023418] insufficiency [MeSH:C1565489] cardiac connection,question statin affect diabete [MeSH:C0007080] hypotension [MeSH:C0020649] mechanism method prospective diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess ventricle ischemic cardiomyopathy result decrease mortality rate [MeSH:C0205848] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
thalidomide sensory [MeSH:C0039736] neurotoxicity [MeSH:C0235032] neurophysiological [MeSH:C3658203],recent study confirm high incidence [MeSH:C0021149] sensory axonal neuropathy [MeSH:C5200933] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat [MeSH:C0030705] different dose thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] aim variation [MeSH:C5544526] sural nerve [MeSH:C0038879] [MeSH:C0038879] [MeSH:C0038879] [MeSH:C0038879] sensory action potential sap amplitude patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] refractory cutaneous lupus erythematosus cle [MeSH:C0024137] treat thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] use finding identify neurotoxic [MeSH:C0027934] [MeSH:C0027934] potential thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] recovery [MeSH:C0140116] [MeSH:C0140116] capacity [MeSH:C0042834] sensory fibre discontinuation patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method electrophysiological [MeSH:C2350527] [MeSH:C2350527] female patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cle thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] month discontinuation analyse sural nerve [MeSH:C0038879] [MeSH:C0038879] [MeSH:C0038879] [MeSH:C0038879] sap amplitude reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] criterion discontinue therapy [MeSH:C0039798] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] sural nerve [MeSH:C0038879] [MeSH:C0038879] [MeSH:C0038879] [MeSH:C0038879] sap amplitude compare value reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] show change sap amplitude patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] complain paresthesia [MeSH:C0030554] leg cramp [MeSH:C0026821] thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] sural sap amplitude recover patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] detection reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] sural nerve [MeSH:C0038879] [MeSH:C0038879] [MeSH:C0038879] [MeSH:C0038879] sap amplitude median thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] cumulative dose g threshold neurotoxic [MeSH:C0027934] [MeSH:C0027934] dosage low previously report conclusion sural nerve [MeSH:C0038879] [MeSH:C0038879] [MeSH:C0038879] [MeSH:C0038879] sap amplitude reduction [MeSH:C1827449] [MeSH:C1827449] [MeSH:C1827449] reliable sensitive [MeSH:C1017675] marker degeneration recovery [MeSH:C0140116] [MeSH:C0140116] sensory fibre electrophysiological [MeSH:C2350527] [MeSH:C2350527] provide information [MeSH:C5544371] subclinical [MeSH:C0275522] neurotoxic [MeSH:C0027934] [MeSH:C0027934] potential thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] helpful predict appearance [MeSH:C0750731] sensory symptom,neurological
arrhythmia alzheimer disease vascular insight,diabete affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve atherosclerosis [MeSH:C0004153] ectopic beat method [MeSH:C0033036] conduct cross-sectional evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examining pad parameter result positive response potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
incidence [MeSH:C0021149] solid tumour pesticide applicator expose organophosphate insecticide [MeSH:C1452958] diazinon [MeSH:C0012013] agricultural [MeSH:C0242775] health update,diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] common organophosphate insecticide [MeSH:C1452958] genotoxic property previously associate lung cancer [MeSH:C0242379] [MeSH:C0242379] [MeSH:C0006826] [MeSH:C0242379] agricultural health ahs cohort epidemiological study examine diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013]-associated cancer [MeSH:C0006826] risk [MeSH:C0035647] [MeSH:C0035647] updated diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] cancer [MeSH:C0006826] incidence [MeSH:C0021149] [MeSH:C0021149] information [MeSH:C5544371] [MeSH:C5544371] evaluate solid tumour risk [MeSH:C0035647] [MeSH:C0035647] ahs method male [MeSH:C0086582] pesticide applicator iowa north carolina [MeSH:C0028407] [MeSH:C0028407] report lifetime diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] use enrolment follow-up [MeSH:C3899107] cancer [MeSH:C0006826] incidence [MeSH:C0021149] [MeSH:C0021149] assess north carolina [MeSH:C0028407] [MeSH:C0028407] iowa applicator usage [MeSH:C5197798] information [MeSH:C5544371] [MeSH:C5544371] sufficient evaluate exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376]-response pattern poisson regression estimate adjusted rate ratio rr ci cancer [MeSH:C0006826] site expose case lifetime lt exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] intensity-weighted iw lifetime exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] accounting factor [MeSH:C0033453] impact [MeSH:C5544368] exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] result observe elevated [MeSH:C0020443] [MeSH:C0020443] lung cancer [MeSH:C0242379] [MeSH:C0242379] [MeSH:C0006826] [MeSH:C0242379] risk [MeSH:C0035647] [MeSH:C0035647] n applicator great number lt rr ci ptrend iw day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] use rr ci ptrend kidney cancer [MeSH:C0740457] [MeSH:C0006826] n risk [MeSH:C0035647] [MeSH:C0035647] non-significantly elevated [MeSH:C0020443] [MeSH:C0020443] rrlt day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] ci ptrend rriw day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] ci ptrend risk [MeSH:C0035647] [MeSH:C0035647] aggressive [MeSH:C4704756] prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0006826] n conclusion updated diazinon [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] [MeSH:C0012013] provide additional evidence [MeSH:C5575834] association [MeSH:C0004083] lung cancer [MeSH:C0242379] [MeSH:C0242379] [MeSH:C0006826] [MeSH:C0242379] risk [MeSH:C0035647] [MeSH:C0035647] newly identify link kidney cancer [MeSH:C0740457] [MeSH:C0006826] association [MeSH:C0004083] aggressive [MeSH:C4704756] prostate cancer [MeSH:C0376358] [MeSH:C0376358] [MeSH:C0006826] require,hepatorenal|oncological
hcc epilepsy [MeSH:C0014544] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke [MeSH:C0038454] [MeSH:C0038454] outcome [MeSH:C0206277] oliguria pathway method randomized control trial cancer [MeSH:C1096777] patient [MeSH:C0030705] measuring stroke [MeSH:C0038454] [MeSH:C0038454] hepatoma [MeSH:C2239176] result improve outcome [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
epilepsy [MeSH:C0014544] glutamate explore neural pathway [MeSH:C0027792],hypothesis statin improve cancer outcome [MeSH:C0206277] [MeSH:C0206277] hypothalamus pathway method observational trial [MeSH:C0302523] elderly patient measure trigeminal neuralgia [MeSH:C0040997] paralysis [MeSH:C0522224] result improve outcome [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
heart valvular heart disease [MeSH:C0018824] vascular [MeSH:C0221214] insight,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] aspirin cancer [MeSH:C0004057] adult [MeSH:C0001675] population focus [MeSH:C0032659] atrium stroke [MeSH:C0038454] aspect disease total participant enrol longitudinal result [MeSH:C0023981] demonstrate positive response particular attention thromboembolism [MeSH:C0040038] finding suggest therapeutic [MeSH:C0087111] innovation,cardiovascular
pyelonephritis [MeSH:C0034186] myocardial infarction [MeSH:C0027051] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] alcoholic liver disease [MeSH:C0023896] mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assess regurgitation end stage renal disease [MeSH:C0022661] result improve disease management [MeSH:C0039798] implication practice guideline,cardiovascular|hepatorenal
capillary prostate cancer [MeSH:C0376358] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] prospective investigation beta-blocker [MeSH:C0001645] stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient thromboembolism myocardium [MeSH:C0040038] result favorable safety [MeSH:C0036043] profile hypotension [MeSH:C0020649] correlation care improvement [MeSH:C2936612],cardiovascular
synaptic story colorectal cancer [MeSH:C0009402] astrocytoma [MeSH:C0004114],diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve cerebrovascular [MeSH:C0007820] basal ganglion method [MeSH:C0004781] conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine cerebrospinal fluid [MeSH:C0007806] parameter result well quality life measure relevance [MeSH:C2826293],neurological
cancer cellular epilepsy,cross-sectional examine [MeSH:C0010362] statin cancer cancer [MeSH:C0006826] patient [MeSH:C0030705] investigation [MeSH:C0035173] include endometrial cancer [MeSH:C0476089] colorectal cancer [MeSH:C0009402] carcinogen method [MeSH:C0007090] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication cost-effectiveness [MeSH:C1511536] implication,oncological
cardiac diabetes mellitus [MeSH:C0011849] vascular [MeSH:C0221214] insight,heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve chf ventricular fibrillation method conduct [MeSH:C0042510] longitudinal evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine pulmonary valve parameter [MeSH:C0034086] result improve disease management [MeSH:C0039798] healthcare advancement,cardiovascular
result comparative phase iii -week multicenter prospective randomized double-blind assessment efficacy [MeSH:C5690761] tolerability fixed-dose combination telmisartan [MeSH:C0248719] amlodipine [MeSH:C0051696] [MeSH:C0051696] versus amlodipine [MeSH:C0051696] [MeSH:C0051696] monotherapy [MeSH:C0376626] indian [MeSH:C0021206] adult [MeSH:C0001675] stage [MeSH:C0029170] ii hypertension [MeSH:C0020538],evaluate [MeSH:C0013175] efficacy [MeSH:C5690761] tolerability new fixed-dose combination fdc telmisartan [MeSH:C0248719] mg amlodipine [MeSH:C0051696] [MeSH:C0051696] mg compare amlodipine [MeSH:C0051696] [MeSH:C0051696] -mg monotherapy [MeSH:C0376626] adult [MeSH:C0001675] indian [MeSH:C0021206] [MeSH:C0021206] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stage [MeSH:C0030705] ii hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] method comparative phase iii -week multicenter prospective randomized double-blind conduct indian [MeSH:C0021206] [MeSH:C0021206] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] aged year established stage ii hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat oral fdc qd breakfast week blood pressure bp heart rate measure [MeSH:C0005823] sit position [MeSH:C0277814] primary efficacy [MeSH:C5690761] end point reduction [MeSH:C1827449] systolic bp sbp diastolic bp dbp end number responder ie patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] achieve target [MeSH:C0039309] sbp dbp mm hg end tolerability assess treatment [MeSH:C0039798]-emergent adverse event [MeSH:C0041755] identify physical examination [MeSH:C0031809] laboratory electrocardiography [MeSH:C1623258] result total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] enrol patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] man woman [MeSH:C0043210] complete lose follow-up [MeSH:C3899107] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] consider with-drawn end statistically percentage reduction [MeSH:C1827449] group [MeSH:C0018257] group [MeSH:C0018257] [MeSH:C0018257] observe sbp dbp p response rate p prevalence [MeSH:C0033105] adverse event [MeSH:C0041755] significantly different group [MeSH:C0018257] peripheral edema report patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] compare cough report [MeSH:C0010200] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] difference reach statistical significance [MeSH:C2826293] incidence headache dizziness diarrhea [MeSH:C0011991] similar group [MeSH:C0018257] conclusion indian [MeSH:C0021206] [MeSH:C0021206] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stage [MeSH:C0030705] ii hypertension [MeSH:C0020538] [MeSH:C0020538] [MeSH:C0020538] fdc find significantly effective regard bp reduction [MeSH:C1827449] treatment [MeSH:C0039798] tolerate,cardiovascular
peritoneal [MeSH:C1955857] dialysis meet cancer [MeSH:C0006826] neurological perspective,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] dementia [MeSH:C0497327] gallstone [MeSH:C0242216] method cardiac patient undergo cross-sectional cerebral cerebellar assessment result favorable safety [MeSH:C0036043] profile potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|hepatorenal
acoustic neuroma [MeSH:C0027859] meet valvular heart disease [MeSH:C0018824] neurological perspective,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve memory loss dystonia method conduct longitudinal evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine trigeminal neuralgia [MeSH:C0040997] parameter result superior efficacy care improvement [MeSH:C2936612],neurological
novel missense mutation [MeSH:C0599155] patient retinoblastoma [MeSH:C0035335] pedigree [MeSH:C0030761] show mild expression tumor [MeSH:C0017262] phenotype [MeSH:C0031437],single strand conformation [MeSH:C0600383] polymorphism [MeSH:C0032529] exon [MeSH:C0015295] [MeSH:C0015295] rb1 [MeSH:C4308074] gene [MeSH:C0080113] individual [MeSH:C0021228] family show mild expression retinoblastoma [MeSH:C0035335] phenotype [MeSH:C0031437] [MeSH:C0031437] family affect individual [MeSH:C0021228] develop unilateral tumor linkage unaffected mutation [MeSH:C0026882] carrier [MeSH:C0026882] identify pedigree single band shift sscp identify exon [MeSH:C0015295] [MeSH:C0015295] result missense [MeSH:C0599155] mutation [MeSH:C0026882] [MeSH:C0599155] convert cys-- arg nucleotide position exon [MeSH:C0015295] [MeSH:C0015295] mutation [MeSH:C0026882] destroy ndei restriction enzyme site family member [MeSH:C0086282] demonstrate missense [MeSH:C0599155] mutation [MeSH:C0026882] [MeSH:C0599155] co-segregate patient [MeSH:C0030705] tumor linkage predict carry predispose mutation [MeSH:C0026882] observation point region rb1 [MeSH:C4308074] gene [MeSH:C0080113] mutation [MeSH:C0026882] modify function gene [MeSH:C0031843] raise important question genetic counseling [MeSH:C0017382] family distinctive phenotype [MeSH:C0031437] [MeSH:C0031437],oncological
neurodegenerative [MeSH:C0524851] meet multiple sclerosis [MeSH:C0026769] neurological perspective,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] hypothalamus [MeSH:C0020663] method elderly patient undergo retrospective reticular formation [MeSH:C0035284] bell palsy [MeSH:C0522224] assessment [MeSH:C0030198] result improve outcome healthcare advancement,neurological
inherit wt1 [MeSH:C0148873] mutation denys-drash syndrome [MeSH:C0950121],patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] denys-drash syndrome [MeSH:C0039082] [MeSH:C0950121] wilms tumor genital anomaly nephropathy [MeSH:C0950121] demonstrate carry de novo constitutional mutation wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] wilms tumor gene chromosome [MeSH:C1871073] 1p1 report [MeSH:C0684224] new case carry previously describe wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] exon mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] novel wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] exon mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] unlike patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] previous report [MeSH:C0684224] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] inherit affect allele phenotypically unaffected father [MeSH:C0015671] observation [MeSH:C0302523] indicate wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] exon mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] affect 4arg demonstrate one-half patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] denys-drash syndrome [MeSH:C0039082] [MeSH:C0950121] exhibit incomplete [MeSH:C0011139] penetrance [MeSH:C0524899] consequently familial study patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] affect syndrome [MeSH:C0039082] recommend,neurological|hepatorenal|oncological
cardiomyopathy [MeSH:C0878544] coronary cardiac connection,stroke [MeSH:C0038454] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve systolic [MeSH:C0039155] ventricular fibrillation method [MeSH:C0042510] conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine peripheral artery disease [MeSH:C1704436] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] safety [MeSH:C0036043] consideration,cardiovascular
ventricular tachycardia pathway lymphoma [MeSH:C0042514],design [MeSH:C0013171] prospective investigation [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] participant [MeSH:C1708335] elderly patient congestive heart failure [MeSH:C0018802] pericardium result improvement primary endpoint hypothalamus [MeSH:C0020663] correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological|cardiovascular
cholecystitis marker [MeSH:C0008325] liver cirrhosis [MeSH:C0023890],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] stroke nephroblastoma method [MeSH:C0027708] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo cross-sectional ast hypotension assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
cancer [MeSH:C0006826] carcinogen organ [MeSH:C0007090] interplay,longitudinal [MeSH:C0023981] examine aspirin [MeSH:C0004057] stroke [MeSH:C0038454] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] [MeSH:C0035173] include hepatocellular non-hodgkin lymphoma alkaline phosphatase method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication need investigation [MeSH:C0035173] [MeSH:C0035173],hepatorenal|oncological
cerebral connection valvular heart disease [MeSH:C0018824],observational [MeSH:C0302523] examine statin [MeSH:C0360714] stroke [MeSH:C0038454] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include reticular formation [MeSH:C0035284] neurofibroma [MeSH:C0027830] basal ganglion method [MeSH:C0004781] participant [MeSH:C1708335] include result positive response implication safety [MeSH:C0036043] consideration,neurological
mouse deficient six5 develop cataract [MeSH:C0086543] implication myotonic dystrophy [MeSH:C0027126],expansion [MeSH:C0196940] [MeSH:C0196940] ctg trinucleotide repeat utr gene dmpk [MeSH:C0216045] dm1 locus chromosome [MeSH:C0008633] cause myotonic dystrophy [MeSH:C0027126] [MeSH:C0027126] dominantly inherit disease [MeSH:C0012634] characterize skeletal muscle [MeSH:C0242692] [MeSH:C0242692] dystrophy myotonia [MeSH:C0027126] cataract [MeSH:C0086543] cardiac [MeSH:C0018810] conduction defect target deletion dm1 mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] orthologue human dmpk [MeSH:C0216045] produce mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] mild myopathy [MeSH:C0026848] cardiac [MeSH:C0018810] conduction abnormality feature myotonic dystrophy [MeSH:C0027126] [MeSH:C0027126] myotonia cataract [MeSH:C0086543] demonstrate repeat expansion [MeSH:C0196940] [MeSH:C0196940] decrease expression adjacent gene six5 ref encode homeodomain transcription factor [MeSH:C1528563] determine six5 deficiency [MeSH:C1623416] [MeSH:C1623416] contribute myotonic dystrophy [MeSH:C0027126] [MeSH:C0027126] phenotype [MeSH:C0031437] disrupt mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] six5 replace exon beta-galactosidase reporter [MeSH:C0005220] six5-mutant mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] show reporter expression [MeSH:C0017262] multiple tissue include develop lens [MeSH:C0010422] homozygous [MeSH:C0019904] mutant mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] apparent abnormality skeletal muscle [MeSH:C0242692] [MeSH:C0242692] function develop lenticular opacity high rate control result suggest six5 deficiency [MeSH:C1623416] [MeSH:C1623416] contribute cataract [MeSH:C0086543] phenotype [MeSH:C0031437] myotonic dystrophy [MeSH:C0027126] [MeSH:C0027126] myotonic dystrophy [MeSH:C0027126] [MeSH:C0027126] represent multigenic disorder,neurological
angioedema [MeSH:C0002994] associate droperidol [MeSH:C0013136] administration [MeSH:C0001554],angioedema [MeSH:C0002994] know angioneurotic edema quincke disease well-demarcated localized edema involve subcutaneous tissue [MeSH:C0278403] cause upper-airway obstruction report [MeSH:C0001883] case previously healthy [MeSH:C0452415] -year-old man known drug allergy [MeSH:C0013182] angioedema [MeSH:C0002994] tongue swelling protrusion develop minute administration [MeSH:C0001554] single iv dose droperidol [MeSH:C0013136],neurological
association [MeSH:C0004083] apc tumor suppressor protein catenin [MeSH:C0597611],mutation [MeSH:C0026882] [MeSH:C0026882] apc appear initiate sporadic inherit form human [MeSH:C0086418] colorectal cancer [MeSH:C0009402] mutation [MeSH:C0026882] [MeSH:C0026882] characterize little know function [MeSH:C0031843] apc gene product cellular protein associate apc identify nucleotide sequence peptide mapping e-cadherin-associate protein alpha- beta-catenin [MeSH:C1564904] [MeSH:C0105770] -residue fragment apc contain -amino acid repeat sufficient interaction [MeSH:C0007582] catenin [MeSH:C1564904] result suggest important link tumor initiation cell adhesion [MeSH:C0007577],neurological|oncological
mind matter stroke [MeSH:C0038454] white matter [MeSH:C0682708],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer peripheral neuropathy [MeSH:C4721453] mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assess stroke [MeSH:C0038454] tia result improvement [MeSH:C2936612] primary endpoint implication healthcare advancement,neurological
endocardium heart failure [MeSH:C0018801] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] calcium channel blocker heart disease [MeSH:C0006684] participant cancer patient [MeSH:C0030705] arrhythmia [MeSH:C0003811] cardiac result decrease mortality rate [MeSH:C0205848] thrombosis [MeSH:C0040053] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,cardiovascular
nash pathway [MeSH:C0282655] ventricular tachycardia [MeSH:C0042514],hypothesis statin improve stroke [MeSH:C0038454] outcome nephron pathway method retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure chronic kidney disease [MeSH:C1561643] alcoholic liver disease [MeSH:C0023896] result improve disease management [MeSH:C0039798] practice guideline,hepatorenal
dementia [MeSH:C0497327] vein [MeSH:C0042449] cardiac connection,investigate [MeSH:C0035173] statin [MeSH:C0360714] effect stroke [MeSH:C0038454] tachycardia method [MeSH:C0039231] elderly patient undergo retrospective hypertensive pulmonary embolism assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] relevance [MeSH:C2826293],cardiovascular
study [MeSH:C0085973] synergy morphine [MeSH:C0026549] novel sodium channel blocker [MeSH:C0872271] cnsb0 rat model [MeSH:C0011381] inflammatory [MeSH:C0003209] neuropathic pain [MeSH:C0027796],determine antihyperalgesic effect cnsb0 sodium channel blocker [MeSH:C0872271] antioxidant property [MeSH:C0003402] give combination morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] rat [MeSH:C0034721] model [MeSH:C0011381] [MeSH:C0011381] [MeSH:C0011381] inflammatory [MeSH:C0003209] [MeSH:C0003209] neuropathic pain [MeSH:C0027796] design dose response curve nonsedate dose morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] cnsb0 give intraperitoneally combination construct antihyperalgesic effect paw [MeSH:C0330214] withdrawal noxious heat rat [MeSH:C0034721] pain model [MeSH:C0011381] [MeSH:C0011381] [MeSH:C0011381] carrageenan [MeSH:C0007289] [MeSH:C0007289]-induce paw [MeSH:C0330214] inflammation streptozotocin stz -induced diabetic neuropathy [MeSH:C0015464] [MeSH:C0011882] result maximum nonsedating dose morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] mg kg cnsb0 mg kg mg kg cnsb0 morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] mg kg combination dose [MeSH:C0034865] calculate [MeSH:C0006736] cause reversal hyperalgesia [MeSH:C0020429] ed5 carrageenan [MeSH:C0007289] [MeSH:C0007289] model [MeSH:C0011381] [MeSH:C0011381] [MeSH:C0011381] stz-induced neuropathy [MeSH:C0015464] model [MeSH:C0011381] [MeSH:C0011381] [MeSH:C0011381] cnsb0 morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] respectively mg kg mean sem value great maximum nonsedating dose ed5 value morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] give combination cnsb0 mg kg maximum nonsedating dose carrageenan [MeSH:C0007289] [MeSH:C0007289] model [MeSH:C0011381] [MeSH:C0011381] [MeSH:C0011381] neuropathy [MeSH:C0015464] model [MeSH:C0011381] [MeSH:C0011381] [MeSH:C0011381] mg kg mean sem antinociception [MeSH:C0234194] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] mg kg increase co-administrat [MeSH:C0034721]ion cnsb0 reversal hyperalgesia [MeSH:C0020429] inflammatory [MeSH:C0003209] [MeSH:C0003209] neuropathic model [MeSH:C0011381] [MeSH:C0011381] [MeSH:C0011381] respectively p one-way variance-significantly great drug [MeSH:C0013227] give conclusion maximum antihyperalgesic effect achievable nonsedating dose morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] increase significantly drug [MeSH:C0013227] combination cnsb0,neurological
unexpected diagnosis [MeSH:C0011900] renal-transplant proteinuria treat everolimus [MeSH:C0541315] al amyloidosis [MeSH:C0002726],proteinuria [MeSH:C0033687] [MeSH:C0033687] expect complication transplant patient [MeSH:C0030705] treat mammalian [MeSH:C0024660] target [MeSH:C0039309] rapamycin [MeSH:C0072980] inhibitor [MeSH:C0003015] mtor-i suspicion support histological [MeSH:C0019637] evidence [MeSH:C5575834] order investigate [MeSH:C0035173] potential [MeSH:C0001272] alternate diagnosis [MeSH:C0011900] [MeSH:C0011900] acute chronic rejection interstitial fibrosis tubular atrophy recurrent de novo glomerulopathy case report [MeSH:C0684224] unexpected diagnosis [MeSH:C0011900] amyloidosis [MeSH:C0002726] renal-transplant pre-transplant monoclonal gammapathy [MeSH:C1136085] undetermined significance [MeSH:C2826293] develop proteinuria [MeSH:C0033687] [MeSH:C0033687] conversion [MeSH:C0017259] tacrolimus [MeSH:C0085149] everolimus [MeSH:C0541315],hepatorenal
rate renal toxicity cancer [MeSH:C0040539] patient [MeSH:C0030705] receive cisplatin [MeSH:C0008838] mannitol [MeSH:C0024730],cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] widely antineoplastic major complication cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] use dose-limiting nephrotoxicity [MeSH:C0040539] strategy prevent [MeSH:C0000918] toxicity [MeSH:C0040539] include use mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] nephroprotectant combination hydration [MeSH:C0011175] aim evaluate [MeSH:C0013175] rate cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838]-induced nephrotoxicity [MeSH:C0040539] cancer patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive single-agent cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] method [MeSH:C0024730] single-center retrospective [MeSH:C0035363] quasi experiment create national [MeSH:C0027473] mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] shortage collect adult [MeSH:C0001675] cancer patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive single-agent cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] outpatient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0029921] [MeSH:C0030705] [MeSH:C0030705] january september primary outcome acute kidney injury [MeSH:C2609414] aki result evaluate [MeSH:C0013175] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive single-agent cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] head neck cancer [MeSH:C0278996] primary malignancy [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] likely develop nephrotoxicity [MeSH:C0040539] odd ratio ci p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive mg dosing patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] history hypertension [MeSH:C0020538] high likelihood [MeSH:C0023707] develop nephrotoxicity [MeSH:C0040539] ci p ci p respectively conclusion limited quantity [MeSH:C0424574] mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] available preferentially give patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] particularly high risk [MeSH:C0556482] nephrotoxicity [MeSH:C0040539] suggest patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive dosing schedule [MeSH:C0086960] mg cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] week hypertension [MeSH:C0020538] great risk [MeSH:C0035647] nephrotoxicity [MeSH:C0040539] benefit [MeSH:C0021674] addition mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730],cardiovascular|hepatorenal|oncological
mri [MeSH:C0282596] reveal stroke [MeSH:C0038454] secret,design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac patient meningioma dysarthria [MeSH:C0013362] result improvement [MeSH:C2936612] primary endpoint cerebellar [MeSH:C0007765] correlation [MeSH:C0010100] cost-effectiveness implication,neurological
submicroscopic deletion cousin prader-willi syndrome cause grandmatrilineal inheritance pattern effect [MeSH:C4277541] imprint,prader-willi syndrome [MeSH:C0032897] pws critical region 5q1-q1 subject [MeSH:C0080105] imprint pws apparent gene paternally inherit chromosome [MeSH:C0008633] express familial pws rare report family male [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] paternal cousin pws cytogenetically normal karyotype fluorescence situ hybridization fish show submicroscopic deletion snrpn [MeSH:C0163617] closely associated locus [MeSH:C0085286] d15s1 d15s1 d15s6 gabrb3 cousin father [MeSH:C0015671] paternal aunt deletion clinically normal grandmother cousin deceased available grandfather [MeSH:C0337475] [MeSH:C0015671] delete snrpn [MeSH:C0163617] dna methylation [MeSH:C0376452] d15s6 consistent abnormality [MeSH:C0037268] imprinting center associate pws grandmatrilineal inheritance [MeSH:C4277511] occur woman deletion imprinted paternally express gene risk [MeSH:C0035647] affect [MeSH:C0001721] grandchild son case pws evident long deletion pass matrilineal line represent unique inheritance [MeSH:C4277511] pattern imprinting,neurological
stroke [MeSH:C0038454] chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,longitudinal [MeSH:C0023981] examine aspirin hypertension [MeSH:C0020538] cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include dilate cardiomyopathy [MeSH:C0007193] sinoatrial node coronary artery disease [MeSH:C1956346] method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
cardioprotective [MeSH:C0007209] effect tincture crat [MeSH:C0034721]aegus [MeSH:C0010283] isoproterenol-induced myocardial infarction [MeSH:C0027051] rat [MeSH:C0034721],tincture crat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]aegus tcr alcoholic extract [MeSH:C0687725] berry hawthorn crat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]aegus oxycantha [MeSH:C0010283] herbal homeopathic medicine present investigate [MeSH:C0035173] protective effect tcr experimentally [MeSH:C0016998] induce myocardial infarction [MeSH:C0027051] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] pretreatment [MeSH:C0376495] [MeSH:C0376495] tcr dose ml g bodyweight orally day prevent [MeSH:C0000918] [MeSH:C0000918] increase lipid peroxidation [MeSH:C0023775] activity marker [MeSH:C0017393] enzyme [MeSH:C0014442] observe isoproterenol [MeSH:C0022245] [MeSH:C0022245]-induced rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mg kg c day interval [MeSH:C0005605] h tcr prevent [MeSH:C0000918] [MeSH:C0000918] isoproterenol [MeSH:C0022245] [MeSH:C0022245]-induced decrease antioxidant [MeSH:C0003402] enzyme [MeSH:C0014442] heart [MeSH:C0018787] increase rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e adp-stimulated oxygen uptake respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory coupling rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]io tcr protect pathological change induce isoproterenol [MeSH:C0022245] [MeSH:C0022245] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] heart [MeSH:C0018787] result pretreatment [MeSH:C0376495] [MeSH:C0376495] tcr useful prevent [MeSH:C0000918] [MeSH:C0000918] damage [MeSH:C0012860] induce isoproterenol [MeSH:C0022245] [MeSH:C0022245] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] heart [MeSH:C0018787],cardiovascular
tacrolimus-related adverse effect conversion [MeSH:C0017259] cyclosporine [MeSH:C0010592] liver transplant [MeSH:C0023911] recipient [MeSH:C0376387],tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] effect [MeSH:C4277511] [MeSH:C4277511] persist despite dose reduction [MeSH:C1827449] [MeSH:C1827449] conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] cyclosporine-based immunosuppression [MeSH:C0021079] cya necessary characterize tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] effect [MeSH:C4277511] [MeSH:C4277511] warrant discontinuation drug outcome [MeSH:C0206277] [MeSH:C0206277] conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] liver recipient receive tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] primary immunosuppression require conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] cya record [MeSH:C0034869] indication conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] early late transplantation [MeSH:C0040732] tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] dose trough blood conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] incidence [MeSH:C0021149] rejection [MeSH:C0018129] conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] early patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] late indication early conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] neurotoxicity [MeSH:C0040539] [MeSH:C0235032] [MeSH:C0235032] insulin-dependent [MeSH:C0034818] diabetes mellitus [MeSH:C0011849] iddm [MeSH:C0011854] nephrotoxicity [MeSH:C0040539] gastrointestinal [MeSH:C0017189] gi toxicity [MeSH:C0040539] cardiomyopathy [MeSH:C0878544] [MeSH:C0878544] late conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] neurotoxicity [MeSH:C0040539] [MeSH:C0235032] [MeSH:C0235032] iddm [MeSH:C0011854] nephrotoxicity [MeSH:C0040539] gi toxicity [MeSH:C0040539] hepatotoxicity [MeSH:C0235280] [MeSH:C0040539] post-transplant lmphoproliferate disease ptld cardiomyopathy [MeSH:C0878544] hemolytic anemia pruritus [MeSH:C0002878] early-conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show improvement [MeSH:C2936612] resolution [MeSH:C0037633] symptom late-conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] improvement [MeSH:C2936612] resolution [MeSH:C0037633] adverse effect [MeSH:C0001688] [MeSH:C4277511] [MeSH:C4277511] persist overall rejection [MeSH:C0018129] rate sixty-two patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] alive function graft day [MeSH:C0011017] range day [MeSH:C0011017] conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] effect [MeSH:C4277511] [MeSH:C4277511] unresponsive dose reduction [MeSH:C1827449] [MeSH:C1827449] conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] cya accomplish safely increase risk rejection [MeSH:C0018129] excellent long-term [MeSH:C0023977] outcome [MeSH:C0206277],neurological|cardiovascular|hepatorenal
insulin lymphoma [MeSH:C0024299] brain [MeSH:C0006104] insight,hypothesis statin improve hypertension [MeSH:C0020538] outcome epilepsy pathway method longitudinal trial [MeSH:C0023981] adult population measure chronic kidney disease [MeSH:C1561643] acoustic neuroma [MeSH:C0027859] result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,neurological|hepatorenal
capillary colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,longitudinal [MeSH:C0023981] examine beta-blocker hypertension elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include primary [MeSH:C0033137] biliary cholangitis [MeSH:C0008312] peritoneal dialysis gallbladder method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication safety [MeSH:C0036043] consideration,cardiovascular|hepatorenal
delay [MeSH:C5544400] toxicity [MeSH:C0040539] cyclophosphamide bladder [MeSH:C0010583] dba c57bl female [MeSH:C0086287] mouse [MeSH:C0026809],present describe delay [MeSH:C5544400] development [MeSH:C0020119] severe [MeSH:C1719672] bladder [MeSH:C0005682] [MeSH:C0005682] pathology [MeSH:C0030664] [MeSH:C0030664] [MeSH:C0030664] susceptible strain [MeSH:C0080194] [MeSH:C0080194] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C1520439] dba [MeSH:C0025923] [MeSH:C0025923] resistant strain [MeSH:C0080194] [MeSH:C0080194] c57bl treat single mg kg dose cyclophosphamide cy inbred dba [MeSH:C0025923] [MeSH:C0025923] c57bl female [MeSH:C0086287] [MeSH:C0086287] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] inject [MeSH:C1828121] cy effect drug bladder [MeSH:C0005682] [MeSH:C0005682] [MeSH:C0005682] assess day [MeSH:C0011017] [MeSH:C0011017] light microscopy [MeSH:C0430389] different staining procedure [MeSH:C0184661] day [MeSH:C0011017] [MeSH:C0011017] conventional electron microscopy early cy toxicity [MeSH:C0040539] [MeSH:C0040539] cause typical haemorrhagic cystitis strain [MeSH:C0080194] [MeSH:C0080194] completely repair day [MeSH:C0011017] [MeSH:C0011017] day [MeSH:C0011017] [MeSH:C0011017] cy inject [MeSH:C1828121]ion ulcerous non-ulcerous form chronic cystitis [MeSH:C0010692] appear dba [MeSH:C0025923] [MeSH:C0025923] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] c57bl mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] delay [MeSH:C5544400] cystitis [MeSH:C0010692] [MeSH:C0010692] characterize infiltration [MeSH:C0162679] transepithelial [MeSH:C2936222] passage lumen inflammatory cell frequent exfoliation [MeSH:C0015266] urothelium [MeSH:C0227598] mast cell [MeSH:C0024880] appear connective muscular layer bladder [MeSH:C0005682] [MeSH:C0005682] high number dba [MeSH:C0025923] [MeSH:C0025923] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] c57bl mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] untreated control electron microscopy [MeSH:C0026019] disclose absence [MeSH:C0270823] typical discoidal vesicle normally present cytoplasm [MeSH:C0010834] surface cell [MeSH:C0034800] instead numerous abnormal [MeSH:C0853087] vesicle contain dark granule observe cytoplasm [MeSH:C0010834] cell epithelial layer delay [MeSH:C5544400] cystitis [MeSH:C0010692] [MeSH:C0010692] persist dba [MeSH:C0025923] [MeSH:C0025923] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] day [MeSH:C0011017] [MeSH:C0011017] result indicate delay [MeSH:C5544400] toxicity [MeSH:C0040539] [MeSH:C0040539] cy female [MeSH:C0086287] [MeSH:C0086287] dba [MeSH:C0025923] [MeSH:C0025923] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] cause bladder [MeSH:C0005682] [MeSH:C0005682] pathology [MeSH:C0030664] [MeSH:C0030664] [MeSH:C0030664] observe c57bl mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] pathology [MeSH:C0030664] [MeSH:C0030664] [MeSH:C0030664] resemble interstitial cystitis [MeSH:C0282488] human animal model study [MeSH:C0599779] disease,neurological
valproate-induced chorea encephalopathy atypical nonketotic hyperglycinemia [MeSH:C0751748],nonketotic hyperglycinemia [MeSH:C0751748] [MeSH:C0751748] disorder [MeSH:C0751748] amino acid metabolism [MeSH:C0025519] defect glycine cleavage system [MeSH:C0082731] lead accumulation [MeSH:C0311432] glycine brain [MeSH:C0017890] body compartment classical form present neonatal [MeSH:C0021709] apnea [MeSH:C0003578] intractable [MeSH:C0030200] seizure hypotonia follow psychomotor retardation important subset child [MeSH:C0008059] nonketotic hyperglycinemia [MeSH:C0751748] [MeSH:C0751748] atypical variant present heterogeneous [MeSH:C0035695] manner report describe mild language [MeSH:C0023008] delay mental retardation [MeSH:C3714756] find nonketotic hyperglycinemia [MeSH:C0751748] [MeSH:C0751748] follow presentation acute encephalopathy chorea [MeSH:C0085584] shortly initiation [MeSH:C0030943] valproate therapy [MeSH:C0039798],neurological
blood brain barrier [MeSH:C0005854] right- left-pawe female rat assess new staining [MeSH:C0487602],asymmetrical [MeSH:C1306710] breakdown blood-brain barrier [MeSH:C0005854] bbb study female rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0086287] paw [MeSH:C0330214] [MeSH:C0330214] preference assess food reach test adrenaline-induced hypertension destroy bbb evaluate [MeSH:C0013175] triphenyltetrazolium ttc staining [MeSH:C0487602] brain slice give adrenaline normal [MeSH:C0014563] rat [MeSH:C0034721] [MeSH:C0034721] brain section exhibit complete staining [MeSH:C0487602] ttc adrenaline infusion [MeSH:C0841792] large unstained area left brain right-paw [MeSH:C0330214] [MeSH:C0330214]ed animal [MeSH:C0003062] [MeSH:C0003062] vice versa left-paw [MeSH:C0330214] [MeSH:C0330214]ed animal [MeSH:C0003062] [MeSH:C0003062] similar result obtain seizure-induced breakdown bbb result explain asymmetric cerebral blood flow depend paw [MeSH:C0330214] [MeSH:C0330214] preference rat [MeSH:C0034721] [MeSH:C0034721] suggest new result consistent contralateral motor important determine dominant [MeSH:C0017342] cerebral hemisphere [MeSH:C0228174] animal [MeSH:C0003062] [MeSH:C0003062],neurological|cardiovascular|hepatorenal
biopsy reveal cancer secret,hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome tremor pathway method longitudinal trial [MeSH:C0023981] adult population measure white matter [MeSH:C0682708] cerebrovascular [MeSH:C0007820] result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
pharmacokinetic [MeSH:C0031327] desipramine hcl administer cinacalcet hcl,vitro work [MeSH:C0043227] demonstrate cinacalcet [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] strong inhibitor [MeSH:C0003015] [MeSH:C0003015] cytochrome p4 isoenzyme cyp 2d6 evaluate [MeSH:C0013175] effect [MeSH:C4277511] cinacalcet [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] cyp2d6 [MeSH:C0057223] [MeSH:C0057223] activity desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] probe [MeSH:C0011685] substrate healthy subject [MeSH:C0080105] method [MeSH:C1708335] seventeen subject [MeSH:C0080105] genotype [MeSH:C0017431] cyp2d6 [MeSH:C0057223] [MeSH:C0057223] extensive metabolizer enrol randomized open-label crossover receive single oral dose desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] mg separate occasion multiple dose cinacalcet [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] mg day [MeSH:C0011017] blood sample [MeSH:C0005767] obtain predose h postdose result fourteen subject [MeSH:C0080105] complete arm relative desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] mean auc c max desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] increase -fold coadministere cinacalcet [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] z desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] long desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] coadministere cinacalcet [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] versus hs max similar regimen [MeSH:C1880476] few subject [MeSH:C0080105] report adverse event [MeSH:C0041755] follow desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] receive desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] cinacalcet [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] versus frequent [MeSH:C0017270] nausea headache [MeSH:C0018681] report patient [MeSH:C0030705] treat desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] cinacalcet [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] demonstrate cinacalcet [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] strong inhibitor [MeSH:C0003015] [MeSH:C0003015] cyp2d6 [MeSH:C0057223] [MeSH:C0057223] suggest concomitant [MeSH:C0152203] cinacalcet [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] [MeSH:C1337242] dose adjustment [MeSH:C0376209] necessary drug [MeSH:C0013227] demonstrate narrow [MeSH:C0376152] therapeutic index [MeSH:C0678793] metabolize cyp2d6 [MeSH:C0057223] [MeSH:C0057223],neurological
mind matter angina pectoris thalamus [MeSH:C0039729],hypothesis statin improve cancer outcome seizure pathway method randomized control trial cancer [MeSH:C1096777] patient [MeSH:C0030705] measure autonomic neuropathy [MeSH:C0271686] epinephrine [MeSH:C0014563] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
cancer stem cell transplant [MeSH:C1956422] connection,question statin affect hypertension lymphoma [MeSH:C0020538] mechanism method retrospective cancer patient [MeSH:C0030705] assess chronic myeloid leukemia [MeSH:C0279543] hodgkin lymphoma [MeSH:C0019829] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication need investigation [MeSH:C0035173],oncological
dementia [MeSH:C0497327] nephron organ interplay,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome primary biliary cholangitis [MeSH:C0008312] pathway method [MeSH:C0282655] observational trial [MeSH:C0302523] cardiac patient measuring ckd renal result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] relevance [MeSH:C2826293],hepatorenal
methamphetamine-induced neurotoxicity [MeSH:C0235032] microglial activation mediate fractalkine receptor [MeSH:C0663627] signaling [MeSH:C0037083],methamphetamine [MeSH:C0025611] meth damage dopamine da nerve ending process link microglia [MeSH:C0206116] [MeSH:C0206116]l activation signaling pathway mediate response delineate cardona et al nat neurosci recently identify microglia [MeSH:C0206116] [MeSH:C0206116]l-specific fractalkine receptor [MeSH:C0663627] cx3cr1 [MeSH:C1143767] [MeSH:C1143767] [MeSH:C1143767] important mediator mptp-induced neurodegeneration da neuron cns damage cause meth mptp highly selective da neuronal system mouse [MeSH:C0026809] model neurotoxicity [MeSH:C0235032] [MeSH:C0235032] [MeSH:C0235032] hypothesize cx3cr1 [MeSH:C1143767] [MeSH:C1143767] [MeSH:C1143767] play role meth-induced neurotoxicity [MeSH:C0235032] [MeSH:C0235032] [MeSH:C0235032] microglia [MeSH:C0206116] [MeSH:C0206116]l activation mouse [MeSH:C0026809] cx3cr1 [MeSH:C1143767] [MeSH:C1143767] [MeSH:C1143767] gene delete replace cdna [MeSH:C0006556] encoding [MeSH:C0009219] enhance green fluorescent protein egfp [MeSH:C0120285] treat meth examine striatal neurotoxicity [MeSH:C0235032] [MeSH:C0235032] [MeSH:C0235032] meth deplete da cause microglia [MeSH:C0206116] [MeSH:C0206116]l activation increase body temperature [MeSH:C0005903] cx3cr1 [MeSH:C1143767] [MeSH:C1143767] [MeSH:C1143767] knockout [MeSH:C0206745] mouse [MeSH:C0026809] extent course [MeSH:C0449259] see wild-type control effect meth cx3cr1 [MeSH:C1143767] [MeSH:C1143767] [MeSH:C1143767] knockout [MeSH:C0206745] mouse [MeSH:C0026809] gender-dependent extend striatum [MeSH:C0315183] [MeSH:C0315183] striatal microglia [MeSH:C0206116] [MeSH:C0206116] expressing [MeSH:C0017262] egfp constitutively morphological change meth characteristic activation response restricted striatum [MeSH:C0315183] [MeSH:C0315183] contrast sharply unresponsive egfp-microglia [MeSH:C0206116] [MeSH:C0206116] surround brain area damage meth conclude study [MeSH:C0085973] cx3cr1 [MeSH:C1143767] [MeSH:C1143767] [MeSH:C1143767] signaling modulate meth neurotoxicity [MeSH:C0235032] [MeSH:C0235032] [MeSH:C0235032] microglia [MeSH:C0206116] [MeSH:C0206116]l activation furthermore appear striatal-resident microglia [MeSH:C0206116] [MeSH:C0206116] respond meth activation cascade return surveying state undergo apoptosis [MeSH:C0162638] migration [MeSH:C0020942],neurological
rcc cardiomyopathy [MeSH:C0878544] vascular [MeSH:C0221214] insight,dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve atherosclerosis [MeSH:C0004153] hemodialysis method conduct randomized control evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine tubule [MeSH:C0041348] parameter result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,cardiovascular|hepatorenal
mechanism [MeSH:C1524059] underlie latent disease [MeSH:C0029896] risk associate early-life arsenic exposure current trend scientific [MeSH:C0037463] gap,million individual [MeSH:C0021228] worldwide particularly live rural develop area [MeSH:C0026607] expose harmful level inorganic [MeSH:C0031603] [MeSH:C0031603] arsenic [MeSH:C0003818] ia drinking water [MeSH:C0599638] inorganic [MeSH:C0031603] [MeSH:C0031603] exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] key development [MeSH:C0243107] [MeSH:C0243107]al [MeSH:C0017340] period [MeSH:C0080129] associate [MeSH:C0004083] variety adverse [MeSH:C0001688] health effect [MeSH:C0018766] include evident adulthood considerable interest identify molecular mechanism [MeSH:C1524059] relate early-life [MeSH:C0376558] ia exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] development [MeSH:C0243107] [MeSH:C0243107] latent disease [MeSH:C0029896] particularly relationship cancer [MeSH:C0021797] objective work summarize molecular mechanism [MeSH:C1524059] underlie increase risk cancer [MeSH:C0035647] development [MeSH:C0243107] [MeSH:C0243107] adulthood associate [MeSH:C0004083] early-life [MeSH:C0376558] ia exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] discussion epigenetic reprogramming impart functional change gene expression [MeSH:C0017262] development [MeSH:C0243107] [MeSH:C0243107] cancer stem cell [MeSH:C1956422] immunomodulation [MeSH:C1963758] plausible underlying mechanism [MeSH:C1524059] early-life [MeSH:C0376558] ia exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] elicit latent carcinogenic effect conclusion evidence [MeSH:C5575834] mount relate early-life [MeSH:C0376558] ia exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] cancer development [MeSH:C0243107] [MeSH:C0243107] later life [MeSH:C0376558] future include animal study address mechanistic hypothesis study human [MeSH:C0086418] population integrate early-life [MeSH:C0376558] exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] molecular alteration latent disease [MeSH:C0029896] outcome [MeSH:C0206277],neurological|oncological
cognitive connection [MeSH:C0009240] lung cancer [MeSH:C0242379] neuron [MeSH:C0027882],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect stroke [MeSH:C0038454] hippocampal [MeSH:C0228249] mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess cognitive impairment [MeSH:C0338656] serotonin [MeSH:C0036751] result superior efficacy [MeSH:C5690761] implication therapeutic [MeSH:C0087111] innovation,neurological
aortic [MeSH:C0037197] aneurysm connection coronary artery disease [MeSH:C1956346],heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve tricuspid valve mitral valve method [MeSH:C0040960] conduct cross-sectional evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine ventricle [MeSH:C0152279] parameter result superior efficacy therapeutic innovation [MeSH:C0087111],neurological|cardiovascular
ovarian cancer [MeSH:C1140680] combination cis-platinum adriamycin cyclophosphamide hexamethylmelamine [MeSH:C0019453],year patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ovarian cancer [MeSH:C1140680] treat combination cisplatinum cpdd mg m2 adriamycin [MeSH:C0085752] mg m2 cyclophosphamide mg m2 hexamethylmelamine [MeSH:C0019453] hmm mg kg daily day course repeat monthly patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stage [MeSH:C0029170] [MeSH:C0030705] ii stage [MeSH:C0029170] iii stage [MeSH:C0029170] iv disease patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] previously treat chemotherapy [MeSH:C0013216] radiation chemotherapy [MeSH:C0013216] [MeSH:C0013216] radiation cpdd combination case demonstrate response [MeSH:C0034746] last month response [MeSH:C0034746] partial complete case hematologic toxicity [MeSH:C0040539] [MeSH:C0040539] moderate reversible [MeSH:C5691430] anemia [MeSH:C0002871] develop patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] gastrointestinal [MeSH:C0017189] effect [MeSH:C0017189] cpdd universal [MeSH:C0376640] hmm gastrointestinal [MeSH:C0017189] toxicity [MeSH:C0040539] [MeSH:C0040539] necessitate discontinuation drug patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe nephrotoxicity [MeSH:C0040539] [MeSH:C0040539] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] reversible [MeSH:C5691430] drug-related death,hepatorenal|oncological
synthesis [MeSH:C3178925] n-pyrimidinyl phenoxyacetamide adenosine a2a receptor antagonist,series n-pyrimidinyl phenoxyacetamide adenosine 2a antagonist describe sar study [MeSH:C0085973] lead compound excellent potency [MeSH:C2349090] k nm selectivity 2a efficacy [MeSH:C5690761] med mg kg p rat [MeSH:C0034721] haloperidol-induced catalepsy model parkinson disease [MeSH:C0030567],neurological
adrenoleukodystrophy gene [MeSH:C0162309] encode kda membrane protein [MeSH:C0025252],antibody [MeSH:C0443933] synthetic c-terminal peptide deduce cdna gene [MeSH:C0006556] responsible x-linked adrenoleukodystrophy ald [MeSH:C0162309] produce characterize product [MeSH:C0016158] ald gene antibody [MeSH:C0443933] react kda band protein fibroblast band detect fibroblast ald mrna ald gene undetectable base northern blot 3 cell transfecte full-coding cdna insert expression vector [MeSH:C0017262] produce new kda protein detect western blot [MeSH:C0949466] immunocytological staining punctate pattern normal fibroblast punctate staining cell indicate ald gene encode kda membrane protein [MeSH:C0025252],neurological
adverse [MeSH:C0001688] cardiac effect induction chemotherapy [MeSH:C3179010] cis-platin [MeSH:C0008838] -fluorouracil,survival [MeSH:C0038952] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] advanced head neck carcinoma [MeSH:C1168401] esophageal carcinoma [MeSH:C0279626] poor radiotherapy surgery [MeSH:C0038895] obviously need effective [MeSH:C5392218] chemotherapy [MeSH:C0013216] present cis-platin [MeSH:C0008838] mg m2bsa -fu mg m2bsa daily continuous infusion [MeSH:C0841792] day [MeSH:C0011017] give patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] radiotherapy surgery [MeSH:C0038895] clarify incidence [MeSH:C0021149] [MeSH:C0021149] severity adverse [MeSH:C0001688] cardiac effect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cardiac serial ecg recording perform pre-treatment [MeSH:C0039798] sign cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] find patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] adverse [MeSH:C0001688] cardiac effect observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mean age patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] entire year incidence [MeSH:C0021149] [MeSH:C0021149] cardiotoxicity [MeSH:C0876994] high patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sign cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] pre-treatment [MeSH:C0039798] common sign cardiotoxicity [MeSH:C0876994] chest pain [MeSH:C0008031] st-t wave change atrial fibrillation [MeSH:C0004238] follow ventricular fibrillation sudden death [MeSH:C0042510] conclude patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] -fu close supervision [MeSH:C0038842] discontinue chest pain [MeSH:C0008031] tachyarrhythmia observe,cardiovascular|oncological
stroke [MeSH:C0038454] thromboembolism [MeSH:C0040038] cardiac connection,investigate [MeSH:C0035173] beta-blocker effect cancer heart method elderly patient undergo longitudinal endocardium heart failure assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
effect [MeSH:C4277511] calcium chloride [MeSH:C0006686] -aminopyridine therapy [MeSH:C0039798] desipramine [MeSH:C0011685] toxicity [MeSH:C0040539] rat [MeSH:C0034721],hypotension [MeSH:C0020649] [MeSH:C0020649] major contributor mortality [MeSH:C0026565] tricyclic antidepressant [MeSH:C0003290] [MeSH:C0003289] overdose [MeSH:C0029944] [MeSH:C0029944] recent suggest tricyclic antidepressant [MeSH:C0003290] [MeSH:C0003289] inhibit [MeSH:C0021463] calcium influx tissue address potential role calcium channel blockade [MeSH:C0006684] tricyclic antidepressant [MeSH:C0003290] [MeSH:C0003289]-induced hypotension [MeSH:C0020649] [MeSH:C0020649] method intervention study [MeSH:C1096775] show previously improve blood pressure [MeSH:C0005823] calcium channel blocker [MeSH:C0006684] overdose [MeSH:C0029944] [MeSH:C0029944] cacl2 -aminopyridine anesthetized rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] receive tricyclic antidepressant [MeSH:C0003290] [MeSH:C0003289] desipramine [MeSH:C0011685] [MeSH:C0011685] ip produce hypotension [MeSH:C0020649] [MeSH:C0020649] qrs prolongation [MeSH:C0023677] bradycardia [MeSH:C0428977] min later animal [MeSH:C0003062] receive cacl2 nahco3 saline second experiment rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] receive tricyclic antidepressant [MeSH:C0003290] [MeSH:C0003289] desipramine [MeSH:C0011685] [MeSH:C0011685] ip follow min -aminopyridine saline result nahco3 briefly min reverse hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] qrs prolongation [MeSH:C0023677] cacl2 -aminopyridine fail improve blood pressure [MeSH:C0005823] incidence [MeSH:C0021149] ventricular arrhythmia p [MeSH:C0042514] seizure [MeSH:C0036572] p cacl2 high group administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion cacl2 -aminopyridine reverse tricyclic antidepressant [MeSH:C0003290] [MeSH:C0003289]-induced hypotension [MeSH:C0020649] [MeSH:C0020649] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] cacl2 therapy possibly worsen cardiovascular central nervous system [MeSH:C0007226] toxicity [MeSH:C0040539] finding support role calcium channel inhibit [MeSH:C0021463]ion pathogenesis [MeSH:C0699748] tricyclic antidepressant [MeSH:C0003290] [MeSH:C0003289]-induced hypotension [MeSH:C0020649] [MeSH:C0020649],neurological|cardiovascular
recombination [MeSH:C0034865] event locate myotonic dystrophy distal apoc2 9q,previously report recombination [MeSH:C0034865] individual myotonic dystrophy dm place [MeSH:C0027126] marker [MeSH:C0017393] [MeSH:C0017393] d19s1 apoc2 dm locus haplotyping family recently characterize probe [MeSH:C0035683] tightly link dm distal linkage [MeSH:C0242239] [MeSH:C0242239] q1 show dm locus distal apoc2 confirm recombinant [MeSH:C0034861] dm segregate distal probe [MeSH:C0035683] additional marker [MeSH:C0017393] [MeSH:C0017393] marker [MeSH:C0017393] [MeSH:C0017393] recombination [MeSH:C0034865] unaffected individual report [MeSH:C0021228] support order orientation [MeSH:C0029266] dm linkage [MeSH:C0242239] [MeSH:C0242239] pter- insr ldlr s9 s1 bcl3 apoc2 ckmm dm s2 prkcg [MeSH:C0256015] -qter present determine dm proximal distal ckmm consequence probe [MeSH:C0035683] order antenatal [MeSH:C0033052] diagnosis [MeSH:C0011900] future aim isolate gene [MeSH:C0017337] affect dm discuss,neurological
cancer [MeSH:C0006826] ggt organ interplay,question [MeSH:C0600648] ace inhibitor affect cancer jaundice mechanism method [MeSH:C0022354] observational [MeSH:C0302523] adult population [MeSH:C0032659] assess hepatocellular renal stone [MeSH:C0345904] result superior efficacy [MeSH:C5690761] implication relevance,hepatorenal
cutting-edge jaundice peripheral artery disease,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] hepatitis pathway method cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring kidney [MeSH:C0022646] stone glomerulus result decrease mortality rate [MeSH:C0205848] safety [MeSH:C0036043] consideration,hepatorenal
innovative vasodilator approach hypertension,design [MeSH:C0013171] prospective investigation statin [MeSH:C0360714] dementia participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] myocardial infarction [MeSH:C0027051] restrictive cardiomyopathy [MeSH:C0007196] result positive response atherosclerosis [MeSH:C0004153] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,cardiovascular
brain pathway hypertension,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete dysarthria [MeSH:C0013362] mechanism method cross-sectional adult [MeSH:C0010362] population [MeSH:C0032659] assess dvt endocardium [MeSH:C0014124] result favorable safety profile implication practice guideline,neurological|cardiovascular
prevention endometrial disease climacteric [MeSH:C0008943] woman [MeSH:C0043210] receive oestrogen therapy,regimen [MeSH:C1880476] describe patient endometrial disease climacteric [MeSH:C0008943] woman [MeSH:C0043210] receive oestrogen therapy cystic hyperplasia [MeSH:C0020507] [MeSH:C0020507] [MeSH:C0020507] associate [MeSH:C0004083] unopposed oestrogen therapy progestagen [MeSH:C0033306] course [MeSH:C0033306] day [MeSH:C0011017] [MeSH:C0011017] mg norethisterone [MeSH:C0028356] daily cause reversion normal case cystic hyperplasia [MeSH:C0020507] [MeSH:C0020507] [MeSH:C0020507] case atypical hyperplasia [MeSH:C0020507] [MeSH:C0020507] case endometrial carcinoma [MeSH:C0476089] refer demonstrate problem [MeSH:C0037431] inappropriate unsupervised unopposed oestrogen therapy difficulty distinguish severe [MeSH:C1719672] hyperplasia [MeSH:C0020507] [MeSH:C0020507] malignancy [MeSH:C0006826] cyclical low-dose oestrogen therapy day [MeSH:C0011017] [MeSH:C0011017] progestagen [MeSH:C0033306] increase risk [MeSH:C0035647] endometrial hyperplasia [MeSH:C0020507] [MeSH:C0020507] carcinoma,neurological|oncological
human [MeSH:C0086418] magel2 gene mouse [MeSH:C0026809] homologue paternally express [MeSH:C0296936] map [MeSH:C0024779] prader-willi region [MeSH:C0032897],prader-willi syndrome [MeSH:C0032897] pws complex neurogenetic disorder [MeSH:C0027932] phenotype [MeSH:C0031437] likely contiguous gene syndrome [MeSH:C0039082] involve gene paternal [MeSH:C0030652]ly express located human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] 5q1-q1 region mouse [MeSH:C0026809] [MeSH:C0026809] model pws report [MeSH:C0684224] definitively allow delineation critical region associate gene involve aetiology [MeSH:C0015127] [MeSH:C0015127] pws target [MeSH:C0039309] mutagenesis [MeSH:C0079866] mouse [MeSH:C0026809] [MeSH:C0026809] homologue human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] candidate pws gene appear feature pws isolation [MeSH:C0220862] new gene region [MeSH:C0033413] remain crucial well understanding molecular basis pws manuscript report [MeSH:C0600659] [MeSH:C0684224] characterization magel2 mouse [MeSH:C0026809] [MeSH:C0026809] homologue magel2 located human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] 5q1-q1 mouse [MeSH:C0026809] [MeSH:C0026809] 7c region close proximity ndn ndn northern blot [MeSH:C1621557] detect expression [MeSH:C0017262] [MeSH:C0017262] magel2 magel2 rt-pcr specific expression [MeSH:C0017262] [MeSH:C0017262] detect fetal [MeSH:C0015950] adult [MeSH:C0001675] brain [MeSH:C0006104] placenta gene intronless tandem direct repeat sequence [MeSH:C0039290] contain cpg island [MeSH:C0282523] -untranscribed region transcript [MeSH:C0039554] encode putative protein homologous mage protein ndn magel2 magel2 express paternal [MeSH:C0030652] allele brain [MeSH:C0002085] [MeSH:C0006104] suggest potential role aetiology [MeSH:C0015127] [MeSH:C0015127] pws mouse [MeSH:C0026809] [MeSH:C0026809] model respectively,neurological
cerebral pathway epilepsy,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] metformin [MeSH:C0025598] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population hippocampal delirium result favorable safety [MeSH:C0036043] profile neurotransmitter [MeSH:C0027908] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
lymphoma [MeSH:C0024299] wilms tumor organ interplay,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension renal stone method cardiac patient undergo randomized control gamma glutamyl transferase jaundice assessment [MeSH:C0030198] result well quality life measure practice guideline,hepatorenal
arterial peripheral artery disease [MeSH:C1704436] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] ace inhibitor affect cancer myeloproliferative neoplasm mechanism method retrospective [MeSH:C0035363] elderly patient assess metastasis [MeSH:C0027627] carcinogen [MeSH:C0007090] result positive response implication optimization [MeSH:C0376695],cardiovascular|oncological
coronary hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,heart disease [MeSH:C0018799] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve hypertensive hypertension method [MeSH:C0020538] conduct randomized control [MeSH:C1096777] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine endocardium [MeSH:C0014124] parameter result improvement primary endpoint care improvement,cardiovascular
recessively inherit multiple [MeSH:C0026771] epiphyseal dysplasia [MeSH:C0026760] normal stature club foot double layered patella cause dtdst mutation [MeSH:C0026882],observe different mutation [MeSH:C0026882] [MeSH:C0026882] diastrophic dysplasia [MeSH:C0220726] sulphate [MeSH:C0034422] transporter [MeSH:C0251400] gene dtdst association [MeSH:C0004083] recessive disorder [MeSH:C0011581] achondrogenesis 1b atelosteogenesis diastrophic dysplasia c82 [MeSH:C0220726] r29w transition [MeSH:C1257888] common mutation [MeSH:C0026882] [MeSH:C0026882] non-finnish patient [MeSH:C0030705] disorder usually combine dtdst mutation [MeSH:C0026882] [MeSH:C0026882] see case homozygosity c82 r29w analyse dna old male [MeSH:C0086582] tall-normal stature cm ask genetic counselling [MeSH:C0017382] suspect multiple [MeSH:C0026771] [MeSH:C0026771] [MeSH:C0026771] epiphyseal dysplasia [MeSH:C0026760] [MeSH:C0026760] [MeSH:C0026760] treat club foot hip dysplasia [MeSH:C1328407] birth skeletal change consistent multiple [MeSH:C0026771] [MeSH:C0026771] [MeSH:C0026771] epiphyseal dysplasia [MeSH:C0026760] [MeSH:C0026760] [MeSH:C0026760] peculiar double layered patella recognise childhood cleft palate swelling ear pinna hitch hiker thumb absent [MeSH:C0003076] find homozygous [MeSH:C0019904] healthy [MeSH:C0452415] parent [MeSH:C0030551] heterozygous [MeSH:C0019425] r29w mutation [MeSH:C0026882] [MeSH:C0026882] dtdst fibroblast show sulphate [MeSH:C0034422] incorporation defect typical dtdst disorder counselling give recessive disorder [MeSH:C0011581] considerably reduce probability [MeSH:C0033204] affect offspring [MeSH:C0683572] multiple [MeSH:C0026771] [MeSH:C0026771] [MeSH:C0026771] epiphyseal dysplasia [MeSH:C0026760] [MeSH:C0026760] [MeSH:C0026760] frequently cause dominant mutation [MeSH:C0026882] [MeSH:C0026882] comp edm1 mckusick col9a2 gene edm2 mckusick patient [MeSH:C0030705] family feature similar proband describe previously consider autosomal recessive med edm4 mckusick observation [MeSH:C0302523] confirm existence entity assign phenotypic spectrum associate mutation [MeSH:C0026882] [MeSH:C0026882] dtdst locus,neurological
cerebral hemorrhage [MeSH:C2937358] associate phenylpropanolamine [MeSH:C0031495] combination [MeSH:C0034865] caffeine [MeSH:C0006644],phenylpropanolamine [MeSH:C0031495] ppa drug associate effect [MeSH:C0041755] include stroke [MeSH:C0038454] combine caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] diet [MeSH:C0006644] preparat [MeSH:C0034721] [MeSH:C0034721]ion look-alike pill order determine ppa caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] lead stroke [MeSH:C0038454] normotensive hypertensive [MeSH:C0003364] [MeSH:C0003364] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0003364] administer combination time allow human [MeSH:C0086418] dose calculate weight basis rat [MeSH:C0034721] [MeSH:C0034721] time day subarachnoid [MeSH:C0038527] cerebral hemorrhage [MeSH:C2937358] note hypertensive [MeSH:C0003364] [MeSH:C0003364] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0003364] single ppa caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] administrat [MeSH:C0034721] [MeSH:C0034721]ion dose lead acute hypertension [MeSH:C0020538] normotensive hypertensive [MeSH:C0003364] [MeSH:C0003364] animal result suggest ppa caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] lead cerebral hemorrhage [MeSH:C2937358] [MeSH:C2937358] previously hypertensive [MeSH:C0003364] [MeSH:C0003364] animal administer great allow dosage [MeSH:C0178655] acute elevation blood pressure contribute factor [MeSH:C0033453],cardiovascular
immunohistochemical study antibody neurofilament protein axonal damage experimental [MeSH:C0016998] focal lesion [MeSH:C0887870] rat [MeSH:C0034721],immunohistochemistry [MeSH:C0021044] monoclonal antibody [MeSH:C0443933] neurofilament nf protein middle high molecular weight [MeSH:C0026385] class nf-m nf-h axonal injury borderzone focal lesion rat [MeSH:C0034721] focal injury cortex produce infusion [MeSH:C0841792] lactate acid ph stab cause needle insertion infarct substantia nigra par reticulata evoke prolonged pilocarpine-induced status epilepticus immunohistochemical staining [MeSH:C0021044] nfs show characteristic terminal club axon borderzone lesion difference labelling pattern occur different antibody [MeSH:C0443933] apparently depend molecular weight [MeSH:C0026385] class nfs phosphorylation state [MeSH:C0031715] immunohistochemical change [MeSH:C0021044] nfs serve marker [MeSH:C0017393] axonal damage experimental traumatic ischemic lesion,neurological
characterization myotonic dystrophy region predict multiple protein isoform-encoding mrna,mutation [MeSH:C0026882] underlie myotonic dystrophy dm [MeSH:C0027126] identify expansion [MeSH:C0196940] polymorphic [MeSH:C1720758] ctg-repeat gene [MeSH:C0017337] encoding protein [MeSH:C0033684] kinase [MeSH:C0033640] activity brain heart transcript [MeSH:C1136156] dm-kinase [MeSH:C0216045] dmr-b1 gene [MeSH:C0017337] subject alternative rna splicing [MeSH:C0035687] human [MeSH:C0086418] [MeSH:C0086418] mouse [MeSH:C0026809] unstable ctg motif find uniquely human [MeSH:C0086418] [MeSH:C0086418] flanking nucleotide [MeSH:C0028630] present mouse [MeSH:C0026809] characterization dm region specie reveal active gene [MeSH:C0017337] dmr-n9 close proximity kinase gene [MeSH:C0017337] dmr-n9 transcript [MeSH:C1136156] mainly express brain testis [MeSH:C0039597] possess single large open reading frame function protein [MeSH:C0033684] product unknown manifestation [MeSH:C0029166] dm cause expand ctg-repeat compromise alternative expression dm-kinase [MeSH:C0216045] dmr-n9 protein [MeSH:C0033684],neurological|cardiovascular
hepatitis [MeSH:C0019158] cardiac function [MeSH:C0018803],diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve regurgitation insufficiency method conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine endothelium [MeSH:C0014257] parameter result improve disease management [MeSH:C0039798] relevance,cardiovascular
differential effect -dihydropyridine calcium channel blocker [MeSH:C0006684] therapeutic [MeSH:C0087111] implication,increase recognition [MeSH:C0871740] importance calcium [MeSH:C0006675] pathogenesis [MeSH:C0699748] cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] stimulate use calcium [MeSH:C0006675] channel blocking agent variety cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] favorable efficacy [MeSH:C5690761] tolerability profile agent attractive therapeutic [MeSH:C0087111] modality application [MeSH:C3658310] calcium [MeSH:C0006675] channel blocker parallel tissue selectivity contrast verapamil [MeSH:C0042523] diltiazem [MeSH:C0012373] roughly equipotent action heart vascular smooth muscle [MeSH:C0026844] dihydropyridine [MeSH:C0220821] calcium [MeSH:C0006675] channel blocker potent peripheral vasodilator agent exert minimal [MeSH:C0003062] electrophysiologic effect [MeSH:C2350527] cardiac nodal conduction tissue dihydropyridine [MeSH:C0220821] available use united state nifedipine [MeSH:C0028066] control angina [MeSH:C0002965] hypertension [MeSH:C0020538] minimal [MeSH:C0003062] depression [MeSH:C0011570] cardiac function [MeSH:C0018803] additional member calcium [MeSH:C0006675] channel blocker study [MeSH:C0085973] variety indication offer advantage current therapy [MeSH:C0039798] twice daily dosage possible nitrendipine nisoldipine [MeSH:C0028116] [MeSH:C0028116] offer convenient administration schedule [MeSH:C0013154] encourage compliance long-term therapy [MeSH:C0039798] hypertension [MeSH:C0020538] coronary vasodilating property nisoldipine [MeSH:C0028116] lead investigation agent use angina [MeSH:C0002965] selectivity cerebrovascular bed make nimodipine [MeSH:C0028094] potentially useful subarachnoid [MeSH:C0038527] hemorrhage migraine headache [MeSH:C0149931] dementia [MeSH:C0497327] stroke [MeSH:C0038454] general dihydropyridine [MeSH:C0220821] calcium [MeSH:C0006675] channel blocker usually tolerate headache facial flush palpitation edema nausea anorexia dizziness common adverse effect [MeSH:C0001688],neurological|cardiovascular
crohn disease [MeSH:C0010346] fusidic acid [MeSH:C0016875] antibiotic [MeSH:C0003232] immunosuppressive property [MeSH:C0021081] similar cyclosporin [MeSH:C0010592],fusidic acid [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] antibiotic t-cell [MeSH:C0003232] specific immunosuppressive effect [MeSH:C0021081] similar cyclosporin [MeSH:C0010592] need development [MeSH:C0243107] new treatment crohn disease pilot [MeSH:C0473169] [MeSH:C0473169] undertake estimate pharmacodynamic tolerability fusidic acid [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] chronic [MeSH:C0150055] active therapy-resistant patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] crohn disease patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] include fusidic acid [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] administer orally dose mg plan week disease activity primarily measure [MeSH:C0079809] modify individual grading score patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] improve fusidic acid [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] week week effect dose reduction [MeSH:C1827449] require patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] nausea biochemically increase alkaline phosphatase [MeSH:C0002059] note case great increase see elevated [MeSH:C0020443] level [MeSH:C0018759] prior reverse pre-treatment [MeSH:C0039798] level [MeSH:C0018759] cessation result pilot [MeSH:C0473169] [MeSH:C0473169] suggest fusidic acid [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] benefit [MeSH:C0021674] select chronic [MeSH:C0150055] active crohn disease patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] conventional ineffective exist scientific rationale use fusidic acid [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] [MeSH:C0016875] cytokine [MeSH:C0079189] inflammatory bowel disease [MeSH:C0021390] suggest role investigate [MeSH:C0035173],neurological
nebulin [MeSH:C0068477] see dmd [MeSH:C1437024] male [MeSH:C0086582] include large dna deletion encompass dmd [MeSH:C1437024] gene,presence nebulin muscle specimen [MeSH:C0200345] duchenne muscular dystrophy [MeSH:C0013264] dmd large deletion preclude possibility protein [MeSH:C0033684] dmd gene product,neurological
use toxicity [MeSH:C0040539] didanosine ddi hiv antibody-positive individual [MeSH:C0021228] intolerant zidovudine azt [MeSH:C0043474],fifty-one patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] intolerant zidovudine azt [MeSH:C0043474] receive didanosine [MeSH:C0012133] [MeSH:C0012133] ddi [MeSH:C0012133] maximum dose mg kg response assess change cd4 lymphocyte subset [MeSH:C0079720] [MeSH:C0079720] count hiv p2 antigen [MeSH:C0003320] weight quality [MeSH:C0034379] life [MeSH:C0376558] seventy patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop major opportunistic infection [MeSH:C0029118] whilst therapy [MeSH:C0039798] aid diagnosis [MeSH:C0011900] minor change cd4 lymphocyte subset [MeSH:C0079720] [MeSH:C0079720] count observe aid patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] rise occur early stage disease positive p2 antigen [MeSH:C0003320] commencement [MeSH:C0282411] show positive response likely cd4 lymphocyte subset [MeSH:C0079720] [MeSH:C0079720] count mm3 positive weight response see patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show improvement [MeSH:C2936612] individual parameter global score quality [MeSH:C0034379] life [MeSH:C0376558] adverse reaction [MeSH:C0041755] possibly attributable didanosine [MeSH:C0012133] [MeSH:C0012133] common common side-effect diarrhoea result cessation therapy [MeSH:C0039798] [MeSH:C0039798] individual peripheral neuropathy [MeSH:C4721453] occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pancreatitis thirteen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop raise serum amylase abdominal pain [MeSH:C0000737] seven patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop glucose tolerance curve [MeSH:C0017741] characteristic diabete mild require return normal cease didanosine [MeSH:C0012133] [MeSH:C0012133],neurological
systemic [MeSH:C5544477] toxicity [MeSH:C0040539] resuscitation bupivacaine- levobupivacaine- ropivacaine-infused [MeSH:C0073571] rat [MeSH:C0034721],compare systemic [MeSH:C5544477] [MeSH:C5544477] toxicity [MeSH:C0040539] [MeSH:C0040539] bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] levobupivacaine [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400] ropivacaine [MeSH:C0073571] [MeSH:C0073571] anesthetize rat [MeSH:C0034721] [MeSH:C0034721] compare ability resuscitate rat [MeSH:C0034721] [MeSH:C0034721] lethal dose [MeSH:C0023378] local anesthetic bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] levobupivacaine [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400] ropivacaine [MeSH:C0073571] [MeSH:C0073571] infuse rat [MeSH:C0034721] [MeSH:C0034721]e mg kg min electrocardiogram [MeSH:C0013798] electroencephalogram arterial pressure continuously monitor asystole [MeSH:C0018790] record drug infusion stop resuscitation [MeSH:C0035273] [MeSH:C0035273] sequence begin epinephrine [MeSH:C0014563] [MeSH:C0014563] mg kg administer [MeSH:C0001554] -min interval [MeSH:C0005605] external [MeSH:C0458561] cardiac compression apply resuscitation [MeSH:C0035273] [MeSH:C0035273] consider successful systolic arterial pressure [MeSH:C0871470] mm hg achieve min cumulative dose levobupivacaine [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400] ropivacaine [MeSH:C0073571] [MeSH:C0073571] produce seizure [MeSH:C0036572] similar large bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] cumulative dose levobupivacaine [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400] produce dysrhythmia [MeSH:C0003811] asystole [MeSH:C0018790] small corresponding dose ropivacaine [MeSH:C0073571] [MeSH:C0073571] large bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] number successful resuscitation [MeSH:C0035273] [MeSH:C0035273] differ group small dose epinephrine [MeSH:C0014563] [MeSH:C0014563] require ropivacaine [MeSH:C0073571] [MeSH:C0073571] group conclude systemic [MeSH:C5544477] [MeSH:C5544477] toxicity [MeSH:C0040539] [MeSH:C0040539] levobupivacaine [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400] intermediate ropivacaine [MeSH:C0073571] [MeSH:C0073571] bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] administer [MeSH:C0001554] rat [MeSH:C0034721] [MeSH:C0034721]e ropivacaine [MeSH:C0073571] [MeSH:C0073571]-induced cardiac arrest appear susceptible induce bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] levobupivacaine [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0006400] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0873118] [MeSH:C0006400],neurological|cardiovascular
brain [MeSH:C0006104] dynamic epilepsy trigeminal neuralgia [MeSH:C0040997],hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve palsy reticular formation method [MeSH:C0035284] conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine convulsion [MeSH:C4048158] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] practice guideline,neurological
torsade de pointe ventricular tachycardia low dose [MeSH:C0078888] intermittent [MeSH:C4704881] dobutamine dilate cardiomyopathy [MeSH:C0007193] congestive heart failure [MeSH:C0018802],author describe case -year-old woman [MeSH:C0043210] chronic severe heart failure [MeSH:C0018801] secondary dilated cardiomyopathy [MeSH:C0007193] absence ventricular arrhythmia [MeSH:C0003811] [MeSH:C0042514] develop qt prolongation torsade de pointe ventricular tachycardia [MeSH:C0042514] cycle [MeSH:C0042514] intermittent [MeSH:C4704881] low dose mcg kg min dobutamine [MeSH:C0012963] report torsade de pointe ventricular tachycardia [MeSH:C0042514] intermittent [MeSH:C4704881] dobutamine [MeSH:C0012963] support hypothesis [MeSH:C3179072] unpredictable fatal arrhythmia [MeSH:C0003811] occur low dose patient history [MeSH:C0019664] rhythm disturbance mechanism proarrhythmic effect dubutamine discuss,neurological|cardiovascular
lymphoma [MeSH:C0024299] cardiac function [MeSH:C0018803],design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] myocardium bradycardia [MeSH:C0428977] result enhance therapeutic response [MeSH:C0087111] aortic aneurysm correlation therapeutic innovation [MeSH:C0087111],cardiovascular
differential modulation estrogen alpha2-adrenergic i1-imidazoline receptor-mediated hypotension female rat,recently show estrogen [MeSH:C0014939] negatively modulate hypotensive effect [MeSH:C4277511] clonidine [MeSH:C0009014] mixed alpha2- i1-receptor agonist female [MeSH:C0086287] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] implicate cardiovascular [MeSH:C0007220] autonomic interaction [MeSH:C0007582] present investigate [MeSH:C0035173] effect [MeSH:C4277511] estrogen [MeSH:C0014939] involve interaction [MeSH:C0007582] alpha2- i1-receptors change evoke single intraperitoneal [MeSH:C0021493] injection [MeSH:C1828121] rilmenidine [MeSH:C0140591] [MeSH:C0140591] [MeSH:C0140591] microg kg alpha-methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] mg kg selective i1- alpha2-receptor agonist respectively blood pressure hemodynamic [MeSH:C0019010] [MeSH:C0019010] [MeSH:C0005823] variability [MeSH:C0003319] [MeSH:C0003319] [MeSH:C0003319] locomotor activity [MeSH:C0023946] [MeSH:C0023946] assess radiotelemetered sham-operat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ed ovariectomized [MeSH:C0029936] ovx sprague-dawley female [MeSH:C0086287] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] -wk estrogen [MeSH:C0014939] replacement domain index hemodynamic [MeSH:C0019010] [MeSH:C0019010] variability [MeSH:C0003319] [MeSH:C0003319] [MeSH:C0003319] employ standard deviation mean arterial pressure blood pressure [MeSH:C1272641] variability [MeSH:C0003319] [MeSH:C0003319] [MeSH:C0003319] standard deviation beat-to-beat interval sdrr root mean square successive difference r-wave-to-r-wave interval measure heart rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e variability [MeSH:C0003319] [MeSH:C0003319] [MeSH:C0003319] sham-operat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] rilmenidine [MeSH:C0140591] [MeSH:C0140591] [MeSH:C0140591] alpha-methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] elicit similar hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] last h associate reduction [MeSH:C1827449] standard deviation mean arterial pressure sdrr reduce alpha-methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] ovx significantly enhance hypotensive response alpha-methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] contrast effect [MeSH:C4277511] rilmenidine [MeSH:C0140591] [MeSH:C0140591] [MeSH:C0140591] hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] enhance alpha-methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] ovx rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] parallel reduction [MeSH:C1827449] sdrr reduce locomotor activity [MeSH:C0023946] [MeSH:C0023946] estrogen [MeSH:C0014939] replacement 7beta-estradiol subcutaneous pellet [MeSH:C0222331] microg wk ovx rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] restore hemodynamic [MeSH:C0019010] [MeSH:C0019010] locomotor effect [MeSH:C4277511] alpha-methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] sham-operat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ed level [MeSH:C0018759] finding suggest estrogen [MeSH:C0014939] downregulate alpha2- i1-receptor-mediate hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] highlight role cardiac autonomic alpha-methyldopa [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741] [MeSH:C0025741]-estrogen [MeSH:C0014939] interaction [MeSH:C0007582],cardiovascular
susceptibility seizure produce pilocarpine [MeSH:C0031923] rat [MeSH:C0034721] microinjection [MeSH:C0025991] isoniazid [MeSH:C0022209] gamma-vinyl-gaba substantia nigra [MeSH:C0048044],pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] give intraperitoneally rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] reproduce neuropathological sequela temporal lobe epilepsy [MeSH:C0014556] provide relevant animal [MeSH:C0003062] [MeSH:C0003062] model [MeSH:C0599779] study [MeSH:C0085973] mechanism [MeSH:C1524059] buildup convulsive activity [MeSH:C0020115] [MeSH:C0020115] pathway operat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ive generalization propagation seizure [MeSH:C0036572] forebrain present effect [MeSH:C4277511] manipulate activity [MeSH:C0020115] [MeSH:C0020115] gamma-aminobutyric acid gaba [MeSH:C0016904] -mediated synaptic inhibition substantia nigra [MeSH:C0038590] seizure [MeSH:C0036572] produce pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] investigate [MeSH:C0035173] animal [MeSH:C0003062] [MeSH:C0003062] pretreate microinjection [MeSH:C0025991] [MeSH:C0025991] isoniazid [MeSH:C0022209] [MeSH:C0022209] microgram [MeSH:C0376691] inhibitor [MeSH:C0003015] [MeSH:C0003015] activity [MeSH:C0020115] [MeSH:C0020115] gaba-synthesizing enzyme l-glutamic acid decarboxylase substantia nigra [MeSH:C0038590] par reticulata [MeSH:C0175413] snr bilaterally non-convulsant dose [MeSH:C0009950] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] mg kg result severe motor limbic seizure [MeSH:C0036572] [MeSH:C0751494] status epilepticus electroencephalographic [MeSH:C0013819] behavioral [MeSH:C0004927] monitoring [MeSH:C0005517] reveal profound reduction threshold [MeSH:C0162703] [MeSH:C0162703] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923]-induced convulsion [MeSH:C4048158] morphological frontal forebrain section light microscopy reveal seizure [MeSH:C0036572]-related damage hippocampal formation thalamus amygdala olfactory cortex substantia nigra [MeSH:C0038590] neocortex [MeSH:C0038590] typically observe pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] dose exceed mg kg bilateral intrastriatal injection [MeSH:C0021498] isoniazid [MeSH:C0022209] [MeSH:C0022209] augment seizure [MeSH:C0036572] produce pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] mg kg application irreversible inhibitor [MeSH:C0003015] [MeSH:C0003015] gaba transaminase [MeSH:C0002543] gamma-vinyl-gaba l amino-hex enoic acid microgram [MeSH:C0376691] snr bilaterally suppress [MeSH:C0017372] appearance [MeSH:C0750731] electrographic [MeSH:C0200125] behavioral [MeSH:C0004927] seizure [MeSH:C0036572] produce pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] mg kg sufficient protect animal [MeSH:C0003062] [MeSH:C0003062] occurrence brain damage [MeSH:C0006109] microinjection [MeSH:C0025991] [MeSH:C0025991] gamma-vinyl-gaba microgram [MeSH:C0048044] [MeSH:C0376691] dorsal striatum bilaterally fail prevent [MeSH:C0000918] development [MeSH:C0243107] convulsion [MeSH:C4048158] produce pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] mg kg result demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e threshold [MeSH:C0162703] [MeSH:C0162703] pilocarpine [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923] [MeSH:C0031923]-induced seizure [MeSH:C0036572] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] subject regulation gaba-mediated synaptic inhibition substantia nigra [MeSH:C0038590],neurological|hepatorenal
uremia [MeSH:C0041948] pathway cancer [MeSH:C0282655],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete nephritis mechanism method cross-sectional adult population assess albumin [MeSH:C0001924] liver transplant [MeSH:C0023911] result decrease mortality rate [MeSH:C0205848] implication healthcare advancement,hepatorenal
late infantile metachromatic leukodystrophy israel [MeSH:C0751278],metachromatic leukodystrophy [MeSH:C0023522] mld neurodegenerative disease [MeSH:C0524851] lysosomal [MeSH:C0024369] enzyme [MeSH:C0014442] aryl sulfatase arsa deficient disease inherit autosomal recessive trait frequency estimate live birth [MeSH:C0005615] gene [MeSH:C0481667] arsa clone [MeSH:C0009013] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cause mld report mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] pd lead deficiency [MeSH:C1623416] enzyme [MeSH:C0014442] vitro pseudodeficiency [MeSH:C1623416] known effect pd mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] frequent [MeSH:C0017270] [MeSH:C0017270] population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] israel [MeSH:C0022271] late infantile [MeSH:C0266836] mld find frequent [MeSH:C0017270] [MeSH:C0017270] small jewish isolate habbanite jew live birth [MeSH:C0005615] molecular demonstrate habbanite population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] occur allele pd [MeSH:C0002085] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] loss arsa activity point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] c lead proline leucine [MeSH:C0023401] mld frequent [MeSH:C0017270] [MeSH:C0017270] moslem arab jerusalem mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] transition [MeSH:C1257888] g destroy splice donor site [MeSH:C0887917] exon mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] report patient [MeSH:C0030705] late infantile [MeSH:C0266836] mld different ethnic group [MeSH:C5441552] christian arab israel [MeSH:C0022271] high incidence [MeSH:C0021149] disease live birth [MeSH:C0005615] mutation [MeSH:C0026882] [MeSH:C0005615] [MeSH:C0026882] [MeSH:C0026882] population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] unknown knowledge different mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cause mld define population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] allow carrier screening program [MeSH:C0019426] carry prevent [MeSH:C0000918] birth [MeSH:C0005615] additional affect child [MeSH:C0008059],neurological
diuretic parkinson disease [MeSH:C0030567] brain [MeSH:C0006104] insight,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] acetylcholine method [MeSH:C0001041] cardiac patient undergo longitudinal [MeSH:C0023981] cerebellar myelopathy [MeSH:C0037928] assessment [MeSH:C0030198] result improvement primary endpoint practice guideline,neurological|oncological
nitrate epilepsy [MeSH:C0014544] brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] oligodendroglioma pathway method randomized control trial [MeSH:C1096777] elderly patient measure gaba tremor [MeSH:C0016904] result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
neural pattern multiple sclerosis [MeSH:C0026769] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome [MeSH:C0206277] locus coeruleus pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure dementia [MeSH:C0497327] encephalitis [MeSH:C0014038] result improve disease management [MeSH:C0039798] healthcare advancement,neurological
explore angina pectoris [MeSH:C0002962] liver fibrosis [MeSH:C0239946],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome bilirubin pathway method observational trial [MeSH:C0302523] adult [MeSH:C0001675] population measure hepatocellular alt [MeSH:C0345904] result superior efficacy [MeSH:C5690761] optimization [MeSH:C0376695],hepatorenal
increase frequency severity [MeSH:C0017270] angio-oedema [MeSH:C0002994] related long-term [MeSH:C0023977] therapy angiotensin-converting enzyme inhibitor [MeSH:C0003015] patient [MeSH:C0030705],adverse reaction [MeSH:C0041755] drug [MeSH:C0013227] [MeSH:C0041755] recognize cause acute chronic urticaria angio-oedema [MeSH:C0002994] angiotensin-converting enzyme ace inhibitor [MeSH:C0003015] [MeSH:C0003015] [MeSH:C0003015] treat hypertension [MeSH:C0020538] congestive heart failure [MeSH:C0018802] introduce europe middle eighty use drug [MeSH:C0013227] increase progressively soon introduction [MeSH:C0033268] ace inhibitor [MeSH:C0003015] [MeSH:C0003015] acute bout angio-oedema [MeSH:C0002994] report association use drug [MeSH:C0013227] wish draw attention possibility adverse reaction [MeSH:C0041755] ace inhibitor [MeSH:C0003015] [MeSH:C0003015] long-term [MeSH:C0023977] use patient [MeSH:C0030705] pre-existing angio-oedema [MeSH:C0002994],cardiovascular
minocycline-induced vasculitis fulfil criterion [MeSH:C0243161] polyarteritis nodosa [MeSH:C0031036],-year-old man take minocycline [MeSH:C0026187] [MeSH:C0026187] palmoplantar pustulosis [MeSH:C0030246] develop fever [MeSH:C0015967] myalgia polyneuropathy [MeSH:C0152025] testicular pain elevated c-reactive protein crp [MeSH:C0006560] myeloperoxidase- proteinase antineutrophil cytoplasmic antibody [MeSH:C0103647] positive manifestation [MeSH:C0029166] meet american [MeSH:C0002454] college rheumatology [MeSH:C0035452] criterion [MeSH:C0243161] classification [MeSH:C0008902] polyarteritis nodosa [MeSH:C0031036] stop minocycline [MeSH:C0026187] [MeSH:C0026187] lead amelioration symptom normalization crp knowledge second case minocycline [MeSH:C0026187] [MeSH:C0026187]-induced vasculitis satisfy criterion [MeSH:C0243161] differential diagnosis [MeSH:C0011906] drug-induced disease [MeSH:C0860207] invaluable patient [MeSH:C0030705] classical polyarteritis nodosa [MeSH:C0031036],neurological
cancer renal [MeSH:C0740457] stone organ [MeSH:C0029250] interplay,question statin affect dementia [MeSH:C0497327] bilirubin mechanism method retrospective [MeSH:C0035363] elderly patient assess polyuria [MeSH:C0032617] cholelithiasis [MeSH:C0008350] result positive response implication healthcare advancement,hepatorenal
anuria [MeSH:C0003460] pathway prostate cancer [MeSH:C0376358],hypothesis [MeSH:C3179072] aspirin improve stroke [MeSH:C0038454] outcome acute kidney injury pathway method [MeSH:C2609414] randomized control trial [MeSH:C1096777] cardiac patient measure renal ast result positive response need investigation [MeSH:C0035173],hepatorenal
duchenne becker muscular dystrophy [MeSH:C3542021] correlation phenotype electroretinography site dystrophin mutation [MeSH:C0079259],dark-adapted electroretinogram erg patient [MeSH:C0030705] [MeSH:C0030705] duchenne becker muscular dystrophy [MeSH:C0917713] dmd [MeSH:C1437024] bmd show marked reduction [MeSH:C1827449] [MeSH:C1827449] b-wave amplitude genotype-phenotype [MeSH:C2717879] [MeSH:C0031437] [MeSH:C0031437] study [MeSH:C2717879] mouse [MeSH:C0026809] [MeSH:C0026809] model dmd [MeSH:C1437024] position-specific effect [MeSH:C3658217] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] phenotype [MeSH:C0031437] [MeSH:C0031437] mouse [MeSH:C0026809] [MeSH:C0026809] defect dystrophin normal [MeSH:C0079259] ergs defect central region normal b-wave amplitude associate prolonged implicit time b-wave oscillatory potential mouse [MeSH:C0026809] [MeSH:C0026809] defect phenotype [MeSH:C0031437] [MeSH:C0031437] similar see dmd [MeSH:C1437024] bmd patient [MeSH:C0030705] [MeSH:C0030705] mouse [MeSH:C0026809] [MeSH:C0026809] study suggest key role carboxyl terminal dystrophin isoform [MeSH:C0597298] dp2 retinal [MeSH:C0035331] [MeSH:C0035331] [MeSH:C0035331] electrophysiology [MeSH:C0013865] undertake systematic [MeSH:C0008902] dmd [MeSH:C1437024] bmd patient [MeSH:C0030705] [MeSH:C0030705] examination review literature [MeSH:C0023866] order determine position-specific effect [MeSH:C3658217] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] note mouse [MeSH:C0026809] [MeSH:C0026809] present man find man wide variation dmd [MeSH:C1437024] defect correlate reduction [MeSH:C1827449] [MeSH:C1827449] b-wave amplitude individual normal ergs mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] predominantly located transcript [MeSH:C1136156] [MeSH:C1136156] initiation [MeSH:C0030943] site dp2 result suggest important determinant erg b-wave phenotype [MeSH:C0031437] [MeSH:C0031437] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] position muscle disease [MeSH:C0043153] severity forty-six cent patient [MeSH:C0030705] [MeSH:C0030705] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] dp2 transcript [MeSH:C1136156] [MeSH:C1136156] start site abnormal [MeSH:C0853087] ergs oppose distal mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] human [MeSH:C0086418] genotype-phenotype [MeSH:C2717879] [MeSH:C0031437] [MeSH:C0031437] correlation consistent role dp2 normal retinal [MeSH:C0035331] [MeSH:C0035331] [MeSH:C0035331] electrophysiology [MeSH:C0013865] reflect expression [MeSH:C0017262] c-terminal dystrophin isoform [MeSH:C0597298] contribution retinal [MeSH:C0035331] [MeSH:C0035331] [MeSH:C0035331] signal transmission [MeSH:C0040722],neurological
dvt cancer vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome arterial pathway method cross-sectional trial cancer [MeSH:C0010362] patient [MeSH:C0030705] measuring myocardium [MeSH:C0027061] endothelial [MeSH:C0225336] result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],cardiovascular
serotonergic drug [MeSH:C0242701] benzodiazepine baclofen [MeSH:C4048284] block muscimol-induced myoclonic jerk strain mouse,male [MeSH:C0086582] swiss [MeSH:C0950143] mouse muscimol [MeSH:C0026818] [MeSH:C0026818] produce myoclonic jerk [MeSH:C0027066] [MeSH:C0027066] mg kg p dose induce response mouse test peak response jerk min observe min increase brain [MeSH:C0006104] serotonin level administration [MeSH:C0001554] -hydroxytryptophan mg kg combination peripheral decarboxylase inhibitor result inhibition [MeSH:C0027790] muscimol [MeSH:C0026818] [MeSH:C0026818] effect similar experiment [MeSH:C0020123] l-dopa [MeSH:C0023570] mg kg effect dose mg kg serotonin receptor agonist [MeSH:C0162757] mk- cause dose-dependent block [MeSH:C5197800]ade response muscimol [MeSH:C0026818] [MeSH:C0026818] benzodiazepine [MeSH:C4048284] clonazepam mg kg find fold potent diazepam [MeSH:C0012010] mg kg block [MeSH:C5197800] myoclonic jerk [MeSH:C0027066] [MeSH:C0027066] -baclofen mg kg prove effective [MeSH:C5392218] antagonist [MeSH:C0033607] muscimol [MeSH:C0026818] [MeSH:C0026818] -isomer mg kg lack property consider fact -htp benzodiazepine [MeSH:C4048284] find beneficial management [MeSH:C0085971] [MeSH:C0085971] myoclonus [MeSH:C0027066] muscimol [MeSH:C0026818] [MeSH:C0026818]-induced myoclonus [MeSH:C0027066] satisfactory animal model [MeSH:C0599779] prove useful development [MeSH:C0243107] new drug treatment [MeSH:C0039798] condition present indicate possible mk- -baclofen management [MeSH:C0085971] [MeSH:C0085971] myoclonus [MeSH:C0027066],neurological
intravenous ribavirin [MeSH:C0035525] severe adenovirus disease [MeSH:C0001483] immunocompromised child [MeSH:C0085393],adenovirus [MeSH:C0001483] [MeSH:C0001483] important cause morbidity [MeSH:C0026538] mortality [MeSH:C0026565] immunocompromise host [MeSH:C0085393] incidence [MeSH:C0021149] severe [MeSH:C1719672] adenovirus [MeSH:C0001483] [MeSH:C0001483] disease pediatric [MeSH:C0237433] increase association grow number immunocompromised child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0085393] [MeSH:C0085393] case fatality [MeSH:C0282250] rate high report approve antiviral [MeSH:C0003451] agent [MeSH:C0003451] prove efficacy [MeSH:C5690761] severe [MeSH:C1719672] adenovirus [MeSH:C0001483] [MeSH:C0001483] disease prospective randomized controlled trial [MeSH:C1096777] potentially useful anti-adenovirus [MeSH:C0001483] [MeSH:C0001483] therapy apparent success severe [MeSH:C1719672] adenovirus [MeSH:C0001483] [MeSH:C0001483] disease limited case report [MeSH:C0684224] small series experience great intravenous [MeSH:C0085297] [MeSH:C0085297] ribavirin [MeSH:C0035525] cidofovir [MeSH:C0286079] [MeSH:C0286079] ribavirin [MeSH:C0035525] guanosine analogue broad antiviral [MeSH:C0003451] activity [MeSH:C0003451] rna dna virus [MeSH:C0012923] include document [MeSH:C0009797] activity adenovirus [MeSH:C0001483] [MeSH:C0001483] vitro ribavirin [MeSH:C0035525] license aerosol form [MeSH:C1112870] respiratory syncytial virus infection [MeSH:C3714514] [MeSH:C0035235] orally combination interferon treat hepatitis c [MeSH:C0019196] intravenous [MeSH:C0085297] [MeSH:C0085297] ribavirin [MeSH:C0035525] choice infection [MeSH:C3714514] hemorrhagic fever virus common adverse effect [MeSH:C0001688] [MeSH:C0001688] intravenous [MeSH:C0085297] [MeSH:C0085297] ribavirin [MeSH:C0035525] reversible mild anemia use cidofovir [MeSH:C0286079] [MeSH:C0286079] severe [MeSH:C1719672] adenovirus [MeSH:C0001483] [MeSH:C0001483] infection [MeSH:C3714514] limit adverse effect [MeSH:C0001688] [MeSH:C0001688] nephrotoxicity report experience intravenous [MeSH:C0085297] [MeSH:C0085297] ribavirin [MeSH:C0035525] therapy severe [MeSH:C1719672] adenovirus [MeSH:C0001483] [MeSH:C0001483] disease series immunocompromised child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0085393] [MeSH:C0085393] review literature design method retrospectively review medical record [MeSH:C0025102] child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] treat intravenous [MeSH:C0085297] [MeSH:C0085297] ribavirin [MeSH:C0035525] document [MeSH:C0009797] severe [MeSH:C1719672] adenovirus [MeSH:C0001483] [MeSH:C0001483] disease patient [MeSH:C0030705] [MeSH:C0030705] develop adenovirus [MeSH:C0001483] [MeSH:C0001483] hemorrhagic cystitis cardiac bone marrow transplant [MeSH:C0005961] [MeSH:C0005961] respectively bone marrow transplant [MeSH:C0005961] receive intravenous [MeSH:C0085297] [MeSH:C0085297] cidofovir [MeSH:C0286079] [MeSH:C0286079] progressive [MeSH:C1449744] disseminate disease additional child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] develop adenovirus [MeSH:C0001483] [MeSH:C0001483] pneumonia neonate partial digeorge syndrome [MeSH:C0012236] remain infant [MeSH:C0021270] recently undergo cardiac transplant [MeSH:C0018823] [MeSH:C0018823] intravenous [MeSH:C0085297] [MeSH:C0085297] ribavirin [MeSH:C0035525] administer compassionate-use protocol result complete recovery [MeSH:C0140116] follow later viral clearance observe child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] cardiac transplant [MeSH:C0018823] [MeSH:C0018823] recipient adenovirus [MeSH:C0001483] [MeSH:C0001483] hemorrhagic cystitis immunocompetent [MeSH:C0020987] neonate adenovirus [MeSH:C0001483] [MeSH:C0001483] pneumonia remain child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] die adenovirus [MeSH:C0001483] [MeSH:C0001483] disease intravenous [MeSH:C0085297] [MeSH:C0085297] ribavirin [MeSH:C0035525] therapy tolerate use cidofovir [MeSH:C0286079] [MeSH:C0286079] child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] associate progressive [MeSH:C1449744] renal failure [MeSH:C0035078] neutropenia discussion [MeSH:C0027947] series patient [MeSH:C0030705] [MeSH:C0030705] representative spectrum immunocompromised [MeSH:C0085393] child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0085393] [MeSH:C0085393] great risk [MeSH:C0035647] severe [MeSH:C1719672] adenovirus [MeSH:C0001483] [MeSH:C0001483] disease solid-organ bone marrow transplant [MeSH:C0005961] recipient neonate child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] immunodeficiency intravenous [MeSH:C0085297] [MeSH:C0085297] ribavirin [MeSH:C0035525] effective [MeSH:C5392218] [MeSH:C5392218] child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] severe [MeSH:C1719672] adenovirus [MeSH:C0001483] [MeSH:C0001483] disease series literature therapy [MeSH:C0023866] unlikely benefit begin late course infection [MeSH:C3714514] early identification [MeSH:C1707660] eg polymerase chain reaction [MeSH:C0032520] [MeSH:C0032520] patient [MeSH:C0030705] [MeSH:C0030705] risk disseminate adenovirus [MeSH:C0001483] [MeSH:C0001483] disease permit early antiviral [MeSH:C0003451] well therapeutic response [MeSH:C0087111] conclusion child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] severe [MeSH:C1719672] adenovirus [MeSH:C0001483] [MeSH:C0001483] disease treat intravenous [MeSH:C0085297] [MeSH:C0085297] ribavirin [MeSH:C0035525] recover availability new rapid diagnostic technique [MeSH:C0011919] polymerase chain reaction [MeSH:C0032520] [MeSH:C0032520] early effective [MeSH:C5392218] [MeSH:C5392218] adenovirus [MeSH:C0001483] [MeSH:C0001483] infection [MeSH:C3714514] possible give seriousness increase prevalence [MeSH:C0033105] adenovirus [MeSH:C0001483] [MeSH:C0001483] disease certain host especially child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0008059] large multicenter trial [MeSH:C0206012] potentially useful anti-adenoviral therapy intravenous [MeSH:C0085297] [MeSH:C0085297] ribavirin [MeSH:C0035525] clearly require demonstrate effective [MeSH:C5392218] [MeSH:C5392218] toxic therapy [MeSH:C0039798],hepatorenal
cancer cellular atrial fibrillation [MeSH:C0004238],hypothesis statin improve stroke outcome thyroid cancer [MeSH:C0549473] pathway method retrospective trial adult [MeSH:C0001675] population measure chemotherapy [MeSH:C0013216] multiple myeloma [MeSH:C0026764] result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],oncological
stenosis [MeSH:C1261287] myocardial infarction [MeSH:C0027051] vascular [MeSH:C0221214] insight,prospective examine beta-blocker hypertension cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include atrioventricular block pe arterial method [MeSH:C0004245] participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication healthcare advancement,cardiovascular
epilepsy [MeSH:C0014544] pe cardiac connection,hypothesis [MeSH:C3179072] aspirin improve diabete outcome [MeSH:C0206277] myocardium pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure aortic aneurysm ventricle [MeSH:C0003486] result improve disease management [MeSH:C0039798] healthcare advancement,cardiovascular
mechanism [MeSH:C1524059] protective effect free radical scavenger [MeSH:C0079381] gentamicin-mediated nephropathy rat [MeSH:C0034721],study [MeSH:C0085973] perform examine mechanism [MeSH:C1524059] [MeSH:C1524059] protective effect free radical scavenger [MeSH:C0079381] gentamicin gm -mediated nephropathy administrat [MeSH:C0034721] [MeSH:C0034721]ion gm mg kg sc day [MeSH:C0011017] rat [MeSH:C0034721] [MeSH:C0034721] induce reduction [MeSH:C1827449] renal [MeSH:C0152169] blood flow [MeSH:C1527409] rbf [MeSH:C0206089] inulin [MeSH:C0021936] clearance [MeSH:C5243473] cin marked tubular damage reduction [MeSH:C1827449] urinary guanosine [MeSH:C0018330] -cyclic monophosphate cgmp excretion [MeSH:C1373187] increase renal [MeSH:C0152169] cortical renin [MeSH:C0022656] endothelin- content [MeSH:C0017177] [MeSH:C0017177] observe gm-mediate nephropathy superoxide dismutase sod [MeSH:C0669516] [MeSH:C0669516] [MeSH:C0038838] dimethylthiourea dmtu significantly lessen gm-induce decrement cin sod [MeSH:C0669516] [MeSH:C0669516]-induced increase glomerular filtrat [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721]e associate marked improvement [MeSH:C2936612] rbf [MeSH:C0206089] increase urinary cgmp excretion [MeSH:C1373187] decrease renal [MeSH:C0152169] renin [MeSH:C0035094] endothelin- content [MeSH:C0017177] [MeSH:C0017177] sod [MeSH:C0669516] [MeSH:C0669516] attenuate [MeSH:C0042211] tubular damage contrast dmtu significantly reduce tubular damage lipid peroxidation [MeSH:C0023775] affect renal [MeSH:C0152169] hemodynamic vasoactive substance sod [MeSH:C0669516] [MeSH:C0669516] dmtu affect renal [MeSH:C0152169] cortical gm content [MeSH:C0017177] [MeSH:C0017177] gm-treate rat [MeSH:C0034721] [MeSH:C0034721] result suggest sod [MeSH:C0669516] [MeSH:C0669516] dmtu protective effect gm-mediate nephropathy mechanism [MeSH:C1524059] [MeSH:C1524059] protective effect differ sod [MeSH:C0669516] [MeSH:C0669516] dmtu superoxide anion [MeSH:C0038836] play critical role gm-induce renal [MeSH:C0152169] vasoconstriction,neurological|hepatorenal
breakthrough [MeSH:C1135120] polycystic kidney disease [MeSH:C0022680] finding cardiomyopathy [MeSH:C0878544],observational [MeSH:C0302523] examine ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include esrd [MeSH:C0022661] cirrhosis cholecystitis [MeSH:C0008325] method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication optimization [MeSH:C0376695],hepatorenal
neuroleptic malignant syndrome [MeSH:C0027849] induce ziprasidone [MeSH:C0380393] second,neuroleptic [MeSH:C0040615] malignant syndrome [MeSH:C0027849] [MeSH:C0027849] nms rare neuroleptic [MeSH:C0040615]-induced movement disorder describe case neuroleptic [MeSH:C0040615] malignant syndrome [MeSH:C0027849] [MeSH:C0027849] nms associate use ziprasidone [MeSH:C0380393] [MeSH:C0380393] [MeSH:C0380393] [MeSH:C0380393] conventional neuroleptic [MeSH:C0040615] frequently associate nms atypical antipsychotic drug [MeSH:C0040615] like ziprasidone [MeSH:C0380393] [MeSH:C0380393] [MeSH:C0380393] [MeSH:C0380393] cause -year-old male history [MeSH:C0019664] schizophrenia [MeSH:C0036341] develop sign symptom nms day [MeSH:C0011017] -mg dose orally administrate ziprasidone [MeSH:C0380393] [MeSH:C0380393] [MeSH:C0380393] [MeSH:C0380393] case early second nms ziprasidone [MeSH:C0380393] [MeSH:C0380393] [MeSH:C0380393] [MeSH:C0380393] report literature,neurological
arrhythmia [MeSH:C0003811] colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome polyuria pathway method prospective trial cardiac patient measure ectopic beat [MeSH:C0033036] hypertrophic cardiomyopathy [MeSH:C0007194] result positive response care improvement [MeSH:C2936612],cardiovascular|hepatorenal
cytogenetic [MeSH:C0010802] action ifosfamide mesna combination peripheral [MeSH:C3658334] rabbit [MeSH:C3887509] lymphocyte vivo [MeSH:C0024264] vitro cytogenetic [MeSH:C0010802],ifosfamide [MeSH:C0020823] ifo alkylate [MeSH:C0002073] nitrogen mustard [MeSH:C0025033] administrate [MeSH:C0001554] antineoplasmic agent [MeSH:C0003392] characterize intense urotoxic action [MeSH:C1256754] lead hemorrhagic cystitis [MeSH:C0267940] effect [MeSH:C4277511] [MeSH:C4277511] ifo raise requirement co-administration [MeSH:C0001554] sodium [MeSH:C0037473] -sulfanylethanesulfonate mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] aim avoid minimize effect [MeSH:C4277511] [MeSH:C4277511] ifo mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] administrate [MeSH:C0001554] separately rabbit [MeSH:C3887509] lymphocyte [MeSH:C0024264] vivo later develop vitro cytogenetic marker [MeSH:C0017393] sister chromatid exchange sce proliferation rate index pri mitotic index record mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] action conjunction ifo reduce frequency [MeSH:C0376249] sce comparison sce recording obtain ifo administer addition high concentration [MeSH:C0311432] mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] administer reduction [MeSH:C1827449] pri note ifo act concentration [MeSH:C0311432] lymphocyte [MeSH:C0024264] mesna [MeSH:C0000294] [MeSH:C0000294] [MeSH:C0000294] significantly reduce ifo genotoxicity [MeSH:C0026878] administer high concentration [MeSH:C0311432] act inhibitory [MeSH:C0167957] fashion cytostatic action drug [MeSH:C0010858],oncological
delayed-onset heparin-induced thrombocytopenia,heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-induced thrombocytopenia [MeSH:C0040034] present day [MeSH:C0011017] heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] exposure [MeSH:C1390376] arterial [MeSH:C0003835] [MeSH:C0003835] venous thromboemboli [MeSH:C1861172] delay recognition heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-induced thrombocytopenia [MeSH:C0040034] contribute poor outcome [MeSH:C0206277] describe increase awareness [MeSH:C0004448] scenario onset manifestation [MeSH:C0029166] heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-induced thrombocytopenia [MeSH:C0040034] delay design retrospective [MeSH:C0035363] case series set large urban [MeSH:C0041933] hospital [MeSH:C0019994] active cardiovascular surgery program [MeSH:C0042381] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] see -year period [MeSH:C0080129] heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-induced thrombocytopenia [MeSH:C0040034] apparent delay presentation thromboembolic [MeSH:C0040038] [MeSH:C0040038] complication [MeSH:C1171258] [MeSH:C1171258] measurement [MeSH:C0030198] platelet count [MeSH:C0032181] onset objectively determined thromboembolism result [MeSH:C0040038] heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-induced platelet factor antibody test outcome [MeSH:C0206277] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] go home hospital [MeSH:C0019994]ization include heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] exposure [MeSH:C1390376] case thrombocytopenia [MeSH:C0040034] recognize return hospital [MeSH:C0019994] median thromboembolic [MeSH:C0040038] [MeSH:C0040038] complication [MeSH:C1171258] [MeSH:C1171258] thromboemboli venous [MeSH:C1861172] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pulmonary embolus [MeSH:C0034065] arterial [MeSH:C0003835] [MeSH:C0003835] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] platelet count [MeSH:C0032181] mildly decrease patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] second presentation readmission [MeSH:C0030700] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive therapeutic [MeSH:C0087111] heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] worsen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] condition case decrease platelet count [MeSH:C0032181] mean readmission [MeSH:C0030700] x cell [MeSH:C0007634] [MeSH:C0007634] l mean nadir heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] re-exposure [MeSH:C3850098] [MeSH:C1390376] x cell [MeSH:C0007634] [MeSH:C0007634] l result serologic test [MeSH:C0036743] heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-induced antibody positive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] subsequent treatment [MeSH:C0039798] include alternative [MeSH:C4255061] anticoagulant [MeSH:C0003280] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] thrombolytic drug patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] inferior vena cava filter patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] eventually warfarin [MeSH:C0043031] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] die conclusion delayed-onset heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-induced thrombocytopenia [MeSH:C0040034] increasingly recognize avoid disastrous outcome [MeSH:C0206277] physician consider heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134]-induced thrombocytopenia [MeSH:C0040034] recently hospital [MeSH:C0019994]ize return thromboembolism therapy [MeSH:C0040038] alternative [MeSH:C4255061] anticoagulant [MeSH:C0003280] heparin [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] [MeSH:C0019134] initiate,neurological|cardiovascular
risk [MeSH:C0035647] coronary artery disease [MeSH:C1956346] associate initial sulphonylurea patient type diabete matched case-control [MeSH:C0007328],aim seek assess risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] develop coronary artery disease [MeSH:C1956346] cad associate [MeSH:C0004083] initial type diabete different sulphonylurea method type diabetic [MeSH:C1263960] patient [MeSH:C0030705] case [MeSH:C0030705] develop cad compare retrospectively control -year risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] cad diagnosis [MeSH:C0011900] diabete ukpds risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] engine match case control [MeSH:C0007328] result case cad compare control hazard [MeSH:C0206213] develop cad ci associate [MeSH:C0004083] initial increase -fold p glibenclamide [MeSH:C0017628] -fold p glipizide [MeSH:C0017642] [MeSH:C0017642] -fold p unchanged metformin [MeSH:C0025598] hazard decrease -fold p glimepiride [MeSH:C0061323] [MeSH:C0061323] -fold p gliclazide [MeSH:C0017631] [MeSH:C0017631] -fold p conclusion initiate type diabete glibenclamide [MeSH:C0017628] [MeSH:C0017628] glipizide [MeSH:C0017642] [MeSH:C0017642] associate [MeSH:C0004083] increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] cad comparison gliclazide [MeSH:C0017631] [MeSH:C0017631] glimepiride [MeSH:C0061323] [MeSH:C0061323] confirm important indian [MeSH:C0021206] patient [MeSH:C0030705] receive cheap old sulphonylurea present guideline [MeSH:C0282423] distinguish individual agent,neurological|cardiovascular
relationship [MeSH:C0021797] hippocampal [MeSH:C0228249] acetylcholine release [MeSH:C0001041] cholinergic [MeSH:C0242893] convulsant [MeSH:C0009950] sensitivity [MeSH:C0036667] withdrawal seizure-prone [MeSH:C0036572] withdrawal seizure-resistant select mouse line [MeSH:C0026809],septo-hippocampal cholinergic [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] pathway implicate epileptogenesis genetic factor influence response cholinergic [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] agent [MeSH:C0242893] limited available cholinergic [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] involvement [MeSH:C0030699] alcohol withdrawal [MeSH:C0001957] [MeSH:C0001957] [MeSH:C0001957] severity relationship [MeSH:C0021797] cholinergic [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] activity [MeSH:C0020115] [MeSH:C0020115] responsiveness alcohol withdrawal [MeSH:C0001957] [MeSH:C0001957] [MeSH:C0001957] investigate [MeSH:C0035173] genetic animal [MeSH:C0003062] model [MeSH:C0599779] ethanol [MeSH:C0001962] [MeSH:C0001962] withdrawal severity method cholinergic [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] convulsant [MeSH:C0009950] [MeSH:C0009950] [MeSH:C0009950] sensitivity [MeSH:C0036667] [MeSH:C0036667] examine alcohol-na withdrawal seizure-prone [MeSH:C0036572] wsp and-resistant wsr mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] animal [MeSH:C0003062] administer nicotine [MeSH:C0028040] [MeSH:C0028040] carbachol [MeSH:C0006945] [MeSH:C0006945] neostigmine [MeSH:C0027679] time tail vein infusion [MeSH:C0841792] latency onset tremor clonu record convert threshold [MeSH:C0162703] dose microdialysis [MeSH:C0206056] basal potassium [MeSH:C0032821]-stimulated acetylcholine ach [MeSH:C0001041] release ca1 region hippocampus [MeSH:C3887642] potassium [MeSH:C0032821] apply reverse dialysis [MeSH:C0011945] twice separate min hippocampal ach [MeSH:C0228249] [MeSH:C0228249] measure testing handling-induced convulsion [MeSH:C4048158] result sensitivity [MeSH:C0036667] [MeSH:C0036667] convulsion [MeSH:C4048158] endpoint induce nicotine [MeSH:C0028040] [MeSH:C0028040] carbachol [MeSH:C0006945] [MeSH:C0006945] neostigmine [MeSH:C0027679] significantly great wsr versus wsp mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] microdialysis [MeSH:C0206056] experiment line differ basal release ach mm kcl increase ach output line [MeSH:C0007165] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] increase release ach produce application [MeSH:C3658310] kcl -fold high [MeSH:C0039866] wsp versus wsr mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] hippocampal ach [MeSH:C0228249] [MeSH:C0228249] measure testing handling-induced convulsion [MeSH:C4048158] extracellular ach [MeSH:C3850090] significantly elevated [MeSH:C0020443] wsp mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] nonsignificantly elevated [MeSH:C0020443] wsr mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] conclusion result suggest difference cholinergic [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] activity [MeSH:C0020115] [MeSH:C0020115] postsynaptic sensitivity [MeSH:C0036667] [MeSH:C1817671] [MeSH:C0036667] cholinergic [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] convulsant [MeSH:C0009950] [MeSH:C0009950] [MeSH:C0009950] associate ethanol [MeSH:C0001962] [MeSH:C0001962] withdrawal severity implicate cholinergic [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] mechanism [MeSH:C1524059] alcohol withdrawal [MeSH:C0001957] [MeSH:C0001957] [MeSH:C0001957] specifically wsp mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] low sensitivity [MeSH:C0036667] [MeSH:C0036667] cholinergic [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] convulsant [MeSH:C0009950] [MeSH:C0009950] [MeSH:C0009950] compare wsr postsynaptic receptor desensitization [MeSH:C5544363] bring high [MeSH:C0039866] activity [MeSH:C0020115] [MeSH:C0020115] cholinergic [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] [MeSH:C0242893] neuron [MeSH:C0027882],neurological
gaba [MeSH:C0016904] meet colorectal cancer [MeSH:C0009402] neurological perspective,diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve seizure [MeSH:C0036572] stroke method conduct retrospective [MeSH:C0035363] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine astrocytoma [MeSH:C0004114] parameter result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],neurological
ecg reveal lymphoma secret,question [MeSH:C0600648] ace inhibitor affect hypertension [MeSH:C0020538] systolic [MeSH:C0039155] mechanism method prospective diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess meningioma hypotensive result superior efficacy [MeSH:C5690761] implication therapeutic [MeSH:C0087111] innovation,neurological|cardiovascular
aki hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] myocardial infarction pathway method [MeSH:C0027051] randomized control trial [MeSH:C1096777] elderly patient measure myocardium [MeSH:C0027061] wilms tumor [MeSH:C0027708] result decrease mortality rate [MeSH:C0205848] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
cardiomyopathy tubule [MeSH:C0878544] organ [MeSH:C0029250] interplay,hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve glomerular filtration rate hematuria method [MeSH:C0017654] conduct observational [MeSH:C0302523] evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine hydronephrosis [MeSH:C0020295] parameter result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
tightly link flanking marker lowe oculocerebrorenal syndrome [MeSH:C0028860] application carrier assessment,lowe oculocerebrorenal syndrome [MeSH:C0028860] ocrl characterize congenital cataract mental retardation [MeSH:C3714756] defective [MeSH:C0011139] renal tubular function map assignment ocrl xq2-q2 previously linkage dxs4 xq2-q2 theta z dxs1 xq2 theta z additional family [MeSH:C0015576] study additional polymorphism [MeSH:C0032529] [MeSH:C0032529] identify dxs4 -kb sequence isolate probe [MeSH:C0035683] detect original polymorphism [MeSH:C0032529] [MeSH:C0032529] dxs4 additional ocrl family [MeSH:C0015576] informative dxs4 theta remain z dxs1 theta z evidence [MeSH:C5575834] place ocrl xq2 come female lowe syndrome [MeSH:C0028860] x translocation [MeSH:C0599893] [MeSH:C0599893] xq2 breakpoint determine position ocrl relative link marker [MeSH:C0017393] derivative chromosome [MeSH:C1836929] isolate away normal counterpart somatic cell hybrid dxs4 map derivative chromosome [MeSH:C1836929] x contain xpterq2 dxs1 map derivative chromosome [MeSH:C1836929] contain xq2-qter marker [MeSH:C0017393] dxs1 dxs4 tight linkage ocrl family [MeSH:C0015576] flank xq2 breakpoint female x translocation [MeSH:C0599893] [MeSH:C0599893] linkage flanking marker [MeSH:C0017393] assess ocrl carrier status woman risk [MeSH:C0035647] result compare carrier determination ophthalmologic examination indicate slit-lamp exam sensitive [MeSH:C1017675] specific carrier determination case,neurological|hepatorenal
brain map [MeSH:C0006104] angina pectoris [MeSH:C0002962] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer neuron [MeSH:C0027882] mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess dementia [MeSH:C0497327] bell palsy [MeSH:C0376175] result improvement primary endpoint implication therapeutic [MeSH:C0087111] innovation,neurological
long-term [MeSH:C0023977] efficacy [MeSH:C5690761] toxicity [MeSH:C0040539] high-dose amiodarone therapy ventricular tachycardia [MeSH:C0042514] ventricular fibrillation [MeSH:C0042510],amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] administer patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sustained symptomatic [MeSH:C3839861] [MeSH:C3839861] [MeSH:C3839861] ventricular tachycardia vt [MeSH:C0042514] n cardiac arrest [MeSH:C0018790] n refractory conventional antiarrhythmic drug [MeSH:C0003195] [MeSH:C0003195] loading dose [MeSH:C0003195] mg week maintenance dose [MeSH:C0024501] mg sixty-nine percent patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] continue amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] recurrence [MeSH:C2825055] symptomatic [MeSH:C3839861] [MeSH:C3839861] [MeSH:C3839861] vt ventricular fibrillation [MeSH:C0042510] vf follow-up [MeSH:C3899107] month mean standard deviation percent patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] nonfatal recurrence [MeSH:C2825055] [MeSH:C2825055] vt successfully manage continue amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] high dose addition conventional antiarrhythmic drug [MeSH:C0003195] [MeSH:C0003195] adverse drug reaction [MeSH:C0041755] occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] adverse effect [MeSH:C0001688] [MeSH:C0001688] force reduction [MeSH:C1827449] dose amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] discontinuation amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] common symptomatic [MeSH:C3839861] [MeSH:C3839861] [MeSH:C3839861] adverse reaction tremor ataxia nausea anorexia [MeSH:C0003123] visual halo blur thyroid function [MeSH:C0040130] abnormality [MeSH:C0037268] pulmonary interstitial infiltrate large-dose amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] highly effective long-term [MeSH:C0023977] vt vf refractory conventional antiarrhythmic drug [MeSH:C0003195] [MeSH:C0003195] cause toxicity [MeSH:C0040539] approximately patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dose adjust base response development adverse effect [MeSH:C0001688] [MeSH:C0001688] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] vt vf successfully manage amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598],neurological
amygdala [MeSH:C0002708] meet leukemia [MeSH:C0023418] neurological perspective,question statin affect cancer huntington disease mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess neurodegenerative amyotrophic lateral sclerosis [MeSH:C0002736] result superior efficacy [MeSH:C5690761] implication optimization [MeSH:C0376695],neurological
cerebrovascular connection hypertension,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] dysarthria mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assessing seizure [MeSH:C0036572] encephalopathy result favorable safety profile implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
abnormal [MeSH:C0853087] myotonic dystrophy protein kinase [MeSH:C0216045] level [MeSH:C0018759] produce mild myopathy [MeSH:C0026848] mouse [MeSH:C0026809],myotonic dystrophy dm [MeSH:C0027126] commonly associate [MeSH:C0004083] ctg repeat expansion gene dm-protein kinase dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] effect [MeSH:C4277511] altered express [MeSH:C0017262]ion [MeSH:C0017262] level dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] ubiquitously express [MeSH:C0017262] muscle cell [MeSH:C0596981] lineage [MeSH:C0282637] development [MeSH:C0243107] examine disrupt endogenous [MeSH:C0205752] dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] gene overexpress [MeSH:C0017262]e normal human [MeSH:C0086418] dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] transgene [MeSH:C0282641] [MeSH:C0282641] mouse [MeSH:C0026809] [MeSH:C0026809] nullizygous mouse [MeSH:C0026809] [MeSH:C0026809] show inconsistent minor size [MeSH:C0162658] change head neck muscle fibre old age animal high dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] transgene [MeSH:C0282641] [MeSH:C0282641] express [MeSH:C0017262]ion [MeSH:C0017262] show hypertrophic cardiomyopathy [MeSH:C0007194] enhance neonatal [MeSH:C0021709] mortality model [MeSH:C0026565] lack frequent dm symptom [MeSH:C3839861] include fibre-type dependent atrophy myotonia [MeSH:C0700153] cataract male-infertility [MeSH:C0021364] result strengthen contention simple loss- gain-of-express [MeSH:C0017262]ion [MeSH:C0017262] dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] crucial requirement development [MeSH:C0020119] [MeSH:C0243107] disease [MeSH:C0012634],neurological|cardiovascular
tachycardia epilepsy [MeSH:C0039231] vascular insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve cancer outcome esrd pathway method longitudinal trial [MeSH:C0023981] elderly patient measure blood pressure anuria [MeSH:C0005823] result enhance therapeutic response [MeSH:C0087111] safety consideration,cardiovascular|hepatorenal
hydroxytyrosol [MeSH:C0243264] ameliorat [MeSH:C0034721]e oxidative stress mitochondrial dysfunction doxorubicin-induced cardiotoxicity rat [MeSH:C0034721] breast cancer [MeSH:C0006142],oxidative stress [MeSH:C0242606] [MeSH:C0242606] involve process include cancer [MeSH:C0006826] aging [MeSH:C0001811] cardiovascular disease [MeSH:C0007222] show potentiate therapeutic effect [MeSH:C1527144] drug doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] cause cardiotoxicity [MeSH:C0040539] [MeSH:C0876994] characterize marked increase oxidative stress [MeSH:C0242606] [MeSH:C0242606] mitochondria [MeSH:C0026237]l dysfunction [MeSH:C3502075] investigate doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-associated chronic cardiac toxicity [MeSH:C0040539] ameliorat [MeSH:C0034721] [MeSH:C0034721]e antioxidant [MeSH:C0003402] hydroxytyrosol [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] rat [MeSH:C0034721] [MeSH:C0034721] breast cancer [MeSH:C0006142] [MeSH:C0006826] thirty-six rat [MeSH:C0034721] [MeSH:C0034721] bear breast tumor [MeSH:C1458155] induce chemically divide group hydroxytyrosol [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] 5 mg kg 5day week doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] 1 mg kg [MeSH:C0013089] week doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] plus hydroxytyrosol [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] cardiac disturbance cellular mitochondria [MeSH:C0026237]l mitochondria [MeSH:C0026237]l electron transport chain complex i-iv apoptosis-inducing factor oxidative stress [MeSH:C0242606] [MeSH:C0242606] marker analyze hydroxytyrosol [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] improve cardiac disturbance enhance doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] significantly reduce percentage alter mitochondria [MeSH:C0026237] oxidative damage [MeSH:C5392203] [MeSH:C5392203] result suggest hydroxytyrosol [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] improve mitochondria [MeSH:C0026237]l electron transport chain demonstrat [MeSH:C0034721] [MeSH:C0034721]e hydroxytyrosol [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] [MeSH:C0243264] protect rat [MeSH:C0034721] [MeSH:C0034721] heart damage provoke doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] decrease oxidative damage [MeSH:C5392203] [MeSH:C5392203] mitochondria [MeSH:C0026237]l alterat [MeSH:C0034721] [MeSH:C0034721]ion,cardiovascular|oncological
leukemia [MeSH:C0023418] ggt organ interplay,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome [MeSH:C0206277] head neck cancer pathway method cross-sectional trial [MeSH:C0010362] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure prostate cancer [MeSH:C0376358] tumor suppressor [MeSH:C0597611] result decrease mortality rate [MeSH:C0205848] practice guideline,hepatorenal|oncological
cardiomyopathy amygdala [MeSH:C0878544] exploring neural pathway [MeSH:C0027792],prospective examine calcium channel blocker hypertension [MeSH:C0006684] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include meningitis paralysis [MeSH:C0025289] alzheimer disease method [MeSH:C0002395] participant [MeSH:C1708335] include result positive response implication relevance,neurological
cancer bone marrow transplant [MeSH:C0005961] connection,hypothesis statin improve stroke [MeSH:C0038454] outcome head neck cancer pathway method prospective trial adult population measure myeloproliferative neoplasm cancer result favorable safety profile relevance [MeSH:C2826293],oncological
use chromosome [MeSH:C0008633] substitution strain identify seizure [MeSH:C0036572] susceptibility [MeSH:C0012655] locus mouse [MeSH:C0085286],seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] susceptibility [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] vary inbred [MeSH:C0025917] mouse [MeSH:C0026809] [MeSH:C0026809] strain chromosome [MeSH:C0008633] substitution strain css single chromosome inbred [MeSH:C0025917] strain donor [MeSH:C0013018] transfer second strain host repeat backcross identify quantitative trait locus [MeSH:C0597336] qtls contribute seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] susceptibility [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] qtls susceptibility [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] pilocarpine-induced seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] model temporal lobe epilepsy [MeSH:C0014556] [MeSH:C0014556] report css previously localize seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] susceptibility [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] gene [MeSH:C0017337] report [MeSH:C0684224] qtls identify b6 host x j donor [MeSH:C0013018] css panel localize gene [MeSH:C0017337] involve susceptibility [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] pilocarpine-induced seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] fifty-five adult [MeSH:C0001675] male [MeSH:C0086582] css mouse [MeSH:C0026809] [MeSH:C0026809] b6 j test susceptibility [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] pilocarpine-induced seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] high stage reach latency stage record mouse [MeSH:C0026809] [MeSH:C0026809] b6 mouse [MeSH:C0026809] [MeSH:C0026809] resistant [MeSH:C2986418] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] slow reach stage compare j mouse [MeSH:C0026809] [MeSH:C0026809] css chromosome [MeSH:C0008633] progress severe stage diverge dramatically b6 phenotype latency stage significantly short css1 css1 mouse [MeSH:C0026809] [MeSH:C0026809] css mapping [MeSH:C0006360] suggest seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] susceptibility [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] [MeSH:C0012655] locus mouse [MeSH:C0026809] [MeSH:C0026809] chromosome approach provide framework [MeSH:C4505073] identify potentially novel homologous candidate gene [MeSH:C0017337] human temporal lobe epilepsy [MeSH:C0014556] [MeSH:C0014556],neurological
cancer code [MeSH:C0006826] multiple sclerosis [MeSH:C0026769] testicular cancer [MeSH:C0153594],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect stroke [MeSH:C0038454] melanoma method elderly patient undergo longitudinal tumor suppressor head neck cancer assessment [MeSH:C0030198] result enhance therapeutic response practice guideline,oncological
huntington disease pathway lymphoma,diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve myocardium [MeSH:C0027061] tic method [MeSH:C0025663] conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine trigeminal neuralgia [MeSH:C0040997] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] care improvement,neurological|cardiovascular
metastasis cancer [MeSH:C0027627] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] prospective investigation [MeSH:C0035173] aspirin cancer [MeSH:C0004057] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient cancer [MeSH:C0030705] carcinoma result favorable safety profile ventricle correlation potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
antituberculosis [MeSH:C0041296] therapy-induced acute liver failure [MeSH:C0162557] magnitude profile prognosis [MeSH:C0033325] predictor outcome [MeSH:C0206277],antituberculosis [MeSH:C0041296] therapy att -associated acute liver failure [MeSH:C0162557] att-alf [MeSH:C1431931] commonest drug-induced [MeSH:C1320835] alf [MeSH:C1431931] south asia prospective study [MeSH:C0033522] att-alf [MeSH:C1431931] lack current prospectively evaluate magnitude course outcome prognostic factor [MeSH:C1514474] att-alf [MeSH:C1431931] january january consecutive alf [MeSH:C1431931] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] evaluate att cause patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] att simultaneous hepatitis virus infection [MeSH:C0019163] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] att prescribe empirically definitive evidence tuberculosis [MeSH:C0041296] att-alf [MeSH:C1431931] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] young year woman [MeSH:C0043210] hyperacute presentation [MeSH:C0022869] [MeSH:C0022869] [MeSH:C0022869] median icterus [MeSH:C0022346] encephalopathy interval day [MeSH:C0011017] median duration att alf [MeSH:C1431931] day [MeSH:C0011017] presentation [MeSH:C0022869] [MeSH:C0022869] [MeSH:C0022869] advanced encephalopathy cerebral edema [MeSH:C0019151] present patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] respectively gastrointestinal bleed seizure infection acute renal failure [MeSH:C0022660] document [MeSH:C0009797] seven seven patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] respectively compare hepatitis e virus hev non-a [MeSH:C0085294] non-e-induce alf [MeSH:C1431931] att-alf [MeSH:C1431931] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] nearly similar presentation [MeSH:C0022869] [MeSH:C0022869] [MeSH:C0022869] old age elevation liver enzyme mortality rate [MeSH:C0205848] [MeSH:C0205848] [MeSH:C0205848] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] att-alf [MeSH:C1431931] high n patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] recover medical multivariate factor independently predict mortality serum [MeSH:C0026565] bilirubin mg dl prothrombin pt prolongation second grade iii iv encephalopathy presentation [MeSH:C0022869] [MeSH:C0022869] [MeSH:C0022869] att-alf [MeSH:C1431931] constitute alf [MeSH:C1431931] center high mortality rate [MeSH:C0205848] [MeSH:C0205848] [MeSH:C0205848] mortality rate [MeSH:C0205848] [MeSH:C0205848] [MeSH:C0205848] high determining factor predictor important high proportion patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] consume att empirically prevent [MeSH:C0000918],neurological|hepatorenal
huntington disease pattern [MeSH:C0020179] prostate cancer [MeSH:C0376358] patient [MeSH:C0030705],observational [MeSH:C0302523] examine metformin [MeSH:C0025598] hypertension [MeSH:C0020538] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] [MeSH:C0035173] include cerebral neurotransmitter meningioma method participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication need investigation [MeSH:C0035173] [MeSH:C0035173],neurological
tumor heterogeneity [MeSH:C0242960] colorectal cancer [MeSH:C0009402],design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] chronic myeloid leukemia [MeSH:C0279543] oncogene [MeSH:C0029016] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cancer correlation optimization [MeSH:C0376695],oncological
epidural blood flow [MeSH:C0005775] prostaglandin e1 trimethaphan [MeSH:C0002335] induced [MeSH:C5392225] hypotension [MeSH:C0020649],evaluate [MeSH:C0013175] effect [MeSH:C4277511] prostaglandin [MeSH:C0033554] e1 pge1 [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] trimethaphan [MeSH:C0041040] tmp induce hypotension [MeSH:C0020649] epidural blood flow [MeSH:C0005775] ebf spinal surgery [MeSH:C0038895] [MeSH:C0038895] ebf measure heat clearance patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo postero-lateral interbody fusion isoflurane anaesthesia initial dose microgram [MeSH:C0376691] [MeSH:C0376691] kg- min- pge1 [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] microgram [MeSH:C0376691] [MeSH:C0376691] kg- min- tmp patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] administer intravenously dural opening dose adjust maintain mean arterial blood pressure map [MeSH:C1272641] mmhg hypotensive drug [MeSH:C0003364] discontinue completion operative procedure [MeSH:C0543467] start pge1 [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] tmp map rate pressure product rpp decrease significantly compare preinfusion [MeSH:C0841792] value p degree hypotension [MeSH:C0020649] pge1 [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] remain constant min discontinuation heart rate [MeSH:C0018810] hr ebff pge1 [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] infusion [MeSH:C0841792] tmp ebf decrease significantly min start tmp preinfusion [MeSH:C0841792] ml 0 g min min ml g min p min ml g min p result suggest pge1 [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] [MeSH:C0002335] preferable tmp hypotensive anaesthesia spinal surgery [MeSH:C0038895] [MeSH:C0038895] tmp decrease ebf,neurological|cardiovascular
stroke [MeSH:C0038454] ventricular fibrillation [MeSH:C0042510] cardiac connection,heart disease [MeSH:C0018799] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve heart valve thrombosis method conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine cerebrovascular [MeSH:C0007820] parameter result superior efficacy [MeSH:C5690761] practice guideline [MeSH:C0282423],cardiovascular
glomerular filtration rate [MeSH:C0017654] meet cardiomyopathy [MeSH:C0878544] neurological perspective,investigate [MeSH:C0035173] beta-blocker effect hypertension substantia nigra method cancer [MeSH:C0038590] patient [MeSH:C0030705] undergo cross-sectional tremor steatosis assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile cost-effectiveness [MeSH:C1511536] implication,neurological|hepatorenal
thalamus [MeSH:C0039729] connection myocardial infarction [MeSH:C0027051],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve diabete outcome myelopathy pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient measure dementia [MeSH:C0497327] dysarthria [MeSH:C0013362] result positive response safety consideration,neurological
cancer lens aphasia,cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve pituitary adenoma [MeSH:C0032000] epilepsy method [MeSH:C0014544] conduct prospective evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine oligodendroglioma [MeSH:C0028945] parameter result well quality life measure need investigation [MeSH:C0035173],neurological
anorexigen pulmonary hypertension [MeSH:C0020542] [MeSH:C0020542] united state result surveillance north american pulmonary hypertension [MeSH:C0020542],use appetite [MeSH:C0003618] suppressant [MeSH:C0003449] europe associate [MeSH:C0004083] development [MeSH:C0020119] primary [MeSH:C0033137] pulmonary hypertension [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] pph recently fenfluramine [MeSH:C0015827] [MeSH:C0015827] [MeSH:C0015827] [MeSH:C0015827] appetite suppressant [MeSH:C0003449] widely united state withdraw september concern adverse effect material [MeSH:C0001688] method conduct prospective surveillance patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0700325] diagnose pulmonary hypertension [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] large referral center north america collect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] see september december include cause pulmonary hypertension [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] severity patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] identifiable cause pulmonary hypertension [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] class pph history [MeSH:C0019664] drug exposure [MeSH:C1390376] take special attention use antidepressant [MeSH:C0003289] anorexigen amphetamine result seventy-nine patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] study [MeSH:C0085973] pph pulmonary hypertension [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] cause secondary pulmonary hypertension [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] sph use anorexigen common group medication survey fenfluramine [MeSH:C0015827] [MeSH:C0015827] [MeSH:C0015827] [MeSH:C0015827] preferential association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] pph compare sph adjusted odd ratio use month confidence interval [MeSH:C0009667] association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] strong long duration use compare short duration use pronounced recent user remote user unexpectedly high number patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sph anorexigen magnitude association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] pph increase association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] increase duration use specificity fenfluramine [MeSH:C0015827] [MeSH:C0015827] [MeSH:C0015827] [MeSH:C0015827] consistent previous study [MeSH:C0085973] indicate fenfluramine [MeSH:C0015827] [MeSH:C0015827] [MeSH:C0015827] [MeSH:C0015827] causally related pph high prevalence anorexigen use patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sph raise possibility drug precipitate pulmonary hypertension [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] [MeSH:C0020542] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] underlying condition associate [MeSH:C0004083] sph,cardiovascular
nitric oxide synthase [MeSH:C0132555] expression course [MeSH:C0017262] lead-induced hypertension,recently show elevated [MeSH:C0020443] reactive oxygen specie ros [MeSH:C0162772] reduce urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] excretion [MeSH:C1373187] [MeSH:C1373187] [MeSH:C1373187] [MeSH:C1859518] metabolite [MeSH:C0003376] nox [MeSH:C0068355] [MeSH:C0068355] [MeSH:C0068355] [MeSH:C0068355] increase sequestrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C2936300] nitrotyrosine tissue [MeSH:C0047645] rat [MeSH:C0034721] [MeSH:C0034721] lead-induced hypertension [MeSH:C0020538] [MeSH:C0020538] design [MeSH:C0013171] discern reduction [MeSH:C1827449] urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] nox [MeSH:C0068355] [MeSH:C0068355] [MeSH:C0068355] [MeSH:C0068355] lead-induced hypertension [MeSH:C0020538] [MeSH:C0020538] depressed synthase nos expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] male sprague-dawley rat [MeSH:C0034721] [MeSH:C0034721] randomly assign lead-treated given lead acetate ppm drinking water [MeSH:C0599638] regular rat [MeSH:C0034721] [MeSH:C0034721] chow given lead vitamin [MeSH:C0042890] e-fortifie chow normal give regular food water [MeSH:C0016452] vitamin [MeSH:C0042890] e-fortifie food week tail blood pressure [MeSH:C0005823] [MeSH:C0005823] [MeSH:C0005823] urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] nox [MeSH:C0068355] [MeSH:C0068355] [MeSH:C0068355] [MeSH:C0068355] excretion [MeSH:C1373187] [MeSH:C1373187] [MeSH:C1373187] plasma [MeSH:C0032105] malondialdehyde [MeSH:C0024643] mda endothelial [MeSH:C0225336] inducible nos enos inos isotype aorta kidney measure lead-treated exhibit rise blood pressure [MeSH:C0005823] [MeSH:C0005823] plasma [MeSH:C0032105] mda concentrat [MeSH:C0034721] [MeSH:C0034721]ion fall urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] nox [MeSH:C0068355] [MeSH:C0068355] [MeSH:C0068355] [MeSH:C0068355] excretion [MeSH:C1373187] [MeSH:C1373187] [MeSH:C1373187] paradoxical [MeSH:C0037322] rise vascular renal tissue [MeSH:C0027668] [MeSH:C0027668] enos inos expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] vitamin [MeSH:C0042890] e supplementation [MeSH:C2350507] ameliorat [MeSH:C0034721] [MeSH:C0034721]e hypertension [MeSH:C0020538] [MeSH:C0020538] lower plasma [MeSH:C0032105] mda concentrat [MeSH:C0034721] [MeSH:C0034721]ion raise urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] nox [MeSH:C0068355] [MeSH:C0068355] [MeSH:C0068355] [MeSH:C0068355] excretion [MeSH:C1373187] [MeSH:C1373187] [MeSH:C1373187] significantly lower vascular renal tissue [MeSH:C0027668] [MeSH:C0027668] enos inos expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] vitamin [MeSH:C0042890] e supplementation [MeSH:C2350507] effect blood pressure [MeSH:C0005823] [MeSH:C0005823] plasma [MeSH:C0032105] mda nos expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] reveal inhibition [MeSH:C0027790] nos enzymatic activity lead cell-free preparat [MeSH:C0034721] [MeSH:C0034721]ion lead-induced hypertension [MeSH:C0020538] [MeSH:C0020538] model [MeSH:C0011381] associate compensatory upregulation renal vascular enos inos expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] ros-mediated inactivation [MeSH:C0043297] lead-associated inhibition [MeSH:C0027790] nos activity stimulatory action [MeSH:C0001164] increase shear stress associate hypertension [MeSH:C0020538] [MeSH:C0020538],cardiovascular|hepatorenal
chemotherapy [MeSH:C0013216] cardiomyopathy brain [MeSH:C0006104] insight,hypothesis statin improve stroke [MeSH:C0038454] outcome cerebral infarction pathway method [MeSH:C0007785] randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring cardiomyopathy [MeSH:C0878544] cognitive impairment [MeSH:C0338656] result decrease mortality rate [MeSH:C0205848] practice guideline,neurological|cardiovascular
asef link tumor suppressor [MeSH:C0597611] apc g-protein signaling,adenomatous polyposis coli gene apc [MeSH:C0162832] [MeSH:C0162832] mutate [MeSH:C0162832] familial adenomatous polyposis [MeSH:C0032580] sporadic colorectal tumor [MeSH:C0009404] apc [MeSH:C0162832] [MeSH:C0162832] gene product [MeSH:C0162832] show bind armadillo repeat domain rac-specific guanine nucleotide exchange factor gef term asef endogenous [MeSH:C0205752] apc [MeSH:C0162832] [MeSH:C0162832] colocalize asef mouse colon epithelial cell [MeSH:C0007634] [MeSH:C0014597] neuronal cell [MeSH:C0007634] furthermore apc [MeSH:C0162832] [MeSH:C0162832] enhance gef activity asef stimulate asef-mediated cell [MeSH:C0007634] flatten membrane ruffling lamellipodia formation mdck cell [MeSH:C0007634] result suggest apc [MeSH:C0162832] [MeSH:C0162832]-asef complex regulate [MeSH:C0851285] actin cytoskeletal network cell [MeSH:C0007634] morphology [MeSH:C0543482] migration [MeSH:C0020942] neuronal function [MeSH:C0031843],neurological|oncological
gfr connection liver cirrhosis [MeSH:C0023890],question statin affect stroke [MeSH:C0038454] convulsion [MeSH:C4048158] mechanism method prospective adult population assess tic sciatica [MeSH:C0036396] result positive response implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|hepatorenal
heart parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect stroke [MeSH:C0038454] septum method adult [MeSH:C0001675] population [MeSH:C0032659] undergo cross-sectional premature beat heart assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,cardiovascular
i17k apc hmlh1 mutation non-jewish family hereditary non-polyposis colorectal cancer [MeSH:C0009402],describe french canadian hereditary non-polyposis colorectal cancer [MeSH:C0006826] [MeSH:C0009402] hnpcc kindred carry novel truncating mutation [MeSH:C0026882] hmlh1 [MeSH:C0252642] interestingly i17k apc [MeSH:C0162832] polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] associate increase risk [MeSH:C0035647] colorectal cancer [MeSH:C0006826] [MeSH:C0009402] present family [MeSH:C0015576] i17k polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] previously identify individual self-reported ashkenazi jewish origin addition family [MeSH:C0015576] appear relationship i17k polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] presence absence [MeSH:C0270823] cancer [MeSH:C0006826],oncological
cancer [MeSH:C0006826] ventricular tachycardia [MeSH:C0042514] cardiac connection,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] dementia [MeSH:C0497327] embolism method [MeSH:C0013922] elderly patient undergo longitudinal endothelium hypotensive assessment result improve outcome [MeSH:C0206277] relevance [MeSH:C2826293],cardiovascular
granulomatous hepatitis [MeSH:C0405469] combination amoxicillin [MeSH:C0002645] clavulanic acid [MeSH:C0055860],report case [MeSH:C0684224] amoxicillin [MeSH:C0002645]-clavulanic acid [MeSH:C0055860]-induced hepatitis histologic [MeSH:C0019637] multiple granuloma type lesion broaden spectrum liver injury drug combination [MeSH:C0013162] mainly represent benign cholestatic syndrome association granuloma eosinophilia [MeSH:C0014461] favor immunoallergic mechanism penicillin derivative amoxicillin [MeSH:C0002645] know induce type lesion amoxicillin [MeSH:C0002645] [MeSH:C0002645] component potentiating effect clavulanic acid [MeSH:C0055860] major role,hepatorenal
breakthrough pkd finding hepatitis [MeSH:C0019158],hypothesis statin improve stroke [MeSH:C0038454] outcome polyuria pathway method prospective trial adult [MeSH:C0001675] population measure anuria [MeSH:C0003460] hepatoma [MeSH:C2239176] result improvement [MeSH:C2936612] primary endpoint relevance,hepatorenal
myocardial pathway chronic kidney disease [MeSH:C1561643],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] [MeSH:C0035173] aspirin [MeSH:C0004057] stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient [MeSH:C0030705] acetylcholine myocardial result improve disease management [MeSH:C0039798] convulsion [MeSH:C4048158] correlation [MeSH:C0010100] need investigation [MeSH:C0035173] [MeSH:C0035173],neurological|cardiovascular
angiography [MeSH:C0002978] reveal angina pectoris [MeSH:C0002962] secret,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome artery pathway method retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure palsy aortic dissection [MeSH:C0340643] result enhance therapeutic response care [MeSH:C0087111] improvement [MeSH:C2936612],neurological|cardiovascular
leukemia [MeSH:C0023418] oliguria [MeSH:C0028961] organ [MeSH:C0029250] interplay,longitudinal [MeSH:C0023981] examine beta-blocker cancer cancer [MeSH:C0006826] patient [MeSH:C0030705] investigation [MeSH:C0035173] include tubule [MeSH:C0041348] transaminase hydronephrosis method participant [MeSH:C1708335] include result favorable safety profile implication therapeutic [MeSH:C0087111] innovation,hepatorenal
angina meet breast cancer [MeSH:C0006142] neurological perspective,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve septum pericardium method conduct observational [MeSH:C0302523] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine pe parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] care improvement,neurological|cardiovascular
comparison unilateral pallidotomy [MeSH:C0195893] subthalamotomy finding advanced idiopathic parkinson disease [MeSH:C0030567],prospective randomized double-blind pilot compare result stereotactic unilateral pallidotomy subthalamotomy advanced idiopathic parkinson disease [MeSH:C0030567] pd refractory medical design consecutive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mean [MeSH:C0030705] age year man woman [MeSH:C0043210] similar characteristic duration disease mean disease year [MeSH:C0013447] disabling motor fluctuation hoehn yahr stage off-drug phase levodopa [MeSH:C0023570] [MeSH:C0023570]-induced dyskinesia select patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] bilateral symptom [MeSH:C3839861] levodopa [MeSH:C0023570] [MeSH:C0023570] equivalent [MeSH:C2355577] dosing analyse patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] operate globus pallidu interna gpi subthalamic nucleus stn include use unified parkinson disease rating scale [MeSH:C0030567] updr hoehn_yahr score [MeSH:C0021504] [MeSH:C0021504] [MeSH:C0021504] schwab england activity daily live adl score [MeSH:C0021504] [MeSH:C0021504] [MeSH:C0021504] -drug condition surgery [MeSH:C0038895] [MeSH:C0038895] month surgery [MeSH:C0038895] statistically improvement contralateral major parkinsonian [MeSH:C0242422] motor sign patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] follow month levodopa [MeSH:C0023570] [MeSH:C0023570] equivalent [MeSH:C2355577] daily intake [MeSH:C0006777] significantly reduce stn change updrs hoehn yahr schwab england adl score [MeSH:C0021504] [MeSH:C0021504] [MeSH:C0021504] similar group [MeSH:C0018257] cognitive function [MeSH:C0009240] unchanged group [MeSH:C0018257] complication [MeSH:C1171258] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] leave homonymous hemianopsia pallidotomy develop leave hemiballistic [MeSH:C0221169] movement [MeSH:C0026649] day [MeSH:C0011017] subthalamotomy partly improve valproate [MeSH:C0080356] mg finding suggest lesion unilateral stn gpi equally effective patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] advanced pd refractory medical,neurological
cirrhosis [MeSH:C1623038] marker [MeSH:C0017393] breast cancer [MeSH:C0006142],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect heart disease [MeSH:C0018799] dvt method adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal arterial cholecystitis assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
risk [MeSH:C0035647] aprotinin [MeSH:C0003641] tranexamic acid [MeSH:C0040613] cardiac surgery [MeSH:C0524727] one-year follow-up consecutive patient [MeSH:C0030705],investigate [MeSH:C0035173] postoperative [MeSH:C0032786] complication [MeSH:C1171258] mortality [MeSH:C0026565] administration [MeSH:C0001554] aprotinin [MeSH:C0003641] [MeSH:C0003641] [MeSH:C0003641] compare tranexamic acid [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] unselected consecutive cohort method perioperative [MeSH:C2712230] consecutive cardiac surgery [MeSH:C0524727] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prospectively collect september june university-affiliated clinic n mo patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive aprotinin [MeSH:C0003641] [MeSH:C0003641] [MeSH:C0003641] mo patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat tranexamic acid [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] antifibrinolytic therapy [MeSH:C0040044] anesthetic surgical protocol remain unchanged result pre- intraoperative [MeSH:C0021889] variable comparable group [MeSH:C0018257] postoperative [MeSH:C0032786]ly significantly high [MeSH:C0039866] incidence seizure [MeSH:C0036572] find vs p difference primary valve surgery [MeSH:C0038895] high [MeSH:C0039866] risk surgery [MeSH:C0038895] [MeSH:C0038895] subgroup [MeSH:C0018257] vs p vs p respectively persistent [MeSH:C0026205] atrial fibrillation [MeSH:C0004238] vs p renal failure [MeSH:C0035078] vs p common primary valve surgery [MeSH:C0038895] subgroup [MeSH:C0018257] contrary primary coronary artery bypass surgery [MeSH:C0010055] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute myocardial infarction renal dysfunction [MeSH:C0027051] vs p vs p respectively -yr mortality [MeSH:C0026565] significantly high [MeSH:C0039866] aprotinin [MeSH:C0003641] [MeSH:C0003641] [MeSH:C0003641] high [MeSH:C0039866] risk surgery [MeSH:C0038895] [MeSH:C0038895] vs p antifibrinolytic drug [MeSH:C0003304] bear risk adverse outcome [MeSH:C4505162] depend type cardiac surgery [MeSH:C0524727] administration aprotinin [MeSH:C0001554] [MeSH:C0003641] [MeSH:C0003641] [MeSH:C0003641] avoid coronary artery bypass graft [MeSH:C0010055] high [MeSH:C0039866] risk patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] administration tranexamic acid [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] recommend valve surgery [MeSH:C0038895],neurological|cardiovascular|hepatorenal
provocation [MeSH:C0006265] postural hypotension [MeSH:C0020651] nitroglycerin [MeSH:C0017887] diabetic [MeSH:C1263960] autonomic neuropathy [MeSH:C0271686],effect [MeSH:C4277511] nitroglycerin [MeSH:C0017887] heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] systolic blood pressure [MeSH:C0005823] [MeSH:C0005823] [MeSH:C0005823] compare normal subject [MeSH:C0080105] [MeSH:C0080105] diabetic [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] subject [MeSH:C0080105] autonomic neuropathy [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] diabetic [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] subject [MeSH:C0080105] autonomic neuropathy [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] magnitude course increase heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] decrease systolic blood pressure [MeSH:C0005823] [MeSH:C0005823] [MeSH:C0005823] nitroglycerin [MeSH:C0017887] similar normal diabetic [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] subject [MeSH:C0080105] autonomic neuropathy [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] less increase heart rate [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] great decrease systolic blood pressure [MeSH:C0005823] [MeSH:C0005823] [MeSH:C0005823] occur diabetic [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] subject [MeSH:C0080105] autonomic neuropathy [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] suggest caution exercise [MeSH:C0015259] prescribe vasodilator drug diabetic [MeSH:C0042402] [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] [MeSH:C1263960] patient [MeSH:C0030705] particularly autonomic neuropathy [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686] [MeSH:C0271686],neurological|cardiovascular
hypertension [MeSH:C0020538] ventricular fibrillation [MeSH:C0042510] cardiac connection,investigate [MeSH:C0035173] statin effect diabete endocardium method [MeSH:C0014124] elderly patient undergo randomized control [MeSH:C1096777] pe bradycardia assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint relevance,cardiovascular
hepatitis lens [MeSH:C0019158] autonomic neuropathy [MeSH:C0271686],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome [MeSH:C0206277] cortical pathway method prospective trial elderly patient measure al meningitis [MeSH:C0025289] result well quality life measure practice guideline,neurological
neuroleptic-associated hyperprolactinemia treat bromocriptine [MeSH:C0006230],stable [MeSH:C1706074] psychiatric outpatient [MeSH:C0030705] [MeSH:C0029921] hyperprolactinemia [MeSH:C0020514] amenorrhea oligomenorrhea [MeSH:C0028949] associate neuroleptic medication [MeSH:C0040615] treat bromocriptine [MeSH:C0006230] [MeSH:C0006230] [MeSH:C0006230] [MeSH:C0006230] daily dosage [MeSH:C0178655] mg correct hyperprolactinemia [MeSH:C0020514] restore menstruation [MeSH:C0025344] patient [MeSH:C0030705] woman [MeSH:C0043210] develop worsen psychiatric symptom take bromocriptine [MeSH:C0006230] [MeSH:C0006230] [MeSH:C0006230] [MeSH:C0006230] discontinue patient [MeSH:C0030705] menstrual irregularity [MeSH:C0156404] successfully correct bromocriptine [MeSH:C0006230] [MeSH:C0006230] [MeSH:C0006230] [MeSH:C0006230] suggest bromocriptine [MeSH:C0006230] [MeSH:C0006230] [MeSH:C0006230] [MeSH:C0006230] evaluate [MeSH:C0013175] potential [MeSH:C0001272] therapy [MeSH:C0039798] neuroleptic-associated hyperprolactinemia [MeSH:C0020514] amenorrhea galactorrhea,neurological
stroke [MeSH:C0038454] encephalopathy [MeSH:C0085584] explore neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] acetylcholine pathway method longitudinal trial [MeSH:C0023981] cardiac patient measure tic neurotransmitter [MeSH:C0027908] result superior efficacy care improvement [MeSH:C2936612],neurological
hyperalgesia [MeSH:C0020429] myoclonus [MeSH:C0027066] terminal cancer patient [MeSH:C0030705] treat continuous intravenous morphine,cancer patient [MeSH:C0030705] terminal stage disease treat high dose intravenous morphine [MeSH:C0026549] [MeSH:C0026549] develop hyperalgesia [MeSH:C0020429] [MeSH:C0020429] [MeSH:C0020429] case retrospectively sample different hospital copenhagen patient [MeSH:C0030705] develop universal [MeSH:C0376640] hyperalgesia [MeSH:C0020429] [MeSH:C0020429] [MeSH:C0020429] hyperesthesia [MeSH:C0020453] case accompany myoclonus [MeSH:C0027066] patient [MeSH:C0027066] [MeSH:C0030705] pre-existing neuralgia [MeSH:C0027796] increase excruciate intensity case myoclonus [MeSH:C0027066] [MeSH:C0027066] occur simultaneously description relationship [MeSH:C0021797] hyperalgesia [MeSH:C0020429] [MeSH:C0020429] [MeSH:C0020429] myoclonus [MeSH:C0027066] high dose morphine [MeSH:C0026549] [MeSH:C0026549] available experimental [MeSH:C0016998] support animal study indicate morphine [MeSH:C0026549] [MeSH:C0026549] metabolite [MeSH:C0003376] play causative role observe behavioural syndrome possible mechanism [MeSH:C1524059] discuss proposal give suggest use efficacious opioid [MeSH:C0242402] excitatory [MeSH:C0243046] potency situation,neurological|oncological
sciatica pattern epilepsy patient [MeSH:C0030705],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin cancer [MeSH:C0004057] participant [MeSH:C1708335] adult [MeSH:C0001675] population blood vessel [MeSH:C0005847] smooth muscle [MeSH:C1267092] result favorable safety profile pericardium correlation potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
stenosis [MeSH:C1261287] parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete hypotensive mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assess endothelial smooth muscle [MeSH:C1267092] result decrease mortality rate [MeSH:C0205848] implication care improvement,cardiovascular
hypertension [MeSH:C0020538] transient ischemic attack [MeSH:C0007787] exploring neural pathway [MeSH:C0027792],question statin affect diabete meningioma mechanism method randomized control [MeSH:C1096777] elderly patient assess hippocampal convulsion result enhance therapeutic response [MeSH:C0087111] implication cost-effectiveness [MeSH:C1511536] implication,neurological
dual effect melatonin [MeSH:C0025219] barbiturat [MeSH:C0034721]e-induced narcosis rat [MeSH:C0034721],melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] affect circadian sleep wake cycle clear influence [MeSH:C0683549] drug-induced narcosis [MeSH:C0234447] sodium thiopenthal administer intraperitoneally male [MeSH:C0086582] rat [MeSH:C0034721] pre-treated melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] mg kg melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] pre-treatment [MeSH:C0039798] affect dual manner barbiturat [MeSH:C0034721]e narcosis [MeSH:C0234447] dose-effect correlation [MeSH:C0010100] find particular low dose reduce latency [MeSH:C0596824] [MeSH:C0596824] prolong durat [MeSH:C0034721]ion barbiturat [MeSH:C0034721]e narcosis [MeSH:C0234447] contrast high dose melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] mg kg cause paradoxical [MeSH:C0037322] increase latency [MeSH:C0596824] [MeSH:C0596824] produce sustained reduction [MeSH:C1827449] durat [MeSH:C0034721]ion narcosis [MeSH:C0234447] reduction [MeSH:C1827449] mortality rat [MeSH:C0034721]e melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] mg kg influence [MeSH:C0683549] durat [MeSH:C0034721]ion latency [MeSH:C0596824] [MeSH:C0596824] ketamine- diazepam-induced narcosis [MeSH:C0234447] dual action melatonin [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] [MeSH:C0025219] pharmacological narcosis [MeSH:C0234447] specific barbiturat [MeSH:C0034721]e mechanism action,neurological
myocardial lymphoma vascular insight,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] elderly [MeSH:C0001792] patient focus septum defibrillator aspect disease total participant [MeSH:C1708335] enrol observational result [MeSH:C0302523] demonstrate improvement [MeSH:C2936612] primary endpoint particular attention aortic [MeSH:C0004268] aneurysm finding suggest cost-effect [MeSH:C4277511]iveness implication,cardiovascular
increase expression [MeSH:C0017262] neuronal nitric oxide synthase bladder [MeSH:C0132555] afferent pathway follow chronic bladder irritation,immunocytochemical technique [MeSH:C0021060] examine alterat [MeSH:C0034721] [MeSH:C0034721]ion expression [MeSH:C0017262] neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882]al nitric oxide synthase nos bladder pathway follow acute [MeSH:C0184567] chronic irritation urinary tract [MeSH:C0042027] [MeSH:C0042027] rat [MeSH:C0034721] [MeSH:C0034721] chemical cystitis [MeSH:C0010692] induce cyclophosphamide cyp metabolize acrolein irritant [MeSH:C0022108] eliminate urine inject [MeSH:C1828121]ion [MeSH:C1828121] cyp n mg kg p hour prior perfusion [MeSH:C0031001] acute [MeSH:C0184567] animal [MeSH:C0003062] [MeSH:C0003062] increase fos-immunoreactivity ir neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] dorsal commissure dorsal horn [MeSH:C0228575] autonomic region spinal segment l1-l2 l6-s1 receive afferent [MeSH:C0027883] [MeSH:C0027883] input bladder urethra ureter [MeSH:C0041951] fos-ir spinal cord change rat [MeSH:C0034721] [MeSH:C0034721] receive chronic cyp n mg kg p 3rd week animal [MeSH:C0003062] [MeSH:C0003062] animal [MeSH:C0003062] [MeSH:C0003062] treat acute [MeSH:C0184567]ly cyp small number nos-ir cell cell [MeSH:C0007634] profile section detect l6-s1 dorsal root ganglion drg [MeSH:C0011928] [MeSH:C0017070] chronic cyp administrat [MeSH:C0034721] [MeSH:C0034721]ion significantly p increase bladder weight increase -fold number nos-immunoreactive ir afferent [MeSH:C0027883] [MeSH:C0027883] neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] l6-s1 drg [MeSH:C0011928] small increase -fold occur l1 drg [MeSH:C0011928] detect l2 l5 drg [MeSH:C0011928] bladder afferent [MeSH:C0027883] [MeSH:C0027883] cell l6-s1 drg [MeSH:C0011928] label fluorogold microliter inject [MeSH:C1828121] bladder wall [MeSH:C0005682] exhibit nos-ir animal [MeSH:C0003062] [MeSH:C0003062] follow chronic cyp administrat [MeSH:C0034721] [MeSH:C0034721]ion percentage bladder afferent [MeSH:C0027883] [MeSH:C0027883] neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882] nos-ir l6 s1 result indicate neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882]al gene expression [MeSH:C0017262] [MeSH:C0017262] visceral sensory pathway upregulate [MeSH:C0041904] chemical irritation afferent [MeSH:C0027883] [MeSH:C0027883] receptor urinary tract [MeSH:C0042027] [MeSH:C0042027] pathological [MeSH:C0030660] change urinary tract [MeSH:C0042027] [MeSH:C0042027] initiate chemical signal alter chemical property [MeSH:C0243178] visceral afferent [MeSH:C0206309] [MeSH:C0027883] [MeSH:C0027883] neuron [MeSH:C0027882] [MeSH:C0027882] [MeSH:C0027882],neurological
conversion [MeSH:C0017259] sirolimus [MeSH:C0072980] ameliorat [MeSH:C0034721]e cyclosporine-induced nephropathy rat [MeSH:C0034721] focus serum urine gene protein [MeSH:C0042036] renal expression biomarker [MeSH:C0005516],protocol [MeSH:C0655632] conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] cyclosporin [MeSH:C0010592] csa sirolimus srl widely immunotherapy transplantation [MeSH:C0021083] prevent [MeSH:C0000918] [MeSH:C0000918] csa-induced nephropathy molecular mechanism underlie protocol [MeSH:C0655632] remain nuclear [MeSH:C0028589] aim identify molecular pathway putative biomarker [MeSH:C0005516] [MeSH:C0017393] csa-to-srl conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] rat [MeSH:C0034721] [MeSH:C0034721] model [MeSH:C0011381] animal group [MeSH:C1318101] n test week csa srl conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] csa week follow srl week classical emergent serum [MeSH:C0229671] urinary kidney [MeSH:C0022646] tissue gene protein [MeSH:C0017337] [MeSH:C0017337] expression marker [MeSH:C0017393] assess renal lesion analyze hematoxylin eosin periodic acid-schiff masson trichrome stain srl-treated rat [MeSH:C0034721] [MeSH:C0034721] present proteinuria [MeSH:C0033687] ngal serum [MeSH:C0229671] urinary good marker [MeSH:C0017393] renal impairment short csa present slight absent kidney [MeSH:C0022646] lesion tgf-b nf- kb mtor [MeSH:C0293060] pcna tp5 kim- ctgf [MeSH:C1137457] relevant gene protein [MeSH:C0017337] [MeSH:C0017337] change prolonged csa exposure [MeSH:C1390376] aggravate renal damage clear change traditional marker [MeSH:C0017393] change serum [MeSH:C0229671] tgf- b il- tbar clearance kidney [MeSH:C0022646] tgf-b mtor [MeSH:C0293060] conversion [MeSH:C0017259] [MeSH:C0017259] [MeSH:C0017259] srl prevent [MeSH:C0000918] [MeSH:C0000918] csa-induced renal damage evolution [MeSH:C1516669] absent mild grade lesion ngal serum [MeSH:C0229671] versus urine [MeSH:C0042036] feasible biomarker [MeSH:C0005516] [MeSH:C0017393] csa replacement srl,neurological|hepatorenal
heart rate pathway stroke [MeSH:C0038454],hypertension [MeSH:C0020538] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve insufficiency hypertension [MeSH:C0020538] method conduct retrospective [MeSH:C0035363] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine myasthenia gravis [MeSH:C0026896] parameter result positive response therapeutic innovation [MeSH:C0087111],neurological|cardiovascular
lymphoma kidney [MeSH:C0022646] stone organ [MeSH:C0029250] interplay,design [MeSH:C0013171] cross-sectional investigation statin [MeSH:C0360714] dementia participant [MeSH:C1708335] cancer patient [MeSH:C0030705] pkd bilirubin [MeSH:C0005437] result positive response interstitial nephritis [MeSH:C0027707] correlation [MeSH:C0010100] relevance [MeSH:C2826293],hepatorenal
cerebrospinal fluid pattern [MeSH:C0007806] epilepsy patient [MeSH:C0030705],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] norepinephrine pathway method longitudinal trial [MeSH:C0023981] adult population measure ataxia dysarthria [MeSH:C0013362] result well quality life measure therapeutic innovation [MeSH:C0087111],neurological
regionally cluster apc mutation [MeSH:C0026882] [MeSH:C0026882] associate severe phenotype [MeSH:C0031437] occur high frequency new mutation [MeSH:C0026882] [MeSH:C0026882] case adenomatous polyposis coli [MeSH:C0032580],germline [MeSH:C0206530] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] apc [MeSH:C0162832] 5q2- result dominantly inherit syndrome [MeSH:C0039082] adenomatous polyposis coli [MeSH:C0032580] apc [MeSH:C0162832] somatic mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] gene early event colorectal tumourigenesis type mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] concentrate half exon single strand conformational [MeSH:C0033625] polymorphism sscp heteroduplex screen variant region gene total affect unrelated [MeSH:C3179133] individual [MeSH:C0021228] [MeSH:C0021228] [MeSH:C0021228] eighteen patient [MeSH:C0030705] [MeSH:C0030705] family history disease classify severe phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] base early age presentation cancer development compare familial case bp deletion codon report occur unselected apc [MeSH:C0162832] patient [MeSH:C0030705] [MeSH:C0030705] worldwide find new mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] case familial case class severe new mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] familial mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] located downstream codon individual [MeSH:C0021228] [MeSH:C0021228] [MeSH:C0021228] similarly class phenotypically severe contrast apc [MeSH:C0162832] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect affect individual [MeSH:C0021228] [MeSH:C0021228] [MeSH:C0021228] average phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] located prior codon frequent association [MeSH:C0004083] severe phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] fresh mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] explain apparent conflict high mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] rate condition average lethal [MeSH:C0017354] post-reproductive age,oncological
state-of-the-art aspirin heart failure,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve diabete outcome pacemaker pathway method cross-sectional trial cancer [MeSH:C0010362] patient [MeSH:C0030705] measuring bundle branch block heart rate [MeSH:C0006384] result improvement primary endpoint practice guideline,cardiovascular
fatty liver pathway [MeSH:C0015695] valvular heart disease [MeSH:C0018824],longitudinal [MeSH:C0023981] examine metformin [MeSH:C0025598] cancer cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include azotemia [MeSH:C0242528] pkd transaminase method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication relevance,hepatorenal
ultrasound [MeSH:C0220934] reveal epilepsy [MeSH:C0014544] secret,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve cancer outcome migraine pathway method retrospective trial cancer patient measure meningioma acetylcholine [MeSH:C0001041] result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],neurological
prevention [MeSH:C2700409] etomidate-induced myoclonus superior fentanyl midazolam [MeSH:C0026056] combination retrospective comparative,retrospective [MeSH:C0035363] comparative aim compare effective [MeSH:C5392218]ness [MeSH:C0010181] fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] midazolam [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] combination fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] midazolam [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] prevent etomidate [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131]-induced myoclonus [MeSH:C0027066] method perform base anesthesia record depend drug [MeSH:C0013227] give induction anesthesia [MeSH:C0002911] etomidate [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131] patient [MeSH:C0030705] [MeSH:C0030705] separate group [MeSH:C0018257] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] np fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] ug kg- f midazolam [MeSH:C0026056] [MeSH:C0026056] mg kg- midazolam [MeSH:C0026056] [MeSH:C0026056] mg kg- fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] ug kg- fm patient [MeSH:C0030705] [MeSH:C0030705] receive anesthetic procedure [MeSH:C0677616] select minute intravenous [MeSH:C0085297] injection [MeSH:C1828121] pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] drug [MeSH:C0013227] anesthesia induce mg kg- etomidate [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131] inject intravenous [MeSH:C0085297]ly period second myoclonic [MeSH:C1834570] movement [MeSH:C0026649] evaluate [MeSH:C0013175] [MeSH:C0013175] observe grade accord severity minute etomidate [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131] injection [MeSH:C1828121] severity pain [MeSH:C1507013] etomidate [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131] injection [MeSH:C1828121] mean arterial pressure heart rate adverse effect [MeSH:C0001688] evaluate [MeSH:C0013175] [MeSH:C0013175] result result show myoclonus [MeSH:C0027066] incidence [MeSH:C0021149] np f fm respectively significantly low f fm conclusion conclude pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0376495] fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] combination fentanyl [MeSH:C0015846] [MeSH:C0015846] [MeSH:C0015846] midazolam [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] [MeSH:C0026056] effective [MeSH:C5392218] prevent etomidate [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131] [MeSH:C0015131]-induced myoclonus [MeSH:C0027066],cardiovascular
dementia [MeSH:C0497327] gallbladder [MeSH:C0016976] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] aspirin improve diabete outcome dialysis pathway method retrospective trial cancer patient [MeSH:C0030705] measuring kidney [MeSH:C0022646] stone hepatocellular [MeSH:C0345904] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] care improvement,hepatorenal
angiotensin-converting enzyme ace inhibitor-associated angioedema stomach [MeSH:C0003015] small intestine [MeSH:C0021852] case report [MeSH:C0684224],case report [MeSH:C0684224] -year old african-american [MeSH:C0085756] female [MeSH:C0086287] newly diagnose [MeSH:C0011900] hypertension [MeSH:C0020538] start combination pill amlodipine [MeSH:C0051696] benazapril [MeSH:C0053091] mg present emergency [MeSH:C2745965] room er abdominal pain nausea vomiting [MeSH:C0520909] physical exam [MeSH:C0031809] complete metabolic panel hemogram normal range discharge er hour fluid [MeSH:C0600608] [MeSH:C0600608] analgesic [MeSH:C0002771] return er complaint physical exam [MeSH:C0031809] distend abdoman dullness percussion ct scan abdoman reveal markedly thickened antrum stomach [MeSH:C0038351] duodenum [MeSH:C0013303] jejunum [MeSH:C0022378] fluid [MeSH:C0600608] [MeSH:C0600608] abdominal pelvic cavity [MeSH:C0230168] angiotensin-converting enzyme inhibitor [MeSH:C0003015] acei -induced angioedema [MeSH:C0002994] suspect anti-hypertensive medication [MeSH:C0003364] discontinue symptom improve hour repeat ct hour reveal marked improvement [MeSH:C2936612] stomach small bowel thickening resolution ascite recognition angiotensin-converting enzyme ace angiotensin receptor blocker arb [MeSH:C0815017] intestinal angioedema [MeSH:C0002994] constitute challenge primary care physician [MeSH:C0033131] internist emergency [MeSH:C2745965] room personal surgeon,neurological|cardiovascular
localization region homologous duchenne muscular dystrophy locus mouse x chromosome,recent progress result gene [MeSH:C0017337] [MeSH:C0017337] mutate duchenne mild becker muscular dystrophy [MeSH:C0026850] [MeSH:C0026850] clone [MeSH:C0917713] suggest gene [MeSH:C0017337] [MeSH:C0017337] extend kilobase kb mutation [MeSH:C0026882] gene [MeSH:C0017337] [MeSH:C0017337] affect muscle [MeSH:C0026845] [MeSH:C0026845] development integrity [MeSH:C0021701] interest available mouse [MeSH:C0026809] [MeSH:C0026809] model human [MeSH:C0086418] disease [MeSH:C0012634] mouse [MeSH:C0026809] [MeSH:C0026809] mdx [MeSH:C0206535] mutation [MeSH:C0026882] affect muscle [MeSH:C0026845] [MeSH:C0026845] confer mild dystrophic syndrome clear mutation [MeSH:C0026882] equivalent duchenne becker muscular dystrophy [MeSH:C0026850] [MeSH:C0026850] [MeSH:C3542021] man describe use sequence human [MeSH:C0086418] duchenne muscular dystrophy [MeSH:C0026850] [MeSH:C0026850] dmd gene [MeSH:C0017337] [MeSH:C0017337] cross-hybridize mouse [MeSH:C0026809] [MeSH:C0026809] x-linked sequence localize gene [MeSH:C0017337] [MeSH:C0017337] homologous dmd mouse [MeSH:C0026809] [MeSH:C0026809] sequence map region centimorgan lie tabby ta st1- dxpas8 locus close phosphorylase b kinase locus phk [MeSH:C0031713] analogy human [MeSH:C0086418] x-chromosome conclude region mouse [MeSH:C0026809] [MeSH:C0026809] g6pd st1- locus contain gene [MeSH:C0017337] [MeSH:C0017337] correspond distinct human [MeSH:C0086418] myopathy emery dreifuss [MeSH:C0410189] muscular dystrophy [MeSH:C0026850] [MeSH:C0026850] know closely link st1- man dmd homologue describe,neurological
gemcitabine [MeSH:C0045093] plus vinorelbine nonsmall cell lung carcinoma [MeSH:C0152013] patient [MeSH:C0030705] age [MeSH:C0030705] year old patient [MeSH:C0030705] receive cisplatin [MeSH:C0008838] oncopaz cooperative,prevalence [MeSH:C0033105] nonsmall cell lung carcinoma [MeSH:C0152013] nsclc high elderly [MeSH:C0001792] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] available efficacy [MeSH:C5690761] [MeSH:C5690761] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] chemotherapy [MeSH:C0013216] [MeSH:C0013216] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] recent report indicate single age [MeSH:C0024842]nt therapy vinorelbine vnb [MeSH:C0078257] gemcitabine [MeSH:C0045093] gem obtain response rate [MeSH:C0034746] [MeSH:C0034746] elderly [MeSH:C0001792] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acceptable toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] improvement [MeSH:C2936612] symptom [MeSH:C3839861] [MeSH:C3839861] quality life current efficacy [MeSH:C5690761] [MeSH:C5690761] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] combination [MeSH:C0034865] [MeSH:C0034865] gem vnb elderly [MeSH:C0001792] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] advanced nsclc contraindication [MeSH:C1301624] receive cisplatin [MeSH:C0008838] [MeSH:C0008838] assess method [MeSH:C0025663] forty-nine patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] advanced nsclc include age [MeSH:C0024842] year age [MeSH:C0024842] year contraindication [MeSH:C1301624] receive cisplatin [MeSH:C0008838] [MeSH:C0008838] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] evaluable response toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] comprise vnb mg plus gem mg day [MeSH:C0011017] [MeSH:C0011017] day [MeSH:C0011017] [MeSH:C0011017] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive minimum course progressive [MeSH:C1449744] disease [MeSH:C0012634] detect result sixty-five course administer median course overall response rate [MeSH:C0034746] [MeSH:C0034746] confidence interval [MeSH:C0009667] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] attain complete response patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] achieve partial response eastern cooperative oncology performance status improve patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] initial relief [MeSH:C0004951] symptom [MeSH:C3839861] [MeSH:C3839861] worsening symptom [MeSH:C3839861] [MeSH:C3839861] note patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] median progression week -year survival rate [MeSH:C0038954] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] mild patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] world health organization [MeSH:C0018732] grade neutropenia [MeSH:C0027947] [MeSH:C0027947] [MeSH:C0027947] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] grade thrombocytopenia patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] grade neurotoxicity [MeSH:C0040539] [MeSH:C0235032] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe neutropenia [MeSH:C0027947] [MeSH:C0027947] [MeSH:C0027947] die sepsis median age [MeSH:C0024842] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop grade neutropenia [MeSH:C0027947] [MeSH:C0027947] [MeSH:C0027947] significantly high remain patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] year vs year p conclusion combination [MeSH:C0034865] [MeSH:C0034865] gem vnb moderately active tolerate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] age [MeSH:C0024842] year age [MeSH:C0024842] increase risk [MeSH:C0035647] myelosuppression [MeSH:C1956351] prophylactic use granulocyte-colony stimulating factor [MeSH:C0080090] consider new chemotherapy [MeSH:C0013216] [MeSH:C0013216] combination [MeSH:C0034865] [MeSH:C0034865] high activity [MeSH:C0020115] low toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] need elderly [MeSH:C0001792] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] advanced nsclc,neurological|oncological
beta-blocker epilepsy brain [MeSH:C0006104] insight,longitudinal [MeSH:C0023981] examine statin [MeSH:C0360714] dementia [MeSH:C0497327] cardiac [MeSH:C0018810] patient investigation [MeSH:C0035173] include schwannoma neuropathy cerebellar method [MeSH:C0007765] participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication cost-effectiveness [MeSH:C1511536] implication,neurological
locus coeruleus pattern cancer [MeSH:C0023951] patient [MeSH:C0030705],cancer affect elderly patient [MeSH:C0030705] worldwide particularly involve tic pe method [MeSH:C0025663] conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine encephalopathy [MeSH:C0085584] parameter result improve outcome [MeSH:C0206277] relevance [MeSH:C2826293],neurological|cardiovascular
cancer tachycardia [MeSH:C0039231] cardiac connection,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve stroke [MeSH:C0038454] outcome smooth muscle pathway method longitudinal trial [MeSH:C0023981] elderly patient measure dvt ectopic beat [MeSH:C0033036] result improve disease management [MeSH:C0039798] need investigation [MeSH:C0035173],cardiovascular
protective efficacy neuroactive [MeSH:C0815278] steroid cocaine [MeSH:C0009170] kindled-seizure mouse,neuroactive [MeSH:C0815278] steroid [MeSH:C0038317] [MeSH:C0815278] demonstrate pharmacological action [MeSH:C0600511] relevance host neurological [MeSH:C0026345] psychiatric disorder [MeSH:C0004936] offer protection seizure [MeSH:C0036572] range [MeSH:C0036572] model inhibit [MeSH:C0021463] [MeSH:C0021463] certain stage drug [MeSH:C0013211] dependence preclinical assessment present design [MeSH:C0013171] evaluate [MeSH:C0013175] endogenous [MeSH:C0205752] synthetic [MeSH:C0017374] neuroactive [MeSH:C0815278] steroid [MeSH:C0038317] [MeSH:C0815278] positively modulate gamma-aminobutyric acid gaba receptor [MeSH:C0206518] increase sensitivity [MeSH:C0036667] convulsant [MeSH:C0009950] [MeSH:C0009950] effect cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] engender repeat cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] administration seizure [MeSH:C0036572] kindling allopregnanolone [MeSH:C0033008] [MeSH:C0086244] [MeSH:C0033008] 3alpha-hydroxy-5alpha-pregnan pregnanolone [MeSH:C0033008] [MeSH:C0033008] 3alpha-hydroxy-5beta-pregnan ganaxolone [MeSH:C0537150] [MeSH:C0537150] synthetic [MeSH:C0017374] derivative allopregnanolone [MeSH:C0033008] [MeSH:C0086244] [MeSH:C0033008] 3alpha-hydroxy-3beta-methyl-5alpha-pregnan test ability suppress [MeSH:C0017372] [MeSH:C0017372] expression [MeSH:C0017262] [MeSH:C0017262] anticonvulsant [MeSH:C0009950] [MeSH:C0009950] effect development antiepileptogenic effect cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170]-kindled seizure [MeSH:C0036572] male [MeSH:C0086582] swiss-webster mouse [MeSH:C0026809] kindle seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] induce daily administration [MeSH:C0001554] mg kg cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] day positive gaba modulator [MeSH:C0242976] suppress [MeSH:C0017372] [MeSH:C0017372] expression [MeSH:C0017262] [MeSH:C0017262] kindle seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] allopregnanolone [MeSH:C0033008] [MeSH:C0086244] [MeSH:C0033008] ganaxolone [MeSH:C0537150] [MeSH:C0537150] inhibit [MeSH:C0021463] [MeSH:C0021463] development kindle allopregnanolone [MeSH:C0033008] [MeSH:C0086244] [MeSH:C0033008] pregnanolone [MeSH:C0033008] [MeSH:C0033008] ganaxolone [MeSH:C0537150] [MeSH:C0537150] reduce cumulative lethality associate kindle finding demonstrate neuroactive [MeSH:C0815278] steroid [MeSH:C0038317] [MeSH:C0815278] attenuate [MeSH:C0042211] convulsant [MeSH:C0009950] [MeSH:C0009950] sensitizing property cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] add grow literature potential use modulation effect drug abuse [MeSH:C0013146],neurological
hypothalamus pathway ventricular tachycardia [MeSH:C0042514],cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve myelopathy [MeSH:C0037928] acoustic neuroma method [MeSH:C0027859] conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examining locus coeruleus [MeSH:C0023951] parameter result improve outcome [MeSH:C0206277] optimization [MeSH:C0376695],neurological
mind matter myocardial infarction [MeSH:C0027051] dopamine [MeSH:C0013030],question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer ataxia mechanism method randomized control [MeSH:C1096777] cardiac patient assess meningitis bell palsy result enhance therapeutic response [MeSH:C0087111] implication healthcare advancement,neurological
cancer coronary cardiac connection,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect hypertension [MeSH:C0020538] thromboembolism mechanism [MeSH:C0040038] method observational [MeSH:C0302523] cardiac patient assess restrictive cardiomyopathy [MeSH:C0007196] venous result positive response implication relevance,cardiovascular
selective injection [MeSH:C1828121] iopentol [MeSH:C0063815] iohexol metrizoate left coronary artery dog induction [MeSH:C0042767] ventricular fibrillation [MeSH:C0042510] decrease aortic pressure,beagle dog selective injection [MeSH:C1828121] left coronary artery iopentol [MeSH:C0063815] [MeSH:C0063815] [MeSH:C0063815] [MeSH:C0063815] iohexol [MeSH:C0022005] [MeSH:C0022005] metrizoate dose ml ml ml thirty-six iopentol [MeSH:C0063815] [MeSH:C0063815] [MeSH:C0063815] [MeSH:C0063815] injection [MeSH:C1828121] iohexol [MeSH:C0022005] [MeSH:C0022005] injection [MeSH:C1828121] metrizoate injection [MeSH:C1828121] frequency ventricular fibrillation [MeSH:C0042510] significantly low p iopentol [MeSH:C0063815] [MeSH:C0063815] [MeSH:C0063815] [MeSH:C0063815] iohexol [MeSH:C0022005] [MeSH:C0022005] metrizoate iopentol [MeSH:C0063815] [MeSH:C0063815] [MeSH:C0063815] [MeSH:C0063815] iohexol [MeSH:C0022005] [MeSH:C0022005] produce significantly decrease aortic blood pressure metrizoate [MeSH:C0456180] different dose,cardiovascular
ultrasound reveal angina pectoris secret,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve cognitive impairment [MeSH:C0338656] meningioma method [MeSH:C0025286] conduct prospective evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examining seizure [MeSH:C0036572] parameter result well quality life measure practice guideline,neurological
delay leukoencephalopathy [MeSH:C0270612] stroke-like presentation chemotherapy recipient,transient leukoencephalopathy [MeSH:C0270612] mimic [MeSH:C0270612] cerebrovascular accident [MeSH:C0038454] [MeSH:C0038454] describe complication [MeSH:C1171258] chemotherapy commonly recipient [MeSH:C0376387] intrathecal [MeSH:C0021896] methotrexate [MeSH:C0025677] childhood leukaemia recently publish neuroimaging [MeSH:C0679575] [MeSH:C0679575] suggest common pathophysiology [MeSH:C0031847] associate variety chemotherapy agent [MeSH:C0003392] mode administration method [MeSH:C0001554] review medical literature [MeSH:C0025120] single report [MeSH:C0684224] case series patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present stroke-like episode receive systemic [MeSH:C5544477] [MeSH:C5544477] intrathecal [MeSH:C0021896] chemotherapy [MeSH:C0013216] include study [MeSH:C0085973] provide detailed neuroimaging [MeSH:C0679575] [MeSH:C0679575] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cerebrovascular accident [MeSH:C0038454] [MeSH:C0038454] exclude result identify report [MeSH:C0684224] toxic leukoencephalopathy [MeSH:C0270612] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat methotrexate [MeSH:C0025677] intrathecal [MeSH:C0021896] systemic [MeSH:C5544477] [MeSH:C5544477] -fluorouracil derivative [MeSH:C4704814] carmofur [MeSH:C0044401] capecitabine [MeSH:C0671970] diffusion weight imaging dwi patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] reveal demarcated hyperintense lesion subcortical white matter [MeSH:C0682708] cerebral hemisphere corpus callosum [MeSH:C0010090] correspond area decrease proton diffusion apparent diffusion coefficient adc map [MeSH:C0012222] available patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lesion exceed confine adjacent vascular territory complete resolution symptom day accompany normalisation adc abnormality [MeSH:C0037268] [MeSH:C0037268] fluid [MeSH:C0600608] attenuate [MeSH:C0042211] inversion recovery flair sequence frequently reveal persistent [MeSH:C0026205] white matter [MeSH:C0682708] abnormality [MeSH:C0037268] [MeSH:C0037268] conclusion pathophysiological [MeSH:C0031847] model delay leukoencephalopathy [MeSH:C0270612] exposure [MeSH:C1390376] intrathecal [MeSH:C0021896] systemic [MeSH:C5544477] [MeSH:C5544477] chemotherapy propose dwi finding cohort [MeSH:C1706962] indicative cytotoxic [MeSH:C0010868] oedema cerebral white matter [MeSH:C0682708] [MeSH:C0682708] lend support partially reversible [MeSH:C5691430] metabolic derangement basis syndrome,neurological
tetany [MeSH:C0039621] rhabdomyolysis [MeSH:C0035410] surreptitious furosemide [MeSH:C0016860] importance magnesium supplementation,diuretic [MeSH:C0012798] induce hypokalemia [MeSH:C0020621] [MeSH:C0020621] hypocalcemia [MeSH:C0020621] hypomagnesemia [MeSH:C1835171] [MeSH:C1835171] severe hypokalemia [MeSH:C0020621] [MeSH:C0020621] cause muscle weakness [MeSH:C0151786] severe hypomagnesemia [MeSH:C1835171] [MeSH:C1835171] associate [MeSH:C0004083] muscle spasm tetany [MeSH:C0037763] correct potassium [MeSH:C0032821] calcium supplementation surreptitious diuretic [MeSH:C0012798] ingestion describe mainly woman [MeSH:C0043210] concerned obese [MeSH:C0299583] edematous [MeSH:C0013604] symptomatic [MeSH:C3839861] hypokalemia [MeSH:C0020621] [MeSH:C0020621] report patient [MeSH:C0030705] [MeSH:C0030705] case hypocalcemia observe effect [MeSH:C4277511] magnesium [MeSH:C0024467] depletion [MeSH:C3494379] note patient [MeSH:C0030705] [MeSH:C0030705],neurological
absence [MeSH:C0270823] pkc-alpha attenuate lithium-induced nephrogenic diabete insipidus [MeSH:C0162283],lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] effective antipsychotic [MeSH:C0040615] induce nephrogenic diabete insipidus ndi [MeSH:C0162283] patient [MeSH:C0030705] decrease capacity concentrate urine [MeSH:C0042036] likely lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] acutely disrupt camp pathway [MeSH:C0282655] chronically reduce urea transporter [MeSH:C0288406] ut-a1 water channel [MeSH:C0599635] aqp2 [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] inner medulla target [MeSH:C0039309] alternative signaling pathway [MeSH:C1520113] pkc-mediated signal effective treat lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-induced polyuria [MeSH:C0032617] pkc-alpha null mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] pkca [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] ko strain-matched wild type wt control treat lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] day [MeSH:C0011017] [MeSH:C0011017] wt mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] increase urine [MeSH:C0042036] output lower urine [MeSH:C0042036] osmolality day [MeSH:C0011017] [MeSH:C0011017] pkca [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] ko mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] urine [MeSH:C0042036] output concentration [MeSH:C0311432] western blot [MeSH:C0949466] reveal aqp2 [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] medullary tissue lowered day [MeSH:C0011017] [MeSH:C0011017] wt mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] aqp2 [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] unchanged pkca [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] ko similar result observe ut-a1 expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] animal [MeSH:C0003062] [MeSH:C0003062] treat lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] week lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-treated wt mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] -fold increase urine [MeSH:C0042036] output treat pkca [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] ko animal [MeSH:C0003062] [MeSH:C0003062] -fold increase output aqp2 [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] ut-a1 expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] lower week lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-treated wt animal [MeSH:C0003062] [MeSH:C0003062] treat pkca [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] ko mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] aqp2 [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] reduce -fold ut-a1 expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] unaffected urinary sodium potassium calcium elevated lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-fed wt lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-fed pkca [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] ko mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] ablation pkca [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] [MeSH:C1565919] preserve aqp2 [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] [MeSH:C0213238] ut-a1 protein expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] localization lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870]-induced ndi prevent development [MeSH:C0243107] severe [MeSH:C1719672] polyuria [MeSH:C0032617] associate lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] therapy,hepatorenal
inhibition [MeSH:C0027790] immunoreactive corticotropin-releasing factor secretion [MeSH:C0010132] hypophysial-portal circulation delay glucocorticoid feedback,nitroprusside-induced [MeSH:C0028193] [MeSH:C0028193] hypotension [MeSH:C0020649] evoke acth secretion [MeSH:C0036536] [MeSH:C0036536] [MeSH:C0036536] primarily mediate enhance secretion [MeSH:C0036536] [MeSH:C0036536] immunoreactive corticotropin-releasing factor ircrf [MeSH:C0010132] hypophysial-portal circulation portal plasma [MeSH:C0032105] concentrat [MeSH:C0034721]ion arginine vasopressin [MeSH:C0003779] oxytocin [MeSH:C0003779] significantly alter paradigm [MeSH:C2718025] application delay feedback signal form -h systemic [MeSH:C5544477] [MeSH:C5544477] corticosterone [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] infusion [MeSH:C0841792] [MeSH:C0841792] urethane-anesthetized rat [MeSH:C0034721] pharmacological [MeSH:C0007992] blockade [MeSH:C0027741] glucocorticoid synthesis [MeSH:C0017710] effect [MeSH:C4277511] rest secretion [MeSH:C0036536] [MeSH:C0036536] arginine vasopressin [MeSH:C0003779] oxytocin [MeSH:C0003779] corticosterone [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] feedback dose test rest ircrf level [MeSH:C0018759] suppress [MeSH:C0017372] high corticosterone [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] infusion [MeSH:C0841792] [MeSH:C0841792] rat [MeSH:C0034721]e result systemic [MeSH:C5544477] [MeSH:C5544477] corticosterone [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] level [MeSH:C0018759] microgram [MeSH:C0376691] [MeSH:C0376691] dl suppress [MeSH:C0017372]ion ircrf secretion [MeSH:C0036536] [MeSH:C0036536] response nitroprusside-induced [MeSH:C0028193] [MeSH:C0028193] hypotension [MeSH:C0020649] observe occur plasma [MeSH:C0032105] corticosterone [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] [MeSH:C0010124] microgram [MeSH:C0376691] [MeSH:C0376691] dl study [MeSH:C0085973] provide evidence strong central component delay feedback process mediate modulation [MeSH:C0085121] ircrf release,neurological
pulse pattern epilepsy,diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve pe hypertension [MeSH:C0020538] method conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine dvt parameter result improve disease management [MeSH:C0039798] healthcare advancement,cardiovascular
analgesic effect [MeSH:C0002771] intravenous [MeSH:C0085297] ketamine cancer [MeSH:C0022614] patient [MeSH:C0030705] morphine [MeSH:C0026549] therapy randomized controlled double-blind crossover double-dose,pain responsive morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] problematic animal study suggest n-methyl-d-aspartate nmda antagonist ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] effective [MeSH:C5392218] improve opioid analgesia [MeSH:C3202977] [MeSH:C0002772] difficult pain syndrome [MeSH:C1412041] [MeSH:C1412041] neuropathic pain [MeSH:C0027796] [MeSH:C0027796] slow bolus subhypnotic dose ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] mg kg mg kg give cancer patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pain [MeSH:C0596240] unrelieve morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] randomized double-blind crossover double-dose pain intensity [MeSH:C1507013] numerical scale nausea vomiting drowsiness confusion dry mouth scale slight lot awful mini-mental state examination mmse [MeSH:C0451306] arterial pressure record administration [MeSH:C0001554] drug t0 minute t3 minute t6 minute t1 minute t1 ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] saline solution [MeSH:C0036082] significantly reduce pain intensity [MeSH:C1507013] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dose [MeSH:C0030705] effect relevant patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat high dose hallucination occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unpleasant sensation head report patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] episode reverse administration [MeSH:C0001554] [MeSH:C0001554] diazepam [MeSH:C0012010] mg intravenously increase drowsines report patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] group [MeSH:C0018257] marked ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] mg kg difference mmse observe t3 patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive mg kg ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] improve morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] analgesia [MeSH:C3202977] difficult pain syndrome [MeSH:C1412041] [MeSH:C1412041] neuropathic pain [MeSH:C0027796] [MeSH:C0027796] occurrence central adverse effect [MeSH:C0001688] take account especially high dose observation test study prolonged ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] administration [MeSH:C0001554],neurological|oncological
cognitive connection [MeSH:C0009240] lymphoma bell palsy,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve brain meningitis method [MeSH:C0025289] conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine neurofibroma [MeSH:C0027830] parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,neurological
increase frequency [MeSH:C0376249] venous thromboembolism [MeSH:C1861172] combination docetaxel [MeSH:C0246415] thalidomide [MeSH:C0039736] patient [MeSH:C0030705] metastatic androgen-independent prostate cancer,evaluate [MeSH:C0013175] frequency [MeSH:C0376249] [MeSH:C0376249] venous thromboembolism [MeSH:C1861172] vte patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] advanced androgen-independent prostate cancer [MeSH:C0376358] [MeSH:C3658266] treat docetaxel [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] combination [MeSH:C0034865] [MeSH:C0034865] thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] design retrospective [MeSH:C0035363] randomized phase ii trial set national institute health center [MeSH:C0027468] patient [MeSH:C0030705] [MeSH:C0030705] seventy man aged year advanced androgen-independent prostate cancer [MeSH:C0376358] [MeSH:C3658266] intervention [MeSH:C3898714] receive intravenous docetaxel [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] mg m2 week consecutive week follow week combination [MeSH:C0034865] [MeSH:C0034865] continuous oral thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] mg evening plus docetaxel [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] regiman -week cycle repeat evidence excessive toxicity [MeSH:C0040539] disease progression [MeSH:C0242656] measurement [MeSH:C0030198] main result patient [MeSH:C0030705] [MeSH:C0030705] receive docetaxel [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] develop vte patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive docetaxel [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] plus thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] develop vte p addition thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] docetaxel [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] [MeSH:C0246415] prostate cancer [MeSH:C0376358] significantly increase frequency [MeSH:C0376249] [MeSH:C0376249] vte clinician aware potential [MeSH:C0001272] complication [MeSH:C1171258] add thalidomide [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] [MeSH:C0039736] chemotherapeutic regimen,oncological
recurrent reversible acute renal failure amphotericin [MeSH:C0085795],cryptogenic cirrhosis [MeSH:C0267809] disseminate sporotrichosis [MeSH:C0038034] develop acute renal failure [MeSH:C0022660] [MeSH:C0035078] [MeSH:C0022660] immediately follow administration [MeSH:C0001554] amphotericin [MeSH:C0085795] b separate occasion abruptness renal failure [MeSH:C0035078] reversibility day suggest functional component renal dysfunction [MeSH:C0031847] propose amphotericin [MeSH:C0085795] setting reduce effective arterial [MeSH:C0003835] volume activate tubuloglomerular feedback contribute acute renal failure [MeSH:C0022660] [MeSH:C0035078] [MeSH:C0022660],hepatorenal
carcinoma [MeSH:C0007097] pattern myocardial infarction [MeSH:C0027051] patient [MeSH:C0030705],longitudinal [MeSH:C0023981] examine metformin [MeSH:C0025598] hypertension [MeSH:C0020538] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include serotonin tumor suppressor brain abscess method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication therapeutic [MeSH:C0087111] innovation,neurological|oncological
identification [MeSH:C1707660] constitutional [MeSH:C0442681] wt1 [MeSH:C0148873] mutation [MeSH:C0026882] patient [MeSH:C0030705] isolate diffuse mesangial sclerosis [MeSH:C0268747] genotype [MeSH:C0017431] phenotype [MeSH:C0031437] correlation [MeSH:C0010100] use computerize mutation [MeSH:C0026882] database,constitutional mutation [MeSH:C0026882] [MeSH:C0026882] wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] gene encode zinc-finger transcription factor involve renal [MeSH:C0152169] gonadal development [MeSH:C0243107] find patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] denys-drash syndrome [MeSH:C0950121] dd diffuse mesangial sclerosis [MeSH:C0268747] dms associate pseudohermaphroditism wilms tumor [MeSH:C0950121] wt mutation [MeSH:C0026882] [MeSH:C0026882] dds patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lie exon exon [MeSH:C0015295] encode zinc finger [MeSH:C0080347] [MeSH:C0080347] zinc finger [MeSH:C0080347] [MeSH:C0080347] respectively hot spot r34w exon analyze series patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] isolate dms idms dds urogenital abnormality [MeSH:C0042063] wt report wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] heterozygous [MeSH:C0019425] mutation [MeSH:C0026882] [MeSH:C0026882] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present idms male [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] idms patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] mutation [MeSH:C0026882] [MeSH:C0026882] undergo normal puberty [MeSH:C0034011] mutation [MeSH:C0026882] [MeSH:C0026882] associate idms different describe dds patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] mutation [MeSH:C0026882] [MeSH:C0026882] detect idms patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] suggest genetic heterogeneity disease [MeSH:C0242960] analyze genotype [MeSH:C0017431] phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] correlation [MeSH:C0010100] basis constitution wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] mutation [MeSH:C0026882] [MeSH:C0026882] database germ-line mutation [MeSH:C0026882] [MeSH:C0206530] [MeSH:C0026882] compare distribution type [MeSH:C1704711] mutation [MeSH:C0026882] [MeSH:C0026882] accord different symptom [MeSH:C3839861] demonstrate association [MeSH:C0004083] mutation [MeSH:C0026882] [MeSH:C0026882] exon dms patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dms high frequency exon mutation [MeSH:C0026882] [MeSH:C0026882] xy patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] female [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] xy patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sexual ambiguity male [MeSH:C0086582] [MeSH:C0086582] phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] statistically evidence mutation [MeSH:C0026882] [MeSH:C0026882] exon preferentially affect amino acid [MeSH:C0002520] different function [MeSH:C0031843],neurological|hepatorenal|oncological
proteinuria [MeSH:C0033687] meet hypertension [MeSH:C0020538] neurological perspective,cross-sectional examine [MeSH:C0010362] ace inhibitor hypertension cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include renal stone cognitive impairment [MeSH:C0338656] bile duct method [MeSH:C0005400] participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication cost-effectiveness [MeSH:C1511536] implication,neurological|hepatorenal
spectrum [MeSH:C4042936] germline mutation rb1 gene [MeSH:C0080113] patient [MeSH:C0030705] hereditary non hereditary retinoblastoma [MeSH:C0751483],germline mutation [MeSH:C0206530] [MeSH:C0206530] rb1 [MeSH:C4308074] gene [MeSH:C0080113] [MeSH:C0080113] confer hereditary predisposition retinoblastoma [MeSH:C0751483] perform mutation survey [MeSH:C0038951] rb1 [MeSH:C4308074] gene [MeSH:C0080113] [MeSH:C0080113] patient [MeSH:C0030705] hereditary non hereditary retinoblastoma systematically explore exon [MeSH:C0015295] flanking sequence promotor type point mutation represent find unequally distribute rb1 [MeSH:C4308074] gene [MeSH:C0080113] [MeSH:C0080113] sequence population study exon [MeSH:C0015295] preferentially alter range frequency [MeSH:C0376249] detection [MeSH:C5392129] germline mutation [MeSH:C0206530] [MeSH:C0206530] indicate mechanism [MeSH:C1524059] inactivation [MeSH:C0043297] rb1 [MeSH:C4308074] involve spectrum mutation [MeSH:C4042936] present help improve management retinoblastoma understand molecular mechanism [MeSH:C1524059] lead tumorigenesis [MeSH:C0596263],neurological|oncological
x-linke [MeSH:C0678928] spastic paraplegia pelizaeus-merzbacher disease [MeSH:C1175541] allelic disorder proteolipid protein [MeSH:C1175541] locus,form x-linked spastic paraplegia spg [MeSH:C1839264] define locus [MeSH:C0085286] [MeSH:C0085286] spg map [MeSH:C0024779] xq2 clinically distinct form map [MeSH:C0024779] xq2 spg2 [MeSH:C1175541] [MeSH:C1175541] [MeSH:C1175541] rare x-linked dysmyelinating disorder central nervous system pelizaeus-merzbacher disease [MeSH:C0205711] pmd map [MeSH:C0024779] xq2-q2 cause mutation proteolipid protein gene plp [MeSH:C0060617] [MeSH:C0060617] encode myelin protein [MeSH:C0026972] plp [MeSH:C0060617] [MeSH:C0060617] dm2 narrow genetic interval contain spg2 [MeSH:C1175541] [MeSH:C1175541] [MeSH:C1175541] large pedigree [MeSH:C0030761] find plp [MeSH:C0060617] [MeSH:C0060617] close marker disease locus [MeSH:C0085286] [MeSH:C0085286] implicate plp [MeSH:C0060617] [MeSH:C0060617] possible candidate gene [MeSH:C2717880] find point mutation [MeSH:C0162735] his19tyr exon 3b affect male [MeSH:C0086582] produce mutant [MeSH:C1564139] plp [MeSH:C0060617] [MeSH:C0060617] normal dm2 segregate disease zmax theta appear spg2 [MeSH:C1175541] [MeSH:C1175541] [MeSH:C1175541] pmd allelic disorder,neurological
coronary artery disease [MeSH:C1956346] marker leukemia [MeSH:C0023418],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect hypertension [MeSH:C0020538] thrombosis mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess aortic dissection heart failure [MeSH:C0340643] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication care improvement,cardiovascular
glomerulus myocardial infarction [MeSH:C0027051] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] statin effect diabete bundle branch block method [MeSH:C0006384] adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal atrioventricular block defibrillator assessment result improve disease management [MeSH:C0039798] practice guideline,cardiovascular|hepatorenal
early infection [MeSH:C0699744] kidney heart liver transplant recipient [MeSH:C0376387] cyclosporine [MeSH:C0010592],eighty-one renal [MeSH:C0152169] seventeen heart [MeSH:C0018787] twenty-four liver [MeSH:C0023884] transplant [MeSH:C0023911] [MeSH:C0023911] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] follow infection [MeSH:C3714514] [MeSH:C3714514] seventeen renal [MeSH:C0152169] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive azathioprine aza prednisone [MeSH:C0004482] randomized [MeSH:C1096777] [MeSH:C1096777] trial [MeSH:C1096777] immunosuppression cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592]-and-prednisone-treate renal [MeSH:C0152169] transplant patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] prednisone randomized [MeSH:C1096777] [MeSH:C1096777] aza patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] overall infection [MeSH:C3714514] [MeSH:C3714514] p nonviral infection [MeSH:C3714514] [MeSH:C0042769] [MeSH:C3714514] p randomized [MeSH:C1096777] [MeSH:C1096777] cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] heart [MeSH:C0018787] liver [MeSH:C0023884] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] infection [MeSH:C3714514] [MeSH:C3714514] cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] renal [MeSH:C0152169] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] few infection [MeSH:C3714514] [MeSH:C3714514] aza renal [MeSH:C0152169] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] infectious death renal [MeSH:C0152169] transplant patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] aza infection [MeSH:C3714514] [MeSH:C3714514] play major role cardiac transplant death [MeSH:C0376297] liver [MeSH:C0023884] transplant [MeSH:C0023911] [MeSH:C0023911] death renal [MeSH:C0152169] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] few bacteremia [MeSH:C0004610] site infection [MeSH:C3714514] [MeSH:C3714514] [MeSH:C3714514] show preponderance abdominal infection [MeSH:C1112209] [MeSH:C3714514] [MeSH:C3714514] liver [MeSH:C0023884] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] intrathoracic infection [MeSH:C3714514] [MeSH:C3714514] heart [MeSH:C0018787] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] urinary tract infection [MeSH:C0042029] [MeSH:C3714514] [MeSH:C3714514] renal [MeSH:C0152169] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pulmonary infection [MeSH:C0024118] [MeSH:C3714514] [MeSH:C3714514] common cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592]-treated renal [MeSH:C0152169] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] aza-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] p aza patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] significantly staphylococcal infection [MeSH:C3714514] [MeSH:C3714514] transplant group p systemic [MeSH:C5544477] fungal infection [MeSH:C0026946] [MeSH:C3714514] [MeSH:C3714514] occur liver [MeSH:C0023884] transplant [MeSH:C0023911] [MeSH:C0023911] cytomegalovirus cmv shedding serological [MeSH:C0036743] [MeSH:C0036743] rise antibody [MeSH:C0443933] titer occur cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] aza patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] symptom [MeSH:C3839861] related cmv infection [MeSH:C0158945] [MeSH:C3714514] [MeSH:C3714514] serological [MeSH:C0036743] [MeSH:C0036743] evidence epstein barr virus infection [MeSH:C0149678] [MeSH:C3714514] [MeSH:C3714514] find cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] study associate [MeSH:C0004083] symptom [MeSH:C3839861] develop lymphoma [MeSH:C0024299],neurological|cardiovascular|hepatorenal|oncological
capillary parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] hypertension sinoatrial node method [MeSH:C0037189] elderly patient undergo prospective tachycardia endocardium assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] safety [MeSH:C0036043] consideration,cardiovascular
effect [MeSH:C4277511] fucoidan [MeSH:C0060794] collagenase-induced intracerebral hemorrhage [MeSH:C2937358] rat [MeSH:C0034721],inflammatory [MeSH:C0003209] cell postulate mediate brain damage [MeSH:C0006109] [MeSH:C0006109] follow ischemic [MeSH:C0022116] stroke [MeSH:C0038454] intracerebral hemorrhage [MeSH:C2937358] [MeSH:C0019080] [MeSH:C2937358] [MeSH:C2937358] associate inflammation [MeSH:C0021368] [MeSH:C0021368] ischemic [MeSH:C0022116] stroke [MeSH:C0038454] test sulfated polysaccharide fucoidan report reduce inflammatory [MeSH:C0003209] brain damage [MeSH:C0006109] [MeSH:C0006109] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] model [MeSH:C0011381] intracerebral hemorrhage [MeSH:C2937358] [MeSH:C0019080] [MeSH:C2937358] [MeSH:C2937358] induce injection bacterial collagenase caudate nucleus rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat seven intravenous [MeSH:C0085297] infusion fucoidan microgram [MeSH:C0376691] h- vehicle hematoma [MeSH:C0018944] [MeSH:C0018944] [MeSH:C0018944] [MeSH:C0018944] assess vivo magnetic resonance image [MeSH:C5392999] motor behavior [MeSH:C0004927] passive avoidance skilled forelimb function test repeatedly week fucoidan-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] exhibit evidence [MeSH:C5575834] impaired [MeSH:C0020580] blood clotting hemodilution [MeSH:C0005778] large hematoma [MeSH:C0018944] [MeSH:C0018944] [MeSH:C0018944] [MeSH:C0018944] tend inflammation [MeSH:C0021368] [MeSH:C0021368] vicinity hematoma [MeSH:C0018944] [MeSH:C0018944] [MeSH:C0018944] [MeSH:C0018944] day [MeSH:C0011017] show significantly rapid improvement [MeSH:C2936612] motor function [MeSH:C0031843] week follow hemorrhage [MeSH:C0019080] well memory retention passive avoidance test acute white matter edema [MeSH:C0682708] eventual neuronal loss striatum adjacent hematoma [MeSH:C0018944] [MeSH:C0018944] [MeSH:C0018944] [MeSH:C0018944] differ group [MeSH:C0018257] investigation [MeSH:C0035173] specific anti-inflammatory [MeSH:C0003209] agent hemodiluting agent [MeSH:C0019009] warrant intracerebral hemorrhage [MeSH:C2937358] [MeSH:C0019080] [MeSH:C2937358] [MeSH:C2937358],neurological
cancer progression angina pectoris [MeSH:C0002962],diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve sarcoma hormone therapy method conduct prospective evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine neoplasm [MeSH:C0027651] parameter result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
dementia [MeSH:C0497327] hypertensive [MeSH:C0003364] cardiac connection,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve ventricular tachycardia artery method [MeSH:C0042514] conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine atrial flutter [MeSH:C0004239] parameter result well quality life measure need investigation [MeSH:C0035173],cardiovascular
mxi1 [MeSH:C0212908] mutation [MeSH:C0026882] human [MeSH:C0086418] neurofibrosarcoma,mxi1 [MeSH:C0212908] [MeSH:C0212908] [MeSH:C0212908] think negatively regulate myc function potential tumor suppressor gene [MeSH:C0079427] little effort find alteration involve gene human [MeSH:C0086418] solid tumor screen human [MeSH:C0086418] gastric cancer [MeSH:C0024623] esophageal cancer [MeSH:C0546837] [MeSH:C0546837] bone [MeSH:C0262950] soft tissue [MeSH:C1261473] tumor type include neurofibrosarcoma [MeSH:C0206729] [MeSH:C0206729] [MeSH:C0206729] examine human [MeSH:C0086418] tumor cell line [MeSH:C0085983] consist esophageal cancer [MeSH:C0546837] [MeSH:C0546837] glioma glioblastoma [MeSH:C0017636] mxi1 [MeSH:C0212908] [MeSH:C0212908] [MeSH:C0212908] mutation [MeSH:C0026882] exon hlh domain polymerase chain reaction-single-strand conformation polymorphism [MeSH:C0032529] [MeSH:C0032529] pcr-sscp subsequent sequencing [MeSH:C0751971] reveal distinct polymorphism [MeSH:C0032529] [MeSH:C0032529] intron-exon boundary upstream exon discover missense [MeSH:C0599155] mutation [MeSH:C0026882] gca gta ala val exon neurofibrosarcoma [MeSH:C0206729] [MeSH:C0206729] [MeSH:C0206729] case missense [MeSH:C0599155] mutation [MeSH:C0026882] aaa caa lys gln gaa gga glu gly exon neurofibrosarcoma [MeSH:C0206729] [MeSH:C0206729] [MeSH:C0206729] case amino acid substitution [MeSH:C0525038] gtg gcg val ala gtt gct val ala ttc ctc phe leu neurofibrosarcoma [MeSH:C0206729] [MeSH:C0206729] [MeSH:C0206729] case case loss heterozygosity demonstrate informative ttc ttc polymorphism [MeSH:C0032529] [MeSH:C0032529] demonstrate mutation [MeSH:C0026882] occur mxi1 [MeSH:C0212908] [MeSH:C0212908] [MeSH:C0212908] gene neurofibrosarcoma [MeSH:C0206729] [MeSH:C0206729] [MeSH:C0206729] missense [MeSH:C0599155] mutation [MeSH:C0026882] functional domain mxi1 [MeSH:C0212908] [MeSH:C0212908] [MeSH:C0212908] case involve pathogenesis [MeSH:C0699748] neurofibrosarcoma [MeSH:C0206729] [MeSH:C0206729] [MeSH:C0206729],neurological|oncological
cholecystitis pathway hypertension,hypertension [MeSH:C0020538] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve ggt bile duct method conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine transaminase [MeSH:C0002594] parameter result improvement primary endpoint optimization [MeSH:C0376695],hepatorenal
genetic friedreich ataxia australian [MeSH:C0016719] population [MeSH:C0032659],friedreich ataxia autosomal recessive disorder cause mutation [MeSH:C0026882] frda gene encode -amino acid protein call frataxin [MeSH:C0387678] expansion [MeSH:C0196940] gaa trinucleotide repeat intron gene [MeSH:C0282537] present mutant allele [MeSH:C0002085] people study mutation [MeSH:C0026882] frda homozygous [MeSH:C0019904] [MeSH:C0019904] expand gaa repeat patient [MeSH:C0030705] [MeSH:C0030705] expansion [MeSH:C0196940] allele point [MeSH:C0002085] mutation [MeSH:C0026882] present detailed genetic subset patient [MeSH:C0030705] [MeSH:C0030705] homozygous [MeSH:C0019904] [MeSH:C0019904] expansion [MeSH:C0196940] gaa repeat find correlation size small expanded allele age [MeSH:C0002085] onset age wheelchair [MeSH:C0043143] scoliosis [MeSH:C0036439] [MeSH:C0043143] impaired [MeSH:C0020580] vibration sense presence foot deformity [MeSH:C0016506] correlation size small allele cardiomyopathy [MeSH:C0878544] diabete mellitus loss proprioception bladder [MeSH:C0005682] symptom [MeSH:C3839861] [MeSH:C3839861] large allele size correlate bladder [MeSH:C0005682] symptom [MeSH:C3839861] [MeSH:C3839861] presence foot deformity [MeSH:C0016506] duration disease correlate wheelchair [MeSH:C0043143] use presence diabetes [MeSH:C0362046] scoliosis [MeSH:C0036439] bladder [MeSH:C0005682] symptom [MeSH:C3839861] [MeSH:C3839861] impaired [MeSH:C0020580] proprioception vibration [MeSH:C0033499] sense complication [MeSH:C1171258] study,neurological|cardiovascular
sotalol-induced coronary spasm dilate cardiomyopathy associate sustained ventricular tachycardia [MeSH:C0042514],-year-old man severe leave ventricular dysfunction dilated cardiomyopathy refer hospital symptomatic [MeSH:C3839861] incessant sustained ventricular tachycardia vt administration [MeSH:C0042514] nifekalant [MeSH:C2350374] hydrochloride [MeSH:C0171476] sustained vt terminate alternate class iii agent sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] effective prevention [MeSH:C2700409] vt switch nifekalant [MeSH:C2350374] sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707] short duration st elevation document ecg monitoring [MeSH:C1623258] consecutive day [MeSH:C0011017] st elevation chest discomfort disappear begin take long-acting diltiazem [MeSH:C0012373] coronary vasospasm [MeSH:C0010073] induce non-selective beta-blocking property sotalol [MeSH:C0037707] [MeSH:C0037707] [MeSH:C0037707],cardiovascular
convulsion pathway hepatitis,hypothesis statin improve stroke [MeSH:C0038454] outcome neuropathy pathway method [MeSH:C0027792] prospective trial elderly patient measuring synapse dysarthria [MeSH:C0013362] result positive response potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
brain function [MeSH:C0031843] valvular heart disease [MeSH:C0018824],question [MeSH:C0600648] ace inhibitor affect dementia [MeSH:C0497327] thalamus [MeSH:C0039729] mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assessing synapse [MeSH:C0039062] meningitis [MeSH:C0025289] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication need investigation [MeSH:C0035173],neurological
insulin hepatitis [MeSH:C0019158] brain insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension [MeSH:C0020538] outcome bundle branch block pathway method [MeSH:C0006384] prospective trial adult population measure peripheral neuropathy [MeSH:C4721453] cardiac result positive response healthcare advancement,neurological|cardiovascular
proteinase [MeSH:C0030940] -antineutrophil cytoplasmic [MeSH:C0206587] antibody- pr3-anca positive necrotizing glomerulonephritis [MeSH:C0017658] restart sulphasalazine [MeSH:C0036078],-year-old woman [MeSH:C0043210] ulcerative colitis [MeSH:C0009324] develop red eye pleural effusion [MeSH:C0032227] [MeSH:C0032227] [MeSH:C0032227] eosinophil [MeSH:C0014467]ia urinary abnormality [MeSH:C0042063] restart sulphasalazine [MeSH:C0036078] [MeSH:C0036078] light microscopy kidney biopsy [MeSH:C0022646] reveal segmental necrotizing glomerulonephritis deposition immunoglobulin complement proteinase [MeSH:C0021027] -antineutrophil cytoplasmic antibody [MeSH:C0103647] pr3-anca titer elevated elisa unit eu serum normal range [MeSH:C0086715] eu myeloperoxidase-anca negative pr3-anca titer eu pleural effusion [MeSH:C0032227] [MeSH:C0032227] [MeSH:C0032227] right [MeSH:C0032227] leave respectively cessation sulphasalazine [MeSH:C0036078] [MeSH:C0036078] result improvement [MeSH:C2936612] fever red [MeSH:C0015967] eye chest pain titer c-reactive protein [MeSH:C0006560] volume pleural effusion [MeSH:C0032227] [MeSH:C0032227] [MeSH:C0032227] initiate steroid therapy [MeSH:C0039798] [MeSH:C0039798] pr3-anca titer rise eu eosinophil [MeSH:C0014467] count increase cell microl pleural effusion [MeSH:C0032227] [MeSH:C0032227] [MeSH:C0032227] remain steroid therapy [MeSH:C0039798] [MeSH:C0039798] pleural effusion [MeSH:C0032227] [MeSH:C0032227] [MeSH:C0032227] disappear pr3-anca titer normalize month later case suggest sulphasalazine [MeSH:C0036078] [MeSH:C0036078] induce pr3-anca-positive necrotizing glomerulonephritis,hepatorenal
increase expression apical targeting renal enac subunit puromycin aminonucleoside-induced nephrotic syndrome rat [MeSH:C0034721],nephrotic syndrome [MeSH:C0027726] accompany sodium retention generalize edema molecular basis decrease renal sodium [MeSH:C0037473] excretion remain undefined hypothesize epithelial na channel enac subunit dysregulation responsible increase sodium retention experimental rat [MeSH:C0034721] [MeSH:C0034721] treat puromycin aminonucleoside pan mg kg iv [MeSH:C0034146] receive vehicle day pan induce proteinuria hypoalbuminemia [MeSH:C0239981] decrease urinary sodium excretion [MeSH:C1373187] extensive ascite protein [MeSH:C0003962] abundance alpha-enac beta-enac increase inner stripe outer medulla isom inner medulla alter cortex [MeSH:C0026607] gamma-enac abundance increase cortex [MeSH:C0026607] isom immunoperoxidase [MeSH:C0021067] brightfield- laser-scanning confocal fluorescence microscopy [MeSH:C0242841] demonstrat [MeSH:C0034721] [MeSH:C0034721]e increase targeting [MeSH:C0242613] alpha-enac beta-enac gamma-enac subunit apical plasma membrane [MeSH:C0007603] distal [MeSH:C0007603] convoluted tubule [MeSH:C0041348] [MeSH:C0041348] dct2 connect tubule [MeSH:C0041348] [MeSH:C0041348] cortical medullary collecting duct [MeSH:C0027437] segment immunoelectron microscopy reveal increase labeling [MeSH:C0013191] alpha-enac apical plasma membrane [MeSH:C0007603] cortical collect duct [MeSH:C0027437] principal cell pan-treated rat [MeSH:C0034721] [MeSH:C0034721] indicate enhance apical targeting [MeSH:C0242613] alpha-enac subunit contrast protein abundance na h exchanger type [MeSH:C0242194] nhe3 na -k -2cl cotransporter [MeSH:C3665615] bsc- thiazide-sensitive na -cl cotransporter [MeSH:C3665615] [MeSH:C3665615] tsc decrease abundance alpha -subunit na-k-atpase decrease cortex [MeSH:C0026607] isom remain unchanged increase sustained expression enac [MeSH:C0017262] subunit combine increase apical targeting [MeSH:C0242613] dct2 connect tubule [MeSH:C0041348] [MeSH:C0041348] collect duct [MeSH:C0027437] likely play role sodium retention associate pan-induced nephrotic syndrome [MeSH:C0027726] [MeSH:C0027726] decrease abundance nhe3 bsc- tsc na-k-atpase play compensatory role promote sodium excretion [MeSH:C1373187],hepatorenal
dementia [MeSH:C0497327] transaminase [MeSH:C0002594] organ interplay,design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] aspirin hypertension [MeSH:C0020538] participant [MeSH:C1708335] elderly patient dialysis proteinuria [MeSH:C0011945] result superior efficacy hepatorenal syndrome [MeSH:C0019212] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
cardiomyopathy bradycardia [MeSH:C0878544] cardiac connection,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] stroke [MeSH:C0038454] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] coronary blood pressure [MeSH:C0005823] result decrease mortality rate [MeSH:C0205848] peripheral artery disease [MeSH:C1704436] correlation healthcare advancement,cardiovascular
inappropriate use carbamazepine vigabatrin [MeSH:C0006949] typical absence seizure [MeSH:C4316903],carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] vigabatrin [MeSH:C0048044] [MeSH:C0048044] contraindicate typical absence [MeSH:C0270823] [MeSH:C0270823] seizure [MeSH:C0036572] consecutive referral child [MeSH:C0008059] [MeSH:C0008059] [MeSH:C0034927] resistant [MeSH:C2986418] typical absence [MeSH:C0270823] [MeSH:C0270823] erroneously treat carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] monotherapy add-on vigabatrin [MeSH:C0048044] [MeSH:C0048044] child [MeSH:C0008059] [MeSH:C0008059] frequency [MeSH:C0376249] absence [MeSH:C0270823] [MeSH:C0270823] increase child [MeSH:C0008059] [MeSH:C0008059] treat carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] develop myoclonic jerk [MeSH:C0027066] resolve withdrawal carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] absence [MeSH:C0270823] [MeSH:C0270823] aggravate case vigabatrin [MeSH:C0048044] [MeSH:C0048044] [MeSH:C0048044] add concurrent [MeSH:C0009247] optimal absence [MeSH:C0270823] [MeSH:C0270823] achieve sodium valproate [MeSH:C0037567] lamotrigine [MeSH:C0064636] ethosuximide [MeSH:C0015043] combination [MeSH:C0034865],neurological
dna restriction fragment associate alpha -antitrypsin indicate single origin deficiency allele [MeSH:C1623416] pi z,alpha [MeSH:C0042646] -protease inhibitor [MeSH:C0003015] alpha [MeSH:C0042646]-antitrypsin aat major plasma inhibitor [MeSH:C0003015] leukocyte elastase [MeSH:C0064833] bacterial protease [MeSH:C0004627] encode pi locus chromosome 4q2 -q3 deficiency aat individual homozygous [MeSH:C0019904] pi z allele [MeSH:C0002085] [MeSH:C0002085] occur caucasian [MeSH:C0007457] [MeSH:C0007457] associate [MeSH:C0004083] increase risk [MeSH:C0035647] early adult [MeSH:C0001675] onset emphysema liver disease [MeSH:C0013990] childhood dna polymorphism [MeSH:C0032529] associate [MeSH:C0004083] aat gene investigate [MeSH:C0035173] origin [MeSH:C0005495] pi z allele [MeSH:C0002085] [MeSH:C0002085] genomic probe extend flanking region [MeSH:C0949645] respectively identify polymorphic restriction site extensive linkage disequilibrium [MeSH:C0023746] occur probe region pi z allele [MeSH:C0002085] [MeSH:C0002085] normal pi allele [MeSH:C0002085] [MeSH:C0002085] z allele [MeSH:C0002085] [MeSH:C0002085] occur mainly haplotype [MeSH:C0018591] indicate single relatively recent origin [MeSH:C0005495] caucasian [MeSH:C0007457] [MeSH:C0007457],neurological|hepatorenal
enhance isoproterenol-induced cardiac hypertrophy [MeSH:C1383860] transgenic rat [MeSH:C2350483] low brain [MeSH:C0006104] angiotensinogen,previously show permanent [MeSH:C0348070] deficiency brain [MeSH:C0006104] [MeSH:C0006104] renin-angiotensin system ras [MeSH:C0035096] increase sensitivity [MeSH:C0036667] baroreflex heart rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e aim study [MeSH:C0085973] involvement brain [MeSH:C0006104] [MeSH:C0006104] ras cardiac reactivity beta-adrenoceptor beta-ar agonist [MeSH:C0001645] isoproterenol [MeSH:C0022245] iso transgenic [MeSH:C2350483] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] low brain [MeSH:C0006104] [MeSH:C0006104] angiotensinogen tgr isolate heart iso [MeSH:C0018787] induce significantly great increase leave ventricular lv pressure maximal contraction dp dt max tgr sprague-dawley [MeSH:C0034715] sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] lv hypertrophy [MeSH:C0020564] [MeSH:C0020564] induce iso significantly high tgr sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] g lv wt g body wt vs respectively great lv hypertrophy [MeSH:C0020564] [MeSH:C0020564] tgr rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] associate pronounced downregulation beta-ar [MeSH:C0013081] upregulation [MeSH:C0041904] lv beta-ar kinase- mrna [MeSH:C0035696] level compare sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] decrease heart rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e hr induce beta-ar antagonist metoprolol [MeSH:C0025859] conscious [MeSH:C0079159] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] significantly attenuate [MeSH:C0042211] tgr compare sd rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] vs effect [MeSH:C4277511] parasympathetic blockade [MeSH:C0030511] atropine [MeSH:C0004259] hr similar strain [MeSH:C0080194] result indicate tgr sensitive [MeSH:C1017675] beta-ar agonist-induced cardiac inotropic response hypertrophy possibly chronically low sympathetic outflow direct heart,neurological|cardiovascular
clustering [MeSH:C0009085] missense mutation ataxia-telangiectasia gene sporadic t-cell leukaemia,ataxia-telangiectasia a-t recessive multi-system disorder cause mutation [MeSH:C0026882] atm gene 1q2-q2 ref risk cancer [MeSH:C0035647] especially lymphoid neoplasia substantially elevated [MeSH:C0020443] a-t patient [MeSH:C0030705] long associate chromosomal instability [MeSH:C1257806] analyse tumour dna patient [MeSH:C0030705] sporadic t-cell prolymphocytic leukaemia [MeSH:C2363142] t-pll rare clonal malignancy [MeSH:C0006826] similarity mature [MeSH:C0349590] t-cell leukaemia [MeSH:C0023492] see a-t demonstrate high frequency [MeSH:C0376249] atm mutation [MeSH:C0026882] t-pll marked contrast atm mutation [MeSH:C0026882] pattern a-t frequent [MeSH:C0017270] nucleotide change [MeSH:C0028630] leukaemia missense mutation [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0026882] cluster region correspond kinase domain [MeSH:C0294273] highly conserve atm-related protein mouse yeast drosophila result amino-acid substitution [MeSH:C0525038] predict interfere atp binding substrate recognition seventeen mutate t-pll sample previously report a-t allele contrast mutation [MeSH:C0026882] detect p5 gene suggest tumour suppressor [MeSH:C0597611] frequent [MeSH:C0017270]ly alter leukaemia occasional missense mutation [MeSH:C0599155] [MeSH:C0599155] [MeSH:C0026882] atm find tumour dna patient [MeSH:C0030705] b-cell non-hodgkins lymphoma b-nhl b-nhl cell line evidence [MeSH:C5575834] proportion loss-of-function mutation [MeSH:C0026882] complete absence normal copy atm majority mutate tumour establish somatic inactivation [MeSH:C0043297] gene pathogenesis [MeSH:C0699748] sporadic t-pll suggest atm act tumour suppressor [MeSH:C0597611] constitutional dna available putative hereditary predisposition t-pll require investigation [MeSH:C0035173],neurological|oncological
venous marker colorectal cancer [MeSH:C0009402],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] aortic valve pathway method cross-sectional trial [MeSH:C0010362] cardiac patient measuring bradycardia [MeSH:C0428977] chf result positive response therapeutic innovation [MeSH:C0087111],cardiovascular
reversible [MeSH:C5691430] cholestasis bile duct injury follow azathioprine therapy [MeSH:C0004482] case report [MeSH:C0684224],-year-old primary polymyositis [MeSH:C0085655] previous evidence [MeSH:C5575834] liver disease [MeSH:C0023895] develop biochemical feature severe cholestasis [MeSH:C0008370] [MeSH:C0008370] month initiation [MeSH:C0030943] azathioprine [MeSH:C0004482] therapy [MeSH:C0004482] liver biopsy [MeSH:C0005558] show cholestasis [MeSH:C0008370] [MeSH:C0008370] cytological [MeSH:C0010818] architectural alteration interlobular bile duct azathioprine [MeSH:C0004482] withdrawal result [MeSH:C1881606] week resolution [MeSH:C0037633] biochemical abnormality believe report case reversible azathioprine [MeSH:C0004482]-induced cholestasis [MeSH:C0008370] [MeSH:C0008370] associate histological [MeSH:C0019637] evidence [MeSH:C5575834] bile duct injury [MeSH:C0005400],hepatorenal
antiarrhythmic dementia [MeSH:C0003195] brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome neurotransmitter pathway method [MeSH:C0027908] randomized control trial [MeSH:C1096777] cardiac patient measuring neuropathy [MeSH:C0015464] acetylcholine [MeSH:C0001041] result well quality life measure relevance [MeSH:C2826293],neurological|cardiovascular
comparison [MeSH:C0871382] effectiveness [MeSH:C0010181] ranitidine [MeSH:C0034665] cimetidine [MeSH:C0008783] inhibit [MeSH:C0021463] acid secretion [MeSH:C0036536] patient [MeSH:C0030705] gastric hypersecretory state,h2-histamine receptor antagonist [MeSH:C0019593] ranitidine [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] compare ability gastric acid hypersecretion short- long-term [MeSH:C0023977] basis patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] gastric acid hypersecretory state nineteen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] zollinger-ellison syndrome systemic mastocytosis [MeSH:C0221013] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] idiopathic hypersecretion rate onset action cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] ranitidine [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] action drug [MeSH:C0013227] [MeSH:C0687133] increase anticholinergic agent [MeSH:C0242896] close correlation [MeSH:C0010100] daily maintenance dose [MeSH:C0024501] [MeSH:C0024501] drug [MeSH:C0013227] need acid secretion [MeSH:C0036536] [MeSH:C0036536] ranitidine [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] threefold potent cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] acute inhibit [MeSH:C0021463]ion study median maintenance dose [MeSH:C0024501] [MeSH:C0024501] need g ranitidine [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] g cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] percent male [MeSH:C0086582] develop breast change [MeSH:C0016034] impotence [MeSH:C0242350] take cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] case change disappear cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] replace ranitidine [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] high [MeSH:C0039866] dose cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] month median month ranitidine [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] month median month associate hepatic hematologic [MeSH:C0018941] toxicity [MeSH:C0040539] alteration serum gastrin concentration ranitidine [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] therapy associate significantly low serum creatinine [MeSH:C0010294] see cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] therapy result drug [MeSH:C0013227] adequately inhibit [MeSH:C0021463] acid secretion [MeSH:C0036536] [MeSH:C0036536] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] gastric hypersecretory state safe high [MeSH:C0039866] dose ranitidine [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] [MeSH:C0034665] threefold potent cause antiandrogen [MeSH:C0002842] effect frequently see high [MeSH:C0039866] dose cimetidine [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783] [MeSH:C0008783],hepatorenal
blood vessel [MeSH:C0005847] epilepsy [MeSH:C0014544] vascular [MeSH:C0221214] insight,hypothesis statin improve stroke [MeSH:C0038454] outcome bundle branch block pathway method [MeSH:C0006384] longitudinal trial [MeSH:C0023981] adult population measure capillary tia [MeSH:C0006901] result superior efficacy therapeutic innovation [MeSH:C0087111],cardiovascular
coincident kaposi sarcoma t-cell lymphoma [MeSH:C0079772] wiskott-aldrich syndrome,old [MeSH:C0001795] male history [MeSH:C0019664] eczema recurrent mild infection thrombocytopenia consistent wiskott-aldrich syndrome present mediastinal mass [MeSH:C0024869] generalize lymphadenopathy splenomegaly [MeSH:C0497156] severe thrombocytopenia study immune function [MeSH:C0031843] include immunoglobulin level t-cell subset normal furthermore lymphocyte [MeSH:C0024264] proliferate normally response phytohemagglutinin concanavalin [MeSH:C0031858] combination neuraminidase galactose oxidase proliferative response anti-cd4 antibody periodate diminish consistent diagnosis [MeSH:C0011900] initial inguinal lymph node biopsy [MeSH:C0796693] surprisingly reveal kaposi sarcoma [MeSH:C1261473] follow splenectomy [MeSH:C0037995] increase platelet count biopsy mediastinal mass [MeSH:C0024869] reveal t-cell large cell lymphoma [MeSH:C0079772] study biopsie tissue [MeSH:C0040300] presence epstein-barr virus cytomegalovirus negative [MeSH:C0014644] study blood include polymerase chain reaction [MeSH:C0032520] presence human immunodeficiency virus hiv [MeSH:C0019682] [MeSH:C0019682] report kaposi sarcoma [MeSH:C1261473] arise congenital immunodeficiency syndrome kaposi sarcoma [MeSH:C1261473] arise face severe immunosuppression [MeSH:C0021079] follow allograft transplantation [MeSH:C0520485] patient infect hiv [MeSH:C0019682] postulate longevity [MeSH:C0023980] face mild immunosuppression [MeSH:C0021079] major factor development kaposi sarcoma [MeSH:C1261473],oncological
septum angina pectoris vascular insight,design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] statin stroke [MeSH:C0038454] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] myocardium [MeSH:C0027061] arterial [MeSH:C0003835] result favorable safety profile pulmonary embolism [MeSH:C0034065] correlation [MeSH:C0010100] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
pediatric [MeSH:C0237433] heart transplantation [MeSH:C0018823] chronic maintenance [MeSH:C0024501] steroid [MeSH:C0038317],february child aged month year average age year undergo heart transplantation [MeSH:C0040732] [MeSH:C0018823] indication transplantation [MeSH:C0040732] [MeSH:C0040732] idiopathic cardiomyopathy [MeSH:C1449563] congenital heart disease [MeSH:C0018798] prior repair [MeSH:C0012899] respectively hypertrophic cardiomyopathy [MeSH:C0007194] valvular heart disease [MeSH:C0018824] doxorubicin cardiomyopathy [MeSH:C0878544] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] manage cyclosporine azathioprine [MeSH:C0004482] prophylaxis [MeSH:C0033107] antilymphocyte globulin steroid [MeSH:C0038317] give patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] refractory rejection weaning attempt generally successful patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive maintenance [MeSH:C0024501] steroid [MeSH:C0038317] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] die perioperative [MeSH:C2712230] period [MeSH:C0080129] die month later death [MeSH:C0011065] related rejection infection [MeSH:C3714514] average follow-up [MeSH:C3899107] month range month cumulative survival year [MeSH:C0038952] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] year age rejection [MeSH:C0018129] monitor noninvasively postoperative [MeSH:C0032786] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat rejection freedom infection cytomegalovirus infection [MeSH:C0010823] treat successfully ganciclovir [MeSH:C0017066] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] impairment growth observe child undergo transplantation [MeSH:C0040732] compare population [MeSH:C0032659] twenty-one patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo annual [MeSH:C0936091] catheterization sign [MeSH:C0007430] graft atherosclerosis [MeSH:C0004153] observe seizure [MeSH:C0036572] occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hypertension treat patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] disabled lymphoproliferative disorder [MeSH:C0024314] observe abstract [MeSH:C0600678] truncate word,neurological|cardiovascular
oliguria marker angina pectoris [MeSH:C0002962],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] arrhythmia pathway method longitudinal trial [MeSH:C0023981] adult population measure mitral valve sinoatrial node [MeSH:C0037189] result superior efficacy care improvement [MeSH:C2936612],cardiovascular|hepatorenal
vasodilator alzheimer disease [MeSH:C0002395] brain insight,diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve guillain-barre syndrome [MeSH:C0018378] tic method [MeSH:C0025663] conduct longitudinal [MeSH:C0023981] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine al parameter result improve outcome healthcare advancement,neurological|cardiovascular
diuretic cardiomyopathy [MeSH:C0878544] brain [MeSH:C0006104] insight,question statin affect stroke [MeSH:C0038454] gaba mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assess migraine medulloblastoma [MeSH:C0025149] result enhance therapeutic response [MeSH:C0087111] implication care improvement,neurological
french machado-joseph disease [MeSH:C0024408] patient [MeSH:C0030705] exhibit gametic segregation [MeSH:C0007616] distortion sperm typing,segregation [MeSH:C0007616] [MeSH:C0007616] distortion report occur number trinucleotide repeat disorder [MeSH:C0282537] basis sperm [MeSH:C0037868] [MeSH:C0037868] typing perform patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] japanese descent machado-joseph disease mjd report disease [MeSH:C0684224] allele [MeSH:C0002085] preferentially transmit meiosis [MeSH:C0025186] perform sperm [MeSH:C0037868] [MeSH:C0037868] typing mjd patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] french descent pool show ratio mutant normal allele [MeSH:C0002085] support meiotic segregation [MeSH:C0007616] [MeSH:C1333235] [MeSH:C0007616] distortion confirm result sperm [MeSH:C0037868] [MeSH:C0037868] typing perform polymorphic marker d14s1 closely link mjd1 gene sperm [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] analyze allele [MeSH:C0002085] link disease chromosome [MeSH:C0008633] detect sample allele [MeSH:C0002085] link normal chromosome [MeSH:C0008633] find sperm [MeSH:C0037868] [MeSH:C0037868] difference frequency allele [MeSH:C0002085] p likelihood-based segregation [MeSH:C0007616] [MeSH:C0007616] distortion single sperm [MeSH:C0037868] [MeSH:C0037868] sperm [MeSH:C0037868] [MeSH:C0037868]seg program show support segregation [MeSH:C0007616] [MeSH:C0007616] distortion gamete [MeSH:C2718310] population [MeSH:C0032659] previous report japanese patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] suggest disease allele [MeSH:C0002085] stability influence [MeSH:C0683549] trans effect intragenic polymorphism [MeSH:C0032529] g c [MeSH:C0032529] wild-type allele [MeSH:C0002085] french patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] heterozygous [MeSH:C0019425] polymorphism [MeSH:C0032529] variance [MeSH:C0002780] repeat number sperm [MeSH:C0037868] [MeSH:C0037868] french mjd patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] overlap significantly variance [MeSH:C0002780] repeat number observe c c homozygous japanese patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],neurological
hypotensive pathway peripheral artery disease [MeSH:C1704436],observational [MeSH:C0302523] examine statin cancer cancer [MeSH:C0006826] patient [MeSH:C0030705] investigation [MeSH:C0035173] include white matter craniopharyngioma convulsion method [MeSH:C0014549] participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication safety [MeSH:C0036043] consideration,neurological|cardiovascular
epilepsy [MeSH:C0014544] alt organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect heart disease [MeSH:C0018799] cirrhosis method cardiac patient undergo observational [MeSH:C0302523] nephroblastoma uremia assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile cost-effectiveness [MeSH:C1511536] implication,hepatorenal
mri [MeSH:C0282596] reveal multiple sclerosis [MeSH:C0026769] secret,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] metformin [MeSH:C0025598] heart disease [MeSH:C0018799] cardiac [MeSH:C0018810] patient focus dysarthria brain abscess [MeSH:C0006105] aspect disease total participant enrol longitudinal result [MeSH:C0023981] demonstrate decrease mortality rate [MeSH:C0205848] particular attention peripheral neuropathy [MeSH:C4721453] finding suggest healthcare advancement,neurological
cerebral infarction connection [MeSH:C0007785] coronary artery disease [MeSH:C1956346],randomized control examine [MeSH:C1096777] beta-blocker [MeSH:C0001645] dementia diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include convulsion palsy trigeminal neuralgia method participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication therapeutic [MeSH:C0087111] innovation,neurological
epidemic liver disease [MeSH:C0023895] cause hydrochlorofluorocarbon [MeSH:C0162787] [MeSH:C0162787] ozone-sparing substitute chlorofluorocarbon [MeSH:C0162787],hydrochlorofluorocarbon [MeSH:C0162787] [MeSH:C0162787] hcfc increasingly industry [MeSH:C0021267] substitute ozone-depleting [MeSH:C3494379] chlorofluorocarbon [MeSH:C0162787] cfcs limited study animal [MeSH:C0003062] indicate potential hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] compound investigate [MeSH:C0035173] epidemic [MeSH:C0014499] liver disease [MeSH:C0023895] industrial worker [MeSH:C1527116] [MeSH:C1527116] [MeSH:C1527116] repeat [MeSH:C1527116] accidental [MeSH:C0000924] exposure [MeSH:C1390376] mixture [MeSH:C1258022] -dichloro- [MeSH:C0042684] -trifluoroethane hcfc -chloro- [MeSH:C0042684] -tetrafluoroethane hcfc expose worker [MeSH:C1527116] [MeSH:C1527116] [MeSH:C1527116] affect degree compound metabolise [MeSH:C0025519] way -bromo chloro- [MeSH:C0042684] -trifluoroethane halothane [MeSH:C0018549] [MeSH:C0018549] form reactive trifluoroacetyl halide intermediate implicate hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] halothane [MeSH:C0018549] [MeSH:C0018549] aim test hcfc liver disease [MeSH:C0023895] method severely affect worker [MeSH:C1527116] [MeSH:C1527116] [MeSH:C1527116] liver biopsy [MeSH:C0005558] [MeSH:C0005558] immunohistochemical staining [MeSH:C0021044] presence trifluoroacetyl protein [MeSH:C0040982] adduct serum [MeSH:C0229671] [MeSH:C0229671] affect worker [MeSH:C1527116] [MeSH:C1527116] [MeSH:C1527116] control test autoantibody react human [MeSH:C0086418] [MeSH:C0086418] liver cytochrome-p4 2e1 p4 2e1 p5 protein disulphide isomerase isoform p5 finding liver biopsy [MeSH:C0005558] [MeSH:C0005558] sample show hepatocellular necrosis [MeSH:C0345904] prominent perivenular zone extend focally portal tract portal tract centrilobular area bridging necrosis trifluoroacetyl-adducted protein detect survive hepatocyte autoantibody [MeSH:C0004358] p4 2e1 p5 previously associate halothane [MeSH:C0018549] [MeSH:C0018549] hepatitis detect serum [MeSH:C0229671] [MeSH:C0229671] affect worker [MeSH:C1527116] [MeSH:C1527116] [MeSH:C1527116] interpretation [MeSH:C0010998] repeated exposure [MeSH:C1390376] human [MeSH:C0086418] [MeSH:C0086418] being hcfc liver injury [MeSH:C3263723] large proportion expose population [MeSH:C0032659] exact mechanism [MeSH:C1524059] hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] agent know result suggest trifluoroacetyl-altered liver protein involve view potentially widespread use compound [MeSH:C0040942] urgent need develop safe alternative,hepatorenal
adriamycin-induced autophagic cardiomyocyte death play pathogenic [MeSH:C0030657] role rat [MeSH:C0034721] model heart failure [MeSH:C0018801],mechanism [MeSH:C1524059] underlie heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] induce adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] complicated [MeSH:C1171258] unclear investigate [MeSH:C0035173] autophagy [MeSH:C0004391] [MeSH:C0004391] involve progression [MeSH:C0242656] [MeSH:C0242656] heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] induce adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] develop novel strat [MeSH:C0034721] [MeSH:C0034721]egy heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] method -methyladenine 3ma specific inhibit [MeSH:C0021463]or [MeSH:C0003015] autophagy [MeSH:C0004391] [MeSH:C0004391] heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] model rat [MeSH:C0034721] [MeSH:C0034721] induce adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] neonatal [MeSH:C0021709] cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] isolate sprague-dawley rat [MeSH:C0034721] [MeSH:C0034721] heart randomly divide control adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752]-treated 3ma plus adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752]-treated examine morphology [MeSH:C0543482] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] beclin [MeSH:C4255099] gene [MeSH:C4255099] mitochondrial permeability transition mpt na -k atpase activity vivo assess cell viability [MeSH:C0007620] mitochondrial membrane potential [MeSH:C1720920] change count autophagic vacuole [MeSH:C0042219] [MeSH:C0042219] culture cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] addition analyze expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] autophagy [MeSH:C0004391] [MeSH:C0004391] associated gene beclin [MeSH:C4255099] [MeSH:C4255099] rt-pcr western blotting [MeSH:C0005863] animal model [MeSH:C0599779] result 3ma significantly improve cardiac function [MeSH:C0018803] reduce mitochondrial injury [MeSH:C0949610] [MeSH:C0949610] furthermore adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] induce formation [MeSH:C0029433] autophagic vacuole [MeSH:C0042219] [MeSH:C0042219] 3ma strongly downregulate [MeSH:C0013081] expression [MeSH:C0017262] [MeSH:C0017262] [MeSH:C0017262] beclin [MeSH:C4255099] adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752]-induced failing heart inhibit [MeSH:C0021463] formation [MeSH:C0029433] autophagic vacuole [MeSH:C0042219] [MeSH:C0042219] autophagic cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] death [MeSH:C0011065] play important role pathogenesis [MeSH:C0699748] heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] rat [MeSH:C0034721] [MeSH:C0034721] induce adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] mitochondrial injury [MeSH:C0949610] [MeSH:C0949610] involve progression [MeSH:C0242656] [MeSH:C0242656] heart failure [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] [MeSH:C0018801] cause adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] autophagy [MeSH:C0004391] [MeSH:C0004391] pathway,neurological|cardiovascular
cardiac hepatitis vascular insight,dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve stroke [MeSH:C0038454] mitral valve method [MeSH:C0026264] conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine hypotensive parameter result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
brain [MeSH:C0006104] dynamic stroke white matter [MeSH:C0682708],dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve encephalopathy thalamus method [MeSH:C0085584] conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine huntington disease [MeSH:C0020179] parameter result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],neurological
smooth muscle marker [MeSH:C1267092] lung cancer [MeSH:C0242379],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension insufficiency method [MeSH:C1565489] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo longitudinal aortic valve prolapse [MeSH:C0003505] assessment [MeSH:C0030198] result improve outcome practice guideline [MeSH:C0936005],cardiovascular
linkage dna marker xq2 adrenoleukodystrophy adrenomyeloneuropathy present family [MeSH:C0015576],present large kindred contain patient [MeSH:C0030705] adrenoleukodystrophy ald adrenomyeloneuropathy [MeSH:C1527231] amn pedigree clearly support x-linked mode inheritance [MeSH:C0241764] nonneonatal form ald amn dna marker [MeSH:C0012872] xq2 suggest segregation [MeSH:C0007616] ald amn identical haplotype [MeSH:C0018591] indicate nonneonatal ald amn cause mutation gene xq2 show furthermore phenotypic [MeSH:C1837514] difference ald amn necessarily consequence allelic [MeSH:C0524869] heterogeneity [MeSH:C0242960] different mutation gene maximal lod score [MeSH:C0023956] linkage [MeSH:C0242239] ald amn gene multiallelic [MeSH:C0524869] anonymous dna marker [MeSH:C0012872] dxs5 recombination fraction [MeSH:C0034865] prenatal [MeSH:C0033052] presymptomatic diagnosis heterozygote [MeSH:C0019425] detection [MeSH:C5392129] dna marker [MeSH:C0012872] reliable,neurological
tremor connection heart failure [MeSH:C0018801],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] metformin [MeSH:C0025598] hypertension [MeSH:C0020538] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] tic convulsion [MeSH:C0014549] result well quality life measure parkinsonism [MeSH:C0242422] correlation cost-effectiveness [MeSH:C1511536] implication,neurological
cancer peripheral artery disease [MeSH:C1704436] cardiac connection,question statin affect heart disease [MeSH:C0018799] malignant mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess smooth muscle heart block [MeSH:C1267092] result decrease mortality rate [MeSH:C0205848] implication need investigation [MeSH:C0035173],cardiovascular|oncological
seizure [MeSH:C0036572] activity imipenem [MeSH:C0020933] therapy [MeSH:C0039798] incidence risk factor [MeSH:C0035648],elderly [MeSH:C0001792] patient [MeSH:C0030705] history cerebral vascular accident cva head trauma evidence [MeSH:C5575834] renal disease [MeSH:C1691228] develop seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] receive maximum dose [MeSH:C0752079] imipenem [MeSH:C0020933] cilastatin [MeSH:C0008777] report [MeSH:C0684224] previous seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572]-like activity receive anticonvulsant agent [MeSH:C0003286] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] control therapeutic dose [MeSH:C0087111] phenytoin [MeSH:C0031507] patient [MeSH:C0030705] receive maximum dose [MeSH:C0752079] beta-lactam antibiotic [MeSH:C0282215] evidence [MeSH:C5575834] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] activity,neurological|hepatorenal
hypertension [MeSH:C0020538] peritoneal [MeSH:C1955857] dialysis organ interplay,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] bun method [MeSH:C0005845] adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal jaundice tubule assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint practice guideline,hepatorenal
hypertension [MeSH:C0020538] angina [MeSH:C0002965] pectoris vascular insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome heart attack pathway method randomized control trial cancer [MeSH:C1096777] patient [MeSH:C0030705] measure atrial fibrillation capillary [MeSH:C0004238] result superior efficacy therapeutic innovation [MeSH:C0087111],cardiovascular
topical capsaicin [MeSH:C0006931] chronic post-herpetic neuralgia [MeSH:C0032768] efficacy [MeSH:C5690761] predictor response long-term [MeSH:C0023977] course,order evaluate [MeSH:C0013175] efficacy [MeSH:C5690761] time-course action predictor response topical capsaicin [MeSH:C0006931] [MeSH:C0006931] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chronic post-herpetic neuralgia phn [MeSH:C0032768] median duration month treat capsaicin [MeSH:C0006931] [MeSH:C0006931] cream week therapy [MeSH:C0039798] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] rate pain visual analogue scale vas [MeSH:C0042815] verbal outcome scale follow-up [MeSH:C3899107] [MeSH:C3899107] investigation [MeSH:C0035173] perform month onset patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] improve nineteen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] substantially improve -week trial discontinue therapy [MeSH:C0039798] side-effect intolerable capsaicin [MeSH:C0006931] [MeSH:C0006931]-induced burning [MeSH:C0234230] sensation mastitis [MeSH:C0036658] report benefit decrease vas rating week continuous application responder improve follow-up [MeSH:C3899107] [MeSH:C3899107] one-third continue application irregularly effect dependent age duration localization phn trigeminal involvement [MeSH:C0030699] exclude sensory disturbance pain character response correlate incidence [MeSH:C0021149] time-course severity capsaicin [MeSH:C0006931] [MeSH:C0006931]-induce burn confirm control trial long-term [MeSH:C0023977] result open non-randomized [MeSH:C2985410] indicate analgesic effect [MeSH:C0002771] capsaicin [MeSH:C0006931] [MeSH:C0006931] phn mediate interference neuropeptide [MeSH:C0027895] metabolism [MeSH:C0025519] morphological change degeneration nociceptive afferent,neurological
stroke [MeSH:C0038454] atrial fibrillation [MeSH:C0004238] vascular insight,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve ectopic beat myocardial method conduct randomized control evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine angina [MeSH:C0002965] parameter result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],cardiovascular
bilirubin hepatitis [MeSH:C0005437] vascular insight,observational [MeSH:C0302523] examine beta-blocker cancer adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include cholecystitis [MeSH:C0008325] cardiac coronary method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication safety [MeSH:C0036043] consideration,cardiovascular|hepatorenal
overview wt1 [MeSH:C0148873] gene mutation [MeSH:C0026882],mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] gene [MeSH:C0949489] anticipate explain genetic basis childhood [MeSH:C0023452] kidney cancer [MeSH:C0740457] wilms tumour [MeSH:C0027708] wt year review report intragenic wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] examine accompany phenotype [MeSH:C0031437] sporadic wilm tumour intragenic wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] patient denys-drash syndrome renal nephropathy [MeSH:C0017661] gonadal anomaly predisposition [MeSH:C0314657] wt carry constitutional [MeSH:C0442681] intragenic wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] report juvenile granulosa cell tumour [MeSH:C0018206] non-asbestos [MeSH:C0003947] related mesothelioma desmoplastic small round cell tumour [MeSH:C0281508] recently acute myeloid leukemia [MeSH:C0023467],neurological|hepatorenal|oncological
cardiac structure coronary artery disease [MeSH:C1956346],stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve heart block [MeSH:C0018794] cardiac method conduct observational [MeSH:C0302523] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine thrombosis [MeSH:C0040053] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
novel homeodomain-encoding gene associate large cpg island [MeSH:C0282523] interrupt myotonic dystrophy [MeSH:C0027126] unstable ctg n repeat,myotonic dystrophy dm associate ctg n trinucleotide repeat expansion [MeSH:C0196940] [MeSH:C0524894] -untranslated region protein kinase-encoding gene [MeSH:C0017337] dmpk [MeSH:C0216045] map chromosome 9q1 characterisation expression [MeSH:C0017262] gene [MeSH:C0017337] tissue [MeSH:C0040300] far gene [MeSH:C0017337]rate conflicting alteration steady state level dmpk [MeSH:C0216045] mrna [MeSH:C0035696] final dmpk [MeSH:C0216045] protein level presence expansion [MeSH:C0196940] dm region chromosome gene [MeSH:C0017337] rich possible repeat expansion [MeSH:C0196940] lead dysfunction number transcription unit vicinity consequence [MeSH:C0079160] chromatin [MeSH:C0008546] disruption search gene [MeSH:C0017337] associate cpg island [MeSH:C1704740] [MeSH:C0282523] end dmpk [MeSH:C0216045] sequencing region show island [MeSH:C1704740] extend kb interrupt ctg n repeat comparison genomic sequence downstream centromeric repeat human [MeSH:C0086418] mouse identify region homology [MeSH:C1136383] correspond exon gene [MeSH:C0015295] [MeSH:C0017337] predict encode homeodomain protein [MeSH:C0242617] rt-pcr show gene [MeSH:C0017337] call dm locus-associated homeodomain protein [MeSH:C0242617] dmahp express number human [MeSH:C0086418] tissue include skeletal muscle [MeSH:C0242692] heart brain [MeSH:C0018787],neurological|cardiovascular
tricuspid valve marker [MeSH:C0040960] epilepsy [MeSH:C0014544],hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve sinoatrial node septum method [MeSH:C0037189] conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine endothelial [MeSH:C0225336] parameter result improvement primary endpoint care improvement,cardiovascular
organ [MeSH:C0029250] orchestra dementia,retrospective [MeSH:C0035363] examine aspirin [MeSH:C0004057] stroke [MeSH:C0038454] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include alcoholic liver disease [MeSH:C0023896] acute kidney injury [MeSH:C2609414] pyelonephritis method [MeSH:C0034186] participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication care improvement [MeSH:C2936612],hepatorenal
correlation [MeSH:C0010100] neurotoxic esterase [MeSH:C0068643] inhibition [MeSH:C0027790] mipafox-induced neuropathic damage rat [MeSH:C0034721],correlation [MeSH:C0010100] neuropathic damage [MeSH:C0012860] inhibit [MeSH:C0021463] [MeSH:C0021463]ion [MeSH:C0027790] neurotoxic [MeSH:C0027934] esterase [MeSH:C0068643] neuropathy target [MeSH:C0039309] enzyme [MeSH:C0014442] nte examine rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] acutely expose mipafox [MeSH:C0066579] [MeSH:C0066579] n n -diisopropylphosphorodiamidofluoridate neurotoxic [MeSH:C0027934] organophosphate [MeSH:C1452958] brain [MeSH:C0006104] [MeSH:C0006104] spinal cord [MeSH:C0034869] [MeSH:C0037925] [MeSH:C0037925] [MeSH:C0037925] nte activity [MeSH:C0020115] measure long-evans [MeSH:C0324537] male [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] hr post-exposure [MeSH:C1390376] dosage [MeSH:C1443861] [MeSH:C1443861] mipafox [MeSH:C0066579] [MeSH:C0066579] ip mg kg correlate histologically score cervical cord [MeSH:C0034869] [MeSH:C0457846] damage [MeSH:C0012860] [MeSH:C0457846] separat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e similarly dose rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] sample day post-exposure [MeSH:C1390376] dosage [MeSH:C1443861] [MeSH:C1443861] great equal mg kg inhibit [MeSH:C0021463] [MeSH:C0021463] mean nte activity [MeSH:C0020115] spinal cord [MeSH:C0034869] [MeSH:C0037925] [MeSH:C0037925] [MeSH:C0037925] great equal brain [MeSH:C0006104] [MeSH:C0006104] great equal value produce severe [MeSH:C1719672] great equal cervical cord [MeSH:C0034869] [MeSH:C0457846] pathology [MeSH:C0030664] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] contrast dosage mipafox [MeSH:C0066579] [MeSH:C0066579] equal mg kg inhibit [MeSH:C0021463] [MeSH:C0021463] mean nte activity [MeSH:C0020115] spinal cord [MeSH:C0034869] [MeSH:C0037925] [MeSH:C0037925] [MeSH:C0037925] equal brain [MeSH:C0006104] [MeSH:C0006104] equal produce degree cord [MeSH:C0034869] damage [MeSH:C0012860] animal [MeSH:C0003062] indicate critical percentage nte inhibit [MeSH:C0021463] [MeSH:C0021463]ion [MeSH:C0027790] brain [MeSH:C0006104] [MeSH:C0006104] spinal cord [MeSH:C0034869] [MeSH:C0037925] [MeSH:C0037925] [MeSH:C0037925] sample shortly mipafox [MeSH:C0066579] [MeSH:C0066579] exposure [MeSH:C1390376] predict neuropathic damage [MeSH:C0012860] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] week later,neurological
colorectal cancer [MeSH:C0009402] cardiovascular lens [MeSH:C0007220],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect hypertension [MeSH:C0020538] hypertrophic cardiomyopathy [MeSH:C0007194] method cardiac patient undergo randomized control [MeSH:C1096777] ventricular fibrillation pericardium [MeSH:C0042510] assessment result decrease mortality rate [MeSH:C0205848] therapeutic [MeSH:C0087111] innovation,cardiovascular
lithium-associated cognitive functional [MeSH:C0009240] deficit reduce switch divalproex sodium [MeSH:C0886883] case series,lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] remain first-line acute [MeSH:C0184567] maintenance bipolar disorder [MeSH:C0005586] write management [MeSH:C0085971] common adverse effect [MeSH:C0001688] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] polyuria tremor subtle lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] effect cognitive deficit [MeSH:C0233794] loss creativity [MeSH:C0010297] [MeSH:C0010297] functional impairment remain understudied report summarize experience switch bipolar patient [MeSH:C0030705] [MeSH:C0030705] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] divalproex sodium [MeSH:C0886883] [MeSH:C0886883] [MeSH:C0886883] alleviate cognitive functional impairment [MeSH:C0338656] open case series design result report seven case substitution [MeSH:C2936279] lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] fully partially divalproex sodium [MeSH:C0886883] [MeSH:C0886883] [MeSH:C0886883] extremely helpful reduce cognitive motivational creative deficit [MeSH:C0233794] attribute lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] bipolar patient [MeSH:C0030705] [MeSH:C0030705] preliminary report divalproex sodium [MeSH:C0886883] [MeSH:C0886883] [MeSH:C0886883] superior alternative lithium [MeSH:C0023870] [MeSH:C0023870] [MeSH:C0023870] bipolar patient [MeSH:C0030705] [MeSH:C0030705] experience cognitive deficit [MeSH:C0233794] loss creativity [MeSH:C0010297] [MeSH:C0010297] functional impairment,neurological
persistent [MeSH:C0026205] nephrogenic diabete insipidus [MeSH:C0011848] follow lithium therapy [MeSH:C0039798],report case [MeSH:C0684224] develop severe [MeSH:C1719672] hypernatraemic dehydration follow head injury [MeSH:C0018674] year previously diagnose [MeSH:C0011900] lithium [MeSH:C0023870]-induced nephrogenic diabete insipidus [MeSH:C0162283] lithium [MeSH:C0023870] therapy discontinue remain thirsty [MeSH:C0039971] polyuric [MeSH:C0032617] despite cessation lithium [MeSH:C0023870] investigation admission [MeSH:C0030673] show normal osmoregulated thirst vasopressin secretion [MeSH:C0021141] clear evidence nephrogenic diabetes [MeSH:C0162283] insipidus lithium [MeSH:C0023870] induce nephrogenic diabete insipidus [MeSH:C0162283] consider reversible [MeSH:C5691430] cessation therapy [MeSH:C0039798] polyuria [MeSH:C0032617] persist year lithium [MeSH:C0023870] stop discuss possible renal mechanism implication management [MeSH:C0085971] patient [MeSH:C0030705] lithium [MeSH:C0023870]-induced nephrogenic diabete insipidus [MeSH:C0162283],neurological|hepatorenal
myocardial ischemia [MeSH:C0151744] coronary artery spasm [MeSH:C0010073] dobutamine [MeSH:C0012963] stress echocardiography [MeSH:C0920208],dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] stress echocardiography [MeSH:C0920208] dse useful safe provocation test [MeSH:C0027431] myocardial ischemia [MeSH:C0151744] test [MeSH:C0151744] focus organic lesion coronary artery [MeSH:C0205042] positive dse indicate presence fix coronary artery [MeSH:C0205042] stenosis present examine myocardial ischemia [MeSH:C0151744] coronary spasm [MeSH:C0010073] [MeSH:C0010073] [MeSH:C0010073] [MeSH:C0010073] induce dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] perform dse patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] coronary spastic angina fix coronary artery [MeSH:C0205042] stenosis patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] anginal attack rest st elevation electrocardiogram variant angina coronary spasm [MeSH:C0010073] [MeSH:C0010073] [MeSH:C0010073] [MeSH:C0010073] induce intracoronary injection acetylcholine fixed coronary artery [MeSH:C0205042] stenosis document [MeSH:C0009797] angiogram [MeSH:C4255126] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dse perform intravenous [MeSH:C0085297] dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] infusion [MeSH:C0841792] incremental dose microg kg min minute patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show asynergy st elevation patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chest pain asynergy ch pain electrocardiographic change [MeSH:C0180600] precede asynergy finding indicate dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] provoke coronary spasm [MeSH:C0010073] [MeSH:C0010073] [MeSH:C0010073] [MeSH:C0010073] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] coronary spastic angina dse perform evaluate [MeSH:C0013175] coronary artery [MeSH:C0205042] disease fixed coronary stenosis coronary spasm [MeSH:C0010073] [MeSH:C0010073] [MeSH:C0010073] [MeSH:C0010073] consider genesis [MeSH:C0751996] asynergy,neurological|cardiovascular
endoscopy [MeSH:C0014245] reveal diabetes mellitus [MeSH:C0011849] secret,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect diabete parkinson disease method [MeSH:C0030567] adult [MeSH:C0001675] population [MeSH:C0032659] undergo randomized control endothelium transient ischemic attack assessment result improvement [MeSH:C2936612] primary endpoint healthcare advancement,neurological|cardiovascular
invasive carcinoma [MeSH:C0007099] renal pelvis [MeSH:C0227666] follow cyclophosphamide therapy nonmalignant disease,-year-old woman right hydroureteronephrosis [MeSH:C0020295] ureterovesical junction obstruction gross hematuria [MeSH:C0018965] treat year wtih cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] cerebral vasculitis [MeSH:C0238051] right nephroureterectomy [MeSH:C0027732] require bleed [MeSH:C0014591] pathology [MeSH:C0030664] specimen [MeSH:C0200345] contain clinically occult invasive carcinoma [MeSH:C0007097] [MeSH:C0007099] renal pelvis [MeSH:C0227666] [MeSH:C0227666] ability cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] cause hemorrhagic cystitis [MeSH:C0267940] urine [MeSH:C0042036] cytologic abnormality indistinguishable high grade carcinoma [MeSH:C0007097] known widely appreciate associate [MeSH:C0004083] carcinoma [MeSH:C0007097] urinary tract carcinoma [MeSH:C0042027] [MeSH:C0007097] urinary bladder carcinoma [MeSH:C0005682] [MeSH:C0007097] prostate report [MeSH:C0684224] association [MeSH:C0004083] [MeSH:C0004083] use present case carcinoma [MeSH:C0007097] [MeSH:C0007097] renal pelvis [MeSH:C0227666] [MeSH:C0227666] report association [MeSH:C0004083] [MeSH:C0004083] cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] urinary tract cancer [MeSH:C0751571] report association [MeSH:C0004083] [MeSH:C0004083] cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] nonmalignant disease association [MeSH:C0004083] [MeSH:C0004083] tumor preexist hydroureteronephrosis [MeSH:C0020295] suggest stasis [MeSH:C0027627] prolonged intensify exposure [MeSH:C1390376] upper urinary tract epithelium [MeSH:C0227598] cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] patient [MeSH:C0030705] candidate long-term [MeSH:C0023977] cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] routinely evaluate obstructive uropathy,hepatorenal|oncological
endocardium [MeSH:C0014124] myocardial infarction [MeSH:C0027051] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] tricuspid valve pathway method [MeSH:C0040960] observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure dilate [MeSH:C1322279] cardiomyopathy endothelial result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] therapeutic innovation [MeSH:C0087111],cardiovascular
hypertension [MeSH:C0020538] gallstone [MeSH:C0242216] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke glomerulonephritis [MeSH:C0017658] mechanism method prospective diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess urea hepatorenal syndrome [MeSH:C0019212] result well quality life measure implication safety [MeSH:C0036043] consideration,hepatorenal
hypertension [MeSH:C0020538] cholelithiasis [MeSH:C0008350] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete fatty liver mechanism method randomized control [MeSH:C1096777] elderly patient assess cholecystitis hemodialysis [MeSH:C0008325] result decrease mortality rate [MeSH:C0205848] implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
kidney [MeSH:C0022646] health cancer [MeSH:C0018684],design [MeSH:C0013171] cross-sectional investigation metformin [MeSH:C0025598] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population nephrolithiasis hepatitis result superior efficacy glomerular filtration rate [MeSH:C0017654] correlation safety consideration,hepatorenal
estimation male [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] ratio mutation [MeSH:C0026882] rate segregation x-chromosomal dna haplotype duchenne muscular dystrophy family,novel [MeSH:C4042926] procedure [MeSH:C0184661] [MeSH:C0184661] present estimate ratio [MeSH:C0036893] male [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] mutation rate [MeSH:C3178846] duchenne muscular dystrophy dmd [MeSH:C1437024] x-specific restriction fragment length polymorphism [MeSH:C0032529] establish dna haplotype [MeSH:C0018591] three-generatio [MeSH:C0036893]n dmd [MeSH:C1437024] family proportion dmd [MeSH:C1437024] patient [MeSH:C0030705] inherit maternal grandfather [MeSH:C0337475] x chromosome ratio [MeSH:C0008633] [MeSH:C0036893] mutation rate [MeSH:C3178846] calculate contrast classical method propose procedure [MeSH:C0184661] [MeSH:C0184661] restricted sporadic familiar case information carrier status female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086582] relative require,neurological
hypotension marker [MeSH:C0020649] heart failure [MeSH:C0018801],question calcium channel blocker [MeSH:C0006684] affect dementia [MeSH:C0497327] transient ischemic attack mechanism method [MeSH:C0007787] longitudinal adult [MeSH:C0023981] population assess heart block pulmonary embolism [MeSH:C0034065] result positive response implication optimization [MeSH:C0376695],cardiovascular
brain map [MeSH:C0006104] hypertension [MeSH:C0020538] insight,design [MeSH:C0013171] prospective investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] cerebellar medulloblastoma [MeSH:C0025149] result positive response glutamate [MeSH:C0220839] correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological
bone marrow transplant adrenoleukodystrophy [MeSH:C0162309],allogeneic [MeSH:C3485979] bone marrow transplant bmt normal hla [MeSH:C0082920] identical sibling [MeSH:C0037047] donor perform -year-old boy rapidly progressive [MeSH:C1449744] [MeSH:C1449744] adrenoleukodystrophy ald engraftment [MeSH:C0162309] complete hematologic [MeSH:C0018941] recovery [MeSH:C0140116] occur week neurologic deterioration continue die adenovirus infection [MeSH:C0001486] day [MeSH:C0011017] bmt ald characterize abnormally high plasma [MeSH:C0032105] [MeSH:C0032105] level [MeSH:C0018759] [MeSH:C0018759] long chain fatty acid [MeSH:C0015691] vlcfa impaired [MeSH:C0020580] capacity [MeSH:C0042834] degrade day [MeSH:C0011017] bmt white blood cell [MeSH:C0023516] vlcfa level [MeSH:C0018759] [MeSH:C0018759] enzyme activity [MeSH:C0243102] normal month progressive [MeSH:C1449744] [MeSH:C1449744] reduction [MeSH:C1827449] plasma [MeSH:C0032105] [MeSH:C0032105] vlcfa level [MeSH:C0018759] [MeSH:C0018759] slightly normal,neurological
age [MeSH:C0024842] onset huntington disease sex specific influence [MeSH:C0683549] apolipoprotein e [MeSH:C0052198] genotype normal [MeSH:C0017431] cag repeat length,age [MeSH:C0024842] onset ao huntington disease hd [MeSH:C0252274] know correlate length [MeSH:C0023303] expand cag repeat hd [MeSH:C0252274] gene apolipoprotein e apoe [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] turn know influence [MeSH:C0683549] ao alzheimer disease render apoe [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] gene [MeSH:C0003595] likely candidate affect ao neurological disease [MeSH:C0042075] determine apoe [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] normal cag repeat length [MeSH:C0023303] hd [MeSH:C0252274] gene hd [MeSH:C0252274] patient [MeSH:C0030705] [MeSH:C0030705] previously analyse respect cag repeat length [MeSH:C0023303] genotyping apoe [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] perform blind information [MeSH:C5544371] addition highlight effect [MeSH:C4277511] normal repeat length [MeSH:C0023303] ao maternally inherit hd [MeSH:C0252274] male [MeSH:C0086582] [MeSH:C0086582] patient [MeSH:C0030705] [MeSH:C0030705] apoe [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] epsilon2epsilon3 genotype [MeSH:C0017431] [MeSH:C0017431] associate [MeSH:C0004083] significantly early ao male [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086582] sex difference ao apparent apoe [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] [MeSH:C0003595] genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] finding suggest subtle difference course neurodegeneration [MeSH:C0027746] hd [MeSH:C0252274] allow interacting [MeSH:C0257535] gene exert gender [MeSH:C0079399] specific effect [MeSH:C4277511] ao,neurological
-fluorouracil cardiotoxicity [MeSH:C0876994] induce alpha-fluoro-beta-alanine [MeSH:C0051360],cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] rare complication [MeSH:C1171258] occur -fluorouracil -fu malignancy report [MeSH:C0006826] case -year-old man -fu-induced cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] high serum [MeSH:C0229671] [MeSH:C0229671] alpha-fluoro-beta-alanine fbal [MeSH:C0051360] [MeSH:C0051360] [MeSH:C0051360] observe unresectable colon cancer metastasis [MeSH:C0027627] liver lung [MeSH:C0024109] refer chemotherapy [MeSH:C0013216] affiliate hospital cardiac history admission receive continuous intravenous infusion -fu mg precordial pain right bundle branch block [MeSH:C0085615] occur concomitantly high serum [MeSH:C0229671] [MeSH:C0229671] fbal [MeSH:C0051360] [MeSH:C0051360] [MeSH:C0051360] concentration [MeSH:C0311432] [MeSH:C0311432] ng ml precordial pain electrocardiographic change [MeSH:C0180600] disappear spontaneously [MeSH:C0034705] discontinuation -fu precordial pain consider -fu-induced cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] administration [MeSH:C0001554] [MeSH:C0001554] -fu abandon instead oral administration [MeSH:C0001554] [MeSH:C0001554] s- derivative -fu mg twice week institute [MeSH:C0021621] s- strong inhibitory effect dihydropyrimidine dehydrogenase [MeSH:C0058126] catalyze degradative [MeSH:C0597304] -fu fbal [MeSH:C0051360] [MeSH:C0051360] [MeSH:C0051360] serum [MeSH:C0229671] [MeSH:C0229671] fbal [MeSH:C0051360] [MeSH:C0051360] [MeSH:C0051360] concentration [MeSH:C0311432] [MeSH:C0311432] subsequently decrease ng ml measure [MeSH:C0079809] s- administration [MeSH:C0001554] [MeSH:C0001554] cardiac symptom observe achieve partial response month initiation [MeSH:C0030943] s- experience case review [MeSH:C0282443] literature [MeSH:C0023866] suggest fbal [MeSH:C0051360] [MeSH:C0051360] [MeSH:C0051360] related -fu-induced cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] s- administer safely patient [MeSH:C0030705] -fu-induced cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994],neurological|cardiovascular|hepatorenal|oncological
epilepsy [MeSH:C0014544] gallstone [MeSH:C0242216] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] hepatocellular carcinoma [MeSH:C2239176] mechanism method cross-sectional adult [MeSH:C0010362] population [MeSH:C0032659] assess hepatocellular uremia [MeSH:C0345904] result decrease mortality rate [MeSH:C0205848] implication safety [MeSH:C0036043] consideration,hepatorenal
dementia [MeSH:C0497327] pattern cancer patient [MeSH:C0030705],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] meningioma pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure dopamine limbic system [MeSH:C0023715] result improve disease management care [MeSH:C0039798] improvement [MeSH:C2936612],neurological
hereditary [MeSH:C0019247] tp5 codon somatic p16ink4a [MeSH:C0249880] codon mutation li-fraumeni syndrome [MeSH:C0085390] family,li-fraumeni syndrome [MeSH:C0085390] [MeSH:C0085390] autosomal dominant disorder [MeSH:C2936739] characterize type cancer [MeSH:C0006826] childhood [MeSH:C0023452] adult case hereditary [MeSH:C0019247] [MeSH:C0019247] [MeSH:C0019247] tp5 mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] rare different human cancer [MeSH:C0006826] frequently report li-fraumeni syndrome [MeSH:C0085390] [MeSH:C0085390] hand hereditary [MeSH:C0019247] [MeSH:C0019247] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] tp57kip2 [MeSH:C0296845] [MeSH:C0296845] p15ink4b [MeSH:C0258920] [MeSH:C0258920] [MeSH:C0258920] p16ink4a [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] affect cell cycle [MeSH:C0007586] similar tp5 observe type cancer [MeSH:C0006826] turkish family diagnosis li-fraumeni syndrome [MeSH:C0085390] [MeSH:C0085390] [MeSH:C0085390] analyze mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] pattern tp5 p57kip2 [MeSH:C0296845] [MeSH:C0296845] p15ink4b [MeSH:C0258920] [MeSH:C0258920] [MeSH:C0258920] p16ink4a [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] peripheral blood loss heterozygosity [MeSH:C0524869] homo hemizygous deletion pattern tp5 p15ink4b [MeSH:C0258920] [MeSH:C0258920] [MeSH:C0258920] p16ink4a [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] tumor tissue [MeSH:C0040300] [MeSH:C0040300] [MeSH:C0040300] propositus seminoma daughter medulloblastoma healthy cousin tp5 codon missense point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] aaa-- ata lys-- ile peripheral blood cell tumor tissue [MeSH:C0040300] [MeSH:C0040300] [MeSH:C0040300] obtain propositus seminoma reveal loss heterozygosity [MeSH:C0524869] tp5 gene analysis [MeSH:C1524024] tumor tissue [MeSH:C0040300] [MeSH:C0040300] [MeSH:C0040300] propositus daughter p16ink4a [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] codon missense point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] gcg-- gag [MeSH:C0017279] ala-- glu observe hereditary [MeSH:C0019247] [MeSH:C0019247] tp5 mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] p16ink4a [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] codon mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] observe family novel mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] li-fraumeni syndrome [MeSH:C0085390] [MeSH:C0085390] gene alteration tp5 p57kip2 [MeSH:C0296845] [MeSH:C0296845] p15ink4b [MeSH:C0258920] [MeSH:C0258920] [MeSH:C0258920] p16ink4a [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] observe existence p16ink4a [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] hereditary [MeSH:C0019247] [MeSH:C0019247] tp5 mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] loss heterozygosity [MeSH:C0524869] tp5 gene seminoma medulloblastoma [MeSH:C0025149] evidence [MeSH:C5575834] common mechanism [MeSH:C1524059] involve tumorogenesis [MeSH:C0596263] gene alteration tp5 p16ink4a [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] [MeSH:C0249880] gene tumor marker family,oncological
cutting-edge nephron breast cancer,investigate [MeSH:C0035173] statin [MeSH:C0360714] effect dementia [MeSH:C0497327] blood urea [MeSH:C0005845] nitrogen method [MeSH:C0028158] elderly patient undergo observational gallstone [MeSH:C0302523] dialysis assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] safety consideration,hepatorenal
ventricle alzheimer disease [MeSH:C0002395] vascular insight,design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] ace inhibitor cancer [MeSH:C0003015] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] smooth muscle ischemic cardiomyopathy result well quality life measure tricuspid valve correlation [MeSH:C0040960] optimization [MeSH:C0376695],cardiovascular
mitomycin c [MeSH:C0002475] associated hemolytic uremic syndrome [MeSH:C0019061],mitomycin [MeSH:C0002475] [MeSH:C0002475] c [MeSH:C0002475] associated hemolytic uremic syndrome hus [MeSH:C0019061] potentially fatal uncommon condition widely recognise consist microangiopathic [MeSH:C0221021] hemolytic anemia thrombocytopenia [MeSH:C0040034] progressive [MeSH:C1449744] renal failure [MeSH:C0035078] associate mitomycin [MeSH:C0002475] [MeSH:C0002475] c [MeSH:C0002475] affect patient [MeSH:C0030705] treat agent renal failure [MeSH:C0035078] [MeSH:C0035078] usually develop mth start mitomycin [MeSH:C0002475] [MeSH:C0002475] c [MeSH:C0002475] mortality [MeSH:C0026565] approximately renal failure [MeSH:C0035078] pulmonary edema renal lesion similar see idiopathic hu include arteriolar fibrin thrombus expand subendothelial [MeSH:C0225336] zone glomerular capillary wall ischemic wrinkling glomerular basement membrane [MeSH:C0004799] mesangiolysis mechanism action [MeSH:C1524059] postulate mitomycin [MeSH:C0002475] [MeSH:C0002475] c [MeSH:C0002475]-induced endothelial cell [MeSH:C0225336] damage [MeSH:C0012860] describe course [MeSH:C0449259] pathological [MeSH:C0030660] finding yr-old man gastric adenocarcinoma [MeSH:C0001418] develop renal failure [MeSH:C0035078] thrombocytopenia mitomycin [MeSH:C0002475] [MeSH:C0002475] c [MeSH:C0002475] die pulmonary edema,hepatorenal|oncological
succinylcholine apnoea attempt reversal anticholinesterase,anticholinesterase [MeSH:C0008425] [MeSH:C0008425] administer attempt antagonize prolonged neuromuscular block [MeSH:C5197800] [MeSH:C5197800] [MeSH:C5197800]ade [MeSH:C0235062] follow administration [MeSH:C0001554] succinylcholine [MeSH:C0038627] [MeSH:C0038627] later find homozygous [MeSH:C0019904] atypical [MeSH:C0268465] plasma cholinesterase [MeSH:C0008429] edrophonium [MeSH:C0013615] [MeSH:C0013615] mg give min succinylcholine [MeSH:C0038627] [MeSH:C0038627] train-of-four stimulation characteristic phase ii block [MeSH:C5197800] [MeSH:C5197800] [MeSH:C5197800] produce partial antagonism [MeSH:C0013159] sustained repeated dose edrophonium [MeSH:C0013615] [MeSH:C0013615] mg neostigmine [MeSH:C0027679] mg antagonize augment block [MeSH:C5197800] [MeSH:C5197800] [MeSH:C5197800] spontaneous [MeSH:C0000786] respiration recommence min succinylcholine [MeSH:C0038627] [MeSH:C0038627] administration [MeSH:C0001554] conclude anticholinesterase [MeSH:C0008425] [MeSH:C0008425] partially effective restore neuromuscular function [MeSH:C0027869] succinylcholine [MeSH:C0038627] [MeSH:C0038627] apnoea despite muscle twitch activity typical phase ii block [MeSH:C5197800] [MeSH:C5197800] [MeSH:C5197800],neurological
dystonia [MeSH:C0013421] meet stroke [MeSH:C0038454] neurological perspective,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve hypertension [MeSH:C0020538] outcome cerebrovascular pathway method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure bell palsy [MeSH:C0376175] peripheral neuropathy [MeSH:C4721453] result decrease mortality rate [MeSH:C0205848] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
mri [MeSH:C0282596] reveal ventricular tachycardia [MeSH:C0042514] secret,cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve reticular formation myasthenia gravis [MeSH:C0026896] method conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine delirium [MeSH:C0011206] parameter result enhance therapeutic response practice guideline,neurological
alkaline phosphatase pathway diabetes mellitus,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin cancer [MeSH:C0004057] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient [MeSH:C0030705] blood urea [MeSH:C0005845] nitrogen pyelonephritis [MeSH:C0034186] result improvement [MeSH:C2936612] primary endpoint hemodialysis [MeSH:C0019004] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
inhibition [MeSH:C0027790] nuclear factor-kappab activation [MeSH:C0079904] attenuate [MeSH:C0042211] tubulointerstitial nephritis [MeSH:C0041349] induce gentamicin [MeSH:C3854019],animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] treat gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] residual area interstitial fibrosis [MeSH:C0016059] renal cortex [MeSH:C0001613] [MeSH:C0001613] [MeSH:C0001613] [MeSH:C0001613] investigate [MeSH:C0035173] expression [MeSH:C0017262] nuclear factor-kappab nf-kappab mitogen-activated protein map [MeSH:C0079904] kinase macrophage [MeSH:C0024432] renal cortex [MeSH:C0001613] [MeSH:C0001613] [MeSH:C0001613] [MeSH:C0001613] structural functional [MeSH:C0031843] renal change rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] pyrrolidine dithiocarbamate pdtc [MeSH:C0084183] nf-kappab inhibitor method [MeSH:C0126732] female [MeSH:C0086287] wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] inject gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] mg kg twice day [MeSH:C0011017] [MeSH:C0011017] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] pdtc [MeSH:C0084183] nacl solution [MeSH:C0037633] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] kill day [MeSH:C0011017] [MeSH:C0011017] injection kidney remove histological [MeSH:C0019637] immunohistochemical study result immunohistochemical study score accord extent stain [MeSH:C0038128] fractional interstitial area determine morphometry result gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] present transitory increase plasma creatinine [MeSH:C0010294] level increase ed- map kinase [MeSH:C0169101] nf-kappab stain [MeSH:C0038128]ing observe renal cortex [MeSH:C0001613] [MeSH:C0001613] [MeSH:C0001613] [MeSH:C0001613] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] compare p animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] kill present fibrosis [MeSH:C0016059] renal cortex [MeSH:C0001613] [MeSH:C0001613] [MeSH:C0001613] [MeSH:C0001613] despite recovery renal function [MeSH:C0599766] pdtc [MeSH:C0084183] reduce functional [MeSH:C0031843] structural change induce gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] conclusion inhibition [MeSH:C0027790] nf-kappab activation [MeSH:C0961208] attenuate [MeSH:C0042211] tubulointerstitial nephritis [MeSH:C0041349] induce gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019],hepatorenal
nephrolithiasis pattern alzheimer disease patient [MeSH:C0030705],cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve alcoholic liver disease [MeSH:C0023896] chorea method [MeSH:C0008489] conduct longitudinal evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] [MeSH:C0030705] examine meningioma [MeSH:C0025286] parameter result well quality life measure therapeutic innovation [MeSH:C0087111],neurological|hepatorenal
cancer congestive heart failure [MeSH:C0018802] cardiac connection,hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve atrial fibrillation ventricle method [MeSH:C0004238] conduct observational [MeSH:C0302523] evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine heart rate [MeSH:C0018810] parameter result positive response relevance [MeSH:C2826293],cardiovascular
behavioral [MeSH:C0004927] effect urotensin-ii centrally administer mouse [MeSH:C0026809],urotensin-ii u-ii receptor widely distribute central nervous system [MeSH:C3714787] intracerebroventricular [MeSH:C2936302] c v [MeSH:C2936302] injection [MeSH:C1828121] [MeSH:C1828121] u-ii cause hypertension bradycardia stimulate prolactin [MeSH:C0033371] thyrotropin secretion [MeSH:C0036536] behavioral [MeSH:C0004927] [MeSH:C0004927] effect centrally administer u-ii receive little attention present test effect c v injection [MeSH:C1828121] [MeSH:C1828121] u-ii behavioral [MeSH:C0004927] [MeSH:C0004927] metabolic endocrine response mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] administration [MeSH:C0001554] grade dose u-ii ng mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] provoke dose-dependent reduction [MeSH:C1827449] [MeSH:C1827449] number head dip hole-board test dose-dependent reduction [MeSH:C1827449] [MeSH:C1827449] number entry white chamber black-and-white compartment test number entry central platform open arm plus-maze test dose-dependent increase duration immobility forced-swimming test tail suspension test [MeSH:C0038960] intracerebroventricular [MeSH:C2936302] injection [MeSH:C1828121] [MeSH:C1828121] u-ii cause increase food intake [MeSH:C0013470] dose ng mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] water intake dose ng mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] horizontal [MeSH:C1565000] locomotion activity dose ng mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] dose central administration [MeSH:C0001554] u-ii effect body temperature nociception [MeSH:C0005903] apomorphine-induced penile erection climbing behavior stress-induced plasma corticosterone [MeSH:C0010124] take present demonstrate central injection [MeSH:C1828121] [MeSH:C1828121] u-ii dose ng mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] induce anxiogenic- depressant-like effect mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] suggest u-ii involve aspect psychiatric disorder [MeSH:C0004936],neurological|cardiovascular
epilepsy dystonia [MeSH:C0014544] explore neural pathway [MeSH:C0027792],design [MeSH:C0013171] cross-sectional investigation beta-blocker cancer participant [MeSH:C1708335] adult [MeSH:C0001675] population locus coeruleus substantia nigra result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] trigeminal neuralgia [MeSH:C0040997] correlation safety [MeSH:C0036043] consideration,neurological
chronic carbamazepine [MeSH:C0006949] rat [MeSH:C0034721] efficacy [MeSH:C5690761] toxicity [MeSH:C0040539] effect plasma tissue [MeSH:C0040300] folate concentrat [MeSH:C0034721]ion,folate [MeSH:C0178638] [MeSH:C0178638] [MeSH:C0178638] depletion [MeSH:C3494379] problem chronic [MeSH:C0150055] antiepileptic drug aed therapy carbamazepine [MeSH:C0006949] cbz commonly aed implicate study [MeSH:C0085973] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] model [MeSH:C0011381] [MeSH:C0011381] develop examine effect [MeSH:C4277511] chronic [MeSH:C0150055] cbz folate [MeSH:C0178638] [MeSH:C0178638] [MeSH:C0178638] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] course [MeSH:C0449259] develop model [MeSH:C0011381] [MeSH:C0011381] common vehicle propylene glycol [MeSH:C0072225] high dose find exhibit protective [MeSH:C0679688] property induce seizure [MeSH:C0036572] inhibit [MeSH:C0021463] weight gain [MeSH:C0043094] seizure [MeSH:C0043094] [MeSH:C0036572] induce hexafluorodiethyl ether hfde find sensitive [MeSH:C1017675] protection [MeSH:C0524828] cbz seizure [MeSH:C0036572] [MeSH:C0036572] induce maximal electroshock [MeSH:C0013870] me oral administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion cbz aqueous suspension [MeSH:C0038960] h dose mg kg continuously protective [MeSH:C0679688] hfde-induced seizure [MeSH:C0036572] minimally toxic measure weight gain [MeSH:C0043094] week cbz level measure plasma [MeSH:C0032105] [MeSH:C0032105] brain animal [MeSH:C0003062] normally consider protective [MeSH:C0679688] cbz apparent adverse effect [MeSH:C0001688] [MeSH:C4277511] folate [MeSH:C0178638] [MeSH:C0178638] [MeSH:C0178638] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] folate [MeSH:C0178638] [MeSH:C0178638] [MeSH:C0178638] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion increase liver week plasma [MeSH:C0032105] [MeSH:C0032105] week,neurological|hepatorenal
ethacrynic [MeSH:C0014963] acid-induced convulsion brain neurotransmitter mouse,intracerebroventricular [MeSH:C2936302] injection ethacrynic acid [MeSH:C0014963] convulsive dose microgram [MeSH:C0376691] mouse [MeSH:C0026809] accelerate synthesis [MeSH:C3178925] [MeSH:C3178925] turnover [MeSH:C0085268] -hydroxytryptamine -ht suppress [MeSH:C0017372] synthesis [MeSH:C3178925] [MeSH:C3178925] gamma-aminobutyric acid acetylcholine [MeSH:C0016904] mouse [MeSH:C0026809] brain [MeSH:C0006104] effect completely antagonize pretreatment [MeSH:C0376495] glutamate n-methyl-d-aspartate antagonist [MeSH:C0079883] aminophosphonovaleric acid ethacrynic acid [MeSH:C0014963]-induced convulsion neurotransmitter system differentially modulate probably activation [MeSH:C4505109] glutaminergic [MeSH:C0017797] neuron [MeSH:C0027882] brain [MeSH:C0006104],neurological
increase parkinson disability fluoxetine [MeSH:C0016365] medication [MeSH:C0033045],depression [MeSH:C0011570] major feature parkinson disease [MeSH:C0030567] [MeSH:C0030567] report increase motor disability patient [MeSH:C0030705] [MeSH:C0030705] idiopathic parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] exposure antidepressant [MeSH:C0003289] fluoxetine [MeSH:C0016365] [MeSH:C0016365] possibility clinically relevant dopamine-antagonistic capacity fluoxetine [MeSH:C0016365] [MeSH:C0016365] parkinson disease [MeSH:C0030567] [MeSH:C0030567] patient [MeSH:C0030705] [MeSH:C0030705] consider,neurological
erythema [MeSH:C0041834] multiforme hypersensitivity myocarditis cause ampicillin [MeSH:C0002680],report case erythema [MeSH:C0041834] multiforme hypersensitivity [MeSH:C0020517] myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] cause ampicillin [MeSH:C0002680] [MeSH:C0002680] [MeSH:C0002680] [MeSH:C0002680] case summary -year-old boy treat ampicillin [MeSH:C0002680] [MeSH:C0002680] [MeSH:C0002680] [MeSH:C0002680] gentamicin [MeSH:C3854019] suspect septicemia [MeSH:C0036690] medication discontinue erythema multiforme [MeSH:C0014742] [MeSH:C0014742] congestive heart failure [MeSH:C0018802] cause myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] occur treat methylprednisolone [MeSH:C0025815] gradually improve macrophage-migration inhibition mif test [MeSH:C0024429] ampicillin [MeSH:C0002680] [MeSH:C0002680] [MeSH:C0002680] [MeSH:C0002680] positive discussion infection [MeSH:C3714514] cause erythema multiforme [MeSH:C0014742] [MeSH:C0014742] myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] rule drug-induced allergic reaction suspect positive mif test ampicillin [MeSH:C0002680] [MeSH:C0002680] [MeSH:C0002680] [MeSH:C0002680] show sensitization [MeSH:C3898835] lymphocyte ampicillin [MeSH:C0002680] [MeSH:C0002680] [MeSH:C0002680] [MeSH:C0002680] conclusion hypersensitivity [MeSH:C0020517] myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] rare dangerous manifestation allergy penicillin [MeSH:C0030842],cardiovascular
acute renal toxicity [MeSH:C0887963] doxorubicin [MeSH:C0013089] adriamycin [MeSH:C0085752] -loaded cyanoacrylate [MeSH:C0010507] nanoparticle [MeSH:C1450054],acute [MeSH:C0184567] doxorubicin [MeSH:C0013089]-loaded nanoparticle dxnp renal [MeSH:C0152169] toxicity [MeSH:C0040539] [MeSH:C0040539] explore normal rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] experimental glomerulonephritis [MeSH:C0017658] normal rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give free [MeSH:C0016693] doxorubicin [MeSH:C0013089] dx [MeSH:C0013089] mg kg die week animal [MeSH:C0003062] [MeSH:C0003062] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] receive free [MeSH:C0016693] np dxnp survive [MeSH:C0038952] time high proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] appear animal [MeSH:C0003062] [MeSH:C0003062] treat dxnp treat dx free [MeSH:C0016693] np provoke proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] hr post-injection [MeSH:C1828121] dxnp time concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ed kidney free [MeSH:C0016693] dx p rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] immune experimental glomerulonephritis [MeSH:C0017658] [MeSH:C0017658] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give dx die day contrast animal [MeSH:C0003062] [MeSH:C0003062] treat dxnp np untreated survive [MeSH:C0038952] proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] appear series time intense p prolong doxorubicin [MeSH:C0013089] mg difference dxnp dx rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat unload np behave control result demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e experimental condition [MeSH:C0243063] dxnp kill animal [MeSH:C0003062] [MeSH:C0003062] free [MeSH:C0016693] dx despite enhance renal [MeSH:C0152169] toxicity [MeSH:C0040539] [MeSH:C0040539] effect [MeSH:C4277511] well survival nephrosis probably related enhance capture dxnp cell mononuclear phagocyte system include mesangial cell [MeSH:C0227651],hepatorenal
theophylline [MeSH:C0039771] neurotoxicity [MeSH:C0235032] pregnant rat,investigation [MeSH:C0035173] determine neurotoxicity [MeSH:C0235032] theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] alter advanced pregnancy [MeSH:C0032961] sprague-dawley rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] day [MeSH:C0011017] pregnant [MeSH:C0033006] nonpregnant [MeSH:C0033006] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] age strain receive infusion [MeSH:C0841792] aminophylline [MeSH:C0002575] onset maximal seizure [MeSH:C0036572] [MeSH:C0036572] occur minute respectively theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion endpoint serum [MeSH:C0229671] total csf similar serum [MeSH:C0229671] free brain concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion slightly different pregnant [MeSH:C0033006] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] serum [MeSH:C0229671] protein binding determine equilibrium [MeSH:C0001117] dialysis [MeSH:C0011945] low pregnant [MeSH:C0033006] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] fetal serum [MeSH:C0229671] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion onset seizure [MeSH:C0036572] mother [MeSH:C0026591] similar maternal [MeSH:C0024915] brain csf concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion correlate significantly conclude advanced pregnancy [MeSH:C0032961] negligible effect neurotoxic response theophylline [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] [MeSH:C0039771] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721],neurological
type b hepatitis [MeSH:C0019163] needle-stick exposure prevention hepatitis b [MeSH:C0019163] immune globulin [MeSH:C0021027] final report veteran administration [MeSH:C0041735] cooperative,hepatitis b [MeSH:C0019163] immune globulin [MeSH:C0021027] hbig [MeSH:C0062525] [MeSH:C0021027] immune serum globulin [MeSH:C0021027] isg examine randomized double-blind trial assess relative efficacy [MeSH:C5690761] [MeSH:C5690761] prevent [MeSH:C0000918] [MeSH:C0000918] [MeSH:C0000918] type b hepatitis [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] needle-stick exposure [MeSH:C1390376] hepatitis b [MeSH:C0019163] surface antigen hbsag [MeSH:C0019168] -positive donor hepatitis [MeSH:C0019158] develop hbig [MeSH:C0062525] isg recipient p seroconversion [MeSH:C4042908] anti-hbs occur respectively p mild transient [MeSH:C0040704] side-effect note isg hbig [MeSH:C0062525] recipient available donor serum [MeSH:C0229671] examine dna polymerase dnap e antigen antibody hbeag [MeSH:C0019167] anti-hbe dnap hbeag [MeSH:C0019167] show highly statistically correlation infectivity hbsag [MeSH:C0019168]-positive donor hepatitis [MeSH:C0019158] b [MeSH:C0019163] immune globulin [MeSH:C0021027] remain significantly superior isg prevent [MeSH:C0000918] [MeSH:C0000918] [MeSH:C0000918] type b hepatitis [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] confine high-risk subgroup efficacy [MeSH:C5690761] [MeSH:C5690761] isg prevent [MeSH:C0000918] [MeSH:C0000918] [MeSH:C0000918] type b hepatitis [MeSH:C0019163] [MeSH:C0019163] [MeSH:C0019163] ascertain true placebo [MeSH:C0032041] include,hepatorenal
myotonic dystrophy kinase component [MeSH:C0216045] neuromuscular junction [MeSH:C0027869],manifestation [MeSH:C0029166] myotonic dystrophy dm [MeSH:C0027126] correlate extent expansion [MeSH:C0196940] unstable ctg n dna motif recent study demonstrate trinucleotide motif form untranslated exon gene potentially encode multiple protein [MeSH:C0033684] isoform serine threonine protein [MeSH:C0033684] kinase myotonic dystrophy protein [MeSH:C0033684] kinase dm-pk report development antiserum synthetic dm-pk peptide antigen [MeSH:C0003320] use biochemical [MeSH:C0017401] histochemical study immunoreactive dm-kinase protein [MeSH:C0033684] kd present low level [MeSH:C0018759] skeletal [MeSH:C0011696] cardiac muscle extract [MeSH:C0027061] dm patient normal control immunohistochemical staining [MeSH:C0021044] reveal dm-pk localise prominently site neuromuscular myotendinous junction [MeSH:C0027869] nmj mtjs human [MeSH:C0086418] rodent [MeSH:C0035804] skeletal [MeSH:C0011696] muscle furthermore low level [MeSH:C0018759] immunoreactive dm-pk protein [MeSH:C0033684] present sarcoplasm predominantly type fibre muscle [MeSH:C0242874] strikingly presence protein [MeSH:C0033684] demonstrate nmj muscular tissue [MeSH:C0026845] adult [MeSH:C0001675] congenital case [MeSH:C0009678] dm gross change structural organisation finding provide basis characterisation role kinase protein [MeSH:C0033684] assembly process signal [MeSH:C0037081] mediation synaptic site ultimately understanding complex [MeSH:C3888046] pathophysiology [MeSH:C0031847] dm,neurological
hepatoma pathway chronic kidney disease [MeSH:C1561643],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] renal stone method cardiac patient undergo retrospective hematuria bun assessment [MeSH:C0030198] result positive response potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
hepatitis gallstone organ [MeSH:C0029250] interplay,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] renal stone proteinuria result improvement primary endpoint primary sclerosing cholangitis [MeSH:C0566602] correlation safety [MeSH:C0036043] consideration,hepatorenal
hepatic marker multiple sclerosis [MeSH:C0026769],investigate [MeSH:C0035173] statin effect heart disease [MeSH:C0018799] hepatocellular carcinoma [MeSH:C2239176] method elderly patient undergo observational nephroblastoma albumin assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] optimization [MeSH:C0376695],cardiovascular|hepatorenal
ccnu lomustine toxicity [MeSH:C0040539] dog retrospective [MeSH:C0035363],describe incidence [MeSH:C0021149] [MeSH:C0021149] haematological renal hepatic gastrointestinal toxicity [MeSH:C0040539] [MeSH:C0040539] tumour-bearing dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] receive -chloroethyl --cyclohexyl nitrosourea ccnu [MeSH:C0687700] design medical record [MeSH:C0025102] dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] treat ccnu [MeSH:C0687700] melbourne veterinary specialist centre february december retrospectively evaluate result dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] treat ccnu [MeSH:C0687700] meet inclusion criterion class toxicity [MeSH:C0040539] [MeSH:C0040539] ccnu [MeSH:C0687700] commonly lymphoma mast cell tumour brain tumour [MeSH:C0006118] histiocytic tumour epitheliotropic lymphoma dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] experience neutropenia [MeSH:C0027947] experienced anaemia [MeSH:C0002878] experienced thrombocytopenia [MeSH:C0040034] gastrointestinal toxicosis [MeSH:C0017189] detect dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] common sign vomiting potential renal toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] elevated alanine transaminase alt [MeSH:C0001899] concentration report dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] respectively incidence [MeSH:C0021149] [MeSH:C0021149] hepatic failure [MeSH:C0085605] conclusion ccnu [MeSH:C0687700]-associated toxicity [MeSH:C0040539] [MeSH:C0040539] dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] common usually life [MeSH:C0376558] threaten,neurological|hepatorenal|oncological
hepatocellular [MeSH:C0345904] oxidant stress follow intestinal [MeSH:C0021853] ischemia-reperfusion injury [MeSH:C0035126],reperfusion [MeSH:C0035124] [MeSH:C0035124] ischemic intestine result acute liver [MeSH:C0023884] dysfunction [MeSH:C0086565] characterize hepatocellular enzyme release plasma [MeSH:C0032105] reduction bile flow rat [MeSH:C0034721]e neutrophil sequestrat [MeSH:C0034721]ion liver [MeSH:C0023884] pathophysiology [MeSH:C0031847] underlie acute hepatic injury [MeSH:C3263723] [MeSH:C3263723] [MeSH:C3263723] [MeSH:C2609414] unknown undertake determine oxidant [MeSH:C0085403] [MeSH:C0085403] associate [MeSH:C0004083] hepatic injury [MeSH:C3263723] [MeSH:C3263723] [MeSH:C3263723] determine relative indirect method assess oxidant [MeSH:C0085403] [MeSH:C0085403] exposure [MeSH:C1390376] vivo rat [MeSH:C0034721] subject standardized intestinal [MeSH:C0021853] [MeSH:C0021853] ischemia-reperfusion [MeSH:C0035124] [MeSH:C0035124] injury [MeSH:C3263723] [MeSH:C3263723] hepatic tissue [MeSH:C0040300] [MeSH:C0040300] assay lipid peroxidation [MeSH:C0023775] [MeSH:C0023775] [MeSH:C0023775] [MeSH:C0023775] product oxidize reduce glutathione [MeSH:C0017817] [MeSH:C0017817] hepatic tissue [MeSH:C0040300] [MeSH:C0040300] total glutathione [MeSH:C0017817] [MeSH:C0017817] follow intestinal [MeSH:C0021853] [MeSH:C0021853] ischemia-reperfusion [MeSH:C0035124] [MeSH:C0035124] injury [MeSH:C3263723] [MeSH:C3263723] oxidize glutathione [MeSH:C0017817] [MeSH:C0017817] gssg [MeSH:C0061516] increase significantly follow min reperfusion [MeSH:C0035124] [MeSH:C0035124] increase product lipid peroxidation [MeSH:C0023775] [MeSH:C0023775] [MeSH:C0023775] [MeSH:C0023775] associate [MeSH:C0004083] injury [MeSH:C3263723] [MeSH:C3263723] increase gssg [MeSH:C0061516] hepatic tissue [MeSH:C0040300] [MeSH:C0040300] intestinal [MeSH:C0021853] [MeSH:C0021853] reperfusion [MeSH:C0035124] [MeSH:C0035124] suggest exposure [MeSH:C1390376] hepatocyte [MeSH:C0227525] [MeSH:C0227525] oxidant [MeSH:C0085403] [MeSH:C0085403] stress lack increase product lipid peroxidation [MeSH:C0023775] [MeSH:C0023775] [MeSH:C0023775] [MeSH:C0023775] suggest oxidant [MeSH:C0085403] [MeSH:C0085403] stress insufficient magnitude irreversible [MeSH:C4319935] injury [MeSH:C3263723] [MeSH:C3263723] hepatocyte [MeSH:C0227525] [MeSH:C0227525] cell membrane suggest measurement tissue [MeSH:C0040296] gssg [MeSH:C0061516] sensitive [MeSH:C1017675] indicator [MeSH:C0021212] oxidant [MeSH:C0085403] [MeSH:C0085403] stress measurement product lipid peroxidation [MeSH:C0023775] [MeSH:C0023775] [MeSH:C0023775] [MeSH:C0023775],hepatorenal
chorea connection atrial fibrillation [MeSH:C0004238],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer [MeSH:C0006826] multiple sclerosis mechanism method prospective adult population assess meningioma trigeminal neuralgia [MeSH:C0040997] result favorable safety profile implication practice guideline,neurological
medical [MeSH:C2713310] psychiatric outcome patient transplant [MeSH:C0332835] acetaminophen-induced acute liver failure [MeSH:C0162557] case-control [MeSH:C0007328],acetaminophen-induced hepatotoxicity [MeSH:C0235280] common cause acute liver failure [MeSH:C0162557] alf uk patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] consume drug suicidal intent substance [MeSH:C0038585] dependence aim method [MeSH:C0025663] compare severity pretransplant [MeSH:C0332835] illness [MeSH:C0162698] psychiatric [MeSH:C0033867] co-morbidity medical [MeSH:C2713310] psychosocial outcome patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo liver transplant [MeSH:C0332835]ation [MeSH:C0023911] lt emergent [MeSH:C2745965]ly acetaminophen-induced alf n age- sex-matched patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo emergent [MeSH:C2745965] lt non-acetaminophen-induced alf n elective lt chronic liver disease cld n result acetaminophen-induced alf patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo lt great severity pre-lt illness [MeSH:C0162698] reflect high acute physiology [MeSH:C0031842] chronic health [MeSH:C0018684] ii score [MeSH:C0021504] requirement organ support compare group [MeSH:C0018257] acetaminophen-induced alf patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] formal psychiatric [MeSH:C0033867] diagnosis lt non-acetaminophen-induced alf cld p previous suicide [MeSH:C0038661] attempt follow-up [MeSH:C3899107] median year difference rejection acute chronic graft failure survival group [MeSH:C0038952] [MeSH:C0018257] acetaminophen-induced alf year non-acetaminophen-induced alf cld p log rank acetaminophen-induced alf patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] reattempte suicide [MeSH:C0038663] [MeSH:C0038661] post-lt die year post-lt conclusion despite high prevalence [MeSH:C0033105] psychiatric [MeSH:C0033867] disturbance outcome patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] transplant [MeSH:C0332835] emergent [MeSH:C2745965]ly acetaminophen-induced alf comparable transplant [MeSH:C0332835] non-acetaminophen-induced alf electively cld multidisciplinary approach [MeSH:C4316843] long-term [MeSH:C0023977] psychiatric [MeSH:C0033867] follow-up [MeSH:C3899107] contribute low post-transplant [MeSH:C0332835] suicide [MeSH:C0038661] rate see low rate graft loss non-compliance [MeSH:C0376405],neurological|hepatorenal
veno-occlusive liver disease [MeSH:C0019156] dacarbazine therapy dtic melanoma [MeSH:C0025202],case veno-occlusive disease [MeSH:C0019156] liver [MeSH:C0023884] [MeSH:C0023884] fatal outcome [MeSH:C0206277] dacarbazine dtic therapy melanoma report fulminant [MeSH:C0302809] course start symptom death autopsy [MeSH:C0004398] liver [MeSH:C0023884] [MeSH:C0023884] enlarge firm sign venous congestion [MeSH:C0042484] small- medium-sized hepatic vein block thrombosis eosinophilic infiltration find vessel [MeSH:C0035330] published case literature review [MeSH:C0282441] pertinent feature discuss,neurological|hepatorenal|oncological
lymphoma [MeSH:C0024299] restrictive cardiomyopathy [MeSH:C0007196] cardiac connection,hypothesis statin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] heart block pathway method longitudinal trial [MeSH:C0023981] adult population measure mitral valve sinoatrial node [MeSH:C0037189] result improve disease management [MeSH:C0039798] practice guideline,cardiovascular
smooth muscle [MeSH:C1267092] stroke [MeSH:C0038454] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome [MeSH:C0206277] bundle branch block pathway method [MeSH:C0006384] randomized control trial cancer [MeSH:C1096777] patient measure thrombosis bradycardia [MeSH:C0428977] result improvement primary endpoint safety [MeSH:C0036043] consideration,cardiovascular
ataxia [MeSH:C0004134] pattern atrial fibrillation [MeSH:C0004238] patient [MeSH:C0030705],investigate [MeSH:C0035173] statin [MeSH:C0360714] effect stroke [MeSH:C0038454] delirium method cancer patient [MeSH:C0030705] undergo observational [MeSH:C0302523] brain abscess [MeSH:C0006105] serotonin assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,neurological
liver [MeSH:C0023884] enzyme level dementia [MeSH:C0497327],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome renal cell carcinoma pathway [MeSH:C0007134] method randomized control trial [MeSH:C1096777] cardiac patient measure wilm tumor [MeSH:C0027708] urea result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cost-effectiveness [MeSH:C1511536] implication,hepatorenal
morphological feature encephalopathy [MeSH:C0085584] chronic administrat [MeSH:C0034721]ion [MeSH:C0001554] antiepileptic drug [MeSH:C0003299] valproate [MeSH:C0080356] rat [MeSH:C0034721] transmission electron microscopic capillary cerebellar cortex,long-term [MeSH:C0023977] intragastric application [MeSH:C3658310] antiepileptic drug sodium valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] vupral polfa effective dose mg kg b w daily rat [MeSH:C0034721] month reveal neurological disorder [MeSH:C0027765] indicate cerebellum damage [MeSH:C0012860] [MeSH:C0007765] valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] encephalopathy [MeSH:C0085584] [MeSH:C0085584] ultrastructural [MeSH:C0041623] change structural element [MeSH:C4277569] [MeSH:C4277569] blood-brain-barri bbb cerebellar cortex [MeSH:C0007759] [MeSH:C0007759] [MeSH:C0007759] detectable month experiment [MeSH:C0020123] [MeSH:C0020123] severe later month experiment [MeSH:C0020123] [MeSH:C0020123] severe month located mainly molecular layer cerebellar cortex [MeSH:C0007759] [MeSH:C0007759] [MeSH:C0007759] lesion capillary [MeSH:C0006901] include necrosis endothelial cell [MeSH:C0225336] organelle cell [MeSH:C0029219] particular mitochondria [MeSH:C0026237] increase number size distinct degenerat [MeSH:C0034721]ion matrix crista golgi apparat [MeSH:C0034721]us alter reduce size capillary lumen occlusion cause swollen endothelial cell [MeSH:C0225336] luminal protrusion swollen microvilli pressure vessel wall produce enlarge perivascular astrocytic process fragment [MeSH:C0021009] necrotic endothelial cell vascular lumen loosening breaking tight cellular junction damage [MeSH:C0012860] vascular basement lamina [MeSH:C0085872] observe damage [MeSH:C0012860] capillary [MeSH:C0006901] accompany marked damage [MeSH:C0012860] neuroglial cell mainly perivascular process astrocyte [MeSH:C0004112] [MeSH:C0004112] proliferat [MeSH:C0034721]ion astrocyte [MeSH:C0004112] [MeSH:C0004112] bergmann particular occasionally oligodendrocyte [MeSH:C0028944] find alterat [MeSH:C0034721]ion structural element [MeSH:C4277569] [MeSH:C4277569] bbb coexist marked lesion neuron cerebellum purkinje cell [MeSH:C0034143] early electron micrograph [MeSH:C2350255] luminal antiluminal side bbb cerebellar cortex [MeSH:C0007759] [MeSH:C0007759] [MeSH:C0007759] similar lesion possible influence hepatic damage [MeSH:C0012860] mainly hyperammonemia [MeSH:C0220994] development [MeSH:C0243107] valproate [MeSH:C0080356] [MeSH:C0080356] [MeSH:C0080356] encephalopathy [MeSH:C0085584] [MeSH:C0085584] discuss,neurological|hepatorenal
nifedipine [MeSH:C0028066] induce bradycardia autonomic neuropathy,old diabetic [MeSH:C1263960] male [MeSH:C0086582] evidence [MeSH:C5575834] peripheral [MeSH:C3658334] autonomic neuropathy [MeSH:C0271686] admit ch pain find atrial flutter ventricular rate min [MeSH:C0152173] slow min nifedipine [MeSH:C0028066] [MeSH:C0028066] mg divided dose paced rate min inconsistent well-established nifedipine [MeSH:C0028066] [MeSH:C0028066] induce tachycardia [MeSH:C0039231] normally innervate heart heart [MeSH:C0018787] deprive compensatory sympathetic drive lead bradycardia [MeSH:C0428977],neurological|cardiovascular
ketanserin [MeSH:C0022616] pretreatment [MeSH:C0376495] reverse alfentanil-induced muscle rigidity,systemic [MeSH:C5544477] pretreatment [MeSH:C0376495] [MeSH:C0376495] ketanserin [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] relatively specific type- serotonin receptor antagonist [MeSH:C0036753] significantly attenuate [MeSH:C0042211] [MeSH:C0042211] muscle rigidity [MeSH:C0026837] [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] [MeSH:C0026837] produce rat [MeSH:C0034721] [MeSH:C0034721] potent short-acting opiate agonist alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] follow placement [MeSH:C2049629] subcutaneous electrode [MeSH:C0222331] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] leave gastrocnemius muscle [MeSH:C0242691] rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] [MeSH:C0026837] assess analyze root-mean-square electromyographic activity [MeSH:C0013839] [MeSH:C0013839] intraperitoneal [MeSH:C0021493] ketanserin [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] administrat [MeSH:C0034721] [MeSH:C0034721]ion dose mg kg prevent alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026]-induced increase electromyographic activity [MeSH:C0013839] [MeSH:C0013839] compare animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] pretreate saline chlordiazepoxide dose mg kg fail significantly influence [MeSH:C0683549] rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] produce alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] despite absence [MeSH:C0270823] rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] receive ketanserin [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] great mg kg p follow alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] motionless flaccid responsive external stimulus animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] receive alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] rat [MeSH:C0034721] [MeSH:C0034721] receive ketanserin [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] alfentanil [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] [MeSH:C0002026] exhibit rearing explorat [MeSH:C0034721] [MeSH:C0034721]ory behavior end -min recording [MeSH:C0039300] period animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] receive ketanserin [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] [MeSH:C0022616] result combination previous work suggest muscle rigidity [MeSH:C0026837] [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] [MeSH:C0026837] clinically relevant side-effect parenteral [MeSH:C0030548] narcotic administrat [MeSH:C0034721] [MeSH:C0034721]ion partly mediate serotonergic pathway pretreatment [MeSH:C0376495] [MeSH:C0376495] type- serotonin antagonist [MeSH:C0036753] clinically useful attenuate [MeSH:C0042211] [MeSH:C0042211] opiate-induced rigidity [MeSH:C1320474] [MeSH:C1320474] [MeSH:C1320474] study necessary assess interaction [MeSH:C0007582] possibly enhance cns [MeSH:C0349606] cardiovascular respirat [MeSH:C0034721] [MeSH:C0034721]ory depression,cardiovascular
novel insight hepatitis hepatoma [MeSH:C0019158],investigate [MeSH:C0035173] beta-blocker effect cancer aki method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo prospective jaundice glomerulus assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
organ [MeSH:C0029250] orchestra cardiomyopathy,prospective examine calcium channel blocker cancer [MeSH:C0006684] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include polyuria [MeSH:C0032617] hemodialysis hydronephrosis method participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
ataxia pathway ventricular tachycardia [MeSH:C0042514],hypothesis statin improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] [MeSH:C0206277] autonomic neuropathy pathway method [MeSH:C0206251] observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure parkinsonism [MeSH:C0242422] cerebrospinal fluid [MeSH:C0007806] result improve outcome [MeSH:C0206277] [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,neurological
heart health [MeSH:C0018684] meet leukemia [MeSH:C0023418],question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] endocardium [MeSH:C0014124] mechanism method cross-sectional [MeSH:C0010362] elderly patient assess aortic valve defibrillator [MeSH:C0003501] result reduction adverse event [MeSH:C0041755] implication therapeutic [MeSH:C0087111] innovation,cardiovascular
gt transition splice donor site cause skipping precede exon phenylketonuria [MeSH:C0031485],classical phenylketonuria pku [MeSH:C0031485] autosomal recessive human [MeSH:C0086418] [MeSH:C0086418] genetic disorder [MeSH:C0019247] cause deficiency hepatic phenylalanine hydroxylase [MeSH:C0751434] pah isolate mutant [MeSH:C1564139] [MeSH:C1564139] pah cdna [MeSH:C0006556] clone [MeSH:C0006556] pku carrier individual [MeSH:C0021228] [MeSH:C0021228] show contain internal base pair deletion [MeSH:C0017260] corresponding precisely exon [MeSH:C0015295] human [MeSH:C0086418] [MeSH:C0086418] chromosomal pah gene deletion [MeSH:C0017260] [MeSH:C0017260] cause synthesis [MeSH:C3178925] truncate protein lack c-terminal amino acid gene transfer [MeSH:C0887912] expression study mutant [MeSH:C1564139] [MeSH:C1564139] pah cdna [MeSH:C0006556] indicate deletion [MeSH:C0017260] abolish pah activity cell protein instability determine molecular basis deletion [MeSH:C0017260] mutant [MeSH:C1564139] [MeSH:C1564139] chromosomal pah gene isolate individual [MeSH:C0021228] [MeSH:C0021228] show contain gt-- great substitution [MeSH:C2936279] splice donor site [MeSH:C0887917] intron [MeSH:C0021920] consequence splice donor site [MeSH:C0887917] mutation [MeSH:C0026882] human [MeSH:C0086418] [MeSH:C0086418] liver skipping precede exon [MeSH:C0015295] rna splicing,hepatorenal
characterization germline mosaicism family lowe syndrome [MeSH:C0028860] identification [MeSH:C1707660] seven novel mutation [MeSH:C0026882] ocrl1 gene,oculocerebrorenal syndrome [MeSH:C0028860] lowe ocrl x-linked disorder characterize major abnormality [MeSH:C0037268] eye nervous system kidney mutation [MeSH:C0026882] ocrl1 gene associate disease ocrl1 encode phosphatidylinositol [MeSH:C0031621] -biphosphate ptdin [MeSH:C0031621] [MeSH:C0031621] p2 -phosphatase examine ocrl1 gene unrelated patient [MeSH:C0030705] ocrl find seven new mutation [MeSH:C0026882] recurrent in-frame deletion new mutation [MeSH:C0026882] nonsense mutation [MeSH:C0026882] r37x e58x frameshift mutation [MeSH:C0079380] [MeSH:C0079380] [MeSH:C0026882] cause premature termination protein missense mutation [MeSH:C0599155] [MeSH:C0026882] r43 g located highly conserve ptdin [MeSH:C0031621] [MeSH:C0031621] p2 -phosphatase domain finally frameshift mutation [MeSH:C0079380] [MeSH:C0079380] [MeSH:C0026882] 9delc modify c-terminal ocrl1 extension amino acid [MeSH:C0002520] altogether missense mutation [MeSH:C0599155] [MeSH:C0026882] located exon mutation [MeSH:C0026882] cluster exon identify new microsatellite marker [MeSH:C1519302] ocrl1 locus detect germline mosaicism [MeSH:C0026578] family observation [MeSH:C0302523] direct implication genetic counseling [MeSH:C0017382] lowe syndrome [MeSH:C0028860] family,hepatorenal
arrhythmia [MeSH:C0003811] heart failure [MeSH:C0018801] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer blood pressure mechanism method randomized control cancer [MeSH:C1096777] patient [MeSH:C0030705] assess heart valve blood vessel [MeSH:C0005847] result improvement [MeSH:C2936612] primary endpoint implication care improvement [MeSH:C2936612],cardiovascular
kidney stone pathway hypertension,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] diabete steatosis [MeSH:C2711227] method cardiac patient undergo retrospective [MeSH:C0035363] ast hepatocellular carcinoma [MeSH:C2239176] assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] practice guideline,hepatorenal
astrocytoma pathway dementia [MeSH:C0497327],assess efficacy [MeSH:C5690761] metformin [MeSH:C0025598] [MeSH:C0025598] hypertension [MeSH:C0020538] focus transient ischemic attack [MeSH:C0007787] huntington disease method adult [MeSH:C0001675] population [MeSH:C0032659] randomized [MeSH:C1096777] receive metformin [MeSH:C0025598] [MeSH:C0025598] placebo [MeSH:C0032041] oligodendroglioma [MeSH:C0028945] monitoring [MeSH:C0005517] result improve outcome safety consideration,neurological
immunohistochemistry [MeSH:C0021044] reveal breast cancer [MeSH:C0006142] secret,investigate [MeSH:C0035173] beta-blocker effect heart disease schwannoma method adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal [MeSH:C0023981] epinephrine [MeSH:C0014563] hypothalamus assessment [MeSH:C0030198] result positive response care improvement [MeSH:C2936612],neurological
rcc [MeSH:C0967777] meet lung cancer [MeSH:C0242379] neurological perspective,investigate [MeSH:C0035173] statin effect heart disease [MeSH:C0018799] renal stone method cancer [MeSH:C0740457] patient [MeSH:C0030705] undergo randomized control peritoneal dialysis oligodendroglioma assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] practice guideline,neurological|hepatorenal
dementia [MeSH:C0497327] rcc [MeSH:C0967777] cardiac connection,hypothesis [MeSH:C3179072] aspirin improve cancer outcome [MeSH:C0206277] endothelial pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure defibrillator pyelonephritis [MeSH:C0034186] result improvement [MeSH:C2936612] primary endpoint healthcare advancement,cardiovascular|hepatorenal
mouse [MeSH:C0026809] homolog [MeSH:C3853771] wiskott-aldrich syndrome protein wasp gene [MeSH:C0258432] highly conserve map [MeSH:C0024779] near scurfy sf mutation x chromosome,mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] gene [MeSH:C0043041] [MeSH:C0043041] homolog [MeSH:C3853771] gene mutate wiskott-aldrich syndrome [MeSH:C0043194] isolate sequence [MeSH:C0162327] [MeSH:C0162327] predict amino acid sequence [MeSH:C0162327] [MeSH:C0002518] [MeSH:C0162327] identical human [MeSH:C0086418] wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] sequence [MeSH:C0162327] [MeSH:C0162327] distinct feature mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] gene expand polymorphic [MeSH:C1720758] gga trinucleotide repeat code polyglycine vary triplet different mus musculus strain [MeSH:C0025914] genomic structure [MeSH:C1136352] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] gene [MeSH:C0043041] [MeSH:C0043041] express approximately -kb mrna [MeSH:C0035696] [MeSH:C0035696] [MeSH:C0035696] thymus spleen chromosomal mapping [MeSH:C0008630] interspecific musculus spretus backcross place wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] locus [MeSH:C0085286] near centromere mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] x chromosome inseparable gata1 [MeSH:C1530719] tcfe3 scurfy sf localization [MeSH:C0037710] make wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] candidate involvement [MeSH:C0030699] scurfy cell-mediated fatal lymphoreticular disease mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] previously propose mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] homolog [MeSH:C3853771] wiskott-aldrich syndrome [MeSH:C0043194] northern [MeSH:C3658205] sf tissue sample indicate presence wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] mrna [MeSH:C0035696] [MeSH:C0035696] [MeSH:C0035696] liver skin [MeSH:C0023884] presumably consequence [MeSH:C0162327] [MeSH:C0162327] lymphocytic infiltration [MeSH:C0079722] non abnormality [MeSH:C0037268] size mrna [MeSH:C0035696] [MeSH:C0035696] [MeSH:C0035696] present,hepatorenal
butyrylcholinesterase gene mutation [MeSH:C0728810] patient [MeSH:C0030705] prolonged apnea succinylcholine [MeSH:C0038627] electroconvulsive therapy [MeSH:C0013806],patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo electroconvulsive therapy [MeSH:C0013806] ect receive succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627] anesthetic procedure [MeSH:C0677616] duration action prolong patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] genetic variant [MeSH:C0042333] [MeSH:C0042333] butyrylcholinesterase enzyme bche [MeSH:C0728810] common k- a-variants assess significance genetic variant [MeSH:C0042333] [MeSH:C0042333] butyrylcholinesterase gene [MeSH:C0728810] bche patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] suspect prolonged duration action succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627] ect method total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] refer danish cholinesterase unit ect month determine bche activity bche genotype [MeSH:C0017431] molecular genetic method duration apnea [MeSH:C0003578] sufficient spontaneous [MeSH:C0000786] ventilation neuromuscular monitoring [MeSH:C3494225] [MeSH:C3494225] duration apnea [MeSH:C0003578] compare publish normal subject result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mutation find bche gene k-variant frequent duration apnea [MeSH:C0003578] min compare min literature [MeSH:C0023866] severe distress [MeSH:C0015930] note recovery [MeSH:C0140116] phase patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] neuromuscular monitoring [MeSH:C3494225] [MeSH:C3494225] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prolonged duration action succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627] mutation bche indicate possible reason prolonged period apnea recommend neuromuscular monitoring [MeSH:C3494225] [MeSH:C3494225] ect,neurological
deliberate hypotension [MeSH:C0020649] induce labetalol [MeSH:C0022860] halothane [MeSH:C0018549] enflurane [MeSH:C0014277] isoflurane [MeSH:C0022180] middle-ear surgery,feasibility [MeSH:C0015730] labetalol [MeSH:C0022860] [MeSH:C0022860] [MeSH:C0022860] alpha- beta-adrenergic blocking agent [MeSH:C0001645] hypotensive agent [MeSH:C0003364] combination inhalation [MeSH:C0004048] anaesthetic [MeSH:C0002932] halothane [MeSH:C0018549] [MeSH:C0018549] enflurane [MeSH:C0014277] isoflurane [MeSH:C0022180] [MeSH:C0022180] study adult [MeSH:C0001675] patient [MeSH:C0030705] [MeSH:C0030705] undergo middle-ear surgery mean arterial pressure [MeSH:C1272641] decrease e mean mmhg mmhg kpa min halothane [MeSH:C0018549] [MeSH:C0018549] h mmhg kpa min enflurane [MeSH:C0014277] e mmhg kpa min isoflurane [MeSH:C0022180] [MeSH:C0022180] mean h concentration [MeSH:C0311432] hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] inspiratory gas vol mean e concentration [MeSH:C0311432] vol mean concentration [MeSH:C0474535] [MeSH:C0311432] vol addition patient [MeSH:C0030705] [MeSH:C0030705] receive fentanyl [MeSH:C0015846] d-tubocurarine [MeSH:C0041345] initial dose labetalol [MeSH:C0022860] [MeSH:C0022860] [MeSH:C0022860] lower blood pressure [MeSH:C0020649] similar mg kg group [MeSH:C0018257] [MeSH:C0018257] hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] heart rate [MeSH:C0018810] stable tachy- bradycardia [MeSH:C0428977] operating condition bleeding estimate double-blind [MeSH:C0013072] manner differ significantly group [MeSH:C0018257] [MeSH:C0018257] hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] serum creatinine concentration [MeSH:C0311432] rise significantly group [MeSH:C0018257] [MeSH:C0018257] value hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] return postoperatively initial group [MeSH:C0018257] [MeSH:C0018257] isoflurane [MeSH:C0022180] [MeSH:C0022180] hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] rebound phenomenon blood pressure heart rate [MeSH:C0005823] [MeSH:C0018810] result indicate labetalol [MeSH:C0022860] [MeSH:C0022860] [MeSH:C0022860] induce easily adjustable hypotension [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] [MeSH:C0020649] compensatory tachycardia rebound hypertension,cardiovascular|hepatorenal
mutation [MeSH:C0026882] vhl gene associate exclusively development non-papillary renal cell carcinoma [MeSH:C1306837],define possible role vhl gene development sporadic renal cell carcinoma [MeSH:C0007134] different parenchymal tumour kidney investigate [MeSH:C0035173] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] vhl gene single strand conformation polymorphism [MeSH:C0032529] sscp [MeSH:C0243031] heteroduplex hd technique chromosome 3p deletion detect cent non-papillary renal cell carcinoma [MeSH:C1306837] [MeSH:C1306837] [MeSH:C1306837] cent chromophobe renal cell carcinoma [MeSH:C1266042] non-papillary renal cell carcinoma [MeSH:C1306837] [MeSH:C1306837] [MeSH:C1306837] abnormal [MeSH:C0853087]ly migrate [MeSH:C0026093] dna band detect sscp [MeSH:C0243031] hd mobility shift see chromophobe renal cell carcinoma [MeSH:C1266042] addition papillary renal cell tumour renal oncocytoma [MeSH:C0346255] characterize genetic change loss chromosome 3p sequence analyse mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] vhl gene tumour show abnormal [MeSH:C0853087] migration pattern result indicate mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] vhl gene associate exclusively development non-papillary renal cell carcinoma [MeSH:C1306837] [MeSH:C1306837] [MeSH:C1306837],hepatorenal|oncological
synaptic [MeSH:C0206181] story valvular heart disease medulloblastoma [MeSH:C0018824],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve diabete outcome cerebral infarction pathway method retrospective trial adult [MeSH:C0001675] population [MeSH:C0032659] measuring al oligodendroglioma [MeSH:C0028945] result improvement primary endpoint safety [MeSH:C0036043] consideration,neurological
seizure [MeSH:C0036572] induce combined levomepromazine-fluvoxamine [MeSH:C0025678],report case combined levomepromazine-fluvoxamine [MeSH:C0085228] [MeSH:C0025678] treatment-induced seizure combined fluvoxamine [MeSH:C0085228] phenothiazine [MeSH:C0031434] possess proconvulsive activity,neurological
neoplasm pathway diabetes mellitus,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve heart disease [MeSH:C0018799] outcome immunotherapy pathway method [MeSH:C0021083] cross-sectional trial [MeSH:C0010362] adult population measure steatosis [MeSH:C2711227] chronic kidney disease [MeSH:C1561643] result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal|oncological
down-regulation [MeSH:C0013081] norepinephrine transporter function [MeSH:C0132800] induce chronic administration [MeSH:C0001554] desipramine [MeSH:C0011685] link alteration sensitivity [MeSH:C0036667] local-anesthetics-induced convulsion [MeSH:C4048158] counteraction co-administration [MeSH:C0001554] local anesthetic,alteration norepinephrine [MeSH:C0028351] [MeSH:C0028351] transporter net function [MeSH:C0031843] [MeSH:C0132800] chronic inhibition [MeSH:C0027790] net relation sensitization seizure [MeSH:C0036572] induce cocaine [MeSH:C0009170] local anesthetic study [MeSH:C0002934] mouse [MeSH:C0026809] daily administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] inhibitor [MeSH:C0011685] net day decrease h norepinephrine [MeSH:C0028351] [MeSH:C0028351] uptake p2 fraction hippocampus [MeSH:C3887642] cortex [MeSH:C3887642] striatum amygdalae [MeSH:C0002708] co-administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] lidocaine [MeSH:C0023660] bupivacaine [MeSH:C0006400] tricaine desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] reverse effect daily cocaine [MeSH:C0009170] increase h norepinephrine [MeSH:C0028351] [MeSH:C0028351] uptake hippocampus [MeSH:C3887642] daily administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] increase incidence [MeSH:C0021149] appearance lidocaine [MeSH:C0023660]-induced convulsion decrease cocaine [MeSH:C0009170]-induced convulsion co-administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] lidocaine [MeSH:C0023660] desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] reverse change convulsive activity lidocaine [MeSH:C0023660] cocaine [MeSH:C0009170] induce repeated administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] result suggest down-regulation [MeSH:C0013081] hippocampal [MeSH:C0228249] net induce chronic administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685] relevant desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685]-induced sensitization lidocaine [MeSH:C0023660] convulsion inhibition [MeSH:C0027790] na channel local anesthetic regulate desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685]-induced down-regulation [MeSH:C0013081] net function [MeSH:C0031843] repeated administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] cocaine [MeSH:C0009170] induce up-regulation [MeSH:C0041904] hippocampal [MeSH:C0228249] net function [MeSH:C0031843] desipramine [MeSH:C0011685] [MeSH:C0011685] [MeSH:C0011685]-induced sensitization lidocaine [MeSH:C0023660] seizure mechanism [MeSH:C1524059] distinct kindling [MeSH:C1720776] result repeated administration [MeSH:C0001554] [MeSH:C0001554] [MeSH:C0001554] cocaine [MeSH:C0009170],neurological
dopamine d2 receptor signaling [MeSH:C0058698] control neuronal cell death [MeSH:C0007587] induce muscarinic glutamatergic drug,dopamine da d1 d2 receptor-mediated signal play major role epileptic seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C4317109] arise limbic system [MeSH:C0023715] excitotoxicity [MeSH:C0235280] lead neuronal cell death affect area major consequence [MeSH:C0079160] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] cellular [MeSH:C1136359] respect little know role da receptor occurrence epilepsy-induced neuronal cell death analyze occurrence seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] neurotoxicity [MeSH:C0235032] [MeSH:C0235032] d2r mouse treat cholinergic [MeSH:C0242893] agonist [MeSH:C0162816] pilocarpine [MeSH:C0031923] compare result previously obtain kainic acid ka [MeSH:C0022471] potent glutamate [MeSH:C0220839] agonist [MeSH:C0162816] importantly d2r mouse develop seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] dose drug epileptogenic wt littermate great neurotoxicity [MeSH:C0235032] [MeSH:C0235032] pilocarpine [MeSH:C0031923]-induced seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] widespread neuronal death wt d2r brain comparison [MeSH:C0871382] ka absence d2r lower threshold [MeSH:C0162703] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] induce glutamate [MeSH:C0220839] acetylcholine dopaminergic epilepsy-induced neurodegeneration [MeSH:C0027746] mediate distinct interaction [MeSH:C0007582] d2r signaling neurotransmitter [MeSH:C0027908],neurological
catalepsy [MeSH:C0007370] induce combination ketamine [MeSH:C0022614] morphine [MeSH:C0026549] potentiation [MeSH:C1136141] antagonism tolerance cross-tolerance rat [MeSH:C0034721],previous study [MeSH:C0085973] [MeSH:C0085973] demonstrat [MeSH:C0034721] [MeSH:C0034721]e ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] induced [MeSH:C5392225] analgesia catalepsy [MeSH:C0007370] [MeSH:C0007370] rat [MeSH:C0034721] [MeSH:C0034721] pre-treatment [MeSH:C0039798] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] produce cross-tolerance morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] pretreatment [MeSH:C0376495] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] induce cross-tolerance ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] augment cataleptic response augmentation [MeSH:C1510606] attribute residual [MeSH:C0543478] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] brain [MeSH:C0006104] present study [MeSH:C0085973] [MeSH:C0085973] explore durat [MeSH:C0034721] [MeSH:C0034721]ion loss right reflex induce sub-effective dose ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] administer simultaneously mutual potentiation sub-effective dose ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] sub-effective dose ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] partly antagonize fully-effective dose morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] latency [MeSH:C0596824] loss right reflex rigidity behavior recovery [MeSH:C0140116] reflect relative predominance ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] combination [MeSH:C0034865] naloxone [MeSH:C0027358] [MeSH:C0027358] inhibit [MeSH:C0021463] induce cataleptic effect degree course development [MeSH:C0243107] tolerance daily administrat [MeSH:C0034721] [MeSH:C0034721]ion sub-effective dose combination [MeSH:C0034865] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] similar rat [MeSH:C0034721] [MeSH:C0034721] tolerant ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614]-dominant combination [MeSH:C0034865] cross-tolerant drug tolerant [MeSH:C0013220] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549]-dominant combination [MeSH:C0034865] cross-tolerant morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] show cross-tolerance augmented [MeSH:C5197824] response ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] mutual potentiation antagonism tolerance suggest common mechanism [MeSH:C1524059] induce catalepsy [MeSH:C0007370] difference latency [MeSH:C0596824] rigidity behavior asymmetry [MeSH:C1306710] cross-tolerance widely-different id5 naloxone [MeSH:C0027358] [MeSH:C0027358] argue action single opioid site,neurological
pelizaeus-merzbacher disease [MeSH:C0205711] x-linked neurologic disorder [MeSH:C1848144] myelin metabolism [MeSH:C0025519] novel mutation gene [MeSH:C0026882] encoding proteolipid protein [MeSH:C1175541],nosology inborn error [MeSH:C0025521] [MeSH:C0025521] myelin metabolism [MeSH:C0025519] [MeSH:C0025519] stymie lack molecular genetic [MeSH:C0086345] historically pelizaeus-merzbacher disease [MeSH:C0205711] [MeSH:C0012634] encompass host neurologic disorder [MeSH:C0027765] present deficit myelin membrane elaborate glial cell encircle successively enwraps axon describe pelizaeus-merzbacher pedigree [MeSH:C0030761] classical type x-linked inheritance [MeSH:C4277511] typical progression [MeSH:C0242656] pathologic [MeSH:C0030664] loss myelinating cell myelin central nervous system [MeSH:C3714787] discriminate variant pelizaeus-merzbacher disease [MeSH:C0205711] [MeSH:C0012634] set oligonucleotide primer construct polymerase-chain-reaction pcr amplify sequence gene encode proteolipid protein [MeSH:C1175541] plp structural protein comprise half protein myelin sheath [MeSH:C0026973] plp gene affect male [MeSH:C0086582] carrier mother [MeSH:C0026591] family exhibit single base difference kb plp gene sequence c----t transition [MeSH:C1257888] create serine [MeSH:C0036720] substitution proline carboxy end protein result delineate feature pelizaeus-merzbacher disease [MeSH:C0205711] [MeSH:C0012634] define possible molecular pathology [MeSH:C0596962] dysmyelinating disorder [MeSH:C0011303] address molecular classification [MeSH:C0008902] inborn error [MeSH:C0025521] [MeSH:C0025521] myelin metabolism [MeSH:C0025519] [MeSH:C0025519] patient [MeSH:C0030705] classical form type severely affect connatal [MeSH:C0009678] variant pelizaeus-merzbacher disease [MeSH:C0205711] [MeSH:C0012634] type ii predict display [MeSH:C0010996] mutation [MeSH:C0026882] plp locus variant type iii-vi categorize pelizaeus-merzbacher disease [MeSH:C0205711] [MeSH:C0012634] represent mutation [MeSH:C0026882] gene encode structural myelin protein protein [MeSH:C0026972] critical myelination,neurological
additional case female [MeSH:C0086287] monozygotic [MeSH:C0041432] twin discordant manifestation [MeSH:C0029166] duchenne muscular dystrophy [MeSH:C0026850] opposite x-chromosome inactivation [MeSH:C0043297],pair [MeSH:C0600436] female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086287] monozygotic mz twin heterozygous carrier deletion dmd gene discordant manifestation [MeSH:C0029166] duchenne muscular dystrophy [MeSH:C0026850] analyze molecular study situ hybridization [MeSH:C0162788] methylation pattern [MeSH:C3849996] x chromosome search [MeSH:C0008633] opposite x inactivation [MeSH:C0043297] [MeSH:C0043297] explanation discordance result lymphocyte skin [MeSH:C0024264] fibroblast cell line [MeSH:C0016030] suggest partial mirror inactivation [MeSH:C0043297] [MeSH:C0043297] normal x chromosome preferentially active [MeSH:C0205681] [MeSH:C0205681] unaffected twin maternal deleted x chromosome preferentially active [MeSH:C0205681] [MeSH:C0205681] affect twin review [MeSH:C0282443] show mz female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086287] twin discordant x-linked disease [MeSH:C1138434] uncommon twinning [MeSH:C5197736] x inactivation [MeSH:C0043297] [MeSH:C0043297] interrelated explain female [MeSH:C0086287] [MeSH:C0086287] [MeSH:C0086287] twin discordant x-linked trait [MeSH:C1537071],neurological
myocardium [MeSH:C0027061] stroke [MeSH:C0038454] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect diabete endothelial method cancer patient [MeSH:C0030705] undergo randomized control pad pacemaker assessment result improve outcome [MeSH:C0206277] therapeutic innovation [MeSH:C0087111],cardiovascular
wilms tumor [MeSH:C0027708] dax- modulate orphan nuclear receptor sf- [MeSH:C1335073] sex-specific gene expression [MeSH:C0017262],product steroidogenic factor sf- [MeSH:C0171961] wilms tumor [MeSH:C0027708] wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] gene essential mammalian [MeSH:C0024660] gonadogenesis prior sexual differentiation [MeSH:C0036874] male [MeSH:C0086582] sf- participate sexual development [MeSH:C0243107] [MeSH:C0233896] regulate [MeSH:C0851285] expression [MeSH:C0017262] polypeptide hormone mullerian [MeSH:C0066928] inhibit [MeSH:C0021463] substance mis wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] -kts isoform [MeSH:C0597298] associate synergize sf- promote mis expression [MeSH:C0017262] contrast wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] missense [MeSH:C0599155] mutation [MeSH:C0026882] associate male [MeSH:C0086582] pseudohermaphroditism denys-drash syndrome fail synergize sf- additionally x-linked candidate dosage-sensitive sex-reversal gene dax- antagonize synergy sf- wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] likely direct interaction [MeSH:C0007582] sf- propose wt1 [MeSH:C0148873] [MeSH:C0148873] [MeSH:C0148873] dax- functionally oppose testis [MeSH:C0039597] development [MeSH:C0243107] modulate sf mediate transactivation [MeSH:C0040624],neurological|oncological
endocardium [MeSH:C0014124] meet dementia [MeSH:C0497327] neurological [MeSH:C0026345] perspective,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve cancer outcome [MeSH:C0206277] astrocytoma pathway method longitudinal trial [MeSH:C0023981] adult population measure amygdala defibrillator [MeSH:C0002708] result favorable safety profile healthcare advancement,neurological|cardiovascular
alpha-blocker [MeSH:C0001641] breast cancer [MeSH:C0006142] brain [MeSH:C0006104] insight,dementia [MeSH:C0497327] [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve cerebral neural method conduct prospective evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine dementia [MeSH:C0497327] [MeSH:C0497327] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
gaucher disease origin ashkenazi jewish n30 4gg acid beta-glucosidase mutation [MeSH:C0017768],type gaucher disease [MeSH:C1961835] gd non-neuronopathic lysosomal storage disorder result deficient activity acid beta-glucosidase [MeSH:C0017768] gba type disease panethnic prevalent individual [MeSH:C0021228] ashkenazi jewish aj descent causative gba mutation [MeSH:C0026882] [MeSH:C0026882] n30s particularly frequent [MeSH:C0017270] aj population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] q approximately 4gg insertion [MeSH:C1512796] q approximately occur exclusively ashkenazim investigate [MeSH:C0035173] genetic history [MeSH:C0019664] mutation [MeSH:C0026882] [MeSH:C0026882] aj population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] short tandem repeat str marker [MeSH:C0017393] [MeSH:C0017393] map -cm region contain gba locus genotype [MeSH:C0017431] aj n30s chromosome europe [MeSH:C0015176]an non-jewish n30s chromosome aj 4gg chromosome [MeSH:C0008633] highly conserve haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] marker [MeSH:C0017393] [MeSH:C0017393] flanking gba pklr d1s1 d1s2 d1s2 observe aj chromosome [MeSH:C0008633] non-jewish n30s chromosome suggest occurrence founder common population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] note presence different divergent haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] suggest occurrence de novo recurrent n30s mutation [MeSH:C0026882] [MeSH:C0026882] contrast different conserve haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] marker [MeSH:C0017393] [MeSH:C0017393] identify 4gg chromosome [MeSH:C0008633] unique aj population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] basis linkage disequilibrium ld delta value non-jewish europe [MeSH:C0015176]an n30s chromosome great haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] diversity [MeSH:C0282469] ld marker [MeSH:C0017393] [MeSH:C0017393] flank conserve haplotype [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] [MeSH:C0018591] aj n30s chromosome consistent presence n30s mutation [MeSH:C0026882] [MeSH:C0026882] non-jewish europe [MeSH:C0015176]an population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] prior founding aj population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] coalescence analysis n30 4gg mutation [MeSH:C0026882] [MeSH:C0026882] estimate similar coalescence time generation ago respectively result study consistent bottleneck occur aj population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] millennium population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] establish europe [MeSH:C0015176],neurological
echocardiography [MeSH:C0013516] reveal stroke [MeSH:C0038454] secret,prospective examine beta-blocker hypertension cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include tia neuropathy [MeSH:C0751932] dopamine method [MeSH:C0013030] participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication practice [MeSH:C0024650] guideline,neurological
amiodarone [MeSH:C0002598] risk [MeSH:C0035647] bradyarrhythmia [MeSH:C0428977] require permanent [MeSH:C0348070] pacemaker [MeSH:C3494452] elderly [MeSH:C0001792] patient [MeSH:C0030705] atrial fibrillation [MeSH:C0004238] prior myocardial infarction [MeSH:C0027051],objective determine use amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] atrial fibrillation [MeSH:C0004238] af increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] bradyarrhythmia [MeSH:C0428977] [MeSH:C0428977] require permanent [MeSH:C0348070] [MeSH:C0348070] [MeSH:C0348070] pacemaker report severe bradyarrhythmia [MeSH:C0428977] [MeSH:C0428977] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] therapy [MeSH:C0039798] infrequent limited study assess therapy [MeSH:C0039798] use management [MeSH:C0085971] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ventricular arrhythmia method [MeSH:C0042514] cohort [MeSH:C1706962] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] age year new diagnosis [MeSH:C0011900] af identify provincewide database [MeSH:C0993637] quebec resident myocardial infarction [MeSH:C0027051] mi nested case-control design case bradyarrhythmia [MeSH:C0428977] [MeSH:C0428977] [MeSH:C0428977] require permanent [MeSH:C0348070] [MeSH:C0348070] [MeSH:C0348070] pacemaker match control multivariable logistic regression estimate odd ratio pacemaker insertion [MeSH:C1512796] [MeSH:C1512796] associate amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] use controlling risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] factor exposure sotalol [MeSH:C0037707] class antiarrhythmic agent [MeSH:C0003195] beta-blocker calcium channel blocker digoxin [MeSH:C0012265] [MeSH:C0006684] result amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] use associate increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] pacemaker insertion [MeSH:C1512796] [MeSH:C1512796] confidence interval [MeSH:C0009667] ci effect modify gender [MeSH:C0079399] great risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] woman [MeSH:C0043210] versus man ci vs ci digoxin [MeSH:C0012265] medication associate increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] pacemaker insertion [MeSH:C1512796] [MeSH:C1512796] ci conclusion suggest use amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] elderly [MeSH:C0001792] [MeSH:C0001792] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] af previous mi increase risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] bradyarrhythmia [MeSH:C0428977] [MeSH:C0428977] require permanent [MeSH:C0348070] [MeSH:C0348070] [MeSH:C0348070] pacemaker augmented risk [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] [MeSH:C0035647] pacemaker insertion [MeSH:C1512796] [MeSH:C1512796] elderly [MeSH:C0001792] [MeSH:C0001792] woman [MeSH:C0043210] receive amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] require investigation [MeSH:C0035173],cardiovascular
embolism [MeSH:C0013922] colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation beta-blocker heart disease participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] transient ischemic attack heart valve result enhance therapeutic response [MeSH:C0087111] ventricular tachycardia [MeSH:C0042514] correlation relevance [MeSH:C2826293],cardiovascular
chronic lymphocytic leukemia [MeSH:C0023434] meet diabetes mellitus [MeSH:C0011849] neurological perspective,prospective examine beta-blocker hypertension diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include acetylcholine ovarian cancer [MeSH:C1140680] dopamine method [MeSH:C0013030] participant [MeSH:C1708335] include result positive response implication care improvement,neurological|oncological
cerebrospinal fluid [MeSH:C0007806] meet peripheral artery disease [MeSH:C1704436] neurological perspective,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome [MeSH:C0206277] substantia nigra pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure neurofibroma meningioma [MeSH:C0027830] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],neurological
case polymyositis [MeSH:C0085655] primary biliary cirrhosis [MeSH:C0023892] treat d-penicillamine [MeSH:C0030817],d-penicillamine [MeSH:C0030817] rheumatologic disease toxicity [MeSH:C0040539] limit usefulness patient [MeSH:C0030705] polymyositis [MeSH:C0085655] dermatomyositis [MeSH:C0011633] develop autoimmune complication d-penicillamine [MeSH:C0030817] exact pathogenesis [MeSH:C0699748] remain unclear report primary biliary cirrhosis [MeSH:C0023892] develop polymyositis [MeSH:C0085655] receive d-penicillamine [MeSH:C0030817] therapy describe special course patient [MeSH:C0030705] receive d-penicillamine [MeSH:C0030817] therapy follow carefully development [MeSH:C0243107] autoimmune complication like polymyositis [MeSH:C0085655] dermatomyositis,hepatorenal
risk [MeSH:C0035647] benefit [MeSH:C0021674] cox- inhibitor [MeSH:C1257954] vs non-selective nsaid cardiovascular risk [MeSH:C4324389] [MeSH:C0035647] exceed gastrointestinal [MeSH:C0017189] benefit [MeSH:C0021674] retrospective [MeSH:C0035363] cohort,objective risk [MeSH:C0035647] [MeSH:C0035647] acute myocardial infarction ami cox- inhibitor [MeSH:C0003015] offset gastrointestinal gi [MeSH:C0017189] benefit [MeSH:C0021674] compare non-selective ns non-steroidal anti-inflammatory drug nsaid [MeSH:C0003211] aim compare risk [MeSH:C0035647] [MeSH:C0035647] hospitalization [MeSH:C0019993] [MeSH:C0019993] ami gi bleed elderly patient cox- inhibitor [MeSH:C0003015] ns-nsaid [MeSH:C0003211] [MeSH:C0003211] [MeSH:C0003211] acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] method [MeSH:C0000970] conduct retrospective [MeSH:C0035363] cohort administrative patient year [MeSH:C0030705] age [MeSH:C0024842] fill prescription [MeSH:C0033080] nsaid acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] outcome compare cox regression model time-dependent exposure [MeSH:C1390376] result person-year exposure [MeSH:C1390376] non-user aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] rofecoxib [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] celecoxib [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] ns-nsaid [MeSH:C0003211] [MeSH:C0003211] [MeSH:C0003211] user aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] rofecoxib [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] celecoxib [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] ns-nsaid [MeSH:C0003211] [MeSH:C0003211] [MeSH:C0003211] acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] non-user aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] adjust hazard ratio confidence interval [MeSH:C0009667] hospitalization [MeSH:C0019993] [MeSH:C0019993] ami gi vs acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] rofecoxib [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] celecoxib [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] naproxen diclofenac ibuprofen [MeSH:C0020740] [MeSH:C0020740] user aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] rofecoxib [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] celecoxib [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] ibuprofen [MeSH:C0020740] diclofenac naproxen [MeSH:C0012091] acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] non-user aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] naproxen carry high risk [MeSH:C0556482] [MeSH:C0035647] [MeSH:C0035647] ami gi bleed ami gi toxic [MeSH:C1256754]ity [MeSH:C0040539] celecoxib [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] similar acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] well rofecoxib [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] [MeSH:C0762662] ns-nsaid [MeSH:C0003211] [MeSH:C0003211] [MeSH:C0003211] user aspirin [MeSH:C0004057] [MeSH:C0004057] [MeSH:C0004057] celecoxib [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] [MeSH:C0538927] naproxen toxic [MeSH:C1256754],cardiovascular
reversible [MeSH:C5691430] valproic [MeSH:C0042291] acid-induced dementia [MeSH:C0497327] case report [MeSH:C0684224],reversible [MeSH:C5691430] valproic [MeSH:C0042291] [MeSH:C0042291] acid-induced dementia [MeSH:C0497327] document [MeSH:C0009797] -year-old man epilepsy [MeSH:C0014544] -year history [MeSH:C0019664] insidious progressive [MeSH:C1449744] decline global [MeSH:C1456573] cognitive ability document [MeSH:C0009797] serial neuropsychological study repeat neuropsychological testing [MeSH:C0027902] week discontinuation drug [MeSH:C0013227] reveal dramatic improvement [MeSH:C2936612] iq memory naming [MeSH:C0025260] task commensurate recovery [MeSH:C0140116] intellectual capacity possible pathophysiological [MeSH:C0031847] mechanism [MeSH:C1524059] operative case include direct central nervous system [MeSH:C3714787] cns toxic effect valproic [MeSH:C0042291] [MeSH:C0042291] acid paradoxical [MeSH:C0037322] epileptogenic effect secondary drug [MeSH:C0013227] indirect cns toxic effect mediate valproic [MeSH:C0042291] [MeSH:C0042291] acid-induced hyperammonemia [MeSH:C0220994],neurological
synaptic story dementia [MeSH:C0497327] glutamate [MeSH:C0220839],prospective examine statin stroke cancer [MeSH:C0038454] patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include basal ganglion convulsion parkinsonism method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication need investigation [MeSH:C0035173] [MeSH:C0035173],neurological
cancer code lymphoma endometrial cancer [MeSH:C0476089],question [MeSH:C0600648] metformin [MeSH:C0025598] affect hypertension [MeSH:C0020538] radiotherapy [MeSH:C0034619] mechanism method cross-sectional diabetic [MeSH:C0010362] patient [MeSH:C0030705] assess immunotherapy carcinoma [MeSH:C0021083] result superior efficacy [MeSH:C5690761] implication need investigation [MeSH:C0035173],oncological
mind matter breast cancer [MeSH:C0006142] cerebrovascular [MeSH:C0007820],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect hypertension [MeSH:C0020538] basal ganglia [MeSH:C0004781] mechanism method observational [MeSH:C0302523] elderly patient assess guillain-barre syndrome [MeSH:C0018378] dementia [MeSH:C0497327] result improve disease management [MeSH:C0039798] implication cost-effectiveness [MeSH:C1511536] implication,neurological
effect [MeSH:C4277511] captopril [MeSH:C0006938] pre-existing [MeSH:C3542017] aminonucleoside-induced proteinuria spontaneously hypertensive rat [MeSH:C0003364],proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] effect [MeSH:C4277511] [MeSH:C4277511] captopril [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] hypertensive [MeSH:C0003364] patient [MeSH:C0030705] possibility reproduce renal abnormality [MeSH:C0037268] captopril [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] examine shr [MeSH:C0034705] oral administration [MeSH:C0001563] captopril [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] mg kg day [MeSH:C0011017] fail aggravate proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] pre-existing shr [MeSH:C0034705] captopril [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] fail potentiate facilitate development [MeSH:C0243107] massive proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] invoke puromycin [MeSH:C0034145] aminonucleoside shr [MeSH:C0034705] captopril [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] little demonstrable effect [MeSH:C4277511] [MeSH:C4277511] serum [MeSH:C0229671] electrolyte concentration excretion [MeSH:C1373187] urine sodium potassium [MeSH:C0032821] endogenous [MeSH:C0205752] creatinine clearance body weight [MeSH:C0005910] food water consumption [MeSH:C0009830] ketone body [MeSH:C0022631] consistently present urine lethality occur multiple dosing captopril [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] [MeSH:C0006938] shr [MeSH:C0034705],hepatorenal
epilepsy [MeSH:C0014544] defibrillator cardiac connection,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve diabete outcome vein pathway method longitudinal trial [MeSH:C0023981] adult population measure heart block insufficiency result improve disease management care [MeSH:C0039798] improvement [MeSH:C2936612],cardiovascular
metastasis pathway leukemia,hypothesis statin improve cancer outcome [MeSH:C0206277] pancreatic cancer pathway method [MeSH:C0346647] cross-sectional trial [MeSH:C0010362] adult [MeSH:C0001675] population [MeSH:C0032659] measuring nephritis hepatocellular result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] relevance [MeSH:C2826293],hepatorenal|oncological
stroke [MeSH:C0038454] hepatorenal lens,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke [MeSH:C0038454] outcome nephrolithiasis pathway method retrospective trial elderly patient measuring end stage renal disease [MeSH:C0022661] jaundice result improve disease management [MeSH:C0039798] therapeutic innovation [MeSH:C0087111],hepatorenal
structure-activity [MeSH:C0038477] dose-effect relationship [MeSH:C0021797] antagonism [MeSH:C0013159] picrotoxin-induced seizure cholecystokinin [MeSH:C0008328] fragment analogue cholecystokinin [MeSH:C0008328] mouse,intraperitoneal administration [MeSH:C0001554] cholecystokinin octapeptide sulphate ester [MeSH:C0037167] cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791] se nonsulphated cholecystokinin octapeptide cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0037167] ns enhance latency seizure [MeSH:C0036572] induce picrotoxin [MeSH:C0031890] mouse experiment n- c-terminal fragment reveal c-terminal tetrapeptide cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791]-- active centre cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791] octapeptide molecule analogue cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791] se cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791] ns dose range mumol kg caerulein [MeSH:C0006639] dose range mumol kg show bell-shaped dose-effect curve great maximum inhibition [MeSH:C0027790] cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791] ns peptide cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791]-- weak anticonvulsant activity [MeSH:C0003286] comparison octapeptide mumol kg large dose reference drug diazepam [MeSH:C0012010] [MeSH:C0012010] totally prevent picrotoxin [MeSH:C0031890]-induced seizure mortality [MeSH:C0026565] maximum effect peptide test [MeSH:C0030956] diazepam [MeSH:C0012010] [MeSH:C0012010] experiment analogue derivative cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791]-- demonstrate effectiveness [MeSH:C0010181] beta-alanyl derivative cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791]-- enhance equipotent cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791] se cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791]-- analogue ser so3h -ac-cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791] se thr so3h -ac-cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791] se hyp so3h -ac-cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791] se slightly active cck [MeSH:C0034791] [MeSH:C0034791] [MeSH:C0034791] se,neurological
vein marker parkinson disease [MeSH:C0030567],investigation [MeSH:C0035173] [MeSH:C0035173] examine effect [MeSH:C4277511] aspirin [MeSH:C0004057] diabete cardiac patient focus heart rate deep vein thrombosis [MeSH:C0149871] aspect disease total participant enrol cross-sectional result [MeSH:C0010362] demonstrate improvement [MeSH:C2936612] primary endpoint particular attention heart valve [MeSH:C0018826] finding suggest need investigation [MeSH:C0035173] [MeSH:C0035173],cardiovascular
embolism diabetes mellitus [MeSH:C0011849] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome cardiomyopathy pathway method prospective trial adult population measure coronary artery disease [MeSH:C1956346] bradycardia result improvement primary endpoint need investigation [MeSH:C0035173],cardiovascular
hepatic pattern parkinson disease [MeSH:C0030567] patient [MeSH:C0030705],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] hepatocellular method cancer [MeSH:C0345904] patient [MeSH:C0030705] undergo longitudinal creatinine huntington disease assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] need investigation [MeSH:C0035173],neurological|hepatorenal
dvt lung cancer [MeSH:C0242379] vascular [MeSH:C0221214] insight,diabete affect cardiac [MeSH:C0018810] patient [MeSH:C0030705] worldwide particularly involve endothelium tachycardia method conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine hypertrophic cardiomyopathy [MeSH:C0007194] parameter result favorable safety profile care improvement [MeSH:C2936612],cardiovascular
eeg [MeSH:C0013819] reveal ventricular tachycardia [MeSH:C0042514] secret,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation calcium channel blocker [MeSH:C0006684] dementia [MeSH:C0497327] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient stroke dysarthria [MeSH:C0013362] result improve disease management [MeSH:C0039798] ectopic beat [MeSH:C0033036] correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological|cardiovascular
encephalitis pathway epilepsy [MeSH:C0014544],longitudinal [MeSH:C0023981] examine metformin cancer elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include norepinephrine peripheral neuropathy [MeSH:C4721453] cerebral cortex method [MeSH:C0007776] participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication cost-effectiveness [MeSH:C1511536] implication,neurological
advanced endoscopy reveal cancer mechanism,design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient pulmonary valve capillary [MeSH:C0034086] result decrease mortality rate [MeSH:C0205848] mitral valve correlation [MeSH:C0026264] optimization [MeSH:C0376695],cardiovascular
tricuspid valve regurgitation [MeSH:C0040961] lithium carbonate [MeSH:C0085217] toxicity [MeSH:C0040539] newborn infant [MeSH:C0021289],newborn [MeSH:C0021289] massive tricuspid regurgitation atrial flutter [MeSH:C0040961] congestive heart failure high serum lithium [MeSH:C0023870] describe initially manifest tricuspid regurgitation atrial flutter [MeSH:C0040961] 1th describe cardiac disease [MeSH:C0018799] infant [MeSH:C0021270] expose lithium compound [MeSH:C0206486] trimester pregnancy [MeSH:C0032961] [MeSH:C0032982] sixty-three percent infant [MeSH:C0021270] tricuspid valve [MeSH:C0040960] involvement lithium carbonate factor [MeSH:C0085217] increase incidence [MeSH:C0021149] congenital heart disease [MeSH:C0018798] take early [MeSH:C3177188] pregnancy [MeSH:C0032961] cause neurologic depression cyanosis cardiac arrhythmia [MeSH:C0003811] consume prior delivery [MeSH:C0011212],neurological|cardiovascular|hepatorenal
polyuria pathway hypertension,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome [MeSH:C0206277] pkd pathway method cross-sectional trial cancer [MeSH:C0010362] patient measure cholangiocarcinoma [MeSH:C0206698] primary biliary cholangitis [MeSH:C0008312] result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
cardiomyopathy polycystic kidney disease [MeSH:C0022680] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve heart disease [MeSH:C0018799] outcome nephroblastoma pathway method observational trial cancer [MeSH:C0302523] patient measure chronic kidney disease [MeSH:C1561643] bilirubin [MeSH:C0005437] result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],hepatorenal
cardiomyopathy [MeSH:C0878544] proteinuria [MeSH:C0033687] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve cancer outcome peritoneal dialysis pathway method longitudinal trial [MeSH:C0023981] cardiac patient measure hepatorenal syndrome [MeSH:C0019212] hemodialysis [MeSH:C0019004] result improve disease management [MeSH:C0039798] practice guideline,hepatorenal
effect [MeSH:C4277511] nondopaminergic drug l-dopa-induce dyskinesia mptp-treated monkey,monkey [MeSH:C0026447] render parkinsonian [MeSH:C0242422] toxin [MeSH:C0242422] mptp treat chronically l-dopa [MeSH:C0023570] [MeSH:C0023570] benserazide [MeSH:C0005014] mg kg give orally daily month dose produce striking antiparkinsonian [MeSH:C0242422] effect animal [MeSH:C0003062] manifest dyskinesia [MeSH:C0013384] [MeSH:C0013384] series agent act primarily neurotransmitter [MeSH:C0027908] dopamine test combination l-dopa [MeSH:C0023570] [MeSH:C0023570] dyskinetic [MeSH:C0013384] [MeSH:C0013384] [MeSH:C0013384] movement [MeSH:C0026649] [MeSH:C0026649] modify drug [MeSH:C0013227] include clonidine [MeSH:C0009014] physostigmine [MeSH:C0031849] methysergide [MeSH:C0025842] -mdot propranolol [MeSH:C0033497] mk- markedly reduce dyskinetic [MeSH:C0013384] [MeSH:C0013384] [MeSH:C0013384] movement [MeSH:C0026649] [MeSH:C0026649] cost [MeSH:C0010186] return parkinsonian [MeSH:C0242422] symptomatology [MeSH:C0029167] yohimbine [MeSH:C0724441] meperidine [MeSH:C0025376] reduce predominantly dyskinetic [MeSH:C0013384] [MeSH:C0013384] [MeSH:C0013384] movement [MeSH:C0026649] [MeSH:C0026649] baclofen useful monkey [MeSH:C0026447] dystonic form dyskinesia [MeSH:C0013384] [MeSH:C0013384] atropine [MeSH:C0004259] convert dystonic movement [MeSH:C0026649] [MeSH:C0026649] chorea,neurological
meningitis [MeSH:C0025289] meet leukemia [MeSH:C0023418] neurological perspective,longitudinal [MeSH:C0023981] examine metformin [MeSH:C0025598] cancer cancer [MeSH:C0006826] patient [MeSH:C0030705] investigation [MeSH:C0035173] include neuron [MeSH:C0027882] encephalitis palsy [MeSH:C0014038] method participant [MeSH:C1708335] include result positive response implication healthcare advancement,neurological
anticoagulant lung cancer [MeSH:C0003280] brain [MeSH:C0006104] insight,hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve septum cortical method conduct prospective evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine myasthenia gravis [MeSH:C0026896] parameter result well quality life measure safety [MeSH:C0036043] consideration,neurological|cardiovascular
mind matter diabetes mellitus [MeSH:C0011849] cerebral infarction [MeSH:C0007785],design [MeSH:C0013171] prospective investigation ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] epinephrine astrocytoma [MeSH:C0014563] result improve disease management [MeSH:C0039798] glutamate [MeSH:C0220839] correlation [MeSH:C0010100] relevance [MeSH:C2826293],neurological
epilepsy [MeSH:C0014544] tricuspid valve [MeSH:C0040960] cardiac connection,dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve embolism [MeSH:C0013922] transient ischemic attack method conduct observational [MeSH:C0302523] evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine hypotension [MeSH:C0020649] parameter result improve disease management [MeSH:C0039798] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
dramatic drop blood pressure [MeSH:C0005823] follow prehospital gtn administration [MeSH:C0001554],male [MeSH:C0086582] sixty history [MeSH:C0019664] cardiac chest pain [MeSH:C0008031] awake ch pain follow afternoon sleep self medicate observation normal limit administer oxygen face mask glyceryl trinitrate gtn [MeSH:C0017887] minute gtn experience sudden drop blood pressure heart rate rectify atropine [MeSH:C0004259] sulphate fluid challenge deterioration [MeSH:C0234985] condition transport hospital document case like prehospital scientific literature cause appear bezold-jarish reflex stimulation ventricular wall turn decrease sympathetic outflow vasomotor centre prehospital care provider manage syncopal [MeSH:C0039070] episode [MeSH:C0085554] fail recover reasonable frame consider bezold-jarisch reflex cause manage accordingly,cardiovascular
coronary artery disease [MeSH:C1956346] meet leukemia [MeSH:C0023418] neurological perspective,hypothesis [MeSH:C3179072] aspirin improve diabete outcome meningioma pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure heart tachycardia [MeSH:C0039231] result positive response cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
pad marker valvular heart disease [MeSH:C0018824],hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve bundle branch block insufficiency method [MeSH:C0006384] conduct longitudinal [MeSH:C0023981] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine ventricular tachycardia [MeSH:C0042514] parameter result improve disease management [MeSH:C0039798] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
cortical connection hepatitis,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] autonomic neuropathy [MeSH:C0271686] method cardiac patient undergo prospective medulloblastoma myelopathy assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|oncological
glucose [MeSH:C0017725] -phosphate dehydrogenase [MeSH:C0030016] variant gd alexandra associate neonatal jaundice [MeSH:C0022353] gd camperdown young [MeSH:C0340037] man lamellar cataract [MeSH:C1861821],male [MeSH:C0086582] subject describe unusual presentation [MeSH:C0022869] hitherto undescribed g6pd variant italian extraction [MeSH:C0036716] suffer severe neonatal [MeSH:C0021709] [MeSH:C0021709] jaundice follow maternal [MeSH:C0024915] ingestion [MeSH:C0232478] fresh broad bean vicia fava [MeSH:C0330788] prenatally postnatally [MeSH:C0032782] expression [MeSH:C0017262] enzymatic defect severe neonatal [MeSH:C0021709] [MeSH:C0021709] period reteste adolescence biochemical [MeSH:C0017401] [MeSH:C0017401] characterization show unique feature justify designation new variant gd alexandra second boy maltese extraction [MeSH:C0036716] find bilateral lamellar cataract age [MeSH:C1861821] year identify g6pd deficient [MeSH:C2939465] survey [MeSH:C0038951] child [MeSH:C0008059] mediterranean [MeSH:C0025138] origin [MeSH:C0005495] unexplained cataract formation [MeSH:C0086543] approximately normal enzyme activity [MeSH:C0243102] unique combination biochemical [MeSH:C0017401] [MeSH:C0017401] characteristic lead designation gd camperdown association [MeSH:C0004083] coincidental prompt attention possibility certain circumstance g6pd deficiency [MeSH:C2939465] favor cataract formation [MeSH:C0086543] case illustrate characterization mutant enzyme unexpected laboratory [MeSH:C0022877] result obtain,neurological
bradycardia pathway [MeSH:C0428977] dementia [MeSH:C0497327],heart disease [MeSH:C0018799] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve pe atrioventricular block method [MeSH:C0004245] conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine atrial flutter [MeSH:C0004239] parameter result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],neurological|cardiovascular
endocrine screening [MeSH:C0220908] man erectile dysfunction [MeSH:C0242350] significance cost-effective strategy,review [MeSH:C0282443] result serum testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] determination [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] refer erectile dysfunction [MeSH:C0242350] [MeSH:C0242350] compare history [MeSH:C0019664] result physical examination [MeSH:C0031809] [MeSH:C0031809] [MeSH:C0031809] etiological investigation [MeSH:C0035173] effect endocrine therapy refine rule cost-effective [MeSH:C1511536] [MeSH:C5392218] [MeSH:C1511536] endocrine screening [MeSH:C0220908] pinpoint actual responsibility hormonal [MeSH:C0037433] abnormal [MeSH:C0853087] [MeSH:C0853087]ity material method testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] determine radioimmunoassay screen [MeSH:C0034580] testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] screen prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] basis [MeSH:C0033371] low sexual desire gynecomastia testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] ng ml determination [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] repeat case abnormal [MeSH:C0853087] [MeSH:C0853087] result prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] result compare previous personal cohort patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] erectile dysfunction [MeSH:C0242350] [MeSH:C0242350] systematic prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] determination [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] main criterion test efficiency [MeSH:C0013682] hormone [MeSH:C0019932] determination [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] low sexual desire small testis [MeSH:C0039597] gynecomastia endocrine therapy consist testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] heptylate human [MeSH:C0086418] chorionic gonadotropin hypogonadism [MeSH:C0271623] bromocriptine [MeSH:C0006230] hyperprolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371]emia result testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] ng ml patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] normal repeat determination [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] prevalence [MeSH:C0033105] [MeSH:C0033105] repeatedly low testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] increase age age [MeSH:C0024842] year year old pituitary tumor [MeSH:C0032019] [MeSH:C0032019] discover testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] determination [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] low testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] level [MeSH:C0018759] nonorganic hypothalamic dysfunction normal serum luteinizing hormone [MeSH:C0019932] prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] small role erectile dysfunction [MeSH:C0242350] [MeSH:C0242350] definite improvement [MeSH:C2936612] androgen therapy [MeSH:C0039798] [MeSH:C0039798] normal morning nocturnal erection definite vasculogenic [MeSH:C0243000] contribution determining testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] case low sexual desire abnormal [MeSH:C0853087] [MeSH:C0853087] physical examination [MeSH:C0031809] [MeSH:C0031809] [MeSH:C0031809] miss case low testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] include subsequently improve androgen therapy [MeSH:C0039798] [MeSH:C0039798] prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] exceed ng ml man normal repeat determination [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371]oma discover low find decade overall prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] great ng ml patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371]oma bromocriptine [MeSH:C0006230] definitely effective [MeSH:C5392218] case prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] great ng ml compare case prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] ng ml testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] low case prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] great ng ml conclusion low prevalence [MeSH:C0033105] [MeSH:C0033105] effect low testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] high prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] erectile dysfunction [MeSH:C0242350] [MeSH:C0242350] justify routine determination [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] [MeSH:C1148554] cost-effective [MeSH:C1511536] [MeSH:C5392218] [MeSH:C1511536] screening strategy [MeSH:C0220908] recommend far miss case improve endocrine therapy pituitary tumor [MeSH:C0032019] [MeSH:C0032019] advocate age year testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] determine case low sexual desire abnormal [MeSH:C0853087] [MeSH:C0853087] physical examination [MeSH:C0031809] [MeSH:C0031809] [MeSH:C0031809] measure man old year prolactin [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] [MeSH:C0033371] determine case low sexual desire gynecomastia testosterone [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] [MeSH:C0039601] ng ml,oncological
jaundice meet myocardial infarction [MeSH:C0027051] neurological perspective,stroke [MeSH:C0038454] affect elderly patient [MeSH:C0030705] worldwide particularly involve cholelithiasis [MeSH:C0008350] sciatica method [MeSH:C0036396] conduct longitudinal evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine hypothalamus [MeSH:C0020663] parameter result well quality life measure therapeutic innovation [MeSH:C0087111],neurological|hepatorenal
chronic carbamazepine [MeSH:C0006949] inhibit [MeSH:C0021463] development [MeSH:C0243107] local anesthetic seizure [MeSH:C0036572] kindle cocaine lidocaine [MeSH:C0023660],effect [MeSH:C4277511] [MeSH:C4277511] carbamazepine [MeSH:C0006949] cbz local anesthetic-kindled seizure lethality evaluate different stage [MeSH:C0029170] kindling process different method [MeSH:C0025663] cbz administrat [MeSH:C0034721]ion [MeSH:C0001554] chronic [MeSH:C0150055] oral cbz inhibit development [MeSH:C0243107] [MeSH:C0243107] lidocaine- cocaine-induced seizure little effect [MeSH:C4277511] [MeSH:C4277511] fully develop local anesthetic seizure [MeSH:C0036572] chronic [MeSH:C0150055] cbz decrease incidence [MeSH:C0021149] seizure-related mortality cocaine-injected rat [MeSH:C0034721] acute cbz range dose mg kg effect [MeSH:C4277511] [MeSH:C4277511] complete lidocaine-kindled acute cocaine-induced seizure repeat p injection cbz mg kg effect [MeSH:C4277511] [MeSH:C4277511] development [MeSH:C0243107] [MeSH:C0243107] lidocaine- cocaine-kindled seizure differential effect [MeSH:C4277511] [MeSH:C4277511] cbz depend stage [MeSH:C0029170] seizure development [MeSH:C0243107] [MeSH:C0243107] suggest distinct mechanism [MeSH:C1524059] underlie development [MeSH:C0243107] [MeSH:C0243107] versus maintenance [MeSH:C0024501] local anesthetic-kindled seizure effect [MeSH:C4277511] [MeSH:C4277511]iveness chronic [MeSH:C0150055] repeat intermittent injection cbz suggest different biochemical [MeSH:C0017401] consequence [MeSH:C0079160] different regimen [MeSH:C1880476] possible utility chronic [MeSH:C0150055] cbz prevent development [MeSH:C0243107] [MeSH:C0243107] toxic [MeSH:C1256754] effect [MeSH:C4277511] [MeSH:C4277511] human [MeSH:C0086418] cocaine user [MeSH:C0009170] suggest remain directly evaluate,neurological
stenosis [MeSH:C1261287] lung cancer [MeSH:C0242379] vascular [MeSH:C0221214] insight,hypothesis statin improve hypertension [MeSH:C0020538] outcome hypertensive pathway method observational trial [MeSH:C0302523] elderly patient measuring pad chemotherapy [MeSH:C0013216] result positive response need investigation [MeSH:C0035173],cardiovascular|oncological
stroke [MeSH:C0038454] radiotherapy exploring neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] bladder cancer [MeSH:C0005684] pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring cancer target therapy result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],neurological|oncological
dsmm xi dose definition intravenous cyclophosphamide [MeSH:C0010583] combination [MeSH:C0034865] bortezomib [MeSH:C1176309] dexamethasone remission [MeSH:C0035052] induction [MeSH:C0042767] patient [MeSH:C0030705] newly diagnose myeloma [MeSH:C0011900],trial initiate evaluate [MeSH:C0013175] recommend dose cyclophosphamide [MeSH:C0010583] combination [MeSH:C0034865] bortezomib [MeSH:C1176309] [MeSH:C1176309] dexamethasone [MeSH:C0011777] [MeSH:C0011777] induction [MeSH:C0042767] stem cell transplantation [MeSH:C1504389] young [MeSH:C0340037] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] newly diagnose [MeSH:C0011900] [MeSH:C0011900] multiple myeloma [MeSH:C0026764] mm thirty patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat -day cycle bortezomib [MeSH:C1176309] [MeSH:C1176309] mg day plus dexamethasone [MeSH:C0011777] [MeSH:C0011777] mg bortezomib [MeSH:C1176309] [MeSH:C1176309] injection plus cyclophosphamide [MeSH:C0010583] mg maximum tolerate dose cyclophosphamide [MeSH:C0010583] define mg dose patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] achieve partial response overall response rate complete response cr plus partial response pr dose level [MeSH:C0018759] cr rate experience progressive [MeSH:C1449744] disease [MeSH:C0012634] frequent adverse event [MeSH:C0041755] hematological [MeSH:C0018941] gastrointestinal toxicity neuropathy result suggest bortezomib [MeSH:C1176309] [MeSH:C1176309] combination [MeSH:C0034865] cyclophosphamide [MeSH:C0010583] mg dexamethasone [MeSH:C0011777] [MeSH:C0011777] effective induction [MeSH:C0042767] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] newly diagnose [MeSH:C0011900] [MeSH:C0011900] mm warrant investigation [MeSH:C0035173],neurological
safety [MeSH:C0036043] lidocaine [MeSH:C0023660] patient [MeSH:C0030705] cocaine-associated myocardial infarction [MeSH:C0027051],evaluate safety [MeSH:C0036043] lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] setting [MeSH:C0023660] [MeSH:C0023660] cocaine [MeSH:C0009170]-induced myocardial infarction [MeSH:C0027051] mi design retrospective [MeSH:C0035363] multicenter set twenty-nine university university-affiliated community hospital [MeSH:C0041740] -year period [MeSH:C0080129] total cumulative hospital-year participant patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine [MeSH:C0009170]-associated mi receive lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] emergency [MeSH:C2745965] department result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] setting [MeSH:C0023660] [MeSH:C0023660] cocaine [MeSH:C0009170]-associated mi die exhibit bradydysrhythmia ventricular tachycardia [MeSH:C0042514] ventricular fibrillation [MeSH:C0042510] experienced seizure [MeSH:C0036572] administration [MeSH:C0001554] lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] confidence interval [MeSH:C0009667] despite theoretical concern lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] enhance cocaine [MeSH:C0009170] toxicity [MeSH:C0040539] [MeSH:C0040539] use lidocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine [MeSH:C0009170]-associated mi associate cardiovascular [MeSH:C0007220] central nervous system toxicity [MeSH:C0040539] [MeSH:C0040539],neurological|cardiovascular
mind matter atrial fibrillation [MeSH:C0004238] hippocampal,question statin affect dementia [MeSH:C0497327] synapse [MeSH:C0039062] mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess glutamate autonomic neuropathy [MeSH:C0271686] result decrease mortality rate [MeSH:C0205848] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
source pain [MeSH:C0011001] primitive dysfunction migraine [MeSH:C0031847] identical site,common migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive side frontotemporal application nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] placebo [MeSH:C0032041] [MeSH:C0032041] ointment [MeSH:C0028912] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] double blind early onset [MeSH:C0031106] migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] attack [MeSH:C0086769] [MeSH:C0086769] induce nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] seven patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] versus placebo [MeSH:C0032041] [MeSH:C0032041] subsequently migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop early onset [MeSH:C0031106] attack [MeSH:C0086769] [MeSH:C0086769] frontotemporal nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] receive drug second induction test body area [MeSH:C0005902] early onset [MeSH:C0031106] migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] observe migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931]-inducing effect nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] depend direct stimulation [MeSH:C0031734] habitual site pain [MeSH:C0030193] suggest frontotemporal region [MeSH:C0039485] crucial importance development [MeSH:C0243107] migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] crisis consistent cns origin migraine [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] [MeSH:C0149931] attack [MeSH:C0086769] [MeSH:C0086769],neurological
stroke [MeSH:C0038454] primary sclerosing cholangitis [MeSH:C0566602] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect hypertension [MeSH:C0020538] gfr mechanism method retrospective diabetic patient [MeSH:C0030705] assess esrd hemodialysis [MeSH:C0019004] result decrease mortality rate [MeSH:C0205848] implication practice guideline,hepatorenal
diastolic marker coronary artery disease [MeSH:C1956346],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] endothelium pathway method randomized control trial [MeSH:C1096777] elderly patient measure restrictive cardiomyopathy [MeSH:C0007196] ventricular fibrillation [MeSH:C0042510] result positive response care improvement [MeSH:C2936612],cardiovascular
phase [MeSH:C0080129] --tetrahydropyranyladriamycin pharmacology [MeSH:C0031330] pharmacokinetic [MeSH:C0031327],phase intravenous [MeSH:C0085297] iv bolus --tetrahydropyranyladriamycin pirarubicin [MeSH:C0071126] [MeSH:C0071126] [MeSH:C0071126] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] good performance status refractory tumor [MeSH:C0030200] twenty-six minimal prior therapy [MeSH:C0039798] [MeSH:C0039798] good risk extensive prior therapy [MeSH:C0039798] [MeSH:C0039798] poor risk renal hepatic dysfunction [MeSH:C0031847] total course dose mg m2 evaluable maximum tolerate dose good-risk patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mg m2 poor-risk patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mg m2 dose-limiting toxic effect transient noncumulative granulocytopenia [MeSH:C0001824] granulocyte nadir range frequent toxic effect include thrombocytopenia [MeSH:C0040034] anemia [MeSH:C0002871] nausea [MeSH:C0027497] mild alopecia phlebitis [MeSH:C0031542] mucositis [MeSH:C0333355] myelosuppression [MeSH:C1956351] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hepatic dysfunction [MeSH:C0031847] pharmacokinetic analysis [MeSH:C4084975] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] reveal pirarubicin [MeSH:C0071126] [MeSH:C0071126] [MeSH:C0071126] plasma [MeSH:C0032105] alpha [MeSH:C0032105] se minute beta minute gamma hour area curve [MeSH:C0376690] ng ml x hour volume [MeSH:C5690805] distribution [MeSH:C1704711] vd l m2 total clearance clt l hour m2 adriamycinol [MeSH:C0050885] doxorubicin [MeSH:C0013089] [MeSH:C0013089] adriamycinone [MeSH:C0101720] tetrahydropyranyladriamycinol [MeSH:C0050885] metabolite [MeSH:C0003376] detect plasma [MeSH:C0032105] doxorubicin [MeSH:C0013089] [MeSH:C0013089] equal total metabolite [MeSH:C0003376] urinary excretion [MeSH:C1859518] pirarubicin [MeSH:C0071126] [MeSH:C0071126] [MeSH:C0071126] hour equal activity [MeSH:C0020115] note mesothelioma [MeSH:C0025500] leiomyosarcoma [MeSH:C0023269] basal cell carcinoma [MeSH:C4721806] recommended start dose phase ii trial mg m2 iv bolus week,hepatorenal|oncological
cholinergic [MeSH:C0242893] toxicity [MeSH:C0040539] result ocular instillation echothiophate iodide [MeSH:C0013530] eye drop [MeSH:C0015399],develop severe cholinergic syndrome [MeSH:C0151500] use echothiophate iodide [MeSH:C0013530] ophthalmic [MeSH:C0014236] drop present profound muscle weakness [MeSH:C0151786] initially give diagnosis myasthenia gravis red blood cell [MeSH:C0014792] serum cholinesterase [MeSH:C0008429] level severely depressed symptom resolve spontaneously [MeSH:C0034705] follow discontinuation eye drop,neurological
cirrhosis [MeSH:C1623038] meet lung cancer [MeSH:C0242379] neurological perspective,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient [MeSH:C0030705] cognitive impairment [MeSH:C0338656] brain abscess [MeSH:C0006105] result improve outcome [MeSH:C0206277] gray matter [MeSH:C0018220] correlation [MeSH:C0010100] need investigation [MeSH:C0035173],neurological|hepatorenal
dementia [MeSH:C0497327] detox dynamic [MeSH:C0058836],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve diabete outcome [MeSH:C0206277] hepatoma pathway method randomized control trial [MeSH:C1096777] elderly patient measuring end stage renal disease [MeSH:C0022661] renal result favorable safety [MeSH:C0036043] profile healthcare advancement,hepatorenal
predictor decrease renal function [MeSH:C0031843] patient [MeSH:C0030705] heart failure [MeSH:C0018801] angiotensin-converting enzyme inhibitor therapy [MeSH:C0003015] result study leave ventricular dysfunction [MeSH:C0242973] solvd,angiotensin-converting enzyme inhibitor therapy [MeSH:C0039798] [MeSH:C0003015] [MeSH:C0003015] reduce mortality rate [MeSH:C0205848] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] congestive heart failure [MeSH:C0018802] chf cause decrease renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] little information [MeSH:C5544371] available predict patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] high risk [MeSH:C0035647] complication quantify specific predictor reduction renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chf prescribe angiotensin-converting enzyme inhibitor therapy [MeSH:C0039798] [MeSH:C0003015] [MeSH:C0003015] analyze study [MeSH:C0085973] leave ventricular dysfunction [MeSH:C0242973] solvd randomized double-blind placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041]-controlled trial enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] chf [MeSH:C0014025] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] randomly assign enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] median follow-up [MeSH:C3899107] [MeSH:C3899107] day [MeSH:C0011017] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] randomly assign placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] mean follow-up [MeSH:C3899107] [MeSH:C3899107] day [MeSH:C0011017] decrease renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] define rise serum creatinine [MeSH:C0010294] mg dl micromol l time-to-event identify potential [MeSH:C0001272] predictor decrease renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] include age ejection fraction creatinine low systolic blood pressure [MeSH:C0005823] mm hg history hypertension diabete use antiplatelet diuretic beta-blocker therapy [MeSH:C0039798] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] randomly assign enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] great likelihood decrease renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] control p multivariate [MeSH:C0026777] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] group [MeSH:C0018257] old age diuretic therapy [MeSH:C0039798] diabete associate decrease renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] beta-blocker therapy [MeSH:C0039798] high ejection fraction [MeSH:C0042508] [MeSH:C0042508] renoprotective old age associate great risk [MeSH:C0035647] [MeSH:C0035647] develop decrease renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] group [MeSH:C0018257] significantly enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] risk [MeSH:C0035647] ratio rr year confidence interval [MeSH:C0009667] ci enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] rr ci diuretic therapy [MeSH:C0039798] likewise associate great risk [MeSH:C0035647] [MeSH:C0035647] decrease renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] rr ci placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] rr ci conversely enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] relative renoprotective effect rr ci compare placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] rr ci patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] diabete low risk [MeSH:C0035647] renal impairment see group [MeSH:C0018257] beta-blocker therapy [MeSH:C0039798] rr ci high ejection fraction [MeSH:C0042508] [MeSH:C0042508] rr increment ci conclusion enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] use cause increase risk [MeSH:C0035647] decrease renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chf diuretic use advanced age increase risk [MeSH:C0035647] diabete associate increase risk [MeSH:C0035647] renal impairment patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chf risk [MeSH:C0035647] [MeSH:C0035647] reduce enalapril [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] [MeSH:C0014025] compare placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] beta-blocker therapy [MeSH:C0039798] high ejection fraction [MeSH:C0042508] [MeSH:C0042508] renoprotective patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] regardless therapy [MeSH:C0039798],cardiovascular|hepatorenal
schwannoma pattern breast cancer patient [MeSH:C0030705],hypothesis statin improve diabete outcome chorea pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient measure convulsion astrocytoma result decrease mortality rate [MeSH:C0205848] therapeutic [MeSH:C0087111] innovation,neurological
effect [MeSH:C4277511] training [MeSH:C2673163] extent experimental [MeSH:C0016998] myocardial infarction [MeSH:C0027051] aging [MeSH:C0001811] rat [MeSH:C0034721],effect [MeSH:C4277511] exercise [MeSH:C0015259] severity isoproterenol-induced myocardial infarct [MeSH:C0021308]ion study [MeSH:C0085973] female [MeSH:C0086287] albino rat [MeSH:C0034721] [MeSH:C0034721] week age [MeSH:C0024842] rat [MeSH:C0034721] [MeSH:C0034721] train swim specific durat [MeSH:C0034721] [MeSH:C0034721]ion particular period [MeSH:C0080129] occurrence infarct [MeSH:C0021308] confirm histological method elevation serum [MeSH:C0229671] get gpt maximum sedentary-isoproterenol minimum exercise [MeSH:C0015259]-control change serum [MeSH:C0229671] transaminase associate corresponding depletion [MeSH:C3494379] cardiac [MeSH:C0018810] get gpt age [MeSH:C0024842] see interfere response [MeSH:C0034746] exhibit young old rat [MeSH:C0034721] [MeSH:C0034721] study [MeSH:C0085973] deal myocardial infarct [MeSH:C0021308]ion informative deal age [MeSH:C0024842],cardiovascular|hepatorenal
choreoathetoid movement [MeSH:C0026649] associate [MeSH:C0004083] rapid adjustment methadone [MeSH:C0025605],choreatiform hyperkinesia [MeSH:C3887506] know occasional movement [MeSH:C0026649] [MeSH:C0026649] abnormality [MeSH:C0037268] [MeSH:C0037268] intoxication cocaine opiate case report euphoria choreoathetoid movement [MeSH:C0026649] [MeSH:C0026649] transiently induce rapid adjustment selective mu-opioid receptor agonist [MeSH:C0162816] methadone inpatient [MeSH:C0021562] previously abuse heroine cocaine [MeSH:C0009170] addition minor eeg [MeSH:C0013819] abnormality [MeSH:C0037268] [MeSH:C0037268] occur possible underlying neurobiological phenomenon [MeSH:C0025950] discuss,neurological
determination [MeSH:C1148554] x-linked adrenoleukodystrophy mutation [MeSH:C0162309] include previously describe,x-linked adrenoleukodystrophy x-ald [MeSH:C0162309] frequent [MeSH:C0017270] peroxisomal disease [MeSH:C0282528] mainly involve nervous system white [MeSH:C0027763] matter adrenal cortex [MeSH:C0001613] testis [MeSH:C0039597] distinct phenotype [MeSH:C0031437] know principal biochemical [MeSH:C0017401] abnormality accumulation [MeSH:C0311432] saturated very-long-chain fatty acid vlcfas c2 mainly c2 impaired capacity [MeSH:C0042834] beta-oxidation peroxisome diagnosis [MeSH:C0011900] usually base vlcfa level [MeSH:C0018759] plasma culture [MeSH:C0010453] skin [MeSH:C1123023] fibroblast patient carrier affect male [MeSH:C0086582] plasma c2 borderline normal obligate female [MeSH:C0086582] carrier normal result effective mutation [MeSH:C0026882] [MeSH:C0026882] detection family fundamental unambiguously determine genetic status individual risk [MeSH:C0035647] particular concern female [MeSH:C0086582] member kindred segregate [MeSH:C0007616] x-ald mutation [MeSH:C0026882] [MeSH:C0026882] normal vlcfa level [MeSH:C0018759] guarantee lack carrier status [MeSH:C0560175] describe fast detection x-ald mutation [MeSH:C0026882] [MeSH:C0026882] base sscp nested pcr fragment follow sequence-determination reaction methodology find x-ald mutation [MeSH:C0026882] [MeSH:C0026882] kindred include previously report,neurological|hepatorenal
anti-epileptic drugs-induced de novo absence seizure [MeSH:C0036572],author present patient [MeSH:C0030705] [MeSH:C0030705] de novo absence [MeSH:C0270823] epilepsy [MeSH:C0014544] [MeSH:C0014544] [MeSH:C0014544] [MeSH:C0014544] administration carbamazepine [MeSH:C0006949] vigabatrin [MeSH:C0048044] despite underlie disease prognosis [MeSH:C0033325] drug [MeSH:C0013227] [MeSH:C0013227]-induced de novo absence [MeSH:C0270823] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] good subside rapidly discontinue use offend drug [MeSH:C0013227] [MeSH:C0013227] gamma-aminobutyric acid-transmitted thalamocortical circuitry account major underlie neurophysiology [MeSH:C0027901] absence [MeSH:C0270823] epilepsy [MeSH:C0014544] [MeSH:C0014544] [MeSH:C0014544] [MeSH:C0014544] drug [MeSH:C0013227] [MeSH:C0013227]-induced de novo absence [MeSH:C0270823] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] rare pro-absence [MeSH:C0270823] drug [MeSH:C0013227] [MeSH:C0013227] consider promote factor [MeSH:C0033453] underlie epileptogenecity patient [MeSH:C0030705] [MeSH:C0030705] synergistic effect accompany drug [MeSH:C0013227] [MeSH:C0013227] require trigger de novo absence [MeSH:C0270823] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] possibility drug [MeSH:C0013227] [MeSH:C0013227]-induced aggravation consider unexpected increase seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] frequency [MeSH:C0376249] new seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] type appear follow drug [MeSH:C0013227] [MeSH:C0013227] understand underlie mechanism [MeSH:C1524059] absence [MeSH:C0270823] epilepsy [MeSH:C0014544] [MeSH:C0014544] [MeSH:C0014544] [MeSH:C0014544] avoid inappropriate use anticonvulsant [MeSH:C0003286] child epilepsy [MeSH:C0014544] [MeSH:C0014544] [MeSH:C0014544] [MeSH:C0014544] prevent [MeSH:C0000918] drug [MeSH:C0013227] [MeSH:C0013227]-induced absence [MeSH:C0270823] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572],neurological
nitrate [MeSH:C0028125] stroke [MeSH:C0038454] brain [MeSH:C0006104] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer brain abscess method [MeSH:C0006105] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo cross-sectional brain [MeSH:C0010362] cortical assessment result positive response therapeutic innovation [MeSH:C0087111],neurological
peripheral neuropathy [MeSH:C4721453] meet stroke [MeSH:C0038454] neurological perspective,cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve brain abscess [MeSH:C0006105] deep vein thrombosis [MeSH:C0149871] method conduct retrospective [MeSH:C0035363] evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine endocardium [MeSH:C0014124] parameter result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],neurological|cardiovascular
prostate cancer [MeSH:C0376358] cardiovascular lens [MeSH:C0007220],prospective examine statin heart disease [MeSH:C0018799] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include dilate cardiomyopathy [MeSH:C0007193] venous systolic method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication safety [MeSH:C0036043] consideration,cardiovascular
neuron [MeSH:C0027882] pattern [MeSH:C3849996] angina pectoris [MeSH:C0002962] patient [MeSH:C0030705],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer guillain-barre syndrome method [MeSH:C0018378] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] cerebral cortex [MeSH:C0007776] parkinson disease [MeSH:C0030567] assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] safety consideration,neurological
cognitive impairment [MeSH:C0338656] connection hypertension [MeSH:C0020538],question [MeSH:C0600648] ace inhibitor affect cancer brain abscess [MeSH:C0006105] mechanism method randomized control cancer [MeSH:C1096777] patient [MeSH:C0030705] assess memory loss encephalopathy [MeSH:C0085584] result improve outcome [MeSH:C0206277] implication optimization [MeSH:C0376695],neurological
longitudinal assessment air [MeSH:C0001861] conduction audiogram phase iii trial difluoromethylornithine [MeSH:C0002260] sulindac prevention sporadic colorectal adenoma [MeSH:C0009402],phase [MeSH:C0080129] iii trial assess recurrence [MeSH:C2825055] adenomatous polyp [MeSH:C0206677] month difluoromethylornithine dfmo [MeSH:C0002260] plus sulindac [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] match placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] temporary hearing loss [MeSH:C1384666] known toxicity [MeSH:C0040539] dfmo comprehensive [MeSH:C0009585] approach develop analyze serial air [MeSH:C0001861] conduction audiogram generalize estimate equation estimate mean difference arm regard air [MeSH:C0001861] conduction pure tone threshold [MeSH:C0162703] [MeSH:C0162703] account within-subject correlation repeat measurement [MeSH:C0030198] frequency [MeSH:C0376249] base subject [MeSH:C0080105] average difference db subject treat dfmo plus sulindac [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] compare treat placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] confidence interval [MeSH:C0009667] db p adjust value age frequency [MeSH:C0376249] normal speech range hz estimate difference db db p detect dose intensity add information model dfmo plus sulindac [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] experience db hearing reduction consecutive frequency [MeSH:C0376249] entire range test p follow-up [MeSH:C3899107] air [MeSH:C0001861] conduction month end show adjusted mean difference hearing threshold [MeSH:C0162703] [MeSH:C0162703] db db p arm difference proportion subject [MeSH:C0080105] dfmo plus sulindac [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] experience clinically hearing loss [MeSH:C1384666] compare placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] estimate attributable risk [MeSH:C0035647] ototoxicity [MeSH:C0235280] [MeSH:C0040539] exposure [MeSH:C1390376] drug confidence interval [MeSH:C0009667] [MeSH:C0009667] p db difference mean threshold [MeSH:C0162703] [MeSH:C0162703] patient treat [MeSH:C0030705] dfmo plus sulindac [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] [MeSH:C0038792] compare treat placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041],neurological
management strategy ribavirin-induced hemolytic anemia hepatitis c economic [MeSH:C0205749] implication,objective recently publish study [MeSH:C0085973] demonstrate increase efficacy [MeSH:C5690761] cost [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186]-effectiveness [MeSH:C1511536] combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] interferon alpha-2b [MeSH:C2937361] ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] compare interferon-alpha monotherapy [MeSH:C0002199] chronic hepatitis c [MeSH:C0524910] chc combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] associate clinically important adverse effect [MeSH:C0001688] [MeSH:C0001688] ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525]-induced hemolytic anemia riha evaluate direct health-care [MeSH:C0086388] cost [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] management riha chc trial set method systematic literature review conduct synthesize information [MeSH:C5544371] incidence [MeSH:C0021149] management riha decision-analytic technique estimate cost [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] treat riha uncertainty [MeSH:C0087130] evaluate sensitivity analysis result riha define reduction [MeSH:C1827449] hemoglobin g [MeSH:C0019046] l occur approximately patient [MeSH:C0030705] treat combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] standard care management [MeSH:C0030677] riha reduction [MeSH:C1827449] discontinuation ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] dosage estimate direct cost [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] treat clinically riha receive combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] -week course [MeSH:C0449259] range result one-way sensitivity analysis range comparison cost [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] week combination therapy [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] [MeSH:C0013218] conclusion direct cost [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] treat clinically riha drug cost [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] question remain optimal dose ribavirin [MeSH:C0035525] [MeSH:C0035525] [MeSH:C0035525] incidence [MeSH:C0021149] riha real-world population despite uncertainty initial direct cost [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] treating riha provide estimate cost [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] [MeSH:C0010186] management implication clinically important adverse effect [MeSH:C0001688] [MeSH:C0001688],hepatorenal
septum epilepsy vascular insight,hypothesis statin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] dilate cardiomyopathy pathway method [MeSH:C0007193] observational trial [MeSH:C0302523] cardiac patient measure blood pressure hypertension [MeSH:C0005823] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
familial mediterranean [MeSH:C0031069] fever [MeSH:C0015967] colchicine [MeSH:C0009262] era fate family [MeSH:C0015576],order demonstrate effect prophylactic colchicine [MeSH:C0009262] [MeSH:C0009262] natural history [MeSH:C0175860] familial mediterranean fever [MeSH:C0031069] fmf family present sibling [MeSH:C0037047] affect fmf represent different stage amyloidotic kidney disease [MeSH:C0022661] fmf effect continuous [MeSH:C3649547] colchicine [MeSH:C0009262] [MeSH:C0009262] course [MeSH:C0449259] consider member [MeSH:C0086282] family present complete genetic [MeSH:C0017380] behavioral picture disease,hepatorenal
topotecan [MeSH:C0146224] combination radiotherapy [MeSH:C0034619] unresectable glioblastoma phase [MeSH:C0017636],improve glioblastoma multiforme [MeSH:C1621958] gbm radio-chemotherapy [MeSH:C0436307] remain challenge topotecan [MeSH:C0146224] [MeSH:C0146224] [MeSH:C0146224] attractive option exhibit growth inhibition [MeSH:C0018282] human [MeSH:C0086418] glioma brain penetration present assess combination radiotherapy [MeSH:C0034619] [MeSH:C0034619] gy fraction day [MeSH:C0011017] topotecan [MeSH:C0146224] [MeSH:C0146224] [MeSH:C0146224] mg day [MeSH:C0011017] week adult [MeSH:C0001675] histologically prove untreated gbm incidence [MeSH:C0021149] non-hematological [MeSH:C0018941] toxicity [MeSH:C0040539] [MeSH:C0040539] low grade hematological [MeSH:C0018941] toxicity [MeSH:C0040539] [MeSH:C0040539] report patient [MeSH:C0030705] [MeSH:C0030705] mainly lymphopenia [MeSH:C0024312] neutropenia partial response stabilization [MeSH:C0017325] rate respectively overall progression [MeSH:C0242656] week one-year overall survival [MeSH:C0038952] [MeSH:C0038952] os rate median os week topotecan [MeSH:C0146224] [MeSH:C0146224] [MeSH:C0146224] combination radiotherapy [MeSH:C0034619] [MeSH:C0034619] tolerate response stabilization [MeSH:C0017325] concerned one-third patient [MeSH:C0030705] [MeSH:C0030705] increase benefit [MeSH:C0021674] term survival [MeSH:C0038952] patient [MeSH:C0030705] [MeSH:C0030705] unresectable gbm,neurological
myotonic dystrophy transgenic mouse [MeSH:C0027126] express expand cug repeat,myotonic dystrophy dm common [MeSH:C0027126] form muscular dystrophy [MeSH:C0026850] adult [MeSH:C0001675] human [MeSH:C0086418] result expansion [MeSH:C0196940] ctg repeat untranslated region dmpk gene mutant [MeSH:C1564139] dmpk messenger rna mrna [MeSH:C0035696] contain expand cug repeat retain nucleus express untranslated cug [MeSH:C0887909] repeat unrelated mrna transgenic mouse [MeSH:C0026809] mouse [MeSH:C0026809] [MeSH:C0025936] express expand cug repeat develop myotonia myopathy [MeSH:C0553604] mouse [MeSH:C0026809] express nonexpanded repeat transcript expand cug repeat sufficient generate dm phenotype [MeSH:C0031437] support role rna gain function disease pathogenesis [MeSH:C0699748],neurological
diuretic [MeSH:C0012798] dementia [MeSH:C0497327] brain [MeSH:C0006104] insight,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation beta-blocker heart disease participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] cortical palsy [MeSH:C0522224] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] gaba correlation safety consideration,neurological
cancer cellular multiple sclerosis [MeSH:C0026769],heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve carcinogen head neck cancer method conduct randomized control evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine bone cancer [MeSH:C0279530] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] therapeutic innovation [MeSH:C0087111],oncological
diuretic peripheral artery disease [MeSH:C1704436] brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] aspirin improve cancer outcome [MeSH:C0206277] neurofibroma pathway method prospective trial cancer patient [MeSH:C0030705] measuring paralysis [MeSH:C0522224] cerebral result improve disease management [MeSH:C0039798] need investigation [MeSH:C0035173],neurological
sex [MeSH:C1522384] difference nmda antagonist enhancement morphine [MeSH:C0026549] antihyperalgesia [MeSH:C0020429] capsaicin [MeSH:C0006931] model [MeSH:C0011381] persistent pain comparison model [MeSH:C0011381] acute pain,acute pain model [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] n-methyl-d-aspartate nmda antagonist enhance antinociceptive effect morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] great extent male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] investigation [MeSH:C0035173] extend finding persistent pain model distinguish acute pain model [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] basis nociceptive fiber [MeSH:C3178766] activate neurochemical substrate duration nociceptive stimulus end persistent hyperalgesia induce administration [MeSH:C0001554] capsaicin [MeSH:C0006931] tail [MeSH:C0039259] [MeSH:C0039259] gonadally intact f3 rat follow tail [MeSH:C0039259] [MeSH:C0039259] immerse mildly noxious thermal stimulus tail [MeSH:C0039259] [MeSH:C0039259]-withdrawal latency measure comparison test conduct acute pain model [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] hotplate warm water tail [MeSH:C0039259] [MeSH:C0039259]-withdrawal procedure male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] non-competitive nmda antagonist dextromethorphan [MeSH:C0011816] [MeSH:C0011816] enhance antihyperalgesic effect low moderate dose morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] dose-and time-dependent manner dose pretreatment time [MeSH:C3494202] examine enhancement [MeSH:C0376317] observe female [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] enhancement [MeSH:C0376317] morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] antinociception [MeSH:C0234194] dextromethorphan [MeSH:C0011816] [MeSH:C0011816] see male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] female [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] acute pain model [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] magnitude effect great male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] finding demonstrate sexually-dimorphic interaction nmda antagonist morphine [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] [MeSH:C0026549] persistent pain model distinguish observe acute pain model [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567] [MeSH:C0184567],neurological
reversible [MeSH:C5691430] myocardial hypertrophy [MeSH:C1383860] induce tacrolimus [MeSH:C0085149] pediatric heart transplant [MeSH:C0018823] recipient case report [MeSH:C0684224],tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] potent immunosuppressant [MeSH:C0021081] frequently organ transplantation [MeSH:C0029216] adverse effect [MeSH:C0001688] include cardiac [MeSH:C0018810] [MeSH:C0018810] toxicity [MeSH:C0040539] describe transient myocardial hypertrophy [MeSH:C1383860] [MeSH:C1383860] [MeSH:C1383860] induce tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] heart transplantation hypertrophy cause symptom [MeSH:C3839861] note elevation plasma brain natriuretic peptide [MeSH:C0054015] concentration [MeSH:C0311432] [MeSH:C0311432] confirm echocardiography [MeSH:C0013516] [MeSH:C0013516] initially allograft rejection [MeSH:C0018129] fear [MeSH:C0015726] myocardial biopsy sample reveal interstitial edema mild myocardial hypertrophy [MeSH:C1383860] [MeSH:C1383860] [MeSH:C1383860] cellular humoral rejection detect blood tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] concentration [MeSH:C0311432] [MeSH:C0311432] high usual tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] dosage reduce myocardial hypertrophy [MeSH:C1383860] [MeSH:C1383860] [MeSH:C1383860] completely resolve reduce target [MeSH:C0039309] concentration [MeSH:C0311432] [MeSH:C0311432] tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] recur confirm echocardiography [MeSH:C0013516] [MeSH:C0013516] myocardial biopsy conclude tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] induce reversible myocardial hypertrophy [MeSH:C1383860] [MeSH:C1383860] [MeSH:C1383860] patient [MeSH:C0030705] receive tacrolimus [MeSH:C0085149] [MeSH:C0085149] [MeSH:C0085149] therapy blood concentration [MeSH:C0684262] [MeSH:C0311432] [MeSH:C0311432] carefully control extreme attention pay cardiac [MeSH:C0018810] [MeSH:C0018810] involvement,neurological|cardiovascular
mutation [MeSH:C0026882] associate lamivudine-resistance therapy-na hepatitis b virus hbv infected patient [MeSH:C0030705] [MeSH:C0030705] hiv co-infection implication antiretroviral therapy [MeSH:C5545321] hbv hiv co-infecte south african [MeSH:C0037712] patient [MeSH:C0030705] [MeSH:C0030705],exploratory investigate lamivudine-resistant [MeSH:C2986418] hepatitis b virus hbv [MeSH:C0062529] [MeSH:C0062529] strain [MeSH:C0080194] select lamivudine-na hbv [MeSH:C0062529] [MeSH:C0062529] [MeSH:C0209738] carrier human immunodeficiency virus hiv co-infection south [MeSH:C0275524] african [MeSH:C5690837] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] thirty-five lamivudine-na hbv [MeSH:C0062529] [MeSH:C0062529] [MeSH:C0209738] infected patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hiv co-infection study chronic hbv [MeSH:C0062529] [MeSH:C0062529] mono-infected patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hbv [MeSH:C0062529] [MeSH:C0062529]-hiv co-infecte [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sub-divide occult hbv [MeSH:C0062529] [MeSH:C0062529] hbsag-negative overt hbv [MeSH:C0062529] [MeSH:C0062529] hbsag- positive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hbsag anti-hbs anti-hbc anti-hiv determine routine diagnosis [MeSH:C0011900] axsym assay [MeSH:C0243073] abbott laboratory north chicago il serum sample pcr amplify hbv [MeSH:C0062529] [MeSH:C0062529] reverse transcriptase rt primer follow direct sequencing [MeSH:C0751971] tyrosine-methionine-aspartate-aspartate ymdd motif major catalytic region c domain hbv [MeSH:C0062529] [MeSH:C0062529] rt enzyme hbv [MeSH:C0062529] [MeSH:C0062529] viral load [MeSH:C0376705] perform amplicor hbv [MeSH:C0062529] [MeSH:C0062529] monitor test v2 roche diagnostic penzberg germany hbv [MeSH:C0062529] [MeSH:C0062529] lamivudine-resistant [MeSH:C2986418] strain [MeSH:C0080194] detect mono-infected chronic hepatitis b [MeSH:C0524909] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hbv [MeSH:C0062529] [MeSH:C0062529]-hiv co-infecte [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] good knowledge constitute report hbv [MeSH:C0062529] [MeSH:C0062529] lamivudine-resistant [MeSH:C2986418] strain [MeSH:C0080194] therapy-na hbv [MeSH:C0062529] [MeSH:C0062529]-hiv co-infecte [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hbv [MeSH:C0062529] [MeSH:C0062529] viral load [MeSH:C0376705] mono-infected co-infecte [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] range x x x copy ml respectively remain see pre-existing antiviral mutation [MeSH:C0003451] widespread emergence hbv [MeSH:C0062529] [MeSH:C0062529] resistant [MeSH:C2986418] strain [MeSH:C0080194] lamivudine-containing [MeSH:C0209738] highly active [MeSH:C0205681] antiretroviral [MeSH:C0599685] arv haart regimen widely apply south africa [MeSH:C0037712] likely potential implication management [MeSH:C0085971] hbv [MeSH:C0062529] [MeSH:C0062529]-hiv co-infecte [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] [MeSH:C0275524] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],hepatorenal
myotonic dystrophy [MeSH:C0027126] evidence [MeSH:C5575834] possible dominant-negative rna mutation,trinucleotide [MeSH:C0028630] expansion [MeSH:C0196940] [MeSH:C0196940] mutation [MeSH:C0026882] [MeSH:C0026882] cause myotonic dystrophy [MeSH:C0027126] [MeSH:C0027126] untranslated region protein kinase [MeSH:C0216045] gene molecular mechanism expand repeat cause clinically variable multisystemic disease [MeSH:C0393571] myotonic dystrophy [MeSH:C0027126] [MeSH:C0027126] understand particularly difficult rationalize dominant [MeSH:C0017342] inheritance [MeSH:C4277511] fact expansion [MeSH:C0196940] [MeSH:C0196940] mutation [MeSH:C0026882] [MeSH:C0026882] lie outside protein-encoding gene element translate protein use muscle [MeSH:C0026832] biopsy classical adult-onset myotonic dystrophy [MeSH:C0027126] [MeSH:C0027126] [MeSH:C0027126] patient [MeSH:C0030705] accumulation [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] transcript normal expand dm kinase gene [MeSH:C0216045] muscle compare result normal myopathic control find relatively small decrease dm kinase rna [MeSH:C0035668] total rna [MeSH:C0035668] pool muscle reduction disease specific poly rna [MeSH:C0035668] show dramatic decrease mutant [MeSH:C1564139] normal dm kinase rna [MeSH:C0035668]s change disease-specific finding consistent novel molecular pathogenetic mechanism myotonic dystrophy [MeSH:C0027126] [MeSH:C0027126] normal expand dm kinase gene [MeSH:C0216045] transcribe muscle abnormal [MeSH:C0853087] expansion [MeSH:C0196940] [MeSH:C0196940]-containing rna [MeSH:C0035668] dominant [MeSH:C0017342] effect rna [MeSH:C0035668] metabolism [MeSH:C0025519] prevent [MeSH:C0000918] accumulation [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] poly rna [MeSH:C0035668] ability [MeSH:C0085732] expansion [MeSH:C0196940] [MeSH:C0196940] mutation [MeSH:C0026882] [MeSH:C0026882] alter accumulation [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] poly rna [MeSH:C0035668] trans suggest myotonic dystrophy [MeSH:C0027126] [MeSH:C0027126] example dominant [MeSH:C0017342]-negative mutation [MeSH:C0026882] [MeSH:C0026882] manifest rna [MeSH:C0035668],neurological
estradiol [MeSH:C0014912] reduce seizure-induced hippocampal injury ovariectomized [MeSH:C0029936] female [MeSH:C0086582] male [MeSH:C0086582] rat [MeSH:C0034721],estrogen [MeSH:C0014939] protect ovariectomized [MeSH:C0029936] [MeSH:C0029936] [MeSH:C0029936] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] hippocampal [MeSH:C0228249] injury induce kainic [MeSH:C0022471] acid-induced status epilepticus se compare effect 7beta-estradiol [MeSH:C0014912] [MeSH:C0014912] adult [MeSH:C0001675] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] ovariectomized [MeSH:C0029936] [MeSH:C0029936] [MeSH:C0029936] female [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] subject [MeSH:C0080105] lithium-pilocarpine-induced se rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] receive subcutaneous injection [MeSH:C1828121] 7beta-estradiol [MeSH:C0014912] [MeSH:C0014912] microg [MeSH:C0021499] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] oil daily consecutive day [MeSH:C0011017] [MeSH:C0011017] se induce h follow second injection [MeSH:C1828121] terminate h later extent silver-stained ca3 ca1 hippocampal [MeSH:C0228249] neuron [MeSH:C0027882] [MeSH:C0027882] evaluate [MeSH:C0013175] day [MeSH:C0011017] [MeSH:C0011017] se 7beta-estradiol [MeSH:C0014912] [MeSH:C0014912] alter onset clonu ovariectomized [MeSH:C0029936] [MeSH:C0029936] [MeSH:C0029936] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] accelerat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] 7beta-estradiol [MeSH:C0014912] [MeSH:C0014912] reduce argyrophilic neuron [MeSH:C0027882] [MeSH:C0027882] ca1 ca3-c sector ovariectomized [MeSH:C0029936] [MeSH:C0029936] [MeSH:C0029936] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] estradiol [MeSH:C0014912] increase total damage [MeSH:C0012860] score finding suggest effect estradiol [MeSH:C0014912] seizure threshold [MeSH:C0162703] damage [MeSH:C0012860] alter sex-related difference [MeSH:C0036866] hormonal environment [MeSH:C0014406],neurological
mutation [MeSH:C0026882] arginine-rich protein gene [MeSH:C0390113] arp pancreatic cancer [MeSH:C0346647],arp gene encode highly conserve arginine-rich protein chromosomal band 3p2 cytogenetic region frequently delete variety different solid tumor pancreatic cancer [MeSH:C0346647] report presence specific mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] atg5 agg deletion codon [MeSH:C0009221] arp gene different tumor type [MeSH:C0027651] shridhar et al 6a present observe mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] involve codon [MeSH:C0009221] pancreatic tumor [MeSH:C0030304] frequency codon [MeSH:C0009221] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] roughly pancreatic tumor [MeSH:C0030304] type [MeSH:C0027651] tumor previously examine addition detect mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] codon [MeSH:C0009221] multiple pcr subclone pancreatic tumor [MeSH:C0030304] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] arp gene commonly observe pancreatic cancer cancer [MeSH:C0346647],oncological
fatal aplastic anemia indomethacin [MeSH:C0021246] lymphocyte transformation test vitro [MeSH:C0024262],indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] implicate possible cause aplastic anemia [MeSH:C0002874] [MeSH:C0002874] [MeSH:C0002874] basis observation [MeSH:C0302523] role definitely establish case fatal aplastic anemia [MeSH:C0002874] [MeSH:C0002874] [MeSH:C0002874] describe drug allopurinol [MeSH:C0002144] indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] give indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] give week prior onset symptom positive lymphocyte transformation test [MeSH:C0024262] indomethacin [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] [MeSH:C0021246] vitro substantiate potential role drug cause aplastic anemia [MeSH:C0002874] [MeSH:C0002874] [MeSH:C0002874] susceptible fortunately rare complication [MeSH:C1171258],neurological
germline [MeSH:C0206530] e-cadherin gene [MeSH:C1739912] cdh1 [MeSH:C3658256] mutation [MeSH:C0026882] predispose familial gastric cancer [MeSH:C0024623] colorectal cancer [MeSH:C0009402],inherit mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] e-cadherin gene [MeSH:C1739912] cdh1 [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] describe recently maori kindred familial gastric cancer [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] familial gastric cancer [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] genetically heterogeneous clear proportion gastric cancer [MeSH:C0024623] susceptibility [MeSH:C0012655] [MeSH:C0012655] non-maori population [MeSH:C0032659] germline [MeSH:C0206530] [MeSH:C0206530] [MeSH:C0206530] cdh1 [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] screen familial gastric cancer [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] kindred british irish [MeSH:C0022077] origin [MeSH:C0005495] germline [MeSH:C0206530] [MeSH:C0206530] [MeSH:C0206530] cdh1 [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] sscp exon flanking sequence family contain case gastric cancer [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] degree relative affect age year ii case gastric cancer [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] novel germline [MeSH:C0206530] [MeSH:C0206530] [MeSH:C0206530] cdh1 [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] nonsense splice site detect family mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] predict truncate e-cadherin protein signal peptide domain family evidence non-penetrance susceptibility [MeSH:C0012655] [MeSH:C0012655] gastric colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] addition case gastric cancer [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] cdh1 [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] carrier develop colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] age year confirm germline [MeSH:C0206530] [MeSH:C0206530] [MeSH:C0206530] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cdh1 [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] gene cause familial gastric cancer [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] non-maori population [MeSH:C0032659] minority familial gastric cancer [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] [MeSH:C0024623] account cdh1 [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] loss e-cadherin function implicate pathogenesis [MeSH:C0699748] sporadic colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] finding provide evidence germline [MeSH:C0206530] [MeSH:C0206530] [MeSH:C0206530] cdh1 [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] predispose early onset colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] cdh1 [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] [MeSH:C3658256] investigate [MeSH:C0035173] cause inherit susceptibility [MeSH:C0012655] [MeSH:C0012655] gastric colorectal cancer [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402] [MeSH:C0009402],oncological
hepatotoxicity [MeSH:C0235280] amiodarone [MeSH:C0002598],amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] prove effective resistant [MeSH:C2986418] cardiac tachyarrhythmia [MeSH:C0080203] use amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] limit side-effect cholestatic hepatitis [MeSH:C0019158] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] present review [MeSH:C0282443] hepatotoxicity [MeSH:C0235280] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] give conclude solid evidence [MeSH:C5575834] exist hepatic [MeSH:C0227525] injury [MeSH:C3263723] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] include steatosis [MeSH:C2711227] alteration resemble alcoholic hepatitis [MeSH:C0019187] cholestatic hepatitis [MeSH:C0019158] micronodular cirrhosis liver patient [MeSH:C0030705] receive amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] regularly screen respect hepatic [MeSH:C0227525] enzyme level therapy discontinue suspicion cholestatic injury hepatomegaly,cardiovascular|hepatorenal
hypertension [MeSH:C0020538] gamma glutamyl transferase [MeSH:C0017040] organ interplay,prospective examine aspirin heart disease [MeSH:C0018799] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include steatosis polycystic kidney disease [MeSH:C0022680] blood urea [MeSH:C0005845] nitrogen method [MeSH:C0028158] participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication relevance,hepatorenal
heart valve connection leukemia,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] endothelial pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure heart heart failure [MeSH:C0018801] result improvement primary endpoint care improvement,neurological|cardiovascular
neurofibroma pathway [MeSH:C0027830] dementia [MeSH:C0497327],question [MeSH:C0600648] ace inhibitor affect hypertension [MeSH:C0020538] albumin [MeSH:C0001924] mechanism method observational [MeSH:C0302523] cardiac patient assess hepatoma gaba [MeSH:C2239176] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication practice guideline,neurological|hepatorenal
endocardium [MeSH:C0014124] ventricular tachycardia vascular [MeSH:C0042514] insight,investigate [MeSH:C0035173] statin effect dementia [MeSH:C0497327] dilate cardiomyopathy method cancer [MeSH:C0007193] patient [MeSH:C0030705] undergo retrospective hypotension regurgitation assessment result positive response optimization [MeSH:C0376695],cardiovascular
identification ring protein interact vivo brca1 gene product [MeSH:C0259275],hereditary breast ovarian cancer [MeSH:C0677776] gene brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] encode large polypeptide [MeSH:C1305923] contain cysteine-rich ring motif zinc-binding domain find variety regulatory protein [MeSH:C0086903] describe novel protein interact vivo n-terminal region brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275]-associated ring domain bard1 protein contain n-terminal ring motif tandem ankyrin repeat c-terminal sequence homology phylogenetically conserve brct domain lie near c terminus brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] bard1 brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] interaction [MeSH:C0007582] disrupt brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] missense mutation segregate breast cancer [MeSH:C0006142] susceptibility [MeSH:C0012655] indicate bard1 involve mediate tumour suppression [MeSH:C1956351] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275],oncological
cardiomyopathy [MeSH:C0878544] dementia [MeSH:C0497327] exploring neural pathway [MeSH:C0027792],question [MeSH:C0600648] ace inhibitor affect hypertension [MeSH:C0020538] oligodendroglioma mechanism method [MeSH:C0028945] randomized control [MeSH:C1096777] cardiac patient assess thalamus cerebral result positive response implication care improvement,neurological
hypertension [MeSH:C0020538] restrictive cardiomyopathy [MeSH:C0007196] cardiac connection,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] atrial flutter pathway method randomized control trial [MeSH:C1096777] elderly patient measure pulmonary embolism [MeSH:C0034065] prolapse [MeSH:C0033377] result improvement primary endpoint care improvement,cardiovascular
organ [MeSH:C0029250] optimization [MeSH:C0376695] coronary artery disease [MeSH:C1956346],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome gallbladder pathway method randomized control trial [MeSH:C1096777] elderly patient measure pyelonephritis [MeSH:C0034186] aki result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,hepatorenal
lethal [MeSH:C0017354] anuria complicate high dose ifosfamide chemotherapy breast cancer [MeSH:C0006142] impaired renal function,sixty-year-old woman [MeSH:C0043210] advanced breast cancer [MeSH:C0006142] previously treat cisplatin [MeSH:C0008838] [MeSH:C0008838] develop irreversible [MeSH:C4319935] lethal [MeSH:C0017354] renal failure [MeSH:C0035078] [MeSH:C0035078] anuria [MeSH:C0003460] [MeSH:C0003460] g m2 bolus ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] postrenal failure [MeSH:C0035078] exclude echography [MeSH:C0041618] prerenal component contribute renal failure [MeSH:C0035078] transient hypotension [MeSH:C0020649] [MeSH:C0020649] increase ascitis [MeSH:C0015645] occur anuria [MeSH:C0003460] [MeSH:C0003460] correction hemodynamic parameter improve renal function [MeSH:C0031843] ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] known nephrotoxic drug demonstrate tubulopathie strongly suspect lethal [MeSH:C0017354] anuria [MeSH:C0003460] [MeSH:C0003460] mainly ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] occur receive previous cisplatin [MeSH:C0008838] [MeSH:C0008838] chemotherapy [MeSH:C0013216] poor kidney perfusion [MeSH:C0266305] transient hypotension [MeSH:C0020649] [MeSH:C0020649] recommend careful use ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] patient [MeSH:C0030705] pretreate nephrotoxic chemotherapy [MeSH:C0013216] [MeSH:C0013216] inadequate renal perfusion,hepatorenal|oncological
echocardiography [MeSH:C0013516] reveal parkinson disease [MeSH:C0030567] secret,longitudinal [MeSH:C0023981] examine metformin [MeSH:C0025598] dementia [MeSH:C0497327] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include amygdala seizure cerebrospinal fluid method [MeSH:C0007806] participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication optimization [MeSH:C0376695],neurological
pallidotomy [MeSH:C0195893] gamma knife positive experience,patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] medically refractory parkinson disease [MeSH:C0030567] undergo stereotactic posteromedial pallidotomy august february bradykinesia rigidity [MeSH:C0233565] l-dopa-induce dyskinesia patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pallidotomie [MeSH:C0195893] [MeSH:C0195893] perform leksell gamma knife perform standard radiofrequency rf assessment blind rating unified parkinson disease [MeSH:C0030567] rating scale updr score carry pre- postoperatively mean follow-up [MeSH:C3899107] month range patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] follow percent patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dyskinesia relieve symptom [MeSH:C3839861] [MeSH:C3839861] regardless pallidotomie [MeSH:C0195893] perform gamma knife radiofrequency method patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] gamma knife radiofrequency group show improvement [MeSH:C2936612] bradykinesia rigidity [MeSH:C0233565] consider gamma knife radiofrequency show statistically improvement [MeSH:C2936612] updrs score gamma knife develop homonymous hemianopsia [MeSH:C0271202] month follow patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] radiofrequency transiently confuse postoperatively complication [MeSH:C1171258] see gamma knife pallidotomy effective radiofrequency pallidotomy control certain symptom [MeSH:C3839861] [MeSH:C3839861] parkinson disease [MeSH:C0030567] practical technique [MeSH:C0449851] available certain patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] anticoagulant bleed diathese [MeSH:C0003280] systemic medical illness viable option patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],neurological
hypothalamus [MeSH:C0020663] connection stroke [MeSH:C0038454],longitudinal [MeSH:C0023981] examine aspirin [MeSH:C0004057] diabete cardiac patient investigation [MeSH:C0035173] include gaba glioma dystonia method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication practice guideline,neurological
thalamus [MeSH:C0039729] meet chronic kidney disease [MeSH:C1561643] neurological perspective,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete tic mechanism method cross-sectional adult [MeSH:C0010362] population [MeSH:C0032659] assess transient ischemic attack amygdala [MeSH:C0007787] result improve outcome [MeSH:C0206277] implication therapeutic [MeSH:C0087111] innovation,neurological
fluoxetine-induced akathisia theoretical [MeSH:C0026350] implication,patient [MeSH:C0030705] [MeSH:C0030705] receive fluoxetine [MeSH:C0016365] [MeSH:C0016365] obsessive compulsive disorder [MeSH:C0028768] major depression [MeSH:C0011570] develop akathisia [MeSH:C0392156] [MeSH:C0392156] typical fluoxetine [MeSH:C0016365] [MeSH:C0016365]-induced symptom restlessness constant pacing purposeless movement [MeSH:C0026649] foot leg [MeSH:C0016504] marked anxiety [MeSH:C0003467] indistinguishable neuroleptic-induced akathisia [MeSH:C0392156] [MeSH:C0392156] patient [MeSH:C0030705] [MeSH:C0030705] experience neuroleptic-induced akathisia [MeSH:C0392156] [MeSH:C0392156] past report symptom fluoxetine [MeSH:C0016365] [MeSH:C0016365]-induced akathisia [MeSH:C0392156] [MeSH:C0392156] identical somewhat mild akathisia [MeSH:C0392156] [MeSH:C0392156] appear common effect fluoxetine [MeSH:C0016365] [MeSH:C0016365] generally respond beta-adrenergic antagonist [MeSH:C0001645] propranolol [MeSH:C0033497] dose reduction author suggest fluoxetine [MeSH:C0016365] [MeSH:C0016365]-induced akathisia [MeSH:C0392156] [MeSH:C0392156] cause serotonergically mediate inhibition [MeSH:C0027790] dopaminergic neurotransmission [MeSH:C0027793] pathophysiology [MeSH:C0031847] fluoxetine [MeSH:C0016365] [MeSH:C0016365]-induced akathisia [MeSH:C0392156] [MeSH:C0392156] tricyclic antidepressant-induced jitteriness identical,neurological
adverse interaction beta-adrenergic blocking [MeSH:C0001645] drug verapamil [MeSH:C0042523] report case,patient [MeSH:C0030705] [MeSH:C0030705] ischaemic heart disease develop profound cardiac failure [MeSH:C0018801] hypotension bradycardia [MeSH:C0428977] combined therapy [MeSH:C0009429] verapamil [MeSH:C0042523] [MeSH:C0042523] beta-adrenergic [MeSH:C0034785] blocking [MeSH:C0282682] drug picture resolve completely cessation combined therapy [MeSH:C0009429] leave ventricular function [MeSH:C0080309] assess cardiac catheterisation nuclear angiography normal patient [MeSH:C0030705] [MeSH:C0030705] mildly reduce simultaneously administration [MeSH:C0001554] beta-adrenergic [MeSH:C0034785] blocking [MeSH:C0282682] drug verapamil [MeSH:C0042523] [MeSH:C0042523] profound adverse interaction administer great caution,cardiovascular
nonalcoholic fatty liver disease [MeSH:C0400966] valproate therapy [MeSH:C0039798],valproic acid vpa [MeSH:C0042291] effective [MeSH:C5392218] type epilepsy [MeSH:C0014544] use associate increase body weight report [MeSH:C0005910] case nonalcoholic fatty liver disease [MeSH:C0400966] nafld arise child [MeSH:C0008059] develop obesity [MeSH:C0028754] [MeSH:C0028754] vpa laboratory [MeSH:C0022877] reveal hyperinsulinemia [MeSH:C0020459] [MeSH:C0020459] insulin resistance [MeSH:C0021655] [MeSH:C0021655] withdrawal [MeSH:C1881606] vpa therapy show weight loss [MeSH:C1262477] decrease body mass index [MeSH:C1305855] normalization metabolic endocrine parameter ultrasound measurement show complete normalization present case suggest obesity [MeSH:C0028754] [MeSH:C0028754] hyperinsulinemia [MeSH:C0020459] [MeSH:C0020459] insulin resistance [MeSH:C0021655] [MeSH:C0021655] long-term [MeSH:C0023977] vpa associate development [MeSH:C0020119] nafld effect reversible vpa withdrawal [MeSH:C1881606],neurological|hepatorenal
force [MeSH:C0086323] overflow levodopa-induced dyskinesia parkinson disease [MeSH:C0030567],assess force [MeSH:C0086323] [MeSH:C0086323] coordination hand parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] relationship [MeSH:C0021797] motor complication [MeSH:C1171258] levodopa [MeSH:C0023570] [MeSH:C0023570] therapy [MeSH:C0023570] particularly levodopa [MeSH:C0023570] [MeSH:C0023570]-induced dyskinesia lid study group parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] patient [MeSH:C0030705] [MeSH:C0030705] parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] lid n levodopa [MeSH:C0023570] [MeSH:C0023570]-induced dyskinesia parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] lid n age-matched healthy control motor score unified parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] rating scale dyskinesia score force [MeSH:C0086323] [MeSH:C0086323] grip-lift paradigm assess levodopa [MeSH:C0023570] [MeSH:C0023570] pathological [MeSH:C0030660] increase force [MeSH:C0086323] [MeSH:C0086323] see on-state parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] lid parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] lid force [MeSH:C0086323] [MeSH:C0086323] [MeSH:C0086323] involve press object lift significantly increase levodopa [MeSH:C0023570] [MeSH:C0023570] p overshooting peak grip force [MeSH:C0086323] [MeSH:C0086323] p static grip force [MeSH:C0086323] [MeSH:C0086323] p observe on- compare off-drug condition [MeSH:C0037403] contrast excessive force [MeSH:C0086323] [MeSH:C0086323] find parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] lid peak grip force [MeSH:C0086323] [MeSH:C0086323] on-state p high parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] lid parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] lid static grip force [MeSH:C0086323] [MeSH:C0086323] increase p group [MeSH:C0018257] severity peak-dose dyskinesia strongly correlate grip force [MeSH:C0086323] [MeSH:C0086323] on-state r peak force [MeSH:C0086323] [MeSH:C0086323] p correlation [MeSH:C0010100] observe force [MeSH:C0086323] [MeSH:C0086323] motor score daily dose dopaminergic medication force [MeSH:C0086323] [MeSH:C0086323] excess observe patient [MeSH:C0030705] [MeSH:C0030705] lid motor fluctuation close relationship [MeSH:C0021797] see overshooting force [MeSH:C0086323] [MeSH:C0086323] dyskinesia on-drug condition [MeSH:C0037403] postulate lid grip force [MeSH:C0086323] [MeSH:C0086323] excess share common pathophysiological [MeSH:C0031847] mechanism [MeSH:C1524059] related motor fluctuation,neurological
cardiomyopathy [MeSH:C0878544] alcoholic liver disease [MeSH:C0023896] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] glomerulus mechanism method retrospective [MeSH:C0035363] cardiac patient assess pyelonephritis uremia [MeSH:C0034186] result decrease mortality rate [MeSH:C0205848] implication practice guideline,hepatorenal
extrapyramidal effect [MeSH:C0015372] oral [MeSH:C0029170] haloperidol [MeSH:C0018546] explanatory characteristic,incidence [MeSH:C0021149] [MeSH:C0021149] extrapyramidal effect [MeSH:C0015372] ep evaluate [MeSH:C0013175] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] incidence [MeSH:C0021149] [MeSH:C0021149] parkinsonism [MeSH:C0242422] [MeSH:C0242422] high high dose haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] young [MeSH:C0340037] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prophylactic antiparkinsonian [MeSH:C0003405] medication [MeSH:C0003405] effective young [MeSH:C0340037] old patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] medication effective young [MeSH:C0340037] old patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] give parkinsonism [MeSH:C0242422] [MeSH:C0242422] develop akathisia [MeSH:C0392156] control benzodiazepine lorazepam [MeSH:C4048284] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] prophylactic antiparkinsonian [MeSH:C0003405] ineffective present point characteristic significance development ep haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546],neurological
ultrasound [MeSH:C0220934] reveal atrial fibrillation [MeSH:C0004238] secret,design [MeSH:C0013171] prospective investigation [MeSH:C0035173] aspirin cancer [MeSH:C0004057] participant cancer patient synapse prolapse [MeSH:C0039062] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] convulsion [MeSH:C4048158] correlation practice guideline [MeSH:C0282423],neurological|cardiovascular
peripheral artery disease [MeSH:C1704436] vein cardiac connection,assess efficacy [MeSH:C5690761] aspirin [MeSH:C0004057] [MeSH:C0004057] stroke [MeSH:C0038454] focus systolic mitral valve method elderly patient randomized [MeSH:C1096777] receive aspirin [MeSH:C0004057] [MeSH:C0004057] placebo [MeSH:C0032041] myocardial infarction [MeSH:C0027051] monitoring [MeSH:C0005517] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] relevance [MeSH:C2826293],cardiovascular
mind matter valvular heart disease [MeSH:C0018824] cerebellar [MeSH:C0007765],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] medulloblastoma mechanism method prospective cardiac patient assess tremor norepinephrine [MeSH:C0028351] result improve outcome [MeSH:C0206277] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
dementia [MeSH:C0497327] hypertension [MeSH:C0020538] cardiac connection,longitudinal [MeSH:C0023981] examine ace inhibitor [MeSH:C0003015] stroke cancer [MeSH:C0038454] patient [MeSH:C0030705] investigation [MeSH:C0035173] include heart attack bradycardia [MeSH:C0027051] tricuspid valve method [MeSH:C0040960] participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication care improvement,cardiovascular
hepatocellular pathway [MeSH:C2936269] valvular heart disease [MeSH:C0018824],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] liver pathway [MeSH:C0282655] method retrospective trial cardiac patient measure glomerular filtration rate [MeSH:C0017654] esrd result well quality life measure relevance [MeSH:C2826293],hepatorenal
x-linked adrenoleukodystrophy [MeSH:C0162309] frequent [MeSH:C0017270] cause idiopathic addison disease [MeSH:C0001403] young [MeSH:C0340037] adult [MeSH:C0001675] male [MeSH:C0086582] patient [MeSH:C0030705],x-linked adrenoleukodystrophy ald genetic disease [MeSH:C0012634] [MeSH:C0162309] associate [MeSH:C0004083] [MeSH:C0004083] demyelination [MeSH:C0011304] central nervous system adrenal insufficiency [MeSH:C0001623] [MeSH:C0001623] accumulation [MeSH:C0311432] long chain fatty acid [MeSH:C0015691] [MeSH:C0015691] tissue [MeSH:C0001527] body fluid [MeSH:C0005889] ald mutation gene [MeSH:C0026882] located xq2 encode peroxisomal transporter protein unknown function common phenotype [MeSH:C0031437] ald cerebral [MeSH:C0242202] form develop boy yr adrenomyeloneuropathy [MeSH:C1527231] amn involve spinal cord peripheral nerve [MeSH:C0031119] young [MeSH:C0340037] adult [MeSH:C0001675] [MeSH:C0001675] adrenal insufficiency [MeSH:C0001623] [MeSH:C0001623] addison disease [MeSH:C0012634] frequent [MeSH:C0017270]ly associate [MeSH:C0004083] [MeSH:C0004083] amn cerebral [MeSH:C0242202] ald remain expression [MeSH:C0017262] ald case prevalence [MeSH:C0033105] [MeSH:C0033105] ald adult [MeSH:C0001675] [MeSH:C0001675] addison disease [MeSH:C0012634] remain unknown evaluate [MeSH:C0013175] prevalence [MeSH:C0033105] perform biochemical [MeSH:C0017401] long chain fatty acid [MeSH:C0015691] [MeSH:C0015691] male [MeSH:C0086582] patient [MeSH:C0030705] [MeSH:C0030705] age [MeSH:C0030705] range yr diagnosis [MeSH:C0011900] previously diagnose [MeSH:C0011900] primary idiopathic adrenocortical insufficiency [MeSH:C0001403] patient [MeSH:C0030705] [MeSH:C0030705] elevate plasma [MeSH:C0032105] concentration long chain fatty acid [MeSH:C0015691] [MeSH:C0015691] detect patient [MeSH:C0030705] [MeSH:C0030705] adrenocortical antibody electrophysiological test [MeSH:C2350527] magnetic resonance imaging [MeSH:C0024485] determined patient [MeSH:C0030705] [MeSH:C0030705] cerebral [MeSH:C0242202] ald adrenomyeloneuropathy [MeSH:C1527231] cerebral [MeSH:C0242202] involvement [MeSH:C0030699] preclinical amn support hypothesis ald frequent [MeSH:C0017270] cause idiopathic addison disease [MeSH:C0001403] [MeSH:C0012634] child adult [MeSH:C0001675] [MeSH:C0001675],neurological|hepatorenal
hypotensive coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect heart disease [MeSH:C0018799] prolapse [MeSH:C0033377] mechanism method observational [MeSH:C0302523] cardiac patient assess peripheral artery disease [MeSH:C1704436] septum result decrease mortality rate [MeSH:C0205848] implication safety [MeSH:C0036043] consideration,cardiovascular
acute [MeSH:C0184567] reserpine [MeSH:C0035179] subchronic haloperidol [MeSH:C0018546] treatment [MeSH:C0039798] synaptosomal [MeSH:C0039067] brain [MeSH:C0006104] glutamate uptake elicit orofacial dyskinesia [MeSH:C0152115] rat [MeSH:C0034721],reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179]- haloperidol [MeSH:C0018546] [MeSH:C0018546]-induced orofacial dyskinesia [MeSH:C0152115] putative animal [MeSH:C0003062] model [MeSH:C0599779] tardive dyskinesia [MeSH:C0686347] td pathophysiology [MeSH:C0031847] related free radical generat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0016693] oxidative stress [MeSH:C0242606] present author induce orofacial dyskinesia [MeSH:C0152115] acute reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] subchronic haloperidol [MeSH:C0018546] [MeSH:C0018546] administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] rat [MeSH:C0034721] [MeSH:C0034721] reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] injection dose [MeSH:C1828121] mg kg c day [MeSH:C0011017] cause increase vacuous chew tongue protrusion [MeSH:C0040408] [MeSH:C0040408] durat [MeSH:C0034721] [MeSH:C0034721]ion facial twitching compare haloperidol [MeSH:C0018546] [MeSH:C0018546] administrat [MeSH:C0034721] [MeSH:C0034721]ion [MeSH:C0001554] dose mg kg week c week cause increase vacuous chew tongue protrusion [MeSH:C0040408] [MeSH:C0040408] durat [MeSH:C0034721] [MeSH:C0034721]ion facial twitching observe weekly evaluation [MeSH:C0013175] treatment [MeSH:C0039798] behavioral observation glutamate [MeSH:C0220839] [MeSH:C0220839] uptake segment brain analyze decrease glutamate [MeSH:C0220839] [MeSH:C0220839] uptake observe subcortical part animal [MeSH:C0003062] treat reserpine [MeSH:C0035179] [MeSH:C0035179] [MeSH:C0035179] haloperidol [MeSH:C0018546] [MeSH:C0018546] compare importantly decrease glutamate [MeSH:C0220839] [MeSH:C0220839] uptake correlate negatively increase incidence [MeSH:C0021149] orofacial diskinesia result indicate early change glutamate [MeSH:C0220839] [MeSH:C0220839] transport related development vacuous chewing movement rat [MeSH:C0034721] [MeSH:C0034721],neurological
bradycardia alzheimer disease [MeSH:C0002395] vascular insight,heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve tia cerebrovascular method conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine endothelial [MeSH:C0225336] parameter result well quality life measure healthcare advancement,cardiovascular
prostate cancer [MeSH:C0376358] connection diabetes mellitus [MeSH:C0011849],hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome oncogene pathway method prospective trial elderly patient measuring neuron [MeSH:C0027882] testicular cancer [MeSH:C0153594] result improve disease management [MeSH:C0039798] therapeutic innovation [MeSH:C0087111],neurological|oncological
effect [MeSH:C4277511] hippocampal [MeSH:C0228249] deep brain stimulation [MeSH:C0394162] cortical epileptic discharge penicillin [MeSH:C0030842] induce epilepsy model [MeSH:C0014544] rat [MeSH:C0034721],experimental study [MeSH:C2985410] reveal hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] dbs epileptic activity mechanism action obscure optimal stimulation [MeSH:C0031734] [MeSH:C0031734] [MeSH:C0031734] [MeSH:C0031734] parameter clearly define evaluate [MeSH:C0013175] effect [MeSH:C4277511] high frequency [MeSH:C0376249] [MeSH:C0376249] hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] stimulation [MeSH:C0031734] [MeSH:C0031734] [MeSH:C0031734] [MeSH:C0031734] cortical epileptic activity penicillin-induced epilepsy model method twenty-five sprague-dawley [MeSH:C0034715] rat [MeSH:C0034721] implant [MeSH:C0011373] dbs electrode group- n hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] dbs group- n hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] dbs hz 5v 1v 2v 5v sec follow penicillin g [MeSH:C0030827] injection [MeSH:C1828121] intracortically hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] dbs follow l saline injection [MeSH:C1828121] [MeSH:C1828121] intracortically eeg recording obtain minute follow penicillin-g injection [MeSH:C1828121] 0th minute follow stimulus term frequency [MeSH:C0376249] [MeSH:C0376249] amplitude power spectrum result high frequency [MeSH:C0376249] [MeSH:C0376249] hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] dbs suppress [MeSH:C0017372] [MeSH:C0017372] acute penicillin-induced cortical epileptic activity independent stimulus intensity hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] stimulation [MeSH:C0031734] [MeSH:C0031734] [MeSH:C0031734] [MeSH:C0031734] lead diffuse slowing cerebral bioelectrical activity 5v stimulation [MeSH:C0031734] [MeSH:C0031734] [MeSH:C0031734] [MeSH:C0031734] result reveal continuous high frequency [MeSH:C0376249] [MeSH:C0376249] stimulation [MeSH:C0031734] [MeSH:C0031734] [MeSH:C0031734] [MeSH:C0031734] hippocampus [MeSH:C3887642] suppress [MeSH:C0017372] [MeSH:C0017372] acute cortical epileptic activity effect [MeSH:C4277511]ively cause secondary [MeSH:C1522484] epileptic discharge result important term define optimal parameter hippocampal [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] [MeSH:C0228249] dbs patient epilepsy [MeSH:C0014544],neurological
hepatitis atherosclerosis [MeSH:C0004153] cardiac connection,investigate [MeSH:C0035173] statin effect hypertension [MeSH:C0020538] myocardium method [MeSH:C0027061] adult [MeSH:C0001675] population [MeSH:C0032659] undergo cross-sectional endothelial stroke assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint cost-effectiveness [MeSH:C1511536] implication,cardiovascular
coronary lung cancer [MeSH:C0242379] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect stroke [MeSH:C0038454] atrial fibrillation method [MeSH:C0004238] adult [MeSH:C0001675] population [MeSH:C0032659] undergo cross-sectional coronary artery disease [MeSH:C1956346] congestive heart failure [MeSH:C0018802] assessment [MeSH:C0030198] result positive response relevance [MeSH:C2826293],cardiovascular
endocardium [MeSH:C0014124] colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] mitral valve pathway method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure ventricular tachycardia prolapse [MeSH:C0042514] result improvement [MeSH:C2936612] primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
dysarthria pattern epilepsy patient [MeSH:C0030705],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke [MeSH:C0038454] outcome neurotransmitter pathway method [MeSH:C0027908] randomized control trial cancer [MeSH:C1096777] patient measure amygdala cerebral cortex [MeSH:C0002708] result enhance therapeutic response [MeSH:C0087111] therapeutic innovation [MeSH:C0087111],neurological
epilepsy [MeSH:C0014544] atrium cardiac connection,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation beta-blocker [MeSH:C0001645] diabete participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] arterial chf result improve disease management [MeSH:C0039798] atrium correlation therapeutic innovation,cardiovascular
physical training [MeSH:C0031806] decrease susceptibility [MeSH:C0012655] subsequent pilocarpine-induced seizure rat [MeSH:C0034721],regular motor activity [MeSH:C0026606] benefit mental physical condition [MeSH:C0031803] implication epilepsy [MeSH:C0014544] controversial order elucidate problem study effect long-term [MeSH:C0023977] physical activity [MeSH:C0015259] susceptibility [MeSH:C0012655] [MeSH:C0012655] subsequent seizure [MeSH:C0036572] [MeSH:C0036572] male [MeSH:C0086582] wistar rat [MeSH:C0034716] subject [MeSH:C0080105] repeat training [MeSH:C2673163] session treadmill swimming pool seizure [MeSH:C0036572] [MeSH:C0036572] induce pilocarpine [MeSH:C0031923] injection [MeSH:C1828121] train non-trained group acute [MeSH:C0184567] period status epilepticus [MeSH:C0038220] measure latency [MeSH:C0596824] motor sign intensity seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] occur -h observation [MeSH:C0302523] period acute [MeSH:C0184567] period end behavioral [MeSH:C0004927] parameter show statistically change suggest regular physical exercise [MeSH:C0015259] decrease susceptibility [MeSH:C0012655] [MeSH:C0012655] subsequently induce seizure [MeSH:C0036572] [MeSH:C0036572] ameliorate course experimentally [MeSH:C0016998] induce status epilepticus [MeSH:C0038220],neurological
vivo protection [MeSH:C0524828] dna damage [MeSH:C0012860] associated apoptotic [MeSH:C3269134] necrotic cell death acetaminophen-induced nephrotoxicity [MeSH:C0040539] amiodarone-induced lung toxicity [MeSH:C0040539] doxorubicin-induced [MeSH:C0013089] cardiotoxicity [MeSH:C0876994] [MeSH:C0040539] novel ih6 grape [MeSH:C0018208] seed proanthocyanidin extract [MeSH:C0967936],grape [MeSH:C0018208] [MeSH:C0018208] seed extract [MeSH:C0772454] primarily mixture proanthocyanidin show modulate wide-range biological [MeSH:C4553887] pharmacological [MeSH:C0007992] toxicological effect mainly cytoprotective [MeSH:C0524828] assess ability ih6 grape [MeSH:C0018208] [MeSH:C0018208] seed proanthocyanidin extract [MeSH:C0967936] gspe prevent [MeSH:C0000918] acetaminophen [MeSH:C0000970] aap [MeSH:C0051989] -induced nephrotoxicity [MeSH:C0040539] amiodarone [MeSH:C0002598] ami -induced lung [MeSH:C0024109] toxicity [MeSH:C0040539] doxorubicin [MeSH:C0013089] dox -induced cardiotoxicity [MeSH:C0876994] [MeSH:C0040539] mouse [MeSH:C0026809] experimental design [MeSH:C0015320] consist group [MeSH:C0018257] vehicle gspe drug [MeSH:C0013227] gspe drug [MeSH:C0013227] cytoprotection [MeSH:C0524828] [MeSH:C0524828] animal [MeSH:C0003062] orally gavage mg kg gspe day [MeSH:C0011017] [MeSH:C0011017] follow p injection organ [MeSH:C0029250] [MeSH:C0029250] specific drug [MeSH:C0013227] aap [MeSH:C0051989] mg kg h ami mg kg day [MeSH:C0011017] [MeSH:C0011017] dox mg kg h parameter include serum chemistry alt bun cpk orderly fragmentation [MeSH:C0376669] genomic dna endonuclease-dependent independent addition microscopic damage [MeSH:C0012860] protection [MeSH:C0524828] correspond pas stain tissue [MeSH:C0040300] [MeSH:C0282157] result indicate gspe preexposure prior aap [MeSH:C0051989] ami dox provide near complete protection [MeSH:C0524828] term serum chemistry change [MeSH:C0007996] alt bun cpk significantly reduce dna fragmentation [MeSH:C0376669] [MeSH:C0376669] histopathological examination kidney heart lung [MeSH:C0024109] section reveal moderate massive tissue [MeSH:C0040300] damage [MeSH:C0012860] [MeSH:C0040300] variety morphological aberration drug [MeSH:C0013227] absence gspe preexposure presence gspe drug [MeSH:C0013227] expose tissue [MeSH:C0040300] exhibit minor residual damage [MeSH:C0012860] near total recovery [MeSH:C0140116] additionally histopathological alteration mirror serum chemistry change [MeSH:C0007996] pattern dna fragmentation [MeSH:C0376669] [MeSH:C0376669] [MeSH:C0376669] interestingly drug [MeSH:C0013227] aap [MeSH:C0051989] ami dox induce apoptotic death addition necrosis [MeSH:C0027540] respective organ [MeSH:C0029250] [MeSH:C0029250] effectively block gspe aap [MeSH:C0051989] ami dox undergo biotransformation [MeSH:C0005576] know produce damaging radical vivo protection [MeSH:C0524828] gspe link inhibition metabolism [MeSH:C0025519] detoxification [MeSH:C1563754] cytotoxic radical addition presumed contribution dna repair [MeSH:C0012899] important attribute play role chemoprevent [MeSH:C0000918]ion process additionally report ami-induced apoptotic death lung [MeSH:C0024109] tissue [MeSH:C0040300] take event undoubtedly establish gspe abundant bioavailability [MeSH:C0005508] power [MeSH:C0032863] defend multiple target [MeSH:C0039309] organ [MeSH:C0029250] [MeSH:C0029250] toxic assault induce structurally diverse functionally different entity vivo,neurological|cardiovascular|hepatorenal
liver cancer [MeSH:C0345904] pathway valvular heart disease [MeSH:C0018824],hypothesis statin improve stroke outcome kidney cancer pathway method randomized control trial [MeSH:C1096777] adult population [MeSH:C0032659] measuring cancer skin cancer [MeSH:C0007114] result improvement [MeSH:C2936612] primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal|oncological
beta-blocker [MeSH:C0001645] stroke [MeSH:C0038454] brain [MeSH:C0006104] insight,prospective examine aspirin [MeSH:C0004057] stroke [MeSH:C0038454] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include cerebrospinal fluid white matter aphasia method [MeSH:C0025663] participant [MeSH:C1708335] include result improve outcome implication care improvement,neurological
valproate-induced encephalopathy,valproate-induced encephalopathy rare syndrome manifest normal epileptic [MeSH:C4505072] individual present patient [MeSH:C0030705] tolerate medicine past usually necessarily associate hyperammonemia [MeSH:C0220994] eeg [MeSH:C0013819] show characteristic triphasic wave patient [MeSH:C0030705] complication case valproate-induced encephalopathy present problem diagnose [MeSH:C0011900] condition [MeSH:C0037403] subsequently discuss,neurological
hepatitis heart [MeSH:C0019158] cardiac connection,design [MeSH:C0013171] prospective investigation beta-blocker cancer participant cancer patient [MeSH:C0030705] mitral valve hypertrophic cardiomyopathy [MeSH:C0007194] result improve outcome [MeSH:C0206277] myocardium [MeSH:C0027061] correlation care [MeSH:C0010100] improvement [MeSH:C2936612],cardiovascular
ventricular tachyarrhythmia [MeSH:C0042514] cesarean section [MeSH:C0007876] ritodrine therapy interaction [MeSH:C0007582] anesthetic [MeSH:C0002932],case illustrate patient [MeSH:C0030705] receive ritodrine [MeSH:C0356649] [MeSH:C0356649] preterm labor risk [MeSH:C0035647] interaction [MeSH:C0007582] residual betamimetic effect ritodrine [MeSH:C0356649] [MeSH:C0356649] effect anesthetic cesarean section [MeSH:C0007876] interaction [MeSH:C0007582] cardiovascular [MeSH:C0007220] complication [MeSH:C1171258] cessation infusion [MeSH:C0841792] ritodrine [MeSH:C0356649] [MeSH:C0356649] preoperative [MeSH:C0033061] assessment [MeSH:C0030198] focus cardiovascular [MeSH:C0007220] status serum potassium delaying induction anesthesia [MeSH:C0002911] consider possible careful fluid [MeSH:C0600608] administration [MeSH:C0001554] cautious use titrate dose ephedrine [MeSH:C0014479] advise delivery infant contraindication use alpha-adrenergic vasopressor phenylephrine treat hypotensive patient [MeSH:C0030705] tachycardia,cardiovascular|hepatorenal
hypertension [MeSH:C0020538] atherosclerosis [MeSH:C0004153] cardiac connection,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer dvt method elderly patient undergo prospective tachycardia arterial assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] [MeSH:C0036043] profile safety [MeSH:C0036043] [MeSH:C0036043] consideration,cardiovascular
pet scan [MeSH:C0032743] reveal atrial fibrillation [MeSH:C0004238] secret,design [MeSH:C0013171] prospective investigation metformin [MeSH:C0025598] diabete participant [MeSH:C1708335] cardiac patient dopamine oligodendroglioma [MeSH:C0028945] result enhance therapeutic response [MeSH:C0087111] encephalopathy [MeSH:C0085584] correlation practice guideline [MeSH:C0936005],neurological
proteinuria pathway dementia [MeSH:C0497327],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke [MeSH:C0038454] renal cyst method cardiac patient undergo prospective liver fibrosis acute kidney injury [MeSH:C2609414] assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] safety [MeSH:C0036043] consideration,hepatorenal
cardiovascular effect [MeSH:C0596270] hypotension [MeSH:C0020649] induce adenosine triphosphate sodium nitroprusside dog denervated heart,adenosine triphosphate atp [MeSH:C0001480] [MeSH:C0001480] sodium nitroprusside snp administer patient [MeSH:C0030705] induce hypotension [MeSH:C0020649] anesthesia [MeSH:C0020649] snp authorize use usa uk atp [MeSH:C0001480] [MeSH:C0001480] clinically country japan investigate [MeSH:C0035173] drug [MeSH:C0013227] act cardiovascular [MeSH:C0007220] system dog [MeSH:C0007226] heart denervate procedure devise atp [MeSH:C0001480] [MeSH:C0001480] dog snp dog administer reduce mean arterial [MeSH:C0003835] pressure induce hypotension [MeSH:C0020649] measure [MeSH:C0079809] major cardiovascular [MeSH:C0007220] parameter hypotension [MeSH:C0020649] induce atp [MeSH:C0001480] [MeSH:C0001480] accompany decrease mean pulmonary arterial [MeSH:C0003835] pressure p [MeSH:C0034094] [MeSH:C0034094] central venous pressure [MeSH:C0428640] [MeSH:C0428640] p leave ventricular end-diastolic pressure [MeSH:C0206177] p total peripheral resistance p rate pressure product p total body oxygen consumption p heart rate [MeSH:C0018810] [MeSH:C0018810] p variable return normal min atp [MeSH:C0001480] [MeSH:C0001480] stop cardiac output [MeSH:C0007165] [MeSH:C0007165] hypotension [MeSH:C0020649] produce snp similar decrease observe mean pulmonary arterial [MeSH:C0003835] pressure p [MeSH:C0034094] [MeSH:C0034094] central venous pressure [MeSH:C0428640] [MeSH:C0428640] p leave ventricular end-diastolic pressure [MeSH:C0206177] p total peripheral resistance p rate pressure product p oxygen content difference arterial [MeSH:C0003835] mixed venous blood p [MeSH:C0042486] heart rate [MeSH:C0018810] [MeSH:C0018810] p cardiac output [MeSH:C0007165] [MeSH:C0007165] p increase recovery [MeSH:C0140116] heart rate [MeSH:C0018810] [MeSH:C0018810] leave ventricular end-diastolic pressure [MeSH:C0206177] show min snp stop atp [MeSH:C0001480] [MeSH:C0001480] snp act pacemaker tissue heart,neurological|cardiovascular
hypercalcemia [MeSH:C0020437] arrhythmia mood stabilizer,recent finding bipolar [MeSH:C0320086] receive maintenance lithium therapy [MeSH:C0039798] develop hypercalcemia [MeSH:C0020437] [MeSH:C0020437] severe bradyarrhythmia [MeSH:C0428977] prompt author conduct retrospective [MeSH:C0035363] bipolar [MeSH:C0320086] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lithium-associated hypercalcemia [MeSH:C0020437] [MeSH:C0020437] printout case hypercalcemia [MeSH:C0020437] [MeSH:C0020437] present -year period [MeSH:C0080129] generate eliminate spurious hypercalcemia [MeSH:C0020437] [MeSH:C0020437] associate intravenous fluid author identify non-lithium-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hypercalcemia [MeSH:C0020437] [MeSH:C0020437] related malignancy [MeSH:C0006826] medical condition [MeSH:C0162518] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lithium-associated hypercalcemia [MeSH:C0020437] [MeSH:C0020437] b patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] b comparable medically compromise receive multiple pharmacotherapie group [MeSH:C0018257] generate c1 include age- sex-comparable lithium-treated bipolar [MeSH:C0320086] normocalcemic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] c2 include bipolar [MeSH:C0320086] normocalcemic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat anticonvulsant mood [MeSH:C0003286] stabilizer [MeSH:C1268905] electrocardiographic ecg finding patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] b compare patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] group [MeSH:C0018257] c1 c2 find group [MeSH:C0018257] differ overall frequency [MeSH:C0376249] ecg abnormality [MeSH:C0037268] difference frequency [MeSH:C0376249] conduction defect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hypercalcemia [MeSH:C0020437] [MeSH:C0020437] result medical disease bipolar [MeSH:C0320086] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lithium-associated hypercalcemia [MeSH:C0020437] [MeSH:C0020437] significantly high frequency [MeSH:C0376249] conduction defect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mortality [MeSH:C0026565] -year follow-up [MeSH:C3899107] contrast [MeSH:C0009924] zero mortality [MeSH:C0026565] group [MeSH:C0018257] implication finding discuss,cardiovascular
hcc ventricular tachycardia vascular [MeSH:C0042514] insight,dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve pad anuria method conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine pkd parameter result well quality life measure need investigation [MeSH:C0035173],cardiovascular|hepatorenal
diuretic [MeSH:C0012798] chronic kidney disease [MeSH:C1561643] brain [MeSH:C0006104] insight,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] ace inhibitor [MeSH:C0003015] hypertension participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] tic stroke [MeSH:C0038454] result enhance therapeutic response [MeSH:C0087111] peripheral neuropathy [MeSH:C4721453] correlation healthcare advancement,neurological
atrium pathway [MeSH:C0282655] parkinson disease [MeSH:C0030567],prospective examine aspirin [MeSH:C0004057] diabete diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include aphasia defibrillator craniopharyngioma method participant [MeSH:C1708335] include result favorable safety profile implication optimization [MeSH:C0376695],neurological|cardiovascular
apci17k allele cancer [MeSH:C0002085] risk [MeSH:C0035647] community-based [MeSH:C5197711] ashkenazi jew,mutation [MeSH:C0026882] apc [MeSH:C0162832] classically associate familial adenomatous polyposis fap [MeSH:C0032580] highly penetrant autosomal dominant disorder [MeSH:C2936739] characterize multiple intestinal polyp [MeSH:C0021846] surgical intervention development colorectal cancer [MeSH:C0009402] crc apc [MeSH:C0162832] tumour-suppressor gene somatic loss occur tumour germline t-to-a transversion [MeSH:C0227386] responsible apc [MeSH:C0162832] i17k allele [MeSH:C0002085] convert wild-type sequence homopolymer tract [MeSH:C0137914] a8 genetically unstable prone somatic mutation [MeSH:C0026882] i17k allele [MeSH:C0002085] find unselected ashkenazi jew high proportion ashkenazim family personal history crc ref evaluate role i17k cancer genotype [MeSH:C0017431] [MeSH:C0017431] ashkenazi volunteer [MeSH:C0042960] community [MeSH:C0009462] survey [MeSH:C0038951] risk [MeSH:C0035647] develop colorectal breast cancer [MeSH:C0009402] compare genotype [MeSH:C0017431] [MeSH:C0017431] i17k carrier non-carrier first-degree relative,oncological
atrium cancer [MeSH:C0006826] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient bundle branch block restrictive cardiomyopathy [MeSH:C0007196] result well quality life measure cerebrovascular [MeSH:C0007820] correlation healthcare advancement,cardiovascular
state-of-the-art chemotherapy angina pectoris,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome peripheral artery disease pathway [MeSH:C1704436] method observational trial [MeSH:C0302523] elderly patient measure diastolic septum result improvement primary endpoint therapeutic innovation [MeSH:C0087111],cardiovascular
pleiotropic defect [MeSH:C2936489] ataxia-telangiectasia [MeSH:C0004135] protein-deficient mouse,generate mouse [MeSH:C0026809] model ataxia-telangiectasia gene target generate mouse [MeSH:C0026809] express atm protein [MeSH:C0033684] [MeSH:C0033684] atm-deficient mouse [MeSH:C0026809] retard growth [MeSH:C0018270] produce mature [MeSH:C0349590] sperm [MeSH:C0037868] exhibit severe defect cell maturation [MeSH:C0036887] go develop thymoma [MeSH:C0040100] atm-deficient fibroblast grow poorly culture display high double-stranded chromosome [MeSH:C0035693] break atm-deficient thymocyte [MeSH:C0814999] undergo spontaneous [MeSH:C0000786] apoptosis [MeSH:C0162638] vitro significantly control atm-deficient mouse [MeSH:C0026809] exhibit symptom [MeSH:C3839861] find ataxia-telangiectasia patient cell [MeSH:C0004135] derive furthermore demonstrate atm protein [MeSH:C0033684] [MeSH:C0033684] exist discrete molecular specie loss lead development disease,neurological
leukemia [MeSH:C0023418] pathway [MeSH:C0282655] ventricular tachycardia [MeSH:C0042514],design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation beta-blocker hypertension participant [MeSH:C1708335] elderly [MeSH:C0001792] patient creatinine [MeSH:C0010294] hepatocellular carcinoma [MeSH:C2239176] result improve outcome polyuria [MeSH:C0032617] correlation [MeSH:C0010100] optimization [MeSH:C0376695],hepatorenal|oncological
meningioma pattern [MeSH:C0025286] dementia [MeSH:C0497327] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome [MeSH:C0206277] restrictive cardiomyopathy pathway method [MeSH:C0007196] cross-sectional trial [MeSH:C0010362] cardiac patient measure aortic dissection [MeSH:C0340643] neurodegenerative [MeSH:C0524851] result well quality life measure therapeutic innovation [MeSH:C0087111],neurological|cardiovascular
chronic myeloid leukemia [MeSH:C0279543] marker alzheimer disease [MeSH:C0002395],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation beta-blocker cancer participant cancer patient stem cell transplant [MeSH:C1504389] aortic valve [MeSH:C0003501] result well quality life measure [MeSH:C0079809] endocardium [MeSH:C0014124] correlation cost-effectiveness [MeSH:C1511536] implication,cardiovascular|oncological
mefenamic [MeSH:C0025152] acid-induced neutropenia renal failure [MeSH:C0035078] elderly [MeSH:C0001792] female hypothyroidism [MeSH:C0020676],report mefenamic [MeSH:C0025152] acid-induced non-oliguric renal failure severe neutropenia [MeSH:C0027947] occur simultaneously elderly female [MeSH:C0001792] neutropenia [MeSH:C0027947] maturation arrest myeloid series patient hypothyroid [MeSH:C0020676] clear predispose factor development [MeSH:C0020119] adverse reaction [MeSH:C0041755] prudent use mefenamic [MeSH:C0025152] acid hypothyroid [MeSH:C0020676] patient hypothyroid [MeSH:C0020676]ism correct,hepatorenal
severe [MeSH:C1719672] congestive heart failure [MeSH:C0018802] amiodarone [MeSH:C0002598] present myxedemic coma [MeSH:C0027145] case report [MeSH:C0684224],case report [MeSH:C0684224] [MeSH:C0684224] myxedema [MeSH:C0027145] coma [MeSH:C0009421] [MeSH:C0009421] [MeSH:C0027145] secondary amiodarone [MeSH:C0002598]-induced hypothyroidism [MeSH:C0271801] severe congestive heart failure [MeSH:C0018802] chf knowledge review [MeSH:C0376554] literature case report [MeSH:C0684224] [MeSH:C0023866] [MeSH:C0684224] myxedema [MeSH:C0027145] coma [MeSH:C0009421] [MeSH:C0009421] [MeSH:C0027145] long term [MeSH:C0023977] amiodarone [MeSH:C0002598] therapy myxedema [MeSH:C0027145] coma [MeSH:C0009421] [MeSH:C0009421] [MeSH:C0027145] life threaten condition [MeSH:C0037403] carry mortality [MeSH:C0026565] reach high condition [MeSH:C0037403] treat intravenous thyroxine t4 intravenous tri-iodo-thyronine t3 patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chf amiodarone [MeSH:C0002598] suffer morbidity [MeSH:C0026538] [MeSH:C0026538] mortality [MeSH:C0026565] hypothyroidism deserve close thyroid stimulating [MeSH:C0040139] hormone tsh level case report [MeSH:C0684224] [MeSH:C0684224] carry important application [MeSH:C3658310] give frequent usage amiodarone [MeSH:C0002598] chf patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] myriad presentation myxedema [MeSH:C0027145] coma [MeSH:C0009421] [MeSH:C0009421] [MeSH:C0027145] morbidity [MeSH:C0026538] [MeSH:C0026538] mortality [MeSH:C0026565] stress need suspect syndrome [MeSH:C0039082] chf patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present hypotension weakness unexplained symptom [MeSH:C3839861],neurological|cardiovascular
recurrent [MeSH:C2825055] myocardial infarction [MeSH:C0027051] postpartum [MeSH:C0086839] receive bromocriptine [MeSH:C0006230],myocardial infarction [MeSH:C0027051] [MeSH:C0027051] puerperium [MeSH:C0034042] [MeSH:C0034042] infrequently report spasm [MeSH:C0037763] coronary dissection [MeSH:C0012737] atheromatous etiology describe bromocriptine [MeSH:C0006230] [MeSH:C0006230] implicate previous case report [MeSH:C0684224] myocardial infarction [MeSH:C0027051] [MeSH:C0027051] puerperium [MeSH:C0034042] [MeSH:C0034042] case include inadvertent rechallenge suggest relationship [MeSH:C0021797] generally regard safe possible cardiac effect bromocriptine [MeSH:C0006230] [MeSH:C0006230] acknowledge,cardiovascular
effect [MeSH:C4277511] ouabain [MeSH:C0029904] myocardial oxygen supply demand patient [MeSH:C0030705] [MeSH:C0030705] chronic coronary artery disease [MeSH:C1956346] hemodynamic [MeSH:C0019010] volumetric [MeSH:C1956110] metabolic [MeSH:C0025517] patient [MeSH:C0030705] [MeSH:C0030705] heart failure [MeSH:C0018801],effect [MeSH:C4277511] [MeSH:C4277511] digitalis glycoside myocardial [MeSH:C0012253] oxygen supply demand particular interest presence obstructive coronary artery disease [MeSH:C0003838] measure [MeSH:C0079809] previously man assess effect [MeSH:C4277511] [MeSH:C4277511] ouabain [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] mg kg body weight [MeSH:C0005910] hemodynamic [MeSH:C0019010] volumetric [MeSH:C1956110] metabolic [MeSH:C0025517] parameter patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe chronic coronary artery disease [MeSH:C1956346] [MeSH:C1956346] congestive heart failure [MeSH:C0018802] [MeSH:C0018802] protocol [MeSH:C0655632] [MeSH:C0655632] long involve intervention [MeSH:C3898714] affect determination study patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] identical protocol [MeSH:C0655632] [MeSH:C0655632] ouabain [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] administration omit leave ventricular end-diastolic pressure [MeSH:C0206177] [MeSH:C0206177] leave ventricular end-diastolic volume [MeSH:C0042509] [MeSH:C0042509] [MeSH:C0042509] fall give ouabain [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] initially elevated [MeSH:C0020443] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] leave ventricular end-diastolic pressure [MeSH:C0206177] [MeSH:C0206177] fall mean -se mm hg p leave ventricular end-diastolic volume [MeSH:C0042509] [MeSH:C0042509] [MeSH:C0042509] fall ml m2 p h ouabain [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] infusion complete maximum velocity contractile element [MeSH:C0009915] shortening increase ml muscle-length p [MeSH:C0517349] consistent increase contractility parameter occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] myocardial oxygen consumption [MeSH:C0030055] occur ouabain [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] administration related great decrease mean arterial pressure [MeSH:C0428886] ouabain [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] conclude patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chronic coronary artery disease [MeSH:C1956346] [MeSH:C1956346] congestive heart failure [MeSH:C0018802] [MeSH:C0018802] leave ventricular end-diastolic volume [MeSH:C0042509] [MeSH:C0042509] [MeSH:C0042509] fall ouabain [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] [MeSH:C0029904] administration initially normal fall associate decrease wall tension myocardial oxygen consumption [MeSH:C0030055] sufficient magnitude prevent [MeSH:C0000918] [MeSH:C0000918] net increase myocardial oxygen consumption [MeSH:C0030055] compensatory mechanism prevent [MeSH:C0000918] [MeSH:C0000918] deterioration [MeSH:C0234985] rest myocardial metabolism,neurological|cardiovascular
hypertension [MeSH:C0020538] proteinuria [MeSH:C0033687] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] hepatorenal syndrome pathway method [MeSH:C0019212] retrospective trial adult [MeSH:C0001675] population measure blood urea [MeSH:C0005845] nitrogen hepatocellular [MeSH:C0345904] result improve disease management [MeSH:C0039798] practice guideline,hepatorenal
ventricle cardiomyopathy [MeSH:C0878544] vascular [MeSH:C0221214] insight,cross-sectional examine [MeSH:C0010362] calcium channel blocker hypertension [MeSH:C0006684] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include hypertrophic cardiomyopathy [MeSH:C0007194] heart valve restrictive cardiomyopathy method [MeSH:C0007196] participant [MeSH:C1708335] include result favorable safety [MeSH:C0036043] profile implication safety [MeSH:C0036043] consideration,cardiovascular
association [MeSH:C0004083] ozone [MeSH:C0030106] pm2 concentration parkinson disease [MeSH:C0030567] participant [MeSH:C1708335] agricultural health [MeSH:C0242775],describe association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] ozone [MeSH:C0030106] fine particulate matter parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] observe farmer north carolina iowa method logistic regression [MeSH:C0206031] determine association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] pollutant [MeSH:C0014417] [MeSH:C0014417] [MeSH:C0014417] self-reported doctor-diagnosed parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] daily predict pollutant [MeSH:C0014417] [MeSH:C0014417] [MeSH:C0014417] concentration [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] derive surrogate long-term [MeSH:C0023977] exposure [MeSH:C1390376] link participant [MeSH:C1708335] geocode [MeSH:C0814798] address result observe positive association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] ozone [MeSH:C0030106] odd ratio ci fine particulate matter odd ratio ci north carolina [MeSH:C0028407] iowa conclusion plausibility effect ambient [MeSH:C0487782] concentration [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] pollutant [MeSH:C0014417] [MeSH:C0014417] [MeSH:C0014417] parkinson disease [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] [MeSH:C0030567] risk support experimental [MeSH:C0016998] demonstrate damage [MeSH:C0012860] dopaminergic neuron [MeSH:C1512035] relevant concentration [MeSH:C0311432] [MeSH:C0311432] [MeSH:C0311432] additional study [MeSH:C0085973] need address uncertainty related confound examine temporal [MeSH:C0039484] aspect association [MeSH:C0004083] [MeSH:C0004083] [MeSH:C0004083] observe,neurological
molecular genetic primary dystonia,primary dystonia [MeSH:C0013421] [MeSH:C0013421] [MeSH:C0752203] movement disorder [MeSH:C0026650] dystonia [MeSH:C0013421] [MeSH:C0013421] major symptom [MeSH:C3839861] frequently inherit mendelian trait clinically distinct autosomal dominant [MeSH:C2936739] [MeSH:C2936739] [MeSH:C2936739] x-linked recessive form addition pedigree analysis [MeSH:C0030761] suggest occurrence autosomal recessive variant classification [MeSH:C0008902] increasingly replace genetic [MeSH:C0017380] date gene locus [MeSH:C0678933] [MeSH:C0678933] identify autosomal dominant [MeSH:C2936739] [MeSH:C2936739] [MeSH:C2936739] form e idiopathic torsion dystonia [MeSH:C0013421] [MeSH:C0013423] [MeSH:C0013423] [MeSH:C0013423] [MeSH:C0013421] 9q3 focal dystonia [MeSH:C0013421] [MeSH:C0013421] 8p adult-onset idiopathic torsion dystonia [MeSH:C0013421] [MeSH:C0013423] [MeSH:C0013423] [MeSH:C0013423] [MeSH:C0013421] mixed type 8p2-q2 dopa-responsive dystonia [MeSH:C0013421] [MeSH:C1851920] [MeSH:C0013421] 4q2 -q2 paroxysmal dystonic choreoathetosis 2q2-q3 1p2-p1 gene locus [MeSH:C0678933] [MeSH:C0678933] x-linked recessive form assign xq1 x-linke dystonia [MeSH:C0013421] [MeSH:C0013421] parkinsonism syndrome xq2 x-linked sensorineural deafness dystonia [MeSH:C0013421] [MeSH:C0018784] [MeSH:C0013421] mental retardation disease [MeSH:C3714756] gene identify autosomal dominant [MeSH:C2936739] [MeSH:C2936739] [MeSH:C2936739] form x-linked recessive form mutation gene code atp-binding protein detect idiopathic torsion dystonia [MeSH:C0013421] [MeSH:C0013423] [MeSH:C0013423] [MeSH:C0013423] [MeSH:C0013421] dyt1 [MeSH:C3888090] gtp cyclohydrolase gene [MeSH:C0018293] mutate dopa-responsive dystonia [MeSH:C0013421] [MeSH:C1851920] [MeSH:C0013421] dyt5 sensorineural deafness dystonia [MeSH:C0013421] [MeSH:C0018784] [MeSH:C0013421] mental retardation mutation [MeSH:C3714756] find gene ddp code polypeptide unknown function article review molecular genetic [MeSH:C0017380] primary dystonia [MeSH:C0013421] [MeSH:C0013421] [MeSH:C0752203] critically discuss present finding propose refer known form distinguish genetic [MeSH:C0017380] criterion dystonia [MeSH:C0013421] [MeSH:C0013421],neurological
sulpiride-induced tardive dystonia,sulpiride [MeSH:C0038803] selective d2-receptor antagonist antipsychotic antidepressant [MeSH:C0040615] property initially think free extrapyramidal effect [MeSH:C0015372] sulpiride [MeSH:C0038803]-induced tardive dyskinesia [MeSH:C0686347] parkinsonism report occasionally study [MeSH:C0085973] -year-old man develop persistent [MeSH:C0026205] segmental dystonia month start sulpiride [MeSH:C0038803] therapy find previous report sulpiride [MeSH:C0038803]-induced tardive dystonia,neurological
breakthrough creatinine [MeSH:C0010294] finding lung cancer [MeSH:C0242379],investigate [MeSH:C0035173] beta-blocker effect diabete nephrolithiasis method [MeSH:C0392525] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo randomized control proteinuria [MeSH:C1096777] hepatic assessment [MeSH:C0030198] result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],hepatorenal
locus [MeSH:C0085286] heterogeneity friedreich ataxia [MeSH:C0016719],friedreich ataxia frda [MeSH:C0016719] common form autosomal recessive ataxia disease [MeSH:C1849140] locus assign chromosome disease gene stm7 x2 isolate date suggest locus homogeneity frda provide strong evidence [MeSH:C5575834] second frda locus study sibling [MeSH:C0037047] frda family detect mutation stm7 x2 haplotype stm7 x2 region chromosome demonstrate relevant portion chromosome [MeSH:C0008633] differ patient patient study [MeSH:C0030705] typical frda sibpair uncommon symptom [MeSH:C3839861] retain tendon reflex [MeSH:C0034943] order investigate retain tendon reflex [MeSH:C0034943] characteristic frda cause second locus frda2 study unrelated frda retain tendon reflex [MeSH:C0034943] observation [MeSH:C0302523] typical mutation stm7 x2 gaa expansion [MeSH:C0196940] demonstrate genetically different form frda distinguish clinically,neurological
amyotrophic lateral sclerosis connection [MeSH:C0002736] stroke [MeSH:C0038454],hypothesis [MeSH:C3179072] aspirin improve diabete outcome encephalopathy pathway method longitudinal trial cancer patient [MeSH:C0030705] measuring chorea alzheimer disease [MeSH:C0002395] result improve disease management care [MeSH:C0039798] improvement [MeSH:C2936612],neurological
brain map [MeSH:C0006104] cardiomyopathy insight,heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve glioma brain method conduct cross-sectional evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine guillain-barre syndrome [MeSH:C0018378] parameter result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,neurological
cholelithiasis [MeSH:C0008350] pathway angina pectoris [MeSH:C0002962],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] blood urea [MeSH:C0005845] nitrogen pathway method cross-sectional trial [MeSH:C0010362] adult [MeSH:C0001675] population [MeSH:C0032659] measuring uremia [MeSH:C0041948] hepatocellular carcinoma [MeSH:C2239176] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] relevance [MeSH:C2826293],hepatorenal
nephrotic syndrome [MeSH:C0027726] connection multiple sclerosis [MeSH:C0026769],question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] uremia [MeSH:C0041948] mechanism method cross-sectional [MeSH:C0010362] elderly patient assess trigeminal neuralgia polycystic kidney disease [MeSH:C0022680] result improvement [MeSH:C2936612] primary endpoint implication relevance,neurological|hepatorenal
medial [MeSH:C3179065] change arterial spasm [MeSH:C0037763] induce l-norepinephrine [MeSH:C0028351],normal rat [MeSH:C0034721] medium small artery mm diameter previously show contain intracellular [MeSH:C0682581] vacuole [MeSH:C0042219] identify ultrastructurally [MeSH:C0041623] herniation smooth muscle cell [MeSH:C1135918] [MeSH:C1135918] hypothesis [MeSH:C3179072] intense vasoconstriction [MeSH:C0042396] increase number vacuole [MeSH:C0042219] test medium saphenous artery distal branch vasoconstriction [MeSH:C0042396] induce l-norepinephrine [MeSH:C0028351] produce cell-to-cell hernia [MeSH:C0007582] minute number reduce original number day vessel restore normal triple stimulation induce severe change medium finding suggest smooth muscle cell [MeSH:C1135918] [MeSH:C1135918] susceptible damage course specific function [MeSH:C0031843] experimental [MeSH:C0016998] discuss relation medial [MeSH:C3179065] change observe instance arterial [MeSH:C0003835] spasm [MeSH:C0037763] endothelial change develop experimental [MeSH:C0016998] model describe previous paper,cardiovascular
renal stone marker [MeSH:C0017393] valvular heart disease [MeSH:C0018824],investigate [MeSH:C0035173] beta-blocker effect cancer arterial method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo retrospective pulmonary valve hepatorenal syndrome assessment [MeSH:C0030198] result well quality life measure cost-effectiveness [MeSH:C1511536] implication,cardiovascular|hepatorenal
coronary diabete mellitus [MeSH:C0011849] vascular insight,cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve endothelium coronary method conduct randomized control evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine bradycardia [MeSH:C0428977] parameter result enhance therapeutic response [MeSH:C0087111] healthcare advancement,cardiovascular
oncological frontier ventricular tachycardia [MeSH:C0042514],investigate [MeSH:C0035173] beta-blocker effect diabete neoplasm [MeSH:C0027651] method cardiac patient undergo prospective lung cancer stem cell transplant assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],oncological
heart failure pathway myocardial infarction [MeSH:C0027051],stroke [MeSH:C0038454] affect elderly patient [MeSH:C0030705] worldwide particularly involve autonomic neuropathy pe method [MeSH:C0271686] conduct observational [MeSH:C0302523] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine atrial fibrillation [MeSH:C0004238] parameter result favorable safety profile practice guideline,neurological|cardiovascular
innovative metformin [MeSH:C0025598] approach ventricular tachycardia [MeSH:C0042514],cross-sectional examine [MeSH:C0010362] metformin [MeSH:C0025598] stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include alkaline phosphatase renal cyst albumin method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication practice guideline,hepatorenal
learning [MeSH:C0023185] rat [MeSH:C0034721] amnesia cause pentobarbital [MeSH:C0030883],dissociate [MeSH:C0004331] learning rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] normal state state amnesia produce pentobarbital [MeSH:C0030883] [MeSH:C0030883] mg kg ip carry rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] train [MeSH:C0870303] [MeSH:C0870303] approach shelf receive food reinforcement [MeSH:C0035009] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] train [MeSH:C0870303] [MeSH:C0870303] influence [MeSH:C0683549] pentobarbital [MeSH:C0030883] [MeSH:C0030883] run shelf normal state rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] train [MeSH:C0870303] [MeSH:C0870303] approach different shelf different drug state [MeSH:C0013227] show memory dissociation occur group difference parameter train [MeSH:C0870303] [MeSH:C0870303]ing influence [MeSH:C0683549] pentobarbital [MeSH:C0030883] [MeSH:C0030883] group reveal finding brain-dissociate [MeSH:C0004331]d state induce pentobarbital [MeSH:C0030883] [MeSH:C0030883] form participation [MeSH:C0030699] mechanism [MeSH:C1524059] information [MeSH:C5544371] perception,neurological
guillain-barre syndrome [MeSH:C0018378] connection dementia [MeSH:C0497327],heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve tremor convulsion method conduct observational [MeSH:C0302523] evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine ataxia [MeSH:C0004134] parameter result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],neurological
ventricle ventricular tachycardia vascular [MeSH:C0042514] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] myocardial [MeSH:C0027061] mechanism method observational [MeSH:C0302523] adult population [MeSH:C0032659] assess restrictive cardiomyopathy bradycardia [MeSH:C0007196] result well quality life measure implication practice guideline [MeSH:C0936005],cardiovascular
limbic system connection [MeSH:C0023715] coronary artery disease [MeSH:C1956346],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] cerebral method adult [MeSH:C0001675] population [MeSH:C0032659] undergo observational [MeSH:C0302523] white matter [MeSH:C0682708] parkinsonism [MeSH:C0242422] assessment [MeSH:C0030198] result improve outcome practice guideline [MeSH:C0936005],neurological
cardiomyopathy [MeSH:C0878544] hcc organ [MeSH:C0029250] interplay,longitudinal [MeSH:C0023981] examine beta-blocker diabete diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include alt nephrolithiasis ggt method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication relevance,hepatorenal
atm p5 cooperate apoptosis [MeSH:C0162638] suppression [MeSH:C1956351] tumorigenesis [MeSH:C0596263] resistance [MeSH:C0034471] acute [MeSH:C0184567] radiation toxicity,mutation atm p5 cause human [MeSH:C0086418] [MeSH:C0086418] cancer-associated disease ataxia-telangiectasia li-fraumeni syndrome respectively gene [MeSH:C0017337] [MeSH:C0017337] [MeSH:C0017337] believe interact number pathway include regulation dna damage-induced cell-cycle checkpoint apoptosis [MeSH:C0162638] radiation [MeSH:C0851346] sensitivity [MeSH:C0036667] cellular proliferation [MeSH:C0596290] atm-null mouse [MeSH:C0026809] null p5 develop mainly t-cell lymphoma [MeSH:C0079772] support view gene [MeSH:C0017337] [MeSH:C0017337] [MeSH:C0017337] similar role thymocyte [MeSH:C0814999] [MeSH:C0814999] development [MeSH:C0243107] interaction [MeSH:C0007582] gene [MeSH:C0017337] [MeSH:C0017337] [MeSH:C0017337] organismal breed [MeSH:C0006159] mouse [MeSH:C0026809] heterozygous [MeSH:C0019425] null allele atm p5 produce genotypic combination mouse [MeSH:C0026809] doubly null atm p5 exhibit dramatic acceleration [MeSH:C0000894] tumour formation relative singly null mouse [MeSH:C0026809] indicate gene [MeSH:C0017337] [MeSH:C0017337] [MeSH:C0017337] collaborate manner prevent [MeSH:C0000918] tumorigene [MeSH:C0017337] [MeSH:C0017337] [MeSH:C0017337]sis respect role apoptosis [MeSH:C0162638] loss atm render thymocyte [MeSH:C0814999] [MeSH:C0814999] partly resistant [MeSH:C2986418] irradiation [MeSH:C0851346]-induced apoptosis [MeSH:C0162638] additional loss p5 engender complete resistance [MeSH:C0034471] imply irradiation [MeSH:C0851346]-induced atm p5 apoptotic pathway completely congruent finally-and contrast prior predictions-atm p5 appear interact acute radiation [MeSH:C0520799] [MeSH:C0851346] toxicity suggest separate atm effector pathway dna damage response [MeSH:C0012860] implication prognosis [MeSH:C0033325] human [MeSH:C0086418] [MeSH:C0086418] tumour,neurological|oncological
pulmonary embolism leukemia [MeSH:C0034065] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] dementia [MeSH:C0497327] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] atrioventricular block atherosclerosis [MeSH:C0004245] result positive response embolism [MeSH:C0013922] correlation [MeSH:C0010100] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
neural regeneration [MeSH:C0034963] myocardial infarction [MeSH:C0027051],heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve amyotrophic lateral sclerosis brain method [MeSH:C0002736] conduct randomized control evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine cerebellar [MeSH:C0007765] parameter result improve disease management [MeSH:C0039798] optimization [MeSH:C0376695],neurological
increase incidence cancer [MeSH:C0021149] patient [MeSH:C0030705] cartilage-hair hypoplasia [MeSH:C0220748],previous report suggest increase risk [MeSH:C0035647] [MeSH:C0035647] cancer [MeSH:C0006826] [MeSH:C0035647] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cartilage-hair hypoplasia chh [MeSH:C0220748] carry evaluate [MeSH:C0013175] risk [MeSH:C0035647] [MeSH:C0035647] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chh first-degree relative design twenty-two patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chh identify countrywide epidemiologic survey [MeSH:C3494349] parent [MeSH:C0030551] [MeSH:C0030551] nonaffected sibling [MeSH:C0037047] identify population [MeSH:C0032659] register center cohort [MeSH:C1706962] undergo follow-up [MeSH:C3899107] cancer [MeSH:C0006826] incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] finnish cancer [MeSH:C0006826] registry end result statistically excess risk [MeSH:C0035647] [MeSH:C0035647] cancer [MeSH:C0006826] [MeSH:C0035647] see patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chh standardized incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] ratio confidence interval [MeSH:C0009667] [MeSH:C0009667] mainly attributable non-hodgkins lymphoma [MeSH:C0024305] [MeSH:C0024305] standardized incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] ratio confidence interval [MeSH:C0009667] [MeSH:C0009667] addition excess risk [MeSH:C0035647] [MeSH:C0035647] basal cell carcinoma [MeSH:C4721806] see standardized incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] ratio confidence interval [MeSH:C0009667] [MeSH:C0009667] cancer [MeSH:C0006826] incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] sibling [MeSH:C0037047] parent [MeSH:C0030551] [MeSH:C0030551] differ average cancer [MeSH:C0006826] incidence [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] finnish population [MeSH:C0032659] conclusion confirm increase risk [MeSH:C0035647] [MeSH:C0035647] cancer [MeSH:C0006826] [MeSH:C0035647] especially non-hodgkins lymphoma [MeSH:C0024305] [MeSH:C0024305] probably attributable defective [MeSH:C0011139] immunity [MeSH:C0020964] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chh,neurological|oncological
acute encephalopathy cerebral vasospasm multiagent chemotherapy include peg-asparaginase [MeSH:C0071568] intrathecal [MeSH:C0021896] cytarabine acute lymphoblastic leukemia,-year-old girl [MeSH:C0043210] unusual reaction induction chemotherapy precursor b-cell acute lymphoblastic leukemia [MeSH:C0023485] describe develop acute encephalopathy [MeSH:C0085584] evidence behavioral change [MeSH:C0004927] aphasia incontinence visual hallucination [MeSH:C0233763] right-sided weakness diffuse cerebral vasospasm magnetic resonance angiography [MeSH:C0243032] [MeSH:C0243032] administration [MeSH:C0001554] intrathecal cytarabine vincristine dexamethasone [MeSH:C0011777] polyethylene [MeSH:C0137914] glycol-asparaginase administer episode [MeSH:C0085554] induction therapy [MeSH:C3179010] neurologic status return day acute event magnetic resonance angiography [MeSH:C0243032] finding return normal month later,neurological|oncological
hepatocellular carcinoma [MeSH:C2239176] pathway liver cirrhosis [MeSH:C0023890],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete nonalcoholic steatohepatitis [MeSH:C3241937] mechanism method prospective elderly patient assess nephritis gamma glutamyl transferase [MeSH:C0017040] result superior efficacy [MeSH:C5690761] implication healthcare advancement,hepatorenal
metastatic pathway heart failure,heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve tumor suppressor skin cancer [MeSH:C0597611] method conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine kidney cancer [MeSH:C0740457] parameter result improve outcome [MeSH:C0206277] therapeutic innovation [MeSH:C0087111],hepatorenal|oncological
peritoneal dialysis pathway [MeSH:C0031139] atrial fibrillation [MeSH:C0004238],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect hypertension nephritis [MeSH:C0020538] method elderly patient undergo cross-sectional oliguria cholangiocarcinoma assessment [MeSH:C0030198] result favorable safety profile practice guideline,hepatorenal
ethopropazine benztropine [MeSH:C0005098] neuroleptic-induced parkinsonism,-week controlled [MeSH:C0020650] ethopropazine [MeSH:C0015042] [MeSH:C0015042] compare benztropine [MeSH:C0005098] parkinsonism [MeSH:C0242422] induce fluphenazine [MeSH:C0016368] enanthate schizophrenic outpatient [MeSH:C0030705] [MeSH:C0030705] ethopropazine [MeSH:C0015042] [MeSH:C0015042] benztropine [MeSH:C0005098] find equally effective control parkinsonian [MeSH:C0242422] symptom [MeSH:C3839861] efficacious procyclidine [MeSH:C0033254] previous antiparkinsonian [MeSH:C0242422] drug benztropine [MeSH:C0005098] treated patient [MeSH:C0030705] [MeSH:C0030705] increase tardive dyskinesia [MeSH:C0686347] compare condition [MeSH:C0037403] procyclindine [MeSH:C0033254] significantly anxiety [MeSH:C0003467] depression [MeSH:C0011570] ethopropazine [MeSH:C0015042] [MeSH:C0015042] treated patient [MeSH:C0030705] [MeSH:C0030705] suggest benztropine [MeSH:C0005098] anticholinergic drug choice neuroleptic-induced parkinsonian [MeSH:C0242422] symptom [MeSH:C3839861] toxic central peripheral atropinic effect,neurological
mind matter heart failure [MeSH:C0018801] gaba,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin hypertension [MeSH:C0020538] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] delirium reticular formation result decrease mortality rate [MeSH:C0205848] white matter [MeSH:C0682708] correlation care [MeSH:C0010100] improvement [MeSH:C2936612],neurological
neuroleptic malignant syndrome [MeSH:C0027849] methylphenidate [MeSH:C0025810],-year-old female [MeSH:C0086287] present neuroleptic malignant syndrome [MeSH:C0027849] [MeSH:C0027849] [MeSH:C0027849] probably cause methylphenidate [MeSH:C0025810] defect [MeSH:C0025810] supratentorial [MeSH:C0751589] brain include basal ganglion [MeSH:C0004781] striatum multicystic encephalomalacia severe perinatal [MeSH:C0242963] hypoxic-ischemic encephalopathy [MeSH:C0752304] consider possible predispose factor [MeSH:C0033453] cause neuroleptic malignant syndrome [MeSH:C0027849] [MeSH:C0027849] [MeSH:C0027849] dopaminergic blockade mechanism [MeSH:C1524059] generally accept pathogenesis syndrome [MeSH:C0699748] methylphenidate [MeSH:C0025810] dopamine agonist [MeSH:C0178601] inhibition [MeSH:C0027790] uptake dopamine dopaminergic system [MeSH:C0013030] brainstem [MeSH:C0006121] mainly midbrain [MeSH:C0025462] spinal cord [MeSH:C0037925] unlikely participate onset syndrome relative gamma-aminobutyric acid-ergic deficiency occur diazepam [MeSH:C0012010] gamma-aminobutyric acid-mimetic agent [MeSH:C0242898] strikingly effective report neuroleptic malignant syndrome [MeSH:C0027849] [MeSH:C0027849] [MeSH:C0027849] probably cause methylphenidate [MeSH:C0025810],neurological
cloning homogentisate -dioxygenase [MeSH:C0062939] gene [MeSH:C0017337] key enzyme alkaptonuria [MeSH:C0002066] mouse [MeSH:C0026809],determine amino acid [MeSH:C0002520] residue peptide homogene [MeSH:C0017337]ous monomer homogentisate -dioxygenase hgo e c mouse [MeSH:C0026809] [MeSH:C0026809] liver digestion trypsin peptide separate reverse phase chromatography amino acid [MeSH:C0002520] sequence [MeSH:C0597410] deduce codon sequence peptide [MeSH:C0037081] derive degene [MeSH:C0017337]rated [MeSH:C3503758] oligo [MeSH:C0599467]mere combine oligo [MeSH:C0599467] able amplify fragment basis b mouse [MeSH:C0026809] [MeSH:C0026809] liver cdna [MeSH:C0006556] [MeSH:C0006556] polymerase chain reaction reverse transcription rt-pcr fragment b clone [MeSH:C0009013] probe screen mouse [MeSH:C0026809] [MeSH:C0026809] liver cdna [MeSH:C0006556] [MeSH:C0006556] library clone [MeSH:C0009013] library [MeSH:C0751608] contain complete cdna [MeSH:C0006556] [MeSH:C0006556]-insert hgo determine sequencing cdna [MeSH:C0006556] [MeSH:C0006556] [MeSH:C0917792] encode protein kda predict cdna [MeSH:C0006556] [MeSH:C0006556] mouse [MeSH:C0026809] [MeSH:C0026809] hgo overall identity [MeSH:C0017249] corresponding gene [MeSH:C0017337] hmga [MeSH:C0949598] aspergillus sequence [MeSH:C0004034] similarity human [MeSH:C0086418] [MeSH:C0086418] express sequence tag [MeSH:C0600510] est clone [MeSH:C0009013] range position conserve amino acid [MeSH:C0002520] determine multiple sequence alignment [MeSH:C0206231] identify intron b mouse [MeSH:C0026809] [MeSH:C0026809] gene [MeSH:C0017337] gene [MeSH:C0017337] hgo express tissue [MeSH:C0040300] show rt-pcr different cdna [MeSH:C0006556] [MeSH:C0006556] fish experiment [MeSH:C0020123] murine [MeSH:C0026802] cdna [MeSH:C0006556] [MeSH:C0006556] probe clearly reveal signal [MeSH:C0037081] human [MeSH:C0086418] [MeSH:C0086418] chromosomal band 3q1 -q2 correspond previous assignment [MeSH:C5691386] locus [MeSH:C0085286] human [MeSH:C0086418] [MeSH:C0086418] alkaptonuria [MeSH:C0002066] gene [MeSH:C0017337] aku chromosomal region multipoint linkage conclude hgo cdna [MeSH:C0006556] [MeSH:C0006556] encode gene [MeSH:C0017337] responsible alkaptonuria [MeSH:C0002066],neurological|hepatorenal
pe peripheral artery disease [MeSH:C1704436] vascular [MeSH:C0221214] insight,retrospective [MeSH:C0035363] examine calcium channel blocker [MeSH:C0006684] dementia [MeSH:C0497327] cardiac patient investigation [MeSH:C0035173] include regurgitation thromboembolism insufficiency method participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
gfr peripheral artery disease [MeSH:C1704436] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect hypertension [MeSH:C0020538] alkaline phosphatase [MeSH:C0002059] mechanism method cross-sectional adult [MeSH:C0010362] population [MeSH:C0032659] assess peritoneal dialysis pericardium [MeSH:C0031139] result improve outcome [MeSH:C0206277] implication optimization [MeSH:C0376695],cardiovascular|hepatorenal
trigeminal neuralgia [MeSH:C0040997] pattern coronary artery disease [MeSH:C1956346] patient [MeSH:C0030705],cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve epinephrine seizure method conduct longitudinal [MeSH:C0023981] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine neurotransmitter [MeSH:C0027908] parameter result well quality life measure healthcare advancement,neurological
immunotherapy [MeSH:C0021083] coronary artery disease [MeSH:C1956346] brain [MeSH:C0006104] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] [MeSH:C0206277] tic pathway method randomized control trial [MeSH:C1096777] cardiac patient measure nephroblastoma convulsion [MeSH:C0027708] result improve outcome [MeSH:C0206277] [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,neurological|hepatorenal
alpha-lipoic acid [MeSH:C0023791] prevent [MeSH:C0000918] mitochondrial damage [MeSH:C0949610] neurotoxicity [MeSH:C0235032] experimental chemotherapy neuropathy,investigate [MeSH:C0035173] [MeSH:C0035173] alpha-lipoic acid [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] neuroprotective chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] induced [MeSH:C5392225] neurotoxicity [MeSH:C0040539] [MeSH:C0235032] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0235032] mitochondria [MeSH:C0026237] [MeSH:C0026237]l damage [MeSH:C0949610] play critical role toxic neurodegenerative cascade [MeSH:C0524851] neuroprotective effect [MeSH:C0815279] [MeSH:C0815279] alpha-lipoic acid [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] depend mitochondria [MeSH:C0026237] [MeSH:C0026237] protection vitro model [MeSH:C0011381] chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] induce peripheral neuropathy [MeSH:C4721453] closely mimic vivo condition expose primary culture [MeSH:C1449562] dorsal root ganglion drg sensory neuron [MeSH:C0034837] [MeSH:C0017070] paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] widely highly effective chemotherapeutic drug approach [MeSH:C0003392] allow investigate [MeSH:C0035173] [MeSH:C0035173] efficacy [MeSH:C5690761] alpha-lipoic acid [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] prevent [MeSH:C0000918] axonal damage apoptosis [MeSH:C0162638] function ultrastructural [MeSH:C0041623] morphology [MeSH:C0543482] mitochondria [MeSH:C0026237] [MeSH:C0026237] exposure [MeSH:C1390376] toxic agent [MeSH:C0010868] alpha-lipoic acid [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] result demonstrate cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] cause early mitochondria [MeSH:C0026237] [MeSH:C0026237]l impairment loss membrane potential [MeSH:C0025251] induction [MeSH:C0042767] autophagic vacuole neuron alpha-lipoic acid [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] exert neuroprotective effect [MeSH:C0815279] [MeSH:C0815279] chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] induce neurotoxicity [MeSH:C0040539] [MeSH:C0235032] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0235032] sensory neuron [MeSH:C0034837] rescue mitochondria [MeSH:C0026237] [MeSH:C0026237]l toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] induce expression [MeSH:C0017262] [MeSH:C0017262] frataxin [MeSH:C0387678] [MeSH:C0387678] essential mitochondria [MeSH:C0026237] [MeSH:C0026237]l protein anti-oxidant [MeSH:C0003402] [MeSH:C0003402] chaperone [MeSH:C0109273] property mitochondria [MeSH:C0026237] [MeSH:C0026237]l toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] early common event paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] cisplatin [MeSH:C0008838] [MeSH:C0008838] [MeSH:C0008838] induce neurotoxicity [MeSH:C0040539] [MeSH:C0235032] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0235032] alpha-lipoic acid [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] protect sensory neuron [MeSH:C0034837] anti-oxidant [MeSH:C0003402] [MeSH:C0003402] mitochondria [MeSH:C0026237] [MeSH:C0026237]l regulatory function possibly induce expression [MeSH:C0017262] [MeSH:C0017262] frataxin [MeSH:C0387678] [MeSH:C0387678] finding suggest alpha-lipoic acid [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] [MeSH:C0023791] reduce risk [MeSH:C0035647] develop peripheral nerve [MeSH:C0031119] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] patient [MeSH:C0030705] undergo chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] encourage confirmatory trial,neurological
postpartum [MeSH:C0086839] psychosis induce bromocriptine [MeSH:C0006230],multigravida patient [MeSH:C0030705] [MeSH:C0030705] prior psychiatric history [MeSH:C0033873] see postpartum psychosis [MeSH:C0033975] [MeSH:C0033975] [MeSH:C0086839] receive bromocriptine [MeSH:C0006230] [MeSH:C0006230] [MeSH:C0006230] inhibition lactation [MeSH:C0022925] bromocriptine [MeSH:C0006230] [MeSH:C0006230] [MeSH:C0006230] give high dose associate psychosis [MeSH:C0033975] [MeSH:C0033975] patient [MeSH:C0030705] [MeSH:C0030705] receive drug parkinson disease [MeSH:C0030567] case demonstrate bromocriptine [MeSH:C0006230] [MeSH:C0006230] [MeSH:C0006230] cause psychosis [MeSH:C0033975] [MeSH:C0033975] give low dose,neurological
organ [MeSH:C0029250] orchestra alzheimer disease,cross-sectional examine [MeSH:C0010362] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include renal cell carcinoma [MeSH:C0007134] blood urea [MeSH:C0005845] nitrogen liver fibrosis method [MeSH:C0239946] participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication therapeutic [MeSH:C0087111] innovation,hepatorenal
regurgitation marker [MeSH:C0026266] parkinson disease [MeSH:C0030567],question calcium channel blocker [MeSH:C0006684] affect stroke [MeSH:C0038454] heart mechanism method retrospective [MeSH:C0035363] adult population [MeSH:C0032659] assess blood vessel [MeSH:C0005847] tricuspid valve [MeSH:C0040960] result well quality life measure implication care improvement,cardiovascular
molecular characterization galactosemia mutation [MeSH:C0026882] polymorphism [MeSH:C0032529] implication structure-function human galactose phosphate uridyltransferase [MeSH:C0016953],report molecular characterization galactosemia [MeSH:C0016952] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] l74p f11s polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] s15l human galactose phosphate uridyltransferase galt galactosemia [MeSH:C0016952] [MeSH:C0016953] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] reduce enzymatic activity [MeSH:C0243102] reconstruct cdna [MeSH:C0006556] overexpresse polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] contrast near normal activity mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] affect evolutionarily conserve residue [MeSH:C0013202] suggest functional [MeSH:C0031843]ly important polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] occur nonconserved domain presumably critical enzymatic function [MeSH:C0031843] f11s mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] close putative active-site nucleophile support notion molecular heterogeneity galactosemia [MeSH:C0016952] suggest galactosemia [MeSH:C0016952] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] galt polymorphism [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] [MeSH:C0032529] useful tool highlight different functional [MeSH:C0031843] domain human galt,neurological
cloning [MeSH:C0009015] human [MeSH:C0086418] very-long-chain acyl-coenzyme dehydrogenase molecular characterization deficiency patient [MeSH:C0030705],overlap cdna [MeSH:C0006556] [MeSH:C0006556] clone [MeSH:C0009013] [MeSH:C0006556] bp bp respectively encode precursor human [MeSH:C0086418] [MeSH:C0086418] mitochondrial [MeSH:C0949610] very-long-chain acyl-coenzyme dehydrogenase vlcad [MeSH:C0065170] clone [MeSH:C0009013] sequence [MeSH:C0162327] cdna [MeSH:C0006556] [MeSH:C0006556] insert [MeSH:C0006556] clone [MeSH:C0009013] encompass region basis encode entire protein amino acid [MeSH:C0002520] include -amino acid leader peptide -amino acid mature polypeptide [MeSH:C1305923] pcr-amplified vlcad cdna [MeSH:C0006556] [MeSH:C0006556] sequence [MeSH:C0162327] culture fibroblast [MeSH:C0016030] [MeSH:C0016030] vlcad-deficient patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] -bp deletion [MeSH:C0017260] encompass basis vlcad cdna [MeSH:C0006556] [MeSH:C0006556] identify deletion [MeSH:C0017260] occur exon skipping processing vlcad pre-mrna demonstration mutation [MeSH:C0026882] cause vlcad deficiency [MeSH:C3887523] [MeSH:C3887523] quantitative [MeSH:C0597336] cdna [MeSH:C0006556] [MeSH:C0006556] expression normal human [MeSH:C0086418] [MeSH:C0086418] vlcad perform patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fibroblast [MeSH:C0016030] [MeSH:C0016030] vaccinia viral system demonstrate deficiency normal vlcad protein [MeSH:C3887523] cause impaired [MeSH:C0020580] long-chain fatty acid beta-oxidation activity patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fibroblast [MeSH:C0016030] [MeSH:C0016030] fibroblast [MeSH:C0016030] [MeSH:C0016030] raise vlcad activity approximately normal fibroblast [MeSH:C0016030] [MeSH:C0016030] activity raise palmitic acid beta-oxidation flux [MeSH:C2936196] find fibroblast [MeSH:C0016030] [MeSH:C0016030] offer important information [MeSH:C5544371] rational design future somatic gene therapy [MeSH:C0037645] vlcad deficiency [MeSH:C3887523] [MeSH:C3887523],neurological
characteristic intergenerational contraction ctg repeat myotonic dystrophy,myotonic dystrophy dm size [MeSH:C0027126] ctg repeat dm kinase gene [MeSH:C0216045] generally increase successive generation evidence anticipation [MeSH:C0600498] [MeSH:C0600498] case intergenerational [MeSH:C0085419] contraction [MeSH:C0700589] [MeSH:C0700589] [MeSH:C0700589] repeat examine dm parent [MeSH:C0030551] [MeSH:C0030551] [MeSH:C0030551]-offspring [MeSH:C0683572] [MeSH:C0683572] [MeSH:C0683572] pair [MeSH:C0600436] [MeSH:C0030542] show contraction [MeSH:C0700589] [MeSH:C0700589] [MeSH:C0700589] peripheral blood leukocyte pbl pair [MeSH:C0600436] allow anticipation [MeSH:C0600498] [MeSH:C0600498] status [MeSH:C4277552] surprising anticipation [MeSH:C0600498] [MeSH:C0600498] occur pair [MeSH:C0600436] clearly show later onset dm symptomatic [MeSH:C3839861] offspring [MeSH:C0683572] [MeSH:C0683572] [MeSH:C0683572] contraction [MeSH:C0700589] [MeSH:C0700589] [MeSH:C0700589] occur paternal transmission [MeSH:C0040722] [MeSH:C0040722] [MeSH:C0040722] maternal [MeSH:C0024915] [MeSH:C0024915] transmission [MeSH:C0040722] anticipation [MeSH:C0600498] [MeSH:C0600498] observe frequently maternal [MeSH:C0024915] [MeSH:C0024915] paternal transmission [MeSH:C0040722] [MeSH:C0040722] [MeSH:C0040722] p dm parent [MeSH:C0030551] [MeSH:C0030551] [MeSH:C0030551] multiple dm offspring [MeSH:C0683572] [MeSH:C0683572] [MeSH:C0683572] ctg repeat contraction [MeSH:C0700589] [MeSH:C0700589] [MeSH:C0700589] frequency [MeSH:C0376249] high frequency [MeSH:C0376249] expect probability [MeSH:C0033204] [MeSH:C0033204] repeat contraction [MeSH:C0700589] [MeSH:C0700589] [MeSH:C0700589] size dm sib population [MeSH:C0032659] dm offspring [MeSH:C0683572] [MeSH:C0683572] [MeSH:C0683572] dm parent [MeSH:C0030551] [MeSH:C0030551] [MeSH:C0030551] dm parent [MeSH:C0030551] [MeSH:C0030551] [MeSH:C0030551] conclude intergenerational [MeSH:C0085419] contraction [MeSH:C0700589] [MeSH:C0700589] [MeSH:C0700589] ctg repeat leukocyte dna frequently accompany apparent [MeSH:C0030551] [MeSH:C0030551] [MeSH:C0030551] anticipation [MeSH:C0600498] [MeSH:C0600498] especially dm maternal [MeSH:C0024915] [MeSH:C0024915]ly transmit paternal origin repeat presence repeat contraction [MeSH:C0700589] [MeSH:C0700589] [MeSH:C0700589] sibling increase probability [MeSH:C0033204] [MeSH:C0033204] ctg repeat contraction [MeSH:C0700589] [MeSH:C0700589] [MeSH:C0700589],neurological
constitutional [MeSH:C0442681] rb1-gene mutation patient [MeSH:C0030705] isolate unilateral retinoblastoma [MeSH:C0035335],patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] isolate unilateral retinoblastoma [MeSH:C0035335] [MeSH:C0035335] tumor [MeSH:C0027651] [MeSH:C0027651] development initiate somatic inactivation allele [MeSH:C0002085] rb1 gene [MeSH:C0080113] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] transmit retinoblastoma [MeSH:C0035335] predisposition [MeSH:C0314657] offspring [MeSH:C0683572] determine frequency [MeSH:C0376249] nature constitutional [MeSH:C0442681] [MeSH:C0442681] [MeSH:C0442681] rb1-gene mutation [MeSH:C0026882] [MeSH:C0026882] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] isolate unilateral retinoblastoma [MeSH:C0035335] [MeSH:C0035335] analyze dna peripheral blood [MeSH:C1518999] tumor [MeSH:C0027651] [MeSH:C0027651] tissue tumor [MeSH:C0027651] [MeSH:C0027651] [MeSH:C0027651] informative patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show loss [MeSH:C2364111] constitutional [MeSH:C0442681] [MeSH:C0442681] [MeSH:C0442681] heterozygosity loh intrage [MeSH:C0024842]nic locus uninformative patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] constitutional [MeSH:C0442681] [MeSH:C0442681] [MeSH:C0442681] deletion randomly select tumor [MeSH:C0027651] [MeSH:C0027651] sscp hetero-duplex sequencing southern blot identify mutation [MeSH:C0026882] [MeSH:C0026882] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect tumor [MeSH:C0027651] [MeSH:C0027651] loh tumor [MeSH:C0027651] [MeSH:C0027651] [MeSH:C0027651] loh mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect tumor [MeSH:C0027651] [MeSH:C0027651] loh mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find total mutation [MeSH:C0026882] [MeSH:C0026882] identify tumor [MeSH:C0027651] [MeSH:C0027651] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] thirty-nine mutation [MeSH:C0026882] [MeSH:C0026882]s-including small mutation [MeSH:C0026882] [MeSH:C0026882] large structural alteration hypermethylation tumor [MeSH:C0027651] [MeSH:C0027651]s-were detect corresponding peripheral blood dna [MeSH:C1518999] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mutation [MeSH:C0026882] [MeSH:C0026882] detect constitutional [MeSH:C0442681] [MeSH:C0442681] [MeSH:C0442681] dna mutation [MeSH:C0026882] [MeSH:C0026882] know associate reduce expressivity presence constitutional [MeSH:C0442681] [MeSH:C0442681] [MeSH:C0442681] mutation [MeSH:C0026882] [MeSH:C0026882] associate early age [MeSH:C0024842] somatic mosaicism [MeSH:C0026578] demonstrate molecular dna rna peripheral blood patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] detectable mutation [MeSH:C0026882] [MeSH:C0026882] peripheral blood mosaicism suggest patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show multifocal tumor [MeSH:C0493722] [MeSH:C0027651] [MeSH:C0027651] later develop bilateral retinoblastoma [MeSH:C0035335] result emphasize manifestation [MeSH:C0029166] transmissibility retinoblastoma [MeSH:C0035335] depend nature mutation [MeSH:C0026882] [MeSH:C0026882] development number type cell affect,oncological
angina marker hepatitis,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] metformin [MeSH:C0025598] stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient focus hypotension tricuspid valve aspect disease [MeSH:C0040960] total participant enrol longitudinal result [MeSH:C0023981] demonstrate well quality [MeSH:C0034379] life measure particular attention atherosclerosis [MeSH:C0004153] finding suggest potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
brca1 deficiency [MeSH:C1623416] result early embryonic [MeSH:C0013947] lethality characterize neuroepithelial abnormality,breast ovarian cancer [MeSH:C1140680] susceptibility [MeSH:C0012655] [MeSH:C0012655] gene brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] clone [MeSH:C0259275] show encode zinc-finger protein unknown function mutation [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] account family breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] non-familial sporadic ovarian cancer [MeSH:C1140680] loss wild-type brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] tumour individual [MeSH:C0021228] carry nonfunctional brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] allele suggest brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] encode tumour suppressor [MeSH:C0597611] inhibit [MeSH:C0021463] proliferation mammary epithelial cell [MeSH:C0014597] examine role brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] normal tissue growth differentiation [MeSH:C2003671] generate potential model cancer susceptibility [MeSH:C0012655] [MeSH:C0012655] associate loss brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] function create mouse [MeSH:C0026809] [MeSH:C0026809] line [MeSH:C0026809] carry mutation [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] allele mouse [MeSH:C0026809] [MeSH:C0026809] homozygous mutant allele indicate brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] critical normal development mouse [MeSH:C0026809] [MeSH:C0026809] die utero day [MeSH:C0011017] gestation [MeSH:C0032961] e1-e1 abnormality [MeSH:C0037268] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275]-deficient embryo evident neural tube embryo [MeSH:C0231024] present vary degree spina bifida anencephaly [MeSH:C0080178] addition neuroepithelium [MeSH:C1449624] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275]-deficient embryo appear disorganized sign rapid proliferation excessive cell death [MeSH:C0007587],neurological|oncological
pe atrial fibrillation [MeSH:C0004238] vascular insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome [MeSH:C0206277] premature beat pathway method observational trial cancer [MeSH:C0302523] patient measure mitral valve cholelithiasis [MeSH:C0008350] result favorable safety profile practice guideline,cardiovascular|hepatorenal
accelerate junctional rhythm oral verapamil therapy [MeSH:C0042523],examine frequency [MeSH:C0376249] atrioventricular av dissociation [MeSH:C0086168] accelerate junctional rhythm patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive oral [MeSH:C0029170] verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] accelerate junctional rhythm av dissociation [MeSH:C0086168] frequent [MeSH:C0017270] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] supraventricular tachyarrhythmia [MeSH:C0042514] particularly av nodal reentry verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] administration [MeSH:C0001554] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] lead asymptomatic increase activity junctional pacemaker patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chest pain syndrome verapamil [MeSH:C0042523] [MeSH:C0042523] [MeSH:C0042523] increase frequency [MeSH:C0376249] junctional rhythm suppress [MeSH:C0017372] role escape rhythm physiologically [MeSH:C0031845] appropriate circumstance,neurological|cardiovascular
oligodendroglioma [MeSH:C0028945] meet stroke [MeSH:C0038454] neurological perspective,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] meningioma [MeSH:C0025286] mechanism method prospective cancer patient [MeSH:C0030705] assess cortical encephalopathy [MeSH:C0085584] result positive response implication relevance,neurological
cervical cancer [MeSH:C4048328] connection heart failure [MeSH:C0018801],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension guillain-barre syndrome method [MeSH:C0018378] elderly patient undergo prospective tumor dementia assessment [MeSH:C0030198] result well quality life measure healthcare advancement,neurological|oncological
glutamate pathway prostate cancer [MeSH:C0376358],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer [MeSH:C0006826] deep vein thrombosis [MeSH:C0149871] mechanism method cross-sectional cardiac patient assess myocardium [MeSH:C0027061] cerebellar [MeSH:C0007765] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication care improvement,neurological|cardiovascular
neurotransmitter pathway cardiomyopathy,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] [MeSH:C0035173] metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] paralysis autonomic neuropathy [MeSH:C0271686] result enhance therapeutic response [MeSH:C0087111] convulsion [MeSH:C4048158] correlation [MeSH:C0010100] need investigation [MeSH:C0035173] [MeSH:C0035173],neurological
state-of-the-art aspirin diabetes mellitus [MeSH:C0011849],cross-sectional examine [MeSH:C0010362] aspirin cancer [MeSH:C0004057] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include insufficiency angina vein method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication need investigation [MeSH:C0035173] [MeSH:C0035173],cardiovascular
atherosclerosis [MeSH:C0004153] valvular heart disease [MeSH:C0018824] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] aspirin improve diabete outcome hypotension pathway method cross-sectional trial [MeSH:C0010362] cardiac patient measuring myocardium tachycardia [MeSH:C0039231] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] therapeutic innovation [MeSH:C0087111],cardiovascular
lone atrial fibrillation [MeSH:C0004238] associate [MeSH:C0004083] creatine monohydrate supplementation,atrial fibrillation [MeSH:C0004238] [MeSH:C0004238] young [MeSH:C0340037] patient [MeSH:C0030705] [MeSH:C0030705] structural heart disease [MeSH:C0018799] rare arrhythmia [MeSH:C0003811] [MeSH:C0003811] present population [MeSH:C0032659] reversible [MeSH:C5691430] cause identify resolve thyroid disorder [MeSH:C0030517] illicit drug stimulant [MeSH:C0086190] use acute alcohol intoxication [MeSH:C0001969] cause report [MeSH:C0684224] case -year-old caucasian [MeSH:C0007457] man come emergency department [MeSH:C0562508] atrial fibrillation [MeSH:C0004238] [MeSH:C0004238] rapid ventricular response medical history [MeSH:C0241889] unremarkable minor fracture finger foot thyroid-stimulating hormone [MeSH:C0040160] magnesium potassium [MeSH:C0032835] level normal limit urine drug screen negative alcohol use [MeSH:C0001956] deny question use herbal product [MeSH:C0376667] supplement [MeSH:C1504473] use creatine [MeSH:C0010286] [MeSH:C0010286] monohydrate reveal admit hospital anticoagulate unfractionated heparin [MeSH:C0019134] give intravenous [MeSH:C0085297] diltiazem rate intravenous [MeSH:C0085297] amiodarone rate rhythm discharge hour later receive metoprolol [MeSH:C0025859] aspirin [MeSH:C0004057] follow-up plan [MeSH:C3899107] echocardiography nuclear imaging [MeSH:C0013516] assess perfusion [MeSH:C0031001] exogenous creatine [MeSH:C0010286] [MeSH:C0010286] athlete [MeSH:C0238703] theoretically improve exercise [MeSH:C0015259] performance [MeSH:C0871966] vegetarian [MeSH:C0042441] creatine [MeSH:C0010286] [MeSH:C0010286] replace consume meat fish [MeSH:C0025017] animal product previous anecdotal report [MeSH:C0684224] link creatine [MeSH:C0010286] [MeSH:C0010286] development arrhythmia [MeSH:C0003811] [MeSH:C0003811] clinician [MeSH:C0028654] diligent interview [MeSH:C0935630] patient [MeSH:C0030705] [MeSH:C0030705] drug therapy [MeSH:C0013216] history include question use herbal product [MeSH:C0376667] dietary supplement [MeSH:C0242295] addition important report [MeSH:C0684224] adverse effect [MeSH:C0001688] associate frequently consume supplement herbal product [MeSH:C0376667] food drug administration [MeSH:C1527425] literature,cardiovascular
dermatofibrosarcoma protuberans-associated collagen type ialpha1 platelet-derived growth factor pdgf b-chain fusion gene [MeSH:C0178648] generate transform protein process functional [MeSH:C0031843] pdgf-bb [MeSH:C0379135],dermatofibrosarcoma [MeSH:C0206647] protuberan dfsp display chromosomal rearrangement involve chromosome fuse collagen type ialpha1 colia1 gene platelet-derived growth factor pdgf [MeSH:C0032200] b-chain pdgfb [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] gene [MeSH:C0751995] characterize functional [MeSH:C0031843] structural property colia1 pdgfb [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] fusion protein generate stable nih3t3 cell line [MeSH:C1257739] contain tumor-derived chimeric gene result coia1 intron [MeSH:C0021920] -pdgfb [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] intron [MeSH:C0021920] fusion expression fusion protein lead morphological transformation increase growth rate [MeSH:C0018270] cell pdgf receptor [MeSH:C0071253] kinase inhibitor cgp58b reverse transform phenotype [MeSH:C0031437] reduce growth rate [MeSH:C0018270] colia1 pdgfb [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480]-expressing cell effect cell presence dimeric colia1 pdgfb [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] precursor demonstrate pdgfb [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] immunoprecipitation [MeSH:C0021069] [MeSH:C0021069] metabolically label cell pdgfb [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] immunoprecipitation [MeSH:C0021069] [MeSH:C0021069] follow immunoblotte colia1 antibody pulse-chase study demonstrate colia1 pdgfb [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] precursor process end product indistinguishable wild-type pdgf-bb [MeSH:C0379135] [MeSH:C0379135] finally colia1 pdgfb [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480]-expressing cell generate tumor c c injection nude mouse tumor growth reduce cgp58b conclude colia1 pdgfb [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] [MeSH:C0072480] fusion associate dfsp contribute tumor development [MeSH:C0026527] ectopic [MeSH:C0019933] production pdgf-bb [MeSH:C0379135] [MeSH:C0379135] formation autocrine loop finding suggest pdgf receptor [MeSH:C0071253] target [MeSH:C0039309] pharmacological dfsp giant cell fibroblastoma e g [MeSH:C3693482] use pdgf receptor [MeSH:C0071253] kinase inhibitor cgp58b,oncological
brain map [MeSH:C0006104] hepatitis [MeSH:C0019158] insight,question [MeSH:C0600648] ace inhibitor affect hypertension [MeSH:C0020538] trigeminal neuralgia [MeSH:C0040997] mechanism method retrospective diabetic patient [MeSH:C0030705] assess cerebrospinal fluid [MeSH:C0007806] serotonin [MeSH:C0036751] result enhance therapeutic response [MeSH:C0087111] implication need investigation [MeSH:C0035173],neurological
component lemon [MeSH:C0009499] essential oil [MeSH:C0028910] attenuate [MeSH:C0042211] dementia [MeSH:C0497327] induce scopolamine [MeSH:C0036442],anti-dementia effect [MeSH:C0242913] s-limonene [MeSH:C0064992] s-perillyl alcohol observe passive avoidance test pa open field habituation test ofh lemon essential oil [MeSH:C0028910] [MeSH:C0028910] show strong ability improve memory impaired scopolamine [MeSH:C0036442] [MeSH:C0036442] s-perillyl alcohol relieve deficit [MeSH:C0233794] associative memory pa improve non-associative memory significantly ofh neurotransmitter [MeSH:C0027908] concentration [MeSH:C0311432] brain region test show dopamine [MeSH:C0013030] concentration [MeSH:C0311432] vehicle scopolamine [MeSH:C0036442] [MeSH:C0036442] significantly low vehicle vehicle phenomenon [MeSH:C2350469] reverse s-limonene [MeSH:C0064992] s-perillyl alcohol administer injection [MeSH:C1828121] scopolamine [MeSH:C0036442] [MeSH:C0036442] simultaneously find lemon essential oil [MeSH:C0028910] [MeSH:C0028910] component inhibit [MeSH:C0021463] acetylcholinesterase activity [MeSH:C0001044] vitro ellman [MeSH:C0012788],neurological
glutamate [MeSH:C0220839] meet diabetes mellitus [MeSH:C0011849] neurological perspective,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve meningitis [MeSH:C0025289] acetylcholine method [MeSH:C0001041] conduct randomized control evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine transient ischemic attack [MeSH:C0007787] parameter result well quality life measure safety [MeSH:C0036043] consideration,neurological
multiple myeloma pathway coronary artery disease,prospective examine statin [MeSH:C0360714] dementia [MeSH:C0497327] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include uremia [MeSH:C0041948] renal chemotherapy method [MeSH:C0013216] participant [MeSH:C1708335] include result positive response implication safety [MeSH:C0036043] consideration,hepatorenal|oncological
psoriasis [MeSH:C0033860] azathioprine [MeSH:C0004482],azathioprine [MeSH:C0004482] benefit [MeSH:C0021674] patient [MeSH:C0030705] suffer severe psoriasis [MeSH:C0033860] haematological complication [MeSH:C1171258] troublesome result biochemical [MeSH:C0017401] liver function test [MeSH:C0023901] remain normal minimal cholestasis [MeSH:C0008370] see case portal fibrosis reversible degree liver biopsy [MeSH:C0005558] undertake regular interval azathioprine [MeSH:C0004482] therapy continue structural [MeSH:C0026349] liver damage detect early reversible stage,hepatorenal
highly accurate low cost test [MeSH:C0010186] brca1 [MeSH:C0259275] mutation,hereditary breast ovarian cancer syndrome [MeSH:C0677776] associate high frequency brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] widespread use brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] testing limit date principal concern fear loss health life insurance uncertain positive test current lack inexpensive sensitive [MeSH:C1017675] screening test [MeSH:C0220908] [MeSH:C0220908] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] develop inexpensive system gene [MeSH:C0017420] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882]al scanning base combination extensive multiplex pcr amplification [MeSH:C3179032] dimensional electrophoresis efficiency system screening test [MeSH:C0220908] [MeSH:C0220908] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] evaluate panel sample high risk woman [MeSH:C0043210] contain previously identify mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify additional previously escape detection addition mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] total different polymorphic [MeSH:C1720758] variant score [MeSH:C0021504] recur confirm nucleotide sequencing [MeSH:C0004793] cost [MeSH:C0010186] screening sample calculate approximately manual [MeSH:C0036886] technique reduce approximately introduction commercially available pcr robotic fluorescent imaging implementation [MeSH:C4704785] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] screening setting permit rapid accrual quantitative [MeSH:C0597336] genotype-phenotype [MeSH:C2717879] association diagnostic testing [MeSH:C0525034],oncological
duplicational mutation duchenne muscular dystrophy [MeSH:C0013264] locus frequency [MeSH:C0017270] distribution origin [MeSH:C1704711] phenotypegenotype [MeSH:C0031437] correlation [MeSH:C0010100],partial gene deletion [MeSH:C0017260] major cause mutation lead duchenne muscular dystrophy [MeSH:C0013264] dmd becker muscular dystrophy [MeSH:C0917713] bmd partial gene duplication [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0017261] recognize case conduct survey duplication [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] unrelated nondeletion patient analyze southern blot hybridization clone [MeSH:C0009013] represent entire dmd cdna [MeSH:C0006556] careful quantitative hybridization band intensity case find carry duplication [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] gene frequency [MeSH:C0017270] nondeletion case case extent duplication [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] characterize accord publish exon-containing hindiii fragment map duplication [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] novel restriction fragment span duplication [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] junction detect result translational reading frame [MeSH:C0080089] [MeSH:C0080089] mrna [MeSH:C0035696] predict duplication [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] shift reading frame [MeSH:C0080089] predict dmd case intermediate case reading frame [MeSH:C0080089] remain uninterrupted bmd case rflp [MeSH:C0035268] quantitative southern blot analysis reveal grandpaternal origin duplication [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] family grandmaternal origin family family duplication [MeSH:C0015576] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] find originate single x chromosome [MeSH:C0008633] unequal sister-chromatid exchange [MeSH:C0037211] propose mechanism formation [MeSH:C1524059] duplication [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871] [MeSH:C0795871],neurological
effect dystrophin gene [MeSH:C0079259] mutation erg mouse [MeSH:C0026809] human [MeSH:C0086418],author early finding negative [MeSH:C3539878] [MeSH:C3539878] electroretinogram [MeSH:C0013867] erg [MeSH:C0295291] boy duchenne muscular dystrophy [MeSH:C0026850] dmd lead investigate dystrophin gene [MeSH:C0079259] [MeSH:C0079259] deletion [MeSH:C0017260] erg [MeSH:C0295291]s boy dmd author want determined similar erg [MeSH:C0295291] finding animal model [MeSH:C0599779] dmd mdx [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] method ganzfeld erg [MeSH:C0295291]s record boy dmd complete ophthalmic examination dystrophin gene [MeSH:C0079259] [MeSH:C0079259] analyze southern blot hybridization erg [MeSH:C0295291]s record anesthetize mdx [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] modify grass photostimulator grass [MeSH:C0018210] instrument company quincy result ophthalmic examination boy normal finding abnormal [MeSH:C0853087] negative [MeSH:C3539878] [MeSH:C3539878] erg [MeSH:C0295291] record subject subject gene deletion [MeSH:C0017260] variable range large deletion detectable deletion erg [MeSH:C0295291]s mdx [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] normal differ significantly mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] conclusion author believe unique erg [MeSH:C0295291] record human [MeSH:C0086418] subject manifestation [MeSH:C0029166] dmd associate defect dystrophin gene [MeSH:C0079259] [MeSH:C0079259] locus represent new entity erg [MeSH:C0295291] mdx [MeSH:C0206535] [MeSH:C0206535] [MeSH:C0206535] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] spare reason include mild effect mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] gene defect difference muscle retinal gene product specie difference biochemical [MeSH:C0017401] role dystrophin erg [MeSH:C0079259] [MeSH:C0295291] show promise noninvasive diagnostic tool [MeSH:C5197797] dmd mild allelic [MeSH:C0524869] form,neurological
stroke [MeSH:C0038454] proteinuria [MeSH:C0033687] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] ace inhibitor affect [MeSH:C0001721] dementia [MeSH:C0497327] nash mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess anuria glomerulonephritis [MeSH:C0017658] result decrease mortality rate [MeSH:C0205848] implication optimization [MeSH:C0376695],hepatorenal
dexrazoxane [MeSH:C0086444] protect myelosuppression [MeSH:C1956351] dna cleavage-enhancing drug etoposide daunorubicin doxorubicin [MeSH:C0013089],anthracycline [MeSH:C0282564] daunorubicin [MeSH:C0011015] doxorubicin [MeSH:C0013089] [MeSH:C0013089] epipodophyllotoxin etoposide [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] potent dna cleavage-enhancing drug widely oncology [MeSH:C0596240] myelosuppression [MeSH:C1956351] cardiac [MeSH:C0018810] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] limit use dexrazoxane [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] icrf- recommend protection [MeSH:C0524828] anthracycline [MeSH:C0282564]-induced cardiotoxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0876994] [MeSH:C0040539] experimental design widespread use hematologic [MeSH:C0018941] [MeSH:C0018941] [MeSH:C0018941] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] follow coadministration [MeSH:C0001554] dexrazoxane [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] structurally different dna cleavage enhancer [MeSH:C1721094] investigate [MeSH:C0035173] sensitivity [MeSH:C0036667] human [MeSH:C0086418] murine [MeSH:C0026802] blood progenitor cell etoposide [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] daunorubicin [MeSH:C0011015] doxorubicin [MeSH:C0013089] [MeSH:C0013089] dexrazoxane [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] determine granulocyte-macrophage colony forming assay [MeSH:C0314589] likewise vivo b6d2f1 mouse [MeSH:C0026809] [MeSH:C0026809] treat etoposide [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] daunorubicin [MeSH:C0011015] doxorubicin [MeSH:C0013089] [MeSH:C0013089] dexrazoxane [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] wide range dose posttreatment [MeSH:C0039798] hematologic [MeSH:C0018941] [MeSH:C0018941] [MeSH:C0018941] result nontoxic dose dexrazoxane [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] reduce myelosuppression [MeSH:C1956351] weight loss daunorubicin [MeSH:C0011015] etoposide [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] mouse [MeSH:C0026809] [MeSH:C0026809] antagonize antiproliferative effect colony assay [MeSH:C0009385] dexrazoxane [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] reduce myelosuppression [MeSH:C1956351] weight loss vitro cytotoxicity [MeSH:C0040539] [MeSH:C0235280] [MeSH:C0040539] [MeSH:C0040539] doxorubicin [MeSH:C0013089] [MeSH:C0013089] finding support observation [MeSH:C0302523] dexrazoxane [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] reduce hematologic [MeSH:C0018941] [MeSH:C0018941] [MeSH:C0018941] activity [MeSH:C0020115] antitumor [MeSH:C2716992] activity [MeSH:C0020115] doxorubicin [MeSH:C0013089] [MeSH:C0013089] clinically potent antagonism [MeSH:C0013159] daunorubicin [MeSH:C0011015] activity [MeSH:C0020115] raise concern possible interference anticancer efficacy [MeSH:C5690761] certainly renew attention [MeSH:C0004268] suggest etoposide [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] dose escalation possible use dexrazoxane [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] trial patient [MeSH:C0030705] brain metastasis [MeSH:C0220650] combine dexrazoxane [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] [MeSH:C0086444] high dose etoposide [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] [MeSH:C0015133] ongoing improve efficacy [MeSH:C5690761] aggravate hematologic [MeSH:C0018941] [MeSH:C0018941] [MeSH:C0018941] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] successful represent exciting mechanism [MeSH:C1524059] pharmacologic regulation [MeSH:C0600511] effect cytotoxic chemotherapy [MeSH:C0013216],neurological|cardiovascular|oncological
revolutionary genetic testing [MeSH:C0679560] heart failure [MeSH:C0018801] diagnosis [MeSH:C0011900],design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation statin [MeSH:C0360714] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] dvt bradycardia [MeSH:C0428977] result favorable safety profile coronary artery disease [MeSH:C1956346] correlation care [MeSH:C0010100] improvement [MeSH:C2936612],cardiovascular
sustained improvement [MeSH:C2936612] decompensated hepatitis b virus-related cirrhosis lamivudine monotherapy [MeSH:C0376626],hepatitis b virus hbv infection [MeSH:C0019163] cause liver cirrhosis [MeSH:C0023890] hepatocellular carcinoma [MeSH:C2239176] remain major health problem asian country recent development vaccine [MeSH:C0042210] prevention report [MeSH:C0684224] successful reduce size [MeSH:C0162658] chronically infected carrier [MeSH:C0007292] standard medical therapy [MeSH:C1257928] establish report [MeSH:C0684224] encounter decompensated hbv-related cirrhosis exhibit dramatic improvement [MeSH:C2936612] antiviral therapy [MeSH:C0039798] [MeSH:C0039798] -year-old woman [MeSH:C0043210] previous conventional medical treatment [MeSH:C0039798] effective refer hospital administration [MeSH:C0001554] [MeSH:C0019948] lamivudine [MeSH:C0209738] reverse transcriptase inhibitor [MeSH:C0282519] month dramatically improve liver severity period [MeSH:C0080129] drug resistant mutant hbv emerge serum [MeSH:C0229671] hbv-dna continuously suppress [MeSH:C0017372] virological response [MeSH:C0034746] maintain antiviral therapy [MeSH:C0039798] [MeSH:C0039798] discontinue hepatitis b surface antigen e antigen [MeSH:C0019168] observe disappear administration [MeSH:C0001554] lamivudine [MeSH:C0209738] patient [MeSH:C0030705] hbv-related cirrhosis like present case consider initial medical therapeutic option [MeSH:C0087111] especially country liver transplantation [MeSH:C0023911] reliably available,hepatorenal|oncological
brain [MeSH:C0006104] dynamic valvular heart disease brain [MeSH:C0006104],randomized control examine [MeSH:C1096777] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include thalamus craniopharyngioma [MeSH:C0010276] palsy method [MeSH:C0522224] participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication practice guideline,neurological
atrioventricular block marker [MeSH:C0004245] parkinson disease [MeSH:C0030567],investigate [MeSH:C0035173] beta-blocker effect hypertension [MeSH:C0020538] pacemaker method cancer patient [MeSH:C0030705] undergo randomized control septum tricuspid valve assessment result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],cardiovascular
organ [MeSH:C0029250] orchestra breast cancer,question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] pkd mechanism method longitudinal diabetic [MeSH:C0023981] patient [MeSH:C0030705] assess hepatic kidney transplant [MeSH:C0022671] result improve disease management [MeSH:C0039798] implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
progesterone [MeSH:C0033308] potentiation [MeSH:C1136141] bupivacaine [MeSH:C0006400] arrhythmogenicity pentobarbital-anesthetized rat [MeSH:C0034721] [MeSH:C0034721] beat rat [MeSH:C0034721] [MeSH:C0034721] heart cell [MeSH:C0018787] culture,effect [MeSH:C4277511] [MeSH:C4277511] progesterone [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] arrhythmogenicity beat rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] heart myocyte [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981] culture [MeSH:C0010453] [MeSH:C0010453] anesthetize rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] determine determine bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] ad5 concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] cause beat rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] heart myocyte [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981] culture [MeSH:C0010453] [MeSH:C0010453] arrhythmic [MeSH:C0003811] determine effect [MeSH:C4277511] [MeSH:C4277511] -hour progesterone [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] hcl exposure [MeSH:C1390376] myocyte [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981] contractile rhythm concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion progesterone [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] microgram [MeSH:C0376691] ml cause concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion-dependent reduction ad5 bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] estradiol increase arrhythmogenicity bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] myocyte [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981] culture [MeSH:C0010453] [MeSH:C0010453] fourth potent progesterone [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] progesterone [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] estradiol effect [MeSH:C4277511] [MeSH:C4277511] bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] arrhythmogenicity potentiate epinephrine [MeSH:C0014563] chronic [MeSH:C0150055] progesterone [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] pretreatment [MeSH:C0376495] mg kg day [MeSH:C0011017] cause increase bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] arrhythmogenicity intact pentobarbital-anesthetized rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] decrease onset arrhythmia [MeSH:C0003811] [MeSH:C0003811] compare nonprogesterone [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] vs min mean se result indicate progesterone [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] [MeSH:C0033308] potentiate bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] arrhythmogenicity vivo vitro [MeSH:C0021135] potentiation [MeSH:C1136141] bupivacaine [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] [MeSH:C0006400] arrhythmia [MeSH:C0003811] [MeSH:C0003811] myocyte [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981] culture [MeSH:C0010453] [MeSH:C0010453] suggest effect [MeSH:C4277511] [MeSH:C4277511] partly mediate myocyte [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981] [MeSH:C0596981],neurological|cardiovascular
regional [MeSH:C0010346] localization [MeSH:C0037710] antagonism [MeSH:C0013159] amphetamine-induced hyperactivity intracerebral calcitonin injection [MeSH:C1828121],calcitonin [MeSH:C0006668] receptor [MeSH:C0054455] find brain intracerebral infusion calcitonin [MeSH:C0006668] produce behavioral [MeSH:C0004927] effect behavioral [MeSH:C0004927] effect decrease food intake [MeSH:C0013470] [MeSH:C0013470] [MeSH:C0013470] decrease amphetamine-induced locomotor activity [MeSH:C0023946] [MeSH:C0023946] previous experiment [MeSH:C0020123] [MeSH:C0020123] find decrease food intake [MeSH:C0013470] [MeSH:C0013470] [MeSH:C0013470] induce local administration [MeSH:C0001554] calcitonin [MeSH:C0006668] hypothalamic site [MeSH:C0751238] nucleus accumben [MeSH:C0028633] present experiment [MeSH:C0020123] [MeSH:C0020123] calcitonin [MeSH:C0006668] decrease locomotor activity [MeSH:C0023946] [MeSH:C0023946] locally inject site [MeSH:C0151735] decrease food intake [MeSH:C0013470] [MeSH:C0013470] [MeSH:C0013470] area calcitonin [MeSH:C0006668] [MeSH:C0006668] effective decrease locomotor activity [MeSH:C0023946] [MeSH:C0023946] located hypothalamus nucleus accumben [MeSH:C0020653] [MeSH:C0028633] suggest area major site action calcitonin [MeSH:C0006668] [MeSH:C0006668] inhibit [MeSH:C0021463] amphetamine-induced locomotor activity [MeSH:C0023946] [MeSH:C0023946],neurological
thromboembolism marker [MeSH:C0040038] liver cirrhosis [MeSH:C0023890],cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve heart failure hypertension method [MeSH:C0018801] conduct longitudinal evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine peripheral artery disease [MeSH:C1704436] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] care improvement,cardiovascular
corticosteroid breast cancer [MeSH:C0001617] brain [MeSH:C0006104] insight,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve meningitis myelopathy method conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine glioma [MeSH:C0017638] parameter result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
tumor terrain [MeSH:C0006118] liver cirrhosis [MeSH:C0023890] exploration [MeSH:C0015329],design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] metastatic endometrial cancer [MeSH:C0476089] result enhance therapeutic response [MeSH:C0087111] breast cancer [MeSH:C0006142] correlation safety [MeSH:C0036043] consideration,oncological
daidzein [MeSH:C0057090] activate choline acetyltransferase mc-ixc cell improve drug-induced amnesia [MeSH:C0013386],choline acetyltransferase [MeSH:C0008407] chat activator [MeSH:C1448135] [MeSH:C1448135] enhance cholinergic [MeSH:C0242893] transmission [MeSH:C0040722] augmentation [MeSH:C1510606] enzymatic production acetylcholine ach [MeSH:C0001041] important factor alzheimer disease [MeSH:C0002395] ad methanolic extract pueraria thunbergiana [MeSH:C1000862] [MeSH:C1000862] exhibit activation effect chat vitro [MeSH:C0021135] sequential isolation [MeSH:C0220862] pueraria thunbergiana [MeSH:C1000862] [MeSH:C1000862] active component ultimately identify daidzein [MeSH:C0057090] [MeSH:C0057090] [MeSH:C0057090] -dihydroxy-isoflavone order investigate [MeSH:C0035173] effect daidzein [MeSH:C0057090] [MeSH:C0057090] [MeSH:C0057090] pueraria thunbergiana [MeSH:C1000862] [MeSH:C1000862] scopolamine [MeSH:C0036442]-induced impairment [MeSH:C1384666] learning memory [MeSH:C4505057] conduct series [MeSH:C0871939] vivo test administration [MeSH:C0001554] daidzein [MeSH:C0057090] [MeSH:C0057090] [MeSH:C0057090] mg kg body weight [MeSH:C0005910] mouse [MeSH:C0026809] [MeSH:C0026809] show significantly reverse scopolamine [MeSH:C0036442]-induced amnesia accord result y-maze test [MeSH:C0242996] [MeSH:C0242996] injection [MeSH:C1828121] scopolamine [MeSH:C0036442] [MeSH:C1828121] mouse [MeSH:C0026809] [MeSH:C0026809] result impaired [MeSH:C0020580] performance [MeSH:C0871966] y-maze test [MeSH:C0242996] [MeSH:C0242996] decrease alternation behavior [MeSH:C0024919] [MeSH:C0024919] way contrast mouse [MeSH:C0026809] [MeSH:C0026809] treat daidzein [MeSH:C0057090] [MeSH:C0057090] [MeSH:C0057090] prior scopolamine [MeSH:C0036442] injection [MeSH:C1828121] noticeably protect performance [MeSH:C0871966] impairment [MeSH:C1384666] approximately decrease alternation behavior [MeSH:C0024919] [MeSH:C0024919] result indicate daidzein [MeSH:C0057090] [MeSH:C0057090] [MeSH:C0057090] play role acetylcholine biosynthesis [MeSH:C0005572] chat activator [MeSH:C1448135] [MeSH:C1448135] ameliorate scopolamine [MeSH:C0036442]-induced amnesia,neurological
chronic nonspherocytic hemolytic anemia [MeSH:C0002882] cnsha glucose phosphate dehydrogenase g6pd deficiency [MeSH:C2939465] familial amyloidotic polyneuropathy fap [MeSH:C0206245],molecular [MeSH:C0026381] new variant g6pd clinic markedly acidic ph optimum new glucose phosphate [MeSH:C0031603] dehydrogenase g6pd variant severe [MeSH:C1719672] erythrocytic g6pd deficiency [MeSH:C2939465] unique ph optimum describe young [MeSH:C0340037] chronic nonspherocytic hemolytic anemia [MeSH:C0002882] cnsha familial amyloidotic polyneuropathy [MeSH:C0206245] fap chronic hemolysis [MeSH:C0019054] present absence [MeSH:C0270823] infection [MeSH:C3714514] oxidant [MeSH:C0085403] drug ingestion [MeSH:C0232478] faba bean [MeSH:C0330788] residual enzyme [MeSH:C0014442] activity normal [MeSH:C0243102] activity erythrocyte leucocyte [MeSH:C0014792] respectively molecular [MeSH:C0026381] standard method show g6pd normal electrophoretic mobility ph normal apparent affinity substrate [MeSH:C0003017] [MeSH:C0003017] km g6p nadp [MeSH:C0027303] slightly abnormal [MeSH:C0853087] utilization substrate [MeSH:C0003017] [MeSH:C0003017] analogue decrease deamino-nadp [MeSH:C0027303] increase -deoxyglucose phosphate [MeSH:C0031603] utilization heat stability [MeSH:C2350440] find markedly decrease residual activity min incubation [MeSH:C0021178] degree c particular characteristic enzyme [MeSH:C0014442] biphasic ph curve greatly increase activity low [MeSH:C0020115] ph molecular [MeSH:C0026381] characteristic variant closely resemble g6pd bangkok g6pd duarte [MeSH:C4742874] distinguish previously report variant virtue unusual ph curve present variant designate g6pd clinic distinguish g6pd variant previously describe,neurological
hypotensive chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve arrhythmia [MeSH:C0003811] dilate cardiomyopathy method [MeSH:C0007193] conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine endothelium [MeSH:C0014257] parameter result positive response optimization [MeSH:C0376695],cardiovascular
neuropathy [MeSH:C0015464] meet leukemia [MeSH:C0023418] neurological perspective,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect heart disease [MeSH:C0018799] cortical method diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo retrospective reticular formation myasthenia gravis assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile optimization [MeSH:C0376695],neurological
cancer meningitis [MeSH:C0025289] exploring neural pathway [MeSH:C0027792],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer heart failure method [MeSH:C0018801] cardiac patient undergo prospective hippocampal [MeSH:C0228249] cerebral assessment result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],neurological|cardiovascular
cholecystitis [MeSH:C0008325] colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve prolapse [MeSH:C0033377] arrhythmia method conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine nash parameter result improve disease management [MeSH:C0039798] cost-effectiveness [MeSH:C1511536] implication,cardiovascular|hepatorenal
trigeminal neuralgia [MeSH:C0040997] meet angina pectoris [MeSH:C0002962] neurological perspective,investigate [MeSH:C0035173] beta-blocker effect diabete myasthenia gravis [MeSH:C0026896] method [MeSH:C0025663] cardiac patient undergo observational [MeSH:C0302523] hypothalamus [MeSH:C0020663] hippocampal assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint healthcare advancement,neurological
fragile x syndrome ccg amplification fmr1 [MeSH:C1506924] deletion,describe typical feature fragile [MeSH:C0016667] x syndrome [MeSH:C0016667] cytogenetic expression [MeSH:C0017262] [MeSH:C0017262] fragile [MeSH:C0016667] x amplify ccg trinucleotide repeat fragment [MeSH:C0282537] previously uncharacterized submicroscopic deletion [MeSH:C0041623] encompass ccg repeat entire fmr1 [MeSH:C1506924] gene megabase flanking sequence confirm fragile [MeSH:C0016667] x phenotype [MeSH:C0031437] exist amplification [MeSH:C0017256] ccg repeat cytogenetic expression [MeSH:C0017262] [MeSH:C0017262] fragile [MeSH:C0016667] x fragile [MeSH:C0016667] x syndrome [MeSH:C0016667] genetically homogeneous disorder involve fmr1 [MeSH:C1506924] find random [MeSH:C5690776] x-inactivation [MeSH:C0043297] mother [MeSH:C0026591] show carrier deletion,neurological
immunohistochemistry [MeSH:C0021044] reveal hypertension [MeSH:C0020538] secret,cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve chorea synapse method conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine deep vein thrombosis [MeSH:C0149871] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],neurological|cardiovascular
hypertension [MeSH:C0020538] detox dynamic [MeSH:C0058836],hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve steatosis [MeSH:C2711227] nonalcoholic steatohepatitis method [MeSH:C3241937] conduct observational [MeSH:C0302523] evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine hepatorenal syndrome [MeSH:C0019212] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] practice guideline,hepatorenal
bradycardia parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome hydronephrosis pathway method randomized control trial [MeSH:C1096777] cardiac patient measure hcc renal cyst [MeSH:C0010709] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cost-effectiveness [MeSH:C1511536] implication,cardiovascular|hepatorenal
seizure pathway [MeSH:C0036572] heart failure [MeSH:C0018801],question statin affect cancer hypertrophic cardiomyopathy [MeSH:C0007194] mechanism method randomized control [MeSH:C1096777] elderly patient assess ventricle cardiomyopathy [MeSH:C0878544] result superior efficacy [MeSH:C5690761] implication relevance,neurological|cardiovascular
chemotherapy [MeSH:C0013216] hypertension [MeSH:C0020538] brain [MeSH:C0006104] insight,design [MeSH:C0013171] prospective investigation beta-blocker cancer participant cancer patient [MeSH:C0030705] serotonin dysarthria [MeSH:C0013362] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] reticular formation [MeSH:C0035284] correlation [MeSH:C0010100] relevance [MeSH:C2826293],neurological|hepatorenal
meningioma pathway coronary artery disease [MeSH:C1956346],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect stroke [MeSH:C0038454] multiple sclerosis method cancer [MeSH:C0026769] patient [MeSH:C0030705] undergo prospective acetylcholine cortical assessment result positive response safety consideration,neurological
definition management anemia [MeSH:C0002871] patient [MeSH:C0030705] infect hepatitis c virus [MeSH:C0220847],chronic infection hepatitis c virus hcv [MeSH:C0524909] progress cirrhosis [MeSH:C1623038] hepatocellular carcinoma [MeSH:C2239176] end-stage liver disease [MeSH:C0745744] current good hcv infection combination therapy [MeSH:C0013218] pegylated interferon ribavirin [MeSH:C0035525] regiman produce sustained virologic response [MeSH:C4050171] svr approximately patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] associate potential [MeSH:C0001272]ly dose-limiting hemolytic anemia [MeSH:C0002878] hemoglobin concentration [MeSH:C0002878] decrease mainly ribavirin [MeSH:C0035525]-induced hemolysis anemia problematic patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hcv infection especially comorbid renal cardiovascular disorder general anemia [MeSH:C0002871] increase risk [MeSH:C0035647] [MeSH:C0035647] morbidity [MeSH:C0026538] mortality [MeSH:C0026565] negative [MeSH:C3539878] effect cerebral function quality life ribavirin [MeSH:C0035525]-associated anemia reverse dose reduction [MeSH:C1827449] discontinuation approach compromise outcome significantly decrease svr rate recombinant human erythropoietin [MeSH:C2976467] manage ribavirin [MeSH:C0035525]-associated anemia potential [MeSH:C0001272] disadvantage [MeSH:C1121259] viramidine [MeSH:C0073221] liver-targeting prodrug ribavirin [MeSH:C0035525] [MeSH:C0035525] potential [MeSH:C0001272] maintain virologic efficacy [MeSH:C5690761] ribavirin [MeSH:C0035525] decrease risk [MeSH:C0035647] [MeSH:C0035647] hemolytic anemia [MeSH:C0002878] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chronic hepatitis c [MeSH:C0524910],cardiovascular|hepatorenal|oncological
antirifampicin [MeSH:C0035608] antibody acute rifampicin-associated renal failure,patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute renal failure [MeSH:C0022660] thrombopenia hemolysis [MeSH:C0040034] induce reintroduction [MeSH:C0033268] rifampicin [MeSH:C0035608] describe correlation [MeSH:C0010100] find severity manifestation total dose take patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] antirifampicin [MeSH:C0035608] antibody [MeSH:C0443933] detect antibody [MeSH:C0443933] suggest igm class detect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hematological disorder [MeSH:C0018939] pattern non-specific acute tubular necrosis [MeSH:C0022672] find biopsie patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] indistinguishable ischemic [MeSH:C0022116] origin raise possibility vascular-mediated damage [MeSH:C0012860] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] possibility trigger immunoallergic mechanism [MeSH:C1524059] discuss,hepatorenal
brain map [MeSH:C0006104] ventricular tachycardia [MeSH:C0042514] insight,prospective examine ace inhibitor [MeSH:C0003015] stroke [MeSH:C0038454] elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include dysarthria astrocytoma [MeSH:C0013362] hippocampal [MeSH:C0228249] method participant [MeSH:C1708335] include result well quality life measure implication practice guideline [MeSH:C0936005],neurological
abnormal [MeSH:C0853087] development purkinje [MeSH:C0034143] cell lymphocyte atm mutant [MeSH:C1564139] mouse [MeSH:C0026809],motor incoordination immune deficiency [MeSH:C1623416] [MeSH:C0398686] increase risk cancer [MeSH:C0035647] characteristic feature hereditary disease ataxia-telangiectasia a-t cause [MeSH:C0004135] mutation atm gene gene targeting [MeSH:C0242613] generate line atm mutant [MeSH:C1564139] [MeSH:C1564139] [MeSH:C1564139] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] atm mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] contrast atm mutant [MeSH:C1564139] [MeSH:C1564139] [MeSH:C1564139] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] atm mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] low incidence [MeSH:C0021149] thymic lymphoma [MeSH:C0024299] survive month age [MeSH:C0024842] atm mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] exhibit deficit motor learning indicative cerebellar dysfunction [MeSH:C0007760] find gross [MeSH:C0018252] cerebellar degeneration old atm animal [MeSH:C0003062] ectopic [MeSH:C0019933] abnormal [MeSH:C0853087]ly differentiate purkinje [MeSH:C0034143] cell [MeSH:C0034143] apparent mutant [MeSH:C1564139] [MeSH:C1564139] [MeSH:C1564139] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] age [MeSH:C0024842] finding establish neuropathological abnormal [MeSH:C0853087]ity see a-t patient [MeSH:C0030705] present atm mutant [MeSH:C1564139] [MeSH:C1564139] [MeSH:C1564139] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] addition report previously unrecognized effect [MeSH:C4277511] atm deficiency [MeSH:C1623416] development [MeSH:C0243107] maintenance [MeSH:C0024501] cd4 [MeSH:C0003323] thymocyte [MeSH:C0814999] discuss finding context hypothesis [MeSH:C3179072] abnormal [MeSH:C0853087] development [MeSH:C0243107] purkinje [MeSH:C0034143] cell [MeSH:C0034143] lymphocyte [MeSH:C0024264] contribute pathogenesis [MeSH:C0699748] a-t,neurological|oncological
hepatitis detox [MeSH:C0019158] dynamic [MeSH:C0058836],question statin affect cancer peritoneal dialysis mechanism method prospective elderly patient assess gfr kidney [MeSH:C0022646] stone result improvement [MeSH:C2936612] primary endpoint implication safety [MeSH:C0036043] consideration,hepatorenal
epilepsy [MeSH:C0014544] pkd organ [MeSH:C0029250] interplay,hypothesis statin improve stroke [MeSH:C0038454] outcome nephron pathway method prospective trial cardiac patient measure primary biliary cholangitis [MeSH:C0008312] gamma glutamyl transferase [MeSH:C0017040] result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],hepatorenal
lymphoma aphasia [MeSH:C0024299] exploring neural pathway [MeSH:C0027792],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete palsy [MeSH:C0522224] mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess convulsion white matter [MeSH:C0682708] result favorable safety profile implication therapeutic [MeSH:C0087111] innovation,neurological
flourouracil-induced apical ballooning syndrome case report [MeSH:C0684224],apical ballooning syndrome [MeSH:C0039082] ab [MeSH:C1739395] recently describe stress-mediated acute cardiac syndrome [MeSH:C0039082] characterize transient wall-motion abnormality [MeSH:C0037268] involve apex [MeSH:C0031266] midventricle hyperkinesis [MeSH:C3887506] basal leave ventricular lv segment obstructive epicardial coronary disease cardiotoxicity [MeSH:C0876994] uncommon adverse effect [MeSH:C0001688] chemotherapeutic agent [MeSH:C0003392] [MeSH:C0003392] report ab secondary chemotherapeutic agent [MeSH:C0003392] [MeSH:C0003392] describe case woman [MeSH:C0043210] develop syndrome [MeSH:C0039082] chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] metastatic cancer [MeSH:C1522484] -year-old woman [MeSH:C0043210] present typical ischemic chest pain [MeSH:C0008031] elevated [MeSH:C0020443] cardiac enzyme st-segment abnormality [MeSH:C0037268] electrocardiogram [MeSH:C0013798] undergo recent chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] fluorouracil metastatic [MeSH:C0016360] colorectal cancer echocardiography [MeSH:C0013516] reveal wall-motion abnormality [MeSH:C0037268] involve apical periapical segment appear akinetic coronary angiography [MeSH:C0085532] reveal obstructive coronary lesion stabilize medical therapy [MeSH:C1257928] week later remain completely asymptomatic [MeSH:C2936329] echocardiogram [MeSH:C0013516] reveal normal ejection fraction resolution apical akinesi pathogenetic mechanism cardiac complication cancer patient [MeSH:C0030705] undergo chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] include coronary vasospasm endothelial damage [MeSH:C0010073] consequent thrombus [MeSH:C0087086] formation supraphysiologic level plasma [MeSH:C0032105] catecholamine stress related neuropeptide [MeSH:C0027895] cause cancer diagnosis [MeSH:C0011900] chemotherapy [MeSH:C0013216] [MeSH:C0013216] [MeSH:C0013216] contribute development [MeSH:C0243107] ab,neurological|cardiovascular|oncological
inactivation [MeSH:C0043297] germline mutant [MeSH:C0206530] apc allele attenuate [MeSH:C0042211] [MeSH:C0042211] somatic mutation molecular genetic mechanism attenuate [MeSH:C0042211] [MeSH:C0042211] familial adenomatous polyposis [MeSH:C0032580],germline mutation [MeSH:C0026882] [MeSH:C0206530] [MeSH:C0206530] adenomatous polyposis coli [MeSH:C0032580] apc [MeSH:C0162832] [MeSH:C0162832] tumor [MeSH:C0027651]-suppressor gene [MeSH:C0079427] familial adenomatous polyposis fap [MeSH:C1622401] [MeSH:C0032580] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fap [MeSH:C1622401] [MeSH:C0030705] typically develop hundred thousand benign [MeSH:C1879828] colorectal tumor [MeSH:C0009404] [MeSH:C0009404] [MeSH:C0009404] [MeSH:C0027651] [MeSH:C0009404] early-onset colorectal cancer [MeSH:C0009402] subset germline apc [MeSH:C0162832] [MeSH:C0162832] mutation [MeSH:C0026882] [MeSH:C0206530] result attenuate [MeSH:C0042211] fap [MeSH:C1622401] afap [MeSH:C1622401] phenotype [MeSH:C0031437] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop few tumor [MeSH:C0027651] develop old age genotype-phenotype [MeSH:C2717879] [MeSH:C0031437] correlation location apc [MeSH:C0162832] [MeSH:C0162832] germline mutation [MeSH:C0026882] [MeSH:C0206530] [MeSH:C0206530] development [MeSH:C0243107] afap [MeSH:C1622401] document mechanism afap [MeSH:C1622401] define investigate [MeSH:C0035173] mechanism afap [MeSH:C1622401] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] carry mutant apc [MeSH:C0162832] [MeSH:C0162832] allele apc [MeSH:C0162832] [MeSH:C0162832] as9 mutation [MeSH:C0026882] alternatively splice region exon apc [MeSH:C0162832] [MeSH:C0162832] as9 find down-regulate [MeSH:C0013081] beta-catenin-regulated transcription major tumor [MeSH:C0027651]-suppressor function apc [MeSH:C0162832] [MeSH:C0162832] wild-type apc [MeSH:C0162832] [MeSH:C0162832] mutation [MeSH:C0026882] show apc [MeSH:C0162832] [MeSH:C0162832] as9 wild-type apc [MeSH:C0162832] [MeSH:C0162832] allele somatically mutate [MeSH:C3178846] colorectal tumor [MeSH:C0009404] [MeSH:C0009404] [MeSH:C0009404] [MeSH:C0027651] [MeSH:C0009404] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] functional show 6insa common somatic mutation [MeSH:C0026882] apc [MeSH:C0162832] [MeSH:C0162832] as9 tumor [MeSH:C0027651] inactivate [MeSH:C0043297] wild-type apc [MeSH:C0162832] [MeSH:C0162832] result indicate carrier [MeSH:C0007292] apc [MeSH:C0162832] [MeSH:C0162832] as9 develop few colorectal tumor [MeSH:C0009404] [MeSH:C0009404] [MeSH:C0009404] [MeSH:C0027651] [MeSH:C0009404] typical patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fap [MeSH:C1622401] [MeSH:C0030705] somatic inactivation apc [MeSH:C0162832] [MeSH:C0162832] allele necessary colorectal tumor [MeSH:C0009404] [MeSH:C0009404] [MeSH:C0009404] [MeSH:C0027651] [MeSH:C0009404]igenesis patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop colorectal tumor [MeSH:C0009404] [MeSH:C0009404] [MeSH:C0009404] [MeSH:C0027651] [MeSH:C0009404] frequently general population [MeSH:C0032659] apc [MeSH:C0162832] [MeSH:C0162832] as9 inactivate [MeSH:C0043297] mutation [MeSH:C0026882] inactivate [MeSH:C0043297] wild-type apc [MeSH:C0162832] [MeSH:C0162832],oncological
acute kidney injury pathway lung cancer [MeSH:C2609414],question statin affect cancer gfr mechanism method prospective adult population assess alt azotemia [MeSH:C0242528] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication therapeutic [MeSH:C0087111] innovation,hepatorenal
severe [MeSH:C1719672] rhabdomyolysis acute renal failure [MeSH:C0022660] secondary concomitant use simvastatin [MeSH:C0074554] amiodarone [MeSH:C0002598] atazanavir [MeSH:C1145759],report case [MeSH:C0684224] severe interaction [MeSH:C0007582] simvastatin [MeSH:C0074554] [MeSH:C0360714] [MeSH:C0360714] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] atazanavir [MeSH:C1145759] [MeSH:C1145759] [MeSH:C1145759] result rhabdomyolysis [MeSH:C0035410] acute renal failure [MeSH:C0022660] -year-old white [MeSH:C5575753] man underlie human immunodeficiency virus [MeSH:C0019682] [MeSH:C0019682] atrial fibrillation coronary artery disease [MeSH:C1956346] hyperlipidemia [MeSH:C0020473] present generalize pain fatigue [MeSH:C0015672] dark orange urine day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] take mg simvastatin [MeSH:C0074554] [MeSH:C0360714] [MeSH:C0360714] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] bedtime initiate day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] early amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] dose mg daily day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] mg daily initiate day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] early mg atazanavir [MeSH:C1145759] [MeSH:C1145759] [MeSH:C1145759] daily initiate year previously laboratory [MeSH:C0022877] reveal u l creatine kinase [MeSH:C0010287] mg dl blood urea nitrogen mg dl creatinine [MeSH:C0010294] u l aspartate aminotransferase u [MeSH:C0004002] l alanine aminotransferase [MeSH:C0001899] simvastatin [MeSH:C0074554] [MeSH:C0360714] [MeSH:C0360714] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] human immunodeficiency virus [MeSH:C0019682] [MeSH:C0019682] medication [MeSH:C0033045] temporarily discontinue give force [MeSH:C0086323] alkaline [MeSH:C0002055] diuresis [MeSH:C0012797] start dialysis [MeSH:C0011945] day [MeSH:C0011017] [MeSH:C0011017] [MeSH:C0011017] later creatine kinase [MeSH:C0010287] drop u l creatinine [MeSH:C0010294] mg dl discharge continue outpatient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0029921] dialysis [MeSH:C0011945] renal function recover discussion risk [MeSH:C0035647] rhabdomyolysis [MeSH:C0035410] increase presence concomitant [MeSH:C0152203] [MeSH:C0152203] drug [MeSH:C0013227] inhibit [MeSH:C0021463] simvastatin [MeSH:C0074554] [MeSH:C0360714] [MeSH:C0360714] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] metabolism [MeSH:C0025519] simvastatin [MeSH:C0074554] [MeSH:C0360714] [MeSH:C0360714] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] metabolize cyp3a4 amiodarone [MeSH:C3714798] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] atazanavir [MeSH:C1145759] [MeSH:C1145759] [MeSH:C1145759] recognize cyp3a4 inhibit [MeSH:C0021463]or conclusion pharmacokinetic difference statin [MeSH:C0360714] [MeSH:C0360714] important consideration assess risk [MeSH:C0035647] potential [MeSH:C0035647] drug [MeSH:C0013227] interaction [MeSH:C0007582] patient [MeSH:C0030705] [MeSH:C0030705] require concurrent [MeSH:C0009247] use statin [MeSH:C0360714] [MeSH:C0360714] cyp3a4 inhibit [MeSH:C0021463]or pravastatin [MeSH:C0085542] [MeSH:C0360714] [MeSH:C0360714] fluvastatin [MeSH:C0082608] [MeSH:C0360714] [MeSH:C0360714] rosuvastatin [MeSH:C0965129] [MeSH:C0360714] [MeSH:C0360714] carry low risk [MeSH:C0035647] [MeSH:C0035647] drug [MeSH:C0013227] interaction [MeSH:C0007582] atorvastatin [MeSH:C0286651] [MeSH:C0360714] [MeSH:C0360714] carry moderate risk [MeSH:C0035647] simvastatin [MeSH:C0074554] [MeSH:C0360714] [MeSH:C0360714] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] [MeSH:C0074554] lovastatin [MeSH:C0024027] [MeSH:C0360714] [MeSH:C0360714] high risk [MeSH:C0556482] [MeSH:C0035647] avoid patient [MeSH:C0030705] [MeSH:C0030705] take concomitant [MeSH:C0152203] [MeSH:C0152203] cyp3a4 inhibit [MeSH:C0021463]or,cardiovascular|hepatorenal
nitrate alzheimer disease brain [MeSH:C0006111] insight,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] parkinsonism pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure gaba autonomic neuropathy [MeSH:C0271686] result improve outcome [MeSH:C0206277] optimization [MeSH:C0376695],neurological
neural connection cardiomyopathy [MeSH:C0878544],question [MeSH:C0600648] metformin [MeSH:C0025598] affect hypertension [MeSH:C0020538] al mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess memory loss tia result positive response implication care improvement,neurological
atrium connection coronary artery disease [MeSH:C1956346],cancer affect elderly patient [MeSH:C0030705] worldwide particularly involve myocardial infarction [MeSH:C0027051] neural method conduct [MeSH:C0027788] longitudinal evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine artery [MeSH:C0003842] parameter result improve disease management [MeSH:C0039798] therapeutic innovation [MeSH:C0087111],neurological|cardiovascular
stroke [MeSH:C0038454] polyuria [MeSH:C0032617] organ [MeSH:C0029250] interplay,diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve nephrotic syndrome [MeSH:C0027726] hemodialysis method [MeSH:C0019004] conduct retrospective [MeSH:C0035363] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine primary sclerosing cholangitis [MeSH:C0566602] parameter result improve outcome [MeSH:C0206277] relevance [MeSH:C2826293],hepatorenal
phenobarbital-induced dyskinesia neurologically-impaired child,-year-old child [MeSH:C0008059] known neurologic impairment [MeSH:C0003910] develop dyskinesia [MeSH:C0013384] soon start phenobarbital [MeSH:C0031412] therapy [MeSH:C0031412] seizure [MeSH:C0036572] known cause movement disorder [MeSH:C0026650] [MeSH:C0026650] eliminate repeat challenge phenobarbital [MeSH:C0031412] dyskinesia [MeSH:C0031412] [MeSH:C0013384] recur phenobarbital [MeSH:C0031412] add list anticonvulsant drug [MeSH:C0003286] cause movement disorder [MeSH:C0026650] [MeSH:C0026650],neurological
hypotension [MeSH:C0020649] heart failure [MeSH:C0018801] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect dementia [MeSH:C0497327] defibrillator mechanism method observational [MeSH:C0302523] adult population [MeSH:C0032659] assess coronary artery disease [MeSH:C1956346] ventricle result positive response implication practice guideline,cardiovascular
pancreatic cancer [MeSH:C0346647] cancer myocardial infarction [MeSH:C0027051],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] [MeSH:C0035173] beta-blocker [MeSH:C0001645] stroke participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] non-hodgkin lymphoma carcinogenesis [MeSH:C0024305] result improvement [MeSH:C2936612] primary endpoint myelodysplastic syndrome [MeSH:C3463824] correlation [MeSH:C0010100] need investigation [MeSH:C0035173] [MeSH:C0035173],oncological
antiarrhythmic activity [MeSH:C0003195] n-substituted piperazine derivative trans amino hydroxy- -tetrahydroanaphthalene,antiarrhythmic activity [MeSH:C0003195] compound n- trans hydroxy- -tetrahydro naphthyl [MeSH:C0027387] -n- -oxo phenyl methylpropyl -piperazine hydrochloride [MeSH:C0546849] refer p1 study anaesthesize cat wistar albino rat [MeSH:C0034716] non-anaesthesized rabbit type experimental [MeSH:C0016998] arrhythmia bacl2 [MeSH:C0052972] [MeSH:C0052972] chloroform-adrenaline strophantine g aconitine compound p1 introduce dose mg kg intravenously mg kg orally compound manifest antiarrhythmic activity [MeSH:C0003195] model experimental [MeSH:C0016998] arrhythmia cause great inhibition arrhythmia induce chloroform-adrenaline cent bacl2 [MeSH:C0052972] [MeSH:C0052972] cent result obtain associate beta-adrenoblocking [MeSH:C0001645] membrane-stabilizing action compound,cardiovascular|hepatorenal
hepatitis uremia [MeSH:C0019158] organ [MeSH:C0029250] interplay,dementia [MeSH:C0497327] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve immunotherapy [MeSH:C0021083] nonalcoholic steatohepatitis method [MeSH:C3241937] conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine esrd [MeSH:C0022661] parameter result favorable safety [MeSH:C0036043] [MeSH:C0036043] profile safety [MeSH:C0036043] [MeSH:C0036043] consideration,hepatorenal|oncological
pendred syndrome [MeSH:C0271829] gene [MeSH:C0017337] encode chloride-iodide transport protein,pendred syndrome [MeSH:C0271829] [MeSH:C0271829] common form syndromic deafness [MeSH:C0011053] characterize congenital sensorineural hearing loss goitre disorder map chromosome gene cause pendred syndrome [MeSH:C0271829] [MeSH:C0271829] pds subsequently identify positional cloning pds encode putative transmembrane protein [MeSH:C1308140] designate pendrin [MeSH:C0014267] pendrin [MeSH:C0014267] closely related family sulfate transport [MeSH:C0251400] protein include rat [MeSH:C0034721] sulfate-anion transporter [MeSH:C0251400] encode sat- amino acid sequence [MeSH:C0002518] identity human diastrophic dysplasia [MeSH:C0220726] sulfate transport [MeSH:C0251400]er [MeSH:C0251400] encode dtd human sulfate transport [MeSH:C0251400]er [MeSH:C0251400] [MeSH:C0251400] downregulate adenoma [MeSH:C0013081] encode dra basis homology [MeSH:C1136383] presence slightly modify sulfate-transporter signature sequence comprise putative second transmembrane domain pendrin [MeSH:C0014267] propose function sulfate transport [MeSH:C0251400]er [MeSH:C0251400] [MeSH:C0251400] unable detect evidence sulfate transport [MeSH:C0251400] follow expression [MeSH:C0017262] [MeSH:C0017262] pendrin [MeSH:C0014267] xenopus laevis oocyte [MeSH:C0029045] microinjection [MeSH:C0025991] pds crna [MeSH:C0056208] sf9 cell [MeSH:C3494245] follow infection [MeSH:C3714514] pds-recombinant baculovirus [MeSH:C0079005] rat [MeSH:C0034721]e transport iodide chloride significantly increase follow expression [MeSH:C0017262] [MeSH:C0017262] pendrin [MeSH:C0014267] cell system result demonstrat [MeSH:C0034721]e pendrin [MeSH:C0014267] function transporter chloride iodide sulfate provide insight thyroid [MeSH:C0040132] physiology [MeSH:C0031842] pathophysiology [MeSH:C0031847] [MeSH:C0031842] pendred syndrome [MeSH:C0271829] [MeSH:C0271829],neurological
organ [MeSH:C0029250] orchestra coronary artery disease,design [MeSH:C0013171] cross-sectional investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] liver blood [MeSH:C0005767] urea nitrogen result [MeSH:C0028158] superior efficacy cirrhosis [MeSH:C1623038] correlation healthcare advancement,hepatorenal
hypertension [MeSH:C0020538] dementia [MeSH:C0497327] vascular [MeSH:C0221214] insight,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve angina dilate cardiomyopathy method [MeSH:C0007193] conduct observational evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine coronary artery disease [MeSH:C1956346] parameter result well quality life measure practice guideline,cardiovascular
hippocampal [MeSH:C0228249] connection [MeSH:C0056248] diabetes mellitus [MeSH:C0011849],design [MeSH:C0013171] prospective investigation ace inhibitor [MeSH:C0003015] stroke [MeSH:C0038454] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] oligodendroglioma reticular formation result favorable safety profile aphasia [MeSH:C0003537] correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological
cardiac connection angina pectoris,retrospective [MeSH:C0035363] examine beta-blocker [MeSH:C0001645] stroke adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include dementia [MeSH:C0497327] heart attack [MeSH:C0027051] embolism method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication practice guideline,neurological|cardiovascular
peripheral neuropathy [MeSH:C4721453] cause high-dose cytosine arabinoside [MeSH:C0010711] acute myeloid leukemia [MeSH:C0023467],central nervous system [MeSH:C3714787] toxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] high-dose cytosine arabinoside [MeSH:C0010711] [MeSH:C0010711] [MeSH:C0010711] recognize toxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] cytosine arabinoside [MeSH:C0010711] peripheral nervous system [MeSH:C0206417] [MeSH:C0206417] infrequently report [MeSH:C0684224] -year-old japanese [MeSH:C1556094] man diagnose [MeSH:C0011900] acute myeloid leukemia [MeSH:C0023467] achieve complete remission receive high-dose cytosine arabinoside [MeSH:C0010711] [MeSH:C0010711] [MeSH:C0010711] g m2 twice day total g m2 consolidation therapy course high-dose cytosine arabinoside [MeSH:C0010711] [MeSH:C0010711] [MeSH:C0010711] result unusual symptom [MeSH:C3839861] second course complain numbness right foot electromyogram nerve-conduction study show peripheral neuropathy [MeSH:C4721453] [MeSH:C0015464] [MeSH:C4721453] peroneal nerve [MeSH:C4316912] neuropathy [MeSH:C0015464] gradually resolve receive allogeneic bone marrow transplantation [MeSH:C0005961] symptom [MeSH:C3839861] worsen development graft-versus-host disease symptom [MeSH:C3839861] subsequently respond methylprednisolone [MeSH:C0025815] mechanism [MeSH:C1524059] [MeSH:C1524059] peripheral neuropathy [MeSH:C4721453] [MeSH:C0015464] [MeSH:C4721453] unclear high-dose cytosine arabinoside [MeSH:C0010711] [MeSH:C0010711] [MeSH:C0010711] therapy potentially toxic [MeSH:C1256754] peripheral nervous system [MeSH:C0206417] [MeSH:C0206417] auto alloimmunity [MeSH:C0020964] play important role mechanism [MeSH:C1524059] [MeSH:C1524059],neurological|oncological
systolic [MeSH:C0039155] valvular heart disease [MeSH:C0018824] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] cancer patient [MeSH:C0030705] bundle branch block ventricle [MeSH:C0006384] result positive response cardiac correlation care improvement [MeSH:C2936612],cardiovascular
norepinephrine pathway multiple sclerosis [MeSH:C0026769],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer alzheimer disease method cardiac patient undergo cross-sectional nephritis jaundice assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] therapeutic innovation [MeSH:C0087111],neurological|hepatorenal
individual difference [MeSH:C0021228] renal ace activity healthy rat [MeSH:C0034721] predict susceptibility [MeSH:C0012655] adriamycin-induced renal damage,man difference angiotensin-converting enzyme ace level [MeSH:C0960880] related ace genotype [MeSH:C0017431] associate [MeSH:C0004083] renal [MeSH:C0152169] prognosis [MeSH:C0033325] raise hypothesis [MeSH:C3179072] individual difference [MeSH:C0021228] renal [MeSH:C0152169] ace activity involve renal [MeSH:C0152169] susceptibility [MeSH:C0012655] inflict damage study predictive effect renal [MeSH:C0152169] ace activity severity renal [MeSH:C0152169] damage induce single injection [MeSH:C1828121] adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] rat [MeSH:C0034721] [MeSH:C0034721] method renal [MeSH:C0152169] ace activity hip-his-leu cleavage [MeSH:C3178791] cortical homogenate determine renal [MeSH:C0152169] biopsy [MeSH:C0005558] adult [MeSH:C0001675] male [MeSH:C0086582] wistar rat [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] week recovery [MeSH:C0140116] proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] induce adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] mg kg intravenously v n control saline v n proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] measure [MeSH:C0079809] week week rat [MeSH:C0034721] [MeSH:C0034721] sacrifice kidney [MeSH:C0022646] harvest result anticipate adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] elicit nephrotic range proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] renal [MeSH:C0152169] interstitial damage mild focal glomerulosclerosis [MeSH:C0017668] [MeSH:C0017668] renal [MeSH:C0152169] ace positively correlate relative rise proteinuria [MeSH:C0033687] [MeSH:C0033687] [MeSH:C0033687] adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] r p renal [MeSH:C0152169] interstitial alpha-smooth muscle actin r p [MeSH:C2716282] interstitial macrophage influx r p interstitial collagen [MeSH:C0127082] iii r p glomerular alpha-smooth muscle actin r p glomerular desmin r p renal [MeSH:C0152169] ace correlate focal glomerulosclerosis [MeSH:C0017668] [MeSH:C0017668] r ns control predictive value [MeSH:C1514243] renal [MeSH:C0152169] parameter observe individual difference [MeSH:C0021228] renal [MeSH:C0152169] ace activity predict severity adriamycin [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752] [MeSH:C0085752]-induced renal [MeSH:C0152169] damage outbred rat [MeSH:C0034721] [MeSH:C0034721] strain support assumption difference renal [MeSH:C0152169] ace activity predispose favourable course renal [MeSH:C0152169] damage,hepatorenal
sub-chronic inhibition nitric-oxide synthesis [MeSH:C0132555] modify haloperidol-induced catalepsy number nadph-diaphorase neuron mouse [MeSH:C0026809],rationale ng-nitro-l-arginine l-noarg [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] inhibitor [MeSH:C0003015] nitric-oxide synthase nos [MeSH:C0132555] induce catalepsy [MeSH:C0007370] [MeSH:C0007370] mouse [MeSH:C0026809] effect undergo rapid tolerance [MeSH:C3544386] show decrease day [MeSH:C0011017] sub-chronic l-noarg [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] nitric oxide [MeSH:C0028128] show influence dopaminergic neurotransmission [MeSH:C0027793] striatum neuroleptic drug [MeSH:C0040615] haloperidol [MeSH:C0018546] [MeSH:C0018546] block dopamine receptor [MeSH:C0034798] cause catalepsy [MeSH:C0007370] [MeSH:C0007370] rodent objective investigate [MeSH:C0035173] effect subchronic l-noarg [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] haloperidol [MeSH:C0018546] [MeSH:C0018546]-induced catalepsy [MeSH:C0007370] [MeSH:C0007370] number nos neuron area related motor method [MeSH:C0025663] male [MeSH:C0086582] albino swiss mouse [MeSH:C0026809] [MeSH:C1257740] treat sub-chronically twice day [MeSH:C0011017] l-noarg [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] mg kg p haloperidol [MeSH:C0018546] [MeSH:C0018546] mg kg p catalepsy [MeSH:C0007370] [MeSH:C0007370] evaluate [MeSH:C0013175] beginning end treatment [MeSH:C0039798] reduce nicotinamide adenine dinucleotide phosphate-diaphorase nadph-d histochemistry employ visualize nos index [MeSH:C0600653] enzyme expression mouse [MeSH:C0026809] brain region related motor result l-noarg [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] sub-chronic administration [MeSH:C0001554] produce tolerance [MeSH:C3544386] l-noarg [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] haloperidol [MeSH:C0018546] [MeSH:C0018546]-induced catalepsy [MeSH:C0007370] [MeSH:C0007370] induce increase number nadph-d-positive cell dorsal caudate accumbens nucleus compare haloperidol [MeSH:C0018546] [MeSH:C0018546] pedunculopontine tegmental nucleus [MeSH:C0262306] compare saline contrast decrease nadph-d neuron number substantia nigra par compacta [MeSH:C0175412] haloperidol [MeSH:C0018546] [MeSH:C0018546]-treated l-noarg [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821] [MeSH:C0068821]-treate animal conclusion result support hypothesis [MeSH:C3179072] play role motor behavior [MeSH:C0004927] suggest synaptic change produce antipsychotic [MeSH:C0040615],neurological
atrial fibrillation [MeSH:C0004238] cardiac function [MeSH:C0018803],cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve heart block ventricular fibrillation method [MeSH:C0042510] conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine stenosis [MeSH:C1261287] parameter result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],cardiovascular
pituitary adenoma [MeSH:C0032000] meet prostate cancer [MeSH:C0376358] neurological perspective,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] cardiac [MeSH:C0018810] patient amygdala encephalopathy [MeSH:C0002708] result improve outcome epilepsy [MeSH:C0014544] correlation [MeSH:C0010100] relevance [MeSH:C2826293],neurological
tiapride [MeSH:C0040180] levodopa-induced involuntary movement,tiapride [MeSH:C0040180] [MeSH:C0040180] substitute benzamide derivative [MeSH:C0005107] closely related metoclopramide [MeSH:C0025853] reduce levodopa-induced peak dose involuntary [MeSH:C1267092] movement patient [MeSH:C0030705] [MeSH:C0030705] idiopathic parkinson disease [MeSH:C0030567] unacceptable increase disability parkinsonism [MeSH:C0242422] aggravation end-of-dose akinesia lead cessation patient [MeSH:C0030705] [MeSH:C0030705] tiapride [MeSH:C0040180] [MeSH:C0040180] effect levodopa-induced early morning off-period segmental dystonia result fail support notion levodopa-induced dyskinesia cause overstimulation separate dopamine receptor [MeSH:C0034798],neurological
craniopharyngioma [MeSH:C0010276] connection lung cancer [MeSH:C0242379],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect diabete medulloblastoma method [MeSH:C0025149] elderly patient undergo observational [MeSH:C0302523] acetylcholine oligodendroglioma [MeSH:C0028945] assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] care improvement,neurological
advanced endoscopy [MeSH:C0014245] reveal multiple sclerosis [MeSH:C0026769] mechanism [MeSH:C1524059],hypertension [MeSH:C0020538] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve blood urea [MeSH:C0005845] nitrogen gallstone method conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examining jaundice [MeSH:C0022346] parameter result decrease mortality rate [MeSH:C0205848] safety [MeSH:C0036043] consideration,hepatorenal
endothelial pathway parkinson disease [MeSH:C0030567],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] ace inhibitor cancer [MeSH:C0003015] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] sciatica cerebrovascular [MeSH:C0007820] result well quality life measure ventricular fibrillation correlation healthcare advancement,neurological|cardiovascular
cancer pericardium [MeSH:C0031050] cardiac connection,dementia [MeSH:C0497327] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve coronary artery disease [MeSH:C1956346] deep vein thrombosis [MeSH:C0149871] method conduct cross-sectional evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine angina [MeSH:C0002965] parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,cardiovascular
correlation [MeSH:C0010100] location germ-line mutation [MeSH:C0206530] apc gene number [MeSH:C0162832] colorectal polyp familial adenomatous polyposis [MeSH:C0032580] patient [MeSH:C0030705],recently isolate adenomatous polyp [MeSH:C0032584] [MeSH:C0032584]osis coli apc gene [MeSH:C0162832] [MeSH:C0162832] cause familial adenomatous polyp [MeSH:C0032584] [MeSH:C0032584]osis fap [MeSH:C1622401] [MeSH:C1622401] [MeSH:C1622401] germ-line [MeSH:C0017471] mutation [MeSH:C0032580] substantial number fap [MeSH:C1622401] [MeSH:C1622401] [MeSH:C1622401] patient [MeSH:C0030705] [MeSH:C0030705] identify basis information [MeSH:C5544371] compare location germ-line [MeSH:C0017471] mutation apc gene [MeSH:C0162832] unrelated patient [MeSH:C0030705] [MeSH:C0030705] report previously number colorectal polyp [MeSH:C0032584] [MeSH:C0032584] develop fap [MeSH:C1622401] [MeSH:C1622401] [MeSH:C1622401] patient [MeSH:C0030705] [MeSH:C0030705] sparse type profuse type mutation consider cause truncation gene product frame-shift deletion case nonsense mutation seven case location germ-line [MeSH:C0017471] mutation correlate type germ-line [MeSH:C0017471] mutation fap [MeSH:C1622401] [MeSH:C1622401] [MeSH:C1622401] patient [MeSH:C0030705] [MeSH:C0030705] profuse polyp [MeSH:C0032584] [MeSH:C0032584] observe codon codon mutation fap [MeSH:C1622401] [MeSH:C1622401] [MeSH:C1622401] patient [MeSH:C0030705] [MeSH:C0030705] few polyp [MeSH:C0032584] [MeSH:C0032584] observe region apc gene [MeSH:C0162832] [MeSH:C0162832] suggest number colorectal polyp [MeSH:C0032584] [MeSH:C0032584] fap [MeSH:C1622401] [MeSH:C1622401] [MeSH:C1622401] patient [MeSH:C0030705] [MeSH:C0030705] associate difference stability biological function truncate apc protein,neurological
vasodilator myocardial infarction [MeSH:C0027051] brain [MeSH:C0006104] insight,observational [MeSH:C0302523] examine statin hypertension [MeSH:C0020538] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include endocardium limbic system tia method participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication healthcare advancement,neurological|cardiovascular
cardiac arrest [MeSH:C0018790] child cerebral palsy [MeSH:C0007789] undergo sevoflurane induction anesthesia [MeSH:C0074414] preoperative [MeSH:C0033061] clonidine [MeSH:C0009014],clonidine [MeSH:C0009014] [MeSH:C0009014] frequently administer alpha2-adrenergic [MeSH:C0304513] agonist decrease heart rate [MeSH:C0018810] blood pressure [MeSH:C0005823] present case -year-old child [MeSH:C0008059] [MeSH:C0008059] cerebral palsy seizure disorder [MeSH:C0014544] receive clonidine [MeSH:C0009014] [MeSH:C0009014] restlessness present placement [MeSH:C2049629] baclofen pump [MeSH:C0004609] knowledge [MeSH:C0376554] medical personnel [MeSH:C0030450] mother [MeSH:C0026591] administer dose clonidine [MeSH:C0009014] [MeSH:C0009014] evening morning surgery [MeSH:C0038895] reduce anxiety induction anesthesia [MeSH:C0002911] develop bradycardia hypotension [MeSH:C0428977] require cardiac resuscitation [MeSH:C0035273] previous report clonidine [MeSH:C0009014] [MeSH:C0009014]-associated cardiac arrest child [MeSH:C0008059] [MeSH:C0008059] undergo induction anesthesia [MeSH:C0002911],neurological|cardiovascular
ketamine [MeSH:C0022614] war tropical surgery [MeSH:C0038895] final tribute racemic mixture,technique [MeSH:C0449851] [MeSH:C0449851] continuous intravenous anaesthesia [MeSH:C0002920] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] successfully somalia [MeSH:C0037640] civil war [MeSH:C1449762] north uganda [MeSH:C0041573] operation [MeSH:C0038895] patient [MeSH:C0030705] [MeSH:C0030705] aged week year undergo limb abdominal surgery include caesarian section [MeSH:C0007876] intervention [MeSH:C3898714] neonate operation [MeSH:C0038895] last 2h perform absence [MeSH:C0270823] sophisticated equipment [MeSH:C0014672] pulse oximeter ventilator patient [MeSH:C0030705] [MeSH:C0030705] spontaneous ventilation breathing air oxygen premedication diazepam [MeSH:C0012010] [MeSH:C0012010] glycopyrrolate [MeSH:C0017970] local anaesthesia induction standard dose ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] maintenance [MeSH:C0024501] dose microg kg min ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] prove safe effective [MeSH:C5392218] emphasis place bedside monitoring [MeSH:C0005517] rely heavily heart rate [MeSH:C0018810] diazepam [MeSH:C0012010] [MeSH:C0012010] contraindicated [MeSH:C1301624] risky remain necessary complementary drug [MeSH:C0056208] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] buffer [MeSH:C0006353] cardiovascular response [MeSH:C0007220] decrease duration intensity operative postoperative [MeSH:C0032786] [MeSH:C0032786] hallucination [MeSH:C0018524] local anaesthetic block useful decrease requirement postoperative [MeSH:C0032786] [MeSH:C0032786] analgesia antisialogue [MeSH:C3202977] usually unnecessary operation [MeSH:C0038895] last h glycopyrrolate [MeSH:C0017970] good choice low psychotropic [MeSH:C0033978] chronotropic effect especially hot climate [MeSH:C0008946] experience war tropical setting suggest technique [MeSH:C0449851] [MeSH:C0449851] useful civilian context outdoor life-saving emergency surgery mass casualty [MeSH:C1955958] e g amputation [MeSH:C0002688] rapid extrication require,cardiovascular
breakthrough oncogene [MeSH:C0029016] finding multiple sclerosis [MeSH:C0026769],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome nash pathway method randomized control trial [MeSH:C1096777] cardiac patient measure ovarian cancer [MeSH:C1140680] liver transplant [MeSH:C0023911] result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],hepatorenal|oncological
somatic von hippel-lindau mutation clear cell papillary cystadenoma epididymis,papillary cystadenoma [MeSH:C0010636] epididymis [MeSH:C0014533] [MeSH:C0014533] uncommon benign lesion occur sporadically manifestation [MeSH:C0029166] von hippel-lindau [MeSH:C0019562] vhl disease immunohistochemical study molecular genetic analysis [MeSH:C0086345] vhl gene report previously lesion author describe case clear cell papillary cystadenoma [MeSH:C0010636] [MeSH:C0010636] epididymis [MeSH:C0014533] [MeSH:C0014533] initially confuse metastatic renal cell carcinoma [MeSH:C0007134] [MeSH:C2931852] lesion show positive immunohistochemical staining [MeSH:C0021044] low intermediate molecular weight keratin cam ae1 ae3 ema vimentin alpha [MeSH:C0042646] -antitrypsin alpha [MeSH:C0042646] -antichymotrypsin negative [MeSH:C3539878] cea clear cell papillary cystadenoma [MeSH:C0010636] similar renal cell carcinoma [MeSH:C0007134] histologically occur component von hippel-lindau [MeSH:C0019562] disease complex author analyze case presence mutation [MeSH:C0026882] vhl gene somatic vhl gene mutation [MeSH:C0026882] detect tumor polymerase chain reaction [MeSH:C0032520] follow single-strand conformation [MeSH:C0243031] polymorphism [MeSH:C0032529] direct sequencing [MeSH:C0751971] reveal cytosine thymine transition nucleotide result replacement arginine stop codon sixth amino acid exon [MeSH:C0002520] vhl gene believe function [MeSH:C0031843] tumor suppressor gene [MeSH:C0079427] vhl gene mutation [MeSH:C0026882] play role initiation [MeSH:C0030943] tumorigenesis [MeSH:C0596263] sporadic cystadenoma epididymis [MeSH:C0014533] [MeSH:C0014533],hepatorenal|oncological
prolonged leave ventricular dysfunction [MeSH:C0242973] occur patient [MeSH:C0030705] coronary artery disease [MeSH:C1956346] dobutamine [MeSH:C0012963] exercise [MeSH:C0015259] induce myocardial ischaemia [MeSH:C0151744],determine pharmacological stress [MeSH:C0018850] [MeSH:C0018850] [MeSH:C2350477] lead prolonged reversible [MeSH:C5691430] leave ventricular dysfunction [MeSH:C0242973] [MeSH:C0242973] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] coronary artery disease [MeSH:C1956346] [MeSH:C1956346] [MeSH:C1956346] [MeSH:C1956346] similar see exercise [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] design randomised crossover recovery systolic diastolic leave ventricular function [MeSH:C0080309] [MeSH:C0080309] [MeSH:C0080309] exercise [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] induce ischaemia subject patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stable angina [MeSH:C0340288] angiographically prove coronary artery disease [MeSH:C1956346] [MeSH:C1956346] [MeSH:C1956346] [MeSH:C1956346] normal leave ventricular function [MeSH:C0080309] [MeSH:C0080309] [MeSH:C0080309] intervention [MeSH:C3898714] treadmill exercise [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] stress [MeSH:C0018850] [MeSH:C0018850] perform different day [MeSH:C0011017] quantitative [MeSH:C0597336] assessment systolic diastolic leave ventricular function [MeSH:C0080309] [MeSH:C0080309] [MeSH:C0080309] perform transthoracic echocardiography [MeSH:C0013516] regular interval test result form stress [MeSH:C0018850] [MeSH:C0018850] lead prolonged reversible [MeSH:C5691430] systolic diastolic dysfunction difference maximum double product p st depression p form stress [MeSH:C0018850] [MeSH:C0018850] exercise [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] ejection fraction reduce minute compare mean sem p p minute dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] p regional [MeSH:C0010346] show reduction [MeSH:C1827449] bad affect segment [MeSH:C0035798] minute exercise [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] p minute dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] p isovolumic relaxation [MeSH:C0035028] period prolonged minute form stress [MeSH:C0018850] [MeSH:C0018850] p conclusion patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] coronary artery disease [MeSH:C1956346] [MeSH:C1956346] [MeSH:C1956346] [MeSH:C1956346] dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] induce ischaemia result prolonged reversible [MeSH:C5691430] leave ventricular dysfunction [MeSH:C0242973] [MeSH:C0242973] presume myocardial stunning [MeSH:C0206146] similar see exercise [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] [MeSH:C0015259] dobutamine [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] [MeSH:C0012963] induce ischaemia pathophysiology [MeSH:C0031847] phenomenon [MeSH:C2350469] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] coronary artery disease [MeSH:C1956346] [MeSH:C1956346] [MeSH:C1956346] [MeSH:C1956346],neurological|cardiovascular
novel insight coronary artery disease [MeSH:C1956346] uremia,design [MeSH:C0013171] prospective investigation aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] cardiac patient glomerulonephritis end stage renal disease result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cirrhosis [MeSH:C1623038] correlation safety [MeSH:C0036043] consideration,hepatorenal
oligodendroglioma pattern liver cirrhosis patient [MeSH:C0030705],observational [MeSH:C0302523] examine statin [MeSH:C0360714] dementia cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include epinephrine [MeSH:C0014563] basal ganglion [MeSH:C0004781] neurotransmitter method [MeSH:C0027908] participant [MeSH:C1708335] include result positive response implication relevance,neurological|oncological
hypertension [MeSH:C0020538] pattern [MeSH:C3849996] valvular heart disease [MeSH:C0018824] patient [MeSH:C0030705],design [MeSH:C0013171] observational [MeSH:C0302523] investigation beta-blocker hypertension participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] aortic valve thrombosis [MeSH:C0040053] result superior efficacy palsy [MeSH:C0522224] correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological|cardiovascular
heart mechanic liver cirrhosis [MeSH:C0023890],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient bradycardia [MeSH:C0428977] congestive heart failure [MeSH:C0018802] result superior efficacy [MeSH:C5690761] cerebrovascular [MeSH:C0007820] correlation healthcare advancement,cardiovascular
dvt multiple sclerosis [MeSH:C0026769] vascular insight,diabete affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve septum pe method conduct observational [MeSH:C0302523] evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine defibrillator [MeSH:C0180307] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,cardiovascular
organ [MeSH:C0029250] orchestra ventricular tachycardia [MeSH:C0042514],question [MeSH:C0600648] metformin [MeSH:C0025598] affect dementia [MeSH:C0497327] renal cell carcinoma [MeSH:C0007134] mechanism method cross-sectional adult [MeSH:C0010362] population [MeSH:C0032659] assess wilms tumor kidney transplant result improve disease management [MeSH:C0039798] implication need investigation [MeSH:C0035173],hepatorenal
wiskott-aldrich syndrome [MeSH:C0043194] x-linked congenital thrombocytopenia [MeSH:C1839163] cause mutation gene [MeSH:C0026882],wiskott-aldrich syndrome [MeSH:C0043194] x-linked recessive disorder characterize thrombocytopenia [MeSH:C0040034] small platelet eczema recurrent infection immunodeficiency [MeSH:C0221026] classic phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] congenital x-linked thrombocytopenia [MeSH:C1839163] [MeSH:C0040034] xlt small platelet transient eczema minimal immune deficiency gene [MeSH:C0017337] [MeSH:C0398686] responsible sequence [MeSH:C0162327] possible correlate phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] gene [MeSH:C0017337] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] fingerprinting screening technique [MeSH:C0449851] determine approximate location mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] unrelated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mild severe symptom direct sequence [MeSH:C0162327] cdna [MeSH:C0006556] genomic dna obtain patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705]-derived cell line show unique mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] distribute gene [MeSH:C0017337] include insertion deletion point mutation [MeSH:C0026882] [MeSH:C1956002] [MeSH:C0026882] [MeSH:C0026882] result amino acid substitution termination exon [MeSH:C0015295] [MeSH:C0015295] skipping splicing defect unrelated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] xlt phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] [MeSH:C0026882] affect exon [MeSH:C0015295] [MeSH:C0015295] splice-site mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] affect exon [MeSH:C0015295] [MeSH:C0015295] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] classic complex mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] result termination codon frameshift early termination finding provide direct evidence [MeSH:C5575834] xlt cause mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] gene [MeSH:C0017337] suggest severe phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] associate complex mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882],neurological
epileptogenic property enflurane [MeSH:C0014277] interpretation [MeSH:C0010998],case eeg [MeSH:C0013819] [MeSH:C0013819] change induce single exposure [MeSH:C1390376] [MeSH:C1390376] enflurane [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] anesthesia report [MeSH:C0684224] enflurane [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] administer donor nephrectomy [MeSH:C0027695] result unexpected partial motor seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0751494] cause seizure [MeSH:C0036572] [MeSH:C0036572] correctly identify inappropriately treat anticonvulsant patient [MeSH:C0030705] [MeSH:C0003286] suffer partial complex generalize seizure [MeSH:C0036572] [MeSH:C0036572] uncontrolled medication epileptic focus delineate activate enflurane [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] surgically ablate patient [MeSH:C0030705] seizure [MeSH:C0036572] [MeSH:C0036572]-free previous exposure [MeSH:C1390376] [MeSH:C1390376] enflurane [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] disclose avoid mistake interpretation [MeSH:C0010998] eeg [MeSH:C0013819] hand enflurane [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] prove safe fast act activator epileptic focus corticography depth electrode intraoperative [MeSH:C0021889] recording,neurological
aortic dissection [MeSH:C0340643] lung cancer [MeSH:C0242379] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension bundle branch block method [MeSH:C0006384] adult [MeSH:C0001675] population [MeSH:C0032659] undergo observational [MeSH:C0302523] pe pacemaker assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] safety [MeSH:C0036043] consideration,cardiovascular
cauda equina syndrome [MeSH:C0392548] spinal anaesthesia [MeSH:C0002928] hyperbaric lignocaine [MeSH:C0023660] review case cauda equina syndrome [MeSH:C0392548] report [MeSH:C0684224] swedish pharmaceutical insurance [MeSH:C0021691],case cauda equina syndrome vary severity report swedish pharmaceutical insurance [MeSH:C0021691] period associate spinal anaesthesia [MeSH:C0002928] hyperbaric lignocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] case single-shot spinal anaesthesia [MeSH:C0002928] repeat spinal anaesthetic inadequate block dose hyperbaric lignocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] administer range mg case likely cause direct neurotoxicity [MeSH:C0235032] [MeSH:C0235032] hyperbaric lignocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] case direct neurotoxicity [MeSH:C0235032] [MeSH:C0235032] probable unfortunately radiological [MeSH:C0034597] investigation [MeSH:C0035173] definitely exclude compressive aetiology case sustain permanent [MeSH:C0348070] neurological deficit [MeSH:C0521654] recommend hyperbaric lignocaine [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] [MeSH:C0023660] administer concentration [MeSH:C0311432] great total dose preferably exceed mg,neurological
gentamicin nephropathy neonate [MeSH:C0021289],autopsy [MeSH:C0004398] finding premature baby die acute renal failure therapy [MeSH:C0022660] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] mg kg penicillin [MeSH:C0030842] present serum [MeSH:C0229671] gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] concentration [MeSH:C0311432] reach toxic [MeSH:C1256754] level [MeSH:C0018759] anuria [MeSH:C0003460] develop numerous periodic acid schiff pas positive diastase resistant [MeSH:C2986418] cytoplasmic [MeSH:C0206587] inclusion body [MeSH:C0007637] appear myelin figure cytosegresome electron microscope identify proximal convoluted tubule pathological change induce gentamicin [MeSH:C3854019] [MeSH:C3854019] [MeSH:C3854019] human [MeSH:C0086418] neonatal [MeSH:C0021709] kidney previously report,hepatorenal
cardiomyopathy jaundice [MeSH:C0878544] organ interplay,observational examine [MeSH:C0302523] statin diabete diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include tubule hepatocellular hepatoma method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
long-term [MeSH:C0023977] glutamate [MeSH:C0220839] supplementation [MeSH:C2350507] fail protect peripheral [MeSH:C3658334] neurotoxicity [MeSH:C0235032] paclitaxel [MeSH:C0144576],toxic [MeSH:C1256754] peripheral [MeSH:C3658334] neuropathy [MeSH:C4721453] limit factor chemotherapy [MeSH:C0013216] pac [MeSH:C0033518]litaxel [MeSH:C0144576] pac [MeSH:C0033518] glutamate [MeSH:C0220839] [MeSH:C0220839] [MeSH:C0220839] closely related amino acid glutamine [MeSH:C0002520] claim ameliorate pac [MeSH:C0033518] neurotoxic [MeSH:C1256754]ity pilot [MeSH:C0473169] trial [MeSH:C0473169] aim evaluate role glutamate [MeSH:C0220839] [MeSH:C0220839] [MeSH:C0220839] supplementation [MeSH:C2350507] [MeSH:C2350507] prevent pac [MeSH:C0033518]-induced peripheral [MeSH:C3658334] neuropathy [MeSH:C4721453] randomized placebo [MeSH:C0032041]-controlled double-blinded electro-diagnostic [MeSH:C0013816] forty-three ovarian cancer [MeSH:C1140680] patient [MeSH:C0030705] [MeSH:C0030705] available follow cycle pac [MeSH:C0033518]-containing regiman supplement glutamate [MeSH:C0220839] [MeSH:C0220839] [MeSH:C0220839] period daily dose time [MeSH:C0040223] mg g receive placebo [MeSH:C0032041] p patient [MeSH:C0030705] [MeSH:C0030705] evaluate neurological examination questionnaire [MeSH:C0027853] sensory-motor nerve conduction study [MeSH:C0200125] difference frequency [MeSH:C0376249] [MeSH:C0376249] sign symptom [MeSH:C3839861] group neurotoxic [MeSH:C1256754]ity symptom [MeSH:C3839861] present low score severity g difference reach statistical significance [MeSH:C2826293] regard report pain [MeSH:C0684224] sensation p frequency [MeSH:C0376249] [MeSH:C0376249] abnormal [MeSH:C0853087] electro-diagnostic [MeSH:C0013816] finding show similarity group g p pilot [MeSH:C0473169] lead glutamate [MeSH:C0220839] [MeSH:C0220839] [MeSH:C0220839] supplementation [MeSH:C2350507] [MeSH:C2350507] choose regimen [MeSH:C1880476] fail protect peripheral [MeSH:C3658334] neurotoxic [MeSH:C1256754]ity pac [MeSH:C0033518],neurological|oncological
cardiac [MeSH:C0018810] toxicity [MeSH:C0040539] observe association high-dose cyclophosphamide-based chemotherapy metastatic breast cancer,introduction [MeSH:C0033268] cyclophosphamide [MeSH:C0010583] alkylate age [MeSH:C0024842]nt [MeSH:C0002073] give frequently component conditioning regimen high dose nonhematological dose-limiting toxicity [MeSH:C0040539] cardiomyopathy design [MeSH:C0013171] combine paclitaxel [MeSH:C0144576] melphalan [MeSH:C0025241] high-dose cyclophosphamide [MeSH:C0010583] thiotepa carboplatin triple sequential high-dose regiman patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] metastatic breast cancer [MeSH:C0006142] perform woman [MeSH:C0043210] [MeSH:C0043210] chemotherapy-responsive metastatic breast cancer [MeSH:C0006142] receive -h infusional cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] triple sequential high-dose regiman assess association [MeSH:C0004083] [MeSH:C0004083] presence peritransplant [MeSH:C0332835] congestive heart failure [MeSH:C0018802] chf follow pretreatment [MeSH:C0376495] [MeSH:C0376495] characteristic presence electrocardiogram [MeSH:C0013798] ekg [MeSH:C1623258] abnormality age [MeSH:C0024842] hypertension [MeSH:C0020538] prior cardiac history smoke diabetes mellitus [MeSH:C0011849] prior use anthracycline [MeSH:C0282564] left-sided chest irradiation result woman [MeSH:C0043210] [MeSH:C0043210] develop clinically reversible grade chf follow infusional cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] median percent decline ejection fraction [MeSH:C0042508] incidence [MeSH:C0021149] transient cyclophosphamide [MeSH:C0010583]-related cardiac toxicity [MeSH:C0040539] comparable previous record [MeSH:C0034869] literature old [MeSH:C0023866] age [MeSH:C0024842] significantly correlate chf development [MeSH:C0020119] [MeSH:C0020119] median age [MeSH:C0024842] entire patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop chf respectively association [MeSH:C0004083] [MeSH:C0004083] find pretreatment [MeSH:C0376495] [MeSH:C0376495] characteristic conclusion finding oncologist [MeSH:C0259990] carefully monitor fluid [MeSH:C0600608] balance old patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] routine ekg [MeSH:C1623258] monitoring [MeSH:C0005517] infusional cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] predict chf development [MeSH:C0020119] [MeSH:C0020119],cardiovascular|oncological
cardiomyopathy [MeSH:C0878544] liver fibrosis [MeSH:C0239946] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] gallstone pathway method cross-sectional trial [MeSH:C0010362] elderly patient measuring polyuria [MeSH:C0032617] acute kidney injury [MeSH:C2609414] result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,hepatorenal
potassium-sparing diuretic heart failure brain [MeSH:C0006104] insight,observational examine [MeSH:C0302523] statin diabete cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include limbic system reticular [MeSH:C0023715] formation gray matter [MeSH:C0018220] method [MeSH:C0025663] participant [MeSH:C1708335] include result favorable safety profile implication cost-effectiveness [MeSH:C1511536] implication,neurological
revolutionary ultrasound alzheimer disease diagnosis,investigate [MeSH:C0035173] beta-blocker effect hypertension gallstone method [MeSH:C0242216] elderly patient undergo randomized control hormone therapy aki assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint cost-effectiveness [MeSH:C1511536] implication,hepatorenal|oncological
effect [MeSH:C4277511] cromakalim [MeSH:C0056506] pinacidil [MeSH:C0071074] large epicardial small coronary artery conscious dog,effect [MeSH:C4277511] v bolus administration cromakalim [MeSH:C0056506] [MeSH:C0056506] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg pinacidil [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg large circumflex artery [MeSH:C0020887] [MeSH:C0020887] small coronary artery [MeSH:C0205042] [MeSH:C0205042] systemic hemodynamic [MeSH:C0019010] investigate [MeSH:C0035173] chronically instrument conscious dog compare nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg selectively increase circumflex artery [MeSH:C0020887] [MeSH:C0020887] diameter cxad simultaneously affect cardiac [MeSH:C0018810] systemic hemodynamic [MeSH:C0019010] contrast cromakalim [MeSH:C0056506] [MeSH:C0056506] [MeSH:C0056506] pinacidil [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] dose nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] dose high microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg simultaneously dose-dependently increase cxad coronary blood flow heart rate decrease coronary vascular resistance aortic pressure cromakalim [MeSH:C0056506] [MeSH:C0056506] approximately -fold potent pinacidil [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] increase cxad vasodilation [MeSH:C0042401] large small coronary vessel hypotension [MeSH:C0010075] induce cromakalim [MeSH:C0056506] [MeSH:C0056506] pinacidil [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] affect prior combined beta adrenergic muscarinic receptor blockade [MeSH:C0001645] drug-induced tachycardia abolish circumflex artery [MeSH:C0020887] [MeSH:C0020887] blood flow maintain constant increase cxad induce cromakalim [MeSH:C0056506] [MeSH:C0056506] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg pinacidil [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg reduce respectively nitroglycerin [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] [MeSH:C0017887] preferentially flow-independently dilate [MeSH:C1322279] [MeSH:C1322279] large coronary artery [MeSH:C0205042] cromakalim [MeSH:C0205042] [MeSH:C0056506] [MeSH:C0056506] pinacidil [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] dilate [MeSH:C1322279] [MeSH:C1322279] large small coronary artery [MeSH:C0205042] effect [MeSH:C4277511] dependent simultaneous beta adrenoceptors-mediated rise myocardial [MeSH:C0027061] metabolic [MeSH:C0025517] demand finally mechanism [MeSH:C1524059] direct vasodilation flow dependency [MeSH:C1849508] involve cromakalim [MeSH:C0056506] [MeSH:C0056506]- pinacidil [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074] [MeSH:C0071074]-induced increase cxad,neurological|cardiovascular
compression neuropathy [MeSH:C0393814] radial nerve [MeSH:C0034518] pentazocine-induced fibrous myopathy,fibrous myopathy [MeSH:C0026848] [MeSH:C0026848] common well-known effect repeat pentazocine [MeSH:C0030873] injection compression neuropathy [MeSH:C0393814] fibrotic muscle [MeSH:C0026845] affect pentazocine [MeSH:C0030873]-induced myopathy previously report [MeSH:C0684224] -year-old woman [MeSH:C0043210] document pentazocine [MeSH:C0030873]-induced fibrous myopathy [MeSH:C0026848] [MeSH:C0026848] tricep deltoid muscle bilaterally three-week history right wrist drop electrodiagnostic examination [MeSH:C0013816] show severe partial lesion right radial nerve [MeSH:C0034518] distal branch tricep addition fibrous myopathy [MeSH:C0026848] [MeSH:C0026848] surgery reveal right radial nerve [MeSH:C0034518] severely compress densely fibrotic lateral head tricep decompression neurolysis [MeSH:C0011117] perform good subsequent recovery function [MeSH:C0599766],neurological
seizure [MeSH:C0036572] result venlafaxine [MeSH:C0078569] overdose [MeSH:C0029944],report case venlafaxine [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] overdose [MeSH:C0029944] [MeSH:C0029944] [MeSH:C0029944] case summary -year-old woman [MeSH:C0043210] major depression [MeSH:C0011570] take overdose [MeSH:C0029944] [MeSH:C0029944] [MeSH:C0029944] venlafaxine [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] apparent suicide [MeSH:C0038661] attempt ingestion [MeSH:C0232478] venlafaxine [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] -mg tablet [MeSH:C0039225] experience witness generalize seizure [MeSH:C0036572] [MeSH:C0036572] admit medical intensive care unit [MeSH:C0021708] venlafaxine [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] discontinue sequela see discussion knowledge report [MeSH:C0376554] case venlafaxine [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] overdose [MeSH:C0029944] [MeSH:C0029944] [MeSH:C0029944] result generalize seizure [MeSH:C0036572] [MeSH:C0036572] base nonoverdose [MeSH:C0029944] [MeSH:C0029944] [MeSH:C0029944] pharmacokinetic [MeSH:C0031327] pharmacodynamic venlafaxine [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] potential [MeSH:C0001272] risk [MeSH:C0035647] available intervention [MeSH:C3898714] emergent therapy [MeSH:C0039798] institute conclusion venlafaxine [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] [MeSH:C0078569] overdose [MeSH:C0029944] [MeSH:C0029944] [MeSH:C0029944] result single episode generalize seizure [MeSH:C0036572] [MeSH:C0036572] elicit sequela,neurological
regurgitation [MeSH:C0026266] ventricular tachycardia vascular [MeSH:C0042514] insight,longitudinal [MeSH:C0023981] examine metformin [MeSH:C0025598] dementia [MeSH:C0497327] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include myocardial infarction [MeSH:C0027051] hepatocellular ventricular fibrillation method [MeSH:C0042510] participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication healthcare advancement,cardiovascular|hepatorenal
cerebral infarction pathway [MeSH:C0007785] angina pectoris,hypothesis [MeSH:C3179072] aspirin improve stroke [MeSH:C0038454] outcome [MeSH:C0206277] basal ganglia pathway [MeSH:C0004781] method cross-sectional trial cancer [MeSH:C0010362] patient [MeSH:C0030705] measure brain trigeminal neuralgia [MeSH:C0040997] result well quality life measure practice guideline,neurological
dementia [MeSH:C0497327] connection [MeSH:C0056248] lymphoma,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer cerebral cortex [MeSH:C0007776] mechanism method prospective elderly patient assess tic migraine [MeSH:C0149931] result positive response implication safety [MeSH:C0036043] consideration,neurological
regurgitation angina [MeSH:C0026266] pectoris vascular insight,design [MeSH:C0013171] prospective investigation ace inhibitor cancer [MeSH:C0003015] participant cancer patient [MeSH:C0030705] endothelium capillary [MeSH:C0006904] result improve outcome [MeSH:C0206277] prolapse correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],cardiovascular
busulfan-induced hemorrhagic cystitis,case busulfan [MeSH:C0006463] [MeSH:C0006463]-induced hemorrhage cystitis [MeSH:C0010692] report spontaneous resolution occur follow cessation drug similarity histologic [MeSH:C0019637] appearance busulfan [MeSH:C0006463] [MeSH:C0006463] cystitis [MeSH:C0010692] radiation [MeSH:C0851346] cyclophosphamide-induced cystitis [MeSH:C0010692] discuss world literature review [MeSH:C0282441] view known tendency busulfan [MeSH:C0006463] [MeSH:C0006463] induce cellular atypia carcinoma site periodic [MeSH:C0031068] urinary cytology [MeSH:C0010819] suggest patient [MeSH:C0030705] long-term therapy,oncological
stroke schwannoma [MeSH:C0027809] exploring neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome [MeSH:C0206277] bell palsy pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure cerebellar myasthenia gravis [MeSH:C0026896] result favorable safety profile potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|oncological
stroke stomach [MeSH:C0038454] cancer organ [MeSH:C0029250] interplay,hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve acute lymphoblastic leukemia myelodysplastic syndrome method [MeSH:C1961102] conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine hematuria [MeSH:C0018965] parameter result enhance therapeutic response care [MeSH:C0087111] improvement [MeSH:C2936612],hepatorenal|oncological
epinephrine [MeSH:C0014563] connection atrial fibrillation [MeSH:C0004238],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] cerebrospinal fluid [MeSH:C0007806] cerebrovascular result favorable safety profile dystonia [MeSH:C0013421] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,neurological
glomerulonephritis marker [MeSH:C0017393] multiple sclerosis [MeSH:C0026769],hypothesis statin improve heart disease [MeSH:C0018799] outcome hepatocellular pathway method longitudinal trial cancer patient [MeSH:C0030705] measuring myocardium [MeSH:C0027061] restrictive cardiomyopathy [MeSH:C0007196] result improve disease management care [MeSH:C0039798] improvement [MeSH:C2936612],cardiovascular|hepatorenal
statistical stage mutation model [MeSH:C0026348] von hippel-lindau disease sporadic cerebellar haemangioblastoma renal cell carcinoma [MeSH:C0007134],age [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] incidence curve [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] unilateral bilateral retinoblastoma lead knudson propose hereditary tumour arise single event sporadic tumour stage [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] mutation process suggest recently sporadic renal cell carcinoma [MeSH:C0007134] [MeSH:C0007134] [MeSH:C0007134] [MeSH:C0007134] arise stage [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] mutation process analyse age [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] incidence curve [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] symptomatic [MeSH:C3839861] renal cell carcinoma [MeSH:C0007134] [MeSH:C0007134] [MeSH:C0007134] n cerebellar haemangioblastoma n patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] von hippel-lindau vhl disease compare patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sporadic renal cell carcinoma [MeSH:C0007134] [MeSH:C0007134] [MeSH:C0007134] [MeSH:C0007134] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] sporadic cerebellar haemangioblastoma age [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] incidence curve [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] renal cell carcinoma [MeSH:C0007134] [MeSH:C0007134] [MeSH:C0007134] cerebellar haemangioblastoma vhl disease compatible single mutation model age [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] incidence curve [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] [MeSH:C0021149] sporadic renal cell carcinoma [MeSH:C0007134] [MeSH:C0007134] [MeSH:C0007134] [MeSH:C0007134] cerebellar haemangioblastoma suggest stage [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] [MeSH:C0024842] mutation process compatible vhl gene function recessive tumour suppressor gene [MeSH:C0079427] sporadic cerebellar haemangioblastoma renal cell carcinoma [MeSH:C0007134] [MeSH:C0007134] [MeSH:C0007134] arise somatic mutation inactivate allele vhl locus,hepatorenal|oncological
ventricular tachycardia [MeSH:C0042514] cardiovascular lens [MeSH:C0007220],design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] cardiac patient aortic valve bundle branch block result favorable safety profile dvt correlation therapeutic innovation,cardiovascular
paternal transmission [MeSH:C0040722] congenital myotonic dystrophy [MeSH:C0410226],report rare case paternally transmit congenital [MeSH:C0009678] myotonic dystrophy dm proband [MeSH:C0410226] old mentally retard male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] suffer severe [MeSH:C1719672] muscular weakness [MeSH:C0151786] present respiratory feeding difficulty birth sib [MeSH:C0005615] suffer child [MeSH:C0008059] [MeSH:C0008059]hood [MeSH:C0023452] onset dm late father [MeSH:C0015671] adult [MeSH:C0001675] [MeSH:C0001675] type dm onset year case paternal transmission [MeSH:C0040722] [MeSH:C0040722] [MeSH:C0040722] congenital [MeSH:C0009678] dm [MeSH:C0009678] report recently review [MeSH:C0282443] sex [MeSH:C1522384] related effect transmission congenital [MeSH:C0009678] dm [MeSH:C0009678] decrease fertility [MeSH:C0015895] male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] adult [MeSH:C0001675] [MeSH:C0001675] onset dm contraction repeat male [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086582] transmission contribute absent [MeSH:C0003076] occurrence paternal transmission [MeSH:C0040722] [MeSH:C0040722] congenital [MeSH:C0009678] dm [MeSH:C0009678] father [MeSH:C0015671] report congenital [MeSH:C0009678]ly [MeSH:C0009678] affect child [MeSH:C0008059] [MeSH:C0008059] show average short ctg repeat length severe [MeSH:C1719672] symptom mother child [MeSH:C0008059] [MeSH:C0008059] congenital [MeSH:C0009678] dm [MeSH:C0009678] conclude paternal transmission [MeSH:C0040722] [MeSH:C0040722] congenital [MeSH:C0009678] dm [MeSH:C0009678] rare preferentially occur onset dm past year father [MeSH:C0015671],neurological
leukemia [MeSH:C0023418] cirrhosis [MeSH:C1623038] explore neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] autonomic neuropathy pathway method [MeSH:C0206251] longitudinal trial [MeSH:C0023981] cardiac patient measure rcc uremia result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],neurological|hepatorenal
complement factor deficiency [MeSH:C3463916] serological family,inherit complement deficiency [MeSH:C0272242] associate variety connective tissue disease [MeSH:C0009782] family inherit deficiency complement factor c2 describe family member [MeSH:C0086282] [MeSH:C0086282] homozygous c2 deficiency develop cutaneous vasculitis sicca syndrome [MeSH:C0262988] family member [MeSH:C0086282] [MeSH:C0086282] heterozygous c2 deficiency member hla-a2 b1 dr2 [MeSH:C0019733] w1 haplotype [MeSH:C0018591] mother [MeSH:C0026591] seropositive rheumatoid arthritis [MeSH:C0003873] study [MeSH:C0085973] show presence cryoglobulin [MeSH:C0010404] antibody endothelial cell anticardiolipin antibody [MeSH:C0162596],cardiovascular
valvular heart disease [MeSH:C0018824] cardiovascular lens [MeSH:C0007220],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect heart disease [MeSH:C0018799] atrioventricular block method [MeSH:C0004245] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] deep vein thrombosis [MeSH:C0149871] hypertrophic cardiomyopathy [MeSH:C0007194] assessment [MeSH:C0030198] result well quality life measure care improvement,cardiovascular
epilepsy [MeSH:C0014544] anuria [MeSH:C0003460] organ [MeSH:C0029250] interplay,hypertension [MeSH:C0020538] affect elderly patient [MeSH:C0030705] worldwide particularly involve wilms tumor ast method conduct [MeSH:C0027708] longitudinal evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine azotemia [MeSH:C0242528] parameter result positive response relevance [MeSH:C2826293],hepatorenal
embolism [MeSH:C0013922] myocardial infarction [MeSH:C0027051] vascular [MeSH:C0221214] insight,question calcium channel blocker [MeSH:C0006684] affect hypertension [MeSH:C0020538] blood vessel [MeSH:C0005847] mechanism method retrospective [MeSH:C0035363] adult population [MeSH:C0032659] assess tachycardia thromboembolism [MeSH:C0040038] result favorable safety profile implication therapeutic [MeSH:C0087111] innovation,cardiovascular
biochemical [MeSH:C0017401] effect solidago virgaurea extract [MeSH:C0771937] experimental [MeSH:C0016998] cardiotoxicity [MeSH:C0876994],cardiovascular disease [MeSH:C0007222] cvds major health problem advanced develop country world [MeSH:C0011750] present investigate [MeSH:C0035173] protective effect solidago virgaurea extract [MeSH:C0771937] isoproterenol [MeSH:C0022245] [MeSH:C0022245]-induced cardiotoxicity [MeSH:C0876994] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] subcutaneous injection [MeSH:C1828121] [MeSH:C0021499] isoproterenol [MeSH:C0022245] [MeSH:C0022245] mg kg rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] twice interval h consecutive day [MeSH:C0011017] lead increase serum lactate dehydrogenase creatine phosphokinase alanine transaminase aspartate transaminase angiotensin-converting enzyme activity total cholesterol triglyceride free serum fatty acid cardiac tissue [MeSH:C0040300] [MeSH:C0040300] malondialdehyde mda nitric oxide [MeSH:C0024643] level [MeSH:C0018759] [MeSH:C0018759] decrease level [MeSH:C0018759] [MeSH:C0018759] glutathione superoxide dismutase [MeSH:C0038838] cardiac tissue [MeSH:C0040300] [MeSH:C0040300] compare normal p pretreatment [MeSH:C0376495] virgaurea extract week dose mg kg follow isoproterenol [MeSH:C0022245] [MeSH:C0022245] injection [MeSH:C1828121] significantly prevent observe alterat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion captopril [MeSH:C0006938] mg kg give orally inhibitor angiotensin-converting enzyme standard cardioprotective drug positive [MeSH:C0033613] present suggest virgaurea extract exert protective effect decrease mda increase antioxidant status [MeSH:C0003402] isoproterenol [MeSH:C0022245] [MeSH:C0022245]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] emphasize beneficial action virgaurea extract cardioprotective agent [MeSH:C0007209],cardiovascular|hepatorenal
meiotic [MeSH:C1155818] segregation [MeSH:C1333235] single-sperm type meiotic [MeSH:C1155818] drive myotonic dystrophy locus [MeSH:C0027126],meiotic [MeSH:C1155818] drive myotonic dystrophy [MeSH:C0027126] dm locus [MeSH:C0027126] recently suggest responsible maintain frequency [MeSH:C0376249] human [MeSH:C0086418] population dm chromosome [MeSH:C0008633] capable expansion [MeSH:C0196940] disease state order test hypothesis study sample single sperm [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] individual heterozygous [MeSH:C0019425] dm locus allele [MeSH:C0002085] large allele [MeSH:C0002085] small ctg repeat guard possible problem differential pcr amplification rate base length allele [MeSH:C0002085] sperm [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] type closely link marker [MeSH:C0017393] allele [MeSH:C0002085] size unrelated allele [MeSH:C0002085] size dm locus statistical model [MeSH:C0011381] [MeSH:C0026348] specifically design [MeSH:C0013171] single-sperm [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] segregation [MeSH:C0007616] [MeSH:C0007616] [MeSH:C0007616] find evidence meiotic [MeSH:C1155818] segregation [MeSH:C0007616] [MeSH:C0007616] [MeSH:C0007616] distortion upper limit two-sided confidence interval estimate common segregation [MeSH:C0007616] [MeSH:C0007616] [MeSH:C0007616] probability donor model [MeSH:C0011381] consider statistically difference detect model [MeSH:C0011381] suggest great segregation [MeSH:C0007616] [MeSH:C0007616] [MeSH:C0007616] distortion myotonic dystrophy [MeSH:C0027126] locus event follow sperm [MeSH:C0037868] [MeSH:C0037868] [MeSH:C0037868] ejaculation [MeSH:C0013746],neurological
state-of-the-art thiazide diuretic prostate cancer,cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve arrhythmia stenosis method [MeSH:C0003811] conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine pulmonary valve [MeSH:C0034086] parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,cardiovascular
ischemic colitis [MeSH:C0162529] sumatriptan [MeSH:C0075632] use,sumatriptan [MeSH:C0075632] [MeSH:C0075632] succinate [MeSH:C0206599] serotonin- -hydroxytryptamine- receptor agonist [MeSH:C3850106] antimigraine [MeSH:C0149931] drug report [MeSH:C0684224] act selectively constrict [MeSH:C0009813] intracranial [MeSH:C0149543] artery [MeSH:C0752138] recently vasopressor response distinct cranial [MeSH:C0149543] circulation demonstrate occur systemic pulmonary coronary circulation case publish [MeSH:C0034057] coronary vasospasm myocardial ischemia [MeSH:C0151744] myocardial infarction [MeSH:C0027051] occur sumatriptan [MeSH:C0075632] [MeSH:C0075632] use report development [MeSH:C0020119] case ischemic colitis [MeSH:C0162529] patient migraine [MeSH:C0149931] treat sumatriptan [MeSH:C0075632] [MeSH:C0075632],cardiovascular
innovative calcium channel blocker approach [MeSH:C0006684] leukemia [MeSH:C0023418],hypertension [MeSH:C0020538] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve glomerulonephritis hepatic method [MeSH:C0017658] conduct longitudinal evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine nonalcoholic steatohepatitis [MeSH:C3241937] parameter result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],hepatorenal
lymphoma chemotherapy [MeSH:C0013216] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] aspirin improve hypertension [MeSH:C0020538] outcome kidney transplant pathway method retrospective trial elderly patient measure interstitial nephritis [MeSH:C0027707] proteinuria [MeSH:C0033687] result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,hepatorenal|oncological
epilepsy [MeSH:C0014544] nonalcoholic steatohepatitis [MeSH:C3241937] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome [MeSH:C0206277] interstitial nephritis pathway method [MeSH:C0027707] prospective trial cardiac patient measure liver transplant [MeSH:C0023911] hepatoma [MeSH:C2239176] result favorable safety profile practice guideline,hepatorenal
mind matter cancer serotonin [MeSH:C0036751],question [MeSH:C0600648] metformin [MeSH:C0025598] affect heart disease [MeSH:C0018799] cerebrovascular mechanism method longitudinal [MeSH:C0023981] elderly patient assess gray matter [MeSH:C0018220] memory [MeSH:C0025260] loss result improve outcome [MeSH:C0206277] implication healthcare advancement,neurological
pharmacokinetic [MeSH:C0031327] chlorpheniramine [MeSH:C0008281] phenytoin [MeSH:C0031507] glipizide [MeSH:C0017642] nifedipine [MeSH:C0028066] individual homozygous cyp2c9 allele,genetic [MeSH:C0017380] polymorphism [MeSH:C0032529] cytochrome p4 cyp family [MeSH:C4277568] widely know contribute interindividual [MeSH:C0021228] [MeSH:C0021228] difference pharmacokinetic drug [MeSH:C0031327] allele [MeSH:C0002085] [MeSH:C0002085] cyp2c9 [MeSH:C1828473] [MeSH:C1828473] [MeSH:C1828473] gene report [MeSH:C0684224] individual [MeSH:C0021228] homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] leu3 variant cyp2c9 [MeSH:C1828473] [MeSH:C1828473] show significantly low drug clearance [MeSH:C5243473] compare ile3 cyp2c9 [MeSH:C1828473] [MeSH:C1828473] homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] individual [MeSH:C0021228] male [MeSH:C0086582] caucasian [MeSH:C0007457] participate [MeSH:C0030699] bioavailability [MeSH:C0005508] study laboratory [MeSH:C0022877] period [MeSH:C0022877] year show extremely low clearance drug phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] glipizide [MeSH:C0017642] [MeSH:C0017642] [MeSH:C0017642] [MeSH:C0017642] substrate [MeSH:C0003017] [MeSH:C0003017] [MeSH:C0003017] [MeSH:C0003017] cyp2c9 [MeSH:C1828473] [MeSH:C1828473] nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] cyp3a4 substrate [MeSH:C0003017] [MeSH:C0003017] [MeSH:C0003017] [MeSH:C0003017] chlorpheniramine [MeSH:C0008281] [MeSH:C0008281] cyp2d6 substrate [MeSH:C0003017] [MeSH:C0003017] [MeSH:C0003017] [MeSH:C0003017] oral [MeSH:C0029170] [MeSH:C0029170] clearance phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] mean individual [MeSH:C0021228] participate [MeSH:C0030699] oral [MeSH:C0029170] [MeSH:C0029170] clearance glipizide [MeSH:C0017642] [MeSH:C0017642] [MeSH:C0017642] second generation sulfonylurea [MeSH:C0075586] structurally similar tolbutamide [MeSH:C0040374] [MeSH:C0040374] mean individual [MeSH:C0021228] oral [MeSH:C0029170] [MeSH:C0029170] clearance nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] chlorpheniramine [MeSH:C0008281] [MeSH:C0008281] differ individual [MeSH:C0021228] study perform laboratory [MeSH:C0022877] additional blood sample [MeSH:C0005767] obtain individual [MeSH:C0021228] determine possess known cyp2c9 [MeSH:C1828473] [MeSH:C1828473] cyp2c1 allelic variant account poor clearance cyp2c9 [MeSH:C1828473] [MeSH:C1828473] substrate [MeSH:C0003017] [MeSH:C0003017] [MeSH:C0003017] [MeSH:C0003017] phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] glipizide [MeSH:C0017642] [MeSH:C0017642] [MeSH:C0017642] [MeSH:C0017642] compare cyp3a4 nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] cyp2d6 chlorpheniramine [MeSH:C0008281] [MeSH:C0008281] substrate [MeSH:C0003017] [MeSH:C0003017] [MeSH:C0003017] [MeSH:C0003017] result genotype testing [MeSH:C0017431] show individual [MeSH:C0021228] homozygous [MeSH:C0019904] [MeSH:C0019904] [MeSH:C0019904] cyp2c9 [MeSH:C1828473] [MeSH:C1828473] allele [MeSH:C0002085] [MeSH:C0002085] possess know defective [MeSH:C0011139] cyp2c1 allele [MeSH:C0002085] [MeSH:C0002085] establish leu3 mutation [MeSH:C0026882] responsible phenytoin [MeSH:C0031507] [MeSH:C0031507] [MeSH:C0031507] glipizide [MeSH:C0017642] [MeSH:C0017642] [MeSH:C0017642] [MeSH:C0017642] tolbutamide [MeSH:C0040374] [MeSH:C0040374] poor metabolizer phenotype [MeSH:C0031437],neurological
toxicity [MeSH:C0040539] rhesus monkey [MeSH:C0024400] follow administration [MeSH:C0001554] -amino [MeSH:C0002520]quinoline -amino [MeSH:C0002520]-l-methylbutyl amino [MeSH:C0002520] l-hexyloxy --methoxy methylquinoline [MeSH:C3643462] wr2,introduction substance form methemoglobin mhb [MeSH:C0025635] effectively counter cyanide [MeSH:C0010505] cn toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] mhb former generally apply treatment [MeSH:C0039798] cn poison [MeSH:C0032346] propose stable long-acting mhb serve cn pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0039798] rationale -aminoquinoline wr2 potent long-lasting mhb rodent beagle [MeSH:C0325564] dog study rhesus monkey [MeSH:C0024400] [MeSH:C0024400] [MeSH:C0024400] advanced development potential cn pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0039798] method wr2 administer intravenously iv female [MeSH:C0086582] [MeSH:C0086582] [MeSH:C0086287] male [MeSH:C0086582] [MeSH:C0086582] rhesus monkey [MeSH:C0024400] [MeSH:C0024400] [MeSH:C0024400] dose mg kg single male [MeSH:C0086582] [MeSH:C0086582] receive wr2 orally po mg kg health status mhb [MeSH:C0018759] level [MeSH:C0018759] monitor follow exposure [MeSH:C1390376] result select dose wr2 produce methemoglobinemia [MeSH:C0025637] beagle [MeSH:C0325564] dog early study conduct produce little mhb mean rhesus monkey [MeSH:C0024400] [MeSH:C0024400] [MeSH:C0024400] furthermore transient [MeSH:C0040704] hemoglobinuria [MeSH:C0019048] note approximately minute postinjection [MeSH:C1828121] wr2 mg kg lethality occur iv po follow mg kg dose myoglobinuria [MeSH:C0027080] observe follow mg kg dose histopathology analysis animal [MeSH:C0003062] [MeSH:C0003062] die reveal liver kidney [MeSH:C0022646] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] great severity orally-treated animal [MeSH:C0003062] [MeSH:C0003062] conclusion demonstrate direct indirect drug-induced [MeSH:C1320835] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] conclude wr2 pursue pretreatment [MeSH:C0376495] [MeSH:C0376495] [MeSH:C0039798] cn poison [MeSH:C0032346]ing anti-cn characteristic compound successfully dissociate [MeSH:C0004331] produce undesirable toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539],hepatorenal
echocardiography [MeSH:C0013516] reveal liver cirrhosis [MeSH:C0023890] secret,heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve guillain-barre syndrome amyotrophic lateral sclerosis method conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine thalamus [MeSH:C0039729] parameter result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],neurological|cardiovascular
epilepsy cholecystitis [MeSH:C0008325] cardiac connection,dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve end stage renal disease [MeSH:C0022661] cholestasis method [MeSH:C0008370] conduct longitudinal evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine aki parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] practice guideline,cardiovascular|hepatorenal
massive proteinuria [MeSH:C0033687] acute renal failure oral [MeSH:C0029170] bisphosphonate [MeSH:C0012544] alendronate [MeSH:C0102118] administration [MeSH:C0001554] focal segmental glomerulosclerosis [MeSH:C0017668],-year-old japanese [MeSH:C1556094] man nephrotic syndrome [MeSH:C0027726] focal segmental glomerulosclerosis [MeSH:C0017668] initially respond steroid therapy [MeSH:C0039798] daily urinary protein [MeSH:C1505427] [MeSH:C1505427] [MeSH:C1505427] decrease g day oral [MeSH:C0029170] bisphosphonate [MeSH:C0012544] [MeSH:C0012544] alendronate [MeSH:C0102118] sodium administration [MeSH:C0001554] daily urinary protein [MeSH:C1505427] [MeSH:C1505427] [MeSH:C1505427] increase rapidly g acute renal failure [MeSH:C0022660] discontinue oral [MeSH:C0029170] alendronate [MeSH:C0102118] undergo cycle hemodialysis cycle ldl apheresis [MeSH:C0005791] urinary volume serum creatinine level recover normal range urinary protein [MeSH:C1505427] [MeSH:C1505427] [MeSH:C1505427] disappear completely day report demonstrate intravenous oral [MeSH:C0085297] [MeSH:C0029170] bisphosphonate [MeSH:C0012544] [MeSH:C0012544] aggravate proteinuria [MeSH:C0033687] acute renal failure [MeSH:C0022660],hepatorenal
cancer esrd [MeSH:C0022661] organ [MeSH:C0029250] interplay,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve hepatitis creatinine method conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine hepatoma [MeSH:C2239176] parameter result improve disease management [MeSH:C0039798] healthcare advancement,hepatorenal
ventricle lymphoma vascular insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete prolapse [MeSH:C0033377] mechanism method cross-sectional [MeSH:C0010362] elderly patient assess pe tia result well quality life measure implication therapeutic [MeSH:C0087111] innovation,cardiovascular
bilirubin pathway leukemia,dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve uremia [MeSH:C0041948] kidney method [MeSH:C0022646] conduct retrospective [MeSH:C0035363] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine primary [MeSH:C0033137] biliary cholangitis [MeSH:C0008312] parameter result well quality life measure cost-effectiveness [MeSH:C1511536] implication,hepatorenal
delirium [MeSH:C0011206] meet valvular heart disease [MeSH:C0018824] neurological perspective,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve cerebral infarction [MeSH:C0007785] neurotransmitter method [MeSH:C0027908] conduct observational [MeSH:C0302523] evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine tremor [MeSH:C0040822] parameter result improvement primary endpoint need investigation [MeSH:C0035173],neurological
cognitive decline cancer [MeSH:C0234985],cancer affect elderly patient [MeSH:C0030705] worldwide particularly involve peripheral neuropathy [MeSH:C4721453] dystonia method conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine bell palsy [MeSH:C0376175] parameter result decrease mortality rate [MeSH:C0205848] healthcare advancement,neurological
explore hypertension [MeSH:C0020538] hepatocellular,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] dementia [MeSH:C0497327] participant [MeSH:C1708335] cardiac patient pkd end stage renal disease [MeSH:C0022661] result improve disease management [MeSH:C0039798] renal cyst [MeSH:C0010709] correlation healthcare advancement,hepatorenal
cervical cancer pathway [MeSH:C4048328] angina pectoris,hypothesis statin improve diabete outcome [MeSH:C0206277] [MeSH:C0206277] wilms tumor pathway method prospective trial elderly patient measure alcoholic liver disease carcinoma [MeSH:C0023896] result improve outcome [MeSH:C0206277] [MeSH:C0206277] therapeutic innovation [MeSH:C0087111],hepatorenal|oncological
cis trans effect myotonic dystrophy dm mutation cell culture model,mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] cause myotonic dystrophy dm identify [MeSH:C0027126] ctg expansion [MeSH:C0196940] -untranslated region -utr dm protein kinase gene dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] mechanism [MeSH:C1524059] pathogenesis [MeSH:C0699748] remain unknown study [MeSH:C0085973] dm material produce confusing result effect dm mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] control environment [MeSH:C0014409] establish cell culture model system [MeSH:C0007585] c2c1 mouse [MeSH:C0026809] myoblast [MeSH:C0596995] [MeSH:C0596995] [MeSH:C0596995] express chimeric reporter construct contain reporter gene [MeSH:C0206414] fuse human dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] -utr identify cis trans effect mediate dm mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mutant dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] -utr ctg negative cis effect protein expression [MeSH:C0017262] result aggregation reporter transcript [MeSH:C1136156] discrete nuclear focus determine deletion [MeSH:C0017260] expand ctg n tract [MeSH:C0017189] sufficient mediate cis effect furthermore contrast normal dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] -utr mrna mutant dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] -utr mrna cug [MeSH:C0035696] selectively inhibit [MeSH:C0021463] [MeSH:C0021463] myogenic differentiation [MeSH:C1571635] c2c1 myoblast [MeSH:C0596995] [MeSH:C0596995] [MeSH:C0596995] genetic [MeSH:C0017380] cre- loxp system clearly demonstrate myoblast [MeSH:C0596995] [MeSH:C0596995] [MeSH:C0596995] fusion defect rescue eliminate expression [MeSH:C0017262] mutant dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] -utr transcript [MeSH:C1136156] characterization spontaneous deletion [MeSH:C0017260] event map [MeSH:C0024779] inhibit [MeSH:C0021463] [MeSH:C0021463]ory effect ctg n expansion [MeSH:C0196940] end dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] -utr result provide evidence [MeSH:C5575834] dm mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] act cis reduce protein production [MeSH:C0033268] consistent dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] haploinsufficiency [MeSH:C2936267] trans riboregulator inhibit [MeSH:C0021463] [MeSH:C0021463] myogenesis [MeSH:C0596997],neurological
eeg [MeSH:C0013819] reveal heart failure [MeSH:C0018801] secret,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome alzheimer disease pathway method observational trial cancer [MeSH:C0302523] patient [MeSH:C0030705] measuring myasthenia gravis [MeSH:C0026896] aphasia result improvement [MeSH:C2936612] primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
somatic mutation brca1 gene [MeSH:C0376571] sporadic ovarian tumour,brca1 [MeSH:C0259275] [MeSH:C0259275] gene chromosome 7q2 responsible autosomal dominant syndrome [MeSH:C0265336] increase susceptibility [MeSH:C0012655] breast ovarian cancer [MeSH:C1140680] somatic mutation [MeSH:C0026882] [MeSH:C0026882] tumour describe potential role brca1 [MeSH:C0259275] [MeSH:C0259275] sporadic carcinogenesis [MeSH:C0596263] analyse genomic dna tumour normal fraction ovarian cancer mutation [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] single-strand conformation polymorphism technique describe somatic mutation [MeSH:C0026882] [MeSH:C0026882] dna tumour loss heterozygosity [MeSH:C0524869] loh brca1 [MeSH:C0259275] [MeSH:C0259275] intragenic marker support tumour suppressor mechanism brca1 [MeSH:C0259275] [MeSH:C0259275] somatic mutation [MeSH:C0026882] [MeSH:C0026882] loh inactivation brca1 [MeSH:C0259275] [MeSH:C0259275] small number ovarian cancer,oncological
hepatitis nephrolithiasis [MeSH:C0392525] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension gfr method cardiac patient undergo longitudinal creatinine alkaline phosphatase assessment [MeSH:C0030198] result well quality life measure need investigation [MeSH:C0035173],hepatorenal
antiarrhythmic lung cancer [MeSH:C0003195] brain [MeSH:C0006104] insight,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve palsy [MeSH:C0522224] epinephrine method [MeSH:C0014563] conduct prospective evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine cerebral infarction [MeSH:C0007785] parameter result positive response practice guideline [MeSH:C0936005],neurological
etoposide-related myocardial infarction [MeSH:C0027051],occurrence myocardial infarction [MeSH:C0027051] report chemotherapy [MeSH:C0013216] contain etoposide [MeSH:C0015133] man risk factor coronary heart disease [MeSH:C0850624] possible causal mechanism [MeSH:C1524059] discuss,neurological|cardiovascular
cardiomyopathy [MeSH:C0878544] diastolic [MeSH:C0012000] cardiac connection,question [MeSH:C0600648] ace inhibitor affect dementia [MeSH:C0497327] hepatocellular [MeSH:C0345904] mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess chronic kidney disease [MeSH:C1561643] alkaline phosphatase [MeSH:C0002059] result enhance therapeutic response [MeSH:C0087111] implication need investigation [MeSH:C0035173],cardiovascular|hepatorenal
effect [MeSH:C4277511] calcium chloride [MeSH:C0006686] gross behavioural change produce carbachol [MeSH:C0006945] eserine [MeSH:C1314787] cat [MeSH:C0007450],effect [MeSH:C4277511] calcium chloride [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] inject cerebral ventricle [MeSH:C0007799] group-housed unanaesthetized cat [MeSH:C0007450] vocalization [MeSH:C0042932] [MeSH:C0042932] [MeSH:C0042932] rage hissing snarl fight attack paw claw defense paw claw bite [MeSH:C0008919] mydriasis [MeSH:C0026961] tremor clonic-tonic convulsion [MeSH:C0014549] [MeSH:C0014549] [MeSH:C0014549] produce carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] eserine [MeSH:C1314787] [MeSH:C1314787] [MeSH:C1314787] [MeSH:C1314787] inject similarly investigate [MeSH:C0035173] calcium chloride [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] depressed completely abolish vocalization [MeSH:C0042932] [MeSH:C0042932] [MeSH:C0042932] fight carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] eserine [MeSH:C1314787] [MeSH:C1314787] [MeSH:C1314787] [MeSH:C1314787] hand mydriasis [MeSH:C0026961] tremor clonic-tonic convulsion [MeSH:C0014549] [MeSH:C0014549] [MeSH:C0014549] evoke carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] eserine [MeSH:C1314787] [MeSH:C1314787] [MeSH:C1314787] [MeSH:C1314787] significantly change calcium chloride [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] apparent calcium chloride [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] dissociate vocalization [MeSH:C0042932] [MeSH:C0042932] [MeSH:C0042932] fight autonomic motor phenomenon mydriasis [MeSH:C0026961] tremor clonic-tonic convulsion [MeSH:C0014549] [MeSH:C0014549] [MeSH:C0014549] cause carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] eserine [MeSH:C1314787] [MeSH:C1314787] [MeSH:C1314787] [MeSH:C1314787] calcium chloride [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] [MeSH:C0006686] inhibit [MeSH:C0021463] vocalization [MeSH:C0042932] [MeSH:C0042932] [MeSH:C0042932] fighting produce carbachol [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] [MeSH:C0006945] eserine [MeSH:C1314787] [MeSH:C1314787] [MeSH:C1314787] [MeSH:C1314787] probably nonspecific [MeSH:C0054741] stabilize action central muscarinic cholinoceptive site result support view calcium ion [MeSH:C0006675] excess atropine-like action central nervous system [MeSH:C3714787],cardiovascular
biopsy [MeSH:C0005558] reveal atrial fibrillation [MeSH:C0004238] secret,question [MeSH:C0600648] metformin [MeSH:C0025598] affect hypertension [MeSH:C0020538] dystonia [MeSH:C0013421] mechanism method cross-sectional [MeSH:C0010362] elderly patient assess glutamate neuron result decrease mortality rate [MeSH:C0205848] implication relevance,neurological
schwartz-jampel syndrome type stuve-wiedemann syndrome [MeSH:C0796176] case lump,recent study demonstrate existence genetically distinct usually lethal [MeSH:C0017354] form schwartz-jampel syndrome [MeSH:C0036391] sjs myotonia [MeSH:C0700153] skeletal dysplasia [MeSH:C2931048] [MeSH:C2931048] [MeSH:C2931048] call sjs type disorder [MeSH:C0040188] [MeSH:C0040188] [MeSH:C0040188] reminiscent rare condition stuve-wiedemann syndrome [MeSH:C0796176] sws comprise campomelia [MeSH:C1861923] birth skeletal dysplasia [MeSH:C2931048] [MeSH:C2931048] [MeSH:C2931048] contracture [MeSH:C0009917] early death test possible nosologic identity [MeSH:C0017249] disorder [MeSH:C0040188] review literature [MeSH:C0023866] obtain follow-up [MeSH:C3899107] [MeSH:C3899107] survive [MeSH:C0038952] patient [MeSH:C0030705] sjs type age year sws age year patient [MeSH:C0030705] report [MeSH:C0684224] neonatal [MeSH:C0021709] sjs sws present combination severe prenatal-onset neuromuscular disorder [MeSH:C0040188] congenital joint contracture [MeSH:C0009917] respiratory feeding difficulty tendency hyperthermia [MeSH:C5232927] frequent death infancy [MeSH:C0549159] distinct campomelic-metaphyseal skeletal dysplasia [MeSH:C2931048] [MeSH:C2931048] [MeSH:C2931048] similarity radiographic [MeSH:C0040404] finding extensive disorder [MeSH:C0040188] appear single entity follow-up [MeSH:C3899107] [MeSH:C3899107] observation [MeSH:C0302523] identical unique pattern progressive [MeSH:C1449744] bone dysplasia [MeSH:C0005941] patient [MeSH:C0030705] sjs type sws survive [MeSH:C0038952] infancy add evidence [MeSH:C5575834] favor identity [MeSH:C0017249] hypothesis [MeSH:C3179072] sws sjs type disorder [MeSH:C0040188] [MeSH:C0040188] [MeSH:C0040188] testable molecular method,neurological
convulsant [MeSH:C0009950] effect [MeSH:C4277511] lindane [MeSH:C0005038] regional [MeSH:C0010346] brain [MeSH:C0006104] concentration gaba dopamine [MeSH:C0016904],lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] gamma-hexachlorocyclohexane [MeSH:C0005038] organochlorine insecticide known neurotoxic [MeSH:C0027934] effect mechanism action [MeSH:C1524059] understand propose lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] act non-competitive antagonist gamma-aminobutyric acid gaba [MeSH:C0242975] -a receptor study effect lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] mg kg gabaergic dopamine [MeSH:C0013030] [MeSH:C0013030]rgic system measure concentration [MeSH:C0311432] [MeSH:C0311432] gaba dopamine [MeSH:C0013030] [MeSH:C0013030] metabolite [MeSH:C0003376] [MeSH:C0003376] brain area [MeSH:C0006104] onset seizure [MeSH:C0036572] animal [MeSH:C0003062] suffer tonic convulsion [MeSH:C0014549] min lindane [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] [MeSH:C0005038] administration [MeSH:C0001554] concentration [MeSH:C0311432] [MeSH:C0311432] gaba slightly significantly decrease colliculi [MeSH:C0021358] modification [MeSH:C0086153] area concentration [MeSH:C0311432] [MeSH:C0311432] dopamine [MeSH:C0013030] [MeSH:C0013030] increase mesencephalon [MeSH:C0025462] metabolite [MeSH:C0003376] [MeSH:C0003376] dopac [MeSH:C0000376] increase mesencephalon [MeSH:C0025462] striatum,neurological
exon duplication [MeSH:C0795871] brca1 gene [MeSH:C0376571] founder mutation [MeSH:C0026882] present geographically diverse population [MeSH:C0032659],brca1 [MeSH:C0259275] exon [MeSH:C0015295] duplication [MeSH:C0795871] screening [MeSH:C0220908] recently -kb duplication [MeSH:C0795871] exon [MeSH:C0015295] create frameshift code sequence brca1 [MeSH:C0259275] gene [MeSH:C0376571] describe unrelated u family european ancestry portuguese family goal [MeSH:C0018017] estimate frequency [MeSH:C0376249] geographic diversity [MeSH:C0282469] carrier duplication [MeSH:C0795871] [MeSH:C0795871] collaborative screening [MeSH:C0220908] set involve institution country include unrelated individual [MeSH:C0021228] family history disease early-onset [MeSH:C3711383] breast ovarian cancer [MeSH:C1140680] case total additional family carry mutation [MeSH:C0026882] identify australia belgium canada great britain united state haplotyping [MeSH:C0018591] show likely derive common ancestor possibly northern [MeSH:C3658205] british origin result demonstrate strongly advisable laboratory [MeSH:C0022877] carry screening [MeSH:C0220908] english-speaking country country historical [MeSH:C5197707] link britain include brca1 [MeSH:C0259275] screening [MeSH:C0220908] protocol polymerase chain reaction-based assay [MeSH:C0032520] describe report [MeSH:C0684224],oncological
domperidone [MeSH:C0013015] potentiate mirtazapine-associated restless leg syndrome,evidence [MeSH:C5575834] suggest central role dopamine [MeSH:C0013030]rgic system restless leg syndrome rls example symptom [MeSH:C3839861] [MeSH:C3839861] rls dramatically improve levodopa [MeSH:C0023570] dopamine [MeSH:C0013030] agonist central dopamine [MeSH:C0013030] d2 receptor antagonist induce aggravate rls symptom [MeSH:C3839861] [MeSH:C3839861] knowledge previous report domperidone [MeSH:C0013015] peripheral [MeSH:C3658334] dopamine [MeSH:C0013030] d2 receptor antagonist induce aggravate symptom [MeSH:C3839861] [MeSH:C3839861] rls mirtazapine [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] noradrenergic [MeSH:C3178786] specific serotonergic antidepressant [MeSH:C0003289] nassa associate rls recent publication author report depressed comorbid postprandial dyspepsia [MeSH:C0013395] develop rls mirtazapine [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] add domperidone [MeSH:C0013015] therapy start symptom [MeSH:C3839861] [MeSH:C3839861] rls treat mirtazapine [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] rls symptom [MeSH:C3839861] [MeSH:C3839861] resolve completely discontinuation mirtazapine [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] temporal [MeSH:C0039484] relationship [MeSH:C0021797] use mirtazapine [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] symptom [MeSH:C3839861] [MeSH:C3839861] rl support potentiating effect domperione [MeSH:C0013015] mirtazapine [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506]-associated rl physician aware possibility mirtazapine [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] [MeSH:C0049506] associate rls individual [MeSH:C0021228] especially receive concomitant [MeSH:C0152203] dopamine [MeSH:C0013030] d2 receptor antagonist,neurological
antitumor [MeSH:C2716992] effect [MeSH:C4277511] cardiotoxicity [MeSH:C0876994] nephrotoxicity doxorubicin igm solid [MeSH:C0013089] immunocytoma-beare lou wsl rat [MeSH:C0034721],antitumor [MeSH:C2716992] [MeSH:C2716992] activity [MeSH:C0020115] cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] nephrotoxicity induce doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] study lou wsl inbred rat [MeSH:C0034721] [MeSH:C0034698] bear transplantable solid igm immunocytoma animal [MeSH:C0003062] tumor diameter mm treat iv injection doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] consecutive day [MeSH:C0011017] follow weekly injection week [MeSH:C1828121] dose range mg kg body wt tumor regression observe mg doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] kg complete disappearance tumor induce mg doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] kg histologic [MeSH:C0019637] evidence [MeSH:C5575834] cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] score grade iii observe dose mg doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] kg light microscopic evidence [MeSH:C5575834] renal damage see dose mg doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] kg result albuminuria [MeSH:C0001925] [MeSH:C0001925] low serum albumin level [MeSH:C0036773] [MeSH:C0036773] receive mg doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] kg serum albumin decrease g liter ascite hydrothorax observe simultaneously experiment [MeSH:C0020123] perform non-tumor-bearing rat [MeSH:C0034721] major difference observe antitumor [MeSH:C2716992] [MeSH:C2716992] activity [MeSH:C0020115] cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] nephrotoxicity study simultaneously lou wsl rat [MeSH:C0034721] albuminuria [MeSH:C0001925] [MeSH:C0001925] renal damage lead extremely low serum albumin level [MeSH:C0036773] [MeSH:C0036773] ascite hydrothorax necessarily consequence observe cardiomyopathy [MeSH:C0878544],cardiovascular|hepatorenal|oncological
functional link ataxia-telangiectasia nijmegen breakage syndrome gene product [MeSH:C0398791],ataxia-telangiectasia a-t nijmegen breakage syndrome [MeSH:C0398791] [MeSH:C0398791] nbs recessive genetic disorder susceptibility cancer [MeSH:C1137611] similar cellular phenotype [MeSH:C0031437] protein product gene responsible a-t designate atm member family kinase [MeSH:C4277570] characterize carboxy-terminal phosphatidylinositol -kinase-like domain nbs1 [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] protein specifically mutate [MeSH:C3178846] patient [MeSH:C0030705] nijmegen breakage syndrome [MeSH:C0398791] form complex dna repair protein [MeSH:C0012899] rad5 mrel1 phosphorylation [MeSH:C0031715] nbs1 [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] induce ionize radiation [MeSH:C0034538] [MeSH:C0034538] [MeSH:C0034538] require catalytically active atm complex contain atm nbs1 [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] exist vivo untreated cell cell [MeSH:C0007634] treat ionize radiation [MeSH:C0034538] [MeSH:C0034538] [MeSH:C0034538] identify residue [MeSH:C0013202] nbs1 [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] ser ser phosphorylate vitro atm modification [MeSH:C0086153] vivo essential [MeSH:C0600449] cellular response dna damage response [MeSH:C0012860] include s-phase checkpoint activation [MeSH:C3178863] formation nbs1 [MeSH:C0674679] [MeSH:C0674679] [MeSH:C0674679] mrel1 rad5 nuclear focus rescue hypersensitivity [MeSH:C0020517] ionize radiation [MeSH:C0034538] [MeSH:C0034538] [MeSH:C0034538] result demonstrate biochemical [MeSH:C0017401] link cell-cycle checkpoint [MeSH:C1155874] activate dna damage dna repair genetic disease [MeSH:C0012899] overlap phenotype [MeSH:C0031437],neurological|oncological
immunopathology [MeSH:C0152036] penicillamine-induced glomerular disease,patient [MeSH:C0030705] rheumatoid arthritis [MeSH:C0003873] develop heavy proteinuria month d-penicillamine light microscopy [MeSH:C0430389] renal biopsy [MeSH:C0005558] sample show minimal glomerular capillary wall thickening mesangial matrix increase departure normal electron microscopy [MeSH:C0026019] reveal subepithelial electron-dense deposit fusion epithelial cell [MeSH:C0014597] foot process [MeSH:C0016504] evidence mesangial cell hyperactivity immunofluorescence microscopy demonstrate granular capillary wall deposit igg c3 [MeSH:C0020852] finding similar early membranous glomerulonephritis [MeSH:C0017665] difference observe result stain early-acting complement component c1q c4 tentatively conclude complement activate classical pathway [MeSH:C0009547],hepatorenal
supplemental [MeSH:C2936424] vitamin c [MeSH:C0003968] increase cardiovascular disease [MeSH:C0007222] risk woman diabete,vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] act potent antioxidant [MeSH:C0003402] prooxidant glycate protein certain circumstance vitro observation [MeSH:C0302523] lead hypothesize high intake [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] diabetic [MeSH:C1263960] [MeSH:C1263960] person [MeSH:C0027361] promote atherosclerosis [MeSH:C0004153] examine relation vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] intake [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] mortality [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] design [MeSH:C0007222] study [MeSH:C0085973] relation vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] intake [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] mortality [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] total cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] n coronary artery disease [MeSH:C1956346] [MeSH:C1956346] n stroke [MeSH:C0038454] [MeSH:C0038454] n postmenopausal [MeSH:C0206159] [MeSH:C0206159] woman report [MeSH:C0043210] diabetic [MeSH:C1263960] [MeSH:C1263960] diet assess food-frequency questionnaire subject initially free coronary artery disease [MeSH:C1956346] [MeSH:C1956346] [MeSH:C1956346] prospectively follow result adjustment cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] risk [MeSH:C0035647] factor type diabete medication duration diabete intake [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] folate [MeSH:C0178638] vitamin e [MeSH:C0042874] beta-carotene [MeSH:C0053396] adjusted relative risk [MeSH:C0035647] [MeSH:C0242492] [MeSH:C0242492] total cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] mortality [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] p trend quintile total vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] intake [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] food supplement [MeSH:C0242295] adjusted relative risk [MeSH:C0035647] [MeSH:C0242492] [MeSH:C0242492] coronary artery disease [MeSH:C1956346] [MeSH:C1956346] p trend stroke [MeSH:C0038454] [MeSH:C0038454] p trend dietary [MeSH:C0012177] supplemental [MeSH:C2936424] vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] analyze separately supplemental [MeSH:C2936424] vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] show positive association [MeSH:C0004083] mortality [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] endpoint vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] intake [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] unrelated mortality [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] nondiabetic [MeSH:C1263960] [MeSH:C1263960] subject high vitamin c [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] [MeSH:C0003968] intake [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] [MeSH:C0006777] supplement associate [MeSH:C0004083] increase risk [MeSH:C0035647] cardiovascular disease [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] [MeSH:C0007222] mortality [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] [MeSH:C0026565] postmenopausal [MeSH:C0206159] [MeSH:C0206159] woman diabete,neurological|cardiovascular
anticoagulant liver cirrhosis [MeSH:C0023890] brain [MeSH:C0006104] insight,question statin affect diabete palsy [MeSH:C0522224] mechanism method retrospective cancer patient [MeSH:C0030705] assess neurodegenerative hypotensive result positive response implication safety [MeSH:C0036043] consideration,neurological|cardiovascular
cancer cellular hypertension,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome carcinogenesis pathway method cross-sectional trial [MeSH:C0010362] elderly patient measure ovarian cancer [MeSH:C1140680] tumor [MeSH:C0027651] result favorable safety profile care improvement [MeSH:C2936612],oncological
carbimazole [MeSH:C0006983] induce anca positive vasculitis [MeSH:C0042384],anti-thyroid drug [MeSH:C0040125] like carbimazole [MeSH:C0006983] [MeSH:C0006983] propylthiouracil ptu commonly prescribe hyperthyroidism [MeSH:C0020550] aware effect antithyroid medication antineutrophil cytoplasmic antibody [MeSH:C0103647] anca --associated vasculitis [MeSH:C0042384] [MeSH:C0042384] [MeSH:C0042384] potentially life-threatening [MeSH:C4303743] adverse effect [MeSH:C0001688] antithyroidmedication report grave disease [MeSH:C0018213] develop anca positive carbimazole [MeSH:C0006983] [MeSH:C0006983] induce vasculitis [MeSH:C0042384] [MeSH:C0042384] [MeSH:C0042384] episode [MeSH:C0085554] characterize vasculitic skin rash associate large joint arthritis pyrexia parotiditis renal pulmonary involvement [MeSH:C0030699] refer neurological difficulty get squatting position suspect myositis [MeSH:C0027121] carbimazole [MeSH:C0006983] [MeSH:C0006983] methimazole low incidence report [MeSH:C0021149] anca positive effect good knowledge anca [MeSH:C0376554] positive carbimazole [MeSH:C0006983] [MeSH:C0006983] induce vasculitis [MeSH:C0042384] [MeSH:C0042384] [MeSH:C0042384] case report india,neurological|hepatorenal
organ [MeSH:C0029250] orchestra colorectal cancer,retrospective [MeSH:C0035363] examine statin heart disease [MeSH:C0018799] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] [MeSH:C0035173] include liver pkd nephrotic syndrome [MeSH:C0027726] method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication need investigation [MeSH:C0035173] [MeSH:C0035173],hepatorenal
heart [MeSH:C0018787] meet peripheral artery disease [MeSH:C1704436] neurological perspective,diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve oligodendroglioma angina method [MeSH:C0028945] conduct observational [MeSH:C0302523] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine arrhythmia [MeSH:C0003811] parameter result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],neurological|cardiovascular
interstitial nephritis pathway [MeSH:C0027707] multiple sclerosis [MeSH:C0026769],retrospective [MeSH:C0035363] examine beta-blocker cancer diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include uremia [MeSH:C0041948] hematuria [MeSH:C0018965] interstitial nephritis [MeSH:C0027707] method participant [MeSH:C1708335] include result positive response implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
myocardial infarction marker [MeSH:C0027051] heart failure [MeSH:C0018801],retrospective [MeSH:C0035363] examine calcium channel blocker [MeSH:C0006684] diabete elderly patient investigation [MeSH:C0035173] include pacemaker [MeSH:C3494452] tia atrioventricular block method [MeSH:C0004245] participant [MeSH:C1708335] include result positive response implication therapeutic [MeSH:C0087111] innovation,cardiovascular
effect [MeSH:C4277511] green tea vitamin e [MeSH:C1384640] combination isoproterenol [MeSH:C0022245] induced [MeSH:C5392225] myocardial infarction [MeSH:C0027051] rat [MeSH:C0034721],present aim investigate [MeSH:C0035173] combined effect green tea vitamin e [MeSH:C1384640] [MeSH:C0042874] heart weight [MeSH:C1821269] body weight [MeSH:C0005910] [MeSH:C0005910] [MeSH:C0005910] serum marker [MeSH:C0162491] [MeSH:C0162491] enzyme lipid peroxidation [MeSH:C0023775] [MeSH:C0023775] [MeSH:C0023775] endogenous [MeSH:C0205752] [MeSH:C0205752] [MeSH:C0205752] antioxidant [MeSH:C0003402] [MeSH:C0003402] membrane [MeSH:C0003402] bound atpase [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] isoproterenol [MeSH:C0022245] iso -induced myocardial infarction [MeSH:C0027051] [MeSH:C0027051] rat [MeSH:C0034721] [MeSH:C0034721] adult [MeSH:C0001675] male [MeSH:C0086582] albino rat [MeSH:C0034721] [MeSH:C0034721] treat iso mg kg c day [MeSH:C0011017] interval h cause p elevation heart weight [MeSH:C1821269] serum marker [MeSH:C0162491] [MeSH:C0162491] enzyme lipid peroxidation [MeSH:C0023775] [MeSH:C0023775] [MeSH:C0023775] atpase [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] p decrease body weight [MeSH:C0005910] [MeSH:C0005910] endogenous [MeSH:C0205752] [MeSH:C0205752] [MeSH:C0205752] antioxidant [MeSH:C0003402] [MeSH:C0003402] na k atpase [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] mg atpase [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] level [MeSH:C0018759] administrat [MeSH:C0034721] [MeSH:C0034721]ion green tea mg kg p vitamin e [MeSH:C0042874] mg kg p consecutive day [MeSH:C0011017] challenge iso 9th 0th show p decrease heart weight [MeSH:C1821269] serum marker [MeSH:C0162491] [MeSH:C0162491] enzyme lipid peroxidation [MeSH:C0023775] [MeSH:C0023775] [MeSH:C0023775] atpase [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] increase body weight [MeSH:C0005910] [MeSH:C0005910] endogenous [MeSH:C0205752] [MeSH:C0205752] [MeSH:C0205752] antioxidant [MeSH:C0003402] [MeSH:C0003402] na k atpase [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] mg atpase [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] [MeSH:C1706373] compare iso treated green tea vitamin e [MeSH:C1384640] [MeSH:C0042874] treat group finding indicate synergistic [MeSH:C0949698] protective effect green tea vitamin e [MeSH:C1384640] [MeSH:C0042874] iso induce myocardial infarction [MeSH:C0027051] [MeSH:C0027051] rat [MeSH:C0034721] [MeSH:C0034721],cardiovascular
stroke [MeSH:C0038454] cardiac [MeSH:C0018810] cardiac [MeSH:C0018810] connection,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] metformin [MeSH:C0025598] diabete [MeSH:C0007080] cardiac patient focus cerebrovascular [MeSH:C0007820] cardiac aspect disease [MeSH:C0018799] total participant enrol longitudinal result [MeSH:C0023981] demonstrate improve disease management [MeSH:C0039798] particular attention [MeSH:C0004268] myocardial [MeSH:C0027061] finding suggest care improvement,cardiovascular
synaptic story prostate cancer [MeSH:C0376358] astrocytoma [MeSH:C0004114],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete cerebral mechanism method randomized control [MeSH:C1096777] cardiac patient assess amyotrophic lateral sclerosis tremor [MeSH:C0002736] result well quality life measure implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
optochiasmatic peripheral neuropathy [MeSH:C4721453] ethambutol [MeSH:C0014964] overtreatment [MeSH:C4046039],ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] know cause optic neuropathy [MeSH:C0029132] rarely axonal polyneuropathy [MeSH:C0152025] characterize neurophysiological neuroimaging finding [MeSH:C0679575] -year-old man develop visual loss paresthesia week exposure [MeSH:C1390376] supratherapeutic [MeSH:C0087111] dose ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] case demonstrate selective vulnerability [MeSH:C4063051] anterior [MeSH:C0032008] visual pathway [MeSH:C0042829] peripheral nerve [MeSH:C0031119] ethambutol [MeSH:C0014964] [MeSH:C0014964] [MeSH:C0014964] toxicity [MeSH:C0040539],neurological
brain dynamic parkinson disease [MeSH:C0030567] serotonin [MeSH:C0036751],hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve limbic system migraine [MeSH:C0023715] method conduct longitudinal evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine acoustic neuroma [MeSH:C0027859] parameter result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,neurological
diastolic cardiomyopathy [MeSH:C0878544] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] ace inhibitor affect cancer pkd mechanism method observational [MeSH:C0302523] cardiac patient assess endothelial atrium [MeSH:C0014257] result enhance therapeutic response [MeSH:C0087111] implication healthcare advancement,cardiovascular|hepatorenal
hematologic [MeSH:C0018941] effect cefonicid cefazedone [MeSH:C0054999] dog potential model cephalosporin [MeSH:C3536856] hematotoxicity [MeSH:C0235280] man,cephalosporin [MeSH:C3536856] antibiotic cause variety hematologic disturbance man pathogenese hematopathology [MeSH:C0030664] remain poorly characterize need well-defined animal model [MeSH:C0011381] [MeSH:C0599779] blood dyscrasia study [MeSH:C0085973] subacute [MeSH:C0376635] toxicity [MeSH:C0040539] study [MeSH:C0085973] intravenous administration [MeSH:C0001554] [MeSH:C0013125] cefonicid [MeSH:C0007551] [MeSH:C0007551] [MeSH:C0007551] cefazedone [MeSH:C0054999] beagle dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] cause dose-dependent incidence [MeSH:C0021149] anemia [MeSH:C0002871] neutropenia thrombocytopenia [MeSH:C0030312] [MeSH:C0030312] [MeSH:C0030312] [MeSH:C0040034] month nonregenerative anemia [MeSH:C0002871] compromising cytopenia [MeSH:C0030312] [MeSH:C0030312] [MeSH:C0030312] occur approximately dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] receive mg kg cefonicid [MeSH:C0007551] [MeSH:C0007551] [MeSH:C0007551] mg kg cefazedone [MeSH:C0054999] cytopenia [MeSH:C0030312] [MeSH:C0030312] [MeSH:C0030312] completely reversible [MeSH:C5691430] follow cessation require recovery [MeSH:C0140116] erythron [MeSH:C0014824] approximately considerably long granulocyte [MeSH:C0018183] platelet hour day [MeSH:C0011017] rechallenge cephalosporin [MeSH:C3536856] hematologic syndrome reproduce dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] test cefonicid [MeSH:C0007551] [MeSH:C0007551] [MeSH:C0007551] cefazedone [MeSH:C0054999] -treated dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] show substantially reduce induction [MeSH:C0042767] period day [MeSH:C0011017] compare exposure [MeSH:C1390376] drug day [MeSH:C0011017] observation rapid rate decline red cell [MeSH:C0007634] [MeSH:C0007634] mass parameter affect dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] suggest hemolytic component complicated red cell [MeSH:C0007634] [MeSH:C0007634] production problem [MeSH:C0037431] multiple toxicologic mechanism contribute cytopenia [MeSH:C0030312] [MeSH:C0030312] [MeSH:C0030312] conclude administration [MeSH:C0001554] high dose cefonicid [MeSH:C0007551] [MeSH:C0007551] [MeSH:C0007551] cefazedone [MeSH:C0054999] dog [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] [MeSH:C0012984] induce hematotoxicity [MeSH:C0235280] [MeSH:C0040539] similar cephalosporin [MeSH:C3536856]-induced blood dyscrasia describe man provide useful model [MeSH:C0011381] study [MeSH:C0085973] mechanism disorder,neurological
bilateral optic neuropathy [MeSH:C0029132] combined ethambutol [MeSH:C0014964] isoniazid [MeSH:C0022209],case -year-old undergo unsuccessful cadaver kidney transplantation [MeSH:C0022671] treat ethambutol [MeSH:C0014964] [MeSH:C0014964] isoniazid [MeSH:C0022209] [MeSH:C0022209] [MeSH:C0014964] report bilateral retrobulbar neuropathy [MeSH:C0085582] unusual central bitemporal hemianopic scotoma find ethambutol [MeSH:C0014964] [MeSH:C0014964] stop [MeSH:C0014964] small improvement [MeSH:C2936612] visual acuity [MeSH:C0042812] [MeSH:C0042812] follow isoniazid [MeSH:C0022209] [MeSH:C0022209] discontinue later follow dramatic improvement [MeSH:C2936612] visual acuity [MeSH:C0042812] [MeSH:C0042812] hazard optic nerve [MeSH:C0029130] toxicity [MeSH:C0040539] ethambutol [MeSH:C0014964] [MeSH:C0014964] know emphasize potential [MeSH:C0001272] danger use ethambutol [MeSH:C0014964] [MeSH:C0014964] isoniazid [MeSH:C0022209] [MeSH:C0022209] [MeSH:C0014964],neurological|hepatorenal
anticoagulant [MeSH:C0003280] dementia [MeSH:C0497327] brain [MeSH:C0006104] insight,dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve craniopharyngioma [MeSH:C0010276] cerebellar method conduct longitudinal [MeSH:C0023981] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examining synapse [MeSH:C0039062] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] therapeutic innovation [MeSH:C0087111],neurological
bradycardia [MeSH:C0428977] pattern ventricular tachycardia [MeSH:C0042514] patient [MeSH:C0030705],diabete affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve meningitis [MeSH:C0025289] huntington disease method conduct prospective evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine atrioventricular block [MeSH:C0004245] parameter result improvement [MeSH:C2936612] primary endpoint safety [MeSH:C0036043] consideration,neurological|cardiovascular
glomerulus epilepsy [MeSH:C0014544] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] statin effect heart disease [MeSH:C0018799] hydronephrosis method [MeSH:C0020295] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo retrospective cholelithiasis [MeSH:C0008350] primary [MeSH:C0033137] biliary cholangitis [MeSH:C0008312] assessment [MeSH:C0030198] result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
epilepsy [MeSH:C0014544] nephrotic syndrome [MeSH:C0027726] organ [MeSH:C0029250] interplay,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve cervical cancer [MeSH:C4048328] chemotherapy method conduct observational [MeSH:C0302523] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine acute myeloid leukemia [MeSH:C0023467] parameter result improve outcome practice guideline [MeSH:C0936005],hepatorenal|oncological
heart lymphoma [MeSH:C0024299] vascular insight,diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve blood pressure pad method [MeSH:C0005823] conduct randomized control evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine transient ischemic attack [MeSH:C0007787] parameter result improvement [MeSH:C2936612] primary endpoint need investigation [MeSH:C0035173],cardiovascular
susceptibility [MeSH:C0012655] ankylosing spondylitis [MeSH:C0038013] twin role [MeSH:C0041427] gene hla environment [MeSH:C0014406],determine relative effect genetic environmental [MeSH:C0014406] factor [MeSH:C0014406] susceptibility [MeSH:C0012655] ankylosing spondylitis method [MeSH:C0038013] twin identify royal national hospital rheumatic disease [MeSH:C0012634] database radiographic examination perform establish diagnosis disease [MeSH:C0012634] [MeSH:C0011900] severity assess combination validate scoring system hla typing [MeSH:C0242318] hla-b2 [MeSH:C0019740] hla-b6 hla-dr1 [MeSH:C0019768] perform polymerase chain reaction sequence-specific primer zygosity assess microsatellite marker [MeSH:C1519302] genetic environmental [MeSH:C0014406] variance component assess program [MeSH:C0376691] mx previous study [MeSH:C0085973] twin result monozygotic [MeSH:C0041432] mz twin pair [MeSH:C0041427] [MeSH:C0041427] disease [MeSH:C0012634] [MeSH:C0012675] concordant compare b2-positive dizygotic dz twin pair [MeSH:C0041427] [MeSH:C0041427] dz twin pair [MeSH:C0041427] [MeSH:C0041427] overall nonsignificant increase similarity regard age disease [MeSH:C0012634] [MeSH:C0012634] onset disease [MeSH:C0012634] severity score assess note disease [MeSH:C0012634]-concordant mz twin compare concordant dz twin hla-b2 [MeSH:C0019740] b6 associate disease [MeSH:C0012634] proband rate disease [MeSH:C0012634] concordance significantly increase dz twin pair [MeSH:C0041427] [MeSH:C0041427] co-twin positive b2 dr1 additive genetic effect [MeSH:C0009246] estimate contribute population variance [MeSH:C0032659] susceptibility [MeSH:C0012655] largely genetically determine environmental [MeSH:C0014406] trigger disease [MeSH:C0012634] probably ubiquitous hla-b2 [MeSH:C0019740] account minority overall genetic susceptibility [MeSH:C0314657] [MeSH:C0012655],neurological
myeloproliferative neoplasm marker dementia [MeSH:C0497327],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin cancer [MeSH:C0004057] participant cancer patient [MeSH:C0030705] bundle branch block esophageal cancer [MeSH:C0006384] result enhance therapeutic response [MeSH:C0087111] heart block [MeSH:C0018794] correlation cost-effectiveness [MeSH:C1511536] implication,cardiovascular|oncological
use propranolol [MeSH:C0033497] idiopathic orthostatic hypotension [MeSH:C2931939],patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] idiopathic orthostatic hypotension [MeSH:C2931939] [MeSH:C2931939] physiologic [MeSH:C0026429] biochemical [MeSH:C0017401] evidence [MeSH:C5575834] severe autonomic dysfunction [MeSH:C0031847] include exhibit markedly reduce plasma [MeSH:C0032105] catecholamine plasma [MeSH:C0032105] renin activity recumbent upright position marked hypersensitivity [MeSH:C0020517] pressor [MeSH:C0033093] effect [MeSH:C4277511] infuse norepinephrine [MeSH:C0028351] propanolol administer intravenously mg produce increase supine [MeSH:C0038845] upright blood pressure [MeSH:C0005823] [MeSH:C0005823] individual rise range mmhg chronic oral administration [MeSH:C0001563] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] mg elevate blood pressure [MeSH:C0005823] [MeSH:C0005823] individual increase order mmg observe marked hypertension [MeSH:C0020538] induce propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] drug [MeSH:C0013227] [MeSH:C0013227] withdraw tolerate important effect [MeSH:C4277511] observe continue individual month persistence [MeSH:C2350288] pressor [MeSH:C0033093] effect [MeSH:C4277511] appear decrease degree response hemodynamic [MeSH:C0019010] measurement patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] demonstrate increase total peripheral resistance [MeSH:C1258192] essentially cardiac output [MeSH:C0007165] follow propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] therapy study [MeSH:C0085973] suggest propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] useful drug [MeSH:C0013227] [MeSH:C0013227] select patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe idiopathic orthostatic hypotension [MeSH:C2931939] [MeSH:C2931939],cardiovascular
cardiomyopathy heart failure [MeSH:C0018801] vascular [MeSH:C0221214] insight,cross-sectional examine [MeSH:C0010362] aspirin [MeSH:C0004057] stroke diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include ventricular tachycardia systolic hypotension method [MeSH:C0042514] participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
retinoschisin x-linked retinoschisis protein [MeSH:C0271091] secrete [MeSH:C0036534] photoreceptor protein [MeSH:C0206428] express release weri-rb1 cell [MeSH:C0007634],x-linked retinoschisis [MeSH:C0271091] [MeSH:C0266508] [MeSH:C0271091] characterize microcystic-like change macular region schisis [MeSH:C0266508] inner retina [MeSH:C0035298]l layer lead visual deterioration [MeSH:C0234985] male [MeSH:C0086582] missense [MeSH:C0599155] protein [MeSH:C0033684]-truncating mutation causative gene rs1 identify think inactivate [MeSH:C0043297] rs1 encode amino acid protein [MeSH:C0033684] retinoschisin [MeSH:C0152439] [MeSH:C0152439] contain discoidin domain unknown function generate polyclonal antibody peptide unique region retinoschisin [MeSH:C0152439] [MeSH:C0152439] detect [MeSH:C0152439] protein [MeSH:C0033684] approximately kda retina [MeSH:C0035298]l [MeSH:C0035331] sample reduce dithiothreitol [MeSH:C0012789] multimer [MeSH:C0376478] sized kda non-reducing condition screen human tissue [MeSH:C0040300] antibody reveal retinoschisin [MeSH:C0152439] [MeSH:C0152439] retina [MeSH:C0035298] [MeSH:C0152439] specific antibody detect protein [MeSH:C0033684] similar size bovine [MeSH:C0007453] murine [MeSH:C0026802] retina [MeSH:C0035298] investigate [MeSH:C0035173] expression pattern retina [MeSH:C0752248] [MeSH:C0035298] rs1 mrna situ hybridization riboprobe retinoschisin [MeSH:C0152439] [MeSH:C0152439] immunohistochemistry [MeSH:C0021044] antisense riboprobe detect rs1 mrna photoreceptor [MeSH:C0206428] layer protein [MeSH:C0033684] product gene present photoreceptor [MeSH:C0206428] inner portion retina [MeSH:C0035298] furthermore differentiate retinoblastoma cell [MeSH:C0007634] [MeSH:C0035335] weri-rb1 cell [MeSH:C0007634] find express rs1 mrna release retinoschisin [MeSH:C0152439] [MeSH:C0152439] result suggest retinoschisin [MeSH:C0152439] [MeSH:C0152439] release photo-receptor function inner retina [MeSH:C0035298]l layer x-linked retinoschisis [MeSH:C0271091] [MeSH:C0266508] [MeSH:C0271091] cause abnormality [MeSH:C0037268] putative secrete [MeSH:C0036534] photoreceptor [MeSH:C0206428] protein [MeSH:C0033684] example secrete [MeSH:C0036534] photo-receptor protein [MeSH:C0033684] associate retina [MeSH:C0035298]l dystrophy,neurological
cancer immunotherapy [MeSH:C0021083] dementia [MeSH:C0497327],question [MeSH:C0600648] ace inhibitor affect dementia [MeSH:C0497327] hormone therapy [MeSH:C0039798] mechanism method retrospective [MeSH:C0035363] cardiac patient assess stem cell transplant [MeSH:C1504389] malignant [MeSH:C0001418] result enhance therapeutic response [MeSH:C0087111] implication relevance,oncological
amnestic syndrome [MeSH:C0001940] associate propranolol [MeSH:C0033497] toxicity [MeSH:C0040539] case report [MeSH:C0684224],elderly [MeSH:C0001792] woman [MeSH:C0043210] develop alzheimer-like subacute dementia [MeSH:C0002395] propranolol [MeSH:C0033497] toxicity [MeSH:C0040539] [MeSH:C0040539] manifestation [MeSH:C0029166] show severe [MeSH:C1719672] impairment memory [MeSH:C1384666] account virtually abnormality [MeSH:C0037268] evidence [MeSH:C5575834] cerebral reaction drug toxicity [MeSH:C0040539] [MeSH:C0040539] exhibit pattern [MeSH:C3849996] suggest highly selective involvement functional [MeSH:C0031843] subdivision brain,neurological
immunotherapy cancer [MeSH:C0021083] liver cirrhosis [MeSH:C0023890],dementia [MeSH:C0497327] affect elderly patient [MeSH:C0030705] worldwide particularly involve malignant [MeSH:C0001418] testicular cancer method [MeSH:C0153594] conduct longitudinal evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine colorectal cancer [MeSH:C0009402] parameter result positive response potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],oncological
ggt connection liver cirrhosis [MeSH:C0023890],design [MeSH:C0013171] prospective investigation [MeSH:C0035173] metformin [MeSH:C0025598] stroke [MeSH:C0038454] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient creatinine [MeSH:C0010294] urea result improve outcome [MeSH:C0206277] rcc [MeSH:C0967777] correlation therapeutic [MeSH:C0087111] innovation,neurological|hepatorenal
cardiomyopathy [MeSH:C0878544] carcinogen [MeSH:C0007090] oncological odyssey,cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve carcinogenesis [MeSH:C0596263] pancreatic cancer [MeSH:C0346647] method conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine carcinoma [MeSH:C0007097] parameter result well quality life measure need investigation [MeSH:C0035173],oncological
gene therapy [MeSH:C0017296] phenylketonuria [MeSH:C0031485],classical phenylketonuria pku [MeSH:C0031485] autosomal recessive disorder [MeSH:C1968689] cause deficiency hepatic phenylalanine hydroxylase [MeSH:C0751434] pah limitation current dietary [MeSH:C0012177] pku lead development [MeSH:C0243107] [MeSH:C0020119] potential [MeSH:C0001272] treatment [MeSH:C0039798] base somatic gene transfer [MeSH:C0887912] different vector [MeSH:C0021573] system examine vector [MeSH:C0021573] derive recombinant retrovirus dna protein complex efficiently transduce [MeSH:C0040661] pah cdna [MeSH:C0006556] pah-deficient hepatocyte [MeSH:C0227525] vitro application [MeSH:C3658310] vector [MeSH:C0021573] system presently limit low transduction efficiency [MeSH:C0013682] vivo contrast vector [MeSH:C0021573] derive recombinant adenovirus restore normal hepatic pah activity pah-deficient mouse completely normalize serum [MeSH:C0229671] phenylalanine level transient [MeSH:C0040704] effectively re-administere presence neutralize antibody [MeSH:C0443933] direct recombinant adenoviral vector [MeSH:C0021573] finding suggest pku completely correct somatic gene therapy [MeSH:C0017296] provide direction [MeSH:C0700158] future development [MeSH:C0243107] adenoviral vector [MeSH:C0021573],neurological|hepatorenal
tumor tale [MeSH:C0027651] hepatitis [MeSH:C0019158] insight,investigate [MeSH:C0035173] beta-blocker effect diabete radiotherapy method [MeSH:C0034619] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo prospective oncogene testicular cancer [MeSH:C0153594] assessment [MeSH:C0030198] result well quality life measure therapeutic innovation [MeSH:C0087111],oncological
detection [MeSH:C5392129] abnormal [MeSH:C0853087] cardiac adrenergic neuron [MeSH:C3178785] activity [MeSH:C0020115] adriamycin-induced cardiomyopathy iodine metaiodobenzylguanidine [MeSH:C0047506],radiolabele metaiodobenzylguanidine mibg [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] analog [MeSH:C0033568] norepinephrine [MeSH:C0028351] ne serve index adrenergic neuron [MeSH:C3178785] integrity function rat [MeSH:C0034721] model [MeSH:C0011381] adriamycin [MeSH:C0085752] [MeSH:C0085752]-induced cardiomyopathy test hypothesis [MeSH:C3179072] abnormal [MeSH:C0853087] cardiac adrenergic neuron [MeSH:C3178785] [MeSH:C3178785] [MeSH:C3178785] activity [MeSH:C0020115] [MeSH:C0020115] appear exacerbate dose-dependently adriamycin [MeSH:C0085752] [MeSH:C0085752] cardiomyopathy [MeSH:C0878544] degree vacuolar degenerat [MeSH:C0034721]ion myocardial [MeSH:C0027061] cell analyze relation durat [MeSH:C0034721]ion adriamycin [MeSH:C0085752] [MeSH:C0085752] mg kg week abnormal [MeSH:C0853087]ity isolate degenerat [MeSH:C0034721]ion -wk group [MeSH:C0018257] isolated scattered degenerat [MeSH:C0034721]ion half -wk frequent [MeSH:C0017270] scattered degenerat [MeSH:C0034721]ion -wk scattered focal degenerat [MeSH:C0034721]ion -wk extensive degenerat [MeSH:C0034721]ion -wk myocardial [MeSH:C0027061] accumulation [MeSH:C0311432] [MeSH:C0311432] 5i mibg [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] hr intravenous injection [MeSH:C0021494] differ control group [MeSH:C0009932] [MeSH:C0018257] treat wk -wk slightly low accumulation [MeSH:C0311432] [MeSH:C0311432] right ventricular wall significantly low accumulation [MeSH:C0311432] [MeSH:C0311432] left ventricular wall p -wk mibg [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] accumulation [MeSH:C0311432] [MeSH:C0311432] right leave ventricular wall control respectively p -wk mibg [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] accumulation [MeSH:C0311432] [MeSH:C0311432] right leave ventricular wall control respectively p mibg [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] accumulation [MeSH:C0311432] [MeSH:C0311432] myocardium decrease adriamycin [MeSH:C0085752] [MeSH:C0085752] dose-dependent manner appearance [MeSH:C0750731] impaired [MeSH:C0020580] cardiac adrenergic neuron [MeSH:C3178785] [MeSH:C3178785] [MeSH:C3178785] activity [MeSH:C0020115] [MeSH:C0020115] presence slight myocardial [MeSH:C0027061] impairment scattered focal vacuolar degenerat [MeSH:C0034721]ion indicate mibg [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] [MeSH:C0047506] scintigraphy useful detection [MeSH:C5392129] adriamycin [MeSH:C0085752] [MeSH:C0085752]-induced cardiomyopathy,neurological|cardiovascular
alstrom syndrome [MeSH:C0039082] evidence linkage human chromosome [MeSH:C0008643] 2p1,alstrom syndrome [MeSH:C0039082] [MeSH:C0039082] rare autosomal recessive disorder [MeSH:C1968689] characterize retinal degeneration [MeSH:C0035304] sensorineural hearing loss [MeSH:C0018784] early-onset [MeSH:C3711383] obesity [MeSH:C0028754] non-insulin-dependent diabetes mellitus gene alstrom syndrome [MeSH:C0039082] [MeSH:C0011860] [MeSH:C0039082] alms1 previously localized human chromosome [MeSH:C0008643] 2p1 homozygosity mapping distinct isolate population [MeSH:C0032659] french acadian north african pair-wise analysis result maximum lod logarithm odds ratio score respectively confirm finding large linkage [MeSH:C0242239] perform additional family [MeSH:C0015576] [MeSH:C0015576] segregate alstrom syndrome [MeSH:C0039082] [MeSH:C0039082] maximum two-point lod score theta marker d2s2 maximum cumulative multipoint lod score marker d2s2 observe support linkage [MeSH:C0242239] chromosome 2p1 evidence genetic heterogeneity [MeSH:C0242960] observe family [MeSH:C0015576] [MeSH:C0015576] meiotic recombination [MeSH:C4505347] event localize critical region contain alms1 -cm interval flank marker d2s3 d2s2 fine resolution radiation hybrid map gene marker [MeSH:C0017393] construct,neurological
tumor [MeSH:C0027651] tale leukemia,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve adrenal cancer [MeSH:C0750887] stomach cancer [MeSH:C0024623] method conduct observational [MeSH:C0302523] evaluate [MeSH:C0013175] calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine sarcoma [MeSH:C1261473] parameter result superior efficacy [MeSH:C5690761] safety [MeSH:C0036043] consideration,oncological
chloroacetaldehyde sulfhydryl reagent [MeSH:C0038738] role critical thiol group ifosfamide nephropathy,chloroacetaldehyde caa metabolite alkylating agent [MeSH:C0002073] ifosfamide [MeSH:C0020823] ifo putatively responsible renal damage follow anti-tumor therapy ifo depletion [MeSH:C3494379] [MeSH:C3494379] sulfhydryl sh group report cell culture [MeSH:C0007585] animal study work effect [MeSH:C4277511] [MeSH:C4277511] caa human [MeSH:C0086418] proximal tubule cell primary culture hrptec investigate [MeSH:C0035173] toxicity [MeSH:C0040539] [MeSH:C0040539] caa determine protein content cell number ldh release trypan blue exclusion assay caspase- activity [MeSH:C0020115] [MeSH:C0020115] free thiol [MeSH:C0038734] measure ellman caa reduce hrptec cell number protein induce loss free intracellular thiol [MeSH:C0038734] increase necrosis marker caa acrolein [MeSH:C0001204] inhibit [MeSH:C0021463] [MeSH:C0021463] cysteine protease [MeSH:C2717970] [MeSH:C2717970] [MeSH:C2717970] caspase- caspase- cathepsin b [MeSH:C0699919] caspase activation cisplatin [MeSH:C0008838] inhibit [MeSH:C0021463] [MeSH:C0021463] caa cell stain fluorescent dye [MeSH:C0016320] target [MeSH:C0039309] lysosome caa [MeSH:C0024369] induce increase lysosomal [MeSH:C0024369] size lysosomal [MeSH:C0024369] leakage effect [MeSH:C4277511] [MeSH:C4277511] caa cysteine protease [MeSH:C2717970] [MeSH:C2717970] [MeSH:C2717970] activity [MeSH:C0020115] [MeSH:C0020115] thiol [MeSH:C0038734] reproduce cell lysate acidification [MeSH:C5690800] slow reaction caa thiol [MeSH:C0038734] donor attenuate [MeSH:C0042211] effect [MeSH:C4277511] [MeSH:C4277511] caa necrosis marker thiol [MeSH:C0038734] depletion [MeSH:C3494379] [MeSH:C3494379] cysteine protease [MeSH:C2717970] [MeSH:C2717970] [MeSH:C2717970] inhibit [MeSH:C0021463] [MeSH:C0021463]ion live cell caa directly react cellular protein non-protein thiol [MeSH:C0038734] mediate toxicity [MeSH:C0040539] [MeSH:C0040539] hrptec effect [MeSH:C4277511] [MeSH:C4277511] reduce acidification [MeSH:C5690800] urinary acidification [MeSH:C5690800] option prevent ifo nephropathy patient [MeSH:C0030705],hepatorenal|oncological
reticular formation connection [MeSH:C0035284] hypertension,question [MeSH:C0600648] ace inhibitor affect cancer thalamus mechanism method randomized control cancer [MeSH:C1096777] patient [MeSH:C0030705] assess delirium paralysis [MeSH:C0011206] result improvement [MeSH:C2936612] primary endpoint implication therapeutic [MeSH:C0087111] innovation,neurological
cancer norepinephrine [MeSH:C0028351] explore neural pathway [MeSH:C0027792],design [MeSH:C0013171] randomized control [MeSH:C1096777] investigation [MeSH:C0035173] statin [MeSH:C0360714] dementia [MeSH:C0497327] participant [MeSH:C1708335] elderly patient bile duct hippocampal [MeSH:C0228249] result enhance therapeutic response [MeSH:C0087111] epilepsy [MeSH:C0014544] correlation healthcare advancement,neurological|hepatorenal
neurodegenerative aspect [MeSH:C0524851] hepatitis [MeSH:C0019158],dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve tic thalamus method [MeSH:C0039729] conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine reticular formation [MeSH:C0035284] parameter result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,neurological
lamivudine prevention [MeSH:C0209738] hepatitis b virus reactivation [MeSH:C0019169] hepatitis-b surface antigen hbsag [MeSH:C0019168] seropositive cancer patient [MeSH:C0030705] undergo cytotoxic chemotherapy [MeSH:C0013216],hepatitis [MeSH:C0019158] [MeSH:C0019158] b virus hbv [MeSH:C0019169] major cause chronic liver disease [MeSH:C0008679] worldwide cancer patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chronic carrier hbv high hepatic complication rate receive cytotoxic chemotherapy [MeSH:C0013216] ct mainly attribute hbv reactivation cancer patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] solid hematological malignancy [MeSH:C0376545] chronic hbv infection [MeSH:C0151317] receive antiviral agent [MeSH:C0003451] lamivudine [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] prior ct compare historical [MeSH:C5197707] receive lamivudine [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] objective assess efficacy [MeSH:C5690761] lamivudine [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] reduce incidence [MeSH:C0021149] [MeSH:C0021149] hbv reactivation diminishing morbidity [MeSH:C0026538] mortality [MeSH:C0026565] ct group compare prophylactic lamivudin [MeSH:C0209738] consist patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive prophylactic lamivudin [MeSH:C0209738]e [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] historical [MeSH:C5197707] control consist consecutive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo ct prophylactic lamivudin [MeSH:C0209738]e [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] follow week ct outcome [MeSH:C0206277] compare group n patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] establish hepatitis [MeSH:C0019158] [MeSH:C0019158] evaluate [MeSH:C0013175] severe [MeSH:C1719672] hepatitis [MeSH:C0019158] [MeSH:C0019158] prophylactic lamivudin [MeSH:C0209738]e [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] severe [MeSH:C1719672] hepatitis [MeSH:C0019158] [MeSH:C0019158] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] p comparison [MeSH:C0871382] mean alt value reveal significantly high mean alanine aminotransferase alt value [MeSH:C0001899] prophylactic lamivudin [MeSH:C0209738]e [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] p suggest prophylactic lamivudin [MeSH:C0209738]e [MeSH:C0209738] [MeSH:C0209738] [MeSH:C0209738] significantly decrease incidence [MeSH:C0021149] [MeSH:C0021149] hbv reactivation overall morbidity [MeSH:C0026538] cancer patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] immunosuppressive therapy [MeSH:C0021079] study [MeSH:C0085973] need determine appropriate nucleoside nucleotide analogue [MeSH:C1579410] antiviral prophylaxis [MeSH:C0033107] ct optimal duration administration [MeSH:C0001554] completion ct,hepatorenal|oncological
identification [MeSH:C1707660] novel nonsense mutation missense [MeSH:C0544885] substitution [MeSH:C2936279] vasopressin-neurophysin ii gene spanish kindred familial neurohypophyseal diabete insipidus [MeSH:C0687720],familial neurohypophyseal diabete insipidus [MeSH:C0687720] fndi autosomal dominant disease [MeSH:C2936739] cause deficiency antidiuretic hormone arginine vasopressin avp encode avp-neurophysin ii avp-npii gene chromosome [MeSH:C0008633] 0p1 analyze family fndi direct automate fluorescent solid phase single-stranded dna sequencing [MeSH:C0012935] pcr-amplified avp-npii dna family [MeSH:C0015576] affect individual present novel nonsense mutation exon gene [MeSH:C0544885] consist g transition [MeSH:C1257888] nucleotide produce stop signal [MeSH:C0242611] codon glu npii premature termination eliminate [MeSH:C0242612] c-terminal domain npii include cysteine residue position involve correct folding [MeSH:C0162847] prohormone [MeSH:C0597049] second family g29a substitution position signal peptide observe affect individual missense mutation [MeSH:C0599155] replace ala thr frequent fndi patient [MeSH:C0030705] think reduce efficiency [MeSH:C0013682] cleavage [MeSH:C3178791] signal peptidase,neurological
increase serum [MeSH:C0229671] soluble [MeSH:C0210233] fas [MeSH:C1454645] patient [MeSH:C0030705] acute liver failure [MeSH:C0162557] paracetamol overdose,aim experimental study [MeSH:C2985410] suggest apoptosis [MeSH:C0162638] fas [MeSH:C1454645] fas [MeSH:C1454645] ligand signaling system [MeSH:C0253023] play important role development acute liver [MeSH:C0023884] failure [MeSH:C0162557] [MeSH:C0162557] investigate [MeSH:C0035173] soluble [MeSH:C0210233] form fas [MeSH:C1454645] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute liver [MeSH:C0023884] failure [MeSH:C0162557] [MeSH:C0162557] methodology serum [MeSH:C0229671] level [MeSH:C0018759] sfas [MeSH:C1454645] soluble [MeSH:C0210233] fas [MeSH:C1454645] measure elisa [MeSH:C0014441] [MeSH:C0014441] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute liver [MeSH:C0023884] failure [MeSH:C0162557] [MeSH:C0162557] normal subject [MeSH:C0080105] serum [MeSH:C0229671] level [MeSH:C0018759] tumor necrosis factor-alpha interferon-gamma determine elisa [MeSH:C0014441] [MeSH:C0014441] result serum [MeSH:C0229671] sfas [MeSH:C1454645] significantly increase patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute liver [MeSH:C0023884] failure [MeSH:C0162557] [MeSH:C0162557] median u ml range u ml compare normal control median u ml range u ml p level [MeSH:C0018759] significantly great patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute liver [MeSH:C0023884] failure [MeSH:C0162557] [MeSH:C0162557] paracetamol overdose [MeSH:C0029944] median u ml range u ml n non-a e hepatitis [MeSH:C0085293] median u ml range u ml n p relationship [MeSH:C0021797] sfas [MeSH:C1454645] eventual outcome [MeSH:C0206277] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] correlation observe serum [MeSH:C0229671] sfas [MeSH:C1454645] level [MeSH:C0018759] aspartate aminotransferase [MeSH:C0004002] r p conclusion increase concentration [MeSH:C0311432] sfas [MeSH:C1454645] serum [MeSH:C0229671] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] acute liver [MeSH:C0023884] failure [MeSH:C0162557] [MeSH:C0162557] reflect activation [MeSH:C4505109] fas [MeSH:C1454645]-mediated apoptosis [MeSH:C0162638] liver [MeSH:C0023884] increase tumor necrosis factor-alpha important factor liver [MeSH:C0023884] cell loss,neurological|hepatorenal|oncological
revolutionary spect imaging heart failure [MeSH:C0018801] diagnosis [MeSH:C0011900],question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] hepatitis [MeSH:C0019158] mechanism method prospective elderly patient assess primary [MeSH:C0033137] biliary cholangitis [MeSH:C0008312] hepatocellular [MeSH:C0345904] result improvement primary [MeSH:C0033137] endpoint implication care improvement,hepatorenal|oncological
small nuclear ribonucleoprotein polypeptide [MeSH:C3887985] n snrpn [MeSH:C0163617] express gene prader-willi syndrome [MeSH:C0032897] critical region,prader-willi syndrome [MeSH:C0032897] pws associate paternal [MeSH:C0030652]ly derive chromosomal deletion region [MeSH:C0008628] 5q1- maternal [MeSH:C0024915] disomy chromosome loss [MeSH:C2364111] [MeSH:C1096168] express paternal [MeSH:C0030652] allele [MeSH:C0002085] maternal [MeSH:C0024915]ly imprinted gene responsible pws phenotype [MeSH:C0031437] [MeSH:C0031437] map [MeSH:C0024779] gene encode small nuclear rna [MeSH:C0035709] associated polypeptide smn [MeSH:C1305923] snrpn [MeSH:C0163617] [MeSH:C0163617] human chromosome [MeSH:C0008643] 5q1 process pseudogene [MeSH:C0033799] snrpn [MeSH:C0163617] [MeSH:C0163617]p1 chromosome region 6pter-p2 furthermore snrpn [MeSH:C0163617] [MeSH:C0163617] map [MeSH:C0024779] minimal deletion interval critical pws fact mouse snrpn [MeSH:C0163617] [MeSH:C1700795] [MeSH:C0163617] gene maternal [MeSH:C0024915]ly imprint brain suggest loss [MeSH:C2364111] paternal [MeSH:C0030652]ly derive snrpn [MeSH:C0163617] [MeSH:C0163617] allele [MeSH:C0002085] involve pws phenotype [MeSH:C0031437] [MeSH:C0031437],neurological
norrie disease [MeSH:C0266526] gene characterization deletion possible function [MeSH:C0031843],positional cloning experiment [MeSH:C0020123] result recently isolation [MeSH:C0220862] [MeSH:C0220862] candidate gene norrie [MeSH:C0266526] disease [MeSH:C0266526] pseudoglioma ndp [MeSH:C0266526] severe x-linked neurodevelopmental disorder [MeSH:C1535926] report isolation [MeSH:C0220862] [MeSH:C0220862] human [MeSH:C0086418] [MeSH:C0086418] genomic dna clone encompass ndp gene gene span kb consist exon [MeSH:C0015295] entirely contain untranslated region [MeSH:C0600680] detailed genomic deletion [MeSH:C0017260] norrie [MeSH:C0266526] patient [MeSH:C0030705] show heterogeneous size position pcr find expression [MeSH:C0017262] ndp gene confine eye brain [MeSH:C0015392] extensive dna protein sequence [MeSH:C0162326] comparison human [MeSH:C0086418] [MeSH:C0086418] ndp gene related gene database [MeSH:C0993637] reveal homology [MeSH:C1136383] cysteine-rich protein-binding domain immediate early gene implicate regulation cell proliferation [MeSH:C0596290] [MeSH:C0596290] propose ndp molecule related function gene involve pathway [MeSH:C0282655] regulate neural cell differentiation [MeSH:C0007589] proliferation [MeSH:C0596290],neurological
atm germline [MeSH:C0206530] mutation classical ataxia-telangiectasia patient dutch population,germline mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] atm gene [MeSH:C0206530] responsible autosomal recessive disorder ataxia-telangiectasia a-t determine atm mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] spectrum classical a-t patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] include immigrant population [MeSH:C0282163] dutch ethnic origin protein truncation test ptt restriction endonuclease fingerprinting ref compare detection [MeSH:C5392129] efficiency [MeSH:C0013682] identify mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] respectively patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] find compound heterozygote [MeSH:C0019425] seventeen mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] distinct report previously mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] small deletion point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] frequently affect splice site [MeSH:C0887916] -kb genomic deletion end gene [MeSH:C0017260] likely recombination line element [MeSH:C0034865] identify frequently find mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify unrelated turkish a-t individual [MeSH:C0021228] previously describe turkish a-t founder mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] presence founder mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] relatively small ethnic population [MeSH:C0032659] group western europe [MeSH:C0043129] indicate high carrier frequency community [MeSH:C0009462] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] dutch ethnic origin founder effect [MeSH:C0242918] identify observe genetic heterogeneity [MeSH:C0242960] include relative high percentage splice-site mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] reflection phenotype [MeSH:C0031437] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] manifest classical a-t increase cellular radioresistant dna synthesis,neurological
memory loss pathway hepatitis,design [MeSH:C0013171] prospective investigation ace inhibitor [MeSH:C0003015] hypertension participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] acetylcholine chorea [MeSH:C0001041] result superior efficacy radiculopathy [MeSH:C0700594] correlation healthcare advancement,neurological
cancer meet ventricular tachycardia [MeSH:C0042514] neurological perspective,dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve myeloproliferative neoplasm gaba method conduct observational [MeSH:C0302523] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine epilepsy [MeSH:C0014544] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] safety [MeSH:C0036043] consideration,neurological|oncological
atrium pattern myocardial infarction [MeSH:C0027051] patient [MeSH:C0030705],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome heart valve pathway method retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure sinoatrial node tremor [MeSH:C0037189] result superior efficacy [MeSH:C5690761] cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
classical galactosemia [MeSH:C0016952] mutation galactose phosphate uridyl transferase galt gene [MeSH:C0016953],classical galactosemia [MeSH:C0016952] cause deficiency activity [MeSH:C0020115] [MeSH:C0020115] [MeSH:C1623416] enzyme galactose phosphate uridyl transferase galt [MeSH:C0016953] turn cause mutation [MeSH:C0026882] galt gene disorder exhibit considerable allelic [MeSH:C0524869] heterogeneity [MeSH:C0242960] [MeSH:C0242960] end different base change record [MeSH:C0034869] different population [MeSH:C0032659] ethnic group [MeSH:C1257890] country worldwide mutation [MeSH:C0026882] frequently cite q18r k25n s15l n34d q18r common mutation [MeSH:C0026882] european population [MeSH:C0032659] [MeSH:C0032659] predominantly european descent overall account mutant chromosome [MeSH:C0008633] difference relative frequency [MeSH:C0017270] individual population [MeSH:C0032659] individual homoallelic [MeSH:C0524869] q18r tend severe phenotype [MeSH:C0031437] [MeSH:C0031437] keep virtually complete loss enzyme activity [MeSH:C0020115] [MeSH:C0020115] observe vitro expression [MeSH:C0017262] system [MeSH:C0017262] globally k25n rare european population [MeSH:C0032659] [MeSH:C0032659] find mutant chromosome [MeSH:C0008633] invariably associate severe phenotype [MeSH:C0031437] [MeSH:C0031437] s15l find exclusively african american [MeSH:C0085756] vitro expression [MeSH:C0017262] result discrepant individual carry s15l appear exhibit galt activity [MeSH:C0020115] [MeSH:C0020115] tissue duarte los angele duarte duarte variant carry amino acid substitution [MeSH:C0525038] n34d d1 associate increase erythrocyte galt activity [MeSH:C0020115] [MeSH:C0020115] d2 reduce activity [MeSH:C0020115] [MeSH:C0020115] n34d linkage disequilibrium base change differ d1 d2 allele n34d impair galt activity [MeSH:C0020115] [MeSH:C0020115] vitro expression [MeSH:C0017262] system [MeSH:C0017262] difference abundance galt protein lymphoblastoid cell line d2 d1 individual unclear specific molecular change distinguish d1 d2 allele account different activity [MeSH:C0020115] [MeSH:C0020115] considerable genetic heterogeneity [MeSH:C0242960] [MeSH:C0242960] [MeSH:C0242960] document [MeSH:C0009797] date undoubtedly contribute phenotypic [MeSH:C1837514] [MeSH:C1837514] heterogeneity [MeSH:C0242960] [MeSH:C0242960] observe galactosemia [MeSH:C0016952] additional effect nonallelic [MeSH:C0524869] variation constitutional factor phenotypic [MeSH:C1837514] [MeSH:C1837514] variability [MeSH:C0003319] remain elucidate,neurological
effect polyethylene glycol [MeSH:C0032483] adriamycin [MeSH:C0085752] toxicity [MeSH:C0040539] mouse [MeSH:C0026809],effect [MeSH:C4277511] widely organic solvent polyethylene glycol peg toxic action acute chronic adriamycin adr evaluate [MeSH:C0013175] mouse [MeSH:C0026809] peg impressively decrease acute high-dose chronic low-dose-adr-associated lethality light microscopic show protection adr-induced cardiac [MeSH:C0018810] morphological alteration diminish adr antitumor activity l1 leukemia [MeSH:C0023418] ehrlich ascite tumor [MeSH:C0007125],oncological
ceftriaxone-associated [MeSH:C0007561] biliary pseudolithiasis paediatric surgical patient,known ceftriaxone [MeSH:C0007561] [MeSH:C0007561] [MeSH:C0007561] lead pseudolithiasis patient experimental study suggest situation cause gallbladder dysfunction [MeSH:C0016976] fasting role development pseudolithiasis prospectively evaluate [MeSH:C0013175] incidence [MeSH:C0021149] [MeSH:C0021149] importance pseudolithiasis paediatric surgical patient receive ceftriaxone [MeSH:C0007561] [MeSH:C0007561] [MeSH:C0007561] fast post-operative [MeSH:C0030201] period child [MeSH:C0008059] give ceftriaxone [MeSH:C0007561] [MeSH:C0007561] [MeSH:C0007561] evaluate [MeSH:C0013175] serial abdominal sonogram develop biliary [MeSH:C0005423] pathology [MeSH:C0030664] comparison patient pseudolithiasis reveal difference respect age sex [MeSH:C1522384] duration starvation [MeSH:C0038187] variable cessation pseudolithiasis resolve spontaneously [MeSH:C0034705] short period incidence [MeSH:C0021149] [MeSH:C0021149] pseudolithiasis affect fast,neurological|hepatorenal
hematuria [MeSH:C0018965] pattern [MeSH:C3849996] myocardial infarction [MeSH:C0027051] patient [MeSH:C0030705],investigate [MeSH:C0035173] statin effect cancer cortical method adult [MeSH:C0001675] population [MeSH:C0032659] undergo longitudinal cholestasis brain abscess assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] relevance [MeSH:C2826293],neurological|hepatorenal
breakthrough [MeSH:C1135120] premature beat [MeSH:C0340464] finding prostate cancer [MeSH:C0376358],design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] cardiac patient myocardial infarction [MeSH:C0027051] arrhythmia [MeSH:C0003811] result improve outcome [MeSH:C0206277] smooth muscle [MeSH:C1267092] correlation safety [MeSH:C0036043] consideration,cardiovascular
mutation [MeSH:C0026882] rb1 gene [MeSH:C0080113] effect transcription [MeSH:C0040648],inactivation [MeSH:C0043297] allele [MeSH:C0002085] rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] gene [MeSH:C0080113] normal retinal [MeSH:C0035331] development [MeSH:C0243107] initiate formation retinoblastoma [MeSH:C0035335] rb tumor [MeSH:C0027651] identify mutation [MeSH:C0026882] [MeSH:C0026882] inactivate rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] rb tumor [MeSH:C0027651] isolate patient [MeSH:C0030705] analyze polymerase chain reaction rnase [MeSH:C0032520] protection assay mutation [MeSH:C0026882] [MeSH:C0026882] identify rb tumor [MeSH:C0027651] tumor [MeSH:C0027651] precise error nucleotide sequence [MeSH:C0004793] characterize germ line mutation [MeSH:C0026882] [MeSH:C0206530] [MeSH:C0026882] involve small deletion duplication [MeSH:C0795871] somatic mutation [MeSH:C0026882] [MeSH:C0026882] point mutation [MeSH:C0026882] [MeSH:C0026882] lead splice alteration loss exon mature rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] mrna [MeSH:C0035696] unable detect expression [MeSH:C0017262] mutant allele [MeSH:C0002085] lymphoblast bilaterally affect patient [MeSH:C0030705] mutation [MeSH:C0026882] [MeSH:C0026882] present genomic dna transcript contain mutation [MeSH:C0026882] [MeSH:C0026882] obvious rb tumor [MeSH:C0027651] absence normal rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] allele [MeSH:C0002085] variation expression [MeSH:C0017262] mutant transcript suggest deregulation [MeSH:C0851285] rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] transcription [MeSH:C0040648] absence functional [MeSH:C0031843] rb1 [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] [MeSH:C4308074] gene [MeSH:C0080113] product,oncological
flumazenil [MeSH:C0016293] induce seizure [MeSH:C0036572] death mixed cocaine-diazepam intoxication [MeSH:C0043049],hypothesis [MeSH:C3179072] administration [MeSH:C0001554] benzodiazepine antagonist flumazenil [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] unmask seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] mixed cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170]-benzodiazepine [MeSH:C4048284] intoxication [MeSH:C0043049] [MeSH:C0043049] design male [MeSH:C0086582] sprague-dawley rat receive mg kg cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] ip mg kg diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] combination [MeSH:C0034865] diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] minute later group [MeSH:C0018257] challenge vehicle [MeSH:C0175845] [MeSH:C0175845] flumazenil [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] mg kg ip animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] behavior [MeSH:C0004935] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] incidence [MeSH:C0021149] death [MeSH:C0021149] incidence [MeSH:C0021149] cortical eeg tracing record intervention [MeSH:C3898714] administration [MeSH:C0001554] flumazenil [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] receive combination [MeSH:C0034865] dose cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] result animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] receive cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] follow vehicle [MeSH:C0175845] [MeSH:C0175845] result develop seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] death receive diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] follow vehicle [MeSH:C0175845] [MeSH:C0175845] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] somnolent [MeSH:C2830004] [MeSH:C2830004] die receive diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] follow mg kg flumazenil [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] animal [MeSH:C0003062] [MeSH:C0003062] [MeSH:C0003062] somnolent [MeSH:C2830004] [MeSH:C2830004] diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] active flumazenil [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] administration [MeSH:C0001554] combination [MeSH:C0034865] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] administer simultaneously result overt eeg-detectable seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] incidence [MeSH:C0021149] death [MeSH:C0021149] receive similar combination [MeSH:C0034865] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] follow later mg kg flumazenil [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] result increase incidence [MeSH:C0021149] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] p death p compare receive cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] follow mg kg flumazenil [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] result increase incidence [MeSH:C0021149] seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] p death p compare flumazenil [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] [MeSH:C0016293] unmask seizure [MeSH:C0036572] [MeSH:C0036572] [MeSH:C0036572] increase incidence [MeSH:C0021149] death [MeSH:C0021149] model combined cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170]-diazepam [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] [MeSH:C0012010] intoxication [MeSH:C0043049] [MeSH:C0043049],neurological
hepatitis rcc [MeSH:C0019158] organ interplay,cancer [MeSH:C0006826] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve hemodialysis [MeSH:C0019004] interstitial nephritis method [MeSH:C0027707] conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] [MeSH:C0030705] examine nephrolithiasis [MeSH:C0392525] parameter result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],hepatorenal
diabetes mellitus [MeSH:C0011849] cardiac function [MeSH:C0018803],prospective examine aspirin hypertension [MeSH:C0020538] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include hypotensive tricuspid valve chf method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication healthcare advancement,cardiovascular
hepatitis chronic kidney disease [MeSH:C1561643] organ [MeSH:C0029250] interplay,question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] kidney [MeSH:C0022646] mechanism method randomized control diabetic patient [MeSH:C0030705] assess dialysis [MeSH:C0011945] hcc result improvement [MeSH:C2936612] primary endpoint implication practice guideline,hepatorenal
innovative central sympatholytic approach liver cirrhosis [MeSH:C0023890],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] kidney [MeSH:C0022646] stone method adult [MeSH:C0001675] population [MeSH:C0032659] undergo observational cirrhosis kidney [MeSH:C0022646] assessment result positive response safety consideration,hepatorenal
oncogene cancer [MeSH:C0029016] myocardial infarction [MeSH:C0027051],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve hypertension [MeSH:C0020538] outcome acute lymphoblastic leukemia pathway [MeSH:C1961102] method randomized control trial cancer [MeSH:C1096777] patient [MeSH:C0030705] measuring hormone therapy [MeSH:C0039798] metastasis [MeSH:C0027627] result well quality life measure optimization [MeSH:C0376695],oncological
schwannoma connection [MeSH:C0027809] breast cancer [MeSH:C0006142],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve stroke [MeSH:C0038454] outcome dystonia pathway method prospective trial elderly patient measure basal ganglion [MeSH:C0004781] glutamate [MeSH:C0220839] result well quality life measure therapeutic innovation [MeSH:C0087111],neurological
multiple myeloma [MeSH:C0026764] connection cardiomyopathy,heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve bone marrow transplant paralysis method conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine oncogene [MeSH:C0029016] parameter result favorable safety [MeSH:C0036043] profile optimization [MeSH:C0376695],neurological|oncological
phase [MeSH:C0080129] ii carboplatin [MeSH:C0079083] liposomal [MeSH:C0023828] doxorubicin patient [MeSH:C0030705] recurrent squamous cell carcinoma cervix [MeSH:C0007137],activity [MeSH:C0020115] [MeSH:C0020115] combination carboplatin [MeSH:C0079083] [MeSH:C0079083] liposomal [MeSH:C0023828] doxorubicin test phase ii patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] recurrent cervical carcinoma [MeSH:C0007097] method combination carboplatin [MeSH:C0079083] [MeSH:C0079083] area concentration curve auc liposomal [MeSH:C0023828] doxorubicin doxil start dose mg administer intravenously day [MeSH:C0011017] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] recurrent squamous cell cervical carcinoma [MeSH:C0007097] [MeSH:C0007137] determine antitumor [MeSH:C2716992] activity [MeSH:C0020115] [MeSH:C0020115] toxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] profile result twenty-nine patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] assessable response patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] assessable toxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] overall response rate [MeSH:C0034746] median response week median duration response week median survival [MeSH:C0038952] week main toxic [MeSH:C1256754] effect myelosuppression [MeSH:C1956351] grade neutropenia [MeSH:C0027947] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] anemia patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] thrombocytopenia patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] neutropenic fever patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] infusion [MeSH:C0841792]-related reaction infusion [MeSH:C0841792] liposomal [MeSH:C0023828] doxorubicin lead discontinuation patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] grade nonhematologic toxic [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] include nausea [MeSH:C0027497] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] emesis [MeSH:C0042963] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] fatigue [MeSH:C0015672] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mucositis stomatitis patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] constipation patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] weight loss patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] hand-foot syndrome [MeSH:C0549410] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] skin reaction patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] conclusion combination carboplatin [MeSH:C0079083] [MeSH:C0079083] liposomal [MeSH:C0023828] doxorubicin modest activity [MeSH:C0020115] [MeSH:C0020115] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] recurrent cervical carcinoma [MeSH:C0007097],oncological
hydronephrosis pathway [MeSH:C0020295] angina pectoris,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect heart disease [MeSH:C0018799] liver mechanism method retrospective [MeSH:C0035363] cardiac patient assess hepatic alcoholic liver disease [MeSH:C0023896] result favorable safety [MeSH:C0036043] profile implication safety [MeSH:C0036043] consideration,hepatorenal
lymphoma aortic valve [MeSH:C0003501] cardiac connection,prospective examine beta-blocker [MeSH:C0001645] stroke adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include aortic dissection coronary artery disease [MeSH:C1956346] ventricular fibrillation method [MeSH:C0042510] participant [MeSH:C1708335] include result improve disease management [MeSH:C0039798] implication care improvement,cardiovascular
brca1 [MeSH:C0259275] secrete [MeSH:C0036534] exhibit property granin [MeSH:C0008586],germline [MeSH:C0206530] mutation brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] responsible case inherit breast ovarian cancer [MeSH:C1140680] function [MeSH:C0031843] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] protein remain elusive brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] encode -kd protein sequence [MeSH:C0162327] homology biochemical analogy granin [MeSH:C0008586] protein family interestingly brca2 [MeSH:C0294028] include motif [MeSH:C0752190] similar granin [MeSH:C0008586] consensus c terminus protein [MeSH:C0376298] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] granin [MeSH:C0008586] localize secretory vesicle [MeSH:C0886515] secrete regulate pathway post-translationally glycosylate responsive hormone regulate secretory protein brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] appear function [MeSH:C0031843] mechanism [MeSH:C1524059] previously describe tumour suppressor gene product [MeSH:C0079427],oncological
target therapy cancer multiple sclerosis [MeSH:C0026769],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease stem cell transplant mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assessing target therapy [MeSH:C2699893] acute lymphoblastic leukemia [MeSH:C1961102] result improvement [MeSH:C2936612] primary endpoint implication optimization [MeSH:C0376695],oncological
homozygosity mapping family microcephaly mental retardation [MeSH:C2678046] short stature cohen syndrome [MeSH:C0878684] region 8q2,-8q2 redefine entity syndrome [MeSH:C0039082] microcephaly progressive [MeSH:C1449744] postnatal [MeSH:C0032782] growth deficiency mental retardation [MeSH:C3714756] [MeSH:C3714756] observe brother cousin [MeSH:C0337527] multiply consanguineous [MeSH:C0009789] kindred lebanese descent hypotonia chorioretinal dystrophy myopia [MeSH:C2931115] identify severity condition vary closely related patient [MeSH:C0030705] absence distinctive facial [MeSH:C0015455] appearance [MeSH:C0750731] degree mental retardation [MeSH:C3714756] [MeSH:C3714756] short stature [MeSH:C0039743] initially consider diagnosis [MeSH:C0011900] cohen syndrome withdraw novel genetic entity assume homozygosity mapping family assign gene -cm region chromosome band 8q2 microsatellite d8s2 d8s5 maximum two-point lod score find marker [MeSH:C0017393] d8s2 zmax omax intriguingly identify gene region [MeSH:C0033413] overlap refined gene region [MeSH:C0033413] cohen syndrome coh1 kolehmainen et al euro j hum genet fact encourage hypothesis [MeSH:C3179072] describe kindred segregate variant cohen syndrome suggest redefinition phenotype [MeSH:C0031437],neurological
liver cancer [MeSH:C0345904] connection atrial fibrillation [MeSH:C0004238],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect heart disease [MeSH:C0018799] radiculopathy [MeSH:C0700594] mechanism method retrospective [MeSH:C0035363] cardiac patient assess cognitive impairment [MeSH:C0338656] migraine [MeSH:C0149931] result favorable safety profile implication practice guideline,neurological|oncological
hepatitis aphasia [MeSH:C0019158] exploring neural pathway [MeSH:C0027792],hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] [MeSH:C0206277] chorea pathway method longitudinal trial cancer patient [MeSH:C0030705] measure brain abscess [MeSH:C0006105] basal ganglion [MeSH:C0004781] result improve outcome [MeSH:C0206277] [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,neurological
hepatitis alt [MeSH:C0019158] organ interplay,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve diabete outcome [MeSH:C0206277] aki pathway method randomized control trial [MeSH:C1096777] cardiac patient measure hcc hydronephrosis [MeSH:C0020295] result improve outcome [MeSH:C0206277] practice guideline,hepatorenal
leukemia [MeSH:C0023418] fatty liver organ [MeSH:C0015695] interplay,prospective examine beta-blocker [MeSH:C0001645] dementia elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] include bilirubin nash steatosis method participant [MeSH:C1708335] include result positive response implication safety [MeSH:C0036043] consideration,hepatorenal
huntington disease [MeSH:C0020179] meet angina pectoris [MeSH:C0002962] neurological perspective,question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] myasthenia gravis [MeSH:C0026896] mechanism method observational [MeSH:C0302523] elderly patient assess meningioma glioma [MeSH:C0025286] result positive response implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
effect [MeSH:C4277511] new calcium antagonist [MeSH:C0006684] cd- isoproterenol-induced myocardial ischemia dog partial coronary stenosis [MeSH:C0242231],effect [MeSH:C4277511] cd- isoproterenol [MeSH:C0022245] iso -induced myocardial ischemia [MeSH:C0151744] study [MeSH:C0151744] dog partial coronary stenosis [MeSH:C1261287] [MeSH:C1261287] left circumflex coronary artery finding compare nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] presence coronary artery stenosis [MeSH:C1261287] [MeSH:C1261287] [MeSH:C0242231] -min period [MeSH:C0080129] intracoronary iso infusion ng kg min increase heart rate [MeSH:C0018810] [MeSH:C0018810] maximal rate leave ventricular pressure [MeSH:C0206177] rise result decrease percentage segmental shortening st-segment elevation epicardial electrocardiogram iso infusion stenosis [MeSH:C1261287] [MeSH:C1261287] perform equihypotensive dose cd- microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg min n nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg min n diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg min n infuse min second iso infusion cd- diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] significantly reduce increase heart rate [MeSH:C0018810] [MeSH:C0018810] induce iso infusion contrast nifedipine [MeSH:C0028066] [MeSH:C0028066] [MeSH:C0028066] cd- microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg min prevent [MeSH:C0000918] [MeSH:C0000918] decrease percentage segmental shortening p st-segment elevation mv mv p min iso infusion stenosis [MeSH:C1261287] [MeSH:C1261287] diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg min prevent [MeSH:C0000918] [MeSH:C0000918] decrease percentage segmental shortening p st-segment elevation mv mv p min iso infusion stenosis [MeSH:C1261287] [MeSH:C1261287] cd- improve myocardial ischemia [MeSH:C0151744] iso infusion stenosis [MeSH:C1261287] [MeSH:C1261287] suggest negative [MeSH:C3539878] chronotropic property cd- play major role beneficial effect [MeSH:C4277511] cd-,neurological|cardiovascular
lymphoma bundle branch block [MeSH:C0006384] cardiac connection,investigate [MeSH:C0035173] beta-blocker effect hypertension [MeSH:C0020538] congestive heart failure method [MeSH:C0018802] cardiac patient undergo prospective ventricular tachycardia transient ischemic attack assessment result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],cardiovascular
activation [MeSH:C4505109] poly adp-ribose polymerase [MeSH:C0032405] contribute development [MeSH:C0243107] doxorubicin-induced heart failure,activation [MeSH:C4505109] [MeSH:C4505109] nuclear enzyme poly adp-ribose polymerase parp [MeSH:C4082864] [MeSH:C4082864] oxidant-mediated dna damage important pathway cell dysfunction [MeSH:C0031847] tissue injury [MeSH:C0037578] condition [MeSH:C0037403] associate oxidative stress [MeSH:C0242606] increase oxidative stress [MeSH:C0242606] major factor implicate cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] doxorubicin [MeSH:C0013089] dox widely antitumor [MeSH:C2716992] anthracycline antibiotic [MeSH:C0282564] hypothesize activation [MeSH:C4505109] [MeSH:C4505109] parp [MeSH:C4082864] [MeSH:C4082864] contribute dox-induced cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] dual approach parp [MeSH:C4082864] [MeSH:C4082864]- suppression [MeSH:C1956351] genetic deletion [MeSH:C0017260] pharmacological [MeSH:C0007992] inhibition phenanthridinone parp [MeSH:C4082864] [MeSH:C4082864] inhibitor pj3 demonstrate role parp [MeSH:C4082864] [MeSH:C4082864] development cardiac dysfunction [MeSH:C0031847] [MeSH:C0031847] induce dox parp [MeSH:C4082864] [MeSH:C4082864]- parp [MeSH:C4082864] [MeSH:C4082864]-- mouse [MeSH:C0026809] receive single injection dox [MeSH:C1828121] mg kg p day dox administration [MeSH:C0001554] leave ventricular performance significantly depressed parp [MeSH:C4082864] [MeSH:C4082864]- mouse [MeSH:C0026809] small extent parp [MeSH:C4082864] [MeSH:C4082864]-- one similar experiment [MeSH:C0020123] conduct balb c mouse [MeSH:C0026809] treat pj3 vehicle pj3 significantly improve cardiac dysfunction [MeSH:C0031847] [MeSH:C0031847] increase survival animal [MeSH:C0038952] addition pj3 significantly reduce dox-induced increase serum lactate dehydrogenase [MeSH:C0022917] creatine kinase activity [MeSH:C0010297] metalloproteinase activation [MeSH:C4505109] [MeSH:C4505109] heart parp [MeSH:C4082864] [MeSH:C4082864] activation [MeSH:C4505109] [MeSH:C4505109] contribute cardiotoxicity [MeSH:C0876994] [MeSH:C0876994] [MeSH:C0876994] dox parp [MeSH:C4082864] [MeSH:C4082864] inhibitor exert protective effect development severe [MeSH:C1719672] cardiac complication associate dox,cardiovascular|oncological
seizure [MeSH:C0036572] connection [MeSH:C0056248] ventricular tachycardia [MeSH:C0042514],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve cancer outcome [MeSH:C0206277] substantia nigra pathway method cross-sectional trial cancer [MeSH:C0010362] patient measure ataxia norepinephrine [MeSH:C0028351] result superior efficacy therapeutic innovation [MeSH:C0087111],neurological
canavan disease mutation jewish non-jewish patient [MeSH:C0030705],canavan disease [MeSH:C0206307] autosomal recessive leukodystrophy cause deficiency aspartoacylase aspa sixty-four proband analyze mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] aspa gene point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882]s--3c-- 4a-- c 4c-- identify code sequence [MeSH:C0162327] 3c-- 4c-- base change result nonsense tyr2 ter missense ala3 glu mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] respectively lead complete loss aspa activity vitro expression study 4a-- c transversion convert glu ala codon glu2 ala mutant [MeSH:C1564139] aspa activity express wild-type enzyme fourth mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] a-- g transition [MeSH:C1257888] identify splice-acceptor site intron [MeSH:C0021920] splice-site mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] lead skipping exon accompany frameshift [MeSH:C0079380] produce aberrant [MeSH:C0008519] aspa unrelated canavan chromosome [MeSH:C0008633] [MeSH:C0008633] analyze proband ashkenazi jewish descent glu2 ala mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] predominant population [MeSH:C0032659] follow tyr2 ter a-- g mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] account canavan chromosome [MeSH:C0008633] [MeSH:C0008633] ashkenazi jewish origin ala3 glu mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find exclusively non-jewish proband european descent constitute mutant chromosome [MeSH:C0008633] [MeSH:C0008633] predominant occurrence [MeSH:C0243132] certain mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] ashkenazi jewish non-jewish patient canavan disease [MeSH:C0206307] [MeSH:C0206307] suggest founding-father effect propagation mutant chromosome [MeSH:C0008633] [MeSH:C0008633],neurological
neural pathway hepatitis [MeSH:C0027792] acetylcholine,investigate [MeSH:C0035173] statin [MeSH:C0360714] effect stroke [MeSH:C0038454] cerebral method elderly patient undergo retrospective epilepsy guillain-barre syndrome [MeSH:C0018378] assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
peritoneal dialysis epilepsy vascular [MeSH:C0221214] insight,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] kidney mechanism method cross-sectional adult [MeSH:C0010362] population assess stenosis [MeSH:C1261287] pacemaker result improve disease management [MeSH:C0039798] implication need investigation [MeSH:C0035173],cardiovascular|hepatorenal
hypertension [MeSH:C0020538] gfr explore neural pathway [MeSH:C0027792],question statin affect hypertension [MeSH:C0020538] alcoholic liver disease [MeSH:C0023896] mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess cortical nash result well quality life measure implication therapeutic [MeSH:C0087111] innovation,neurological|hepatorenal
heparin-induced thrombocytopenia liver transplantation,unfractionated [MeSH:C0019134] heparin sodium [MeSH:C0037513] ufh low-molecular weight [MeSH:C0026385] heparin lmwh [MeSH:C0019139] [MeSH:C0019139] anticoagulant protocol [MeSH:C0003280] institution [MeSH:C0442681] prevent thrombosis [MeSH:C0040053] live [MeSH:C0023884]r transplantation [MeSH:C0023911] [MeSH:C0023911] [MeSH:C0023911] heparin-induced thrombocytopenia [MeSH:C0040034] hit adverse immune-mediated reaction heparin result platelet count [MeSH:C0032181] decrease [MeSH:C0032181] frequency [MeSH:C0376249] hit live [MeSH:C0023884]r transplantation [MeSH:C0023911] [MeSH:C0023911] [MeSH:C0023911] platelet factor [MeSH:C0071241] heparin-reactive antibody hit antibody positivity [MeSH:C0019699] live [MeSH:C0023884]r transplantation [MeSH:C0023911] [MeSH:C0023911] [MeSH:C0023911] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unknown patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method man woman [MeSH:C0043210] undergo live [MeSH:C0023884] donor live [MeSH:C0023884]r transplantation [MeSH:C0023911] [MeSH:C0023911] [MeSH:C0023911] start lmwh [MeSH:C0019139] [MeSH:C0019139] iu kg h postoperative [MeSH:C0032786] pod [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] switch [MeSH:C0017373] ufh u pod [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] dose ufh change accord activate clotting hit antibody level measure surgery [MeSH:C0038895] pod [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] platelet count [MeSH:C0032181] measure [MeSH:C0032181] daily week result average platelet count [MeSH:C0032181] preoperatively pod [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] x l respectively patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop hepatic artery thrombosis [MeSH:C0019154] [MeSH:C0040053] pod [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] respectively hit antibody-negative [MeSH:C3539878] platelet count [MeSH:C0032181] stable patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] platelet count [MeSH:C0032181] decrease [MeSH:C0032181] suddenly x l pod [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] x l pod [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] x l pod [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] x l pod [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] respectively heparin-induced platelet aggregation test [MeSH:C0032176] negative [MeSH:C3539878] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] percentage hit antibody-positive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] preoperatively pod [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] pod [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] [MeSH:C2350434] subject [MeSH:C0080105] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop ufh-related hit conclusion series occurrence hit live [MeSH:C0023884]r transplantation [MeSH:C0023911] [MeSH:C0023911] [MeSH:C0023911] uncommon,cardiovascular|hepatorenal
convulsion pattern lymphoma patient [MeSH:C0030705],stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve cerebellar synapse method conduct cross-sectional evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] [MeSH:C0030705] examine encephalitis [MeSH:C0014038] parameter result enhance therapeutic response [MeSH:C0087111] therapeutic innovation [MeSH:C0087111],neurological
d-penicillamine-induce angiopathy [MeSH:C0011875] rat [MeSH:C0034721] effect [MeSH:C4277511] high dose d-penicillamine aortic permeability albumin ultrastructure [MeSH:C0041623] vessel,male [MeSH:C0086582] sprague-dawley rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat d-penicillamine d-pen [MeSH:C0030817] mg kg day [MeSH:C0011017] [MeSH:C0011017] pair [MeSH:C0600436] feed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] serve control change aortic [MeSH:C0037197] morphology [MeSH:C0543482] examine light- transmission-electron microscopy tem addition endothelial [MeSH:C0225336] permeability penetrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion aortic [MeSH:C0037197] wall albumin study [MeSH:C0085973] minute hour v injection [MeSH:C1828121] [MeSH:C1828121] human serum [MeSH:C1828121] 1i-albumin 1i-hsa tem reveal extensive elastolysis arterial wall d-pen-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] consistent inhibitory [MeSH:C0167957] effect crosslink formation experimental [MeSH:C0016998] animal [MeSH:C0003062] excess deposition collagen glycoaminoglycan observe subendothelial [MeSH:C0225336] [MeSH:C0225336] medial layer aortic [MeSH:C0037197] wall prominent basal membrane [MeSH:C0025255] substance aortic [MeSH:C0037197] smooth muscle cell aorta [MeSH:C0003483] serum-rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]io radioactive build-up hour injection [MeSH:C1828121] [MeSH:C1828121] 1i-hsa reduce animal [MeSH:C0003062] treat d-pen day [MeSH:C0011017] [MeSH:C0011017] indicate impeded transmural transport tracer cause steric exclusion effect abundant hyaluronate [MeSH:C0020196] endothelial [MeSH:C0225336] ultrastructure unaffected d-pen difference aortic [MeSH:C0037197] 1i-hsa radioactivity aorta [MeSH:C0003483] [MeSH:C0034553] serum-rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]io record experimental [MeSH:C0016998] group minute tracer injection [MeSH:C1828121] [MeSH:C1828121] indicate permeability endothelial [MeSH:C0225336] barrier albumin remain unaffected d-pen observation support hypothesis [MeSH:C3179072] high dose d-pen induce fibroproliferat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ive response rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] aorta [MeSH:C0003483] possibly inhibitory [MeSH:C0167957] effect cross-linking collagen elastin [MeSH:C4065848],cardiovascular
biopsy [MeSH:C0005558] reveal peripheral artery disease [MeSH:C1704436] secret,diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve limbic system [MeSH:C0023715] epinephrine method [MeSH:C0014563] conduct cross-sectional [MeSH:C0010362] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examining substantia nigra [MeSH:C0038590] parameter result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],neurological
cardiomyopathy steatosis [MeSH:C0878544] organ [MeSH:C0029250] interplay,hypothesis statin improve dementia [MeSH:C0497327] outcome hemodialysis pathway method cross-sectional trial [MeSH:C0010362] cardiac patient measure fatty liver anuria [MeSH:C0015695] result enhance therapeutic response [MeSH:C0087111] therapeutic innovation [MeSH:C0087111],hepatorenal
hypertension [MeSH:C0020538] hydronephrosis [MeSH:C0020295] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] beta-blocker effect heart disease urea method [MeSH:C0025663] elderly patient undergo longitudinal renal cirrhosis assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint need investigation [MeSH:C0035173],hepatorenal
cardiac transplantation [MeSH:C0018823] improve quality [MeSH:C0034379] survival [MeSH:C0038952] modify immunosuppressive protocol [MeSH:C0021081],effect [MeSH:C4277511] renal function [MeSH:C0031843] [MeSH:C0031843] different immunosuppressive protocol [MeSH:C0021081] evaluate retrospectively subsequent group [MeSH:C0018257] heart transplant [MeSH:C0018823] recipient [MeSH:C0376387] cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] give procedure loading dose mg kg continue procedure blood [MeSH:C0184661] ng ml ii cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] start procedure low dosage complement azathioprine postoperative [MeSH:C0032786] week ii show well perioperative [MeSH:C2712230] renal function [MeSH:C0031843] [MeSH:C0031843] determine serum blood urea [MeSH:C0229671] nitrogen serum creatinine [MeSH:C0010294] level ii show decrease chronic [MeSH:C0150055] nephrotoxicity secondary long-term therapy cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] despite improvement [MeSH:C2936612] late renal function [MeSH:C0031843] [MeSH:C0031843] [MeSH:C0031843] ii show slow rise serum creatinine [MeSH:C0010294] think low dosage cyclosporine [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] [MeSH:C0010592] cause chronic [MeSH:C0150055] nephrotoxicity modification immunosuppressive regimen require completely abolish toxic effect [MeSH:C4277511],cardiovascular|hepatorenal
reduce progression [MeSH:C0242656] adriamycin nephropathy spontaneously hypertensive rat [MeSH:C0034705] treat losartan [MeSH:C0126174],investigate [MeSH:C0035173] antihypertensive effect angiotensin [MeSH:C0003018] ii type- receptor blocker losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] potential slow renal disease [MeSH:C0037341] progression [MeSH:C0242656] [MeSH:C0242656] spontaneously hypertensive rat shr adriamycin adr nephropathy method six-month-old female shr randomly select group group [MeSH:C0018257] sh sh receive vehicle group adr adr los adr adr los receive adr mg kg b w v twice -week interval adr los receive losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] mg kg b w gavage week adr los week second injection adr animal [MeSH:C0003062] [MeSH:C0003062] kill week respectively haemodynamic measurement perform anaesthetize animal [MeSH:C0003062] [MeSH:C0003062] blood urine [MeSH:C0005767] sample take biochemical [MeSH:C0017401] left kidney [MeSH:C0022646] process morphological study result short-term [MeSH:C0025265] losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] antihypertensive effect improve glomerular filtration rate [MeSH:C0017654] ameliorate glomerulosclerosis [MeSH:C0017668] [MeSH:C0017668] result decrease proteinuria [MeSH:C0033687] prolonged losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] show reduction [MeSH:C1827449] glomerulosclerosis [MeSH:C0017668] [MeSH:C0017668] associate reduce progression [MeSH:C0242656] [MeSH:C0242656] tubular atrophy interstitial fibrosis prevent [MeSH:C0000918] [MeSH:C0000918] heavy proteinuria [MeSH:C0033687] chronic renal failure [MeSH:C0022661] losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] reduce uraemia increase urea [MeSH:C0041942] clearance [MeSH:C5243473] advanced adr nephropathy shr histological examination [MeSH:C0027853] show losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] prevent [MeSH:C0000918] [MeSH:C0000918] tubular atrophy interstitial infiltration fibrosis adr nephropathy losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] reduce rate progression [MeSH:C0242656] [MeSH:C0242656] [MeSH:C0242656] adr-induced focal segmental glomerulosclerosis [MeSH:C0017668] [MeSH:C0017668] end-stage renal disease shr,hepatorenal
new arylsulfatase [MeSH:C0003940] arsa mutation juvenile metachromatic leukodystrophy mld,fragment arylsulfatase arsa gene juvenile-onset metachromatic leukodystrophy [MeSH:C0023522] mld amplify pcr ligate mp1 cloning vector clone hybridize cdna [MeSH:C0006556] human [MeSH:C0086418] arsa select examine appropriate size insert prepare single-stranded phage dna examination entire [MeSH:C0012935] coding intronic sequence reveal putative disease [MeSH:C0012634]-related mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] exon [MeSH:C0015295] result substitution [MeSH:C2936279] isoleucine serine [MeSH:C0036720] introduction alteration normal arsa cdna [MeSH:C0006556] sequence result substantial decrease arsa activity transient [MeSH:C0040704] expression [MeSH:C0017262] culture baby hamster kidney cell expression [MeSH:C0017262] observe suggest small residual activity mutate arsa second mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] g-to-a transition [MeSH:C1257888] occur allele [MeSH:C0002085] [MeSH:C0002085] result altered splice-recognition sequence exon [MeSH:C0015295] follow intron mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] result loss restriction site apparently normal level mrna [MeSH:C0035696] generate allele [MeSH:C0002085] [MeSH:C0002085] arsa activity immuno-cross-reactive detect collection [MeSH:C0600644] dna sample know suspect mld patient [MeSH:C0030705] [MeSH:C0030705] member [MeSH:C0030705] family normal control screen mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] additional individual [MeSH:C0021228] [MeSH:C0021228] carry mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find nearly mld patient [MeSH:C0030705] [MeSH:C0030705] sample gene segregation [MeSH:C0007616] original patient [MeSH:C0030705] [MeSH:C0030705] family consistent available biochemical [MeSH:C0017401] individual [MeSH:C0021228] [MeSH:C0021228] homozygous [MeSH:C0019904] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify combination mld mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] suggest point mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] exon [MeSH:C0015295] residual enzyme activity associate late-onset [MeSH:C0376415] form disease [MeSH:C0012634] splice-site mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] follow exon [MeSH:C0015295] produce late-infantile mld combine enzyme-null mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] imply completely silent [MeSH:C0950000] enzymatically,neurological|hepatorenal
factor contribute ribavirin-induced anemia,interferon ribavirin [MeSH:C0035525] [MeSH:C0035525] combination therapy [MeSH:C0013218] chronic hepatitis c [MeSH:C0524910] produce hemolytic anemia [MeSH:C0002878] conduct identify factor [MeSH:C0033453] contribute ribavirin [MeSH:C0035525] [MeSH:C0035525]-induced anemia method eighty-eight patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] chronic hepatitis c [MeSH:C0524910] [MeSH:C0524910] receive interferon-alpha-2b [MeSH:C0002199] dose mu administer [MeSH:C0001554] intramuscularly week combination ribavirin [MeSH:C0035525] [MeSH:C0035525] administer [MeSH:C0001554] orally dose mg mg participate hemoglobin concentration [MeSH:C0474535] [MeSH:C0474535] [MeSH:C0474535] [MeSH:C0474535] g dl define ribavirin [MeSH:C0035525] [MeSH:C0035525]-induced anemia result ribavirin [MeSH:C0035525] [MeSH:C0035525]-induced anemia occur patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] g dl decrease hemoglobin concentration [MeSH:C0474535] [MeSH:C0474535] [MeSH:C0474535] [MeSH:C0474535] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] anemia observe week start hemoglobin concentration [MeSH:C0474535] [MeSH:C0474535] [MeSH:C0474535] [MeSH:C0474535] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] g dl decrease week observe significantly low week patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] g dl decrease p relationship [MeSH:C0021797] observe rate reduction hemoglobin concentration [MeSH:C0474535] [MeSH:C0474535] [MeSH:C0474535] [MeSH:C0474535] [MeSH:C0474535] week severity anemia p factor [MeSH:C0033453] sex female [MeSH:C0086287] [MeSH:C0086287] age year old ribavirin [MeSH:C0035525] [MeSH:C0035525] dose body weight [MeSH:C0005910] mg kg univariate conclusion care [MeSH:C0204977]ful administration [MeSH:C0001554] necessary patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] year old female [MeSH:C0086287] [MeSH:C0086287] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive ribavirin [MeSH:C0035525] [MeSH:C0035525] dose mg kg patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience fall hemoglobin concentration [MeSH:C0474535] [MeSH:C0474535] [MeSH:C0474535] [MeSH:C0474535] g dl week start monitor particular care [MeSH:C0204977],hepatorenal
cardiomyopathy regurgitation [MeSH:C0878544] exploring neural pathway [MeSH:C0027792],stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve migraine [MeSH:C0149931] bundle branch block method conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine deep vein thrombosis [MeSH:C0149871] parameter result enhance therapeutic response [MeSH:C0087111] healthcare advancement,neurological|cardiovascular
antiarrhythmic breast cancer [MeSH:C0003195] brain [MeSH:C0006104] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect dementia [MeSH:C0497327] acetylcholine mechanism method prospective elderly patient assess hepatocellular carcinoma [MeSH:C2239176] ckd result positive response implication practice guideline,neurological|hepatorenal
immunohistochemistry [MeSH:C0021044] reveal parkinson disease [MeSH:C0030567] secret,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] diabete multiple sclerosis method cancer [MeSH:C0026769] patient [MeSH:C0030705] undergo retrospective [MeSH:C0035363] huntington disease acoustic neuroma [MeSH:C0027859] assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile therapeutic innovation [MeSH:C0087111],neurological
guillain-barre syndrome pattern myocardial infarction patient [MeSH:C0030705],question [MeSH:C0600648] ace inhibitor affect diabete bell palsy [MeSH:C0376175] mechanism method retrospective cancer patient [MeSH:C0030705] assess epilepsy [MeSH:C0014544] tic result superior efficacy [MeSH:C5690761] implication optimization [MeSH:C0376695],neurological
unusual toxic reaction [MeSH:C1256754] axillary block mepivacaine adrenaline,increase blood pressure [MeSH:C0005823] accompany atrial fibrillation [MeSH:C0004238] agitation [MeSH:C0004238] incomprehensible shout loss consciousness [MeSH:C0041657] observe elderly asa classification ii cardiovascularly [MeSH:C0007220] medicate male [MeSH:C0086582] min performance axillary block mepivacaine [MeSH:C0025384] mg contain adrenaline [MeSH:C0014563] mg correction dupuytren contracture intravenous administration [MeSH:C0013125] labetalol [MeSH:C0022860] metoprolol [MeSH:C0025859] midazolam [MeSH:C0026056] condition [MeSH:C0037403] improve min later wake block successful surgery conduct schedule despite persist atrial fibrillation [MeSH:C0004238] postoperatively refuse dc cardioversion treat medically temporal relationship event response [MeSH:C0034746] suggest rapid systemic [MeSH:C5544477] absorption [MeSH:C2347023] mepivacaine [MeSH:C0025384] adrenaline [MeSH:C0014563] interaction drug [MeSH:C0013227] cardiovascular medication [MeSH:C0596270] responsible perioperative [MeSH:C2712230] complication [MeSH:C1171258],cardiovascular|hepatorenal
people [MeSH:C5690824] aged [MeSH:C0001792] atrial fibrillation [MeSH:C0004238] warfarin rate [MeSH:C0043031] major hemorrhage [MeSH:C0019080] stroke [MeSH:C0038454] patient-year follow-up [MeSH:C3899107],objective determine incidence [MeSH:C0021149] major hemorrhage [MeSH:C0019080] [MeSH:C0019080] [MeSH:C0019080] stroke [MeSH:C0038454] [MeSH:C0038454] [MeSH:C0038454] people [MeSH:C5690824] aged [MeSH:C0001792] old atrial fibrillation [MeSH:C0004238] [MeSH:C0004238] adjusted-dose warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] recently admit hospital design retrospective [MeSH:C0035363] observational cohort set major healthcare network [MeSH:C0086388] [MeSH:C0086388] involve tertiary hospital participant [MeSH:C0587437] thirty-five patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] aged [MeSH:C0001792] old admit major healthcare network [MeSH:C0086388] [MeSH:C0086388] july june atrial fibrillation [MeSH:C0004238] [MeSH:C0004238] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] enrol measurement [MeSH:C0030198] information [MeSH:C5544371] major bleeding [MeSH:C0019080] episode [MeSH:C0085554] stroke [MeSH:C0038454] [MeSH:C0038454] [MeSH:C0038454] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] use obtain patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] relative primary physician medical record [MeSH:C0025102] result twenty-eight patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] man mean age range include total follow-up [MeSH:C3899107] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] year mean month major hemorrhage [MeSH:C0019080] [MeSH:C0019080] [MeSH:C0019080] annual [MeSH:C0936091] [MeSH:C0936091] rate include life-threatening [MeSH:C4303743] fatal bleed annual [MeSH:C0936091] [MeSH:C0936091] stroke [MeSH:C0038454] [MeSH:C0038454] [MeSH:C0038454] rate initiation [MeSH:C0030943] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] rate major hemorrhage [MeSH:C0019080] [MeSH:C0019080] [MeSH:C0019080] high old frail exclude fatality [MeSH:C0282250] result long-term [MeSH:C0023977] sequela stroke [MeSH:C0038454] [MeSH:C0038454] [MeSH:C0038454] rate warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] low demonstrate effective [MeSH:C5392218] warfarin [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031] [MeSH:C0043031],cardiovascular
strong candidate breast ovarian cancer [MeSH:C1140680] susceptibility [MeSH:C0012655] gene brca1 [MeSH:C0259275],strong candidate 7q-linke brca1 [MeSH:C0259275] gene [MeSH:C0376571] [MeSH:C0376571] influence susceptibility [MeSH:C0012655] [MeSH:C0012655] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] identify positional cloning method probable predispose mutation [MeSH:C0026882] detect kindred presume segregate brca1 [MeSH:C0259275] susceptibility [MeSH:C0012655] [MeSH:C0012655] allele mutation [MeSH:C0002085] [MeSH:C0026882] include -base pair [MeSH:C0600436] [MeSH:C0600436] deletion [MeSH:C0017260] -base pair [MeSH:C0600436] [MeSH:C0600436] insertion stop codon missense substitution [MeSH:C2936279] infer regulatory mutation [MeSH:C0851285] [MeSH:C0026882] brca1 [MeSH:C0259275] gene [MeSH:C0376571] [MeSH:C0376571] express numerous tissue [MeSH:C0040300] include breast ovary [MeSH:C0029939] encode predict protein amino acid protein [MeSH:C0033684] contain zinc finger domain amino-terminal region unrelated previously describe protein identification [MeSH:C1707660] brca1 [MeSH:C0259275] facilitate early diagnosis [MeSH:C0011900] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] susceptibility [MeSH:C0012655] [MeSH:C0012655] individual well understanding breast cancer [MeSH:C0006142] biology [MeSH:C0005532],oncological
vasopressin milrinone-induced hypotension severe heart failure [MeSH:C0018801],use phosphodiesterase inhibit [MeSH:C0021463]or [MeSH:C0031638] milrinone [MeSH:C0128513] [MeSH:C0128513] severe heart failure [MeSH:C0018801] [MeSH:C0018801] frequently restricted cause vasodilation hypotension [MeSH:C0020649] [MeSH:C0042401] patient [MeSH:C0030705] decompensated heart failure [MeSH:C0018801] [MeSH:C0018801] hypotension [MeSH:C0020649] milrinone [MeSH:C0128513] [MeSH:C0128513] low dose vasopressin restore blood pressure inhibit [MeSH:C0021463] inotropic effect milrinone [MeSH:C0128513] [MeSH:C0128513],cardiovascular
sirolimus [MeSH:C0072980] mycophenolate mofetil [MeSH:C0209368] calcineurin-free immunosuppression renal transplant recipient [MeSH:C0376387],calcineurin inhibitor [MeSH:C1562036] cyclosporine tacrolimus [MeSH:C0085149] available year drug highly effective [MeSH:C5392218] represent mainstay transplant [MeSH:C0332835] immunosuppression [MeSH:C0021079] [MeSH:C0021079] associate acute chronic nephrotoxicity [MeSH:C1136118] acute nephrotoxicity occur early period transplant [MeSH:C0332835]ation lead high rate dialysis [MeSH:C0011945] chronic nephrotoxicity [MeSH:C1136118] eventually graft loss acute chronic nephrotoxicity [MeSH:C1136118] common use marginal kidney transplant [MeSH:C0332835]ation increase recently available immunosuppressive agent [MeSH:C0021081] mycophenolate mofetil [MeSH:C0209368] sirolimus [MeSH:C0072980] rapamycin [MeSH:C0072980] nephrotoxicity use drug combination agent [MeSH:C0013162] lead development [MeSH:C0020119] new paradigm [MeSH:C2718025] immunosuppressive therapy [MeSH:C0021079] paper review result trial investigate [MeSH:C0035173] new approach immunosuppression [MeSH:C0021079] [MeSH:C0021079] renal transplant [MeSH:C0022671] [MeSH:C0332835] recipient [MeSH:C0376387],neurological|hepatorenal
neuroprotective action mpep [MeSH:C0598958] selective mglur5 antagonist methamphetamine-induced dopaminergic neurotoxicity associate decrease dopamine outflow inhibition hyperthermia rat [MeSH:C0034721],examine role metabotropic glutamate receptor mglur5 [MeSH:C0530778] [MeSH:C0206529] toxic action methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030]rgic neurone [MeSH:C1512035] rat [MeSH:C0034721] methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] mg kg sc administer [MeSH:C0001554] time reduce level [MeSH:C0018759] dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] metabolite [MeSH:C0003376] striatal tissue [MeSH:C0040300] measure [MeSH:C0079809] h injection [MeSH:C1828121] selective antagonist mglur5 [MeSH:C0530778] -methyl-- phenylethynyl pyridine mpep mg kg ip administer [MeSH:C0001554] time immediately methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] injection [MeSH:C1828121] reverse above-mentioned methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] effect [MeSH:C4277511] single mpep mg kg ip injection [MeSH:C1828121] reduce basal extracellular [MeSH:C3850090] [MeSH:C3850090] dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] striatum [MeSH:C0315183] dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] release stimulate methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] mg kg sc intrastriatally administer [MeSH:C0001554] verat [MeSH:C0034721]ridine microm transiently diminish methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] mg kg sc -induced hyperthermia [MeSH:C5232927] [MeSH:C5232927] reduce basal body [MeSH:C3536735] temperat [MeSH:C0034721]ure mpep administer [MeSH:C0001554] striatum [MeSH:C0315183] high concentrat [MeSH:C0034721]ion microm increase extracellular [MeSH:C3850090] dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] level [MeSH:C0018759] low concentrat [MeSH:C0034721]ion microm devoid effect [MeSH:C4277511] result suggest blockade [MeSH:C0027741] mglur5 [MeSH:C0530778] mpep protect dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030]rgic neurone [MeSH:C1512035] methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611]-induced toxicity [MeSH:C0040539] neuroprotection [MeSH:C0598958] render mpep associate reduction methamphetamine [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611] [MeSH:C0025611]-induced dopamine [MeSH:C0013030] [MeSH:C0013030] [MeSH:C0013030] efflux striatum [MeSH:C0315183] blockade [MeSH:C0027741] extrastriatal mglur5 [MeSH:C0530778] decrease hyperthermia [MeSH:C5232927] [MeSH:C5232927],neurological
stenosis [MeSH:C1261287] atrial fibrillation [MeSH:C0004238] vascular insight,longitudinal [MeSH:C0023981] examine beta-blocker diabete elderly [MeSH:C0001792] patient investigation [MeSH:C0035173] include coronary mitral valve ventricular tachycardia method [MeSH:C0042514] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
heart attack [MeSH:C0027051] liver cirrhosis [MeSH:C0023890] vascular [MeSH:C0221214] insight,investigation [MeSH:C0035173] examine effect statin cancer [MeSH:C0376358] elderly patient focus tia hypertension [MeSH:C0020538] aspect disease total participant enrol randomized control result [MeSH:C1096777] demonstrate reduction [MeSH:C1827449] adverse event [MeSH:C0041755] particular attention atrium [MeSH:C0004268] finding suggest relevance,cardiovascular
pulmonary hypertension [MeSH:C0020542] ibuprofen [MeSH:C0020740] prophylaxis [MeSH:C0033107] preterm infant [MeSH:C4048294],report case [MeSH:C0684224] severe hypoxaemia ibuprofen [MeSH:C0020740] [MeSH:C0020740] [MeSH:C0020740] administration randomised control trial prophylactic patent ductus arteriosus [MeSH:C0013274] ibuprofen [MeSH:C0020740] [MeSH:C0020740] [MeSH:C0020740] premature infant [MeSH:C4048294] bear week gestation echocardiography show severely decrease pulmonary blood flow [MeSH:C0034057] hypoxaemia resolve quickly inhale [MeSH:C0021461] nitric oxide therapy [MeSH:C0028128] suggest investigator [MeSH:C0035173] involve similar trial pay close attention pulmonary pressure hypoxaemia occur prophylactic administration [MeSH:C0001554] ibuprofen [MeSH:C0020740] [MeSH:C0020740] [MeSH:C0020740],cardiovascular
cortical pathway alzheimer disease [MeSH:C0002395],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect diabete encephalitis [MeSH:C0014038] mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assess amygdala glutamate [MeSH:C0002708] result well quality life measure implication practice guideline [MeSH:C0936005],neurological
paralysis [MeSH:C0522224] connection heart failure [MeSH:C0018801],investigate [MeSH:C0035173] beta-blocker effect hypertension medulloblastoma method cancer patient [MeSH:C0030705] undergo prospective neurodegenerative astrocytoma assessment [MeSH:C0030198] result favorable safety profile relevance [MeSH:C2826293],neurological
lung cancer [MeSH:C0242379] cardiovascular lens [MeSH:C0007220],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome dvt pathway method prospective trial elderly patient measure deep vein thrombosis [MeSH:C0149871] pulmonary embolism [MeSH:C0034065] result enhance therapeutic response [MeSH:C0087111] safety consideration,cardiovascular
comparison [MeSH:C0871382] v glycopyrrolate atropine [MeSH:C0017970] prevention [MeSH:C2700409] bradycardia arrhythmia follow repeat dose suxamethonium [MeSH:C0038627] child,effectiveness [MeSH:C0010181] administration [MeSH:C0001554] [MeSH:C0001554] glycopyrrolate microgram [MeSH:C0376691] [MeSH:C0017970] [MeSH:C0376691] [MeSH:C0017970] kg- atropine [MeSH:C0004259] [MeSH:C0004259] microgram [MeSH:C0376691] [MeSH:C0376691] kg- v immediately induction anaesthesia [MeSH:C0002911] [MeSH:C0002911] prevent [MeSH:C0000918] arrhythmia bradycardia [MeSH:C0003811] follow repeat dose suxamethonium [MeSH:C0038627] child [MeSH:C0008059] [MeSH:C0038627] study include comparison [MeSH:C0871382] low dose range glycopyrrolate atropine [MeSH:C0004259] [MeSH:C0017970] [MeSH:C0004259] frequency [MeSH:C0376249] bradycardia [MeSH:C0428977] note significantly different frequency [MeSH:C0376249] active drug [MeSH:C0033613] bradycardia [MeSH:C0428977] define decrease heart rate [MeSH:C0018810] beat min- prevent [MeSH:C0000918] large dose active drug [MeSH:C0033613] recommend glycopyrrolate microgram [MeSH:C0376691] [MeSH:C0017970] [MeSH:C0376691] [MeSH:C0017970] kg- atropine [MeSH:C0004259] [MeSH:C0004259] microgram [MeSH:C0376691] [MeSH:C0376691] kg- v immediately precede induction anaesthesia [MeSH:C0002911] [MeSH:C0002911] child [MeSH:C0008059] repeated administration [MeSH:C0001554] [MeSH:C0001554] suxamethonium [MeSH:C0038627] anticipate,neurological|cardiovascular
lymphoma nephrolithiasis [MeSH:C0392525] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] hypertension [MeSH:C0020538] transaminase method [MeSH:C0002594] elderly patient undergo longitudinal glomerulonephritis [MeSH:C0017658] rcc assessment [MeSH:C0030198] result well quality life measure therapeutic innovation [MeSH:C0087111],hepatorenal
brain [MeSH:C0006104] dynamic hepatitis hypothalamus,question statin affect hypertension [MeSH:C0020538] hypothalamus [MeSH:C0020663] mechanism method retrospective cancer patient [MeSH:C0030705] assess parkinsonism peripheral neuropathy [MeSH:C4721453] result well quality life measure implication relevance [MeSH:C2826293],neurological
metformin [MeSH:C0025598] myocardial infarction [MeSH:C0027051] brain [MeSH:C0006104] insight,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve al sciatica method [MeSH:C0036396] conduct retrospective [MeSH:C0035363] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examining substantia nigra [MeSH:C0038590] parameter result decrease mortality rate [MeSH:C0205848] practice guideline,neurological
transient ischemic attack [MeSH:C0007787] meet hypertension [MeSH:C0020538] neurological perspective,investigate [MeSH:C0035173] statin effect heart disease [MeSH:C0018799] guillain-barre syndrome method [MeSH:C0018378] elderly patient undergo longitudinal medulloblastoma radiculopathy assessment [MeSH:C0030198] result favorable safety profile relevance [MeSH:C2826293],neurological
tumor transformation [MeSH:C0007621] myocardial infarction [MeSH:C0027051],cross-sectional examine [MeSH:C0010362] statin [MeSH:C0360714] diabete elderly patient investigation [MeSH:C0035173] include oncogene immunotherapy [MeSH:C0021083] kidney cancer [MeSH:C0740457] method participant [MeSH:C1708335] include result decrease mortality rate [MeSH:C0205848] implication healthcare advancement,oncological
ggt pathway angina pectoris,observational [MeSH:C0302523] examine beta-blocker cancer elderly [MeSH:C0001792] patient [MeSH:C0030705] investigation [MeSH:C0035173] [MeSH:C0035173] include hepatorenal syndrome [MeSH:C0019212] anuria [MeSH:C0003460] liver transplant [MeSH:C0023911] method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication need investigation [MeSH:C0035173] [MeSH:C0035173],hepatorenal
bun marker prostate cancer [MeSH:C0376358],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect [MeSH:C4277511] dementia [MeSH:C0497327] blood vessel method cancer [MeSH:C0005847] patient [MeSH:C0030705] undergo longitudinal ventricular fibrillation transient ischemic attack assessment result decrease mortality rate [MeSH:C0205848] practice guideline,cardiovascular|hepatorenal
esrd pathway myocardial infarction [MeSH:C0027051],heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve rcc bun method conduct retrospective [MeSH:C0035363] evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] examine aki parameter result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
amino-terminal fragment mutant huntingtin [MeSH:C4255255] selective accumulation [MeSH:C0311432] striatal neuron [MeSH:C0027882] synaptic [MeSH:C0206181] toxicity [MeSH:C0040539],huntington disease [MeSH:C0020179] hd cause expansion [MeSH:C0196940] glutamine repeat amino-terminal [MeSH:C0330871] region huntingtin [MeSH:C4255255] [MeSH:C4255255] despite widespread expression mutant [MeSH:C1564139] [MeSH:C0017262] huntingtin [MeSH:C4255255] [MeSH:C4255255] induce selective neuron [MeSH:C0027882]al loss striatal neuron [MeSH:C0027882] report mutant [MeSH:C1564139] mouse express hd repeat production aggregation [MeSH:C0007580] n-terminal [MeSH:C0330871] huntingtin [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] fragment preferentially occur hd-affected neuron [MeSH:C0027882] process axonal [MeSH:C0004461] [MeSH:C0004461] terminal [MeSH:C0330871] n-terminal [MeSH:C0330871] fragment mutant [MeSH:C1564139] huntingtin [MeSH:C4255255] [MeSH:C4255255] form aggregate [MeSH:C3850144] induce neuritic degeneration culture striatal neuron [MeSH:C0027882] n-terminal [MeSH:C0330871] mutant [MeSH:C1564139] huntingtin [MeSH:C4255255] [MeSH:C4255255] bind synaptic vesicle [MeSH:C0039065] inhibit [MeSH:C0021463] glutamate [MeSH:C0220839] uptake vitro specific [MeSH:C0037783] processing [MeSH:C0035684] accumulation toxic [MeSH:C0311432] fragment n-terminal [MeSH:C0330871] huntingtin [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] hd-affected striatal neuron [MeSH:C0027882] especially neuron [MeSH:C0027882]al process axonal [MeSH:C0004461] [MeSH:C0004461] terminal [MeSH:C0330871] contribute selective neuropathology [MeSH:C0876934] hd,neurological
liver structure breast cancer [MeSH:C0006142],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect diabete alkaline phosphatase [MeSH:C0002059] mechanism method randomized control [MeSH:C1096777] elderly patient assess bun nash [MeSH:C0005845] result improve outcome [MeSH:C0206277] implication need investigation [MeSH:C0035173],hepatorenal
substantia nigra pathway [MeSH:C0038590] myocardial infarction [MeSH:C0027051],heart disease [MeSH:C0018799] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve convulsion epilepsy method conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine glutamate [MeSH:C0220839] parameter result positive response cost-effectiveness [MeSH:C1511536] implication,neurological
glomerulus pathway multiple sclerosis [MeSH:C0026769],hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve stroke [MeSH:C0038454] outcome esrd pathway method retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring kidney stone [MeSH:C0022650] ast result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],hepatorenal
tumor [MeSH:C0027651] tale lung cancer [MeSH:C0242379] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect heart disease [MeSH:C0018799] acute lymphoblastic leukemia [MeSH:C1961102] mechanism method randomized control cancer [MeSH:C1096777] patient [MeSH:C0030705] assess myelodysplastic syndrome [MeSH:C3463824] pancreatic cancer [MeSH:C0346647] result favorable safety profile implication healthcare advancement,oncological
cerebral cortex [MeSH:C0007776] connection diabetes mellitus [MeSH:C0011849],question [MeSH:C0600648] ace inhibitor affect diabete serotonin mechanism method longitudinal [MeSH:C0023981] elderly patient assess ataxia paralysis [MeSH:C0522224] result positive response implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
tumor pathway [MeSH:C0282655] atrial fibrillation [MeSH:C0004238],question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] proteinuria [MeSH:C0033687] mechanism method retrospective [MeSH:C0035363] elderly patient assess primary sclerosing cholangitis [MeSH:C0566602] carcinogen [MeSH:C0007090] result well quality life measure implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal|oncological
hypertension [MeSH:C0020538] cirrhosis [MeSH:C1623038] cardiac connection,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome regurgitation pathway method randomized control trial [MeSH:C1096777] cardiac patient measure rcc heart rate [MeSH:C0018810] result enhance therapeutic response [MeSH:C0087111] cost-effectiveness [MeSH:C1511536] implication,cardiovascular|hepatorenal
mind matter chronic kidney disease [MeSH:C1561643] stroke [MeSH:C0038454],question statin affect dementia [MeSH:C0497327] amyotrophic lateral sclerosis mechanism method [MeSH:C0002736] randomized control [MeSH:C1096777] cardiac patient assess bell palsy parkinsonism [MeSH:C0242422] result positive response implication care improvement,neurological
extrapyramidal effect [MeSH:C0015372] risperidone [MeSH:C0073393] haloperidol [MeSH:C0018546] comparable d2 receptor occupancy level,risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] antipsychotic drug [MeSH:C0040615] high affinity dopamine d2 serotonin -ht2 receptor [MeSH:C0386482] previous study propose risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] pharmacologic profile [MeSH:C0600511] produce improve efficacy [MeSH:C5690761] negative [MeSH:C3539878] psychotic symptom decrease propensity extrapyramidal effect [MeSH:C0015372] [MeSH:C0015372] feature share so-called atypical neuroleptic [MeSH:C0040615] determine routine risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] associate unique degree d2 receptor [MeSH:C0386482] occupancy [MeSH:C0004909] [MeSH:C0004909] pattern effect 3i ibzm [MeSH:C0047499] spect [MeSH:C0040399] determine d2 occupancy [MeSH:C0004909] [MeSH:C0004909] [MeSH:C0004909] subject treat routine dose risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] n haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] n risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] produce d2 occupancy [MeSH:C0004909] [MeSH:C0004909] [MeSH:C0004909] level approximately standard dose [MeSH:C2936643] difference occupancy [MeSH:C0004909] [MeSH:C0004909] level obtain haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] drug-induced parkinsonism [MeSH:C0270730] observe subject treat risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] observe occupancy [MeSH:C0004909] [MeSH:C0004909] level base observation conclude -ht2 blockade [MeSH:C0027741] obtain risperidone [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] [MeSH:C0073393] d2 occupancy [MeSH:C0004909] [MeSH:C0004909] [MeSH:C0004909] rate appear protect risk [MeSH:C0035647] extrapyramidal effect [MeSH:C0015372] [MeSH:C0015372],neurological
linkage [MeSH:C0242239] x-linked adrenoleukodystrophy [MeSH:C0162309] application [MeSH:C3658310] post- prenatal diagnosis [MeSH:C0033053],perform linkage dna marker dxs5 clot factor viii gene [MeSH:C0017337] f8c large family x-linked adrenoleukodystrophy ald tight linkage [MeSH:C0162309] dxs5 extend give maximal lod score [MeSH:C0023956] cm f8c tightly link ald maximal lod score [MeSH:C0023956] recombination multipoint linkage marker dxs3 dxs5 f8c indicate gene [MeSH:C0017337] ald f8c distal dxs5 patient [MeSH:C0030705] ald major structural rearrangement xqter region observe particular abnormality [MeSH:C0037268] vision blindness [MeSH:C0456909] gene [MeSH:C0017337] dna appear use determination carrier status female risk [MeSH:C0086287] determination origin mutation [MeSH:C0026882] particular family prenatal diagnosis [MeSH:C0033053],neurological
molecular [MeSH:C0026381] reveal atrial fibrillation [MeSH:C0004238] secret,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect dementia [MeSH:C0497327] brain [MeSH:C0006104] mechanism method randomized control diabetic patient [MeSH:C0030705] assess craniopharyngioma gray matter [MeSH:C0010276] result well quality life measure implication optimization [MeSH:C0376695],neurological
association [MeSH:C0004083] tranexamic acid [MeSH:C0040613] convulsive seizure [MeSH:C0751494] cardiac surgery [MeSH:C0524727] multivariate patient,lack contemporary seizure cardiac surgery [MeSH:C0524727] [MeSH:C0524727] [MeSH:C0524727] undertake retrospective [MeSH:C0035363] prospectively collect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cardiopulmonary bypass january december convulsive seizure [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] define transient episode disturb brain function [MeSH:C0031843] characterise abnormal [MeSH:C0853087] involuntary motor movement [MeSH:C0427086] multivariate regression perform identify independent predictor postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] seizure total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] convulsive seizure [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] generalised focal seizure [MeSH:C0751495] identify patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] respectively median iqr range surgery seizure [MeSH:C0036572] occur h h respectively epileptiform finding electroencephalography [MeSH:C0013819] see patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] independent predictor postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] seizure include age [MeSH:C0024842] female [MeSH:C0086287] sex redo cardiac surgery [MeSH:C0524727] [MeSH:C0524727] [MeSH:C0524727] calcification [MeSH:C0040432] ascend aorta [MeSH:C0003483] congestive heart failure [MeSH:C0018802] deep hypothermic circulatory [MeSH:C1564655] arrest duration aortic cross-clamp tranexamic acid [MeSH:C0040613] [MeSH:C0040613] test [MeSH:C0040613] multivariate regression tranexamic acid [MeSH:C0040613] [MeSH:C0040613] strong independent predictor seizure [MeSH:C0036572] ci p patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] convulsive seizure [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] time high in-hospital [MeSH:C0085556] mortality rate twice length hospital stay compare patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] convulsive seizure [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] mean iqr range length stay intensive care unit [MeSH:C0021708] h patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] convulsive seizure [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] compare h patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] seizure p convulsive seizure [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] [MeSH:C0751494] postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] complication [MeSH:C1171258] cardiac surgery [MeSH:C0524727] [MeSH:C0524727] [MeSH:C0524727] tranexamic acid [MeSH:C0040613] [MeSH:C0040613] modifiable factor administration [MeSH:C0001554] particularly dose exceed mg kg weigh risk postoperative [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] [MeSH:C0032786] seizure,neurological|cardiovascular
oncological frontier valvular heart disease [MeSH:C0018824],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer chronic lymphocytic leukemia [MeSH:C0023434] method cancer [MeSH:C0025663] patient [MeSH:C0030705] undergo retrospective [MeSH:C0035363] metastasis endometrial cancer [MeSH:C0476089] assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],oncological
dialysis breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,stroke [MeSH:C0038454] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve polycystic kidney disease defibrillator method [MeSH:C0022680] conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine azotemia [MeSH:C0242528] parameter result decrease mortality rate [MeSH:C0205848] therapeutic [MeSH:C0087111] innovation,cardiovascular|hepatorenal
synaptic story cancer synapse [MeSH:C0039062],question [MeSH:C0600648] metformin [MeSH:C0025598] affect hypertension [MeSH:C0020538] norepinephrine mechanism method retrospective cancer patient [MeSH:C0030705] assess tremor cerebrospinal fluid [MeSH:C0007806] result decrease mortality rate [MeSH:C0205848] implication need investigation [MeSH:C0035173],neurological
statin [MeSH:C0360714] dementia [MeSH:C0497327] brain [MeSH:C0006104] insight,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation calcium channel blocker [MeSH:C0006684] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] locus coeruleus sciatica [MeSH:C0023951] result superior efficacy amygdala correlation [MeSH:C0002708] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
germline [MeSH:C0206530] intronic exonic mutation wilms tumour gene [MeSH:C0079433] wt1 affect urogenital development [MeSH:C0017340],denys-drash syndrome [MeSH:C0950121] rare human [MeSH:C0086418] developmental disorder affect urogenital system [MeSH:C0042066] lead renal failure [MeSH:C0035078] intersex disorder [MeSH:C0237873] wilms tumour report [MeSH:C0027708] individual syndrome describe carry germline point mutation [MeSH:C0026882] [MeSH:C0206530] wilms tumour suppressor gene [MeSH:C0079433] wt1 [MeSH:C0148873] [MeSH:C0148873] mutation [MeSH:C0026882] zinc finger domain [MeSH:C0080347] wt1 [MeSH:C0148873] [MeSH:C0148873] fourth occur intron [MeSH:C0021920] prevent splicing [MeSH:C0376437] alternatively choose splice donor site exon assay vitro result provide genetic evidence distinct functional [MeSH:C0031843] role wt1 [MeSH:C0148873] [MeSH:C0148873] isoform [MeSH:C0597298] urogenital development [MeSH:C0017340],neurological|hepatorenal|oncological
randomized double-blind trial mazindol [MeSH:C0024977] duchenne dystrophy,evidence [MeSH:C5575834] growth hormone [MeSH:C0037663] related progression weakness duchenne dystrophy conduct -month control trial mazindol [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] putative growth hormone [MeSH:C0037663] secretion inhibitor boy duchenne dystrophy muscle strength contracture functional ability pulmonary function test [MeSH:C0024119] month mazindol [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] mg placebo design power great detect slowing expect rate progression [MeSH:C0242656] weakness p mazindol [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] benefit strength point effect attributable mazindol [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] include decrease appetite dry mouth behavioral [MeSH:C0004927] gastrointestinal symptom mazindol [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] dosage [MeSH:C0178655] reduce patient [MeSH:C0030705] effect [MeSH:C4277541] mazindol [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] gh secretion [MeSH:C0036536] estimate indirectly compare postabsorptive [MeSH:C0271708] igf-i level [MeSH:C0018759] [MeSH:C0018759] obtain follow month mazindol [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] treat placebo group mazindol [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977]-treated patient [MeSH:C0030705] gain weight height [MeSH:C1821269] placebo-treated patient [MeSH:C0030705] effect [MeSH:C4277541] igf-i level [MeSH:C0018759] [MeSH:C0018759] observe mazindol [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] [MeSH:C0024977] dose slow progression weakness duchenne dystrophy,neurological
hepatic lung cancer [MeSH:C0345904] vascular [MeSH:C0221214] insight,hypothesis statin improve dementia [MeSH:C0497327] outcome esrd pathway method prospective trial elderly patient measure stenosis [MeSH:C1261287] renal cyst [MeSH:C0010709] result well quality life measure potential [MeSH:C0001272] therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
comparison [MeSH:C0871382] effect isotonic sodium chloride [MeSH:C0037494] diltiazem prevention [MeSH:C2700409] contrast-induced nephropathy,introduction [MeSH:C0033268] contrast-induced nephropathy cin significantly increase morbidity [MeSH:C0026538] mortality [MeSH:C0026565] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] investigate compare protective effect isotonic sodium chloride [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] sodium bicarbonate [MeSH:C0074722] infusion [MeSH:C0841792] [MeSH:C0841792] isotonic sodium chloride [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] infusion [MeSH:C0841792] [MeSH:C0841792] diltiazem [MeSH:C0012373] [MeSH:C0012373] calcium channel blocker [MeSH:C0006684] prevent [MeSH:C0000918] cin material method include patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] administer ml iodinated contrast agent [MeSH:C0009924] percutaneous coronary angiography [MeSH:C0085532] pcag creatinine value mg dl patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] divide group patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] administer isotonic sodium chloride [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] second administer solution dextrose sodium bicarbonate administer isotonic sodium chloride [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] contrast injection [MeSH:C1828121] receive additional injection diltiazem [MeSH:C0012373] [MeSH:C0012373] [MeSH:C0012373] day contrast injection [MeSH:C1828121] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] plasma blood [MeSH:C0032105] urea nitrogen bun creatinine level [MeSH:C0018759] measure [MeSH:C0079809] second seventh administration [MeSH:C0001554] intravenous contrast result basal creatinine [MeSH:C0010294] level [MeSH:C0018759] similar group p total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] include patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop acute renal failure [MeSH:C0022660] arf second contrast inject number patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop arf second injection second p difference isotonic sodium chloride [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] sodium bicarbonate [MeSH:C0074722] isotonic sodium chloride [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] [MeSH:C0037494] diltiazem [MeSH:C0012373] [MeSH:C0012373] application prevent [MeSH:C0000918]ion cin,cardiovascular|hepatorenal
blood flow angina pectoris [MeSH:C0005775],investigate [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] effect [MeSH:C4277511] stroke [MeSH:C0038454] aortic dissection method [MeSH:C0340643] adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective prolapse heart valve assessment [MeSH:C0079485] result improve outcome healthcare advancement,cardiovascular
oxidative damage [MeSH:C5392203] precede nitrative damage adriamycin-induced cardiac mitochondrial injury,present determine elevated [MeSH:C0020443] reactive oxygen ros nitrogen specie rns [MeSH:C0969698] report present adriamycin adr -induced cardiotoxicity [MeSH:C0876994] actually result cardiomyocyte [MeSH:C0225828] oxidative nitrative damage quantitative [MeSH:C0597336]ly determine course [MeSH:C0449259] subcellular localization postulated damage product vivo approach b6c3 mouse treat single dose mg kg adr ultrastructural [MeSH:C0041623] damage level [MeSH:C0018759] [MeSH:C0018759] -hydroxy nonenal 4hne -protein adduct [MeSH:C0242958] [MeSH:C0242958] [MeSH:C0242958] -nitrotyrosine 3nt analyze quantitative [MeSH:C0597336] ultrastructural [MeSH:C0041623] damage computerize image technique [MeSH:C0449851] show cardiomyocyte [MeSH:C0225828] injury [MeSH:C3263723] early hour mitochondria [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237] extensively progressive [MeSH:C1449744]ly injure subcellular organelle 4hne protein adduct [MeSH:C0242958] [MeSH:C0242958] [MeSH:C0242958] immunogold electron microscopy show appearance [MeSH:C0750731] 4hne protein adduct [MeSH:C0242958] [MeSH:C0242958] [MeSH:C0242958] mitochondria [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237] early hour peak hour subsequent decline hour 3nt level [MeSH:C0018759] [MeSH:C0018759] significantly increase subcellular compartment hour subsequently decline hour show adr induce 4hne-protein adduct [MeSH:C0242958] [MeSH:C0242958] [MeSH:C0242958] mitochondria [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237] point mitochondria [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237]l injury [MeSH:C3263723] initially appear result document [MeSH:C0009797] vivo mitochondria [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237]l oxidative damage precede nitrative damage progressive [MeSH:C1449744] nature mitochondria [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237]l injury [MeSH:C3263723] suggest mitochondria [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237] [MeSH:C0026237] subcellular organelle major site intracellular [MeSH:C0682581] injury [MeSH:C3263723],cardiovascular
hypertension [MeSH:C0020538] nephroblastoma [MeSH:C0027708] organ interplay,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect stroke primary sclerosing cholangitis [MeSH:C0566602] method adult [MeSH:C0001675] population [MeSH:C0032659] undergo observational [MeSH:C0302523] lymphoma hepatic assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal|oncological
leukemia [MeSH:C0023418] endothelial [MeSH:C0225336] cardiac connection,longitudinal [MeSH:C0023981] examine statin stroke [MeSH:C0038454] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include hypotension [MeSH:C0020649] systolic tachycardia method [MeSH:C0039231] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
antiarrhythmic plasma [MeSH:C0003195] concentration cibenzoline canine ventricular arrhythmia [MeSH:C0042514],two-stage coronary ligation [MeSH:C0023690]- digitalis- adrenaline [MeSH:C0014563]-induced canine ventricular arrhythmia [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0042514] antiarrhythmic effect [MeSH:C0003195] cibenzoline [MeSH:C0055720] [MeSH:C0055720] examine minimum effective plasma [MeSH:C0032105] [MeSH:C0032105] concentration [MeSH:C0311432] arrhythmia [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] model determine cibenzoline [MeSH:C0055720] [MeSH:C0055720] suppress [MeSH:C0017372] arrhythmia [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] minimum effective plasma [MeSH:C0032105] [MeSH:C0032105] concentration [MeSH:C0311432] arrhythmia [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] induce -h coronary ligation [MeSH:C0023690] -h coronary ligation [MeSH:C0023690] digitali adrenaline [MeSH:C0014563] mg kg v mg kg v mg kg v mg kg v microgram [MeSH:C0376691] ml respectively mean sdm n concentration [MeSH:C0311432] adrenaline [MeSH:C0014563]-induced arrhythmia [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] significantly high type arrhythmia [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] pharmacological profile similar mexiletine [MeSH:C0025887] tocainide [MeSH:C0085237] drug central nervous system [MeSH:C0007680] cns stimulant [MeSH:C0002763] action cibenzoline [MeSH:C0055720] [MeSH:C0055720] weak hypotensive sinus node depressive effect find orally active give coronary ligation [MeSH:C0023690] arrhythmia [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] [MeSH:C0003811] dog usefulness expect,neurological|cardiovascular|hepatorenal
capillary marker hepatitis,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome defibrillator pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient measure artery heart valve [MeSH:C0018826] result improvement primary endpoint cost-effectiveness [MeSH:C1511536] implication,cardiovascular
prolapse [MeSH:C0033377] valvular heart disease [MeSH:C0018824] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] hypotensive pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure heart pacemaker result superior efficacy [MeSH:C5690761] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
cardiomyopathy [MeSH:C0878544] renal [MeSH:C0152169] stone cardiac connection,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect hypertension [MeSH:C0020538] cardiac method cardiac patient undergo cross-sectional ckd arterial assessment [MeSH:C0030198] result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
lymphoma [MeSH:C0024299] tia cardiac connection,randomized control [MeSH:C1096777] examine beta-blocker hypertension cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include ventricular fibrillation diastolic hypertension [MeSH:C0042510] method participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication optimization [MeSH:C0376695],cardiovascular
sarcoma cancer [MeSH:C1261473] dementia [MeSH:C0497327],hypothesis statin improve diabete outcome metastasis pathway method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure liver cancer [MeSH:C0345904] neoplasm [MeSH:C0027651] result decrease mortality rate [MeSH:C0205848] therapeutic [MeSH:C0087111] innovation,oncological
distribution [MeSH:C1704711] emerin [MeSH:C0295734] lamin heart [MeSH:C0018787] implication emery-dreifuss muscular dystrophy [MeSH:C0026850],emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] nuclear membrane [MeSH:C0028584] protein [MeSH:C0028584] missing defective [MeSH:C0011139] emery-dreifuss [MeSH:C0410189] muscular dystrophy edmd member family lamina-associated protein include lap1 lap2 lamin b receptor lbr panel monoclonal antibody mab map [MeSH:C0024779] specific site emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] molecule phage-displayed peptide library localize emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] human [MeSH:C0086418] rabbit heart mab different emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] epitope recognize intercalated discs heart recognize cardiomyocyte [MeSH:C0225828] nucleus [MeSH:C0034910] [MeSH:C0034910] [MeSH:C0225828] strongly rim intranuclear spot channel polyclonal rabbit antiserum emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] recognize nuclear membrane [MeSH:C0028584] intercalated discs affinity purification [MeSH:C4704846] pure-emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] band western blot stain nuclear membrane [MeSH:C0028584] result expect immunostaining intercalated discs product emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] gene cast doubt hypothesis [MeSH:C3179072] cardiac defect [MeSH:C0018816] edmd cause absence emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] intercalated discs emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] abundant membrane cardiomyocyte [MeSH:C0225828] [MeSH:C0225828] nucleus [MeSH:C0034910] [MeSH:C0034910] [MeSH:C0225828] absent non-myocyte cell heart distribution emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] similar lamin candidate gene autosomal form edmd contrast lamin b1 [MeSH:C0377299] absent cardiomyocyte [MeSH:C0225828] nucleus [MeSH:C0034910] [MeSH:C0034910] [MeSH:C0225828] show lamin b1 [MeSH:C0377299] essential localization [MeSH:C0037710] emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] nuclear lamina lamin b1 [MeSH:C0377299] completely absent skeletal muscle [MeSH:C0242692] nucleus [MeSH:C0034910] [MeSH:C0034910] edmd additional absence lamin b1 [MeSH:C0377299] heart skeletal muscle [MeSH:C0242692] nucleus [MeSH:C0034910] [MeSH:C0034910] lack emerin [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] [MeSH:C0295734] offer alternative explanation tissue particularly affect,neurological|cardiovascular
diastolic [MeSH:C0012000] epilepsy vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] deep vein thrombosis pathway [MeSH:C0149871] method randomized control trial [MeSH:C1096777] cardiac patient measure myocardial infarction [MeSH:C0027051] myocardium [MeSH:C0027061] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] relevance [MeSH:C2826293],cardiovascular
mouse [MeSH:C0026809] lack mpges- resistant [MeSH:C2986418] lithium-induced polyuria,cyclooxygenase- activity [MeSH:C0020115] require development [MeSH:C0243107] lithium [MeSH:C0023870]-induced polyuria [MeSH:C0032617] involvement [MeSH:C0030699] specific terminal prostaglandin pg isomerase evaluate [MeSH:C0013175] present undertake assess lithium [MeSH:C0023870]-induced polyuria [MeSH:C0032617] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] deficient [MeSH:C0531328] microsomal prostaglandin e [MeSH:C0033554] synthase- mpge [MeSH:C0033559] [MeSH:C0033559]s- -wk administration licl mmol kg ip mpge [MeSH:C0033559] [MeSH:C0033559]s- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] lead marked polyuria [MeSH:C0032617] hyposmotic urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] associate elevated renal mpge [MeSH:C0033559] [MeSH:C0033559]s- protein expression [MeSH:C0017262] increase urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] pge [MeSH:C0033559] [MeSH:C0033559] excretion [MeSH:C1373187] contrast mpge [MeSH:C0033559] [MeSH:C0033559]s- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] largely resistant [MeSH:C2986418] lithium [MeSH:C0023870]-induced polyuria [MeSH:C0032617] urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] concentrate defect accompany nearly complete blockade [MeSH:C0027741] high urine [MeSH:C0042036] [MeSH:C0042036] [MeSH:C0042036] pge [MeSH:C0033559] [MeSH:C0033559] camp output immunoblotte immunohistochemistry quantitative [MeSH:C0597336] q rt-pcr consistently detect decrease aquaporin- aqp2 [MeSH:C0213238] protein [MeSH:C0213238] expression [MeSH:C0017262] renal cortex [MeSH:C0001613] medulla [MeSH:C0037925] lithium [MeSH:C0023870]-treated mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] decrease significantly attenuate [MeSH:C0042211] [MeSH:C0042211] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] qrt-pcr detect similar pattern [MeSH:C3849996] change aqp2 [MeSH:C0213238] mrna [MeSH:C0035696] medulla [MeSH:C0037925] cortex similarly total protein abundance na-k-2cl cotransporter nkcc2 medulla [MeSH:C0037925] cortex mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] significantly reduce lithium [MeSH:C0023870] contrast dowregulation renal medulla [MeSH:C0037925]ry nkcc2 expression significantly attenuate [MeSH:C0042211] [MeSH:C0042211] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] conclude mpge [MeSH:C0033559] [MeSH:C0033559] derive pge [MeSH:C0033559] [MeSH:C0033559] mediate lithium [MeSH:C0023870]-induced polyuria [MeSH:C0032617] likely inhibition [MeSH:C0027790] aqp2 [MeSH:C0213238] nkcc2 expression,hepatorenal
innovative dietary change approach colorectal cancer [MeSH:C0009402],design [MeSH:C0013171] cross-sectional investigation ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient kidney transplant [MeSH:C0022671] polyuria result well quality life measure proteinuria [MeSH:C0033687] correlation [MeSH:C0010100] optimization [MeSH:C0376695],hepatorenal
dementia [MeSH:C0497327] anuria [MeSH:C0003460] organ [MeSH:C0029250] interplay,dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve nephrotic syndrome [MeSH:C0027726] wilms tumor method [MeSH:C0027708] conduct randomized control evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine anuria [MeSH:C0003460] parameter result improvement primary endpoint healthcare advancement,hepatorenal
cardiomyopathy angina [MeSH:C0878544] cardiac connection,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension [MeSH:C0020538] outcome aortic dissection pathway method observational trial [MeSH:C0302523] elderly patient measure chronic myeloid leukemia [MeSH:C0279543] ovarian cancer [MeSH:C1140680] result decrease mortality rate [MeSH:C0205848] practice guideline,cardiovascular|oncological
animal model [MeSH:C0599779] norrie disease [MeSH:C0266526] nd gene [MeSH:C0017337] targeting [MeSH:C0242613] mouse [MeSH:C0026809] nd gene [MeSH:C0017337],order elucidate cellular molecular process involve norrie disease [MeSH:C0266526] nd gene [MeSH:C0017337] targeting [MeSH:C0242613] technology [MeSH:C0039421] gene [MeSH:C0017337]rate nd mutant [MeSH:C1564139] mouse [MeSH:C0026809] murine [MeSH:C0026802] homologue nd gene [MeSH:C0017337] clone [MeSH:C0009013] show encode polypeptide [MeSH:C1305923] share amino acid sequence [MeSH:C0002518] human [MeSH:C0086418] counterpart rna situ hybridization [MeSH:C0162788] reveal expression [MeSH:C0017262] retina brain olfactory bulb epithelium [MeSH:C0599332] week old mouse [MeSH:C0026809] hemizygous mouse [MeSH:C0026809] carry replacement mutation exon nd gene [MeSH:C0017337] develop retrolental structure vitreous body [MeSH:C0042905] show overall disorganization [MeSH:C0029246] retinal ganglion cell layer outer plexiform layer disappear occasionally result juxtapose inner outer nuclear layer region outer segment photoreceptor cell layer [MeSH:C0230759] long present ocular finding consistent observation [MeSH:C0302523] nd patient [MeSH:C0030705] gene [MeSH:C0017337]rate mouse [MeSH:C0026809] line provide faithful model [MeSH:C0011381] early pathogenic event severe x-linked recessive neurological disorder [MeSH:C1848144],neurological
safety [MeSH:C0036043] side-effect alprazolam [MeSH:C0002333] controlled agoraphobia panic disorder [MeSH:C0030319],widespread use benzodiazepine [MeSH:C4048284] lead increase recognition [MeSH:C0871740] unwanted effect efficacy alprazolam [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] placebo [MeSH:C0032041] panic disorder [MeSH:C0030319] [MeSH:C0030319] agoraphobia side-effect adverse effect [MeSH:C0001688] [MeSH:C0001688] profile drug [MeSH:C0013227] group measure london toronto patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] meet dsm-iii criterion [MeSH:C0243161] panic disorder [MeSH:C0030319] [MeSH:C0030319] agoraphobia randomised alprazolam [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] placebo [MeSH:C0032041] subject drug [MeSH:C0013227] receive exposure [MeSH:C1390376] relaxation [MeSH:C0035028] week taper week result mean alprazolam [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] dose mg daily compare placebo [MeSH:C0032041] subject alprazolam [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop adverse reaction [MeSH:C0041755] v depression [MeSH:C0011570] enuresis disinhibition aggression [MeSH:C0001807] side-effect particularly sedation [MeSH:C0079159] irritability impaired [MeSH:C0020580] memory weight loss ataxia [MeSH:C1262477] side-effect tend diminish remain week despite drop-out rate low conclusion alprazolam [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] [MeSH:C0002333] cause side-effect adverse effect [MeSH:C0001688] [MeSH:C0001688] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] willing accept,neurological
cardiomyopathy bone cancer [MeSH:C0878544] explore neural pathway [MeSH:C0027792],hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide partic [MeSH:C0278076]ularly involve chronic myeloid leukemia [MeSH:C0279543] migraine method [MeSH:C0149931] conduct retrospective [MeSH:C0035363] evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine tic [MeSH:C0278076] parameter result improve disease management practic [MeSH:C0278076]e guideline,neurological|oncological
central excitatory action flurazepam,toxic [MeSH:C1256754] action flurazepam fzp study cat [MeSH:C0007450] [MeSH:C0007450] mouse [MeSH:C0026809] rat [MeSH:C0034721] [MeSH:C0034721] high dose cause apparent central excitation clearly see clonic convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] superimpose general depression follow lethal dose death associate convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] compare relative sensitivity [MeSH:C0037786] central depression excitation reveal rat [MeSH:C0034721] [MeSH:C0034721] likely convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] dose cause loss consciousness [MeSH:C0041657] cat [MeSH:C0007450] [MeSH:C0007450] clearly show marked central excitatory action sign fzp toxocity cat [MeSH:C0007450] [MeSH:C0007450] include excessive salivation [MeSH:C0036104] extreme apprehensive behavior retch muscle tremor convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] interaction [MeSH:C0007582] fzp pentylenetetrazol ptz [MeSH:C0030903] show pretreate mouse [MeSH:C0026809] fzp ptz challenge function dose fzp protect convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] death high dose convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] emerge dose fzp low cause convulsion [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] [MeSH:C4048158] result relevant use fzp situation increase neural excitability epilepsy sedative-hypnotic drug withdrawal,neurological
multiple [MeSH:C0026771] effect penicillamine therapy [MeSH:C0030817] rheumatoid arthritis [MeSH:C0003873],skin rash [MeSH:C0015230] proteinuria [MeSH:C0033687] systemic lupus erythematosus polymyositis [MeSH:C0024141] myasthenia gravis record complication [MeSH:C1171258] penicillamine [MeSH:C0030817] therapy [MeSH:C0030817] patient [MeSH:C0030705] [MeSH:C0030705] rheumatoid arthritis [MeSH:C0003873] [MeSH:C0003873] develop describe skin lesion resemble elastosis perforans serpiginosa [MeSH:C0221271] report rare effect patient [MeSH:C0030705] [MeSH:C0030705] wilson disease patient [MeSH:C0030705] [MeSH:C0030705] rheumatoid arthritis [MeSH:C0003873] [MeSH:C0003873] treat penicillamine [MeSH:C0030817],hepatorenal
myocardial infarction [MeSH:C0027051] atrial flutter [MeSH:C0004239] cardiac connection,assess efficacy [MeSH:C5690761] ace inhibitor [MeSH:C0003015] cancer [MeSH:C0003015] focus systolic myocardium method cancer patient [MeSH:C0030705] randomized [MeSH:C1096777] receive ace inhibitor [MeSH:C0003015] placebo [MeSH:C0032041] arterial [MeSH:C0003835] monitoring result decrease mortality rate [MeSH:C0205848] care improvement [MeSH:C2936612],cardiovascular
organ [MeSH:C0029250] orchestra peripheral artery disease,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve hypertension [MeSH:C0020538] outcome kidney transplant pathway method longitudinal trial [MeSH:C0023981] elderly patient measure gfr cirrhosis result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],hepatorenal
mind matter dementia [MeSH:C0497327] dysarthria [MeSH:C0013362],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome schwannoma pathway method [MeSH:C0027809] longitudinal trial [MeSH:C0023981] elderly patient measuring substantia nigra chorea [MeSH:C0038590] result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],neurological
encephalopathy [MeSH:C0085584] meet heart failure [MeSH:C0018801] neurological perspective,heart disease [MeSH:C0018799] affect cardiac patient [MeSH:C0030705] worldwide particularly involve hepatoma [MeSH:C2239176] urea method conduct observational [MeSH:C0302523] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] examine pituitary adenoma [MeSH:C0032000] parameter result enhance therapeutic response [MeSH:C0087111] therapeutic innovation [MeSH:C0087111],neurological|hepatorenal
epilepsy [MeSH:C0014544] hepatorenal lens,diabete affect elderly patient [MeSH:C0030705] worldwide particularly involve proteinuria [MeSH:C0033687] hcc method conduct retrospective [MeSH:C0035363] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine cholangiocarcinoma [MeSH:C0206698] parameter result superior efficacy [MeSH:C5690761] healthcare advancement,hepatorenal
restoration [MeSH:C4505207] photoreceptor [MeSH:C0206428] ultrastructure function retinal degeneration slow mouse gene therapy [MeSH:C0035304],gene prph2 encode photoreceptor-specific membrane glycoprotein peripherin [MeSH:C3658334]- know peripherin [MeSH:C3658334] rds insert rim photoreceptor outer segment discs complex rom- ref complex necessary stabilization discs renew constantly life contain visual pigment [MeSH:C0035323] necessary photon capture mutation prph2 show variety photoreceptor dystrophy include autosomal dominant [MeSH:C2936739] retinitis pigmentosa macular dystrophy [MeSH:C0035334] common feature disease loss photoreceptor function see retinal degeneration [MeSH:C0035304] slow rds prph2 rd2 rd2 mouse [MeSH:C0026809] [MeSH:C0026809] homozygous [MeSH:C0019904] null mutation [MeSH:C4505108] prph2 characterize complete [MeSH:C0011455] failure [MeSH:C0035078] develop photoreceptor discs [MeSH:C0206428] outer segment downregulation [MeSH:C0013081] rhodopsin [MeSH:C0035499] apoptotic loss photoreceptor cell electroretinogram ergs prph2rd2 rd2 mouse [MeSH:C0026809] [MeSH:C0026809] greatly diminish a-wave b-wave amplitude decline virtually undetectable concentration [MeSH:C0311432] month subretinal [MeSH:C1959691] injection recombinant adeno-associated virus aav [MeSH:C0319124] encode prph2 transgene [MeSH:C0282641] result stable generation outer segment structure formation new stack discs contain perpherin- rhodopsin [MeSH:C0035499] case morphologically similar normal outer segment [MeSH:C0230759] re-establishment structural [MeSH:C0026349] integrity [MeSH:C0021701] photoreceptor layer result electrophysiological correction study [MeSH:C0887875] demonstrate complex ultrastructural [MeSH:C0026349] cell defect correct morphologically functionally vivo gene transfer [MeSH:C0887912],neurological
next-generation eeg colorectal cancer [MeSH:C0009402],investigate [MeSH:C0035173] statin effect hypertension [MeSH:C0020538] bun method [MeSH:C0005845] diabetic [MeSH:C1263960] patient [MeSH:C0030705] undergo cross-sectional dvt renal assessment result improvement [MeSH:C2936612] primary endpoint therapeutic innovation [MeSH:C0087111],cardiovascular|hepatorenal
endoscopy [MeSH:C0014245] reveal multiple sclerosis [MeSH:C0026769] secret,heart disease [MeSH:C0018799] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve dystonia [MeSH:C0013421] pituitary adenoma method [MeSH:C0032000] conduct observational evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine neural [MeSH:C1522467] parameter result superior efficacy [MeSH:C5690761] relevance,neurological
tumor [MeSH:C0027651] tale parkinson disease [MeSH:C0030567] insight,cancer [MeSH:C0006826] affect elderly patient worldwide particularly involve metastasis stomach cancer [MeSH:C0006826] [MeSH:C0024623] method conduct cross-sectional [MeSH:C0010362] evaluate beta-blocker [MeSH:C0001645] patient examine cancer [MeSH:C0006826] parameter result improve outcome practice guideline [MeSH:C0936005],oncological
cholestasis [MeSH:C0008370] breast cancer [MeSH:C0006142] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve heart disease [MeSH:C0018799] outcome albumin pathway method observational trial cancer [MeSH:C0302523] patient [MeSH:C0030705] measuring pacemaker nephron result superior efficacy [MeSH:C5690761] need investigation [MeSH:C0035173],cardiovascular|hepatorenal
diuretic potassium arrhythmia [MeSH:C0003811] hypertensive coronary disease [MeSH:C0010068],propose modest change plasma potassium [MeSH:C0032821] [MeSH:C0032821] alter tendency cardiac arrhythmia [MeSH:C0003811] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] coronary artery disease [MeSH:C1956346] [MeSH:C1956346] especially susceptible myocardial [MeSH:C0027061] [MeSH:C0027061] electrical excitability [MeSH:C4277734] [MeSH:C4277734] measure patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mild essential hypertension known coronary artery disease [MeSH:C1956346] [MeSH:C1956346] week potassium-conserving diuretic [MeSH:C0012798] amiloride [MeSH:C0002502] [MeSH:C0002502] similar period potassium-losing diuretic [MeSH:C0012798] chlorthalidone [MeSH:C0008294] [MeSH:C0008294] [MeSH:C0008294] randomised plasma potassium [MeSH:C0032821] [MeSH:C0032821] concentration [MeSH:C0311432] average mmol l low chlorthalidone [MeSH:C0008294] [MeSH:C0008294] [MeSH:C0008294] phase [MeSH:C0080129] compare amiloride [MeSH:C0002502] [MeSH:C0002502] therapy blood pressure volume state [MeSH:C0005850] assess bodyweight plasma renin noradrenaline [MeSH:C0028351] norepinephrine [MeSH:C0028351] concentration [MeSH:C0311432] similar regimen [MeSH:C1880476] compare amiloride [MeSH:C0002502] [MeSH:C0002502] chlorthalidone [MeSH:C0008294] [MeSH:C0008294] [MeSH:C0008294] phase [MeSH:C0080129] associate increase frequency [MeSH:C0376249] ventricular ectopic beat [MeSH:C0033036] -hour holter [MeSH:C0013801] monitor high lown grade increase upslope duration monophasic action potential prolonged ventricular effective refractory period [MeSH:C0034955] increase electrical instability program [MeSH:C0376691] ventricular stimulation result indicate potassium-losing diuretic [MeSH:C0012798] therapy increase myocardial [MeSH:C0027061] [MeSH:C0027061] electrical excitability [MeSH:C4277734] [MeSH:C4277734] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] ischaemic heart disease [MeSH:C0151744] minor fall plasma potassium [MeSH:C0032821] [MeSH:C0032821] concentration [MeSH:C0311432] probably well avoid patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705],cardiovascular|hepatorenal
novel multiple symptom model obsessive-compulsive-like behavior [MeSH:C0028768] animal [MeSH:C0003062],current animal model [MeSH:C0011381] [MeSH:C0599779] obsessive-compulsive disorder [MeSH:C0028768] ocd typically involve acute [MeSH:C0184567] drug-induced symptom [MeSH:C3839861] provocation genetic association stereotypie anxiety [MeSH:C0003467] current model [MeSH:C0011381] demonstrat [MeSH:C0034721] [MeSH:C0034721]e multiple ocd-like behavior method neonatal [MeSH:C0021709] rat [MeSH:C0034721] [MeSH:C0034721] treat tricyclic antidepressant [MeSH:C0003290] clomipramine [MeSH:C0009010] [MeSH:C0009010] vehicle day [MeSH:C0011017] twice daily behavioral [MeSH:C0004927] [MeSH:C0004927]ly test [MeSH:C0683444] adulthood result clomipramine [MeSH:C0009010] [MeSH:C0009010] exposure [MeSH:C1390376] immature [MeSH:C1512631] rat [MeSH:C0034721] [MeSH:C0034721] produce behavioral [MeSH:C0004927] [MeSH:C0004927] biochemical [MeSH:C0017401] change include enhance anxiety [MeSH:C0003467] elevated plus maze marble burying behavioral [MeSH:C0004927] [MeSH:C0004927] inflexibility [MeSH:C0242808] perseverat [MeSH:C0034721] [MeSH:C0034721]ion spontaneous alternation task impaired reversal learning [MeSH:C0035375] work memory [MeSH:C0025265] impairment e g win-shift paradigm [MeSH:C2718025] hoard corticostriatal dysfunction [MeSH:C0031847] dopamine d2 receptor [MeSH:C0058698] elevated striatum serotonin 2c serotonin 1a receptor [MeSH:C0379900] elevated orbital frontal cortex [MeSH:C0016733] conclusion demonstrat [MeSH:C0034721] [MeSH:C0034721]ion multiple symptom [MeSH:C3839861] consistent ocd-like profile animal behavior [MeSH:C0004935] accompany biochemical [MeSH:C0017401] change brain region previously identify relevant ocd novel model [MeSH:C0011381] ocd demonstrat [MeSH:C0034721] [MeSH:C0034721]e drug exposure [MeSH:C1390376] [MeSH:C1390376] sensitive [MeSH:C1017675] period program [MeSH:C0376691] disease-like system permanently implication current future therapeutic strat [MeSH:C0034721] [MeSH:C0034721]egy psychiatric disorder [MeSH:C0004936],neurological
preliminary [MeSH:C4505218] efficacy [MeSH:C5690761] assessment [MeSH:C0030198] intrathecal [MeSH:C0021896] injection american formulation adenosine human [MeSH:C0001443],preclinical study [MeSH:C0008972] intrathecal adenosine [MeSH:C0001443] [MeSH:C0001443] [MeSH:C0001443] suggest effective [MeSH:C5392218] acute [MeSH:C0184567] [MeSH:C0184567] chronic pain [MeSH:C0150055] human [MeSH:C0086418] [MeSH:C0086418] preliminary study volunteer [MeSH:C0042960] patient [MeSH:C0030705] [MeSH:C0030705] swedish formulation [MeSH:C0524527] [MeSH:C0524527] adenosine [MeSH:C0001443] [MeSH:C0001443] [MeSH:C0001443] suggest effective [MeSH:C5392218] hypersensitivity state [MeSH:C0020517] acute [MeSH:C0184567] [MeSH:C0184567] noxious stimulation screen efficacy [MeSH:C5690761] different formulation [MeSH:C0524527] [MeSH:C0524527] adenosine [MeSH:C0001443] [MeSH:C0001443] [MeSH:C0001443] market acute [MeSH:C0184567] [MeSH:C0184567] noxious stimulation capsaicin [MeSH:C0006931] [MeSH:C0006931] [MeSH:C0006931]-evoked mechanical hypersensitivity method [MeSH:C0020517] follow food drug administration [MeSH:C0041714] institutional review [MeSH:C0086911] board approval write informed consent [MeSH:C0021430] volunteer [MeSH:C0042960] study trial open-label dose-escalating trial intrathecal adenosine [MeSH:C0001443] [MeSH:C0001443] [MeSH:C0001443] dose mg double-blind [MeSH:C0013072] placebo-controlled trial adenosine [MeSH:C0001443] [MeSH:C0001443] [MeSH:C0001443] mg cerebrospinal fluid [MeSH:C0007806] obtain pharmacokinetic pain [MeSH:C0031327] rating response acute [MeSH:C0184567] [MeSH:C0184567] heat stimulus area mechanical hyperalgesia [MeSH:C2936719] [MeSH:C2936719] allodynia intradermal [MeSH:C0021881] [MeSH:C0021881] capsaicin [MeSH:C0006931] [MeSH:C0006931] [MeSH:C0006931] injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] determine result adenosine [MeSH:C0001443] [MeSH:C0001443] [MeSH:C0001443] produce effect pain report acute [MeSH:C0184567] [MeSH:C0184567] noxious thermal chemical stimulation [MeSH:C0038337] reduce mechanical hyperalgesia [MeSH:C2936719] [MeSH:C2936719] allodynia intradermal [MeSH:C0021881] [MeSH:C0021881] capsaicin [MeSH:C0006931] [MeSH:C0006931] [MeSH:C0006931] injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] h contrast residence adenosine [MeSH:C0001443] [MeSH:C0001443] [MeSH:C0001443] cerebrospinal fluid [MeSH:C0007806] short h conclusion result selective inhibition intrathecal adenosine [MeSH:C0001443] [MeSH:C0001443] [MeSH:C0001443] hypersensitivity presume reflect central sensitization [MeSH:C2938905] human [MeSH:C0086418] [MeSH:C0086418] peripheral [MeSH:C3658334] capsaicin [MeSH:C0006931] [MeSH:C0006931] [MeSH:C0006931] injection [MeSH:C1828121] [MeSH:C1828121] [MeSH:C1828121] long-lasting effect consistent observe preliminary report patient [MeSH:C0030705] [MeSH:C0030705] chronic neuropathic pain [MeSH:C0027796] prolonged residence adenosine [MeSH:C0001443] [MeSH:C0001443] [MeSH:C0001443] cerebrospinal fluid [MeSH:C0007806],neurological
chorea pattern cancer patient [MeSH:C0030705],question [MeSH:C0600648] ace inhibitor [MeSH:C0003015] affect stroke [MeSH:C0038454] metastatic mechanism method observational [MeSH:C0302523] cardiac patient assess radiculopathy esophageal cancer [MeSH:C0546837] result decrease mortality rate [MeSH:C0205848] implication relevance,neurological|oncological
ataxia [MeSH:C0004134] connection alzheimer disease,question [MeSH:C0600648] ace inhibitor affect [MeSH:C0001721] dementia [MeSH:C0497327] als mechanism method prospective cardiac patient assess cerebral infarction [MeSH:C0007785] gaba result improve outcome [MeSH:C0206277] implication therapeutic [MeSH:C0087111] innovation,neurological
leukemia [MeSH:C0023418] tia cardiac connection,cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve endothelial blood vessel method [MeSH:C0005847] conduct randomized control evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine dilate cardiomyopathy [MeSH:C0007193] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],cardiovascular
identification [MeSH:C1707660] localization [MeSH:C0037710] huntingtin brain [MeSH:C4255255] human [MeSH:C0086418] lymphoblastoid cell line anti-fusion protein antibody,huntington disease [MeSH:C0020179] hd [MeSH:C0252274] phenotype [MeSH:C0031437] associate expansion [MeSH:C0196940] trinucleotide repeat it1 gene [MeSH:C0282537] predict encode -kda protein [MeSH:C0033684] name huntington polyclonal monoclonal anti-fusion protein [MeSH:C0033684] antibody identify native [MeSH:C3494467] huntingtin [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] rat [MeSH:C0034721] [MeSH:C0034721] monkey human [MeSH:C0086418] [MeSH:C0086418] western blot reveal protein [MeSH:C0033684] expect molecular weight [MeSH:C0026385] present soluble [MeSH:C0210233] fraction rat [MeSH:C0034721] [MeSH:C0034721] monkey brain [MeSH:C0006104] tissue [MeSH:C0040300] lymphoblastoid cell [MeSH:C0002199] case lymphoblastoid cell [MeSH:C0002199] line juvenile-onset heterozygote [MeSH:C0019425] hd [MeSH:C0252274] case normal mutant [MeSH:C1564139] huntingtin [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] express increase repeat expansion [MeSH:C0196940] lead low level mutant [MeSH:C1564139] protein [MeSH:C0033684] immunocytochemistry indicate huntingtin [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] located neuron [MeSH:C0027882] [MeSH:C0027882] brain [MeSH:C0006104] high level evident large neuron [MeSH:C0027882] [MeSH:C0027882] human [MeSH:C0086418] [MeSH:C0086418] striatum [MeSH:C0315183] huntingtin [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] enriched patch-like distribution [MeSH:C1704711] potentially corresponding area affect hd [MeSH:C0252274] subcellular [MeSH:C0038528] localization [MeSH:C0037710] huntingtin [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] consistent cytosolic protein [MeSH:C1383501] [MeSH:C0033684] primarily find somatodendritic region huntingtin [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] appear particularly associate microtubule [MeSH:C0026046] [MeSH:C0026046] associate synaptic vesicle [MeSH:C0242915] basis [MeSH:C0039065] localization [MeSH:C0037710] huntingtin [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] [MeSH:C4255255] association microtubule [MeSH:C0026046] [MeSH:C0026046] speculate mutation [MeSH:C0026882] impair cytoskeletal anchoring [MeSH:C0010852] transport [MeSH:C0007292] mitochondria [MeSH:C0026237] vesicle [MeSH:C0242915] organelle molecule [MeSH:C0029219],neurological
vein alzheimer disease vascular [MeSH:C0002395] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer ectopic beat method cancer patient [MeSH:C0030705] undergo retrospective stenosis ventricular fibrillation [MeSH:C0042510] assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] practice guideline,cardiovascular
mind matter hepatitis cerebrospinal fluid [MeSH:C0007806],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect hypertension [MeSH:C0020538] hypothalamus [MeSH:C0020663] mechanism method prospective cancer patient [MeSH:C0030705] assess glioma cerebral [MeSH:C0017638] result improve disease management [MeSH:C0039798] implication cost-effectiveness [MeSH:C1511536] implication,neurological
dysfunctional [MeSH:C0031847] overnight memory consolidation [MeSH:C0679057] ecstasy user [MeSH:C0115471],sleep play important role consolidation [MeSH:C0679057] [MeSH:C0679057] integration [MeSH:C0085224] memory [MeSH:C0025260] process [MeSH:C0025260] call overnight memory [MeSH:C0025260] consolidation [MeSH:C0679057] [MeSH:C0679057] [MeSH:C0679057] [MeSH:C0679057] [MeSH:C0679057] previous study [MeSH:C0085973] indicate ecstasy user [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] marked persistent [MeSH:C0026205] neurocognitive sleep-related impairment [MeSH:C1384666] [MeSH:C0338656] extend past examine overnight memory [MeSH:C0025260] consolidation [MeSH:C0679057] [MeSH:C0679057] [MeSH:C0679057] [MeSH:C0679057] [MeSH:C0679057] regular ecstasy user [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] n drug naive healthy control n memory [MeSH:C0025260] recall word pair evaluate [MeSH:C0013175] period sleep interference [MeSH:C1136031] prior test addition assess neurocognitive performance task learn memory [MeSH:C0025260] executive function [MeSH:C0935584] ecstasy user [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] demonstrate impaired [MeSH:C0020580] overnight memory [MeSH:C0025260] consolidation [MeSH:C0679057] [MeSH:C0679057] [MeSH:C0679057] [MeSH:C0679057] [MeSH:C0679057] pronounced follow associative [MeSH:C0234471] interference [MeSH:C1136031] additionally ecstasy user [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] demonstrate impairment [MeSH:C1384666] task recruit frontostriatal hippocampal [MeSH:C0228249] neural circuitry domain proactive interference [MeSH:C1136031] [MeSH:C1136031] memory [MeSH:C0025260] long-term [MeSH:C0023977] memory [MeSH:C0025260] encode work memory [MeSH:C0025260] complex planning suggest ecstasy-associated dysfunction fronto-temporal circuitry underlie overnight consolidation [MeSH:C0679057] [MeSH:C0679057] memory [MeSH:C0025260] impairment [MeSH:C1384666] regular ecstasy user [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471] [MeSH:C0115471],neurological
neuropathy [MeSH:C0015464] pattern prostate cancer [MeSH:C0376358] patient [MeSH:C0030705],retrospective [MeSH:C0035363] examine metformin [MeSH:C0025598] hypertension cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include memory loss sciatica myelopathy method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication optimization [MeSH:C0376695],neurological
renal papillary necrosis naproxen,-year-old man rheumatoid arthritis [MeSH:C0003873] previously treat sulindac [MeSH:C0038792] [MeSH:C0038792] fenoprofen [MeSH:C0015837] calcium high dose salicylate [MeSH:C0036075] gold salt [MeSH:C0018026] develop renal [MeSH:C0152169] papillary necrosis rpn month institution [MeSH:C0442681] naproxen [MeSH:C0027396] therapy factor predispose rpn discover sulindac [MeSH:C0038792] [MeSH:C0038792] substitute naproxen [MeSH:C0027396] adverse renal [MeSH:C0152169] effect [MeSH:C4277511] occur month review [MeSH:C0282443] previous report link rpn antiinflammatory drug [MeSH:C0003209] use discuss possible advantage sulindac [MeSH:C0038792] [MeSH:C0038792] patient [MeSH:C0030705] experience renal [MeSH:C0152169] toxicity [MeSH:C0040539] antiinflammatory agent [MeSH:C0003209],hepatorenal
meningitis [MeSH:C0025289] connection myocardial infarction [MeSH:C0027051],design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin cancer [MeSH:C0376358] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] serotonin heart block [MeSH:C0018794] result superior efficacy [MeSH:C5690761] restrictive cardiomyopathy [MeSH:C0878544] correlation safety [MeSH:C0036043] consideration,neurological|cardiovascular
insulin [MeSH:C0021641] liver cirrhosis [MeSH:C0023890] brain [MeSH:C0006104] insight,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve myelopathy [MeSH:C0037928] aortic aneurysm method conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine parkinson disease [MeSH:C0030567] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] therapeutic innovation [MeSH:C0087111],neurological|cardiovascular
acetylcholine pathway peripheral artery disease [MeSH:C1704436],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect cancer thalamus mechanism method randomized control [MeSH:C1096777] elderly patient assess dopamine [MeSH:C0013030] al result favorable safety [MeSH:C0036043] profile implication safety [MeSH:C0036043] consideration,neurological
polyuria [MeSH:C0032617] marker diabetes mellitus [MeSH:C0011849],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension [MeSH:C0020538] outcome polyuria pathway method prospective trial cancer patient measure heart endocardium [MeSH:C0014124] result improvement [MeSH:C2936612] primary endpoint optimization [MeSH:C0376695],cardiovascular|hepatorenal
glyburide-induced hepatitis,drug-induced hepatotoxicity [MeSH:C0235280] [MeSH:C5197787] common report infrequently sulfonylurea glyburide [MeSH:C0017628] second-generation sulfonylurea brief report hepatotoxicity [MeSH:C0235280] exist patient [MeSH:C0030705] type [MeSH:C0030705] ii diabetes mellitus [MeSH:C0011849] develop acute hepatitis-like syndrome soon initiation glyburide [MeSH:C0017628] therapy serologic [MeSH:C0036743] evidence viral infection [MeSH:C0042769] liver biopsy [MeSH:C0005558] sample show histologic pattern consistent drug-induced hepatitis [MeSH:C1262760] patient [MeSH:C0030705] recover quickly stop glyburide [MeSH:C0017628] therapy remain follow-up [MeSH:C3899107] period [MeSH:C0080129] glyburide [MeSH:C0017628] produce acute hepatitis-like illness person,hepatorenal
binasal visual field defect [MeSH:C0042826] specific vigabatrin [MeSH:C0048044],investigate [MeSH:C0035173] visual defect associate antiepileptic drug [MeSH:C0003299] vigabatrin [MeSH:C0048044] vgb people [MeSH:C5690824] epilepsy [MeSH:C0014544] group [MeSH:C0018257] basis antiepileptic drug [MeSH:C0003299] therapy current previous exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] vgb group [MeSH:C0018257] match respect age [MeSH:C0024842] gender seizure [MeSH:C0036572] frequency [MeSH:C0376249] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo assessment [MeSH:C0030198] electrophysiological function [MeSH:C2350527] wide-field multifocal electroretinography conventional visual field [MeSH:C0042826] testing [MeSH:C0042825] static perimetry [MeSH:C0031061] bilateral visual field [MeSH:C0042826] constriction [MeSH:C0042826] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] currently take vgb patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] previously take vgb patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] vgb assessment [MeSH:C0030198] retinal [MeSH:C0035331] function [MeSH:C0031843] reveal abnormal response current vgb user prior vgb user patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] previous exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] vgb bilateral visual field [MeSH:C0042826] abnormality common treat epilepsy [MeSH:C0014544] population irrespective drug history assessment [MeSH:C0030198] conventional static perimetry [MeSH:C0031061] sufficiently sensitive [MeSH:C1017675] specific reliably identify retinal [MeSH:C0035331] toxicity [MeSH:C0040539] associate vgb,neurological
functional [MeSH:C0031843] consequence mutation [MeSH:C0026882] early growth response [MeSH:C1566493] gene egr2 [MeSH:C1505738] correlate severity human [MeSH:C0086418] myelinopathie,early [MeSH:C3177188] growth response [MeSH:C1566493] gene egr2 [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] cys2his2zinc finger transcription factor think play role regulation peripheral nervous system myelination [MeSH:C0027763] idea base partly phenotype [MeSH:C0031437] homozygous [MeSH:C0019904] krox2 egr2 [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] knockout mouse [MeSH:C0206745] display hypomyelination pns block schwann cell early [MeSH:C3177188] stage differentiation [MeSH:C0007589] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] human [MeSH:C0086418] egr2 [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] gene recently associate inherit peripheral neuropathy [MeSH:C4721453] charcot-marie-tooth type dejerine-sottas syndrome [MeSH:C0007959] congenital hypomyelinating neuropathy [MeSH:C0393818] egr2 [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] dominant [MeSH:C0017342] occur zinc finger dna-binding domain fourth mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] recessive affect inhibitory [MeSH:C0167957] domain r1 bind nab transcriptional [MeSH:C0162493] co-repressor [MeSH:C2717951] combination dna-binding assay transcriptional [MeSH:C0162493] determine functional [MeSH:C0031843] consequence mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] zinc finger mutation [MeSH:C0026882] [MeSH:C0080347] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] affect dna binding residual binding [MeSH:C0012940] directly correlate disease severity [MeSH:C0521117] r1 domain mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] prevent interaction [MeSH:C0007582] egr2 [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] nab co-repressor [MeSH:C2717951] increase transcriptional [MeSH:C0162493] activity provide insight possible disease mechanism underlie egr2 [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] [MeSH:C1505738] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] reason vary severity difference inheritance [MeSH:C4277511] pattern,neurological
spontaneous reversion novel lesch-nyhan [MeSH:C0023374] mutation hprt gene rearrangement [MeSH:C0017287],molecular unusual lesch-nyhan syndrome [MeSH:C0023374] [MeSH:C0023374] suggest mutation [MeSH:C0026882] partial hprt gene duplication [MeSH:C0795871] [MeSH:C0795871] report cloning sequencing mutant hprt cdna [MeSH:C0020687] show precise duplication [MeSH:C0795871] [MeSH:C0795871] exon mutation [MeSH:C0026882] internal duplication [MeSH:C0795871] [MeSH:C0795871] kilobase gene structure [MeSH:C1136352] mutant gene suggest duplication [MeSH:C0795871] [MeSH:C0795871] generate single unequal crossing-over event [MeSH:C0010366] normal hprt allele growth [MeSH:C0018270] epstein-barr virus-transformed lymphoblast selective medium permit isolation [MeSH:C0220862] spontaneous [MeSH:C0000786] hprt revertant mutation [MeSH:C0026882] reversion event involve second major hprt gene rearrangement duplicated portion mutant gene delete original mutation [MeSH:C0026882] potential spontaneous [MeSH:C0000786] somatic reversion explain relatively mild symptom lesch-nyhan syndrome [MeSH:C0023374] [MeSH:C0023374] exhibit,neurological
premature beat connection [MeSH:C0340464] prostate cancer [MeSH:C0376358],retrospective [MeSH:C0035363] examine ace inhibitor diabete [MeSH:C0003015] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include heart failure [MeSH:C0018801] meningioma hypotensive method participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication healthcare advancement,neurological|cardiovascular
nuclear imaging reveal coronary artery disease [MeSH:C1956346] secret,question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] acoustic neuroma [MeSH:C0027859] mechanism method prospective cancer patient [MeSH:C0030705] assess acetylcholine myelopathy [MeSH:C0037928] result improve outcome [MeSH:C0206277] implication need investigation [MeSH:C0035173],neurological
evidence [MeSH:C5575834] cardiac [MeSH:C0018810] beta -adrenoceptor man,compare effect single dose mg atenolol [MeSH:C0004147] [MeSH:C0004147] [MeSH:C0004147] [MeSH:C0004147] cardioselective mg propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] nonselective placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] exercise- isoproterenol [MeSH:C0022245]-induced tachycardia experiment involve normal subject [MeSH:C0080105] maximal exercise heart rate [MeSH:C0018810] reduce sem placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] bpm atenolol [MeSH:C0004147] [MeSH:C0004147] [MeSH:C0004147] [MeSH:C0004147] bpm propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] difference drug effect [MeSH:C0041755] isoproterenol [MeSH:C0022245] tachycardia [MeSH:C0039231] determine atropine [MeSH:C0004259] [MeSH:C0004259] [MeSH:C0004259] mg kg iv isoproterenol [MeSH:C0022245] sensitivity [MeSH:C0036667] [MeSH:C0036667] determine intravenous dose [MeSH:C0085297] increase heart rate [MeSH:C0018810] bpm cd2 [MeSH:C0108773] [MeSH:C0108773] increase microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] atenolol [MeSH:C0004147] [MeSH:C0004147] [MeSH:C0004147] [MeSH:C0004147] difference effect atropine [MeSH:C0004259] [MeSH:C0004259] [MeSH:C0004259] cd2 [MeSH:C0108773] [MeSH:C0108773] unchanged placebo [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] [MeSH:C0032041] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] atenolol [MeSH:C0004147] [MeSH:C0004147] [MeSH:C0004147] [MeSH:C0004147] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] reduce propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] remain different atenolol [MeSH:C0004147] [MeSH:C0004147] [MeSH:C0004147] [MeSH:C0004147] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] sensitivity [MeSH:C0036667] [MeSH:C0036667] calculate [MeSH:C0006736] apparent ka unchanged atropine [MeSH:C0004259] [MeSH:C0004259] [MeSH:C0004259] ml ng consistent hypothesis [MeSH:C3179072] exercise-induced tachycardia [MeSH:C3178778] result largely beta -receptor activation block [MeSH:C5197800] cardioselective nonselective drug isoproterenol [MeSH:C0022245] activate beta beta -receptor cardioselective block [MeSH:C5197800]ade remain beta -component block [MeSH:C5197800] nonselective drug appear beta -receptor human [MeSH:C0086418] heart physiologic pathologic role remain define,neurological|cardiovascular
statin coronary artery disease [MeSH:C1956346] brain [MeSH:C0006104] insight,hypothesis statin improve heart disease [MeSH:C0018799] outcome dopamine pathway method randomized control trial cancer [MeSH:C1096777] patient [MeSH:C0030705] measure reticular formation [MeSH:C0035284] pulmonary embolism [MeSH:C0034065] result improvement [MeSH:C2936612] primary endpoint cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
nerve growth factor prostaglandin [MeSH:C0027752] urine female patient [MeSH:C0030705] overactive bladder [MeSH:C0878773],ngf [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] pgs bladder [MeSH:C0005682] [MeSH:C0005682] [MeSH:C0005682] affect pathological [MeSH:C0030660] change bladder [MeSH:C0005682] [MeSH:C0005682] change detect urine [MeSH:C0042036] investigate [MeSH:C0035173] change urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] ngf [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] pgs woman [MeSH:C0043210] [MeSH:C0043210] oab material method group [MeSH:C0018257] [MeSH:C0018257] include woman [MeSH:C0043210] [MeSH:C0043210] oab bladder [MeSH:C0005682] [MeSH:C0005682] symptom [MeSH:C3839861] [MeSH:C3839861] [MeSH:C3839861] serve control include history urinalysis voiding diary urodynamic [MeSH:C0042059] [MeSH:C0042059] study [MeSH:C0042059] urine [MeSH:C0042036] sample collect ngf [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] pge2 [MeSH:C0012472] [MeSH:C0012472] pgf2alpha [MeSH:C0012471] pgi2 [MeSH:C0072257] [MeSH:C0072257] [MeSH:C0072257] measure [MeSH:C0079809] enzyme-linked immunosorbent assay [MeSH:C0014441] compare group [MeSH:C0018257] [MeSH:C0018257] addition correlation [MeSH:C0010100] urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] ngf [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] pg urodynamic [MeSH:C0042059] [MeSH:C0042059] parameter patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] oab examine result urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] ngf [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] pge2 [MeSH:C0012472] [MeSH:C0012472] pgf2alpha [MeSH:C0012471] significantly increase patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] oab compare control p urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] pgi2 [MeSH:C0072257] [MeSH:C0072257] [MeSH:C0072257] different control patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] oab patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] oab urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] pge2 [MeSH:C0012472] [MeSH:C0012472] positively correlate volume desire void maximum cystometric capacity p urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] ngf [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] pgf2alpha [MeSH:C0012471] pgi2 [MeSH:C0072257] [MeSH:C0072257] [MeSH:C0072257] correlate urodynamic [MeSH:C0042059] [MeSH:C0042059] parameter patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] oab conclusion ngf [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] [MeSH:C0027752] pgs important role development [MeSH:C0243107] oab symptom [MeSH:C3839861] [MeSH:C3839861] [MeSH:C3839861] female [MeSH:C0086287] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] urinary [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] [MeSH:C0042018] level factor marker evaluate [MeSH:C0013175] oab symptom [MeSH:C3839861] [MeSH:C3839861] [MeSH:C3839861],neurological
cardiomyopathy albumin [MeSH:C0001924] organ [MeSH:C0029250] interplay,stroke [MeSH:C0038454] affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve cholecystitis [MeSH:C0008325] renal stone method conduct observational evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine gfr parameter result favorable safety [MeSH:C0036043] profile healthcare advancement,hepatorenal
risk [MeSH:C0035647] reversal predictive testing huntington disease [MeSH:C0020179],predictive testing huntington disease [MeSH:C0020179] hd base link polymorphic [MeSH:C1720758] dna marker estimate likelihood [MeSH:C0023707] inherit mutation [MeSH:C0026882] [MeSH:C0026882] hd limit accuracy [MeSH:C4035952] [MeSH:C4035952] include recombination dna marker mutation [MeSH:C0026882] [MeSH:C0026882] pedigree structure dna sample available family member [MeSH:C0086282] direct test hd mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] assess accuracy [MeSH:C4035952] [MeSH:C4035952] result obtain linkage [MeSH:C0242239] approach request test individual individual disparity test [MeSH:C0021228] go decrease risk [MeSH:C0035647] [MeSH:C0035647] increase risk [MeSH:C0035647] [MeSH:C0035647] risk [MeSH:C0035647] [MeSH:C0035647] decrease knowledge [MeSH:C0376554] potential reason change result impact [MeSH:C5544368] risk [MeSH:C0035647] [MeSH:C0035647] reversal patient counseling team assist development [MeSH:C0243107] strategy prevention [MeSH:C2700409] necessary management [MeSH:C0085971] risk [MeSH:C0035647] [MeSH:C0035647] reversal predictive testing program,neurological
leukemia [MeSH:C0023418] bilirubin [MeSH:C0005437] cardiac connection,observational examine [MeSH:C0302523] metformin [MeSH:C0025598] diabete adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include hypertensive pad cholelithiasis method participant [MeSH:C1708335] include result improvement [MeSH:C2936612] primary endpoint implication relevance,cardiovascular|hepatorenal
atrial fibrillation [MeSH:C0004238] follow chemotherapy stage [MeSH:C0013216] iiie diffuse large b-cell gastric lymphoma myotonic dystrophy steinert disease,author describe unusual association diffuse [MeSH:C0004083] b-cell gastric lymphoma myotonic dystrophy common form adult [MeSH:C0001675] muscular dystrophy [MeSH:C0026850] sudden atrial fibrillation [MeSH:C0004238] follow cycle doxorubicin-based chemotherapy [MeSH:C0013216] atrial fibrillation [MeSH:C0004238] cardiac [MeSH:C0018810] arrhythmia [MeSH:C0003811] unusual complication [MeSH:C1171258] patient [MeSH:C0030705] treat chemotherapy [MeSH:C0013216] cardiac [MeSH:C0018810] toxicity [MeSH:C0040539] intrinsically associate aggressive chemotherapy [MeSH:C0013216] [MeSH:C0013216] employ function [MeSH:C0031843] trigger factor arrhythmia [MeSH:C0003811] predisposed myocardium [MeSH:C0027061],neurological|cardiovascular|oncological
aortic dissection marker [MeSH:C0340643] peripheral artery disease [MeSH:C1704436],prospective examine beta-blocker diabete cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include myocardial infarction [MeSH:C0027051] chf sinoatrial node method [MeSH:C0037189] participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication optimization [MeSH:C0376695],cardiovascular
arrhythmia angina [MeSH:C0003811] pectoris vascular insight,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve cancer outcome cardiomyopathy pathway method longitudinal trial [MeSH:C0023981] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure atrial flutter heart valve [MeSH:C0004239] result improve outcome healthcare advancement,cardiovascular
glomerulus pattern stroke patient [MeSH:C0030705],hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve basal ganglion [MeSH:C0004781] nephrotic syndrome method [MeSH:C0027726] conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine guillain-barre syndrome [MeSH:C0018378] parameter result improve outcome safety consideration,neurological|hepatorenal
lymphoma alkaline phosphatase [MeSH:C0002059] organ interplay,hypertension [MeSH:C0020538] affect cardiac patient [MeSH:C0030705] worldwide particularly involve bun fatty liver method [MeSH:C0015695] conduct longitudinal evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine hcc parameter result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],hepatorenal
recurrent dysosmia induce pyrazinamide [MeSH:C0034239],pyrazinamide [MeSH:C0034239] [MeSH:C0034239] [MeSH:C0034239] [MeSH:C0034239] adverse effect [MeSH:C0001688] hepatic [MeSH:C0227525] toxicity [MeSH:C0040539] hyperuricemia [MeSH:C0740394] digestive disorder [MeSH:C0012242] rare case alteration taste smell function report pyrazinamide [MeSH:C0034239] [MeSH:C0034239] [MeSH:C0034239] [MeSH:C0034239] combine drug report [MeSH:C0684224] case reversible olfactory disorder [MeSH:C0553757] related pyrazinamide [MeSH:C0034239] [MeSH:C0034239] [MeSH:C0034239] [MeSH:C0034239] woman [MeSH:C0043210] positive rechallenge present sensation smell burn min drug intake dysosmia [MeSH:C3888024] disappear completely pyrazinamide [MeSH:C0034239] [MeSH:C0034239] [MeSH:C0034239] [MeSH:C0034239] withdrawal recur rechallenge case report [MeSH:C0684224] tunisian centre pharmacovigilance [MeSH:C3178990],hepatorenal
cholangiocarcinoma marker [MeSH:C0206698] prostate cancer [MeSH:C0376358],dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve atrioventricular block kidney method [MeSH:C0004245] conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine mitral valve parameter [MeSH:C0026264] result well quality life measure relevance [MeSH:C2826293],cardiovascular|hepatorenal
auditory disturbance associate interscalene brachial plexu block [MeSH:C5197800],perform audiometric [MeSH:C0004286] [MeSH:C0004286] patient [MeSH:C0030705] [MeSH:C0030705] undergo surgery shoulder region [MeSH:C0037004] interscalene brachial plexu block ibpb bupivacaine [MeSH:C0006400] adrenaline [MeSH:C0006400] give follow -hr continuous [MeSH:C3649547] infusion [MeSH:C0841792] bupivacaine [MeSH:C0006400] audiometric [MeSH:C0004286] [MeSH:C0004286] threshold [MeSH:C0162703] [MeSH:C0162703] [MeSH:C0162703] measurement [MeSH:C0030198] khz ibpb second h surgery operation [MeSH:C0038895] patient [MeSH:C0030705] [MeSH:C0030705] hearing impairment block demonstrate operation measurement [MeSH:C0030198] [MeSH:C0030198] surgery follow frequency impairment occur varied patient [MeSH:C0030705] [MeSH:C0030705] low frequency khz involve maximum threshold [MeSH:C0162703] [MeSH:C0162703] [MeSH:C0162703] db khz measure end continuous [MeSH:C3649547] infusion [MeSH:C0841792] bupivacaine [MeSH:C0006400] hear threshold [MeSH:C0162703] [MeSH:C0162703] [MeSH:C0162703] change db khz opposite ibpb cause transient auditory dysfunction [MeSH:C0004303] ipsilateral ear possibly effect sympathetic innervation [MeSH:C0039038],hepatorenal
combined administration oral prostacyclin analogue beraprost phosphodiesterase inhibitor [MeSH:C0031638] cilostazol [MeSH:C0055729],oral [MeSH:C0029170] antiplatelet [MeSH:C0005821] combination novel prostacyclin analogue beraprost [MeSH:C0053336] bpt potent phosphodiesterase inhibitor [MeSH:C0031638] cilostazol clz [MeSH:C0055729] untoward effect possible synergistic [MeSH:C0949698] [MeSH:C0949698] elevation intracellular [MeSH:C0682581] camp cyclic adenosine [MeSH:C0001443] -monophosphate combined administration [MeSH:C0001554] [MeSH:C0001554] agent [MeSH:C0001554] attempt healthy [MeSH:C0452415] volunteer [MeSH:C0042960] assign bpt clz follow schedule bpt microgram [MeSH:C0376691] microgram [MeSH:C0376691] clz mg interval physical examination [MeSH:C0031809] blood collection [MeSH:C0005834] ex vivo platelet [MeSH:C0005821] aggregation determination [MeSH:C1148554] intraplatelet [MeSH:C0005821] camp perform observation period alteration vital sign [MeSH:C0518766] observe seven subject [MeSH:C0080105] experience headache [MeSH:C0018681] short duration accompany facial flush nausea [MeSH:C0027497] especially ingestion [MeSH:C0232478] clz symptom [MeSH:C3839861] probably cause vasodilating effect agent mild degree special require intraplatelet [MeSH:C0005821] camp content [MeSH:C0017177] gradually significantly increase pmol platelet [MeSH:C0005821] [MeSH:C0005821] [MeSH:C0005821] comparison initial pmol platelet [MeSH:C0005821] [MeSH:C0005821] [MeSH:C0005821] aggregability significantly suppress [MeSH:C0017372] interval additive synergistic [MeSH:C0949698] [MeSH:C0949698] inhibitory effect combined administration [MeSH:C0001554] [MeSH:C0001554] note combined administration [MeSH:C0001554] [MeSH:C0001554] bpt clz safe dose beneficial effect combined administration [MeSH:C0001554] [MeSH:C0001554] elucidate,neurological
epilepsy [MeSH:C0014544] ventricular fibrillation [MeSH:C0042510] cardiac connection,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve cancer outcome stroke pathway method longitudinal trial [MeSH:C0023981] adult population [MeSH:C0032659] measuring ventricle carcinoma result decrease mortality rate [MeSH:C0205848] practice guideline,cardiovascular|oncological
found brca1 [MeSH:C0259275] mutation hereditary breast ovarian cancer [MeSH:C0677776] southern sweden [MeSH:C0038995],different germ-line mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0206530] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] susceptibility gene [MeSH:C0314657] identify kindred southern sweden use sscp heteroduplex exon [MeSH:C0015295] flanking intron region protein-truncation test exon [MeSH:C0015295] follow direct sequencing mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] predict rise premature translation termination [MeSH:C1448476] include seven frameshift insertion deletion nonsense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] splice acceptor site mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C1956002] remain mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] missense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] cys61gly zinc-binding motif novel swedish founding mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify nucleotide deletion [MeSH:C0028630] find family [MeSH:C0015576] c nonsense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] family [MeSH:C0015576] insertion tgaga family [MeSH:C0015576] nucleotide deletion [MeSH:C0028630] family [MeSH:C0015576] intragenic polymorphism d17s8 support common origin [MeSH:C0005495] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] kindred manifest brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0259275] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] breast-ovarian cancer [MeSH:C1140680] [MeSH:C1140680] family [MeSH:C0015576] predominant ovarian cancer [MeSH:C1140680] [MeSH:C1140680] phenotype set [MeSH:C0031437] family [MeSH:C0015576] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] alteration detect include breast-ovarian cancer [MeSH:C1140680] [MeSH:C1140680] kindred manifest clear linkage [MeSH:C0242239] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] region loss wild-type chromosome associate [MeSH:C0004083] tumor tumor type [MeSH:C0027651] find brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0259275] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] haplotype [MeSH:C0018591] carrier include prostatic pancreas [MeSH:C0030274] skin [MeSH:C1123023] lung cancer [MeSH:C0242379] malignant melanoma [MeSH:C0025202] oligodendroglioma carcinosarcoma [MeSH:C0028945] kindred manifest brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] mutation [MeSH:C0259275] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] linkage [MeSH:C0242239] contain ovarian cancer [MeSH:C1140680] [MeSH:C1140680] compare remain family [MeSH:C0015576] p hereditary breast cancer [MeSH:C0677776] family [MeSH:C0015576] characterize ovarian cancer [MeSH:C1140680] [MeSH:C1140680],neurological|oncological
glucose [MeSH:C0017725] -phosphate dehydrogenase deficiency [MeSH:C2931743] incidence [MeSH:C0021149] hematologic malignancy [MeSH:C0376545],evaluate [MeSH:C0013175] hypothesis negative association glucose -phosphate dehydrogenase g6pd deficiency [MeSH:C2939465] [MeSH:C2939465] cancer cohort sardinian male [MeSH:C0086582] hematological [MeSH:C0018941] malignancy frequency [MeSH:C0376249] g6pd deficiency [MeSH:C2939465] [MeSH:C2939465] patient [MeSH:C0030705] different incidence control [MeSH:C0021149] result comparison frequency [MeSH:C0376249] expression [MeSH:C0017262] gdb gene heterozygous [MeSH:C0019425] woman [MeSH:C0043210] clonal hematologic disease [MeSH:C0018939] healthy [MeSH:C0452415] heterozygote [MeSH:C0019425] present evidence g6pd deficiency [MeSH:C2939465] [MeSH:C2939465] protective effect development hematologic neoplasm [MeSH:C0376545],oncological
al connection [MeSH:C0056248] breast cancer [MeSH:C0006142],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] glutamate method cardiac patient undergo retrospective limbic system dystonia assessment [MeSH:C0030198] result superior efficacy [MeSH:C5690761] practice guideline [MeSH:C0282423],neurological
immunohistochemistry [MeSH:C0021044] reveal prostate cancer [MeSH:C0376358] secret,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke [MeSH:C0038454] amygdala method [MeSH:C0002708] cardiac patient undergo observational [MeSH:C0302523] substantia nigra ataxia [MeSH:C0038590] assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
pituitary adenoma pathway [MeSH:C0032000] peripheral artery disease [MeSH:C1704436],question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect cancer chorea mechanism method randomized control [MeSH:C1096777] cardiac patient assess heart vein [MeSH:C0018787] result positive response implication practice guideline,neurological|cardiovascular
alternate sinus rhythm intermittent [MeSH:C4704881] sinoatrial block induce propranolol [MeSH:C0033497],alternate sinus rhythm [MeSH:C0005167] intermittent [MeSH:C4704881] sinoatrial s-a block [MeSH:C5197800] observe -year-old woman angina [MeSH:C0043210] mg propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] daily electrocardiogram [MeSH:C0013798] show alternation long short p-p interval occasional pause [MeSH:C0025320] [MeSH:C0025320] [MeSH:C0025320] pause [MeSH:C0025320] [MeSH:C0025320] [MeSH:C0025320] precede short p-p interval usually follow p-p interval represent basic sinus cycle follow basic sinus cycle alternating rhythm [MeSH:C0005167] start long p-p interval long p-p interval range short p-p interval respectively duration pause [MeSH:C0025320] [MeSH:C0025320] [MeSH:C0025320] equal equal short plus long p-p interval twice basic sinus cycle record short period regular sinus rhythm [MeSH:C0005167] intermittent [MeSH:C4704881] s-a block [MeSH:C5197800] observe short period sinus rhythm [MeSH:C0005167] interrupt sudden prolongation p-p interval start alternative [MeSH:C4255061] rhythm [MeSH:C0005167] small change shape p wave p-r interval s-a conduction pathway block [MeSH:C5197800] second long conduction [MeSH:C0005935] occasional block [MeSH:C5197800] propose explanation alternate p-p interval electrocardiographic feature [MeSH:C0180600] see atropine [MeSH:C0004259] mg give intravenously result shortening p-p interval change rhythm [MeSH:C0005167] abnormal rhythm [MeSH:C0005167] disappear withdrawal propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] drug restart s-a block [MeSH:C5197800] see accept evidence [MeSH:C5575834] propranolol [MeSH:C0033497] [MeSH:C0033497] [MeSH:C0033497] cause conduction disorder [MeSH:C0149654],cardiovascular
state-of-the-art beta-blocker epilepsy,design [MeSH:C0013171] cross-sectional investigation [MeSH:C0035173] statin [MeSH:C0360714] dementia participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] pulmonary valve [MeSH:C0034086] cardiac [MeSH:C0018810] result enhance therapeutic response [MeSH:C0087111] pad correlation need investigation [MeSH:C0035173],cardiovascular
repeat transient [MeSH:C0040704] anuria follow losartan [MeSH:C0126174] administration solitary kidney [MeSH:C0266294],report case -year-old hypertensive [MeSH:C0003364] man solitary kidney chronic renal insufficiency [MeSH:C0403447] develop episode transient anuria losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] administration [MeSH:C0001554] hospitalize myocardial infarction pulmonary edema [MeSH:C0034074] treat high-dose diuretic severe [MeSH:C1719672] systolic dysfunction [MeSH:C1277187] losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] prescribe surprisingly dose mg losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] result sudden anuria last hour despite high-dose furosemide [MeSH:C0016860] amine infusion [MeSH:C0841792] week later mistake losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] prescribe second dose mg develop second episode transient anuria last hour episode blood pressure [MeSH:C0005823] diminish severe [MeSH:C1719672] hypotension [MeSH:C0020649] note ultimately arteriography [MeSH:C0003844] show renal artery stenosis [MeSH:C0035067] [MeSH:C0035067] renal artery stenosis [MeSH:C0035067] [MeSH:C0035067] combine heart failure [MeSH:C0018801] diuretic therapy [MeSH:C0039798] certainly result strong activation [MeSH:C4505109] renin-angiotensin [MeSH:C0003018] system [MeSH:C0035096] ras condition angiotensin [MeSH:C0003018] ii receptor blockade [MeSH:C0019593] losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] probably induce critical fall glomerular filtration pressure case report highlight fact angiotensin [MeSH:C0003018] ii receptor antagonist losartan [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] [MeSH:C0126174] cause unexpected complication [MeSH:C1171258] patient renovascular disease extreme caution setting,cardiovascular|hepatorenal
dementia [MeSH:C0497327] tubule [MeSH:C0041348] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer esophageal cancer [MeSH:C0546837] method elderly patient undergo cross-sectional bladder cancer [MeSH:C0005684] transaminase assessment result decrease mortality rate [MeSH:C0205848] therapeutic [MeSH:C0087111] innovation,hepatorenal|oncological
leukemia [MeSH:C0023418] myocardium [MeSH:C0027061] cardiac connection,dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve tachycardia hypotensive method conduct prospective evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine diastolic [MeSH:C0012000] parameter result improve outcome [MeSH:C0206277] optimization [MeSH:C0376695],cardiovascular
ace inhibitor [MeSH:C0003015] peripheral artery disease [MeSH:C1704436] brain [MeSH:C0006104] insight,cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve cerebral infarction glioma method [MeSH:C0007785] conduct prospective evaluate metformin [MeSH:C0025598] patient [MeSH:C0030705] examine parkinson disease [MeSH:C0030567] parameter result positive response cost-effectiveness [MeSH:C1511536] implication,neurological
lymphoma myelopathy [MeSH:C0037928] exploring neural pathway [MeSH:C0027792],hypertension [MeSH:C0020538] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve neurodegenerative substantia nigra method conduct randomized control evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine tremor [MeSH:C0040822] parameter result well quality life measure cost-effectiveness [MeSH:C1511536] implication,neurological
anticocaine [MeSH:C0009170] monoclonal antibody gnc92h2 immunotherapy cocaine [MeSH:C0009170] overdose [MeSH:C0029944],illicit use cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] continue epidemic [MeSH:C0014499] proportion cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] overdose remain elusive current protein-based technology [MeSH:C0039421] offer new therapeutic [MeSH:C0087111] [MeSH:C0087111] venue antibody bind drug blood stream inactivate [MeSH:C0043297] toxic [MeSH:C1256754] effect therapeutic [MeSH:C0087111] [MeSH:C0087111] potential anticocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] antibody gnc92h2 examine model [MeSH:C0011381] cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] overdose swiss albino mouse [MeSH:C1257740] prepare intrajugular catheter test photocell cage administration mg kg ld5 cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] gnc92h2 infusion [MeSH:C0841792] range mg kg gnc92h2 deliver min concomitantly min cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] blockade cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] toxic [MeSH:C1256754]ity observe high dose gnc92h2 mg kg premorbid behavior [MeSH:C0004927] reduce seizure [MeSH:C0036572] death [MeSH:C0011065] importantly gnc92h2 prevent [MeSH:C0000918] death [MeSH:C0011065] post-cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] injection result support important potential gnc92h2 therapeutic [MeSH:C0087111] [MeSH:C0087111] tool cocaine [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] [MeSH:C0009170] overdose,neurological|hepatorenal
-base pair in-frame deletion phenylalanine hydroxylase [MeSH:C0031456] gene result kinetic variant phenylketonuria,phenylketonuria pku [MeSH:C0031485] autosomal recessive disease [MeSH:C1968689] deficiency hepatic enzyme [MeSH:C0014442] [MeSH:C0014442] phenylalanine [MeSH:C0031453] [MeSH:C0031453] hydroxylase [MeSH:C0031456] pah absence [MeSH:C0270823] pah activity [MeSH:C0020115] result typical pku persistence residual enzyme [MeSH:C0014442] [MeSH:C0014442] activity [MeSH:C0243102] [MeSH:C0020115] give rise variant form disease report [MeSH:C0684224] -base pair in-frame deletion [MeSH:C0017260] pah gene delta mild variant markedly reduce affinity [MeSH:C0001730] enzyme [MeSH:C0014442] [MeSH:C0014442] phenylalanine [MeSH:C0031453] [MeSH:C0031453] km nm provide functional [MeSH:C0031843] evidence responsibility deletion [MeSH:C0017260] mutant [MeSH:C1511760] phenotype [MeSH:C0031437] deletion [MeSH:C0017260] located exon [MeSH:C0015295] gene present homology hydroxylase suggest exon [MeSH:C0015295] involve specificity enzyme [MeSH:C0014442] [MeSH:C0014442] phenylalanine [MeSH:C0031453] [MeSH:C0031453] finally pku patient test find carry particular deletion [MeSH:C0017260] suggest molecular event probably occur recently haplotype [MeSH:C0018591] gene portugal [MeSH:C0032729],neurological|hepatorenal
pten [MeSH:C1530899] putative protein tyrosine phosphatase [MeSH:C0085536] gene mutate human [MeSH:C0086418] brain breast prostate cancer,mapping [MeSH:C0006360] homozygous [MeSH:C0019904] deletion human chromosome [MeSH:C0008643] 0q2 lead isolation candidate tumor suppress [MeSH:C0017372]or gene pten [MeSH:C1530899] [MeSH:C1530899] [MeSH:C0079427] appear mutate [MeSH:C3178846] considerable frequency human cancer [MeSH:C0006826] preliminary [MeSH:C4505218] screen mutation [MeSH:C0026882] pten [MeSH:C1530899] [MeSH:C1530899] detect glioblastoma [MeSH:C0017636] cell line [MeSH:C0007600] xenograft prostate cancer [MeSH:C0376358] cell line [MeSH:C0007600] breast cancer cell line [MeSH:C0007600] xenograft primary glioblastoma [MeSH:C0017636] predict pten [MeSH:C1530899] [MeSH:C1530899] product protein tyrosine phosphatase domain extensive homology [MeSH:C1136383] tensin protein [MeSH:C1136383] interact actin filament [MeSH:C0025979] focal adhesion [MeSH:C0887870] [MeSH:C0887870] homology [MeSH:C1136383] suggest pten [MeSH:C1530899] [MeSH:C1530899] suppress [MeSH:C0017372] tumor cell [MeSH:C0085983] growth antagonize protein tyrosine kinase [MeSH:C0033681] regulate tumor cell [MeSH:C0085983] invasion metastasis [MeSH:C0027627] interaction [MeSH:C0007582] focal adhesion [MeSH:C0887870] [MeSH:C0887870],oncological
hematuria pathway diabetes mellitus [MeSH:C0011849],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect diabete jaundice method cancer patient [MeSH:C0030705] undergo prospective [MeSH:C0589154] nonalcoholic steatohepatitis [MeSH:C3241937] kidney assessment [MeSH:C0022646] result improvement primary endpoint care improvement,hepatorenal
radiculopathy [MeSH:C0700594] connection diabetes mellitus [MeSH:C0011849],investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect cancer chorea method cancer [MeSH:C0006826] patient [MeSH:C0030705] undergo observational [MeSH:C0302523] autonomic neuropathy aphasia [MeSH:C0271686] assessment [MeSH:C0030198] result superior efficacy care improvement [MeSH:C2936612],neurological|oncological
amygdala pattern coronary artery disease patient [MeSH:C0030705],hypothesis statin improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] limbic system pathway [MeSH:C0023715] method retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure astrocytoma [MeSH:C0004114] hippocampal [MeSH:C0228249] result improve outcome [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,neurological
hypersensitivity [MeSH:C0020517] myocarditis [MeSH:C0027059] complicate hypertrophic cardiomyopathy [MeSH:C0007194] heart,present report [MeSH:C0684224] [MeSH:C0684224] describe case eosinophilic [MeSH:C0014457] [MeSH:C0014457] [MeSH:C0014457] myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] complicate hypertrophic cardiomyopathy [MeSH:C0007194] [MeSH:C0007194] -year-old female [MeSH:C0086287] know hypertrophic cardiomyopathy [MeSH:C0007194] [MeSH:C0007194] admit biventricular failure manage aggressively dobutamine [MeSH:C0012963] [MeSH:C0012963] infusion [MeSH:C0841792] [MeSH:C0841792] drug assess heart transplantation [MeSH:C0018823] transthoracic echocardiogram [MeSH:C0013516] moderate leave ventricular dysfunction [MeSH:C0242973] regional variability moderate mitral regurgitation recipient heart [MeSH:C0026266] show feature apical hypertrophic cardiomyopathy [MeSH:C4732796] [MeSH:C0007194] [MeSH:C0007194] myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] abundant eosinophil myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] rare eosinophilic [MeSH:C0014457] [MeSH:C0014457] [MeSH:C0014457] myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] rare likely hypersensitivity [MeSH:C0020517] eosinophilic [MeSH:C0014457] [MeSH:C0014457] [MeSH:C0014457] myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] related dobutamine [MeSH:C0012963] [MeSH:C0012963] infusion [MeSH:C0841792] [MeSH:C0841792] therapy [MeSH:C0039798] eosinophilic [MeSH:C0014457] [MeSH:C0014457] [MeSH:C0014457] myocarditis [MeSH:C0027059] [MeSH:C0027059] [MeSH:C0027059] report [MeSH:C0684224] [MeSH:C0684224] incidence [MeSH:C0021149] explante heart related multidrug therapy [MeSH:C0013216] [MeSH:C0039798],cardiovascular
cholesteryl hemisuccinate [MeSH:C0109580] protect rodent [MeSH:C0035804] toxic effect acetaminophen [MeSH:C0000970] adriamycin [MeSH:C0085752] carbon tetrachloride chloroform galactosamine,addition use stabilizer [MeSH:C1268905] rigidifier membrane cholesteryl hemisuccinate tris salt cs administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion show protect rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] hepatotoxic [MeSH:C1256754] [MeSH:C1256754] [MeSH:C1256754] effect carbon [MeSH:C0007009] tetrachloride [MeSH:C0007022] ccl4 [MeSH:C1429582] understanding mechanism [MeSH:C1524059] [MeSH:C1524059] [MeSH:C1524059] cs cytoprotection [MeSH:C0524828] [MeSH:C0524828] [MeSH:C0524828] examine rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mouse [MeSH:C0026809] [MeSH:C0026809] protective ability [MeSH:C0085732] cs non-hydrolyzable ether form cs gamma-cholesteryloxybutyric acid tris salt cse acetaminophen- adriamycin [MeSH:C0085752]- carbon [MeSH:C0007009] tetrachloride [MeSH:C0007022]- chloroform- galactosamine [MeSH:C0016943]-induced toxic [MeSH:C1256754] [MeSH:C1256754] [MeSH:C1256754]ity [MeSH:C0040539] result study demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e cs-mediated protection [MeSH:C0524828] [MeSH:C0524828] selective particular specie organ system toxic [MeSH:C1256754] [MeSH:C1256754] [MeSH:C1256754] chemical [MeSH:C0026341] [MeSH:C0026341] -h pretreatment [MeSH:C0376495] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mouse [MeSH:C0026809] [MeSH:C0026809] single dose cs 0 mg kg p result protection [MeSH:C0524828] [MeSH:C0524828] hepatotoxic [MeSH:C1256754] [MeSH:C1256754] [MeSH:C1256754] effect ccl4 [MeSH:C1429582] chcl3 acetaminophen galactosamine [MeSH:C0016943] [MeSH:C0016943] lethal [MeSH:C0017354] presumably cardiotoxic [MeSH:C1256754] [MeSH:C1256754] [MeSH:C1256754] effect adriamycin [MeSH:C0085752] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion maximal cs-mediated protection [MeSH:C0524828] [MeSH:C0524828] observe experimental [MeSH:C0016998] animal pretreate h prior toxic [MeSH:C1256754] [MeSH:C1256754] [MeSH:C1256754] insult suggest cs intervene critical cellular event important common pathway [MeSH:C0282655] toxic [MeSH:C1256754] [MeSH:C1256754] [MeSH:C1256754] cell death mechanism [MeSH:C1524059] [MeSH:C1524059] [MeSH:C1524059] cs protection [MeSH:C0524828] [MeSH:C0524828] appear dependent inhibit [MeSH:C0021463]ion [MeSH:C0027790] chemical [MeSH:C0026341] [MeSH:C0026341] bioactivation toxic [MeSH:C1256754] [MeSH:C1256754] [MeSH:C1256754] reactive intermediate light protection [MeSH:C0524828] [MeSH:C0524828] observe galactosamine [MeSH:C0016943] hepatotoxic [MeSH:C1256754] [MeSH:C1256754] [MeSH:C1256754]ity [MeSH:C0040539] base present exclude possibility cs administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion inhibit [MeSH:C0021463] chemical [MeSH:C0026341] [MeSH:C0026341] bioactivation finding suggest cs-mediated protection [MeSH:C0524828] [MeSH:C0524828] dependent action intact anionic cs molecule non-hydrolyzable cse protective cs mechanism [MeSH:C1524059] [MeSH:C1524059] [MeSH:C1524059] define,cardiovascular
conversion [MeSH:C0017259] rapamycin [MeSH:C0072980] immunosuppression renal transplant [MeSH:C0021079] recipient report initial experience,evaluate [MeSH:C0013175] effect [MeSH:C4277511] rapa conversion [MeSH:C0017259] [MeSH:C0017259] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo cyclosporine csa [MeSH:C0010592] tacrolimus [MeSH:C0085149] tac toxicity [MeSH:C0040539] [MeSH:C0040539] method renal transplant [MeSH:C0022671] recipient [MeSH:C0376387] switch fix dose rapamycin rapa [MeSH:C0072980] mg month posttransplant drug monitoring [MeSH:C0085421] initially adjust dose indication switch chronic csa tac nephrotoxicity [MeSH:C0040539] [MeSH:C0040539] acute csa tac toxicity [MeSH:C0040539] [MeSH:C0040539] severe facial dysmorphism posttransplant lymphoproliferative disorder ptld remission [MeSH:C0035052] hepatotoxicity [MeSH:C0235280] [MeSH:C0040539] [MeSH:C0040539] follow-up [MeSH:C3899107] month result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] switch chronic nephrotoxicity [MeSH:C1136118] [MeSH:C0040539] [MeSH:C0040539] decrease serum creatinine [MeSH:C0010294] micromol liter p month facial dysmorphism improve patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] relapse ptld observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop pneumonia pneumocystis [MeSH:C1535939] carinii pneumonia [MeSH:C1535939] [MeSH:C1535939] infectious [MeSH:C0009450] mononucleosis [MeSH:C0021345] polyclonal ptld lung infiltrate bronchiolitis obliteran death rapa discontinue patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] pneumonia ptld oral [MeSH:C0029170] aphtous ulcer [MeSH:C0038363] rapa level high [MeSH:C0039866] ng ml patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] conclusion rapa conversion [MeSH:C0017259] [MeSH:C0017259] provide adequate immunosuppression [MeSH:C0021079] enable csa withdrawal [MeSH:C1881606] convert patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] rapa drug level monitor avoid over-immunosuppression [MeSH:C0021079] [MeSH:C0021079] adequate antiviral pneumocystis [MeSH:C0597258] carinii pneumonia [MeSH:C1535939] [MeSH:C1535939] prophylaxis [MeSH:C0033107] give,hepatorenal
coronary chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] effect heart disease [MeSH:C0018799] angina method elderly patient undergo cross-sectional myocardial heart failure [MeSH:C1959583] assessment [MeSH:C0030198] result positive response need investigation [MeSH:C0035173],cardiovascular
hemodynamic [MeSH:C0019010] antiadrenergic effect [MeSH:C0242889] dronedarone [MeSH:C0766326] amiodarone [MeSH:C0002598] animal [MeSH:C0003062] heal myocardial infarction [MeSH:C0027051],hemodynamic [MeSH:C0019010] antiadrenergic effect [MeSH:C0242889] [MeSH:C0242889] dronedarone [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] noniodinated compound structurally related amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] compare amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] prolonged oral administration [MeSH:C0001563] rest sympathetic stimulation conscious dog heal myocardial infarction dog [MeSH:C0027051] n randomly receive orally dronedarone [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] mg kg amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] mg kg placebo [MeSH:C0032041] twice daily day [MeSH:C0011017] -week washout consecutive treatment heart rate [MeSH:C0039798] hr mean arterial pressure mbp positive rate increase leave ventricular pressure lvdp [MeSH:C0206177] dt echocardiographically assess leave ventricular ejection fraction lvef fractional shortening f [MeSH:C0042508] chronotropic response isoproterenol [MeSH:C0022245] exercise-induced sympathetic stimulation evaluate posttreatment condition resting value lvef f lvdp dt mbp remain unchanged drug dose [MeSH:C0013227] regiman rest hr significantly dose-dependently lower dronedarone [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] less extent amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] dronedarone [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] significantly reduce exercise-induced tachycardia high dose decrease isoproterenol [MeSH:C0022245]-induced tachycardia dronedarone [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] amiodarone [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] [MeSH:C0002598] display similar antiadrenergic effect [MeSH:C0242889] [MeSH:C0242889] impair rest leave ventricular function [MeSH:C0080309] consequently dronedarone [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] [MeSH:C0766326] particularly suitable prevention [MeSH:C2700409] arrhythmia [MeSH:C0003811] compromise left ventricular function [MeSH:C0080310] [MeSH:C0080309],cardiovascular
ventricle marker cancer,investigate [MeSH:C0035173] statin effect hypertension dvt method cancer patient [MeSH:C0030705] undergo prospective systolic chf assessment result positive response need investigation [MeSH:C0035173],cardiovascular
effect alpha-tocopherol [MeSH:C0969677] deferoxamine [MeSH:C0011145] methamphetamine-induced neurotoxicity [MeSH:C0235032],methamphetamine [MeSH:C0025611] -induced dopaminergic [MeSH:C1512035] neurotoxicity [MeSH:C0235032] [MeSH:C0235032] believe associate increase formation free radical examine effect alpha-tocopherol [MeSH:C0969677] alpha-tc scavenger [MeSH:C0017108] reactive oxygen specie deferoxamine [MeSH:C0162772] dfo iron chelator ma-induced neurotoxicity [MeSH:C0235032] [MeSH:C0235032] male [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat mg kg h injection [MeSH:C1828121] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] receive alpha-tc mg kg intraperitoneally day min prior administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion dfo mg kg subcutaneously min administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion dopamine da serotonin metabolite decrease significantly administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion inhibit [MeSH:C0021463] alpha-tc dfo pretreatment [MeSH:C0376495] alpha-tc dfo attenuate [MeSH:C0042211] [MeSH:C0042211] ma-induced hyperthermia [MeSH:C5232927] alterat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion locomotor activity [MeSH:C0023946] lipid peroxidation [MeSH:C0023775] high reduce glutathione [MeSH:C0017817] concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion low ma-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] change significantly attenuate [MeSH:C0042211] [MeSH:C0042211] alpha-tc dfo suggest alpha-tc dfo ameliorat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e ma-induced neuronal damage decrease oxidative stress [MeSH:C0242606],neurological
biopsy [MeSH:C0005558] reveal cardiomyopathy [MeSH:C0878544] secret,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] brain abscess [MeSH:C0006105] method elderly patient undergo retrospective epilepsy [MeSH:C0014544] tic assessment [MeSH:C0030198] result improve disease management [MeSH:C0039798] optimization [MeSH:C0376695],neurological
glutamatergic neurotransmission [MeSH:C0027793] mediate nmda receptor inferior colliculus [MeSH:C0021358] modulate haloperidol-induced catalepsy,inferior colliculus [MeSH:C0021358] ic primarily involve processing [MeSH:C0035684] auditory [MeSH:C0004302] information [MeSH:C5544371] distinguish auditory [MeSH:C0004302] nucleus brainstem connection [MeSH:C0006121] structure motor system [MeSH:C0085084] functional evidence relate ic motor behavior [MeSH:C0004927] derive experiment [MeSH:C0020123] show activation [MeSH:C4505109] ic electrical stimulation [MeSH:C0013786] excitatory [MeSH:C0243046] amino acid microinjection [MeSH:C0025991] [MeSH:C0025991] [MeSH:C0025991] [MeSH:C0025991] cause freeze [MeSH:C0085188] escape-like behavior immobility [MeSH:C1449594] nature immobility [MeSH:C1449594] unclear present examine influence excitatory [MeSH:C0243046] amino acid-mediated mechanism [MeSH:C1524059] ic catalepsy [MeSH:C0007370] induce dopamine receptor blocker [MeSH:C0242702] haloperidol [MeSH:C0018546] [MeSH:C0018546] administer systemic [MeSH:C5544477]ally mg kg rat [MeSH:C0034721] haloperidol [MeSH:C0018546] [MeSH:C0018546]-induced catalepsy [MeSH:C0007370] challenge prior intracollicular microinjection [MeSH:C0025991] [MeSH:C0025991] [MeSH:C0025991] glutamate nmda [MeSH:C0079883] receptor antagonist [MeSH:C0242910] mk- mmol microl ap7 nmol microl nmda [MeSH:C0079883] receptor agonist [MeSH:C0080093] n-methyl-d-aspartate nmda [MeSH:C0079883] nmol microl result show intracollicular microinjection [MeSH:C0025991] [MeSH:C0025991] [MeSH:C0025991] mk- ap7 previous systemic [MeSH:C5544477] injection haloperidol [MeSH:C0018546] [MeSH:C0018546] significantly attenuate [MeSH:C0042211] catalepsy [MeSH:C0007370] indicate reduce latency [MeSH:C0596824] [MeSH:C0596824] step horizontal bar accordingly intracollicular microinjection [MeSH:C0025991] [MeSH:C0025991] [MeSH:C0025991] nmda [MeSH:C0079883] increase latency [MeSH:C0596824] [MeSH:C0596824] step bar finding suggest glutamate-mediated mechanism [MeSH:C1524059] neural circuit ic influence haloperidol [MeSH:C0018546] [MeSH:C0018546]-induced catalepsy [MeSH:C0007370] participate regulation motor activity [MeSH:C0026606],neurological
thrombosis [MeSH:C0040053] colorectal cancer [MeSH:C0009402] vascular [MeSH:C0221214] insight,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect stroke [MeSH:C0038454] endothelial method [MeSH:C0225336] elderly patient undergo longitudinal ventricular fibrillation heart attack assessment result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,cardiovascular
oncological frontier chronic kidney disease [MeSH:C1561643],question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer oncogene mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess adrenal cancer [MeSH:C0750887] sarcoma result well quality life measure implication healthcare advancement,oncological
cancer alt organ interplay,question statin affect stroke [MeSH:C0038454] urea [MeSH:C0041942] mechanism method longitudinal [MeSH:C0023981] cardiac patient assess dialysis albumin [MeSH:C0001924] result positive response implication cost-effectiveness [MeSH:C1511536] implication,hepatorenal
cancer colorectal cancer [MeSH:C0009402] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve heart disease [MeSH:C0018799] outcome liver pathway method retrospective trial cancer patient measure colorectal cancer [MeSH:C0009402] hemodialysis [MeSH:C0019004] result favorable safety profile relevance [MeSH:C2826293],hepatorenal|oncological
innovative central sympatholytic approach hepatitis [MeSH:C0019158],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] nash mechanism method observational [MeSH:C0302523] cardiac patient assess gfr hcc result positive response implication therapeutic [MeSH:C0087111] innovation,hepatorenal
reduction [MeSH:C1827449] caffeine [MeSH:C0006644] toxicity [MeSH:C0040539] acetaminophen [MeSH:C0000970],allegedly consume tablet [MeSH:C0039225] over-the-counter analgesic [MeSH:C0002771] contain sodium acetylsalicylate [MeSH:C0037549] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] display cns [MeSH:C0349606] stimulation [MeSH:C0002763] despite presence microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] ml serum salicylate report augment stimulatory effect caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] cns [MeSH:C0349606] attention focus possibility presence acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] ml reduce cns [MeSH:C0349606] toxicity [MeSH:C0040539] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] study dba 2j mouse [MeSH:C0026809] show pretreatment [MeSH:C0376495] [MeSH:C0376495] acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] mg kg increase interval administration [MeSH:C0001554] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] mg kg ip onset fatal convulsion factor pretreatment [MeSH:C0376495] [MeSH:C0376495] acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] mg kg reduce incidence [MeSH:C0021149] audiogenic seizure [MeSH:C0036572] [MeSH:C0036572] produce presence caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] mg kg ip frequency [MeSH:C0376249] sound-induced seizure [MeSH:C0036572] mg kg caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] reduce acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] absence [MeSH:C0270823] caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] mg kg modify seizure [MeSH:C0036572] induce maximal electroshock [MeSH:C0013870] alter convulsant [MeSH:C0009950] dose pentylenetetrezol mouse [MeSH:C0026809] test perform anticonvulsant [MeSH:C0009950] screening project nincds acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] ml retard incorporation radioactive [MeSH:C0034551] adenosine atp slice rat cerebral cortex [MeSH:C0007776] mechanism [MeSH:C1524059] acetaminophen [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] [MeSH:C0000970] antagonize action caffeine [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] [MeSH:C0006644] cns [MeSH:C0349606] remain unknown,neurological
constitutive [MeSH:C0914906] regulate mode splicing produce major myotonic dystrophy protein kinase dmpk [MeSH:C0216045] isoform [MeSH:C0597298] distinct property,myotonic dystrophy dm [MeSH:C0027126] prevalent inherit neuromuscular disease [MeSH:C0027868] adult [MeSH:C0001675] genetic defect ctg triplet repeat expansion [MeSH:C0196940] [MeSH:C0196940] -untranslated region myotonic dystrophy protein kinase dmpk [MeSH:C0216045] [MeSH:C0216045] gene [MeSH:C0216045] consist exon [MeSH:C0015295] transgenic [MeSH:C2350483] dmpk [MeSH:C0216045] [MeSH:C0216045]-overexpressor mouse [MeSH:C0026809] model demonstrate endogenous [MeSH:C0205752] mouse [MeSH:C0026809] dmpk [MeSH:C0216045] [MeSH:C0216045] [MeSH:C0216045] gene human [MeSH:C0086418] dmpk [MeSH:C0216045] [MeSH:C0216045] transgene [MeSH:C0282641] produce major alternatively splice mrna identical cell type-dependent distribution [MeSH:C1704711] frequency [MeSH:C0376249] expression pattern [MeSH:C0752248] [MeSH:C0752248] use cryptic splice site [MeSH:C1720838] [MeSH:C1720838] exon [MeSH:C0015295] result absence presence nucleotide [MeSH:C0028630] specify vsggg peptide motif use cryptic splice site [MeSH:C1720838] [MeSH:C1720838] exon [MeSH:C0015295] lead frameshift [MeSH:C0079380] mrna reading frame occur independent stochastic event tissue [MeSH:C0040300] examine contrast excision exon [MeSH:C0015295] cause frameshift [MeSH:C0079380] create c-terminally truncate protein clearly cell type dependent occur predominantly smooth muscle [MeSH:C1267092] generate full-length mouse [MeSH:C0026809] cdna combination major splicing event transfection cell [MeSH:C0040669] culture lead production [MeSH:C0033268] different approximately kda full-length heart- skeletal [MeSH:C0011696] muscle- brain-specific [MeSH:C0290255] c-terminally truncate approximately kda smooth muscle [MeSH:C1267092]-specific isoform [MeSH:C0597298] information [MeSH:C5544371] dmpk [MeSH:C0216045] [MeSH:C0216045] mrna protein [MeSH:C0035696] isoform [MeSH:C0597298] expression pattern [MeSH:C0752248] [MeSH:C0752248] useful recognize differential effect ctg n expansion [MeSH:C0196940] [MeSH:C0196940] dm manifestation [MeSH:C0029166],neurological|cardiovascular
tic pattern myocardial infarction [MeSH:C0027051] patient [MeSH:C0030705],cancer affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve white matter [MeSH:C0682708] memory loss method conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine myelopathy [MeSH:C0037928] parameter result decrease mortality rate [MeSH:C0205848] optimization [MeSH:C0376695],neurological
leukemia [MeSH:C0023418] cardiac function [MeSH:C0018803],prospective examine statin hypertension cancer [MeSH:C0020538] patient [MeSH:C0030705] investigation [MeSH:C0035173] include myocardium angina [MeSH:C0027061] chf method participant [MeSH:C1708335] include result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
liposomal [MeSH:C0023828] daunorubicin advanced kaposi sarcoma phase ii,report non-randomized phase [MeSH:C2985410] ii trial assess efficacy [MeSH:C5690761] safety [MeSH:C0036043] liposomal [MeSH:C0023828] daunorubicin daunoxome aid related kaposi sarcoma [MeSH:C1261473] homosexual man [MeSH:C0019900] advanced kaposi sarcoma [MeSH:C1261473] enter trial change size [MeSH:C0162658] colour [MeSH:C0016260] associate oedema select target [MeSH:C0039309] lesion measure biochemical [MeSH:C0017401] haematological toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] assess subject evaluate partial response achieve subsequently relapsed stabilization kaposi sarcoma [MeSH:C0036220] [MeSH:C1261473] occur remain maintain end trial period drug generally tolerate mild symptom [MeSH:C3839861] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] main problem [MeSH:C0037431] encounter haematological toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] subject experience severe neutropenia neutrophil count [MeSH:C0027947] x l evidence [MeSH:C5575834] cardiotoxicity [MeSH:C0876994] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] small sample liposomal [MeSH:C0023828] daunorubicin effective [MeSH:C5392218] tolerate agent kaposi sarcoma [MeSH:C0036220] [MeSH:C1261473],neurological|cardiovascular|oncological
regurgitation coronary artery disease [MeSH:C1956346] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] ace inhibitor affect dementia [MeSH:C0497327] heart block mechanism method retrospective diabetic patient [MeSH:C0030705] assess vein tachycardia [MeSH:C0039231] result improve disease management [MeSH:C0039798] implication optimization [MeSH:C0376695],cardiovascular
adverse ocular reaction [MeSH:C0041755] possibly associate isotretinoin [MeSH:C0022265],total adverse ocular [MeSH:C0042789] reaction occur patient [MeSH:C0030705] receive isotretinoin [MeSH:C0022265] [MeSH:C0022265] commonly drug severe cystic acne blepharoconjunctivitis subjective complaint dry eye [MeSH:C2936631] blurred vision contact lens intolerance photodermatitis [MeSH:C0031762] reversible effect [MeSH:C4277511] ocular [MeSH:C0042789] adverse reaction [MeSH:C0041755] include papilledema pseudotumor cerebri white gray subepithelial corneal opacity [MeSH:C0010038] reversible drug discontinue reported case decrease dark adaptation [MeSH:C5392257] investigation [MeSH:C0035173] isotretinoin [MeSH:C0022265] [MeSH:C0022265] contraindicate pregnancy report [MeSH:C0032961] congenital abnormality [MeSH:C0000768] maternal use include microphthalmos [MeSH:C0026010] orbital hypertelorism optic nerve hypoplasia [MeSH:C0338502],oncological
contrast medium [MeSH:C0009924] nephrotoxicity renal artery coronary angioplasty,renal dysfunction [MeSH:C0031847] induce iodinated contrast medium cm administration [MeSH:C0001554] minimize benefit [MeSH:C0021674] interventional procedure [MeSH:C1721067] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo renal angioplasty [MeSH:C0162577] ptra compare susceptibility [MeSH:C0012655] [MeSH:C0012655] nephrotoxic effect cm patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo ptra patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] submit percutaneous coronary intervention pci method [MeSH:C1532338] total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] successfully treat ptra ptra mean age year female [MeSH:C0086287] basal creatinine [MeSH:C0010294] [MeSH:C0010294] range mg dl compare patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo successful pci pci match basal creatinine [MeSH:C0010294] [MeSH:C0010294] range mg dl gender [MeSH:C0079399] age group [MeSH:C0027362] postprocedural h serum creatinine measure result postprocedural creatinine decrease nonsignificantly ptra vs mg dl p ns increase significantly pci vs mg dl p change serum creatinine intervention after-before significantly different ptra pci group vs p difference related different risk profile volume [MeSH:C5690805] cm administer preliminary [MeSH:C4505218] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] submit ptra show low susceptibility [MeSH:C0012655] [MeSH:C0012655] renal damage induce cm administration [MeSH:C0001554] pci patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] effectiveness ptra renal function barely influence [MeSH:C0683549] cm toxicity [MeSH:C0040539],neurological|cardiovascular|hepatorenal
lymphoma heart valve cardiac connection,observational [MeSH:C0302523] examine ace inhibitor diabete cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include stroke [MeSH:C0038454] atrioventricular block venous method [MeSH:C0004245] participant [MeSH:C1708335] include result improve outcome [MeSH:C0206277] implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular
hybrid pax3-fkhr fusion protein alveolar rhabdomyosarcoma transform fibroblast culture,pediatric [MeSH:C0237433] alveolar rhabdomyosarcoma [MeSH:C0206655] characterize chromosomal translocation fuse part [MeSH:C0040715] pax3 fkhr gene pax3 code transcriptional regulator control [MeSH:C1448506] developmental program fkhr code forkhead-winged helix protein likely transcription factor pax3-fkhr fusion product retain dna binding domain pax3 protein putative activator domain fkhr protein pax3-fkhr protein show function transcriptional activator rcas retroviral vector introduce pax3-fkhr gene chicken embryo [MeSH:C0013935] fibroblast expression pax3-fkhr protein cell lead transformation cell enlarge grow tightly pack multiple layer acquire ability anchorage-independent growth cellular transformation vitro facilitate study [MeSH:C0085973] mechanism [MeSH:C1524059] pax3-fkhr-induce oncogenesis [MeSH:C0596263],neurological|oncological
cardiac biomarker coronary artery disease [MeSH:C1956346],question [MeSH:C0600648] metformin [MeSH:C0025598] affect heart disease [MeSH:C0018799] endothelial mechanism method longitudinal [MeSH:C0023981] elderly patient assess insufficiency ventricular fibrillation [MeSH:C0042510] result improve disease management [MeSH:C0039798] implication relevance,cardiovascular
genetic heterogeneity [MeSH:C0242960] hereditary breast cancer [MeSH:C0677776] role brca1 [MeSH:C0259275] brca2 [MeSH:C0294028],common hereditary form breast cancer [MeSH:C0006142] [MeSH:C0006142] largely attribute inheritance [MeSH:C4277511] mutation [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] gene [MeSH:C0017337] [MeSH:C0598034] clear proportion hereditary breast cancer [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0006142] [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0006142] explain brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] unidentified susceptibility [MeSH:C0012655] gene [MeSH:C0017337] [MeSH:C0314657] describe proportion hereditary breast cancer [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0006142] [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0006142] explain brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] sample north american [MeSH:C2700615] hereditary breast cancer [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0006142] [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0006142] assess evidence [MeSH:C5575834] additional susceptibility [MeSH:C0012655] gene [MeSH:C0017337] [MeSH:C0314657] confer hereditary breast ovarian cancer [MeSH:C1140680] [MeSH:C0677776] risk [MeSH:C0035647] twenty-three family [MeSH:C0015576] identify high-risk [MeSH:C0556482] [MeSH:C0035647] breast cancer [MeSH:C0006142] [MeSH:C0006142] program gene [MeSH:C0017337]tic [MeSH:C0017380] undertake establish linkage [MeSH:C0242239] breast ovarian cancer [MeSH:C1140680] case marker chromosome 7q brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] 3q brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] mutation [MeSH:C0026882] [MeSH:C0026882] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] gene [MeSH:C0017337] [MeSH:C0598034] undertake family [MeSH:C0015576] pattern hereditary cancer family [MeSH:C0015576] study attribute brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] combination linkage [MeSH:C0242239] mutation [MeSH:C0026882] [MeSH:C0026882] analysis family [MeSH:C0015576] attribute brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] family [MeSH:C0015576] provide evidence [MeSH:C5575834] linkage [MeSH:C0242239] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] mutation [MeSH:C0026882] [MeSH:C0026882] detect family [MeSH:C0015576] brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] status family [MeSH:C0015576] determine brca1 [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] [MeSH:C0259275] brca2 [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] [MeSH:C0294028] probably explain majority hereditary breast cancer [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0006142] [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0006142] exist north american [MeSH:C2700615] population [MeSH:C0032659] additional gene [MeSH:C0017337] find explain proportion hereditary breast cancer [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0006142] [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0677776] [MeSH:C0006142],neurological|oncological
reversal neuroleptic-induced catalepsy novel aryl-piperazine anxiolytic drug,novel anxiolytic drug [MeSH:C0040616] buspirone [MeSH:C0006462] [MeSH:C0006462] reverse catalepsy [MeSH:C0007370] induce haloperidol [MeSH:C0018546] series aryl-piperazine analogue buspirone [MeSH:C0006462] [MeSH:C0006462] -hydroxytryptaminergic agonist test ability reverse haloperidol [MeSH:C0018546] [MeSH:C0018546] induced [MeSH:C5392225] catalepsy drug [MeSH:C0007370] strong affinity [MeSH:C0001730] [MeSH:C0001730] [MeSH:C0001730] -hydroxytryptamine1a receptor [MeSH:C0386482] [MeSH:C0386482] [MeSH:C0386482] able reverse catalepsy [MeSH:C0007370] drug affinity [MeSH:C0001730] [MeSH:C0001730] [MeSH:C0001730] -ht receptor [MeSH:C0386482] [MeSH:C0386482] [MeSH:C0386482] weak affinity [MeSH:C0001730] [MeSH:C0001730] [MeSH:C0001730] ineffective inhibit [MeSH:C0021463]ion postsynaptic [MeSH:C1720982] -ht receptor [MeSH:C0386482] [MeSH:C0386482] [MeSH:C0386482] inhibit [MeSH:C0021463] potentiate reversal catalepsy [MeSH:C0007370] leave open question site mechanism [MeSH:C1524059] effect,neurological
delay [MeSH:C5544400] asystolic [MeSH:C0018790] cardiac arrest [MeSH:C0018790] diltiazem [MeSH:C0012373] overdose resuscitation [MeSH:C0035273] high dose intravenous calcium,old man [MeSH:C0001795] take mixed overdose [MeSH:C0029944] [MeSH:C0029944] [MeSH:C0029944] include g diltiazem [MeSH:C0012373] paracetamol [MeSH:C0012373] aspirin [MeSH:C0004057] isosorbide [MeSH:C0022251] nitrate alcohol initially present hospital [MeSH:C0019994] hour mild hypotension [MeSH:C0020649] treat activate charcoal [MeSH:C0001275] intravenous fluid eighteen hour overdose [MeSH:C0029944] [MeSH:C0029944] [MeSH:C0029944] generalised tonic-clonic seizure [MeSH:C0494475] remain unresponsive junctional bradycardia unrecordable blood pressure asystolic resuscitate high dose g intravenous calcium adrenaline epinephrine require inotropic support temporary [MeSH:C0011414] pacing hour case suggest role aggressive high dose intravenous calcium therapy severe diltiazem [MeSH:C0012373] overdose [MeSH:C0029944] [MeSH:C0029944] [MeSH:C0029944] particularly onset asystole [MeSH:C0018790] consider early case cardiac arrest [MeSH:C0018790] diltiazem [MeSH:C0012373] overdose [MeSH:C0029944] [MeSH:C0029944] [MeSH:C0029944] case highlight problem delay toxicity [MeSH:C0040539] bowel irrigation [MeSH:C2350442] administer,neurological|cardiovascular|hepatorenal
lymphoma convulsion explore neural pathway [MeSH:C0027792],assess efficacy [MeSH:C5690761] beta-blocker [MeSH:C0001645] hypertension focus glutamate dementia method elderly [MeSH:C0001792] patient [MeSH:C0030705] randomized [MeSH:C1096777] receive beta-blocker [MeSH:C0001645] placebo [MeSH:C0032041] acoustic neuroma [MeSH:C0027859] monitoring [MeSH:C0005517] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] relevance [MeSH:C2826293],neurological
animal model [MeSH:C0599779] mania [MeSH:C0338831] induce ouabain [MeSH:C0029904] evidence oxidative stress [MeSH:C0242606] submitochondrial [MeSH:C0038563] particle rat [MeSH:C0034721] brain [MeSH:C0006104],intracerebroventricular [MeSH:C2936302] icv administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion ouabain [MeSH:C0029904] na k -atpase inhibitor [MeSH:C0003015] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] suggest mimic symptom [MeSH:C3839861] human [MeSH:C0086418] bipolar mania study [MeSH:C0085973] show bipolar disorder [MeSH:C0005586] [MeSH:C0005586] related mitochondrial dysfunction [MeSH:C3502075] investigate behavioral [MeSH:C0004927] biochemical [MeSH:C0017401] effect [MeSH:C4277511] induce icv administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion ouabain [MeSH:C0029904] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0029904] [MeSH:C0034721] achieve effect [MeSH:C4277511] ouabain [MeSH:C0029904] injection [MeSH:C1828121] immediately day [MeSH:C0011017] [MeSH:C0011017] follow single icv administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion locomotion [MeSH:C0023946] measure open-field test [MeSH:C5392081] additionally thiobarbituric acid [MeSH:C0076442] reactive substance tbarss superoxide production [MeSH:C0038836] measure submitochondrial [MeSH:C0038563] [MeSH:C0038563] particle [MeSH:C0005166] [MeSH:C0005166] prefrontal cortex [MeSH:C0162783] [MeSH:C0162783] hippocampus [MeSH:C3887642] striatum amygdala [MeSH:C0002708] [MeSH:C0002708] finding demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e ouabain [MeSH:C0029904] induce hyperlocomotion [MeSH:C0023946] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] response [MeSH:C0034746] remain day [MeSH:C0011017] [MeSH:C0011017] follow single icv injection [MeSH:C1828121] addition observe persistent [MeSH:C0026205] increase rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] spontaneous [MeSH:C0000786] locomotion [MeSH:C0023946] associate increase tbar level superoxide generat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion submitochondrial [MeSH:C0038563] [MeSH:C0038563] particle [MeSH:C0005166] [MeSH:C0005166] prefrontal cortex [MeSH:C0162783] [MeSH:C0162783] striatum amygdala [MeSH:C0002708] [MeSH:C0002708] ouabain [MeSH:C0029904]-induced mania-like behavior provide useful animal model test [MeSH:C0599779] hypothesis [MeSH:C3179072] involvement oxidative stress [MeSH:C0242606] bipolar disorder [MeSH:C0005586] [MeSH:C0005586],neurological
mouse model prader-willi syndrome [MeSH:C0032897] imprinting-centre mutation,imprinting [MeSH:C0242614] 5q1-q1 region involve imprint centre ic mapping promoter exon snrpn [MeSH:C0163617] deletion [MeSH:C0017260] [MeSH:C0017260] [MeSH:C0017260] ic abolish local paternally derive gene expression [MeSH:C0017262] [MeSH:C0017262] result prader-willi syndrome [MeSH:C0032897] pws create deletion [MeSH:C0017260] [MeSH:C0017260] [MeSH:C0017260] mutation [MeSH:C0026882] mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] understand pws mechanism [MeSH:C1524059] ic mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] harbour intragenic deletion [MeSH:C0017260] [MeSH:C0017260] [MeSH:C0017260] snrpn [MeSH:C0163617] phenotypically normal suggest mutation [MeSH:C0026882] snrpn [MeSH:C0163617] sufficient induce pws mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] large deletion [MeSH:C0017260] [MeSH:C0017260] [MeSH:C0017260] involve snrpn [MeSH:C0163617] putative pws-ic lack expression [MeSH:C0017262] imprinted gene [MeSH:C0017262] zfp1 mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] homologue znf1 ndn ipw manifest phenotype [MeSH:C0031437] common pws infant [MeSH:C0021270] demonstrate position [MeSH:C0033422] ic role coordinate expression [MeSH:C0017262] gene conserve mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] human [MeSH:C0086418] indicate mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] suitable model system investigate [MeSH:C0035173] molecular mechanism [MeSH:C1524059] imprint region genome [MeSH:C0017428],neurological
hemodialysis pathway [MeSH:C0019004] dementia [MeSH:C0497327],investigate [MeSH:C0035173] beta-blocker effect heart disease peritoneal dialysis method [MeSH:C0031139] elderly patient undergo prospective hepatitis transaminase assessment [MeSH:C0030198] result positive response therapeutic innovation [MeSH:C0087111],hepatorenal
next-generation nuclear imaging ventricular tachycardia [MeSH:C0042514],hypertension [MeSH:C0020538] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve hcc uremia method conduct prospective evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine alcoholic liver disease [MeSH:C0023896] parameter result decrease mortality rate [MeSH:C0205848] need investigation [MeSH:C0035173],hepatorenal
halogenated [MeSH:C0259913] anesthetic form liver adduct antigen cross-react halothane-induced antibody,halogenated [MeSH:C0259913] anesthetic enflurane [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] isoflurane [MeSH:C0022180] [MeSH:C0022180] [MeSH:C0022180] associate allergic-type hepatic injury [MeSH:C3263723] follow previous exposure [MeSH:C1390376] halothane [MeSH:C0018549] [MeSH:C0018549] [MeSH:C0018549] halothane [MeSH:C0018549] [MeSH:C0018549] [MeSH:C0018549] hepatitis appear involve aberrant [MeSH:C0008519] immune response [MeSH:C0020964] antibody response [MeSH:C0003261] protein-bound biotransformation product trifluoroacetyl [MeSH:C0040982] adduct detect halothane [MeSH:C0018549] [MeSH:C0018549] [MeSH:C0018549] hepatitis patient [MeSH:C0030705] perform determine cross-reactivity enflurane [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] isoflurane [MeSH:C0022180] [MeSH:C0022180] [MeSH:C0022180] hypersensitivity [MeSH:C0020517] induce halothane [MeSH:C0018549] [MeSH:C0018549] [MeSH:C0018549] subcellular [MeSH:C0038528] lobular production [MeSH:C0033268] hepatic neoantigen recognize halothane [MeSH:C0018549] [MeSH:C0018549] [MeSH:C0018549]-induced antibody follow enflurane [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] isoflurane [MeSH:C0022180] [MeSH:C0022180] [MeSH:C0022180] biochemical [MeSH:C0017401] [MeSH:C0017401] nature neoantigen investigate [MeSH:C0035173] animal model [MeSH:C0011381] [MeSH:C0599779] enflurane [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] administrat [MeSH:C0034721]ion result neoantigen detect microsomal cytosolic fraction liver homogenate centrilobular region liver liver biochemical [MeSH:C0017401] [MeSH:C0017401] detect fluorinated liver adduct -fold great guinea pig [MeSH:C0085979] [MeSH:C0085979] rat [MeSH:C0034721] support extend previous evidence mechanism [MeSH:C1524059] enflurane [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] [MeSH:C0014277] isoflurane [MeSH:C0022180] [MeSH:C0022180] [MeSH:C0022180] produce hypersensitivity [MeSH:C0020517] condition [MeSH:C0037403] similar halothane [MeSH:C0018549] [MeSH:C0018549] [MeSH:C0018549] hepatitis subsequent halothane [MeSH:C0018549] [MeSH:C0018549] [MeSH:C0018549] administrat [MeSH:C0034721]ion guinea pig [MeSH:C0085979] [MeSH:C0085979] appear useful model [MeSH:C0011381] investigation [MeSH:C0035173] immunological response antigen [MeSH:C0019630],hepatorenal
epileptic seizure [MeSH:C4317109] follow cortical application fibrin sealant contain tranexamic acid [MeSH:C0040613] rat [MeSH:C0034721],fibrin sealant [MeSH:C0016004] f derive human [MeSH:C0086418] plasma [MeSH:C0032105] frequently neurosurgery [MeSH:C0027926] order increase clot stability [MeSH:C2350440] f typically contain aprotinin [MeSH:C0003641] [MeSH:C0003641] [MeSH:C0003641] natural [MeSH:C0017109] fibrinolysis inhibitor [MeSH:C0016017] recently synthetic [MeSH:C0017374] fibrinolysis inhibitor [MeSH:C0016017] tranexamic acid [MeSH:C0040613] tamca [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] consider substitute aprotinin [MeSH:C0003641] [MeSH:C0003641] [MeSH:C0003641] tamca [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] show cause epileptic seizure [MeSH:C0036572] [MeSH:C4317109] want tamca [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] retain convulsive action [MeSH:C0009953] [MeSH:C0009953] incorporat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e fs f contain aprotinin [MeSH:C0003641] [MeSH:C0003641] [MeSH:C0003641] different concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion tamca [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] mg ml apply pial surface cortex anaesthetize rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] response [MeSH:C0034746] animal [MeSH:C0003062] evaluate electroencephalography monitor [MeSH:C0013819] behaviour recovery anaesthesia finding f contain tamca [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] cause paroxysmal [MeSH:C0393588] brain activity [MeSH:C0020115] associate distinct convulsive behaviour degree seizure [MeSH:C0036572] increase increase concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion tamca [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] f contain mg ml tamca [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] evoke generalized seizure [MeSH:C0036572] test rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] n low concentrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion tamca [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] mg ml evoke brief episode [MeSH:C0085554] jerk-correlated convulsive potential rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] contrast f [MeSH:C0009924] contain aprotinin [MeSH:C0003641] [MeSH:C0003641] [MeSH:C0003641] evoke paroxysmal [MeSH:C0393588] activity interpretation tranexamic acid [MeSH:C0040613] retain convulsive action [MeSH:C0009953] [MeSH:C0009953] f use f contain tamca [MeSH:C0040613] [MeSH:C0040613] [MeSH:C0040613] surgery close cns pose substantial risk,neurological
nephrotic syndrome pathway [MeSH:C0027726] liver cirrhosis [MeSH:C0023890],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve hypertension [MeSH:C0020538] outcome renal cell carcinoma pathway [MeSH:C0007134] method randomized control trial [MeSH:C1096777] adult population [MeSH:C0032659] measuring kidney nephrotic syndrome result well quality life measure safety [MeSH:C0036043] consideration,hepatorenal
identification [MeSH:C1707660] wasp [MeSH:C0043041] mutation [MeSH:C0026882] mutation [MeSH:C0026882] hotspot genotype-phenotype [MeSH:C2717879] disparity patient wiskott-aldrich syndrome,wiskott-aldrich syndrome [MeSH:C0043194] x-linked immunodeficiency disease [MeSH:C1279481] cause mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] recently isolate gene [MeSH:C0017337] encoding protein wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0258432] know associate extensive heterogene [MeSH:C0017337]ity cumulative mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] reveal wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] highly variable [MeSH:C0013675] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] relationship phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] disease remain unclear address issue [MeSH:C0040300] characterize wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] unrelated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] include boy severe classical boy express mild form disease examine degree correlation [MeSH:C0010100] previously publish wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] disease severity compile mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] demonstrate clustering [MeSH:C0009085] wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] n-terminal exon gene [MeSH:C0017337] identify site region hotspot wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] characteristic observe severe mild case disease similarly cumulative reveal predominance missense [MeSH:C0599155] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] gene [MeSH:C0017337] lesion observe boy isolate thrombocytopenia [MeSH:C0040034] missense [MeSH:C0599155] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] exclusively associate mild phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] comprise substantial portion wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] gene [MeSH:C0017337] defect find patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] severe disease finding detection [MeSH:C5392129] identical wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] disparate phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] reveal lack phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] concordance genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] imply phenotypic outcome disease reliably predict solely basis wasp [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] [MeSH:C0043041] genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431],neurological
efficacy [MeSH:C5690761] tolerability lovastatin [MeSH:C0024027] woman [MeSH:C0043210] moderate hypercholesterolemia [MeSH:C0020443],evaluate [MeSH:C0013175] efficacy [MeSH:C5690761] [MeSH:C5690761] safety [MeSH:C0036043] [MeSH:C0036043] lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] moderate hypercholesterolemia [MeSH:C0020443] design [MeSH:C0013171] expand lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] excel multicenter double-blind [MeSH:C0013072] diet- placebo [MeSH:C0032041]-controlled trial participant [MeSH:C1708335] randomly assign receive placebo [MeSH:C0032041] lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] dose mg daily mg twice daily week set ambulatory patient recruit participating center united state patient woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] n total cohort volunteer measurement [MeSH:C0030198] plasma [MeSH:C0032105] total low-density lipoprotein ldl high-density lipoprotein hdl cholesterol [MeSH:C0023822] triglyceride laboratory evidence adverse event [MeSH:C0041755] monitor periodically result woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] mg produce sustained -week dose-related change p decrease ldl cholesterol triglyceride [MeSH:C0023824] increase hdl cholesterol [MeSH:C0023822] depend dose lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027]-treated woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] achieve national cholesterol education program goal [MeSH:C0018017] [MeSH:C0018017] ldl cholesterol level [MeSH:C0023824] mmol l mg dl achieve goal [MeSH:C0018017] [MeSH:C0018017] mmol l mg dl successive transaminase [MeSH:C0002594] elevation great time upper limit normal occur woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] dose dependent [MeSH:C0101555] -mg dose myopathy [MeSH:C0026848] define muscle [MeSH:C0026845] symptom [MeSH:C3839861] creatine kinase elevation [MeSH:C0010287] great time upper limit normal rare associate high recommend daily dose lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] mg estrogen-replacement therapy [MeSH:C0039798] [MeSH:C0014935] appear effect efficacy [MeSH:C5690761] [MeSH:C5690761] safety [MeSH:C0036043] [MeSH:C0036043] profile lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] lovastatin [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] [MeSH:C0024027] highly effective [MeSH:C5392218] generally tolerate therapy [MeSH:C0039798] primary [MeSH:C0033137] hypercholesterolemia [MeSH:C0020443] woman [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210] [MeSH:C0043210],neurological|hepatorenal
pyelonephritis marker [MeSH:C0034186] colorectal cancer [MeSH:C0009402],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation beta-blocker hypertension participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient gallbladder [MeSH:C0016976] renal stone result favorable safety [MeSH:C0036043] profile alcoholic liver disease [MeSH:C0023896] correlation [MeSH:C0010100] therapeutic innovation [MeSH:C0087111],cardiovascular|hepatorenal
glioma pathway coronary artery disease [MeSH:C1956346],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] cancer cerebrospinal fluid method [MeSH:C0007806] elderly patient undergo prospective neurotransmitter [MeSH:C0027908] epinephrine assessment result well quality life measure relevance [MeSH:C2826293],neurological
lung cancer [MeSH:C0242379] cardiac function [MeSH:C0018803],prospective examine statin stroke [MeSH:C0038454] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include atrial flutter ventricle hypertrophic cardiomyopathy [MeSH:C0007194] method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication optimization [MeSH:C0376695],cardiovascular
effect [MeSH:C4277511] active constituent crocus sativus [MeSH:C0946614] l crocin streptozocin-induced [MeSH:C0038432] model sporadic alzheimer disease [MeSH:C0002395] male [MeSH:C0086582] rat [MeSH:C0034721],involvement water-soluble carotenoid crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] main active component crocus sativus l extract learning [MeSH:C0023185] memory process propose present effect [MeSH:C4277511] crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] sporadic alzheimer disease [MeSH:C0002395] [MeSH:C0002395] induce intracerebroventricular icv streptozocin stz male [MeSH:C0086582] [MeSH:C0086582] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] investigate [MeSH:C0035173] method [MeSH:C0025663] male [MeSH:C0086582] [MeSH:C0086582] adult wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] [MeSH:C0034721] n g divide crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] mg kg stz stz crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] mg kg group [MeSH:C0018257] alzheimer disease [MeSH:C0002395] group [MeSH:C0018257] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] inject stz-icv bilaterally mg kg day [MeSH:C0011017] later similar stz-icv application repeat stz crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] animal [MeSH:C0003062] group [MeSH:C0018257] crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] apply dose mg kg p pre-surgery [MeSH:C0038895] continue week prescription [MeSH:C0033080] crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] dose repeat day [MeSH:C0011017] learning memory performance [MeSH:C0871966] assess passive avoidance paradigm [MeSH:C2718025] spatial cognition [MeSH:C0009240] y-maze task result find crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] mg kg -treated stz-injected rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] high correct choice low error y-maze vehicle-treated stz-injected rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] addition crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] mention dose significantly attenuate [MeSH:C0042211] learning memory impairment treat stz-injected passive avoidance test result demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e effect [MeSH:C4277511]iveness crocin [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] [MeSH:C0056503] mg kg antagonize cognitive deficit cause stz-icv rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] potential neurodegenerat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ive disease alzheimer disease [MeSH:C0002395],neurological
optimal precurarizing dose rocuronium [MeSH:C0209337] decrease fasciculation myalgia [MeSH:C0015644] follow succinylcholine administration [MeSH:C0038627],succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627] commonly produce frequent [MeSH:C0017270] adverse effect [MeSH:C0001688] include muscle fasciculation [MeSH:C0015644] myalgia [MeSH:C0231528] current identify optimal dose rocuronium [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] prevent [MeSH:C0000918] succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627]-induced fasciculation myalgia [MeSH:C0231528] evaluate [MeSH:C0013175] influence [MeSH:C0683549] rocuronium [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] speed [MeSH:C2009910] onset produce succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627] method randomized [MeSH:C1096777] double-blinded conduct patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] randomly allocate group [MeSH:C0018257] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] randomized [MeSH:C1096777] receive mg kg rocuronium [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] precurarize dose neuromuscular monitoring precurarize [MeSH:C3494225] dose record adductor pollicis muscle acceleromyography train-of-four stimulation [MeSH:C1301770] ulnar nerve [MeSH:C0041602] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627] mg kg minute precurarization assess incidence [MeSH:C0021149] [MeSH:C0021149] severity fasciculation myalgia [MeSH:C0231528] assess hour surgery [MeSH:C0038895] result incidence [MeSH:C0021149] [MeSH:C0021149] severity visible [MeSH:C0242377] muscle fasciculation [MeSH:C0015644] significantly increase precurarize dose rocuronium [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] p myalgia [MeSH:C0231528] tend decrease accord increase precurarize dose rocuronium [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] significance [MeSH:C2826293] p onset succinylcholine [MeSH:C0038627] [MeSH:C0038627] [MeSH:C0038627] significantly long increase precurarize dose rocuronium [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] p conclusion precurarization mg kg rocuronium [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] [MeSH:C0209337] optimal dose consider reduction [MeSH:C1827449] incidence [MeSH:C0021149] [MeSH:C0021149] severity fasciculation myalgia [MeSH:C0231528] acceptable onset safe effective precurarization,neurological
sirolimus-associated proteinuria renal dysfunction,sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] novel immunosuppressant [MeSH:C0021081] potent antiproliferative action ability inhibit [MeSH:C0021463] raptor-containing mammalian target [MeSH:C0039309] rapamycin protein kinase [MeSH:C0072980] sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] represent major therapeutic [MeSH:C0087111] advance prevention acute renal allograft [MeSH:C0450127] rejection [MeSH:C0018129] chronic allograft nephropathy role therapy [MeSH:C0039798] glomerulonephritis autoimmunity [MeSH:C0004368] cystic renal disease [MeSH:C1691228] renal cancer [MeSH:C0740457] investigation [MeSH:C0035173] sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] share vasomotor renal adverse effect [MeSH:C0001688] exhibit calcineurin inhibit [MeSH:C0021463]or designate non-nephrotoxic drug report suggest circumstance sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] associate proteinuria [MeSH:C0033687] acute renal dysfunction [MeSH:C0031847] common risk factor [MeSH:C0035648] appear presence pre-existing chronic renal damage [MeSH:C0006109] mechanism [MeSH:C1524059] sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980]-associated proteinuria [MeSH:C0033687] multifactorial [MeSH:C0600599] increase glomerular capillary pressure follow calcineurin inhibit [MeSH:C0021463]or withdrawal [MeSH:C1881606] suggest sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] directly cause increase glomerular permeability injury evidence [MeSH:C5575834] mechanism [MeSH:C1524059] currently inconclusive acute renal dysfunction [MeSH:C0031847] associate sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] delay graft function suppression [MeSH:C1956351] compensatory renal cell proliferation survival repair process adverse effect [MeSH:C0001688] occur patient [MeSH:C0030705] occurrence minimise knowledge molecular effect sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] kidney use sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] appropriate population [MeSH:C0032659] close monitoring [MeSH:C0005517] proteinuria [MeSH:C0033687] renal function use angiotensin-converting enzyme inhibit [MeSH:C0021463]or angiotensin ii receptor blocker proteinuria [MeSH:C0033687] occur withdrawal [MeSH:C1881606] need long-term [MeSH:C0023977] renal allograft [MeSH:C0450127] study sirolimus [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] [MeSH:C0072980] de novo immunosuppression [MeSH:C0021079] [MeSH:C1956351] laboratory study refine issue [MeSH:C0040300] future,neurological|hepatorenal|oncological
ifosfamide [MeSH:C0020823] related encephalopathy [MeSH:C0085584] need timely eeg [MeSH:C0013819],ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] alkylating agent [MeSH:C0002073] useful wide range cancer include sarcoma lymphoma gynecologic testicular cancer [MeSH:C0153594] encephalopathy [MeSH:C0085584] [MeSH:C0085584] report [MeSH:C0085584] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive high-dose iv ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] highlight role electroencephalogram [MeSH:C1527380] eeg [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] early detection [MeSH:C2607925] management ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] related encephalopathy [MeSH:C0085584] [MeSH:C0085584] method [MeSH:C0085584] retrospective chart review include eeg [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] recording patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] admit md anderson cancer center year develop ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] related acute encephalopathy [MeSH:C0085584] [MeSH:C0085584] [MeSH:C0085584] result patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience symptom encephalopathy [MeSH:C0085584] [MeSH:C0085584] [MeSH:C0085584] soon h- day receive ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] develop generalized convulsion develop continuous [MeSH:C3649547] non-convulsive status epilepticus ncse require icu admission intubation [MeSH:C0021925] initial eeg [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] show epileptiform discharge patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] run triphasic wave moderate degree diffuse generalize slow mixed pattern presence sharps triphasic wave note repeat eeg [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] h symptom onset show marked improvement [MeSH:C2936612] [MeSH:C2936612] correlate improvement [MeSH:C2936612] [MeSH:C2936612] conclusion severity ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] related encephalopathy [MeSH:C0085584] [MeSH:C0085584] correlate eeg [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] change suggest timely eeg [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] [MeSH:C0013819] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive ifosfamide [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] [MeSH:C0020823] develop feature encephalopathy [MeSH:C0085584] [MeSH:C0085584],neurological|oncological
acute [MeSH:C0184567] psychosis [MeSH:C0033975] phenytoin [MeSH:C0031507] nonepileptic,development [MeSH:C0243107] psychosis [MeSH:C0033975] [MeSH:C0033975] related antiepileptic [MeSH:C4505072] [MeSH:C4505072] drug [MeSH:C0003299] usually attribute interaction [MeSH:C0007582] epileptic [MeSH:C4505072] [MeSH:C4505072] brain substratum antiepileptic [MeSH:C4505072] [MeSH:C4505072] drug [MeSH:C0003299] case nonepileptic [MeSH:C4505072] [MeSH:C4505072] develop psychosis [MeSH:C0033975] [MeSH:C0033975] follow phenytoin [MeSH:C0031507] trigeminal neuralgia [MeSH:C0040997] describe case suggest psychotic [MeSH:C1001324] symptom [MeSH:C3839861] occur follow phenytoin [MeSH:C0031507] epileptic [MeSH:C4505072] [MeSH:C4505072] patient [MeSH:C0030705] direct medication [MeSH:C0025081] unrelated seizure [MeSH:C0036572],neurological
japanese [MeSH:C1556094] family adrenoleukodystrophy codon deletion [MeSH:C0162309] biochemical [MeSH:C0017401] pathological [MeSH:C0030660] genetic report [MeSH:C0684224],report japanese [MeSH:C1556094] family adrenoleukodystrophy ald base pair deletion delgag ald gene variety phenotype [MeSH:C0031437] observe family proband classify rare intermediate type [MeSH:C0439879] adult cerebral cerebello-brain stem form young brother nephew childhood [MeSH:C0023452] ald type nephew classify adolescent [MeSH:C0205653] form tau [MeSH:C0085401] [MeSH:C0085401] cerebrospinal fluid [MeSH:C0007806] csf high [MeSH:C0039866] patient [MeSH:C0030705] alzheimer disease ad brain magnetic resonance image mri [MeSH:C0024485] show abnormality [MeSH:C0037268] bilateral cerebellar hemisphere [MeSH:C0228174] brain stem cerebral white matter marked reduction [MeSH:C1827449] cerebral blood flow [MeSH:C0428714] oxygen metabolism [MeSH:C0025519] clearly demonstrate positron emission tomography pet [MeSH:C0031268] [MeSH:C0032743] patient [MeSH:C0030705] autopsy [MeSH:C0004398] finding show massive demyelination cerebral white matter sparing u-fiber compatible finding childhood ald oleic erucic acid [MeSH:C0059531] lorenzo oil [MeSH:C0212874] administer patient [MeSH:C0030705] sufficient effectiveness [MeSH:C0010181] obtain finding family suggest delgag2 cause japanese [MeSH:C1556094] ald phenotypic [MeSH:C1837514] variation scale limited possibility pet [MeSH:C0031268] detect insidious lesion undetectable computed tomogram ct [MeSH:C1956110] mri high [MeSH:C0039866] tau [MeSH:C0085401] [MeSH:C0085401] reflect process neuronal degeneration [MeSH:C0027746] ald lorenzo oil [MeSH:C0212874] give early stage,neurological
alpha-blocker [MeSH:C0001641] dementia [MeSH:C0497327] brain [MeSH:C0006104] insight,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] diabete participant [MeSH:C1708335] adult [MeSH:C0001675] population ataxia convulsion result decrease mortality rate [MeSH:C0205848] norepinephrine [MeSH:C0028351] correlation safety consideration,neurological
cloning breakpoint chromosome [MeSH:C2717920] translocation [MeSH:C0599893] identify an2 [MeSH:C1853761] locus,chromosome [MeSH:C0008633] translocation [MeSH:C0599893] [MeSH:C0599893] [MeSH:C0599893] involve 1p1 associate familial aniridia kindred highlight chromosomal localization an2 locus [MeSH:C0085286] locus [MeSH:C0085286] wagr complex [MeSH:C0206115] wilms tumor aniridia [MeSH:C0027708] genitourinary abnormality [MeSH:C0042063] mental retardation [MeSH:C3714756] kindred translocation [MeSH:C0599893] [MeSH:C0599893] [MeSH:C0599893] associate deletion probe region identify clone breakpoint [MeSH:C2717920] translocation [MeSH:C0599893] [MeSH:C0599893] [MeSH:C0599893] second kindred comparison phage restriction map exclude presence sizable deletion case sequence chromosome [MeSH:C0008633] breakpoint conserve multiple [MeSH:C0026771] specie suggest translocation [MeSH:C0599893] [MeSH:C0599893] [MeSH:C0599893] fall an2 gene,neurological|oncological
liver hypertension [MeSH:C0020538] vascular [MeSH:C0221214] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect cancer hepatorenal syndrome [MeSH:C0019212] mechanism method retrospective [MeSH:C0035363] elderly patient assess smooth muscle renal cyst [MeSH:C1267092] result enhance therapeutic response [MeSH:C0087111] implication healthcare advancement,cardiovascular|hepatorenal
production [MeSH:C0033268] autochthonous prostate cancer [MeSH:C0376358] lobund-wistar rat [MeSH:C0034721] treatment [MeSH:C0039798] n-nitroso-n-methylurea testosterone [MeSH:C0039601],lobund-wistar l-w strain rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] develop large palpable prostate adenocarcinoma [MeSH:C0001418] pas follow treatment n-nitroso-n-methylurea cas testosterone propionate tp cas tumor-bearing rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] manifest metastatic lesion [MeSH:C1522484] incubation period average month timeframe l-w rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] develop similar palpable pa treat tp l-w rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] tp act tumor enhancement [MeSH:C0376317] agent primary emphasis development [MeSH:C0020119] prostate cancer [MeSH:C0376358],oncological
hepatitis primary [MeSH:C0019158] biliary cholangitis [MeSH:C0008312] organ [MeSH:C0029250] interplay,hypertension [MeSH:C0020538] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve pkd aki method conduct prospective evaluate calcium channel blocker [MeSH:C0006684] patient [MeSH:C0030705] [MeSH:C0030705] examine renal cell carcinoma [MeSH:C0007134] parameter result enhance therapeutic response [MeSH:C0087111] relevance [MeSH:C2826293],hepatorenal
hypertension [MeSH:C0020538] heart attack [MeSH:C0027051] cardiac connection,question [MeSH:C0600648] ace inhibitor affect dementia [MeSH:C0497327] esophageal cancer [MeSH:C0546837] mechanism method longitudinal [MeSH:C0023981] cardiac patient assess pulmonary embolism embolism [MeSH:C0034065] result improvement primary endpoint implication cost-effectiveness [MeSH:C1511536] implication,cardiovascular|oncological
neural [MeSH:C1522467] correlate s-ketamine [MeSH:C2825616] induced [MeSH:C5392225] psychosis [MeSH:C0033975] overt continuous verbal fluency,glutamatergic n-methyl-d-aspartate nmda receptor [MeSH:C0080093] implicate pathophysiology [MeSH:C0031847] [MeSH:C0031847] schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] administer healthy [MeSH:C0452415] volunteer [MeSH:C0042960] subanesthetic [MeSH:C0002932] dose non-competitive nmda receptor antagonist ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] lead psychopathological [MeSH:C0033927] symptom [MeSH:C3839861] similar observe schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] patient [MeSH:C0030705] schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] exacerbate core symptom [MeSH:C3839861] illness support hypothesis glutamatergic dysfunction counterbalanced placebo [MeSH:C0032041]-controlled double-blind [MeSH:C0013072] design healthy [MeSH:C0452415] subject administer continuous subanesthetic [MeSH:C0002932] s-ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C2825616] [MeSH:C0022614] [MeSH:C0022614] infusion [MeSH:C0841792] difference bold response measure fmri detect scanning period subject perform continuous overt verbal fluency task phonological [MeSH:C4019167] [MeSH:C4019167] lexical semantic [MeSH:C0036612] [MeSH:C0036612] [MeSH:C0036612] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614]-induced psychopathological [MeSH:C0033927] symptom [MeSH:C3839861] assess positive negative syndrome scale pans ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] elicit psychosis [MeSH:C0033975] like psychopathology [MeSH:C0033927] post-hoc t-test reveal difference placebo [MeSH:C0032041] ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] amount word generate lexical semantic [MeSH:C0036612] [MeSH:C0036612] [MeSH:C0036612] verbal fluency phonological [MeSH:C4019167] [MeSH:C4019167] domain remain unaffected ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] lead enhance cortical activation [MeSH:C4505109] supramarginal frontal brain region phonological [MeSH:C4019167] [MeSH:C4019167] lexical verbal fluency semantic [MeSH:C0036612] [MeSH:C0036612] [MeSH:C0036612] verbal fluency ketamine [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] [MeSH:C0022614] induce activation [MeSH:C4505109] change healthy [MeSH:C0452415] subject similar observe patient [MeSH:C0030705] schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] particularly frontal temporal brain region [MeSH:C0039485] result provide support hypothesis nmda receptor dysfunction pathophysiology [MeSH:C0031847] [MeSH:C0031847] schizophrenia [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341] [MeSH:C0036341],neurological
organ [MeSH:C0029250] orchestra angina pectoris [MeSH:C0002962],design [MeSH:C0013171] observational [MeSH:C0302523] investigation beta-blocker cancer participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] azotemia cholangiocarcinoma [MeSH:C0206698] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cholelithiasis [MeSH:C0008350] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
mutation [MeSH:C0026882] vhl gene sporadic renal cell carcinoma [MeSH:C0007134] definition risk factor [MeSH:C0035648] vhl patient develop rcc [MeSH:C0967777],investigate [MeSH:C0035173] nature somatic von hippel-lindau vhl mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] analyze primary sporadic human renal cell carcinoma [MeSH:C0007134] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] vhl tumor suppressor gene polymerase chain reaction pcr single-strand conformational polymorphism sscp dna detect abnormal [MeSH:C0853087] sscp pattern sample sequencing identify microdeletion case microinsertion nonsense mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0544885] missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] correspond new mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] vhl mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] find nonpapillary renal cell carcinoma [MeSH:C1306837] rcc [MeSH:C0967777] subtype previously report compare somatic germline mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0206530] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] vhl database include mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882]al event reveal difference somatic germline mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0206530] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] lead truncate protein observe somatic mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] vs germline mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0206530] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] p vhl mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] associate sporadic rcc [MeSH:C0967777] pattern correspond mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] lead mainly truncate protein specific missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] analyze occurrence rcc [MeSH:C0967777] vhl family base nature mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] observe rcc [MeSH:C0967777] member vhl family case mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] lead truncate protein versus case missense mutation [MeSH:C0026882] [MeSH:C0599155] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] p rcc [MeSH:C0967777] vhl patient,hepatorenal|oncological
dependence [MeSH:C0016073] plasma [MeSH:C0032105] malondialdehyde [MeSH:C0024643] oxypurine [MeSH:C0030086] nucleoside [MeSH:C0028621] incomplete cerebral ischemia [MeSH:C0917798] rat [MeSH:C0034721],incomplete [MeSH:C0011139] cerebral ischemia [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0917798] min induce rat [MeSH:C0034721] bilaterally clamp common carotid artery peripheral [MeSH:C0007272] venous blood sample withdraw femoral vein time min [MeSH:C0015809] ischemia [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] min ischemia [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] extract [MeSH:C0032081] analyze highly sensitive [MeSH:C1017675] high-performance liquid chromatographic [MeSH:C0008562] direct determination [MeSH:C1148554] [MeSH:C1148554] malondialdehyde [MeSH:C0024643] [MeSH:C0024643] [MeSH:C0024643] oxypurine [MeSH:C0030086] nucleoside [MeSH:C0028621] ischemia [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0028621] [MeSH:C0022116] time-dependent increase plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] oxypurine [MeSH:C0030086] nucleoside [MeSH:C0028621] observe plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] malondialdehyde [MeSH:C0024643] [MeSH:C0024643] [MeSH:C0024643] present minimal [MeSH:C0003062] zero mumol liter plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] sd increase min ischemia [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] result fivefold increase min carotid occlusion mumol liter plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] sd increase plasma [MeSH:C0032105] [MeSH:C0032105] [MeSH:C0032105] malondialdehyde [MeSH:C0024643] [MeSH:C0024643] [MeSH:C0024643] record group animal subject [MeSH:C0080105] experimental model [MeSH:C0086272] receive mg kg b w cyclooxygenase inhibitor [MeSH:C0085387] acetylsalicylate [MeSH:C0101202] intravenously immediately ischemia [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] receive microgram [MeSH:C0376691] kg b w hypotensive drug [MeSH:C0003364] nitroprusside flow rat [MeSH:C0034721]e microliter min intravenously ischemia [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0022116] malondialdehyde [MeSH:C0024643] [MeSH:C0024643] [MeSH:C0024643] significantly high present indicate determination [MeSH:C1148554] [MeSH:C1148554] malondialdehyde [MeSH:C0024643] [MeSH:C0024643] [MeSH:C0024643] oxypurine [MeSH:C0030086] nucleoside [MeSH:C0028621] peripheral blood monitor metabolic [MeSH:C0025517] alterat [MeSH:C0034721]ion tissue occur ischemic [MeSH:C0022116] phenomenon [MeSH:C2350469] abstract [MeSH:C0600678] truncate word,neurological
carcinogenesis cancer [MeSH:C0596263] epilepsy [MeSH:C0014544],dementia [MeSH:C0497327] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve non-hodgkin lymphoma adrenal cancer [MeSH:C0006826] method conduct retrospective [MeSH:C0035363] evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine bone marrow transplant [MeSH:C0005961] parameter result favorable safety [MeSH:C0036043] profile optimization [MeSH:C0376695],oncological
synaptic dynamic alzheimer disease,hypothesis [MeSH:C3179072] aspirin improve hypertension [MeSH:C0020538] outcome astrocytoma pathway method retrospective trial adult [MeSH:C0001675] population [MeSH:C0032659] measuring schwannoma meningitis [MeSH:C0027809] result superior efficacy [MeSH:C5690761] relevance,neurological
leukemia cancer [MeSH:C0023418] coronary artery disease [MeSH:C1956346],observational [MeSH:C0302523] examine beta-blocker diabete adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] [MeSH:C0035173] include bone cancer [MeSH:C0279530] lung cancer [MeSH:C0242379] liver cancer [MeSH:C0345904] method participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication need investigation [MeSH:C0035173] [MeSH:C0035173],oncological
organ [MeSH:C0029250] orchestra cancer,question [MeSH:C0600648] metformin [MeSH:C0025598] affect heart disease [MeSH:C0018799] oliguria mechanism method longitudinal [MeSH:C0023981] cardiac patient assess wilms tumor gamma glutamyl transferase result reduction adverse event [MeSH:C0041755] implication practice guideline,hepatorenal
bradycardia [MeSH:C0428977] biperiden [MeSH:C0005578],-year-old male [MeSH:C0086582] suffer severe [MeSH:C1719672] postzosteric trigeminal neuralgia [MeSH:C0040997] intravenous application mg biperiden [MeSH:C0005578] lactate [MeSH:C0053663] lead long-lasting paradoxical reaction characterize considerable bradycardia dysarthria dysphagia heart rate [MeSH:C0018810] normal hour administration [MeSH:C0001554] orciprenaline [MeSH:C0029193] cardiac [MeSH:C0018810] monitoring [MeSH:C0005517] intensive care unit [MeSH:C0021708] bradycardia induce biperiden [MeSH:C0005578] attribute speed [MeSH:C2009910] injection [MeSH:C1828121] dose-related dual effect atropine-like drug muscarine receptor [MeSH:C0034826],cardiovascular|hepatorenal
interstitial nephritis [MeSH:C0027707] connection multiple sclerosis [MeSH:C0026769],heart disease [MeSH:C0018799] affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve oliguria [MeSH:C0028961] acoustic neuroma method [MeSH:C0027859] conduct retrospective [MeSH:C0035363] evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine astrocytoma [MeSH:C0004114] parameter result enhance therapeutic response [MeSH:C0087111] need investigation [MeSH:C0035173],neurological|hepatorenal
adenomatous polyposis coli cytogenetic deletion chromosome result maternal [MeSH:C0024915] intrachromosomal insertion,present laboratory finding [MeSH:C0022877] institutionalise adult originally refer autism [MeSH:C0004352] high risk colorectal cancer [MeSH:C0009402] predict interstitial deletion long arm chromosome del [MeSH:C0265404] q15q2 detect lymphocyte deletion mcc apc gene [MeSH:C0017337] confirm molecular adenomatous polyposis coli carcinoma rectum [MeSH:C0032580] subsequently diagnose [MeSH:C0011900] profoundly mentally [MeSH:C0025360] retard autistic [MeSH:C0004352] minor dysmorphic feature consistent previous patient [MeSH:C0030705] [MeSH:C0030705] similar deletion deletion arise [MeSH:C0017260] recombination [MeSH:C0034865] small insertion [MeSH:C1512796] loop form meiosis [MeSH:C0025186] direct insertion [MeSH:C1512796] dir in q2 3q1 2q1 find patient [MeSH:C0030705] [MeSH:C0030705] mother [MeSH:C0026591] family confirm cytogene [MeSH:C0017337]tic mapping mcc apc gene [MeSH:C0017337] 5q2 comparison [MeSH:C0871382] recent case suggest gene [MeSH:C0017337] closely link marker [MeSH:C0017393] lie 5q2 subband,neurological|oncological
repeated trimipramine [MeSH:C0041056] induce dopamine d2 d3 alpha1-adrenergic up-regulation [MeSH:C0041904],trimipramine [MeSH:C0020934] [MeSH:C0041056] tri show antidepressant [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] activity [MeSH:C0020115] [MeSH:C0020115] chemically [MeSH:C0007994] related imipramine [MeSH:C0020934] inhibit [MeSH:C0021463] reuptake noradrenaline [MeSH:C0028351] -hydroxytryptamine induce beta-adrenergic down-regulation [MeSH:C0013081] mechanism antidepressant [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] activity [MeSH:C0020115] [MeSH:C0020115] unknown present find tri give repeatedly able induce adaptive change dopaminergic alpha1-adrenergic system demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e previously antidepressant [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] tri give male [MeSH:C0086582] [MeSH:C0086582] wistar rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034716] male [MeSH:C0086582] [MeSH:C0086582] albino swiss [MeSH:C1257740] mouse [MeSH:C0026809] [MeSH:C0026809] perorally twice daily day acute [MeSH:C0184567] experiment [MeSH:C0020123] tri give p antagonize reserpine [MeSH:C0035179] hypothermia [MeSH:C0020672] mouse [MeSH:C0026809] [MeSH:C0026809] potentiate -hydroxytryptophan head twitch rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] tri give repeatedly rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] increase locomotor hyperactivity [MeSH:C0020115] [MeSH:C0023946] [MeSH:C0020115] induce d-amphetamine [MeSH:C0011812] quinpirole [MeSH:C0072892] --hydroxy-dipropyloaminotetralin dopamine d2 d3 effect stereotypie induce d-amphetamine [MeSH:C0011812] apomorphine potentiate tri increase behaviour stimulation evoke phenylephrine [MeSH:C0031469] give intraventricularly [MeSH:C0206177] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] evaluate [MeSH:C0013175] open field test [MeSH:C5392081] aggressiveness evoke clonidine [MeSH:C0009014] mouse [MeSH:C0026809] [MeSH:C0026809] effect mediate alpha1-adrenergic receptor [MeSH:C0034784] conclude like tricyclic antidepressant [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003290] [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] study previously tri give repeatedly increase responsiveness brain dopamine d2 d3 locomotor activity [MeSH:C0020115] [MeSH:C0020115] stereotypy alpha1-adrenergic receptor [MeSH:C0034784] agonist question arise reuptake inhibit [MeSH:C0021463]ion importance adaptive change induce repeat antidepressant [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] suggest responsible antidepressant [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] [MeSH:C0003289] activity [MeSH:C0020115] [MeSH:C0020115],neurological|hepatorenal
angiography [MeSH:C0002978] reveal chronic kidney disease [MeSH:C1561643] secret,question [MeSH:C0600648] beta-blocker [MeSH:C0001645] affect heart disease [MeSH:C0018799] delirium mechanism method observational cancer [MeSH:C0302523] patient [MeSH:C0030705] assess vein hypertensive [MeSH:C0003364] result favorable safety profile implication optimization [MeSH:C0376695],neurological|cardiovascular
vivo evidence [MeSH:C5575834] suggest role oxidative stress [MeSH:C0242606] pathogenesis [MeSH:C0699748] vancomycin-induced nephrotoxicity protection erdosteine [MeSH:C0059506],aim examine vancomycin [MeSH:C0042313] vcm -induced oxidative stress [MeSH:C0242606] [MeSH:C0242606] promote production [MeSH:C0033268] reactive oxygen specie ros [MeSH:C0162772] investigate [MeSH:C0035173] role erdosteine [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] expectorant agent [MeSH:C0015314] antioxidant [MeSH:C0003402] property kidney tissue possible vcm-induced renal impairment rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] divide group [MeSH:C0018257] sham vcm vcm plus erdosteine [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] vcm administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e intraperitoneally p 0mgkg twice daily day erdosteine [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] administer orally vcm administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] significantly increase renal malondialdehyde [MeSH:C0024643] mda urinary [MeSH:C0042018] n-acetyl-beta-d-glucosaminidase nag marker [MeSH:C0001057] renal tubular injury excretion [MeSH:C1373187] [MeSH:C1373187] decrease superoxide dismutase [MeSH:C0038838] sod [MeSH:C0669516] [MeSH:C0669516] catalase cat activity [MeSH:C0020115] erdosteine [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion vcm injection [MeSH:C1828121] cause significantly decrease renal mda urinary [MeSH:C0042018] nag excretion [MeSH:C1373187] [MeSH:C1373187] increase sod [MeSH:C0669516] [MeSH:C0669516] activity cat activity [MeSH:C0020115] renal tissue [MeSH:C0040300] compare vcm erdosteine [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] show histopathological protection [MeSH:C0524828] vcm-induced nephrotoxicity dilatation tubular lumen extensive epithelial cell [MeSH:C0014597] vacuolization atrophy [MeSH:C0333641] desquamation necrosis vcm-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] erdosteine [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] group [MeSH:C0018257] erdosteine [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] cause marked reduction [MeSH:C1827449] extent tubular damage conclude oxidative tubular damage play important role vcm-induced nephrotoxicity modulation [MeSH:C0085121] oxidative stress [MeSH:C0242606] [MeSH:C0242606] erdosteine [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] [MeSH:C0059506] reduce vcm-induced kidney damage biochemical [MeSH:C0017401] histological [MeSH:C0019637] level,neurological|hepatorenal
stroke [MeSH:C0038454] parkinson disease [MeSH:C0030567] vascular [MeSH:C0221214] insight,heart disease [MeSH:C0018799] affect elderly patient [MeSH:C0030705] worldwide particularly involve aortic aneurysm transient ischemic attack method [MeSH:C0007787] conduct retrospective [MeSH:C0035363] evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine capillary [MeSH:C0006901] parameter result improve disease management [MeSH:C0039798] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
liver disease [MeSH:C0023895] cause propylthiouracil [MeSH:C0033511],report [MeSH:C0684224] present laboratory light electron microscopic observation chronic active aggressive hepatitis cause administration propylthiouracil addition list drug [MeSH:C0013227] consider chronic liver disease [MeSH:C0008679],hepatorenal
pad leukemia [MeSH:C0023418] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] aspirin [MeSH:C0004057] improve heart disease [MeSH:C0018799] outcome [MeSH:C0206277] atrial fibrillation pathway method [MeSH:C0004238] prospective trial elderly patient measure nonalcoholic steatohepatitis [MeSH:C3241937] aortic valve [MeSH:C0003501] result improve outcome [MeSH:C0206277] healthcare advancement,cardiovascular|hepatorenal
stroke [MeSH:C0038454] hypotension [MeSH:C0020649] cardiac connection,design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation statin hypertension [MeSH:C0020538] participant [MeSH:C1708335] elderly patient tia pacemaker [MeSH:C3494452] result favorable safety profile smooth muscle [MeSH:C1267092] correlation [MeSH:C0010100] relevance [MeSH:C2826293],cardiovascular
atm bax [MeSH:C0219474] cooperate ionize radiation-induced apoptosis central nervous system [MeSH:C3714787],ataxia-telangiectasia hereditary multisystemic disease result mutation ataxia telangiectasia mutate [MeSH:C0298973] atm characterize neurodegeneration cancer [MeSH:C0027746] immune defect [MeSH:C0155017] hypersensitivity [MeSH:C0020517] ionize radiation molecular detail atm function [MeSH:C0031843] nervous system [MeSH:C0027763] unclear neurological lesion ataxia-telangiectasia apparent early life suggest developmental origin [MeSH:C0017340] central nervous system cns [MeSH:C3714787] atm-null mouse [MeSH:C0026809] [MeSH:C0026809] show pronounced defect [MeSH:C0155017] apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] induce genotoxic stress [MeSH:C1257899] suggest atm function [MeSH:C0031843] eliminate neuron [MeSH:C0027882] excessive genomic damage report death effector bax [MeSH:C0219474] [MeSH:C0219474] require large proportion atm-dependent apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] develop cns ionize radiation ir region cns bax [MeSH:C0219474] [MeSH:C0219474]- atm- mouse [MeSH:C0026809] [MeSH:C0026809] radioresistant mouse [MeSH:C0026809] [MeSH:C0026809] nullizygous bax [MeSH:C0219474] [MeSH:C0219474] atm show additional reduction [MeSH:C1827449] ir-induced apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] cns major ir-induced apoptotic pathway [MeSH:C1720828] cns require atm bax [MeSH:C0219474] [MeSH:C0219474] p5-dependent collateral pathway [MeSH:C0027792] exist atm- bax [MeSH:C0219474] [MeSH:C0219474]-independent branch atm- bax [MeSH:C0219474] [MeSH:C0219474]-dependent apoptosis [MeSH:C0162638] [MeSH:C0162638] [MeSH:C0162638] cns require caspase- activation [MeSH:C4505109] implicate bax [MeSH:C0219474] [MeSH:C0219474] caspase- death effector neurodegenerative pathway,neurological|oncological
recent preclinical study [MeSH:C0008972] thymidylate synthase inhibitor [MeSH:C0040085] n1-propargyl- -dideazafolic acid cb,cb n1-propargyl- -dideazafolic acid tight-binding inhibitor thymidylate synthase ts [MeSH:C0040085] cytotoxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0235280] [MeSH:C0235280] mediate solely inhibition [MeSH:C0027790] enzyme recent preclinical study [MeSH:C0008972] focus intracellular [MeSH:C0682581] formation [MeSH:C0029433] [MeSH:C0029433] cb polyglutamate [MeSH:C0220897] follow [MeSH:C3899107] -hour exposure [MeSH:C1390376] l1 cell microm 3h cb extractable radioactivity [MeSH:C0020115] [MeSH:C0034553] account cb tetra- pentaglutamate determine high-pressure liquid chromatography hplc analysis inhibitor isolate l1 ts cb di- tri- tetra- pentaglutamate -fold potent cb respectively formation [MeSH:C0029433] [MeSH:C0029433] important determinant [MeSH:C0003316] cb cytotoxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0235280] [MeSH:C0235280] early study cb activity [MeSH:C0020115] see breast cancer [MeSH:C0006142] ovarian cancer [MeSH:C1140680] hepatoma mesothelioma [MeSH:C0025500] toxicity [MeSH:C0040539] [MeSH:C0040539] include hepatotoxicity [MeSH:C0235280] [MeSH:C0040539] [MeSH:C0235280] [MeSH:C0040539] malaise dose-limiting nephrotoxicity [MeSH:C0040539] [MeSH:C0040539] effect [MeSH:C4277511] think drug precipitation renal [MeSH:C0152169] tubule poor solubility [MeSH:C0037628] cb acidic condition attempt overcome problem trial [MeSH:C0037431] cb administer alkaline [MeSH:C0002055] [MeSH:C0002055] diuresis [MeSH:C0012797] [MeSH:C0012797] way preliminary result mg m2 suggest reduction [MeSH:C1827449] nephrotoxicity [MeSH:C0040539] [MeSH:C0040539] achieve instance renal [MeSH:C0152169] toxicity [MeSH:C0040539] [MeSH:C0040539] patient [MeSH:C0030705] [MeSH:C0030705] hepatotoxicity [MeSH:C0235280] [MeSH:C0040539] [MeSH:C0235280] [MeSH:C0040539] malaise frequent effect [MeSH:C4277511] evidence antitumor activity [MeSH:C0020115] see patient [MeSH:C0030705] [MeSH:C0030705] pharmacokinetic investigation show alkaline [MeSH:C0002055] [MeSH:C0002055] diuresis [MeSH:C0012797] [MeSH:C0012797] alter cb plasma [MeSH:C0032105] level [MeSH:C0018759] urinary excretion [MeSH:C1859518] satisfactory urinary alkalinization readily achieve,hepatorenal|oncological
dysarthria connection [MeSH:C0013362] diabetes mellitus [MeSH:C0011849],investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect heart disease [MeSH:C0018799] chorea method [MeSH:C0008489] cardiac patient undergo prospective serotonin myelopathy [MeSH:C0037928] assessment [MeSH:C0030198] result enhance therapeutic response [MeSH:C0087111] cost-effectiveness [MeSH:C1511536] implication,neurological
effect [MeSH:C4277511] increase intraperitoneal [MeSH:C0021493] infusion [MeSH:C0841792] rate bupropion [MeSH:C0085208] hydrochloride-induced seizure mouse [MeSH:C0026809],know relationship [MeSH:C0021797] [MeSH:C0021797] input rate incidence [MeSH:C0021149] [MeSH:C0021149] bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208]-induced seizure important different control release formulation [MeSH:C0524527] bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] release active drug [MeSH:C0033613] different rate method [MeSH:C0025663] investigate [MeSH:C0035173] effect [MeSH:C4277511] vary intraperitoneal [MeSH:C0021493] [MeSH:C0021493] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] rate bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] hcl mg kg known convulsive dose [MeSH:C0009953] cd5 [MeSH:C0054964] incidence [MeSH:C0021149] [MeSH:C0021149] severity bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208]-induced convulsion [MeSH:C4048158] swiss albino mouse [MeSH:C0026809] [MeSH:C0026809] total mouse [MeSH:C0026809] [MeSH:C0026809] approximately week age [MeSH:C0024842] weigh g randomly assign bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] hcl mg kg intraperitoneal [MeSH:C0021493] [MeSH:C0021493] ip administration [MeSH:C0001554] group [MeSH:C0001554] animal [MeSH:C0003062] bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] hcl infuse surgically implant ip dosing catheter infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] min min min min min min min number onset duration intensity convulsion [MeSH:C4048158] absence convulsion [MeSH:C4048158] record result result show ip administration [MeSH:C0001554] bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] hcl mg kg bolus injection [MeSH:C1828121] [MeSH:C1828121] induce convulsion [MeSH:C4048158] mouse [MeSH:C0026809] [MeSH:C0026809] convulse [MeSH:C0009950] mouse [MeSH:C0026809] [MeSH:C0026809] logistic regression [MeSH:C0206031] reveal infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] p odd ratio increase ip infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] hcl mg kg associate reduce odd convulsion [MeSH:C4048158] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] time min compare bolus injection [MeSH:C1828121] [MeSH:C1828121] increase infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] result reduction [MeSH:C1827449] [MeSH:C1827449] odd convulsion [MeSH:C4048158] reduction [MeSH:C1827449] [MeSH:C1827449] min demonstration inverse relationship [MeSH:C0021797] [MeSH:C0021797] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] fixed convulsive dose [MeSH:C0009953] bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] risk convulsion [MeSH:C4048158] prospective novel,neurological
pattern exon deletion duchenne becker muscular dystrophy [MeSH:C3542021],panel patient [MeSH:C0030705] duchenne becker muscular dystrophy [MeSH:C0917713] dmd [MeSH:C1437024] bmd screen cdna probe [MeSH:C0006556] cf56a cf23a detect exon [MeSH:C0015295] central dmd [MeSH:C1437024] gene exon [MeSH:C0015295] delete patient [MeSH:C0030705] deletion map prove heterogeneous size extent [MeSH:C1449716] particularly dmd [MeSH:C1437024] deletion specific dmd [MeSH:C1437024] bmd describe half bmd patient [MeSH:C0030705] deletion particular small exon [MeSH:C0015295] small deletion produce severe dmd [MeSH:C1437024],neurological
lymphoma [MeSH:C0024299] gfr organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve heart disease [MeSH:C0018799] outcome azotemia pathway method retrospective trial cardiac patient measure acute kidney injury [MeSH:C2609414] cirrhosis [MeSH:C1623038] result positive response practice guideline [MeSH:C0936005],hepatorenal
mri [MeSH:C0282596] reveal hypertension [MeSH:C0020538] secret,hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve stroke [MeSH:C0038454] outcome [MeSH:C0206277] glutamate pathway method observational trial [MeSH:C0302523] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure neurodegenerative cerebellar result improve disease management [MeSH:C0039798] safety consideration,neurological
atrial thrombosis [MeSH:C0040053] involve heart f- [MeSH:C0018787] rat [MeSH:C0034721] ingest quinacrine hydrochloride [MeSH:C0282331],quinacrine [MeSH:C0034403] hydrochloride toxic heart f- rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat ppm quinacrine [MeSH:C0034403] hydrochloride diet develop high incidence [MeSH:C0021149] leave atrial thrombosis [MeSH:C0040053] lesion associate [MeSH:C0004083] cardiac hypertrophy [MeSH:C1383860] [MeSH:C1383860] dilatation focal myocardial degenerat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] die cardiac hypertrophy [MeSH:C1383860] [MeSH:C1383860] severe acute chronic congestion lung liver organ seventy percent rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] give ppm quinacrine [MeSH:C0034403] hydrochloride ppm sodium nitrite [MeSH:C0037532] [MeSH:C0037532] simultaneously diet thrombosis [MeSH:C0040053] atrium heart untreated [MeSH:C0018792] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] laborat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory atrial thrombosis [MeSH:C0040053] sodium nitrite [MeSH:C0037532] [MeSH:C0037532] combination quinacrine [MeSH:C0034403] hydrochloride appear additional effect [MeSH:C4277511],cardiovascular|hepatorenal
dialysis myocardial infarction [MeSH:C0027051] vascular [MeSH:C0221214] insight,randomized control examine [MeSH:C1096777] beta-blocker diabete diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include bradycardia stroke jaundice method participant [MeSH:C1708335] include result well quality life measure implication healthcare advancement,cardiovascular|hepatorenal
hypertension [MeSH:C0020538] kidney [MeSH:C0022646] explore neural pathway [MeSH:C0027792],investigate [MeSH:C0035173] beta-blocker [MeSH:C0001645] effect dementia [MeSH:C0497327] trigeminal neuralgia method [MeSH:C0040997] adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective cerebral infarction ataxia [MeSH:C0007785] assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],neurological|hepatorenal
biopsy [MeSH:C0005558] reveal lung cancer [MeSH:C0242379] secret,question [MeSH:C0600648] metformin [MeSH:C0025598] affect hypertension [MeSH:C0020538] amyotrophic lateral sclerosis mechanism method [MeSH:C0002736] longitudinal [MeSH:C0023981] cardiac patient assess dysarthria thalamus [MeSH:C0013362] result enhance therapeutic response [MeSH:C0087111] implication care improvement,neurological|cardiovascular
endocardium [MeSH:C0014124] prostate cancer [MeSH:C0376358] vascular [MeSH:C0221214] insight,hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve diabete outcome [MeSH:C0206277] restrictive cardiomyopathy pathway method [MeSH:C0007196] observational trial [MeSH:C0302523] elderly patient measure blood vessel thrombosis [MeSH:C0005847] result improvement [MeSH:C2936612] primary endpoint optimization [MeSH:C0376695],cardiovascular
detection [MeSH:C5392129] unstable fragment dna [MeSH:C0376669] specific individual myotonic dystrophy [MeSH:C0027126],myotonic dystrophy dm common [MeSH:C0027126] form adult [MeSH:C0001675] muscular dystrophy [MeSH:C0026850] prevalence [MeSH:C0033105] individual [MeSH:C0021228] disease [MeSH:C0012634] characterize progressive [MeSH:C1449744] muscle weakness [MeSH:C0151786] sustained muscle contraction [MeSH:C0026820] wide range accompany symptom age [MeSH:C3839861] onset severity disease [MeSH:C0521117] [MeSH:C0521117] [MeSH:C0012634] extreme variation family despite variability [MeSH:C0003319] dominant condition segregate single locus chromosome [MeSH:C0008633] 9q1 population study flank tightly link genetic marker [MeSH:C0017393] ercc1 proximally d19s5 distally define dm critical region report isolation express sequence region detect dna fragment [MeSH:C0021009] [MeSH:C0376669] large affect individual [MeSH:C0021228] normal sibling [MeSH:C0037047] [MeSH:C0037047] unaffected control size [MeSH:C0162658] fragment [MeSH:C0021009] vary affect sibling [MeSH:C0037047] increase size [MeSH:C0162658] generation parallel increase severity disease [MeSH:C0521117] [MeSH:C0521117] [MeSH:C0012634] postulate unstable dna sequence [MeSH:C0162326] molecular feature underlie dm,neurological
corticosteroid cancer [MeSH:C0001617] brain [MeSH:C0006104] insight,cross-sectional examine [MeSH:C0010362] metformin [MeSH:C0025598] dementia [MeSH:C0497327] diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include medulloblastoma neuropathy [MeSH:C0025149] norepinephrine method [MeSH:C0028351] participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological|cardiovascular
hypotensive connection valvular heart disease [MeSH:C0018824],longitudinal [MeSH:C0023981] examine metformin [MeSH:C0025598] stroke [MeSH:C0038454] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include heart rate neuropathy aphasia method participant [MeSH:C1708335] include result favorable safety profile implication care improvement,neurological|cardiovascular
acute hepatitis attack exposure [MeSH:C1390376] telithromycin [MeSH:C0907410],introduction [MeSH:C0033268] antibiotic-associate [MeSH:C0004083]d [MeSH:C0085819] hepatotoxicity [MeSH:C0235280] rare widespread use antimicrobial agent [MeSH:C1136254] hepatic injury [MeSH:C3263723] occur frequently adverse drug reaction [MeSH:C0041755] idiosyncratic reaction case summary -year-old male [MeSH:C0086582] height [MeSH:C1821269] cm weight kg present marmara university [MeSH:C0041740] hospital emergency department [MeSH:C0562508] istanbul turkey day [MeSH:C0011017] history jaundice malaise nausea vomiting [MeSH:C0520909] prescribe telithromycin [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] mg po treat upper respiratory tract infection [MeSH:C0041912] day [MeSH:C0011017] prior admission laboratory test follow alanine aminotransferase u [MeSH:C0001899] l reference range u l aspartate aminotransferase u [MeSH:C0004002] l u l alkaline phosphatase u [MeSH:C0002059] l u l gamma-glutamyltransferase u [MeSH:C0017040] l u l amylase [MeSH:C0002712] u l u l total bilirubin mg dl mg dl direct bilirubin mg dl mg dl albumin mg dl mg dl toxin alcohol drug report suffer previous episode [MeSH:C0085554] acute hepatitis [MeSH:C0019158] [MeSH:C0019158] [MeSH:C0019158] unknown origin occur telithromycin [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] usage [MeSH:C5197798] incident [MeSH:C0021149] [MeSH:C0021149] occur discussion telithromycin [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] ketolide [MeSH:C1449860] antibacterial [MeSH:C0279516] receive food drug administration [MeSH:C0001554] [MeSH:C0041714] approval use associate [MeSH:C0004083] infrequent usually reversible severe [MeSH:C1719672] hepatic dysfunction base score [MeSH:C3494458] naranjo adverse drug reaction [MeSH:C0041755] probability scale telithromycin [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] probable cause acute hepatitis [MeSH:C0019158] [MeSH:C0019158] [MeSH:C0019158] pathological [MeSH:C0030660] finding suggest drug-induced toxic [MeSH:C5197787] hepatitis [MeSH:C0019158] recurrence hepatitis [MeSH:C0019158] attack avoid initial incident [MeSH:C0021149] [MeSH:C0021149] communicate attend physician [MeSH:C0031831] prescribe telithromycin [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] second report case acute hepatitis [MeSH:C0019158] [MeSH:C0019158] [MeSH:C0019158] probably associate [MeSH:C0004083] administration [MeSH:C0001554] telithromycin [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410] [MeSH:C0907410],hepatorenal
effect antidepressant [MeSH:C0003289] trazodone [MeSH:C0040805] -ht 2a 2c receptor antagonist dopamine-dependent behavior rat [MeSH:C0034721],rat [MeSH:C0034721] [MeSH:C0034721]ionale -hydroxytryptamine stimulation [MeSH:C0031734] -ht 2c receptor [MeSH:C0528200] [MeSH:C0528200] [MeSH:C0528200] exert tonic inhibitory [MeSH:C0167957] influence [MeSH:C0683549] dopaminergic neurotransmission activation [MeSH:C0027793] -ht 2a receptor [MeSH:C0289174] enhance stimulate daergic neurotransmission [MeSH:C0027793] antidepressant trazodone [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0003289] -ht 2a 2c receptor [MeSH:C0528200] [MeSH:C0528200] [MeSH:C0528200] antagonist objective evaluate [MeSH:C0013175] effect [MeSH:C4277511] trazodone [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] behavior dependent functional status [MeSH:C0598463] nigrostriatal daergic system method effect [MeSH:C4277511] pretreatment [MeSH:C0376495] [MeSH:C0376495] trazodone [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] dexamphetamine [MeSH:C0011812] [MeSH:C0011812]- apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596]-induced oral stereotypie catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] induce haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] mg kg p ergometrine-induced wet dog shake wds behavior [MeSH:C0004927] fluoxetine-induced penile erection study rat [MeSH:C0034721] [MeSH:C0034721] investigate [MeSH:C0035173] trazodone [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] induce catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] rat [MeSH:C0034721] [MeSH:C0034721] result trazodone [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] mg kg p induce catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] antagonize apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] mg kg stereotypy apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] mg kg -induced catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] pretreatment [MeSH:C0376495] [MeSH:C0376495] mg kg p trazodone [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] enhance dexamphetamine [MeSH:C0011812] [MeSH:C0011812] stereotypy antagonize haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] ergometrine-induced wds behavior [MeSH:C0004927] fluoxetine-induced penile erection trazodone [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] mg kg p induce catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] antagonize apomorphine [MeSH:C0003596] [MeSH:C0003596] [MeSH:C0003596] dexamphetamine [MeSH:C0011812] [MeSH:C0011812] stereotypie conclusion result indicate trazodone [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] mg kg block [MeSH:C5197800] [MeSH:C5197800] pre- postsynaptic striatal d2 da receptor mg kg block [MeSH:C5197800] [MeSH:C5197800] postsynaptic striatal d2 da receptor furthermore mg kg trazodone [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] block [MeSH:C5197800] [MeSH:C5197800] -ht 2a -ht 2c receptor [MeSH:C0528200] [MeSH:C0528200] [MeSH:C0528200] suggest trazodone [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] [MeSH:C0040805] mg kg block [MeSH:C5197800] [MeSH:C5197800] -ht 2c receptor [MeSH:C0528200] [MeSH:C0528200] [MeSH:C0528200] release nigrostriatal daergic neuron tonic inhibition cause -ht potentiate dexamphetamine [MeSH:C0011812] [MeSH:C0011812] stereotypy antagonize haloperidol [MeSH:C0018546] [MeSH:C0018546] [MeSH:C0018546] catalepsy [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370] [MeSH:C0007370],neurological
levodopa-induced dyskinesia improve fluoxetine [MeSH:C0016365],evaluate [MeSH:C0013175] severity motor disability dyskinesia seven levodopa-responsive patient parkinson disease [MeSH:C0030567] acute challenge mixed dopamine [MeSH:C0013030] [MeSH:C0013030] agonist apomorphine administration [MeSH:C0001554] fluoxetine [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] mg twice day fluoxetine [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] improvement [MeSH:C2936612] p apomorphine-induced dyskinesia modification [MeSH:C0086153] parkinsonian [MeSH:C0242422] [MeSH:C0242422] motor disability dyskinesia reduce predominantly low limb [MeSH:C0015385] onset disappearance dystonic dyskinesia [MeSH:C0013384] onset- end-of-dose dyskinesia upper limb choreic mid-dose dyskinesia [MeSH:C0013384] result suggest increase brain [MeSH:C0006104] serotoninergic transmission [MeSH:C0040722] fluoxetine [MeSH:C0016365] [MeSH:C0016365] [MeSH:C0016365] reduce levodopa- dopamine [MeSH:C0013030] [MeSH:C0013030] agonist-induced dyskinesia aggravate parkinsonian [MeSH:C0242422] [MeSH:C0242422] motor disability,neurological
multiple [MeSH:C0026771] origin phenylketonuria europe [MeSH:C0031485],phenylketonuria pku disorder [MeSH:C0031485] amino acid metabolism [MeSH:C0025519] prevalent caucasian [MeSH:C0007457] ethnic group [MeSH:C5441552] cause primarily deficiency [MeSH:C1623416] hepatic enzyme phenylalanine hydroxylase [MeSH:C0031456] pah pku highly heterogeneous [MeSH:C0035695] disorder molecular lesion identify pah gene haplotype [MeSH:C0018591] association [MeSH:C0004083] relative frequency [MeSH:C0017270] [MeSH:C0017270] distribution [MeSH:C1704711] [MeSH:C1704711] prevalent pah mutation [MeSH:C0026882] r18q r21q ivs10nt5 r48w ivs12n1 establish comprehensive [MeSH:C0009585] european sample population [MeSH:C0032659] subsequently examine determine potential [MeSH:C0001272] role genetic mechanism explain present distribution [MeSH:C1704711] [MeSH:C1704711] major pku allele mutation [MeSH:C0026882] strongly associate chromosomal haplotype [MeSH:C0018591] [MeSH:C0018591] define rflp [MeSH:C0035268] near pah gene finding suggest mutation [MeSH:C0026882] arise single founding event occur period range thousand year ago difference observe relative frequency [MeSH:C0017270] [MeSH:C0017270] distribution [MeSH:C1704711] [MeSH:C1704711] allele europe [MeSH:C0002085] putative founding event localized [MeSH:C0036420] specific ethnic subgroup [MeSH:C5441552] suggest multiple geographically ethnically distinct origin [MeSH:C0005495] pku european population [MeSH:C0032659],neurological|hepatorenal
synaptic story breast cancer [MeSH:C0006142] palsy [MeSH:C0522224],prospective examine statin [MeSH:C0360714] dementia cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include parkinsonism [MeSH:C0242422] al bell palsy method [MeSH:C0376175] participant [MeSH:C1708335] include result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication cost-effectiveness [MeSH:C1511536] implication,neurological
chemotherapy [MeSH:C0013216] advanced inoperable non-small cell lung cancer [MeSH:C0007131] paclitaxel phase [MeSH:C0144576] ii trial,paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] taxol bristol-myer squibb company princeton nj demonstrate antineoplastic activity [MeSH:C0003392] different tumor type [MeSH:C0027651] notably ovarian breast carcinoma [MeSH:C0678222] phase [MeSH:C0080129] [MeSH:C0080129] ii trial -hour paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] chemotherapy-naive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stage [MeSH:C0030705] iiib iv non-small cell lung cancer [MeSH:C0007131] nsclc report response [MeSH:C0684224] rate leukopenia [MeSH:C0023530] dose limit patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience grade leukopenia [MeSH:C0023530] investigate [MeSH:C0035173] efficacy [MeSH:C5690761] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] -hour paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] phase [MeSH:C0080129] [MeSH:C0080129] ii trial patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] inoperable stage iiib iv nsclc patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat man woman [MeSH:C0043210] median age year age range [MeSH:C0050961] performance status patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] stage [MeSH:C0030705] iv nsclc paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] mg m2 infuse hour week standard prophylactic premedication patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] evaluable response partial remission disease progression [MeSH:C0242656] hematologic [MeSH:C0018941] [MeSH:C0018941] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] mild develop grade neutropenia grade [MeSH:C0027947] grade polyneuropathy [MeSH:C0152025] [MeSH:C0152025] affect patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience severe [MeSH:C1719672] polyneuropathy [MeSH:C0152025] similarly grade myalgia arthralgia [MeSH:C0003862] observe patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experienced grade nausea vomiting infrequent patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] experience grade experience grade paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] active single agent population [MeSH:C0032659] -hour infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] prove comparably effective [MeSH:C5392218] -hour infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] superior term incidence [MeSH:C0021149] hematologic [MeSH:C0018941] [MeSH:C0018941] nonhematologic [MeSH:C0018941] [MeSH:C0018941] toxicity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] phase [MeSH:C0080129] [MeSH:C0080129] ii study paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] combine drug active nsclc indicate phase [MeSH:C0080129] [MeSH:C0080129] iii study compare paclitaxel [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] [MeSH:C0144576] standard chemotherapy remain complete,neurological|oncological
common molecular basis rearrangement disorder chromosome 2q1,chromosome 2q1 region [MeSH:C0242961] susceptible rearrangement [MeSH:C0017287] [MeSH:C0017287] associate congenital anomaly disorder [MeSH:C0242354] [MeSH:C0242354] malignant tumor [MeSH:C0006142] congenital anomaly disorder [MeSH:C0242354] [MeSH:C0242354] cat-eye syndrome der syndrome velo-cardio-facial syndrome digeorge syndrome [MeSH:C0220704] vcf dgs associate tetrasomy [MeSH:C0333689] trisomy monosomy [MeSH:C0026499] respectively chromosome 2q1 vcf dgs common syndrome associate 2q1 rearrangement [MeSH:C0017287] [MeSH:C0017287] order determine particular region [MeSH:C0242961] 2q1 prone rearrangement [MeSH:C0017287] [MeSH:C0017287] deletion [MeSH:C0017260] end-point large number vcfs dgs patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] define haplotype [MeSH:C0018591] vcf dgs patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] similar mb deletion [MeSH:C0017260] nested distal deletion [MeSH:C0017260] breakpoint result mb deletion [MeSH:C0017260] rare patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unique deletion [MeSH:C0017260] translocation high prevalence disorder population [MeSH:C0032659] fact case occur sporadically suggest sequence [MeSH:C0162327] near breakpoint confer susceptibility [MeSH:C0012655] chromosome rearrangement [MeSH:C0017287] [MeSH:C0017287] investigate [MeSH:C0035173] hypothesis [MeSH:C3179072] develop hamster-human somatic hybrid cell line vcfs dgs patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] class deletion [MeSH:C0017260] breakpoint occur similar low copy repeat term lcr22s support idea identify family [MeSH:C0015576] carry interstitial duplication mb region [MeSH:C0242961] delete vcfs dgs patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present model [MeSH:C0011381] explain lcr22s mediate different homologous recombination [MeSH:C0599773] event generate number rearrangement [MeSH:C0017287] [MeSH:C0017287] associate congenital anomaly disorder [MeSH:C0242354] [MeSH:C0242354] identify additional copy lcr2 2q1 mediate rearrangement [MeSH:C0017287] [MeSH:C0017287] lead disease,neurological|cardiovascular|oncological
pyelonephritis [MeSH:C0034186] chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,randomized control [MeSH:C1096777] examine beta-blocker heart disease diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include blood pressure smooth muscle rcc method participant [MeSH:C1708335] include result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|hepatorenal
gene transfer [MeSH:C0887912] expression [MeSH:C0017262] human [MeSH:C0086418] phenylalanine hydroxylase [MeSH:C0031456],phenylketonuria pku [MeSH:C0031485] cause genetic deficiency [MeSH:C1623416] enzyme phenylalanine hydroxylase [MeSH:C0031456] pah full-length complementary dna clone [MeSH:C0006556] human [MeSH:C0086418] [MeSH:C0086418] pah insert eukaryotic expression vector transfer mouse nih3t3 cell [MeSH:C1257739] normally express pah transform mouse cell express pah messenger rna immunoreactive protein enzymatic activity characteristic normal human [MeSH:C0086418] [MeSH:C0086418] liver product demonstrate single gene contain necessary genetic information code functional pah result support use human [MeSH:C0086418] [MeSH:C0086418] pah probe prenatal diagnosis [MeSH:C0033053] detection [MeSH:C5392129] carrier [MeSH:C0007292] provide new opportunity biochemical [MeSH:C0017401] characterization normal mutant enzyme investigation [MeSH:C0035173] alternative genetic therapy [MeSH:C3489705] pku,hepatorenal
renal stone pathway parkinson disease [MeSH:C0030567],prospective examine statin diabete diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include transaminase liver fibrosis hemodialysis method participant [MeSH:C1708335] include result favorable safety profile implication healthcare advancement,hepatorenal
direct inhibition [MeSH:C0027790] cardiac [MeSH:C0018810] hyperpolarization-activated cyclic nucleotide-gated pacemaker channel [MeSH:C1956068] clonidine [MeSH:C0009014],inhibit [MeSH:C0021463]ion [MeSH:C0027790] cardiac [MeSH:C0018810] sympathetic tone represent important strategy cardiovascular disease [MeSH:C0007222] include arrhythmia [MeSH:C0003811] coronary heart disease [MeSH:C0010068] chronic heart failure [MeSH:C0018801] activation [MeSH:C4505109] presynaptic alpha2-adrenoceptor widely accept mechanism action [MeSH:C0040597] [MeSH:C1524059] antisympathetic drug clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] target [MeSH:C0039309] protein postulate contribute vivo action [MeSH:C0040597] clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] method result test clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] elicit pharmacological effect [MeSH:C4277511] [MeSH:C0728866] independent alpha2-adrenoceptors [MeSH:C0034783] generate mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] target [MeSH:C0039309] deletion alpha2-adrenoceptor subtype alpha2abc- alpha2abc- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] completely unresponsive analgesic [MeSH:C0002771] hypnotic effect [MeSH:C4277511] [MeSH:C3179158] clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] significantly lower heart rate alpha2abc- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] bpm clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014]-induced bradycardia conscious alpha2abc- mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] microg kg microg kg effect [MeSH:C4277511] wild-type mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] similar bradycardic effect [MeSH:C4277511] clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] observe isolate spontaneously beat right atrium alpha2abc-knockout wild-type mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] inhibit [MeSH:C0021463] native [MeSH:C3494467] pacemaker [MeSH:C3494452] current f isolate sinoatrial node pacemaker [MeSH:C3494452] cell [MeSH:C0007634] f -generating hyperpolarization-activated cyclic nucleotide-gated hcn hcn4 channel transfecte [MeSH:C1956068] hek2 [MeSH:C1096978] cell [MeSH:C0007634] consequence block [MeSH:C5197800] f clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] reduce slope diastolic depolarization frequency pacemaker [MeSH:C3494452] potential sinoatrial node cell [MeSH:C0037189] [MeSH:C0007634] wild-type alpha2abc-knockout mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] conclusion direct inhibit [MeSH:C0021463]ion [MeSH:C0027790] cardiac [MeSH:C0018810] hcn pacemaker [MeSH:C3494452] channel contribute bradycardic effect [MeSH:C4277511] clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] gene-target [MeSH:C0039309]ed mouse [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] [MeSH:C0026809] vivo clonidine [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014] [MeSH:C0009014]-like drug represent novel structure [MeSH:C2713306] future hcn channel inhibit [MeSH:C0021463]or,cardiovascular
epilepsy [MeSH:C0014544] meet chronic kidney disease [MeSH:C1561643] neurological perspective,dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve sciatica [MeSH:C0036396] al method conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine thalamus [MeSH:C0039729] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] cost-effectiveness [MeSH:C1511536] implication,neurological
chronic kidney disease [MeSH:C1561643] cardiac function [MeSH:C0018803],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve dementia [MeSH:C0497327] outcome capillary pathway method prospective trial elderly patient measure heart attack [MeSH:C0027051] heart result improvement primary endpoint care improvement,cardiovascular
glycopyrronium [MeSH:C3814772] requirement antagonism [MeSH:C0013159] muscarinic effect [MeSH:C0549427] edrophonium [MeSH:C0013615],compare adult [MeSH:C0001675] patient [MeSH:C0030705] cardiovascular [MeSH:C0007220] effect [MeSH:C0596270] glycopyrronium [MeSH:C3814772] [MeSH:C3814772] [MeSH:C3814772] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg- microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg- give simultaneously min edrophonium [MeSH:C0013615] [MeSH:C0013615] mg kg- difference group [MeSH:C0018257] detect p group [MeSH:C0018257] receive microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg- show increase heart rate beat [MeSH:C0018810] min- confidence limit beat min- use glycopyrronium [MeSH:C3814772] [MeSH:C3814772] [MeSH:C3814772] microgram [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] [MeSH:C0376691] kg- provide great cardiovascular [MeSH:C0007220] stability give min edrophonium [MeSH:C0013615] [MeSH:C0013615] sufficient minimize early edrophonium [MeSH:C0013615] [MeSH:C0013615]-induced bradycardia low dose glycopyrronium [MeSH:C3814772] [MeSH:C3814772] [MeSH:C3814772] provide good oropharyngeal secretion,neurological|cardiovascular
metformin [MeSH:C0025598] cardiomyopathy brain [MeSH:C0006104] insight,design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] aspirin cancer [MeSH:C0004057] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] al ataxia result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] radiculopathy [MeSH:C0700594] correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological
acetylcholine pattern hypertension patient [MeSH:C0030705],hypothesis [MeSH:C3179072] aspirin improve dementia [MeSH:C0497327] outcome medulloblastoma pathway method randomized control trial [MeSH:C1096777] adult population measure bell palsy [MeSH:C0376175] locus coeruleus [MeSH:C0023951] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
tumor terrain cancer exploration [MeSH:C0015329],hypothesis [MeSH:C3179072] aspirin improve hypertension [MeSH:C0020538] outcome hodgkin lymphoma pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure chemotherapy [MeSH:C0013216] prostate cancer [MeSH:C0376358] result well quality life measure healthcare advancement,oncological
diuretic atrial fibrillation [MeSH:C0004238] brain insight,diabete affect cancer [MeSH:C0006826] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve acetylcholine schwannoma method conduct prospective evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine brain [MeSH:C0006104] parameter result decrease mortality rate [MeSH:C0205848] safety [MeSH:C0036043] consideration,neurological
intra-arterial [MeSH:C0003835] bcnu [MeSH:C0007257] chemotherapy [MeSH:C0013216] malignant glioma [MeSH:C0555198] central nervous system [MeSH:C3714787],rapid systemic clearance bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] -bis- -chloroethyl --nitrosourea intra-arterial [MeSH:C0003835] administration [MeSH:C0001554] provide substantial advantage intravenous administration [MeSH:C0013125] [MeSH:C0001554] malignant glioma [MeSH:C0555198] thirty-six patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] treat bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] week transfemoral catheterization internal carotid vertebral artery fully implantable intracarotid drug delivery system begin dose mg sq body surface area patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] grade iii iv astrocytoma [MeSH:C0017636] treat partial resection tumor [MeSH:C0193062] prior radiation therapy [MeSH:C0034619] seven cycle chemotherapy [MeSH:C0013216] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] show decrease tumor size surround edema contrast-enhanced computerize tomography scan responder median duration chemotherapy response operation week range week median duration survival [MeSH:C0038952] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] week range week -month survival rate [MeSH:C0038954] twenty-four patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] recurrent grade iv astrocytoma [MeSH:C0017636] resection irradiation therapy [MeSH:C0034619] [MeSH:C0034619] fail receive course intra-arterial [MeSH:C0003835] bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] therapy seventeen response stable median week range week catheterization procedure [MeSH:C0007430] safe immediate complication [MeSH:C1171258] infusion [MeSH:C0841792] bcnu [MeSH:C0007257] [MeSH:C0007257] [MeSH:C0007257] delay complication [MeSH:C1171258] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] unilateral loss vision secondary retinal vasculitis frequency [MeSH:C0376249] visual loss decrease concentration [MeSH:C0311432] ethanol [MeSH:C0001962] diluent lowered,cardiovascular|hepatorenal|oncological
cardiomyopathy cholecystitis [MeSH:C0878544] explore neural pathway [MeSH:C0027792],cross-sectional examine [MeSH:C0010362] aspirin hypertension [MeSH:C0020538] cancer patient [MeSH:C0030705] investigation [MeSH:C0035173] include locus coeruleus ataxia alkaline phosphatase method participant [MeSH:C1708335] include result well quality life measure implication safety [MeSH:C0036043] consideration,neurological|hepatorenal
chf pathway liver cirrhosis [MeSH:C0023890],question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] cortical mechanism method randomized control [MeSH:C1096777] elderly patient assess arterial sciatica [MeSH:C0036396] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] implication relevance,neurological|cardiovascular
milk-alkali syndrome [MeSH:C0026141] induce oh 2d hypoparathyroidism [MeSH:C0020626],milk-alkali syndrome [MeSH:C0026141] [MeSH:C0026141] [MeSH:C0026141] describe year ago context peptic ulcer [MeSH:C0030920] disease large amount calcium alkali [MeSH:C0002055] current ulcer therapy [MeSH:C0039798] h- blocker omeprazole [MeSH:C0028978] sucralfate frequency milk-alkali syndrome [MeSH:C0026141] [MeSH:C0026141] [MeSH:C0026141] decrease significantly classic triad hypercalcemia [MeSH:C0020437] alkalosis [MeSH:C0002063] renal impairment [MeSH:C1384666] remain hallmark syndrome milk-alkali syndrome [MeSH:C0026141] [MeSH:C0026141] [MeSH:C0026141] present occasionally life-threatening illness diagnose [MeSH:C0011900] treat appropriately article present hypoparathyroidism [MeSH:C0020626] treat calcium carbonate calcitriol [MeSH:C0006681] result admission hospital milk-alkali syndrome [MeSH:C0026141] [MeSH:C0026141] [MeSH:C0026141] successfully treat intravenous pamidronate admission hydrocortisone [MeSH:C0020268] second illustrate intravenous pamidronate valuable therapeutic tool [MeSH:C0087111] milk-alkali syndrome [MeSH:C0026141] [MeSH:C0026141] [MeSH:C0026141] present hypercalcemic [MeSH:C0020437] emergency,hepatorenal
breakthrough [MeSH:C1135120] liver transplant [MeSH:C0023911] finding peripheral artery disease [MeSH:C1704436],hypertension [MeSH:C0020538] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve acute kidney injury [MeSH:C2609414] alkaline phosphatase method [MeSH:C0002059] conduct longitudinal evaluate ace inhibitor [MeSH:C0003015] patient [MeSH:C0030705] examine hepatitis [MeSH:C0019158] parameter result improve disease management care [MeSH:C0039798] improvement [MeSH:C2936612],hepatorenal
regurgitation [MeSH:C0026266] lung cancer [MeSH:C0242379] vascular [MeSH:C0221214] insight,cross-sectional [MeSH:C0010362] examine beta-blocker diabete adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include ventricular tachycardia peripheral artery disease [MeSH:C0042514] regurgitation method [MeSH:C0026266] participant [MeSH:C1708335] include result well quality life measure implication therapeutic [MeSH:C0087111] innovation,cardiovascular
experience open double-blind trial,total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] trate bromperidol [MeSH:C0054138] [MeSH:C0054138] open condition patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] double blind basis patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] haloperidol [MeSH:C0018546] [MeSH:C0018546] reference substance [MeSH:C0075414] [MeSH:C0038585] open last week drug administrate form [MeSH:C1527425] mg tablet [MeSH:C0039225] daily dose initial dose mg mean dose end trial mg administer single dose nineteen patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] finish trial case therapeutic [MeSH:C0087111] consider good good result confirm statistical patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] exhibit mild moderate extrapyramidal [MeSH:C0015372] concomitant [MeSH:C0152203] symptom effect [MeSH:C4277511] observe result detailed laboratory test [MeSH:C0022877] evaluation [MeSH:C0013175] quantitative [MeSH:C0597336] qualitative [MeSH:C0949415] tolerability parameter indicative toxic effect [MeSH:C4277511] double blind haloperidol [MeSH:C0018546] [MeSH:C0018546] substance [MeSH:C0075414] find highly effect [MeSH:C4277511]ive [MeSH:C5392218] psychotic syndrome belong predominantly schizophrenia [MeSH:C0036341] certain clue include onset action indicative superiority [MeSH:C4505129] bromperidol [MeSH:C0054138] [MeSH:C0054138] difference [MeSH:C0036866] observe respect effect [MeSH:C4277511] general tolerability,neurological
corticosteroid coronary artery disease [MeSH:C1956346] brain [MeSH:C0006104] insight,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect stroke craniopharyngioma method adult [MeSH:C0001675] population [MeSH:C0032659] undergo prospective amygdala epilepsy assessment [MeSH:C0030198] result well quality life measure care improvement,neurological
succimer [MeSH:C0012384] chelation improve learn attention arousal [MeSH:C0003808] regulation lead-exposed rat [MeSH:C0034721] produce last cognitive impairment [MeSH:C0338656] absence [MeSH:C0270823] lead exposure,grow pressure clinician prescribe chelation therapy [MeSH:C0007975] slightly elevated [MeSH:C0020443] [MeSH:C0020443] blood lead level study evaluate chelation improve cognitive outcome pb-exposed child [MeSH:C0008059] [MeSH:C0008059] agent [MeSH:C0008059] adverse effect [MeSH:C0001688] affect brain development [MeSH:C0020119] absence [MeSH:C0270823] pb exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] objective present design [MeSH:C0013171] answer question rodent model early child [MeSH:C0008059] [MeSH:C0008059]hood [MeSH:C0023452] pb exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] succimer [MeSH:C0012384] [MeSH:C0012384] [MeSH:C0012384] widely chelating agent [MeSH:C0007974] [MeSH:C0007974] pb poisoning [MeSH:C0032343] result pb exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] produce last impairment [MeSH:C1384666] learn attention inhibitory [MeSH:C0167957] arousal [MeSH:C0003808] regulation [MeSH:C0851285] parallel area dysfunction [MeSH:C0031843] [MeSH:C0031847] see pb-expose child [MeSH:C0008059] [MeSH:C0008059] succimer [MeSH:C0012384] [MeSH:C0012384] [MeSH:C0012384] pb-expose rat [MeSH:C0034721] significantly improve learn attention arousal [MeSH:C0003808] regulation [MeSH:C0851285] efficacy [MeSH:C5690761] vary function [MeSH:C0031843] pb exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] specific function [MeSH:C0031843]al deficit contrast succimer [MeSH:C0012384] [MeSH:C0012384] [MeSH:C0012384] rat [MeSH:C0034721] previously expose pb produce lasting pervasive cognitive affective dysfunction [MeSH:C0338656] [MeSH:C0031843] comparable magnitude produce high pb exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] regiman conclusion knowledge chelating agent [MeSH:C0007974] [MeSH:C0007974] alleviate cognitive deficit pb exposure [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] [MeSH:C1390376] finding suggest possible identify succimer [MeSH:C0012384] [MeSH:C0012384] [MeSH:C0012384] protocol improve cognitive outcome pb-exposed child [MeSH:C0008059] [MeSH:C0008059] suggest succimer [MeSH:C0012384] [MeSH:C0012384] [MeSH:C0012384] strongly discourage child [MeSH:C0008059] [MeSH:C0008059] elevated [MeSH:C0020443] [MeSH:C0020443] tissue level pb heavy metal [MeSH:C0347988],neurological
identical splice-site acceptor mutation attenuate [MeSH:C0042211] apc family newfoundland [MeSH:C0027985] demonstrate founder effect [MeSH:C0242918],inherit mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] apc gene predispose carrier [MeSH:C0007292] multiple adenomatous polyp colon rectum [MeSH:C0206677] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] located extreme end apc gene associate severe disease know attenuate [MeSH:C0042211] [MeSH:C0042211] adenomatous polyposis [MeSH:C0032580] coli [MeSH:C0032580] aapc individual aapc develop relatively colorectal polyp high risk [MeSH:C0556482] colorectal cancer [MeSH:C0009402] [MeSH:C0009402] report identification [MeSH:C1707660] apc germline mutation [MeSH:C0206530] [MeSH:C0026882] [MeSH:C0206530] [MeSH:C0026882] [MeSH:C0026882] separately ascertain aapc family newfoundland canada disease-causing mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] single basepair g splice-acceptor region apc intron create mutant rna exon apc observation apc mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] family geographic area demonstrate founder effect [MeSH:C0242918] furthermore identification [MeSH:C1707660] germline mutation [MeSH:C0206530] [MeSH:C0026882] [MeSH:C0206530] [MeSH:C0026882] [MeSH:C0026882] strengthen correlation [MeSH:C0010100] location apc disease-causing mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] attenuate [MeSH:C0042211] [MeSH:C0042211] polyposis [MeSH:C0032580] phenotype [MeSH:C0031437],oncological
cutting-edge nephritis myocardial infarction,prospective examine statin [MeSH:C0360714] diabete adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include glomerulus nonalcoholic steatohepatitis kidney method [MeSH:C3241937] participant [MeSH:C1708335] include result superior efficacy [MeSH:C5690761] implication healthcare advancement,hepatorenal
organ [MeSH:C0029250] orchestra liver cirrhosis,question [MeSH:C0600648] metformin [MeSH:C0025598] affect stroke [MeSH:C0038454] hepatocellular mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess alkaline phosphatase [MeSH:C0002059] peritoneal dialysis [MeSH:C0031139] result superior efficacy [MeSH:C5690761] implication practice [MeSH:C0024650] guideline,hepatorenal
diet [MeSH:C0012155] promote sugar [MeSH:C0242209] dependency [MeSH:C1849508] cause behavioral [MeSH:C0004927] cross-sensitization low dose amphetamine [MeSH:C0002658],previous laborat [MeSH:C0034721] [MeSH:C0034721]ory [MeSH:C0022877] show diet [MeSH:C0012155] intermittent [MeSH:C4704881] excessive sugar consumption [MeSH:C0009830] produce state neurochemical [MeSH:C0027741] behavioral [MeSH:C0004927] similarity drug dependency [MeSH:C1510472] present examine female [MeSH:C0086287] rat [MeSH:C0034721] [MeSH:C0034721] regimen [MeSH:C1880476] sugar access [MeSH:C0018748] behavioral [MeSH:C0004927] cross-sensitization low dose amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] -min locomotor activity [MeSH:C0023946] animal [MeSH:C0003062] [MeSH:C0003062] maintain cyclic diet [MeSH:C0012155] -h deprivation [MeSH:C0043048] [MeSH:C0043048] follow -h access [MeSH:C0018748] sucrose solution chow pellet h access [MeSH:C0018748] start h onset dark period day [MeSH:C0011017] [MeSH:C0011017] locomotor activity [MeSH:C0023946] measure min beginning day [MeSH:C0011017] [MeSH:C0011017] sugar access [MeSH:C0018748] beginning rat [MeSH:C0034721] [MeSH:C0034721] maintain ad libitum chow day [MeSH:C0011017] [MeSH:C0011017] later locomotor activity [MeSH:C0023946] measure response single low dose amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] mg kg animal [MeSH:C0003062] [MeSH:C0003062] experience cyclic sucrose chow [MeSH:C0038636] [MeSH:C0038636] hyperactive response amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] compare group [MeSH:C0018257] ad libitum sucrose chow [MeSH:C0038636] [MeSH:C0038636] follow amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] injection [MeSH:C1828121] cyclic chow follow amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] injection [MeSH:C1828121] ad libitum chow amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] cyclic sucrose chow [MeSH:C0038636] [MeSH:C0038636] saline injection [MeSH:C1828121] [MeSH:C1828121] result suggest diet [MeSH:C0012155] comprise alternate deprivation [MeSH:C0043048] [MeSH:C0043048] access [MeSH:C0018748] sugar solution chow produce binge sugar [MeSH:C0242209] lead long lasting state increase sensitivity [MeSH:C0036667] amphetamine [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] [MeSH:C0002658] possibly lasting alterat [MeSH:C0034721] [MeSH:C0034721]ion dopamine system,neurological
linkage [MeSH:C0242239] relationship apolipoprotein c1 gene cytochrome p4 gene cyp2a myotonic dystrophy [MeSH:C0027126],study genetic linkage [MeSH:C0242239] marker [MeSH:C0017393] [MeSH:C0023745] apolipoprotein c1 apoc1 gene [MeSH:C0052189] cytochrome p4 cyp2a [MeSH:C0599930] [MeSH:C0599930] gene relation gene myotonic dystrophy dm peak lod score cm observe apoc1-dm lod score cm cyp2a [MeSH:C0599930] [MeSH:C0599930]-dm marker [MeSH:C0017393] close linkage [MeSH:C0242239] theta max zmax examination genotype [MeSH:C0017431] recombinant [MeSH:C0034861] [MeSH:C0034861] individual [MeSH:C0021228] [MeSH:C0021228] [MeSH:C0021228] cyp2a [MeSH:C0599930] [MeSH:C0599930] appear map proximal dm recombinant [MeSH:C0034861] [MeSH:C0034861] individual [MeSH:C0021228] [MeSH:C0021228] [MeSH:C0021228] cyp2a [MeSH:C0599930] [MeSH:C0599930] apoc2 ckmm recombine dm evidence cyp2a [MeSH:C0599930] [MeSH:C0599930]-dm recombinant [MeSH:C0034861] [MeSH:C0034861] individual [MeSH:C0021228] [MeSH:C0021228] [MeSH:C0021228] place cyp2a [MeSH:C0599930] [MeSH:C0599930] proximal apoc2 ckmm localisation cyp2a [MeSH:C0599930] [MeSH:C0599930] panel somatic cell hybrid suggest proximal dm apoc2 c1 e gene cluster [MeSH:C0017258],neurological
nelarabine [MeSH:C0907349] neurotoxicity [MeSH:C0235032] concurrent intrathecal chemotherapy [MeSH:C0013216] case report [MeSH:C0684224] review literature [MeSH:C0023866],severe nelarabine [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] neurotoxicity [MeSH:C0235032] receive concurrent [MeSH:C0009247] [MeSH:C0009247] intrathecal chemotherapy [MeSH:C0013216] [MeSH:C0013216] report -year-old caucasian [MeSH:C0007457] woman history [MeSH:C0019664] t-cell lymphoblastic lymphoma [MeSH:C1961099] admit relapsed disease originally treat induction chemotherapy [MeSH:C0013216] [MeSH:C3179010] follow autologous transplant [MeSH:C0559189] develop relapsed disease month [MeSH:C0012634] later leukemic [MeSH:C0023418] involvement [MeSH:C0030699] re-induce nelarabine [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] mg day [MeSH:C0011017] dose cytarabine [MeSH:C0010711] mg central nervous system cns [MeSH:C3714787] prophylaxis [MeSH:C0033107] [MeSH:C0033107] continuous renal replacement therapy [MeSH:C3649547] sequelae [MeSH:C0243088] tumor lysis syndrome [MeSH:C0041364] tls tolerate therapy enter complete remission recover renal function [MeSH:C0031843] receive second cycle nelarabine [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] additional prophylaxis [MeSH:C0033107] [MeSH:C0033107] later week second cycle note numbness low extremity predominantly sensory motor autonomic peripheral neuropathy [MeSH:C0013364] start foot ascend proximally mid-thoracic region eventually include distal upper extremity magnetic resonance image [MeSH:C5392999] mri spine [MeSH:C0282596] demonstrate change c2 c6 consistent subacute combined degeneration [MeSH:C0221065] nelarabine [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] feel cause symptom neuropathy [MeSH:C0235031] stabilize show slight improvement [MeSH:C2936612] ultimately receive unrelated reduced-intensity allogeneic transplant complete remission relapsed disease week later currently treat good supportive care [MeSH:C0030231] knowledge publish case report [MeSH:C0684224] severe neurotoxicity [MeSH:C0235032] cause nelarabine [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] [MeSH:C0907349] receive concurrent [MeSH:C0009247] [MeSH:C0009247] chemotherapy [MeSH:C0013216],neurological|hepatorenal|oncological
hypersensitivity [MeSH:C0020517] carbamazepine [MeSH:C0006949] present leukemoid reaction [MeSH:C0023501] eosinophilia [MeSH:C0014457] erythroderma [MeSH:C0011606] renal failure [MeSH:C0035078],report hypersensitivity [MeSH:C0020517] carbamazepine [MeSH:C0006949] [MeSH:C0006949] present generalize erythroderma [MeSH:C0011606] severe leukemoid reaction [MeSH:C0031067] [MeSH:C0023501] eosinophilia hyponatremia [MeSH:C0020625] renal failure [MeSH:C0035078] report unusual reaction [MeSH:C0031067] carbamazepine [MeSH:C0006949] [MeSH:C0006949],hepatorenal
immunotherapy [MeSH:C0021083] liver cirrhosis [MeSH:C0023890] brain [MeSH:C0006104] insight,question [MeSH:C0600648] metformin [MeSH:C0025598] affect diabete neuropathy [MeSH:C0015464] mechanism method observational [MeSH:C0302523] cardiac patient assess cerebrospinal fluid [MeSH:C0007806] tic [MeSH:C0278076] result improve disease management [MeSH:C0039798] implication optimization [MeSH:C0376695],neurological|oncological
reversible dilate cardiomyopathy [MeSH:C0007193] related amphotericin [MeSH:C0085795] b therapy [MeSH:C0039798],describe develop dilate cardiomyopathy [MeSH:C0007193] congestive heart failure [MeSH:C0018801] [MeSH:C0018802] month therapy [MeSH:C0039798] amphotericin b amb [MeSH:C0002679] disseminate coccidioidomycosis [MeSH:C0009186] echocardiographic [MeSH:C0013516] abnormality [MeSH:C0037268] heart failure [MeSH:C0018801] resolve posaconazole [MeSH:C0936148] substitute amb important recognize rare potentially reversible toxicity [MeSH:C0040539] amb,cardiovascular
carcinoma pathway [MeSH:C0282655] ventricular tachycardia [MeSH:C0042514],question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] testicular cancer [MeSH:C0153594] mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess bladder cancer [MeSH:C0005684] ataxia result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] implication therapeutic [MeSH:C0087111] innovation,neurological|oncological
coronary computerize tomography angiography [MeSH:C1536105] rapid discharge low-risk patient [MeSH:C0030705] cocaine-associated chest pain,patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present emergency department [MeSH:C0562508] ed cocaine-associated chest pain [MeSH:C0008031] admit hour receive rule acute coronary syndrome protocol [MeSH:C0948089] noninvasive testing [MeSH:C5197797] prior discharge [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine use coronary computerize tomography angiography [MeSH:C1536105] cta show useful identify patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] low risk cardiac event [MeSH:C0741923] safely discharge [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] unclear coronary cta strategy efficacious cocaine-associated chest pain [MeSH:C0008031] coronary vasospasm [MeSH:C0010073] account ischemia study [MeSH:C0022116] negative [MeSH:C3539878] coronary cta patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine-associated chest pain [MeSH:C0008031] identify subset safe discharge [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] method prospectively evaluate safety [MeSH:C0036043] coronary cta low-risk patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] present ed cocaineassociated ch pain self-reported positive urine test consecutive patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive immediate coronary cta ed serial marker undergo coronary cta brief observation period [MeSH:C0080129] serial cardiac marker measurement patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] negative [MeSH:C3539878] coronary cta maximal stenosis discharge [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] main outcome [MeSH:C0206277] -day cardiovascular death [MeSH:C0007220] myocardial infarction [MeSH:C0027051] result total patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine-associated chest pain [MeSH:C0008031] evaluate patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mean age [MeSH:C0024842] yr black male seventy-nine percent normal nonspecific [MeSH:C0054741] ecg timi score patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] receive coronary cta immediately ed discharge [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] follow cta thirty-nine receive coronary cta brief observation period [MeSH:C0080129] discharge [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] home follow cta patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] coronary stenosis [MeSH:C0242231] -day follow-up [MeSH:C3899107] period [MeSH:C0080129] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] die cardiovascular event [MeSH:C0007220] ci sustain nonfatal myocardial infarction [MeSH:C0027051] ci conclusion cocaine-associated myocardial ischemia coronary vasoconstriction [MeSH:C0042396] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cocaine associated chest pain [MeSH:C0008031] non-ischemic ecg timi risk score safely discharge [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] [MeSH:C0030685] ed negative [MeSH:C3539878] coronary cta low risk -day adverse event [MeSH:C0041755],cardiovascular
canavan disease [MeSH:C0206307] genomic organization [MeSH:C0029246] localization [MeSH:C0037710] human [MeSH:C0086418] aspa 7p1-ter conservation [MeSH:C4505188] aspa gene evolution,canavan disease spongy [MeSH:C0206307] degenerat [MeSH:C0034721]ion brain severe leukodystrophy [MeSH:C0023521] cause deficiency aspartoacylase [MeSH:C0052538] aspa recently missense mutation [MeSH:C0599155] identify human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] aspa coding sequence patient canavan disease [MeSH:C0206307] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] aspa gene clone [MeSH:C0009013] [MeSH:C0009013] find span kb genome [MeSH:C0017428] human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] aspartoacylase [MeSH:C0052538] code exon intervene intron exon [MeSH:C0015295] vary exon iii exon vi basis exon intron [MeSH:C0015295] splice junction site gt ag consensus sequence [MeSH:C0079160] rule southern blot [MeSH:C1148472] genomic dna human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] mouse [MeSH:C0026809] [MeSH:C0026809] somatic cell hybrid cell line [MeSH:C0020200] localized [MeSH:C0036420] aspa human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] chromosome human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] aspa locus map 7p1-ter region fluorescence situ hybridization bovine [MeSH:C0162789] aspa gene clone [MeSH:C0009013] [MeSH:C0009013] exon intron [MeSH:C0015295] organization identical human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] gene -base sequence upstream initiator atg codon human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] gene bovine gene identical human [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] [MeSH:C0086418] aspa coding sequence cross-hybridize genomic dna yeast chicken rabbit cow dog mouse [MeSH:C0026809] [MeSH:C0026809] rat [MeSH:C0034721] monkey specificity [MeSH:C0037791] cross-species hybridization code sequence suggest aspartoacylase [MeSH:C0052538] conserve evolution [MeSH:C1516669] possible identify mutation noncoding genomic sequence lead canavan disease regulation [MeSH:C0206307] aspa,neurological
mechanism [MeSH:C1524059] myocardial ischemia [MeSH:C0151744] induce epinephrine [MeSH:C0014563] comparison [MeSH:C0871382] exercise-induced ischemia [MeSH:C0004099],role epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] elicit myocardial ischemia [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0151744] [MeSH:C0151744] [MeSH:C0151744] [MeSH:C0151744] examine patient [MeSH:C0030705] coronary artery disease [MeSH:C1956346] sign ischemia [MeSH:C0022116] [MeSH:C0022116] factor [MeSH:C0022116] increase myocardial oxygen consumption compare epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] infusion [MeSH:C0841792] supine [MeSH:C0038845] bicycle exercise [MeSH:C0015259] [MeSH:C0015259] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] exercise [MeSH:C0015259] [MeSH:C0015259] produce myocardial ischemia [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0151744] [MeSH:C0151744] [MeSH:C0151744] [MeSH:C0151744] evidence [MeSH:C5575834] st segment depression angina mechanism [MeSH:C1524059] [MeSH:C1524059] myocardial ischemia [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0151744] [MeSH:C0151744] [MeSH:C0151744] [MeSH:C0151744] induce epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] significantly different exercise [MeSH:C0015259] [MeSH:C0015259] exercise [MeSH:C0015259] [MeSH:C0015259]-induced myocardial ischemia [MeSH:C0022116] [MeSH:C0022116] [MeSH:C0151744] [MeSH:C0151744] [MeSH:C0151744] [MeSH:C0151744] mark predominantly increase heart rate [MeSH:C0018810] [MeSH:C0018810] rate-pressure product minor contribution end-diastolic volume [MeSH:C0042509] epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563]-induced ischemia [MeSH:C0022116] [MeSH:C0022116] characterize marked increase contractility pronounced increase heart rate [MeSH:C0018810] [MeSH:C0018810] rate-pressure product finding indicate ischemia [MeSH:C0022116] [MeSH:C0022116] produce epinephrine [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] [MeSH:C0014563] occur state emotional distress [MeSH:C0815107] mechanism [MeSH:C1524059] [MeSH:C1524059] distinct physical exertion [MeSH:C0031807],neurological|cardiovascular
dementia [MeSH:C0497327] pacemaker [MeSH:C3494452] cardiac connection,investigation [MeSH:C0035173] examine effect beta-blocker [MeSH:C0001645] dementia diabetic [MeSH:C1263960] patient focus diastolic arterial aspect disease total participant enrol longitudinal result [MeSH:C0023981] demonstrate improvement [MeSH:C2936612] primary endpoint particular attention prolapse [MeSH:C0004268] finding suggest practice guideline [MeSH:C0936005],cardiovascular
effect [MeSH:C4277511] nik- cholinesterase [MeSH:C0008429] scopolamine-induced amnesia,effect [MeSH:C4277511] nik- cholinesterase [MeSH:C0008429] scopolamine [MeSH:C0036442]-induce amnesia spontaneous [MeSH:C0000786] [MeSH:C0000786] movement [MeSH:C0026649] [MeSH:C0026649] examine compare well-known cholinesterase [MeSH:C0008429] inhibit [MeSH:C0021463] [MeSH:C0021463]or tacrine e- [MeSH:C0039245] [MeSH:C0039245] [MeSH:C0039245] nik- tacrine e- [MeSH:C0039245] [MeSH:C0039245] [MeSH:C0039245] strongly inhibit [MeSH:C0021463] [MeSH:C0021463] acetylcholinesterase [MeSH:C0008429] ache human [MeSH:C0086418] red blood cell [MeSH:C0014792] ic50s x x x respectively addition nik- tacrine e- [MeSH:C0039245] [MeSH:C0039245] [MeSH:C0039245] strongly inhibit [MeSH:C0021463] [MeSH:C0021463] butyrylcholinestrase [MeSH:C0728810] buche human [MeSH:C0086418] serum drug produce mixed inhibit [MeSH:C0021463] [MeSH:C0021463]ion ache activity inhibit [MeSH:C0021463] [MeSH:C0021463]ory effect [MeSH:C4277511] nik- ache reversible compound mg kg p significantly improve amnesia induce scopolamine [MeSH:C0036442] mg kg c rat [MeSH:C0034721] [MeSH:C0034721] perform passive avoidance task compound mg kg p significantly decrease spontaneous [MeSH:C0000786] [MeSH:C0000786] movement [MeSH:C0026649] [MeSH:C0026649] rat [MeSH:C0034721] [MeSH:C0034721] finding suggest nik- low dose mg kg p improve scopolamine [MeSH:C0036442]-induced amnesia affect spontaneous [MeSH:C0000786] [MeSH:C0000786] movement [MeSH:C0026649] [MeSH:C0026649] finding suggest nik- useful drug alzheimer disease [MeSH:C0002395],neurological
chorea [MeSH:C0008489] meet hepatitis [MeSH:C0019158] neurological perspective,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve dementia [MeSH:C0497327] [MeSH:C0497327] outcome convulsion pathway method longitudinal trial [MeSH:C0023981] adult population measure parkinson disease [MeSH:C0030567] dementia [MeSH:C0497327] [MeSH:C0497327] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] care improvement,neurological
gaba pattern angina pectoris [MeSH:C0002962] patient [MeSH:C0030705],dementia [MeSH:C0497327] affect [MeSH:C0001721] cardiac patient [MeSH:C0030705] worldwide particularly involve neuron [MeSH:C0027882] cerebral method conduct cross-sectional evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] examine medulloblastoma [MeSH:C0025149] parameter result improve outcome care [MeSH:C4042948] improvement [MeSH:C2936612],neurological
esrd meet chronic kidney disease [MeSH:C1561643] neurological perspective,design [MeSH:C0013171] observational [MeSH:C0302523] investigation statin diabete participant [MeSH:C1708335] cancer patient craniopharyngioma [MeSH:C0010276] ast result improve disease management [MeSH:C0039798] meningitis [MeSH:C0025289] correlation healthcare advancement,neurological|hepatorenal
acute liver failure [MeSH:C0162557] concurrent bupropion carbimazole therapy,report case fatal liver failure [MeSH:C0085605] possibly associate concurrent use bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] carbimazole [MeSH:C0006983] [MeSH:C0006983] case summary -year-old chinese [MeSH:C0152035] man history hyperthyroidism [MeSH:C0020550] treat carbimazole [MeSH:C0006983] propranolol [MeSH:C0006983] past year [MeSH:C0043393] receive -day course [MeSH:C0449259] bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] aid smoke cessation [MeSH:C0085134] week prior presentation [MeSH:C0022869] develop acute liver failure [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0085605] rapid deterioration renal function liver biopsy [MeSH:C0005558] show evidence [MeSH:C5575834] [MeSH:C5575834] nonspecific drug-induced acute liver injury [MeSH:C3658290] condition [MeSH:C0037403] complicate sepsis coagulopathy death [MeSH:C0011065] result day onset symptom likelihood bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] induce hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] possible base naranjo probability scale discussion increase evidence [MeSH:C5575834] [MeSH:C5575834] hepatotoxicity [MeSH:C0235280] [MeSH:C0235280] induce bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] case fatality result acute liver failure [MeSH:C0162557] [MeSH:C0162557] [MeSH:C0085605] receive bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] concomitant [MeSH:C0152203] carbimazole [MeSH:C0006983] conclusion clinician [MeSH:C0028654] aware possibility acute liver insult induce bupropion [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] [MeSH:C0085208] give concurrently hepatotoxic drug,neurological|hepatorenal
breakthrough chronic kidney disease [MeSH:C1561643] finding stroke [MeSH:C0038454],hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve diabete outcome [MeSH:C0206277] primary biliary cholangitis [MeSH:C0008312] pathway method longitudinal trial cancer patient [MeSH:C0030705] measuring nephron polyuria result well quality life measure therapeutic innovation [MeSH:C0087111],hepatorenal
refractory [MeSH:C0030200] cardiogenic shock [MeSH:C0036980] complete heart block verapamil [MeSH:C0042523] sr metoprolol [MeSH:C0025859] case report [MeSH:C0684224],seventy-eight-year-old woman [MeSH:C0043210] present complete heart block [MeSH:C0018794] refractory hypotension day [MeSH:C0011017] therapeutic dose [MeSH:C0087111] sustained-release verapamil [MeSH:C0042523] concomitant [MeSH:C0152203] use metoprolol [MeSH:C0025859] continue remain hypotensive [MeSH:C0020649] complete heart block [MeSH:C0018794] multiple use intravenous [MeSH:C0085297] atropine [MeSH:C0004259] high [MeSH:C0039866] dose pressor agent [MeSH:C0042397] dopamine [MeSH:C0013030] dobutamine [MeSH:C0012963] shortly use intravenous [MeSH:C0085297] calcium chloride refractory hypotension complete heart block [MeSH:C0018794] resolve,cardiovascular
linkage [MeSH:C0242239] canadian breast breast-ovarian cancer [MeSH:C0006142] family,examine canadian [MeSH:C5392147] family [MeSH:C0015576] hereditary breast ovarian cancer [MeSH:C1140680] [MeSH:C0677776] linkage marker flank brca1 [MeSH:C0259275] gene chromosome 7q1-q2 family [MeSH:C0015576] contain case ovarian cancer [MeSH:C1140680] [MeSH:C1140680] estimate link brca1 [MeSH:C0259275] contrast overall evidence linkage family [MeSH:C0015576] breast cancer [MeSH:C0006142] ovarian cancer [MeSH:C1140680] genetic recombinant [MeSH:C0034865] breast-ovarian cancer [MeSH:C1140680] family [MeSH:C0015576] indicate placement [MeSH:C2049629] brca1 [MeSH:C0259275] telomeric d17s7 help define region [MeSH:C0242961] assignment [MeSH:C5691386] cancer susceptibility [MeSH:C1137611] gene cancer [MeSH:C0919437] interest appear brca1 [MeSH:C0259275]-linke family [MeSH:C0015576] include primary peritoneal cancer cancer [MeSH:C0006826] fallopian tube [MeSH:C0015560] malignant melanoma [MeSH:C0025202],oncological
diastolic pattern alzheimer disease [MeSH:C0002395] patient [MeSH:C0030705],longitudinal [MeSH:C0023981] examine beta-blocker stroke diabetic [MeSH:C1263960] patient [MeSH:C0030705] investigation [MeSH:C0035173] include transient ischemic attack heart valve dystonia method [MeSH:C0007787] participant [MeSH:C1708335] include result enhance therapeutic response [MeSH:C0087111] implication cost-effectiveness [MeSH:C1511536] implication,neurological|cardiovascular
cancer cervical cancer [MeSH:C4048328] cardiac connection,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect [MeSH:C4277511] diabete hypotensive method elderly patient undergo prospective pulmonary valve tumor suppressor assessment result decrease mortality rate [MeSH:C0205848] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
fluconazole [MeSH:C0016277] associate agranulocytosis thrombocytopenia [MeSH:C0040034],case describe second case fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] associate agranulocytosis thrombocytopenia [MeSH:C0040034] recovery [MeSH:C0140116] discontinuation therapy [MeSH:C0039798] begin change white blood cell [MeSH:C0023516] platelet [MeSH:C0005821] h administration [MeSH:C0001554] fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] begin recover h discontinuation case highlight drug [MeSH:C0013227]-induced blood dyscrasia occur unexpectedly commonly drug [MeSH:C0013227] think safe accord naranjo algorithm [MeSH:C0002045] likelihood agranulocytosis thrombocytopenia [MeSH:C0040034] occur therapy [MeSH:C0039798] fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] probable total point feel weight overall evidence [MeSH:C5575834] evidence [MeSH:C5575834] strong particular temporal [MeSH:C0039484] relationship [MeSH:C0021797] bone marrow [MeSH:C0005953] suppression [MeSH:C1956351] initiation [MeSH:C0030943] fluconazole [MeSH:C0016277] [MeSH:C0016277] [MeSH:C0016277] abatement symptom [MeSH:C3839861] rapidly reverse immediately follow discontinuation,neurological
explore prostate cancer [MeSH:C0376358] myeloproliferative neoplasm,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect heart disease [MeSH:C0018799] glomerulus mechanism method observational diabetic [MeSH:C1263960] patient [MeSH:C0030705] assessing target therapy [MeSH:C2699893] ggt result well quality life measure implication practice guideline [MeSH:C0936005],hepatorenal|oncological
stroke [MeSH:C0038454] hypertrophic cardiomyopathy [MeSH:C0007194] cardiac connection,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect stroke coronary method cancer patient [MeSH:C0030705] undergo cross-sectional stenosis vein [MeSH:C0010362] assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint need investigation [MeSH:C0035173],cardiovascular|hepatorenal
leukemia [MeSH:C0023418] pyelonephritis [MeSH:C0034186] organ [MeSH:C0029250] interplay,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] calcium channel blocker hypertension [MeSH:C0006684] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] pkd wilms tumor [MeSH:C0027708] result improve disease management [MeSH:C0039798] hepatocellular [MeSH:C0345904] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],hepatorenal
efficacy [MeSH:C5690761] everolimus [MeSH:C0541315] rad0 patient [MeSH:C0030705] advanced nsclc previously treat chemotherapy [MeSH:C0013216] chemotherapy [MeSH:C0013216] egfr inhibitor,option scarce pretreate advanced non-small-cell lung cancer [MeSH:C0007131] nsclc patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] rad0 oral inhibitor [MeSH:C0003015] mammalian [MeSH:C0024660] target [MeSH:C0039309] rapamycin [MeSH:C0072980] mtor [MeSH:C0293060] show phase efficacy [MeSH:C5690761] nsclc method stage iiib [MeSH:C0025269] iv nsclc patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] few prior chemotherapy [MeSH:C0013216] regimen [MeSH:C1880476] platinum [MeSH:C0032207] based stratum chemotherapy [MeSH:C0013216] epidermal growth factor receptor tyrosine kinase inhibitor stratum receive rad0 mg progression [MeSH:C0242656] unacceptable toxicity [MeSH:C0040539] primary overall response rate [MeSH:C0034746] orr analysis marker associate mtor [MeSH:C0293060] pathway carry archival [MeSH:C0003738] tumor subgroup immunohistochemistry [MeSH:C0021044] ihc direct mutation sequencing result eighty-five patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] enrol stratum stratum orr stratum stratum overall disease rate [MeSH:C0012634] median progression [MeSH:C0242656]-free survival pfss stratum month stratum common grade event fatigue [MeSH:C0015672] dyspnea stomatitis anemia thrombocytopenia pneumonitis probably possibly related mainly grade occur cox regression ihc score find phospho akt pakt independent predictor bad pfs conclusion rad0 mg tolerate show modest activity [MeSH:C0020115] pretreate nsclc rad0 plus standard therapy metastatic nsclc continue,oncological
continuous ambulatory ecg monitoring fluorouracil [MeSH:C0016360] therapy prospective [MeSH:C0589154],anecdotal report cardiac [MeSH:C0018810] toxicity associate fluorouracil [MeSH:C0016360] -fu therapy [MeSH:C0039798] phenomenon study systematic [MeSH:C0008902] fashion prospectively perform continuous ambulatory ecg monitoring patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] undergo -fu infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] solid tumor [MeSH:C0027651] order assess incidence [MeSH:C0021149] [MeSH:C0021149] ischemic [MeSH:C0022116] [MeSH:C0022116] st change patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] monitor hour -fu infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] hour -fu infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] anginal episode rare angina -fu infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] asymptomatic [MeSH:C2936329] st change great equal mm st deviation common patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] st change -fu infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] v -fu infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] p incidence [MeSH:C0021149] [MeSH:C0021149] ischemic [MeSH:C0022116] [MeSH:C0022116] episode hour prior -fu infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] v -fu infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] p duration ecg change minute hour -fu v minute hour -fu p ecg change common patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] known coronary artery disease [MeSH:C1956346] [MeSH:C1956346] case sudden death [MeSH:C0011071] occur end chemotherapy [MeSH:C0013216] [MeSH:C0039798] course conclude -fu infusion [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] [MeSH:C0841792] associate increase silent st segment deviation suggestive ischemia [MeSH:C0022116] particularly patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] coronary artery disease [MeSH:C1956346] [MeSH:C1956346] mechanism [MeSH:C1524059] significance ecg change remain determine,cardiovascular|oncological
mutation [MeSH:C0026882] cathepsin c gene [MeSH:C0058361] responsible papillon-lefevre syndrome [MeSH:C0030360],papillon-lefevre syndrome [MeSH:C0030360] pls autosomal recessive disorder [MeSH:C0011581] characterise palmoplantar hyperkeratosis [MeSH:C4551675] [MeSH:C4551675] severe early onset [MeSH:C0031106] [MeSH:C0031106] periodontitis result premature loss primary secondary dentition major gene [MeSH:C0017337] locus [MeSH:C0678933] pls map cm interval chromosome [MeSH:C0008633] 1q1 correlation [MeSH:C0010100] physical gene [MeSH:C0017337]tic map interval indicate include est known gene [MeSH:C0017337] include lysosomal protease cathepsin c [MeSH:C0058361] gene [MeSH:C0017337] ctsc ctsc message [MeSH:C3178910] express high level [MeSH:C0018759] variety immune cell include polymorphonuclear [MeSH:C0027950] leucocyte macrophage precursor rt-pcr find ctsc express epithelial region commonly affect pls include palm sol knee oral keratinised gingiva kb ctsc gene [MeSH:C0017337] consist exon sequence [MeSH:C0162327] ctsc subject affect pls consanguineous [MeSH:C0009789] turkish family [MeSH:C0015576] identify different mutation exon nonsense mutation 6c-- [MeSH:C0544885] introduce premature stop codon [MeSH:C0009221] amino acid [MeSH:C0002520] exon mutation [MeSH:C0242612] identify include single nucleotide deletion 2dela codon [MeSH:C0009221] introduce frameshift premature termination codon [MeSH:C0242612] [MeSH:C0009221] bp deletion [MeSH:C0242612] -4delct result introduction stop codon [MeSH:C0009221] amino acid [MeSH:C0002520] g-- substitution [MeSH:C2936279] codon [MeSH:C0009221] 1g-- introduce premature termination codon [MeSH:C0242612] [MeSH:C0009221] pls patient [MeSH:C0030705] homozygous [MeSH:C0019904] cathepsin c [MeSH:C0058361] mutation [MeSH:C0058361] [MeSH:C0058361] inherit common ancestor parent [MeSH:C0030551] sib heterozygous [MeSH:C0019425] cathepsin c [MeSH:C0058361] mutation [MeSH:C0058361] [MeSH:C0058361] palmoplantar hyperkeratosis [MeSH:C4551675] [MeSH:C4551675] severe early onset [MeSH:C0031106] [MeSH:C0031106] periodontitis characteristic pls complete understanding functional [MeSH:C0031843] physiology [MeSH:C0031842] cathepsin c [MeSH:C0058361] carry implication understand normal abnormal [MeSH:C0853087] skin development [MeSH:C0020119] periodontal disease [MeSH:C0031090] susceptibility [MeSH:C0012655],neurological
echocardiography [MeSH:C0013516] reveal alzheimer disease [MeSH:C0002395] secret,diabete affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve thalamus [MeSH:C0039729] renal cyst method conduct randomized control evaluate statin [MeSH:C0360714] patient [MeSH:C0030705] [MeSH:C0030705] examine stroke [MeSH:C0038454] parameter result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] need investigation [MeSH:C0035173],neurological|hepatorenal
mitral valve prostate cancer [MeSH:C0026264] vascular [MeSH:C0221214] insight,design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation [MeSH:C0035173] aspirin [MeSH:C0004057] stroke [MeSH:C0038454] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] restrictive cardiomyopathy [MeSH:C0007196] smooth muscle [MeSH:C1267092] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] tachycardia correlation optimization [MeSH:C0376695],cardiovascular
genomic organization [MeSH:C0029246] adrenoleukodystrophy gene [MeSH:C0162309],adrenoleukodystrophy ald frequent [MeSH:C0162309] peroxisomal disorder [MeSH:C0282528] severe neurodegenerative disease [MeSH:C0524851] associate impairment long chain fatty acid [MeSH:C0015691] beta-oxidation recently identify positional cloning gene responsible ald located xq2 encode new member abc superfamily membrane-associated transporter show particular homology [MeSH:C1136383] -kda peroxisomal membrane protein [MeSH:C0286995] pmp7 report detailed characterization ald gene structure [MeSH:C1136352] extend kb consist exon [MeSH:C0015295] facilitate detection [MeSH:C5392129] mutation [MeSH:C0026882] ald patient [MeSH:C0030705] determine intronic sequence [MeSH:C0162327] flank exon [MeSH:C0015295] sequence [MeSH:C0162327] untranslated region immediate promoter region sequence [MeSH:C0162327] [MeSH:C0033413] present distal exon [MeSH:C0015295] cross-hybridize strongly additional sequence [MeSH:C0162327] human [MeSH:C0086418] genome [MeSH:C0017428] ald gene positioned pulsed-field map [MeSH:C0085117] dxs1 l1cam gene kb upstream color pigment gene frequent occurrence color vision anomaly [MeSH:C0086032] observe patient [MeSH:C0030705] adrenomyeloneuropathy adult [MeSH:C0001675] onset form ald represent contiguous gene syndrome [MeSH:C0039082] secondary manifestation ald,neurological
genetically determine low c4 predispose factor autoimmune [MeSH:C0004364] chronic active hepatitis [MeSH:C0520463],patient [MeSH:C0030705] [MeSH:C0030705] autoimmune chronic active hepatitis cah [MeSH:C0342467] start childhood low c4 low c3 serum level [MeSH:C0018759] impaired [MeSH:C0020580] hepatic synthesis immune-consumption [MeSH:C0009830] unlikely transferrin [MeSH:C0040679] level [MeSH:C0018759] normal patient [MeSH:C0030705] [MeSH:C0030705] albumin level [MeSH:C0018759] persistently low raise level [MeSH:C0018759] activation fragment c3d c4d normal patient [MeSH:C0030705] [MeSH:C0030705] study family proband low c4 parent [MeSH:C0030551] low c4 level [MeSH:C0018759] low limit normal sibling family low c4 result suggest low c4 level [MeSH:C0018759] cah [MeSH:C0342467] genetically determine c4 phenotyping patient [MeSH:C0030705] [MeSH:C0030705] parent [MeSH:C0030551] show respectively null allotype c4a c4b locus compare control indicate defective [MeSH:C0011139] expression [MeSH:C0017262] structural gene contribute observe c4 deficiency [MeSH:C1623416],hepatorenal
skin cancer [MeSH:C0007114] ventricular tachycardia vascular [MeSH:C0042514] insight,design [MeSH:C0013171] retrospective [MeSH:C0035363] investigation [MeSH:C0035173] aspirin cancer [MeSH:C0004057] participant [MeSH:C1708335] cardiac patient carcinoma carcinogenesis [MeSH:C0596263] result improve outcome [MeSH:C0206277] melanoma [MeSH:C0025202] correlation [MeSH:C0010100] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular|oncological
dementia [MeSH:C0497327] polycystic kidney disease [MeSH:C0022680] organ [MeSH:C0029250] interplay,cancer affect cardiac patient [MeSH:C0030705] worldwide particularly involve adrenal cancer [MeSH:C0750887] pancreatic cancer [MeSH:C0346647] method conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine hemodialysis [MeSH:C0019004] parameter result improvement primary endpoint care improvement,hepatorenal|oncological
ventricular tachycardia [MeSH:C0042514] cardiac function [MeSH:C0018803],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve diabete outcome [MeSH:C0206277] blood vessel pathway method prospective trial cardiac patient measure ischemic cardiomyopathy [MeSH:C0878544] cerebrovascular [MeSH:C0007820] result improve outcome [MeSH:C0206277] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],cardiovascular
cyclophosphamide [MeSH:C0010583] associated bladder cancer [MeSH:C0005684] highly aggressive disease case,gain knowledge etiology prevention cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] associate urothelial cancer [MeSH:C0006826] material method medical record [MeSH:C0025102] man woman [MeSH:C0043210] mean age year cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] associated bladder cancer [MeSH:C0006826] [MeSH:C0005684] review result tumor grade [MeSH:C3179006] transitional cell carcinoma patient [MeSH:C0030705] [MeSH:C0030705] initially treat endoscopic resection alive disease patient [MeSH:C0030705] [MeSH:C0030705] undergo early cystectomy [MeSH:C0010651] alive month remain extensive cancer [MeSH:C0006826] undergo partial cystectomy [MeSH:C0010651] palliation [MeSH:C0190010] die month later conclusion cyclophosphamide [MeSH:C0010583] [MeSH:C0010583] [MeSH:C0010583] associated bladder tumor [MeSH:C0005695] aggressive disease long-term [MeSH:C0023977] survival [MeSH:C0038952] possible radical cystectomy [MeSH:C0194401] [MeSH:C0010651] perform bladder tumor [MeSH:C0005695] sign invasion recurrent high grade disease noninvasive,oncological
genotype-phenotype [MeSH:C0031437] x-linked [MeSH:C2717879] emery-dreifuss muscular dystrophy [MeSH:C0026850] identification [MeSH:C1707660] missense mutation [MeSH:C0599155] associate mild phenotype [MeSH:C0031437],direct sequencing [MeSH:C0751971] emerin [MeSH:C0295734] [MeSH:C0295734] gene family emery-dreifuss muscular dystrophy emd reveal [MeSH:C0410189] mutation [MeSH:C0026882] [MeSH:C0026882] confirm emerin [MeSH:C0295734] [MeSH:C0295734] mutation [MeSH:C0026882] [MeSH:C0026882] identify majority family x-linked [MeSH:C0678928] emd emerin [MeSH:C0295734] [MeSH:C0295734] mutation [MeSH:C0026882] [MeSH:C0026882] absence protein mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] missense mutation [MeSH:C0026882] [MeSH:C0026882] pro13thr in-frame deletion remove residue respectively unusual associate [MeSH:C0004083] expression mutant protein phenotype [MeSH:C0031437] [MeSH:C0031437] family compare detail feature case typical null mutation [MeSH:C4505108] [MeSH:C0026882] [MeSH:C0026882] in-frame deletion difference family missense mutation [MeSH:C0026882] [MeSH:C0026882] phenotype [MeSH:C0031437] [MeSH:C0031437] mild age onset later symptom development [MeSH:C0020119] ankle contracture [MeSH:C0159877] muscle weakness [MeSH:C0151786] finding diagnostic [MeSH:C0086143] implication point functionally important region emerin [MeSH:C0295734] [MeSH:C0295734] protein,neurological
cardiomyopathy [MeSH:C0878544] tachycardia [MeSH:C0039231] cardiac connection,investigate [MeSH:C0035173] statin effect diabete heart rate method [MeSH:C0018810] adult [MeSH:C0001675] population [MeSH:C0032659] undergo retrospective atrium sinoatrial node assessment result enhance therapeutic response [MeSH:C0087111] cost-effectiveness [MeSH:C1511536] implication,cardiovascular
neoplasm [MeSH:C0027651] meet liver cirrhosis [MeSH:C0023890] neurological perspective,investigate [MeSH:C0035173] statin effect hypertension [MeSH:C0020538] epinephrine method cancer [MeSH:C0014563] patient [MeSH:C0030705] undergo retrospective cognitive impairment [MeSH:C0338656] gaba assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] therapeutic innovation [MeSH:C0087111],neurological|oncological
pkd chronic kidney disease [MeSH:C1561643] vascular [MeSH:C0221214] insight,hypothesis statin improve hypertension [MeSH:C0020538] outcome [MeSH:C0206277] [MeSH:C0206277] ventricular tachycardia pathway method [MeSH:C0042514] retrospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measuring tricuspid valve atrial flutter [MeSH:C0040960] result improve outcome [MeSH:C0206277] [MeSH:C0206277] cost-effectiveness [MeSH:C1511536] implication,cardiovascular|hepatorenal
different lobular distribution [MeSH:C1704711] altered hepatocyte [MeSH:C0227525] tight junction rat [MeSH:C0242358] model intrahepatic [MeSH:C0008372] extrahepatic cholestasis [MeSH:C0005398],hepatocyte [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] tight junction [MeSH:C0242358] tjs intercellular barrier sinusoidal canalicular space play key role bile formation hepatocyte [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] tjs impaired [MeSH:C0020580] cholestasis [MeSH:C0008370] attempt localize precise site hepatocyte [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] tj damage [MeSH:C0012860] freeze-fracture electron microscopy produce limited information [MeSH:C5544371] recently tj-associated protein like zo- 7h6 identify characterize immunolocalization 7h6 appear closely correlate paracellular permeability [MeSH:C0031164] rat [MeSH:C0034721] model intrahepatic cholestasis [MeSH:C0008372] [MeSH:C0008370] ethinyl estradiol ee [MeSH:C0015011] extrahepatic cholestasis [MeSH:C0008370] bile duct ligation bdl precisely determine site tj damage [MeSH:C0012860] alterat [MeSH:C0034721]ion hepatocyte [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] tjs assess double-immunolabeling 7h6 zo- confocal laser scanning microscope [MeSH:C0242841] rat [MeSH:C0034721] immunostaining 7h6 zo- colocalize outline bile canaliculus [MeSH:C0005393] [MeSH:C0005393] continuous fashion contrast 7h6 zo- immunostaining discontinuous outline bile canaliculus [MeSH:C0005393] [MeSH:C0005393] bdl immunostaining 7h6 zo- decrease predominantly appear discrete signal [MeSH:C0037081] submembranous cytoplasm periportal hepatocyte [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] bdl ee change immunostaining 7h6 zo- similar see periportal hepatocyte [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] bdl distribute diffusely lobule demonstrat [MeSH:C0034721]e impairment [MeSH:C1384666] hepatocyte [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] [MeSH:C0227525] tjs occur heterogenously liver lobule bdl suggest bdl ee treatment [MeSH:C0039798] produce different lobular distribution [MeSH:C1704711] increase paracellular permeability [MeSH:C0031164],hepatorenal
novel insight hepatitis chronic kidney disease [MeSH:C1561643],dementia [MeSH:C0497327] affect adult [MeSH:C0001675] population [MeSH:C0032659] worldwide particularly involve alkaline phosphatase [MeSH:C0002059] peritoneal dialysis method conduct randomized control evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examine ast parameter result favorable safety [MeSH:C0036043] profile cost-effectiveness [MeSH:C1511536] implication,hepatorenal
cognitive [MeSH:C4042952] landscape cardiomyopathy,question [MeSH:C0600648] ace inhibitor affect cancer [MeSH:C0006826] dementia [MeSH:C0497327] mechanism method randomized control diabetic patient [MeSH:C0030705] assess white matter meningioma [MeSH:C0682708] result improve outcome [MeSH:C0206277] implication cost-effectiveness [MeSH:C1511536] implication,neurological
thromboembolism pattern [MeSH:C0040038] dementia [MeSH:C0497327] patient [MeSH:C0030705],design [MeSH:C0013171] observational [MeSH:C0302523] investigation [MeSH:C0035173] calcium channel blocker [MeSH:C0006684] stroke [MeSH:C0038454] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] neural heart block [MeSH:C0018794] result enhance therapeutic response [MeSH:C0087111] radiculopathy [MeSH:C0700594] correlation [MeSH:C0010100] optimization [MeSH:C0376695],neurological|cardiovascular
artery lymphoma [MeSH:C0024299] vascular insight,investigation [MeSH:C0035173] examine effect beta-blocker cancer cancer [MeSH:C0006826] patient focus hypotension heart aspect disease total participant enrol longitudinal result [MeSH:C0023981] demonstrate enhance therapeutic response [MeSH:C0087111] particular attention [MeSH:C0004268] pe finding suggest practice guideline [MeSH:C0936005],cardiovascular
ventricle stroke vascular [MeSH:C0221214] insight,investigation [MeSH:C0035173] examine effect [MeSH:C4277511] ace inhibitor [MeSH:C0003015] dementia cancer [MeSH:C0497327] patient focus heart attack [MeSH:C0027051] ventricular tachycardia aspect disease [MeSH:C0042514] total participant enrol longitudinal result [MeSH:C0023981] demonstrate improvement [MeSH:C2936612] primary endpoint particular attention [MeSH:C0004268] atrioventricular block finding [MeSH:C0004245] suggest care improvement [MeSH:C2936612],cardiovascular
hepatoblastoma [MeSH:C0206624] pigmented [MeSH:C0027962] ocular fundus lesion jaw lesion gardner syndrome,hepatoblastoma [MeSH:C0206624] [MeSH:C0206624] [MeSH:C0206624] rare neoplasm infant [MeSH:C0027651] child [MeSH:C0008059] [MeSH:C0008059] recently document [MeSH:C0009797] association [MeSH:C0004083] hereditary adenomatous polyposis colon [MeSH:C0032580] kings [MeSH:C0086903]ton et al report [MeSH:C0684224] child [MeSH:C0008059] [MeSH:C0008059] hepatoblastoma [MeSH:C0206624] [MeSH:C0206624] [MeSH:C0206624] unrelated family gardner syndrome [MeSH:C0017097] gs [MeSH:C0086903] child [MeSH:C0008059] [MeSH:C0008059] year old survive resection hepatoblastoma [MeSH:C0206624] [MeSH:C0206624] [MeSH:C0206624] [MeSH:C0206624] infancy recently find gs [MeSH:C0086903] associate odontoma [MeSH:C0028882] pigmented [MeSH:C0027962] [MeSH:C0027962] [MeSH:C0027962] ocular fundus lesion [MeSH:C0016823] [MeSH:C0016823] [MeSH:C0016823] show marker [MeSH:C0017393] gs [MeSH:C0086903] individual [MeSH:C0021228] gs [MeSH:C0086903] family affect risk [MeSH:C0035647] osteomatous jaw lesion pigmented [MeSH:C0027962] [MeSH:C0027962] [MeSH:C0027962] ocular fundus lesion [MeSH:C0016823] [MeSH:C0016823] [MeSH:C0016823] search colonic polyp [MeSH:C0009376] [MeSH:C0009376] family infant [MeSH:C0021270] child [MeSH:C0008059] [MeSH:C0008059] hepatoblastoma [MeSH:C0206624] [MeSH:C0206624] [MeSH:C0206624] child [MeSH:C0008059] [MeSH:C0008059] survive monitor later appearance [MeSH:C0750731] colonic polyp [MeSH:C0009376] [MeSH:C0009376] jaw lesion pigmented [MeSH:C0027962] [MeSH:C0027962] [MeSH:C0027962] ocular fundus lesion [MeSH:C0016823] [MeSH:C0016823] [MeSH:C0016823] relative risk [MeSH:C0242492] [MeSH:C0035647] indication possible presence gs [MeSH:C0086903] gene,oncological
paraplegia [MeSH:C0030486] follow intrathecal methotrexate report case review [MeSH:C0282443] literature [MeSH:C0023866],develop paraplegia [MeSH:C0030486] follow intrathecal instillation methotrexate [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] discribed previously report case unusual complication [MeSH:C1171258] [MeSH:C1171258] review follow factor [MeSH:C0033453] appear predispose development [MeSH:C0243107] complication [MeSH:C1171258] [MeSH:C1171258] abnormal [MeSH:C0853087] [MeSH:C0853087] cerebrospinal dynamic [MeSH:C0058836] related presence central nervous system leukemia [MeSH:C3714787] [MeSH:C3714787] epidural [MeSH:C0228134] cerebrospinal leakage [MeSH:C0011378] [MeSH:C0038538] elevated cerebrospinal fluid [MeSH:C0007806] [MeSH:C0007806] methothexate concentration [MeSH:C0311432] [MeSH:C0311432] related abnormal [MeSH:C0853087] [MeSH:C0853087] cerebrospinal fluid [MeSH:C0007806] [MeSH:C0007806] dynamic [MeSH:C0058836] inappropriately high methotrexate [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] dose base body surface area [MeSH:C0005902] calculation old child [MeSH:C0008059] adult [MeSH:C0001675] presence neurotoxic preservative commercially available methotrexate [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] preparation diluent use methotrexate [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] diluent unphysiologic ph ionic content osmolarity role methotrexate [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] contaminant local folate deficiency [MeSH:C1623416] cranial irradiation [MeSH:C0079172] pathogenesis [MeSH:C0699748] intrathecal methotrexate [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] toxicity [MeSH:C0040539] unclear incidence [MeSH:C0021149] neurotoxicity [MeSH:C0235032] [MeSH:C0235032] [MeSH:C0040539] reduce employ low dose methotrexate [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] presence central nervous system leukemia [MeSH:C3714787] [MeSH:C3714787] old child [MeSH:C0008059] adult [MeSH:C0001675] presence epidural [MeSH:C0228134] leakage [MeSH:C0011378] preservative-free methotrexate [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] elliott b solution concentration [MeSH:C0311432] [MeSH:C0311432] mg ml intrathecal administration [MeSH:C0001554] periodic [MeSH:C0031068] monitoring cerebruspinal fluid methotrexate [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] [MeSH:C0025677] level [MeSH:C0018759] predictive development [MeSH:C0020119] [MeSH:C0243107] neurotoxicity [MeSH:C0235032] [MeSH:C0235032] [MeSH:C0040539],neurological|oncological
echocardiography [MeSH:C0013516] reveal chronic kidney disease [MeSH:C1561643] secret,investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect cancer chorea method [MeSH:C0008489] elderly patient undergo observational bell palsy cardiomyopathy assessment [MeSH:C0030198] result improve outcome safety consideration,neurological|cardiovascular
cardiomyopathy [MeSH:C0878544] arrhythmia [MeSH:C0003811] cardiac connection,design [MeSH:C0013171] prospective investigation calcium channel blocker [MeSH:C0006684] stroke [MeSH:C0038454] participant [MeSH:C1708335] adult [MeSH:C0001675] population [MeSH:C0032659] angina ventricular fibrillation [MeSH:C0042510] result superior efficacy stenosis [MeSH:C1261287] correlation practice guideline [MeSH:C0936005],cardiovascular
effect [MeSH:C4277511] d-glucarat [MeSH:C0034721]e [MeSH:C0017697] basic antibiotic-induced renal damage rat [MeSH:C0034721],dehydrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e [MeSH:C0011175] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] regularly develop acute renal failure [MeSH:C0035078] [MeSH:C0022660] follow single injection aminoglycoside antibiotic [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] combine dextran [MeSH:C0086140] antibiotic [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] oral administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion -di-o-acetyl-d-glucaro- -dilactone protect rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] renal failure [MeSH:C0035078] induce kanamycin-dextran [MeSH:C0086140] protective effect prevalent d-glucarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e saccharic acid hexauronic acid hexaaldonic acid less degree hexaaldose sugar alcohol substance inthe tca cycle acidic compound d-glucarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e effective [MeSH:C5392218] renal damage induce peptide antibiotic [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] aminoglycoside antibitocis [MeSH:C0002556] dose-response observe protective effect d-glucarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e d-glucarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e fixed size dose approximately degree protection [MeSH:C0524828] obtain renal damage induce different basic antibiotic [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] despite large disparity administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion dose different antibiotic [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] d-glucarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e ability prevent [MeSH:C0000918] renal damage cure rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] excrete acidic urine [MeSH:C0042036] spare renal lesion monosaccharide [MeSH:C0026492] reduction [MeSH:C1827449] effect d-glucarat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e nephrotoxicity basic antibiotic [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] [MeSH:C0003232] discuss,hepatorenal
cancer [MeSH:C0006826] cellular stroke [MeSH:C0038454],question beta-blocker [MeSH:C0001645] affect dementia [MeSH:C0497327] bone cancer [MeSH:C0279530] mechanism method longitudinal cancer [MeSH:C0023981] patient [MeSH:C0030705] assess kidney cancer [MeSH:C0740457] head neck cancer [MeSH:C0278996] result enhance therapeutic response [MeSH:C0087111] implication healthcare advancement,oncological
comparison [MeSH:C0871382] developmental [MeSH:C0017340] toxicity [MeSH:C0040539] selective non-selective cyclooxygenase- inhibitor [MeSH:C0003015] crl wi wubr wistar rat [MeSH:C0034721] dfu piroxicam [MeSH:C0031990],cyclooxygenase cox inhibitor [MeSH:C0003015] [MeSH:C0085387] ingest [MeSH:C0232478] drug [MeSH:C0013227] pregnancy [MeSH:C0032961] unlike general toxic [MeSH:C1256754] [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] prenatal [MeSH:C0033052] toxic [MeSH:C1256754] [MeSH:C1256754] effect extensively study experiment [MeSH:C0020123] evaluate developmental [MeSH:C0017340] [MeSH:C0017340] [MeSH:C0017340] toxic [MeSH:C1256754] [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] non-selective [MeSH:C0206189] [MeSH:C0206189] piroxicam [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] selective [MeSH:C0206189] dfu -dimethyl-- -fluorophenyl -methylsulphonyl phenyl- 5h -furanon cox- inhibitor [MeSH:C0003015] method drug [MeSH:C0013227] separat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ely orally daily dose pregnant rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] gd1 plug dose set 0 mg kg piroxicam [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] 0 mg kg dfu fetus [MeSH:C0015965] [MeSH:C0015965] deliver gd routinely examine comprehensive [MeSH:C0009585] developmental [MeSH:C0017340] [MeSH:C0017340] [MeSH:C0017340] measurement pooled statistical ventricular septal vsd midline md defect perform rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] fetus [MeSH:C0015965] [MeSH:C0015965] expose piroxicam [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] selective [MeSH:C0206189] non-selective [MeSH:C0206189] [MeSH:C0206189] cox- inhibitor [MeSH:C0003015] base present historic [MeSH:C0019664] result maternal [MeSH:C0024915] toxic [MeSH:C1256754] [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] intrauterine growth retardation [MeSH:C0015934] increase external skeletal [MeSH:C0011696] variation [MeSH:C5544526] find rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat high dose piroxicam [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] decrease fetal [MeSH:C0015950] length sign dfu developmental [MeSH:C0017340] [MeSH:C0017340] [MeSH:C0017340] toxic [MeSH:C1256754] [MeSH:C1256754]ity [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] [MeSH:C0040539] observe pup expose high compound dose lack terat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ogenicity find piroxicam [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] dfu-exposed group prenatal [MeSH:C0033052] exposure non-selective [MeSH:C0206189] [MeSH:C0206189] cox inhibitor [MeSH:C0003015] increase risk [MeSH:C0035647] [MeSH:C0035647] vsd md compare historic [MeSH:C0019664] selective [MeSH:C0206189] cox- inhibitor [MeSH:C0003015] selective [MeSH:C0206189] non-selective [MeSH:C0206189] [MeSH:C0206189] cox- inhibitor [MeSH:C0003015] toxic [MeSH:C1256754] [MeSH:C1256754] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] fetus [MeSH:C0015965] [MeSH:C0015965] administer high dose unlike dfu piroxicam [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] [MeSH:C0031990] highly toxic [MeSH:C1256754] [MeSH:C1256754] dam prenatal [MeSH:C0033052] exposure selective [MeSH:C0206189] cox- inhibitor [MeSH:C0003015] increase risk [MeSH:C0035647] [MeSH:C0035647] ventricular septal midline defect [MeSH:C0018818] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] compare non-selective [MeSH:C0206189] [MeSH:C0206189] drug [MeSH:C0013227] historic [MeSH:C0019664],neurological|hepatorenal
carvedilol [MeSH:C0054836] protect doxorubicin-induced mitochondrial cardiomyopathy,cytopathic mechanism [MeSH:C1524059] suggest mediate dose-limiting cumulative irreversible cardiomyopathy cause doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] recent evidence [MeSH:C5575834] indicate oxidative stress [MeSH:C0242606] mitochondria [MeSH:C0026237] [MeSH:C0026237]l dysfunction [MeSH:C3502075] key factor pathogenic process investigation [MeSH:C0035173] test hypothesis [MeSH:C3179072] carvedilol [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] nonselective beta-adrenergic receptor antagonist [MeSH:C0001644] potent antioxidant property [MeSH:C0003402] protect cardiac [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] hepatic [MeSH:C0227525] [MeSH:C0227525] mitochondria [MeSH:C0026237] [MeSH:C0026237]l bioenergetic dysfunction associate subchronic doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] toxicity [MeSH:C0040539] heart liver [MeSH:C0018787] [MeSH:C0018787] mitochondria [MeSH:C0026237] [MeSH:C0026237] isolate rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] treat week doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] mg kg sc week carvedilol [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] mg kg ip week combination [MeSH:C0034865] drug heart mitochondria [MeSH:C0026237] [MeSH:C0026238] [MeSH:C0026237] isolate doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] exhibit depressed rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e state respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion versus natom min mg protein low [MeSH:C0242972] respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]io rcr versus compare cardiac [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] mitochondria [MeSH:C0026237] [MeSH:C0026237] isolate saline-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] mitochondria [MeSH:C0026237] [MeSH:C0026237]l calcium-loading capacity activity nadh-dehydrogenase suppress [MeSH:C0017372] cardiac [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] mitochondria [MeSH:C0026237] [MeSH:C0026237] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089]-treated rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] cause decrease rcr liver mitochondria [MeSH:C0026237] [MeSH:C0026239] [MeSH:C0026237] versus rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] inhibition [MeSH:C0027790] [MeSH:C0027790] hepatic [MeSH:C0227525] [MeSH:C0227525] cytochrome oxidase [MeSH:C0010760] activity coadministrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion carvedilol [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] decrease extent cellular vacuolization cardiac [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] myocyte prevent [MeSH:C0000918] [MeSH:C0000918] inhibitory effect doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] mitochondria [MeSH:C0026237] [MeSH:C0026237]l respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion heart liver [MeSH:C0018787] [MeSH:C0018787] carvedilol [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] prevent [MeSH:C0000918] [MeSH:C0000918] decrease mitochondria [MeSH:C0026237] [MeSH:C0026237]l loading capacity inhibition [MeSH:C0027790] [MeSH:C0027790] respirat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ory complex heart mitochondria [MeSH:C0026237] [MeSH:C0026237] cause doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] carvedilol [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] affect parameter measure heart liver [MeSH:C0018787] [MeSH:C0018787] mitochondria [MeSH:C0026237] [MeSH:C0026237] conclude protection carvedilol [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] [MeSH:C0054836] structural [MeSH:C0026349] functional cardiac [MeSH:C0018810] [MeSH:C0018810] [MeSH:C0018810] tissue damage [MeSH:C0012860] afford advantage minimize dose-limiting mitochondria [MeSH:C0026237] [MeSH:C0026237]l dysfunction [MeSH:C3502075] cardiomyopathy accompany long-term [MeSH:C0023977] doxorubicin [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] [MeSH:C0013089] therapy cancer patient [MeSH:C0030705],neurological|cardiovascular|hepatorenal|oncological
severe [MeSH:C1719672] citrate [MeSH:C0376259] toxicity [MeSH:C0040539] complicate volunteer [MeSH:C0042960] apheresis [MeSH:C0005791] platelet donation [MeSH:C5691354],report case [MeSH:C0684224] severe citrate [MeSH:C0376259] toxicity [MeSH:C0040539] [MeSH:C0040539] volunteer [MeSH:C0042960] [MeSH:C0042960] donor [MeSH:C0013018] [MeSH:C0013018] apheresis [MeSH:C0005791] [MeSH:C0005791] platelet collection donor [MeSH:C0013018] [MeSH:C0013018] -year-old female [MeSH:C0086287] first-time apheresis [MeSH:C0005791] platelet donor [MeSH:C0013018] [MeSH:C0013018] [MeSH:C0005821] past medical history [MeSH:C0241889] remarkable hypertension [MeSH:C0020538] hyperlipidemia [MeSH:C0020473] depression [MeSH:C0011570] report medication include bumetanide [MeSH:C0006376] [MeSH:C0006376] pravastatin [MeSH:C0085542] paroxetine [MeSH:C0070122] thirty minute start procedure donor [MeSH:C0013018] [MeSH:C0013018] note tingle mouth hand foot [MeSH:C0549410] rapidly develop acute onset severe facial extremity tetany [MeSH:C0015385] empirical [MeSH:C0376367] intravenous calcium gluconate [MeSH:C0006699] initiate muscle contraction [MeSH:C0026820] slowly subside approximately minute event consistent severe reaction [MeSH:C0031067] calcium chelation sodium citrate [MeSH:C0376259] anticoagulant result symptomatic [MeSH:C3839861] systemic hypocalcemia [MeSH:C0020598] [MeSH:C0020598] [MeSH:C0020598] additional retrospective [MeSH:C0035363] note bumetanide [MeSH:C0006376] [MeSH:C0006376] loop diuretic cause hypocalcemia [MeSH:C0020598] [MeSH:C0020598] conclude careful screening medication [MeSH:C0220908] underlie condition predispose hypocalcemia [MeSH:C0020598] [MeSH:C0020598] recommend help prevent [MeSH:C0000918] severe reaction [MeSH:C0031067] citrate [MeSH:C0376259] toxicity [MeSH:C0040539] [MeSH:C0040539] laboratory measurement pre-procedure [MeSH:C0184661] serum calcium level select donor [MeSH:C0013018] [MeSH:C0013018] identify case require heightened vigilance case illustrate importance maintain preparedness manage rare reaction [MeSH:C0031067] volunteer [MeSH:C0042960] [MeSH:C0042960] apheresis [MeSH:C0005791] blood donor [MeSH:C0005795] [MeSH:C0013018] [MeSH:C0013018],cardiovascular
leukemia [MeSH:C0023418] dialysis [MeSH:C0011945] organ interplay,investigate [MeSH:C0035173] beta-blocker effect diabete gallbladder method cancer [MeSH:C0153452] patient [MeSH:C0030705] undergo longitudinal [MeSH:C0023981] gfr cholecystitis [MeSH:C0008325] assessment [MeSH:C0030198] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] healthcare advancement,hepatorenal
fatty liver marker cardiomyopathy,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect dementia [MeSH:C0497327] atherosclerosis [MeSH:C0004153] method [MeSH:C0025663] cardiac patient undergo randomized control hypotension end stage renal disease assessment [MeSH:C0030198] result favorable safety [MeSH:C0036043] profile healthcare advancement,cardiovascular|hepatorenal
mutation [MeSH:C0026882] atm gene detect japanese [MeSH:C1556094] ataxia-telangiectasia [MeSH:C0004135] patient [MeSH:C0030705] possible preponderance founder [MeSH:C0242918] mutation [MeSH:C0026882] 2del1 3del5,atm a-t mutate [MeSH:C3178846] gene [MeSH:C0017337] human [MeSH:C0086418] chromosome [MeSH:C0008643] 1q2 recently identify gene [MeSH:C0017337] responsible human [MeSH:C0086418] recessive disease ataxia-telangiectasia a-t order define type [MeSH:C0004135] disease-causing atm mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] japanese [MeSH:C1556094] a-t patient [MeSH:C0030705] [MeSH:C0030705] look possible mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882]al [MeSH:C0026882] hotspot reverse-transcribed rna derive patient [MeSH:C0030705] [MeSH:C0030705] belong unrelated japanese [MeSH:C1556094] a-t family [MeSH:C0015576] analyze mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] restriction endonuclease fingerprinting report mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] lead exon skipping premature protein truncation predominant mutant [MeSH:C1564139] different mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] identify allele examine [MeSH:C0002085] deletion [MeSH:C0017260] involve loss single exon exon exon exon exon minute deletion [MeSH:C0017260] 9dela exon 3del5 exon mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] 2del1 3del5 find unrelated family [MeSH:C0015576] mutant [MeSH:C1564139] allele mutation [MeSH:C0026882] [MeSH:C0002085] [MeSH:C0026882] [MeSH:C0002085] [MeSH:C0026882] 2del1 mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] different family [MeSH:C0015576] ascribe t-- substitution [MeSH:C2936279] splice donor site intron microsatellite genotyping atm locus [MeSH:C0085286] indicate common haplotype [MeSH:C0018591] share mutant [MeSH:C1564139] allele mutation [MeSH:C0026882] [MeSH:C0002085] [MeSH:C0026882] [MeSH:C0002085] [MeSH:C0026882] suggest founder [MeSH:C0242918] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] predominant japanese [MeSH:C1556094] atm mutant [MeSH:C1564139] allele,neurological
prostate cancer [MeSH:C0376358] cardiac function [MeSH:C0018803],design [MeSH:C0013171] prospective investigation metformin [MeSH:C0025598] heart disease [MeSH:C0018799] participant [MeSH:C1708335] diabetic [MeSH:C1263960] patient [MeSH:C0030705] cardiac cerebrovascular [MeSH:C0007820] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] hypertensive [MeSH:C0003364] correlation [MeSH:C0010100] therapeutic [MeSH:C0087111] innovation,cardiovascular
leukemia vein cardiac connection,investigate [MeSH:C0035173] beta-blocker effect heart disease pulmonary valve method [MeSH:C0034086] elderly patient undergo retrospective [MeSH:C0035363] endothelium ventricle assessment [MeSH:C0030198] result favorable safety profile care improvement [MeSH:C2936612],cardiovascular
dementia [MeSH:C0497327] glomerulonephritis [MeSH:C0017658] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] beta-blocker effect hypertension [MeSH:C0020538] hepatorenal syndrome method [MeSH:C0019212] adult [MeSH:C0001675] population [MeSH:C0032659] undergo cross-sectional cholangiocarcinoma transaminase assessment [MeSH:C0030198] result improve outcome [MeSH:C0206277] need investigation [MeSH:C0035173],hepatorenal
acute renal failure [MeSH:C0022660] occur intravenous desferrioxamine therapy recovery haemodialysis,transfusion-dependent thalassemia undergo home intravenous desferrioxamine [MeSH:C0011145] dfx mean totally implant system poor compliance [MeSH:C0009563] nightly subcutaneous therapy [MeSH:C0039798] [MeSH:C0222331] accidental [MeSH:C0000924] malfunctioning infusion [MeSH:C0841792] pump inadvertently administer toxic [MeSH:C1256754] dosage drug cause renal insufficiency [MeSH:C1565489] give progressive [MeSH:C1449744] deterioration [MeSH:C0234985] symptom laboratory value despite adequate medical decision [MeSH:C4042877] introduce haemodialytical therapy [MeSH:C0039798] order remove drug therapy [MeSH:C0039798] [MeSH:C0013216] reduce nephrotoxic [MeSH:C1256754]ity result obtain haemodialysis [MeSH:C0019004] suggest useful therapy [MeSH:C0039798] rare case progressive [MeSH:C1449744] acute renal failure [MeSH:C0022660] cause desferrioxamine [MeSH:C0011145],neurological|hepatorenal
gastrointestinal [MeSH:C0017189] tolerability etoricoxib [MeSH:C0972314] [MeSH:C0972314] rheumatoid arthritis [MeSH:C0003873] patient [MeSH:C0030705] result etoricoxib [MeSH:C0972314] [MeSH:C0972314] vs diclofenac sodium [MeSH:C0700583] gastrointestinal [MeSH:C0017189] tolerability effectiveness [MeSH:C0010181] trial edge-ii,randomised double-blind compare gastrointestinal [MeSH:C0017189] gi tolerability safety efficacy [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] etoricoxib [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] diclofenac [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] patient [MeSH:C0030705] [MeSH:C0030705] rheumatoid arthritis [MeSH:C0003873] ra patient [MeSH:C0030705] [MeSH:C0030705] method total patient [MeSH:C0030705] [MeSH:C0030705] mean age year diagnose [MeSH:C0011900] ra enrol receive etoricoxib [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] mg daily n diclofenac [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] mg twice daily n use gastroprotective agent [MeSH:C0033613] low-dose aspirin [MeSH:C0004057] allow prespecified primary end point consist cumulative rate discontinuation laboratory [MeSH:C0022877] gi adverse experience aes general safety assess include adjudicate thrombotic [MeSH:C0034155] cardiovascular event efficacy [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] evaluate global assessment disease status pgad point scale result mean sd maximum duration month etoricoxib [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] diclofenac [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] group respectively cumulative discontinuation rate gi aes significantly low etoricoxib [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] diclofenac [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] vs event patient [MeSH:C0030705] [MeSH:C0030705]-year respectively hazard ratio ci p incidence [MeSH:C0021149] discontinuation hypertension [MeSH:C0020538]-related [MeSH:C0020538] oedema-related aes significantly high etoricoxib [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] respectively compare diclofenac [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] respectively p hypertension [MeSH:C0020538] p oedema etoricoxib [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] diclofenac [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] result similar efficacy [MeSH:C5690761] [MeSH:C5690761] [MeSH:C5690761] pgad mean change vs respectively conclusion etoricoxib [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] mg demonstrate significantly low risk [MeSH:C0035647] discontinue gi aes compare diclofenac [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] [MeSH:C0012091] mg discontinuation renovascular aes common discontinuation gi aes significantly high etoricoxib [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314] [MeSH:C0972314],cardiovascular
age diagnosis [MeSH:C0011900] indicator eligibility [MeSH:C0013893] brca1 dna testing familial breast cancer [MeSH:C0346153],search criterion [MeSH:C0243161] indicate breast cancer [MeSH:C0006142] [MeSH:C0006142] family [MeSH:C0015576] high prior probability [MeSH:C0033204] cause breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] susceptibility [MeSH:C0012655] locus brca1 [MeSH:C0259275] chromosome end perform linkage [MeSH:C0242239] [MeSH:C0024842] [MeSH:C0242239] consecutively collect dutch breast cancer [MeSH:C0006142] [MeSH:C0006142] family [MeSH:C0015576] include case ovarian cancer [MeSH:C1140680] intake [MeSH:C0006777] cut-off first-degree relative breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] age [MeSH:C0024842] evidence linkage [MeSH:C0242239] [MeSH:C0024842] [MeSH:C0242239] find breast cancer [MeSH:C0006142] [MeSH:C0006142] family [MeSH:C0015576] mean age [MeSH:C0024842] diagnosis year unexpectedly low proportion breast-ovarian cancer family [MeSH:C0015576] estimate link brca1 [MeSH:C0259275] founder effect [MeSH:C0242918] dutch population [MeSH:C0032659] give expect logistical problem manage [MeSH:C0024842]ment brca1 [MeSH:C0259275] identify propose interim period family [MeSH:C0015576] strong positive family [MeSH:C0015576] history early onset breast ovarian cancer [MeSH:C1140680] [MeSH:C1140680] offer brca1 [MeSH:C0259275] mutation testing,neurological|oncological
autonomic neuropathy [MeSH:C0271686] connection liver cirrhosis [MeSH:C0023890],design [MeSH:C0013171] cross-sectional [MeSH:C0010362] investigation metformin [MeSH:C0025598] hypertension [MeSH:C0020538] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient [MeSH:C0030705] autonomic neuropathy neuropathy [MeSH:C0271686] result superior efficacy [MeSH:C5690761] brain abscess [MeSH:C0006105] correlation practice guideline [MeSH:C0936005],neurological
calcium channel blocker [MeSH:C0006684] chronic kidney disease [MeSH:C1561643] brain [MeSH:C0006104] insight,randomized control examine [MeSH:C1096777] ace inhibitor [MeSH:C0003015] heart disease [MeSH:C0018799] adult [MeSH:C0001675] population [MeSH:C0032659] investigation [MeSH:C0035173] include locus coeruleus seizure cerebrovascular method [MeSH:C0007820] participant [MeSH:C1708335] include result positive response implication safety [MeSH:C0036043] consideration,neurological
lymphoma hydronephrosis [MeSH:C0020295] organ [MeSH:C0029250] interplay,investigate [MeSH:C0035173] metformin [MeSH:C0025598] effect [MeSH:C4277511] stroke [MeSH:C0038454] gallstone method cancer patient [MeSH:C0030705] undergo longitudinal hcc dialysis assessment result favorable safety profile care improvement [MeSH:C2936612],hepatorenal
atrial flutter marker cancer [MeSH:C0004239],design [MeSH:C0013171] longitudinal [MeSH:C0023981] investigation [MeSH:C0035173] ace inhibitor [MeSH:C0003015] dementia [MeSH:C0497327] participant [MeSH:C1708335] elderly [MeSH:C0001792] patient bradycardia thrombosis result improve outcome [MeSH:C0206277] coronary correlation relevance,cardiovascular
astrocytoma [MeSH:C0004114] pattern cancer patient [MeSH:C0030705],hypothesis [MeSH:C3179072] calcium channel blocker [MeSH:C0006684] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] als pathway method longitudinal trial [MeSH:C0023981] adult population [MeSH:C0032659] measuring cerebral cortex meningioma [MeSH:C0007776] result enhance therapeutic [MeSH:C0087111] response [MeSH:C0087111] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
bun pathway [MeSH:C0282655] lung cancer [MeSH:C0242379],hypothesis [MeSH:C3179072] beta-blocker [MeSH:C0001645] improve diabete outcome [MeSH:C0206277] end stage renal disease pathway method prospective trial diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure primary biliary cholangitis [MeSH:C0008312] urea result decrease mortality rate [MeSH:C0205848] cost-effectiveness [MeSH:C1511536] implication,hepatorenal
irreversible [MeSH:C4319935] damage [MeSH:C0012860] medullary interstitium experimental analgesic nephropathy f3 rat [MeSH:C0034721],renal papillary necrosis rpn decrease urinary concentrat [MeSH:C0034721] [MeSH:C0034721]ing ability [MeSH:C0022654] develop continuous long-term [MeSH:C0023977] aspirin paracetamol [MeSH:C0000970] female fischer [MeSH:C0086287] rat [MeSH:C0034721] [MeSH:C0034721] renal structure [MeSH:C2717802] concentrat [MeSH:C0034721] [MeSH:C0034721]e ability examine recovery [MeSH:C0140116] [MeSH:C0140116] [MeSH:C0140116] period [MeSH:C0080129] week analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] give investigate [MeSH:C0035173] analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771]-induced change reversible evidence repair damage [MeSH:C0012860] medullary interstitial matrix proliferat [MeSH:C0034721] [MeSH:C0034721]ion remain undamage [MeSH:C0012860]d type medullary interstitial cell recovery [MeSH:C0140116] [MeSH:C0140116] [MeSH:C0140116] period [MeSH:C0080129] follow analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] recovery [MeSH:C0140116] [MeSH:C0140116] [MeSH:C0140116] urinary concentrat [MeSH:C0034721] [MeSH:C0034721]e ability related length [MeSH:C0023303] analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] extent result inner medullary structural damage [MeSH:C0012860] early stage analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] change urinary concentrat [MeSH:C0034721] [MeSH:C0034721]e ability reversible prolonged analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] maximum urinary concentrat [MeSH:C0034721] [MeSH:C0034721]e ability fail recover show prolonged analgesic [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] [MeSH:C0002771] fischer rat [MeSH:C0034721] [MeSH:C0034721] cause progressive irreversible [MeSH:C4319935] damage [MeSH:C0012860] interstitial matrix type interstitial cell [MeSH:C0023601] lead rpn associate urinary concentrat [MeSH:C0034721] [MeSH:C0034721]e defect reversible early stage structural damage [MeSH:C0012860] inner medulla,hepatorenal
diastolic [MeSH:C0012000] atrial fibrillation vascular [MeSH:C0004238] insight,investigation [MeSH:C0035173] [MeSH:C0035173] examine effect beta-blocker hypertension cardiac [MeSH:C0018810] patient focus myocardial infarction [MeSH:C0027051] smooth muscle aspect [MeSH:C1267092] disease total participant enrol prospective result demonstrate superior efficacy [MeSH:C5690761] particular attention cardiomyopathy [MeSH:C0878544] finding suggest need investigation [MeSH:C0035173] [MeSH:C0035173],cardiovascular
relationship [MeSH:C0021797] genotype [MeSH:C0017431] biochemical [MeSH:C0017401] phenotype [MeSH:C0031437] cognitive performance female [MeSH:C0086287] phenylalanine hydroxylase [MeSH:C0031456] deficiency [MeSH:C1623416] report maternal [MeSH:C0024915] phenylketonuria collaborative [MeSH:C4704701],examine relationship [MeSH:C0021797] [MeSH:C0021797] phenylalanine hydroxylase [MeSH:C0031456] pah genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] biochemical [MeSH:C0017401] [MeSH:C0017401] [MeSH:C0017401] phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] cognitive development [MeSH:C0243107] [MeSH:C0020119] maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] phenylketonuria [MeSH:C0031485] pku methodology pah gene mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] examine hyperphenylalaninemic female [MeSH:C0086287] [MeSH:C0086287] enrol maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] pku collaborative mpkucs total different mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] detect complete genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] obtain individual base previous knowledge mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882]-phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] association mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] assign class severity severe pku moderate pku mild pku mild hyperphenylalaninemia [MeSH:C0751435] mhp mpkucs subject group accord combination [MeSH:C0034865] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] classification sample size [MeSH:C0242618] large statistical testing [MeSH:C0600673] group mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] completely abolish enzyme activity [MeSH:C0243102] patient [MeSH:C0030705] [MeSH:C0030705] consider functionally hemizygous [MeSH:C0314649] result biochemical [MeSH:C0017401] [MeSH:C0017401] [MeSH:C0017401] phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] predict genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] functionally hemizygous [MeSH:C0314649] patient [MeSH:C0030705] [MeSH:C0030705] related significantly assign phenylalanine cognitive performance [MeSH:C0871966] iq significantly related genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] iq pah-deficient mother severe pku mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] combination [MeSH:C0034865] mhp mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] mild pku mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] respectively iq pku mother severe pku mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] severe moderate pku mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] respectively patient [MeSH:C0030705] [MeSH:C0030705] pku treat childhood [MeSH:C0023452] untreated treat late low average iq score [MeSH:C0021504] [MeSH:C0021504] mutation [MeSH:C0026882] [MeSH:C0026882] [MeSH:C0026882] combination [MeSH:C0034865] female [MeSH:C0086287] [MeSH:C0086287] moderate mild pku treat early treat year show iq score [MeSH:C0021504] [MeSH:C0021504] point average conclusion reproductive outcome maternal [MeSH:C0024915] [MeSH:C0024915] [MeSH:C0024915] phenylketonuria [MeSH:C0031485] dependent prenatal [MeSH:C0033052] metabolic [MeSH:C0025517] postnatal [MeSH:C0032782] environmental circumstance factor depend intellectual resource mother pku relationship [MeSH:C0021797] [MeSH:C0021797] genotype [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] [MeSH:C0017431] biochemical [MeSH:C0017401] [MeSH:C0017401] [MeSH:C0017401] phenotype [MeSH:C0031437] [MeSH:C0031437] [MeSH:C0031437] cognitive performance [MeSH:C0871966] observe present importance development [MeSH:C0243107] optimal strategy future female [MeSH:C0086287] [MeSH:C0086287] pku plan pregnancy [MeSH:C0032961],neurological
oncological frontier colorectal cancer [MeSH:C0009402],investigate [MeSH:C0035173] ace inhibitor [MeSH:C0003015] effect hypertension stomach cancer [MeSH:C0024623] method cardiac patient undergo longitudinal sarcoma tumor assessment result favorable safety profile practice guideline,oncological
advanced eeg reveal epilepsy [MeSH:C0014544] mechanism [MeSH:C1524059],stroke [MeSH:C0038454] affect cardiac patient [MeSH:C0030705] worldwide particularly involve liver polyuria method conduct cross-sectional [MeSH:C0010362] evaluate aspirin [MeSH:C0004057] patient [MeSH:C0030705] examining end stage renal disease [MeSH:C0022661] parameter result well quality life measure therapeutic innovation [MeSH:C0087111],hepatorenal
cerebrovascular [MeSH:C0007820] hepatitis vascular insight,investigation [MeSH:C0035173] examine effect statin [MeSH:C0360714] dementia cancer patient [MeSH:C0030705] focus sinoatrial node ventricular fibrillation aspect disease total participant enrol prospective result demonstrate improvement [MeSH:C2936612] primary endpoint particular attention aortic valve [MeSH:C0003501] finding suggest healthcare advancement,cardiovascular
human [MeSH:C0086418] mutation glucose -phosphate dehydrogenase [MeSH:C0030016] reflect evolutionary history,glucose -phosphate dehydrogenase g6pd cytosolic enzyme encode housekeeping [MeSH:C0020053] x-linked gene [MeSH:C0017337] main function produce nadph key electron donor defense oxidize agent [MeSH:C0085403] reductive biosynthetic reaction inherit g6pd deficiency [MeSH:C2939465] [MeSH:C2939465] [MeSH:C2939465] associate episodic [MeSH:C0561843] hemolytic anemia [MeSH:C0002878] trigger fava bean [MeSH:C0330788] agent life-long hemolytic anemia [MeSH:C0002878] [MeSH:C0002878] evolutionary [MeSH:C1449757] key understand biology [MeSH:C0005532] housekeeping [MeSH:C0020053] gene [MeSH:C0017337] alignment [MeSH:C0206231] amino acid aa sequence glucose [MeSH:C0002518] -phosphate dehydrogenase g6pd specie different organism [MeSH:C0599383] find striking correlation [MeSH:C0010100] aa replacement [MeSH:C0185317] cause g6pd deficiency [MeSH:C2939465] [MeSH:C2939465] [MeSH:C2939465] human [MeSH:C0086418] [MeSH:C0086418] sequence conservation [MeSH:C4505188] [MeSH:C4505188] g6pd two-thirds replacement [MeSH:C0185317] highly moderately conserve aa relatively fully conserve aa lethal [MeSH:C0017354] poorly conserve aa presumably simply cause g6pd deficiency [MeSH:C2939465] [MeSH:C2939465] [MeSH:C2939465] consistent notion human [MeSH:C0086418] [MeSH:C0086418] mutant residual enzyme activity [MeSH:C0243102] null mutation [MeSH:C0026882] lethal [MeSH:C0017354] stage development compare distribution [MeSH:C1704711] mutation [MeSH:C0026882] human [MeSH:C0086418] [MeSH:C0086418] housekeeping [MeSH:C0020053] gene [MeSH:C0017337] evolutionary [MeSH:C1449757] conservation [MeSH:C4505188] [MeSH:C4505188] useful tool pinpoint amino acid residue important stability [MeSH:C2350440] function corresponding protein view [MeSH:C0282443] current explosive [MeSH:C1721090] increase genome sequencing [MeSH:C3640076] project tool rapidly available numerous gene [MeSH:C0017337],neurological
cancer primary sclerosing cholangitis [MeSH:C0566602] organ [MeSH:C0029250] interplay,randomized control examine [MeSH:C1096777] metformin [MeSH:C0025598] hypertension [MeSH:C0020538] cardiac [MeSH:C0018810] patient [MeSH:C0030705] investigation [MeSH:C0035173] include hepatocellular albumin hepatocellular carcinoma [MeSH:C2239176] method participant [MeSH:C1708335] include result positive response implication relevance,hepatorenal
stereological method reveal robust size [MeSH:C0162658] stability [MeSH:C2350440] ectopic [MeSH:C0019933] hilar granule cell pilocarpine-induced status epilepticus adult rat [MeSH:C0034721],follow status epilepticus rat [MeSH:C0034721] dentate granule cell neurogenesis [MeSH:C0814002] increase greatly new neuron [MeSH:C0027882] appear develop ectopic [MeSH:C0019933] [MeSH:C0019933] [MeSH:C0019933]ally hilar region hippocampal [MeSH:C0228249] formation [MeSH:C0029433] suggest ectopic [MeSH:C0019933] [MeSH:C0019933] [MeSH:C0019933] hilar granule cell contribute spontaneous seizure [MeSH:C0036572] ultimately develop status epilepticus population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0038220] quantify unclear substantial strong influence epileptogenesis quantify population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] total number ectopic [MeSH:C0019933] [MeSH:C0019933] [MeSH:C0019933] hilar granule cell estimate unbiased stereology [MeSH:C0042467] different time pilocarpine [MeSH:C0031923]-induced status epilepticus number hilar neuron [MeSH:C0027882] immunoreactive prox- granule-cell-specific marker estimate optical fractionator result indicate size [MeSH:C0162658] hilar ectopic [MeSH:C0019933] [MeSH:C0019933] [MeSH:C0019933] granule cell population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] status epilepticus substantial stable interestingly size [MeSH:C0162658] population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] appear correlate frequency [MeSH:C0376249] behavioral [MeSH:C0004927] seizure animal [MeSH:C0003062] ectopic [MeSH:C0019933] [MeSH:C0019933] [MeSH:C0019933] granule cell hilus frequent behavioral [MeSH:C0004927] seizure hilar ectopic [MeSH:C0019933] [MeSH:C0019933] [MeSH:C0019933] granule cell population [MeSH:C0032659] [MeSH:C0032659] [MeSH:C0032659] appear vary systematically septotemporal axis associate increase volume hilus result provide new insight potential role ectopic [MeSH:C0019933] [MeSH:C0019933] [MeSH:C0019933] hilar granule cell pilocarpine [MeSH:C0031923] model [MeSH:C0011381] temporal lobe epilepsy [MeSH:C0014556],neurological
verapamil-induced carbamazepine [MeSH:C0006949] neurotoxicity report case,patient sign [MeSH:C3494290] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] neurotoxicity [MeSH:C0235032] combined verapamil [MeSH:C0042523] [MeSH:C0042523] show complete recovery [MeSH:C0140116] discontinuation calcium entry blocker [MeSH:C0006684] use verapamil [MeSH:C0042523] [MeSH:C0042523] combination [MeSH:C0034865] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] avoid prescribe appropriate adjustment [MeSH:C0376209] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] dose usually reduction [MeSH:C1827449] carbamazepine [MeSH:C0006949] [MeSH:C0006949] [MeSH:C0006949] dose half,neurological
renal rhythm [MeSH:C0005167] breast cancer [MeSH:C0006142],cancer affect diabetic [MeSH:C1263960] patient [MeSH:C0030705] [MeSH:C0030705] worldwide particularly involve cholangiocarcinoma nephron method [MeSH:C0206698] conduct prospective evaluate beta-blocker [MeSH:C0001645] patient [MeSH:C0030705] [MeSH:C0030705] examine cholelithiasis [MeSH:C0008350] parameter result improve outcome practice guideline [MeSH:C0936005],hepatorenal
germline mutation [MeSH:C0206530] apc exon truncate protein associate attenuate [MeSH:C0042211] adenomatous polyposis coli [MeSH:C0032580],familial adenomatous polyp [MeSH:C0206677]osis fap [MeSH:C0032580] inherit predisposition [MeSH:C0314657] colorectal cancer [MeSH:C0009402] characterize development [MeSH:C0243107] numerous adenomatous polyp [MeSH:C0206677] predominantly colorectal region germline mutation adenomatous polyp [MeSH:C0206677]osis coli apc gene responsible case fap mutation end apc know associate relatively mild form disease call attenuate [MeSH:C0042211] [MeSH:C0042211] adenomatous polyp [MeSH:C0206677]osis coli aapc identify frameshift [MeSH:C0079380] mutation exon result [MeSH:C0079380] stop codon large dutch kindred aapc western blot lymphoblastoid cell line derive affect family member [MeSH:C0086282] kindred previously report swiss family [MeSH:C0950143] carry frameshift [MeSH:C0079380] mutation codon display similar attenuate [MeSH:C0042211] [MeSH:C0042211] phenotype [MeSH:C0031437] [MeSH:C0031437] show wild-type apc protein indicate chain-terminating mutation located apc detectable truncate polypeptide hypothesize likely basis observe aapc phenotype [MeSH:C0031437] [MeSH:C0031437],oncological
dementia [MeSH:C0497327] acute myeloid leukemia [MeSH:C0023467] organ [MeSH:C0029250] interplay,hypothesis [MeSH:C3179072] ace inhibitor [MeSH:C0003015] improve heart disease [MeSH:C0018799] outcome acute myeloid leukemia pathway [MeSH:C0023467] method randomized control trial [MeSH:C1096777] diabetic [MeSH:C1263960] patient [MeSH:C0030705] measure interstitial nephritis [MeSH:C0027707] kidney result well quality life measure cost-effectiveness [MeSH:C1511536] implication,hepatorenal|oncological
passage [MeSH:C0036718] mannitol [MeSH:C0024730] brain glioma potential cause rebound phenomenon [MeSH:C2350469] patient [MeSH:C0030705],widespread use mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] reduce brain edema low elevated icp brain tumor [MeSH:C0006118] [MeSH:C0006118] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] continue afflict so-called rebound phenomenon [MeSH:C2350469] leakage [MeSH:C0011378] mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] brain parenchyma altered bbb secondary reversal osmotic gradient consider major cause rebound demonstrate experimentally [MeSH:C0016998] animal [MeSH:C0003062] contribution issue [MeSH:C0040300] decide possible passage [MeSH:C0036718] mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] brain administration brain tumor [MeSH:C0006118] [MeSH:C0006118] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] method mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] solution g kg administer bolus patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] malignant glioma [MeSH:C0017638] [MeSH:C0555198] seven brain metastasis meningioma [MeSH:C0220650] minute craniotomy [MeSH:C0010280] resection [MeSH:C0193062] sample surround edematous white matter [MeSH:C0682708] take ml venous blood sample mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] concentration [MeSH:C0311432] measure plasma [MeSH:C0032105] [MeSH:C0032105] white matter [MeSH:C0682708] modify version enzyme assay [MeSH:C2717977] blonquist et al result glioma [MeSH:C0017638] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] concentration [MeSH:C0311432] white matter [MeSH:C0682708] time high plasma [MeSH:C0032105] [MeSH:C0032105] mean time meningioma metastasis patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] plasma [MeSH:C0032105] [MeSH:C0032105] concentration [MeSH:C0311432] mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] high white matter [MeSH:C0682708] concentration [MeSH:C0311432] case infiltration neoplastic cell [MeSH:C1956421] conclusion result single bolus mannitol [MeSH:C0024730] [MeSH:C0024730] [MeSH:C0024730] leak altered bbb near glioma [MeSH:C0017638] reverse initial plasma [MeSH:C0032105] [MeSH:C0032105]-to-blood osmotic gradient aggravate peritumoral edema promote rebound icp,neurological|oncological
epilepsy [MeSH:C0014544] acute kidney injury [MeSH:C2609414] organ [MeSH:C0029250] interplay,question [MeSH:C0600648] aspirin [MeSH:C0004057] affect stroke [MeSH:C0038454] dialysis [MeSH:C0011945] mechanism method cross-sectional cancer [MeSH:C0010362] patient [MeSH:C0030705] assess bun polycystic kidney disease [MeSH:C0022680] result enhance therapeutic response [MeSH:C0087111] implication relevance,hepatorenal
nephrotoxicity tobramycin gentamicin [MeSH:C3854019] prospective,nearly million people [MeSH:C5690824] country receive aminoglycoside antibiotic annually gentamicin [MeSH:C3854019] [MeSH:C3854019] sulfate [MeSH:C0546866] tobramycin sulfate continue demonstrate ototoxicity [MeSH:C0235280] nephrotoxicity animal study patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] confirm initial normal renal function [MeSH:C0031843] treat mg kg gentamicin [MeSH:C3854019] [MeSH:C3854019] sulfate [MeSH:C0546866] tobramycin sulfate minimum seven day [MeSH:C0011017] follow prospectively development [MeSH:C0020119] aminoglycoside-related renal failure [MeSH:C0035078] define one-third reduction [MeSH:C1827449] renal function [MeSH:C0031843] patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] cause renal failure [MeSH:C0035078] identify tobramycin-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] gentamicin [MeSH:C3854019] [MeSH:C3854019]-treated patient [MeSH:C0030705] [MeSH:C0030705] [MeSH:C0030705] renal failure [MeSH:C0035078] gentamicin [MeSH:C3854019] [MeSH:C3854019] associate [MeSH:C0004083] renal failure [MeSH:C0035078] time tobramycin,hepatorenal
distinct mutation [MeSH:C0026882] single bamhi site phenylketonuria [MeSH:C0031485],classical phenylketonuria [MeSH:C0031485] autosomal recessive disease cause deficiency hepatic phenylalanine hydroxylase [MeSH:C0751434] pah abolition invariant bamhi site located code sequence [MeSH:C0162327] pah gene exon [MeSH:C0015295] lead recognition [MeSH:C0871740] new point mutation [MeSH:C0026882] codon 2gly----stop 3ser----phe respectively mutation [MeSH:C0026882] detect north eastern france belgium occur rflp [MeSH:C0035268] haplotype [MeSH:C0018591] allele [MeSH:C0002085] present support view heterogeneity pku [MeSH:C0242960] account large variety mutant [MeSH:C1564139] genotype [MeSH:C0017431] associate pah deficiency [MeSH:C0751434],hepatorenal
coincidence novel arylsulfatase allele mutation 1 g family metachromatic leukodystrophy [MeSH:C0023522] molecular basis phenotypic [MeSH:C1837514] heterogeneity [MeSH:C0242960],family sibling [MeSH:C0037047] [MeSH:C0037047] [MeSH:C0037047] develop classical late infantile metachromatic leukodystrophy [MeSH:C0023522] mld fatal age year deficient [MeSH:C0531328] arylsulfatase [MeSH:C0003940] arsa activity increase galactosylsulfatide gs [MeSH:C0086903] excretion [MeSH:C1373187] sibling [MeSH:C0037047] [MeSH:C0037047] apparently healthy [MeSH:C0452415] year respectively father [MeSH:C0015671] apparently healthy [MeSH:C0452415] present arsa gs [MeSH:C0086903] value range mld patient [MeSH:C0030705] [MeSH:C0030705] mutation [MeSH:C0026882] [MeSH:C0026882] screening sequence disclose involvement [MeSH:C0030699] different arsa mutation [MeSH:C0026882] [MeSH:C0026882] molecular basis intrafamilial phenotypic [MeSH:C1837514] heterogeneity [MeSH:C0242960] late infantile inherit mother [MeSH:C0026591] frequent [MeSH:C0017270] -type mutation [MeSH:C0026882] [MeSH:C0026882] 1 g father [MeSH:C0015671] novel single basepair microdeletion guanine nucleotide exon [MeSH:C0028630] 7delg clinically unaffected sibling [MeSH:C0037047] [MeSH:C0037047] carry maternal [MeSH:C0024915] mutation [MeSH:C0026882] [MeSH:C0026882] 1 g paternal allele [MeSH:C0002085] [MeSH:C0002085] novel cytosine thymidine transition nucleotide exon [MeSH:C0028630] result substitution alanine valine [MeSH:C0001898] a44v father [MeSH:C0015671] genotype [MeSH:C0017431] 7delg a44v mutation [MeSH:C0026882] [MeSH:C0026882] a44v find unrelated mld patient [MeSH:C0030705] [MeSH:C0030705] control a44v clearly modify arsa gs [MeSH:C0086903] level [MeSH:C0018759] apparently bear little significance manifestation [MeSH:C0029166] mld mimic frequent [MeSH:C0017270] arsa pseudodeficiency [MeSH:C1623416] allele [MeSH:C0002085] [MeSH:C0002085] result demonstrate certain genetic condition mld-like arsa gs [MeSH:C0086903] value need parallel disease diagnostic [MeSH:C0086143] prognostic implication arsa allele [MeSH:C0002085] [MeSH:C0002085] functionally similar a44v exist -type mutation [MeSH:C0026882] [MeSH:C0026882] cause pathological [MeSH:C0030660] arsa gs [MeSH:C0086903] level [MeSH:C0018759] outbreak disease [MeSH:C0012652],neurological
effect recombinant human [MeSH:C2240523] insulin-like growth factor-i chronic puromycin aminonucleoside nephropathy rat [MeSH:C0034721],recently demonstrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]e recombinant [MeSH:C0034861] hgh [MeSH:C0122592] exacerbate renal [MeSH:C0152169] functional [MeSH:C0598463] structural injury chronic puromycin aminonucleoside pan nephropathy [MeSH:C0017661] [MeSH:C0017661] experimental model glomerular disease examine recombinant [MeSH:C0034861] human rh igf-i safe alternative growth failure rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] chronic pan nephropathy [MeSH:C0017661] [MeSH:C0017661] glomerulopathy induce seven serial injection pan wk experimental animal [MeSH:C0003062] [MeSH:C0003048] n receive rhigf-i microgram rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] n receive vehicle [MeSH:C0175845] rhigf-i improve weight gain [MeSH:C0043094] p alter hematocrit blood pressure rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] renal [MeSH:C0152169] disease urinary protein [MeSH:C1505427] excretion [MeSH:C1373187] unaltered rhigf-i rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] chronic pan nephropathy [MeSH:C0017661] [MeSH:C0017661] wk inulin [MeSH:C0021936] clearance [MeSH:C5243473] high rhigf-i-treate rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] versus ml min g body weight [MeSH:C0005910] untreated pan nephropathy [MeSH:C0017661] [MeSH:C0017661] animal [MeSH:C0003062] p improvement [MeSH:C2936612] gfr associate enhance glomerular hypertrophy [MeSH:C0020564] increase segmental glomerulosclerosis tubulointerstitial [MeSH:C0041349] injury [MeSH:C0333497] renal [MeSH:C0152169] cortical malondialdehyde [MeSH:C0024643] content rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] pan nephropathy [MeSH:C0017661] [MeSH:C0017661] administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion rhigf-i increase igf-i gh receptor gene expression [MeSH:C0017262] alter steady state igf-i receptor mrna [MeSH:C0035696] normal rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] intact kidney rhigf-i administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion n alter weight gain [MeSH:C0043094] blood pressure proteinuria gfr glomerular planar area renal [MeSH:C0152169] cortical malondialdehyde [MeSH:C0024643] content glomerular tubulointerstitial [MeSH:C0041349] damage compare untreated animal [MeSH:C0003062] n rhigf-i reduce steady state renal [MeSH:C0152169] igf-i mrna [MeSH:C0035696] modify gene expression [MeSH:C0017262] igf-i gh receptor conclude administrat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721]ion rhigf-i improve growth gfr [MeSH:C0018270] rat [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] [MeSH:C0034721] chronic pan nephropathy [MeSH:C0017661] [MeSH:C0017661] unlike rhgh [MeSH:C0122592] long-term use rhigf-i worsen renal [MeSH:C0152169] functional [MeSH:C0598463] structural injury disease model,neurological|cardiovascular|hepatorenal
eeg [MeSH:C0013819] reveal leukemia [MeSH:C0023418] secret,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve dementia [MeSH:C0497327] outcome [MeSH:C0206277] palsy pathway method observational trial cancer [MeSH:C0302523] patient [MeSH:C0030705] measuring locus coeruleus paralysis [MeSH:C0023951] result reduction [MeSH:C1827449] adverse event [MeSH:C0041755] potential therapeutic [MeSH:C0087111] benefit [MeSH:C0021674],neurological
venous pathway [MeSH:C0282655] angina pectoris,hypothesis [MeSH:C3179072] metformin [MeSH:C0025598] improve heart disease [MeSH:C0018799] outcome epinephrine pathway method cross-sectional trial [MeSH:C0010362] cardiac patient measure dementia artery [MeSH:C0497327] result decrease mortality rate [MeSH:C0205848] relevance [MeSH:C2826293],neurological|cardiovascular
thyroxine abuse [MeSH:C0040165] unusual case thyrotoxicosis [MeSH:C0040156] pregnancy [MeSH:C0032961],eat disorder [MeSH:C0040188] [MeSH:C0040188] [MeSH:C0040188] associate behavioural problem [MeSH:C0037431] drug abuse uncommon pregnancy [MeSH:C0032961] [MeSH:C0032961] occur unrecognized denial pose risk [MeSH:C0035647] mother [MeSH:C0026591] fetus [MeSH:C0015965] case illustrate number problem [MeSH:C0037431] encounter woman [MeSH:C0043210] eat disorder [MeSH:C0040188] [MeSH:C0040188] [MeSH:C0040188] pregnancy [MeSH:C0032961] [MeSH:C0032961] include prolonged recurrent metabolic disturbance diuretic abuse [MeSH:C0012798] particular illustrate derangement thyroid function see pregnant woman [MeSH:C0033011] [MeSH:C0043210] eat disorder [MeSH:C0040188] [MeSH:C0040188] [MeSH:C0040188] remind cause thyrotoxicosis [MeSH:C0040156] remain obscure thyroxine abuse [MeSH:C0040165] consider explore,neurological
hepatitis hypertensive cardiac connection,investigate [MeSH:C0035173] aspirin [MeSH:C0004057] effect heart disease [MeSH:C0018799] pulmonary embolism method cancer [MeSH:C0034065] patient [MeSH:C0030705] undergo prospective defibrillator ovarian cancer assessment [MeSH:C0030198] result improvement [MeSH:C2936612] primary endpoint relevance,cardiovascular|oncological
